en en http://nmrml.org/examples/ This artefact is an MSI-approved controlled vocabulary primarily developed under COSMOS EU and PhenoMeNal EU governance. The nmrCV is supporting the nmrML XML format with standardized terms. nmrML is a vendor agnostic open access NMR raw data standard. Its primaly role is analogous to the mzCV for the PSI-approved mzML XML format. It uses BFO2.0 as its Top level. This CV was derived from two predecessors (The NMR CV from the David Wishart Group, developed by Joseph Cruz) and the MSI nmr CV developed by Daniel Schober at the EBI. This simple taxonomy of terms (no DL semantics used) serves the nuclear magnetic resonance markup language (nmrML) with meaningful descriptors to amend the nmrML xml file with CV terms. Metabolomics scientists are encouraged to use this CV to annotrate their raw and experimental context data, i.e. within nmrML. The approach to have an exchange syntax mixed of an xsd and CV stems from the PSI mzML effort. The reason to branch out from an xsd into a CV is, that in areas where the terminology is likely to change faster than the nmrML xsd could be updated and aligned, an externally and decentrallised maintained CV can accompensate for such dynamics in a more flexible way. A second reason for this set-up is that semantic validity of CV terms used in an nmrML XML instance (allowed CV terms, position/relation to each other, cardinality) can be validated by rule-based proprietary validators: By means of cardinality specifications and XPath expressions defined in an XML mapping file (an instances of the CvMappingRules.xsd ), one can define what ontology terms are allowed in a specific location of the data model. BFO 2 Reference: BFO does not claim to be a complete coverage of all entities. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning – coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation [17 BFO 2 Reference: BFO does not claim to provide complete coverage of entities of all types. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning - coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation. BFO 2 Reference: BFO's treatment of continuants and occurrents - as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality - earlier called the 'SNAP' and 'SPAN' perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science. BFO 2 Reference: BFO’s treatment of continuants and occurrents – as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality – earlier called the ‘SNAP’ and ‘SPAN’ perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science [30 BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. 'Entity' is an example of a primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. ‘Entity’ is an example of one such primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. Product version In case we like to be able to convert this owl CV back into the obo format, we should only use DL/owl constructs that are supported by obo. Hence, editors of this CV should take care not to use any higher descriptrion logics semantics, i.e. cardinality restrictions or defined terms using constructors. We should start to build the taxonomic backbone first and later connect the main axis via relations. If we want to use restrictions, we should only use existential quantifiers as the OBO format does not support universal quantification. List of terms required by current XSD (August 2013): these were bookmarked in CV (annotation property) and are visible in the new nmrTab: CVTerm occurrences: buffer-->buffer solvent-->solvent concentration standard type-->calibration compound , what is chemical shift reference ? What calibration_reference_shift under calibration compound ? concentration standard name we here see a use-mention problem arising for the CV. The xsd should probably change here to avoid this. encoding method (Quadrature detection method) is this the same as encoding method ? sample container-->NMR_sample_holder (spectrum) y axis type-->coordinate system descriptor post acquisition solvent suppression method Two usages in xsd, but with differrent type ? -->solvent suppression method calibration compound Two usages in xsd, but with differrent type ?-->calibration compound data transformation method-->data transformation method (spectral) projection method-->projection method spectral denoising method-->spectral denoising method window function method-->window function method baseline correction method-->baseline correction sample type-->NMR sample CVParam occurrences: file content-->data file content software type-->software source file type-->data file attribute (needs refactoring) instrument configuration type-->instrument configuration processing method type-->data processing method CVParamType occurrences: chemical shift standard-->chemical shift standard solvent suppression method-->solvent suppression method encoding scheme (Quadrature detection method)-->encoding method window function parameter-->window function parameter CVParamWithUnitType occurrences: CVParamWithUnitType is currently not used in the xsd and dangling ! I assume ValueWithUnitType substitutes it ? UserParamType occurrences: No CV terms needed ValueWithUnitType occurrences: These will have to be used from the Unit ontology. Ontology for Biomedical Investigations 1.4 Adam Goldstein Advisors for this project come from the IFOMIS group, Saarbruecken and from the Co-ODE group in Manchester Alan Ruttenberg Alan Ruttenberg Albert Goldfain Albert Goldfain Alejandra Gonzalez-Beltran Ali Ayadi Andrea Porzel Andrew Lane Annick Moing Barry Smith Barry Smith Bill Duncan Bjoern Peters Bjoern Peters Carlo Torniai Catherine Deborde Chris Mungall Chris Mungall Chris Stoeckert Chris Taylor Christian A. Boelling Clint Dowland Colin Batchelor Contributors are those that engage in discussions in the context of SIO (in alphabetical order): sivaram arabandi christopher baker joachim baran jerven bolleman matthew brush alison callahan leonid chepelev kevin cohen melanie courtot geraint duck laura furlong elisa kendall tatsuya kushida luke mccarthy jim mccusker jose miguel cruz-toledo chris mungall robert hoehndorf simon jupp jin-dong kim dana klassen thomas luetteke james malone chris mungall david osumi-sutherland tazro ohta nuria queralt stephen reed alexandre riazanov matthias samwald robert stevens mark wilkinson karin verspoor natalia villanueva-rosales Cristian Munteanu Daniel Jacob Daniel Schober Darrell R. Abernethy Darren Natale David Osumi-Sutherland David Osumi-Sutherland David Shotton David Wishart Denise Slenter Dennis Rubtsov Egon Willighagen Elizabeth Blair Evan Bolton Fabian Neuhaus Friederike Ehrhart Gang Fu Gareth Owen Gwen Frishkoff Haralambos Sarimveis Helen Jenkins Holger Stenzhorn Holger Stenzhorn Hunter Moseley Irena Spasic Izabela Birsanescu James A. Overton James A. Overton James Malone Janna Hastings Javier Millan Acosta Jennifer Fostel Jiakang Chang Jie Zheng Jie Zheng Jonathan Bona Jonathan Rees Joseph Cruz Keith Burkhart Larisa Soldatova Larissa Soldatova Larry Hunter Laurent Winckers Lawrence Hunter Leonard Jacuzzo Leonid Chepelev Linda Rieswijk Luca Toldo Ludger Jansen Mark Davies Mark Ressler Marta Cascante Mathias Brochhausen Mathias Brochhausen Matt Brush Mauricio Almeida Melanie Courtot Melanie Courtot Michael Wilson Michel Dumontier Michel Dumontier NanoinformaTIX - Development and Implementation of a Sustainable Modelling Platform for NanoInformatics (Grant Agreement 814426) Consortium Nina Jeliazkova Oana Florean Ola Spjuth Paolo Ciccarese Paolo Ciccarese Pat Hayes Pedro Ramon de Atauri Carulla Philip Doganis Philippe Rocca-Serra Pierre Grenon Randall Dipert Randy Dipert Reza Salek Robert Rovetto Ron Rudnicki Ron Rudnicki Satya Sahoo Selja Seppälä Silvia Marin Since this is a prolonged effort spanning a larger time period, there naturally were many people involved in the creation over the years and during different times. People involved in the term creation from ID >1400000 : This part of the NMR ontology was originally developed by the ontology working group (http://msi-ontology.sourceforge.net/) of the msi-metabolomicssociety (msi-workgroups.sf.net): Dennis Rubtsov (Un of Cambridge, UK) Helen Jenkins (Un of Wales, Aberystwyth, UK) Irena Spasic (Center for Integrative Systems Biology, Manchester, UK) Larissa Soldatova (University of Wales, Aberystwyth, UK) Philippe Rocca-Serra (EBI and MGED Society) Susanna-Assunta Sansone (EBI) People involved in the term creation from ID<1400000: Joseph Cruz Daniel Schober Michael Wilson Reza Salek Daniel Jacob David Wishart Terms with IDs ID<1400000 that were NOT asserted in the original Wishart obo file were created by Daniel Schober (COSMOS WP2). Its IDs were autogenerated with the Protege ID generator. Other people that substantially helped in revising the latest and Cosmos governed CV additions were: Michael Wilson, Wishart Group, Edmonton, Alberta, Canada Daniel Jacob, INRA, Bordeaux, France Annick Moing, INRA, Bordeaux, France Catherine Deborde, INRA, Bordeaux, France Reza Salek, EBI, Hinxton, UK Philippe Rocca-Serra, University of Oxford, Oxford, UK Andrea Porzel, IPB-Halle, Germany and the COSMOS WP2 team A paper describing the overall nmrML data standard and CV has been accepted by Analytical Chemistry (Manuscript ID: ac-2017-02795f.R1), title `nmrML: a community supported open data standard for the description, storage, and exchange of NMR data`, author(s): Schober, Daniel; Jacob, Daniel; Wilson, Michael; Cruz, Joseph; Marcu, Ana; Grant, Jason; Moing, Annick; Deborde, Catherine; de Figueiredo, Luis; Haug, Kenneth; Rocca-Serra, Philippe; Easton, John; Ebbels, Timothy; Hao, Jie; Ludwig, Christian; Günther, Ulrich; Rosato, Antonio; Klein, Matthias; Lewis, Ian; Luchinat, Claudio; Jones, Andrew; Grauslys, Arturas; Larralde, Martin; Yokochi, Masashi; Kobayashi, Naohiro; Porzel, Andrea; Griffin, Julian; Viant, Mark; Wishart, David; Steinbeck, Christoph; Salek, Reza; Neumann, Steffen Sivaram Arabandi Stefan Schulz Steffen Neumann Susanna-Assunta Sansone Sydni Joubran Teresa Fan The ACEnano - Analytical and Characterisation Excellence in nanomaterial risk assessment: A tiered approach (Grant Agreement 720952) Consortium The NanoCommons Consortium The RiskGONE Consortium The eNanoMapper Consortium Thomas Bittner Tim Clark Vitaly Selivanov Werner Ceusters Werner Ceusters William Duncan William Hogan Yongqun "Oliver" He Yongqun (Oliver) He Nuclear magnetic resonance (NMR) data annotation as required by the msi sanctioned open access nmrML XML format developed by the COSMOS EU project. "Asiyah" Yu Lin Abra Guo Adrien Barton Alan Ruttenberg Allyson Lister Barry Smith Barry Smith Bill Bug Bingjian Yang Bjoern Peters Carlo Torniai Chris Mungall Chris Stoeckert Chris Taylor Christian Bolling Cristian Cocos Daniel Rubin Daniel Schober David Ameriguian David Shotton Dawn Field Dennis G. Thomas Desikan Jagannathan Dirk Derom Edison Ong Elisabetta Manduchi Eric Deutsch Frank Gibson Gautier Koscielny Gilberto Fragoso Helen C. Causton Helen Parkinson Holger Stenzhorn Huan Li Human Phenotype Ontology Consortium James A. Overton James Malone Jay Greenbaum Jean-François Ethier Jeffrey Grethe Jennifer Fostel Jessica DeGuise Jessica Turner Jiangan "Hardy" Xie Jiangan Xie Jie Zheng Joe White John Westbrook Kelly Yang Kevin Clancy Kevin Mo Larisa Soldatova Laura Huerta Martinez Lawrence Hunter Liju Fan Ling Wan Liwei Wang Luisa Montecchi Marcy Harris Matthew Brush Matthew Pocock Meiu Wong Melanie Courtot Melissa Haendel Mervi Heiskanen Michel Dumontier Michel Dumontier Monarch Initiative Monnie McGee Noemi Garg Norman Morrison Olamidipupo Ajigboye Paola Roncaglia Paolo Ciccarese Peter Robinson Philippe Rocca-Serra Philippe Rocca-Serra Phillip Lord Pierre Grenon Qingping Liu Qingzhi Liu Qiuyue Yang Rebecca Racz Richard Bruskiewich Richard Scheuermann Robert Stevens Ryan R. Brinkman Sebastian Köhler Shelley Zhang Silvio Peroni Sirarat Sarntivijai Stefan Wiemann Susanna-Assunta Sansone Sydni Joubran Tanya Gray Tina Hernandez-Boussard Trish Whetzel Trish Whetzel Yongqun "Oliver" He Yongqun "Oliver" He (YH) Yongqun He Yu Lin Zoe May Pendlington Zuoshuang "Allen" Xiang http://orcid.org/0000-0002-6601-2165 http://orcid.org/0000-0002-8343-612X http://orcid.org/0000-0003-1604-1512 05/09/2013 2009-07-31 2016-07-11 2018-03-29 2022-8-15 8 Jul 2021 March 28, 2022 A structured controlled vocabulary for the source of an enzyme comprising tissues, cell lines, cell types and cell cultures. An ontology for representing biomedical investigations, including study designs, the collection and preparation of the targets of investigation, assays, instrumentation and reagents used, as well as the data generated and the types of analysis performed on the data to reach conclusions, and their documentation. An ontology of cell types. An ontology of phenotypic qualities (properties, attributes or characteristics). CHMO, the chemical methods ontology, describes methods used to collect data in chemical experiments, such as mass spectrometry and electron microscopy prepare and separate material for further analysis, such as sample ionisation, chromatography, and electrophoresis synthesise materials, such as epitaxy and continuous vapour deposition It also describes the instruments used in these experiments, such as mass spectrometers and chromatography columns. It is intended to be complementary to the Ontology for Biomedical Investigations (OBI). ENVO is an ontology which represents knowledge about environments,environmental processes, ecosystems, habitats, and related entities FaBiO, the FRBR-aligned Bibliographic Ontology, is an ontology for recording and publishing on the Semantic Web descriptions of entities that are published or potentially publishable, and that contain or are referred to by bibliographic references, or entities used to define such bibliographic references. FaBiO entities are primarily textual publications such as books, magazines, newspapers and journals, and items of their content such as poems, conference papers and editorials. However, they also include blogs, web pages, datasets, computer algorithms, experimental protocols, formal specifications and vocabularies, legal records, governmental papers, technical and commercial reports and similar publications, and also anthologies, catalogues and similar collections. FaBiO classes are structured according to the FRBR schema of Works, Expressions, Manifestations and Items. Additional properties have been added to extends the FRBR data model by linking Works and Manifestations (fabio:hasManifestation and fabio:isManifestationOf), Works and Items (fabio:hasPortrayal and fabio:isPortrayedBy), and Expressions and Items (fabio:hasRepresentation and fabio:isRepresentedBy). NanoParticle Ontology (NPO): An ontology for representing the knowledge underlying the description and characterization of nanoparticles. OBCS stands for the Ontology of Biological and Clinical Statistics. OBCS is an ontology in the domain of biological and clinical statistics. It is aligned with the Basic Formal Ontology (BFO) and the Ontology for Biomedical Investigations (OBI). OBCS imports all possible biostatistics terms in OBI and includes many additional biostatistics terms, some of which were proposed and discussed in the OBI face-to-face workshop in Ann Arbor in 2012. The Gene Ontology (GO) provides a framework and set of concepts for describing the functions of gene products from all organisms. The Human Phenotype Ontology (HPO) provides a standardized vocabulary of phenotypic abnormalities and clinical features encountered in human disease. The Information Artifact Ontology (IAO) is an ontology of information entities, originally driven by work by the OBI digital entity and realizable information entity branch. The Ontology of Adverse Eventsy (OAE) is a biomedical ontology in the domain of adverse events. OAE aims to standardize adverse event annotation, integrate various adverse event data, and support computer-assisted reasoning. OAE is a community-based ontology. Its development follows the OBO Foundry principles. Vaccine adverse events have been used as an initial testing use case. OAE also studies adverse events associated with the administration of drug and nutritional products, the operation of surgeries, and the usage of medical devices, etc. The eNanoMapper project (https://www.enanomapper.net/), NanoCommons project (https://www.nanocommons.eu/) and ACEnano project (http://acenano-project.eu/) are creating a pan-European computational infrastructure for toxicological data management for ENMs, based on semantic web standards and ontologies. This ontology is an application ontology targeting the full domain of nanomaterial safety assessment. It re-uses several other ontologies including the NPO, CHEMINF, ChEBI, and ENVO. This vocabulary is an expression in OWL 2 DL of the basic concepts and relations described in the IFLA report on the Functional Requirements for Bibliographic Records (FRBR), also described in Ian Davis's RDF vocabulary (http://vocab.org/frbr/core). Uberon is an integrated cross-species anatomy ontology representing a variety of entities classified according to traditional anatomical criteria such as structure, function and developmental lineage. The ontology includes comprehensive relationships to taxon-specific anatomical ontologies, allowing integration of functional, phenotype and expression data. an application ontology for supporting description and annotation of mass-spectrometry and nmr-spectroscopy based metabolomics experiments and fluxomics studies. OWL OWL OWL-DL application/rdf+xml http://purl.bioontology.org/ontology/npo en CC-BY 3.0 https://creativecommons.org/licenses/by/3.0/ CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ http://uberon.org Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* Copyright [2014] EMBL - European Bioinformatics Institute Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License. You may obtain a copy of the License at http://www.apache.org/licenses/LICENSE-2.0 Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License. Peter Robinson, Sebastian Koehler, The Human Phenotype Ontology Consortium, and The Monarch Initiative This work is distributed under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/). http://creativecommons.org/licenses/by/3.0/ ISBN:0030229073 Invertebrate Zoology, Barnes ISBN:0073040584 Vertebrates, Kardong ISBN:0123813611 Comparative Anatomy and Histology: A Mouse and Human Atlas, Treuting and Dintzis ISBN:0226313379 Fins into Limbs: Evolution, Development, and Transformation, Hall ISBN:0443065837 Human embryology, Larsen ISBN:0471888893 Comparative Vertebrate Neuroanatomy: Evolution and Adaptation by Butler and Hodos ISBN:0683400088 Stedman's Medical Dictionary ISBN:1588900649 Color Atlas and Textbook of Human Anatomy: Nervous system and sensory organs By Werner Kahle, Michael Frotscher ISBN:1588903958 Principles and practice of pediatric neurosurgery By A. Leland Albright, P. David Adelson, Ian F. Pollack ISBN:1607950324 Craniofacial Embryogenetics & Development, 2nd edition, Sperber ISBN:978-0-12-369548-2 Principles of Developmental Genetics, Sally A Moody ISBN:9780120749034 The laboratory rat ISBN:9780397517251 Surgical anatomy of the hand and upper extremity. By James R. Doyle and Michael J. Botte ISBN:9780674021839 The Tree of Life - Guillaume Lecointre, Herve Le Guyader ISBN:9780878932504 Developmental Biology MESH PMID:11433360 Placental development: lessons from mouse mutants PMID:16417468 Forgotten and novel aspects in pancreas development, Pieler and Chen aggregates AAO from 13:04:2012 aggregates TAO from 09:08:2012 aggregates VSAO from 16:07:2012 http://wiki.phenotypercn.org/wg/phenotypercn/index.php?title=Neural_Crest_Workshop http://wiki.phenotypercn.org/wiki/August_2012_Notes https://docs.google.com/document/d/16JZOuH9sh_a8uIXA4cqg0Q1H6MV5yCj3-rhuKsZoV_U/edit https://docs.google.com/document/d/1MnUgispgGfNQoezYzWzzGTnkAnI0gzRnJIwdip6MMtw/edit https://docs.google.com/document/d/1cPWBqrl_Qy7XHEWFqtR_PgQX61yRkgGuLaiDpnEXxkE/edit https://docs.google.com/document/d/1r9kNPpFYGdu0SpJDLyFAVQczBlG0wAZCBMd18gG3Ot8/edit# https://docs.google.com/spreadsheet/ccc?key=0Aj8NJdyb-leqdDM0R3hTVTRHRExDVjRCSkZEbDc5N1E#gid=0 An ontology for the annotation of biomedical and functional genomics experiments. An ontology for the annotation of the adverse event domain. Phenotypic abnormalities encountered in human disease CDK descriptor algorithm implementations Cell Ontology Chemical Methods Ontology Essential FRBR in OWL2 DL FaBiO, the FRBR-aligned Bibliographic Ontology Gene Ontology Human Phenotype Ontology Information Artifact Ontology (IAO) Metabolomics Standards Initiative Ontology (MSIO) OAE: Ontology of Adverse Events PATO - the Phenotype And Trait Ontology Supporting terminology for chemical information ontology (cheminf) The BRENDA Tissue Ontology (BTO) The Environment Ontology Uber-anatomy ontology chemical information ontology (cheminf) - information entities about chemical entities eNanoMapper ontology nuclear magnetic resonance CV http://orcid.org/0000-0003-4727-9435 The semanticscience integrated ontology (SIO) provides a simple, integrated ontology (types, relations) for objects, processes and their attributes. This project provides foundational support for the Bio2RDF (http://bio2rdf.org) and SADI (http://sadiframework.org) projects. website: http://semanticscience.org email: sio-ontology@googlegroups.com mailing list: http://groups.google.com/group/sio-ontology http://genomebiology.com/2012/13/1/R5 http://www.ncbi.nlm.nih.gov/pubmed/22293552 2010-03-29 http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/publicdomain/zero/1.0/ https://creativecommons.org/licenses/by/4.0/ www.apache.org/licenses/LICENSE-2.0 free to use,share,modify. modify with attribution [http://creativecommons.org/licenses/by/4.0/]. Ontology for Biomedical Investigations Semanticscience Integrated Ontology (SIO) http://bioassayontology.org/bao/bao_complete_merged.owl http://data.bioontology.org/ontologies/NCIT/submissions/82/download?apikey=8b5b7825-538d-40e0-9e9e-5ab9274a9aeb http://ftp.ebi.ac.uk/pub/databases/chebi/ontology/chebi.owl http://purl.obolibrary.org/obo/bfo/classes-only.owl http://purl.obolibrary.org/obo/bto.owl http://purl.obolibrary.org/obo/chmo.owl http://purl.obolibrary.org/obo/cl.owl http://purl.obolibrary.org/obo/envo.owl http://purl.obolibrary.org/obo/go.owl http://purl.obolibrary.org/obo/iao.owl http://purl.obolibrary.org/obo/oae.owl http://purl.obolibrary.org/obo/obcs.owl http://purl.obolibrary.org/obo/obi.owl http://purl.obolibrary.org/obo/pato.owl http://purl.obolibrary.org/obo/uberon.owl http://purl.obolibrary.org/obo/uo.owl http://semanticchemistry.github.io/semanticchemistry/ontology/cheminf.owl http://www.ebi.ac.uk/efo/efo.owl https://raw.githubusercontent.com/enanomapper/aop-ontology/patch/hpoUpdate/aopo.owl https://raw.githubusercontent.com/enanomapper/npo/master/npo-inferred.owl https://raw.githubusercontent.com/enanomapper/ontologies/master/internal/ccont-ext.owl https://raw.githubusercontent.com/jmillanacosta/MSIO/master/MSIO-edit.owl https://raw.githubusercontent.com/micheldumontier/semanticscience/master/ontology/sio.owl https://svn.code.sf.net/p/sempublishing/code/FaBiO/2016-07-11-fabio-1_9_3.owl http://www.jbiomedsem.com/content/5/1/14 fabio sio http://purl.org/spar/fabio/ http://semanticscience.org/resource/ general class inclusion axioms: 'is part of' some 'physical entity' subClassOf 'is located in' some 'physical entity' role chains: 'has capability' o 'is realized in' -> 'is participant in' https://github.com/EnvironmentOntology/envo/ https://github.com/cmungall/uberon/ https://obo.svn.sourceforge.net/svnroot/obo/uberon/ This CV is to be used by metabolomics researchers, or basically any chenomics or proteomics researchers who apply the nmrML xml to store their NMRraw data in a vendor agnostic manner. But nmrML can also be used to capture experimental results and (limited) basic metadata like molecule to spectral feature assignments. https://github.com/EnvironmentOntology/envo/issues/ https://github.com/nmrML/nmrML/issues https://github.com/obophenotype/uberon/issues/ Daniel Schober https://github.com/nmrML/nmrML https://github.com/nmrML/nmrML/tree/master/ontologies https://groups.google.com/forum/?hl=en#!forum/nmrml/join https://lists.sourceforge.net/lists/listinfo/obo-anatomy http://www.metabolomics-msi.org/ http://phenomenal-h2020.eu/home/ http://www.cosmos-fp7.eu/WP2 Catherine Leroy Dani Welter Drashtti Vasant Ele Holloway Eleanor Williams Emma Kate Hastings Helen Parkinson James Malone Jon Ison Matthias Ganzinger, matthias.ganzinger@med.uni-heidelberg.de Natalja Kurbatova Simon Jupp Sirarat Sarntivijai Tomasz Adamusiak OBO-Edit 2.2 OBO-Edit 2.3.1 Slimmer Daniel Schober 2017-10-19T10:11:26Z 09:06:2022 14:24 2022-08-11 21:08:09 2022-08-11 21:37:39 2023-06-08 11:39:04 2023-07-12 12:46:47 2023-07-12 12:46:50 2023-07-12 12:46:56 2023-07-12 12:46:58 2023-07-12 12:47:02 2023-07-12 13:30:32 2023-07-12 13:30:48 2023-07-12 13:37:44 2023-07-12 13:37:51 2023-07-12 13:37:56 2023-07-12 13:38:26 2023-07-12 13:38:32 2023-07-12 13:42:41 2023-07-12 13:42:52 2023-07-12 13:42:56 2023-07-12 13:43:02 2023-07-12 13:43:13 2023-07-12 13:43:17 2023-07-12 13:43:44 2023-07-12 13:43:48 2023-07-12 16:05:49 23:10:2021 16:56 27:05:2023 19:23 BrendaTissueOBO ENVO chebi_ontology gene_ontology human_phenotype quality uberon 1.2 has_part Marion Peter Robinson, Sebastian Koehler, Sandra Doelken, Chris Mungall, Melissa Haendel, Nicole Vasilevsky, Monarch Initiative, et al. batchelorc chebi AEO BILA BSPO CARO EFO GO OG VSAO EHDAA EV NCIT OGES SCTID VHOG AAO part_of NCBITaxon:8292 DHBA part_of NCBITaxon:9606 EHDAA2 part_of NCBITaxon:9606 EMAPA part_of NCBITaxon:10090 FBbt part_of NCBITaxon:7227 FBdv part_of NCBITaxon:7227 FMA part_of NCBITaxon:9606 HAO part_of NCBITaxon:7399 HBA part_of NCBITaxon:9606 HsapDv part_of NCBITaxon:9606 MA part_of NCBITaxon:10090 MFO part_of NCBITaxon:8089 MmusDv part_of NCBITaxon:10090 OlatDv part_of NCBITaxon:8089 PBA part_of NCBITaxon:9443 SPD part_of NCBITaxon:6893 TADS part_of NCBITaxon:6939 TAO part_of NCBITaxon:32443 TGMA part_of NCBITaxon:44484 WBbt part_of NCBITaxon:6237 WBls part_of NCBITaxon:6237 XAO part_of NCBITaxon:8353 ZFA part_of NCBITaxon:7954 ZFS part_of NCBITaxon:7954 2023-07-05 An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO Aurelie Comte, Bill Bug, Catherine Leroy, Duncan Davidson and Trish Whetzel are also contributors. However their ORCIDs were not found. Author: ChEBI curation team ChEBI Release version 211 ChEBI Release version 222 ChEBI subsumes and replaces the Chemical Ontology first Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* Document containing upporting external terms FaBiO, the FRBR-aligned Bibliographic Ontology, is an ontology for recording and publishing on the Semantic Web bibliographic records of scholarly endeavours. It forms part of SPAR, a suite of Semantic Publishing and Referencing Ontologies. Other SPAR ontologies are described at http://purl.org/spar/. This ontology is available at http://purl.org/spar/fabio, and uses the namespace prefix fabio. For any queries contact chebi-help@ebi.ac.uk IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/TEMP>) VersionIRI(<null>))) [Axioms: 437 Logical Axioms: 0] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/chemical_concentration.owl>) VersionIRI(<null>))) [Axioms: 679 Logical Axioms: 119] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute.owl>) VersionIRI(<null>))) [Axioms: 206 Logical Axioms: 34] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute_location.owl>) VersionIRI(<null>))) [Axioms: 168 Logical Axioms: 29] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_quality_location.owl>) VersionIRI(<null>))) [Axioms: 40 Logical Axioms: 6] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/process_attribute.owl>) VersionIRI(<null>))) [Axioms: 21 Logical Axioms: 2] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/uberon-bridge-to-bfo.owl>) VersionIRI(<null>))) [Axioms: 20 Logical Axioms: 9] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/uberon/disjoint_union_over.owl>) VersionIRI(<null>))) [Axioms: 38 Logical Axioms: 38] Inferred version created with Pellet reasoner in Protege editor (v. 4.1) NCI Thesaurus, a controlled vocabulary in support of NCI administrative and scientific activities. Produced by the Enterprise Vocabulary System (EVS), a project by the NCI Center for Biomedical Informatics and Information Technology. National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, U.S.A. Please cite the OBI consortium http://purl.obolibrary.org/obo/obi where traditional citation is called for. However it is adequate that individual terms be attributed simply by use of the identifying PURL for the term, in projects that refer to them. Please see license of HPO at http://www.human-phenotype-ontology.org Please see the project site https://github.com/BFO-ontology/BFO, the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel, the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx. This ontology is generated from a specification at https://github.com/BFO-ontology/BFO/tree/master/src/ontology/owl-group/specification/ and with the code that generates the OWL version in https://github.com/BFO-ontology/BFO/tree/master/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif. See PMID:15693950, PMID:12799354, PMID:20123131, PMID:21208450; Contact Alexander Diehl, addiehl@buffalo.edu, University at Buffalo. The BSD license on the BFO project site refers to code used to build BFO. The Essential FRBR in OWL2 DL Ontology (FRBR) is an expression in OWL 2 DL of the basic concepts and relations described in the IFLA report on the Functional Requirements for Bibliographic Records (FRBR), also described in Ian Davis's RDF vocabulary. **URL:** http://purl.org/spar/frbr **Creators**: [Paolo Ciccarese](http://orcid.org/0000-0002-5156-2703), [Silvio Peroni](http://orcid.org/0000-0003-0530-4305) **Contributors:**: [David Shotton](http://orcid.org/0000-0001-5506-523X) **License:** [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/legalcode) **Website:** http://www.sparontologies.net/ontologies/frbr The NPO was primarily developed by Dennis G. Thomas in collaboration with Nathan A. Baker and Rohit V. Pappu. This development was supported by the NIH through grants U54 CA119342 and U54 HG004028. The chemical information ontology (cheminf) describes information entities about chemical entities. It provides qualitative and quantitative attributes to richly describe chemicals. The chemical information ontology (cheminf) intends to describe information entities about chemical entities. It means to provide qualitative and quantitative attributes to richly describe chemicals. The eNanoMapper project (https://www.enanomapper.net/), NanoCommons project (https://www.nanocommons.eu/) and ACEnano project (http://acenano-project.eu/) are creating a pan-European computational infrastructure for toxicological data management for ENMs, based on semantic web standards and ontologies. This ontology is an application ontology targeting the full domain of nanomaterial safety assessment. It re-uses several other ontologies including the NPO, CHEMINF, ChEBI, and ENVO. The eNanoMapper project (www.enanomapper.net) is creating a pan-European computational infrastructure for toxicological data management for ENMs, based on semantic web standards and ontologies. This ontology is an application ontology targeting the full domain of nanomaterial safety assessment. It re-uses several other ontologies including the NPO, CHEMINF, ChEBI, and ENVO. The http://purl.obolibary.org/obo/bfo/classes-only.owl variant of BFO ("bfo_classes_only.owl") includes only the class hierarchy and annotations from the full OWL version of BFO 2: http://purl.obolibary.org/obo/bfo.owl ("bfo.owl"). There are no object properties or logical axioms that use the object properties in bfo_classes_only.owl. As the logical axioms in the bfo_classes_only.owl variant are limited to subclass and disjoint assertions they are much weaker than the logical axioms in bfo.owl. If you plan to use the relations that define BFO 2, you should import bfo.owl instead of bfo_classes_only.owl. To the extent that the relations are used without importing bfo.owl, be mindful that they should be used in a manner consistent with their use in bfo.owl. Otherwise if your ontology is imported by a another ontology that imports bfo.owl there may be inconsistencies. See the BFO 2 release notes for further information about BFO 2. Please note that the current release of bfo.owl uses temporal relations when the subject or object is a continuant, a major change from BFO 1. There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. contact: Stephan Schurer: stephan dot schurer at gmail dot com These toxicological endpoints correspond to those listed in the OECD Harmonized Templates and associated guidelines for determining the toxicological effects of substances. This BFO 2.0 version represents a major update to BFO and is not strictly backwards compatible with BFO 1.1. The previous OWL version of BFO, version 1.1.1 will remain available at http://ifomis.org/bfo/1.1 and will no longer be updated. The BFO 2.0 OWL is a classes-only specification. The incorporation of core relations has been held over for a later version. This file is part of the eNanoMapper ontology project (http://www.enanomapper.net/) This is an early version of BFO version 2 and has not yet been extensively reviewed by the project team members. Please see the project site http://code.google.com/p/bfo/ , the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel , the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx . This ontology is generated from a specification at http://bfo.googlecode.com/svn/trunk/src/ontology/owl-group/specification/ and with the code that generates the OWL version in http://bfo.googlecode.com/svn/trunk/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif This ontology contains proposed extensions to the Basic Formal ON, which in due course will be submitted to the BFO. This ontology contains proposed extensions to the Chemical Entities of Biological Interest, which in due course will be submitted to the ChEBI. This ontology contains proposed extensions to the Chemical Methods Ontology, which in due course will be submitted to the CHMO. This ontology contains proposed extensions to the NanoParticle Ontology, which in due course will be submitted to the NPO. This ontology contains proposed extensions to the Ontology for Biomedical Investigations, which in due course will be submitted to the OBI. This ontology contains proposed extensions to the Phenotype And Trait Ontology, which in due course will be submitted to the PATO. This version (1.1.0) uses the Basic Formal Ontology (BFO) as its top level ontology. We might at some point close the resulting semantic gap by using OBI and IAO as intermediate bridges. To develop the ontology, you must change the default auto-create settings in Protege 4. Go to file>preferences>New Entities. Change the following: specified URI = http://semanticscience.org/resource/ Followed by '/', End with : AutoID AutoID - digit count = 6, prefix = CHEMINF_ created by: Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* developed by Michael Ashburner & Pankaj Jaiswal. BAO BioAssay Ontology bioassay ontology cell culture ontology (CCONT) http://sio.semanticscience.org http://www.metabolomicscentre.ca/nmrML/msi-nmr.obo 1.0 1.0.1 1.1 1.1.0 1.2.47 1.59 1.9.2 1.9.3 10.0 101 2.1 2.1.0 2.7.2 2013-05-31 (yyyy-mm-dd) 2022-11-07 2023-02-13 2023-03-10 2023-05-18 2023-05-25 2023-06-11 2023-06-22 2023-06-27 22.03d 3.55.1 Generated 04-11-2012 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. alpha http://environmentontology.org/ http://nmrml.org/cv/ http://uberon.org Snomedid A1 Conceptual Entity Role Has Domain Role_Has_Domain Role_Has_Domain An association that specifies the parent of the branch encompassing a role's domain. Role_Has_Domain Role_Has_Domain PT NCI An association that specifies the parent of the branch encompassing a role's domain. NCI A10 Conceptual Entity Has CDRH Parent Has_CDRH_Parent Has_CDRH_Parent An association created to allow the source CDRH to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source. Has_CDRH_Parent Has_CDRH_Parent PT NCI An association created to allow the source CDRH to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source. NCI A11 Conceptual Entity Has_NICHD_Parent Has_NICHD_Parent An association created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are a contributing source. Has_NICHD_Parent Has_NICHD_Parent PT NCI An association created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are a contributing source. NCI A12 Conceptual Entity Has Data Element Has_Data_Element Has_Data_Element An association created to relate a data element concept to the codelist term that is used to bundle its subset of valid value concepts. Has_Data_Element Has_Data_Element PT NCI An association created to relate a data element concept to the codelist term that is used to bundle its subset of valid value concepts. NCI A13 Conceptual Entity Related_To_Genetic_Biomarker Related_To_Genetic_Biomarker An association that indicates that a finding or lab test is related to a gene, possibly through a variant or product. Related_To_Genetic_Biomarker An association that indicates that a finding or lab test is related to a gene, possibly through a variant or product. NCI Related_To_Genetic_Biomarker PT NCI A14 Conceptual Entity Neoplasm_Has_Special_Category Neoplasm_Has_Special_Category An association that indicates that a neoplastic disease can have the characteristics defined by a Neoplasm by Special Category concept. Neoplasm_Has_Special_Category Neoplasm_Has_Special_Category PT NCI An association that indicates that a neoplastic disease can have the characteristics defined by a Neoplasm by Special Category concept. NCI A15 Conceptual Entity Has_CTCAE_5_Parent Has_CTCAE_5_Parent An association created to allow the source CTCAE 5.0 to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which CTCAE is the contributing source. Has_CTCAE_5_Parent Has_CTCAE_5_Parent PT NCI An association created to allow the source CTCAE 5.0 to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which CTCAE is the contributing source. NCI A16 Conceptual Entity Has_INC_Parent Has_INC_Parent An association created to allow the source INC to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source. Has_INC_Parent Has_INC_Parent PT NCI An association created to allow the source INC to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source. NCI A17 Conceptual Entity Has_Pharmaceutical_State_Of_Matter Has_Pharmaceutical_State_Of_Matter State of Matter An association that specifies the physical conditions describing the molecular form of a product. The target value should belong to the EDQM-HC State of Matter Terminology. Has_Pharmaceutical_State_Of_Matter Has_Pharmaceutical_State_Of_Matter PT NCI State of Matter PT EDQM-HC An association that specifies the physical conditions describing the molecular form of a product. The target value should belong to the EDQM-HC State of Matter Terminology. NCI A18 Conceptual Entity Has_Pharmaceutical_Basic_Dose_Form Basic Dose Form Has_Pharmaceutical_Basic_Dose_Form An association that specifies the category of the pharmaceutical dose form, used to group together related pharmaceutical dose forms. The target value should belong to the EDQM-HC Basic Dose Form Terminology. Has_Pharmaceutical_Basic_Dose_Form Basic Dose Form PT EDQM-HC Has_Pharmaceutical_Basic_Dose_Form PT NCI An association that specifies the category of the pharmaceutical dose form, used to group together related pharmaceutical dose forms. The target value should belong to the EDQM-HC Basic Dose Form Terminology. NCI A19 Conceptual Entity Has_Pharmaceutical_Administration_Method Administration Method Has_Pharmaceutical_Administration_Method An association that specifies the methods by which a pharmaceutical product is intended to be administered to the patient. The target value should belong to the EDQM-HC Administration Method Terminology. Has_Pharmaceutical_Administration_Method Administration Method PT EDQM-HC Has_Pharmaceutical_Administration_Method PT NCI An association that specifies the methods by which a pharmaceutical product is intended to be administered to the patient. The target value should belong to the EDQM-HC Administration Method Terminology. NCI A2 Conceptual Entity Role Has Range Role_Has_Range Role_Has_Range An association that specifies the parent of the branch encompassing the role's range. Role_Has_Range Role_Has_Range PT NCI An association that specifies the parent of the branch encompassing the role's range. NCI A20 Conceptual Entity Has_Pharmaceutical_Intended_Site Has_Pharmaceutical_Intended_Site Intended Site An association that specifies the general body sites at which a pharmaceutical product is intended to be administered. The target value should belong to the EDQM-HC Intended Site of Administration Terminology. Has_Pharmaceutical_Intended_Site Has_Pharmaceutical_Intended_Site PT NCI Intended Site EDQM-HC PT An association that specifies the general body sites at which a pharmaceutical product is intended to be administered. The target value should belong to the EDQM-HC Intended Site of Administration Terminology. NCI A21 Conceptual Entity Has_Pharmaceutical_Release_Characteristics Has_Pharmaceutical_Release_Characteristics Release Characteristics An association that specifies the timing by which an active ingredient is made available in the body after administration of the pharmaceutical product, in comparison with a conventional, direct release of the active ingredient. The target value should belong to the EDQM-HC Release Characteristics Terminology. Has_Pharmaceutical_Release_Characteristics Has_Pharmaceutical_Release_Characteristics PT NCI Release Characteristics PT EDQM-HC An association that specifies the timing by which an active ingredient is made available in the body after administration of the pharmaceutical product, in comparison with a conventional, direct release of the active ingredient. The target value should belong to the EDQM-HC Release Characteristics Terminology. NCI A22 Conceptual Entity Has_Pharmaceutical_Transformation Has_Pharmaceutical_Transformation Transformation An association that specifies the procedures that are carried out in order to convert a manufactured item that requires such a procedure into a pharmaceutical product. The target value should belong to the EDQM-HC Transformation Terminology. Has_Pharmaceutical_Transformation Has_Pharmaceutical_Transformation PT NCI Transformation PT EDQM-HC An association that specifies the procedures that are carried out in order to convert a manufactured item that requires such a procedure into a pharmaceutical product. The target value should belong to the EDQM-HC Transformation Terminology. NCI A23 Conceptual Entity Has_PCDC_Data_Type Has_PCDC_Data_Type An association that specifies one of three data types for a particular variable, String, Code or Number. Has_PCDC_Data_Type Has_PCDC_Data_Type PT NCI An association that specifies one of three data types for a particular variable, String, Code or Number. NCI A24 Conceptual Entity Is_PCDC_AML_Permissible_Value_For_Variable Is_PCDC_AML_Permissible_Value_For_Variable An association that indicates a PCDC AML concept is a Permissible Value for a PCDC AML Variable concept. Is_PCDC_AML_Permissible_Value_For_Variable Is_PCDC_AML_Permissible_Value_For_Variable PT NCI An association that indicates a PCDC AML concept is a Permissible Value for a PCDC AML Variable concept. NCI A25 Conceptual Entity Value_Set_Is_Paired_With Value_Set_Is_Paired_With An association that specifies the paired ‘Test or Parameter Name’ codelist that goes with the ‘Test or Parameter Code’ codelist. This association uni-directionally points from a Test/Parameter Code Codelist to the Test/Parameter Name Codelist. Value_Set_Is_Paired_With Value_Set_Is_Paired_With PT NCI An association that specifies the paired ‘Test or Parameter Name’ codelist that goes with the ‘Test or Parameter Code’ codelist. This association uni-directionally points from a Test/Parameter Code Codelist to the Test/Parameter Name Codelist. NCI A26 Conceptual Entity Has_PCDC_AML_Permissible_Value Has_PCDC_AML_Permissible_Value An association that indicates a concept contains a dedicated permissible value concept. Has_PCDC_AML_Permissible_Value Has_PCDC_AML_Permissible_Value PT NCI An association that indicates a concept contains a dedicated permissible value concept. NCI A27 Conceptual Entity Has_CTDC_Value Has_CTDC_Value An association connecting a CTDC Property concept to its dedicated permissible value concept(s). Has_CTDC_Value Has_CTDC_Value PT NCI An association connecting a CTDC Property concept to its dedicated permissible value concept(s). NCI A28 Conceptual Entity Is_PCDC_EWS_Permissible_Value_For_Variable Is_PCDC_EWS_Permissible_Value_For_Variable An association that indicates a PCDC EWS concept is a Permissible Value for a specific PCDC EWS Variable concept. Is_PCDC_EWS_Permissible_Value_For_Variable Is_PCDC_EWS_Permissible_Value_For_Variable PT NCI An association that indicates a PCDC EWS concept is a Permissible Value for a specific PCDC EWS Variable concept. NCI A29 Conceptual Entity Has_PCDC_EWS_Permissible_Value Has_PCDC_EWS_Permissible_Value An association that shows which Permissible Values are possible for a specific PCDC EWS Variable concept. Has_PCDC_EWS_Permissible_Value Has_PCDC_EWS_Permissible_Value PT NCI An association that shows which Permissible Values are possible for a specific PCDC EWS Variable concept. NCI A3 Conceptual Entity Role Has Parent Role_Has_Parent Role_Has_Parent An association that specifies that a role exists as part of a role hierarchy and specifies the role's parent, the role that this role specializes. Role_Has_Parent Role_Has_Parent PT NCI An association that specifies that a role exists as part of a role hierarchy and specifies the role's parent, the role that this role specializes. NCI A30 Conceptual Entity Has_ICDC_Value Has_ICDC_Value An association connecting an ICDC Property concept to its dedicated permissible value concept(s). Has_ICDC_Value Has_ICDC_Value PT NCI An association connecting an ICDC Property concept to its dedicated permissible value concept(s). NCI A31 Conceptual Entity Has_GDC_Value Has_GDC_Value An association that connects a concept representing a GDC property to its dedicated permissible value concept(s). Has_GDC_Value Has_GDC_Value PT NCI An association that connects a concept representing a GDC property to its dedicated permissible value concept(s). NCI A32 Conceptual Entity Is_Value_For_GDC_Property Is_Value_For_GDC_Property An association that that connects a concept representing a GDC value to any associated GDC property concept(s). Is_Value_For_GDC_Property Is_Value_For_GDC_Property PT NCI An association that that connects a concept representing a GDC value to any associated GDC property concept(s). NCI A33 Conceptual Entity Is_PCDC_GCT_Permissible_Value_For_Variable Is_PCDC_GCT_Permissible_Value_For_Variable An association that indicates a concept is a dedicated Permissible Value concept for a specific PCDC GCT Variable. Is_PCDC_GCT_Permissible_Value_For_Variable Is_PCDC_GCT_Permissible_Value_For_Variable PT NCI An association that indicates a concept is a dedicated Permissible Value concept for a specific PCDC GCT Variable. NCI A34 Conceptual Entity Has_PCDC_GCT_Permissible_Value Has_PCDC_GCT_Permissible_Value An association that shows which Permissible Values are possible for a specific PCDC GCT Variable. Has_PCDC_GCT_Permissible_Value Has_PCDC_GCT_Permissible_Value PT NCI An association that shows which Permissible Values are possible for a specific PCDC GCT Variable. NCI A35 Conceptual Entity Is_PCDC_ALL_Permissible_Value_For_Variable Is_PCDC_ALL_Permissible_Value_For_Variable An association that indicates a concept contains dedicated permissible value concept for a specific PCDC ALL Variable. Is_PCDC_ALL_Permissible_Value_For_Variable Is_PCDC_ALL_Permissible_Value_For_Variable PT NCI An association that indicates a concept contains dedicated permissible value concept for a specific PCDC ALL Variable. NCI A36 Conceptual Entity Has_PCDC_ALL_Permissible_Value Has_PCDC_ALL_Permissible_Value An association that shows which PCDC ALL Permissible Values are possible for a specific Variable. Has_PCDC_ALL_Permissible_Value Has_PCDC_ALL_Permissible_Value PT NCI An association that shows which PCDC ALL Permissible Values are possible for a specific Variable. NCI A37 Conceptual Entity Has_SeroNet_Permissible_Value Has_SeroNet_Permissible_Value An association that shows which Permissible Values are possible for a specific SeroNet Variable. Has_SeroNet_Permissible_Value Has_SeroNet_Permissible_Value PT NCI An association that shows which Permissible Values are possible for a specific SeroNet Variable. NCI A38 Conceptual Entity Has_PCDC_OS_Permissible_Value Has_PCDC_OS_Permissible_Value An association that shows which Permissible Values are possible for a specific PCDC OS Variable. Has_PCDC_OS_Permissible_Value Has_PCDC_OS_Permissible_Value PT NCI An association that shows which Permissible Values are possible for a specific PCDC OS Variable. NCI A39 Conceptual Entity Has_PCDC_HL_Permissible_Value Has_PCDC_HL_Permissible_Value An association that shows which Permissible Values are possible for a specific PCDC HL Variable. Has_PCDC_HL_Permissible_Value Has_PCDC_HL_Permissible_Value PT NCI An association that shows which Permissible Values are possible for a specific PCDC HL Variable. NCI A4 Conceptual Entity Qualifier Applies To Qualifier_Applies_To Qualifier_Applies_To An association that indicates the property or association that the qualifier is to be used with. Qualifier_Applies_To Qualifier_Applies_To PT NCI An association that indicates the property or association that the qualifier is to be used with. NCI A40 Conceptual Entity Has_DIPG_DMG_Permissible_Value Has_DIPG_DMG_Permissible_Value An association that shows which Permissible Values are possible for a specific DIPG/DMG Variable. Has_DIPG_DMG_Permissible_Value Has_DIPG_DMG_Permissible_Value PT NCI An association that shows which Permissible Values are possible for a specific DIPG/DMG Variable. NCI A5 Conceptual Entity Has Salt Form Has_Salt_Form Has_Salt_Form An association that connects the salt form of a drug with its free acid or free base. USAGE NOTE: A salt form of a drug consists of 2 parts, one acidic and one basic group that are readily disassociated in liquid phase. Salt forms are either salts of strong acids and basic drugs (e.g. Atropine Sulfate, Cetirizine Hydrochloride) or salts of strong bases and acidic drugs (Allopurinol Sodium). This association is usually used in conjunction with Has_Free_Acid_Or_Base_Form. Has_Salt_Form Has_Salt_Form PT NCI An association that connects the salt form of a drug with its free acid or free base. NCI A6 Conceptual Entity Has Free Acid Or Base Form Has_Free_Acid_Or_Base_Form Has_Free_Acid_Or_Base_Form An association that connects the salt form of a drug with its free acid or free base. The free acid or base is responsible for the drug's therapeutic effect. Hence, the salt form of a drug has the same mechanism of action as the free acid or base form. Has_Free_Acid_Or_Base_Form Has_Free_Acid_Or_Base_Form PT NCI An association that connects the salt form of a drug with its free acid or free base. NCI A7 Conceptual Entity Has Target Has_Target Has_Target An association that connects a drug or other agent to a clinically intended, molecular-scale target. The target value may be a gene, gene product, anatomic structure, cell, biological process, or other concept, where the effect of the agent on the target is thought to be of therapeutic, diagnostic, or other clinical relevance to a disease process. The effect is most often direct, as defined at a molecular scale, but may also be indirect and/or defined at a larger scale. Has_Target Has_Target PT NCI An association that connects a drug or other agent to a clinically intended, molecular-scale target. The target value may be a gene, gene product, anatomic structure, cell, biological process, or other concept, where the effect of the agent on the target is thought to be of therapeutic, diagnostic, or other clinical relevance to a disease process. The effect is most often direct, as defined at a molecular scale, but may also be indirect and/or defined at a larger scale. NCI A8 Conceptual Entity Concept Is In Subset Concept_In_Subset Concept_In_Subset An association that connects the concept defining a particular terminology subset with concepts that belong to this subset. Concept_In_Subset Concept_In_Subset PT NCI An association that connects the concept defining a particular terminology subset with concepts that belong to this subset. NCI A9 Conceptual Entity Is Related To Endogenous Product Is_Related_To_Endogenous_Product Is_Related_To_Endogenous_Product An association that is asserted when there is a relationship or association between the therapeutic moiety and the endogenous gene product. Is_Related_To_Endogenous_Product Is_Related_To_Endogenous_Product PT NCI An association that is asserted when there is a relationship or association between the therapeutic moiety and the endogenous gene product. NCI NHC0 Conceptual Entity code code A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Thesaurus. true code code PT NCI A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Thesaurus. NCI P100 Conceptual Entity OMIM Number OMIM_Number OMIM_Number A property representing the accession number for a Protein or Gene within the OMIM database. OMIM_Number OMIM_Number PT NCI A property representing the accession number for a Protein or Gene within the OMIM database. NCI P101 Conceptual Entity Homologous Gene Homologous_Gene Homologous_Gene A property representing genes from other organisms that are similar in sequence and provide insight to the gene's function. Homologous_Gene Homologous_Gene PT NCI A property representing genes from other organisms that are similar in sequence and provide insight to the gene's function. NCI P102 Conceptual Entity GenBank Accession Number GenBank_Accession_Number GenBank_Accession_Number A property representing the accession number for a Gene within the GenBank database. GenBank_Accession_Number GenBank_Accession_Number PT NCI A property representing the accession number for a Gene within the GenBank database. NCI P106 Conceptual Entity Semantic Type Semantic_Type Semantic_Type A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network. In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned. We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS. Semantic_Type Semantic_Type PT NCI A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network. NCI P107 Conceptual Entity Display Name Display_Name Display Name Display_Name A property representing an alternative Preferred Name for use in some NCI systems. Display_Name Display Name SY NCI Display_Name PT NCI A property representing an alternative Preferred Name for use in some NCI systems. NCI P108 Conceptual Entity Preferred Name Preferred_Name Preferred Name Preferred Term Preferred_Name A property representing the word or phrase that NCI uses by preference to refer to the concept. Preferred_Name Preferred Name SY NCI Preferred Term SY NCI Preferred_Name PT NCI A property representing the word or phrase that NCI uses by preference to refer to the concept. NCI P167 Conceptual Entity Image Link Image_Link Image_Link A property representing a link to an image in an external database. Image_Link Image_Link PT NCI A property representing a link to an image in an external database. NCI P171 Conceptual Entity PubMedID Primary Reference PubMedID_Primary_Reference PubMedID_Primary_Reference A property used to provide a primary reference for descriptions of an NCI Thesaurus concept. PubMedID_Primary_Reference PubMedID_Primary_Reference PT NCI A property used to provide a primary reference for descriptions of an NCI Thesaurus concept. NCI P175 Conceptual Entity NSC Number NSC Number NSC Number NSC_Code NSC_Number NSC_Number_Property A property representing a numeric identifier for substances submitted to the National Cancer Institute (NCI) for testing and evaluation. It is named after the Cancer Chemotherapy National Service Center (CCNSC), created in 1955, which originally ran the testing program and assigned these numbers. The testing program and repository is now run by the NCI Developmental Therapeutics Program (DTP). Assignment of NSC numbers was never done in a way that would guarantee one and only one NSC number would be assigned to a particular substance. NSC Number NSC Number PT NCI NSC_Code SY NCI NSC_Number SY NCI NSC_Number_Property SY NCI A property representing a numeric identifier for substances submitted to the National Cancer Institute (NCI) for testing and evaluation. It is named after the Cancer Chemotherapy National Service Center (CCNSC), created in 1955, which originally ran the testing program and assigned these numbers. The testing program and repository is now run by the NCI Developmental Therapeutics Program (DTP). Assignment of NSC numbers was never done in a way that would guarantee one and only one NSC number would be assigned to a particular substance. NCI P200 Conceptual Entity OLD PARENT OLD_PARENT OLD_PARENT A property used to store the name of parent concepts present at the time a concept was retired. OLD_PARENT OLD_PARENT PT NCI A property used to store the name of parent concepts present at the time a concept was retired. NCI P201 Conceptual Entity OLD CHILD OLD_CHILD OLD_CHILD A property used to store the name of children concepts present at the time a concept was retired. OLD_CHILD OLD_CHILD PT NCI A property used to store the name of children concepts present at the time a concept was retired. NCI P203 Conceptual Entity OLD KIND OLD_KIND OLD_KIND Used to store the name of the concept's kind at the time a concept was retired. OLD_KIND OLD_KIND PT NCI Used to store the name of the concept's kind at the time a concept was retired. NCI P204 Conceptual Entity OLD ROLE OLD_ROLE OLD_ROLE A property used to store the name and value of asserted roles present at the time a concept was retired. OLD_ROLE OLD_ROLE PT NCI A property used to store the name and value of asserted roles present at the time a concept was retired. NCI P205 Conceptual Entity OLD STATE OLD_STATE OLD_STATE A property used to store the state of a concept, primitive or defined, at the time a concept was retired. OLD_STATE OLD_STATE PT NCI A property used to store the state of a concept, primitive or defined, at the time a concept was retired. NCI P207 Conceptual Entity UMLS CUI UMLS_CUI UMLS_CUI A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept. UMLS_CUI UMLS_CUI PT NCI A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept. NCI P208 Conceptual Entity NCI Metathesaurus CUI NCI_META_CUI NCI_META_CUI A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS). NCI_META_CUI NCI_META_CUI PT NCI A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS). NCI P210 Conceptual Entity CAS Registry Number CAS_Registry CAS_Registry A property representing the Chemical Abstracts Service number for a Chemical or Drug. CAS_Registry CAS_Registry PT NCI A property representing the Chemical Abstracts Service number for a Chemical or Drug. NCI P211 Conceptual Entity GO Annotation GO_Annotation GO_Annotation A property that contains information that can be used for cross-referencing to relevant entries in the Gene Ontology (GO) database including term name, code, and evidence code. GO_Annotation GO_Annotation PT NCI A property that contains information that can be used for cross-referencing to relevant entries in the Gene Ontology (GO) database including term name, code, and evidence code. NCI P215 Conceptual Entity KEGG ID KEGG_ID KEGG_ID A property representing the KEGG ID code for a pathway. It can be used to link a KEGG pathway reference to the primary pathway information. KEGG_ID KEGG_ID PT NCI A property representing the KEGG ID code for a pathway. It can be used to link a KEGG pathway reference to the primary pathway information. NCI P216 Conceptual Entity BioCarta ID BioCarta_ID BioCarta_ID A property representing the BioCarta ID code for a pathway. It can be used to link a BioCarta pathway reference to the primary pathway information. BioCarta_ID BioCarta_ID PT NCI A property representing the BioCarta ID code for a pathway. It can be used to link a BioCarta pathway reference to the primary pathway information. NCI P302 Conceptual Entity Accepted Therapeutic Use For Accepted_Therapeutic_Use_For Accepted_Therapeutic_Use_For A property representing a disease or condition for which this drug is an accepted treatment. Used in the Drug, Food, Chemical or Biomedical Material branch. Accepted_Therapeutic_Use_For Accepted_Therapeutic_Use_For PT NCI A property representing a disease or condition for which this drug is an accepted treatment. Used in the Drug, Food, Chemical or Biomedical Material branch. NCI P310 Conceptual Entity Concept Status Concept_Status Concept_Status A property used to indicate the standing of a concept in relation to currently accepted classifications and concepts. In NCI Thesaurus concept status subtype indicates concepts with unusual and problematic characteristics that should be evaluated by people and/or programs before those concept are used. Concept_Status Concept_Status PT NCI A property used to indicate the standing of a concept in relation to currently accepted classifications and concepts. In NCI Thesaurus concept status subtype indicates concepts with unusual and problematic characteristics that should be evaluated by people and/or programs before those concept are used. NCI P315 Conceptual Entity SNP ID SNP_ID SNP_ID A property representing the dbSNP id number for the genetic polymorphism due to base substitutions. SNP_ID SNP_ID PT NCI A property representing the dbSNP id number for the genetic polymorphism due to base substitutions. NCI P316 Conceptual Entity Relative Enzyme Activity Relative_Enzyme_Activity Relative_Enzyme_Activity A property representing drug efficacy of the allelic product. Relative_Enzyme_Activity Relative_Enzyme_Activity PT NCI A property representing drug efficacy of the allelic product. NCI P317 Conceptual Entity FDA Table FDA_Table FDA_Table A property used to flag terms that are part of an FDA data standard manual, including Route of Administration, Dosage Form, Package Type and Potency. FDA_Table FDA_Table PT NCI A property used to flag terms that are part of an FDA data standard manual, including Route of Administration, Dosage Form, Package Type and Potency. NCI P319 Conceptual Entity FDA UNII Code FDA_UNII_Code FDA_UNII_Code A property representing the FDA Unique Ingredient Identifier, a key component of the federal drug information model. FDA_UNII_Code FDA_UNII_Code PT NCI A property representing the FDA Unique Ingredient Identifier, a key component of the federal drug information model. NCI P320 Conceptual Entity OID OID OID A property representing a globally unique identifier standardized by the International Organization for Standardization (ISO) for naming computational objects consistently and unambiguously. Object identifiers (OID) are assigned by a regulatory association. The NCI Thesaurus OID was asssigned by and is registered with the HL7 OID Registry and is the following string: 2.16.840.1.113883.3.26.1.1. OID OID PT NCI A property representing a globally unique identifier standardized by the International Organization for Standardization (ISO) for naming computational objects consistently and unambiguously. Object identifiers (OID) are assigned by a regulatory association. The NCI Thesaurus OID was asssigned by and is registered with the HL7 OID Registry and is the following string: 2.16.840.1.113883.3.26.1.1. NCI P321 Conceptual Entity EntrezGene ID EntrezGene_ID EntrezGene_ID GeneID Locus_ID A property representing the accession number for a Gene within the Entrez Gene database. This property has replaced Locus_ID. EntrezGene_ID EntrezGene_ID PT NCI GeneID SY NCI Locus_ID SY NCI A property representing the accession number for a Gene within the Entrez Gene database. NCI P322 Conceptual Entity Contributing Source Contributing_Source Contributing_Source A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake. Contributing_Source Contributing_Source PT NCI A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake. NCI P325 Conceptual Entity [source] Definition ALT_DEFINITION ALT_DEFINITION A property representing the English language definition of a concept from a source other than NCI. ALT_DEFINITION ALT_DEFINITION PT NCI A property representing the English language definition of a concept from a source other than NCI. NCI P329 Conceptual Entity PDQ Open Trial Search ID PDQ_Open_Trial_Search_ID PDQ_Open_Trial_Search_ID A property representing the identifier used by NCI's Cancer.gov Web site to retrieve PDQ Clinical Trials data for open trials involving specific clinical trials agents. While the identifier is the same for both open and closed trials two properties are used to support requirements of the current browser interface, as well as the possibility of providing values where only open trials will be retrieved. PDQ_Open_Trial_Search_ID PDQ_Open_Trial_Search_ID PT NCI A property representing the identifier used by NCI's Cancer.gov Web site to retrieve PDQ Clinical Trials data for open trials involving specific clinical trials agents. While the identifier is the same for both open and closed trials two properties are used to support requirements of the current browser interface, as well as the possibility of providing values where only open trials will be retrieved. NCI P330 Conceptual Entity PDQ Closed Trial Search ID PDQ_Closed_Trial_Search_ID PDQ_Closed_Trial_Search_ID A property representing the identifier used by NCI's Cancer.gov web site to retrieve PDQ Clinical Trials data for closed trials that involved specific clinical trials agents. While the identifier is the same for both open and closed trials two properties are used to support requirements of the current browser interface, as well as the possibility of providing values where only closed trials will be retrieved. PDQ_Closed_Trial_Search_ID PDQ_Closed_Trial_Search_ID PT NCI A property representing the identifier used by NCI's Cancer.gov web site to retrieve PDQ Clinical Trials data for closed trials that involved specific clinical trials agents. While the identifier is the same for both open and closed trials two properties are used to support requirements of the current browser interface, as well as the possibility of providing values where only closed trials will be retrieved. NCI P331 Conceptual Entity NCBI Taxon ID NCBI_Taxon_ID NCBI_Taxon_ID A property that is used to establish correspondence between the NCI Thesaurus concept representing a taxon (species) and the NCBI/NLM Species Taxonomy ID assigned by the NCBI to that taxon. NCBI_Taxon_ID NCBI_Taxon_ID PT NCI A property that is used to establish correspondence between the NCI Thesaurus concept representing a taxon (species) and the NCBI/NLM Species Taxonomy ID assigned by the NCBI to that taxon. NCI P332 Conceptual Entity MGI Accession ID MGI_Accession_ID MGI_Accession_ID A property representing the identifier used by Jackson Laboratories Mouse Genome Informatics group to label inbred mouse strains maintained by Jackson Laboratory and other things such as mouse genes and alleles. MGI_Accession_ID MGI_Accession_ID PT NCI A property representing the identifier used by Jackson Laboratories Mouse Genome Informatics group to label inbred mouse strains maintained by Jackson Laboratory and other things such as mouse genes and alleles. NCI P333 Conceptual Entity Use For Use_For Use_For A property representing a term that had been used in a coding system and then subsumed by the given NCIt concept. Use_For Use_For PT NCI A property representing a term that had been used in a coding system and then subsumed by the given NCIt concept. NCI P334 Conceptual Entity ICD-O-3 Code ICD-O-3_Code ICD-O-3_Code A property representing the matching ICD-O-3 code for the NCI Thesaurus concept. ICD-O-3_Code ICD-O-3_Code PT NCI A property representing the matching ICD-O-3 code for the NCI Thesaurus concept. NCI P350 Conceptual Entity Chemical Formula Chemical_Formula CRCH Chemical Formula Chemical_Formula A property representing a concise expression about the atoms that constitute a particular chemical compound. Chemical_Formula Chemical Formula PT CRCH Chemical_Formula PT NCI A property representing a concise expression about the atoms that constitute a particular chemical compound. NCI P351 Conceptual Entity US FNB Recommends Intake US_Recommended_Intake CRCH A property indicating that the Food and Nutrition Board of the National Academy of Science has established an average daily intake for this nutrient that is sufficient to meet the nutritional requirements of most individuals in the general U.S. population. Recommended Intake Required_Intake US_Recommended_Intake US_Recommended_Intake A property indicating that the Food and Nutrition Board of the National Academy of Science has established an average daily intake for this nutrient that is sufficient to meet the nutritional requirements of most individuals in the general U.S. population. CRCH Recommended Intake PT CRCH Required_Intake SY NCI US_Recommended_Intake PT NCI P352 Conceptual Entity Tolerable Level Tolerable_Level CRCH A property indicating that the Food and Nutrition Board of the National Academy of Science has established a highest level of daily intake for this food component that is likely to pose no risk of adverse health effects for almost all individuals in the general U.S. population. Tolerable Level Tolerable_Level Tolerable_Level A property indicating that the Food and Nutrition Board of the National Academy of Science has established a highest level of daily intake for this food component that is likely to pose no risk of adverse health effects for almost all individuals in the general U.S. population. CRCH Tolerable Level PT CRCH Tolerable_Level PT NCI P353 Conceptual Entity INFOODS Tag Name INFOODS CRCH INFOODS A property representing uppercase abbreviations assigned by the International Network of Food Data Systems. INFOODS INFOODS PT CRCH INFOODS PT NCI A property representing uppercase abbreviations assigned by the International Network of Food Data Systems. NCI P354 Conceptual Entity USDA ID USDA_ID CRCH USDA ID USDA_ID A property representing a numeric ID assignment by United States Department of Agriculture. USDA_ID USDA ID PT CRCH USDA_ID PT NCI A property representing a numeric ID assignment by United States Department of Agriculture. NCI P355 Conceptual Entity Unit Used Unit CRCH Unit A property representing the unit of measure in which a nutrient or food component is typically expressed, ex., gram (g), minigram (mg), microgram (mcg), joule, or kilojoule. Unit Unit PT CRCH Unit PT NCI A property representing the unit of measure in which a nutrient or food component is typically expressed, ex., gram (g), minigram (mg), microgram (mcg), joule, or kilojoule. NCI P356 Conceptual Entity Is An Essential Amino Acid Essential_Amino_Acid Essential_Amino_Acid A property used to indicate that an amino acid is essential and must be included in the diet. Essential_Amino_Acid Essential_Amino_Acid PT NCI A property used to indicate that an amino acid is essential and must be included in the diet. NCI P357 Conceptual Entity Is An Essential Fatty Acid Essential_Fatty_Acid CRCH Essential Fatty Acid Essential_Fatty_Acid A property used to indicate a fatty acid that is not efficiently synthesized by humans and must be included in the diet. Essential_Fatty_Acid Essential Fatty Acid PT CRCH Essential_Fatty_Acid PT NCI A property used to indicate a fatty acid that is not efficiently synthesized by humans and must be included in the diet. NCI P358 Conceptual Entity Is A Nutrient Nutrient CRCH A property indicating that a food component must be taken into the body preformed and in sufficient quantity to meet the body's needs for growth, reproduction and/or maintenance of health. Nutrient Nutrient A property indicating that a food component must be taken into the body preformed and in sufficient quantity to meet the body's needs for growth, reproduction and/or maintenance of health. CRCH Nutrient PT CRCH Nutrient PT NCI P359 Conceptual Entity Is A Micronutrient Micronutrient CRCH A property indicating a class of food components required for proper health and that are typically consumed in microgram or milligram amounts. mg Micronutrient Micronutrient A property indicating a class of food components required for proper health and that are typically consumed in microgram or milligram amounts. CRCH Micronutrient PT CRCH Micronutrient PT NCI P360 Conceptual Entity Macronutrient Macronutrient CRCH A property indicating a class of food components that contribute energy to the diet and that are typically consumed in multi-gram amounts. g Macronutrient Macronutrient A property indicating a class of food components that contribute energy to the diet and that are typically consumed in multi-gram amounts. CRCH Macronutrient PT CRCH Macronutrient PT NCI P361 Conceptual Entity Extensible_List Extensible_List List Extensible A property representing the ability to extend the set of values in a particular list. Extensible_List Extensible_List PT NCI List Extensible SY NCI A property representing the ability to extend the set of values in a particular list. NCI P362 Conceptual Entity miRBase_ID miRBase_ID A property representing the accession number for an miRNA within the Sanger miRBase database. miRBase_ID miRBase_ID PT NCI A property representing the accession number for an miRNA within the Sanger miRBase database. NCI P363 Conceptual Entity Neoplastic Status Neoplastic_Status FDA Neoplastic_Status A property representing the morphologic, clinical, and genetic profile of a neoplastic growth that defines it as benign, malignant, or of uncertain cancerous potential. Neoplastic_Status Neoplastic_Status PT NCI A property representing the morphologic, clinical, and genetic profile of a neoplastic growth that defines it as benign, malignant, or of uncertain cancerous potential. NCI P364 Conceptual Entity OLD_ASSOCIATION OLD_ASSOCIATION A property used to store the name and value of associations present at the time a concept was retired. OLD_ASSOCIATION OLD_ASSOCIATION PT NCI A property used to store the name and value of associations present at the time a concept was retired. NCI P365 OLD_SOURCE_ASSOCIATION OLD_SOURCE_ASSOCIATION A property used to temporarily store the name and value of associations present at the time a concept is premerged or preretired, where the target of the association is the concept being retired. Values stored in this property are restored as associations on the source concept if the merge or retire is rejected. OLD_SOURCE_ASSOCIATION OLD_SOURCE_ASSOCIATION PT NCI A property used to temporarily store the name and value of associations present at the time a concept is premerged or preretired, where the target of the association is the concept being retired. Values stored in this property are restored as associations on the source concept if the merge or retire is rejected. NCI P366 Conceptual Entity Legacy Concept Name Legacy Concept Name Legacy_Concept_Name A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding. true Legacy Concept Name Legacy Concept Name PT NCI Legacy_Concept_Name SY NCI A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding. NCI P367 Conceptual Entity PID_ID PID_ID A property representing the NCI/Nature Pathway Interaction Database (PID) code for a pathway. It can be used by the NCIt Browser to link a pathway concept to the source pathway information. PID_ID PID_ID PT NCI A property representing the NCI/Nature Pathway Interaction Database (PID) code for a pathway. It can be used by the NCIt Browser to link a pathway concept to the source pathway information. NCI P368 Conceptual Entity CHEBI_ID CHEBI_ID A property representing that a concept in the 'Drug, Food, Chemical or Biomedical Material' branch of the NCI thesaurus maps to a specific concept in the EBI Chemical Entities of Biological Interest (CHEBI) database. CHEBI_ID CHEBI_ID PT NCI A property representing that a concept in the 'Drug, Food, Chemical or Biomedical Material' branch of the NCI thesaurus maps to a specific concept in the EBI Chemical Entities of Biological Interest (CHEBI) database. NCI P369 Conceptual Entity HGNC_ID HGNC_ID HUGO_ID A property representing that a concept in the 'Gene' branch of the NCI thesaurus maps to a HUGO Gene Nomenclature Committee (HGNC) certified gene. HGNC_ID HGNC_ID PT NCI HUGO_ID SY NCI A property representing that a concept in the 'Gene' branch of the NCI thesaurus maps to a HUGO Gene Nomenclature Committee (HGNC) certified gene. NCI P371 Conceptual Entity NICHD_Hierarchy_Term NICHD NICHD_Hierarchy_Term A property representing a term chosen by NICHD to be used in the representation of the NICHD hierarchy. NICHD_Hierarchy_Term NICHD_Hierarchy_Term PT NCI A property representing a term chosen by NICHD to be used in the representation of the NICHD hierarchy. NCI P372 Conceptual Entity Publish_Value_Set Publish_Value_Set A property representing whether a value set is ready for publication in the browser. Publish_Value_Set Publish_Value_Set PT NCI A property representing whether a value set is ready for publication in the browser. NCI P375 Conceptual Entity Maps_To Maps_To A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms. Maps_To Maps_To PT NCI A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms. NCI P376 Conceptual Entity Term_Browser_Value_Set_Description Term_Browser_Value_Set_Description A property used to house the text on the introductory page on the NCI Term Browser for the Value Set named by a concept when that text differs from the DEFINITION for that concept. Term_Browser_Value_Set_Description Term_Browser_Value_Set_Description PT NCI A property used to house the text on the introductory page on the NCI Term Browser for the Value Set named by a concept when that text differs from the DEFINITION for that concept. NCI P377 def-definition def-definition P378 Conceptual Entity Definition Source Definition Source A property representing the organization that is the supplier or owner of each DEFINITION or ALT_DEFINITION associated with a concept. true Definition Source Definition Source PT NCI A property representing the organization that is the supplier or owner of each DEFINITION or ALT_DEFINITION associated with a concept. NCI P379 Definition_Reviewer_Name true Definition_Reviewer_Name P380 Definition_Review_Date true Definition_Review_Date P381 Conceptual Entity attribution attribution A property indicating that some of the information in a DEFINITION or ALT_DEFINITION was derived from a source other than the def-source. attribution attribution PT NCI A property indicating that some of the information in a DEFINITION or ALT_DEFINITION was derived from a source other than the def-source. NCI P382 term-name term-name P383 Conceptual Entity term-group A property representing a two or three character abbreviation that indicates the nature of each FULL_SYN term associated with a concept. (e.g., PT=Preferred Term; SY=Synonym) true Term Type P384 Conceptual Entity term-source NCI A property representing the organization that is the supplier or owner of each FULL_SYN term. true Term Source P385 Conceptual Entity Source Code Source Code source-code A property representing an identifier associated with a FULL_SYN term that is supplied by the term-source. Source Code Source Code PT NCI source-code SY NCI A property representing an identifier associated with a FULL_SYN term that is supplied by the term-source. NCI P386 Conceptual Entity Subsource Name Subsource Name subsource-name A property indicating that a subgroup within the term-source is the supplier or owner of a FULL_SYN term. Subsource Name Subsource Name PT NCI subsource-name SY NCI A property indicating that a subgroup within the term-source is the supplier or owner of a FULL_SYN term. NCI P387 go-id A property representing a unique zero-padded seven digit identifier supplied by the Gene Ontology (GO) that has no inherent meaning or relation to the position of the term in GO and is prefixed by "GO:". true go-id A property representing a unique zero-padded seven digit identifier supplied by the Gene Ontology (GO) that has no inherent meaning or relation to the position of the term in GO and is prefixed by "GO:". NCI http://www.geneontology.org/page/ontology-structure P388 go-term go-term P389 go-evi A property representing a three letter code that indicates the type of supporting evidence for each GO_Annotation associated with a concept. true go-evi A property representing a three letter code that indicates the type of supporting evidence for each GO_Annotation associated with a concept. NCI http://www.geneontology.org/page/guide-go-evidence-codes P390 go-source A property representing the organization that is the supplier or owner of each GO_Annotation associated with a concept. true go-source A property representing the organization that is the supplier or owner of each GO_Annotation associated with a concept. NCI P391 source-date A property representing the date each GO_Annotation was added to a concept. true source-date A property representing the date each GO_Annotation was added to a concept. NCI P392 Target_Term A property representing the term in an outside source that has been mapped to a term within the NCI Thesaurus. Target_Term A property representing the term in an outside source that has been mapped to a term within the NCI Thesaurus. NCI P393 Conceptual Entity Relationship_to_Target A property representing the relationship of the NCI Thesaurus (NCIt) concept to the term from the outside source. There are four possibilities: 1) Has Synonym: the two terms are synonymous; 2) Broader Than: the NCIt concept is broader than the mapped (target) term; 3) Narrower Than: the NCIt concept is narrower than the mapped (target) term; 4) Related To: the NCIt concept is somehow related to the mapped (target) term. true Relationship_to_Target A property representing the relationship of the NCI Thesaurus (NCIt) concept to the term from the outside source. There are four possibilities: 1) Has Synonym: the two terms are synonymous; 2) Broader Than: the NCIt concept is broader than the mapped (target) term; 3) Narrower Than: the NCIt concept is narrower than the mapped (target) term; 4) Related To: the NCIt concept is somehow related to the mapped (target) term. NCI P394 Conceptual Entity Target_Term_Type A property representing the term type designation in the mapped (target) database. true Target_Term_Type A property representing the term type designation in the mapped (target) database. NCI P395 Conceptual Entity Target_Code NCI A property representing the code assigned to the target term in the mapped (target) database. Some databases may not have codes. true Target_Code A property representing the code assigned to the target term in the mapped (target) database. Some databases may not have codes. NCI P396 Conceptual Entity Target_Terminology A property representing the name of the terminology to which the NCI Thesaurus term is being mapped. true Target_Terminology A property representing the name of the terminology to which the NCI Thesaurus term is being mapped. NCI P397 Conceptual Entity Target_Terminology_Version Target_Terminology_Version A property representing the version of the terminology to which the NCI Thesaurus term is being mapped. Target_Terminology_Version Target_Terminology_Version PT NCI A property representing the version of the terminology to which the NCI Thesaurus term is being mapped. NCI P398 Conceptual Entity Value_Set_Pair CDISC Value_Set_Pair A property that indicates whether or not a value set is part of a paired set of codelists for publication processing purposes. Value_Set_Pair Value_Set_Pair PT NCI A property that indicates whether or not a value set is part of a paired set of codelists for publication processing purposes. NCI P399 Conceptual Entity NCI_Drug_Dictionary_ID NCI_Drug_Dictionary_ID A property representing the numerical CDR ID, which is the NCI Drug Dictionary identifier for a chemical or pharmaceutical agent. NCI_Drug_Dictionary_ID NCI_Drug_Dictionary_ID PT NCI A property representing the numerical CDR ID, which is the NCI Drug Dictionary identifier for a chemical or pharmaceutical agent. NCI P400 Conceptual Entity ClinVar_Variation_ID ClinVar_Variation_ID A property representing the numerical Variation ID assigned to a molecular abnormality entry by ClinVar. ClinVar_Variation_ID ClinVar_Variation_ID PT NCI A property representing the numerical Variation ID assigned to a molecular abnormality entry by ClinVar. NCI P90 Conceptual Entity Term & Source Data FULL_SYN FULL_SYN Synonym with Source Data A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software. FULL_SYN FULL_SYN PT NCI Synonym with Source Data SY NCI A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software. NCI P92 Conceptual Entity Subsource Subsource Subsource A property used by MMHCC to identify the source of various mouse disease concepts. Subsource Subsource PT NCI A property used by MMHCC to identify the source of various mouse disease concepts. NCI P93 Conceptual Entity Swiss Prot Swiss_Prot Swiss_Prot A property representing the accession number for a protein within the Swiss-Prot database. Swiss_Prot Swiss_Prot PT NCI A property representing the accession number for a protein within the Swiss-Prot database. NCI P96 Conceptual Entity Gene Encodes Product Gene_Encodes_Product Gene_Encodes_Product A property representing the protein or RNA product expressed by a gene. This represents the reciprocal relationship of the role Gene_Product_Encoded_by_Gene Gene_Encodes_Product Gene_Encodes_Product PT NCI A property representing the protein or RNA product expressed by a gene. NCI P97 Conceptual Entity Definition DEFINITION DEFINITION A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software. DEFINITION DEFINITION PT NCI A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software. NCI P98 Conceptual Entity DesignNote DesignNote DesignNote A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept. DesignNote DesignNote PT NCI A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept. NCI Conceptual Entity xRef Source A property representing the name of the organization to which an NCI Thesaurus concept is being linked to by cross reference. xRef Source A property representing the name of the organization to which an NCI Thesaurus concept is being linked to by cross reference. NCI Used to support Merge and Retire DesignNote Used to support Merge and Retire Editor_Note PrefLabel BFO OWL specification label Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. Really of interest to developers only BFO OWL specification label BFO OWL specification label BFO CLIF specification label Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 Person:Alan Ruttenberg Really of interest to developers only BFO CLIF specification label BFO CLIF specification label An annotation property that represents an ID used in the NIH LINCS project. An annotation property that represents an LINCS ID of a cell line. 表示细胞系的LINCS ID的注释属性。 Oliver He, Jiangan Xie Oliver He, Jiangan Xie Oliver He, Jiangan Xie, Jie Zheng Cell line LINCS ID LINCS ID 细胞系LINCS ID 细胞系LINCS ID https://pubchem.ncbi.nlm.nih.gov/help.html An annotation property that represents a PubMed BioAssay Identifier accession number. Oliver He PubChem AID editor preferred label editor preferred label editor preferred term editor preferred term editor preferred term~editor preferred label 编辑首选术语 编辑首选标签 The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) 对于一类或属性的简洁的、有意义的、与人类友好的名称由本体开发商首选。 （美国英语） PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> editor preferred label editor preferred label editor preferred term editor preferred term editor preferred term~editor preferred label editor preferred term~editor preferred label 编辑首选术语 编辑首选术语 编辑首选术语~编辑首选标签 编辑首选标签 编辑首选标签 example example of usage 例子 用法示例 A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold. 短语描述一个类的名字应该如何使用。也可包括其他类型有助于直接理解类的语义的例子，如广为人知的类的原型子类或实例。虽然高水平的术语必不可少，对于低级别术语的示例（例如，Affymetrix HU133阵列）不 PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> IAO:0000112 uberon example_of_usage true example_of_usage example of usage example of usage 用法示例 用法示例 in branch An annotation property indicating which module the terms belong to. This is currently experimental and not implemented yet. GROUP:OBI OBI_0000277 in branch has curation status 有管理状态 PERSON:Alan Ruttenberg PERSON:Bill Bug PERSON:Melanie Courtot OBI_0000281 has curation status has curation status 有管理状态 有管理状态 definition definition textual definition textual definition 定义 A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software. OBI的官方定义，解释类或属性的含义。应该是亚里士多德式的，形式化和规范化的。 可以通过口语定义进行扩充。 The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. 官方的定义，解释类或属性的含义。应该是亚里士多德式的，形式化和规范化的。 可以通过口语定义进行扩充。 2012-04-05: Barry Smith OBI的官方定义解释了一个类或属性的含义：'应该是亚里士多德式的，形式化和规范化的。可以用口语定义'是糟糕的。 您能解决这样的问题吗？ 解释关于类或属性的表达含义的必要和充分条件的陈述。 Alan Ruttenberg 您提出的定义是一个合理的备选，除非它很常见，没有给出必要和充分的条件。大多数情况下它们是必要的，偶尔是必要的，充分的或者仅仅仅充分的。它们通常使用不是自己定义的术语，因此它们实际上不能通过这些标准进行评估。 关于拟议定义的具体内容： 我们没有“含义”，或“表达”或“属性”的定义。对于在预期意义上的“参考”，我认为我们使用术语“指示”。对于'表达'，我认为我们和你的意思是符号，或标识符。对于“含义”，它不同于类和属性。对于类，我们希望文档能够让读者确定一个实体是否是该类的实例。对于属性，让我们的目标读者决定，给定一对潜在的关系，判断关系成立的断言正确与否。 “目标读者”部分表明我们也指定了我们期望的能够理解定义的人，并且概括了人类和计算机读者以包含文本和逻辑定义。 就我个人而言，我更愿意削弱对文档的定义，并指出什么是可取的。 我们还有一个悬而未决的问题，就是如何针对不同的受众定位不同的定义。临床读者阅读chebi需要来自受过化学训练的受众的不同类型的定义文档/定义，同样需要一个适合本体工作者的定义。 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> DEFINITION definition definition textual definition textual definition 定义 定义 文本定义 文本定义 editor note 编者注 An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. 管理者注释用于其编辑器。它可能不包含在本体的出版版本中，所以它应该不包含最终用户了解本体所需的信息。 PERSON:Daniel Schober GROUP:OBI:<http://purl.obfoundry.org/obo/obi> GROUP:OBI:<http://purl.obofoundry.org/obo/obi> IAO:0000116 IAO:0000116 uberon uberon editor_note editor_note 编辑_注释 true editor_note editor_note 编辑_注释 IAO:0000116 IAO:0000116 uberon uberon editor_note editor_note 1 true editor_note editor_note editor note editor note 编者注 编者注 definition editor term editor 术语编辑者 Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people 输入文件中术语编辑者的名称。术语编辑者是有关术语的信息交汇点。术语编辑者可以是，但并不总是，定义的作者，这可能是由几个人完成 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. 20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115. 20110707，MC：术语编辑和定义进行相应的修改。见http://code.google.com/p/information-artifact-ontology/issues/detail?id=115。 PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition editor definition editor term editor term editor 术语编辑者 术语编辑者 alternative label alternative term 替代术语 A label for a class or property that can be used to refer to the class or property instead of the preferred rdfs:label. Alternative labels should be used to indicate community- or context-specific labels, abbreviations, shorthand forms and the like. An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) 一类或属性的替代名称，这意味着与所述首选名称同样的事物（语义上等价） OBO Operations committee PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> Consider re-defing to: An alternative name for a class or property which can mean the same thing as the preferred name (semantically equivalent, narrow, broad or related). alternative label alternative term alternative term 替代术语 替代术语 definition source 定义来源 Formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 正式引用，例如在外部数据库中的标识符，用于表示/定义的属性源（S）。自由文本表示/为定义属性源（S）。实例：在2007年1月31日的作者姓名，URI，MeSH术语C04，PUBMEDID，维基uri PERSON:Daniel Schober Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> 论OBO-讨论邮件-列表，请参阅http://bit.ly/hgm99w definition source definition source 定义来源 定义来源 has obsolescence reason Relates an annotation property to an obsolescence reason. The values of obsolescence reasons come from a list of predefined terms, instances of the class obsolescence reason specification. PERSON:Alan Ruttenberg PERSON:Melanie Courtot has obsolescence reason curator note An administrative note of use for a curator but of no use for a user PERSON:Alan Ruttenberg IAO:0000232 uberon curator_notes 1 true curator_notes curator note curator note curator notes term tracker item the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/ An IRI or similar locator for a request or discussion of an ontology term. Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg IAO:0000233 external uberon term_tracker_item true true term_tracker_item The 'tracker item' can associate a tracker with a specific ontology term. term tracker item term tracker item ontology term requester The name of the person, project, or organization that motivated inclusion of an ontology term by requesting its addition. Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg The 'term requester' can credit the person, organization or project who request the ontology term. ontology term requester is denotator type Relates an class defined in an ontology, to the type of it's denotator relates an class defined in an ontology, to the type of it's denotator In OWL 2 add AnnotationPropertyRange('is denotator type' 'denotator type') In OWL 2 add AnnotationPropertyRange('is denotator type' 'denotator type') Alan Ruttenberg Alan Ruttenberg is denotator type is denotator type imported from 引自 For external terms/classes, the ontology from which the term was imported 外部术语/类，术语引入的本体 PERSON:Alan Ruttenberg PERSON:Melanie Courtot GROUP:OBI:<http://purl.obolibrary.org/obo/obi> imported from imported from 引自 引自 expand expression to ObjectProperty: RO_0002104 Label: has plasma membrane part Annotations: IAO_0000424 "http://purl.obolibrary.org/obo/BFO_0000051 some (http://purl.org/obo/owl/GO#GO_0005886 and http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" A macro expansion tag applied to an object property (or possibly a data property) which can be used by a macro-expansion engine to generate more complex expressions from simpler ones Chris Mungall Chris Mungall expand expression to expand expression to expand assertion to ObjectProperty: RO??? Label: spatially disjoint from Annotations: expand_assertion_to "DisjointClasses: (http://purl.obolibrary.org/obo/BFO_0000051 some ?X) (http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" A macro expansion tag applied to an annotation property which can be expanded into a more detailed axiom. Chris Mungall expand assertion to expand assertion to first order logic expression PERSON:Alan Ruttenberg first order logic expression antisymmetric property part_of antisymmetric property xsd:true Use boolean value xsd:true to indicate that the property is an antisymmetric property use boolean value xsd:true to indicate that the property is an antisymmetric property Alan Ruttenberg antisymmetric property OBO foundry unique label An alternative name for a class or property which is unique across the OBO Foundry. The intended usage of that property is as follow: OBO foundry unique labels are automatically generated based on regular expressions provided by each ontology, so that SO could specify unique label = 'sequence ' + [label], etc. , MA could specify 'mouse + [label]' etc. Upon importing terms, ontology developers can choose to use the 'OBO foundry unique label' for an imported term or not. The same applies to tools . The intended usage of that property is as follow: OBO foundry unique labels are automatically generated based on regular expressions provided by each ontology, so that SO could specify unique label = 'sequence ' + [label], etc. , MA could specify 'mouse + [label]' etc. Upon importing terms, ontology developers can choose to use the 'OBO foundry unique label' for an imported term or not. The same applies to tools . PERSON:Alan Ruttenberg PERSON:Bjoern Peters PERSON:Chris Mungall PERSON:Melanie Courtot GROUP:OBO Foundry <http://obofoundry.org/> OBO foundry unique label has ID digit count Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Relates an ontology used to record id policy to the number of digits in the URI. The URI is: the 'has ID prefix" annotation property value concatenated with an integer in the id range (left padded with "0"s to make this many digits) Relates an ontology used to record id policy to the number of digits in the URI. The URI is: the 'has ID prefix" annotation property value concatenated with an integer in the id range (left padded with "0"s to make this many digits) Person:Alan Ruttenberg Person:Alan Ruttenberg has ID digit count has ID range allocated Datatype: idrange:1 Annotations: 'has ID range allocated to': "Chris Mungall" EquivalentTo: xsd:integer[> 2151 , <= 2300] Datatype: idrange:1 Annotations: 'has ID range allocated to': "Chris Mungall" EquivalentTo: xsd:integer[> 2151 , <= 2300] Relates a datatype that encodes a range of integers to the name of the person or organization who can use those ids constructed in that range to define new terms Relates a datatype that encodes a range of integers to the name of the person or organization who can use those ids constructed in that range to define new terms Person:Alan Ruttenberg Person:Alan Ruttenberg has ID range allocated to has ID policy for Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Relating an ontology used to record id policy to the ontology namespace whose policy it manages Relating an ontology used to record id policy to the ontology namespace whose policy it manages Person:Alan Ruttenberg Person:Alan Ruttenberg has ID policy for has ID policy for has ID prefix Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Relates an ontology used to record id policy to a prefix concatenated with an integer in the id range (left padded with "0"s to make this many digits) to construct an ID for a term being created. Person:Alan Ruttenberg has ID prefix elucidation person:Alan Ruttenberg Person:Barry Smith Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms elucidation elucidation has associated axiom(nl) Person:Alan Ruttenberg Person:Alan Ruttenberg An axiom associated with a term expressed using natural language has associated axiom(nl) has associated axiom(nl) has associated axiom(fol) Person:Alan Ruttenberg Person:Alan Ruttenberg An axiom expressed in first order logic using CLIF syntax has associated axiom(fol) has associated axiom(fol) is allocated id range Add as annotation triples in the granting ontology Relates an ontology IRI to an (inclusive) range of IRIs in an OBO name space. The range is give as, e.g. "IAO_0020000-IAO_0020999" PERSON:Alan Ruttenberg Add as annotation triples in the granting ontology is allocated id range retired from use as of relates a class of CRID to the date after which further instances should not be made, according to the central authority In OWL 2 add AnnotationPropertyRange xsd:dateTimeStamp Alan Ruttenberg retired from use as of has ontology root term Ontology annotation property. Relates an ontology to a term that is a designated root term of the ontology. Display tools like OLS can use terms annotated with this property as the starting point for rendering the ontology class hierarchy. There can be more than one root. Nicolas Matentzoglu IAO:0000700 uberon has_ontology_root_term true has_ontology_root_term has ontology root term has ontology root term preferred_root may be identical to A annotation relationship between two terms in an ontology that may refer to the same (natural) type but where more evidence is required before terms are merged. David Osumi-Sutherland #40 VFB Edges asserting this should be annotated with to record evidence supporting the assertion and its provenance. may be identical to scheduled for obsoletion on or after Used when the class or object is scheduled for obsoletion/deprecation on or after a particular date. Chris Mungall, Jie Zheng https://github.com/geneontology/go-ontology/issues/15532 https://github.com/information-artifact-ontology/ontology-metadata/issues/32 GO ontology IAO:0006012 uberon scheduled_for_obsoletion_on_or_after true scheduled_for_obsoletion_on_or_after scheduled for obsoletion on or after scheduled for obsoletion on or after has axiom id Person:Alan Ruttenberg Person:Alan Ruttenberg A URI that is intended to be unique label for an axiom used for tracking change to the ontology. For an axiom expressed in different languages, each expression is given the same URI has axiom label has axiom label term replaced by IAO_0000125 Add as annotation triples in the granting ontology Use on obsolete terms, relating the term to another term that can be used as a substitute Use on obsolete terms, relating the term to another term that can be used as a substitute Add as annotation triples in the granting ontology Person:Alan Ruttenberg Person:Alan Ruttenberg Person:Alan Ruttenberg Add as annotation triples in the granting ontology term replaced by term replaced by true A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Thesaurus. NHC0 Conceptual Entity code code code A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network. P106 Conceptual Entity Semantic Type Semantic_Type In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned. We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS. Semantic_Type Semantic_Type A property representing an alternative Preferred Name for use in some NCI systems. P107 Conceptual Entity Display Name Display_Name Display Name Display_Name Display_Name A property representing the word or phrase that NCI uses by preference to refer to the concept. P108 Conceptual Entity Preferred Name Preferred_Name Preferred Name Preferred Term Preferred_Name Preferred_Name A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept. P207 Conceptual Entity UMLS CUI UMLS_CUI UMLS_CUI UMLS_CUI A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS). P208 Conceptual Entity NCI Metathesaurus CUI NCI_META_CUI NCI_META_CUI NCI_META_CUI A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake. P322 Conceptual Entity Contributing Source Contributing_Source Contributing_Source Contributing_Source A property representing the English language definition of a concept from a source other than NCI. P325 Conceptual Entity [source] Definition ALT_DEFINITION ALT_DEFINITION ALT_DEFINITION true A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding. P366 Conceptual Entity Legacy Concept Name Legacy Concept Name Legacy_Concept_Name Legacy Concept Name A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms. P375 Conceptual Entity Maps_To Maps_To Maps_To A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept. P98 Conceptual Entity DesignNote DesignNote DesignNote DesignNote YH, JX a chinese translation represents a chinese translation of the existing term. Chinese translation Chinese translation The AE 'cough AE' has the 'label of AE outcome' of 'cough'; 'infection AE' has the 'label of AE outcom' of 'infection'. an annotation property that represents the label of an adverse event Yongqun Oliver He, Jiangan Hardy Xie label of adverse event outcome adverse event outcome adverse event outcome has_MedDRA_id has_MedDRA_id A normal distribution probability density function has a formula of: f(x) = 1/(√(2 π) σ) e^-((x - μ)^2/(2 σ^2)) an annotation property that represents a mathematical formula. Asiyah Yu Lin, Jie Zheng, Yongqun He mathematical formula ISA alternative term An alternative term used by the ISA tools project (http://isa-tools.org). Requested by Alejandra Gonzalez-Beltran https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891&atid=886178 Person: Alejandra Gonzalez-Beltran Person: Philippe Rocca-Serra ISA tools project (http://isa-tools.org) ISA alternative term NIAID GSCID-BRC alternative term An alternative term used by the National Institute of Allergy and Infectious Diseases (NIAID) Genomic Sequencing Centers for Infectious Diseases (GSCID) and Bioinformatics Resource Centers (BRC). PERSON: Chris Stoeckert, Jie Zheng NIAID GSCID-BRC metadata working group NIAID GSCID-BRC alternative term IEDB alternative term An alternative term used by the IEDB. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IEDB alternative term FGED alternative term An alternative term used by the Functional Genomics Data (FGED) Society. PERSON: Chris Stoeckert, Jie Zheng Penn Group FGED alternative term This is an annotation used on an object property to indicate a logical characterstic beyond what is possible in OWL. OBO Operations call logical characteristic of object property 'part disjoint with' 'defined by construct' """ PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX : <http://example.org/ CONSTRUCT { [ a owl:Restriction ; owl:onProperty :part_of ; owl:someValuesFrom ?a ; owl:disjointWith [ a owl:Restriction ; owl:onProperty :part_of ; owl:someValuesFrom ?b ] ] } WHERE { ?a :part_disjoint_with ?b . } Links an annotation property to a SPARQL CONSTRUCT query which is meant to provide semantics for a shortcut relation. defined by construct temporal interpretation An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context. temporal interpretation temporal interpretation https://oborel.github.io/obo-relations/temporal-semantics/ https://code.google.com/p/obo-relations/wiki/ROAndTime https://github.com/oborel/obo-relations/wiki/ROAndTime tooth SubClassOf 'never in taxon' value 'Aves' S never_in_taxon T iff: S SubClassOf in_taxon only not T S never_in_taxon T iff: S SubClassOf in_taxon only not T. x never in taxon T if and only if T is a class, and x does not instantiate the class expression "in taxon some T". Note that this is a shortcut relation, and should be used as a hasValue restriction in OWL. Chris Mungall ?X DisjointWith RO_0002162 some ?Y Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: ?X and (RO_0002162 some ?Y) Class: ?X DisjointWith: RO_0002162 some ?Y PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX never_in_taxon: <http://purl.obolibrary.org/obo/RO_0002161> CONSTRUCT { in_taxon: a owl:ObjectProperty . ?x owl:disjointWith [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . ?x rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom [ a owl:Class ; owl:complementOf ?taxon ] ] . } WHERE { ?x never_in_taxon: ?taxon . } RO:0002161 uberon never_in_taxon true true never_in_taxon never in taxon never_in_taxon S never_in_taxon T iff: S SubClassOf in_taxon only not T PMID:20973947 S never_in_taxon T iff: S SubClassOf in_taxon only not T. PMID:20973947 A is mutually_spatially_disjoint_with B if both A and B are classes, and there exists no p such that p is part_of some A and p is part_of some B. non-overlapping with shares no parts with Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (BFO_0000050 some ?Y) PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX part_of: <http://purl.obolibrary.org/obo/BFO_0000050> PREFIX mutually_spatially_disjoint_with: <http://purl.obolibrary.org/obo/RO_0002171> CONSTRUCT { part_of: a owl:ObjectProperty . [ a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?x ; owl:disjointWith [ a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?y ] ] } WHERE { ?x mutually_spatially_disjoint_with: ?y . } RO:0002171 uberon mutually_spatially_disjoint_with true true mutually_spatially_disjoint_with mutually spatially disjoint with mutually_spatially_disjoint_with https://github.com/obophenotype/uberon/wiki/Part-disjointness-Design-Pattern An assertion that holds between an ontology class and an organism taxon class, which is intepreted to yield some relationship between instances of the ontology class and the taxon. taxonomic class assertion taxonomic class assertion S ambiguous_for_taxon T if the class S does not have a clear referent in taxon T. An example would be the class 'manual digit 1', which encompasses a homology hypotheses that is accepted for some species (e.g. human and mouse), but does not have a clear referent in Aves - the referent is dependent on the hypothesis embraced, and also on the ontogenetic stage. S ambiguous_for_taxon T if the class S does not have a clear referent in taxon T. An example would be the class 'manual digit 1', which encompasses a homology hypotheses that is accepted for some species (e.g. human and mouse), but does not have a clear referent in Aves - the referent is dependent on the hypothesis embraced, and also on the ontogenetic stage. [PHENOSCPAE:asilomar_mtg] RO:0002173 uberon ambiguous_for_taxon true true ambiguous_for_taxon ambiguous for taxon ambiguous_for_taxon S ambiguous_for_taxon T if the class S does not have a clear referent in taxon T. An example would be the class 'manual digit 1', which encompasses a homology hypotheses that is accepted for some species (e.g. human and mouse), but does not have a clear referent in Aves - the referent is dependent on the hypothesis embraced, and also on the ontogenetic stage. PHENOSCPAE:asilomar_mtg S dubious_for_taxon T if it is probably the case that no instances of S can be found in any instance of T. RO:0002174 uberon dubious_for_taxon 1 true 1 true dubious_for_taxon This relation lacks a strong logical interpretation, but can be used in place of never_in_taxon where it is desirable to state that the definition of the class is too strict for the taxon under consideration, but placing a never_in_taxon link would result in a chain of inconsistencies that will take ongoing coordinated effort to resolve. Example: metencephalon in teleost this relation lacks a strong logical interpretation, but can be used in place of never_in_taxon where it is desirable to state that the definition of the class is too strict for the taxon under consideration, but placing a never_in_taxon link would result in a chain of inconsistencies that will take time to resolve. Example: metencephalon in teleost dubious for taxon dubious_for_taxon S dubious_for_taxon T if it is probably the case that no instances of S can be found in any instance of T. https://orcid.org/0000-0002-6601-2165 S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S. PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX present_in_taxon: <http://purl.obolibrary.org/obo/RO_0002175> CONSTRUCT { in_taxon: a owl:ObjectProperty . ?witness rdfs:label ?label . ?witness rdfs:subClassOf ?x . ?witness rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . } WHERE { ?x present_in_taxon: ?taxon . BIND(IRI(CONCAT( "http://purl.obolibrary.org/obo/RO_0002175#", MD5(STR(?x)), "-", MD5(STR(?taxon)) )) as ?witness) BIND(CONCAT(STR(?x), " in taxon ", STR(?taxon)) AS ?label) } RO:0002175 applicable for taxon uberon present_in_taxon 1 true 1 true present_in_taxon The SPARQL expansion for this relation introduces new named classes into the ontology. For this reason it is likely that the expansion should only be performed during a QC pipeline; the expanded output should usually not be included in a published version of the ontology. present in taxon present_in_taxon S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S. https://orcid.org/0000-0002-6601-2165 defined by inverse An assertion that involves at least one OWL object that is intended to be expanded into one or more logical axioms. The logical expansion can yield axioms expressed using any formal logical system, including, but not limited to OWL2-DL. logical macro assertion logical macro assertion https://github.com/oborel/obo-relations/wiki/ShortcutRelations A logical macro assertion whose domain is an IRI for a class The domain for this class can be considered to be owl:Class, but we cannot assert this in OWL2-DL logical macro assertion on a class logical macro assertion on a class A logical macro assertion whose domain is an IRI for a property logical macro assertion on a property logical macro assertion on a property logical macro assertion on an object property logical macro assertion on an object property logical macro assertion on an annotation property logical macro assertion on an annotation property 'pectoral appendage skeleton' has no connections with 'pelvic appendage skeleton' A is has_no_connections_with B if there are no parts of A or B that have a connection with the other. shares no connection with Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (RO_0002170 some (BFO_0000050 some ?Y)) RO:0002475 uberon has_no_connections_with true true has_no_connections_with has no connections with has_no_connections_with A is has_no_connections_with B if there are no parts of A or B that have a connection with the other. https://orcid.org/0000-0002-6601-2165 relation p is the direct form of relation q iff p is a subPropertyOf q, p does not have the Transitive characteristic, q does have the Transitive characteristic, and for all x, y: x q y -> exists z1, z2, ..., zn such that x p z1 ... z2n y If we have the annotation P is-direct-form-of Q, and we have inverses P' and Q', then it follows that P' is-direct-form-of Q' Chris Mungall is direct form of If R <- P o Q is a defining property chain axiom, then it also holds that R -> P o Q. Note that this cannot be expressed directly in OWL is a defining property chain axiom If R <- P o Q is a defining property chain axiom, then (1) R -> P o Q holds and (2) Q is either reflexive or locally reflexive. A corollary of this is that P SubPropertyOf R. is a defining property chain axiom where second argument is reflexive 'anterior end of organism' is-opposite-of 'posterior end of organism' 'increase in temperature' is-opposite-of 'decrease in temperature' x is the opposite of y if there exists some distance metric M, and there exists no z such as M(x,z) <= M(x,y) or M(y,z) <= M(y,x). RO:0002604 quality is_opposite_of true true is_opposite_of is opposite of is_opposite_of 2018-03-14T00:03:24Z is negative form of An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. UBPROP:0000001 uberon external_definition 1 true external_definition This annotation property may be replaced with an annotation property from an external ontology such as IAO This annotation property may be replaced with an annotation property from an external ontology such as IAO external_definition An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. https://orcid.org/0000-0002-6601-2165 A textual description of an axiom loss in this ontology compared to an external ontology. UBPROP:0000002 uberon axiom_lost_from_external_ontology 1 true axiom_lost_from_external_ontology This annotation property may be replaced with an annotation property from an external ontology such as IAO axiom_lost_from_external_ontology A textual description of an axiom loss in this ontology compared to an external ontology. https://orcid.org/0000-0002-6601-2165 Notes on the homology status of this class. UBPROP:0000003 uberon homology_notes 1 true homology_notes This annotation property may be replaced with an annotation property from an external ontology such as IAO This annotation property may be replaced with an annotation property from an external ontology such as IAO homology_notes Notes on the homology status of this class. https://orcid.org/0000-0002-6601-2165 UBPROP:0000004 uberon provenance_notes true provenance_notes provenance_notes An alternate comment for a class taken unmodified from an external source. Note that obo format only allows a single comment for a class, and does not provide a structured means of adding provenance info. UBPROP:0000005 uberon external_comment 1 true external_comment This annotation property may be replaced with an annotation property from an external ontology such as IAO external_comment An alternate comment for a class taken unmodified from an external source. Note that obo format only allows a single comment for a class, and does not provide a structured means of adding provenance info. https://orcid.org/0000-0002-6601-2165 UBPROP:0000006 uberon implements_design_pattern 1 true implements_design_pattern implements_design_pattern Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. UBPROP:0000007 uberon has_relational_adjective 1 true has_relational_adjective Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. has_relational_adjective Notes on the how instances of this class vary across species. UBPROP:0000008 uberon taxon_notes 1 true taxon_notes taxon_notes Notes on the how instances of this class vary across species. https://orcid.org/0000-0002-6601-2165 Notes on the evolved function of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000009 uberon function_notes 1 true function_notes function_notes Notes on the evolved function of instances of this class. https://orcid.org/0000-0002-6601-2165 Notes on the structure, composition or histology of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000010 uberon structure_notes 1 true structure_notes structure_notes Notes on the structure, composition or histology of instances of this class. https://orcid.org/0000-0002-6601-2165 Notes on the ontogenic development of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000011 uberon development_notes 1 true development_notes development_notes Notes on the ontogenic development of instances of this class. https://orcid.org/0000-0002-6601-2165 Notes on how similar or equivalent classes are represented in other ontologies. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000012 uberon external_ontology_notes 1 true external_ontology_notes external_ontology_notes Notes on how similar or equivalent classes are represented in other ontologies. https://orcid.org/0000-0002-6601-2165 Notes on how lexical conventions regarding this class, in particular any issues that may arise due to homonyny or synonymy. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000013 uberon terminology_notes 1 true terminology_notes terminology_notes Notes on how lexical conventions regarding this class, in particular any issues that may arise due to homonyny or synonymy. https://orcid.org/0000-0002-6601-2165 Notes on how instances of this class functon biomechanically. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000014 uberon action_notes true action_notes actions_notes Notes on how instances of this class functon biomechanically. https://orcid.org/0000-0002-6601-2165 Notes on the location, position or part-parents of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000015 uberon location_notes true location_notes location_notes Notes on the location, position or part-parents of instances of this class. https://orcid.org/0000-0002-6601-2165 UBPROP:0000100 uberon is_count_of 1 true is_count_of is count of A property used in conjunction with repeated_element_number to indicate an axis and directionality along that axis. If P preceding_element_is R, and P is_count_of S, and X P N, and X' P N+1, then it follows that every X R some X', and the class expression [S and R some X' and inv(R) some X] is empty (i.e. X is followed by X', with no intermediates) A property used in conjunction with repeated_element_number to indicate an axis and directionality along that axis. If P preceding_element_is R, and P is_count_of S, and X P N, and X' P N+1, then it follows that every X R some X', and the class expression [S and R some X' and inv(R) some X] is empty (i.e. X is followed by X', with no intermediates). UBPROP:0000101 uberon preceding_element_is 1 true preceding_element_is preceding element is A property used in conjunction with repeated_element_number to indicate an axis and directionality along that axis. If P preceding_element_is R, and P is_count_of S, and X P N, and X' P N+1, then it follows that every X R some X', and the class expression [S and R some X' and inv(R) some X] is empty (i.e. X is followed by X', with no intermediates) https://orcid.org/0000-0002-6601-2165 A property used in conjunction with repeated_element_number to indicate an axis and directionality along that axis. If P preceding_element_is R, and P is_count_of S, and X P N, and X' P N+1, then it follows that every X R some X', and the class expression [S and R some X' and inv(R) some X] is empty (i.e. X is followed by X', with no intermediates). https://orcid.org/0000-0002-6601-2165 A property used to indicate the position of an element where that element is of a type that is serially repeated linearly along some axis for which a total ordering exists. The ordering may represent an ancestral condition. UBPROP:0000102 uberon repeated_element_number true repeated_element_number The range is currently non-negative integer repeated element number A property used to indicate the position of an element where that element is of a type that is serially repeated linearly along some axis for which a total ordering exists. The ordering may represent an ancestral condition. https://orcid.org/0000-0002-6601-2165 x pharyngeal_arch_number N if and only if (i) x is a pharyngeal arch, and (ii) x is ancestrally pharyngeal arch number N in a series of pharyngeal arches repeated along a antero-posterior axis, with arch_number 1 being the mandibular arch. gill arch N = PA N-2. the term branchial_arch is ambiguous. UBPROP:0000103 uberon pharyngeal_arch_number 1 true pharyngeal_arch_number pharyngeal arch number x pharyngeal_arch_number N if and only if (i) x is a pharyngeal arch, and (ii) x is ancestrally pharyngeal arch number N in a series of pharyngeal arches repeated along a antero-posterior axis, with arch_number 1 being the mandibular arch. https://orcid.org/0000-0002-6601-2165 x ray_number N if and only if (i) x is a ray, and (ii) x is ancestrally associated with ray number N in a series of phalanges repeated along a radio-ulnar or equivalent axis, with ray_number 1 being the anteriormost ray. UBPROP:0000104 uberon ray_number true ray_number The correct terminology is yet to be established; in tetrapods 'ray' might mean the mereological sum of the phalanges of a manual digit plus a metatarsal bone (or equivalent for hindlimb) ray number x ray_number N if and only if (i) x is a ray, and (ii) x is ancestrally associated with ray number N in a series of phalanges repeated along a radio-ulnar or equivalent axis, with ray_number 1 being the anteriormost ray. https://orcid.org/0000-0002-6601-2165 x phalanx_number N if and only if (i) x is a phalanx, and (ii) x is phalanx number N in a series of phalanges repeated along an prixomo-distal axis, with phalanx_number 1 being the proximalmost phalanx. Note that in humans, the distalmost phalanx has phlanax_number 3, except in ray_number 1, where the distalmost has phalanx_number 2 x phalanx_number N if and only if (i) x is a phalanx, and (ii) x is phalanx number N in a series of phalanges repeated along an prixomo-distal axis, with phalanx_number 1 being the proximalmost phalanx. Note that in humans, the distalmost phalanx has phlanax_number 3, except in ray_number 1, where the distalmost has phalanx_number 2. UBPROP:0000105 uberon phalanx_number 1 true phalanx_number Most land mammals including humans have a 2-3-3-3-3 formula in both the hands (or paws) and feet. Primitive reptiles typically had the formula 2-3-4-4-5, and this pattern, with some modification, remained in many later reptiles and in the mammal-like reptiles. The phalangeal formula in the flippers of cetaceans (marine mammals) is 2-12-8-1 phalanx number x phalanx_number N if and only if (i) x is a phalanx, and (ii) x is phalanx number N in a series of phalanges repeated along an prixomo-distal axis, with phalanx_number 1 being the proximalmost phalanx. Note that in humans, the distalmost phalanx has phlanax_number 3, except in ray_number 1, where the distalmost has phalanx_number 2. Wikipedia:Phalanx_bone#Phalangeal_formula https://orcid.org/0000-0002-6601-2165 x rib_number N if and only if (i) x is a rib, and (ii) x is rib number N in a series of ribs repeated along an anterior-posterior axis, with rib_number 1 being the anteriormost rib. Note that this property counts ribs, *not* the adjoining vertebrae. In the early tetrapods, every vertebra bore a pair of ribs, although those on the thoracic vertebrae are typically the longest. In most subsequent forms, many of these early ribs have been lost, and in living amphibians and reptiles, there is great variation in rib structure and number. For example, turtles have only eight pairs of ribs, which are developed into a bony or cartilagenous carapace and plastron, while snakes have numerous ribs running along the full length of their trunk. Frogs typically have no ribs, aside from a sacral pair, which form part of the pelvis. Mammals usually also only have distinct ribs on the thoracic vertebra, although fixed cervical ribs are also present in monotremes. In marsupials and placental mammals, the cervical and lumbar ribs are found only as tiny remnants fused to the vertebrae, where they are referred to as transverse processes. In general, the structure and number of the true ribs in humans is similar to that in other mammals. Unlike reptiles, caudal ribs are never found in mammals. Note that in TAO, ribs are numbered by *vertebrae* UBPROP:0000106 uberon rib_number true rib_number rib number x rib_number N if and only if (i) x is a rib, and (ii) x is rib number N in a series of ribs repeated along an anterior-posterior axis, with rib_number 1 being the anteriormost rib. Note that this property counts ribs, *not* the adjoining vertebrae. https://orcid.org/0000-0002-6601-2165 Note that in TAO, ribs are numbered by *vertebrae* TAO x vertebra_number N if and only if (i) x is a vertebra, and (ii) x is vertebra number N in a series of vertebras repeated along an anterior-posterior axis, with vertebra_number 1 being the anteriormost vertebra (also known as the atlas). UBPROP:0000107 uberon vertebra_number true vertebra_number vertebra number x vertebra_number N if and only if (i) x is a vertebra, and (ii) x is vertebra number N in a series of vertebras repeated along an anterior-posterior axis, with vertebra_number 1 being the anteriormost vertebra (also known as the atlas). https://orcid.org/0000-0002-6601-2165 x somite_number N if and only if (i) x is a somite, and (ii) x is somite number N in a series of somites repeated along an anterior-posterior axis, with somite_number 1 being the anteriormost somite. UBPROP:0000108 uberon somite_number true somite_number somite number x somite_number N if and only if (i) x is a somite, and (ii) x is somite number N in a series of somites repeated along an anterior-posterior axis, with somite_number 1 being the anteriormost somite. https://github.com/obophenotype/uberon/issues/100 https://orcid.org/0000-0002-6601-2165 x paired_appendage_number N if and only if (i) x is a paired_appendage, and (ii) x is paired_appendage number N in a series of paired_appendages repeated along an anterior-posterior axis, with paired_appendage_number 1 being the anteriormost paired_appendage. In vertebrates, this is the pectoral appendage. UBPROP:0000109 uberon paired_appendage_number true paired_appendage_number paired_appendage number x paired_appendage_number N if and only if (i) x is a paired_appendage, and (ii) x is paired_appendage number N in a series of paired_appendages repeated along an anterior-posterior axis, with paired_appendage_number 1 being the anteriormost paired_appendage. In vertebrates, this is the pectoral appendage. https://orcid.org/0000-0002-6601-2165 x appendage_segment_number N if and only if (i) x is a appendage_segment, and (ii) x is appendage_segment number N in a series of appendage_segments repeated along an proximo-distal axis, with appendage_segment_number 1 being the proximalmost appendage_segment (in tetrapods this would be the stylopod, as we do not classify girdles as appendage segments). UBPROP:0000110 uberon appendage_segment_number true appendage_segment_number Examples: in dropsphila coxa=1, trochanter=2, femur=3, tibia=4, tarsal segments 1-5=5-9, pretarsus=10 appendage segment number x appendage_segment_number N if and only if (i) x is a appendage_segment, and (ii) x is appendage_segment number N in a series of appendage_segments repeated along an proximo-distal axis, with appendage_segment_number 1 being the proximalmost appendage_segment (in tetrapods this would be the stylopod, as we do not classify girdles as appendage segments). https://orcid.org/0000-0002-6601-2165 x rhombomere_number N if and only if (i) x is a rhombomere, and (ii) x is rhombomere number N in a series of rhombomeres repeated along an anterior-posterior axis, with rhombomere_number 1 being the anteriormost rhombomere. UBPROP:0000111 uberon rhombomere_number true rhombomere_number rhombomere number x rhombomere_number N if and only if (i) x is a rhombomere, and (ii) x is rhombomere number N in a series of rhombomeres repeated along an anterior-posterior axis, with rhombomere_number 1 being the anteriormost rhombomere. https://orcid.org/0000-0002-6601-2165 x tooth_number N if and only if (i) x is a tooth, and (ii) x is ancestrally tooth number N in a series of teeth repeated along an anterior-posterior axis, typically on the lateral side of a structure such as a jaw, with tooth_number 1 being the anteriormost. Note that this count refers to the total number of teeth starting from the first, regardless of the type of tooth. If sub-systems are required for numbering within a series of teeth of the same type, consider a subproperty. For example, in a human, maxillary canine = tooth 3 of upper jaw = canine_tooth 1 of upper jaw. UBPROP:0000112 uberon tooth_number true tooth_number tooth number Syntax: upper/lower = I.C.P.M / I.C.P.M. When used with generic tooth class applies to both deciduous and primary. Should also be used with a taxon property. UBPROP:0000113 uberon dental_formula true dental_formula dental formula Syntax: upper/lower = I.C.P.M / I.C.P.M. When used with generic tooth class applies to both deciduous and primary. Should also be used with a taxon property. Wikipedia:Dentition#Dental_formula UBPROP:0000201 uberon source_atlas true source_atlas source atlas FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term UBPROP:0000202 uberon fma_set_term 1 true fma_set_term FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term fma_set_term FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term FMA synonym typically used in the context of vertebrate anatomy LANGUAGE FRENCH LANGUAGE GERMAN MISSPELLING SCIENTIFIC NAME BRAND NAME INN IUPAC NAME Preliminary entries Annotated by 3rd party Manually annotated by ChEBI Team Non-mining synonym 2022-03-29T15:09:49Z abbreviation 2023-03-31T09:17:34Z a subset of general classes related to blood and the immune system, primarily of hematopoietic origin blood_and_immune_upper_slim a subset of general classes related to specific cell types in the eye. eye_upper_slim a subset of general classes of cell types in the cell ontology. general_cell_types_upper_slim EnvO-Lite-GSC plurals A is disconnected_from B if they have no parts in common. Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (BFO_0000050 some ?Y) non_overlapping_with ENVO disconnected_from true true disconnected_from A is disconnected_from B if they have no parts in common. Disposition slim environmental_hazards envoANZSoil envoAstro envoAtmo envoCesab envoCmecs envoEOVs envoEmpo envoMarine envoMeo envoNceas envoOmics envoPlastics envoPolar Pathology slim nlcd2011 Relational slim: types of quality that require an additional entity in order to exist ro-eco Scalar slim Value slim wwfBiome Rhea list of ChEBI terms representing the major species at pH 7.3. Term not to be used for direct annotation Term not to be used for direct manual annotation AGR slim Aspergillus GO slim Candida GO slim ChEMBL protein targets summary Drosophila GO slim FlyBase Drosophila GO ribbon slim Generic GO slim Metagenomics GO slim Mouse GO slim PIR GO slim Plant GO slim Fission yeast GO slim synapse GO slim Yeast GO slim GO subset for prokaryotes label approved by the SynGO project Systematic synonym HPO:skoehler abbreviation 2018-07-05T13:18:08Z peter display label Core clinical terminology is_observable_through HPO:skoehler layperson term 2018-05-05T19:01:17Z peter discarded/obsoleted synonym HPO:skoehler plural form Consequence of a disorder in another organ system. HPO:skoehler UK spelling Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Relates an ontology used to record id policy to a prefix concatenated with an integer in the id range (left padded with "0"s to make this many digits) to construct an ID for a term being created. Person:Alan Ruttenberg has ID prefix Abnormal/normal slim Absent/present slim Attribute slim cell_quality Disposition slim Human phenotype slim Pathology slim Relational slim: types of quality that require an additional entity in order to exist Scalar slim Value slim eco subset preferred term when talking about an instance of this class in Homo sapiens latin term plural term S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S applicable for taxon uberon present_in_taxon true true present_in_taxon S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S https://orcid.org/0000-0002-6601-2165 A is spatially_disjoint_from B if they have no parts in common. Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (BFO_0000050 some ?Y) non_overlapping_with shares_no_parts_with uberon spatially_disjoint_from true true spatially_disjoint_from A is spatially_disjoint_from B if they have no parts in common. SO:cjm abbreviation brain name abbreviations (drosophila) preferred term in the context of comparative anatomy A historic synonym, no longer encouraged developmental term dubious or contested synonym a synonym made on the basis of a possibly homologous structure in another species preferred term when talking about an instance of this class in Homo sapiens indicates that a synonym is used in an inconsistent or confusing way, typically between species latin term a mis-spelling that is in common use and thus recorded synonym that is inappropriate for amniotes synonym that is inappropriate for mammals expert consultation and attribution required plural term taxonomic disambiguation a systematic synonym used as the base name for design patterns Classes tagged with this subset property were added upon request from the Human Cell Atlas (HCA). Terms applicable across life, not restricted to Metazoa CUMBO cyclostome structures brain region defined by cyto-architecture classes that are defined by relative position counting from first in a series of elements along an axis in an individual organism rather than by strict homology developmental_classification Indicates that subclasses in AOs may be inappropriately linked A class that represents an early developmental structure, like a blastocyst. This part of the ontology is undergoing review to remove inappropriate grouping classes. EFO slim derived from the union of EHDAA2 and EMAPA - still to be checked subset of classes that have logical defs text defs and synonyms aligned with FEED functional_classification Subset consisting of classes creating for grouping purposes uberon homologous_in true Status: experimental homologous_in A grouping class that depends on an assumption of homology between subclasses classes that have some inconsistency with FMA somewhat fuzzy grouping for analysis purposes, currently composed of something like: liver, heart, skeletal, kidney, bladder, brain, skin, mouth, esophagus, stomach, small intestine, large intestines, trachea nose, lungs, brain, spinal cord, peripheral nerves, kidneys, ureters, bladder, urethra, gonads core classes typically found across metazoa. one purpose is to create a rough set of terms that could be used to start a new metazoan AO. Note this subset is not yet fully fleshed out abstract class brought in to group ontology classes but not informative organs, excluding individual muscles and skeletal elements Phenotype slim A subset specifically created for the 2012 Phenotype RCN meeting. Includes some human-specific terms that may eventually be removed when they are adequately represented with part of relationships in FMA Uberon slim - subset that excludes obscure terms and deep compositional terms Indicates that the class encompasses classes from other AOs that have not been verified abstract upper-level terms not directly useful for analysis core classes typically found across vertebrates. one purpose is to create a rough set of terms that could be used to start a new vertebrate AO abstract upper-level terms not directly useful for analysis Examples of a Contributor include a person, an organisation, or a service. Typically, the name of a Contributor should be used to indicate the entity. http://purl.org/dc/elements/1.1/contributor uberon dc-contributor 1 true dc-contributor An entity responsible for making contributions to the content of the resource. Contributor Contributor contributor Coverage will typically include spatial location (a place name or geographic coordinates), temporal period (a period label, date, or date range) or jurisdiction (such as a named administrative entity). Recommended best practice is to select a value from a controlled vocabulary (for example, the Thesaurus of Geographic Names [TGN]) and that, where appropriate, named places or time periods be used in preference to numeric identifiers such as sets of coordinates or date ranges. The extent or scope of the content of the resource. Coverage Coverage Examples of a Creator include a person, an organisation, or a service. Typically, the name of a Creator should be used to indicate the entity. http://purl.org/dc/elements/1.1/creator uberon dc-creator true dc-creator An entity primarily responsible for making the content of the resource. Creator Creator creator Typically, Date will be associated with the creation or availability of the resource. Recommended best practice for encoding the date value is defined in a profile of ISO 8601 [W3CDTF] and follows the YYYY-MM-DD format. A date associated with an event in the life cycle of the resource. Date Date Description may include but is not limited to: an abstract, table of contents, reference to a graphical representation of content or a free-text account of the content. http://purl.org/dc/elements/1.1/description uberon dc-description true dc-description An account of the content of the resource. Description Description description Typically, Format may include the media-type or dimensions of the resource. Format may be used to determine the software, hardware or other equipment needed to display or operate the resource. Examples of dimensions include size and duration. Recommended best practice is to select a value from a controlled vocabulary (for example, the list of Internet Media Types [MIME] defining computer media formats). The physical or digital manifestation of the resource. Format Format Recommended best practice is to identify the resource by means of a string or number conforming to a formal identification system. Example formal identification systems include the Uniform Resource Identifier (URI) (including the Uniform Resource Locator (URL)), the Digital Object Identifier (DOI) and the International Standard Book Number (ISBN). An unambiguous reference to the resource within a given context. Resource Identifier Resource Identifier Recommended best practice is to use RFC 3066 [RFC3066], which, in conjunction with ISO 639 [ISO639], defines two- and three-letter primary language tags with optional subtags. Examples include "en" or "eng" for English, "akk" for Akkadian, and "en-GB" for English used in the United Kingdom. A language of the intellectual content of the resource. Language Language Examples of a Publisher include a person, an organisation, or a service. Typically, the name of a Publisher should be used to indicate the entity. http://purl.org/dc/elements/1.1/publisher uberon dc-publisher true dc-publisher An entity responsible for making the resource available Publisher Publisher publisher Recommended best practice is to reference the resource by means of a string or number conforming to a formal identification system. A reference to a related resource. Relation Relation Typically, a Rights element will contain a rights management statement for the resource, or reference a service providing such information. Rights information often encompasses Intellectual Property Rights (IPR), Copyright, and various Property Rights. If the Rights element is absent, no assumptions can be made about the status of these and other rights with respect to the resource. Information about rights held in and over the resource. Rights Management Rights Management The present resource may be derived from the Source resource in whole or in part. Recommended best practice is to reference the resource by means of a string or number conforming to a formal identification system. http://purl.org/dc/elements/1.1/source uberon dc-source true dc-source A reference to a resource from which the present resource is derived. Source Source derived from resource Typically, a Subject will be expressed as keywords, key phrases or classification codes that describe a topic of the resource. Recommended best practice is to select a value from a controlled vocabulary or formal classification scheme. The topic of the content of the resource. Subject and Keywords Subject and Keywords Typically, a Title will be a name by which the resource is formally known. http://purl.org/dc/elements/1.1/title uberon dc-title true dc-title A name given to the resource. Title Title title Type includes terms describing general categories, functions, genres, or aggregation levels for content. Recommended best practice is to select a value from a controlled vocabulary (for example, the DCMI Type Vocabulary [DCMITYPE]). To describe the physical or digital manifestation of the resource, use the Format element. The nature or genre of the content of the resource. Resource Type Resource Type http://purl.org/dc/terms/contributor uberon dc-contributor true dc-contributor contributor http://purl.org/dc/terms/date uberon dcterms-date true dcterms-date date http://purl.org/dc/terms/isReferencedBy uberon dcterms-isReferencedBy true dcterms-isReferencedBy is referenced by Mark Miller 2018-05-11T13:47:29Z http://purl.org/dc/terms/license uberon dcterms-license true dcterms-license license http://usefulinc.com/ns/doap#GitRepository uberon doap-GitRepository true doap-GitRepository Git repository http://usefulinc.com/ns/doap#SVNRepository uberon doap-SVNRepository true doap-SVNRepository SVN repository http://usefulinc.com/ns/doap#bug-database uberon doap-bug-database true doap-bug-database bug database http://usefulinc.com/ns/doap#mailing-list uberon doap-mailing-list true doap-mailing-list mailing list http://usefulinc.com/ns/doap#wiki uberon doap-wiki true doap-wiki wiki Do not use this property for anything. It is an accidental duplication of another property that was released and has now been obsoleted following the accepted obsolence procedure http://www.ebi.ac.uk/efo/gwas_trait 2.89 accidental duplication of property gwas_trait obsolete_gwas_trait true paola Term added upon request from Human Cell Atlas curators. added_for_HCA For use in the EMBL-EBI ArrayExpress interface. definition true A definition citation is a document, ontology class, person or organization from which the definition of the class is derived. It is used in the same sense as a citation in literature, in that the definition may have been derived from these sources or that this definition is related to these source. definition_citation subset_property synonym_type_property consider created_by creation_date has_alternative_id An alternative label for a class or property which has a more general meaning than the preferred name/primary label. https://github.com/information-artifact-ontology/ontology-metadata/issues/18 has broad synonym has_broad_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/18 Conceptual Entity xRef A property representing a reference to an identical or very similar object in another database. database_cross_reference database_cross_reference xRef 数据库_交叉_引用 数据库_交叉_引用 A property representing a reference to an identical or very similar object in another database. NCI http://www.geneontology.org/page/ontology-structure A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software. An alternative label for a class or property which has the exact same meaning than the preferred name/primary label. An alternative label for a given entity such as a commonly used abbreviation or synonym. https://github.com/information-artifact-ontology/ontology-metadata/issues/20 FULL_SYN Synonym with Source Data alternative_term has exact synonym has exact synonym has_exact_synonym has_exact_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/20 An alternative label for a class or property which has a more specific meaning than the preferred name/primary label. https://github.com/information-artifact-ontology/ontology-metadata/issues/19 has narrow synonym has_narrow_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/19 has_obo_format_version has_obo_format_version disease_ontology has_obo_namespace has_obo_namespace 有_obo_命名空间 有_obo_命名空间 An alternative label for a class or property that has been used synonymously with the primary term name, but the usage is not strictly correct. https://github.com/information-artifact-ontology/ontology-metadata/issues/21 has related synonym has_related_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/21 has_scope has_synonym_type id An association that connects the concept defining a particular terminology subset with concepts that belong to this subset. Concept_In_Subset in subset in_subset logical-definition-view-relation shorthand shorthand treat-xrefs-as-equivalent treat-xrefs-as-has-subclass treat-xrefs-as-is_a treat-xrefs-as-reverse-genus-differentia label label label 标签 http://www.w3.org/2000/01/rdf-schema#seeAlso spatial uberon seeAlso true seeAlso see also A skos concept mapping used to link two concepts, indicating a high degree of confidence that the concepts can be used interchangeably. has exact match A skos concept mapping used to state a hierarchical mapping link between two concepts where the DO concept is narrow (DO represents subtypes) and the xref is broad. has narrower match The preferred lexical label for a resource, in a given language. A resource has no more than one value of skos:prefLabel per language tag. The range of skos:prefLabel is the class of RDF plain literals. skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise disjoint properties. preferred label skos:note http://xmlns.com/foaf/0.1/depicted_by uberon depicted_by foaf-depicted_by 1 true depicted_by foaf-depicted_by depicted by depicted_by http://xmlns.com/foaf/0.1/homepage uberon foaf-homepage true foaf-homepage homepage http://xmlns.com/foaf/0.1/page uberon foaf-page true foaf-page page Concept_Pending_Approval Deprecated_Concept Header_Concept Obsolete_Concept Provisional_Concept Retired_Concept ACC ACC/AHA BRIDG CBDD CCPS CDISC CDISC-GLOSS COH CPTAC CRCH CTCAE CTDC CTEP CTRP CareLex Cellosaurus DIPG/DMG EDQM-HC FDA GAIA GDC HL7 ICD-10 ICDC ICH INC MedDRA NAACCR NCCN NCPDP NDC NICHD PCDC PI-RADS SEER SeroNet UCUM WHO NCI Drug Dictionary NA No Yes Device Problem Code (Appendix B) Dosage Form (C-DRG-00201) Marketing Category (C-DRG-0935) Package Type (C-DRG-00907) Patient Code (Appendix B) Plant Part (C-DRG-00924) Potency (C-DRG-00501) Route of Administration (C-DRG-00301) SPL Color (C-DRG-00927) SPL DEA Schedule (C-DRG-0933) SPL Flavor (C-DRG-0934) SPL Shape (C-DRG-00929) Benign Malignant Precancerous Uncertain Malignant Potential Undetermined Alliance COG CTRP Biomarker Abstraction DCP Data Commons Framework Duke Sarcoma Project GDC NCCN NCI CCR PDC PopSci SIG Rave SEER SEER CAN TCGA caDSR General No Yes Broader Than Has Synonym Narrower Than Related To Acquired Abnormality Activity Age Group Amino Acid Sequence Amino Acid, Peptide, or Protein Amphibian Anatomical Abnormality Anatomical Structure Animal Antibiotic Archaeon Bacterium Behavior Biologic Function Biologically Active Substance Biomedical Occupation or Discipline Biomedical or Dental Material Bird Body Location or Region Body Part, Organ, or Organ Component Body Space or Junction Body Substance Body System Carbohydrate Sequence Cell Cell Component Cell Function Cell or Molecular Dysfunction Chemical Chemical Viewed Functionally Chemical Viewed Structurally Classification Clinical Attribute Clinical Drug Conceptual Entity Congenital Abnormality Daily or Recreational Activity Diagnostic Procedure Disease or Syndrome Drug Delivery Device Educational Activity Element, Ion, or Isotope Embryonic Structure Entity Environmental Effect of Humans Enzyme Eukaryote Event Experimental Model of Disease Family Group Finding Fish Food Fully Formed Anatomical Structure Functional Concept Fungus Gene or Genome Genetic Function Geographic Area Governmental or Regulatory Activity Group Group Attribute Hazardous or Poisonous Substance Health Care Activity Health Care Related Organization Hormone Human Human-caused Phenomenon or Process Idea or Concept Immunologic Factor Indicator, Reagent, or Diagnostic Aid Individual Behavior Injury or Poisoning Inorganic Chemical Intellectual Product Laboratory Procedure Laboratory or Test Result Language Machine Activity Mammal Manufactured Object Medical Device Mental Process Mental or Behavioral Dysfunction Molecular Biology Research Technique Molecular Function Molecular Sequence Natural Phenomenon or Process Neoplastic Process Nucleic Acid, Nucleoside, or Nucleotide Nucleotide Sequence Occupation or Discipline Occupational Activity Organ or Tissue Function Organic Chemical Organism Organism Attribute Organism Function Organization Pathologic Function Patient or Disabled Group Pharmacologic Substance Phenomenon or Process Physical Object Physiologic Function Plant Population Group Professional Society Professional or Occupational Group Qualitative Concept Quantitative Concept Receptor Regulation or Law Reptile Research Activity Research Device Self-help or Relief Organization Sign or Symptom Social Behavior Spatial Concept Substance Temporal Concept Therapeutic or Preventive Procedure Tissue Vertebrate Virus Vitamin TVS_ADaM_Component TVS_CDASH_Component TVS_CDISC_ADaM TVS_CDISC_CDASH TVS_CDISC_Clinical_Classification TVS_CDISC_Component TVS_CDISC_Functional_Test TVS_CDISC_Glossary TVS_CDISC_Protocol TVS_CDISC_Questionnaire TVS_CDISC_SDTM TVS_CDISC_SEND TVS_CDRH_GUID_Component TVS_CareLex TVS_Clinical_Classification_Component TVS_DICOM_Component TVS_EDQM-HC TVS_EDQM-HC_Component TVS_FDA_Device TVS_FDA_Device_Component TVS_FDA_PQCMC TVS_FDA_PQCMC_Component TVS_FDA_PQCMC_Test_Category TVS_FDA_PQCMC_Test_Category_Component TVS_FDA_QM TVS_FDA_QM_Component TVS_FDA_SPL TVS_FDA_SPL_Biz_Ops TVS_FDA_SPL_Biz_Ops_Component TVS_FDA_SPL_Blood TVS_FDA_SPL_Blood_Component TVS_FDA_SPL_Blood_Tissue TVS_FDA_SPL_Blood_Tissue_Component TVS_FDA_SPL_Component TVS_FDA_SPL_REMS TVS_FDA_SPL_REMS_Component TVS_FDA_SPL_Tissue TVS_FDA_SPL_Tissue_Component TVS_FDA_UNII TVS_FDA_eManufacturing_Component TVS_Functional_Test_Component TVS_GAIA TVS_GAIA_Component TVS_ICSR TVS_ICSR_Component TVS_IDMP_Component TVS_NCI_CTS-API_Disease_Category TVS_NCI_CTS-API_Disease_Category_Component TVS_NCI_Component TVS_NCI_Drug_Component TVS_NCI_Neoplasm_Component TVS_NCPDP TVS_NCPDP_Component TVS_NICHD TVS_NICHD_Component TVS_PIRADS_Component TVS_Protocol_Component TVS_Questionnaire_Component TVS_SDTM_Component TVS_SEND_Component TVS_UCUM_Component TVS_eCTD_Component LLT PT SY EDQM-HC GAIA GDC ICD10 2016 ICD10CM 2017 ICD9CM 2014 ICDO3 MedDRA MedDRA 18.1 MedDRA 20.1 MedDRA 22.0 No Yes ACC ACC/AHA BIOCARTA BRIDG BRIDG 3.0.3 BRIDG 5.3 CBDD CCPS CDISC CDISC-GLOSS CRCH CSP2000 CSP2003 CTCAE CTCAE 3.0 CTCAE 5.0 CTDC CTEP CareLex DICOM DIPG/DMG EDQM-HC FDA GAIA ICD03 INC KEGG MMHCC MSH2001 MSH2002_06_01 MSH2003_2003_05_12 NAACCR NCI NCI-DEFCURATOR NCI-GLOSS NICHD PCDC PQCMC SPL WHO CGAP NCBI NCI AB AD AQ AQS BR CA2 CA3 CN CNU CS DN FB HD LLT PT SN SY ACC ACC/AHA ANSI BIOCARTA BRIDG BRIDG 3.0.3 BRIDG 5.3 CBDD CCPS CDC CDISC CDISC-GLOSS CPTAC CRCH CTCAE CTCAE 3.0 CTCAE 5.0 CTDC CTEP CTRP CareLex Cellosaurus DCP DICOM DIPG/DMG DTP EDQM-HC FDA GAIA GDC GENC HGNC HL7 ICD-10 ICDC ICH INC JAX KEGG MTH MedDRA NAACCR NCI NCI-GLOSS NCPDP NDC NICHD PCDC PI-RADS PID SEER SeroNet UCUM WHO caDSR IMDRF UBERON Transitive parthood relation in which one entity has itself, or another entity as a part, and the relation is valid for use only between continuants or between occurrents but not between a continuant and an occurrent. has part (source): OBO Relation Ontology (release version 0.99, date 07:14:2006); Barry Smith et al, Relations in biomedical ontologies, Genome Biology (2005) If C and C1 are continuant classes, then C has_part C1 means that every instance of C at any time has part some instances of C1 at the same time. [formal definition]: C has_part C1 holds true if and only if every continuant c that instantiates C at some time t, there is some continuant c1 that instantiates C1 at t such that c1 is part of c at t. Examples: fluorescein isothiocyanate has_part isothiocyanate group gold quantum dot has_part gold core-shell nanoparticle has_part core core-shell nanoparticle has_part shell If P and P1 are occurrent classes, then P has_part P1 means that every instance of P has part some instances of P1. [formal definition]:P has_part P1 if and only if every occurrent p that instantiates P there is some occurrent p1 that instantiates P1 such that p1 is part of p. Examples: covalent linkage has_part covalent interaction visualization of cellular uptake of nanoparticles has_part imaging of nanoparticles participates in this blood clot participates in this blood coagulation this input material (or this output material) participates in this process this investigator participates in this investigation a relation between a continuant and a process, in which the continuant is somehow involved in the process participates_in RO:0000056 external participates_in participates_in participates in participates in Example: We share Galileo's opinion: the Earth moves [X]. The citing entity agrees with statements, ideas or conclusions presented in the cited entity. agrees with The citing entity cites the cited entity, either directly and explicitly (as in the reference list of a journal article), indirectly (e.g. by citing a more recent paper by the same group on the same topic), or implicitly (e.g. as in artistic quotations or parodies, or in cases of plagiarism). cites Example: Italy has more than ten thousand kilometers of shoreline: see [X]. The citing entity cites the cited entity as source of data. cites as data source Example: We found an unquestionable demonstration of our hypothesis in [X]. The citing entity cites the cited entity as source of factual evidence for statements it contains. cites as evidence Example: Basic bibliographic, entity and project metadata relating to this article, recorded in a structured machine-readable form, is available as an additional file [X] accompanying this paper. The citing entity cites the cited entity as being the container of metadata describing the citing entity. cites as metadata document Example: This risk could be avoided using the approach shown in [X]. The citing entity cites the cited entity as providing or containing a possible solution to the issues being discussed. cites as potential solution Example: To our knowledge, [X] is the best source of exercises about UML, making it a valuable proposal for beginners. The citing entity cites the cited entity as an item of recommended reading. This property can be used, for example, to describe references in a lecture reading list, where the cited references are relevant to the general topic of the lecture, but might not be individually cited within the text of the lecture. Similarly, it could be used to describe items in a 'Suggested further reading' list at the end of a book chapter. cites as recommended reading Example: An analysis similar to what we proposed here is presented in [X]. The citing entity cites the cited entity as one that is related. cites as related Example: Several sections of this work are based on our literature review of the topic published as journal article [X]. The citing entity cites the cited entity as being the entity from which the citing entity is derived, or about which the citing entity contains metadata. cites as source document Example: The grammar of Pascal was introduced in [X]. The citing entity cites the cited entity as a source of information on the subject under discussion. cites for information Example: This book gathers interviews with academic researchers of several disciplines [X]. Note: This property has been imported from the CiTO4Data ontology, usage of which has been deprecated. The citing entity is used to create or compile the cited entity. compiles Example: Our findings are similar to those published in [X]. The citing entity confirms facts, ideas or statements presented in the cited entity. confirms Example: We think that to stand on the top of giants [X] is a valuable principle to follow for our own research. The citing entity contains a statement of fact or a logical assertion (or a collection of such facts and/or assertions) originally present in the cited entity. This object property is designed to be used to relate a separate abstract, summary or nanopublication to the cited entity upon which it is based. contains assertion from Example: The result published in [X] is partially wrong, the correct result is 42. The citing entity corrects statements, ideas or conclusions presented in the cited entity. corrects Example: Galileo was the first to observe Jupiter's satellites [X]. The citing entity acknowledges contributions made by the cited entity. credits Example: The ideas presented in [X] are badly substantantiated. The citing entity critiques statements, ideas or conclusions presented in the cited entity. critiques Example: The ideas published in [X] are incredibly stupid. The citing entity express derision for the cited entity, or for ideas or conclusions contained within it. derides Example: Galileo's book [X] is a dialog among three scientists about Copernicus' eliocentric theory. The citing entity describes the cited entity. describes Example: We do not share Galileo's opinion [X]: the Earth does not move. The citing entity disagrees with statements, ideas or conclusions presented in the cited entity. disagrees with Example: We now examine if Galileo is right when he writes [X] that the Earth moves. The citing entity discusses statements, ideas or conclusions presented in the cited entity. discusses Example: We doubt that Galileo is right when he writes [X] that the Earth moves. The citing entity disputes statements, ideas or conclusions presented in the cited entity. disputes Example: Herein we report in detail the complete set of ontological rules defined in the Overlapping Ontology [X]. The citing entity documents information about the cited entity. documents Example: We add to Galileo's findings concerning the Earth [X] that also the Moon moves. The citing entity extends facts, ideas or understandings presented in the cited entity. extends An excerpt is more general than a quotation. It is generally used to indicate a re-published extract from a book, instruction manual, film, radio programme, etc, that need not be what someone said. For example: Oxford 01865 Oxshott 01372 Oxted 01883 Oxton 01578 is an excerpt from the UK Dialling Codes section of the Oxford Telephone Directory. Example: In her work, the author states that even though most Human Information Behaviour researchers are familiar with the literature related to their studies, it is not uncommon for investigators to fail to see the benefits they may gain from previous mistakes [X]. The citing entity includes one or more excerpts from the cited entity. includes excerpt from A quotation is a repetition of what someone has said, and is presented "within quotation marks", for example: On June 4th 1940, Winston Churchill made a speech on the radio that has since become famous, that included the words: " . . . we shall fight on the beaches, we shall fight on the landing grounds, we shall fight in the fields and in the streets, we shall fight in the hills; we shall never surrender . . ." Example: As Newton wrote in [X]: "We are like dwarfs standing on the shoulders of giants". The citing entity includes one or more quotations from the cited entity. includes quotation from Example: The BioSharing registry (https://biosharing.org) can be of use as it describes the standards in detail, including versions where applicable. The citing entity provides a link, in the form of an HTTP Uniform Resource Locator (URL), to the cited entity. links to Example: There is a need for more observational studies and studies using narrative causation to describe the potential contribution of information in problem-solving and decision-making [X]; our work addresses these needs. The citing entity obtains background information from the cited entity. obtains background from Example: Our ideas were also shared by Doe et al. [X]. The citing entity obtains intellectual or factual support from the cited entity. obtains support from Example: We act as giants on the shoulders of dwarfs [X]! The citing entity imitates the characteristic style or content of the cited entity for comic effect, usually without explicit citation. parodies Example: The conclusion of our dissertation can be summarised by the following motto, we created specifically for this purpose: we are like dwarfs standing on the shoulders of giants. A property indicating that the author of the citing entity plagiarizes the cited entity, by including textual or other elements from the cited entity without formal acknowledgement of their source. The citing entity thus contains no explicit citation of the cited entity, according to the norms of scholarly practice, but cites it implicitly. plagiarizes Example: Galileo's masterpiece 'Dialogo sopra i due massimi sistemi del mondo' [X] is formally a dialog and substantially a scientific pamphlet. The citing entity qualifies or places conditions or restrictions upon statements, ideas or conclusions presented in the cited entity. qualifies Example: We do not think that all their arguments in favour of their own and against the other strategies are equally convincing [X]. The citing entity refutes statements, ideas or conclusions presented in the cited entity. refutes Example: We will not investigate the issues of the approach proposed in [X] here, but rather we introduce yet another alternative. The citing entity replies to statements, ideas or criticisms presented in the cited entity. replies to Example: We wrote that the Earth moves in [X]; we now retire such statement. The citing entity constitutes a formal retraction of the cited entity. retracts Example: This paper discusses Toulmin's methodology in modelling argumentation [X], focussing on highlighting advantages and drawbacks of the application of such a methodology in the Social Web. The citing entity reviews statements, ideas or conclusions presented in the cited entity. reviews Example: Galileo said that the Earth "moves" [X]; really? And where is it going? The citing entity ridicules the cited entity or aspects of its contents. ridicules Example: We believe that if Galileo believed that Earth goes around the Sun [X], he also should believe that Moon goes around Earth. The citing entity speculates on something within or related to the cited entity, without firm evidence. speculates on Example: We support Galileo's statement [X], that Earth moves. The citing entity provides intellectual or factual support for statements, ideas or conclusions presented in the cited entity. supports Example: Earth moves, said Galileo [X]; in addition, we can say now it moves very fast. The citing entity updates statements, ideas, hypotheses or understanding presented in the cited entity. updates Example: Building upon Galileo's findings [X], we discovered that all the planets move. The citing entity describes work that uses conclusions presented in the cited entity. uses conclusions from Example: Using the information collected from our recent study [X], we can estimate that there are tens of millions of HTML forms with potentially useful deep-web content. The citing entity describes work that uses data presented in the cited entity. uses data from Example: We follow [X] in using design patterns for testing. The citing entity describes work that uses a method detailed in the cited entity. uses method in This property is defined in schema.org and has been added here to align schema.org with CiTO. The object property schema:citation expresses similar semantics to cito:cites except for the explicit definition of domain and range classes, that are schema:CreativeWork according to schema.org. For that reason, it is here defined as a subproperty of cito:cites. citation has attribute has unit is a relation between a quantity and the unit it is a multiple of. core has unit has endpoint has measure group has concentration A relation between a informational entity and its actual value (numeric, date, text, etc). core nlp relations sadi has value aop_ontology:AdverseOutcome Any undesired and harmful effect or outcome. aop_ontology:AdverseOutcomePathway An Adverse Outcome Pathway (AOP) is a conceptual framework that portrays existing knowledge concerning the linkage between two anchor points - the Molecular Initiating Event (MIE), and an Adverse Outcome (AO), connected by a chain of Key Events (KE) and the relationships between them (KER). aop_ontology:AopEntity An entity that is part of an adverse outcome pathway aop_ontology:KeyEvent A necessary event that must occur for an adverse outcome to develop or be triggered. aop_ontology:MolecularInitiatingEvent ccont:CCONT_0000047 mixture ccont:CCONT_0000048 FBS fetal bovine serum ccont:CCONT_0000049 bovine calf serum ccont:CCONT_0000050 bovine serum ccont:CCONT_0000051 newborn calf serum ccont:CCONT_0000052 chicken Serum ccont:CCONT_0000053 goat serum ccont:CCONT_0000054 porcine Serum ccont:CCONT_0000055 rabbit serum ccont:CCONT_0000056 sheep serum ccont:CCONT_0000057 human serum ccont:CCONT_0000058 horse serum Thesaurus:C104504 C104504 Intellectual Product Batch Number C3641829 CDISC A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product that is produced in a manner that is expected to render it homogeneous. BATCH Batch Code Batch Identifier Batch Number A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product that is produced in a manner that is expected to render it homogeneous. A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product that is produced in a manner that is expected to render it homogeneous. Batch Number A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product that is produced in a manner that is expected to render it homogeneous. CDISC BATCH PT CDISC SDTM-DIPARMCD Batch Code SY NCI Batch Identifier SY CDISC Batch Identifier SY NCI Batch Number PT CDISC SDTM-DIPARM Batch Number PT NCI Batch Number SY CDISC A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product that is produced in a manner that is expected to render it homogeneous. NCI Thesaurus:C111093 C111093 Conceptual Entity Software Version C3827995 CDISC A form or variant of software; one of a sequence of copies of a software program, each incorporating new modifications. (NCI) SFTWRVER Software Version A form or variant of software; one of a sequence of copies of a software program, each incorporating new modifications. A form or variant of software; one of a sequence of copies of a software program, each incorporating new modifications. Software Version A form or variant of software; one of a sequence of copies of a software program, each incorporating new modifications. (NCI) CDISC SFTWRVER PT CDISC SDTM-DOTESTCD SFTWRVER PT CDISC SDTM-DUTESTCD Software Version PT CDISC SDTM-DOTEST Software Version PT CDISC SDTM-DUTEST Software Version PT NCI Software Version SY CDISC A form or variant of software; one of a sequence of copies of a software program, each incorporating new modifications. NCI Thesaurus:C112332 C112332 Quantitative Concept Material Pore Size C3829176 CDISC FDA A quantitative or qualitative measurement of the physical dimensions of the pores in a material. Material Pore Size PORESIZE Pore Size A quantitative or qualitative measurement of the physical dimensions of the pores in a material. A quantitative or qualitative measurement of the physical dimensions of the pores in a material. Material Pore Size A quantitative or qualitative measurement of the physical dimensions of the pores in a material. CDISC Material Pore Size PT NCI PORESIZE PT CDISC SDTM-DOTESTCD Pore Size PT CDISC SDTM-DOTEST Pore Size PT FDA CDRH-GUDID Pore Size SY CDISC A quantitative or qualitative measurement of the physical dimensions of the pores in a material. NCI Thesaurus:C117376 C117376 Conceptual Entity Version of the Reference Terminology C3897197 VCDVER Version of the Reference Terminology The version information of the terminology system that is being used. The version information of the terminology system that is being used. Version of the Reference Terminology VCDVER PT CDISC Version of the Reference Terminology PT NCI The version information of the terminology system that is being used. NCI Thesaurus:C117461 C117461 Intellectual Product Trial Summary Parameter Version of the Reference Terminology C3897326 TSVCDVER Trial Summary Parameter Version of the Reference Terminology The version information of the terminology system that is being used for the trial summary parameter. The version information of the terminology system that is being used for the trial summary parameter. Trial Summary Parameter Version of the Reference Terminology TSVCDVER PT CDISC Trial Summary Parameter Version of the Reference Terminology PT NCI The version information of the terminology system that is being used for the trial summary parameter. NCI Thesaurus:C119826 C119826 Activity Exposure Method C2702546 EXMETHOD Exposure Method The technique used to administer the exposure treatment. The technique used to administer the exposure treatment. Exposure Method EXMETHOD PT CDISC Exposure Method PT NCI The technique used to administer the exposure treatment. NCI Thesaurus:C120569 C120569 Organic Chemical Pentetate Calcium C3535910 2531-75-1 W0655Y0HSJ FDA Ca-DTPA Calcium DTPA Calcium N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycinate (1:1) Diethylenetriaminepentaacetic Acid, Calcium Salt PENTETATE CALCIUM Pentetate Calcium The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. Pentetate Calcium Ca-DTPA AB NCI Calcium DTPA SY NCI Calcium N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycinate (1:1) SN NCI Diethylenetriaminepentaacetic Acid, Calcium Salt SY NCI PENTETATE CALCIUM PT FDA W0655Y0HSJ UNII Pentetate Calcium PT NCI The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. NCI Thesaurus:C120570 C120570 Organic Chemical Pentetate Zinc C0043501 65229-17-6 828I5G7VJ6 FDA Diethylenetriaminepentaacetic Acid, Zinc Salt PENTETATE ZINC Pentetate Zinc Zinc DTPA Zinc, (((Carboxymethylimino)bis(ethylenenitrilo))tetraacetato)- Zincate(3-), (N,N-bis(2-(((carboxy-kappaO)methyl)(carboxymethyl)amino-kappaN)ethyl)glycinato(5-)-kappaN,kappaO)-, Trihydrogen Zn-DTPA ZnDTPA The zinc salt form of diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. The zinc salt form of diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. Pentetate Zinc Diethylenetriaminepentaacetic Acid, Zinc Salt SY NCI PENTETATE ZINC PT FDA 828I5G7VJ6 UNII Pentetate Zinc PT NCI Zinc DTPA SY NCI Zinc, (((Carboxymethylimino)bis(ethylenenitrilo))tetraacetato)- SY NCI Zincate(3-), (N,N-bis(2-(((carboxy-kappaO)methyl)(carboxymethyl)amino-kappaN)ethyl)glycinato(5-)-kappaN,kappaO)-, Trihydrogen SN NCI Zn-DTPA AB NCI ZnDTPA AB NCI The zinc salt form of diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. NCI Thesaurus:C120925 C120925 Intellectual Product Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.1 C4053990 CDISC The 3.1 version of the standard for exchange of nonclinical data (SEND) implementation guide. (NCI) SEND IG Version 3.1 SEND IMPLEMENTATION GUIDE VERSION 3.1 Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.1 The 3.1 version of the standard for exchange of nonclinical data (SEND) implementation guide. The 3.1 version of the standard for exchange of nonclinical data (SEND) implementation guide. Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.1 The 3.1 version of the standard for exchange of nonclinical data (SEND) implementation guide. (NCI) CDISC SEND IG Version 3.1 SY CDISC SEND IMPLEMENTATION GUIDE VERSION 3.1 PT CDISC Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.1 PT NCI The 3.1 version of the standard for exchange of nonclinical data (SEND) implementation guide. NCI Thesaurus:C124638 C124638 Intellectual Product SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.0 C4086834 CDISC The 1.0 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology implementation guide. SEND DART IG v1.0 SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.0 SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.0 SEND IG DART Version 1.0 The 1.0 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide. The 1.0 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide. SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.0 The 1.0 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology implementation guide. CDISC SEND DART IG v1.0 SY NCI SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.0 PT CDISC SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.0 PT NCI SEND IG DART Version 1.0 SY CDISC The 1.0 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide. NCI Thesaurus:C128640 C128640 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadopiclenol Gadopiclenol CL509066 933983-75-6 S276568KOY CTRP FDA 783022 783022 783022 (alpha3,alpha6,alpha9-Tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-kappaN3,kappaN6,kappaN9,kappaN15,kappaO3,kappaO6,kappaO9)gadolinium GADOPICLENOL GBCA P03277 Gadolinium-based Magnetic Resonance Contrast Agent P03277 Gadopiclenol P 03277 P03277 WHO 10744 A gadolinium-based paramagnetic contrast agent, with potential imaging enhancing activity upon magnetic resonance imaging (MRI). Upon administration of gadopiclenol and placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues is enhanced compared to unenhanced MRI. A gadolinium-based paramagnetic contrast agent, with potential imaging enhancing activity upon magnetic resonance imaging (MRI). Upon administration of gadopiclenol and placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues is enhanced compared to unenhanced MRI. Gadopiclenol (alpha3,alpha6,alpha9-Tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-kappaN3,kappaN6,kappaN9,kappaN15,kappaO3,kappaO6,kappaO9)gadolinium SY NCI GADOPICLENOL PT FDA S276568KOY UNII GBCA P03277 SY NCI Gadolinium-based Magnetic Resonance Contrast Agent P03277 SY NCI Gadopiclenol DN CTRP Gadopiclenol PT NCI P 03277 CN NCI P03277 CN NCI WHO 10744 SY NCI A gadolinium-based paramagnetic contrast agent, with potential imaging enhancing activity upon magnetic resonance imaging (MRI). Upon administration of gadopiclenol and placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues is enhanced compared to unenhanced MRI. NCI Thesaurus:C129651 C129651 Indicator, Reagent, or Diagnostic Aid Organic Chemical Polysiloxane/Gadolinium Chelates-based Nanoparticles Polysiloxane/Gadolinium Chelates-based Nanoparticles CL512625 CTRP 784215 784215 784215 AGuIX AGuIX-NP Gadolinium-Based Nanoparticle Polysiloxane Matrix-gadolinium Chelates-based Nanoparticles Polysiloxane/Gadolinium Chelates-based Nanoparticles Polysiloxane/Gadolinium-DOTA Chelates-based Nanoparticles A nanoparticle formulation composed of a polysiloxane-based inorganic matrix bound to cyclic chelates composed of the chelating agent DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently bound to the paramagnetic contrast enhancer gadolinium (Gd), a high-Z material, with potential use in enhancing diagnostic images upon magnetic resonance imaging (MRI) and potential radiosensitizing activity. Upon intravenous administration of polysiloxane matrix-gadolinium chelates-based nanoparticles, the nanoparticles extravasate to tumor sites due to the unique, hyperpermeable environment of the tumor vasculature. In addition, the small nanoparticles allow for deep penetration into the tumor, where they subsequently accumulate. Upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues are enhanced compared to unenhanced MRI. The ultra-small nanoparticles, less than 5 nm in diameter, allow for rapid renal clearance and reduced toxicity. Due to their magnetic properties, these nanoparticles make tumor cells more sensitive to radiation therapy. A nanoparticle formulation composed of a polysiloxane-based inorganic matrix bound to cyclic chelates composed of the chelating agent DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently bound to the paramagnetic contrast enhancer gadolinium (Gd), a high-Z material, with potential use in enhancing diagnostic images upon magnetic resonance imaging (MRI) and potential radiosensitizing activity. Upon intravenous administration of polysiloxane matrix-gadolinium chelates-based nanoparticles, the nanoparticles extravasate to tumor sites due to the unique, hyperpermeable environment of the tumor vasculature. In addition, the small nanoparticles allow for deep penetration into the tumor, where they subsequently accumulate. Upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues are enhanced compared to unenhanced MRI. The ultra-small nanoparticles, less than 5 nm in diameter, allow for rapid renal clearance and reduced toxicity. Due to their magnetic properties, these nanoparticles make tumor cells more sensitive to radiation therapy. Polysiloxane/Gadolinium Chelates-based Nanoparticles AGuIX FB NCI AGuIX-NP SY NCI Gadolinium-Based Nanoparticle SY NCI Polysiloxane Matrix-gadolinium Chelates-based Nanoparticles SY NCI Polysiloxane/Gadolinium Chelates-based Nanoparticles DN CTRP Polysiloxane/Gadolinium Chelates-based Nanoparticles PT NCI Polysiloxane/Gadolinium-DOTA Chelates-based Nanoparticles SY NCI A nanoparticle formulation composed of a polysiloxane-based inorganic matrix bound to cyclic chelates composed of the chelating agent DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently bound to the paramagnetic contrast enhancer gadolinium (Gd), a high-Z material, with potential use in enhancing diagnostic images upon magnetic resonance imaging (MRI) and potential radiosensitizing activity. Upon intravenous administration of polysiloxane matrix-gadolinium chelates-based nanoparticles, the nanoparticles extravasate to tumor sites due to the unique, hyperpermeable environment of the tumor vasculature. In addition, the small nanoparticles allow for deep penetration into the tumor, where they subsequently accumulate. Upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues are enhanced compared to unenhanced MRI. The ultra-small nanoparticles, less than 5 nm in diameter, allow for rapid renal clearance and reduced toxicity. Due to their magnetic properties, these nanoparticles make tumor cells more sensitive to radiation therapy. NCI Thesaurus:C1333 C1333 Organic Chemical Pharmacologic Substance Dexrazoxane Dexrazoxane 169780 C0086444 24584-09-6 Chemotherapy-induced cardiomyopathy 048L81261F CTRP FDA PCDC The active ingredient in a drug used to treat severe side effects caused by certain anticancer drugs. Under the brand name Totect it is used to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. Under the brand name Zinecard it is used to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor. C11H16N4O4 Dexrazoxane CHEBI:50223 Dexrazoxane (+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione) 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI) 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI) 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI) 2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI) ADR-529 DEXRAZOXANE Dexrazoxane ICRF-187 Razoxane (+)-form Soluble ICRF (L-isomer) dexrazoxane A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. Dexrazoxane The active ingredient in a drug used to treat severe side effects caused by certain anticancer drugs. Under the brand name Totect it is used to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. Under the brand name Zinecard it is used to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor. NCI-GLOSS Dexrazoxane Has Synonym PT therapeutic_agents GDC (+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione) SN NCI 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI) SY DTP NSC0169780 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI) SY DTP NSC0169780 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI) SN NCI 2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI) SN NCI ADR-529 CN NCI DEXRAZOXANE PT FDA 048L81261F UNII Dexrazoxane DN CTRP Dexrazoxane PT DCP 06178 Dexrazoxane PT NCI Dexrazoxane PT PCDC AML Dexrazoxane PT PCDC HL ICRF-187 CN NCI ICRF-187 SY DTP NSC0169780 Razoxane (+)-form SY NCI Soluble ICRF (L-isomer) SY DTP NSC0169780 dexrazoxane PT NCI-GLOSS CDR0000045220 A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. NCI Thesaurus:C133974 C133974 Laboratory Procedure Crystallinity CL521822 Crystallinity The detection and quantification of the amount of amorphous material within a highly crystalline substance. The detection and quantification of the amount of amorphous material within a highly crystalline substance. Crystallinity Crystallinity PT NCI The detection and quantification of the amount of amorphous material within a highly crystalline substance. NCI Thesaurus:C142663 C142663 Idea or Concept Raw Data CL540608 CDISC-GLOSS Data as originally collected. Distinct from derived. Raw data includes records of original observations, measurements, and activities (such as laboratory notes, evaluations, data recorded by automated instruments) without conclusions or interpretations. Researcher's records of subjects/patients, such as patient medical charts, hospital records, X-rays, and attending physician's notes. NOTE: These records may or may not accompany an application to a Regulatory authority, but must be kept in the researcher's file. See also eSource, source data, source documents. Raw Data raw data The original information, collected from the primary source. The original information, collected from the primary source. Raw Data Data as originally collected. Distinct from derived. Raw data includes records of original observations, measurements, and activities (such as laboratory notes, evaluations, data recorded by automated instruments) without conclusions or interpretations. Researcher's records of subjects/patients, such as patient medical charts, hospital records, X-rays, and attending physician's notes. NOTE: These records may or may not accompany an application to a Regulatory authority, but must be kept in the researcher's file. See also eSource, source data, source documents. CDISC-GLOSS Raw Data PT NCI raw data PT CDISC-GLOSS The original information, collected from the primary source. NCI Thesaurus:C1496 C1496 Organic Chemical Pharmacologic Substance DOTMP 681106 C0217981 91987-74-5 65F5KPT4JK FDA DOTMP (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene))tetrakisphosphonic Acid 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetramethylene-Phosphonic Acid DOTMP A bone-seeking chelating agent. Has been used as a radiopharmaceutical in complexes with radioactive metals for bone marrow ablation. A bone-seeking chelating agent. Has been used as a radiopharmaceutical in complexes with radioactive metals for bone marrow ablation. DOTMP (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene))tetrakisphosphonic Acid SN NCI 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetramethylene-Phosphonic Acid SN NCI DOTMP PT FDA 65F5KPT4JK UNII DOTMP PT NCI A bone-seeking chelating agent. Has been used as a radiopharmaceutical in complexes with radioactive metals for bone marrow ablation. NCI Thesaurus:C153135 C153135 Intellectual Product Study Subject Experience Document Version CL554392 BRIDG Study Subject Experience Document Version StudySubjectExperienceDocumentVersion A document capturing the actual end-to-end (or beginning to point-in-time) experience of a single study subject within the context of a particular study. A document capturing the actual end-to-end (or beginning to point-in-time) experience of a single study subject within the context of a particular study. Study Subject Experience Document Version Study Subject Experience Document Version PT NCI StudySubjectExperienceDocumentVersion SY BRIDG A document capturing the actual end-to-end (or beginning to point-in-time) experience of a single study subject within the context of a particular study. NCI Thesaurus:C156231 C156231 Therapeutic or Preventive Procedure Reactive Therapy Reactive Therapy CL563205 CTRP Reactive Reactive Therapy Therapy that is received or administered after a condition or symptom begins. Therapy that is received or administered after a condition or symptom begins. Reactive Therapy Reactive SY NCI Reactive Therapy DN CTRP Reactive Therapy PT NCI Therapy that is received or administered after a condition or symptom begins. NCI Thesaurus:C156604 C156604 Conceptual Entity Study Data Tabulation Model Implementation Guide Version CL935792 CDISC The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission. SDTIGVER SDTM IG Version SDTM Implementation Guide Version Study Data Tabulation Model Implementation Guide Version The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission. The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission. Study Data Tabulation Model Implementation Guide Version The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission. CDISC SDTIGVER PT CDISC SDTM-TSPARMCD SDTM IG Version PT CDISC SDTM-TSPARM SDTM IG Version SY CDISC SDTM IG Version SY NCI SDTM Implementation Guide Version SY CDISC Study Data Tabulation Model Implementation Guide Version PT NCI The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission. NCI Thesaurus:C156605 C156605 Conceptual Entity Study Data Tabulation Model Version CL935785 CDISC The version of the CDISC Study Data Tabulation Model that is being used in the study submission. SDTM Version SDTMVER Study Data Tabulation Model Version The version of the CDISC Study Data Tabulation Model that is being used in the study submission. The version of the CDISC Study Data Tabulation Model that is being used in the study submission. Study Data Tabulation Model Version The version of the CDISC Study Data Tabulation Model that is being used in the study submission. CDISC SDTM Version PT CDISC SDTM-TSPARM SDTM Version SY CDISC SDTM Version SY NCI SDTMVER PT CDISC SDTM-TSPARMCD Study Data Tabulation Model Version PT NCI The version of the CDISC Study Data Tabulation Model that is being used in the study submission. NCI Thesaurus:C156616 C156616 Conceptual Entity SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.1 CL935776 CDISC The 1.1 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology implementation guide. SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.1 SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.1 SEND IG DART Version 1.1 The 1.1 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide. The 1.1 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide. SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.1 The 1.1 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology implementation guide. CDISC SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.1 PT CDISC SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.1 PT NCI SEND IG DART Version 1.1 SY CDISC The 1.1 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide. NCI Thesaurus:C157206 C157206 Phenomenon or Process Adsorption C0001674 CBDD Adsorption The adhesion of a gas, liquid or dissolved solid chemical of interest onto a solid surface. The adhesion of a gas, liquid or dissolved solid chemical of interest onto a solid surface. Adsorption Adsorption PT CBDD Adsorption PT NCI The adhesion of a gas, liquid or dissolved solid chemical of interest onto a solid surface. NCI Thesaurus:C160684 C160684 Pharmacologic Substance Tetrathiomolybdate Tetrathiomolybdate CL969619 16330-92-0 91U3TGV99T CTRP FDA Tetrathiomolybdate CCRIS 9412 Molybdate(2-), Tetrathioxo-, (T-4)- (9CI) TIOMOLIBDATE ION TM Tetrathiomolybdate Tetrathioxomolybdate(2-) An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. Tetrathiomolybdate Tetrathiomolybdate Has Synonym PT therapeutic_agents GDC CCRIS 9412 CN NCI Molybdate(2-), Tetrathioxo-, (T-4)- (9CI) SN NCI TIOMOLIBDATE ION PT FDA 91U3TGV99T UNII TM AB NCI Tetrathiomolybdate DN CTRP Tetrathiomolybdate PT NCI Tetrathioxomolybdate(2-) SY NCI An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. NCI Thesaurus:C161425 C161425 Conceptual Entity CDISC SDTM Model Version 1.1 CL971247 CDISC Version 1.1 of the CDISC Study Data Tabulation Model (SDTM). 1.1 CDISC SDTM Model Version 1.1 SDTM Version 1.1 The 1.1 version of the CDISC Study Data Tabulation Model (SDTM). The 1.1 version of the CDISC Study Data Tabulation Model (SDTM). CDISC SDTM Model Version 1.1 Version 1.1 of the CDISC Study Data Tabulation Model (SDTM). CDISC 1.1 PT CDISC CDISC SDTM Model Version 1.1 PT NCI SDTM Version 1.1 SY CDISC The 1.1 version of the CDISC Study Data Tabulation Model (SDTM). NCI Thesaurus:C161426 C161426 Conceptual Entity CDISC SDTM Model Version 1.2 CL971181 CDISC Version 1.2 of the CDISC Study Data Tabulation Model (SDTM). 1.2 CDISC SDTM Model Version 1.2 SDTM Version 1.2 The 1.2 version of the CDISC Study Data Tabulation Model (SDTM). The 1.2 version of the CDISC Study Data Tabulation Model (SDTM). CDISC SDTM Model Version 1.2 Version 1.2 of the CDISC Study Data Tabulation Model (SDTM). CDISC 1.2 PT CDISC CDISC SDTM Model Version 1.2 PT NCI SDTM Version 1.2 SY CDISC The 1.2 version of the CDISC Study Data Tabulation Model (SDTM). NCI Thesaurus:C161427 C161427 Conceptual Entity CDISC SDTM Model Version 1.3 CL971166 CDISC Version 1.3 of the CDISC Study Data Tabulation Model (SDTM). 1.3 CDISC SDTM Model Version 1.3 SDTM Version 1.3 The 1.3 version of the CDISC Study Data Tabulation Model (SDTM). The 1.3 version of the CDISC Study Data Tabulation Model (SDTM). CDISC SDTM Model Version 1.3 Version 1.3 of the CDISC Study Data Tabulation Model (SDTM). CDISC 1.3 PT CDISC CDISC SDTM Model Version 1.3 PT NCI SDTM Version 1.3 SY CDISC The 1.3 version of the CDISC Study Data Tabulation Model (SDTM). NCI Thesaurus:C161428 C161428 Conceptual Entity CDISC SDTM Model Version 1.4 CL971168 CDISC Version 1.4 of the CDISC Study Data Tabulation Model (SDTM). 1.4 CDISC SDTM Model Version 1.4 SDTM Version 1.4 The 1.4 version of the CDISC Study Data Tabulation Model (SDTM). The 1.4 version of the CDISC Study Data Tabulation Model (SDTM). CDISC SDTM Model Version 1.4 Version 1.4 of the CDISC Study Data Tabulation Model (SDTM). CDISC 1.4 PT CDISC CDISC SDTM Model Version 1.4 PT NCI SDTM Version 1.4 SY CDISC The 1.4 version of the CDISC Study Data Tabulation Model (SDTM). NCI Thesaurus:C161429 C161429 Conceptual Entity CDISC SDTM Model Version 1.5 CL971207 CDISC Version 1.5 of the CDISC Study Data Tabulation Model (SDTM). 1.5 CDISC SDTM Model Version 1.5 SDTM Version 1.5 The 1.5 version of the CDISC Study Data Tabulation Model (SDTM). The 1.5 version of the CDISC Study Data Tabulation Model (SDTM). CDISC SDTM Model Version 1.5 Version 1.5 of the CDISC Study Data Tabulation Model (SDTM). CDISC 1.5 PT CDISC CDISC SDTM Model Version 1.5 PT NCI SDTM Version 1.5 SY CDISC The 1.5 version of the CDISC Study Data Tabulation Model (SDTM). NCI Thesaurus:C161430 C161430 Conceptual Entity CDISC SDTM Model Version 1.6 CL971230 CDISC Version 1.6 of the CDISC Study Data Tabulation Model (SDTM). 1.6 CDISC SDTM Model Version 1.6 SDTM Version 1.6 The 1.6 version of the CDISC Study Data Tabulation Model (SDTM). The 1.6 version of the CDISC Study Data Tabulation Model (SDTM). CDISC SDTM Model Version 1.6 Version 1.6 of the CDISC Study Data Tabulation Model (SDTM). CDISC 1.6 PT CDISC CDISC SDTM Model Version 1.6 PT NCI SDTM Version 1.6 SY CDISC The 1.6 version of the CDISC Study Data Tabulation Model (SDTM). NCI Thesaurus:C161431 C161431 Conceptual Entity CDISC SDTM Model Version 1.7 CL971229 CDISC Version 1.7 of the CDISC Study Data Tabulation Model (SDTM). 1.7 CDISC SDTM Model Version 1.7 SDTM Version 1.7 The 1.7 version of the CDISC Study Data Tabulation Model (SDTM). The 1.7 version of the CDISC Study Data Tabulation Model (SDTM). CDISC SDTM Model Version 1.7 Version 1.7 of the CDISC Study Data Tabulation Model (SDTM). CDISC 1.7 PT CDISC CDISC SDTM Model Version 1.7 PT NCI SDTM Version 1.7 SY CDISC The 1.7 version of the CDISC Study Data Tabulation Model (SDTM). NCI Thesaurus:C161432 C161432 Conceptual Entity CDISC SDTM Implementation Guide Version 3.1.1 CL970056 CDISC Version 3.1.1 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. 3.1.1 CDISC SDTM Implementation Guide Version 3.1.1 SDTMIG Version 3.1.1 The 3.1.1 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. The 3.1.1 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. CDISC SDTM Implementation Guide Version 3.1.1 Version 3.1.1 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. CDISC 3.1.1 PT CDISC CDISC SDTM Implementation Guide Version 3.1.1 PT NCI SDTMIG Version 3.1.1 SY CDISC The 3.1.1 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. NCI Thesaurus:C161433 C161433 Conceptual Entity CDISC SDTM Implementation Guide Version 3.1.2 CL971243 CDISC Version 3.1.2 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. 3.1.2 CDISC SDTM Implementation Guide Version 3.1.2 SDTMIG Version 3.1.2 The 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. The 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. CDISC SDTM Implementation Guide Version 3.1.2 Version 3.1.2 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. CDISC 3.1.2 PT CDISC CDISC SDTM Implementation Guide Version 3.1.2 PT NCI SDTMIG Version 3.1.2 SY CDISC The 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. NCI Thesaurus:C161434 C161434 Conceptual Entity CDISC SDTM Implementation Guide Version 3.1.2 Amendment 1 CL970055 CDISC Amendment 1 of the 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. CDISC SDTM Implementation Guide Version 3.1.2 Amendment 1 SDTMIG Version 3.1.2 Amendment 1 Version 3.1.2 Amendment 1 Amendment 1 of the 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. Amendment 1 of the 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. CDISC SDTM Implementation Guide Version 3.1.2 Amendment 1 Amendment 1 of the 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. CDISC CDISC SDTM Implementation Guide Version 3.1.2 Amendment 1 PT NCI SDTMIG Version 3.1.2 Amendment 1 SY CDISC Version 3.1.2 Amendment 1 PT CDISC Amendment 1 of the 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. NCI Thesaurus:C161435 C161435 Conceptual Entity CDISC SDTM Implementation Guide Version 3.1.3 CL970054 CDISC Version 3.1.3 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. 3.1.3 CDISC SDTM Implementation Guide Version 3.1.3 SDTMIG Version 3.1.3 The 3.1.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. The 3.1.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. CDISC SDTM Implementation Guide Version 3.1.3 Version 3.1.3 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. CDISC 3.1.3 PT CDISC CDISC SDTM Implementation Guide Version 3.1.3 PT NCI SDTMIG Version 3.1.3 SY CDISC The 3.1.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. NCI Thesaurus:C161436 C161436 Conceptual Entity CDISC SDTM Implementation Guide Version 3.2 CL971214 CDISC Version 3.2 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. 3.2 CDISC SDTM Implementation Guide Version 3.2 SDTMIG Version 3.2 The 3.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. The 3.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. CDISC SDTM Implementation Guide Version 3.2 Version 3.2 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. CDISC 3.2 PT CDISC CDISC SDTM Implementation Guide Version 3.2 PT NCI SDTMIG Version 3.2 SY CDISC The 3.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. NCI Thesaurus:C161437 C161437 Conceptual Entity CDISC SDTM Implementation Guide Version 3.3 CL971233 CDISC Version 3.3 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. 3.3 CDISC SDTM Implementation Guide Version 3.3 SDTMIG Version 3.3 The 3.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. The 3.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. CDISC SDTM Implementation Guide Version 3.3 Version 3.3 of the CDISC Study Data Tabulation Model (SDTM) Implementation Guide. CDISC 3.3 PT CDISC CDISC SDTM Implementation Guide Version 3.3 PT NCI SDTMIG Version 3.3 SY CDISC The 3.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide. NCI Thesaurus:C162667 C162667 Conceptual Entity Principal Statistical Analysis Plan Version CL973121 BRIDG A type of statistical analysis plan that is the main, comprehensive, pre-specified collection of analyses that support the Clinical Study Report (CSR) or other similar study report. Principal Statistical Analysis Plan Version PrincipalStatisticalAnalysisPlanVersion Principal Statistical Analysis Plan Version A type of statistical analysis plan that is the main, comprehensive, pre-specified collection of analyses that support the Clinical Study Report (CSR) or other similar study report. BRIDG Principal Statistical Analysis Plan Version PT NCI PrincipalStatisticalAnalysisPlanVersion PT BRIDG Thesaurus:C162668 C162668 Conceptual Entity Statistical Analysis Plan Document Version CL973118 BRIDG A representation, conceptually a document, that is created to convey the statistical analysis plan version structured content to human beings. Statistical Analysis Plan Document Version StatisticalAnalysisPlanDocumentVersion Statistical Analysis Plan Document Version A representation, conceptually a document, that is created to convey the statistical analysis plan version structured content to human beings. BRIDG Statistical Analysis Plan Document Version PT NCI StatisticalAnalysisPlanDocumentVersion PT BRIDG Thesaurus:C164455 C164455 Conceptual Entity Assembly Version CL977755 BRIDG Assembly Version assemblyVersion The version identifier for the assembly. The version identifier for the assembly. Assembly Version Assembly Version PT NCI assemblyVersion PT BRIDG 5.3 The version identifier for the assembly. NCI Thesaurus:C164815 C164815 Conceptual Entity Genome Assembly Version CL977899 BRIDG CTDC The source-specific version of the genome assembly. EXAMPLE(S): (Human Genome) Build 35 OTHER NAME(S): NOTE(S): Genome Assembly Version Genome.assemblyVersion reference genome reference_genome The source-specific version of the published genome assembly. The source-specific version of the published genome assembly. Genome Assembly Version The source-specific version of the genome assembly. EXAMPLE(S): (Human Genome) Build 35 OTHER NAME(S): NOTE(S): BRIDG 5.3 Genome Assembly Version PT NCI Genome.assemblyVersion PT BRIDG 5.3 reference genome SY CTDC reference_genome PT CTDC The source-specific version of the published genome assembly. NCI Thesaurus:C165152 C165152 Intellectual Product Study Site Investigator Identifier CL978303 BRIDG A unique symbol that establishes identity of the study site investigator. EXAMPLE(S): OTHER NAME(S): NOTE(S): Open issue: Need to know if this is actually an identifier specifically assigned to an investigator specific to a particular study and site. Study Site Investigator Identifier StudySiteInvestigator.identifier Study Site Investigator Identifier A unique symbol that establishes identity of the study site investigator. EXAMPLE(S): OTHER NAME(S): NOTE(S): Open issue: Need to know if this is actually an identifier specifically assigned to an investigator specific to a particular study and site. BRIDG 5.3 Study Site Investigator Identifier PT NCI StudySiteInvestigator.identifier PT BRIDG 5.3 Thesaurus:C16583 C16583 Activity Filtration C0016107 Filtration Filtration Fractionation, Filtration The process of passing a liquid or gas through a filter. The process of passing a liquid or gas through a filter. Filtration Filtration PT NCI Fractionation, Filtration SY NCI The process of passing a liquid or gas through a filter. NCI Thesaurus:C166514 C166514 Indicator, Reagent, or Diagnostic Aid Gadocoletic Acid CL971513 280765-60-8 1S4079691T FDA GADOCOLETIC ACID Gadocoletic Acid Gadocoletic Acid GADOCOLETIC ACID PT FDA 1S4079691T UNII Gadocoletic Acid PT NCI Thesaurus:C166741 C166741 Indicator, Reagent, or Diagnostic Aid Gadoxanum CL971736 177072-49-0 49HMY3U54K FDA GADOXANUM Gadoxanum Gadoxanum GADOXANUM PT FDA 49HMY3U54K UNII Gadoxanum PT NCI Thesaurus:C166753 C166753 Pharmacologic Substance Deferitazole CL971748 945635-15-4 4D8DC53Y1L FDA DEFERITAZOLE Deferitazole Deferitazole DEFERITAZOLE PT FDA 4D8DC53Y1L UNII Deferitazole PT NCI Thesaurus:C166785 C166785 Pharmacologic Substance Emeramide CL971780 351994-94-0 4U7K5X4ANS FDA EMERAMIDE Emeramide Emeramide EMERAMIDE PT FDA 4U7K5X4ANS UNII Emeramide PT NCI Thesaurus:C166881 C166881 Pharmacologic Substance Pendetide CL972127 148805-91-8 60C8D1C9UJ FDA PENDETIDE Pendetide Pendetide PENDETIDE PT FDA 60C8D1C9UJ UNII Pendetide PT NCI Thesaurus:C167212 C167212 Pharmacologic Substance Phytate Persodium CL972437 17211-15-3 3F6PM8J684 FDA Myo-Inositol, Hexakis(dihydrogen Phosphate), Dodecasodium Salt PHYTATE PERSODIUM Phytate Persodium Phytate Persodium Myo-Inositol, Hexakis(dihydrogen Phosphate), Dodecasodium Salt SN NCI PHYTATE PERSODIUM PT FDA 3F6PM8J684 UNII Phytate Persodium PT NCI Thesaurus:C1710 C1710 Organic Chemical Pharmacologic Substance Pentetic Acid Calcium Pentetic Acid Calcium C4048602 2531-75-1 CTRP A drug that protects healthy tissues from the toxic effects of anticancer drugs. 42562 42562 Pentetic_Acid_Calcium 42562 Ca-DTPA Calcium DTPA Calcium Pentetic Acid Calcium-DTPA Pentetic Acid Calcium pentetic acid calcium The calcium salt of pentetic acid, a synthetic chelating agent related to the chelating agent ethylenediaminetetraacetic acid (EDTA). Pentetic acid chelates with the metallic radioisotopic moieties of unbound, extracellular radioimmunotherapeutic agents, resulting in higher specific tumor cell binding of radioimmunotherapeutic agents; this results in improved tumor cell radiocytotoxicity and the sparing of normal cells and tissues from the radiocytotoxic effects of these agents. The calcium salt of pentetic acid, a synthetic chelating agent related to the chelating agent ethylenediaminetetraacetic acid (EDTA). Pentetic acid chelates with the metallic radioisotopic moieties of unbound, extracellular radioimmunotherapeutic agents, resulting in higher specific tumor cell binding of radioimmunotherapeutic agents; this results in improved tumor cell radiocytotoxicity and the sparing of normal cells and tissues from the radiocytotoxic effects of these agents. Pentetic Acid Calcium A drug that protects healthy tissues from the toxic effects of anticancer drugs. NCI-GLOSS Ca-DTPA AB NCI Calcium DTPA SY NCI Calcium Pentetic Acid SY NCI Calcium-DTPA SY NCI Pentetic Acid Calcium DN CTRP Pentetic Acid Calcium PT NCI pentetic acid calcium PT NCI-GLOSS CDR0000045514 The calcium salt of pentetic acid, a synthetic chelating agent related to the chelating agent ethylenediaminetetraacetic acid (EDTA). Pentetic acid chelates with the metallic radioisotopic moieties of unbound, extracellular radioimmunotherapeutic agents, resulting in higher specific tumor cell binding of radioimmunotherapeutic agents; this results in improved tumor cell radiocytotoxicity and the sparing of normal cells and tissues from the radiocytotoxic effects of these agents. NCI Thesaurus:C171757 C171757 Pharmacologic Substance Cabiotraxetan CL1405746 451478-45-8 A62K1QBW55 FDA CABIOTRAXETAN Cabiotraxetan Cabiotraxetan CABIOTRAXETAN PT FDA A62K1QBW55 UNII Cabiotraxetan PT NCI Thesaurus:C171822 C171822 Pharmacologic Substance Deferitazole Magnesium CL1405989 1173092-59-5 BG3Q8O5L5B FDA DEFERITAZOLE MAGNESIUM Deferitazole Magnesium Deferitazole Magnesium DEFERITAZOLE MAGNESIUM PT FDA BG3Q8O5L5B UNII Deferitazole Magnesium PT NCI Thesaurus:C173314 C173314 Conceptual Entity Adverse Event System Grading Version CL1407177 PCDC AE_SYSTEM_VERSION Adverse Event System Grading Version The version of the adverse event grading system. The version of the adverse event grading system. Adverse Event System Grading Version AE_SYSTEM_VERSION PT PCDC HL Adverse Event System Grading Version PT NCI The version of the adverse event grading system. NCI AE_SYSTEM_VERSION PT PCDC ALL AE_SYSTEM_VERSION PT PCDC AML AE_SYSTEM_VERSION PT PCDC EWS Thesaurus:C173567 C173567 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadolinium-based Contrast Agent BAY1747846 Gadolinium-based Contrast Agent BAY1747846 CL1407306 CTRP 802236 802236 802236 BAY 1747846 BAY-1747846 BAY1747846 GBCA BAY1747846 Gadolinium-based Contrast Agent BAY1747846 Gd-based Contrast Agent BAY1747846 A gadolinium (Gd)-based contrast agent (GBCA) that can potentially be used for contrast-enhanced MRI (CE-MRI). Upon intravenous administration of GBCA BAY1747846, and upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated due to abnormal vascularity and altered perfusion. This allows for enhanced contrast and visualization of those tissues compared to unenhanced MRI. A gadolinium (Gd)-based contrast agent (GBCA) that can potentially be used for contrast-enhanced MRI (CE-MRI). Upon intravenous administration of GBCA BAY1747846, and upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated due to abnormal vascularity and altered perfusion. This allows for enhanced contrast and visualization of those tissues compared to unenhanced MRI. Gadolinium-based Contrast Agent BAY1747846 BAY 1747846 CN NCI BAY-1747846 CN NCI BAY1747846 CN NCI GBCA BAY1747846 SY NCI Gadolinium-based Contrast Agent BAY1747846 DN CTRP Gadolinium-based Contrast Agent BAY1747846 PT NCI Gd-based Contrast Agent BAY1747846 SY NCI A gadolinium (Gd)-based contrast agent (GBCA) that can potentially be used for contrast-enhanced MRI (CE-MRI). Upon intravenous administration of GBCA BAY1747846, and upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated due to abnormal vascularity and altered perfusion. This allows for enhanced contrast and visualization of those tissues compared to unenhanced MRI. NCI Thesaurus:C174386 C174386 Intellectual Product SEND Animal Rule Implementation Guide Version 1.0 CL1411958 CDISC The 1.0 version of the standard for exchange of nonclinical data (SEND) animal rule implementation guide. SEND ANIMAL RULE IMPLEMENTATION GUIDE VERSION 1.0 SEND Animal Rule Implementation Guide Version 1.0 SEND IG AR Version 1.0 SENDIG AR Version 1.0 SENDIG-AR 1.0 The 1.0 version of the standard for exchange of nonclinical data (SEND) animal rule implementation guide. The 1.0 version of the standard for exchange of nonclinical data (SEND) animal rule implementation guide. SEND Animal Rule Implementation Guide Version 1.0 The 1.0 version of the standard for exchange of nonclinical data (SEND) animal rule implementation guide. CDISC SEND ANIMAL RULE IMPLEMENTATION GUIDE VERSION 1.0 PT CDISC SEND Animal Rule Implementation Guide Version 1.0 PT NCI SEND IG AR Version 1.0 SY CDISC SENDIG AR Version 1.0 SY CDISC SENDIG-AR 1.0 SY CDISC The 1.0 version of the standard for exchange of nonclinical data (SEND) animal rule implementation guide. NCI Thesaurus:C174713 C174713 Indicator, Reagent, or Diagnostic Aid Gadomelitol CL1412257 308814-41-7 ML3LD67ALG FDA GADOMELITOL Gadomelitol Gadomelitol GADOMELITOL PT FDA ML3LD67ALG UNII Gadomelitol PT NCI Thesaurus:C174900 C174900 Indicator, Reagent, or Diagnostic Aid Gadoteric Acid CL1412138 72573-82-1 QVF9Y6955W FDA GADOTERIC ACID Gadoteric Acid Gadoteric Acid GADOTERIC ACID PT FDA QVF9Y6955W UNII Gadoteric Acid PT NCI Thesaurus:C174908 C174908 Pharmacologic Substance Barzuxetan CL1412448 157380-45-5 R6D8CX2KCP FDA BARZUXETAN Barzuxetan Barzuxetan BARZUXETAN PT FDA R6D8CX2KCP UNII Barzuxetan PT NCI Thesaurus:C175042 C175042 Conceptual Entity Response Criteria Version CL1412316 PCDC RESPONSE_CRITERIA_VERSION Response Criteria Version The version of the response criteria. The version of the response criteria. Response Criteria Version RESPONSE_CRITERIA_VERSION PT PCDC EWS RESPONSE_CRITERIA_VERSION PT PCDC GCT Response Criteria Version PT NCI The version of the response criteria. NCI Thesaurus:C17564 C17564 Intellectual Product Guideline C0162791 Guidelines Guideline Guidelines A systematic statement of policy rules or principles. Guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by convening expert panels. A systematic statement of policy rules or principles. Guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by convening expert panels. Guideline Guideline PT NCI Guidelines SY NCI A systematic statement of policy rules or principles. Guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by convening expert panels. NCI Thesaurus:C177919 C177919 Conceptual Entity CDISC Define-XML Version For Study CL1647710 CDISC The version of the CDISC Define-XML specification associated with the study submission. CDISC Define-XML Version For Study DFXMLVER Define-XML Version The version of the CDISC Define-XML specification associated with the study submission. The version of the CDISC Define-XML specification associated with the study submission. CDISC Define-XML Version For Study The version of the CDISC Define-XML specification associated with the study submission. CDISC CDISC Define-XML Version For Study PT NCI DFXMLVER PT CDISC SEND-STSPRMCD Define-XML Version PT CDISC SEND-STSPRM Define-XML Version SY CDISC The version of the CDISC Define-XML specification associated with the study submission. NCI Thesaurus:C178061 C178061 Conceptual Entity CDISC Define-XML Version 2.1 CL1647624 CDISC The 2.1 version of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML specification. CDISC Define-XML Version 2.1 DEFINE-XML 2.1 The 2.1 version of the CDISC Define-XML specification. The 2.1 version of the CDISC Define-XML specification. CDISC Define-XML Version 2.1 The 2.1 version of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML specification. CDISC CDISC Define-XML Version 2.1 PT NCI DEFINE-XML 2.1 PT CDISC The 2.1 version of the CDISC Define-XML specification. NCI Thesaurus:C178062 C178062 Conceptual Entity CDISC Define-XML Version 2.0 CL1647621 CDISC The 2.0 version of the Clinical Data Interchange specifications Consortium (CDISC) Define-XML specification. CDISC Define-XML Version 2.0 DEFINE-XML 2.0 The 2.0 version of the CDISC Define-XML specification. The 2.0 version of the CDISC Define-XML specification. CDISC Define-XML Version 2.0 The 2.0 version of the Clinical Data Interchange specifications Consortium (CDISC) Define-XML specification. CDISC CDISC Define-XML Version 2.0 PT NCI DEFINE-XML 2.0 PT CDISC The 2.0 version of the CDISC Define-XML specification. NCI Thesaurus:C178063 C178063 Conceptual Entity CDISC Define-XML Version 1.0 CL1647622 CDISC The 1.0 version of the Clinical Data Interchange specifications Consortium (CDISC) Define-XML specification. CDISC Define-XML Version 1.0 DEFINE-XML 1.0 The 1.0 version of the CDISC Define-XML specification. The 1.0 version of the CDISC Define-XML specification. CDISC Define-XML Version 1.0 The 1.0 version of the Clinical Data Interchange specifications Consortium (CDISC) Define-XML specification. CDISC CDISC Define-XML Version 1.0 PT NCI DEFINE-XML 1.0 PT CDISC The 1.0 version of the CDISC Define-XML specification. NCI Thesaurus:C178064 C178064 Pharmacologic Substance Iron Chelating Agent SP-420 Iron Chelating Agent SP-420 CL1647645 911714-45-9 WBX54NZ436 CTRP FDA (4S)-4,5-Dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic Acid Chelating Agent SP-420 Iron Chelating Agent SP-420 Iron Chelator SP-420 SP 420 SP-420 SP420 An orally bioavailable iron-chelating agent and derivative of desferrithiocin, with iron chelating and protective activities in diseases of iron overload. Upon oral administration, the iron chelating agent SP-420 targets, binds to and chelates free iron. This induces the excretion of iron, prevents iron accumulation and prevents cellular and/or tissue damage associated with iron overload. An orally bioavailable iron-chelating agent and derivative of desferrithiocin, with iron chelating and protective activities in diseases of iron overload. Upon oral administration, the iron chelating agent SP-420 targets, binds to and chelates free iron. This induces the excretion of iron, prevents iron accumulation and prevents cellular and/or tissue damage associated with iron overload. Iron Chelating Agent SP-420 (4S)-4,5-Dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic Acid SN NCI Chelating Agent SP-420 SY NCI Iron Chelating Agent SP-420 DN CTRP Iron Chelating Agent SP-420 PT NCI Iron Chelator SP-420 SY NCI SP 420 CN NCI SP-420 CN NCI SP-420 PT FDA WBX54NZ436 UNII SP420 CN NCI An orally bioavailable iron-chelating agent and derivative of desferrithiocin, with iron chelating and protective activities in diseases of iron overload. Upon oral administration, the iron chelating agent SP-420 targets, binds to and chelates free iron. This induces the excretion of iron, prevents iron accumulation and prevents cellular and/or tissue damage associated with iron overload. NCI Thesaurus:C181705 C181705 Intellectual Product ASCII Encoding Version for Read Group QC CL1770574 GDC ASCII Encoding Version for Read Group QC encoding The version of ASCII used to encode the read group quality control data. The version of ASCII used to encode the read group quality control data. ASCII Encoding Version for Read Group QC ASCII Encoding Version for Read Group QC PT NCI encoding PT GDC VAR The version of ASCII used to encode the read group quality control data. NCI Thesaurus:C181950 C181950 Conceptual Entity Nucleotide Base Caller Version CL1664921 GDC Nucleotide Base Caller Version base caller version base_caller_version The version of the software used to call the nucleotide bases in a sequencing assay. The version of the software used to call the nucleotide bases in a sequencing assay. Nucleotide Base Caller Version Nucleotide Base Caller Version PT NCI base caller version SY GDC VAR base_caller_version PT GDC VAR The version of the software used to call the nucleotide bases in a sequencing assay. NCI Thesaurus:C182087 C182087 Conceptual Entity Sequencing Library Preparation Kit Version CL1770697 GDC Sequencing Library Preparation Kit Version library preparation kit version library_preparation_kit_version The version for the nucleotide sequencing library kit. The version for the nucleotide sequencing library kit. Sequencing Library Preparation Kit Version Sequencing Library Preparation Kit Version PT NCI library preparation kit version SY GDC VAR library_preparation_kit_version PT GDC VAR The version for the nucleotide sequencing library kit. NCI Thesaurus:C182117 C182117 Conceptual Entity Data Analysis Workflow Version CL1770617 GDC Data Analysis Workflow Version workflow version workflow_version The version of the workflow used in data analysis. The version of the workflow used in data analysis. Data Analysis Workflow Version Data Analysis Workflow Version PT NCI workflow version SY GDC VAR workflow_version PT GDC VAR The version of the workflow used in data analysis. NCI Thesaurus:C184906 C184906 Pharmacologic Substance Hexasodium Phytate CL1772975 34367-89-0 ZBX50UG81V FDA HEXASODIUM PHYTATE Hexasodium Phytate Hexasodium Phytate HEXASODIUM PHYTATE PT FDA ZBX50UG81V UNII Hexasodium Phytate PT NCI Thesaurus:C184920 C184920 Indicator, Reagent, or Diagnostic Aid Gadoquatrane CL1772980 2048221-65-2 OZG7J613HK FDA GADOQUATRANE Gadoquatrane Gadoquatrane GADOQUATRANE PT FDA OZG7J613HK UNII Gadoquatrane PT NCI Thesaurus:C185281 C185281 Organic Chemical Pharmacologic Substance Intrathecal Deferoxamine Intrathecal Deferoxamine CL1773375 CTRP IT Deferoxamine IT Desferrioxamine IT-DFO Intrathecal Deferoxamine An intrathecal (IT) formulation of deferoxamine (DFO), an iron-chelating agent that can be used to deplete free iron and lower iron levels, and with potential antineoplastic activity. Upon IT administration via Ommaya reservoir, DFO chelates free iron within the cerebrospinal fluid (CSF) by forming the iron complex ferrioxamine. This lowers the amount of iron available for cancer cell growth and survival. Cancer cells show increased iron uptake as iron is needed for rapid tumor cell proliferation. An intrathecal (IT) formulation of deferoxamine (DFO), an iron-chelating agent that can be used to deplete free iron and lower iron levels, and with potential antineoplastic activity. Upon IT administration via Ommaya reservoir, DFO chelates free iron within the cerebrospinal fluid (CSF) by forming the iron complex ferrioxamine. This lowers the amount of iron available for cancer cell growth and survival. Cancer cells show increased iron uptake as iron is needed for rapid tumor cell proliferation. Intrathecal Deferoxamine IT Deferoxamine SY NCI IT Desferrioxamine SY NCI IT-DFO AB NCI Intrathecal Deferoxamine DN CTRP Intrathecal Deferoxamine PT NCI An intrathecal (IT) formulation of deferoxamine (DFO), an iron-chelating agent that can be used to deplete free iron and lower iron levels, and with potential antineoplastic activity. Upon IT administration via Ommaya reservoir, DFO chelates free iron within the cerebrospinal fluid (CSF) by forming the iron complex ferrioxamine. This lowers the amount of iron available for cancer cell growth and survival. Cancer cells show increased iron uptake as iron is needed for rapid tumor cell proliferation. NCI Thesaurus:C185691 C185691 Conceptual Entity CTCAE Version PCDC CTCAE Version LE_CTCAE_VERSION The version ofthe Common Terminology Criteria for Adverse Events (CTCAE) Terminology. The version ofthe Common Terminology Criteria for Adverse Events (CTCAE) Terminology. CTCAE Version CTCAE Version PT NCI LE_CTCAE_VERSION PT PCDC HL The version ofthe Common Terminology Criteria for Adverse Events (CTCAE) Terminology. NCI Thesaurus:C1972 C1972 Organic Chemical Pharmacologic Substance Deferoxamine Hydrochloride 268993 C1511755 1950-39-6 G9VYJ96FOJ FDA C25H48N6O8.HCl Deferoxamine_Hydrochloride Ba 29837 Ba-29837 DEFEROXAMINE HYDROCHLORIDE Deferoxamine HCl Deferoxamine Hydrochloride Deferoxamine hydrochloride The hydrochloride salt form of deferoxamine, an iron chelating agent. Deferoxamine chelates iron from intra-lysosomal ferritin and hemosiderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile. This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI) The hydrochloride salt form of deferoxamine, an iron chelating agent. Deferoxamine chelates iron from intra-lysosomal ferritin and hemosiderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile. This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI) Deferoxamine Hydrochloride Ba 29837 SY DTP NSC0527604 Ba-29837 CN NCI Ba-29837 SY DTP NSC0268993 DEFEROXAMINE HYDROCHLORIDE PT FDA G9VYJ96FOJ UNII Deferoxamine HCl SY NCI Deferoxamine Hydrochloride PT NCI Deferoxamine hydrochloride SY DTP NSC0268993 The hydrochloride salt form of deferoxamine, an iron chelating agent. Deferoxamine chelates iron from intra-lysosomal ferritin and hemosiderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile. This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI) NCI Thesaurus:C20610 C20610 Quantitative Concept Partition Coefficient C1518903 Partition_Coefficient Partition Coefficient A constant symbolizing the ratio of a dissolved substance in a two-phase system. (from EPA Terminology Reference System) A constant symbolizing the ratio of a dissolved substance in a two-phase system. (from EPA Terminology Reference System) Partition Coefficient Partition Coefficient PT NCI A constant symbolizing the ratio of a dissolved substance in a two-phase system. (from EPA Terminology Reference System) NCI Thesaurus:C25284 C25284 Functional Concept Type C0332307 BRIDG CDISC CareLex GDC An identifiable class based on common distinguishable qualities. Something distinguishable as an identifiable class based on common qualities.[NCI] Type Kind TYPE Type type Something distinguishable as an identifiable class based on common qualities. Something distinguishable as an identifiable class based on common qualities. Type An identifiable class based on common distinguishable qualities. CDISC Something distinguishable as an identifiable class based on common qualities.[NCI] CareLex Kind SY NCI TYPE PT CDISC Type PT CareLex Type PT NCI Type SY CDISC Type SY caDSR type PT BRIDG 5.3 type PT GDC VAR Something distinguishable as an identifiable class based on common qualities. NCI Thesaurus:C25365 C25365 Intellectual Product Description C0678257 BRIDG CDISC CareLex A written or verbal account, representation, statement, or explanation of something. (NCI) An account of the resource or content item. Description DESCR Desc Description Descriptive Descriptor description A written or verbal account, representation, statement, or explanation of something. A written or verbal account, representation, statement, or explanation of something. Description A written or verbal account, representation, statement, or explanation of something. (NCI) CDISC An account of the resource or content item. CareLex DESCR PT CDISC SDTM-PHSPRPCD Desc AB NCI Description PT CDISC SDTM-PHSPRP Description PT CareLex Description PT NCI Description SY CDISC Description SY caDSR Descriptive AD NCI Descriptor SY NCI description PT BRIDG 3.0.3 description PT BRIDG 5.3 A written or verbal account, representation, statement, or explanation of something. NCI Thesaurus:C25572 C25572 Qualitative Concept Modification Properties_or_Attributes Properties_or_Attributes_Kind Retired_Concept Changed Modification Modified The act of making a change or the change made; changed or altered in form or character. The act of making a change or the change made; changed or altered in form or character. Modification true Changed AD NCI Modification PT NCI Modified AD NCI The act of making a change or the change made; changed or altered in form or character. NCI Thesaurus:C25714 C25714 Conceptual Entity Version CL335552 Version VERS Version Versioned A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications. A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications. Version VERS PT CDISC Version PT NCI Version SY caDSR Versioned AD NCI A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications. NCI Thesaurus:C2588 C2588 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadopentetate Dimeglumine Gadopentetate Dimeglumine C0060934 86050-77-3 Angiography for Leptomeningeal Metastases and Multiple Sclerosis and Magnetic Resonance Imaging for Spine and Brain. RH248G8V27 CTRP FDA A substance used in magnetic resonance imaging (MRI) to help make clear pictures of the brain, spine, heart, soft tissue of joints, and inside bones. Gadopentetate dimeglumine is being studied in the diagnosis of cancer. It is a type of contrast agent. 37987 37987 C14H18N3O10.2C7H17NO5.2"H".Gd Gadopentetate_Dimeglumine CHEBI:31797 37987 GADOPENTETATE DIMEGLUMINE Gadolinium DTPA Gadopentetate Dimeglumine Gd-DTPA Magnevist Meglumine Gadopentetate SH L 451 A ZK 93035 gadopentetate dimeglumine A gadolinium complex of diethylenetriamine pentaacetic acid with ionic paramagnetic properties. Gadopentetate dimeglumine may provide contrast enhancement during magnetic resonance imaging (MRI) of intracranial lesions with abnormal vascularity or of abnormalities in the blood-brain barrier (BBB). (NCI04) A gadolinium complex of diethylenetriamine pentaacetic acid with ionic paramagnetic properties. Gadopentetate dimeglumine may provide contrast enhancement during magnetic resonance imaging (MRI) of intracranial lesions with abnormal vascularity or of abnormalities in the blood-brain barrier (BBB). (NCI04) Gadopentetate Dimeglumine A substance used in magnetic resonance imaging (MRI) to help make clear pictures of the brain, spine, heart, soft tissue of joints, and inside bones. Gadopentetate dimeglumine is being studied in the diagnosis of cancer. It is a type of contrast agent. NCI-GLOSS GADOPENTETATE DIMEGLUMINE PT FDA RH248G8V27 UNII Gadolinium DTPA SY NCI Gadopentetate Dimeglumine DN CTRP Gadopentetate Dimeglumine PT NCI Gd-DTPA AB NCI Gd-DTPA PT NCI-GLOSS CDR0000546740 Magnevist BR NCI Magnevist PT NCI-GLOSS CDR0000546741 Meglumine Gadopentetate SY NCI SH L 451 A CN NCI ZK 93035 CN NCI gadopentetate dimeglumine PT NCI-GLOSS CDR0000524255 A gadolinium complex of diethylenetriamine pentaacetic acid with ionic paramagnetic properties. Gadopentetate dimeglumine may provide contrast enhancement during magnetic resonance imaging (MRI) of intracranial lesions with abnormal vascularity or of abnormalities in the blood-brain barrier (BBB). (NCI04) NCI Thesaurus:C2751 C2751 Pharmacologic Substance Buffered Intrathecal Electrolyte/Dextrose Injection 614386 C0059031 Elliotts_B_Solution Buffered Intrathecal Electrolyte/Dextrose Injection ELLIOTTS B SOLUTION Elliott's B Solution Elliotts B Solution Buffered Intrathecal Electrolyte/Dextrose Injection Buffered Intrathecal Electrolyte/Dextrose Injection PT NCI ELLIOTTS B SOLUTION SY DTP NSC0614386 Elliott's B Solution SY NCI Elliotts B Solution BR NCI Thesaurus:C2752 C2752 Indicator, Reagent, or Diagnostic Aid EPL Diluent 704057 C1512124 EPL_Diluent EPL Diluent EPL Diluent EPL Diluent PT NCI Thesaurus:C2789 C2789 Indicator, Reagent, or Diagnostic Aid PEG Diluent 651935 C1518786 PEG_Diluent PEG Diluent PEG Diluent PEG Diluent PT NCI Thesaurus:C28284 C28284 Biomedical or Dental Material Filler CL336349 An inactive substance used to make a product bigger or easier to handle. For example, fillers are often used to make pills or capsules because the amount of active drug is too small to be handled conveniently. Filler Filler filler Filler An inactive substance used to make a product bigger or easier to handle. For example, fillers are often used to make pills or capsules because the amount of active drug is too small to be handled conveniently. NCI-GLOSS Filler PT NCI filler PT NCI-GLOSS CDR0000044205 Thesaurus:C28961 C28961 Indicator, Reagent, or Diagnostic Aid Diluent 12 C1511965 Diluent_12 Diluent 12 Diluent 12 Diluent 12 PT NCI Thesaurus:C28962 C28962 Indicator, Reagent, or Diagnostic Aid Diluent for BCG-TICE 5 C1511967 Diluent_for_BCG-Tice Diluent for BCG-TICE Diluent for BCG-TICE Diluent for BCG-TICE PT NCI Thesaurus:C28963 C28963 Indicator, Reagent, or Diagnostic Aid Diluent for Hepsulfam C1511968 Diluent_for_Hepsulfam Diluent for Hepsulfam Diluent for Hepsulfam Diluent for Hepsulfam PT NCI Thesaurus:C29405 C29405 Indicator, Reagent, or Diagnostic Aid Rhizoxin Diluent 649688 C1514940 Rhizoxin_Diluent Rhizoxin Diluent Rhizoxin Diluent Rhizoxin Diluent PT NCI Thesaurus:C334 C334 Organic Chemical Pharmacologic Substance Edetate Calcium Disodium Edetate Calcium Disodium 310151 C0006692 23411-34-9 25IH6R4SGF CTRP FDA 42300 42300 C10H12N2O8.Ca.2Na.2H2O Edetate_Calcium_Disodium 42300 C10H12CaN2Na2O8 Calcium Disodium Ethylenediaminetetraacetate Calcium Disodium Versenate Calcium EDTA Calcium disodium edetate Calcium disodium ethylenediaminetetraacetate Disodium calcium ethylenediaminetetraacetate EDETATE CALCIUM DISODIUM EDTA Calcium Edetate Calcium Disodium Contracted name for a salt of ethylenediaminetetraacetate, an agent used as a chelator of lead and some other heavy metals. C10H12CaN2Na2O8. Contracted name for a salt of ethylenediaminetetraacetate, an agent used as a chelator of lead and some other heavy metals. C10H12CaN2Na2O8. Edetate Calcium Disodium C10H12CaN2Na2O8 SY NCI Calcium Disodium Ethylenediaminetetraacetate SY NCI Calcium Disodium Versenate SY NCI Calcium EDTA SY DTP NSC0310151 Calcium disodium edetate SY DTP NSC0310151 Calcium disodium ethylenediaminetetraacetate SY DTP NSC0310151 Disodium calcium ethylenediaminetetraacetate SY DTP NSC0310151 EDETATE CALCIUM DISODIUM PT FDA 25IH6R4SGF UNII EDTA Calcium SY NCI Edetate Calcium Disodium DN CTRP Edetate Calcium Disodium PT NCI Contracted name for a salt of ethylenediaminetetraacetate, an agent used as a chelator of lead and some other heavy metals. C10H12CaN2Na2O8. NCI Thesaurus:C360 C360 Chemical Viewed Functionally Chelating Agent C1881795 FDA A chemical compound that binds tightly to metal ions. In medicine, chelating agents are used to remove toxic metals from the body. They are also being studied in the treatment of cancer. Used to sequester ions from solution and to form stable complexes (e.g. sequestering agent). (Pharmaceutical Excipients: A review Shilpa P Chaudhari and Pradeep S Patil Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune, Maharashtra, India. USP <1059>) Chelating_Agent Metal_Chelator CHEBI:38161 Chelating Agent Chelating agent Chelators Metal Chelant Metal Chelating Agent Metal Chelator chelating agent An inorganic or organic molecule which binds metal ions. Metal chelators are frequently polydentate, indicating that they form multiple bonds with the metal ion, resulting in more stable coordination complexes. An inorganic or organic molecule which binds metal ions. Metal chelators are frequently polydentate, indicating that they form multiple bonds with the metal ion, resulting in more stable coordination complexes. Chelating Agent A chemical compound that binds tightly to metal ions. In medicine, chelating agents are used to remove toxic metals from the body. They are also being studied in the treatment of cancer. NCI-GLOSS Used to sequester ions from solution and to form stable complexes (e.g. sequestering agent). (Pharmaceutical Excipients: A review Shilpa P Chaudhari and Pradeep S Patil Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune, Maharashtra, India. USP <1059>) PQCMC Chelating Agent PT NCI Chelating agent PT FDA PQCMC Chelators SY NCI Metal Chelant SY NCI Metal Chelating Agent SY NCI Metal Chelator SY NCI chelating agent PT NCI-GLOSS CDR0000613204 An inorganic or organic molecule which binds metal ions. Metal chelators are frequently polydentate, indicating that they form multiple bonds with the metal ion, resulting in more stable coordination complexes. NCI Thesaurus:C38389 C38389 Organism Attribute Sex Personal_Attribute Properties_or_Attributes_Kind Retired_Concept Sex Sex true Sex PT NCI Thesaurus:C41130 C41130 Functional Concept Significant C0750502 Significant Significance Significant A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent. A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent. Significant Significance SY NCI Significant PT NCI A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent. NCI Thesaurus:C41146 C41146 Quantitative Concept Speed C0678536 CDISC A scalar measure of the rate of movement of the object expressed as the distance traveled divided by the elapsed time. Speed SPEED Speed A scalar measure of the rate of movement of the object expressed either as the distance travelled divided by the time taken (average speed) or the rate of change of position with respect to time at a particular point (instantaneous speed). A scalar measure of the rate of movement of the object expressed either as the distance travelled divided by the time taken (average speed) or the rate of change of position with respect to time at a particular point (instantaneous speed). Speed A scalar measure of the rate of movement of the object expressed as the distance traveled divided by the elapsed time. CDISC SPEED PT CDISC SDTM-D1FATSCD SPEED PT CDISC SDTM-FATESTCD Speed PT CDISC SDTM-D1FATS Speed PT CDISC SDTM-FATEST Speed PT NCI Speed SY CDISC A scalar measure of the rate of movement of the object expressed either as the distance travelled divided by the time taken (average speed) or the rate of change of position with respect to time at a particular point (instantaneous speed). NCI Thesaurus:C416 C416 Organic Chemical Pharmacologic Substance Deferoxamine Deferoxamine 527604 C0011145 70-51-9 J06Y7MXW4D CTRP FDA An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death. It is used in conjunction with other anticancer agents in pediatric neuroblastoma therapy. C25H48N6O8 Deferoxamine CHEBI:4356 Deferoxamine 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane DEFEROXAMINE Deferoxamine Desferrioxamine N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxybutanediamide N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic Acid deferoxamine An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile. This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04) An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile. This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04) Deferoxamine An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death. It is used in conjunction with other anticancer agents in pediatric neuroblastoma therapy. NCI-GLOSS Deferoxamine Has Synonym PT therapeutic_agents GDC 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane SN NCI DEFEROXAMINE PT FDA J06Y7MXW4D UNII Deferoxamine DN CTRP Deferoxamine PT NCI Desferrioxamine SY DTP NSC0527604 Desferrioxamine SY NCI N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxybutanediamide PT DCP 09403 N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxybutanediamide SN NCI N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic Acid SN NCI deferoxamine PT NCI-GLOSS CDR0000045388 An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile. This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04) NCI Thesaurus:C417 C417 Organic Chemical Pharmacologic Substance Deferoxamine Mesylate Deferoxamine Mesylate 644468 C0011148 138-14-7 V9TKO7EO6K CTRP FDA 41696 41696 C25H48N6O8.CH4O3S Deferoxamine_Mesylate CHEBI:31460 Deferoxamine Mesylate 41696 DEFEROXAMINE MESYLATE DFM Deferoxamine B Deferoxamine Mesylate Deferoxamine Methanesulfonate Deferoxamine mesylate Deferrioxamine B Desferal Desferrioxamine Mesylate The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome. The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome. Deferoxamine Mesylate Deferoxamine Mesylate Has Synonym PT therapeutic_agents GDC DEFEROXAMINE MESYLATE PT FDA V9TKO7EO6K UNII DFM AB NCI Deferoxamine B SY NCI Deferoxamine Mesylate DN CTRP Deferoxamine Mesylate PT NCI Deferoxamine Methanesulfonate SY NCI Deferoxamine mesylate SY DTP NSC0644468 Deferrioxamine B SY NCI Desferal BR NCI Desferal SY DTP NSC0527604 Desferrioxamine Mesylate SY NCI The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome. NCI Thesaurus:C42614 C42614 Conceptual Entity Name C0027365 BRIDG Name_Generic_Concept Name name The words or language units by which a thing is known. The words or language units by which a thing is known. Name Name PT NCI Name SY caDSR name PT BRIDG 3.0.3 name PT BRIDG 5.3 The words or language units by which a thing is known. NCI Thesaurus:C42709 C42709 Human Parent C0030551 CDISC FDA GDC A mother or a father. Parent Parent PARENT Parent Parental A mother or a father; an immediate progenitor. A mother or a father; an immediate progenitor. Parent A mother or a father. CDISC Parent Has Synonym PT relationship_type GDC PARENT PT CDISC Parent PT FDA ICSR Parent PT GDC Parent PT NCI Parent SY caDSR Parental AD NCI A mother or a father; an immediate progenitor. NCI Thesaurus:C432 C432 Organic Chemical Pharmacologic Substance Ditiocarb C0012194 147-84-2 99Z2744345 FDA 40247 40247 C5H11NS2 Diethyldithiocarbamate Ditiocarb 40247 DDTC DIECA DITIOCARB DTC Diethylcarbamodithioic Acid Diethyldione Diethyldithiocarbamate Diethyldithiocarbamic Acid Diethyldithiocarbaminic Acid Diethyldithione Ditiocarb A sulfhydryl-containing carbamate that is the primary in vivo metabolite of disulfiram. Diethyldithiocarbamate chelates zinc, thereby inhibiting metalloproteinases, thereby preventing the degradation of the extracellular matrix and inhibiting an initial step in cancer metastasis and angiogenesis. A known inhibitor of superoxide dismutase, this agent can either potentiate or protect against cell oxidative damage caused by ionizing radiation, depending on the time of administration. (NCI04) A sulfhydryl-containing carbamate that is the primary in vivo metabolite of disulfiram. Diethyldithiocarbamate chelates zinc, thereby inhibiting metalloproteinases, thereby preventing the degradation of the extracellular matrix and inhibiting an initial step in cancer metastasis and angiogenesis. A known inhibitor of superoxide dismutase, this agent can either potentiate or protect against cell oxidative damage caused by ionizing radiation, depending on the time of administration. (NCI04) Ditiocarb Ditiocarb Has Synonym PT therapeutic_agents GDC DDTC AB NCI DIECA AB NCI DITIOCARB PT FDA 99Z2744345 UNII DTC AB NCI Diethylcarbamodithioic Acid PT DCP 01360 Diethylcarbamodithioic Acid SY NCI Diethyldione SY NCI Diethyldithiocarbamate SY NCI Diethyldithiocarbamic Acid SY NCI Diethyldithiocarbaminic Acid SY NCI Diethyldithione SY NCI Ditiocarb PT NCI A sulfhydryl-containing carbamate that is the primary in vivo metabolite of disulfiram. Diethyldithiocarbamate chelates zinc, thereby inhibiting metalloproteinases, thereby preventing the degradation of the extracellular matrix and inhibiting an initial step in cancer metastasis and angiogenesis. A known inhibitor of superoxide dismutase, this agent can either potentiate or protect against cell oxidative damage caused by ionizing radiation, depending on the time of administration. (NCI04) NCI Thesaurus:C43520 C43520 Intellectual Product Gene Ontology C1138831 Gene_Ontology GO GO Ontology Gene Ontology The Gene Ontology (GO) project is a collaborative effort to address the need for consistent descriptions of gene products in different databases. The goal of the Gene Ontology project is to produce a controlled vocabulary that can be applied to all organisms even as knowledge of gene and protein roles in cells is accumulating and changing. GO provides three structured networks of defined terms, molecular function, biological process, and cellular component, to describe gene product attributes. The Gene Ontology (GO) project is a collaborative effort to address the need for consistent descriptions of gene products in different databases. The goal of the Gene Ontology project is to produce a controlled vocabulary that can be applied to all organisms even as knowledge of gene and protein roles in cells is accumulating and changing. GO provides three structured networks of defined terms, molecular function, biological process, and cellular component, to describe gene product attributes. Gene Ontology GO SY NCI GO Ontology SY NCI Gene Ontology PT NCI The Gene Ontology (GO) project is a collaborative effort to address the need for consistent descriptions of gene products in different databases. The goal of the Gene Ontology project is to produce a controlled vocabulary that can be applied to all organisms even as knowledge of gene and protein roles in cells is accumulating and changing. GO provides three structured networks of defined terms, molecular function, biological process, and cellular component, to describe gene product attributes. NCI from http://www.geneontology.org/ Thesaurus:C43530 C43530 Professional or Occupational Group Supplier CL448677 Supplier Supplier Someone whose business is to supply a particular service or commodity. Someone whose business is to supply a particular service or commodity. Supplier Supplier PT NCI Someone whose business is to supply a particular service or commodity. NCI Thesaurus:C43531 C43531 Cell Function Developmental Stage C0870411 The physical, mental, and emotional stages a child goes through as he or she grows and matures. Developmental_Stage Developmental Stage developmental stage A general term that usually refers to named landmark events during development of an organism. A general term that usually refers to named landmark events during development of an organism. Developmental Stage The physical, mental, and emotional stages a child goes through as he or she grows and matures. NCI-GLOSS Developmental Stage PT NCI developmental stage PT NCI-GLOSS CDR0000450103 A general term that usually refers to named landmark events during development of an organism. NCI Thesaurus:C44374 C44374 Hazardous or Poisonous Substance Diesel Exhaust Particulate C1707741 Diesel_Exhaust_Particulate Diesel Exhaust Particulate Diesel Exhaust Particulates A complex mixture of combustion products of diesel fuel including carbon monoxide, carbon dioxide, sulfur oxides, nitrogen oxides, volatile hydrocarbons, aldehydes, alkenes, alkanes and nitroarenes, polycyclic aromatic hydrocarbons and other derivates. Lymphocyte-DNA adduct formation is associated with exposure to diesel exhaust particulates and may be associated with an increased risk of developing lung cancer. Diesel Exhaust Particulate is reasonably anticipated to be a human carcinogen. (NCI05) A complex mixture of combustion products of diesel fuel including carbon monoxide, carbon dioxide, sulfur oxides, nitrogen oxides, volatile hydrocarbons, aldehydes, alkenes, alkanes and nitroarenes, polycyclic aromatic hydrocarbons and other derivates. Lymphocyte-DNA adduct formation is associated with exposure to diesel exhaust particulates and may be associated with an increased risk of developing lung cancer. Diesel Exhaust Particulate is reasonably anticipated to be a human carcinogen. (NCI05) Diesel Exhaust Particulate Diesel Exhaust Particulate PT NCI Diesel Exhaust Particulates SY NCI A complex mixture of combustion products of diesel fuel including carbon monoxide, carbon dioxide, sulfur oxides, nitrogen oxides, volatile hydrocarbons, aldehydes, alkenes, alkanes and nitroarenes, polycyclic aromatic hydrocarbons and other derivates. Lymphocyte-DNA adduct formation is associated with exposure to diesel exhaust particulates and may be associated with an increased risk of developing lung cancer. Diesel Exhaust Particulate is reasonably anticipated to be a human carcinogen. (NCI05) NCI Thesaurus:C45378 C45378 Intellectual Product Technology Platform Version C1710360 GDC Technology_Platform Platform Platform Version Technology Platform Technology Platform Version platform The specific version (manufacturer, model, etc.) of a technology that is used to carry out a laboratory or computational experiment. The specific version (manufacturer, model, etc.) of a technology that is used to carry out a laboratory or computational experiment. Technology Platform Version Platform SY NCI Platform Version SY NCI Technology Platform SY NCI Technology Platform Version PT NCI platform PT GDC VAR The specific version (manufacturer, model, etc.) of a technology that is used to carry out a laboratory or computational experiment. NCI Thesaurus:C45998 C45998 Natural Phenomenon or Process Oxidation-Reduction Potential C1709375 Oxidation-Reduction_Potential Oxidation-Reduction Potential Redox Potential The potential developed by a metallic electrode when placed in a solution containing a species in two different oxidation states. The potential developed by a metallic electrode when placed in a solution containing a species in two different oxidation states. Oxidation-Reduction Potential Oxidation-Reduction Potential PT NCI Redox Potential SY NCI The potential developed by a metallic electrode when placed in a solution containing a species in two different oxidation states. NCI http://www.flw.com/define_r.htm Thesaurus:C460 C460 Organic Chemical Pharmacologic Substance Pentetic Acid 7340 C0013254 67-43-6 7A314HQM0I FDA 42451 42451 C14H23N3O10 Pentetic_Acid CHEBI:35739 42451 (Diethylenetriamine)pentaacetic acid DTPA Detapac Detarex Diethylenetriamine Pentaacetic Acid Diethylenetriamine-N,N,N',N'',N''-pentaacetic Acid PENTETIC ACID Pentetic Acid An edetate and a chelating agent used in preparing radiopharmaceuticals. Pentetic acid (DTPA) has strong affinity for iron but also shows affinities for other heavy metals, thereby is used in the treatment of iron-storage disease and poisoning from heavy and radioactive metals. DTPA may chelate metallic moieties of unbound, extracellular radioimmunotherapeutics, thereby aggregating radioimmunotherapeutics locally to higher concentrations, and improving tumor cell radiocytotoxicity, while sparing normal tissues from the radiocytotoxic effects. In addition, DTPA is used in radioimaing procedures when complexes with radioisotopes, ex., Tc 99m or In 111. An edetate and a chelating agent used in preparing radiopharmaceuticals. Pentetic acid (DTPA) has strong affinity for iron but also shows affinities for other heavy metals, thereby is used in the treatment of iron-storage disease and poisoning from heavy and radioactive metals. DTPA may chelate metallic moieties of unbound, extracellular radioimmunotherapeutics, thereby aggregating radioimmunotherapeutics locally to higher concentrations, and improving tumor cell radiocytotoxicity, while sparing normal tissues from the radiocytotoxic effects. In addition, DTPA is used in radioimaing procedures when complexes with radioisotopes, ex., Tc 99m or In 111. Pentetic Acid (Diethylenetriamine)pentaacetic acid SY DTP NSC0007340 DTPA AB NCI Detapac BR NCI Detapac SY DTP NSC0007340 Detarex FB NCI Detarex SY DTP NSC0007340 Diethylenetriamine Pentaacetic Acid SY NCI Diethylenetriamine-N,N,N',N'',N''-pentaacetic Acid SN NCI PENTETIC ACID PT FDA 7A314HQM0I UNII Pentetic Acid PT NCI An edetate and a chelating agent used in preparing radiopharmaceuticals. Pentetic acid (DTPA) has strong affinity for iron but also shows affinities for other heavy metals, thereby is used in the treatment of iron-storage disease and poisoning from heavy and radioactive metals. DTPA may chelate metallic moieties of unbound, extracellular radioimmunotherapeutics, thereby aggregating radioimmunotherapeutics locally to higher concentrations, and improving tumor cell radiocytotoxicity, while sparing normal tissues from the radiocytotoxic effects. In addition, DTPA is used in radioimaing procedures when complexes with radioisotopes, ex., Tc 99m or In 111. NCI Thesaurus:C47381 C47381 Pharmacologic Substance Acetohydroxamic Acid 176136 C0050451 546-88-3 4RZ82L2GY5 FDA C2H5NO2 Acetohydroxamic_Acid CHEBI:27777 2-Hydroxyamino-2-ethanal ACETOHYDROXAMIC ACID AHA Acetohydroxamic Acid Acetohydroximic Acid Lithostat N-Acetyl Hydroxyacetamide N-Hydroxy-acetamide Acetohydroxamic Acid 2-Hydroxyamino-2-ethanal SN NCI ACETOHYDROXAMIC ACID PT FDA 4RZ82L2GY5 UNII AHA AB NCI AHA PT NCI-GLOSS CDR0000613194 Acetohydroxamic Acid PT NCI Acetohydroximic Acid SY NCI Lithostat BR NCI N-Acetyl Hydroxyacetamide SY NCI N-Hydroxy-acetamide SY NCI Thesaurus:C47494 C47494 Pharmacologic Substance Dimercaprol 39515 C0012383 59-52-9 0CPP32S55X FDA C3H8OS2 Dimercaprol CHEBI:64198 1,2-Dithioglycerol 2,3-Dimercapto-1-propanol BAL in Oil DIMERCAPROL Dimercaprol A metal chelating agent that is used as an antidote in arsenic, gold, lead, mercury and other heavy metal poisoning. Metals form ligands in the body with the sulfhydryl groups of the pyruvate-oxidase enzyme system. This leads to an inhibition of the normal functioning of these enzymes that are dependent on free sulfhydryl groups for their activity. Dimercaprol reverses the enzyme inhibition by chelating the metal and regenerates free sulfhydryl groups, thereby preventing and reversing the metals toxic effects. A metal chelating agent that is used as an antidote in arsenic, gold, lead, mercury and other heavy metal poisoning. Metals form ligands in the body with the sulfhydryl groups of the pyruvate-oxidase enzyme system. This leads to an inhibition of the normal functioning of these enzymes that are dependent on free sulfhydryl groups for their activity. Dimercaprol reverses the enzyme inhibition by chelating the metal and regenerates free sulfhydryl groups, thereby preventing and reversing the metals toxic effects. Dimercaprol 1,2-Dithioglycerol SN NCI 2,3-Dimercapto-1-propanol SN NCI BAL in Oil BR NCI DIMERCAPROL PT FDA 0CPP32S55X UNII Dimercaprol PT DCP 30435 Dimercaprol PT NCI A metal chelating agent that is used as an antidote in arsenic, gold, lead, mercury and other heavy metal poisoning. Metals form ligands in the body with the sulfhydryl groups of the pyruvate-oxidase enzyme system. This leads to an inhibition of the normal functioning of these enzymes that are dependent on free sulfhydryl groups for their activity. Dimercaprol reverses the enzyme inhibition by chelating the metal and regenerates free sulfhydryl groups, thereby preventing and reversing the metals toxic effects. NCI Thesaurus:C47532 C47532 Pharmacologic Substance Ferric Ferrocyanide 8665 C0303918 14038-43-8 TLE294X33A FDA 18CN.7Fe Ferric_Hexacyanoferrate_II CHEBI:30069 Antidotum Thallii-Heyl FERRIC FERROCYANIDE Ferric Ferrocyanide Ferric Hexacyanoferrate (II) Ferrocin Insoluble Prussian Blue Iron Ferrocyanide Radiogardase-Cs A chelating agent with strong binding affinity for thallium, cesium, and other ions. Ferric hexacyanoferrate is used for the treatment of acute and chronic thallium and cesium poisoning. This agent is not absorbed in the gastrointestinal tract and it chelates thallium or cesium ion in the intestines. The resulting complex is eliminated via the feces. A chelating agent with strong binding affinity for thallium, cesium, and other ions. Ferric hexacyanoferrate is used for the treatment of acute and chronic thallium and cesium poisoning. This agent is not absorbed in the gastrointestinal tract and it chelates thallium or cesium ion in the intestines. The resulting complex is eliminated via the feces. Ferric Ferrocyanide Antidotum Thallii-Heyl BR NCI FERRIC FERROCYANIDE PT FDA TLE294X33A UNII Ferric Ferrocyanide PT NCI Ferric Hexacyanoferrate (II) SY NCI Ferrocin SY NCI Insoluble Prussian Blue SY NCI Iron Ferrocyanide SY NCI Radiogardase-Cs BR NCI A chelating agent with strong binding affinity for thallium, cesium, and other ions. Ferric hexacyanoferrate is used for the treatment of acute and chronic thallium and cesium poisoning. This agent is not absorbed in the gastrointestinal tract and it chelates thallium or cesium ion in the intestines. The resulting complex is eliminated via the feces. NCI Thesaurus:C47545 C47545 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadoversetamide C0754820 131069-91-5 RLM74T3Z9D FDA C20H34N5O10.Gd Gadoversetamide CHEBI:31644 (N,N-Bis(2-((carboxymethyl)(((2-methoxyethyl)carbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium GADOVERSETAMIDE Gadoversetamide Optimark A paramagnetic extracellular magnetic resonance imaging (MRI) contrast agent that facilitates visualization of abnormal vascularity. When placed in a magnetic field, gadoversetamide decreases T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time) values in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity. Gadoversetamide does not cross the intact blood-brain barrier. However, abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoversetamide. (NCI05) A paramagnetic extracellular magnetic resonance imaging (MRI) contrast agent that facilitates visualization of abnormal vascularity. When placed in a magnetic field, gadoversetamide decreases T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time) values in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity. Gadoversetamide does not cross the intact blood-brain barrier. However, abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoversetamide. (NCI05) Gadoversetamide (N,N-Bis(2-((carboxymethyl)(((2-methoxyethyl)carbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium SN NCI GADOVERSETAMIDE PT FDA RLM74T3Z9D UNII Gadoversetamide PT NCI Optimark BR NCI A paramagnetic extracellular magnetic resonance imaging (MRI) contrast agent that facilitates visualization of abnormal vascularity. When placed in a magnetic field, gadoversetamide decreases T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time) values in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity. Gadoversetamide does not cross the intact blood-brain barrier. However, abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoversetamide. (NCI05) NCI Thesaurus:C47723 C47723 Pharmacologic Substance Sodium Gluconate C0142853 527-07-1 R6Q3791S76 FDA C6H11O7.Na Sodium_Gluconate D-Gluconic Acid, Monosodium Salt Glonsen Gluconic Acid Sodium Salt SODIUM GLUCONATE Sodium Gluconate The sodium salt of gluconic acid with chelating property. Sodium gluconate chelates and forms stable complexes with various ions, preventing them from engaging in chemical reactions. The sodium salt of gluconic acid with chelating property. Sodium gluconate chelates and forms stable complexes with various ions, preventing them from engaging in chemical reactions. Sodium Gluconate D-Gluconic Acid, Monosodium Salt SY NCI Glonsen SY NCI Gluconic Acid Sodium Salt SY NCI SODIUM GLUCONATE PT FDA R6Q3791S76 UNII Sodium Gluconate PT DCP 50741 Sodium Gluconate PT NCI The sodium salt of gluconic acid with chelating property. Sodium gluconate chelates and forms stable complexes with various ions, preventing them from engaging in chemical reactions. NCI Thesaurus:C47874 C47874 Research Device Separation Column C1705246 Separation_Column Column Separation Column A tube used in column chromatography. A tube used in column chromatography. Separation Column Column SY NCI Separation Column PT NCI A tube used in column chromatography. NCI Thesaurus:C47904 C47904 Conceptual Entity Build C1707059 Build Build Pre-Release Version A pre-release version of a computer program. A pre-release version of a computer program. Build Build PT NCI Pre-Release Version SY NCI A pre-release version of a computer program. NCI Thesaurus:C48040 C48040 Laboratory Procedure Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Matrix-Assisted Laser Desorption Ionization Mass Spectrometry C0282597 CDISC CTRP A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample- matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. (CHI) Matrix-Assisted_Laser_Desorption_Ionization_Mass_Spectrometry MALDI Matrix Assisted Laser Desorption Ionization Mass Spectrometry Matrix-Assisted Laser Desorption Ionization Mass Spectrometry A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample- matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. (CHI) A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample- matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. (CHI) Matrix-Assisted Laser Desorption Ionization Mass Spectrometry A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample- matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. (CHI) CDISC MALDI PT CDISC MALDI SY NCI Matrix Assisted Laser Desorption Ionization Mass Spectrometry SY NCI Matrix-Assisted Laser Desorption Ionization Mass Spectrometry DN CTRP Matrix-Assisted Laser Desorption Ionization Mass Spectrometry PT NCI Matrix-Assisted Laser Desorption Ionization Mass Spectrometry SY CDISC A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample- matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. (CHI) NCI Thesaurus:C48160 C48160 Activity Freezing CL448709 CDISC The process whereby cold changes the water component from a liquid to a solid. Freeze_Technique FREEZING Freeze Freeze Technique Freezing Frozen The act or event which causes the transition from a liquid to solid matter phase when the temperature is lowered. The act or event which causes the transition from a liquid to solid matter phase when the temperature is lowered. Freezing The process whereby cold changes the water component from a liquid to a solid. CDISC FREEZING PT CDISC Freeze SY NCI Freeze Technique SY NCI Freezing PT NCI Freezing SY caDSR Frozen AD NCI Frozen SY caDSR The act or event which causes the transition from a liquid to solid matter phase when the temperature is lowered. NCI Thesaurus:C48384 C48384 Pharmacologic Substance Deferasirox Deferasirox C1619629 201530-41-8 V8G4MOF2V9 CTRP FDA A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a group of diseases in which the bone marrow does not make enough healthy blood cells) and other conditions. Deferasirox binds to extra iron in the blood. The drug and the iron are passed from the body in urine. It is a type of chelating agent. 435986 435986 C21H15N3O4 Deferasirox CHEBI:49005 435986 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid DEFERASIROX Deferasirox Exjade deferasirox A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life. A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life. Deferasirox A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a group of diseases in which the bone marrow does not make enough healthy blood cells) and other conditions. Deferasirox binds to extra iron in the blood. The drug and the iron are passed from the body in urine. It is a type of chelating agent. NCI-GLOSS 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid SN NCI DEFERASIROX PT FDA V8G4MOF2V9 UNII Deferasirox DN CTRP Deferasirox PT DCP 50595 Deferasirox PT NCI Exjade BR NCI Exjade PT NCI-GLOSS CDR0000535471 deferasirox PT NCI-GLOSS CDR0000514444 A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life. NCI Thesaurus:C49236 C49236 Therapeutic or Preventive Procedure Therapeutic Procedure Therapeutic Procedure C0087111 CDISC-GLOSS CTRP GDC ICDC NICHD Medical care given to a patient to mitigate or cure an illness, injury, or reduced health status. NOTE: May include prescribed drugs, biologics, surgery, devices, and physical or psychotherapies, but not diagnostics or prophylaxis. See also intervention, diagnosis. Treatment. Therapeutic_Procedure TREAT TX Therapeutic Interventions Therapeutic Method Therapeutic Procedure Therapeutic Technique Therapy Treatment any therapy any_therapy therapy treatment treatment or therapy treatment_or_therapy An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process. An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process. Therapeutic Procedure Medical care given to a patient to mitigate or cure an illness, injury, or reduced health status. NOTE: May include prescribed drugs, biologics, surgery, devices, and physical or psychotherapies, but not diagnostics or prophylaxis. See also intervention, diagnosis. CDISC-GLOSS Treatment. NCI-GLOSS TREAT PT HL7 TX AB NCI Therapeutic Interventions SY NCI Therapeutic Method SY NCI Therapeutic Procedure DN CTRP Therapeutic Procedure PT NCI Therapeutic Procedure PT NICHD Therapeutic Procedure SY caDSR Therapeutic Technique SY NCI Therapy SY NCI Treatment PT ICDC Canine Glioma Treatment SY caDSR any therapy SY ICDC ICDC any_therapy PT ICDC ICDC therapy SY CDISC-GLOSS therapy SY NCI-GLOSS CDR0000044737 treatment PT CDISC-GLOSS treatment or therapy SY GDC VAR treatment_or_therapy PT GDC VAR An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process. NCI Thesaurus:C50400 C50400 Classification Age Unit C1706749 CDISC Those units of time that are routinely used to express the age of a person. (NCI) Age_Units AGEU Age Unit Unit of Age Those units of time that are routinely used to express the age of a person or thing. Those units of time that are routinely used to express the age of a person or thing. Age Unit Those units of time that are routinely used to express the age of a person. (NCI) CDISC AGEU PT CDISC SDTM-VARIABLE AGEU PT CDISC SEND-STSPRMCD Age Unit PT CDISC SEND-STSPRM Age Unit PT NCI Age Unit SY CDISC Unit of Age SY NCI Those units of time that are routinely used to express the age of a person or thing. NCI Thesaurus:C53414 C53414 Qualitative Concept Composition C0486616 CDISC GDC The materials from which something is made. Composition COMPOS Composition composition The way in which something is made, especially in terms of its different parts; its constituents. The way in which something is made, especially in terms of its different parts; its constituents. Composition The materials from which something is made. CDISC COMPOS PT CDISC SDTM-DOTESTCD Composition PT CDISC SDTM-DOTEST Composition PT NCI Composition SY CDISC composition PT GDC VAR The way in which something is made, especially in terms of its different parts; its constituents. NCI Thesaurus:C54072 C54072 Qualitative Concept Stability CL448538 Stability Stability Stable The quality of being free from change or variation or not taking part readily in chemical change. The quality of being free from change or variation or not taking part readily in chemical change. Stability Stability PT NCI Stable AD NCI The quality of being free from change or variation or not taking part readily in chemical change. NCI Thesaurus:C556 C556 Organic Chemical Pharmacologic Substance Hydroxamic Acids C0020314 Hydroxamic_Acids CHEBI:24650 Hydroxamic Acids A group of weak acids with the general chemical formula RC(=O)N(R')OH and antineoplastic and antimicrobial activities. Hydroxamic acids covalently bind to the zinc(II) ion in the active sites of matrix metalloproteinases (MMP), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04) A group of weak acids with the general chemical formula RC(=O)N(R')OH and antineoplastic and antimicrobial activities. Hydroxamic acids covalently bind to the zinc(II) ion in the active sites of matrix metalloproteinases (MMP), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04) Hydroxamic Acids Hydroxamic Acids PT NCI A group of weak acids with the general chemical formula RC(=O)N(R')OH and antineoplastic and antimicrobial activities. Hydroxamic acids covalently bind to the zinc(II) ion in the active sites of matrix metalloproteinases (MMP), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04) NCI Thesaurus:C60823 C60823 Indicator, Reagent, or Diagnostic Aid Diluent C1875022 Diluent Diluent Any liquid or solid material used to lessen the strength or flavor of a solution or mixture of another ingredient. Any liquid or solid material used to lessen the strength or flavor of a solution or mixture of another ingredient. Diluent Diluent PT NCI Any liquid or solid material used to lessen the strength or flavor of a solution or mixture of another ingredient. NCI Thesaurus:C61412 C61412 Activity Contribution C1880177 Contribution Contribute Contributing Contribution Contributory The part played by somebody or something in bringing about an end or result. The part played by somebody or something in bringing about an end or result. Contribution Contribute SY NCI Contributing AD NCI Contribution PT NCI Contributory SY caDSR The part played by somebody or something in bringing about an end or result. NCI Thesaurus:C61741 C61741 Pharmacologic Substance Edetate Disodium C0012695 6381-92-6 7FLD91C86K FDA C10H12N2O8.2"H".2Na.2H2O Edetate_Disodium CHEBI:64758 EDETATE DISODIUM Edetate Disodium The disodium salt form of edetate, a heavy metal chelating agent with anti-hypercalcemic and anti-arrhythmic properties. Edetate, a heavy metal antagonist, chelates divalent and trivalent metals, forming soluble stable complexes which are readily excreted by the kidneys, thereby can be used to lower serum calcium concentrations. In addition, this agent exerts a negative inotropic effect on the heart through a transiently induced hypocalcemic state, thereby antagonizing the inotropic and chronotropic effects of digitalis glycosides on the ventricles of the heart. Upon ocular administration, edetate exerts its ophthalmic effect by chelating calcium to form soluble complexes, thereby removing corneal calcium deposits. The disodium salt form of edetate, a heavy metal chelating agent with anti-hypercalcemic and anti-arrhythmic properties. Edetate, a heavy metal antagonist, chelates divalent and trivalent metals, forming soluble stable complexes which are readily excreted by the kidneys, thereby can be used to lower serum calcium concentrations. In addition, this agent exerts a negative inotropic effect on the heart through a transiently induced hypocalcemic state, thereby antagonizing the inotropic and chronotropic effects of digitalis glycosides on the ventricles of the heart. Upon ocular administration, edetate exerts its ophthalmic effect by chelating calcium to form soluble complexes, thereby removing corneal calcium deposits. Edetate Disodium EDETATE DISODIUM PT FDA 7FLD91C86K UNII Edetate Disodium PT NCI The disodium salt form of edetate, a heavy metal chelating agent with anti-hypercalcemic and anti-arrhythmic properties. Edetate, a heavy metal antagonist, chelates divalent and trivalent metals, forming soluble stable complexes which are readily excreted by the kidneys, thereby can be used to lower serum calcium concentrations. In addition, this agent exerts a negative inotropic effect on the heart through a transiently induced hypocalcemic state, thereby antagonizing the inotropic and chronotropic effects of digitalis glycosides on the ventricles of the heart. Upon ocular administration, edetate exerts its ophthalmic effect by chelating calcium to form soluble complexes, thereby removing corneal calcium deposits. NCI Thesaurus:C61742 C61742 Pharmacologic Substance Edetic Acid C0013618 60-00-4 9G34HU7RV0 FDA C10H16N2O8 Edetic_Acid CHEBI:42191 EDETIC ACID EDTA Edetic Acid Ethylenediaminetetraacetic Acid The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning. The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning. Edetic Acid EDETIC ACID PT FDA 9G34HU7RV0 UNII EDTA AB NCI Edetic Acid PT DCP 06375 Edetic Acid PT NCI Ethylenediaminetetraacetic Acid SY NCI The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning. NCI Thesaurus:C61777 C61777 Pharmacologic Substance Gluconic Acid 77381 C0220836 133-42-6 R4R8J0Q44B FDA C6H12O7 Gluconic_Acid CHEBI:24266 GLUCONIC ACID Gluconic Acid The carboxylic acid formed by the oxidation of the first carbon of glucose with antiseptic and chelating properties. Gluconic acid, found abundantly in plant, honey and wine, can be prepared by fungal fermentation process commercially. This agent and its derivatives can used in formulation of pharmaceuticals, cosmetics and food products as additive or buffer salts. Aqueous gluconic acid solution contains cyclic ester glucono delta lactone structure, which chelates metal ions and forms very stable complexes. In alkaline solution, this agent exhibits strong chelating activities towards anions, i.e. calcium, iron, aluminium, copper, and other heavy metals. The carboxylic acid formed by the oxidation of the first carbon of glucose with antiseptic and chelating properties. Gluconic acid, found abundantly in plant, honey and wine, can be prepared by fungal fermentation process commercially. This agent and its derivatives can used in formulation of pharmaceuticals, cosmetics and food products as additive or buffer salts. Aqueous gluconic acid solution contains cyclic ester glucono delta lactone structure, which chelates metal ions and forms very stable complexes. In alkaline solution, this agent exhibits strong chelating activities towards anions, i.e. calcium, iron, aluminium, copper, and other heavy metals. Gluconic Acid GLUCONIC ACID PT FDA R4R8J0Q44B UNII Gluconic Acid PT NCI The carboxylic acid formed by the oxidation of the first carbon of glucose with antiseptic and chelating properties. Gluconic acid, found abundantly in plant, honey and wine, can be prepared by fungal fermentation process commercially. This agent and its derivatives can used in formulation of pharmaceuticals, cosmetics and food products as additive or buffer salts. Aqueous gluconic acid solution contains cyclic ester glucono delta lactone structure, which chelates metal ions and forms very stable complexes. In alkaline solution, this agent exhibits strong chelating activities towards anions, i.e. calcium, iron, aluminium, copper, and other heavy metals. NCI Thesaurus:C61953 C61953 Pharmacologic Substance Succimer Succimer C0012384 304-55-2 DX1U2629QE CTRP FDA 798947 798947 C4H6O4S2 Succimer CHEBI:63623 798947 Butanedioic Acid, 2,3-Dimercapto-, (2R,3S)-rel- Chemet DMSA Meso 2, 3-Dimercaptosuccinic Acid SUCCIMER Succimer An orally active mercaptodicarboxylic acid, with heavy metal chelating activity. As a strong chelator, succimer is able to bind to heavy metals, such as lead, in the bloodstream, thereby forming a water-soluble complex that can be eliminated via urinary excretion. This prevents heavy metal poisoning. In addition, succimer is able to chelate the alpha particle emitter and radionuclide polonium Po 210 ((Po-210), thereby increasing its excretion and reducing the toxic effects of Po-210. An orally active mercaptodicarboxylic acid, with heavy metal chelating activity. As a strong chelator, succimer is able to bind to heavy metals, such as lead, in the bloodstream, thereby forming a water-soluble complex that can be eliminated via urinary excretion. This prevents heavy metal poisoning. In addition, succimer is able to chelate the alpha particle emitter and radionuclide polonium Po 210 ((Po-210), thereby increasing its excretion and reducing the toxic effects of Po-210. Succimer Butanedioic Acid, 2,3-Dimercapto-, (2R,3S)-rel- SN NCI Chemet BR NCI DMSA AB NCI Meso 2, 3-Dimercaptosuccinic Acid SY NCI SUCCIMER PT FDA DX1U2629QE UNII Succimer DN CTRP Succimer PT NCI Succimer SY caDSR An orally active mercaptodicarboxylic acid, with heavy metal chelating activity. As a strong chelator, succimer is able to bind to heavy metals, such as lead, in the bloodstream, thereby forming a water-soluble complex that can be eliminated via urinary excretion. This prevents heavy metal poisoning. In addition, succimer is able to chelate the alpha particle emitter and radionuclide polonium Po 210 ((Po-210), thereby increasing its excretion and reducing the toxic effects of Po-210. NCI Thesaurus:C61987 C61987 Pharmacologic Substance Trientine Hydrochloride Trientine Hydrochloride C0770325 38260-01-4 HC3NX54582 CTRP FDA 683662 683662 C6H18N4.2HCl Trientine_Hydrochloride Trientine Hydrochloride 683662 N,N-bis (2-aminoethyl)-1,2-ethanediamine Dihydrochloride Syprine TRIENTINE HYDROCHLORIDE Trientine Hydrochloride The hydrochloride salt form of a metal chelating agent with potential anti-angiogenic activity. Trientine chelates excess copper (Cu) ions in the body; the excess copper is subsequently removed from the body through the kidneys. As Cu is an essential cofactor for cuproenzymes, such as superoxide dismutase 1 (SOD1), depletion of copper may inhibit the activation of signal transduction pathways required for cellular proliferation and angiogenesis. In addition, trientine may inhibit copper-induced secretion of interleukin-8 (IL-8). The hydrochloride salt form of a metal chelating agent with potential anti-angiogenic activity. Trientine chelates excess copper (Cu) ions in the body; the excess copper is subsequently removed from the body through the kidneys. As Cu is an essential cofactor for cuproenzymes, such as superoxide dismutase 1 (SOD1), depletion of copper may inhibit the activation of signal transduction pathways required for cellular proliferation and angiogenesis. In addition, trientine may inhibit copper-induced secretion of interleukin-8 (IL-8). Trientine Hydrochloride Trientine Hydrochloride Has Synonym PT therapeutic_agents GDC N,N-bis (2-aminoethyl)-1,2-ethanediamine Dihydrochloride SN NCI Syprine BR NCI TRIENTINE HYDROCHLORIDE PT FDA HC3NX54582 UNII Trientine Hydrochloride DN CTRP Trientine Hydrochloride PT DCP 50560 Trientine Hydrochloride PT NCI The hydrochloride salt form of a metal chelating agent with potential anti-angiogenic activity. Trientine chelates excess copper (Cu) ions in the body; the excess copper is subsequently removed from the body through the kidneys. As Cu is an essential cofactor for cuproenzymes, such as superoxide dismutase 1 (SOD1), depletion of copper may inhibit the activation of signal transduction pathways required for cellular proliferation and angiogenesis. In addition, trientine may inhibit copper-induced secretion of interleukin-8 (IL-8). NCI Thesaurus:C62321 C62321 Laboratory Procedure Field Flow Fractionation C1135847 Field_Flow_Fractionation AFFF Asymmetrical Flow Field-Flow Fractionation Electrical Field-Flow Fractionation FFF Field Flow Fractionation Field-Flow Fractionation Flow Field-Flow Fractionation Sedimentation Field-Flow Fractionation Thermal Field-Flow Fractionation An analytical technique used to separate a multi-component sample by applying a retarding force or gradient to a sample in a solvent stream, which drives the sample toward a thin channel wall. The velocity at which a component leaves the center solvent stream is dependent on its physical characteristics. An analytical technique used to separate a multi-component sample by applying a retarding force or gradient to a sample in a solvent stream, which drives the sample toward a thin channel wall. The velocity at which a component leaves the center solvent stream is dependent on its physical characteristics. Field Flow Fractionation AFFF AB NCI Asymmetrical Flow Field-Flow Fractionation SY NCI Electrical Field-Flow Fractionation SY NCI FFF AB NCI Field Flow Fractionation PT NCI Field-Flow Fractionation SY NCI Flow Field-Flow Fractionation SY NCI Sedimentation Field-Flow Fractionation SY NCI Thermal Field-Flow Fractionation SY NCI An analytical technique used to separate a multi-component sample by applying a retarding force or gradient to a sample in a solvent stream, which drives the sample toward a thin channel wall. The velocity at which a component leaves the center solvent stream is dependent on its physical characteristics. NCI Thesaurus:C62358 C62358 Indicator, Reagent, or Diagnostic Aid Gadolinium-Chelate Gadolinium-Chelate C1880883 CTRP 584170 584170 Gadolinium-Chelate 584170 Gadolinium Coordination Complex Gadolinium-Chelant Complex Gadolinium-Chelate Gadolinium-based Contrast Agent A coordination complex consisting of a gadolinium ion bound to a hexadentate organic chelating agent such as diethylenetriaminepentaacetic acid. Chelates of gadolinium are frequently utilized as magnetic resonance imaging (MRI) contrast agents and can be used to track nanoparticle-mediated drug delivery. A coordination complex consisting of a gadolinium ion bound to a hexadentate organic chelating agent such as diethylenetriaminepentaacetic acid. Chelates of gadolinium are frequently utilized as magnetic resonance imaging (MRI) contrast agents and can be used to track nanoparticle-mediated drug delivery. Gadolinium-Chelate Gadolinium Coordination Complex SY NCI Gadolinium-Chelant Complex SY NCI Gadolinium-Chelate DN CTRP Gadolinium-Chelate PT NCI Gadolinium-based Contrast Agent SY NCI A coordination complex consisting of a gadolinium ion bound to a hexadentate organic chelating agent such as diethylenetriaminepentaacetic acid. Chelates of gadolinium are frequently utilized as magnetic resonance imaging (MRI) contrast agents and can be used to track nanoparticle-mediated drug delivery. NCI Thesaurus:C62381 C62381 Classification Engineered Nanoparticle C1880513 Engineered_Nanoparticle Designed Nanoparticle Engineered Nanoparticle A nanoparticle intentionally designed with specific physical properties to meet performance requirements. A nanoparticle intentionally designed with specific physical properties to meet performance requirements. Engineered Nanoparticle Designed Nanoparticle SY NCI Engineered Nanoparticle PT NCI A nanoparticle intentionally designed with specific physical properties to meet performance requirements. NCI Thesaurus:C63495 C63495 Chemical Viewed Functionally Additive C1550602 Additive Additive A substance that is added to a system or compound to improve its characteristics. A substance that is added to a system or compound to improve its characteristics. Additive Additive PT NCI A substance that is added to a system or compound to improve its characteristics. NCI Thesaurus:C63813 C63813 Conceptual Entity Hydrophobicity C0598629 Hydrophobic Hydrophobic Hydrophobicity The inherent characteristic of a molecule or substance to be immiscible in water. The property means that the moiety of interest does not dissolve in, absorb, or mix easily with water. The inherent characteristic of a molecule or substance to be immiscible in water. The property means that the moiety of interest does not dissolve in, absorb, or mix easily with water. Hydrophobicity Hydrophobic AD NCI Hydrophobicity PT NCI The inherent characteristic of a molecule or substance to be immiscible in water. The property means that the moiety of interest does not dissolve in, absorb, or mix easily with water. NCI Thesaurus:C64657 C64657 Activity Dilute C0079240 CDISC EDQM-HC To make something thinner, weaker, less concentrated, or less pure by adding something to it. To reduce in strength or concentration by the addition of diluent. Transformation of a concentrate into a liquid of greater volume and lower concentration by mixing it with a specified solvent. Dilute DILUTING Dilute Dilution dil. dilute To reduce in strength or concentration, especially by the addition of water. To reduce in strength or concentration, especially by the addition of water. Dilute To make something thinner, weaker, less concentrated, or less pure by adding something to it. NCI-GLOSS To reduce in strength or concentration by the addition of diluent. CDISC Transformation of a concentrate into a liquid of greater volume and lower concentration by mixing it with a specified solvent. EDQM-HC DILUTING PT CDISC Dilute PT NCI Dilution PT EDQM-HC 0038 TRA Dilution SY NCI dil. AB NCI dilute PT NCI-GLOSS CDR0000462674 To reduce in strength or concentration, especially by the addition of water. NCI Thesaurus:C65508 C65508 Pharmacologic Substance Edetate Disodium Anhydrous C1875875 139-33-3 8NLQ36F6MM FDA C10H12N2O8.2"H".2Na Edetate_Disodium_Anhydrous CHEBI:64734 EDETATE DISODIUM ANHYDROUS Edetate Disodium Anhydrous Edetate Disodium Anhydrous EDETATE DISODIUM ANHYDROUS PT FDA 8NLQ36F6MM UNII Edetate Disodium Anhydrous PT NCI Thesaurus:C65795 C65795 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadodiamide Gadodiamide C0082646 131410-48-5 84F6U3J2R6 CTRP FDA 779661 779661 C16H26GdN5O8 Gadodiamide CHEBI:37333 779661 DV 7572 GADODIAMIDE Gadodiamide Gadolinium, (5,8-bis((carboxy-kappaO)methyl)-11-(2-(methylamino)-2-(oxo-kappaO)ethyl)-3-(oxo-kappaO)-2,5,8,11-tetraazatridecan-13-oato(3-)-kappaN5,kappaN8,kappaN11,kappaO13)- Gadolinium-DTPA-BMA Gd-DTPA-BMA HSDB 7547 OmniScan A paramagnetic gadolinium-based contrast agent (GBCA), with imaging activity upon magnetic resonance imaging (MRI). When placed in a magnetic field, gadodiamide generates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, iincreases the MRI signal intensity of tissues in which gadodiamide has accumulated; therefore, visualization of those tissues is enhanced. A paramagnetic gadolinium-based contrast agent (GBCA), with imaging activity upon magnetic resonance imaging (MRI). When placed in a magnetic field, gadodiamide generates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, iincreases the MRI signal intensity of tissues in which gadodiamide has accumulated; therefore, visualization of those tissues is enhanced. Gadodiamide DV 7572 CN NCI GADODIAMIDE PT FDA 84F6U3J2R6 UNII Gadodiamide DN CTRP Gadodiamide PT NCI Gadolinium, (5,8-bis((carboxy-kappaO)methyl)-11-(2-(methylamino)-2-(oxo-kappaO)ethyl)-3-(oxo-kappaO)-2,5,8,11-tetraazatridecan-13-oato(3-)-kappaN5,kappaN8,kappaN11,kappaO13)- SN NCI Gadolinium-DTPA-BMA SY NCI Gd-DTPA-BMA AB NCI HSDB 7547 CN NCI OmniScan BR NCI A paramagnetic gadolinium-based contrast agent (GBCA), with imaging activity upon magnetic resonance imaging (MRI). When placed in a magnetic field, gadodiamide generates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, iincreases the MRI signal intensity of tissues in which gadodiamide has accumulated; therefore, visualization of those tissues is enhanced. NCI Thesaurus:C65796 C65796 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadoteridol C0060930 120066-54-8 0199MV609F FDA C17H29GdN4O7 Gadoteridol CHEBI:31643 (+-)-(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium (10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato)gadolinium GADOTERIDOL GD-HP-DO3A Gadoteridol Gadoteridolum HSDB 7549 ProHance SQ 32692 Gadoteridol (+-)-(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium SN NCI (10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato)gadolinium SN NCI GADOTERIDOL PT FDA 0199MV609F UNII GD-HP-DO3A AB NCI Gadoteridol PT NCI Gadoteridolum SY NCI HSDB 7549 CN NCI ProHance BR NCI SQ 32692 CN NCI Thesaurus:C66592 C66592 Pharmacologic Substance Tetraxetan C0088359 60239-18-1 1HTE449DGZ FDA C16H28N4O8 Tetraxetan CHEBI:61028 1,4,7,10-Dota 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid DOTA DOTA Acid TETRAXETAN Tetraxetan Tetraxetan 1,4,7,10-Dota SY NCI 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid SN NCI 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid SN NCI DOTA AB NCI DOTA Acid SY NCI TETRAXETAN PT FDA 1HTE449DGZ UNII Tetraxetan PT NCI Thesaurus:C66633 C66633 Pharmacologic Substance Trientine C0040976 112-24-3 SJ76Y07H5F FDA C6H18N4 Trientine CHEBI:39501 TRIENTINE Trientine Trientine TRIENTINE PT FDA SJ76Y07H5F UNII Trientine PT NCI Thesaurus:C66945 C66945 Pharmacologic Substance Dexrazoxane Hydrochloride Dexrazoxane Hydrochloride C0982118 149003-01-0 severe side effects caused by certain types of chemotherapy including extravasation, cardiac side effects by doxorubicin. 5346058Q7S CTRP FDA A drug used to treat severe side effects caused by certain anticancer drugs. It is used under the brand name Totect to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. It is also used under the brand name Zinecard to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane hydrochloride is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor. 39485 39485 C11H16N4O4.HCl Dexrazoxane_Hydrochloride CHEBI:50224 Dexrazoxane Hydrochloride 39485 Cardioxane DEXRAZOXANE HYDROCHLORIDE Dexrazoxane Hydrochloride Totect Zinecard dexrazoxane hydrochloride The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. Dexrazoxane Hydrochloride A drug used to treat severe side effects caused by certain anticancer drugs. It is used under the brand name Totect to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. It is also used under the brand name Zinecard to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane hydrochloride is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor. NCI-GLOSS Dexrazoxane Hydrochloride Has Synonym PT therapeutic_agents GDC Cardioxane BR NCI DEXRAZOXANE HYDROCHLORIDE PT FDA 5346058Q7S UNII Dexrazoxane Hydrochloride DN CTRP Dexrazoxane Hydrochloride PT NCI Totect BR NCI Totect PT NCI-GLOSS CDR0000572245 Zinecard BR NCI Zinecard PT NCI-GLOSS CDR0000572249 dexrazoxane hydrochloride PT NCI-GLOSS CDR0000572255 The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. NCI Thesaurus:C67311 C67311 Quantitative Concept Microgram per Square Centimeter C1631160 CDISC UCUM A unit of area density defined as a spread rate at which one microgram of a substance is spread over the area of one square centimeter. The unit is also used as a dose calculation unit. Microgram_per_Square_Centimeter Microgram per Centimeter Squared Microgram per Square Centimeter Microgram/Square Centimeter mcg/cm2 microgram per centimeter squared ug/cm2 A metric unit of areal density equal to approximately 2.94935E-4 ounce per square yard. Also used as a dose calculation unit. A metric unit of areal density equal to approximately 2.94935E-4 ounce per square yard. Also used as a dose calculation unit. Microgram per Square Centimeter A unit of area density defined as a spread rate at which one microgram of a substance is spread over the area of one square centimeter. The unit is also used as a dose calculation unit. CDISC Microgram per Centimeter Squared SY NCI Microgram per Square Centimeter PT NCI Microgram/Square Centimeter SY NCI mcg/cm2 AB NCI mcg/cm2 SY CDISC microgram per centimeter squared PT UCUM ug/cm2 AB NCI ug/cm2 AB UCUM ug/cm2 PT CDISC A metric unit of areal density equal to approximately 2.94935E-4 ounce per square yard. Also used as a dose calculation unit. NCI Thesaurus:C70675 C70675 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadobutrol Gadobutrol C0291216 138071-82-6 Diagnostic Magnetic Resonance Imaging 1BJ477IO2L CTRP FDA 570641 570641 C18H31N4O9.Gd Gadobutrol 570641 (10-((1RS,2SR)-2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium BAY86-4875 GADOBUTROL Gadavist Gadobutrol Gadograf Gadovist Protovis ZK 135079 A gadolinium-based, hydrophilic, macrocyclic, electrically neutral contrast agent used in contrast-enhanced MRI (CE-MRI). Gadobutrol is a non-ionic, paramagnetic complex consisting of gadolinium (Gd3+) chelated with the macrocyclic compound dihydroxy-hydroxymethylpropyl-tetraazacyclododecane-triacetic acid (butrol). Following intravenous administration, gadobutrol may increase MRI sensitivity for the detection of tumors and inflammatory and demyelinating diseases of the central nervous system (CNS) that are associated with areas with blood-brain barrier defects due to altered perfusion or an enlarged extracellular space. This agent is eliminated in an unchanged form via the kidneys; extra-renal elimination is negligible. A gadolinium-based, hydrophilic, macrocyclic, electrically neutral contrast agent used in contrast-enhanced MRI (CE-MRI). Gadobutrol is a non-ionic, paramagnetic complex consisting of gadolinium (Gd3+) chelated with the macrocyclic compound dihydroxy-hydroxymethylpropyl-tetraazacyclododecane-triacetic acid (butrol). Following intravenous administration, gadobutrol may increase MRI sensitivity for the detection of tumors and inflammatory and demyelinating diseases of the central nervous system (CNS) that are associated with areas with blood-brain barrier defects due to altered perfusion or an enlarged extracellular space. This agent is eliminated in an unchanged form via the kidneys; extra-renal elimination is negligible. Gadobutrol (10-((1RS,2SR)-2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium SN NCI BAY86-4875 CN NCI GADOBUTROL PT FDA 1BJ477IO2L UNII Gadavist BR NCI Gadobutrol DN CTRP Gadobutrol PT NCI Gadograf BR NCI Gadovist BR NCI Protovis BR NCI ZK 135079 CN NCI A gadolinium-based, hydrophilic, macrocyclic, electrically neutral contrast agent used in contrast-enhanced MRI (CE-MRI). Gadobutrol is a non-ionic, paramagnetic complex consisting of gadolinium (Gd3+) chelated with the macrocyclic compound dihydroxy-hydroxymethylpropyl-tetraazacyclododecane-triacetic acid (butrol). Following intravenous administration, gadobutrol may increase MRI sensitivity for the detection of tumors and inflammatory and demyelinating diseases of the central nervous system (CNS) that are associated with areas with blood-brain barrier defects due to altered perfusion or an enlarged extracellular space. This agent is eliminated in an unchanged form via the kidneys; extra-renal elimination is negligible. NCI Thesaurus:C72097 C72097 Pharmacologic Substance Egtazic Acid C0013714 67-42-5 526U7A2651 FDA C14H24N2O10 Egtazic_Acid CHEBI:30740 (Ethylenebis(Oxyethylenenitrilo))Tetraacetic Acid 6,9-Dioxa-3,12-Diazatetradecanedioic Acid, 3,12-Bis(Carboxymethyl)- EGTA EGTAZIC ACID Egtazic Acid Egtazic Acid (Ethylenebis(Oxyethylenenitrilo))Tetraacetic Acid SN NCI 6,9-Dioxa-3,12-Diazatetradecanedioic Acid, 3,12-Bis(Carboxymethyl)- SN NCI EGTA AB NCI EGTAZIC ACID PT FDA 526U7A2651 UNII Egtazic Acid PT NCI Thesaurus:C73030 C73030 Pharmacologic Substance Deferiprone C0043832 30652-11-0 Hemosiderosis 2BTY8KH53L FDA 761978 761978 C7H9NO2 Deferiprone 761978 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl- APO-066 CP20 DEFERIPRONE DN-180-01-AF Deferiprone Ferriprox An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. Deferiprone 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl- SN NCI APO-066 CN NCI CP20 CN NCI DEFERIPRONE PT FDA 2BTY8KH53L UNII DN-180-01-AF CN NCI Deferiprone PT NCI Ferriprox BR NCI An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. NCI Thesaurus:C74001 C74001 Pharmacologic Substance Tiomolibdate Diammonium 286644 714598 C0076339 15060-55-6 4V6I63LW1E FDA A substance being studied in the treatment of many types of cancer. Ammonium tetrathiomolybdate removes extra copper from the body. Removing the copper may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. Ammonium tetrathiomolybdate is a type of chelating agent and a type of antiangiogenesis agent. 467218 467218 MoS4.2H4N Ammonium_Tetrathiomolybdate Tiomolibdate Diammonium 467218 ATTM Ammonium Molybdenum Sulfide Ammonium Tetrathiomolybdate Coprexa Diammonium Tetrathiomolybdate Molybdate(2-), Tetrathioxo-, Ammonium (1:2), (T-4)- Molybdate(2-), Tetrathioxo-, Diammonium, (T-4)- TIOMOLIBDATE DIAMMONIUM Tiomolibdate Diammonium ammonium tetrathiomolybdate An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects. An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects. Tiomolibdate Diammonium A substance being studied in the treatment of many types of cancer. Ammonium tetrathiomolybdate removes extra copper from the body. Removing the copper may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. Ammonium tetrathiomolybdate is a type of chelating agent and a type of antiangiogenesis agent. NCI-GLOSS Tiomolibdate Diammonium Has Synonym PT therapeutic_agents GDC ATTM AB NCI Ammonium Molybdenum Sulfide SY NCI Ammonium Tetrathiomolybdate SY NCI Coprexa BR NCI Diammonium Tetrathiomolybdate SY NCI Molybdate(2-), Tetrathioxo-, Ammonium (1:2), (T-4)- SN NCI Molybdate(2-), Tetrathioxo-, Diammonium, (T-4)- SN NCI TIOMOLIBDATE DIAMMONIUM PT FDA 4V6I63LW1E UNII Tiomolibdate Diammonium PT NCI ammonium tetrathiomolybdate PT NCI-GLOSS CDR0000599961 An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects. NCI Thesaurus:C74565 C74565 Functional Concept Employee Job Class C2699869 CDISC A code qualifying the employment in various ways, such as, full-time vs. part time, etc. Employee_Job_Class Employee Job Class Employment Status JOBCLAS A coding system used to specify attributes of an occupation. A coding system used to specify attributes of an occupation. Employee Job Class A code qualifying the employment in various ways, such as, full-time vs. part time, etc. CDISC Employee Job Class PT CDISC SDTM-SCTEST Employee Job Class PT NCI Employee Job Class SY CDISC Employment Status SY CDISC JOBCLAS PT CDISC SDTM-SCTESTCD A coding system used to specify attributes of an occupation. NCI Thesaurus:C74576 C74576 Organic Chemical Pentetate Calcium Trisodium 34249 C0520458 12111-24-9 G79YN26H5B FDA C14H18N3O10.Ca.3Na Pentetate_Calcium_Trisodium Calcium Trisodium DTPA Ditripentat-Heyl PENTETATE CALCIUM TRISODIUM Pentacine Pentetate Calcium Trisodium Trisodium Calcium Diethylenetriaminepentaacetate The trisodium salt form of calcium diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination with any of these radionuclides thereby increasing their excretion. The trisodium salt form of calcium diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination with any of these radionuclides thereby increasing their excretion. Pentetate Calcium Trisodium Calcium Trisodium DTPA SY NCI Ditripentat-Heyl FB NCI PENTETATE CALCIUM TRISODIUM PT FDA G79YN26H5B UNII Pentacine BR NCI Pentetate Calcium Trisodium PT NCI Pentetate Calcium Trisodium SY caDSR Trisodium Calcium Diethylenetriaminepentaacetate SY NCI The trisodium salt form of calcium diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination with any of these radionuclides thereby increasing their excretion. NCI Thesaurus:C76043 C76043 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadobenic Acid C0246154 113662-23-0 15G12L5X8K FDA C22H26N3O11.Gd.2H Gadobenic_Acid GADOBENIC ACID Gadobenate Gadobenic Acid Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, Dihydrogen Gadobenic Acid GADOBENIC ACID PT FDA 15G12L5X8K UNII Gadobenate SY NCI Gadobenic Acid PT NCI Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, Dihydrogen SN NCI Thesaurus:C76044 C76044 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadopentetate C2700227 544697-52-1 V7OK6J19HQ FDA C14H18GdN3O10 Gadopentetate CHEBI:35778 GADOPENTETATE Gadopentetate Gadopentetate GADOPENTETATE PT FDA V7OK6J19HQ UNII Gadopentetate PT NCI Thesaurus:C76597 C76597 Pharmacologic Substance Deferitrin C0769436 239101-33-8 T69Y9LDN44 FDA C11H11NO4S Deferitrin 4-Hydroxydesazadesferrithiocin DEFERITRIN Deferitrin GT-56-252 Deferitrin 4-Hydroxydesazadesferrithiocin SN NCI DEFERITRIN PT FDA T69Y9LDN44 UNII Deferitrin PT NCI GT-56-252 CN NCI Thesaurus:C76598 C76598 Pharmacologic Substance Edetate Sodium C0982132 64-02-8 MP1J8420LU FDA C10H12N2O8.4Na Edetate_Sodium EDETATE SODIUM Edetate Sodium Edetate Sodium EDETATE SODIUM PT FDA MP1J8420LU UNII Edetate Sodium PT NCI Thesaurus:C76599 C76599 Pharmacologic Substance Edetate Trisodium C0357217 150-38-9 420IP921MB FDA C10H13N2O8.3Na Edetate_Trisodium CHEBI:63125 EDETATE TRISODIUM Edetate Trisodium Edetate Trisodium EDETATE TRISODIUM PT FDA 420IP921MB UNII Edetate Trisodium PT NCI Thesaurus:C76600 C76600 Pharmacologic Substance Gluceptate Sodium C0993220 13007-85-7 3D49LE7HM2 FDA C7H13O8.Na Gluceptate_Sodium GLUCEPTATE SODIUM Gluceptate Sodium Monosodium D-glycero-D-gulo-heptonate Sodium D-glycero-D-gulo-heptonate Sodium Gluceptate Gluceptate Sodium GLUCEPTATE SODIUM PT FDA 3D49LE7HM2 UNII Gluceptate Sodium PT NCI Monosodium D-glycero-D-gulo-heptonate SN NCI Sodium D-glycero-D-gulo-heptonate SN NCI Sodium Gluceptate SY NCI Thesaurus:C76601 C76601 Pharmacologic Substance Tropantiol C2700084 189950-11-6 7844H41L5Z FDA C21H34ClN3S2 Tropantiol TROPANTIOL Tropantiol Tropantiol TROPANTIOL PT FDA 7844H41L5Z UNII Tropantiol PT NCI Thesaurus:C76602 C76602 Pharmacologic Substance Ranelic Acid C2699005 135459-90-4 K9CCS0RIBT FDA C12H10N2O8S Ranelic_Acid 5-(Bis(carboxymethyl)amino)-2-carboxy-4-cyano-3-thiopheneacetic Acid RANELIC ACID Ranelic Acid Ranelic Acid 5-(Bis(carboxymethyl)amino)-2-carboxy-4-cyano-3-thiopheneacetic Acid SN NCI RANELIC ACID PT FDA K9CCS0RIBT UNII Ranelic Acid PT NCI Thesaurus:C76632 C76632 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadopenamide C0644003 117827-80-2 VC7M3XD17L FDA C22H34N5O10.Gd Gadopenamide (N,N-Bis(2-((carboxymethyl)((morpholinocarbonyl)methyl)amino)ethyl)glycinato(3-))gadolinium GADOPENAMIDE Gadopenamide Gadopenamide (N,N-Bis(2-((carboxymethyl)((morpholinocarbonyl)methyl)amino)ethyl)glycinato(3-))gadolinium SN NCI GADOPENAMIDE PT FDA VC7M3XD17L UNII Gadopenamide PT NCI Thesaurus:C77547 C77547 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadobenate Dimeglumine C0209453 127000-20-8 3Q6PPC19PO FDA A drug used in MRI to help make clear pictures of blood vessels in the brain, spine, and nearby tissues. It is also being studied as a way to find abnormal areas in the liver and other organs and to help diagnose cancer. Gadobenate dimeglumine is a type of contrast agent. 617168 617168 C22H28N3O11.2C7H17NO5.Gd Gadobenate_Dimeglumine 617168 (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2) GADOBENATE DIMEGLUMINE Gadobenate Dimeglumine Gd-BOPTA MultiHance gadobenate dimeglumine A gadolinium-based paramagnetic contrast agent. When placed in a magnetic field, gadobenate dimeglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI. A gadolinium-based paramagnetic contrast agent. When placed in a magnetic field, gadobenate dimeglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI. Gadobenate Dimeglumine A drug used in MRI to help make clear pictures of blood vessels in the brain, spine, and nearby tissues. It is also being studied as a way to find abnormal areas in the liver and other organs and to help diagnose cancer. Gadobenate dimeglumine is a type of contrast agent. NCI-GLOSS (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2) SN NCI GADOBENATE DIMEGLUMINE PT FDA 3Q6PPC19PO UNII Gadobenate Dimeglumine PT NCI Gd-BOPTA AB NCI MultiHance BR NCI MultiHance PT NCI-GLOSS CDR0000642139 gadobenate dimeglumine PT NCI-GLOSS CDR0000642138 A gadolinium-based paramagnetic contrast agent. When placed in a magnetic field, gadobenate dimeglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI. NCI Thesaurus:C77548 C77548 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadoxetate Disodium Gadoxetate Disodium C1714000 135326-22-6 HOY74VZE0M CTRP FDA 617182 617182 C23H28N3O11.Gd.2Na Gadoxetate_Disodium 617182 Disodium (N-((2S)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-) Eovist GADOXETATE DISODIUM Gadolinium EOB DTPA Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid Gadoxetate Disodium Gadoxetic Acid Disodium Gd-(S)-EOB-DTPA Gd-EOB-DTPA Primovist ZK 139834 A paramagnetic contrast agent consisting of the disodium salt of the gadolinium ion chelated with the lipophilic moiety ethoxybenzyl (EOB) bound to diethylenetriamine pentaacetic acid (DTPA). When placed in a magnetic field, gadolinium produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because this agent is excreted in the bile, it may be used to visualize the biliary system using MRI. A paramagnetic contrast agent consisting of the disodium salt of the gadolinium ion chelated with the lipophilic moiety ethoxybenzyl (EOB) bound to diethylenetriamine pentaacetic acid (DTPA). When placed in a magnetic field, gadolinium produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because this agent is excreted in the bile, it may be used to visualize the biliary system using MRI. Gadoxetate Disodium Disodium (N-((2S)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-) SN NCI Eovist BR NCI GADOXETATE DISODIUM PT FDA HOY74VZE0M UNII Gadolinium EOB DTPA SY NCI Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid SY NCI Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid SY NCI Gadoxetate Disodium DN CTRP Gadoxetate Disodium PT NCI Gadoxetic Acid Disodium SY NCI Gd-(S)-EOB-DTPA AB NCI Gd-EOB-DTPA AB NCI Primovist FB NCI ZK 139834 CN NCI A paramagnetic contrast agent consisting of the disodium salt of the gadolinium ion chelated with the lipophilic moiety ethoxybenzyl (EOB) bound to diethylenetriamine pentaacetic acid (DTPA). When placed in a magnetic field, gadolinium produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because this agent is excreted in the bile, it may be used to visualize the biliary system using MRI. NCI Thesaurus:C77549 C77549 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadoxetic Acid C0166237 135326-11-3 3QJA87N40S FDA C23H28N3O11.2"H".Gd Gadoxetic_Acid Dihydrogen (N((2s)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-) GADOXETIC ACID Gadoxetic Acid Gadoxetic Acid Dihydrogen (N((2s)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-) SN NCI GADOXETIC ACID PT FDA 3QJA87N40S UNII Gadoxetic Acid PT NCI Thesaurus:C77834 C77834 Pharmacologic Substance Edetate Tripotassium C2699851 17572-97-3 KIA5203U1H FDA C10H13N2O8.3K Edetate_Tripotassium EDETATE TRIPOTASSIUM EDTA Tripotassium Edetate Tripotassium Edetate Tripotassium EDETATE TRIPOTASSIUM PT FDA KIA5203U1H UNII EDTA Tripotassium SY NCI Edetate Tripotassium PT NCI Thesaurus:C77835 C77835 Pharmacologic Substance Pentetate Zinc Trisodium C1337329 125833-02-5 NXU65IC8PG FDA C14H18N3O10.3Na.Zn Pentetate_Zinc_Trisodium PENTETATE ZINC TRISODIUM Pentetate Zinc Trisodium Trisodium Zinc DTPA Zinc Trisodium DTPA Zinc Trisodium Diethylenetriaminepentaacetate The trisodium salt form of zinc diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. The trisodium salt form of zinc diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. Pentetate Zinc Trisodium PENTETATE ZINC TRISODIUM PT FDA NXU65IC8PG UNII Pentetate Zinc Trisodium PT NCI Pentetate Zinc Trisodium SY caDSR Trisodium Zinc DTPA SY NCI Zinc Trisodium DTPA SY NCI Zinc Trisodium Diethylenetriaminepentaacetate SN NCI The trisodium salt form of zinc diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. NCI Thesaurus:C79889 C79889 Classification Authority C0599437 Authority Authority A person or group with the power or right to give orders or make decisions for a particular area of activity. A person or group with the power or right to give orders or make decisions for a particular area of activity. Authority Authority PT NCI A person or group with the power or right to give orders or make decisions for a particular area of activity. NCI Thesaurus:C801 C801 Organic Chemical Pharmacologic Substance Razoxane 129943 C0034738 21416-67-1 21416-87-5 5AR83PR647 FDA 39480 39480 C11H16N4O4 Razoxane CHEBI:50225 Razoxane 39480 ICI 59118 ICRF 159 ICRF-159 ICRF159 RAZOXANE Razoxane Razoxin An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown. An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown. Razoxane Razoxane Has Synonym PT therapeutic_agents GDC ICI 59118 CN NCI ICRF 159 CN NCI ICRF 159 SY DTP NSC0129943 ICRF-159 CN NCI ICRF159 CN NCI RAZOXANE PT FDA 5AR83PR647 UNII Razoxane PT NCI Razoxin FB NCI Razoxin SY DTP NSC0129943 An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown. NCI Thesaurus:C80124 C80124 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadoterate Meglumine Gadoterate Meglumine C0060929 92943-93-6 L0ND3981AG CTRP FDA 618206 618206 C16H24N4O8.C7H17NO5."H".Gd Gadoterate_Meglumine 618206 DOTAREM GADOTERATE MEGLUMINE Gadoterate Meglumine Gd-DOTA A gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI. A gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI. Gadoterate Meglumine DOTAREM BR NCI GADOTERATE MEGLUMINE PT FDA L0ND3981AG UNII Gadoterate Meglumine DN CTRP Gadoterate Meglumine PT NCI Gd-DOTA SY NCI A gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI. NCI Thesaurus:C80963 C80963 Pharmacologic Substance Ditiocarb Sodium 38583 C0700086 148-18-5 A5304YEB5E FDA 802912 802912 C5H10NS2.Na Ditiocarb_Sodium 802912 DITIOCARB SODIUM Diethylcarbamodithioic Acid, Sodium Salt Ditiocarb Sodium Imuthiol Sodium Diethyldithiocarbamate The sodium salt form of ditiocarb, an active metabolite of disulfiram, with potential antineoplastic and chemosensitizing activities. Upon administration, ditiocarb sodium may form a complex with copper (Cu), a metal that selectively accumulates in cancer cells. This complex may inhibit the nuclear factor-kB (NF-kB) pathway activated by tumor hypoxia, thereby inhibiting tumor cell growth. It may also reverse chemoresistance and enhance cytotoxicity of other chemotherapeutic agents. The sodium salt form of ditiocarb, an active metabolite of disulfiram, with potential antineoplastic and chemosensitizing activities. Upon administration, ditiocarb sodium may form a complex with copper (Cu), a metal that selectively accumulates in cancer cells. This complex may inhibit the nuclear factor-kB (NF-kB) pathway activated by tumor hypoxia, thereby inhibiting tumor cell growth. It may also reverse chemoresistance and enhance cytotoxicity of other chemotherapeutic agents. Ditiocarb Sodium DITIOCARB SODIUM PT FDA A5304YEB5E UNII Diethylcarbamodithioic Acid, Sodium Salt SN NCI Ditiocarb Sodium PT NCI Imuthiol BR NCI Sodium Diethyldithiocarbamate SY NCI The sodium salt form of ditiocarb, an active metabolite of disulfiram, with potential antineoplastic and chemosensitizing activities. Upon administration, ditiocarb sodium may form a complex with copper (Cu), a metal that selectively accumulates in cancer cells. This complex may inhibit the nuclear factor-kB (NF-kB) pathway activated by tumor hypoxia, thereby inhibiting tumor cell growth. It may also reverse chemoresistance and enhance cytotoxicity of other chemotherapeutic agents. NCI Thesaurus:C81056 C81056 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadofosveset C1698893 201688-00-8 E65RW73PHS FDA C33H38N3O14P.3"H".Gd Gadofosveset EPIX GADOFOSVESET Gadofosveset An injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. An injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. Gadofosveset EPIX AB NCI GADOFOSVESET PT FDA E65RW73PHS UNII Gadofosveset PT NCI An injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. NCI Thesaurus:C81057 C81057 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadofosveset Trisodium Gadofosveset Trisodium C1433439 211570-55-7 XM33Q67UVH CTRP FDA 712739 712739 C33H38N3O14P.Gd.3Na.H2O Gadofosveset_Trisodium 712739 Ablavar GADOFOSVESET TRISODIUM Gadofosveset Trisodium MS-325 Vasovist The trisodium salt form of gadofosveset, an injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. The trisodium salt form of gadofosveset, an injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. Gadofosveset Trisodium Ablavar BR NCI GADOFOSVESET TRISODIUM PT FDA XM33Q67UVH UNII Gadofosveset Trisodium DN CTRP Gadofosveset Trisodium PT NCI MS-325 CN NCI Vasovist BR NCI The trisodium salt form of gadofosveset, an injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. NCI Thesaurus:C81058 C81058 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadofosveset Trisodium Anhydrous C2825433 193901-90-5 9430ZR8ZAN FDA C33H38N3O14P.Gd.3Na Gadofosveset_Trisodium_Anhydrous GADOFOSVESET TRISODIUM ANHYDROUS Gadofosveset Trisodium Anhydrous The anhydrous form of gadofosveset, an injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. The anhydrous form of gadofosveset, an injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. Gadofosveset Trisodium Anhydrous GADOFOSVESET TRISODIUM ANHYDROUS PT FDA 9430ZR8ZAN UNII Gadofosveset Trisodium Anhydrous PT NCI The anhydrous form of gadofosveset, an injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders. NCI Thesaurus:C83078 C83078 Intellectual Product Investigator Identifier C2826689 Investigator_Identifier INVID Investigator Identifier A sequence of characters used to identify, name, or characterize the study investigator. A sequence of characters used to identify, name, or characterize the study investigator. Investigator Identifier INVID PT CDISC Investigator Identifier PT NCI A sequence of characters used to identify, name, or characterize the study investigator. NCI Thesaurus:C83121 C83121 Functional Concept Exposure Route of Administration C2826731 Exposure_Route_of_Administration EXROUTE Exposure Route of Administration Designation of the part of the body through which the exposure is introduced. Designation of the part of the body through which the exposure is introduced. Exposure Route of Administration EXROUTE PT CDISC Exposure Route of Administration PT NCI Designation of the part of the body through which the exposure is introduced. NCI Thesaurus:C83444 C83444 Intellectual Product Trial Inclusion Exclusion Criteria Version C2827032 Trial_Inclusion_Exclusion_Criteria_Version TIVERS Trial Inclusion Exclusion Criteria Version A specific variant of the original trial inclusion exclusion criterion. A specific variant of the original trial inclusion exclusion criterion. Trial Inclusion Exclusion Criteria Version TIVERS PT CDISC Trial Inclusion Exclusion Criteria Version PT NCI A specific variant of the original trial inclusion exclusion criterion. NCI Thesaurus:C85574 C85574 Laboratory Procedure Atomic Absorption Spectroscopy C0037806 CDISC A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. ATOMIC ABSORPTION SPECTROMETRY Atomic Absorption Spectroscopy A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. Atomic Absorption Spectroscopy A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. CDISC ATOMIC ABSORPTION SPECTROMETRY PT CDISC Atomic Absorption Spectroscopy PT NCI A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. NCI Thesaurus:C87416 C87416 Organic Chemical 2,3-Dimercapto-1-Propanesulfonic Acid CL416204 74-61-3 086L82361J FDA C3H8O3S3 CHEBI:888 (+/-)-2,3-Dimercapto-1-Propanesulfonic Acid 1-Propanesulfonic Acid, 2,3-Dimercapto- 2,3-DIMERCAPTO-1-PROPANESULFONIC ACID 2,3-Dimercapto-1-Propanesulfonic Acid DMPS 2,3-Dimercapto-1-Propanesulfonic Acid (+/-)-2,3-Dimercapto-1-Propanesulfonic Acid SN NCI 1-Propanesulfonic Acid, 2,3-Dimercapto- SN NCI 2,3-DIMERCAPTO-1-PROPANESULFONIC ACID PT FDA 086L82361J UNII 2,3-Dimercapto-1-Propanesulfonic Acid PT NCI DMPS AB NCI Thesaurus:C87690 C87690 Pharmacologic Substance Phytate Sodium C0037545 7205-52-9 88496G1ERL FDA C6H6O24P6.3"H".9Na Myo-Inositol, Hexakis(Dihydrogen Phosphate), Nonasodium Salt PHYTATE SODIUM Phytate Sodium Phytate Sodium Myo-Inositol, Hexakis(Dihydrogen Phosphate), Nonasodium Salt SN NCI PHYTATE SODIUM PT FDA 88496G1ERL UNII Phytate Sodium PT NCI Thesaurus:C87691 C87691 Pharmacologic Substance Unithiol C0041738 4076-02-2 690VN2L7TK FDA C3H7O3S3.Na 2,3-Dimercaptopropane-1-Sulfonate Sodium Sodium 2,3-Dimercaptopropanesulfonate UNITHIOL Unithiol Unitiol Unithiol 2,3-Dimercaptopropane-1-Sulfonate Sodium SN NCI Sodium 2,3-Dimercaptopropanesulfonate SN NCI UNITHIOL PT FDA 690VN2L7TK UNII Unithiol PT NCI Unitiol SY NCI Thesaurus:C87737 C87737 Indicator, Reagent, or Diagnostic Aid Organic Chemical Gadopentetic Acid C0060933 80529-93-7 K2I13DR72L FDA C14H18N3O10.2"H".Gd GADOPENTETIC ACID Gadopentetic Acid Gadopentetic Acid GADOPENTETIC ACID PT FDA K2I13DR72L UNII Gadopentetic Acid PT NCI Thesaurus:C90453 C90453 Intellectual Product SEND Version 3.0 Draft A C2983661 SEND Version 3.0 Draft A The A draft of the standard for the exchange of non-clinical data (SEND) implementation guide. The A draft of the standard for the exchange of non-clinical data (SEND) implementation guide. SEND Version 3.0 Draft A SEND Version 3.0 Draft A PT NCI The A draft of the standard for the exchange of non-clinical data (SEND) implementation guide. NCI Thesaurus:C90454 C90454 Intellectual Product SEND Version 3.0 Draft B C2983662 SEND Version 3.0 Draft B The B draft of the standard for the exchange of non-clinical data (SEND) implementation guide. The B draft of the standard for the exchange of non-clinical data (SEND) implementation guide. SEND Version 3.0 Draft B SEND Version 3.0 Draft B PT NCI The B draft of the standard for the exchange of non-clinical data (SEND) implementation guide. NCI Thesaurus:C90458 C90458 Intellectual Product Standard for the Exchange of Nonclinical Data Implementation Guide Version C3272336 CDISC The version of the Standard for the Exchange of Nonclinical Data Implementation Guide that is being used in the study submission. SEND IG Version SEND Implementation Guide Version SNDIGVER Standard for the Exchange of Nonclinical Data Implementation Guide Version The version of the Standard for the Exchange of Non-clinical Data that is being used in the study. The version of the Standard for the Exchange of Non-clinical Data that is being used in the study. Standard for the Exchange of Nonclinical Data Implementation Guide Version The version of the Standard for the Exchange of Nonclinical Data Implementation Guide that is being used in the study submission. CDISC SEND IG Version SY CDISC SEND Implementation Guide Version PT CDISC SEND-STSPRM SEND Implementation Guide Version SY CDISC SNDIGVER PT CDISC SEND-STSPRMCD Standard for the Exchange of Nonclinical Data Implementation Guide Version PT NCI The version of the Standard for the Exchange of Non-clinical Data that is being used in the study. NCI Thesaurus:C90829 C90829 Organic Chemical Pharmacologic Substance Edetate Calcium Disodium Anhydrous C2983900 62-33-9 8U5D034955 FDA C10H12N2O8.Ca.2Na EDETATE CALCIUM DISODIUM ANHYDROUS Edetate Calcium Disodium Anhydrous Edetate Calcium Disodium Anhydrous EDETATE CALCIUM DISODIUM ANHYDROUS PT FDA 8U5D034955 UNII Edetate Calcium Disodium Anhydrous PT NCI Thesaurus:C90830 C90830 Organic Chemical Pharmacologic Substance Lexidronam C2344045 1429-50-1 V4CP8RSX7V FDA C6H20N2O12P4 EDTMP Ethylenediamine Tetra(methylene Phosphonic Acid) LEXIDRONAM Lexidronam Lexidronam EDTMP AB NCI Ethylenediamine Tetra(methylene Phosphonic Acid) SN NCI LEXIDRONAM PT FDA V4CP8RSX7V UNII Lexidronam PT NCI Thesaurus:C90831 C90831 Organic Chemical Pharmacologic Substance Tiomolibdic Acid C2983902 13818-85-4 206J6X63BE FDA H2MoS4 TIOMOLIBDIC ACID Tiomolibdic Acid Tiomolibdic Acid TIOMOLIBDIC ACID PT FDA 206J6X63BE UNII Tiomolibdic Acid PT NCI Thesaurus:C93400 C93400 Intellectual Product Material Identifier C2985613 BRIDG A unique symbol that establishes identity of the material. EXAMPLE(S): serial number, product number, model number OTHER NAME(S): NOTE(S): There are multiple ways in which an identifier can be associated to a product; inherited from MaterialIdentifier.identifier, the association to ProcessedProduct.identifier, and the association to ProductRelationship.identifier. If there is no context associated with the identifier, then MaterialIdentifier.identifier should be used. However, if the identifier for a product would be different in different context, one of the other identifiers should be used. If a kind of product is produced by different processors, and each processor assigns the product a different identifier, then ProcessedProduct.identifier should be used. If the product is used in multiple assemblies, and in each assembly it would be assigned a different identifier, then ProductRelationship.identifier should be used. The unique identification of a material in a specific context. NOTE(S): This class is a resolution of the requirement for noting the type of an identifier which is not handled by the purely technical HL7 II data type. Material Identifier Material.identifier MaterialIdentifier The unique identification of a material in a specific context. The unique identification of a material in a specific context. Material Identifier A unique symbol that establishes identity of the material. EXAMPLE(S): serial number, product number, model number OTHER NAME(S): NOTE(S): There are multiple ways in which an identifier can be associated to a product; inherited from MaterialIdentifier.identifier, the association to ProcessedProduct.identifier, and the association to ProductRelationship.identifier. If there is no context associated with the identifier, then MaterialIdentifier.identifier should be used. However, if the identifier for a product would be different in different context, one of the other identifiers should be used. If a kind of product is produced by different processors, and each processor assigns the product a different identifier, then ProcessedProduct.identifier should be used. If the product is used in multiple assemblies, and in each assembly it would be assigned a different identifier, then ProductRelationship.identifier should be used. BRIDG 5.3 The unique identification of a material in a specific context. NOTE(S): This class is a resolution of the requirement for noting the type of an identifier which is not handled by the purely technical HL7 II data type. BRIDG 3.0.3 Material Identifier PT NCI Material.identifier PT BRIDG 5.3 MaterialIdentifier PT BRIDG 3.0.3 The unique identification of a material in a specific context. NCI Thesaurus:C93484 C93484 Intellectual Product Document Version C2985694 BRIDG A representation of a particular edition or snapshot of a document as it exists at a particular point in time. EXAMPLE(S): Version 3 of a case report form (CRF) for a physical exam, version 2 of an informed consent form. OTHER NAME(S): NOTE(S): A representation of a particular edition or snapshot of a document as it exists at a particular point in time. EXAMPLE(S): Version 3 of a case report form (CRF) for a physical exam, version 2 of a informed consent form. Document Version DocumentVersion A representation of a particular edition or snapshot of a document as it exists at a particular point in time. A representation of a particular edition or snapshot of a document as it exists at a particular point in time. Document Version A representation of a particular edition or snapshot of a document as it exists at a particular point in time. EXAMPLE(S): Version 3 of a case report form (CRF) for a physical exam, version 2 of an informed consent form. OTHER NAME(S): NOTE(S): BRIDG 5.3 A representation of a particular edition or snapshot of a document as it exists at a particular point in time. EXAMPLE(S): Version 3 of a case report form (CRF) for a physical exam, version 2 of a informed consent form. BRIDG 3.0.3 Document Version PT NCI DocumentVersion PT BRIDG 3.0.3 DocumentVersion PT BRIDG 5.3 A representation of a particular edition or snapshot of a document as it exists at a particular point in time. NCI Thesaurus:C93485 C93485 Intellectual Product Expanded Access Study Protocol Version C2985695 BRIDG An action plan of a pre-clinical or clinical study describing the procedure for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet eligibility criteria for enrollment, or who are otherwise unable to participate in a controlled clinical study. NOTE(S): This type of study is used to register all types of non-protocol access to experimental treatments, including protocol exception, single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track. (Parallel track means there is separate group of subjects that go through the same protocol activities but that didn't get on the main trial due to different reasons such as eligibility criteria, location, etc. and their outcome data is collected and analyzed, just not analyzed with the other data, rather in parallel.) Expanded Access Study Protocol Version ExpandedAccessStudyProtocolVersion An action plan of a pre-clinical or clinical study describing the procedure for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet eligibility criteria for enrollment, or who are otherwise unable to participate in a controlled clinical study. An action plan of a pre-clinical or clinical study describing the procedure for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet eligibility criteria for enrollment, or who are otherwise unable to participate in a controlled clinical study. Expanded Access Study Protocol Version An action plan of a pre-clinical or clinical study describing the procedure for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet eligibility criteria for enrollment, or who are otherwise unable to participate in a controlled clinical study. NOTE(S): This type of study is used to register all types of non-protocol access to experimental treatments, including protocol exception, single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track. (Parallel track means there is separate group of subjects that go through the same protocol activities but that didn't get on the main trial due to different reasons such as eligibility criteria, location, etc. and their outcome data is collected and analyzed, just not analyzed with the other data, rather in parallel.) BRIDG 3.0.3 Expanded Access Study Protocol Version PT NCI ExpandedAccessStudyProtocolVersion PT BRIDG 3.0.3 An action plan of a pre-clinical or clinical study describing the procedure for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet eligibility criteria for enrollment, or who are otherwise unable to participate in a controlled clinical study. NCI Thesaurus:C93486 C93486 Intellectual Product Interventional Study Protocol Version C2985696 BRIDG A study protocol version in which study subjects or experimental units are assigned by an investigator based on a protocol to receive specific interventions. EXAMPLE(S): Version dates for "A Randomizaed Phase 3 Trial of Treatment 1 and Treatment 2 in Patients with Stage III Colon Cancer" VERSION 1: Activation February 10, 2004 VERSION 2: Addendum 7 January 4, 2008 VERSION 3: Addendum 8 May 12, 2008 OTHER NAME(S): NOTE(S): Study subjects or experimental units may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The study subjects or experimental units are then followed and biomedical and/or health outcomes are assessed. An action plan of a pre-clinical or clinical study in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Study subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed. Interventional Study Protocol Version InterventionalStudyProtocolVersion An action plan of a pre-clinical or clinical study in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Study subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed. An action plan of a pre-clinical or clinical study in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Study subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed. Interventional Study Protocol Version A study protocol version in which study subjects or experimental units are assigned by an investigator based on a protocol to receive specific interventions. EXAMPLE(S): Version dates for "A Randomizaed Phase 3 Trial of Treatment 1 and Treatment 2 in Patients with Stage III Colon Cancer" VERSION 1: Activation February 10, 2004 VERSION 2: Addendum 7 January 4, 2008 VERSION 3: Addendum 8 May 12, 2008 OTHER NAME(S): NOTE(S): Study subjects or experimental units may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The study subjects or experimental units are then followed and biomedical and/or health outcomes are assessed. BRIDG 5.3 An action plan of a pre-clinical or clinical study in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Study subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed. BRIDG 3.0.3 Interventional Study Protocol Version PT NCI InterventionalStudyProtocolVersion PT BRIDG 3.0.3 InterventionalStudyProtocolVersion PT BRIDG 5.3 An action plan of a pre-clinical or clinical study in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Study subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed. NCI Thesaurus:C93487 C93487 Intellectual Product Observational Study Protocol Version C2985697 BRIDG A study protocol version in which biomedical and/or health outcomes are assessed in pre-defined groups of study subjects or experimental units. Study subjects or experimental units in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study subjects or experimental units of the study. EXAMPLE(S): OTHER NAME(S): NOTE(S): An action plan of a pre-clinical or clinical study in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Study subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study subjects or experimental units of the study. Observational Study Protocol Version ObservationalStudyProtocolVersion An action plan of a pre-clinical or clinical study in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Study subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study subjects or experimental units of the study. An action plan of a pre-clinical or clinical study in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Study subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study subjects or experimental units of the study. Observational Study Protocol Version A study protocol version in which biomedical and/or health outcomes are assessed in pre-defined groups of study subjects or experimental units. Study subjects or experimental units in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study subjects or experimental units of the study. EXAMPLE(S): OTHER NAME(S): NOTE(S): BRIDG 5.3 An action plan of a pre-clinical or clinical study in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Study subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study subjects or experimental units of the study. BRIDG 3.0.3 Observational Study Protocol Version PT NCI ObservationalStudyProtocolVersion PT BRIDG 3.0.3 ObservationalStudyProtocolVersion PT BRIDG 5.3 An action plan of a pre-clinical or clinical study in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Study subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study subjects or experimental units of the study. NCI Thesaurus:C93489 C93489 Intellectual Product Study Protocol Document Version C2985699 BRIDG A representation of a particular edition or snapshot of a document containing a study protocol as it exists at a particular point in time. EXAMPLE(S): Version 3 of a breast cancer protocol. NOTE(S): A version of the study protocol represents the characteristics and plan of the study which can be distilled into or abstracted from a version of the study protocol document. A StudyProtocolDocumentVersion is related to other supporting document versions involved in the study, including (but not limited to) informed consent documents, case report forms (CRFs), regulatory and approval documentation, correlative studies, etc. via the inherited association to DocumentVersionRelationship. The term "Amendment" needs to be disambiguated since it sometimes refers to the amended version of the protocol (BRIDG's StudyProtoclDocumentVersion) and other times refers to the summary of changes. A variant or snapshot of the study protocol document at a particular point in time. EXAMPLE(S): Version 3 of a breast cancer protocol document. OTHER NAME(S): Amendment NOTE(S): A study protocol document version is one component of the overall concept of a study protocol. The complete notion of the study protocol is represented in BRIDG by the classes StudyProtocol, StudyProtocolVersion, StudyProtocolDocument, StudyProtocolDocumentVersion and all their associations. - The StudyProtocol class represents the content of the study protocol which includes characteristics and plan of the study which can be distilled into or abstracted from a version of the study protocol document and can exist even before the information is put into document form. - The StudyProtocolVersion class represents the details of the study protocol that may change over time. - The StudyProtocolDocument class represents the document form of the study protocol and is a grouping of the various study protocol document versions. - The StudyProtocolDocumentVersion class represents the document form of the study protocol version and is the details of the study protocol document that may change over time. The term "Amendment" needs to be disambiguated since it sometimes refers to the amended version of the protocol (StudyProtocolDocumentVersion) and other times refers to the summary of changes (AmendmentChangeSummaryVersion). Study Protocol Document Version StudyProtocolDocumentVersion A representation of a particular edition or snapshot of a document containing a study protocol as it exists at a particular point in time. A representation of a particular edition or snapshot of a document containing a study protocol as it exists at a particular point in time. Study Protocol Document Version A representation of a particular edition or snapshot of a document containing a study protocol as it exists at a particular point in time. EXAMPLE(S): Version 3 of a breast cancer protocol. NOTE(S): A version of the study protocol represents the characteristics and plan of the study which can be distilled into or abstracted from a version of the study protocol document. A StudyProtocolDocumentVersion is related to other supporting document versions involved in the study, including (but not limited to) informed consent documents, case report forms (CRFs), regulatory and approval documentation, correlative studies, etc. via the inherited association to DocumentVersionRelationship. The term "Amendment" needs to be disambiguated since it sometimes refers to the amended version of the protocol (BRIDG's StudyProtoclDocumentVersion) and other times refers to the summary of changes. BRIDG 3.0.3 A variant or snapshot of the study protocol document at a particular point in time. EXAMPLE(S): Version 3 of a breast cancer protocol document. OTHER NAME(S): Amendment NOTE(S): A study protocol document version is one component of the overall concept of a study protocol. The complete notion of the study protocol is represented in BRIDG by the classes StudyProtocol, StudyProtocolVersion, StudyProtocolDocument, StudyProtocolDocumentVersion and all their associations. - The StudyProtocol class represents the content of the study protocol which includes characteristics and plan of the study which can be distilled into or abstracted from a version of the study protocol document and can exist even before the information is put into document form. - The StudyProtocolVersion class represents the details of the study protocol that may change over time. - The StudyProtocolDocument class represents the document form of the study protocol and is a grouping of the various study protocol document versions. - The StudyProtocolDocumentVersion class represents the document form of the study protocol version and is the details of the study protocol document that may change over time. The term "Amendment" needs to be disambiguated since it sometimes refers to the amended version of the protocol (StudyProtocolDocumentVersion) and other times refers to the summary of changes (AmendmentChangeSummaryVersion). BRIDG 5.3 Study Protocol Document Version PT NCI StudyProtocolDocumentVersion PT BRIDG 3.0.3 StudyProtocolDocumentVersion PT BRIDG 5.3 A representation of a particular edition or snapshot of a document containing a study protocol as it exists at a particular point in time. NCI Thesaurus:C93490 C93490 Intellectual Product Study Protocol Version C2985700 BRIDG CDISC A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. (BRIDG) A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. NOTE(S): The notion of a study includes (but is not limited to) the design, statistical considerations and activities to test a particular hypothesis or answer a particular question that is the basis of the study. The study may be of any type that involves subjects, including prevention, therapeutic, interventional or observational. Subjects may be biological entities (human, animal, specimen, tissue, organ, etc.) or products. The complete notion of the study is represented by the Study class and all its associations which make explicit the details identified in the StudyProtocolDocument. A variant or snapshot of the study protocol at a particular point in time. EXAMPLE(S): OTHER NAME(S): NOTE(S): A change in virtually any aspect of a study protocol can trigger the creation of a new study protocol version. The kinds of changes that can trigger creation of a new study protocol version include (but are not limited to) changes to the design, statistical considerations, activities to test a particular hypothesis or answer a particular question that is the basis of the study, characteristics, specifications, objective(s), background, pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization), supporting documents such as informed consent documents, case report forms (CRFs), regulatory and approval documentation, correlative studies, etc. The complete notion of the study protocol is represented in BRIDG by the classes StudyProtocol, StudyProtocolVersion, StudyProtocolDocument, StudyProtocolDocumentVersion and all their associations. - The StudyProtocol class represents the content of the study protocol which includes characteristics and plan of the study which can be distilled into or abstracted from a version of the study protocol document and can exist even before the information is put into document form. - The StudyProtocolVersion class represents the details of the study protocol that may change over time. - The StudyProtocolDocument class represents the document form of the study protocol and is a grouping of the various study protocol document versions. - The StudyProtocolDocumentVersion class represents the document form of the study protocol version and is the details of the study protocol document that may change over time. Study Protocol Version StudyProtocolVersion A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. Study Protocol Version A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. (BRIDG) CDISC A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. NOTE(S): The notion of a study includes (but is not limited to) the design, statistical considerations and activities to test a particular hypothesis or answer a particular question that is the basis of the study. The study may be of any type that involves subjects, including prevention, therapeutic, interventional or observational. Subjects may be biological entities (human, animal, specimen, tissue, organ, etc.) or products. The complete notion of the study is represented by the Study class and all its associations which make explicit the details identified in the StudyProtocolDocument. BRIDG 3.0.3 A variant or snapshot of the study protocol at a particular point in time. EXAMPLE(S): OTHER NAME(S): NOTE(S): A change in virtually any aspect of a study protocol can trigger the creation of a new study protocol version. The kinds of changes that can trigger creation of a new study protocol version include (but are not limited to) changes to the design, statistical considerations, activities to test a particular hypothesis or answer a particular question that is the basis of the study, characteristics, specifications, objective(s), background, pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization), supporting documents such as informed consent documents, case report forms (CRFs), regulatory and approval documentation, correlative studies, etc. The complete notion of the study protocol is represented in BRIDG by the classes StudyProtocol, StudyProtocolVersion, StudyProtocolDocument, StudyProtocolDocumentVersion and all their associations. - The StudyProtocol class represents the content of the study protocol which includes characteristics and plan of the study which can be distilled into or abstracted from a version of the study protocol document and can exist even before the information is put into document form. - The StudyProtocolVersion class represents the details of the study protocol that may change over time. - The StudyProtocolDocument class represents the document form of the study protocol and is a grouping of the various study protocol document versions. - The StudyProtocolDocumentVersion class represents the document form of the study protocol version and is the details of the study protocol document that may change over time. BRIDG 5.3 Study Protocol Version PT CDISC Study Protocol Version PT NCI StudyProtocolVersion PT BRIDG 3.0.3 StudyProtocolVersion PT BRIDG 5.3 A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. NCI Thesaurus:C93591 C93591 Temporal Concept Manufacture Date C2985794 BRIDG Manufacture Date manufactureDate The date and/or time on which a product is made. The date and/or time on which a product is made. Manufacture Date Manufacture Date PT NCI manufactureDate PT BRIDG 3.0.3 manufactureDate PT BRIDG 5.3 The date and/or time on which a product is made. NCI Thesaurus:C94088 C94088 Intellectual Product Unique Study Investigator Identifier C2986286 BRIDG A unique symbol that establishes identity of the study investigator. A unique symbol that establishes identity of the study investigator. EXAMPLE(S): OTHER NAME(S): NOTE(S): StudyInvestigator.identifier Unique Study Investigator Identifier A unique symbol that establishes identity of the study investigator. A unique symbol that establishes identity of the study investigator. Unique Study Investigator Identifier A unique symbol that establishes identity of the study investigator. BRIDG 3.0.3 A unique symbol that establishes identity of the study investigator. EXAMPLE(S): OTHER NAME(S): NOTE(S): BRIDG 5.3 StudyInvestigator.identifier PT BRIDG 3.0.3 StudyInvestigator.identifier PT BRIDG 5.3 Unique Study Investigator Identifier PT NCI A unique symbol that establishes identity of the study investigator. NCI Thesaurus:C94237 C94237 Indicator, Reagent, or Diagnostic Aid Carrier Oil C2986420 An oil with little or no scent that is used to dilute or "carry" essential oils (scented liquid taken from plants). Carrier Oil carrier oil Carrier Oil An oil with little or no scent that is used to dilute or "carry" essential oils (scented liquid taken from plants). NCI-GLOSS Carrier Oil PT NCI carrier oil PT NCI-GLOSS CDR0000462669 Thesaurus:C96370 C96370 Conceptual Entity Standard for the Exchange of Nonclinical Data Controlled Terminology Version C3272741 CDISC The version of the Standard for the Exchange of Nonclinical Data Controlled Terminology that is being used in the study. SEND Controlled Terminology Version SNDCTVER Standard for the Exchange of Nonclinical Data Controlled Terminology Version The version number of the Standard for the Exchange of Nonclinical Data (SEND) controlled terminology that is being used in the study. The version number of the Standard for the Exchange of Nonclinical Data (SEND) controlled terminology that is being used in the study. Standard for the Exchange of Nonclinical Data Controlled Terminology Version The version of the Standard for the Exchange of Nonclinical Data Controlled Terminology that is being used in the study. CDISC SEND Controlled Terminology Version PT CDISC SEND-STSPRM SEND Controlled Terminology Version SY CDISC SNDCTVER PT CDISC SEND-STSPRMCD Standard for the Exchange of Nonclinical Data Controlled Terminology Version PT NCI The version number of the Standard for the Exchange of Nonclinical Data (SEND) controlled terminology that is being used in the study. NCI Thesaurus:C96371 C96371 Intellectual Product Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.0 C3272742 CDISC The 3.0 version of the standard for exchange of nonclinical data (SEND) implementation guide. (NCI) SEND IG Version 3.0 SEND IMPLEMENTATION GUIDE VERSION 3.0 Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.0 The 3.0 version of the standard for exchange of nonclinical data (SEND) implementation guide. The 3.0 version of the standard for exchange of nonclinical data (SEND) implementation guide. Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.0 The 3.0 version of the standard for exchange of nonclinical data (SEND) implementation guide. (NCI) CDISC SEND IG Version 3.0 SY CDISC SEND IMPLEMENTATION GUIDE VERSION 3.0 PT CDISC Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.0 PT NCI The 3.0 version of the standard for exchange of nonclinical data (SEND) implementation guide. NCI npo:NPO_100 NPO_100 NCIT:C63806 cylindrical shape cylindrical cylindrical shape npo:NPO_1018 This term had the preferred name "nanostructure" in version 2010-10-31. NPO_1018 nano-object nano-object npo:NPO_102 NPO_102 prolate spheroidal shape prolate spheroidal shape npo:NPO_104 NPO_104 methotrexate-loaded nanoparticle methotrexate-loaded nanoparticle npo:NPO_109 NPO_109 lipid-coated nanoparticle lipid-coated nanoparticle npo:NPO_112 NPO_112 multi-walled nanotube multi-walled nanotube npo:NPO_115 NPO_115 nanodevice nanodevice npo:NPO_1155 NPO_1155 polydispersity index PDI polydispersity index npo:NPO_1193 NPO_1193 cell concentration cell concentration npo:NPO_1204 NPO_1204 isoelectric point isoelectric point npo:NPO_122 NPO_122 NCIT: C62373 nanorod [NCI_Thesaurus definition]: Nanoscale structures that are shaped like long dowels. The structures have a diameter that is measured in the nanoscale with an extended length parameter. nanorod npo:NPO_1235 NPO_1235 surface area surface area npo:NPO_126 NPO_126 NCIT: C73455 nanotube nanotube npo:NPO_1302 NPO_1302 NCIT:C62354 zeta potential zeta potential npo:NPO_1315 NPO_1315 electrophoretic mobility electrophoretic mobility npo:NPO_1338 NPO_1338 NCIT:C27990 toxicity toxicity npo:NPO_1339 NPO_1339 NCIT:C63814 immunotoxicity immunotoxicity npo:NPO_1340 NPO_1340 NCIT:C27988 cytotoxicity cytotoxicity npo:NPO_1341 NPO_1341 NCIT:C27955 drug toxicity drug toxicity npo:NPO_1351 NPO_1351 PATO:0001521 amplitude of sound wave amplitude of sound sound amplitude amplitude of sound wave npo:NPO_1364 NPO_1364 surface property surface property npo:NPO_1365 NPO_1365 aspect ratio aspect ratio npo:NPO_1367 NPO_1367 coat coating surface coating coat npo:NPO_1370 NPO_1370 magnetic nanoparticle magnetic nanoparticle npo:NPO_1373 NPO_1373 silica nanoparticle silicon dioxide nanoparticle silica nanoparticle npo:NPO_1374 NPO_1374 superparamagnetic iron oxide nanoparticle SPIO nanoparticle superparamagnetic iron oxide nanoparticle npo:NPO_1375 NPO_1375 polymeric nanoparticle polymer nanoparticle polymeric nanoparticle npo:NPO_1377 NPO_1377 fluorescent nanoparticle fluorescent nanoparticle npo:NPO_1378 NPO_1378 hydrogel nanoparticle hydrogel nanoparticle npo:NPO_138 NPO_138 encapsulation encapsulation npo:NPO_1384 NPO_1384 metal nanoparticle metallic nanoparticle metal nanoparticle npo:NPO_1404 NPO_1404 nanoparticle sample nanoparticle sample npo:NPO_1405 [DGT, June 10, 2010]: Description for a specific type of technique could contain the following types of information: 1) principle used in the technique (e.g. NMR for NMR spectroscopy), 2) description of the principle if the term that describes the principle is not represented in the ontology, 3) tool used in a technique (e.g., scanning electron microscope in scanning electron miroscopy), 4) applications of the technique, and 5) information on how to use the technique for each type of application. NPO_1405 technique technique npo:NPO_1407 NPO_1407 experiment experiment npo:NPO_1414 NPO_1414 emulsifier emulsifying agent emulsifier npo:NPO_1415 NPO_1415 microscopy microscopy technique microscopy npo:NPO_1416 NPO_1416 separation technique separation method separation technique npo:NPO_1417 NPO_1417 centrifugation centrifugation npo:NPO_1418 NPO_1418 electrophoresis electrophoresis npo:NPO_1419 NPO_1419 NCIT:C18091 gel electrophoresis gel electrophoresis npo:NPO_1420 NPO_1420 NCIT:C16537 agarose gel electrophoresis agarose gel electrophoresis npo:NPO_1421 NPO_1421 NCIT:C16539 polyacrylamide gel electrophoresis polyacrylamide gel electrophoresis npo:NPO_1427 NPO_1427 SDS polyacrylamide gel electrophoresis SDS-PAGE sodium dodecyl sulfate - polyacrylamide gel electrophoresis SDS polyacrylamide gel electrophoresis npo:NPO_1428 NPO_1428 electron microscopy electron microscopy npo:NPO_1429 NPO_1429 scanning electron microscopy SEM technique scanning electron microscopy npo:NPO_1430 NPO_1430 transmission electron microscopy TEM technique A light source at the top of the TEM emits the electrons that travel through vacuum in the column of the microscope. Instead of glass lenses focusing the light in the light microscope, the TEM uses electromagnetic lenses to focus the electrons into a very thin beam. The electron beam then travels through the specimen you want to study. Depending on the density of the material present, some of the electrons are scattered and disappear from the beam. At the bottom of the microscope the unscattered electrons hit a fluorescent screen, which gives rise to a shadow image of the specimen with its different parts displayed in varied darkness according to their density. The image can be studied directly by the operator or photographed with a camera. [source: http://Nobelprize.org] transmission electron microscopy npo:NPO_1431 NPO_1431 optical microscopy light microscopy optical microscopy npo:NPO_1432 NPO_1432 fluorescence microscopy fluorescence microscopy npo:NPO_1433 NPO_1433 NCIT:C20346 scanning probe microscopy scanning probe microscopy npo:NPO_1434 NPO_1434 atomic force microscopy scanning force microscopy atomic force microscopy npo:NPO_1435 NPO_1435 scanning tunneling microscopy scanning tunneling microscopy npo:NPO_1436 NPO_1436 instrument equipment instrument npo:NPO_1437 NPO_1437 NCIT:C20677 microscope microscope npo:NPO_1438 NPO_1438 NCIT:C28219 electron microscope Electron Microscopes(EMs) function exactly as their optical counterparts except that they use a focused beam of electrons instead of light to "image" the specimen and gain information as to its structure and composition. The basic steps involved in all EMs: 1. A stream of electrons is formed (by the Electron Source) and accelerated toward the specimen using a positive electrical potential 2. This stream is confined and focused using metal apertures and magnetic lenses into a thin, focused, monochromatic beam. 3. This beam is focused onto the sample using a magnetic lens 4. Interactions occur inside the irradiated sample, affecting the electron beam These interactions and effects are detected and transformed into an image The above steps are carried out in all EMs regardless of type. [source: http://unl.edu/CMRAcfem/em.htm] electron microscope npo:NPO_1439 NPO_1439 NCIT:C28265 optical microscope light microscope optical microscope npo:NPO_1440 NPO_1440 NCIT:C78814 scanning electron microscope SEM scanning electron microscope npo:NPO_1441 NPO_1441 NCIT: C78813 transmission electron microscope TEM TEMs use electrons as light source and their much lower wavelength makes it possible to get a resolution a thousand times better than with a light microscope.[source: http://Nobelprize.org] transmission electron microscope npo:NPO_1442 NPO_1442 NCIT:C78803 scanning probe microsope SPM scanning probe microsope npo:NPO_1443 NPO_1443 fluorescence microscope [definition: adapted from http://nobelprize.org; http://en.wikipedia.org/wiki/Fluorescence_microscope ] fluorescence microscope npo:NPO_1445 NPO_1445 NCIT:C78804 atomic force microscope AFM SFM scanning force microscope [definition: adapted from NCIT, http://www.thefreedictionary.com, http://en.wikipedia.org] atomic force microscope npo:NPO_1446 NPO_1446 NCIT:C17374 scanning tunneling microscope STM [definition: adapted from http://www.thefreedictionary.com] scanning tunneling microscope npo:NPO_1447 NPO_1447 magnetic force microscope MFM [definition: adapted from http://encyclopedia.thefreedictionary.com] magnetic force microscope npo:NPO_145 NPO_145 doxorubicin-loaded nanoparticle adriamycin-loaded nanoparticle doxorubicin-loaded nanoparticle npo:NPO_1451 NPO_1451 high resolution transmission electron microscopy high resolution transmission electron microscopy npo:NPO_1452 NPO_1452 high resolution transmission electron microscope HRTEM [definition source]: http://en.wikipedia.org high resolution transmission electron microscope npo:NPO_1453 NPO_1453 scanning transmission electron microscope STEM scanning transmission electron microscope npo:NPO_1454 NPO_1454 scanning transmission electron microscopy scanning transmission electron microscopy npo:NPO_1455 NPO_1455 differential interference contrast microscope DIC microscope DIC microscope is based on interferometry, which is the technique of superposing (interfering) two or more waves, to detect differences between them. In interferometry, a single ray of light is split into two rays, one traversing and the other missing the specimen but interacting with the background. The rays are then recombined at the image plane, where wave interference may occur. Image contrast can be modified by altering the phase difference between the reference and specimen rays. [source: http://encyclopedia.thefreedictionary.com] differential interference contrast microscope npo:NPO_1456 NPO_1456 differential interference contrast microscopy differential interference contrast microscopy npo:NPO_1465 NPO_1465 NCIT:C16585 flow cytometry [definition: adapted from NCIT, http://encyclopedia.thefreedictionary.com] flow cytometry npo:NPO_1467 NPO_1467 phase analysis light scattering PALS [definition: adapted from http://www.unisa.edu.au/laser/Research/PALS.asp] phase analysis light scattering npo:NPO_1468 NPO_1468 NCIT: C17155 spectroscopy spectroscopic technique spectroscopy npo:NPO_1469 NPO_1469 NCIT:C62329 dynamic light scattering DLS PCS QELS Quasi-Elastic Light Scattering photon correlation spectroscopy [definition source: NCI] dynamic light scattering npo:NPO_1470 NPO_1470 NCIT:C16810 nuclear magnetic resonance spectroscopy NMR spectroscopy magnetic resonance spectroscopy Depending on the local chemical environment, different protons in a molecule resonate at slightly different frequencies. Since this frequency shift is proportional to the strength of the magnetic field, it is converted into a field-independent dimensionless value known as the chemical shift. The chemical shift is reported as a relative measure from some reference resonance frequency. (For the nuclei1H, 13C, and 29Si, TMS (tetramethylsilane) is commonly used as a reference.) This difference between the frequency of the signal and the frequency of the reference is divided by frequency of the reference signal to give the chemical shift. The frequency shifts are extremely small in comparison to the fundamental NMR frequency. A typical frequency shift might be 100 Hz, compared to a fundamental NMR frequency of 100 MHz, so the chemical shift is generally expressed in parts per million (ppm). By understanding different chemical environments, the chemical shift can be used to obtain some structural information about the molecule in a sample. The conversion of the raw data to this information is called assigning the spectrum. [source: http://encyclopedia.thefreedictionary.com] When placed in a magnetic field, NMR active nuclei (such as 1H or 13C) absorb at a frequency characteristic of the isotope. The resonant frequency, energy of the absorption and the intensity of the signal are proportional to the strength of the magnetic field. nuclear magnetic resonance spectroscopy npo:NPO_1476 NPO_1476 NCIT:C17738 fluorescence spectroscopy fluorometry spectrofluorometry fluorescence spectroscopy npo:NPO_1477 NPO_1477 NCIT:C17369 imaging technique imaging method imaging technique npo:NPO_1479 NPO_1479 tomography tomography npo:NPO_1480 NPO_1480 NCIT:C17204 computed tomography CT computed tomography npo:NPO_1481 NPO_1481 NCIT:C17203 single photon emission computed tomography SPECT single photon emission computed tomography npo:NPO_1482 NPO_1482 NCIT:C17007 positron emission tomography PET [definition source: NCI] positron emission tomography npo:NPO_1483 NPO_1483 MeSH:D008279 NCIT:C16809 magnetic resonance imaging MRI [definition: adapted from MeSH] magnetic resonance imaging npo:NPO_1484 NPO_1484 NCIT:C17230 ultrasound imaging ultrasound imaging npo:NPO_1486 NPO_1486 titanium oxide nanoparticle TiO2 nanoparticle titanium oxide nanoparticle npo:NPO_1487 NPO_1487 sample sample npo:NPO_1491 NPO_1491 molecular component in nanoparticle formulation molecular component in nanoparticle formulation npo:NPO_1493 NPO_1493 functionalizing agent functionalizing agent npo:NPO_1494 NPO_1494 chemical component in nanoparticle formulation chemical component in nanoparticle formulation npo:NPO_1495 NPO_1495 molecular component in nanoparticle molecular component in nanoparticle npo:NPO_1496 NPO_1496 nanoparticle component nanoparticle component npo:NPO_1497 NPO_1497 chemical component chemical component npo:NPO_1499 NPO_1499 repeat unit repeat unit npo:NPO_1501 NPO_1501 fluid state fluid state npo:NPO_1502 NPO_1502 gaseous state gaseous state npo:NPO_1503 NPO_1503 vapor state vapor state npo:NPO_1504 NPO_1504 liquid state liquid state npo:NPO_1505 NPO_1505 state of mixture state of mixture npo:NPO_1506 NPO_1506 state of suspension state of suspension npo:NPO_1507 NPO_1507 colloidal state colloidal state npo:NPO_1508 NPO_1508 state of emulsion state of emulsion npo:NPO_1509 NPO_1509 gel state gel state npo:NPO_1510 NPO_1510 state of sol state of sol npo:NPO_1511 NPO_1511 solid state solid state npo:NPO_1512 NPO_1512 crystalline state crystalline state npo:NPO_1513 NPO_1513 glassy state glassy state npo:NPO_1514 NPO_1514 granular state granular state npo:NPO_1515 NPO_1515 powdered state powdered state npo:NPO_1523 NPO_1523 area under the plasma concentration time curve AUC area under curve area under the plasma concentration time curve npo:NPO_1524 NPO_1524 volume of distribution Vd volume of distribution npo:NPO_1525 NPO_1525 drug clearance CI clearance drug clearance npo:NPO_1526 NPO_1526 elimination rate constant kel elimination rate constant npo:NPO_1527 NPO_1527 NCIT:C70918 Cmax maximum concentration peak concentration Cmax npo:NPO_1528 NPO_1528 NCIT:C70919 Tmax time to maximum concentration time to peak concentation Tmax npo:NPO_1529 NPO_1529 bioavailability biopersistence persistence bioavailability npo:NPO_1530 NPO_1530 pharmacokinetic parameter pharmacokinetic parameter npo:NPO_1533 NPO_1533 therapeutic payload agent therapeutic payload agent npo:NPO_1534 NPO_1534 imaging payload agent imaging payload agent npo:NPO_1537 NPO_1537 superparamagnetic nanoparticle superparamagnetic nanoparticle npo:NPO_1538 NPO_1538 pH-sensitive polymeric nanoparticle pH-sensitive polymeric nanoparticle npo:NPO_1539 NPO_1539 particle diameter particle diameter npo:NPO_1541 NPO_1541 metal oxide nanoparticle metal oxide nanoparticle npo:NPO_1542 NPO_1542 zinc oxide nanoparticle ZnO nanoparticle zinc oxide nanoparticle npo:NPO_1544 NPO_1544 copper oxide nanoparticle copper oxide nanoparticle npo:NPO_1548 NPO_1548 iron (II,III) oxide nanoparticle Fe3O4 nanoparticle iron (II,III) oxide nanoparticle npo:NPO_1549 NPO_1549 dextran-coated iron oxide nanoparticle iron oxide nanoparticle coated with dextran dextran-coated iron oxide nanoparticle npo:NPO_1550 NPO_1550 iron (III) oxide nanoparticle Fe2O3 nanoparticle iron (III) oxide nanoparticle npo:NPO_1551 NPO_1551 spherical nanoparticle spherical nanoparticle npo:NPO_1552 NPO_1552 lipid nanoparticle lipid nanoparticle npo:NPO_1553 NPO_1553 fluorescent silica nanoparticle fluorescent silica nanoparticle npo:NPO_1555 NPO_1555 gelatin nanoparticle gelatin nanoparticle npo:NPO_1559 NPO_1559 PLGA nanoparticle poly(lactic-co-glycolic acid) nanoparticle PLGA nanoparticle npo:NPO_156 NPO_156 ellipsoidal shape ellipsoidal ellipsoidal shape npo:NPO_1562 NPO_1562 fluorescent core-shell silica nanoparticle fluorescent core-shell silica nanoparticle npo:NPO_1568 NPO_1568 hydroxyapatite nanoparticle hydroxyapatite nanoparticle npo:NPO_1569 NPO_1569 gadolinium-loaded nanoparticle gadolinium-loaded nanoparticle npo:NPO_157 NPO_157 single-walled nanotube single-walled nanotube npo:NPO_1571 NPO_1571 chitosan-coated magnetic nanoparticle chitosan-coated magnetic nanoparticle npo:NPO_1572 NPO_1572 core-shell silica nanoparticle core-shell silica nanoparticle npo:NPO_159 NPO_159 thioether linkage between thiol and maleimide derivative thioether linkage between thiol and maleimide derivative npo:NPO_1591 NPO_1591 long circulating nanoparticle long circulating nanoparticle npo:NPO_1597 NPO_1597 fiat material part fiat material part npo:NPO_1598 NPO_1598 fluorescence imaging fluorescence imaging npo:NPO_1599 NPO_1599 optical imaging optical imaging npo:NPO_160 NPO_160 cadmium selenide quantum dot CdSe quantum dot cadmium selenide quantum dot npo:NPO_1610 NPO_1610 phase phase npo:NPO_1611 NPO_1611 solid phase solid phase npo:NPO_1612 NPO_1612 liquid phase liquid phase npo:NPO_1613 NPO_1613 gas phase gas phase npo:NPO_1614 NPO_1614 dispersed phase dispersed phase npo:NPO_1615 NPO_1615 continuous phase continuous phase npo:NPO_1616 NPO_1616 functionalization of nanoparticle functionalization of nanoparticle npo:NPO_1617 NPO_1617 core core npo:NPO_1628 NPO_1628 NCIT:C40492 DNA intercalation DNA intercalation npo:NPO_1642 NPO_1642 surface modification of nanoparticle surface modification of nanoparticle npo:NPO_1680 NPO_1680 parameter parameter npo:NPO_1681 NPO_1681 wave parameter wave parameter npo:NPO_1682 NPO_1682 wave amplitude wave amplitude npo:NPO_1683 NPO_1683 wave frequency wave frequency npo:NPO_1684 NPO_1684 wave speed wave speed npo:NPO_1692 NPO_1692 independent specific individual quality independent specific individual quality npo:NPO_1694 NPO_1694 particle size size of particle particle size npo:NPO_1697 NPO_1697 size distribution size distribution npo:NPO_1698 NPO_1698 molecular weight distribution molecular weight distribution npo:NPO_1699 NPO_1699 particle size distribution particle size distribution npo:NPO_1709 NPO_1709 LDH release assay LDH assay lactate dehydrogenase assay LDH release assay npo:NPO_1710 Absorption spectroscopy is used to determine the presence of or amount of a particular substance in a sample from its absorption spectrum. When the sample interacts with the radiating field, the sample absorbs energy, i.e. photons, and the intensity of absorption (radiation absorbed by the sample) varies as a function of frequency, and this variation is the absorption spectrum. (references: wikipedia, May 27, 2010) NPO_1710 absorption spectroscopy absorption spectroscopy npo:NPO_1711 Emission spectroscopy is used to determine the elemental composition of a material from its emission spectrum obtained by measuring the intensity of electromagnetic radiation emitted by the atoms or molecules in the material at different wavelengths. Atoms or molecules in a material undergo transition from an excited state to a lower energy state, and during this transition, and they emit photons. Each element emits (radiates) photons at a characteristic set of discrete wavelengths according to its electronic structure. Hence, by examining these wavelengths in the emission spectrum of the material, the elemental composition of the material can be determined. They are different ways to excite the atoms. (based on source: wikipedia, May 27, 2010) NPO_1711 emission spectroscopy emission spectroscopy npo:NPO_1712 NPO_1712 light scattering spectroscopy light scattering spectroscopy npo:NPO_175 NPO_175 arylthioether linkage between thiol and fluorobenzene derivative arylthioether linkage between thiol and fluorobenzene derivative npo:NPO_1762 NPO_1762 cell counting technique cell counting technique npo:NPO_1763 NPO_1763 fluorescent cell counting technique fluorescent cell counting technique npo:NPO_1764 NPO_1764 confocal laser scanning microscopy CLSM confocal laser scanning microscopy npo:NPO_1765 NPO_1765 NCIT: C78807 hemocytometer hemocytometer npo:NPO_1766 NPO_1766 dynamic light scattering instrument DLS instrument dynamic light scattering instrument npo:NPO_1767 NPO_1767 phase analysis light scattering instrument PALS instrument phase analysis light scattering instrument npo:NPO_1768 NPO_1768 NCIT: C78860 environmental transmission electron microscope EC-TEM ETEM environmental cell-transmission electron microscope environmental transmission electron microscope npo:NPO_1769 NPO_1769 NCIT: C78806 flow cytometer flow cytometer npo:NPO_1770 NPO_1770 NCIT: C80370 analytical balance analytical balance npo:NPO_1771 NPO_1771 NCIT: C62330 coulter counter particle count analyzer particle count and size analyzer particle counter particle size analyzer coulter counter npo:NPO_1772 NPO_1772 NCIT:C80371 photometer photometer npo:NPO_1773 NPO_1773 NCIT: C62333 spectrophotometer spectrometer spectrophotometer npo:NPO_1774 NPO_1774 X-ray photoelectron spectrometer X-ray photoelectron spectrometer npo:NPO_1775 NPO_1775 zeta potential analyzer zeta potential analyzer npo:NPO_1776 NPO_1776 capillary electrophoresis instrument capillary electrophoresis instrument npo:NPO_1777 NPO_1777 NCIT: C78805 energy dispersive spectrometer EDS EDX energy dispersive X-ray spectrometer energy dispersive spectrometer npo:NPO_1778 NPO_1778 gel filtration column gel filtration column npo:NPO_1779 NPO_1779 datum value datum value npo:NPO_1780 NPO_1780 number number npo:NPO_1793 NPO_1793 quantitative value quantitative value npo:NPO_1794 NPO_1794 qualitative value qualitative value npo:NPO_1795 NPO_1795 computed value calculated value computed value npo:NPO_1796 NPO_1796 counted value counted value npo:NPO_1797 NPO_1797 statistical measure statistical measure npo:NPO_1798 NPO_1798 measure of variability measure of variability npo:NPO_1799 NPO_1799 measure of central tendency measure of central tendency npo:NPO_180 NPO_180 fiat dendrimer part fiat dendrimer part npo:NPO_1800 NPO_1800 mean average average value mean value mean npo:NPO_1801 NPO_1801 median median npo:NPO_1802 NPO_1802 mode mode npo:NPO_1803 NPO_1803 variance variance npo:NPO_1804 NPO_1804 standard deviation standard deviation npo:NPO_1805 NPO_1805 measured value measured value npo:NPO_1806 NPO_1806 temperature value temperature value npo:NPO_1807 NPO_1807 size value size value npo:NPO_1811 NPO_1811 surface composition surface composition npo:NPO_1812 NPO_1812 surface charge surface charge npo:NPO_1813 NPO_1813 body weight value body weight value npo:NPO_1814 NPO_1814 pH value pH value npo:NPO_1815 NPO_1815 zeta potential value zeta potential value npo:NPO_1816 NPO_1816 percent cell viability percent cell viability npo:NPO_1817 NPO_1817 time value time value npo:NPO_1822 NPO_1822 mean particle size average particle size mean particle size npo:NPO_1825 NPO_1825 test sample experimental sample test sample npo:NPO_1826 NPO_1826 conjugated component conjugated component npo:NPO_1827 NPO_1827 encapsulated component encapsulated component npo:NPO_1828 NPO_1828 entrapped component entrapped component npo:NPO_1829 NPO_1829 mean polydispersity index mean polydispersity index npo:NPO_183 NPO_183 fiber-optic nanosensor fiber-optic nanosensor npo:NPO_1830 NPO_1830 particle concentration particle concentration npo:NPO_1849 NPO_1849 polydispersity index value PDI value polydispersity index value npo:NPO_1851 NPO_1851 refractive index value refractive index value npo:NPO_1853 NPO_1853 medium medium npo:NPO_1854 NPO_1854 aqueous medum aqueous medum npo:NPO_1855 NPO_1855 solvent medium solvent medium npo:NPO_1856 NPO_1856 suspending medium dispersing medium suspending medium npo:NPO_1857 NPO_1857 viscosity value viscosity value npo:NPO_186 NPO_186 gold quantum dot Au quantum dot gold quantum dot npo:NPO_1860 NPO_1860 organic core organic core npo:NPO_1861 NPO_1861 inorganic core inorganic core npo:NPO_1862 NPO_1862 polymeric core polymer core polymeric core npo:NPO_1863 NPO_1863 metallic core metal core metallic core npo:NPO_1864 NPO_1864 metal oxide core metal oxide core npo:NPO_1865 NPO_1865 silica core silica core npo:NPO_1866 NPO_1866 semiconducting core semiconducting core npo:NPO_1868 NPO_1868 inorganic shell inorganic shell npo:NPO_1869 NPO_1869 organic shell organic shell npo:NPO_1870 NPO_1870 polymeric shell polymeric shell npo:NPO_1871 NPO_1871 metallic shell metallic shell npo:NPO_1872 NPO_1872 metal oxide shell metal oxide shell npo:NPO_1873 NPO_1873 silica shell silica shell npo:NPO_1874 NPO_1874 semiconductive shell semiconducting shell semiconductive shell npo:NPO_1875 NPO_1875 superparamagnetic core superparamagnetic core npo:NPO_1876 NPO_1876 superparamagnetic iron oxide core superparamagnetic iron oxide core npo:NPO_1881 NPO_1881 surface-functionalized nanoparticle surface-functionalized nanoparticle npo:NPO_1883 NPO_1883 surface functionalization of nanoparticle functionalization of nanoparticle surface surface functionalization of nanoparticle npo:NPO_1884 NPO_1884 surface functionalizing agent surface functionalizing agent npo:NPO_1885 NPO_1885 surface modified nanoparticle surface modified nanoparticle npo:NPO_1886 NPO_1886 water-soluble nanoparticle water soluble nanoparticle water-soluble nanoparticle npo:NPO_1887 NPO_1887 hydrophilic coat water-soluble coat hydrophilic coat npo:NPO_1888 NPO_1888 core component core component npo:NPO_1889 NPO_1889 shell component shell component npo:NPO_1890 NPO_1890 coat component coat component npo:NPO_1892 NPO_1892 silver nanoparticle Ag nanoparticle silver nanoparticle npo:NPO_1893 NPO_1893 bimetallic nanoparticle bimetallic nanoparticle npo:NPO_1895 NPO_1895 particle particle npo:NPO_1896 NPO_1896 primary particle primary particle npo:NPO_1897 NPO_1897 secondary particle secondary particle npo:NPO_1909 NPO_1909 engineered nanomaterial engineered nanomaterial npo:NPO_191 NPO_191 biodegradable e.g., biodegradable nanoparticle biodegradable npo:NPO_1910 NPO_1910 nanostructured material nanostructured material npo:NPO_1911 NPO_1911 MTT assay MTT cytoxicity assay MTT assay npo:NPO_1914 NPO_1914 hydrodynamic size hydrodynamic size npo:NPO_1915 NPO_1915 hydrodynamic diameter hydrodynamic diameter npo:NPO_1916 NPO_1916 z-average z-average npo:NPO_1921 NPO_1921 material synthesis technique method of synthesis synthesis method synthesis technique material synthesis technique npo:NPO_1922 NPO_1922 solution-based chemistry technique solution based chemistry method solution-based chemistry solution-based chemistry technique npo:NPO_1923 NPO_1923 hydrothermal method hydrothermal technique hydrothermal method npo:NPO_1924 NPO_1924 micro-emulsion method micro-emulsion technique micro-emulsion method npo:NPO_1925 NPO_1925 sol-gel chemical process sol-gel chemical process npo:NPO_1926 NPO_1926 solvent displacement method solvent displacement method npo:NPO_1927 NPO_1927 sonochemical method sonochemical method npo:NPO_1928 NPO_1928 template-assisted solution-based synthesis template-assisted solution-based synthesis npo:NPO_1929 NPO_1929 thin film deposition technique thin film deposition technique npo:NPO_193 NPO_193 zinc sulfide quantum dot ZnS quantum dot zinc sulfide quantum dot npo:NPO_1930 NPO_1930 chemical vapor deposition CVD CVD technique chemical vapor deposition technique chemical vapor deposition npo:NPO_1931 NPO_1931 atomic layer deposition atomic layer deposition technique atomic layer deposition npo:NPO_1932 NPO_1932 metal-organic chemical vapor deposition MOCVD MOVPE OMVPE metalorganic vapor phase epitaxy organometallic vapor phase epitaxy metal-organic chemical vapor deposition npo:NPO_1933 NPO_1933 plasma-enhanced chemical vapor deposition PECVD plasma-enhanced chemical vapor deposition npo:NPO_1934 NPO_1934 thermal chemical vapor deposition TCVD rapid thermal CVD rapid thermal chemical vapor deposition thermal CVD thermal chemical vapor deposition npo:NPO_1935 NPO_1935 physical vapor deposition PVD physical vapor deposition technique physical vapor deposition npo:NPO_1936 NPO_1936 pulsed laser deposition pulsed laser deposition technique pulsed laser deposition npo:NPO_1937 NPO_1937 sputter deposition sputter deposition technique sputter deposition npo:NPO_1938 NPO_1938 magnetron sputtering magnetron sputtering npo:NPO_1939 NPO_1939 thermal evaporation thermal evaporation method thermal evaporation technique thermal evaporation npo:NPO_1940 NPO_1940 electron beam physical vapor deposition EBPVD electron beam physical vapor deposition npo:NPO_1941 NPO_1941 molecular beam epitaxy molecular beam epitaxy npo:NPO_1942 NPO_1942 resistive heating resistive heating npo:NPO_1943 NPO_1943 RF-induction technique RF-induction technique npo:NPO_1944 NPO_1944 synthesis part synthesis part npo:NPO_1945 NPO_1945 macroscopic synthesis part macroscopic synthesis part npo:NPO_1946 NPO_1946 precipitation precipitation npo:NPO_1947 NPO_1947 co-precipitation co-precipitation npo:NPO_1948 NPO_1948 purification purification npo:NPO_1949 NPO_1949 quenching quenching npo:NPO_195 NPO_195 linkage association chemical association linkage npo:NPO_1950 NPO_1950 rinsing rinsing npo:NPO_1951 NPO_1951 shaking shaking npo:NPO_1952 NPO_1952 vortex shaking vortex shaking npo:NPO_1954 NPO_1954 cooling cooling npo:NPO_1955 NPO_1955 dissolution dissolution npo:NPO_1956 NPO_1956 drying drying npo:NPO_1957 NPO_1957 freeze-drying freeze-drying npo:NPO_1958 NPO_1958 heating heating npo:NPO_1959 NPO_1959 homogenization homogenization npo:NPO_1960 NPO_1960 mixing mixing npo:NPO_1961 NPO_1961 sonication sonication npo:NPO_1962 NPO_1962 surface coating surface coating npo:NPO_1963 NPO_1963 washing washing npo:NPO_1964 NPO_1964 microscopic synthesis part microscopic synthesis part npo:NPO_1965 NPO_1965 PEGylation PEGylation npo:NPO_1966 NPO_1966 agglomeration agglomeration npo:NPO_1967 NPO_1967 aggregation aggregation npo:NPO_1968 NPO_1968 crosslinking crosslinking npo:NPO_1969 NPO_1969 dispersion dispersion npo:NPO_197 NPO_197 gold nanocage Gold nanocages, some 40 nanometers in diameter can be made by replacing the silver atoms of silver nanotubes. gold nanocage npo:NPO_1970 NPO_1970 self-assembly self-assembly npo:NPO_199 [Previous definition]: A material entity which is synthesized, characterized, and which has at least one spatial size dimension distinguishable in the nanoscale (1-100 nm) range. NPO_199 nanomaterial nanomaterial npo:NPO_1997 NPO_1997 coagulometer coagulometer npo:NPO_1999 NPO_1999 centrifuge centrifuge npo:NPO_2000 NPO_2000 incubation incubation npo:NPO_211 NPO_211 attachment chemical conjugation attachment npo:NPO_212 NPO_212 sulfonamide linkage sulfonamide linkage npo:NPO_218 NPO_218 polymer-coated nanoparticle polymer-coated nanoparticle npo:NPO_224 NPO_224 dendrimer generation layer dendrimer generation layer npo:NPO_226 NPO_226 two-dimensional nano-object 2-D nano-object two-dimensional nano-object npo:NPO_231 NPO_231 isothiourea linkage isothiourea linkage npo:NPO_236 NPO_236 carbamate ester linkage between primary amine and carbonate ester carbamate ester linkage between primary amine and carbonate ester npo:NPO_238 NPO_238 amidine linkage amidine linkage npo:NPO_239 NPO_239 NCIT: C62367 nanobomb An explosive device comprised of carbon nanotubes. These nanoscale devices have desirable optical and thermal properties that can be exploited for novel cancer therapeutics. The ability to manipulate these properties facilitates a controlled, localized activation and clearance mechanism of diseased or abnormal cells. nanobomb npo:NPO_240 NPO_240 isourea linkage isourea linkage npo:NPO_241 NPO_241 oblate spheroidal shape oblate spheroidal shape npo:NPO_247 NPO_247 imide linkage imide linkage npo:NPO_261 NPO_261 chitosan nanoparticle chitosan nanoparticle npo:NPO_270 NPO_270 nanoshell nanoshell npo:NPO_272 NPO_272 three-dimensional nano-object 3-D nano-object three-dimensional nano-object npo:NPO_274 NPO_274 shape The spatial arrangement of something as distinct from its substance. [source: NCI, WordNet] shape npo:NPO_278 NPO_278 secondary amine linkage secondary amine linkage npo:NPO_279 NPO_279 dendrimer core dendrimer core npo:NPO_284 NPO_284 two-dimensional nanoparticle 2-D nanoparticle two-dimensional nanoparticle npo:NPO_286 NPO_286 spherical shape spherical spherical shape npo:NPO_291 NPO_291 hydrazone linkage between carbohydrazide and aldehyde hydrazone linkage between carbohydrazide and aldehyde npo:NPO_295 NPO_295 sulfonamide linkage between primary amine and sulfonyl chloride derivative sulfonamide linkage between primary amine and sulfonyl chloride derivative npo:NPO_301 NPO_301 double-walled carbon nanotube double-walled carbon nanotube npo:NPO_307 NPO_307 disc-shaped disclike disk-shaped disklike disc-shaped npo:NPO_311 NPO_311 amide linkage between primary amine and acid anhydride amide linkage between primary amine and acid anhydride npo:NPO_320 NPO_320 spheroidal shape spheroidal shape npo:NPO_324 NPO_324 manganese manganese npo:NPO_342 NPO_342 circular shape circular [definition based on source]:http://www.cycfoundation.org, http://www.thefreedictionary.com, NCI circular shape npo:NPO_354 NPO_354 multi-walled carbon nanotube MWCNT multi-walled carbon nanotube npo:NPO_360 NPO_360 NCIT:C32345 colloid colloid npo:NPO_372 NPO_372 linkage between primary amine and isothiocyanate linkage between primary amine and isothiocyanate npo:NPO_376 NPO_376 isourea linkage between primary amine and isocyanate isourea linkage between primary amine and isocyanate npo:NPO_383 NPO_383 NCIT: C62376 nanowire nanowire npo:NPO_389 NPO_389 arylamine linkage between primary amine and fluorobenzene derivative arylamine linkage between primary amine and fluorobenzene derivative npo:NPO_393 NPO_393 NCIT: C62369 nanoemulsion nanoparticle emulsion nanoemulsion npo:NPO_395 NPO_395 drug-loaded nanoparticle drug-loaded nanoparticle npo:NPO_398 NPO_398 double-walled nanotube double-walled nanotube npo:NPO_401 NPO_401 gold nanoparticle Au nanoparticle gold nanoparticle npo:NPO_411 NPO_411 one-dimensional nano-object 1-D nano-object one-dimensional nano-object npo:NPO_414 NPO_414 thioether linkage between thiol and acryloyl compound thioether linkage between thiol and acryloyl compound npo:NPO_416 NPO_416 hydrazone linkage between carbohydrazide and ketone hydrazone linkage between carbohydrazide and ketone npo:NPO_421 NPO_421 electronegativity [definition source]: http://hyperphysics.phy-astr.gsu.edu/Hbase/hframe.html electronegativity npo:NPO_430 NPO_430 hydrazone linkage hydrazone linkage npo:NPO_447 NPO_447 nanopipette nanopipette npo:NPO_451 NPO_451 thioester linkage thioester linkage npo:NPO_453 NPO_453 gold nanocantilever gold nanocantilever npo:NPO_456 NPO_456 carbamate ester linkage carbamate linkage carbamate ester linkage npo:NPO_457 NPO_457 NCIT: C62386 nanohorn [NCI_Thesaurus definition]: A fullerene-like nanostructure that consists of graphene cylinders and exhibits an irregular horn-like shape. nanohorn npo:NPO_461 NPO_461 NCIT:C64352 rod-shaped rodlike rod-shaped npo:NPO_464 NPO_464 etoposide-loaded nanoparticle etoposide-loaded nanoparticle npo:NPO_466 NPO_466 carboxylic ester linkage between organo hydroxy compound and acid anhydride carboxylic ester linkage between organo hydroxy compound and acid anhydride npo:NPO_471 NPO_471 entrapment entrapment npo:NPO_485 NPO_485 spacer spacer arm [definition source]: Wikipedia spacer npo:NPO_500 NPO_500 solubility in water water solubility solubility in water npo:NPO_504 NPO_504 thioether linkage thioether linkage npo:NPO_507 NPO_507 imine linkage between primary amine and aldehyde imine linkage between primary amine and aldehyde npo:NPO_514 NPO_514 soluble in water water-soluble soluble in water npo:NPO_515 NPO_515 conical shape conical conical shape npo:NPO_524 NPO_524 shell of nanocapsule shell of nanocapsule npo:NPO_526 NPO_526 imine linkage imine linkage npo:NPO_532 NPO_532 NCIT:C45304 suspension suspension npo:NPO_537 NPO_537 carbohydrate-coated nanoparticle carbohydrate-coated nanoparticle npo:NPO_551 NPO_551 gold quantum dot-entrapped poly(amidoamine) dendrimer nanoparticle gold quantum dot-entrapped poly(amidoamine) dendrimer nanoparticle npo:NPO_563 NPO_563 covalent linkage covalent attachment covalent conjugation covalent linkage npo:NPO_580 NPO_580 imine linkage between secondary amine and aldehyde imine linkage between secondary amine and aldehyde npo:NPO_589 NPO_589 quantum dot QD (NCI_Thesaurus definition): Nanometer-sized semiconductor particles, made of cadmium selenide (CdSe), cadmium sulfide (CdS) or cadmium telluride (CdTe) with an inert polymer coating. The semiconductor material used for the core is chosen based upon the emission wavelength range being targeted: CdS for UV-blue, CdSe for the bulk of the visible spectrum, and CdTe for far red and near-infrared. The size of the particle determines the exact color of a given quantum dot. The polymer coating protects cells from cadmium toxicity but also facilitates the attachment of a variety of targeting molecules, including monoclonal antibodies directed to tumor-specific biomarkers. Because of their small size, quantum dots can function as cell- and even molecule-specific markers that will not interfere with the normal cellular functions. quantum dot npo:NPO_598 NPO_598 insoluble in water water-insoluble insoluble in water npo:NPO_601 NPO_601 gel gel npo:NPO_602 NPO_602 carbon nanofiber carbon nanofiber npo:NPO_606 NPO_606 carbon nanotube carbon nanotube npo:NPO_618 NPO_618 paclitaxel-loaded nanoparticle paclitaxel-loaded nanoparticle npo:NPO_619 NPO_619 nanocage nanocage npo:NPO_621 NPO_621 dendrimer repeat unit dendrimer repeat unit npo:NPO_626 NPO_626 amide linkage amide bond amide linkage npo:NPO_631 NPO_631 solid lipid nanoparticle solid lipid nanoparticle npo:NPO_636 NPO_636 nanosphere nanosphere npo:NPO_637 NPO_637 amidine linkage between primary amine and imidoester amidine linkage between primary amine and imidoester npo:NPO_639 NPO_639 NCIT:C63807 emulsion [source]: http://www.thefreedictionary.com emulsion npo:NPO_644 NPO_644 thioether linkage between thiol and iodoacetyl derivative thioether linkage between thiol and iodoacetyl derivative npo:NPO_648 NPO_648 arylthioether linkage arylthioether linkage npo:NPO_661 NPO_661 core-shell nanoparticle core-shell nanoparticle npo:NPO_665 NPO_665 nanocantilever Nanocantilevers are often used to explore and characterize the surfaces of biological systems. The motion of the device is recorded and transformed mathematically to provide information about these surface characteristics. nanocantilever npo:NPO_666 NPO_666 hexahedral shape hexahedral [source]: WordNet hexahedral shape npo:NPO_667 NPO_667 one-dimensional nanoparticle 1-D nanoparticle one-dimensional nanoparticle npo:NPO_677 NPO_677 biopolymer-coated nanoparticle biopolymer-coated nanoparticle npo:NPO_684 NPO_684 NCIT: C62372 nanoprobe nanoprobe npo:NPO_691 NPO_691 NCIT:C62340 nanoarray nanoarray npo:NPO_699 NPO_699 tamoxifen-loaded nanoparticle tamoxifen-loaded nanoparticle npo:NPO_705 NPO_705 nanochannel [definition source]: Lesinski et al, Biomedical Microdevices, vol 7, number 1, 71-79, 2005 nanochannel npo:NPO_707 NPO_707 nanoparticle Definition is partly based on ASTM E 2456-06 (Terminology for Nanotechnology). nanoparticle npo:NPO_711 NPO_711 nanobud [definition source]: Nasibulin, A. G., Peter. V. Pikhitsa, Hua. Jiang, David. P. Brown, A. V. Krasheninnikov, Anton S. Anisimov, Paula Queipo, Anna Moisala, David Gonzalez, Gunther Lientschnig, Abdou Hassanien, Sergey D. Shandakov, Giulio Lolli, Daniel E. Resasco, Mansoo Choi, David Tománek, and Esko I. Kauppinen "A Novel Hybrid Carbon Nanomaterial". Nature Nanotechnology 2(3), 156-161 (2007). nanobud npo:NPO_719 NPO_719 liposome liposome vesicle liposome npo:NPO_723 NPO_723 nanocell Nanocell was first used for sequential delivery of anti-angiogenesis and chemotherapeutic agent to solid tumors.The chemotherapeutic agent can be conjugated to a nanoparticle in the core, while the anti-angiogenesis agent can be encapsulated in the lipid membrane.It was designed to first cause membrane disruption for release of anti-angiogenesis agent, which causes tumor vascular collapse, and finally cause intra-tumoral trapping of the core chemotherapeutic drug-conjugated nanoparticles. [definition source]: Sengupta et al, Nature Letters, vol 436, 2005 nanocell npo:NPO_724 NPO_724 nanocapsule Nanocapsule npo:NPO_729 NPO_729 iron oxide nanoparticle iron oxide nanoparticle npo:NPO_732 NPO_732 amphiphilic amphipathic amphiphilic npo:NPO_735 NPO_735 MESH:D050091 dendrimer [MeSH definition]: Tree-like, highly branched, polymeric compounds. They grow three-dimensionally by the addition of shells of branched molecules to a central core. The overall globular shape and presence of cavities gives potential as drug carriers and CONTRAST AGENTS. [NCI_THESAURUS definition]: A polymeric molecule which has a highly-branched, three-dimensional architecture. Dendrimers are synthesized from monomers and new branches are added in discrete steps to form a tree-like architecture. A high level of synthetic control is achieved through step-wise reactions and purification at each step to regulate the size, architecture, functionality and monodispersity of the molecules. These polymers have desirable pharmacokinetic properties and a polyvalent array of surface groups that make them potential drug delivery vesicles. dendrimer npo:NPO_738 NPO_738 amide linkage between primary amine and carboxylic ester amide linkage between primary amine and carboxylic ester npo:NPO_745 NPO_745 carboxylic ester linkage ester linkage carboxylic ester linkage npo:NPO_748 NPO_748 diazo linkage diazo linkage npo:NPO_759 NPO_759 nanofilm nanofilm npo:NPO_760 NPO_760 shell shell npo:NPO_762 NPO_762 silicon nanotube silicon nanotube npo:NPO_771 NPO_771 hydrogel hydrogel npo:NPO_776 NPO_776 dendrimer branch dendrimer branch npo:NPO_779 NPO_779 NCIT: C62374 nanosensor nanosensor npo:NPO_801 NPO_801 PEGylated nanoparticle PEG-coated nanoparticle PEG-modified nanoparticle poly(ethylene) glycol-coated nanoparticle PEGylated nanoparticle npo:NPO_802 NPO_802 NCIT: C63848 organic definition for organic is based on the CHEBI definition for organic compounds (CHEBI:25700) organic npo:NPO_803 NPO_803 dendrimer core molecule core initiator group dendrimer core molecule npo:NPO_807 NPO_807 amide linkage between primary amine and carboxylic acid amide linkage between primary amine and carboxylic acid npo:NPO_821 NPO_821 polydispersity polydispersity npo:NPO_827 NPO_827 nanoparticle surface modifying agent coating agent surface modifying agent npo:NPO_833 NPO_833 porous shell of nanocage porous shell of nanocage npo:NPO_835 NPO_835 NCIT:C73489 sol sol npo:NPO_836 NPO_836 biodegradable nanoparticle biodegradable nanoparticle npo:NPO_843 NPO_843 arylamine linkage arylamine linkage npo:NPO_850 NPO_850 elliptical shape elliptical [definition based on source]:http://www.cycfoundation.org, http://www.thefreedictionary.com, NCI elliptical shape npo:NPO_852 NPO_852 needle shape needle shape npo:NPO_858 NPO_858 polyhedral shape polyhedral [source]: WordNet polyhedral shape npo:NPO_861 NPO_861 cubical shape cubical [source]:WordNet cubical shape npo:NPO_867 NPO_867 polydisperse polydisperse npo:NPO_868 NPO_868 nanoparticle formulation Nanotechnology involves the application of scientific knowledge from multidisciplinary fields of science and engineering, towards understanding, manipulating and controlling the properties of matter at the nanoscale (1-100 nm) size dimensions. nanoparticle formulation npo:NPO_870 NPO_870 NCIT: C62387 single-walled nanohorn [definition source]: NCI_Thesaurus single-walled nanohorn npo:NPO_887 NPO_887 disulfide linkage between two thiols disulfide linkage between two thiols npo:NPO_888 NPO_888 physical state state of matter physical state npo:NPO_891 NPO_891 amide linkage between primary amine and acyl azide amide linkage between primary amine and acyl azide npo:NPO_892 NPO_892 monodisperse monodisperse npo:NPO_893 NPO_893 nanofiber nanofiber npo:NPO_905 NPO_905 three-dimensional nanoparticle 3-D nanoparticle three-dimensional nanoparticle npo:NPO_938 NPO_938 biocompatible biocompatible npo:NPO_943 NPO_943 single-walled carbon nanotube SWCNT single-walled carbon nanotube npo:NPO_949 NPO_949 dextran-coated nanoparticle dextran-coated nanoparticle npo:NPO_963 NPO_963 pH-sensitive linker pH-sensitive spacer pH-sensitive linker npo:NPO_965 NPO_965 poly(amidoamine) dendrimer PAMAM dendrimer poly(amidoamine) dendrimer npo:NPO_987 NPO_987 disulfide linkage disulfide linkage npo:NPO_988 NPO_988 thioether linkage between thiol and aziridine derivative thioether linkage between thiol and aziridine derivative An IC50 calculated with the Hill model fitting algorithm. IC50 (Hill model) The HPRT assay is an in vitro mammalian cell gene mutation test. This test system is appropriate for use in the initial assessment of the genotoxicity of a test article. HPRT - gene mutation base test Toxicity to some part or aspect of the environment. environmental toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing birds toxicity to birds A toxicity disposition that inheres in a substance that is capable of causing harm to or killing earthworms toxicity to earthworms A toxicity disposition that inheres in a substance that is capable of causing harm to or killing fish toxicity to fish A toxicity disposition that inheres in a substance that is capable of causing harm to or killing aquatic algae and cyanobacteria toxicity to aquatic algae and cyanobacteria A toxicity disposition that inheres in a substance that is capable of causing harm to or killing aquatic invertebrates toxicity to aquatic invertebrates A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms in the aquatic environment aquatic environmental toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing soil microorganisms toxicity to soil microorganisms A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms that exist in sediment sediment toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing fish rapidly acute toxicity to fish short-term toxicity to fish A toxicity disposition that inheres in a substance that is capable of causing harm to or killing fish over a longer time period long-term toxicity to fish A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms that exist in sediment soil toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing macroorganisms that exist in soil toxicity to soil macroorganisms A toxicity disposition that inheres in a substance that is capable of causing harm to or killing terrestrial organisms toxicity to terrestrial organisms A toxicity disposition that inheres in a substance that is capable of causing harm to or killing microorganisms toxicity to microorganisms A toxicity disposition that inheres in a substance that is capable of causing harm to or killing terrestrial arthropods toxicity to terrestrial arthropods A toxicity disposition that inheres in a substance that is capable of causing harm to or killing terrestrial plants toxicity to terrestrial plants A quantitive or qualitative interpretable standardized representation of a perturbation of relevance in toxicology that is measured by a toxicological assay. toxicological endpoint A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms when ingested via the mouth oral toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms quickly when ingested via the mouth acute oral toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms when ingested via the mouth over several repeated doses repeated dose oral toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms when inhaled inhalation toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms quickly when inhaled acute inhalation toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms when inhaled multiple times repeated dose inhalation toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms when exposed to the skin dermal toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms quickly when exposed to the skin acute dermal toxicity A toxicity disposition that inheres in a substance that is capable of causing harm to or killing organisms when exposed to the skin multiple times repeated dose dermal toxicity A toxicity disposition that inheres in a substance that is capable of damaging the genetic information within the cells of an organism, causing mutations which may lead to cancer. genotoxicity genetic toxicity A toxicity disposition that inheres in a substance that is directly involved in causing cancer. carcinogenicity A toxicity disposition that inheres in a substance that is capable of interfering with normal reproduction, including adverse effects on sexuality, fertility, and the developing offspring. reproductive toxicity A toxicity disposition that inheres in a substance that is capable of causing adverse effects on a developing embryo or foetus. pre-natal developmental toxicity teratogenicity Skin irritation or corrosion are localized toxic effects resulting from exposure to an agent. skin corrosion skin irritation Eye irritation or corrosion are localized toxic effects resulting from exposure to an agent. eye corrosion eye irritation Skin sensitization is induced sensitivity to an agent that in time leads to an allergic response to that agent. skin sensitisation skin sensitization physchem property endpoint Pro-inflammatory response Oxidative stress Uptake genotoxicity single and double strand breaks base DNA damage mutagenicity Biological property endpoint Barrier integrity Transport of NPs across barrier immunotox Immunotoxicity chemical property endpoint A toxicity that inheres in any substances capable of interfering with normal growth, differentiation, development or behaviour as a consequence of developmental insult. developmental toxicity The effective concentration which produces 10% of the maximum possible response. EC10 The effective concentration that produces 20% of the maximum possible response. EC20 The effective concentration that produces 80% of the maximum possible response. EC80 The effective concentration that produces 90% of the maximum possible response. EC90 The exposure concentration that produces a 50% respiratory rate decrease RD50 Greatest concentration or amount of a substance that causes no alteration of morphology, functional capacity, growth, development or life span of target organisms distinguishable from those observed in normal (control) organisms of the same species and strain under the same defined conditions of exposure. no observed effect level. IUPAC Gold Book NOEL Greatest concentration or amount of a substance that causes no adverse alteration of morphology, functional capacity, growth, development or life span of target organisms distinguishable from those observed in normal (control) organisms of the same species and strain under the same defined conditions of exposure. no observed adverse effect level IUPAC Gold Book NOAEL Lowest concentration or amount of a substance, found by experiment or observation, which causes an adverse alteration of morphology, functional capacity, growth, development, or life span of a target organism distinguishable from normal (control) organisms of the same species and strain under defined conditions of exposure. lowest observed adverse effect level IUPAC Gold Book LOAEL Lowest concentration or amount of a substance, found by experiment or observation, that causes any alteration in morphology, functional capacity, growth, development, or life span of target organisms distinguishable from normal (control) organisms of the same species and strain under the same defined conditions of exposure. lowest observed effect level IUPAC Gold Book LOEL The highest concentration of a substance to which organisms are exposed that causes no observable adverse effect on the test organisms. no observed effect concentration This value is used, along with other factors, to determine toxicity limits in permits. NOEC barrier crossing Cell Transformation Assay Cell Transformation Assay cytotoxicity endpoint Technique used to determine the surface area of solid particles. Brunauer–Emmett–Teller analysis Particle sizing technique based on Brownian motion and scattered light. Nanoparticle Tracking Analysis nm deposition occular irritaton viability Air liquid interface Broncho alveolar Lavage bio distribution ecotox A liquid used to extract a substance from another material. extractant organ burden pattern distribution Physiologically based pharmacokinetic PBPK pulmonary tox long term batch dispersion composition chemical crystalline phase density dustiness isoelectric point isoelectric point potentiometry size endpoint solubility surface chemistry specific surface area VSSA zeta potential effective density average size force tensiometry redox speciation disc centrifuge osmotic concentration Chloride concentration Preferential orientation Time resolved Single Particle Inductively Coupled Plasma Mass Spectrometry Time resolved nanoparticle tracking analysis Deposition rate Homoaggregation rate Column test An organism living an in water environment aquatic organism The evolutionary process by which populations evolve to become distinct species. Speciation protein corona graphene oxide nanoparticle GO nanoparticle graphene oxide nanoparticle cobalt (II) oxide nanoparticle CoO nanoparticle cobalt oxide nanoparticle cobalt oxide nanoparticle cobalt oxide nanoparticle yttrium oxide nanoparticle Y2O3 nanoparticle yttrium oxide nanoparticle lanthanum oxide nanoparticle La2O3 nanoparticle lanthanum oxide nanoparticle neodymium oxide nanoparticle Nd2O3 nanoparticle neodymium oxide nanoparticle samarium oxide nanoparticle Sm2O3 nanoparticle samarium oxide nanoparticle gadolinium oxide nanoparticle Gd2O3 nanoparticle gadolinium oxide nanoparticle dysprosium oxide nanoparticle Dy2O3 nanoparticle dysprosium oxide nanoparticle erbium oxide nanoparticle Er2O3 nanoparticle erbium oxide nanoparticle ytterbium oxide nanoparticle Yb2O3 nanoparticle ytterbium oxide nanoparticle A metal oxide nanoparticle which is composed of cobalt and iron. cobalt ferrite The amount of dissolved substance versus time (determined by the crystal forces) as an experimental value, where solid particles (usually crystalline) are released into solution as individual free molecules. Dissolution rate algorithm type Supervised learning is the machine learning task of inferring a function from labeled training data. The training data consist of a set of training examples. In supervised learning, each example is a pair consisting of input data (input variables) and a desired output values (predicted variables). Supervised learning Unsupervised learning is the machine learning task of inferring a function to describe hidden structure from unlabeled data. Since the examples given to the learner are unlabeled, there is no error or reward signal to evaluate a potential solution. This distinguishes unsupervised learning from supervised learning and reinforcement learning. https://en.wikipedia.org/wiki/Unsupervised_learning Unsupervised Learning A statistical process for estimating the relationships among variables. https://en.wikipedia.org/wiki/Regression_analysis regression Classification is the problem of identifying to which of a set of categories (sub-populations) a new observation belongs, on the basis of a training set of data containing observations (or instances) whose category membership is known. https://en.wikipedia.org/wiki/Statistical_classification classification A methodology that groups data objects based only on information found in the data that describes the objects and their relationships. clustering A hierarchical clustering approach where each observation starts in its own cluster, and pairs of clusters are merged as one moves up the hierarchy. https://en.wikipedia.org/wiki/Hierarchical_clustering agglomeration clustering methodologies a data mining method that simultaneously clusters both rows and columns of a matrix biclustering Hierarchical clustering is a set of nested clusters that are organized as a tree (source: https://www-users.cs.umn.edu/~kumar/dmbook/ch8.pdf). hierarchical clustering Naive Bayes classifiers are a family of simple probabilistic classifiers based on applying Bayes' theorem with strong (naive) independence assumptions between the features. In the multivariate Bernoulli event model, features are independent booleans (binary variables) describing inputs. https://en.wikipedia.org/wiki/Naive_Bayes_classifier#Bernoulli_naive_Bayes bernoulli naive bayes Naive Bayes classifiers are a family of simple probabilistic classifiers based on applying Bayes' theorem with strong (naive) independence assumptions between the features. https://en.wikipedia.org/wiki/Naive_Bayes_classifier generalised naive bayes In Multinomial Naive Bayes samples (feature vectors) represent the frequencies with which certain events have been generated by a multinomial (p_1,..., p_n) where p_i is the probability that event i occurs (or K such multinomials in the multiclass case). https://en.wikipedia.org/wiki/Naive_Bayes_classifier#Multinomial_naive_Bayes multinomial naive bayes numeric data entry Classification based on models. model-based classification Classification where classes are constructed directly from the training instances themselves. https://en.wikipedia.org/wiki/Instance-based_learning instance-based classification Regression that is instance-based, that is it constructs hypotheses directly from the training instances themselves. https://en.wikipedia.org/wiki/Instance-based_learning instance-based regression Regression that produces models. model-based regression Classification performed using artificial neural networks. artificial neural network classification The molecular descriptor is the final result of a logic and mathematical procedure which transforms chemical information encoded within a symbolic representation of a molecule into a useful number or the result of some standardized experiment. https://en.wikipedia.org/wiki/Molecular_descriptor descriptor A class of descriptors derived by Image analysis methodologies, developed within the eNanoMapper project. https://www.enanomapper.net/deliverables/d4/150801_eNanoMapper-D4_2final.pdf image analysis descriptors data type numeric string interconnected neurons used to estimate functions that can depend on a large number of inputs and are generally unknown https://en.wikipedia.org/wiki/Artificial_neural_network artificial neural network regression Variable Importance in Projection (VIP) scores estimate the importance of each variable in the projection used in a PLS model. http://wiki.eigenvector.com/index.php?title=Vip variable importance in projection scores The domain of applicability of a QSAR model is the physico-chemical, structural or biological space, knowledge or information on which the training set of the model has been developed, and for which it is applicable to make predictions for new compounds. https://en.wikipedia.org/wiki/Applicability_domain domain of applicability Descriptors derived from quantum mechanical calculations. quantum mechanical descriptor A radial basis function network is an artificial neural network that uses radial basis functions as activation functions. The output of the network is a linear combination of radial basis functions of the inputs and neuron parameters. https://en.wikipedia.org/wiki/Radial_basis_function_network radial basis function artificial neural networks regression Descriptors derived from biological information (partially or fully). biological descriptor Aspect ratio X, defined as AR_x=dmin_x/max_y, doi: 10.3109/17435390.2014.930195 aspect ratio x Aspect ratio Y, defined as AR_y=dmin_y/max_x, doi: 10.3109/17435390.2014.930195 aspect ratio y The smallest rectangle enclosing the selection. Uses the headings BX, BY, Width and Height, where BX and BY are the coordinates of the upper left corner of the rectangle. https://imagej.nih.gov/ij/docs/guide/146-30.html bounding rectangle This is the brightness-weighted average of the x and y coordinates all pixels in the image or selection. Uses the XM and YM headings. These coordinates are the first order spatial moments. https://imagej.nih.gov/ij/docs/guide/146-30.html centre of mass The central point of the selection. This is the average of the x and y coordinates of all of the pixels in the image or selection. Uses the X and Y Results table headings. https://imagej.nih.gov/ij/docs/guide/146-30.html centroid Circularity, equal to 4π × [Area]/[Perimeter]^2 ranges from 0 (infinitely elongated polygon) to 1 (perfect circle). https://imagej.nih.gov/ij/docs/guide/146-30.html circularity Size of the core. core size The longest distance between any two points along the selection boundary, also known as maximum caliper. https://imagej.nih.gov/ij/docs/guide/146-30.html feret diameter Fit an ellipse to the selection. Uses the headings Major, Minor and Angle. Major and Minor are the primary and secondary axes of the best fitting ellipse. Angle (0-180 degrees) is the angle between the primary axis and a line parallel to the x-axis of the image. The coordinates of the centre of the ellipse are displayed as X and Y if Centroid is checked. Note that ImageJ cannot calculate the length of either the major or the minor axis if Pixel Aspect Ratio in the Set Scale dialog is not 1.0. https://imagej.nih.gov/ij/docs/guide/146-30.html fit ellipse Calculates and displays two values: "IntDen" (the product of Area and Mean Grey Value) and "RawIntDen" (the sum of the pixel values in the image or selection). "IntDen" and "RawIntDen" values are the same for uncalibrated image. doi: 10.3109/17435390.2014.930195 integrated density The fourth order moment about the mean. doi: 10.3109/17435390.2014.930195 kurtosis Average grey value within the selection. In this value the sum of all pixels within the selection is divided by the count of pixels. If the image is not in grey scale then a transformation is made according to the following formula: grey=0.299red+0.587green+0.114blue. http://www.enanomapper.net/deliverables/d4/150801_eNanoMapper-D4_2final.pdf mean grey value The median value of the pixels in the image or selection. median The lowest grey scale values appearing in the selection. min grey levels The highest grey scale values appearing in the selection. max grey levels Stands for the most frequently occurring grey value within the selection. modal grey value The size of the particle as measured when in a specific media. particle size in media The sum of the relative differences in intensities between values of neighboring pixels (xi and yi) along the X axis. porosity x The sum of the relative differences in intensities between values of neighboring pixels (xi and yi) along the Y axis. porosity y The inverse of Aspect Ratio, or 4 ×[Area]/π × [Major axis]2. https://imagej.nih.gov/ij/docs/guide/146-30.html roundness This is a group of descriptors (Circularity, Aspect Ratio, Roundness and Solidity) that are all calculated when the "Shape descriptors" option is used. http://www.enanomapper.net/deliverables/d4/150801_eNanoMapper-D4_2final.pdf shape descriptors A measure of asymmetry of a frequency distribution; specifically the quotient of the difference between the arithmetic mean and the mode divided by the standard deviation. Positive skewness is defined for the longer slope of the plotted distribution in the direction of increasing variate values (mean greater than mode, or coarser particles exceed finer particles in a particle-size distribution); negative skewness is defined for the longer slope of the plotted distribution in the direction of decreasing variate values (mode greater than mean, or finer particles exceed coarser particles in a particle-size distribution). http://www.oceanscience.net/inletsonline/glossary.php3?name=skewness&start=s1 skewness Solidity equals to [Area]/[Convex area]. https://imagej.nih.gov/ij/docs/guide/146-30.html solidity The ratio of the surface area of a sphere - with the same volume as the particle considered - to the surface area of the particle. sphericity The diameter of a sphere having the same surface area as the projected particle surface diameter The sum of the all non-zero pixels. doi: 10.3109/17435390.2014.930195 area An exposure medium is a substance through which something else is transmitted or carried during an exposure. exposure medium The sum of all non-zero pixels episodes, combining measures of contour elements, assuming that the contour is a square with a side equal to the unity. doi: 10.3109/17435390.2014.930195 volume Volume/ mass diameter doi: 10.3109/17435390.2014.930195 volume mass diameter Volume/ surface diameter, doi: 10.3109/17435390.2014.930195 volume surface diameter The aspect ratio of the particle’s fitted ellipse, i.e., [Major Axis]/[Minor Axis]. https://imagej.nih.gov/ij/docs/guide/146-30.html aspect ratio A decision tree is a decision support tool that uses a tree-like graph or model of decisions and their possible consequences. https://en.wikipedia.org/wiki/Decision_tree decision tree GO descriptor BIO descriptor using Gene Ontology information gene ontology descriptors Biology descriptors derived from omics data and integrated biological pathway/activities information BIO descriptors bundle Categorical data is the statistical data type consisting of categorical variables or of data that has been converted into that form, for example as grouped data. https://en.wikipedia.org/wiki/Categorical_variable categorical data Builds a decision tree which at each node recursively splits the data into subsets using conditional mutual information (CMI) as a criterion. It is a modified version of ID3/C4.5 decision trees. cmi decision tree Iterative Dichotomiser 3. Decision Tree which uses information gain as data split criterion https://en.wikipedia.org/wiki/ID3_algorithm id3 decision trees The leverage method is used to assess the Domain of Applicability, is based on the assumption of a Gaussian data distribution and measures the distance of an observation to the center of X observations. https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive_toxicology/information-sources/qsar-document-area/applicability_domain1.pdf leverage method The functions and objects offered by an information processing system. information resource Read-across uses relevant information from analogous (‘source') substances to predict the properties of ‘target' substances. http://echa.europa.eu/support/grouping-of-substances-and-read-across read accross (Machine) Learning explores the study and construction of algorithms that can learn from and make predictions on data. https://en.wikipedia.org/wiki/Machine_learning learning A (mathematical) model is a description of a system using mathematical concepts and language. https://en.wikipedia.org/wiki/Mathematical_model model The tasks performed on a dataset to prepare it for machine learning applications. preprocessing A summary of the most important results of machine learning calculations. report A process run internally in the system in order to complete request. task Validation is the process of deciding whether the numerical results quantifying hypothesized relationships between variables, obtained from regression analysis, are acceptable as descriptions of the data. https://en.wikipedia.org/wiki/Regression_validation validation A field for multi dimensional array results array calculations A field for single value results single calculations Elastic net is a shrinkage and selection regression method that linearly combines the L1 and L2 penalties of the lasso and ridge methods. https://en.wikipedia.org/wiki/Elastic_net_regularization elastic net The dependent features represent the output or outcome whose variation is being studied. dependent feature When studying the variation of an output or outcome, the independent variables represent inputs or causes, i.e. potential reasons for variation. independent feature Data required as input to produce predictions or classifications. input data A variable required as input to a model. The values of input variables are used to produce predictions on certain variables (predicted variables or predicted features). input variable Parameter of a model model parameter A feature derived as a result of calculations from known values of other variables (input variables). predicted feature Independent variables of a model's 1st transformation sub-model. required feature Algorithm that finds a linear model by projecting the predicted variables and the observable variables to a new space. https://en.wikipedia.org/wiki/Partial_least_squares_regression partial least squares Linear Model trained with L1 prior as regularizer. Optimises the same objective function as Elastic Net. lasso Algorithm that finds a linear model by projecting the predicted variables and the observable variables to a new space. https://en.wikipedia.org/wiki/Partial_least_squares_regression partial least squares Ridge Regression is a technique for analyzing multiple regression data that suffer from multicollinearity. When multicollinearity occurs, least squares estimates are unbiased, but their variances are large so they may be far from the true value. By adding a degree of bias to the regression estimates, ridge regression reduces the standard errors. http://www.ncss.com/wp-content/themes/ncss/pdf/Procedures/NCSS/Ridge_Regression.pdf ridge regression Binary data is data whose unit can take on only two possible states. https://en.wikipedia.org/wiki/Binary_data binary data Parameter data parameter data Normalization is performed in order to bring the entire probability distributions of adjusted values into alignment and consists of substitung each value of a dataset with the result of this formula: (Xi-μ)/σ, where Xi is each element of the dataset, μ is the average value and σ is the standard deviation. normalization Scaling is a method used to standardize the range of independent variables or features of data. In data processing, it is also known as data normalization and is generally performed during the data preprocessing step. https://en.wikipedia.org/wiki/Feature_scaling scaling Chemical hardness (η) is proportional to the second derivative of the total energy of a chemical system with respect to changes in the number of electrons at a fixed nuclear environment. https://en.wikipedia.org/wiki/HSAB_theory#Chemical_hardness chemical hardness The conduction band is the lowest range of vacant electronic states. https://en.wikipedia.org/wiki/Valence_and_conduction_bands conduction band Electronic chemical potential, μ, is a measure of the escaping tendency of an electronic cloud and corresponds to the negative of the electronegativity c. Considering a finite difference approximation and a quadratic dependence of energy on the number of electrons, the electronegativity approximates the loss or gain in charge by the ionization potential IP and electron affinity EA, that is χMU is approximately (IP+EA)/2=-μ , χMU is Mulliken electronegativity. electronic chemical potential Mulliken electronegativity = -α, where α = the average of the HOMO and LUMO energies, i.e., α = ½(εhomo+ εlumo) http://openmopac.net/manual/super.html Mullikens electronegativity Xc Parr & Pople absolute hardness = ½(εhomo- εlumo) http://openmopac.net/manual/super.html parr and poples absolute hardness Polarizability derived from the dipole moment Ad polarizability derived from the dipole moment ad Polarizability derived from the heat of formation Ahof. polarizability derived from the heat of formation ahof Schuurmann MO shift alpha = α, where α = the average of the HOMO and LUMO energies, i.e., α = ½(εhomo+ εlumo) http://openmopac.net/manual/super.html schuurmann mo shift alpha The solvent accessible surface is a continuous surface of the molecule which can be reached by the center of charge of a solvent molecule. http://openmopac.net/manual/cosmo.html solvent accessible surface Total energy equals to (Eelect + Enuc), where Eelect is the electronic energy, Enuc is the nuclear-nuclear repulsion energy. http://openmopac.net/manual/SCF_calc_hof.html total energy The total softness S is defined as S=0.5*η, where η is the absolute hardness. Defined in page 629 of: Molecular descriptors for chemoinformatics (2 volumes), Roberto Todeschini, Viviana Consonni, 2009, Volume 41, Wiley-VCH. total softness The valance band is the highest range of electron energies in which electrons are normally present at absolute zero temperature. https://en.wikipedia.org/wiki/Valence_and_conduction_bands valance band Zeta potential derived from Quantum Mechanics Calculations. zeta potential External validation is performed by splitting the available data set into training set for model development and prediction set for model predictivity check.https://en.wikipedia.org/wiki/Quantitative_structure–activity_relationship external validation Split validation splits up the example set into a training and test set and evaluates the model. split validation Information on the validation. validation information Statistical information on the classification. classification statistics Information on results from the cross validation. cross validation information Statistical information on the regression. regression statistics Y Scrambling, also called response permutation, removes the correspondence between the potency and prediction properties of the molecules but keeps the relationships between the individual predictor properties. (p.153) Quantitative Drug Design: A Critical Introduction, Second Edition, Yvonne C. Martin, CRC Press, May 6, 2010 y scrambling Statistical information on the class values of the classification. class value statistics A confusion matrix, also known as an error matrix,[3] is a specific table layout that allows visualization of the performance of an algorithm, typically a supervised learning one (in unsupervised learning it is usually called a matching matrix). https://en.wikipedia.org/wiki/Confusion_matrix confusion matrix A radial basis function network is an artificial neural network that uses radial basis functions as activation functions. The output of the network is a linear combination of radial basis functions of the inputs and neuron parameters. https://en.wikipedia.org/wiki/Radial_basis_function_network radial basis function artificial neural networks classification Read-across uses relevant information from analogous (‘source') substances to predict the properties of ‘target' substances. http://echa.europa.eu/support/grouping-of-substances-and-read-across read accross Substance or material that is used to avoid condensation on surfaces and in the atmosphere. anticondensation agent A substance added to fluids, especially water, to reduce the freezing point of the mixture, or applied to surfaces to melt or prevent the build-up of ice. Examples of products include antifreeze liquids, windshield de-icers, aircraft de-icers, lock release agents, ice melting crystals, and rock salt. antifreeze agent Any substance that prevents dirt and grease from resettling on a cleaned surface or that helps keep soils from re-depositing onto clothing in the wash water after they have been removed. Antiredeposition agents are water-soluble and typically negatively charged. antiredeposition agent Substances added to products to prevent the build-up of inorganic oxide deposits. The formation of scale can be caused by the deposition of salts or minerals and may not necessarily lead to surface corrosion, therefore these chemicals are not corrosion inhibitors. Substances prevent the build-up or removes limescale and fouling. These substances are also called ‘Descalers’. antiscaling agent Antistain agent is a substance that provides stain blocking and soil resistance to soft surface cleaners and protectors. antistain agent Any substance that prevents or reduces the tendency of a material to accumulate a static charge or alters the electrical properties of materials by reducing their tendency to acquire an electrical charge. antistatic agent A substance which serves to enhance evaporation or reduce film formation in order to prevent the formulation of streaks on a surface during cleaning. antistreaking agent Substance that terminates the growth of a molecular chain and forms a new radical that can act as the initiator for a new chain. chain transfer agent Substance or material used to remove dirt or impurities from surfaces; acts to loosen and remove dirt and grease from surfaces. cleaning agent Ingredients that decrease the minimum film-forming temperature (MFT) and, upon evaporation, yield a hard film. In polishes, the most common coalescing agent is glycol ether however, pyrrolidines and benzoates are also used. coalescing agent Material used to conduct electrical current. conductive agent Substance added to a suspending medium or suspension to improve the separation of particles; to ensure proper dispersion; to prevent settling or clumping; to encourage uniform and maximum separation of individual, extremely fine solid particles or liquid droplets, often of colloidal size. A typical use is dispersal of dyes to ensure uniform coloration. dispersing agent Durability agents are ingredients added to increase the durability and therefore the functional life of a material. durability agent Substance that is dusted onto the surface of a material (e.g., rubber) to reduce surface tack. dusting agent Substance used for the preservation of biological tissue. embalming agent Etching Agent is a substance that removes unprotected areas of metal or glass surfaces. Etching agents are usually acids or bases. etching agent Chemical substances used to impart such functions as softening, staticproofing, wrinkle resistance, and water repellence. Substances may be applied to textiles, paper, and leather. finishing agents Any agent incorporated or applied to slow down combustion once started; Removes heat faster than it is released; separates the fuel and oxidizing agent; dilutes the vapour phase concentration of the fuel and oxidizing agent below what is needed for combustion. fire extinguishing agent Substance used to interact with a dye on fibres to improve fastness. fixing agent A flocculating agent is a chemical or substance that facilitates flocculation of suspended solids in liquid. Flocculating agents are chemical additives, which, at relatively low levels compared to the weight of the solid phase, increase the degree of flocculation of a suspension. They act on a molecular level on the surfaces of the particles to reduce repulsive forces and increase attractive forces. The principal use of flocculating agents is to aid in making solid–liquid separations. flocculating agent Substance used to concentrate and obtain minerals from ores. flotation agent Substance used to promote the fusing of minerals or prevent oxide formation; for casting or joining materials. flux agent Materials used to enhance friction between two objects. friction agent Substance used to transmit or to remove heat from another material. heat transferring agent Substance used to admix with solid materials, which retain their original form. impregnation agent Substance that is used to emit electromagnetic radiation at high temperature. incandescent agent Chemical substances, usually in the form of a solid matrix, that are used to selectively remove targeted ions from a solution. In ion exchange, ions of a given charge (either cations or anions) in a solution are adsorbed on a solid material (the ion exchanger) and are replaced by equivalent quantities of other ions of the same charge released by the solid. ion exchange agent Substance that, when added to a solvent, aids in the dissolution of a component of an insoluble solid mixture. leaching agent Substance introduced between two moving surfaces or adjacent solid surface to reduce the friction between them, improve efficiency, reduce wear, and reduce heat generation; enhance the lubricity of other substances. These lubricating films are designed to minimize contact between the rubbing surfaces and to shear easily so that the frictional force opposing the rubbing motion is low. lubricating agent Substance that emits visible radiation upon absorption of energy in the form of photons, charged particles, or chemical change. luminescent agent Oxidizing agent is a substance that gains electrons during their reaction with a reducing agent. Oxidizing agents commonly contribute oxygen to other substances. oxidizing agent Maintains the desired pH range of a substance; used to alter, stabilize, or control the pH (hydrogen ion concentration). Substances used to alter or stabilize the hydrogen ion concentration (pH). pH regulating agent Substances/materials used as a source for a layer of metal deposited on another surface, or that aid in such a deposition. These are used in processes such as electroplating, galvanization or coating. plating agent Lubricating oil and grease additive that prevents metal to metal contact at high temperatures or under heavy loads where severe sliding conditions exist. Functions by reacting with the sliding metal surfaces to form oil-insoluble surface films. pressure transfer agent Substance that is used for expelling products from pressurized containers (aerosol products); used to dissolve or suspend other substances and either to expel those substances from a container in the form of an aerosol or to impart a cellular structure to plastics, rubber, or thermo set resins; provides the force necessary to expel the contents of aerosol containers; liquefied or compressed gas within which substances are dissolved or suspended and expelled from a container upon discharge of the internal pressure through expansion of the gas. The formulated product in the pressurized container may be solution, emulsion, or suspension. blowing agents Substance that reacts with and removes surface contaminants and is generally consumed, e.g., oxides, sulfides. removal agent Substance applied to substrates such as fabric, yarn, paper products, or plaster to increase abrasive resistance, stiffness, strength, smoothness, or reduce absorption. sizing agent Chemical substances used to promote the separation of suspended solids from a liquid. solids separation (precipitating) agent A substance that tends to keep a compound, solution, or mixture from changing its form or chemical nature; renders or maintains a solution, mixture, suspension, or state resistant to chemical change; used to prevent or slow down spontaneous changes in and ageing of materials. stabilizing agent Substance used for treating hides and skins. tanning agent Any of a variety of hydrophilic substances used to increase the viscosity of liquid mixtures and solutions and to aid in maintaining stability by their emulsifying properties.Four classifications are recognized: 1) Starches, gums, casein, gelatin and phycocolloids; 2) semisynthetic cellulose derivatives (e.g. carboxymethyl-cellulose); 3) polyvinyl alcohol and carboxy-vinylates (synthetic); and 4) bentonite, silicates, and colloidal silica. thickening agent A water repellent material functions by lowering the surface energy to protect surfaces against water by making water bead. waterproofing agent Substance that is applied to a substrate to protect it from heat by dissipating heat through the process of erosion, melting, or vaporization of the material. ablative An abrasive is a substance used to abrade, smooth, or polish an object. Abrasives are used to remove imperfections from a surface; used to smooth, scour, scrub, clean, wear down, or polish surfaces by rubbing against the surface; usually fine powders of hard substances. Examples include sandstones, pumice, quartz, silicates, aluminium oxides, and glass. abrasive Chemical substance used to retain other substances by assimilation. absorbent Any substance, inorganic or organic, natural or synthetic, used to join opposite surfaces to each other, promote bonding between other substances, promote adhesion of surfaces, or fasten other materials together. They are generally applied from a solvent solution and allowed to dry on the two facing surfaces. adhesion promotor Chemical substance used to retain other substances by accumulation on their surface; substance with a large surface area which can attract dissolved or finely dispersed substances from another medium. adsorbent Substance that influences the amount of air or gases entrained in a material. aerating and dearating agents Substances that are added to metals alloys like steel to modify its properties such as strength, hardness, or to facilitate its treatment. alloying element Substance that prevents or reduces the adhesion of a material to itself or to another material; prevents bonding between other substances by discouraging surface attachment; functions as the antitheses of adhesive. antiadhesive Material designed only to fill up a space, prevent seepage of moisture or air, passage of liquid or gas. The spaces can be joints, gaps or cavities that occur between two substrates. barrier Any cementitious material that is used to hold dry powders or aggregate together; added to compounded dry powder mixtures of solids to provide adhesive qualities during and after compression to make tablets or cakes; is soft at high temperatures and hard at room temperature. binder Substance intended for preventing, neutralizing, destroying, repelling, or mitigating the effects of any pest or microorganism; that inhibits the growth, reproduction, and activity of organisms, including fungal cells; decreases the number of fungi or pests present; deters microbial growth and degradation of other ingredients in the formulation. biocide Substance that is used to brighten, whiten, or enhance the appearance of colour of fabric and paper, usually by absorbing light in the ultraviolet and violet region (340-370 nm) of the electromagnetic spectrum, and re-emitting light in the blue region (420-470 nm). This causes a "whitening" effect by increasing the overall amount of blue light reflected. Optically colourless on the substrate and do not absorb in the visible part of the spectrum. brightener Substance that depresses the temperature at which solids begin to separate from a liquid, at a temperature lower than that normally allowed. cloud-point depressant Enables a reaction between two or more dissimilar polymers, allowing them to become more intimately mixed than before. compatibilizer Substance used to reduce or increase crystal growth. crystal growth modifiers Substance used to fluidize concentrated slurries to reduce their bulk viscosity or stickiness in processing or handling. deflocculant Chemical that is used to control foam; prevents foam from forming; breaks down any foam that does form; reduces foaming from proteins, gases, or nitrogenous materials. They reduce the tendency of finished products to generate foam on shaking or agitation. The ability of a material to act as an antifoam depends on its tendency to concentrate on the surface of existing or forming bubbles and to disrupt the continuous films of liquid surrounding them. As process aid, it improves filtration, dewatering, washing, and drainage of many types of suspensions, mixtures, and slurries. defoamer Substance used to destroy an emulsion or prevent its formation. demulsifier Substance that modifies the density of a material. density modifier Substance that reduces or eliminates unpleasant odour and protects against the formation of malodour on body surfaces. Counteraction, sometimes referred to as neutralization, occurs when two odorous substances are mixed in a given ratio and the resulting odour of the mixture is less intense than that of the separate components. deodorizer These substances, which speed the drying of paint, ink, etc., are often organometallic compounds. drier Substance used to control finely grained solid particles to reduce their discharge into the air. dust suppressant Substance that increases the elasticity of a material. elasticizer Substance characterized by chemical stability, but may be induced to undergo rapid chemical change without an outside source of oxygen, rapidly producing a large quantity of energy and gas accompanied by a large increase in volume and an explosion, bursting, or expansion. energy releasers Substance used to reduce the explosion potential of flammable materials. explosion inhibitor Chemical substance used to increase the productivity and quality of farm crops, including plants, animals, and forestry; added to soil to supply chemical elements needed for plant nutrition. fertilizers Any component of a material that aids the material in forming a thin continuous sheet on its substrate. This sheet will act as a barrier between the environment and its substrate. Silicone is a good film-former in furniture polishes because of its ease of application, soil removal, and depth of glossiness. Polymers are the most commonly used film formers. film former Substance that reduces drag in fluids in motion and between a fluid and a conduit surface. flow promoter Any substance that promotes or enhances formation of a lather or foam (i.e., a dispersion of a gas in a liquid or solid); used to form physically, by expansion of compressed gases or vaporization of liquid, or chemically, by decomposition evolving a gas, a foam or cellular structure in a plastic or rubber material. foamant Substance used in food or animal feedstuffs to produce or enhance taste or odour or nutritional value. Flavour compounds are molecules that stimulate the human taste chemical senses. food flavouring and nutrient These synthetic resin emulsions or synthetic lattices enable paints, coatings, and other products to retain original consistency and to resist coagulation when exposed to freezing and thawing prior to application. freeze-thaw additive Substance that influences the formation or destruction of a gel. gelling modifier Increases the strength, hardness, and abrasion resistance of coatings, adhesives, sealants, elastomers, and other products hardener Substance that protect polymers from the chemical degrading effects of heat or UV irradiation. heat stabilizer Liquid or gaseous chemical substances used for transmitting pressure and EP-additives. Transfer power in hydraulic machinery. hydraulic fluids Substances used to prevent or inhibit the flow of heat, electrical current, light, and the transmission of sound between two media. (acoustic, electrical, and thermal insulators). insulators Chemical substances consumed in a reaction in order to manufacture other chemical substances at an industrial processing facility. intermediate Substance added into materials in order to make them magnetic. magnetic element Substance usually containing carbon and of a low molecular weight and simple structure which is capable of conversion to polymers, synthetic resins, or elastomers by repetitive combination with itself or other similar molecules. monomers To be used in the cases where the substance does not fulfil any particular technical function during the use described (e.g. case where a processing aid remains in the matrix of an article without fulfilling any technical function during service life) no technical function Substance that renders solutions opaque; reduces transparency or the ability of light to pass through solution; added to finished products to reduce their clear or transparent appearance. opacifier Chemical substance used for its ability to alter its physical or chemical structure through absorption of light, resulting in the emission of light, dissociation, discoloration, or other chemical reaction; used to create a permanent photographic image. photochemical Chemical substance used to change the rate of a chemical reaction, start or stop the reaction, or otherwise influence the course of the reaction. May be consumed or become part of the reaction product. process regulator Chemical substances used to improve the processing characteristics or the operation of process equipment or to alter or buffer the pH of the substance or mixture, when added to a process or to a substance or mixture to be processed. Processing agents do not become a part of the reaction product and are not intended to affect the function of a substance or article created. processing aid Substances used within machines such as air conditioning units, refrigerators, and walk in freezers to cool indoor air and reduce temperatures. refrigerants Usually high molecular weight polymers that lower viscosity. Thermoplastic resins soften when exposed to heat and return to original form at room temperature, and thermosetting resins solidify irreversibly when heated due to cross-linking. resins Substance that has resistivity between that of insulators and metals; usually changeable by light, heat or electrical or magnetic field; generates electromotive force upon the incidence of radiant energy. semiconductor and photovoltaic agent Substance used for softening materials to improve feel, to facilitate finishing process, or to impart flexibility or workability; used in textile finishing to impart superior "hand" to the fabric and facilitate mechanical processing; has the capability of imparting softness and pliability to washable textile fabrics. softener A chemical additive that prevents chemicals or materials from separating or falling out of solution. Solubility enhancers are often used in concentrated formulations. solubility enhancer Substance that may be added to other ingredients to adjust the optical properties associated with the surface of a material. These substances are designed to affect the luster, increase gloss, and alter the reflectance exhibited by a surface. surface modifier Provides stickiness tackifier Substance that reacts with the end of a growing polymer chain, stopping further polymerization (terminator) or a substance used to protect a reactive moiety on a precursor during organic synthesis of a product that is subsequently removed regenerating the reactive moiety (blocker). terminator Substance that protects the product from chemical or physical deterioration induced by ultraviolet light; absorbs UV radiation, thereby protecting varnishes and pigments against UV degradation. UV stabilizer Substance added to a liquid to modify its vapour pressure (e.g., to reduce evaporation). vapour pressure modifiers The vehicle dissolves or disperses solid components of a substance, allowing even dispersion throughout application. The vehicle carries the other particles within a substance. vehicle Substance used to alter the viscosity of another substance; used to decrease or increase the viscosity of finished products; used to modify the flow characteristics of other substances, or mixtures, to which they are added; controls the deformation or flow ability of a wax product. Resins generally lower viscosity while thickeners (e.g., gums and hydroxyethyl cellulose) increase viscosity. viscosity modifier Substance use to block or attenuate X-rays. X-Ray Absorber Aerosol Characterisation Assay Alamar Blue assay dustiness assay Aspect of deposit barrier integrity assay batch dispersion assay biochem analysis inhalation biochemical analysis Biodistribution Blood counts cell counts PVP-coated TiO2 nanoparticle TiO2 PVP nanoparticle A titanium dioxide nanoparticle coated with poly(vinylpyrrolidone). poly(vinylpyrrolidone)-coated TiO2 nanoparticle colony forming efficiency (CFE) assay chromosomal damage in vitro coating_MALDI-TOF coating_STEM-EDS COMET - systemic genotoxicity composition_EDX composition ICP-OES Confocal Raman Microscopy (CRM) Cytokine secretion MPh Cytokine levels density assay DNA-damage lung Dustiness (large drum) assay Dustiness (other set-up) assay Dustiness (small drum) assay Dustiness (Vortex Shaker) assay effective density assay ICP-MS CHN analysis FACS analysis filtration_ICP-MS filtration_WDXRF functional groups_ATR-FTIR functional groups_TGA hCTA hemolysis histopathology hystopathology IBM Impedence_flow cytom isoElectric point LDH lung genotoxicity mass concentration Micronuclei - sistemic genotox Micronucleus mRNA expression in vivo MTS MW digestion + ICP-MS neutral red uptake assay NO production NP crossing ICP-OES NP crossing ToF-SIMS NP intracell pen(confocal micro NPs crossing TEM-SEM oral mucosa 3Dmodel penetration PIG-A sistemic genotox Polyclonal proliferation Potentiometry_H2O sosp RT- Impedence_adherence cell Serum cytokine Serum total antibodies size distribution size PTA size SAXS size TEM size and PSD sp-ICP-MS size_DLS size_WAXD size_XRD soil - C. Elegans TEER TEM observation TEM-SEM - intracell penetration ToF-SIMS water - algae - P.subcap water - fish - D Rerio water - microalgae - D. Magna WAXD XRD z-pot research organisation registry identifier lowest observed effects concentration LOEC A collection of weakly bound particles or aggregates where the resulting surface area is similar to the sum of the surface areas of the individual components. http://publications.jrc.ec.europa.eu/repository/bitstream/JRC73260/irmm_nanomaterials%20%28online%29.pdf agglomerate A composite particle, comprising of strongly bound or fused smaller particles, where the resulting external surface area may be significantly smaller than the sum of calculated surface areas of the individual components. Adapted from that given in http://publications.jrc.ec.europa.eu/repository/bitstream/JRC73260/irmm_nanomaterials%20%28online%29.pdf aggregate The propensity of a powder to become aerosolised by mechanical agitation. The dustiness of a particular sample is very dependent on its moisture content and static electrical properties. RSC technical brief on nanomaterial characterization dustiness Pour density requires the weighing of a known volume of freshly poured powder. RSC technical brief on nanomaterial characterization pour density A nanoparticle which is basically composed of aluminium oxide. aluminium oxide nanoparticle A nanoparticle which is basically composed of cerium oxide. cerium oxide nanoparticle Nanoclays are nanoparticles of layered mineral silicates. nanoclay A nanoparticle that is spherical and composed of polystyrene. polystyrene nanosphere An assay that measures the surface chemistry of an entity, e.g. of a nanoparticle. surface chemistry assay The date beyond which a substance is no longer regarded as fit for use. expiration date shelf life expiry date TNF assay tumor necrosis factor assay synonyms: triclinic hemihedral, C(1) triclinic-pedial wst-1 cell proliferation assay is a sensitive and accurate assay for cell proliferation and cytotoxicity. WST-1 An inorganic nanoparticle consisting of a metalloid (any element with properties that are intermediate between a metal and a non-metal; generally considered to include B, Si, Ge, As, Sb, and Te) metalloid nanoparticle Physicochemical Characterization A metallic nanoparticle that consists of copper. copper nanoparticle DNA Damage Assay Cell Membrane Integrity Assay A metallic nanoparticle that consists of germanium. germanium nanoparticle A metallic nanoparticle that consists of aluminum. aluminum nanoparticle A crystalline state that is one of the 7 basic crystal systems and the least symmetric of the 14 Bravais lattices. Characteristic for this system is that the three basis vectors are of unequal lengths and none of the angles between any two vectors is 90°. triclinic A metall oxide nanoparticle that consists of molybdenum trioxide. molybdenum trioxide nanoparticle A metal oxide nanoparticle that consists of cadmium (II) oxide. cadmium(II) oxide nanoparticle A metal oxide nanoparticle that consists of manganese (IV) dioxide. manganese (IV) dioxide nanoparticle Fullerenol is a fullerene with hydroxy groups. fullerenol nanoparticle A nanoparticle that consists of poly ethylen glycol (PEG). polyethylenglycol nanoparticle An inorganic nanoparticle that consists of tricalcium phosphate. tricalcium phosphate nanoparticle A crystalline state that is one of the 7 basic crystal systems. Characteristic for this system is that the three basis vectors are of unequal lengths and in which two of the vectors are perpendiular, while the third meeds the other two at an angle other than 90°. monoclinic synonyms: triclinic normal, C(i), S(2) triclinic-pinacoidal A crystalline state that is one of the 7 basic crystal systems. Characteristic for this system is that the three basis vectors are orthogonal but of unequal lengths. orthorhombic A crystalline state that is one of the 7 basic crystal systems. Characteristic for this system is that the three basis vectors are orthogonal and two of them are of equal length tetragonal The hexagonal-trigonal crystal system is one of 7 crystal systems. hexagonal-trigonal The hexagonal-hexagonal crystal system is one of 7 crystal systems. hexagonal-hexagonal Cubic (or isometric) crystal systems have the shape of a cube. cubic Bravais lattices are a system to describe crystal structures. Bravais lattice Space groups describe crystallic structures. space group Miller indices are a notation system in crystallography. Miller index synonyms: C(2) monoclinic-sphenoidal synonyms: C(1h), C(1v), C(s) monoclinic-domatic synonyms: C(2h) monoclinic-prismatic synonyms: D(2) orthorhombic-sphenoidal synonyms: C(2v) orthorhombic-pyramidal synonyms: D(2h) orthorhombic-bipyramidal synonyms: C(4) tetragonal-pyramidal synonyms: S(4) tetragonal-disphenoidal synonyms: C(4h) tetragonal-dipyramidal synonyms: D(4) tetragonal-trapezoidal A sequence of characters used to identify the premises where a measurement, sample, or experiment has been performed. Synonym: location identifier, measuring point identifier. premises identifier synonyms: C(4v) ditetragonal-pyramidal synonyms: D(2d) tetragonal-scalenoidal ditetragonal-dipyramidal synonyms: C(3h) trigonal-pyramidal synonyms: S(6), C(3i) rhombohedral synonyms: D(3) trigonal-trapezoidal synonyms: C(3v) ditrigonal-pyramidal synonyms: D(3d) ditrigonal-scalahedral synonyms: C(6) hexagonal-pyramidal synonyms: C(3h) trigonal-dipyramidal synonyms: C(6h) hexagonal-dipyramidal synonyms: D(6) hexagonal-trapezoidal synonyms: C(6v) dihexagonal-pyramidal synonyms: D(3h) ditrigonal-dipyramidal synonyms: D(6h) dihexagonal-dipyramidal synonyms: T tetrahedral synonyms: T(d) hextetrahedral synonyms: T(h) diploidal synonyms: O gyroidal synonyms: O(h) hexoctahedral A sequence of characters used to identify, name, or characterize the measurement. Measurements are part of a study. Synonym: assay ID, experiment ID measurement identifier A sequence of characters used to identify a sample. sample identifier The ability of a chemical substance to dissolve in a solid, liquid, or gaseous solvent to form a homogeneous solution. The solubility of a given substance is dependent on the solvent used, as well as on temperature and pressure. solubility endpoint NPO_1892 manganese nanoparticle Mn nanoparticle manganese nanoparticle ENM_9000074 JRCNM01000a JRCNM01000a ENM_9000075 JRCNM01001a JRCNM01001a ENM_9000076 JRCNM01002a JRCNM01002a ENM_9000077 JRCNM01005a JRCNM01005a ENM_9000078 JRCNM01100a JRCNM01100a ENM_9000079 JRCNM62101a JRCNM62101a ENM_9000080 JRCNM04000a JRCNM04000a ENM_9000081 JRCNM04001a JRCNM04001a The ability of a chemical substance to dissolve in some organic molecules. Solubility in organic solvents ENM_9000083 JRCNM01003a JRCNM01003a ENM_9000084 JRCNM01004a JRCNM01004a ENM_9000085 coated zinc oxide nanoparticle ENM_9000086 JRCNM01101a JRCNM01101a ENM_9000087 JRCNM02000a JRCNM02000a ENM_9000088 JRCNM02001a JRCNM02001a ENM_9000089 JRCNM02002a JRCNM02002a ENM_9000090 JRCNM02003a JRCNM02003a ENM_9000091 JRCNM02004a JRCNM02004a ENM_9000092 JRCNM02004b JRCNM02004b ENM_9000093 JRCNM10404 JRCNM10404 ENM_9000094 JRCNM10201a JRCNM10201a ENM_9000095 JRCNM62001a JRCNM62001a ENM_9000096 JRCNM62002a JRCNM62002a ENM_9000097 JRCNM03300a JRCNM03300a ENM_9000098 JRCNM03301a JRCNM03301a ENM_9000099 NM-103 coated titanium dioxide nanoparticle The boiling point of a substance is the temperature at which the vapor pressure of the liquid equals the pressure surrounding the liquid and the liquid changes into a vapor. The boiling point of a liquid varies depending upon the surrounding environmental pressure. boiling point Percential description of the particle size where it indicates the size at which 1% of the particles is smaller than this size. D1 Percential description of the particle size where it indicates the size at which 2% of the particles is smaller than this size. D2 Percential description of the particle size where it indicates the size at which 3% of the particles is smaller than this size. D3 Percential description of the particle size where it indicates the size at which 4% of the particles is smaller than this size. D4 Percential description of the particle size where it indicates the size at which 5% of the particles is smaller than this size. D5 Percential description of the particle size where it indicates the size at which 6% of the particles is smaller than this size. D6 Percential description of the particle size where it indicates the size at which 7% of the particles is smaller than this size. D7 Percential description of the particle size where it indicates the size at which 8% of the particles is smaller than this size. D8 Percential description of the particle size where it indicates the size at which 9% of the particles is smaller than this size. D9 Percential description of the particle size where it indicates the size at which 10% of the particles is smaller than this size. D10 Percential description of the particle size where it indicates the size at which 11% of the particles is smaller than this size. D11 Percential description of the particle size where it indicates the size at which 12% of the particles is smaller than this size. D12 Percential description of the particle size where it indicates the size at which 13% of the particles is smaller than this size. D13 Percential description of the particle size where it indicates the size at which 14% of the particles is smaller than this size. D14 Percential description of the particle size where it indicates the size at which 15% of the particles is smaller than this size. D15 Percential description of the particle size where it indicates the size at which 16% of the particles is smaller than this size. D16 Percential description of the particle size where it indicates the size at which 17% of the particles is smaller than this size. D17 Percential description of the particle size where it indicates the size at which 18% of the particles is smaller than this size. D18 Percential description of the particle size where it indicates the size at which 19% of the particles is smaller than this size. D19 Percential description of the particle size where it indicates the size at which 20% of the particles is smaller than this size. D20 Percential description of the particle size where it indicates the size at which 21% of the particles is smaller than this size. D21 Percential description of the particle size where it indicates the size at which 22% of the particles is smaller than this size. D22 Percential description of the particle size where it indicates the size at which 23% of the particles is smaller than this size. D23 Percential description of the particle size where it indicates the size at which 24% of the particles is smaller than this size. D24 Percential description of the particle size where it indicates the size at which 25% of the particles is smaller than this size. D25 Percential description of the particle size where it indicates the size at which 26% of the particles is smaller than this size. D26 Percential description of the particle size where it indicates the size at which 27% of the particles is smaller than this size. D27 Percential description of the particle size where it indicates the size at which 28% of the particles is smaller than this size. D28 Percential description of the particle size where it indicates the size at which 29% of the particles is smaller than this size. D29 Percential description of the particle size where it indicates the size at which 30% of the particles is smaller than this size. D30 Percential description of the particle size where it indicates the size at which 31% of the particles is smaller than this size. D31 Percential description of the particle size where it indicates the size at which 32% of the particles is smaller than this size. D32 Percential description of the particle size where it indicates the size at which 33% of the particles is smaller than this size. D33 Percential description of the particle size where it indicates the size at which 34% of the particles is smaller than this size. D34 Percential description of the particle size where it indicates the size at which 35% of the particles is smaller than this size. D35 Percential description of the particle size where it indicates the size at which 36% of the particles is smaller than this size. D36 Percential description of the particle size where it indicates the size at which 37% of the particles is smaller than this size. D37 Percential description of the particle size where it indicates the size at which 38% of the particles is smaller than this size. D38 Percential description of the particle size where it indicates the size at which 39% of the particles is smaller than this size. D39 Percential description of the particle size where it indicates the size at which 40% of the particles is smaller than this size. D40 Percential description of the particle size where it indicates the size at which 41% of the particles is smaller than this size. D41 Percential description of the particle size where it indicates the size at which 42% of the particles is smaller than this size. D42 Percential description of the particle size where it indicates the size at which 43% of the particles is smaller than this size. D43 Percential description of the particle size where it indicates the size at which 44% of the particles is smaller than this size. D44 Percential description of the particle size where it indicates the size at which 45% of the particles is smaller than this size. D45 Percential description of the particle size where it indicates the size at which 46% of the particles is smaller than this size. D46 Percential description of the particle size where it indicates the size at which 47% of the particles is smaller than this size. D47 Percential description of the particle size where it indicates the size at which 48% of the particles is smaller than this size. D48 Percential description of the particle size where it indicates the size at which 49% of the particles is smaller than this size. D49 Percential description of the particle size where it indicates the size at which 50% of the particles is smaller than this size. D50 Percential description of the particle size where it indicates the size at which 51% of the particles is smaller than this size. D51 Percential description of the particle size where it indicates the size at which 52% of the particles is smaller than this size. D52 Percential description of the particle size where it indicates the size at which 53% of the particles is smaller than this size. D53 Percential description of the particle size where it indicates the size at which 54% of the particles is smaller than this size. D54 Percential description of the particle size where it indicates the size at which 55% of the particles is smaller than this size. D55 Percential description of the particle size where it indicates the size at which 56% of the particles is smaller than this size. D56 Percential description of the particle size where it indicates the size at which 57% of the particles is smaller than this size. D57 Percential description of the particle size where it indicates the size at which 58% of the particles is smaller than this size. D58 Percential description of the particle size where it indicates the size at which 59% of the particles is smaller than this size. D59 Percential description of the particle size where it indicates the size at which 60% of the particles is smaller than this size. D60 Percential description of the particle size where it indicates the size at which 61% of the particles is smaller than this size. D61 Percential description of the particle size where it indicates the size at which 62% of the particles is smaller than this size. D62 Percential description of the particle size where it indicates the size at which 63% of the particles is smaller than this size. D63 Percential description of the particle size where it indicates the size at which 64% of the particles is smaller than this size. D64 Percential description of the particle size where it indicates the size at which 65% of the particles is smaller than this size. D65 Percential description of the particle size where it indicates the size at which 66% of the particles is smaller than this size. D66 Percential description of the particle size where it indicates the size at which 67% of the particles is smaller than this size. D67 Percential description of the particle size where it indicates the size at which 68% of the particles is smaller than this size. D68 Percential description of the particle size where it indicates the size at which 69% of the particles is smaller than this size. D69 Percential description of the particle size where it indicates the size at which 70% of the particles is smaller than this size. D70 Percential description of the particle size where it indicates the size at which 71% of the particles is smaller than this size. D71 Percential description of the particle size where it indicates the size at which 72% of the particles is smaller than this size. D72 Percential description of the particle size where it indicates the size at which 73% of the particles is smaller than this size. D73 Percential description of the particle size where it indicates the size at which 74% of the particles is smaller than this size. D74 Percential description of the particle size where it indicates the size at which 75% of the particles is smaller than this size. D75 Percential description of the particle size where it indicates the size at which 76% of the particles is smaller than this size. D76 Percential description of the particle size where it indicates the size at which 77% of the particles is smaller than this size. D77 Percential description of the particle size where it indicates the size at which 78% of the particles is smaller than this size. D78 Percential description of the particle size where it indicates the size at which 79% of the particles is smaller than this size. D79 Percential description of the particle size where it indicates the size at which 80% of the particles is smaller than this size. D80 Percential description of the particle size where it indicates the size at which 81% of the particles is smaller than this size. D81 Percential description of the particle size where it indicates the size at which 82% of the particles is smaller than this size. D82 Percential description of the particle size where it indicates the size at which 83% of the particles is smaller than this size. D83 Percential description of the particle size where it indicates the size at which 84% of the particles is smaller than this size. D84 Percential description of the particle size where it indicates the size at which 85% of the particles is smaller than this size. D85 Percential description of the particle size where it indicates the size at which 86% of the particles is smaller than this size. D86 Percential description of the particle size where it indicates the size at which 87% of the particles is smaller than this size. D87 Percential description of the particle size where it indicates the size at which 88% of the particles is smaller than this size. D88 Percential description of the particle size where it indicates the size at which 89% of the particles is smaller than this size. D89 Percential description of the particle size where it indicates the size at which 90% of the particles is smaller than this size. D90 Percential description of the particle size where it indicates the size at which 91% of the particles is smaller than this size. D91 Percential description of the particle size where it indicates the size at which 92% of the particles is smaller than this size. D92 Percential description of the particle size where it indicates the size at which 93% of the particles is smaller than this size. D93 Percential description of the particle size where it indicates the size at which 94% of the particles is smaller than this size. D94 Percential description of the particle size where it indicates the size at which 95% of the particles is smaller than this size. D95 Percential description of the particle size where it indicates the size at which 96% of the particles is smaller than this size. D96 Percential description of the particle size where it indicates the size at which 97% of the particles is smaller than this size. D97 Percential description of the particle size where it indicates the size at which 98% of the particles is smaller than this size. D98 Percential description of the particle size where it indicates the size at which 99% of the particles is smaller than this size. D99 iron nanoparticle Fe nanoparticle iron nanoparticle ENM_9000201 NM-100 ENM_9000202 NM-101 ENM_9000203 NM-102 ENM_9000204 NM-105 NM-105 ENM_9000205 NM-110 ENM_9000206 NM-400 ENM_9000207 NM-401 ENM_9000208 NM-103 ENM_9000209 NM-104 ENM_9000210 NM-111 ENM_9000211 NM-200 ENM_9000212 NM-201 ENM_9000213 NM-202 ENM_9000214 NM-203 ENM_9000215 NM-204 ENM_9000216 JRCNM40001a JRCNM40001a NM-330 ENM_9000217 JRCNM40002a JRCNM40002a NM-330 DIS ENM_9000218 JRCNM40003a JRCNM40003a ENM_9000219 JRCNM40004a JRCNM40004a ENM_9000220 JRCNM40005a JRCNM40005a ENM_9000221 JRCNM40006a JRCNM40006a ENM_9000222 JRCNM40007a JRCNM40007a ENM_9000223 JRCNM40008a JRCNM40008a ENM_9000224 JRCNM40009a JRCNM40009a ENM_9000225 JRCNM40010a JRCNM40010a ENM_9000226 NM-211 ENM_9000227 NM-212 ENM_9000228 NM-213 ENM_9000229 NM-402 ENM_9000230 NM-403 ENM_9000231 JRCNM10200a ENM_9000232 JRCNM10202a ENM_9000233 NM-600 ENM_9000234 JRCNM06000a ENM_9000235 NM-300 ENM_9000236 NM-300K ENM_9000237 JRCNM02101a ENM_9000238 JRCNM02102a Mitsui MWCNT-7 Mitsui MWCNT-7 NM-220 BaSO4 nanoparticle NM-220 A metal oxide nanoparticle that consists of zirconium (IV) dioxide. zirconium (IV) dioxide nanoparticle A core in which impurities have been intentionally introduced. doped core A nanocrystal particle made up from cellulose. cellulose nanocrystal selenium nanoparticle Se nanoparticle selenium nanoparticle titanium nanoparticle Ti nanoparticle titanium nanoparticle copper sulfide nanoparticle CuS nanoparticle copper sulfide nanoparticle bismuth nanoparticle Bi nanoparticle bismuth nanoparticle cobalt nanoparticle Co nanoparticle cobalt nanoparticle PLGA nanoparticle γ-poly(L-glutamic acid) polymer nanoparticle PLGA nanoparticle cadmium oxide nanoparticle CdO polymer nanoparticle cadmium oxide nanoparticle manganese oxide nanoparticle MnO polymer nanoparticle manganese oxide nanoparticle magnesium oxide nanoparticle MgO polymer nanoparticle magnesium oxide nanoparticle molybdenum nanoparticle Mo nanoparticle molybdenum nanoparticle cobalt oxide nanoparticle Co3O4 nanoparticle cobalt oxide nanoparticle ENM_9000255 JRCNM03000a ENM_9000256 JRCNM50001a ENM_9000257 tungsten carbide nanoparticle Assay measuring the surface reactivity of nanomaterials under physiological conditions to determine their dose-dependent oxidative damage FRAS Ferric Reduction Ability of Serum Cell proliferation assay used to assess cytotoxicity. It measures the extracellular conversion of tetrazolium salt WST-8 to formazan products by intracellular mitochondrial oxidoreductases in viable cells. WST-8 WST-8 Cell Proliferation Assay Pulmonary exposure is performed by instillation of test substance dispersed in a liquid vehicle. The liquid is delivered/blown into the lungs of sedated animals. The exposure is a bolus exposure and the dose is delivered within seconds. Pulmonary instillation Assay used to separate proteins according to their electrophoretic mobility, which is a function of their dimensions, conformation and charge. SDS-PAGE assay Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) assay Bioassay which measures the opposition to the flow of electrical current (impedance) through tissues, cell monolayers and single cells when an external alternating current (AC) field is applied. This assay is label-free and constitutes a reliable alternative with the potential to become a method of choice for the initial screening of toxic effects in nanomaterials. Impedance-based monitoring takes advantage of the passive properties of an object, which occur when the object is composed of dissipative elements, such as ohmic resistors or conservative elements, such as capacitances and inductances . It measures the opposition to the flow of electrical current (impedance) through tissues, cell monolayers and single cells when an external alternating current (AC) field is applied. Bioimpedance assay Impedance-based cell assay Optical system that uses laser diffraction to measure particle size. Mastersizer Malvern Zetasizer BFO:0000001 entity Entity Julius Caesar Verdi’s Requiem the Second World War your body mass index BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81 Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) entity Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf per discussion with Barry Smith An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) BFO:0000015 process Process a process of cell-division, \ a beating of the heart a process of meiosis a process of sleeping the course of a disease the flight of a bird the life of an organism your process of aging. A process is an entity that exists in time by occurring or happening, has temporal parts and always involves and depends on some entity during the time it occurs. An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) James Malone (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] http://www.ebi.ac.uk/efo/EFO_0001433 true An occurrent [span:Occurrent] that exists in time by occurring or happening, has temporal parts and always involves and depends on some entity. http://www.ifomis.org/bfo/1.1/span#ProcessualEntity NCIt:C29862 SNOMEDCT:415178003 process process p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] BFO:0000016 disposition Disposition an atom of element X has the disposition to decay to an atom of element Y certain people have a predisposition to colon cancer children are innately disposed to categorize objects in certain ways. the cell wall is disposed to filter chemicals in endocytosis and exocytosis BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] disposition b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] BFO:0000019 quality Quality the ambient temperature of this portion of air the color of a tomato the length of the circumference of your waist the mass of this piece of gold. the shape of your nose the shape of your nostril A quality is an entity that describes some aspect which is intrinsic to that particular object and is dependent on or more material entities in which it inheres in or is borne by. Example the color of a tomato, the ambient temperature of air, the circumference of a waist, the shape of a nose, the mass of a piece of gold, the weight of a chimpanzee James Malone a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] http://www.ebi.ac.uk/efo/EFO_0001436 true A specifically dependent continuant [snap:SpecificallyDependentContinuant] that is exhibited if it inheres in an entity or entities at all (a categorical property). http://www.ifomis.org/bfo/1.1/snap#Quality NCIt:C25283 SNOMEDCT:263496004 Definition: A specifically dependent continuant [snap:SpecificallyDependentContinuant] that is exhibited if it inheres in an entity or entities at all (a categorical property). Examples: the color of a tomato, the ambient temperature of air, the circumference of a waist, the shape of a nose, the mass of a piece of gold, the weight of a chimpanzee quality quality a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] BFO:0000034 function Function the function of a hammer to drive in nails the function of a heart pacemaker to regulate the beating of a heart through electricity the function of amylase in saliva to break down starch into sugar BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc. A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] function A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] BFO:0000040 material MaterialEntity material entity a flame a forest fire a human being a hurricane a photon a puff of smoke a sea wave a tornado an aggregate of human beings. an energy wave an epidemic the undetached arm of a human being An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time. BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] material entity material entity A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] Established from a human primary embryonal kidney transformed by adenovirus type 5. BrendaTissueOBO 293 cell A-293 cell A293 cell HEK cell HEK293 cell human embryonal kidney cell human embryonic kidney cell BTO:0000007 HEK-293 cell BTO:0000007 Human lung carcinoma established from an explanted lung tumor which was removed from a 58-year-old Caucasian man in 1972; cells were described to induce tumors in athymic mice and to synthesize lecithin. BrendaTissueOBO A549 cell NCI-A549 cell BTO:0000018 A-549 cell BTO:0000018 Malignant tumour cell of lymphoblasts derived from B-lymphocytes. Most commonly affects children in tropical Africa: both Epstein-Barr virus and immunosuppression due to malarial infection are involved. BrendaTissueOBO African lymphoma cell Burkitt's lymphoma cell Burkitts lymphoma cell BTO:0000164 Burkitt lymphoma cell BTO:0000164 BTO:0000256 Cell lines derived from myoblast cells BrendaTissueOBO myoblast cell line The part of the large intestine that extends from the cecum to the rectum. BrendaTissueOBO BTO:0000269 colon BTO:0000269 The part of the large intestine that extends from the cecum to the rectum. From_Merriam-Webster's_Online_Dictionary_at_www.Merriam-Webster.com:http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=colon The thin muscle below the lungs and heart that separates the chest from the abdomen. BrendaTissueOBO diaphragm muscle midriff phren thoracic diaphragm BTO:0000341 diaphragm BTO:0000341 The thin muscle below the lungs and heart that separates the chest from the abdomen. Cancer.gov_Dictionary:http://www.nci.nih.gov/dictionary BTO:0000383 RCC cell line hypernephroma cell line kidney adenocarcinoma cell line renal cell adenocarcinoma cell line renal cell carcinoma cell line Cell line of a malignant neoplasm of the bone-forming tissues. BrendaTissueOBO osteoblastic sarcoma cell line osteogenic sarcoma cell line BTO:0000407 osteosarcoma cell line BTO:0000407 BrendaTissueOBO brain tumor cell line BTO:0000690 brain cancer cell line BTO:0000690 A cell line of leukemia characterized by proliferation of myeloid tissue (as of the bone marrow and spleen) and an abnormal increase in the number of granulocytes, myelocytes, and myeloblasts in the circulating blood. BrendaTissueOBO granulocytic leukemia cell line myelocytic leukemia cell line myelogenous leukemia cell line BTO:0000740 myeloid leukemia cell line BTO:0000740 1: A large very vascular glandular organ of vertebrates that secretes bile and causes important changes in many of the substances contained in the blood (as by converting sugars into glycogen which it stores up until required and by forming urea). 2: Any of various large compound glands associated with the digestive tract of invertebrate animals and probably concerned with the secretion of digestive enzymes. BrendaTissueOBO BTO:0000759 liver BTO:0000759 1: A large very vascular glandular organ of vertebrates that secretes bile and causes important changes in many of the substances contained in the blood (as by converting sugars into glycogen which it stores up until required and by forming urea). 2: Any of various large compound glands associated with the digestive tract of invertebrate animals and probably concerned with the secretion of digestive enzymes. From_Merriam-Webster's_Online_Dictionary_at_www.Merriam-Webster.com:http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=liver One of the usually paired compound saccular thoracic organs that constitute the basic respiratory organ of air-breathing vertebrates. BrendaTissueOBO lung parenchyma parenchyma of lung BTO:0000763 lung BTO:0000763 One of the usually paired compound saccular thoracic organs that constitute the basic respiratory organ of air-breathing vertebrates. From_Merriam-Webster's_Online_Dictionary_at_www.Merriam-Webster.com:http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=lung BrendaTissueOBO colon cancer cell line colon carcinoma cell line colonic carcinoma cell line BTO:0000797 colonic cancer cell line BTO:0000797 BTO:0000849 melanoma cell line A mixture of monocytes and lymphocytes; blood leucocytes from which granulocytes have been separated and removed. BrendaTissueOBO PBM cell PBMC PBMC cell BTO:0001025 peripheral blood mononuclear cell BTO:0001025 A mixture of monocytes and lymphocytes; blood leucocytes from which granulocytes have been separated and removed. The_Dictionary_of_Cell_and_Molecular_Biology:Third_Edition Mouse, BALB/c, blood, not defined tumor cell line. Recloned from J774.1 original ascites and solid tumour. Produces IL-1. BrendaTissueOBO BTO:0001030 J774.2 cell BTO:0001030 BrendaTissueOBO CaP cell CaP cell line PCa cell PCa cell line prostate carcinoma cell line prostate gland cancer cell line prostate tumor cell line BTO:0001033 prostate cancer cell line BTO:0001033 Mouse, BALB/cxNZB F1, lymphoblastic lymphoma cell line. Morphology: Lymphoblast Mouse B cell lymphoma. BrendaTissueOBO BTO:0001093 WEHI-231 cell BTO:0001093 BrendaTissueOBO PAEC cell BTO:0001141 pulmonary artery endothelial cell BTO:0001141 Rat, nervous system, immature, Schwann cell derived cell line. BrendaTissueOBO D6P2T cell BTO:0001205 RT4-D6P2T cell BTO:0001205 The cord of nervous tissue that extends from the brain lengthwise along the back in the vertebral canal, gives off the pairs of spinal nerves, carries impulses to and from the brain, and serves as a center for initiating and coordinating many reflex acts. BrendaTissueOBO medulla spinalis spinal medulla BTO:0001279 spinal cord BTO:0001279 The cord of nervous tissue that extends from the brain lengthwise along the back in the vertebral canal, gives off the pairs of spinal nerves, carries impulses to and from the brain, and serves as a center for initiating and coordinating many reflex acts. From_Merriam-Webster's_Online_Dictionary_at_www.Merriam-Webster.com:http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=spinal+cord BTO:0001516 Mouse pro B cell line. IL-3 dependent murine pro B cell line established from peripheral blood; apparently derived from BALB/c mouse. BA/F3 cell BrendaTissueOBO B-cell lymphoma cell line BTO:0001518 B-lymphoma cell line BTO:0001518 BrendaTissueOBO CRC cell line BTO:0001616 colorectal cancer cell line BTO:0001616 Human, blood, leukemia, T cell line, clone E6.1. ATCC:TIB-152 Jurkat E6.1 Jurkat cell E-6.1 Jurkat cell E6.1 TIB-152 BrendaTissueOBO JURKAT E-61 cell BTO:0001948 This is a pseudodiploid human cell line. The modal chromosome number is 46, occurring in 74% with polyploidy at 5.3%. The karyotype is 46,XY,-2,-18,del(2) (p21p23),del(18) (p11.2). Most cells had normal X and Y chromosomes. JURKAT E-6.1 cell BTO:0001948 BrendaTissueOBO cervical carcinoma cell line cervix cancer cell BTO:0001967 cervical cancer cell line BTO:0001967 BTO:0002178 "Human Mammary Epithelial Cells (HMEpC) are derived from normal adult mammary glands." [Cell Applications Inc.:http\://cellapplications.com/] BrendaTissueOBO HMEC cell human mammary epithelial cell HMEpC cell BTO:0002179 "The 184A1N4 and 184B5 cell lines are nontumorigenic cell lines derived from primary cultures of HMECs that were immortalized with benzo(a)pyrene." [PMID:15827326] BrendaTissueOBO A1N4 cell 184A1N4 cell BTO:0002180 "The 184A1N4 and 184B5 cell lines are nontumorigenic cell lines derived from primary cultures of HMECs that were immortalized with benzo(a)pyrene." [PMID:15827326] BrendaTissueOBO 184B5 cell BrendaTissueOBO BTO:0002278 macrophage cell line BTO:0002278 Mouse macrophage cell line. BrendaTissueOBO J774 cell BTO:0002279 J-774 cell BTO:0002279 BrendaTissueOBO BTO:0002488 uterine leiomyosarcoma cell line BTO:0002488 BTO:0002599 "Rat brain-derived type-2 astrocyte cell line." [PMID:14575868] BrendaTissueOBO RBA-2 cell BrendaTissueOBO MDDC cell BTO:0002900 monocyte-derived dendritic cell BTO:0002900 A normal cell of the bronchial epithelium. BrendaTissueOBO bronchial epithelium cell BTO:0002922 bronchial epithelial cell BTO:0002922 A normal cell of the bronchial epithelium. curators:mg Human pulmonary artery endothelial cell line. BrendaTissueOBO human pulmonary artery endothelial cell BTO:0003151 HPAEC cell BTO:0003151 Human pulmonary artery endothelial cell line. PMID:18373958 BrendaTissueOBO colon epithelial cell line colonic epithelial cell line BTO:0003250 colonic epithelium cell line BTO:0003250 A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineage; established from an adult female Jackson Laboratory-inbred C57BLy6J mouse. BrendaTissueOBO HL1 cell BTO:0003264 HL-1 cell BTO:0003264 BTO:0003699 The HLA-A,B negative mutant cell line C1R is widely used as a transfection recipient in functional studies of class I MHC genes. It was derived from a normal B cell line. C1R cell BTO:0004059 Human normal colon fibroblast cell line established from a black 2.5-months-old human female. CCD-18Co cell BTO:0004263 "A differentiating cell line, established from the mouse myoblastic cell line C2C12." [PMID:9227903] BrendaTissueOBO COM3 cell COM-3 cell BTO:0004264 "A non-differentiating cell line, established from the mouse myoblastic cell line C2C12." [PMID:9227903] BrendaTissueOBO INC2 cell INC-2 cell Human esophageal cell line; derived in 1986 from human esophageal autopsy tissue by transfection with plasmid pRSV-T consisting of the RSV-LTR promoter and the sequence encoding the simian virus 40 large T-antigen. Marion 2010-02-02T02:40:45Z BrendaTissueOBO HET1A cell BTO:0004433 HET-1A cell BTO:0004433 Human esophageal cell line; derived in 1986 from human esophageal autopsy tissue by transfection with plasmid pRSV-T consisting of the RSV-LTR promoter and the sequence encoding the simian virus 40 large T-antigen. ATCC_American_Cell_Type_Culture_Collection:http://www.lgcstandards-atcc.org/ Human aortic endothelial cell line. mgr 2010-04-13T09:34:08Z BrendaTissueOBO HAEC cell BTO:0004602 human aortic endothelial cell BTO:0004602 Human aortic endothelial cell line. Invitrogen:http://products.invitrogen.com/ Mouse embryonic stem cell line. XPMUser 2011-05-11T10:03:05Z BrendaTissueOBO E-14 cell E14 cell BTO:0005136 ES-E14 cell BTO:0005136 Established melanoma cell line from the Skin Cancer Unit at the German Cancer Research Center, Heidelberg. XPMUser 2012-03-23T09:11:06Z BrendaTissueOBO BTO:0005339 Ma-Mel-11 cell BTO:0005339 A dopamine agonist that binds to and activates the dopamine receptor D1. Wikipedia:Dopamine_receptor_D1 chebi_ontology D1 agonist D1 agonists dopamine D1 receptor agonist dopamine D1 receptor agonists dopamine receptor D1 agonists CHEBI:131795 dopamine receptor D1 agonist CHEBI:131795 D1 agonist ChEBI D1 agonists ChEBI dopamine D1 receptor agonist ChEBI dopamine D1 receptor agonists ChEBI dopamine receptor D1 agonists ChEBI An inorganic nanoparticle consisting of cobalt cations and phosphide(3-) anions. Depending on the method of preparation, the formula can vary from CoP through Co3P2 to Co2P. PMID:25856205 chebi_ontology CHEBI:131895 cobalt phosphide nanoparticle CHEBI:131895 PMID:25856205 Europe PMC A nanoparticle consisting of tungsten atoms. PMID:24643208 PMID:25269307 chebi_ontology CHEBI:131897 tungsten nanoparticle CHEBI:131897 PMID:24643208 Europe PMC PMID:25269307 Europe PMC A bimetallic nanoparticle consisting of platinum and copper atoms. chebi_ontology CHEBI:131898 platinum copper nanoparticle CHEBI:131898 A compound used with herbicides that reduces the effect of the herbicide on crop plants or otherwise improves the selectivity of the herbicide for weed species over the crop plant. PMID:12222792 PMID:23564986 Wikipedia:Herbicide_safener chebi_ontology herbicide safeners CHEBI:132272 herbicide safener CHEBI:132272 PMID:12222792 Europe PMC PMID:23564986 Europe PMC herbicide safeners ChEBI A reagent that lightens or whitens a substrate through chemical reaction. Bleaching reactions usually involve oxidative or reductive processes that degrade colour systems. Bleaching can occur by destroying one or more of the double bonds in the conjugated chain, by cleaving the conjugated chain, or by oxidation of one of the other moieties in the conjugated chain. Their reactivity results in many bleaches having strong bactericidal, disinfecting, and sterilising properties. Wikipedia:Bleach chebi_ontology CHEBI:132717 bleaching agent CHEBI:132717 CHEBI:132889 A single carbon layer of the graphite oxide structure. PMCID:PMC8540551 PMCID:PMC8582055 PMCID:PMC8585176 PMID:20023850 PMID:33668189 PMID:34270266 PMID:34327598 PMID:34371431 PMID:34443964 PMID:34668901 chebi_ontology GO CHEBI:132889 graphene oxide CHEBI:132889 PMCID:PMC8540551 Europe PMC PMCID:PMC8582055 Europe PMC PMCID:PMC8585176 Europe PMC PMID:20023850 Europe PMC PMID:33668189 Europe PMC PMID:34270266 Europe PMC PMID:34327598 Europe PMC PMID:34371431 Europe PMC PMID:34443964 Europe PMC PMID:34668901 Europe PMC GO ChEBI A drug that makes increases the sensitivity of tumour cells to radiation therapy. PMID:12520460 Wikipedia:Radiosensitizer chebi_ontology radiosensitiser radiosensitisers radiosensitising agent radiosensitising agents radiosensitizer radiosensitizers radiosensitizing agents CHEBI:132992 radiosensitizing agent CHEBI:132992 PMID:12520460 Europe PMC radiosensitiser ChEBI radiosensitisers ChEBI radiosensitising agent ChEBI radiosensitising agents ChEBI radiosensitizer ChEBI radiosensitizers ChEBI radiosensitizing agents ChEBI CHEBI:133326 A metal sulfate with formula BaO4S. Virtually insoluble in water at room temperature, it is mostly used as a component in oil well drilling fluid it occurs naturally as the mineral barite. 0 BaO4S InChI=1S/Ba.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2 TZCXTZWJZNENPQ-UHFFFAOYSA-L 233.391 233.85698 [O-]S([O-])(=O)=O.[Ba+2] CAS:7727-43-7 KEGG:D02052 PMID:22831859 PMID:25710096 PMID:26903568 Reaxys:11343139 Wikipedia:Barium_sulfate barium sulfate chebi_ontology BaSO4 Baritop Barosperse Barotrast E-Z-Paque Enamel White EneCat EneMark EntroBar Esophotrast Liquipake Macropaque Micropaque Microtrast Pigment White 22 Radiobaryt Radiopaque Readi-CAT barite blanc fixe sulfuric acid, barium salt (1:1) CHEBI:133326 barium sulfate CHEBI:133326 CAS:7727-43-7 ChemIDplus PMID:22831859 Europe PMC PMID:25710096 Europe PMC PMID:26903568 Europe PMC Reaxys:11343139 Reaxys barium sulfate IUPAC BaSO4 ChEBI Baritop ChemIDplus Barosperse ChemIDplus Barotrast ChemIDplus E-Z-Paque ChemIDplus Enamel White ChemIDplus EneCat ChemIDplus EneMark ChemIDplus EntroBar ChemIDplus Esophotrast ChemIDplus Liquipake ChemIDplus Macropaque ChemIDplus Micropaque ChemIDplus Microtrast ChemIDplus Pigment White 22 ChemIDplus Radiobaryt ChemIDplus Radiopaque ChemIDplus Readi-CAT ChemIDplus barite ChemIDplus blanc fixe ChemIDplus sulfuric acid, barium salt (1:1) ChemIDplus A mixed metal oxide with formula Fe2NiO4. 0 Fe2NiO4 InChI=1S/2Fe.Ni.4O NQNBVCBUOCNRFZ-UHFFFAOYSA-N 234.381 233.78487 [Fe](=O)O[Ni]O[Fe]=O PMID:23622034 PMID:26199745 PMID:27374991 chebi_ontology Ni(II)Fe(III)2O4 NiFe2O4 CHEBI:133333 nickel ferrite CHEBI:133333 PMID:23622034 Europe PMC PMID:26199745 Europe PMC PMID:27374991 Europe PMC Ni(II)Fe(III)2O4 ChEBI NiFe2O4 ChEBI A mixed metal oxide with formula Fe2O4Zn. 0 Fe2O4Zn InChI=1S/2Fe.4O.Zn WGEATSXPYVGFCC-UHFFFAOYSA-N 241.083 239.77867 [Fe](=O)O[Zn]O[Fe]=O CAS:12063-19-3 Reaxys:23151227 Wikipedia:Zinc_ferrite chebi_ontology ZnFe2O4 diiron zinc tetraoxide iron zinc oxide zinc iron oxide CHEBI:133337 zinc ferrite CHEBI:133337 CAS:12063-19-3 ChemIDplus Reaxys:23151227 Reaxys ZnFe2O4 ChEBI diiron zinc tetraoxide ChemIDplus iron zinc oxide ChemIDplus zinc iron oxide ChemIDplus A (1->4)-beta-D-glucan consisting of elementary cellulose fibrils or their bundles, whose diameter lies typically in the range of 20-40 nm, but may be as small as 3-10 nm. The fibrils can exceed 1 mum in length. PMID:21395236 PMID:22750440 PMID:22994958 PMID:24512093 PMID:25837659 PMID:26150482 Wikipedia:Nanocellulose chebi_ontology NFC cellulose nanofibers cellulose nanofibres microfibrillar cellulose microfibrillated cellulose nanocellulose nanofibrillated cellulose CHEBI:133349 nanofibrillar cellulose CHEBI:133349 PMID:21395236 Europe PMC PMID:22750440 Europe PMC PMID:22994958 Europe PMC PMID:24512093 Europe PMC PMID:25837659 Europe PMC PMID:26150482 Europe PMC NFC ChEBI cellulose nanofibers ChEBI cellulose nanofibres ChEBI microfibrillar cellulose ChEBI microfibrillated cellulose ChEBI nanocellulose ChEBI nanofibrillated cellulose ChEBI The non-crystalline allotrope of elemental silicon. It is used as semiconductor material in thin-film transistors. PMID:23581344 PMID:23898166 PMID:24577075 PMID:24922389 PMID:26028125 PMID:26523743 PMID:26621791 Wikipedia:Amorphous_silicon chebi_ontology a-Si silicon (amorphous) CHEBI:133352 amorphous silicon CHEBI:133352 PMID:23581344 Europe PMC PMID:23898166 Europe PMC PMID:24577075 Europe PMC PMID:24922389 Europe PMC PMID:26028125 Europe PMC PMID:26523743 Europe PMC PMID:26621791 Europe PMC a-Si ChEBI silicon (amorphous) ChEBI An aluminosilicate mineral consisting mostly of montmorillonite. The different types of bentonite (aluminium bentonite; calcium bentonite; potassium bentonite; sodium bentonite) are named after their dominant element. CAS:1302-78-9 Reaxys:8194168 Wikipedia:Bentonite chebi_ontology CHEBI:133354 bentonite CHEBI:133354 CAS:1302-78-9 ChemIDplus Reaxys:8194168 Reaxys Any form of carbon black which has a particle size of less than 100 nm in each dimension. PMCID:PMC3190904 PMID:21525001 PMID:22753103 PMID:24078381 PMID:24283474 PMID:25056782 PMID:25071917 PMID:25184212 PMID:25451823 PMID:25833640 PMID:25966413 PMID:26066782 PMID:26551751 PMID:26914170 PMID:27460290 PMID:27534448 chebi_ontology carbon black nanoparticles CHEBI:133602 carbon black nanoparticle CHEBI:133602 PMCID:PMC3190904 Europe PMC PMID:21525001 Europe PMC PMID:22753103 Europe PMC PMID:24078381 Europe PMC PMID:24283474 Europe PMC PMID:25056782 Europe PMC PMID:25071917 Europe PMC PMID:25184212 Europe PMC PMID:25451823 Europe PMC PMID:25833640 Europe PMC PMID:25966413 Europe PMC PMID:26066782 Europe PMC PMID:26551751 Europe PMC PMID:26914170 Europe PMC PMID:27460290 Europe PMC PMID:27534448 Europe PMC carbon black nanoparticles ChEBI A role borne by a molecule that acts to counteract or neutralise the deleterious effects of barbiturates. PMID:15432128 chebi_ontology antidote to barbiturate overdose CHEBI:134173 antidote to barbiturate poisoning CHEBI:134173 PMID:15432128 Europe PMC antidote to barbiturate overdose ChEBI An inorganic nanoparticle consisting of copper(II) oxide. chebi_ontology Cu2O nanoparticle copper(I) oxide nanoparticle CHEBI:134402 cuprous oxide nanoparticle CHEBI:134402 Cu2O nanoparticle ChEBI copper(I) oxide nanoparticle ChEBI A nanoparticle composed of poly(styrene). chebi_ontology polystyrene nanoparticle CHEBI:134403 poly(styrene) nanoparticle CHEBI:134403 polystyrene nanoparticle ChEBI A nanoparticle composed of graphene. PMID:24674462 PMID:24854092 PMID:24983698 PMID:26317666 PMID:26731007 chebi_ontology CHEBI:134404 graphene nanoparticle CHEBI:134404 PMID:24674462 Europe PMC PMID:24854092 Europe PMC PMID:24983698 Europe PMC PMID:26317666 Europe PMC PMID:26731007 Europe PMC A nanoparticle consisting of titanium(III) oxide. 0 O3Ti2 InChI=1S/3O.2Ti GQUJEMVIKWQAEH-UHFFFAOYSA-N 143.732 143.88063 [Ti](=O)O[Ti]=O chebi_ontology Ti2O3 nanoparticle CHEBI:134440 titanium(III) oxide nanoparticle CHEBI:134440 Ti2O3 nanoparticle ChEBI A nanoparticle composed of any titanium oxide. chebi_ontology CHEBI:134441 titanium oxide nanoparticle CHEBI:134441 A prodrug that, on administration, undergoes chemical conversion by biochemical (enzymatic), chemical (possibly following an enzymatic step), or physical (e.g. photochemical) activation processes before becoming the pharmacologically active pesticide for which it is a propesticide. AGR:IND84086009 PMID:26449612 chebi_ontology pro-pesticide pro-pesticides propesticides CHEBI:136643 propesticide CHEBI:136643 AGR:IND84086009 Europe PMC PMID:26449612 Europe PMC pro-pesticide ChEBI pro-pesticides ChEBI propesticides ChEBI A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active insecticide for which it is a proinsecticide. AGR:IND20386178 AGR:IND84086011 AGR:IND89021681 AGR:IND92003154 PMID:16172027 PMID:26449612 PMID:27414472 PMID:27976502 chebi_ontology pro-insecticide pro-insecticides proinsecticides CHEBI:136644 proinsecticide CHEBI:136644 AGR:IND20386178 Europe PMC AGR:IND84086011 Europe PMC AGR:IND89021681 Europe PMC AGR:IND92003154 Europe PMC PMID:16172027 Europe PMC PMID:26449612 Europe PMC PMID:27414472 Europe PMC PMID:27976502 Europe PMC pro-insecticide ChEBI pro-insecticides ChEBI proinsecticides ChEBI A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active fungicide for which it is a profungicide. PMID:11929539 PMID:25746994 PMID:26449612 chebi_ontology pro-fungicide pro-fungicides profungicides CHEBI:136645 profungicide CHEBI:136645 PMID:11929539 Europe PMC PMID:25746994 Europe PMC PMID:26449612 Europe PMC pro-fungicide ChEBI pro-fungicides ChEBI profungicides ChEBI A compound that, on administration, must undergo chemical conversion by biochemical (enzymatic), chemical (possibly following an enzymatic step), or physical (e.g. photochemical) activation processes before becoming the pharmacologically active herbicide for which it is a proherbicide. AGR:IND43789627 PMID:12232216 PMID:26449612 PMID:27280658 chebi_ontology pro-herbicide pro-herbicides proherbicides CHEBI:136646 proherbicide CHEBI:136646 AGR:IND43789627 Europe PMC PMID:12232216 Europe PMC PMID:26449612 Europe PMC PMID:27280658 Europe PMC pro-herbicide ChEBI pro-herbicides ChEBI proherbicides ChEBI A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active insecticide for which it is a proacaricide. PMID:17046600 PMID:19330529 PMID:26449612 chebi_ontology pro-acaricide pro-acaricides proacaricides CHEBI:136647 proacaricide CHEBI:136647 PMID:17046600 Europe PMC PMID:19330529 Europe PMC PMID:26449612 Europe PMC pro-acaricide ChEBI pro-acaricides ChEBI proacaricides ChEBI A compound that, on administration, must undergo chemical conversion by biochemical (enzymatic), chemical (possibly following an enzymatic step), or physical (e.g. photochemical) activation processes before becoming the pharmacologically active herbicide savener for which it is a prosafener. PMID:26449612 chebi_ontology pro-safener pro-safeners prosafeners CHEBI:136648 prosafener CHEBI:136648 PMID:26449612 Europe PMC pro-safener ChEBI pro-safeners ChEBI prosafeners ChEBI A compound that, on administration, undergoes conversion by biochemical (enzymatic), chemical (possibly following an enzymatic step), or physical (e.g. photochemical) activation processes before becoming the active agent for which it is a pro-agent. PMID:26449612 chebi_ontology pro-agents proagent proagents CHEBI:136859 pro-agent CHEBI:136859 PMID:26449612 Europe PMC pro-agents ChEBI proagent ChEBI proagents ChEBI A role borne by a molecule that acts to counteract or neutralise the nerve agent sarin. chebi_ontology CHEBI:136860 antidote to sarin poisoning CHEBI:136860 A cardiovascular drug that tends to raise reduced blood pressure. Wikipedia:Antihypotensive_agent chebi_ontology antihypotensive agents pressor pressors vasopressor agent vasopressor agents CHEBI:137431 antihypotensive agent CHEBI:137431 antihypotensive agents ChEBI pressor ChEBI pressors ChEBI vasopressor agent ChEBI vasopressor agents ChEBI Any psychotropic drug that induces anxiety or panic. Wikipedia:Anxiogenic chebi_ontology anxiogenics panicogenic panicogenics CHEBI:137736 anxiogenic CHEBI:137736 anxiogenics ChEBI panicogenic ChEBI panicogenics ChEBI Any compound that can disrupt the functions of the endocrine (hormone) system PMID:27929035 PMID:28356401 PMID:28526231 Wikipedia:Endocrine_disruptor chebi_ontology endocrine disrupting chemical endocrine disrupting chemicals endocrine disrupting compound endocrine disrupting compounds endocrine disruptors endocrine-disrupting chemical endocrine-disrupting chemicals hormonally active agent hormonally active agents CHEBI:138015 endocrine disruptor CHEBI:138015 PMID:27929035 Europe PMC PMID:28356401 Europe PMC PMID:28526231 Europe PMC endocrine disrupting chemical ChEBI endocrine disrupting chemicals ChEBI endocrine disrupting compound ChEBI endocrine disrupting compounds ChEBI endocrine disruptors ChEBI endocrine-disrupting chemical ChEBI endocrine-disrupting chemicals ChEBI hormonally active agent ChEBI hormonally active agents ChEBI A hormone antagonist that acts at angiotensin receptors. chebi_ontology angiotensin receptor agonists CHEBI:138416 angiotensin receptor agonist CHEBI:138416 angiotensin receptor agonists ChEBI Any main group molecular entity that is gaseous at standard temperature and pressure (STP; 0degreeC and 100 kPa). Wikipedia:https://en.wikipedia.org/wiki/Gas chebi_ontology gas molecular entities gaseous molecular entities gaseous molecular entity CHEBI:138675 gas molecular entity CHEBI:138675 gas molecular entities ChEBI gaseous molecular entities ChEBI gaseous molecular entity ChEBI A probe that is a small labelled and chemical active peptide which has been structurally modified for reacting with, for example, the beta-lactam moieties of various penicillin-type compounds. PMID:28987997 chebi_ontology CHEBI:139246 peptide probe CHEBI:139246 PMID:28987997 Europe PMC An iron oxide nanoparticle consisting of a magnetic iron oxide core (usually magnetite, Fe3O4, or maghemite, gamma-Fe2O3). They may be coated with a biocompatible polymer or precipitated within the pores of a porous biocompatible polymer, which can be attached to cytotoxic drugs or antibodies. These can be targeted to the required area using external magnets; after the external magnetic field is removed, the particles no longer show magnetic interaction. PMID:20685224 PMID:26520409 PMID:27998240 PMID:28102523 PMID:28182122 PMID:28454771 PMID:28478508 PMID:28748623 PMID:28786283 PMID:28837060 PMID:28877348 PMID:28901350 PMID:28946493 PMID:28956266 PMID:29058880 PMID:29078147 PMID:29111382 PMID:29166921 PMID:29169120 PMID:29173814 PMID:29188240 PMID:29232855 PMID:29239410 PMID:29287105 PMID:29289736 PMID:29305666 PMID:29334739 PMID:29349357 chebi_ontology SPION SPIONs superparamagnetic iron oxide nanoparticles CHEBI:139547 superparamagnetic iron oxide nanoparticle CHEBI:139547 PMID:20685224 Europe PMC PMID:26520409 Europe PMC PMID:27998240 Europe PMC PMID:28102523 Europe PMC PMID:28182122 Europe PMC PMID:28454771 Europe PMC PMID:28478508 Europe PMC PMID:28748623 Europe PMC PMID:28786283 Europe PMC PMID:28837060 Europe PMC PMID:28877348 Europe PMC PMID:28901350 Europe PMC PMID:28946493 Europe PMC PMID:28956266 Europe PMC PMID:29058880 Europe PMC PMID:29078147 Europe PMC PMID:29111382 Europe PMC PMID:29166921 Europe PMC PMID:29169120 Europe PMC PMID:29173814 Europe PMC PMID:29188240 Europe PMC PMID:29232855 Europe PMC PMID:29239410 Europe PMC PMID:29287105 Europe PMC PMID:29289736 Europe PMC PMID:29305666 Europe PMC PMID:29334739 Europe PMC PMID:29349357 Europe PMC SPION ChEBI SPIONs ChEBI superparamagnetic iron oxide nanoparticles ChEBI A superparamagnetic iron oxide nanoparticle consisting of maghemite, Fe2O3. PMID:29188240 chebi_ontology gamma-Fe2O3 nanoparticle CHEBI:139552 maghemite nanoparticle CHEBI:139552 PMID:29188240 Europe PMC gamma-Fe2O3 nanoparticle ChEBI A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation. Wikipedia:Specialized_pro-resolving_mediators chebi_ontology SPM SPMs specialised pro-resolving mediators specialised proresolving mediator specialised proresolving mediators specialized pro-resolving mediator specialized pro-resolving mediators specialized proresolving mediator specialized proresolving mediators CHEBI:140399 specialised pro-resolving mediator CHEBI:140399 SPM ChEBI SPMs ChEBI specialised pro-resolving mediators ChEBI specialised proresolving mediator ChEBI specialised proresolving mediators ChEBI specialized pro-resolving mediator ChEBI specialized pro-resolving mediators ChEBI specialized proresolving mediator ChEBI specialized proresolving mediators ChEBI A mitochondrial cytochrome-bc1 complex inhibitor that acts at the Quinone 'outer' (Qo) binding site of the cytochrome-bc1 complex. Wikipedia:QoI chebi_ontology QOI QOIs Qo inhibitor Qo inhibitors quinone outside inhibitors CHEBI:141153 quinone outside inhibitor CHEBI:141153 QOI ChEBI QOIs ChEBI Qo inhibitor ChEBI Qo inhibitors ChEBI quinone outside inhibitors ChEBI A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active nematicide for which it is a pronematicide. chebi_ontology pronematicides pronematocide pronematocides CHEBI:141301 pronematicide CHEBI:141301 pronematicides ChEBI pronematocide ChEBI pronematocides ChEBI chebi_ontology CHEBI:143001 GABAB receptor agonist CHEBI:143001 A chemical role played by any unwanted chemical substance inside a confined amount of liquid, gas, or solid, which differs from the chemical composition of the material or compound. For example, an impurity can be an undesired by-product of a chemical reaction or manufacturing process, a drug contaminant, or can be created upon degradation during storage. Wikipedia:Impurity impurity chebi_ontology contaminant contaminants impurities CHEBI:143130 impurity CHEBI:143130 impurity ChEBI contaminant ChEBI contaminants ChEBI impurities ChEBI An agent that destroy spermatozoa in the male genitalia and block spermatogenesis. PMID:16371305 chebi_ontology antispermatogenic antispermatogenic agents antispermatogenics CHEBI:145047 antispermatogenic agent CHEBI:145047 PMID:16371305 Europe PMC antispermatogenic ChEBI antispermatogenic agents ChEBI antispermatogenics ChEBI chebi_ontology CHEBI:145515 GABAA receptor antagonist CHEBI:145515 A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent. antiatherosclerotic agent chebi_ontology anti-atherosclerotic agent anti-atherosclerotic agents anti-atherosclerotic drug anti-atherosclerotic drugs antiatherosclerotic agents antiatherosclerotic drug antiatherosclerotic drugs CHEBI:145947 antiatherosclerotic agent CHEBI:145947 antiatherosclerotic agent ChEBI anti-atherosclerotic agent ChEBI anti-atherosclerotic agents ChEBI anti-atherosclerotic drug ChEBI anti-atherosclerotic drugs ChEBI antiatherosclerotic agents ChEBI antiatherosclerotic drug ChEBI antiatherosclerotic drugs ChEBI chebi_ontology CHEBI:146222 ryanoid insecticide CHEBI:146222 Any substance that produces or enhances dream-like states of consciousness. Wikipedia:Oneirogen chebi_ontology oneirogens CHEBI:146270 oneirogen CHEBI:146270 oneirogens ChEBI A reagent used in electron paramagnetic resonance (EPR) spectroscopy to react covalently with radical products whose half-life is be too short to detect. The resulting adducts are more stable enabling their paramagnetic resonance spectra to be obtained. Wikipedia:Spin_trapping chebi_ontology spin trap spin trapping reagents spin traps CHEBI:149497 spin trapping reagent CHEBI:149497 spin trap ChEBI spin trapping reagents ChEBI spin traps ChEBI Any agent that induces nausea and vomiting. chebi_ontology emetics CHEBI:149552 emetic CHEBI:149552 emetics ChEBI CHEBI:15379 0 O2 InChI=1S/O2/c1-2 MYMOFIZGZYHOMD-UHFFFAOYSA-N 31.998 31.98983 O=O CHEBI:10745 CHEBI:13416 CHEBI:23833 CHEBI:25366 CHEBI:30491 CHEBI:44742 CHEBI:7860 CAS:7782-44-7 Gmelin:485 HMDB:HMDB0001377 KEGG:C00007 KEGG:D00003 MetaCyc:OXYGEN-MOLECULE MolBase:750 PDBeChem:OXY PMID:10906528 PMID:16977326 PMID:18210929 PMID:18638417 PMID:19840863 PMID:7710549 PMID:9463773 Wikipedia:Oxygen dioxygen chebi_ontology Disauerstoff E 948 E-948 E948 O2 OXYGEN MOLECULE Oxygen [OO] dioxygene molecular oxygen CHEBI:15379 dioxygen CHEBI:15379 CAS:7782-44-7 ChemIDplus CAS:7782-44-7 KEGG COMPOUND CAS:7782-44-7 NIST Chemistry WebBook Gmelin:485 Gmelin PMID:10906528 Europe PMC PMID:16977326 Europe PMC PMID:18210929 Europe PMC PMID:18638417 Europe PMC PMID:19840863 Europe PMC PMID:7710549 Europe PMC PMID:9463773 Europe PMC dioxygen IUPAC Disauerstoff ChEBI E 948 ChEBI E-948 ChEBI E948 ChEBI O2 IUPAC O2 KEGG_COMPOUND O2 UniProt OXYGEN MOLECULE PDBeChem Oxygen KEGG_COMPOUND [OO] MolBase dioxygene ChEBI molecular oxygen ChEBI Any compound that exhibits antagonist activity at the kappa-opioid receptor. chebi_ontology kappa-opioid antagonist kappa-opioid antagonists kappa-opioid receptor antagonists CHEBI:167165 kappa-opioid receptor antagonist CHEBI:167165 kappa-opioid antagonist ChEBI kappa-opioid antagonists ChEBI kappa-opioid receptor antagonists ChEBI A substance which is poisonous to fish and is primarily used to eliminate dominant species of fish in water. Wikipedia:Piscicide chebi_ontology piscicides CHEBI:167183 piscicide CHEBI:167183 piscicides ChEBI Any insecticide that is capable of killing egg cells. chebi_ontology ovicides CHEBI:167523 ovicide CHEBI:167523 ovicides ChEBI An antiparasitic agent which is effective against amoeba, a genus of single-celled amoeboids in the family Amoebidae. chebi_ontology amebicide amebicides amoebicide amoebicides anti-amoebic agent anti-amoebic agents anti-amoebic drug anti-amoebic drugs antiamoebic antiamoebic agents antiamoebic drug antiamoebic drugs antiamoebics CHEBI:171664 antiamoebic agent CHEBI:171664 amebicide ChEBI amebicides ChEBI amoebicide ChEBI amoebicides ChEBI anti-amoebic agent ChEBI anti-amoebic agents ChEBI anti-amoebic drug ChEBI anti-amoebic drugs ChEBI antiamoebic ChEBI antiamoebic agents ChEBI antiamoebic drug ChEBI antiamoebic drugs ChEBI antiamoebics ChEBI Any compound that supports healthy aging, slows the biological aging process, or extends lifespan. PMID:23372317 PMID:28580190 PMID:30885572 PMID:33144142 PMID:33973253 PMID:34606237 Wikipedia:Geroprotector chebi_ontology anti-aging agent anti-aging agents anti-aging drug anti-aging drugs geroprotective agent geroprotective agents geroprotectors CHEBI:176497 geroprotector CHEBI:176497 PMID:23372317 Europe PMC PMID:28580190 Europe PMC PMID:30885572 Europe PMC PMID:33144142 Europe PMC PMID:33973253 Europe PMC PMID:34606237 Europe PMC anti-aging agent ChEBI anti-aging agents ChEBI anti-aging drug ChEBI anti-aging drugs ChEBI geroprotective agent ChEBI geroprotective agents ChEBI geroprotectors ChEBI A beta-D-glucan in which the glucose units are connected by (1->4) linkages. 0 (C6H10O5)nH2O CHEBI:10812 CHEBI:23063 CHEBI:3529 CAS:9004-34-6 HMDB:HMDB0006944 KEGG:C00760 KEGG:D00093 KEGG:G10481 (1->4)-beta-D-glucopyranan chebi_ontology (1,4-beta-D-Glucosyl)n (1,4-beta-D-Glucosyl)n+1 (1,4-beta-D-Glucosyl)n-1 (1,4-beta-D-glucosyl)n 1,4-beta-D-Glucan Cellulose CHEBI:18246 (1->4)-beta-D-glucan CHEBI:18246 CAS:9004-34-6 ChemIDplus CAS:9004-34-6 KEGG COMPOUND (1->4)-beta-D-glucopyranan IUPAC (1,4-beta-D-Glucosyl)n KEGG_COMPOUND (1,4-beta-D-Glucosyl)n+1 KEGG_COMPOUND (1,4-beta-D-Glucosyl)n-1 KEGG_COMPOUND (1,4-beta-D-glucosyl)n IUBMB (1,4-beta-D-glucosyl)n UniProt 1,4-beta-D-Glucan KEGG_COMPOUND Cellulose KEGG_COMPOUND a group of substances that bind to a receptor to change that receptor's response to stimulus. chebi_ontology CHEBI:189675 PAR2 negative allosteric modulator CHEBI:189675 Any receptor modulator acting on sigma receptors. Wikipedia:Sigma_receptor chebi_ontology sigma receptor modulators sigma-receptor modulator sigma-receptor modulators CHEBI:189683 sigma receptor modulator CHEBI:189683 sigma receptor modulators ChEBI sigma-receptor modulator ChEBI sigma-receptor modulators ChEBI A sigma receptor modulator that activates the sigma-2 receptor. Wikipedia:Sigma-2_receptor chebi_ontology sigma 2 receptor agonist sigma 2 receptor agonists sigma-2 receptor agonists sigma2 receptor agonist sigma2 receptor agonists sigma2R agonist sigma2R agonists CHEBI:189684 sigma-2 receptor agonist CHEBI:189684 sigma 2 receptor agonist ChEBI sigma 2 receptor agonists ChEBI sigma-2 receptor agonists ChEBI sigma2 receptor agonist ChEBI sigma2 receptor agonists ChEBI sigma2R agonist ChEBI sigma2R agonists ChEBI A class of diuretics which promote aquaresis (the excretion of water without electrolyte loss). PMID:12107918 PMID:17430186 PMID:21088744 PMID:24853354 PMID:28194573 PMID:28652798 PMID:29259382 PMID:36156485 PMID:8738740 PMID:8998673 Wikipedia:Aquaretic chebi_ontology aquaretic agent aquaretic agents aquaretics CHEBI:194423 aquaretic CHEBI:194423 PMID:12107918 Europe PMC PMID:17430186 Europe PMC PMID:21088744 Europe PMC PMID:24853354 Europe PMC PMID:28194573 Europe PMC PMID:28652798 Europe PMC PMID:29259382 Europe PMC PMID:36156485 Europe PMC PMID:8738740 Europe PMC PMID:8998673 Europe PMC aquaretic agent ChEBI aquaretic agents ChEBI aquaretics ChEBI A drug used to treat myopathy. Wikipedia:Myopathy chebi_ontology antimyopathic agents antimyopathic drug antimyopathic drugs CHEBI:194430 antimyopathic agent CHEBI:194430 antimyopathic agents ChEBI antimyopathic drug ChEBI antimyopathic drugs ChEBI A substance used to destroy pests of the subclass Acari (mites and ticks). Wikipedia:Acaricide chebi_ontology Akarizid Akarizide acaricides miticide CHEBI:22153 acaricide CHEBI:22153 Akarizid ChEBI Akarizide ChEBI acaricides ChEBI miticide ChEBI A substance that prevents pests from feeding. chebi_ontology antifeedants CHEBI:22583 antifeedant CHEBI:22583 antifeedants ChEBI A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. chebi_ontology antioxidants antioxydant antoxidant CHEBI:22586 antioxidant CHEBI:22586 antioxidants ChEBI antioxydant ChEBI antoxidant ChEBI An insecticide compound naturally occurring in plants. chebi_ontology botanical insecticide botanical insecticides phytogenic insecticides CHEBI:22917 phytogenic insecticide CHEBI:22917 botanical insecticide ChEBI botanical insecticides ChEBI phytogenic insecticides ChEBI A substance intended to sterilize any organism. Wikipedia:Chemosterilant chebi_ontology chemosterilants CHEBI:23092 chemosterilant CHEBI:23092 chemosterilants ChEBI chebi_ontology CHEBI:23100 chitin synthesis inhibitor CHEBI:23100 Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity. molecular entity chebi_ontology entidad molecular entidades moleculares entite moleculaire molecular entities molekulare Entitaet CHEBI:23367 molecular entity CHEBI:23367 molecular entity IUPAC entidad molecular IUPAC entidades moleculares IUPAC entite moleculaire IUPAC molecular entities IUPAC molekulare Entitaet ChEBI chebi_ontology CHEBI:23529 cytochrome-b6f complex inhibitor CHEBI:23529 A herbicide which when sprayed or dusted on plants causes its leaves to fall off. chebi_ontology Defoliationsmittel Entlaubungsmittel defoliants CHEBI:23582 defoliant CHEBI:23582 Defoliationsmittel ChEBI Entlaubungsmittel ChEBI defoliants ChEBI Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances. chebi_ontology drugs medicine CHEBI:23888 drug CHEBI:23888 drugs ChEBI medicine ChEBI chebi_ontology CHEBI:23891 ecdysone antagonists CHEBI:23891 A substance used to destroy fungal pests. chebi_ontology fungicides CHEBI:24127 fungicide CHEBI:24127 fungicides ChEBI A substance used to destroy plant pests. Wikipedia:Herbicide chebi_ontology Herbizid Unkrautbekaempfungsmittel Unkrautvertilgungsmittel Wildkrautbekaempfungsmittel herbicides CHEBI:24527 herbicide CHEBI:24527 Herbizid ChEBI Unkrautbekaempfungsmittel ChEBI Unkrautvertilgungsmittel ChEBI Wildkrautbekaempfungsmittel ChEBI herbicides ChEBI A growth regulator that inhibits the life cycle of an insect. chebi_ontology insect growth regulators CHEBI:24851 insect growth regulator CHEBI:24851 insect growth regulators ChEBI Strictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects. Wikipedia:Insecticide chebi_ontology insecticides CHEBI:24852 insecticide CHEBI:24852 insecticides ChEBI chebi_ontology CHEBI:24941 juvenile hormone antagonists CHEBI:24941 chebi_ontology CHEBI:24942 juvenile hormone mimic CHEBI:24942 CHEBI:25108 magnesium molecular entity chebi_ontology magnesium compounds magnesium molecular entities CHEBI:25108 magnesium molecular entity CHEBI:25108 magnesium molecular entity ChEBI magnesium compounds ChEBI magnesium molecular entities ChEBI CHEBI:25370 chebi_ontology molybdenum compounds molybdenum molecular entities CHEBI:25370 molybdenum molecular entity CHEBI:25370 molybdenum compounds ChEBI molybdenum molecular entities ChEBI A substance used to destroy pests of the phylum Nematoda (roundworms). Wikipedia:Nematicide chebi_ontology nematicides nematocide nematocides CHEBI:25491 nematicide CHEBI:25491 nematicides ChEBI nematocide ChEBI nematocides ChEBI A class of neuro-active insecticides that act at the nicotinic acetylcholine receptor. CHEBI:25498 Wikipedia:Neonicotinoid chebi_ontology neonicotinoid insectides nicotinoid insectide nicotinoid insectides CHEBI:25540 neonicotinoid insectide CHEBI:25540 neonicotinoid insectides ChEBI nicotinoid insectide ChEBI nicotinoid insectides ChEBI A substance that increases the efficacy of a pesticide. chebi_ontology pesticide synergists CHEBI:25943 pesticide synergist CHEBI:25943 pesticide synergists ChEBI Strictly, a substance intended to kill pests. In common usage, any substance used for controlling, preventing, or destroying animal, microbiological or plant pests. Wikipedia:Pesticide pesticide chebi_ontology Pestizid Pestizide pesticides CHEBI:25944 pesticide CHEBI:25944 pesticide IUPAC Pestizid ChEBI Pestizide ChEBI pesticides ChEBI chebi_ontology CHEBI:26087 photosynthetic electron-transport chain inhibitor CHEBI:26087 chebi_ontology CHEBI:26088 photosystem-I inhibitor CHEBI:26088 chebi_ontology CHEBI:26089 photosystem-II inhibitor CHEBI:26089 An endogenous molecular entity that results in a colour of an organism as the consequence of the selective absorption of light. chebi_ontology pigments CHEBI:26130 biological pigment CHEBI:26130 pigments ChEBI chebi_ontology CHEBI:26220 precocenes CHEBI:26220 chebi_ontology pyrethroid insecticides CHEBI:26413 pyrethroid insecticide CHEBI:26413 pyrethroid insecticides ChEBI CHEBI:26628 selenium molecular entity chebi_ontology selenium molecular entities CHEBI:26628 selenium molecular entity CHEBI:26628 selenium molecular entity ChEBI selenium molecular entities ChEBI A surfactant (or a mixture containing one or more surfactants) having cleaning properties in dilute solutions. CHEBI:23648 CHEBI:4456 KEGG:C01689 detergent chebi_ontology Detergents CHEBI:27780 detergent CHEBI:27780 detergent IUPAC Detergents KEGG_COMPOUND 0 CSi InChI=1S/CSi/c1-2 HBMJWWWQQXIZIP-UHFFFAOYSA-N 40.09620 39.97693 [C-]#[Si+] CAS:409-21-2 Gmelin:13642 carbidosilicon silicon carbide chebi_ontology SiC Siliciumcarbid Siliziumkarbid [SiC] carborundum silicon monocarbide silicon(IV) carbide CHEBI:29390 silicon carbide CHEBI:29390 CAS:409-21-2 ChemIDplus CAS:409-21-2 NIST Chemistry WebBook Gmelin:13642 Gmelin carbidosilicon IUPAC silicon carbide IUPAC SiC IUPAC Siliciumcarbid ChEBI Siliziumkarbid ChEBI [SiC] IUPAC carborundum NIST_Chemistry_WebBook silicon monocarbide NIST_Chemistry_WebBook silicon(IV) carbide NIST_Chemistry_WebBook A silicon oxide made up of linear triatomic molecules in which a silicon atom is covalently bonded to two oxygens. 0 O2Si InChI=1S/O2Si/c1-3-2 VYPSYNLAJGMNEJ-UHFFFAOYSA-N 60.08430 59.96676 O=[Si]=O BPDB:2487 CAS:7631-86-9 Drug_Central:4284 Gmelin:200274 KEGG:C19572 MolBase:887 PMID:8991630 PPDB:282 Reaxys:3902804 VSDB:2487 silicon dioxide silicon(IV) oxide chebi_ontology (SiO2)n Kieselsaeureanhydrid SiO2 Silica, amorphous Siliziumdioxid [SiO2] silica silicic anhydride CHEBI:30563 silicon dioxide CHEBI:30563 CAS:7631-86-9 ChemIDplus CAS:7631-86-9 KEGG COMPOUND CAS:7631-86-9 NIST Chemistry WebBook Drug_Central:4284 DrugCentral Gmelin:200274 Gmelin PMID:8991630 Europe PMC Reaxys:3902804 Reaxys silicon dioxide IUPAC silicon(IV) oxide IUPAC (SiO2)n ChEBI Kieselsaeureanhydrid ChEBI SiO2 IUPAC Silica, amorphous KEGG_COMPOUND Siliziumdioxid ChEBI [SiO2] MolBase silica ChEBI silicic anhydride NIST_Chemistry_WebBook A calcium salt with formula CCaO3. 0 CCaO3 CO3.Ca InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2 VTYYLEPIZMXCLO-UHFFFAOYSA-L 100.087 99.94733 [Ca+2].C(=O)([O-])[O-] BPDB:108 CAS:471-34-1 DrugBank:DB06724 KEGG:C08129 KEGG:D00932 PPDB:108 Reaxys:8008338 Wikipedia:Calcium_carbonate Calcium carbonate calcium carbonate calcium trioxidocarbonate chebi_ontology CaCO3 Calciumcarbonat E 170 Kalziumkarbonat Precipitated calcium carbonate calcium carbonate (1:1) carbonate de calcium carbonato de calcio carbonic acid calcium salt (1:1) kohlensaurer Kalk CHEBI:3311 calcium carbonate CHEBI:3311 CAS:471-34-1 ChemIDplus CAS:471-34-1 KEGG COMPOUND CAS:471-34-1 NIST Chemistry WebBook Reaxys:8008338 Reaxys Calcium carbonate KEGG_COMPOUND calcium carbonate IUPAC calcium trioxidocarbonate IUPAC CaCO3 IUPAC Calciumcarbonat ChEBI E 170 ChEBI Kalziumkarbonat ChEBI Precipitated calcium carbonate KEGG_COMPOUND calcium carbonate (1:1) ChemIDplus carbonate de calcium ChEBI carbonato de calcio ChEBI carbonic acid calcium salt (1:1) ChemIDplus kohlensaurer Kalk ChEBI 0 C60 InChI=1S/C60/c1-2-5-6-3(1)8-12-10-4(1)9-11-7(2)17-21-13(5)23-24-14(6)22-18(8)28-20(12)30-26-16(10)15(9)25-29-19(11)27(17)37-41-31(21)33(23)43-44-34(24)32(22)42-38(28)48-40(30)46-36(26)35(25)45-39(29)47(37)55-49(41)51(43)57-52(44)50(42)56(48)59-54(46)53(45)58(55)60(57)59 XMWRBQBLMFGWIX-UHFFFAOYSA-N 720.64200 720.00000 c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%11c2c2c7c3c3c8c4c4c9c5c1c1c6c2c3c41 Beilstein:5901022 CAS:99685-96-8 Chemspider:110185 Gmelin:100331 PMID:22498298 PMID:25118710 Reaxys:5901022 (C60-Ih)[5,6]fullerene chebi_ontology Buckminsterfulleren Buckyball [5,6]fullerene-C60-Ih [60-Ih]fullerene [60]fullerene buckminsterfulereno buckminsterfullerene footballene fullerene 60 fullerene C60 soccerballene CHEBI:33128 C60 fullerene CHEBI:33128 Beilstein:5901022 Beilstein CAS:99685-96-8 ChemIDplus CAS:99685-96-8 NIST Chemistry WebBook Gmelin:100331 Gmelin PMID:22498298 Europe PMC PMID:25118710 Europe PMC Reaxys:5901022 Reaxys (C60-Ih)[5,6]fullerene IUPAC Buckminsterfulleren ChEBI Buckyball ChEBI [5,6]fullerene-C60-Ih ChemIDplus [60-Ih]fullerene IUPAC [60]fullerene IUPAC buckminsterfulereno ChEBI buckminsterfullerene NIST_Chemistry_WebBook footballene ChemIDplus fullerene 60 ChemIDplus fullerene C60 ChemIDplus soccerballene ChEBI 0 C70 InChI=1S/C70/c1-2-22-5-6-24-13-14-26-11-9-23-4-3(21(1)51-52(22)54(24)55(26)53(23)51)33-31(1)61-35-7-8-27-15-16-29-19-20-30-18-17-28-12-10(25(7)56-57(27)59(29)60(30)58(28)56)37(35)63(33)65-36(4)40(9)67(44(17)42(12)65)69-46(11)47(14)70(50(20)49(18)69)68-43(13)39(6)66(45(16)48(19)68)64-34(5)32(2)62(61)38(8)41(15)64 ATLMFJTZZPOKLC-UHFFFAOYSA-N 840.74900 840.00000 c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%10c%11c2c2c%11c7c3c3c%11c7c(c%102)c2c6c1c1c5c9c5c6c4c8c3c6c7c2c15 Beilstein:6843004 CAS:115383-22-7 (C70-D5h(6))[5,6]fullerene C70 fullerene chebi_ontology [70-D5h]fullerene fullerene 70 fullerene C70 rugbyballene CHEBI:33195 C70 fullerene CHEBI:33195 Beilstein:6843004 Beilstein CAS:115383-22-7 ChemIDplus CAS:115383-22-7 NIST Chemistry WebBook (C70-D5h(6))[5,6]fullerene IUPAC C70 fullerene ChemIDplus [70-D5h]fullerene IUPAC fullerene 70 ChemIDplus fullerene C70 ChemIDplus rugbyballene ChEBI A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis. chebi_ontology antitubercular antitubercular agents antitubercular drug antitubercular drugs tuberculostatic agent CHEBI:33231 antitubercular agent CHEBI:33231 antitubercular ChEBI antitubercular agents ChEBI antitubercular drug ChEBI antitubercular drugs ChEBI tuberculostatic agent ChEBI CHEBI:33232 Intended use of the molecular entity or part thereof by humans. chebi_ontology CHEBI:33232 application CHEBI:33232 A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. CHEBI:22582 PMID:12964249 PMID:22117953 PMID:22439833 PMID:22849268 PMID:22849276 PMID:22958833 chebi_ontology Antibiotika Antibiotikum antibiotic antibiotics antibiotique antimicrobial antimicrobial agents antimicrobials microbicide microbicides CHEBI:33281 antimicrobial agent CHEBI:33281 PMID:12964249 Europe PMC PMID:22117953 Europe PMC PMID:22439833 Europe PMC PMID:22849268 Europe PMC PMID:22849276 Europe PMC PMID:22958833 Europe PMC Antibiotika ChEBI Antibiotikum ChEBI antibiotic ChEBI antibiotics ChEBI antibiotique IUPAC antimicrobial ChEBI antimicrobial agents ChEBI antimicrobials ChEBI microbicide ChEBI microbicides ChEBI An agrochemical is a substance that is used in agriculture or horticulture. Wikipedia:Agrochemical chebi_ontology agrichemical agrichemicals agricultural chemicals agrochemicals CHEBI:33286 agrochemical CHEBI:33286 agrichemical ChEBI agrichemicals ChEBI agricultural chemicals ChEBI agrochemicals ChEBI A fertilizer is any substance that is added to soil or water to assist the growth of plants. chebi_ontology fertiliser fertilizers CHEBI:33287 fertilizer CHEBI:33287 fertiliser ChEBI fertilizers ChEBI A substance used to destroy rodent pests. Wikipedia:Rodenticide chebi_ontology rodenticides CHEBI:33288 rodenticide CHEBI:33288 rodenticides ChEBI A substance used to destroy bird pests (class Aves). Wikipedia:Avicide chebi_ontology avicides CHEBI:33289 avicide CHEBI:33289 avicides ChEBI An energy-rich substance that can be transformed with release of usable energy. chebi_ontology CHEBI:33292 fuel CHEBI:33292 A substance administered to aid diagnosis of a disease. chebi_ontology diagnostic aid CHEBI:33295 diagnostic agent CHEBI:33295 diagnostic aid ChEBI CHEBI:33416 A compound composed solely of an even number of carbon atoms, which form a cage-like fused-ring polycyclic system with twelve five-membered rings and the rest six-membered rings. The term has been broadened to include any closed cage structure consisting entirely of three-coordinate carbon atoms. fullerene fullerenes chebi_ontology Fulleren fulereno fulerenos fullereno fullerenos CHEBI:33416 fullerene CHEBI:33416 fullerene IUPAC fullerenes IUPAC Fulleren ChEBI fulereno ChEBI fulerenos ChEBI fullereno IUPAC fullerenos IUPAC CHEBI:33888 cobalt molecular entity chebi_ontology cobalt compounds cobalt molecular entities CHEBI:33888 cobalt molecular entity CHEBI:33888 cobalt molecular entity ChEBI cobalt compounds ChEBI cobalt molecular entities ChEBI CHEBI:33893 A substance used in a chemical reaction to detect, measure, examine, or produce other substances. reagent chebi_ontology reactif reactivo reagents CHEBI:33893 reagent CHEBI:33893 reagent IUPAC reactif IUPAC reactivo IUPAC reagents ChEBI A substance used to destroy pests of the phylum Mollusca. Wikipedia:Molluscicide chebi_ontology molluscicides CHEBI:33904 molluscicide CHEBI:33904 molluscicides ChEBI A substance which lowers the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces. surfactant chebi_ontology surface active agent surfactants CHEBI:35195 surfactant CHEBI:35195 surfactant IUPAC surface active agent IUPAC surfactants ChEBI A role played by a foreign substance mixed with or attached to a given substance to enable the distribution or location of the latter to be determined subsequently. tracer chebi_ontology CHEBI:35204 tracer CHEBI:35204 tracer IUPAC A role played by a chemical compound with properties similar to those of the substance being traced with which it is mixed homogeneously. chemical tracer chebi_ontology CHEBI:35205 chemical tracer CHEBI:35205 chemical tracer IUPAC A tracer which only differs in isotopic composition from the substance to be traced. isotopic tracer chebi_ontology CHEBI:35206 isotopic tracer CHEBI:35206 isotopic tracer IUPAC A tracer containing a radioactive label. radioactive tracer chebi_ontology CHEBI:35207 radioactive tracer CHEBI:35207 radioactive tracer IUPAC A physical tracer is one that is attached by physical means to the object being traced. physical tracer chebi_ontology CHEBI:35208 physical tracer CHEBI:35208 physical tracer IUPAC A role played by a part of a molecular entity distinguishable by the observer but not by the system and used to identify a tracer. label chebi_ontology CHEBI:35209 label CHEBI:35209 label IUPAC A role played by a stable paramagnetic group that is attached to a part of a molecular entity whose microscopic environment is of interest and may be revealed by the electron spin resonance (ESR) spectroscopy. spin label chebi_ontology CHEBI:35210 spin label CHEBI:35210 spin label IUPAC radioactive label chebi_ontology CHEBI:35211 radioactive label CHEBI:35211 radioactive label IUPAC A substance that increases the rate of a reaction without modifying the overall standard Gibbs energy change in the reaction. catalyst chebi_ontology Katalysator catalizador catalyseur CHEBI:35223 catalyst CHEBI:35223 catalyst IUPAC Katalysator ChEBI catalizador ChEBI catalyseur ChEBI A role played by a stable paramagnetic molecular entity used to study the microscopic environment by electron paramagnetic resonance (EPR) spectroscopy without covalent attachment to the molecular entity of interest. Wikipedia:Spin_probe spin probe chebi_ontology CHEBI:35226 spin probe CHEBI:35226 spin probe IUPAC A fuel such as coal, oil and natural gas which has formed over many years through the decomposition of deposited vegetation which was under extreme pressure of an overburden of earth. fossil fuel chebi_ontology CHEBI:35230 fossil fuel CHEBI:35230 fossil fuel IUPAC Material containing fissile nuclides, which when placed in a reactor, enables a chain reaction to be achieved. nuclear fuel chebi_ontology CHEBI:35231 nuclear fuel CHEBI:35231 nuclear fuel IUPAC Any pharmaceutical compound containing a radioisotope. Wikipedia:Radiopharmaceutical chebi_ontology radiopharmaceuticals CHEBI:35232 radiopharmaceutical CHEBI:35232 radiopharmaceuticals ChEBI Any drug that enhances the activity of the central nervous system. Wikipedia:Central_nervous_system_stimulants central nervous system stimulant chebi_ontology CNS stimulant analeptic analeptic agent analeptic drug analeptics central stimulant CHEBI:35337 central nervous system stimulant CHEBI:35337 central nervous system stimulant ChEBI CNS stimulant ChEBI analeptic ChEBI analeptic agent ChEBI analeptic drug ChEBI analeptics ChEBI central stimulant ChEBI A substance used in the prophylaxis or therapy of infectious diseases. chebi_ontology anti-infective agents anti-infective drugs antiinfective agents antiinfective drug CHEBI:35441 antiinfective agent CHEBI:35441 anti-infective agents ChEBI anti-infective drugs ChEBI antiinfective agents ChEBI antiinfective drug ChEBI A substance used to treat or prevent parasitic infections. Wikipedia:Antiparasitic chebi_ontology antiparasitic drugs antiparasitics parasiticides CHEBI:35442 antiparasitic agent CHEBI:35442 antiparasitic drugs ChEBI antiparasitics ChEBI parasiticides ChEBI Substance intended to kill parasitic worms (helminths). anthelminthic chebi_ontology anthelminthics anthelmintic anthelmintics antihelminth antihelmintico vermifuge CHEBI:35443 anthelminthic drug CHEBI:35443 anthelminthic IUPAC anthelminthics ChEBI anthelmintic IUPAC anthelmintics ChEBI antihelminth ChEBI antihelmintico ChEBI vermifuge ChEBI A substance used in the treatment or control of nematode infestations. chebi_ontology antinematodal agent antinematodal drugs antinematodals CHEBI:35444 antinematodal drug CHEBI:35444 antinematodal agent ChEBI antinematodal drugs ChEBI antinematodals ChEBI An EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1). Wikipedia:ACE_inhibitor chebi_ontology ACE inhibitor ACE inhibitors DCP inhibitor DCP inhibitors EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitors EC 3.4.15.1 inhibitor EC 3.4.15.1 inhibitors PDH inhibitor PDH inhibitors angiotensin I-converting enzyme inhibitor angiotensin I-converting enzyme inhibitors angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors carboxycathepsin inhibitor carboxycathepsin inhibitors dipeptidase inhibitor dipeptidase inhibitors dipeptide hydrolase inhibitor dipeptide hydrolase inhibitors dipeptidyl carboxypeptidase I inhibitor dipeptidyl carboxypeptidase I inhibitors dipeptidyl carboxypeptidase inhibitor dipeptidyl carboxypeptidase inhibitors endothelial cell peptidyl dipeptidase inhibitor endothelial cell peptidyl dipeptidase inhibitors kininase II inhibitor kininase II inhibitors peptidase P inhibitor peptidase P inhibitors peptidyl dipeptidase A inhibitor peptidyl dipeptidase A inhibitors peptidyl dipeptidase I inhibitor peptidyl dipeptidase I inhibitors peptidyl dipeptidase-4 inhibitor peptidyl dipeptidase-4 inhibitors peptidyl dipeptide hydrolase inhibitor peptidyl dipeptide hydrolase inhibitors peptidyl-dipeptidase A (EC 3.4.15.1) inhibitor peptidyl-dipeptidase A (EC 3.4.15.1) inhibitors peptidyl-dipeptidase A inhibitor peptidyl-dipeptidase A inhibitors peptidyl-dipeptide hydrolase inhibitor peptidyl-dipeptide hydrolase inhibitors peptidyldipeptide hydrolase inhibitor peptidyldipeptide hydrolase inhibitors CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor CHEBI:35457 ACE inhibitor ChEBI ACE inhibitors ChEBI DCP inhibitor ChEBI DCP inhibitors ChEBI EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitors ChEBI EC 3.4.15.1 inhibitor ChEBI EC 3.4.15.1 inhibitors ChEBI PDH inhibitor ChEBI PDH inhibitors ChEBI angiotensin I-converting enzyme inhibitor ChEBI angiotensin I-converting enzyme inhibitors ChEBI angiotensin-converting enzyme inhibitor ChEBI angiotensin-converting enzyme inhibitors ChEBI carboxycathepsin inhibitor ChEBI carboxycathepsin inhibitors ChEBI dipeptidase inhibitor ChEBI dipeptidase inhibitors ChEBI dipeptide hydrolase inhibitor ChEBI dipeptide hydrolase inhibitors ChEBI dipeptidyl carboxypeptidase I inhibitor ChEBI dipeptidyl carboxypeptidase I inhibitors ChEBI dipeptidyl carboxypeptidase inhibitor ChEBI dipeptidyl carboxypeptidase inhibitors ChEBI endothelial cell peptidyl dipeptidase inhibitor ChEBI endothelial cell peptidyl dipeptidase inhibitors ChEBI kininase II inhibitor ChEBI kininase II inhibitors ChEBI peptidase P inhibitor ChEBI peptidase P inhibitors ChEBI peptidyl dipeptidase A inhibitor ChEBI peptidyl dipeptidase A inhibitors ChEBI peptidyl dipeptidase I inhibitor ChEBI peptidyl dipeptidase I inhibitors ChEBI peptidyl dipeptidase-4 inhibitor ChEBI peptidyl dipeptidase-4 inhibitors ChEBI peptidyl dipeptide hydrolase inhibitor ChEBI peptidyl dipeptide hydrolase inhibitors ChEBI peptidyl-dipeptidase A (EC 3.4.15.1) inhibitor ChEBI peptidyl-dipeptidase A (EC 3.4.15.1) inhibitors ChEBI peptidyl-dipeptidase A inhibitor ChEBI peptidyl-dipeptidase A inhibitors ChEBI peptidyl-dipeptide hydrolase inhibitor ChEBI peptidyl-dipeptide hydrolase inhibitors ChEBI peptidyldipeptide hydrolase inhibitor ChEBI peptidyldipeptide hydrolase inhibitors ChEBI Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. chebi_ontology antidepressant drugs antidepressants thymoanaleptics thymoleptic drugs thymoleptics CHEBI:35469 antidepressant CHEBI:35469 antidepressant drugs ChEBI antidepressants ChEBI thymoanaleptics ChEBI thymoleptic drugs ChEBI thymoleptics ChEBI A class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system. chebi_ontology CNS agent CNS drugs central nervous system agents CHEBI:35470 central nervous system drug CHEBI:35470 CNS agent ChEBI CNS drugs ChEBI central nervous system agents ChEBI A loosely defined grouping of drugs that have effects on psychological function. Wikipedia:Psychotropic_drug chebi_ontology psychoactive agent psychoactive drugs psychopharmaceuticals psychotropic drugs CHEBI:35471 psychotropic drug CHEBI:35471 psychoactive agent ChEBI psychoactive drugs ChEBI psychopharmaceuticals ChEBI psychotropic drugs ChEBI A substance that reduces or suppresses inflammation. chebi_ontology anti-inflammatory drugs antiinflammatory agent antiinflammatory drug antiinflammatory drugs CHEBI:35472 anti-inflammatory drug CHEBI:35472 anti-inflammatory drugs ChEBI antiinflammatory agent ChEBI antiinflammatory drug ChEBI antiinflammatory drugs ChEBI A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour. chebi_ontology ataractics tranquilising drug tranquilizing drugs tranquillising agent tranquillizing agents CHEBI:35473 tranquilizing drug CHEBI:35473 ataractics ChEBI tranquilising drug ChEBI tranquilizing drugs ChEBI tranquillising agent ChEBI tranquillizing agents ChEBI Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. chebi_ontology anti-anxiety agents anti-anxiety drugs anxiolytic agents anxiolytics minor tranquilisers minor tranquilizers minor tranquilizing agents CHEBI:35474 anxiolytic drug CHEBI:35474 anti-anxiety agents ChEBI anti-anxiety drugs ChEBI anxiolytic agents ChEBI anxiolytics ChEBI minor tranquilisers ChEBI minor tranquilizers ChEBI minor tranquilizing agents ChEBI An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Wikipedia:Non-steroidal_anti-inflammatory_drug chebi_ontology NSAID NSAIDs non-steroidal anti-inflammatory agent non-steroidal anti-inflammatory drugs CHEBI:35475 non-steroidal anti-inflammatory drug CHEBI:35475 NSAID ChEBI NSAIDs ChEBI non-steroidal anti-inflammatory agent ChEBI non-steroidal anti-inflammatory drugs ChEBI Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. chebi_ontology Neuroleptikum antipsychotic agents antipsychotic drug antipsychotic drugs antipsychotics antipsychotiques grosser Tranquilizer major tranquilizers major tranquilizing agents neuroleptic neuroleptic agents neuroleptics neuroleptique neuroleptiques CHEBI:35476 antipsychotic agent CHEBI:35476 Neuroleptikum ChEBI antipsychotic agents ChEBI antipsychotic drug ChEBI antipsychotic drugs ChEBI antipsychotics ChEBI antipsychotiques ChEBI grosser Tranquilizer ChEBI major tranquilizers ChEBI major tranquilizing agents ChEBI neuroleptic ChEBI neuroleptic agents ChEBI neuroleptics ChEBI neuroleptique ChEBI neuroleptiques ChEBI Antimanic drugs are agents used to treat bipolar disorders or mania associated with other affective disorders. chebi_ontology antimanic agent antimanic drugs antimanics CHEBI:35477 antimanic drug CHEBI:35477 antimanic agent ChEBI antimanic drugs ChEBI antimanics ChEBI An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. chebi_ontology CHEBI:35480 analgesic CHEBI:35480 A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. chebi_ontology CHEBI:35481 non-narcotic analgesic CHEBI:35481 A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood. chebi_ontology narcotic narcotic analgesic narcotic analgesics narcotics opioid analgesics CHEBI:35482 opioid analgesic CHEBI:35482 narcotic ChEBI narcotic analgesic ChEBI narcotic analgesics ChEBI narcotics ChEBI opioid analgesics ChEBI A loosely defined group of drugs that tend to reduce the activity of the central nervous system. chebi_ontology CNS depressants central nervous system depressants CHEBI:35488 central nervous system depressant CHEBI:35488 CNS depressants ChEBI central nervous system depressants ChEBI A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever. Wikipedia:Antipyretic chebi_ontology anti-pyretic CHEBI:35493 antipyretic CHEBI:35493 anti-pyretic ChEBI A compound which inhibits or antagonises the biosynthesis or actions of androgens. Wikipedia:Antiandrogen chebi_ontology antiandrogen CHEBI:35497 androgen antagonist CHEBI:35497 antiandrogen ChEBI An agent that promotes the excretion of urine through its effects on kidney function. chebi_ontology diuretics CHEBI:35498 diuretic CHEBI:35498 diuretics ChEBI Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking. chebi_ontology hallucinogenic agents hallucinogenic drugs hallucinogens psychedelic agents psychedelics CHEBI:35499 hallucinogen CHEBI:35499 hallucinogenic agents ChEBI hallucinogenic drugs ChEBI hallucinogens ChEBI psychedelic agents ChEBI psychedelics ChEBI An agent that selectively binds to and activates beta-adrenergic receptors. chebi_ontology beta-adrenergic agonists beta-adrenergic receptor agonist beta-adrenoceptor agonists CHEBI:35522 beta-adrenergic agonist CHEBI:35522 beta-adrenergic agonists ChEBI beta-adrenergic receptor agonist ChEBI beta-adrenoceptor agonists IUPHAR An agent that causes an increase in the expansion of a bronchus or bronchial tubes. chebi_ontology bronchodilator bronchodilator agents broncholytic agent CHEBI:35523 bronchodilator agent CHEBI:35523 bronchodilator ChEBI bronchodilator agents ChEBI broncholytic agent ChEBI A drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. chebi_ontology sympathomimetic sympathomimetics CHEBI:35524 sympathomimetic agent CHEBI:35524 sympathomimetic ChEBI sympathomimetics ChEBI A drug which lowers the blood glucose level. chebi_ontology antidiabetic antihyperglycemic antihyperglycemic agent antihyperglycemic agents antihyperglycemic drug antihyperglycemic drugs antihyperglycemics hypoglycemic agents hypoglycemic drug hypoglycemic drugs CHEBI:35526 hypoglycemic agent CHEBI:35526 antidiabetic ChEBI antihyperglycemic ChEBI antihyperglycemic agent ChEBI antihyperglycemic agents ChEBI antihyperglycemic drug ChEBI antihyperglycemic drugs ChEBI antihyperglycemics ChEBI hypoglycemic agents ChEBI hypoglycemic drug ChEBI hypoglycemic drugs ChEBI An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety. chebi_ontology beta-adrenergic antagonists beta-adrenergic blocker beta-adrenergic blockers beta-adrenergic receptor blockaders beta-adrenoceptor antagonists beta-blocker beta-blockers CHEBI:35530 beta-adrenergic antagonist CHEBI:35530 beta-adrenergic antagonists ChEBI beta-adrenergic blocker ChEBI beta-adrenergic blockers ChEBI beta-adrenergic receptor blockaders ChEBI beta-adrenoceptor antagonists IUPHAR beta-blocker ChEBI beta-blockers ChEBI A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. chebi_ontology cardiovascular agent cardiovascular drugs CHEBI:35554 cardiovascular drug CHEBI:35554 cardiovascular agent ChEBI cardiovascular drugs ChEBI An agent that selectively binds to and activates alpha-adrenergic receptors. chebi_ontology alpha-adrenergic agonists alpha-adrenergic receptor agonist alpha-adrenoceptor agonists CHEBI:35569 alpha-adrenergic agonist CHEBI:35569 alpha-adrenergic agonists ChEBI alpha-adrenergic receptor agonist ChEBI alpha-adrenoceptor agonists IUPHAR A substance that inhibits or prevents the proliferation of neoplasms. chebi_ontology anticancer agent anticancer agents antineoplastic antineoplastic agents cytostatic CHEBI:35610 antineoplastic agent CHEBI:35610 anticancer agent ChEBI anticancer agents ChEBI antineoplastic ChEBI antineoplastic agents ChEBI cytostatic ChEBI A food additive that is used to added improve the taste or odour of a food. chebi_ontology flavoring agent flavoring agents flavour enhancer flavour enhancers flavouring agents CHEBI:35617 flavouring agent CHEBI:35617 flavoring agent ChEBI flavoring agents ChEBI flavour enhancer ChEBI flavour enhancers ChEBI flavouring agents ChEBI A drug used to cause dilation of the blood vessels. chebi_ontology vasodilator vasodilator agents CHEBI:35620 vasodilator agent CHEBI:35620 vasodilator ChEBI vasodilator agents ChEBI A drug used to prevent seizures or reduce their severity. chebi_ontology Antiepileptika Antiepileptikum Antikonvulsiva Antikonvulsivum anti-convulsant anti-convulsants anti-convulsive agent anti-convulsive agents anticonvulsants anticonvulsive agent anticonvulsive agents antiepileptic antiepileptics antiepileptique antiepileptiques CHEBI:35623 anticonvulsant CHEBI:35623 Antiepileptika ChEBI Antiepileptikum ChEBI Antikonvulsiva ChEBI Antikonvulsivum ChEBI anti-convulsant ChEBI anti-convulsants ChEBI anti-convulsive agent ChEBI anti-convulsive agents ChEBI anticonvulsants ChEBI anticonvulsive agent ChEBI anticonvulsive agents ChEBI antiepileptic ChEBI antiepileptics ChEBI antiepileptique ChEBI antiepileptiques ChEBI Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. chebi_ontology ARI NERI NRI adrenergic reuptake inhibitor adrenergic reuptake inhibitors adrenergic uptake inhibitors norepinephrine reuptake inhibitor norepinephrine reuptake inhibitors CHEBI:35640 adrenergic uptake inhibitor CHEBI:35640 ARI ChEBI NERI ChEBI NRI ChEBI adrenergic reuptake inhibitor ChEBI adrenergic reuptake inhibitors ChEBI adrenergic uptake inhibitors ChEBI norepinephrine reuptake inhibitor ChEBI norepinephrine reuptake inhibitors ChEBI Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. Wikipedia:Antihypertensive_drug chebi_ontology antihypertensive antihypertensive agents antihypertensive drug antihypertensive drugs CHEBI:35674 antihypertensive agent CHEBI:35674 antihypertensive ChEBI antihypertensive agents ChEBI antihypertensive drug ChEBI antihypertensive drugs ChEBI A drug that binds to and activates histamine receptors. Although they have been suggested for a variety of clinical applications, histamine agonists have so far been more widely used in research than therapeutically. chebi_ontology histamine agonists CHEBI:35678 histamine agonist CHEBI:35678 histamine agonists ChEBI A substance used to treat hyperlipidemia (an excess of lipids in the blood). Wikipedia:Hypolipidemic_agent chebi_ontology antihyperlipemic antihyperlipemics antihyperlipidaemic agent antihyperlipidaemic agents antihyperlipidaemic drug antihyperlipidaemic drugs antihyperlipidemic antihyperlipidemic agent antihyperlipidemic agents antihyperlipidemic drug antihyperlipidemic drugs antihyperlipidemics antilipemic antilipemic drugs antilipemics hypolipidemic agent hypolipidemic agents lipid-lowering agent lipid-lowering agents lipid-lowering drug lipid-lowering drugs CHEBI:35679 antilipemic drug CHEBI:35679 antihyperlipemic ChEBI antihyperlipemics ChEBI antihyperlipidaemic agent ChEBI antihyperlipidaemic agents ChEBI antihyperlipidaemic drug ChEBI antihyperlipidaemic drugs ChEBI antihyperlipidemic ChEBI antihyperlipidemic agent ChEBI antihyperlipidemic agents ChEBI antihyperlipidemic drug ChEBI antihyperlipidemic drugs ChEBI antihyperlipidemics ChEBI antilipemic ChEBI antilipemic drugs ChEBI antilipemics ChEBI hypolipidemic agent ChEBI hypolipidemic agents ChEBI lipid-lowering agent ChEBI lipid-lowering agents ChEBI lipid-lowering drug ChEBI lipid-lowering drugs ChEBI An agent used to treat cestode, trematode, or other flatworm infestations in man or animals. chebi_ontology antiplatyhelmintic agent antiplatyhelmintic drugs CHEBI:35684 antiplatyhelmintic drug CHEBI:35684 antiplatyhelmintic agent ChEBI antiplatyhelmintic drugs ChEBI An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. chebi_ontology immunosuppressant immunosuppressive agents inmunosupresor CHEBI:35705 immunosuppressive agent CHEBI:35705 immunosuppressant ChEBI immunosuppressive agents ChEBI inmunosupresor ChEBI A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. chebi_ontology hypnotics hypnotics and sedatives sedative drug sedatives sedatives and hypnotics CHEBI:35717 sedative CHEBI:35717 hypnotics ChEBI hypnotics and sedatives ChEBI sedative drug ChEBI sedatives ChEBI sedatives and hypnotics ChEBI A substance that suppresses Mycobacterium leprae, ameliorates the clinical manifestations of leprosy, and/or reduces the incidence and severity of leprous reactions. chebi_ontology leprostatic leprostatic agent leprostatic drugs CHEBI:35816 leprostatic drug CHEBI:35816 leprostatic ChEBI leprostatic agent ChEBI leprostatic drugs ChEBI An agent useful in the treatment or prevention of coccidiosis in man or animals. chebi_ontology anticoccidial agent coccidiostats CHEBI:35818 coccidiostat CHEBI:35818 anticoccidial agent ChEBI coccidiostats ChEBI Any antimicrobial drug which is used to treat or prevent protozoal infections. Wikipedia:Antiprotozoal_agent chebi_ontology antiprotozoal agent antiprotozoal agents antiprotozoal drugs CHEBI:35820 antiprotozoal drug CHEBI:35820 antiprotozoal agent ChEBI antiprotozoal agents ChEBI antiprotozoal drugs ChEBI A substance used to lower plasma cholesterol levels. CHEBI:64906 chebi_ontology anticholesteremic anticholesteremic agent anticholesteremic drugs antihypercholesterolemic antihypercholesterolemic agent antihypercholesterolemic agents antihypercholesterolemic drug antihypercholesterolemic drugs antihypercholesterolemics cholesterol inhibitor cholesterol-lowering agent cholesterol-lowering agents cholesterol-lowering drug cholesterol-lowering drugs hypocholesteremic agent CHEBI:35821 anticholesteremic drug CHEBI:35821 anticholesteremic ChEBI anticholesteremic agent ChEBI anticholesteremic drugs ChEBI antihypercholesterolemic ChEBI antihypercholesterolemic agent ChEBI antihypercholesterolemic agents ChEBI antihypercholesterolemic drug ChEBI antihypercholesterolemic drugs ChEBI antihypercholesterolemics ChEBI cholesterol inhibitor ChEBI cholesterol-lowering agent ChEBI cholesterol-lowering agents ChEBI cholesterol-lowering drug ChEBI cholesterol-lowering drugs ChEBI hypocholesteremic agent ChEBI A gout suppressant that acts directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma. chebi_ontology uricosuric agent uricosuric drugs CHEBI:35841 uricosuric drug CHEBI:35841 uricosuric agent ChEBI uricosuric drugs ChEBI A drug used to treat rheumatoid arthritis. chebi_ontology anti-rheumatic drugs antirheumatic agent antirheumatic drugs CHEBI:35842 antirheumatic drug CHEBI:35842 anti-rheumatic drugs ChEBI antirheumatic agent ChEBI antirheumatic drugs ChEBI A drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout. chebi_ontology gout suppressants CHEBI:35845 gout suppressant CHEBI:35845 gout suppressants ChEBI A drug used for its effect on the kidneys' regulation of body fluid composition and volume. chebi_ontology renal agents CHEBI:35846 renal agent CHEBI:35846 renal agents ChEBI An agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders. chebi_ontology 5-HT agonist 5-hydroxytryptamine agonist serotonergic agonists serotonin agonist serotonin agonists CHEBI:35941 serotonergic agonist CHEBI:35941 5-HT agonist ChEBI 5-hydroxytryptamine agonist ChEBI serotonergic agonists ChEBI serotonin agonist ChEBI serotonin agonists ChEBI A substance used for its pharmacological action on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. chebi_ontology neurotransmitter agents CHEBI:35942 neurotransmitter agent CHEBI:35942 neurotransmitter agents ChEBI A drug used to treat or prevent microbial infections. chebi_ontology antimicrobial drugs CHEBI:36043 antimicrobial drug CHEBI:36043 antimicrobial drugs ChEBI A substance used in the prophylaxis or therapy of virus diseases. chebi_ontology anti-viral drug anti-virus drug antiviral drugs CHEBI:36044 antiviral drug CHEBI:36044 anti-viral drug ChEBI anti-virus drug ChEBI antiviral drugs ChEBI A drug used to treat or prevent bacterial infections. Wikipedia:Antibacterial chebi_ontology antibacterial drugs CHEBI:36047 antibacterial drug CHEBI:36047 antibacterial drugs ChEBI A drug used in the treatment of infections with bacteria of the genus Treponema. chebi_ontology antitreponemal agent antitreponemal drugs CHEBI:36050 antitreponemal drug CHEBI:36050 antitreponemal agent ChEBI antitreponemal drugs ChEBI A substance that is used in the treatment of syphilis. chebi_ontology antisyphilitic agent antisyphilitic agents antisyphilitic drugs antisyphilitics CHEBI:36051 antisyphilitic drug CHEBI:36051 antisyphilitic agent ChEBI antisyphilitic agents ChEBI antisyphilitic drugs ChEBI antisyphilitics ChEBI A drug used to treat infestations with arthropods of the subclass Acari (mites and ticks). Wikipedia:Acaricide chebi_ontology acaricide drugs CHEBI:36053 acaricide drug CHEBI:36053 acaricide drugs ChEBI A drug that stimulates contraction of the myometrium. Oxytocics are used to induce labour, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients). oxytocic chebi_ontology oxytocic agents oxytocic drugs uterine stimulants CHEBI:36063 oxytocic CHEBI:36063 oxytocic ChEBI oxytocic agents ChEBI oxytocic drugs ChEBI uterine stimulants ChEBI Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block. local anaesthetic chebi_ontology Lokalanaesthetikum anesthesique local local anaesthetics local anesthetics CHEBI:36333 local anaesthetic CHEBI:36333 local anaesthetic IUPAC Lokalanaesthetikum ChEBI anesthesique local ChEBI local anaesthetics ChEBI local anesthetics ChEBI A drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida. chebi_ontology antitrypanosomal agent antitrypanosomal agents antitrypanosomal drug antitrypanosomal drugs trypanocidal drugs trypanocide trypanosomicidal agents CHEBI:36335 trypanocidal drug CHEBI:36335 antitrypanosomal agent ChEBI antitrypanosomal agents ChEBI antitrypanosomal drug ChEBI antitrypanosomal drugs ChEBI trypanocidal drugs ChEBI trypanocide ChEBI trypanosomicidal agents ChEBI An agent that promotes the production and release of interferons. chebi_ontology interferon inducers CHEBI:36710 interferon inducer CHEBI:36710 interferon inducers ChEBI CHEBI:37196 bismuth molecular entity chebi_ontology bismuth compounds bismuth molecular entities CHEBI:37196 bismuth molecular entity CHEBI:37196 bismuth molecular entity ChEBI bismuth compounds ChEBI bismuth molecular entities ChEBI CHEBI:37217 titanium molecular entity chebi_ontology titanium compounds titanium molecular entities CHEBI:37217 titanium molecular entity CHEBI:37217 titanium molecular entity ChEBI titanium compounds ChEBI titanium molecular entities ChEBI A substance administered to enhance contrast in images of the inside of the body obtained using X-rays, gamma-rays, sound waves, radio waves (MRI), or radioactive particles in order to diagnose disease. chebi_ontology CHEBI:37334 diagnostic imaging agent CHEBI:37334 chebi_ontology CHEBI:37335 MRI contrast agent CHEBI:37335 chebi_ontology CHEBI:37336 radioactive imaging agent CHEBI:37336 chebi_ontology CHEBI:37337 ultrasound contrast agent CHEBI:37337 A substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays. Wikipedia:Contrast_medium chebi_ontology contrast media radiocontrast agent radiocontrast agents radioopaque media radiopaque media radiopaque medium CHEBI:37338 radioopaque medium CHEBI:37338 contrast media ChEBI radiocontrast agent ChEBI radiocontrast agents ChEBI radioopaque media ChEBI radiopaque media ChEBI radiopaque medium ChEBI An agent that selectively binds to and activates adrenergic receptors. chebi_ontology adrenergic agonists adrenergic receptor agonist adrenoceptor agonists adrenomimetic adrenomimetics CHEBI:37886 adrenergic agonist CHEBI:37886 adrenergic agonists ChEBI adrenergic receptor agonist ChEBI adrenoceptor agonists IUPHAR adrenomimetic ChEBI adrenomimetics ChEBI An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. chebi_ontology adrenergic antagonists adrenergic blockaders adrenergic blocker adrenergic blockers adrenergic receptor blockaders adrenoceptor antagonists CHEBI:37887 adrenergic antagonist CHEBI:37887 adrenergic antagonists ChEBI adrenergic blockaders ChEBI adrenergic blocker ChEBI adrenergic blockers ChEBI adrenergic receptor blockaders ChEBI adrenoceptor antagonists IUPHAR An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. chebi_ontology alpha-adrenergic antagonists alpha-adrenergic blocker alpha-adrenergic blockers alpha-adrenergic receptor blockaders alpha-adrenoceptor antagonists CHEBI:37890 alpha-adrenergic antagonist CHEBI:37890 alpha-adrenergic antagonists ChEBI alpha-adrenergic blocker ChEBI alpha-adrenergic blockers ChEBI alpha-adrenergic receptor blockaders ChEBI alpha-adrenoceptor antagonists IUPHAR chebi_ontology phenothiazine antipsychotic drugs phenothiazine antipsychotics phenothiazine neuroleptics CHEBI:37930 phenothiazine antipsychotic drug CHEBI:37930 phenothiazine antipsychotic drugs ChEBI phenothiazine antipsychotics ChEBI phenothiazine neuroleptics ChEBI H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. PMID:22035879 chebi_ontology H1 antihistaminics H1 receptor antagonists H1 receptor blockaders H1-receptor antagonists H1-receptor blocker H1-receptor blockers classical antihistamines classical antihistaminics CHEBI:37955 H1-receptor antagonist CHEBI:37955 PMID:22035879 Europe PMC H1 antihistaminics ChEBI H1 receptor antagonists IUPHAR H1 receptor blockaders ChEBI H1-receptor antagonists ChEBI H1-receptor blocker ChEBI H1-receptor blockers ChEBI classical antihistamines ChEBI classical antihistaminics ChEBI Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. PMID:22035879 Wikipedia:Antihistamines chebi_ontology antihistamine antihistamines antihistaminico antihistaminics histamine receptor blocker histamine receptor blockers CHEBI:37956 histamine antagonist CHEBI:37956 PMID:22035879 Europe PMC antihistamine ChEBI antihistamines ChEBI antihistaminico ChEBI antihistaminics ChEBI histamine receptor blocker ChEBI histamine receptor blockers ChEBI Drugs used for their actions on histaminergic systems. chebi_ontology histamine agents histamine drugs histaminergic agent histaminergic agents histaminergic drugs CHEBI:37957 histaminergic drug CHEBI:37957 histamine agents ChEBI histamine drugs ChEBI histaminergic agent ChEBI histaminergic agents ChEBI histaminergic drugs ChEBI chebi_ontology Farbstoff Farbstoffe colorante colorantes dyes teinture teintures CHEBI:37958 dye CHEBI:37958 Farbstoff ChEBI Farbstoffe ChEBI colorante ChEBI colorantes ChEBI dyes ChEBI teinture ChEBI teintures ChEBI H2-receptor antagonists are the drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of endogenous histamine. chebi_ontology H2 receptor antagonists H2 receptor blockaders H2-receptor blocker H2-receptor blockers histamine H2 receptor antagonist histamine H2 receptor antagonists CHEBI:37961 H2-receptor antagonist CHEBI:37961 H2 receptor antagonists IUPHAR H2 receptor blockaders ChEBI H2-receptor blocker ChEBI H2-receptor blockers ChEBI histamine H2 receptor antagonist ChEBI histamine H2 receptor antagonists ChEBI Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter. chebi_ontology adrenergic agents adrenergic drug adrenergic drugs adrenergic neuron agents adrenergics CHEBI:37962 adrenergic agent CHEBI:37962 adrenergic agents ChEBI adrenergic drug ChEBI adrenergic drugs ChEBI adrenergic neuron agents ChEBI adrenergics ChEBI chebi_ontology CHEBI:38060 triazine insecticide CHEBI:38060 A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. chebi_ontology antimalarials CHEBI:38068 antimalarial CHEBI:38068 antimalarials ChEBI A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. chebi_ontology anti-arrhythmia agent antiarrhythmic agent CHEBI:38070 anti-arrhythmia drug CHEBI:38070 anti-arrhythmia agent ChEBI antiarrhythmic agent ChEBI A drug that has a strengthening effect on the heart or that can increase cardiac output. chebi_ontology cardiotonic drugs CHEBI:38147 cardiotonic drug CHEBI:38147 cardiotonic drugs ChEBI Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. chebi_ontology cholinergic agent cholinergic drugs cholinomimetic CHEBI:38323 cholinergic drug CHEBI:38323 cholinergic agent ChEBI cholinergic drugs ChEBI cholinomimetic ChEBI Any drug that binds to and activates cholinergic receptors. chebi_ontology acetylcholine agonist acetylcholine agonists acetylcholine receptor agonist cholinergic agonists cholinomimetic cholinomimetics CHEBI:38324 cholinergic agonist CHEBI:38324 acetylcholine agonist ChEBI acetylcholine agonists ChEBI acetylcholine receptor agonist IUPHAR cholinergic agonists ChEBI cholinomimetic ChEBI cholinomimetics ChEBI Any drug that binds to and activates a muscarinic cholinergic receptor. chebi_ontology muscarinic acetylcholine receptor agonist muscarinic agonists muscarinic cholinergic agonist muscarinic cholinergic agonists CHEBI:38325 muscarinic agonist CHEBI:38325 muscarinic acetylcholine receptor agonist ChEBI muscarinic agonists ChEBI muscarinic cholinergic agonist ChEBI muscarinic cholinergic agonists ChEBI chebi_ontology ecdysone agonists ecdysone mimetic CHEBI:38456 ecdysone agonist CHEBI:38456 ecdysone agonists ChEBI ecdysone mimetic ChEBI Derivatives of carbamic acid with insecticidal properties of general formula ROC(=O)NR(1)R(2), where ROH is an alcohol, oxime, or phenol and R(1) is hydrogen or methyl. Like organophosphate insecticides, they are cholinesterase inhibitors, but carbamate insecticides differ in action from the organophosphates in that the inhibitory effect on cholinesterase is generally brief. chebi_ontology carbamate insecticides CHEBI:38461 carbamate insecticide CHEBI:38461 carbamate insecticides ChEBI Substance used to treat lice (genus Pediculus) infestation. chebi_ontology pediculicides CHEBI:38706 pediculicide CHEBI:38706 pediculicides ChEBI A surfactant with an uncharged hydrophilic headgroup. chebi_ontology non-ionic surfactant nonionic surfactants CHEBI:38828 nonionic surfactant CHEBI:38828 non-ionic surfactant ChEBI nonionic surfactants ChEBI A substance that can carry oxygen to and carbon dioxide away from the tissues when introduced into the blood stream. Blood substitutes are used to replace hemoglobin in severe hemorrhage and also to perfuse isolated organs. chebi_ontology artificial blood blood substitutes oxygen carrier CHEBI:38849 blood substitute CHEBI:38849 artificial blood ChEBI blood substitutes ChEBI oxygen carrier ChEBI Substance which produces loss of feeling or sensation. anaesthetic chebi_ontology Anaesthetika Anaesthetikum anaesthetics anesthetic agent anesthetic drug anesthetics CHEBI:38867 anaesthetic CHEBI:38867 anaesthetic IUPAC Anaesthetika ChEBI Anaesthetikum ChEBI anaesthetics ChEBI anesthetic agent ChEBI anesthetic drug ChEBI anesthetics ChEBI Substance that produces loss of consciousness. general anaesthetic chebi_ontology Allgemeinanaesthetika Allgemeinanaesthetikum general anaesthetics general anesthetics CHEBI:38869 general anaesthetic CHEBI:38869 general anaesthetic IUPAC Allgemeinanaesthetika ChEBI Allgemeinanaesthetikum ChEBI general anaesthetics ChEBI general anesthetics ChEBI chebi_ontology Inhalationsanaesthetika Inhalationsanaesthetikum Inhalationsnarkotika Inhalationsnarkotikum anesthetic gases inhalation anesthetics CHEBI:38870 inhalation anaesthetic CHEBI:38870 Inhalationsanaesthetika ChEBI Inhalationsanaesthetikum ChEBI Inhalationsnarkotika ChEBI Inhalationsnarkotikum ChEBI anesthetic gases ChEBI inhalation anesthetics ChEBI chebi_ontology i.v.-Anaesthetika i.v.-Anaesthetikum intravenous anesthetics CHEBI:38877 intravenous anaesthetic CHEBI:38877 i.v.-Anaesthetika ChEBI i.v.-Anaesthetikum ChEBI intravenous anesthetics ChEBI Drugs that used to treat infestations by flukes (trematodes) of the genus Schistosoma. chebi_ontology antischistosoma antischistosomal drug schistosomicide schistosomicide drugs schistosomicides CHEBI:38941 schistosomicide drug CHEBI:38941 antischistosoma ChEBI antischistosomal drug ChEBI schistosomicide ChEBI schistosomicide drugs ChEBI schistosomicides ChEBI chebi_ontology ectoparasiticides CHEBI:38956 ectoparasiticide CHEBI:38956 ectoparasiticides ChEBI chebi_ontology pyrethroid ester insecticides CHEBI:39116 pyrethroid ester insecticide CHEBI:39116 pyrethroid ester insecticides ChEBI chebi_ontology CHEBI:39208 antibiotic insecticide CHEBI:39208 chebi_ontology CHEBI:39215 antibiotic pesticide CHEBI:39215 chebi_ontology CHEBI:39216 antibiotic acaricide CHEBI:39216 chebi_ontology CHEBI:39217 antibiotic nematicide CHEBI:39217 chebi_ontology CHEBI:39259 pyrethroid ester acaricide CHEBI:39259 A volatile or volatilizable chemical compound utilized for control of pests in buildings, soil, grain, as well as during processing of goods to be imported or exported to prevent transfer of exotic organisms. Wikipedia:Fumigation chebi_ontology fumigant pesticide fumigants CHEBI:39276 fumigant CHEBI:39276 fumigant pesticide ChEBI fumigants ChEBI chebi_ontology fumigant insecticides CHEBI:39277 fumigant insecticide CHEBI:39277 fumigant insecticides ChEBI chebi_ontology CHEBI:39301 sulfite ester acaricide CHEBI:39301 chebi_ontology CHEBI:39316 mite growth regulator CHEBI:39316 chebi_ontology CHEBI:39318 tetrazine acaricide CHEBI:39318 chebi_ontology pyrethroid ether insecticides CHEBI:39351 pyrethroid ether insecticide CHEBI:39351 pyrethroid ether insecticides ChEBI chebi_ontology pyrethroid ether acaricides CHEBI:39369 pyrethroid ether acaricide CHEBI:39369 pyrethroid ether acaricides ChEBI chebi_ontology CHEBI:39378 homopteran inhibitor of chitin biosynthesis CHEBI:39378 chebi_ontology CHEBI:39379 lepidopteran inhibitor of chitin biosynthesis CHEBI:39379 chebi_ontology bridged diphenyl acaricides CHEBI:39412 bridged diphenyl acaricide CHEBI:39412 bridged diphenyl acaricides ChEBI chebi_ontology dinitrophenol insecticides CHEBI:39415 dinitrophenol insecticide CHEBI:39415 dinitrophenol insecticides ChEBI A role played by a fluorescent molecular entity used to study the microscopic environment by fluorescence spectroscopy. chebi_ontology CHEBI:39442 fluorescent probe CHEBI:39442 Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye. chebi_ontology anti-glaucoma agent anti-glaucoma agents anti-glaucoma drug anti-glaucoma drugs antiglaucoma agent antiglaucoma drugs CHEBI:39456 antiglaucoma drug CHEBI:39456 anti-glaucoma agent ChEBI anti-glaucoma agents ChEBI anti-glaucoma drug ChEBI anti-glaucoma drugs ChEBI antiglaucoma agent ChEBI antiglaucoma drugs ChEBI Fibrous incombustible mineral composed of magnesium and calcium silicates with or without other elements. CAS:1332-21-4 KEGG:C16442 asbestos chebi_ontology Asbest asbesto CHEBI:46661 asbestos CHEBI:46661 CAS:1332-21-4 ChemIDplus CAS:1332-21-4 KEGG COMPOUND asbestos ChemIDplus Asbest ChemIDplus asbesto ChEBI 0 H8Mg6O18Si4 554.225 551.78902 CAS:12001-29-5 Gmelin:37576 Gmelin:462680 Gmelin:484250 Chrysotile chebi_ontology Chrysotile asbestos Mg3(Si2O5)(OH)4 Mg6(Si4O10)(OH)8 Serpentine chrysotile CHEBI:46664 chrysotile CHEBI:46664 CAS:12001-29-5 ChemIDplus Gmelin:37576 Gmelin Gmelin:462680 Gmelin Gmelin:484250 Gmelin Chrysotile ChemIDplus Chrysotile asbestos ChemIDplus Mg3(Si2O5)(OH)4 ChEBI Mg6(Si4O10)(OH)8 ChEBI Serpentine chrysotile ChemIDplus 0 Fe5H2Na2O24Si8 935.890 935.36324 CAS:12001-28-4 Gmelin:1280433 Crocidolite asbestos chebi_ontology Blauasbest Crocidolite Fibrous crocidolite asbestos Krokydolith Krokydolith Asbest Na2Fe(2+)3Fe(3+)2Si8O22(OH)2 Na2Fe3Fe2Si8O22(OH)2 Na2Fe5Si8O22(OH)2 blue asbestos CHEBI:46666 crocidolite asbestos CHEBI:46666 CAS:12001-28-4 ChemIDplus Gmelin:1280433 Gmelin Crocidolite asbestos ChemIDplus Blauasbest ChEBI Crocidolite ChemIDplus Fibrous crocidolite asbestos ChemIDplus Krokydolith ChemIDplus Krokydolith Asbest ChEBI Na2Fe(2+)3Fe(3+)2Si8O22(OH)2 ChEBI Na2Fe3Fe2Si8O22(OH)2 ChEBI Na2Fe5Si8O22(OH)2 ChEBI blue asbestos ChEBI 0 Ca2H2Mg5O24Si8 812.366 809.55940 CAS:14567-73-8 Gmelin:19375 Tremolite asbestos chebi_ontology Ca2Mg5Si8O22(OH)2 Tremolite Tremolitena asbestiform tremolite CHEBI:46676 tremolite asbestos CHEBI:46676 CAS:14567-73-8 ChemIDplus Gmelin:19375 Gmelin Tremolite asbestos ChemIDplus Ca2Mg5Si8O22(OH)2 ChEBI Tremolite ChemIDplus Tremolitena ChemIDplus asbestiform tremolite ChEBI A class of asbestos minerals that includes silicates of magnesium, iron, calcium, and sodium. CAS:1318-09-8 chebi_ontology Hornblendeasbest amphibole amphibole-group minerals amphiboles anfibol anfiboles CHEBI:46677 amphibole asbestos CHEBI:46677 CAS:1318-09-8 ChemIDplus Hornblendeasbest ChemIDplus amphibole ChemIDplus amphibole-group minerals ChemIDplus amphiboles ChemIDplus anfibol ChEBI anfiboles ChEBI 0 Fe7H2O24Si8 1001.601 1001.25358 CAS:12172-73-5 chebi_ontology Amosit Amosite Brown asbestos Grunerite asbestos Mysorite asbestiform gruenerite brauner Asbest CHEBI:46678 amosite asbestos CHEBI:46678 CAS:12172-73-5 ChemIDplus Amosit ChEBI Amosite ChemIDplus Brown asbestos ChemIDplus Grunerite asbestos ChemIDplus Mysorite ChemIDplus asbestiform gruenerite ChEBI brauner Asbest ChEBI CAS:132207-32-0 chebi_ontology White asbestos CHEBI:46680 serpentine asbestos CHEBI:46680 CAS:132207-32-0 ChemIDplus White asbestos ChemIDplus 0 H2Mg7O24Si8 780.820 777.60431 CAS:17068-78-9 Anthophyllite asbestos chebi_ontology asbestiform anthophyllite CHEBI:46682 anthophyllite asbestos CHEBI:46682 CAS:17068-78-9 ChemIDplus Anthophyllite asbestos ChemIDplus asbestiform anthophyllite ChEBI chebi_ontology asbestiform actinolite CHEBI:46684 actinolite asbestos CHEBI:46684 asbestiform actinolite ChEBI 0 CCaO3 100.087 99.94733 CAS:13397-26-7 calcite chebi_ontology Calcit Kalzit calcita CHEBI:46719 calcite CHEBI:46719 CAS:13397-26-7 ChemIDplus calcite ChEBI Calcit ChEBI Kalzit ChEBI calcita ChEBI 0 O2Si 60.084 59.96676 CAS:14808-60-7 KEGG:C16459 Quartz chebi_ontology Quarz Tiefquarz alpha-quartz silicon oxide CHEBI:46727 quartz CHEBI:46727 CAS:14808-60-7 ChemIDplus CAS:14808-60-7 KEGG COMPOUND CAS:14808-60-7 NIST Chemistry WebBook Quartz ChemIDplus Quartz KEGG_COMPOUND Quarz ChEBI Tiefquarz ChEBI alpha-quartz ChemIDplus silicon oxide NIST_Chemistry_WebBook 0 O2Si 60.084 59.96676 CAS:14639-89-5 Chalcedony chebi_ontology Chalcedon Chalzedon calcedoine CHEBI:46728 chalcedony CHEBI:46728 CAS:14639-89-5 ChemIDplus Chalcedony ChemIDplus Chalcedon ChEBI Chalzedon ChEBI calcedoine ChEBI 0 O2Si 60.084 59.96676 CAS:60676-86-0 chebi_ontology amorphous silica fused silica silica glass CHEBI:46729 vitreous silica CHEBI:46729 CAS:60676-86-0 ChemIDplus CAS:60676-86-0 NIST Chemistry WebBook amorphous silica ChemIDplus fused silica NIST_Chemistry_WebBook silica glass NIST_Chemistry_WebBook A liquid that can dissolve other substances (solutes) without any change in their chemical composition. Wikipedia:Solvent chebi_ontology Loesungsmittel solvant solvents CHEBI:46787 solvent CHEBI:46787 Loesungsmittel ChEBI solvant ChEBI solvents ChEBI Anything used in a scientific experiment to indicate the presence of a substance or quality, change in a body, etc. chebi_ontology Indikator CHEBI:47867 indicator CHEBI:47867 Indikator ChEBI A chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells. chebi_ontology photosensitising agent CHEBI:47868 photosensitizing agent CHEBI:47868 photosensitising agent ChEBI An agonist that selectively binds to and activates a nicotinic acetylcholine receptor. CHEBI:82738 Wikipedia:Nicotinic_acetylcholine_receptor chebi_ontology muscarinic agonists nicotinic acetylcholine receptor agonists nicotinic agonist nicotinic agonists CHEBI:47958 nicotinic acetylcholine receptor agonist CHEBI:47958 muscarinic agonists ChEBI nicotinic acetylcholine receptor agonists ChEBI nicotinic agonist ChEBI nicotinic agonists ChEBI A substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body). Wikipedia:Antiseptic chebi_ontology antiseptic antiseptic agent antiseptic agents antiseptics local antiinfective agents local microbicides topical antiinfective agents topical microbicides CHEBI:48218 antiseptic drug CHEBI:48218 antiseptic ChEBI antiseptic agent ChEBI antiseptic agents ChEBI antiseptics ChEBI local antiinfective agents ChEBI local microbicides ChEBI topical antiinfective agents ChEBI topical microbicides ChEBI chebi_ontology serotonergic agents serotonergic drugs serotonin drugs CHEBI:48278 serotonergic drug CHEBI:48278 serotonergic agents ChEBI serotonergic drugs ChEBI serotonin drugs ChEBI Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. chebi_ontology 5-HT antagonists 5-hydroxytryptamine antagonists antiserotonergic agents serotonin antagonists serotonin blockaders CHEBI:48279 serotonergic antagonist CHEBI:48279 5-HT antagonists ChEBI 5-hydroxytryptamine antagonists ChEBI antiserotonergic agents ChEBI serotonin antagonists ChEBI serotonin blockaders ChEBI A substance, extract, or preparation for diffusing or imparting an agreeable or attractive smell. chebi_ontology Parfuem aroma arome essence parfum perfume scent CHEBI:48318 fragrance CHEBI:48318 Parfuem ChEBI aroma ChEBI arome ChEBI essence ChEBI parfum ChEBI perfume ChEBI scent ChEBI A solvent that is composed of polar molecules. Polar solvents can dissolve ionic compounds or ionisable covalent compounds. polar solvent chebi_ontology polar solvents CHEBI:48354 polar solvent CHEBI:48354 polar solvent IUPAC polar solvents ChEBI chebi_ontology CHEBI:48355 non-polar solvent CHEBI:48355 A polar solvent that is capable of acting as a hydron (proton) donor. protogenic solvent chebi_ontology CHEBI:48356 protic solvent CHEBI:48356 protogenic solvent IUPAC chebi_ontology CHEBI:48357 aprotic solvent CHEBI:48357 A solvent with a comparatively high relative permittivity (or dielectric constant), greater than ca. 15, and a sizable permanent dipole moment, that cannot donate suitably labile hydrogen atoms to form strong hydrogen bonds. dipolar aprotic solvent chebi_ontology CHEBI:48358 polar aprotic solvent CHEBI:48358 dipolar aprotic solvent IUPAC Solvent that is capable of acting as a hydron (proton) acceptor. protophilic solvent chebi_ontology HBA solvent hydrogen bond acceptor solvent CHEBI:48359 protophilic solvent CHEBI:48359 protophilic solvent IUPAC HBA solvent ChEBI hydrogen bond acceptor solvent ChEBI Self-ionizing solvent possessing both characteristics of Bronsted acids and bases. amphiprotic solvent chebi_ontology CHEBI:48360 amphiprotic solvent CHEBI:48360 amphiprotic solvent IUPAC A drug used in the treatment of Parkinson's disease. Wikipedia:Antiparkinson chebi_ontology antiparkinson agent CHEBI:48407 antiparkinson drug CHEBI:48407 antiparkinson agent ChEBI An agent and endogenous substances that antagonize or inhibit the development of new blood vessels. CHEBI:67170 Wikipedia:Angiogenesis_inhibitor chebi_ontology angiogenesis antagonist angiostatic agents anti-angiogenic agent CHEBI:48422 angiogenesis inhibitor CHEBI:48422 angiogenesis antagonist ChEBI angiostatic agents ChEBI anti-angiogenic agent ChEBI A local anesthetic that is used to numb the surface of a body part. chebi_ontology topical anaesthetics topical anesthetic CHEBI:48425 topical anaesthetic CHEBI:48425 topical anaesthetics ChEBI topical anesthetic ChEBI A drug that it mimics the action of calcium on tissues. chebi_ontology calcimimetics CHEBI:48525 calcimimetic CHEBI:48525 calcimimetics ChEBI Any drug that acts on an alpha-adrenergic receptor. chebi_ontology alpha-adrenergic drugs CHEBI:48539 alpha-adrenergic drug CHEBI:48539 alpha-adrenergic drugs ChEBI Any of the drugs that act on beta-adrenergic receptors. chebi_ontology beta-adrenergic drugs CHEBI:48540 beta-adrenergic drug CHEBI:48540 beta-adrenergic drugs ChEBI A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. chebi_ontology dopamine agent dopamine agents dopamine drug dopamine drugs dopaminergic agents CHEBI:48560 dopaminergic agent CHEBI:48560 dopamine agent ChEBI dopamine agents ChEBI dopamine drug ChEBI dopamine drugs ChEBI dopaminergic agents ChEBI A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. chebi_ontology dopamine antagonist dopamine blocker dopamine receptor antagonist dopaminergic antagonists CHEBI:48561 dopaminergic antagonist CHEBI:48561 dopamine antagonist ChEBI dopamine blocker ChEBI dopamine receptor antagonist ChEBI dopaminergic antagonists ChEBI A role played by a substance that can react readily with, and thereby eliminate, radicals. chebi_ontology free radical scavengers free-radical scavenger CHEBI:48578 radical scavenger CHEBI:48578 free radical scavengers ChEBI free-radical scavenger ChEBI A drug that prevent fibrinolysis or lysis of a blood clot or thrombus. chebi_ontology antifibrinolytic agent antifibrinolytic agents antifibrinolytic drugs CHEBI:48675 antifibrinolytic drug CHEBI:48675 antifibrinolytic agent ChEBI antifibrinolytic agents ChEBI antifibrinolytic drugs ChEBI A drug that affects the function of fibrin in blood coagulation. chebi_ontology fibrin modulating agent fibrin modulating agents fibrin modulating drugs CHEBI:48676 fibrin modulating drug CHEBI:48676 fibrin modulating agent ChEBI fibrin modulating agents ChEBI fibrin modulating drugs ChEBI Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. chebi_ontology Anticholinergika Anticholinergikum acetylcholine antagonists acetylcholine receptor antagonist agent anticholinergique agente anticolinergico agentes anticolinergicos anticholinergic agents anticholinergics anticholinergiques anticolinergicos cholinergic-blocking agents CHEBI:48873 cholinergic antagonist CHEBI:48873 Anticholinergika ChEBI Anticholinergikum ChEBI acetylcholine antagonists ChEBI acetylcholine receptor antagonist IUPHAR agent anticholinergique ChEBI agente anticolinergico ChEBI agentes anticolinergicos ChEBI anticholinergic agents ChEBI anticholinergics ChEBI anticholinergiques ChEBI anticolinergicos ChEBI cholinergic-blocking agents ChEBI A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists. chebi_ontology Antimuskarinika Antimuskarinikum agente antimuscarinico agentes antimuscarinicos agents antimuscariniques antimuscarinic agents antimuscarinicos muscarinic acetylcholine receptor antagonist muscarinic antagonists CHEBI:48876 muscarinic antagonist CHEBI:48876 Antimuskarinika ChEBI Antimuskarinikum ChEBI agente antimuscarinico ChEBI agentes antimuscarinicos ChEBI agents antimuscariniques ChEBI antimuscarinic agents ChEBI antimuscarinicos ChEBI muscarinic acetylcholine receptor antagonist ChEBI muscarinic antagonists ChEBI An antagonist at the nicotinic cholinergic receptor. Wikipedia:Nicotinic_antagonist chebi_ontology agente antinicotinico agentes antinicotinicos agents antinicotiniques antinicotinicos nicotinic acetylcholine receptor antagonist nicotinic acetylcholine receptor antagonists nicotinic antagonists nicotinic cholinergic antagonist nicotinic cholinergic antagonists CHEBI:48878 nicotinic antagonist CHEBI:48878 agente antinicotinico ChEBI agentes antinicotinicos ChEBI agents antinicotiniques ChEBI antinicotinicos ChEBI nicotinic acetylcholine receptor antagonist ChEBI nicotinic acetylcholine receptor antagonists ChEBI nicotinic antagonists ChEBI nicotinic cholinergic antagonist ChEBI nicotinic cholinergic antagonists ChEBI A chemical substance which inhibits the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. chebi_ontology hormone antagonists CHEBI:49020 hormone antagonist CHEBI:49020 hormone antagonists ChEBI A compound that inhibits the action of prostaglandins. Wikipedia:Prostaglandin_antagonist chebi_ontology prostaglandin inhibitor CHEBI:49023 prostaglandin antagonist CHEBI:49023 prostaglandin inhibitor ChEBI A drug that acts principally at one or more sites within the peripheral neuroeffector systems, the autonomic system, and motor nerve-skeletal system. chebi_ontology peripheral nervous system agent peripheral nervous system drugs CHEBI:49110 peripheral nervous system drug CHEBI:49110 peripheral nervous system agent ChEBI peripheral nervous system drugs ChEBI A drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. chebi_ontology LTRA leukotriene antagonists leukotriene receptor antagonist leukotriene receptor antagonists CHEBI:49159 leukotriene antagonist CHEBI:49159 LTRA DrugBank leukotriene antagonists ChEBI leukotriene receptor antagonist ChEBI leukotriene receptor antagonists ChEBI A drug used to treat asthma. chebi_ontology anti-asthmatic agent anti-asthmatic agents anti-asthmatic drugs CHEBI:49167 anti-asthmatic drug CHEBI:49167 anti-asthmatic agent ChEBI anti-asthmatic agents ChEBI anti-asthmatic drugs ChEBI One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. chebi_ontology anti-ulcer agent anti-ulcer agents anti-ulcer drugs CHEBI:49201 anti-ulcer drug CHEBI:49201 anti-ulcer agent ChEBI anti-ulcer agents ChEBI anti-ulcer drugs ChEBI A chemical substance that prevents or reduces the probability of conception. chebi_ontology contraceptive agent contraceptive drugs CHEBI:49323 contraceptive drug CHEBI:49323 contraceptive agent ChEBI contraceptive drugs ChEBI A chemical substance or agent with contraceptive activity in females. chebi_ontology female contraceptive agent female contraceptive drugs CHEBI:49324 female contraceptive drug CHEBI:49324 female contraceptive agent ChEBI female contraceptive drugs ChEBI A compound, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. chebi_ontology oral contraceptives CHEBI:49325 oral contraceptive CHEBI:49325 oral contraceptives ChEBI An oral contraceptive which owes its effectiveness to synthetic preparation. chebi_ontology synthetic oral contraceptives CHEBI:49326 synthetic oral contraceptive CHEBI:49326 synthetic oral contraceptives ChEBI An agent that binds to and activates excitatory amino acid receptors. chebi_ontology excitatory amino acid agonists excitatory amino acid receptor agonist excitatory amino acid receptor agonists CHEBI:50103 excitatory amino acid agonist CHEBI:50103 excitatory amino acid agonists ChEBI excitatory amino acid receptor agonist ChEBI excitatory amino acid receptor agonists ChEBI Any compound that exhibits antagonist activity at the mu-opioid receptor chebi_ontology mu-opioid antagonist mu-opioid antagonists mu-opioid receptor antagonists CHEBI:50137 mu-opioid receptor antagonist CHEBI:50137 mu-opioid antagonist ChEBI mu-opioid antagonists ChEBI mu-opioid receptor antagonists ChEBI A drug which causes a narrowing of the lumen of a bronchus or bronchiole. chebi_ontology bronchoconstrictor agents bronchoconstrictor drug CHEBI:50141 bronchoconstrictor agent CHEBI:50141 bronchoconstrictor agents ChEBI bronchoconstrictor drug ChEBI A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. chebi_ontology desquamating agent keratolytic agent keratolytic drugs skin-peeling agent CHEBI:50176 keratolytic drug CHEBI:50176 desquamating agent ChEBI keratolytic agent ChEBI keratolytic drugs ChEBI skin-peeling agent ChEBI A drug used to treat or prevent skin disorders or for the routine care of skin. chebi_ontology dermatologic agent dermatologic drugs dermatological agent CHEBI:50177 dermatologic drug CHEBI:50177 dermatologic agent ChEBI dermatologic drugs ChEBI dermatological agent ChEBI Any protective agent counteracting or neutralizing the action of poisons. chebi_ontology antidotes CHEBI:50247 antidote CHEBI:50247 antidotes ChEBI Drug that acts on blood and blood-forming organs and those that affect the hemostatic system. chebi_ontology hematologic agents CHEBI:50248 hematologic agent CHEBI:50248 hematologic agents ChEBI An agent that prevents blood clotting. chebi_ontology anticoagulante anticoagulants CHEBI:50249 anticoagulant CHEBI:50249 anticoagulante ChEBI anticoagulants ChEBI A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. PMID:23993918 PMID:23998799 PMID:24329110 PMID:24628402 PMID:24709544 PMID:25144792 PMID:25157234 PMID:25269430 PMID:25391982 PMID:25591121 PMID:25620096 PMID:25795057 PMID:26028253 PMID:26184144 PMID:28070577 PMID:28215138 PMID:28219047 PMID:28259775 PMID:28319647 PMID:28329729 PMID:28334528 Wikipedia:Prodrug chebi_ontology Prodrugs CHEBI:50266 prodrug CHEBI:50266 PMID:23993918 Europe PMC PMID:23998799 Europe PMC PMID:24329110 Europe PMC PMID:24628402 Europe PMC PMID:24709544 Europe PMC PMID:25144792 Europe PMC PMID:25157234 Europe PMC PMID:25269430 Europe PMC PMID:25391982 Europe PMC PMID:25591121 Europe PMC PMID:25620096 Europe PMC PMID:25795057 Europe PMC PMID:26028253 Europe PMC PMID:26184144 Europe PMC PMID:28070577 Europe PMC PMID:28215138 Europe PMC PMID:28219047 Europe PMC PMID:28259775 Europe PMC PMID:28319647 Europe PMC PMID:28329729 Europe PMC PMID:28334528 Europe PMC Prodrugs ChEBI Synthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. chebi_ontology chemoprotectant chemoprotectants chemoprotective agent chemoprotective agents protective agents CHEBI:50267 protective agent CHEBI:50267 chemoprotectant ChEBI chemoprotectants ChEBI chemoprotective agent ChEBI chemoprotective agents ChEBI protective agents ChEBI A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act. chebi_ontology GABA modulators CHEBI:50268 GABA modulator CHEBI:50268 GABA modulators ChEBI Any cholinergic antagonist that inhibits the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the muscarinic antagonists. chebi_ontology parasympatholytics CHEBI:50370 parasympatholytic CHEBI:50370 parasympatholytics ChEBI A role played by a molecular entity used to study the microscopic environment. chebi_ontology CHEBI:50406 probe CHEBI:50406 An acid or base which exhibits a colour change on neutralization by the basic or acidic titrant at or near the equivalence point of a titration. acid-base indicator chebi_ontology Saeure-Base-Indikator Saeure-Base-Indikatoren indicador acido-base indicateur acide-base CHEBI:50407 acid-base indicator CHEBI:50407 acid-base indicator IUPAC Saeure-Base-Indikator ChEBI Saeure-Base-Indikatoren ChEBI indicador acido-base IUPAC indicateur acide-base IUPAC Anything used in a scientific experiment that gives a visual change to indicate the presence of a substance or quality, change in a body, etc. visual indicator chebi_ontology indicador visual indicateur visuel CHEBI:50408 visual indicator CHEBI:50408 visual indicator IUPAC indicador visual IUPAC indicateur visuel IUPAC A substance which is adsorbed or desorbed with concomitant colour change at or near the equivalence point of a titration. adsorption indicator chebi_ontology indicador de adsorcion indicateur par adsorption CHEBI:50409 adsorption indicator CHEBI:50409 adsorption indicator IUPAC indicador de adsorcion IUPAC indicateur par adsorption IUPAC colour indicator chebi_ontology indicador de color indicateur colore indicateurs colores CHEBI:50410 colour indicator CHEBI:50410 colour indicator IUPAC indicador de color IUPAC indicateur colore IUPAC indicateurs colores ChEBI A colour indicator that is colourless on one side of the transition interval. one-colour indicator chebi_ontology indicador monocolor indicador monocromico indicateur monocolore CHEBI:50411 one-colour indicator CHEBI:50411 one-colour indicator IUPAC indicador monocolor IUPAC indicador monocromico IUPAC indicateur monocolore IUPAC A colour indicator that possesses a different colour on each side of the transition interval. two-colour indicator chebi_ontology indicador bicolor indicateur bicolore CHEBI:50412 two-colour indicator CHEBI:50412 two-colour indicator IUPAC indicador bicolor IUPAC indicateur bicolore IUPAC A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. chebi_ontology platelet aggregation inhibitors CHEBI:50427 platelet aggregation inhibitor CHEBI:50427 platelet aggregation inhibitors ChEBI Antagonist of platelet surface glycoprotein-IIb/IIIa which has a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Wikipedia:Glycoprotein_IIb/IIIa_inhibitors chebi_ontology GPIIb/IIIa antagonist GPIIb/IIIa antagonists fibrinogen receptor antagonist fibrinogen receptor antagonists glycoprotein-IIb/IIIa receptor antagonist glycoprotein-IIb/IIIa receptor antagonists platelet glycoprotein-IIb/IIIa receptor antagonists CHEBI:50433 platelet glycoprotein-IIb/IIIa receptor antagonist CHEBI:50433 GPIIb/IIIa antagonist ChEBI GPIIb/IIIa antagonists ChEBI fibrinogen receptor antagonist ChEBI fibrinogen receptor antagonists ChEBI glycoprotein-IIb/IIIa receptor antagonist ChEBI glycoprotein-IIb/IIIa receptor antagonists ChEBI platelet glycoprotein-IIb/IIIa receptor antagonists ChEBI An agent that produces a soft formed stool, and relaxes and loosens the bowels, typically used over a protracted period, to relieve constipation. Compare with cathartic, which is a substance that accelerates defecation. A substances can be both a laxative and a cathartic. chebi_ontology aperient aperients laxante laxatives purgative purgatives CHEBI:50503 laxative CHEBI:50503 aperient ChEBI aperients ChEBI laxante ChEBI laxatives ChEBI purgative ChEBI purgatives ChEBI Compound that increase urine volume by increasing the amount of osmotically active solute in the urine. It also increases the osmolarity of plasma. chebi_ontology CHEBI:50504 osmotic diuretic CHEBI:50504 Substance that sweeten food, beverages, medications, etc. chebi_ontology sweetener sweeteners CHEBI:50505 sweetening agent CHEBI:50505 sweetener ChEBI sweeteners ChEBI Agent that is used to decrease appetite. chebi_ontology CHEBI:50507 appetite depressant CHEBI:50507 Agent that dilates the pupil. Used in eye diseases and to facilitate eye examination. It may be either a sympathomimetic or parasympatholytic. The latter cause cycloplegia or paralysis of accommodation at high doses and may precipitate glaucoma. chebi_ontology mydriatics CHEBI:50513 mydriatic agent CHEBI:50513 mydriatics ChEBI Drug used to cause constriction of the blood vessels. chebi_ontology CHEBI:50514 vasoconstrictor agent CHEBI:50514 chebi_ontology CHEBI:50533 protein denaturant CHEBI:50533 An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. CHEBI:72497 Wikipedia:Osteoporosis chebi_ontology anti-osteopenia agent anti-osteopenia agents anti-osteopenia drug anti-osteopenia drugs anti-osteoporosis agent anti-osteoporosis agents anti-osteoporosis drug anti-osteoporosis drugs anti-osteoporotic anti-osteoporotic agent anti-osteoporotic agents anti-osteoporotic drug anti-osteoporotic drugs anti-osteoporotics antiosteoporotic antiosteoporotics bone density conservation agents bone density conservation drug bone density conservation drugs CHEBI:50646 bone density conservation agent CHEBI:50646 anti-osteopenia agent ChEBI anti-osteopenia agents ChEBI anti-osteopenia drug ChEBI anti-osteopenia drugs ChEBI anti-osteoporosis agent ChEBI anti-osteoporosis agents ChEBI anti-osteoporosis drug ChEBI anti-osteoporosis drugs ChEBI anti-osteoporotic ChEBI anti-osteoporotic agent ChEBI anti-osteoporotic agents ChEBI anti-osteoporotic drug ChEBI anti-osteoporotic drugs ChEBI anti-osteoporotics ChEBI antiosteoporotic ChEBI antiosteoporotics ChEBI bone density conservation agents ChEBI bone density conservation drug ChEBI bone density conservation drugs ChEBI A drug used to treat hyperthyroidism by reducing the excessive production of thyroid hormones. Wikipedia:Antithyroid_agent chebi_ontology antithyroid agent antithyroid agents antithyroid drugs CHEBI:50671 antithyroid drug CHEBI:50671 antithyroid agent ChEBI antithyroid agents ChEBI antithyroid drugs ChEBI A reagent with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between macromolecules, principally side chains of amino acids in proteins, allowing the locations of naturally reactive areas within the proteins to be identified. chebi_ontology cross-linking reagents CHEBI:50684 cross-linking reagent CHEBI:50684 cross-linking reagents ChEBI A drug used to treat trichomonas infections. chebi_ontology antitrichomonal agent CHEBI:50685 antitrichomonal drug CHEBI:50685 antitrichomonal agent ChEBI A substance used either in the prevention or facilitation of pregnancy. chebi_ontology reproductive control agent reproductive control drugs CHEBI:50689 reproductive control drug CHEBI:50689 reproductive control agent ChEBI reproductive control drugs ChEBI A chemical substance that interrupts pregnancy after implantation. Wikipedia:Abortifacient chebi_ontology abortifacient agent abortifacient agents abortifacient drug abortifacient drugs abortifacients CHEBI:50691 abortifacient CHEBI:50691 abortifacient agent ChEBI abortifacient agents ChEBI abortifacient drug ChEBI abortifacient drugs ChEBI abortifacients ChEBI A product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. chebi_ontology Dietary Supplement Food Supplementation Nutritional supplement CHEBI:50733 nutraceutical CHEBI:50733 Dietary Supplement ChEBI Food Supplementation ChEBI Nutritional supplement ChEBI A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure. chebi_ontology CHEBI:50739 estrogen receptor modulator CHEBI:50739 Any retinoic acid receptor (RAR) agonist with specificity for RARalpha and RARbeta. chebi_ontology RAR alpha/beta agonist CHEBI:50741 retinoic acid receptor alpha/beta agonist CHEBI:50741 RAR alpha/beta agonist ChEBI A drug used to treat psoriasis. chebi_ontology antipsoriatic agent antipsoriatic drug CHEBI:50748 antipsoriatic CHEBI:50748 antipsoriatic agent ChEBI antipsoriatic drug ChEBI A drug which acts to reduce estrogenic activity in the body, either by reducing the amount of estrogen or by reducing the activity of whatever estrogen is present. Wikipedia:Antiestrogen chebi_ontology anti-estrogenic agent anti-estrogenic drug anti-oestrogen anti-oestrogenic agent anti-oestrogenic drug antiestrogen antiestrogenic agent antiestrogenic drug antioestrogen antioestrogenic agent antioestrogenic drug CHEBI:50751 anti-estrogen CHEBI:50751 anti-estrogenic agent ChEBI anti-estrogenic drug ChEBI anti-oestrogen ChEBI anti-oestrogenic agent ChEBI anti-oestrogenic drug ChEBI antiestrogen ChEBI antiestrogenic agent ChEBI antiestrogenic drug ChEBI antioestrogen ChEBI antioestrogenic agent ChEBI antioestrogenic drug ChEBI A drug which increases appetite. Wikipedia:Appetite_stimulants chebi_ontology appetite enhancing drug appetite stimulant orexigenic CHEBI:50779 appetite enhancer CHEBI:50779 appetite enhancing drug ChEBI appetite stimulant ChEBI orexigenic ChEBI An agent which regulates the physiologic mechanisms that control the appetite and food intake. chebi_ontology appetite regulators CHEBI:50780 appetite regulator CHEBI:50780 appetite regulators ChEBI An antagonist at the estrogen receptor. chebi_ontology estrogen receptor antagonists CHEBI:50792 estrogen receptor antagonist CHEBI:50792 estrogen receptor antagonists ChEBI A nanoparticle consisting of magnetite, Fe(2+)Fe(3+)2O4. PMID:29188240 Wikipedia:Magnetite chebi_ontology CHEBI:50823 magnetite nanoparticle CHEBI:50823 PMID:29188240 Europe PMC An iron oxide nanoparticle composed of hematite (Fe2O3). 0 Fe2O3 159.689 159.85462 Wikipedia:Hematite chebi_ontology haematite nanoparticle CHEBI:50824 hematite nanoparticle CHEBI:50824 haematite nanoparticle ChEBI A drug used to treat hyperparathyroidism by reducing the excessive production of parathyroid hormones. chebi_ontology antiparathyroid agent antiparathyroid agents antiparathyroid drugs CHEBI:50827 antiparathyroid drug CHEBI:50827 antiparathyroid agent ChEBI antiparathyroid agents ChEBI antiparathyroid drugs ChEBI A nanoparticle consisting of silicon dioxide. 0 O2Si 60.084 59.96676 chebi_ontology silica nanoparticle CHEBI:50828 silicon dioxide nanoparticle CHEBI:50828 silica nanoparticle ChEBI A nanoparticle consisting of cadmium sulfide. 0 CdS 144.478 145.87543 chebi_ontology CHEBI:50832 cadmium sulfide nanoparticle CHEBI:50832 0 CdSe 191.37100 193.81989 chebi_ontology CHEBI:50835 cadmium selenide nanoparticle CHEBI:50835 A compound which inhibits or antagonises the biosynthesis or actions of estrogens. chebi_ontology oestrogen antagonist CHEBI:50837 estrogen antagonist CHEBI:50837 oestrogen antagonist ChEBI A compound which inhibits or antagonizes the biosynthesis or actions of mineralocorticoids, a class of steroid hormones characterised by their similarity to aldosterone and their influence on salt and water balance. chebi_ontology CHEBI:50843 antimineralocorticoid CHEBI:50843 chebi_ontology CHEBI:50844 aldosterone antagonist CHEBI:50844 Biologically active substance whose activity affects or plays a role in the functioning of the immune system. Wikipedia:Immunotherapy chebi_ontology Biomodulator Immune factor Immunologic factor Immunological factor immunomodulators CHEBI:50846 immunomodulator CHEBI:50846 Biomodulator ChEBI Immune factor ChEBI Immunologic factor ChEBI Immunological factor ChEBI immunomodulators ChEBI A substance that augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level. A classical agent (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contains bacterial antigens. It could also be endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Its mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy is related to its antigen-specific immunoadjuvanticity. Wikipedia:Immunologic_adjuvant chebi_ontology Immunoactivator Immunoadjuvant Immunologic adjuvant Immunopotentiator Immunostimulant CHEBI:50847 immunological adjuvant CHEBI:50847 Immunoactivator ChEBI Immunoadjuvant ChEBI Immunologic adjuvant ChEBI Immunopotentiator ChEBI Immunostimulant ChEBI A cardiovascular drug that prevents atherogenesis, the accumulation of lipid-containing plaques on the innermost layers of the arteries. Compare with antiatherosclerotic agent. PMID:14592471 PMID:16366593 PMID:17990280 PMID:20222342 PMID:21074432 PMID:21172387 PMID:21649483 PMID:3288054 PMID:9796331 antiatherogenic agent chebi_ontology anti-atherogenic agent anti-atherogenic agents anti-atherogenic drug anti-atherogenic drugs antiatherogenic agents antiatherogenic drug antiatherogenic drugs CHEBI:50855 antiatherogenic agent CHEBI:50855 PMID:14592471 Europe PMC PMID:16366593 Europe PMC PMID:17990280 Europe PMC PMID:20222342 Europe PMC PMID:21074432 Europe PMC PMID:21172387 Europe PMC PMID:21649483 Europe PMC PMID:3288054 Europe PMC PMID:9796331 Europe PMC antiatherogenic agent ChEBI anti-atherogenic agent ChEBI anti-atherogenic agents ChEBI anti-atherogenic drug ChEBI anti-atherogenic drugs ChEBI antiatherogenic agents ChEBI antiatherogenic drug ChEBI antiatherogenic drugs ChEBI A drug used to treat allergic reactions. chebi_ontology anti-allergic agents anti-allergic drug anti-allergic drugs CHEBI:50857 anti-allergic agent CHEBI:50857 anti-allergic agents ChEBI anti-allergic drug ChEBI anti-allergic drugs ChEBI An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). chebi_ontology PPAR-gamma agonist PPAR-gamma agonists PPARgamma agonist PPARgamma agonists glitazonas glitazone drug glitazones insulin sensitisers insulin sensitizers insulin-sensitising drug insulin-sensitizing agent peroxisome proliferator-activated receptor gamma agonist peroxisome proliferator-activated receptor gamma agonists proliferator activated receptor gamma agonist proliferator activated receptor gamma agonists thiazolidinediones tiazolidinedionas CHEBI:50864 insulin-sensitizing drug CHEBI:50864 PPAR-gamma agonist ChEBI PPAR-gamma agonists ChEBI PPARgamma agonist ChEBI PPARgamma agonists ChEBI glitazonas ChEBI glitazone drug ChEBI glitazones ChEBI insulin sensitisers ChEBI insulin sensitizers ChEBI insulin-sensitising drug ChEBI insulin-sensitizing agent ChEBI peroxisome proliferator-activated receptor gamma agonist ChEBI peroxisome proliferator-activated receptor gamma agonists ChEBI proliferator activated receptor gamma agonist ChEBI proliferator activated receptor gamma agonists ChEBI thiazolidinediones ChEBI tiazolidinedionas ChEBI A role is particular behaviour which a material entity may exhibit. chebi_ontology CHEBI:50906 role CHEBI:50906 A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors. Wikipedia:Antiemetic chebi_ontology anti-emetic anti-emetics antiemetico antiemetics CHEBI:50919 antiemetic CHEBI:50919 anti-emetic ChEBI anti-emetics ChEBI antiemetico ChEBI antiemetics ChEBI An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents. chebi_ontology CHEBI:50926 angiogenesis modulating agent CHEBI:50926 A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. Wikipedia:Selective_serotonin_reuptake_inhibitor chebi_ontology SSRI serotonin reuptake inhibitor CHEBI:50949 serotonin uptake inhibitor CHEBI:50949 SSRI ChEBI serotonin reuptake inhibitor ChEBI A dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake. Wikipedia:Dopamine_uptake_inhibitor chebi_ontology DARI DRI dopamine reuptake inhibitor dopamine reuptake inhibitors dopamine uptake inhibitors CHEBI:51039 dopamine uptake inhibitor CHEBI:51039 DARI ChEBI DRI ChEBI dopamine reuptake inhibitor ChEBI dopamine reuptake inhibitors ChEBI dopamine uptake inhibitors ChEBI A nanoparticle consisting of titanium dioxide. 0 O2Ti 79.866 79.93778 chebi_ontology TiO2 nanoparticle CHEBI:51050 titanium dioxide nanoparticle CHEBI:51050 TiO2 nanoparticle ChEBI A chemical substance which binds to specific hormone receptors activating the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. chebi_ontology CHEBI:51060 hormone agonist CHEBI:51060 A drug that modulates the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. chebi_ontology hormone receptor modulators CHEBI:51061 hormone receptor modulator CHEBI:51061 hormone receptor modulators ChEBI A drug that binds to and activates dopamine receptors. chebi_ontology Agonista dopaminergico Dopamine receptor agonist Dopaminergic agonist CHEBI:51065 dopamine agonist CHEBI:51065 Agonista dopaminergico ChEBI Dopamine receptor agonist ChEBI Dopaminergic agonist ChEBI An agent causing contraction of the pupil of the eye. Because the size of the pupil is under the antagonistic control of the sympathetic and parasympathetic systems, drugs affecting either system can cause miosis. Drugs that mimic or potentiate the parasympathetic input to the circular constrictor muscle and drugs that inhibit sympathetic input to the radial dilator muscle tend to contract the pupils. chebi_ontology Miotico miotics CHEBI:51068 miotic CHEBI:51068 Miotico ChEBI miotics ChEBI A compound that inhibits the growth of marine organisms. chebi_ontology Antifoulant Antifouling agent Marine pesticide CHEBI:51076 antifouling biocide CHEBI:51076 Antifoulant ChEBI Antifouling agent ChEBI Marine pesticide ChEBI CHEBI:51086 A role played by the molecular entity or part thereof within a chemical context. chebi_ontology CHEBI:51086 chemical role CHEBI:51086 A group that is introduced into a molecule by chemical modification of a functional group in order to obtain chemoselectivity in a subsequent chemical reaction. chebi_ontology Schutzgruppe Schutzgruppen groupe protecteur protective group CHEBI:51087 protecting group CHEBI:51087 Schutzgruppe ChEBI Schutzgruppen ChEBI groupe protecteur ChEBI protective group ChEBI chebi_ontology fluorescent dyes CHEBI:51121 fluorescent dye CHEBI:51121 fluorescent dyes ChEBI A role played by a phosphonium ylide in a Wittig reaction. Wittig reagents chebi_ontology reactif de Wittig reactivo de Wittig reactivos de Wittig CHEBI:51166 Wittig reagent CHEBI:51166 Wittig reagents IUPAC reactif de Wittig IUPAC reactivo de Wittig IUPAC reactivos de Wittig IUPAC An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration. chebi_ontology anti-tussive cough suppressant cough suppressants CHEBI:51177 antitussive CHEBI:51177 anti-tussive ChEBI cough suppressant ChEBI cough suppressants ChEBI A fluorescent dye used to stain biological specimens. chebi_ontology fluorochromes CHEBI:51217 fluorochrome CHEBI:51217 fluorochromes ChEBI A role played by an organomagnesium halide in a Grignard reaction. chebi_ontology Grignards Reagens CHEBI:51237 Grignard reagent CHEBI:51237 Grignards Reagens ChEBI chebi_ontology CHEBI:51266 gelator CHEBI:51266 A role played by a compound in a fluid state in swelling a gel, network, or solid. chebi_ontology CHEBI:51267 swelling agent CHEBI:51267 A role played by a compound that facilitates the rapid drying of gels without their cracking. chebi_ontology CHEBI:51268 drying control chemical additive CHEBI:51268 A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis. chebi_ontology muscle relaxants CHEBI:51371 muscle relaxant CHEBI:51371 muscle relaxants ChEBI A drug used for its actions on skeletal muscle. chebi_ontology CHEBI:51372 neuromuscular agent CHEBI:51372 A drug that binds to and activates gamma-aminobutyric acid receptors. chebi_ontology GABA agonists GABA receptor agonist GABA receptor agonists gamma-aminobutyric acid receptor agonist gamma-aminobutyric acid receptor agonists CHEBI:51373 GABA agonist CHEBI:51373 GABA agonists ChEBI GABA receptor agonist ChEBI GABA receptor agonists ChEBI gamma-aminobutyric acid receptor agonist ChEBI gamma-aminobutyric acid receptor agonists ChEBI A substance, such as agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function, used for its pharmacological actions on GABAergic systems. chebi_ontology CHEBI:51374 GABA agent CHEBI:51374 A hormone antagonist that blocks endothelin receptors. chebi_ontology ERA CHEBI:51451 endothelin receptor antagonist CHEBI:51451 ERA ChEBI A endothelin receptor antagonist is a drug which selectively blocks endothelin A receptors. chebi_ontology CHEBI:51452 endothelin A receptor antagonist CHEBI:51452 A compound which binds and activates the prostacyclin receptor IP1, but has only partial efficacy at the receptor relative to a full agonist. chebi_ontology CHEBI:51577 partial prostacyclin agonist CHEBI:51577 A chemical role played by the molecular entity or part thereof in a photochemical process. chebi_ontology photochemical roles CHEBI:52215 photochemical role CHEBI:52215 photochemical roles ChEBI Any substance introduced into a living organism with therapeutic or diagnostic purpose. CHEBI:33293 CHEBI:33294 chebi_ontology farmaco medicament pharmaceuticals CHEBI:52217 pharmaceutical CHEBI:52217 farmaco ChEBI medicament ChEBI pharmaceuticals ChEBI 0 CCaO3 100.087 99.94733 CAS:14791-73-2 aragonite chebi_ontology Aragonit aragonita aragonito CHEBI:52239 aragonite CHEBI:52239 CAS:14791-73-2 ChemIDplus aragonite ChEBI Aragonit ChEBI aragonita ChEBI aragonito ChEBI 0 CCaO3 100.087 99.94733 PMID:32722123 PMID:34442948 PMID:34851105 PMID:35334765 Wikipedia:Vaterite vaterite chebi_ontology Vaterit mu-CaCO3 mu-calcium carbonate CHEBI:52241 vaterite CHEBI:52241 PMID:32722123 Europe PMC PMID:34442948 Europe PMC PMID:34851105 Europe PMC PMID:35334765 Europe PMC vaterite ChEBI Vaterit ChEBI mu-CaCO3 ChEBI mu-calcium carbonate ChEBI An organic dye characterized by an aromatic four-membered ring system derived from squaric acid. chebi_ontology CHEBI:52271 squaraine dye CHEBI:52271 An antiviral drug targeted at influenza viruses. Its mode of action consists of blocking the function of the viral neuraminidase protein (EC 3.2.1.18), thus preventing the virus from budding from the host cell. chebi_ontology EC 3.2.1.18 (exo-alpha-sialidase) inhibitors EC 3.2.1.18 inhibitor EC 3.2.1.18 inhibitors N-acylneuraminate glycohydrolase inhibitor N-acylneuraminate glycohydrolase inhibitors acetylneuraminidase inhibitor acetylneuraminidase inhibitors acetylneuraminyl hydrolase inhibitor acetylneuraminyl hydrolase inhibitors alpha-neuraminidase inhibitor alpha-neuraminidase inhibitors exo-alpha-sialidase (EC 3.2.1.18) inhibitor exo-alpha-sialidase (EC 3.2.1.18) inhibitors exo-alpha-sialidase inhibitor exo-alpha-sialidase inhibitors neuraminidase inhibitor neuraminidase inhibitors sialidase inhibitor sialidase inhibitors CHEBI:52425 EC 3.2.1.18 (exo-alpha-sialidase) inhibitor CHEBI:52425 EC 3.2.1.18 (exo-alpha-sialidase) inhibitors ChEBI EC 3.2.1.18 inhibitor ChEBI EC 3.2.1.18 inhibitors ChEBI N-acylneuraminate glycohydrolase inhibitor ChEBI N-acylneuraminate glycohydrolase inhibitors ChEBI acetylneuraminidase inhibitor ChEBI acetylneuraminidase inhibitors ChEBI acetylneuraminyl hydrolase inhibitor ChEBI acetylneuraminyl hydrolase inhibitors ChEBI alpha-neuraminidase inhibitor ChEBI alpha-neuraminidase inhibitors ChEBI exo-alpha-sialidase (EC 3.2.1.18) inhibitor ChEBI exo-alpha-sialidase (EC 3.2.1.18) inhibitors ChEBI exo-alpha-sialidase inhibitor ChEBI exo-alpha-sialidase inhibitors ChEBI neuraminidase inhibitor ChEBI neuraminidase inhibitors ChEBI sialidase inhibitor ChEBI sialidase inhibitors ChEBI A gold nanoparticle covered with a thin coat of palladium atoms. chebi_ontology Pd core/Au shell bimetallic nanoparticle Pd-Au bimetallic nanoparticle Pd-Au nanoparticle Pd-on-Au nanoparticle Pd/Au NP Pd/Au nanoparticle PdAu bimetallic nanoparticle PdAu nanoparticle bimetallic PdAu nanoparticle CHEBI:52523 palladium-gold nanoparticle CHEBI:52523 Pd core/Au shell bimetallic nanoparticle ChEBI Pd-Au bimetallic nanoparticle ChEBI Pd-Au nanoparticle ChEBI Pd-on-Au nanoparticle ChEBI Pd/Au NP ChEBI Pd/Au nanoparticle ChEBI PdAu bimetallic nanoparticle ChEBI PdAu nanoparticle ChEBI bimetallic PdAu nanoparticle ChEBI chebi_ontology CHEBI:52526 silicon nanoparticle CHEBI:52526 A drug that blocks the action of proteasomes, cellular complexes that break down proteins. chebi_ontology proteasome inhibitors CHEBI:52726 proteasome inhibitor CHEBI:52726 proteasome inhibitors ChEBI A nanoparticle consisting of dieuropium trioxide. chebi_ontology Eu2O3 nanoparticle dieuropium trioxide nanoparticles CHEBI:52733 dieuropium trioxide nanoparticle CHEBI:52733 Eu2O3 nanoparticle ChEBI dieuropium trioxide nanoparticles ChEBI CHEBI:52855 A nanoparticle that contains no carbon. chebi_ontology inorganic nanoparticles CHEBI:52855 inorganic nanoparticle CHEBI:52855 inorganic nanoparticles ChEBI A group that serves to protect a phosphate group in the context of a synthesis. chebi_ontology phosphate protecting groups CHEBI:52941 phosphate protecting group CHEBI:52941 phosphate protecting groups ChEBI A group that serves to protect a carboxylic acid function in the context of a synthesis. chebi_ontology carboxylic acid protecting groups CHEBI:52943 carboxylic acid protecting group CHEBI:52943 carboxylic acid protecting groups ChEBI A drug that binds to and activates gamma-hydroxybutyric acid receptors. chebi_ontology GHB receptor agonists CHEBI:53353 GHB receptor agonist CHEBI:53353 GHB receptor agonists ChEBI CHEBI:53374 A macromolecule composed of repeating gamma-linked L-glutamyl units. 0 H2O.(C5H7NO3)n CAS:25513-46-6 chebi_ontology Glutamic acid polymer PLGA Poly(alpha-L-glutamic acid) Poly-L-glutamate Polyglutamic acid alpha-L-Glutamic acid polymer gamma-poly(L-glutamic acid) poly(L-glutamic acid) poly(L-glutamicacid) CHEBI:53374 gamma-poly(L-glutamic acid) macromolecule CHEBI:53374 CAS:25513-46-6 ChemIDplus Glutamic acid polymer ChemIDplus PLGA SUBMITTER Poly(alpha-L-glutamic acid) ChemIDplus Poly-L-glutamate ChemIDplus Polyglutamic acid ChemIDplus alpha-L-Glutamic acid polymer ChemIDplus gamma-poly(L-glutamic acid) ChEBI poly(L-glutamic acid) ChEBI poly(L-glutamicacid) SUBMITTER A drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder. chebi_ontology antispasmodics CHEBI:53784 antispasmodic drug CHEBI:53784 antispasmodics ChEBI A compound that exhibits agonist activity at the mu-opioid receptor. CHEBI:50136 chebi_ontology mu opioid agonist mu-opioid agonists mu-opioid receptor agonists CHEBI:55322 mu-opioid receptor agonist CHEBI:55322 mu opioid agonist ChEBI mu-opioid agonists ChEBI mu-opioid receptor agonists ChEBI Any drug found useful in the symptomatic treatment of diarrhoea. chebi_ontology antidiarrheal antidiarrheal agent antidiarrheal agents antidiarrheal drug antidiarrheal drugs antidiarrheals antidiarrhoeal antidiarrhoeal agent antidiarrhoeal agents antidiarrhoeal drugs antidiarrhoeals antiperistaltic antiperistaltic agent antiperistaltic agents antiperistaltic drug antiperistaltic drugs antiperistaltics CHEBI:55323 antidiarrhoeal drug CHEBI:55323 antidiarrheal ChEBI antidiarrheal agent ChEBI antidiarrheal agents ChEBI antidiarrheal drug ChEBI antidiarrheal drugs ChEBI antidiarrheals ChEBI antidiarrhoeal ChEBI antidiarrhoeal agent ChEBI antidiarrhoeal agents ChEBI antidiarrhoeal drugs ChEBI antidiarrhoeals ChEBI antiperistaltic ChEBI antiperistaltic agent ChEBI antiperistaltic agents ChEBI antiperistaltic drug ChEBI antiperistaltic drugs ChEBI antiperistaltics ChEBI A drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion. chebi_ontology gastrointestinal agent gastrointestinal agents gastrointestinal drugs CHEBI:55324 gastrointestinal drug CHEBI:55324 gastrointestinal agent ChEBI gastrointestinal agents ChEBI gastrointestinal drugs ChEBI A drug or agent applied to the skin to control seborrhea or seborrheic dermatitis. chebi_ontology antiseborrheic agent antiseborrheic agents antiseborrheic drug antiseborrheics CHEBI:59010 antiseborrheic CHEBI:59010 antiseborrheic agent ChEBI antiseborrheic agents ChEBI antiseborrheic drug ChEBI antiseborrheics ChEBI A substance used as an indicator of a biological state. chebi_ontology biological marker CHEBI:59163 biomarker CHEBI:59163 biological marker ChEBI A chemical substance which inhibits the function of gonadotrophin-releasing hormone (GnRH). chebi_ontology GnRH antagonists gonadotrophin-releasing hormone antagonist gonadotrophin-releasing hormone antagonists CHEBI:59229 GnRH antagonist CHEBI:59229 GnRH antagonists ChEBI gonadotrophin-releasing hormone antagonist ChEBI gonadotrophin-releasing hormone antagonists ChEBI A compound that exhibits agonist activity at the kappa-opioid receptor. chebi_ontology kappa-opioid agonist kappa-opioid receptor agonists CHEBI:59282 kappa-opioid receptor agonist CHEBI:59282 kappa-opioid agonist ChEBI kappa-opioid receptor agonists ChEBI Any compound that exhibits antagonist activity at the delta-opioid receptor. chebi_ontology delta-opioid antagonist delta-opioid antagonists CHEBI:59283 delta-opioid receptor antagonist CHEBI:59283 delta-opioid antagonist ChEBI delta-opioid antagonists ChEBI Any drug which blocks vasopressin receptors. chebi_ontology antidiuretic hormone inhibitor antidiuretic hormone inhibitors arginine vasopressin receptor antagonist arginine vasopressin receptor antagonists argipressin receptor antagonist argipressin receptor antagonists vasopressin receptor antagonists CHEBI:59680 vasopressin receptor antagonist CHEBI:59680 antidiuretic hormone inhibitor ChEBI antidiuretic hormone inhibitors ChEBI arginine vasopressin receptor antagonist ChEBI arginine vasopressin receptor antagonists ChEBI argipressin receptor antagonist ChEBI argipressin receptor antagonists ChEBI vasopressin receptor antagonists ChEBI A drug, usually applied topically, that relieves pruritus (itching). chebi_ontology anti-itching drug anti-itching drugs antipruritic agent antipruritic agents antipruritic drugs CHEBI:59683 antipruritic drug CHEBI:59683 anti-itching drug ChEBI anti-itching drugs ChEBI antipruritic agent ChEBI antipruritic agents ChEBI antipruritic drugs ChEBI Any drug which binds to vasopressin receptors and triggers a response. chebi_ontology antidiuretic hormone agonist antidiuretic hormone agonists arginine vasopressin receptor agonist arginine vasopressin receptor agonists argipressin receptor agonist argipressin receptor agonists vasopressin receptor agonists CHEBI:59727 vasopressin receptor agonist CHEBI:59727 antidiuretic hormone agonist ChEBI antidiuretic hormone agonists ChEBI arginine vasopressin receptor agonist ChEBI arginine vasopressin receptor agonists ChEBI argipressin receptor agonist ChEBI argipressin receptor agonists ChEBI vasopressin receptor agonists ChEBI A reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner. chebi_ontology electrophile electrophiles electrophilic reagents CHEBI:59739 electrophilic reagent CHEBI:59739 electrophile ChEBI electrophiles ChEBI electrophilic reagents ChEBI A reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons. chebi_ontology nucleophile nucleophiles nucleophilic reagents CHEBI:59740 nucleophilic reagent CHEBI:59740 nucleophile ChEBI nucleophiles ChEBI nucleophilic reagents ChEBI A reagent used to improve selectivity in chromatographic analyses or separations, e.g. by formation of a derivative or by modification of the mobile phase. chebi_ontology derivatising reagents derivatizing reagent derivatizing reagents CHEBI:59745 chromatographic reagent CHEBI:59745 derivatising reagents ChEBI derivatizing reagent ChEBI derivatizing reagents ChEBI A surfactant molecule with hydrophilic groups at both ends of a hydrophobic hydrocarbon chain chebi_ontology alpha-omega-type surfactant bolaamphiphiles bolaform surfactant bolaphile CHEBI:59752 bolaamphiphile CHEBI:59752 alpha-omega-type surfactant ChEBI bolaamphiphiles ChEBI bolaform surfactant ChEBI bolaphile ChEBI A drug used for the treatment of hyperplasia (increaced cell production within an organ or tissue). chebi_ontology antihypergenesis drug antihypergenesis drugs antihyperplasia drugs antihyperplastic CHEBI:59844 antihyperplasia drug CHEBI:59844 antihypergenesis drug ChEBI antihypergenesis drugs ChEBI antihyperplasia drugs ChEBI antihyperplastic ChEBI Any drug used to depigment skin, normally by decreasing the excretion of melanin from melanocytes. chebi_ontology depigmentation agent depigmentation agents depigmentation drugs depigmentor depigmentors CHEBI:59864 depigmentation drug CHEBI:59864 depigmentation agent ChEBI depigmentation agents ChEBI depigmentation drugs ChEBI depigmentor ChEBI depigmentors ChEBI A drug which interferes with the binding, fusion and entry of an HIV virion to a human cell. By blocking this step in HIV's replication cycle, such agents slow the progression from HIV infection to AIDS. PMID:22470838 Wikipedia:Entry_inhibitor chebi_ontology HIV entry inhibitor HIV entry inhibitors HIV fusion inhibitors CHEBI:59886 HIV fusion inhibitor CHEBI:59886 PMID:22470838 Europe PMC HIV entry inhibitor ChEBI HIV entry inhibitors ChEBI HIV fusion inhibitors ChEBI A surfactant molecule possessing both hydrophilic and lipophilic properties. chebi_ontology amphiphiles CHEBI:59941 amphiphile CHEBI:59941 amphiphiles ChEBI A chemical substance is a portion of matter of constant composition, composed of molecular entities of the same type or of different types. chebi_ontology Chemische Substanz CHEBI:59999 chemical substance CHEBI:59999 Chemische Substanz ChEBI A mixture is a chemical substance composed of multiple molecules, at least two of which are of a different kind. chebi_ontology Mischung CHEBI:60004 mixture CHEBI:60004 Mischung ChEBI Any member of the class of herbicides whose members contain a phenoxy or substituted phenoxy group. Wikipedia:Phenoxy_herbicide chebi_ontology phenoxy herbicides CHEBI:60575 phenoxy herbicide CHEBI:60575 phenoxy herbicides ChEBI Any agent that acts on an opioid receptor or affects the life cycle of an opioid transmitter. chebi_ontology opioid agents CHEBI:60598 opioid agent CHEBI:60598 opioid agents ChEBI Any agent that acts on a mu-opioid receptor. chebi_ontology mu-opioid agents CHEBI:60599 mu-opioid agent CHEBI:60599 mu-opioid agents ChEBI Any agent that acts on a delta-opioid receptor. chebi_ontology delta-opioid agents CHEBI:60601 delta-opioid agent CHEBI:60601 delta-opioid agents ChEBI Any agent that acts on a kappa-opioid receptor. chebi_ontology kappa-opioid agents CHEBI:60603 kappa-opioid agent CHEBI:60603 kappa-opioid agents ChEBI An agent that binds to but does not activate an opioid receptor thereby blocking the actions of endogenous or exogenous opioid receptor agonists. Wikipedia:Opioid_antagonist chebi_ontology opiate antagonist opiate antagonists opioid antagonist opioid antagonists opioid receptor antagonists CHEBI:60605 opioid receptor antagonist CHEBI:60605 opiate antagonist ChEBI opiate antagonists ChEBI opioid antagonist ChEBI opioid antagonists ChEBI opioid receptor antagonists ChEBI An agent that selectively binds to and activates an opioid receptor. chebi_ontology opiate agonist opiate agonists opioid agonist opioid agonists opioid receptor agonists CHEBI:60606 opioid receptor agonist CHEBI:60606 opiate agonist ChEBI opiate agonists ChEBI opioid agonist ChEBI opioid agonists ChEBI opioid receptor agonists ChEBI A chiral compound used to induce stereoselectivity into a reaction. chebi_ontology CHEBI:60646 chiral reagent CHEBI:60646 An agent which blocks glucagon receptors. chebi_ontology glucagon receptor antagonists CHEBI:60649 glucagon receptor antagonist CHEBI:60649 glucagon receptor antagonists ChEBI Any substance that possesses little anaesthetic effect by itself, but which enhances or potentiates the anaesthetic action of other drugs when given at the same time. chebi_ontology anaesthesia adjuvants anaesthestic adjuvant anaesthestic adjuvants CHEBI:60807 anaesthesia adjuvant CHEBI:60807 anaesthesia adjuvants ChEBI anaesthestic adjuvant ChEBI anaesthestic adjuvants ChEBI Any pharmacological or immunological agent that modifies the effect of other agents such as drugs or vaccines while having few if any direct effects when given by itself. chebi_ontology adjuvants CHEBI:60809 adjuvant CHEBI:60809 adjuvants ChEBI A hormone antagonist that blocks angiotensin receptors. chebi_ontology angiotensin receptor antagonists CHEBI:61016 angiotensin receptor antagonist CHEBI:61016 angiotensin receptor antagonists ChEBI A drug used in the treatment of bile or liver disorders. chebi_ontology bile therapy agent bile therapy agents bile therapy drugs CHEBI:61026 bile therapy drug CHEBI:61026 bile therapy agent ChEBI bile therapy agents ChEBI bile therapy drugs ChEBI A polymer substance, composed of dendritic macromolecules. chebi_ontology dendrimer dendron polymer CHEBI:61483 dendritic polymer CHEBI:61483 dendrimer ChEBI dendron polymer ChEBI Any additive that enhances the efficiency of fuel. chebi_ontology fuel additives fuel enhancer CHEBI:62803 fuel additive CHEBI:62803 fuel additives ChEBI fuel enhancer ChEBI Any compound that is able to prevent damage to the liver. chebi_ontology antihepatotoxic agent hepatoprotective agents hepatoprotector CHEBI:62868 hepatoprotective agent CHEBI:62868 antihepatotoxic agent ChEBI hepatoprotective agents ChEBI hepatoprotector ChEBI A (1->4)-beta-D-glucan (cellulose) in amorphous form with a structure consisting of several hundred to over ten thousand D-glucose residues joined by beta(1->4) glycosidic linkages. Wikipedia:Cellulose chebi_ontology CHEBI:62967 amorphous cellulose CHEBI:62967 A (1->4)-beta-D-glucan (cellulose) in crystalline form with a structure consisting of several hundred to over ten thousand D-glucose residues joined by beta(1->4) glycosidic linkages. Wikipedia:Cellulose chebi_ontology microcrystalline cellulose CHEBI:62968 crystalline cellulose CHEBI:62968 microcrystalline cellulose ChEBI A food additive used to form or maintain a uniform emulsion of two (or more) phases in a food. chebi_ontology food emulsifiers CHEBI:63047 food emulsifier CHEBI:63047 food emulsifiers ChEBI The element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species. Wikipedia:Reducing_agent chebi_ontology reducer reducers reducing agents reductant reductants CHEBI:63247 reducing agent CHEBI:63247 reducer ChEBI reducers ChEBI reducing agents ChEBI reductant ChEBI reductants ChEBI Any drug which binds to gonadotropin-releasing hormone receptors and triggers a response. Wikipedia:Gonadotropin-releasing_hormone_agonist chebi_ontology GnRH agonist GnRH agonists GnRH-A gonadotrophin releasing hormone agonist gonadotrophin releasing hormone agonists gonadotropin releasing hormone agonists CHEBI:63533 gonadotropin releasing hormone agonist CHEBI:63533 GnRH agonist ChEBI GnRH agonists ChEBI GnRH-A ChEBI gonadotrophin releasing hormone agonist ChEBI gonadotrophin releasing hormone agonists ChEBI gonadotropin releasing hormone agonists ChEBI Any compound that can be used for the treatment of neurodegenerative disorders. chebi_ontology neuroprotectant neuroprotectants neuroprotective agents CHEBI:63726 neuroprotective agent CHEBI:63726 neuroprotectant ChEBI neuroprotectants ChEBI neuroprotective agents ChEBI Any substance which is added to food to preserve or enhance its flavour and/or appearance. Wikipedia:Food_additive chebi_ontology food additives CHEBI:64047 food additive CHEBI:64047 food additives ChEBI A food additive that is used to change or otherwise control the acidity or alkalinity of foods. They may be acids, bases, neutralising agents or buffering agents. Wikipedia:Acidity_regulator chebi_ontology acidity regulator acidity regulators food acidity regulators pH control agent pH control agents CHEBI:64049 food acidity regulator CHEBI:64049 acidity regulator ChEBI acidity regulators ChEBI food acidity regulators ChEBI pH control agent ChEBI pH control agents ChEBI chebi_ontology CHEBI:64054 delta-opioid receptor agonist CHEBI:64054 A histamine agonist that binds to and activates histamine H3-receptors. chebi_ontology H3-receptor agonists histamine H3-receptor agonist histamine H3-receptor agonists CHEBI:64154 H3-receptor agonist CHEBI:64154 H3-receptor agonists ChEBI histamine H3-receptor agonist ChEBI histamine H3-receptor agonists ChEBI A histamine agonist that binds to and activates H4-receptors. chebi_ontology H4-receptor agonists CHEBI:64155 H4-receptor agonist CHEBI:64155 H4-receptor agonists ChEBI A histamine antagonist that selectively binds to but does not activate histamine H3 receptors, thereby blocking the actions of endogenous histamine. chebi_ontology H3-receptor antagonists histamine H3-receptor antagonist histamine H3-receptor antagonists CHEBI:64176 H3-receptor antagonist CHEBI:64176 H3-receptor antagonists ChEBI histamine H3-receptor antagonist ChEBI histamine H3-receptor antagonists ChEBI A compound used to form the matrix for MALDI (matrix-assisted laser desorption/ionization) mass spectrometry. MALDI matrix materials are crystalline compounds with a fairly low molecular weight, so as to allow facile vaporization, have strong absorption at UV or IR wavelengths (to rapidly and efficiently absorb laser irradiation), generally contain polar groups (enabling them to be used in aqueous solutions) and are frequently acidic (so assisting ionisation of the compound being studied, which is contained within the matrix material). PMID:15373456 Patent:EP2060919 Wikipedia:Matrix-assisted_laser_desorption/ionization#Matrix chebi_ontology 'matrix-assisted laser desorption/ionization' matrix material 'matrix-assisted laser desorption/ionization' matrix materials MALDI matrix materials MALDI matrix solution MALDI matrix solutions CHEBI:64345 MALDI matrix material CHEBI:64345 PMID:15373456 Europe PMC 'matrix-assisted laser desorption/ionization' matrix material ChEBI 'matrix-assisted laser desorption/ionization' matrix materials ChEBI MALDI matrix materials ChEBI MALDI matrix solution ChEBI MALDI matrix solutions ChEBI A neurotransmitter transporter modulator that activates glutamate transporters. chebi_ontology excitatory amino-acid transporter activator excitatory amino-acid transporter activators glutamate transporter activators CHEBI:64370 glutamate transporter activator CHEBI:64370 excitatory amino-acid transporter activator ChEBI excitatory amino-acid transporter activators ChEBI glutamate transporter activators ChEBI A membrane transport modulator that affects the transport of neurotransmitters. chebi_ontology neurotransmitter transporter modulators CHEBI:64371 neurotransmitter transporter modulator CHEBI:64371 neurotransmitter transporter modulators ChEBI An excitatory amino acid agonist which binds to NMDA receptors and triggers a response. chebi_ontology N-methyl-D-aspartate receptor agonist N-methyl-D-aspartate receptor agonists NMDA receptor agonists NMDAR agonist NMDAR agonists CHEBI:64571 NMDA receptor agonist CHEBI:64571 N-methyl-D-aspartate receptor agonist ChEBI N-methyl-D-aspartate receptor agonists ChEBI NMDA receptor agonists ChEBI NMDAR agonist ChEBI NMDAR agonists ChEBI A food additive which is added to flour or dough to improve baking quality and/or colour. Wikipedia:Flour_treatment_agent flour treatment agent chebi_ontology dough improver dough improvers improving agent improving agents CHEBI:64577 flour treatment agent CHEBI:64577 flour treatment agent ChEBI dough improver ChEBI dough improvers ChEBI improving agent ChEBI improving agents ChEBI The role played by a substance in enhancing the appearance or odour of the human body; a name given to the substance itself or to a component of it. Wikipedia:Cosmetics chebi_ontology cosmetic component cosmetics CHEBI:64857 cosmetic CHEBI:64857 cosmetic component ChEBI cosmetics ChEBI A drug used to treat or prevent infections caused by Mycobacteria, a genus of actinobacteria. Aerobic and nonmotile, members of the genus include the pathogens responsible for causing tuberculosis and leprosy. chebi_ontology antimycobacterial agent antimycobacterial agents antimycobacterial drugs antimycobacterials antimycobacterium CHEBI:64912 antimycobacterial drug CHEBI:64912 antimycobacterial agent ChEBI antimycobacterial agents ChEBI antimycobacterial drugs ChEBI antimycobacterials ChEBI antimycobacterium ChEBI An antiparasitic drug which is effective against Apicomplexan parasites in the genus Plasmodium. The genus contains over 200 species and includes those responsible for malaria. chebi_ontology antiplasmodial agent antiplasmodial agents antiplasmodial drugs antiplasmodium agent antiplasmodium agents antiplasmodium drug antiplasmodium drugs CHEBI:64915 antiplasmodial drug CHEBI:64915 antiplasmodial agent ChEBI antiplasmodial agents ChEBI antiplasmodial drugs ChEBI antiplasmodium agent ChEBI antiplasmodium agents ChEBI antiplasmodium drug ChEBI antiplasmodium drugs ChEBI A depigmentation agent which inhibits the synthesis of melanin. chebi_ontology melanin biosynthesis inhibitor melanin biosynthesis inhibitors melanin synthesis inhibitors melanogenesis inhibitor melanogenesis inhibitors CHEBI:64933 melanin synthesis inhibitor CHEBI:64933 melanin biosynthesis inhibitor ChEBI melanin biosynthesis inhibitors ChEBI melanin synthesis inhibitors ChEBI melanogenesis inhibitor ChEBI melanogenesis inhibitors ChEBI Any compound that has anti-asthmatic effects. chebi_ontology anti-asthmatic agents antiasthmatic agent antiasthmatic agents CHEBI:65023 anti-asthmatic agent CHEBI:65023 anti-asthmatic agents ChEBI antiasthmatic agent ChEBI antiasthmatic agents ChEBI Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased. Wikipedia:Typical_antipsychotic chebi_ontology first generation antipsychotic agent first generation antipsychotic agents first generation antipsychotic drug first generation antipsychotic drugs first generation antipsychotics typical antipsychotic typical antipsychotic agent typical antipsychotic agents typical antipsychotic drug typical antipsychotic drugs typical antipsychotics CHEBI:65190 first generation antipsychotic CHEBI:65190 first generation antipsychotic agent ChEBI first generation antipsychotic agents ChEBI first generation antipsychotic drug ChEBI first generation antipsychotic drugs ChEBI first generation antipsychotics ChEBI typical antipsychotic ChEBI typical antipsychotic agent ChEBI typical antipsychotic agents ChEBI typical antipsychotic drug ChEBI typical antipsychotic drugs ChEBI typical antipsychotics ChEBI Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements. chebi_ontology atypical antipsychotic atypical antipsychotic agent atypical antipsychotic agents atypical antipsychotic drug atypical antipsychotic drugs atypical antipsychotics second generation antipsychotic agent second generation antipsychotic agents second generation antipsychotic drug second generation antipsychotic drugs second generation antipsychotics CHEBI:65191 second generation antipsychotic CHEBI:65191 atypical antipsychotic ChEBI atypical antipsychotic agent ChEBI atypical antipsychotic agents ChEBI atypical antipsychotic drug ChEBI atypical antipsychotic drugs ChEBI atypical antipsychotics ChEBI second generation antipsychotic agent ChEBI second generation antipsychotic agents ChEBI second generation antipsychotic drug ChEBI second generation antipsychotic drugs ChEBI second generation antipsychotics ChEBI Substances which are added to food in order to prevent decomposition caused by microbial growth or by undesirable chemical changes. chebi_ontology food preservatives CHEBI:65255 food preservative CHEBI:65255 food preservatives ChEBI A food preservative which prevents decomposition of food by preventing the growth of fungi or bacteria. In European countries, E-numbers for permitted food preservatives are from E200 to E299, divided into sorbates (E200-209), benzoates (E210-219), sulfites (E220-229), phenols and formates (E230-239), nitrates (E240-259), acetates (E260-269), lactates (E270-279), propionates (E280-289) and others (E290-299). chebi_ontology antimicrobial food preservatives antimicrobial preservative antimicrobial preservatives CHEBI:65256 antimicrobial food preservative CHEBI:65256 antimicrobial food preservatives ChEBI antimicrobial preservative ChEBI antimicrobial preservatives ChEBI A compound that inhibits the action of gamma-aminobutyric acid. Wikipedia:GABA_antagonist chebi_ontology GABA antagonists gamma-aminobutyric acid receptor antagonist gamma-aminobutyric acid receptor antagonists CHEBI:65259 GABA antagonist CHEBI:65259 GABA antagonists ChEBI gamma-aminobutyric acid receptor antagonist ChEBI gamma-aminobutyric acid receptor antagonists ChEBI Any substance which is used to neutralise stomach acidity. Wikipedia:Antacid chebi_ontology antacids CHEBI:65265 antacid CHEBI:65265 antacids ChEBI Any compound which can be used to treat or alleviate the symptoms of dyskinesia. chebi_ontology antidyskinesia agents antidyskinesia drug antidyskinesia drugs antidyskinetic agent antidyskinetic agents antidyskinetic drug antidyskinetic drugs CHEBI:66956 antidyskinesia agent CHEBI:66956 antidyskinesia agents ChEBI antidyskinesia drug ChEBI antidyskinesia drugs ChEBI antidyskinetic agent ChEBI antidyskinetic agents ChEBI antidyskinetic drug ChEBI antidyskinetic drugs ChEBI Any compound that improves mental functions such as cognition, memory, intelligence, motivation, attention, and concentration. PMID:22393531 PMID:22647316 PMID:22742585 PMID:22795553 PMID:22828638 PMID:22837964 Wikipedia:Nootropic chebi_ontology cognitive enhancer cognitive enhancers intelligence enhancer intelligence enhancers memory enhancer memory enhancers neuro enhancer neuro enhancers nootropic nootropic agents nootropic drug nootropic drugs nootropics smart drug smart drugs CHEBI:66980 nootropic agent CHEBI:66980 PMID:22393531 Europe PMC PMID:22647316 Europe PMC PMID:22742585 Europe PMC PMID:22795553 Europe PMC PMID:22828638 Europe PMC PMID:22837964 Europe PMC cognitive enhancer ChEBI cognitive enhancers ChEBI intelligence enhancer ChEBI intelligence enhancers ChEBI memory enhancer ChEBI memory enhancers ChEBI neuro enhancer ChEBI neuro enhancers ChEBI nootropic ChEBI nootropic agents ChEBI nootropic drug ChEBI nootropic drugs ChEBI nootropics ChEBI smart drug ChEBI smart drugs ChEBI Any compound used for the treatment of eye conditions or eye diseases. chebi_ontology ophthalmic ophthalmic agent ophthalmic agents ophthalmics ophthalmological ophthalmologicals ophthalmology agent ophthalmology agents ophthalmology drugs CHEBI:66981 ophthalmology drug CHEBI:66981 ophthalmic ChEBI ophthalmic agent ChEBI ophthalmic agents ChEBI ophthalmics ChEBI ophthalmological ChEBI ophthalmologicals ChEBI ophthalmology agent ChEBI ophthalmology agents ChEBI ophthalmology drugs ChEBI Any compound that is able to protect normal cells from the damage caused by radiation therapy. chebi_ontology radiation mitigation agent radiation mitigation agents radiation protective agents radiation protective drug radiation protective drugs radioprotective agent radioprotective agents radioprotector radioprotectors CHEBI:66987 radiation protective agent CHEBI:66987 radiation mitigation agent ChEBI radiation mitigation agents ChEBI radiation protective agents ChEBI radiation protective drug ChEBI radiation protective drugs ChEBI radioprotective agent ChEBI radioprotective agents ChEBI radioprotector ChEBI radioprotectors ChEBI Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS). Wikipedia:Sympatholytic chebi_ontology sympatholytic sympatholytic agents sympatholytic drug sympatholytic drugs sympatholytics CHEBI:66991 sympatholytic agent CHEBI:66991 sympatholytic ChEBI sympatholytic agents ChEBI sympatholytic drug ChEBI sympatholytic drugs ChEBI sympatholytics ChEBI Any compound used to suppress premature labour and immature birth by suppressing uterine contractions. Wikipedia:Tocolytic chebi_ontology anti-contraction drug anti-contraction drugs anti-contraction medication anti-contraction medications labour repressant labour repressants tocolytic tocolytic agents tocolytic drug tocolytic drugs tocolytics CHEBI:66993 tocolytic agent CHEBI:66993 anti-contraction drug ChEBI anti-contraction drugs ChEBI anti-contraction medication ChEBI anti-contraction medications ChEBI labour repressant ChEBI labour repressants ChEBI tocolytic ChEBI tocolytic agents ChEBI tocolytic drug ChEBI tocolytic drugs ChEBI tocolytics ChEBI Any compound that has anti-inflammatory effects. chebi_ontology anti-inflammatory agents antiinflammatory agent antiinflammatory agents CHEBI:67079 anti-inflammatory agent CHEBI:67079 anti-inflammatory agents ChEBI antiinflammatory agent ChEBI antiinflammatory agents ChEBI A chemosterilant intended to sterilize insects. chebi_ontology insect chemosterilant insect chemosterilants insect sterilants CHEBI:67105 insect sterilant CHEBI:67105 insect chemosterilant ChEBI insect chemosterilants ChEBI insect sterilants ChEBI A reagent used in the determination of the concentration of a coloured chemical element or chemical compound in solution. chebi_ontology color reagent color reagents colorimetric reagents colour reagent colour reagents CHEBI:67126 colorimetric reagent CHEBI:67126 color reagent ChEBI color reagents ChEBI colorimetric reagents ChEBI colour reagent ChEBI colour reagents ChEBI In NMR spectroscopy a reagent added to a solution to induce chemical shifts and thus simplify complex spectra. chebi_ontology NMR shift reagents lanthanide shift reagent lanthanide shift reagents nuclear magnetic resonance shift reagent nuclear magnetic resonance shift reagents CHEBI:67137 NMR shift reagent CHEBI:67137 NMR shift reagents ChEBI lanthanide shift reagent ChEBI lanthanide shift reagents ChEBI nuclear magnetic resonance shift reagent ChEBI nuclear magnetic resonance shift reagents ChEBI An agonist that selectively binds to and activates a retinoic acid receptor. Wikipedia:Retinoic_acid_receptor chebi_ontology retinoic acid receptor agonists CHEBI:67198 retinoic acid receptor agonist CHEBI:67198 retinoic acid receptor agonists ChEBI A hormone agonist that binds to and activates progesterone receptors. chebi_ontology PR agonist PR agonists progesterone receptor agonists CHEBI:70709 progesterone receptor agonist CHEBI:70709 PR agonist ChEBI PR agonists ChEBI progesterone receptor agonists ChEBI An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania. chebi_ontology antileishmanial agents antileishmanial drug antileishmanial drugs CHEBI:70868 antileishmanial agent CHEBI:70868 antileishmanial agents ChEBI antileishmanial drug ChEBI antileishmanial drugs ChEBI Any entity used to generate reactive oxygen species. chebi_ontology ROS generator ROS generators reactive oxygen species generators CHEBI:70982 reactive oxygen species generator CHEBI:70982 ROS generator ChEBI ROS generators ChEBI reactive oxygen species generators ChEBI A hormone receptor modulator that acts as a complete or partial agonist or as an antagonist at the progesterone receptor. Wikipedia:Selective_progesterone_receptor_modulator chebi_ontology progesterone receptor modulators CHEBI:71027 progesterone receptor modulator CHEBI:71027 progesterone receptor modulators ChEBI Any drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease. PMID:20036435 PMID:20800761 PMID:21180460 PMID:21682893 PMID:21947805 PMID:22363762 PMID:22366309 PMID:22371464 PMID:22731105 PMID:22739138 PMID:22747423 PMID:22814659 PMID:22814660 PMID:22973866 PMID:22981668 PMID:22989856 PMID:23013790 PMID:23090701 PMID:23109143 PMID:23129684 Wikipedia:Orphan_drug chebi_ontology orphan drugs CHEBI:71031 orphan drug CHEBI:71031 PMID:20036435 Europe PMC PMID:20800761 Europe PMC PMID:21180460 Europe PMC PMID:21682893 Europe PMC PMID:21947805 Europe PMC PMID:22363762 Europe PMC PMID:22366309 Europe PMC PMID:22371464 Europe PMC PMID:22731105 Europe PMC PMID:22739138 Europe PMC PMID:22747423 Europe PMC PMID:22814659 Europe PMC PMID:22814660 Europe PMC PMID:22973866 Europe PMC PMID:22981668 Europe PMC PMID:22989856 Europe PMC PMID:23013790 Europe PMC PMID:23090701 Europe PMC PMID:23109143 Europe PMC PMID:23129684 Europe PMC orphan drugs ChEBI A histamine agonist that binds to and activates H1-receptors. Wikipedia:Histamine_H1_receptor chebi_ontology H1-receptor agonists histamine H1-receptor agonist histamine H1-receptor agonists CHEBI:71173 H1-receptor agonist CHEBI:71173 H1-receptor agonists ChEBI histamine H1-receptor agonist ChEBI histamine H1-receptor agonists ChEBI An insecticide that acts as a repellent to insects. Wikipedia:Insect_repellent chebi_ontology insect repellents CHEBI:71692 insect repellent CHEBI:71692 insect repellents ChEBI Any molecule shown to have the potentiality in stimulating the effect of nerve growth factor. chebi_ontology NGF stimulator NGF stimulators nerve growth factor stimulators CHEBI:72294 nerve growth factor stimulator CHEBI:72294 NGF stimulator ChEBI NGF stimulators ChEBI nerve growth factor stimulators ChEBI Any compound that promotes the growth of new blood vessels from pre-existing vessels. CHEBI:50927 chebi_ontology angiogenesis inducing agent angiogenesis inducing agents pro-angiogenic agents proangiogenic agent proangiogenic agents CHEBI:72571 pro-angiogenic agent CHEBI:72571 angiogenesis inducing agent ChEBI angiogenesis inducing agents ChEBI pro-angiogenic agents ChEBI proangiogenic agent ChEBI proangiogenic agents ChEBI Any compound that protects plants by activating their defence mechanisms. chebi_ontology plant activators CHEBI:73182 plant activator CHEBI:73182 plant activators ChEBI A hormone antagonist that inhibits the action of the peptide hormone cholecystokinin. Wikipedia:Cholecystokinin_antagonist chebi_ontology CCK antagonist CCK antagonists cholecystokinin antagonists CHEBI:73296 cholecystokinin antagonist CHEBI:73296 CCK antagonist ChEBI CCK antagonists ChEBI cholecystokinin antagonists ChEBI An acaricide that kills mites of the genus Sarcoptes. Wikipedia:Scabicide chebi_ontology scabicides CHEBI:73333 scabicide CHEBI:73333 scabicides ChEBI A hormone agonist that binds to and activates a thyroid hormone receptor. Wikipedia:Thyroid_hormone_receptor chebi_ontology thyroid hormone agonists thyromimetic thyromimetics CHEBI:73334 thyroid hormone agonist CHEBI:73334 thyroid hormone agonists ChEBI thyromimetic SUBMITTER thyromimetics ChEBI A drug used in treating and healing of wounds. Wikipedia:Wound_healing chebi_ontology vulneraries wound-healing agent wound-healing agents wound-healing drug wound-healing drugs CHEBI:73336 vulnerary CHEBI:73336 vulneraries ChEBI wound-healing agent ChEBI wound-healing agents ChEBI wound-healing drug ChEBI wound-healing drugs ChEBI Any agent used to determine the amino-acid sequence in a polypeptide. chebi_ontology protein-sequencing agents sequencing agent sequencing agents CHEBI:73352 protein-sequencing agent CHEBI:73352 protein-sequencing agents ChEBI sequencing agent ChEBI sequencing agents ChEBI A reagent used in the determination by spectrophotometry of the concentration of a chemical element or chemical compound in solution. chebi_ontology spectrophotometric reagents CHEBI:73618 spectrophotometric reagent CHEBI:73618 spectrophotometric reagents ChEBI A reagent used to couple amino acids during artificial peptide synthesis. chebi_ontology peptide coupling reagents CHEBI:73668 peptide coupling reagent CHEBI:73668 peptide coupling reagents ChEBI Substance used to set dyes on fabrics or tissue sections by forming a coordination complex with the dye which then attaches to the fabric or tissue. Wikipedia:Mordant chebi_ontology CHEBI:74152 mordant CHEBI:74152 A role borne by a molecule that acts to counteract or neutralize the deleterious effects of paracetamol (acetaminophen). PMID:16354242 PMID:16573399 PMID:16575097 PMID:22348679 PMID:22352734 PMID:22353666 PMID:22835053 PMID:22998987 PMID:7112203 chebi_ontology Tylenol poisoning antidote Tylenol poisoning antidotes acetaminophen poisoning antidote acetaminophen poisoning antidotes antidote to Tylenol poisoning antidote to acetaminophen poisoning antidotes to Tylenol poisoning antidotes to acetaminophen poisoning antidotes to paracetamol poisoning paracetamol poisoning antidote paracetamol poisoning antidotes CHEBI:74529 antidote to paracetamol poisoning CHEBI:74529 PMID:16354242 Europe PMC PMID:16573399 Europe PMC PMID:16575097 Europe PMC PMID:22348679 Europe PMC PMID:22352734 Europe PMC PMID:22353666 Europe PMC PMID:22835053 Europe PMC PMID:22998987 Europe PMC PMID:7112203 Europe PMC Tylenol poisoning antidote ChEBI Tylenol poisoning antidotes ChEBI acetaminophen poisoning antidote ChEBI acetaminophen poisoning antidotes ChEBI antidote to Tylenol poisoning ChEBI antidote to acetaminophen poisoning ChEBI antidotes to Tylenol poisoning ChEBI antidotes to acetaminophen poisoning ChEBI antidotes to paracetamol poisoning ChEBI paracetamol poisoning antidote ChEBI paracetamol poisoning antidotes ChEBI A role borne by a molecule that acts to counteract or neutralize the deleterious effects of curare. PMID:13358565 PMID:13386996 PMID:14128111 PMID:1579914 PMID:3896015 PMID:5333582 PMID:5352084 PMID:7720787 chebi_ontology antidote to curare antidote to tubocurarine antidote to tubocurarine poisoning antidotes to curare antidotes to curare poisoning antidotes to tubocurarine antidotes to tubocurarine poisoning curare antidote curare antidotes curare poisoning antidote curare poisoning antidotes tubocurarine antidote tubocurarine antidotes CHEBI:74530 antidote to curare poisoning CHEBI:74530 PMID:13358565 Europe PMC PMID:13386996 Europe PMC PMID:14128111 Europe PMC PMID:1579914 Europe PMC PMID:3896015 Europe PMC PMID:5333582 Europe PMC PMID:5352084 Europe PMC PMID:7720787 Europe PMC antidote to curare ChEBI antidote to tubocurarine ChEBI antidote to tubocurarine poisoning ChEBI antidotes to curare ChEBI antidotes to curare poisoning ChEBI antidotes to tubocurarine ChEBI antidotes to tubocurarine poisoning ChEBI curare antidote ChEBI curare antidotes ChEBI curare poisoning antidote ChEBI curare poisoning antidotes ChEBI tubocurarine antidote ChEBI tubocurarine antidotes ChEBI A compound that causes the contraction of body tissues, typically used to reduce bleeding from minor abrasions. Wikipedia:Astringent chebi_ontology adstringent adstringents astringents CHEBI:74783 astringent CHEBI:74783 adstringent ChEBI adstringents ChEBI astringents ChEBI A compound used as a probe during microarray analysis of oligosaccharide-protein interactions. chebi_ontology CHEBI:74886 neoglycolipid probe CHEBI:74886 A reagent used in the immobilization of compounds prior to their use in microarray analysis. chebi_ontology microarray analysis reagents CHEBI:74914 microarray analysis reagent CHEBI:74914 microarray analysis reagents ChEBI Colourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates. chebi_ontology chromogen chromogenic compounds chromogens CHEBI:75050 chromogenic compound CHEBI:75050 chromogen ChEBI chromogenic compounds ChEBI chromogens ChEBI A generally pharmacologically inactive substance that is formulated with the active ingredient of a medication. PMID:19709488 PMID:21086329 PMID:22707004 PMID:22877709 PMID:23450581 PMID:23525964 PMID:23657359 Wikipedia:Excipient excipient chebi_ontology bulking agent bulking agents filler fillers CHEBI:75324 excipient CHEBI:75324 PMID:19709488 Europe PMC PMID:21086329 Europe PMC PMID:22707004 Europe PMC PMID:22877709 Europe PMC PMID:23450581 Europe PMC PMID:23525964 Europe PMC PMID:23657359 Europe PMC excipient ChEBI bulking agent ChEBI bulking agents ChEBI filler ChEBI fillers ChEBI A chemical additive used to toughen or harden a polymer material by cross-linking of polymer chains. chebi_ontology curing agents vulcanization agent vulcanization agents vulcanizing agent vulcanizing agents CHEBI:75358 curing agent CHEBI:75358 curing agents ChEBI vulcanization agent ChEBI vulcanization agents ChEBI vulcanizing agent ChEBI vulcanizing agents ChEBI A compound which increases either the number of red cells or the amount of haemoglobin in the blood. chebi_ontology anti-anaemic agents anti-anaemic drug anti-anaemic drugs anti-anemia agent anti-anemia agents anti-anemia drug anti-anemia drugs anti-anemic agent anti-anemic agents anti-anemic drug anti-anemic drugs antianaemia agent antianaemia agents antianaemia drug antianaemia drugs antianaemic agent antianaemic agents antianaemic drug antianaemic drugs antianemia drug antianemia drugs CHEBI:75835 anti-anaemic agent CHEBI:75835 anti-anaemic agents ChEBI anti-anaemic drug ChEBI anti-anaemic drugs ChEBI anti-anemia agent ChEBI anti-anemia agents ChEBI anti-anemia drug ChEBI anti-anemia drugs ChEBI anti-anemic agent ChEBI anti-anemic agents ChEBI anti-anemic drug ChEBI anti-anemic drugs ChEBI antianaemia agent ChEBI antianaemia agents ChEBI antianaemia drug ChEBI antianaemia drugs ChEBI antianaemic agent ChEBI antianaemic agents ChEBI antianaemic drug ChEBI antianaemic drugs ChEBI antianemia drug ChEBI antianemia drugs ChEBI A compressed gas or liquid with a boiling point lower than room temperature which to used to propel and dispense liquids such as deodorants, insecticides, paints, etc. from aerosol cans. PMID:22519407 PMID:24001847 chebi_ontology propellants CHEBI:76414 propellant CHEBI:76414 PMID:22519407 Europe PMC PMID:24001847 Europe PMC propellants ChEBI Any protective agent that is able to prevent damage to the kidney. chebi_ontology nephroprotective agents CHEBI:76595 nephroprotective agent CHEBI:76595 nephroprotective agents ChEBI A compound used to return an excited fluorophore to the ground state by transfer of energy from fluorophore to quencher without the emission of light, with the quencher being promoted to its own excited state. chebi_ontology fluorescence quenchers CHEBI:76648 fluorescence quencher CHEBI:76648 fluorescence quenchers ChEBI A drug which increases the blood glucose level. chebi_ontology diabetes inducer hyperglycemic agents CHEBI:76916 hyperglycemic agent CHEBI:76916 diabetes inducer ChEBI hyperglycemic agents ChEBI A hormone antagonist that blocks corticotropin-releasing factor receptors chebi_ontology CRF antagonist CRF antagonists corticotropin-releasing factor receptor antagonists CHEBI:76977 corticotropin-releasing factor receptor antagonist CHEBI:76977 CRF antagonist ChEBI CRF antagonists ChEBI corticotropin-releasing factor receptor antagonists ChEBI A synthetic or semi-synthetic compound that has oestrogenic activity. Wikipedia:Xenoestrogen chebi_ontology xenoestrogens CHEBI:76988 xenoestrogen CHEBI:76988 xenoestrogens ChEBI A compound that alters the structure of mucus so as to decrease its viscosity and thereby facilitate its removal by ciliary action and expectoration. Compare with antitussives, which suppress the cough reflex, and expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing. PMID:17419975 PMID:17594730 PMID:20031934 PMID:2117172 PMID:22895919 chebi_ontology mucolytics CHEBI:77034 mucolytic CHEBI:77034 PMID:17419975 Europe PMC PMID:17594730 Europe PMC PMID:20031934 Europe PMC PMID:2117172 Europe PMC PMID:22895919 Europe PMC mucolytics ChEBI Compounds that are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing. Compare with mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration, and antitussives, which suppress the cough reflex. PMID:17594730 chebi_ontology expectorants CHEBI:77035 expectorant CHEBI:77035 PMID:17594730 Europe PMC expectorants ChEBI A dye used in microscopic or electron microscopic examination of cells and tissues to give contrast and to highlight particular features of interest, such as nuclei and cytoplasm. PMID:21756020 PMID:21838612 PMID:23901948 chebi_ontology biological stain biological stains histological dyes histological stain histological stains CHEBI:77178 histological dye CHEBI:77178 PMID:21756020 Europe PMC PMID:21838612 Europe PMC PMID:23901948 Europe PMC biological stain ChEBI biological stains ChEBI histological dyes ChEBI histological stain ChEBI histological stains ChEBI A food additive that imparts colour to food. In European countries, E-numbers for permitted food colours are from E 100 to E 199, divided into yellows (E 100-109), oranges (E 110-119), reds (E 120-129), blues and violets (E 130-139), greens (E 140-149), browns and blacks (E 150-159), and others (E 160-199). Wikipedia:Food_coloring chebi_ontology food coloring food colorings food colourings CHEBI:77182 food colouring CHEBI:77182 food coloring ChEBI food colorings ChEBI food colourings ChEBI Any protective agent that is able to prevent damage to the heart. chebi_ontology cardioprotective agents CHEBI:77307 cardioprotective agent CHEBI:77307 cardioprotective agents ChEBI A phsychotropic drug that improves wakefulness and alertness, and reduces tiredness, drowsiness, and the need for sleep. Eugeroics are relatively non-addictive and are used in the treatment of narcolepsy and other sleep disorders. Wikipedia:Wakefulness-promoting_agent chebi_ontology eugeroics vigilance promoting agent vigilance promoting agents vigilance promoting drug vigilance promoting drugs vigilance-promoting agent vigilance-promoting agents vigilance-promoting drug vigilance-promoting drugs wake-promoting agent wake-promoting agents wake-promoting drug wake-promoting drugs wakefulness-promoting agent wakefulness-promoting agents wakefulness-promoting drug wakefulness-promoting drugs CHEBI:77567 eugeroic CHEBI:77567 eugeroics ChEBI vigilance promoting agent ChEBI vigilance promoting agents ChEBI vigilance promoting drug ChEBI vigilance promoting drugs ChEBI vigilance-promoting agent ChEBI vigilance-promoting agents ChEBI vigilance-promoting drug ChEBI vigilance-promoting drugs ChEBI wake-promoting agent ChEBI wake-promoting agents ChEBI wake-promoting drug ChEBI wake-promoting drugs ChEBI wakefulness-promoting agent ChEBI wakefulness-promoting agents ChEBI wakefulness-promoting drug ChEBI wakefulness-promoting drugs ChEBI A diuretic that acts on the ascending loop of Henle in the kidney. Wikipedia:Loop_diuretic chebi_ontology loop diuretics CHEBI:77608 loop diuretic CHEBI:77608 loop diuretics ChEBI A drug used to relieve nasal congestion in the upper respiratory tract. Wikipedia:Decongestant chebi_ontology decongestant decongestants nasal decongestants CHEBI:77715 nasal decongestant CHEBI:77715 decongestant ChEBI decongestants ChEBI nasal decongestants ChEBI A food additive that is used to make or keep fruit or vegetable tissues firm and crisp. or which interacts with gelling agents such as pectin to produce or strengthen a gel. Wikipedia:Firming_agent chebi_ontology firming agent firming agents food firming agents CHEBI:77960 food firming agent CHEBI:77960 firming agent ChEBI firming agents ChEBI food firming agents ChEBI An antioxidant that used as a food additives to help guard against food deterioration. chebi_ontology food antioxidants CHEBI:77962 food antioxidant CHEBI:77962 food antioxidants ChEBI A food preservative that acts by chelating with metal cations (particularly those of copper, iron and nickel) that catalyse the oxidation of fats in food. Wikipedia:Sequestrant chebi_ontology sequestrants CHEBI:77963 sequestrant CHEBI:77963 sequestrants ChEBI A substance added to powdered or granulated materials in order to prevent the formation of lumps and so facilitate its packaging or transport. Wikipedia:Anti-caking_agent chebi_ontology anti-caking agent anti-caking agents anticaking agents CHEBI:77964 anticaking agent CHEBI:77964 anti-caking agent ChEBI anti-caking agents ChEBI anticaking agents ChEBI An anticaking agent that is used to reduced the tendency of particles of food to adhere to one another. food anticaking agent chebi_ontology food anti-caking agent food anti-caking agents CHEBI:77965 food anticaking agent CHEBI:77965 food anticaking agent ChEBI food anti-caking agent ChEBI food anti-caking agents ChEBI A food additive that is used to preserve the structure of food. Wikipedia:Stabiliser_(food) chebi_ontology food stabilisers food stabilizer food stabilizers stabiliser stabilisers stabilizer stabilizers CHEBI:77966 food stabiliser CHEBI:77966 food stabilisers ChEBI food stabilizer ChEBI food stabilizers ChEBI stabiliser ChEBI stabilisers ChEBI stabilizer ChEBI stabilizers ChEBI A compound that is used to keep a substance moist. Wikipedia:humectant chebi_ontology humectants CHEBI:77968 humectant CHEBI:77968 humectants ChEBI A humectant that is used as a food additive to prevent foodstuffs from drying out. chebi_ontology food humectants CHEBI:77969 food humectant CHEBI:77969 food humectants ChEBI A food additive that is used to increase the viscosity of foodstuffs. chebi_ontology food thickening agents thickening agent thickening agents CHEBI:77970 food thickening agent CHEBI:77970 food thickening agents ChEBI thickening agent ChEBI thickening agents ChEBI A food additive which liberates gas so as to increase the volume of a dough or batter, resulting in a lighter and softer finished product. Wikipedia:Leavening_agent chebi_ontology food raising agent food raising agents leavening agent leavening agents raising agents CHEBI:77971 raising agent CHEBI:77971 food raising agent ChEBI food raising agents ChEBI leavening agent ChEBI leavening agents ChEBI raising agents ChEBI A food additive that is applied to the external surface or a food in order to give a smooth shiny appearance and/or to provide a protective coating to foodstuffs. Wikipedia:Glazing_agent chebi_ontology food glazing agents glazing agent glazing agents CHEBI:77972 food glazing agent CHEBI:77972 food glazing agents ChEBI glazing agent ChEBI glazing agents ChEBI A substance that reduces and hinders the formation of foam in solutions and other liquids during their industrial or laboratory processing. Wikipedia:Defoamer chebi_ontology antifoaming agents defoamer defoamers CHEBI:77973 antifoaming agent CHEBI:77973 antifoaming agents ChEBI defoamer ChEBI defoamers ChEBI A food additive that is a (generally inert) gas which is used to envelop foodstuffs during packing and so protect them from unwanted chemical reactions such as food spoilage or oxidation during subsequent transport and storage. The term includes propellant gases, used to expel foods from a container. Wikipedia:Packaging_gas chebi_ontology food packaging gases CHEBI:77974 food packaging gas CHEBI:77974 food packaging gases ChEBI A food additive that is used for the purpose of decolourising food. chebi_ontology food bleaching agents CHEBI:78003 food bleaching agent CHEBI:78003 food bleaching agents ChEBI A food additive that contributes to the bulk of a food without significantly contributing to its available energy value. chebi_ontology filler fillers food bulking agents CHEBI:78004 food bulking agent CHEBI:78004 filler ChEBI fillers ChEBI food bulking agents ChEBI A food additive that intensifies, retains or stabilises the colour of a food. chebi_ontology color retention agent color retention agents colour retention agent colour retention agents food color retention agent food color retention agents food colour retention agents CHEBI:78006 food colour retention agent CHEBI:78006 color retention agent ChEBI color retention agents ChEBI colour retention agent ChEBI colour retention agents ChEBI food color retention agent ChEBI food color retention agents ChEBI food colour retention agents ChEBI A food additive that makes it possible to form or maintain a uniform dispersion of a gaseous phase in a liquid or solid phase. chebi_ontology foaming agents CHEBI:78007 foaming agent CHEBI:78007 foaming agents ChEBI A food additive that enhances the texture of a foodstuff by gel formation. chebi_ontology food gelling agents CHEBI:78016 food gelling agent CHEBI:78016 food gelling agents ChEBI A propellant that is used to expel foods from an aerosol container. chebi_ontology food propellants CHEBI:78017 food propellant CHEBI:78017 food propellants ChEBI A food additive that is used to reduce or prevent foaming during the processing or manufacture of foodstuffs. chebi_ontology food antifoaming agents food defoamer food defoamers CHEBI:78058 food antifoaming agent CHEBI:78058 food antifoaming agents ChEBI food defoamer ChEBI food defoamers ChEBI A food additive that is used to dilute, disperse or dissolve a food additive or nutrient without altering its function. Carriers are used to facilitate the handling or use of the food additive or nutrient. CHEBI:78005 chebi_ontology carrier carriers food additive carriers CHEBI:78059 food additive carrier CHEBI:78059 carrier ChEBI carriers ChEBI food additive carriers ChEBI Any small molecule that mimics the action of an enzyme. chebi_ontology enzyme mimetic enzyme mimetics enzyme mimics CHEBI:78152 enzyme mimic CHEBI:78152 enzyme mimetic ChEBI enzyme mimetics ChEBI enzyme mimics ChEBI Any minor or unwanted substance introduced into the environment that can have undesired effects. chebi_ontology environmental contaminants CHEBI:78298 environmental contaminant CHEBI:78298 environmental contaminants ChEBI A substance used in a thermodynamic heat pump cycle or refrigeration cycle that undergoes a phase change from a gas to a liquid and back. Refrigerants are used in air-conditioning systems and freezers or refrigerators and are assigned a "R" number (by ASHRAE - formerly the American Society of Heating, Refrigerating and Air Conditioning Engineers), which is determined systematically according to their molecular structure. Wikipedia:Refrigerant chebi_ontology refrigerants CHEBI:78433 refrigerant CHEBI:78433 refrigerants ChEBI An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid). 0 C34H24N6Na4O14S4 C34H24N6O14S4.4Na InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4/b39-37+,40-38+;;;; GLNADSQYFUSGOU-GPTZEZBUSA-J 960.80500 959.98241 [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1c(O)c2c(N)cc(cc2cc1S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2c(O)c3c(N)cc(cc3cc2S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 CAS:72-57-1 KEGG:C19307 PMID:23889365 PMID:24238944 PMID:24464534 PMID:24512297 PMID:24519684 PMID:24643390 PMID:24652322 PMID:24867494 PMID:25717323 PMID:25815522 PMID:25840295 PMID:26379749 PMID:26529666 Reaxys:4360496 Wikipedia:Trypan_blue tetrasodium 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate) chebi_ontology C.I. 23850 C.I. Direct Blue 14 C.I. Direct Blue 14, tetrasodium salt Niagara blue 3B Sodium ditolyl-diazobis-8-amino-1-naphthol-3,6-disulfonate Sodium ditolyldisazobis-8-amino-1-naphthol-3,6-disulfonate Sodium ditolyldisazobis-8-amino-1-naphthol-3,6-disulphonate direct blue 14 CHEBI:78897 trypan blue CHEBI:78897 CAS:72-57-1 ChemIDplus CAS:72-57-1 KEGG COMPOUND PMID:23889365 Europe PMC PMID:24238944 Europe PMC PMID:24464534 Europe PMC PMID:24512297 Europe PMC PMID:24519684 Europe PMC PMID:24643390 Europe PMC PMID:24652322 Europe PMC PMID:24867494 Europe PMC PMID:25717323 Europe PMC PMID:25815522 Europe PMC PMID:25840295 Europe PMC PMID:26379749 Europe PMC PMID:26529666 Europe PMC Reaxys:4360496 Reaxys tetrasodium 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate) IUPAC C.I. 23850 ChEBI C.I. Direct Blue 14 ChemIDplus C.I. Direct Blue 14, tetrasodium salt ChemIDplus Niagara blue 3B ChEBI Sodium ditolyl-diazobis-8-amino-1-naphthol-3,6-disulfonate ChemIDplus Sodium ditolyldisazobis-8-amino-1-naphthol-3,6-disulfonate ChemIDplus Sodium ditolyldisazobis-8-amino-1-naphthol-3,6-disulphonate ChemIDplus direct blue 14 ChEBI Any compound that is used as an additive to increase the plasticity or fluidity of a substance, particularly but not exclusively to synthetic polymers. Wikipedia:Plasticizer chebi_ontology plasticisers plasticizer plasticizers CHEBI:79056 plasticiser CHEBI:79056 plasticisers ChEBI plasticizer ChEBI plasticizers ChEBI Any compound that is added to manufactured materials to inhibit, suppress, or delay the production of flames and so prevent the spread of fire. Wikipedia:Flame_retardant chebi_ontology flame retardants CHEBI:79314 flame retardant CHEBI:79314 flame retardants ChEBI CHEBI:82283 CAS:12070-12-1 KEGG:C19183 chebi_ontology WC CHEBI:82283 Tungsten carbide CHEBI:82283 CAS:12070-12-1 KEGG COMPOUND WC KEGG_COMPOUND An elemental carbon in the form of virtually pure colloidal particles that are produced by incomplete combustion or thermal decomposition of gaseous or liquid hydrocarbons under controlled conditions. A black, finely divided pellet or powder, its properties of specific surface area, particle size and structure, conductivity and colour can be varied by varying the exact conditions for its production. It is used in tyres, rubber and plastic products, printing inks and coatings. CAS:1333-86-4 KEGG:C19202 PMID:24291665 PMID:24669321 PMID:25071917 PMID:26803751 Wikipedia:Carbon_black chebi_ontology CHEBI:82297 carbon black CHEBI:82297 CAS:1333-86-4 ChemIDplus CAS:1333-86-4 KEGG COMPOUND PMID:24291665 Europe PMC PMID:24669321 Europe PMC PMID:25071917 Europe PMC PMID:26803751 Europe PMC Substances that are administered to farmed animals to improve productivity by promoting weight gain, increasing muscle mass, limiting fat deposition, reducing feed consumption, and reducing waste production. PMID:22444918 PMID:2745641 PMID:6226938 chebi_ontology animal growth promotants animal growth promoter animal growth promoters CHEBI:82655 animal growth promotant CHEBI:82655 PMID:22444918 Europe PMC PMID:2745641 Europe PMC PMID:6226938 Europe PMC animal growth promotants ChEBI animal growth promoter ChEBI animal growth promoters ChEBI A form of silicon dioxide composed of skeletons of prehistoric diatoms (a type of hard-shelled algae). It can absorb up to four times its weight in water, and is used as an absorbent, filtration aid, and mild abrasive. CAS:61790-53-2 PMID:24516665 PMID:24767070 PMID:25024689 Wikipedia:Diatomaceous_earth chebi_ontology Celite diatomite fossil flour kieselguhr siliceous earth CHEBI:82661 diatomaceous earth CHEBI:82661 CAS:61790-53-2 ChemIDplus PMID:24516665 Europe PMC PMID:24767070 Europe PMC PMID:25024689 Europe PMC Celite ChemIDplus diatomite ChEBI fossil flour ChemIDplus kieselguhr ChemIDplus siliceous earth ChemIDplus Any silver nanoparticle that is specially coated to produce tailored nanoparticles for specific applications. PMID:24568198 chebi_ontology coated Ag NP coated Ag NPs coated Ag nanoparticle coated Ag nanoparticles coated silver nanoparticles encapsulated Ag NP encapsulated Ag NPs encapsulated Ag nanoparticle encapsulated Ag nanoparticles encapsulated silver nanoparticle encapsulated silver nanoparticles CHEBI:82776 coated silver nanoparticle CHEBI:82776 PMID:24568198 Europe PMC coated Ag NP ChEBI coated Ag NPs ChEBI coated Ag nanoparticle ChEBI coated Ag nanoparticles ChEBI coated silver nanoparticles ChEBI encapsulated Ag NP ChEBI encapsulated Ag NPs ChEBI encapsulated Ag nanoparticle ChEBI encapsulated Ag nanoparticles ChEBI encapsulated silver nanoparticle ChEBI encapsulated silver nanoparticles ChEBI Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by citrate. PMID:22148238 chebi_ontology citrate-coated Ag NP citrate-coated Ag NPs citrate-coated Ag nanoparticle citrate-coated Ag nanoparticles citrate-coated silver nanoparticles CHEBI:82778 citrate-coated silver nanoparticle CHEBI:82778 PMID:22148238 Europe PMC citrate-coated Ag NP ChEBI citrate-coated Ag NPs ChEBI citrate-coated Ag nanoparticle ChEBI citrate-coated Ag nanoparticles ChEBI citrate-coated silver nanoparticles ChEBI Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by polyvinylpyrrolidone (PVP). PMID:22148238 chebi_ontology PVP-AgNP PVP-AgNPs poly(vinylpyrrolidone)-coated Ag NP poly(vinylpyrrolidone)-coated Ag NPs poly(vinylpyrrolidone)-coated Ag nanoparticles polyvinylpyrrolidone-coated Ag NP polyvinylpyrrolidone-coated Ag NPs polyvinylpyrrolidone-coated Ag nanoparticle polyvinylpyrrolidone-coated Ag nanoparticles CHEBI:82780 poly(vinylpyrrolidone)-coated Ag nanoparticle CHEBI:82780 PMID:22148238 Europe PMC PVP-AgNP ChEBI PVP-AgNPs ChEBI poly(vinylpyrrolidone)-coated Ag NP ChEBI poly(vinylpyrrolidone)-coated Ag NPs ChEBI poly(vinylpyrrolidone)-coated Ag nanoparticles ChEBI polyvinylpyrrolidone-coated Ag NP ChEBI polyvinylpyrrolidone-coated Ag NPs ChEBI polyvinylpyrrolidone-coated Ag nanoparticle ChEBI polyvinylpyrrolidone-coated Ag nanoparticles ChEBI Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by gum arabic. PMID:22148238 chebi_ontology gum arabic-coated Ag NPs gum arabic-coated Ag nanoparticle gum arabic-coated Ag nanoparticles gum arabic-coated silver nanoparticle gum arabic-coated silver nanoparticles CHEBI:82781 gum arabic-coated Ag NP CHEBI:82781 PMID:22148238 Europe PMC gum arabic-coated Ag NPs ChEBI gum arabic-coated Ag nanoparticle ChEBI gum arabic-coated Ag nanoparticles ChEBI gum arabic-coated silver nanoparticle ChEBI gum arabic-coated silver nanoparticles ChEBI Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by 8 nm thick polyvinylpyrrolidone (PVP). PMID:22148238 PMID:24726479 chebi_ontology PVP8-Ag NPs polyvinylpyrrolidone (8 nm) coated-Ag nanoparticle polyvinylpyrrolidone (8 nm) coated-Ag nanoparticles CHEBI:82783 PVP8-Ag NP CHEBI:82783 PMID:22148238 Europe PMC PMID:24726479 Europe PMC PVP8-Ag NPs ChEBI polyvinylpyrrolidone (8 nm) coated-Ag nanoparticle ChEBI polyvinylpyrrolidone (8 nm) coated-Ag nanoparticles ChEBI Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by 38 nm thick polyvinylpyrrolidone (PVP). PMID:22148238 PMID:24726479 chebi_ontology PVP38-Ag NPs polyvinylpyrrolidone (38 nm) coated-Ag nanoparticle polyvinylpyrrolidone (38 nm) coated-Ag nanoparticles CHEBI:82784 PVP38-Ag NP CHEBI:82784 PMID:22148238 Europe PMC PMID:24726479 Europe PMC PVP38-Ag NPs ChEBI polyvinylpyrrolidone (38 nm) coated-Ag nanoparticle ChEBI polyvinylpyrrolidone (38 nm) coated-Ag nanoparticles ChEBI Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by 5 nm thick gum arabic. PMID:22148238 chebi_ontology GA5-Ag NPs gum arabic (5 nm)-coated Ag nanoparticle gum arabic (5 nm)-coated Ag nanoparticles CHEBI:82785 GA5-Ag NP CHEBI:82785 PMID:22148238 Europe PMC GA5-Ag NPs ChEBI gum arabic (5 nm)-coated Ag nanoparticle ChEBI gum arabic (5 nm)-coated Ag nanoparticles ChEBI Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by 22 nm thick gum arabic. PMID:22148238 chebi_ontology GA22-Ag NPs gum arabic (22 nm)-coated Ag nanoparticle gum arabic (22 nm)-coated Ag nanoparticles CHEBI:82786 GA22-Ag NP CHEBI:82786 PMID:22148238 Europe PMC GA22-Ag NPs ChEBI gum arabic (22 nm)-coated Ag nanoparticle ChEBI gum arabic (22 nm)-coated Ag nanoparticles ChEBI An inorganic nanoparticle consisting of copper(II) oxide. chebi_ontology CuO nanoparticle cupric oxide nanoparticle CHEBI:83159 copper(II) oxide nanoparticle CHEBI:83159 CuO nanoparticle ChEBI cupric oxide nanoparticle ChEBI Any cosmetic used to lighten the colour of skin by reducing the concentration of melanin. PMID:21265866 PMID:22132817 PMID:22314516 PMID:23891889 PMID:23974587 PMID:25535470 PMID:25574195 PMID:25643794 Wikipedia:Skin_whitening chebi_ontology melanogenesis inhibitor melanogenesis inhibitors skin bleaching agent skin bleaching agents skin depigmenting agent skin depigmenting agents skin lightening agents skin whitening agent skin whitening agents CHEBI:85046 skin lightening agent CHEBI:85046 PMID:21265866 Europe PMC PMID:22132817 Europe PMC PMID:22314516 Europe PMC PMID:23891889 Europe PMC PMID:23974587 Europe PMC PMID:25535470 Europe PMC PMID:25574195 Europe PMC PMID:25643794 Europe PMC melanogenesis inhibitor ChEBI melanogenesis inhibitors ChEBI skin bleaching agent ChEBI skin bleaching agents ChEBI skin depigmenting agent ChEBI skin depigmenting agents ChEBI skin lightening agents ChEBI skin whitening agent ChEBI skin whitening agents ChEBI A compound that inhibits the re-uptake of the neurotransmitter GABA from the synapse into the pre-synaptic neuron, so increasing the extracellular concentrations of the neurotransmitter and hence increasing neurotransmission. Wikipedia:GABA_reuptake_inhibitor chebi_ontology GABA re-uptake inhibitor GABA re-uptake inhibitors GABA reuptake inhibitors gamma-aminobutyric acid re-uptake inhibitor gamma-aminobutyric acid re-uptake inhibitors gamma-aminobutyric acid reuptake inhibitor gamma-aminobutyric acid reuptake inhibitors CHEBI:85384 GABA reuptake inhibitor CHEBI:85384 GABA re-uptake inhibitor ChEBI GABA re-uptake inhibitors ChEBI GABA reuptake inhibitors ChEBI gamma-aminobutyric acid re-uptake inhibitor ChEBI gamma-aminobutyric acid re-uptake inhibitors ChEBI gamma-aminobutyric acid reuptake inhibitor ChEBI gamma-aminobutyric acid reuptake inhibitors ChEBI Any antifungal agent used to prevent or treat fungal infections in humans or animals. Wikipedia:Antifungal chebi_ontology anti-fungal drug anti-fungal drugs anti-fungal medication anti-fungal medications antifungal drugs antifungal medication antifungal medications pharmaceutical fungicide pharmaceutical fungicides CHEBI:86327 antifungal drug CHEBI:86327 anti-fungal drug ChEBI anti-fungal drugs ChEBI anti-fungal medication ChEBI anti-fungal medications ChEBI antifungal drugs ChEBI antifungal medication ChEBI antifungal medications ChEBI pharmaceutical fungicide ChEBI pharmaceutical fungicides ChEBI Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. chebi_ontology agrichemical fungicide agrichemical fungicides agrochemical fungicide agrochemical fungicides anti-fungal agrichemical anti-fungal agrichemicals anti-fungal agrochemical anti-fungal agrochemicals antifungal agrichemical antifungal agrichemicals antifungal agrochemicals CHEBI:86328 antifungal agrochemical CHEBI:86328 agrichemical fungicide ChEBI agrichemical fungicides ChEBI agrochemical fungicide ChEBI agrochemical fungicides ChEBI anti-fungal agrichemical ChEBI anti-fungal agrichemicals ChEBI anti-fungal agrochemical ChEBI anti-fungal agrochemicals ChEBI antifungal agrichemical ChEBI antifungal agrichemicals ChEBI antifungal agrochemicals ChEBI 0 C12H7NO4 InChI=1S/C12H7NO4/c14-7-1-3-9-11(5-7)17-12-6-8(15)2-4-10(12)13(9)16/h1-6,14H PLXBWHJQWKZRKG-UHFFFAOYSA-N 229.189 229.03751 Oc1ccc2[n+]([O-])c3ccc(=O)cc3oc2c1 CAS:550-82-3 KEGG:C11178 Resazurin chebi_ontology CHEBI:8806 Resazurin CHEBI:8806 CAS:550-82-3 KEGG COMPOUND Resazurin KEGG_COMPOUND Any drug which causes the onset of an allergic reaction. chebi_ontology allergenic drug CHEBI:88188 drug allergen CHEBI:88188 allergenic drug ChEBI Any retinoic acid receptor (RAR) agonist with specificity for RARgamma. PMID:11829754 Wikipedia:Retinoic_acid_receptor_gamma chebi_ontology NR1B3 agonist NR1B3 agonists RARgamma agonist RARgamma agonists nuclear receptor subfamily 1, group B, member 3 agonist nuclear receptor subfamily 1, group B, member 3 agonists retinoic acid receptor gamma agonists CHEBI:88336 retinoic acid receptor gamma agonist CHEBI:88336 PMID:11829754 Europe PMC NR1B3 agonist ChEBI NR1B3 agonists ChEBI RARgamma agonist ChEBI RARgamma agonists ChEBI nuclear receptor subfamily 1, group B, member 3 agonist ChEBI nuclear receptor subfamily 1, group B, member 3 agonists ChEBI retinoic acid receptor gamma agonists ChEBI A nuclear receptor modulator that affects the retinoic acid receptor chebi_ontology retinoic acid receptor modulators CHEBI:90708 retinoic acid receptor modulator CHEBI:90708 retinoic acid receptor modulators ChEBI Any receptor modulator acting on nuclear receptors chebi_ontology nuclear receptor modulators CHEBI:90709 nuclear receptor modulator CHEBI:90709 nuclear receptor modulators ChEBI A drug that acts as an antagonist, agonist, reverse agonist, or in some other fashion when interacting with cellular receptors. chebi_ontology receptor modulators CHEBI:90710 receptor modulator CHEBI:90710 receptor modulators ChEBI A retinoic acid receptor antagonist that antagonises retinoic acid receptor alpha. chebi_ontology RAR alpha antagonist RAR alpha antagonists RARalpha antagonist RARalpha antagonists retinoic acid receptor alpha antagonists CHEBI:90713 retinoic acid receptor alpha antagonist CHEBI:90713 RAR alpha antagonist ChEBI RAR alpha antagonists ChEBI RARalpha antagonist ChEBI RARalpha antagonists ChEBI retinoic acid receptor alpha antagonists ChEBI An antagonist that acts at the retinoic acid receptor. chebi_ontology RAR antagonist RAR antagonists retinoic acid receptor antagonists CHEBI:90714 retinoic acid receptor antagonist CHEBI:90714 RAR antagonist ChEBI RAR antagonists ChEBI retinoic acid receptor antagonists ChEBI Any retinoic acid receptor (RAR) agonist with specificity for RARbeta. chebi_ontology RAR beta agonist RAR beta agonists RARbeta agonist RARbeta agonists retinoic acid receptor beta agonists CHEBI:90742 retinoic acid receptor beta agonist CHEBI:90742 RAR beta agonist ChEBI RAR beta agonists ChEBI RARbeta agonist ChEBI RARbeta agonists ChEBI retinoic acid receptor beta agonists ChEBI A retinoic acid receptor antagonist that antagonises retinoic acid receptor gamma. chebi_ontology RAR gamma antagonist RAR gamma antagonists RARgamma antagonist RARgamma antagonists retinoic acid receptor gamma antagonists CHEBI:90744 retinoic acid receptor gamma antagonist CHEBI:90744 RAR gamma antagonist ChEBI RAR gamma antagonists ChEBI RARgamma antagonist ChEBI RARgamma antagonists ChEBI retinoic acid receptor gamma antagonists ChEBI A role borne by a molecule that acts to counteract or neutralize the deleterious effects of cyanide. chebi_ontology CHEBI:90749 antidote to cyanide poisoning CHEBI:90749 A role borne by a molecule that acts to counteract or neutralise the deleterious effects of organophosphates or acetylcholinesterase inhibitors (nerve agents). CHEBI:90758 chebi_ontology antidote to acetylcholinesterase inhibitor poisoning antidote to nerve agents CHEBI:90753 antidote to organophosphate poisoning CHEBI:90753 antidote to acetylcholinesterase inhibitor poisoning ChEBI antidote to nerve agents ChEBI A role borne by a molecule that acts to counteract or neutralise the deleterious effects of opioids. PMID:24510187 PMID:24868924 chebi_ontology antidote to opioid overdose CHEBI:90755 antidote to opioid poisoning CHEBI:90755 PMID:24510187 Europe PMC PMID:24868924 Europe PMC antidote to opioid overdose ChEBI A role borne by a molecule that acts to counteract or neutralise the deleterious effects of benzodiazepines. chebi_ontology antidote to benzodiazepine overdose CHEBI:90757 antidote to benzodiazepine poisoning CHEBI:90757 antidote to benzodiazepine overdose ChEBI A chemical compound that, when added to a liquid or gas, decreases the corrosion rate of a material, typically a metal or an alloy. PMID:23636692 PMID:25594340 PMID:25839822 PMID:25912625 PMID:25955130 PMID:26160863 PMID:26343626 PMID:26347374 PMID:26364631 PMID:26727190 Wikipedia:Corrosion_inhibitor chebi_ontology corrosion inhibitors CHEBI:91015 corrosion inhibitor CHEBI:91015 PMID:23636692 Europe PMC PMID:25594340 Europe PMC PMID:25839822 Europe PMC PMID:25912625 Europe PMC PMID:25955130 Europe PMC PMID:26160863 Europe PMC PMID:26343626 Europe PMC PMID:26347374 Europe PMC PMID:26364631 Europe PMC PMID:26727190 Europe PMC corrosion inhibitors ChEBI A GABA receptor agonist specific for GABAA receptors, ligand-gated ion channels (also known as ionotropic receptors). chebi_ontology GABAA receptor agonists CHEBI:91016 GABAA receptor agonist CHEBI:91016 GABAA receptor agonists ChEBI CHMO:0000087 Any type of light microscopy assay where the specimen can be made to fluoresce (emit energy as visible light) by illuminating it with light of specific wavelengths. These specimens are called fluorophores. FM fluorescence imaging fluorescence microscopic imaging CHMO fluorescence microscopy assay CHMO:0000089 Microscopy where the specimen can be made to fluoresce (emit energy as visible light) by scanning a gas (Ar or Kr) laser spot of specific wavelength over its surface and using a spatial pinhole to eliminate out-of-focus fluorescence. CLSM LSCM confocal fluorescence imaging confocal laser scanning fluorescence microscopy confocal laser scanning microscopy confocal-laser scanning microscopy fluorescence confocal microscopy fluorescence confocal scanning laser microscopy scanning confocal fluorescence microscopy CHMO confocal fluorescence microscopy assay Microscopy where ions are used to produce an image. FIX:0000962 IM CHMO:0000097 ion microscopy CHMO:0000097 Microscopy where ions are used to produce an image. https://orcid.org/0000-0002-0640-0422 Microscopy where atoms of an inert gas in the vicinty of the specimen (which is in the form of a very sharp tip <10 m diameter) are ionised by the application of a strong electric field to the tip and an image is produced by the projection of the ions onto a fluorescent screen. The image consists of a pattern of spots of light which correspond to individual atoms on the specimen surface. FIM field ionisation microscopy field ionization microscopy field-ion microscopy field-ionisation microscopy field-ionization microscopy CHMO:0000098 field ion microscopy CHMO:0000098 Microscopy where atoms of an inert gas in the vicinty of the specimen (which is in the form of a very sharp tip <10 m diameter) are ionised by the application of a strong electric field to the tip and an image is produced by the projection of the ions onto a fluorescent screen. The image consists of a pattern of spots of light which correspond to individual atoms on the specimen surface. Orange:17.2.7 Microscopy where atoms in the vicinty of the specimen (which is in the form of a very sharp tip <10 m diameter) are ionised by the application of a strong electric field to the tip and an image is produced by the projection of the ions onto a fluorescent screen. The image consists of a pattern of spots of light which correspond to individual atoms on the specimen surface. When a sudden voltage pulse is applied to the tip, atoms from the surface of the specimen itself are be ejected and travel down a drift tube where their arrival time (a measure of the mass of the atom) can be determined. This allows the atomic composition of the specimen to be determined. AP FIM AP field ionisation microscopy AP field ionization microscopy AP field-ion microscopy AP field-ionisation microscopy AP field-ionization microscopy AP-FIM AP/FIM APFIM atom probe field ionisation microscopy atom probe field ionization microscopy atom probe field-ion microscopy atom probe field-ionisation microscopy atom probe field-ionization microscopy atom-probe field-ion microscopy CHMO:0000099 atom probe field ion microscopy CHMO:0000099 Microscopy where atoms in the vicinty of the specimen (which is in the form of a very sharp tip <10 m diameter) are ionised by the application of a strong electric field to the tip and an image is produced by the projection of the ions onto a fluorescent screen. The image consists of a pattern of spots of light which correspond to individual atoms on the specimen surface. When a sudden voltage pulse is applied to the tip, atoms from the surface of the specimen itself are be ejected and travel down a drift tube where their arrival time (a measure of the mass of the atom) can be determined. This allows the atomic composition of the specimen to be determined. https://orcid.org/0000-0002-0640-0422 Microscopy where atoms of He gas in the vicinty of the specimen are ionised and an image is produced by the projection of the ions onto a fluorescent screen. The image consists of a pattern of spots of light which correspond to individual atoms on the specimen surface. CHMO:0000100 helium-ion microscopy CHMO:0000100 Microscopy where atoms of He gas in the vicinty of the specimen are ionised and an image is produced by the projection of the ions onto a fluorescent screen. The image consists of a pattern of spots of light which correspond to individual atoms on the specimen surface. https://orcid.org/0000-0002-0640-0422 Microscopy where an ion beam is scanned over the specimen surface and the secondary electrons emitted are detected. FIX:0000963 SIM CHMO:0000101 scanning ion microscopy CHMO:0000101 Microscopy where an ion beam is scanned over the specimen surface and the secondary electrons emitted are detected. https://orcid.org/0000-0002-0640-0422 SIM CHMO:0000102 Microscopy where the specimen is illuminated with visible light and a system of lenses is used to produce an image. OM light microscopy optical microscopy CHMO light microscopy assay A method for determining structure by measuring the change in direction or energy of X-rays scattered by a sample at low angles (0–10°). SAXS small angle X-ray scattering CHMO:0000204 small-angle X-ray scattering CHMO:0000204 A method for determining structure by measuring the change in direction or energy of X-rays scattered by a sample at low angles (0–10°). FIX:0000223 https://orcid.org/0000-0002-0640-0422 A method for determining structure by measuring the change in direction or energy of X-rays scattered by a sample at wide angles (>10°). Wide-angle X-ray scattering is used for determining the structure of polymers. WAXS wide angle X-ray scattering CHMO:0000207 wide-angle X-ray scattering CHMO:0000207 A method for determining structure by measuring the change in direction or energy of X-rays scattered by a sample at wide angles (>10°). Wide-angle X-ray scattering is used for determining the structure of polymers. FIX:0001128 https://orcid.org/0000-0002-0640-0422 A type of atomic emission spectrometry where a high energy laser pulse is used to generate a plasma which acts as the excitation source. LIBS LIPS laser induced plasma spectrometry laser induced plasma spectroscopy laser-induced breakdown atomic emission spectrometry laser-induced breakdown atomic-emission spectrometry laser-induced plasma atomic emission spectrometry laser-induced plasma atomic emission spectroscopy laser-induced plasma spectrometry laser-induced plasma spectroscopy CHMO:0000258 laser-induced breakdown spectroscopy CHMO:0000258 A type of atomic emission spectrometry where a high energy laser pulse is used to generate a plasma which acts as the excitation source. https://orcid.org/0000-0002-0640-0422 X-ray absorption spectroscopy where changes in the X-ray absorption coefficient measured within 40 eV of the absorption edge (the part of the spectrum where the incident X-ray energy matches the binding energy of an electron) are determined as a function of incident X-ray energy. NEXAF spectroscopy NEXAFS NEXAFS spectrometry NEXAFSS X-ray absorption near edge structure (XANES) spectroscopy X-ray absorption near edge structure spectrometry X-ray absorption near edge structure spectroscopy X-ray absorption near-edge structure XANES XANES spectrometry XANES spectroscopy near edge X-ray absorption spectroscopy near-edge X-ray absorption fine structure spectrometry CHMO:0000305 near-edge X-ray absorption fine structure spectroscopy CHMO:0000305 X-ray absorption spectroscopy where changes in the X-ray absorption coefficient measured within 40 eV of the absorption edge (the part of the spectrum where the incident X-ray energy matches the binding energy of an electron) are determined as a function of incident X-ray energy. FIX:0000025 FIX:0000376 https://orcid.org/0000-0002-0640-0422 Spectroscopy where a high energy photon ionises a core electron and an electron from a higher energy level descends to take its place, releasing sufficient energy to eject a second so-called 'Auger' electron and the energy of the Auger electron is detected as a function of incident photon energy. AEES Auger electron emission spectroscopy Auger electron spectrometry Auger spectrometry Auger spectroscopy AES CHMO:0000339 Auger electron spectroscopy CHMO:0000339 Spectroscopy where a high energy photon ionises a core electron and an electron from a higher energy level descends to take its place, releasing sufficient energy to eject a second so-called 'Auger' electron and the energy of the Auger electron is detected as a function of incident photon energy. ISBN:0-471-96523-5 AES Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of emission angle. ADAS ARAES angle-resolved Auger electron spectrometry angle-resolved Auger electron spectroscopy angular dependent Auger spectrometry CHMO:0000340 angular dependent Auger electron spectroscopy CHMO:0000340 Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of emission angle. https://orcid.org/0000-0002-0640-0422 Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The wavelength of the incident photons is scanned over an absorption edge in the sample and the Auger electrons emitted are detected as a function of energy. RAES resonance AES resonance Auger electron spectrometry resonance Auger electron spectroscopy resonance Auger spectrometry resonance Auger spectroscopy resonant AES resonant Auger electron spectrometry resonant Auger spectrometry resonant Auger spectroscopy CHMO:0000341 resonant Auger electron spectroscopy CHMO:0000341 Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The wavelength of the incident photons is scanned over an absorption edge in the sample and the Auger electrons emitted are detected as a function of energy. https://doi.org/10.1103/PhysRevLett.88.243001 Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The wavelength of the incident photons is scanned over an absorption edge in the sample and the Auger electrons emitted are detected as a function of emission angle. angle-resolved resonance Auger electron spectrometry angle-resolved resonance Auger electron spectroscopy angle-resolved resonant Auger electron spectrometry CHMO:0000342 angle-resolved resonant Auger electron spectroscopy CHMO:0000342 Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The wavelength of the incident photons is scanned over an absorption edge in the sample and the Auger electrons emitted are detected as a function of emission angle. https://orcid.org/0000-0002-0640-0422 Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. Only the Auger electrons emitted at a particular photon energy are detected. APYS Auger electron partial yield spectrometry CHMO:0000343 Auger electron partial yield spectroscopy CHMO:0000343 Spectroscopy where bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. Only the Auger electrons emitted at a particular photon energy are detected. OrangeBook:17.2.1.4 Spectroscopy where electron bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electron and the energies of these Auger electrons are detected as a function of incident electron energy. EAES EEAES EIAES electron-excited Auger electron spectrometry electron-induced Auger electron spectrometry electron-induced Auger electron spectroscopy CHMO:0000344 electron-excited Auger electron spectroscopy CHMO:0000344 Spectroscopy where electron bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electron and the energies of these Auger electrons are detected as a function of incident electron energy. Orange:17.2.4 Spectroscopy where bombardment of a sample with a finely focused (<10 m diameter) beam of electrons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of incident electron energy. Auger electron microanalysis EMAS electron microprobe Auger electron spectrometry CHMO:0000345 electron microprobe Auger spectroscopy CHMO:0000345 Spectroscopy where bombardment of a sample with a finely focused (<10 m diameter) beam of electrons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of incident electron energy. https://orcid.org/0000-0002-0640-0422 Spectroscopy where ion bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident ion energy. IAES IEAES IIAES ion neutralisation spectrometry ion neutralisation spectroscopy ion neutralization spectrometry ion neutralization spectroscopy ion-electron spectroscopy ion-excited Auger spectrometry ion-induced Auger electron spectrometry ion-induced Auger electron spectroscopy ionelectron spectroscopy INS CHMO:0000346 ion-excited Auger electron spectroscopy CHMO:0000346 Spectroscopy where ion bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident ion energy. Orange:17.2.4 Spectroscopy where the bombardment of a sample with He+ ions results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident He+ ion energy. HAES He+-excited Auger electron spectrometry CHMO:0000347 He+-excited Auger electron spectroscopy CHMO:0000347 Spectroscopy where the bombardment of a sample with He+ ions results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident He+ ion energy. https://orcid.org/0000-0002-0640-0422 Spectroscopy where the bombardment of a sample with protons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident proton energy. PAES proton-induced Auger electron spectrometry CHMO:0000348 proton-induced Auger electron spectroscopy CHMO:0000348 Spectroscopy where the bombardment of a sample with protons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident proton energy. https://orcid.org/0000-0002-0640-0422 Spectroscopy where ion bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of emission angle. AIRES angle-resolved ion-electron spectrometry angle-resolved ion-electron spectroscopy CHMO:0000349 angle-resolved ion-excited Auger electron spectroscopy CHMO:0000349 Spectroscopy where ion bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of emission angle. https://orcid.org/0000-0002-0640-0422 Spectroscopy where a high-energy photon beam is scanned over the surface of a sample resulting in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of incident photon energy. SAES scanning Auger electron spectrometry scanning Auger spectrometry scanning Auger spectroscopy CHMO:0000350 scanning Auger electron spectroscopy CHMO:0000350 Spectroscopy where a high-energy photon beam is scanned over the surface of a sample resulting in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of incident photon energy. https://orcid.org/0000-0002-0640-0422 Spectroscopy where the bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of incident photon energy and a magnet is used to align all electron spins parallel to the emitting surface. SPAES spin-polarized Auger electron spectrometry CHMO:0000351 spin-polarised Auger electron spectroscopy CHMO:0000351 Spectroscopy where the bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of incident photon energy and a magnet is used to align all electron spins parallel to the emitting surface. OrangeBook:17.2.4 Spectroscopy where the bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of emission angle and a magnet is used to align all electron spins parallel to the emitting surface. SPARPES spin-polarized angle-resolved Auger electron spectrometry CHMO:0000352 spin-polarised angle-resolved Auger electron spectroscopy CHMO:0000352 Spectroscopy where the bombardment of a sample with high-energy photons results in the ionisation of core electrons and the emission of so-called 'Auger' electrons. The energies of these Auger electrons are detected as a function of emission angle and a magnet is used to align all electron spins parallel to the emitting surface. https://orcid.org/0000-0002-0640-0422 Spectroscopy where X-ray bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident X-ray energy. X-ray excited Auger electron spectrometry X-ray induced Auger electron spectrometry X-ray induced Auger electron spectroscopy XAES XEAES XIAES CHMO:0000353 X-ray excited Auger electron spectroscopy CHMO:0000353 Spectroscopy where X-ray bombardment of a sample results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected as a function of incident X-ray energy. Orange:17.2.4 Spectroscopy where the bombardment of a sample with a continuous X-ray source (X-rays generated when electrons, or other high energy charged particles such as protons or alpha-particles, lose energy whilst passing through the Coulomb field of a nucleus) results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected. CX-AES CXAES bremsstrahlung Auger electron spectrometry bremsstrahlung Auger electron spectroscopy bremsstrahlung Auger spectrometry bremsstrahlung Auger spectroscopy continuous X-ray-induced Auger electron spectrometry continuous X-ray-induced Auger spectrometry continuous X-ray-induced Auger spectroscopy CHMO:0000354 continuous X-ray-induced Auger electron spectroscopy CHMO:0000354 Spectroscopy where the bombardment of a sample with a continuous X-ray source (X-rays generated when electrons, or other high energy charged particles such as protons or alpha-particles, lose energy whilst passing through the Coulomb field of a nucleus) results in the ionisation of core electrons and the emission of so-called 'Auger' electrons, which are detected. ISBN:0824706005 Spectroscopy where a beam of electrons with a known, narrow range of kinetic energies is transmitted through a sample and the energy distribution of the transmitted electrons is measured. CHMO:0002296 ETS TEELS electron transmission spectrometry electron transmission spectroscopy CHMO:0000373 transmission electron energy loss spectroscopy CHMO:0000373 Spectroscopy where a beam of electrons with a known, narrow range of kinetic energies is transmitted through a sample and the energy distribution of the transmitted electrons is measured. https://doi.org/10.1351/goldbook.T06480 Spectroscopy where the sample is illuminated with X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. FIX:0000041 ESCA PESIS X-ray photoelectron emission spectroscopy X-ray photoelectron scattering (XPS) spectroscopy X-ray photoelectron scattering spectroscopy X-ray photoelectron spectrometry X-ray photoemission spectroscopy XPES XPS electron spectrometry for chemical analysis electron spectrometry for chemical applications electron spectroscopy for chemical analysis electron spectroscopy for chemical applications photoelectron spectroscopy of the inner shell CHMO:0000404 X-ray photoelectron spectroscopy CHMO:0000404 Spectroscopy where the sample is illuminated with X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. https://doi.org/10.1351/goldbook.X06716 Spectroscopy where the sample is illuminated with X-rays causing ionisation and the emission of photoelectrons, which are detected as a function of emission angle. ARXPS angle-resolved X-ray photoelectron spectrometry CHMO:0000405 angle-resolved X-ray photoelectron spectroscopy CHMO:0000405 Spectroscopy where the sample is illuminated with X-rays causing ionisation and the emission of photoelectrons, which are detected as a function of emission angle. FIX:0000684 https://orcid.org/0000-0002-0640-0422 Spectroscopy where the sample is illuminated with monochromatic X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. HR-XPS HRXPS high resolution X-ray photoelectron spectrometry high resolution X-ray photoelectron spectroscopy high resolution X-ray photoemission spectrometry high resolution X-ray photoemission spectroscopy high-resolution X-ray photoelectron spectrometry high-resolution X-ray photoemission spectrometry CHMO:0000406 high-resolution X-ray photoelectron spectroscopy CHMO:0000406 Spectroscopy where the sample is illuminated with monochromatic X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. https://orcid.org/0000-0002-0640-0422 Spectroscopy where the sample is illuminated with 'soft' (<300 eV) X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. SXPS soft X-ray photoelectron spectrometry CHMO:0000407 soft X-ray photoelectron spectroscopy CHMO:0000407 Spectroscopy where the sample is illuminated with 'soft' (<300 eV) X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. Orange:17.2.1.2 Spectroscopy where the sample is illuminated with monochromatic 'soft' (<300 eV) X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. HR-SXPS HRSXPS high resolution soft X-ray photoelectron spectrometry high resolution soft X-ray photoelectron spectroscopy high resolution soft X-ray photoemission spectrometry high resolution soft X-ray photoemission spectroscopy high-resolution soft X-ray photoelectron spectrometry high-resolution soft X-ray photoemission spectrometry CHMO:0000408 high-resolution soft X-ray photoelectron spectroscopy CHMO:0000408 Spectroscopy where the sample is illuminated with monochromatic 'soft' (<300 eV) X-rays causing ionisation and the emission of photoelectrons, the energies of which are measured. https://doi.org/10.1107/S0909049502009214 A type of activation analysis where atomic nuclei are excited (by a heavy ion beam or by collision with another nucleus) and their decaying gamma-ray emissions are measured and compared to reference spectra. NAA CHMO:0000420 nuclear activation analysis CHMO:0000420 A type of activation analysis where atomic nuclei are excited (by a heavy ion beam or by collision with another nucleus) and their decaying gamma-ray emissions are measured and compared to reference spectra. https://orcid.org/0000-0002-0640-0422 CHMO:0000538 Plasma mass spectrometry where the plasma has been generated by electromagnetic induction. FIX:0000863 ICP-MS ICPMS inductively coupled plasma-mass spectrometry inductively coupled plasma-mass spectroscopy CHMO:0000538 inductively coupled plasma mass spectrometry CHMO:0000538 Plasma mass spectrometry where the plasma has been generated by electromagnetic induction. https://orcid.org/0000-0002-0640-0422 Plasma mass spectrometry where the sample is vaporised by depositing it on a probe which is rapidly heated (to >1000 deg C) by passing a current through it. FIX:0000864 ETV-ICP-MS ETV-ICPMS electrothermal vaporisation inductively coupled plasma mass spectroscopy electrothermal vaporization inductively coupled plasma mass spectrometry electrothermal vaporization inductively coupled plasma mass spectroscopy CHMO:0000539 electrothermal vaporisation inductively coupled plasma mass spectrometry CHMO:0000539 Plasma mass spectrometry where the sample is vaporised by depositing it on a probe which is rapidly heated (to >1000 deg C) by passing a current through it. ISBN:978-0-470-51634-8 ETV-ICP-MS where the solid sample is prepared by grinding into a fine powder and suspension in a diluent such as 0.1% HNO3. slurry electrothermal vaporisation inductively coupled plasma mass spectroscopy slurry electrothermal vaporization inductively coupled plasma mass spectrometry slurry electrothermal vaporization inductively coupled plasma mass spectroscopy slurry sampling electrothermal vaporisation inductively coupled plasma mass spectrometry slurry sampling electrothermal vaporisation inductively coupled plasma mass spectroscopy slurry sampling electrothermal vaporization inductively coupled plasma mass spectrometry slurry sampling electrothermal vaporization inductively coupled plasma mass spectroscopy CHMO:0000540 slurry electrothermal vaporisation inductively coupled plasma mass spectrometry CHMO:0000540 ETV-ICP-MS where the solid sample is prepared by grinding into a fine powder and suspension in a diluent such as 0.1% HNO3. ISBN:1566701554 Mass spectrometry where a solid sample is ground to a fine powder and suspended in a diluent (such as 0.1% HNO3) before being vaporised by a probe which is rapidly heated by passing a current through it. The vaporised sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. SN-ETV-ICP-MS SN-ETV-ICPMS slurry nebulisation electrothermal vaporisation inductively coupled plasma mass spectroscopy slurry nebulization electrothermal vaporization inductively coupled plasma mass spectrometry slurry nebulization electrothermal vaporization inductively coupled plasma mass spectroscopy CHMO:0000541 slurry nebulisation electrothermal vaporisation inductively coupled plasma mass spectrometry CHMO:0000541 Mass spectrometry where a solid sample is ground to a fine powder and suspended in a diluent (such as 0.1% HNO3) before being vaporised by a probe which is rapidly heated by passing a current through it. The vaporised sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where a solid sample is vaporised by depositing it on a probe which is rapidly heated by passing a current through it. The vaporised sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. SS-ETV-ICP-MS SS-ETV-ICPMS direct solid sampling electrothermal vaporisation inductively coupled plasma mass spectroscopy direct solid sampling electrothermal vaporization inductively coupled plasma mass spectrometry direct solid sampling electrothermal vaporization inductively coupled plasma mass spectroscopy direct solid-sampling electrothermal vaporisation inductively coupled plasma mass spectrometry direct solid-sampling electrothermal vaporisation inductively coupled plasma mass spectroscopy direct solid-sampling electrothermal vaporization inductively coupled plasma mass spectrometry direct solid-sampling electrothermal vaporization inductively coupled plasma mass spectroscopy solid sampling electrothermal vaporisation inductively coupled plasma mass spectroscopy solid sampling electrothermal vaporization inductively coupled plasma mass spectrometry solid sampling electrothermal vaporization inductively coupled plasma mass spectroscopy solid-sampling electrothermal vaporisation inductively coupled plasma mass spectrometry solid-sampling electrothermal vaporisation inductively coupled plasma mass spectroscopy solid-sampling electrothermal vaporization inductively coupled plasma mass spectrometry solid-sampling electrothermal vaporization inductively coupled plasma mass spectroscopy CHMO:0000542 solid sampling electrothermal vaporisation inductively coupled plasma mass spectrometry CHMO:0000542 Mass spectrometry where a solid sample is vaporised by depositing it on a probe which is rapidly heated by passing a current through it. The vaporised sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by high-performance liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. HPLC ICP MS HPLC-ICP-MS HPLC-ICPMS HPLC/ICP-MS high performance liquid chromatography inductively coupled plasma mass spectrometry high performance liquid chromatography-ICPMS high performance liquid chromatography-inductively coupled plasma mass spectrometry high pressure liquid chromatography inductively coupled mass spectroscopy CHMO:0000543 high performance liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0000543 A method where a sample mixture is first separated by high-performance liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. https://doi.org/10.1039/b813118j A method where a sample mixture is first separated by high-performance liquid chromatography with fluorescence detection before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. HPLC-FD-ICP-MS high performance liquid chromatography fluorescence detection inductively coupled plasma mass spectrometry high performance liquid chromatography fluorescence detection inductively coupled plasma mass spectroscopy CHMO:0000544 high-performance liquid chromatography fluorescence detection-inductively coupled plasma mass spectrometry CHMO:0000544 A method where a sample mixture is first separated by high-performance liquid chromatography with fluorescence detection before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by high-performance liquid chromatography with photodiode array detection before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. HPLC-PDA-ICP-MS high performance liquid chromatography photodiode array inductively coupled plasma mass spectrometry high performance liquid chromatography photodiode array inductively coupled plasma mass spectroscopy CHMO:0000545 high-performance liquid chromatography photodiode array-inductively coupled plasma mass spectrometry CHMO:0000545 A method where a sample mixture is first separated by high-performance liquid chromatography with photodiode array detection before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The 'exact' mass of the sample ions is then determined as opposed to the 'nominal' mass (the number of protons and neutrons). HR-ICP-MS HR-ICPMS high resolution inductively coupled plasma mass spectrometry high resolution inductively coupled plasma mass spectroscopy CHMO:0000546 high-resolution inductively coupled plasma mass spectrometry CHMO:0000546 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The 'exact' mass of the sample ions is then determined as opposed to the 'nominal' mass (the number of protons and neutrons). https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The beam of ions is then directed into magnetic field, the orientation of which is perpendicular to the beam. The magnetic field forces the charged particles into different circular trajectories, the radii of which depend on the strength of the magnetic field, the accelerating voltage, and the mass of the ion. ICP-SF-MS inductively coupled plasma field sector mass spectroscopy CHMO:0000547 inductively coupled plasma field sector mass spectrometry CHMO:0000547 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The beam of ions is then directed into magnetic field, the orientation of which is perpendicular to the beam. The magnetic field forces the charged particles into different circular trajectories, the radii of which depend on the strength of the magnetic field, the accelerating voltage, and the mass of the ion. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The mass-to-charge ratio of the sample ions is then measured whilst the ions are held in a stable orbit by an electric field generated by three electrodes. ICP-three dimensional-Q-MS ICP-three dimensional-QMS inductively coupled plasma three dimensional quadrupole mass spectroscopy CHMO:0000548 inductively coupled plasma three dimensional quadrupole mass spectrometry CHMO:0000548 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The mass-to-charge ratio of the sample ions is then measured whilst the ions are held in a stable orbit by an electric field generated by three electrodes. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The sample ions with different masses are then accelerated to the same (known) kinetic energy and the time taken for each ion to reach a detector at a known distance is measured. ICP-TOF-MS ICP-TOFMS ICP-ToF-MS inductively coupled plasma time of flight mass spectrometry inductively coupled plasma time of flight mass spectroscopy inductively coupled plasma time-of-flight mass spectroscopy CHMO:0000549 inductively coupled plasma time-of-flight mass spectrometry CHMO:0000549 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The sample ions with different masses are then accelerated to the same (known) kinetic energy and the time taken for each ion to reach a detector at a known distance is measured. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is vaporised using a laser pulse then ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. LA ICP-MS LA-ICP-MS LA-ICPMS laser ablation ICP-MS laser ablation inductively coupled plasma mass spectroscopy laser ablation-ICPMS CHMO:0000550 laser ablation inductively coupled plasma mass spectrometry CHMO:0000550 Mass spectrometry where the sample is vaporised using a laser pulse then ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. ISBN:978-0-470-51634-8 Mass spectrometry where the sample is vaporised using a laser pulse then ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The sample ions with different masses are then accelerated to the same (known) kinetic energy and the time taken for each ion to reach a detector at a known distance is measured. LA-ICP-TOF-MS LA-ICP-ToF-MS laser ablation inductively coupled plasma time of flight mass spectrometry laser ablation inductively coupled plasma time of flight mass spectroscopy laser ablation inductively coupled plasma time-of-flight mass spectroscopy CHMO:0000551 laser ablation inductively coupled plasma time-of-flight mass spectrometry CHMO:0000551 Mass spectrometry where the sample is vaporised using a laser pulse then ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The sample ions with different masses are then accelerated to the same (known) kinetic energy and the time taken for each ion to reach a detector at a known distance is measured. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. LC-ICP-MS LC-ICPMS LC/ICP-MS liquid chromatography inductively coupled plasma mass spectroscopy liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0000552 liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0000552 A method where a sample mixture is first separated by liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. FIX:0000865 https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. A series of collectors ised used to detect several ion beams simultaneously. MC-ICP-MS MC-ICPMS multi collector-inductively coupled plasma mass spectrometry multicollector inductively coupled plasma mass spectrometry multicollector inductively coupled plasma mass spectroscopy multiple collector inductively coupled plasma mass spectroscopy CHMO:0000553 multiple collector inductively coupled plasma mass spectrometry CHMO:0000553 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. A series of collectors ised used to detect several ion beams simultaneously. https://doi.org/10.1039/b808232d A method where a sample mixture is first separated by size-exclusion chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. CHMO:0000755 SEC-ICP-MS SEC-ICPMS SEC/ICPMS size-exclusion chromatography inductively coupled mass spectrometry size-exclusion chromatography inductively coupled mass spectroscopy size-exclusion chromatography-inductively coupled plasma mass spectroscopy CHMO:0000554 size-exclusion chromatography-inductively coupled plasma mass spectrometry CHMO:0000554 A method where a sample mixture is first separated by size-exclusion chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by size-exclusion and high-performance liquid chromatographies before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. SEC-HPLC-ICP-MS size-exclusion chromatography-high performance liquid chromatography inductively coupled plasma mass spectrometry size-exclusion chromatography-high performance liquid chromatography-inductively coupled plasma mass spectroscopy CHMO:0000555 size-exclusion chromatography-high-performance liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0000555 A method where a sample mixture is first separated by size-exclusion and high-performance liquid chromatographies before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where a sample mixture (a solution in dilute HNO3) is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. solution ICP-MS solution ICPMS solution inductively coupled plasma mass spectroscopy solution-ICP-MS CHMO:0000556 solution inductively coupled plasma mass spectrometry CHMO:0000556 Mass spectrometry where a sample mixture (a solution in dilute HNO3) is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where a sample mixture (a solution in dilute HNO3) is passed through a nebuliser to form a mist of finely dispersed droplets before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. SN-ICP-MS solution nebulisation inductively coupled plasma mass spectroscopy solution nebulization inductively coupled plasma mass spectrometry solution nebulization inductively coupled plasma mass spectroscopy CHMO:0000557 solution nebulisation inductively coupled plasma mass spectrometry CHMO:0000557 Mass spectrometry where a sample mixture (a solution in dilute HNO3) is passed through a nebuliser to form a mist of finely dispersed droplets before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is bombarded with a stream of primary mass-selected particles and the secondary ions ejected from the sample are detected by accelerating them to the same (known) kinetic energy and measuring the time taken for each ion to reach a detector at a known distance. This time is dependent on the mass-to-charge ratio of the ion. TOF-SIMS ToF-SIMS time-of-flight secondary ion mass spectroscopy CHMO:0000565 time-of-flight secondary ion mass spectrometry CHMO:0000565 Mass spectrometry where the sample is bombarded with a stream of primary mass-selected particles and the secondary ions ejected from the sample are detected by accelerating them to the same (known) kinetic energy and measuring the time taken for each ion to reach a detector at a known distance. This time is dependent on the mass-to-charge ratio of the ion. FIX:0000959 https://orcid.org/0000-0002-0640-0422 Spectroscopy where the diffuse reflection of a single pulse of infrared radiation by a sample is measured, and the spectrum obtained is subject to a Fourier transform. DRIFT DRIFTS diffuse reflectance infra-red Fourier transform spectrometry diffuse reflectance infrared Fourier transform spectrometry diffuse reflectance infrared Fourier transform spectroscopy diffuse reflectance infrared spectroscopy by Fourier transform CHMO:0000645 diffuse reflectance infrared Fourier transform spectroscopy CHMO:0000645 Spectroscopy where the diffuse reflection of a single pulse of infrared radiation by a sample is measured, and the spectrum obtained is subject to a Fourier transform. FIX:0000657 https://orcid.org/0000-0002-0640-0422 Spectroscopy where the Raman scattering of monochromatic light, from a visible laser (500–650 nm), by metal surfaces, where scattering is enhanced by the optical near-field of a metal-coated scanning probe microscopy tip, is detected. TERS tip-enhanced Raman scattering spectrometry tip-enhanced Raman scattering spectroscopy CHMO:0000678 tip-enhanced Raman spectroscopy CHMO:0000678 Spectroscopy where the Raman scattering of monochromatic light, from a visible laser (500–650 nm), by metal surfaces, where scattering is enhanced by the optical near-field of a metal-coated scanning probe microscopy tip, is detected. https://doi.org/10.1002/anie.200460656 https://doi.org/10.1039/b9nr00156e The measurement of the mass of a sample as a function of temperature. TG TG analysis TG measurements TGA thermal gravimetric analysis thermo-gravimetric analysis thermogravimetric (TG) analyses thermogravimetric (TG) analysis thermogravimetric (TGA) analysis thermogravimetric analysis CHMO:0000690 thermogravimetry CHMO:0000690 The measurement of the mass of a sample as a function of temperature. https://orcid.org/0000-0002-0640-0422 CHMO:0000701 A method where a sample mixture is first separated by liquid chromatography before being ionised and characterised by mass-to-charge ratio and relative abundance using two mass spectrometers in series. LC-MS-MS LC-MS/MS LC-MS2 LC-MSMS LC/MS/MS LCMSMS liquid chromatography tandem mass spectrometry liquid chromatography tandem mass spectroscopy liquid chromatography-tandem mass spectroscopy CHMO liquid chromatography-tandem mass spectrometry Mass spectrometry where a sample mixture is first separated by capillary electrophoresis, before being ionised in a plasma which has been generated by electromagnetic induction and characterised according to mass-to-charge ratio and relative abundance. CE-ICP-MS CE-ICPMS CE/ICP/MS capillary electrophoresis inductively coupled plasma-mass spectrometry capillary electrophoresis-ICPMS CHMO:0000703 capillary electrophoresis-inductively coupled plasma mass spectrometry CHMO:0000703 Mass spectrometry where a sample mixture is first separated by capillary electrophoresis, before being ionised in a plasma which has been generated by electromagnetic induction and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by capillary liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction and characterised according to mass-to-charge ratio and relative abundance. CapLC-ICPMS cap-LC-ICPMS capLC-ICPMS capillary liquid chromatography inductively coupled plasma mass spectroscopy CHMO:0000750 capillary liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0000750 A method where a sample mixture is first separated by capillary liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 A type of activation analysis where a sample is bombarded with neutrons, the capture of which results in the generation of radioactive nuclei for most elements in the sample. These activated nuclei then decay according to their characteristic half-lives. NAA CHMO:0000782 neutron activation analysis CHMO:0000782 A type of activation analysis where a sample is bombarded with neutrons, the capture of which results in the generation of radioactive nuclei for most elements in the sample. These activated nuclei then decay according to their characteristic half-lives. https://orcid.org/0000-0002-0640-0422 The FTIR analysis of volatile compounds released during the measurement of the mass of a sample as a function of temperature. TG-FT-IR TG-FTIR TG/FTIR TGA-FT-IR TGA-FTIR thermogravimetry coupled to Fourier transform infrared spectroscopy thermogravimetry-FTIR CHMO:0000859 thermogravimetry-Fourier transform infrared spectroscopy CHMO:0000859 The FTIR analysis of volatile compounds released during the measurement of the mass of a sample as a function of temperature. https://orcid.org/0000-0002-0640-0422 The MS analysis of volatile compounds released during the measurement of the mass of a sample as a function of temperature. TG-MS TG/MS TGA-MS TGA/MS thermogravimetry coupled to mass spectrometry CHMO:0000860 thermogravimetry-mass spectrometry CHMO:0000860 The MS analysis of volatile compounds released during the measurement of the mass of a sample as a function of temperature. https://orcid.org/0000-0002-0640-0422 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The sample is held in a dynamic reaction cell which contains a reagent gas that reacts preferentially with certain species, in order to allow only the analyte ions into the mass-to-charge analyser and the detector. DRC-ICP-MS ICP-DRC-MS dynamic reaction cell inductively coupled plasma mass spectroscopy CHMO:0000871 dynamic reaction cell inductively coupled plasma mass spectrometry CHMO:0000871 Mass spectrometry where the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. The sample is held in a dynamic reaction cell which contains a reagent gas that reacts preferentially with certain species, in order to allow only the analyte ions into the mass-to-charge analyser and the detector. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by gas chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. GC-ICP-MS GC-ICP/MS gas chromatography inductively coupled plasma mass spectrometry gas chromatography inductively coupled plasma mass spectroscopy CHMO:0000872 gas chromatography-inductively coupled plasma mass spectrometry CHMO:0000872 A method where a sample mixture is first separated by gas chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by ion-exchange chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. IC-ICP-MS IC-ICP/MS IEC-ICP-MS ion chromatography inductively coupled plasma mass spectrometry ion chromatography inductively coupled plasma mass spectroscopy ion chromatography-inductively coupled plasma mass spectrometry CHMO:0000873 ion-exchange chromatography-inductively coupled plasma mass spectrometry CHMO:0000873 A method where a sample mixture is first separated by ion-exchange chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 CHMO:0001075 A process where a sample is analyzed for its elemental and sometimes isotopic composition (the elements present and sometimes their weight percentage). EA CHMO:0001075 elemental analysis CHMO:0001075 A process where a sample is analyzed for its elemental and sometimes isotopic composition (the elements present and sometimes their weight percentage). https://orcid.org/0000-0002-0640-0422 A type of elemental analysis accomplished by combustion of the sample at 1200 °C in a stream of unreactive gas and excess oxygen and collection of the products (CO2, H2O and NOx). The masses of these combustion products can be used to calculate the composition of the unknown sample. C, H, N analysis C, H, N elemental analysis C,H,N analysis CHN analysis CHMO:0001076 carbon, hydrogen and nitrogen elemental analysis CHMO:0001076 A type of elemental analysis accomplished by combustion of the sample at 1200 °C in a stream of unreactive gas and excess oxygen and collection of the products (CO2, H2O and NOx). The masses of these combustion products can be used to calculate the composition of the unknown sample. https://orcid.org/0000-0002-0640-0422 The measurement of the osmotic strength of a substance which often used to determine its molecular weight. CHMO:0001082 osmometry CHMO:0001082 The measurement of the osmotic strength of a substance which often used to determine its molecular weight. https://orcid.org/0000-0002-0640-0422 A technique used to determine the concentration of osmotically active particles that reduce the vapor pressure of a solution. Vapour pressure osmometry is used to measure the average molecular weight of polymers. VPO vapor pressure osmometry vapor pressure osometry vapor-pressure osmometry vapour pressure osometry vapour-pressure osmometry CHMO:0001083 vapour pressure osmometry CHMO:0001083 A technique used to determine the concentration of osmotically active particles that reduce the vapor pressure of a solution. Vapour pressure osmometry is used to measure the average molecular weight of polymers. https://orcid.org/0000-0002-0640-0422 A kind of elemental or isotopic analysis based on the measurement of characteristic radiation from nuclides formed directly or indirectly by activation of the test portion. https://orcid.org/0000-0001-5985-7429 2009-03-25T12:02:33Z CHMO:0001224 activation analysis CHMO:0001224 A kind of elemental or isotopic analysis based on the measurement of characteristic radiation from nuclides formed directly or indirectly by activation of the test portion. https://doi.org/10.1351/goldbook.A00096 A kind of activation analysis in which the elemental concentrations in the material are calculated from known nuclear constants, irradiation and measurement parameters, rather than by comparing with known standards. https://orcid.org/0000-0001-5985-7429 2009-03-25T12:05:01Z CHMO:0001225 absolute activation analysis CHMO:0001225 A kind of activation analysis in which the elemental concentrations in the material are calculated from known nuclear constants, irradiation and measurement parameters, rather than by comparing with known standards. https://doi.org/10.1351/goldbook.A00018 A method where a sample mixture is first separated by reversed-phase high-performance liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. https://orcid.org/0000-0001-5985-7429 2009-05-06T02:16:07Z RP-HPLC-ICPMS reversed phase high performance liquid chromatography inductively coupled plasma mass spectrometry reversed phase high pressure liquid chromatography inductively coupled plasma mass spectrometry reversed-phase HPLC-ICPMS reversed-phase high performance liquid chromatography inductively coupled plasma mass spectrometry reversed-phase high pressure liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0001277 reversed-phase high-performance liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0001277 A method where a sample mixture is first separated by reversed-phase high-performance liquid chromatography before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first separated by high-performance liquid chromatography (flow rate nL min-1) before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. https://orcid.org/0000-0001-5985-7429 2009-05-06T02:39:15Z nHPLC-ICPMS nanoHPLC-ICPMS nanoflow HPLC ICP MS nanoflow HPLC-ICP-MS nanoflow HPLC-ICPMS nanoflow HPLC/ICP-MS nanoflow high performance liquid chromatography inductively coupled plasma mass spectrometry nanoflow high performance liquid chromatography-ICPMS nanoflow high pressure liquid chromatography inductively coupled mass spectroscopy CHMO:0001281 nanoflow high-performance liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0001281 A method where a sample mixture is first separated by high-performance liquid chromatography (flow rate nL min-1) before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised by mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 Inductively coupled plasma mass spectrometry where the sample mixture is first separated by reversed-phase nanoflow high performance liquid chromatography. https://orcid.org/0000-0001-5985-7429 2009-05-06T02:56:31Z reversed phase nanoflow high performance liquid chromatography inductively coupled plasma mass spectrometry reversed phase nanoflow high performance liquid chromatography-ICPMS reversed phase nanoflow high pressure liquid chromatography inductively coupled mass spectroscopy reversed-phase nHPLC-ICPMS reversed-phase nanoHPLC-ICPMS reversed-phase nanoflow HPLC ICP MS reversed-phase nanoflow HPLC-ICP-MS reversed-phase nanoflow HPLC-ICPMS reversed-phase nanoflow HPLC/ICP-MS CHMO:0001283 reversed-phase nanoflow high-performance liquid chromatography-inductively coupled plasma mass spectrometry CHMO:0001283 Inductively coupled plasma mass spectrometry where the sample mixture is first separated by reversed-phase nanoflow high performance liquid chromatography. https://orcid.org/0000-0002-0640-0422 The transfer of a solute from a liquid phase to another immiscible or partially-miscible liquid phase in contact with it. CHMO:0001577 extraction CHMO:0001577 The transfer of a solute from a liquid phase to another immiscible or partially-miscible liquid phase in contact with it. OrangeBook:9.4.1 Mass spectrometry where a solid sample is vaporised by depositing it on a probe which is rapidly heated (to <1000 °C) by passing a current through it. The vaporised sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. https://orcid.org/0000-0001-5985-7429 2009-05-20T02:37:17Z LTETV-ICPMS LTEV-ICPMS low temperature electrothermal vaporisation inductively coupled plasma mass spectrometry low temperature electrothermal vaporization inductively coupled plasma mass spectrometry low-temperature electrothermal vaporization inductively coupled plasma mass spectrometry CHMO:0001791 low-temperature electrothermal vaporisation inductively coupled plasma mass spectrometry CHMO:0001791 Mass spectrometry where a solid sample is vaporised by depositing it on a probe which is rapidly heated (to <1000 °C) by passing a current through it. The vaporised sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction. https://doi.org/10.1021/ac035437e A method where a sample mixture is first adsorbed onto packed tubes (e.g. Tenax) then each tube is automatically moved into a desorption oven and heated (100–280 °C for 5–20 min) to promote thermal desorption of the mixture into the headspace of the tube. The headspace is sampled and used for gas chromatography and the eluent is then ionised and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0001-5985-7429 2009-06-08T01:31:14Z ATC-GCMS ATD, GC/MS ATD-GC-MS ATD-GC/MS ATD/GC-MS ATD/GC/MS automated thermal desorption gas chromatography mass spectrometry automated thermodesorption-gas chromatography mass spectrometry CHMO:0001931 automated thermal desorption-gas chromatography mass spectrometry CHMO:0001931 A method where a sample mixture is first adsorbed onto packed tubes (e.g. Tenax) then each tube is automatically moved into a desorption oven and heated (100–280 °C for 5–20 min) to promote thermal desorption of the mixture into the headspace of the tube. The headspace is sampled and used for gas chromatography and the eluent is then ionised and characterised according to mass-to-charge ratio and relative abundance. ISBN:0751401587 The measurement of the size distribution in a collection of grains. https://orcid.org/0000-0001-5985-7429 2009-07-08T09:57:28Z CHMO:0002119 granulometry CHMO:0002119 The measurement of the size distribution in a collection of grains. https://orcid.org/0000-0002-0640-0422 The measurement of the pore diameter, pore-size distribution and total pore volume of a sample. https://orcid.org/0000-0001-5985-7429 2009-08-05T06:14:39Z CHMO:0002249 porosimetry CHMO:0002249 The measurement of the pore diameter, pore-size distribution and total pore volume of a sample. https://orcid.org/0000-0002-0640-0422 The measurement of the pore diameter, pore-size distribution and total pore volume of a thin porous film sample by measuring the changes in intensity and polarisation of reflected light during vapour adsorption and desorption. https://orcid.org/0000-0001-5985-7429 2009-08-05T06:16:26Z EP CHMO:0002250 ellipsometric porosimetry CHMO:0002250 The measurement of the pore diameter, pore-size distribution and total pore volume of a thin porous film sample by measuring the changes in intensity and polarisation of reflected light during vapour adsorption and desorption. https://doi.org/10.1016/j.tsf.2005.08.334 A method where a sample mixture is first separated by ion-pair chromatography (where sample ions are 'paired' or neutralised and separated as an ion pair on a reversed-phase column) before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0001-5985-7429 2009-08-19T02:02:55Z IP-ICP-MS IP-ICP/MS IPC-ICP-MS IPC-ICP/MS ion pairing chromatography-inductively coupled plasma mass spectrometry ion-pair chromatography inductively coupled plasma mass spectrometry ion-pair chromatography inductively coupled plasma mass spectroscopy ion-pairing chromatography-inductively coupled plasma mass spectrometry CHMO:0002281 ion-pair chromatography-inductively coupled plasma mass spectrometry CHMO:0002281 A method where a sample mixture is first separated by ion-pair chromatography (where sample ions are 'paired' or neutralised and separated as an ion pair on a reversed-phase column) before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 An electrode which responds to the activity of a primary ion in presence of various other (interfering) ions in the sample solution. Ion-selective electrodes contain a selective membrane which contains fixed or mobile sites that interact with ions in solution. https://orcid.org/0000-0001-5985-7429 2009-09-16T11:06:31Z ISE CHMO:0002393 ion-selective electrode CHMO:0002393 An electrode which responds to the activity of a primary ion in presence of various other (interfering) ions in the sample solution. Ion-selective electrodes contain a selective membrane which contains fixed or mobile sites that interact with ions in solution. ISBN:978-3-540-74597-6 A method where a sample mixture is first separated by gas chromatography before part of the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. Another part of the sample is simultaneously ionised by electrons (energy 70 eV) which have been emitted from a glowing filament and accelerated through an electric field. The ions are then characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0001-5985-7429 2009-10-21T06:00:00Z GC-EI-MS/ICP-MS GC/EI-MS/ICP-MS CHMO:0002538 parallel ICP-MS and EI-MS detection after GC separation CHMO:0002538 A method where a sample mixture is first separated by gas chromatography before part of the sample is ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. Another part of the sample is simultaneously ionised by electrons (energy 70 eV) which have been emitted from a glowing filament and accelerated through an electric field. The ions are then characterised according to mass-to-charge ratio and relative abundance. https://doi.org/10.1039/b822668f A method where a sample mixture is first separated by low-temperature gas chromatography (-78°C) before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0001-5985-7429 2009-10-21T06:07:24Z LT-GC-ICP-MS LT-GC/ICP-MS low temperature gas chromatography (LT-GC) coupled on-line with inductively coupled plasma mass spectrometry (ICP-MS) low-temperature gas chromatography inductively coupled plasma mass spectrometry low-temperature gas chromatography inductively coupled plasma mass spectroscopy CHMO:0002539 low-temperature gas chromatography-inductively coupled plasma mass spectrometry CHMO:0002539 A method where a sample mixture is first separated by low-temperature gas chromatography (-78°C) before being ionised in a plasma (a partially ionised gas–-such as Ar–-containing free electrons) which has been generated by electromagnetic induction, and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 A method where a sample mixture is first adsorbed onto packed tubes (e.g. Tenax) then moved into a desorption oven and heated (100–280 °C for 5–20 min) to promote thermal desorption of the mixture into the headspace of the tube. The headspace is sampled and used for gas chromatography and the eluent is then ionised and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0001-5985-7429 2009-12-11T01:18:41Z TD GC-MS TD GC/MS TD-GC-MS TD-GC/MS TD-GCMS TD/GC-MS TD/GC/MS thermal desorption GC-MS thermal desorption GC/MS thermal desorption gas chromatography mass spectrometry thermodesorption GC-MS thermodesorption GC/MS thermodesorption-gas chromatography mass spectrometry CHMO:0002640 thermal desorption-gas chromatography mass spectrometry CHMO:0002640 A method where a sample mixture is first adsorbed onto packed tubes (e.g. Tenax) then moved into a desorption oven and heated (100–280 °C for 5–20 min) to promote thermal desorption of the mixture into the headspace of the tube. The headspace is sampled and used for gas chromatography and the eluent is then ionised and characterised according to mass-to-charge ratio and relative abundance. https://orcid.org/0000-0002-0640-0422 The measurement of the temperature difference between the sample and a reference material during the measurement of the mass of the sample as a function of temperature. https://orcid.org/0000-0001-5985-7429 2010-01-04T04:19:21Z DTA-TG DTA-TGA DTA/TG DTA/TGA TG-DTA TGA-DTA TGDTA differential thermal analysis and thermal gravimetry analysis differential thermalgravimetric analysis thermogravimetric and differential thermal analyses thermogravimetry coupled to differential thermal analysis CHMO:0002651 thermogravimetry-differential thermal analysis CHMO:0002651 The measurement of the temperature difference between the sample and a reference material during the measurement of the mass of the sample as a function of temperature. https://orcid.org/0000-0002-0640-0422 Diffuse reflectance infrared Fourier transform spectroscopy of a sample that is carried out in the environment where the sample might be used. in situ DRIFT in situ DRIFTS CHMO:0002813 For example, the sample might be a catalyst, so during those catalytic processes. in situ diffuse reflectance infrared Fourier transform spectroscopy CHMO:0002813 Diffuse reflectance infrared Fourier transform spectroscopy of a sample that is carried out in the environment where the sample might be used. https://orcid.org/0000-0001-5985-7429 The mass of the product of a synthesis expressed as a percentage of the theoretical maxiμm mass given the masses of the reactants. CHMO:0002855 percentage yield CHMO:0002855 The mass of the product of a synthesis expressed as a percentage of the theoretical maxiμm mass given the masses of the reactants. https://orcid.org/0000-0001-5985-7429 Spectroscopy that uses thermal analysis to probe the surface chemistry of heterogeneous catalysts. http://orcid.org/0000-0002-4166-7093 TPSR temperature programmed surface reaction spectroscopy CHMO:0002928 temperature-programmed surface reaction spectroscopy CHMO:0002928 CLO:0010521 ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT GM08388 cell GM08388 CLO:0010523 ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT GM08390 cell GM08390 CLO:0010526 APPARENTLY HEALTHY NON-FETAL TISSUE GM08398 cell GM08398 CLO:0010557 ATAXIA-TELANGIECTASIA; AT ATAXIA-TELANGIECTASIA MUTATED GENE; ATM GM08436 cell GM08436 CLO:0011234 ATAXIA-TELANGIECTASIA; AT GM08931 cell GM08931 CLO:0011235 ATAXIA-TELANGIECTASIA; AT GM08930 cell GM08930 CLO:0011237 ATAXIA-TELANGIECTASIA; AT GM08928 cell GM08928 CLO:0011391 ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT GM09585 cell GM09585 CLO:0011394 ATAXIA-TELANGIECTASIA; AT GM09583 cell GM09583 CLO:0011436 ATAXIA-TELANGIECTASIA; AT GM09581 cell GM09581 CLO:0011438 ATAXIA-TELANGIECTASIA; AT GM09579 cell GM09579 CLO:0012496 PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND03432 cell ND03432 CLO:0013077 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17289 cell GM17289 CLO:0013080 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17288 cell GM17288 CLO:0013082 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17287 cell GM17287 CLO:0013086 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17286 cell GM17286 CLO:0013090 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17285 cell GM17285 CLO:0013092 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17284 cell GM17284 CLO:0013094 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17282 cell GM17282 CLO:0013095 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17283 cell GM17283 CLO:0013096 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM17280 cell GM17280 CLO:0013097 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 GM17281 cell GM17281 CLO:0013124 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17296 cell GM17296 CLO:0013127 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17295 cell GM17295 CLO:0013135 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17291 cell GM17291 CLO:0013136 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17292 cell GM17292 CLO:0013137 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17293 cell GM17293 CLO:0013138 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17294 cell GM17294 CLO:0013140 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17290 cell GM17290 CLO:0013163 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17265 cell GM17265 CLO:0013168 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17264 cell GM17264 CLO:0013169 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17263 cell GM17263 CLO:0013173 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17262 cell GM17262 CLO:0013176 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17269 cell GM17269 CLO:0013177 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17268 cell GM17268 CLO:0013179 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17267 cell GM17267 CLO:0013181 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17266 cell GM17266 CLO:0013182 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17260 cell GM17260 CLO:0013183 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17261 cell GM17261 CLO:0013193 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17274 cell GM17274 CLO:0013197 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17273 cell GM17273 CLO:0013199 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17276 cell GM17276 CLO:0013202 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17275 cell GM17275 CLO:0013204 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17278 cell GM17278 CLO:0013208 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17277 cell GM17277 CLO:0013210 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17279 cell GM17279 CLO:0013212 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17270 cell GM17270 CLO:0013213 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17271 cell GM17271 CLO:0013214 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17272 cell GM17272 CLO:0013751 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17180 cell GM17180 CLO:0013752 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17184 cell GM17184 CLO:0013753 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17183 cell GM17183 CLO:0013754 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17182 cell GM17182 CLO:0013755 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17181 cell GM17181 CLO:0013775 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17187 cell GM17187 CLO:0013777 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17188 cell GM17188 CLO:0013781 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17185 cell GM17185 CLO:0013784 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17186 cell GM17186 CLO:0013790 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17189 cell GM17189 CLO:0013793 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17191 cell GM17191 CLO:0013794 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17190 cell GM17190 CLO:0013795 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17193 cell GM17193 CLO:0013796 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17192 cell GM17192 CLO:0013797 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17195 cell GM17195 CLO:0013798 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17194 cell GM17194 CLO:0013816 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17196 cell GM17196 CLO:0013818 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17197 cell GM17197 CLO:0013823 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17198 cell GM17198 CLO:0013826 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17199 cell GM17199 CLO:0013833 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17206 cell GM17206 CLO:0013834 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17205 cell GM17205 CLO:0013835 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17204 cell GM17204 CLO:0013836 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17203 cell GM17203 CLO:0013837 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17202 cell GM17202 CLO:0013839 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17201 cell GM17201 CLO:0013840 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17200 cell GM17200 CLO:0013875 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17209 cell GM17209 CLO:0013881 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17207 cell GM17207 CLO:0013884 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17208 cell GM17208 CLO:0013885 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17215 cell GM17215 CLO:0013886 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17214 cell GM17214 CLO:0013887 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17217 cell GM17217 CLO:0013888 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17216 cell GM17216 CLO:0013890 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17211 cell GM17211 CLO:0013891 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17210 cell GM17210 CLO:0013893 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17213 cell GM17213 CLO:0013895 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17212 cell GM17212 CLO:0013921 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17218 cell GM17218 CLO:0013924 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17219 cell GM17219 CLO:0013935 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17140 cell GM17140 CLO:0013936 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17144 cell GM17144 CLO:0013937 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17143 cell GM17143 CLO:0013938 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17142 cell GM17142 CLO:0013939 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17141 cell GM17141 CLO:0013940 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17148 cell GM17148 CLO:0013941 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17147 cell GM17147 CLO:0013942 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17146 cell GM17146 CLO:0013943 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17145 cell GM17145 CLO:0013947 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17149 cell GM17149 CLO:0013956 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17150 cell GM17150 CLO:0013960 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17155 cell GM17155 CLO:0013961 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17154 cell GM17154 CLO:0013962 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17157 cell GM17157 CLO:0013963 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17156 cell GM17156 CLO:0013964 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17159 cell GM17159 CLO:0013965 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 SNP500 PANEL GM17158 cell GM17158 CLO:0013982 SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17161 cell GM17161 CLO:0013983 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17162 cell GM17162 CLO:0013984 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17160 cell GM17160 CLO:0013987 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17168 cell GM17168 CLO:0013989 SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17167 cell GM17167 CLO:0013990 SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17166 cell GM17166 CLO:0013993 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17165 cell GM17165 CLO:0013994 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17164 cell GM17164 CLO:0013996 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17163 cell GM17163 CLO:0014022 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17170 cell GM17170 CLO:0014024 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17171 cell GM17171 CLO:0014025 SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17172 cell GM17172 CLO:0014026 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17173 cell GM17173 CLO:0014028 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17179 cell GM17179 CLO:0014029 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17178 cell GM17178 CLO:0014033 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17175 cell GM17175 CLO:0014034 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17174 cell GM17174 CLO:0014037 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17177 cell GM17177 CLO:0014039 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17176 cell GM17176 CLO:0014327 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17239 cell GM17239 CLO:0014330 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17237 cell GM17237 CLO:0014332 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17238 cell GM17238 CLO:0014334 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17235 cell GM17235 CLO:0014336 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17236 cell GM17236 CLO:0014338 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17233 cell GM17233 CLO:0014340 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17234 cell GM17234 CLO:0014341 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17231 cell GM17231 CLO:0014344 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17232 cell GM17232 CLO:0014347 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17230 cell GM17230 CLO:0014356 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17226 cell GM17226 CLO:0014358 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17227 cell GM17227 CLO:0014359 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17228 cell GM17228 CLO:0014362 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17229 cell GM17229 CLO:0014366 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17222 cell GM17222 CLO:0014367 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17223 cell GM17223 CLO:0014369 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17224 cell GM17224 CLO:0014371 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17225 cell GM17225 CLO:0014375 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17220 cell GM17220 CLO:0014377 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17221 cell GM17221 CLO:0014388 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17259 cell GM17259 CLO:0014389 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17253 cell GM17253 CLO:0014390 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17254 cell GM17254 CLO:0014391 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 GM17251 cell GM17251 CLO:0014392 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17252 cell GM17252 CLO:0014393 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17257 cell GM17257 CLO:0014394 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17258 cell GM17258 CLO:0014395 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17255 cell GM17255 CLO:0014396 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17256 cell GM17256 CLO:0014397 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17250 cell GM17250 CLO:0014404 PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES ND02579 cell ND02579 CLO:0014408 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17248 cell GM17248 CLO:0014409 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17249 cell GM17249 CLO:0014410 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17240 cell GM17240 CLO:0014411 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17241 cell GM17241 CLO:0014412 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17242 cell GM17242 CLO:0014413 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17243 cell GM17243 CLO:0014414 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17244 cell GM17244 CLO:0014415 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17245 cell GM17245 CLO:0014416 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17246 cell GM17246 CLO:0014417 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17247 cell GM17247 CLO:0014788 ATAXIA-TELANGIECTASIA; AT GM02783 cell GM02783 CLO:0014806 ANEUPLOID CHROMOSOME NUMBER - TRISOMY TRISOMY 21 GM02767 cell GM02767 CLO:0014887 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 GM17109 cell GM17109 CLO:0014889 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17108 cell GM17108 CLO:0014896 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17102 cell GM17102 CLO:0014898 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17103 cell GM17103 CLO:0014900 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17104 cell GM17104 CLO:0014901 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17105 cell GM17105 CLO:0014902 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17106 cell GM17106 CLO:0014903 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17107 cell GM17107 CLO:0014942 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17119 cell GM17119 CLO:0014943 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17113 cell GM17113 CLO:0014945 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 GM17114 cell GM17114 CLO:0014947 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 GM17111 cell GM17111 CLO:0014948 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17112 cell GM17112 CLO:0014950 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17117 cell GM17117 CLO:0014951 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17118 cell GM17118 CLO:0014952 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17115 cell GM17115 CLO:0014953 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17116 cell GM17116 CLO:0014964 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 GM17110 cell GM17110 CLO:0015081 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17132 cell GM17132 CLO:0015082 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17133 cell GM17133 CLO:0015085 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17130 cell GM17130 CLO:0015087 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17131 cell GM17131 CLO:0015088 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 GM17136 cell GM17136 CLO:0015090 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17137 cell GM17137 CLO:0015093 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17134 cell GM17134 CLO:0015094 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17135 cell GM17135 CLO:0015097 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17138 cell GM17138 CLO:0015098 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17139 cell GM17139 CLO:0015112 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17120 cell GM17120 CLO:0015115 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17121 cell GM17121 CLO:0015117 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17122 cell GM17122 CLO:0015119 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17123 cell GM17123 CLO:0015121 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17124 cell GM17124 CLO:0015123 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17125 cell GM17125 CLO:0015124 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17126 cell GM17126 CLO:0015126 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17127 cell GM17127 CLO:0015128 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17128 cell GM17128 CLO:0015130 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17129 cell GM17129 CLO:0015209 PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND02852 cell ND02852 CLO:0016362 PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND01737 cell ND01737 CLO:0016449 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17852 cell GM17852 CLO:0016450 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17850 cell GM17850 CLO:0016453 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17845 cell GM17845 CLO:0016454 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17844 cell GM17844 CLO:0016455 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17847 cell GM17847 CLO:0016456 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17846 cell GM17846 CLO:0016457 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17842 cell GM17842 CLO:0016458 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17843 cell GM17843 CLO:0016489 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17798 cell GM17798 CLO:0016490 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17799 cell GM17799 CLO:0016491 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17800 cell GM17800 CLO:0016492 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17801 cell GM17801 CLO:0016493 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17796 cell GM17796 CLO:0016494 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17797 cell GM17797 CLO:0016495 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17802 cell GM17802 CLO:0016496 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17803 cell GM17803 CLO:0016497 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17804 cell GM17804 CLO:0016498 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17805 cell GM17805 CLO:0016499 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17811 cell GM17811 CLO:0016500 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17812 cell GM17812 CLO:0016501 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17809 cell GM17809 CLO:0016502 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17810 cell GM17810 CLO:0016503 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17807 cell GM17807 CLO:0016504 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17808 cell GM17808 CLO:0016505 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17806 cell GM17806 CLO:0016506 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17815 cell GM17815 CLO:0016507 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17813 cell GM17813 CLO:0016508 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17814 cell GM17814 CLO:0016509 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17816 cell GM17816 CLO:0016510 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17817 cell GM17817 CLO:0016511 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17818 cell GM17818 CLO:0016515 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17823 cell GM17823 CLO:0016516 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17824 cell GM17824 CLO:0016517 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17825 cell GM17825 CLO:0016518 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17826 cell GM17826 CLO:0016519 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17833 cell GM17833 CLO:0016520 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17835 cell GM17835 CLO:0016521 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17828 cell GM17828 CLO:0016522 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17831 cell GM17831 CLO:0016523 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17839 cell GM17839 CLO:0016524 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17840 cell GM17840 CLO:0016525 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17837 cell GM17837 CLO:0016526 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17838 cell GM17838 CLO:0016527 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17841 cell GM17841 CLO:0016528 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17827 cell GM17827 CLO:0016554 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17756 cell GM17756 CLO:0016555 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17755 cell GM17755 CLO:0016558 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17754 cell GM17754 CLO:0016560 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17753 cell GM17753 CLO:0016561 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17752 cell GM17752 CLO:0016564 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17749 cell GM17749 CLO:0016565 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17747 cell GM17747 CLO:0016566 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17746 cell GM17746 CLO:0016567 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17745 cell GM17745 CLO:0016568 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17744 cell GM17744 CLO:0016593 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17767 cell GM17767 CLO:0016594 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17766 cell GM17766 CLO:0016597 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17768 cell GM17768 CLO:0016600 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17762 cell GM17762 CLO:0016601 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17761 cell GM17761 CLO:0016602 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17765 cell GM17765 CLO:0016604 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17764 cell GM17764 CLO:0016606 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17757 cell GM17757 CLO:0016607 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17759 cell GM17759 CLO:0016608 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17758 cell GM17758 CLO:0016635 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17779 cell GM17779 CLO:0016636 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17776 cell GM17776 CLO:0016638 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17775 cell GM17775 CLO:0016641 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17774 cell GM17774 CLO:0016642 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17782 cell GM17782 CLO:0016643 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17780 cell GM17780 CLO:0016645 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17773 cell GM17773 CLO:0016646 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17771 cell GM17771 CLO:0016647 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17770 cell GM17770 CLO:0016648 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17769 cell GM17769 CLO:0016672 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17792 cell GM17792 CLO:0016675 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17791 cell GM17791 CLO:0016676 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17794 cell GM17794 CLO:0016678 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17793 cell GM17793 CLO:0016682 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17795 cell GM17795 CLO:0016684 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17783 cell GM17783 CLO:0016685 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17787 cell GM17787 CLO:0016686 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17785 cell GM17785 CLO:0016687 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17790 cell GM17790 CLO:0016688 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17789 cell GM17789 CLO:0016951 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 SNP500 PANEL HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 CEPH/UTAH PEDIGREE 1345 GM07348 cell GM07348 CLO:0016995 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17733 cell GM17733 CLO:0017020 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17741 cell GM17741 CLO:0017021 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17740 cell GM17740 CLO:0017022 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17739 cell GM17739 CLO:0017023 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17738 cell GM17738 CLO:0017024 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17743 cell GM17743 CLO:0017025 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17742 cell GM17742 CLO:0017043 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17736 cell GM17736 CLO:0017044 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17737 cell GM17737 CLO:0017045 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17734 cell GM17734 CLO:0017046 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17735 cell GM17735 CLO:0018566 LATE ONSET PARKINSON'S DNA PANEL, AFFECTED INDIVIDUALS PARKINSON'S DISEASE ND06449 cell ND06449 CLO:0019004 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1375 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM12264 cell GM12264 CLO:0020019 CEPH/UTAH PEDIGREE 1349 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM11840 cell GM11840 CLO:0021459 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG10941 cell AG10941 CLO:0021565 LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS AG11498 cell AG11498 CLO:0021597 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG11364 cell AG11364 CLO:0021875 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG10049 cell AG10049 CLO:0021913 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG09699 cell AG09699 CLO:0021943 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG09877 cell AG09877 CLO:0022101 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG13150 cell AG13150 CLO:0022107 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG13145 cell AG13145 CLO:0022132 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG13066 cell AG13066 CLO:0022320 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG14446 cell AG14446 CLO:0022362 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG11696 cell AG11696 CLO:0022371 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG11726 cell AG11726 CLO:0022604 LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS AG11513 cell AG11513 CLO:0023783 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1424 GM10845 cell GM10845 CLO:0023784 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1423 GM10842 cell GM10842 CLO:0023785 CEPH/UTAH PEDIGREE 1423 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM10843 cell GM10843 CLO:0023794 SNP500 PANEL CEPH/UTAH PEDIGREE 1413 GM10832 cell GM10832 CLO:0023795 CEPH/UTAH PEDIGREE 1413 SNP500 PANEL GM10833 cell GM10833 CLO:0025850 TRANSLOCATED CHROMOSOME TRISOMY 21 GM00144 cell GM00144 CLO:0026349 POPULATION/CONVENIENCE CONTROL ND00259 cell ND00259 CLO:0026399 POPULATION/CONVENIENCE CONTROL ND00268 cell ND00268 CLO:0026786 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15386 cell GM15386 CLO:0026789 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15385 cell GM15385 CLO:0027048 ISCHEMIC STROKE NDPT081 ISCHEMIC STROKE DNA PANEL ND00397 cell ND00397 CLO:0027182 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15324 cell GM15324 CLO:0027328 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15268 cell GM15268 CLO:0027391 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15245 cell GM15245 CLO:0027447 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15242 cell GM15242 CLO:0027467 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15236 cell GM15236 CLO:0027473 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15227 cell GM15227 CLO:0027483 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15223 cell GM15223 CLO:0027484 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15224 cell GM15224 CLO:0027486 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15226 cell GM15226 CLO:0027487 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15221 cell GM15221 CLO:0027491 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 GM15216 cell GM15216 CLO:0027492 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15215 cell GM15215 CLO:0027493 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15213 cell GM15213 CLO:0028103 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15590 cell GM15590 CLO:0028397 PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES ND01173 cell ND01173 CLO:0029036 POPULATION/CONVENIENCE CONTROL ND06229 cell ND06229 CLO:0029732 POPULATION/CONVENIENCE CONTROL ND00051 cell ND00051 CLO:0029916 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15144 cell GM15144 CLO:0030105 POPULATION/CONVENIENCE CONTROL ND00022 cell ND00022 CLO:0030305 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 GM15029 cell GM15029 CLO:0030309 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15038 cell GM15038 CLO:0030311 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15036 cell GM15036 CLO:0030324 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15061 cell GM15061 CLO:0030328 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15056 cell GM15056 CLO:0030337 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15072 cell GM15072 CLO:0030688 POPULATION/CONVENIENCE CONTROL ND00151 cell ND00151 CLO:0031189 APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14381 cell GM14381 CLO:0031198 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14382 cell GM14382 CLO:0031201 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14405 cell GM14405 CLO:0031225 APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14414 cell GM14414 CLO:0031226 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14409 cell GM14409 CLO:0031227 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14408 cell GM14408 CLO:0031228 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14406 cell GM14406 CLO:0031232 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG08904 cell AG08904 CLO:0031234 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14439 cell GM14439 CLO:0031236 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14433 cell GM14433 CLO:0031238 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14432 cell GM14432 CLO:0031239 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14417 cell GM14417 CLO:0031253 APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS GM14453 cell GM14453 CLO:0031254 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14454 cell GM14454 CLO:0031256 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14455 cell GM14455 CLO:0031257 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14440 cell GM14440 CLO:0031260 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14447 cell GM14447 CLO:0031261 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14448 cell GM14448 CLO:0031263 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14452 cell GM14452 CLO:0031272 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14475 cell GM14475 CLO:0031274 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14476 cell GM14476 CLO:0031275 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14465 cell GM14465 CLO:0031276 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14467 cell GM14467 CLO:0031278 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14464 cell GM14464 CLO:0031280 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14474 cell GM14474 CLO:0031281 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14468 cell GM14468 CLO:0031504 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14501 cell GM14501 CLO:0031509 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14503 cell GM14503 CLO:0031510 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14502 cell GM14502 CLO:0031516 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14504 cell GM14504 CLO:0031517 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14507 cell GM14507 CLO:0031519 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14506 cell GM14506 CLO:0031529 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14478 cell GM14478 CLO:0031531 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14477 cell GM14477 CLO:0031533 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14481 cell GM14481 CLO:0031534 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14480 cell GM14480 CLO:0031535 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14479 cell GM14479 CLO:0031580 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14568 cell GM14568 CLO:0031581 APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS GM14569 cell GM14569 CLO:0031585 APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14581 cell GM14581 CLO:0031600 APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14535 cell GM14535 CLO:0031601 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14536 cell GM14536 CLO:0031606 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14532 cell GM14532 CLO:0031607 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14533 cell GM14533 CLO:0031609 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14509 cell GM14509 CLO:0031610 MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14508 cell GM14508 CLO:0031611 NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14520 cell GM14520 CLO:0031612 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14521 cell GM14521 CLO:0031665 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14583 cell GM14583 CLO:0031666 MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14582 cell GM14582 CLO:0031668 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14584 cell GM14584 CLO:0031953 NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14679 cell GM14679 CLO:0032601 PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND04158 cell ND04158 CLO:0032713 COLORECTAL CANCER, FAMILIAL GM13649 cell GM13649 CLO:0033199 ATAXIA-TELANGIECTASIA; AT GM13883 cell GM13883 CLO:0033570 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG08048 cell AG08048 CLO:0033577 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG08046 cell AG08046 CLO:0033628 ATAXIA-TELANGIECTASIA; AT GM13811 cell GM13811 CLO:0033747 PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND04424 cell ND04424 CLO:0033909 ATAXIA-TELANGIECTASIA; AT GM13995 cell GM13995 CLO:0034375 ATAXIA-TELANGIECTASIA; AT GM14153 cell GM14153 CLO:0034780 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG04147 cell AG04147 CLO:0034796 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG04351 cell AG04351 CLO:0034915 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG04655 cell AG04655 CLO:0035232 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG05416 cell AG05416 CLO:0035254 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG06237 cell AG06237 CLO:0035579 BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG07307 cell AG07307 CLO:0035608 GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG07139 cell AG07139 CLO:0036460 TRANSLOCATED CHROMOSOME GM06944 cell GM06944 CLO:0036870 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1340 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM07029 cell GM07029 CL:0000000 A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane. CALOHA:TS-2035 FBbt:00007002 FMA:68646 GO:0005623 KUPO:0000002 MESH:D002477 VHOG:0001533 WBbt:0004017 XAO:0003012 The definition of cell is intended to represent all cells, and thus a cell is defined as a material entity and not an anatomical structure, which implies that it is part of an organism (or the entirety of one). cell A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane. CARO:mah CL:0000003 A cell that is found in a natural setting, which includes multicellular organism cells 'in vivo' (i.e. part of an organism), and unicellular organisms 'in environment' (i.e. part of a natural environment). CARO:0000013 cell in vivo To accommodate unicellular organisms better, 'cell in vivo' has been re-labeled 'native cell' to better represent its intended meaning - that is, that it is a cell in the context of a multicellular organism or in a natural environment. 'Native' is intended to contrast with 'in vitro', which refers to cells or other biological entities that have been intentionally placed in a controlled, non-natural setting for the purpose of study or manipulation. (MAH 1.12.12). native cell A cell that is found in a natural setting, which includes multicellular organism cells 'in vivo' (i.e. part of an organism), and unicellular organisms 'in environment' (i.e. part of a natural environment). CARO:mah CL:0000010 A cell in vitro that is or has been maintained or propagated as part of a cell culture. MESH:D002478 MO:562 MeSH:D002460 NCIt:C16403 Note that this class was re-labeled to 'cultured cell' instead of 'cell line cell', as it intent was clarified to cover any cultured cells of multicellular and unicellular organisms. This includes cells actively being cultured, or cells that have been cultured but are stored in a quiescent state for future use. In having been cultured, cells must establish homeostasis and often replicate in a foreign environment. Accomodation of this stress initiates a selection of cells fit for such challenges, wherein necessary adaptive biochemical and.or genetic changes can occur. These changes can set them apart from the in vivo cells from which they derive, and such changes will typically accumulate and change over increasing time in culture. cultured cell A cell in vitro that is or has been maintained or propagated as part of a cell culture. ReO:mhb CL:0001034 A cell that is maintained or propagated in a controlled artificial environment for use in an investigation. 2012-01-12T09:58:38Z 'In vitro', translating literally to 'in glass', typically refers to a controlled, often sterile, laboratory setting where cells or other specimens are placed by some agent for the purpose of studying or manipulating them as part of some research investigation. 'In vitro' is intended to contrast with 'native',which refers to cells or other biological entities that are found in a natural setting. It describes unicellular organisms removed from a natural environement and multicellular organism cells removed from an organism, or cells derived in culture from such displaced cells. cell in vitro A cell that is maintained or propagated in a controlled artificial environment for use in an investigation. ReO:mhb CL:0010004 A mononuclear cell that is part_of a bone marrow. bone marrow mononuclear cell mononuclear cell of bone marrow CL:1001603 Circulating macrophages and tissue macrophages (alveolar macrophages) of lung. CALOHA:TS-0576 lung macrophages lung macrophage Circulating macrophages and tissue macrophages (alveolar macrophages) of lung. HPA:HPA NPX:PDR lung macrophages CALOHA:TS-0576 ENVO:00000003 Mine tailings are the materials left over after the process of separating the valuable fraction from the uneconomic fraction (gangue) of an ore. tailing FTT:625 FTT:631 mine tailing Mine tailings are the materials left over after the process of separating the valuable fraction from the uneconomic fraction (gangue) of an ore. https://en.wikipedia.org/wiki/Tailings tailing ADL:FTT ENVO:00000134 An environmental material which is 1) composed primarily of soil or rock and included ice or organic material and 2) at or below the freezing point of water for two or more years. LTER:408 https://en.wikipedia.org/wiki/Permafrost envoPolar Ice is not always present, as may be in the case of nonporous bedrock, but it frequently occurs and it may be in amounts exceeding the potential hydraulic saturation of the ground material. permafrost An environmental material which is 1) composed primarily of soil or rock and included ice or organic material and 2) at or below the freezing point of water for two or more years. https://en.wikipedia.org/wiki/Permafrost Broken rock that appears at the bottom of crags, mountain cliffs or valley shoulders. EcoLexicon:scree FTT:1078 FTT:96 Geonames:T.TAL SWEETRealm:Talus TGN:21508 https://en.wikipedia.org/wiki/Scree ENVO TALUS talus slope ENVO:00000194 scree ENVO:00000194 Broken rock that appears at the bottom of crags, mountain cliffs or valley shoulders. https://en.wikipedia.org/wiki/Scree TALUS USGS:SDTS talus slope Geonames:feature talus slope Getty:TGN ENVO:00000338 A bodily fluid material which is composed primarily of vomit, a bodily fluid consisting of the expulsed contents of the stomach of an organism disgorged through the mouth or nose. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. vomit material A bodily fluid material which is composed primarily of vomit, a bodily fluid consisting of the expulsed contents of the stomach of an organism disgorged through the mouth or nose. ENVOC:nm GEMINA:ls https://en.wikipedia.org/wiki/Vomit ENVO:00000428 A biome is an ecosystem to which resident ecological communities have evolved adaptations. LTER:809 EcoLexicon:biome major habitat type EcosytemType There has been some concern raised (see Issue #143) about the usefulness of the assertion that organisms have evolved within a given biome. They may have evolved adaptations elsewhere and demonstrating one or the other is often not feasible. Consider relabelling to "environmental system determined by an ecological community" or similar. biome A biome is an ecosystem to which resident ecological communities have evolved adaptations. DOI:10.1186/2041-1480-4-43 https://en.wikipedia.org/wiki/Biome LTER:809 https://vocab.lternet.edu/vocab/vocab/index.php?tema=809&/biomes major habitat type WWF:Biome EcosytemType NASA:earthrealm ENVO:00000446 A biome which is primarily or completely situated on a landmass. LTER:798 SPIRE:Terrestrial terrestrial realm terrestrial biome A biome which is primarily or completely situated on a landmass. https://en.wikipedia.org/wiki/Biome#Terrestrial_biomes ENVO:00000447 An aquatic biome which is determined by a marine water body. SPIRE:Marine marine realm envoPolar This biome includes open-ocean and unprotected coastal ecosystems, characterized by exposure to wave action, tidal fluctuation, and ocean currents as well as systems that largely resemble these. Water in the marine biome is generally within the salinity range of seawater: 30 to 38 ppt. marine biome An aquatic biome which is determined by a marine water body. ISBN:978-0-618-45504-1 MA:ma https://en.wikipedia.org/wiki/Ocean ENVO:00000546 Lake sediment is sediment which covers the bottom of a lake. Lake sediments are comprised mainly of clastic material (sediment of clay, silt, and sand sizes), organic debris, chemical precipitates, or combinations of these. SedimentLayer lake sediment Lake sediment is sediment which covers the bottom of a lake. Lake sediments are comprised mainly of clastic material (sediment of clay, silt, and sand sizes), organic debris, chemical precipitates, or combinations of these. URL:http://www.britannica.com/EBchecked/topic/328083/lake/59070/Sediments-and-sedimentation SedimentLayer NASA:earthrealm ENVO:00000873 An aquatic biome which is determined by a body of freshwater. SPIRE:Freshwater freshwater realm envoPolar freshwater biome An aquatic biome which is determined by a body of freshwater. MA:ma ENVO:00000887 A freshwater river biome which is determined by a large river. wwfBiome "Large" is ambiguous. For details on "Large rivers" (e.g. the Mekong river) see http://worldwildlife.org/biomes/large-river-ecosystems This class will be replaced with a less ambiguous class. large river biome ENVO:00000888 A freshwater river biome which is determined by the headwaters of a large river. wwfBiome "Large" is ambiguous. For details on "Large river headwaters" (e.g. the Upper Amazon headwaters) see http://worldwildlife.org/biomes/large-river-headwater-ecosystems This class will be replaced with a less ambiguous class. large river headwater biome ENVO:00000889 A freshwater river biome which is determined by the delta of a large river. wwfBiome "Large" is ambiguous. For details on "Large river deltas" (e.g. the Niger river delta) see http://worldwildlife.org/biomes/large-river-delta-ecosystems This class will be replaced with a less ambiguous class. large river delta biome ENVO:00000890 A freshwater river biome which is determined by a small river. wwfBiome "Small" is ambiguous. For details on "Small rivers" (e.g. the Salween river) see http://worldwildlife.org/biomes/small-river-ecosystems. This class will be replaced with a less ambiguous class. small river biome ENVO:00000891 A freshwater biome which is determined by a large lake. wwfBiome "Large" is ambiguous. For details on "Large lakes" (e.g. African rift lakes) see http://worldwildlife.org/biomes/large-lake-ecosystems This class will be replaced with a less ambiguous class. large freshwater lake biome ENVO:00000892 A freshwater lake biome which is determined by a small lake. wwfBiome "Small" is ambiguous. For details on "Small lakes" (e.g. Cameroon crater lakes) see http://worldwildlife.org/biomes/small-lake-ecosystems. This class will be replaced with a less ambiguous class. small freshwater lake biome ENVO:00000893 A biome which has little permanent surface water and a low relative abundance of springs. The WWF definition is somewhat ambiguous, but workable. wwfBiome xeric basin biome A biome which has little permanent surface water and a low relative abundance of springs. https://www.worldwildlife.org/biomes/xeric-basin-ecosystems ENVO:00001995 A rock is a naturally occurring solid aggregate of one or more minerals or mineraloids. EcoLexicon:rock FTT:1010 FTT:145 Geonames:T.RK Geonames:T.RKS SWEETRealm:Rock TGN:21444 https://en.wikipedia.org/wiki/Rock From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which can be an aggregate of minerals or non-minerals and does not have a specific chemical composition. The exact definition of a mineral is under debate, especially with respect to the requirement a valid species be abiogenic, and to a lesser extent with regards to it having an ordered atomic structure. rock A rock is a naturally occurring solid aggregate of one or more minerals or mineraloids. MA:ma https://en.wikipedia.org/wiki/Rock_(geology) ENVO:00001998 An environmental material which is primarily composed of minerals, varying proportions of sand, silt, and clay, organic material such as humus, interstitial gases, liquids, and a broad range of resident micro- and macroorganisms. The various 'has part' and 'has quality' relations may not hold true for all soils; however, I have yet to find counter examples. Require input from a pedologist or similar. [pbuttigieg] regolith LTER:535 SPIRE:Soil SWEETRealm:Soil https://en.wikipedia.org/wiki/Soil 'In engineering terms, soil is referred to as regolith, or loose rock material that lies above the 'solid geology'. Soil is commonly referred to as "earth" or "dirt"; technically, the term "dirt" should be restricted to displaced soil.' https://en.wikipedia.org/wiki/Soil " The upper limit of soil is the boundary between soil and air, shallow water, live plants, or plant materials that have not begun to decompose. Areas are not considered to have soil if the surface is permanently covered by water too deep (typically more than 2.5 meters) for the growth of rooted plants. The lower boundary that separates soil from the nonsoil underneath is most difficult to define. Soil consists of horizons near the Earth's surface that, in contrast to the underlying parent material, have been altered by the interactions of climate, relief, and living organisms over time. Commonly, soil grades at its lower boundary to hard rock or to earthy materials virtually devoid of animals, roots, or other marks of biological activity. For purposes of classification, the lower boundary of soil is arbitrarily set at 200 cm." Soil taxonomy, 2nd Ed., quoted in http://www.nrcs.usda.gov/wps/portal/nrcs/detail/soils/edu/?cid=nrcs142p2_054280 soil An environmental material which is primarily composed of minerals, varying proportions of sand, silt, and clay, organic material such as humus, interstitial gases, liquids, and a broad range of resident micro- and macroorganisms. https://en.wikipedia.org/wiki/Soil Water that has been adversely affected in quality by anthropogenic influence. EcoLexicon:waste_water SWEETRealm:Wastewater https://en.wikipedia.org/wiki/Waste_water ENVO ENVO:00002001 waste water ENVO:00002001 Water that has been adversely affected in quality by anthropogenic influence. https://en.wikipedia.org/wiki/Wastewater ENVO:00002003 An excreta material which is composed primarily of feces, an excreta consisting of waste products expelled from an animal's digestive tract through the anus (or cloaca) during defecation. EcoLexicon:drop SPIRE:Dung SWEETRealm:Drop faeces material feces material droppings frass pellet ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. This is distinct from classes such as http://purl.obolibrary.org/obo/UBERON_0001988 in that it refers to the environmental material composed primarily of feces rather than 'just' feces. fecal material An excreta material which is composed primarily of feces, an excreta consisting of waste products expelled from an animal's digestive tract through the anus (or cloaca) during defecation. https://en.wikipedia.org/wiki/Feces ENVO:00002005 The mixture of gases (roughly (by molar content/volume: 78% nitrogen, 20.95% oxygen, 0.93% argon, 0.038% carbon dioxide, trace amounts of other gases, and a variable amount (average around 1%) of water vapor) that surrounds the planet Earth. EcoLexicon:air LTER:18 SWEETRealm:Air https://en.wikipedia.org/wiki/Air envoPolar air The mixture of gases (roughly (by molar content/volume: 78% nitrogen, 20.95% oxygen, 0.93% argon, 0.038% carbon dioxide, trace amounts of other gases, and a variable amount (average around 1%) of water vapor) that surrounds the planet Earth. https://en.wikipedia.org/wiki/Air ENVO:00002006 An environmental material primarily composed of dihydrogen oxide in its liquid form. water EcoLexicon:water LTER:617 https://en.wikipedia.org/wiki/Water liquid water An environmental material primarily composed of dihydrogen oxide in its liquid form. MA:ma ENVO:00002007 Sediment is an environmental substance comprised of any particulate matter that can be transported by fluid flow and which eventually is deposited as a layer of solid particles on the bedor bottom of a body of water or other liquid. EcoLexicon:sediment EcoLexicon:sedimentation LTER:492 LTER:493 SWEETRealm:Sediment https://en.wikipedia.org/wiki/Sediment envoPolar It is recommended to use a combination of sediment terms to describe a more specific sediment type. sediment Sediment is an environmental substance comprised of any particulate matter that can be transported by fluid flow and which eventually is deposited as a layer of solid particles on the bedor bottom of a body of water or other liquid. https://en.wikipedia.org/wiki/Sediment ENVO:00002008 Particulate environmental material with diameters less than 500 micrometers. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. EcoLexicon:dust SWEETRealm:Dust https://en.wikipedia.org/wiki/Dust envoPolar Dust occurs in and may be deposited from the atmosphere. dust Particulate environmental material with diameters less than 500 micrometers. https://en.wikipedia.org/wiki/Dust ENVO:00002010 Water which contains a significant concentration of dissolved salts. EcoLexicon:saltwater SWEETRealm:SalineWater SWEETRealm:SaltWater https://en.wikipedia.org/wiki/Saline_water salt water The threshold salt concentration for classifying water as saline varies, but typically begins at about 1,000 to 3,000 parts salt per million parts water or 0.1–0.3% salt by weight. saline water ENVO:00002011 Water which has a low concentration of dissolved solutes, particularly that of sodium chloride. EcoLexicon:fresh_water LTER:216 SWEETRealm:FreshWater https://en.wikipedia.org/wiki/Fresh_water freshwater sweet water envoEmpo envoPolar The lower bound of solute concentration required for water to be considered freshwater is variable, but is always less than that of seawater, and often cited as less than 1 gram of solutes per 1 litre of water. fresh water ENVO:00002012 Water which contains a highly increased concentration of dissolved salts, surpassing the average salinity of seawater. We make no commitment to a particular threshold; this should be described on the data/information layer according to the norms of a discipline, accepted standard, or similar reference. envoPolar The average salinity of sea water is assumed to be around 35,000 ppm, equivalent to 35 grams of salt per one liter (or kilogram) of water. hypersaline water ENVO:00002013 Rock formed from molten magma. EcoLexicon:igneous_rock SWEETRealm:IgneousRock https://en.wikipedia.org/wiki/Igneous_rock igneous rock Rock formed from molten magma. https://en.wikipedia.org/wiki/Rock_%28geology%29 An igneous rock that results from the crystallization of a magma below the surface of the Earth. SWEETRealm:IntrusiveRock https://en.wikipedia.org/wiki/Plutonic_rock ENVO intrusive rock ENVO:00002014 plutonic rock ENVO:00002014 An igneous rock that results from the crystallization of a magma below the surface of the Earth. https://en.wikipedia.org/wiki/Plutonic_rock An igneous rock that results from magma reaching the surface either as lava or fragmental ejecta. EcoLexicon:volcanic_rock SWEETRealm:VolcanicRock https://en.wikipedia.org/wiki/Volcanic_rock ENVO ENVO:00002015 Due to the general suggestion that volcanic rock simply comes from a volcanic process, it's not immediately clear whether this is interchangeable with igneous rock. volcanic rock ENVO:00002015 An igneous rock that results from magma reaching the surface either as lava or fragmental ejecta. https://en.wikipedia.org/wiki/Rock_%28geology%29 A rock formed by deposition of either clastic sediments, organic matter, or chemical precipitates (evaporites), followed by compaction of the particulate matter and cementation during diagenesis. EcoLexicon:sedimentary_rock SWEETRealm:SedimentaryRock https://en.wikipedia.org/wiki/Sedimentary_rock ENVO ENVO:00002016 sedimentary rock ENVO:00002016 A rock formed by deposition of either clastic sediments, organic matter, or chemical precipitates (evaporites), followed by compaction of the particulate matter and cementation during diagenesis. https://en.wikipedia.org/wiki/Rock_%28geology%29 A rock formed by subjecting any rock type (including previously-formed metamorphic rock) to different temperature and pressure conditions than those in which the original rock was formed. These temperatures and pressures are always higher than those at the Earth's surface and must be sufficiently high so as to change the original minerals into other mineral types or else into other forms of the same minerals (e.g. by recrystallisation). EcoLexicon:metamorphic_rock SWEETRealm:MetamorphicRock https://en.wikipedia.org/wiki/Metamorphic_rock ENVO ENVO:00002017 metamorphic rock ENVO:00002017 A rock formed by subjecting any rock type (including previously-formed metamorphic rock) to different temperature and pressure conditions than those in which the original rock was formed. These temperatures and pressures are always higher than those at the Earth's surface and must be sufficiently high so as to change the original minerals into other mineral types or else into other forms of the same minerals (e.g. by recrystallisation). https://en.wikipedia.org/wiki/Rock_%28geology%29 Wastewater that is contaminated with feces or urine, SWEETRealm:Sewage https://en.wikipedia.org/wiki/Sewage ENVO ENVO:00002018 sewage ENVO:00002018 Wastewater that is contaminated with feces or urine, https://en.wikipedia.org/wiki/Wastewater ENVO:00002019 Water which has a higher salinity than fresh water but a lower salinity than marine water. EcoLexicon:brackish_water LTER:702 SPIRE:Brackish_water SWEETRealm:BrackishWater https://en.wikipedia.org/wiki/Brackish_water envoPolar brackish water ENVO:00002030 A biome which is determined by a water body and which has ecological climax communities adapted to life in or on water. LTER:41 aquatic biome EcoLexicon:wood LTER:637 SWEETRealm:Wood https://en.wikipedia.org/wiki/Wood ENVO ENVO:00002040 wood ENVO:00002040 ENVO:00002042 Water that is found on the surface of an astronomical object. surface water Water that is found on the surface of an astronomical object. https://en.wikipedia.org/wiki/Surface_water ENVO:00002044 The residual semi-solid material left from domestic or industrial processes, or wastewater treatment processes. EcoLexicon:sludge https://en.wikipedia.org/wiki/Sludge sludge The residual semi-solid material left from domestic or industrial processes, or wastewater treatment processes. https://en.wikipedia.org/wiki/Sludge Sediment characterised by the absence of oxygen. anoxic sediment ENVO ENVO:00002045 envoPolar anaerobic sediment ENVO:00002045 Sediment characterised by the absence of oxygen. ORCID:0000-0002-4366-3088 EcoLexicon:active_sludge https://en.wikipedia.org/wiki/Activated_sludge ENVO ENVO:00002046 activated sludge ENVO:00002046 ENVO:00002047 An excreta material which is composed primarily of urine, a liquid excreta containing water and waste products made by the kidneys, stored in the bladder, and leaves the body through the urethra. https://en.wikipedia.org/wiki/Urine ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. urine material An excreta material which is composed primarily of urine, a liquid excreta containing water and waste products made by the kidneys, stored in the bladder, and leaves the body through the urethra. MA:ma URL:http://www.stjude.org/stjude/hospital/med_terms.jsp ENVO:00002053 A sedimentary rock which is composed primarily of calcium carbonate in the form of calcite or aragnoite. An interesting reasoning error was generated when this class had "composed primariy of some CHEBI:calcium carbonate". As that was a CHEBI:mineral, and minerals are disjoint from ENVO:rock, it led to an unsatisfiable class. The current axiom works around this, but this is requires some sort of geological convention to diffferentiate between masses of minerals and rocks that are composed primarily of minerals. EcoLexicon:limestone https://en.wikipedia.org/wiki/Limestone limestone A sedimentary rock which is composed primarily of calcium carbonate in the form of calcite or aragnoite. https://en.wikipedia.org/wiki/Limestone ENVO:00002054 Limestone which is soft, white, and porous. https://en.wikipedia.org/wiki/Chalk chalk Limestone which is soft, white, and porous. MA:ma A sedimentary rock composed mainly of sand-size mineral or rock grains. EcoLexicon:sandstone https://en.wikipedia.org/wiki/Sandstone ENVO ENVO:00002055 sandstone ENVO:00002055 A sedimentary rock composed mainly of sand-size mineral or rock grains. https://en.wikipedia.org/wiki/Sandstone A fine-grained sedimentary rock whose original constituents were clays or muds. It is characterized by thin laminae breaking with an irregular curving fracture, often splintery and usually parallel to the often-indistinguishable bedding plane. https://en.wikipedia.org/wiki/Shale ENVO ENVO:00002056 shale ENVO:00002056 A fine-grained sedimentary rock whose original constituents were clays or muds. It is characterized by thin laminae breaking with an irregular curving fracture, often splintery and usually parallel to the often-indistinguishable bedding plane. https://en.wikipedia.org/wiki/Shale ENVO ENVO:00002057 raw primary sludge ENVO:00002057 ENVO ENVO:00002058 secondary sludge ENVO:00002058 A treated form of sludge, sometimes used as a fertilizer in agriculture. https://en.wikipedia.org/wiki/Biosolids ENVO ENVO:00002059 biosolids ENVO:00002059 A treated form of sludge, sometimes used as a fertilizer in agriculture. https://en.wikipedia.org/wiki/Sludge A solid or gel in motor oil caused by the oil gelling or solidifying, usually at temperatures lower than 100deg C. https://en.wikipedia.org/wiki/Oil_sludge ENVO ENVO:00002060 oil sludge ENVO:00002060 A solid or gel in motor oil caused by the oil gelling or solidifying, usually at temperatures lower than 100deg C. https://en.wikipedia.org/wiki/Oil_sludge Sediment that accumulates in the flat or very gently sloping areas of the deep ocean basin floor. The three main types of deep marine sediment, also known as pelagic sediment, are siliceous oozes, calcareous oozes, and red clays. EcoLexicon:marine_sediment EcoLexicon:marine_sedimentation SWEETRealm:MarineSediment https://en.wikipedia.org/wiki/Marine_sediment deep marine sediments ENVO pelagic sediment {alternative name} ENVO:00002113 envoPolar deep marine sediment ENVO:00002113 Sediment that accumulates in the flat or very gently sloping areas of the deep ocean basin floor. The three main types of deep marine sediment, also known as pelagic sediment, are siliceous oozes, calcareous oozes, and red clays. https://en.wikipedia.org/wiki/Marine_sediment#_note-8 ENVO:00002114 Sediment which has increased levels of one or more chemical compounds. chemically enriched sediment ENVO:00002115 Organically enriched sediment which has increased levels of petroleum. petroleum enriched sediment A portion of contaminated soil is a portion of soil with elevated levels of some contaminant. ENVO ENVO:00002116 "contaminant" is more of a disposition - any material entity can be a contaminant in particular circumstances. contaminated soil ENVO:00002116 ENVO:00002117 Soil which has elevated concentrations of creosote. creosote contaminated soil ENVO ENVO:00002118 sea sand ENVO:00002118 ENVO:00002122 Mud which has elevated concentrations of arsenic. arsenic-rich mud ENVO ENVO:00002127 Revise adjacent to. Consider sampled stream sediment. Dry stream sediment. stream sediment ENVO:00002127 ENVO ENVO:00002129 anaerobic sludge ENVO:00002129 ENVO:00002133 Mud which has no or neglible concentrations of dissolved oxygen. anoxic mud anaerobic mud ENVO ENVO:00002134 anaerobic stream sediment ENVO:00002134 https://en.wikipedia.org/wiki/Treated_wood ENVO ENVO:00002135 treated wood ENVO:00002135 ENVO ENVO:00002136 arsenate treated wood ENVO:00002136 ENVO ENVO:00002138 beach sand ENVO:00002138 The liquid produced when water percolates through any permeable material. It can contain either dissolved or suspended material, or usually both. https://en.wikipedia.org/wiki/Leachate ENVO ENVO:00002141 leachate ENVO:00002141 The liquid produced when water percolates through any permeable material. It can contain either dissolved or suspended material, or usually both. https://en.wikipedia.org/wiki/Leachate ENVO ENVO:00002142 borax leachate ENVO:00002142 ENVO:00002145 Soil which has elevated concentrations of chromate. chromate contaminated soil ENVO:00002146 Soil which has elevated concentrations of xylene. xylene contaminated soil ENVO:00002147 Coal mine lake sediment is lake sediment which covers the bottom of a coal mine lake. coal mine lake sediment ENVO ENVO:00002148 coarse beach sand ENVO:00002148 ENVO:00002149 Water which has physicochemical properties that have been determined by the processes occuring in a sea or ocean. When we have more classes representing the various processes which make seawater seawater, we can further axiomatise this class. EcoLexicon:sea_water LTER:701 SWEETRealm:SeaWater https://en.wikipedia.org/wiki/Sea_water ocean water seawater This definition refers to water that is actually in a sea or ocean. This water may have a wide range of salinity levels. sea water ENVO:00002150 Coastal sea water is sea water that is adjacent to a coast. coastal water coastal ocean water coastal oceanic water coastal seawater envoPolar The limits of what qualifies as "adjacent to" vary greatly. This should be defined on a data level and is left intentionally fuzzy here. The label is "coastal sea water" rather than "coastal water" as some large lakes are often said to have coasts. coastal sea water ENVO ENVO:00002154 radioactive sediment ENVO:00002154 ENVO:00002155 high-level radioactive sediment ENVO ENVO:00002158 ditch water ENVO:00002158 ENVO ENVO:00002159 drilling bore water ENVO:00002159 ENVO:00002160 Mud which is part of an estuary. estuarine mud ENVO:00002164 A solid environmental material which is formed by the replacement of organic substances (including those in soils and sediments) with mineral material. SWEETRealm:Fossil https://en.wikipedia.org/wiki/Fossil fossil material A solid environmental material which is formed by the replacement of organic substances (including those in soils and sediments) with mineral material. https://en.wikipedia.org/wiki/Fossil ENVO:00002170 Manure which has been derived from the aerobically decomposed remnants of organic materials. https://en.wikipedia.org/wiki/Compost compost Manure which has been derived from the aerobically decomposed remnants of organic materials. https://en.wikipedia.org/wiki/Compost ENVO ENVO:00002171 hay compost ENVO:00002171 ENVO ENVO:00002176 contaminated sludge ENVO:00002176 ENVO ENVO:00002177 1,4-dioxane contaminated sludge ENVO:00002177 ENVO ENVO:00002179 intertidal sediment ENVO:00002179 ENVO:00002180 Organically enriched sediment which has increased levels of naphthalene. naphthalene enriched sediment ENVO:00002182 Organically enriched sediment which has increased levels of nitrobenzene. nitrobenzene enriched sediment EcoLexicon:water_pollution https://en.wikipedia.org/wiki/Contaminated_water polluted water ENVO ENVO:00002186 contaminated water ENVO:00002186 ENVO:00002191 Straw or other material strewn in an animal's enclosure (e.g. a stable) for it to sleep on and to absorb its faeces and urine. animal litter Straw or other material strewn in an animal's enclosure (e.g. a stable) for it to sleep on and to absorb its faeces and urine. https://en.wikipedia.org/wiki/Litter_%28disambiguation%29 https://en.wikipedia.org/wiki/Poultry_litter ENVO ENVO:00002192 poultry litter ENVO:00002192 ENVO ENVO:00002193 pulp-bleaching waste water ENVO:00002193 ENVO ENVO:00002194 oil field production water ENVO:00002194 ENVO:00002200 Water ice which has formed by the freezing of sea water. Parse comment from GCW and new subclases where appropriate. http://sweetontology.net/realmCryo/SeaIce https://en.wikipedia.org/wiki/Sea_ice envoPolar In the United States, NOAA sea ice operations does not include superstructure icing as being sea ice. In sea ice operations however, sea ice is any form of ice found at sea which has originated from the freezing of sea water. It presents the main kind of floating ice encountered at sea. Except where it forms ridges, sea ice is up to a few metres thick, in which respect it differs from shelf ice. Sea ice may be discontinuous pieces (ice floes) moved on the ocean surface by wind and currents (pack ice), or a motionless sheet attached to the coast (land-fast ice). In brief, it forms first as lolly ice (frazil crystals), thickens into sludge, and coagulates into sheet ice, pancake ice, or into floes of various shapes and sizes. Thereafter, sea ice may develop into pack ice and/or become a form of pressure ice. Sea ice less than one year old is called first-year ice. Perennial ice is sea ice that survives at least one summer. It may be subdivided into second-year ice and multi-year ice, where multiyear ice has survived at least two summers. sea ice In the United States, NOAA sea ice operations does not include superstructure icing as being sea ice. In sea ice operations however, sea ice is any form of ice found at sea which has originated from the freezing of sea water. It presents the main kind of floating ice encountered at sea. Except where it forms ridges, sea ice is up to a few metres thick, in which respect it differs from shelf ice. Sea ice may be discontinuous pieces (ice floes) moved on the ocean surface by wind and currents (pack ice), or a motionless sheet attached to the coast (land-fast ice). In brief, it forms first as lolly ice (frazil crystals), thickens into sludge, and coagulates into sheet ice, pancake ice, or into floes of various shapes and sizes. Thereafter, sea ice may develop into pack ice and/or become a form of pressure ice. Sea ice less than one year old is called first-year ice. Perennial ice is sea ice that survives at least one summer. It may be subdivided into second-year ice and multi-year ice, where multiyear ice has survived at least two summers. https://orcid.org/0000-0003-4808-4736 ENVO:00002201 Organically enriched sediment which has increased levels of cis-dichloroethane. cis-dichloroethane contaminated sediment ENVO:00002202 Chemically-enriched sediment which has increased levels of organic compounds. organically enriched sediment ENVO:00002203 Chemically-enriched sediment which has increased levels of inorganic compounds. inorganically enriched sediment coal mine waste ENVO coal refuse ENVO:00002206 coal mine waste material ENVO:00002206 self-heating coal mine waste ENVO ENVO:00002207 self-heating coal mine waste material ENVO:00002207 ENVO:00002209 Saline lake sediment is sediment which covers the bottom of a saline lake. soda lake sediment saline lake sediment ENVO ENVO:00002212 thermophilic granular sludge ENVO:00002212 ENVO:00002223 Water which has very low concentrations of nutrients. oligotrophic water Water which has very low concentrations of nutrients. MA:ma ENVO:00002224 Water with a high nutrient level. eutrophic water Water with a high nutrient level. MA:ma Water with a nutrient level intermediate between eutrophic and oligotrophic. ENVO ENVO:00002225 mesotrophic water ENVO:00002225 Water with a nutrient level intermediate between eutrophic and oligotrophic. MA:ma ENVO ENVO:00002228 pond water ENVO:00002228 ENVO:00002229 Arenosols are sandy soils, including both soils developed in residual sands after in situ weathering of usually quartz-rich sediments or rock, and soils developed in recently deposited sands such as dunes in deserts and beach lands. https://en.wikipedia.org/wiki/Arenosol psamment sandy soil arenosol Arenosols are sandy soils, including both soils developed in residual sands after in situ weathering of usually quartz-rich sediments or rock, and soils developed in recently deposited sands such as dunes in deserts and beach lands. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf sandy soil ORCID:0000-0001-8743-9574 ENVO:00002230 Anthrosols comprise soils that have been modified profoundly through human activities, such as addition of organic materials or household wastes, irrigation and cultivation. anthrosol Anthrosols comprise soils that have been modified profoundly through human activities, such as addition of organic materials or household wastes, irrigation and cultivation. http://anzsoil.org/anzsoilml/ http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Alisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Alisols have a low base saturation at certain depths and high-activity clays throughout the argic horizon. They lack the albeluvic tonguing as in Albeluvisols. They occur predominantly in humid tropical, humid subtropical and warm temperate regions. ENVO ENVO:00002231 alisol ENVO:00002231 Alisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Alisols have a low base saturation at certain depths and high-activity clays throughout the argic horizon. They lack the albeluvic tonguing as in Albeluvisols. They occur predominantly in humid tropical, humid subtropical and warm temperate regions. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002232 Andosols are soils that develop in volcanic ejecta or glasses under almost any climate (except under hyperarid climate conditions). However, Andosols may also develop in other silicate-rich materials under acid weathering in humid and perhumid climates. andosol Andosols are soils that develop in volcanic ejecta or glasses under almost any climate (except under hyperarid climate conditions). However, Andosols may also develop in other silicate-rich materials under acid weathering in humid and perhumid climates. Albeluvisols are soils that have, beginning within 1 m of the soil surface, a clay illuviation horizon with an irregular or broken upper boundary resulting in tonguing of bleached soil material into the illuviation horizon. ENVO ENVO:00002233 albeluvisol ENVO:00002233 Albeluvisols are soils that have, beginning within 1 m of the soil surface, a clay illuviation horizon with an irregular or broken upper boundary resulting in tonguing of bleached soil material into the illuviation horizon. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Acrisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Acrisols have in certain depths a low base saturation and low-activity clays. https://en.wikipedia.org/wiki/Acrisol ENVO ENVO:00002234 acrisol ENVO:00002234 Acrisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Acrisols have in certain depths a low base saturation and low-activity clays. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002235 Cambisols combine soils with at least an incipient subsurface soil formation. Transformation of parent material is evident from structure formation and mostly brownish discoloration, increasing clay percentage, and/or carbonate removal. cambisol Cambisols combine soils with at least an incipient subsurface soil formation. Transformation of parent material is evident from structure formation and mostly brownish discoloration, increasing clay percentage, and/or carbonate removal. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002236 Cryosols comprise mineral soils formed in a permafrost environment. Where water is present, it occurs primarily in the form of ice. Cryogenic processes are the dominant soil-forming processes. https://en.wikipedia.org/wiki/Cryosol gelisol envoPolar cryosol Cryosols comprise mineral soils formed in a permafrost environment. Where water is present, it occurs primarily in the form of ice. Cryogenic processes are the dominant soil-forming processes. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Chernozems are soils with a thick black surface layer that is rich in organic matter. https://en.wikipedia.org/wiki/Chernozem ENVO black earth boroll ENVO:00002237 chernozem ENVO:00002237 Chernozems are soils with a thick black surface layer that is rich in organic matter. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002238 Durisols are associated mainly with old surfaces in arid and semi-arid environments and accommodate very shallow to moderately deep, moderately well- to well-drained soils that contain cemented secondary silica (SiO2) within 100 cm of the soil surface. https://en.wikipedia.org/wiki/Durisol durisol Durisols are associated mainly with old surfaces in arid and semi-arid environments and accommodate very shallow to moderately deep, moderately well- to well-drained soils that contain cemented secondary silica (SiO2) within 100 cm of the soil surface. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002239 Calcisols are soils in which there is substantial secondary accumulation of lime. Calcisols are common in highly calcareous parent materials and widespread in arid and semi-arid environments. calcarosol calcisol Calcisols are soils in which there is substantial secondary accumulation of lime. Calcisols are common in highly calcareous parent materials and widespread in arid and semi-arid environments. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Kastanozems are dry grassland soils, among them the zonal soils of the short-grass steppe belt, south of the Eurasian tall-grass steppe belt with Chernozems. Kastanozems have a similar profile to that of Chernozems but the humus-rich surface horizon is thinner and not as dark as that of the Chernozems and they show more prominent accumulation of secondary carbonates. ENVO ENVO:00002240 kastanozem ENVO:00002240 Kastanozems are dry grassland soils, among them the zonal soils of the short-grass steppe belt, south of the Eurasian tall-grass steppe belt with Chernozems. Kastanozems have a similar profile to that of Chernozems but the humus-rich surface horizon is thinner and not as dark as that of the Chernozems and they show more prominent accumulation of secondary carbonates. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002241 Leptosols are very shallow soils over continuous rock and soils that are extremely gravelly and/or stony. Leptosols are azonal soils and particularly common in mountainous regions. gravelly soil stony soil leptosol Leptosols are very shallow soils over continuous rock and soils that are extremely gravelly and/or stony. Leptosols are azonal soils and particularly common in mountainous regions. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Lixisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Lixisols have a high base saturation and low-activity clays at certain depths. https://en.wikipedia.org/wiki/Lixisol ENVO ENVO:00002242 lixisol ENVO:00002242 Lixisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Lixisols have a high base saturation and low-activity clays at certain depths. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002243 Histosols comprise soils formed in organic material. These vary from soils developed in predominantly moss peat in boreal, arctic and subarctic regions, via moss peat, reeds/ sedge peat (fen) and forest peat in temperate regions to mangrove peat and swamp forest peat in the humid tropics. Histosols are found at all altitudes, but the vast majority occurs in lowlands. https://en.wikipedia.org/wiki/Histosol histosol Histosols comprise soils formed in organic material. These vary from soils developed in predominantly moss peat in boreal, arctic and subarctic regions, via moss peat, reeds/ sedge peat (fen) and forest peat in temperate regions to mangrove peat and swamp forest peat in the humid tropics. Histosols are found at all altitudes, but the vast majority occurs in lowlands. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Gleysols are wetland soils that, unless drained, are saturated with groundwater for long enough periods to develop a characteristic gleyic colour pattern. This pattern is essentially made up of reddish, brownish or yellowish colours at ped surfaces and/or in the upper soil layer or layers, in combination with greyish/bluish colours inside the peds and/or deeper in the soil. https://en.wikipedia.org/wiki/Gleysol ENVO gley soil ENVO:00002244 gleysol ENVO:00002244 Gleysols are wetland soils that, unless drained, are saturated with groundwater for long enough periods to develop a characteristic gleyic colour pattern. This pattern is essentially made up of reddish, brownish or yellowish colours at ped surfaces and/or in the upper soil layer or layers, in combination with greyish/bluish colours inside the peds and/or deeper in the soil. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Gypsisols are soils with substantial secondary accumulation of gypsum (calcium sulfate). These soils are found in the driest parts of the arid climate zone. https://en.wikipedia.org/wiki/Gypsisol ENVO ENVO:00002245 gypsisol ENVO:00002245 Gypsisols are soils with substantial secondary accumulation of gypsum (calcium sulfate). These soils are found in the driest parts of the arid climate zone. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002246 Ferralsols represent the classical, deeply weathered, red or yellow soils of the humid tropics. These soils have diffuse horizon boundaries, a clay assemblage dominated by low-activity clays (mainly kaolinite) and a high content of sesquioxides. https://en.wikipedia.org/wiki/Ferralsol oxisol ferralsol Ferralsols represent the classical, deeply weathered, red or yellow soils of the humid tropics. These soils have diffuse horizon boundaries, a clay assemblage dominated by low-activity clays (mainly kaolinite) and a high content of sesquioxides. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002247 Nitisols are deep, well-drained, red, tropical soils with diffuse horizon boundaries and a subsurface horizon with more than 30 percent clay and moderate to strong angular blocky structure elements that easily fall apart into characteristic shiny, polyhedric (nutty) elements. Weathering is relatively advanced but Nitisols are far more productive than most other red, tropical soils. nitisol Nitisols are deep, well-drained, red, tropical soils with diffuse horizon boundaries and a subsurface horizon with more than 30 percent clay and moderate to strong angular blocky structure elements that easily fall apart into characteristic shiny, polyhedric (nutty) elements. Weathering is relatively advanced but Nitisols are far more productive than most other red, tropical soils. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002248 Luvisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Luvisols have high-activity clays throughout the argic horizon and a high base saturation at certain depths. luvisol Luvisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Luvisols have high-activity clays throughout the argic horizon and a high base saturation at certain depths. http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Phaeozems accommodate soils of relatively wet grassland and forest regions in moderately continental climates. Phaeozems are much like Chernozems and Kastanozems but are leached more intensively. Consequently, they have dark, humus rich surface horizons that, in comparison with Chernozems and Kastanozems, are less rich in bases. Phaeozems may or may not have secondary carbonates but have a high base saturation in the upper metre of the soil. ENVO ENVO:00002249 phaeozem ENVO:00002249 Phaeozems accommodate soils of relatively wet grassland and forest regions in moderately continental climates. Phaeozems are much like Chernozems and Kastanozems but are leached more intensively. Consequently, they have dark, humus rich surface horizons that, in comparison with Chernozems and Kastanozems, are less rich in bases. Phaeozems may or may not have secondary carbonates but have a high base saturation in the upper metre of the soil. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Plinthosols are soils with plinthite, petroplinthite or pisoliths. Plinthite is an Fe-rich (in some cases also Mn-rich), humus-poor mixture of kaolinitic clay (and other products of strong weathering such as gibbsite) with quartz and other constituents that changes irreversibly to a layer with hard nodules, a hardpan or irregular aggregates on exposure to repeated wetting and drying. Petroplinthite is a continuous, fractured or broken sheet of connected, strongly cemented to indurated nodules or mottles. Pisoliths are discrete strongly cemented to indurated nodules. Both petroplinthite and pisoliths develop from plinthite by hardening. ENVO ENVO:00002250 plinthosol ENVO:00002250 Plinthosols are soils with plinthite, petroplinthite or pisoliths. Plinthite is an Fe-rich (in some cases also Mn-rich), humus-poor mixture of kaolinitic clay (and other products of strong weathering such as gibbsite) with quartz and other constituents that changes irreversibly to a layer with hard nodules, a hardpan or irregular aggregates on exposure to repeated wetting and drying. Petroplinthite is a continuous, fractured or broken sheet of connected, strongly cemented to indurated nodules or mottles. Pisoliths are discrete strongly cemented to indurated nodules. Both petroplinthite and pisoliths develop from plinthite by hardening. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Planosols are soils with a light-coloured, surface horizon that shows signs of periodic water stagnation and abruptly overlies a dense, slowly permeable subsoil with significantly more clay than the surface horizon. ENVO ENVO:00002251 planosol ENVO:00002251 Planosols are soils with a light-coloured, surface horizon that shows signs of periodic water stagnation and abruptly overlies a dense, slowly permeable subsoil with significantly more clay than the surface horizon. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Solonchaks are soils that have a high concentration of soluble salts at some time in the year. Solonchaks are largely confined to the arid and semi-arid climate zones and to coastal regions in all climates. https://en.wikipedia.org/wiki/Solonchak ENVO ENVO:00002252 solonchak ENVO:00002252 Solonchaks are soils that have a high concentration of soluble salts at some time in the year. Solonchaks are largely confined to the arid and semi-arid climate zones and to coastal regions in all climates. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002253 Umbrisols are soils in which organic matter has accumulated within the mineral surface soil (in most cases with low base saturation) to the extent that it significantly affects the behaviour and utilization of the soil. https://en.wikipedia.org/wiki/Umbrisol umbrisol Umbrisols are soils in which organic matter has accumulated within the mineral surface soil (in most cases with low base saturation) to the extent that it significantly affects the behaviour and utilization of the soil. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf A soil in which there is a high content of expansive clay known as montmorillonite that forms deep cracks in drier seasons or years. Alternate shrinking and swelling causes self-mulching, where the soil material consistently mixes itself, causing vertisols to have an extremely deep A horizon and no B horizon. https://en.wikipedia.org/wiki/Vertisol ENVO ENVO:00002254 vertisol ENVO:00002254 A soil in which there is a high content of expansive clay known as montmorillonite that forms deep cracks in drier seasons or years. Alternate shrinking and swelling causes self-mulching, where the soil material consistently mixes itself, causing vertisols to have an extremely deep A horizon and no B horizon. https://en.wikipedia.org/wiki/Vertisol Solonetz are soils with a dense, strongly structured, clayey subsurface horizon that has a high proportion of adsorbed Na and/or Mg ions. Solonetz that contain free soda (Na2CO3) are strongly alkaline (field pH > 8.5). https://en.wikipedia.org/wiki/Solonetz ENVO ENVO:00002255 solonetz ENVO:00002255 Solonetz are soils with a dense, strongly structured, clayey subsurface horizon that has a high proportion of adsorbed Na and/or Mg ions. Solonetz that contain free soda (Na2CO3) are strongly alkaline (field pH > 8.5). FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Regosols form a taxonomic remnant group containing all soils that could not be accommodated in any of the other RSGs. In practice, Regosols are very weakly developed mineral soils in unconsolidated materials that do not have a mollic or umbric horizon, are not very shallow or very rich in gravels (Leptosols), sandy (Arenosols) or with fluvic materials (Fluvisols). Regosols are extensive in eroding lands, particularly in arid and semi-arid areas and in mountainous terrain. https://en.wikipedia.org/wiki/Regosol ENVO ENVO:00002256 regosol ENVO:00002256 Regosols form a taxonomic remnant group containing all soils that could not be accommodated in any of the other RSGs. In practice, Regosols are very weakly developed mineral soils in unconsolidated materials that do not have a mollic or umbric horizon, are not very shallow or very rich in gravels (Leptosols), sandy (Arenosols) or with fluvic materials (Fluvisols). Regosols are extensive in eroding lands, particularly in arid and semi-arid areas and in mountainous terrain. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002257 Podzols are soils with a typically ash-grey upper subsurface horizon, bleached by loss of organic matter and iron oxides, on top of a dark accumulation horizon with brown, reddish or black illuviated humus and/or reddish Fe compounds. Podzols occur in humid areas in the boreal and temperate zones and locally also in the tropics. https://en.wikipedia.org/wiki/Podzol podsol podosolic soil podzol Podzols are soils with a typically ash-grey upper subsurface horizon, bleached by loss of organic matter and iron oxides, on top of a dark accumulation horizon with brown, reddish or black illuviated humus and/or reddish Fe compounds. Podzols occur in humid areas in the boreal and temperate zones and locally also in the tropics. http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf ENVO:00002258 A soil which is composed of approximately equal proportions of sand and silt, with a smaller proportion of clay. EcoLexicon:loam SWEETRealm:Loam Some authorities consider loam to be any soil material that contains 7 to 27% clay, 28 to 50% silt, and less than 52% sand. loam A soil which is composed of approximately equal proportions of sand and silt, with a smaller proportion of clay. https://en.wikipedia.org/wiki/Loam Some authorities consider loam to be any soil material that contains 7 to 27% clay, 28 to 50% silt, and less than 52% sand. https://sis.agr.gc.ca/cansis/glossary/t/index.html ENVO:00002259 Soil which is part of an ecosystem used for agricultural activities. agricultural soil ENVO:00002260 Soil which is part of some dune. dune soil ENVO:00002261 A portion of soil which is found in a forested area. forest soil ENVO:00002262 Soil which is primarily composed of clay. clay soil ENVO:00002263 A portion of soil which is found in a garden. garden soil A material which is not the desired output of a process and which is typically the input of a process which removes it from its producer (e.g. a disposal process). This seems more like a role than a material. Anything can be waste. Thus, a "waste" role or disposition will be created and this class can then be populated by inference: any environmental material which has [role,disposition] waste will be considered a waste material. EcoLexicon:waste SWEETRealm:Waste https://en.wikipedia.org/wiki/Waste ENVO ENVO:00002264 waste material ENVO:00002264 chicken breeding waste ENVO chicken yard waste ENVO:00002266 chicken breeding waste material ENVO:00002266 Industrial wastes are liquid, solid and gaseous wastes originating from the manufacture of specific products. This will become a defined class, with subclasses added through inference based on material having a 'waste role' and being associated with industrial entities. industrial waste ENVO ENVO:00002267 industrial waste material ENVO:00002267 Industrial wastes are liquid, solid and gaseous wastes originating from the manufacture of specific products. ISBN:978-92-1-161386-5 http://stats.oecd.org/glossary/detail.asp?ID=1340 ENVO:00002273 Fluvisols accommodate genetically young, azonal soils in alluvial deposits. https://en.wikipedia.org/wiki/Fluvisols fluvisol Fluvisols accommodate genetically young, azonal soils in alluvial deposits. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Stagnosols are soils with a perched water table showing redoximorphic features caused by surface water. Stagnosols are periodically wet and mottled in the topsoil and subsoil, with or without concretions and/or bleaching. ENVO ENVO:00002274 stagnosol ENVO:00002274 Stagnosols are soils with a perched water table showing redoximorphic features caused by surface water. Stagnosols are periodically wet and mottled in the topsoil and subsoil, with or without concretions and/or bleaching. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf Technosols are soils whose properties and pedogenesis are dominated by their technical origin. They contain a significant amount of artefacts (something in the soil recognizably made or extracted from the earth by humans), or are sealed by technic hard rock (material created by humans, having properties unlike natural rock). They include soils from wastes (landfills, sludge, cinders, mine spoils and ashes), pavements with their underlying unconsolidated materials, soils with geomembranes and constructed soils in human-made materials. ENVO ENVO:00002275 technosol ENVO:00002275 Technosols are soils whose properties and pedogenesis are dominated by their technical origin. They contain a significant amount of artefacts (something in the soil recognizably made or extracted from the earth by humans), or are sealed by technic hard rock (material created by humans, having properties unlike natural rock). They include soils from wastes (landfills, sludge, cinders, mine spoils and ashes), pavements with their underlying unconsolidated materials, soils with geomembranes and constructed soils in human-made materials. FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf This will become a defined class, with subclasses added through inference based on material having a 'waste role' and being associated with animal metabolism. animal waste SWEETRealm:AnimalWaste https://en.wikipedia.org/wiki/Animal_waste ENVO ENVO:00002276 animal waste material ENVO:00002276 Hay is grass, legumes or other herbaceous plants that have been cut, dried, and stored for use as animal fodder, particularly for grazing livestock such as cattle, horses, goats, and sheep. https://en.wikipedia.org/wiki/Hay ENVO ENVO:00002869 hay ENVO:00002869 Hay is grass, legumes or other herbaceous plants that have been cut, dried, and stored for use as animal fodder, particularly for grazing livestock such as cattle, horses, goats, and sheep. https://en.wikipedia.org/wiki/Hay ENVO:00002870 A natural building material mode from sand, clay, water, and some kind of fibrous or organic material (sticks, straw, and/or manure). adobe A natural building material mode from sand, clay, water, and some kind of fibrous or organic material (sticks, straw, and/or manure). https://en.wikipedia.org/wiki/Adobe ENVO:00002871 Soil which has been eroded and influenced by flowing water and redeposited in a non-marine setting. https://en.wikipedia.org/wiki/Alluvial_soil alluvial soil ENVO:00002872 The biomass remaining after sugarcane stalks are crushed to extract their juice. https://en.wikipedia.org/wiki/Bagasse sugarcane bagasse bagasse The biomass remaining after sugarcane stalks are crushed to extract their juice. https://en.wikipedia.org/wiki/Bagasse This should probably be merged with biological waste material. organic waste https://en.wikipedia.org/wiki/Organic_waste ENVO ENVO:00002873 organic waste material ENVO:00002873 ENVO:00002875 Soil which has elevated concentrations of oil. oil contaminated soil ENVO:00002982 Particulate environmental material which 1) is composed primarily of clay particles, with only minor proportions of other materials, 2) demonstrates plasticity when wet, and 3) is capable of hardening when dried or fired. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. EcoLexicon:clay SWEETRealm:Clay This definition is intentionally ambiguous to support the multiple thresholds set by different authorities.The distinction between silt and clay varies by discipline. Geologists and soil scientists usually consider the separation to occur at a particle size of 2 μm (clays being finer than silts), sedimentologists often use 4–5 μm, and colloid chemists use 1 μm. Geotechnical engineers distinguish between silts and clays based on the plasticity properties of the soil, as measured by the soils' Atterberg limits. ISO 14688 grades clay particles as being smaller than 2 μm and silt particles as being larger. Mixtures of sand, silt and less than 40% clay are called loam. Similar mixtures with greater than 40% clay are often considered clay soils. clay Particulate environmental material which 1) is composed primarily of clay particles, with only minor proportions of other materials, 2) demonstrates plasticity when wet, and 3) is capable of hardening when dried or fired. https://en.wikipedia.org/wiki/Clay This definition is intentionally ambiguous to support the multiple thresholds set by different authorities.The distinction between silt and clay varies by discipline. Geologists and soil scientists usually consider the separation to occur at a particle size of 2 μm (clays being finer than silts), sedimentologists often use 4–5 μm, and colloid chemists use 1 μm. Geotechnical engineers distinguish between silts and clays based on the plasticity properties of the soil, as measured by the soils' Atterberg limits. ISO 14688 grades clay particles as being smaller than 2 μm and silt particles as being larger. Mixtures of sand, silt and less than 40% clay are called loam. Similar mixtures with greater than 40% clay are often considered clay soils. ENVO:00002983 An oil which 1) is liquid at room temperature (approximately 20 degrees Celsius) 2) is intended to be burned in a furnace or boiler for the generation of heat or used in an engine for the generation of power, 3) is obtained from petroleum distillation, either as a distillate or a residue, 4) composed of long hydrocarbon chains, particularly alkanes, cycloalkanes and aromatics. furnace oil heavy oil marine fuel Oils having a flash point of approximately 42 degrees Celsius and oils burned in cotton or wool-wick burners are not typically considered fuel oils. The term fuel oil is also used in a stricter sense to refer only to the heaviest commercial fuel that can be obtained from crude oil, i.e., heavier than gasoline and naphtha. fuel oil An oil which 1) is liquid at room temperature (approximately 20 degrees Celsius) 2) is intended to be burned in a furnace or boiler for the generation of heat or used in an engine for the generation of power, 3) is obtained from petroleum distillation, either as a distillate or a residue, 4) composed of long hydrocarbon chains, particularly alkanes, cycloalkanes and aromatics. https://en.wikipedia.org/wiki/Fuel_oil Oils having a flash point of approximately 42 degrees Celsius and oils burned in cotton or wool-wick burners are not typically considered fuel oils. The term fuel oil is also used in a stricter sense to refer only to the heaviest commercial fuel that can be obtained from crude oil, i.e., heavier than gasoline and naphtha. https://en.wikipedia.org/wiki/Fuel_oil ENVO:00002984 A naturally occurring flammable liquid consisting of a complex mixture of hydrocarbons of various molecular weights and other liquid organic compounds, that are found in geologic formations beneath the planetary surfaces. https://en.wikipedia.org/wiki/Petroleum crude oil petroleum A naturally occurring flammable liquid consisting of a complex mixture of hydrocarbons of various molecular weights and other liquid organic compounds, that are found in geologic formations beneath the planetary surfaces. https://en.wikipedia.org/wiki/Petroleum ENVO:00002985 A nonpolar, hydrophobic, and lipophilic material which is a viscous liquid at ambient temperatures (about 20 degrees Celsius) or slightly warmer. EcoLexicon:oil oil A nonpolar, hydrophobic, and lipophilic material which is a viscous liquid at ambient temperatures (about 20 degrees Celsius) or slightly warmer. https://en.wikipedia.org/wiki/Oil A fermented, high-moisture forage that can be fed to ruminants. https://en.wikipedia.org/wiki/Silage ENVO ENVO:00003030 silage ENVO:00003030 A fermented, high-moisture forage that can be fed to ruminants. https://en.wikipedia.org/wiki/Silage ENVO:00003031 Manure which is derived from the waste products of animals. This is interesting in that the "role" aspect of "waste" is (or can be) replaced by another role "fertilizer". Thus, the positioning of "manure" under waste may not be totally correct. animal manure ENVO ENVO:00003032 fresh animal manure ENVO:00003032 A compost which generally consists of a combination of wheat straw, dried blood, horse manure and ground chalk, composted together and is the residual compost waste generated by industrial mushroom production. https://en.wikipedia.org/wiki/Mushroom_compost ENVO ENVO:00003033 mushroom compost ENVO:00003033 ENVO:00003044 Water saturated or nearly saturated with salt (NaCl). EcoLexicon:brine SWEETRealm:Brine https://en.wikipedia.org/wiki/Brine envoPolar It is used (now less popular than historically) to preserve vegetables, fish, and meat. brine Water saturated or nearly saturated with salt (NaCl). https://en.wikipedia.org/wiki/Brine ENVO ENVO:00003045 bacon curing brine ENVO:00003045 Drinking water is water which may be consumed by humans with no adverse effects on their health. EcoLexicon:drinking_water SWEETRealm:DrinkingWater https://en.wikipedia.org/wiki/Drinking_water potable water ENVO ENVO:00003064 drinking water ENVO:00003064 https://en.wikipedia.org/wiki/Distilled_water ENVO ENVO:00003065 distilled water ENVO:00003065 ENVO ENVO:00003071 grass silage ENVO:00003071 ENVO:00003081 Soil which has elevated concentrations of metals. metal contaminated soil ENVO:00003082 A portion of enriched soil is a portion of soil with elevated levels of some material entity. This could be demoted to an inferred class if issues with double inheritance arise. enriched soil A portion of sarcosine enriched soil is a portion of soil with elevated levels of sarcosine. ENVO ENVO:00003083 sarcosine enriched soil ENVO:00003083 A portion of trimethylamine enriched soil is a portion of soil with elevated levels of trimethylamine. ENVO ENVO:00003084 trimethylamine enriched soil ENVO:00003084 A portion of skatole enriched soil is a portion of soil with elevated levels of skatole. ENVO ENVO:00003085 skatole enriched soil ENVO:00003085 ENVO:00003086 A portion of ethanol enriched soil is a portion of soil with elevated levels of ethanol. ethanol enriched soil A portion of acetamide enriched soil is a portion of soil with elevated levels of acetamide. ENVO ENVO:00003087 acetamide enriched soil ENVO:00003087 A portion of pantothenate enriched soil is a portion of soil with elevated levels of pantothenate. ENVO ENVO:00003088 pantothenate enriched soil ENVO:00003088 A portion of testosterone enriched soil is a portion of soil with elevated levels of testosterone. ENVO ENVO:00003089 testosterone enriched soil ENVO:00003089 A portion of kynurenate enriched soil is a portion of soil with elevated levels of kynurenate. ENVO ENVO:00003090 kynurenate enriched soil ENVO:00003090 A portion of threonine enriched soil is a portion of soil with elevated levels of threonine. ENVO ENVO:00003091 threonine enriched soil ENVO:00003091 A portion of salicylate enriched soil is a portion of soil with elevated levels of salicylate. ENVO ENVO:00003092 salicylate enriched soil ENVO:00003092 ENVO:00003093 A portion of poly-beta-hydroxybutyrate enriched soil is a portion of soil with elevated levels of poly-beta-hydroxybutyrate. poly-beta-hydroxybutyrate enriched soil A portion of L-(+)-tartrate enriched soil is a portion of soil with elevated levels of L-(+)-tartrate. ENVO ENVO:00003094 L-(+)-tartrate enriched soil ENVO:00003094 A portion of quinate enriched soil is a portion of soil with elevated levels of quinate. ENVO ENVO:00003095 quinate enriched soil ENVO:00003095 https://en.wikipedia.org/wiki/Tap_water ENVO ENVO:00003096 tap water ENVO:00003096 ENVO ENVO:00003097 bore hole water ENVO:00003097 https://en.wikipedia.org/wiki/Horse_manure ENVO ENVO:00003859 horse manure ENVO:00003859 ENVO:00003860 Manure which is primarily composed of pig feces. pig manure An agricultural byproduct, the dry stalk of a cereal plant, after the nutrient grain or seed has been removed. https://en.wikipedia.org/wiki/Straw ENVO ENVO:00003869 straw ENVO:00003869 An agricultural byproduct, the dry stalk of a cereal plant, after the nutrient grain or seed has been removed. https://en.wikipedia.org/wiki/Straw ENVO ENVO:00003870 rice straw ENVO:00003870 ENVO ENVO:00003884 farmyard manure ENVO:00003884 ENVO ENVO:00003900 rye grass silage ENVO:00003900 https://en.wikipedia.org/wiki/Aviation_fuel ENVO jet fuel ENVO:00003903 aviation fuel ENVO:00003903 ENVO ENVO:00003908 poultry deep litter ENVO:00003908 ENVO:00003914 Soil which has increased levels of chalk. chalk soil ENVO ENVO:00003927 stable manure ENVO:00003927 A layer of impurities that accumulates at the surface of a liquid (especially water or molten metal). https://en.wikipedia.org/wiki/Scum ENVO ENVO:00003930 scum ENVO:00003930 A layer of impurities that accumulates at the surface of a liquid (especially water or molten metal). https://en.wikipedia.org/wiki/Scum ENVO ENVO:00003965 anaerobic digester sludge ENVO:00003965 ENVO ENVO:00003978 potato silage ENVO:00003978 ENVO:00003982 Limestone which is deposited from the water of mineral springs or streams saturated with calcium carbonate. https://en.wikipedia.org/wiki/Travertine travertine Limestone which is deposited from the water of mineral springs or streams saturated with calcium carbonate. https://en.wikipedia.org/wiki/Travertine ENVO:00005738 An environmental material which has the quality of a foam. foamy environmental material An environmental material which has the quality of a foam. A foamy environmental material which 1) is created by the agitation of seawater, 2) whose stability depends on the content of the seawater. ENVO ENVO:00005739 The lifetime of sea foam can vary from only seconds to several hours or days. The longer-lasting foam are formed in particular when seawater contain higher concentration of dissolved organic matter that derived from sources such as algal blooms. sea foam ENVO:00005739 A foamy environmental material which 1) is created by the agitation of seawater, 2) whose stability depends on the content of the seawater. The lifetime of sea foam can vary from only seconds to several hours or days. The longer-lasting foam are formed in particular when seawater contain higher concentration of dissolved organic matter that derived from sources such as algal blooms. ENVO:00005740 Soil which is part of a paddy field. rice paddy soil paddy field soil ENVO:00005741 Soil which is part of an alpine environment. envoPolar alpine soil ENVO:00005742 Soil which is capable of supporting the growth of crops. envoMeo arable soil Soil which is capable of supporting the growth of crops. A portion of soil which is found in a roadside area. ENVO ENVO:00005743 roadside soil ENVO:00005743 ENVO:00005744 Soil which is part of an allotment garden. allotment garden soil ENVO:00005746 A portion of soil which is found in a savanna. savanna soil ENVO:00005747 Soil which is derived from compost. compost soil ENVO:00005748 Soil which has little to no water content and in which minerals and other soluble chemical entities have either bonded or become adsorbed to sold particles due to insufficient water availability. dry soil ENVO:00005749 A portion of soil which is part of a cropland or a rangeland biome. farm soil ENVO:00005750 A portion of soil which is found in a grassland. grassland soil ENVO:00005751 Soil which is part of a densely forested area subject to tropical climate patterns. jungle soil ENVO:00005752 Soil which is part of a sawah, a wet or irrigated rice field. sawah soil Soil which is part of a sawah, a wet or irrigated rice field. A portion of urea enriched soil is a portion of soil with elevated levels of urea. ENVO ENVO:00005753 urea enriched soil ENVO:00005753 ENVO:00005754 Soil which has been amended with fertilizers. fertilized soil ENVO:00005755 Soil which is part of an agricultural field. field soil ENVO:00005756 Soil which is formulated to promote the growth of grasses or other plants used to establish managed areas of vegetation. lawn soil Soil which is formulated to promote the growth of grasses or other plants used to establish managed areas of vegetation. A portion of bacteria enriched soil is a portion of soil with elevated bacterial abundance. ENVO ENVO:00005757 bacteria enriched soil ENVO:00005757 ENVO:00005758 A portion of alluvial soil which is part of a swamp ecosystem. alluvial swamp soil ENVO:00005759 Alluvial soil whichi is part of a paddy field. alluvial paddy field soil ENVO:00005760 Soil which has been transformed through a combustion process. burnt soil burned soil ENVO:00005761 Soil which is part of a meadow. meadow soil A portion of chloropicrin enriched soil is a portion of soil with elevated levels of chloropicrin. ENVO ENVO:00005762 chloropicrin enriched soil ENVO:00005762 ENVO:00005763 Soil which 1) has increased levels of humus, 2) has low pH levels, 3) has increased levels of mineral ash. humus-rich acidic ash soil ENVO:00005764 Soil which is adjacent to a pond. pond soil ENVO:00005765 Compost soil which is frozen. frozen compost soil ENVO:00005766 Soil which has been amended with mineral additives to increase its pH. Common liming agents include calcium- and magnesium-rich materials in various forms, including marl, chalk, limestone, burnt lime or hydrated lime. Liming often improves plant growth and increases the activity of soil bacteria, but oversupply may result in harm to plant life. Liming can also improve aggregate stability on clay soils. For this purpose structure lime, products containing calcium oxide (CaO) or hydroxide (Ca(OH)2) in mixes with calcium carbonate (CaCO3), are often used. Structure liming can reduce losses of clay and nutrients from soil aggregates. limed soil Soil which has been amended with mineral additives to increase its pH. Common liming agents include calcium- and magnesium-rich materials in various forms, including marl, chalk, limestone, burnt lime or hydrated lime. Liming often improves plant growth and increases the activity of soil bacteria, but oversupply may result in harm to plant life. Liming can also improve aggregate stability on clay soils. For this purpose structure lime, products containing calcium oxide (CaO) or hydroxide (Ca(OH)2) in mixes with calcium carbonate (CaCO3), are often used. Structure liming can reduce losses of clay and nutrients from soil aggregates. ENVO:00005767 Soil which has, as a part, a portion of either fresh or processed animal manure. manured soil ENVO:00005768 Soil which has properties to which plants in the Family Orchidaceae have adapted, including increased levels of aeration and drainage. orchid soil ENVO:00005769 Soil which is part of a forest growing on a mountain. mountain forest soil ENVO:00005770 Soil which is part of a forest whose communites of arborescent plants are dominated the genus Fagus. beech forest soil Soil which is part of a forest whose communites of arborescent plants are dominated the genus Fagus. ENVO:00005771 Soil which is composed of a large proportion of mud, thus having properties resembling mud. muddy soil ENVO:00005772 Soil in which trees from an orchard grow. orchard soil ENVO:00005773 Soil which is found in a pasture and in which vegetation, such as the grass used for the grazing of ungulates, grows. pasture soil ENVO:00005774 A histosol which is formed by the decomposition of vegetation or organic matter. turf EcoLexicon:peat SWEETRealm:Peat peat peat soil A histosol which is formed by the decomposition of vegetation or organic matter. peat ENVO:00005775 Soil which has elevated concentrations of sodium chloride. salty soil salt contaminated soil ENVO:00005776 Paddy field soil which has increased levels of peat. peaty paddy field soil ENVO:00005777 A portion of soil which is found in a steppe. steppe soil ENVO:00005778 Soil which is part of a tropical environment. tropical soil ENVO:00005779 Garden soil which is part of a garden used for the cultivation of vegetables. vegetable garden soil ENVO:00005780 A portion of soil which is found in a greenhouse. greenhouse soil ENVO:00005781 Soil which is has been heated such that its chemical, physical, or biological properties are destabilised. heat stressed soil ENVO:00005782 Soil which is formed from avian fecal matter. ornithogenic soil Soil which is formed from avian fecal matter. http://dx.doi.org/10.1099/00207713-46-4-841 http://phenomena.nationalgeographic.com/2015/01/20/science-word-of-the-day-ornithogenic/ ENVO:00005783 Soil which is part of a woodland dominated by leafy trees. leafy wood soil ENVO:00005784 Soil which is part of a forest whose communites of arborescent plants are dominated the genus Picea. spruce forest soil Soil which is part of a forest whose communites of arborescent plants are dominated the genus Picea. ENVO:00005786 Soil which is part of some elevated land. upland soil Soil which is part of some elevated land. ENVO:00005787 Soil which is part of a forest whose communites of arborescent plants are dominated the genus Eucalyptus. eucalyptus forest soil Soil which is part of a forest whose communites of arborescent plants are dominated the genus Eucalyptus. ENVO:00005788 Soil which is part of a rubber plantation. rubber plantation soil Bluegrass field soil is a soil which is found in a field of Kentucky Bluegrass (Poa pratensis). ENVO ENVO:00005789 bluegrass field soil ENVO:00005789 ENVO:00005790 Soil which has 1) low concentrations of nutrients and humus, 2) low water retention capacity, 3) textural variation from sand to clay, 4) a porous and friable structure, and 5) low concentrations of soluble salts. Red soil typically derives from crystalline rock in warm, temperate, moist climates under deciduous or mixed forest. It has thin organic and organic-mineral layers, a black brown leached layer resting on an illuvium red layer. The majority of red soils have a loamy texture. Their chemical composition varies across regions, but often includes non-soluble material 90.47%, iron 3.61%, aluminium 2.92%, organic matter 1.01%, magnesium 0.70%, lime 0.56%, carbon dioxide 0.30%, potash 0.24%, soda 0.12%, phosphorus 0.09% and nitrogen 0.08%. On the uplands, they are thin, poor and gravelly, sandy, or stony and porous, light-colored soils on which food crops like bajra can be grown. In contrast, on the lower plains and valleys they are rich, deep, dark colored fertile loam on which, under irrigation, can produce excellent crops like cotton, wheat, pulses, tobacco, jowar, linseed, millet, potatoes and fruits. red soil Soil which has 1) low concentrations of nutrients and humus, 2) low water retention capacity, 3) textural variation from sand to clay, 4) a porous and friable structure, and 5) low concentrations of soluble salts. Red soil typically derives from crystalline rock in warm, temperate, moist climates under deciduous or mixed forest. It has thin organic and organic-mineral layers, a black brown leached layer resting on an illuvium red layer. The majority of red soils have a loamy texture. Their chemical composition varies across regions, but often includes non-soluble material 90.47%, iron 3.61%, aluminium 2.92%, organic matter 1.01%, magnesium 0.70%, lime 0.56%, carbon dioxide 0.30%, potash 0.24%, soda 0.12%, phosphorus 0.09% and nitrogen 0.08%. On the uplands, they are thin, poor and gravelly, sandy, or stony and porous, light-colored soils on which food crops like bajra can be grown. In contrast, on the lower plains and valleys they are rich, deep, dark colored fertile loam on which, under irrigation, can produce excellent crops like cotton, wheat, pulses, tobacco, jowar, linseed, millet, potatoes and fruits. ENVO:00005791 Sterile water is water which does not contain lliving organisms. sterile water ENVO:00005792 Water which has physicochemical properties determined by processes which occur beneath the planetary crust. SWEETRealm:UndergroundWater subterranean water envoPolar This class references any water that's under a planetary surface. For water that is in an aquifer, see "groundwater" (ENVO:01001004). Previously, this class included both. underground water ENVO ENVO:00005793 muddy water ENVO:00005793 ENVO ENVO:00005794 water scum ENVO:00005794 ENVO:00005795 Mud which is part of a marine ecosystem. envoPolar marine mud ENVO ENVO:00005796 marine sludge ENVO:00005796 ENVO:00005797 Mud which constitutes the bed of a lake. lake bottom mud ENVO ENVO:00005798 acid dune sand ENVO:00005798 ENVO ENVO:00005799 rocky sand ENVO:00005799 ENVO:00005800 Sand which is part of a desert. desert sand Soil that is not penetrated by the root systems of plants. https://en.wikipedia.org/wiki/Bulk_soil ENVO ENVO:00005802 bulk soil ENVO:00005802 Soil that is not penetrated by the root systems of plants. https://en.wikipedia.org/wiki/Bulk_soil ENVO:00010483 A portion of environmental material is a fiat object part which forms the medium or part of the medium of an environmental system. portion of environmental material Everything under this parent must be a mass noun. All subclasses are to be understood as being composed primarily of the named entity, rather than restricted to that entity. For example, "ENVO:water" is to be understood as "environmental material composed primarly of some CHEBI:water". This class is currently being aligned to the Basic Formal Ontology. Following this alignment, its definition and the definitions of its subclasses will be revised. environmental material A portion of environmental material is a fiat object part which forms the medium or part of the medium of an environmental system. DOI:10.1186/2041-1480-4-43 MA:ma ORCID:0000-0002-4366-3088 URL:http://ontology.buffalo.edu/smith/articles/niches.html ENVO:00010504 A layer of some material entity which is adjacent to one or more of its external boundaries and directly interacts with its immediate surroundings. EcoLexicon:surface http://sweetontology.net/reprSpaceGeometry/Surface https://en.wikipedia.org/wiki/Surface This class is distinct from a geometric surface, which is two-dimensional. The idea of "uppermost" may be problematic. Further, the definition of layer (the superclass of surface in rev 133) references surface. This may be another issue. Perhaps this can be made into an inferred class using 'bounding layer of' some material entity, note that 'bounding layer' implies containment, which may not be valid here. surface layer A layer of some material entity which is adjacent to one or more of its external boundaries and directly interacts with its immediate surroundings. URL:http://www.merriam-webster.com/dictionary/surface ENVO:00010505 Airborne solid particles (also called dust or particulate matter (PM)) or liquid droplets. EcoLexicon:aerosol SWEETRealm:Aerosol envoAtmo Should connect to PATO as "quality of an aerosol" aerosol Airborne solid particles (also called dust or particulate matter (PM)) or liquid droplets. https://en.wikipedia.org/wiki/Aerosol ENVO:00010506 A mixture of two immiscible (unblendable) substances. One substance (the dispersed phase) is dispersed in the other (the continuous phase). https://en.wikipedia.org/wiki/Emulsion emulsion A mixture of two immiscible (unblendable) substances. One substance (the dispersed phase) is dispersed in the other (the continuous phase). https://en.wikipedia.org/wiki/Emulsion ENVO:00010622 A vivarium is an enclosure for keeping and raising organisms for observation or research. Often, a portion of the ecosystem for a particular species is simulated on a smaller scale, with controls for environmental conditions. https://en.wikipedia.org/wiki/Vivarium vivarium A vivarium is an enclosure for keeping and raising organisms for observation or research. Often, a portion of the ecosystem for a particular species is simulated on a smaller scale, with controls for environmental conditions. https://en.wikipedia.org/wiki/Vivarium A sedimentary carbonate rock and a mineral, both composed of calcium magnesium carbonate CaMg(CO3)2 found in crystals. https://en.wikipedia.org/wiki/Dolomite ENVO ENVO:00010623 dolomite ENVO:00010623 A sedimentary carbonate rock and a mineral, both composed of calcium magnesium carbonate CaMg(CO3)2 found in crystals. https://en.wikipedia.org/wiki/Dolomite Anthropogenic material in or on which organisms may live. ENVO ENVO:0010001 anthropogenic environmental material ENVO:0010001 Anthropogenic material in or on which organisms may live. MA:ma ENVO:0010003 This class will be depopulated and eventually deprecated. Convenience class. This is quite odd and it probably should be obsoleted. Any material that is a participant in an agricultural process can be seen as an agricultural material. agricultural environmental material This is quite odd and it probably should be obsoleted. Any material that is a participant in an agricultural process can be seen as an agricultural material. ORCID:0000-0002-4366-3088 ENVO:01000000 Organic matter in soil which has reached a point of stability, where it will break down no further and might, if conditions do not change, remain essentially as it is for centuries, or millennia. EcoLexicon:humus SWEETRealm:Humus https://en.wikipedia.org/wiki/Humus humus Organic matter in soil which has reached a point of stability, where it will break down no further and might, if conditions do not change, remain essentially as it is for centuries, or millennia. https://en.wikipedia.org/wiki/Humus ENVO:01000001 An environmental material which is a liquid or semi-liquid mixture of water and some combination of soil, silt, and clay particles. EcoLexicon:mud LTER:356 SWEETRealm:Mud https://en.wikipedia.org/wiki/Mud mud An environmental material which is a liquid or semi-liquid mixture of water and some combination of soil, silt, and clay particles. https://en.wikipedia.org/wiki/Mud ENVO:01000004 The concentration basin mediterranean sea biome comprises expressions of the mediterranean sea biome that have higher salinity than bordering oceans due to evaporation. Water exchange consists of inflow of the fresher oceanic water in the upper layer and outflow of the saltier mediterranean water in the lower layer of the connecting channel. ORCID:0000-0002-4366-3088 2010-03-19T09:32:59Z concentration basin mediterranean sea biome The concentration basin mediterranean sea biome comprises expressions of the mediterranean sea biome that have higher salinity than bordering oceans due to evaporation. Water exchange consists of inflow of the fresher oceanic water in the upper layer and outflow of the saltier mediterranean water in the lower layer of the connecting channel. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Mediterranean_sea ENVO:01000016 Particulate environmental material which is primarily composed of silt particles. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. EcoLexicon:silt SWEETRealm:Silt https://en.wikipedia.org/wiki/Silt This definition is intentionally ambiguous to support the multiple thresholds set by different authorities. Some authorities consider this soil material that contains 80% or more silt and less than 12% clay. In the Udden-Wentworth scale (due to Krumbein), silt particles range between 0.0039 to 0.0625 mm, larger than clay but smaller than sand particles. ISO 14688 grades silts between 0.002 mm and 0.063 mm. In actuality, silt is chemically distinct from clay, and unlike clay, grains of silt are approximately the same size in all dimensions; furthermore, their size ranges overlap. Clays are formed from thin plate-shaped particles held together by electrostatic forces, so present a cohesion. According to the U.S. Department of Agriculture Soil Texture Classification system, the sand-silt distinction is made at the 0.05 mm particle size. The USDA system has been adopted by the Food and Agriculture Organization (FAO). In the Unified Soil Classification System (USCS) and the AASHTO Soil Classification system, the sand-silt distinction is made at the 0.075 mm particle size (i.e., material passing the #200 sieve). Silts and clays are distinguished mechanically by their plasticity. silt Particulate environmental material which is primarily composed of silt particles. This definition is intentionally ambiguous to support the multiple thresholds set by different authorities. Some authorities consider this soil material that contains 80% or more silt and less than 12% clay. In the Udden-Wentworth scale (due to Krumbein), silt particles range between 0.0039 to 0.0625 mm, larger than clay but smaller than sand particles. ISO 14688 grades silts between 0.002 mm and 0.063 mm. In actuality, silt is chemically distinct from clay, and unlike clay, grains of silt are approximately the same size in all dimensions; furthermore, their size ranges overlap. Clays are formed from thin plate-shaped particles held together by electrostatic forces, so present a cohesion. According to the U.S. Department of Agriculture Soil Texture Classification system, the sand-silt distinction is made at the 0.05 mm particle size. The USDA system has been adopted by the Food and Agriculture Organization (FAO). In the Unified Soil Classification System (USCS) and the AASHTO Soil Classification system, the sand-silt distinction is made at the 0.075 mm particle size (i.e., material passing the #200 sieve). Silts and clays are distinguished mechanically by their plasticity. ENVO:01000017 Particulate environmental material which is composed primarily of particles of sand with only minor proportions of other substances. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. EcoLexicon:sand LTER:484 SWEETRealm:Sand https://en.wikipedia.org/wiki/Sand This definition is intentionally ambiguous to support the multiple thresholds set by different authorities. Some authorities consider as sands soil material that contains 85% or more sand; the percentage of silt plus 1.5 times the percentage of clay does not exceed 15. coarse sand (sable grossier) 25% or more very coarse and coarse sand, and less than 50% any other one grade of sand. sand Particulate environmental material which is composed primarily of particles of sand with only minor proportions of other substances. https://en.wikipedia.org/wiki/Sand This definition is intentionally ambiguous to support the multiple thresholds set by different authorities. Some authorities consider as sands soil material that contains 85% or more sand; the percentage of silt plus 1.5 times the percentage of clay does not exceed 15. coarse sand (sable grossier) 25% or more very coarse and coarse sand, and less than 50% any other one grade of sand. https://sis.agr.gc.ca/cansis/glossary/t/index.html ENVO:01000018 An environmental material which is composed primarily of pieces of gravel. EcoLexicon:gravel SWEETRealm:Gravel As with all size-based classifications, there is considerable variation in what is considered gravel. gravel An environmental material which is composed primarily of pieces of gravel. https://en.wikipedia.org/wiki/Gravel ENVO:01000020 Expressions of the estuarine biome occur at wide lower courses of a rivers where they flow into a sea. Estuaries experience tidal flows and their water is a changing mixture of fresh and salt. ORCID:0000-0002-4366-3088 2010-03-15T11:17:06Z SPIRE:Estuarine estuarine biome Expressions of the estuarine biome occur at wide lower courses of a rivers where they flow into a sea. Estuaries experience tidal flows and their water is a changing mixture of fresh and salt. ISBN:978-92-1-161386-5 ORCID:0000-0002-4366-3088 The marine salt marsh biome comprises marshes that are transitional intertidals between land and salty or brackish marine water (e.g.: sloughs, bays, estuaries). It is dominated by halophytic (salt tolerant) herbaceous plants. The daily tidal surges bring in nutrients, which tend to settle in roots of the plants within the salt marsh. The natural chemical activity of salty (or brackish) water and the tendency of algae to bloom in the shallow unshaded water also allow for great biodiversity. ORCID:0000-0002-4366-3088 2010-03-15T11:17:06Z ENVO ENVO:01000022 marine salt marsh biome ENVO:01000022 The marine salt marsh biome comprises marshes that are transitional intertidals between land and salty or brackish marine water (e.g.: sloughs, bays, estuaries). It is dominated by halophytic (salt tolerant) herbaceous plants. The daily tidal surges bring in nutrients, which tend to settle in roots of the plants within the salt marsh. The natural chemical activity of salty (or brackish) water and the tendency of algae to bloom in the shallow unshaded water also allow for great biodiversity. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Salt_marsh The marine pelagic biome (pelagic meaning open sea) is that of the marine water column, from the surface to the greatest depths. ORCID:0000-0002-4366-3088 2010-03-15T11:17:06Z ENVO ENVO:01000023 envoPolar marine pelagic biome ENVO:01000023 The marine pelagic biome (pelagic meaning open sea) is that of the marine water column, from the surface to the greatest depths. ISBN:978-0-7506-3384-0 ENVO:01000024 The marine benthic biome (benthic meaning 'bottom') encompasses the seafloor and includes such areas as shores, littoral or intertidal areas, marine coral reefs, and the deep seabed. ORCID:0000-0002-4366-3088 2010-03-15T11:17:06Z SPIRE:Benthic envoPolar marine benthic biome The marine benthic biome (benthic meaning 'bottom') encompasses the seafloor and includes such areas as shores, littoral or intertidal areas, marine coral reefs, and the deep seabed. ISBN:978-0-7506-3384-0 ORCID:0000-0002-4366-3088 ENVO:01000025 The marine neritic zone biome comprises sea floor from the high tide mark to a continental shelf break. This zone generally extends to 200 m below average sea level. ORCID:0000-0002-4366-3088 2010-03-15T11:18:40Z envoPolar marine neritic benthic zone biome The marine neritic zone biome comprises sea floor from the high tide mark to a continental shelf break. This zone generally extends to 200 m below average sea level. ISBN:978-0-444-82619-0 ISBN:978-0-7506-3384-0 ORCID:0000-0002-4366-3088 ENVO:01000026 The marine bathyal zone biome comprises regions of the marine benthic biome between approximately 200 m and 3000 m depth. This zone generally coincides with the continental slope. ORCID:0000-0002-4366-3088 2010-03-15T11:18:40Z marine bathyal zone biome The marine bathyal zone biome comprises regions of the marine benthic biome between approximately 200 m and 3000 m depth. This zone generally coincides with the continental slope. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 ENVO:01000027 The marine abyssal zone biome comprises regions of the marine benthic biome between approximately 2500 m and 6000 m depth. This zone generally coincides with the continental rise and the abyssal plain. ORCID:0000-0002-4366-3088 2010-03-15T11:18:40Z marine abyssal zone biome The marine abyssal zone biome comprises regions of the marine benthic biome between approximately 2500 m and 6000 m depth. This zone generally coincides with the continental rise and the abyssal plain. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 ENVO:01000028 The marine hadal zone biome describes sea floor deeper than 6000 m such as that of the oceanic trenches. ORCID:0000-0002-4366-3088 2010-03-15T11:18:40Z marine hadal zone biome The marine hadal zone biome describes sea floor deeper than 6000 m such as that of the oceanic trenches. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 ENVO:01000029 A biome expressed by strips or ridges of rocks, sand, or coral that rises to or near the surface of a body of marine water. ORCID:0000-0002-4366-3088 2010-03-15T11:18:40Z marine reef biome A biome expressed by strips or ridges of rocks, sand, or coral that rises to or near the surface of a body of marine water. ISBN:978-0-618-45504-1 ORCID:0000-0002-4366-3088 ENVO:01000030 The marine hydrothermal vent biome comprises regions of the marine benthic biome where heat generated due to tectonic activity, either at divergent plate boundaries or convergent ocean plates where back-arc spreading occurs, is released or 'vented' to the surface. The resultant high temperature water jets are laden with dissolved metals and minerals. ORCID:0000-0002-4366-3088 2010-03-15T11:18:40Z marine hydrothermal vent biome The marine hydrothermal vent biome comprises regions of the marine benthic biome where heat generated due to tectonic activity, either at divergent plate boundaries or convergent ocean plates where back-arc spreading occurs, is released or 'vented' to the surface. The resultant high temperature water jets are laden with dissolved metals and minerals. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 The neritic epipelagic zone biome comprises the marine water column above a continental shelf. ORCID:0000-0002-4366-3088 2010-03-15T11:19:19Z ENVO ENVO:01000032 neritic pelagic zone biome ENVO:01000032 The neritic epipelagic zone biome comprises the marine water column above a continental shelf. ISBN:978-0-444-82619-0 ISBN:978-0-7506-3384-0 ORCID:0000-0002-4366-3088 The oceanic epipelagic zone biome comprises the marine water column offshore, beyond a continental shelf. ORCID:0000-0002-4366-3088 2010-03-15T11:19:19Z ENVO ENVO:01000033 oceanic pelagic zone biome ENVO:01000033 The oceanic epipelagic zone biome comprises the marine water column offshore, beyond a continental shelf. ISBN:978-0-444-82619-0 ISBN:978-0-7506-3384-0 ORCID:0000-0002-4366-3088 The oceanic sea surface microlayer (SML) biome comprises the top 1000 micrometers of the marine surface waters occurring offshore, away from a continental shelf. It is the boundary layer where all exchange occurs between the atmosphere and the ocean. The chemical, physical, and biological properties of the SML differ greatly from the sub-surface water just a few centimeters beneath. ORCID:0000-0002-4366-3088 2010-03-15T11:21:03Z ENVO ENVO:01000034 oceanic sea surface microlayer biome ENVO:01000034 The oceanic sea surface microlayer (SML) biome comprises the top 1000 micrometers of the marine surface waters occurring offshore, away from a continental shelf. It is the boundary layer where all exchange occurs between the atmosphere and the ocean. The chemical, physical, and biological properties of the SML differ greatly from the sub-surface water just a few centimeters beneath. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Sea_surface_microlayer The oceanic epipelagic zone biome comprises regions of the marine water column that occur offshore, beyond a continental shelf. This biome extends from the surface of the ocean to a depth of ca. 200-250m. Throughout the zone the light field tends to be asymmetrical vertically, so that the direction and elevation of the sun can still be detected. The oceanic epipelagic zone biome encompasses the euphotic zone and, where and when it occurs, the seasonal thermocline. ORCID:0000-0002-4366-3088 2010-03-15T11:21:03Z ENVO ENVO:01000035 oceanic epipelagic zone biome ENVO:01000035 The oceanic epipelagic zone biome comprises regions of the marine water column that occur offshore, beyond a continental shelf. This biome extends from the surface of the ocean to a depth of ca. 200-250m. Throughout the zone the light field tends to be asymmetrical vertically, so that the direction and elevation of the sun can still be detected. The oceanic epipelagic zone biome encompasses the euphotic zone and, where and when it occurs, the seasonal thermocline. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 The oceanic mesopelagic zone biome comprises regions of the marine water column that occur offshore, beyond a continental shelf. This biome extends through the water column from approximately 200-1000 m depth - the maximal depth of light penetration in all but the clearest oligotrophic ocean regions. In comparison to the epipelagic zone, dominant forms of pelagic organisms do not change very much; however, there are marked changes in species composition and the proportion of smaller-sized individuals decreases. ORCID:0000-0002-4366-3088 2010-03-15T11:21:03Z ENVO ENVO:01000036 oceanic mesopelagic zone biome ENVO:01000036 The oceanic mesopelagic zone biome comprises regions of the marine water column that occur offshore, beyond a continental shelf. This biome extends through the water column from approximately 200-1000 m depth - the maximal depth of light penetration in all but the clearest oligotrophic ocean regions. In comparison to the epipelagic zone, dominant forms of pelagic organisms do not change very much; however, there are marked changes in species composition and the proportion of smaller-sized individuals decreases. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 The bathypelagic zone biome comprises the marine water column below approximately 1000 m water depth - the maximum depth to which detectable daylight penetrates in all but the clearest oligotrophic waters - and extends to about 2500 - 2700 m water depth. In the temperate Atlantic, the beginning of the bathypelagic zone biome approximates to the deep oxygen minimum and the base of the permanent thermocline. ORCID:0000-0002-4366-3088 2010-03-15T11:21:03Z ENVO ENVO:01000037 oceanic bathypelagic zone biome ENVO:01000037 The bathypelagic zone biome comprises the marine water column below approximately 1000 m water depth - the maximum depth to which detectable daylight penetrates in all but the clearest oligotrophic waters - and extends to about 2500 - 2700 m water depth. In the temperate Atlantic, the beginning of the bathypelagic zone biome approximates to the deep oxygen minimum and the base of the permanent thermocline. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 The abyssopelagic zone biome comprises the marine water column below the bathypelagic zone biome at approximately 2500 -2700 m and extends either to the hadal pelagic zone biome (at approximately 6000 m) or to the benthopelagic zone biome within ca. 100 m of the seafloor. The depth of 2700 m may be critical for physiological reasons as the change in hydrostatic pressure across this depth may preclude organism migration. ORCID:0000-0002-4366-3088 2010-03-15T11:21:03Z ENVO ENVO:01000038 oceanic abyssopelagic zone biome ENVO:01000038 The abyssopelagic zone biome comprises the marine water column below the bathypelagic zone biome at approximately 2500 -2700 m and extends either to the hadal pelagic zone biome (at approximately 6000 m) or to the benthopelagic zone biome within ca. 100 m of the seafloor. The depth of 2700 m may be critical for physiological reasons as the change in hydrostatic pressure across this depth may preclude organism migration. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 The oceanic hadal pelagic zone biome comprises the water column in oceanic trenches occurring at depths between 6000m and 10,000m. ORCID:0000-0002-4366-3088 2010-03-15T11:21:03Z ENVO ENVO:01000039 oceanic hadal pelagic zone biome ENVO:01000039 The oceanic hadal pelagic zone biome comprises the water column in oceanic trenches occurring at depths between 6000m and 10,000m. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 The benthopelagic zone biome comprises regions of the marine water column which usually coincide with the benthic boundary layer (BBL) - the layer of isothermal and isohaline water contiguous to the sea floor. A general reversal in the declining gradient of pelagic biomass may be observed here, perhaps explained by viable nutrition on the sea floor being resuspended by bottom currents. This zone typically extends 100 m above the seafloor, but may reach upto1000 m during benthic storms. ORCID:0000-0002-4366-3088 2010-03-15T11:21:03Z ENVO ENVO:01000040 oceanic benthopelagic zone biome ENVO:01000040 The benthopelagic zone biome comprises regions of the marine water column which usually coincide with the benthic boundary layer (BBL) - the layer of isothermal and isohaline water contiguous to the sea floor. A general reversal in the declining gradient of pelagic biomass may be observed here, perhaps explained by viable nutrition on the sea floor being resuspended by bottom currents. This zone typically extends 100 m above the seafloor, but may reach upto1000 m during benthic storms. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 The neritic sea surface microlayer (SML) biome comprises the top 1000 micrometers of marine surface waters occurring above a continental shelf. It is the boundary layer where all exchange occurs between the atmosphere and the ocean. The chemical, physical, and biological properties of the SML differ greatly from the sub-surface water just a few centimeters beneath. ORCID:0000-0002-4366-3088 2010-03-15T11:22:09Z ENVO ENVO:01000041 neritic sea surface microlayer biome ENVO:01000041 The neritic sea surface microlayer (SML) biome comprises the top 1000 micrometers of marine surface waters occurring above a continental shelf. It is the boundary layer where all exchange occurs between the atmosphere and the ocean. The chemical, physical, and biological properties of the SML differ greatly from the sub-surface water just a few centimeters beneath. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Sea_surface_microlayer The neritic epipelagic zone biome comprises the marine water column that occurs above a continental shelf and extends from the surface of the ocean to a depth of ca. 200-250m. Throughout the zone the light field tends to be asymmetrical vertically, so that the direction and elevation of the sun can still be detected. The epipelagic zone encompasses the euphotic zone and, where and when it occurs, the seasonal thermocline. ORCID:0000-0002-4366-3088 2010-03-15T11:22:09Z ENVO ENVO:01000042 neritic epipelagic zone biome ENVO:01000042 The neritic epipelagic zone biome comprises the marine water column that occurs above a continental shelf and extends from the surface of the ocean to a depth of ca. 200-250m. Throughout the zone the light field tends to be asymmetrical vertically, so that the direction and elevation of the sun can still be detected. The epipelagic zone encompasses the euphotic zone and, where and when it occurs, the seasonal thermocline. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 ENVO:01000043 The neritic mesopelagic zone biome comprises the marine column that occurs above a continental shelf and extends from approximately 200 to 1000 m depth - the maximal depth of light penetration in all but the clearest oligotrophic ocean regions. In comparison to the epipelagic zone, dominant forms of pelagic organisms do not change very much; however, there are marked changes in species composition and the proportion of smaller-sized individuals decreases. ORCID:0000-0002-4366-3088 2010-03-15T11:22:09Z neritic mesopelagic zone biome The neritic mesopelagic zone biome comprises the marine column that occurs above a continental shelf and extends from approximately 200 to 1000 m depth - the maximal depth of light penetration in all but the clearest oligotrophic ocean regions. In comparison to the epipelagic zone, dominant forms of pelagic organisms do not change very much; however, there are marked changes in species composition and the proportion of smaller-sized individuals decreases. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 ENVO:01000045 The epeiric sea (also known as an epicontinental sea) biome comprises a shallow seas that extend over part of a continent. Epeiric seas are usually associated with the marine transgressions of the geologic past, which have variously been due to either global eustatic sea level changes, local tectonic deformation, or both, and are occasionally semi-cyclic. ORCID:0000-0002-4366-3088 2010-03-15T11:23:23Z epicontinental sea biome epeiric sea biome The epeiric sea (also known as an epicontinental sea) biome comprises a shallow seas that extend over part of a continent. Epeiric seas are usually associated with the marine transgressions of the geologic past, which have variously been due to either global eustatic sea level changes, local tectonic deformation, or both, and are occasionally semi-cyclic. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Epeiric_sea epicontinental sea biome https://en.wikipedia.org/wiki/Epeiric_sea ENVO:01000046 The marginal sea biome comprises parts of an ocean partially enclosed by land such as islands, archipelagos, or peninsulas. Unlike mediterranean seas, marginal seas have ocean currents caused by ocean winds. Many marginal seas are enclosed by island arcs that were formed from the subduction of one oceanic plate beneath another. ORCID:0000-0002-4366-3088 2010-03-15T11:23:23Z marginal sea biome The marginal sea biome comprises parts of an ocean partially enclosed by land such as islands, archipelagos, or peninsulas. Unlike mediterranean seas, marginal seas have ocean currents caused by ocean winds. Many marginal seas are enclosed by island arcs that were formed from the subduction of one oceanic plate beneath another. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Marginal_sea ENVO:01000047 The mediterranean sea biome comprises mostly enclosed seas that have limited exchange of deep water with outer oceans and where the water circulation is dominated by salinity and temperature differences rather than winds. ORCID:0000-0002-4366-3088 2010-03-15T11:23:23Z mediterranean sea biome The mediterranean sea biome comprises mostly enclosed seas that have limited exchange of deep water with outer oceans and where the water circulation is dominated by salinity and temperature differences rather than winds. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Mediterranean_sea ENVO:01000048 A marine biome which is determined by an ocean. ORCID:0000-0002-4366-3088 2010-03-15T11:23:23Z envoPolar Ocean biomes are determined by major bodies of saline water, principal components of the hydrosphere. Approximately 71% of the Earth's surface is covered by ocean, a continuous body of water that is customarily divided into several principal oceans and smaller seas. More than half of this area is over 3,000 metres (9,800 ft) deep. Average oceanic salinity is around 35 parts per thousand (ppt) (3.5%), and nearly all seawater has a salinity in the range of 30 to 38 ppt. ocean biome A marine biome which is determined by an ocean. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Ocean The marine coral reef biome comprises constructional wave-resistant entities which are primarily built by corals and are often cemented together. The growth of these structures is aided by zooxanthellae, algae that are symbiotic with the reef-building corals. ORCID:0000-0002-4366-3088 2010-03-15T11:27:06Z ENVO ENVO:01000049 marine coral reef biome ENVO:01000049 The marine coral reef biome comprises constructional wave-resistant entities which are primarily built by corals and are often cemented together. The growth of these structures is aided by zooxanthellae, algae that are symbiotic with the reef-building corals. ISBN:978-0-7506-3384-0 ORCID:0000-0002-4366-3088 The marine rocky subtidal reef biome comprises regions of the marine reef biome composed mainly of rock and which harbour abundant communities of algae and invertebrates. These reefs are often very patchy, with alterations of rocks dominated by rich invertebrate assemblages and turf-forming calcareous red algae. ORCID:0000-0002-4366-3088 2010-03-15T11:27:06Z ENVO ENVO:01000050 marine subtidal rocky reef biome ENVO:01000050 The marine rocky subtidal reef biome comprises regions of the marine reef biome composed mainly of rock and which harbour abundant communities of algae and invertebrates. These reefs are often very patchy, with alterations of rocks dominated by rich invertebrate assemblages and turf-forming calcareous red algae. ISBN:978-0-7506-3384-0 ORCID:0000-0002-4366-3088 A marine black smoker biome comprises regions of the marine hydrothermal vent biome characterised by a black vent plume. This black plume is a consequence of dissolved metals and minerals forming complexes with sulphide and indicates polymetallic sulphide mineral deposits beneath the surface. ORCID:0000-0002-4366-3088 2010-03-15T11:29:37Z ENVO ENVO:01000051 marine black smoker biome ENVO:01000051 A marine black smoker biome comprises regions of the marine hydrothermal vent biome characterised by a black vent plume. This black plume is a consequence of dissolved metals and minerals forming complexes with sulphide and indicates polymetallic sulphide mineral deposits beneath the surface. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 A marine white smoker biome comprises regions of the marine hydrothermal vent biome characterised by lightly hued plumes, typically containing barium, calcium, and silicon. These vents tend to have lower temperature plumes when compared to black smoker environments. ORCID:0000-0002-4366-3088 2010-03-15T11:29:37Z ENVO ENVO:01000052 marine white smoker biome ENVO:01000052 A marine white smoker biome comprises regions of the marine hydrothermal vent biome characterised by lightly hued plumes, typically containing barium, calcium, and silicon. These vents tend to have lower temperature plumes when compared to black smoker environments. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Hydrothermal_vent A marine ultramafic hydrothermal vent biome comprises regions of themarine hydrothermal vent biome hosted on ultramafic (also referred to as ultrabasic) rocks. Ultramafic rocks are igneous and meta-igneous rocks with very low silica content (less than 45%), generally >18% MgO, high FeO, low potassium, and are composed of usually greater than 90% mafic minerals (dark colored, high magnesium and iron content). The Earth's mantle is composed of ultramafic rocks. ORCID:0000-0002-4366-3088 2010-03-15T11:29:37Z ENVO ENVO:01000053 marine ultramafic hydrothermal vent biome ENVO:01000053 A marine ultramafic hydrothermal vent biome comprises regions of themarine hydrothermal vent biome hosted on ultramafic (also referred to as ultrabasic) rocks. Ultramafic rocks are igneous and meta-igneous rocks with very low silica content (less than 45%), generally >18% MgO, high FeO, low potassium, and are composed of usually greater than 90% mafic minerals (dark colored, high magnesium and iron content). The Earth's mantle is composed of ultramafic rocks. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Ultramafic A marine basaltic hydrothermal vent biome comprises regions of the marine hydrothermal vent biome hosted on basaltic rocks. Basalt generally has a composition of 45 to 55 wt % SiO2, 2 to 6 wt % total alkalis, 0.5 to 2.0 wt % TiO2, 5 to 14 wt % FeO and 14 wt % or more Al2O3. Contents of CaO are commonly near 10 wt %, those of MgO commonly in the range 5 to 12 wt %. ORCID:0000-0002-4366-3088 2010-03-15T11:29:37Z ENVO ENVO:01000054 marine basaltic hydrothermal vent biome ENVO:01000054 A marine basaltic hydrothermal vent biome comprises regions of the marine hydrothermal vent biome hosted on basaltic rocks. Basalt generally has a composition of 45 to 55 wt % SiO2, 2 to 6 wt % total alkalis, 0.5 to 2.0 wt % TiO2, 5 to 14 wt % FeO and 14 wt % or more Al2O3. Contents of CaO are commonly near 10 wt %, those of MgO commonly in the range 5 to 12 wt %. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Basalt ENVO:01000060 An environmental material which is composed primarily of particles. Do not oversimplify this branch with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. particulate matter envoAtmo envoPolar particulate environmental material ENVO:01000063 A portion of planktonic material is a portion of environmental material primarily composed of plankton. See Issue #251. Awaiting class creation in PCO to attempt logical definitions. envoPolar planktonic material Sediment comprised of weathered continental rocks, wind blown dust, volcanic ash or other terrestrial material. ORCID:0000-0002-4366-3088 2010-03-17T01:14:02Z EcoLexicon:terrigenous_sediment SWEETRealm:TerrigenousSediment ENVO ENVO:01000070 terrigenous sediment ENVO:01000070 Sediment comprised of weathered continental rocks, wind blown dust, volcanic ash or other terrestrial material. ORCID:0000-0002-4366-3088 Biogenous sediment is derived from living organisms, typically planktonic organisms possessing shells, frustules or coccoliths. ORCID:0000-0002-4366-3088 2010-03-17T01:14:02Z ENVO ENVO:01000082 envoPolar biogenous sediment ENVO:01000082 Biogenous sediment is derived from living organisms, typically planktonic organisms possessing shells, frustules or coccoliths. ORCID:0000-0002-4366-3088 ENVO:01000110 Hydrogenous sediment is derived from solutes that precipitate out of sea water by a variety of chemical reactions. These are typically less abundant than other sediment types. ORCID:0000-0002-4366-3088 2010-03-17T01:14:02Z SWEETRealm:HydrogenousSediment hydrogenous sediment Hydrogenous sediment is derived from solutes that precipitate out of sea water by a variety of chemical reactions. These are typically less abundant than other sediment types. ORCID:0000-0002-4366-3088 Cosmogenous sediment is derived from extraterrestrial dust and debris in the form of meteorites and similar entities. ORCID:0000-0002-4366-3088 2010-03-17T01:14:02Z ENVO ENVO:01000111 cosmogenous sediment ENVO:01000111 Cosmogenous sediment is derived from extraterrestrial dust and debris in the form of meteorites and similar entities. ORCID:0000-0002-4366-3088 Polymetallic nodules, also called manganese nodules, are rock concretions on the sea bottom formed of concentric layers of iron and manganese hydroxides around a core. Nodules vary in size from tiny particles visible only under a microscope to large pellets more than 20 centimetres (8 in) across. However, most nodules are between 5 and 10 cm in diameter. ORCID:0000-0002-4366-3088 2010-03-17T01:14:02Z manganese nodule ENVO ENVO:01000112 polymetallic nodule ENVO:01000112 Polymetallic nodules, also called manganese nodules, are rock concretions on the sea bottom formed of concentric layers of iron and manganese hydroxides around a core. Nodules vary in size from tiny particles visible only under a microscope to large pellets more than 20 centimetres (8 in) across. However, most nodules are between 5 and 10 cm in diameter. https://en.wikipedia.org/wiki/Manganese_nodule manganese nodule https://en.wikipedia.org/wiki/Manganese_nodule Suspended sediment, or suspended load, is the term for the particles settle slowly enough to be carried in flowing water (such as a stream or coastal area) either without touching the bed or while only intermittently touching it. These particles are generally of the fine sand, silt and clay size, although larger particles may be carried as well depending on the intensity of the flow. ORCID:0000-0002-4366-3088 2010-03-17T01:17:02Z ENVO ENVO:01000113 suspended sediment ENVO:01000113 Suspended sediment, or suspended load, is the term for the particles settle slowly enough to be carried in flowing water (such as a stream or coastal area) either without touching the bed or while only intermittently touching it. These particles are generally of the fine sand, silt and clay size, although larger particles may be carried as well depending on the intensity of the flow. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Suspended_load Sediment characterised by an average particle diameter greater than 256 mm. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z ENVO ENVO:01000114 boulder sediment ENVO:01000114 Sediment characterised by an average particle diameter greater than 256 mm. https://en.wikipedia.org/wiki/Particle_size ENVO:01000115 Sediment characterised by an average particle diameter between 64 and 256 mm. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z cobble sediment Sediment characterised by an average particle diameter between 64 and 256 mm. https://en.wikipedia.org/wiki/Particle_size Sediment characterised by an average particle diameter between 4 and 32 mm. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z ENVO ENVO:01000116 pebble sediment ENVO:01000116 Sediment characterised by an average particle diameter between 4 and 32 mm. https://en.wikipedia.org/wiki/Particle_size ENVO:01000117 Sediment characterised by an average particle diameter between 2 and 4 mm. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z granular sediment Sediment characterised by an average particle diameter between 2 and 4 mm. https://en.wikipedia.org/wiki/Particle_size Sediment characterised by an average particle diameter between 62.5 micrometers and 2 mm. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z ENVO ENVO:01000118 sandy sediment ENVO:01000118 Sediment characterised by an average particle diameter between 62.5 micrometers and 2 mm. https://en.wikipedia.org/wiki/Particle_size ENVO:01000119 Sediment characterised by an average particle diameter between 3.9 and 62.5 micrometers. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z silty sediment Sediment characterised by an average particle diameter between 3.9 and 62.5 micrometers. https://en.wikipedia.org/wiki/Particle_size ENVO:01000120 Sediment characterised by an average particle diameter between 1 and 3.9 micrometers. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z clay sediment Sediment characterised by an average particle diameter between 1 and 3.9 micrometers. https://en.wikipedia.org/wiki/Particle_size ENVO:01000121 Sediment characterised by an average particle diameter below 1 micrometer. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z Note that by the particle-size-based definition used here, colloidal sediment need not actually be a colloid. If that is the case, please use "suspended colloidal sediment". colloidal sediment Sediment characterised by an average particle diameter below 1 micrometer. https://en.wikipedia.org/wiki/Particle_size The marine sponge reef biome comprises marine reefs primarily built by marine sponges. The primary frame-building sponges are all members of the order Hexactinosa. They are found only in glacier-scoured troughs of low-angle continental shelf. The seafloor is stable and consists of rock, coarse gravel, and large boulders. ORCID:0000-0002-4366-3088 2010-03-17T04:43:05Z ENVO ENVO:01000123 marine sponge reef biome ENVO:01000123 The marine sponge reef biome comprises marine reefs primarily built by marine sponges. The primary frame-building sponges are all members of the order Hexactinosa. They are found only in glacier-scoured troughs of low-angle continental shelf. The seafloor is stable and consists of rock, coarse gravel, and large boulders. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Sponge_reef ENVO:01000127 A marine benthic biome which is determined by a cold seep. 2010-03-19T08:33:56Z The marine cold seep biome comprises regions of the marine benthic biome where seepage of methane, hydrogen sulphide, hydrocarbon rich fluids and other fluids occurs. marine cold seep biome A marine benthic biome which is determined by a cold seep. https://en.wikipedia.org/wiki/Cold_seep ENVO:01000128 The dilution basin mediterranean sea biome comprises expressions of the mediterranean sea biome with lower salinity than the surrounding ocean due to freshwater gains such as rainfall and rivers. Water exchange consists of outflow of the fresher mediterranean water in the upper layer and inflow of the saltier oceanic water in the lower layer of the channel. Renewal of deep water may not be sufficient to supply oxygen to the bottom. ORCID:0000-0002-4366-3088 2010-03-19T09:32:59Z dilution basin mediterranean sea biome The dilution basin mediterranean sea biome comprises expressions of the mediterranean sea biome with lower salinity than the surrounding ocean due to freshwater gains such as rainfall and rivers. Water exchange consists of outflow of the fresher mediterranean water in the upper layer and inflow of the saltier oceanic water in the lower layer of the channel. Renewal of deep water may not be sufficient to supply oxygen to the bottom. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Mediterranean_sea Sediment characterised by a temperature of 15-45 degrees Celsius and high-to-low oxygenation. Often impacted by hydrothermal fluid flows. ORCID:0000-0002-4366-3088 2010-03-20T07:15:20Z ENVO ENVO:01000131 mesophilic sediment ENVO:01000131 Sediment characterised by a temperature of 15-45 degrees Celsius and high-to-low oxygenation. Often impacted by hydrothermal fluid flows. ORCID:0000-0002-4366-3088 ENVO:01000132 Sediment characterised by a temperature of 45-75 degrees Celsius and low to no oxygen content. Often impacted by hydrothermal fluid flows. ORCID:0000-0002-4366-3088 2010-03-20T07:18:16Z thermophilic sediment Sediment characterised by a temperature of 45-75 degrees Celsius and low to no oxygen content. Often impacted by hydrothermal fluid flows. ORCID:0000-0002-4366-3088 ENVO:01000133 Sediment characterised by a temperature of 80-125 degrees Celsius and no oxygen content. Often impacted by hydrothermal fluid flows. ORCID:0000-0002-4366-3088 2010-03-20T07:18:16Z hyperthermophilic sediment Sediment characterised by a temperature of 80-125 degrees Celsius and no oxygen content. Often impacted by hydrothermal fluid flows. ORCID:0000-0002-4366-3088 ENVO:01000134 High temperature water ejected from hydrothermal vents and laden with dissolved metals and minerals as a result of percolation through crustal rocks. ORCID:0000-0002-4366-3088 2010-03-20T08:19:19Z hydrothermal fluid High temperature water ejected from hydrothermal vents and laden with dissolved metals and minerals as a result of percolation through crustal rocks. ISBN:978-0-444-82619-0 ORCID:0000-0002-4366-3088 Sediment hosting and characterised by active nitrate reducing microbial communities. ORCID:0000-0002-4366-3088 2010-03-20T08:33:33Z ENVO ENVO:01000135 envoPolar nitrate-reducing sediment ENVO:01000135 Sediment hosting and characterised by active nitrate reducing microbial communities. ORCID:0000-0002-4366-3088 Sediment hosting and characterised by active manganese reducing microbial communities. ORCID:0000-0002-4366-3088 2010-03-20T08:33:33Z ENVO ENVO:01000151 envoPolar manganese-reducing sediment ENVO:01000151 Sediment hosting and characterised by active manganese reducing microbial communities. ORCID:0000-0002-4366-3088 Sediment hosting and characterised by active iron reducing microbial communities. ORCID:0000-0002-4366-3088 2010-03-20T08:33:33Z ENVO ENVO:01000152 envoPolar iron-reducing sediment ENVO:01000152 Sediment hosting and characterised by active iron reducing microbial communities. ORCID:0000-0002-4366-3088 ENVO:01000153 Sediment hosting and characterised by active sulphate reducing microbial communities. ORCID:0000-0002-4366-3088 2010-03-20T08:33:33Z envoPolar sulphate-reducing sediment Sediment hosting and characterised by active sulphate reducing microbial communities. ORCID:0000-0002-4366-3088 Sediment hosting and characterised by active carbon dioxide reducing microbial communities. ORCID:0000-0002-4366-3088 2010-03-20T08:33:33Z ENVO ENVO:01000154 envoPolar carbon dioxide-reducing sediment ENVO:01000154 Sediment hosting and characterised by active carbon dioxide reducing microbial communities. ORCID:0000-0002-4366-3088 ENVO:01000155 Environmental material derived from living organisms and composed primarily of one or more biomacromolecules. ORCID:0000-0002-4366-3088 2010-03-20T08:40:04Z EcoLexicon:organic_material biomass organic material Environmental material derived from living organisms and composed primarily of one or more biomacromolecules. ISBN:978-0-618-45504-1 ORCID:0000-0002-4366-3088 Material derived from a biofilm, an aggregate of microorganisms in which cells adhere to each other and/or to a surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS). Biofilm EPS, which is also referred to as slime, is a polymeric conglomeration generally composed of extracellular DNA, proteins, and polysaccharides in various configurations. ORCID:0000-0002-4366-3088 2010-03-20T08:51:49Z ENVO ENVO:01000156 biofilm material ENVO:01000156 Material derived from a biofilm, an aggregate of microorganisms in which cells adhere to each other and/or to a surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS). Biofilm EPS, which is also referred to as slime, is a polymeric conglomeration generally composed of extracellular DNA, proteins, and polysaccharides in various configurations. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Biofilm Material derived from a microbial mat, a multi-layered sheet of micro-organisms, mainly bacteria and archaea. Microbial mats create a wide range of internal chemical environments. ORCID:0000-0002-4366-3088 2010-03-20T08:51:49Z ENVO ENVO:01000157 envoPolar microbial mat material ENVO:01000157 Material derived from a microbial mat, a multi-layered sheet of micro-organisms, mainly bacteria and archaea. Microbial mats create a wide range of internal chemical environments. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Microbial_mat ENVO:01000158 Marine snow is a continuous shower of mostly organic detritus falling from the upper layers of the water column. Its origin lies in activities within the productive photic zone. ORCID:0000-0002-4366-3088 2010-03-20T08:51:49Z EcoLexicon:marine_snow envoPolar marine snow Marine snow is a continuous shower of mostly organic detritus falling from the upper layers of the water column. Its origin lies in activities within the productive photic zone. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Marine_snow ENVO:01000173 Water which lacks dissolved oxygen. ORCID:0000-0002-4366-3088 2010-03-21T06:05:53Z anaerobic water reducing water anoxic water Water which lacks dissolved oxygen. ORCID:0000-0002-4366-3088 ENVO:01000175 A woodland biome is a terrestrial biome which includes, across its entire spatial extent, woody plants spaced sufficiently far apart to allow light penetration to support communities of herbaceous plants or shrubs living closer to the woodland floor. ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z Preliminary definition. woodland biome ENVO:01000176 A shrubland biome is a terrestrial biome which includes, across its entire spatial extent, dense groups of shrubs. ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z Preliminary definition. shrubland biome ENVO:01000178 A woodland biome which has seasonal water availability and includes trees spaced sufficiently far apart to allow an unbroken layer of grass, sedge (Cyperaceae) or rush (Juncaceae) communities to live. ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z SPIRE:Savannah_or_grassland savanna biome ENVO:01000180 A terrestrial biome which comprises a tundra ecosystem that has reached its climax community. ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z SPIRE:Tundra envoPolar wwfBiome Preliminary definition. tundra biome ENVO:01000181 A mangrove biome is a terrestrial biome which includes, across its spatial extent, mangrove plants (Rhizophoraceae). Mangrove plants are able to withstand high levels of salinity as well as regions of anoxia and frequent tidal inundation. Mangrove biomes often occur near tropical and sub-tropical estuaries and depositional marine coastal environments where fine sediments (often with high organic content) collect in areas protected from high energy wave action. ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z LTER:322 wwfBiome Preliminary definition. Depending on whether mangrove trees or shrubs are present, this class could be a child of shrubland biome or woodland biome. Consider creating the appropriate classes. mangrove biome A mangrove biome is a terrestrial biome which includes, across its spatial extent, mangrove plants (Rhizophoraceae). Mangrove plants are able to withstand high levels of salinity as well as regions of anoxia and frequent tidal inundation. Mangrove biomes often occur near tropical and sub-tropical estuaries and depositional marine coastal environments where fine sediments (often with high organic content) collect in areas protected from high energy wave action. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Mangrove ENVO:01000187 A savanna biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:28:51Z wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical savanna biome ENVO:01000188 A savanna biome which is subject to tropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:28:51Z wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical savanna biome ENVO:01000189 A savanna biome which is subject to temperate climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:28:51Z prairie biome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate savanna biome ENVO:01000190 A flooded savanna biome is a savanna biome which has very wet to saturated soil moisture content. ORCID:0000-0002-4366-3088 2013-04-07T14:28:51Z swamp marsh wwfBiome flooded savanna biome A flooded savanna biome is a savanna biome which has very wet to saturated soil moisture content. https://en.wikipedia.org/wiki/Flooded_grasslands_and_savannas ENVO:01000208 A subtropical woodland biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. mediterranean woodland biome ENVO:01000213 A shrubland biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical shrubland biome ENVO:01000214 A shrubland biome which is subject to tropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical shrubland biome ENVO:01000215 A shrubland biome which is subject to temperate climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z prairie biome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate shrubland biome ENVO:01000216 A montane shrubland biome is a shrubland biome which occurs in regions elevated above sea level and which has community structure determined by elevation-dependent environmental conditions. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z wwfBiome Preliminary definition. montane shrubland biome ENVO:01000217 A mediterranean shrubland biome is a subtropical shrubland biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. mediterranean shrubland biome ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z ENVO ENVO:01000218 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. xeric shrubland biome ENVO:01000218 ENVO:01000219 An anthropogenic terrestrial biome is a terrestrial biome which has community structures determined by human activity. ORCID:0000-0002-4366-3088 2013-04-07T14:45:22Z anthrome human biome Preliminary definition. anthropogenic terrestrial biome An anthropogenic terrestrial biome is a terrestrial biome which has community structures determined by human activity. http://www.eoearth.org/view/article/150128/ ENVO:01000220 A woodland biome which is subject to tropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical woodland biome ENVO:01000221 A woodland biome which is subject to temperate climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate woodland biome ENVO:01000222 A woodland biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical woodland biome ENVO:01000223 A montane savanna biome is a savanna biome which occurs in regions elevated above sea level and which has community structure determined by elevation-dependent environmental conditions. ORCID:0000-0002-4366-3088 2013-04-07T16:50:01Z Preliminary definition. montane savanna biome ENVO:01000229 A savanna biome which is subject to mediterranean climate patterns. ORCID:0000-0002-4366-3088 2013-04-24T12:20:42Z wwfBiome mediterranean savanna biome ENVO:01000231 Lava is a mixture of molten or semi-molten rock, volatiles, and solids which has extruded beyond a planetary crust. PLB 2013-05-05T16:52:47Z EcoLexicon:lava SWEETRealm:Lava Some use 'lava' to refer to rock that is formed when lava cools. This is not the intended meaning of this class. See 'igneous rock' or similar. lava Lava is a mixture of molten or semi-molten rock, volatiles, and solids which has extruded beyond a planetary crust. https://en.wikipedia.org/wiki/Lava Felsic lava is lava which is high in silica (> 69 percent by weight), aluminium, potassium, sodium, and calcium, forming a polymerized liquid rich in feldspar and quartz. Felsic lava has a higher viscosity than other magma types. Felsic magmas can erupt at temperatures as low as 650 to 750 °C. Unusually hot (>950 °C) rhyolite lavas, however, may flow for distances of many tens of kilometres PLB 2013-05-05T16:56:29Z silicic lava ENVO ENVO:01000232 felsic lava ENVO:01000232 Felsic lava is lava which is high in silica (> 69 percent by weight), aluminium, potassium, sodium, and calcium, forming a polymerized liquid rich in feldspar and quartz. Felsic lava has a higher viscosity than other magma types. Felsic magmas can erupt at temperatures as low as 650 to 750 °C. Unusually hot (>950 °C) rhyolite lavas, however, may flow for distances of many tens of kilometres https://en.wikipedia.org/wiki/Igneous_rock https://en.wikipedia.org/wiki/Lava silicic lava https://en.wikipedia.org/wiki/Lava Intermediate lava is lava which, relative to felsic lava, is lower in aluminium and silica (between 52 and 63 percent by weight), and usually somewhat richer in magnesium and iron. The temperature of intermediate lava ranges from 750 to 950 degrees Celsius, destroying polymerized bonds and promoting more fluid behaviour relative to felsic lavas and also a greater tendency to form phenocrysts. Higher iron and magnesium tends to manifest as a darker groundmass, and also occasionally amphibole or pyroxene phenocrysts. PLB 2013-05-05T16:56:29Z andesitic lava ENVO ENVO:01000233 intermediate lava ENVO:01000233 Intermediate lava is lava which, relative to felsic lava, is lower in aluminium and silica (between 52 and 63 percent by weight), and usually somewhat richer in magnesium and iron. The temperature of intermediate lava ranges from 750 to 950 degrees Celsius, destroying polymerized bonds and promoting more fluid behaviour relative to felsic lavas and also a greater tendency to form phenocrysts. Higher iron and magnesium tends to manifest as a darker groundmass, and also occasionally amphibole or pyroxene phenocrysts. https://en.wikipedia.org/wiki/Intermediate_composition andesitic lava https://en.wikipedia.org/wiki/Lava ENVO:01000234 Mafic lava is lava which, relative to other lava types other than ultramafic lava, has a high ferromagnesian content and low aluminium and silica content, with silca making up between 45 and 52 percent of its weight. 2013-05-05T16:56:29Z basaltic lava Mafic lava generally erupts at temperatures in excess of 950 degrees Celsius. The high temperature and low polymerisation in mafic lava favors low viscosity and chemical diffusion, promoting the formation of large, well-formed phenocrysts. mafic lava Mafic lava is lava which, relative to other lava types other than ultramafic lava, has a high ferromagnesian content and low aluminium and silica content, with silca making up between 45 and 52 percent of its weight. https://en.wikipedia.org/wiki/Igneous_rock https://en.wikipedia.org/wiki/Lava basaltic lava https://en.wikipedia.org/wiki/Lava ENVO:01000235 Lava which, relative to other lava types, has very high magnesium oxide content and less than 45 percent silica by weight. 2013-05-05T16:56:29Z Ultramafic lava generally erupts at temperatures of 1600 degrees Celsius. Due to its high temperature and composition, the viscosity of ultramafic lava is very low. ultramafic lava Lava which, relative to other lava types, has very high magnesium oxide content and less than 45 percent silica by weight. https://en.wikipedia.org/wiki/Igneous_rock https://en.wikipedia.org/wiki/Lava ENVO:01000236 Basalt is a volcanic rock which is formed by the rapid cooling of basaltic lava. PLB 2013-05-05T17:07:15Z EcoLexicon:basalt SWEETRealm:Basalt basalt Basalt is a volcanic rock which is formed by the rapid cooling of basaltic lava. https://en.wikipedia.org/wiki/Basalt ENVO:01000246 A village biome is an anthropogenic terrestrial biome which contains settlements such as villages, towns, and/or small cities and which is primarily used for agricultural activity. ORCID:0000-0002-4366-3088 2013-06-14T11:45:47Z Villages are also described as agricultural settlements with greater than 100 persons per square kilometre; however, no upper limit is defined. village biome A village biome is an anthropogenic terrestrial biome which contains settlements such as villages, towns, and/or small cities and which is primarily used for agricultural activity. DOI:10.1111/j.1466-8238.2010.00540.x DOI:10.1890/070062 ENVO:01000247 A rangeland biome is an anthropogenic terrestrial biome which is primarily used for the rearing and grazing of livestock. ORCID:0000-0002-4366-3088 2013-06-14T11:45:47Z rangeland biome A rangeland biome is an anthropogenic terrestrial biome which is primarily used for the rearing and grazing of livestock. DOI:10.1111/j.1466-8238.2010.00540.x DOI:10.1890/070062 A dense settlement biome is an anthropogenic terrestrial biome which is primarily used for human habitation, recreation, and industry within built structures with little other land use. ORCID:0000-0002-4366-3088 2013-06-14T11:45:47Z ENVO ENVO:01000248 dense settlement biome ENVO:01000248 A dense settlement biome is an anthropogenic terrestrial biome which is primarily used for human habitation, recreation, and industry within built structures with little other land use. DOI:10.1111/j.1466-8238.2010.00540.x DOI:10.1890/070062 An urban biome is a dense settlement biome which has been urbanised. ORCID:0000-0002-4366-3088 2013-06-14T11:45:47Z SPIRE:Urban ENVO ENVO:01000249 urban biome ENVO:01000249 An urban biome is a dense settlement biome which has been urbanised. DOI:10.1111/j.1466-8238.2010.00540.x DOI:10.1890/070062 ENVO:01000252 A biome which is determined by a freshwater lake. 2013-09-19T11:11:01Z freshwater lake biome ENVO:01000253 A freshwater biome which is determined by a freshwater river. 2013-09-19T11:11:01Z freshwater river biome ENVO:01000256 A mineral material is an environmental material which is primarily composed of some substance that is naturally occurring, solid and stable at room temperature, representable by a chemical formula, usually abiogenic, and that has an ordered atomic structure. Look for "mineral" in a chemical or geochemical ontology to formalise the composed primarily of link. From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which can be an aggregate of minerals or non-minerals and does not have a specific chemical composition. The exact definition of a mineral is under debate, especially with respect to the requirement a valid species be abiogenic, and to a lesser extent with regards to it having an ordered atomic structure. ORCID:0000-0002-4366-3088 2013-10-05T12:37:41Z LTER:341 mineral material A mineral material is an environmental material which is primarily composed of some substance that is naturally occurring, solid and stable at room temperature, representable by a chemical formula, usually abiogenic, and that has an ordered atomic structure. https://en.wikipedia.org/wiki/Mineral ENVO:01000266 Water vapour is a vapour which is the gas phase of water. ORCID:0000-0002-4366-3088 2013-10-10T07:58:18Z aqueous vapor aqueous vapour water vapor Perhaps a better relation between water vapour and water can be found in or added to RO? water vapour Water vapour is a vapour which is the gas phase of water. https://en.wikipedia.org/wiki/Water_vapor aqueous vapor https://en.wikipedia.org/wiki/Water_vapor aqueous vapour https://en.wikipedia.org/wiki/Water_vapor water vapor https://en.wikipedia.org/wiki/Water_vapor Atmospheric water vapour is water vapour that is part of an atmosphere. ORCID:0000-0002-4366-3088 2013-10-10T08:22:07Z atmospheric water vapor ENVO ENVO:01000268 envoPolar atmospheric water vapour ENVO:01000268 Atmospheric water vapour is water vapour that is part of an atmosphere. https://en.wikipedia.org/wiki/Water_vapor atmospheric water vapor https://en.wikipedia.org/wiki/Water_vapor A sedimentary rock which is composed mainly of silt. This rock has a grainsize in the silt range, finer than sandstone and coarser than claystones. ORCID:0000-0002-4366-3088 2013-10-12T14:51:19Z ENVO ENVO:01000269 siltstone ENVO:01000269 A sedimentary rock which is composed mainly of silt. This rock has a grainsize in the silt range, finer than sandstone and coarser than claystones. https://en.wikipedia.org/wiki/Siltstone A clastic sedimentary rock which is composed primarily of clay sized particles. ORCID:0000-0002-4366-3088 2013-10-12T14:51:19Z ENVO ENVO:01000270 claystone ENVO:01000270 A clastic sedimentary rock which is composed primarily of clay sized particles. https://en.wikipedia.org/wiki/Claystone Clastic sedimentary rocks are sedimentary rocks that are composed of silicate minerals and rock fragments that were transported by moving fluids. Clastic rocks are composed largely of quartz, feldspar, rock (lithic) fragments, clay minerals, and mica; numerous other minerals may be present as accessories and may be important locally. ORCID:0000-0002-4366-3088 2013-10-12T14:51:19Z ENVO ENVO:01000271 clastic sedimentary rock ENVO:01000271 Clastic sedimentary rocks are sedimentary rocks that are composed of silicate minerals and rock fragments that were transported by moving fluids. Clastic rocks are composed largely of quartz, feldspar, rock (lithic) fragments, clay minerals, and mica; numerous other minerals may be present as accessories and may be important locally. https://en.wikipedia.org/wiki/Sedimentary_rock#Clastic_sedimentary_rocks A mudstone is a clastic sedimentary rock which contains a mixture of at least one third of silt- and one third of clay-sized particles. ORCID:0000-0002-4366-3088 2013-10-12T14:51:19Z ENVO ENVO:01000272 There is debate on the usage of mudstone and mudrock, and some ambiguity is to be expected. https://en.wikipedia.org/wiki/ The terminology of "mudstone" is not to be confused with the Dunham classification scheme for limestones. In Dunham's classification, a mudstone is any limestone containing less than ten percent carbonate grains. Note, a siliciclastic mudstone does not deal with carbonate grains. Friedman, Sanders, and Kopaska-Merkel (1992) suggest the use of "lime mudstone" to avoid confusion with siliciclastic rocks. mudstone ENVO:01000272 A mudstone is a clastic sedimentary rock which contains a mixture of at least one third of silt- and one third of clay-sized particles. https://en.wikipedia.org/wiki/Mudrock#Nomenclature https://en.wikipedia.org/wiki/Mudstone ENVO:01000273 Lime mudstone is a limestone which is primarily composed of either clay-size or both silt-size and clay-size detrital (transported) carbonate grains. ORCID:0000-0002-4366-3088 2013-10-12T14:51:19Z calcilutite cementstone https://en.wikipedia.org/wiki/ The terminology of "mudstone" is not to be confused with the Dunham classification scheme for limestones. In Dunham's classification, a mudstone is any limestone containing less than ten percent carbonate grains. Note, a siliciclastic mudstone does not deal with carbonate grains. Friedman, Sanders, and Kopaska-Merkel (1992) suggest the use of "lime mudstone" to avoid confusion with siliciclastic rocks. lime mudstone Lime mudstone is a limestone which is primarily composed of either clay-size or both silt-size and clay-size detrital (transported) carbonate grains. https://en.wikipedia.org/wiki/Calcilutite https://en.wikipedia.org/wiki/Mudstone calcilutite https://en.wikipedia.org/wiki/Calcilutite cementstone https://en.wikipedia.org/wiki/Calcilutite ENVO:01000274 Slate is a metamorphic rock which is fine-grained, foliated, homogeneous, Slates are derived from clastic sedimentary rocks. ORCID:0000-0002-4366-3088 2013-10-12T14:51:19Z slate Slate is a metamorphic rock which is fine-grained, foliated, homogeneous, Slates are derived from clastic sedimentary rocks. https://en.wikipedia.org/wiki/Slate ENVO:01000277 Ice which is formed from water. 2013-10-13T12:01:28Z LTER:262 ice envoPolar Water ice can appear transparent or opaque bluish-white color, depending on the presence of impurities or air inclusions. The addition of other materials such as soil may further alter its appearance. When speaking about ice on Earth, usually water ice is meant - the solid, crystalline form of water found in the atmosphere as snow crystals, hail, ice pellets, etc., and on the earth's surface in forms such as hoarfrost, rime, glaze, sea ice, glacier ice, ground ice, frazil, anchor ice, etc. This form of water is, strictly speaking, called ice Ih, the Roman numeral I distinguishing it from more than a dozen other phases and the letter h distinguishing it from the metastable cubic phase ice Ic. Ice Ih is the only one of the several known phases of water ice that is stable at commonly occurring temperatures and pressures. (Some of the other forms have very unusual properties, ice VII, for example, being stable only at pressures above 22 400 kg/cm^2, but then existing at temperatures up to about 100C.) It has an open structure with a specific gravity of 0.9166 which is slightly less than water; because the water molecules bond to their neighbors covalently only in four directions; it therefore floats on higher density water, where broken molecular bonds permit closer packing. All commonly occurring forms of ice are crystalline, although large single crystals are relatively rare except in glaciers. The ice crystal lattice possesses hexagonal symmetry that manifests itself in the gross forms of such single crystals as are sometimes found in snow. At an air pressure of one atmosphere, ice melts at 0 C by definition of the Celsius temperature scale. (Strictly speaking the equilibrium point among water, ice, and vapor occurs at +0.01C, the triple point.) On the other hand, ice does not invariably form in liquid water cooled below this temperature; it has a tendency to supercool, more so in the absence of ice nuclei. In permafrost regions, ice may occupy voids in soils and rocks and may develop in a variety of forms. Ice may be colourless to pale blue or greenish-blue. It may appear white due to included gas bubbles; in exposures, ground ice may also appear black. In nature ice is formed either by: (a) the freezing of water, (b) the condensation of atmospheric water vapour direct into ice crystals, (c) the compaction of snow with or without the motion of a glacier, or (d) the impregnation of porous snow masses with water which subsequently freeze. water ice Ice which is formed from water. https://en.wikipedia.org/wiki/Ice ice http://www.eionet.europa.eu/gemet/concept/4131 Brackish water which is part of an estuary. ORCID:0000-0002-4366-3088 2013-10-19T11:30:46Z ENVO ENVO:01000301 estuarine water ENVO:01000301 Brackish water which is part of an estuary. https://en.wikipedia.org/wiki/Estuary ENVO:01000339 A biome which is subject to polar climatic conditions. envoPolar This class is primarily for inference and, in general, should not be used directly by annotators. If you're an annotator, please consider using a more informative term such as 'tundra biome'. polar biome ENVO:01000349 An organic material primarily composed of a portion of plant root. Requested in Issue 115 as part of the annotation of metagenomic submissions present in the European Nucleotide Archive. root matter ENVO:01000350 Autoclaved sand is sand that has been sterlised by exposure to high pressure saturated steam at at least 121 degrees Celsius. Requested in Issue 116 as part of the annotation of metagenomic submissions present in the European Nucleotide Archive. autoclaved sand ENVO:01000356 A portion of granite is a portion of igneous rock which is intrusive, felsic, granular, and phaneritic. Requested in issue 45. Some relations to PATO and SWEET classes suggested. granite A portion of granite is a portion of igneous rock which is intrusive, felsic, granular, and phaneritic. https://en.wikipedia.org/wiki/Granite ENVO:01000357 A portion of alkaline water is a portion of water with a pH greater than 7. Here, we commit to a threshold of pH as this is almost universally accepted. alkaline water ENVO:01000358 A portion of acidic water is a portion of water with a pH less than 7. acidic water ENVO:01000371 Agricultural waste is waste produced as a result of various agricultural operations. It includes manure and other wastes from farms, poultry houses and slaughterhouses; harvest waste; fertilizer run- off from fields; pesticides that enter into water, air or soils; and salt and silt drained from fields. agricultural waste As with other wastes, this is more a role than a material in itself. This should be revised. agricultural waste material Agricultural waste is waste produced as a result of various agricultural operations. It includes manure and other wastes from farms, poultry houses and slaughterhouses; harvest waste; fertilizer run- off from fields; pesticides that enter into water, air or soils; and salt and silt drained from fields. ISBN:978-92-1-161386-5 http://stats.oecd.org/glossary/detail.asp?ID=77 ENVO:01000372 Household waste refers to waste material usually generated in the residential environment. Waste with similar characteristics may be generated in other economic activities and can thus be treated and disposed of together with household waste. This will become a defined class, with subclasses added through inference based on material having a 'waste role' and being associated with domestic entities. household waste household waste material Household waste refers to waste material usually generated in the residential environment. Waste with similar characteristics may be generated in other economic activities and can thus be treated and disposed of together with household waste. ISBN:978-92-1-161386-5 http://stats.oecd.org/glossary/detail.asp?ID=1261 ENVO:01000373 Biological waste is waste containing mostly natural organic materials (remains of plants, animal excrement, biological sludge from waste-water treatment plants and so forth). This will become a defined class, with subclasses added through inference based on material having a 'waste role' and being composed primarily of some organic or biological matter. biological waste biological waste material Biological waste is waste containing mostly natural organic materials (remains of plants, animal excrement, biological sludge from waste-water treatment plants and so forth). ISBN:978-92-1-161386-5 http://stats.oecd.org/glossary/detail.asp?ID=3097 ENVO:01000405 A portion of respirable suspended particulate matter is a form of particulate matter composed primarily of solid particles each with a diameter of 10 micrometers or less. PM10 respirable suspended particulate matter A portion of respirable suspended particulate matter is a form of particulate matter composed primarily of solid particles each with a diameter of 10 micrometers or less. https://en.wikipedia.org/wiki/Particulates ENVO:01000406 Snow is an environmental material which is primarily composed of flakes of crystalline water ice. envoPolar snow Snow is an environmental material which is primarily composed of flakes of crystalline water ice. http://www.eionet.europa.eu/gemet/concept/7769 https://en.wikipedia.org/wiki/Snow ENVO:01000415 A portion of fine respirable suspended particulate matter is a form of particulate matter composed primarily of solid particles each with a diameter of 2.5 micrometers or less. PM2.5 fine respirable suspended particulate matter A portion of fine respirable suspended particulate matter is a form of particulate matter composed primarily of solid particles each with a diameter of 2.5 micrometers or less. https://en.wikipedia.org/wiki/Particulates ENVO:01000416 A portion of fine respirable suspended particulate matter is a form of particulate matter composed primarily of solid particles each with a diameter of 100 nanometers or less. Regulations do not exist for this size class of ambient air pollution particles, which are far smaller than the regulated PM10 and PM2.5 particle classes and are believed to have several more aggressive health implications than those classes of larger particulates. ultrafine respirable suspended particulate matter A portion of fine respirable suspended particulate matter is a form of particulate matter composed primarily of solid particles each with a diameter of 100 nanometers or less. https://en.wikipedia.org/wiki/Particulates https://en.wikipedia.org/wiki/Ultrafine_particle ENVO:01000427 A portion of carbon nanotube enriched soil is a portion of soil with elevated levels of carbon nanotubes. Logical definition will be created pending import of "carbon nanotube" from CHEBI carbon nanotube enriched soil ENVO:01000436 Particulate environmental material in which small portions of solid material are surrounded by water. This class should be populated by inference, relying on 'composed primarily of', many 'pieces of solid material' and 'surrounded by' some 'water'. waterborne particulate matter ENVO:01000441 Andesite is an extrusive igneous, volcanic rock, of intermediate composition, with aphanitic to porphyritic texture. In a general sense, it is the intermediate type between basalt and dacite, and ranges from 57 to 63 percent silicon dioxide as illustrated in TAS diagrams. The mineral assemblage is typically dominated by plagioclase plus pyroxene and/or hornblende. Magnetite, zircon, apatite, ilmenite, biotite, and garnet are common accessory minerals. Alkali feldspar may be present in minor amounts. andesite Andesite is an extrusive igneous, volcanic rock, of intermediate composition, with aphanitic to porphyritic texture. https://en.wikipedia.org/wiki/Andesite ENVO:01000442 Dacite is an igneous, volcanic rock. It has an aphanitic to porphyritic texture and is intermediate in composition between andesite and rhyolite. Dacite consists mostly of plagioclase feldspar with biotite, hornblende, and pyroxene (augite and/or enstatite). It has quartz as rounded, corroded phenocrysts, or as an element of the ground-mass. The plagioclase ranges from oligoclase to andesine and labradorite. Sanidine occurs, although in small proportions, in some dacites, and when abundant gives rise to rocks that form transitions to the rhyolites. dacite Dacite is an igneous, volcanic rock. It has an aphanitic to porphyritic texture and is intermediate in composition between andesite and rhyolite. Dacite consists mostly of plagioclase feldspar with biotite, hornblende, and pyroxene (augite and/or enstatite). It has quartz as rounded, corroded phenocrysts, or as an element of the ground-mass. The plagioclase ranges from oligoclase to andesine and labradorite. Sanidine occurs, although in small proportions, in some dacites, and when abundant gives rise to rocks that form transitions to the rhyolites. https://en.wikipedia.org/wiki/dacite ENVO:01000444 Lava which is high in silica and low in alkali metal oxides. Rapid solidification of this lava forms dacite. dacitic lava Lava which is high in silica and low in alkali metal oxides. ENVO:01000451 Atmospheric carbon dioxide is an environmental material composed of carbon dioxide in its gaseous form present in an atmosphere. ORCID:0000-0002-4366-3088 envoPolar This could also be considered a part of an environmental material like air. atmospheric carbon dioxide ENVO:01000458 Concrete is a composite material composed of an aggregate bonded together with a fluid cement which hardens over time. ORCID:0000-0002-4366-3088 Missing the class for "aggregate" - tricky to define what it is, exactly. Again, seems more like some sort of material/disposition hybrid. concrete Concrete is a composite material composed of an aggregate bonded together with a fluid cement which hardens over time. https://en.wikipedia.org/wiki/Concrete ENVO:01000459 Asphaltic concrete is a concrete which uses refined asphalt as a cement. ORCID:0000-0002-4366-3088 asphaltic concrete road pavement asphalt concrete Asphaltic concrete is a concrete which uses refined asphalt as a cement. https://en.wikipedia.org/wiki/Concrete ENVO:01000460 Asphalt also known as bitumen is a sticky, black, and highly viscous liquid or semi-solid form of petroleum. asphaltum bitumen crude bitumen pitch tar This class refers to naturally-occuring asphalt or bitumen. asphalt Asphalt also known as bitumen is a sticky, black, and highly viscous liquid or semi-solid form of petroleum. https://en.wikipedia.org/wiki/Asphalt ENVO:01000461 Refined asphalt is a sticky, black, and highly viscous liquid or semi-solid with a boiling point above 500 degrees Celsius, obtained from the fractional distillation of crude oil. ORCID:0000-0002-4366-3088 refined bitumen refined asphalt Refined asphalt is a sticky, black, and highly viscous liquid or semi-solid with a boiling point above 500 degrees Celsius, obtained from the fractional distillation of crude oil. https://en.wikipedia.org/wiki/Asphalt ENVO:01000462 Masonry cement is a substance used in construction that has the disposition to set and harden and thus may be used to bind materials together. ORCID:0000-0002-4366-3088 cement "Cement" refers more to a disposition than a specific material. masonry cement Masonry cement is a substance used in construction that has the disposition to set and harden and thus may be used to bind materials together. https://en.wikipedia.org/wiki/Cement ENVO:01000463 Hydraulic cement is a masonry cement which contains activated aluminium silicates or pozzolans, such as fly ash, allowing it to set in wet conditions or underwater. ORCID:0000-0002-4366-3088 hydraulic cement Hydraulic cement is a masonry cement which contains activated aluminium silicates or pozzolans, such as fly ash, allowing it to set in wet conditions or underwater. https://en.wikipedia.org/wiki/Cement ENVO:01000464 Non-hydraulic cement is a cement which sets by reacting with carbon dioxide in the air and will not set in wet conditions or underwater. It is susceptible to attack by aggresive chemicals after setting. ORCID:0000-0002-4366-3088 non-hydraulic cement Non-hydraulic cement is a cement which sets by reacting with carbon dioxide in the air and will not set in wet conditions or underwater. It is susceptible to attack by aggresive chemicals after setting. https://en.wikipedia.org/wiki/Cement ENVO:01000473 Thatch is material composed of dry vegetation such as straw, water reed, sedge (Cladium mariscus), rushes, or heather. Some sort of logical definition towards: composed_primarily_of some ((straw or 'water reed' or rushes or sedge or heather) and has_quality dry) should be considered, where "rushes", "sedge", etc are represented as materials rather than some sort of taxon. thatch Thatch is material composed of dry vegetation such as straw, water reed, sedge (Cladium mariscus), rushes, or heather. https://en.wikipedia.org/wiki/Thatching ENVO:01000474 A portion of brick material is a material derived from a brick which is composed of kneaded clay-bearing soil, expanded clay aggregate, sand and lime, or concrete that has been fire-hardened or air-dried. ORCID:0000-0002-4366-3088 brick material A portion of brick material is a material derived from a brick which is composed of kneaded clay-bearing soil, expanded clay aggregate, sand and lime, or concrete that has been fire-hardened or air-dried. https://en.wikipedia.org/wiki/Brick ENVO:01000476 Plaster is a building material which has the disposition to harden when it reacts with water, liberating heat through crystallization. Plaster is manufactured as a dry powder and is mixed with water to form a paste when used. ORCID:0000-0002-4366-3088 render stucco plaster Plaster is a building material which has the disposition to harden when it reacts with water, liberating heat through crystallization. Plaster is manufactured as a dry powder and is mixed with water to form a paste when used. https://en.wikipedia.org/wiki/Plaster ENVO:01000477 Gypsum plaster is a plaster which is formed by partially dehydrating gypsum by heating it to approximately 150 degrees Celsius and grinding the product into a powder. Gypsum anhydride - formed by heating gypsum above 200 degrees Celsius - may also be used as plaster. ORCID:0000-0002-4366-3088 plaster of Paris gypsum plaster Gypsum plaster is a plaster which is formed by partially dehydrating gypsum by heating it to approximately 150 degrees Celsius and grinding the product into a powder. Gypsum anhydride - formed by heating gypsum above 200 degrees Celsius - may also be used as plaster. https://en.wikipedia.org/wiki/Plaster ENVO:01000478 ORCID:0000-0002-4366-3088 cement render cement stucco cement plaster ENVO:01000479 Lime plaster is a plaster which is primarily composed of calcium hydroxide and an inert filler (such as sand). Coversion of the calcium hydroxide to calcium carbonate through a reaction with carbon dioxide in the air causes the plaster to set. ORCID:0000-0002-4366-3088 lime render lime stucco slaked lime plaster lime plaster Lime plaster is a plaster which is primarily composed of calcium hydroxide and an inert filler (such as sand). Coversion of the calcium hydroxide to calcium carbonate through a reaction with carbon dioxide in the air causes the plaster to set. https://en.wikipedia.org/wiki/Plaster ENVO:01000480 Glass is an amorphous (non-crystalline) solid which is often transparent. ORCID:0000-0002-4366-3088 This class refers to all forms of glass. For the familiar form present in window panes and drinking glasses, consider silica-based glass. glass Glass is an amorphous (non-crystalline) solid which is often transparent. https://en.wikipedia.org/wiki/Glass ENVO:01000481 Silica-based glass is a glass composed primarily of silicon dioxide, the primary constituent of sand. glass Silica-based glasses are the most common manufactured variety of glass. silica-based glass ENVO:01000482 Soda-lime glass is a silica-based glass which is composed of approximately 75% silicon dioxide, with sodium oxide and calcium oxide consituting most of its remaining composition. ORCID:0000-0002-4366-3088 glass soda-lime-silica glass This type of glass constitutes 90% of manufactured glass. soda-lime glass Soda-lime glass is a silica-based glass which is composed of approximately 75% silicon dioxide, with sodium oxide and calcium oxide consituting most of its remaining composition. https://en.wikipedia.org/wiki/Soda-lime_glass This type of glass constitutes 90% of manufactured glass. https://en.wikipedia.org/wiki/Glass ENVO:01000483 Flat glass is a soda-lime glass which is composed of approximately 73% silicon dioxide (silica), 14% sodium oxide, 9% calcium oxide, 4% magnesium oxide, 0.15% aluminium oxide, 0.03% potassium oxide, 0.02% titanum dioxide, and 0.01% iron III oxide. ORCID:0000-0002-4366-3088 plate glass sheet glass Most flat glass is soda-lime glass produced by the float glass process. It is more water soluble than container glass. flat glass Flat glass is a soda-lime glass which is composed of approximately 73% silicon dioxide (silica), 14% sodium oxide, 9% calcium oxide, 4% magnesium oxide, 0.15% aluminium oxide, 0.03% potassium oxide, 0.02% titanum dioxide, and 0.01% iron III oxide. https://en.wikipedia.org/wiki/Soda-lime_glass ENVO:01000484 Container glass is a soda-lime glass which is composed of approximately 74% silicon dioxide (silica), 13% sodium oxide, 10.5% calcium oxide, 1.3% aluminium oxide, 0.3% potassium oxide, 0.2% sulphur trioxide, 0.2% magnesium oxide, 0.04% iron III oxide, and 0.01% titanum dioxide. ORCID:0000-0002-4366-3088 Container glass is less water soluble than flat glass. container glass Container glass is a soda-lime glass which is composed of approximately 74% silicon dioxide (silica), 13% sodium oxide, 10.5% calcium oxide, 1.3% aluminium oxide, 0.3% potassium oxide, 0.2% sulphur trioxide, 0.2% magnesium oxide, 0.04% iron III oxide, and 0.01% titanum dioxide. https://en.wikipedia.org/wiki/Soda-lime_glass ENVO:01000485 Quartz glass is a glass which is composed of silica in amorphous (non-crystalline) form. ORCID:0000-0002-4366-3088 fused quartz fused silica This is "pure" silica glass. As an ENVO:"environmental material" this class assumes that there remains some possibility that 'contaminants' being present. quartz glass Quartz glass is a glass which is composed of silica in amorphous (non-crystalline) form. https://en.wikipedia.org/wiki/Fused_quartz ENVO:01000508 salt material ENVO:01000537 Atmospheric ozone is an environmental material primarily composed of ozone in its gaseous form and present in an atmosphere. ORCID:0000-0002-4366-3088 atmospheric ozone atmospheric ozone atmospheric ozone http://www.eionet.europa.eu/gemet/concept/632 ENVO:01000551 A fuel oil which is 1) composed primarily of alkanes having between 5-15 carbon atoms with the general formula CnH2n+2, 2) is generally odorless or has only a slight odor, 3) produces only small amounts of soot relative to other fuel oils, 4) is highly refined. paraffin liquid paraffin paraffin oil A fuel oil which is 1) composed primarily of alkanes having between 5-15 carbon atoms with the general formula CnH2n+2, 2) is generally odorless or has only a slight odor, 3) produces only small amounts of soot relative to other fuel oils, 4) is highly refined. https://en.wikipedia.org/wiki/Kerosene https://www.differencebetween.com/difference-between-paraffin-and-kerosene/ ENVO:01000552 Natural gas is a hydrocarbon gas mixture consisting primarily of methane, but commonly includes varying amounts of other higher alkanes and sometimes a usually lesser percentage of carbon dioxide, nitrogen, and/or hydrogen sulfide. Natural gas is a fossil fuel formed when layers of buried plants and gases are exposed to intense heat and pressure over thousands of years. natural gas Natural gas is a hydrocarbon gas mixture consisting primarily of methane, but commonly includes varying amounts of other higher alkanes and sometimes a usually lesser percentage of carbon dioxide, nitrogen, and/or hydrogen sulfide. Natural gas is a fossil fuel formed when layers of buried plants and gases are exposed to intense heat and pressure over thousands of years. https://en.wikipedia.org/wiki/Natural_gas ENVO:01000553 Liquified petroleum gas or liquid petroleum gas (LPG or LP gas), also referred to as simply propane or butane, are flammable mixtures of hydrocarbon gases used as fuel in heating appliances, cooking equipment, and vehicles. LP gas LPG liquid petroleum gas liquified natural gas liquefied petroleum gas Liquified petroleum gas or liquid petroleum gas (LPG or LP gas), also referred to as simply propane or butane, are flammable mixtures of hydrocarbon gases used as fuel in heating appliances, cooking equipment, and vehicles. https://en.wikipedia.org/wiki/Liquefied_petroleum_gas ENVO:01000554 A gas that is primarily composed of hydrocarbon molecules. envoPolar hydrocarbon gas ENVO:01000555 Compressed natural gas is a natural gas stored at high pressures, typically 20–25 Megapascals. compressed natural gas Compressed natural gas is a natural gas stored at high pressures, typically 20–25 Megapascals. https://en.wikipedia.org/wiki/Compressed_natural_gas ENVO:01000556 Biogas is a mixture of different gases produced by the breakdown of organic matter in the absence of oxygen, is primarily composed of methane and carbon dioxide, and may have small amounts of hydrogen sulfide, water, and siloxanes. This is distinct from natural gas which is a fossil fuel product. biogas Biogas is a mixture of different gases produced by the breakdown of organic matter in the absence of oxygen, is primarily composed of methane and carbon dioxide, and may have small amounts of hydrogen sulfide, water, and siloxanes. https://en.wikipedia.org/wiki/ ENVO:01000557 Liquefied natural gas (LNG) is natural gas (predominantly methane, CH4) that has been converted to liquid form for ease of storage or transport. It takes up about 1/600th the volume of natural gas in the gaseous state. It is odorless, colorless, non-toxic and non-corrosive. LNG achieves a higher reduction in volume than compressed natural gas (CNG) so that the (volumetric) energy density of LNG is 2.4 times greater than that of CNG or 60 percent of that of diesel fuel. LNG liquified natural gas liquefied natural gas Liquefied natural gas (LNG) is natural gas (predominantly methane, CH4) that has been converted to liquid form for ease of storage or transport. It takes up about 1/600th the volume of natural gas in the gaseous state. It is odorless, colorless, non-toxic and non-corrosive. LNG achieves a higher reduction in volume than compressed natural gas (CNG) so that the (volumetric) energy density of LNG is 2.4 times greater than that of CNG or 60 percent of that of diesel fuel. https://en.wikipedia.org/wiki/Liquefied_natural_gas ENVO:01000558 envoPolar liquefied hydrocarbon gas ENVO:01000559 Compressed biogas is biogas stored at increased pressures. This is distinct from compressed natural gas, which refers to the compressed form of a fossil fuel. compressed biogas ENVO:01000560 Charcoal is a light, black residue, consisting of carbon and any remaining ash, obtained by removing water and other volatile constituents from animal and vegetation substances. Charcoal is usually produced by slow pyrolysis, the heating of wood or other substances in the absence of oxygen. charcoal Charcoal is a light, black residue, consisting of carbon and any remaining ash, obtained by removing water and other volatile constituents from animal and vegetation substances. Charcoal is usually produced by slow pyrolysis, the heating of wood or other substances in the absence of oxygen. https://en.wikipedia.org/wiki/Charcoal ENVO:01000575 A wax is an environmental material which is primarily composed of lipids or other organic compounds that consist of long alkyl chains. Waxes are are malleable near ambient temperatures and melt at approximately 45 degrees Celsius. wax A wax is an environmental material which is primarily composed of lipids or other organic compounds that consist of long alkyl chains. Waxes are are malleable near ambient temperatures and melt at approximately 45 degrees Celsius. https://en.wikipedia.org/wiki/Wax ENVO:01000599 river water ENVO:01000600 Rainwater is liquid water which has precipitated in the form of droplets through the condensation of atmospheric water vapour. rainwater Rainwater is liquid water which has precipitated in the form of droplets through the condensation of atmospheric water vapour. https://en.wikipedia.org/wiki/Rain ENVO:01000620 A mesocosm is a vivarium that is embedded within a natural environment and is used to place a relatively small part of that environment under experimental control for the purposes of scientific investigation. mesocosm A mesocosm is a vivarium that is embedded within a natural environment and is used to place a relatively small part of that environment under experimental control for the purposes of scientific investigation. https://en.wikipedia.org/wiki/Mesocosm ENVO:01000628 Leaf litter is dead plant material, such as leaves, bark, needles, and twigs, that has fallen to the ground. duff leaf litter litterfall soil litter tree litter plant litter Leaf litter is dead plant material, such as leaves, bark, needles, and twigs, that has fallen to the ground. https://en.wikipedia.org/wiki/Plant_litter ENVO:01000637 Outer space is a hard vacuum containing a low density of particles, predominantly a plasma of hydrogen and helium as well as electromagnetic radiation, magnetic fields, neutrinos, dust and cosmic rays that exists between celestial bodies. space envoAstro outer space Outer space is a hard vacuum containing a low density of particles, predominantly a plasma of hydrogen and helium as well as electromagnetic radiation, magnetic fields, neutrinos, dust and cosmic rays that exists between celestial bodies. https://en.wikipedia.org/wiki/Outer_space ENVO:01000648 Magma is a mixture of molten or semi-molten rock, volatiles, and solids that is found beneath the uppermost solid layer of a planetary body. Besides molten rock, magma may also contain suspended crystals, dissolved gas and sometimes gas bubbles. magma Magma is a mixture of molten or semi-molten rock, volatiles, and solids that is found beneath the uppermost solid layer of a planetary body. Besides molten rock, magma may also contain suspended crystals, dissolved gas and sometimes gas bubbles. https://en.wikipedia.org/wiki/Magma ENVO:01000660 Tephra is fragmental material produced by a volcanic eruption regardless of composition, fragment size or emplacement mechanism. tephra Tephra is fragmental material produced by a volcanic eruption regardless of composition, fragment size or emplacement mechanism. https://en.wikipedia.org/wiki/Tephra ENVO:01000661 Tuff is a type of rock made of volcanic ash ejected from a vent during a volcanic eruption. tuff Tuff is a type of rock made of volcanic ash ejected from a vent during a volcanic eruption. https://en.wikipedia.org/wiki/Tuff ENVO:01000662 Scoria is a highly vesicular, dark colored volcanic rock that may or may not contain crystals. cinder Scoria differs from pumice in having larger vesicles, thicker vesicle walls and being dark colored and denser. scoria Scoria is a highly vesicular, dark colored volcanic rock that may or may not contain crystals. https://en.wikipedia.org/wiki/Scoria ENVO:01000663 Pumice is a volcanic rock that consists of highly vesicular rough textured volcanic glass, which may or may not contain crystals. Scoria differs from pumice in having larger vesicles, thicker vesicle walls and being dark colored and denser. pumice Pumice is a volcanic rock that consists of highly vesicular rough textured volcanic glass, which may or may not contain crystals. https://en.wikipedia.org/wiki/Pumice ENVO:01000676 Contaminated air is air which has sufficient concentrations of environmental pollutants such that it may adversely affect a given ecosystem. contaminated air ENVO:01000681 A mineral material composed primarily of sodium chloride. This class is for material primarily composed of sodium chloride. For other pure chemical salts, consider a CHEBI class. Request new ENVO terms for environmental samples of other chemical salts. salt envoPolar sodium chloride salt ENVO:01000701 Volcanic ash is an environmental material which consists of fragments of pulverized rock, minerals, and volcanic glass, created during volcanic eruptions and measuring less than 2 millimetres in diameter. Volcanic ash is formed during explosive volcanic eruptions, phreatomagmatic eruptions and during transport in pyroclastic density currents. volcanic ash Volcanic ash is an environmental material which consists of fragments of pulverized rock, minerals, and volcanic glass, created during volcanic eruptions and measuring less than 2 millimetres in diameter. Volcanic ash is formed during explosive volcanic eruptions, phreatomagmatic eruptions and during transport in pyroclastic density currents. https://en.wikipedia.org/wiki/Volcanic_ash ENVO:01000722 Meltwater is the water released by the melting of snow or ice, including glacial ice, tabular icebergs and ice shelves over oceans. meltwater Meltwater is the water released by the melting of snow or ice, including glacial ice, tabular icebergs and ice shelves over oceans. https://en.wikipedia.org/wiki/Meltwater ENVO:01000751 A lithified mass of rock that lies under the loose softer material (regolith) at the surface of the Earth or other terrestrial planet. bedrock A lithified mass of rock that lies under the loose softer material (regolith) at the surface of the Earth or other terrestrial planet. https://en.wikipedia.org/wiki/Bedrock ENVO:01000770 A volume of carbon dioxide gas emitted by a carbon dioxide emission process. This is a working definition for #280. Which processes will ultimately be included in the axioms is still open. carbon dioxide emission ENVO:01000789 A portion of gas which is emitted by a fire or other exothermic reaction, is of increased temperature, and typically emits light in the visible range. flame A portion of gas which is emitted by a fire or other exothermic reaction, is of increased temperature, and typically emits light in the visible range. https://en.wikipedia.org/wiki/Flame ENVO:01000790 A flame which is produced by the combustion of hydrocarbon fuel. hydrocarbon flame ENVO:01000797 A material entity which is composed of one or more chemical entities and has neither independent shape nor volume but tends to expand indefinitely. This class is to be populated by inference. gas gaseous environmental material A material entity which is composed of one or more chemical entities and has neither independent shape nor volume but tends to expand indefinitely. http://www.merriam-webster.com/dictionary/gas ENVO:01000798 A material entity which is composed of a volume of unbound positive and negative particles in roughly equal numbers, conducts electricity, and possesses internal magnetic fields. An NTR for `quality of a plasma` has been posted on the PATO tracker: https://github.com/pato-ontology/pato/issues/88 plasma A material entity which is composed of a volume of unbound positive and negative particles in roughly equal numbers, conducts electricity, and possesses internal magnetic fields. http://www.merriam-webster.com/dictionary/plasma https://en.wikipedia.org/wiki/Plasma_%28physics%29 ENVO:01000814 An environmental material which is in a solid state. This is a defined class: its subclasses will not be asserted, but filled by inference. solid environmental material ENVO:01000815 An environmental material which is in a liquid state. envoPolar This is a defined class: most of its subclasses will not be asserted, but filled by inference. liquid environmental material ENVO:01000828 Air which has increased levels of water vapour. humid air ENVO:01000829 Air which has a partial pressure of water vapour equal or near equal to its equilibrium vapor pressure at a given temperature. water-vapour-saturated air wet air "Near equal" is meant to reflect that there will be fluctuations around the equilibrium point. water vapour saturated air ENVO:01000838 Smoke is a collection of airborne solid and liquid particulates and gases emitted when a material undergoes combustion or pyrolysis, together with the quantity of gas that is entrained or otherwise mixed into the mass smoke Smoke is a collection of airborne solid and liquid particulates and gases emitted when a material undergoes combustion or pyrolysis, together with the quantity of gas that is entrained or otherwise mixed into the mass https://en.wikipedia.org/wiki/Smoke ENVO:01000842 A fog which is intermixed with smoke or other combustion products and their derivatives. smog ENVO:01000844 A visible mass of cloud water droplets or ice crystals suspended in the air at or near the surface of an astronomical body. haar envoCryo Fog is more opaque than mist, reducing visibility to under one kilometre. This class refers only to fog formed by materials primarily composed of water. "Fog can be considered a type of low-lying cloud and is heavily influenced by nearby bodies of water, topography, and wind conditions. In turn, fog has affected many human activities, such as shipping, travel, and warfare." https://en.wikipedia.org/wiki/Fog fog A visible mass of cloud water droplets or ice crystals suspended in the air at or near the surface of an astronomical body. https://en.wikipedia.org/wiki/Fog ENVO:01000845 A solid material whose constituents, such as atoms, molecules or ions, are arranged in a highly ordered microscopic structure, forming a crystal lattice that extends in all directions. This class refers to a portion of crystal and not an individual crystal. crystal A solid material whose constituents, such as atoms, molecules or ions, are arranged in a highly ordered microscopic structure, forming a crystal lattice that extends in all directions. https://en.wikipedia.org/wiki/Crystal ENVO:01000846 A crystal which is primarily composed of water ice. ice crystal envoPolar Any one of a number of macroscopic, crystalline forms in which ice appears, including hexagonal columns, hexagonal platelets, dendritic crystals, ice needles, and combinations of these forms. The crystal lattice of ice is hexagonal in its symmetry under most atmospheric conditions. water ice crystal Any one of a number of macroscopic, crystalline forms in which ice appears, including hexagonal columns, hexagonal platelets, dendritic crystals, ice needles, and combinations of these forms. The crystal lattice of ice is hexagonal in its symmetry under most atmospheric conditions. ENVO:01000847 A type of water ice that forms on dead wood with the assistance of the fungus Exidiopsis effusa and takes the shape of fine, silky hair. Add quality like filamentous from PATO frost beard ice wool envoPolar hair ice A type of water ice that forms on dead wood with the assistance of the fungus Exidiopsis effusa and takes the shape of fine, silky hair. https://en.wikipedia.org/wiki/Hair_ice ENVO:01000850 A material which is primarily composed of a substance arranged as a lattice which can trap or contain other molecules. Not sure if this should be a subclass of crystal. If it is removed, remember to assert that it is a solid. clathrate compound material clathrate crystal material envoPolar This class is not to be confused with CHEBI's "clathrate". The latter refers to the pure substance, while this class refers to clathrates found in nature. "Traditionally, clathrate compounds are polymeric and completely envelop the guest molecule, but in modern usage clathrates also include host-guest complexes and inclusion compounds." https://en.wikipedia.org/wiki/Clathrate_compound clathrate material A material which is primarily composed of a substance arranged as a lattice which can trap or contain other molecules. https://en.wikipedia.org/wiki/Clathrate_compound ENVO:01000851 A clathrate material in which a large amount of methane is trapped within a crystal structure of water, forming a solid similar to ice. fire ice gas hydrate hydromethane methane hydrate methane ice natural gas hydrate envoPolar methane clathrate A clathrate material in which a large amount of methane is trapped within a crystal structure of water, forming a solid similar to ice. https://en.wikipedia.org/wiki/Methane_clathrate ENVO:01000853 Marl is a mass of calcium carbonate derived from mollusk shells and mixed with silt and clay. A request from the Agronomy Ontology in Issue #345. marl Marl is a mass of calcium carbonate derived from mollusk shells and mixed with silt and clay. http://corn.agronomy.wisc.edu/Management/pdfs/a3671.pdf ENVO:01000854 A marine coral reef biome which is located in a region with a tropical climate. wwfBiome tropical marine coral reef biome ENVO:01000856 A marginal sea biome which is located in a region with a temperate climate. A component of the WWF Temperate Shelf and seas ecoregions grouping wwfBiome temperate marginal sea biome ENVO:01000857 A mediterranean sea biome which is subject to temperate climate patterns. wwfBiome temperate mediterranean sea biome ENVO:01000858 A marine biome which contains communities adapted to living in an environment determined by an upwelling process. marine upwelling biome ENVO:01000859 A marine upwelling biome which is subject to tropical climate patterns. wwfBiome tropical marine upwelling biome ENVO:01000860 A marine upwelling biome which is located in a region subject to temperate climate patterns. wwfBiome temperate marine upwelling biome ENVO:01000872 Ballast water is water contained in the ballast tanks of sea-going vessels. This definition could be improved, as ballast water is often used in more general ways, beyond the water contained in a ballast tank at any given time. For example, water which has just been released from a ballast tank is often still refered to as ballast water. ballast water Ballast water is water contained in the ballast tanks of sea-going vessels. http://www.nature.com/news/four-routes-to-better-maritime-governance-1.21051?WT.mc_id=TWT_NatureNews https://en.wikipedia.org/wiki/Ballast_water_discharge_and_the_environment https://en.wikipedia.org/wiki/Sailing_ballast#Water_ballast ENVO:01000939 An open system in non-equilibrium with its environment that exhibits time translation symmetry breaking. space-time crystal While the usage of the term is still debated, the general idea is that time crystals (which have been made using ytterbium ions and defect-bearing diamonds) break temporal symmetry analogously to how mineral crystal break spatial symmetry. While spatial crystals are inhomogeneous in space (vs a gas, which is distributed evenly) due to the ordering of their atoms, the properties of atoms in a time crystal are inhomogeneous in the time dimension. time crystal An open system in non-equilibrium with its environment that exhibits time translation symmetry breaking. https://en.wikipedia.org/wiki/Time_crystal https://dx.doi.org/10.1038/543164a ENVO:01000940 Water which is partially contained within a fissure or a geological fracture. The axiomatisation should be more tuned to the site within the fissure. fracture water While containment is often enough to classify this subtype of water, it is expected that the water's composition is altered by contact with the solid material bounding the fissure's site. fissure water Water which is partially contained within a fissure or a geological fracture. https://github.com/EnvironmentOntology/envo/issues/466 ENVO:01000962 A sedimentary rock which is primarily composed of the fossilized, siliceous remains of diatoms mixed with varying amounts of other clays and minerals. kieselguhr kieselgur D.E. diatomaceous earth This material is easily crumbled into a fine white to off-white powder. The powder has a particle size ranging from less than 3 micrometres to more than 1 millimetre, but typically 10 to 200 micrometres. The diatoms in each deposit contain different amounts of silica, depending on the age of the deposit. The species of diatom may differ among deposits. The species of diatom is dependent upon the age and paleo-environment of the deposit. In turn, the shape of a diatom is determined by its species. The typical chemical composition of oven-dried diatomaceous earth is 80 to 90% silica, with 2 to 4% alumina (attributed mostly to clay minerals) and 0.5 to 2% iron oxide. diatomite A sedimentary rock which is primarily composed of the fossilized, siliceous remains of diatoms mixed with varying amounts of other clays and minerals. https://en.wikipedia.org/wiki/Diatomaceous_earth This material is easily crumbled into a fine white to off-white powder. The powder has a particle size ranging from less than 3 micrometres to more than 1 millimetre, but typically 10 to 200 micrometres. The diatoms in each deposit contain different amounts of silica, depending on the age of the deposit. The species of diatom may differ among deposits. The species of diatom is dependent upon the age and paleo-environment of the deposit. In turn, the shape of a diatom is determined by its species. The typical chemical composition of oven-dried diatomaceous earth is 80 to 90% silica, with 2 to 4% alumina (attributed mostly to clay minerals) and 0.5 to 2% iron oxide. https://en.wikipedia.org/wiki/Diatomaceous_earth#Geology_and_occurrence ENVO:01000964 Wastewater which is produced by industrial activity and which contains chemical contaminants other than those associated with urine and fecal matter. industrial wastewater ENVO:01001004 Underground water which is located in pore spaces found in rock or unconsolidated deposits such as soil, clay, or gravel. ground water The definition of aquifer is quite permissive, referencing any water bearing rock or unconsolidated material. groundwater Underground water which is located in pore spaces found in rock or unconsolidated deposits such as soil, clay, or gravel. https://en.wikipedia.org/wiki/Groundwater ENVO:01001018 Water which has a very high concentration of nutrients. The thresholds of eutrophy are fluid and often locally defined. hypereutrophic water Water which has a very high concentration of nutrients. https://github.com/EnvironmentOntology/envo/issues/528 ENVO:01001028 Sediment which has its porespace filled by water which has very low levels of sodium chloride and/or other salts. envoEmpo envoOmics We do not specify numeric thresholds for saline vs. non-saline here, as this is variable. Consider specifying this on the information and/or data layer for your purposes. If you require an ENVO class with a fixed threshold, please request one using our issue tracker. sediment permeated by freshwater ENVO:01001036 Sediment which has its porespace filled by water with increased levels of sodium chloride and other salts. envoEmpo envoOmics We do not specify numeric thresholds for saline vs. non-saline here, as this is variable. Consider specifying this on the information and/or data layer for your purposes. If you require an ENVO class with a fixed threshold, please request one using our issue tracker. sediment permeated by saline water ENVO:01001037 Water which contains a slightly increased concentration of dissolved salts, relative to their concentration in freshwater. EcoLexicon:saltwater SWEETRealm:SalineWater SWEETRealm:SaltWater https://en.wikipedia.org/wiki/Saline_water slightly salty water The United States Geological Survey classifies slightly saline water as having around 1,000 to 3,000 ppm (0.1–0.3%) of dissolved salts. slightly saline water ENVO:01001038 Water which contains a moderately increased concentration of dissolved salts, relative to their concentration in freshwater. EcoLexicon:saltwater SWEETRealm:SalineWater SWEETRealm:SaltWater https://en.wikipedia.org/wiki/Saline_water moderately salty water The United States Geological Survey classifies moderately saline water as having around 3,000 to 10,000 ppm (0.3–1%) of dissolved salts. moderately saline water ENVO:01001039 Water which contains a highly increased concentration of dissolved salts, relative to their concentration in freshwater. EcoLexicon:saltwater SWEETRealm:SalineWater SWEETRealm:SaltWater https://en.wikipedia.org/wiki/Saline_water highly salty water The United States Geological Survey classifies highly saline water as having around 10,000 to 35,000 ppm (1–3.5%) of dissolved salts. highly saline water ENVO:01001059 A cell culture which is composed of a microbial community of known composition. Mock community envoEmpo envoOmics Mock communities are typically used as positive controls in experiments. mock community culture Mock community http://press.igsb.anl.gov/earthmicrobiome/protocols-and-standards/emp-ontology-empo/ ENVO:01001060 A cell culture which is composed of a single population of bacterial or archaeal cells. Single strain envoEmpo envoOmics single strain cell culture Single strain http://press.igsb.anl.gov/earthmicrobiome/protocols-and-standards/emp-ontology-empo/ ENVO:01001063 Water which has an appreciable concentration of dissolved oxygen. ORCID:0000-0002-4366-3088 2010-03-21T06:05:53Z The threshold dissolved oxygen concentration past which water is considered oxic is variable. Typically, this is understood as the concentration at and beyond which organisms inhabiting that water can sustain aerobic metabolism and good health. For most systems, this is above 80% oxygen saturation. Input is welcome here https://github.com/EnvironmentOntology/envo/issues/536 oxic water Water which has an appreciable concentration of dissolved oxygen. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Hypoxia_(environmental) ENVO:01001064 Water which has low levels of dissolved oxygen. ORCID:0000-0002-4366-3088 2010-03-21T06:05:53Z As with oxic and anoxic water, the thresholds for hypoxia are variable. Typically, a hypoxic state is asserted when dissolved oxygen levels decrease to a level where they have detrimental effects on aerobic aquatic organisms, typically below 30% oxygen saturation. hypoxic water Water which has low levels of dissolved oxygen. ORCID:0000-0002-4366-3088 https://en.wikipedia.org/wiki/Hypoxia_(environmental) ENVO:01001069 A material which is composed primarily of one or more pure metals and which shows their properties. Far more axiomatisation can be done should the qualities of metals be added to PATO or a similar quality ontology. However, note that there are many exceptions to the typical qualities of the majority of metals. metal While this class allows for some degree of contamination by non-metal substances, the material represented should show at least some of the typical features of a pure metal: hardness (except for liquid metals), opacity, lustre, malleability, fusibility, ductile and good electrical and thermal conductivity. metallic material A material which is composed primarily of one or more pure metals and which shows their properties. https://en.wikipedia.org/wiki/Metal ENVO:01001088 An aerosol which has non-gaseous parts that are primarily composed of liquid droplets. SWEETRealm:Aerosol liquid aerosol envoAtmo aerosolised liquids An aerosol which has non-gaseous parts that are primarily composed of liquid droplets. https://en.wikipedia.org/wiki/Aerosol ENVO:01001089 An aerosol which has non-gaseous parts that are primarily composed of solid particles. SWEETRealm:Aerosol solid aerosol envoAtmo aerosolised solids An aerosol which has non-gaseous parts that are primarily composed of solid particles. https://en.wikipedia.org/wiki/Aerosol ENVO:01001103 An organic material which is primarily composed of dead particulate matter. detritus An organic material which is primarily composed of dead particulate matter. https://en.wikipedia.org/wiki/Detritus ENVO:01001113 Material which is primarily conposed of the vegetation present in tended pastures: mainly grasses, with an interspersion of legumes and other forbs. forage forage material Material which is primarily conposed of the vegetation present in tended pastures: mainly grasses, with an interspersion of legumes and other forbs. ENVO:01001116 Manure which has been collected directly or indirectly from dairy cattle, as from flushing of manure from concrete feed lanes, free stalls, and milking facilities. bovine dairy liquid manure Manure which has been collected directly or indirectly from dairy cattle, as from flushing of manure from concrete feed lanes, free stalls, and milking facilities. http://manuremanagement.ucdavis.edu/files/134369.pdf http://orcid.org/0000-0002-8844-9165 ENVO:01001117 Manure which is composed primarily of the feces of poultry. poultry manure Manure which is composed primarily of the feces of poultry. http://orcid.org/0000-0002-8844-9165 ENVO:01001118 Manure which has been subjected to heat treatment for solidification and/or sterilization purposes. heat-treated animal manure Manure which has been subjected to heat treatment for solidification and/or sterilization purposes. http://orcid.org/0000-0002-8844-9165 ENVO:01001119 Manure which has been subjected to a natural process of 'rotting' or decomposition of its organic matter content by microorganisms under controlled conditions. composted animal manure Manure which has been subjected to a natural process of 'rotting' or decomposition of its organic matter content by microorganisms under controlled conditions. http://orcid.org/0000-0002-8844-9165 ENVO:01001121 Organic material which is primarily composed of plant structures, living or dead. plant matter ENVO:01001125 An ice is an environmental material which is either frozen or which is maintained in a solid state by gravitational forces or pressure. Note that ice may be formed at very high temperatures, due to gravitational effects and/or pressure. ice ENVO:01001126 An astrogeological volatile which is composed primarily of chemical compounds with freezing points above an approximate threshold of 100 Kelvin. ice envoAstro This is a term native to the fields of planetary science and astrophysics. Water, ammonia, and methane are considered "ices" with freezing points of 273 K, 195 K, and 91 K, respectively. astrogeological ice An astrogeological volatile which is composed primarily of chemical compounds with freezing points above an approximate threshold of 100 Kelvin. https://en.wikipedia.org/wiki/Ice_giant ENVO:01001138 Ice which is primarily composed of carbon dioxide. dry ice envoAstro carbon dioxide ice Ice which is primarily composed of carbon dioxide. https://en.wikipedia.org/wiki/Ice ENVO:01001139 Ice which is primarily composed of methane. envoAstro methane ice Ice which is primarily composed of methane. https://en.wikipedia.org/wiki/Ice ENVO:01001140 Ice which is primarily composed of ammonia. envoAstro ammonia ice Ice which is primarily composed of ammonia. https://en.wikipedia.org/wiki/Ice ENVO:01001141 Ice which is primarily composed of carbon monoxide. envoAstro carbon monoxide ice Ice which is primarily composed of carbon monoxide. https://en.wikipedia.org/wiki/Ice ENVO:01001154 A material which is composed primarily of chemical elements and compounds with relatively low boiling points, equilibrium condensation temperatures below 1300 Kelvin, and which are part of the crust or atmosphere of a moon or planet. Add and axiomatise with moon and lunar crust volatile envoAstro Examples include nitrogen, water, carbon dioxide, ammonia, hydrogen, methane and sulfur dioxide. In astrogeology, these compounds, in their solid state, often comprise large proportions of the crusts of moons and dwarf planets. volatile astrogeological material A material which is composed primarily of chemical elements and compounds with relatively low boiling points, equilibrium condensation temperatures below 1300 Kelvin, and which are part of the crust or atmosphere of a moon or planet. https://en.wikipedia.org/wiki/Volatiles Examples include nitrogen, water, carbon dioxide, ammonia, hydrogen, methane and sulfur dioxide. In astrogeology, these compounds, in their solid state, often comprise large proportions of the crusts of moons and dwarf planets. https://en.wikipedia.org/wiki/Volatiles ENVO:01001155 An astrogeological volatile which is composed primarily of chemical compounds with boiling points around those of hydrogen and helium. gas envoAstro This is a term native to the fields of planetary science and astrophysics. Hydrogen has a boiling point of 20.271 Kelvin and a melting point of 13.99 Kelvin. Helium has a boiling point of 4.222 Kelvin and a melting point of 0.95 Kelvin. astrogeological gas An astrogeological volatile which is composed primarily of chemical compounds with boiling points around those of hydrogen and helium. https://en.wikipedia.org/wiki/Volatiles ENVO:01001156 A material which is composed primarily of chemical elements and compounds which have equilibrium condensation temperatures above approximately 1300 Kelvin and which are part of the crust or atmosphere of a moon or planet. Add and axiomatise with moon and lunar crust refractory material envoAstro The refractory group includes elements and compounds like metals and silicates (commonly termed rocks) which make up the bulk of the mass of the terrestrial planets and asteroids in the inner belt. refractory astrogeological material A material which is composed primarily of chemical elements and compounds which have equilibrium condensation temperatures above approximately 1300 Kelvin and which are part of the crust or atmosphere of a moon or planet. https://en.wikipedia.org/wiki/Refractory_(planetary_science) The refractory group includes elements and compounds like metals and silicates (commonly termed rocks) which make up the bulk of the mass of the terrestrial planets and asteroids in the inner belt. https://en.wikipedia.org/wiki/Refractory_(planetary_science) ENVO:01001185 Soil which has increased levels of molecules or ions capable of donating a hydron (proton or hydrogen ion) to other chemical entities, or, alternatively, capable of forming covalent bonds with other chemicals via the acceptance of an electron pair, resulting in a bulk pH measurement of less than 7. acidic soil Soil which has increased levels of molecules or ions capable of donating a hydron (proton or hydrogen ion) to other chemical entities, or, alternatively, capable of forming covalent bonds with other chemicals via the acceptance of an electron pair, resulting in a bulk pH measurement of less than 7. https://en.wikipedia.org/wiki/Acid ENVO:01001186 Volcanic ash which has increased levels of molecules or ions capable of donating a hydron (proton or hydrogen ion) to other chemical entities, or, alternatively, capable of forming covalent bonds with other chemicals via the acceptance of an electron pair, resulting in a bulk pH measurement of less than 7. acidic volcanic ash ENVO:01001189 This class will be axiomatised with "alga" once an approach to handle this term's ambiguous semantics has been agreed with PCO. An organic material which is primarily composed of living or dead algae, along with their exudates. algal material An organic material which is primarily composed of living or dead algae, along with their exudates. https://en.wikipedia.org/wiki/Algae ENVO:01001190 Sea ice which has a brown colouration, either due to 1) the presence of pigments which are or were contained in the members of ecological assemblages, such as algal communities, living or trapped within the ice or 2) due to the presence of trapped sediments. brownish colored sea ice brown sea ice Sea ice which has a brown colouration, either due to 1) the presence of pigments which are or were contained in the members of ecological assemblages, such as algal communities, living or trapped within the ice or 2) due to the presence of trapped sediments. http://dx.doi.org/10.1016/j.csr.2017.04.010 http://dx.doi.org/10.1038/nrmicro3522 http://dx.doi.org/10.1371/journal.pone.0122418 https://github.com/EnvironmentOntology/envo/issues/564 ENVO:01001192 The surface layer of a mass of sediment. surface of a sedimentary mass surface sediment sediment surface ENVO:01001202 Soil or sediment which has been eroded and influenced by flowing water and redeposited in a non-marine setting. alluvium Soil or sediment which has been eroded and influenced by flowing water and redeposited in a non-marine setting. https://en.wikipedia.org/wiki/Alluvium ENVO:01001203 Sediment which has been transported by flowing water and redeposited in a non-marine setting. alluvial sediment Sediment which has been transported by flowing water and redeposited in a non-marine setting. https://en.wikipedia.org/wiki/Alluvial_soil https://en.wikipedia.org/wiki/Alluvium ENVO:01001204 A rock which is formed as a result of the lithification of alluvium. alluvial deposit A rock which is formed as a result of the lithification of alluvium. https://en.wikipedia.org/wiki/Alluvium ENVO:01001230 A marginal sea biome which is located in a region with a tropical climate. A class which is complementary to the WWF Temperate Shelf and Seas ecoregions grouping tropical marginal sea biome ENVO:01001231 Organic material which is in a solid phase and contained in sedimentary rock. kerogen Organic material which is in a solid phase and contained in sedimentary rock. https://en.wikipedia.org/wiki/Kerogen ENVO:01001232 Kerogen which cotains alginite, amorphous organic matter, cyanobacteria, freshwater algae, and land plant resins, thus having a hydrogen to carbon ratio above 1.25, and oxygen to carbon ratio below 0.15, readily produces liquid hydrocarbons, has reduced concentrations of aromatic structures, and primarily derived from proteins and lipids. sapropelic kerogen Kerogen which cotains alginite, amorphous organic matter, cyanobacteria, freshwater algae, and land plant resins, thus having a hydrogen to carbon ratio above 1.25, and oxygen to carbon ratio below 0.15, readily produces liquid hydrocarbons, has reduced concentrations of aromatic structures, and primarily derived from proteins and lipids. https://en.wikipedia.org/wiki/Kerogen ENVO:01001233 Kerogen from which heavy hydrocarbons (such as oils) are derived following chemical break down. labile kerogen Kerogen from which heavy hydrocarbons (such as oils) are derived following chemical break down. https://en.wikipedia.org/wiki/Kerogen ENVO:01001234 Kerogen from which light hydrocarbons (such as hydrocarbon gases) are derived following chemical break down. recalcitrant kerogen Kerogen from which light hydrocarbons (such as hydrocarbon gases) are derived following chemical break down. https://en.wikipedia.org/wiki/Kerogen ENVO:01001235 Kerogen which is enriched in sulfur compounds, has a hydrogen to carbon ratio under 1.25, an oxygen to carbon ratio between 0.03 and 0.18, derives into mixtures of hydrocarbon gas and oil, and derives from marine organic materials (primarily lipids) which are formed in reducing environments. planktonic kerogen Kerogen which is enriched in sulfur compounds, has a hydrogen to carbon ratio under 1.25, an oxygen to carbon ratio between 0.03 and 0.18, derives into mixtures of hydrocarbon gas and oil, and derives from marine organic materials (primarily lipids) which are formed in reducing environments. https://en.wikipedia.org/wiki/Kerogen ENVO:01001236 Planktonic kerogen which has high concentrations of sulfur compounds. sulfrous kerogen Planktonic kerogen which has high concentrations of sulfur compounds. https://en.wikipedia.org/wiki/Kerogen ENVO:01001237 Kerogen which derives from land plants, resembles wood or coral in structure, has a hydrogen to carbon ratio under 1, an oxygen to carbon ratio between 0.03 to 0.3, and which primarily produces coal or hydrocarbon gas on degradation. humic kerogen Kerogen which derives from land plants, resembles wood or coral in structure, has a hydrogen to carbon ratio under 1, an oxygen to carbon ratio between 0.03 to 0.3, and which primarily produces coal or hydrocarbon gas on degradation. https://en.wikipedia.org/wiki/Kerogen ENVO:01001238 Kerogen which has a hydrogen to carbon ratio less than 0.5 and primarily composed of polycyclic aromatic hydrocarbons. residual kerogen Kerogen which has a hydrogen to carbon ratio less than 0.5 and primarily composed of polycyclic aromatic hydrocarbons. https://en.wikipedia.org/wiki/Kerogen ENVO:01001257 Saline water which is derived from sea water and used during the cultivation of crustaceans. saline shrimp pond water ENVO:01001258 A fog which is composed of liquid aerosols and gases derived from volcanic gas emissions (primarily sulfur oxides), formed when sulfur-bearing gases react with sunlight, oxygen, and moisture in an atmosphere. "Vog and smog are different. Vog is formed when sulfur oxides emitted by a volcano react with moisture to form an aerosol. The aerosol scatters light, thus making the vog visible. Smog is formed largely from the incomplete combustion of fuel, reacting with nitrogen oxides and ozone produced from carbon monoxide by reactions with sunlight. The result is also a visible aerosol." vog A fog which is composed of liquid aerosols and gases derived from volcanic gas emissions (primarily sulfur oxides), formed when sulfur-bearing gases react with sunlight, oxygen, and moisture in an atmosphere. https://en.wikipedia.org/wiki/Vog "Vog and smog are different. Vog is formed when sulfur oxides emitted by a volcano react with moisture to form an aerosol. The aerosol scatters light, thus making the vog visible. Smog is formed largely from the incomplete combustion of fuel, reacting with nitrogen oxides and ozone produced from carbon monoxide by reactions with sunlight. The result is also a visible aerosol." https://en.wikipedia.org/wiki/Vog ENVO:01001267 Water which accumulates on a solid surface during precipitation events and snow/ice melt. storm water "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." stormwater Water which accumulates on a solid surface during precipitation events and snow/ice melt. https://en.wikipedia.org/wiki/Stormwater "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." https://en.wikipedia.org/wiki/Stormwater ENVO:01001268 Stormwater which accumulates in an urban ecosystem. urban storm water "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." urban stormwater Stormwater which accumulates in an urban ecosystem. https://en.wikipedia.org/wiki/Stormwater "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." https://en.wikipedia.org/wiki/Stormwater ENVO:01001270 Stormwater which accumulates in a rural ecosystem. rural storm water "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." rural stormwater Stormwater which accumulates in a rural ecosystem. https://en.wikipedia.org/wiki/Stormwater "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." https://en.wikipedia.org/wiki/Stormwater ENVO:01001282 Dust which is composed primarily of slicon dioxide. silica dust ENVO:01001283 Dust which is primarily composed of aluminium particles. aluminium dust ENVO:01001284 Dust which is primarily composed of barium particles. barium dust ENVO:01001285 Dust which is primarily composed of hydrated magnesium silicate (talc) particles. talc dust ENVO:01001286 Dust which is primarily composed of slate particles. slate dust ENVO:01001288 Dust which is primarily composed of kaolinite particles. kaolinite dust kaolin dust ENVO:01001369 A shrubland biome which is densely vegetated by dwarf or short mangroves (and associates) that are generally less than 6 meters in height, is tidally influenced, is located in tropical or subtropical areas. CMECS:577 https://cmecscatalog.org/cmecs/classification/unit/577.html envoCmecs envoMarine This class aligns to the Coastal and Marine Ecological Classification Standard (CMECS). In ENVO, we may adapt the definition for consistency, but the semantics (meaning) of the term should be unaffected. Please consult the CMECS catalogue (https://cmecscatalog.org/) for authoritative and semantically unconstrained definitions. CMECS provides the following notes: "Commonly found on intertidal mud flats along the shores of estuaries. Tidal mangrove shrublands may include immature stands or stunted mature trees that indicate a harsh growing environment. Areas characterized by tall mangroves (> 6 meters) are placed in the Tidal Mangrove Forest Biotic Group. Where tidal amplitude is relatively low, the vegetation forms narrow bands along the coastal plains, and it rarely penetrates inland more than several kilometers along rivers. Where tidal amplitude is greater, mangroves extend further inland along river courses, forming extensive stands in the major river deltas. Also, mangrove cays may occur within the lagoon complex of barrier reefs. The list of biotic communities for this group is long: a few examples are provided below, and the complete list is available in Appendix F" tidal mangrove shrubland ENVO:01001391 An organic environmental material which is primarily composed of gill tissue. gill tissue material ENVO:01001392 Gill tissue material which is part of salt-water mussel in the family Mytilidae mussel gill tissue material ENVO:01001393 Mussel gill tissue material which is part of a member of the genus Bathymodiolus. Bathymodiolus gill tissue material ENVO:01001395 Biomass which is composed primarily of dead organisms, their parts, or their organic derivatives. dead biological matter dead biomass necromass ENVO:01001396 Clay which is part of an abyssal plain. abyssal clay ENVO:01001397 A soil which has high mineral content and which contain no calcareous material, have less than 10% weatherable minerals its surface layer, and have less than 35% base saturation throughout its volume. red clay soil The word "ultisol" is derived from "ultimate", because ultisols were seen as the ultimate product of continuous weathering of minerals in a humid, temperate climate without new soil formation via glaciation. ultisol A soil which has high mineral content and which contain no calcareous material, have less than 10% weatherable minerals its surface layer, and have less than 35% base saturation throughout its volume. https://en.wikipedia.org/wiki/Ultisol The word "ultisol" is derived from "ultimate", because ultisols were seen as the ultimate product of continuous weathering of minerals in a humid, temperate climate without new soil formation via glaciation. https://en.wikipedia.org/wiki/Ultisol ENVO:01001402 An aersolised mass of dust, smoke, or other dry particulates which scatters visible light thus obsscuring visibility through an atmosphere. envoAtmo haze An aersolised mass of dust, smoke, or other dry particulates which scatters visible light thus obsscuring visibility through an atmosphere. https://en.wikipedia.org/wiki/Haze ENVO:01001458 A visible mass of water droplets or ice crystals suspended in the air at or near a planetary surface, formed when humid air cools rapidly. This class refers only to mist formed by materials primarily composed of water. Mist is less dense than fog, and visibility is typically greater than one kilometre. mist A visible mass of water droplets or ice crystals suspended in the air at or near a planetary surface, formed when humid air cools rapidly. https://en.wikipedia.org/wiki/Mist ENVO:01001495 Dioxygen which is the solute in a solution with ocean water as its solvent. 2018-11-10T15:49:02Z dissolved oxygen oceanic oxygen oxygen envoEOVs envoMarine dioxygen dissolved in marine water oxygen This is the label that GOOS uses in its EOV specification sheet, found here: https://www.goosocean.org/components/com_oe/oe.php?task=download&id=35904&version=2.0&lang=1&format=1 ENVO:01001505 A tundra biome which exists at high altitudes and where vegetation - dominated by a few species of dwarf shrubs, a few grasses, sedges, lichens, and mosses - is stunted due to low temperatures and high winds. 2019-01-14T16:26:18Z SPIRE:Tundra http://sweetontology.net/realmCryo/AlpineTundra mountain tundra envoPolar The absence of trees in this biome is primarily due to high altitude rather than high latitude. On Earth, it lies roughly between the summer isotherm of 10 degrees Centigrade and the snow line. Primary productivity is low in this biome because of the extremes of climate. alpine tundra biome A tundra biome which exists at high altitudes and where vegetation - dominated by a few species of dwarf shrubs, a few grasses, sedges, lichens, and mosses - is stunted due to low temperatures and high winds. https://en.wikipedia.org/wiki/Alpine_tundra mountain tundra https://orcid.org/0000-0003-4808-4736 The absence of trees in this biome is primarily due to high altitude rather than high latitude. On Earth, it lies roughly between the summer isotherm of 10 degrees Centigrade and the snow line. Primary productivity is low in this biome because of the extremes of climate. https://orcid.org/0000-0003-4808-4736 ENVO:01001511 2019-01-14T18:55:42Z Water ice which is formed by the freezing of fresh water. freshwater ice ENVO:01001512 Sea ice which 1) has formed on the submerged surface (i.e. the base) of an existing mass of sea ice and 2) is composed of columnar crystals due to the downward growth of the crystals into the water. 2019-01-14T18:56:29Z black ice Congelation ice usually forms through the fusion/coalescence of platelets into solid ice. congelation sea ice Sea ice which 1) has formed on the submerged surface (i.e. the base) of an existing mass of sea ice and 2) is composed of columnar crystals due to the downward growth of the crystals into the water. https://en.wikipedia.org/wiki/Congelation_ice https://orcid.org/0000-0003-4808-4736 black ice Common in limnology, but frequently used in other contexts (e.g. on roads). ENVO:01001513 Water ice which has formed in a mass of permafrost. 2019-01-14T19:11:56Z permafrost congelation ice Water ice which has formed in a mass of permafrost. https://en.wikipedia.org/wiki/Congelation_ice https://orcid.org/0000-0003-4808-4736 ENVO:01001514 Freshwater ice which forms downward from the surface of a freshwater water body and is transparent due to a reduced number of air bubbles trapped in its mass. 2019-01-14T19:18:06Z black ice congelation ice in a fresh water body Freshwater ice which forms downward from the surface of a freshwater water body and is transparent due to a reduced number of air bubbles trapped in its mass. https://en.wikipedia.org/wiki/Congelation_ice ENVO:01001515 Freshwater ice which forms on a solid substrate through the freezing of freshwater. 2019-01-14T19:25:08Z freshwater congelation ice Freshwater ice which forms on a solid substrate through the freezing of freshwater. https://en.wikipedia.org/wiki/Congelation_ice ENVO:01001516 Freshwater congelation ice which has formed on a solid substrate in an ice cave. 2019-01-14T19:25:08Z 2019-01-14T19:27:40Z ice cave congelation ice Freshwater congelation ice which has formed on a solid substrate in an ice cave. https://en.wikipedia.org/wiki/Congelation_ice https://www.researchgate.net/publication/257694900_A_process-based_classification_of_alpine_ice_caves ENVO:01001523 Small, needle-like (spicules), plate-like, or discoid crystals derived from nearly pure fresh water, suspended in a water body. Needs to have axioms added pertaining to the semantics of colloids and suspensions once they have been resolved see: https://github.com/pato-ontology/pato/issues/91#issuecomment-290711238 Currently the new ice classes are not specific to sea water as they may form in non marine systems, but it would be good to confirm this especially for frazil ice. 2019-01-14T21:09:21Z frazil crystals needle ice envoPolar Typically 3 to 4 millimeters in diameter. These may form in both marine water and fresh water. They represent the first stages of sea ice growth; they merge under calm conditions to form thin sheets of ice on the surface (frazil ice), and consist of nearly pure fresh water. In fresh water, they form in supercooled water that is too turbulent to permit coagulation into sheet ice. This is most common in swiftly flowing streams. They may accumulate as anchor ice on submerged objects obstructing the water flow. frazil Small, needle-like (spicules), plate-like, or discoid crystals derived from nearly pure fresh water, suspended in a water body. https://nsidc.org/cryosphere/glossary/term/frazil Typically 3 to 4 millimeters in diameter. These may form in both marine water and fresh water. They represent the first stages of sea ice growth; they merge under calm conditions to form thin sheets of ice on the surface (frazil ice), and consist of nearly pure fresh water. In fresh water, they form in supercooled water that is too turbulent to permit coagulation into sheet ice. This is most common in swiftly flowing streams. They may accumulate as anchor ice on submerged objects obstructing the water flow. https://orcid.org/0000-0003-4808-4736 ENVO:01001525 Frozen soil which is firmly cemented by water ice, is subject to brittle failure, and exhibits practically no consolidation under load. 2019-01-14T21:23:25Z hard-frozen soil Frozen soil which is firmly cemented by water ice, is subject to brittle failure, and exhibits practically no consolidation under load. https://orcid.org/0000-0003-4808-4736 ENVO:01001526 Soil which is below the freezing point of water. 2019-01-14T21:26:59Z frozen soil ENVO:01001527 Frozen soil which is cemented by water ice but has viscous properties due to its high, unfrozen water content and therefore will compress and deform under load. 2019-01-14T21:23:25Z 2019-01-14T21:28:28Z plastic-frozen soil Frozen soil which is cemented by water ice but has viscous properties due to its high, unfrozen water content and therefore will compress and deform under load. https://orcid.org/0000-0003-4808-4736 ENVO:01001528 Frozen soil which has very low total water content and is not cemented by ice; its compressibility is the same as that of unfrozen soils having the same composition, total water content and density. 2019-01-14T21:33:56Z dry-frozen soil friable-frozen soil Frozen soil which has very low total water content and is not cemented by ice; its compressibility is the same as that of unfrozen soils having the same composition, total water content and density. https://orcid.org/0000-0003-4808-4736 ENVO:01001557 Ice which has formed as the result of freezing of water which was part of a water body. 2019-02-27T20:07:15Z In the United States, NOAA considers ice formed from the freezing of the waters of the Great Lakes as being the same as sea ice. This class attempts to provide a distinction for clarity. water-body-derived ice Ice which has formed as the result of freezing of water which was part of a water body. https://orcid.org/0000-0003-4808-4736 In the United States, NOAA considers ice formed from the freezing of the waters of the Great Lakes as being the same as sea ice. This class attempts to provide a distinction for clarity. https://orcid.org/0000-0003-4808-4736 ENVO:01001560 An environmental material which is primarily composed of a dispersed phase of insoluable particles, approximately between 1 nanometer and 1 micrometer in maximum dimension, distributed throughout a material acting as a medium of suspension. 2019-03-02T12:39:26Z colloid Wikipedia lists several forms of colloidal suspension such as colloidal aerosols, colloidal emulsions, colloidal foams, colloidal dispersions, or hydrosols. colloidal suspension An environmental material which is primarily composed of a dispersed phase of insoluable particles, approximately between 1 nanometer and 1 micrometer in maximum dimension, distributed throughout a material acting as a medium of suspension. https://en.wikipedia.org/wiki/Colloid ENVO:01001561 An environmental material which is solid, jelly-like, and exhibits no flow when in steady state material and which contains liquid dispersed in and held in place by cross-linked structures of a solid medium. 2019-03-02T12:48:05Z gel An environmental material which is solid, jelly-like, and exhibits no flow when in steady state material and which contains liquid dispersed in and held in place by cross-linked structures of a solid medium. https://en.wikipedia.org/wiki/Gel ENVO:01001562 A gel which is primarily composed of a network of polymer chains that are hydrophilic, sometimes found as a colloidal gel in which water is the dispersion medium. 2019-03-02T12:54:02Z hydrogel A gel which is primarily composed of a network of polymer chains that are hydrophilic, sometimes found as a colloidal gel in which water is the dispersion medium. https://en.wikipedia.org/wiki/Gel#Hydrogels ENVO:01001563 Particulate environmental material which 1) is primarily composed of a fine, granular material such as sand, silt, or clay suspended in and saturated by water and 2) readily liquefies when weight is applied, losing strength and permitting objects to sink until their weight and buoyancy offset the weight of the displaced quicksand. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. 2019-03-02T13:00:27Z quicksand Particulate environmental material which 1) is primarily composed of a fine, granular material such as sand, silt, or clay suspended in and saturated by water and 2) readily liquefies when weight is applied, losing strength and permitting objects to sink until their weight and buoyancy offset the weight of the displaced quicksand. https://en.wikipedia.org/wiki/Quicksand ENVO:01001608 A fuel oil which 1) is derived from petroleum oil, 2) has a strong odor, 3) produces large quantities of soot relative to other fuel oils, 4) is less refined than fuel oils such as paraffin. 2019-03-21T16:13:05Z kerosene kerosine kerosine oil liquid kerosene For speakers of British English, kerosene is often referred to as paraffin. kerosene oil A fuel oil which 1) is derived from petroleum oil, 2) has a strong odor, 3) produces large quantities of soot relative to other fuel oils, 4) is less refined than fuel oils such as paraffin. https://en.wikipedia.org/wiki/Kerosene https://www.nationwidefuels.co.uk/difference-kerosene-paraffin/ https://www.differencebetween.com/difference-between-paraffin-and-kerosene/ ENVO:01001614 Permafrost which contains inclusions of water-based ice. 2019-04-09T13:45:40Z ice-bearing permafrost ENVO:01001616 Soil which is directly exposed to the atmosphere - with no intervening layer of plant life or other cover - and thus the effects of weathering and erosion. 2019-04-15T10:15:14Z bare soil ENVO:01001638 Soil in which segregated ice will form (causing frost heave) under the required conditions of moisture supply and temperature. The label would apply to all soils in which frost can form, however, the definition of this class suggests that ice segregation is a key property that differentiates this type of soil from others. 2019-05-30T19:07:20Z frost-susceptible soil Soil in which segregated ice will form (causing frost heave) under the required conditions of moisture supply and temperature. The authoritative definition can be found in the USPA Glossary. Note that the original definition references "earth materials" rather than "soil". ENVO:01001644 2019-06-02T07:35:09Z Carbonate which is formed as the result of some biological process. material primarily composed of biogenic carbonates ENVO:01001646 A solid material which does not have a regularly organised internal structure. 2019-06-02T11:07:47Z amorphous solid ENVO:01001647 A colloidal suspension which is dispersed through a part of a hydrosphere. 2019-06-02T11:11:54Z colloid suspended in a hydrosphere ENVO:01001648 Colloidal sediment which is suspended in a part of the hydrosphere. 2019-06-02T11:19:48Z suspended colloidal sediment ENVO:01001649 An environmental material which is denser than bromoform. Axiomatising this with relational density qualities pinned to bromoform would be the next step. 2019-06-02T11:25:56Z heavy fraction material An environmental material which is denser than bromoform. ENVO:01001650 An environmental material which is less dense than bromoform. Axiomatising this with relational density qualities pinned to bromoform would be the next step. 2019-06-02T11:33:10Z light fraction material An environmental material which is less dense than bromoform. ENVO:01001651 Waterborne particulate matter which is part of a hydrosphere. 2019-06-02T11:43:36Z particulate matter in a hydrosphere ENVO:01001652 An aerosol that is suspended in an atmosphere. 2019-06-03T12:24:09Z atmospheric aerosol ENVO:01001820 2019-11-05T13:09:22Z cultured organic material ENVO:01001821 Sediment through which hydrothermally modified fluids flow, altering its properties through interaction with their own. 2019-11-05T17:28:10Z hydrothermally-influenced sediment ENVO:01001830 A biome which is subject to tropical climatic conditions. 2019-11-06T15:56:17Z tropical biome ENVO:01001831 A biome which is subject to temperate climatic conditions. 2019-11-06T15:57:04Z temperate biome ENVO:01001832 A biome which is subject to subtropical climatic conditions. 2019-11-06T15:57:36Z subtropical biome ENVO:01001833 A biome which is subject to mediterranean climatic conditions. 2019-11-06T15:58:10Z mediterranean biome ENVO:01001834 A biome which is subject to subpolar climatic conditions. 2019-11-06T15:58:56Z subpolar biome ENVO:01001835 A biome which is subject to alpine altitudinal conditions. 2019-11-06T15:59:35Z alpine biome ENVO:01001836 A biome which is subject to montane altitudinal conditions. 2019-11-06T16:00:33Z montane biome ENVO:01001837 A biome which is subject to subapline altitudinal conditions. 2019-11-06T16:01:49Z subalpine biome ENVO:01001838 A biome which is subject to arid environmental conditions. 2019-11-06T16:06:47Z arid biome ENVO:01001841 An andosol which derives its silica content from glass and tephra ejected during a volcanic eruption. 2019-11-08T16:48:01Z volcanic soil An andosol which derives its silica content from glass and tephra ejected during a volcanic eruption. ENVO:01001845 Frost which is composed of interlocking ice crystals formed by vapour transfer (sublimation followed by deposition) of water vapour on some surface. 2020-02-12T20:54:38Z hoar frost white frost hoar Frost which is composed of interlocking ice crystals formed by vapour transfer (sublimation followed by deposition) of water vapour on some surface. ENVO:01001846 Hoar which is usually cup-shaped and facetted and which forms within dry, low-density snow beneath the snow surface. 2020-02-12T20:58:41Z Depth hoar is associated with very fast crystal growth under large temperature gradients. Sometimes a layer of depth hoar forms just above, and may assist in identifying the summer surface. The low density and low strength of depth hoar can make it difficult to retrieve unbroken core sections during coring, and can complicate estimates of accumulation by microwave remote sensing. Layers of depth hoar also increase the likelihood of avalanching. This is one way in which firn formation may begin. Depth hoar is similar in physical origin to crevasse hoar. depth hoar Hoar which is usually cup-shaped and facetted and which forms within dry, low-density snow beneath the snow surface. ENVO:01001847 2020-02-12T21:03:38Z hoarfrost ENVO:01001848 Water ice which 1) has a white or milky and opaque appearance, 2) has a granular texture, and 3) is formed as a result of the deposition and rapid freezing of supercooled water drops as they make contact with an exposed object. The previously use definition was: Frost which is 1) composed primarily of granular ice tufts, 2) formed on the windward sides of exposed objects through contact with supercooled fog or cloud, and 3) built out directly against the wind. 2020-02-12T21:03:46Z 2020-11-18T19:59:42.028Z envoCryo envoPolar Rime is denser and harder than hoarfrost, but lighter, softer, and less transparent than glaze. Rime is composed essentially of discrete ice granules and has densities as low as 0.2-0.3 g cm-3. Glaze is generally continuous but with some air pockets and has much higher densities. Factors that favor rime formation are small drop size, slow accretion, a high degree of supercooling, and rapid dissipation of latent heat of fusion. The opposite effects favor glaze formation. Both rime and glaze occur when supercooled water drops strike an object at a temperature below freezing. Such formation on terrestrial objects constitutes an ice storm; on aircraft, it is called aircraft icing (where rime is known as rime ice). Either rime or glaze may form on snow crystals, droxtals, or other ice particles in the atmosphere. When such a deposit is wholly or chiefly of rime, snow pellets result; when most or all of the deposit is glaze, ordinary hail or ice pellets result. The alternating clear and opaque layers of some hailstones represent glaze and rime, deposited under varying conditions around the growing hailstone. rime Water ice which 1) has a white or milky and opaque appearance, 2) has a granular texture, and 3) is formed as a result of the deposition and rapid freezing of supercooled water drops as they make contact with an exposed object. Rime is denser and harder than hoarfrost, but lighter, softer, and less transparent than glaze. Rime is composed essentially of discrete ice granules and has densities as low as 0.2-0.3 g cm-3. Glaze is generally continuous but with some air pockets and has much higher densities. Factors that favor rime formation are small drop size, slow accretion, a high degree of supercooling, and rapid dissipation of latent heat of fusion. The opposite effects favor glaze formation. Both rime and glaze occur when supercooled water drops strike an object at a temperature below freezing. Such formation on terrestrial objects constitutes an ice storm; on aircraft, it is called aircraft icing (where rime is known as rime ice). Either rime or glaze may form on snow crystals, droxtals, or other ice particles in the atmosphere. When such a deposit is wholly or chiefly of rime, snow pellets result; when most or all of the deposit is glaze, ordinary hail or ice pellets result. The alternating clear and opaque layers of some hailstones represent glaze and rime, deposited under varying conditions around the growing hailstone. ENVO:01001849 2020-02-12T21:04:27Z glaze ENVO:01001850 An environmental material which is primarily composed of minute ice crystals forming a fuzzy layer over a cold surface by direct deposition of water vapor. 2020-02-12T21:05:54Z In British usage, a day on which the minimum temperature at the level of the ground or on the tops of low, close-growing vegetation falls to -0.9C (30.4F) or below (also called a "day with ground frost"). In more general usage, "frost" can refer to the condition that exists when the temperature of the Earth's surface and Earthbound objects fall below the melting point of water (0 degrees Celsius or 32 degrees Fahrenheit). Depending upon the actual values of ambient-air temperature, dewpoint, and the temperature attained by surface objects, frost may occur in a variety of forms. These include a general freeze, hoarfrost (or white frost), and dry freeze (or black frost). If a frost period is sufficiently severe to end the growing season (or delay its beginning), it is commonly referred to as a killing frost. frost An environmental material which is primarily composed of minute ice crystals forming a fuzzy layer over a cold surface by direct deposition of water vapor. ENVO:01001869 A liquid environmental material which is composed primarily of water ammended with thickening agents and proppants. 2020-06-02T17:50:36Z fracking water fracking liquid A liquid environmental material which is composed primarily of water ammended with thickening agents and proppants. ENVO:01001876 Snow which is composed of heavily rimed particles typically 2 to 5 millimeters in diameter (0.1 to 0.2 inch). Subclass by shape into conical, hexagonal, and lump (irregular) graupel. Mark Parsons notes that the formational processes may be a source of useful differentia to distinguish graupel from other snow types. 2020-07-22T19:10:46Z snow pellets Often indistinguishable from very small soft hail except for the size convention that hail must have a diameter greater than 5 mm. Sometimes distinguished by shape into conical, hexagonal, and lump (irregular) graupel. graupel Snow which is composed of heavily rimed particles typically 2 to 5 millimeters in diameter (0.1 to 0.2 inch). ENVO:01001882 Hoar which a) forms on surfaces, b) occurs when the temperature of the surface is colder than the air above and colder than the frost point of that air. 2020-09-09T19:10:18Z When buried by snowfall, surface hoar may be considered depth hoar. The crystals formed by surface hoar are usually leaf-, fern- or plate-shaped and facetted. Two types of surface hoar are the fernlike ice crystals deposited directly on a snow surface and the hoarfrost that has grown primarily in two dimensions, as on a window or other smooth surface. surface hoar Hoar which a) forms on surfaces, b) occurs when the temperature of the surface is colder than the air above and colder than the frost point of that air. ENVO:01001883 A water ice crystal which is a part of a deposit of hoarfrost and which only grows by desublimation. 2020-09-09T19:31:29Z white frost crystal hoar frost crystal hoar crystal A water ice crystal which is a part of a deposit of hoarfrost and which only grows by desublimation. Nesting material is an animal habitation consisting of matierals used to cushion, insulate and protect the young of the organism. The adult will use the material to form a protective structure to house and raise their young. Nests are built primarily by birds, but also by mammals, fish, insects and reptiles. ENVO ENVO:02000004 nesting material ENVO:02000004 Nesting material is an animal habitation consisting of matierals used to cushion, insulate and protect the young of the organism. The adult will use the material to form a protective structure to house and raise their young. Nests are built primarily by birds, but also by mammals, fish, insects and reptiles. https://en.wikipedia.org/wiki/Nest ENVO:02000008 A cell culture is a growth of cells in vitro in an artificial medium for experimental research. https://en.wikipedia.org/wiki/Cell_culture cell culture A cell culture is a growth of cells in vitro in an artificial medium for experimental research. URL:http://stemcells.nih.gov/StemCells/Templates/StemCellContentPage.aspx?NRMODE=Published&NRNODEGUID=%7b3C35BAB6-0FE6-4C4E-95F2-2CB61B58D96D%7d&NRORIGINALURL=%2finfo%2fglossary%2easp&NRCACHEHINT=NoModifyGuest#cellculture ENVO:02000019 An organic material which is primarily composed of some natural bodily fluid or secretion such as blood, semen, saliva, blood plasma, intracellular and interstitial fluids. https://en.wikipedia.org/wiki/Bodily_fluid ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. bodily fluid material An organic material which is primarily composed of some natural bodily fluid or secretion such as blood, semen, saliva, blood plasma, intracellular and interstitial fluids. URL:http://medical-dictionary.thefreedictionary.com/bodily+fluid https://en.wikipedia.org/wiki/Body_fluid ENVO:02000020 A bodily fluid material which is composed primarily of blood, a bodily fluid composed of blood plasma and blood cells suspended within the plasma that circulates around the organism's body. Blood performs may important functions including the supplying of oxygen and nutrients, removal of waste, circulation of white blood cells, detection of antibodes, coagulation, transportation of antibodies and the regulation of pH and body temperature. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. blood material A bodily fluid material which is composed primarily of blood, a bodily fluid composed of blood plasma and blood cells suspended within the plasma that circulates around the organism's body. Blood performs may important functions including the supplying of oxygen and nutrients, removal of waste, circulation of white blood cells, detection of antibodes, coagulation, transportation of antibodies and the regulation of pH and body temperature. https://en.wikipedia.org/wiki/Blood https://en.wikipedia.org/wiki/Body_fluid ENVO:02000021 A bodily fluid material which is composed primarily of amniotic fluid, a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. amniotic fluid material A bodily fluid material which is composed primarily of amniotic fluid, a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. URL:http://en.wikipedia.org/wiki/Amniotic_fluid ENVO:02000022 A bodily fluid material which is composed primarily of excreta, bodily fluids consisting of matter which contains the waste products of biological processes, including urine or feces, discharged from an organism's body. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. excreta material A bodily fluid material which is composed primarily of excreta, bodily fluids consisting of matter which contains the waste products of biological processes, including urine or feces, discharged from an organism's body. URL:http://medical-dictionary.thefreedictionary.com/excreta ENVO:02000023 A bodily fluid material which is composed primarily of bile, a bodily fluid consisting of a bitter, yellow or green alkaline fluid secreted by hepatocytes from the liver of most vertebrates. In many species, bile is stored in the gallbladder between meals and upon eating is discharged into the duodenum where the bile aids the process of digestion of lipids. gall ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. bile material A bodily fluid material which is composed primarily of bile, a bodily fluid consisting of a bitter, yellow or green alkaline fluid secreted by hepatocytes from the liver of most vertebrates. In many species, bile is stored in the gallbladder between meals and upon eating is discharged into the duodenum where the bile aids the process of digestion of lipids. https://en.wikipedia.org/wiki/Bile ENVO:02000024 A bodily fluid material which is composed primarily of aqueous humour, a bodily fluid consisting of a thick watery substance that fills the space between the lens and the cornea. https://en.wikipedia.org/wiki/Aqueous_humour ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. aqueous humour material A bodily fluid material which is composed primarily of aqueous humour, a bodily fluid consisting of a thick watery substance that fills the space between the lens and the cornea. https://en.wikipedia.org/wiki/Aqueous_humour ENVO:02000025 An excreta material which is composed primarily of sweat, an excreta consisting primarily of water as well as a smaller amount of sodium chloride that is excreted by the sweat glands in the skin of mammals. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. sweat material An excreta material which is composed primarily of sweat, an excreta consisting primarily of water as well as a smaller amount of sodium chloride that is excreted by the sweat glands in the skin of mammals. http://en.wikipedia.org/wiki/Sweat ENVO:02000026 A bodily fluid material which is composed primarily of chyme, a bodily fluid consisting of a liquid substance found in the stomach before passing through the pyloric valve and entering the duodenum. It results from the mechanical and chemical breakdown of a bolus and consists of partially digested food, water, hydrochloric acid, and various digestive enzymes. chymus ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. chyme material A bodily fluid material which is composed primarily of chyme, a bodily fluid consisting of a liquid substance found in the stomach before passing through the pyloric valve and entering the duodenum. It results from the mechanical and chemical breakdown of a bolus and consists of partially digested food, water, hydrochloric acid, and various digestive enzymes. https://en.wikipedia.org/wiki/Chyme ENVO:02000027 A bodily fluid material which is composed primarily of blood plasma, a bodily fluid that comprises the liquid component of blood, in which the blood cells are suspended. It makes up about 55% of total blood volume. https://en.wikipedia.org/wiki/Blood_plasma ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. blood plasma material A bodily fluid material which is composed primarily of blood plasma, a bodily fluid that comprises the liquid component of blood, in which the blood cells are suspended. It makes up about 55% of total blood volume. https://en.wikipedia.org/wiki/Blood_plasma ENVO:02000028 A bodily fluid material which is composed primarily of ear wax, a bodily fluid consisting of a yellowish, waxy substance secreted in the ear canal of humans and many other mammals. It plays an important role in the human ear canal, assisting in cleaning and lubrication, and also provides some protection from bacteria, fungi, and insects. https://en.wikipedia.org/wiki/Ear_wax cerumen material ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. ear wax material A bodily fluid material which is composed primarily of ear wax, a bodily fluid consisting of a yellowish, waxy substance secreted in the ear canal of humans and many other mammals. It plays an important role in the human ear canal, assisting in cleaning and lubrication, and also provides some protection from bacteria, fungi, and insects. https://en.wikipedia.org/wiki/Cerumen ENVO:02000029 A bodily fluid material which is composed primarily of cerebrospinal fluid, a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. CSF is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. https://en.wikipedia.org/wiki/Cerebrospinal_fluid CSF material Liquor cerebrospinalis ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. cerebrospinal fluid material A bodily fluid material which is composed primarily of cerebrospinal fluid, a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. CSF is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. https://en.wikipedia.org/wiki/Cerebrospinal_fluid ENVO:02000030 A bodily fluid material which is composed primarily of chyle, a bodily fluid consisting of a milky fluid consisting of lymph and emulsified fats; formed in the small intestine during digestion of ingested fats. https://en.wikipedia.org/wiki/Chyle ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. chyle material A bodily fluid material which is composed primarily of chyle, a bodily fluid consisting of a milky fluid consisting of lymph and emulsified fats; formed in the small intestine during digestion of ingested fats. URL:http://wordnet.princeton.edu/perl/webwn?s=chyle https://en.wikipedia.org/wiki/Chyle ENVO:02000031 A bodily fluid material which is composed primarily of breast milk, is a bodily fluid produced that is secreted from two milk-secreting glandular organs on a female's chest. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. breast milk material A bodily fluid material which is composed primarily of breast milk, is a bodily fluid produced that is secreted from two milk-secreting glandular organs on a female's chest. URL:http://www.fcs.uga.edu/ext/bbb/info/glossary.htm https://en.wikipedia.org/wiki/Breast_milk ENVO:02000032 A bodily fluid material which is composed primarily of vitreous humor, a bodily fluid consisting of a clear gel that fills the space between the lens and the retina of the eyeball of humans and other vertebrates. vitreous humour material ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. vitreous humor material A bodily fluid material which is composed primarily of vitreous humor, a bodily fluid consisting of a clear gel that fills the space between the lens and the retina of the eyeball of humans and other vertebrates. https://en.wikipedia.org/wiki/Vitreous_humour ENVO:02000033 A bodily fluid material which is composed primarily of a pleural effusion, a bodily fluid that is produced in excess and accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs. Excessive amounts of such fluid can impair breathing by limiting the expansion of the lungs during inhalation. https://en.wikipedia.org/wiki/Pleural_effusion pleural effusion material A bodily fluid material which is composed primarily of a pleural effusion, a bodily fluid that is produced in excess and accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs. Excessive amounts of such fluid can impair breathing by limiting the expansion of the lungs during inhalation. https://en.wikipedia.org/wiki/Pleural_fluid ENVO:02000034 A bodily fluid material which is composed primarily of a volume of tears, a bodily fluid consisting of a drop of the clear salty liquid secreted by glands (lacrimal glands) in the eyes. Tears wet the membrane covering the eye and help rid the eye of irritating substances. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. tear material A bodily fluid material which is composed primarily of a volume of tears, a bodily fluid consisting of a drop of the clear salty liquid secreted by glands (lacrimal glands) in the eyes. Tears wet the membrane covering the eye and help rid the eye of irritating substances. URL:http://www.thefreedictionary.com/tear ENVO:02000035 A bodily fluid material which is composed primarily of an oronasal secretion, a bodily fluid secreted from the body via the mouth or nose. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. oronasal secretion material A bodily fluid material which is composed primarily of an oronasal secretion, a bodily fluid secreted from the body via the mouth or nose. Gemina:ls ENVO:02000036 A bodily fluid material which is composed primarily of saliva, a slightly alkaline secretion of water, mucin, protein, salts, and often a starch-splitting enzyme (as ptyalin) that is secreted into the mouth by salivary glands, lubricates ingested food, and often begins the breakdown of starches. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. saliva material A bodily fluid material which is composed primarily of saliva, a slightly alkaline secretion of water, mucin, protein, salts, and often a starch-splitting enzyme (as ptyalin) that is secreted into the mouth by salivary glands, lubricates ingested food, and often begins the breakdown of starches. URL:http://medical.merriam-webster.com/medical/saliva ENVO:02000037 A bodily fluid material which is composed primarily of sebum, an oily bodily fluid secreted from the sebaceous glads that is made of fat (lipids) and the debris of dead fat-producing cells. In the glands, sebum is produced within specialized cells and is released as these cells burst. Sebum acts to protect and waterproof hair and skin, and keep them from becoming dry, brittle and cracked. It can also inhibit the growth of microorganisms on skin. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. sebum material A bodily fluid material which is composed primarily of sebum, an oily bodily fluid secreted from the sebaceous glads that is made of fat (lipids) and the debris of dead fat-producing cells. In the glands, sebum is produced within specialized cells and is released as these cells burst. Sebum acts to protect and waterproof hair and skin, and keep them from becoming dry, brittle and cracked. It can also inhibit the growth of microorganisms on skin. https://en.wikipedia.org/wiki/Sebaceous_gland ENVO:02000038 A bodily fluid material which is composed primarily of pus, a bodily fluid consisting of a whitish-yellow or yellow substance produced during inflammatory responses of the body that can be found in regions of pyogenic bacterial infections. Pus is produced from the dead and living cells which travel into the intercellular spaces around the affected cells. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. pus material A bodily fluid material which is composed primarily of pus, a bodily fluid consisting of a whitish-yellow or yellow substance produced during inflammatory responses of the body that can be found in regions of pyogenic bacterial infections. Pus is produced from the dead and living cells which travel into the intercellular spaces around the affected cells. https://en.wikipedia.org/wiki/Pus ENVO:02000039 A bodily fluid material which is composed primarily of synovial fluid, a bodily fluid secreted by the synovial membrane into the joint cavity to form a thin layer at the surface of cartilage. https://en.wikipedia.org/wiki/Synovial_fluid ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. synovial fluid material A bodily fluid material which is composed primarily of synovial fluid, a bodily fluid secreted by the synovial membrane into the joint cavity to form a thin layer at the surface of cartilage. https://en.wikipedia.org/wiki/Synovial_fluid ENVO:02000040 A bodily fluid material which is composed primarily of mucus, a bodily fluid consisting of a slippery secretion of the lining of the mucous membranes in the body. It is a viscous colloid containing antiseptic enzymes (such as lysozyme) and immunoglobulins. Mucus is produced by goblet cells in the mucous membranes that cover the surfaces of the membranes. It is made up of mucins and inorganic salts suspended in water. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. mucus material A bodily fluid material which is composed primarily of mucus, a bodily fluid consisting of a slippery secretion of the lining of the mucous membranes in the body. It is a viscous colloid containing antiseptic enzymes (such as lysozyme) and immunoglobulins. Mucus is produced by goblet cells in the mucous membranes that cover the surfaces of the membranes. It is made up of mucins and inorganic salts suspended in water. https://en.wikipedia.org/wiki/Mucus ENVO:02000041 A bodily fluid material which is composed primarily of lymph, a bodily fluid consisting of a usually clear coagulable fluid that passes from intercellular spaces of body tissue into the lymphatic vessels, is discharged into the blood by way of the thoracic duct and right lymphatic duct, and resembles blood plasma in containing white blood cells and especially lymphocytes but normally few red blood cells and no platelets. ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. lymph material A bodily fluid material which is composed primarily of lymph, a bodily fluid consisting of a usually clear coagulable fluid that passes from intercellular spaces of body tissue into the lymphatic vessels, is discharged into the blood by way of the thoracic duct and right lymphatic duct, and resembles blood plasma in containing white blood cells and especially lymphocytes but normally few red blood cells and no platelets. URL:http://medical.merriam-webster.com/medical/lymph ENVO:02000042 A bodily fluid material which is composed primarily of interstitial fluid, a bodily fluid consisting of a solution which bathes and surrounds the cells of multicellular animals. It is the main component of the extracellular fluid, which also includes plasma and transcellular fluid. https://en.wikipedia.org/wiki/Interstitial_fluid intercellular fluid material tissue fluid material ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. interstitial fluid material A bodily fluid material which is composed primarily of interstitial fluid, a bodily fluid consisting of a solution which bathes and surrounds the cells of multicellular animals. It is the main component of the extracellular fluid, which also includes plasma and transcellular fluid. https://en.wikipedia.org/wiki/Interstitial_fluid Siliceous ooze is a marine sediment composed of the debris of plankton with silica shells, such as diatoms and radiolaria. This ooze is limited to areas with high biological productivity, such as the polar oceans, and upwelling zones near the equator. The least common type of sediment, it covers only 15% of the ocean floor. It accumulates at a slower rate than calcareous ooze: 0.2-1 cm / 1000 yr. https://en.wikipedia.org/wiki/Siliceous_ooze ENVO ENVO:02000044 envoPolar siliceous ooze ENVO:02000044 Siliceous ooze is a marine sediment composed of the debris of plankton with silica shells, such as diatoms and radiolaria. This ooze is limited to areas with high biological productivity, such as the polar oceans, and upwelling zones near the equator. The least common type of sediment, it covers only 15% of the ocean floor. It accumulates at a slower rate than calcareous ooze: 0.2-1 cm / 1000 yr. https://en.wikipedia.org/wiki/Marine_sediment#_note-8 Red clay, also known as pelagic clay, accumulates in the deepest and most remote areas of the ocean. Containing less than 30% biogenic material, its composition is a varied mix of very fine quartz and clay minerals, authigenic deposits precipitated directly from seawater, and micrometeorites. Though called "red" because it sometimes takes the color of oxidized iron minerals, it is usually brownish in color. Its ultimate origin is uncertain, but red clay seems to be mostly derived from distant rivers, and windblown dust. Covering 38% of the ocean floor, it accumulates more slowly than any other sediment type, at only 0.1-0.5 cm / 1000 yr. ENVO ENVO:02000045 red clay ENVO:02000045 Red clay, also known as pelagic clay, accumulates in the deepest and most remote areas of the ocean. Containing less than 30% biogenic material, its composition is a varied mix of very fine quartz and clay minerals, authigenic deposits precipitated directly from seawater, and micrometeorites. Though called "red" because it sometimes takes the color of oxidized iron minerals, it is usually brownish in color. Its ultimate origin is uncertain, but red clay seems to be mostly derived from distant rivers, and windblown dust. Covering 38% of the ocean floor, it accumulates more slowly than any other sediment type, at only 0.1-0.5 cm / 1000 yr. https://en.wikipedia.org/wiki/Pelagic_sediments Calcareous ooze is a marine sediment composed primarily of the shells--also known as tests--of foraminifera, coccolithophores, and pteropods. This is the most common pelagic sediment by area, covering 48% of the world ocean's floor. This type of ooze is limited to depths above the Carbonate Compensation Depth at time of burial. It accumulates more rapidly than any other pelagic sediment type, with a rate that varies from 0.3 - 5 cm / 1000 yr. ENVO ENVO:02000046 calcareous ooze ENVO:02000046 Calcareous ooze is a marine sediment composed primarily of the shells--also known as tests--of foraminifera, coccolithophores, and pteropods. This is the most common pelagic sediment by area, covering 48% of the world ocean's floor. This type of ooze is limited to depths above the Carbonate Compensation Depth at time of burial. It accumulates more rapidly than any other pelagic sediment type, with a rate that varies from 0.3 - 5 cm / 1000 yr. https://en.wikipedia.org/wiki/Marine_sediment#_note-8 ENVO:02000047 Food material which can be used to meet nutritional requirements of animals, particularly livestock such as cattle, goats, sheep, horses, chickens and pigs. https://en.wikipedia.org/wiki/Animal_feed fodder Most animal feed is from plants but some is of animal origin. Fodder refers particularly to food given to the animals (including plants cut and carried to them), rather than that which they forage for themselves. It includes hay, straw, silage, compressed and pelleted feeds, oils and mixed rations, and also sprouted grains and legumes. animal feed Food material which can be used to meet nutritional requirements of animals, particularly livestock such as cattle, goats, sheep, horses, chickens and pigs. https://en.wikipedia.org/wiki/Fodder ENVO:02000048 Contaminated animal feed is an animal feed that has become contaminated with or come contact with microorganisms or toxic chemicals. contaminated animal feed Contaminated animal feed is an animal feed that has become contaminated with or come contact with microorganisms or toxic chemicals. URL:http://www.cdc.gov/oralhealth/infectioncontrol/glossary.htm A skin obtained from animals for human use typically from deer or cattle sources used to produce leather, shoes, fashion accessories, musical instruments. https://en.wikipedia.org/wiki/Hide ENVO ENVO:02000053 hide ENVO:02000053 A skin obtained from animals for human use typically from deer or cattle sources used to produce leather, shoes, fashion accessories, musical instruments. https://en.wikipedia.org/wiki/Hides ENVO:02000054 A mixture of crushed and coarsely ground bones that is used as an organic fertilizer for plants and formerly in animal feed. https://en.wikipedia.org/wiki/Bone_meal bone meal A mixture of crushed and coarsely ground bones that is used as an organic fertilizer for plants and formerly in animal feed. https://en.wikipedia.org/wiki/Bone_meal ENVO:02000055 Food material which can be used to meet nutritional requirements of plants. plant feed A soil consisting of the upper layer of soil on the surface consisting of loose material capable of supporting life composed of a mixture of mineral and organic matter. topsoil ENVO ENVO:02000059 surface soil ENVO:02000059 A soil consisting of the upper layer of soil on the surface consisting of loose material capable of supporting life composed of a mixture of mineral and organic matter. URL:http://www.answers.com/topic/topsoil?cat=technology https://en.wikipedia.org/wiki/Soil#_note-0 ENVO ENVO:02000084 goat manure ENVO:02000084 ENVO:02000090 An environmental material that is the non-aqueous, non-gaseous residues that remain after something is burned. ash An environmental material that is the non-aqueous, non-gaseous residues that remain after something is burned. https://en.wikipedia.org/wiki/Ash ENVO:02000091 A combustible black or brownish-black sedimentary rock usually occurring in rock strata in layers or veins called coal beds or coal seams. coal A combustible black or brownish-black sedimentary rock usually occurring in rock strata in layers or veins called coal beds or coal seams. ENVO:02000094 a type of rock that contains sufficient minerals with important elements including metals that can be economically extracted from the rock. ore ENVO:02000095 Ore which contains uranium. The primary uranium ore mineral is uraninite uranium ore ENVO:02000096 iron ore ENVO:02000097 gold ore ENVO:02000098 platinum ore ENVO:02000099 Dust which is derived from coal. coal dust ENVO:02000100 Dust which is derived from mineral material. mineral dust ENVO:02000101 Dust which is composed of fibrous material. fibrous dust ENVO:02000102 fibrous glass dust ENVO:02000103 Dust which is composed primarily of some metallic material. metallic dust ENVO:02000104 cement dust ENVO:02000105 Dust which is derived from clay material. clay dust ENVO:02000106 Dust which is derived from asbestos asbestos dust ENVO:02000107 Dust that comes from grain and all the other substances associated with its cultivation & harvesting. grain dust Dust that comes from grain and all the other substances associated with its cultivation & harvesting. http://www.cdc.gov/niosh/npg/npgd0305.html ENVO:02000108 cotton dust ENVO:02000109 dust from plant parts ENVO:02000111 copper ore ENVO:02000112 A gas, smoke, or vapor that smells strongly or is dangerous to inhale. fume ENVO:02000113 welding fume ENVO:02000114 paraffin wax fume ENVO:02000115 Respirable vapor of vanadium. vanadium fume Respirable vapor of vanadium. ENVO:02000116 aluminum welding fume ENVO:02000117 A wax that is naturally synthesized by a plant or animal. natural wax ENVO:02000118 A white or colourless soft solid derivable from petroleum, coal or oil shale, that consists of a mixture of hydrocarbon molecules containing between twenty and forty carbon atoms. paraffin wax A white or colourless soft solid derivable from petroleum, coal or oil shale, that consists of a mixture of hydrocarbon molecules containing between twenty and forty carbon atoms. ENVO:02000119 An organic-rich fine-grained sedimentary rock containing kerogen from which liquid hydrocarbons called shale oil can be produced. kerogen shale oil shale An organic-rich fine-grained sedimentary rock containing kerogen from which liquid hydrocarbons called shale oil can be produced. kerogen shale ENVO:02000120 zinc chloride fume ENVO:02000123 Any liquid, liquefiable, or mastic composition that, after application to a substrate in a thin layer, converts to a solid film. It is most commonly used to protect, color, or provide texture to objects. paint Any liquid, liquefiable, or mastic composition that, after application to a substrate in a thin layer, converts to a solid film. It is most commonly used to protect, color, or provide texture to objects. ENVO:02000124 Paint that contains lead. lead paint Paint that contains lead. ENVO:02000126 the residue powder that is derived from the combustion of wood. wood ash the residue powder that is derived from the combustion of wood. https://en.wikipedia.org/wiki/Wood_ash ENVO:02000127 Ash that is produced from the burning of coal. coal combustion residuals coal ash Ash that is produced from the burning of coal. https://www.epa.gov/coalash/coal-ash-basics coal combustion residuals https://www.epa.gov/coalash/coal-ash-basics ENVO:02000128 A very fine, powdery material composed mostly of silica made from the burning of finely ground coal in a boiler. fly ash A very fine, powdery material composed mostly of silica made from the burning of finely ground coal in a boiler. https://www.epa.gov/coalash/coal-ash-basics ENVO:02000129 a coarse, angular ash particle that is too large to be carried up into the smoke stacks so it forms in the bottom of the coal furnace. bottom ash a coarse, angular ash particle that is too large to be carried up into the smoke stacks so it forms in the bottom of the coal furnace. https://www.epa.gov/coalash/coal-ash-basics ENVO:02000130 molten bottom ash from slag tap and cyclone type furnaces that turns into pellets that have a smooth glassy appearance after it is cooled with water. boiler slag molten bottom ash from slag tap and cyclone type furnaces that turns into pellets that have a smooth glassy appearance after it is cooled with water. https://www.epa.gov/coalash/coal-ash-basics ENVO:02000131 a material leftover from the process of reducing sulfur dioxide emissions from a coal-fired boiler that can be a wet sludge consisting of calcium sulfite or calcium sulfate or a dry powered material that is a mixture of sulfites and sulfates. https://www.epa.gov/coalash/coal-ash-basics flue gas desulfurization material ENVO:02000138 Soil which is located in a mangrove biome. mangrove soil Mangrove soils are typically saline, anoxic, acidic and frequently waterlogged. mangrove biome soil Soil which is located in a mangrove biome. https://doi.org/10.1093/treephys/tpq048 ENVO:02000140 A liquid or a gas. fluid fluid environmental material A liquid or a gas. https://github.com/EnvironmentOntology/envo/issues/940 ENVO:03000000 Partially compacted granular snow, which has undergone several cycles of melting and refreezing while being compacted, usually found on the atmosphere-exposed surface of a glacier. http://orcid.org/0000-0002-3410-4655 névé envoPolar Névé that survives a full season of ablation turns into firn. neve Partially compacted granular snow, which has undergone several cycles of melting and refreezing while being compacted, usually found on the atmosphere-exposed surface of a glacier. https://en.wikipedia.org/wiki/N%C3%A9v%C3%A9 ENVO:03000002 Granular snow which contains a proportion of fused granules formed through melting and re-thawing while being compacted by the weight of overlying material and which contains interconnected gaseous pores. http://orcid.org/0000-0002-3410-4655 envoPolar Firn derives from névé which has survived a full season of ablation and has undergone a metamorphic transition. firn Granular snow which contains a proportion of fused granules formed through melting and re-thawing while being compacted by the weight of overlying material and which contains interconnected gaseous pores. https://en.wikipedia.org/wiki/Firn ENVO:03000004 Any water ice that is part of a glacier. It is suggested that users complement this term with ice terms that are more descriptive of the ice itself, rather than its location/parthood. http://orcid.org/0000-0002-3410-4655 envoPolar glacial ice Any water ice that is part of a glacier. https://en.wikipedia.org/wiki/Glacier ENVO:03000005 Glacial ice which contains material liberated during a glacial erosion process. http://orcid.org/0000-0002-3410-4655 envoPolar erosionally enriched glacial ice Glacial ice which contains material liberated during a glacial erosion process. https://www.asf.alaska.edu/blog/why-is-glacier-ice-blue/ ENVO:03000007 Water ice containing little to no air bubbles resulting in a reduction of internal light scattering and, given sufficient volume, a blue appearance. http://orcid.org/0000-0002-3410-4655 envoPolar The blue 'appearance' is to be understood as that within the visual range of humans. blue ice Water ice containing little to no air bubbles resulting in a reduction of internal light scattering and, given sufficient volume, a blue appearance. https://en.wikipedia.org/wiki/Blue_ice_(glacial) https://en.wikipedia.org/wiki/Glacier ENVO:03000021 Particulate environmental material which is composed primarily of carbon particles formed through the incomplete combustion of hydrocarbons. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. http://orcid.org/0000-0002-3410-4655 envoPolar soot Particulate environmental material which is composed primarily of carbon particles formed through the incomplete combustion of hydrocarbons. https://en.wikipedia.org/wiki/Soot ENVO:03000025 Water ice which contains material liberated during an erosion process. http://orcid.org/0000-0002-3410-4655 envoPolar erosionally enriched ice Water ice which contains material liberated during an erosion process. https://www.asf.alaska.edu/blog/why-is-glacier-ice-blue/ ENVO:03000027 Uncompacted snow containing trapped atmospheric gases. http://orcid.org/0000-0002-3410-4655 envoPolar Described as having a fluffy appearance. powdery snow Uncompacted snow containing trapped atmospheric gases. https://en.wikipedia.org/wiki/Types_of_snow https://nsidc.org/cryosphere/snow/science/characteristics.html ENVO:03000033 Sediment which has been transported through the marine water column, settling on the seafloor. http://orcid.org/0000-0002-3410-4655 marine sediments envoPolar Particles of marine sediment are primarily generated by 1) processes in terrestrial systems and transported to the marine realm by the action of rivers or aeolian processes (amongst other routes) , 2) marine organisms, 3) chemical processes in seawater, or 4) cosmogeneous input. marine sediment Sediment which has been transported through the marine water column, settling on the seafloor. https://en.wikipedia.org/wiki/Pelagic_sediment#_note-8 ENVO:03000034 Marine sediment soured from either terrestrial systems, marine organisms, seawater and or cosmogeneous sources, which is transported through the marine water column, and accumulates within shallow regions of the oceanic basin close to continents, such as the continental shelf, or continental slope. In this definition we refer to sedimentation processes that occured above the shelf, however this should be relaxed to include the continental shelf and slope. output of sedimentation process which occured in neritic zone biome http://orcid.org/0000-0002-3410-4655 shallow marine sediments neritic marine sediment envoPolar shallow marine sediment Marine sediment soured from either terrestrial systems, marine organisms, seawater and or cosmogeneous sources, which is transported through the marine water column, and accumulates within shallow regions of the oceanic basin close to continents, such as the continental shelf, or continental slope. https://en.wikipedia.org/wiki/Continental_shelf https://en.wikipedia.org/wiki/Pelagic_sediment#_note-8 ENVO:03000038 Particulate environmental material which is composed primarily of dust, rock, and soot, as well as the microbial communities associated with these materials, deposited on an ice mass by an aeolian process. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. This actually is formed as a result of an accumulation process involving the constituents of cryoconite. When their semantics are more stable, we can axiomatise this fully. http://orcid.org/0000-0001-5812-6405 http://orcid.org/0000-0002-3410-4655 envoPolar cryoconite deposit Particulate environmental material which is composed primarily of dust, rock, and soot, as well as the microbial communities associated with these materials, deposited on an ice mass by an aeolian process. http://www.nature.com/nrmicro/journal/v13/n11/full/nrmicro3522.html https://en.wikipedia.org/wiki/Cryoconite ENVO:03000046 New ice which is composed frazil which has congealed into a thin sheet. Needs to have axioms added pertaining to the semantics of colloids and suspensions once they have been resolved see: https://github.com/pato-ontology/pato/issues/91#issuecomment-290711238 Currently the new ice classes are not specific to sea water as they may form in non marine systems, but it would be good to confirm this especially for frazil ice. http://orcid.org/0000-0002-3410-4655 http://sweetontology.net/realmCryo/FrazilIce envoPolar Typically 3 to 4 millimeters in diameter. These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. frazil ice New ice which is composed frazil which has congealed into a thin sheet. https://nsidc.org/cryosphere/glossary/term/frazil ENVO:03000063 Water ice which is formed from freezing water and is suspended in a water body. Currently the new ice classes are not specific to sea water as they may form in non marine systems, but it would be good to confirm this especially for frazil ice. http://orcid.org/0000-0002-3410-4655 envoPolar sea ice types include frazil, grease ice, slush, and shuga. These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. new ice Water ice which is formed from freezing water and is suspended in a water body. https://nsidc.org/cryosphere/glossary/term/new-ice ENVO:03000071 Sea ice which has formed over a single freezing season. http://orcid.org/0000-0002-3410-4655 http://sweetontology.net/realmCryo/SeasonalIce seasonal ice envoPolar Sea ice develops from young ice; thickness from 0.3 to 2 meters (1 to 6.6 feet). Sea ice be subdivided into thin first-year ice (white ice), medium first-year ice, and thick first-year ice. First-year ice is distinguished from older ice primarily by having a higher salinity. Undeformed first-year ice differs from older ice in that it is smoother and lacks refrozen melt ponds. Characteristically level where undisturbed by pressure, but where ridges occur, they distinguished by being larger, more angular, and more porous than multiyear ridges. first year ice Sea ice which has formed over a single freezing season. http://nsidc.org/arcticseaicenews/tag/first-year-ice/ https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice https://orcid.org/0000-0003-4808-4736 seasonal ice First year ice which melts before the next freezing season is often referred to as seasonal ice. By definition, seasonal ice cannot become second year ice. Sea ice develops from young ice; thickness from 0.3 to 2 meters (1 to 6.6 feet). Sea ice be subdivided into thin first-year ice (white ice), medium first-year ice, and thick first-year ice. First-year ice is distinguished from older ice primarily by having a higher salinity. Undeformed first-year ice differs from older ice in that it is smoother and lacks refrozen melt ponds. Characteristically level where undisturbed by pressure, but where ridges occur, they distinguished by being larger, more angular, and more porous than multiyear ridges. https://orcid.org/0000-0003-4808-4736 ENVO:03000072 Sea ice which is thicker than first year ice, and has survived a seasonal melting process. http://orcid.org/0000-0002-3410-4655 envoPolar second year ice Sea ice which is thicker than first year ice, and has survived a seasonal melting process. https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice ENVO:03000073 Sea ice which is thicker than second year ice, and has survived more than two seasonal melting process. http://orcid.org/0000-0002-3410-4655 envoPolar multiyear ice Sea ice which is thicker than second year ice, and has survived more than two seasonal melting process. https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice ENVO:03000075 New ice, which is spongy, lumpy and opaque, and forms from water which freezes in an agitated water body. http://orcid.org/0000-0002-3410-4655 envoPolar These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. shuga New ice, which is spongy, lumpy and opaque, and forms from water which freezes in an agitated water body. http://encyclopedia2.thefreedictionary.com/shuga https://nsidc.org/cryosphere/glossary/term/shuga ENVO:03000076 A slurry of frazil, snow, and liquid water. http://orcid.org/0000-0002-3410-4655 envoPolar These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. slush ice A slurry of frazil, snow, and liquid water. https://en.wikipedia.org/wiki/Slush https://nsidc.org/cryosphere/glossary/term/slush ENVO:03000088 Permafrost which contains pockets of trapped methane gas. It would probably be better to assert parthood between the permafrost and cavities filled with gas rather than the gases themselves. http://orcid.org/0000-0002-3410-4655 bulgunyakh envoPolar Other hydrocarbon gasses such as carbon dioxide may also be present. These pockets can be sufficently large that the permafrost surface will undulate when pressure is applied. methane-laden permafrost Permafrost which contains pockets of trapped methane gas. http://www.nature.com/news/mysterious-siberian-crater-attributed-to-methane-1.15649 http://www.sciencealert.com/7-000-huge-gas-bubbles-have-formed-under-siberia-and-could-explode-at-any-moment ENVO:03000108 Snow which is cohesive, hard and overlies weaker snow. http://orcid.org/0000-0002-3410-4655 envoPolar slab snow Snow which is cohesive, hard and overlies weaker snow. http://www.fsavalanche.org/slab ENVO:03000133 An agricultural environmental material which 1) is composed of a mixture of materials such as peat, composted bark, sand, perlite, or compost, and 2) serves as a medium in which to grow plants. http://orcid.org/0000-0002-3410-4655 potting soil Potting soil can be composed of a wide range of materials in varying ratios, often containing little or no actual soil. agricultural potting mixture An agricultural environmental material which 1) is composed of a mixture of materials such as peat, composted bark, sand, perlite, or compost, and 2) serves as a medium in which to grow plants. ENVO:03000137 A fog the droplets of which freeze upon contact with exposed objects, forming a coating of rime or glaze. 2020-10-14T20:13:10.917Z envoCryo envoPolar Freezing fog forms when the air temperature is below freezing and the water droplets in the fog become supercooled. freezing fog A fog the droplets of which freeze upon contact with exposed objects, forming a coating of rime or glaze. Freezing fog forms when the air temperature is below freezing and the water droplets in the fog become supercooled. https://www.treehugger.com/what-is-freezing-fog-4863382 ENVO:03000139 Fog which is composed of particles of ice. In future will add computable renditions of size and temperature constraints. The synonyms of this class can be quite confusing, as they reference entities like frost (which requires a surface for deposition). Might need to add a new droxtal class see https://glossary.ametsoc.org/wiki/Droxtal. 2020-11-18T20:48:37.965Z frozen fog ice-crystal fog pogonip air hoar frost flakes frost fog rime fog envoCryo envoPolar The suspended particles may be partly ice crystals 20 to 100 micron in diameter, but chiefly, especially when dense, droxtals 12-20 micron in diameter. Ice fog is formed by direct freezing of supercooled water droplets with little growth directly from the vapor. It occurs at very low temperatures, and usually in clear, calm weather in high latitudes. The sun is usually visible and may cause halo phenomena or luminous pillars. Ice fog is rare at temperatures warmer than -30 °C, and increases in frequency with decreasing temperature until it is almost always present at air temperatures of -45 °C in the vicinity of a source of water vapor. Such sources are the open water of fast-flowing streams or of the sea, herds of animals, volcanoes, and especially products of combustion for heating or propulsion. At temperatures warmer than -30 °C, these sources can cause steam fog of liquid water droplets, which may turn into ice fog when cooled. ice fog Fog which is composed of particles of ice. The suspended particles may be partly ice crystals 20 to 100 micron in diameter, but chiefly, especially when dense, droxtals 12-20 micron in diameter. Ice fog is formed by direct freezing of supercooled water droplets with little growth directly from the vapor. It occurs at very low temperatures, and usually in clear, calm weather in high latitudes. The sun is usually visible and may cause halo phenomena or luminous pillars. Ice fog is rare at temperatures warmer than -30 °C, and increases in frequency with decreasing temperature until it is almost always present at air temperatures of -45 °C in the vicinity of a source of water vapor. Such sources are the open water of fast-flowing streams or of the sea, herds of animals, volcanoes, and especially products of combustion for heating or propulsion. At temperatures warmer than -30 °C, these sources can cause steam fog of liquid water droplets, which may turn into ice fog when cooled. ENVO:03501252 Poultry manure made of chicken feces. 2021-03-15T04:00:01.750Z chicken manure Poultry manure made of chicken feces. ENVO:03501253 A soft sulfate mineral composed of calcium sulfate dihydrate. 2021-03-15T04:00:01.750Z gypsum A soft sulfate mineral composed of calcium sulfate dihydrate. ENVO:03501259 Environmental material consisting of waste products that have been discarded at an unsuitable location. 2021-03-15T04:00:01.750Z litter Environmental material consisting of waste products that have been discarded at an unsuitable location. ENVO:03501300 An environmental material consisting of organic matter from plants and/or animals that is used in agriculture as fertilizer. 2021-03-15T04:00:01.750Z animal manure compost farm slurry green manure liquid manure Most manure consists of animal feces; other sources include compost and green manure. manure An environmental material consisting of organic matter from plants and/or animals that is used in agriculture as fertilizer. ENVO:03501302 Plant matter consisting of an impermeable buoyant material, the phellem layer of bark tissue. 2021-03-15T04:00:01.750Z cork Plant matter consisting of an impermeable buoyant material, the phellem layer of bark tissue. ENVO:03501303 Macromolecules that are obtained naturally from plants or animals. 2021-03-15T04:00:01.750Z natural-based polymer Macromolecules that are obtained naturally from plants or animals. ENVO:03501304 A thin, transparent sheet made of regenerated cellulose. 2021-03-15T04:00:01.750Z Plastic Wrap Cellophane is used for food packaging. cellophane A thin, transparent sheet made of regenerated cellulose. ENVO:03501305 Synthetic plastic which is composed of a glossy, moistureproof membrane made of rubber hydrochloride. 2021-03-15T04:00:01.750Z pliofilm Synthetic plastic which is composed of a glossy, moistureproof membrane made of rubber hydrochloride. ENVO:03501306 A polyester film made from stretched polyethylene terephthalate (PET). 2021-03-15T04:00:01.750Z BoPET (Biaxially-oriented polyethylene terephthalate) mylar A polyester film made from stretched polyethylene terephthalate (PET). ENVO:03501307 A solid environmental material that is hard, brittle, heat-resistant and corrosion-resistant, made by shaping and then firing a nonmetallic mineral at a high temperature. 2021-03-15T04:00:01.750Z ceramic A solid environmental material that is hard, brittle, heat-resistant and corrosion-resistant, made by shaping and then firing a nonmetallic mineral at a high temperature. ENVO:03501324 A stable dispersion (emulsion) of polymer microparticles in an aqueous medium. 2021-03-15T04:00:01.750Z Natural rubber, India rubber, Gum elastic, Non-vulcanized rubber Latex is made by some plants, but synthetic latexes can be manufactured as well. latex A stable dispersion (emulsion) of polymer microparticles in an aqueous medium. ENVO:03501370 A liquid water which has no current or flow and is susceptible to contamination by pathogens or pathogenic vectors. 2021-12-09T00:00:00Z wet stagnant water A liquid water which has no current or flow and is susceptible to contamination by pathogens or pathogenic vectors. ENVO:03510000 Dust which is 1) generated when wood is processed and 2) composed primarily of cellulose, polyoses, and lignin. 2020-08-03T17:28:49Z http://purl.obolibrary.org/obo/NCIT_C44463 Wood dust is typically generated through processes where wood is chipped, sawed, turned, drilled or sanded. The chemical composition of wood dust depends on the species of tree. Wood dust is not typically produced for specific uses. However, it is used commercially for wood composts. The primary routes of potential human exposure to wood dust are inhalation and dermal contact. It is known to be a human carcinogen. wood dust ENVO:03510006 A liquid fuel used in diesel engines, whose fuel ignition takes place, without any spark, as a result of compression of the inlet air mixture and then injection of fuel. 2020-08-03T17:39:59Z petroleum distillate fuel oil diesel fuel A liquid fuel used in diesel engines, whose fuel ignition takes place, without any spark, as a result of compression of the inlet air mixture and then injection of fuel. https://en.wikipedia.org/wiki/Diesel_fuel https://www.eia.gov/energyexplained/diesel-fuel/ ENVO:03510007 A clear petroleum-derived flammable liquid which is used as fuel in most spark-ignited internal combustion engines. 2020-08-03T17:41:45Z gas petrol Gasoline consists mostly of organic compounds obtained by the fractional distillation of petroleum, enhanced with a variety of additives. gasoline A clear petroleum-derived flammable liquid which is used as fuel in most spark-ignited internal combustion engines. https://en.wikipedia.org/wiki/Gasoline ENVO:03510008 A gas which results from the incomplete or complete combustion of diesel fuel. 2020-08-03T17:43:30Z 2021-02-12T15:10:14.018Z http://purl.obolibrary.org/obo/NCIT_C113679 diesel exhaust ENVO:03510009 A gas which results from the complete or incomplete combustion of gasoline fuel. 2020-08-03T17:44:42Z 2021-02-12T15:10:14.018Z gasoline exhaust A gas which results from the complete or incomplete combustion of gasoline fuel. https://www.ncbi.nlm.nih.gov/books/NBK531367/ ENVO:03510015 A polysaccharide that functions as an emulsifier, stabilizer, and thickener in mixtures. 2020-08-03T17:52:46Z http://purl.obolibrary.org/obo/DRON_00723355 http://purl.obolibrary.org/obo/FOODON_03413321 http://purl.obolibrary.org/obo/NCIT_C84244 xanthan gum ENVO:03510016 A naturally occurring plant-based gum, which functions as a viscous, odorless, tasteless, water-soluble mixture of polysaccharides that absorbs water to become a gel/paste. 2020-08-03T17:54:12Z http://purl.obolibrary.org/obo/DRON_00723978 http://purl.obolibrary.org/obo/FOODON_03413310 http://purl.obolibrary.org/obo/NCIT_C84223 http://purl.obolibrary.org/obo/OMIT_0014984 shiraz gum tragacanth gum Tragacanth has many uses, including as an emulsifier, thickener, stabilizer, and texturant additive for foods, pharmaceuticals, and art materials. tragacanth ENVO:03510018 A solid or highly viscous plant or synthetic based substance that is typically convertible into polymers. 2020-08-03T17:58:04Z resin A solid or highly viscous plant or synthetic based substance that is typically convertible into polymers. https://en.wikipedia.org/wiki/Resin ENVO:03510023 A resin secreted by the female lac bug, which is dissolved in alcohol to be used as a brush-on colorant, food glaze, and wood finish. 2020-08-03T18:09:37Z shellack shellac A resin secreted by the female lac bug, which is dissolved in alcohol to be used as a brush-on colorant, food glaze, and wood finish. https://en.wikipedia.org/wiki/Shellac ENVO:03510029 A paint product which adheres to surfaces and forms a binding layer, preparing it to receive paint. 2020-08-03T18:17:39Z primer (paint) A paint product which adheres to surfaces and forms a binding layer, preparing it to receive paint. https://en.wikipedia.org/wiki/Primer_(paint) ENVO:03510031 A slow-drying paint that consists of particles of pigment suspended in a drying oil, commonly linseed oil. 2020-08-03T18:21:06Z oil paint oil-based paint A slow-drying paint that consists of particles of pigment suspended in a drying oil, commonly linseed oil. https://en.wikipedia.org/wiki/Oil_paint ENVO:03510032 A water soluble, fast-drying paint made of pigment suspended in acrylic polymer emulsion. 2020-08-03T18:22:26Z acrylic paint A water soluble, fast-drying paint made of pigment suspended in acrylic polymer emulsion. https://en.wikipedia.org/wiki/Acrylic_paint ENVO:03510033 A paint that exhibits luminescence, giving off visible light through fluorescence, phosphorescence, or radioluminescence. 2020-08-03T18:23:19Z luminous paint luminescent paint A paint that exhibits luminescence, giving off visible light through fluorescence, phosphorescence, or radioluminescence. https://en.wikipedia.org/wiki/Luminous_paint ENVO:03510036 Dust which is composed of minerals and trace elements, generated by finely crushed rock. 2020-08-03T18:27:44Z mineral fines rock flour soil remineralization rock powder Rock dust is widely used in mining to prevent coal dust explosions, or in agriculture for organic farming uses. rock dust Dust which is composed of minerals and trace elements, generated by finely crushed rock. https://en.wikipedia.org/wiki/Rockdust ENVO:03510037 Any material containing unstable atoms that emit ionizing radiation as it decays. 2020-08-03T18:32:42Z radioactive material Any material containing unstable atoms that emit ionizing radiation as it decays. https://www.ehs.iastate.edu/research/radiation/radioactive-materials ENVO:03510038 An environmental material which is primarily composed of cyanoacrolate. 2020-08-03T18:34:01Z Cyanoacrylates have industrial, medical, and household uses. A strong fast-acting adhesive which is an ester of cyanoacrylic acid. volume of cyanoacrylate An environmental material which is primarily composed of cyanoacrolate. https://en.wikipedia.org/wiki/Cyanoacrylate ENVO:03510055 An environmental material which is composed of elastic polymers mixed in a solvent. 2021-02-12T15:10:14.018Z cow gum Solvents typically used include acetone, hexane, heptane or toluene. rubber cement ENVO:03510056 An environmental material which is 1) composed primarily of methyl cellulose and water, and 2) formulated to fix wallpaper to walls. 2021-02-12T15:10:14.018Z wallpaper adhesive wallpaper paste methyl cellulose paste ENVO:03510057 An environmental material which is 1) manufactured and 2) primarily composed of hydrogen peroxide and ammonia, and 3) when applied to hair, can alter the natural hair pigments for 6-8 weeks. 2021-02-12T15:10:14.018Z hair color permanent hair dye ENVO:03510058 A colorant fluid which is 1) manufactured and 2) composed of alcohol, titanium dioxide, and propylene glycol. 2021-02-12T15:10:14.018Z pharmaceutical ink ENVO:03510060 A colorant fluid which is 1) manufactured and 2) composed of copper phthalocyanine, iron oxides, water, and biopolymers. 2021-02-12T15:10:14.018Z gel ink ENVO:03510061 A colorant fluid which is 1) manufactured and 2) primarily composed of soybean oil, as well as pigment, resin, and wax. 2021-02-12T15:10:14.018Z soy ink ENVO:03510062 A colorant fluid which is 1) manufactured, 2) primarily composed of water, as well as glycol, and dye, and 3) intended for use in inkjet printers. 2021-02-12T15:10:14.018Z aqueous inkjet printer ink ENVO:03510064 An environmental material which is composed primarily of gases and particles produced by the combustion of petroleum fuels. 2021-02-12T15:10:14.018Z emissions from petroleum combustion ENVO:03510065 A liquid environmental material which 1) contains at least one substance which can act as a chemical colorant. 2021-04-15T15:10:14.018Z colorant fluid ENVO:03510070 Waste which contains toxic components (e.g., heavy metals or radiation) which can cause harm to organisms and/or the environment. 2022-01-18T17:35:02Z toxic waste Waste which contains toxic components (e.g., heavy metals or radiation) which can cause harm to organisms and/or the environment. https://en.wikipedia.org/wiki/Toxic_waste ENVO:03520007 A water ice crystal which is constituted by water molecules aligned in a hexagonal array. snowflake snow crystal A water ice crystal which is constituted by water molecules aligned in a hexagonal array. snowflake Snow crystals and snowflakes are often noted as synonyms, however, the term "snowflake" is generally used more loosely. Some sites mention that snow crystals refer to individual crystals of ice, while the term "snowflake" can refer both to an individual crystal of ice and to a bundle of snow crystals. Please see here [https://github.com/EnvironmentOntology/envo/issues/998#issuecomment-685649444] ENVO:03600001 Sediment which contains some chemical contaminant. See https://github.com/EnvironmentOntology/envo/issues/1102 for a possible design pattern. Uses undesirability standard, compared to polluted river's ecological impact standard. What is the relation to ENVO:00002114 'chemically enriched sediment'? Does 'element' in the definition refer to something found in the periosic table (like selenium) or the member of some set, aka an entity? 2021-04-05T16:38:47.162Z chemically contaminated sediment Sediment which contains some chemical contaminant. ENVO:03600002 Liquid water which is a participant in a water cooling process. 2021-02-02T21:33:40.901Z Cooling water is commonly used for cooling automobile internal combustion engines and power stations. cooling water Liquid water which is a participant in a water cooling process. Cooling water is commonly used for cooling automobile internal combustion engines and power stations. ENVO:03600006 A waste material which is primarily composed of uneaten food and removed from the food supply chain. does FoodOn want this? 2021-04-05T16:38:47.162Z food loss The causes of food waste or loss are numerous and can occur during production, processing, distribution, retail and consumption. food waste A waste material which is primarily composed of uneaten food and removed from the food supply chain. The causes of food waste or loss are numerous and can occur during production, processing, distribution, retail and consumption. ENVO:03600007 A fluid environmental material which is contained in geologic formations naturally. assert contained in some child of astronmical body part? cavity? Parent class could use a better definition? 2021-04-05T16:38:47.162Z formation fluid A fluid environmental material which is contained in geologic formations naturally. ENVO:03600009 Liquid water which occurs naturally within the pores of rocks and sediments. 2021-04-05T16:38:47.162Z interstitial water Liquid water which occurs naturally within the pores of rocks and sediments. ENVO:03600013 An environmental material which consists of either loose sands or partially consolidated sandstone, containing a naturally occurring mixture of sand, clay, and water, soaked with a dense and extremely viscous form of petroleum. TODO: create an astonomical body part 'bituminous sands" and assert composed primarily of realtionship. Xref https://github.com/EnvironmentOntology/envo/issues/1154. TREATED THIS as a material entity. could add something like "oil sands deposit" as a geospatial location later. 2021-04-05T16:38:47.162Z crude bitumen oil sands tar sands bituminous sand An environmental material which consists of either loose sands or partially consolidated sandstone, containing a naturally occurring mixture of sand, clay, and water, soaked with a dense and extremely viscous form of petroleum. ENVO:03600016 Rock which is derived from bedrock through chemical weathering add chemcical weathering term to improve axiomitization 2021-04-05T16:38:47.162Z saprolite Rock which is derived from bedrock through chemical weathering ENVO:03600017 An environmental material which is composed of insoluble solid particles suspended in a liquid. term requester also included <denser than water> and <usually suspended in water>, but they may only be found in wikipedia's definition 2021-04-05T16:38:47.162Z slurry An environmental material which is composed of insoluble solid particles suspended in a liquid. ENVO:03600036 Soil which has properties that restrict a pathogen's ability to establish itself, persist, or cause disease that results in long-term harm. 2021-06-24T03:53:29.138Z disease-suppressive soil The pathogenicity that is suppressed is typically directed towards plants, especially crops. Soils are typically classified as pathogen-suppressive if a pathogen 1) cannot establish itself or persist, 2) is able to establish itself, but causes little or no damage, or 3) is able to establishe itself, but only causes disease that does not result in long-term harm. pathogen-suppressive soil Soil which has properties that restrict a pathogen's ability to establish itself, persist, or cause disease that results in long-term harm. ENVO:03600042 Liquid water which is either part of or was removed from a marine lake. 2021-06-24T03:53:29.138Z marine lake water Liquid water which is either part of or was removed from a marine lake. ENVO:03600064 A sedimentary rock which is made of carbonate mud whose formation is mediated by microbes in the benthic zone. 2021-07-03T00:22:16.764Z microbialite A sedimentary rock which is made of carbonate mud whose formation is mediated by microbes in the benthic zone. ENVO:03600065 Water which comes from a spring. 2021-07-03T00:22:16.764Z spring water Water which comes from a spring. ENVO:03600081 Fresh water which is harvested from cloud. 2021-07-03T00:22:16.764Z cloud water Fresh water which is harvested from cloud. ENVO:03600082 Fluid environmental material which is present in the continental crust and dictates the nature and extent of crustal deformation. 2021-07-03T00:22:16.764Z The presence or absence of fluids exerts a fundamental control on rheology. crustal fluid Fluid environmental material which is present in the continental crust and dictates the nature and extent of crustal deformation. ENVO:03600084 An organic material which is derived from lichen mats. 2021-07-03T00:22:16.764Z lichen material An organic material which is derived from lichen mats. ENVO:04000007 Water which is part of a lake. 2019-03-20T20:15:54Z envoNceas lake water ENVO:04000008 Organic material in soil, which consists of plant and animal residues at various stages of decomposition, cells and tissues of soil organisms, and substances synthesized by soil organisms. 2019-04-05T00:53:06Z envoNceas soil organic matter Organic material in soil, which consists of plant and animal residues at various stages of decomposition, cells and tissues of soil organisms, and substances synthesized by soil organisms. https://en.wikipedia.org/wiki/Soil_organic_matter ENVO:04000012 Particulate environmental material which is composed primarily of organic material. Do not oversimplify the particulate environmental material subclasses with design patterns or similar. The materials have properties that their components do not - write full definitions including these where possible. 2019-04-30T18:33:18Z envoNceas particulate organic matter Particulate environmental material which is composed primarily of organic material. https://en.wikipedia.org/wiki/Particulate_organic_matter ENVO:04000013 Particulate organic matter which is composed primarily of carbon. 2019-04-30T18:33:35Z envoNceas particulate organic carbon Particulate organic matter which is composed primarily of carbon. https://serc.carleton.edu/microbelife/research_methods/biogeochemical/organic_carbon.html ENVO:04000014 Particulate organic matter which is composed primarily of nitrogen. 2019-04-30T18:33:45Z envoNceas particulate organic nitrogen ENVO:06105003 An environmental material which is capable of, repeatedly, becoming plastic when heated and hardening again when cooled. 2021-04-27T09:45:29Z envoPlastics thermoplastic material An environmental material which is capable of, repeatedly, becoming plastic when heated and hardening again when cooled. ENVO:06105016 A plastic which has a matrix- or sponge-like structure with numerous, hollow internal spaces. 2021-05-07T12:26:54Z cellular polymers expanded polymers geschäumter Kunststoff plastic foam envoPlastics foamed plastic A plastic which has a matrix- or sponge-like structure with numerous, hollow internal spaces. ENVO:06105101 An environnmental material which 1) is composed primarily of polymers with high molecular mass and 2) once deformed does not spontaneously return to its original shape. 2021-04-07T14:40:26Z Plastik plastica 塑膠 Kunststoff envoPlastics "High molecular mass" can be ambiguous as it does not set a threshold for what is considered "high". Here we make no commitment to a threshold. plastic An environnmental material which 1) is composed primarily of polymers with high molecular mass and 2) once deformed does not spontaneously return to its original shape. Kunststoff In German "Kunststoff" connotes those plastics which have intentionally been shaped by some art, thus "Kunst". ENVO:06105111 Plastic which is composed primarily of polymers produced by processes whose agents do not include humans or their technologies. The corresponding subclass axiom will be added in the second phase of this project. 2021-05-07T09:09:37Z envoPlastics natural plastic ENVO:06105112 A plastic which is composed primarily of polymers produced by a manufacturing process. The corresponding subclass axiom will be added in the second phase of this project. 2021-05-07T09:12:35Z manufactured plastic envoPlastics envoPolar synthetic plastic ENVO:06105211 Liquid water which 1) flows over land and 2) is not absorbed or retained by the materials if flows over or through. 2021-11-18T17:01:38Z overland flow surface runoff Runoff often gathers debris and solutes from the materials it flows over or through, and often flows into a water body. runoff Liquid water which 1) flows over land and 2) is not absorbed or retained by the materials if flows over or through. ENVO:06105238 Liquid water which is present in soils as discontinuous volumnes of water in contact with solid and gaseous components of the soil. 2021-12-20T03:37:25Z residual water in soil Liquid water which is present in soils as discontinuous volumnes of water in contact with solid and gaseous components of the soil. https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.87.3867&rep=rep1&type=pdf ENVO:06105268 Waste water which was converted into an effluent that can be either returned to the water cycle with minimal environmental issues or reused. 2021-12-23T04:16:42Z treated wastewater Waste water which was converted into an effluent that can be either returned to the water cycle with minimal environmental issues or reused. https://www.usgs.gov/special-topics/water-science-school/science/wastewater-treatment-water-use ENVO:06105269 Saline water from which minerals have been removed to produce fresh water suitable for human consumption or irrigation. 2021-12-23T04:26:38Z desalinated water Saline water from which minerals have been removed to produce fresh water suitable for human consumption or irrigation. https://www.usgs.gov/special-topics/water-science-school/science/desalination ENVO:06105272 Soil which is primarily composed of sand with silt and clay in progressively smaller proportions. 2021-12-26T22:01:51Z Some authorities consider this a soil type, composed of 70-86% of sand, 0-30% of silt and 0-15% of clay. Others consider this a soil material that contains at the upper limit 85 to 90% sand, and the percentage of silt plus 1.5 times the percentage of clay is not less than 15, at the lower limit it contains not less than 70 to 85% sand, and the percentage of silt plus twice the percentage of clay does not exceed 30. loamy sand Soil which is primarily composed of sand with silt and clay in progressively smaller proportions. https://www.fao.org/fishery/docs/CDrom/FAO_Training/FAO_Training/General/x6706e/x6706e06.htm USDA textural classes of soils Some authorities consider this a soil type, composed of 70-86% of sand, 0-30% of silt and 0-15% of clay. Others consider this a soil material that contains at the upper limit 85 to 90% sand, and the percentage of silt plus 1.5 times the percentage of clay is not less than 15, at the lower limit it contains not less than 70 to 85% sand, and the percentage of silt plus twice the percentage of clay does not exceed 30. https://sis.agr.gc.ca/cansis/glossary/t/index.html ENVO:06105273 Sand which is composed primarily of fine particles. 2021-12-26T22:04:18Z Thresholds for what particle size is considered "fine" vary by region and authority, as well as the tolerance for proportions of other particle sizes. fine sand ENVO:06105274 Loam which has a high proportion of sand in its composition. 2021-12-26T22:08:11Z Some authorities consider sandy loam to be a soil composed of 50-70% sand, 0-50% silt, and 0-20% clay. Others, a soil material that contains either 20% or less clay, with a percentage of silt plus twice the percentage of clay that exceeds 30, and 52% or more sand; or less than 7% clay, less than 50% silt, and between 43% and 52% sand. sandy loam Some authorities consider sandy loam to be a soil composed of 50-70% sand, 0-50% silt, and 0-20% clay. Others, a soil material that contains either 20% or less clay, with a percentage of silt plus twice the percentage of clay that exceeds 30, and 52% or more sand; or less than 7% clay, less than 50% silt, and between 43% and 52% sand. https://sis.agr.gc.ca/cansis/glossary/t/index.html https://www.fao.org/fishery/docs/CDrom/FAO_Training/FAO_Training/General/x6706e/x6706e06.htm USDA textural classes of soils ENVO:06105275 Loam which has a high proportion of silt in its composition. 2021-12-26T22:10:33Z Some authorities consider silt loam to be a soil composed of 20-50% of sand, 74-88% silt and 0-27% of clay. USDA textural classes of soils silty loam Some authorities consider silt loam to be a soil composed of 20-50% of sand, 74-88% silt and 0-27% of clay. https://sis.agr.gc.ca/cansis/glossary/t/index.html ENVO:06105276 Clay loam which has a high proportion of sand in its composition. 2021-12-26T22:11:57Z Some authorities consider sandy clay loam to be a soil composed of 45-80% sand, 0-28% silt, and 20-35% clay. sandy clay loam Some authorities consider sandy clay loam to be a soil composed of 45-80% sand, 0-28% silt, and 20-35% clay. https://sis.agr.gc.ca/cansis/glossary/t/index.html ENVO:06105277 Loam which has a high proportion of clay in its composition. Interestingly, some instances of this class may not actually conform to the definition of loam, by having roughly unequal proportions of sand and silt and quite a large proportion of clay. 2021-12-26T22:12:30Z Some authorities consider clay loam to be a soil composed of 20-45% sand, 15-52% silt, and 27 to 40% clay. clay loam Some authorities consider clay loam to be a soil composed of 20-45% sand, 15-52% silt, and 27 to 40% clay. https://sis.agr.gc.ca/cansis/glossary/t/index.html USDA textural classes of soils ENVO:06105278 Clay loam which has a high proportion of silt in its composition. 2021-12-26T22:13:01Z Some authorities consider silty clay loam to be a soil composed of 0-20% of sand, 40-73 of silt and 27-40% of clay. silty clay loam Some authorities consider silty clay loam to be a soil composed of 0-20% of sand, 40-73 of silt and 27-40% of clay. https://www.fao.org/fishery/docs/CDrom/FAO_Training/FAO_Training/General/x6706e/x6706e06.htm USDA textural classes of soils ENVO:06105279 Clay which has a high proportion of sand in its composition. If this is a soil (in which case the differntia must be made clear) it should be moved (or a new class created) and labelled 'sandy clay soil'. 2021-12-26T22:13:44Z Some authorities consider sandy clay to be a soil composed of 45-65% of sand, 0-20% of silt and 35-55% of clay. If the proportion of sand exceeds that of clay, it is unclear whether this is still considered clay (due to other properties) or whether a new class "clay sand" should be created. sandy clay Some authorities consider sandy clay to be a soil composed of 45-65% of sand, 0-20% of silt and 35-55% of clay. If the proportion of sand exceeds that of clay, it is unclear whether this is still considered clay (due to other properties) or whether a new class "clay sand" should be created. https://www.fao.org/fishery/docs/CDrom/FAO_Training/FAO_Training/General/x6706e/x6706e06.htm USDA textural classes of soils ENVO:06105280 Clay which has a high proportion of silt in its composition. If this is a soil (in which case the differntia must be made clear) it should be moved (or a new class created) and labelled 'silty clay soil'. 2021-12-26T22:14:11Z Some authorities consider this a soil composed of 0-20% of sand, 40-60% of silt and 40-60% of clay. If the proportion of silt exceeds that of clay, it is unclear whether this is still considered clay (due to other properties) or whether a new class "clay silt" should be created. silty clay Some authorities consider this a soil composed of 0-20% of sand, 40-60% of silt and 40-60% of clay. If the proportion of silt exceeds that of clay, it is unclear whether this is still considered clay (due to other properties) or whether a new class "clay silt" should be created. https://www.fao.org/fishery/docs/CDrom/FAO_Training/FAO_Training/General/x6706e/x6706e06.htm USDA textural classes of soils ENVO:1000746 A gelatinous material primarily composed of exopolymeric compounds with colloidal properties, formed through the aggregation of marine snow particles, often found in large sheets, flocs, and clouds. See issue #276. This class is complex as marine mucilage is quite complex. It will also requre new class creation in GO process for deeper semantics. sea snot The formation of marine mucilage is often associated with conditions which stress marine microorganisms such as diatoms. marine mucilage A gelatinous material primarily composed of exopolymeric compounds with colloidal properties, formed through the aggregation of marine snow particles, often found in large sheets, flocs, and clouds. DOI:10.1371/journal.pone.0007006 ENVO:2000007 charcoal that is used as a soil amendment. 2018-11-03T19:28:29Z biochar charcoal that is used as a soil amendment. https://en.wikipedia.org/wiki/Biochar ENVO:2000008 A soft, brown, combustible, sedimentary rock formed from naturally compressed peat. 2018-11-03T19:43:59Z brown coal It is considered the lowest rank of coal due to its relatively low heat content. It has a carbon content around 60–70 percent. lignite A soft, brown, combustible, sedimentary rock formed from naturally compressed peat. https://en.wikipedia.org/wiki/Lignite brown coal https://en.wikipedia.org/wiki/Lignite ENVO:2000009 2018-11-03T19:47:13Z sub-bitumous coal ENVO:2000010 a relatively soft coal containing a tarlike substance called bitumen or asphalt. It is of higher quality than lignite coal but of poorer quality than anthracite. It is an organic sedimentary rock formed by diagenetic and sub metamorphic compression of peat bog material. 2018-11-03T19:47:22Z black coal bitumous coal a relatively soft coal containing a tarlike substance called bitumen or asphalt. It is of higher quality than lignite coal but of poorer quality than anthracite. It is an organic sedimentary rock formed by diagenetic and sub metamorphic compression of peat bog material. https://en.wikipedia.org/wiki/Bituminous_coal ENVO:2000011 A hard, compact variety of coal that has a submetallic luster. It has the highest carbon content, the fewest impurities, and the highest energy density of all types of coal and is the highest ranking of coal. 2018-11-03T19:47:32Z hard coal anthracite A hard, compact variety of coal that has a submetallic luster. It has the highest carbon content, the fewest impurities, and the highest energy density of all types of coal and is the highest ranking of coal. https://en.wikipedia.org/wiki/Anthracite hard coal https://en.wikipedia.org/wiki/Anthracite ENVO:2000044 Coal heated in the absence of air. 2018-11-03T21:29:33Z coke ENVO:2000045 2018-11-03T21:35:24Z hydrocarbon-based environmental material FOODON:00001001 orange juice (liquid) FOODON:00001002 Food material for humans and animals which is processed with the intention that it be consumable as a whole or added to other food products. Damion Dooley Foodon product type https://en.wikipedia.org/wiki/Food The FoodOn "food product" class is provided as a branch under which new food product categories and food products themselves can be placed. Here classes are provided to differentiate a food product by its food composition, processing and/or consumption characteristics. This avoids brand name products but it may include generic food dish categories. It has a much greater depth and polyhierarchy than other agency product type schemes have in an effort to group related products together. The upper level basis of this tree originated in the environment ontology (ENVO) and from the US Code of Federal Regulations. food product FOODON:00001003 The juice products which are made from the fermented sap of the maguey (agave) plant. fermented agave juice FOODON:00001004 This food product type includes food products which are made from fermentation of juice extracted from pressed sugarcane. fermenting sugar cane juice FOODON:00001005 fermenting elaeis palm sap food product FOODON:00001006 A food product made of meat, the skeletal muscle and associated fat, and other edible tissues such as organs, livers, skin, brains, bone marrow, kidneys, or lungs, of mammals. SUBSET_SIREN:F17332 mammalian meat food product FOODON:00001007 A processed meat food product that is made from a sausage. 2022-10-28T11:02:42Z sausage food product FOODON:00001008 Damion Dooley http://langual.org 2019-06-11T23:00:48Z SUBSET_SIREN:F17604 subset_siren SIREN DB annotation: * has quality 'semisolid with smooth consistency' (http://purl.obolibrary.org/obo/FOODON_03430119) * derives from 'liver' (http://purl.obolibrary.org/obo/UBERON_0002107) liver paste https://madison.com/lifestyles/chicken-liver-paste-is-still-a-tasty-treat/article_2194b8cb-82b5-5112-9a97-0042571e90d1.html FOODON:00001009 A hot dog is a moist sausage of soft, even texture and flavor, often made from advanced meat recovery or meat slurry. Most types are fully cooked, cured or smoked. It is often placed hot in a special purpose soft, sliced hot dog bun. Damion Dooley hotdog frankfurter hot dog FOODON:00001010 processed meat food product FOODON:00001011 milk formula food product FOODON:00001013 Cheese is a food derived from milk that is produced in a wide range of flavors, textures, and forms by coagulation of the milk protein casein. SUBSET_SIREN:F1076 https://en.wikipedia.org/wiki/Cheese cheese cheese food product FOODON:00001014 A dairy product produced by bacterial fermentation of milk. Damion Dooley https://en.wikipedia.org/wiki/Yogurt https://upload.wikimedia.org/wikipedia/commons/thumb/2/23/Cacik-1.jpg/549px-Cacik-1.jpg yoghourt yoghurt yougert The bacteria used to make yogurt are known as yogurt cultures. The fermentation of lactose by these bacteria produces lactic acid, which acts on milk protein to give yogurt its texture and characteristic tart flavor. yogurt food product FOODON:00001015 This class includes food products which are derived from or produced by a plant. plant food product FOODON:00001016 Cabbage or headed cabbage (comprising several cultivars of Brassica oleracea) is a leafy green or purple biennial plant, grown as an annual vegetable crop for its dense-leaved heads. https://en.wikipedia.org/wiki/Cabbage cabbage food product FOODON:00001017 commercial yogurt FOODON:00001019 wort food product FOODON:00001020 beer wort food product FOODON:00001021 acifified beer wort food product FOODON:00001023 Cream component produced by churning and containing not less than 80% milkfat. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=C0179 mammalian milk butter FOODON:00001024 pickled cabbage food product FOODON:00001025 camembert cheese food product FOODON:00001027 cheddar cheese food product FOODON:00001028 Brie cheese food product FOODON:00001029 gouda cheese food product FOODON:00001031 gorgonzola cheese food product FOODON:00001032 swiss cheese food product FOODON:00001033 emmenthal cheese food product FOODON:00001035 new zealand cheddar cheese food product FOODON:00001036 pont ieveque cheese food product FOODON:00001037 vacherin mont dor cheese food product FOODON:00001038 A food product made from domestic pig meat (Sus domesticus or Sus scrofa scrofa). Damion Dooley http://en.wikipedia.org/wiki/Pork pork pork meat food product FOODON:00001039 cured meat food product FOODON:00001040 chicken meat food product FOODON:00001041 beef food product FOODON:00001045 ice cream ice-cream ice cream food product FOODON:00001046 A seafood product is a vertebrate or invertibrate organism from an aquatic environment. Some of the subclasses are currently freshwater organisms. Damion Dooley animal seafood product FOODON:00001048 meshanger cheese food product FOODON:00001049 pork chop food product FOODON:00001050 A food product having tempeh as a defining ingredient Damion Dooley tempeh food product FOODON:00001051 fermented rice beverage FOODON:00001052 amasake food product FOODON:00001053 fermented dairy food product FOODON:00001054 fermented fish or seafood food product FOODON:00001055 sea water fish food product FOODON:00001056 A fine powder made from cereals or other starchy food sources. Damion Dooley Wikipedia:Flour http://www.langual.org/langual_thesaurus.asp?termid=H0152 flour added flour food product FOODON:00001057 A food product derived from plant fruit. plant fruit food product FOODON:00001058 fruit extract food product FOODON:00001059 Apple juice is a fruit juice made by the maceration and pressing of an apple. https://en.wikipedia.org/wiki/Apple_juice http://langual.org SUBSET_SIREN:F1419 apple juice subset_siren apple juice FOODON:00001060 awamori food product FOODON:00001061 Any of certain cuts of meat taken from the sides, belly or back of a pig that may be cured and/or smoked. Damion Dooley https://en.wikipedia.org/wiki/Bacon bacon food product FOODON:00001062 fermented millet food product FOODON:00001063 bantu beer millet beer food product FOODON:00001064 bottled beer food product FOODON:00001065 SUBSET_SIREN:F1128 subset_siren SIREN DB annotation: * has quality 'solid' (http://purl.obolibrary.org/obo/FOODON_03430151) * derives from 'curd' (http://purl.obolibrary.org/obo/FOODON_03420245) * formed as a result of 'curing or aging process' (http://purl.obolibrary.org/obo/FOODON_03460253) * formed as a result of 'interior mold curing process' (http://purl.obolibrary.org/obo/FOODON_03460331) blue cheese food product https://en.wikipedia.org/wiki/List_of_blue_cheeses FOODON:00001067 buttermilk food product FOODON:00001069 fermented fruit food product FOODON:00001070 A food produced by fermenting rice, barley and/or soybeans, with salt and the mold koji-kin (Aspergillus oryzae). Damion Dooley SUBSET_SIREN:F1971 subset_siren SIREN DB annotation: * has quality 'semisolid' (http://purl.obolibrary.org/obo/FOODON_03430144) * has quality 'fully heat-treated' (http://purl.obolibrary.org/obo/FOODON_03440014) * derives from 'seed, skin present, germ present' (http://purl.obolibrary.org/obo/FOODON_03420133) * formed as a result of 'fermentation/modification process, multiple component' (http://purl.obolibrary.org/obo/FOODON_03460128) * formed as a result of 'salted' (http://purl.obolibrary.org/obo/FOODON_03460173) * formed as a result of 'curing or aging process' (http://purl.obolibrary.org/obo/FOODON_03460253) * formed as a result of 'preservation by fermentation' (http://purl.obolibrary.org/obo/FOODON_03470104) miso food product FOODON:00001071 A grape berry food product which is the juice of freshly pressed grapes that contains some amount of pulp, skins, stems, and seeds. https://en.wikipedia.org/wiki/Must#Winemaking Grape pomace components typically comprises between 7 to 23 percent of the total weight of must. [https://en.wikipedia.org/wiki/Must] grape must FOODON:00001073 vinegar food product FOODON:00001074 barley malt vinegar FOODON:00001075 mammalian milk (nonfat, dry) FOODON:00001076 Sake is a fermented rice beverage resulting from the fermentation of rice with the mold Aspergillus oryzae and, in parallel, with the yeast Saccharomyces cerevisiae [wikipedia:sake] sake food product FOODON:00001077 salt pork meat food product FOODON:00001078 A food product having fermented soyabeans as a defining ingredient fermented soybean food product FOODON:00001079 A food preserved by soaking and storing it in vinegar or brine. SUBSET_SIREN:F1302 SUBSET_SIREN:F16510 pickled subset_siren subset_siren SIREN DB annotation: * has quality 'solid' (http://purl.obolibrary.org/obo/FOODON_03430151) * formed as a result of 'pickling process' (http://purl.obolibrary.org/obo/FOODON_03460190) food (pickled) FOODON:00001080 tape kefan food product FOODON:00001081 Bondon cheese food product FOODON:00001082 bitter cheese food product FOODON:00001083 sugar condiment FOODON:00001086 kefir food product FOODON:00001087 A lipid material derived from plants. Physically, oils are liquid at room temperature. Damion Dooley vegetable oil food product FOODON:00001088 An oil used as a nutritional supplement and is a traditional European ethnic food, highly regarded for its nutty flavor. http://langual.org 2019-09-19T21:51:42Z http://www.langual.org/langual_thesaurus.asp?termid=H0852 flax oil flax seed oil linseed oil linseed oil Food-grade flaxseed oil is cold-pressed, obtained without solvent extraction, in the absence of oxygen, and marketed as edible flaxseed oil.[wikipedia] flaxseed oil FOODON:00001089 corn flour food product FOODON:00001090 sour milk beverage FOODON:00001091 dried milk food product FOODON:00001092 A food product which is derived from or produced by an animal that has a vertibrae. Damion Dooley vertebrate animal food product FOODON:00001093 cereal grain food product FOODON:00001094 Damion Dooley http://langual.org 2019-06-11T07:25:19Z SUBSET_SIREN:F5644 alcoholic beverage subset_siren SIREN DB annotation: * has quality 'liquid' (http://purl.obolibrary.org/obo/FOODON_03430130) * formed as a result of 'microbial/enzymatic modification process' (http://purl.obolibrary.org/obo/FOODON_03460119) * formed as a result of 'curing or aging process' (http://purl.obolibrary.org/obo/FOODON_03460253) fermented beverage FOODON:00001096 fermented elaeis palm beverage FOODON:00001097 fermented sugar cane beverage FOODON:00001098 fermented apple fermented apple beverage FOODON:00001099 apple beverage FOODON:00001100 Damion Dooley http://langual.org 2019-06-20T07:47:47Z SUBSET_SIREN:F2385 subset_siren SIREN DB annotation: * has quality 'liquid, low viscosity' (http://purl.obolibrary.org/obo/FOODON_03430109) * formed as a result of 'acidified' (http://purl.obolibrary.org/obo/FOODON_03460200) * has substance added 'water addition process' (http://purl.obolibrary.org/obo/FOODON_03460148) * has substance added 'sweetener added' (http://purl.obolibrary.org/obo/FOODON_03460202) * has substance added 'flavoring, spice or herb added' (http://purl.obolibrary.org/obo/FOODON_03460227) orange fruit beverage FOODON:00001102 fermented grain beverage FOODON:00001103 This food product type includes beverage products which are made from the fermented sap of the maguey (agave) plant. fermented agave beverage FOODON:00001104 This food product type includes food products which are made from eggs laid by the sea water fish. sea water fish egg food product FOODON:00001105 A food product made from an avian egg. avian egg food product FOODON:00001106 camelid dairy food product FOODON:00001107 bovine dairy food product FOODON:00001111 equine dairy food product FOODON:00001114 zebra dairy food product FOODON:00001118 cattle dairy food product FOODON:00001120 camelid milk beverage FOODON:00001121 equine milk beverage FOODON:00001124 caprine cheese food product FOODON:00001125 ovine cheese food product FOODON:00001126 bovine cheese food product FOODON:00001127 cow milk cheese FOODON:00001128 A very strong smelling, soft cow's milk cheese made by fermentation involving the bacterium Brevibacterium linens. Limburger cheese food product FOODON:00001129 goat milk cheese food product FOODON:00001130 sheep milk cheese food product FOODON:00001131 A food product made from domesticated bird meat. Damion Dooley poultry meat food product FOODON:00001132 Suidae is a family of artiodactyl mammals which are commonly called pigs, hogs or boars. In addition to numerous fossil species, 17 extant species are currently recognized (or 18 counting domestic pigs and wild boars separately), classified into between four and eight genera. The family includes the domestic pig, Sus scrofa domesticus or Sus domesticus, in addition to numerous species of wild pig, such as babirusas and warthogs. All suids, or swine, are native to the Old World, ranging from Asia to Europe and Africa. Damion Dooley https://en.wikipedia.org/wiki/Suidae porcine meat swine food product FOODON:00001133 A relish, sauce, or seasoning added to food to impart a particular flavour or to complement the dish. Damion Dooley https://en.wikipedia.org/wiki/Condiment condiment condiment food product FOODON:00001134 bovine meat food product FOODON:00001135 distilled fermented grain beverage FOODON:00001136 distilled fermented beverage FOODON:00001138 A beverage product derived from leaves of the tea plant (Camellia sinensis). Damion Dooley "While fermentation is also referred to in the production of brewed teas, this is inaccurate. Some herbal teas on the market today include probiotic cultures alongside tea leaves to maintain gut health but the tea itself hasn't been fermented. Most dried teas however don't use live cultures at all during production. Instead, harvested tea leaves undergo a natural chemical process known as oxidation, which also changes the color, flavor and level of health benefits in the resulting brew." [https://eatcultured.com/blogs/our-awesome-blog/fermented-tea] tea based beverage product FOODON:00001139 coffee and coffee products coffee based beverage product FOODON:00001140 fruit juice food product FOODON:00001141 wheat food product FOODON:00001142 A food product deriving primarily from corn (maize). Damion Dooley maize food product maize (corn) food product FOODON:00001146 tuber solanaceous root food product FOODON:00001147 A food product derived from or produced by a plant root. plant root food product FOODON:00001148 A potato food product is any product derived from potatoes. Damion Dooley potato food product FOODON:00001149 Food items that are rich in sugar, any one or type of which is called a confection. Modern usage may include substances rich in artificial sweeteners as well. confectionery food product FOODON:00001150 cucurbit fruit food product FOODON:00001151 A citrus fruit is botanically classified as a type of berry called a hesperidium that has a thick, leathery rind, with numerous oil glands, and a large flesh portion composed of several wedge-shaped sections. Unlike pome fruit, such as the apple, the citrus fruit is derived from a superior ovary, an ovary completely separate from the calyx. Damion Dooley https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/hesperidium citrus citrus fruit food product FOODON:00001152 The fleshy fruit (false berry) of a plant of the family Cucurbitaceae. melon fruit food product FOODON:00001153 muskmelon (Cucumis melo) fruit food product FOODON:00001154 Citrullus lanatus is a plant species in the family Cucurbitaceae, a vine-like (scrambler and trailer) flowering plant originally from sub-Saharan Africa. It is cultivated for its fruit. The subdivision of this species into two varieties, watermelons (Citrullus lanatus (Thunb.) var. lanatus) and citron melons (Citrullus lanatus var. citroides (L. H. Bailey) Mansf.) Damion Dooley citrullus lanatus fruit food product FOODON:00001156 citrus fruit juice FOODON:00001157 pomaceous fruit juice beverage FOODON:00001158 pomes pomaceous fruit food product FOODON:00001159 fermented pomaceous fruit beverage FOODON:00001160 pomaceous fruit extract FOODON:00001161 citrus fruit extract food product FOODON:00001162 grape extract FOODON:00001163 solanaceous fruit food product FOODON:00001164 A food product deriving from one or more tomatoes. tomato food product FOODON:00001165 solanaceous food product FOODON:00001166 plant inflorescence food product FOODON:00001169 cruciferous food product FOODON:00001170 grape berry food product FOODON:00001171 cruciferous inflorescence food product FOODON:00001172 The default nut product is a whole, raw nut - meaning that the kernel is whole, and moderately or significantly dried, but not baked. Minimal references to nuts often leave ambiguous whether the shell is on or off. "I ate a peanut" doesn't clarify whether I ate a shell-off nut or whether I did the shelling. Damion Dooley SUBSET_SIREN:F16972 nut food product FOODON:00001173 plant seed food product FOODON:00001174 plant lipid food product FOODON:00001175 plant stem food product FOODON:00001176 invertebrate animal food product FOODON:00001177 insect food product FOODON:00001178 honey food product FOODON:00001180 Food product that is 1) ready or nearly ready for consumption; 2) usually a composite of several foods or ingredients that often belong to distinct product types; 3) usually formulated, mixed and partially or fully cooked. prepared prepared food product FOODON:00001181 Damion Dooley cooked food (cooked) FOODON:00001182 pickled cruciferous food product FOODON:00001183 bread food product FOODON:00001184 This food product type includes food products which are derived from a large, diverse group of photosynthetic organisms. http://langual.org SUBSET_SIREN:F10419 subset_siren algal food product FOODON:00001185 rice food product FOODON:00001186 buckewheat food product FOODON:00001187 sorghum food product FOODON:00001189 common oat food product oat food product FOODON:00001190 rye food product FOODON:00001191 barley food product FOODON:00001192 quinoa food product FOODON:00001193 fonio food product FOODON:00001194 A product of the dry seeds of plants of the genus Pisum. Damion Dooley http://en.wikipedia.org/wiki/Legume dry pea food product FOODON:00001196 A product of the dry seeds of Cajanus cajan. http://en.wikipedia.org/wiki/Legume pigeon pea (whole, dried) FOODON:00001197 A bambara groundnut food product is a product derived from fresh or dried beans of the bambara groundnut plant. Damion Dooley https://en.wikipedia.org/wiki/Vigna_subterranea Bambara nut Bambara-bean Congo goober earth pea ground-bean hog-peanut bambara groundnut food product FOODON:00001198 A product of the dry seeds of plants of the genus Vicia. http://en.wikipedia.org/wiki/Legume dried fava bean broad bean (whole, dried) FOODON:00001199 A product of the dry seeds of Cicer arietinum. http://en.wikipedia.org/wiki/Legume garbanzo bean food product Bengal gram Egyptian pea gram chickpea food product FOODON:00001200 A product of the dry seeds of Vigna unguiculata. https://en.wikipedia.org/wiki/Legume cowpea (pulse) food product FOODON:00001201 A dry bean food product refers to a bean product made from a Phaseolus species plant whose seeds are harvested at complete maturity. Damion Dooley https://en.wikipedia.org/wiki/Phaseolus_vulgaris kidney, haricot bean (Ph. vulgaris); lima, butter bean (Ph. lunatus); adzuki bean (Ph. angularis); mungo bean, golden, green gram (Ph. aureus); black gram, urd (Ph. mungo); scarlet runner bean (Ph. coccineus); rice bean (Ph. calcaratus); moth bean (Ph. aconitifolius); tepary bean (Ph. acutifolius) FAO notes: "Only species of Phaseolus should be included, though several countries also include certain types of beans. Commonly classified as Vigna (angularis, mungo, radiata, aconitifolia). In the past, these species were also classified as Phaseolus." dry bean food product http://www.fao.org/WAICENT/faoinfo/economic/faodef/fdef04e.htm#4.02 FOODON:00001202 The winged bean food category covers beans of the winged bean plant Damion Dooley https://en.wikipedia.org/wiki/Winged_bean winged bean food product FOODON:00001203 A product of the dry seeds of Vicia sativa. vetch seed (whole, dried) FOODON:00001204 Pachyrhizus erosus, commonly known as jicama Mexican yam bean, or Mexican turnip, is the name of a native Mexican vine, although the name most commonly refers to the plant's edible tuberous root. Jícama is a species in the genus Pachyrhizus in the bean family (Fabaceae). Plants in this genus are commonly referred to as yam bean, although the term "yam bean" can be another name for jícama. In contrast to the root, the remainder of the jícama plant is very poisonous; the seeds contain the toxin rotenone, which is used to poison insects and fish. FAO: The yam bean is a legume but unlike its close relatives the soybean and other beans, the yam bean is cultivated for its large, tuberous roots. Damion Dooley https://en.wikipedia.org/wiki/Pachyrhizus_erosus http://en.wikipedia.org/wiki/Legume yam bean food product FOODON:00001205 A product of the dry seeds of Mucuna pruriens var. utilis. http://en.wikipedia.org/wiki/Legume velvet bean (whole, dried) FOODON:00001206 lupin seed food product FOODON:00001207 A dry seed of the jack-bean plant. http://en.wikipedia.org/wiki/Legume jack bean (whole, dried) FOODON:00001208 hyacinth bean food product FOODON:00001209 PULSES are annual leguminous crops yielding from one to 12 grains or seeds of variable size, shape and colour within a pod. They are used for both food and feed. The term "pulses" is limited to crops harvested solely for dry grain, thereby excludingcrops harvested green for food (green peas, green beans, etc.) which are classified as vegetable crops. Also excluded are those crops used mainly for oil extraction (e.g.soybeand and groundnuts) and leguminous crops (e.g. seeds of clover and alfalfa) that are used exclusively for sowing purposes. Damion Dooley http://www.fao.org/WAICENT/faoinfo/economic/faodef/fdef04e.htm#4.02 pulse pulses pulse food product https://en.wikipedia.org/wiki/Legume#Classification_of_pulses FOODON:00001210 wheat flour food product FOODON:00001211 pasta food product FOODON:00001212 pastry food product FOODON:00001214 A confection made from a concentrated solution of sugar in water, to which flavorings and colorants are added. Damion Dooley candy food product FOODON:00001215 A food product derived from Theobroma cacao. cocoa and cocoa products cacao food product FOODON:00001216 LANGUAL:C0195 sweet cream cream food product FOODON:00001217 mammalian milk beverage FOODON:00001218 bee food product FOODON:00001219 sausage (cooked, smoked) FOODON:00001220 sausage (smoked) FOODON:00001221 sausage (raw, smoked) FOODON:00001222 A sausage made from meats that have not been previously cured. https://en.wikipedia.org/wiki/Sausage SUBSET_SIREN:F1113 sausage (raw) FOODON:00001223 A cured sausage that is fermented and dried. Damion Dooley http://en.wikipedia.org/wiki/Sausage sausage (dried, fermented) FOODON:00001224 A sausage made with fresh meats, and then fully cooked. Damion Dooley sausage (cooked) FOODON:00001225 smoked meat food product FOODON:00001229 processed cheese food product FOODON:00001230 A product made from the seeds of a mustard plant (white or yellow mustard, Sinapis hirta; brown or Indian mustard, Brassica juncea; or black mustard, Brassica nigra). mustard seed food product FOODON:00001231 creamy salad dressing FOODON:00001232 vinaigrette dressing food product FOODON:00001233 nut oil food product FOODON:00001234 mayonnaise food product FOODON:00001235 soy sauce food product FOODON:00001241 processed pork meat food product FOODON:00001242 A vegetable product such as leaves, flowers, seeds and roots that is rich in essential oils and aromatic principles. Used mainly a a condiment. Damion Dooley http://www.fao.org/WAICENT/faoinfo/economic/faodef/fdef10e.htm#1.01 http://www.langual.org/langual_thesaurus.asp?termid=H0151 herb and spice herb or spice spice or herb FOODON:00001243 animal lipid food product FOODON:00001244 A brewed drink prepared from roasted seeds, commonly called coffee beans, of the coffee plant. Damion Dooley coffee beverage FOODON:00001245 A beverage prepared from the cured leaves of Camellia sinensis by combination with hot or boiling water. Damion Dooley tea beverage (liquid) FOODON:00001246 hot chocolate food product FOODON:00001247 mate food product FOODON:00001248 A fish food product includes products made from any fish species (aquatic vertebrate with gills and fins). Damion Dooley fish food product FOODON:00001250 fish egg food product FOODON:00001251 avian food product FOODON:00001252 animal derived beverage FOODON:00001253 plant derived beverage FOODON:00001254 plant derived fermented beverage FOODON:00001255 nonfermented plant derived beverage product FOODON:00001256 A dairy food product has mammilian milk or a milk component as an ingredient. Damion Dooley http://www.langual.org/langual_thesaurus.asp?termid=H0242 dairy product milk product dairy food product FOODON:00001257 milk or milk based food product FOODON:00001258 Are all fermented foods considered preserved to some extent? Damion Dooley food (fermented) FOODON:00001259 non-fruit wine food product FOODON:00001260 Beer is a fermented cereal beverage resulting from the fermentation most commonly of malted barley (though wheat, corn, or rice may included), by a yeast, most commonly Saccharomyces cerevisiae, and flavored by dried flowers of hops, Humulus lupulus. https://en.wikipedia.org/wiki/Beer beer beverage FOODON:00001261 Any plant food product which, typically, is constituted by intact parts from one or more annual plants cultivated as field and garden crops in the open and under glass, and used almost exclusively for food. vegetable food product FOODON:00001262 botanical fruit food product FOODON:00001264 A one-celled fruit (pod) usually dehiscing down both sutures, and having the seed attached along a ventral suture. (Roubik 1995) http://www.fao.org/pollination/resources/glossary/en/ legume http://purl.obolibrary.org/obo/FOODON_03411254 http://purl.obolibrary.org/obo/FOODON_03411338 legume food product FOODON:00001266 camel milk beverage FOODON:00001272 zebra milk beverage FOODON:00001274 Regarding American regulatory aspects of egg products, see this summary: https://www.politico.com/agenda/story/2016/03/crazy-us-chicken-egg-regulation-graphic-000077 egg food product FOODON:00001275 A hen egg food product is any food product consisting mainly of hen eggs or derivatives. https://en.wikipedia.org/wiki/Egg_as_food SUBSET_SIREN:F1074 hen egg food product FOODON:00001276 Cider, hard apple cider, or hard cider in the US, is an alcoholic beverage made from the fermented juice of apples. Damion Dooley https://en.wikipedia.org/wiki/Cider cider apple cider (alcoholic) FOODON:00001277 orange juice (unpasteurized) FOODON:00001278 cake food product FOODON:00001279 cake icing food product FOODON:00001280 chocolate food product FOODON:00001281 A food involving whipped and cooked milk, sugar and egg yolk mixtures. sweet custard custard dessert food product FOODON:00001282 A ground beef product is made of beef that has been finely chopped with a knife or a meat grinder (American English) or mincing machine (British English). Ground beef is used in many recipes including hamburgers and spaghetti Bolognese. beef mince beef mince ground beef hamburger meat minced beef ground beef food product FOODON:00001283 A food product from a category of domestic birds kept for meat, eggs, and feathers including fowl such as chickens, turkeys, and waterfowls such as domestic ducks and geese and other meat birds such as pigeons and doves and games birds including pheasants. Damion Dooley poultry food product FOODON:00001284 duck meat food product FOODON:00001285 goose meat food product FOODON:00001286 A turkey meat food product is any food product made predominantly of turkey parts. Damion Dooley turkey meat food product FOODON:00001288 Cantaloupe (also known as muskmelon (India and the United States), mushmelon, rockmelon (in Australian states and in New Zealand), sweet melon, spanspek (South Africa), or capuchin (Scotland) refers to a variety of the Cucumis melo species in the Cucurbitaceae family. Damion Dooley cantaloup muskmelon cantaloupe fruit food product FOODON:00001289 potato salad food product FOODON:00001290 A sauce for a salad. http://en.wikipedia.org/wiki/Salad_dressing#Dressings salad dressing FOODON:00001291 clam food product FOODON:00001292 oyster food product FOODON:00001293 shellfish food product FOODON:00001294 goat milk cheese (unpasteurized) FOODON:00001295 A family of hard Italian cheeses made from sheep milk. Damion Dooley pecorino cheese FOODON:00001296 sheep milk cheese (unpasteurized) FOODON:00001298 unpasteurized camel milk beverage FOODON:00001610 apple condiment FOODON:00001611 apple food product FOODON:00001613 apple vinegar food product FOODON:00001626 bakery food product FOODON:00001632 barley flour food product FOODON:00001635 A bean vegetable food product is a human or animal food product - such as a snap, shell or dry bean product - derived from the fruit pod, seed, or leaf of one of several genera of the flowering plant family Fabaceae. Note, this was previously labelled "Bean (vegetable) food product". We have been listing both dry and freshly harvested moist beans here, so have broadened the name scope. Damion Dooley bean food product http://purl.obolibrary.org/obo/FOODON_00002428 http://www.fao.org/es/faodef/fdef04e.htm#4.02 https://oconto.extension.wisc.edu/files/2011/02/The-Importance-of-Dry-Beans-in-Your-Diet.pdf FOODON:00001640 berry food product FOODON:00001665 A broad bean food product is a product derived from the broad bean plant. Damion Dooley broad bean food product FOODON:00001675 cabbage juice food product FOODON:00001696 cattle cured meat food product FOODON:00001714 A food product which normally exists as an ingredient to another food product, rather than eaten on its own, and is more complex than a chemical food component. food product component FOODON:00001747 cocoa beverage FOODON:00001757 common bean food product FOODON:00001771 cow milk based food product FOODON:00001777 cow milk dessert FOODON:00001783 cowpea vegetable food product FOODON:00001800 dairy dessert food product FOODON:00001838 fermented cereal beverage FOODON:00001857 food flavoring or seasoning product FOODON:00001859 linseed food product flaxseed food product FOODON:00001867 food dressing product FOODON:00001878 frozen dairy dessert FOODON:00001879 frozen dairy food product FOODON:00001891 fruit salad food product FOODON:00001919 grain based vinegar food product FOODON:00001994 A food product made from legumes that are considered vegetables, such as immature raw legume pods or seeds. Damion Dooley leguminous vegetable food product FOODON:00002012 lupin lupine bean food product FOODON:00002029 melon food product FOODON:00002035 milk dessert food product FOODON:00002038 millet food product FOODON:00002044 mollusk food product mollusc food product FOODON:00002053 mustard food product FOODON:00002071 orange food product FOODON:00002115 A product containing primarily immature ripe pigeon peas. Damion Dooley 2019-07-14T10:26:00 pigeon pea vegetable food product FOODON:00002125 plant based bakery food product FOODON:00002126 plant-based candy FOODON:00002131 plant based refined or partially-refined food product FOODON:00002132 plant based salad food product FOODON:00002139 An edible plant fat or oil product with characteristics that consumers desire such as bland flavour and odour, clear appearance, light colour, stability to oxidation and suitability for frying, and which is the result of a refining process that removes free fatty acids. Damion Dooley plant fat or oil refined food product FOODON:00002141 A plant fruit food product which is labeled (in common language or by regulation) as a vegetable food product. plant fruit as vegetable food product FOODON:00002146 plant product dressing FOODON:00002151 plant seed based bakery food product FOODON:00002153 plant seed vegetable food product FOODON:00002156 plant stem or spear vegetable food product FOODON:00002157 plant sweetener FOODON:00002158 Damion Dooley preserved food (preserved) FOODON:00002165 organ meat product FOODON:00002175 A prepared hen egg product is a product predominantly made of hen egg that has been cooked and may only require defrosting or reheating for consumption. Damion Dooley prepared hen egg product FOODON:00002196 refined or partially-refined food product FOODON:00002219 salad food product FOODON:00002252 soft cheese food product FOODON:00002262 soybean condiment FOODON:00002265 soybean seed (field) food product http://purl.obolibrary.org/obo/FOODON_00002266 FOODON:00002266 A soybean food product is a product derived from the soybean plant. Damion Dooley soy product soybean food product http://purl.obolibrary.org/obo/FOODON_00002265 FOODON:00002275 steeped beverage product FOODON:00002300 http://www.langual.org/langual_thesaurus.asp?termid=H0202 sweetener food product FOODON:00002301 pork cured meat food product FOODON:00002316 tomato juice food product FOODON:00002333 vegetable pickle food product FOODON:00002364 wine or wine-like food product FOODON:00002373 A meal type is the name of an eating occasion that may have location, food type, or other customary contextual features. (Damion's 1st draft definition) Damion Dooley food product by meal type FOODON:00002381 A food product consisting of food material derived primarily from a single organism. Damion Dooley food product by organism FOODON:00002403 Any substance that can be consumed by an organism to satisfy nutritional or other health needs, or to provide a social or organoleptic food experience food foodstuff nourishment sustenance This class is the top of FOODON's main food product hierarchy which is described in the https://www.foodon.org website, and can be searched in lookup services like https://www.ebi.ac.uk/ols/ food material FOODON:00002423 agave food product FOODON:00002450 multi-component honey product FOODON:00002454 A class which contains food product categories qualified by a quality such as granularity or temperature, which is useful for tasks like food inspection where little prior knowledge of how the food came to be is available. Some terms like "food (frozen)" are both a quality descriptor and the output of a process. Damion Dooley food product by quality FOODON:00002456 baked baked food product food (baked) FOODON:00002501 A food product consisting of food material derived from ingredients sourced from multiple organisms. Damion Dooley 2019-01-23T22:40:32Z multi-ingredient The definition of this is being discussed in issue: https://github.com/FoodOntology/foodon/issues/57 Namely, how to characterize the threshold of ingredients that make for multi-component classification? Salt, pepper, spices wouldn't normally make a food multi-component? multi-component food product FOODON:00002643 requires discussion A preserved food, where the moisture levels in the food product have been reduced to low levels to improve shelf life. Damion Dooley https://www.sciencedirect.com/topics/food-science/food-dehydration https://orcid.org/0000-0002-8844-9165 | https://orcid.org/0000-0001-5193-0062 | https://orcid.org/0000-0001-8008-8249 2019-05-23T19:53:09Z food (dessicated) food (dehydrated) FOODON:00002645 A food product organized by the process which it results from. Damion Dooley 2019-05-23T23:02:07Z food product by process FOODON:00002663 Damion Dooley 2019-06-14T04:23:35Z pork food product FOODON:00002664 A lipid food product is a food product made primarily of plant or animal fat or oil Damion Dooley 2019-06-11T09:18:41Z fats and oils oils and fats lipid food product FOODON:00002752 A whole dried bean is a bean resulting from natural or mechanical air drying applied to a bean or bean pod. Damion Dooley 2019-06-29T14:48:10Z dried bean bean (whole, dried) http://www.fao.org/es/faodef/fdef04e.htm#4.02 FOODON:00002753 A seed of a bean plant from one of several genera of the flowering plant family (Fabaceae). Damion Dooley's note. This could be enhanced to explicitly state the anatomical parts of a seed - seed coat, cotyledons, embryo etc. Currently the Plant Ontology is not explicit about this yet. Damion Dooley https://orcid.org/0000-0001-5275-8866 2020-10-14T07:28:59 bean bean (whole) FOODON:00002762 Cooked bean material is the bean material output of a cooking process applied to dry, rehydrated, or raw (fresh) beans. Damion Dooley 2019-07-08T21:47:07Z bean (cooked) FOODON:00002778 A seed of a jack seed plant (Canavalia ensiformis). Damion Dooley https://en.wikipedia.org/wiki/Canavalia_ensiformis 2019-07-09T22:17:36 jack bean jack bean (whole) FOODON:00002779 Damion Dooley 2019-07-09T22:21:16Z jack-bean food product FOODON:00002780 A pigeon pea food product is a food product derived from the pigeon pea plant Damion Dooley 2019-07-09T22:29:17Z pigeon pea food product https://en.wikipedia.org/wiki/Pigeon_pea FOODON:00002781 A seed of a pigeon pea plant (Cajanus cajan). http://orcid.org/0000-0002-8844-9165 https://en.wikipedia.org/wiki/Pigeon_pea 2019-07-09T22:29:49 pigeon pea pigeon pea (whole) FOODON:00002786 A seed of a velvet bean plant (Mucuna pruriens) Damion Dooley http://en.wikipedia.org/wiki/Legume https://en.wikipedia.org/wiki/Mucuna_pruriens 2019-07-10T00:00:22 tericopelo bean tericopelo bean velvet bean velvet bean (whole) FOODON:00002787 Damion Dooley 2019-07-10T00:16:38Z vetch food product FOODON:00002791 A seed of a vetch plant. Damion Dooley https://en.wikipedia.org/wiki/Vicia 2019-07-10T01:33:15Z vetch seed vetch seed (whole) FOODON:00002813 Damion Dooley 2019-07-12T17:18:31Z pea food product FOODON:00002819 A liver food product is a food product that derives from one or more liver organs. Damion Dooley 2019-08-02T18:22:37Z liver food product FOODON:00003341 A genus of plants in the mustard family (Brassicaceae). The members of the genus are informally known as cruciferous vegetables, cabbages, or mustard plants. bok choy vegetable food product bomdong vegetable food product broccolini vegetable food product chinese cabbage vegetable food product choy sum vegetable food product collard greens vegetable food product gai lan vegetable food product komatsuna vegetable food product mizuna vegetable food product rutabaga vegetable food product savoy cabbage vegetable food product tatsoi vegetable food product cole crop vegetable food product cruciferous vegetable food product brassica food product FOODON:00003395 2020-09-06T15:59:54Z multi-component wheat food product FOODON:00004156 A bean food product made from velvet bean. 2021-12-24T00:12:16Z velvet bean food product FOODON:00004242 A food product deriving from one or more animals. 2022-09-01T16:31:09Z animal food product FOODON:03301073 http://langual.org SUBSET_SIREN:F1073 subset_siren SIREN DB annotation: * has quality 'crystal' (http://purl.obolibrary.org/obo/FOODON_03430143) * has quality 'fully heat-treated' (http://purl.obolibrary.org/obo/FOODON_03440014) * derives from 'sugar' (http://purl.obolibrary.org/obo/FOODON_03420108) * formed as a result of 'water removal process' (http://purl.obolibrary.org/obo/FOODON_03460138) * formed as a result of 'preservation by dehydration or drying' (http://purl.obolibrary.org/obo/FOODON_03470116) sugar (granulated) FOODON:03301103 http://langual.org SUBSET_SIREN:F1103 SUBSET_SIREN:F11069 subset_siren SIREN DB annotation: * has quality 'liquid, low viscosity, with small particles' (http://purl.obolibrary.org/obo/FOODON_03430114) * derives from 'fruit, peel removed, core, pit or seed removed' (http://purl.obolibrary.org/obo/FOODON_03420229) orange juice FOODON:03301227 A seed of a broad bean plant (Vicia faba). http://orcid.org/0000-0002-8844-9165 http://langual.org SUBSET_SIREN:F1227 Windsor bean broad bean broadbean faba bean fava bean Horse bean field bean tic bean tick bean subset_siren broad bean (whole) FOODON:03301444 http://langual.org SUBSET_SIREN:F1444 subset_siren SIREN DB annotation: * has quality 'liquid' (http://purl.obolibrary.org/obo/FOODON_03430130) * derives from 'part of plant' (http://purl.obolibrary.org/obo/FOODON_03420174) vegetable juice food product FOODON:03301467 A bean substance is a substance made by processing seed from a bean plant. Damion Dooley's note: This class is intended to provide the most generic reference to bean, as it does not imply any more information about the state of a bean - whether it is whole or in fragments, or fragments of several beans, whether it is dry, raw, or cooked etc. Damion Dooley https://en.wikipedia.org/wiki/Bean http://langual.org SUBSET_SIREN:F1467 subset_siren SIREN DB annotation: * derives from 'seed (anatomical part)' (http://purl.obolibrary.org/obo/FOODON_03420155) bean substance FOODON:03301977 A liquid prepared for consumption, or a product that can be combined with water or milk to make one. Damion Dooley http://langual.org 2019-09-12T00:00:00 beverage food product FOODON:03302001 http://langual.org SUBSET_SIREN:F2001 subset_siren SIREN DB annotation: * derives from 'part of animal' (http://purl.obolibrary.org/obo/FOODON_03420164) animal-derived food FOODON:03302082 http://langual.org SUBSET_SIREN:F2082 subset_siren SIREN DB annotation: * has quality 'solid' (http://purl.obolibrary.org/obo/FOODON_03430151) * derives from 'skeletal meat part, without bone or shell' (http://purl.obolibrary.org/obo/FOODON_03420125) * formed as a result of 'water removal process' (http://purl.obolibrary.org/obo/FOODON_03460138) * formed as a result of 'preservation by dehydration or drying' (http://purl.obolibrary.org/obo/FOODON_03470116) beef (dehydrated) FOODON:03303220 http://langual.org SUBSET_SIREN:F3220 desert preparation dessert subset_siren SIREN DB annotation: * has substance added 'sugar or sugar syrup added' (http://purl.obolibrary.org/obo/FOODON_03460136) dessert food FOODON:03303909 A cultured dairy product is a fermented dairy product in which a microbial starter was introduced to the fermentation process. http://langual.org SUBSET_SIREN:F3909 subset_siren SIREN DB annotation: * derives from 'milk (mammary secretion)' (http://purl.obolibrary.org/obo/UBERON_0001913) * formed as a result of 'microbial/enzymatic modification process' (http://purl.obolibrary.org/obo/FOODON_03460119) cultured dairy product FOODON:03304497 http://langual.org SUBSET_SIREN:F4497 subset_siren SIREN DB annotation: * has quality 'whole, natural shape' (http://purl.obolibrary.org/obo/FOODON_03430150) * derives from 'seed (anatomical part)' (http://purl.obolibrary.org/obo/FOODON_03420155) edible seed food product FOODON:03305536 http://langual.org SUBSET_SIREN:F5536 subset_siren SIREN DB annotation: * has quality 'liquid, high viscosity, with no visible particles' (http://purl.obolibrary.org/obo/FOODON_03430139) * has quality 'fully heat-treated' (http://purl.obolibrary.org/obo/FOODON_03440014) * derives from 'sugar syrup or syrup solids' (http://purl.obolibrary.org/obo/FOODON_03420271) * has substance added 'honey added' (http://purl.obolibrary.org/obo/FOODON_03460149) honey blend table syrup FOODON:03307345 http://langual.org SUBSET_SIREN:F7345 subset_siren SIREN DB annotation: * has quality 'crystal' (http://purl.obolibrary.org/obo/FOODON_03430143) * has quality 'fully heat-treated' (http://purl.obolibrary.org/obo/FOODON_03440014) * derives from 'white sugar' (http://purl.obolibrary.org/obo/FOODON_03420157) sugar (refined) FOODON:03307539 http://langual.org SUBSET_SIREN:F7539 subset_siren SIREN DB annotation: * formed as a result of 'water removal process' (http://purl.obolibrary.org/obo/FOODON_03460138) * formed as a result of 'preservation by dehydration or drying' (http://purl.obolibrary.org/obo/FOODON_03470116) food (dried) FOODON:03310006 http://langual.org SUBSET_SIREN:F10006 subset_siren SIREN DB annotation: * derives from 'seed (anatomical part)' (http://purl.obolibrary.org/obo/FOODON_03420155) * formed as a result of 'microbial/enzymatic modification process' (http://purl.obolibrary.org/obo/FOODON_03460119) * formed as a result of 'curing or aging process' (http://purl.obolibrary.org/obo/FOODON_03460253) fermented bean product FOODON:03310387 http://langual.org SUBSET_SIREN:F10387 subset_siren SIREN DB annotation: * has quality 'liquid, high viscosity, with no visible particles' (http://purl.obolibrary.org/obo/FOODON_03430139) * derives from 'fat or oil' (http://purl.obolibrary.org/obo/FOODON_03420190) oil FOODON:03311737 http://langual.org SUBSET_SIREN:F11737 subset_siren processed food product FOODON:03312053 http://langual.org SUBSET_SIREN:F12053 subset_siren SIREN DB annotation: * has quality 'divided or disintegrated' (http://purl.obolibrary.org/obo/FOODON_03430122) * has quality 'fully heat-treated' (http://purl.obolibrary.org/obo/FOODON_03440014) * derives from 'skeletal meat part, without bone, without skin' (http://purl.obolibrary.org/obo/FOODON_03420268) * formed as a result of 'microbial/enzymatic modification process' (http://purl.obolibrary.org/obo/FOODON_03460119) * formed as a result of 'water removal process' (http://purl.obolibrary.org/obo/FOODON_03460138) * formed as a result of 'preservation by dehydration or drying' (http://purl.obolibrary.org/obo/FOODON_03470116) pork (dehydrated) FOODON:03315150 http://langual.org SUBSET_SIREN:F15150 subset_siren SIREN DB annotation: * derives from 'milk (mammary secretion)' (http://purl.obolibrary.org/obo/UBERON_0001913) mammalian milk product FOODON:03315173 A fish product is a home-made or commercially produced or retail or wholesale product containing substantial amounts of freshwater or saltwater fish and/or shellfish flesh. Note that this category should avoid items that mention a particular species of fish or shellfish. Damion Dooley http://langual.org SUBSET_SIREN:F15173 subset_siren SIREN DB annotation: * derives from 'skeletal meat part' (http://purl.obolibrary.org/obo/FOODON_03420175) fish product (unspecified species) https://en.wikipedia.org/wiki/Fish_products FOODON:03315302 http://langual.org SUBSET_SIREN:F15302 subset_siren SIREN DB annotation: * derives from 'seed, skin present, germ present' (http://purl.obolibrary.org/obo/FOODON_03420133) * formed as a result of 'microbial/enzymatic modification process' (http://purl.obolibrary.org/obo/FOODON_03460119) * formed as a result of 'curing or aging process' (http://purl.obolibrary.org/obo/FOODON_03460253) cocoa food product FOODON:03315552 http://langual.org SUBSET_SIREN:F15552 juice subset_siren juice beverage FOODON:03315904 A food product that is highly seasoned minced meat and is encased in a skin in the shape of a cylinder. https://en.wikipedia.org/wiki/Sausage http://langual.org SUBSET_SIREN:F15904 sausage subset_siren SIREN DB annotation: * has quality 'whole, shape achieved by forming' (http://purl.obolibrary.org/obo/FOODON_03430147) * derives from 'meat part of animal' (http://purl.obolibrary.org/obo/FOODON_03420103) * has substance added 'flavoring, spice or herb added' (http://purl.obolibrary.org/obo/FOODON_03460227) sausage (whole) FOODON:03315925 http://langual.org SUBSET_SIREN:F15925 subset_siren SIREN DB annotation: * has quality 'solid' (http://purl.obolibrary.org/obo/FOODON_03430151) * derives from 'meat part of animal' (http://purl.obolibrary.org/obo/FOODON_03420103) pate FOODON:03316079 http://langual.org SUBSET_SIREN:F16079 subset_siren SIREN DB annotation: * has quality 'liquid' (http://purl.obolibrary.org/obo/FOODON_03430130) * has quality 'heat-treated' (http://purl.obolibrary.org/obo/FOODON_03440022) * derives from 'part of plant' (http://purl.obolibrary.org/obo/FOODON_03420174) * formed as a result of 'steeping' (http://purl.obolibrary.org/obo/FOODON_03450036) herbal infusion FOODON:03316271 http://langual.org SUBSET_SIREN:F16271 subset_siren SIREN DB annotation: * derives from 'sugar' (http://purl.obolibrary.org/obo/FOODON_03420108) sugar product FOODON:03316579 http://langual.org SUBSET_SIREN:F16579 subset_siren SIREN DB annotation: * derives from 'part of plant' (http://purl.obolibrary.org/obo/FOODON_03420174) multi-component plant food product FOODON:03316694 http://langual.org SUBSET_SIREN:F16694 subset_siren SIREN DB annotation: * derives from 'fat or oil' (http://purl.obolibrary.org/obo/FOODON_03420190) vegetable fat food product FOODON:03317170 A meat product is a product organized by the form of - or processing done to - its meat component (a skeletal meat part of an animal or crustacean). http://langual.org SUBSET_SIREN:F17170 subset_siren SIREN DB annotation: * derives from 'animal body or body part' (http://purl.obolibrary.org/obo/FOODON_03420127) meat (whole or parts) FOODON:03400115 Natural cheese, cured or uncured, cheese product (which is further processed), or cheese product analog. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0115 cheese or cheese product (us cfr) FOODON:03400143 Fruit in all forms; includes fruit juices and fruit juice drinks, fruit butters, jellies, preserves, and related products. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0143 pie filling, fruit fruit or fruit product (us cfr) FOODON:03400147 Food product having functional characteristics similar to milk or milk products, including cream product analogs, margarine, and milk analogs. Certain alternate ingredients are substituted for those components that are responsible for specific functional properties. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0147 milk or milk product analog (us cfr) FOODON:03400148 Milk in all forms, milk-based beverage, cultured milk product, or milk or milk product analog. Index infant formula under *MEAL REPLACEMENT*. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0148 milk or milk product (us cfr) FOODON:03400155 Semisolid or jelled food prepared from fruit or fruit juice and other ingredients prescribed for the individual products (21 CFR 150). http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0155 fruit butter, jelly, preserve or related product (us cfr) FOODON:03400164 Milk, a product derived from milk, or a dairy product analog; includes cheese and frozen dairy desserts. [FDA CFSAN 1995] http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0164 dairy product (us cfr) FOODON:03400187 Cheese made from milk or milk components, such as cream, by the following process: (1) produce curd through coagulation of milk by bacterial action and/or enzymes and/or acidification and draining of whey. (2) For cured cheese only: cure the curd. Excludes products made through further processing, such as comminuting (see *CHEESE PRODUCT*). http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0187 natural cheese (us cfr) FOODON:03400188 Candy or other food product made with sweeteners and frequently containing nuts, fruits, starches, flavorings and other foods (21 CFR 170.3(n)(9). [FDA CFSAN 1995] http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0188 confectionery (us cfr) FOODON:03400204 Food product prepared by heating a mixture of sweeteners and other optional ingredients according to the specific formula for each subgroup. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0204 candy (us cfr) FOODON:03400209 Jelled product made from one or more fruit juices and optional ingredients. Includes both fruit jelly, which may be sweetened with nutritive carbohydrate sweeteners, (21 CFR 150.140), and artificially sweetened fruit jelly (21 CFR 150.141). The finished fruit jelly must have a soluble solid content of no less than 65% and the ratio by weight of the fruit ingredient to sweetener in the starting mixture must be no less than 45:55. Artificially sweetened fruit jelly must contain no less than 55% fruit ingredient by weight. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0209 fruit jelly (us cfr) FOODON:03400213 Soft candy prepared by boiling milk, sugar, salt and optional ingredients to the soft-ball stage (238 degrees F.). http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0213 fudge (us cfr) FOODON:03400231 Food product having functional characteristics similar to those of butter; it is in plastic form or liquid emulsion and contains not less than 80% fat whose origin is vegetable or rendered animal carcass fats or a mixture of these as well as other optional ingredients specified by 21 CFR 166.110. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0231 margarine (us cfr) FOODON:03400257 Fruits and vegetables in all forms. [FDA CFSAN 1995] http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0257 fruit or vegetable product (us cfr) FOODON:03400289 Food group having common consumption, functional or manufacturing characteristics, e.g. *FRUIT OR VEGETABLE PRODUCT*, *DAIRY PRODUCT*, *CONFECTIONARY*, *PREPARED FOOD PRODUCT*, etc. [FDA CFSAN 1995] http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0289 LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. USA agency food product type FOODON:03400293 Candy prepared by cooking a mixture of water, sugars and optional ingredients to a temperature of 250 degrees F. or less. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0293 soft candy (us cfr) FOODON:03400294 Food product having functional characteristics similar to a butter product; it may be nutritionally equivalent or inferior to the product it purports to resemble. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0294 butter substitute butter, imitation imitation butter butter product analog (us cfr) FOODON:03400352 Renamed from *PRODUCT TYPE, CODEX ALIMENTARIUS* in LanguaL 2008. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0352 LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. international agency food product type FOODON:03400356 http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0356 LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. European Union agency food product type FOODON:03400361 An agency food product type is a class of food product defined by an agency or consortium. Damion Dooley http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0361 This class is designed to hold 3rd party food classification schemes which are being mapped to FoodOn classes using the 'has member' relation. The two hierarchies are not melded into a subclass polyhierarchy because of possible logical inconsistencies in the agency schemes. The hierarchies of agency schemes are as true to their agency representation as possible. agency food product type FOODON:03400643 Codex Alimentarius, Volume 2 - 1993, Section 2: Pesticide Residues in Food. The Codex Classification of food and animal feed commodities moving in trade and the description of the various items and groups of food and animal feedstuffs included in the present document have been developed by the Codex Committee on Pesticide Residues. It was first adopted by the 18th Session of the Codex Alimentarius Commission, (1989). The Codex Classification includes food commodities and animal feedstuffs for which Codex maximum residue limits will not necessarily be established. The Classification is intended to be as complete a listing of food commodities in trade as possible, classified into groups on the basis of the commodity's similar potential for pesticide residues. The Classification may also be appropriate for other purposes such as setting maximum levels for other types of residues or for other contaminants in food. The Codex Classification should be consulted in order to obtain a precise description of the food or animal feed commodities and, especially, in cases where Codex maximum residue limits have been set for groups of food and groups of animal feedstuffs. The Codex Classification is intended to promote harmonization of the terms used to describe commodities which are subject to maximum residue limits and of the approach to grouping commodities with similar potential for residue for which a common group maximum residue limit can be set. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0643 LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. Codex Alimentarius classification of food and feed commodities FOODON:03400644 http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0644 LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. a. primary food commodities of plant origin (ccpr) FOODON:03400650 Vegetables are foods derived from many different kinds of plants mostly annual and usually cultivated, commonly known by custom and tradition as "vegetables". In several countries, some of these commodities grown on large areas are distinguished as "field crops" or arable crops e.g. sugar beet. For the sake of convenience in this guide such crops are classified under Type 2 Vegetables. Exposure to pesticides is dependent on the particular part of the plant used for food and the growing practices. Vegetables may be consumed in whole or in part and in the form of fresh, dried or processed foods. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0650 02 vegetables (ccpr) FOODON:03400680 Pulses are derived from the mature seeds naturally or artificially dried, of leguminous plants known as beans (dry) and peas (dry). The seeds in the pods are protected from most pesticides applied during the growing season except pesticides which show a systemic action. The dried beans and peas however are often exposed to post-harvest treatments. The dry pulses are consumed after processing or household cooking. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0680 015 pulses (vd) (ccpr) FOODON:03400777 http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0777 LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. eurofir food classification FOODON:03400801 The group includes marine or freshwater fish, molluscs, crustaceans, and other fauna such as reptiles, insects or frogs not in the “Meats” group. The group also includes seafood product analogs and seafood-based sausage or luncheon meat as well as such products as squid ink and clam juice. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0801 seafood or related product (eurofir) FOODON:03400803 includes fish offal; a food product whose predominant constituent is fish (e.g. dried and salted fish, smoked fish, canned fish, pickled fish, restructured fish and fish analogues, surimi; fish paste, pâté). http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0803 seafood product (eurofir) FOODON:03400840 Alcoholic or non-alcoholic beverage; excludes milk and milk-based beverages. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0840 beverage (non-milk) (eurofir) FOODON:03400842 Beverage containing no more than 0.5% alcohol; it may be flavoured, sweetened or carbonated; includes soft drinks and steeped beverages; excludes milk in all forms, fruit juices and vegetable juices. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0842 non alcoholic beverage (eurofir) FOODON:03400845 Beverage prepared by extracting flavour and other components from food sources by percolation and/or immersion in water, usually at near-boiling temperature. The group includes coffee (e.g. instant coffee, coffee and chicory essence), tea, herbal tea (e.g. green tea, black tea, tisane), cocoa beverage and beverage powder. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0845 infusion steeped beverage LanguaL curation note: Renamed from *COFFEE, TEA, COCOA (EUROFIR)* (LanguaL 2010). coffee, tea, cocoa or infusion (eurofir) FOODON:03400852 EFG group 32, Eurocode-2 group 12. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0852 LanguaL curation note: Use for foods and ingredients that could not fit into any of the above classes. miscellaneous food product (eurofir) FOODON:03400861 This subgroup includes multicomponent meals, sauces, retail salads, desserts, soups, snacks and other foods where similarity of the product type is more significant than the source of the principal ingredient(s). http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0861 soup, sauce or miscellaneous food product prepared food product (eurofir) FOODON:03400865 A liquid food made by simmering meat, poultry, seafood or vegetables, being clear or thickened to the consistency of a thin puree or having milk or cream added, and often containing pieces of solid food such as meat, shellfish, pasta or vegetables. Soup takes precedence over other food products. Examples are egg and lemon soup, oxtail soup, fish soup, rice soup, lentil soup, minestrone, cherry soup. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0865 soup (eurofir) FOODON:03400874 The Global System 1 (GS1) Global Product Classification (GPC) is a system that gives buyers and sellers a common language for grouping products in the same way, everywhere in the world.$br/$ The GS1 GPC classification in facet A is currently updated based on June 2017 release of GS1 GPC Standard for Food/Beverage/Tobacco, except for codes pertaining to tobacco. See the GS1 site for details [https://www.gs1.org/standards/gpc]. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0874 GS1 Global Product Classification (GPC) FOODON:03400960 http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0960 50220000 - cereal/grain/pulse products (gs1 gpc) FOODON:03400969 http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A0969 50221200 - processed cereal products (gs1 gpc) FOODON:03401061 http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A1061 50190000 - prepared/preserved foods (gs1 gpc) FOODON:03401095 http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A1095 50192900 - pasta/noodles (gs1 gpc) FOODON:03401270 Food and Drugs, title 21, Code of Federal Regulations. Original food classification in LanguaL. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=A1270 LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. U.S. code of federal regulations, title 21 food product type https://www.ecfr.gov/cgi-bin/text-idx?SID=87f720ce0d0b6c4548f4bbfd1f8e4c3d&mc=true&tpl=/ecfrbrowse/Title21/21chapterI.tpl FOODON:03420108 A broad term that includes the nutritive sweeteners dextrose, fructose, galactose, lactose, maltose and sucrose, which are simple carbohydrates with molecules composed of one or two saccharide units. Note that on a product label or in a recipe, 'sugar' means *SUCROSE* and should be so indexed. Use the broad term *SUGAR* only if the specific sugar used is not known or not listed in the vocabulary. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=C0108 sugar FOODON:03420152 Extract, concentrate or isolate high in sugar, oligosaccharide or polysaccharide. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=C0152 carbohydrate extract, concentrate, or isolate FOODON:03420156 Soft sugar whose crystals are covered by a film of refined dark syrup that imparts color, flavor, and moisture. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=C0156 brown sugar FOODON:03420228 A physical-chemical component separated from the food source or its parts by extraction, centrifugation, filtration, heat processing, expressing or a similar process. The separated component may be converted through further processing. If this is done, the final substance is indexed. A water-extracted component may remain in aqueous dispersion. The extract, concentrate or isolate is indexed in preference to the anatomic part from which it is derived. For example, peanut oil is indexed under *PEANUT* combined wih *FAT OR OIL* rather than with *SEED OR KERNEL*. On the other hand, fruit and vegetable juices can be indexed under *FRUIT JUICE OR NECTAR* or *VEGETABLE JUICE* (A. PRODUCT TYPE); therefore the anatomic part of the plant should be indexed. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=C0228 Damion Dooley's note: Items in this branch will be merged into foodon food product branch. extract, concentrate or isolate of plant or animal FOODON:03420244 The serum or watery part of milk that is separated from the thicker or more coagulable part or curd, espcially in the process of making cheese; it contains lactose, minerals and lactalbumin. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=C0244 whey mammalian milk whey FOODON:03420307 The oil produced by pressing or extracting lipids from plant seeds (e.g. grapeseed oil, rapeseed oil, linseed oil) /AM http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=C0307 seed oil FOODON:03430109 A liquid that flows very easily at room temperature. Examples are: water, apple juice, sherry, acidophilus milk, whipping cream and some heavy liqueurs. The range of low viscosity liquid spans sucrose solutions between 0 and 45% solids (viscosity range from 1 to 10 centipoise). Prefer 'solid pieces' factor term to 'small particles' if both appear in the food. http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=E0109 liquid, thin food (liquid, low viscosity) FOODON:03430130 A state of matter between a solid and a gas, in which a substance has the capacity to flow and conforms to the shape of the container. Liquids range from water to honey, corresponding to a range in viscosity (or apparent viscosity) from 1 to 500 centipoise (viscosity is a measure of a liquid's resistance to flow). Products that are pourable but have a higher viscosity are *SEMILIQUID*. http://langual.org SUBSET_SIREN:F5105 http://www.langual.org/langual_thesaurus.asp?termid=E0130 fluid SIREN DB annotation: * has quality 'liquid' (http://purl.obolibrary.org/obo/FOODON_03430130) food (liquid) FOODON:03460177 This disjunction is provided for food indexers who used the LanguaL category per guidelines. Currently, by specifying the more specific nut or seed as ingredient instead, this category can be inferred. nut or seed added http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=H0177 LanguaL curation note: With the exception of peanut (see *PEANUT OR PEANUT BUTTER ADDED*), used when a nut or seed ingredient is the second ingredient in order of predominance. plant seed or nut food product FOODON:03460231 chocolate or cocoa added http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=H0231 LanguaL curation note: Used when chocolate or cocoa is added at any level or when chocolate is used as a coating. chocolate or cocoa FOODON:03460263 A fat or oil derived from vegetable material Damion Dooley vegetable fat or oil added http://langual.org http://www.langual.org/langual_thesaurus.asp?termid=H0263 This is a convenience class inherited from LanguaL vegetable fat or oil Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic. Wikipedia:Enzyme enzyme activity molecular_function GO:0003824 catalytic activity GO:0003824 Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic. GOC:vw ISBN:0198506732 enzyme activity GOC:dph GOC:tb A type of horizontal gene transfer in which genetic material is introduced into a cell mediated by a virus. https://github.com/geneontology/go-ontology/issues/22952 Wikipedia:Transduction_(genetics) biological_process GO:0009293 This process occurs both in prokaryotes and in eukaryotes. transduction GO:0009293 A type of horizontal gene transfer in which genetic material is introduced into a cell mediated by a virus. PMID:18265289 PMID:33597173 GO:0050663 true Death within the first 24 months of life. true HP:0003816 HP:0003817 HP:0003818 HP:0003823 HP:0003827 UMLS:C1844947 UMLS:C1858430 Death in infancy Infantile death Lethal in infancy Death in early childhood HP:0001522 Death in infancy HP:0001522 Death within the first 24 months of life. Death in infancy Infantile death Lethal in infancy Death in early childhood The age group in which disease manifestations appear. HP:0003588 HP:0003590 HP:0003597 HP:0003602 HP:0003603 HP:0003618 HP:0003626 HP:0003628 HP:0003630 HP:0003663 HP:0003664 HP:0003668 HP:0011007 MSH:D017668 MeSH:D017668 UMLS:C0206132 Age of onset Age symptoms begin HP:0003674 Adolescent is defined by WHO as a person between 10-19 years of age. Onset HP:0003674 The age group in which disease manifestations appear. Age symptoms begin Death within the first 28 days of life. HP:0003820 HP:0003824 MSH:D066087 SNOMEDCT_US:276506001 UMLS:C0410916 Neonatal lethal HP:0003811 Neonatal death HP:0003811 Death within the first 28 days of life. Neonatal lethal Death of the fetus in utero after at least 22 weeks of gestation. HP:0001624 HP:0001625 MSH:D005313 MSH:D050497 SNOMEDCT_US:237364002 SNOMEDCT_US:276507005 UMLS:C0015927 UMLS:C0595939 Late fetal death Stillbirth Stillborn Fetal death Fetal demise Foetal death HP:0003826 The age at which fetal demise is legally classified asa a miscarriage varies between countries with the US being 20 gestational weeks and the UK being 24 gestational weeks. The HPO chooses the average of these age ranges. Stillbirth HP:0003826 Death of the fetus in utero after at least 22 weeks of gestation. Stillbirth Stillborn Fetal death Foetal death A pregnancy that ends at a stage in which the fetus is incapable of surviving on its own, defined as the spontaneous loss of a fetus before the 22th week of pregnancy. MSH:D000022 SNOMEDCT_US:17369002 UMLS:C0000786 Early fetal demise Spontaneous abortion HP:0005268 The age at which fetal demise is legally classified asa a miscarriage varies between countries with the US being 20 gestational weeks and the UK being 24 gestational weeks. The HPO chooses the average of these age ranges. Miscarriage HP:0005268 A pregnancy that ends at a stage in which the fetus is incapable of surviving on its own, defined as the spontaneous loss of a fetus before the 22th week of pregnancy. HP:0034241 Death of a fetus in the uterus. 2022-04-10T17:51:32Z Death before birth Intrauterine death Prenatal death Death before birth Death between the age of 16 and 40 years. 2010-12-28T11:12:21Z UMLS:C4022012 Death in early adulthood HP:0100613 Death in early adulthood HP:0100613 Death between the age of 16 and 40 years. Death in early adulthood IAO:0000013 journal article Examples are articles published in the journals, Nature and Science. The content can often be cited by reference to a paper based encoding, e.g. Authors, Title of article, Journal name, date or year of publication, volume and page number. A report that is published in a journal. PERSON: Alan Ruttenberg PERSON: Chris Stoeckert OBI_0000159 group:OBI journal article IAO:0000027 data item Data items include counts of things, analyte concentrations, and statistical summaries. An information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements. a data item is an information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements. 2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers. 2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum. 2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym. 2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/ JAR: datum -- well, this will be very tricky to define, but maybe some information-like stuff that might be put into a computer and that is meant, by someone, to denote and/or to be interpreted by some process... I would include lists, tables, sentences... I think I might defer to Barry, or to Brian Cantwell Smith JAR: A data item is an approximately justified approximately true approximate belief PERSON: Alan Ruttenberg PERSON: Chris Stoeckert PERSON: Jonathan Rees data data item IAO:0000030 information content entity Examples of information content entites include journal articles, data, graphical layouts, and graphs. A generically dependent continuant that is about some thing. 2014-03-10: The use of "thing" is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ). information_content_entity 'is_encoded_in' some digital_entity in obi before split (040907). information_content_entity 'is_encoded_in' some physical_document in obi before split (040907). Previous. An information content entity is a non-realizable information entity that 'is encoded in' some digital or physical entity. PERSON: Chris Stoeckert OBI_0000142 information content entity IAO:0000064 algorithm PMID: 18378114.Genomics. 2008 Mar 28. LINKGEN: A new algorithm to process data in genetic linkage studies. A plan specification which describes the inputs and output of mathematical functions as well as workflow of execution for achieving an predefined objective. Algorithms are realized usually by means of implementation as computer programs for execution by automata. Philippe Rocca-Serra PlanAndPlannedProcess Branch OBI_0000270 adapted from discussion on OBI list (Matthew Pocock, Christian Cocos, Alan Ruttenberg) algorithm IAO:0000088 report Examples of reports are gene lists and investigation reports. These are not published (journal) articles but may be included in a journal article. A document assembled by an author for the purpose of providing information for the audience. A report is the output of a documenting process and has the objective to be consumed by a specific audience. Topic of the report is on something that has completed. A report is not a single figure. Examples of reports are journal article, patent application, grant progress report, case report (not patient record). 2009-03-16: comment from Darren Natale: I am slightly uneasy with the sentence "Topic of the report is on something that has completed." Should it be restricted to those things that are completed? For example, a progress report is (usually) about something that definitely has *not* been completed, or may include (only) projections. I think the definition would not suffer if the whole sentence is deleted. 2009-03-16: this was report of results with definition: A report is a narrative object that is a formal statement of the results of an investigation, or of any matter on which definite information is required, made by some person or body instructed or required to do so. 2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI. 2009-08-10 Alan Ruttenberg: Larry Hunter suggests that this be obsoleted and replaced by 'document'. Alan restored as there are OBI dependencies and this merits further discussion disagreement about where reports go. alan: only some gene lists are reports. Is a report all the content of some document? The example of usage suggests that a report may be part of some article. Term needs clarification PERSON: Alan Ruttenberg PERSON: Chris Stoeckert PERSON: Melanie Courtot GROUP: OBI OBI_0000099 report IAO:0000100 data set Intensity values in a CEL file or from multiple CEL files comprise a data set (as opposed to the CEL files themselves). A data item that is an aggregate of other data items of the same type that have something in common. Averages and distributions can be determined for data sets. 2009/10/23 Alan Ruttenberg. The intention is that this term represent collections of like data. So this isn't for, e.g. the whole contents of a cel file, which includes parameters, metadata etc. This is more like java arrays of a certain rather specific type 2014-05-05: Data sets are aggregates and thus must include two or more data items. We have chosen not to add logical axioms to make this restriction. person:Allyson Lister person:Chris Stoeckert OBI_0000042 group:OBI data set IAO:0000301 citation Verspoor, K., Cohen, KB., Hunter, L. Textual characteristics of traditional and Open Access scientific journals are similar, BMC Bioinformatics 2009, 10:183. A textual entity intended to identify a particular publication. PERSON: Lawrence Hunter citation IAO:0000311 publication journal article, newspaper story, book, etc. A document that is the output of a publishing process. PERSON: Chris Stoeckert PERSON: Jie Zheng PERSON: Lawrence Hunter published document Revisit the term in Octorber 2020. Improve the defintion. publication IAO:0000312 publication about an investigation Most scientific journal articles A publication that is about an investigation PERSON: Lawrence Hunter scientific publication publication about an investigation IAO:0000584 pmid:20604925 - time-lapse live cell microscopy A data set that is an aggregate of data recording some measurement at a number of time points. The time series data set is an ordered list of pairs of time measurement data and the corresponding measurement data acquired at that time. Alan Ruttenberg experimental time series time sampled measurement data set MSIO:0000175 a "lethal dose" represents a dose (usually recorded as dose per kilogram of subject body weight) at which a given percentage of subjects will die. Philippe Rocca-Serra EU H2020 PhenoMenAl https://en.wikipedia.org/wiki/Lethal_dose lethal dose NCIT:C101294 A procedure that can determine the DNA sequence for nearly the entire genome of an individual. C101294 Molecular Biology Research Technique Whole Genome Sequencing Whole Genome Sequencing C3640076 CDISC CTRP GDC ICDC A DNA sequencing technique in which the entirety of the individual's genome is sequenced. WGS WGS WHOLE GENOME SEQUENCING Whole Genome Sequencing Whole Genome Sequencing NCIT:C122936 The transfer of a tumor fragment from a patient into an immunodeficient mouse. C122936 Experimental Model of Disease Patient Derived Xenograft Patient Derived Xenograft C4050317 CTRP PDTX PDX Patient Derived Xenograft Patient-Derived Xenograft Patient-Derived Xenograft Model Patient Derived Xenograft NCIT:C127803 A study of the effect of dose changes on the efficacy of a drug in order to determine the dose-response relationship and optimal dose of a therapy. C127803 Research Activity Dose Response Study CL509446 CDISC A study of the effect of dose changes on the efficacy of a drug in order to determine the dose-response relationship and optimal dose of a therapy. DOSE RESPONSE Dose Response Study Dose Response Study NCIT:C134270 The determination of the strength of a material, as measured by the ability to produce a specific response. The potency of a pharmacologic substance is measured by the amount needed to produce a certain effect. C134270 Laboratory Procedure Potency Assay CL521998 Potency Assay Potency Assay NCIT:C16681 The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs. In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains. C16681 Biomedical Occupation or Discipline Histology C0019638 FDA GDC The study of tissues and cells under a microscope. Histology Histology Histology Microanatomy histology Histology NCIT:C17376 Production of genetic alterations by any technique, including chemicals, radiation, recombination, or other molecular biology methods. C17376 Laboratory Procedure Mutagenesis C0079866 Mutagenesis Genetics-Mutagenesis Molecular Biology, Mutagenesis Mutagenesis Mutagenesis NCIT:C18079 Cardiovascular Pharmacology; the study of the effects of drugs upon the heart or circulatory system C18079 Biomedical Occupation or Discipline Cardiovascular Pharmacology C0596271 CDISC The study of the effects of drugs upon the heart or circulatory system. Cardiovascular_Pharmacology CARDIOVASCULAR PHARMACOLOGY Cardiovascular Pharmacology Cardiovascular Pharmacology NCIT:C18639 Autoradiographic analysis performed in accordance with specified guidelines that will result in a defined correspondence between the intensity of the autoradiographic image and the amount of radioactivity present in the sample. This permits assignment of a value to the amount of radioactive material in the object under study. C18639 Research Activity Quantitative Autoradiography C1510991 Autoradiography_Quantitative Autoradiography, Quantitative Quantitative Autoradiography Quantitative Autoradiography NCIT:C18803 Models of human disease produced through gene knockout methods C18803 Experimental Model of Disease Gene Knock-Out Model C1517490 Gene_Knock-Out_Model Gene Knock-Out Model Gene Knock-Out Model NCIT:C18996 The science concerned with drugs and their actions and uses in kidney biology and the treatment of kidney disease. C18996 Biomedical Occupation or Discipline Renal Pharmacology C0596818 CDISC The science concerned with drugs and their actions and uses in kidney biology and the treatment of kidney disease. (NCI) Renal_Pharmacology RENAL PHARMACOLOGY Renal Pharmacology Renal Pharmacology NCIT:C19286 A technology used for preclinical research as an alternative to some animal testing. Micrometer-thin slices of various organs are incubated with various experimental compounds for assays involving toxicology, absorption, distribution, and metabolism. C19286 Research Activity Tissue Slice Technology C1519528 Tissue_Slice_Technology Tissue Slice Technology Tissue Slice Technology NCIT:C19425 An in vitro assay in which cultured cells are monitored and analyzed for their ability to move into an acellular area of a culture material. C19425 Laboratory Procedure Migration Assay C1513300 Migration_Assays Cell Migration Assay Migration Assay Migration Assays Migration Assay NCIT:C19812 An experimental system in which (usually) human tumor cells are transplanted into immunocompromised mice that do not reject human cells; cells may be implanted under the skin or into the organ type in which the tumor originated. These model systems may be used for drug development and studies of molecular biological mechanisms of cancer. C19812 Experimental Model of Disease Xenograft Model C1520166 Xenograft_Model Xenograft Model Xenograft Model NCIT:C20604 The strength of noncovalent chemical binding between two substances as measured by the dissociation constant of the complex. C20604 Qualitative Concept Affinity C1510827 In chemistry and biology, the strength of the attaction between two substances, such as two chemicals, or an antigen and an antibody. Affinity Affinity affinity Affinity NCIT:C79364 C79364 Regulation or Law Pharmacology: Primary Pharmacodynamics C2698783 CDISC FDA The branch of pharmacology that deals with the biochemical and physiological effects of a drug and the mechanism of drug action in relation to its desired therapeutic target. Pharmacology_Primary_Pharmacodynamics FDA RPS Pharmacology: Primary Pharmacodynamics PRIMARY PHARMACODYNAMICS Pharmacology: Primary Pharmacodynamics Pharmacology: Primary Pharmacodynamics NCIT:C79365 C79365 Regulation or Law Pharmacology: Secondary Pharmacodynamics C2698785 CDISC FDA The branch of pharmacology that deals with the biochemical and physiological effects of a drug and the mechanism of drug action not related to its desired therapeutic target. Pharmacology_Secondary_Pharmacodynamics FDA RPS Pharmacology: Secondary Pharmacodynamics Pharmacology: Secondary Pharmacodynamics SECONDARY PHARMACODYNAMICS Pharmacology: Secondary Pharmacodynamics NCIT:C79367 C79367 Regulation or Law Pharmacology: Pharmacodynamic Drug Interactions C2698782 CDISC FDA The branch of pharmacology that deals with the mechanism of action and biochemical and physiological effects of drug-drug interactions. Pharmacology_Pharmacodynamic_Drug_Interactions FDA RPS Pharmacology: Pharmacodynamic Drug Interactions PHARMACODYNAMIC DRUG INTERACTIONS Pharmacology: Pharmacodynamic Drug Interactions Pharmacology: Pharmacodynamic Drug Interactions NCIT:C89775 The amount of time it take for a cessation of bleeding. It is a measurement of the ability of capillaries and platelets to interact to form a blood clot. C89775 Laboratory Procedure Bleeding Time C0005729 CDISC A measurement of the time from the start to cessation of an induced bleed. BLEEDT Bleeding Time Clotting Time Homeostasis Bleeding Time NCIT:C90370 The branch of pharmacology that deals with the central nervous system. C90370 Biomedical Occupation or Discipline Central Nervous System Pharmacology C2983593 CDISC The branch of pharmacology that deals with the central nervous system. (NCI) CNS PHARMACOLOGY Central Nervous System Pharmacology Central Nervous System Pharmacology NCIT:C90449 The branch of pharmacology that deals with the respiratory system. C90449 Biomedical Occupation or Discipline Respiratory Pharmacology C0597399 CDISC The branch of pharmacology that deals with the respiratory system. (NCI) RESPIRATORY PHARMACOLOGY Respiratory Pharmacology Respiratory Pharmacology OAE:0000001 a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event. Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'. YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device. YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention. YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action). Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623. YH: The current term 'adverse event' is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. We made the name changing in order to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term 'adverse event' is stil under the OGMS:pathological bodily process. The 'adverse event' defined in the above paper has now been changed to a new term: 'causal adverse event'. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29 doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740. YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events. YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'. Yongqun He AE adverse reaction WEB: http://en.wikipedia.org/wiki/Adverse_event WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068 The OAE official website is: http://www.oae-ontology.org/. adverse event OAE:0000003 an adverse event which is a causal adverse event, a pathological bodily process that is induced by a medical intervention. YH: The term 'causal adverse event' has the same meaning as we previously defined as 'adverse event'. Reference: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. We made the name changing as a way to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. YH adverse effect He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. YH: the term "adverse effect" has the same meaning of "causal adverse event". causal adverse event OAE:0000004 an adverse event that occurs after a vaccination. YH vaccine adverse event OAE:0000005 an adverse event that occurs after a drug administration YH, JX ADE ADR adverse drug reaction drug adverse event adverse drug event OAE:0000007 an adverse event that is associated with eating a medical food. YH medical food adverse event OAE:0000008 an adverse event that is induced by consuming a nutritional product. YH nutritional product adverse event OAE:0000009 an adverse event that is associated with consuming a dietary supplement. YH dietary supplement adverse event OAE:0000010 an adverse event that is associated with consuming an infant formula. YH infant formula adverse event OAE:0000017 an imaging investigation result abnormal AE that is characterized by an abnormal X-ray SS, YH, EB 10048065 X-ray result abnormal AE OAE:0000018 an X-ray result abnormal AE that has an outcome of an abnormality in chest X-ray test SS, YH 10008499 chest X-ray abnormal AE OAE:0000019 a haematoma AE that has an outcome of contusion. SS, YH WEB: http://en.wikipedia.org/wiki/Bruise 10050584 Contusion is a type of relatively minor hematoma of tissue in which capillaries and sometimes venules are damaged by trauma, allowing blood to seep into the surrounding interstitial tissues. contusion AE OAE:0000020 a digestive system AE which has an outcome of dry throat, which is a sensation of dryness in the throat. SS, YH 10013789 dry throat AE OAE:0000021 a skin discoloration AE which has an outcome of flushing, a sudden reddening of the face, neck, or upper chest SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003241.htm 脸红 10016825 flushing AE CTCAE:E13771 HPO: HP_0001033 NCIt:C26775 SIDER: C0016382 OAE:0000022 a pain AE where the pain reachs an extreme level. SS, YH, MW 10033425 pain in extremity AE CTCAE: E12512 HPO: HP_0009763 NCIt: C78515 SIDER: C0030196 OAE:0000023 a respiratory system AE which has an outcome of postnasal drip, which occurs when excessive mucus is produced by the nasal Mucosa. The excess mucus accumulates in the throat or back of the nose. SS, YH PDN UACS Upper Airway Cough Syndrome WEB: http://en.wikipedia.org/wiki/Post-nasal_drip 10036402 postnasal drip AE CTCAE: E13514 NCIt: C78566 OAE:0000024 a syndrome AE that is subclassified as five defined entities which represent clinical circumstances in which both the heart and the kidney are involved in a bidirectional injury and dysfunction via a final common pathway of cell-to-cell death and accelerated apoptosis mediated by oxidative stress. Types 1 and 2 involve acute and chronic cardiovascular disease (CVD) scenarios leading to acute kidney injury or accelerated chronic kidney disease. Types 2 and 3 describe acute and chronic kidney disease leading primarily to heart failure, although it is possible that acute coronary syndromes, stroke, and arrhythmias could be CVD outcomes in these forms of CRS. Finally, CRS type 5 describes a simultaneous insult to both heart and kidneys, such as sepsis, where both organs are injured simultaneously. SS, YH CRS WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030731/ 10068230 cardiorenal syndrome AE OAE:0000026 A bursal disorder AE that has an outcome of the symptom of bursitis. SS, YH bursa inflammation WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001456/ bursitis AE OAE:0000027 an adverse event that has an outcome of abnormal sign in a musculoskeletal or connective tissue. YH, RR, JX musculoskeletal and connective tissue disorder AE WEB: http://www.cdc.gov/niosh/programs/msd/ 10028395 A musculoskeletal disorder is an injury or disorder of the muscles, nerves, tendons, joints, cartilage, or supporting structures of the upper or lower limbs, neck, or lower back that are caused, precipitated, or exacerbated by sudden exertion or prolonged exposure to physical factors such as repetition, force, vibration, or awkward posture musculoskeletal or connective tissue AE CTCAE: E13872 OAE:0000029 a musculoskeletal system AE which has an outcome of bursal disorder YH bursal disorder AE OAE:0000030 a vaccine adverse event that is induced by an influenza vaccine. YH: This term is just used as an example of vaccine induced adverse events. Specific vaccine-associated and vaccine-induced adverse events are now represented with the Ontology of Vaccine Adverse Events (OVAE).: http://www.violinet.org/ovae/. YH influenza vaccine-induced adverse event OAE:0000031 an influenza vaccine adverse event that is induced by a killed influenza vaccine (KIV). YH KIV-induced adverse event OAE:0000032 A KIV-induced AE that results in a GBS. YH VAERS statistical data analysis There is little evidence to support a causal association between GBS and most vaccines. The evidence for a causal association is strongest for the swine influenza vaccine that was used in 1976-77. Studies of influenza vaccines used in subsequent years, however, have found small or no increased risk of GBS. Reference: http://www.ncbi.nlm.nih.gov/pubmed?term=19388722. KIV-induced GBS averse event in 1976-1977 OAE:0000033 a muscle pain AE that is induced by Afluria influenza vaccine administration YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf Afluria-induced muscle ache AE OAE:0000034 a behavior and neurological AE that has an outcome of fatigue, which is a state of awareness describing a range of afflictions, usually associated with physical and/or mental weakness, though varying from a general state of lethargy to a specific work-induced burning sensation within one's muscles. Physical fatigue is the inability to continue functioning at the level of one's normal abilities. lethargy is sometimes reported as an extreme fatigue: http://the-difference-between.com/lethargy/fatigue they are sometimes regarded as synonyms: https://www.nlm.nih.gov/medlineplus/ency/article/003088.htm SS, YH, MW lethargy AE WEB: http://en.wikipedia.org/wiki/Fatigue_%28medical%29 10016256 10024264 fatigue AE CTCAE: E11098 (fatigue); CTCAE: E12709 (lethargy) HPO: HP_0003388 NCIt: C3036; NCIt: C78416 SIDER: C0015672 OAE:0000035 a microbiology and serology investigation result abnormal AE that has an outcome of CSF culture negative. The negative result means no bacteria, viruses, or fungi grew in the laboratory dish. YH: The negative result is normal. It is not an AE. SS, YH, EB CSF culture negative AE OAE:0000036 a lab test abnormal AE that has an outcome of an abnormal result in a blood cell lab test SS, YH blood cell lab test abnormal AE OAE:0000037 an eosinophil percentage abnormal AE that has an outcome of increased eosinophil percentage YH, EB 10052222 eosinophil percentage increased AE OAE:0000038 a cardiac disorder AE that is characterized by a necrosis of the myocardium caused by an obstruction of the blood supply to the heart SS WEB: http://www.ncbi.nlm.nih.gov/mesh/68009203 心肌梗塞 10028596 myocardial infarction AE CTCAE: E10152 HPO: HP_0001658 NCIt: C27996 SIDER: C0027051 OAE:0000039 a neutrophil count abnormal AE that has an outcome of increased neutrophil count YH 10029368 neutrophil count increased AE HPO: HP_0011991 SIDER: NA OAE:0000040 an adverse event that shows a complication that occurs after a medical procedure such as a surgery. SS, YH post-procedural AE procedural disorder AE procedure AE procedural complication AE OAE:0000041 an adverse event that has an outcome of injury after a medical intervention. SS, YH 10022116 injury AE OAE:0000042 an injury AE which has an outcome of head injury SS, YH 10019196 head injury AE OAE:0000043 a behavior and neurological AE that has an abnormal outcome in social behavior SS, YH social behavior AE OAE:0000044 a social behavior AE that has an outcome of impaired work ability SS, YH impaired work ability AE OAE:0000045 an allergy AE which has an outcome of injection-site allergic reaction 10022095 injection-site allergic reaction AE OAE:0000046 a myelitis AE which has an outcome of myelitis transverse. Transverse myelitis (in Latin nomenclature: myelitis transversa) is a neurological disorder caused by an inflammatory process of the spinal cord, and can cause axonal demyelination. SS, YH WEB: http://en.wikipedia.org/wiki/Transverse_myelitis 10028527 myelitis transverse AE OAE:0000047 a skin adverse even that has an outcome of warm skin SS, YH skin warm AE OAE:0000048 Nystagmus AE is an eye AE that is a condition of involuntary eye movement, acquired in infancy or later in life, that may result in reduced or limited vision. Due to the involuntary movement of the eye, it is often called "dancing eyes". JX, LW, YH WEB: http://en.wikipedia.org/wiki/Nystagmus 10029864 nystagmus AE CTCAE:E12748 NCIt:C3282 眼球震颤 OAE:0000049 a dermatitis AE that has an outcome of dermatitis bullous SS, YH bullous pemphigoid AE 10012441 Bullous pemphigoid is a skin disorder characterized by large blisters. dermatitis bullous AE HPO: HP_0011123 SIDER: C0085932 OAE:0000050 a skin adverse event that is characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling. SS, YH, MW hot flash AE hot flashes AE hot flush AE 10020407 hot flushes AE CTCAE: E13781 HPO: HP_0008209 NCIt: C3109 SIDER: C0600142 OAE:0000051 a KIV-induced adverse event that has an outcome of Afluria-induced adverse event YH Afluria-induced adverse event OAE:0000052 an adverse event that results in the outcome of a tumor. mass AE nodule AE tumour AE 10026865 YH, RR tumor AE OAE:0000053 a respiratory system AE which has an outcome of wheezing, a high-pitched whistling sound made while breathing. SS, YH, MW WEB: http://www.mayoclinic.org/symptoms/wheezing/basics/definition/sym-20050764 10047924 wheezing AE CTCAE:E13605 NCIt:C78718 OAE:0000054 a behavior and neurological AE that has an outcome of weight bearing difficulty weight bearing difficulty is a behavior AE that results in difficulty in managing the amount of weight a patient puts on the leg on which surgery has been performed. In general, it is described as a percentage of the body weight, because each leg of a healthy person carries the full body weight when walking, in an alternating fashion. SS, YH WEB: http://en.wikipedia.org/wiki/Weight-bearing weight bearing difficulty AE OAE:0000057 an Afluria-induced adverse event that has an outcome of Afluria-induced fever in child YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf Afluria-induced fever AE in child OAE:0000058 an Afluria-induced adverse event that has an outcome of Afluria-induced cough in child YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf Afluria-induced cough AE in child OAE:0000059 an Afluria-induced adverse event which has an outcome of Afluria-induced injection site pain YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf Afluria-induced injection site pain AE OAE:0000060 an Afluria-induced adverse event that has an outcome of Afluria-induced injection site redness YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf Afluria-induced injection site redness AE OAE:0000061 an Afluria-induced AE that has an outcome of Afluria-induced inject site swelling YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf Afluria-induced inject site swelling AE OAE:0000062 an Afluria-induced adverse event that has an outcome of Afluria-induced headache YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf Afluria-induced headache AE OAE:0000063 an adverse event that occurs systematically throughout the systemic circulation. This is different from local adverse event that is limited or a certain location. YH, JX systematic adverse event URL: https://en.wikipedia.org/wiki/Adverse_drug_reaction systematic AE OAE:0000064 A pregnancy, neonatal and perinatal AE that displays a disorder associated with pregnancy. prenatal AE WEB: https://en.wikipedia.org/wiki/Complications_of_pregnancy WEB: https://en.wikipedia.org/wiki/Prenatal_diagnosis YH, JX pregnancy AE OAE:0000066 a procedure complication AE that occurs after a surgery. YH surgery AE surgery adverse event surgical procedure AE The key difference between a surgery and a procedure is the need for an incision. Making an incision, or cutting into the skin to gain access to the body’s deeper tissues or organs, is a defining characteristic of surgery. Technically speaking, a surgery is a specific type of procedure. A procedure is a broad general term that refers to any series of pre-defined steps that should be followed to achieve a desired result. Therefore, a “surgical procedure” is synonymous with a “surgery.” See more: http://www.wisegeekhealth.com/what-is-the-difference-between-a-surgery-and-a-procedure.htm. surgery adverse event OAE:0000068 a sugery adverse event that has an outcome of pressure ulcer. YH surgery-induced bedsore AE surgery-induced decubitus ulcer AE surgery-induced pressure ulcer AE OAE:0000069 an adverse event which occurs in a metabolism process (including anabolism and catabolism), endocrine system, or exocrine system. SS, YH, JX metabolism, endocrine, and exocrine system AE 10027433 metabolism, endocrine or exocrine system AE MP: 0005266 OAE:0000070 an adverse event that occurs in clinical trial. YH clinical trial adverse event OAE:0000073 an influenza vaccine adverse event that is induced by a live attenuated influenza vaccine (LAIV). YH LAIV-induced adverse event OAE:0000074 an LAIV-induced adverse event that is caused by the FluMist LAIV. YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123743.pdf FluMist-induced adverse event OAE:0000075 a FluMist-induced adverse event that has an outcome of FluMist-induced runny nose YH FluMist-induced runny nose AE OAE:0000076 a FluMist-induced AE that has an outcome of FluMist-induced nasal congestion YH FluMist-induced nasal congestion AE OAE:0000078 A FluMist-induced AE that has an outcome of sore throat YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123743.pdf FluMist-induced sore throat AE in adult OAE:0000079 a tumore AE that results in the outcome of a benign tumor. YH benign tumor AE OAE:0000080 a tumore AE that results in the outcome of a malignant tumor. YH malignant tumor AE OAE:0000081 a sensory capability AE that resuls in an uncomfortable feeling. YH discomfort AE HPO: HP_0010832 SIDER: C0234215 OAE:0000082 a reproductive system AE that occurs on the female side. YH 10038604 female reproductive system AE OAE:0000083 a reproductive system AE that occurs on the male side. YH male reproductive system AE OAE:0000084 a cardiovascular disorder AE that has a cardiac disorder outcome. SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/heart+disease Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23091623 10007541 10061024 cardiac disorder AE HPO: HP_0001627 SIDER: C0018799 OAE:0000085 a cardiovascular disorder AE that has a vascular disorder outcome 10047065 vascular disorder AE OAE:0000086 a skin adverse event that results in an inflammation of skin SS, YH 10012431 dermatitis AE HPO: HP_0011123 SIDER: C0011603 OAE:0000087 a drug adverse event that is induced by aspirin. YH WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm aspirin-induced adverse event OAE:0000088 an aspirin-induced adverse event that is induced by the aspirin drug Aspidrox. Aspidrox-induced adverse event OAE:0000089 an aspirin-induced adverse event that has an outcome of nausea YH WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm aspirin-induced nausea AE OAE:0000090 an aspirin-induced adverse event that has an outcome of vomiting YH WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm aspirin-induced vomiting AE OAE:0000091 an aspirin-induced adverse event that has an outcome of stomach pain YH WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm aspirin-induced stomach pain AE OAE:0000092 an aspirin-induced adverse event that has an outcome of heartburn YH WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm aspirin-induced heartburn AE OAE:0000093 an aspirin-induced adverse event that has an outcome of rash symptom. YH WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm aspirin-induced rash AE OAE:0000095 YH a drug adverse event that is caused by a drug adiministration. Here a causal effect is established between the drug administration and the adverse event. causal adverse drug event OAE:0000096 a medical device adverse event that is induced or caused by a medical device. There is a causal relation between the adverse event and the usage of a medical device. YH adverse event induced by medical device OAE:0000097 an adverse event that is induced by a vaccination. YH vaccine-induced adverse event OAE:0000098 a surgery adverse event that is caused by a surgery. YH surgery-induced adverse event OAE:0000099 YH a nutritional product adverse event that has a causal assocition with the usage of the nutritional product. nutritional product-induced adverse event OAE:0000100 influenza like illness AE is an adverse event that has an outcome of a medical diagnosis of possible influenza or other illness causing a set of common symptoms SS, YH acute respiratory infection, ARI, flu-like syndrome WEB: http://en.wikipedia.org/wiki/Influenza-like_illness 10016791 influenza like illness AE HPO: HP_0005376 MDR: 10022004 SIDER: C0521839 OAE:0000103 YH a pathogen infection adverse event that has an outcome of a fungal infection. 10017533 fungal infection AE HPO: HP_0002841 SIDER: C0026946 OAE:0000162 a peripheral neuropathy AE which has an outcome of sensory neuropathy that involves damage to nerves of the peripheral nervous system. YH, AG sensory neuropathy AE sensory neuropathy AE OAE:0000163 a sensory neuropathy AE which has an outcome of distal sensory neuropathy that involves damage to distal sensory nerves of the peripheral nervous system. YH, AG distal sensory neuropathy AE OAE:0000164 a distal sensory neuropathy AE that is chronic. YH, AG chronic distal sensory neuropathy AE OAE:0000165 a neuropathy AE that is induced by a drug administration AG, YH https://medlineplus.gov/ency/article/000700.htm drug-induced neuropathy AE OAE:0000166 Tremor AE is a behavior and neurological AE that has an outcome of an involuntary trembling or quivering, and muscle contraction and relaxation. SS, YH WEB: http://www.nlm.nih.gov/medlineplus/tremor.html 10044565 tremor AE CTCAE: E12837 HPO: HP_0001337 NCIt: C38038 SIDER: C0040822 OAE:0000167 a neuropathy AE which shows symptoms due to the damage to the autonomic nerves. This damage disrupts signals between the brain and portions of the autonomic nervous system, such as the heart, blood vessels and sweat glands. This can cause decreased or abnormal performance of one or more involuntary body functions. AG, YH WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm#types_of_neuropathy WEB: http://www.mayoclinic.org/diseases-conditions/autonomic-neuropathy/basics/definition/con-20029053 10061666 autonomic neuropathy AE HPO: HP_0002270 SIDER: C0259749 UMLS CUI: C0259749 OAE:0000168 a peripheral neuropathy AE which is caused by a damage to motor neurons AG, YH motor neuropathy AE OAE:0000169 A peripheral neuropathy AE which is characterized by damage to more than one nerve AG, YH, RR WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html 10036105 polyneuropathy AE HPO: HP_0001271 SIDER: C0152025 OAE:0000170 a neuropathy AE which is characterized by isolated damage of a single nerve AG, YH 10062203 mononeuropathy AE OAE:0000171 a peripheral neuropathy AE which affects extremities, such as, toes, fingers, hand and feet. AG, YH axonal neuropathy AE WEB: http://www.livestrong.com/article/184686-distal-neuropathy-symptoms/ distal neuropathy AE OAE:0000172 a nervous system AE that affects the neuronal cell body AG, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922643/ neuronopathy AE OAE:0000173 A neuritis AE which has an outcome of mononeuritis characterized by isolated inflammation of one nerve. AG, YH 10027910 mononeuritis AE OAE:0000174 A neuritis AE which has an outcome of polyneuritis characterized by isolated inflammation of many nerves. AG, YH polyneuritis AE OAE:0000175 a mononeuritis AE which has an outcome of mononeuritis multiplex which involves damage to at least two seperate unrelated nerve area. AG, YH mononeuritis multiplex AE OAE:0000176 a sensory neuropathy AE which has an outcome of acute sensory neuropathy that is characterized by rapid onset AG, YH acute sensory neuropathy AE OAE:0000179 a causal adverse drug event that is induced by a drug-drug interaction. YH, LT WEB: http://medical-dictionary.thefreedictionary.com/drug+interaction 10013710 causal adverse drug event due to drug-drug interaction OAE:0000180 a causal adverse drug event that is induced by a food-drug interaction. YH, LT causal adverse drug event due to food-drug interaction OAE:0000181 a causal adverse drug event that is induced bygenetic predisposition. YH, LT causal adverse drug event due to genetic predisposition OAE:0000182 a causal adverse drug event due to genetic predisposition that is specifically induced by SNP. YH, LT causal adverse drug event due to SNP OAE:0000183 a cardiovascular disorder AE that is a result of insufficient blood flow throughout the body. Shock often accompanies severe injury or illness. physiological shock AE shock WEB: http://en.wikipedia.org/wiki/Shock_%28circulatory%29 WEB: http://njcc.nl/sites/default/files/pdf/review-2_1.pdf (Lima A. Circulatory shock and peripheral circulatory failure: a historical perspective. Netherlands Journal of Critical Care. 2014. 18:6. 14-18) WEB: https://www.nlm.nih.gov/medlineplus/ency/article/000039.htm 休克 10040560 Circulatory shock is not related to the emotional state of shock. Here is the Kumar and Parrilo definition of shock: "The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury". Reference: Kumar A, Parillo JE. Shock: pathophysiology, classification and approach to management. In: Parrillo JE, Parrillo JE, Bone RC (eds): Critical care medicine: Principles of diagnosis and management. Mosby: Toronto, 1995, pp 371-420. circulatory shock AE OAE:0000184 a psychiatric disorder AE that has an outcome of a loss of brain function and causes a long term and often gradual decrease in the ability to think and remember such that a person's daily functioning is affected. YH, MW WEB: https://en.wikipedia.org/wiki/Dementia 痴呆 10012272 Dementia is a loss of brain function that occurs with certain diseases or pathological processes. dementia AE HPO: HP_0000726 SIDER: C0497327 OAE:0000185 A vascular disorder AE that results in the presence of blood clot along the wall of a blood vessel, frequently causing vascular obstruction. Some authorities differentiate thrombus formation from simple coagulation or clot formation. SS, YH, MW 血栓症; 血栓生成 10043607 thrombosis AE HPO: HP_0004419 SIDER: C0040053 OAE:0000187 a metabolic disorder AE that has an outcome of cell death. SS, YH 10057248 cell death AE GO: GO_0008219 SIDER: C0007587 OAE:0000188 a respiratory system AE which has an outcome of some respiratory tract neoplasm. YH 10029107 respiratory tract neoplasm AE OAE:0000194 an inflammation AE that shows the result of an inflammation located in a vein, usually in the legs. YH, MW 10034879 phlebitis AE CTCAE:E13815 HPO: HP_0004419 NCIt:C38003 SIDER: C0031542 OAE:0000195 a liver, biliary, and pancreatic AE that has an outcome of pancreatitis. YH, MW 10033645 10033646 pancreatitis AE CTCAE: E10930 HPO: HP_0001733 NCIt: C3306 SIDER: C0030305 OAE:0000196 a cell death AE that has an outcome of apoptosis, a form of programmed cell death that occurs in multicellular organisms. SS, YH https://en.wikipedia.org/wiki/Apoptosis 10059512 apoptosis AE OAE:0000197 a cell death AE that has an outcome of necrosis SS, YH necrosis AE HPO: HP_0003713 SIDER: C0027540 OAE:0000198 A cardiovascular disorder AE that results in Insufficient blood supply for the need of a part of the body, usually as a result of a disease of the blood vessels supplying that part. SS, YH ischaemia AE 10061255 Note: also spelt ischemia. ischemia AE HPO: HP_0002597 SIDER: C0022116 OAE:0000199 an adverse event that occurs in hair, skin, or nail. hair, skin, and nail AE YH, SS, JX hair, skin or nail AE OAE:0000200 a hair, skin, and nail AE that occurs in hair. YH, SS hair AE OAE:0000201 a hair, skin, and nail AE that occurs in nail. YH, SS nail AE OAE:0000202 a metabolism, endocrine, and exocrine system AE that occurs in endocrine system. 10014698 YH, SS endocrine system AE OAE:0000203 a metabolism, endocrine, and exocrine system AE that occurs in exocrine system YH, SS exocrine system AE OAE:0000204 an adverse event that displays a congential and genetic disorder. congenital abnormality AE 10010331 YH, SS congenital AE OAE:0000205 a muscular weakness AE that shows weakness or inability to move a body part, often used to describe a neurologic condition. WEB: https://en.wikipedia.org/wiki/Paresis 局部麻痹 10033800 Neurologists use the term paresis to describe weakness, and plegia to describe paralysis in which all voluntary movement is lost. (Reference: https://en.wikipedia.org/wiki/Paresis) paresis AE HPO: HP_0008153 SIDER: C0030552 OAE:0000206 a syndrome AE that has an outcome of cystic fibrosis, an inherited disease that affects the lungs, digestive system, sweat glands, and male fertility. YH WEB: http://medical-dictionary.thefreedictionary.com/cystic+fibrosis 10011762 cystic fibrosis AE HPO: HP_0006552 SIDER: C0010674 OAE:0000207 a tumore AE that results in the outcome of hyperplasia, an abnormal increase in the number of normal cells in normal arrangement in an organ or tissue, which increases its volume. YH, SS hyperplasia AE HPO: HP_0010279 SIDER: C0020507 OAE:0000208 an adverse event that displays a disorder in abdomen. YH, SS abdominal AE OAE:0000209 an adverse event that results in genetic disorder. genetic disorder AE YH, SS genetic AE OAE:0000210 a liver, biliary, and pancreatic AE that has an outcome of hepatitis. YH hepatitis AE HPO: HP_0006562 SIDER: C0019158 OAE:0000211 an adverse event that displays an outcome of ulcer. YH, SS ulcer AE HPO: HP_0005229 SIDER: C0041582 OAE:0000212 a musculoskeletal and connective tissue AE that displays an outcome of fistula, a permanent abnormal passageway between two organs in the body or between an organ and the exterior of the body. WEB: http://medical-dictionary.thefreedictionary.com/fistula 10067143 YH, SS fistula AE HPO: HP_0010294 SIDER: C0016169 OAE:0000214 an adverse event that displays an outcome of an sclerosis, the stiffening of a structure, usually caused by a replacement of the normal organ-specific tissue with connective tissue. YH, SS sclerosis AE OAE:0000215 a crying abnormal AE that has an outcome of abnormal inconsolable crying in a patient YH 10065283 inconsolable crying AE OAE:0000216 a crying abnormal AE that has an outcome of abnormal unusual high-pitched crying in a patient YH unusual high-pitched crying AE OAE:0000217 a crying abnormal AE that has an outcome of abnormal prolonged crying in a patient YH prolonged crying AE OAE:0000218 a decreased heart rate AE that results in a resting heart rate of under 60 beats per minutes (BPM). WEB: http://en.wikipedia.org/wiki/Bradycardia WEB: http://medical-dictionary.thefreedictionary.com/bradycardia 10006093 bradycardia AE HPO: HP_0001662 SIDER: C0428977 OAE:0000219 an adverse event that displays a disorder associated with child birth, newborn infant, or an infant. pregnancy, neonatal and perinatal disorder AE 10036585 YH, JX prenatal, perinatal or neonatal disorder AE OAE:0000222 a bupropion-induced adverse event that is induced by aplenzin administration YH aplenzin-induced adverse event OAE:0000226 an adverse event that occurs in the site of a medical intervention (e.g., vaccination injection site). YH application site reaction 10003055 medical intervention site AE OAE:0000231 A pregnancy, neonatal and perinatal AE that displays a disorder associated with newborn infant or an infant. YH neonatal AE OAE:0000232 A pregnancy, neonatal and perinatal AE that displays a disorder associated with childbirth YH perinatal AE OAE:0000236 a vascular disorder AE that affects the artery SS arterial disease AE arterial disorder AE HPO: HP_0002620 SIDER: C0852949 OAE:0000237 an artery disorder AE that is characterized by a narrowing of the blood vessels outside of the heart. SS peripheral artery disease AE peripheral artery disorder AE WEB: http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3Aproject=medlineplus&query=peripheral+arterial+disease 10067825 peripheral arterial disease AE HPO: HP_0004950 SIDER: C1704436 OAE:0000238 an autoimmune disease AE that shows a symptom of dry red patches on the skin. SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/psoriasis WEB: https://en.wikipedia.org/wiki/Psoriasis 10037153 psoriasis AE HPO: HP_0003765 SIDER: C0033860 OAE:0000239 a distal sensory neuropathy AE characterized by an increase in degree (cumulative) AG, YH cumulative distal sensory neuropathy AE OAE:0000240 a behavior and neurological AE that has an outcome of stress in a patient YH stress AE OAE:0000241 an abscess AE that has an outcome of a pocket of infected fluid and pus located inside the abdominal cavity DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000212.htm 10060921 abdominal abscess AE OAE:0000242 a discomfort AE that has an outcome of a stomach ache DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Abdominal+discomfort 10000059 abdominal discomfort AE HPO: HP_0002027 SIDER: C0232487 OAE:0000243 a sensory capability AE that results in a sensation of elevated abdominal pressure and volume DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0003609/ 10000060 abdominal distension AE CTCAE: E10456 HPO: HP_0003270 NCIt: C78161 SIDER: C0000731 OAE:0000244 a sepsis AE that has an outcome of sepsis in the abdominal area DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001687/ 10058040 abdominal sepsis AE OAE:0000245 an abdominal abscess AE that has an outcome of a collection of pus in the abdominal wall, causes inflammation DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002329/ 10000099 abdominal wall abscess AE OAE:0000247 a behavioral and neurological AE that results in odd dreams DJ, SS, YH 10000125 abnormal dreams AE OAE:0000248 an abortion AE that has an outcome of expulsion of a fetus from the uterus brought on intentionally by medication or instrumentation DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/induced+abortion 10000220 abortion induced AE OAE:0000249 an abortion AE that results in a miscarriage DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002458/ 10000234 abortion spontaneous AE HPO: HP_0005268 SIDER: C0000786 OAE:0000250 a skin AE that is characterized by pimples generally on the face, chest and back, caused by clogging of the pores DJ, SS, YH acne vulgaris AE WEB: http://medical-dictionary.thefreedictionary.com/acne 10000496 acne AE HPO: HP_0001061 SIDER: C0702166 OAE:0000251 a immune system disorder AE that is caused by the HIV virus DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/hivaids.html 10000565 acquired immunodeficiency syndrome AE HPO: HP_0002721 SIDER: C0001175 OAE:0000252 a hematopoietic system AE that has an outcome of a prolonged time taken for blood to clot. The partial thromboplastin time (PTT) is a blood test that looks at how long it takes for blood to clot. PTT measures the efficacy of the comon coagulation pathways and helps tell if bleeding or clotting problems exist. DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003653.htm 10000636 activated partial thromboplastin time prolonged AE CTCAE: E12073 HPO: HP_0003645 NCIt: C27028 SIDER: C0853223 OAE:0000253 a digestive system AE that has an outcome of a complication during stem cell or bone marrow transplant in which the newly transplanted donor cells in the intestine attack the transplant recipient's body DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001309.htm 10066264 acute graft versus host disease in intestine AE OAE:0000254 a skin AE that has an outcome of a complication during stem cell or bone marrow transplant in which the newly transplanted donor cells in the skin attack the transplant recipient's body DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001309.htm 10066262 acute graft versus host disease in skin AE OAE:0000255 a hematopoietic system AE that has an outcome of a type of acute leukemia, characterized by anemia, fatigue, weight loss, easy bruising, thrombocytopenia, granulocytopenia with bacterial infections, and bone pain DJ, SS, YH acute lymphocytic leukaemia AE WEB: http://medical-dictionary.thefreedictionary.com/Blast+count 10000846 acute lymphocytic leukemia AE HPO: HP_0006721 SIDER: C0023449 OAE:0000256 a hematopoietic system AE that has an outcome of the reoccurance of fast-growing cancer of the white blood cells where abnormal blasts do not fight infections after a period of remission DJ, SS, YH acute lymphocytic leukaemia recurrent AE WEB: http://marrow.org/Patient/Disease_and_Treatment/About_Your_Disease/ALL/Acute_Lymphoblastic_Leukemia_(ALL).aspx 10063620 acute lymphocytic leukemia recurrent AE OAE:0000257 a hematopoietic system AE that has an outcome of cancer in the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells DJ, SS, YH acute myeloid leukaemia AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001569/ 10000880 acute myeloid leukemia AE HPO: HP_0004808 SIDER: C0023467 OAE:0000258 an acute myeloid leukemia AE that shows an recurrence of acute myeloid leukemia DJ, SS, YH acute myeloid leukaemia recurrent AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001569/ 10059034 acute myeloid leukemia recurrent AE OAE:0000259 a lung disorder AE that has the outcome fluid accumulation in the air spaces and parenchyma of the lungs with rapid onset DJ, SS, YH acute pulmonary oedema AE WEB: http://medical-dictionary.thefreedictionary.com/Acute+pulmonary+edema 10001029 acute pulmonary edema AE HPO: HP_0100598 SIDER: C0155919 OAE:0000260 a respiratory distress AE that prevents enough oxygen from getting to the lungs and into the blood DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001164/ 10001052 acute respiratory distress syndrome AE HPO: HP_0002093 SIDER: C0035222 OAE:0000261 a lung disorder AE that has an outcome of a condition in which not enough oxygen passes from the lungs into the blood, with rapid onset DJ, SS, YH, MW WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/rf/ 10001053 acute respiratory failure AE HPO: HP_0002093 SIDER: C0264490 OAE:0000262 a syncope AE that results in sudden episodes of fainting and sometimes seizures DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1518479/ 10001115 adams-stokes syndrome AE OAE:0000263 a reproductive system AE that results in the thickening of the walls of the uterus. This ccurs when endometrial tissue, which normally lines the uterus, moves into the outer muscular walls of the uterus. DJ, SS, YH endrometriosis interma AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002481/ 10056268 adenomyosis AE OAE:0000264 a viral infection that occurs in the respiratory system and has an outcome of viral infection by nonenveloped icosahedral viruses causing illness in the respiratory system DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Adenovirus+Infections 10060931 adenovirus infection AE HPO: HP_0004429 SIDER: C0001486 OAE:0000265 a tumor AE that results in an abnormal number of cells proliferating on the kidney(s) DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22486993 10061588 adrenal neoplasm AE OAE:0000266 an endocrine system AE that results in the suppression of the functions of the adrenal glands DJ, SS, YH 10001382 adrenal suppression AE OAE:0000267 a behavior and neurological AE that results in an increase in hostile behavior DJ, SS, YH 10001488 aggression AE HPO: HP_0000718 SIDER: C0001807 OAE:0000268 a hematopoietic system AE that has an outcome of acute leukopenia, or lowered white blood cell count, most commonly of neutrophils causing neutropenia in circulating blood JX, DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001295.htm 粒性白血球缺乏症 10001507 agranulocytosis AE HPO: HP_0001913 SIDER: C0001824 OAE:0000269 an embolism AE that is caused by an air bubble in the vessel DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23295634 10001526 air embolism AE OAE:0000270 a liver related investigation result abnormal AE that has an outcome of an abnormal blood level of alanine aminotransferase DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23139615 10001547 alanine aminotransferase level abnormal AE OAE:0000271 an alanine aminotransferase level abnormal AE that has an outcome of a decrease in alanine aminotransferase level in body DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/23139615 10001549 alanine aminotransferase level decreased AE OAE:0000272 an alanine aminotransferase level abnormal AE that has an outcome of elevated levels of alanine transaminase, an enzyme most commonly found in the liver DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/23139615 10001551 alanine aminotransferase level increased AE CTCAE: E12077 NCIt: C26948 OAE:0000273 a liver/biliary system AE that is characterized by liver disease caused by the patient's alcoholic activity DJ, SS, YH 10001627 alcoholic liver disease AE OAE:0000274 a behavior and neurological AE that has an outcome of significantly different waking beta wave state DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/20182997 10001854 altered state of consciousness AE OAE:0000275 a female reproductive system AE that is characterized by the absence of menstrual period in a woman of reproductive age DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21942684 10001928 amenorrhoea AE HPO: HP_0000141 SIDER: C0002453 OAE:0000276 an abnormal fluid regulation AE that results in a decreased volume of amniotic fluid during pregnancy DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22039031 10063356 amniotic fluid volume decreased AE OAE:0000277 an anus AE that has an outcome of a split or tear in the mucosa lining the lower rectum DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002116/ 10002153 anal fissure AE HPO: HP_0004378 SIDER: C0016167 OAE:0000278 an ulcer AE that has an outcome of an ulcer in the anal cavity DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/17073250 10002180 anal ulcer AE CTCAE: E10496 NCIt: C79536 OAE:0000279 a vascular disorder AE that has an outcome of a leakage at the site of the intersection of two blood vessels DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23122582 10050456 anastomotic leak AE OAE:0000280 a cardiac disorder AE that is stable and shows the symptom of a chest pain due to ischemia of the heart DJ, SS, YH stable angina AE WEB: http://www.heart.org/HEARTORG/Conditions/HeartAttack/SymptomsDiagnosisofHeartAttack/Angina-Pectoris-Stable-Angina_UCM_437515_Article.jsp# WEB: http://www.ncbi.nlm.nih.gov/pubmed/23016723 10002383 angina pectoris AE HPO: HP_0001681 SIDER: C0002962 OAE:0000281 a angina AE that is unstable and has an outcome of a condition in which the heart doesn't get enough blood flow through the blood vessels of the heart muscle, may lead to heart attack. DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001250/ 10002388 angina unstable AE HPO: HP_0001681 SIDER: C0002965 OAE:0000282 an immunology and allergy investigation result abnormal AE that is characterized by antibodies present that are against cell-membrane phospholipids that provoke blood clots DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/23231732 10048678 antiphospholipid antibodies positive AE OAE:0000283 a urinary system AE that has an outcome of the absence of urine formation DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/anuria 10002847 anuria AE HPO: HP_0100519 SIDER: C0003460 OAE:0000284 a vascular disorder AE that results in a condition affecting the aorta and aortic valves DJ, SS, YH WEB: http://www.rightdiagnosis.com/medical/aorta_disorder.htm 10058648 aortic disorder AE HPO: HP_0001679 SIDER: C0003493 OAE:0000285 a cardiac valve disease AE that has an outcome of inability of the aortic valve to function effectively DJ, SS, YH WEB: http://www.rightdiagnosis.com/a/aortic_valve_incompetence/intro.htm 10002915 aortic valve incompetence AE HPO: HP_0001659 SIDER: C0003504 OAE:0000286 a congenital abnormality AE with an outcome of defective development or congenital absense of an organ or tissue DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/737831 10002961 aplasia AE HPO: HP_0010515 SIDER: C0243065 OAE:0000287 Aplastic anaemia AE is an anemia AE that occurs when the bone marrow, and the blood stem cells that reside there are damaged. This causes a deficiency of all three blood cell types (pancytopenia): red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia). DJ, SS, JX, YH aplastic anemia WEB: http://www.ncbi.nlm.nih.gov/pubmed/23292240 再生障碍性贫血 10002967 aplastic anaemia AE HPO: HP_0001915 SIDER: C0002874 OAE:0000288 a serious AE that is due to an allergic brochospasm, which causes a serious problem with breathing and requires treatment in an emergency room. YH, JX URL: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm URL: https://en.wikipedia.org/wiki/Bronchospasm allergic brochospasm AE that requires treatment in emergency OAE:0000289 a hypersensitivity AE that occurs at the site of an application of a medical intervention (e.g., drug administration or vaccination). DJ, SS, YH 10063683 application site hypersensitivity AE OAE:0000290 an infection AE that occurs at the site of drug application DJ, SS, YH 10049041 application site infection AE OAE:0000291 a hemorrhage AE that has an outcome of bleeding in the arteries DJ, SS, YH arterial bleeding AE arterial haemorrhage AE 10060964 arterial hemorrhage AE OAE:0000292 CSF protein increased AE is an abnormal cerebrospinal fluid production that results in and increase in blood level CSF protein SS, YH 10011575 CSF protein increased AE OAE:0000293 a neurological, special senses and psychiatric investigation result abnormal AE that has an outcome of an abnormal result in the cerebrospinal fluid (CSF) collection test that examines the fluid that surrounds the brain and spinal cord This should be inferred as a "AE: lab test abnormal". SS, YH, EB WEB: www.nlm.nih.gov/medlineplus/ency/article/003428.htm 10059703 CSF test result abnormal AE OAE:0000294 Henoch-Schonlein purpura AE is a purpura AE, a systemic vasculitis (inflammation of blood vessels) characterized by deposition of immune complexes containing the antibody IgA in the skin and kidney. This results from some allergic response, SS, YH allergic purpura, anaphylactoid purpura, vascular purpura WEB: http://en.wikipedia.org/wiki/Henoch-Schonlein_purpura 10019617 Henoch-Schonlein purpura AE HPO: HP_0000979 SIDER: C0034152 OAE:0000295 SS, YH WEB: http://en.wikipedia.org/wiki/Abasia 10049460 a movement disorder AE that has an outcome of abasia, a movement disorder that results in and inability to walk due to impaired muscle coordination abasia AE HPO: HP_0002540 SIDER: C0877217 OAE:0000296 a stomach pain AE that is observed in upper stomach SS, YH 10000087 abdominal pain upper AE HPO: HP_0002027 SIDER: C0232492 OAE:0000297 a behavior and neurological AE that has an outcome of loss of taste functions of the tongue, particularly the inability to detect sweetness, sourness, bitterness, saltiness, and umami (the taste of monosodium glutamate). SS, YH WEB: http://en.wikipedia.org/wiki/Ageusia 10001480 ageusia AE OAE:0000298 a sensory neuropathy AE that has an outcome of chronic sensory neuropathy characterized by being persistent or long-lasting in nature AG, YH chronic sensory neuropathy AE OAE:0000299 a behavior and neurological AE that has an outcome of a lack of functioning olfaction, an inability to perceive odors SS, YH WEB: http://en.wikipedia.org/wiki/Olfaction 10002653 anosmia AE HPO: HP_0010632 SIDER: C0003126 OAE:0000300 a psychiatric disorder AE that has an outcome of a psychological and physiological state characterized by cognitive, somatic, emotional, and behavioral components. These components combine to create an unpleasant feeling that is typically associated with uneasiness, fear, or worry. SS, YH WEB: http://en.wikipedia.org/wiki/Anxiety 10002855 anxiety AE CTCAE: E12883 HPO: HP_0000739 NCIt: C26696 SIDER: C0003467 OAE:0000301 an arrhythmia AE that is characterized by rapid regular atrial contractions occurring usually at rates between 250 and 400 per minute and often producing saw-tooth waves in an electrocardiogram. SS AF auricular flutter WEB: http://medical-dictionary.thefreedictionary.com/atrial+flutter 10003662 atrial flutter AE CTCAE: E10087 HPO: HP_0004749 NCIt: C51224 SIDER: C0004239 OAE:0000302 a behavior and neurological AE that has an outcome of a disturbance that causes an individual to feel unsteady, giddy, woozy, or have a sensation of movement, spinning, or floating. SS, YH WEB: http://en.wikipedia.org/wiki/Balance_disorder 10049848 balance disorder AE HPO: HP_0002141 SIDER: C0575090 OAE:0000303 blister AE is a skin adverse event that results in a small pocket of fluid within the upper layers of the skin SS, YH WEB: http://en.wikipedia.org/wiki/Blister 10005191 blister AE HPO: HP_0008066 SIDER: C0005758 OAE:0000304 cellulitis AE is an inflammation AE that is a diffuse inflammation of connective tissue with severe inflammation of dermal and subcutaneous layers of the skin SS, YH WEB: http://en.wikipedia.org/wiki/Cellulitis 10007882 cellulitis AE HPO: HP_0003553 SIDER: C0007642 OAE:0000305 a behavior and neurological AE that has an outcome of a type of perspiration usually associated with anxiety or fear SS, YH WEB: http://en.wikipedia.org/wiki/Cold_sweat cold sweat AE OAE:0000306 convulsion AE is a muscle adverse event that results in a medical condition where body muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body SS, YH WEB: http://en.wikipedia.org/wiki/Convulsion 10010904 convulsion AE HPO: HP_0001250 SIDER: C0009951 OAE:0000307 SS, YH a movement disorder AE that has an outcome of difficulty in walking properly difficulty in walking AE OAE:0000308 a behavior and neurological AE that has an outcome of distortion of the sense of taste SS, YH, MW WEB: http://en.wikipedia.org/wiki/Dysgeusia 10013911 dysgeusia AE CTCAE:E12643 HPO: HP_0000223 NCIt:C28145 SIDER: C0013378 OAE:0000309 a movement disorder AE that has an outcome of dyskinesia SS, YH WEB: http://en.wikipedia.org/wiki/Dyskinesia 10013916 dyskinesia is a movement disorder which consists of effects including diminished voluntary movements and the presence of involuntary movements dyskinesia AE HPO: HP_0100660 SIDER: C0013384 OAE:0000310 An abnormal respiration AE that is characterized by a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. MedDRA: 10013968 is for "dyspnoea"; MedDRA: 10013963 is for "dyspnea". SS, YH air hunger dyspnoea shortness of breath WEB: http://en.wikipedia.org/wiki/Dyspnoea https://en.wikipedia.org/wiki/Shortness_of_breath https://www.mayoclinic.org/symptoms/shortness-of-breath/basics/definition/sym-20050890 呼吸困难 10013963 10013968 dyspnea AE CTCAE: E13368 HPO: HP_0002094 NCIt: C2998 SIDER: C0013404 UMLS CUI: C0013404 OAE:0000311 SS, YH, EB WEB: http://en.wikipedia.org/wiki/Electromyography 10014431 a neurological, special senses and psychiatric investigation result abnormal AE that has an outcome of abnormal activity in skeletal muscles evaluted and measured by electromyography electromyogram result abnormal AE OAE:0000312 eye irritation AE is an eye disorder AE that results in mild eye redness, itching, or tearing SS, YH WEB: http://www.freemd.com/eye-irritation/ 10015946 eye irritation AE HPO: HP_0000478 SIDER: C0235266 OAE:0000313 eye pruritus AE is a pruritus AE (an unpleasant sensation that evokes the desire or reflex to scratch) at the eye area SS, YH 10052140 eye pruritus AE HPO: HP_0000989 SIDER: C0022281 OAE:0000314 glomerulonephritis AE is a kidney disorder AE that results in a renal disease that is characterized by inflammation of the glomeruli, or small blood vessels in the kidneys. SS, YH glomerular nephritis AE WEB: http://en.wikipedia.org/wiki/Glomerulonephritis glomerulonephritis AE HPO: HP_0000099 SIDER: C0017658 OAE:0000315 A conduction system disorder AE that is a condition in which the electrical impulse from the bundle of His to the ventricles is delayed or fails to conduct along the right bundle branch, resulting in right ventricular depolarization by cell-to-cell conduction spreading from the interventricular septum and left ventricle to the right ventricle–ie, slow and uncoordinated Natural history Surgically induced RBBB has few acute hemodynamic consequences and a generally benign course long term; rarely, progression to complete heart block and sudden death occur, especially if accompanied by major His-Purkinje system–eg, left anterior hemiblock, first-degree AV block–injury; tetralogy of Fallot repair with an RBBB and a markedly prolonged QRS duration >180 ms have an ↑ risk for ventricular arrhythmias and sudden death. SS RBBB right bundle branch block WEB: http://medical-dictionary.thefreedictionary.com/right+bundle+branch+block 10006582 bundle branch block right AE HPO: HP_0011712 SIDER: C0085615 OAE:0000316 a cardiac disorder AE of the electrical conduction system that controls the heart rate, generates and conducts electrical impulses throughout the muscle of the heart, stimulating the heart to contract and pump blood. SS cardiac conduction disorder AE conduction disorder AE WEB: http://www.medterms.com/script/main/art.asp?articlekey=8407 10000032 10010276 conduction system disorder AE CTCAE: E10114 NCIt: C78245 OAE:0000317 a sensory capability AE that has an outcome of hypoaesthesia, meaning that skin loses some of its sensitivity to pain or touch SS, YH disesthesia AE hypoaesthesia AE WEB:http://medguides.medicines.org.uk/document.aspx?name=hypoaesthesia 10020937 hypoesthesia AE HPO: HP_0010830 SIDER: C0020580 OAE:0000318 a thrombosis AE that has an outcome of a blood clot within an artery [SS] Per DRA and KKB's comment, arterial thrombosis may also be characterized as an embolism. DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23236330 10003178 arterial thrombosis AE HPO: HP_0004420 SIDER: C0151942 OAE:0000319 a viral infection AE that demonstrates an influenza viral infection. Influenza is an infectious disease caused by RNA viruses of the family Orthomyxoviridae (the influenza viruses), that affects birds and mammals SS, YH WEB: http://en.wikipedia.org/wiki/Influenza influenza AE HPO: HP_0005376 MDR: 10022000 SIDER: C0021400 OAE:0000320 a coronary artery disease AE with the outcome hardening of the coronary artery due to a build up of waxy plaque on the inside of blood vessels DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Coronary+Arteriosclerosis 10003211 arteriosclerosis coronary artery AE HPO: HP_0004929 SIDER: C0010054 OAE:0000321 injected limb mobility decreased AE is a mobility decreased AE that occurs in the limb in which injection is administered SS, YH injected limb mobility decreased AE OAE:0000322 a haematoma AE that has an outcome of injection-site haematoma, which results in a collection of blood outside the blood vessels at the physical area of injection SS, YH injection-site haematoma AE WEB: http://medical-dictionary.thefreedictionary.com/hematoma http://en.wikipedia.org/wiki/Hematoma 10022066 injection-site hematoma AE OAE:0000323 injection-site induration AE is an skin AE that results in hardening or thickening of tissue at the physical injection site SS, YH WEB: http://wordnetweb.princeton.edu/perl/webwn?s=induration injection-site induration AE OAE:0000324 injection-site pruritus AE is an pruritus AE that results in an unpleasant sensation that evokes the desire or reflex to scratch at the physical area of injection SS, YH WEB: http://en.wikipedia.org/wiki/Itch WEB: http://medical-dictionary.thefreedictionary.com/pruritus 10022093 injection-site pruritus AE OAE:0000325 injection-site rash AE is a rash AE that results in a change of the skin which affects its color, appearance or texture at the physical injection site SS, YH WEB: http://en.wikipedia.org/wiki/Rash injection-site rash AE OAE:0000326 injection-site warmth AE is a homeostasis AE that results in feeling of warmth at the physical injection site SS, YH injection-site warmth AE OAE:0000327 A joint disorder AE that has an outcome of joint swelling, which is a joint disorder that results in a buildup of fluid in the soft tissue surrounding the joint SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003262.htm 10023232 joint swelling AE HPO: HP_0005833 SIDER: C0152031 OAE:0000328 an adverse event that occurs in kidney. SS, YH, DA abnormal renal function AE renal disorder AE https://medlineplus.gov/ency/article/001265.htm 10038428 kidney AE OAE:0000329 a behavior and neurological AE that has an outcome of an increase in production, secretion, and shedding of tears SS, YH WEB: http://en.wikipedia.org/wiki/Tears WEB: http://www.medterms.com/script/main/art.asp?articlekey=6199 10023644 lacrimation increased AE HPO: HP_0009926 SIDER: C0152227 OAE:0000330 lip swelling AE is an edema (swelling) AE that results in enlargement or protuberance in the lip SS, YH WEB: http://en.wikipedia.org/wiki/Swelling_%28medical%29 10024570 lip swelling AE HPO: HP_0000159 SIDER: C0240211 OAE:0000331 A lymphadenopathy AE that results in swollen/enlarged lymph nodes SS, YH WEB: http://en.wikipedia.org/wiki/Lymphadenopathy lymphadenitis AE HPO: HP_0002840 SIDER: C0024205 OAE:0000332 mobility decreased AE is a nervous system AE that results in difficulty in movement leading to less ability to move part(s) of body SS, YH 10048334 mobility decreased AE HPO: HP_0006217 SIDER: C0700572 OAE:0000333 a muscle AE that has an outcome of muscular weakness AE (i.e., lack of muscle strength). SS, YH WEB: http://en.wikipedia.org/wiki/Muscular_weakness 10028372 muscular weakness AE HPO: HP_0001324 SIDER: C0151786 OAE:0000334 a sensory capability AE that has an outcome of a sensation of stiffness in muscles and skeleton SS, YH 10052904 musculoskeletal stiffness AE HPO: HP_0003552 SIDER: C0948525 OAE:0000335 nasal congestion AE is a respiratory system AE that results in a blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels SS, YH WEB: http://en.wikipedia.org/wiki/Nasal_congestion 10028735 nasal congestion AE CTCAE: E13450 HPO: HP_0001742 NCIt: C78500 SIDER: C0027424 OAE:0000336 a respiratory system inflammation AE which has an outcome of nasopharyngitis, a respiratory system inflammation that results in common cold, a contagious, viral infectious disease of the upper respiratory system a respiratory system inflammation AE which has an outcome of nasopharyngitis, a respiratory system inflammation that results in common cold, a contagious, viral infectious disease of the upper respiratory system SS, YH common cold AE WEB: http://en.wikipedia.org/wiki/Nasopharyngitis nasopharyngitis AE HPO: HP_0002087 SIDER: C0027441 OAE:0000337 an neuropathy AE that results in a damage to the peripheral nervous system (PNS, outside the brain and spinal cord), the vast communication network that transmits information from the brain and the spinal cord (the central nervous system) to every other part of the body. SS, YH neuropathy peripheral AE WEB: http://en.wikipedia.org/wiki/Peripheral_neuropathy WEB: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm 10029331 peripheral neuropathy AE OAE:0000338 ocular hyperaemia AE is an eye disorder AE that results in severe redness and irritation of the eyes SS, YH ocular hyperaemia AE WEB: http://www.med.miami.edu/news/view.asp?id=259 10030041 ocular hyperemia AE OAE:0000339 a pain AE that has an outcome of oropharyngeal pain SS, YH WEB: http://en.wikipedia.org/wiki/Oropharyngeal_airway 10068319 oropharyngeal pain is a pain in oral airway oropharyngeal pain AE HPO: HP_0010833 SIDER: C2363731 OAE:0000340 an ear disorder AE which has an outcome of otitis media that results in inflammation of the middle ear, or middle ear infection SS, YH WEB: http://en.wikipedia.org/wiki/Otitis_media 10033078 otitis media AE CTCAE: E11477 HPO: HP_0008623 NCIt: C34885 SIDER: C0029882 OAE:0000341 an inflammation AE that has an outcome of pericaditis, which is a cardiovascular disorder that results in a condition in which the sac-like covering around the heart (pericardium) becomes inflamed SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000182.htm 10034484 pericarditis AE CTCAE: E10180 HPO: HP_0001701 NCIt: C34915 SIDER: C0031046 OAE:0000342 pharyngeal edema AE is an edema AE that results in an bbnormal fluid accumulation in TISSUES or body cavities in pharynx (throat swelling). SS, YH pharyngeal oedema AE WEB: http://www.ncbi.nlm.nih.gov/mesh/68004487?ordinalpos=1&itool=EntrezSystem2.PEntrez.Mesh.Mesh_ResultsPanel.Mesh_RVDocSum pharyngeal edema AE OAE:0000343 pharyngitis AE is a digestive system AE that results in an inflammation of the throat or pharynx SS, YH WEB: http://en.wikipedia.org/wiki/Pharyngitis 10034835 pharyngitis AE CTCAE: E11525 HPO: HP_0100776 NCIt: C26851 SIDER: C0031350 OAE:0000344 a pain AE that shows a pain in sinus and throat SS, YH, MW WEB: http://www.wordinfo.info/words/index/info/view_unit/1631/ 10034844 pharyngolaryngeal pain AE CTCAE: E13482 HPO: HP_0010833 NCIt: C78556 SIDER: C0858635 OAE:0000345 rash macular AE is a rash AE that results in a skin eruption in which the lesions are flat and less than 1 cm in diameter SS, YH rash macular AE WEB: http://medical-dictionary.thefreedictionary.com/macular+rash macular rash AE HPO: HP_0000988 SIDER: C0221201 OAE:0000346 a rash AE that shows clustered papules, i.e., small, round, raised bumps that have clear borders. SS, YH rash papular AE WEB: http://en.wikipedia.org/wiki/Rash WEB: http://www.healthline.com/symptom/papule WEB: http://www.rightdiagnosis.com/sym/papular_rash.htm 10037876 papular rash AE HPO: HP_0007432 SIDER: C0221202 OAE:0000347 A respiratory system AE thta is characterized by inflammation of the lung parenchyma leading to impaired gas exchange with concomitant systemic release of inflammatory mediators causing inflammation, hypoxemia and frequently resulting in multiple organ failure. SS, YH WEB: http://en.wikipedia.org/wiki/Acute_respiratory_distress_syndrome 10038687 respiratory distress AE HPO: HP_0002747 SIDER: C0476273 OAE:0000348 respiratory tract congestion AE is a respiratory system AE that results in congestion in respiratory tract SS, YH respiratory tract congestion AE OAE:0000349 retching AE is a digestive system AE that results in a process in the human body where gastric (and sometimes duodenal) contents are forced into the esophagus, but do not enter the pharynx SS, YH WEB: http://en.wikipedia.org/wiki/Retching 10038776 retching AE OAE:0000350 rhinitis AE is a respiratory system inflammation characterized by runny nose,irritation and inflammation of some internal areas of the nose SS, YH runny nose WEB: http://en.wikipedia.org/wiki/Rhinitis WEB: http://medical-dictionary.thefreedictionary.com/rhinitis 10028116 rhinitis AE HPO: HP_0002257 SIDER: C0035455 OAE:0000351 rhinorrhoea AE is a respiratory system AE that results in runny nose, an unusually significant amount of nasal fluid SS, YH rhinorrhoea AE WEB: http://en.wikipedia.org/wiki/Rhinorrhoea rhinorrhea AE OAE:0000352 a pain AE that occurs in shoulder shoulder pain is a pain iin or around the shoulder joint SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003171.htm shoulder pain AE OAE:0000353 sinus congestion AE is a nasal congestion AE that results in blockage of the air cavities in the cranial bones or nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels SS, YH WEB: http://en.wikipedia.org/wiki/Sinus_%28anatomy%29, http://en.wikipedia.org/wiki/Nasal_congestion sinus congestion AE HPO: HP_0002257 SIDER: C0152029 OAE:0000354 sneezing AE is a respiratory system adverse event that results in sternutation, a semi-autonomous, convulsive expulsion of air from the lungs through the nose and mouth, usually caused by foreign particles irritating the nasal mucosa SS, YH, MW sternutation WEB: http://en.wikipedia.org/wiki/Sneezing 10041232 sneezing AE CTCAE:E13572 NCIt:C50746 OAE:0000355 an increased heart rate AE where the heart rate exceeds the normal range for a resting heartrate (heartrate in an inactive or sleeping individual) SS, YH WEB: http://en.wikipedia.org/wiki/Tachycardia 10043071 tachycardia AE HPO: HP_0001649 SIDER: C0039231 OAE:0000356 a tendon disorder AE that has an outcome of tendonitis SS, YH tendinitis AE WEB: http://en.wikipedia.org/wiki/Tendinitis tendonitis is a tendon disorder that results in an inflammation of a tendon tendonitis AE HPO: HP_0100261 SIDER: C0039503 OAE:0000357 a sensory capability AE that has an outcome of a sensation of tightness in the throat 10043528 throat tightness AE OAE:0000358 an infection AE is a respiratory system AE that results in illnesses caused by an acute infection which involves the upper respiratory tract: nose, sinuses, pharynx or larynx SS, YH URI, URTI WEB: http://en.wikipedia.org/wiki/Upper_respiratory_tract_infection 10046300 upper respiratory tract infection AE CTCAE: E11604 HPO: HP_0002788 NCIt: C35650 SIDER: C0041912 OAE:0000359 a viral infection AE that results in an acute contagious diseased caused by herpes varicella zoster virus; causes a rash of vesicles on the face and body. SS, YH chicken pox AE varicella zoster virus infection AE WEB: http://wordnetweb.princeton.edu/perl/webwn?s=varicella varicella AE HPO: HP_0005428 SIDER: C0008049 OAE:0000360 a paresthesia AE that occurs in oral area. SS, YH paraesthesia oral AE http://www.answers.com/topic/oral-paresthesia 10057372 paraesthesia oral is a paresthesia that results in a numbness or tingling that occurs in the mucosa or tissues of the oral cavity. paresthesia oral AE HPO: HP_0003401 SIDER: C0521591 OAE:0000361 an abnormal body temperature AE which has an outcome of fever YH, SS, MW body temperature increased AE febrile response pyrexia AE Axelrod YK1, Diringer MN. Temperature management in acute neurologic disorders. Neurol Clin. 2008 May;26(2):585-603, xi. doi: 10.1016/j.ncl.2008.02.005. PMID: 18514828. WEB: http://en.wikipedia.org/wiki/Pyrexia 10005911 10016558 10037660 Fever is a frequent medical sign that describes an increase in internal body temperature to levels above normal. Fever is characterized as a temporary elevation in the body's thermoregulatory set-point, usually by about 1-2 °F). fever AE CTCAE: E11102 NCIt: C3038 OAE:0000362 a skin AE that shows the symptom of rash, i.e., an abnormal change in skin color, appearance, or texture. A rash may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful. YH URL: http://en.wikipedia.org/wiki/Rash URL: http://www.webmd.com/skin-problems-and-treatments/guide/common-rashes Wick JY. Drug-induced rash: nuisance or threat? Consult Pharm. 2013 Mar;28(3):160-6. PMID: 23462025. 10037844 Drug-induced rash is the most commonly reported drug reaction. rash AE HPO: HP_0000988 SIDER: C0015230 OAE:0000363 an adverse event that has an outcome of a pathogen infection, i.e., an infection caused by a pathogen such as a virus, bacterium, or parasite. change of name from 'infection adverse event' to 'infectious adverse event' on 09/23/13 for a better clinical relevance, move 'infection adverse event' as an alternative term - SS YH, JX infectious adverse event WEB: http://medical-dictionary.thefreedictionary.com/infection infection 10021789 infection AE OAE:0000364 An AE that has an outcome of syndrome. Syndrome is the association of several clinically recognizable features, signs (observed by a physician), symptoms (reported by the patient), phenomena or characteristics that often occur together, so that the presence of one feature alerts the physician to the presence of the others. YH syndrome AE OAE:0000365 a psychiatric disorder AE that has an outcome of emotional state of excitement or restlessness YH, MW 10001497 agitation AE CTCAE:E12874 HPO: HP_0000711 NCIt:C79530 SIDER: C0085631 OAE:0000366 injection-site AE is an AE that occurs in an injection site (e.g., during vaccination). YH, JX, SS injection site AE injection-site adverse event injection-site reaction local reaction AE 10022095 injection-site AE CTCAE: E11138 NCIt: C3508 OAE:0000367 a hypersensitivity AE which has an outcome of injection-site hypersensitivity YH injection-site hypersensitivity AE OAE:0000368 an edema AE which occurs at the injection site. In this case, a collection of fluid at the injection site is found. YH, RR injection-site oedema AE injection-site swelling AE WEB: http://www.uptodate.com/contents/edema-swelling-beyond-the-basics 10053425 injection-site edema AE OAE:0000369 a pain AE that occurs in an injection site of a medical intervention YH 10022086 injection-site pain AE OAE:0000370 an inflammation AE which has an outcome of injection-site inflammation YH injection-site inflammation AE OAE:0000371 a hemorrhage AE that has an outcome of injection-site hemorrhage YH 10022067 injection-site hemorrhage AE OAE:0000372 a tumor or mass AE that occurs in an injection-site YH, SS injection site nodule AE injection-site mass is a mass at physical injection site injection-site mass AE OAE:0000373 a skin adverse event that has an outcome of pruritus YH, SS, MW itch itching pruritus generalised AE WEB: http://www.ncbi.nlm.nih.gov/sites/entrez?db=mesh&cmd=DetailsSearch&term=pruritus+generalised&log$=activity 10037087 Pruritus is an itch (Latin: pruritus), i.e., an unpleasant sensation that evokes the desire or reflex to scratch. pruritus AE CTCAE:E13686 HPO: HP_0000989 NCIt:C3344 SIDER: C0033774 OAE:0000374 a sensory capability AE that has an outcome of pain in a patient YH, MW 10033371 pain AE CTCAE: E11167 HPO: HP_0010833 NCIt: C3303 SIDER: C0030193 OAE:0000375 a pain AE that has outcome of myalgia. Myalgia means "muscle pain" and is a symptom of many diseases and disorders. YH, MW muscle pain AE 10028411 myalgia AE CTCAE:E12485 HPO: HP_0003326 NCIt:C27009 SIDER: C0231528 OAE:0000376 Urticaria AE is a rash AE notable for dark red, raised, itchy bumps. YH, MW hives 10046735 urticaria AE CTCAE:E13746 HPO: HP_0001025 NCIt:C3432 SIDER: C0042109 OAE:0000377 a pain AE that has an outcome of headache YH, MW 10019211 headache AE CTCAE: E12678 HPO: HP_0002315 NCIt: C34661 SIDER: C0018681 OAE:0000378 an AE that occurs in respiratory system. I created this term and make it to be an umbrella term for different disorder terms related to respiratory system. --Oliver He YH respiratory system AE OAE:0000379 a leukocyte cell number abnormal AE that has an outcome of greater than normal number of leukocytes, or nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue According to the Vaccine Adverse Event Reporting System (VAERS), 'leukocytosis' is an adverse event that was mentioned in 1,021 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). SS, YH, EB increased leukocyte cell number AE leukocytosis AE white blood cell count increased AE WEB: http://en.wikipedia.org/wiki/Leukocytosis 10024378 10047943 leukocyte cell number increased AE CTCAE: E10048 MP: MP_0000218 NCIt: C35524 OAE:0000380 a leukocyte cell number abnormal AE that has an outcome of reduction in the number of leukocytes, or of nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue According to the Vaccine Adverse Event Reporting System (VAERS), 'leukopenia' is an adverse event that was mentioned in 417 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). decreased leukocyte cell number AE white blood cell count decreased AE 10047942 leukocyte cell number decreased AE CTCAE: E12232 MP: MP_0000221 NCIt: C26816 OAE:0000381 a cardiovascular disorder AE that has an outcome of abnormal blood pressure, representing altered tension of the blood within the systemic arteries abnormal blood pressure AE MP: MP_0000230 OAE:0000382 a muscle adverse event which has an outcome of asthenia, which is a medical term denoting symptoms of physical weakness and loss of strength. YH 10003549 asthenia AE HPO: HP_0001324 SIDER: C0004093 OAE:0000383 a muscle pain AE that has an outcome of muscle ache. YH muscle ache AE OAE:0000384 A rash AE that shows a flat, red area on the skin overed with small confluent bumps. YH, MW maculopapular rash AE rash maculo-papular AE rash maculopapular AE WEB: http://en.wikipedia.org/wiki/Maculopapular_rash 10037868 The term "maculopapular" is a compound: macules are small, flat discolored spots on the surface of the skin; and papules are small, raised bumps. maculo-papular rash AE CTCAE:E13700 NCIt:C75579 OAE:0000385 An joint disorder AE that has an outcome of arthralgia. Arthralgia means joint pain. It is a symptom of injury, infection, illnesses (in particular arthritis) or an allergic reaction to medication. According to MeSH, the term "arthralgia" should only be used when the condition is non-inflammatory, and the term "arthritis" should be used when the condition is inflammatory. YH, MW 10003239 arthralgia AE CTCAE:E12374 HPO: HP_0002829 NCIt:C50464 SIDER: C0003862 OAE:0000386 vesiculobullous rash AE is a rash AE characterized by serous-fluid-filled vesicles (blisters) YH vesiculobullous rash AE HPO: HP_0000988 SIDER: C0151883 OAE:0000387 a syndrome AE which has an outcome of screaming syndrome YH screaming syndrome AE OAE:0000388 a sensory capability AE that has an outcome of dizziness YH, SS, MW 10013573 Dizziness describes a number of subjective symptoms, which the patient may describe as feelings of lightheadedness, floating, wooziness, giddiness, confusion, disorientation or loss of balance. Medical terms include vertigo, disequilibrium, pre-syncope or syncoptic episode. Causes may stem from a variety of failures of equilibrioception, hypotension, cerebral hypoxia or a reaction to environmental chemicals or drugs. dizziness AE CTCAE:E12631 HPO: HP_0002321 NCIt:C37943 SIDER: C0012833 OAE:0000389 peripheral edema AE is an edema AE that results in swelling of tissues, usually in the lower limbs, due to the accumulation of fluids YH, SS edema peripheral AE oedema peripheral AE peripheral edema AE WEB: http://en.wikipedia.org/wiki/Peripheral_edema 10030124 10050068 edema limbs AE CTCAE: E11086 NCIt: C78262 OAE:0000390 a sensory capability AE that has an outcome of malaise YH 10025482 Malaise is a feeling of general discomfort or uneasiness, an "out of sorts" feeling. Malaise is often the first indication of an infection or other disease. Vaccination may induce malaise. malaise AE CTCAE: E11152 HPO: HP_0002321 NCIt: C3832 SIDER: C0231218 OAE:0000391 a behavior and neurological AE that has an outcome of somnolence YH, SS, MW drowsiness 10041349 Somnolence (or "drowsiness") is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods (c.f. hypersomnia). somnolence AE CTCAE:E12814 HPO: HP_0001262 NCIt:C26754 SIDER: C2830004 OAE:0000392 a sensory neuropathy AE that shows a sensation of tingling, pricking, or numbness of a person's skin with no apparent long-term physical effect. YH, MW paraesthesia AE WEB: http://en.wikipedia.org/wiki/Paraesthesia 10033775 10033987 Paresthesia is more generally known as the feeling of "pins and needles" or of a limb being "asleep" (although this is not directly related to the phenomenon of sleep). The manifestation of paresthesia may be transient or chronic. paresthesia AE CTCAE: E12758 NCIt: C28177 OAE:0000393 a behavior and neurological AE that has an outcome of abnormal crying in a patient YH 10011469 crying abnormal AE OAE:0000394 a sensory capability AE that has an outcome of chills YH feeling cold AE 10008531 Chills refers to feeling cold after an exposure to a cold environment. The word can also refer to an episode of shivering, accompanied by paleness and feeling cold. chills AE CTCAE: E11074 HPO: HP_0001945 NCIt: C35143 SIDER: C0085593 OAE:0000395 a behavior and neurological AE that has an outcome of stupor YH 10042264 Stupor is the lack of critical cognitive function and level of consciousness wherein a sufferer is almost entirely unresponsive and only responds to base stimuli such as pain. The word derives from the Latin stupure, meaning insensible. Being characterised by impairments of reactions to external stimuli, in this case, vaccine immunization. stupor AE HPO: HP_0004372 SIDER: C0085628 OAE:0000396 a gustatory system AE which demonstrates a decreased sensation of appetite. YH, MW anorexia nervosa AE decreased appetite AE WEB: http://www.mayoclinic.org/diseases-conditions/anorexia/basics/definition/con-20033002 厌食症 10002646 10002649 10061428 anorexia AE CTCAE: E12252 HPO: HP_0002039 NCIt: C2875 SIDER: C0003123 OAE:0000397 face edema AE is an edema AE that results in facial swelling, the build-up of fluid in the tissues of the face. Swelling may also affect the neck and upper arms YH, SS, MW emema face AE face oedema AE oedema face AE WEB:http://www.nlm.nih.gov/medlineplus/ency/article/003105.htm swelling face 10014222 10016029 10042682 face edema AE CTCAE: E11082 NCIt: C78289 OAE:0000398 an abnormal respiration AE that shows a sudden and often repetitively occurring reflex to keep the throat and airways clear YH, SS, MW coughing AE WEB: http://medical-dictionary.thefreedictionary.com/cough WEB: http://www.nlm.nih.gov/medlineplus/cough.html cough 10011224 cough AE CTCAE:E13364 NCIt:C37935 OAE:0000399 a syndrome AE that has an outcome of a flu syndrome AE and occurs after a medical intervention. YH flu-like symptom AE flu syndrome AE CTCAE: E11108 NCIt: C78302 OAE:0000400 a sensory capability AE that has an outcome of loss of consciousness, fainting YH, SS, MW Syncope is the medical term for fainting, a sudden, usually temporary, loss of consciousness. fainting WEB: http://en.wikipedia.org/wiki/Syncope_%28medicine%29 WEB: http://en.wikipedia.org/wiki/Unconsciousness 10024855 10042772 syncope AE CTCAE: E12832 HPO: HP_0001279 NCIt: C35053 SIDER: C0039070 OAE:0000401 a skin adverse event that has an outcome of sweating According to the Vaccine Adverse Event Reporting System (VAERS), 'sweating' is an adverse event that was mentioned in 2,301 VAERS reports (1.8%) during1991-2001 (Reference: PMID: 12825543). YH sweating AE HPO: HP_0000975 SIDER: C0038990 OAE:0000402 According to the Vaccine Adverse Event Reporting System (VAERS), 'abdominal pain' is an adverse event that was mentioned in 2,254 VAERS reports (1.8%) during1991-2001 (Reference: PMID: 12825543). YH, SS WEB: http://en.wikipedia.org/wiki/Abdominal_pain 10000081 a pain AE that is observed in abdominal cavity abdominal pain AE HPO: HP_0002027 SIDER: C0000737 OAE:0000403 an abnormal blood pressure AE that has an outcome of sustained high blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states YH, SS, MW blood pressure increased WEB: http://www.ncbi.nlm.nih.gov/pubmed/21722707 10005750 10020772 hypertension AE CTCAE: E13785 HPO: HP_0000822 MP: MP_0000231 NCIt: C3117 SIDER: C0020538 OAE:0000404 a cardiac valve disease AE that is characterized by a condition of the heart in which the aortic valve, located between the aorta and left ventricle of the heart, is norrower than normal size SS WEB: http://medical-dictionary.thefreedictionary.com/aortic+valve+stenosis 10002918 aortic valve stenosis AE HPO: HP_0005173 SIDER: C0003507 OAE:0000405 a muscular weakness AE that has an outcome of myasthenia. Myasthenia represenats myasthenia gravis, a neuromuscular disease leading to fluctuating muscle weakness and fatiguability. YH, SS myasthenia gravis myasthenia syndrome AE myasthenic syndrome AE myasthenia AE HPO: HP_0001324 SIDER: C0947912 OAE:0000406 a pain AE that occurs at the chest According to the Vaccine Adverse Event Reporting System (VAERS), 'chest pain' was mentioned in 1,752 VAERS reports (1.4%) during1991-2001 (Reference: PMID: 12825543). YH 10008479 chest pain AE HPO: HP_0001681 SIDER: C0008031 OAE:0000407 a sensory neuropathy AE which has an outcome of sensory axonal characterized by damage to axonas of the peripheral nervous system (PNS) AG, YH sensory axonal AE OAE:0000409 a movement disorder AE that has an outcome of twitching, an involuntary sudden movement of part of the body. According to the Vaccine Adverse Event Reporting System (VAERS), 'twitching' is an adverse event that was mentioned in 1,511 VAERS reports (1.2%) during1991-2001 (Reference: PMID: 12825543). YH twitching AE OAE:0000410 a seizure AE that has an outcome of a seizure disorder associated with an elevated temperature YH, BY http://emedicine.medscape.com/article/1176205-overview febrile seizure AE OAE:0000411 a respiratory system AE which has an outcome of asthma YH 哮喘 10003553 Asthma is a common chronic lung disease. It has been defined by the National Heart, Lung and Blood Institute as a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness (bronchospasm), and an underlying inflammation. asthma AE HPO: HP_0002099 SIDER: C0004096 OAE:0000412 a pain AE that has an outcome of neck pain According to the Vaccine Adverse Event Reporting System (VAERS), 'neck pain' was mentioned in 1,323 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). YH, MW 10028836 neck pain AE CTCAE: E12493 HPO: HP_0003418 NCIt: C50663 SIDER: C0007859 OAE:0000413 an arthritis AE that has an outcome of inflammation of a joint, resulting from infectious agents, such as bacteria and viruses DJ, SS, YH WEB: http://www.rightdiagnosis.com/i/infectious_arthritis/intro.htm 10060968 arthritis infective AE HPO: HP_0003095 SIDER: C0003869 OAE:0000414 a pain AE that has an outcome of back pain According to the Vaccine Adverse Event Reporting System (VAERS), 'back pain' was mentioned in 1,277 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). YH, MW 10003988 back pain AE CTCAE:E12388 HPO: HP_0003418 NCIt:C41830 SIDER: C0004604 OAE:0000415 a hair AE that has an outcome of alopecia and occurs after a medical intervention. VAE, MW 10001760 alopecia means the absence of hair or loss of hair. It is not usually in reference to primary genetic hairlessness but may be due to dietary, stress, secondary to immune condition. alopecia AE CTCAE:E13611 HPO: HP_0001596 MP: MP_0000414 NCIt:C50575 SIDER: C0002170 OAE:0000416 a hemorrhage AE that has an outcome of gastrointestinal hemorrhage gastrointestinal haemorrhage AE WEB: http://medical-dictionary.thefreedictionary.com/gastrointestinal+hemorrhage 10017955 bleeding in the stomach and/or the intestines gastrointestinal hemorrhage AE MP: MP_0000465 OAE:0000417 a movement disorder AE that has an outcome of eyes gaze upward According to the Vaccine Adverse Event Reporting System (VAERS), 'eyes gaze upward' was mentioned in 1,249 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). YH eyes gaze upward AE OAE:0000418 a nervous system AE that shows a damage to or disease affecting the nerves. Neuropathy is often classified according to the types or location of nerves that are affected. Neuropathy can also be classified according to the disease causing it. (For example, neuropathy from the effects of diabetes is called diabetic neuropathy. Ref: http://www.emedicinehealth.com/neuropathy/article_em.htm#types_of_neuropathy. YH, RR WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm#types_of_neuropathy WEB: http://www.medicalnewstoday.com/articles/147963.php WEB: http://www.neuropathy.org/ 神经病变 neuropathy AE HPO: HP_0007141 SIDER: C0442874 OAE:0000419 a skin adverse event that has an outcome of skin nodule According to the Vaccine Adverse Event Reporting System (VAERS), 'skin nodule' was mentioned in 1,134 VAERS reports (0.9%) during1991-2001 (Reference: PMID: 12825543). YH skin nodule AE HPO: HP_0200036 SIDER: C0037287 OAE:0000420 a movement disorder AE that has an outcome of arthrosis. YH Arthrosis is an articular illness that produces fibrosis or degeneration of the cartilage. arthrosis AE OAE:0000421 a muscle adverse event which has an outcome of hypokinesia, refering to slow or diminished movement of body musculature. YH 10021021 hypokinesia AE HPO: HP_0002375 SIDER: C0086439 OAE:0000422 Muscle twitch AE is a twitching AE that is a small, local, involuntary muscle contraction and relaxation which may be visible under the skin. JX, YH WEB: http://en.wikipedia.org/wiki/Fasciculation fasciculation AE muscle contraction AE myokymia AE 10028346 muscle twitch AE OAE:0000423 skin discoloration AE is a skin adverse event that results in change in color of skin or mucus membranes According to the Vaccine Adverse Event Reporting System (VAERS), 'skin discoloration' is an adverse event that was mentioned in 909 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). YH, SS skin discolouration AE 10040829 skin discoloration AE OAE:0000424 a varicella zoster virus infection AE that occurs in adults and rarely in children. YH herpes zoster AE zoster AE WEB: http://www.mayoclinic.org/diseases-conditions/shingles/basics/causes/con-20019574 10019974 Herpes zoster is a viral disease characterized by a painful skin rash with blisters in a limited area on one side of the body, often in a stripe. The initial infection with varicella zoster virus (VZV) causes the acute (short-lived) illness chickenpox, and generally occurs in children and young people. Once an episode of chickenpox has resolved, the virus is not eliminated from the body but can go on to cause shingles (an illness with very different symptoms) often many years after the initial infection. shingles AE HPO: HP_0005353 SIDER: C0019360 OAE:0000425 a movement disorder AE that has an outcome of laryngismus According to the Vaccine Adverse Event Reporting System (VAERS), 'laryngismus' is an adverse event that was mentioned in 881 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). YH laryngospasm sudden laryngeal spasm with crowing inhalation and cyanosis Laryngismus is an uncontrolled/involuntary muscular contraction (spasm) of the laryngeal cords. laryngismus AE OAE:0000426 a behavior and neurological AE that has an outcome of disorder in speech YH 10041466 speech disorder AE HPO: HP_0006977 SIDER: C0037822 OAE:0000427 a cardiovascular disorder AE that has an outcome of hemorrhage bleeding AE haemorrhage AE WEB: http://medical-dictionary.thefreedictionary.com/hemorrhage 10055798 loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels hemorrhage AE MP: MP_0001914 OAE:0000428 a bone disorder AE which has an outcome of neck rigidity YH neck rigidity AE OAE:0000429 a nervous system AE that has the symptom of GBS. Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances, the weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until the muscles cannot be used at all and the patient is almost totally paralyzed. In these cases, the disorder is life-threatening and is considered a medical emergency. Usually Guillain-Barre occurs a few days or weeks after the patient has had symptoms of a respiratory or gastrointestinal viral infection. Occasionally, surgery or vaccinations will trigger the syndrome. Reference: http://www.ninds.nih.gov/disorders/gbs/gbs.htm. YH, SS GBS AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23299621 10018767 Guillain-Barre syndrome AE HPO: HP_0007131 SIDER: C0018378 OAE:0000430 an abnormal digestion AE which has an outcome of nausea and vomiting According to the Vaccine Adverse Event Reporting System (VAERS), 'nausea and vomiting' is an adverse event that was mentioned in 812 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). This term will most likely removed since it is just a combination of nausea and vomiting. YH nausea and vomiting AE OAE:0000431 a sudden death AE that occurs to an infant. According to the Vaccine Adverse Event Reporting System (VAERS), 'sudden infant death' is an adverse event that was mentioned in 808 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). YH sudden infant death AE OAE:0000432 a fever AE that has an outcome of fever with chills, which is successive stages of chills and fever. This is a symptom of malaria. YH chills and fever AE 10016559 fever with chills AE OAE:0000433 a psychiatric disorder AE that is characterized by enduring maladaptive patterns of behavior, cognition, and inner experience, exhibited across many contexts and deviating markedly from those accepted by the individual's culture. YH, MW WEB: https://en.wikipedia.org/wiki/Personality_disorder 10034721 personality disorder AE HPO: HP_0000751 SIDER: C0031212 OAE:0000434 a respiratory system AE which has an outcome of lung disorder YH lung disorder AE 10025082 lung AE HPO: HP_0006552 SIDER: C0024115 OAE:0000435 a musculoskeletal system AE that occurs in muscle. YH muscle AE OAE:0000436 an adverse event that occurs in liver, biliary, and pancreatic areas. YH, JX liver, biliary, and pancreatic disorder AE URL: http://www.ijhpd.com/ WEB: http://www.uchospitals.edu/online-library/content=P00670 hepatobiliary or pancreatic AE OAE:0000437 a liver/biliary system AE which has an outcome of an enlarged liver, or larger than average size of the liver According to the Vaccine Adverse Event Reporting System (VAERS), 'hepatomegaly' was mentioned in 106 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). enlarged liver AE MP: MP_0000599 OAE:0000438 a brain inflammation AE which results in an inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. The inflammation is caused by infection with viruses, bacteria, or other microorganisms, and less commonly by certain drugs or diseases. YH, JX WEB: http://www.cdc.gov/meningitis/index.html 脑膜炎 10027199 meningitis AE CTCAE: E11458 HPO: HP_0001287 NCIt: C26828 SIDER: C0025289 OAE:0000439 an AE that occurs in digestive system. YH digestive system AE OAE:0000440 a paralysis AE that has an outcome of paralysis in face According to the Vaccine Adverse Event Reporting System (VAERS), 'facial paralysis' was mentioned in 580 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). YH facial paralysis AE HPO: HP_0007209 SIDER: C0015469 OAE:0000441 a psychiatric disorder AE that has an outcome of confusion, which is a mild form of delirium. YH, KM confused state AE mental confusion AE WEB: http://medical-dictionary.thefreedictionary.com/mental+confusion 10010300 10010305 confusion AE CTCAE: E12889 NCIt: C37928 OAE:0000442 a musculoskeletal system AE which has an outcome of joint disorder YH joint disorder AE OAE:0000443 an AE that occurs in eye. YH eye disorder AE 10015916 eye AE HPO: HP_0000496 SIDER: C0015397 OAE:0000444 a behavior and neurological AE that has an outcome of autism YH Autism is a brain development disorder characterized by impaired social interaction and communication, and by restricted and repetitive behavior. autism AE OAE:0000445 a hematopoietic system AE which has an outcome of sedimentation rate increased According to the Vaccine Adverse Event Reporting System (VAERS), 'sedimentation rate increased' is an adverse event that was mentioned in 530 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). This term should be inferred to lab test abnormal. YH ESR erythrocyte sedimentation rate red blood cell sedimentation rate increased AE sedrate Sedimentation rate is a diagnostic test for inflammation. The test measures the rate at which red blood cells fall to the bottom of a tube over time. An increased sedimentation rate corresponds to increased non-specific inflammation in the body. It is often called "sedrate" for short. red blood cell sedimentation rate increased AE is an AE: sedimentation rate increased that has an increase in rate at which red blood cells precipitate in a period of 1 hour. sedimentation rate increased AE OAE:0000446 an arthritis AE that has an outcome of arthritis due to an infection in another part of the body DJ, SS, YH, DA reactive arthritis AE reiter's syndrome AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/16822921 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563769/ https://www.ncbi.nlm.nih.gov/pubmed/18436339 10003267 10038294 arthritis reactive AE OAE:0000447 an abnormal vision AE which has an outcome of amblyopia YH 10001906 amblyopia AE HPO: HP_0000646 SIDER: C0002418 OAE:0000448 a psychiatric disorder AE that has an outcome of mental retardation YH mental retardation AE HPO: HP_0001249 SIDER: C0025362 OAE:0000449 a rash AE which shows red, target-shaped or "bulls-eye" patches or sores on the skin. YH, MW WEB: http://kidshealth.org/parent/infections/skin/erythema_multiforme.html WEB: https://en.wikipedia.org/wiki/Erythema_multiforme 10015218 The erythema multiforme rash usually begins on the arms, hands, legs, and feet, but you might also find it on the face, neck, and body. It also can affect the lips and inside the mouth. It usuallys follows an infection or drug exposure. erythema multiforme AE CTCAE:E13627 HPO: HP_0010783 NCIt:C3024 SIDER: C0014742 OAE:0000450 a lab test abnormal AE that has an outcome of SGOT increased According to the Vaccine Adverse Event Reporting System (VAERS), 'SGOT increased' is an adverse event that was mentioned in 477 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH SGOT respresents serum glutamic oxaloacetic transaminase, an enzyme that is normally present in liver and heart cells. SGOT is released into blood when the liver or heart is damaged. The blood SGOT levels are thus elevated with liver damage (for example, from viral hepatitis) or with an insult to the heart (for example, from a heart attack). Some medications can also raise SGOT levels. SGOT is also called aspartate aminotransferase (AST). SGOT increased AE OAE:0000451 a lab test abnormal AE that has an outcome of SGPT increased According to the Vaccine Adverse Event Reporting System (VAERS), 'SGPT increased' is an adverse event that was mentioned in 459 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH SGPT represents serum glutamic pyruvic transaminase, an enzyme that is normally present in liver and heart cells. SGPT is released into blood when the liver or heart are damaged. The blood SGPT levels are thus elevated with liver damage (for example, from viral hepatitis) or with an insult to the heart (for example, from a heart attack). Some medications can also raise SGPT levels. SGPT is also called alanine aminotransferase (ALT). SGPT increased AE OAE:0000452 a behavioral and neurological AE that has an outcome of thinking abnormality According to the Vaccine Adverse Event Reporting System (VAERS), 'thinking abnormality' is an adverse event that was mentioned in 457 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH, JX 10043431 thinking abnormality AE OAE:0000453 an abnormal digestion AE which has an outcome of dyspepsia According to the Vaccine Adverse Event Reporting System (VAERS), 'dyspepsia' is an adverse event that was mentioned in 454 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH 10013946 Dyspepsia is popularly known as indigestion, meaning hard or difficult digestion. It is a medical condition characterized by chronic or recurrent pain in the upper abdomen, upper abdominal fullness and feeling full earlier than expected when eating. dyspepsia AE CTCAE: E10617 HPO: HP_0002577 NCIt: C26756 SIDER: C0013395 OAE:0000454 an allergy AE which has an outcome of anaphylactoid reaction AE is an acute systemic (multi-system) and very severe Type I Hypersensitivity allergic reaction in humans and other mammals. Minute amounts of allergens may cause a life-threatening anaphylactic reaction. According to the Vaccine Adverse Event Reporting System (VAERS), 'anaphylactoid reaction' was mentioned in 452 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22293078 10002198 10002216 anaphylactoid reaction AE HPO: HP_0100845 SIDER: C0340865 OAE:0000455 a digestive system AE which has an outcome of a gastrointestinal disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'gastrointestinal disorder' is an adverse event that was mentioned in 449 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH gastrointestinal disorder AE HPO: HP_0011024 SIDER: C0017178 OAE:0000456 an edema AE that has an outcome of accumulation of fluid in the peritoneal cavity DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23296107 10003445 ascites AE CTCAE: E10502 HPO: HP_0001541 NCIt: C2885 SIDER: C0003962 OAE:0000457 a hypersensitivity AE which has an outcome of serum sickness According to the Vaccine Adverse Event Reporting System (VAERS), 'serum sickness' is an adverse event that was mentioned in 428 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH, MW 10040400 Serum sickness is a reaction to proteins in antiserum derived from an animal source. It is a type of hypersensitivity, specifically immune complex hypersensitivity (type III). serum sickness AE CTCAE: E11276 NCIt: C79718 OAE:0000458 an abscess AE which has an outcome of injection-site abscess YH injection-site abscess AE OAE:0000459 a neurological, special senses and psychiatric investigation result abnormal AE that is the abnormal result of a procedure that uses small, flat metal discs (electrodes) attached to your scalp to detect electrical activity in your brain According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal electroencephalogram' is an adverse event that was mentioned in 420 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH, EB WEB: http://www.mayoclinic.com/health/eeg/MY00296 10000130 abnormal electroencephalogram result AE OAE:0000460 a dizziness AE that has an outcome of vertigo According to the Vaccine Adverse Event Reporting System (VAERS), 'vertigo' was mentioned in 412 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH 10047340 Vertigo is a specific type of dizziness, a major symptom of a balance disorder. It is the sensation of spinning or swaying while the body is actually stationary with respect to the surroundings. The effects of vertigo may be slight. It can cause nausea and vomiting and, in severe cases, it may give rise to difficulties with standing and walking. vertigo AE CTCAE: E10291 HPO: HP_0002321 NCIt: C38057 SIDER: C0042571 OAE:0000461 a cardiac disorder AE that has an outcome of heartarrest, the abrupt cessation of normal circulation of the blood due to failure of the heart to contract effectively during systole. YH cardiopulmonary arrest circulatory arrest heart arrest AE WEB: http://en.wikipedia.org/wiki/Myocardial_infarction WEB: http://medical-dictionary.thefreedictionary.com/cardiac+arrest 10007515 10007617 10028596 cardiac arrest CTCAE: E10101 NCIT: C50479 OAE:0000462 a respiratory system inflammation AE which has an outcome of bronchitis YH Bronchitis is an inflammation of the air passages within the lungs. It occurs when the trachea (windpipe) and the large and small bronchi (airways) within the lungs become inflamed because of infection or other causes. bronchitis AE HPO: HP_0002837 SIDER: C0006277 OAE:0000463 a seizure AE that has an outcome of grand malconvulsion YH A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). grand malconvulsion AE OAE:0000464 a liver related investigation result abnormal AE which shows an abnormal test result in a liver function test, indicating aberrant function of liver. According to the Vaccine Adverse Event Reporting System (VAERS), 'liver function tests abnormal' was mentioned in 717 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). WEB: http://medical-dictionary.thefreedictionary.com/hepatic+function 10019670 10024690 liver function test abnormal AE MP: MP_0000609 OAE:0000465 an AE that occurs in ear. YH ear disorder AE ear AE HPO: HP_0000598 SIDER: C0013447 OAE:0000466 an infection AE that results in detrimental colonization of a host organism by virus YH, SS viral infection WEB: http://en.wikipedia.org/wiki/Viral_infection viral infection AE HPO: HP_0005364 SIDER: C0042769 OAE:0000467 a movement disorder AE that has an outcome of lacrimation disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'lacrimation disorder' was mentioned in 334 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH Lacrimation is the production, secretion, and shedding of tears. lacrimation disorder AE OAE:0000468 a liver/biliary system AE which has an outcome of jaundice, which is the clinical manifestation of hyperbilirubinemia, with deposition of bile pigments in the skin, resulting in yellowish staining of the skin and mucous membranes According to the Vaccine Adverse Event Reporting System (VAERS), 'jaundice' is an adverse event that was mentioned in 317 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). SS, YH icterus AE WEB: http://en.wikipedia.org/wiki/Jaundice 10023126 jaundice AE HPO: HP_0000952 MP: MP_0000611 SIDER: C0022346 OAE:0000469 an immune system disorder AE which shows an enclosed collection of liquefied tissue, known as pus, somewhere in the body. Abscess is the result of the body's defensive reaction to foreign material. YH abscessus WEB: http://medical-dictionary.thefreedictionary.com/abscess 10000269 An abscess is a collection of pus (dead neutrophils) that has accumulated in a cavity formed by the tissue on the basis of an infectious process (usually caused by bacteria or parasites) or other foreign materials (e.g. splinters, bullet wounds, or injecting needles). It is a defensive reaction of the tissue to prevent the spread of infectious materials to other parts of the body. abscess AE HPO: HP_0002722 SIDER: C0000833 OAE:0000470 a pain AE that has an outcome of eye pain According to the Vaccine Adverse Event Reporting System (VAERS), 'eye pain' is an adverse event that was mentioned in 316 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH 10015958 eye pain AE CTCAE: E10376 HPO: HP_0200025 NCIt: C78287 SIDER: C0151827 OAE:0000471 a sensory capability AE that has an outcome of palpitation YH WEB: http://en.wikipedia.org/wiki/Palpitations 10033557 A palpitation is an abnormal awareness of the beating of the heart, whether it is too slow, too fast, irregular, or at its normal frequency. palpitation AE OAE:0000472 an edema AE which has an outcome of tongue edema YH, RR tongue oedema AE tongue swelling AE WEB: http://www.medterms.com/script/main/art.asp?articlekey=97582 10042727 tongue edema AE OAE:0000473 a pain AE that has an outcome of ear pain According to the Vaccine Adverse Event Reporting System (VAERS), 'ear pain' was mentioned in 302 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH 10014020 ear pain AE CTCAE: E10262 HPO: HP_0010833 NCIt: C37944 SIDER: C0013456 OAE:0000474 an edema AE which has an outcome of angioedema YH, SJ angioneurotic edema WEB: http://www.mayoclinic.org/diseases-conditions/hives-and-angioedema/basics/definition/con-20014815 10002473 Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues often around the eyes and lips. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis. angioedema AE OAE:0000475 An arthritis AE that has the outcome of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints and may also cause inflammation of the tissue around the joints, as well as other organs in the body. YH rheumatoid arthritis AE HPO: HP_0005681 SIDER: C0003873 OAE:0000476 an AE that occurs in immune system. According to the Vaccine Adverse Event Reporting System (VAERS), 'immune system disorder' was mentioned in 292 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH immune system disorder AE immune system AE HPO: HP_0002715 SIDER: C0021053 OAE:0000477 an immune system disorder AE which has an outcome of antinuclear antibody present According to the Vaccine Adverse Event Reporting System (VAERS), 'antinuclear antibody present'; is an adverse event that was mentioned in 288 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH anti-nuclear factor present The presence of anti-nuclear antibodies (ANAs) that are antibodies directed against contents of the cell nucleus. ANAs are present in higher than normal numbers in autoimmune disease. The ANA test measures the pattern and amount of autoantibody which can attack the body's tissues as if they were foreign material. Autoantibodies are present in low titers in the general population, but in about 5% of the population, their concentration is increased, and about half of this 5% have an autoimmune disease. antinuclear antibody present AE OAE:0000478 a nervous system AE which involves inflammation of the spinal cord, which disrupts central nervous system functions linking the brain and limbs. YH, MW 10028524 myelitis AE CTCAE: E12732 NCIt: C26832 OAE:0000479 a headache AE that has an outcome of migraine According to the Vaccine Adverse Event Reporting System (VAERS), 'migraine'; is an adverse event that was mentioned in 267 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH migraine headache A migraine is a very painful type of headache. People who get migraines often describe the pain as pulsing or throbbing in one area of the head. During migraines, people are very sensitive to light and sound. They may also become nauseated and vomit. migraine AE HPO: HP_0002076 SIDER: C0149931 OAE:0000480 Thrombocytopenic purpura AE are purpura AE associated with a reduction in circulating blood platelets which can result from a variety of causes. According to the Vaccine Adverse Event Reporting System (VAERS), 'thrombocytopenic purpura'; is an adverse event that was mentioned in 267 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH 10043561 thrombocytopenic purpura AE HPO: HP_0004829 SIDER: C0857305 OAE:0000481 multiple sclerosis AE is an immune system disorder AE, or an autoimmune condition in which the immune system attacks the central nervous system, leading to demyelination. YH MS disseminated sclerosis encephalomyelitis disseminata 10028245 multiple sclerosis AE OAE:0000482 a behavior and neurological AE that has an outcome of amnesia in a patient YH, MW 10001949 Amnesia is a short term memory condition in which memory is disturbed. In simple terms it is the loss of memory. amnesia AE CTCAE:E12585 HPO: HP_0002354 NCIt:C2867 SIDER: C0002622 OAE:0000483 a movement disorder AE that has an outcome of incoordination According to the Vaccine Adverse Event Reporting System (VAERS), 'incoordination' was mentioned in 261 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH a lack of normal adjustment of muscular action so that the intended movement of the limb or other part is not made smoothly and harmoniously, and does not accurately achieve its objective. If the abnormality is hypermetric, the condition is referred to as ataxia. If it is inclined to weakness, e.g. knuckling at the turn, stumbling, failure to flex limbs properly, or to misdirection as in a proprioceptive deficit, it is called incoordination. incoordination AE OAE:0000484 a speech disorder that has an outcome of voice alteration YH, MW 10047681 voice alteration AE CTCAE: E13601 NCIt: C61043 OAE:0000485 a pregnancy AE that is the termination of a pregnancyby the removal or expulsion from the uterus of a fetus or embryo, resulting in or caused by its death. According to the Vaccine Adverse Event Reporting System (VAERS), 'abortion'; is an adverse event that was mentioned in 257 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH, SS WEB: http://en.wikipedia.org/wiki/Abortion 10000210 abortion AE OAE:0000486 a psychiatric disorder AE that has an outcome of shock YH acute stress disorder AE acute stress reaction AE mental shock AE 10001084 Mental shock (or shock) is a psychological condition arising in response to a terrifying event. It should not be confused with the unrelated circulatory condition of shock. There are two types of shocks. Another is circulatory shock which is physiological with MedDRA ID of 10040560. psychological shock AE OAE:0000487 a skin discoloration AE which has an outcome of purpura According to the Vaccine Adverse Event Reporting System (VAERS), 'purpura'; is an adverse event that was mentioned in 251 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH, MW 紫癜 10037549 Purpura is the appearance of red or purple discolorations on the skin that do not blanch on applying pressure. They are caused by bleeding underneath the skin. This is common with typhus and can be present with meningitis caused by meningococcal meningitis or septicaemia. Reference: http://en.wikipedia.org/wiki/Purpura. purpura AE CTCAE:E13690 HPO: HP_0000979 NCIt:C78787 SIDER: C0034150 OAE:0000488 an infection AE that results in detrimental colonization of a host organism by bacteria YH, SS bacterial infection AE WEB: http://en.wikipedia.org/wiki/Bacterial_infection 10060945 bacterial infection AE HPO: HP_0002718 SIDER: C0004623 OAE:0000489 a skin adverse event that has an outcome of skin striae that displays irregular areas of skin that look like bands, stripes, or lines. Striae are seen when a person grows or gains weight rapidly or has certain diseases or conditions. According to the Vaccine Adverse Event Reporting System (VAERS), 'skin striae'; is an adverse event that was mentioned in 247 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH stretch marks striae distensae skin striae AE HPO: HP_0001065 SIDER: C0152459 OAE:0000490 a syndrome AE that has an outcome of an acute brain syndrome AE and occurs after a medical intervention. YH acute brain syndrome AE OAE:0000491 a sensory capability AE that has an outcome of coma YH 10010071 Coma is a profound state of unconsciousness. A comatose person cannot be awakened, fails to respond normally to pain or light, does not have sleep-wake cycles, and does not take voluntary actions. coma AE HPO: HP_0001259 SIDER: C0009421 OAE:0000492 a muscle adverse event which has an outcome of hyperkinesia, an abnormal increase in muscular activity. YH 10020651 hyperkinesia AE HPO: HP_0002487 SIDER: C0424295 OAE:0000493 an AE that occurs in cardiovascular system. YH cardiovascular disorder AE 10007649 cardiovascular AE HPO: HP_0001626 SIDER: C0007222 OAE:0000494 a nervous system AE which has an outcome of encephalopathy, which is disorder or disease of the brain. YH, MW 10014625 encephalopathy AE CTCAE:E12652 HPO: HP_0007239 NCIt:C26920 SIDER: C0085584 OAE:0000495 a urinary system AE that has an outcome of urine abnormality AE YH urine abnormality AE HPO: HP_0011036 SIDER: C0235639 OAE:0000496 a gastrointestinal disorder AE which has an outcome of gastroenteritis, an inflammation occuring in the gastrointestinal tract that involves both the stomach and the small intestine, often results in diarrhea, vomiting and abdominal pain and cramping According to the Vaccine Adverse Event Reporting System (VAERS), 'gastroenteritis' was mentioned in 218 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). YH WEB: http://medical-dictionary.thefreedictionary.com/gastroenteritis 10017888 gastroenteritis AE HPO: HP_0004386 SIDER: C0017160 OAE:0000497 a cardiovascular disorder AE that has an outcome of peripheral vascular disorder YH peripheral vascular disorder AE HPO: HP_0005299 SIDER: C0085096 OAE:0000498 a urinary tract disoder AE that has an outcome of urnary tract infection AE YH 10046571 urinary tract infection AE CTCAE: E11614 HPO: HP_0000094 NCIt: C50791 SIDER: C0042029 OAE:0000499 an abnormal salivary gland physiology AE which has an outcome of increased salivation, meaning greater than normal amounts of flowing saliva According to the Vaccine Adverse Event Reporting System (VAERS), 'increased salivation' is an adverse event that was mentioned in 336 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). increased salivation AE MP: MP_0000622 OAE:0000500 a psychiatric disorder AE that has an outcome of depression. Depression causes a persistent feeling of sadness and loss of interest. YH, MW WEB: http://www.mayoclinic.org/diseases-conditions/depression/basics/definition/con-20032977 10012378 depression AE CTCAE:E12909 HPO: HP_0000716 NCIt:C2982 SIDER: C0011570 OAE:0000501 a glucose homeostasis AE which has an outcome of diabetes mellitus YH diabetes AE 10012601 Diabetes mellitus, often referred to simply as diabetes, is a syndrome of disordered metabolism, usually due to a combination of hereditary and environmental causes, resulting in abnormally high blood sugar levels (hyperglycemia). diabetes mellitus AE HPO: HP_0000819 SIDER: C0011849 OAE:0000502 a respiratory system inflammation AE which has an outcome of laryngitis According to the Vaccine Adverse Event Reporting System (VAERS), 'laryngitis'; is an adverse event that was mentioned in 190 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH 10023874 Laryngitis is an inflammation of the larynx. It causes hoarse voice or the complete loss of the voice because of irritation to the vocal folds (vocal cords). laryngitis AE CTCAE: E11435 HPO: HP_0001600 NCIt: C26811 SIDER: C0023067 OAE:0000503 a muscle spasm AE which has an outcome of generalized spasm, which is an involuntary contraction of a muscle or group of muscles. Spasms may involve skeletal muscle (MUSCLE, SKELETAL) or smooth muscle (MUSCLE, SMOOTH). YH generalized spasm AE OAE:0000505 a digestive system AE which has an outcome of dry mouth, which is dryness of the mouth resulting from reduced salivary secretion According to the Vaccine Adverse Event Reporting System (VAERS), 'dry mouth'; is an adverse event that was mentioned in 171 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH xerostomia 10013781 dry mouth AE CTCAE: E10578 HPO: HP_0000217 NCIt: C26917 SIDER: C0043352 OAE:0000506 a neuritis AE which has an outcome of optic neuritis YH 10030942 optic neuritis AE HPO: HP_0100653 SIDER: C0029134 OAE:0000508 a hemorrhage AE that has an outcome of epistaxis YH, MW nosebleed 10015090 Epistaxis is the relatively common occurrence of hemorrhage from the nose, usually noticed when the blood drains out through the nostrils. epistaxis AE CTCAE:E13374 HPO: HP_0000421 NCIt:C26766 SIDER: C0014591 OAE:0000509 a syndrome AE that displays a lupus syndrome. Lupus is an autoimmune disease where the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. YH, JX lupus syndrome AE 狼疮样综合征 WEB: http://www.medicalnewstoday.com/info/lupus/ lupus AE OAE:0000510 an eye disorder AE which has an outcome of photophobia YH 10034960 Photophobia is a symptom of excessive sensitivity to light and the aversion to sunlight or well-lit places. In medical terms it is not fear, but an experience of discomfort or pain to the eyes due to light exposure. photophobia AE CTCAE: E10416 HPO: HP_0000613 NCIt: C28210 SIDER: C0085636 OAE:0000511 a digestive system AE which has an outcome of abnormal salivary gland physiology, which is any functional anomaly of any of the glands in the mouth that secrete saliva abnormal salivary gland physiology AE MP: MP_0005310 OAE:0000512 a psychiatric disorder AE that has an outcome of hallucination YH, MW hallucinations AE 10019063 10019077 A hallucination, in the broadest sense, is a perception in the absence of a stimulus. In a stricter sense, hallucinations are defined as perceptions in a conscious and awake state in the absence of external stimuli which have qualities of real perception, in that they are vivid, substantial, and located in external objective space. hallucination AE CTCAE: E12919 HPO: HP_0000738 NCIt: C37961 SIDER: C0018524 OAE:0000513 a digestive system AE which has an outcome of tongue disorder According to the Vaccine Adverse Event Reporting System (VAERS), 'tongue disorder'; is an adverse event that was mentioned in 156 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH tongue disorder HPO: HP_0000157 SIDER: C0040409 OAE:0000514 a pain AE that has an outcome of neuralgia According to the Vaccine Adverse Event Reporting System (VAERS), 'neuralgia'; is an adverse event that was mentioned in 155 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH, MW 10029223 Neuralgia or neuropathic pain can be defined most simply as non-nociceptive pain. Neuralgia is pain produced by a change in neurological structure or function. Unlike nociceptive pain, Neuralgia exists with no continuous nociceptive input. Neuralgia falls into two categories: central Neuralgia and peripheral Neuralgia. neuralgia AE CTCAE:E12744 HPO: HP_0003489 NCIt:C79695 SIDER: C0027796 OAE:0000515 an edema AE which has an outcome of lung edema YH lung edema AE OAE:0000516 a paresthesia AE that occurs around the mouth. YH circumoral paresthesia AE HPO: HP_0003401 SIDER: C0151838 OAE:0000517 an abnormal fluid regulation AE which has an outcome of thirst YH 10043458 Thirst is the craving for liquids, resulting in the basic instinct of humans or animals to drink. It is an essential mechanism involved in fluid balance. thirst AE HPO: HP_0001959 SIDER: C0039971 OAE:0000518 a musculoskeletal system AE that occurs in the bone YH bone disorder 10005956 bone AE HPO: HP_0000924 SIDER: C0005940 OAE:0000519 a perinatal AE that displays fetal disorder. YH fetal disorder AE OAE:0000520 a sensory capability AE that has an outcome of emotional liability YH emotional liability AE OAE:0000521 a muscle adverse event which has an outcome of muscle spasm, which is an involuntary and often painful muscle contraction or cramps having a number of causes ranging from nutritional deficiency to serious nervous system conditions SS, YH WEB: http://en.wikipedia.org/wiki/Spasm 10028334 muscle spasm AE MP: MP_0000743 OAE:0000522 a connective tissue disorder AE that occurs at the location of tendon A tendon (or sinew) is a tough band of fibrous connective tissue that usually connects muscle to bone and is capable of withstanding tension. According to the Vaccine Adverse Event Reporting System (VAERS), 'tendon disorder'; is an adverse event that was mentioned in 137 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH Tendon disorder is a medical condition that results in a tendon not functioning normally. tendon disorder AE OAE:0000523 a behavior and neurological AE that has an outcome of hostility YH 10020400 hostility AE OAE:0000524 an eye disorder AE which has an outcome of visual field defect SS, YH visual impairment AE WEB: http://en.wikipedia.org/wiki/Visual_impairment 10047555 10047571 visual field defect AE OAE:0000525 a muscle adverse event which has an outcome of myopathy AE, an abnormal condition or disease of the skeletal muscle 10028641 myopathy AE HPO: HP_0003198 MP: MP_0000751 SIDER: C0026848 OAE:0000526 a behavior and neurological AE that has an outcome of apathy state YH impassivity perfunctoriness 10002942 Apathy is a state of indifference, or the suppression of emotions such as concern, excitement, motivation and passion. An apathetic individual has an absence of interest or concern to emotional, social, or physical life. They may also exhibit an insensibility or sluggishness. apathy AE HPO: HP_0000741 SIDER: C0085632 OAE:0000527 a paralysis AE that has an outcome of hemiplegia According to the Vaccine Adverse Event Reporting System (VAERS), 'hemiplegia'; is an adverse event that was mentioned in 129 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). YH 10019468 Hemiplegia is total paralysis of the arm, leg, and trunk on the same side of the body. Hemiplegia is more severe than hemiparesis, wherein one half of the body is weakened but not paralysed. hemiplegia AE HPO: HP_0002301 SIDER: C0018991 OAE:0000528 a rash AE that is characterized by a circumscribed and elevated skin lesion filled with pus. According to the Vaccine Adverse Event Reporting System (VAERS), 'pustular rash'; is an adverse event that was mentioned in 128 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH rash pustular AE 10037888 pustular rash AE CTCAE: E11545 NCIt: C80119 OAE:0000529 a blood creatine phosphokinase level abnormal AE that is characterized by an increased level of creatine phosphokinase (CPK) or phosphocreatine kinase, an enzyme expressed by various tissue types that catalyses the conversion of creatine and consumes adenosine triphosphate (ATP) to create phosphocreatine and adenosine diphosphate (ADP) YH, EB elevated serum creatine phosphate kinase AE 10005470 blood creatine phosphokinase level increased AE OAE:0000530 a hypertension AE that has an outcome of elevated pressure in the skull. YH, SS WEB: http://www.ihrfoundation.org/intracranial/hypertension/info/C16 10049977 intracranial hypertension AE OAE:0000531 a sensory neuropathy AE which shows a painful neuropathy characterized by damage to sensory and motor nerves AG, YH sensorimotor painful neuropathy AE OAE:0000532 a digestive system AE which has an outcome of abnormal stool According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal stools' was mentioned in 111 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH abnormal stool AE OAE:0000533 a pain AE that has an outcome of bone pain According to the Vaccine Adverse Event Reporting System (VAERS), 'bone pain' was mentioned in 109 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH, MW 10006002 bone pain AE CTCAE:E12392 HPO: HP_0002653 NCIt:C38644 SIDER: C0151825 OAE:0000534 a cardiovascular disorder AE that comes with cerebrovascular accident YH stroke 10008190 Cerebrovascular accident: The sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture of an artery to the brain. A CVA is also referred to as a stroke. cerebrovascular accident AE HPO: HP_0001297 SIDER: C0038454 OAE:0000535 a digestive system AE which has an outcome of parotid gland enlargement According to the Vaccine Adverse Event Reporting System (VAERS), 'parotid gland enlargement' was mentioned in 103 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH 10034023 parotid gland enlargement AE OAE:0000536 a movement disorder AE that has an outcome of flatulence According to the Vaccine Adverse Event Reporting System (VAERS), 'flatulence' was mentioned in 102 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH 10016766 Flatulence is the production of a mixture of gases in the digestive tract of mammals or other animals that are byproducts of the digestion process. Such a mixture of gases is known as flatus, and is expelled from the rectum in a process colloquially referred to as "passing gas" or "farting". flatulence AE CTCAE: E10697 HPO: HP_0011024 NCIt: C37954 SIDER: C0016204 OAE:0000537 a liver/biliary system AE which has an outcome of liver damage According to the Vaccine Adverse Event Reporting System (VAERS), 'liver damage' was mentioned in 102 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). YH liver damage AE OAE:0000538 a respiratory system AE which has an outcome of sore throat YH, MW 10041367 sore throat AE CTCAE: E13575 NCIt: C50747 OAE:0000539 a movement disorder AE that results in the loss of power of voluntary movement in a muscle through injury or disease of its nerve supply According to the Vaccine Adverse Event Reporting System (VAERS), 'paralysis' is an adverse event that was mentioned in 574 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). SS, YH WEB: https://www.nlm.nih.gov/medlineplus/paralysis.html 瘫痪 10033799 paralysis AE HPO: HP_0010549 MP: MP_0000753 SIDER: C0522224 OAE:0000540 a bone disorder AE that has an outcome of cellular death of bone components due to interupption of blood supply DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/avascular+necrosis 10003460 aseptic necrosis bone AE OAE:0000541 a physical examination result abnormal AE that has an outcome of weight loss, which is the progressive reduction of body weight below normal average for age MW, YH weight decreased AE 10047895 10047900 weight loss AE CTCAE: E12228 MP: MP_0001263 NCIt: C3445 OAE:0000542 According to the Vaccine Adverse Event Reporting System (VAERS), 'ataxia' is an adverse event that was mentioned in 555 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). YH, MW 10003591 a movement disorder AE that has an outcome of ataxia, inability to coordinate voluntary muscular movements ataxia AE CTCAE:E12597 HPO: HP_0001251 MP: MP_0001393 NCIt:C26702 SIDER: C0004134 OAE:0000543 a hair, skin, and nail AE that occurs in skin. YH WEB: http://www.thefreedictionary.com/skin+disorder 10040831 skin AE OAE:0000544 a movement disorder AE that has an outcome of unusual or distinctive way of walking According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal gait' is an adverse event that was mentioned in 998 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). SS, YH gait disturbance AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/21224774 10017577 abnormal gait AE CTCAE: E11112 MP: MP_0001406 NCIt: C78303 OAE:0000545 an abnormal fluid regulation AE which has an outcome of dehydration, which is an excessive water loss from the body or from an organ or bodily part YH, SS, MW hypohydration 10012174 dehydration AE CTCAE:E12258 HPO: HP_0001944 MP: MP_0001429 NCIt:C26740 SIDER: C0011175 OAE:0000546 a homeostasis AE which has an outcome of abnormal fluid regulation, which is any anomaly in the control of intracellular and/or extracellular fluid abnormal fluid regulation AE MP: MP_0001784 OAE:0000547 a glucose homeostasis AE which has an outcome of hyperglycemia, which is an abnormally high concentration of glucose in the blood; generally refers to a pathological state YH, MW WEB: http://medical-dictionary.thefreedictionary.com/hyperglycemia 10020635 10020639 hyperglycemia AE CTCAE: E12276 MP: MP_0001559 NCIt: C26797 OAE:0000548 a homeostasis AE which has an outcome of abnormal ciculating bilirubin level, which is aberrant concentration in the blood of this yellow heme breakdown product According to the Vaccine Adverse Event Reporting System (VAERS), 'bilirubinemia'; is an adverse event that was mentioned in 221 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). abnormal circulating bilirubin level AE MP: MP_0001569 OAE:0000549 a skin adverse event that has an outcome of cyanosis, a dark bluish or purple skin discoloration resulting from deficient oxygenation of the blood According to the Vaccine Adverse Event Reporting System (VAERS), 'cyanosis' is an adverse event that was mentioned in 1,804 VAERS reports (1.4%) during1991-2001 (Reference: PMID: 12825543). 10011703 cyanosis AE HPO: HP_0000961 MP: MP_0001575 SIDER: C0010520 OAE:0000550 a hematopoietic system AE which has an outcome of anemia, which is less than normal levels of red blood cells and/or hemoglobin within red blood cells, or volume of packed red blood cells in the bloodstream, resulting in insufficient oxygenation of tissues and organs anaemia AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001586/ 10002034 10002272 anemia AE CTCAE: E10010 MP: MP_0001577 NCIt: C2869 OAE:0000551 an abnormal blood pressure AE that has an outcome of sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states YH, MW blood pressure decreased, low blood pressure 10005734 10021097 hypotension AE CTCAE: E13791 HPO: HP_0002615 MP: MP_0001596 NCIt: C3128 SIDER: C0020649 OAE:0000552 an arrhythmia AE that has an outcome of uneven timing of heart contraction irregular heartbeat AE MP: MP_0001636 OAE:0000553 an electrolyte lab test abnormal AE that shows an abnormal level of an electrolyte in the blood YH, MW electrolyte blood test abnormal AE OAE:0000554 a digestive system AE which has an outcome of abnormal digestion, which is an altered ability of the mechanical, chemical, and enzymatic processes of the body to convert ingested food into material suitable for assimilation for synthesis of tissues or liberation of energy abnormal digestion AE MP: MP_0001664 OAE:0000555 an AE that occurs in the homeostasis system. anomaly in the processes involved in the maintenance of an internal equilibrium of various functions and chemical or protein composition of the fluids and tissues homeostasis AE MP: MP_0001764 OAE:0000556 an abnormal fluid regulation AE which has an outcome of edema, which is an accumulation of an excessive amount of watery fluid in cells or intercellular tissues oedema, swelling, dropsy WEB: http://en.wikipedia.org/wiki/Oedema WEB: http://en.wikipedia.org/wiki/Swelling_(medical) 10016807 10030095 10042674 edema AE MP: MP_0001785 OAE:0000557 an immune system disorder AE that results in complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue greater than expected response to injury, infection, or insult. SS, YH WEB: http://en.wikipedia.org/wiki/Inflammation 10061218 inflammation AE HPO: HP_0007891 MP: MP_0001846 SIDER: C0021368 OAE:0000558 an inflammation AE which has an outcome of brain inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the brain According to the Vaccine Adverse Event Reporting System (VAERS), 'encephalitis' is an adverse event that was mentioned in 480 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). brain inflammation AE MP: MP_0001847 OAE:0000559 an ear disorder AE which has an outcome of increased susceptibility to otitis media, which is greater likelihood of middle ear inflammation, with an accumulation of a thick, mucous-like fluid; usually associated with a viral or bacterial respiratory infection increased susceptibility to otitis media AE MP: MP_0001850 OAE:0000560 an eye disorder AE which has an outcome of eye inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the eye 10015943 eye inflammation AE HPO: HP_0100533 MP: MP_0001851 SIDER: C0239429 OAE:0000561 an eye inflammation AE which has an outcome of conjunctivitis, which is inflammation of the mucous membrane that lines the inner surface of the eyelids and the front of the eyeball 10010741 conjunctivitis AE CTCAE: E10355 HPO: HP_0000509 MP: MP_0001852 NCIt: C34504 SIDER: C0009763 OAE:0000562 an inflammation AE that shows a local accumulation of fluid, plasma proteins, and leukocytes in the liver According to the Vaccine Adverse Event Reporting System (VAERS), 'hepatitis' was mentioned in 387 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). YH, JX liver inflammation AE MP: MP_0001860 OAE:0000563 aa inflammation AE which has an outcome of lung inflammation, a local accumulation of fluid, plasma proteins, and leukocytes in the lung According to the Vaccine Adverse Event Reporting System (VAERS), 'pneumonia' was mentioned in 879 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). lung inflammation AE MP: MP_0001861 OAE:0000564 an inflammation AE which occurs in the respiratory system, which is reflected with the local accumulation of fluid, plasma proteins, and leukocytes in the respiratory system respiratory system inflammation AE MP: MP_0002405 OAE:0000565 an inflammation AE that has an outcome of vasculitis, which is an inflammation of a blood or lymph vessel It's an inflammation. YH, MW 10047115 vasculitis AE CTCAE:E13837 HPO: HP_0002633 MP: MP_0001864 NCIt:C26912 SIDER: C0042384 OAE:0000566 an inflammation AE which has an outcome of salivary gland inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the salivary gland salivary gland inflammation AE MP: MP_0001870 OAE:0000567 a respiratory system inflammation AE which has an outcome of sinus inflammation, an inflammation of paranasal sinuses, which may be due to infection, allergy, or autoimmune issues. According to the Vaccine Adverse Event Reporting System (VAERS), 'sinusitis'; is an adverse event that was mentioned in 298 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). SS, YH, RR sinus inflammation AE WEB: http://en.wikipedia.org/wiki/Sinusitis 10040753 sinusitis AE CTCAE: E11563 HPO: HP_0000246 MP: MP_0001872 NCIt: C35024 SIDER: C0037199 OAE:0000568 a hypersensitivity AE which results in an allergic response showing a marked increase in reactivity to an antigen upon subsequent exposure. JX, LW, YH allergic reaction AE allergic response AE anaphylactic reaction AE WEB: http://en.wikipedia.org/wiki/Allergy 变态反应 过敏反应 10001718 10001738 allergy AE CTCAE: E11248 MP: MP_0001878 NCIt: C3114 OAE:0000569 a nervous system AE which has an outcome of abnormal cerebrospinal fluid production, an anomaly in the normal output of the fluid that fills the ventricles and other cavities of the brain and spinal cord abnormal cerebrospinal fluid production AE MP: MP_0001911 OAE:0000570 an AE that occurs in nervous system. KY, YH nervous system disorder AE URL: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/overview_of_nervous_system_disorders_85,P00799/ 10029202 nervous system AE MP: MP_0003633 OAE:0000571 a respiratory system AE which has an outcome of abnormal respiration, an anomaly in the movement of gases into and out of the lung According to the Vaccine Adverse Event Reporting System (VAERS), 'respiratory disorder' is an adverse event that was mentioned in 556 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). Not sure if it is same as respiratory system disorder or abnormal respiration. --Oliver He abnormal respiration AE MP: MP_0001943 OAE:0000572 an abnormal respiration AE which has an outcome of apnea, temporary cessation of breathing; sometimes episodic According to the Vaccine Adverse Event Reporting System (VAERS), 'apnea' is an adverse event that was mentioned in 1,618 VAERS reports (1.3%) during1991-2001 (Reference: PMID: 12825543). JX, YH, MW MedDRA: 10002974 is for "apnoea"; MedDRA: 10002972 is for "apnea". apnoea AE respiratory arrest AE WEB: http://medical-dictionary.thefreedictionary.com/apnea apnea AE CTCAE: E13306 MP: MP_0001957 NCIt: C26698 UMLS CUI: C0003578 OAE:0000573 an ear disorder AE which has an outcome of deafness, which is an inability to hear 10011878 deafness AE HPO: HP_0000365 MP: MP_0001967 SIDER: C0011053 OAE:0000574 an adverse event that occurs in a gustatory system YH, JX gustatory system AE MP: MP_0001985 OAE:0000575 a gustatory system AE which has an outcome of taste sensitivity, or changes in the ability to perceive a particular flavor or suggestion of something imparting a flavor by the chemoreceptors of the gustatory system taste sensitivity AE MP: MP_0001986 OAE:0000576 a urinary system AE that has an outcome of excessive or abnormally large production or passage of urine. LW, ML, JX, YH WEB: http://en.wikipedia.org/wiki/Polyuria 多尿 10036142 polyuria AE OAE:0000577 an abnormal vision AE which has an outcome of blindness, which is loss of the sense of sight 10005169 blindness AE HPO: HP_0000618 MP: MP_0002001 SIDER: C0456909 OAE:0000578 an eye disorder AE which has an outcome of abnormal vision, which is an inability or decreased ability to see abnormal vision AE MP: MP_0002090 OAE:0000579 a behavior and neurological AE that shows a sudden surge of electrical activity in the brain. YH, JX, YH WEB: http://www.healthline.com/symptom/seizures 突然发作 10039906 10039910 seizure AE CTCAE: E12804 MP: MP_0002064 NCIt: C2962 OAE:0000580 an adverse event that has an outcome of an abnormal behavior and neurological phenotype. YH, JX behavior AE behavioral AE behavioral disorder AE disruptive behavioral disorder AE WEB: http://www.psychguides.com/guides/behavioral-disorder-symptoms-causes-and-effects/ any anomaly in the actions, reactions, or performance of an organism in response to external or internal stimuli compared to controls behavioral and neurological AE MP: MP_0004924 OAE:0000581 a behavior and neurological AE that has an outcome of altered ability to coordinate voluntary movement or repetitive, compulsive movements 10028035 movement disorder AE HPO: HP_0100022 MP: MP_0002066 SIDER: C0026650 OAE:0000582 a behavior and neurological AE that has an outcome of inability or altered ability to respond to a sensory stimulus sensory capability AE MP: MP_0002067 OAE:0000583 a homeostasis AE which has an outcome of glucose homeostasis, which is an anomaly in the processes involved in the maintenance of an internal equilibrium of glucose in the fluids and tissues glucose homeostasis AE MP: MP_0002078 OAE:0000584 Hypersensitivity AE is a immune system AE that is a set of undesirable reactions produced by the normal immune system, including allergies and autoimmunity. These reactions may be damaging, uncomfortable, or occasionally fatal. JX, LW, YH hypersensitivity reaction AE WEB: http://en.wikipedia.org/wiki/Hypersensitivity 超敏反应 10020751 hypersensitivity AE HPO: HP_0100326 MP: MP_0002148 SIDER: C0020517 OAE:0000585 YH Muscle atrophy is a wasting of muscle tissue resulting in a derangement of the muscle fibers; occurs with age, immobilization, weightlessness, malnutrition or denervation. a muscle adverse event AE which has an outcome of muscular atrophy. muscular atrophy AE MP: MP_0002269 OAE:0000586 an abnormal respiration AE which has an outcome of hyperventilation, i.e., increased alveolar ventilation relative to metabolic carbon dioxide production; results in carbon dioxide pressure decreasing below normal According to the Vaccine Adverse Event Reporting System (VAERS), 'Petechiae' was mentioned in 510 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). 10020910 hyperventilation AE HPO: HP_0002883 MP: MP_0002320 SIDER: C0020578 OAE:0000587 an abnormal respiration AE which has an outcome of hypoventilation, i.e., reduced alveolar ventilation relative to metabolic carbon dioxide production; results in alveolar carbon dioxide pressure increasing above normal According to the Vaccine Adverse Event Reporting System (VAERS), 'hypoventilation' is an adverse event that was mentioned in 321 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). QL, YH respiratory depression AE WEB: https://en.wikipedia.org/wiki/Hypoventilation 呼吸抑制 10021133 10038678 hypoventilation AE HPO: HP_0007110 MP: MP_0002321 SIDER: C0398353 OAE:0000588 an adverse event which occurs in a hematopoietic system, which is any structural or developmental anomaly of the blood cells or the organs associated with the development and formation of blood cells hematopoietic system AE MP: MP_0002396 OAE:0000589 an eye disorder AE which has an outcome of mydriasis, which is dilation of one or both pupils regardless of light conditions 10028521 mydriasis AE HPO: HP_0011499 MP: MP_0002546 SIDER: C0026961 OAE:0000590 an arrhythmia AE that has an outcome of greater than average resting heart beats per minute, usually measured by the number of times the heart ventricles contract per unit of time, usually per minute tachycardia WEB: http://en.wikipedia.org/wiki/Tachycardia 10019303 increased heart rate AE MP: MP_0002626 OAE:0000591 a behavior and neurological AE that has an outcome of exaggerated reflex action hyperresponsive to tactile stimuli AE MP: MP_0002738 OAE:0000592 a muscle spasm AE that has an outcome of opisthotonus YH 10030899 opisthotonus is a form of tetanic spasm in which the head, neck and spine are bent backward and the body is bowed forward opisthotonus AE HPO: HP_0002179 MP: MP_0002880 SIDER: C0151818 OAE:0000593 An joint disorder AE that has an outcome of joint inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the joints YH joint inflammation AE MP: MP_0002933 OAE:0000594 an abnormal enzyme level AE which has an outcome of incraesed lactate dehydrogenase level, which is greater than the normal concentration of this enzyme, which catalyzes the interconversion of lactate and pyruvate increased lactate dehydrogenase level AE MP: MP_0002944 OAE:0000595 an abnormal enzyme level AE which has an outcome of increased circulating alkaline phophatase level, which is an elevated activity of this enzyme, which hydrolyzes orthophosphoric monoesters, found in the blood increased circulating alkaline phosphatase level AE MP: MP_0002968 OAE:0000596 A joint inflammation AE that has an outcome of arthritis, marked by changes in the synovial membranes and thickening of articular structures, widespread degeneration of the collagen fibers in connective tissues, and by atrophy and rarefaction of bony structures YH, MW 关节炎 10003246 arthritis AE CTCAE:E12378 HPO: HP_0001369 MP: MP_0002993 NCIt:C2883 SIDER: C0003864 OAE:0000597 a digestive system AE which has an outcome of dysphagia, which is a behavior and neurological AE that has an outcome of difficulty in swallowing food or liquid 10013950 dysphagia AE CTCAE: E10621 HPO: HP_0002015 MP: MP_0003158 NCIt: C2980 SIDER: C0011168 OAE:0000598 an ear disorder AE which has an outcome of decreased lateral semicircular canal size, which is small size of the lateral long bony tube of the labyrinth that is involved in the sense of balance decreased lateral semicircular canal size AE MP: MP_0003162 OAE:0000599 a hematopoietic system AE which has an outcome of decreased platelet count, which is fewer than the normal numbers of the non-nucleated cells found in the blood and involved in blood coagulation SS, YH decreased platelet cell number AE 10035528 platelet count decreased AE CTCAE: E12207 HPO: HP_0001873 MP: MP_0003179 NCIt: C3408 SIDER: C0392386 OAE:0000600 an abnormal digestion AE which has an outcome of nausea, a gastric discomfort associated with the inclination to vomit 10028813 nausea AE CTCAE: E10878 HPO: HP_0002018 MP: MP_0003259; MDR: 10028813 NCIt: C3258 SIDER: C0027497 OAE:0000601 regurgitation AE 10047700 an abnormal digestion AE which has an outcome of vomiting, the retrograde expulsion of gastric contents through the oral cavity vomiting AE CTCAE: E11068 HPO: HP_0002013 MP: MP_0003260; MDR: 10047700 NCIt: C3442 SIDER: C0042963 OAE:0000602 an abnormal defecation AE that has an outcome of constipation, which is incomplete, infrequent or difficult evacuation of fecal matter According to the Vaccine Adverse Event Reporting System (VAERS), 'constipation'; is an adverse event that was mentioned in 242 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). infrequent bowel movements AE 10010774 constipation AE CTCAE: E10562 HPO: HP_0002019 MP: MP_0003267 NCIt: C37930 SIDER: C0009806 OAE:0000603 a digestive system AE that has an outcome of abnormal defecation, an anomaly in the production and excretion of feces abnormal defecation AE MP: MP_0003866 OAE:0000604 a urinary system AE that has an outcome of the symptom of urinary incontinence, which is the inability to control the urinary excretory functions. YH, MW MedDRA: 10046543 WEB: http://www.nlm.nih.gov/medlineplus/urinaryincontinence.html urinary incontinence AE CTCAE: E13042 HPO: HP_0000020 MP: MP_0003280 NCIt: C78497 SIDER: C0042024 OAE:0000605 clonus AE is a series of involuntary, rhythmic, muscular contractions and relaxations. SJ, YH WEB: http://en.wikipedia.org/wiki/Clonus 10009346 clonus AE causes large motions that are usually initiated by a reflex. clonus AE OAE:0000606 a skin discoloration AE which has an outcome of pallor, an unnatural paleness to the skin, generally attributable to anemia 10033546 pallor AE HPO: HP_0008361 MP: MP_0003717 SIDER: C0030232 OAE:0000607 an hearing disorder AE that shows a persistent sensation of buzzing, ringing, clicking, or other noises in the ear 10043882 tinnitus AE CTCAE: E10287 HPO: HP_0000360 MP: MP_0003741 NCIt: C50772 SIDER: C0040264 OAE:0000608 a digestive system AE which has an outcome of stomatitis, which is an inflammation of the mucous lining of the mouth This is a type of inflammation. WEB: http://medical-dictionary.thefreedictionary.com/stomatitis 10042128 stomatitis AE HPO: HP_0010280 MP: MP_0003746 SIDER: C0038362 OAE:0000609 a digestive system AE which has an outcome of mouth mucosal ulceration, which is lesions through the mucous membrane of the mouth, usually associated with loss of tissue According to the Vaccine Adverse Event Reporting System (VAERS), 'mouth ulceration' was mentioned in 246 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). mouth mucosal ulceration AE MP: MP_0003747 OAE:0000610 a muscle adverse event AE that has an outcome of abnormal muscle tone, which is an anomaly in the resting tautness or laxity of a muscle, normally somewhere in the middle of the range between total contraction and total relaxation YH abnormal muscle tone AE MP: MP_0004142 OAE:0000611 an abnormal muscle tone AE which has an outcome of hypertonia, which is increased muscle tension resulting in stiffness of the muscles in the resting state YH 10020852 hypertonia AE HPO: HP_0001276 MP: MP_0004143 SIDER: C0026826 OAE:0000612 an abnormal muscle tone AE which has an outcome of hypotonia, which is decreased muscle tension resulting in limpness of the muscles in the resting state, not to be confused with weakness YH 10021118 hypotonia AE HPO: HP_0009062 MP: MP_0004144 SIDER: C0026827 OAE:0000613 a muscle inflammation AE which has an outcome of myositis, which is an inflammation of skeletal muscle; local accumulation of fluid, plasma proteins, and leukocytes in the striated muscle YH, MW 10028653 myositis AE CTCAE:E12489 HPO: HP_0009071 MP: MP_0004510 NCIt:C27578 SIDER: C0027121 OAE:0000614 a muscle adverse event which has an outcome of muscle inflammation, which is a local accumulation of fluid, plasma proteins, and leukocytes in muscle YH muscle inflammation AE MP: MP_0004511 OAE:0000615 a lymphocyte count abnormal AE that has an outcome of greater than normal number of the cells involved in adaptive immune reactions of the body in most inflammatory and autoimmune diseases, including B cells, T cells and natural killer cells According to the Vaccine Adverse Event Reporting System (VAERS), 'lymphocytosis'; is an adverse event that was mentioned in 129 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). EB increased lymphocyte cell number AE lymphocyte cell number increased AE 10025258 lymphocyte count increased AE CTCAE: E12195 MP: MP_0005013 NCIt: C34791 OAE:0000616 an abnormal defecation AE that has an outcome of diarrhea, which is abnormally frequent discharge of semi-solid or fluid fecal matter from the bowel diarrhoea AE WEB: http://medical-dictionary.thefreedictionary.com/diarrhea 10012735 diarrhea AE CTCAE: E10572 MP: MP_0005036 NCIt: C2987 OAE:0000617 a homeostasis AE which has an outcome of hypoxia, which is a reduced concentration of O2 in the blood, alveoli or other tissues resulting in the decreased pressure of this component of body gases YH, MW WEB: http://medical-dictionary.thefreedictionary.com/hypoxia 10021143 hypoxia AE CTCAE:E13388 HPO: HP_0002795 MP: MP_0005039 NCIt:C3890 SIDER: C0242184 OAE:0000618 an infectious adverse event which has an outcome of the presence of various pathogenic organisms, or their toxins, in the blood or tissues that results in the infections in blood stream. According to the Vaccine Adverse Event Reporting System (VAERS), 'sepsis' was mentioned in 416 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). SS 10040047 sepsis AE CTCAE: E11560 HPO: HP_0002718 MP: MP_0005044 NCIt: C3364 SIDER: C0243026 OAE:0000619 a urinary system AE that results in the presence of blood in the urine YH, SJ, MW UMLS CUI: C0018965 (hematuria AND haematuria); UMLS CUI: C0947999 (blood urine presence) blood urine blood urine presence haematuria AE WEB: http://kidney.niddk.nih.gov/kudiseases/pubs/hematuria/ 10018867 10018870 10019450 hematuria Hematuria AE can be caused by menstruation, vigorous exercise, sexual activity, viral illness, trauma, or infection, such as a urinary tract infection (UTI), along with more serious disorders such as cancer, disease, and clotting. hematuria AE CTCAE: E13000 MP: MP_0005161 NCIt: C3090 OAE:0000620 a homeostasis AE which has an outcome of abnormal enzyme level, which is an altered level of any enzyme or their cofactors, that act as catalysts to induce chemical changes in other substances abnormal enzyme level AE MP: MP_0005319 OAE:0000621 an arrhythmia AE that has an outcome of fewer than average resting heart beats per minute, usually measured by the number of times the heart ventricles contract per unit of time, usually per minute YH, JX heart rate decreased AE 10019301 decreased heart rate AE MP: MP_0005333 OAE:0000622 an adverse event that has an outcome of urinary system AE is a functional anomaly of any of the organs involved in the production or excretion of urine YH urinary system AE MP: MP_0005502 OAE:0000623 an abnormal body temperature AE which has an outcome of decreased body temperature, which is less than the level of heat natural to a living being YH, SJ decreased body temperature AE 10021113 Hypothermia AE is a medical emergency that occurs when your body loses heat faster than it can produce heat, causing a dangerously low body temperature. hypothermia AE CTCAE: E11122 MP: MP_0005534 NCIt: C78351 OAE:0000624 a homeostasis AE whic has an outcome of abnomal body temperature, which is a deviation in the level of heat natural to a living being abnormal body temperature AE MP: MP_0005535 OAE:0000625 a peripheral neuropathy AE which has an outcome of neuritis, the local accumulation of fluid, plasma proteins, and leukocytes in the brain and/or spinal cord 10029240 neuritis AE MP: MP_0006082 OAE:0000626 diplopia AE 10013036 an abnormal vision AE which has an outcome of double vision, which is two images perceived when only a single object is present double vision AE MP: MP_0006150 OAE:0000627 an anemia AE which has an outcome of hypochromic anemia, which is a hemoglobin deficiency resulting from a reduction in the concentration of hemoglobin in red cells, resulting in insufficient oxygenation of tissues and organs hypochromic anemia AE MP: MP_0008387 OAE:0000628 an adverse event that is indicated by an abnormal result of an investigation that uses some laboratory equipment, device, or medical technology. This term is used to replace 'lab test abnormal AE'. The reason for this is that some test, like X-ray test, is not considered by many physicians as a lab test. Therefore, we have used this new term to cover a broader scope. All terms asserted under this term represent the investigation results without defined conclusion of disease. EB, SS, YH laboratory test abnormal 10061253 investigation result abnormal AE OAE:0000629 a movement disorder AE that has an outcome of nervous According to the Vaccine Adverse Event Reporting System (VAERS), 'nervousness' is an adverse event that was mentioned in 583 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). increased, skittish, behavior induced by stimulation such as handling, touching or noise nervous AE MP: MP_0008912 OAE:0000630 a hemorrhage AE that has an outcome of ecchymosis 10014080 an ecchymosis is a spot caused by loss of blood from a vessel; it implies a larger size than a petechiae, and has a more diffuse border than purpura; an ecchymosis can be caused by a bruise (which implies trauma), but can also be caused by bleeding diathesis ecchymosis AE HPO: HP_0000978 MP: MP_0009276 SIDER: C0013491 OAE:0000631 serious adverse event is an adverse event that requires in-patient hospitalization, or prolongation of existing hospitalization, or that causes congenital malformation, or that results in persistent or significant disability or incapacity, or that is life threatening or results in death. YH, MC serious adverse event severe adverse event WEB: http://en.wikipedia.org/wiki/Serious_adverse_event WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm WEB: http://www.google.ca/url?sa=t&source=web&ct=res&cd=1&ved=0CA4QFjAA&url=http%3A%2F%2Fwww.irrd.ca%2Fethics%2Fimages%2FAdverse-event-definition.doc&ei=eqFMS-yFNZSoswOt6siKAQ&usg=AFQjCNGnQcwI8OXH7dqxwo4RgZEEn8X6lg&sig2=UNngkCdO5ZTFvbIB1pKuaA serious adverse event OAE:0000632 a serious adverse event that has an outcome of death. YH WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm 10011906 10011914 death death AE CTCAE: E11080 HPO: HP_0001645 NCIt: C28554 SIDER: C1306577 OAE:0000633 a serious AE that is suspected to put the patient at substantial risk of dying at the time of the adverse event, or that the use or continued use of the device or other medical product might have resulted in the death of the patient. DJ, SS, YH, JX apparent life threatening event AE WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm 10065044 life-threating AE OAE:0000634 a serious adverse event that leads to hospitalization. Such an adverse event resulted in an admission to the hospital or prolongation of hospitalization. YH, JX adverse event leading to hospitalization WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm hospitalization AE OAE:0000635 a serious adverse event that leads to disability or permanent damage. Such an adverse event results in a substantial disruption of a person's ability to conduct normal life functions, i.e., the adverse event resulted in a significant, persistent or permanent change, impairment, damage or disruption in the patient's body function/structure, physical activities and/or quality of life. YH, JX adverse event leading to disability WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm disability or permanent damage AE OAE:0000636 a serious adverse event that resulted in congenital anomaly and bith defect, leading to suspicions that an exposure to a medical product prior to conception or during pregnancy resulted in an adverse outcome in the child. YH, JX adverse event leading to congenital anomaly WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm WEB: http://www.thefreedictionary.com/birth+defect 10010356 congenital anomaly or birth defect AE OAE:0000637 a serious adverse event which is an adverse event that requires intervention to prevent permanent impairment or damage leads to suspicions that the use of a medical product may result in a condition which requires a medical or surgical intervention to preclude permanent impairment or damage to a patient. YH, JX WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm adverse event that requires intervention to prevent permanent impairment or damage OAE:0000638 an adverse event that is considered not serious. YH, MC WEB: http://www.google.ca/url?sa=t&source=web&ct=res&cd=1&ved=0CA4QFjAA&url=http%3A%2F%2Fwww.irrd.ca%2Fethics%2Fimages%2FAdverse-event-definition.doc&ei=eqFMS-yFNZSoswOt6siKAQ&usg=AFQjCNGnQcwI8OXH7dqxwo4RgZEEn8X6lg&sig2=UNngkCdO5ZTFvbIB1pKuaA non-serious adverse event OAE:0000639 low-grade fever AE is a fever adverse event with a temperature between 100° F and 102.2° F (37.8° C and 39° C). YH WEB: http://www.toyourhealth.com/mpacms/tyh/article.php?id=1521 The low-grade level of fever is beneficial. With most microbes/"bugs" that a child will be exposed to, this fever will assist the body in repelling the invader. low-grade fever AE OAE:0000640 moderate-grade fever AE is a fever adverse event with a temperature typically between 102.2° F and 104.5° F (39° C and 40° C). YH WEB: http://www.toyourhealth.com/mpacms/tyh/article.php?id=1521 This moderate-grade fever temperature is still considered beneficial. If a child's body has reached this temperature, it's what's needed to kill whatever bacteria or virus their body is attempting to fight. moderate-grade fever AE OAE:0000641 high-grade fever AE is a fever adverse event with a fever temperature greater than 104.5° F (40° C). YH WEB: http://www.toyourhealth.com/mpacms/tyh/article.php?id=1521 This fever may cause the child some discomfort and result in crankiness. Generally indicative of a bacterial infection, this fever means that the body is fighting something more serious than the common cold. high-grade fever AE OAE:0000642 hyperpyrexia AE is a fever adverse event that has an outcome of an excessive and unusual elevation of set body temperature greater than or equal to 41 °C. It is an extremely high fever. Such a high temperature is considered a medical emergency as it may indicate a serious underlying condition such as sepsis. YH extreme pyrexia AE Axelrod YK1, Diringer MN. Temperature management in acute neurologic disorders. Neurol Clin. 2008 May;26(2):585-603, xi. doi: 10.1016/j.ncl.2008.02.005. PMID: 18514828. WEB: http://en.wikipedia.org/wiki/Hyperpyrexia 10020741 hyperpyrexia AE HPO: HP_0001945 SIDER: C0392676 OAE:0000643 a pain AE that has an outcome of musculoskeletal pain SS, YH WEB: http://www.webmd.com/pain-management/guide/musculoskeletal-pain 10028391 Musculoskeletal pain is pain that affects the muscles, ligaments and tendons, along with the bones. musculoskeletal pain AE HPO: HP_0003326 SIDER: C0026858 OAE:0000644 injection-site erythema AE is an erythema AE that results in redness of skin, caused by hyperermia of the capillaries in the lower layers of the skin at the physical area of injection SS, YH WEB: http://en.wikipedia.org/wiki/Erythema WEB: http://medical-dictionary.thefreedictionary.com/erythema 10022061 injection-site erythema AE OAE:0000645 Erythema AE is a skin adverse event that showns redness of the skin caused by hyperemia of the capillaries in the lower layers of the skin. SS, YH reddish skin WEB: http://en.wikipedia.org/wiki/Erythema 10015150 erythema AE HPO: HP_0010783 MP:0001190 SIDER: C0041834 OAE:0000646 a headache AE that has an outcome of sinus headache YH, SS WEB: http://american-rhinologic.org/patientinfo.headache.phtml sinus headache is a headache located over the sinuses, (forehead, corners of the eye, and cheek areas). On occasion, the pain will be felt behind the eyes, in the back of the neck, or may extend into the upper teeth. sinus headache AE HPO: HP_0002315 SIDER: C0037195 OAE:0000647 an inflammation AE that occurs in the lung. It is often characterized as including inflammation of the parenchyma of the lung (that is, the alveoli) and abnormal alveolar filling with fluid (consolidation and exudation). SS, YH WEB: http://en.wikipedia.org/wiki/Pneumonia 10035664 pneumonia AE HPO: HP_0002090 SIDER: C0032285 OAE:0000648 lobar pneumonia is pneumonia AE that affects a large and continuous area of the lobe of a lung SS, YH WEB: http://en.wikipedia.org/wiki/Lobar_pneumonia 10024738 lobar pneumonia AE HPO: HP_0002090 SIDER: C0032300 OAE:0000649 axillary pain AE is a pain AE that occurs in the underarm (the area on the human body directly under the join where the arm connects to the shoulder) SS, YH axillary pain AE OAE:0000650 an cardiovascular adverse event that is a collection of blood outside the blood vessels, generally the result of hemorrhage, or more specifically, internal bleeding. It is commonly called a bruise. YH: MedDRA ID: 10018852 is for "haematoma"; MedDRA ID: 10019428 is for "hematoma". SS, YH bruise AE bruising AE ecchymoses AE haematoma AE WEB: http://en.wikipedia.org/wiki/Hematoma 10006504 10018852 10019428 hematoma AE CTCAE: E13775 (hematoma); CTCAE: E11666 (brruising) HPO: HP_0001892 NCIt: C37921 (Bruising); NCIt: C50579 (Hematoma) SIDER: C0018944 OAE:0000651 reproductive system AE is an AE that occurs in the reproductive system. YH, SS reproductive system AE OAE:0000652 an immune system disorder AE which has an outcome of antinuclear antibody negative SS, YH antinuclear antibody negative AE OAE:0000653 a CSF test result abnormal AE that has an outcome of CSF white blood cell count negative SS, YH, EB 10061099 CSF white blood cell count negative AE OAE:0000654 a microbiology and serology investigation result abnormal AE that has an outcome of positive influenza serology test result SS, YH, EB 10060078 influenza serology positive AE OAE:0000655 YH a paralysis AE that has an outcome of VIIth nerve paralysis 10050040 VIIth nerve paralysis AE HPO: HP_0006824 SIDER: C0919980 OAE:0000656 an aspartate aminotransferase level abnormal AE that has an outcome of an increased amount of AST, an enzyme normally present in body tissues especially of the heart and liver DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/aspartate+aminotransferase 10003481 aspartate aminotransferase level increased AE CTCAE: E12087 NCIt: C26947 OAE:0000658 an immune system disorder AE which has an outcome of acute disseminated encephalomyelitis SS, YH WEB: http://en.wikipedia.org/wiki/Acute_disseminated_encephalomyelitis 10000709 Acute disseminated encephalomyelitis (ADEM) is an immune mediated disease of the brain. It usually occurs following a viral infection but may appear following vaccination, bacterial or parasitic infection, or even appear spontaneously. As it involves autoimmune demyelination, it is similar to multiple sclerosis, and is considered part of the Multiple sclerosis borderline diseases. acute disseminated encephalomyelitis AE OAE:0000659 an arrhythmia AE that involves the two upper chambers (atria) of the heart SS, YH AF WEB: http://en.wikipedia.org/wiki/Atrial_fibrillation WEB: http://medical-dictionary.thefreedictionary.com/atrial+fibrillation 10003658 Atrial fibrillation (AF or A-fib) is the most common cardiac arrhythmia (abnormal heart rhythm), and involves the two upper chambers (atria) of the heart. Its name comes from the fibrillating (i.e., quivering) of the heart muscles of the atria, instead of a coordinated contraction. atrial fibrillation AE CTCAE: E10081 HPO: HP_0005110 NCIt: C50466 SIDER: C0004238 OAE:0000660 a cardiac disorder AE which has an outcome of abnormal heart rhythm SS, YH abnormal heartbeat AE cardiac arrhythmia AE WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/arr/ 10003119 arrhythmia AE HPO: HP_0011675 MP: MP_0004085 SIDER: C0003811 OAE:0000661 a cardiac valve disease AE that is characterized by a condition of the heart in which one of the valve openings has become narrow and restricts the flow of blood from the upper left chamber (left atrium) to the lower left chamber (left ventricle). SS WEB: http://medical-dictionary.thefreedictionary.com/mitral+valve+stenosis 10027733 mitral valve stenosis AE OAE:0000662 a blood creatinine level abnormal AE that has an outcome of decreased blood creatine SS, YH, EB 10005482 blood creatinine level decreased AE OAE:0000663 SS, YH, EB 10007223 carbon dioxide decreased AE a carbon dioxide abnormal AE that has an outcome of a decreased level of carbon dioxide in the blood OAE:0000665 an infection adverse event that has an outcome of croup infection SS, YH WEB: http://www.medicinenet.com/croup/article.htm Croup is an infectious illness of the respiratory system involving the vocal cords (larynx), the windpipe (trachea), and the upper airways of the lungs (bronchial tubes). The majority of a child's symptoms reflect involvement of the larynx. Croup is usually a viral infection and maybe caused by many different viruses, including those responsible for the common cold and influenza. Rarely, croup is caused by a bacterial infection. croup infection AE OAE:0000666 a respiratory system AE that has an outcome of the drawing of a foreign substance into the respiratory tract during inhalation DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/aspiration 10003504 aspiration AE CTCAE:E13310 HPO: HP_0002835 NCIt:C15631 SIDER: C0700198 OAE:0000667 a respiratory system AE that has an outcome of the removal of gas or fluid from the pleural cavity of the lungs DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/aspiration 10003522 aspiration pleural cavity AE OAE:0000668 a skin adverse event which has an outcome of excoriation AE is an injury to a surface of the body caused by trauma, such as scratching, abrasion, or a chemical or thermal burn. SS, YH WEB: http://medical-dictionary.thefreedictionary.com/excoriation 10049796 excoriation AE OAE:0000669 a pain AE that has an outcome of facial pain SS, YH WEB: http://www.bettermedicine.com/article/facial-pain 10016059 facial pain is a pain in facial area (eyes, eyebrows, forehead, nose, cheeks, mouth, teeth and chin). Facial pain may include injuries to the nerves or bones that coordinate many of your face’s actions. facial pain AE CTCAE: E11094 HPO: HP_0100661 NCIt: C79594 SIDER: C0015468 OAE:0000670 a hematology investigation result abnormal AE that has an outcome of abnormal full blood count SS, YH, EB 10017412 10064198 full blood count abnormal AE OAE:0000672 a tumor AE that is characterized by cancer in the brain DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/astrocytoma 10003571 astrocytoma AE HPO: HP_0009592 SIDER: C0004114 OAE:0000674 a lung disorder AE that has an outcome of collapse in part of or all of a lung DJ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001130/ 10003598 atelectasis AE CTCAE:E13316 HPO: HP_0001642 NCIt:C2888 SIDER: C0004144 OAE:0000675 an influenza serology positive AE that has an outcome of positive result in an influenza virus test SS, YH, EB 10070717 influenza virus test positive AE OAE:0000676 joint range of motion decreased AE is a mobility decreased AE that results in limited or decreased range of joint motion SS, YH, MW 10048706 joint range of motion decreased AE CTCAE: E12435 NCIt: C78403 OAE:0000677 a muscle spasm AE which has an outcome of laryngospasm, which is an uncontrolled/involuntary muscular contraction (spasm) of the laryngeal cords. The condition typically lasts less than 60 seconds, and causes a partial blocking of breathing in, while breathing out remains easier. It may be triggered when the vocal cords or the area of the trachea below the cords detects the entry of water, mucus, blood, or other substance. It is characterized by stridor and or retractions. SS, YH, MW WEB: http://en.wikipedia.org/wiki/Laryngospasm 10023891 laryngospasm AE CTCAE:E13439 HPO: HP_0006511 NCIt:C79609 SIDER: C0023066 OAE:0000678 a lymphocyte percentage abnormal AE that has an outcome of decreased lymphocyte percentage SS, YH, EB 10052231 lymphocyte percentage decreased AE OAE:0000679 a monocyte percentage abnormal AE that has an outcome of increased monocyte percentage SS, YH, EB 10052230 monocyte percentage increased AE OAE:0000680 a nuclear magnetic resonance imaging result abnormal AE that has an outcome of abnormal nuclear magnetic resonance imaging test of the brain SS, YH 10029818 nuclear magnetic resonance imaging brain abnormal AE OAE:0000681 periorbial edema AE is an edema AE that has an outcome of swelling around the eye. MedDRA: 10034545 is for "periorbital edema"; MedDRA: 10054541 is for "periorbital oedema" SS, YH periorbital oedema AE periorbital puffiness WEB: http://en.wikipedia.org/wiki/Periorbital_puffiness Periorbital puffiness, also known as "puffy eyes" or swelling around the eyes, refers to the appearance of swelling in the tissues around the eyes, called the orbits. periorbital edema AE CTCAE: E13676 NCIt: C78530 UMLS CUI: C0151205 OAE:0000683 a blood magnesium abnormal AE that has an outcome of an abnormally high concentration of magnesium in the blood plasma, and may cause nausea, weakness and tremors. YH, MW WEB: http://emedicine.medscape.com/article/246489-overview 10020670 hypermagnesemia AE CTCAE: E12288 NCIt: C37969 UMLS CUI: C0151714 OAE:0000684 a sensory capability AE that has an outcome of a sensation feeling of foreign body SS, YH 10061549 sensation of foreign body AE OAE:0000685 a sensory capability AE that has an outcome of a sensation feeling of heaviness SS, YH feeling heavy AE sensation of heaviness AE OAE:0000686 a sensory capability AE that has an outcome of a loss of sensation SS, YH 10040030 sensory loss AE HPO: HP_0003474 SIDER: C0278134 OAE:0000687 a skin adverse event that has an outcome of skin exfoliation SS, YH 10040844 skin exfoliation AE HPO: HP_0007549 SIDER: C0237849 OAE:0000688 a digestive system AE which has an outcome of stomach discomfort SS, YH stomach upset AE 胃部不适 10042124 stomach discomfort AE OAE:0000689 an immunology and allergy investigation result abnormal AE that has an outcome of autoantibodies present DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/autoantibody 10060973 autoantibody positive AE OAE:0000690 a wheezing AE which has an outcome of stridor, a high pitched wheezing sound resulting from turbulent air flow in the upper airway. It is primarily inspiratory. It can be indicative of serious airway obstruction from severe conditions such as epiglottitis, a foreign body lodged in the airway, or a laryngeal tumor. SS, YH, MW WEB: http://en.wikipedia.org/wiki/Stridor 10042241 stridor AE CTCAE:E13579 HPO: HP_0010307 NCIt:C78632 SIDER: C0038450 OAE:0000691 a skin AE that shows a result of skin ulcer, i.e., a sore on the skin or a mucous membrane, accompanied by the disintegration of tissue. Ulcers can result in complete loss of the epidermis and often portions of the dermis and even subcutaneous fat. SS, YH, MW skin ulcer AE WEB: http://en.wikipedia.org/wiki/Ulcer_%28dermatology%29 10040943 10040947 skin ulceration AE CTCAE: E13730 HPO: HP_0200042 NCIt: C54247 SIDER: C0037299 OAE:0000693 a respiratory tract congestion AE which has an outcome of upper respiratory tract congestion SS, YH upper respiratory tract congestion AE OAE:0000694 a urinary system investigation result abnormal AE that has an outcome of a urine analysis abnormality SS, YH, EB 10062226 urine analysis result abnormal AE OAE:0000695 a urine analysis result abnomal AE that shows ketone body present in urine SS, YH, EB, QL 10057597 urine ketone body present AE OAE:0000696 a liver/biliary system AE that has an outcome of inflammation of the liver that occurs when immune cells mistake the liver's normal cells for harmful invaders and attack them DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001291/ 10003827 autoimmune hepatitis AE HPO: HP_0004787 SIDER: C0241910 OAE:0000697 a hemorrhage AE that has an outcome of vaginal hemorrhage MedDRA: 10046910 is for "vaginal haemorrhage"; MedDRA: 10046912 is for "vaginal hemorrhage" SS, YH, MW vaginal haemorrhage AE WEB: http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/AbnormalBleeding/Bleeding.htm vaginal hemorrhage is irregular/heavy bleeding from the vagina. Vaginal hemorrhage is more often associated with pregnancy complications such as miscarriage or placental abruption, but certainly can occur in the absence of pregnancy. vaginal hemorrhage AE CTCAE: E13264 NCIt: C26945 OAE:0000698 SS, YH WEB: http://en.wikipedia.org/wiki/Vasodilation a cardiovascular disorder AE which has an outcome of vasodilatation, which refers to the widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls, particularly in the large arteries, smaller arterioles and large veins. vasodilatation AE HPO: HP_0004927 SIDER: C0595862 OAE:0000699 a bacterial infection AE that has an outcome of bacteria in the blood DJ, SS, YH bacteraemia AE WEB: http://medical-dictionary.thefreedictionary.com/bacteremia 10003997 bacteremia AE OAE:0000700 a sepsis AE caused by bacterial infection in the bloodstream or body tissues DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/sepsis 10053840 bacterial sepsis AE OAE:0000701 a skin AE that has an outcome of a slow-growing nonmelanoma skin cancer DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001827/ 10004146 basal cell carcinoma AE HPO: HP_0002671 SIDER: C0007117 OAE:0000702 a basophil count abnormal AE that is characterized by increase in the number of basophils in the body DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/basophil+granulocyte 10004169 basophil count increased AE OAE:0000703 an ulcer AE that is characterized by ulcers in the mouth that may decrease ocular functionality DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/behcet's+disease 10004213 behcet's syndrome AE OAE:0000704 a musculoskeletal system AE that has an outcome of low muscle tone DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/hypotonia 10051900 benign congenital hypotonia AE OAE:0000705 a female reproductive system AE that has an outcome of a non-fertilized egg that implants itself in the uterus and turns a normal pregnancy into an abnormal one DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/hydatidiform+mole 10004272 benign hydatidiform mole AE OAE:0000706 a benign tumor AE that has an outcome of a benign tumor in their ovaries DJ, SS, YH benign ovarian tumour AE 10004433 benign ovarian tumor AE OAE:0000707 a digestive system AE that has an outcome of a blockage in the tubes that carry bile from the liber to the gallbladder and small intestine DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000263.htm 10056375 bile duct obstruction AE OAE:0000708 a liver/biliary system AE that has an outcome of dilating or stretching of the bile duct DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21843715 10057202 biliary dilatation AE OAE:0000709 an eating disorder that is characterized by episodes of uncontrollable eating. DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/binge+eating 10004716 binge eating AE OAE:0000710 an eye disorder AE that has an outcome of binocular eye movement disorder where control and alignment of eyes are compromised DJ, SS, YH WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/23201436 Secondary Source: http://brain.oxfordjournals.org/content/119/6/1933.full.pdf 10061010 binocular eye movement disorder AE OAE:0000711 a digestive system AE that has an outcome of cancer that starts in the bladder, the body part that holds and releases urine in the center of the lower belly area DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001517/ 10005003 bladder cancer AE HPO: HP_0009725 SIDER: C0005684 OAE:0000712 a blast cell count abnormal AE that has an outcome of an increased amount of immature precursors of either lymphocytes or granulocytes that do not normally appear in peripheral blood. May indicate acute leukemia DJ, SS, YH WEB: http://meds.queensu.ca/medicine/deptmed/hemonc/anemia/blast.htm 10062274 blast cell count increased AE OAE:0000713 a hematopoietic system AE that has an outcome of a sudden, severe change in the course of chronic granulocytic leukemia with an increase in the proportion of myeloblasts DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/blast+crisis 10053747 blast cell crisis AE OAE:0000714 a hematopoietic system AE that has an outcome of myeloblasts or myeloid blasts. Presence of these abnormal blasts prevent production of adequate platelets, red blood cells and white blood cells, can be associated with leukemia DJ, SS, YH WEB: http://lymphoma.about.com/od/glossary/ss/Blast-Cells.htm 10057107 blast cells present AE OAE:0000715 a hematopoietic system AE that has an outcome of the last stage of chronic myelogenous leukemia characterized by rapid progression and short survival with an increase of myeloblasts or lymphoblasts in the blood or bone marrow DJ, SS, YH blast crisis in myelogenous leukaemia AE WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/blast+crisis , Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23171293 10050282 blast crisis in myelogenous leukemia AE OAE:0000716 an eye inflammation AE that has an outcome of swelling in the eyelids, usually where eyelash follicles are located DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002586/ 10005148 blepharitis AE HPO: HP_0000498 SIDER: C0005741 OAE:0000717 a blood albumin level abnormal AE with an outcome of a decrease in the amount of albumin, a protein made by the liver DJ, SS, YH, EB hypoalbuminemia AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003480.htm 10005287 blood albumin level decreased AE OAE:0000718 a liver related investigation result abnormal AE that has an outcome of an abnormal level of alkaline phosphatase in the blood DJ, SS, YH, EB 10059571 blood alkaline phosphatase level abnormal AE OAE:0000719 a blood alkaline phosphatase abnormal AE that has an outcome of a decreased level of alkaline phosphatase in the blood DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/alkaline+phosphatase 10059569 blood alkaline phosphatase decreased AE OAE:0000720 a blood alkaline phosphatase abnormal AE that has an outcome of elevated levels of alkaline phosphatase, an enzyme responsible for removing phosphate groups. a liver/biliary system AE that has an outcome of an increased amount of ALP, an isoenzyme that removes phosphate groups commonly found in the bile ducts but also found in the bone DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/alkaline+phosphatase 10001675 10059570 blood alkaline phosphatase increased AE CTCAE: E12082 HPO: HP_0003155 NCIt: C35607 SIDER: C0852911 OAE:0000721 a distal neuropathy AE which shows a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. It is caused by the loss of myelin sheath of the peripheral nerves. AG, YH CIDP Chronic Inflammatory Demyelinating Polyneuropathy WEB: http://www.ninds.nih.gov/disorders/cidp/cidp.htm chronic inflammatory demyelinating neuropathy AE OAE:0000722 a blood amylase level abnormal AE that has an outcome of an increased amount of amylase, an enzyme that helps digest carbohydrates; may indicate disease or inflammation of the pancreas DJ, SS, YH, EB serum amylase increased AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003464.htm 10005328 10040139 blood amylase level increased AE CTCAE: E12212 NCIt: C78608 OAE:0000723 a liver related investigation result abnormal AE that has an outcome of an abnormal amount of bilirubin in the blood DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/bilirubin 10058477 blood bilirubin level abnormal AE OAE:0000724 a blood bilirubin level abnormal AE with an outcome of a increased amount of bilirubin, or a yellow breakdown product (broken down hemoglobin) of normal heme catabolism, in the blood DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/bilirubin 10005364 blood bilirubin level increased AE CTCAE: E12096 NCIt: C27088 OAE:0000727 a blood cholesterol abnormal AE with the result of an increase in cholesterol level in the blood DJ, SS, YH, EB 10005425 blood cholesterol increased AE CTCAE: E12127 HPO: HP_0003124 NCIt: C37967 SIDER: C0595930 OAE:0000728 an enzyme investigation result abnormal AE that has an outcome of abnormal levels of creatine phosphokinase in the blood DJ, SS, YH, EB 10005468 blood creatine phosphokinase level abnormal AE OAE:0000729 a blood creatinine level abnormal AE that has an outcome of an increased level of creatinine in the blood (due to lack of kidney activity) DJ, SS, YH, EB creatinine increased AE serum creatinine increased WEB: http://medical-dictionary.thefreedictionary.com/creatinine 10005483 10011368 blood creatinine level increased AE CTCAE: E12137 NCIt: C78249 OAE:0000730 an infection adverse event that has an outcome of bacteria or yeasts in the blood DJ, SS, YH WEB: http://labtestsonline.org/understanding/analytes/blood-culture/tab/test 10005488 blood culture positive AE OAE:0000731 a hematopoietic system AE that has an outcome of disease in the blood, a living tissue made up of plasma and red blood cells, white blood cells and platelets. Blood disorders affect one or more parts of the blood and prevent the blood from doing this job. DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/blooddisorders.html 10061590 blood disorder AE OAE:0000732 a blood folate abnormal AE that has an outcome of a decreased level of folate in the blood DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/folate 10005527 blood folate level decreased AE OAE:0000733 a blood glucose level abnormal AE that has an outcome of a decrease of glucose levels in blood DJ, SS, YH, EB 10005555 blood glucose level decreased AE OAE:0000734 a blood glucose level abnormal AE that has an outcome of an increased glucose level in blood DJ, SS, YH, EB 10005557 blood glucose level increased AE OAE:0000735 a blood homocysteine level abnormal AE that has an outcome of an increased levels of homocysteine in the blood DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/homocysteine 10049733 blood homocysteine level increased AE OAE:0000736 an immunology and allergy investigation result abnormal AE that results in an increased immunoglobulin a level in the blood DJ, SS, YH, EB IgA level increased WEB: http://medical-dictionary.thefreedictionary.com/immunoglobulin+A 10005586 blood immunoglobulin A level increased AE OAE:0000737 a blood lactate dehydrogenase level abnormal AE that has an outcome of an increased amount of LDH, an enzyme that could indicate tissue damage DJ, SS, YH, EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003471.htm 10005630 blood lactate dehydrogenase level increased AE OAE:0000739 a blood parathyroid hormone level abnormal AE that has an outcome of a decrease in the level of parathyroid hormone in the blood DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/parathyroid+hormone 10005702 blood parathyroid hormone decreased AE OAE:0000742 a hypotension AE that has an outcome of a decrease in the amount of pressure in the arteries when the heart is at rest between beats DJ, SS, YH WEB: http://www.mayoclinic.com/health/low-blood-pressure/DS00590/DSECTION=causes 10005737 blood pressure diastolic decreased AE OAE:0000743 a hypotension AE that has an outcome of immeasurable blood pressure DJ, SS, YH 10005748 blood pressure immeasurable AE OAE:0000745 a blood thromboplastin level abnormal AE that has an outcome of an increase in the level of thromboplastin in the blood DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/thromboplastin 10005827 blood thromboplastin level increased AE OAE:0000746 a blood urea level abnormal AE with an outcome of a decreased amount of urea nitrogen in the blood, below 7 to 21 mg of urea per 100 ml DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/blood+urea+nitrogen 10005850 blood urea level decreased AE OAE:0000747 a blood urea level abnormal AE that results in an increase in amount of urea in blood DJ, SS, YH, EB 10005851 blood urea level increased AE OAE:0000748 a blood uric acid level abnormal AE that has an outcome of an increase in uric acid in the blood; excess purines may accumulate in tissues and form crystals DJ, SS, YH, EB WEB: http://chemocare.com/chemotherapy/side-effects/hyperuricemia-high-uric-acid.aspx 10005861 blood uric acid level increased AE OAE:0000749 a bone disorder AE that has an outcome of a cyst that forms on the bone DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/bone+cyst 10005952 bone cyst AE OAE:0000750 a bone disorder AE that has an outcome of surgery to clean and flush out the infected bone DJ, SS, YH WEB: http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Osteomyelitis 10057612 bone debridement AE OAE:0000751 a bone disorder AE that has an outcome of an anomlay in the growth or structure of a bone DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/20972590 10061728 bone lesion AE OAE:0000752 a bone marrow disorder AE that has an outcome of an abnormal condition in which the bone marrow is unable to produce normal amounts of red blood cells, white blood cells and platelets DJ, SS, YH, MW bone marrrow hypocellular hypocellular bone marrow WEB: http://en.diagnosispro.com/differential_diagnosis-for/bx-bone-marrow-biopsy-hypocellular/29777-154.html WEB: http://www.drugs.com/condition/bone-marrow-depression-low-blood-counts.html 10005986 10048580 Bone marrow produces three types of blood cells; red blood cells, white blood cells and platelets. Bone marrow depression is characterized by an inability or reduced ability of the bone marrow to produce these cells. A low blood count can involve just one or all three types of blood cells. bone marrow depression AE CTCAE: E10022 HPO: HP_0012145 NCIt: C35167 SIDER: C0151773 UMLS: C0151773 OAE:0000753 a hematopoietic system AE that has an outcome of disease in the bone marrow, the spongy tissue inside of some bones that contain stem cells that can develop into red blood cells, white blood cells or platelets DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/bonemarrowdiseases.html 10061729 bone marrow disorder AE OAE:0000754 a bone marrow disorder AE that has an outcome of an insufficient amount of red blood cells, white blood cells or platelets, associated with fanconii anemia, dyskeratosis congenita, and aplastic anemia DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23271412 10065553 bone marrow failure AE OAE:0000755 a bone marrow disorder AE that has an outcome of an excess formation of connective tissue in the bone marrow DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22246040 10069678 bone marrow reticulin fibrosis AE OAE:0000756 a bone marrow disorder AE that has an outcome of the decrease in cells responsible for providing immunity, carrying oxygen and blood clotting DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/12806941 10051779 bone marrow toxicity AE HPO: HP_0005561 SIDER: C0948168 OAE:0000757 a bone marrow disorder AE that has an outcome of the replacement of damaged bone marrow with healthy bone marrow stem cells DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003009.htm 10061730 bone marrow transplant AE OAE:0000758 a swelling AE that results in swelling around a bone DJ, SS, YH 10053631 bone swelling AE OAE:0000759 a skin adverse event that has an outcome of an early stage of squamous cell carcinoma DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/bowen's+disease 10006059 bowen's disease AE OAE:0000760 a bradycardia AE that results in a decreased heart rate in a neonate DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/10822186 10056471 bradycardia neonatal AE HPO: HP_0001662 SIDER: C1112488 OAE:0000761 an edema AE that has an outcome of edema or swelling of the extravascular compartment from uptake of water in the gray and white matter DJ, SS, YH brain oedema AE WEB: http://medical-dictionary.thefreedictionary.com/cerebral+edema 10048962 brain edema AE HPO: HP_0002181 SIDER: C1527311 OAE:0000762 a tumor AE that has an outcome of cancer in the breast DJ, SS, YH 10006187 breast cancer AE HPO: HP_0003002 SIDER: C0006142 OAE:0000763 a breast cancer AE that has an outcome of cancerous cells spreading to the breast DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001911/ 10055113 breast cancer metastatic AE OAE:0000764 a breast cancer AE that has an outcome of breast cancer at the stage III level DJ, SS, YH 10006201 breast cancer stage iii AE OAE:0000765 an infection AE that results in the breast becoming infected DJ, SS, YH 10006259 breast infection AE CTCAE: E11318 HPO: HP_0002726 NCIt: C53662 SIDER: C0392317 OAE:0000766 a pain AE that results in pain in the breast DJ, SS, YH, MW 10006298 breast pain AE CTCAE:E13073 HPO: HP_0000769 NCIt:C78223 SIDER: C0024902 OAE:0000767 a reproductive system AE that has an outcome of pain or discomfort in the breast, may be caused by small benign tumors DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21979747 10006313 breast tenderness AE HPO: HP_0100749 SIDER: C0262397 OAE:0000768 a pneumonia AE that has an outcome of acute inflammation of the walls of the smaller bronchial tubes, with irregular areas of consolidation due to spread of inflammation into peribronchiolar alveoli and the alveolar ducts of the lungs DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/bronchopneumonia 10006469 bronchopneumonia AE HPO: HP_0006538 SIDER: C0006285 OAE:0000769 an immune system disorder AE that has an outcome of an exaggerated response of the immune system to the fungus Aspergillus DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/bronchopulmonary+aspergillosis 10006473 bronchopulmonary aspergillosis AE HPO: HP_0002724 SIDER: C2350530 OAE:0000770 a lung disorder AE that has an outcome of a sudden constriction of the muscles in the walls of the bronchioles DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/bronchospasm 10006482 bronchospasm AE CTCAE:E13352 HPO: HP_0002099 NCIt:C34439 SIDER: C0006266 OAE:0000771 a sensory capability AE that results in a feeling of burning DJ, SS, YH 10006784 burning sensation AE OAE:0000772 a syndrom AE that has an outcome of a wasting syndrome characterized by weight loss, muscle atrophy, fatigue, and loss of appetite, often occurs with cancer. DJ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/Wasting+Syndrome Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23279159 10006895 cachexia AE HPO: HP_0004326 SIDER: C0006625 OAE:0000773 a digestive system AE that has an outcome of inflammation of the caecum, part of the large intestine DJ, SS, YH caecitis AE typhlitis AE WEB: http://medical-dictionary.thefreedictionary.com/caecitis 10006919 10045271 cecitis AE CTCAE: E11058 NCIt: C38043 OAE:0000774 an endocrine system AE that has an outcome of deficiency of calcium in the body DJ, SS, YH 10006956 calcium deficiency AE OAE:0000775 a cardiovascular disorder AE that has an outcome of self-reversing episodes during which the endothelial cells which line the capillaries are thought to separate for a few days, allowing for a leakage of fluid from the circulatory system to the interstitial space, resulting in hypotension, hemoconcentration, and hypoalbuminemia DJ, SS, YH, MW Clarkson's Disease AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/22873043 10007196 capillary leak syndrome AE CTCAE:E13766 NCIt:C62578 OAE:0000776 a cytogenetic investigation result abnormal AE that has an outcome of an increase in a type of protein typically associated with tumors and the developing fetus DJ, SS, YH, EB WEB: http://www.medicinenet.com/carcinoembryonic_antigen/article.htm 10007266 carcinoembryonic antigen increased AE OAE:0000777 a tumor AE that has an outcome of a carcinoid tumor that forms somewhere in the body DJ, SS, YH carcinoid tumour AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23307266 10007275 carcinoid tumor AE HPO: HP_0006723 SIDER: C0007095 OAE:0000778 a blood chloride abnormal AE with an outcome of decrease in amount of chloride ion in the blood, excessive loss may be due to sweating, vomiting and adrenal gland/kidney disease YH, MW WEB: https://en.wikipedia.org/wiki/Hypochloremia 10020957 hypochloremia AE HPO: HP_0003113 UMLS CUI: C0085680 OAE:0000779 a cardiovascular disorder AE that results in the inability of the heart to provide sufficient pump action to distribute blood flow to meet the needs of the body DJ, SS, YH heart failure WEB: http://medical-dictionary.thefreedictionary.com/cardiac+failure 10007554 10019279 cardiac failure AE CTCAE: E10124 HPO: HP_0001635 NCIt: C50577 SIDER: C0018801 OAE:0000780 a cardiovascular disorder AE that results in an inability of the heart to provide sufficient pump action to distribute blood flow to meet the needs of the body DJ, SS, YH congestive heart failure WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/congestive+heart+failure Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/21676684 10007559 cardiac failure congestive AE HPO: HP_0001635 SIDER: C0018802 OAE:0000782 a cardiac disorder AE that has an outcome of disease involving one or more of the valves of the heart DJ, SS, YH valvular disease AE WEB: http://medical-dictionary.thefreedictionary.com/valvular+heart+disease 10061406 cardiac valve disease AE HPO: HP_0001654 SIDER: C0018824 OAE:0000783 a cardiac disorder AE that has an outcome of a disorder involving the ventricle(s) in the heart DJ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/ventricular Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/15473469 10057455 cardiac ventricular disorder AE OAE:0000784 a hypotension AE that has an outcome of the inability of the heart to supply enough blood to the organs of the body because of heart damage DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001237/ 10007625 cardiogenic shock AE OAE:0000785 a cardiovascular disorder AE that has an outcome of deterioration of the function of the myocardium, usually leads to heart failure DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/cardiomyopathy WEB: https://en.wikipedia.org/wiki/Cardiomyopathy 10007636 cardiomyopathy AE HPO: HP_0001638 SIDER: C0878544 OAE:0000786 a cardiovascular disorder AE that has an outcome of heart electrophysiology dysfunction and/or muscle damage. Is not efficient at pumping/circulating blood DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/cardiomyopathy 10048610 cardiotoxicity AE OAE:0000787 a coronary artery disorder AE that results in lesion in carotid artery DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/8198401 10067116 carotid arteriosclerosis AE OAE:0000788 a musculoskeletal system AE that has an outcome of loss of muscle tone due to emotional responses like laughing and crying DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/cataplexy 10007737 cataplexy AE HPO: HP_0002524 SIDER: C0007384 OAE:0000789 a eye disorder AE that results in cloudiness that develops in the eye DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/cataract 10007739 cataract AE CTCAE: E10350 HPO: HP_0000518 NCIt: C26713 SIDER: C0086543 OAE:0000790 a sugery AE that has an adverse outcome related to the use of catheter, a thin tube inserted in the body DJ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/catheter Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23306712 10052253 catheter related complication AE OAE:0000791 an infection AE that has an outcome of an infection (e.g., bacterial colonisation) at the catheter site DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/8825104 10007810 10056520 catheter related infection AE CTCAE: E11328 HPO: HP_0002719 NCIt: C78232 SIDER: C0860239 OAE:0000792 a bacterial infection AE that is located at the catheter site DJ, SS, YH 10056520 catheter site infection AE OAE:0000793 a sugery AE that has an adverse outcome at the site where a catheter was used DJ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/catheter Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23074085 10007811 catheter site related reaction AE OAE:0000794 a cardiac disorder AE that has an outcome of a problem after inserting a catheter into the heart DJ, SS, YH catheterisation cardiac abnormal AE WEB: http://medical-dictionary.thefreedictionary.com/cardiac+catheterization 10007816 catheterization cardiac abnormal AE OAE:0000795 a behavior and neurological AE that has an outcome of an acute loss of function of the lumbar plexus DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23230403 10007821 cauda equina syndrome AE OAE:0000796 a bacterial infection AE that is located at the central-line catheter site DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/7580945 10054192 central line infection AE HPO: HP_0002719 SIDER: C1096243 OAE:0000797 an infection AE that is located in the central nervous system DJ, SS, YH 10061036 central nervous system infection AE HPO: HP_0005381 SIDER: C0007684 OAE:0000798 a tumor AE that has an outcome of lymphoma in the central nervous system DJ, SS, YH 10007953 central nervous system lymphoma AE OAE:0000799 an ataxia AE that is located in the cerebellum DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23283615 10008025 cerebellar ataxia AE HPO: HP_0001251 SIDER: C0007758 OAE:0000800 a brain disorder AE that has an outcome of an inherited brain disorder that affects muscle coordination, may involve the tendency for limb movements to overshoot or undershoot a target, tremors and impaired rhythm DJ, SS, YH WEB: http://www.rightdiagnosis.com/medical/cerebellar_syndrome.htm 10008072 cerebellar syndrome AE HPO: HP_0001317 SIDER: C0007760 OAE:0000801 a brain disorder AE with the outcome of hemorrhage or blood in the brain DJ, SS, YH cerebral haemorrhage AE 10008111 cerebral hemorrhage AE HPO: HP_0001342 SIDER: C2937358 OAE:0000802 a brain disorder AE that results in the sudden death of brain cells in a localized area due to inadequate blood flow DJ, SS, YH cerebral ischaemia AE ischemic stroke AE WEB: http://medical-dictionary.thefreedictionary.com/Cerebral+ischaemia 10008120 cerebral ischemia AE HPO: HP_0002637 SIDER: C0917798 OAE:0000803 a nervous system AE that has an outcome of pain or another sensation in the patient's neck and shoulder region DJ, SS, YH WEB: http://www.mdguidelines.com/cervicobrachial-syndrome/definition 10008334 cervicobrachial syndrome AE OAE:0000804 a skin AE that has an outcome of dry lips caused by the evaporation of moisture. DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/9433089 10049047 chapped lips AE OAE:0000805 an inflammation AE that occurs in the lip DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/cheilitis 10008417 cheilitis AE CTCAE: E10517 HPO: HP_0100825 NCIt: C79545 SIDER: C0007971 OAE:0000806 a skin AE that has an outcome of a burn due to chemicals on the skin DJ, SS, YH 10057941 chemical burn of skin AE OAE:0000807 a discomfort AE that has an outcome of pain in the chest DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/chest+pain 10008469 chest discomfort AE HPO: HP_0001681 SIDER: C0235710 OAE:0000808 alcohol cardiomyopathy AE OAE:0000809 a progressive tumor AE that has an outcome of multiple, malignant, localized green masses of abnormal cells, usually myeloblasts, especially beneath the periosteum of the skull, spine and ribs DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/chloroma 10008583 chloroma AE OAE:0000810 a digestive system AE that has an outcome of infection in the common bile duct, usually by bacterial infection DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001335/ 10008604 cholangitis AE HPO: HP_0011040 SIDER: NA OAE:0000811 a liver/biliary system AE that has an outcome of a condition in which the flow of bile from the liver is slowed or blocked DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001263/ 10008635 cholestasis AE HPO: HP_0001396 SIDER: C0008370 OAE:0000812 an adverse event that has an outcome of calcium crystals of calcium pyrophosphate dihydrate accumulated in the connective tissues of the patient DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/chondrocalcinosis 10008690 chondrocalcinosis pyrophosphate AE OAE:0000813 a cytogenetic investigation result abnormal AE that has an outcome of an abnormal chromosome pattern DJ, SS, YH, EB WEB: http://www.miscarriageclinic.co.uk/causes-and-treatments/chromosome-abnormality/ 10008817 chromosome analysis abnormal AE OAE:0000814 a peripheral neuropathy AE which has an outcome of a chemotherapy-induced neuropathy that affects nerves of the peripheral nervous system (PNS) AG, YH CIPN WEB: http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/chemotherapyeffects/peripheralneuropathy/peripheral-neuropathy-caused-by-chemotherapy-what-is-cipn chemotherapy-induced peripheral neuropathy AE OAE:0000815 a hematopoietic system AE that has an outcome of cancer of the white blood cells characterized by increased and unregulated growth of myeloid cells in the bone marrow DJ, SS, YH chronic myeloid leukaemia AE WEB: http://medical-dictionary.thefreedictionary.com/chronic+myelogenous+leukemia 10009013 chronic myeloid leukemia AE HPO: HP_0005506 SIDER: C0023473 OAE:0000816 a hematopoietic system AE that has an outcome of cancer of the white blood cells characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. May transform from chronic myeloid leukaemia to acute myeloid leukaemia DJ, SS, YH chronic myeloid leukaemia transformation AE WEB: http://www.jci.org/articles/view/41246 10068232 chronic myeloid leukemia transformation AE OAE:0000817 a lung disorder AE that has an outcome of breathing difficulty with two main forms: chronic bronchitis and emphysema DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001153/ 10009033 chronic obstructive pulmonary disease AE HPO: HP_0006510 SIDER: C0024117 OAE:0000818 a respiratory system AE that results in inadequate gas exchange by the respiratory system DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/respiratory+failure 10009126 chronic respiratory failure AE OAE:0000819 a respiratory system AE that has an outcome of inflammation in the cavities around the nasal passages DJ, SS, YH WEB: http://www.mayoclinic.com/health/chronic-sinusitis/DS00232 10009137 chronic sinusitis AE OAE:0000820 a lung disorder AE that has an outcome of lymphatic fluid accumulating in the pleural cavity, the space between two pleura of the lungs DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/chylothorax 10051228 chylothorax AE CTCAE:E13358 NCIt:C79546 OAE:0000821 a cardiovascular disorder AE that has an outcome of insufficient circulation without congestive heart failure DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/circulatory+collapse 10009192 circulatory collapse AE OAE:0000822 a bacterial infection AE that has an outcome of invasion by anaerobic bacteria of the genus Clostridium, can cause tetanus and botulism DJ, SS, YH WEB: http://www.medicinenet.com/clostridium_difficile_colitis/page2.htm 10061043 clostridial infection AE HPO: HP_0004798 SIDER: C0009062 OAE:0000823 a digestive system AE that has an outcome of bacterial infection by clostridium difficile colitis, commonly results in diarrhea and colitis DJ, SS, YH 10009657 clostridium difficile colitis AE HPO: HP_0002583 SIDER: C0238106 OAE:0000824 a coagulation factor v level abnormal AE that has an outcome of a decreased level of the factor V protein in the coagulation system of the body DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/22781721 10009754 coagulation factor v level decreased AE OAE:0000825 an inflammation AE that occurs at the large intestine DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002112/ 10009887 colitis AE CTCAE: E10521 HPO: HP_0002583 NCIt: C26723 SIDER: C0009319 OAE:0000826 a lung disorder AE that has an outcome of a collapsed lung, refering to the space between the wall of the chest cavity and the lung filling with air, causing all or a portion of the lung to collapse DJ, SS, YH Pneumothorax 10009913 collapse of lung AE OAE:0000827 a tumor AE that has an outcome of cancer that starts in the large intestine or the rectum DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001308/ 10009944 colon cancer AE HPO: HP_0003003 SIDER: C0007102 OAE:0000828 a colon AE that has an outcome of cancerous cells spreading to the colon DJ, SS, YH WEB: http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic 10055114 colon cancer metastatic AE OAE:0000829 a colon cancer AE that has an outcome of colon cancer at stage IV DJ, SS, YH 10009956 colon cancer stage iv AE OAE:0000830 a digestive system AE that has an outcome of cancer that starts in the large intestine or rectum. DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001308/ 10061451 colorectal cancer AE HPO: HP_0003003 SIDER: C1527249 OAE:0000831 a digestive system AE that has an outcome of cancer in the large intestine and the rectum. When metastatic, the cancer has already spead to distant sites and is considered stage IV. DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22642873 10052358 colorectal cancer metastatic AE HPO: HP_0003003 SIDER: C0948380 OAE:0000832 an imaging investigation result abnormal AE that has an abnormal result of an imaging method in which a cross-sectional image of the structures in a body plane is reconstructed by a computer program from the x-ray absorption of beams projected through the body in the image plane DJ, SS, YH, EB computerised tomogram abnormal AE WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/computerized+tomography , Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23271098 WEB: http://medical-dictionary.thefreedictionary.com/computed+tomography 10010235 computerized tomography result abnormal AE OAE:0000833 an adverse event that has an outcome of progression of underlying conditions that may affect drug distribution or metabolism DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Concomitant+disease 10048659 concomitant disease progression AE OAE:0000834 an adverse event that has an outcome of condition that worsens DJ, SS, YH 10010264 condition aggravated AE OAE:0000835 a congenital abnormality AE that has an outcome of an abnormality in heart which is present at birth DJ, SS, YH WEB: http://www.thefreedictionary.com/congenital+heart+defect 10061054 congenital cardiovascular anomaly AE HPO: HP_0001626 SIDER: C0243050 OAE:0000836 a cardiomyopathy AE that is characterized by the walls of the heart chambers stretching to hold a greater volume of blood than normal DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/congestive+cardiomyopathy 10056370 congestive cardiomyopathy AE HPO: HP_0001635 SIDER: C0007193 OAE:0000837 an eye disorder AE that has an outcome of a problem involving the insides of the patient's eyelids DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/conjunctiva 10061446 conjunctival disorder AE HPO: HP_0000502 SIDER: C0009759 OAE:0000838 a hemorrhage AE that has an outcome of a bright hemorrhagic patch on the bulbar conjunctiva caused by rupture and bleeding of a superficial small capillary due to increased pressure DJ, SS, YH conjunctival haemorrhage AE 10010719 conjunctival hemorrhage AE HPO: HP_0007902 SIDER: C0009760 OAE:0000839 an adverse event that has an outcome of disease in the biological tissue that supports, binds together and protects organs DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/connective+tissue+disease 10061087 connective tissue disorder AE HPO: HP_0003549 SIDER: C0009782 OAE:0000840 an eye disorder AE that has a result of the inability to use contact lenses DJ, SS, YH 10010804 contact lens intolerance AE OAE:0000841 a hematology investigation result abnormal AE that has an outcome of a positive coombs test, which is a blood test that identifies the causes of anemia DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/Coombs'+Tests WEB: http://medical-dictionary.thefreedictionary.com/test 10061090 coombs' test positive AE OAE:0000842 a behavior and neurological AE that results in a loss of coordination DJ, SS, YH 10010947 coordination abnormal AE HPO: HP_0011443 SIDER: C0520966 OAE:0000844 a coronary artery disorder AE that has an outcome of an blockage in the coronary artery DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22953315 10011084 coronary artery embolism AE OAE:0000845 a coronary artery disorder AE that has an outcome of an insufficient amount of blood circulates through the coronary arteries DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/coronary+insufficiency 10052895 coronary artery insufficiency AE HPO: HP_0001677 SIDER: C0542052 OAE:0000846 a tumor AE that has an outcome of a brain tumor derived from the embryonic tissue of the pituitary gland DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/craniopharyngioma 10011318 craniopharyngioma AE OAE:0000847 a c-reactive protein level abnormal AE that has an outcome of an increased amount of CRP, a protein that measure general levels of inflammation in the body DJ, SS, YH, EB WEB: http://www.webmd.com/a-to-z-guides/c-reactive-protein-crp moved "c-reactive protein increased AE" from "cardiac AE" to "lab test abnormal AE" EB 10006825 c-reactive protein level increased AE OAE:0000848 viral cardiomyopathy AE OAE:0000849 a nervous system AE that has an outcome of increased pressure in the skull DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/intracranial+pressure 10011570 csf pressure increased AE OAE:0000850 a urine analysis result abnormal AE that has an outcome of high bacterial colonization counts in the urine DJ, SS, YH, EB WEB: http://labtestsonline.org/understanding/analytes/urine-culture/tab/test 10011640 culture urine positive AE OAE:0000851 an inflammation AE that has an outcome of inflamed blood vessels in the skin DJ, SS, YH WEB: http://dermnetnz.org/vascular/vasculitis.html 皮肤血管炎 10011686 cutaneous vasculitis AE HPO: HP_0200029 SIDER: C0262988 OAE:0000852 a urinary system AE that has an outcome of cystitis with severe hemorrhage, a dose-limiting toxic condition with administration of ifosfamide and cyclophosphamide or a complication of bone marrow transplantation DJ, SS, YH cystitis haemorrhagic AE WEB: http://medical-dictionary.thefreedictionary.com/hemorrhagic+cystitis 10011793 cystitis hemorrhagic AE OAE:0000853 a genetic disorder AE that has an outcome of an atypical number of chromosomes or a structural abnormality in one or more chromosomes DJ, SS, YH 10067477 cytogenetic abnormality AE OAE:0000854 an inflammation AE that has an outcome of release of cytokines by T cells that causes inflammation DJ, SS, YH WEB: http://encyclopedia.thefreedictionary.com/cytokine+release+syndrome 10052015 cytokine release syndrome AE CTCAE: E11264 NCIt: C78251 OAE:0000855 a liver/biliary system AE that has an outcome of liver cells carrying excess water, causing inflammation along with hepatitis DJ, SS, YH WEB: http://www.thirdage.com/hc/c/q/hepatitis/1550008/what-is-cytolytic-hepatitis 10050904 cytolytic hepatitis AE HPO: HP_0004787 SIDER: C0919823 OAE:0000856 an inflammation AE that results in the inflammation of the colon DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22874621 10048983 cytomegalovirus colitis AE OAE:0000857 a viral infection AE that is caused by cytomegalovirus DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/cytomegalovirusinfections.html 10011831 cytomegalovirus infection AE HPO: HP_0004429 SIDER: C0010823 OAE:0000858 a skin AE that has an outcome of shedding of the dead skin cells from the scalp DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/dandruff 10011859 dandruff AE HPO: HP_0001051 SIDER: C0221244 OAE:0000860 a skin ulcer AE that has an outcome of localized injuries to the skin and/or underlying tissue usually over a bony prominence as a result of pressure DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/pressure+ulcer 10011985 decubitus ulcer AE HPO: HP_0200042 SIDER: C0011127 OAE:0000861 a venous thrombosis that is characterized by a blood clot that forms in a vein deep in the body. Blood clots occur when blood thickens and clumps together. Most deep vein blood clots occur in the lower leg or thigh. They also can occur in other parts of the body. DJ, SS, YH DVT WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/dvt/ Moved from Cardiac AE to thombosis AE by LB 10051055 deep vein thrombosis AE HPO: HP_0004850 SIDER: C0149871 OAE:0000862 a psychiatric disorder AE that results in a decline in level of cognitive function DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/delirium 10012218 delirium AE CTCAE:E12898 NCIt:C2981 OAE:0000863 a tooth disorder AE that has an outcome of bacterial infection that causes demineralization and destruction of the hard tissues, resulting in dental cavities DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/dental+caries 10012318 dental caries AE CTCAE: E10568 HPO: HP_0000670 NCIt: C52593 SIDER: C0011334 OAE:0000864 a sensory capability AE that results in a lower level of arousal than normal DJ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmed/23167919 10012373 depressed level of consciousness AE CTCAE:E12625 HPO: HP_0004372 NCIt:C78253 SIDER: C0549249 OAE:0000865 a dermatitis ae that is characterized by the eruption of papules and pustules, typically on the face, scalp, upper chest and back. DJ, SS, YH WEB: https://www.medify.com/conditions/acneiform-dermatitis 10012432 dermatitis acneiform AE HPO: HP_0001051 SIDER: C0234894 OAE:0000866 a dermatitis ae that is characterized by an inflammatory skin disease with erythmea and scaling, that has an outcome of widespread scaling of the skin, often with itching, skin redness and hair loss DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001610.htm 10012455 dermatitis exfoliative AE HPO: HP_0011123 SIDER: C0011606 OAE:0000867 a muscle AE that has an outcome of muscle weakness, inflammation, skin rash and difficulty swallowing DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001842/ 10012503 dermatomyositis AE OAE:0000868 a motor neuropathy AE that has an outcome of poor coordination DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001533.htm 10012557 developmental coordination disorder AE OAE:0000869 an injury and procedural complication AE that results in the dislocation of a device DJ, SS, YH 10064684 device dislocation AE OAE:0000870 an injury and procedural complication AE that results in the expulsion (vomiting) of medical device from body DJ, SS, YH 10012578 device expulsion AE OAE:0000871 an injury and procedural complication AE that results in an infection related to medical device DJ, SS, YH 10064687 device related infection AE CTCAE: E11356 HPO: HP_0002719 NCIt: C79705 SIDER: C1619702 OAE:0000872 a coma AE which is induced by the condition that the patient has extremely high levels of sugar in the blood without ketones DJ, SS, YH diabetic hyperglycaemic coma AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000304.htm 10012668 diabetic hyperglycemic coma AE OAE:0000873 a respiratory system AE that has an outcome of an abnormal hole in the diaphragm DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23288807 10012713 diaphragmatic hernia AE HPO: HP_0000776 SIDER: C0019284 OAE:0000874 a paralysis AE that has an outcome of a paralyzed diaphragm DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/19452391 10012725 diaphragmatic paralysis AE OAE:0000875 a diarrhea AE that has an outcome of rectal bleeding and bloody diarrhea DJ, SS, YH diarrhoea haemorrhagic AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/19292138 10012741 diarrhea hemorrhagic AE HPO: HP_0002255 SIDER: C0151594 OAE:0000876 a diarrhea AE that has an outcome of diarrhea is caused by infection DJ, SS, YH diarrhoea infectious AE 10012742 diarrhea infectious AE OAE:0000877 a cardiac disorder AE with an outcome of decline in performance of one or both ventricles of the heart during the time phase of diastole, when heart filling with incoming blood DJ, SS, YH WEB: http://encyclopedia.thefreedictionary.com/diastolic+dysfunction 10052337 diastolic dysfunction AE OAE:0000878 a cardiac ventricular disorder AE that has an outcome of enlargement of a heart chamber that pumps blood away from the heart DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1721391/ 10013012 dilatation ventricular AE OAE:0000879 an adverse event with an outcome of worsening of the disease DJ, SS, YH 10061818 disease progression AE HPO: HP_0004738 SIDER: C0242656 OAE:0000880 a bone disorder AE that has an outcome of dislocation of vertebra DJ, SS, YH 10013183 dislocation of vertebra AE OAE:0000881 a sensory capability AE that results in the senses of time, direction, and recognition of people and places becoming difficult to distinguish DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/disorientation 10013395 disorientation AE HPO: HP_0001289 SIDER: C0233407 OAE:0000882 a hematopoietic system AE with an outcome of a serious disorder in which proteins that control blood clotting become abnormally active DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000573.htm 10013442 disseminated intravascular coagulation AE CTCAE: E10028 HPO: HP_0005521 NCIt: C2992 SIDER: C0012739 OAE:0000883 a behavior and neurological AE that results in a loss of attention DJ, SS, YH 10013496 disturbance in attention AE HPO: HP_0007018 SIDER: C0233414 OAE:0000884 a digestive system AE with an outcome of perforation of small sacs or pockets in the wall of the colon DJ, SS, YH WEB: http://www.webmd.com/digestive-disorders/diverticular-disease 10061820 diverticular perforation AE OAE:0000885 a digestive system AE that has an outcome of infection and inflammation in the small, bulging sacs or pouches of the inner lining of the intestine DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001303/ 10013538 diverticulitis AE HPO: HP_0002253 SIDER: C0012813 OAE:0000886 a hemorrhage AE that has an outcome of bleeding in the intestine due to diverticulitis DJ, SS, YH diverticulitis intestinal haemorrhagic AE WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780263/ 10013541 diverticulitis intestinal hemorrhagic AE OAE:0000887 an adverse event that has an outcome of a decreased amount of the drug excreted by the body DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/drug+clearance 10049463 drug clearance decreased AE OAE:0000888 an adverse drug event that results in the development of a dependence on the drug DJ, SS, YH 10013663 drug dependence AE HPO: HP_0000722 SIDER: C1510472 OAE:0000889 a skin AE that has an outcome of a range of adverse drugs reactions of the skin, most commonly rashes resembling measles DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/drug+eruption 10013687 drug eruption AE OAE:0000890 a hypersensitivity AE that has an outcome of allergic reactions to certain drugs DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23192511 10013700 drug hypersensitivity AE HPO: HP_0100326 SIDER: C0013182 OAE:0000891 a drug AE that has an outcome of lower threshold to the normal pharmacologic action of a drug DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/drug+intolerance 10061822 drug intolerance AE OAE:0000892 a headache AE that has an outcome of headaches due to drug withdrawal DJ, SS, YH 10013753 drug withdrawal headache AE OAE:0000893 an adverse event that results in symptoms that occur after the discontinuation of the use of a certain drug DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/withdrawal 10013754 drug withdrawal syndrome AE OAE:0000894 a skin AE that is characterized by epidermis that lacks moisture, has an outcome of fine lines, scaling and itching DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/dry+skin 10013786 dry skin AE CTCAE:E13623 HPO: HP_0000958 NCIt:C74592 SIDER: C0151908 OAE:0000895 a duodenum AE that has an outcome of a peptic ulcer, or a defect in the lining of the stomach or the first part of the small intestine, located in the duodenum DJ, SS, YH peptic ulcer AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ 10013836 duodenal ulcer AE CTCAE: E10611 HPO: HP_0002588 NCIt: C26755 SIDER: C0013295 OAE:0000896 a duodenal ulcer AE with an outcome of bleeding in an ulcer, or a defect, in the lining of the stomach or first part of the small intestine called the duodenum DJ, SS, YH duodenal ulcer haemorrhage AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ 10013839 duodenal ulcer hemorrhage AE HPO: HP_0002588 SIDER: C0151966 OAE:0000897 a duodenal ulcer AE that has an outcome of perforation, or complete penetration, of an ulcer located in an area of the small intestine called the duodenum DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ 10013849 duodenal ulcer perforation AE HPO: HP_0002588 SIDER: C0740401 OAE:0000898 a speech disorder that results in a motor speech disorder DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/dysarthria 10013887 dysarthria AE CTCAE:E12635 HPO: HP_0001260 NCIt:C79549 SIDER: C0013362 OAE:0000899 a behavioral and neurological AE that results in difficulty reading (mixing up letters) DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/dyslexia 10013932 dyslexia AE HPO: HP_0010522 SIDER: C0476254 OAE:0000900 a speech disorder AE that results in disorders of voice DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/dysphonia 10013952 dysphonia AE HPO: HP_0001618 SIDER: C1527344 OAE:0000901 a dyspnoea AE that has an outcome of shortness of breath during exercise, produces a sensation of not being able to get enough air DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22760109 10013971 dyspnoea exertional AE HPO: HP_0002875 SIDER: C0231807 OAE:0000902 Dysuria AE is an urinary system AE that results in painful urination JX, DJ, SS, YH urination disorders AE WEB: http://medical-dictionary.thefreedictionary.com/dysuria 排尿困难 10013990 dysuria AE HPO: HP_0100518 SIDER: C0013428 OAE:0000903 a gustatory system AE which has an outcome of abrnormal or disturbed eating habits DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/eating+disorder 10014062 eating disorder AE OAE:0000904 a female reproductive system AE that results in an ectopic pregnancy that occurs along with the use of an IUD DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/ectopic+pregnancy 10067037 ectopic pregnancy with intrauterine device AE OAE:0000905 a skin AE that has an outcome of a long term skin disorder that involves scaly and itchy rashes DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001856/ 10014184 eczema AE HPO: HP_0000964 SIDER: C0013595 OAE:0000906 an abnormal fluid regulation AE that has an outcome of escape of a fluid into a part DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/effusion 10063045 effusion AE OAE:0000907 a male reproductive system AE that has an outcome of a delay of ejaculation DJ, SS, YH 10014325 ejaculation delayed AE HPO: HP_0000022 SIDER: NA OAE:0000908 a left ventricular dysfunction AE that has an outcome of decreased percentage of blood leaving the heart each time it contracts DJ, SS, YH WEB: http://www.mayoclinic.com/health/ejection-fraction/AN00360 10050528 ejection fraction decreased AE CTCAE: E12142 NCIt: C83492 OAE:0000909 a cardiac function test abnormal AE that has an outcome of abnormal electrical activity in the heart DJ, SS, YH, EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003868.htm 10014363 electrocardiogram result abnormal AE OAE:0000910 an electrocardiogram result abnormal AE that has an outcome of an abnormal depolarization of the right and left ventricles of the heart that is detected on an electrocardiogram test DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/23238367 10014378 electrocardiogram qrs complex abnormal AE OAE:0000911 an electrocardiogram result abnormal AE that has an outcome of a prolonged time between the start of the Q wave and the end of the T wave in the heart's electrical cycle; a biomarker for ventricular tachyarrhythmias DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/23275261 10014387 electrocardiogram qt prolonged AE HPO: HP_0001657 SIDER: C0151878 OAE:0000912 an electrocardiogram result abnormal AE in which the T wave appears increased in amplitude and cresting at a point DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/23301064; http://www.medaphile.com/medical-dictionary/t-wave-peaked 10014396 electrocardiogram t wave peaked AE OAE:0000913 a homeostasis AE that has an outcome of abnormalities in electrolytes (sodium, potassium, calcium) DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/electrolyte+imbalance 10014418 electrolyte imbalance AE HPO: HP_0003111 SIDER: C0342579 OAE:0000914 a psychiatric disorder AE that results in an abnormal expression of emotions DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/emotional+disorder 10014551 emotional disorder AE HPO: HP_0100851 SIDER: C0233459 OAE:0000915 an inflammation AE that occurs in the inside lining of the heart chambers and heart valves DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002088/ 10014665 endocarditis AE HPO: HP_0100584 SIDER: C0014118 OAE:0000916 a digestive system AE with an outcome of inflammation in the intestine, especially the small intestine DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/enteritis 10014866 enteritis AE HPO: HP_0004387 SIDER: C0014335 OAE:0000917 a digestive system AE that has an outcome of disease in the digestive tract caused by infection DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/enterocolitis 10014893 enterocolitis AE CTCAE: E10627 HPO: HP_0004387 NCIt: C79573 SIDER: C0014356 OAE:0000918 an digestive system AE that has an outcome of an infection by enteric viruses or enterotoxigenic bacterias, usually in the intestines, that presents with diarrhea, abdominal pain, perianal discomfort, incontinence and hemorrhage. DJ, SS, YH WEB: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-0792-2..50022-5--cesec139&isbn=978-1-4377-0792-2&type=bookPage&from=content&uniqId=376758653-2 10058838 enterocolitis infectious AE OAE:0000919 an eosinophil count abnormal AE that has an outcome of an increased amount of eosinophils, a type of white blood cell that becomes active with allergic diseases and infections DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003649.htm 10014945 eosinophil count increased AE HPO: HP_0001880 SIDER: C2240374 OAE:0000920 a hematopoietic system AE that has an outcome of higher than normal levels of eosinophils, a type of white blood cell DJ, SS, YH WEB: http://www.mayoclinic.com/health/eosinophilia/MY00399 10014950 eosinophilia AE HPO: HP_0001880 SIDER: C0014457 OAE:0000921 a male reproductive system AE that results in the inability to develop/maintain an erection of penis DJ, SS, JX, LW, YH, MW astyphia AE impotence AE WEB: http://en.wikipedia.org/wiki/Erectile_dysfunction 阳痿/勃起功能障碍 10061461 erectile dysfunction AE CTCAE:E13088 HPO: HP_0008652 NCIt:C3133 SIDER: C0242350 OAE:0000922 a skin AE that has an outcome of an infection caused by a Streptococcus bacteria that causes blisters, fever and skin lesion and sores DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001643/ 10015145 erysipelas AE HPO: HP_0001055 SIDER: C0014733 OAE:0000923 a psoriasis AE that has an outcome of psoriasis that affects all sites on the body DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/psoriatic+erythroderma 10015278 erythrodermic psoriasis AE OAE:0000924 a bacterial infection AE with an outcome of invasion by Escherichia coli bacteria, commonly found in the lower intestine and can cause serious food poisoning, but can also be found in various parts of body DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/escherichia+coli 10061126 escherichia infection AE OAE:0000925 a microbiology and serology investigation result abnormal AE that has an outcome of a positive escherichia test DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/Escherichia 10070090 escherichia test positive AE OAE:0000926 an urinary tract infection AE that has an outcome of infection caused by E. coli bacteria DJ, SS, YH WEB: http://www.medicinenet.com/urine_infection/article.htm 10052238 escherichia urinary tract infection AE OAE:0000927 a connective tissue AE that has an outcome of excess perfused, fibrous connective tissue that replaces a fibrin clot in healing wounds. DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/19594571 10063560 excessive granulation tissue AE OAE:0000928 a rash AE that has an outcome of erythema, desquamation, scaling, itching of the skin and loss of hair DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/exfoliative+dermatitis 10064579 exfoliative rash AE OAE:0000929 a congenital abnormality that results in a weakness of the baby's abdominal wall where the umbilical cord joins it. This weakness allows the abdominal contents to protrude outside the abdominal cavity DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/exomphalos 10015677 exomphalos AE HPO: HP_0001539 SIDER: C1306503 OAE:0000930 an injury and procedural complication AE that results in the patient being exposed to a contaminated device DJ, SS, YH 10068515 exposure to contaminated device AE OAE:0000931 a procedural complication AE that results in the patient being exposed to a toxic agent DJ, SS, YH 10053487 exposure to toxic agent AE OAE:0000932 an abscess AE that results in a collection of pus between a person's skull and dura DJ, SS, YH WEB: http://www.meb.uni-bonn.de/dtc/primsurg/docbook/html/x1217.html 10061846 extradural abscess AE OAE:0000933 a paresis AE that results in a partial loss of voluntary movement in their extraocular muscles DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22824489 10015829 extraocular muscle paresis AE CTCAE: E10367 NCIt: C78286 OAE:0000934 coagulopathy AE results in the impairment of blood to clot causing ecessive or prolonged bleeding. SJ, YH bleeding disorder clotting disorder WEB: http://en.wikipedia.org/wiki/Coagulopathy 10009802 coagulopathy AE OAE:0000935 a hemorrhage AE that has an outcome of hemorrhage occuring in the blood vessels in the eye DJ, SS, YH eye haemorrhage AE subconjunctival haemorrhage AE WEB: http://www.webmd.com/eye-health/bleeding-in-the-eye 10015926 eye hemorrhage AE HPO: HP_0011885 SIDER: C0015402 OAE:0000936 a eye disorder AE that has an outcome of swelling in the tissues around the eyes, called the orbits, caused by fluid buildup DJ, SS, YH perioribtal puffiness AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/21115963 10015967 eye swelling AE OAE:0000937 an eye edema AE that has an outcome of swelling in either or both the lower and upper eyelids, due to fluid buildup or inflammation in the delicate tissues surrounding the eye. DJ, SS, YH eyelid oedema AE WEB: http://www.localhealth.com/article/eyelid-swelling 10015993 eyelid edema AE HPO: HP_0100539 SIDER: C0162285 OAE:0000938 A pregnancy, neonatal and perinatal AE that displays the result of failure to thrive (FTT), which refers to a baby or child that is not developing as well as desired. DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000991.htm WEB: http://www.stanfordchildrens.org/en/topic/default?id=failure-to-thrive-90-P02297 10016165 failure to thrive AE HPO: HP_0001531 SIDER: C0015544 OAE:0000939 a behavior and neurological AE that has an outcome of patient falling DJ, SS, YH 10016173 fall AE CTCAE: E11687 HPO: HP_0002359 NCIt: C50558 SIDER: C0085639 OAE:0000940 a behavior and neurological AE that results in the extreme fear of needles DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23225704 10068298 fear of needles AE OAE:0000941 a hematopoietic system AE that has an outcome of inadequate blood cell formation by bone marrow accompanied by a fever DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Bone+marrow+aplasia 10053213 febrile bone marrow aplasia AE OAE:0000942 a fever AE that has an outcome of an infection along/because of a fever DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/febrile 10051998 febrile infection AE OAE:0000943 a neutropenia AE, generally a complication of chemotherapy, that has an outcome of an abnormally low neutrophil granulocyte count, accompanied by fever DJ, SS, YH neutropenic sepsis AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23303687 10016288 febrile neutropenia AE CTCAE: E10033 HPO: HP_0001875 NCIt: C35665 SIDER: C0746883 OAE:0000944 an injury and procedural complication AE that has an outcome of an complication due to the use of enteral feeding tube DJ, SS, YH enteral feeding AE WEB: http://www.thirdage.com/hc/p/197842/what-is-tube-feeding 10056661 feeding tube complication AE OAE:0000945 a sensory capabilty AE that results in the patient feeling different than normal after a medical intervention such as taking drug DJ, SS, YH 10016322 feeling abnormal AE HPO: HP_0010870 SIDER: C1443060 OAE:0000946 Feeling hot AE is a feeling abnormal AE that a patient feels hot. DJ, SS, YH 10016334 feeling hot AE OAE:0000947 a hypoaesthesia AE that has an outcome of a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli in the oral area SS, YH hypoaesthesia oral AE WEB: http://en.wikipedia.org/wiki/Hypoesthesia 10057371 hypoesthesia oral AE HPO: HP_0010830 SIDER: C0521592 OAE:0000948 a fistula AE that has an outcome of discharge that occurs as the result of the connection between two body cavities DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed?term=fistula%20discharge%20%5BTI%5D 10067143 fistula discharge AE OAE:0000949 an abnormal fluid regulation AE with an outcome of decrease in ingestion of water or other fluids DJ, SS, YH 10056291 fluid intake reduced AE OAE:0000950 a hematopoietic system AE that has an outcome of too much fluid in the blood, can occur due to increase in total body sodium DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22827112 10016803 fluid overload AE OAE:0000951 a hyperplasia AE that has an outcome of a benign tumor in the liver DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/focal+nodular+hyperplasia 10052285 focal nodular hyperplasia AE OAE:0000952 a congenital abnormality disorder AE that has an outcome of a decreased heart rate in a fetus DJ, SS, YH foetal heart rate deceleration AE 10058322 fetal heart rate deceleration AE OAE:0000953 a skin AE with the outcome disease involving of one more more hair follicles, commonly displays rash, itching and pustules near the hair follicles DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001826/ 10016936 folliculitis AE OAE:0000954 a respiratory system AE that has an outcome of a decreased volume of air expired from the lungs DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/forced+expiratory+volume 10016987 forced expiratory volume decreased AE CTCAE: E12156 NCIt: C50524 OAE:0000955 a bone disorder AE that has an outcome of fracture located in the arm DJ, SS, YH 10016997 forearm fracture AE OAE:0000956 a bone disorder AE that has an outcome of complete or incomplete break in a bone resulting from the application of excessive force DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Fractures 10017076 fracture AE CTCAE: E11703 NCIt: C3046 OAE:0000957 a full blood count abnormal AE that has an outcome of a decrease in full blood cell count DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/full+blood+count 10017413 full blood count decreased AE OAE:0000958 a digestive system AE that has an outcome of inflammation in the esophagus due to fungus DJ, SS, YH fungal oesophagitis AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002138/ 10049656 fungal esophagitis AE OAE:0000959 a digestive system AE that has an outcome of an abnormal enlargement in the size of the gallbladder DJ, SS, YH 10062693 gallbladder enlargement AE OAE:0000960 a digestive system AE that has an outcome of an abnormal hole in the patient's gallbladder DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/gallbladder+perforation 10017639 gallbladder perforation AE CTCAE: E11208 NCIt: C78309 OAE:0000961 a digestive system AE that has an outcome of an abnormal growth (accumulation of mucous membrane tissue) in the gallbladder DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/19556839 10049704 gallbladder polyp AE OAE:0000962 an arrhythmia AE that results in an abnormal heart sound DJ, SS, YH WEB: http://circ.ahajournals.org/content/20/6/1053.full.pdf 10017648 gallop rhythm present AE OAE:0000963 a liver related investigation result abnormal AE that has an outcome of an abnormal level of gamma-glutamyltransferase (GGT); GGT is involved in the transfer of amino acids across the cellular membrane DJ, SS, YH, EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003458.htm 10017688 gamma-glutamyltransferase level abnormal AE OAE:0000964 a gamma-glutamyltransferase level abnormal AE that has an outcome of an increase in gamma-glutamyltransferase enzyme presence in the liver DJ, SS, YH, EB GGT increased WEB: http://www.ncbi.nlm.nih.gov/pubmed/23258530 10017693 10056910 gamma-glutamyltransferase level increased AE CTCAE: E12161 NCIt: C26943 OAE:0000965 a gastric disorder AE that has an outcome of cancer that starts in the stomach DJ, SS, YH 10017758 gastric cancer AE HPO: HP_0006753 SIDER: C0024623 OAE:0000966 a tumor AE that has an outcome of cancer in the stomach DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/stomach+cancer 10061968 gastric neoplasm AE OAE:0000967 a gastric disorder AE that has an outcome of a defect in the lining of the stomach DJ, SS, YH 胃溃疡 WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ 10017822 gastric ulcer AE CTCAE: E10727 HPO: HP_0002592 NCIt: C3388 SIDER: C0038358 OAE:0000968 a gastric disorder AE that has an outcome of inflammation in the lining of the stomach DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002135/ 10017853 gastritis AE CTCAE: E10733 HPO: HP_0005263 NCIt: C26780 SIDER: C0017152 OAE:0000969 a gastritis AE that has an outcome of inflammation in the stomach mucosa DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/2789800 10017860 gastritis atrophic AE OAE:0000970 a gastritis AE that has an outcome of gastric mucosal erosion caused by damage to mucosal defences DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/gastritis 10017865 gastritis erosive AE HPO: HP_0005263 SIDER: C2243088 OAE:0000972 a gastroenteritis AE that has an outcome of disease caused by the norovirus DJ, SS, YH WEB: http://www.cdc.gov/ncidod/dvrd/revb/gastro/faq.htm 10068189 gastroenteritis norovirus AE OAE:0000973 a gastroenteritis AE that has an outcome of disease due to radiation DJ, SS, YH 10017912 gastroenteritis radiation AE OAE:0000974 a digestive system AE that results in mucosal damage caused by acid from stomach coming up to the esophagus DJ, SS, YH GERD AE esophageal reflux AE gastrooesophageal reflux disease AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23301861 10017885 10066874 gastroesophageal reflux disease AE CTCAE: E10739 NCIt: C26781 OAE:0000975 a gastrointestinal disorder AE with an outcome of infection in the digestive tract caused by bacteria, viruses or parasites DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Gastrointestinal+infection 10017964 gastrointestinal infection AE HPO: HP_0004798 SIDER: C1264613 OAE:0000976 a gastrointestinal disoder AE that has an outcome of an injury in the gastrointestinal area DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23207874 10061172 gastrointestinal injury AE OAE:0000977 a gastrointestinal disoder AE that has an outcome of premature death in cells of living tissue in the stomach and intestines DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/necrosis 10017982 gastrointestinal necrosis AE OAE:0000978 an adverse event induced by administration of a bupropion drug YH bupropion-induced adverse event OAE:0000979 a gastrointestinal disorder AE that results in a hole in the wall of the esophagus, stomch, small intestine, large bowel, rectum or gallbladder DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001282/ 10018001 gastrointestinal perforation AE HPO: HP_0011024 SIDER: C0151664 OAE:0000980 a tumor AE that has an outcome of a tumor in the gastrointestinal tract, thought to grow from specialized cells found in the tract called interstitial cells of Cajal DJ, SS, YH gastrointestinal stromal tumour AE WEB: http://ghr.nlm.nih.gov/condition/gastrointestinal-stromal-tumor 10051066 gastrointestinal stromal tumor AE HPO: HP_0007378 SIDER: C0238198 OAE:0000981 a gastrointestinal disorder AE that has an outcome of poison affecting the stomach and/or intestinal tracts, often accompanied by abdominal pain, diarrhea and vomiting DJ, SS, YH WEB: http://www.theodora.com/drugs/valcyte_tablets_roche_laboratories.html 10059024 gastrointestinal toxicity AE HPO: HP_0011024 SIDER: C1142499 OAE:0000982 a cytogenetic investigation result abnormal AE that has an outcome of a positive test for gene mutation, deletions and duplications that could indicate large disease risk DJ, SS, YH, EB WEB: https://www.duchenneconnect.org/index.php?option=com_content&view=article&id=346&Itemid=392&lang=en 10063478 gene mutation identification test positive AE OAE:0000983 a systematic adverse event that has an outcome of worsening of physical health DJ, SS, YH 10049438 general physical health deterioration AE OAE:0000984 an edema AE that has an outcome of edema where causes of edema are generalized to the whole body, can cause edema in multiple organs and peripherally DJ, SS, YH generalised oedema AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/16491771 10018092 generalized edema AE HPO: HP_0007430 SIDER: C0151603 OAE:0000985 a skin ulcer AE that results in an ulcer in the genital area usually resulting from an STD DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23064541 10018180 genital ulceration AE HPO: HP_0003249 SIDER: C0151281 OAE:0000986 an abscess AE that has an outcome of a gum-line of the teeth due to pus-filled sacs DJ, SS, YH WEB: http://www.mdguidelines.com/gingival-abscess 10052359 gingival abscess AE OAE:0000987 a digestive system AE that has an outcome of abnormally enlarged, bulging or protruding gums DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003066.htm 10018291 gingival swelling AE OAE:0000988 a kidney disorder AE that has an outcome of a decreased rate per minute at which the blood passes through the glomeruli or the filters in the kidneys DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007305.htm 10018358 glomerular filtration rate decreased AE HPO: HP_0000083 SIDER: C0853068 OAE:0000989 a digestive system AE that has an outcome of a burning or tingling sensation on the lips, tongue or entire mouth DJ, SS, YH burning tongue AE WEB: http://medical-dictionary.thefreedictionary.com/glossodynia 10018388 glossodynia AE HPO: HP_0000157 SIDER: C0017672 OAE:0000990 a glycosylated hemoglobin level abnormal AE that has an outcome of decreased levels of glycosylated hemoglobin in the blood DJ, SS, YH, EB WEB: http://www.ncbi.nlm.nih.gov/pubmed/23015148 10018482 glycosylated hemoglobin level decreased AE OAE:0000992 an infection AE that results in a graft infection DJ, SS, YH 10056559 graft infection AE OAE:0000993 a sensorimotor painful neuropathy AE which has an outcome of distal sensory neuropathy characterized by damage to sensory and motor nerves distal sensorimotor painful neuropathy OAE:0000994 a microbiology and serology investigation result abnormal AE that has an outcome of detection of gram-positive bacteria DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/gram+stain 10018656 gram stain positive AE OAE:0000995 a nervous system AE that results in a generalized seizure that affects the entire brain DJ, SS, YH, SJ tonic seizure WEB: http://www.mayoclinic.com/health/grand-mal-seizure/DS00222 10018659 grand mal convulsion AE HPO: HP_0002197 SIDER: C0014549 OAE:0000996 a granulocyte count abnormal AE that has an outcome of compromise to the immune system where the number of neutrophil granulocytes, a type of white blood cell, is lower than the normal range of ~1700 per microliter. DJ, SS, YH, EB neutropenia AE 10018681 granulocyte count decreased AE OAE:0000998 a hematopoietic system AE that has an outcome of a marked decrease in number of granulocytes, a type of white blood cell filled with microscopic granules that are little sacs containing enzymes that digest microorganisms DJ, SS, YH WEB: http://www.medterms.com/script/main/art.asp?articlekey=8817 10018687 granulocytopenia AE OAE:0000999 a psorisis AE that has an outcome of psoriasis that appears on the back and extremities of the patients DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/20860740 10018797 guttate psoriasis AE OAE:0001001 a male reproductive system AE that has an outcome of abnormal development of large mammary glands in males resulting in breast enlargement DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/gynecomastia 10018800 gynaecomastia AE HPO: HP_0000771 SIDER: C0018418 OAE:0001003 a vomiting AE that results in the vomiting of blood DJ, SS, YH haematemesis AE WEB: http://medical-dictionary.thefreedictionary.com/hematemesis 10018830 hematemesis AE HPO: HP_0002248 SIDER: C0018926 OAE:0001004 a digestive system AE that has an outcome of the passage of bloody stools DJ, SS, YH haematochezia AE WEB: http://medical-dictionary.thefreedictionary.com/hematochezia 10018836 hematochezia AE HPO: HP_0002573 SIDER: C0018932 OAE:0001005 a hematocrit abnormal AE with an outcome of decreased volume percentage of red blood cells in blood DJ, SS, YH, EB haematocrit decreased AE WEB: http://medical-dictionary.thefreedictionary.com/hematocrit 10018838 hematocrit decreased AE OAE:0001006 an infection AE that has an outcome of infection in a hematoma DJ, SS, YH haematoma infection AE WEB: http://medical-dictionary.thefreedictionary.com/hematoma 10051564 hematoma infection AE OAE:0001007 a hematopoietic system AE that has an outcome of toxins that destroy red blood cells, disrupt blood clotting, and/or cause organ degeneration and generalized tissue damage DJ, SS, YH haematotoxicity AE 10061188 hematotoxicity AE OAE:0001008 A conduction system disorder AE that is a condition in which ventricular contraction is not completely synchronized due to a block in conduction of an electrical impulse to the ventricles; in LBBB, right ventricular endocardial activation begins before, and is often completed before, initiation of left ventricular endocardial activation; benign LBBB is rare; preexisting LBBB in absence of clinical evidence of heart disease is rare; newly acquired LBBB has a 10-fold ↑ in mortality Clinical Generally asymptomatic, or absent or diminished 1st heart sound–HS and reversed splitting of 2nd HS EKG Lead V1–QS or rS; lead V6–late intrinsicoid deflection, monophasic R; lead I–monophasic R Management Pacemaker, if syncope or significant arrhythmias Followup Telemetry PRN. YH, SS LBBB left bundle branch block WEB: http://medical-dictionary.thefreedictionary.com/left+bundle+branch+block 10006580 bundle branch block left AE HPO: HP_0011713 SIDER: C0023211 OAE:0001009 a red blood cell profile abnormal AE that has an outcome of an abnormal count of hemoglobin, or iron-containing oxygen-transport metalloprotein in red blood cells DJ, SS, YH, EB haemoglobin abnormal AE WEB: http://medical-dictionary.thefreedictionary.com/hemoglobin 10018879 hemoglobin level abnormal AE OAE:0001012 a hematopoietic system AE that has an outcome of hemolytic anemia, acute kidney failure and a low platelet count DJ, SS, YH haemolytic uraemic syndrome AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23307876 10018932 10019515 hemolytic uremic syndrome AE CTCAE: E10043 HPO: HP_0005575 NCIt: C75545 SIDER: C0019061 OAE:0001013 a respiratory system AE that has an outcome of expectoration of blood or blood-stained sputum from the bronchi, larynx, trachea or lungs DJ, SS, YH haemoptysis AE WEB: http://medical-dictionary.thefreedictionary.com/hemoptysis 10018964 hemoptysis AE HPO: HP_0002105 SIDER: C0019079 OAE:0001014 a nervous system AE that has an outcome of accumulation of blood within the cranial vault DJ, SS, YH haemorrhage intracranial AE WEB: http://emedicine.medscape.com/article/1163977-overview 10018985 hemorrhage intracranial AE HPO: HP_0002170 SIDER: C0151699 OAE:0001015 a female reproductive system AE that results in a 'blood cyst' where the walls of ovarian cysts are lined with blood vessels, which when rupture fill the cyst with blood. DJ, SS, YH haemorrhagic ovarian cyst AE 10060781 hemorrhagic ovarian cyst AE OAE:0001018 a digestive system AE that has an outcome of bleeding in hemorrhoids, vascular structures in the anal canal which help with stool control DJ, SS, YH haemorrhoidal haemorrhage AE WEB: http://medical-dictionary.thefreedictionary.com/hemorrhoid 10054787 10060640 hemorrhoidal hemorrhage AE CTCAE: E10767 NCIt: C78337 OAE:0001019 a digestive system AE that has an outcome of painful, swollen veins in the lower portion of the rectum or anus DJ, SS, YH haemorrhoids AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001337/ 10019022 10019611 hemorrhoids AE CTCAE: E10773 HPO: HP_0004296 NCIt: C26792 OAE:0001020 a lung disorder AE that has an outcome of a collection of blood in the space between the chest wall and the lung DJ, SS, YH haemothorax AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001183/ 10019027 hemothorax AE OAE:0001021 a hair AE that has an outcome of abnormal growth of facial or body hair DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Hair+growth 10019044 hair growth abnormal AE HPO: HP_0010720 SIDER: C0232409 OAE:0001023 a hemoglobin level abnormal AE with an outcome of decrease in amount of iron-containing oxygen-transport metalloprotein in the red blood cells DJ, SS, YH, EB haemoglobin decreased AE WEB: http://medical-dictionary.thefreedictionary.com/hemoglobin 10018884 hemoglobin level decreased AE OAE:0001024 a liver/biliary system AE that has an outcome of a chronic degenerative disease in which normal liver cells are damaged and then replaced by scar tissue DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Hepatic+cirrhosis 10019641 hepatic cirrhosis AE HPO: HP_0001394 SIDER: C0023890 OAE:0001025 a lab test abnormal AE that has an outcome of an increase in amount of hepatic enzyme in body, a liver/biliary system AE that has an outcome of elevated levels of liver enzymes, commonly ALT and AST, may indicate inflammation or damage to liver cells DJ, SS, YH elevated liver enzyme AE WEB: http://www.mayoclinic.com/health/elevated-liver-enzymes/MY00508 10060795 hepatic enzyme increased AE HPO: HP_0002910 SIDER: C0235996 OAE:0001026 a liver/biliary system AE that has an outcome of the inability of the liver to perform its normal synthetic and metabolic function DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/liver+failure 10019663 hepatic failure AE CTCAE: E11211 HPO: HP_0001399 NCIt: C26922 SIDER: C0085605 OAE:0001027 a liver/biliary system AE that results in incorrect blood flow to liver DJ, SS, YH WEB: http://archinte.jamanetwork.com/article.aspx?articleid=571358 10019680 hepatic infarction AE OAE:0001029 a liver/biliary system AE with an outcome of a lesion, an abnormality in the tissue caused by disease or trauma, located in the liver DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21275132 10061998 hepatic lesion AE OAE:0001030 a liver/biliary system AE that has an outcome of death of hepatic parenchyma which may be single cell, or multicell in piecemeal, focal, periacinar, midzonal, periportal or paracentral locations DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/hepatic+necrosis 10019692 hepatic necrosis AE CTCAE: E11221 HPO: HP_0002605 NCIt: C78340 SIDER: C0151798 OAE:0001031 a tumor AE that has an outcome of a malignant tumor in the liver DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23302476 10019695 hepatic neoplasm AE HPO: HP_0002896 SIDER: C0023903 OAE:0001032 Acanthosis nigricans AE is a skin AE that is a brown to black, poorly defined, velvety hyperpigmentation of the skin. It is usually found in body folds, such as the posterior and lateral folds of the neck, the armpits, groin, navel, forehead, and other areas. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Acanthosis_nigricans 黑棘皮病 10000350 acanthosis nigricans AE OAE:0001033 a hepatitis AE that has an outcome of irritation and swelling of the liver due to infection with the heptitis B virus DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001324/ 10019731 hepatitis B AE HPO: HP_0006562 SIDER: C0019163 OAE:0001034 a hepatitis AE that has an outcome of liver inflammation due to a hepatitis viral infection DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/viral+hepatitis 10019799 hepatitis viral AE CTCAE: E11410 HPO: HP_0006562 NCIt: C35124 SIDER: C0042721 OAE:0001035 a liver/biliary system AE that has an outcome of swelling of the liver DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003275.htm 10019842 hepatomegaly AE HPO: HP_0002240 SIDER: C0019209 OAE:0001036 a liver damage AE that has an outcome of chemically driven liver damage DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/hepatotoxicity 10019851 hepatotoxicity AE OAE:0001038 an inflammation AE that has an outcome of an inflammatory infiltrate around the eccrine sweat gland DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/hidradenitis 10020040 hidradenitis AE OAE:0001039 an immune system disorder AE that has an outcome of abnormal proliferation of histiocytes, a type of immune cell that eats foreign substances DJ, SS, YH histiocytosis haematophagic AE WEB: http://www.medterms.com/script/main/art.asp?articlekey=11478 10048595 histiocytosis hematophagic AE OAE:0001040 a fungal infection AE that results in an infection that occurs from breathing in the spores of the fungus Histoplasma Capsulatum DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001082.htm 10020144 histoplasmosis disseminated AE OAE:0001042 a urinary system AE that has an outcome of distension and dilation of the renal pelvis and calyces, usually caused by the osbtruction of urine flow from the kidney DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/hydronephrosis 10020524 hydronephrosis AE HPO: HP_0000126 SIDER: C0020295 OAE:0001043 a congenital abnormality AE that results in the yellowing of the skin of infants DJ, SS, YH hyperbilirubinaemia neonatal AE WEB: http://medical-dictionary.thefreedictionary.com/neonatal+jaundice 10020580 hyperbilirubinemia neonatal AE OAE:0001044 a blood calcium abnormal AE that has an outcome of an elevated calcium level in the blood, above normal range of 9-10.5 mg/dL YH, MW hypercalcaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hypercalcemia 10020583 10020587 hypercalcemia AE CTCAE: E12270 HPO: HP_0003072 NCIt: C3112 SIDER: C0020437 OAE:0001045 a skin AE that results in excess perspiration DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/hyperhidrosis 10020642 hyperhidrosis AE CTCAE:E13645 HPO: HP_0000975 NCIt:C78345 SIDER: C0020458 OAE:0001046 a blood potassium abnormal AE that has a lab test outcome of an abnormally increased concentration of potassium in blood YH, MW hyperkalaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hyperkalemia 10020646 10020647 hyperkalemia AE CTCAE: E12282 HPO: HP_0002153 NCIt: C37968 SIDER: C0020461 OAE:0001047 toxin-induced cardiomyopathy AE OAE:0001048 cocaine-induced cardiomyopathy AE OAE:0001049 an abnormal fluid regulation AE that has an outcome of an excessive secretion of the parathyroid hormone by the parathyroid gland DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23267748 10020708 hyperparathyroidism secondary AE HPO: HP_0003106 SIDER: C0020503 OAE:0001050 a paresis AE that shows muscle weakness affecting the lower limbs. JX, YH WEB: http://www.merriam-webster.com/medical/paraparesis 下肢轻瘫 10033885 paraparesis AE OAE:0001051 a systemic hypertension AE that has an outcome of hypertension with systolic blood pressure >180 mm Hg or a diastolic pressure >120 mm, can be further classified as hypertensive urgency or hypertensive emergency depending on end-organ involvement DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/20160537 10020802 hypertensive crisis AE HPO: HP_0000875 SIDER: C0020546 OAE:0001052 a hematopoietic system AE that has an outcome of high blood levels of triglycerides, abundant fatty molecules DJ, SS, YH, MW hypertriglyceridaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hypertriglyceridemia 10020869 10020870 hypertriglyceridemia AE CTCAE: E12299 HPO: HP_0002155 NCIt: C37971 SIDER: C0020557 OAE:0001053 an arthritis AE that has an outcome of uric acid building up in blood and causes joint inflammation DJ, SS, YH, MW gout AE hyperuricaemia AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001459/ 10020903 10020907 hyperuricemia AE CTCAE: E12305 HPO: HP_0002149 NCIt: C3961 SIDER: C0740394 OAE:0001054 a blood albumin abnormal AE that shows an abnormally low level of albumin protein in the blood. DJ, SS, YH hypoalbuminaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hypoalbuminemia 10020942 10020943 hypoalbuminemia AE CTCAE: E12310 HPO: HP_0003073 NCIt: C37972 SIDER: C0239981 OAE:0001055 a blood calcium abnormal AE that has an outcome of abnormally low calcium levels, can present with convulsions, arrythmias, tetany and numbness YH, MW hypocalcaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hypocalcemia 低血钙 10020947 10020949 hypocalcemia AE CTCAE: E12316 HPO: HP_0002901 NCIt: C37973 SIDER: C0020598 OAE:0001056 a blood carbon dioxide abnormal AE in which the levels of carbon dioxide in the blood is abnormally low. DJ, SS, YH, MW WEB: https://en.wikipedia.org/wiki/Hypocapnia 10020952 hypocapnia AE UMLS CUI: C0085383 OAE:0001057 a glucose homeostasis AE that results in a abnormally diminished content of glucose in the blood DJ, SS, YH, MW hypoglycaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hypoglycemia 10020993 10021005 hypoglycemia AE CTCAE: E12322 HPO: HP_0005969 NCIt: C3126 SIDER: C0020615 OAE:0001058 a neurological, special senses and psychiatric investigation result abnormal AE that is the abnormal result of the recording of the level of consciousness in a person after a brain injuiry. YH, SJ WEB: http://www.brainline.org/content/2010/10/what-is-the-glasgow-coma-scale.html 10069709 Clinicians use the Galscow coma scale to rate the best eye opening response, the best verbal response, and the best motor response an individual makes. The final GCS score or grade is the sum of these numbers. Glascow coma scale abnormal AE OAE:0001059 a blood magnesium abnormal AE that has an outcome of an abnormal concentration of magnesium in the blood plasma, and may cause nausea, weakness and tremors. YH, MW hypomagnesaemia AE WEB: http://medical-dictionary.thefreedictionary.com/Hypomagnesaemia 10021027 10021028 hypomagnesemia AE CTCAE: E12333 HPO: HP_0002917 NCIt: C37975 SIDER: C0151723 UMLS CUI: C0151723 OAE:0001060 a conduction system disorder AE that refers to the slow conduction of electricity through ventricular walls of the heart. SS IVCD BOOK: Taber's Cyclopedic Medical Dictionary;2005, p1134 WEB: http://connection.ebscohost.com/c/reference-entries/21232773/intraventricular-conduction-delay intraventricular conduction delay AE OAE:0001061 a gustatory system AE with an outcome of reduced food intake DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/hypophagia 10063743 hypophagia AE OAE:0001062 a hematopoietic system AE that has an outcome of abnormally low phosphate levels, can present with muscle dysfunction, white cell dysfunction, pulp chambers and mental status changes DJ, SS, YH, MW hypophosphataemia AE WEB: http://medical-dictionary.thefreedictionary.com/hypophosphatemia 10021058 10021059 hypophosphatemia AE CTCAE: E12344 HPO: HP_0008285 NCIt: C37977 SIDER: C0085682 UMLS CUI: C0085682 OAE:0001063 an endocrine system AE with the outcome of the thyroid gland does not make enough thyroid hormone DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001393/ 10021114 hypothyroidism AE CTCAE: E10334 HPO: HP_0008245 NCIt: C26800 SIDER: C0020676 OAE:0001064 a cardiovascular disorder AE that is characterized by decreased blood plasma volume DJ, SS, YH hypovolaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hypovolemia 10021137 hypovolemia AE HPO: HP_0011106 SIDER: C0546884 OAE:0001066 a cardiovascular disorder AE that has the outcome of severe blood and fluid loss that makes the heart unable to pump enough blood to the body, often leads to organ failure DJ, SS, YH hypovolaemic shock AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000167.htm 10021138 hypovolemic shock AE HPO: HP_0011106 SIDER: C0020683 OAE:0001067 a digestive system AE that has an outcome of holes in the ileum of the small intestine DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/ileum 10021305 ileal perforation AE CTCAE: E10795 NCIt: C78355 OAE:0001068 a digestive system AE that has an outcome of a partially or completely blocked bowel DJ, SS, YH intestinal obstruction AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001306/ 10021328 ileus AE CTCAE: E10812 HPO: HP_0002595 NCIt: C37979 SIDER: C1258215 OAE:0001069 a digestive system AE that has an outcome of intestinal blockage in the absence of an actual physical obstruction, can be caused by a malfunction in nerves and muscles in the intestine DJ, SS, YH WEB: http://www.localhealth.com/article/paralytic-ileus 10021333 ileus paralytic AE HPO: HP_0002590 SIDER: C0030446 OAE:0001070 A cardiac disorder AE that has an outcome of an abnormal enlargement of the heart YH, SS WEB: http://medical-dictionary.thefreedictionary.com/cardiomegaly added MedDRA term LB 10007632 cardiomegaly AE HPO: HP_0001640 SIDER: C0018800 OAE:0001071 a drug adverse event that has an outcome of decreased levels of immunosuppressant drugs in the patient's body DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Immunosuppresant 10062014 immunosuppressant drug level decreased AE OAE:0001072 an immune system disorder AE that has an outcome of reduced or absent immune response DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001821/ 10062016 immunosuppression AE OAE:0001073 an injury AE that has an outcome of impairment to the process of restoring a state of soundness to any interupption in the continuity of external surfaces of the body DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/wound+healing 10021519 impaired healing AE HPO: HP_0001058 SIDER: C0151692 OAE:0001074 a pain AE that has an outcome of pain at the site of an implant DJ, SS, YH 10063782 implant site pain AE OAE:0001076 a respiratory system AE that has an outcome of increased thickness of the secretions of the bronchi DJ, SS, YH 10054761 increased viscosity of bronchial secretion AE OAE:0001077 an infection AE that results in infection by a parasite DJ, SS, YH 10021857 infection parasitic AE HPO: HP_0002719 SIDER: C0747256 OAE:0001078 an immune system disorder AE that has an outcome of increased susceptibility to infection DJ, SS, YH 10021866 infection susceptibility increased AE HPO: HP_0002719 SIDER: C0236171 OAE:0001079 an infection AE that has an outcome of an increase in severity of cystic fibrosis in the patient SZ, DJ, SS, YH 10070608 infective pulmonary exacerbation of cystic fibrosis AE OAE:0001081 a immune system AE that results in an allergic reaction to foreign protein, but can also be caused by cytokine release. SZ, DJ, SS, YH WEB: http://www.ons.org/Publications/VJC/media/ons/docs/publications/VJC/vjc-apr10cjon.pdf 10051792 10053483 infusion related reaction AE CTCAE: E11127 NCIt: C78361 OAE:0001082 an extravasation AE that has an outcome of leaking of pharmacologic or biological substance from infusion site into surrounding tissue. Symptoms include induration, erythema, swelling, burning sensation and pain SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/extravasation 10064774 infusion site extravasation AE CTCAE: E11133 NCIt: C78362 OAE:0001083 Infection AE that results in the patient gets infected at the sight of an infusion SZ, DJ, SS, YH 10054997 infusion site infection AE OAE:0001084 Rash AE that results in patient has a rash at the site of infusion SZ, DJ, SS, YH 10059830 infusion site rash AE OAE:0001085 an allergy AE that has an outcome of infusion site allergic reaction SZ, DJ, SS, YH 10054996 infusion site reaction AE OAE:0001086 a nail disorder AE that results in a nail growing into the sides of the paronychium SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/ingrowing+nail 10022013 ingrowing nail AE OAE:0001087 a skin discoloration AE that results in a discoloration of the skin at the site of injection of the drug SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/macule 10067255 injection-site macule AE OAE:0001088 Inflammation AE that results in swelling of the veins at the site of drug injection SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/phlebitis 10022090 injection-site phlebitis AE OAE:0001090 an adverse event that results in the patient developing a scab at the site of drug injection SZ, DJ, SS, YH 10066210 injection-site scab AE OAE:0001091 a pain AE that results in pain at the site of instillation SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/instillation 10022459 instillation site pain AE OAE:0001092 a tremor AE that results in the patient undergoing a broad, coarse, low frequency muscle tremor SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23094990 10022520 intention tremor AE HPO: HP_0002345 SIDER: C0234376 OAE:0001093 an adverse drug event that results in the intentional use of a drug in the wrong way (recreationally etc) SZ, DJ, SS, YH 10065679 intentional drug misuse AE OAE:0001095 a lung disorder AE that has an outcome of a disease affecting the interstitium, the tissue and space around the air sacs of the lungs SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23289473 10022611 interstitial lung disease AE HPO: HP_0006530 SIDER: C0206062 OAE:0001096 a bone disorder AE that has an outcome of the protrusion of the nucleus pulposus or anulus fibrosus of the intervertebral disk, which may impinge on nerve roots SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/herniation+of+intervertebral+disk 10050296 intervertebral disc protrusion AE OAE:0001097 an ischaemia AE that has an outcome of blocked or narrowed blood vessels to the small or large intestines, can cause pain and permanent damage to the intestines SZ, DJ, SS, YH intestinal ischaemia AE 10022680 intestinal ischemia AE OAE:0001098 a gastrointestinal disorder AE that has an outcome of a blockage that keeps substance from passing through the intestine, may be caused by fibrous bands of tissue in the abdomen, inflamed/infected pouches in the intestine, or hernias and tumors SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001306/ 10022687 intestinal obstruction AE HPO: HP_0005250 SIDER: C0021843 OAE:0001099 a gastrointestinal disorder AE that has an outcome of perforation, or complete penetration, of the wall of the intestines SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001282/ 10022694 intestinal perforation AE OAE:0001100 a thrombosis AE that has an outcome of thrombi in the ventricles SZ, DJ, SS, YH WEB: http://www.cvimaging.northwestern.edu/for-physicians/cardiovascular-mri/indications/intracardiac-thrombus/ 10048620 intracardiac thrombus AE OAE:0001101 a nervous system AE that has an outcome of a rise in the pressure inside the skull that can result from or cause brain injury SZ, DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000793.htm 10022773 intracranial pressure increased AE HPO: HP_0002516 SIDER: C0151740 OAE:0001102 a neurological, special senses and psychiatric investigation result abnormal AE that results in an abnormal intraocular pressure in the eye SZ, DJ, SS, YH, EB 10060951 intraocular pressure test result abnormal AE OAE:0001104 an anemia AE that has an outcome of fewer healthy red blood cells because the body does not have enough iron SZ, DJ, SS, YH iron deficiency anaemia AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000584.htm 10022972 iron deficiency anemia AE HPO: HP_0001891 SIDER: C0162316 OAE:0001105 Behavior and Neurological AE that results in the patient being easily annoyed/irritated SZ, DJ, SS, YH feverish (subjective) AE 10022998 irritability AE CTCAE: E11144 HPO: HP_0000737 NCIt: C50623 SIDER: C0022107 OAE:0001106 a jaundice AE that results in an abnormal bile flow in the liver SZ, DJ, SS, YH cholestasis jaundice AE WEB: http://medical-dictionary.thefreedictionary.com/cholestatic+jaundice 10023129 jaundice cholestatic AE HPO: HP_0006575 SIDER: C0022354 OAE:0001107 a bone disorder AE that has an outcome of disease in the set of bones that hold the teeth SZ, DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/jawinjuriesanddisorders.html 10061257 jaw disorder AE OAE:0001108 a bone disorder AE that has an outcome of break in the jaw bone SZ, DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000019.htm 10023149 jaw fracture AE OAE:0001109 a thrombosis AE with an outcome of formation of a blood clot located in the internal jugular vein SZ, DJ, SS, YH 10023237 jugular vein thrombosis AE OAE:0001110 a bacterial infection AE with an outcome of invasion by Klebsiella pneumonia, a form of bacterial pneumonia SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/17307769 10061259 klebsiella infection AE HPO: HP_0002742 SIDER: C0022729 OAE:0001111 a bone disorder a that results in the knee becoming deformed SZ, DJ, SS, YH 10062061 knee deformity AE OAE:0001112 a speech disorder AE that results in the inability of a patient to speak properly SZ, DJ, SS, YH 10023615 lack of spontaneous speech AE OAE:0001113 a congetical abnormality AE that results in the patient's baby being larger than it should be at the time in their pregnancy SZ, DJ, SS, YH 10023789 large for dates baby AE OAE:0001114 an immune system disorder AE that has an outcome of an increase in the number or proportion of natural killer cells, or cytotoxic lymphocytes critical to the innate immune system SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/10761014 10023791 large granular lymphocytosis AE OAE:0001115 a gastrointestinal disorder AE that has an outcome of an ulcer in the large intestine SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Intestinal+ulcer 10023799 large intestinal ulcer AE OAE:0001116 a digestive system AE that has an outcome of perforation, or complete penetration, of the walls of the large intestine SZ, DJ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000235.htm 10023804 large intestine perforation AE HPO: HP_0002250 SIDER: NA OAE:0001117 an immunology and allergy investigation result abnormal that results in LE cells (neutrophil or macrophage that has phagocytized the denatured nuclear material of another cell) being detected SZ, DJ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/LE+cell 10024062 le cells present AE OAE:0001118 a dilatation atrial AE that results in the left atrium of the heart becoming enlarged SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096293/ 10067286 left atrial dilatation AE OAE:0001119 a cardiac ventricular disorder AE that has an outcome of inability of the left ventricle to pump blood, may lead to heart failure SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766527/ 10049694 left ventricular dysfunction AE CTCAE: E10130 NCIt: C64251 OAE:0001120 a left ventricular dysfunction AE that has an outcome of congestive heart failure marked by pulmonary congestion and edema, the left ventricle fals to contract forcefully enough to maintain normal cardiac output and peripheral perfusion SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/left+ventricular+failure 10024119 left ventricular failure AE HPO: HP_0001635 SIDER: C0023212 OAE:0001121 a left ventricular dysfunction disorder AE that has an outcome of the thickening of the myocardium of the left ventricle of the heart SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/18030317 10049773 left ventricular hypertrophy AE OAE:0001122 a hematopoietic system AE that has an outcome of cancer of the white blood cells characterized by return of symptoms after remission SZ, DJ, SS, YH leukaemia recurrent AE WEB: http://www.yourcancertoday.com/Cancers/Leukemia-Acute-Myeloid-Adult/53 10062489 leukemia recurrent AE OAE:0001123 a nervous system AE that has an outcome of cancerous white blood cells infiltrating the brain SZ, DJ, SS, YH leukaemic infiltration brain AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/1454121 10064987 leukemic infiltration brain AE OAE:0001124 Immune system disorder AE that results in an increase in white blood cell count as a result of stress or infection SZ, DJ, SS, YH leukaemoid reaction AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000575.htm 10024328 leukemoid reaction AE HPO: HP_0001909 SIDER: C0023501 OAE:0001126 an vasculitis AE that has an outcome of fragmented cells, and debris in the blood vessels. May develop skin lesions, accompanied by arthralgia and fever SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/leukocytoclastic+vasculitis 白细胞破碎性血管炎 10024377 leukocytoclastic vasculitis AE HPO: HP_0011944 SIDER: C2973529 OAE:0001127 Urinary system AE that results in white blood cells in the urine SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/leukocyturia 10050791 leukocyturia AE OAE:0001128 an encephalopathy AE that has an outcome of brain white matter disease SZ, DJ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/leukoencephalopathy 10024382 leukoencephalopathy AE CTCAE:E12712 HPO: HP_0002352 NCIt:C27059 SIDER: C0270612 OAE:0001129 a hematopoietic system AE that has an outcome of a lower than normal number of leukocytes, or nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2154209/ 10024384 leukopenia AE HPO: HP_0001882 SIDER: C0023530 OAE:0001130 a psychiatric disorder AE that results in a disorder in the patient's desire for sexual interaction SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750/ 10061221 libido disorder AE OAE:0001131 a skin AE that has an outcome of an itchy rash on the skin or in the mouth SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001870/ 10024429 lichen planus AE OAE:0001132 a skin erosion AE that results in the deterioration of the lip skin SZ, DJ, SS, YH 10051992 lip erosion AE OAE:0001133 a digestive system AE that has an outcome of an excess of lipase, a pancreatic enzyme, may indicate a problem related to pancreas SZ, DJ, SS, YH hyperlipasemia AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/15653991 10024574 lipase increased AE CTCAE: E12185 NCIt: C78435 OAE:0001135 Liver/biliary system AE that results in the disease of the liver SZ, DJ, SS, YH liver disorder WEB: http://www.nlm.nih.gov/medlineplus/liverdiseases.html 10024670 liver AE HPO: HP_0006706 SIDER: C0023895 OAE:0001136 a localized edema AE that shows the outcome of swelling. SZ, DJ, SS, YH 10024770 local swelling AE OAE:0001137 an infection AE located in a certain area SZ, DJ, SS, YH localised infection AE 10024774 localized infection AE HPO: HP_0002719 SIDER: C0016397 OAE:0001138 Abnormal fluid regulation AE that results in a collection of fluid in the intraabdominal area SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/intra-abdominal 10066768 localised intraabdominal fluid collection AE OAE:0001139 an edema AE occuring in a specific region SZ, DJ, SS, YH localised edema AE localised oedema AE WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1115975/ 10048961 10062466 localized edema AE CTCAE: E11148 HPO: HP_0000969 NCIt: C78437 SIDER: C0013609 OAE:0001140 a movement disorder AE that has an outcome of loss of the sense of the relative position of neighbouring parts of the body and strength of effort being employed in movement SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/8294975 10057332 loss of proprioception AE OAE:0001141 a gastrointestinal hemorrhage AE that has an outcome of bleeding in the lower gastrointestinal tract SZ, DJ, SS, YH lower gastrointestinal haemorrhage AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003133.htm 10050953 lower gastrointestinal hemorrhage AE HPO: HP_0002239 SIDER: C0024050 OAE:0001142 an infection AE that has an outcome of infection in the lower respiratory tract, includes pneumonea as well as lung abscess and acute bronchitis SZ, DJ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/books/NBK8142/ 10024968 lower respiratory tract infection AE HPO: HP_0002783 SIDER: C0149725 OAE:0001143 a lung disorder AE that has an outcome of liquid filling a region of lung tissue, marked by induration of a normally aerated lung SZ, DJ, SS, YH pulmonary consolidation AE WEB: http://medical-dictionary.thefreedictionary.com/consolidation 10025080 lung consolidation AE OAE:0001144 an infection AE that has an outcome of infection in the lungs SZ, DJ, SS, YH WEB: http://www.livestrong.com/lung-infection/ 10061229 lung infection AE CTCAE: E11444 HPO: HP_0002783 NCIt: C26873 SIDER: C0876973 OAE:0001145 a lung disorder AE that has an outcome of an abnormal presence of granulomas, fluid, inflammatory exudates or cells in the lung tissue SZ, DJ, SS, YH WEB: http://www.blurtit.com/q840550.html 10025102 lung infiltration AE HPO: HP_0005828 SIDER: C0235896 OAE:0001146 a tumor AE that has an outcome of a malignant tumor in the lung SZ, DJ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Lung+neoplasm 10062042 lung neoplasm AE HPO: HP_0100526 SIDER: C0024121 OAE:0001147 an immune system disorder AE that has an outcome of lymphadenopathy, which is a term meaning "disease of the lymph nodes" . It is generally a disease or inflammation of the lymph nodes, could be due to infection, auto-immune disease or malignancy SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/lymphadenopathy 10025197 lymphadenopathy AE HPO: HP_0002716 SIDER: C0497156 OAE:0001148 an inflammation AE occuring in the lymph vessels secondary to a malignancy SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/8930034 10053132 lymphangiosis carcinomatosa AE OAE:0001149 a lymphocyte count abnormal AE that has an outcome of a decreased amount of lymphocytes in the blood, a type of white blood cell in the immune system SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003657.htm 10025256 lymphocyte count decreased AE CTCAE: E12190 NCIt: C26823 OAE:0001150 a lymphocyte percentage abnormal AE that results in an increase in the levels of lymphocytes in the blood SZ, SS, YH, EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003657.htm 10052232 lymphocyte percentage increased AE OAE:0001151 an immune system disorder AE that results in lymphocytes being infiltrated by harmful substances SZ, SS, YH WEB: http://emedicine.medscape.com/article/1098654-overview 10062049 lymphocytic infiltration AE OAE:0001152 an immune system disorder AE that has an outcome of an increase in the number or proportion of lymphocytes in the blood SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/lymphocytosis 10025280 lymphocytosis AE HPO: HP_0012141 SIDER: C0024282 OAE:0001153 an edema AE that has an outcome of localized fluid retention and tissue swelling caused by a compromised lymphatic system SZ, SS, YH WEB: Primary Source: http://emedicine.medscape.com/article/1087313-overview Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23073712 10025282 lymphoedema AE HPO: HP_0001004 SIDER: C0024236 OAE:0001154 a hematopoietic system AE that has an outcome of reduction in the number of lymphocytes in the blood SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/lymphopenia 10025327 lymphopenia AE HPO: HP_0001888 SIDER: C0024312 OAE:0001155 a eye disorder AE that has an outcome of cell death in the macula of the eye, destroying central vision SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/maculardegeneration.html 10025409 macular degeneration AE HPO: HP_0007673 SIDER: C0024437 OAE:0001156 a male reproductive system disorder AE that results in the inability of the male to achieve an orgasm despite lengthy sexual contact SZ, SS, YH WEB: http://www.minddisorders.com/Kau-Nu/Male-orgasmic-disorder.html#b 10025513 male orgasmic disorder AE OAE:0001157 a tumor AE that has an outcome of growth or proliferation of an abnormal mass of tissue SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/19824467 10061309 malignant neoplasm progression AE OAE:0001158 an respiratory system AE that has an outcome of abnormal amount of fluid collecting between the layers of tissue lining the outside of the lung and wall of chest cavity, caused by cancer SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/11529302 10026673 malignant pleural effusion AE OAE:0001161 an arterial disorder AE that resuts in arteries that supply blood to heart muscle become hardened and narrowed. YH, SS coronary artery disese AE WEB: http://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html 10011078 10011082 coronary artery disorder AE OAE:0001162 a hematopoietic system AE that has an outcome of bone marrow that contains an excess of blood cells SZ, SS, YH WEB: http://www.mayoclinic.com/health/aplastic-anemia/DS00322/DSECTION=causes 10026851 marrow hyperplasia AE OAE:0001163 a perinatal AE that results in the drugs being taken by the mother affecting unborn fetus in mother SZ, SS, YH maternal drugs affecting foetus AE 10026923 maternal drugs affecting fetus AE OAE:0001164 an adverse event that results in a problem in the mediastinum of the patient (undelineated group of structures in the thorax surrounded by loose connective tissue) SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Mediastinal+diseases 10061280 mediastinal disorder AE HPO: HP_0000765 SIDER: C0025061 OAE:0001165 a digestive system AE that has an outcome of abnormal dilation of the colon, often accompanied by paralysis of the peristaltic movements of the bowel SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/megacolon 10027110 megacolon AE HPO: HP_0002251 SIDER: C0025160 OAE:0001166 Abnormal defecation AE that results in black feces associated with gastrointestinal hemorrhage SZ, SS, YH melaena AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003130.htm 10027141 melena AE HPO: HP_0002249 SIDER: C0025222 OAE:0001167 Behavior and Neurological AE that results in the loss of memory SZ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/impaired+memory 10027175 memory impairment AE CTCAE:E12718 HPO: HP_0002354 NCIt:C78444 SIDER: C0233794 OAE:0001168 a brain inflammation AE that results in the layers lining the brain becoming inflamed, not due to pygonenic bacteria SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/aseptic+meningitis 10027201 meningitis aseptic AE HPO: HP_0001287 SIDER: C0025290 OAE:0001169 Hematuria AE that results in excessive uterine bleeding occurs irregularly and more frequently than normal SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/menometrorrhagia 10027295 menometrorrhagia AE HPO: HP_0100608 SIDER: C0232943 OAE:0001170 Female Reproductive System AE that results in abnormally heavy and prolonged menstrual period SZ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0014910/ 10027313 menorrhagia AE CTCAE:E13132 HPO: HP_0000132 NCIt:C26829 SIDER: C0025323 OAE:0001171 a psychiatric disorder AE that has an outcome of changes in mental status SZ, SS, YH, Izabela Birsanescu WEB: http://www.medicinenet.com/altered_mental_status/symptoms.htm 10048294 A mental status change does not have to be a disorder or even an adverse event. It can be a good change, from a disorder status to a normal recovered status. mental status changes AE OAE:0001172 a metabolism, endocrine, and exocrine system AE that has an outcome of abnormal chemical reactions in the body that disrupts a metabolic process SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/metabolicdisorders.html 10058097 metabolic disorder AE OAE:0001173 A cardiac disorder AE that has an outcome of enlargement of the heart YH, SS atrial dilatation, atrial enlargement 10013002 dilatation atrial AE OAE:0001174 an abdominal AE that shows the spreading of the cancer cells to the abdominal cavity of the patient SZ, SS, YH WEB: Primary Source: http://www.nlm.nih.gov/medlineplus/ency/article/002260.htm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/19373966 10027450 metastasis to abdominal cavity AE OAE:0001175 a tumor AE that has an outcome of cancerous cells spreading to the bone from elsewhere SZ, SS, YH 10027452 metastasis to bone AE OAE:0001176 a tumor AE that results in cancerous cells spreading from a primary tumor to the central nervous system SZ, SS, YH WEB: http://theoncologist.alphamedpress.org/content/8/5/398.long, http://www.ncbi.nlm.nih.gov/pubmed/19373966 10059282 metastasis to central nervous system AE OAE:0001177 a tumor AE that results in cancerous cells spreading to the liver organ SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000277.htm 10027457 metastasis to liver AE OAE:0001178 a tumor AE that results in cancerous cells spreading to the lung SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000097.htm 10027458 metastasis to lung AE OAE:0001179 a tumor AE that has an outcome cancerous cells spreaing from primary tumor to the thin layers of tissue that protect the brain and spinal cord, may experience increased intracranial pressure SZ, SS, YH meningeal metastasis AE WEB: 1. http://theoncologist.alphamedpress.org/content/1/1/56.full 2. http://www.cancer.gov/dictionary?cdrid=45782 10051696 metastasis to meninges AE OAE:0001180 a tumor AE that results in cancerous cells spreading from primary tumor to the lining of the abdominal cavity or the coelom. SZ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/peritoneum Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed?term=metastasis%20to%20peritoneum%20%5BTI%5D 10051676 metastasis to peritoneum AE OAE:0001181 a tumor AE that results in a disease spreading to the pleural cavity due to cancerous activities SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/pleuraldisorders.html 10027463 metastasis to pleura AE OAE:0001183 a tumor AE that results in cancerous cells spreading to the spine SZ, SS, YH WEB: http://emedicine.medscape.com/article/1157987-overview 10027468 metastasis to spine AE OAE:0001184 a tumor AE with an outcome of spreading of disease from one organ to another non-adjacent organ or part SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/002260.htm 10062194 metastasis AE OAE:0001185 a tumor AE with an outcome of spreading of cancerous cells from abnormal mass of tissue SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/20121607 10061289 metastatic neoplasm AE OAE:0001186 Urinary System AE that is characterized by uterine bleeding at irregular intervals SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/metrorrhagia 10027514 metrorrhagia AE HPO: HP_0100608 SIDER: C0025874 OAE:0001187 Cardiovascular disorder AE that results in a fragmentation of red blood cells resulting from the narrowing of small blood vessels SZ, SS, YH microangiopathic haemolytic anaemia AE WEB: http://medical-dictionary.thefreedictionary.com/microangiopathic+hemolytic+anemia 10027527 microangiopathic hemolytic anemia AE HPO: HP_0001937 SIDER: C0221021 OAE:0001188 a cardiac valve disease AE that is characterized by the inability of the heart's mitral valve to close tightly, allowing blood to flow backward in the heart SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Mitral+Valve+Insufficiency 10027727 mitral valve incompetence AE HPO: HP_0001653 SIDER: C0026266 OAE:0001189 a digestive system AE that has an outcome of bleeding from blood vessels located in the mouth SZ, SS, YH mouth haemorrhage AE WEB: http://sideeffects.embl.de/se/C0029163/ 10028024 mouth hemorrhage AE HPO: HP_0000167 SIDER: C0029163 OAE:0001190 a digestive system AE that has an outcome of sores or open lesions in the mouth SZ, SS, YH aphthous stomatitis AE canker sore AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001448.htm 10028034 mouth ulceration AE HPO: HP_0000155 SIDER: C0149745 OAE:0001191 Multiple Sclerosis AE that is characterized by a relapse of Multiple Sclerosis SZ, SS, YH WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/ Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/22980532 10048393 multiple sclerosis relapse AE OAE:0001192 a muscle contraction AE that has an outcome of painful sensations, associated with muscle fatigue and low sodium/potassium SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/musclecramps.html 10028294 muscle cramp AE OAE:0001193 a muscle enzyme level abnormal AE that results in an increased level of muscle enzyme SZ, SS, YH 10057945 muscle enzyme level increased AE OAE:0001194 a muscle AE that results in the musculoskeletal system being weakened at locomotion is hampered SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002172/ 10028356 muscular dystrophy AE OAE:0001195 a pain AE located in musculoskeletal structures of the chest wall, atypical or noncardiac chest pain SZ, SS, YH WEB: http://www.uptodate.com/contents/major-causes-of-musculoskeletal-chest-pain?source=see_link 10050819 musculoskeletal chest pain AE HPO: HP_0006649 SIDER: C0476280 OAE:0001196 Bacterial infection AE that results in the patient being infected with the Mycoplasma bacteria SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/15142464 10061300 mycoplasma infection AE OAE:0001198 a hematopoietic system AE that has an outcome of ineffective production of the myeloid class of blood cells SZ, SS, YH, MW WEB: http://www.nlm.nih.gov/medlineplus/myelodysplasticsyndromes.html 10028533 myelodysplastic syndrome AE CTCAE:E12552 HPO: HP_0006730 NCIt:C3247 SIDER: C0026986 OAE:0001199 a hematopoietic system AE that has an outcome of bone marrow being replaced by scar tissue SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001558/ 10028537 myelofibrosis AE HPO: HP_0011974 SIDER: C0026987 OAE:0001200 a cardiac disorder AE that has an outcome of an imbalance between myocardial oxygen supply and demand SZ, SS, YH myocardial ischaemia AE WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1768241/ 10028600 myocardial ischemia AE HPO: HP_0001637 SIDER: C0151744 OAE:0001201 an inflammation AE that has an outcome of inflammation of the heart muscle SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001204/ 10028606 myocarditis AE CTCAE: E10157 NCIt: C34831 OAE:0001202 a bone disorder AE, most commonly fungal infection, that is characterized by discoloration, painful swelling, pits, lesions and brown bands SZ, SS, YH WEB: http://www.umm.edu/altmed/articles/nail-disorders-000116.htm 10028694 nail disorder AE HPO: HP_0001597 SIDER: C0027339 OAE:0001203 a nail AE around the nail area, tends to be fungal SZ, SS, YH WEB: http://www.emedicinehealth.com/paronychia_nail_infection/article_em.htm 10061304 nail infection AE HPO: HP_0008396 SIDER: C0343026 OAE:0001204 Cell death AE that results in necrosis occurring due to a local deprivation of blood SZ, SS, YH necrosis ischaemic AE WEB: http://medical-dictionary.thefreedictionary.com/ischemic+necrosis 10028862 necrosis ischemic AE OAE:0001205 a progressive tumor AE that has an outcome of an abnormal mass of cells that metastasizes SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/malignant+neoplasm 10028997 neoplasm malignant AE HPO: HP_0002664 SIDER: C0006826 OAE:0001206 an tumor AE that has an outcome of growth of the neoplasm, an abnormal mass of tissue in the body SZ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/neoplasm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23263846 10061309 neoplasm progression AE OAE:0001207 a tumor AE that has an outcome of microscopic cells of the original neoplasm escaping therapeutic intervention and later becoming clinically visible at the original site SZ, SS, YH 10061864 neoplasm recurrence AE OAE:0001208 Kidney disorder AE that results in an increased amount of calcium deposits in the renal parenchyma SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001522/ 10029146 nephrocalcinosis AE HPO: HP_0000121 SIDER: C0027709 OAE:0001209 a kidney disorder AE that has an outcome of a group of symptoms that include protein in the urine, low blood protein levels, high cholesterol levels, high triglyceride levels and swelling SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001520/ 10029164 nephrotic syndrome AE HPO: HP_0000100 SIDER: C0027726 OAE:0001210 a neuropathy AE that has an outcome of direct pressure on a single nerve, can cause pain, tingling and muscle weakness SZ, SS, YH WEB: http://nerve.wustl.edu/nd_compression.php 10029174 nerve compression AE OAE:0001211 Nervous System AE that results in pressure on a root nerve SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/6719259 10061866 nerve root compression AE OAE:0001212 Nervous system AE that results in a lesion occurring on a nerve root SZ, SS, YH 10029188 nerve root lesion AE OAE:0001213 A nervous system AE that has an outcome of inability of maintaining neurological functions. SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/decompensation 10068357 neurological decompensation AE OAE:0001214 Tumor AE that results in a tumor growing on nerve tissue SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/neuroma 10029308 neuroma AE HPO: HP_0009588 SIDER: C0027858 OAE:0001215 a nervous system AE that alters the normal activity of the nervous system due to exposure to neurotoxins (which can be natural or artificial toxic substances), and causes damage to nervous tissue SZ, SS, YH, QL toxic neuropathy AE WEB: http://en.wikipedia.org/wiki/Neurotoxicity 10029350 10067722 neurotoxicity AE OAE:0001216 an immunolgy and allergy investigation result abnormal AE that is chracterized by neutralising antibodies detected in the blood SZ, SS, YH, EB neutralising antibodies positive AE WEB: http://medical-dictionary.thefreedictionary.com/neutralizing+antibody 10064980 neutralizing antibodies positive AE OAE:0001217 a neutropenia AE that compromises the immune system where the number of neutrophil granulocytes, a type of white blood cell, is abnormally low. A neutropenia makes body vulnerable to bacterial and fungal infections. SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/neutropenia 10029354 neutropenia AE HPO: HP_0001875 SIDER: C0027947 OAE:0001218 a neutropenia AE that results in an abnormal number of neutrophils in a newborn infant SZ, SS, YH WEB: http://www.thefreedictionary.com/neonatal, http://medical-dictionary.thefreedictionary.com/neonatal+neutropenia,+alloimmune 10029358 neutropenia neonatal AE OAE:0001219 a gastrointestinal Inflammation AE that results in the cecum, part of the large intestine, being inflamed SZ, SS, YH WEB: http://emedicine.medscape.com/article/183791-overview 10062959 neutropenic colitis AE HPO: HP_0002583 SIDER: C0400823 OAE:0001220 a sepsis AE caused by neutropenia or an abnormally low neutrophil count SZ, SS, YH WEB: http://guidance.nice.org.uk/CG151 10049151 neutropenic sepsis AE OAE:0001221 a white blood cell profile abnormal AE that results in an abnormal number of neutrophil granulocytes, a type of white blood cell (outside the normal range of ~1700 per microliter) SZ, SS, YH, EB WEB: http://www.medterms.com/script/main/art.asp?articlekey=20030 10061313 neutrophil count abnormal AE OAE:0001222 a neutrophil count abnormal AE that has an outcome of decreased neutrophil count SZ, SS, YH, EB neutropenia AE WEB: http://www.mayoclinic.com/health/neutropenia/MY00110 10029366 neutrophil count decreased AE CTCAE: E12198 HPO: HP_0011991 NCIt: C80520 SIDER: NA OAE:0001223 a neutrophil percentage abnormal AE that has an outcome of increase in percentage of neutrophils, a type of white blood cell SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/neutrophil 10052224 neutrophil percentage increased AE OAE:0001224 a hyperplasia AE that has an outcome of liver/biliary system cell overproduction, associated with portal hypertension SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070012/ 10051081 nodular regenerative hyperplasia AE OAE:0001225 a lung disorder AE that has an outcome of adenocarcinomas in an outer area of the lung, squamous cell carcinomas in the center of the lung or large cell carcinomas in any part of the lung SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004462/ 10061873 non-small cell lung cancer AE OAE:0001226 a lung disorder AE that results in the patient suffering from lung cancer at state IV SZ, SS, YH 10029522 non-small cell lung cancer stage iv AE OAE:0001227 an anemia AE that has an outcome of insufficient numbers of red blood cells despite a normal concentration of hemoglobin in the cells SZ, SS, YH normochromic normocytic anaemia AE WEB: http://medical-dictionary.thefreedictionary.com/normocytic+normochromic+anemia 10029783 normochromic normocytic anemia AE HPO: HP_0001897 SIDER: C0271899 OAE:0001229 a respiratory system AE that has an outcome of chronic bronchitis or emphysema which causes the airways to narrow over time SZ, SS, YH WEB: http://www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/article.htm 10061877 obstructive airways disorder AE HPO: HP_0006536 SIDER: C0600260 OAE:0001230 a gastrointestinal investigation result abnormal AE that results in blood that is present in amounts too small to be seen and can be detected only by chemical analysis or microscopic examination SZ, SS, YH, EB WEB: http://dictionary.reference.com/browse/occult+blood WEB: http://medical-dictionary.thefreedictionary.com/occult+blood\ 10061878 occult blood AE OAE:0001231 a gustatory system AE that has an outcome of painful swallowing in the mouth or esophagus. Can lead to weight loss. SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/odynophagia 10030094 odynophagia AE OAE:0001232 a pain AE located in the esophagus SZ, SS, YH oesophageal pain AE WEB: http://medical-dictionary.thefreedictionary.com/oesophageal 10015388 10030180 esophageal pain AE CTCAE: E10661 HPO: HP_0010833 NCIt: C78280 SIDER: C0221727 OAE:0001233 an esophagus AE that results in a narrowing in the esophagus caused by buildup of scar tissue or by a congenital defect SZ, SS, YH oesophageal stenosis AE WEB: http://esophagealstenosis.org/ 10015448 10030194 esophageal stenosis AE CTCAE: E10670 HPO: HP_0010450 NCIt: C34595 SIDER: C0014866 OAE:0001234 an esophagus AE located in the esophagus, can present with heartburn, and nausea SZ, SS, YH oesophagitis AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002138/ 10015461 10030216 esophagitis AE CTCAE: E10687 HPO: HP_0100633 NCIt: C9224 SIDER: C0014868 OAE:0001235 a reproductive system AE that has an outcome of insufficient placenta, the baby may get less oxygen and nutrients SZ, SS, YH placental dysfunction AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002455/ 10030289 oligohydramnios AE HPO: HP_0001562 SIDER: C0079924 OAE:0001236 a nail disorder AE that has an outcome of pain in the fingernails or toenails SZ, SS, YH WEB: http://dictionary.reference.com/browse/onychalgia 10064251 onychalgia AE OAE:0001237 a nail disorder AE that results in the breaking of the fingernails or toenails SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/onychoclasis 10048886 onychoclasis AE HPO: HP_0001808 SIDER: C0546956 OAE:0001238 a nail disorder AE that results in the nail separating from the nail bed starting at distal or lateral attachment SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/16422468 10030337 onycholysis AE HPO: HP_0008400 SIDER: C0085661 OAE:0001240 a nail disorder AE that results in nails spontaneously shedding starting from the proximal end SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/onychomadesis 10049274 onychomadesis AE OAE:0001241 Eye disorder AE that results in chronic glaucoma progressing slowly SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002587/ 10030348 open angle glaucoma AE HPO: HP_0000501 SIDER: C0017612 OAE:0001242 a toxicology drug screen result abnormal AE that results in the patient testing positive for opiates SZ, SS, YH, EB 10063232 opiates positive AE OAE:0001243 a digestive system AE that has an outcome of a fungal infection located in the mouth caused by the candida fungus SZ, SS, YH thrush AE WEB: http://www.medicinenet.com/thrush/article.htm 10030963 oral candidiasis AE HPO: HP_0009098 SIDER: C0006849 OAE:0001244 a digestive system AE that has an outcome of fistula, or an abnormal connection between two epithelium-lined organs or vessels, located in the oral cavity SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/fistula 10065720 oral cavity fistula AE CTCAE: E10888 NCIt: C78506 OAE:0001245 a digestive system AE that has an outcome of a viral infection located in the mouth caused by herpes simplex virus, causes painful sores SZ, SS, YH WEB: http://www.emedicinehealth.com/oral_herpes/article_em.htm 10067152 oral herpes AE OAE:0001246 a gustatory system AE that has an outcome of a decreased amount of substance in food or drinking water ingested SZ, SS, YH oral intake reduced AE OAE:0001247 Digestive System AE that results in oral lesions SZ, SS, YH 10064594 oral mucosa erosion AE OAE:0001248 an erythema AE that results in redness of the oral mucosa area SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/17767983 10067418 oral mucosal erythema AE OAE:0001249 a pain AE located in the oral cavity, pertaining to the mouth SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/oral 10031009 oral pain AE CTCAE: E10904 HPO: HP_0010833 NCIt: C78509 SIDER: C0221776 OAE:0001250 a digestive system AE that has an outcome of disease in the soft tissue of the mouth or systemic diseases involving the mouth SZ, SS, YH WEB: http://clinicaltrials.gov/show/NCT00001601 10031015 oral soft tissue disorder AE OAE:0001252 an edema that results in swelling around the eyes SZ, SS, YH orbital oedema AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/7654583 10031051 orbital edema AE HPO: HP_0100539 SIDER: C0424813 OAE:0001253 a pneumonia AE that results in the healing process being characterized by organization and cicatrizaion of the exudate rather than resolution SZ, SS, YH organising pneumonia AE WEB: Primary Source: http://thorax.bmj.com/content/55/4/318.full Secondary Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1745738/ 10067472 organizing pneumonia AE HPO: HP_0002090 SIDER: C0264383 OAE:0001254 Digestive System AE that is characterized by fungus (mainly Candida albicans, but can be other Candida species - C.glabrata, C. tropicalis, C. krusei) in throat or mouth (Thrush) SZ, SS, YH WEB: http://www.cdc.gov/fungal/candidiasis/thrush/ 10050346 oropharyngeal candidiasis AE HPO: HP_0009098 SIDER: C0919659 OAE:0001255 a digestive system AE that has an outcome of muscle spasm in the oropharynx area SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Oropharyngeal+airway 10031111 oropharyngeal spasm AE HPO: HP_0003739 SIDER: C0234952 OAE:0001256 a bone disorder AE that has an outcome of bacterial infection in the bone SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001473/ 10031252 osteomyelitis AE HPO: HP_0007626 SIDER: C0029443 OAE:0001257 a bone disorder AE that has an outcome of chronic infection of the bone or bone marrow SZ, SS, YH WEB: Primary Source: http://www.posna.org/education/StudyGuide/chronicOsteomyelitis.asp Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/20471296 10031256 osteomyelitis chronic AE OAE:0001259 a bone disorder AE that has an outcome of bone death due to the loss of blood supply, leading to pain and arthritis SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/osteonecrosis.html 10031264 osteonecrosis AE HPO: HP_0010885 SIDER: C0029445 OAE:0001260 a bone disorder AE that has an outcome of disease that affects the maxilla and the mandible, characterized through exposure of the bone through lesions in the gingiva that do not heal SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/16702591 10064658 osteonecrosis of jaw AE HPO: HP_0010885 SIDER: C1401381 OAE:0001261 a bone disorder AE that has an outcome of necrosis or death of bone as a result of exposure to radiation SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/osteoradionecrosis 10067352 osteoradionecrosis AE OAE:0001262 a bone disorder AE that has an outcome of elevation in bone density SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/osteosclerosis 10031298 osteosclerosis AE HPO: HP_0011001 SIDER: C0029464 OAE:0001263 a female reproductive system AE that has an outcome of cancer that starts in the ovaries, female reproductive organs that produce eggs SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001891/ 10033128 ovarian cancer AE HPO: HP_0100615 SIDER: C1140680 OAE:0001264 Female reproductive system AE that results in an enlargement of the patient's ovaries SZ, SS, YH 10033157 ovarian enlargement AE OAE:0001265 a female reproductive system AE that has an outcome of an abnormal mass appearing in the patient's ovaries SZ, SS, YH 10058823 ovarian mass AE OAE:0001267 an oxygen saturation abnormal AE that has an outcome of a decreased percentage of hemoglobin binding sites in the bloodstream occupied by oxygen SZ, SS, YH, EB WEB: Primary Source: http://www.mayoclinic.com/health/hypoxemia/MY00219\ Secondary Source: http://medical-dictionary.thefreedictionary.com/oxygen+saturation 10033318 oxygen saturation decreased AE OAE:0001268 a pain AE that has an outcome of pain in the set of bones that hold the teeth SZ, SS, YH 10033433 pain in jaw AE HPO: HP_0200023 SIDER: C0236000 OAE:0001269 a pain AE located in the skin SZ, SS, YH, MW 10033474 pain of skin AE CTCAE:E13668 HPO: HP_0010833 NCIt:C78516 SIDER: C0241136 OAE:0001270 a erythema AE that is characterized by the reddening of the palms at the thenar and hypothenar eminences SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/18039017 10033551 palmar erythema AE HPO: HP_0007548 SIDER: C0014745 OAE:0001271 a skin AE generally caused by chemotherapy that is characterized by the palms and soles becoming red, swollen, numb and the skin peeling. YH: MedDRA: 10033553 is for "palmar-plantar erythrodysaesthesia syndrome"; MedDRA: 10054524 is for "palmar-plantar erythrodysesthesia syndrome". SZ, SS, YH, MW Hand Food Syndrome AE palmar-plantar erythrodysaesthesia syndrome AE WEB: http://news.cancerconnect.com/hand-foot-syndrome-palmar-plantar-erythrodysesthesia/ palmar-plantar erythrodysesthesia syndrome AE CTCAE: E13672 NCIt: C27177 UMLS CUI: C0549410 OAE:0001272 Tumor AE that results in an undifferentiated growth in the patient's pancreas SZ, SS, YH WEB: Primary Source: http://stanfordhospital.org/digestivehealth/pancreas/conditions/pancreatic-cysts-symptoms-diagnosis.html Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/22855657 10049082 pancreatic mass AE OAE:0001273 a pancreatitis AE that has an outcome of sudden inflammation of the pancreas SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000287.htm 10033647 pancreatitis acute AE HPO: HP_0001735 SIDER: C0001339 OAE:0001274 a pancreatitis AE that results in pancreatitis reoccurring in the patient SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002129/ 10033657 pancreatitis relapsing AE OAE:0001275 Hematopoietic System AE that results in a reduction in the amount of red and white blood cells and platelets in blood SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/pancytopenia 10033661 pancytopenia AE HPO: HP_0001876 SIDER: C0030312 OAE:0001276 an edema AE that has an outcome of optic disc swelling that is caused by increased intracranial pressure SZ, SS, YH papilledema AE WEB: http://medical-dictionary.thefreedictionary.com/Papilloedema 10033703 10033712 papilloedema AE CTCAE: E10411 HPO: HP_0001085 NCIt: C3307 SIDER: C0030353 OAE:0001278 Tumor AE that results in a benign tumor in the parathyroid region SZ, SS, YH parathyroid tumour benign AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001188.htm 10033964 parathyroid tumor benign AE OAE:0001279 a skin infection AE thar occurs around the fingernails and toenailsnail. Bacteria or a type of yeast called Candida cause this infection. Bacteria and yeast can even combine into one infection. SZ, SS, YH, MW nail infection AE WEB: http://www.healthline.com/health/paronychia WEB: https://en.wikipedia.org/wiki/Paronychia 10034016 paronychia AE HPO: HP_0001818 SIDER: C0030578 OAE:0001280 a bone disorder AE that has an outcome of a broken bone caused by disease leading to weakenss of the bone, commonly osteoporosis SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/pathological+fracture 10034156 pathological fracture AE HPO: HP_0005744 SIDER: C0016663 OAE:0001281 a cardiac disorder AE that has an outcome of abnormal accumulation of fluid in the pericardial cavity SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110902/ 10034474 pericardial effusion AE CTCAE: E10172 HPO: HP_0001698 NCIt: C3319 SIDER: C0031039 OAE:0001282 a pain AE that results in soreness around the vaginal opening after giving birth SZ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmed/20002420 10061339 perineal pain AE CTCAE:E13175 NCIt:C78529 OAE:0001283 a digestive system AE that has an outcome of inflammation and infection that destroys the tissues that support the teeth, including the gums, the periodontal ligaments and the tooth sockets SZ, SS, YH gingivitis AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002051/ 牙龈炎 10034536 periodontal disease AE CTCAE: E10935 HPO: HP_0000704 NCIt: C63743 SIDER: C0031090 OAE:0001284 a bone disorder AE that has an outcome of inflammation and infection of the ligaments and bones that support the teeth SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002054/ 10034539 periodontitis AE HPO: HP_0000704 SIDER: C0031099 OAE:0001285 an ischaemia AE that has an outcome of restriction in blood supply to tissues, causing a shortage of oxygen and glucose needed for cellular metabolism YH: MedDRA: 10034576 is for "peripheral ischaemia"; MedDRA: 10034578 is for "peripheral ischemia". SZ, SS, YH peripheral ischaemia AE WEB: Primary Source: http://www.medterms.com/script/main/art.asp?articlekey=4052 Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/6430442 外周缺血 10034576 10034578 peripheral ischemia AE CTCAE:E13810 HPO: HP_0002597 NCIt: C78535 SIDER: C0235490 OAE:0001286 a motor neuropathy AE that results in damage to the nerves outside of the brain and spinal cord SZ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001619/ 10034580 peripheral motor neuropathy AE CTCAE:E12762 HPO: HP_0007178 NCIt:C3500 SIDER: C0235025 OAE:0001287 a peripheral sensory neuropathy AE that results in the patient losing the ability to move or feel. SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000750.htm 10056673 Neuropathy can affect nerves that provide feeling (sensory neuropathy) or cause movement (motor neuropathy). It can also affect both, in which case it is called a sensorimotor neuropathy. peripheral sensorimotor neuropathy AE OAE:0001288 a sensory neuropathy AE that has an outcome of damaged nerves outside the brain and spinal cord SZ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/Peripheral+sensory+neuropathy 10034620 peripheral sensory neuropathy AE CTCAE:E12768 HPO: HP_0000763 NCIt:C3501 SIDER: C0151313 OAE:0001289 an abscess AE that results in a collection of infected material around the tonsils SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001981/ 10034686 peritonsillar abscess AE HPO: HP_0001739 SIDER: C0031157 OAE:0001290 Respiratory system AE characterized by the whooping cough SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002528/ 10034738 pertussis AE OAE:0001291 a hemorrhage AE that has an outcome of tiny pinpoint red dots that form due to broken blood vessels under the skin SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003235.htm 10034754 petechiae AE HPO: HP_0000967 MP: MP_0008816 SIDER: C0031256 OAE:0001292 Inflammation AE that results in an inflammation of the pharyngeal region SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/11172144 10065716 pharyngeal inflammation AE OAE:0001293 a phlebitis that is characterized by blood clots that occur in different locations SZ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/Thrombophlebitis Secondary Source: http://emedicine.medscape.com/article/463256-overview 10034902 phlebitis superficial AE OAE:0001294 a skin AE that results in the patient's skin becoming diseased due to exposure to sunlight SZ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/photodermatosis Secondary Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063367/ 10051246 photodermatosis AE HPO: HP_0000992 SIDER: C0920193 OAE:0001295 a skin AE that shows a cutaneous disease as a result of sun allergy and may be induced by different triggers such as a chemical. MedDRA: 10034972 and UMLS CUI: C0162830 are for "photosensitivity reaction"; MedDRA: 10034966 and UMLS CUI: C0349506 are for "photosensitivity". SZ, SS, YH, MW photosensitivity AE WEB: http://emedicine.medscape.com/article/1049648-overview WEB: http://www.merckmanuals.com/home/skin-disorders/sunlight-and-skin-damage/photosensitivity-reactions 10034966 10034972 photosensitivity reaction AE CTCAE: E13680 HPO: HP_0000992 NCIt: C38004 SIDER: C0162830 UMLS CUI: C0349506; UMLS CUI: C0162830 OAE:0001296 a skin AE that has an outcome of loss or reduction in human skin color, may be related to loss of melanocytes or inability of melanocytes to produce melanin SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/skinpigmentationdisorders.html 10062080 pigmentation disorder AE HPO: HP_0001000 SIDER: C0549567 OAE:0001297 a conduction system disorder AE that refers to partial or complete block of electrical impulses originating in the atrium or sinus node, preventing them from reaching the AV node and ventricles SS AV block heart block WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 10003671 atrioventricular block AE HPO: HP_0001678 SIDER: C0004245 OAE:0001298 a respiratory system AE that has an outcome of fluid buildup between the layers of tissue that line the lungs and chest cavity SZ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001150/ 10035598 pleural effusion AE CTCAE:E13486 HPO: HP_0002202 NCIt:C3331 SIDER: C0032227 OAE:0001299 a hemorrhage AE that has an outcome of bleeding in the pleural cavity, the potential space between the two pleura of the lungs MedDRA: 10035601 is for "pleural haemorrhage"; MedDRA: 10055319 is for "pleural hemorrhage". SZ, SS, YH pleural haemorrhage AE WEB: http://medical-dictionary.thefreedictionary.com/hemothorax 10035601 10055319 pleural hemorrhage AE CTCAE: E13492 NCIt: C50582 UMLS CUI: C0019123 OAE:0001300 a lung disorder AE that has an outcome of inflammation of the lining of the lungs and chest that leads to chest pain SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002347/ 10035618 pleurisy AE HPO: HP_0002102 SIDER: C0032231 OAE:0001301 a pain AE induced by inflammation in the lungs that is characterized by sharp or stabbing pain in the chest SZ, SS, YH, MW WEB: http://pleuriticchestpain.net/, http://medical-dictionary.thefreedictionary.com/Pleuritic+chest+pain 10035623 pleuritic pain AE CTCAE:E13498 NCIt:C78564 OAE:0001302 a gastrointestinal disorder AE that results in gas cysts developing within the walls of the small or large intestine SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/9530294 10057030 pneumatosis intestinalis AE OAE:0001303 a pneumonia AE that has an outcome of a fungal infection of the lungs by Pneumocystis jiroveci SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001692/ 10064108 pneumocystis jiroveci pneumonia AE HPO: HP_0002096 SIDER: C1535939 OAE:0001304 Respiratory System AE that results in air being present in the mediastinum SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001148/ 10050184 pneumomediastinum AE OAE:0001305 a pneumonia AE that has an outcome of inflammation in the lungs and airways to the lungs from breathing in foreign material SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000121.htm 10035669 pneumonia aspiration AE HPO: HP_0002100 SIDER: C0032290 OAE:0001306 a pneumonia AE that has an outcome of an acute systemic disease with involvement of the lungs, caused by Mycoplasma pneumoniAE and marked by high fever and cough SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/primary+atypical+pneumonia 10035730 pneumonia primary atypical AE OAE:0001307 a lung inflammation AE located in the lung tissue SZ, SS, YH, MW pulmonitis AE WEB: http://medical-dictionary.thefreedictionary.com/pneumonitis 10035742 pneumonitis AE CTCAE:E13502 NCIt:C3333 OAE:0001308 a lung disorder AE that has an outcome of a collapsed lung due to collection of air in the space around the lungs. SZ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001151/ 10035759 pneumothorax AE CTCAE:E13508 HPO: HP_0006522 NCIt:C38006 SIDER: C0032326 OAE:0001309 a urinary system AE that results in abnormally frequent urination SZ, SS, YH frequent micturition AE polyuria AE WEB: http://www.merriam-webster.com/medical/pollakiuria 10036018 pollakiuria AE HPO: HP_0000103 SIDER: C0042023 OAE:0001310 a hematopoietic disorder AE that results in the bone marrow producing too many red blood cells SZ, SS, YH polycythaemia vera AE WEB: http://medical-dictionary.thefreedictionary.com/Polycythaemia+vera 10036057 polycythemia vera AE OAE:0001311 a hypertension AE located in the heptatic portal system caused by obstruction or occlusion that produces splenomegaly and ascites in its later stages SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21129318 http://www.merriam-webster.com/medlineplus/portal%20hypertension 10036200 portal hypertension AE CTCAE: E11238 HPO: HP_0001409 NCIt: C3119 SIDER: C0020541 OAE:0001312 a thrombosis AE that has an outcome of formation of a blood clot affecting the hepatic portal vein, can lead to hypertension or reduction of blood supply to the liver SZ, SS, YH PVT WEB: http://medical-dictionary.thefreedictionary.com/portal+vein+thrombosis 10036206 portal vein thrombosis AE CTCAE: E11243 NCIt: C78565 OAE:0001313 a syndrome that results in the patient suffering a set of problems after having a spinal tap procedure SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/19921503 10060854 post lumbar puncture syndrome AE OAE:0001314 Fever AE that results in a fever occurring after an operation SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22774619 10050087 postoperative fever AE OAE:0001315 A thrombosis AE that occurs after an operation that results in a blood clot in a blood vessel disrupting blood flow throughout the body SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/19756494 10050902 postoperative thrombosis AE OAE:0001316 Female reproductive system AE that results in the patient getting pregnant even when using a contraceptive SZ, SS, YH 10067667 pregnancy on contraceptive AE OAE:0001317 a perinatal AE that has an outcome of premature baby SZ, SS, YH 10036590 premature baby AE OAE:0001318 a pregnancy AE that has an outcome of labor beginning prior to the 37th week of gestation SZ, SS, YH premature labour AE preterm labor AE WEB: http://wordnetweb.princeton.edu/perl/webwn?s=premature%20labor 10036600 premature labor AE OAE:0001319 a sensory capability AE that has an outcome of a near-fainting episode which may include lightheadedness, dizziness, severe weakness, blurred vision, which may precede syncopal episode SZ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/presyncope 10036653 presyncope AE CTCAE:E12778 HPO: HP_0002321 NCIt:C80100 SIDER: C0700200 OAE:0001320 a bone disorder AE that has an outcome of a piece of dead bone that completely separates from sound bone during the process of necrosis SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/primary+sequestrum 10052460 primary sequestrum AE OAE:0001321 a coronary artery disorder AE that results in cardiac pain at rest that occurs in cycles SZ, SS, YH Prinzmetal's angina AE coronary vessel spasm AE WEB: http://medical-dictionary.thefreedictionary.com/prinzmetal+angina 10036759 prinzmetal angina AE HPO: HP_0001681 SIDER: C0002963 OAE:0001322 a digestive system AE that results in the pain located at the anus or in the rectum SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/proctalgia 10036772 proctalgia AE HPO: HP_0004378 SIDER: C0034886 OAE:0001323 A medical intervention that is a procedure occuring in the inside structures of the tooth, including the dental pulp and tooth root, and the periapical tissue surrounding the root. YH, SS WEB: http://medical-dictionary.thefreedictionary.com/endodontic 10051085 endodontic procedure OAE:0001326 a cough AE that has an outcome of secretions that could be mucous or blood SZ, SS, YH, MW WEB: http://coldflu.about.com/od/glossary/g/productivecough.htm 10036790 productive cough AE CTCAE:E13517 NCIt:C78569 OAE:0001327 a tumor AE that has an outcome of cancer that starts in the prostate gland, the small structure that wraps around the urethra carrying urine out of the body SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001418/ 10060862 prostate cancer AE HPO: HP_0012125 SIDER: C0376358 OAE:0001328 a physical examination result abnormal AE that results in a prostate exam being different than expected SZ, SS, EB 10055025 prostate examination abnormal AE OAE:0001329 a male reproductive system AE that has an outcome of an increased amount of prostatic specific antigen, a glycoprotein enzyme present in small quantities in the serum of men with healthy prostates. May indicate prostate cancer or prostate disorders SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23277770 10036975 prostatic specific antigen increased AE OAE:0001330 a protein and chemistry analysis result abnormal AE that is characterized by the protein level in the body being abnormal SZ, SS, YH, EB 10037012 protein total abnormal AE OAE:0001331 a prothrombin level abnormal AE that is characterized by a decrease in level of prothrombin in body SZ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/prothrombin 10037050 prothrombin level decreased AE OAE:0001332 a prothrombin time abnormal AE that has an outcome of prolonged time for plasma in the blood to clot SZ, SS, YH, EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003652.htm 10037063 prothrombin time prolonged AE OAE:0001333 a digestive system AE that has an outcome of infection in the large intestine with an overgrowth of Clostridium difficile bacteria SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001305/ 10037128 pseudomembranous colitis AE HPO: HP_0002583 SIDER: C1257843 OAE:0001334 a bacterial infection AE that has an outcome of infection by genus Pseudomonas, typically targets respiratory tract SZ, SS, YH WEB: http://emedicine.medscape.com/article/970904-overview 10061471 pseudomonas infection AE HPO: HP_0005429 SIDER: C0033817 OAE:0001335 a psychiatric disorder AE that results in physical pain being caused by the patient's life stresses SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/psychosomatic+disease 10049587 psychosomatic disease AE OAE:0001336 A mental disorder AE that results in abnormal condition of the mind SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/psychotic+disorder 10061920 psychotic disorder AE HPO: HP_0000709 SIDER: C0033975 OAE:0001338 a lung disorder AE that has an outcome of hypertension or abnormally high blood pressure in the arteries of the lungs SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001171/ 10064911 pulmonary arterial hypertension AE HPO: HP_0002092 SIDER: C2973725 OAE:0001339 a lung disorder AE that has an outcome of engorgement of pulmonary vessels with transudation of fluid into the alveolar and interstitial spaces, seen in cardiac disease, infections, and certain injuries SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/pulmonary+congestion 10037368 pulmonary congestion AE HPO: HP_0004930 SIDER: C0242073 OAE:0001340 an arterial embolism AE that results in the blockage of the main artery of a lung or one of its branches by a substance that has travelled from elsewhere in the body through the bloodstream [SS] moved by relation 'SubclassOf' from lung disorder AE to arterial embolism on 01/07/14 SZ, SS, YH pulmonary artery thrombosis AE pulmonary thrombosis AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23299609 10037377 10037437 pulmonary embolism AE HPO: HP_0002204 SIDER: C0034065 OAE:0001341 a lung disorder AE wih the outcome of damaged or scarred lung tissue. Thickened tissue impairs lung function SZ, SS, YH, MW WEB: http://www.mayoclinic.com/health/pulmonary-fibrosis/DS00927 10037383 pulmonary fibrosis AE CTCAE:E13527 HPO: HP_0002206 NCIt:C26869 SIDER: C0034069 OAE:0001342 a lung disorder AE that has an outcome of acute bleeding from the lung, especially in the upper respiratory tract and the endotracheal tube SZ, SS, YH pulmonary haemorrhage AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23217914 10037394 pulmonary hemorrhage AE OAE:0001343 a lung disorder AE that has an outcome of abnormally high blood pressure in the arteris of the lungs SZ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001171/ 10037400 pulmonary hypertension AE CTCAE:E13539 HPO: HP_0002092 NCIt:C3120 SIDER: C0020542 OAE:0001344 a lung disorder AE that has an outcome of an abnormal spot in the lungs that is more than 3 cm in size SZ, SS, YH WEB: http://lungcancer.about.com/od/whatislungcancer/a/Lung-Mass.htm 10056342 pulmonary mass AE OAE:0001345 a lung disorder AE that has an outcome of edema or abnormal buildup of fluid in the air sacs of the lungs, leads to shortness of breath MedDRA: 10037423 is for "pulmonary oedema"; MedDRA: 10037375 is for "pulmonary edema" SZ, SS, YH, MW pulmonary oedema AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001195/ pulmonary edema AE CTCAE: E13521 HPO: HP_0100598 NCIt: C26868 SIDER: C0034063 UMLS CUI: C0034063 OAE:0001346 a cardiovascular disorder AE that has an outcome of an inability to detect pulse SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003078.htm 10037469 pulse absent AE OAE:0001347 a cardiovascular disorder AE that has an outcome of abnormally low pulse pressure, less than 25% of systolic value. Can indicate blood loss or low stroke volume SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/pulse+pressure 10037480 pulse pressure decreased AE OAE:0001348 an adverse event with an outcome of the release or secretion of pus SZ, SS, YH WEB: http://www.medterms.com/script/main/art.asp?articlekey=21858 10037569 purulent discharge AE OAE:0001349 a kidney disorder AE that is characterized by the dilation of calices, usually due to obstruction or infection SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/calicectasis 10061927 pyelocaliectasis AE OAE:0001350 an injury AE caused by ionizing radiation SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Radiation+Injuries 10037760 radiation injury AE OAE:0001351 a digestive system AE that results in the inflammation of mucous membranes lining the digestive tract. Caused by radiation, can lead to mouth sores SZ, SS, YH WEB: http://www.medterms.com/script/main/art.asp?articlekey=19881 10037763 radiation mucositis AE OAE:0001352 a digestive system AE that has an outcome of inflammation that radiation causes swelling of the esophagus SZ, SS, YH radiation oesophagitis AE WEB: http://medical-dictionary.thefreedictionary.com/esophagitis 10048899 radiation esophagitis AE OAE:0001353 a lung inflammation AE due to radiation therapy SZ, SS, YH WEB: http://www.medterms.com/script/main/art.asp?articlekey=8091 10037765 radiation pneumonitis AE OAE:0001354 a skin AE that has an outcome of injury to the skin and underlying tissues from exposure to a large external dose of radiation SZ, SS, YH WEB: http://www.bt.cdc.gov/radiation/criphysicianfactsheet.asp 10063562 radiation skin injury AE NCIt: C3349 OAE:0001355 a respiratory system AE that has an outcome of clicking, rattling or crackling noises made by one or both lungs during inhalation SZ, SS, YH Crackles WEB: http://medical-dictionary.thefreedictionary.com/crackles 10037833 rales AE OAE:0001356 a rash ae adverse event that results in redness of the skin, caused by hyperemia of the capillaries in the lower layers of the skin SZ, SS, YH rash erythematous AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23145421 10037855 erythematous rash AE HPO: HP_0007432 SIDER: C0234913 OAE:0001357 a rash AE occuring in several areas of the body SZ, SS, YH rash (generalized) AE rash generalised AE WEB: http://www.freemd.com/rash-generalized/overview.htm 10037858 generalized rash AE HPO: HP_0000988 SIDER: C0497365 OAE:0001358 a rash AE that has an outcome of an unpleasant sensation of the skin that provokes the uge to scratch SZ, SS, YH WEB: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/dermatology/pruritus-itch/ 10037884 rash pruritic AE OAE:0001359 an inflammation AE that has an outcome of an inflammatory reaction limited to a previously X-irradiated field when the patient is treated months/years later with certain drugs SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/7577597 10060856 recall phenomenon AE OAE:0001360 Digestive System AE that results in bleeding in the rectal area SZ, SS, YH rectal haemorrhage AE 10038063 10038064 rectal hemorrhage AE CTCAE: E10955 HPO: HP_0002573 NCIt: C27054 SIDER: C0267596 OAE:0001361 a red blood cell count abnormal AE that has an outcome of a decrease in red blood cells SZ, SS, YH, EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003644.htm 10038153 red blood cell count decreased AE HPO: HP_0001903 SIDER: C0427457 OAE:0001362 a digestive system disorder AE that results in the inflammation of the stomach lining due to reflux SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/gastritis 10057969 reflux gastritis AE OAE:0001363 a digestive system AE located in the esophagus, can present with heartburn, and nausea, caused by gastroesophageal reflux disease SZ, SS, YH reflux oesophagitis AE WEB: http://medical-dictionary.thefreedictionary.com/esophagitis 10038263 reflux esophagitis AE HPO: HP_0100633 SIDER: C0014869 OAE:0001364 a kidney disorder AE that results in kidneys failing to adequately filter toxins and waste from the blood SZ, SS, YH kidney failure AE renal insufficiency AE WEB: http://medical-dictionary.thefreedictionary.com/renal+failure 10038435 renal failure AE HPO: HP_0000083 SIDER: C0035078 OAE:0001365 a kidney disorder AE that results in the rapid loss or decline of kidney function As shown on the renal.org website (http://www.renal.org/guidelines/modules/acute-kidney-injury), Acute kidney injury (AKI) has now replaced the term acute renal failure. SZ, SS, YH, Izabela Birsanescu, MW AKI renal failure acute AE WEB: http://medical-dictionary.thefreedictionary.com/acute+renal+failure WEB: http://www.mayoclinic.org/diseases-conditions/kidney-failure/basics/definition/con-20024029 10038436 10069339 Acute kidney failure occurs when kidneys become unable to filter waste products from blood. acute kidney injury AE CTCAE:E12973 HPO: HP_0001919 NCIt:C26808 SIDER: C0022660 OAE:0001366 a kidney disorder AE that results in the kidneys failing to adequately filter toxins and waste from the blood SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23263712 10062237 renal impairment AE HPO: HP_0000082 SIDER: C0341697 OAE:0001367 kidney disorder AE that results in the renal tubule wasting away and losing strength/functional abilities SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/nephron 10038536 renal tubular atrophy AE OAE:0001368 a kidney disorder AE that results in the renal artery narrowing SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/renal+artery+stenosis 10038553 renal vessel disorder AE OAE:0001369 Respiratory system AE that is characterized by conditions that affect organs and systems that deal with gas exchange SZ, SS, YH WEB: http://www.thefreedictionary.com/respiratory+disorder 10038683 respiratory disorder AE HPO: HP_0002086 SIDER: C0035204 OAE:0001370 a respiratory system AE that has an outcome of a condition where lungs cannot remove all the carbon dioxide the body produces, makes body fluid too acidic SZ, SS, YH respiratory failure AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001154/ 10038695 respiratory acidosis AE CTCAE:E13545 HPO: HP_0004877 NCIt:C26872 SIDER: C1145670 OAE:0001371 a respiratory system AE that has an outcome of a ventilory rate greater than 20 breaths per minute SZ, SS, YH WEB: http://www.thefreedictionary.com/tachypnea 10038712 respiratory rate increased AE OAE:0001372 Respiratory System AE that results in bleeding somewhere in the respiratory system SZ, SS, YH respiratory tract haemorrhage AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/8692086 10038727 respiratory tract hemorrhage AE OAE:0001373 an infection AE that has an outcome of infection in the respiratory tract, includes pneumonia as well as lung abscess and acute bronchitis SZ, SS, YH WEB: http://www.thefreedictionary.com/respiratory+tract+infection 10062352 respiratory tract infection AE HPO: HP_0002873 SIDER: C0035243 OAE:0001374 an eye disorder AE that has an outcome of bleeding in the eye SZ, SS, YH retinal haemorrhage AE WEB: http://medical-dictionary.thefreedictionary.com/retinal+hemorrhage 10038867 retinal hemorrhage AE HPO: HP_0000573 SIDER: C0035317 OAE:0001375 Eye Disorder AE that results in a tearing of retinal pigment epithelial tissue SZ, SS, YH 10062971 retinal pigment epithelial tear AE OAE:0001376 Amnesia AE that results in the patient forgeting things that happened before the onset of an injury or disease SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/retrograde+amnesia 10038965 retrograde amnesia AE HPO: HP_0002354 SIDER: C0002624 OAE:0001377 an encephalopathy AE that is characterized by headache, confusion, seizures and visual loss, tends to resolve over time SZ, SS, YH, MW 10063761 reversible posterior leukoencephalopathy syndrome AE CTCAE:E12798 NCIt:C78598 OAE:0001378 a muscle adverse event that results in damaged skeletal muscle tissue breaks down rapidly SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/rhabdomyolysis 10039020 rhabdomyolysis AE HPO: HP_0009045 SIDER: C0035410 OAE:0001379 a right ventricular dysfunction AE that has an outcome of congestive heart failure manifested by distention of the neck veins, enlargement of the liver, and dependent edema SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/right+ventricular+failure 10039163 right ventricular failure AE HPO: HP_0001708 SIDER: C2939447 OAE:0001380 A pregnancy AE that results in the growing pregnancy in a woman's fallopian tube becoming larger than the tube and causing it to rupture SZ, SS, YH WEB: http://www.freemd.com/ruptured-ectopic-pregnancy/overview.htm 10048407 ruptured ectopic pregnancy AE OAE:0001381 an abnormal salivary gland physiology AE that results in the salivary glands becoming irritated and/or swollen SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/salivaryglanddisorders.html 10061935 salivary gland disorder AE HPO: HP_0010286 SIDER: C0036093 OAE:0001382 a skin AE that has an outcome of a hard coating formed during the wound healing reconstruction phase SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/scab 10039509 scab AE HPO: HP_0007564 SIDER: C0205204 OAE:0001383 a nervous system AE that results in the sciatic nerve losing its sensory capabilities SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21995439 10039670 sciatic nerve injury AE OAE:0001384 an eye disorder AE that is characterized by an excessive accumulation of blood in the eye SZ, SS, YH scleral hyperaemia AE WEB: http://medical-dictionary.thefreedictionary.com/hyperaemia 10052130 scleral hyperemia AE OAE:0001385 a dementia AE that results in an elderly patient suffering from dementia SZ, SS, YH 10039966 senile dementia AE OAE:0001386 a sensory capability AE that results in the patient feeling their blood flow SZ, SS, YH 10039996 sensation of blood flow AE OAE:0001387 a shock AE that has an outcome of life-threatening low blood pressure SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001689/ 10040070 septic shock AE HPO: HP_0002718 SIDER: C0036983 OAE:0001389 Blood cell lab test abnormal AE showing an increase in the number of immature leukocytes in peripheral blood. (in hematology) a predominance of immature leukocytes noted in a differential white blood cell count. It is usually indicative of an infection or inflammation. The term derives from a graph of blood components in which immature cell frequencies appear on the left side of the graph. SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/shift 10056383 shift to the left AE OAE:0001390 a physiological shock AE that has an outcome of hypovolemic shock resulting from acute hemorrhage and characterized by hypotension, tachycardia, oliguria, and by pale, cold and clammy skin SZ, SS, YH shock haemorrhagic AE WEB: http://medical-dictionary.thefreedictionary.com/hemorrhagic+shock 10049771 shock hemorrhagic AE OAE:0001391 a gastrointestinal disorder AE that results in the sigmoid colon being inflamed SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/sigmoiditis 10052058 sigmoiditis AE OAE:0001392 a respiratory system AE that has an outcome of disease in the air-filled spaces that surround the nasal cavity, above the eyes and behind the ethmoids SZ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/paranasal+sinuses 10062244 sinus disorder AE CTCAE:E13560 NCIt:C26843 OAE:0001393 a tachycardia AE that has an outcome of elevated impulses originating from the sinoatrial node, greater than 100 bpm SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/sinus+tachycardia 10040752 sinus tachycardia AE CTCAE: E10214 HPO: HP_0001649 NCIt: C26889 SIDER: C0039239 OAE:0001394 a skin AE that is characterized by sore, cracked, or rough skin, usually on the hands, face and lips. SZ, SS, YH WEB: http://wellbeing.doctissimo.com/wellbeing-a-z/chapped-skin.html 10040813 skin chapped AE OAE:0001395 a skin AE that results in linear-like cleavages in the skin SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/fissure 10040849 skin fissures AE OAE:0001396 a skin AE that has an outcome of bleeding at the skin SZ, SS, YH skin haemorrhage AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003235.htm 10064265 skin hemorrhage AE HPO: HP_0000967 SIDER: C0852361 OAE:0001397 a skin AE that has an outcome of darkening in an area of skin or nails caused by increased melanin SZ, SS, YH, MW WEB: http://medical-dictionary.thefreedictionary.com/hyperpigmentation 10040865 skin hyperpigmentation AE CTCAE:E13718 HPO: HP_0010284 NCIt:C79731 SIDER: C0162834 OAE:0001398 a skin AE that has an outcome of infection. Can be bacterial, fungal, parasitic or viral SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/skin+infection 10040872 skin infection AE CTCAE: E11568 HPO: HP_0001581 NCIt: C35025 SIDER: C0037278 OAE:0001399 a skin AE that has an outcome of a jagged wound, can be shallow cuts or deep gahes that penetrate through muscle to internal organs and bone SZ, SS, YH WEB: http://www.mdguidelines.com/lacerations 10058818 skin laceration AE OAE:0001400 a skin AE that has an outcome of a superficial growth or patch of the skin that does not resemble the area surrounding it SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Skin+Lesions 10040882 skin lesion AE HPO: HP_0011355 SIDER: C0037284 OAE:0001401 a skin AE that has an outcome of exposure of skin to nonspecific irritants or from the action of specific allergens SZ, SS, YH WEB: http://encyclopedia2.thefreedictionary.com/Skin+Reactions 10040914 skin reaction AE OAE:0001402 a skin AE that has an outcome of irritation, sensitization and phototoxicity SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/dermal+toxicity 10059516 skin toxicity AE OAE:0001403 a behavior and neurological AE that results in irregular sleep patterns SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/sleep+disorder 10040984 sleep disorder AE HPO: HP_0002360 SIDER: C0851578 OAE:0001404 an eating disorder AE that is characterized by patient searching for food while asleep SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23205019 10067315 sleep-related eating disorder AE OAE:0001405 a gastrointestinal disorder AE that has an outcome of a blockage that keeps substance from passing through the small intestine, may be caused by fibrous bands of tissue in the abdomen, inflamed/infected pouches in the intestine, or hernias and tumors SZ, SS, YH WEB: http://www.mayoclinic.com/health/intestinal-obstruction/DS00823 10041101 small intestinal obstruction AE CTCAE: E11021 HPO: HP_0005214 NCIt: C78615 SIDER: C0235329 OAE:0001407 a gastrointestinal disorder AE in which the blood vessels in the small intestine narrow SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/stenosis 10062263 small intestinal stenosis AE CTCAE: E11032 NCIt: C78617 OAE:0001408 a tumor AE that results in cancer in the small intestine SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/small+intestine+cancer 10054184 small intestine carcinoma AE OAE:0001409 a gastrointestinal disorder AE that results in an ulcer in the patient's small intestine SZ, SS, YH 10041133 small intestine ulcer AE CTCAE: E11038 NCIt: C78619 OAE:0001410 a connective tissue disorder AE that occurs in the non-skeletal tissue, usually subcutaneous and muscle tissue SZ, SS, YH WEB: http://www.reference.md/files/D018/mD018461.html 10062255 soft tissue infection soft tissue infection AE CTCAE: E11579 HPO: HP_0002719 NCIt: C79745 SIDER: C0149778 OAE:0001411 a connective tissue disorder AE that results in damage to muscles, ligaments, and tendons throughout the body SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22964676 10041291 soft tissue injury AE OAE:0001412 a necrosis AE that results in necrosis occurring in soft tissue SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/necrosis 10065769 soft tissue necrosis AE OAE:0001413 a behavior and neurological AE that results in the patient hvings a mental disorder with symptoms that may suggest physical illness or injury SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/somatoform+disorder 10054153 somatoform disorder AE OAE:0001414 a bone disorder AE that has an outcome of vertebra collapse caused by small hairline fractures SZ, SS, YH WEB: http://www.webmd.com/osteoporosis/guide/spinal-compression-fractures-causes 10041541 spinal compression fracture AE OAE:0001415 a nervious system AE that has an outcome of spinal cord compressed by bone fragments from a vertebral fracture, a tumor, abscess, ruptured intervertebral disc or other lesion SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/spinal+cord+compression 10041549 spinal cord compression AE HPO: HP_0002176 SIDER: C0037926 OAE:0001416 Tumor AE that results in a tumor in the patient's spinal cord SZ, SS, YH 10062261 spinal cord neoplasm AE OAE:0001417 Spinal osteoarthritis AE is a osteoarthritis AE that has an outcome of degeneration of the protective cartilage that cushions the tops of bones, causes swelling and pain and may cause development of osteophytes. SZ, SS, YH WEB: http://www.webmd.com/osteoarthritis/guide/spinal-osteoarthritis-degenerative-arthritis-of-the-spine 10041591 spinal osteoarthritis AE HPO: HP_0002758 SIDER: C0949690 OAE:0001418 an immune system disorder AE that has an outcome of a larger-than-normal spleen, affects blood filtration SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003276.htm 10041660 splenomegaly AE HPO: HP_0001744 SIDER: C0038002 OAE:0001419 a microbiology and serology investigation result abnormal AE that has an outcome of bacterial infection in the lungs or breathing passages SZ, SS, YH, EB WEB: http://www.webmd.com/lung/sputum-culture 10051612 sputum culture positive AE OAE:0001420 a respiratory system AE that shows increased sputum, which results in mucous material coughed up from the lungs by the patient. SZ, SS, YH WEB: http://www.medterms.com/script/main/art.asp?articlekey=5539 10041812 sputum increased AE HPO: HP_0002105 SIDER: C0235567 OAE:0001421 a skin AE that has an outcome of a type of nonmelanoma skin cancer SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001832/ 10041823 squamous cell carcinoma AE HPO: HP_0006739 SIDER: C0007137 OAE:0001422 a bacterial infection AE that has an outcome of invasion by Staphylococcus, can present with pus, fever, chills and low blood pressure SZ, SS, YH WEB: http://www.medicinenet.com/staph_infection/page2.htm 10058080 staphylococcal infection AE HPO: HP_0007499 SIDER: C0038160 OAE:0001423 a skin AE that results in the skin in the leg undergoing discoloration due to blood pooling as a result of insufficient venous return SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000834.htm 10041955 stasis dermatitis AE OAE:0001424 a device occlusion AE that has an outcome of blockage of the stent, or a tube inserted into body to prevent or counteract a disease-induced, localized flow constriction SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/002303.htm 10049936 stent occlusion AE OAE:0001425 a skin adverse event that is characterized by cell death causing the epidermis to separate from the dermis SZ, SS, YH, MW WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001854/ 10042033 stevens-johnson syndrome AE CTCAE:E13736 HPO: HP_0000951 NCIt:C79484 SIDER: C0038325 OAE:0001426 a stress AE that results in patient experiencing stress at work SZ, SS, YH 10042210 stress at work AE OAE:0001428 a nervous system AE that has an outcome of bleeding in the area between the brain and the thin tissues that cover the brain SZ, SS, YH subarachnoid haemorrhage AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001720/ 10042316 subarachnoid hemorrhage AE HPO: HP_0002138 SIDER: C0038525 OAE:0001429 a nervous system AE that has an outcome of a collection of blood on the surface of the brain SZ, SS, YH subdural haematoma AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001732/ 10042361 subdural hematoma AE HPO: HP_0100309 SIDER: C0018946 OAE:0001430 A gastrointestinal hemorrhage AE that has an outcome of the bleeding in the stomach YH, SS gastric haemorrhage AE 10017788 10017789 gastric hemorrhage AE CTCAE: E10706 NCIt: C54582 OAE:0001431 a death AE that has an outcome of unexpected death, 1 to 24 hours after the onset of symptoms SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/sudden+death 10042434 10042435 sudden death AE CTCAE: E11171 HPO: HP_0001645 NCIt: C50911 SIDER: C0011071 OAE:0001432 a psychiatric disorder AE that results in thoughts about suicide SZ, SS, YH, MW WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/Suicidal+ideation Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/10193592 10042458 suicidal ideation AE CTCAE:E12964 NCIt:C80102 OAE:0001433 a psychiatric disorder AE that results in attempted suicide SZ, SS, YH, MW 10042464 suicide attempt AE CTCAE:E12969 HPO: HP_0000708 NCIt:C80111 SIDER: C0038663 OAE:0001434 a viral infection AE that has an outcome of a cell that was previously infected being coinfected with a different strain of the virus SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/superinfection 10042566 superinfection AE HPO: HP_0005364 SIDER: C0038826 OAE:0001435 a venous thrombosis AE in which a stroke occurs as a result of thrombosis. uncommon cerebrovascular accident that is frequently associated with diseases that may contribute to the development of thrombosis through hypercoagulability, stasis of the local blood stream, and abnormalities of the vessel wall. SZ, SS, YH SSST WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1026412 WEB: http://www.ncbi.nlm.nih.gov/pubmed/1455986 10042567 superior sagittal sinus thrombosis AE OAE:0001436 an arrhythmia AE that has an outcome of premature atrial contractions or beats caused by signals originating from ectopic atrial sites SZ, SS, YH WEB: http://sideeffects.embl.de/se/C0033036/ 10042602 supraventricular extrasystoles AE HPO: HP_0005115 SIDER: C0033036 OAE:0001437 a tachycardia AE that has an outcome of rapid heart rhythm originating at or above the atrioventricular node SZ, SS, YH WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001235/ Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23233691 10042604 supraventricular tachycardia AE CTCAE: E10218 HPO: HP_0004765 NCIt: C35061 SIDER: C0039240 OAE:0001438 Adverse event that is characterized by the patient becoming increasingly suspicious SZ, SS, YH 10042635 suspiciousness AE OAE:0001439 an injury and procedural complication AE that results in a complication resulting from a suture SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/17276274 10059059 suture related complication AE OAE:0001440 a surgery AE that results in a suture being used to hold body tissues together, ruptures SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21266279 10048547 suture rupture AE OAE:0001441 an increased heartbeat AE that is characterized by a distburance of the heart rhythm in which heart rate is abnormally increased SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/tachyarrhythmia 10049447 tachyarrhythmia AE HPO: HP_0001649 SIDER: C0080203 OAE:0001442 a tachycardia AE that results in tachycardia beginings and ending in an acute manner SZ, SS, YH WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/11208235 Secondary Source: http://www.nlm.nih.gov/medlineplus/ency/article/000183.htm 10043079 tachycardia paroxysmal AE OAE:0001443 an abnormal repiration AE that shows an outcome of tachypnoea (i.e., abnormally rapid breathing or respiration) SZ, SS, YH tachypnoea AE 10043089 tachypnea AE HPO: HP_0004346 SIDER: C0231835 OAE:0001445 Behavior and neurological AE that results in the patient having recurring seizures SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001714/ 10043209 temporal lobe epilepsy AE OAE:0001446 An immune system disorder AE that is a complication that can occur after a stem or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body YH, SS GVHD WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001309.htm 10018651 graft versus host disease AE OAE:0001447 a hematopoietic system AE that has an outcome of too many blood platelets or thrombocytes, can result in headache, lightheadedness, vision changes and limb numbness SZ, SS, YH thrombocythaemia AE WEB: http://www.mayoclinic.com/health/thrombocythemia/DS01087 10015493 thrombocythemia AE OAE:0001448 a hematopoietic system AE that has an outcome of decrease in platelets in the blood SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm 10043554 thrombocytopenia AE HPO: HP_0001873 SIDER: C0040034 OAE:0001449 a phlebitis AE located in the vein, caused by a blood clot SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002098/ WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001108.htm 10043570 thrombophlebitis AE HPO: HP_0004418 SIDER: C0040046 OAE:0001450 a thrombosis AE that is characterized by a pathological process involving thrombocytopenia, microangiopathic haemolytic anaemia and microvascular occlusion SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/22802583 WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/18215115 Secondary Source: http://www.nejm.org/doi/full/10.1056/NEJMra020528 10043645 thrombotic microangiopathy AE HPO: HP_0002597 SIDER: C2717961 OAE:0001451 a tumor AE that results in a benign tumor in the thyroid SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004524/ 10043688 thyroid adenoma AE HPO: HP_0000854 SIDER: C0151468 OAE:0001452 a tumor AE that results in the patient hvings a mass growing in their thyroid SZ, SS, YH 10058900 thyroid mass AE OAE:0001453 an arrhythmia AE that has an outcome of an irregular rate of the heartbeat YH, SS 10019304 heart rate irregular AE HPO: HP_0011675 SIDER: C0237314 OAE:0001454 a syndrome AE that results in the patient suffering from withdrawal from not using tobacco SZ, SS, YH 10059612 tobacco withdrawal symptoms AE OAE:0001455 a tongue AE that has an outcome of open sores or cuts on the tongue SZ, SS, YH WEB: http://www.localhealth.com/article/tongue-ulcers 10043991 tongue ulceration AE HPO: HP_0000155 SIDER: C0235351 OAE:0001456 Tumor AE that results in cancer in the patient's tonsils SZ, SS, YH 10044002 tonsil cancer AE OAE:0001457 a bone disorder AE that has an outcome of an abscess located in the tooth or a bacterial infection in the center of a tooth SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002055/ 10044016 tooth abscess AE HPO: HP_0000164 SIDER: C0518988 OAE:0001458 a bone disorder AE that has an outcome of disease in the teeth SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/toothdisorders.html 10044034 tooth disorder AE HPO: HP_0000164 SIDER: C0040435 OAE:0001459 a bone disorder AE that has an outcome of a break or rupture in a bone SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/tooth+fracture 10062544 tooth fracture AE OAE:0001460 a bone disorder AE that has an outcome of one or more teeth coming loose and falling out SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/23253824 10044044 tooth loss AE HPO: HP_0006349 SIDER: C0080233 OAE:0001461 a bone disorder AE that has an outcome of an aching pain in or around a tooth SZ, SS, YH odontalgia AE WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/toothache Seconday Source: http://www.ncbi.nlm.nih.gov/pubmed/22157099 10044055 toothache AE CTCAE: E11054 HPO: HP_0000164 NCIt: C78640 SIDER: C0040460 OAE:0001462 a endocrine system AE that has an outcome of an excess production of thryoid hormone, characterized by functionally autonomous nodules SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000317.htm 10044242 toxic nodular goitre AE OAE:0001463 A liver AE that has an outcome of an abnormal functionality of the liver YH, SS hepatic function abnormal AE HPO: HP_0001410 SIDER: C0086565 OAE:0001464 a respiratory system AE that results in the trachea being infected by a bacteria SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001983/ 10044302 10066798 tracheitis AE CTCAE: E11599 NCIt: C78647 OAE:0001465 a respiratory system AE that is characterized by the inflammation of the muscous membranes of the trachea and bronchi SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/tracheobronchitis 10044314 tracheobronchitis AE HPO: HP_0002837 SIDER: C0040586 OAE:0001466 a behavior and neurological AEthat results in the patient being in a state of trance SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/trance 10044334 trance AE OAE:0001467 a transaminase level abnormal AE that has an outcome of elevated levels of alanine transaminase and aspartate transaminase SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Transaminases 10054889 transaminase level increased AE OAE:0001468 A cardiomyopathy AE that has an outcome of a condition in which the heart muscle becomes thick. Often, only one part of the heart is thicker than the other parts. The thickening can make it harder for blood to leave the heart, forcing the heart to work harder to pump blood. It also can make it harder for the heart to relax and fill with blood. YH, SS HCM WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001243/ 10020871 hypertrophic cardiomyopathy AE HPO: HP_0001639 SIDER: C0007194 OAE:0001469 a vascular disorder AE that results in an abnormal spatial arrangement of any of the primary blood vessels SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002535/ 10044443 transposition of the great vessels AE OAE:0001470 a blood chloride abnormal AE that is characterized by an abnormally high level of chloride in the blood YH, MW 10020599 hyperchloremia AE UMLS CUI: C0085679 OAE:0001471 a cardiac valve disease AE that is characterized by a tricuspid valve that does not close tightly enough to prevent leakage SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Tricuspid+Valve+Insufficiency 10044640 tricuspid valve incompetence AE OAE:0001472 a tri-iodothyronine level abnormal AE that results in a decreased level of tri-iodothyronine SZ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/Tri-iodothyronine 10044594 tri-iodothyronine decreased AE OAE:0001473 a troponin level abnormal AE that has an outcome of an increased amount of troponin, a protein released when the heart muscle is damaged SZ, SS, YH, EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007452.htm 10058267 troponin level increased AE OAE:0001474 a bacterial infection AE that is caused by M. tuberculosis. SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001141/ 10044755 tuberculosis AE OAE:0001476 Tumor AE that results in a tumor reoccurring SZ, SS, YH tumour flare AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/21523725 10045169 tumor flare AE OAE:0001477 an hemorrhage AE that has an outcome of bleeding in the tumour SZ, SS, YH tumour haemorrhage AE WEB: http://calder.med.miami.edu/pointis/tbifam/cause3.html 10049750 tumour hemorrhage AE OAE:0001478 a syndrome AE that has an outcome of a group of metabolic complications that can occur after treatment of cancer SZ, SS, YH tumour lysis syndrome AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/15384972 10045152 10045170 tumor lysis syndrome AE CTCAE: E12365 NCIt: C3425 OAE:0001479 a cytogenetic investigation result abnormal AE that has an outcome of an increase in a substance found in the blood, urine, or body tissues that can be elevated in cancer, among other tissue types SZ, SS, YH, EB tumour marker increased AE WEB: http://www.cancer.gov/cancertopics/factsheet/detection/tumor-markers 10048621 tumor marker increased AE OAE:0001480 a necrosis AE that has an outcome of death of tumor tissue, tumor rapidly outgrows its blood supply SZ, SS, YH tumour necrosis AE WEB: http://medical-dictionary.thefreedictionary.com/tumor+necrosis 10054094 tumor necrosis AE OAE:0001481 a keratitis AE that has an outcome of disrupted epithelial layer and stroma of the cornea, may become blind SZ, SS, YH corneal ulcer AE WEB: http://medical-dictionary.thefreedictionary.com/Ulcerative+keratitis 10064996 ulcerative keratitis AE HPO: HP_0007812 SIDER: C0010043 OAE:0001482 Homeostasis AE that results in an inability to achieve adequate fluid balance SZ, SS, YH 10069568 ultrafiltration failure AE OAE:0001483 Respiratory system AE that is characterized by the patient having an obstruction in their upper airway SZ, SS, YH 10067775 upper airway obstruction AE HPO: HP_0002781 SIDER: C0740852 OAE:0001484 a gastrointestinal hemorrhage AE that has an outcome of bleeding in the upper gastrointestinal tract SZ, SS, YH upper gastrointestinal haemorrhage AE WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/gastrointestinal+bleeding Secondary Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1237869/ 10046274 10055356 upper gastrointestinal hemorrhage AE CTCAE: E11062 HPO: HP_0002239 NCIt: C78660 SIDER: C0041909 OAE:0001485 a urinary system AE that has an outcome of a blockage in the urinary tract, can result in pain, fever, infection, loss of kidney function, sepsis or death if severe SZ, SS, YH WEB: http://www.mayoclinic.org/ureteral-obstruction/ 10046406 ureteric obstruction AE HPO: HP_0006000 SIDER: C0041956 OAE:0001486 Urinary system AE that results in the urethra becoming obstructed SZ, SS, YH 10046459 urethral obstruction AE HPO: HP_0000796 SIDER: C0041972 OAE:0001487 Urinary System AE that results in the urethra becoming narrowed at the external meatus SZ, SS, YH WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/urethral+meatal+stenosis Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/22710090 10065584 urethral stenosis AE OAE:0001488 a urinary incontinence AE that results in the patient feeling a sudden urgency or need to urinate. SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002250/ 10046494 urge incontinence AE HPO: HP_0000012 SIDER: C0150045 OAE:0001489 Urinary system AE that results in an inability to urinate SZ, SS, YH, MW WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/urinary+retention Secondary Source: http://www.medtronic.com/patients/urinary-retention/index.htm 10046555 urinary retention AE CTCAE:E13046 HPO: HP_0000016 NCIt:C50790 SIDER: C0080274 OAE:0001490 a urinary tract infection AE that results in the infection of the urinary tract by the Pseudomonas Aeruginosa organism SZ, SS, YH WEB: http://www.jiph.org/article/S1876-0341(09)00058-6/abstract 10062279 urinary tract infection pseudomonal AE OAE:0001491 a urinary tract infection AE that results in the urinary tract being infected with the staphylococcal bacteria SZ, SS, YH 10062280 urinary tract infection staphylococcal AE OAE:0001492 a toxicology drug screen result abnormal AE that results in a positive result for amphetamines in the urine SZ, SS, YH, EB 10051400 urine amphetamine positive AE OAE:0001493 a urine abnormality AE that has an outcome of decreased urine output, less than 500 milliliters of urine in 24 hours SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003147.htm 10059895 urine output decreased AE CTCAE: E12217 NCIt: C80522 OAE:0001494 a urinary system AE caused by an infection in the urinary tract that has an outcome of accumulation of pus-forming bacteria or toxins in the blood of the urinary tract. SZ, SS, YH WEB: http://www.primehealthchannel.com/urosepsis-definition-symptoms-causes-diagnosis-and-treatment.html 10048709 urosepsis AE OAE:0001495 an urticaria AE that results in the appearance of "wheals" on skin SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/papular+urticaria 10046750 urticaria papular AE OAE:0001496 a uterine AE that results in uterine contractions during pregnancy SZ, SS, YH 10049975 uterine contractions during pregnancy AE OAE:0001497 a uterine AE that has an outcome of bleeding from the uterus MedDRA: 10046788 is for "uterine haemorrhage"; MedDRA: 10046789 is for "uterine hemorrhage" SZ, SS, YH, MW uterine haemorrhage AE 10046788 10046789 uterine hemorrhage AE CTCAE: E13237 HPO: HP_0000130 NCIt: C78686 SIDER: C0042134 OAE:0001498 a uterine AE that results in the patient undergoing a single uterine contraction for over two minutes during pregnancy SZ, SS, YH WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/12192488 Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/12192488 10046790 uterine hypertonus AE HPO: HP_0000130 SIDER: C0269842 OAE:0001499 an infection AE that results in infection of the vagina SZ, SS, YH 10046914 vaginal infection AE CTCAE: E11624 HPO: HP_0000142 NCIt: C26911 SIDER: C0404521 OAE:0001500 a digestive system AE that has an outcome of dilated sub-mucosal veins in the lower third of the esophagus SZ, SS, YH varices oesophageal AE WEB: http://www.mayoclinic.com/health/esophageal-varices/DS00820 10056091 varices esophageal AE HPO: HP_0002040 SIDER: C0014867 OAE:0001501 a dementia AE that results in problems with reasoning, judgement, and memory resulting from brain damage from impaired blood flow to the brain SZ, SS, YH WEB: http://www.mayoclinic.com/health/vascular-dementia/DS00934 10057678 vascular dementia AE OAE:0001502 a vascular disorder AE that results in the veins becoming discoloured SZ, SS, YH vein discolouration AE 10047183 vein discoloration AE OAE:0001503 a thrombosis AE that has an outcome of a blood clot in the inferior vena cava SZ, SS, YH vena cava embolism AE WEB: http://emedicine.medscape.com/article/1933035-overview, http://www.nlm.nih.gov/medlineplus/ency/article/000156.htm 10047193 10047195 vena cava thrombosis AE OAE:0001504 a vascular disorder AE that results in an injury to the vein(s) SZ, SS, YH 10047228 venous injury AE CTCAE: E12051 NCIt: C78711 OAE:0001505 a thrombosis AE that has an outcome of a blood clot that forms within a vein SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000156.htm 10047249 venous thrombosis AE HPO: HP_0004850 SIDER: C0042487 OAE:0001506 a cardiac ventricular disorder AE that has an outcome of an abnormality in the contraction of the ventricles or the motion of the cells SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/ventricular+dysfunction 10059056 ventricular dysfunction AE OAE:0001508 an ear disorder that results in irritation and swelling (inflammation) of the inner ear SZ, SS, YH lybyrinthitis AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002049/ 10047393 vestibular neuronitis AE OAE:0001509 an abnormal vision AE that results in unclear vision SZ, SS, YH blurred vision AE WEB: Primary Source: http://www.nlm.nih.gov/medlineplus/ency/article/003029.htm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23111613 10005886 10047513 vision blurred AE CTCAE: E10346 HPO: HP_0000622 NCIt: C27123 SIDER: C0344232 OAE:0001510 an abnormal vision AE that results in a decrease in clearness of vision SZ, SS, YH WEB: Primary Source: http://www.nlm.nih.gov/medlineplus/ency/article/003396.htm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23329671 10047531 visual acuity reduced AE HPO: HP_0000572 SIDER: C0234632 OAE:0001511 an abnormal vision AE that results in the patient suffering from an enhanced brightness in their vision SZ, SS, YH 10049155 visual brightness AE OAE:0001512 a gustatory system AE that has an outcome of a shortage of vitamin D which is essential for strong bones SZ, SS, YH WEB: http://www.webmd.com/diet/vitamin-d-deficiency 10047626 vitamin d deficiency AE HPO: HP_0100513 SIDER: C0042870 OAE:0001514 Inflammation AE that is characterized by an inflammatory reaction of the vitreous or hyaloid membrane as a result of disease in adjacent structures SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/vitritis 10047663 vitritis AE OAE:0001515 a physical examination result abnormal AE that shows an increase (gain) in weight of a patient SZ, SS, YH weight gain AE 10047896 10047899 weight increased AE CTCAE: E12224 HPO: HP_0004324 NCIt: C62754 SIDER: C0043094 OAE:0001516 a conduction system disorder AE that results in an abnormal accessory electrical conduction pathway between the atria and ventricles SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001206/ 10048015 wolff-parkinson-white syndrome AE CTCAE: E10244 NCIt: C35132 OAE:0001517 a wound AE that has an outcome of complication to the wound SZ, SS, YH WEB: https://en.wikipedia.org/wiki/Wound 10053692 wound complication AE CTCAE: E12057 NCIt: C78719 OAE:0001518 a wound AE that has an outcome of a wound breaking open along the surgical sutures SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/wound+dehiscence 10048031 wound dehiscence AE CTCAE: E12063 NCIt: C50863 OAE:0001519 A wound AE that has an outcome of secretions or pus produced by damaged tissue particles and repairing mechanisms intitiated by the body SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/2815962 10048629 wound secretion AE OAE:0001520 an abnormal vision AEthat results in the patient seeing a predominance of yellow in their vision SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/xanthopsia 10048216 xanthopsia AE HPO: HP_0000551 SIDER: C0221185 OAE:0001521 an immune system disorder AE that results in a fungal infection of the sinuses, brain, or lungs that occurs in some people with a weakened immune system SZ, SS, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001672/ 10061418 zygomycosis AE OAE:0001522 A cardiomyopathy AE that has an outcome of a heart failure with left ventricular dilatation resulting from ischemic heart disease. YH, SS ischaemic cardiomyopathy AE WEB: http://medical-dictionary.thefreedictionary.com/ischemic+cardiomyopathy 10048858 ischemic cardiomyopathy AE OAE:0001524 An adverse event that is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles normally. YL http://en.wikipedia.org/wiki/Narcolepsy YL narcolepsy AE OAE:0001526 An inflammation AE that has an outcome of tissue swelling and other inflammatory response in the mouth YH, SS oral mucositis 10028116 10028130 mucosal inflammation AE CTCAE: E10872 NCIt: C26887 OAE:0001527 A systematic adverse event that has an outcome of failure in mulitple organs YH, SS 10028154 multi-organ failure AE CTCAE: E11155 NCIt: C75568 OAE:0001528 Pleomorphic rash AE is rash AE that is a rash characterized by many-formed. JX, LW, YH 多形性皮疹 pleomorphic rash AE OAE:0001529 A bone disorder AE that has an outcome of the weakening or brittle bone YH, SS, MW WEB: http://www.mayoclinic.com/health/osteoporosis/DS00128 10031282 osteoporosis AE CTCAE:E12508 HPO: HP_0000939 NCIt:C3298 SIDER: C0029456 OAE:0001530 A groupd of disroders where the genetic susceptibility plays an important role to the seletctive susceptibility to poorly pathogenic mycobacterial species such as bacille Calmette-Guérin and environmental mycobacteria. MSMD http://www.ncbi.nlm.nih.gov/pubmed/20718793 YL Mendelian susceptibility to mycobacterial disease OAE:0001531 A cardiomyopathy AE that has an outcome of a condition that the heart cannot relax normally during the time between heartbeats when the blood returns from the body (diastole). YH, SS infiltrative cardiomyopathy WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000189.htm 10038748 restrictive cardiomyopathy AE CTCAE: E10192 NCIt: C62798 OAE:0001535 A cardiomyopathy AE that is a temporary heart condition brought on by stressful situations, such as the death of a loved one. People with broken heart syndrome may have sudden chest pain or think they're having a heart attack. These broken heart syndrome symptoms may be brought on by the heart's reaction to a surge of stress hormones. In broken heart syndrome, a part of your heart temporarily enlarges and doesn't pump well, while the remainder of the heart functions normally or with even more forceful contractions. YH, SS takotsubo cardiomyopathy, broken heart syndrome, stress-induced cardiomyopathy, apical ballooning syndrome WEB: http://www.mayoclinic.com/health/broken-heart-syndrome/DS01135/METHOD=print 10066286 stress cardiomyopathy AE OAE:0001537 A skin adverse event that has an outcome of an eruption caused by ingestion, injection, inhalation, or insertion of a drug, often a result of allergic sensitization. Also called dermatitis medicamentosa, dermatosis medicamentosa, drug rash YH, SS dermatitis medicamentosa, dermatosis medicamentosa, drug rash WEB: http://medical-dictionary.thefreedictionary.com/drug+eruption 10057970 toxic skin eruption AE OAE:0001538 An arrythmia AE that has an outcome of a severely abnormal heart rhythm (arrhythmia) that can be life-threatening. YH, SS VF WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004467/ 10047290 ventricular fibrillation AE CTCAE: E10236 HPO: HP_0001663 NCIt: C50799 SIDER: C0042510 OAE:0001539 an atrioventricular block AE that there is some prolongation of AV conduction time (PR interval). The heart's electrical signals are slowed as they move from the atria to the ventricles (the heart's upper and lower chambers, respectively). This results in a longer, flatter line between the P and the R waves on the EKG (electrocardiogram). SS atrioventricular block first degree first degree heart block WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html 10003674 first degree atrioventricular block AE CTCAE: E10098 NCIt: C62015 OAE:0001541 A thyroiditis AE that shows a self-limited thyroid condition associated with a triphasic clinical course of hyperthyroidism, hypothyroidism, and return to normal thyroid function. YL, YH SAT painless thyroiditis AE silent thyroiditis AE http://emedicine.medscape.com/article/125648-overview https://en.wikipedia.org/wiki/Subacute_lymphocytic_thyroiditis subacute thyroiditis AE OAE:0001542 Macrophagic myofasciitis (MMF) is a rare inflammatory muscle disorder characterized by a characteristic infiltration of muscle tissue by PAS-positive macrophages, which is caused by pathological persistence of vaccine-derived aluminium hydroxide. The diagnosis can only be established by an open muscle biopsy from the muscle that was used for intramuscular vaccination. YL MMF http://www.ncbi.nlm.nih.gov/pubmed/14593574 YL macrophagic myofasciitis AE OAE:0001543 BCG infection following BCG injection. It is often related with the vaccinee's immunodeficiency. YL YL disseminated BCG infection AE OAE:0001544 An adverse event that is a disorder of neural development characterized by impaired social interaction and communication, and by restricted and repetitive behavior. YL http://en.wikipedia.org/wiki/Autism autism AE HPO: HP_0000717 SIDER: C0004352 OAE:0001545 an adverse event that is a type of encephalitis triggered by vaccination. Autoimmune Encephalitis may be triggered by infection in which case the term "Post-infectious Encephalitis" is used. ADEM( Acute Disseminated Encephalomyelitis ) is a Post-infectious Encephalitis. The illness usually follows in the wake of a mild viral infection (such as those that cause rashes in childhood) or immunisations. Typically there is a delay of days to two to three weeks between the triggering infection and development of the encephalitis. It has recently been recognised that there are other types of Autoimmune Encephalitis resulting from an attack of the brain by the body's immune system. Some of these types of autoimmune encephalitis are identified by finding a specific antibody in blood. These conditions include Potassium channel complex antibody associated encephalitis, NMDAR and Hashimoto's encephalitis. http://www.encephalitis.info/information/the-illness/types-of-autoimmune-encephalitis/ YL autoimmune encephalitis AE OAE:0001546 an injection-site AE that display an redness in the injection-site YH injection-site redness AE OAE:0001547 a sensory capability AE that shows up skin tenderness and occurs in an injection site of a medical intervention YH 10043224 injection-site tenderness AE OAE:0001548 YH a movement disorder AE that has an outcome of arm motion limitation arm motion limitation AE OAE:0001549 a sensory capability AE that shows up muscular soreness at the injection site of a medical intervention YH 10028332 injection-site muscular soreness AE OAE:0001550 a sleep disorder AE that shows up sleepiness (Sluggish from sleep, inactive, quiet). YH 10041014 sleepiness AE OAE:0001551 an adverse event that occurs in brain. YH brain disorder AE brain AE OAE:0001552 a hypersensitivity AE that is mild. YH mild hypersensitivity AE OAE:0001553 YH an injection-site edema AE that occurs in the arm. injection-site arm edema AE OAE:0001554 a psychiatric disorder AE that shows restlessness YH, MW WEB: http://dictionary.reference.com/browse/restlessness 10038743 restlessness AE CTCAE:E12960 NCIt:C74533 UMLS_CUI: C0085631 OAE:0001555 a sensory capability AE that results in a sensation of induration with tenderness. YH induration with tenderness AE OAE:0001556 a sensory capability AE that results in a sensation of fussiness YH fussiness AE OAE:0001557 a sleep disorder AE that shows decreased sleep YH decreased sleep AE OAE:0001558 a sleep disorder AE that shows increased sleep YH increased sleep AE OAE:0001559 a pain AE that occurs at a joint YH joint pain AE OAE:0001560 Tiredness AE is a sensory capability AE that results in a sensation of tiredness. This term appears to be a synonym to the 'fatigue AE'. JX, LW, YH hypodynamia AE 疲劳/乏力 10043890 tiredness AE OAE:0001561 nasal discomfort AE is a respiratory system AE that shows a discomfort from the nose YH nasal discomfort AE HPO: HP_0010640 SIDER: C0858259 OAE:0001567 an imaging investigation result abnormal AE that is indicated by an abnormal result of a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body EB 10029816 nuclear magnetic resonance imaging result abnormal AE OAE:0001568 a computerized tomography abnormal AE that is an imaging method that uses x-rays to create pictures of cross-sections of the body using a dye, called oral contrast, that shows up on the CT images to help better define internal organs EB computerised tomogram with contrast abnormal AE computerized tomogram with contrast abnormal AE OAE:0001569 a computerized tomography abnormal AE that is an imaging method that uses x-rays to create pictures of cross-sections of the body EB computerised tomogram without contrast abnormal AE computerized tomogram without contrast abnormal AE OAE:0001570 an investigation result abnormal AE that involves an abnormal result of an investigation involving the cardiovascular system EB, YH 10007512 cardiovascular investigation result abnormal AE OAE:0001571 an atrioventricular block AE that some but not all atrial impulses fail to reach the ventricles, thus some ventricular beats are dropped. Electrical signals between the atria and ventricles are slowed to a large degree. Some signals don't reach the ventricles. On an EKG, the pattern of QRS waves doesn't follow each P wave as it normally would. SS atrioventricular block second degree second degree heart block WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html 10003677 second degree atrioventricular block AE OAE:0001572 a cardiac and vascular investigation result abnormal AE that is an abnormal result of a test that uses sound waves to create a moving picture of the heart EB 10061593 echocardiogram result abnormal AE OAE:0001573 an investigation result abnormal AE that involves an abnormal electrolyte value EB 10047843 electrolyte lab test abnormal AE OAE:0001574 an electrolyte lab test abnormal AE that shows an abnormal blood phosphorus level EB 10054823 blood phosphorus abnormal AE OAE:0001576 an atrioventricular block AE that complete atrioventricular dissociation occurs; atria and ventricles beat independently. None of the electrical signals reach the ventricles. This type also is called complete heart block or complete AV block. When complete heart block occurs, special areas in the ventricles may create electrical signals to cause the ventricles to contract. This natural backup system is slower than the normal heart rate and isn't coordinated with the contraction of the atria. On an EKG, the normal pattern is disrupted. The P waves occur at a faster rate that isn't coordinated with the QRS waves. SS atrioventricular block complete complete heart block third degree atrioventricular block third degree heart block WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html 10003673 complete atrioventricular block AE CTCAE: E10093 NCIt: C50501 OAE:0001577 an electrolyte lab test abnormal AE that results in an abnormal level of potassium in the blood EB 10005722 blood potassium abnormal AE HPO: HP_0011042 SIDER: C0853759 OAE:0001579 an electrolyte lab test abnormal AE that results in an abnormal level of sodium in the blood EB 10005800 blood sodium abnormal AE OAE:0001581 an electrolyte lab test abnormal AE that results in an abnormal level of magnesium in the blood EB 10005652 blood magnesium abnormal AE OAE:0001583 an electrolyte lab test abnormal AE that results in an abnormal level of chloride in the blood EB 10005417 blood chloride abnormal AE OAE:0001585 an electrolyte lab test abnormal AE that results in an abnormal level of calcium in the blood EB 10005393 blood calcium abnormal AE OAE:0001587 an investigation result abnormal AE that involves the renal and urinary tract and urinalyses EB, YH renal and urinary tract investigation and urinalysis result abnormal AE renal system investigation result abnormal AE 10038362 urinary system investigation result abnormal AE OAE:0001588 a urinary system investigation result abnormal AE that is characterized by an abnormal level of creatinine in the blood EB 10005481 blood creatinine level abnormal AE OAE:0001589 a urinary system investigation result abnormal AE that is characterized by an abnormal level of urea in the blood EB 10005846 blood urea level abnormal AE OAE:0001590 an investigation result abnormal AE that involves an abnormal result of a lipid analyses EB 10024580 lipid analysis result abnormal AE OAE:0001591 a lipid analysis result abnormal AE that results in an abnormal blood cholesterol level EB 10005423 blood cholesterol abnormal AE OAE:0001592 a blood cholesterol abnormal AE that results in a decreased amount of cholesterol in the blood EB 10005424 blood cholesterol decreased AE OAE:0001593 a lipid analysis result abnormal AE that is characterized by an abnormal amount of high density lipoprotein EB 10020051 high density lipoprotein abnormal AE OAE:0001594 a high density lipoprotein abnormal AE that is characterized by an increased amount of high density lipoprotein EB 10020061 high density lipoprotein increased AE OAE:0001595 a high density lipoprotein abnormal AE that is characterized by a decreased amount of high density lipoprotein EB 10020060 high density lipoprotein decreased AE HPO: HP_0003233 SIDER: C0151691 OAE:0001596 a lipid analysis result abnormal AE that is characterized by an abnormal amount of low density lipoprotein EB 10024901 low density lipoprotein abnormal AE OAE:0001597 a low density lipoprotein abnormal AE that is characterized by an increased amount of low density lipoprotein EB 10024910 low density lipoprotein increased AE HPO: HP_0003141 SIDER: C0549399 OAE:0001598 a low density lipoprotein abnormal AE that is characterized by a decreased amount of low density lipoprotein EB 10024909 low density lipoprotein decreased AE OAE:0001599 a lipid analysis result abnormal AE that is characterized by an abnormal amount of triglycerides in the blood EB 10005837 blood triglycerides abnormal AE OAE:0001600 a blood triglycerides abnormal AE that is characterized by an increased amount of triglycerides in the blood EB 10005839 blood triglycerides increased AE HPO: HP_0002155 SIDER: C0853692 OAE:0001601 a blood triglycerides abnormal AE that is characterized by a decreased amount of triglycerides in the blood EB 10005838 blood triglycerides decreased AE OAE:0001602 an investigation result abnormal AE that involves an abnormal result for an immunology and allergy investigation EB 10021505 immunology and allergy investigation result abnormal AE OAE:0001603 a second degree atrioventricular block AE that the electrical signals are delayed more and more with each heartbeat, until the heart skips a beat. On the EKG, the delay is shown as a line (called the PR interval) between the P and QRS waves. The line gets longer and longer until the QRS waves don't follow the next P wave. MedDRA: 10050797 is a LLT for type I second degree atrioventricular block MedDRA (LLT): 10047909 exists for Wenckebach phenomeono MedDRA (LLT): 10047908 exists for Wenchebach MedDRA (LLT): 10027787 for Mobit type I SS, MW, YH Mobitz type 1 block Wenckebach Phenomenon Wenckebach's block type 1 second degree atrioventricular block type I second degree atrioventricular block WEB: https://www.nhlbi.nih.gov/health/health-topics/topics/hb/types 10027787 10047908 10047909 10050797 Mobitz type I block AE CTCAE: E10146 NCIt: C62017 OAE:0001604 an immunology and allergy investigation result abnormal AE that is characterized by antibodies for epstein barr virus being detected EB 10056906 Epstein-Barr virus antibody positive AE OAE:0001605 an immunology and allergy investigations result abnormal AE that is characterized by an abnormal microbiology and serology investigation EB 10027529 microbiology and serology investigation result abnormal AE OAE:0001606 a microbiology and serology investigation result abnormal AE that is characterized by a positive CSF culture EB 10011529 CSF culture positive AE OAE:0001607 an investigation result abnormal AE that involves an abnormal result of a metabolic and nutritional investigation EB 10027432 metabolic and nutritional investigation result abnormal AE OAE:0001608 a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal glycosylated hemoglobin level EB 10055587 glycosylated hemoglobin level abnormal AE OAE:0001609 a glycosylated hemoglobin level abnormal AE that is charaterized by an increased glycosylated hemoglobin level EB 10055587 glycosylated hemoglobin level increased AE OAE:0001610 This is an AE which is a symptom associated with both non-serious and serious medical issues. a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood folate level EB QY, JX, HY http://en.volupedia.org/wiki/Abdominal_pain 腹挤压伤 10000044 10005525 abdomen crushing AE blood folate level abnormal AE OAE:0001611 a blood folate abnormal AE that is charaterized by an increased blood folate level EB 10005528 blood folate level increased AE OAE:0001612 a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood glucose level EB 10005554 blood glucose level abnormal AE OAE:0001613 a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood homocysteine EB 10049735 blood homocysteine level abnormal AE OAE:0001614 a blood homocysteine level abnormal AE that is charaterized by a decreased blood homocysteine EB 10049734 blood homocysteine level decreased AE OAE:0001615 a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood uric acid level EB 10061727 blood uric acid level abnormal AE OAE:0001616 a blood uric acid level abnormal AE that is characterized by a decreased blood uric acid EB 10005860 blood uric acid level decreased AE OAE:0001617 a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal vitamin B12 level EB 10062187 vitamin B12 level abnormal AE OAE:0001618 a vitamin B12 level abnormal AE that is characterized by an increased vitamin B12 level EB 10047610 vitamin B12 level increased AE OAE:0001619 a vitamin B12 level abnormal AE that is characterized by a decreased vitamin B12 level EB 10047608 vitamin B12 level decreased AE OAE:0001620 a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal brain natriuretic peptide level EB 10053408 brain natriuretic peptide level abnormal AE OAE:0001621 a brain natriuretic peptide level abnormal AE that is characterized by an increased brain natriuretic peptide level EB 10053405 brain natriuretic peptide level increased AE OAE:0001622 a brain natriuretic peptide level abnormal AE that is characterized by a decreased brain natriuretic peptide level EB 10053407 brain natriuretic peptide level decreased AE OAE:0001623 a hematology investigation result abnormal AE that involves an abnormal result of the oxygen and carbon dioxide content of arterial blood, measured by various methods to assess the adequacy of ventilation and oxygenation and the acid-base status of the body EB, SJ WEB: http://medical-dictionary.thefreedictionary.com/arterial+blood+gas WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003855.htm 10005539 10027432 blood gases abnormal AE may be a result of lung, kidney, or metablolic diseases or the result of abnormal breathing after a head or neck injur blood gas investigation result abnormal AE OAE:0001624 a blood gas investigation result abnormal AE that is characterized by an abnormal amount of carbon dioxide in the blood EB WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003469.htm 10064156 carbon dioxide abnormal AE OAE:0001625 a carbon dioxide abnormal AE that is characterized by an increased carbon dioxide level in the blood EB 10007225 carbon dioxide increased AE HPO: HP_0005972 SIDER: C0860713 OAE:0001626 a blood gas investigation result abnormal AE that is characterized by an abnormal acidity or alkalinity of blood EB WEB: http://www.medterms.com/script/main/art.asp?articlekey=10001 10005705 blood pH abnormal AE OAE:0001627 a blood pH abnormal AE that is characterized by an increased blood pH EB 10005708 blood pH increased AE OAE:0001628 This is an AE which is the protrusion of contents of the abdomen through a defect or weakness in the abdominal wall. a blood pH abnormal AE that is characterized by a decreased blood pH EB QY, JX, HY http://en.volupedia.org/wiki/Eventration 疝腹脏突出 10005706 10057391 blood pH decreased AE hernial eventration AE OAE:0001630 a blood gas investigation result abnormal AE that is characterized by an abnormal oxygen saturation in the blood EB 10033317 oxygen saturation abnormal AE OAE:0001631 an oxygen saturation abnormal AE that is characterized by an increased percentage of hemoglobin binding sites in the bloodstream occupied by oxygen EB 10033320 oxygen saturation increased AE OAE:0001632 a blood gas investigation result abnormal AE that is characterized by an abnormal carbon dioxide partial pressure or tension in the blood EB WEB: http://medical-dictionary.thefreedictionary.com/PCO2 10058982 PCO2 abnormal AE OAE:0001633 a PCO2 abnormal AE that is characterized by an increased carbon dioxide partial pressure or tension in the blood EB 10034183 PCO2 increased AE OAE:0001634 a pPCO2 abnormal AE that is characterized by a decreased carbon dioxide partial pressure or tension in the blood EB 10034181 PCO2 decreased AE OAE:0001635 This is an AE which is most commonly caused by abdominal surgical procedures and the adhesions start to form within hours of surgery and may cause internal organs to attach to other organs in the abdominal cavity. a blood gas investigation result abnormal AE that is characterized by an abnormal oxygen partial pressure in the blood EB QY, JX, HY WEB: http://medical-dictionary.thefreedictionary.com/PO2 http://en.volupedia.org/wiki/Adhesion_(medicine)#Abdominal_adhesions 腹部粘连 10000050 10062087 PO2 abnormal AE abdominal adhesions AE OAE:0001636 a PO2 abnormal AE that is characterized by an increased oxygen partial pressure in the blood EB 10035769 PO2 increased AE OAE:0001637 a PO2 abnormal AE that is characterized by a decreased oxygen partial pressure in the blood EB 10035768 PO2 decreased AE OAE:0001638 an investigation result abnormal AE that results from an abnormal toxicology screen EB 10044260 toxicology drug screen result abnormal AE OAE:0001639 a toxicology drug screen result abnormal AE that is characterized by positive barbiturates EB 10063230 barbiturates positive AE OAE:0001640 a toxicology drug screen result abnormal AE that is characterized by positive cocaine EB 10063230 cocaine positive AE OAE:0001641 a second degree atrioventricular block AE that some of the electrical signals don't reach the ventricles. However, the pattern is less regular than it is in Mobitz type I. Some signals move between the atria and ventricles normally, while others are blocked. On an EKG, the QRS wave follows the P wave at a normal speed. Sometimes, though, the QRS wave is missing (when a signal is blocked). SS, YH, MW Mobitz (type) II atrioventricular block AE Mobitz type 2 block type 2 second degree atrioventricular block type II second degree atrioventricular block WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html 10027786 10050798 Mobitz type II block AE CTCAE: E10140 NCIt: C62018 OAE:0001642 a toxicology drug screen result abnormal AE that is characterized by increased urine cannabinoids EB 10062228 urine cannabinoids increased AE OAE:0001643 an investigation result abnormal AE that involves an abnormal result of a neurological, special senses and psychiatric investigation EB neurological, special senses and psychiatric investigation result abnormal AE 10029295 behavioral and neurological test abnormal AE OAE:0001644 an investigation result abnormal AE resulting from an abnormal physical examination finding EB 10062078 10071940 physical examination result abnormal AE OAE:0001645 an investigation result abnormal AE that involves an abnormal result of an investigation related to chromosomal abnormalities and pathologic conditions EB WEB: http://medical-dictionary.thefreedictionary.com/Cytogenetic+analysis 10011822 cytogenetic investigation result abnormal AE OAE:0001646 an investigation result abnormal AE that involves an abnormal respiratory and pulmonary investigation EB 10038668 respiratory and pulmonary investigation result abnormal AE OAE:0001647 an investigation result abnormal AE that involves an abnormal result of an endocrine investigation EB 10014706 endocrine investigation result abnormal AE OAE:0001649 an endocrine investigation result abnormal AE that is characterized by an abnormal blood parathyroid hormone level EB 10005700 blood parathyroid hormone level abnormal AE OAE:0001650 a blood parathyroid hormone level abnormal AE that is characterized by an increased blood parathyroid hormone level EB 10005703 blood parathyroid hormone increased AE OAE:0001651 an endocrine investigation result abnormal AE that is characterized by an abnormal tri-iodothyronine level EB 10044592 tri-iodothyronine level abnormal AE OAE:0001652 a tri-iodothyronine level abnormal AE that is characterized by an increased tri-iodothyronine level EB 10044596 tri-iodothyronine increased AE OAE:0001653 an investigation result abnormal AE that involves an abnormal protein and chemistry analysis result EB 10037000 protein and chemistry analysis result abnormal AE OAE:0001654 a protein and chemistry analysis result abnormal AE that is characterized by an abnormal blood albumin level EB 10005286 blood albumin level abnormal AE OAE:0001655 a blood albumin level abnormal AE that is characterized by an increased blood albumin level EB 10005288 blood albumin level increased AE OAE:0001656 a protein and chemistry analysis result abnormal AE that is characterized by an abnormal c-reactive protein level EB 10068559 c-reactive protein level abnormal AE OAE:0001657 a c-reactive protein level abnormal AE that is characterized by a decreased c-reactive protein level EB 10049220 c-reactive protein level decreased AE OAE:0001658 This is an AE which occurs when the abdomen becomes subject to increased pressure reaching past the point of intra-abdominal hypertension (IAH). a protein total abnormal AE that is characterized by an increased protein total EB QY, JX, HY http://en.volupedia.org/wiki/Abdominal_compartment_syndrome 腹腔间室综合征 10037016 10058808 abdominal compartment syndrome AE protein total increased AE OAE:0001659 a protein total abnormal AE that is characterized by a decreased protein total EB 10037014 protein total decreased AE OAE:0001660 a cardiac and vascular investigation result abnormal AE that involves an abnormal result from a test using a radioactive tracer (called a radionuclide) and a special camera to take pictures of your heart as it pumps blood EB WEB: http://www.heart.org/HEARTORG/Conditions/HeartAttack/SymptomsDiagnosisofHeartAttack/Radionuclide-Ventriculography-or-Radionuclide-Angiography-MUGA-Scan_UCM_446354_Article.jsp 10028146 MUGA scan result abnormal AE OAE:0001661 a cardiac function test abnormal AE that shows an abnormal result on a cardiac stress test. EB, YH WEB: http://medical-dictionary.thefreedictionary.com/Stress+Test WEB: https://en.wikipedia.org/wiki/Cardiology_diagnostic_tests_and_procedures 10055014 cardiac stress test result abnormal AE OAE:0001662 an investigation result abnormal AE that is characterized by an abnormal result of an enzyme investigation EB 10014938 enzyme investigation result abnormal AE OAE:0001663 a blood creatine phosphokinase level abnormal AE that is characterized by a decreased blood creatine phosphokinase EB 10067760 blood creatine phosphokinase level decreased AE OAE:0001664 an investigation result abnormal AE that is characterized by an abnormal result of a hematology investigation EB MedDRA: 10057755 haematology investigation abnormal AE 10018851 hematology investigation result abnormal AE OAE:0001665 a hematology investigation result abnormal AE that results in an abnormal red blood cell profile EB 20000029 red blood cell profile abnormal AE OAE:0001666 a hematology investigation result abnormal AE that is characterized by an abnormal white blood cell profile EB 20000030 white blood cell profile abnormal AE OAE:0001667 a white blood cell profile abnormal AE that is characterized by an abnormal percentage of neutrophils EB 10058134 neutrophil percentage abnormal AE OAE:0001668 a neutrophil percentage abnormal AE that is characterized by a decreased percentage of neutrophils EB 10052223 neutrophil percentage decreased AE OAE:0001669 a white blood cell profile abnormal AE that is characterized by an abnormal basophil count EB 10060978 basophil count abnormal AE OAE:0001670 a basophil count abnormal AE that is characterized by a decreased basophil count EB 10004167 basophil count decreased AE OAE:0001671 a white blood cell profile abnormal AE that is characterized by an abnormal eosinophil percentage EB 10058133 eosinophil percentage abnormal AE OAE:0001672 an eosinophil percentage abnormal AE that is characterized by a decreased eosinophil percentage EB 10052221 eosinophil percentage decreased AE OAE:0001673 a white blood cell profile abnormal AE that is characterized by an abnormal leukocyte cell number EB leukocyte cell number abnormal AE OAE:0001674 a white blood cell profile abnormal AE that is characterized by an abnormal granulocyte count EB 10018678 granulocyte count abnormal AE OAE:0001675 a granulocyte count abnormal AE that is characterized by an increased granulocyte count EB 10018683 granulocyte count increased AE OAE:0001676 a white blood cell profile abnormal AE that is characterized by an abnormal lymphocyte cell number EB 10025252 lymphocyte count abnormal AE OAE:0001677 a white blood cell profile abnormal AE that is characterized by an abnormal lymphocyte percentage EB lymphocyte percentage abnormal AE OAE:0001678 a white blood cell profile abnormal AE that is characterized by an abnormal monocyte percentage EB 10067238 monocyte percentage abnormal AE OAE:0001679 This is an AE which is the abnormal exit of tissue or an organ, such as the bowel, through the wall of the cavity in which it normally resides. a monoctyte percentage abnormal AE that is characterized by a decreased monocyte percentage EB QY, JX, HY http://en.volupedia.org/wiki/Hernia#Individual_hernias 腹疝 10052229 10060954 abdominal hernia AE monocyte percentage decreased AE OAE:0001680 an enzyme investigation result abnormal AE that is characterized by an abnormal blood lactate dehydrogenase level EB 10005627 blood lactate dehydrogenase level abnormal AE OAE:0001681 a blood lactate dehydrogenase level abnormal AE that is characterized by a decreased blood lactate dehydrogenase EB 10005629 blood lactate dehydrogenase level decreased AE OAE:0001682 an enzyme investigation result abnormal AE that is characterized by an abnormal troponin level EB troponin level abnormal AE OAE:0001683 an enzyme investigation result abnormal AE that is characterized by an abnormal muscle enzyme level EB muscle enzyme level abnormal AE OAE:0001684 a muscle enzyme level abnormal AE that is characterized by a decreased muscle enzyme level EB 10057952 muscle enzyme level decreased AE OAE:0001685 an enzyme investigation result abnormal AE that is characterized by an abnormal myoglobin level in the blood EB myoglobin blood abnormal AE OAE:0001686 a myoglobin blood abnormal AE that is characterized by an increased myoglobin level in the blood EB 10028625 myoglobin blood increased AE OAE:0001687 a myoglobin blood abnormal AE that is characterized by a decreased myoglobin level in the blood 10059940 myoglobin blood decreased AE OAE:0001688 an investigation result abnormal AE that is characterized by an abnormal result of a gastrointestinal investigation EB 10017971 gastrointestinal investigation result abnormal AE OAE:0001689 a gastrointestinal investigation result abnormal AE that is characterized by an abnormal blood amylase level EB 10054822 blood amylase level abnormal AE OAE:0001690 a blood amylase level abnormal AE that is characterized by a decreased blood amylase level EB 10005327 blood amylase level decreased AE OAE:0001691 a gastrointestinal investigation result abnormal AE that is characterized by an abnormal lipase level EB 10054821 lipase level abnormal AE OAE:0001692 a lipase level abnormal AE that is characterized by an increased lipase level EB 10024574 lipase level increased AE OAE:0001693 a lipase level abnormal AE that is characterized by a decreased lipase level EB 10024573 lipase level decreased AE OAE:0001694 an investigation result abnormal AE that is characterized by an abnormal liver related investigation result EB 20000008 liver related investigation result abnormal AE OAE:0001695 a liver related investigation result abnormal AE that is characterized by an abnormal level of transaminases EB 10062688 transaminase level abnormal AE OAE:0001696 a transaminase level abnormal AE that is characterized by a decreased level of transaminases EB 10054795 transaminase level decreased AE OAE:0001697 a liver related investigation result abnormal AE that is characterized by an abnormal aspartate aminotransferase level EB 10003477 aspartate aminotransferase level abnormal AE OAE:0001698 an aspartate aminotransferase level abnormal AE that is characterized by a decreased aspartate aminotransferase level EB 10003479 aspartate aminotransferase level decreased AE OAE:0001699 a gamma-glutamyltransferase level abnormal AE that is characterized by a decreased gamma-glutamyltransferase level EB 10017690 gamma-glutamyltransferase level decreased AE OAE:0001700 a blood bilirubin level abnormal AE that is characterized by a decreased blood bilirubin level EB 10049869 blood bilirubin level decreased AE OAE:0001701 an investigation result abnormal AE that is characterized by an abnormal result of an imaging investigation EB 10022893 imaging investigation result abnormal AE OAE:0001702 a hematology investigation result abnormal AE that is characterized by an abnormal blood thromboplastin level EB 10005824 blood thromboplastin level abnormal AE OAE:0001703 a blood thromboplastin level abnormal AE that is characterized by a decreased blood thromboplastin level EB 10005826 blood thromboplastin level decreased AE OAE:0001704 a hematology investigations result abnormal AE that is characterized by an abnormal coagulation factor v level EB 10061771 coagulation factor v level abnormal AE OAE:0001705 a coagulation factor v level abnormal AE that is characterized by an increased coagulation factor v level EB 10009756 coagulation factor v level increased AE OAE:0001706 a hematology investigation result abnormal AE that is characterized by an abnormal prothrombin level EB 10037048 prothrombin level abnormal AE OAE:0001707 a prothrombin level abnormal AE that is characterized by an increased prothrombin level EB 10037051 prothrombin level increased AE HPO: HP_0003645 SIDER: C0151872 OAE:0001708 a hematology investigation result abnormal AE that is characterized by an abnormal prothrombin time EB 10037057 prothrombin time abnormal AE OAE:0001709 a prothrombin time abnormal AE that is characterized by a shortened prothrombin time EB 10037070 prothrombin time shortened AE OAE:0001710 a full blood count abnormal AE that is characterized by an increased full blood count EB 10052239 full blood count increased AE OAE:0001711 a red blood cell profile abnormal AE that is characterized by an abnormal red blood cell count EB 10038151 red blood cell count abnormal AE OAE:0001712 a red blood cell count abnormal AE that is characterized by an increased red blood cell count EB 10038155 red blood cell count increased AE OAE:0001713 a red blood cell profile abnormal AE that is characterized by an abnormal hematocrit EB 10057763 hematocrit abnormal AE OAE:0001714 a hematocrit abnormal AE that is characterized by an increased hematocrit EB 10019424 hematocrit increased AE OAE:0001715 a hemoglobin level abnormal AE that is characterized by an increased hemoglobin level EB 10055599 hemoglobin level increased AE CTCAE: E12171 NCIt: C78333 OAE:0001716 a red blood cell profile abnormal AE that is characterized by an abnormal mean corpuscular volume EB 10027009 mean corpuscular volume abnormal AE OAE:0001717 a mean corpuscular volume abnormal AE that is characterized by an increased mean corpuscular volume EB 10051859 mean corpuscular volume increased AE OAE:0001718 a mean corpuscular volume abnormal AE that is characterized by a decreased mean corpuscular volume EB 10051858 mean corpuscular volume decreased AE OAE:0001719 a red blood cell profile abnormal AE that is characterized by an abnormal mean cell hemoglobin level EB mean cell hemoglobin level abnormal AE OAE:0001720 a mean cell hemoglobin level abnormal AE that is characterized by an increased mean cell hemoglobin level EB 10055622 mean cell hemoglobin level increased AE OAE:0001721 a mean cell hemoglobin level abnormal AE that is characterized by a decreased mean cell hemoglobin level EB 10055621 mean cell hemoglobin level decreased AE OAE:0001722 a red blood cell profile abnormal AE that is characterized by an abnormal mean cell hemoglobin concentration EB 10067730 mean cell hemoglobin concentration abnormal AE OAE:0001723 a mean cell hemoglobin concentration abnormal AE that is characterized by an increased mean cell hemoglobin concentration EB 10026992 mean cell hemoglobin concentration increased AE OAE:0001724 a mean cell hemoglobin concentration abnormal AE that is characterized by a decreased mean cell hemoglobin concentration EB 10026991 mean cell hemoglobin concentration decreased AE OAE:0001725 a conduction system disorder that refers to abnormalities in SN impulse formation and propagation and includes sinus bradycardia, sinus pause/arrest, chronotropic incompetence, and sinoatrial exit block. SS SND sinus node dysfunction WEB: http://emedicine.medscape.com/article/158064-overview sinoatrial node dysfunction AE OAE:0001726 a coronary artery disorder AE that takes place in or is related to the coronary inside the heart Even though 'coronary disorder AE' seems to be a more general term of 'coronary artery disorder AE' that should place 'coronary disorder AE' as a parent of 'coronary artery disorder AE', KB's comment from clinical perspective is that these two terms are synonymous in practice, and coronary disorder almost always means coronary artery disorder. If 'coronary disorder AE' gets picked up from reports, it is a generalized term of 'coronary artery disorder AE'; and thereofore, we created a place holder for this term under 'coronary artery disorder AE' SS coronary disorder AE OAE:0001727 a myocardial infarction AE in which the inferior wall of the heart is involved. It is often caused by occlusion of the right coronary artery. SS myocardial infarction, inferior wall AE WEB: http://www.ncbi.nlm.nih.gov/mesh/?term=inferior+wall+myocardial+infarction inferior wall myocardial infarction AE OAE:0001728 a myocardial infarction AE in which the anterior wall of the heart is involved. Anterior wall myocardial infarction is often caused by occlusion of the left anterior descending coronary artery. It can be categorized as anteroseptal or anterolateral wall myocardial infarction. SS myocardial infarction, anterior wall AE WEB: http://www.ncbi.nlm.nih.gov/mesh/?term=anterior+wall+myocardial+infarction anterior wall myocardial infarction AE OAE:0001729 a hematology investigation result abnormal AE that is characterized by an abnormal blast cell count EB blast cell count abnormal AE OAE:0001730 a blast cell count abnormal AE that is characterized by a decreased blast cell count EB 10062275 blast cell count decreased AE OAE:0001731 a hematology investigation result abnormal AE that is characterized by an abnormal platelet count EB 10035526 platelet count abnormal AE HPO: HP_0011873 SIDER: C0580317 OAE:0001732 a platelet count abnormal AE that is characterized by an increased platelet count SZ, SS, YH, EB WEB: http://medical-dictionary.thefreedictionary.com/thrombocytosis 10051608 platelet count increased AE OAE:0001733 a white blood cell profile abnormal AE that is characterized by an abnormal eosinophil count EB 10061125 eosinophil count abnormal AE OAE:0001734 an eosinophil count abnormal AE that is characterized by a decreased eosinophil count EB 10014943 eosinophil count decreased AE OAE:0001736 a hypertension AE that is characterized by high blood pressure in the systemic arteries - the vessels that carry blood from the heart to the body's tissues (other than the lungs). SS WEB: http://www.pted.org/?id=syshypertension1 systemic hypertension AE OAE:0001737 a hypotension AE that has an outcome of a decrease in the amount of pressure the heart generates when pumping blood through arteries to the rest of the body SS WEB: http://www.mayoclinic.com/health/low-blood-pressure/DS00590/DSECTION=causes 10005758 blood pressure systolic decreased AE HPO: HP_0006673 SIDER: C0277885 OAE:0001738 a cardiac valve disease AE that is characterized by an impaired function of a papillary muscle, usually due to ischemia or infarction, with resulting incompetence of the mitral (rarely tricuspid) valve. SS papillary muscle dysfunction papillary muscle syndrome WEB: http://medical-dictionary.thefreedictionary.com/papillary+muscle+dysfunction 10061330 papillary muscle disorder AE OAE:0001739 a hypertension AE that has an outcome of an increase in the amount of pressure in the arteries when the heart is at rest between beats SS WEB: http://www.webmd.com/hypertension-high-blood-pressure/guide/diastolic-and-systolic-blood-pressure-know-your-numbers 10005739 blood pressure diastolic increased AE HPO: HP_0005117 SIDER: C0277889 OAE:0001740 a hypertension AE that has an outcome of an increase in the amount of pressure the heart generates when pumping blood through arteries to the rest of the body SS WEB: http://www.webmd.com/hypertension-high-blood-pressure/guide/diastolic-and-systolic-blood-pressure-know-your-numbers 10005760 blood pressure systolic increased AE HPO: HP_0004421 SIDER: C0277884 OAE:0001741 a cardiac ventricular disorder AE that is a condition in nwhich the right ventricle of the heart was functionally impaired. This condition usually leads to heart failure or myocardial infarction, and other cardiovascular complicationns. SS WEB: http://www.ncbi.nlm.nih.gov/mesh/?term=right%20ventricular%20dysfunction 10058597 right ventricular dysfunction AE CTCAE: E10196 NCIt: C50733 OAE:0001742 an arrhythmia AE that is characterized by a premature contraction of the ventricle SS infranodal extrasystoles AE WEB: http://dictionary.reference.com/browse/ventricular+extrasystole 10047289 ventricular extrasystoles AE HPO: HP_0006696 SIDER: C0151636 OAE:0001743 an embolism disorder AE that is a result of an obstruction in a cardiac vessel due to a blood clot or other foreign matters SS heart embolism AE WEB: http://medical-dictionary.thefreedictionary.com/Heart+embolism cardiac embolism AE OAE:0001744 a vascular disorder AE that is characterized by an obstruction in a blood vessel due to a blood clot or other foreign matter that gets stuck while traveling through the bloodstream. SS WEB: http://medical-dictionary.thefreedictionary.com/embolism 栓塞 10014523 embolism AE HPO: HP_0001907 SIDER: C0013922 OAE:0001746 an arrhythmia AE that results in extra, abnormal heartbeats that begin in one of the heart's two lower pumping chambers (ventricles). These extra beats disrupt the regular heart rhythm, sometimes causing the patient to feel a flip-flop or skipped beat in the chest. SS PVCs WEB: http://www.mayoclinic.com/health/premature-ventricular-contractions/DS00949 10036614 premature ventricular contractions AE OAE:0001747 a cardiac valve disease AE that is charaterized by the backflow of blood from the pulmonary artery into the right ventricle, owing to imperfect functioning of the pulmonary valve SS pulmonic incompetence AE WEB: http://www.rightdiagnosis.com/medical/pulmonary_valve_incompetence.htm 10037448 pulmonary valve incompetence AE HPO: HP_0010444 SIDER: C0034088 OAE:0001748 a cardiac vavle disease AE that is characterized by a congenital heart defect in which blood flow from the heart to the pulmonary artery is blocked SS pulmonic stenosis AE WEB: http://medical-dictionary.thefreedictionary.com/Pulmonary+Valve+Stenosis 10037450 pulmonary valve stenosis AE OAE:0001749 a vasculitis AE that is an inflammation specific to an artery or arteries SS WEB: http://medical-dictionary.thefreedictionary.com/arteritis 10003230 arteritis AE HPO: HP_0005291 SIDER: C0003860 OAE:0001751 a vascular disorder AE that results in an abnormal widening or ballooning of a portion of an artery due to weakness in the wall of the blood vessel SS WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001122.htm 10002329 aneurysm AE HPO: HP_0002617 SIDER: C0002940 OAE:0001752 a vascular disorder that affects the veins or blood circulation of the veins SS venous disorder AE OAE:0001753 an aneurysm AE that results in the weakening of the balloon-like bulge that the blood pressure causes the artery wall to leak or burst SS SAH ruptured aneurysm AE subarachnoid hemorrhage AE WEB: http://www.mayfieldclinic.com/PE-AneurRupt.htm#.Uor4tI3QHh0 10048380 aneurysm ruptured AE HPO: HP_0002617 SIDER: C0162869 OAE:0001754 an aneurysm AE that refers to an aneurysm involving cardiac tissue. This most often occurs as a ventricular aneurysm following a myocardial infarction SS aneurysm of heart AE heart aneurysm AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/19239694 10007513 cardiac aneurysm AE OAE:0001755 an aneurysm AE that occurs in the aorta SS WEB: http://www.webmd.com/heart-disease/tc/aortic-aneurysm-overview 10002882 aortic aneurysm AE HPO: HP_0004942 SIDER: C0003486 OAE:0001756 an aneurysm ruptured AE that occurs in the aorta SS ruptured aortic aneurysm AE 10002886 aortic aneurysm rupture AE HPO: HP_0002622 SIDER: C0741160 OAE:0001757 an aortic disorder AE in which there is a separation of the aorta walls. The small tear can become larger. It can lead to bleeding into and along the wall of the aorta, the major artery carrying blood out of the heart. SS WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000181.htm 10002895 aortic dissection AE HPO: HP_0004933 SIDER: C0340643 OAE:0001758 an aneurysm ruptured AE that occurs in the brain where blood spurts into the subarachnoid space under arterial pressure, continuing until increased local or generalized intracranial pressure stops the bleeding. SS WEB: http://ether.stanford.edu/library/neuroanesthesia/Journal%20Articles/Ruptured%20cerebral%20aneurysms.pdf WEB: http://www.ncbi.nlm.nih.gov/pubmed/15647574 10039330 ruptured cerebral aneurysm AE OAE:0001759 an aneurysm AE that occurs in the brain SS brain aneurysm AE cerebral aneurysm AE intracerebral aneurysm AE WEB: http://www.ninds.nih.gov/disorders/cerebral_aneurysm/detail_cerebral_aneurysms.htm 10022758 intracranial aneurysm AE HPO: HP_0004944 SIDER: C0007766 OAE:0001760 a thrombosis AE that is a rare lesion and may be defined as a thrombosis of a vessel without any obvious underlying cause that occurs in the aorta SS WEB: http://circ.ahajournals.org/content/17/5/941.full.pdf 10002910 aortic thrombosis AE OAE:0001761 an arterial thrombosis AE that is characterized by the occurrence of a thrombus in the carotid arteries (two large blood vessels that supply oxygenated blood to the large, front part of the brain) SS WEB: http://www.webmd.com/heart-disease/carotid-artery-disease-causes-symptoms-tests-and-treatment 10007688 carotid artery thrombosis AE OAE:0001762 an arterial embolism AE that occurs in the cerebral artery SS cerebral embolism AE embolic stroke AE thrombotic stroke AE WEB: http://medical-dictionary.thefreedictionary.com/cerebral+embolism 10008088 10014498 10043647 cerebral artery embolism AE OAE:0001763 an arterial thrombosis AE that occurs in the cerebral artery, also referred to as an embolism AE [SS] Per DRA and KKB's comment, this term may also be characterized as a type of embolism even though labeled thrombosis. cerebral thrombosis AE 10008092 10008132 cerebral artery thrombosis AE OAE:0001764 a venous thrombosis AE that is characterized by thrombosis of the venous channels in the brain. It is an uncommon cause of cerebral infarction relative to arterial disease, but it is an important consideration because of its potential morbidity. [SS] From http://medical-dictionary.thefreedictionary.com/cerebral+venous+thrombosis, Merwarth syndrome - progressive hemiplegia due to venous occlusion. Synonym(s): cerebral venous thrombosis SS WEB: http://emedicine.medscape.com/article/1162804-overview 10008138 cerebral venous thrombosis AE OAE:0001765 a venous thrombosis AE that occurs when a blood clot forms in the brain’s venous sinuses that prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage. SS CVST WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/cerebral_venous_sinus_thrombosis_134,69/ 10061251 intracranial venous sinus thrombosis AE OAE:0001766 an embolism AE that is caused by a gas bubble that enters the vein [SS] The term 'gas embolism' is listed as a unique term, and not a superset or a synonym of 'air embolism' due to the different pathology reconized by physicians that air embolism is mostly recognized when an air bubble caused by IV or other injection device enters the vein, while a gas embolism is mostly caused by a gas bubble released as a product of an infection, or other devices such as nitrogen tank. SS gas embolilsm AE OAE:0001767 a thrombosis that is characterized by a clot that blocks blood flow a mesenteric vein, one of two veins through which blood leaves the intestine. The condition interrupts the blood supply to the intestine and can result in damage to the intestines. [SS] http://emedicine.medscape.com/article/193921-overview, Mesenteric venous thrombosis (also known as visceral venous thrombosis) is a rare but lethal form of mesenteric ischemia (see the image below). Antonio Hodgson first described mesenteric ischemia in the latter part of the 15th century. In 1895, Elliot first described mesenteric venous thrombosis as a cause of mesenteric ischemia. By the turn of the 19th century, many review articles and texts were describing the recent advances in the characterization and treatment of mesenteric ischemia, particularly venous thrombosis. In 1935, Warren and Eberhard reported that intestinal infarction resulted from ischemia due to venous thrombosis, and they reported a mortality rate of 34% in patients with venous thrombosis after resection. Unfortunately, despite improvements in therapy, this mortality rate still holds. SS mesenteric venous thrombosis AE visceral venous thrombosis AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001157.htm 10027402 mesenteric vein thrombosis AE OAE:0001768 a thrombosis AE that is an uncommon condition induced by thrombotic or nonthrombotic obstruction of hepatic venous outflow and characterized by hepatomegaly, ascites, and abdominal pain. SS WEB: http://emedicine.medscape.com/article/184430-overview 10006537 Budd-Chiari syndrome AE OAE:0001769 a thrombosis AE that occurs in the vein carrying the blood away from the retina [SS] The term 'retinal vein thrombosis' is listed as a different class from 'retinal vein occlusion' for the difference in the pathological process of how the blockage occurs in the vein. SS 10038908 retinal vein thrombosis AE OAE:0001771 an embolism AE that occurs in the artery. It is a sudden interruption of blood flow to an organ or body part due to a clot (embolus). SS embolism arterial AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001102.htm 10014513 arterial embolism AE OAE:0001772 a thrombosis AE* that is a result of when a blood vessel is obstructed by a blood clot (embolus) that has been carried in the bloodstream from the site of its formation. Thromboembolic disease includes both venous thromboembolism (VTE) and arterial thrombosis. VTE is an general term which refers to mainly two conditions: deep vein thrombosis (DVT) and its potentially fatal acute complication, pulmonary embolism (PE). Arterial embolism is a frequent complication in patients with atrial fibrillation (AF) and can lead to stroke or systemic embolism. * see editor note [SS] Per DRA and KKB's comment, this term is synonymous to venous thrombosis even though labeled embolism. Cross-reference is made via seeAlso. SS VTE embolism venous AE venous thromboembolism AE WEB: http://www.boehringer-ingelheim.com/products/prescription_medicines/thromboembolic_diseases.html 10014522 venous embolism AE OAE: 0001505 OAE:0001773 an embolism AE that is characterized by the obstruction of blood vessel by fat droplets SS WEB: http://emedicine.medscape.com/article/460524-overview#showall 10016246 fat embolism AE OAE:0001774 a embolism AE that is infected with bacteria containing pus SS septic embolism AE WEB: http://www.medicalnewstoday.com/articles/153704.php 10040067 septic embolus AE OAE:0001775 a thrombosis AE that occurs in or may be caused by an implanted device in the body SS 10062546 thrombosis in device AE OAE:0001777 an arterial thrombosis AE that occurs in the limb(s) of the body SS 10003180 arterial thrombosis limb AE OAE:0001778 an inflammation AE that occurs in eye. YH, JX eye inflammation AE OAE:0001779 SS 10022104 injection site thrombosis AE OAE:0001780 a deep vein thrombosis AE that occurs in the pelvis. Ovarian vein thrombosis arises out of the coincident conditions of venous stasis and hypercoagulability, which are commonly present in the recently postpartum patient. SS ovarian vein thrombosis AE WEB: http://emedicine.medscape.com/article/404364-overview 10034272 pelvic venous thrombosis AE OAE:0001781 an embolism AE that is charaterized by a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. SS PE WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/pe/ 10061340 peripheral embolism AE OAE:0001782 a thrombosis AE that occurs in subclavian vein. Among patients with effort-induced thrombosis with subclavian vein stenosis, the thrombosis occurs in the dominant arm in 80% of cases. SS WEB: http://emedicine.medscape.com/article/424777-overview#showall 10049446 subclavian vein thrombosis AE OAE:0001783 a thrombophlebitis AE that is characterized by an inflammation of a vein due to a blood clot in a vein located just below the skin's surface. YH: MedDRA: 10043595 is for "thrombophlebitis superficial"; MedDRA: 10042554 is for "superficial thrombophlebitis" SS, YH, MW thrombophlebitis superficial AE WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000199.htm 表在性血栓性静脈炎 superficial thrombophlebitis AE CTCAE: E13817 NCIt: C78634 UMLS CUI: C1510431 OAE:0001784 SS 10061408 venous thrombosis limb AE OAE:0001785 a thrombosis that is characterized by a blockage of the small veins that carry blood away from the retina. The retina is the layer of tissue at the back of the inner eye that converts light images to nerve signals and sends them to the brain. SS RVO WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007330.htm 10038907 retinal vein occlusion AE OAE:0001786 a thrombosis AE that occurs in the atrium (left or right) SS WEB: http://ehjcimaging.oxfordjournals.org/content/9/1/204.full 10048632 atrial thrombosis AE OAE:0001787 an arterial thrombosis AE that occurs in the coronary artery SS coronary embolism AE WEB: http://medical-dictionary.thefreedictionary.com/Coronary+embolism 10011084 10011091 coronary artery thrombosis AE OAE:0001790 a brain AE that occurs when flow of oxygen-rich blood to a portion of the brain is blocked JX, LW, YH cardiovascular accident AE WEB: http://en.wikipedia.org/wiki/Stroke WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/stroke/ 中风 10042244 stroke AE CTCAE: E12826 NCIt: C3390 OAE:0001791 a stroke AE that occurs when a blood vessel that supplies the brain becomes blocked or "clogged" and impairs blood flow to part of the brain. SS ischaemic stroke AE WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ 10061256 ischemic stroke AE OAE:0001792 a stroke AE that occurs when a blood vessel that supplies the brain ruptures and bleeds causing the deficiency of oxygen and nutrients to brain cells and tissues SS haemorrhagic stroke AE WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ 10019016 hemorrhagic stroke AE OAE:0001793 a haemorrhagic stroke AE that is cuased by hypertension (high blood pressure), and bleeding occurs suddenly and rapidly. SS intracerebral haemorrhagic stroke AE WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ intracerebral hemorrhagic stroke AE OAE:0001794 a haemorrhagic stroke AE that is cuased by the bleeding (haemorrhage) between the brain and the meninges (the membrane that covers the brain) in the subarachnoid space. SS subarachnoid haemorrhagic stroke AE WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ subarachnoid hemorrhagic stroke AE OAE:0001795 an ischaemic stroke AE that is caused by a thrombus (blood clot) that develops in the arteries supplying blood to the brain SS WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ 10043647 thrombotic stroke AE OAE:0001796 an ischaemic stroke AE that is caused by an embolus (a blood clot that formms elsewhere in the body and travels through the bloodstream to the brain). SS WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ 10014498 embolic stroke AE OAE:0001797 a behavior and neurological AE that has an outcome of a mental illness or psychiatiric disorder. The mental illness is a mental or behavioral pattern or anomaly that causes either suffering or an impaired ability to function in ordinary life (disability), and which is not developmentally or socially normative. YH, Izabela Birsanescu mental disorder AE WEB: http://en.wikipedia.org/wiki/Mental_disorder 10037175 psychiatric disorder AE OAE:0001798 a psychiatric disorder AE that has an outcome of a adjustment disorder. An adjustment disorder is an unexpectedly strong emotional or behavioral reaction that occurs in response to an identifiable stressful life event or life change that occurred within the previous three months. Yongqun He, Izabela Birsanescu WEB: http://www.healthline.com/health/adjustment-disorder 10001301 10001302 adjustment disorder AE OAE:0001799 an adjustment disorder AE that has an additional depressed mood. The person is more depressed than would be expected after a stressful event. Yongqun He, Izabela Birsanescu WEB: http://www.summitmedicalgroup.com/library/adult_health/bha_adjustment_disorder_with_depressed_mood/ 10001297 adjustment disorder with depressed mood AE OAE:0001800 a hemorrhage AE that has an outcome of bleeding from anastomosis site. Anastomosis: pathological formation of an opening between two normally distinct spaces or organs. Yongqun He, Izabela Birsanescu WEB: http://medical-dictionary.thefreedictionary.com/anastomosis 10071781 anastomotic bleeding AE OAE:0001801 a clostridial infection AE that is caused by C. difficule. Yongqun He, Izabela Birsanescu WEB: http://www.mayoclinic.org/diseases-conditions/c-difficile/basics/definition/CON-20029664?p=1 10054236 Clostridium difficile infection AE OAE:0001802 Yongqun He, Izabela Birsanescu a bacteraemia AE that is more specifically associated with a Gram-negative bacterium. 10054228 Gram-negative bacteremia AE OAE:0001805 a hemorrhage AE that has an outcome of massive amounts of blood loss. A typical Intraoperative hemorrhage has a blood loss exceeding 1000 mL or requires a blood transfusion Yongqun He, Izabela Birsanescu WEB: http://www.uptodate.com/contents/management-of-hemorrhage-in-gynecologic-surgery 10055298 Intraoperative hemorrhage AE CTCAE: E11810 NCIt: C35135 OAE:0001806 an abscess AE that shows a cavity of pus within the pancreas Yongqun He, Izabela Birsanescu WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000270.htm 10048984 pancreatic abscess AE OAE:0001807 a sugery AE that has an adverse outcome where the recipient’s body rejects the pancreas transplantation. Yongqun He, Izabela Birsanescu WEB: http://www.medscape.com/viewarticle/436542_13 10049169 pancreas transplant rejection AE OAE:0001808 an infection AE that has an outcome of a severe local inflammation, usually with pus formation, generally caused by one of the pyogenic bacteria. Yongqun He, Izabela Birsanescu WEB: http://www.medilexicon.com/medicaldictionary.php?t=44396 10021861 pyogenic infection AE OAE:0001809 a fever AE that has unknown origin. Yongqun He, Izabela Birsanescu WEB: http://medicine.academic.ru/123590/fever_of_unknown_origin 10016563 fever of unknown origin AE OAE:0001841 a blood phosphate abnormal AE that has an abnormally increased amount of phosphate in the blood EB, YH, MW WEB: https://en.wikipedia.org/wiki/Hyperphosphatemia 10020712 hyperphosphatemia AE HPO: HP_0002905 OAE:0001843 a respiratory distress AE that is characterized by insufficient oxygen flow in the heart and respiratory system. SS, YH WEB: http://medicalcenter.osu.edu/patientcare/healthcare_services/lung_diseases/about/signs/Pages/index.aspx, http://www.merriam-webster.com/dictionary/cardiorespiratory 10049874 cardio-respiratory distress AE OAE:0001844 A joint disorder AE that has the presence of increased intra-articular fluid. It can be caused by trauma, arthritis, or gout and often affects the knee. RR, YH, MW PMID: 19915432 WEB: http://en.wikipedia.org/wiki/Joint_effusion 10023215 joint effusion AE CTCAE:E12431 NCIt:C49052 OAE:0001845 a gastrointestinal disorder AE that shows a problem with the stomach, ranging from indigestion and heartburn to peptic ulcers and GERD. RR, YH stomach disorder AE WEB: http://www.nlm.nih.gov/medlineplus/stomachdisorders.html 10056819 gastric disorder AE OAE:0001847 An inflammation AE that displays an inflammation (not an infection) of the thyroid gland. http://www.endocrineweb.com/conditions/thyroid/thyroiditis yongqun he, liwei wang thyroiditis AE OAE:0001848 a urinary system AE that has an outcome of the excretion of glucose into the urine. web: http://en.wikipedia.org/wiki/glycosuria LW, YH glucosuria AE OAE:0001850 an inflammation AE that shows localized nodular inflammation found in tissues. KM, JX, YH WEB: http://en.wikipedia.org/wiki/Granuloma WEB: http://www.mayoclinic.org/granuloma/expert-answers/faq-20057838 WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=3629 10018691 granuloma AE OAE:0001851 a burning sensation AE that occurs at the skin. KM, JX, YH 10054786 skin burning sensation AE OAE:0001852 a sensory capability AE that has an outcome of numbness, a loss of sensation of feeling in a part of the body. YH, JS WEB: http://www.mayoclinic.org/symptoms/numbness/basics/definition/sym-20050938 10029829 numbness AE OAE:0001853 a pneumonia AE that occurs at the interstitial lung. Interstitial pneumonia is often caused by an infection of bacteria, viruses, or fungii. A bacterium called Mycoplasma pneumonia is the most common cause. JX, YH WEB: http://www.webmd.com/lung/interstitial-lung-disease 10022617 interstitial pneumonia AE OAE:0001854 a numbness AE that occurs around the mouth. The terms 'circumoral numbness AE' and 'circumoral paresthesia AE' appear to be synonyms. YH, JS WEB: http://link.springer.com/referenceworkentry/10.1007%2F3-540-29623-9_6515 10049339 circumoral numbness AE OAE:0001855 Skin necrosis AE is a necrosis AE that results in the death of the skin tissue. Skin necrosis often occurs when not enough blood and oxygen are supplied to a given skin region. JX, LW, YH 皮肤坏死 10040893 skin necrosis AE UMLS ID: C0151799 OAE:0001856 Systemic lupus erythematosus (SLE) syndrome AE is a lupus syndrome AE that is systemic and disseminated. SLE most often harms the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system. Although “lupus” actually includes a number of different diseases, SLE is the most common type of lupus, and when people say “lupus,” they are often referring to SLE. JX, LW, YH SLE systemic lupus erythematosus syndrome AE 系统性红斑狼疮 WEB: http://en.wikipedia.org/wiki/Systemic_lupus_erythematosus WEB: http://www.healthline.com/health/systemic-lupus-erythematosus#Overview1 系统性红斑狼疮综合征 systemic lupus erythematosus AE OAE:0001857 Urgent urination AE is a urinary system AE that has an outcome of a sudden, compelling urge to urinate, along with discomfort in the bladder. JX, LW, YH micturition urgency urinary urgency WEB: http://sideeffects.embl.de/se/C0085606/ WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003140.htm 尿急 10046593 urgent urination AE CTCAE: E13062 NCIt: C50792 UMLS CUI: C0439609 OAE:0001858 Precordialgia AE is a pain AE that pain located in the precordial region. JX, LW, YH WEB: http://www.drugs.com/dict/precordialgia.html 心前痛 precordialgia AE OAE:0001859 Dyshidrosis AE is a skin AE that shows a disorder of eccrine sweat glands, characterized by small blisters on the hands or feet. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Dyshidrosis 汗疱疹 10013912 dyshidrosis AE OAE:0001860 Ankle swelling AE is an edema AE that shows abnormal buildup of fluid in the ankles. Ankle swelling is a sign of fluid buildup or inflammation of the joint and tissues of the ankle. Mild ankle swelling is a common occurrence after standing for a long period. JX, LW, YH WEB: http://www.healthgrades.com/symptoms/ankle-swelling 踝部水肿 10002554 ankle swelling AE UMLS ID: C0235439 OAE:0001861 Renal dysfunction AE is a kidney AE that has an outcome of reduced capacity to excrete metabolic products which accumulate systemically and are detectable clinicopathologically by renal function tests. The early stage of uremia. This term appears to be a synonym to the 'renal failure AE'. JX, LW, YH hepatic and renal function disorder AE 肾功能障碍 renal dysfunction AE UMLS ID: C0859242 OAE:0001862 Epiphora AE is a eye AE that shows an overflow of tears onto the face. In this case, there is insufficient tear film drainage from the eyes, and the tears will drain down the face rather than through the nasolacrimal system. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Epiphora_(medicine) 泪溢 10015068 epiphora AE UMLS ID: C0152227 OAE:0001863 Hemolytic anemia AE is an anemia AE associated with hemolysis, the abnormal breakdown of red blood cells (RBCs), either in the blood vessels (intravascular hemolysis) or elsewhere in the human body (extravascular). Such an AE can be relatively harmless or life-threatening. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Hemolytic_anemia 溶血性贫血 10019493 hemolytic anemia AE OAE:0001864 a behavioral and neurological AE where somniloquy also is called sleep-talking, a parasomnia that refers to talking aloud while asleep. Somniloquy can be quite loud, ranging from simple mumbling sounds to loud shouts and long frequently inarticulate speeches, and can occur many times during a sleep cycle. As with sleepwalking and night terrors, sleeptalking usually occurs during the less-deep delta-wave NREM sleep stages or during temporary arousals therefrom. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Somniloquy 梦呓 somniloquy AE OAE:0001865 Cholelithiasis AE is a liver, biliary, and pancreatic AE that shows hard deposits forming inside the gallbladder. Gallstones may be as small as a grain of sand or as large as a golf ball. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Gallstone 10008629 cholelithiasis AE UMLS ID: C1328486 OAE:0001866 Blepharoptosis AE is an eye AE that shows droopy upper eyelid or ptosis that presents with substantial blockage upper part of field of vision, risk of amblyopia among young children, and dramatic change in the facial appearance. JX, LW, YH WEB: http://eyewiki.aao.org/Blepharoptosis 眼睑下垂 10005157 blepharoptosis AE OAE:0001874 an epileptic seizure AE that is characterized by tonic-clonic seizures, involving two phases -- the tonic phase in which the body becomes rigid, and clonic phase in which there is uncontrolled jerking. JX, LW, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=32957 癫痫大发作 10018658 grand mal AE OAE:0001875 Erythema simplex AE is an erythema AE that accompany with blushing or redness of the skin caused by a toxic reaction or a neurovascular phenomenon. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/erythema+simplex 单纯性红斑 erythema simplex AE OAE:0001876 Pelvic pain AE is a pain AE that occurs in the lower abdomen area. The pain might be steady, or it might come and go. If the pain is severe, it might get in the way of people's daily activities. JX, LW, YH, MW WEB: http://www.nlm.nih.gov/medlineplus/pelvicpain.html 骨盆痛 10034263 pelvic pain AE CTCAE:E13167 NCIt:C40122 OAE:0001877 Extrasystoles AE is an arrhythmia AE that shows a premature contraction of the heart that is independent of the normal rhythm of the heart and arises in response to an impulse in some part of the heart other than the normal impulse from the sinoatrial node. The extrasystole is followed by a pause, as the heart electrical system "resets" itself and the contraction following the pause is usually more forceful than normal. JX, LW, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=32159 早搏（额外收缩） 10015856 extrasystoles AE OAE:0001878 An increased upper airway secretion AE is a respiratory system AE characterized by an increased secretion at the upper airway location. RR, YH 10062717 increased upper airway secretion AE OAE:0001879 Feeling of body temperature change AE is a feeling abnormal AE that a patient feels a change in body temperature. RR, YH 10061458 feeling of body temperature change AE OAE:0001880 Heartburn AE is a gastric disorder AE that also known as pyrosis, cardialgia, or acid indigestion. It's a burning sensation in the chest, just behind the breastbone or in the epigastrium, the upper central abdomen. The pain often rises in the chest and may radiate to the neck, throat, or angle of the jaw. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Heartburn 胃灼热（烧心） 10019326 heartburn AE OAE:0001881 Tonsillitis AE is an inflammation AE that is inflammation of the tonsils most commonly caused by viral or bacterial infection. Symptoms may include sore throat and fever. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Tonsillitis 扁桃体炎 10044008 tonsillitis AE OAE:0001882 Non-insulin-dependent diabetes mellitus AE is a diabetes mellitus AE which is also called diabetes mellitus type 2, it's characterized by hyperglycemia (high blood sugar) in the context of insulin resistance and relative lack of insulin. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 非胰岛素依赖型糖尿病 10029505 non-insulin-dependent diabetes mellitus AE OAE:0001883 Insulin dependent diabetes mellitus AE is a diabetes mellitus AE which is also called diabetes mellitus type 1. It results from the autoimmune destruction of the insulin-producing beta cells in the pancreas. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Diabetes_mellitus_type_1 胰岛素依赖型糖尿病 10022497 insulin dependent diabetes mellitus AE OAE:0001884 a hyporeflexia AE where the patient shows no sign of reflexes. JX, LW, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=20423 反射消失 10003084 areflexia AE OAE:0001885 Mastauxea AE is a reproductive system AE that shows enlargement of the breast. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/mastauxe 乳房增大 mastauxe AE OAE:0001886 Uveitis AE is an inflammation AE that is inflammation of the uvea, which lines the inside of the eye behind the cornea. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Uveitis 色素层炎 10046851 uveitis AE CTCAE: E10442 NCIt: C26909 OAE:0001887 Sexual dysfunctions AE is a reproductive system AE that is difficulty experienced by an individual or a couple during any stage of a normal sexual activity, including physical pleasure, desire, preference, arousal or orgasm. JX, LW, YH sexual malfunction AE WEB: http://en.wikipedia.org/wiki/Sexual_dysfunction 性功能障碍 10040477 sexual dysfunctions AE OAE:0001888 Hypomnesia AE is a behavior and neurological AE that is an archaic term applied to poor memory, the impaired ability to recall information previously memorized. JX, LW, YH WEB: http://psychology.wikia.com/wiki/Hypomnesia 记忆减退 10021035 hypomnesia AE OAE:0001889 Phobia AE is a behavior and neurological AE that is a type of anxiety disorder, usually defined as a persistent fear of an object or situation in which the sufferer commits to great lengths in avoiding, typically disproportional to the actual danger posed, often being recognized as irrational. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Phobia 恐惧症 10034912 phobia AE OAE:0001890 Lymphadenectasis AE is an edema AE that shows enlargement of the lymph node. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/lymphadenectasis 淋巴结肿大 10025282 lymphadenectasis AE OAE:0001891 Asterixis AE is a tremor AE that also called the flapping tremor, or liver flap, which is a tremor of the hand when the wrist is extended, sometimes said to resemble a bird flapping its wings. This motor disorder is characterized by an inability to actively maintain a position, which is demonstrated by jerking movements of the outstretched hands when bent upward at the wrist. The tremor is caused by abnormal function of the diencephalic motor centers in the brain, which regulate the muscles involved in maintaining position. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Asterixis 扑翼样震颤 10003547 asterixis AE OAE:0001892 Parageusia AE is a gustatory system AE which is the medical term for a bad taste in the mouth. One common form of parageusia is a metallic taste of food. This can be a side effect of several medications, such as acetazolamide, eszopiclone, zopiclone, metronidazole, or etoposide. Metallic taste is also a type of dysgeusia which is frequently associated with infections in the mouth or upper airways. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Parageusia 味觉颠倒 10033793 parageusia AE OAE:0001893 Brain damage AE is a brain AE that also called brain injury is the destruction or degeneration of brain cells. In general, brain damage refers to significant, undiscriminating trauma-induced damage. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Brain_damage 脑损伤 10056389 brain damage AE OAE:0001894 Frequent bowel movements AE is a abnormal stool AE that people are having more bowel movements than is normal for them. Often, frequent bowel movements are accompanied by diarrhea, the passage of loosely formed stool. JX, LW, YH WEB: http://www.healthgrades.com/symptoms/frequent-bowel-movements 大便频繁 10017367 frequent bowel movements AE OAE:0001895 Hyperprolactinemia AE is an endocrine investigation result abnormal AE that is the presence of abnormally high levels of prolactin in the blood. Normal levels are less than 500 mIU/L [20 ng/mL or µg/L] for women, and less than 450 mIU/L for men. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Hyperprolactinaemia 高泌乳素血症 10020739 hyperprolactinemia AE OAE:0001896 Galactorrhea AE is a reproductive system AE that is the spontaneous flow of milk from the breast, unassociated with childbirth or nursing. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Galactorrhea 乳溢 10017592 galactorrhea AE OAE:0001897 Sitophobia AE is a behavior and neurological AE that shows a morbid or insane dread of eating. JX, LW, YH WEB: http://en.wiktionary.org/wiki/sitophobia 畏食 sitophobia AE OAE:0001898 Ejection murmur AE is a cardiac disorder AE which is due to turbulent forward flow across the right and left ventricular outflow tract, aortic or pulmonary valve, or through the aorta or pulmonary artery. JX, LW, YH WEB: http://www.cardiologysite.com/auscultation/html/ejection_murmurs.html 收缩期喷射性杂音 ejection murmur AE OAE:0001899 Hypoactive sexual desire disorder AE is a libido disorder AE that is considered a sexual dysfunction and is characterized as a lack or absence of sexual fantasies and desire for sexual activity, as judged by a clinician. JX, LW, YH hyposexuality AE WEB: http://en.wikipedia.org/wiki/Hypoactive_sexual_desire_disorder 性欲减退 10020933 hypoactive sexual desire disorder AE OAE:0001900 Bigotry AE is a behavior and neurological AE that is a state of mind where a person strongly and unfairly dislikes other people, ideas, etc. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Bigotry 偏执 bigotry AE OAE:0001901 Somnambulisma AE is a behavior and neurological AE that also known as sleepwalking or noctambulism, which is a sleep disorder belonging to the parasomnia family. It arise from the slow wave sleep stage in a state of low consciousness and perform activities that are usually performed during a state of full consciousness. These activities can be as benign as sitting up in bed, walking to the bathroom, and cleaning, or as hazardous as cooking, driving, violent gestures, grabbing at hallucinated objects, or even homicide. JX, LW, YH noctambulism AE sleepwalking AE WEB: http://en.wikipedia.org/wiki/Sleepwalking 梦游症 10041347 somnambulism AE OAE:0001902 Hyperphagia AE is an eating disorder AE that also called polyphagia. It's a medical sign meaning excessive hunger and abnormally large intake of solids by mouth. It can be caused by disorders such as diabetes, Kleine–Levin syndrome (a malfunction in the hypothalamus), the genetic disorders Prader–Willi syndrome, and Bardet–Biedl syndrome. JX, LW, YH polyphagia AE 食欲过盛 WEB: http://en.wikipedia.org/wiki/Polyphagia 10020710 hyperphagia AE OAE:0001903 Corneal pigmentation is a eye AE shows that the melanin is in the superficial stroma and the basal layer of the corneal epithelium. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/corneal+pigmentation 角膜色素沉着 10011040 corneal pigmentation AE OAE:0001904 Chromatos AE is a skin AE shows that deposit of pigment in a normally unpigmented area or excessive pigmentation in a normally pigmented site. JX, LW, YH WEB: http://www.merriam-webster.com/medical/chromatosis 色素沉着 chromatosis AE OAE:0001905 Subclavian steal syndrome AE is an ischaemia AE that is a constellation of signs and symptoms that arise from retrograde (reversed) flow of blood in the vertebral artery or the internal thoracic artery, due to a proximal stenosis (narrowing) and/or occlusion of the subclavian artery. The arm may be supplied by blood flowing in a retrograde direction down the vertebral artery at the expense of the vertebrobasilar circulation. This is called the subclavian steal. JX, LW, YH subclavian steal phenomenon AE subclavian steal steno-occlusive disease AE 锁骨下动脉盗血综合征 10042335 subclavian steal syndrome AE OAE:0001906 Allergic rhinitis AE is a rhinitis AE that is an allergic inflammation of the nasal airways. It occurs when an allergen, such as pollen, dust, or animal dander (particles of shed skin and hair) is inhaled by an individual with a sensitized immune system. JX, LW, YH, MW WEB: http://en.wikipedia.org/wiki/Allergic_rhinitis 过敏性鼻炎 10001723 allergic rhinitis AE CTCAE:E13303 NCIt:C79532 OAE:0001907 Ventricular ectopic beats AE is a cardiac ventricular disorder AE that is a disturbance of the cardiac rhythm frequently related to the electrical conduction system of the heart, in which beats arise from fiber or group of fibers outside the region in the heart muscle ordinarily responsible for impulse formation. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Ectopic_beat 心室异位搏动 10058291 ventricular ectopic beats AE OAE:0001908 Sjogren syndrome AE is a eye AE that is a chronic autoimmune disease in which the body's white blood cells destroy the exocrine glands, specifically the salivary and lacrimal glands, that produce saliva and tears, respectively. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Sj%C3%B6gren's_syndrome 干燥综合症 10040767 sjogren syndrome AE OAE:0001909 Nocturia AE is a urine abnormality AE that is defined by the International Continence Society as “the complaint that the individual has to wake at night one or more times for voiding”. JX, LW, YH nycturia AE WEB: http://en.wikipedia.org/wiki/Nocturia 夜尿症 10029446 nocturia AE OAE:0001910 Night sweat is a sweating AE that is the occurrence of excessive sweating (hyperhidrosis and focal hyperhidrosis) during sleep. The sufferer may or may not also suffer from excessive perspiration while awake. JX, LW, YH sleep hyperhidrosis AE WEB: http://en.wikipedia.org/wiki/Night_sweats 夜汗 10029409 night sweat AE OAE:0001911 Increased appetite AE is a gustatory system AE that is when people want to eat much more often or in larger quantities than their body requires. JX, LW, YH WEB: http://www.healthline.com/symptom/increased-appetite 食欲增加 10021654 increased appetite AE OAE:0001912 Vascular dilatation headache AE is a headache AE that shows headache which caused by vascular dilatation. JX, LW, YH WEB: http://www.headaches.org/education/Headache_Topic_Sheets/Vascular_Headaches 血管扩张性头痛 vascular dilatation headache AE OAE:0001913 Bundle-branch block AE is a conduction system disorder AE that refers to a defect of the heart's electrical conduction system. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Bundle_branch_block 束支传导阻滞 10006578 bundle-branch block AE OAE:0001914 Unstable diabetes AE is a diabetes mellitus AE that is a type of diabetes when a person's blood glucose level often swings quickly from high to low and from low to high. JX, LW, YH brittle diabetes AE labile diabetes AE WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=7271 不稳定型糖尿病 10006372 unstable diabetes AE OAE:0001915 Tendon rupture AE is a tendon disorder AE shows a tearing of the tendon that occurs when the forces placed upon the tendon exceed its tensile strength. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/Tendon+rupture 肌腱断裂 10043248 tendon rupture AE OAE:0001916 Tendovaginitis AE is an inflammation AE that is an acute or chronic inflammation of the tendon sheath, occurring in the region of the hand, the wrist joint, the forearm (radial and ulnar tenobursitis), the foot, the ankle joint, and the Achilles tendon (achillobursitis). JX, LW, YH tenovaginitis AE WEB: http://encyclopedia2.thefreedictionary.com/Tendovaginitis 腱鞘炎 10067216 tendovaginitis AE OAE:0001917 Loose stools AE is a abnormal stool AE that is usually a form of diarrhea and many conditions causing loose stool will be listed under diarrhea. It may also be related to watery stool (also within the spectrum of diarrhea). JX, LW, YH WEB: http://www.rightdiagnosis.com/sym/loose_stool.htm 稀便 10024840 loose stools AE OAE:0001918 Cystitis AE is an inflammation AE that is the medical term for inflammation of the bladder. Most of the time, the inflammation is caused by a bacterial infection, and it's called a urinary tract infection. JX, LW, YH WEB: http://www.mayoclinic.org/diseases-conditions/cystitis/basics/definition/con-20024076 膀胱炎 10011781 cystitis AE OAE:0001919 Eructation AE is a digestive system AE that is the release of gas from the digestive tract (mainly esophagus and stomach) through the mouth. It is usually accompanied with a typical sound and, at times, an odor. JX, LW, YH belching AE burping AE ructus AE WEB: http://en.wikipedia.org/wiki/Burping 嗳气 10015137 eructation AE OAE:0001920 Glossolalia AE is a speech disorder AE that is the fluid vocalizing of speech-like syllables that lack any readily comprehended meaning. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Glossolalia 语言不清 glossolalia AE OAE:0001921 Leg pain AE is a pain AE that is a common problem in leg, it can be due to a cramp, injury, or other cause. JX, LW, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003182.htm 腿痛 10024130 leg pain AE OAE:0001922 Stomachache AE is a pain AE that the pain in or near your stomach. It is a common symptom associated with transient disorders or serious disease. JX, LW, YH abdominal pain AE stomach pain AE stomachache AE WEB: http://en.wikipedia.org/wiki/Abdominal_pain http://www.nhs.uk/conditions/stomach-ache-abdominal-pain/Pages/Introduction.aspx 胃痛 10042126 stomach ache AE CTCAE: E10460 NCIt: C26682 OAE:0001923 Conduction block AE is a conduction system disorder AE that shows failure of impulse transmission at some point along a nerve fiber, although conduction along the segments proximal and distal to it are unaffected. JX, LW, YH WEB: http://www.medilexicon.com/medicaldictionary.php?t=10757 传导阻滞 conduction block AE OAE:0001924 Photodermatitis AE is a dermatitis AE that referred to as sun poisoning or photoallergy, is a form of allergic contact dermatitis in which the allergen must be activated by light to sensitize the allergic response, and to cause a rash or other systemic effects on subsequent exposure. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Photodermatitis 光敏性皮炎 photodermatitis AE OAE:0001925 Pygalgia AE is a pain AE that is a rarely used term meaning pain in the buttocks. JX, LW, YH WEB: http://www.medilexicon.com/medicaldictionary.php?t=74312 臀痛 pygalgia AE OAE:0001926 Throat irritation AE is a discomfort AE that refers to a dry cough, a scratchy feeling at the back of the throat, or a sensation of a lumpy feeling or something stuck at the back of the throat. JX, LW, YH throat discomfort AE WEB: http://en.wikipedia.org/wiki/Throat_irritation 咽喉不适 10043521 throat irritation AE OAE:0001927 Interstitial nephritis AE is an inflammation AE that is a form of nephritis affecting the interstitium of the kidneys surrounding the tubules. This disease can be either acute, meaning it occurs suddenly, or chronic, meaning it is ongoing and eventually ends in kidney failure. JX, LW, YH tubulointerstitial nephritis AE WEB: http://en.wikipedia.org/wiki/Interstitial_nephritis 间质肾炎 10048302 interstitial nephritis AE OAE:0001928 Hoarseness AE is a hoarseness AE that refers to a difficulty making sounds when trying to speak. Vocal sounds may be weak, breathy, scratchy, or husky, and the pitch or quality of the voice may change. JX, LW, YH, MW WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003054.htm 声音嘶哑 10020201 hoarseness AE CTCAE:E13384 NCIt:C47813 OAE:0001929 Photosensitization AE is a hypersensitivity AE that refers to development of abnormally heightened reactivity of the skin or eyes to sunlight. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/photosensitization 光敏 photosensitization AE OAE:0001930 Fanconi syndrome AE is a kidney AE that is a disease of the proximal renal tubules of the kidney in which glucose, amino acids, uric acid, phosphate and bicarbonate are passed into the urine, instead of being reabsorbed. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Fanconi_syndrome 范可尼综合征 10016219 fanconi syndrome AE OAE:0001931 Keratoconjunctivitis AE is an inflammation AE that is inflammation of the cornea and conjunctiva. When only the cornea is inflamed, it is called keratitis; when only the conjunctiva is inflamed, it is called conjunctivitis. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Keratoconjunctivitis 角膜结膜炎 10023348 keratoconjunctivitis AE OAE:0001932 Hepatic insufficiency AE is a liver disorder AE that shows a failure or partial failure of normal liver function. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/hepatic+insufficiency 肝功能不全 10056542 hepatic insufficiency AE OAE:0001933 Hypoxemia AE is a blood gas investigation result abnormal AE that is an abnormally low level of oxygen in the blood. More specifically, it is oxygen deficiency in arterial blood. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Hypoxemia 低血氧症 10021142 hypoxemia AE OAE:0001934 Irritant contact dermatitis AE is a dermatitis AE that is a form of contact dermatitis that can be divided into forms caused by chemical irritants and those caused by physical irritants. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Irritant_contact_dermatitis 刺激性接触性皮炎 irritant contact dermatitis AE OAE:0001935 Pitting edema AE is an edema AE that shows observable swelling of body tissues due to fluid accumulation that may be demonstrated by applying pressure to the swollen area (such as by depressing the skin with a finger). JX, LW, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=88528 指压性水肿 10054547 pitting edema AE OAE:0001936 Acute bronchitis AE is a bronchitis AE that is an inflammation of the large bronchi (medium-size airways) in the lungs that is usually caused by viruses or bacteria and may last several days or weeks. Characteristic symptoms include cough, sputum (phlegm) production, and shortness of breath and wheezing related to the obstruction of the inflamed airways. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Acute_bronchitis 急性支气管炎 10000687 acute bronchitis AE OAE:0001937 Renal calculus AE is a kidney AE that is a solid concretion or crystal aggregation formed in the kidneys from minerals in the urine. Kidney stones typically leave the body by passage in the urine stream, and many stones are formed and passed without causing symptoms. If stones grow to sufficient size (usually at least 3 millimeters (0.12 in)) they can cause blockage of the ureter. This leads to pain, most commonly beginning in the flank or lower back and often radiating to the groin or genitals. JX, LW, YH CTCAE: E13018 NCIt: C26807 kidney stone AE nephrolithiasis AE renal calculi AE WEB: http://en.wikipedia.org/wiki/Kidney_stone 肾结石 10038385 10038386 renal calculus AE OAE:0001938 Clouding of consciousness AE is a sensory capability AE that is a term used in conventional medicine denoting an abnormality in the "regulation" of the "overall level" of consciousness that is mild and less severe than a delirium. The sufferer experiences a subjective sensation of mental clouding described as feeling "foggy". JX, LW, YH brain fog AE mental fog AE WEB: http://en.wikipedia.org/wiki/Clouding_of_consciousness 意识模糊 clouding of consciousness AE OAE:0001939 Reflex tachycardia AE is a tachycardia AE that shows increased heart rate in response to some stimulus conveyed through the cardiac nerves. JX, LW, YH WEB: http://www.medilexicon.com/medicaldictionary.php?t=89526 反射性心动过速 10063096 reflex tachycardia AE OAE:0001940 Joint sprain AE is a joint disorder AE that is damage to one or more ligaments in a joint, often caused by trauma or the joint being taken beyond its functional range of motion. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Sprain 关节扭伤 10023229 joint sprain AE OAE:0001941 Epicondylitis AE is an inflammation AE that is a type of musculoskeletal disorder that refers to an inflammation of an epicondyle. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Epicondylitis 上髁炎 10014971 epicondylitis AE OAE:0001942 Melanoglosia AE is a tongue AE that shows tongue turn black. Any blackening of the tongue associated with certain disorders and diseases in animals and humans. JX, LW, YH WEB: http://encyclopedia2.thefreedictionary.com/melanoglosia 舌黑 10014971 melanoglosia AE OAE:0001943 Ventricular tachycardia AE is a tachycardia AE that is a type of tachycardia, or a rapid heart beat that arises from improper electrical activity of the heart presenting as a rapid heart rhythm, that starts in the bottom chambers of the heart, called the ventricles. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Ventricular_tachycardia 心室性心搏过速 10047302 ventricular tachycardia AE CTCAE: E10239 NCIt: C50802 OAE:0001944 Granulomatous hepatitis AE is a hepatitis AE that refers to an inflammatory liver disease associated with granuloma formation in the liver. JX, LW, YH WEB: http://radiopaedia.org/articles/granulomatous-hepatitis 肉芽肿性肝炎 granulomatous hepatitis AE OAE:0001945 Hypogeusia AE is a gustatory system AE that is a reduced ability to taste things (to taste sweet, sour, bitter, or salty substances). JX, LW, YH WEB: http://en.wikipedia.org/wiki/Hypogeusia 味觉减弱 10020989 hypogeusia AE OAE:0001946 Dysphoria AE is a behavior and neurological AE that is a profound state of unease or dissatisfaction. In a psychiatric context, dysphoria may accompany depression, anxiety, or agitation. Common reactions to dysphoria include emotional distress or indifference. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Dysphoria 烦躁不安 10013954 dysphoria AE OAE:0001947 Oneirism AE is a behavior and neurological AE that is a state of abnormal consciousness in which dream-like experiences and hallucinations happen while awake. JX, LW, YH WEB: http://en.wiktionary.org/wiki/oneirism 梦幻症 10030332 oneirism AE OAE:0001948 Podalgia AE is a pain AE that shows pain in the foot. JX, LW, YH WEB: http://en.wiktionary.org/wiki/podalgia 足痛 podalgia AE OAE:0001949 Brachialgia AE is a pain AE that shows pain in the arm. JX, LW, YH WEB: http://en.wiktionary.org/wiki/brachialgia 臂痛 10068901 brachialgia AE OAE:0001950 Coxalgia AE is a pain AE that shows pain in the hip. JX, LW, YH WEB: http://en.wiktionary.org/wiki/coxalgia 髋痛 10011249 coxalgia AE OAE:0001951 Limb injury AE is an injury AE which involve damage to bones, joints, ligament, musles, the major blood vessels and nerves of the limb. JX, LW, YH 肢体伤 10061225 limb injury AE OAE:0001952 Polymyalgia rheumatica AE is a muscle pain AE that is a syndrome with pain or stiffness, usually in the neck, shoulders, and hips. The pain can be very sudden, or can occur gradually over a period. It may be caused by an inflammatory condition of blood vessels such as temporal arteritis. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Polymyalgia_rheumatica 风湿性多发性肌痛 10036099 polymyalgia rheumatica AE OAE:0001953 Fibromyalgia AE is a muscle pain AE that is characterised by chronic widespread pain and allodynia (a heightened and painful response to pressure). Fibromyalgia symptoms are not restricted to pain, leading to the use of the alternative term fibromyalgia syndrome for the condition. Other symptoms include debilitating fatigue, sleep disturbance, and joint stiffness. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Fibromyalgia 纤维肌痛 10048439 fibromyalgia AE OAE:0001954 Hepatic encephalopathy AE is an encephalopathy AE that is the occurrence of confusion, altered level of consciousness, and coma as a result of liver failure. In the advanced stages it is called hepatic coma or coma hepaticum. JX, LW, YH portosystemic encephalopathy AE WEB: http://en.wikipedia.org/wiki/Hepatic_encephalopathy 10019660 hepatic encephalopathy AE OAE:0001955 a behavior and neurological AE AE that is an abnormal involuntary movement disorder, one of a group of neurological disorders called dyskinesias. JX, LW, YH choreia AE WEB: http://en.wikipedia.org/wiki/Chorea 舞蹈症 10008748 chorea AE OAE:0001956 Nightmare AE is a sleep disorder AE that is an unpleasant dream that can cause a strong emotional response from the mind, typically fear or horror but also despair, anxiety and great sadness. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Nightmare 梦魇 10029412 nightmare AE OAE:0001957 a psychiatric disorder AE that is an anomaly of self-awareness. It consists of a feeling of watching oneself act, while having no control over a situation. Subjects feel they have changed, and the world has become vague, dreamlike, less real, or lacking in significance. It can be a disturbing experience, since many feel that, indeed, they are living in a "dream". JX, LW, YH depersonalisation AE WEB: http://en.wikipedia.org/wiki/Depersonalization 人格解体 10012359 depersonalization AE OAE:0001958 a psychiatric disorder AE that refers to a state of mind where one is not disturbed by the passions. JX, LW, YH apathia AE WEB: http://en.wikipedia.org/wiki/Apatheia 情感冷漠 apatheia AE OAE:0001959 Parosmia AE is a sensory capability AE that is an olfactory dysfunction which is characterized by the inability of the brain to properly identify an odor’s “natural” smell. JX, LW, YH cacosmia AE troposmia AE 味觉倒错 WEB: http://en.wikipedia.org/wiki/Parosmia 10034018 parosmia AE OAE:0001960 Xerophthalmia AE is an eye AE that is a medical condition in which the eye fails to produce tears. JX, LW, YH xerophthalmus AE WEB: http://en.wikipedia.org/wiki/Xerophthalmia 干眼病 10048221 xerophthalmia AE OAE:0001961 Chondropathy AE is a bone disorder AE that refers to a disease of the cartilage. It is frequently divided into 5 grades, with 0-2 defined as normal, and 3-4 defined as diseased. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Chondropathy 软骨病 10061762 chondropathy AE OAE:0001962 Teratogenesis AE is a female reproductive system AE that is a prenatal toxicity characterized by structural or functional defects in the developing embryo or fetus. It also includes intrauterine growth retardation, death of the embryo or fetus, and transplacental carcinogenesis. JX, LW, YH WEB: http://www.britannica.com/EBchecked/topic/587782/teratogenesis 畸胎 teratogenesis AE OAE:0001963 Premature atrial contraction AE is an arrhythmia AE that is a common cardiac dysrhythmia characterized by premature heartbeats originating in the atria. JX, LW, YH atrial premature beats AE atrial premature complexes AE WEB: http://en.wikipedia.org/wiki/Premature_atrial_contraction 早搏 10056964 premature atrial contraction AE OAE:0001964 An inflammation AE that courrs in one or both parotid glands, the major salivary glands located on either side of the face, in humans. The parotid gland is the salivary gland most commonly affected by inflammation. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Parotitis 腮腺炎 10034038 parotitis AE OAE:0001965 Glossitis AE is an inflammation AE that can mean soreness of the tongue, or more usually inflammation with depapillation of the dorsal surface of the tongue, leaving a smooth and erythematous surface. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Glossitis 舌炎 10018386 glossitis AE OAE:0001966 Genital edema AE is an edema AE that can be the result of interruption to the lymphatic drainage of this area caused by tumor, surgical removal of lymph nodes, radiotherapy or infection. Congenital disorders causing inadequate lymphatics can sometimes lead to the development of this condition. JX, LW, YH, MW WEB: http://www.lymphoedemanz.org.nz/About+Lymphoedema/Genital+Oedema.html 生殖器水肿 10018146 genital edema AE CTCAE:E13111 NCIt:C78324 OAE:0001967 Orgasm incapacity AE is a reproductive system AE that the disorder characterized by an inability to achieve orgasm. JX, LW, YH 缺乏性高潮 orgasm incapacity AE OAE:0001968 Sedation AE is a behavior and neurological AE that is the reduction of irritability or agitation by administration of sedative drugs, generally to facilitate a medical procedure or diagnostic procedure. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Sedation 镇静 10039897 sedation AE OAE:0001969 Sinus bradycardia AE is a bradycardia AE that is a heart rhythm that originates from the sinus node and has a rate that is lower than normal. In humans, bradycardia is generally defined to be a rate of under 60 beats per minute. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Sinus_bradycardia 窦性心动过缓 10040741 sinus bradycardia AE CTCAE: E10208 NCIt: C26923 OAE:0001970 Cardiac output decreased AE is a cardiac disorder AE that shows a state in which the blood pumped by an individual's heart is sufficiently reduced that it is inadequate to meet the needs of the body's tissues. Cardiac output is the volume of blood being pumped by the heart, in particular by a left or right ventricle in the time interval of one minute. JX, LW, YH WEB: http://www1.us.elsevierhealth.com/MERLIN/Gulanick/archive/Constructor/gulanick10.html http://en.wikipedia.org/wiki/Cardiac_output 心输出量减少 10007595 cardiac output decreased AE OAE:0001971 Steatorrhea AE is a digestive system AE that is the presence of excess fat in feces. Stools may also float due to excess lipid, have an oily appearance and can be especially foul-smelling. JX, LW, YH steatorrhoea AE WEB: http://en.wikipedia.org/wiki/Steatorrhea 脂溢 10041968 steatorrhea AE OAE:0001972 Malabsorption syndrome AE is a digestive system AE that refers to a number of disorders in which the intestine’s ability to absorb certain nutrients, such as vitamin B12 and iron, into the bloodstream is negatively affected. JX, LW, YH WEB: http://www.healthline.com/health/malabsorption#Overview1 吸收不良综合症 10025479 malabsorption syndrome AE OAE:0001973 Sialadenitis AE is an inflammation AE that is inflammation of a salivary gland. It may be subdivided temporally into acute, chronic and recurrent forms. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Sialadenitis 唾液腺炎 10040627 sialadenitis AE OAE:0001974 a nervous system AE that shows a degenerative disorder of the central nervous system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain, the cause of this cell death is unknown. JX, LW, YH choreia AE hypokinetic rigid syndrome AE idiopathic/primary parkinsonism AE paralysis agitans AE WEB: http://en.wikipedia.org/wiki/Parkinson's_disease 帕金森综合症 10061536 parkinson's disease AE OAE:0001975 Urinary calculus AE a urinary system AE that is solid particles in the urinary system. They may cause pain, nausea, vomiting, hematuria, and, possibly, chills and fever due to secondary infection. JX, LW, YH urinary calculi AE WEB: http://www.merckmanuals.com/professional/genitourinary_disorders/urinary_calculi/urinary_calculi.html 尿结石 10046531 urinary calculus AE OAE:0001976 Sinoatrial block AE is a conduction system disorder AE that shows the electrical impulse is delayed or blocked on the way to the atria, thus delaying atrial depolarization. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Sinoatrial_block 窦房阻滞 10040736 sinoatrial block AE OAE:0001977 Hyperthyroidism AE is an endocrine system AE that is a condition in which the thyroid gland produces and secretes excessive amounts of the free (not protein bound circulating in the blood) thyroid hormones -triiodothyronine (T3) and/or thyroxine (T4). JX, LW, YH WEB: http://en.wikipedia.org/wiki/Hyperthyroidism 甲状腺机能亢进 10020850 hyperthyroidism AE CTCAE: E10322 NCIt: C3123 OAE:0001978 Akathisia AE is a behavior and neurological AE that is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. People with akathisia are unable to sit or keep still, complain of restlessness, fidget, rock from foot to foot, and pace. JX, LW, YH, MW acathisia AE WEB: http://en.wikipedia.org/wiki/Akathisia 静坐困难 10001540 akathisia AE CTCAE:E12581 NCIt:C78163 OAE:0001979 Retinopathy AE is an eye AE that is due to persistent or acute damage to the retina of the eye. Ongoing inflammation and vascular remodeling may occur over periods of time where the patient is not fully aware of the extent of the disease. Frequently, retinopathy is an ocular manifestation of systemic disease as seen in diabetes or hypertension. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Retinopathy 视网膜病变 10038923 retinopathy AE CTCAE: E10432 NCIt: C62601 OAE:0001980 Sinus arrest AE is an arrhythmia AE that is a medical condition wherein the sinoatrial node of the heart transiently ceases to generate the electrical impulses that normally stimulate the myocardial tissues to contract and thus the heart to beat. It is defined as lasting from 2.0 seconds to several minutes. JX, LW, YH sinoatrial arrest AE sinus pause AE WEB: http://en.wikipedia.org/wiki/Sinoatrial_arrest 窦性停搏 10040738 sinus arrest AE OAE:0001981 ST segment depression AE is an electrocardiogram result abnormal AE that refers to a finding on an electrocardiogram. It may be determined by measuring the vertical distance between the patient's trace and the isoelectric line at a location 2-3 millimeters from the QRS complex. It is significant if it is more than 1 mm in V5-V6, or 1.5 mm in AVF or III. JX, LW, YH WEB: http://en.wikipedia.org/wiki/ST_depression ST段下降 10041892 ST segment depression AE OAE:0001982 T-wave inversion AE is an electrocardiogram result abnormal AE that can be a sign of coronary ischemia, Wellens' syndrome, left ventricular hypertrophy, or CNS disorder. In electrocardiography, the T wave represents the repolarization (or recovery) of the ventricles. JX, LW, YH WEB: http://en.wikipedia.org/wiki/T_wave T波倒置 10042966 T-wave inversion AE OAE:0001983 Hyperthermia AE is an abnormal body temperature AE that is elevated body temperature due to failed thermoregulation that occurs when a body produces or absorbs more heat than it dissipates. Extreme temperature elevation then becomes a medical emergency requiring immediate treatment to prevent disability or death. JX, LW, YH, SJ WEB: http://en.wikipedia.org/wiki/Hyperthermia 体温过高 10020843 hyperthermia AE OAE:0001984 Priapism AE a male reproductive system AE that is a potentially painful medical condition in which the erect penis does not return to its flaccid state, despite the absence of both physical and psychological stimulation, within four hours. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Priapism 阴茎持续勃起 10036661 priapism AE OAE:0001985 Gingival bleeding AE is a hemorrhage AE that is a term used by dentists and dental hygienists when referring to bleeding that is induced by gentle manipulation of the tissue at the depth of the gingival sulcus, or interface between the gingiva and a tooth. Bleeding on probing, often abbreviated BOP, is a sign of inflammation and indicates some sort of destruction and erosion to the lining of the sulcus or the ulceration of sulcular epithelium. The blood comes from lamina propria after the ulceration of the lining. JX, LW, YH bleeding gums AE bleeding on probing AE WEB: http://en.wikipedia.org/wiki/Bleeding_on_probing 牙龈出血 10018276 gingival bleeding AE OAE:0001986 a hearing disorder AE that is a partial or total inability to hear. In children it may affect the development of language and can cause work related difficulties for adults. JX, LW, YH anacusis AE deafness AE hard of hearing AE hearing impaired AE hearing impairment AE WEB: http://en.wikipedia.org/wiki/Hearing_loss 听力下降 10019245 10019246 hearing loss AE CTCAE: E10276 NCIt: C50576 OAE:0001987 Muscle fatigue AE is a muscle adverse event that is the decline in ability of a muscle to generate force. It can be a result of vigorous exercise but abnormal fatigue may be caused by barriers to or interference with the different stages of muscle contraction. JX, LW, YH physical fatigue AE WEB: http://en.wikipedia.org/wiki/Muscle_fatigue 肌肉疲劳 10049565 muscle fatigue AE OAE:0001988 Regurgitation AE is a digestive system AE that is the expulsion of material from the pharynx, or esophagus, usually characterized by the presence of undigested food or blood. JX, LW, YH http://en.wikipedia.org/wiki/Regurgitation_%28digestion%29 反胃 10067171 regurgitation AE OAE:0001989 Skin irritation AE is a skin AE that is a mild inflammatory dermal tissue reaction, it can be caused by physical contact with an irritant or can be a local response to a systemic trigger. JX, LW, YH 皮肤刺激 10040880 skin irritation AE OAE:0001990 a herpes viral infection AE tha is caused by both Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). JX, LW, YH herpes catarrhalis AE WEB: http://en.wikipedia.org/wiki/Herpes_simplex 单纯疱疹 10019948 herpes simplex AE OAE:0001991 Measles AE is a viral infection AE is an infection of the respiratory system, immune system and skin caused by a virus, specifically a paramyxovirus of the genus Morbillivirus. JX, LW, YH English measles AE morbilli AE rubeola AE WEB: http://en.wikipedia.org/wiki/Measles 麻疹 10027011 measles AE OAE:0001992 Hypercholesteremia AE is a blood cholesterol abnormal AE that is the presence of high levels of cholesterol in the blood. JX, LW, YH cholesterol high AE dyslipidemia hypercholesterolemia AE WEB: http://en.wikipedia.org/wiki/Hypercholesterolemia 高胆固醇血症 10005425 10008661 10020604 hypercholesteremia AE OAE:0001993 Toxic epidermal necrolysis AE is a skin AE that is a rare, life-threatening skin condition which is usually caused by a reaction to drugs. JX, LW, YH, MW Lyell's syndrome AE WEB: http://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis 中毒性表皮坏死溶解症 10044223 toxic epidermal necrolysis AE CTCAE:E13743 NCIt:C79777 OAE:0001994 Atrioventricular junctional rhythm AE is an arrhythmia AE that is an electrocardiographic finding in which the pacer of the heart is located in the AV junction, presenting with a narrow QRS complex and a rate of 40-60 beats per minute. JX, LW, YH 房室交界性心律 atrioventricular junctional rhythm AE OAE:0001995 Unconsciousness AE is a sensory capability AE that is a state which occurs when the ability to maintain a awareness of self and environment is lost, it involves a complete or near-complete lack of responsiveness to people and other environmental stimuli. JX, LW, YH loss of consciousness AE WEB: http://en.wikipedia.org/wiki/Unconsciousness 意识丧失 10045481 unconsciousness AE OAE:0001996 Pemphigus AE is a skin AE that is a rare group of blistering autoimmune diseases that affect the skin and mucous membranes. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Pemphigus 天疱疮 10034280 pemphigus AE OAE:0001997 Onychomycosis AE is a nail infection AE that is a fungal infection of the nail. It is the most common disease of the nails and constitutes about half of all nail abnormalities. JX, LW, YH dermatophytic onychomycosis AE tinea unguium AE WEB: http://en.wikipedia.org/wiki/Onychomycosis 甲癣 onychomycosis AE OAE:0001998 Miosis AE is an eye AE that is a term with various definitions, which generally include constriction of the pupil. JX, LW, YH myosis AE WEB: http://en.wikipedia.org/wiki/Miosis 瞳孔缩小 10027646 miosis AE OAE:0001999 an optic neuropathy AE that shows the loss of some or most of the nerve fibers in the optic nerve. The effects range from visual change to severe visual loss. JX, LW, YH WEB: http://www.kellogg.umich.edu/patientcare/conditions/optic.atrophy.html 视神经萎缩 10030910 optic atrophy AE OAE:0002000 Albuminuria AE is a urine abnormality AE that is a pathological condition wherein albumin is present in the urine. It is a type of proteinuria. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Albuminuria 蛋白尿 10001580 albuminuria AE OAE:0002001 Enuresis AE is a urine abnormality AE that refers to a repeated inability to control urination. Use of the term is usually limited to describing individuals old enough to be expected to exercise such control. This term appears to be a synonym to the 'urinary incontinence AE'. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Enuresis 遗尿 10014928 enuresis AE OAE:0002002 Gum hypertrophy AE is a digestive system AE that is an increase in the size of the gingiva (gums). It is a common feature of gingival disease. Gingival enlargement can be caused by a number of factors, including inflammatory conditions and the side effects of certain medications. JX, LW, YH gingival enlargement AE gingival hyperplasia AE gingival hypertrophy AE gingival over-growth AE hypertrophic gingivitis AE WEB: http://en.wikipedia.org/wiki/Gingival_enlargement 牙龈增生 10018781 gum hypertrophy AE OAE:0002003 Contact dermatitis AE is a dermatitis AE that is a type of skin inflammation.It results from exposure to allergens (allergic contact dermatitis) or irritants (irritant contact dermatitis). Phototoxic dermatitis occurs when the allergen or irritant is activated by sunlight. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Contact_dermatitis 接触性皮炎 10010790 contact dermatitis AE OAE:0002004 Necrotizing vasculitis AE is a vasculitis AE that is a rare condition which involves inflammation of the blood vessel walls. JX, LW, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000432.htm 坏死性血管炎 10028892 necrotizing vasculitis AE OAE:0002005 Carpal tunnel syndrome AE is a peripheral neuropathy AE that is a median entrapment neuropathy that causes paresthesia, pain, numbness, and other symptoms in the distribution of the median nerve due to its compression at the wrist in the carpal tunnel. JX, LW, YH median nerve neuropathy AE WEB: http://emedicine.medscape.com/article/1141168-clinical#showall WEB: http://en.wikipedia.org/wiki/Carpal_tunnel_syndrome 腕管综合征 10007697 carpal tunnel syndrome AE OAE:0002006 Erythromelalgia AE is a peripheral arterial disease AE that is a rare neurovascular peripheral pain disorder in which blood vessels, usually in the lower extremities or hands, are episodically blocked (frequently on and off daily), then become hyperemic and inflamed. JX, LW, YH Mitchell's disease AE acromelalgia AE erythermalgia AE red neuralgia AE WEB: http://en.wikipedia.org/wiki/Erythromelalgia 红斑性肢痛症 10015284 erythromelalgia AE OAE:0002007 a syndrome AE which results in the Raynaud's syndrome, a rare disease causes some areas of your body — such as your fingers and toes — to feel numb and cold in response to cold temperatures or stress. In Raynaud's disease, smaller arteries that supply blood to your skin narrow, limiting blood circulation to affected areas (vasospasm). JX, LW, YH Raynaud's disease AE Raynaud's phenomenon AE WEB: http://www.mayoclinic.org/diseases-conditions/raynauds-disease/basics/definition/con-20022916 雷诺综合症 10037914 Raynaud's syndrome AE OAE:0002008 Extrapyramidal syndrome AE is a nervous system AE that is drug induced movement disorders which include acute and tardive symptoms. JX, LW, YH extrapyramidal side effects AE vertebral body outside the beam syndrome AE WEB: http://en.wikipedia.org/wiki/Extrapyramidal_symptoms 椎体外系综合征 10015836 extrapyramidal syndrome AE OAE:0002009 an electrolyte lab test abnormal AE that is when the kidneys hold on to more sodium and do not excrete it with the kidneys. This tends to expand the blood volume, which can elevate the blood pressure. JX, LW, YH WEB: https://answers.yahoo.com/question/index?qid=20100823074826AAcg7WV 钠潴留 10041277 sodium retention AE OAE:0002011 Sciatica AE is a pain AE that is a set of symptoms including pain caused by general compression or irritation of one of five spinal nerve roots of each sciatic nerve or by compression or irritation of the left or right or both sciatic nerves. JX, LW, YH lumbar radiculopathy AE sciatic neuralgia AE sciatic neuritis AE WEB: http://en.wikipedia.org/wiki/Sciatica 坐骨神经痛 10039674 sciatica AE OAE:0002012 Joint stiffness AE is a joint disorder AE that may be either the symptom of pain on moving a joint, the symptom of loss of range of motion or the physical sign of reduced range of motion. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Joint_stiffness 关节僵硬 10023230 joint stiffness AE OAE:0002013 Breast engorgement AE is a reproductive system AE that occurs in the mammary glands due to expansion and pressure exerted by the synthesis and storage of breast milk. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Breast_engorgement 乳房充盈 10006240 breast engorgement AE OAE:0002014 Nervous tension AE is a behavior and neurological AE that might be said to be a physical expression of how people deal with negatively experienced emotion. JX, LW, YH WEB: http://helpmetosleep.org/featured-articles/how-to-relieve-nervous-tension/ 神经紧张 10029214 nervous tension AE OAE:0002015 Nervousness AE is a behavior and neurological AE that shows an uneasy psychological state which including anxiety, neurosis, neuroticism, and worry, etc. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Nervousness 神经过敏 10029216 nervousness AE OAE:0002016 Osteoarthritis AE is an arthritis AE that is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Osteoarthritis is not an inflammatory disease even-though the name suggest one. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. JX, LW, YH degenerative arthritis AE degenerative joint disease AE osteoarthrosis AE WEB: http://en.wikipedia.org/wiki/Osteoarthritis 骨关节炎 10031161 osteoarthritis AE OAE:0002017 Methemoglobinemia AE is a red blood cell profile abnormal AE that is a disorder characterized by the presence of a higher than normal level of methemoglobin (metHb, i.e., ferric [Fe3+] rather than ferrous [Fe2+] haemoglobin) in the blood. It's a form of hemoglobin that contains ferric [Fe3+] iron and has a decreased ability to bind oxygen. JX, LW, YH methaemoglobinaemia AE WEB: http://en.wikipedia.org/wiki/Methemoglobinemia 高铁血红蛋白症 10027506 methemoglobinemia AE OAE:0002018 Hemiageusia AE is a ageusia AE that shows loss of taste from one side of the tongue. JX, LW, YH hemiageustia AE hemigeusia AE WEB: http://www.medilexicon.com/medicaldictionary.php?t=39885 偏侧味觉缺失 hemiageusia AE OAE:0002019 Skin swelling AE is an edema AE that has an outcome of the occurrence of swelling which is located on the skin. JX, LW, YH WEB: http://www.rightdiagnosis.com/sym/skin_swelling.htm 胕肿 10053262 skin swelling AE OAE:0002020 Fibrosing alveolitis AE is a lung inflammation AE that is a disease of unknown cause mainly involving the gas-exchanging portions of the lungs. It may occur in isolation and be called cryptogenic or idiopathic, in which case the clinical manifestations are mainly respiratory, or it may be associated with other disorders, such as rheumatoid arthritis. JX, LW, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1818528/ 纤维化肺泡炎 10016640 fibrosing alveolitis AE OAE:0002021 an electrolyte chloride abnormal AE where the patient's body has abnormally low levels of chloride. This condition usually results from an extremely high loss of chloride, rather than a low intake of it. JX, LW, YH WEB: http://www.wisegeek.com/what-is-hypochloremic-alkalosis.htm 低氯性碱中毒 10020958 hypochloremic alkalosis AE OAE:0002022 Erythema annulare centrifugum AE is an erythema AE that is a descriptive term for a skin lesion. The lesions form consists of redness (erythema) in a ring form (anulare) that spreads from the center (centrifugum). JX, LW, YH MedDRA: 10015154 deep gyrate erythema AE erythema perstans AE palpable migrating erythema AE superficial gyrate erythema AE WEB: http://en.wikipedia.org/wiki/Erythema_annulare_centrifugum 离心性环形红斑 erythema annulare centrifugum AE OAE:0002023 Irritation is a behavior and neurological AE that is a state of inflammation or painful reaction to allergy or cell-lining damage. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Irritation 刺激 10029216 irritation AE OAE:0002024 a psychiatric disorder AE that is a fundamental personality trait in the study of psychology characterized by anxiety, fear, moodiness, worry, envy, frustration, jealousy, and loneliness. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Neuroticism 神经质 neuroticism AE OAE:0002025 Hyperirritability AE is a behavior and neurological AE that shows abnormally great or uninhibited response to stimuli. This term appears to be a synonym to the 'irritability AE'. JX, LW, YH WEB: http://www.merriam-webster.com/medical/hyperirritability; http://en.wikipedia.org/wiki/Irritability 过激 hyperirritability AE OAE:0002026 Rhinostenosis AE is a respiratory system AE that shows narrowing or obliteration of the nasal airway by scar formation JX, LW, YH WEB: http://www.drugs.com/dict/rhinostenosis.html 鼻道狭窄 rhinostenosis AE OAE:0002027 Sino-auricular heart-block AE is a conduction system disorder AE that refers to a rare heart condition caused by abnormalities in the heart's electrical system rather than arterial disease. JX, LW, YH WEB: http://www.rightdiagnosis.com/s/sino_auricular_heart_block/intro.htm 窦房传导阻滞 sino-auricular heart-block AE OAE:0002028 Anisosphygmia AE is a cardiovascular disorder AE that shows difference in volume, force, or time of the pulse in the corresponding arteries on two sides of the body, the two radials, or femorals. JX, LW, YH WEB: http://www.medilexicon.com/medicaldictionary.php?t=4352 脉搏不规则 anisosphygmia AE OAE:0002029 Rubefaction AE is a skin AE that refers to erythema of the skin caused by local application of a counterirritant. JX, LW, YH WEB: http://www.medilexicon.com/medicaldictionary.php?t=79112 发红 rubefaction AE OAE:0002030 Myodystony AE is an abnormal muscle tone AE that refers to a condition of slow relaxation, interrupted by a succession of slight contractions, following electrical stimulation of a muscle. JX, LW, YH WEB: http://www.drugs.com/dict/myodystony.html 肌张力不全 myodystony AE OAE:0002031 Allotriosmia is a behavior and neurological AE that shows incorrect recognition of odors. JX, LW, YH heterosmia AE WEB: http://www.medilexicon.com/medicaldictionary.php?t=2401 嗅觉异常 10029216 allotriosmia AE OAE:0002032 Pharyngotonsillitis is an inflammation AE that is a medical condition characterized by an inflammation of both the tonsils and the pharynx (located at the back of the throat). It occurs due to viral or bacterial infections. JX, LW, YH WEB: http://www.persify.com/en/perspectives/medical-conditions-diseases/pharyngotonsillitis-_-951000101807 咽扁桃体炎 10049140 pharyngotonsillitis AE OAE:0002033 Hypersensitivity pneumonitis AE is a pneumonia AE that is an inflammation of the alveoli within the lung caused by hypersensitivity to inhaled organic dusts. Sufferers are commonly exposed to the dust by their occupation or hobbies. JX, LW, YH extrinsic allergic alveolitis AE WEB: http://en.wikipedia.org/wiki/Hypersensitivity_pneumonitis 过敏性肺炎 10015887 hypersensitivity pneumonitis AE OAE:0002034 Stagger AE is a movement disorder AE that shows an unsteady movement of the body in walking or standing, as if one were about to fall. JX, LW, YH WEB: http://en.wiktionary.org/wiki/stagger 蹒跚 stagger AE OAE:0002035 Myocardial anoxia AE is a hypoxia AE that shows a reduced concentration of O2 in the myocardium. JX, LW, YH 心肌缺氧 myocardial anoxia AE OAE:0002036 Biliary colic AE is a pain AE that is the term used to describe a type of pain related to the gallbladder that occurs when a gallstone transiently obstructs the cystic duct and the gallbladder contracts. JX, LW, YH cholecystalgia AE WEB: http://en.wikipedia.org/wiki/Biliary_colic 胆绞痛 10004663 biliary colic AE OAE:0002037 Hyperemia AE is a cardiovascular disorder AE that is the increase of blood flow to different tissues in the body. It can have medical implications, but is also a regulatory response, allowing change in blood supply to different tissues through vasodilation. JX, LW, YH hyperaemia AE WEB: http://en.wikipedia.org/wiki/Hyperaemia 充血 hyperemia AE OAE:0002038 a sensory capability AE that has an outcome increased sensitivity to pain in a patient RR WEB: http://www.oxforddictionaries.com/us/definition/american_english/tenderness 10043224 tenderness AE OAE:0002039 a skin AE with the outcome of induration, which is an increase in the fibrous elements in tissue commonly associated with inflammation and marked by loss of elasticity and pliability or a hardened mass or formation RR WEB: http://www.merriam-webster.com/medical/induration 10060708 induration AE OAE:0002040 an eye AE which has an outcome of a foreign body sensation in the eye, or the sensation that something is in or scratching the eye RR WEB: http://www.richmondeye.com/eyehealth_foreignbody/ 10051116 foreign body sensation in eyes AE OAE:0002041 a cellulititis AE that occurs at an injection-site. RR WEB: http://www.nhs.uk/Conditions/Cellulitis/Pages/Symptoms.aspx 10050057 injection site cellulitis AE OAE:0002042 a sensory capability AE that has an outcome of peripheral coldness, or coldness of extremeties RR WEB: http://www.patient.co.uk/leaflets/peripheral_coldness.htm 10034568 peripheral coldness AE OAE:0002043 a hypoaesthesia AE that has an outcome of a decrease in facial sensitivity RR hypoaesthesia facial AE hypoesthesia facial AE WEB: http://www.webster-dictionary.org/definition/hypoesthesia 10065312 hypoesthesia facial AE OAE:0002044 a sleep disorder AE that shows poor quality sleep RR 10062519 poor quality sleep AE OAE:0002045 a rash AE characterized by the formation of vesicles RR rash vesicular AE WEB: http://www.merriam-webster.com/medical/vesicular 10037898 vesicular rash AE OAE:0002046 a discomfort AE that occurs at a limb RR 10061224 limb discomfort AE OAE:0002047 an eye disorder AE which has an outcome of discoloration of the sclera, or the whites of the eyes RR scleral discolouration AE 10039696 scleral discoloration AE OAE:0002048 an urticaria AE that occurs in an injection site RR WEB: http://www.uptodate.com/contents/hives-urticaria-beyond-the-basics 10022107 injection site urticaria AE OAE:0002049 a behavior and neurological AE that results in dysstasia, or difficulty standing RR WEB: http://www.medilexicon.com/medicaldictionary.php?t=27458 10050256 dysstasia AE OAE:0002050 a sensory capability AE that has an outcome of hyperaesthesia, meaning unusual or pathological sensitivity of the skin or of a particular sense RR hyperaesthesia AE WEB: http://www.merriam-webster.com/dictionary/hyperesthesia 神经过敏 10020568 hyperesthesia AE OAE:0002051 a nuclear magnetic resonance imaging result abnormal AE that has an outcome of abnormal nuclear magnetic resonance imaging test of the spinal cord RR 10069585 nuclear magnetic resonance imaging spinal cord abnormal AE OAE:0002052 an eye disorder AE which has an outcome of ocular icterus, or jaundice of the eye RR WEB: http://www.merriam-webster.com/dictionary/icterus 10058117 ocular icterus AE OAE:0002053 An edema AE that occurs in the mouth RR oedema mouth AE 10030110 edema mouth AE OAE:0002054 a respiratory system AE which has an outcome of painful respiration, an unpleasant sensation ranging from mild discomfort to unbearable agony while breathing RR WEB: http://www.healthline.com/health/painful-respiration 10033517 painful respiration AE OAE:0002055 a neurological, special senses and psychiatric investigation result abnormal AE that results in an abnormal ophthalmological examination RR 10056836 ophthalmological examination abnormal AE OAE:0002056 an optic neuropahty AE which shows an infarction of the optic disk which presents as painless vision loss RR optic ischemic neuropathy AE WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ WEB: http://www.merckmanuals.com/professional/eye_disorders/optic_nerve_disorders/ischemic_optic_neuropathy.html 10030924 ischemic optic neuropathy AE OAE:0002057 a bacterial infection AE with an outcome of Lyme disease, a tick-bourne illness cause by the bacterium B. burgdorferi that causes dermatologic, rheumatologic, neurologic, and cardiac abnormalities RR WEB: http://wwwn.cdc.gov/nndss/script/casedef.aspx?CondYrID=752&DatePub=1/1/2011 10025169 lyme disease AE OAE:0002058 a pain AE that has an outcome of lymph node pain RR 10025182 lymph node pain AE CTCAE: E10052 NCIt: C78440 OAE:0002059 RR 10024860 a movement disorder AE that has an outcome of loss of control of patient's legs loss of control of legs AE OAE:0002060 a vascular disorder AE that has an outcome of levedo reticularis, a condition of the peripheral blood vessels characterized by reddish blue mottling of the skin especially of the extremeties usually upon exposure to cold RR WEB: http://www.merriam-webster.com/medical/livedo%20reticularis 10024648 livedo reticularis AE OAE:0002061 a muscle adverse event AE that has an outcome of muscle strain, which happens when a muscle is stretched too much and tears RR pulled muscle AE WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001109/ 10050031 muscle strain AE OAE:0002062 a muscle adverse event AE that has an outcome of muscle tightness, which is a tense feeling in muscles RR WEB: http://www.chirocommunity.com/muscletightness.htm 10049816 muscle tightness AE OAE:0002063 a muscle adverse event AE that has an outcome of muscle rigidity, a state of continuous firm, tense muscles with marked resistance to passive movement RR WEB: http://www.healthline.com/symptom/muscle-rigidity 肌肉僵硬 10028330 muscle rigidity AE OAE:0002064 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barre syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes RR WEB: http://www.ninds.nih.gov/disorders/miller_fisher/miller_fisher.htm 10049567 Miller Fisher syndrome AE OAE:0002065 a hypersensitivity AE which has an outcome of type III immune complex mediated reaction, a type of hypersensitivity reaction in which circulating antigen-antibody immune complexes are deposited in post-capillary venules, with subsequent complement fixation RR WEB: http://emedicine.medscape.com/article/136217-overview 10053614 type III immune complex mediated reaction AE OAE:0002066 a tonsilitis AE with the outcome of tonsilar hypertrophy, or enlargement of the tonsils RR WEB: http://www.cchi.com.hk/symposia/s3_ear_1.htm 10044003 tonsilar hypertrophy AE OAE:0002067 a sensory capability AE that results in temperature intolerance RR 10057040 temperature intolerance AE OAE:0002068 a sensory capability AE that results in the patient being unresponsive to stimuli RR 10045555 unresponsive to stimuli AE OAE:0002069 a respiratory system AE that shows discolored sputum RR 10041806 sputum discolored AE OAE:0002070 a musculoskeletal system AE that has an outcome of spinal column stenosis, or narrowing of spaces in the spine that results in pressure on the spinal cord and/or nerve roots RR WEB: http://www.niams.nih.gov/Health_Info/Spinal_Stenosis/ 10041540 spinal column stenosis AE OAE:0002071 a skin AE with the outcome of skin tightness RR 10050637 skin tightness AE OAE:0002072 a pain AE with the outcome of ligament pain RR 10068790 ligament pain AE OAE:0002073 a thrombocytopenic purpura AE with no known cause (idiopathic). Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which are necesssary for normal blood clotting. Persons with this disorder have too few platelets in the blood. RR WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000535.htm 特发性血小板减少性紫癜 10021245 idiopathic thrombocytopenic purpura AE OAE:0002074 A palsy AE that shows cerebral palsy, a disorder of movement, muscle tone, or posture that is caused by an insult to the immature, developing brain, most often before birth RR WEB: http://www.mayoclinic.org/diseases-conditions/cerebral-palsy/basics/definition/con-20030502 10008129 cerebral palsy AE OAE:0002075 a neurological AE with the outcome of chronic inflammatory demyelinating polyradiculoneuropathy, a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms caused by damage to the myelin sheath of the peripheral nerves RR WEB: http://www.ninds.nih.gov/disorders/cidp/cidp.htm 10057645 chronic inflammatory demyelinating polyradiculoneuropathy AE OAE:0002076 an allergy AE which displays an allergic skin response following contact of an allergen, with the skin typically marked by an itchy red rash often accompanied by swelling and watery blisters. RR, JX, YH dermatitis allergic AE WEB: http://www.merriam-webster.com/dictionary/allergic%20contact%20dermatitis 10012434 allergic dermatitis AE OAE:0002077 a behavior and neurological AE with an outcome of the patient refusing to eat RR 10012775 diet refusal AE OAE:0002078 an abnormal blood pressure AE that has an outcome of blood pressure fluctuations RR 10005746 blood pressure fluctuation AE OAE:0002079 a digestive system AE which has an outcome of aphagia, which is the loss of the ability to swallow RR WEB: http://www.merriam-webster.com/medical/aphagia 10049866 aphagia AE OAE:0002080 a speech disorder AE with an outcome of aphonia, or loss of voice and of all but whispered speech RR, MW WEB: http://www.merriam-webster.com/dictionary/aphonia 10002953 aphonia AE CTCAE:E12589 NCIt:C79539 OAE:0002082 a stomach pain AE that is observed in lower stomach RR WEB: http://www.mayoclinic.org/symptoms/abdominal-pain/basics/definition/sym-20050728 10000084 abdominal pain lower AE OAE:0002083 an eye AE with an outcome of an abnormal sensation in the eye RR 10000173 abnormal sensation in eye AE OAE:0002084 a behavior and neurological AE which has an outcome of impaired driving ability RR 10049564 impaired driving ability AE OAE:0002085 a respiratory system AE that has an outcome of increased bronchial secretion, or an increase in the substance produced in the bronchial tree, which includes mucus, protein salts, plasma fluid, and proteins RR WEB: http://medical-dictionary.thefreedictionary.com/bronchial+secretion 10062530 increased bronchial secretion AE OAE:0002086 an injection-site AE that displays injection site streaking, a red pattern on the skin localized to the injection site RR WEB: http://www.bannerhealth.com/incfiles/housecalls/peds/FeverInfectionsCrying/ImmunizationReactions.htm 10066778 injection site streaking AE OAE:0002087 an injection-site AE that displays injection site streaking, which are small, fluid-filled blisters localized to the injection site RR WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003939.htm 10022111 injection site vesicles AE OAE:0002088 a lab test abnormal AE that has an outcome of an increased international normalized ratio, indicating an individual is more prone to bleeding RR, MW, YH INR increased AE WEB: http://circ.ahajournals.org/content/126/5/e52.full 10022402 10022595 international normalized ratio increased AE CTCAE: E12175 NCIt: C78366 OAE:0002089 a sleep disorder AE with the outcome of irregular sleep phase, which is an abnormality in the timing of sleep RR WEB: http://www.mayoclinic.org/diseases-conditions/delayed-sleep-phase/basics/definition/con-20035242 10022995 irregular sleep phase AE OAE:0002090 an injection-site AE that displays injection site anesthesia, or numbness at the injection site RR 10022047 injection site anesthesia AE OAE:0002091 an infection AE that occurs at an injection-site RR WEB: http://www.merriam-webster.com/dictionary/infection 10022076 injection site infection AE OAE:0002092 a behavior and neurological AE which has an outcome of decreased grip strength, or a reduction in the force applied by the hand to pull on or suspend from objects RR WEB: http://www.krepublishers.com/02-Journals/JLS/JLS-01-0-000-09-Web/JLS-01-1-000-09-Abst-PDF/JLS-01-01-057-09-020-Koley-S/JLS-01-01-057-09-020-Koley-S-Tt.pdf 10062556 grip strength decreased AE OAE:0002093 an eye AE with the outcome of eyelid margin crusting RR 10052132 eyelid margin crusting AE OAE:0002094 an ear AE with the outcome of ear discomfort, an uncomfortable or painful feeling in the ear RR WEB: http://www.merriam-webster.com/dictionary/discomfort 10052137 ear discomfort AE OAE:0002095 an abnormal defecation AE that has an outcome of fecal incontinence, the accidental passing of solid or liquid stool or mucus from the rectum RR, MW, YH faecal incontinence AE WEB: http://digestive.niddk.nih.gov/ddiseases/pubs/fecalincontinence/#what 10016092 10016296 fecal incontinence AE CTCAE: E10693 NCIt: C78498 OAE:0002096 a behavior and neurological AE that has an outcome of fear, which is to be afraid and/or worried RR WEB: http://www.merriam-webster.com/dictionary/fear 10016275 fear AE OAE:0002097 a pain AE that has an outcome of pain in gums RR WEB: http://www.merriam-webster.com/dictionary/gingival 10018286 gingival pain AE CTCAE: E10763 NCIt: C78325 OAE:0002098 a tongue disorder with the outcome of glossitis, a condition in which the tongue is swollen and changes color, which may make the tongue appear smooth RR WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001053.htm 10018386 glossitis AE OAE:0002099 an injury AE which has an outcome of muscle injury RR 10028314 muscle injury AE OAE:0002100 a sensory capability AE that has an outcome of sensory disturbance RR 10040026 sensory disturbance AE OAE:0002101 an edema AE with an outcome of tracheal edema, which is the swelling of the airway between the throat and the lungs RR WEB: http://firstaidcalgary.ca/causes-of-tracheal-edema/ 10044296 tracheal edema AE OAE:0002102 Allergic eruption AE is a skin AE that is most drug-induced cutaneous reactions, especially found in younger adults. Sometimes also be diagnosed with eczema. This term appears to be a synonym to the 'eczema AE'. JX, LW, YH 过敏性皮疹 allergic eruption AE OAE:0002103 Erythrodermia AE is a skin AE that is an inflammatory skin disease with erythema and scaling that affects nearly the entire cutaneous surface. JX, LW, YH dermatitis exfoliativa AE exfoliative dermatitis AE red man syndrome AE WEB: http://en.wikipedia.org/wiki/Erythroderma 红皮病 10037165 erythrodermia AE OAE:0002104 Mycotic dermatitis is a dermatitis AE that is a inflammation of skin which induced by mycetes. JX, LW, YH 真菌性皮炎 mycotic dermatitis AE OAE:0002105 Peritendinitis symptom AE is an inflammation AE that has an outcome of inflammation of the synovial lining of a tendon sheath. Causes include trauma, tendon stress, bacterial disease (gonorrhea, tuberculosis), rheumatic disease, and gout. Common sites are the hand, wrist, shoulder capsule, hip capsule, hamstring muscles, and Achilles tendon. The tendon sheaths become inflamed and painful, and accumulate fluid. Joint mobility is usually reduced. JX, LW, YH 腱鞘炎样症状 peritendinitis symptom AE OAE:0002106 Orthostatic hypotension AE is a hypotension AE that is a form of hypotension in which a person's blood pressure falls when suddenly standing up or stretching. In medical terms, it is defined as a fall in systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg when a person assumes a standing position. JX, LW, YH orthostasis AE postural hypotension AE WEB: http://en.wikipedia.org/wiki/Orthostatic_hypotension 直立性低血压 10031127 orthostatic hypotension AE OAE:0002107 JX, LW, YH chromatopsia AE WEB: http://ghr.nlm.nih.gov/condition/color-vision-deficiency 色视力缺乏 Color vision deficiency AE is an abnormal vision AE that is a group of conditions that affect the perception of color. They cause a range of changes in color vision, from mild difficulty with distinguishing shades to a total inability to detect color. These conditions are divided into three major categories: red-green color vision defects, blue-yellow color vision defects, and a complete absence of color vision. color vision deficiency AE OAE:0002108 Carcinogenesis AE is a tumor AE that is literally the 'creation' of cancer. It is a process by which normal cells are transformed into cancer cells. JX, LW, YH oncogenesis AE tumorigenesis AE WEB: http://en.wikipedia.org/wiki/Carcinogenesis 致癌 carcinogenesis AE OAE:0002109 a circulatory AE that is a serious allergic reaction associated with systemic vasodilation that causes low blood pressure which is by definition 30% lower than the person's baseline or below standard values. JX, LW, YH, RR WEB: http://en.wikipedia.org/wiki/Anaphylaxis WEB: http://smschile.cl/documentos/cursos2010/MedicalClinicsNorthAmerica/Acute%20Symptoms%20of%20Drug%20Hypersensitivity%20%28Urticaria,%20Angioedema,%20Anaphylaxis,%20Anaphylactic%20Shock%29.pdf WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=10092 过敏性休克 10002199 anaphylactic shock AE OAE:0002110 Pituitary adenomas AE is a tumor AE that is a tumor which occur in the pituitary gland. Pituitary adenomas are generally divided into three categories dependent upon their biological functioning: benign adenoma, invasive adenoma, and carcinomas, with carcinomas accounting for 0.1% to 0.2%, approximately 35% being invasive adenomas and most being benign adenomas. Pituitary adenomas represent from 10% to 25% of all intracranial neoplasms and the estimated prevalence rate in the general population is approximately 17%. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Pituitary_adenoma pituitary adenomas AE OAE:0002111 Fatty infiltration AE is an embolism AE that shows the abnormal accumulation of fat droplets in the cytoplasm of cells. JX, LW, YH WEB: http://dictionary.reference.com/browse/fatty+infiltration 脂肪侵润 fatty infiltration AE OAE:0002112 Epigastric discomfort is a discomfort AE that shows discomfort in the upper central region of the abdomen. JX, LW, YH upper Abdominal discomfort AE WEB: http://www.rightdiagnosis.com/sym/epigastric_discomfort.htm 上腹部不适 10053155 epigastric discomfort AE OAE:0002113 Acute intravascular hemolysis AE is a cardiovascular AE that has an outcome of disruption of red blood cells occurs while they are within blood vessels. JX, LW, YH 急性血管内溶血 acute intravascular hemolysis AE OAE:0002114 Allergic hepatitis AE is a hepatitis AE that is a tissue-specific inflammatory diease caused by hepersensitivity to a particular drug, accomopanied by a systemic allergic reaction such as eosinophilia. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/viral+hepatitis 过敏性肝炎 10071198 allergic hepatitis AE OAE:0002115 Paranoid anxiety AE is a anxiety AE that is a term used in object relations theory, particularity in discussions about the Paranoid-schizoid and depressive positions. The term was frequently used by Melanie Klein, especially to refer to a pre-depressive and persecutory sense of anxiety characterised by the psychological splitting of objects. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Paranoid_anxiety 偏执性焦虑 paranoid anxietas AE OAE:0002116 Thrombotic thrombocytopenic purpura AE is a thrombocytopenic purpura AE that is a rare disorder of the blood-coagulation system, causing extensive microscopic clots to form in the small blood vessels throughout the body. JX, LW, YH moschcowitz syndrome AE WEB: http://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura 血栓性血小板减少性紫癜 10043648 thrombotic thrombocytopenic purpura AE CTCAE: E10061 NCIt: C78797 OAE:0002117 Glaucoma AE is an eye AE that is a term describing a group of ocular (eye) disorders resulting in optic nerve damage or loss to the field of vision, in many patients caused by a clinically characterized pressure buildup in regards to the fluid of the eye (intraocular pressure-associated optic neuropathy). JX, LW, YH WEB: http://en.wikipedia.org/wiki/Glaucoma 青光眼 10018304 glaucoma AE CTCAE: E10392 NCIt: C26782 OAE:0002118 an allergy AE that shows a serious allergic reaction that is rapid in onset and may cause death. It typically causes a number of symptoms including an itchy rash, throat swelling, and low blood pressure. Common causes include insect bites and stings, foods, and medications. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Anaphylaxis 过敏症 10002218 anaphylaxis AE CTCAE: E11254 NCIt: C50460 OAE:0002119 an allergy AE which occur during certain times of the year, usually when outdoor molds release their spores, and trees, grasses, and weeds release tiny pollen particles into the air to fertilize other plants. JX, LW, YH WEB: http://kidshealth.org/parent/medical/allergies/seasonal_allergies.html 季节性变态反应 10048908 seasonal allergy AE OAE:0002120 a blood sodium abnormal AE with an abnormally decreased sodium concentration in the blood YH, MW hyponatraemia AE WEB: http://www.mayoclinic.org/diseases-conditions/hyponatremia/basics/definition/con-20031445 10021036 10021038 hyponatremia AE CTCAE: E12339 NCIt: C37976 OAE:0002121 Skin redness AE is an erythema AE that is abnormal redness of the skin, often signaling a pathological condition, such as inflammation, infection, or sunburn. JX, LW, YH WEB: http://www.healthline.com/health/skin-redness 皮肤发红 skin redness AE OAE:0002122 a chest pain that is caused when your heart muscle doesn't get enough oxygen-rich blood. DJ, SS, YH chest pain - cardiac AE tight chest AE WEB: http://www.ncbi.nlm.nih.gov/pubmed/23016723 10002383 10008481 angina AE CTCAE: E10110 HPO: HP_0001681 NCIt: C51221 SIDER: C0002962 OAE:0002123 an angina AE that is aggravating. JX, YH aggravating angina AE OAE:0002124 an aggravating angina AE that is caused by severe hypotension JX, YH 严重低血压导致心绞痛症状加重现象 severe hypotension caused angina symptom aggravating AE OAE:0002125 an eye AE that shows abnormal involuntary blinking of the eyelids JX, LW, YH corneal reflex abnormal AE URL: https://en.wikipedia.org/wiki/Corneal_reflex 睑闭反射反常 10058960 blink reflex abnormal AE OAE:0002126 Dazzling AE is a eye disorder AE that has an outcome of the consequence of illumination too intense for adaptation by the eye. In contrast to glare, dazzling is alleviated by appropriate tinted glasses. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/dazzling 目眩 dazzling AE OAE:0002127 Ventricular rhythm AE is an arrhythmia AE that shows the electrocardiographic finding of an ectopic ventricular rhythm with three or more consecutive ventricular premature beats with a rate less than 100 beats per minute. JX, LW, YH 室性心律 10047297 ventricular rhythm AE OAE:0002128 Extrapyramidal signs AE is a nervous system AE that shows defects in basal ganglia function. It characterized by changes in muscle tone, poverty of voluntary movements (akinesia), or abnormal involuntary movements (dyskinesia). JX, LW, YH 锥体外体征 extrapyramidal signs AE OAE:0002129 Hearing disorder AE is an ear disorder that shows impairment of the sense of hearing. JX, LW, YH 听觉障碍 10019243 hearing disorder AE OAE:0002130 Yellow urine AE is a urine abnormality AE that may be due to excretion of picric acid, dinitrophenol, phenacetin or chrysarobin or in alkaline pH, to increased secretion of anthocyanin, or associated with ingestion of beets or blackberries. Pure yellow urine is associated with increased acriflavine and has a green fluorescence; yellow-orange urine may be highly concentrated or contain increased bilirubin and biliverdin. JX, LW, YH 尿液呈黄色 yellow urine AE OAE:0002131 Epidermal necrosis AE is a necrosis AE that shows widespread keratinocyte cell death via apoptosis results in the tissue damage. JX, LW, YH 表皮坏死 10059284 epidermal necrosis AE OAE:0002132 Arthromeningitis AE is an inflammation AE that shows inflammation of a synovial membrane, usually painful, particularly on motion, and characterized by fluctuating swelling, due to effusion in a synovial sac. JX, LW, YH 滑膜炎 arthromeningitis AE OAE:0002133 Pulmonary tuberculosis AE is a lung disorder AE that is a contagious bacterial infection that involves the lungs. It may spread to other organs. JX, LW, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000077.htm 10037440 pulmonary tuberculosis AE OAE:0002134 Coronary heart disease AE is a cardiovascular disorder AE that is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle. JX, LW, YH WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/cad/ 冠心病 10068617 coronary heart disease AE OAE:0002135 Increased defecation frequency AE is a abnormal stool AE that shows defecation number increased. JX, LW, YH 大便次数增加 increased defecation frequency AE OAE:0002136 Symptomatic hypotension AE is a hypotension AE that shows blood pressure that less than 90/60 mm Hg with dizziness, vertigo etc. JX, LW, YH 症状性低血压 symptomatic hypotension AE OAE:0002137 Non-specific gastrointestinal dysfunction AE is a gastrointestinal disorder AE that shows non-specific gastrointestinal dysfunction. JX, LW, YH 非特异性胃肠功能紊乱 non-specific gastrointestinal dysfunction AE OAE:0002138 Abnormal sclerotin AE is a bone disorder AE that shows abnormal sclerotin. JX, LW, YH 骨质异常 abnormal sclerotin AE OAE:0002139 Fast and weak heart beat AE is a cardiac disorder AE that shows fast and weak heart beat. JX, LW, YH 心跳快而弱 fast and weak heart beat AE OAE:0002140 Pain over the liver AE is a pain AE that shows pain over the liver. JX, LW, YH 肝区痛 pain over the liver AE OAE:0002141 Increased biliary calculus AE is a liver, biliary, and pancreatic AE that shows increased biliary calculus. JX, LW, YH 胆石增加 increased biliary calculus AE OAE:0002142 Muscle function disorder AE is a muscle AE that shows muscle function disorder. JX, LW, YH 肌肉功能失调 muscle function disorder AE OAE:0002143 Accidental injury AE is a fall AE that shows accidental falls. JX, LW, YH 意外跌倒 accidental fall AE OAE:0002144 Accidental injury AE is an injury AE that shows accidedntal injury. JX, LW, YH 意外损伤 10000380 accidental injury AE OAE:0002145 Abnormal ejaculation AE is a male reproductive system AE that shows abnormal ejaculation. JX, LW, YH 异常射精 10000128 abnormal ejaculation AE OAE:0002146 Distention of head AE is a cardiovascular AE that shows distention of head. JX, LW, YH 头胀 distention of head AE OAE:0002147 Water-sodium retention AE is an abnormal fluid regulation AE that shows water-sodium retention. JX, LW, YH WEB: http://www.livestrong.com/article/485782-sodium-retention-weight-gain/ 水钠潴留 water-sodium retention AE OAE:0002148 Dizziness when standing up AE is a dizziness AE that shows dizziness when standing up. JX, LW, YH 站起时头晕 dizziness when standing up AE OAE:0002149 Change of gustation AE is a gustatory system AE that shows the change of gustation. JX, LW, YH 味觉改变 change of gustation AE OAE:0002150 Vascular stimulation of pain AE is a pain AE that shows pain which due to vascular stimulation. JX, LW, YH 血管刺激性疼痛 vascular stimulation of pain AE OAE:0002151 Vascular pain AE is a pain AE that shows vascular pain. JX, LW, YH 血管疼痛 vascular pain AE OAE:0002152 Heaviness sense of arm AE is a sensation of heaviness AE that shows a sensation feeling of heaviness in the arm. JX, LW, YH 手臂沉重感 heaviness sense of arm AE OAE:0002153 Breast swelling AE is an edema AE that is common for almost all women in the second half of their menstrual cycle. It in the premenstrual portion of the cycle can be mild to severe. JX, LW, YH WEB: http://www.healthgrades.com/symptoms/breast-swelling 乳房肿胀 10006312 breast swelling AE OAE:0002154 Gastrointestinal cramp AE is a muscle spasm AE that shows abnormal contractions of the gastrointestinal muscles. JX, LW, YH 肠胃痉挛 10049136 gastrointestinal cramp AE OAE:0002155 Heart discomfort AE is a discomfort AE that shows an uncomfortable feeling in the heart. JX, LW, YH 心脏不适 heart discomfort AE OAE:0002156 Angiectopia of skin AE a vascular disorder AE that shows abnormal position or course of a vessel in the skin. JX, LW, YH 皮肤血管异位 angiectopia of skin AE OAE:0002157 Joint discomfort AE is a discomfort AE that shows an uncomfortable feeling in the joint. JX, LW, YH 关节不适 joint discomfort AE OAE:0002158 Eye discomfort AE is a discomfort AE that shows an uncomfortable feeling in the eye. JX, LW, YH 眼部不适 eye discomfort AE OAE:0002159 Instability of gait AE is a abnormal gait AE that shows instability of gait. JX, LW, YH 步态不稳 instability of gait AE OAE:0002160 Pemphigoid injury AE is an injury AE that shows a skin disorder where one has large blisters on the skin. JX, LW, YH 类天疱疮样损伤 pemphigoid injury AE OAE:0002161 Pulse frequency change AE is a cardiovascular AE that shows dpulse frequency change. JX, LW, YH pulse abnormal AE 脉搏频率变化 pulse frequency change AE OAE:0002162 Inhibition of myocardial contraction force AE is a cardiac disorder AE that shows inhibition of myocardial contraction force. JX, LW, YH 抑制心肌收缩力 inhibition of myocardial contraction force AE OAE:0002163 Decreased of atrial conduction velocity AE is a conduction system disorder AE that shows decreased of atrial conduction velocity. JX, LW, YH 心房传导速度减慢 decreased of atrial conduction velocity AE OAE:0002164 Spasm of lower limbs AE is a muscle spasm AE that shows tightening and spasms of the muscles in the legs. JX, LW, YH 下肢痉挛 spasm of lower limbs AE OAE:0002165 Electrocardiogram prolonged PR interval AE is an electrocardiogram result abnormal AE that shows a prolonged time between the onset of atrial depolarization (P wave) to the beginning of ventricular depolarization (QRS complex). JX, LW, YH 心电图出现PR间期延长 electrocardiogram prolonged PR interval AE OAE:0002166 Qrs wave broadening AE is a electrocardiogram qrs complex abnormal AE that shows broadening qrs complex in the electrocardiogram. JX, LW, YH QRS波增宽 qrs wave broadening AE OAE:0002167 Edema of lower limbs AE is an edema AE that shows enlargement of the leg, due to the accumulation of fluids. JX, LW, YH 下肢浮肿 edema of lower limbs AE OAE:0002168 Accelerated pulse AE is a cardiovascular AE that shows increased of the number of pulsations per minute palpable in an artery. JX, LW, YH 脉搏加快 accelerated pulse AE OAE:0002169 Bitter taste of mouth AE is a digestive system AE that is not from a bitter substance is a distorted sense of taste. A persistent bad taste in the mouth, whether bitter, metallic or foul, is called dysgeusia. JX, LW, YH WEB: http://www.healthgrades.com/symptoms/bitter-taste-in-mouth 口苦 bitter taste of mouth AE OAE:0002170 Skin irritant reaction AE is a skin AE that shows rash, inflammation, swelling, scaling, or abnormal tissue which growth in the affected area. JX, LW, YH 皮肤刺激反应 skin irritant reaction AE OAE:0002171 Vitreous suspended substance AE is an eye AE shows vitreous suspended substance in the eyes. JX, LW, YH 玻璃体悬浮物 vitreous suspended substance AE OAE:0002172 Dreaminess AE is a sleep disorder AE that shows dreaminess in the sleeping. JX, LW, YH 多梦 dreaminess AE OAE:0002173 Abdominal spasm AE is a muscle spasm AE that is typically a feeling of cramping in the abdomen caused by a rigid expansion of muscles. It can vary from mild discomfort to moderate or severe pain. JX, LW, YH WEB: http://www.wisegeekhealth.com/what-are-abdominal-spasms.htm 腹部痉挛 10051889 abdominal spasm AE OAE:0002174 Coronary contraction AE is a coronary artery disorder AE that shows coronary contraction. JX, LW, YH 冠状动脉收缩 coronary contraction AE OAE:0002175 Lower extremity edema caused by blood vessels AE is an edema AE that shows excess fluid accumalated in the leg dut to blood vessels. JX, LW, YH 因血管扩张引起的下肢水肿 lower extremity edema caused by blood vessels AE OAE:0002176 Asthenia of lower limbs AE is a asthenia AE that occurs in the lower limbs. It is a condition typified by a weakness of voluntary movement. JX, LW, YH 下肢无力 asthenia of lower limbs AE OAE:0002177 Small bronchial lumen occlusion AE is a lung disorder AE that shows small bronchial lumen occlusion. JX, LW, YH 小支气管腔闭塞 small bronchial lumen occlusion AE OAE:0002178 Prolonged orthostatic hypotension AE is a orthostatic hypotension AE that shows prolonged orthostatic hypotension. JX, LW, YH 延长体位性低血压时间 prolonged orthostatic hypotension AE OAE:0002179 an allergy AE that shows produce cross or incomplete cross allergic reaction to similar medicinal chemistry structure. JX, LW, YH 交叉过敏反应 cross allergic reaction AE OAE:0002180 Deep venous thrombophlebitis AE is a thrombophlebitis AE that is causes by a blood clot blocking in the deep vein. JX, LW, YH 深静脉血栓静脉炎 deep venous thrombophlebitis AE OAE:0002181 Change of hematology AE is a hematology investigation result abnormal AE that shows the change of hematology. JX, LW, YH 血液学改变 change of hematology AE OAE:0002182 Cardiac depression AE is a cardiac disorder AE that shows cardiac depression. JX, LW, YH 抑制心脏 cardiac depression AE OAE:0002183 Side limb numbness AE is a numbness AE that shows reduced or loss of sensation on the skin of an arm and leg on the same side of the body. JX, LW, YH 侧肢的麻木感 side limb numbness AE OAE:0002184 Numbness of tongue AE is a numbness AE that shows abnormal feeling or loss of sensation in the tongue. JX, LW, YH 舌部麻木 numbness of tongue AE OAE:0002185 Numbness of the limbs AE is a numbness AE that shows reduced or loss of sensation on the skin of the arm and leg. JX, LW, YH 肢体麻木 numbness of the limbs AE OAE:0002186 Lip numbness AE is a numbness AE that shows abnormal feeling in the lips, including numbness and tingling. JX, LW, YH 嘴唇发麻 lip numbness AE OAE:0002187 Reflex Increased pulse rate AE is a cardiovascular AE that shows increased pulse rate. JX, LW, YH 反射性脉率增加 reflex Increased pulse rate AE OAE:0002188 Irritation of the digestive tract AE is a digestive system AE that shows irritation of the digestive tract. JX, LW, YH 消化道刺激 irritation of the digestive tract AE OAE:0002189 Unconscious chorea AE is a chorea AE that is characterized by brief, non-repetitive irregular muscle contractions. JX, LW, YH 不自觉舞蹈症 unconscious chorea AE OAE:0002190 Phlebectasia of limbs AE is a vasodilatation AE that shows dilation of the veins in the extremity. JX, LW, YH 肢端静脉扩张 phlebectasia of limbs AE OAE:0002191 Heart beat skip AE is a irregular heartbeat AE which is sometimes called as either heart palpitation, or premature atrial or ventricular contraction are very common occurrences. They may or may not be accompanied by heart conditions or heart problems. JX, LW, YH WEB: http://ehealthwall.com/heart-skips-a-beat-causes-symptoms-treatment/ 漏跳 heart beat skip AE OAE:0002192 Fatal liver cell necrosis AE is a hepatic necrosis AE that has an outcome of fatal liver cell necrosis. JX, LW, YH 致命性肝细胞坏死 fatal liver cell necrosis AE OAE:0002193 Warm and hot feeling in the neck AE is a skini warm AE that shows warm and hot feeling in the neck. JX, LW, YH 颈感觉温热 warm and hot feeling in the neck AE OAE:0002194 Facial warm feeling AE is a skin warm AE that shows a warm feeling in the face. JX, LW, YH 面部感觉温热 facial warm feeling AE OAE:0002195 Increased peripheral vascular resistance AE is a vascular disorder AE that shows increased peripheral vascular resistance, the degree to which the blood vessels impede the flow of blood. High resistance causes an increase in blood pressure, which increases the workload of the heart. JX, LW, YH 外周血管阻力升高 increased peripheral vascular resistance AE OAE:0002196 Venous ischemia AE is an ischaemia AE that shows in insufficient blood supply in the vein. JX, LW, YH 静脉供血不足 venous ischemia AE OAE:0002197 Increased blood creatine AE is a metabolic and nutritional investigation result abnormal AE that shows an increased creatine level in blood. JX, LW, YH 血肌酸增加 increased blood creatine AE OAE:0002198 Increased nonprotein nitrogen AE is an investigation result abnormal AE that shows increased nonprotein nitrogen, the nitrogenous constituents of the blood exclusive of the protein bodies, consisting of the nitrogen of urea, uric acid, creatine, creatinine, amino acids, polypeptides, and an undetermined part known as rest nitrogen. JX, LW, YH 非蛋白氮增加 increased nonprotein nitrogen AE OAE:0002199 Soft feces AE is a abnormal stool AE that shows soft and shapeless of the feces. JX, LW, YH 软便 soft feces AE OAE:0002200 Increased hepatic function AE is a hepatic function abnormal AE that shows the values of liver function tests (LFTs) high than the normal. JX, LW, YH WEB: http://www.webmd.com/a-to-z-guides/liver-function-test-lft 肝功能升高 increased hepatic function AE OAE:0002201 Knee pain AE is a pain AE that shows discomfort in the structures of both knees. Keen pain may be due to injury, inflammation or infection. JX, LW, YH WEB: http://www.mayoclinic.org/diseases-conditions/knee-pain/basics/definition/CON-20029534 膝痛 10023477 knee pain AE OAE:0002202 Loss of libido AE is a libido disorder AE that shows loss of the desire for sexual interaction. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Hypoactive_sexual_desire_disorder 性欲丧失 10024870 loss of libido AE OAE:0002203 Over sedation AE is a behavior and neurological AE that shows the over reduction of irritability or agitation. JX, LW, YH 过度镇静 over sedation AE OAE:0002204 Finger tremor AE is a tremor AE that shows involuntary muscle contraction and relaxation in the finger. JX, LW, YH 手指强硬颤动 finger tremor AE OAE:0002205 Leg cramp AE is a muscle cramp AE that shows tightening, or spasms, of the muscles in the legs. JX, LW, YH 腿部痉挛 leg cramp AE OAE:0002206 a sleep disorder AE in which there is an inability to fall asleep or to stay asleep as long as desired. YH, MW WEB: https://en.wikipedia.org/wiki/Insomnia 10022437 Insomnia is a symptom of a sleeping disorder characterized by persistent difficulty falling asleep or staying asleep despite the opportunity. Insomnia is a symptom, not a stand-alone diagnosis or a disease. insomnia AE CTCAE: E12925 HPO: HP_0002360 SIDER: C0917801 OAE:0002207 Terminal insomnia AE is a insomnia AE that is a medical condition affecting sleep patterns. Typically, people who suffer from terminal insomnia wake up after only four to five hours of sleep. For those afflicted, getting back to sleep can be difficult, resulting in fatigue, irritability, and lack of concentration. JX, LW, YH matutinal insomnia AE WEB: http://www.wisegeek.com/what-is-terminal-insomnia.htm 早醒 10068932 terminal insomnia AE OAE:0002208 Bone marrow granuloma AE is a bone marrow disorder AE that shows an organized collection of macrophages in the bone marrow. JX, LW, YH 骨髓肉芽肿 10066816 bone marrow granuloma AE OAE:0002209 Cholestatic liver injury AE is a liver damage AE that shows buildup of bile acids in hepatocytes, then causes hepatocellular injury. JX, LW ,YH 胆汁郁积性肝损伤 10067969 cholestatic liver injury AE OAE:0002210 Distant heart sounds AE is a cardiac disorder AE that shows distant heart sounds. JX, LW, YH 心音遥远 distant heart sounds AE OAE:0002211 Pink skin AE is a skin AE that shows pink skin. JX, LW, YH 皮肤粉红 pink skin AE OAE:0002212 Acute laryngeal edema AE is an edema AE that shows acute laryngeal edema, abnormal accumulation of fluid in tissues of any part of the larynx, commonly associated with laryngeal injuries and allergic reactions. JX, LW, YH 急性喉头水肿 10066705 acute laryngeal edema AE OAE:0002213 Hypoplastic bone marrow AE is a bone marrow disorder AE that shows insufficient blood stem cells in the marrow. JX, LW, YH 骨髓发育不全 hypoplastic bone marrow AE OAE:0002214 Bleeding and coagulation disorders AE is a hematopoietic system AE that shows bleeding and coagulation disorders. JX, LW, YH 出凝血功能障碍 bleeding and coagulation disorders AE OAE:0002215 Polymorphic ventricular tachycardia AE is a ventricular tachycardia AE that is an abnormally fast heart rhythm starting in the ventricles, the lower chambers of the heart. JX, LW, YH WEB: http://www.healthguideinfo.com/arrhythmias-heart-palpitations/p110132/ 多行性室性心动过速 10036095 polymorphic ventricular tachycardia AE OAE:0002216 Monomorphic ventricular tachycardia AE is a ventricular tachycardia AE that is a type of tachycardia which has a uniform beat-to-beat QRS morphology. JX, LW, YH 单行性室性心动过速 10058185 monomorphic ventricular tachycardia AE OAE:0002217 Respiratory tract symptoms AE is a respiratory system AE that is a series of discomforts which occurs in respiratory tract. JX, LW, YH 呼吸道症状 respiratory tract symptoms AE OAE:0002218 Clammy skin AE is a skin AE that occurs when the skin turns cooler than normal and is moist, despite a cooler surface temperature. Clammy skin is often pale. JX, LW, YH WEB: http://www.healthgrades.com/symptoms/clammy-skin 皮肤湿冷 clammy skin AE OAE:0002219 Abnormal visual accommodation AE is an abnormal vision AE that shows abnormal visual accommodation. Accommodation is the process by which the vertebrate eye changes optical power to maintain a clear image or focus on an object as its distance varies. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Accommodation_%28eye%29 视调节异常 abnormal visual accommodation AE OAE:0002220 an allergy AE that shows swelling and irritation of the skin, caused by an allergy to a substance in the environment. JX, LW, YH 皮肤过敏 skin allergy AE OAE:0002221 Heaviness of the head AE is a sensation of heaviness AE that shows a sensation feeling of heaviness in the head. JX, LW, YH 头重感 10049121 heaviness of the head AE OAE:0002222 Rheumatoid factor positive AE is an immunology and allergy investigation result abnormal AE that shows positive of the rheumatoid factor. Rheumatoid factor is a blood test that measures the amount of the RF antibody in the blood. JX, LW, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003548.htm 类风湿因子阳性 10039080 rheumatoid factor positive AE OAE:0002223 Retinal detachment AE is an eye AE that is a separation of the retina from its attachments to the underlying tissue within the eye. JX, LW, YH WEB: http://www.medicinenet.com/retinal_detachment/article.htm 视网膜脱离 10038848 retinal detachment AE CTCAE: E10420 NCIT: C26874 NCIt: C26874 OAE:0002224 Arm pain AE is a pain AE that shows discomfort in the structures of the arm. It can be caused by a wide variety of problems, ranging from joint injuries to compressed nerves. JX, LW, YH WEB: http://www.mayoclinic.org/symptoms/arm-pain/basics/definition/SYM-20050870 手臂疼痛 arm pain AE OAE:0002225 Peripheric paresthesia AE is a paresthesia AE that shows paresthesia in the peripheric area. JX, LW, YH 外周感觉异常 peripheric paresthesia AE OAE:0002226 Edema of glottis AE is an edema AE that is a swelling caused by fluid accumulation in the soft tissues of the larynx. The condition, usually inflammatory, may result from an infection, injury, allergy, or inhalation of toxic substances. JX, LW, YH 声门肿胀 edema of glottis AE OAE:0002227 Prolonged qrs complex AE is a electrocardiogram qrs complex abnormal AE that shows qrs complex prolonged. The QRS complex is a name for the combination of three of the graphical deflections seen on a typical electrocardiogram. JX, LW, YH QRS时间延长 prolonged qrs complex AE OAE:0002228 Prolonged bleeding time AE is a hematology investigation result abnormal AE that shows prolonged time for small blood vessels in the skin close to stop from bleeding. JX, LW, YH 出血时间延长 prolonged bleeding time AE OAE:0002229 Acute generalized exanthematous pustulosis AE is a skin AE that is a not uncommon cutaneous reaction pattern that in 90% of cases is related to medication administration, characterized by a sudden eruption that appears on average five days after the medication is started. JX, LW, YH pustular drug eruption AE toxic pustuloderma AE WEB: http://en.wikipedia.org/wiki/Acute_generalized_exanthematous_pustulosis 急性全身性浓疱病 10062372 acute generalized exanthematous pustulosis AE OAE:0002230 Upper and lower limbs flare AE is an edema AE that shows edema in the upper and lower limbs, which is an accumulation of an excessive amount of watery fluid in cells or intercellular tissues. JX, LW, YH 上下肢红肿 upper and lower limbs flare AE OAE:0002231 Abnormal blood sugar with empty stomach AE is a blood glucose level abnormal AE that shows abnormal blood glucose level with empty stomach. JX, LW, YH 空腹时血糖异常 abnormal blood sugar with empty stomach AE OAE:0002232 Increased blood sugar with empty stomach AE is blood glucose level decreased AE that shows an increased glucose level in blood with empty stomach. JX, LW, YH 空腹时血糖升高 increased blood sugar with empty stomach AE OAE:0002233 Hydrochloric acid in gastric juice secretion increased AE is a gastric disorder AE that shows increased gastric acid. JX, LW, YH 胃酸分泌增多 hydrochloric acid in gastric juice secretion increased AE OAE:0002234 Torsades de pointes AE is a ventricular tachycardia AE that is a polymorphic ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Torsades_de_pointes 扭转性室速 10044067 torsades de pointes AE OAE:0002235 Proximal myasthenia AE is a myasthenia AE that shows proximal myasthenia. Myasthenia represents myasthenia gravis, a neuromuscular disease leading to fluctuating muscle weakness and fatigability. JX, LW, YH 近端肌无力 proximal myasthenia AE OAE:0002236 Dilated skin vessels AE is a vasodilatation AE that shows vasodilatation in the skin, which refers to the widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls, particularly in the large arteries, smaller arterioles and large veins. JX, LW, YH 皮肤血管扩张 dilated skin vessels AE OAE:0002237 Numbness of oral mucosa AE is a numbness AE that shows an abnormal feeling or loss of sensation in the oral mucosa. JX, LW, YH 口腔黏膜发麻 numbness of oral mucosa AE OAE:0002238 Orthostatic dizziness AE is a dizziness AE that shows dizziness provocation by sudden postural change. JX, LW, YH 体位性头晕 10031125 orthostatic dizziness AE OAE:0002239 Acid reflux AE is a digestive system AE that shows the acid and pepsin secreted in the stomach back up in to the esophagus. JX, LW, YH 反酸 10066872 acid reflux AE OAE:0002240 Jugular phlebectasia AE is a vasodilatation AE that is an isolated saccular or fusiform dilation of a vein without tortuosity. JX, LW, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708235/ 颈静脉扩张 jugular phlebectasia AE OAE:0002241 Laryngeal edema AE is an edema AE that shows abnormal accumulation of fluid in tissues of any part of the larynx, commonly associated with laryngeal injuries and allergic reactions. JX, LW, YH, MW laryngeal oedema AE 喉肿胀 10023838 laryngeal edema AE CTCAE:E13393 NCIt:C79607 OAE:0002242 Flatus AE is a digestive system AE that shows gas or air expelled through the anus. JX, LW, YH 排气 10016769 flatus AE OAE:0002243 Continuous polymorphic ventricular tachycardia AE is a polymorphic ventricular tachycardia AE that shows polymorphic ventricular tachycardia is constantly. JX, LW, YH 连续性多形性室性心动过速 continuous polymorphic ventricular tachycardia AE OAE:0002244 Continuous polymorphic ventricular tachycardia AE is a polymorphic ventricular tachycardia AE that shows polymorphic ventricular tachycardia is intermittent. JX, LW, YH 间歇性多形性室性心动过速 intermittent polymorphic ventricular tachycardia AE OAE:0002245 Aggravated ulcer AE is a ulcer AE that shows aggravated ulcer. JX, LW, YH 溃疡加重 aggravated ulcer AE OAE:0002246 Heart failure increased AE is a cardiovascular disorder AE that shows aggravated heart failure. JX, LW, YH 心脏衰竭加重 heart failure increased AE OAE:0002247 Aggravated angina symptoms AE is a angina pectoris AE that shows aggravated angina symptoms. JX, LW, YH 心绞痛症状加剧 aggravated angina symptoms AE OAE:0002248 Aggravated renal injury AE is a renal impairment AE that shows aggravated renal injury. JX, LW, YH 肾损害加剧 aggravated renal injury AE OAE:0002249 Aggravated fatigue AE is a fatigue AE that shows aggravated fatigue. JX, LW, YH 脱力感加重 aggravated fatigue AE OAE:0002250 Persistent nausea AE is a nausea AE that shows constant nausea. Nausea is considered "persistent" if it continues for more than 2 days, or keeps recurring even after treatment. JX, LW, YH WEB: http://www.all4naturalhealth.com/persistent-nausea.html 持续恶心 persistent nausea AE OAE:0002251 Aggravated Raynaud's syndrome AE is a Raynaud's syndrome AE that shows aggravated Raynaud's syndrome. JX, LW, YH Raynaud综合征加重 aggravated Raynaud's syndrome AE OAE:0002252 Increased gastric acid secretion with high dose AE is a gastric disorder AE that shows increased gastric acid secretion with high dose. JX, LW, YH 高剂量时胃酸分泌增加 increased gastric acid secretion with high dose AE OAE:0002253 Persistent vomiting AE is a vomiting AE that occurs frequently throughout the day and is often triggered by even small meals. JX, LW, YH WEB: http://www.healthhype.com/persistent-and-recurrent-vomiting-emesis-in-adults-and-children.html 持续呕吐 10034716 persistent vomiting AE OAE:0002254 Hypoacusis AE is a hearing disorder AE that shows partial or complete loss of the ability to detect or understand sounds resulting from damage to the outer, middle, or inner ear structures. Causes include exposure to loud noise, ear infections, injuries to the ear, genetic, and congenital disorders. JX, LW, YH WEB: http://medical-dictionary.thefreedictionary.com/hypoacusis 突发听力减退 10048865 hypoacusis AE OAE:0002255 Lip cyanosis AE is a cyanosis AE that is a condition in which the lips have a bluish discoloration due to a lack of oxygen in the tissues. JX, LW, YH WEB: http://www.rightdiagnosis.com/sym/lip_cyanosis.htm 嘴唇发紫 lip cyanosis AE OAE:0002256 Nail cyanosis AE is a cyanosis AE that shows a dark bluish or purple nail resulting from deficient oxygenation of the blood. JX, LW, YH 指甲青紫 nail cyanosis AE OAE:0002257 Renal dysfunction AE is a kidney AE that has an outcome of reduced capacity to excrete metabolic products which accumulate systemically and are detectable clinicopathologically by renal function tests. The early stage of uremia. This term appears to be a synonym to the 'renal failure AE'. JX, LW, YH hepatic and renal function disorder AE 肾功能障碍 renal insufficiency AE UMLS ID: C0859242 OAE:0002258 JX, LW, YH Hemolysis AE is a hematopoietic system AE that is the rupturing of erythrocytes (red blood cells) and the release of their contents (cytoplasm) into surrounding fluid. WEB: http://en.wikipedia.org/wiki/Hemolysis 溶血 10019491 hemolysis AE CTCAE: E10037 NCIt: C37965 OAE:0002259 Lip angioedema AE is a angioedema AE that shows lip angioedema, which is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. JX, LW, YH 唇血管神经性水肿 lip angioedema AE OAE:0002260 Tongue angioedema AE is a angioedema AE that shows tongue angioedema, which is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. JX, LW, YH 舌血管神经性水肿 tongue angioedema AE OAE:0002261 Acousma AE is a sensory capability AE that shows a hallucinatory impression of strange sounds. JX, LW, YH 幻听 acousma AE OAE:0002262 Eye burning AE is a eye AE that shows a feeling of burning in the eye. JX, LW, YH 眼睛灼烧感 eye burning AE OAE:0002263 Worsening renal function AE is a kidney AE that shows worsening renal function. JX, LW, YH 肾功能恶化 worsening renal function AE OAE:0002264 Mild change of hematology AE is a change of hematology AE that shows mild change of hematology. JX, LW, YH 轻度的血液学改变 mild change of hematology AE OAE:0002265 Moderate change of hematology AE is a change of hematology AE that shows moderate change of hematology. JX, LW, YH 中度的血液学改变 moderate change of hematology AE OAE:0002266 Severe lower blood pressure AE is a hypotension AE that shows severe sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH significantly decreased blood pressure AE 严重的血压降低 severe lower blood pressure AE OAE:0002267 Elevated blood transaminase reversibility AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase reversibly. JX, LW, YH 血氨基转移酶可逆性升高 elevated blood transaminase reversibility AE OAE:0002268 Mild gastrointestinal tract reaction AE is a gastrointestinal disorder AE that shows a mild gastrointestinal disorder. JX, LW, YH 轻度胃肠道反应 mild gastrointestinal tract reaction AE OAE:0002269 Temporary abdominal distention AE is a abdominal distension AE that shows a temporary sensation of elevated abdominal pressure and volume. JX, LW, YH 暂时性腹胀 temporary abdominal distention AE OAE:0002270 Transient nausea AE is a nausea AE that is a gastric discomfort associated with the inclination to vomit. JX, LW, YH 暂时性恶心 transient nausea AE OAE:0002271 Persistent tachycardia AE is a tachycardia AE that is an increased heart rate that exceeds the normal range for a resting heartrate (heartrate in an inactive or sleeping individual). It's a constant process. JX, LW, YH 持续心动过速 persistent tachycardia AE OAE:0002272 Mild headache AE is a headache AE that shows mild headache. JX, LW, YH 轻度头痛 mild headache AE OAE:0002273 Transient hypoxemia AE is a hypoxia AE that is a reduced concentration of O2 in the blood, alveoli or other tissues resulting in the decreased pressure of this component of body gases. JX, LW, YH 瞬态低氧血症 transient hypoxemia AE OAE:0002274 Transient neuroticism AE is a neuroticism AE that is a type of personality trait that contrasts adjustment or emotional stability with maladjustment. Experience of anxiety, anger, disgust, sadness, embarrassment, and a variety of other negative emotions. JX, LW, YH 瞬态神经质 transient neuroticism AE OAE:0002275 Constant irritability AE is a irritability AE that shows in the patient being easily annoyed/irritated constantly. JX, LW, YH 持续烦躁 constant irritability AE OAE:0002276 Abnormal atony AE is a asthenia AE that is a medical term denoting symptoms of physical weakness and loss of strength. JX, LW, YH 异常无力 abnormal atony AE OAE:0002277 Secondary hypotension AE is a hypotension AE that is a type of hypertension which by definition is caused by an identifiable underlying secondary cause. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Secondary_hypertension 继发性高血压 secondary hypotension AE OAE:0002278 Transient elevated serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase transiently. JX, LW, YH 瞬时血清转氨酶升高 transient elevated serum transaminase AE OAE:0002279 Transient elevated blood urea nitrogen AE is a blood urea level increased AE that shows a transient increase in amount of urea in blood. JX, LW, YH 瞬时血尿素氮升高 transient elevated blood urea nitrogen AE OAE:0002280 Apparent increased blood creatine phosphokinase AE is a blood creatine phosphokinase level increased AE that is characterized by an apparent increased level of creatine phosphokinase or phosphocreatine kinase. JX, LW, YH 明显的血肌酸磷酸激酶增高 apparent increased blood creatine phosphokinase AE OAE:0002281 Severe rhabdomyolysis AE is a rhabdomyolysis AE that shows in severe damaged skeletal muscle tissue breaks down rapidly. JX, LW, YH 严重的横纹肌溶解症 severe rhabdomyolysis AE OAE:0002282 Mild gastrointestinal bleeding AE is a gastrointestinal hemorrhage AE that shows mild gastrointestinal hemorrhage. JX, LW, YH 胃肠道轻微出血 mild gastrointestinal bleeding AE OAE:0002283 Occult gastrointestinal tract bleeding AE is a gastrointestinal hemorrhage AE that shows occult gastrointestinal hemorrhage. JX, LW, YH 胃肠道隐匿性出血 occult gastrointestinal tract bleeding AE OAE:0002284 Nitrate headache AE is a headache AE that that is a special headache induced by nitrate. JX, LW, YH 硝酸盐性头痛 nitrate headache AE OAE:0002285 Pantomorphia erythema exudativum AE is a skin AE that is a skin condition of unknown cause, possibly mediated by deposition of immune complex (mostly IgM) in the superficial microvasculature of the skin and oral mucous membrane that usually follows an infection or drug exposure. It is an uncommon disorder, with peak incidence in the second and third decades of life. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Erythema_multiforme 多形性渗出性红斑 pantomorphia erythema exudativum AE OAE:0002286 High hypodynamia AE is a fatigue AE that is a state of awareness describing a range of afflictions, usually associated with physical and/or mental weakness, though varying from a general state of lethargy to a specific work-induced burning sensation within one's muscles. Physical fatigue is the inability to continue functioning at the level of one's normal abilities. JX, LW, YH 高度乏力 high hypodynamia AE OAE:0002287 Short-time nausea AE is a nausea AE that shows a gastric discomfort associated with the inclination to vomit. JX, LW, YH 短暂的恶心 short-time nausea AE OAE:0002288 Slightly increased aspartic transaminase AE is a aspartate aminotransferase level increased AE that shows a slightly increased amount of AST which is an enzyme normally present in body tissues especially of the heart and liver, JX, LW, YH 门冬氨酸氨基转移酶轻度升高 slightly increased aspartic transaminase AE OAE:0002289 Slightly increased alanine aminotransferase AE is a alanine aminotransferase level increased AE that shows elevated levels of alanine transaminase slightly. JX, LW, YH 丙氨酸氨基转移酶轻度升高 slightly increased alanine aminotransferase AE OAE:0002290 Slightly increased lactic dehydrogenase AE is a blood lactate dehydrogenase level increased AE that shows a slightly increased amount of LDH which is an enzyme that could indicate tissue damage. JX, LW, YH 乳酸脱氢酶轻度升高 slightly increased lactic dehydrogenase AE OAE:0002291 Slightly increased alkaline phosphatase AE is a blood alkaline phosphatase increased AE that shows elevated levels of alkaline phosphatase slightly. JX, LW, YH 碱性磷酸酶轻度升高 slightly increased alkaline phosphatase AE OAE:0002292 Slightly increased glutamic-oxalacetic transaminase AE is a aspartate aminotransferase level increased AE that shows a slightly increased amount of glutamic-oxalacetic transaminase in the heart and liver. JX, LW, YH 谷草转氨酶轻度升高 slightly increased glutamic-oxalacetic transaminase AE OAE:0002293 Slightly increased glutamic pyruvic transaminase AE is a alanine aminotransferase level increased AE that shows eelevated levels of glutamic pyruvic transaminase in the liver. JX, LW, YH 谷丙转氨酶轻度升高 slightly increased glutamic pyruvic transaminase AE OAE:0002294 Transient ischemic stroke AE is a ischemic stroke AE that occurs when a blood vessel that supplies the brain becomes blocked or "clogged" and impairs blood flow to part of the brain. JX, LW, YH 暂时性缺血性中风 transient ischemic stroke AE OAE:0002295 Evidently increased hepatic lipase AE is a hepatic enzyme increased AE that shows an evidently increase in amount of hepatic enzyme in body, commonly includes ALT and AST. It may indicate inflammation or damage to liver cells. JX, LW, YH 肝酶显著增加 evidently increased hepatic lipase AE OAE:0002296 Mild decline in blood pressure AE is a hypotension AE that shows mild sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH 血压轻度下降 mild decline in blood pressure AE OAE:0002297 Transient cerebral ischemic attacks AE is a cerebral ischemia AE that shows the sudden death of brain cells in a localized area due to inadequate blood flow. JX, LW, YH 短暂脑缺血发作 transient cerebral ischemic attacks AE OAE:0002298 Transient hypotension AE is a hypotension AE that shows transient sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH 瞬时低血压 transient hypotension AE OAE:0002299 Obviously decreased blood pressure AE is a hypotension AE that shows obviously sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH significantly decreased blood pressure AE 血压明显下降 obviously decreased blood pressure AE OAE:0002300 Transient dizzy AE is a dizziness AE that shows transient dizziness. JX, LW, YH 瞬时头晕 transient dizzy AE OAE:0002301 Short-time hepatic function disorder AE is a hepatic function abnormal AE that shows a short-time abnormal functionality of the liver. JX, LW, YH 短暂肝功能异常 short-time hepatic function disorder AE OAE:0002302 A slightly elevated plasma creatinine level AE is a blood creatinine level increased AE that shows an slightly increased level of creatinine in the blood (due to lack of kidney activity). JX, LW, YH 血浆肌酐水平的轻微升高 a slightly elevated plasma creatinine level AE OAE:0002303 Sudden fall of blood pressure AE is a hypotension AE that shows sudden sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH 血压突然降低 sudden fall of blood pressure AE OAE:0002304 Severe hypertension AE is a hypotension AE that shows severe sustained high blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH 严重高血压 severe hypertension AE OAE:0002305 Severe arrhythmia AE is an arrhythmia AE that shows severe abnormal heart rhythm. JX, LW, YH 严重心律失常 severe arrhythmia AE OAE:0002306 Clinically significant rise of serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase significantly. JX, LW, YH 血清转氨酶有临床显著升高 clinically significant rise of serum transaminase AE OAE:0002307 Instantaneous sand-blind AE is a vision blurred AE that shows in instantaneous unclear vision. JX, LW, YH 瞬时视觉模糊 instantaneous sand-blind AE OAE:0002308 Moderately increased urinary nitrogen AE is a blood urea level increased AE that shows a moderately increase in amount of urea in blood. JX, LW, YH 尿素中度升高 moderately increased urinary nitrogen AE OAE:0002309 Slightly increased urinary nitrogen AE is a blood urea level increased AE that shows a slightly increase in amount of urea in blood. JX, LW, YH 尿素水平轻微升高 slightly increased urinary nitrogen AE OAE:0002310 Moderately elevated serum creatinine AE is a blood creatinine level increased AE that shows an moderately increased level of creatinine in the blood (due to lack of kidney activity). JX, LW, YH 血肌酐中度升高 moderately elevated serum creatinine AE OAE:0002311 Slightly increased aminotransferase AE is a transaminase level increased AE that shows slightly elevated levels of alanine transaminase and aspartate transaminase. JX, LW, YH 轻度氨基转氨酶升高 slightly increased aminotransferase AE OAE:0002312 Severe dizziness AE is a dizziness AE that shows severe dizziness. JX, LW, YH 严重眩晕 severe dizziness AE OAE:0002313 Mild abdominal discomfort AE is a abdominal discomfort AE that shows a mild stomach ache. JX, LW, YH 轻微腹部不适 mild abdominal discomfort AE OAE:0002315 Rebound Increased blood pressure AE is a hypertension AE that shows rebound sustained high blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH 反跳性血压升高 rebound Increased blood pressure AE OAE:0002316 Excessive lowering of blood pressure AE is a hypotension AE that shows excessive sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH 血压过度降低 excessive lowering of blood pressure AE OAE:0002317 Short-time increased blood sugar AE is a blood glucose level increased AE that shows a short-time increased glucose level in blood. JX, LW, YH 短暂血糖升高 short-time increased blood sugar AE OAE:0002318 Mild nausea AE is a nausea AE that shows mild nausea. JX, LW, YH 轻度恶心 mild nausea AE OAE:0002319 Significant and persistent rise of serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase significantly and persistently. JX, LW, YH 血清氨基转移酶显著和持续性升高 significant and persistent rise of serum transaminase AE OAE:0002320 Elevated serum transaminase reversibility AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase reversibly. JX, LW, YH 血清氨基转移酶可逆性升高 elevated serum transaminase reversibility AE OAE:0002321 Reversible increased creatine phosphokinase AE is a blood creatine phosphokinase level increased AE that is characterized by an reversible increased level of creatine phosphokinase or phosphocreatine kinase. JX, LW, YH 肌酸磷酸激酶可逆性升高 reversible increased creatine phosphokinase AE OAE:0002322 Persistent and significant increase of serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase significantly and persistently. JX, LW, YH 血清转氨酶显著和持续性升高 persistent and significant increase of serum transaminase AE OAE:0002323 Severe bradycardia AE is a bradycardia AE that shows in a resting heart rate of under 60 beats per minutes (BPM). JX, LW, YH 严重心动过缓 severe bradycardia AE OAE:0002324 Apparent hypotensive reaction AE is a hypotension AE that shows apparent sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. JX, LW, YH 显著的低血压反应 apparent hypotensive reaction AE OAE:0002325 Severe skin flush AE is a hot flush AE that shows severe hot flush. JX, LW, YH 显著皮肤潮红 severe skin flush AE OAE:0002326 Transient sinus cardiac arrest AE is a sinus arrest AE that shows an electrocardiographic finding of transient impulse formation failure in the sinus node. JX, LW, YH 瞬时窦性停搏 transient sinus cardiac arrest AE OAE:0002327 Low-grade gastralgia AE is a stomacheache AE that shows a low-grade painful sensation in the stomach. JX, LW, YH 轻度胃痛 low-grade gastralgia AE OAE:0002328 Severe headache AE is a headache AE that shows severe headache. JX, LW, YH 严重头痛 severe headache AE OAE:0002329 Persistent headache AE is a headache AE that shows persistent headache. JX, LW, YH 持续头痛 persistent headache AE OAE:0002330 Proarrhythmic effect AE is an arrhythmia AE that is a new or more frequent occurrence of pre-existing arrhythmias, paradoxically precipitated by antiarrhythmic therapy, which means it is a side effect associated with the administration of some existing antiarrhythmic drugs, as well as drugs for other indications. In other words, it is a tendency of antiarrhythmic drugs to facilitate emergence of new arrhythmias. JX, LW, YH arhythmia auxo-action AE WEB: http://en.wikipedia.org/wiki/Proarrhythmia 致心律失常 10036766 proarrhythmic effect AE OAE:0002331 a metabolism, endocrine, and exocrine system AE that has an outcome of acidosis, i.e., too much acid in the body fluids. Blood pH Decreased URL: http://www.nlm.nih.gov/medlineplus/ency/article/001181.htm 10000486 10005706 YH, SJ, MW acidosis AE CTCAE:E12237 NCIt:C28228 OAE:0002332 Increased tendency of biliary calculus AE is a liver, biliary, and pancreatic AE that shows an increased tendency of biliary calculus. JX, LW, YH 胆石增加的趋势 increased tendency of biliary calculus AE OAE:0002333 Temporarily lose consciousness AE is a sensory capability AE that shows temporarily lose consciousness. JX, LW, YH 暂时失去知觉 temporarily lose consciousness AE OAE:0002334 Increase breast cancer occurrence AE is a breast cancer AE that shows increase breast cancer occurrence. JX, LW, YH 乳腺癌发生增加 increase breast cancer occurrence AE OAE:0002335 Anticholinergic effect AE is a conduction system disorder AE that is physical symptoms resulting from agents that counter the action of acetylcholine, a neurotransmitter (chemical within the nervous system) that is involved in many major bodily functions. These anticholinergic effects typically include constipation, dry mouth, blurred vision, dizziness, and slowing of urination. JX, LW, YH WEB: http://ibs.about.com/od/glossary/g/Anticholeffect.htm 经讯号传导阻断效应 anticholinergic effect AE OAE:0002336 a musculoskeletal system AE that has an outcome of diaphragmatic muscle replaced by fibroelestic tissue. The diaphragm retains its continuity and attachments to the costal margin. However, the weakened hemidiaphragm is displaced into the thorax, which can compromise breathing. SJ, YH URL: http://www.uptodate.com/contents/eventration-of-the-diaphragm-in-infants 10000486 acquired diaphragmatic eventration AE OAE:0002337 Neutrophilopenia AE is a neutrophil count decreased AE that shows the number of neutrophil is decreased. JX, LW, YH 中性白细胞减少 neutrophilopenia AE OAE:0002338 Abnormal leucocyte neutrophil AE is a neutrophil percentage abnormal AE that shows abnormal leucocyte neutrophil. JX, LW, YH 嗜中性白细胞异常 abnormal leucocyte neutrophil AE OAE:0002339 Abnormal eosinocyte AE is an eosinophil count abnormal AE that shows abnormal eosinocyte. JX, LW, YH 嗜酸性粒细胞异常 abnormal eosinocyte AE OAE:0002340 Eosinopenia AE is an eosinophil count abnormal AE that is a form of agranulocytosis where the number of eosinophil granulocytes is lower than expected. JX, LW, YH WEB: http://en.wikipedia.org/wiki/Eosinopenia 嗜酸细胞减少症 10014940 eosinopenia AE OAE:0002341 Aggravated peptic ulcer AE is a duodenal ulcer AE that shows aggravated peptic ulcer. JX, LW, YH 消化性溃疡加重 aggravated peptic ulcer AE OAE:0002342 Local tissue necrosis AE is a necrosis AE that shows local tissue necrosis. JX, LW, YH 局部组织坏死 local tissue necrosis AE OAE:0002343 a cardiac disorder AE that is characterized by a necrosis of the myocardium caused by diminished blood supply to the heart SJ, YH URL: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/acute-myocardial-infarction/ 10000891 acute myocardial infarction AE OAE:0002344 an endocrine system AE that results in a life threatening condition due to a lack of cortisol produced by the adrenal glands SJ, YH URL: http://www.nlm.nih.gov/medlineplus/ency/article/000357.htm 10001389 acute adrenal crisis AE OAE:0002345 YH, SJ URL http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2814%2970102-4/abstract 10053552 a pain AE that results in pain from a stimulus that does not usually provoke pain allodynia AE OAE:0002346 an embolism AE in which amniotic fluid, fetal cells, hair or other debris enter the maternal circulation resulting in cardiorespiratory collapse SJ, YH Anaphylactoid Syndrome of Pregnancy WEB: http://emedicine.medscape.com/article/253068-overview 10001977 amniotic fluid embolism AE OAE:0002347 a muscular weakness AE that has an outcome of weakness followed by wasting of muscles, and excruciating pain in the muscles of the thigh, hip, and buttocks YH, SJ diabetic lumbosacral radiculoplexus neuropathy diabetic polyradiculoneuropathy proximal diabetic neuropathy 10002027 diabetic amyotrophy AE OAE:0002348 an adverse drug event that results in unexpected and unwanted events due to anesthetic drug treatment SJ, YH WEB: https://www.dha.gov.ae/EN/Facilities/Hospitals/RashidHospital/SpecializedMedicalService/ClinicalServices/Anesthesiologyandinterventionalpain/pages/sideeffects.aspx 10060938 anesthetic complication AE OAE:0002349 an anus AE that results in the development of a small channel between the end of the bowel and the skin near the anus SJ, YH WEB: http://www.webmd.boots.com/digestive-disorders/anal-fistula 10002156 anal fistula AE CTCAE: E10464 NCIt: C60785 OAE:0002350 postoperative anemia AE is an anemia AE that occurs when a patient with acute bleeding loses enough blood to become anemic SJ, YH bleeding and acute blood loss anemia WEB: http://www.acphospitalist.org/archives/2012/02/coding.htm 10054312 postoperative anemia AE OAE:0002351 a behavior and neurological AE that results in antagonism toward someone or something you feel has deliberately done you wrong: excessive anger can cause problems including increased blood pressure and other physical changes that make it difficult to think straight and can harm your physical and mental health. SJ, YH WEB: http://apa.org/topics/anger/index.aspx 10002368 anger AE OAE:0002352 a musculoskeletal system AE that results in the formation of fibrous band between tissues and organs, often as a result of injury during surgery SJ, YH URL: http://en.wikipedia.org/wiki/Adhesion_%28medicine%29 10059837 adhesion AE OAE:0002353 a crying abnormal AE that refers to a neurologic disorder characterized by involuntary crying or uncontrollable episodes of crying and/or laughing, or other emotional displays YH, SJ emotional incontinence emotional lability labile affect WEB: http://en.wikipedia.org/wiki/Pseudobulbar_affect 10054196 pseudobulbar affect AE OAE:0002354 cardiovascular AE that results in disease of the arteries, veins, and capillaries SJ, YH macroangiopathy microangiopathy WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=6853 10059245 angiopathy AE OAE:0002355 a cardiovascular AE that results in the walls of small blood vessels becoming so thick and weak that they bleed, leak protein, and slow the flow of blood SJ, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=6853 10062198 microangiopathy AE OAE:0002356 a cardiovascualr AE that results in the build up of fat and blood clots in the large blood vessels, stick to the vessel walls, and block the flow of blood SJ, YH cerebrovascular disease coronary artery disease peripheral vascular disease WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=6853 10054805 macroangiopathy AE OAE:0002357 a muscle AE that results in a congenital anomaly in which a short, lingual frenulum or a highly-attached genioglossus muscle restricts tongue movement SJ, YH tongue-tie WEB: http://www.uptodate.com/contents/ankyloglossia-tongue-tie-in-infants-and-children 10049244 ankyloglossia AE OAE:0002358 a digestive system AE that results in a group of medical disorders that occur at the junction of the anal canal and the rectum SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/Anorectal+Disorders 10002644 anorectal disorder AE OAE:0002359 a hemorrhage AE that has an outcome of bleeding from or in to the genital tract, occurring from 24 weeks of pregnancy and prior to the birth of the baby. YH, SJ WEB: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg63_05122011aph.pdf 10055228 antepartum hemorrhage AE OAE:0002360 Brain damage AE that results in a persistent vegetative state SJ, YH WEB: http://www.rightdiagnosis.com/a/apallic_syndrome/intro.htm 10002941 apallic syndrome AE OAE:0002361 APGAR is a quick test performed on a neonate at 1 and 5 minutes after birth. The 1-minute score determines how well the baby tolerated the birthing process. The 5-minute score tells the doctor how well the baby is doing outside the mother's womb. Any score lower than 7 is a sign that the baby needs medical attention. The lower the score, the more help the baby needs to adjusting outside the mother's womb YH, SJ WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003402.htm 10002944 10062552 APGAR score low AE OAE:0002362 a brain disorder AE that causes a person to lose the ability to communicate. Aphasia can affect the ability to express and understand language, both verbal and written. Aphasia typically occurs suddenly after a stroke or a head injury, but it can also come on gradually from a slowly growing brain tumor or a degenerative disease SJ, YH WEB: http://www.mayoclinic.org/diseases-conditions/aphasia/basics/definition/con-20027061 10002948 aphasia AE OAE:0002363 a tumor AE that results in pouches of cerebrospinal fluid covered by arachnoidal cells and collagen that may develop between the surface of the brain and the cranial base or on the arachnoid membrane SJ, YH WEB:http://en.wikipedia.org/wiki/Arachnoid_cyst 10049005 arachnoid cyst AE OAE:0002364 a brain disorder AE that causes inflammation of the arachnoid, one of the membranes known as meninges that surround and protect the nerves of the central nervous system, including the brain and spinal cord. SJ, YH, MW WEB: http://en.wikipedia.org/wiki/Arachnoiditis 10003074 arachnoiditis AE CTCAE:E12591 NCIt:C37913 OAE:0002365 A pregnancy AE that results in an interruption in the labor process that is associated with uterine contractions. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/arrested+labor 10003118 arrested labor AE OAE:0002366 an arrhythmia AE that is characterized by shortness of breath, heart palpitations, chest tightness, and a very fast pulse. Supraventricular arrhythmias begin in the areas above the heart’s lower chambers, such as the upper chambers (the atria) or the atrial conduction pathways. SJ, YH atrial arrhythmia WEB: http://www.texasheart.org/HIC/Topics/cond/arrhycat.cfm 10003130 supraventricular arrhythmia AE OAE:0002367 a cardiac disorder AE which causes a spasm of the large- or medium-sized coronary arteries SJ, YH coronary artery spasm coronary artery vasospasm coronary vasospasm WEB: http://sideeffects.embl.de/se/C0010073/pt 10003225 coronary arteriospasm AE OAE:0002368 joint range of motion decreased AE caused by an excessive amount of scar tissue forming within the joint and surrounding soft tissue spaces SJ, YH WEB: http://en.wikipedia.org/wiki/Arthrofibrosis 10058029 arthrofibrosis AE OAE:0002369 arteriosclerosis AE is a cardiovascular AE that results in blood vessels and arteries becoming thick and stiff which can restrict blood flow to organs and tissues. SJ, YH WEB: http://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/basics/definition/con-20026972 10003210 arteriosclerosis AE OAE:0002370 atheroslcerosis AE is a specific arteriosclerosis AE that refers to the buildup of fats, cholesterol and other substances in and on artery walls which can restrict blood flow. SJ, YH WEB: http://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/basics/definition/con-20026972 10003601 atherosclerosis AE OAE:0002371 atrial tachycardia AE is a tachycardia AE that results in a fast heart rate beginning in the upper chambers of the heart SJ, YH paroxysmal atrial tachycardia paroxysmal supraventricular tachycardia supraventricular tachycardia WEB: http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Tachycardia-Fast-Heart-Rate_UCM_302018_Article.jsp# 10003668 10034040 atrial tachycardia AE CTCAE: E10166 NCIt: C34900 OAE:0002372 a hematology investigation result abnormal AE that results in high blood cortisol levels SJ, YH URL: http://www.nlm.nih.gov/medlineplus/ency/article/003693.htm 10005458 blood cortisol decreased AE may indicate that the patient has cushing disease, ectopic cushing syndrome, or a tumor of the adrenal gland that is producing too much cortisol. blood cortisol increased AE OAE:0002373 a cardiovascular disorder AE that results in easy or excessive bruising and bleeding. The bleeding results from unusually low levels of platelets. SJ, YH immune thrombocytopenic purpura WEB: http://www.mayoclinic.org/diseases-conditions/idiopathic-thrombocytopenic-purpura/basics/definition/con-20034239 10050245 idiopathic thrombocytopenic purpura AE OAE:0002374 YH, SJ WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=2477 10005063 a pain AE that is observed in the bladder, usually a symptom of bladder infection. bladder pain AE OAE:0002375 an eye AE that results in involuntary, forcible closure of the eyelids.The spasms may leave the eyelids completely closed, causing functional blindness even though the eyes and vision are normal. SJ, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=2481 10005159 blepharospasm AE OAE:0002376 an abnormal vision AE which has an outcome of loss of vision in one eye that is not permanent. SJ, YH blindness unilateral WEB: http://en.wikipedia.org/wiki/Amaurosis_fugax 10005186 amaurosis fugax AE OAE:0002377 a hematology investigation result abnormal AE that results in low blood cortisol levels SJ, YH URL: http://www.nlm.nih.gov/medlineplus/ency/article/003693.htm 10005457 blood cortisol decreased AE may indicate that the patient has addison disease, hypopituitarism, suppression of normal pituitary or adrenal function. blood cortisol decreased AE OAE:0002378 a hematology investigation result abnormal AE that results in high blood creatine levels SJ, YH URL: http://www.mayoclinic.org/tests-procedures/creatinine/basics/definition/prc-20014534 10005464 blood creatine increased AE may indicate that the kidneys are not fucntioning properly blood creatine increased AE OAE:0002380 a hematology investigation result abnormal AE that signifies that a patient is allergic to a particular substance SJ, YH WEB: http://kidshealth.org/parent/system/medical/test_ige.html 10005591 blood immunoglobin E increased AE OAE:0002381 a hematology investigation result abnormal AE that results in low levels of testosterone which can lead to infertility and a low sex drive SJ, YH WEB: http://www.webmd.com/men/testosterone-15738 10005814 blood testosterone decreased AE OAE:0002382 A macrocytic anemia AE is an anemia AE that has an outcome of a macrocytic anemia, which is an anemia (defined as blood with an insufficient concentration of hemoglobin) in which the red blood cells (erythrocytes) are larger than their normal volume. KM, YH WEB: http://en.wikipedia.org/wiki/Macrocytic_anemia 10002064 macrocytic anemia AE OAE:0002383 a bone disorder AE that has an outcome of low bone densityl, but not low enough to be considered osteoporosis SJ, YH WEB: http://nof.org/articles/9 10049470 low bone density AE OAE:0002384 a surgical AE that occurs after a bone graftr procedure, which replaces missing bone in order to repair bone fractures that are extremely complex, pose a significant health risk to the patient, or fail to heal properly. SJ, YH WEB: http://en.wikipedia.org/wiki/Bone_grafting bone graft AE OAE:0002385 bone marrow edema AE is an edema AE that occurs when excess fluids in the bone marrow buildup and cause swelling. This condition is often caused by a protective reaction of the body in response to an injury or inflammation SJ, YH WEB: http://www.wisegeek.com/what-is-bone-marrow-edema.htm 10051763 bone marrow edema AE OAE:0002386 an investigation result abnormal AE that detects areas of increased or decreased bone activity. These may indicate bone injury or disease. SJ, YH WEB: http://www.mountsinai.org/patient-care/health-library/treatments-and-procedures/bone-scan 10061941 bone scan abnormal AE OAE:0002387 Nervous system AE that covers a variety of conditions that may impair function of the brachial plexus nerve network, most of which are caused by trauma. SJ, YH WEB: http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/peripheral_nerve_surgery/conditions/brachial_plexus_injury_bpi.html 10006074 brachial plexus injury AE OAE:0002388 a bradycardia AE that results in a disturbance in the heart rhythm in which the heart rate is abnormally slowed. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/bradyarrhythmia 10049765 bradyarrhythmia AE OAE:0002389 a bradycardia AE that results in a fetal heart rate of less than 120 beats per minute, generally associatedwith hypoxia SJ, YH WEB:http://medical-dictionary.thefreedictionary.com/fetal+bradycardia 10006094 bradycardia fetal AE OAE:0002390 a brain disorder AE that results in the complete and irreversible loss of brain function SJ, YH WEB: http://en.wikipedia.org/wiki/Brain_death 10049054 brain death AE OAE:0002391 a brain disorder AE that results in brain tissue, cerebrospinal fluid, and blood vessels being moved or pressed away from their usual position inside the skull. SJ, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001421.htm 10006126 brain herniation AE OAE:0002392 a brain injury AE,  injury to the brain caused by an external force, that results in a brain AE SJ, YH Traumatic Brain Injury WEB: http://www.biausa.org/FAQRetrieve.aspx?ID=43913 10067967 brain injury AE OAE:0002393 a brain mass AE is a mass or growth of abnormal cells in your brain or close to your brain SJ, YH Brain Neoplasm Brain Tumor Intercranial Neosplasm WEB: http://www.mayoclinic.org/diseases-conditions/brain-tumor/home/ovc-20117132 10052334 10061019 brain mass AE OAE:0002394 an imaging investigation result abnormal AE shows how the brain and its tissues are working. Abnormal results may be due to: Alzheimer’s disease or dementia, brain tumors, epilepsy, and movement disorders. SJ, YH PET scan WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007341.htm 10061943 brain scan abnormal AE OAE:0002395 Eyelid disorder AE is a eye AE that is a condition specifically affects the eyelid. It can include drooping, twitching, inflammation, paralysis, and growths. Occasional fluttering of one eyelid is normal. JX, LW WEB: http://www.healthline.com/health/eyelid-disorders#Overview1 10061130 eyelid disorder AE OAE:0002396 Hepatic steatosis AE is a liver disorder AE than popularly called as ‘fatty liver’ is a pathological aspect of liver, whose specific cells (hepatocytes) are filled with lipids (fats). It is a reversible liver disease: ‘is not still very ill, but cries for help’. JX, LW WEB: http://www.bendomd.com/272-hepatic-steatosis-causes-symptoms-treatment.html 10019708 hepatic steatosis AE OAE:0002397 An arthropathy AE is a joint pain AE that has an outcome of arthropahty, which is any disorder of the joints. This is an AE which is an injury to the abdomen and its signs and symptoms include abdominal pain, tenderness, rigidity, and bruising of the external abdomen. KM, YH QY, JX, HY WEB: http://en.wikipedia.org/wiki/Arthropathy, http://medical-dictionary.thefreedictionary.com/arthropathy http://en.volupedia.org/wiki/Abdominal_trauma 腹部损伤 10003285 10060924 abdominal injury AE arthropathy AE NCIT: C35760 OAE:0002398 A balantis AE is a reproductive system AE that has an outcome of a balantis, which is an infectious or non-infectious inflammatory process that affects the glans penis. Symptoms include redness and pain of the glans penis and foreskin and discharge. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000862.htm, http://en.wikipedia.org/wiki/Balanitis 10004073 balanitis AE OAE:0002399 Pruritus genital AE is a pruritus AE that also called genital itching, Itching in the genital region can result from irritation, allergy, inflammation, infection or cancer. Irritation can occur as a result of exposure to chemicals in soaps, feminine hygiene products, perfumes, lubricants, douches, and creams. JX, LW genital itching AE WEB: http://www.healthgrades.com/symptoms/genital-itching 10037093 pruritus genital AE OAE:0002400 cholecystitis AE is an gallbladder enlargement AE that has an outcome of cholecystitis, which is an acute or chronic inflammation involving the gallbladder wall. It may be associated with the presence of gallstones. KM, YH WEB: http://en.wikipedia.org/wiki/Cholecystitis, http://www.mayoclinic.org/diseases-conditions/cholecystitis/basics/definition/con-20034277 10008612 cholecystitis AE CTCAE: E11184 NCIT: C34465 NCIt: C34465 OAE:0002401 Chromaturia AE is an urine abnormality AE that has an outcome of chromaturia, which is an abnormal coloration of the urine. KM, YH WEB: http://medical-dictionary.thefreedictionary.com/chromaturia 10008796 chromaturia AE OAE:0002402 Chromosome abnormality AE is a genetic AE that has an outcome of chromsome abnormality which is a missing, extra, or irregular protion of chromosomal DNA. KM, YH WEB: http://en.wikipedia.org/wiki/Chromosome_abnormality 10008815 chromosome abnormality AE OAE:0002403 A coagulopathy AE is a blood disorder AE that has an outcome of coagulopathy, which is a condition in which there is a deviation from or interruption of the normal coagulation properties of the blood. KM, YH WEB: http://en.wikipedia.org/wiki/Coagulopathy 10009802 coagulopathy AE OAE:0002404 Combined immunodeficiency AE is an immune system AE that has an outcome of combined immunodeficiency, which represents a group of rare, sometimes fatal, congenital disorders characterized by little or no immune response. KM, YH WEB: http://www.ncbi.nlm.nih.gov/books/NBK22254/ 10010099 combined immunodeficiency AE OAE:0002405 Hepatic enzyme abnormal AE is a liver related investigation result abnormal AE that the lab test result of hepatic enzyme deviates from its normal value. JX, YH 10062685 hepatic enzyme abnormal AE OAE:0002406 A coronary artery aneurysm AE is a coronary artery disorder AE that has an outcome of coronary artery aneurysm, which is a coronary dilatation which exceeds the diameter of normal adjacent segments or the diameter of the patient's largest coronary vessel by 1.5 times. KM, YH WEB: http://en.wikipedia.org/wiki/Coronary_artery_aneurysm WEB: http://www.ncbi.nlm.nih.gov/pubmed/9247557 10011071 coronary artery aneurysm AE OAE:0002407 Injection site atrophy AE is an injection-site AE that muscle atrophy occur in the injection site. JX, YH 10022048 injection site atrophy AE OAE:0002408 A cutaneous tuberculosis AE is a tuberculosis AE that has an outcome of cutaneous tuberculosis, which is an invasion of the skin by Mycobacterium tuberculosis. KM, YH WEB: http://www.dermnetnz.org/bacterial/tuberculosis.html 10011684 cutaneous tuberculosis AE OAE:0002409 Breath sounds abnormal AE is a respiratory system AE that is characterized by abnormal breath sound, it can indicate fluid in the lungs or asthma. JX, LW WEB: http://www.healthline.com/health/breath-sounds#Overview1 10064780 breath sounds abnormal AE OAE:0002410 Skin abrasion AE is a skin AE that is a wound caused by superficial damage to the skin, no deeper than the epidermis. JX, YH WEB: http://en.wikipedia.org/wiki/Abrasion_%28medical%29 10064990 skin abrasion AE OAE:0002411 Trigeminal neuralgia AE is a neuralgia AE that is a neuropathic disorder characterized by episodes of intense pain in the face, originating from the trigeminal nerve. The clinical association between TN and hemifacial spasm is the so-called tic douloureux. JX, YH Fothergill's disease AE prosopalgia AE WEB: http://en.wikipedia.org/wiki/Trigeminal_neuralgia 10044652 trigeminal neuralgia AE OAE:0002412 Face injury AE is an injury AE that injury occurs in the face. JX, YH 10050392 face injury AE OAE:0002413 Muscle contrature AE is a muscle AE that can occur for many reasons, such as paralysis, muscular atrophy, and forms of muscular dystrophy. Fundamentally, the muscle and its tendons shorten, resulting in reduced flexibility. JX, YH WEB: http://en.wikipedia.org/wiki/Muscle_contracture 10062575 muscle contrature AE OAE:0002414 A palsy AE that has a symmetric limitation of the movements of both eyes in the same direction. JX, YH WEB: http://one.aao.org/bcscsnippetdetail.aspx?id=f5a77965-de2a-4fb0-82fb-5f4089671ad6 10056696 gaze palsy AE OAE:0002415 Conjugate gaze palsy AE is a gaze palsy AE that is a disorder affecting the ability to move both eyes in the same direction. These palsies can affect gaze in a horizontal, upward, or downward direction. JX, YH WEB: http://en.wikipedia.org/wiki/Conjugate_gaze_palsy conjugate gaze palsy AE OAE:0002416 Horizontal gaze palsy AE is a gaze palsy AE that is the paresis of conjugate eye movements. JX, YH WEB: http://en.wikipedia.org/wiki/Horizontal_gaze_palsy horizontal gaze palsy AE OAE:0002417 a behavioral and neurological AE that refers to rigid body movements and chronic abnormal positions of the body. This symptom is not the same as showing poor posture or slumping over. Rather, it is often the result of a serious spinal cord or brain injury. JX, YH WEB: http://www.healthline.com/symptom/posture-abnormal 10036436 posture abnormal AE OAE:0002418 a behavioral and neurological AE that shows the body becomes entire rigid and uncontrolled jerking. They may last mere seconds, or continue for several minutes. JX, YH 10051171 tonic clonic movements AE OAE:0002419 Eyelid ptosis AE is an eye disorder AE that is a drooping or falling of the upper or lower eyelid. JX, LW WEB: http://en.wikipedia.org/wiki/Ptosis_%28eyelid%29 10015995 eyelid ptosis AE OAE:0002420 Facial paresis AE is a paresis AE that is a common problem that involves the paralysis of any structures innervated by the facial nerve. JX, YH facial nerve paralysis AE WEB: http://en.wikipedia.org/wiki/Facial_nerve_paralysis 10051267 facial paresis AE OAE:0002421 Menstrual disorder AE is an abnormal condition in a woman's menstrual cycle. WEB: http://en.wikipedia.org/wiki/Menstrual_disorder 10027327 JX, YH menstrual disorder AE OAE:0002422 Fluid retention AE is an abnormal fluid regulation AE that is excess fluid that collects in the tissues in your body. Most commonly, fluid retention is marked by swelling of your feet and lower legs, but swelling could also occur in your arms, hands, face, or other areas of the body. JX, YH WEB: http://www.healthgrades.com/symptoms/fluid-retention 10016807 fluid retention AE OAE:0002423 Emotional distress AE is a emotional disorder AE that is a Mental distress or anxiety suffered as a response to a sudden, severe, and saddening experience. JX, YH WEB: http://en.wikipedia.org/wiki/Emotional_distress 10049119 emotional distress AE OAE:0002424 Encephalitis AE is a nervous system AE that is an acute inflammation of the brain. JX, YH WEB: http://en.wikipedia.org/wiki/Encephalitis 10014581 encephalitis AE OAE:0002425 a psychiatric disorder AE that is a category of mental health disorders that primarily affect learning, memory, perception, and problem solving, and include amnesia, dementia, and delirium. JX, YH WEB: http://en.wikipedia.org/wiki/Cognitive_disorder 10057668 cognitive disorder AE OAE:0002426 Incoherent AE is a speech disorder AE that shows unable to express one's thoughts or ideas in an orderly, intelligible manner. JX, YH WEB: http://medical-dictionary.thefreedictionary.com/incoherent 10021630 incoherent AE OAE:0002427 Exercise tolerance decreased AE is a systematic AE that shows exercise tolerance decreased. The exercise tolerance refers to the exercise capacity of an individual as measured by their ability to endure exercise and/or the maximum work load achieved during the exercise period. JX, YH WEB: http://copd.about.com/od/glossaryofcopdterms/g/activitytoleran.htm 10051301 exercise tolerance decreased AE OAE:0002428 a burn AE that is a type of burn resulted from making contact with heated objects, such as boiling water, steam, hot cooking oil, fire, and hot objects. JX, LW WEB: http://en.wikipedia.org/wiki/Thermal_burn 10053615 thermal burn AE OAE:0002429 a psychiatric disorder AE that describes a wide array of experiences from mild detachment from immediate surroundings to more severe detachment from physical and emotional experience. JX, YH WEB: http://en.wikipedia.org/wiki/Dissociation_%28psychology%29 10013457 dissociation AE OAE:0002431 Mucous membrane disorder AE is a systematic AE that the diseases occur in mucous membrane, which is a lining of mostly endodermal origin. JX, YH WEB: http://en.wikipedia.org/wiki/Mucous_membrane 10028133 mucous membrane disorder AE OAE:0002432 a polyneuropathy AE that arises when the myelin sheaths around nerve cells are damaged. Myelin, the insulating layer of tissue that surrounds nerve cells, helps ensure that signals from the brain are rapidly transmitted to the proper places in the body. When myelin is damaged or destroyed, it can lead to problems with communication between the brain and the body. JX, YH WEB: http://www.healthgrades.com/conditions/chronic-inflammatory-demyelinating-polyneuropathy 10061811 demyelinating polyneuropathy AE OAE:0002433 a syndrome AE that results in increased pressure in a muscle compartment which can lead to nerve damage and impaired blood flow. SJ, YH URL: http://www.nlm.nih.gov/medlineplus/ency/article/001224.htm 10010121 Thick layers of tissue, called fascia, separate groups of muscles in the arms and legs from each other. Inside each layer of fascia is a confined space, called a compartment. The compartment includes the muscle tissue, nerves, and blood vessels. compartment syndrome AE OAE:0002434 Therapeutic response decreased is found among people who take Cialis, especially for people who are male, 60+ old, have been taking the drug for < 1 month, also take medication Aspirin, and have Erection problems. JX, LW WEB: http://www.ehealthme.com/ds/cialis/therapeutic+response+decreased 10043414 therapeutic response decreased OAE:0002436 a seizure AE that resutls in impariment of awareness and involuntary but coordinated and repeated movements. YH, SJ WEB: http://www.webmd.com/epilepsy/guide/types-of-seizures-their-symptoms?page=2 10010145 complex partial seizure AE OAE:0002437 Autoimmune disorder AE is an immune system AE that arises from an abnormal immune response of the body against substances and tissues normally present in the body (autoimmunity). JX, YH WEB: http://en.wikipedia.org/wiki/Autoimmune_disease 10061664 autoimmune disorder AE CTCAE: E11258 NCIt: C2889 OAE:0002438 a hemorrhage AE that has an outcome of bleeding into the pons or mesencephalon. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/brainstem+hemorrhage 10006146 brain stem hemorrhage AE is often secondary to brainstem distortion due to rapidly expanding intracranail lessions. brainstem hemorrhage AE OAE:0002439 Menstruation irregular AE is a endocrine system AE that is an abnormal variation in length of menstrual cycles in a female. JX, YH, MW irregular menstruation AE WEB: http://en.wikipedia.org/wiki/Irregular_menstruation 10022992 10027339 menstruation irregular AE CTCAE: E13125 NCIt: C35219 OAE:0002440 Generalised tonic-clonic seizure AE is a seizure AE that is a type of generalized seizure that affects the entire brain. Tonic–clonic seizures are the seizure type most commonly associated with epilepsy and seizures in general, though it is a misconception that they are the only type. JX, YH WEB: http://en.wikipedia.org/wiki/Tonic%E2%80%93clonic_seizure 10018100 generalised tonic-clonic seizure AE OAE:0002441 a psychiatric disorder AE that an involuntary flexion or extension of the arms and legs, indicating severe brain injury. JX, YH WEB: http://en.wikipedia.org/wiki/Abnormal_posturing 10036437 posturing AE OAE:0002443 Demyelination AE is a nervous system AE that is any disease of the nervous system in which the myelin sheath of neurons is damaged. JX, YH WEB: http://en.wikipedia.org/wiki/Demyelinating_disease 10012305 demyelination AE OAE:0002444 Gram stain negative AE is a microbiology and serology investigation result abnormal AE that has an outcome of detection of gram-negative bacteria. JX, YH WEB: http://en.wikipedia.org/wiki/Gram-negative_bacteria 10018656 gram stain negative AE OAE:0002445 Red blood cells CSF positive AE is a CSF test result abnormal AE that has an outcome of CSF red blood cells count positive. JX, YH 10038173 red blood cells CSF positive AE OAE:0002446 CSF white blood cell count increased AE is a CSF test result abnormal AE that has an outcome of CSF white blood cell count increased. JX, YH 10053805 CSF white blood cell count increased AE OAE:0002447 Influenza A virus test positive AE is a influenza virus test positive AE that has an outcome of positive result in an influenza A virus test. JX, YH 10070215 influenza A virus test positive AE OAE:0002448 a behavior and neurological test abnormal AE that shows a abnormal result of nerve conduction study (NCS). NCS is a medical diagnostic test commonly used to evaluate the function, especially the ability of electrical conduction, of the motor and sensory nerves of the human body. JX, YH WEB: http://en.wikipedia.org/wiki/Nerve_conduction_study 10029175 nerve conduction study abnormal AE OAE:0002449 Myocardial necrosis AE is a cardiac disorder AE that shows death of the cells of an area of the heart muscle (myocardium) as a result of oxygen deprivation, which in turn is caused by obstruction of the blood supply. JX, YH URL: http://medical-dictionary.thefreedictionary.com/myocardial+necrosis 10028602 myocardial necrosis AE OAE:0002450 a brainstem infarction AE is a stroke AE that occurs when blood cannot flow to the brainstem, when oxygen cannot get to an area of the brain, tissue in that area may be damaged. SJ, YH brainstem stroke WEB: http://en.wikipedia.org/wiki/Brain_stem_stroke_syndrome WEB: http://www.drugs.com/cg/brain-stem-infarction.html 10006147 A person may have vertigo, dizziness and severe imbalance without the hallmark of most strokes – weakness on one side of the body. But dizziness alone is not a sign of stroke. Brain stem stroke can also cause diplopia, slurred speech and decreased level of consciousness. brainstem infarction AE OAE:0002451 a lung disorder AE that occurs when the noises produced by the structures of the lungs during breathing are decreased or absent. SJ, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007535.htm 10006333 Absent or decreased breath sounds can indicate air or fluid around the lungs, increased thickness of chest wall, over-inflation of part of the lungs, or reduced airflow to part of the lungs. breath sounds decreased AE OAE:0002452 a syndrome AE that is characterised by abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death. SJ, YH sudden adult death syndrome (SADS) WEB: http://en.wikipedia.org/wiki/Brugada_syndrome 10059027 Brugada syndrome AE OAE:0002453 Buttock pain AE is a pain AE that is a common problem in the butt, it can be due to bursitis, bruising, piriformis syndrome, and shingles,or due to more serious diseases with long-term consequences, such as cancer, arthritis of the sacroiliac joints, and herniated disc with sciatica. SJ, YH, MW Butt Pain WEB:http://www.medicinenet.com/buttock_pain/symptoms.htm 10048677 buttock pain AE CTCAE:E12396 NCIt:C78228 OAE:0002454 a digestive system AE with an outcome of small white calcium lumps forming under the skin that may leak a chalky white fluid. These lumps are formed becuase of too much calcium in the diet. SJ, YH WEB: http://www.sclero.org/medical/symptoms/skin/calcinosis.html 10006938 These most commonly occur on the hands, or near joints such as elbows or knees, although they may appear anywhere. Calcinosis may range from one very tiny deposit, to large (and often painful) clusters. calcinosis AE OAE:0002455 an infection adverse event that caused by a species of the yeast Candida. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/candidiasis 10007152 This is a common cause of vaginal infections in women. Also, Candida may cause mouth infections in people with reduced immune function, or in patients taking certain antibiotics. Candida can be found in virtually all normal people but causes problems in only a fraction. candidiasis AE OAE:0002456 a hematology investigation result abnormal AE that occurs when the cardaic enzymes and proteins leak out of damaged heart muscle cells, and their levels in the bloodstream rise. SJ, YH URL: http://www.webmd.com/heart-disease/cardiac-enzyme-studies 10007548 cardiac enzymes increased AE may indicate that the heart muscle is injured, such as from a heart attack. cardiac enzymes increased AE OAE:0002457 Acute decompensated heart failure AE is a cardiovascular disorder AE that shows a worsening of the symptoms, typically shortness of breath (dyspnea), edema, and fatigue, in a patient with existing heart disease. SJ, YH Cardiac Failure Acute WEB: http://en.wikipedia.org/wiki/Acute_decompensated_heart_failure 10007556 10064653 acute decompensated heart failure AE OAE:0002459 Cardiac murmur AE is a cardiac disorder AE that is characterised by abnormal sounds during the heartbeat cycle — such as whooshing or swishing — made by turbulent blood in or near the heart. SJ, YH Heart Murmur WEB: http://www.mayoclinic.org/diseases-conditions/heart-murmurs/basics/definition/con-20028706 10007586 cardiac murmur AE OAE:0002460 a behavior and neurological AE that is seen most frequently in schizophrenia, characterized by muscular rigidity and mental stupor, sometimes alternating with great excitement and confusion. YH, SJ WEB: http://dictionary.reference.com/browse/catatonia 10007776 catatonia AE OAE:0002461 a coronary artery disorder AE that results in narrowing of the inner surface of the carotid atery. SJ, YH WEB: http://en.wikipedia.org/wiki/Carotid_artery_stenosis 10007687 carotid artery stenosis AE OAE:0002462 orbital cellulitis AE is a sudden infection of the tissues around the eye, affecting the eyelid, eyebrow, and cheek. SJ, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001012.htm 10007918 orbital cellulitis AE OAE:0002463 Chronic cholecystitis AE the inflammation of the gallbladder persisting for a prolonged period of time or having repeated attacks. SJ, YH WEB: http://www.healthline.com/health/chronic-cholecystitis#Overview1 10008617 chronic cholecystitis AE OAE:0002464 a brain lesion AE is an area of injury or disease within the brain. SJ, YH WEB: http://www.webmd.com/brain/brain-lesions-causes-symptoms-treatments 10051290 brain lesion AE OAE:0002465 Central venous pressure increased AE is a mesaurement of the pressure of the blood within the superior and inferior vena cava and large veins of the body. Increased pressure can be the result of cardiac failure and congestion of circulation. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/central+venous+pressure 10007980 central venous pressure increased AE OAE:0002466 a brain disorder AE occurs when the brain is damaged by injury, disease, or health conditions. SJ, YH WEB: http://www.healthline.com/health/brain-disorders#Overview1 10054938 Brain disorders may affect the main areas of your brain that control how you move, think, and behave. Some tumors can constrict the blood vessels in your brain. brain disorder AE OAE:0002467 a cerebral infarction is a type of ischaemic stroke AE that is caused by a blockage in the blood vessels supplying blood to the brain. SJ WEB: http://en.wikipedia.org/wiki/Cerebral_infarction 10008118 cerebral infarction AE OAE:0002468 a nervous system AE that occurs when the cerebrospinal fluid leaks through a defect in the dura or the skull and out through the nose or ear resulting from a tear in the dura. SJ, YH, MW cerebrospinal fluid leakage AE WEB: http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/brain_tumor/center/skull-base/types/csf-leak.html 10008164 cerebrospinal fluid leak AE CTCAE: E12611 NCIt: C50487 OAE:0002469 a female reproductive system AE that refers to abnormal changes in the cells on the surface of the cervix. The changes are not cancer. But they can lead to cancer of the cervix if not treated. SJ, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001491.htm 10008263 cervical dysplasia AE OAE:0002470 a bone disorder AE that results in pain and neurological symptoms resulting from any type of condition that irritates a nerve in the cervical spine. SJ, YH WEB: http://www.spine-health.com/conditions/neck-pain/what-cervical-radiculopathy 10008303 cervical radiculopathy AE OAE:0002471 Cervical spinal stenosis AE is a nervous system AE that occurs when the spinal canal in the neck narrows. SJ, YH WEB: http://www.webmd.com/back-pain/tc/cervical-spinal-stenosis-topic-overview 10008313 cervical spinal stenosis AE OAE:0002472 a respiratory AE that results in the inability to breath because something gets stuck in the throat or because the air is not good for breathing SJ, YH WEB: http://www.merriam-webster.com/dictionary/choke 10008589 choking AE OAE:0002473 a musculoskeletal and connective tissue AE that results in tlhe disappearance of articular cartilage as the result of disintegration or dissolution of the cartilage matrix and cells. SJ, YH WEB: http://www.medilexicon.com/medicaldictionary.php?t=17184 10058112 chondrolysis AE OAE:0002474 A joint disorder AE in which the cartilage on the undersurface of the patella deteriorates and softens. SJ, YH WEB: http://www.healthline.com/health/chondromalacia-patella#Overview1 10008729 chondromalacia AE OAE:0002475 an adverse event that occurs after a therapeutic intervention YH, JX therapy adverse event OAE:0002477 a seizure AE that resutls in jerking and muscle rigidity, unusual sensations affecting vision, hearing, smell, taste or touch, and memory or emothional disturbances. YH, SJ WEB: http://www.webmd.com/epilepsy/guide/types-of-seizures-their-symptoms?page=2 10040703 simple partial seizure AE OAE:0002478 chemosis AE is a conjunctival disorder AE that results in swelling of the conjunctiva die to exudation of abnormaly permeable capillaries. SJ, YH conjunctival edema WEB: http://en.wikipedia.org/wiki/Chemosis 10053163 chemosis AE OAE:0002480 a behavior and neurological AE that results in the expression of psychlogical stress in physical ways or a mental or emotional crises that begins to have a physical affect. YH, SJ functional neurological symptom disorder WEB: http://www.mayoclinic.org/diseases-conditions/conversion-disorder/basics/definition/con-20029533 10010893 conversion disorder AE OAE:0002481 a cardiac disorder AE which causes a thickening and loss of elasticity of the coronary arteries, leading to progressive insufficiency of the arteries. SJ, YH arteriosclerotic coronary artery disease coronary artery atherosclerosis WEB: http://ghr.nlm.nih.gov/glossary=coronaryarteriosclerosis 10011076 coronary arteriosclerosis AE OAE:0002482 a cardiac disorder AE which causes a partial or complete blockage of the coronary artery which can lead to heart attack. SJ, YH WEB: http://en.wikipedia.org/wiki/Coronary_occlusion 10011086 coronary occlusion AE OAE:0002483 a cardiac disorder AE which results in inflammation and the buildup of plaque which narrow the coronary arteries. SJ, YH WEB: http://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/basics/definition/con-20032038 10011089 coronary artery disease AE OAE:0002484 An joint disorder AE that results in the noise produced by the rubbing together of bone or irregular cartilage surfaces. YH, SJ WEB: http://medical-dictionary.thefreedictionary.com/crepitation 10011376 crepitation AE OAE:0002485 cryptorchidism AE is a male reproductive system AE which results in the absence of one or both testes from the scrotum. YH, SJ undescended testis WEB: http://en.wikipedia.org/wiki/Cryptorchidism 10011498 cryptorchidism AE OAE:0002486 CSF glucose is proportional to blood glucose levels which correspond to 60-70% of the concentration in blood. SJ, YH hypoglycorrhachia 10011537 decreased CSF glucose AE can be caused by CNS infections, inflammatory conditions, subarachnoid hemorrhage, hypoglycemia, impaired glucose transport, increased CNS glycolytic activity and metastatic carcinoma. decreased CSF glucose AE OAE:0002487 wound culture positive AE is a a test to find and identify germs that may be growing on the skin or in a wound. If something that can cause infection grows, the culture is positive. The type of organisms may be identified with a microscope, chemical tests, or both. SJ, YH WEB: http://www.webmd.com/a-to-z-guides/skin-and-wound-cultures 10011643 wound culture positive AE OAE:0002488 skin cyst AE is a skin AE that occurs when a cluster of cells that have grouped together to form a sac which may contain air, fluids, or semi-solid material. YH, SJ cyst WEB: http://en.wikipedia.org/wiki/Cyst 10011732 skin cyst AE OAE:0002489 conductive hearing loss AE is a hearing loss AE that results from probelms with the ear canal, ear drum, or middle ear and its little bones. SJ, YH sensorineural hearing loss (SNHL) WEB: http://www.hearingloss.org/content/types-causes-and-treatment 10010282 conductive hearing loss AE OAE:0002490 transient hearing loss AE is a hearing loss AE that results from poor ventilation of the middle ear in children. SJ, YH deafness transitory WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139416/ 10011900 transient hearing loss AE OAE:0002491 a psychiatric disorder AE that results in a persistent false psychotic belief regarding the self or objects outside the self that is maintained despite indisputable evidence to the contrary. SJ, YH WEB: http://www.merriam-webster.com/dictionary/delusion 10012239 delusion AE OAE:0002492 a behavioral and neurological AE that results in long-standing need for the person to be taken care of and a fear of being abandoned or separated from important individuals. SJ, YH WEB: http://psychcentral.com/disorders/dependent-personality-disorder-symptoms/ 10012355 Individuals with Dependent Personality Disorder are often characterized by pessimism and self-doubt, and tend to belittle their abilities and assets. This leads the person to engage in dependent and submissive behaviors that are designed to elicit care-giving behaviors in others. dependent personality disorder AE OAE:0002493 Nervous system AE that results in failure to meet certain developmental milestones, such as sitting, walking, and talking, at the average age. Developmental delay may indicate a problem in development of the central nervous system. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/developmental+delay 10012559 developmental delay AE OAE:0002494 diabetic ketoacidosis AE is a cardiovascular AE that develops when your body is unable to produce enough insulin and begins to break down fat as an alternate fuel, this process produces a buildup of toxic acids in the bloodstream called ketones. SJ, YH WEB: http://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/basics/definition/con-20026470 10012671 diabetic ketoacidosis AE OAE:0002496 congenital diaphragmatic hernia AE is a congential disorder in which an absent or partially formed diaphragm results in an abnormal opening that allows the stomach and intestines to move into the chest cavity and crowd the heart and lungs. This crowding can lead to underdevelopment of the lungs, potentially resulting in life-threatening breathing difficulties that are apparent from birth. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/aspiration 10061106 congenital diaphragmatic hernia AE OAE:0002497 a paralysis AE that has an outcome of paralysis affecting symmetrical parts of the body. SJ, YH WEB: http://en.wikipedia.org/wiki/Diplegia 10013033 diplegia AE OAE:0002498 cystitis interstitial AE is a cystitis AE that has an outcome of cystitis interstitial, which is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/interstitialcystitis.html 10011796 cystitis interstitial AE OAE:0002499 A disseminated tuberculosis AE is a tuberculosis AE that has an outcome of disseminated tuberculosis, which is a contagious bacterial infection in which TB bacteria has spread from the lungs to other parts of the body through the blood or lymph system. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000624.htm 10013453 disseminated tuberculosis AE OAE:0002500 Exotosis AE is a bone pain AE that has resulted in a non-neoplastic overgrowth of bone. KM, YH WEB: http://en.wikipedia.org/wiki/Exostosis 10015688 exotosis AE OAE:0002501 An exudative retinopathy AE is an eye AE that shows an outcome of exudative retinopathy marked by masses of white or yellowish exudate in the posterior part of the fundus oculi, with deposits of cholesterol and blood debris from retinal hemorrhage, that leads to destruction of the macula and blindness. KM, YH Coats' disease, Coats' retinitis WEB: http://medical-dictionary.thefreedictionary.com/exudative+retinopathy 10015901 exudative retinopathy AE OAE:0002502 A tendon disorder AE that has an outcome of tendinous which is damage to a tendon at a cellular level. It is thought to be caused by microtears in the connective tissue in and around the tendon, leading to an increase in tendon repair cells. KM, YH WEB: http://en.wikipedia.org/wiki/Tendinosis 10016662 tendinous AE OAE:0002503 A monocyte percentage abnormal AE that results in abnormally high levels of monocytes in the blood. KM, YH WEB: http://en.wikipedia.org/wiki/Monocytosis 10027906 monocytosis AE NCIT: C35147 OAE:0002504 A male reproductive system AE that has an outcome of genital candidiasis, which is a fungal infection due to any types of Candida (types of yeasts). This is a fungal infection of the genital region. KM, YH WEB: http://en.wikipedia.org/wiki/Candidiasis WEB: http://www.cdc.gov/fungal/diseases/candidiasis/genital/ 10018143 genital candidiasis AE OAE:0002505 KM, YH WEB: http://www.webmd.com/pain-management/tc/groin-problems-and-injuries-topic-overview 10018735 A groin pain AE is a pain AE that shows a pain in the groin area. groin pain AE OAE:0002506 A blood disorder AE that has an outcome of the breakdown of red blood cells. KM, YH hemolysis WEB: http://www.nlm.nih.gov/medlineplus/ency/article/002372.htm 10018910 haemolysis AE OAE:0002507 A hepatosplenomegaly AE is a liver inflammation AE that has an outcome of an abnormal enlargement of the liver and spleen. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/imagepages/17215.htm WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=3716 10019847 hepatosplenomegaly AE OAE:0002508 A gastric disorder AE that occurs when part of your stomach pushes upward through your diaphragm. KM, YH WEB: http://www.mayoclinic.org/diseases-conditions/hiatal-hernia/basics/definition/con-20030640 10020028 hiatus hernia AE OAE:0002509 A viral infection AE that is caused by the human immunodeficiency virus. KM, YH 10020161 HIV infection AE NCIT: C3108 OAE:0002510 A hypertonic bladder AE is a digestive system AE that where the bladder-storage function that causes a sudden urge to urinate. SJ, YH irritable bladder overactive bladder WEB: http://healbladder.info/healbladder/hypertonic-bladder WEB: http://www.mayoclinic.org/diseases-conditions/overactive-bladder/basics/definition/con-20027632 10020853 hypertonic bladder AE OAE:0002511 A hypovitaminosis AE is a gustatory system AE which shows an insufficiency of one or more essential vitamins. KM, YH WEB: http://en.wikipedia.org/wiki/Hypovitaminosis 10021135 hypovitaminosis AE OAE:0002512 A gastrointestinal disorder AE that shows the inflammation of the ileum. KM, YH WEB: http://en.wikipedia.org/wiki/Ileitis 10021312 ileitis AE NCIT: C84782 OAE:0002513 A joint pain AE that occurs when there is an abnormal separation in the joint, where two or more bones meet. KM, YH dislocated joint, luxation WEB: http://en.wikipedia.org/wiki/Joint_dislocation 10023204 joint dislocation AE OAE:0002514 A syndrome AE that shows Kawasaki's disease, a vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling. KM, YH Mucocutaneous Lymph Node Syndrome WEB: http://en.wikipedia.org/wiki/Kawasaki_disease 10023320 kawasaki disease AE NCIT: C34825 OAE:0002515 An abscess AE where a bacterial, parasitic, or fungal abscess that develops in the liver. It is usually the result of an abdominal infection, trauma, or surgery in the right upper quadrant. Signs and symptoms include abdominal pain, nausea, vomiting, and fever. KM, YH WEB: http://en.wikipedia.org/wiki/Liver_abscess 10024652 liver abscess AE NCIT: C99089 OAE:0002516 A blood disorder AE that the body's blood supply will stop moving after the heart has stopped pumping it around the inside of the deceased. KM, YH WEB: http://www.exploreforensics.co.uk/rigor-mortis-and-lividity.html 10024728 lividity AE OAE:0002517 A lymphangitis AE is an inflammation AE that has an infection of the lymph vessels (channels). KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007296.htm 10025226 lymphangitis AE OAE:0002518 An infection adverse event that results in malaria, a protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia. KM, YH WEB: http://en.wikipedia.org/wiki/Malaria 10025487 malaria AE NCIT: C34797 OAE:0002519 A metabolic disoder AE where there is increased acidity in the blood secondary to acid base imbalance. Causes include diabetes, kidney failure and shock. KM, YH Acidosis WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000335.htm 10027417 metabolic acidosis AE NCIT: C28228 OAE:0002520 An abnormal stool AE that has an outcome of a significant amount of mucus in the stool. The mucus is accompanied by diarrhea, pain or blood may signify an intestinal condition such as infection or inflammation. Increased amounts of mucus in the stool can also occur with cancers of the colon or rectum or with bowel obstruction. KM, YH WEB: http://www.healthgrades.com/symptoms/mucus-in-stool 10028140 mucous stool AE OAE:0002521 A muscle spasm AE that has an outcome of tight or stiff muscles and an inability to control those muscles. KM, YH, MW, MW spasticity AE WEB: http://www.webmd.com/pain-management/pain-management-spasticity 10028335 10041416 muscle spasticity AE CTCAE: E12820 NCIt: C79750 OAE:0002522 A respiratory distress AE that has an outcome of a newborn dyspnea (i.e., impaired breathing) with cyanosis, most frequently occurring in premature infants, children of diabetic mothers and infants delivered by cesarean section, and sometimes with no predisposing cause. KM, YH Newborn Respiratory Distress Syndrome WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001563.htm 10001052 neonatal respiratory distress AE NCIT: C27560 OAE:0002523 A neutrophil count increased AE that has an outcome of an abnormally high level of neutrophils in the blood. KM, YH WEB: http://en.wikipedia.org/wiki/Neutrophilia 10029379 neutrophilia AE NCIT: C35164 OAE:0002524 A male reproductive system AE that results in an inflammation of one or both testes due to viral or bacterial infections. Signs and symptoms include enlargement or tenderness of the affected testis, inguinal lymphadenopathy, blood in the semen, and pain during urination, intercourse, or ejaculation. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001280.htm 10031064 orchitis AE NCIT: C97145 OAE:0002525 an inflammation AE that occurs in a bone. KM, YH Osteitis fibrosa WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001252.htm 10031149 osteitis AE OAE:0002526 A bone disorder AE that has an dissolution of bone, especially the removal or loss of the calcium of bone. KM, YH WEB: http://en.wikipedia.org/wiki/Osteolysis 10031248 osteolysis AE NCIT: C50681 OAE:0002527 An arrhythmia AE that has an outcome of palpitations, an abnormality of heartbeat characterized by simultaneous awareness of one’s pulse and discomfort. KM, YH WEB: http://en.wikipedia.org/wiki/Palpitations 10033557 palpitations AE CTCAE: E10163 NCIt: C37999 OAE:0002528 A skin AE that shows a solid, raised spot on the skin that is up to 0.5 centimeter wide, which is a type of skin lesion. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003233.htm 10033733 papule AE OAE:0002529 A parotid gladn enlargement AE that has an outcome of parotitis, the inflammation of one or more of the parotid glands. KM, YH WEB: http://emedicine.medscape.com/article/882461-overview WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001041.htm 10034038 parotitis AE OAE:0002530 A male reproductive system AE that has an disorder in a penis, including priapism, Peyronie's disease, balanitis, phimosis, paraphimosis, and penile cancer. KM, YH WEB: http://www.medicinenet.com/penis_disorders/article.htm 10034336 penis disorder AE OAE:0002531 An abdominal AE that shows an inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs. KM, YH WEB: http://en.wikipedia.org/wiki/Peritonitis 10034674 peritonitis AE NCIT: C26849 OAE:0002533 An arthritis AE that has an outcome of polyarthritis, which includes any type of arthritis that involves 5 or more joints simultaneously. KM, YH WEB: http://en.wikipedia.org/wiki/Polyarthritis 10036030 polyarthritis AE OAE:0002534 A male reproductive system AE that affects prostatic gland in the male reproductive system. KM, YH WEB: http://www.britannica.com/EBchecked/topic/479519/prostatic-disorder 10036956 prostatic disorder AE OAE:0002535 A tumor AE that shows a benign disorder of lymphoid cells or histiocytes that produces clinical features of a malignant lymphoma. KM, YH WEB: http://medical-dictionary.thefreedictionary.com/pseudolymphoma 10037108 pseudo lymphoma AE OAE:0002536 A skin AE that shows a pyogenic skin disease. These include superficial bacterial infections such as impetigo, impetigo contagiosa, ecthyma, folliculitis, Bockhart's impetigo, furuncle, carbuncle, tropical ulcer, etc. KM, YH WEB: http://en.wikipedia.org/wiki/Pyoderma 10037632 pyoderma AE OAE:0002537 A urine abnormality AE that shows the presence of white blood cells or pus in the urine, usually a sign of urinary tract infection. KM, YH WEB: http://en.wikipedia.org/wiki/Pyuria WEB: http://medical-dictionary.thefreedictionary.com/pyuria 10037686 pyuria AE OAE:0002538 a blood sodium abnormal AE that is characterized by an abnormally high level of sodium in the blood YH, MW hypernaetremia WEB: http://emedicine.medscape.com/article/241094-overview 10020679 10020680 hypernatremia AE CTCAE: E12293 HPO: HP_0003228 NCIt: C37970 SIDER: C0595878 OAE:0002539 A rash AE that shows a rash like measles. The rash consists of macular lesions that are red and usually 2–10 mm in diameter but may be confluent in places. KM, YH measles-like maculopapular rash AE WEB: http://en.wikipedia.org/wiki/Morbilliform WEB: http://www.wisegeek.com/what-is-a-morbilliform-rash.htm 10037870 morbilliform rash AE OAE:0002540 A rash AE that shows a raised, blistery rash. KM, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=11955 10037898 vesicular rash AE OAE:0002541 A red blood cell count increased AE that has an increased count of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003637.htm 10038792 reticulocyte count increased AE OAE:0002542 a behavior and neurological AE that results in impaired or inhibited ego functioning in which the ability to process reality-based information is diminished and disordered. SJ, YH WEB: http://medical-dictionary.thefreedictionary.com/acute+psychosis 10001022 acute psychosis AE OAE:0002543 An eye AE that shows an abnormal blood vessel development in the retina of the eye and it occurs in infants that are born too early. KM, YH Terry syndrome retrolental fibroplasia retrolental fibroplasia (RLF) WEB: http://en.wikipedia.org/wiki/Retinopathy_of_prematurity WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001618.htm 10038933 retinopathy of prematurity AE OAE:0002544 A skin AE that results in a scar, a mark left on the skin. KM, YH WEB: http://en.wikipedia.org/wiki/Scar 10039580 scar AE NCIT: C34483 OAE:0002545 A skin AE that has an outcome of a localized or systemic chronic and progressive autoimmune disorder characterized by thickening of the skin and the connective tissues. KM, YH WEB: http://en.wikipedia.org/wiki/Scleroderma 10039710 Localized scleroderma affects only the skin. Systemic scleroderma affects internal organs, including the heart, lungs, gastrointestinal tract, and kidneys. scleroderma AE NCIT: C26746 OAE:0002546 A male reproductive system AE that has an outcome of an abnormal enlargement of the scrotum, the sac surrounding the testicles. KM, YH scrotal edema scrotal swelling WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003161.htm 10039755 scrotal oedema AE OAE:0002547 A skin AE that results in the degeneration and thinning of the epidermis and dermis. KM, YH, MW atrophy of the skin WEB: http://www.wisegeek.com/what-is-skin-atrophy.htm 10040799 skin atrophy AE CTCAE:E13714 NCIT: C35163 NCIt:C35163 OAE:0002548 A skin discoloration AE that shows the lightening of the skin, or loss of pigment. KM, YH Depigmentation WEB: http://en.wikipedia.org/wiki/Depigmentation 皮肤脱色 10040825 skin depigmentation AE OAE:0002549 A skin discoloration AE that shows abnormal lightening of skin due to decreased melanin production or deposition. KM, YH, MW Hypopigmentation, Pigment Dilution WEB: http://en.wikipedia.org/wiki/Hypopigmentation 10040868 Vitiligo, albinism, and leukoderma are among the disorders that are associated with skin hypopigmentation. skin hypopigmentation AE CTCAE:E13721 NCIt:C78610 http://en.wikipedia.org/wiki/Hypopigmentation OAE:0002550 An immune system disorder AE that has an disorder in spleen, the largest organ in the lymphatic system. KM, YH splenic diseases WEB: http://en.wikipedia.org/wiki/Splenic_disease WEB: http://www.livescience.com/44725-spleen.html 10041633 spleen disorder AE CTCAE: E10056 NCIt: C35823 OAE:0002551 a muscle AE that shows the absence or loss of control of voluntary muscle movements. SJ, YH URL: http://medical-dictionary.thefreedictionary.com/akinesia 10001541 akinesia AE OAE:0002552 a seizure AE that shows a brief episode of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. JX, YH epilepsy WEB: http://en.wikipedia.org/wiki/Epileptic_seizure 癫痫 epileptic seizure AE OAE:0002553 a cranial neuropathy AE which shows an damage or abnormality to the nerves in the eyes. RR, YH WEB: http://www.allaboutvision.com/conditions/optic-neuritis.htm 10061323 optic neuropathy AE OAE:0002554 an optic neuropathy AE characterized by optic disc swelling, peripapillary and macular hard exudates, and vitreous cells. RR, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/6466175 10060701 neuroretinitis AE OAE:0002555 an optic neuropathy AE characterized by vision loss, optic disc swelling, flame hemorrhages, and cotton-wool exudates. It occurs when blood flow is interrupted to the front (anterior) part of the optic nerve (also called optic nerve head). RR, YH AION WEB: http://emedicine.medscape.com/article/1216891-overview WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ 10068250 anterior ischemic optic neuropathy AE OAE:0002556 a type of anterior ischemic optic neuropathy AE that presents primarily with vision loss, especially upon wakening, and sectorial disc edema. RR, YH WEB: http://emedicine.medscape.com/article/1216891-clinical#a0217 10068249 non-arteritic anterior ischemic optic neuropathy AE OAE:0002557 a peripheral neuropathy AE that shows a combination of axonal and demyelinating neuropathy. RR, YH WEB: http://www.aafp.org/afp/2010/0401/p887.html mixed neuropathy AE OAE:0002558 a peripheral sensory neuropathy AE that shows neuropathy in many sensory nerves at one time RR, YH WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html sensory peripheral polyneuropathy AE OAE:0002559 a peripheral neuropathy AE that results from the loss of the myelin sheath on peripheral nerves roughly evenly distributed on both sides of the body RR, YH peripheral demyelinating polyneuropathy AE OAE:0002560 a neuropathy AE that shows nerve damage and occurs in a patient with diabetes RR, YH WEB: http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/definition/con-20033336 10012680 diabetic neuropathy AE OAE:0002561 a nervous system AE that is an umbrella term referring to conditions relating to the nervous system, including loss of sensation and paralysis RR, YH WEB: http://en.wikipedia.org/wiki/Functional_neurological_deficit neurological deficit AE OAE:0002562 An abscess AE that is caused by an Staphylococcus aureus infection. KM, YH abscess http://medical-dictionary.thefreedictionary.com/staphylococcal+abscess 10041917 staphylococcal abscess AE OAE:0002563 An eye AE that results in an intermittent or constant misalignment of an eye so that its line of vision is not pointed at the same object. Strabismus is caused by an imbalance in the extraocular muscles which control the positioning of the eyes. KM, YH cross-eyed heterotropia wall-eyed WEB: http://en.wikipedia.org/wiki/Strabismus 10042159 strabismus AE OAE:0002564 A vein discoloration AE that has an outcome of local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes. KM, YH, MW http://en.wikipedia.org/wiki/Telangiectasia 10043189 telangiectasia AE CTCAE:E13740 NCIT: C28194 NCIt:C28194 OAE:0002565 A muscle spasm AE that results in the lack of ability to open the mouth fully due to decreased range of motion of the muscles of mastication. KM, YH, MW WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=40739 10044684 Trismus is a symptom of tetanus. trismus AE CTCAE:E12541 NCIt: C78651 OAE:0002566 A bacterial infection AE with an outcome of thypoid fever, a bacterial infectious disorder caused by the Salmonella typhi bacteria. KM, YH tyhpoid WEB: http://www.webmd.com/a-to-z-guides/typhoid-fever 10045275 Typhoid fever is often contracted by consumption of food or drink contaminated with Salmonella typhi. typhoid fever AE NCIT: C35089 OAE:0002567 a urinary system AE that results in the inflammation (swelling and irritation) of the urethra. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000439.htm 10046480 urethritis AE OAE:0002568 a skin discoloration AE which shows a chronic skin disease characterized by portions of the skin losing their pigment. KM, YH WEB: http://en.wikipedia.org/wiki/Vitiligo 白癫风；白驳风；白斑 10047642 vitiligo AE NCIT: C26915 OAE:0002569 an injury AE that displays a type of injury to flesh or skin caused by heat, electricity, chemicals, friction, or radiation. YH WEB: http://en.wikipedia.org/wiki/Burn 10006634 burn AE CTCAE: E11669 NCIt: C34441 OAE:0002570 a hematopoietic system AE which has a decreased erythrocyte sedimentation rate (ESR). EST is the rate at which red blood cells sediment in a period of one hour. KM, YH ESR erythrocyte sedimentation rate red blood cell sedimentation rate decreased AE Westergren ESR decreased AE http://en.wikipedia.org/wiki/Erythrocyte_sedimentation_rate 10049188 sedimentation rate decreased AE OAE:0002571 a skin AE that has decreased skin turgor which is the skin's ability to change shape and return to normal (elasticity). KM, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003281.htm 10049428 skin turgor decreased AE OAE:0002572 A tumor AE that shows a tumor occuring in the gastrointestinal tract. KM, YH WEB: http://ghr.nlm.nih.gov/condition/gastrointestinal-stromal-tumor 10051066 gastrointestinal stromal tumour AE OAE:0002573 A bacterial infection AE that has the presence of pus in a bacterial infection. KM, YH WEB: http://dermatology.about.com/library/bldeffluctuance.htm 10051723 fluctuance AE OAE:0002574 A bacterial infection AE which is caused by Acinetobacter. KM, YH WEB: http://www.cdc.gov/HAI/organisms/acinetobacter.html 10051894 Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings. acinetobacter infection AE OAE:0002575 an injury AE that breaks the skin or other body tissues. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/woundsandinjuries.html 10052428 wound AE OAE:0002576 a tuberculosis AE which is an invasion of the peritoneum by Mycobacterium tuberculosis. KM, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/21215540 10053583 peritoneal tuberculosis AE OAE:0002577 a tumor AE that shows a benigh tumor of vascular origin usually seen in early childhood. YH WEB: http://radiopaedia.org/articles/haemangioma haemangioma AE OAE:0002578 a vascular disorder AE that has an outcome of the blockage of a blood vessel, usually with a clot. KM, YH WEB: http://en.wikipedia.org/wiki/Vascular_occlusion 10053648 vascular occlusion AE OAE:0002579 a tuberculosis AE that shows an tuberculosis of the joints. KM, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1577591/ 10056367 joint tuberculosis AE OAE:0002580 an arrhythmia AE that shows abnormal heart rhythms that originate in the bottom chambers of the heart called the ventricles. LW, YH WEB: http://my.clevelandclinic.org/services/heart/departments-centers/ventricular-arrhythmia-center 室性心律失常 10047281 ventricular arrhythmia AE CTCAE: E10230 NCIt: C26924 OAE:0002581 A bacterial infection AE that is caused by Salmonella. KM, YH WEB: http://en.wikipedia.org/wiki/Salmonella 10058878 Salmonella AE OAE:0002582 a blood potassium abnormal AE that has a lab test outcome of abnormally lower than normal amount of potassium in the blood YH, MW hypokalemia AE hypopotassaemia AE hypopotassemia AE potassium depletion AE WEB: http://en.wikipedia.org/wiki/Hypokalemia WEB: http://medical-dictionary.thefreedictionary.com/hyperkalemia WEB: http://www.emedicinehealth.com/low_potassium/article_em.htm 血钾过少 10021015 10021018 hypokalaemia AE CTCAE: E12327 NCIt: C37974 OAE:0002583 a necrosis AE, tumor necrosis factor (TNF, tumor necrosis factor alpha, TNFα, cachexin, or cachectin) is a cell signaling protein (adipokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. KM, YH WEB: http://en.wikipedia.org/wiki/Tumor_necrosis_factor_alpha 10059981 alpha tumour necrosis factor AE OAE:0002584 a tumor AE that that is a benign or malignant neoplasm involving the oral cavity and/or the lips. KM, YH WEB: http://www.nlm.nih.gov/medlineplus/oralcancer.html 10061325 oral neoplasm AE NCIT: C8989 OAE:0002585 a cardiac disorder AE that can present clinically as acute pericarditis, pericardial effusion, cardiac tamponade, and constrictive pericarditis. KM, YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878263/ 10061338 pericardial disease AE OAE:0002586 a tumor AE that shows a benign or malignant neoplasm that affects the peritoneal cavity. KM, YH WEB: http://www.webmd.com/cancer/peritoneal-cancer-prognosis-symptoms-treatments 10061344 Representative examples of benign neoplasms include adenomatoid tumor and disseminated peritoneal leiomyomatosis. Representative examples of malignant neoplasms include primary peritoneal carcinoma, metastatic carcinoma to the peritoneum, and malignant mesothelioma. peritoneal neoplasm AE NCIT: C3322 OAE:0002587 an inflammation AE that shows the formation or presence of pus. KM, YH MedDRA: 10061926 WEB: http://medical-dictionary.thefreedictionary.com/purulence purulence AE OAE:0002588 a bacterial infection AE with bacteria of the genus Mycobacterium. KM, YH Mycobacterium Infection WEB: http://www.nlm.nih.gov/medlineplus/mycobacterialinfections.html 10062207 mycobacterial infection AE NCIT: C26831 OAE:0002589 a tumor AE that shows the most common benign spinal neoplasm, often located in the thoracic and lumbar spine, with a peak incidence of occurrence in the fourth to sixth decades. KM, YH WEB: http://radiopaedia.org/articles/vertebral-haemangioma 10065275 spinal haemangioma AE OAE:0002590 a syndrome AE that reuslts in an autosomal recessive combined immunodeficiency syndrome caused by mutations in the RAG-1 and RAG-2 genes. It is characterized by the presence of alopecia, erythroderma, desquamation, lymphadenopathy, and chronic diarrhea. YH: This is also a genetic AE. We will later find a way to link to there. KM, YH WEB: http://en.wikipedia.org/wiki/Omenn_syndrome 10069097 Omenn syndrome AE NCIT: C61240 OAE:0002591 a immune system AE that results in a state in which the immune system's ability to fight infectious disease is compromised or entirely absent. KM, YH WEB: http://en.wikipedia.org/wiki/Immunodeficiency immunodeficiency AE OAE:0002592 a hepatitis AE that resutls in a hepatitis C viral infection. KM, YH HCV WEB: http://en.wikipedia.org/wiki/Hepatitis_C_virus hepatitis C AE NCIT: C14312 OAE:0002593 a blood phosphorus abnormal AE that shows an abnormal blood phosphate level EB 10054823 blood phosphate abnormal AE OAE:0002594 a hematology investigation result abnormal AE that results in an abnormal level of albumin in the blood EB 10005800 blood albumin abnormal AE OAE:0002595 an electrolyte blood lab test abnormal AE that results in an abnormal level of sodium in the blood YH, MW blood carbon dioxide abnormal AE' OAE:0002596 a blood carbon dioxide abnormal AE in which the levels of carbon dioxide in the blood is abnormally high DJ, SS, YH, MW CO2 retention AE hypercapnea AE hypercarbia AE WEB: https://en.wikipedia.org/wiki/Hypercapnia 10020591 hypercapnia AE UMLS CUI: C0020440 OAE:0002599 a rash AE that shows follicular eruptions characterized by papules and pustules resembling acne. YH, MW acneiform eruption AE rash acneiform AE WEB: http://en.wikipedia.org/wiki/Acne_vulgaris WEB: http://en.wikipedia.org/wiki/Acneiform_eruption 10037847 The term "acneiform", literally, refers to an appearance similar to acne. Acne vulgaris (or simply acne) is a long-term skin condition characterized by areas of blackheads, whiteheads, pimples, greasy skin, and possibly scarring. acneiform rash AE CTCAE: E13694 NCIt: C35277 OAE:0002600 A rash AE that is characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. YH WEB: http://www.medaphile.com/medical-dictionary/papulopustular-rash 10069138 Unlike acne, papulopustular rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions. papulopustular rash AE CTCAE: E11491 NCIt: C80119 OAE:0002601 an neuropathy AE that occurs when any of the twelve cranial nerves (nerves that exit from the brain directly) are damaged. MW, YH WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm#types_of_neuropathy 10061096 cranial neuropathy AE OAE:0002602 a cranial neuropathy AE which shows an damage or abnormality to the nerve that carries signals from the inner ear to the brain and is responsible for hearing. MW, YH WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm#types_of_neuropathy auditory neuropathy AE OAE:0002603 a cognitive disorder AE that shows conspicuous changes in cognitive functions. MW, YH 10009845 cognitive disturbance AE CTCAE: E12617 NCIt: C27101 OAE:0002604 an neuropathy AE that is restricted to one nerve or group of nerves, or one area of the body MW, YH WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm#types_of_neuropathy focal neuropathy AE OAE:0002605 a vascular disorder AE that form in a blood vessel a clot (thrombus) that breaks loose and is carried by the blood stream to plug another vessel. MW, YH thromboembolic event AE WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=25032 10043565 thromboembolism AE CTCAE: E13825 OAE:0002606 an injury AE that occurs in the cardiovascular system YH 10007654 cardiovascular injury AE UMLS CUI: C0560570 OAE:0002607 a cardiovascular injury AE that occurs in a heart. YH 10061200 heart injury AE UMLS CUI: C0018805 OAE:0002608 a heart injury AE that shows a laceration or tearing of the myoardium, which is the muscular tissue of the heart. YH WEB: https://en.wikipedia.org/wiki/Myocardial_rupture 10028604 myocardial rupture AE UMLS CUI: C0018813 OAE:0002609 a cardiomyopathy AE that is characterized by a weekened heart caused by the effects of high blood pressure. YH WEB: http://www.freemd.com/hypertensive-cardiomyopathy/overview.htm 10058222 hypertensive cardiomyopathy AE UMLS CUI: C1144799 OAE:0002610 A hypertrophic cardiomyopathy AE where the distortion of normal heart anatomy causes an obstruction of the outflow of blood from the left ventricle of the heart YH ASH HOCM IHSS asymmetric septal hypertrophy idiopathic hypertrophic subaortic stenosis WEB: https://en.wikipedia.org/wiki/Hypertrophic_cardiomyopathy#Obstructive_and_non-obstructive 10020204 hypertrophic obstructive cardiomyopathy AE UMLS CUI: C0007194 OAE:0002611 A hypertrophic cardiomyopathy AE where the distortion of normal heart anatomy does not cause an obstruction of the outflow of blood from the left ventricle of the heart YH Yamaguchi Hypertrophy Yamaguchi Syndrome apical hypertrophic cardiomyopathy idiopathic hypertrophic subaortic stenosis non-obstructive cardiomyopathy WEB: http://medical-dictionary.thefreedictionary.com/cardiomyopathy WEB: https://en.wikipedia.org/wiki/Hypertrophic_cardiomyopathy#Obstructive_and_non-obstructive hypertrophic non-obstructive cardiomyopathy AE OAE:0002612 a cardiovascular investigation result abnormal AE that results in an abnormal result on a test used to evaluate heart function YH WEB: http://www.drsinatra.com/heart-function-tests-to-assess-heart-disease-risk/ WEB: https://en.wikipedia.org/wiki/Cardiology_diagnostic_tests_and_procedures 10058479 cardiac function test abnormal AE UMLS CUI: C0438177 OAE:0002613 a cardiac disorder AE that results in multiple cardiac defects. YH WEB: https://en.wikipedia.org/wiki/Cardiology_diagnostic_tests_and_procedures 10058479 multiple cardiac defects AE UMLS CUI: C0438177 OAE:0002614 an injury and procedural complication AE that results in a blockage of a device. YH 10064685 device occlusion AE UMLS CUI: C1608397 OAE:0002617 a procedural complication AE that occurs after the usage of a medical device. YH device AE device adverse event medical device adverse event OAE:0002618 a skin ulceration AE that has a combined area of ulcers <1 cm and nonblanchable erythema of intact skin with associated warmth or edema MW, YH WEB: http://www.nhs.uk/Conditions/Pressure-ulcers/Pages/Symptoms.aspx Grade 1 skin ulceration AE CTCAE: E13731 OAE:0002619 a skin ulceration AE that has a combined area of ulcers 1 - 2 cm and partial thickness skin loss involving skin or subcutaneous fat MW, YH WEB: http://www.nhs.uk/Conditions/Pressure-ulcers/Pages/Symptoms.aspx Grade 2 skin ulceration AE CTCAE: E13732 OAE:0002620 a skin ulceration AE that has a combined area of ulcers >2 cm and full-thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to fascia MW, YH WEB: http://www.nhs.uk/Conditions/Pressure-ulcers/Pages/Symptoms.aspx Grade 3 skin ulceration AE CTCAE: E13733 OAE:0002621 a skin ulceration AE that has any size ulcer with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures with or without full thickness skin loss MW, YH WEB: http://www.nhs.uk/Conditions/Pressure-ulcers/Pages/Symptoms.aspx Grade 4 skin ulceration AE CTCAE: E13734 OAE:0002622 A dysesthesia AE that shows an uncomfortable persistent sensation in the area of the laryngopharynx. MW, YH 10062667 Laryngopharyngeal dysesthesia AE CTCAE: E13433 NCIt: C78414 OAE:0002623 a hospitalization AE that leads to an intial hospitalization. YH, JX WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm initial hospitalization AE OAE:0002624 a hospitalization AE that leads to a prolonged hospitalization. YH, JX WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm prolonged hospitalization AE OAE:0002625 an adverse event that occurs locally in a certain location. This is different from the systematci adverse event that occurs throughout the systemtic circulation. YH, JX URL: https://en.wikipedia.org/wiki/Adverse_drug_reaction local AE OAE:0002627 a nervous system AE that occurs in the central nervous system JX, YH central nervous system AE OAE:0002628 a nervous system AE that occurs in the area of meninges JX, YH WEB: https://en.wikipedia.org/wiki/Meninges meninges AE OAE:0002629 an inflammation AE which has an outcome of brain inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the brain According to the Vaccine Adverse Event Reporting System (VAERS), 'encephalitis' is an adverse event that was mentioned in 480 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). meninges inflammation AE MP: MP_0001847 OAE:0002630 a mental disorder that has false personal beliefs held contrary to reality, despite contradictory evidence and common sense. MW, YH 10012260 delusions AE CTCAE: E12904 NCIt: C26741 OAE:0002631 an inflammation AE that has an inflammation involving the larynx. MW, YH 10065735 laryngeal inflammation AE CTCAE: E13411 NCIt: C26811 OAE:0002632 a male reproductive system AE that has involvement of the testis. MW, YH 10043306 testicular disorder AE CTCAE: E13215 NCIt: C26890 OAE:0002633 an urinary system AE that has urination at short intervals. MW, YH 10046539 urinary frequency AE CTCAE: E13039 NCIt: C26906 OAE:0002634 a reproduction system inflammation AE that has inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge. MW, YH 10046916 vaginal inflammation AE CTCAE: E13270 NCIt: C26911 OAE:0002635 a cranial neuropathy AE that has involvement of the trigeminal nerve (fifth cranial nerve). MW, YH 10060890 trigeminal nerve disorder AE CTCAE: E12841 NCIt: C26952 OAE:0002636 cranial neuropathy AE that has involvement of the accessory nerve (eleventh cranial nerve). MW, YH 10060929 accessory nerve disorder AE CTCAE: E12573 NCIt: C26953 OAE:0002637 a cranial neuropathy AE that has involvement of the hypoglossal nerve (twelfth cranial nerve). MW, YH 10061212 hypoglossal nerve disorder AE CTCAE: E12692 NCIt: C26954 OAE:0002638 a hemorrhage AE that has bleeding from the pharynx. MW, YH 10055315 pharyngeal hemorrhage AE CTCAE: E13460 NCIt: C26986 OAE:0002639 a distal neuropathy AE that has regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand. MW, YH 10065417 brachial plexopathy AE CTCAE: E12601 NCIt: C27194 OAE:0002640 a cranial neuropathy AE that has involvement of the acoustic nerve (eighth cranial nerve) MW, YH 10000521 acoustic nerve disorder NOS AE CTCAE: E12577 NCIt: C27207 OAE:0002641 a cranial neuropathy AE that has involvement of the olfactory nerve (first cranial nerve). MW, YH 10056388 olfactory nerve disorder AE CTCAE: E12755 NCIt: C27210 OAE:0002642 a cranial neuropathy AE that has involvement of the glossopharyngeal nerve (ninth cranial nerve). MW, YH 10061185 glossopharyngeal nerve disorder AE CTCAE: E12672 NCIt: C27211 OAE:0002643 a cranial neuropathy AE that has involvement of the vagus nerve (tenth cranial nerve). MW, YH 10061403 vagus nerve disorder AE CTCAE: E12845 NCIt: C27591 OAE:0002644 a cranial neuropathy AE that has involvement of the abducens nerve (sixth cranial nerve). MW, YH 10053662 abducens nerve disorder AE CTCAE: E12569 NCIt: C27593 OAE:0002645 a cranial neuropathy AE that has involvement of the facial nerve (seventh cranial nerve). MW, YH 10061457 facial nerve disorder AE CTCAE: E12668 NCIt: C27594 OAE:0002646 a cranial neuropathy AE that has involvement of the oculomotor nerve (third cranial nerve). MW, YH 10053661 oculomotor nerve disorder AE CTCAE: E12751 NCIt: C27598 OAE:0002647 a sensory neuropathy AE that has distortion of sensory perception, resulting in an abnormal and unpleasant sensation. MW, YH 10062872 dysesthesia AE CTCAE: E12639 NCIt: C28246 OAE:0002648 a pain AE that has painful or difficult coitus. MW, YH 10013941 dyspareunia AE CTCAE: E13081 NCIt: C2997 OAE:0002649 a bone disorder AE that has non-neoplastic overgrowth of bone. MW, YH 10015688 exostosis AE CTCAE: E12404 NCIt: C3029 OAE:0002650 an endocrine system AE that has excessive development of the breasts in males. MW, YH 10018801 gynecomastia AE CTCAE: E13115 NCIt: C3073 OAE:0002651 a brain edema AE that has an abnormal increase of cerebrospinal fluid in the ventricles of the brain. MW, YH 10020508 hydrocephalus AE CTCAE: E12682 NCIt: C3111 OAE:0002652 an edema AE that has excessive fluid collection in tissues that causes swelling. MW, YH 10025233 lymphedema AE CTCAE: E13802 NCIt: C3207 OAE:0002653 a menstrual disorder AE that has the permanent cessation of menses, usually defined by 12 consecutive months of amenorrhea in a woman over 45 years of age. MW, YH 10027308 menopause AE CTCAE: E13750 NCIt: C3231 OAE:0002654 a physical examination result abnormal AE that is having a high amount of body fat. MW, YH 10029883 obesity AE CTCAE: E12361 NCIt: C3283 OAE:0002655 a lung inflammation AE that has progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. MW, YH 10001409 adult respiratory distress syndrome AE CTCAE: E13299 NCIt: C3353 OAE:0002656 a cardiovascular AE that has obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache. MW, YH Superior vena cava syndrome AE CTCAE: E13819 NCIt: C3396 OAE:0002657 a menstrual disorder AE that has abnormally painful abdominal cramps during menses. MW, YH 10013934 dysmenorrhea AE CTCAE: E13077 NCIt: C34559 OAE:0002658 a behavior and neurological AE that has an exaggerated feeling of well-being which is disproportionate to events and stimuli. MW, YH 10015533 euphoria AE CTCAE: E12915 NCIt: C34598 OAE:0002659 a pain AE that has marked discomfort sensation on the lateral side of the body in the region below the ribs and above the hip. MW, YH 10016750 flank pain flank pain AE CTCAE: E12414 NCIt: C34615 OAE:0002660 a metabolic disorder AE that has an inability to properly metabolize glucose. MW, YH 10052426 glucose intolerance AE CTCAE: E12264 NCIt: C34646 OAE:0002661 a urine abnormality AE that has laboratory test results that indicate the presence of free hemoglobin in the urine. MW, YH haemoglobinuria AE 10018906 10019489 hemoglobinuria AE CTCAE: E13006 NCIt: C34677 OAE:0002662 a sweating AE that has reduced sweating. MW, YH 10021013 hypohidrosis AE CTCAE: E13652 NCIt: C34718 OAE:0002663 a bone disorder AE that has an abnormal increase in the curvature of the thoracic portion of the spine. MW, YH 10023509 kyphosis AE CTCAE: E12447 NCIt: C34754 OAE:0002664 a bone disorder AE that has an abnormal increase in the curvature of the lumbar portion of the spine. MW, YH 10024842 lordosis AE CTCAE: E12451 NCIt: C34787 OAE:0002665 a male reproductive system AE that has a decrease in the number of spermatozoa in the semen. MW, YH 10030300 oligospermia AE CTCAE: E13141 NCIt: C34860 OAE:0002666 a necrosis AE that has necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure. MW, YH 10066480 avascular necrosis AE CTCAE: E12382 NCIt: C34880 OAE:0002667 an inflammation AE that has inflammation of the skin characterized by the presence of bullae which are filled with fluid. MW, YH 10006556 bullous dermatitis AE CTCAE: E13617 NCIt: C35149 OAE:0002668 a speech disorder AE that has impairment of verbal communication skills, often resulting from brain damage. MW, YH 10013951 dysphasia AE CTCAE: E12646 NCIt: C35546 OAE:0002669 a female reproductive system AE that has a narrowing of the vaginal canal. MW, YH 10053496 vaginal stricture AE CTCAE: E13290 NCIt: C36064 OAE:0002670 a metabolism, endocrine, and exocrine system AE that has abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues. MW, YH 10001680 alkalosis AE CTCAE: E12247 NCIt: C37909 OAE:0002671 a gastrointestinal disorder AE that has repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm. MW, YH 10020039 Hiccups AE CTCAE: E13380 NCIt: C37966 OAE:0002672 an urine abnormality AE that has laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin. MW, YH 10037032 proteinuria AE CTCAE: E13008 NCIt: C38012 OAE:0002673 an inflammation AE that has generalized inflammatory erythema and exfoliation. The inflammatory process involves > 90% of the body surface area. MW, YH 10015277 erythroderma AE CTCAE: E13633 NCIt: C39646 OAE:0002674 a syndrome AE that has dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination. MW, YH 10063636 pyramidal tract syndrome AE CTCAE: E12780 NCIt: C43245 OAE:0002675 a brain edema AE that has swelling due to an excessive accumulation of fluid in the brain. MW, YH 10014217 edema cerebral AE CTCAE: E12650 NCIt: C4909 OAE:0002676 a tumor AE that has development of a malignancy most probably as a result of treatment for a previously existing malignancy. MW, YH 10049737 treatment related secondary malignancy AE CTCAE: E12561 NCIt: C4969 OAE:0002677 a hemorrhage AE that has bleeding from the cranium. MW, YH 10022763 intracranial hemorrhage AE CTCAE: E12696 NCIt: C50438 OAE:0002678 a death AE that has death in utero; failure of the product of conception to show evidence of respiration, heartbeat, or definite movement of a voluntary muscle after expulsion from the uterus, without possibility of resuscitation. MW, YH 10016479 fetal death AE CTCAE: E12855 NCIt: C50620 OAE:0002679 a ischemia AEE that has a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit. MW, YH 10044391 transient ischemic attacks AE CTCAE: E12834 NCIt: C50781 OAE:0002680 afemale reproductive system AE that has vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years. MW, YH 10046901 vaginal discharge AE CTCAE: E13251 NCIt: C50795 OAE:0002681 a sensory capability AE that has a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve. MW, YH 10047166 vasovagal reaction AE CTCAE: E12851 NCIt: C50798 OAE:0002682 apregnancy AE that has delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation. MW, YH 早产 10036595 premature delivery AE CTCAE: E12867 NCIt: C50917 OAE:0002683 a psychiatric disorder AE that has excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood. MW, YH 10026749 mania AE CTCAE: E12936 NCIt: C61374 OAE:0002684 a hair growth abnormal AE that has the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen) MW, YH 10020112 hirsutism AE CTCAE: E13642 NCIt: C61444 OAE:0002685 a necrosis AE that has a necrotic process occurring in the bone of the mandible. MW, YH 10064658 osteonecrosis of jaw AE CTCAE: E12502 NCIt: C63924 OAE:0002686 a necrosis AE that has a necrotic process occurring in the soft tissues of the abdominal wall. MW, YH 10065775 abdominal soft tissue necrosis AE CTCAE: E12369 NCIt: C78165 OAE:0002687 a metabolic disorder AE that has an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches. MW, YH 10001598 alcohol intolerance AE CTCAE: E12242 NCIt: C78167 OAE:0002688 a psychiatric disorder AE that has an inability to achieve orgasm. MW, YH 10002652 anorgasmia AE CTCAE: E12880 NCIt: C78177 OAE:0002689 an urinary system AE that has a rupture in the bladder wall. MW, YH 10063575 bladder perforation AE CTCAE: E12979 NCIt: C78208 OAE:0002690 an urinary system AE that has a sudden and involuntary contraction of the bladder wall. MW, YH 10048994 bladder spasm AE CTCAE: E12984 NCIt: C78210 OAE:0002691 a hemorrhage AE that is bleeding from the bronchial wall and/or lung parenchyma. MW, YH 10065746 bronchopulmonary hemorrhage AE CTCAE: E13346 NCIt: C78224 OAE:0002692 a respiratory system AE that has blockage of a bronchus passage, most often by bronchial secretions and exudates. MW, YH 10006440 bronchial obstruction AE CTCAE: E13328 NCIt: C78225 OAE:0002693 a respiratory system AE that has a narrowing of the bronchial tube. MW, YH 10063524 bronchial stricture AE CTCAE: E13334 NCIt: C78226 OAE:0002694 a necrosis AE that has a necrotic process occurring in the brain and/or spinal cord. MW, YH 10065784 central nervous system necrosis AE CTCAE: E12605 NCIt: C78236 OAE:0002695 a pain AE that has marked discomfort sensation in the chest wall region. MW, YH 10008496 chest wall pain AE CTCAE: E12400 NCIt: C78238 OAE:0002696 a cystitis AE that has inflammation of the bladder which is not caused by an infection of the urinary tract. MW, YH 10063057 cystitis noninfective AE CTCAE: E12994 NCIt: C78250 OAE:0002697 a psychiatric disorder AE that has sexual dysfunction characterized by a delay in climax. MW, YH 10057066 delayed orgasm AE CTCAE: E12895 NCIt: C78252 OAE:0002698 a male reproductive system AE that has problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation. MW, YH 10014326 ejaculation disorder AE CTCAE: E13085 NCIt: C78264 OAE:0002699 a muscular weakness AE that has a reduction in the strength of the facial muscles. MW, YH 10051272 facial muscle weakness AE CTCAE: E12664 NCIt: C78290 OAE:0002700 a female reproductive system AE that has blockage of the normal flow of the contents in the fallopian tube. MW, YH 10065789 fallopian tube obstruction AE CTCAE: E13092 NCIt: C78293 OAE:0002701 a female reproductive system AE that has a narrowing of the fallopian tube lumen. MW, YH 10065791 fallopian tube stenosis AE CTCAE: E13096 NCIt: C78295 OAE:0002702 a connective tissue disorder AE that has shrinking of adipose tissue. MW, YH 10016241 fat atrophy AE CTCAE: E13638 NCIt: C78297 OAE:0002703 a fistula AE that has an abnormal communication between a female reproductive system organ and another organ or anatomic site. MW, YH 10061149 female genital tract fistula AE CTCAE: E13102 NCIt: C78298 OAE:0002704 an endocrine system AE that has the development of secondary female sex characteristics in males due to extrinsic factors. MW, YH 10054382 feminization acquired AE CTCAE: E13108 NCIt: C78299 OAE:0002705 a connective tissue disorder AE that has fibrotic degeneration of the deep connective tissues. MW, YH 10065799 fibrosis deep connective tissue AE CTCAE: E12408 NCIt: C78301 OAE:0002706 a muscular weakness AE that has a reduction in the strength of muscles in multiple anatomic sites. MW, YH 10062572 generalized muscle weakness AE CTCAE: E12418 NCIt: C78323 OAE:0002707 a musculoskeletal and connective tissue AE that has stature that is smaller than normal as expected for age. MW, YH 10018761 growth suppression AE CTCAE: E12422 NCIt: C78328 OAE:0002708 a necrosis AE that has a necrotic process occurring in the soft tissues of the head. MW, YH 10065779 head soft tissue necrosis AE CTCAE: E12426 NCIt: C78331 OAE:0002709 a female reproductive system AE that has the presence of blood in a fallopian tube. MW, YH 10060602 hematosalpinx AE CTCAE: E13119 NCIt: C78332 OAE:0002710 a sleep disorder AE that has characterized by excessive sleepiness during the daytime. MW, YH 10020765 hypersomnia AE CTCAE: E12688 NCIt: C78346 OAE:0002711 a homeostasis AE that has accumulation of iron in the tissues. MW, YH 10065973 iron overload AE CTCAE: E12350 NCIt: C78393 OAE:0002712 an ischemia AE that has a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage. MW, YH 10023030 ischemia cerebrovascular AE CTCAE: E12702 NCIt: C78394 OAE:0002713 a cranial neuropathy AE that has involvement of the trochlear nerve (fourth cranial nerve). MW, YH 10065836 IVth nerve disorder AE CTCAE: E12705 NCIt: C78395 OAE:0002714 a joint disorder AE that has a decrease in flexibility of a cervical spine joint. MW, YH 10065796 joint range of motion decreased cervical spine AE CTCAE: E12439 NCIt: C78404 OAE:0002715 a joint disorder AE that has a decrease in flexibility of a lumbar spine joint. MW, YH 10065800 joint range of motion decreased lumbar spine AE CTCAE: E12443 NCIt: C78405 OAE:0002716 a fistula AE that has an abnormal communication between the larynx and another organ or anatomic site. MW, YH 10065786 laryngeal fistula AE CTCAE: E13399 NCIt: C78410 OAE:0002717 a hemorrhage AE that has bleeding from the larynx. MW, YH 10065759 laryngeal hemorrhage AE CTCAE: E13405 NCIt: C78411 OAE:0002718 an inflammation AE that has an inflammation involving the mucous membrane of the larynx. MW, YH 10065880 laryngeal mucositis AE CTCAE: E13415 NCIt: C78412 OAE:0002719 a respiratory system AE that has blockage of the laryngeal airway. MW, YH 10059639 laryngeal obstruction AE CTCAE: E13421 NCIt: C78413 OAE:0002720 a libido disorder AE that has a decrease in sexual desire. MW, YH 10024419 libido decreased AE CTCAE: E12929 NCIt: C78432 OAE:0002721 a libido disorder AE that has an increase in sexual desire. MW, YH 10024421 libido increased AE CTCAE: E12932 NCIt: C78433 OAE:0002722 a skin AE that has hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin. MW, YH 10062315 lipohypertrophy AE CTCAE: E13657 NCIt: C78436 OAE:0002723 an immune system AE that has the loss of lymph fluid into the surrounding tissue or body cavity. MW, YH 10065773 lymph leakage AE CTCAE: E13797 NCIt: C78439 OAE:0002724 an immune system AE that has a cystic lesion containing lymph. MW, YH 10048642 lymphocele AE CTCAE: E13806 NCIt: C78442 OAE:0002725 a hemorrhage AE that has bleeding from the mediastinum. MW, YH 10056356 mediastinal hemorrhage AE CTCAE: E13444 NCIt: C78443 OAE:0002726 a movement disorder AE that has uncontrolled and purposeless movements. MW, YH 10028041 movements involuntary AE CTCAE: E12728 NCIt: C78453 OAE:0002727 a muscular weakness AE that has a reduction in the strength of the muscles on the left side of the body. MW, YH 10065780 muscle weakness left-sided AE CTCAE: E12455 NCIt: C78455 OAE:0002728 a muscular weakness AE that has a reduction in the strength of the lower limb muscles. MW, YH 10065776 muscle weakness lower limb AE CTCAE: E12459 NCIt: C78456 OAE:0002729 a muscular weakness AE that has a reduction in the strength of the muscles on the right side of the body. MW, YH 10065794 muscle weakness right-sided AE CTCAE: E12463 NCIt: C78457 OAE:0002730 a muscular weakness AE that has a reduction in the strength of the trunk muscles. MW, YH 10065795 muscle weakness trunk AE CTCAE: E12467 NCIt: C78458 OAE:0002731 a muscular weakness AE that has a reduction in the strength of the upper limb muscles. MW, YH 10065895 muscle weakness upper limb AE CTCAE: E12471 NCIt: C78459 OAE:0002732 a musculoskeletal and connective tissue AE that has a malformation of the musculoskeletal system. MW, YH 10065783 musculoskeletal deformity AE CTCAE: E12481 NCIt: C78488 OAE:0002733 a nail AE that has a change in the color of the nail plate. MW, YH 10028691 nail discoloration AE CTCAE: E13661 NCIt: C78492 OAE:0002734 a nail AE that has loss of all or a portion of the nail. MW, YH 10049281 nail loss AE CTCAE: E13663 NCIt: C78494 OAE:0002735 a nail AE that has vertical or horizontal ridges on the nails. MW, YH 10062283 nail ridging AE CTCAE: E13666 NCIt: C78499 OAE:0002736 a necrosis AE that has a necrotic process occurring in the soft tissues of the neck. MW, YH 10065781 neck soft tissue necrosis AE CTCAE: E12497 NCIt: C78502 OAE:0002737 a female reproductive system AE that has a malformation of the nipple. MW, YH 10065823 nipple deformity AE CTCAE: E13138 NCIt: C78503 OAE:0002738 a hemorrhage AE that has bleeding from the ovary. MW, YH 10065763 ovarian hemorrhage AE CTCAE: E13145 NCIt: C78511 OAE:0002739 a female reproductive system AE that is tearing or disruption of the ovarian tissue. MW, YH 10033279 ovarian rupture AE CTCAE: E13151 NCIt: C78513 OAE:0002740 a pain AE that has marked discomfort sensation in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle. MW, YH 10033314 ovulation pain AE CTCAE: E13157 NCIt: C78514 OAE:0002741 a muscular weakness AE that has a reduction in the strength of the muscles of the pelvic floor. MW, YH 10064026 pelvic floor muscle weakness AE CTCAE: E13161 NCIt: C78524 OAE:0002742 a necrosis AE that has a necrotic process occurring in the soft tissues of the pelvis. MW, YH 10065793 pelvic soft tissue necrosis AE CTCAE: E12516 NCIt: C78525 OAE:0002743 a pain AE that has marked discomfort sensation in the penis. MW, YH 10034310 penile pain AE CTCAE: E13171 NCIt: C78527 OAE:0002744 a psychiatric disorder AE that has a conspicuous change in a person's behavior and thinking. MW, YH 10034719 personality change AE CTCAE: E12942 NCIt: C78548 OAE:0002745 a fistula AE that has an abnormal communication between the pharynx and another organ or anatomic site. MW, YH 10034825 pharyngeal fistula AE CTCAE: E13454 NCIt: C78551 OAE:0002746 an inflammation AE that has an inflammation involving the mucous membrane of the pharynx. MW, YH 10065881 pharyngeal mucositis AE CTCAE: E13466 NCIt: C78553 OAE:0002747 a necrosis AE that has a necrotic process occurring in the pharynx. MW, YH 10065706 pharyngeal necrosis AE CTCAE: E13472 NCIt: C78554 OAE:0002748 a respiratory system AE that has a narrowing of the pharyngeal airway. MW, YH 10050028 pharyngeal stenosis AE CTCAE: E13476 NCIt: C78555 OAE:0002749 a hemorrhage AE that has bleeding from the prostate gland. MW, YH 10055325 prostatic hemorrhage AE CTCAE: E13181 NCIt: C78572 OAE:0002750 a prostatic disorder AE that has compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder). MW, YH 10055026 prostatic obstruction AE CTCAE: E13187 NCIt: C78573 OAE:0002751 a pain AE that has a sensation of marked discomfort in the prostate gland. MW, YH 10036968 prostatic pain AE CTCAE: E13191 NCIt: C78574 OAE:0002752 a psychiatric disorder AE that has personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor. MW, YH 10037234 psychosis AE CTCAE: E12954 NCIt: C78576 OAE:0002753 a fistula AE that has an abnormal communication between the lung and another organ or anatomic site. MW, YH 10065873 pulmonary fistula AE CTCAE: E13533 NCIt: C78577 OAE:0002754 an inflammation AE that has inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root. MW, YH 10061928 radiculitis AE CTCAE: E12786 NCIt: C78581 OAE:0002755 a recurrent alsy AE that occurs at the laryngeal nerve. MW, YH 10038130 recurrent laryngeal nerve palsy AE CTCAE: E12792 NCIt: C78592 OAE:0002756 a renal calculus AE that has paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of kidney stones. MW, YH 10038419 renal colic AE CTCAE: E13024 NCIt: C78593 OAE:0002757 a hemorrhage AE that has bleeding from the kidney. MW, YH 10038463 renal hemorrhage AE CTCAE: E13028 NCIt: C78594 OAE:0002758 a syndrome AE that has weight gain, dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans retinoic acid. MW, YH 10038921 retinoic acid syndrome AE CTCAE: E13554 NCIt: C78597 OAE:0002759 a bone disorder AE that has a malformed, lateral curvature of the spine. MW, YH 10039722 scoliosis AE CTCAE: E12521 NCIt: C78603 OAE:0002760 a pain AE that has marked discomfort sensation in the scrotal area. MW, YH 10039757 scrotal pain AE CTCAE: E13201 NCIt: C78607 OAE:0002761 a pain AE that has marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses. MW, YH 10040747 sinus pain AE CTCAE: E12810 NCIt: C78609 OAE:0002762 an induration AE that has an area of hardness in the skin. MW, YH 10051837 skin induration AE CTCAE: E13724 NCIt: C78611 OAE:0002763 a necrosis AE that has a necrotic process occurring in the soft tissues of the lower extremity. MW, YH 10065777 soft tissue necrosis lower limb AE CTCAE: E12525 NCIt: C78620 OAE:0002764 a necrosis AE that has a necrotic process occurring in the soft tissues of the upper extremity. MW, YH 10065778 soft tissue necrosis upper limb AE CTCAE: E12530 NCIt: C78621 OAE:0002765 a hemorrhage AE that has bleeding from the spermatic cord. MW, YH 10065762 spermatic cord hemorrhage AE CTCAE: E13205 NCIt: C78623 OAE:0002766 a male reproductive system AE that has blockage of the normal flow of the contents of the spermatic cord. MW, YH 10065805 spermatic cord obstruction AE CTCAE: E13211 NCIt: C78624 OAE:0002767 a connective tissue disorder AE that has fibrotic degeneration of the superficial soft tissues. MW, YH 10065798 superficial soft tissue fibrosis AE CTCAE: E12535 NCIt: C78633 OAE:0002768 a hemorrhage AE that has bleeding from the testis. MW, YH 10055347 testicular hemorrhage AE CTCAE: E13221 NCIt: C78635 OAE:0002769 a pain AE that has a sensation of marked discomfort in the testis. MW, YH 10043345 testicular pain AE CTCAE: E13227 NCIt: C78636 OAE:0002770 a fistula AE that hasan abnormal communication between the trachea and another organ or anatomic site. MW, YH 10065787 tracheal fistula AE CTCAE: E13583 NCIt: C78641 OAE:0002771 an inflammation AE that has an inflammation involving the mucous membrane of the trachea. MW, YH 10065900 tracheal mucositis AE CTCAE: E13589 NCIt: C78644 OAE:0002772 a respiratory system AE that has a narrowing of the trachea. MW, YH 10050816 tracheal stenosis AE CTCAE: E13595 NCIt: C78646 OAE:0002773 a pain AE that has marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis. MW, YH 10045158 tumor pain AE CTCAE: E12565 NCIt: C78656 OAE:0002774 a musculoskeletal and connective tissue AE that hasa discrepancy between the lengths of the lower or upper extremities. MW, YH 10065738 unequal limb length AE CTCAE: E12545 NCIt: C78657 OAE:0002775 an urine abnormality AE that has a change in the color of the urine. MW, YH 10046628 urine discoloration AE CTCAE: E13065 NCIt: C78678 OAE:0002776 a fistula AE that has an abnormal communication between the uterus and another organ or anatomic site. MW, YH 10065811 uterine fistula AE CTCAE: E13231 NCIt: C78685 OAE:0002777 an urinary system AE that has blockage of the uterine outlet. MW, YH 10065928 uterine obstruction AE CTCAE: E13243 NCIt: C78693 OAE:0002778 a pain AE that has a sensation of marked discomfort in the uterus. MW, YH 10046809 uterine pain AE CTCAE: E13247 NCIt: C78694 OAE:0002779 a female reproductive system AE that has an uncomfortable feeling of itching and burning in the vagina. MW, YH 10046904 vaginal dryness AE CTCAE: E13254 NCIt: C78699 OAE:0002780 a female reproductive system AE that has blockage of vaginal canal. MW, YH 10065817 vaginal obstruction AE CTCAE: E13276 NCIt: C78700 OAE:0002781 a pain AE that has a sensation of marked discomfort in the vagina. MW, YH 10046937 vaginal pain AE CTCAE: E13280 NCIt: C78701 OAE:0002782 a female reproductive system AE that has a rupture in the vaginal wall. MW, YH 10065818 vaginal perforation AE CTCAE: E13284 NCIt: C78702 OAE:0002783 a female reproductive system AE that hasinvoluntary spasms of the pelvic floor muscles, resulting in pathologic tightness of the vaginal wall during penetration such as during sexual intercourse. MW, YH 10046947 vaginismus AE CTCAE: E13295 NCIt: C78703 OAE:0002784 an ischemia AE that has a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery. MW, YH 10054692 visceral arterial ischemia AE CTCAE: E13843 NCIt: C78712 OAE:0002785 a skin AE that has an abnormal body smell resulting from the growth of bacteria on the body. MW, YH 10005901 body odor AE CTCAE: E13614 NCIt: C79542 OAE:0002786 a fistula AE that has an abnormal communication between the bronchus and another organ or anatomic site. MW, YH 10006437 bronchial fistula AE CTCAE: E13322 NCIt: C79543 OAE:0002787 a nervous system AE that has an abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness. MW, YH 10015832 extrapyramidal disorder AE CTCAE: E12658 NCIt: C79593 OAE:0002788 a hair growth abnormal AE that has hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race. MW, YH 10020864 hypertrichosis AE CTCAE: E13649 NCIt: C79597 OAE:0002789 a female reproductive system AE that has disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males. MW, YH 10061261 lactation disorder AE CTCAE: E13129 NCIt: C79606 OAE:0002790 a respiratory system AE that has a narrowing of the laryngeal airway. MW, YH 10023862 laryngeal stenosis AE CTCAE: E13427 NCIt: C79608 OAE:0002791 a nervous system AE that has neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges. MW, YH 10027198 meningismus AE CTCAE: E12722 NCIt: C79694 OAE:0002792 a pain AE that has marked discomfort related to a limb or an organ that is removed from or is not physically part of the body. MW, YH 10056238 phantom pain AE CTCAE: E12774 NCIt: C79703 OAE:0002793 a pain AE that has marked discomfort sensation in the skin covering the top and the back of the head. MW, YH 10049120 scalp pain AE CTCAE: E13704 NCIt: C79716 OAE:0002794 a pregnancy AE that has an unexpected pregnancy at the time of conception. MW, YH 10045542 unintended pregnancy AE CTCAE: E12872 NCIt: C79801 OAE:0002795 a urinary tract disoder AE that has blockage of the normal flow of contents of the urinary tract. MW, YH 10061574 urinary tract obstruction AE CTCAE: E13052 NCIt: C79805 OAE:0002796 a fistula AE that has an abnormal communication between the vagina and another organ or anatomic site. MW, YH 10065813 vaginal fistula AE CTCAE: E13258 NCIt: C79847 OAE:0002797 a fistula AE that has an abnormal communication between any part of the urinary system and another organ or anatomic site. MW, YH 10065368 urinary fistula AE CTCAE: E13034 NCIt: C79850 OAE:0002798 a male reproductive system AE that has laboratory test results that indicate complete absence of spermatozoa in the semen. MW, YH 10003883 azoospermia AE CTCAE: E13067 NCIt: C80076 OAE:0002799 a renal failure AE that has gradual and usually permanent loss of kidney function resulting in renal failure. MW, YH 10064848 chronic kidney disease AE CTCAE: E12988 NCIt: C80078 OAE:0002800 a behavior and neurological AE that has a deterioration in the ability to concentrate. MW, YH 10010250 concentration impairment AE CTCAE: E12621 NCIt: C80081 OAE:0002801 a fetal disorder AE that has inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight. MW, YH 10054746 fetal growth retardation AE CTCAE: E12857 NCIt: C80083 OAE:0002802 a menstrual disorder AE that has ovarian failure before the age of 40. Symptoms include hot flashes, night sweats, mood swings and a decrease in sex drive. MW, YH 10036601 premature menopause AE CTCAE: E13179 NCIt: C80099 OAE:0002803 a tumor AE that has leukemia arising as a result of the mutagenic effect of chemotherapy agents. MW, YH 10048293 leukemia secondary to oncology chemotherapy AE CTCAE: E12549 NCIt: C80691 OAE:0002804 a fistula AE that has an abnormal communication between a bronchus and the pleural cavity. MW, YH 10053481 bronchopleural fistula AE CTCAE: E13340 NCIt: C80694 OAE:0002805 a pain AE that has a sensation of marked discomfort in the urinary tract. MW, YH 10062225 urinary tract pain AE CTCAE: E13058 NCIt: C83493 OAE:0002806 a female reproductive system AE that has underdevelopment of the breast. MW, YH 10006179 breast atrophy AE CTCAE: E13069 NCIt: C83494 OAE:0002808 an AE that occurs in an incision site. YH, SS incision site AE OAE:0002810 a hymphedema AE that has trace thickening or faint discoloration YH, MW Grade 1 lymphedema AE CTCAE: E13803 OAE:0002811 a hymphedema AE that has marked discoloration; leathery skin texture; papillary formation; limiting instrumental ADL YH, MW Grade 2 lymphedema AE CTCAE: E13804 OAE:0002812 a superior vena cava syndrome AE that has asymptomatic; incidental finding of SVC thrombosis YH, MW Grade 1 superior vena cava syndrome AE CTCAE: E13820 OAE:0002813 a superior vena cava syndrome AEthat has symptomatic; medical intervention indicated (e.g., anticoagulation, radiation or chemotherapy) YH, MW Grade 2 superior vena cava syndrome AE CTCAE: E13821 OAE:0002814 a superior vena cava syndrome AE that has severe symptoms; multi-modality intervention indicated (e.g., anticoagulation, chemotherapy, radiation, stenting) YH, MW Grade 3 superior vena cava syndrome AE CTCAE: E13822 OAE:0002815 a superior vena cava syndrome AE that has life-threatening consequences; urgent multi-modality intervention indicated (e.g., lysis, thrombectomy, surgery) YH, MW Grade 4 superior vena cava syndrome AE CTCAE: E13823 OAE:0002816 a thromboembolic event AE that has venous thrombosis (e.g., superficial thrombosis) YH, MW Grade 1 thromboembolic event AE CTCAE: E13826 OAE:0002817 a thromboembolic event AE that has venous thrombosis (e.g., uncomplicated deep vein thrombosis), medical intervention indicated YH, MW Grade 2 thromboembolic event AE CTCAE: E13827 OAE:0002818 a thromboembolic event AE that has thrombosis (e.g., uncomplicated pulmonary embolism [venous], non-embolic cardiac mural [arterial] thrombus), medical intervention indicated YH, MW Grade 3 thromboembolic event AE CTCAE: E13828 OAE:0002819 a thromboembolic event AE that has life-threatening (e.g., pulmonary embolism, cerebrovascular event, arterial insufficiency); hemodynamic or neurologic instability; urgent intervention indicated YH, MW Grade 4 thromboembolic event AE CTCAE: E13829 OAE:0002820 a visceral arterial ischemia AE that has brief (<24 hrs) episode of ischemia managed medically and without permanent deficit YH, MW Grade 2 visceral arterial ischemia AE CTCAE: E13844 OAE:0002821 a visceral arterial ischemia AE that has prolonged (>=24 hrs) or recurring symptoms and/or invasive intervention indicated YH, MW Grade 3 visceral arterial ischemia AE CTCAE: E13845 OAE:0002822 a menopause AE that the menopause occurres at age 46 - 53 years of age YH, MW Grade 1 menopause AE CTCAE: E13751 OAE:0002823 a menopause AE that the menopause occurres at age 40 - 45 years of age YH, MW Grade 2 menopause AE CTCAE: E13752 OAE:0002824 a menopause AE that the menopause occurres before age 40 years of age YH, MW Grade 3 menopause AE CTCAE: E13753 OAE:0002825 a body odor AE that has mild odor; physician intervention not indicated; self care interventions YH, MW Grade 1 body odor AE CTCAE: E13615 OAE:0002826 a body odor AE that has pronounced odor; psychosocial impact; patient seeks medical intervention YH, MW Grade 2 body odor AE CTCAE: E13616 OAE:0002827 a bullous AE that has asymptomatic; blisters covering <10% BSA YH, MW Grade 1 bullous dermatitis AE CTCAE: E13618 OAE:0002828 a bullous AE that has blisters covering 10 - 30% BSA; painful blisters; limiting instrumental ADL YH, MW Grade 2 bullous dermatitis AE CTCAE: E13619 OAE:0002829 a bullous AE that has blisters covering >30% BSA; limiting self care ADL YH, MW Grade 3 bullous dermatitis AE CTCAE: E13620 OAE:0002830 a bullous AE that has blisters covering >30% BSA; associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated YH, MW Grade 4 bullous dermatitis AE CTCAE: E13621 OAE:0002831 an erythroderma AE that has erythema covering >90% BSA without associated symptoms; limiting instrumental ADL YH, MW Grade 2 erythroderma AE CTCAE: E13634 OAE:0002832 an erythroderma AE that has erythema covering >90% BSA with associated symptoms (e.g., pruritus or tenderness); limiting self care ADL YH, MW Grade 3 erythroderma AE CTCAE: E13635 OAE:0002833 an erythroderma AE that has erythema covering >90% BSA with associated fluid or electrolyte abnormalities; ICU care or burn unit indicated YH, MW Grade 4 erythroderma AE CTCAE: E13636 OAE:0002834 a fat atrophy AE that is covering <10% BSA and asymptomatic YH, MW Grade 1 fat atrophy AE CTCAE: E13639 OAE:0002835 a fat atrophy AE that is covering 10 - 30% BSA and associated with erythema or tenderness; limiting instrumental ADL YH, MW Grade 2 fat atrophy AE CTCAE: E13640 OAE:0002836 a fat atrophy AE that is covering >30% BSA; associated with erythema or tenderness; limiting self-care ADL YH, MW Grade 3 fat atrophy AE CTCAE: E13641 OAE:0002837 a hirsutism AE that is In women, increase in length, thickness or density of hair in a male distribution that the patient is able to camouflage by periodic shaving, bleaching, or removal of hair YH, MW Grade 1 hirsutism AE CTCAE: E13643 OAE:0002838 a hirsutism AE that In women, increase in length, thickness or density of hair in a male distribution that requires daily shaving or consistent destructive means of hair removal to camouflage; associated with psychosocial impact YH, MW Grade 2 hirsutism AE CTCAE: E13644 OAE:0002839 a hypertrichosis AE that has increased in length, thickness or density of hair. The patient is either able to camouflage by periodic shaving or removal of hairs or is not concerned enough about the overgrowth to use any form of hair removal YH, MW Grade 1 hypertrichosis AE CTCAE: E13650 OAE:0002840 a hypertrichosis AE that has increased in length, thickness or density of hair at least on the usual exposed areas of the body [face (not limited to beard/moustache area) plus/minus arms] that requires frequent shaving or use of destructive means of hair removal to camouflage; associated with psychosocial impact YH, MW Grade 2 hypertrichosis AE CTCAE: E13651 OAE:0002841 a hypertrichosis AE that has increased in body temperature; limiting self care ADL YH, MW Grade 3 hypohidrosis AE CTCAE: E13654 OAE:0002842 a hypertrichosis AE that has heat stroke YH, MW Grade 4 hypohidrosis AE CTCAE: E13655 OAE:0002843 a lipohypertrophy AE that has asymptomatic and covering <10% BSA YH, MW Grade 1 lipohypertrophy AE CTCAE: E13658 OAE:0002844 a lipohypertrophy AE that covers 10 - 30% BSA and associated tenderness; limiting instrumental ADL YH, MW Grade 2 lipohypertrophy AE CTCAE: E13659 OAE:0002845 a lipohypertrophy AE that covers >30% BSA and associated tenderness and narcotics or NSAIDs indicated; lipohypertrophy; limiting self care ADL YH, MW Grade 3 lipohypertrophy AE CTCAE: E13660 OAE:0002846 a nail loss AE that has asymptomatic separation of the nail bed from the nail plate or nail loss YH, MW Grade 1 nail loss AE CTCAE: E13664 OAE:0002847 a nail loss AE that has symptomatic separation of the nail bed from the nail plate or nail loss; limiting instrumental ADL YH, MW Grade 2 nail loss AE CTCAE: E13665 OAE:0002848 a rash acneiform AE that has papules and/or pustules covering <10% BSA, which may or may not be associated with symptoms of pruritus or tenderness YH, MW Grade 1 rash acneiform AE CTCAE: E13695 OAE:0002849 a rash acneiform AE that has papules and/or pustules covering 10 - 30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL YH, MW Grade 2 rash acneiform AE CTCAE: E13696 OAE:0002850 a rash acneiform AE that has papules and/or pustules covering >30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; limiting self care ADL; associated with local superinfection with oral antibiotics indicated YH, MW Grade 3 rash acneiform AE CTCAE: E13697 OAE:0002851 a rash acneiform AE that has papules and/or pustules covering any % BSA, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated; life-threatening consequences YH, MW Grade 4 rash acneiform AE CTCAE: E13698 OAE:0002852 a rash maculopapular AE that has macules/papules covering <10% BSA with or without symptoms (e.g., pruritus, burning, tightness) YH, MW Grade 1 rash maculo-papular AE CTCAE: E13701 OAE:0002853 a rash maculopapular AE that has macules/papules covering 10 - 30% BSA with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental ADL YH, MW Grade 2 rash maculo-papular AE CTCAE: E13702 OAE:0002854 a rash maculopapular AE that has macules/papules covering >30% BSA with or without associated symptoms; limiting self care ADL YH, MW Grade 3 rash maculo-papular AE CTCAE: E13703 OAE:0002855 a skin induration AE that has mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up) YH, MW Grade 1 skin induration AE CTCAE: E13725 OAE:0002856 a skin induration AE that has moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL YH, MW Grade 2 skin induration AE CTCAE: E13726 OAE:0002857 a skin induration AE that has severe induration, unable to slide or pinch skin; limiting joint movement or orifice (e.g., mouth, anus); limiting self care ADL YH, MW Grade 3 skin induration AE CTCAE: E13727 OAE:0002858 a skin induration AE that has generalized; associated with signs or symptoms of impaired breathing or feeding YH, MW Grade 4 skin induration AE CTCAE: E13728 OAE:0002859 a bronchial fistula AE that has symptomatic; tube thoracostomy or medical management indicated; limiting instrumental ADL YH, MW Grade 2 bronchial fistula AE CTCAE: E13324 OAE:0002860 a bronchial fistula AE that has severe symptoms; limiting self care ADL; endoscopic or operative intervention indicated (e.g., stent or primary closure) YH, MW Grade 3 bronchial fistula AE CTCAE: E13325 OAE:0002861 a bronchial fistula AE that has life-threatening consequences; urgent operative intervention with thoracoplasty, chronic open drainage or multiple thoracotomies indicated YH, MW Grade 4 bronchial fistula AE CTCAE: E13326 OAE:0002862 a bronchial obstruction AE that has symptomatic (e.g., mild wheezing); endoscopic evaluation indicated; radiographic evidence of atelectasis/lobar collapse; medical management indicated (e.g., steroids, bronchodilators) YH, MW Grade 2 bronchial obstruction AE CTCAE: E13330 OAE:0002863 a bronchial obstruction AE that has shortness of breath with stridor; endoscopic intervention indicated (e.g., laser, stent placement) YH, MW Grade 3 bronchial obstruction AE CTCAE: E13331 OAE:0002864 a bronchial stricture AE that AE symptomatic (e.g., rhonchi or wheezing) but without respiratory distress; medical intervention indicated (e.g., steroids, bronchodilators) YH, MW Grade 2 bronchial stricture AE CTCAE: E13336 OAE:0002865 a bronchial stricture AE that AE shortness of breath with stridor; endoscopic intervention indicated (e.g., laser, stent placement) YH, MW Grade 3 bronchial stricture AE CTCAE: E13337 OAE:0002866 a bronchopleural fistula AE that has severe symptoms; limiting self care ADL; endoscopic or operative intervention indicated (e.g., stent or primary closure) YH, MW Grade 3 bronchopleural fistula AE CTCAE: E13343 OAE:0002867 a bronchopleural fistula AE that has life-threatening consequences; urgent operative intervention with thoracoplasty, chronic open drainage or multiple thoracotomies indicated YH, MW Grade 4 bronchopleural fistula AE CTCAE: E13344 OAE:0002868 a laryngeal fistula AE that has symptomatic; tube thoracostomy or medical management indicated; limiting instrumental ADL YH, MW Grade 2 laryngeal fistula AE CTCAE: E13401 OAE:0002869 a laryngeal fistula AE that has severe symptoms; limiting self care ADL; endoscopic or operative intervention indicated (e.g., stent or primary closure) YH, MW Grade 3 laryngeal fistula AE CTCAE: E13402 OAE:0002870 a laryngeal fistula AE that has life-threatening consequences; urgent operative intervention indicated (e.g., thoracoplasty, chronic open drainage or multiple thoracotomies) YH, MW Grade 4 laryngeal fistula AE CTCAE: E13403 OAE:0002871 a laryngeal hemorrhage AE that has mild cough or trace hemoptysis; laryngoscopic findings YH, MW Grade 1 laryngeal hemorrhage AE CTCAE: E13406 OAE:0002872 a laryngeal inflammation AE that has mild sore throat; raspy voice YH, MW Grade 1 laryngeal inflammation AE CTCAE: E13412 OAE:0002873 a laryngeal inflammation AE that has moderate sore throat; analgesics indicated YH, MW Grade 2 laryngeal inflammation AE CTCAE: E13413 OAE:0002874 a laryngeal inflammation AE that has severe throat pain; endoscopic intervention indicated YH, MW Grade 3 laryngeal inflammation AE CTCAE: E13414 OAE:0002875 a laryngeal mucositis AE that has endoscopic findings only; mild discomfort with normal intake YH, MW Grade 1 laryngeal mucositis AE CTCAE: E13416 OAE:0002876 a laryngeal mucositis AE that has moderate discomfort; altered oral intake YH, MW Grade 2 laryngeal mucositis AE CTCAE: E13417 OAE:0002877 a laryngeal mucositis AE that has severe pain; severely altered eating/swallowing; medical intervention indicated YH, MW Grade 3 laryngeal mucositis AE CTCAE: E13418 OAE:0002878 a laryngeal mucositis AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 laryngeal mucositis AE CTCAE: E13419 OAE:0002879 a laryngeal obstruction AE that has symptomatic (e.g., noisy airway breathing), but causing no respiratory distress; medical management indicated (e.g., steroids); limiting instrumental ADL YH, MW Grade 2 laryngeal obstruction AE CTCAE: E13423 OAE:0002880 a laryngeal obstruction AE that has limiting self care ADL; stridor; endoscopic intervention indicated (e.g., stent, laser) YH, MW Grade 3 laryngeal obstruction AE CTCAE: E13424 OAE:0002881 a laryngeal stenosis AE that has symptomatic (e.g., noisy airway breathing), but causing no respiratory distress; medical management indicated (e.g., steroids) YH, MW Grade 2 laryngeal stenosis AE CTCAE: E13429 OAE:0002882 a laryngeal stenosis AE that has limiting self care ADL; stridor; endoscopic intervention indicated (e.g., stent, laser) YH, MW Grade 3 laryngeal stenosis AE CTCAE: E13430 OAE:0002883 a laryngopharyngeal dysesthesia AE that has moderate symptoms; mild anxiety, but no dyspnea; short duration of observation and or anxiolytic indicated; limiting instrumental ADL YH, MW Grade 2 laryngopharyngeal dysesthesia AE CTCAE: E13435 OAE:0002884 a laryngopharyngeal dysesthesia AE that has severe symptoms; dyspnea and swallowing difficulty; limiting self care ADL YH, MW Grade 3 laryngopharyngeal dysesthesia AE CTCAE: E13436 OAE:0002885 a laryngospasm AE that has transient episode; intervention not indicated YH, MW Grade 2 laryngospasm AE CTCAE: E13440 OAE:0002886 a laryngospasm AE that has recurrent episodes; noninvasive intervention indicated (e.g., breathing technique, pressure point massage) YH, MW Grade 3 laryngospasm AE CTCAE: E13441 OAE:0002887 a laryngospasm AE that has persistent or severe episodes associated with syncope; urgent intervention indicated (e.g., fiberoptic laryngoscopy, intubation, botox injection) YH, MW Grade 4 laryngospasm AE CTCAE: E13442 OAE:0002888 a pharyngeal fistula AE that has symptomatic; tube thoracostomy or medical intervention indicated; limiting instrumental ADL YH, MW Grade 2 pharyngeal fistula AE CTCAE: E13456 OAE:0002889 a pharyngeal fistula AE that has severe symptoms; limiting self care ADL; endoscopic or operative intervention indicated (e.g., stent or primary closure) YH, MW Grade 3 pharyngeal fistula AE CTCAE: E13457 OAE:0002890 a pharyngeal mucositis AE that has endoscopic findings only; minimal symptoms with normal oral intake; mild pain but analgesics not indicated YH, MW Grade 1 pharyngeal mucositis AE CTCAE: E13467 OAE:0002891 a pharyngeal mucositis AE that has moderate pain and analgesics indicated; altered oral intake; limiting instrumental ADL YH, MW Grade 2 pharyngeal mucositis AE CTCAE: E13468 OAE:0002892 a pharyngeal mucositis AE that has severe pain; unable to adequately aliment or hydrate orally; limiting self care ADL YH, MW Grade 3 pharyngeal mucositis AE CTCAE: E13469 OAE:0002893 a pharyngeal necrosis AE that has inability to aliment adequately by GI tract; tube feeding or TPN indicated; radiologic, endoscopic, or operative intervention indicated YH, MW Grade 3 pharyngeal necrosis AE CTCAE: E13473 OAE:0002894 a pharyngeal stenosis AE that has symptomatic (e.g., noisy airway breathing), but causing no respiratory distress; medical management indicated (e.g., steroids); limiting instrumental ADL YH, MW Grade 2 pharyngeal stenosis AE CTCAE: E13478 OAE:0002895 a pharyngeal stenosis AE that has limiting self care ADL; stridor; endoscopic intervention indicated (e.g., stent, laser) YH, MW Grade 3 pharyngeal stenosis AE CTCAE: E13479 OAE:0002896 a pharyngeal stenosis AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 pharyngeal stenosis AE CTCAE: E13480 OAE:0002897 a pulmonary fistula AE that has symptomatic; tube thoracostomy or medical management indicated; limiting instrumental ADL YH, MW Grade 2 pulmonary fistula AE CTCAE: E13535 OAE:0002898 a pulmonary fistula AE that has limiting self care ADL; endoscopic stenting or operative intervention indicated YH, MW Grade 3 pulmonary fistula AE CTCAE: E13536 OAE:0002899 a retinoic acid syndrome AE that has fluid retention; <3 kg of weight gain; intervention with fluid restriction and/or diuretics indicated YH, MW Grade 1 retinoic acid syndrome AE CTCAE: E13555 OAE:0002904 a tracheal fistula AE that has symptomatic; tube thoracostomy or medical intervention indicated; limiting instrumental ADL YH, MW Grade 2 tracheal fistula AE CTCAE: E13585 OAE:0002905 a tracheal fistula AE that has severe symptoms; limiting self care ADL; endoscopic or operative intervention indicated (e.g., stent or primary closure) YH, MW Grade 3 tracheal fistula AE CTCAE: E13586 OAE:0002906 a tracheal fistula AE that has life-threatening consequences; urgent operative intervention indicated (e.g., thoracoplasty, chronic open drainage or multiple thoracotomies) YH, MW Grade 4 tracheal fistula AE CTCAE: E13587 OAE:0002907 a tracheal mucositis AE that has endoscopic findings only; minimal hemoptysis, pain, or respiratory symptoms YH, MW Grade 1 tracheal mucositis AE CTCAE: E13590 OAE:0002908 a tracheal mucositis AE that has severe pain; hemorrhage or respiratory symptoms; limiting self care ADL YH, MW Grade 3 tracheal mucositis AE CTCAE: E13592 OAE:0002909 a tracheal stenosis AE that has symptomatic (e.g., noisy airway breathing), but causing no respiratory distress; medical management indicated (e.g., steroids) YH, MW Grade 2 tracheal stenosis AE CTCAE: E13597 OAE:0002910 a tracheal stenosis AE that has stridor or respiratory distress limiting self care ADL; endoscopic intervention indicated (e.g., stent, laser) YH, MW Grade 3 tracheal stenosis AE CTCAE: E13598 OAE:0002911 a tracheal stenosis AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 tracheal stenosis AE CTCAE: E13599 OAE:0002912 an azoospermia AE that has absence of sperm in ejaculate YH, MW Grade 3 azoospermia AE CTCAE: E13068 OAE:0002913 A breast atrophy AE that has asymmetry >1/3 of breast volume; severe atrophy YH, MW Grade 3 breast atrophy AE CTCAE: E13072 OAE:0002914 an ejaculation disorder AE that has diminished ejaculation YH, MW Grade 1 ejaculation disorder AE CTCAE: E13086 OAE:0002915 an ejaculation disorder AE that has anejaculation or retrograde ejaculation YH, MW Grade 2 ejaculation disorder AE CTCAE: E13087 OAE:0002916 a genital edema AE that has mild swelling or obscuration of anatomic architecture on close inspection YH, MW Grade 1 genital edema AE CTCAE: E13112 OAE:0002917 a genital edema AE that has readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour YH, MW Grade 2 genital edema AE CTCAE: E13113 OAE:0002918 a genital edema AE that has lymphorrhea; gross deviation from normal anatomic contour; limiting self care ADL YH, MW Grade 3 genital edema AE CTCAE: E13114 OAE:0002919 a gynecomastia AE that has asymptomatic breast enlargement YH, MW Grade 1 gynecomastia AE CTCAE: E13116 OAE:0002920 a gynecomastia AE that has symptomatic (e.g., pain or psychosocial impact) YH, MW Grade 2 gynecomastia AE CTCAE: E13117 OAE:0002921 a hematosalpinx AE that has minimal bleeding identified on imaging study or laparoscopy; intervention not indicated YH, MW Grade 1 hematosalpinx AE CTCAE: E13120 OAE:0002922 an irregular menstruation AE that has intermittent menses with skipped menses for no more than 1 to 3 months YH, MW Grade 1 irregular menstruation AE CTCAE: E13126 OAE:0002923 an irregular menstruation AE that has intermittent menses with skipped menses for more than 4 to 6 months YH, MW Grade 2 irregular menstruation AE CTCAE: E13127 OAE:0002924 an irregular menstruation AE that has persistent amenorrhea for more than 6 months YH, MW Grade 3 irregular menstruation AE CTCAE: E13128 OAE:0002925 a lactation disorder AE that has mild changes in lactation, not significantly affecting production or expression of breast milk YH, MW Grade 1 lactation disorder AE CTCAE: E13130 OAE:0002926 a lactation disorder AE that has changes in lactation, significantly affecting breast production or expression of breast milk YH, MW Grade 2 lactation disorder AE CTCAE: E13131 OAE:0002927 a nipple deformity AE that has asymptomatic; asymmetry with slight retraction and/or thickening of the nipple areolar complex YH, MW Grade 1 nipple deformity AE CTCAE: E13139 OAE:0002928 a nipple deformity AE that has symptomatic; asymmetry of nipple areolar complex with moderate retraction and/or thickening of the nipple areolar complex YH, MW Grade 2 nipple deformity AE CTCAE: E13140 OAE:0002929 an oligospermia AE requires sperm concentration >48 million/mL or motility >68% YH, MW Grade 1 oligospermia AE CTCAE: E13142 OAE:0002930 an oligospermia AE requires sperm concentration 13 - 48 million/mL or motility 32 - 68% YH, MW Grade 2 oligospermia AE CTCAE: E13143 OAE:0002931 an oligospermia AE requires sperm concentration <13 million/mL or motility <32% YH, MW Grade 3 oligospermia AE CTCAE: E13144 OAE:0002932 a testicular disorder AE that has symptomatic but not interfering with urination or sexual activities; intervention not indicated; limiting instrumental ADL YH, MW Grade 2 testicular disorder AE CTCAE: E13217 OAE:0002933 a testicular disorder AE that has severe symptoms; interfering with urination or sexual function; limiting self care ADL; intervention indicated YH, MW Grade 3 testicular disorder AE CTCAE: E13218 OAE:0002934 a vaginal discharge AE that has mild vaginal discharge (greater than baseline for patient) YH, MW Grade 1 vaginal discharge AE CTCAE: E13252 OAE:0002935 a vaginal discharge AE that has moderate to heavy vaginal discharge; use of perineal pad or tampon indicated YH, MW Grade 2 vaginal discharge AE CTCAE: E13253 OAE:0002936 a bladder spasm AE that has antispasmodics indicated YH, MW Grade 2 bladder spasm AE CTCAE: E12986 OAE:0002937 a bladder spasm AE that has hospitalization indicated YH, MW Grade 3 bladder spasm AE CTCAE: E12987 OAE:0002938 a chronic kidney disease AE that requires eGFR (estimated Glomerular Filtration Rate) or CrCl (creatinine clearance) <LLN - 60 ml/min/1.73 m2 or proteinuria 2+ present; urine protein/creatinine >0.5 YH, MW Grade 1 chronic kidney disease AE CTCAE: E12989 OAE:0002939 a chronic kidney disease AE that requires eGFR or CrCl 59 - 30 ml/min/1.73 m2 YH, MW Grade 2 chronic kidney disease AE CTCAE: E12990 OAE:0002940 a chronic kidney disease AE that requires eGFR or CrCl 29 - 15 ml/min/1.73 m2 YH, MW Grade 3 chronic kidney disease AE CTCAE: E12991 OAE:0002941 a chronic kidney disease AE that requires eGFR or CrCl <15 ml/min/1.73 m2; dialysis or renal transplant indicated YH, MW Grade 4 chronic kidney disease AE CTCAE: E12992 OAE:0002942 a cystitis noninfective AE that has microscopic hematuria; minimal increase in frequency, urgency, dysuria, or nocturia; new onset of incontinence YH, MW Grade 1 cystitis noninfective AE CTCAE: E12995 OAE:0002943 a cystitis noninfective AE that has moderate hematuria; moderate increase in frequency, urgency, dysuria, nocturia or incontinence; urinary catheter placement or bladder irrigation indicated; limiting instrumental ADL YH, MW Grade 2 cystitis noninfective AE CTCAE: E12996 OAE:0002944 a cystitis noninfective AE that has gross hematuria; transfusion, IV medications or hospitalization indicated; elective endoscopic, radiologic or operative intervention indicated YH, MW Grade 3 cystitis noninfective AE CTCAE: E12997 OAE:0002945 a proteinuria AE that requires 1+ proteinuria; urinary protein <1.0 g/24 hrs YH, MW Grade 1 proteinuria AE CTCAE: E13009 OAE:0002946 a proteinuria AE that requires YH, MW Grade 2 proteinuria AE CTCAE: E13010 OAE:0002947 a proteinuria AE that requires YH, MW Grade 3 proteinuria AE CTCAE: E13011 OAE:0002948 a renal calculi AE that has asymptomatic or mild symptoms; occasional use of nonprescription analgesics indicated YH, MW Grade 1 renal calculi AE CTCAE: E13019 OAE:0002949 a renal calculi AE that has symptomatic; oral antiemetics indicated; around the clock nonprescription analgesics or any oral narcotic analgesics indicated YH, MW Grade 2 renal calculi AE CTCAE: E13020 OAE:0002950 a renal calculi AE that has hospitalization indicated; IV intervention (e.g., analgesics, antiemetics); elective endoscopic or radiologic intervention indicated YH, MW Grade 3 renal calculi AE CTCAE: E13021 OAE:0002951 an urinary fistula AE that has noninvasive intervention indicated; urinary or suprapubic catheter placement indicated YH, MW Grade 2 urinary fistula AE CTCAE: E13035 OAE:0002952 an urinary fistula AE that has limiting self care ADL; elective radiologic, endoscopic or operative intervention indicated; permanent urinary diversion indicated YH, MW Grade 3 urinary fistula AE CTCAE: E13036 OAE:0002953 an urinary tract obstruction AE that has symptomatic but no hydronephrosis, sepsis or renal dysfunction; urethral dilation, urinary or suprapubic catheter indicated YH, MW Grade 2 urinary tract obstruction AE CTCAE: E13054 OAE:0002954 an urinary tract obstruction AE that has symptomatic and altered organ function (e.g., hydronephrosis, or renal dysfunction); elective radiologic, endoscopic or operative intervention indicated YH, MW Grade 3 urinary tract obstruction AE CTCAE: E13055 OAE:0002955 a mania AE that has mild manic symptoms (e.g., elevated mood, rapid thoughts, rapid speech, decreased need for sleep) YH, MW Grade 1 mania AE CTCAE: E12937 OAE:0002956 a mania AE that has moderate manic symptoms (e.g., relationship and work difficulties; poor hygiene) YH, MW Grade 2 mania AE CTCAE: E12938 OAE:0002957 a mania AE that has severe manic symptoms (e.g., hypomania; major sexual or financial indiscretions); hospitalization not indicated YH, MW Grade 3 mania AE CTCAE: E12939 OAE:0002958 a fetal growth retardation AE that has <10% percentile of weight for gestational age YH, MW Grade 2 fetal growth retardation AE CTCAE: E12858 OAE:0002959 a fetal growth retardation AE that has <5% percentile of weight for gestational age YH, MW Grade 3 fetal growth retardation AE CTCAE: E12859 OAE:0002960 a fetal growth retardation AE that has <1% percentile of weight for gestational age YH, MW Grade 4 fetal growth retardation AE CTCAE: E12860 OAE:0002961 a premature delivery AE that has delivery of a liveborn infant at >34 to 37 weeks gestation YH, MW Grade 1 premature delivery AE CTCAE: E12868 OAE:0002962 a premature delivery AE that has delivery of a liveborn infant at >28 to 34 weeks gestation YH, MW Grade 2 premature delivery AE CTCAE: E12869 OAE:0002963 a premature delivery AE that has delivery of a liveborn infant at 24 to 28 weeks gestation YH, MW Grade 3 premature delivery AE CTCAE: E12870 OAE:0002964 a premature delivery AE that has delivery of a liveborn infant at 24 weeks of gestation or less YH, MW Grade 4 premature delivery AE CTCAE: E12871 OAE:0002965 a spasticity AE that has mild or slight increase in muscle tone YH, MW Grade 1 spasticity AE CTCAE: E12821 OAE:0002966 a spasticity AE that has moderate increase in muscle tone and increase in resistance through range of motion YH, MW Grade 2 spasticity AE CTCAE: E12822 OAE:0002967 a spasticity AE that has severe increase in muscle tone and increase in resistance through range of motion YH, MW Grade 3 spasticity AE CTCAE: E12823 OAE:0002968 a spasticity AE that has life-threatening; unable to move active or passive range of motion YH, MW Grade 4 spasticity AE CTCAE: E12824 OAE:0002969 a treatment related secondary malignancy AE that has non life-threatening secondary malignancy YH, MW Grade 3 treatment related secondary malignancy AE CTCAE: E12562 OAE:0002970 a treatment related secondary malignancy AE that has acute life-threatening secondary malignancy; blast crisis in leukemia YH, MW Grade 4 treatment related secondary malignancy AE CTCAE: E12563 OAE:0002971 an abdominal soft tissue necrosis AE that has local wound care; medical intervention indicated (e.g., dressings or topical medications) YH, MW Grade 2 abdominal soft tissue necrosis AE CTCAE: E12370 OAE:0002972 an abdominal soft tissue necrosis AE that has operative debridement or other invasive intervention indicated (e.g. tissue reconstruction, flap or grafting) YH, MW Grade 3 abdominal soft tissue necrosis AE CTCAE: E12371 OAE:0002973 a fibrosis deep connective tissue AE that has mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up) YH, MW Grade 1 fibrosis deep connective tissue AE CTCAE: E12409 OAE:0002974 a fibrosis deep connective tissue AE that has moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL YH, MW Grade 2 fibrosis deep connective tissue AE CTCAE: E12410 OAE:0002975 a fibrosis deep connective tissue AE that has severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g. mouth, anus); limiting self care ADL YH, MW Grade 3 fibrosis deep connective tissue AE CTCAE: E12411 OAE:0002976 a fibrosis deep connective tissue AE that has generalized; associated with signs or symptoms of impaired breathing or feeding YH, MW Grade 4 fibrosis deep connective tissue AE CTCAE: E12412 OAE:0002977 a growth suppression AE that has reduction in growth velocity by 10 - 29% ideally measured over the period of a year YH, MW Grade 1 growth suppression AE CTCAE: E12423 OAE:0002978 a growth suppression AE that has reduction in growth velocity by 30 - 49% ideally measured over the period of a year or 0 - 49% reduction in growth from the baseline growth curve YH, MW Grade 2 growth suppression AE CTCAE: E12424 OAE:0002979 a growth suppression AE that has reduction in growth velocity of >=50% ideally measured over the period of a year YH, MW Grade 3 growth suppression AE CTCAE: E12425 OAE:0002980 a head soft tissue necrosis AE that has local wound care; medical intervention indicated (e.g., dressings or topical medications) YH, MW Grade 2 head soft tissue necrosis AE CTCAE: E12427 OAE:0002981 a head soft tissue necrosis AE that has operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap or grafting) YH, MW Grade 3 head soft tissue necrosis AE CTCAE: E12428 OAE:0002982 a joint range of motion decreased cervical spine AE that has mild restriction of rotation or flexion between 60 - 70 degrees YH, MW Grade 1 joint range of motion decreased cervical spine AE CTCAE: E12440 OAE:0002983 a joint range of motion decreased cervical spine AE that has rotation <60 degrees to right or left; <60 degrees of flexion YH, MW Grade 2 joint range of motion decreased cervical spine AE CTCAE: E12441 OAE:0002984 a joint range of motion decreased cervical spine AE that has ankylosed/fused over multiple segments with no C-spine rotation YH, MW Grade 3 joint range of motion decreased cervical spine AE CTCAE: E12442 OAE:0002985 a joint range of motion decreased lumbar spine AE that has stiffness; difficulty bending to the floor to pick up a very light object but able to do athletic activity YH, MW Grade 1 joint range of motion decreased lumbar spine AE CTCAE: E12444 OAE:0002986 a joint range of motion decreased lumbar spine AE that has pain with range of motion (ROM) in lumbar spine; requires a reaching aid to pick up a very light object from the floor YH, MW Grade 2 joint range of motion decreased lumbar spine AE CTCAE: E12445 OAE:0002987 a joint range of motion decreased lumbar spine AE that requires <50% lumbar spine flexion; associated with symptoms of ankylosis or fused over multiple segments with no L-spine flexion (e.g., unable to reach to floor to pick up a very light object) YH, MW Grade 3 joint range of motion decreased lumbar spine AE CTCAE: E12446 OAE:0002988 a neck soft tissue necrosis AE that has local wound care; medical intervention indicated (e.g., dressings or topical medications) YH, MW Grade 2 neck soft tissue necrosis AE CTCAE: E12498 OAE:0002989 a neck soft tissue necrosis AE that has operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap or grafting) YH, MW Grade 3 neck soft tissue necrosis AE CTCAE: E12499 OAE:0002990 a pelvic soft tissue necrosis AE that has local wound care; medical intervention indicated (e.g., dressings or topical medications) YH, MW Grade 2 pelvic soft tissue necrosis AE CTCAE: E12517 OAE:0002991 a pelvic soft tissue necrosis AE that has operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap or grafting) YH, MW Grade 3 pelvic soft tissue necrosis AE CTCAE: E12518 OAE:0002992 a scoliosis AE that requires <20 degrees; clinically undetectable YH, MW Grade 1 scoliosis AE CTCAE: E12522 OAE:0002993 a scoliosis AE that requires >20 - 45 degrees; visible by forward flexion; limiting instrumental ADL YH, MW Grade 2 scoliosis AE CTCAE: E12523 OAE:0002994 a scoliosis AE that requires >45 degrees; scapular prominence in forward flexion; operative intervention indicated; limiting self care ADL; disabling YH, MW Grade 3 scoliosis AE CTCAE: E12524 OAE:0002995 a soft tissue necrosis lower limb AE that has local wound care; medical intervention indicated (e.g., dressings or topical medications) YH, MW Grade 2 soft tissue necrosis lower limb AE CTCAE: E12526 OAE:0002996 a soft tissue necrosis lower limb AE that has operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap or grafting) YH, MW Grade 3 soft tissue necrosis lower limb AE CTCAE: E12527 OAE:0002997 a soft tissue necrosis upper limb AE that has local wound care; medical intervention indicated (e.g., dressings or topical medications) YH, MW Grade 2 soft tissue necrosis upper limb AE CTCAE: E12531 OAE:0002998 a soft tissue necrosis upper limb AE that has operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap or grafting) YH, MW Grade 3 soft tissue necrosis upper limb AE CTCAE: E12532 OAE:0002999 a Superficial soft tissue fibrosis AE that has mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up) YH, MW Grade 1 superficial soft tissue fibrosis AE CTCAE: E12536 OAE:0003000 a Superficial soft tissue fibrosis AE that has moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL YH, MW Grade 2 superficial soft tissue fibrosis AE CTCAE: E12537 OAE:0003001 a Superficial soft tissue fibrosis AE that has severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self care ADL YH, MW Grade 3 superficial soft tissue fibrosis AE CTCAE: E12538 OAE:0003002 a superficial soft tissue fibrosis AE that has generalized; associated with signs or symptoms of impaired breathing or feeding YH, MW Grade 4 superficial soft tissue fibrosis AE CTCAE: E12539 OAE:0003003 a trismus AE that has decreased ROM (range of motion) without impaired eating YH, MW Grade 1 trismus AE CTCAE: E12542 OAE:0003004 a trismus AE that has decreased ROM requiring small bites, soft foods or purees YH, MW Grade 2 trismus AE CTCAE: E12543 OAE:0003005 a trismus AE that has decreased ROM with inability to adequately aliment or hydrate orally YH, MW Grade 3 trismus AE CTCAE: E12544 OAE:0003006 An unequal limb length AE that has mild length discrepancy <2 cm YH, MW Grade 1 unequal limb length AE CTCAE: E12546 OAE:0003007 An unequal limb length AE that has moderate length discrepancy 2 - 5 cm; shoe lift indicated; limiting instrumental ADL YH, MW Grade 2 unequal limb length AE CTCAE: E12547 OAE:0003008 An unequal limb length AE that has severe length discrepancy >5 cm; limiting self care ADL; disabling; operative intervention indicated YH, MW Grade 3 unequal limb length AE CTCAE: E12548 OAE:0003009 a alkalosis AE that requires pH >normal, but <=7.5 YH, MW Grade 1 alkalosis AE CTCAE: E12248 OAE:0003010 a alkalosis AE that requires pH >7.5 YH, MW Grade 3 alkalosis AE CTCAE: E12249 OAE:0003011 a glucose intolerance AE that has symptomatic; dietary modification or oral agent indicated YH, MW Grade 2 glucose intolerance AE CTCAE: E12266 OAE:0003012 a glucose intolerance AE that has severe symptoms; insulin indicated YH, MW Grade 3 glucose intolerance AE CTCAE: E12267 OAE:0003013 a hypermagnesemia AE that requires >ULN - 3.0 mg/dL; >ULN - 1.23 mmol/L YH, MW Grade 1 hypermagnesemia AE CTCAE: E12289 OAE:0003014 a hypermagnesemia AE that requires >3.0 - 8.0 mg/dL; >1.23 - 3.30 mmol/L YH, MW Grade 3 hypermagnesemia AE CTCAE: E12290 OAE:0003015 a hypermagnesemia AE that requires >8.0 mg/dL; >3.30 mmol/L; life-threatening consequences YH, MW Grade 4 hypermagnesemia AE CTCAE: E12291 OAE:0003016 a hypernatremia AE that requires >ULN - 150 mmol/L YH, MW Grade 1 hypernatremia AE CTCAE: E12294 OAE:0003017 a hypernatremia AE that requires >150 - 155 mmol/L YH, MW Grade 2 hypernatremia AE CTCAE: E12295 OAE:0003018 a hypernatremia AE that requires >155 - 160 mmol/L; hospitalization indicated YH, MW Grade 3 hypernatremia AE CTCAE: E12296 OAE:0003019 a hypernatremia AE that requires >160 mmol/L; life-threatening consequences YH, MW Grade 4 hypernatremia AE CTCAE: E12297 OAE:0003020 a hypokalemia AE that requires <LLN - 3.0 mmol/L YH, MW Grade 1 hypokalemia AE CTCAE: E12328 OAE:0003021 a hypokalemia AE that requires <LLN - 3.0 mmol/L; symptomatic; intervention indicated YH, MW Grade 2 hypokalemia AE CTCAE: E12329 OAE:0003022 a hypokalemia AE that requires <3.0 - 2.5 mmol/L; hospitalization indicated YH, MW Grade 3 hypokalemia AE CTCAE: E12330 OAE:0003023 a hypokalemia AE that requires <2.5 mmol/L; life-threatening consequences YH, MW Grade 4 hypokalemia AE CTCAE: E12331 OAE:0003024 a hyponatremia AE that requires <LLN - 130 mmol/L YH, MW Grade 1 hyponatremia AE CTCAE: E12340 OAE:0003025 a hyponatremia AE that requires <130 - 120 mmol/L YH, MW Grade 3 hyponatremia AE CTCAE: E12341 OAE:0003026 a hyponatremia AE that requires <120 mmol/L; life-threatening consequences YH, MW Grade 4 hyponatremia AE CTCAE: E12342 OAE:0003027 an obesity AE that requires BMI 25 - 29.9 kg/m2 YH, MW Grade 2 obesity AE CTCAE: E12362 OAE:0003028 an obesity AE that requires BMI 30 - 39.9 kg/m2 YH, MW Grade 3 obesity AE CTCAE: E12363 OAE:0003029 an obesity AE that requires BMI >=40 kg/m2 YH, MW Grade 4 obesity AE CTCAE: E12364 OAE:0003030 a flushing AE that has symptomatic, associated with hypotension and/or tachycardia; limiting self care ADL YH, MW Grade 3 flushing AE CTCAE: E13774 OAE:0003031 a hematoma AE that requires minimally invasive evacuation or aspiration YH, MW Grade 2 hematoma AE CTCAE: E13777 OAE:0003032 a hematoma AE that requires transfusion, radiologic, endoscopic, or elective operative intervention YH, MW Grade 3 hematoma AE CTCAE: E13778 OAE:0003033 an hypertension AE that has prehypertension (systolic BP 120 - 139 mm Hg or diastolic BP 80 - 89 mm Hg) YH, MW Grade 1 hypertension AE CTCAE: E13786 OAE:0003034 an hypertension AE that for Adult: has stage 1 hypertension (systolic BP 140 - 159 mm Hg or diastolic BP 90 - 99 mm Hg); medical intervention indicated; recurrent or persistent (>=24 hrs); symptomatic increase by >20 mm Hg (diastolic) or to >140/90 mm Hg if previously WNL; monotherapy indicated; for Pediatric: recurrent or persistent (>=24 hrs) BP >ULN; monotherapy indicated. YH, MW Grade 2 hypertension AE CTCAE: E13787 OAE:0003035 an hypertension AE that for Adult has Stage 2 hypertension (systolic BP >=160 mm Hg or diastolic BP >=100 mm Hg); medical intervention indicated; more than one drug or more intensive therapy than previously used indicated; for Pediatric: Same as adult. YH, MW Grade 3 hypertension AE CTCAE: E13788 OAE:0003036 an hypertension AE that for Adult has life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis); urgent intervention indicated; for Pediatric: Same as adult YH, MW Grade 4 hypertension AE CTCAE: E13789 OAE:0003037 a peripheral ischaemia AE that has brief (<24 hrs) episode of ischemia managed non-surgically and without permanent deficit YH, MW Grade 2 peripheral ischemia AE CTCAE: E13811 OAE:0003038 a peripheral ischaemia AE that has a recurring or prolonged (>=24 hrs) and/or invasive intervention indicated YH, MW Grade 3 peripheral ischemia AE CTCAE: E13812 OAE:0003039 a vasculitis AE that shows severe symptoms, medical intervention indicated (e.g., steroids) YH, MW Grade 3 vasculitis AE CTCAE: E13840 OAE:0003040 a vasculitis AE that shows threatening; evidence of peripheral or visceral ischemia; urgent intervention indicated YH, MW Grade 4 vasculitis AE CTCAE: E13841 OAE:0003041 an alopecia AE that has hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be required to cover the hair loss but it does not require a wig or hair piece to camouflage YH, MW Grade 1 alopecia AE CTCAE: E13612 OAE:0003042 an alopecia AE that has hair loss of >=50% normal for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact YH, MW Grade 2 alopecia AE CTCAE: E13613 OAE:0003043 a dry skin AE that is coverying <10% BSA and no associated erythema or pruritus YH, MW Grade 1 dry skin AE CTCAE: E13624 OAE:0003044 a dry skin AE that is coverying 10 - 30% BSA and associated with erythema or pruritus; limiting instrumental ADL YH, MW Grade 2 dry skin AE CTCAE: E13625 OAE:0003045 a dry skin AE that is coverying >30% BSA and associated with pruritus; limiting self care ADL YH, MW Grade 3 dry skin AE CTCAE: E13626 OAE:0003046 an erythema multiforme AE that has target lesions covering <10% BSA and not associated with skin tenderness YH, MW Grade 1 erythema multiforme AE CTCAE: E13628 OAE:0003047 an erythema multiforme AE that has target lesions covering 10 - 30% BSA and associated with skin tenderness YH, MW Grade 2 erythema multiforme AE CTCAE: E13629 OAE:0003048 an erythema multiforme AE that has target lesions covering >30% BSA and associated with oral or genital erosions YH, MW Grade 3 erythema multiforme AE CTCAE: E13630 OAE:0003049 an erythema multiforme AE that has target lesions covering >30% BSA; associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated YH, MW Grade 4 erythema multiforme AE CTCAE: E13631 OAE:0003050 a hyperhidros AE that shows limited to one site (palms, soles, or axillae); self care interventions YH, MW Grade 1 hyperhidrosis AE CTCAE: E13646 OAE:0003051 a hyperhidros AE that has Involving >1 site; patient seeks medical intervention; associated with psychosocial impact YH, MW Grade 2 hyperhidrosis AE CTCAE: E13647 OAE:0003052 a hyperhidros AE that has Generalized involving sites other than palms, soles, or axillae; associated with electrolyte/hemodynamic imbalance YH, MW Grade 3 hyperhidrosis AE CTCAE: E13648 OAE:0003053 a palmar-plantar erythrodysesthesia syndrome AE that has minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis) without pain YH, MW Grade 1 palmar-plantar erythrodysesthesia syndrome AE CTCAE: E13673 OAE:0003054 a palmar-plantar erythrodysesthesia syndrome AE that has skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting instrumental ADL YH, MW Grade 2 palmar-plantar erythrodysesthesia syndrome AE CTCAE: E13674 OAE:0003055 a palmar-plantar erythrodysesthesia syndrome AE that has severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self care ADL YH, MW Grade 3 palmar-plantar erythrodysesthesia syndrome AE CTCAE: E13675 OAE:0003056 a periorbital edema AE that has soft or non-pitting YH, MW Grade 1 periorbital edema AE CTCAE: E13677 OAE:0003057 a periorbital edema AE that has indurated or pitting edema; topical intervention indicated YH, MW Grade 2 periorbital edema AE CTCAE: E13678 OAE:0003058 a periorbital edema AE that has edema associated with visual disturbance; increased intraocular pressure, glaucoma or retinal hemorrhage; optic neuritis; diuretics indicated; operative intervention indicated YH, MW Grade 3 periorbital edema AE CTCAE: E13679 OAE:0003059 a photosensitivity reaction AE that has painless erythema and erythema covering <10% BSA YH, MW Grade 1 photosensitivity AE CTCAE: E13681 OAE:0003060 a photosensitivity reaction AE that has tender erythema covering 10 - 30% BSA YH, MW Grade 2 photosensitivity AE CTCAE: E13682 OAE:0003061 a photosensitivity reaction AE that has erythema covering >30% BSA and erythema with blistering; photosensitivity; oral corticosteroid therapy indicated; pain control indicated (e.g., narcotics or NSAIDs) YH, MW Grade 3 photosensitivity AE CTCAE: E13683 OAE:0003062 a pruritus AE that has mild or localized; topical intervention indicated YH, MW Grade 1 pruritus AE CTCAE: E13687 OAE:0003063 a pruritus AE that has intense or widespread; intermittent; skin changes from scratching (e.g., edema, papulation, excoriations, lichenification, oozing/crusts); oral intervention indicated; limiting instrumental ADL YH, MW Grade 2 pruritus AE CTCAE: E13688 OAE:0003064 a pruritus AE that has intense or widespread; constant; limiting self care ADL or sleep; oral corticosteroid or immunosuppressive therapy indicated YH, MW Grade 3 pruritus AE CTCAE: E13689 OAE:0003065 a purpura AE that has combined area of lesions covering <10% BSA YH, MW Grade 1 purpura AE CTCAE: E13691 OAE:0003066 a purpura AE that has combined area of lesions covering 10 - 30% BSA; bleeding with trauma YH, MW Grade 2 purpura AE CTCAE: E13692 OAE:0003067 a purpura AE that has combined area of lesions covering >30% BSA; spontaneous bleeding YH, MW Grade 3 purpura AE CTCAE: E13693 OAE:0003068 a skin atrophy AE that has covering <10% BSA; associated with telangiectasias or changes in skin color YH, MW Grade 1 skin atrophy AE CTCAE: E13715 OAE:0003069 a skin atrophy AE that has covering 10 - 30% BSA; associated with striae or adnexal structure loss YH, MW Grade 2 skin atrophy AE CTCAE: E13716 OAE:0003070 a skin atrophy AE that has covering >30% BSA; associated with ulceration YH, MW Grade 3 skin atrophy AE CTCAE: E13717 OAE:0003071 a skin hyperpigmentation AE that has hyperpigmentation covering <10% BSA; no psychosocial impact YH, MW Grade 1 skin hyperpigmentation AE CTCAE: E13719 OAE:0003072 a skin hyperpigmentation AE that has hyperpigmentation covering >10% BSA; associated psychosocial impact YH, MW Grade 2 skin hyperpigmentation AE CTCAE: E13720 OAE:0003073 a skin hypopigmentation AE that has hypopigmentation or depigmentation covering <10% BSA; no psychosocial impact YH, MW Grade 1 skin hypopigmentation AE CTCAE: E13722 OAE:0003074 a skin hypopigmentation AE that has hypopigmentation or depigmentation covering >10% BSA; associated psychosocial impact YH, MW Grade 2 skin hypopigmentation AE CTCAE: E13723 OAE:0003075 a stevens-johnson syndrome AE that has skin sloughing covering <10% BSA with associated signs (e.g., erythema, purpura, epidermal detachment and mucous membrane detachment) YH, MW Grade 3 stevens-Johnson syndrome AE CTCAE: E13737 OAE:0003076 a stevens-johnson syndrome AE that has skin sloughing covering 10 - 30% BSA with associated signs (e.g., erythema, purpura, epidermal detachment and mucous membrane detachment) YH, MW Grade 4 stevens-Johnson syndrome AE CTCAE: E13738 OAE:0003077 a telangiectasia AE that has telangiectasias covering <10% BSA YH, MW Grade 1 telangiectasia AE CTCAE: E13741 OAE:0003078 a telangiectasia AE that has telangiectasias covering >10% BSA; associated with psychosocial impact YH, MW Grade 2 telangiectasia AE CTCAE: E13742 OAE:0003079 a toxic epidermal necrolysis AE that has skin sloughing covering >=30% BSA with associated symptoms (e.g., erythema, purpura, or epidermal detachment) YH, MW Grade 4 toxic epidermal necrolysis AE CTCAE: E13744 OAE:0003080 an urticaria AE that has urticarial lesions covering <10% BSA; topical intervention indicated YH, MW Grade 1 urticaria AE CTCAE: E13747 OAE:0003081 an urticaria AE that has urticarial lesions covering 10 - 30% BSA; oral intervention indicated YH, MW Grade 2 urticaria AE CTCAE: E13748 OAE:0003082 an urticaria AE that has urticariallesions covering >30% BSA; IV intervention indicated YH, MW Grade 3 urticaria AE CTCAE: E13749 OAE:0003083 an aspiration AE that has altered eating habits; coughing or choking episodes after eating or swallowing; medical intervention indicated (e.g., suction or oxygen) YH, MW Grade 2 aspiration AE CTCAE: E13312 OAE:0003084 an aspiration AE that has dyspnea and pneumonia symptoms (e.g., aspiration pneumonia); hospitalization indicated; unable to aliment orally YH, MW Grade 3 aspiration AE CTCAE: E13313 OAE:0003085 an atelectasis AE that has symptomatic (e.g., dyspnea, cough); medical intervention indicated (e.g., chest physiotherapy, suctioning); bronchoscopic suctioning YH, MW Grade 2 atelectasis AE CTCAE: E13318 OAE:0003086 an atelectasis AE that has oxygen indicated; hospitalization or elective operative intervention indicated (e.g., stent, laser) YH, MW Grade 3 atelectasis AE CTCAE: E13319 OAE:0003087 a chylothorax AE that has symptomatic; thoracentesis or tube drainage indicated YH, MW Grade 2 chylothorax AE CTCAE: E13360 OAE:0003088 a chylothorax AE that has severe symptoms; elective operative intervention indicated YH, MW Grade 3 chylothorax AE CTCAE: E13361 OAE:0003089 an epistaxis AE that has moderate symptoms; medical intervention indicated (e.g., nasal packing, cauterization; topical vasoconstrictors) YH, MW Grade 2 epistaxis AE CTCAE: E13376 OAE:0003090 a Hiccups AE that has interfering with sleep; limiting self care ADL YH, MW Grade 3 hiccups AE CTCAE: E13383 OAE:0003091 a hoarseness AE that has mild or intermittent voice change; fully understandable; self-resolves YH, MW Grade 1 hoarseness AE CTCAE: E13385 OAE:0003092 a hoarseness AE that has Moderate or persistent voice changes; may require occasional repetition but understandable on telephone; medical evaluation indicated YH, MW Grade 2 hoarseness AE CTCAE: E13386 OAE:0003093 a hoarseness AE that has severe voice changes including predominantly whispered speech YH, MW Grade 3 hoarseness AE CTCAE: E13387 OAE:0003094 a hypoxia AE that has decreased oxygen saturation with exercise (e.g., pulse oximeter <88%); intermittent supplemental oxygen YH, MW Grade 2 hypoxia AE CTCAE: E13389 OAE:0003095 a hypoxia AE that has decreased oxygen saturation at rest (e.g., pulse oximeter <88% or PaO2 <=55 mm Hg) YH, MW Grade 3 hypoxia AE CTCAE: E13390 OAE:0003096 a hypoxia AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 hypoxia AE CTCAE: E13391 OAE:0003097 a laryngeal edema AE that has stridor; respiratory distress; hospitalization indicated YH, MW Grade 3 laryngeal edema AE CTCAE: E13396 OAE:0003098 a laryngeal edema AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 laryngeal edema AE CTCAE: E13397 OAE:0003099 a pleural effusion AE that has symptomatic; intervention indicated (e.g., diuretics or limited therapeutic thoracentesis) YH, MW Grade 2 pleural effusion AE CTCAE: E13488 OAE:0003100 a pleural effusion AE that has symptomatic with respiratory distress and hypoxia; surgical intervention including chest tube or pleurodesis indicated YH, MW Grade 3 pleural effusion AE CTCAE: E13489 OAE:0003101 a pleural hemorrhage AE that has asymptomatic; mild hemorrhage confirmed by thoracentesis YH, MW Grade 1 pleural hemorrhage AE CTCAE: E13493 OAE:0003102 a pleural hemorrhage AE that has symptomatic or associated with pneumothorax; chest tube drainage indicated YH, MW Grade 2 pleural hemorrhage AE CTCAE: E13494 OAE:0003103 a pleural hemorrhage AE that has >1000 ml of blood evacuated; persistent bleeding (150-200 ml/hr for 2 - 4 hr); persistent transfusion indicated; elective operative intervention indicated YH, MW Grade 3 pleural hemorrhage AE CTCAE: E13495 OAE:0003104 a pneumonitis AE that has severe symptoms; limiting self care ADL; oxygen indicated YH, MW Grade 3 pneumonitis AE CTCAE: E13505 OAE:0003105 a pneumonitis AE that has life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 pneumonitis AE CTCAE: E13506 OAE:0003106 a pneumothorax AE that has symptomatic; intervention indicated (e.g., tube placement without sclerosis) YH, MW Grade 2 pneumothorax AE CTCAE: E13510 OAE:0003107 a pneumothorax AE that has sclerosis and/or operative intervention indicated; hospitalization indicated YH, MW Grade 3 pneumothorax AE CTCAE: E13511 OAE:0003108 a productive cough AE that has occasional/minimal production of sputum with cough YH, MW Grade 1 productive cough AE CTCAE: E13518 OAE:0003109 a productive cough AE that has moderate sputum production; limiting instrumental ADL YH, MW Grade 2 productive cough AE CTCAE: E13519 OAE:0003110 a productive cough AE that has persistent or copious production of sputum; limiting self care ADL YH, MW Grade 3 productive cough AE CTCAE: E13520 OAE:0003111 a pulmonary edema AE that has radiologic findings only; minimal dyspnea on exertion YH, MW Grade 1 pulmonary edema AE CTCAE: E13522 OAE:0003112 a pulmonary edema AE that has moderate dyspnea on exertion; medical intervention indicated; limiting instrumental ADL YH, MW Grade 2 pulmonary edema AE CTCAE: E13523 OAE:0003113 a pulmonary edema AE that has severe dyspnea or dyspnea at rest; oxygen indicated; limiting self care ADL YH, MW Grade 3 pulmonary edema AE CTCAE: E13524 OAE:0003114 a pulmonary edema AE that has life-threatening respiratory compromise; urgent intervention or intubation with ventilatory support indicated YH, MW Grade 4 pulmonary edema AE CTCAE: E13525 OAE:0003115 a pulmonary fibrosis AE that has mild hypoxemia; radiologic pulmonary fibrosis <25% of lung volume YH, MW Grade 1 pulmonary fibrosis AE CTCAE: E13528 OAE:0003116 a pulmonary fibrosis AE that has moderate hypoxemia; evidence of pulmonary hypertension; radiographic pulmonary fibrosis 25 - 50% YH, MW Grade 2 pulmonary fibrosis AE CTCAE: E13529 OAE:0003117 a pulmonary fibrosis AE that has severe hypoxemia; evidence of right-sided heart failure; radiographic pulmonary fibrosis >50 - 75% YH, MW Grade 3 pulmonary fibrosis AE CTCAE: E13530 OAE:0003118 a pulmonary fibrosis AE that has life-threatening consequences (e.g., hemodynamic/pulmonary complications); intubation with ventilatory support indicated; radiographic pulmonary fibrosis >75% with severe honeycombing YH, MW Grade 4 pulmonary fibrosis AE CTCAE: E13531 OAE:0003119 a pulmonary hypertension AE that has minimal dyspnea; findings on physical exam or other evaluation YH, MW Grade 1 pulmonary hypertension AE CTCAE: E13540 OAE:0003120 a pulmonary hypertension AE that has moderate dyspnea, cough; requiring evaluation by cardiac catheterization and medical intervention YH, MW Grade 2 pulmonary hypertension AE CTCAE: E13541 OAE:0003121 a pulmonary hypertension AE that has severe symptoms, associated with hypoxemia, right heart failure; oxygen indicated YH, MW Grade 3 pulmonary hypertension AE CTCAE: E13542 OAE:0003122 a pulmonary hypertension AE that has life-threatening airway consequences; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 pulmonary hypertension AE CTCAE: E13543 OAE:0003123 a sinus disorder AE that has asymptomatic mucosal crusting; blood-tinged secretions YH, MW Grade 1 sinus disorder AE CTCAE: E13561 OAE:0003124 a sinus disorder AE that has symptomatic stenosis or edema/narrowing interfering with airflow; limiting instrumental ADL YH, MW Grade 2 sinus disorder AE CTCAE: E13562 OAE:0003125 a sinus disorder AE that has stenosis with significant nasal obstruction; limiting self care ADL YH, MW Grade 3 sinus disorder AE CTCAE: E13563 OAE:0003126 a sinus disorder AE that has necrosis of soft tissue or bone; urgent operative intervention indicated YH, MW Grade 4 sinus disorder AE CTCAE: E13564 OAE:0003127 a sore throat AE that has Severe pain; limiting self care ADL; limiting ability to swallow YH, MW Grade 3 sore throat AE CTCAE: E13578 OAE:0003128 a stridor AE that has respiratory distress limiting self care ADL; medical intervention indicated YH, MW Grade 3 stridor AE CTCAE: E13580 OAE:0003129 a stridor AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) YH, MW Grade 4 stridor AE CTCAE: E13581 OAE:0003130 a voice alteration AE that has mild or intermittent change from normal voice YH, MW Grade 1 voice alteration AE CTCAE: E13602 OAE:0003131 a voice alteration AE that has moderate or persistent change from normal voice; still understandable YH, MW Grade 2 voice alteration AE CTCAE: E13603 OAE:0003132 a voice alteration AE that has severe voice changes including predominantly whispered speech; may require frequent repetition or face-to-face contact for understandability; may require assistive technology YH, MW Grade 3 voice alteration AE CTCAE: E13604 OAE:0003133 a wheezing AE that has detectable airway noise with minimal symptoms YH, MW Grade 1 wheezing AE CTCAE: E13606 OAE:0003134 a wheezing AE that has severe respiratory symptoms limiting self care ADL; oxygen therapy or hospitalization indicated YH, MW Grade 3 wheezing AE CTCAE: E13608 OAE:0003135 a menorrhagia AE that has moderate symptoms; medical intervention indicated (e.g., hormones) YH, MW Grade 2 menorrhagia AE CTCAE: E13134 OAE:0003136 a menorrhagia AE that has severe; transfusion indicated; surgical intervention indicated (e.g., hysterectomy) YH, MW Grade 3 menorrhagia AE CTCAE: E13135 OAE:0003137 an acute kidney injury AE that has creatinine level increase of >0.3 mg/dL; creatinine 1.5 - 2.0 x above baseline YH, MW Grade 1 acute kidney injury AE CTCAE: E12974 OAE:0003138 an acute kidney injury AE that has creatinine 2 - 3 x above baseline YH, MW Grade 2 acute kidney injury AE CTCAE: E12975 OAE:0003139 an acute kidney injury AE that has creatinine >3 x baseline or >4.0 mg/dL; hospitalization indicated YH, MW Grade 3 acute kidney injury AE CTCAE: E12976 OAE:0003140 a hematuria AE that has symptomatic; urinary catheter or bladder irrigation indicated; limiting instrumental ADL YH, MW Grade 2 hematuria AE CTCAE: E13002 OAE:0003141 a hematuria AE that has gross hematuria; transfusion, IV medications or hospitalization indicated; elective endoscopic, radiologic or operative intervention indicated; limiting self care ADL YH, MW Grade 3 hematuria AE CTCAE: E13003 OAE:0003142 an urinary incontinence AE that has occasional (e.g., with coughing, sneezing, etc.), pads not indicated YH, MW Grade 1 urinary incontinence AE CTCAE: E13043 OAE:0003143 an urinary incontinence AE that has spontaneous; pads indicated; limiting instrumental ADL YH, MW Grade 2 urinary incontinence AE CTCAE: E13044 OAE:0003144 an urinary incontinence AE that has Intervention indicated (e.g., clamp, collagen injections); operative intervention indicated; limiting self care ADL YH, MW Grade 3 urinary incontinence AE CTCAE: E13045 OAE:0003145 an urinary retention AE that has urinary, suprapubic or intermittent catheter placement not indicated; able to void with some residual YH, MW Grade 1 urinary retention AE CTCAE: E13047 OAE:0003146 an urinary retention AE that has placement of urinary, suprapubic or intermittent catheter placement indicated; medication indicated YH, MW Grade 2 urinary retention AE CTCAE: E13048 OAE:0003147 an urinary retention AE that has elective operative or radiologic intervention indicated; substantial loss of affected kidney function or mass YH, MW Grade 3 urinary retention AE CTCAE: E13049 OAE:0003148 a suicidal ideation AE that has increased thoughts of death but no wish to kill oneself YH, MW Grade 1 suicidal ideation AE CTCAE: E12965 OAE:0003149 a suicidal ideation AE that has suicidal ideation with no specific plan or intent YH, MW Grade 2 suicidal ideation AE CTCAE: E12966 OAE:0003150 a suicidal ideation AE that has specific plan to commit suicide without serious intent to die which may not require hospitalization YH, MW Grade 3 suicidal ideation AE CTCAE: E12967 OAE:0003151 a suicidal ideation AE that has specific plan to commit suicide with serious intent to die which requires hospitalization YH, MW Grade 4 suicidal ideation AE CTCAE: E12968 OAE:0003152 a suicide attempt AE that has suicide attempt or gesture without intent to die which may not require hospitalization YH, MW Grade 3 suicide attempt AE CTCAE: E12970 OAE:0003153 a suicide attempt AE that has suicide attempt with intent to die which requires hospitalization YH, MW Grade 4 suicide attempt AE CTCAE: E12971 OAE:0003154 an aphonia AE that has voicelessness; unable to speak YH, MW Grade 3 aphonia AE CTCAE: E12590 OAE:0003155 a depressed level of consciousness AE that has decreased level of alertness YH, MW Grade 1 depressed level of consciousness AE CTCAE: E12626 OAE:0003156 a depressed level of consciousness AE that has Sedation; slow response to stimuli; limiting instrumental ADL YH, MW Grade 2 depressed level of consciousness AE CTCAE: E12627 OAE:0003157 a depressed level of consciousness AE that is difficult to arouse YH, MW Grade 3 depressed level of consciousness AE CTCAE: E12628 OAE:0003158 a dysgenusia AE that has altered taste but no change in diet YH, MW Grade 1 dysgeusia AE CTCAE: E12644 OAE:0003159 a dysgenusia AE that has altered taste with change in diet (e.g., oral supplements); noxious or unpleasant taste; loss of taste YH, MW Grade 2 dysgeusia AE CTCAE: E12645 OAE:0003160 a leukoencephalopathy AE that has asymptomatic; small focal T2/FLAIR hyperintensities; involving periventricular white matter or <1/3 of susceptible areas of cerebrum +/- mild increase in subarachnoid space (SAS) and/or mild ventriculomegaly YH, MW Grade 1 leukoencephalopathy AE CTCAE: E12713 OAE:0003161 a leukoencephalopathy AE that has moderate symptoms; focal T2/FLAIR hyperintensities, involving periventricular white matter extending into centrum semiovale or involving 1/3 to 2/3 of susceptible areas of cerebrum +/- moderate increase in SAS and/or moderate ventriculomegaly YH, MW Grade 2 leukoencephalopathy AE CTCAE: E12714 OAE:0003162 a leukoencephalopathy AE that has severe symptoms; extensive T2/FLAIR hyperintensities, involving periventricular white matter involving 2/3 or more of susceptible areas of cerebrum +/- moderate to severe increase in SAS and/or moderate to severe ventriculomegaly YH, MW Grade 3 leukoencephalopathy AE CTCAE: E12715 OAE:0003163 a leukoencephalopathy AE that has life-threatening consequences; extensive T2/FLAIR hyperintensities, involving periventricular white matter involving most of susceptible areas of cerebrum +/- moderate to severe increase in SAS and/or moderate to severe ventriculomegaly YH, MW Grade 4 leukoencephalopathy AE CTCAE: E12716 OAE:0003164 a myelitis AE that has asymptomatic; mild signs (e.g., Babinski's reflex or Lhermitte's sign) YH, MW Grade 1 myelitis AE CTCAE: E12733 OAE:0003165 a myelitis AE that has moderate weakness or sensory loss; limiting instrumental ADL YH, MW Grade 2 myelitis AE CTCAE: E12734 OAE:0003166 a myelitis AE that has severe weakness or sensory loss; limiting self care ADL YH, MW Grade 3 myelitis AE CTCAE: E12735 OAE:0003167 a presyncope AE that has present (e.g., near fainting) YH, MW Grade 2 presyncope AE CTCAE: E12779 OAE:0003168 a seizure AE that has brief partial seizure; no loss of consciousness YH, MW Grade 1 seizure AE CTCAE: E12805 OAE:0003169 a seizure AE that has brief generalized seizure YH, MW Grade 2 seizure AE CTCAE: E12806 OAE:0003170 a seizure AE that has multiple seizures despite medical intervention YH, MW Grade 3 seizure AE CTCAE: E12807 OAE:0003171 a seizure AE that has life-threatening; prolonged repetitive seizures YH, MW Grade 4 seizure AE CTCAE: E12808 OAE:0003172 a somnolence AE that has mild but more than usual drowsiness or sleepiness YH, MW Grade 1 somnolence AE CTCAE: E12815 OAE:0003173 a somnolence AE that has moderate sedation; limiting instrumental ADL YH, MW Grade 2 somnolence AE CTCAE: E12816 OAE:0003174 a somnolence AE that has obtundation or stupor YH, MW Grade 3 somnolence AE CTCAE: E12817 OAE:0003175 a syncope AE that has fainting; orthostatic collapse YH, MW Grade 3 syncope AE CTCAE: E12833 OAE:0003176 an arthritis AE that has mild pain with inflammation, erythema, or joint swelling YH, MW Grade 1 arthritis AE CTCAE: E12379 OAE:0003177 an arthritis AE that has moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL YH, MW Grade 2 arthritis AE CTCAE: E12380 OAE:0003178 an arthritis AE that has severe pain associated with signs of inflammation, erythema, or joint swelling; irreversible joint damage; disabling; limiting self care ADL YH, MW Grade 3 arthritis AE CTCAE: E12381 OAE:0003179 a joint range of motion decreased AE that requires <=25% loss of ROM (range of motion); decreased ROM limiting athletic activity YH, MW Grade 1 joint range of motion decreased AE CTCAE: E12436 OAE:0003180 a joint range of motion decreased AE that requires >25 - 50% decrease in ROM; limiting instrumental ADL YH, MW Grade 2 joint range of motion decreased AE CTCAE: E12437 OAE:0003181 a joint range of motion decreased AE that requires >50% decrease in ROM; limiting self care ADL; disabling YH, MW Grade 3 joint range of motion decreased AE CTCAE: E12438 OAE:0003182 an osteoporosis AE that has radiologic evidence of osteoporosis or Bone Mineral Density (BMD) t-score -1 to -2.5 (osteopenia); no loss of height or intervention indicated YH, MW Grade 1 osteoporosis AE CTCAE: E12509 OAE:0003183 an osteoporosis AE that has BMD t-score <-2.5; loss of height <2 cm; anti-osteoporotic therapy indicated; limiting instrumental ADL YH, MW Grade 2 osteoporosis AE CTCAE: E12510 OAE:0003184 an osteoporosis AE that has loss of height >=2 cm; hospitalization indicated; limiting self care ADL YH, MW Grade 3 osteoporosis AE CTCAE: E12511 OAE:0003185 an acidosis AE that has pH <normal, but >=7.3 YH, MW Grade 1 acidosis AE CTCAE: E12238 OAE:0003186 an acidosis AE that has pH <7.3 YH, MW Grade 3 acidosis AE CTCAE: E12239 OAE:0003187 an anorexia AE that has loss of appetite without alteration in eating habits YH, MW Grade 1 anorexia AE CTCAE: E12253 OAE:0003188 an anorexia AE that has oral intake altered without significant weight loss or malnutrition; oral nutritional supplements indicated YH, MW Grade 2 anorexia AE CTCAE: E12254 OAE:0003189 an anorexia AE that has associated with significant weight loss or malnutrition (e.g., inadequate oral caloric and/or fluid intake); tube feeding or TPN indicated YH, MW Grade 3 anorexia AE CTCAE: E12255 OAE:0003190 a dehydration AE that has increased oral fluids indicated; dry mucous membranes; diminished skin turgor YH, MW Grade 1 dehydration AE CTCAE: E12259 OAE:0003191 a dehydration AE that requires IIV fluids indicated <24 hrs YH, MW Grade 2 dehydration AE CTCAE: E12260 OAE:0003192 a hypercalcemia AE that has corrected serum calcium of >ULN - 11.5 mg/dL; >ULN - 2.9 mmol/L; Ionized calcium >ULN - 1.5 mmol/L YH, MW Grade 1 hypercalcemia AE CTCAE: E12271 OAE:0003193 a hypercalcemia AE that has corrected serum calcium of >11.5 - 12.5 mg/dL; >2.9 - 3.1 mmol/L; Ionized calcium >1.5 - 1.6 mmol/L; symptomatic YH, MW Grade 2 hypercalcemia AE CTCAE: E12272 OAE:0003194 a hypercalcemia AE that has corrected serum calcium of >12.5 - 13.5 mg/dL; >3.1 - 3.4 mmol/L; Ionized calcium >1.6 - 1.8 mmol/L; hospitalization indicated YH, MW Grade 3 hypercalcemia AE CTCAE: E12273 OAE:0003195 a hypercalcemia AE that has corrected serum calcium of >13.5 mg/dL; >3.4 mmol/L; Ionized calcium >1.8 mmol/L; life-threatening consequences YH, MW Grade 4 hypercalcemia AE CTCAE: E12274 OAE:0003196 a hypeglycemia AE that has fasting glucose value >ULN - 160 mg/dL; Fasting glucose value >ULN - 8.9 mmol/L YH, MW Grade 1 hyperglycemia AE CTCAE: E12277 OAE:0003197 a hypeglycemia AE that has fasting glucose value >160 - 250 mg/dL; Fasting glucose value >8.9 - 13.9 mmol/L YH, MW Grade 2 hyperglycemia AE CTCAE: E12278 OAE:0003198 a hypeglycemia AE that has >250 - 500 mg/dL; >13.9 - 27.8 mmol/L; hospitalization indicated YH, MW Grade 3 hyperglycemia AE CTCAE: E12279 OAE:0003199 a hypeglycemia AE that has >500 mg/dL; >27.8 mmol/L; life-threatening consequences YH, MW Grade 4 hyperglycemia AE CTCAE: E12280 OAE:0003200 a hyperkalemia AE that requires >ULN - 5.5 mmol/L YH, MW Grade 1 hyperkalemia AE CTCAE: E12283 OAE:0003201 a hyperkalemia AE that requires >5.5 - 6.0 mmol/L YH, MW Grade 2 hyperkalemia AE CTCAE: E12284 OAE:0003202 a hyperkalemia AE that requires >6.0 - 7.0 mmol/L; hospitalization indicated YH, MW Grade 3 hyperkalemia AE CTCAE: E12285 OAE:0003203 a hyperkalemia AE that requires >7.0 mmol/L; life-threatening consequences YH, MW Grade 4 hyperkalemia AE CTCAE: E12286 OAE:0003204 a hypertriglyceridemia AE that requires 150 mg/dL - 300 mg/dL; 1.71 mmol/L - 3.42 mmol/L YH, MW Grade 1 hypertriglyceridemia AE CTCAE: E12300 OAE:0003205 a hypertriglyceridemia AE that requires >300 mg/dL - 500 mg/dL; >3.42 mmol/L - 5.7 mmol/L YH, MW Grade 2 hypertriglyceridemia AE CTCAE: E12301 OAE:0003206 a hypertriglyceridemia AE that requires >500 mg/dL - 1000 mg/dL; >5.7 mmol/L - 11.4 mmol/L YH, MW Grade 3 hypertriglyceridemia AE CTCAE: E12302 OAE:0003207 a hypertriglyceridemia AE that requires >1000 mg/dL; >11.4 mmol/L; life-threatening consequences YH, MW Grade 4 hypertriglyceridemia AE CTCAE: E12303 OAE:0003208 a hyperuricemia AE that requires >ULN - 10 mg/dL (0.59 mmol/L) without physiologic consequences YH, MW Grade 1 hyperuricemia AE CTCAE: E12306 OAE:0003209 a hyperuricemia AE that requires >ULN - 10 mg/dL (0.59 mmol/L) with physiologic consequences YH, MW Grade 3 hyperuricemia AE CTCAE: E12307 OAE:0003210 a hyperuricemia AE that requires >10 mg/dL; >0.59 mmol/L; life-threatening consequences YH, MW Grade 4 hyperuricemia AE CTCAE: E12308 OAE:0003211 a hypoalbuminemia AE that requires NCI<LLN - 3 g/dL; <LLN - 30 g/L YH, MW Grade 1 hypoalbuminemia AE CTCAE: E12311 OAE:0003212 a hypoalbuminemia AE that requires NCI<3 - 2 g/dL; <30 - 20 g/L YH, MW Grade 2 hypoalbuminemia AE CTCAE: E12312 OAE:0003213 a hypoalbuminemia AE that requires NCI<2 g/dL; <20 g/L YH, MW Grade 3 hypoalbuminemia AE CTCAE: E12313 OAE:0003214 a hypocalcemia AE that requires corrected serum calcium of <LLN - 8.0 mg/dL; <LLN - 2.0 mmol/L; Ionized calcium <LLN - 1.0 mmol/L YH, MW Grade 1 hypocalcemia AE CTCAE: E12317 OAE:0003215 a hypocalcemia AE that requires corrected serum calcium of <8.0 - 7.0 mg/dL; <2.0 - 1.75 mmol/L; Ionized calcium <1.0 - 0.9 mmol/L; symptomatic YH, MW Grade 2 hypocalcemia AE CTCAE: E12318 OAE:0003216 a hypocalcemia AE that requires corrected serum calcium of <7.0 - 6.0 mg/dL; <1.75 - 1.5 mmol/L; Ionized calcium <0.9 - 0.8 mmol/L; hospitalization indicated YH, MW Grade 3 hypocalcemia AE CTCAE: E12319 OAE:0003217 a hypocalcemia AE that requires corrected serum calcium of <6.0 mg/dL; <1.5 mmol/L; Ionized calcium <0.8 mmol/L; life-threatening consequences YH, MW Grade 4 hypocalcemia AE CTCAE: E12320 OAE:0003218 a hypoglycernia AE that requires <LLN - 55 mg/dL; <LLN - 3.0 mmol/L YH, MW Grade 1 hypoglycemia AE CTCAE: E12323 OAE:0003219 a hypoglycernia AE that requires <55 - 40 mg/dL; <3.0 - 2.2 mmol/L YH, MW Grade 2 hypoglycemia AE CTCAE: E13874 OAE:0003220 a hypoglycernia AE that requires <40 - 30 mg/dL; <2.2 - 1.7 mmol/L YH, MW Grade 3 hypoglycemia AE CTCAE: E12324 OAE:0003221 a hypoglycernia AE that requires <30 mg/dL; <1.7 mmol/L; life-threatening consequences; seizures YH, MW Grade 4 hypoglycemia AE CTCAE: E12325 OAE:0003222 a hypomagnesemia AE that requires <LLN - 1.2 mg/dL; <LLN - 0.5 mmol/L YH, MW Grade 1 hypomagnesemia AE CTCAE: E12334 OAE:0003223 a hypomagnesemia AE that requires <1.2 - 0.9 mg/dL; <0.5 - 0.4 mmol/L YH, MW Grade 2 hypomagnesemia AE CTCAE: E12335 OAE:0003224 a hypomagnesemia AE that requires <0.9 - 0.7 mg/dL; <0.4 - 0.3 mmol/L YH, MW Grade 3 hypomagnesemia AE CTCAE: E12336 OAE:0003225 a hypomagnesemia AE that requires <0.7 mg/dL; <0.3 mmol/L; life-threatening consequences YH, MW Grade 4 hypomagnesemia AE CTCAE: E12337 OAE:0003226 a hypophosphatemia AE that requires <LLN - 2.5 mg/dL; <LLN - 0.8 mmol/L YH, MW Grade 1 hypophosphatemia AE CTCAE: E12345 OAE:0003227 a hypophosphatemia AE that requires <2.5 - 2.0 mg/dL; <0.8 - 0.6 mmol/L YH, MW Grade 2 hypophosphatemia AE CTCAE: E12346 OAE:0003228 a hypophosphatemia AE that requires <2.0 - 1.0 mg/dL; <0.6 - 0.3 mmol/L YH, MW Grade 3 hypophosphatemia AE CTCAE: E12347 OAE:0003229 a hypophosphatemia AE that requires <1.0 mg/dL; <0.3 mmol/L; life-threatening consequences YH, MW Grade 4 hypophosphatemia AE CTCAE: E12348 OAE:0003231 a cough AE that shows an increased rate of coughing YH, JX WEB: http://medical-dictionary.thefreedictionary.com/cough 10011228 cough increased AE OAE:0003233 a viral infection AE that is caused by a herpes virus. Note that there are 8 herpesvirus types. YH, JX WEB: https://en.wikipedia.org/wiki/Herpesviridae 10019972 herpes viral infection AE OAE:0003234 a herpez zoster AE that occurs in children. YH, JX WEB: https://en.wikipedia.org/wiki/Varicella_zoster_virus chickenpox AE OAE:0003235 a nervous system AE that shows abnormal neurologic reflexes, which can be tesetd by the knee jerk reaction. JX, YH WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=20423 10038254 abnormal reflex AE OAE:0003236 an abnormal reflex AE where the patient has a condition of below normal or absent reflexes (areflexia). Hyporeflexia is the condition of below normal or absent reflexes. Hyporeflexia is generally associated with a lower motor neuron deficit (at the alpha motor neurons from the spinal cord to muscle). SS, JX, YH reflexes decreased AE WEB: http://en.wikipedia.org/wiki/Hyporeflexia WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=20423 10021089 hyporeflexia AE HPO: HP_0009072 SIDER: C0151888 OAE:0003237 an abnormal reflex AE that has an outcome of overactive reflexes, indicative of upper motor neuron disease as well as lessening or loss of control ordinarily exerted by higher brain centers of lower neural pathways. JX, YH WEB: https://en.wikipedia.org/wiki/Hyperreflexia 10020745 hyperreflexia AE HPO: HP_0001347 SIDER: C0151889 OAE:0003238 a cardiac arrest AE where there is no discernible electrical activity on the ECG monitor. YH, MW asystole WEB: http://www.cardiachealth.org/asystole-and-pulseless-electrical-activity 10003586 Asystole is the absence of electrical activity in the heart, as evidenced by a flat line on an EKG. Cardiac arrest is a more general term for conditions where the heart is not circulating blood. Ventricular fibrillation (V-fib) or pulseless Ventricular tachycardia (V-tach) are examples of EKG rhythms which also will produce cardiac arrest, but are not asystole. Pulseless electrical activity (PEA) is another catch-all where there is an otherwise survivable EKG, but no blood is circulating. This can be caused by trauma to the heart, or tremendous blood loss, among other reasons. See: https://answers.yahoo.com/question/index?qid=20081027100243AAy0yt4 asystole AE CTCAE: E10077 NCit:C50479 OAE:0003239 an eye inflammation AE that occurs at the corneal area. MW, YH WEB: http://www.mayoclinic.org/diseases-conditions/keratitis/basics/definition/con-20035288 10023332 keratitis AE CTCAE: E10397 NCIT: C26805 OAE:0003240 an infection AE where one or two eyes get infected by bacteria, fungi, or viruses. MW, YH WEB: https://www.nlm.nih.gov/medlineplus/eyeinfections.html 10015929 eye infection AE CTCAE: E11391 NCIT: C45372 OAE:0003241 an inflammation AE that shows inflammation at the location of appendix. MW, YH 10003011 appendicitis AE CTCAE: E11292 NCIt: C35145 OAE:0003242 an electrocardiogram QT prolonged AE that estimates the QT interval at a heart rate of 60 bpm. MW, YH WEB: http://lifeinthefastlane.com/ecg-library/basics/qt_interval/ 10014383 electrocardiogram QT corrected interval prolonged AE CTCAE: E12146 NCIt: C71034 UMLS: C0855333 OAE:0003244 an anorexia AE that has loss of appetite of greasy food. QL, YH WEB: http://www.anxietycare.org.uk/docs/eating.asp aversion to greasy food AE OAE:0003246 a skin AE that has an outcome of injury to the skin and underlying tissues from exposure to a large external dose of radiation MW, YH WEB: http://www.dermnetnz.org/reactions/radiation-dermatitis.html 10061103 dermatitis radiation AE CTCAE: E11675 NCIt: C0034561 OAE:0003247 a gastric disorder AE that shows an rupture in the stomach QL, YH stomach rupture WEB: http://medical-dictionary.thefreedictionary.com/gastrorrhexis gastrorrhexis AE OAE:0003248 an injury AE that refers to break or burst suddenly (esp. of a pipe, a vessel, or a bodily part such as an organ or membrane) YH. QL WEB: https://en.wikipedia.org/wiki/Rupture rupture AE OAE:0003249 a radiation skin injury AE that shows skin burn from exposure to a large external dose of radiation MW, YH WEB: https://en.wikipedia.org/wiki/Radiation_burn 10063640 radiation burn AE OAE:0003250 a troponin AE which indicates increased levels of cardiac troponin I in a biological specimen MW, YH 10007612 cardiac troponin I increased AE CTCAE: E12116 NCIt: C78230 OAE:0003251 a musculoskeletal or connective tissue AE that has greater growth than expected for age. MW, YH 10018746 growth accelerated AE CTCAE: E10317 NCIt: C83495 OAE:0003252 a surgery AE that has the finding of a previously undocumented problem that occurs after a thoracic procedure. MW, YH 10056745 postoperative thoracic procedure complication AE CTCAE: E11909 NCIt: C78567 OAE:0003253 a uterine AE that has a rupture in the uterine wall. MW, YH 10046810 uterine perforation AE CTCAE: E12028 NCIt: C50793 OAE:0003254 a female reproductive system AE that has the finding of rupture of the fallopian tube wall. MW, YH 10065790 fallopian tube perforation AE CTCAE: E11697 NCIt: C78294 OAE:0003255 an endocrine system AE that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency. MW, YH 10001367 adrenal insufficiency AE CTCAE: E10298 NCIt: C26691 OAE:0003256 an endocrine system AE that has signs and symptoms that resemble Cushing's disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids. MW, YH 10011655 cushingoid AE CTCAE: E10304 NCIt: C37938 OAE:0003257 an endocrine system AE that has unusually late sexual maturity. MW, YH 10012205 delayed puberty AE CTCAE: E10308 NCIt: C62587 OAE:0003258 an endocrine system AE that has an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood). MW, YH 10020705 hyperparathyroidism AE CTCAE: E10319 NCIt: C48259 OAE:0003259 an endocrine system AE that has a decrease in production of parathyroid hormone by the parathyroid glands. MW, YH 10021041 hypoparathyroidism AE CTCAE: E10328 NCIt: C78350 OAE:0003260 an endocrine system AE that has inappropriate masculinization occurring in a female or prepubertal male. MW, YH 10047488 virilization AE CTCAE: E10343 NCIt: C79859 OAE:0003261 an endocrine system AE that has unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys. MW, YH 10058084 precocious puberty AE CTCAE: E10340 NCIt: C79704 OAE:0003262 a medical intervention site AE that has the finding of tumor-like collection of serum in the tissues. MW, YH 10040102 seroma AE CTCAE: E11938 NCIt: C50739 OAE:0003263 a medical intervention site AE that has a circumscribed, inflammatory and necrotic erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure. MW, YH 10042127 stomal ulcer AE CTCAE: E11965 NCIt: C79766 OAE:0003264 a medical intervention site AE that has a finding of blood leakage from the intestinal stoma. MW, YH 10049468 intestinal stoma site bleeding AE CTCAE: E11764 NCIt: C78371 OAE:0003265 a medical intervention site AE that has the finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures). MW, YH 10050457 pancreatic anastomotic leak AE CTCAE: E11891 NCIt: C78518 OAE:0003266 a medical intervention site AE that has the finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures). MW, YH 10050458 biliary anastomotic leak AE CTCAE: E11654 NCIt: C78183 OAE:0003267 a medical intervention site AE that has the finding of blockage of the normal flow of the contents of the intestinal stoma. MW, YH 10059094 intestinal stoma leak AE CTCAE: E11759 NCIt: C78370 OAE:0003268 a medical intervention site AE that has the finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body). MW, YH 10059095 intestinal stoma leak AE CTCAE: E11753 NCIt: C78369 OAE:0003269 a medical intervention site AE that has the finding of a previously undocumented problem related to the vascular access site. MW, YH 10062169 vascular access complication AE CTCAE: E12046 NCIt: C78709 OAE:0003270 a medical intervention site AE that has the finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065705 pharyngeal anastomotic leak AE CTCAE: E11897 NCIt: C78550 OAE:0003271 a medical intervention site AE that has the finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface. MW, YH 10065745 prolapse of intestinal stoma AE CTCAE: E11914 NCIt: C78570 OAE:0003272 a medical intervention site AE that has the finding of bleeding from the urostomy site. MW, YH 10065748 urostomy site bleeding AE CTCAE: E12011 NCIt: C78682 OAE:0003273 a medical intervention site AE that has the finding of blood leakage from the tracheostomy site. MW, YH 10065749 tracheostomy site bleeding AE CTCAE: E11981 NCIt: C78648 OAE:0003274 a medical intervention site AE that has the finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065788 fallopian tube anastomotic leak AE CTCAE: E11691 NCIt: C78292 OAE:0003275 a medical intervention site AE that has the finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065802 bladder anastomotic leak AE CTCAE: E11660 NCIt: C78206 OAE:0003276 a medical intervention site AE that has the finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065803 kidney anastomotic leak AE CTCAE: E11879 NCIt: C78406 OAE:0003277 a medical intervention site AE that has the finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065814 ureteric anastomotic leak AE CTCAE: E11987 NCIt: C78662 OAE:0003278 a medical intervention site AE that has the finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065815 urethral anastomotic leak CTCAE: E11993 NCIt: C78667 OAE:0003279 a medical intervention site AE that has the finding of displacement of the urostomay MW, YH 10065822 prolapse of urostomy AE CTCAE: E11920 NCIt: C78571 OAE:0003280 a medical intervention site AE that has the finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065879 gastrointestinal anastomotic leak CTCAE: E11715 NCIt: C78318 OAE:0003281 a medical intervention site AE that has the finding of leakage of contents from a urostomy. MW, YH 10065882 urostomy leak AE CTCAE: E11999 NCIt: C78679 OAE:0003282 a medical intervention site AE that has the finding of blockage of the urostomy. MW, YH 10065883 urostomy obstruction AE CTCAE: E12005 NCIt: C78680 OAE:0003283 a medical intervention site AE that has the finding of narrowing of the opening of a urostomy. MW, YH 10065885 urostomy stenosis AE CTCAE: E12017 NCIt: C78683 OAE:0003284 a medical intervention site AE that has the finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065886 uterine anastomotic leak AE CTCAE: E12022 NCIt: C78684 OAE:0003285 a medical intervention site AE that has the finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065887 vaginal anastomotic leak AE CTCAE: E12034 NCIt: C78698 OAE:0003286 a medical intervention site AE that has the finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065888 vas deferens anastomotic leak AE CTCAE: E12040 NCIt: C78704 OAE:0003287 a medical intervention site AE that has the finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine. MW, YH 10065891 large intestinal anastomotic leak AE CTCAE: E11885 NCIt: C78408 OAE:0003288 a medical intervention site AE that has the finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel. MW, YH 10065892 small intestinal anastomotic leak AE CTCAE: E11942 NCIt: C78612 OAE:0003289 a medical intervention site AE that has the finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065893 gastric anastomotic leak AE CTCAE: E11709 NCIt: C78310 OAE:0003290 a medical intervention site AE that has the finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065894 rectal anastomotic leak AE CTCAE: E11932 NCIt: C78583 OAE:0003291 a medical intervention site AE that has the finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065897 spermatic cord anastomotic leak AE CTCAE: E11948 NCIt: C78622 OAE:0003292 a medical intervention site AE that has the finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body). MW, YH 10065898 stenosis of gastrointestinal stoma AE CTCAE: E11960 NCIt: C78628 OAE:0003293 a medical intervention site AE that has the finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures). MW, YH 10065961 esophageal anastomotic leak AE CTCAE: E11681 NCIt: C78270 OAE:0003294 an infection AE that has an infectious process involving the bladder. MW, YH 10005047 bladder infection AE CTCAE: E11309 NCIt: C26738 OAE:0003295 an infection AE that has an infectious process involving the uterine cervix. MW, YH 10008330 cervicitis infection AE CTCAE: E11337 NCIt: C78360 OAE:0003296 an infection AE that has an infectious process involving the brain tissue. MW, YH 10014594 encephalitis infection AE CTCAE: E11365 NCIt: C79550 OAE:0003297 an infection AE that has an infectious process involving the brain and spinal cord tissues. MW, YH 10014621 encephalomyelitis infection AE CTCAE: E11369 NCIt: C79551 OAE:0003298 an infection AE that has an infectious process involving the endocardial layer of the heart. MW, YH 10014678 endocarditis infective AE CTCAE: E11373 NCIt: C78265 OAE:0003299 an infection AE that has an infectious process involving the gums. MW, YH 10018784 gum infection AE CTCAE: E11400 NCIt: C78329 OAE:0003300 an infection AE that has an infectious process involving the skeletal muscles. MW, YH 10021918 infective myositis AE CTCAE: E11421 NCIt: C26984 OAE:0003301 an infection AE that has an infectious process involving a joint. MW, YH 10023216 joint infection AE CTCAE: E11426 NCIt: C78402 OAE:0003302 an infection AE that has an infectious process involving the kidney. MW, YH 10023424 kidney infection AE CTCAE: E11431 NCIt: C34965 OAE:0003303 an infection AE that has an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer's ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage. MW, YH 10033072 otitis externa AE CTCAE: E11472 NCIt: C3299 OAE:0003304 an infection AE that has an infectious process involving the salivary gland. MW, YH 10039413 salivary gland infection AE CTCAE: E11550 NCIt: C78601 OAE:0003305 an infection AE that has an infectious process involving the wound. MW, YH 10048038 wound infection AE CTCAE: E11635 NCIt: C45234 OAE:0003306 an infection AE that has an infectious process involving a tooth. MW, YH 10048762 tooth infection AE CTCAE: E11594 NCIt: C78639 OAE:0003307 an infection AE that has an infectious process involving the prostate gland. MW, YH 10050662 prostate infection AE CTCAE: E11540 NCIt: C27615 OAE:0003308 an infection AE that has an infectious process involving the lymph nodes. MW, YH 10050823 lymph gland infection AE CTCAE: E11449 NCIt: C26821 OAE:0003309 an infection AE that has an infectious process involving the pancreas. MW, YH 10051741 pancreas infection AE CTCAE: E11487 NCIt: C78517 OAE:0003310 an infection AE that has an infectious process involving the urethra. MW, YH 10052298 urethral infection AE CTCAE: E11609 NCIt: C78671 OAE:0003311 an infection AE that has an infectious process involving the ovary. MW, YH 10055005 ovarian infection AE CTCAE: E11482 NCIt: C78512 OAE:0003312 an infection AE that has an infectious process involving the abdominal cavity. MW, YH 10056519 abdominal infection AE CTCAE: E11282 NCIt: C35669 OAE:0003313 an infection AE that has an infectious process involving the liver. MW, YH 10056522 hepatic infection AE CTCAE: E11406 NCIt: C78339 OAE:0003314 an infection AE that has an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein. MW, YH 10056627 phlebitis infective AE CTCAE: E11530 NCIt: C78558 OAE:0003315 an infection AE that has an infectious process involving the peritoneum. MW, YH 10057262 peritoneal infection AE CTCAE: E11521 NCIt: C78540 OAE:0003316 an infection AE that has an infectious process involving the mediastinum. MW, YH 10057483 mediastinal infection AE CTCAE: E11454 NCIt: C26827 OAE:0003317 an infection AE that has an infectious process involving the pelvic cavity. MW, YH 10058674 pelvic infection AE CTCAE: E11501 NCIt: C3889 OAE:0003318 an infection AE that has an infectious process involving the esophagus. MW, YH 10058804 esophageal infection AE CTCAE: E11386 NCIt: C78277 OAE:0003319 an infection AE that has an infectious process involving the small and large intestines. MW, YH 10058838 enterocolitis infectious AE CTCAE: E11381 NCIt: C80513 OAE:0003320 an infection AE that has an infectious process involving the nasal mucosal. MW, YH 10059827 rhinitis infective AE CTCAE: E11548 NCIt: C78599 OAE:0003321 an infection AE that has an infectious process involving the bones. MW, YH 10061017 bone infection AE CTCAE: E11314 NCIt: C26839 OAE:0003322 an infection AE that has an infectious process involving the pleura. MW, YH 10061351 pleural infection AE CTCAE: E11535 NCIt: C78563 OAE:0003323 an infection AE that has an infectious process involving the anal area and the rectum. MW, YH 10061640 anorectal infection AE CTCAE: E11286 NCIt: C78174 OAE:0003324 an infection AE that has an infectious process involving the biliary tract. MW, YH 10061695 biliary tract infection AE CTCAE: E11305 NCIt: C26718 OAE:0003325 an infection AE that has an infectious process involving the penis. MW, YH 10061912 penile infection AE CTCAE: E11506 NCIt: C78526 OAE:0003326 an infection AE that has an infectious process involving the spleen. MW, YH 10062112 splenic infection AE CTCAE: E11584 NCIt: C78627 OAE:0003327 an infection AE that has an infectious process involving the scrotum. MW, YH 10062156 scrotal infection AE CTCAE: E11555 NCIt: C78606 OAE:0003328 an infection AE that has an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues. MW, YH 10062233 uterine infection AE CTCAE: E11619 NCIt: C26764 OAE:0003329 an infection AE that has an infectious process involving the gallbladder. MW, YH 10062632 gallbladder infection AE CTCAE: E11396 NCIt: C78306 OAE:0003330 an infection AE that has an infectious process involving a stoma (surgically created opening on the surface of the body). MW, YH 10064505 stoma site infection AE CTCAE: E11588 NCIt: C78629 OAE:0003331 an infection AE that has an infectious process involving an artery. MW, YH 10065744 arteritis infective AE CTCAE: E11301 NCIt: C34399 OAE:0003332 an infection AE that has an infectious process involving the duodenum. MW, YH 10065752 duodenal infection AE CTCAE: E11360 NCIt: C78258 OAE:0003333 an infection AE that has an infectious process involving the lips. MW, YH 10065755 lip infection AE CTCAE: E11440 NCIt: C78434 OAE:0003334 an infection AE that has an infectious process involving the cecum. MW, YH 10065761 cecal infection AE CTCAE: E11333 NCIt: C78235 OAE:0003335 an infection AE that has an infectious process involving a mucosal surface. MW, YH 10065764 mucosal infection AE CTCAE: E11462 NCIt: C78454 OAE:0003336 an infection AE that has an infectious process involving a cranial nerve. MW, YH 10065765 cranial nerve infection AE CTCAE: E11352 NCIt: C78248 OAE:0003337 an infection AE that has an infectious process involving the peripheral nerves. MW, YH 10065766 peripheral nerve infection AE CTCAE: E11516 NCIt: C27589 OAE:0003338 an infection AE that has an infectious process involving the small intestine. MW, YH 10065771 small intestine infection AE CTCAE: E11574 NCIt: C78618 OAE:0003339 an infection AE that has an infectious process involving the vulva. MW, YH 10065772 vulval infection AE CTCAE: E11629 NCIt: C78716 OAE:0003340 a pain AE that has a sensation of marked discomfort in the anal region. MW, YH 10002167 anal pain AE CTCAE: E10486 NCIt: C78172 OAE:0003341 a pain AE that has a sensation of marked discomfort in the gallbladder region. MW, YH 10017638 gallbladder pain AE CTCAE: E11204 NCIt: C78304 OAE:0003342 a pain AE that has a sensation of marked discomfort in the gastrointestinal region. MW, YH 10017999 gastrointestinal pain AE CTCAE: E10755 NCIt: C78320 OAE:0003343 a pain AE that has a sensation of marked discomfort in the liver region. MW, YH 10019705 hepatic pain AE CTCAE: E11224 NCIt: C78341 OAE:0003344 a pain AE that has a sensation of marked discomfort of the lip. MW, YH 10024561 lip pain AE CTCAE: E10857 NCIt: C79684 OAE:0003345 a pain AE that has a sensation of marked discomfort in the rectal region. MW, YH 10038072 rectal pain AE CTCAE: E10977 NCIt: C78587 OAE:0003346 a pain AE that has a sensation of marked discomfort in the stomach. MW, YH 10042112 stomach pain AE CTCAE: E11044 NCIt: C78630 OAE:0003347 a chest pain AE that has discomfort in the chest unrelated to a heart disorder. MW, YH 10062501 non-cardiac chest pain AE CTCAE: E11163 NCIt: C78504 OAE:0003348 a respiratory system AE that has the finding of blockage of the lumen of the trachea. MW, YH 10044291 tracheal obstruction AE CTCAE: E11975 NCIt: C78645 OAE:0003349 a hemorrhage AE that has bleeding from the colon. MW, YH 10009998 colonic hemorrhage AE CTCAE: E10533 NCIt: C78240 OAE:0003350 a hemorrhage AE that has bleeding from the esophagus. MW, YH 10015384 esophageal hemorrhage AE CTCAE: E10645 NCIt: C78271 OAE:0003351 a hemorrhage AE that has bleeding from esophageal varices. MW, YH 10015453 esophageal varices hemorrhage AE CTCAE: E10682 NCIt: C78282 OAE:0003352 a hemorrhage AE that has bleeding from the liver. MW, YH 10019678 hepatic hemorrhage AE CTCAE: E11215 NCIt: C78338 OAE:0003353 a hemorrhage AE that has bleeding from the mouth. MW, YH 10030980 oral hemorrhage AE CTCAE: E10898 NCIt: C79699 OAE:0003354 a hemorrhage AE that has bleeding from the pancreas. MW, YH 10033626 pancreatic hemorrhage AE CTCAE: E10920 NCIt: C78521 OAE:0003355 a hemorrhage AE that has bleeding from the retroperitoneal area. MW, YH 10038981 retroperitoneal hemorrhage AE CTCAE: E10998 NCIt: C26944 OAE:0003356 a hemorrhage AE that has bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus). MW, YH 10051746 lower gastrointestinal hemorrhage AE CTCAE: E10861 NCIt: C78438 OAE:0003357 a hemorrhage AE that has bleeding from the duodenum. MW, YH 10055242 duodenal hemorrhage AE CTCAE: E10588 NCIt: C78257 OAE:0003358 a hemorrhage AE that has bleeding from the ileal wall. MW, YH 10055287 ileal hemorrhage AE CTCAE: E10783 NCIt: C78353 OAE:0003359 a hemorrhage AE that has bleeding in the abdominal cavity. MW, YH 10055291 intra-abdominal hemorrhage AE CTCAE: E10817 NCIt: C78372 OAE:0003360 a hemorrhage AE that has bleeding from the jejunal wall. MW, YH 10055300 jejunal hemorrhage AE CTCAE: E10828 NCIt: C78397 OAE:0003361 a hemorrhage AE that has the finding of bleeding occurring after a surgical procedure. MW, YH 10055322 postoperative hemorrhage AE CTCAE: E11903 NCIt: C34938 OAE:0003362 a hemorrhage AE that has the finding of bleeding from the trachea. MW, YH 10062548 tracheal hemorrhage AE CTCAE: E11969 NCIt: C78642 OAE:0003363 a hemorrhage AE that has bleeding from the cecum. MW, YH 10065747 cecal hemorrhage AE CTCAE: E10511 NCIt: C78234 OAE:0003364 an anus AE that has a narrowing of the lumen of the anal canal. MW, YH 10002176 anal stenosis AE CTCAE: E10490 NCIt: C78173 OAE:0003365 a digestive system AE that has an abnormal communication between the bile ducts and another organ or anatomic site. MW, YH 10004665 biliary fistula AE CTCAE: E11179 NCIt: C79540 OAE:0003366 a digestive system AE that has subject-reported feeling of uncomfortable fullness of the abdomen. MW, YH 10005265 bloating AE CTCAE: E10508 NCIt: C78213 OAE:0003367 a digestive system AE that has an abnormal communication between the large intestine and another organ or anatomic site. MW, YH 10009995 colonic fistula AE CTCAE: E10527 NCIt: C78239 OAE:0003368 a digestive system AE that has blockage of the normal flow of the intestinal contents in the colon. MW, YH 10010000 colonic obstruction AE CTCAE: E10539 NCIt: C78241 OAE:0003369 a digestive system AE that has a rupture in the colonic wall. MW, YH 10010001 colonic perforation AE CTCAE: E10545 NCIt: C78242 OAE:0003370 a digestive system AE that has a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the colon. MW, YH 10010006 colonic ulcer AE CTCAE: E10556 NCIt: C78244 OAE:0003371 a duodenum AE that has an abnormal communication between the duodenum and another organ or anatomic site. MW, YH 10013828 duodenal fistula AE CTCAE: E10582 NCIt: C78256 OAE:0003372 a duodenum AE that has blockage of the normal flow of stomach contents through the duodenum. MW, YH 10013830 duodenal obstruction AE CTCAE: E10594 NCIt: C79548 OAE:0003373 a duodenum AE that has a rupture in the duodenal wall. MW, YH 10013832 duodenal perforation AE CTCAE: E10600 NCIt: C78259 OAE:0003374 an esophagus AE that has blockage of the normal flow of the contents in the esophagus. MW, YH 10015387 esophageal obstruction AE CTCAE: E10655 NCIt: C78279 OAE:0003375 an esophagus AE that has a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the esophageal wall. MW, YH 10015451 esophageal ulcer AE CTCAE: E10676 NCIt: C26950 OAE:0003376 a digestive system AE that has an abnormal communication between the gallbladder and another organ or anatomic site. MW, YH 10017631 gallbladder fistula AE CTCAE: E11189 NCIt: C78305 OAE:0003377 a digestive system AE that has blockage of the normal flow of the contents of the gallbladder. MW, YH 10017636 gallbladder obstruction AE CTCAE: E11198 NCIt: C78308 OAE:0003378 a gastrointestinal perforation AE that occurs in the stomach wall. MW, YH 10017815 gastric perforation AE CTCAE: E10716 NCIt: C78316 OAE:0003379 a gastrointestinal disoder AE that has an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site. MW, YH 10017877 gastrointestinal fistula AE CTCAE: E10749 NCIt: C78319 OAE:0003380 a gastric AE that has an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine. MW, YH 10018043 gastroparesis AE CTCAE: E10759 NCIt: C80512 OAE:0003381 a digestive system AE that has a narrowing of the lumen of the ileum. MW, YH 10021307 ileal stenosis AE CTCAE: E10800 NCIt: C78356 OAE:0003382 a digestive system AE that has a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the ileum. MW, YH 10021309 ileal ulcer AE CTCAE: E10806 NCIt: C78357 OAE:0003383 a digestive system AE that has a rupture in the jejunal wall. MW, YH 10023174 jejunal perforation AE CTCAE: E10840 NCIt: C78399 OAE:0003384 a digestive system AE that has a narrowing of the lumen of the jejunum. MW, YH 10023176 jejunal stenosis AE CTCAE: E10845 NCIt: C78400 OAE:0003385 a digestive system AE that has a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the jejunum. MW, YH 10023177 jejunal ulcer AE CTCAE: E10851 NCIt: C78401 OAE:0003386 a digestive system AE that has inadequate absorption of nutrients in the small intestine. Symptoms include abdominal marked discomfort, bloating and diarrhea. MW, YH 10025476 malabsorption AE CTCAE: E10867 NCIt: C3214 OAE:0003387 a digestive system AE that has blockage of the normal flow of the contents in the stomach. MW, YH 10029957 obstruction gastric AE CTCAE: E10882 NCIt: C78505 OAE:0003388 a digestive system AE that has a rupture in the wall of the extrahepatic or intrahepatic bile duct. MW, YH 10034405 perforation bile duct AE CTCAE: E11234 NCIt: C78528 OAE:0003389 a digestive system AE that has an abnormal communication between the rectum and another organ or anatomic site. MW, YH 10038062 rectal fistula AE CTCAE: E10949 NCIt: C79713 OAE:0003390 a digestive system AE that has a rupture in the rectal wall. MW, YH 10038073 rectal perforation AE CTCAE: E10981 NCIt: C78588 OAE:0003391 a digestive system AE that has a narrowing of the lumen of the rectum. MW, YH 10038079 rectal stenosis AE CTCAE: E10986 NCIt: C78589 OAE:0003392 a digestive system AE that has a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the rectum. MW, YH 10038080 rectal ulcer AE CTCAE: E10992 NCIt: C78590 OAE:0003393 a digestive system AE that has an abnormal communication between a salivary gland and another organ or anatomic site. MW, YH 10039411 salivary gland fistula AE CTCAE: E11009 NCIt: C79715 OAE:0003394 a digestive system AE that has a rupture in the small intestine wall. MW, YH 10041103 small intestinal perforation AE CTCAE: E11027 NCIt: C78616 OAE:0003395 a digestive system AE that has an abnormal communication between the pancreas and another organ or anatomic site. MW, YH 10049192 pancreatic fistula AE CTCAE: E10914 NCIt: C79701 OAE:0003396 a duodenum AE that has a narrowing of the lumen of the duodenum. MW, YH 10050094 duodenal stenosis AE CTCAE: E10605 NCIt: C78260 OAE:0003397 a digestive system AE that has a narrowing of the lumen of the bile duct. MW, YH 10051341 bile duct stenosis AE CTCAE: E11173 NCIt: C78182 OAE:0003398 a gastric disorder AE that has a necrotic process occurring in the gastric wall. MW, YH 10051886 gastric necrosis AE CTCAE: E10712 NCIt: C78314 OAE:0003399 a digestive system AE that has a necrotic process occurring in the pancreas. MW, YH 10058096 pancreatic necrosis AE CTCAE: E10926 NCIt: C78522 OAE:0003400 a digestive system AE that has a necrotic process occurring in the gallbladder. MW, YH 10059446 gallbladder necrosis AE CTCAE: E11195 NCIt: C78307 OAE:0003401 a gastric disorder AE that has a narrowing of the lumen of the stomach. MW, YH 10061970 gastric stenosis AE CTCAE: E10721 NCIt: C78317 OAE:0003402 a digestive system AE that has an abnormal communication between the urinary bladder and the intestine. MW, YH 10062570 enterovesical fistula AE CTCAE: E10633 NCIt: C78266 OAE:0003403 a digestive system AE that has a narrowing of the lumen of the pancreatic duct. MW, YH 10065703 pancreatic duct stenosis AE CTCAE: E10908 NCIt: C78519 OAE:0003404 a digestive system AE that has a necrotic process occurring in the peritoneum. MW, YH 10065704 peritoneal necrosis AE CTCAE: E10939 NCIt: C78543 OAE:0003405 a digestive system AE that has blockage of the normal flow of the intestinal contents in the rectum. MW, YH 10065707 rectal obstruction AE CTCAE: E10971 NCIt: C78586 OAE:0003406 a gastrointestinal disoder AE that has the finding of a necrotic process occurring in the gastrointestinal tract stoma. MW, YH 10065712 gastrointestinal stoma necrosis CTCAE: E11721 NCIt: C78321 OAE:0003407 a gastric disorder AE that has an abnormal communication between the stomach and another organ or anatomic site. MW, YH 10065713 gastric fistula AE CTCAE: E10700 NCIt: C79595 OAE:0003408 a digestive system AE that has an abnormal communication between the jejunum and another organ or anatomic site. MW, YH 10065719 jejunal fistula AE CTCAE: E10822 NCIt: C78396 OAE:0003409 an anus AE that has a necrotic process occurring in the anal region. MW, YH 10065722 anal necrosis AE CTCAE: E10482 NCIt: C78171 OAE:0003410 an esophagus AE that has a necrotic process occurring in the esophageal wall. MW, YH 10065727 esophageal necrosis AE CTCAE: E10651 NCIt: C78278 OAE:0003411 a digestive system AE that has an abnormal communication between the ileum and another organ or anatomic site. MW, YH 10065728 ileal fistula AE CTCAE: E10777 NCIt: C78352 OAE:0003412 a digestive system AE that has blockage of the normal flow of the intestinal contents in the ileum. MW, YH 10065730 ileal obstruction AE CTCAE: E10789 NCIt: C78354 OAE:0003413 a digestive system AE that has blockage of the normal flow of the intestinal contents in the jejunum. MW, YH 10065732 jejunal obstruction AE CTCAE: E10834 NCIt: C78398 OAE:0003414 an esophagus AE that has an abnormal communication between the esophagus and another organ or anatomic site. MW, YH 10065851 esophageal fistula AE CTCAE: E10639 NCIt: C79574 OAE:0003415 an eye AE that has dryness of the cornea and conjunctiva. MW, YH 10013774 dry eye AE CTCAE: E10363 NCIt: C34553 OAE:0003416 an eye AE that has a sudden or brief burst of light. MW, YH 10016757 flashing lights AE CTCAE: E10384 NCIt: C50568 OAE:0003417 an eye AE that has an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens. MW, YH 10016778 floaters AE CTCAE: E10388 NCIt: C37955 OAE:0003418 an eye AE that has an inability to see clearly in dim light. MW, YH 10029404 night blindness AE CTCAE: E10401 NCIt: C34850 OAE:0003419 an eye AE that has a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters. MW, YH 10038897 retinal tear AE CTCAE: E10425 NCIt: C50732 OAE:0003420 an eye AE that has pathological retinal blood vessels that adversely affects vision. MW, YH 10038901 retinal vascular disorder AE CTCAE: E10429 NCIt: C35170 OAE:0003421 an eye AE that has blood extravasation into the vitreous humor. MW, YH 10047656 vitreous hemorrhage AE CTCAE: E10447 NCIt: C50469 OAE:0003422 an eye AE that has excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct. MW, YH 10047848 watering eyes AE CTCAE: E10452 NCIt: C78717 OAE:0003423 an eye AE that has involvement of the optic nerve (second cranial nerve). MW, YH 10061322 optic nerve disorder AE CTCAE: E10406 NCIt: C79698 OAE:0003424 an eye AE that has involvement of the sclera of the eye. MW, YH 10061510 scleral disorder AE CTCAE: E10437 NCIt: C79717 OAE:0003425 an ear AE that has dizziness, imbalance, nausea, and vision problems. MW, YH 10047386 vestibular disorder AE CTCAE: E10295 NCIt: C27166 OAE:0003426 an ear pain AE that has a sensation of marked discomfort in the external ear region. MW, YH 10065785 external ear pain AE CTCAE: E10272 NCIt: C78285 OAE:0003427 a cardiovascular AE that has a thickened and fibrotic pericardial sac; these fibrotic changes impede normal myocardial function by restricting myocardial muscle action. MW, YH 10010783 constrictive pericarditis AE CTCAE: E10120 NCIt: C78246 OAE:0003428 a cardiovascular AE that has a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by syncope, fatigue and dizziness. MW, YH 10040639 sick sinus syndrome AE CTCAE: E10202 NCIt: C62244 OAE:0003429 a cardiovascular AE that has an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium. MW, YH 10053565 pericardial tamponade AE CTCAE: E10177 NCIt: C50481 OAE:0003430 a cardiovascular AE that has a defect in tricuspid valve function or structure. MW, YH 10061389 tricuspid valve disease AE CTCAE: E10224 NCIt: C78649 OAE:0003431 a cardiovascular AE that has a defect in mitral valve function or structure. MW, YH 10061532 mitral valve disease AE CTCAE: E10134 NCIt: C78446 OAE:0003432 a cardiovascular AE that has a defect in pulmonary valve function or structure. MW, YH 10061541 pulmonary valve disease AE CTCAE: E10186 NCIt: C78579 OAE:0003433 a cardiovascular AE that has a defect in aortic valve function or structure. MW, YH 10061589 aortic valve disease AE CTCAE: E10071 NCIt: C78650 OAE:0003434 a bone AE that has a change in tooth hue or tint. MW, YH 10044031 tooth discoloration AE CTCAE: E11052 NCIt: C80112 OAE:0003435 an edema AE that has swelling due to an accumulation of excessive fluid in the neck. MW, YH 10054482 neck edema AE CTCAE: E11159 NCIt: C78501 OAE:0003436 an edema AE that has swelling due to excessive fluid accumulation in the trunk area. MW, YH 10058720 edema trunk AE CTCAE: E11090 NCIt: C78263 OAE:0003437 an inflammation AE that has inflammation of the rectum. MW, YH 10036774 proctitis AE CTCAE: E10943 NCIt: C38011 OAE:0003438 an inflammation AE that has inflammation of the mucous membrane of the rectum MW, YH 10063190 rectal mucositis AE CTCAE: E10961 NCIt: C78584 OAE:0003439 an inflammation AE that has inflammation of the mucous membrane of the anus. MW, YH 10065721 anal mucositis AE CTCAE: E10476 NCIt: C78170 OAE:0003440 an inflammation AE that has inflammation, swelling and redness to the outer ear and ear canal. MW, YH 10065837 external ear inflammation AE CTCAE: E10266 NCIt: C79601 OAE:0003441 an inflammation AE that has inflammation (physiologic response to irritation), swelling and redness to the middle ear. MW, YH 10065838 middle ear inflammation AE CTCAE: E10281 NCIt: C34885 OAE:0003442 a death AE that has cessation of life occurring during the first 28 days of life. MW, YH 10011912 death neonatal AE CTCAE: E11078 NCIt: C80082 OAE:0003443 a fracture AE that has a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot. MW, YH 10002544 ankle fracture AE CTCAE: E11640 NCIt: C26989 OAE:0003444 a fracture AE that has the finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken. MW, YH 10020100 hip fracture AE CTCAE: E11726 NCIt: C26794 OAE:0003445 a fracture AE that has the finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken. MW, YH 10041569 spinal fracture AE CTCAE: E11954 NCIt: C80516 OAE:0003446 a fracture AE that has the finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken. MW, YH 10048049 wrist fracture AE CTCAE: E12069 NCIt: C80517 OAE:0003447 a lung infection AE that has an infectious process involving the bronchi. MW, YH 10055078 bronchial infection AE CTCAE: E11323 NCIt: C2911 OAE:0003448 a muscle enzyme level increased AE that has the finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen. MW, YH 10011268 CPK increased AE CTCAE: E12132 NCIt: C78247 OAE:0003449 a recall phenomenon AE that has the finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent. MW, YH 10037767 radiation recall reaction (dermatologic) AE CTCAE: E11926 NCIt: C78580 OAE:0003450 an immunology and allergy investigation result abnormal AE that has the finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen. MW, YH 10007839 CD4 lymphocytes decreased AE CTCAE: E12122 NCIt: C78233 OAE:0003451 a respiratory and pulmonary investigation result abnormal AE that has the finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value. MW, YH 10047580 vital capacity abnormal AE CTCAE: E12220 NCIt: C78715 OAE:0003452 a respiratory and pulmonary investigation result abnormal AE that has the finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide. MW, YH 10065906 carbon monoxide diffusing capacity decreased AE CTCAE: E12112 NCIt: C78229 OAE:0003453 an endocrine investigation result abnormal AE that has the finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen. MW, YH 10005332 blood antidiuretic hormone abnormal AE CTCAE: E12092 NCIt: C78214 OAE:0003454 an endocrine investigation result abnormal AE that has the finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen. MW, YH 10005452 blood corticotrophin decreased AE CTCAE: E12101 NCIt: C78215 OAE:0003455 an endocrine investigation result abnormal AE that has the finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen. MW, YH 10005561 blood gonadotrophin abnormal AE CTCAE: E12105 NCIt: C78216 OAE:0003456 an endocrine investigation result abnormal AE that has the finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen. MW, YH 10005778 blood prolactin abnormal AE CTCAE: E12109 NCIt: C78217 OAE:0003457 an endocrine investigation result abnormal AE that has the finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen. MW, YH 10018748 growth hormone abnormal AE CTCAE: E12166 NCIt: C78327 OAE:0003458 an enzyme investigation result abnormal AE that has the finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen. MW, YH 10062646 pancreatic enzymes decreased AE CTCAE: E12203 NCIt: C78520 OAE:0003459 a hematology investigation result abnormal AE that has the finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen. MW, YH 10016596 fibrinogen decreased AE CTCAE: E12151 NCIt: C78300 OAE:0003460 a hematology investigation result abnormal with the finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen. MW, YH 10019150 haptoglobin decreased AE CTCAE: E12169 NCIt: C78330 OAE:0003461 a coronary heart disease AE that has signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction. MW, YH 10051592 acute coronary syndrome AE CTCAE: E10066 NCIt: C53652 OAE:0003462 an eyelid disorder AE that has impaired eyelid function. MW, YH 10061145 eyelid function disorder AE CTCAE: E10380 NCIt: C78288 OAE:0003463 an injury AE that has the finding of damage to the aorta. MW, YH 10002899 aortic injury AE CTCAE: E11644 NCIt: C35623 OAE:0003464 an injury AE that has the finding of damage to an artery MW, YH 10003162 arterial injury AE CTCAE: E11648 NCIt: C35401 OAE:0003465 an injury AE that has the finding of damage to the carotid artery. MW, YH 10022161 injury to carotid artery AE CTCAE: E11730 NCIt: C79599 OAE:0003466 an injury AE that has the finding of damage to the inferior vena cava. MW, YH 10022213 injury to inferior vena cava AE CTCAE: E11734 NCIt: C78363 OAE:0003467 an injury AE that has the finding of damage to the superior vena cava. MW, YH 10022356 injury to superior vena cava AE CTCAE: E11741 NCIt: C78365 OAE:0003468 an injury AE that has the finding of damage to the gastrointestinal system during a surgical procedure. MW, YH 10065825 intraoperative gastrointestinal injury AE CTCAE: E11798 NCIt: C78380 OAE:0003469 an injury AE that has the finding of damage to an artery during a surgical procedure. MW, YH 10065826 intraoperative arterial injury AE CTCAE: E11770 NCIt: C78375 OAE:0003470 an injury AE that has the finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure. MW, YH 10065827 intraoperative hepatobiliary injury AE CTCAE: E11814 NCIt: C78382 OAE:0003471 an injury AE that has the finding of damage to the urinary system during a surgical procedure. MW, YH 10065828 intraoperative urinary injury AE CTCAE: E11867 NCIt: C78391 OAE:0003472 an injury AE that has the finding of damage to the musculoskeletal system during a surgical procedure. MW, YH 10065829 intraoperative musculoskeletal injury AE CTCAE: E11820 NCIt: C78383 OAE:0003473 an injury AE that has the finding of damage to the nervous system during a surgical procedure. MW, YH 10065830 intraoperative neurological injury AE CTCAE: E11826 NCIt: C78384 OAE:0003474 an injury AE that has the finding of damage to the breast parenchyma during a surgical procedure. MW, YH 10065831 intraoperative breast injury AE CTCAE: E11776 NCIt: C78376 OAE:0003475 an injury AE that has the finding of damage to the respiratory system during a surgical procedure. MW, YH 10065832 intraoperative respiratory injury AE CTCAE: E11850 NCIt: C78388 OAE:0003476 an injury AE that has the finding of damage to the endocrine gland during a surgical procedure. MW, YH 10065834 intraoperative endocrine injury AE CTCAE: E11792 NCIt: C78379 OAE:0003477 an injury AE that has the finding of damage to the reproductive organs during a surgical procedure. MW, YH 10065840 intraoperative reproductive tract injury AE CTCAE: E11844 NCIt: C78387 OAE:0003478 an injury AE that has the finding of damage to the eye during a surgical procedure. MW, YH 10065841 intraoperative ocular injury AE CTCAE: E11832 NCIt: C78385 OAE:0003479 an injury AE that has the finding of damage to the head and neck during a surgical procedure. MW, YH 10065842 lintraoperative head and neck injury AE CTCAE: E11804 NCIt: C78381 OAE:0003480 an injury AE that has the finding of damage to the heart during a surgical procedure. MW, YH 10065843 intraoperative cardiac injury AE CTCAE: E11782 NCIt: C78377 OAE:0003481 an injury AE that has the finding of damage to the ear during a surgical procedure. MW, YH 10065844 intraoperative ear injury AE CTCAE: E11786 NCIt: C78378 OAE:0003482 an injury AE that has the finding of damage to the kidney during a surgical procedure. MW, YH 10065845 intraoperative renal injury AE CTCAE: E11838 NCIt: C78386 OAE:0003483 an injury AE finding of damage to the skin during a surgical procedure. MW, YH 10065846 intraoperative skin injury AE CTCAE: E11856 NCIt: C78389 OAE:0003484 an injury AE that has the finding of damage to the spleen during a surgical procedure. MW, YH 10065847 intraoperative splenic injury AE CTCAE: E11862 NCIt: C78390 OAE:0003485 an injury AE that has the finding of damage to a vein during a surgical procedure. MW, YH 10065848 intraoperative venous injury AE CTCAE: E11873 NCIt: C78392 OAE:0003486 an injury AE that has the finding of damage to the jugular vein. MW, YH 10065849 injury to jugular vein AE CTCAE: E11737 NCIt: C78364 OAE:0003487 an appendicitis AE that has acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity. MW, YH 10003012 appendicitis perforated AE CTCAE: E11296 NCIt: C78178 OAE:0003488 a troponin AE which indicates increased levels of cardiac troponin T in a biological specimen MW, YH 10007613 cardiac troponin T increased CTCAE: E12119 NCIt: C78231 OAE:0003489 an eye infection AE that has an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes. MW, YH 10010742 conjunctivitis infective AE CTCAE: E11342 NCIt: C35704 OAE:0003490 an eye infection AE that has an infectious process involving the internal structures of the eye. MW, YH 10014801 endophthalmitis AE CTCAE: E11377 NCIt: C34586 OAE:0003491 an eye infection AE that has an infectious process involving the orbit of the eye. MW, YH 10051472 periorbital infection AE CTCAE: E11511 NCIt: C78531 OAE:0003492 an eye infection AE that has an infectious process involving the cornea. MW, YH 10061788 corneal infection AE CTCAE: E11347 NCIt: C26805 OAE:0003493 a fatigue AE that has fatigue relieved by rest MW, YH Grade 1 fatigue AE CTCAE: E11099 OAE:0003494 a fatigue AE that has fatigue not relieved by rest; limiting instrumental activities of daily living MW, YH Grade 2 fatigue AE CTCAE: E11100 OAE:0003495 a fatigue AE that has fatigue not relieved by rest, limiting self care activities of daily living MW, YH Grade 3 fatigue AE CTCAE: E11101 OAE:0003496 a myocardial infarction AE that has asymptomatic and cardiac enzymes minimally abnormal and no evidence of ischemic ECG changes MW, YH Grade 2 myocardial infarction AE CTCAE: E10153 OAE:0003497 a myocardial infarction AE that has severe symptoms; cardiac enzymes abnormal; hemodynamically stable; ECG changes consistent with infarction MW, YH Grade 3 myocardial infarction AE CTCAE: E10154 OAE:0003498 a pancreatitis AE that has enzyme elevation or radiologic findings only MW, YH Grade 3 pancreatitis AE CTCAE: E10931 OAE:0003499 a pancreatitis AE that has severe pain; vomiting; medical intervention indicated (e.g., analgesia, nutritional support) MW, YH Grade 3 pancreatitis AE CTCAE: E10932 OAE:0003500 an activated partial thromboplastin time prolonged AE that is greater than the upper limit of normal to 1.5 times the upper limit of normal MW, YH Grade 1 activated partial thromboplastin time prolonged AE CTCAE: E12074 OAE:0003501 an activated partial thromboplastin time prolonged AE that is 1.5-2.5 times the upper limit of normal MW, YH Grade 2 activated partial thromboplastin time prolonged AE CTCAE: E12075 OAE:0003502 an activated partial thromboplastin time prolonged AE that is greater than 2.5 times the upper limit of normal; hemorrhage MW, YH Grade 3 activated partial thromboplastin time prolonged AE CTCAE: E12076 OAE:0003503 an alanine aminotransferase level increased AE that is greater than the upper limit of normal to 3 times the upper limit of normal MW, YH Grade 1 alanine aminotransferase level increased AE CTCAE: E12078 OAE:0003504 an alanine aminotransferase level increased AE that is greater than 3 to 5 times the upper limit of normal MW, YH Grade 2 alanine aminotransferase level increased AE CTCAE: E12079 OAE:0003505 an alanine aminotransferase level increased AE that is greater than 5 to 20 times the upper limit of normal MW, YH Grade 3 alanine aminotransferase level increased AE CTCAE: E12080 OAE:0003506 an alanine aminotransferase level increased AE that is greater than 20 times the upper limit of normal MW, YH Grade 4 alanine aminotransferase level increased AE CTCAE: E12081 OAE:0003507 an anal ulcer AE that is symptomatic; altered GI function MW, YH Grade 2 anal ulcer AE CTCAE: E10498 OAE:0003508 an anal ulcer AE that has severely altered GI function; TPN indicated; elective operative or endoscopic intervention indicated; disabling MW, YH Grade 3 anal ulcer AE CTCAE: E10499 OAE:0003509 an atrial flutter AE that has symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation MW, YH Grade 3 atrial flutter AE CTCAE: E10090 OAE:0003510 an otitis media AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 otitis media AE CTCAE: E11478 OAE:0003511 an otitis media AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 otitis media AE CTCAE: E11479 OAE:0003512 a pericarditis AE that has asymptomatic, ECG or physical findings (e.g., rub) consistent with pericarditis MW, YH Grade 1 pericarditis AE CTCAE: E10181 OAE:0003513 a pericarditis AE that has symptomatic pericarditis (e.g., chest pain) MW, YH Grade 2 pericarditis AE CTCAE: E10182 OAE:0003514 a pericarditis AE that has pericarditis with physiologic consequences (e.g., pericardial constriction) MW, YH Grade 3 pericarditis AE CTCAE: E10183 OAE:0003515 a pharyngitis AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 pharyngitis AE CTCAE: E11526 OAE:0003516 a pharyngitis AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 pharyngitis AE CTCAE: E11527 OAE:0003517 a fever AE that has 38.0 - 39.0 degrees C (100.4 - 102.2 degrees F) MW, YH Grade 1 fever AE CTCAE: E11103 OAE:0003518 a fever AE that has greater than 39.0 - 40.0 degrees C (102.3 - 104.0 degrees F) MW, YH Grade 2 fever AE CTCAE: E11104 OAE:0003519 a fever AE that has greater than 40.0 degrees C (greater than104.0 degrees F) for less than or equal to 24 hrs MW, YH Grade 3 fever AE CTCAE: E11105 OAE:0003520 a fever AE that has greater than 40.0 degrees C (greater than104.0 degrees F) for more than 24 hrs MW, YH Grade 4 fever AE CTCAE: E11106 OAE:0003521 an injection-site adverse event characterized by tenderness with or without associated symptoms (e.g., warmth, erythema, itching) MW, YH Grade 1 injection-site adverse event CTCAE: E11139 OAE:0003522 an injection-site adverse event characterized by pain; lipodystrophy; edema; phlebitis MW, YH Grade 2 injection-site adverse event CTCAE: E11140 OAE:0003523 an injection-site adverse event characterized by ulceration or necrosis; severe tissue damage; operative intervention indicated MW, YH Grade 3 injection-site adverse event CTCAE: E11141 OAE:0003524 a leukocyte cell number increased AE where leukocytes are greater than 100,000/mm3 MW, YH Grade 3 leukocytosis AE CTCAE: E10049 OAE:0003525 a leukocyte cell number increased AE that has clinical manifestations of leucostasis; urgent intervention indicated MW, YH Grade 4 leukocytosis AE CTCAE: E10050 OAE:0003526 a leukocyte cell number decreased AE that is less than the lower limit of normal - 3000/mm3; less than the lower limit of normal - 3.0 x 10e9 /L MW, YH Grade 1 leukocyte cell number decreased AE CTCAE: E12233 OAE:0003527 a leukocyte cell number decreased AE that is less than 3000 - 2000/mm3; less than 3.0 - 2.0 x 10e9 /L MW, YH Grade 2 leukocyte cell number decreased AE CTCAE: E12234 OAE:0003528 a leukocyte cell number decreased AE that is less than 2000 - 1000/mm3; less than 2.0 - 1.0 x 10e9 /L MW, YH Grade 3 leukocyte cell number decreased AE CTCAE: E12235 OAE:0003529 a leukocyte cell number decreased AE that is less than 1000/mm3; less than 1.0 x 10e9 /L MW, YH Grade 4 leukocyte cell number decreased AE CTCAE: E12236 OAE:0003530 a malaise AE that has uneasiness or lack of well being MW, YH Grade 1 malaise AE CTCAE: E11153 OAE:0003531 a malaise AE that has uneasiness or lack of well being; limiting instrumental activities of daily living MW, YH Grade 2 malaise AE CTCAE: E11154 OAE:0003532 a chills AE that has mild sensation of cold; shivering; chattering of teeth MW, YH Grade 1 chills AE CTCAE: E11075 OAE:0003533 A chills AE that has moderate tremor of the entire body; narcotics indicated MW, YH Grade 2 chills AE CTCAE: E11076 OAE:0003534 a chills AE that has severe or prolonged, not responsive to narcotics MW, YH Grade 3 chills AE CTCAE: E11077 OAE:0003535 an edema face AE that has localized facial edema MW, YH Grade 1 edema face AE CTCAE: E11083 OAE:0003536 a meningitis AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated; focal neurologic deficit MW, YH Grade 3 meningitis AE CTCAE: E11459 OAE:0003537 a serum sickness AE that has moderate arthralgia; fever, rash, urticaria, antihistamines indicated MW, YH Grade 2 serum sickness AE CTCAE: E11278 OAE:0003538 a serum sickness AE that has severe arthralgia or arthritis; extensive rash; steroids or IV fluids indicated MW, YH Grade 3 serum sickness AE CTCAE: E11279 OAE:0003539 a urinary tract infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 urinary tract infection AE CTCAE: E11615 OAE:0003540 a urinary tract infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 urinary tract infection AE CTCAE: E11616 OAE:0003541 a laryngitis AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 laryngitis AE CTCAE: E11436 OAE:0003542 a laryngitis AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 laryngitis AE CTCAE: E11437 OAE:0003543 a dry mouth AE that is symptomatic (e.g., dry or thick saliva) without significant dietary alteration; unstimulated saliva flow greater than0.2 ml/min MW, YH Grade 1 dry mouth AE CTCAE: E10579 OAE:0003544 a dry mouth AE that has moderate symptoms; oral intake alterations (e.g., copious water, other lubricants, diet limited to purees and/or soft, moist foods); unstimulated saliva 0.1 to 0.2 ml/min MW, YH Grade 2 dry mouth AE CTCAE: E10580 OAE:0003545 a dry mouth AE that has the inability to adequately aliment orally; tube feeding or TPN indicated; unstimulated saliva <0.1 ml/min MW, YH Grade 3 dry mouth AE CTCAE: E10581 OAE:0003546 a pustular rash AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 pustular rash AE CTCAE: E11546 OAE:0003547 a pustular rash AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 pustular rash AE CTCAE: E11547 OAE:0003548 a flatulence AE that has moderate; persistent; psychosocial sequelae MW, YH Grade 2 flatulence AE CTCAE: E10699 OAE:0003549 a weight loss AE that is 5 to less than 10% from baseline; intervention not indicated MW, YH Grade 1 weight loss AE CTCAE: E12229 OAE:0003550 a weight loss AE that is 10 - less than 20% from baseline; nutritional support indicated MW, YH Grade 2 weight loss AE CTCAE: E12230 OAE:0003551 a weight loss AE that is greater than or equal to 20% from baseline; tube feeding or TPN indicated MW, YH Grade 3 weight loss AE CTCAE: E12231 OAE:0003552 an abnormal gait AE that has mild change in gait (e.g., wide-based, limping or hobbling) MW, YH Grade 1 abnormal gait AE CTCAE: E11113 OAE:0003553 an abnormal gait AE that has moderate change in gait (e.g., wide-based, limping or hobbling); assistive device indicated; limiting instrumental activities of daily living MW, YH Grade 2 abnormal gait AE CTCAE: E11114 OAE:0003554 an anemia AE where hemoglobin (Hgb) is less than the lower limit of normal (LLN), which is 10.0 g/dL, 6.2 mmol/L, or 100 g/L. MW, YH Grade 1 anemia AE CTCAE: E10011 OAE:0003555 an anemia AE where hemoglobin (Hgb) is less than 10.0-8.0 g/dL, 6.2 -4.9 mmol/L, or 100 - 80 g/L. MW, YH Grade 2 anemia AE CTCAE: E10012 OAE:0003556 an anemia AE where hemoglobin (Hgb) is less than 8.0 g/dL, 4.9 mmol/L, or 80 g/L. MW, YH Grade 3 anemia AE CTCAE: E10013 OAE:0003557 a sinusitis AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 sinusitis AE CTCAE: E11564 OAE:0003558 a sinusitis AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 sinusitis AE CTCAE: E11565 OAE:0003559 an allergy AE that has transient flushing or rash, drug fever <38 degrees C (<100.4 degrees F); intervention not indicated MW, YH Grade 1 allergy AE CTCAE: E11249 OAE:0003560 an allergy AE where intervention or infusion interruption indicated; responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics); prophylactic medications indicated for less than or equal to 24 hrs MW, YH Grade 2 allergy AE CTCAE: E11250 OAE:0003561 an allergy AE that is prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae (e.g., renal impairment, pulmonary infiltrates) MW, YH Grade 3 allergy AE CTCAE: E11251 OAE:0003562 a dysphagia AE that is symptomatic, able to eat regular diet MW, YH Grade 1 dysphagia AE CTCAE: E10622 OAE:0003563 a dysphagia AE that is symptomatic and altered eating/swallowing MW, YH Grade 2 dysphagia AE CTCAE: E10623 OAE:0003564 a dysphagia AE that has severely altered eating/swallowing; tube feeding or TPN or hospitalization indicated MW, YH Grade 3 dysphagia AE CTCAE: E10624 OAE:0003565 a platelet count decreased AE that is less than the lower limit of normal - 75,000/mm3; less than the lower limit of normal - 75.0 x 10e9 /L MW, YH Grade 1 platelet count decreased AE CTCAE: E12208 OAE:0003566 a platelet count decreased AE that is less than 75,000 - 50,000/mm3; less than 75.0 - 50.0 x 10e9 /L MW, YH Grade 2 platelet count decreased AE CTCAE: E12209 OAE:0003567 a platelet count decreased AE that is less than 50,000 - 25,000/mm3; less than 50.0 - 25.0 x 10e9 /L MW, YH Grade 3 platelet count decreased AE CTCAE: E12210 OAE:0003568 a platelet count decreased AE that is less than 25,000/mm3; less than 25.0 x 10e9 /L MW, YH Grade 4 platelet count decreased AE CTCAE: E12211 OAE:0003569 a vomiting AE that has 1 - 2 episodes (separated by 5 minutes) in 24 hrs MW, YH Grade 1 vomiting AE CTCAE: E11069 OAE:0003570 a vomiting AE that has 3 - 5 episodes (separated by 5 minutes) in 24 hrs MW, YH Grade 2 vomiting AE CTCAE: E11070 OAE:0003571 a vomiting AE that has 6 or more episodes (separated by 5 minutes) in 24 hrs; tube feeding, TPN or hospitalization indicated MW, YH Grade 3 vomiting AE CTCAE: E11071 OAE:0003572 a constipation AE that has occasional or intermittent symptoms; occasional use of stool softeners, laxatives, dietary modification, or enema MW, YH Grade 1 constipation AE CTCAE: E10563 OAE:0003573 a constipation AE that has persistent symptoms with regular use of laxatives or enemas; limiting instrumental activities of daily living MW, YH Grade 2 constipation AE CTCAE: E10564 OAE:0003574 a constipation AE that has obstipation with manual evacuation indicated; limiting self care activities of daily living MW, YH Grade 3 constipation AE CTCAE: E10565 OAE:0003575 a lymphocyte count increased AE that is greater than 4000/mm3 - 20,000/mm3 MW, YH Grade 2 lymphocyte count increased AE CTCAE: E12196 OAE:0003576 a lymphocyte count increased AE that is greater than 20,000/mm3 MW, YH Grade 3 lymphocyte count increased AE CTCAE: E12197 OAE:0003577 a hypothermia AE that has 35 - greater than 32 degrees C; 95 - greater than 89.6 degrees F MW, YH Grade 2 hypothermia AE CTCAE: E11123 OAE:0003578 a hypothermia AE that has 32 - greater than 28 degrees C; 89.6 - greater than 82.4 degrees F MW, YH Grade 3 hypothermia AE CTCAE: E11124 OAE:0003579 a hypothermia AE that has less than or equal to 28 degrees C; 82.4 degrees F; life-threatening consequences (e.g., coma, hypotension, pulmonary edema, acidemia, ventricular fibrillation) MW, YH Grade 4 hypothermia AE CTCAE: E11125 OAE:0003580 a hematoma AE that is localized or in a dependent area MW, YH Grade 1 hematoma AE CTCAE: E11667 OAE:0003581 a hematoma AE that is generalized MW, YH Grade 2 hematoma AE CTCAE: E11668 OAE:0003582 an aspartate aminotransferase level increased AE that is greater than the upper limit of normal to 3 times the upper limit of normal MW, YH Grade 1 aspartate aminotransferase level increased AE CTCAE: E12088 OAE:0003583 an aspartate aminotransferase level increased AE that is greater than 3 to 5 times the upper limit of normal MW, YH Grade 2 aspartate aminotransferase level increased AE CTCAE: E12089 OAE:0003584 an aspartate aminotransferase level increased AE that is greater than 5 to 20 times the upper limit of normal MW, YH Grade 3 aspartate aminotransferase level increased AE CTCAE: E12090 OAE:0003585 an aspartate aminotransferase level increased AE that is greater than 20 times the upper limit of normal MW, YH Grade 4 aspartate aminotransferase level increased AE CTCAE: E12091 OAE:0003586 an atrial fibrillation AE that has symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation MW, YH Grade 3 atrial fibrillation AE CTCAE: E10084 OAE:0003587 a blood alkaline phosphatase increased AE that is greater than the upper limit of normal to 2.5 times the upper limit of normal MW, YH Grade 1 blood alkaline phosphatase increased AE CTCAE: E12083 OAE:0003588 a blood alkaline phosphatase increased AE that is greater than 2.5 to 5 times the upper limit of normal MW, YH Grade 2 blood alkaline phosphatase increased AE CTCAE: E12084 OAE:0003589 a blood alkaline phosphatase increased AE that is greater than 5 to 20 times the upper limit of normal MW, YH Grade 3 blood alkaline phosphatase increased AE CTCAE: E12085 OAE:0003590 a blood alkaline phosphatase increased AE that is greater than 20 times the upper limit of normal MW, YH Grade 4 blood alkaline phosphatase increased AE CTCAE: E12086 OAE:0003591 a blood amylase level increased AE that is greater than the upper limit of normal - 1.5 times the upper limit of normal MW, YH Grade 1 blood amylase level increased AE CTCAE: E12213 OAE:0003592 a blood amylase level increased AE that is greater than 1.5 - 2.0 times the upper limit of normal MW, YH Grade 2 blood amylase level increased AE CTCAE: E12214 OAE:0003593 a blood amylase level increased AE that is greater than 2.0 - 5.0 times the upper limit of normal MW, YH Grade 3 blood amylase level increased AE CTCAE: E12215 OAE:0003594 a blood amylase level increased AE that is greater than 5.0 times the upper limit of normal MW, YH Grade 4 blood amylase level increased AE CTCAE: E12216 OAE:0003595 a blood bilirubin level increased AE that is greater than the upper limit of normal to 1.5 times the upper limit of normal MW, YH Grade 1 blood bilirubin level increased AE CTCAE: E12097 OAE:0003596 a blood bilirubin level increased AE that is greater than 1.5 to 3 times the upper limit of normal MW, YH Grade 2 blood bilirubin level increased AE CTCAE: E12098 OAE:0003597 a blood bilirubin level increased AEgreater than3.0 - 10.0 x upper limit of normal MW, YH Grade 3 blood bilirubin level increased AE CTCAE: E12099 OAE:0003598 a blood bilirubin level increased AE that is greater than 10 times the upper limit of normal MW, YH Grade 4 blood bilirubin level increased AE CTCAE: E12100 OAE:0003599 a blood cholesterol increased AE that is greater than the upper limit of normal to 300 mg/dL; greater than the upper limit of normal to 7.75 mmol/L MW, YH Grade 1 blood cholesterol increased AE CTCAE: E12128 OAE:0003600 a blood cholesterol increased AE that is greater than 300 - 400 mg/dL; greater than 7.75 - 10.34 mmol/L MW, YH Grade 2 blood cholesterol increased AE CTCAE: E12129 OAE:0003601 a blood cholesterol increased AE that is greater than 400 - 500 mg/dL; greater than 10.34 - 12.92 mmol/L MW, YH Grade 3 blood cholesterol increased AE CTCAE: E12130 OAE:0003602 a blood cholesterol increased AE that is greater than 500 mg/dL; greater than 12.92 mmol/L MW, YH Grade 4 blood cholesterol increased AE CTCAE: E12131 OAE:0003603 a blood creatinine level increased AE that is greater than 1 - 1.5 times the baseline; greater than the upper limit of normal - 1.5 times the upper limit of normal MW, YH Grade 1 blood creatinine level increased AE CTCAE: E12138 OAE:0003604 a blood creatinine level increased AE that is greater than 1.5 - 3.0 times the baseline; greater than 1.5 - 3.0 times the upper limit of normal MW, YH Grade 2 blood creatinine level increased AE CTCAE: E12139 OAE:0003605 a blood creatinine level increased AE that is greater than 3.0 times the baseline; greater than 3.0 - 6.0 times the upper limit of normal MW, YH Grade 3 blood creatinine level increased AE CTCAE: E12140 OAE:0003606 a blood creatinine level increased AE that is greater than 6.0 times the upper limit of normal MW, YH Grade 4 blood creatinine level increased AE CTCAE: E12141 OAE:0003607 a bone marrow depression AE categorized as mildly hypocellular or less than or equal to 25% reduction from normal cellularity for age MW, YH Grade 1 bone marrow depression AE CTCAE: E10023 OAE:0003608 a bone marrow depression AE categorized as moderately hypocellular or greater than 25 to less than 50% reduction from normal cellularity for age MW, YH Grade 2 bone marrow depression AE CTCAE: E10024 OAE:0003609 a bone marrow depression AE cateogirzed as severely hypocellular or greater than 50 to less than or equal to 75% reduction cellularity from normal for age MW, YH Grade 3 bone marrow depression AE CTCAE: E10025 OAE:0003610 a bone marrow depression AE categorized as aplastic persistent for longer than 2 weeks MW, YH Grade 4 bone marrow depression AE CTCAE: E10026 OAE:0003611 a breast infection AE that has local infection with moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 breast infection AE CTCAE: E11319 OAE:0003612 a breast infection AE that has severe infection; axillary adenitis; IV antibacterial, antifungal, or antiviral intervention indicated MW, YH Grade 3 breast infection AE CTCAE: E11320 OAE:0003613 a cardiac failure AE that is asymptomatic with laboratory (e.g., BNP [B-Natriuretic Peptide ]) or cardiac imaging abnormalities MW, YH Grade 1 cardiac failure AE CTCAE: E10125 OAE:0003614 a cardiac failure AE that has symptoms with mild to moderate activity or exertion MW, YH Grade 2 cardiac failure AE CTCAE: E10126 OAE:0003615 a cardiac failure AE that has severe with symptoms at rest or with minimal activity or exertion; intervention indicated MW, YH Grade 3 cardiac failure AE CTCAE: E10127 OAE:0003616 a cardiac failure AE that has life-threatening consequences; urgent intervention indicated (e.g., continuous IV therapy or mechanical hemodynamic support) MW, YH Grade 4 cardiac failure AE CTCAE: E10128 OAE:0003617 a cataract AE that is symptomatic; moderate decrease in visual acuity (20/40 or better) MW, YH Grade 2 cataract AE CTCAE: E10352 OAE:0003618 a cataract AE that is symptomatic with marked decrease in visual acuity (worse than 20/40 but better than 20/200); operative intervention indicated (e.g., cataract surgery) MW, YH Grade 3 cataract AE CTCAE: E10353 OAE:0003619 a cataract AE that is characterized by blindness (20/200 or worse) in the affected eye MW, YH Grade 4 cataract AE CTCAE: E10354 OAE:0003620 a catheter related infection AE that is localized; local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 catheter related infection AE CTCAE: E11329 OAE:0003621 a catheter related infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 catheter related infection AE CTCAE: E11330 OAE:0003622 a colitis AE that has abdominal pain; mucus or blood in stool MW, YH Grade 2 colitis AE CTCAE: E10523 OAE:0003623 a colitis AE that has severe abdominal pain; change in bowel habits; medical intervention indicated; peritoneal signs MW, YH Grade 3 colitis AE CTCAE: E10524 OAE:0003624 a cytokine release syndrome AE that has a mild reaction; infusion interruption not indicated; intervention not indicated MW, YH Grade 1 cytokine release syndrome AE CTCAE: E11265 OAE:0003625 a cytokine release syndrome AE where therapy or infusion interruption indicated but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for less than or equal to 24 hrs MW, YH Grade 2 cytokine release syndrome AE CTCAE: E11266 OAE:0003626 a cytokine release syndrome AEthat is prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae (e.g., renal impairment, pulmonary infiltrates) MW, YH Grade 3 cytokine release syndrome AE CTCAE: E11267 OAE:0003627 a dental caries AE that has one or more dental caries, not involving the root MW, YH Grade 1 dental caries AE CTCAE: E10569 OAE:0003628 a dental caries AE that has dental caries involving the root MW, YH Grade 2 dental caries AE CTCAE: E10570 OAE:0003629 a dental caries AE that has dental caries resulting in pulpitis or periapical abscess or resulting in tooth loss MW, YH Grade 3 dental caries AE CTCAE: E10571 OAE:0003630 a device related infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 device related infection AE CTCAE: E11357 OAE:0003631 a disseminated intravascular coagulation AE that has laboratory findings with no bleeding MW, YH Grade 2 disseminated intravascular coagulation AE CTCAE: E10029 OAE:0003632 a disseminated intravascular coagulation AE that has laboratory findings and bleeding MW, YH Grade 3 disseminated intravascular coagulation AE CTCAE: E10030 OAE:0003633 an ejection fraction decreased AE where the resting ejection fraction (EF) 50 - 40%; 10 - 19% drop from baseline MW, YH Grade 2 ejection fraction decreased AE CTCAE: E12143 OAE:0003634 an ejection fraction decreased AE where the resting ejection fraction (EF) 39 - 20%; greater than 20% drop from baseline MW, YH Grade 3 ejection fraction decreased AE CTCAE: E12144 OAE:0003635 an ejection fraction decreased AE where the resting ejection fraction (EF) less than 20% MW, YH Grade 4 ejection fraction decreased AE CTCAE: E12145 OAE:0003636 an electrocardiogram qt prolonged AE where the QTc 450 - 480 ms MW, YH Grade 1 electrocardiogram qt prolonged AE CTCAE: E12147 OAE:0003637 an electrocardiogram qt prolonged AE where the QTc 481 - 500 ms MW, YH Grade 2 electrocardiogram qt prolonged AE CTCAE: E12148 OAE:0003638 an electrocardiogram qt prolonged AE where the QTc is greater than or equal to 501 ms on at least two separate ECGs MW, YH Grade 3 electrocardiogram qt prolonged AE CTCAE: E12149 OAE:0003639 an electrocardiogram qt prolonged AE where the QTc is greater than or equal to 501 or greater than 60 ms change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia MW, YH Grade 4 electrocardiogram qt prolonged AE CTCAE: E12150 OAE:0003640 an enterocolitis AE that has abdominal pain; mucus or blood in stool MW, YH Grade 2 enterocolitis AE CTCAE: E10629 OAE:0003641 an enterocolitis AE that has severe or persistent abdominal pain; fever; ileus; peritoneal signs MW, YH Grade 3 enterocolitis AE CTCAE: E10630 OAE:0003642 a fall AE that is minor with no resultant injuries; intervention not indicated MW, YH Grade 1 fall AE CTCAE: E11688 OAE:0003643 a fall AE where hospitalization indicated MW, YH Grade 3 fall AE CTCAE: E11690 OAE:0003644 a febrile neutropenia AE categorized as anC less than 1000/mm3 with a single temperature of greater than 38.3 degrees C (101 degrees F) or a sustained temperature of greater than or equal to 38 degrees C (100.4 degrees F) for more than one hour. MW, YH Grade 3 febrile neutropenia AE CTCAE: E10034 OAE:0003645 a forced expiratory volume decreased AE where FEV1% (percentages of observed FEV1 and FVC related to their respective predicted values) 99 - 70% predicted MW, YH Grade 1 forced expiratory volume decreased AE CTCAE: E12157 OAE:0003646 a forced expiratory volume decreased AE where FEV1 60 - 69% MW, YH Grade 2 forced expiratory volume decreased AE CTCAE: E12158 OAE:0003647 a forced expiratory volume decreased AE where FEV1 50 - 59% MW, YH Grade 3 forced expiratory volume decreased AE CTCAE: E12159 OAE:0003648 a forced expiratory volume decreased AE where FEV1 is less than or equal to 49% MW, YH Grade 4 forced expiratory volume decreased AE CTCAE: E12160 OAE:0003649 a fracture AE that is symptomatic but non-displaced; immobilization indicated MW, YH Grade 2 fracture AE CTCAE: E11705 OAE:0003650 a fracture AE that has severe symptoms; displaced or open wound with bone exposure; disabling; operative intervention indicated MW, YH Grade 3 fracture AE CTCAE: E11706 OAE:0003651 a gamma-glutamyltransferase level increased AE that is greater than the upper limit of normal - 2.5 times upper limit of normal MW, YH Grade 1 gamma-glutamyltransferase level increased AE CTCAE: E12162 OAE:0003652 a gamma-glutamyltransferase level increased AE that is greater than 2.5 - 5.0 times the upper limit of normal MW, YH Grade 2 gamma-glutamyltransferase level increased AE CTCAE: E12163 OAE:0003653 a gamma-glutamyltransferase level increased AE that is greater than 5.0 - 20.0 times the upper limit of normal MW, YH Grade 3 gamma-glutamyltransferase level increased AE CTCAE: E12164 OAE:0003654 a gamma-glutamyltransferase level increased AE that is greater than 20.0 times the upper limit of normal MW, YH Grade 4 gamma-glutamyltransferase level increased AE CTCAE: E12165 OAE:0003655 a gastric ulcer AE that is symptomatic; altered GI function; medical intervention indicated; limiting instrumental activities of daily living MW, YH Grade 2 gastric ulcer AE CTCAE: E10729 OAE:0003656 a gastric ulcer AE that has severely altered GI function; TPN indicated; elective operative or endoscopic intervention indicated; limiting self care activities of daily living; disabling MW, YH Grade 3 gastric ulcer AE CTCAE: E10730 OAE:0003657 a gastritis AE that is symptomatic; altered GI function; medical intervention indicated MW, YH Grade 2 gastritis AE CTCAE: E10735 OAE:0003658 a gastritis AE that has severely altered eating or gastric function; TPN or hospitalization indicated MW, YH Grade 3 gastritis AE CTCAE: E10736 OAE:0003659 a hemolytic uremic syndrome AE that has evidence of RBC destruction (schistocytosis) without clinical consequences MW, YH Grade 1 hemolytic uremic syndrome AE CTCAE: E10044 OAE:0003660 a hemolytic uremic syndrome AE that has laboratory findings with clinical consequences (e.g., renal insufficiency, petechiae) MW, YH Grade 3 hemolytic uremic syndrome AE CTCAE: E10045 OAE:0003661 a hemolytic uremic syndrome AE that has life-threatening consequences, (e.g., CNS hemorrhage or thrombosis/embolism or renal failure) MW, YH Grade 4 hemolytic uremic syndrome AE CTCAE: E10046 OAE:0003662 a hemorrhoidal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 hemorrhoidal hemorrhage AE CTCAE: E10770 OAE:0003663 a hepatic failure AE that has asterixis; mild encephalopathy; limiting self care activities of daily living MW, YH Grade 3 hepatic failure AE CTCAE: E11212 OAE:0003664 a hepatic failure AE that has moderate to severe encephalopathy; coma; life-threatening consequences MW, YH Grade 4 hepatic failure AE CTCAE: E11213 OAE:0003665 a hepatitis viral AE that has symptomatic liver dysfunction; fibrosis by biopsy; compensated cirrhosis; reactivation of chronic hepatitis MW, YH Grade 3 hepatitis viral AE CTCAE: E11412 OAE:0003666 a hepatitis viral AE that has decompensated liver function (e.g., ascites, coagulopathy, encephalopathy, coma) MW, YH Grade 4 hepatitis viral AE CTCAE: E11413 OAE:0003667 an ileus AE that is symptomatic; altered GI function; bowel rest indicated MW, YH Grade 2 ileus AE CTCAE: E10813 OAE:0003668 an ileus AE that has severely altered GI function; TPN indicated MW, YH Grade 3 ileus AE CTCAE: E10814 OAE:0003669 an infusion related reaction AE that has mild transient reaction; infusion interruption not indicated; intervention not indicated MW, YH Grade 1 infusion related reaction AE CTCAE: E11128 OAE:0003670 an infusion related reaction AE where therapy or infusion interruption indicated but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for less than or equal to 24 hrs MW, YH Grade 2 infusion related reaction AE CTCAE: E11129 OAE:0003671 an infusion related reaction AE that is prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae MW, YH Grade 3 infusion related reaction AE CTCAE: E11130 OAE:0003672 an infusion site extravasation AE that has erythema with associated symptoms (e.g., edema, pain, induration, phlebitis) MW, YH Grade 2 infusion site extravasation AE CTCAE: E11134 OAE:0003673 an infusion site extravasation AE that has ulceration or necrosis; severe tissue damage; operative intervention indicated MW, YH Grade 3 infusion site extravasation AE CTCAE: E11135 OAE:0003674 an irritability AE that has mild; easily consolable MW, YH Grade 1 irritability AE CTCAE: E11145 OAE:0003675 an irritability AE that has moderate; limiting instrumental activities of daily living; increased attention indicated MW, YH Grade 2 irritability AE CTCAE: E11146 OAE:0003676 an irritability AE that has severe abnormal or excessive response; limiting self care activities of daily living; inconsolable MW, YH Grade 3 irritability AE CTCAE: E11147 OAE:0003677 a left ventricular dysfunction AE that has symptomatic due to drop in ejection fraction responsive to intervention MW, YH Grade 3 left venticular systolic dysfuction AE CTCAE: E10131 OAE:0003678 a left ventricular dysfunction AE chracterized as refractory or poorly controlled heart failure due to drop in ejection fraction; intervention such as ventricular assist device, intravenous vasopressor support, or heart transplant indicated MW, YH Grade 4 left ventricular systolic dysfuction AE CTCAE: E10132 OAE:0003679 a lipase increased AE that is greater than the upper limit of normal - 1.5 times upper limit of normal MW, YH Grade 1 lipase increased AE CTCAE: E12186 OAE:0003680 a lipase increased AE that is greater than 1.5 - 2.0 times upper limit of normal MW, YH Grade 2 lipase increased AE CTCAE: E12187 OAE:0003681 a lipase increased AE that is greater than 2.0 - 5.0 times upper limit of normal MW, YH Grade 3 lipase increased AE CTCAE: E12188 OAE:0003682 a lipase increased AE that is greater than 5.0 times upper limit of normal MW, YH Grade 4 lipase increased AE CTCAE: E12189 OAE:0003683 a localized edema AE that has localized to dependent areas, no disability or functional impairment MW, YH Grade 1 localized edema AE CTCAE: E11149 OAE:0003684 a lung infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 lung infection AE CTCAE: E11445 OAE:0003685 a lung infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 lung infection AE CTCAE: E11446 OAE:0003686 a lymphocyte count decreased AE that is less than the lower limit of normal - 800/mm3; less than the lower limit of normal - 0.8 x 10e9 /L MW, YH Grade 1 lymphocyte count decreased AE CTCAE: E12191 OAE:0003687 a lymphocyte count decreased AE that is less than 800 - 500/mm3; less than 0.8 - 0.5 x 10e9 /L MW, YH Grade 2 lymphocyte count decreased AE CTCAE: E12192 OAE:0003688 a lymphocyte count decreased AE that is less than 500 - 200/mm3; less than 0.5 - 0.2 x 10e9 /L MW, YH Grade 3 lymphocyte count decreased AE CTCAE: E12193 OAE:0003689 a lymphocyte count decreased AE that is less than 200/mm3; less than 0.2 x 10e9 /L MW, YH Grade 4 lymphocyte count decreased AE CTCAE: E12194 OAE:0003690 a myocarditis AE that has asymptomatic with laboratory (e.g., BNP [B-Natriuretic Peptide ]) or cardiac imaging abnormalities MW, YH Grade 1 myocarditis AE CTCAE: E10158 OAE:0003691 a myocarditis AE that has symptoms with mild to moderate activity or exertion MW, YH Grade 2 myocarditis AE CTCAE: E10159 OAE:0003692 a myocarditis AE that has severe with symptoms at rest or with minimal activity or exertion; intervention indicated MW, YH Grade 3 myocarditis AE CTCAE: E10160 OAE:0003693 a myocarditis AE that has life-threatening consequences; urgent intervention indicated (e.g., continuous IV therapy or mechanical hemodynamic support) MW, YH Grade 4 myocarditis AE CTCAE: E10161 OAE:0003694 a neutrophil count decreased AE that is less than the lower limit of normal - 1500/mm3; less than the lower limit of normal - 1.5 x 10e9 /L MW, YH Grade 1 neutrophil count decreased AE CTCAE: E12199 OAE:0003695 a neutrophil count decreased AE that is less than 1500 - 1000/mm3; less than 1.5 - 1.0 x 10e9 /L MW, YH Grade 2 neutrophil count decreased AE CTCAE: E12200 OAE:0003696 a neutrophil count decreased AE that is less than 1000 - 500/mm3; less than 1.0 - 0.5 x 10e9 /L MW, YH Grade 3 neutrophil count decreased AE CTCAE: E12201 OAE:0003697 a neutrophil count decreased AE that is less than 500/mm3; less than 0.5 x 10e9 /L MW, YH Grade 4 neutrophil count decreased AE CTCAE: E12202 OAE:0003698 an esophageal stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 esophageal stenosis AE CTCAE: E10672 OAE:0003699 an esophageal stenosis AE that has severely altered GI function; tube feeding; hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 esophageal stenosis AE CTCAE: E10673 OAE:0003700 an esophagitis AE that is symptomatic; altered eating/swallowing; oral supplements indicated MW, YH Grade 2 esophagitis AE CTCAE: E10689 OAE:0003701 an esophagitis AE that has severely altered eating/swallowing; tube feeding, TPN or hospitalization indicated MW, YH Grade 3 esophagitis AE CTCAE: E10690 OAE:0003702 an oral cavity fistula AE that is symptomatic; altered GI function MW, YH Grade 2 oral cavity fistula AE CTCAE: E10890 OAE:0003703 an oral cavity fistula AE that has severely altered GI function; TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 oral cavity fistula AE CTCAE: E10891 OAE:0003704 a papilloedema AE that has a symptomatic decline in vision; visual field defect present sparing the central 20 degrees MW, YH Grade 2 papilledema AE CTCAE: E10413 OAE:0003705 a papilloedema AE that has a marked visual field defect (worse than 20/40 but better than 20/200) MW, YH Grade 3 papilledema AE CTCAE: E10414 OAE:0003706 a papilloedema AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 papilledema AE CTCAE: E10415 OAE:0003707 a pericardial effusion AE that has asymptomatic effusion size small to moderate MW, YH Grade 2 pericardial effusion AE CTCAE: E10173 OAE:0003708 a pericardial effusion AE that has effusion with physiologic consequences MW, YH Grade 3 pericardial effusion AE CTCAE: E10174 OAE:0003709 a portal hypertension AE that has decreased portal vein flow MW, YH Grade 2 portal hypertension AE CTCAE: E11239 OAE:0003710 a portal hypertension AE that has reversal/retrograde portal vein flow; associated with varices and/or ascites MW, YH Grade 3 portal hypertension AE CTCAE: E11240 OAE:0003711 a dermatitis radiation AE that has faint erythema or dry desquamation MW, YH Grade 1 dermatitis radiation AE CTCAE: E11676 OAE:0003712 a dermatitis radiation AE that has moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema MW, YH Grade 2 dermatitis radiation AE CTCAE: E11677 OAE:0003713 a dermatitis radiation AE that has moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion MW, YH Grade 3 dermatitis radiation AE CTCAE: E11678 OAE:0003714 a dermatitis radiation AE that has life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated MW, YH Grade 4 dermatitis radiation AE CTCAE: E11679 OAE:0003715 a rectal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 rectal hemorrhage AE CTCAE: E10958 OAE:0003716 a skin infection AE that is localized, local intervention indicated MW, YH Grade 1 skin infection AE CTCAE: E11569 OAE:0003717 a skin infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 skin infection AE CTCAE: E11570 OAE:0003718 a skin infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 skin infection AE CTCAE: E11571 OAE:0003719 a small intestinal obstruction AE that is symptomatic; altered GI function; limiting instrumental activities of daily living MW, YH Grade 2 small intestinal obstruction AE CTCAE: E11023 OAE:0003720 a small intestinal stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 small intestinal stenosis AE CTCAE: E11034 OAE:0003721 a small intestinal stenosis AE that is symptomatic and severely altered GI function; tube feeding, TPN or hospitalization indicated; non-emergent operative intervention indicated MW, YH Grade 3 small intestinal stenosis AE CTCAE: E11035 OAE:0003722 a soft tissue infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 soft tissue infection AE CTCAE: E11580 OAE:0003723 a soft tissue infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 soft tissue infection AE CTCAE: E11581 OAE:0003724 a gastric hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 gastric hemorrhage AE CTCAE: E10709 OAE:0003725 a tracheitis AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 tracheitis AE CTCAE: E11600 OAE:0003726 a tracheitis AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 tracheitis AE CTCAE: E11601 OAE:0003727 an upper gastrointestinal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 upper gastrointestinal hemorrhage AE CTCAE: E11065 OAE:0003728 a urine output decreased AE that has oliguria (less than 80 ml in 8 hr) MW, YH Grade 3 urine output decreased AE CTCAE: E12218 OAE:0003729 a urine output decreased AE that has anuria (less than 240 ml in 24 hr) MW, YH Grade 4 urine output decreased AE CTCAE: E12219 OAE:0003730 a vaginal infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 vaginal infection AE CTCAE: E11625 OAE:0003731 a vaginal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 vaginal infection AE CTCAE: E11626 OAE:0003732 a venous injury AE that is symptomatic (e.g., claudication); repair or revision not indicated MW, YH Grade 2 venous injury AE CTCAE: E12053 OAE:0003733 a venous injury AE that has severe symptoms; limiting self care activities of daily living; repair or revision indicated; disabling MW, YH Grade 3 venous injury AE CTCAE: E12054 OAE:0003734 a venous injury AE that has life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated MW, YH Grade 4 venous injury AE CTCAE: E12055 OAE:0003735 a weight increased AE that is 5 - less than 10% from baseline MW, YH Grade 1 weight increased AE CTCAE: E12225 OAE:0003736 a weight increased AE that is 10 - less than 20% from baseline MW, YH Grade 2 weight increased AE CTCAE: E12226 OAE:0003737 a weight increased AE that is greater than or equal to 20% from baseline MW, YH Grade 3 weight increased AE CTCAE: E12227 OAE:0003738 a wolff-parkinson-white syndrome AE that is symptomatic and incompletely controlled medically or controlled with procedure MW, YH Grade 3 Wolff-Parkinson-White syndrom AE CTCAE: E10247 OAE:0003739 a wound complication AE that has incisional separation of less than or equal to 25% of wound, no deeper than superficial fascia MW, YH Grade 1 wound complication AE CTCAE: E12058 OAE:0003740 a wound complication AE that has incisional separation greater than 25% of wound; local care indicated MW, YH Grade 2 wound complication AE CTCAE: E12059 OAE:0003741 a wound complication AE that has hernia without evidence of strangulation; fascial disruption/dehiscence; primary wound closure or revision by operative intervention indicated MW, YH Grade 3 wound complication AE CTCAE: E12060 OAE:0003742 a wound complication AE that has hernia with evidence of strangulation; major reconstruction flap, grafting, resection, or amputation indicated MW, YH Grade 4 wound complication AE CTCAE: E12061 OAE:0003743 a wound dehiscence AE that has incisional separation of less than or equal to 25% of wound, no deeper than superficial fascia MW, YH Grade 1 wound dehiscence AE CTCAE: E12064 OAE:0003744 a wound dehiscence AE that has incisional separation greater than 25% of wound with local care; asymptomatic hernia or symptomatic hernia without evidence of strangulation MW, YH Grade 2 wound dehiscence AE CTCAE: E12065 OAE:0003745 a wound dehiscence AE that has fascial disruption or dehiscence without evisceration; primary wound closure or revision by operative intervention indicated MW, YH Grade 3 wound dehiscence AE CTCAE: E12066 OAE:0003746 a wound dehiscence AE that has life-threatening consequences; symptomatic hernia with evidence of strangulation; fascial disruption with evisceration; major reconstruction flap, grafting, resection, or amputation indicated MW, YH Grade 4 wound dehiscence AE CTCAE: E12067 OAE:0003747 a multi-organ failure AE chracterized by shock with azotemia and acid-base disturbances; significant coagulation abnormalities MW, YH Grade 3 multi-organ failure AE CTCAE: E11156 OAE:0003748 a multi-organ failure AE that has life-threatening consequences (e.g., vasopressor dependent and oliguric or anuric or ischemic colitis or lactic acidosis) MW, YH Grade 4 multi-organ failure AE CTCAE: E11157 OAE:0003749 a restrictive cardiomyopathy AE that has symptomatic heart failure or other cardiac symptoms, responsive to intervention MW, YH Grade 3 restrictive cardiomyopathy AE CTCAE: E10193 OAE:0003750 a restrictive cardiomyopathy AE that has refractory heart failure or other poorly controlled cardiac symptoms MW, YH Grade 4 restrictive cardiomyopathy AE CTCAE: E10194 OAE:0003751 a complete atrioventricular block AE that has symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker) MW, YH Grade 3 atrioventricular block complete AE CTCAE: E10095 OAE:0003752 a Mobitz type I block AE that has symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker) MW, YH Grade 3 Mobitz type I block AE CTCAE: E10149 OAE:0003753 a Mobitz type II block AE that has symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker) MW, YH Grade 3 Mobitz type II atrioventricular block AE CTCAE: E10143 OAE:0003754 a hemoglobin level increased AE where the increase is greater than 0 - 2 gm/dL above upper limit of normal or above baseline if baseline is above upper limit of normal MW, YH Grade 1 hemoglobin level increased AE CTCAE: E12172 OAE:0003755 a hemoglobin level increased AE where the increase is greater than 2 - 4 gm/dL above the upper limit of normal or above baseline if baseline is above upper limit of normal MW, YH Grade 2 hemoglobin level increased AE CTCAE: E12173 OAE:0003756 a hemoglobin level increased AE where the increase is greater than 4 gm/dL above the upper limit of normal or above baseline if baseline is above upper limit of normal MW, YH Grade 3 hemoglobin level increased AE CTCAE: E12174 OAE:0003757 a right ventricular dysfunction AE that has asymptomatic with laboratory (e.g., BNP [B-Natriuretic Peptide ]) or cardiac imaging abnormalities MW, YH Grade 1 right ventricular dysfuction AE CTCAE: E10197 OAE:0003758 a right ventricular dysfunction AE that has symptoms with mild to moderate activity or exertion MW, YH Grade 2 right ventricular dysfuction AE CTCAE: E10198 OAE:0003759 a right ventricular dysfunction AE that has severe symptoms, associated with hypoxemia, right heart failure; oxygen indicated MW, YH Grade 3 right ventricular dysfuction AE CTCAE: E10199 OAE:0003760 a right ventricular dysfunction AE that has life-threatening consequences; urgent intervention indicated (e.g., ventricular assist device); heart transplant indicated MW, YH Grade 4 right ventricular dysfunction AE CTCAE: E10200 OAE:0003761 a Intraoperative hemorrhage AE where postoperative radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 intraoperative hemorrhage AE CTCAE: E11811 OAE:0003762 an uveitis AE that has anterior uveitis; medical intervention indicated MW, YH Grade 2 uveitis AE CTCAE: E10444 OAE:0003763 an uveitis AE that has posterior or pan-uveitis MW, YH Grade 3 uveitis AE CTCAE: E10445 OAE:0003764 an uveitis AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 uveitis AE CTCAE: E10446 OAE:0003765 a retinopathy AE that is symptomatic with moderate decrease in visual acuity (20/40 or better); limiting instrumental activities of daily living MW, YH Grade 2 retinopathy AE CTCAE: E10434 OAE:0003766 a retinopathy AE that is symptomatic with marked decrease in visual acuity (worse than 20/40); disabling; limiting self care activities of daily living MW, YH Grade 3 retinopathy AE CTCAE: E10435 OAE:0003767 a retinopathy AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 retinopathy AE CTCAE: E10436 OAE:0003768 a hearing loss AE for adults enrolled on a Monitoring Program (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): Threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear. Adults not enrolled in Monitoring Program: subjective change in hearing in the absence of documented hearing loss. Pediatric (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): Threshold shift greater than20 dB at 8 kHz in at least one ear. MW, YH Grade 1 hearing loss AE CTCAE: E10277 OAE:0003769 a hearing loss AE for adults enrolled in Monitoring Program (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): Threshold shift of greater than25 dB averaged at 2 contiguous test frequencies in at least one ear. Adults not enrolled in Monitoring Program: hearing loss but hearing aid or intervention not indicated; limiting instrumental activities of daily living. Pediatric (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): Threshold shift greater than20 dB at 4 kHz and above in at least one ear. MW, YH Grade 2 hearing loss AE CTCAE: E10278 OAE:0003770 a hearing loss AE for adults enrolled in Monitoring Program (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): Threshold shift of greater than25 dB averaged at 3 contiguous test frequencies in at least one ear; therapeutic intervention indicated. Adults not enrolled in Monitoring Program: hearing loss with hearing aid or intervention indicated; limiting self care activities of daily living. Pediatric (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): hearing loss sufficient to indicate therapeutic intervention, including hearing aids; threshold shift greater than20 dB at 3 kHz and above in at least one ear; additional speech-language related services indicated. MW, YH Grade 3 hearing loss AE CTCAE: E10279 OAE:0003771 a hearing loss AE for adults: Decrease in hearing to profound bilateral loss (absolute threshold greater than80 dB HL at 2 kHz and above); non-servicable hearing. Pediatric: Audiologic indication for cochlear implant and additional speech-language related services indicated. MW, YH Grade 4 hearing loss AE CTCAE: E10280 OAE:0003772 a international normalized ratio increased AE that is greater than 1 - 1.5 times the upper limit of normal; greater than 1 - 1.5 times above baseline if on anticoagulation MW, YH Grade 1 international normalized ratio increased AE CTCAE: E12176 OAE:0003773 a international normalized ratio increased AE that is greater than 1.5 - 2.5 times the upper limit of normal; greater than 1.5 - 2.5 times above baseline if on anticoagulation MW, YH Grade 2 international normalized ratio increased AE CTCAE: E12177 OAE:0003774 a international normalized ratio increased AE that is greater than 2.5 times the upper limit of normal; greater than 2.5 times above baseline if on anticoagulation MW, YH Grade 3 international normalized ratio increased AE CTCAE: E12178 OAE:0003775 a fecal incontinence AE that has occasional use of pads required MW, YH Grade 1 fecal incontinence AE CTCAE: E10694 OAE:0003776 a fecal incontinence AE that has daily use of pads required MW, YH Grade 2 fecal incontinence AE CTCAE: E10695 OAE:0003777 a fecal incontinence AE that has severe symptoms; elective operative intervention indicated MW, YH Grade 3 fecal incontinence AE CTCAE: E10696 OAE:0003778 a thrombotic thrombocytopenic purpura AE that has evidence of RBC destruction (schistocytosis) without clinical consequences MW, YH Grade 1 thrombotic thrombocytopenic purpura AE CTCAE: E10062 OAE:0003779 a thrombotic thrombocytopenic purpura AE charaterized by laboratory findings with clinical consequences (e.g., renal insufficiency, petechiae) MW, YH Grade 3 thrombotic thrombocytopenic purpura AE CTCAE: E10063 OAE:0003780 a thrombotic thrombocytopenic purpura AE that has life-threatening consequences, (e.g., CNS hemorrhage or thrombosis/embolism or renal failure) MW, YH Grade 4 thrombotic thrombocytopenic purpura AE CTCAE: E10064 OAE:0003781 a glaucoma AE that has elevated intraocular pressure (EIOP) with single topical agent for intervention; no visual field deficit MW, YH Grade 1 glaucoma AE CTCAE: E10393 OAE:0003782 a glaucoma AE that has elevated intraocular pressure causing early visual field deficits; multiple topical or oral agents indicated; limiting instrumental activities of daily living MW, YH Grade 2 glaucoma AE CTCAE: E10394 OAE:0003783 a glaucoma AE that has elevated intraocular pressure causing marked visual field deficits (e.g., involving both superior and inferior visual fields); operative intervention indicated; limiting self care activities of daily living MW, YH Grade 3 glaucoma AE CTCAE: E10395 OAE:0003784 a glaucoma AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 glaucoma AE CTCAE: E10396 OAE:0003785 an anaphylaxis AE that has symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy-related edema/angioedema; hypotension MW, YH Grade 3 anaphylaxis AE CTCAE: E11255 OAE:0003786 a retinal detachment AE that has exudative and visual acuity 20/40 or better MW, YH Grade 2 retinal detachment AE CTCAE: E10422 OAE:0003787 a retinal detachment AE that has rhegmatogenous or exudative detachment; operative intervention indicated; decline in vision (worse than 20/40 but better than 20/200) MW, YH Grade 3 retinal detachment AE CTCAE: E10423 OAE:0003788 a retinal detachment AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 retinal detachment AE CTCAE: E10424 OAE:0003789 a hemolysis AE that has laboratory evidence of hemolysis only (e.g., direct antiglobulin test; DAT; Coombs'; schistocytes; decreased haptoglobin) MW, YH Grade 1 hemolysis AE CTCAE: E10038 OAE:0003790 a hemolysis AE that has evidence of hemolysis and greater than or equal to 2 gm decrease in hemoglobin. MW, YH Grade 2 hemolysis AE CTCAE: E10039 OAE:0003791 a hemolysis AE where transfusion or medical intervention is indicated (e.g., steroids) MW, YH Grade 3 hemolysis AE CTCAE: E10040 OAE:0003792 an anal fistula AE that is symptomatic; altered GI function MW, YH Grade 2 anal fistula AE CTCAE: E10466 OAE:0003793 an anal fistula AE that has severely altered GI function; tube feeding, TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 anal fistula AE CTCAE: E10467 OAE:0003794 an atrial tachycardia AE where IV medication is indicated MW, YH Grade 3 atrial tachycardia AE CTCAE: E10169 OAE:0003795 an atrial tachycardia AE that has life-threatening consequences; incompletely controlled medically; cardioversion indicated MW, YH Grade 4 atrial tachycardia AE CTCAE: E10170 OAE:0003796 a cholecystitis AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 cholecystitis AE CTCAE: E11186 OAE:0003797 an autoimmune disorder AE that is asymptomatic; serologic or other evidence of autoimmune reaction, with normal organ function; intervention not indicated MW, YH Grade 1 autoimmune disorder AE CTCAE: E11259 OAE:0003798 an autoimmune disorder AE that has evidence of autoimmune reaction involving a non-essential organ or function (e.g., hypothyroidism) MW, YH Grade 2 autoimmune disorder AE CTCAE: E11260 OAE:0003799 an autoimmune disorder AE that has autoimmune reactions involving major organ (e.g., colitis, anemia, myocarditis, kidney) MW, YH Grade 3 autoimmune disorder AE CTCAE: E11261 OAE:0003800 a spleen disorder AE that has incidental findings (e.g., Howell-Jolly bodies); mild degree of thrombocytosis and leukocytosis MW, YH Grade 1 spleen disorder AE CTCAE: E10057 OAE:0003801 a spleen disorder AE when prophylactic antibiotics are indicated MW, YH Grade 2 spleen disorder AE CTCAE: E10058 OAE:0003802 a burn AE that requires medical intervention; minimal debridement indicated MW, YH Grade 2 burn AE CTCAE: E11671 OAE:0003803 a burn AE that requires moderate to major debridement or reconstruction indicated MW, YH Grade 3 burn AE CTCAE: E11672 OAE:0003804 a papulopustular rash AE that has papules and/or pustules covering less than 10% body surface area which may or may not be associated with symptoms of pruritus or tenderness MW, YH Grade 1 papulopustular rash AE CTCAE: E11492 OAE:0003805 a papulopustular rash AE that has papules and/or pustules covering 10-30% body surface area, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental activities of daily living MW, YH Grade 2 papulopustular rash AE CTCAE: E11493 OAE:0003806 a papulopustular rash AE that has papules and/or pustules covering greater than 30% body surface area, which may or may not be associated with symptoms of pruritus or tenderness; limiting self-care activities of daily living; associated with local superinfection with oral antibiotics indicated MW, YH Grade 3 papulopustular rash AE CTCAE: E11494 OAE:0003807 a papulopustular rash AE that has papules and/or pustules covering any % body surface area, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated; life-threatening consequences MW, YH Grade 4 papulopustular rash AE CTCAE: E11495 OAE:0003808 an acute coronary syndrome AE that has symptomatic, progressive angina; cardiac enzymes normal; hemodynamically stable MW, YH Grade 2 acute coronary syndrome AE CTCAE: E10067 OAE:0003809 an acute coronary syndrome AE that has symptomatic, unstable angina and/or acute myocardial infarction, cardiac enzymes abnormal, hemodynamically stable MW, YH Grade 3 acute coronary syndrome AE CTCAE: E10068 OAE:0003810 an acute coronary syndrome AE that has symptomatic, unstable angina and/or acute myocardial infarction, cardiac enzymes abnormal, hemodynamically unstable MW, YH Grade 4 acute coronary syndrome AE CTCAE: E10069 OAE:0003811 an aortic valve disease AE that has asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging MW, YH Grade 1 aortic valve disease AE CTCAE: E10072 OAE:0003812 an aortic valve disease AE that has symptomatic; moderate regurgitation or stenosis by imaging MW, YH Grade 2 aortic valve disease AE CTCAE: E10073 OAE:0003813 an aortic valve disease AE that has symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention MW, YH Grade 3 aortic valve disease AE CTCAE: E10074 OAE:0003814 an aortic valve disease AE that has life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty) MW, YH Grade 4 aortic valve disease AE CTCAE: E10075 OAE:0003815 an asystole AE that has periods of asystole; non-urgent medical management indicated MW, YH Grade 1 asystole AE CTCAE: E10078 OAE:0003816 a constrictive pericarditis AE that has symptomatic heart failure or other cardiac symptoms, responsive to intervention MW, YH Grade 3 constrictive pericarditis AE CTCAE: E10121 OAE:0003817 a constrictive pericarditis AE that has refractory heart failure or other poorly controlled cardiac symptoms MW, YH Grade 4 constrictive pericarditis AE CTCAE: E10122 OAE:0003818 a mitral valve disease AE that has asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging MW, YH Grade 1 mitral valve disease AE CTCAE: E10135 OAE:0003819 a mitral valve disease AE that has asymptomatic; moderate regurgitation or stenosis by imaging MW, YH Grade 2 mitral valve disease AE CTCAE: E10136 OAE:0003820 a mitral valve disease AE that has symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention MW, YH Grade 3 mitral valve disease AE CTCAE: E10137 OAE:0003821 a mitral valve disease AE that has life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty) MW, YH Grade 4 mitral valve disease AE CTCAE: E10138 OAE:0003822 a pulmonary valve disease AE that has asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging MW, YH Grade 1 pulmonary valve disease AE CTCAE: E10187 OAE:0003823 a pulmonary valve disease AE that has asymptomatic; moderate regurgitation or stenosis by imaging MW, YH Grade 2 pulmonary valve disease AE CTCAE: E10188 OAE:0003824 a pulmonary valve disease AE that has symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention MW, YH Grade 3 pulmonary valve disease AE CTCAE: E10189 OAE:0003825 a pulmonary valve disease AE that has life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty) MW, YH Grade 4 pulmonary valve disease AE CTCAE: E10190 OAE:0003826 a tricuspid valve disease AE that has asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis MW, YH Grade 1 tricuspid valve disease AE CTCAE: E10225 OAE:0003827 a tricuspid valve disease AE that is asymptomatic; moderate regurgitation or stenosis by imaging MW, YH Grade 2 tricuspid valve disease AE CTCAE: E10226 OAE:0003828 a tricuspid valve disease AE that is symptomatic; severe regurgitation or stenosis; symptoms controlled with medical intervention MW, YH Grade 3 tricuspid valve disease AE CTCAE: E10227 OAE:0003829 a tricuspid valve disease AE that has life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty) MW, YH Grade 4 tricuspid valve disease AE CTCAE: E10228 OAE:0003830 an external ear inflammation AE that has external otitis with erythema or dry desquamation MW, YH Grade 1 external ear inflammation AE CTCAE: E10267 OAE:0003831 an external ear inflammation AE that has external otitis with moist desquamation, edema, enhanced cerumen or discharge; tympanic membrane perforation; tympanostomy MW, YH Grade 2 external ear inflammation AE CTCAE: E10268 OAE:0003832 an external ear inflammation AE that has external otitis with mastoiditis; stenosis or osteomyelitis; necrosis of soft tissue or bone MW, YH Grade 3 external ear inflammation AE CTCAE: E10269 OAE:0003833 an external ear inflammation AE where urgent operative intervention indicated MW, YH Grade 4 external ear inflammation AE CTCAE: E10270 OAE:0003834 a middle ear inflammation AE that has serous otitis MW, YH Grade 1 middle ear inflammation AE CTCAE: E10282 OAE:0003835 a middle ear inflammation AE that has serous otitis, medical intervention indicated MW, YH Grade 2 middle ear inflammation AE CTCAE: E10283 OAE:0003836 a middle ear inflammation AE that has mastoiditis; necrosis of canal soft tissue or bone MW, YH Grade 3 middle ear inflammation AE CTCAE: E10284 OAE:0003837 a delayed puberty AE that has no breast development by age 13 yrs for females; testes volume of <3 cc or no Tanner Stage 2 development by age 14.5 yrs for males MW, YH Grade 2 delayed puberty AE CTCAE: E10309 OAE:0003838 a delayed puberty AE that has no breast development by age 14 yrs for females; no increase in testes volume or no Tanner Stage 2 by age 16 yrs for males; hormone replacement indicated MW, YH Grade 3 delayed puberty AE CTCAE: E10310 OAE:0003839 a growth accelerated AE that has greater than or equal to +2 SD (standard deviation) above mid parental height or target height MW, YH Grade 2 growth accelerated AE CTCAE: E10318 OAE:0003840 a precocious puberty AE that has physical signs of puberty with no biochemical markers for females younger than 8 years and males younger than 9 years MW, YH Grade 1 precocious puberty AE CTCAE: E10341 OAE:0003841 a precocious puberty AE that has physical signs and biochemical markers of puberty for females younger than 8 years and males younger than 9 years MW, YH Grade 2 precocious puberty AE CTCAE: E10342 OAE:0003842 a corneal ulcer AE that has limiting self care activities of daily living declining vision (worse than 20/40 but better than 20/200) MW, YH Grade 3 corneal ulcer AE CTCAE: E10361 OAE:0003843 a corneal ulcer AE that has perforation or blindness (20/200 or worse) in the affected eye MW, YH Grade 4 corneal ulcer AE CTCAE: E10362 OAE:0003844 a dry eye AE that is asymptomatic; clinical or diagnostic observations only; mild symptoms relieved by lubricants MW, YH Grade 1 dry eye AE CTCAE: E10364 OAE:0003845 a dry eye AE that has a decrease in visual acuity (<20/40); limiting self care activities of daily living MW, YH Grade 3 dry eye AE CTCAE: E10366 OAE:0003846 a keratitis AE that has a decline in vision (worse than 20/40 but better than 20/200); limiting self care activities of daily living MW, YH Grade 3 keratitis AE CTCAE: E10399 OAE:0003847 a keratitis AE that has perforation or blindness (20/200 or worse) in the affected eye MW, YH Grade 4 keratitis AE CTCAE: E10400 OAE:0003848 a night blindness AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 night blindness AE CTCAE: E10405 OAE:0003849 an optic nerve disorder AE that has limiting vision of the affected eye (20/40 or better) MW, YH Grade 2 optic nerve disorder AE CTCAE: E10408 OAE:0003850 an optic nerve disorder AE that has limiting vision in the affected eye (worse than 20/40 but better than 20/200) MW, YH Grade 3 optic nerve disorder AE CTCAE: E10409 OAE:0003851 an optic nerve disorder AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 optic nerve disorder AE CTCAE: E10410 OAE:0003852 a retinal tear AE where laser therapy or pneumopexy indicated MW, YH Grade 2 retinal tear AE CTCAE: E10426 OAE:0003853 a retinal tear AE where vitroretinal surgical repair indicated MW, YH Grade 3 retinal tear AE CTCAE: E10427 OAE:0003854 a retinal tear AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 retinal tear AE CTCAE: E10428 OAE:0003855 a retinal vascular disorder AE where topical medication indicated MW, YH Grade 2 retinal vascular disorder AE CTCAE: E10430 OAE:0003856 a retinal vascular disorder AE where intravitreal medication; operative intervention indicated MW, YH Grade 3 retinal vascular disorder AE CTCAE: E10431 OAE:0003857 a scleral disorder AE that is symptomatic, limiting instrumental activities of daily living; moderate decrease in visual acuity (20/40 or better) MW, YH Grade 2 scleral disorder AE CTCAE: E10439 OAE:0003858 a scleral disorder AE that is symptomatic, limiting self care activities of daily living; marked decrease in visual acuity (worse than 20/40) MW, YH Grade 3 scleral disorder AE CTCAE: E10440 OAE:0003859 a scleral disorder AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 scleral disorder AE CTCAE: E10441 OAE:0003860 a vitreous hemorrhage AE that has limiting self care activities of daily living; vitrectomy indicated MW, YH Grade 3 vitreous hemorrhage AE CTCAE: E10450 OAE:0003861 a vitreous hemorrhage AE that has blindness (20/200 or worse) in the affected eye MW, YH Grade 4 vitreous hemorrhage AE CTCAE: E10451 OAE:0003862 an anal necrosis AE where TPN or hospitalization indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 anal necrosis AE CTCAE: E10483 OAE:0003863 an anal stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 anal stenosis AE CTCAE: E10492 OAE:0003864 an anal stenosis AE that is symptomatic and severely altered GI function; non-emergent operative intervention indicated; TPN or hospitalization indicated MW, YH Grade 3 anal stenosis AE CTCAE: E10493 OAE:0003865 a bloating AE that has no change in bowel function or oral intake MW, YH Grade 1 bloating AE CTCAE: E10509 OAE:0003866 a bloating AE that is symptomatic, decreased oral intake; change in bowel function MW, YH Grade 2 bloating AE CTCAE: E10510 OAE:0003867 a cecal hemorrhage AE that has moderate symptoms; medical intervention or minor cauterization indicated MW, YH Grade 2 cecal hemorrhage AE CTCAE: E10513 OAE:0003868 a cecal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 cecal hemorrhage AE CTCAE: E10514 OAE:0003869 a colonic fistula AE that is symptomatic; altered GI function MW, YH Grade 2 colonic fistula AE CTCAE: E10529 OAE:0003870 a colonic fistula AE that has severely altered GI function; bowel rest, TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 colonic fistula AE CTCAE: E10530 OAE:0003871 a colonic hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 colonic hemorrhage AE CTCAE: E10536 OAE:0003872 a colonic obstruction AE that is symptomatic; altered GI function MW, YH Grade 2 colonic obstruction AE CTCAE: E10541 OAE:0003873 a colonic ulcer AE that is symptomatic; altered GI function MW, YH Grade 2 colonic ulcer AE CTCAE: E10558 OAE:0003874 a colonic ulcer AE that has severely altered GI function; TPN indicated; elective operative or endoscopic intervention indicated; disabling MW, YH Grade 3 colonic ulcer AE CTCAE: E10559 OAE:0003875 a duodenal fistula AE that is symptomatic; altered GI function MW, YH Grade 2 duodenal fistula AE CTCAE: E10584 OAE:0003876 a duodenal fistula AE that has severely altered GI function; tube feeding, TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 duodenal fistula AE CTCAE: E10585 OAE:0003877 a duodenal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 duodenal hemorrhage AE CTCAE: E10591 OAE:0003878 a duodenal obstruction AE that is symptomatic; altered GI function MW, YH Grade 2 duodenal obstruction AE CTCAE: E10596 OAE:0003879 a duodenal stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 duodenal stenosis AE CTCAE: E10607 OAE:0003880 a duodenal stenosis AE that has severely altered GI function; tube feeding; hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 duodenal stenosis AE CTCAE: E10608 OAE:0003881 an esophageal fistula AE that is symptomatic; altered GI function MW, YH Grade 2 esophageal fistula AE CTCAE: E10641 OAE:0003882 an esophageal fistula AE that has severely altered GI function; tube feeding, TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 esophageal fistula AE CTCAE: E10642 OAE:0003883 an esophageal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 esophageal hemorrhage AE CTCAE: E10648 OAE:0003884 an esophageal necrosis AE that has inability to aliment adequately by GI tract; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 esophageal necrosis AE CTCAE: E10652 OAE:0003885 an esophageal obstruction AE that is symptomatic; altered GI function; limiting instrumental activities of daily living MW, YH Grade 2 esophageal obstruction AE CTCAE: E10657 OAE:0003886 an esophageal ulcer AE that is symptomatic; altered GI function; limiting instrumental activities of daily living MW, YH Grade 2 esophageal ulcer AE CTCAE: E10678 OAE:0003887 an esophageal ulcer AE that has severely altered GI function; TPN indicated; elective operative or endoscopic intervention indicated; limiting self care activities of daily living; disabling MW, YH Grade 3 esophageal ulcer AE CTCAE: E10679 OAE:0003888 an esophageal varices hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 esophageal varices hemorrhage AE CTCAE: E10684 OAE:0003889 a gastric fistula AE that is symptomatic; altered GI function MW, YH Grade 2 gastric fistula AE CTCAE: E10702 OAE:0003890 a gastric fistula AE that has severely altered GI function; bowel rest; tube feeding, TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 gastric fistula AE CTCAE: E10703 OAE:0003891 a gastric necrosis AE that has inability to aliment adequately by GI tract; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 gastric necrosis AE CTCAE: E10713 OAE:0003892 a gastric stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 gastric stenosis AE CTCAE: E10723 OAE:0003893 a gastric stenosis AE that has severely altered GI function; tube feeding; hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 gastric stenosis AE CTCAE: E10724 OAE:0003894 a gastrointestinal fistula AE that is symptomatic; altered GI function MW, YH Grade 2 gastrointestinal fistula AE CTCAE: E10751 OAE:0003895 a gastrointestinal fistula AE that has severely altered GI function; tube feeding, TPN or hospitalization indicated MW, YH Grade 3 gastrointestinal fistula AE CTCAE: E10752 OAE:0003896 a gastroparesis AE that has mild nausea, early satiety and bloating, able to maintain caloric intake on regular diet MW, YH Grade 1 gastroparesis AE CTCAE: E10760 OAE:0003897 a gastroparesis AE that has moderate symptoms; able to maintain nutrition with dietary and lifestyle modifications; may need pharmacologic intervention MW, YH Grade 2 gastroparesis AE CTCAE: E10761 OAE:0003898 a gastroparesis AE that has weight loss; refractory to medical intervention; unable to maintain nutrition orally MW, YH Grade 3 gastroparesis AE CTCAE: E10762 OAE:0003899 an ileal fistula AE that is symptomatic; altered GI function MW, YH Grade 2 ileal fistula AE CTCAE: E10779 OAE:0003900 an ileal fistula AE that has severely altered GI function; TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 ileal fistula AE CTCAE: E10780 OAE:0003901 an ileal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 ileal hemorrhage AE CTCAE: E10786 OAE:0003902 an ileal obstruction AE that is symptomatic; altered GI function; limiting instrumental activities of daily living MW, YH Grade 2 ileal obstruction AE CTCAE: E10791 OAE:0003903 an ileal stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 ileal stenosis AE CTCAE: E10802 OAE:0003904 an ileal stenosis AE that has severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 ileal stenosis AE CTCAE: E10803 OAE:0003905 an ileal ulcer AE that is symptomatic; altered GI function MW, YH Grade 2 ileal ulcer AE CTCAE: E10808 OAE:0003906 an ileal ulcer AE that has severely altered GI function; TPN indicated; elective operative or endoscopic intervention indicated; disabling MW, YH Grade 3 ileal ulcer AE CTCAE: E10809 OAE:0003907 an intra-abdominal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 intra-abdominal hemorrhage AE CTCAE: E10819 OAE:0003908 a jejunal fistula AE that is symptomatic; altered GI function MW, YH Grade 2 jejunal fistula AE CTCAE: E10824 OAE:0003909 a jejunal fistula AE that has severely altered GI function; TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 jejunal fistula AE CTCAE: E10825 OAE:0003910 ajejunal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 jejunal hemorrhage AE CTCAE: E10831 OAE:0003911 a jejunal obstruction AE that is symptomatic; altered GI function; limiting instrumental activities of daily living MW, YH Grade 2 jejunal obstruction AE CTCAE: E10836 OAE:0003912 a jejunal stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 jejunal stenosis AE CTCAE: E10847 OAE:0003913 a jejunal stenosis AE that has severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 jejunal stenosis AE CTCAE: E10848 OAE:0003914 a jejunal ulcer AE that is symptomatic; altered GI function MW, YH Grade 2 jejunal ulcer AE CTCAE: E10853 OAE:0003915 a jejunal ulcer AE that has severely altered GI function; TPN indicated; elective operative or endoscopic intervention indicated; disabling MW, YH Grade 3 jejunal ulcer AE CTCAE: E10854 OAE:0003916 a lower gastrointestinal hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 lower gastrointestinal hemorrhage AE CTCAE: E10864 OAE:0003917 a malabsorption AE where altered diet; oral intervention indicated MW, YH Grade 2 malabsorption AE CTCAE: E10868 OAE:0003918 a malabsorption AE that has inability to aliment adequately; TPN indicated MW, YH Grade 3 malabsorption AE CTCAE: E10869 OAE:0003919 an obstruction gastric AE that is symptomatic; altered GI function; limiting instrumental activities of daily living MW, YH Grade 2 obstruction gastric AE CTCAE: E10884 OAE:0003920 an oral hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 oral hemorrhage AE CTCAE: E10901 OAE:0003921 a pancreatic duct stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 pancreatic duct stenosis AE CTCAE: E10910 OAE:0003922 a pancreatic duct stenosis AE that has severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 pancreatic duct stenosis AE CTCAE: E10911 OAE:0003923 a pancreatic fistula AE that is symptomatic; altered GI function MW, YH Grade 2 pancreatic fistula AE CTCAE: E10916 OAE:0003924 a pancreatic fistula AE that has severely altered GI function; tube feeding or TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 pancreatic fistula AE CTCAE: E10917 OAE:0003925 a pancreatic hemorrhage AE where transfusion, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 pancreatic hemorrhage AE CTCAE: E10923 OAE:0003926 a pancreatic necrosis AE where tube feeding or TPN indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 pancreatic necrosis AE CTCAE: E10927 OAE:0003927 a peritoneal necrosis AE where tube feeding or TPN indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 peritoneal necrosis AE CTCAE: E10940 OAE:0003928 a proctitis AE that has rectal discomfort, intervention not indicated MW, YH Grade 1 proctitis AE CTCAE: E10944 OAE:0003929 a proctitis AE that has symptoms (e.g., rectal discomfort, passing blood or mucus); medical intervention indicated; limiting instrumental activities of daily living MW, YH Grade 2 proctitis AE CTCAE: E10945 OAE:0003930 a proctitis AE that has severe symptoms; fecal urgency or stool incontinence; limiting self care activities of daily living MW, YH Grade 3 proctitis AE CTCAE: E10946 OAE:0003931 a rectal fistula AE that is symptomatic; altered GI function MW, YH Grade 2 rectal fistula AE CTCAE: E10951 OAE:0003932 a rectal fistula AE that has severely altered GI function; TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 rectal fistula AE CTCAE: E10952 OAE:0003933 a rectal obstruction AE that is symptomatic; altered GI function; limiting instrumental activities of daily living MW, YH Grade 2 rectal obstruction AE CTCAE: E10973 OAE:0003934 a rectal stenosis AE that is symptomatic; altered GI function MW, YH Grade 2 rectal stenosis AE CTCAE: E10988 OAE:0003935 a rectal stenosis AE that has severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 rectal stenosis AE CTCAE: E10989 OAE:0003936 a rectal ulcer AE that is symptomatic; altered GI function (e.g. altered dietary habits, vomiting, diarrhea) MW, YH Grade 2 rectal ulcer AE CTCAE: E10994 OAE:0003937 a rectal ulcer AE that has severely altered GI function; TPN indicated; elective operative or endoscopic intervention indicated; disabling MW, YH Grade 3 rectal ulcer AE CTCAE: E10995 OAE:0003938 a retroperitoneal hemorrhage AE where transfusion, medical, radiologic, endoscopic, or elective operative intervention indicated MW, YH Grade 3 retroperitoneal hemorrhage AE CTCAE: E11000 OAE:0003939 a salivary gland fistula AE that is symptomatic; altered GI function; tube feeding indicated MW, YH Grade 2 salivary gland fistula AE CTCAE: E11011 OAE:0003940 a salivary gland fistula AE that has severely altered GI function; hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 salivary gland fistula AE CTCAE: E11012 OAE:0003941 a tooth discoloration AE that has surface stains MW, YH Grade 1 tooth discoloration AE CTCAE: E11053 OAE:0003942 an edema limbs AE that has 5 - 10% inter-limb discrepancy in volume or circumference at point of greatest visible difference; swelling or obscuration of anatomic architecture on close inspection MW, YH Grade 1 edema limbs AE CTCAE: E11087 OAE:0003943 an edema limbs AE that has more than 10 to 30% inter-limb discrepancy in volume or circumference at point of greatest visible difference; readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour; limiting instrumental activities of daily living MW, YH Grade 2 edema limbs AE CTCAE: E11088 OAE:0003944 an edema limbs AE that has more than 30% inter-limb discrepancy in volume; gross deviation from normal anatomic contour; limiting self care activities of daily living MW, YH Grade 3 edema limbs AE CTCAE: E11089 OAE:0003945 an edema trunk AE that has swelling or obscuration of anatomic architecture on close inspection MW, YH Grade 1 edema trunk AE CTCAE: E11091 OAE:0003946 an edema trunk AE that has readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour; limiting instrumental activities of daily living MW, YH Grade 2 edema trunk AE CTCAE: E11092 OAE:0003947 an edema trunk AE that has gross deviation from normal anatomic contour; limiting self care activities of daily living MW, YH Grade 3 edema trunk AE CTCAE: E11093 OAE:0003948 A neck edema AE that has moderate neck edema; slight obliteration of anatomic landmarks; limiting instrumental activities of daily living MW, YH Grade 2 neck edema AE CTCAE: E11161 OAE:0003949 a neck edema AE that has generalized neck edema (e.g., difficulty in turning neck); limiting self care activities of daily living MW, YH Grade 3 neck edema AE CTCAE: E11162 OAE:0003950 a bile duct stenosis AE that is symptomatic; altered GI function; IV fluids indicated <24 hrs MW, YH Grade 2 bile duct stenosis AE CTCAE: E11175 OAE:0003951 a bile duct stenosis AE that has severely altered GI function; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 bile duct stenosis AE CTCAE: E11176 OAE:0003952 a biliary fistula AE that has severely altered GI function; TPN indicated; endoscopic intervention indicated; elective operative intervention indicated MW, YH Grade 3 biliary fistula AE CTCAE: E11181 OAE:0003953 a gallbladder fistula AE that is symptomatic or severely altered GI function; TPN indicated; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 gallbladder fistula AE CTCAE: E11192 OAE:0003954 a gallbladder obstruction AE that is symptomatic; altered GI function; IV fluids indicated <24 hrs MW, YH Grade 2 gallbladder obstruction AE CTCAE: E11200 OAE:0003955 a gallbladder obstruction AE that is symptomatic and severely altered GI function; tube feeding, TPN or hospitalization indicated; non-emergent operative intervention indicated MW, YH Grade 3 gallbladder obstruction AE CTCAE: E11201 OAE:0003956 a hepatic hemorrhage AE where transfusion indicated MW, YH Grade 3 hepatic hemorrhage AE CTCAE: E11218 OAE:0003957 a perforation bile duct AE where radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 perforation bile duct AE CTCAE: E11235 OAE:0003958 an abdominal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 abdominal infection AE CTCAE: E11283 OAE:0003959 an anorectal infection AE that is localized; local intervention indicated MW, YH Grade 1 anorectal infection AE CTCAE: E11287 OAE:0003960 an anorectal infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 anorectal infection AE CTCAE: E11288 OAE:0003961 an anorectal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 anorectal infection AE CTCAE: E11289 OAE:0003962 an appendicitis AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 appendicitis AE CTCAE: E11293 OAE:0003963 an arteritis infective AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 arteritis infective AE CTCAE: E11302 OAE:0003964 a biliary tract infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 biliary tract infection AE CTCAE: E11306 OAE:0003965 a bladder infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 bladder infection AE CTCAE: E11310 OAE:0003966 a bladder infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 bladder infection AE CTCAE: E11311 OAE:0003967 a bone infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 bone infection AE CTCAE: E11315 OAE:0003968 a bronchial infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 bronchial infection AE CTCAE: E11324 OAE:0003969 a bronchial infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 bronchial infection AE CTCAE: E11325 OAE:0003970 a cecal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 cecal infection AE CTCAE: E11334 OAE:0003971 a cervicitis infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 cervicitis infection AE CTCAE: E11338 OAE:0003972 a cervicitis infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 cervicitis infection AE CTCAE: E11339 OAE:0003973 a conjunctivitis infective AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 conjunctivitis infective AE CTCAE: E11343 OAE:0003974 a conjunctivitis infective AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 conjunctivitis infective AE CTCAE: E11344 OAE:0003975 a corneal infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 corneal infection AE CTCAE: E11348 OAE:0003976 a corneal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 corneal infection AE CTCAE: E11349 OAE:0003977 a cranial nerve infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 cranial nerve infection AE CTCAE: E11353 OAE:0003978 a duodenal infection AE that has moderate symptoms; medical intervention indicated (e.g., oral antibiotics) MW, YH Grade 2 duodenal infection AE CTCAE: E11361 OAE:0003979 a duodenal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 duodenal infection AE CTCAE: E11362 OAE:0003980 an encephalitis infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; severe changes in mental status; self-limited seizure activity; focal neurologic abnormalities MW, YH Grade 3 encephalitis infection AE CTCAE: E11366 OAE:0003981 an encephalomyelitis infection AE when IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 encephalomyelitis infection AE CTCAE: E11370 OAE:0003982 an endocarditis infective AE when IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 endocarditis infective AE CTCAE: E11374 OAE:0003983 an endophthalmitis AE that has blindness (20/200 or worse) MW, YH Grade 4 endophthalmitis AE CTCAE: E11380 OAE:0003984 an enterocolitis infectious AE that has the passage of more than 3 unformed stools per 24 hrs or duration of illness longer than 48 hrs; moderate abdominal pain MW, YH Grade 2 enterocolitis infectious AE CTCAE: E11382 OAE:0003985 an enterocolitis infectious AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated; profuse watery diarrhea with signs of hypovolemia; bloody diarrhea; fever; severe abdominal pain; hospitalization indicated MW, YH Grade 3 enterocolitis infectious AE CTCAE: E11383 OAE:0003986 an esophageal infection AE where local intervention indicated (e.g., oral antibiotic, antifungal, antiviral) MW, YH Grade 2 esophageal infection AE CTCAE: E11387 OAE:0003987 an esophageal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 esophageal infection AE CTCAE: E11388 OAE:0003988 an eye infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 eye infection AE CTCAE: E11392 OAE:0003989 an eye infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 eye infection AE CTCAE: E11393 OAE:0003990 an eye infection AE that has life-threatening consequences; urgent intervention indicated; enucleation MW, YH Grade 4 eye infection AE CTCAE: E11394 OAE:0003991 a gallbladder infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 gallbladder infection AE CTCAE: E11397 OAE:0003992 a gum infection AE where local therapy indicated (swish and swallow) MW, YH Grade 1 gum infection AE CTCAE: E11401 OAE:0003993 a gum infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 gum infection AE CTCAE: E11402 OAE:0003994 a gum infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 gum infection AE CTCAE: E11403 OAE:0003995 a hepatic infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 hepatic infection AE CTCAE: E11407 OAE:0003996 a infective myositis AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 infective myositis AE CTCAE: E11422 OAE:0003997 a infective myositis AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 infective myositis AE CTCAE: E11423 OAE:0003998 a joint infection AE that is localized; local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, antiviral); needle aspiration indicated (single or multiple) MW, YH Grade 2 joint infection AE CTCAE: E11427 OAE:0003999 a joint infection AE where arthroscopic intervention indicated (e.g., drainage) or arthrotomy (e.g., open surgical drainage) MW, YH Grade 3 joint infection AE CTCAE: E11428 OAE:0004000 a kidney infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 kidney infection AE CTCAE: E11432 OAE:0004001 a lip infection AE that is localized, local intervention indicated MW, YH Grade 1 lip infection AE CTCAE: E11441 OAE:0004002 a lip infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 lip infection AE CTCAE: E11442 OAE:0004003 a lip infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 lip infection AE CTCAE: E11443 OAE:0004004 a lymph gland infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 lymph gland infection AE CTCAE: E11450 OAE:0004005 a lymph gland infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 lymph gland infection AE CTCAE: E11451 OAE:0004006 a mediastinal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 mediastinal infection AE CTCAE: E11455 OAE:0004007 a mucosal infection AE that is localized, local intervention indicated MW, YH Grade 1 mucosal infection AE CTCAE: E11463 OAE:0004008 a mucosal infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 mucosal infection AE CTCAE: E11464 OAE:0004009 a mucosal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 mucosal infection AE CTCAE: E11465 OAE:0004010 a nail infection AE that is localized, local intervention indicated MW, YH Grade 1 nail infection AE CTCAE: E11469 OAE:0004011 a nail infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 nail infection AE CTCAE: E11470 OAE:0004012 a nail infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 nail infection AE CTCAE: E11471 OAE:0004013 an otitis externa AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 otitis externa AE CTCAE: E11473 OAE:0004014 an otitis externa AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 otitis externa AE CTCAE: E11474 OAE:0004015 an ovarian infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 ovarian infection AE CTCAE: E11483 OAE:0004016 an ovarian infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 ovarian infection AE CTCAE: E11484 OAE:0004017 a pancreas infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 pancreas infection AE CTCAE: E11488 OAE:0004018 a paronychia AE that has nail fold edema or erythema; disruption of the cuticle MW, YH Grade 1 paronychia AE CTCAE: E11498 OAE:0004019 a paronychia AE where localized intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, antiviral); nail fold edema or erythema with pain; associated with discharge or nail plate separation; limiting instrumental activities of daily living MW, YH Grade 2 paronychia AE CTCAE: E11499 OAE:0004020 a paronychia AE where surgical intervention or IV antibiotics indicated; limiting self care activities of daily living MW, YH Grade 3 paronychia AE CTCAE: E11500 OAE:0004021 a pelvic infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 pelvic infection AE CTCAE: E11502 OAE:0004022 a pelvic infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 pelvic infection AE CTCAE: E11503 OAE:0004023 a penile infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 penile infection AE CTCAE: E11507 OAE:0004024 a penile infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 penile infection AE CTCAE: E11508 OAE:0004025 a periorbital infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 periorbital infection AE CTCAE: E11512 OAE:0004026 a periorbital infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 periorbital infection AE CTCAE: E11513 OAE:0004027 a peripheral nerve infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 peripheral nerve infection AE CTCAE: E11517 OAE:0004028 a peripheral nerve infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 peripheral nerve infection AE CTCAE: E11518 OAE:0004029 a peritoneal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 peritoneal infection AE CTCAE: E11522 OAE:0004030 a phlebitis infective AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 phlebitis infective AE CTCAE: E11531 OAE:0004031 a phlebitis infective AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 phlebitis infective AE CTCAE: E11532 OAE:0004032 a pleural infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 pleural infection AE CTCAE: E11536 OAE:0004033 a pleural infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 pleural infection AE CTCAE: E11537 OAE:0004034 a prostate infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 prostate infection AE CTCAE: E11541 OAE:0004035 a prostate infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 prostate infection AE CTCAE: E11542 OAE:0004036 a rhinitis infective AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 rhinitis infective AE CTCAE: E11549 OAE:0004037 a salivary gland infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 salivary gland infection AE CTCAE: E11551 OAE:0004038 a salivary gland infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 salivary gland infection AE CTCAE: E11552 OAE:0004039 a scrotal infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 scrotal infection AE CTCAE: E11556 OAE:0004040 a scrotal infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 scrotal infection AE CTCAE: E11557 OAE:0004041 a small intestine infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 small intestine infection AE CTCAE: E11575 OAE:0004042 a small intestine infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 small intestine infection AE CTCAE: E11576 OAE:0004043 a splenic infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 splenic infection AE CTCAE: E11585 OAE:0004044 a stoma site infection AE that is localized, local intervention indicated MW, YH Grade 1 stoma site infection AE CTCAE: E11589 OAE:0004045 a stoma site infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 stoma site infection AE CTCAE: E11590 OAE:0004046 a stoma site infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 stoma site infection AE CTCAE: E11591 OAE:0004047 a tooth infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 tooth infection AE CTCAE: E11595 OAE:0004048 a tooth infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 tooth infection AE CTCAE: E11596 OAE:0004049 an upper respiratory infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 upper respiratory infection AE CTCAE: E11605 OAE:0004050 an upper respiratory infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 upper respiratory infection AE CTCAE: E11606 OAE:0004051 a urethral infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 urethral infection AE CTCAE: E11610 OAE:0004052 a urethral infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 urethral infection AE CTCAE: E11611 OAE:0004053 a uterine infection AE that has moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 uterine infection AE CTCAE: E11620 OAE:0004054 a uterine infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 uterine infection AE CTCAE: E11621 OAE:0004055 a vulval infection AE that is localized, local intervention indicated MW, YH Grade 1 vulval infection AE CTCAE: E11630 OAE:0004056 A vulval infection AE where oral intervention indicated (e.g., antibiotic, antifungal, antiviral) MW, YH Grade 2 vulval infection AE CTCAE: E11631 OAE:0004057 a vulval infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 vulval infection AE CTCAE: E11632 OAE:0004058 a wound infection AE that is localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral) MW, YH Grade 2 wound infection AE CTCAE: E11636 OAE:0004059 a wound infection AE where IV antibiotic, antifungal, or antiviral intervention indicated; radiologic or operative intervention indicated MW, YH Grade 3 wound infection AE CTCAE: E11637 OAE:0004060 an ankle fracture AE that is mild; non-surgical intervention indicated MW, YH Grade 1 ankle fracture AE CTCAE: E11641 OAE:0004061 an ankle fracture AE that is limiting instrumental activities of daily living; operative intervention indicated MW, YH Grade 2 ankle fracture AE CTCAE: E11642 OAE:0004062 an ankle fracture AE that is limiting self care activities of daily living; elective surgery indicated MW, YH Grade 3 ankle fracture AE CTCAE: E11643 OAE:0004063 an aortic injury AE that has severe symptoms; limiting self care activities of daily living; disabling; repair or revision indicated MW, YH Grade 3 aortic injury AE CTCAE: E11645 OAE:0004064 an aortic injury AE that has life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated MW, YH Grade 4 aortic injury AE CTCAE: E11646 OAE:0004065 an arterial injury AE that is symptomatic (e.g., claudication); repair or revision not indicated MW, YH Grade 2 arterial injury AE CTCAE: E11650 OAE:0004066 an arterial injury AE that has severe symptoms; limiting self care activities of daily living; disabling; repair or revision indicated MW, YH Grade 3 arterial injury AE CTCAE: E11651 OAE:0004067 an arterial injury AE that has life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated MW, YH Grade 4 arterial injury AE CTCAE: E11652 OAE:0004068 a biliary anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 biliary anastomotic leak AE CTCAE: E11657 OAE:0004069 a bladder anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 bladder anastomotic leak AE CTCAE: E11663 OAE:0004070 an esophageal anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 esophageal anastomotic leak AE CTCAE: E11684 OAE:0004071 a fallopian tube anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 fallopian tube anastomotic leak AE CTCAE: E11694 OAE:0004072 a fallopian tube perforation AE that has life-threatening consequences; urgent operative intervention indicated (e.g., organ resection) MW, YH Grade 4 fallopian tube perforation AE CTCAE: E11701 OAE:0004073 a gastric anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 gastric anastomotic leak AE CTCAE: E11712 OAE:0004074 a gastrointestinal anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 gastrointestinal anastomotic leak CTCAE: E11718 OAE:0004075 a gastrointestinal stoma necrosis AE that is a superficial necrosis; intervention not indicated MW, YH Grade 2 gastrointestinal stoma necrosis CTCAE: E11722 OAE:0004076 a hip fracture AE that has a hairline fracture; mild pain; limiting instrumental activities of daily living; non-surgical intervention indicated MW, YH Grade 2 hip fracture AE CTCAE: E11727 OAE:0004077 a hip fracture AE that has severe pain; hospitalization or intervention indicated for pain control (e.g., traction); operative intervention indicated MW, YH Grade 3 hip fracture AE CTCAE: E11728 OAE:0004078 a hip fracture AE that has life-threatening consequences; symptoms associated with neurovascular compromise MW, YH Grade 4 hip fracture AE CTCAE: E11729 OAE:0004079 an injury to carotid artery AE that has severe symptoms; limiting self care activities of daily living (e.g., transient cerebral ischemia); repair or revision indicated MW, YH Grade 3 injury to carotid artery AE CTCAE: E11731 OAE:0004080 an injury to jugular vein AE that is symptomatic limiting self care activities of daily living; disabling; repair or revision indicated MW, YH Grade 3 injury to jugular vein AE CTCAE: E11738 OAE:0004081 an injury to superior vena cava AE that has severe symptoms; limiting self care activities of daily living; disabling; repair or revision indicated MW, YH Grade 3 injury to superior vena cava AE CTCAE: E11744 OAE:0004082 a injury to superior vena cava AE that has life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated MW, YH Grade 4 injury to superior vena cava AE CTCAE: E11745 OAE:0004083 an intestinal stoma leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 intestinal stoma leak AE CTCAE: E11756 OAE:0004084 an intestinal stoma leak AE that has severe symptoms; IV fluids, tube feeding, or TPN indicated greater than or equal to 24 hrs; elective operative intervention indicated MW, YH Grade 3 intestinal stoma leak AE CTCAE: E11761 OAE:0004085 an intestinal stoma site bleeding AE that has minimal bleeding identified on clinical exam; intervention not indicated MW, YH Grade 1 intestinal stoma site bleeding AE CTCAE: E11765 OAE:0004086 an intestinal stoma site bleeding AE that has severe bleeding; transfusion indicated; radiologic or endoscopic intervention indicated MW, YH Grade 3 intestinal stoma site bleeding AE CTCAE: E11767 OAE:0004087 an intraoperative arterial injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative arterial injury AE CTCAE: E11771 OAE:0004088 an intraoperative arterial injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative arterial injury AE CTCAE: E11772 OAE:0004089 an intraoperative arterial injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative arterial injury AE CTCAE: E11773 OAE:0004090 an intraoperative breast injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative breast injury AE CTCAE: E11777 OAE:0004091 an intraoperative breast injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative breast injury AE CTCAE: E11778 OAE:0004092 an intraoperative breast injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative breast injury AE CTCAE: E11779 OAE:0004093 an intraoperative cardiac injury AE where primary repair of injured organ/structure indicated MW, YH Grade 3 intraoperative cardiac injury AE CTCAE: E11783 OAE:0004094 an intraoperative ear injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative ear injury AE CTCAE: E11787 OAE:0004095 an intraoperative ear injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative ear injury AE CTCAE: E11788 OAE:0004096 an intraoperative ear injury AE where complete resection of injured organ/structure indicated; disabling (e.g., impaired hearing; impaired balance) MW, YH Grade 3 intraoperative ear injury AE CTCAE: E11789 OAE:0004097 an intraoperative endocrine injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative endocrine injury AE CTCAE: E11793 OAE:0004098 an intraoperative endocrine injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative endocrine injury AE CTCAE: E11794 OAE:0004099 an intraoperative endocrine injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative endocrine injury AE CTCAE: E11795 OAE:0004100 an intraoperative gastrointestinal injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative gastrointestinal injury AE CTCAE: E11799 OAE:0004101 an intraoperative gastrointestinal injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative gastrointestinal injury AE CTCAE: E11800 OAE:0004102 an intraoperative gastrointestinal injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative gastrointestinal injury AE CTCAE: E11801 OAE:0004103 a lintraoperative head and neck injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 lintraoperative head and neck injury AE CTCAE: E11805 OAE:0004104 a lintraoperative head and neck injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 lintraoperative head and neck injury AE CTCAE: E11806 OAE:0004105 a lintraoperative head and neck injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 lintraoperative head and neck injury AE CTCAE: E11807 OAE:0004106 an intraoperative hepatobiliary injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative hepatobiliary injury AE CTCAE: E11815 OAE:0004107 an intraoperative hepatobiliary injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative hepatobiliary injury AE CTCAE: E11816 OAE:0004108 an intraoperative hepatobiliary injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative hepatobiliary injury AE CTCAE: E11817 OAE:0004109 an intraoperative musculoskeletal injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative musculoskeletal injury AE CTCAE: E11821 OAE:0004110 an intraoperative musculoskeletal injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative musculoskeletal injury AE CTCAE: E11822 OAE:0004111 an intraoperative musculoskeletal injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative musculoskeletal injury AE CTCAE: E11823 OAE:0004112 an intraoperative neurological injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative neurological injury AE CTCAE: E11827 OAE:0004113 an intraoperative neurological injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative neurological injury AE CTCAE: E11828 OAE:0004114 an intraoperative neurological injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative neurological injury AE CTCAE: E11829 OAE:0004115 an intraoperative ocular injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative ocular injury AE CTCAE: E11833 OAE:0004116 an intraoperative ocular injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative ocular injury AE CTCAE: E11834 OAE:0004117 an intraoperative ocular injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative ocular injury AE CTCAE: E11835 OAE:0004118 an intraoperative renal injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative renal injury AE CTCAE: E11839 OAE:0004119 an intraoperative renal injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative renal injury AE CTCAE: E11840 OAE:0004120 an intraoperative renal injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative renal injury AE CTCAE: E11841 OAE:0004121 an intraoperative reproductive tract injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative reproductive tract injury AE CTCAE: E11845 OAE:0004122 an intraoperative reproductive tract injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative reproductive tract injury AE CTCAE: E11846 OAE:0004123 an intraoperative reproductive tract injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative reproductive tract injury AE CTCAE: E11847 OAE:0004124 an intraoperative respiratory injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative respiratory injury AE CTCAE: E11851 OAE:0004125 an intraoperative respiratory injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative respiratory injury AE CTCAE: E11852 OAE:0004126 an intraoperative respiratory injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative respiratory injury AE CTCAE: E11853 OAE:0004127 an intraoperative skin injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative skin injury AE CTCAE: E11857 OAE:0004128 an intraoperative skin injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative skin injury AE CTCAE: E11858 OAE:0004129 an intraoperative skin injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative skin injury AE CTCAE: E11859 OAE:0004130 an intraoperative splenic injury AE where primary repair of injured organ/structure indicated MW, YH Grade 2 intraoperative splenic injury AE CTCAE: E11863 OAE:0004131 an intraoperative splenic injury AE where resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative splenic injury AE CTCAE: E11864 OAE:0004132 an intraoperative urinary injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative urinary injury AE CTCAE: E11868 OAE:0004133 an intraoperative urinary injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative urinary injury AE CTCAE: E11869 OAE:0004134 an intraoperative urinary injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative urinary injury AE CTCAE: E11870 OAE:0004135 an intraoperative venous injury AE where primary repair of injured organ/structure indicated MW, YH Grade 1 intraoperative venous injury AE CTCAE: E11874 OAE:0004136 an intraoperative venous injury AE where partial resection of injured organ/structure indicated MW, YH Grade 2 intraoperative venous injury AE CTCAE: E11875 OAE:0004137 an intraoperative venous injury AE where complete resection or reconstruction of injured organ/structure indicated; disabling MW, YH Grade 3 intraoperative venous injury AE CTCAE: E11876 OAE:0004138 a kidney anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 kidney anastomotic leak AE CTCAE: E11882 OAE:0004139 a large intestinal anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 large intestinal anastomotic leak AE CTCAE: E11888 OAE:0004140 a pancreatic anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 pancreatic anastomotic leak AE CTCAE: E11894 OAE:0004141 a pharyngeal anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 pharyngeal anastomotic leak AE CTCAE: E11900 OAE:0004142 a postoperative hemorrhage AE that has moderate bleeding; radiologic, endoscopic, or operative intervention indicated MW, YH Grade 2 postoperative hemorrhage AE CTCAE: E11905 OAE:0004143 a postoperative hemorrhage AE where transfusion indicated of greather than or equal to 2 units (10 cc/kg for pediatrics) pRBCs beyond protocol specification; urgent radiologic, endoscopic, or operative intervention indicated MW, YH Grade 3 postoperative hemorrhage AE CTCAE: E11906 OAE:0004144 a postoperative thoracic procedure complication AE when the patient is extubated within 24 - 72 hrs postoperatively MW, YH Grade 2 postoperative thoracic procedure complication AE CTCAE: E11910 OAE:0004145 a postoperative thoracic procedure complication AE when the patient is extubated more than 72 hrs postoperatively, but before tracheostomy indicated MW, YH Grade 3 postoperative thoracic procedure complication AE CTCAE: E11911 OAE:0004146 a postoperative thoracic procedure complication AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) MW, YH Grade 3 postoperative thoracic procedure complication AE CTCAE: E11912 OAE:0004147 a prolapse of intestinal stoma AE that is asymptomatic; reducible MW, YH Grade 1 prolapse of intestinal stoma AE CTCAE: E11915 OAE:0004148 a prolapse of intestinal stoma AE that is recurrent after manual reduction; local irritation or stool leakage; difficulty to fit appliance; limiting instrumental activities of daily living MW, YH Grade 2 prolapse of intestinal stoma AE CTCAE: E11916 OAE:0004149 a prolapse of urostomy AE treated with local care or maintenance; minor revision indicated MW, YH Grade 2 prolapse of urostomy AE CTCAE: E11922 OAE:0004150 a prolapse of urostomy AE that has dysfunctional stoma; elective operative intervention or major stomal revision indicated MW, YH Grade 3 prolapse of urostomy AE CTCAE: E11923 OAE:0004151 a radiation recall reaction (dermatologic) AE that has faint erythema or dry desquamation MW, YH Grade 1 radiation recall reaction (dermatologic) AE CTCAE: E11927 OAE:0004152 a radiation recall reaction (dermatologic) AE that has moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema MW, YH Grade 2 radiation recall reaction (dermatologic) AE CTCAE: E11928 OAE:0004153 a radiation recall reaction (dermatologic) AE that has moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion MW, YH Grade 3 radiation recall reaction (dermatologic) AE CTCAE: E11929 OAE:0004154 a radiation recall reaction (dermatologic) AE that has life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated MW, YH Grade 4 radiation recall reaction (dermatologic) AE CTCAE: E11930 OAE:0004155 a rectal anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 rectal anastomotic leak AE CTCAE: E11935 OAE:0004156 a seroma AE that is symptomatic; simple aspiration indicated MW, YH Grade 2 seroma AE CTCAE: E11940 OAE:0004157 a seroma AE that is symptomatic, elective radiologic or operative intervention indicated MW, YH Grade 3 seroma AE CTCAE: E11941 OAE:0004158 a small intestinal anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 small intestinal anastomotic leak AE CTCAE: E11945 OAE:0004159 a spermatic cord anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 spermatic cord anastomotic leak AE CTCAE: E11951 OAE:0004160 a spinal fracture AE that has mild back pain; nonprescription analgesics indicated MW, YH Grade 1 spinal fracture AE CTCAE: E11955 OAE:0004161 a spinal fracture AE that has moderate back pain; prescription analgesics indicated; limiting instrumental activities of daily living MW, YH Grade 2 spinal fracture AE CTCAE: E11956 OAE:0004162 a spinal fracture AE that has severe back pain; hospitalization or intervention indicated for pain control (e.g., vertebroplasty); limiting self care activities of daily living; disability MW, YH Grade 3 spinal fracture AE CTCAE: E11957 OAE:0004163 a spinal fracture AE that has life-threatening consequences; symptoms associated with neurovascular compromise MW, YH Grade 4 spinal fracture AE CTCAE: E11958 OAE:0004164 a stenosis of gastrointestinal stoma AE that is symptomatic; IV fluids indicated <24 hrs; manual dilation at bedside MW, YH Grade 2 stenosis of gastrointestinal stoma AE CTCAE: E11961 OAE:0004165 a stenosis of gastrointestinal stoma AE that has severely altered GI function; tube feeding, TPN or hospitalization indicated; elective operative intervention indicated MW, YH Grade 3 stenosis of gastrointestinal stoma AE CTCAE: E11962 OAE:0004166 a tracheal hemorrhage AE that has severe bleeding; transfusion indicated; radiologic or endoscopic intervention indicated MW, YH Grade 3 tracheal hemorrhage AE CTCAE: E11972 OAE:0004167 a tracheal obstruction AE that has partial asymptomatic obstruction on examination (e.g., visual, radiologic or endoscopic) MW, YH Grade 1 tracheal obstruction AE CTCAE: E11976 OAE:0004168 a tracheal obstruction AE that is symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental activities of daily living MW, YH Grade 2 tracheal obstruction AE CTCAE: E11977 OAE:0004169 a tracheal obstruction AE that has stridor; radiologic or endoscopic intervention indicated (e.g., stent, laser); limiting self care activities of daily living MW, YH Grade 3 tracheal obstruction AE CTCAE: E11978 OAE:0004170 a tracheal obstruction AE that has life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) MW, YH Grade 4 tracheal obstruction AE CTCAE: E11979 OAE:0004171 a tracheostomy site bleeding AE that has severe bleeding; transfusion indicated; radiologic or endoscopic intervention indicated MW, YH Grade 3 tracheostomy site bleeding AE CTCAE: E11984 OAE:0004172 an ureteric anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 ureteric anastomotic leak AE CTCAE: E11990 OAE:0004173 an urethral anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 urethral anastomotic leak CTCAE: E11996 OAE:0004174 a urostomy leak AESevere symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 urostomy leak AE CTCAE: E12002 OAE:0004175 a urostomy obstruction AE that is symptomatic; dilation or endoscopic repair or stent placement indicated MW, YH Grade 2 urostomy obstruction AE CTCAE: E12007 OAE:0004176 a urostomy site bleeding AE that has severe bleeding; transfusion indicated; radiologic or endoscopic intervention indicated MW, YH Grade 3 urostomy site bleeding AE CTCAE: E12014 OAE:0004177 a urostomy stenosis AE that is symptomatic but no hydronephrosis, no sepsis or no renal dysfunction; dilation or endoscopic repair or stent placement indicated MW, YH Grade 2 urostomy stenosis AE CTCAE: E12018 OAE:0004178 a urostomy stenosis AE that is symptomatic (e.g., hydronephrosis, or renal dysfunction); elective operative intervention indicated MW, YH Grade 3 urostomy stenosis AE CTCAE: E12019 OAE:0004179 a uterine anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 uterine anastomotic leak AE CTCAE: E12025 OAE:0004180 a vaginal anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 vaginal anastomotic leak AE CTCAE: E12037 OAE:0004181 a vas deferens anastomotic leak AE that has severe symptoms; radiologic, endoscopic or elective operative intervention indicated MW, YH Grade 3 vas deferens anastomotic leak AE CTCAE: E12043 OAE:0004182 a vascular access complication AE that has device dislodgement, blockage, leak, or malposition; device replacement indicated MW, YH Grade 2 vascular access complication AE CTCAE: E12047 OAE:0004183 A vascular access complication AE that has deep vein or cardiac thrombosis; intervention indicated (e.g., anticoagulation, lysis, filter, invasive procedure) MW, YH Grade 3 vascular access complication AE CTCAE: E12048 OAE:0004184 a vascular access complication AE that has embolic event including pulmonary embolism or life-threatening thrombus MW, YH Grade 4 vascular access complication AE CTCAE: E12049 OAE:0004185 a blood antidiuretic hormone abnormal AE where hospitalization indicated MW, YH Grade 3 blood antidiuretic hormone abnormal AE CTCAE: E12095 OAE:0004186 a blood corticotrophin decreased AE where hospitalization indicated MW, YH Grade 3 blood corticotrophin decreased AE CTCAE: E12104 OAE:0004187 a carbon monoxide diffusing capacity decreased AE that is 3 - 5 units below lower limit of normal; for follow-up, a decrease of 3 - 5 units (ml/min/mm Hg) below the baseline value MW, YH Grade 1 carbon monoxide diffusing capacity decreased AE CTCAE: E12113 OAE:0004188 a carbon monoxide diffusing capacity decreased AE that is 6 - 8 units below lower limit of normal; for follow-up, an asymptomatic decrease of greater than 5 - 8 units (ml/min/mm Hg) below the baseline value MW, YH Grade 2 carbon monoxide diffusing capacity decreased AE CTCAE: E12114 OAE:0004189 a carbon monoxide diffusing capacity decreased AE that is an asymptomatic decrease of greater than 8 units drop; greater than 5 units drop along with the presence of pulmonary symptoms (e.g. , greater than Grade 2 hypoxia or greater than Grade 2 or higher dyspnea) MW, YH Grade 3 carbon monoxide diffusing capacity decreased AE CTCAE: E12115 OAE:0004190 a cardiac troponin I increased AE that has levels above the upper limit of normal and below the level of myocardial infarction as defined by the manufacturer MW, YH Grade 1 cardiac troponin I increased AE CTCAE: E12117 OAE:0004191 a cardiac troponin I increased AE that has levels consistent with myocardial infarction as defined by the manufacturer MW, YH Grade 3 cardiac troponin I increased AE CTCAE: E12118 OAE:0004192 a cardiac troponin T increased AE that has levels above the upper limit of normal and below the level of myocardial infarction as defined by the manufacturer MW, YH Grade 1 cardiac troponin T increased AE CTCAE: E12120 OAE:0004193 a cardiac troponin T increased AE that has levels consistent with myocardial infarction as defined by the manufacturer MW, YH Grade 3 cardiac troponin T increased AE CTCAE: E12121 OAE:0004194 a CD4 lymphocytes decreased AE that is less than the lower limit of normal to 500/mm3 or 0.5 x 10e9 /L MW, YH Grade 1 CD4 lymphocytes decreased AE CTCAE: E12123 OAE:0004195 a CD4 lymphocytes decreased AE that is less than 500 - 200/mm3; less than 0.5 - 0.2 x 10e9 /L MW, YH Grade 2 CD4 lymphocytes decreased AE CTCAE: E12124 OAE:0004196 a CD4 lymphocytes decreased AE that is less than 200 - 50/mm3; less than 0.2 x 0.05 - 10e9 /L MW, YH Grade 3 CD4 lymphocytes decreased AE CTCAE: E12125 OAE:0004197 a CD4 lymphocytes decreased AE that is less than 50/mm3; less than 0.05 x 10e9 /L MW, YH Grade 4 CD4 lymphocytes decreased AE CTCAE: E12126 OAE:0004198 a CPK increased AE that is greater than the upper limit of normal to 2.5 times the upper limit of normal MW, YH Grade 1 CPK increased AE CTCAE: E12133 OAE:0004199 a CPK increased AE that is greater than 2.5 -5 times the upper limit of normal MW, YH Grade 2 CPK increased AE CTCAE: E12134 OAE:0004200 a CPK increased AE that is greater than 5 to 10 times the upper limit of normal MW, YH Grade 3 CPK increased AE CTCAE: E12135 OAE:0004201 a CPK increased AE that is greater than 10 times the upper limit of normal MW, YH Grade 4 CPK increased AE CTCAE: E12136 OAE:0004202 a fibrinogen decreased AE that is less than 1.0 - 0.75 times the lower limit of normal or less than 25% decrease from baseline MW, YH Grade 1 fibrinogen decreased AE CTCAE: E12152 OAE:0004203 a fibrinogen decreased AE that is less than 0.75 - 0.5 times the lower limit of normal or 25 - less than 50% decrease from baseline MW, YH Grade 2 fibrinogen decreased AE CTCAE: E12153 OAE:0004204 a fibrinogen decreased AE that is less than 0.5 - 0.25 times the lower limit of normal or 50 - less than 75% decrease from baseline MW, YH Grade 3 fibrinogen decreased AE CTCAE: E12154 OAE:0004205 a fibrinogen decreased AE that is less than 0.25 times the lower limit of normal or 75% decrease from baseline or absolute value less than 50 mg/dL MW, YH Grade 4 fibrinogen decreased AE CTCAE: E12155 OAE:0004206 a haptoglobin decreased AE that is less than the lower limit of normal MW, YH Grade 1 haptoglobin decreased AE CTCAE: E12170 OAE:0004207 a pancreatic enzymes decreased AE that is less than the lower limit of normal and asymptomatic MW, YH Grade 1 pancreatic enzymes decreased AE CTCAE: E12204 OAE:0004208 a pancreatic enzymes decreased AE that has an increase in stool frequency, bulk, or odor; steatorrhea MW, YH Grade 2 pancreatic enzymes decreased AE CTCAE: E12205 OAE:0004209 a pancreatic enzymes decreased AE that has sequelae of absorption deficiency MW, YH Grade 3 pancreatic enzymes decreased AE CTCAE: E12206 OAE:0004210 a vital capacity abnormal AE that has 90 - 75% of predicted value MW, YH Grade 1 vital capacity abnormal AE CTCAE: E12221 OAE:0004211 a vital capacity abnormal AE that is less than 75 - 50% of predicted value; limiting instrumental activities of daily living MW, YH Grade 2 vital capacity abnormal AE CTCAE: E12222 OAE:0004212 a vital capacity abnormal AE that is less than 50% of predicted value; limiting self care activities of daily living MW, YH Grade 3 vital capacity abnormal AE CTCAE: E12223 OAE:0004213 a seizure AE that occurs in a pregnant women that follows a preeclampsia. Such a seizure is not related to an existing brain condition. JS, YH WEB: https://en.wikipedia.org/wiki/Eclampsia WEB: https://www.nlm.nih.gov/medlineplus/ency/article/000899.htm 10014129 eclampsia AE OAE:0004214 a gastric disorder AE that shows the body under stress, causing acute erosion, bleeding and ulcers, stomach or duodenal mucosa damage collectively. The main clinical manifestations include upper gastrointestinal bleeding and a small perforation. QL, YH AGML AE WEB: http://medmantic.com/wiki/Acute_Gastric_Mucosal_Lesion 急性胃黏膜损害 10000753 acute gastric mucosal lesion AE OAE:0004215 a bowel sounds abnormal AE that shows an increased amount of bowel sounds. QL, YH WEB: https://www.nlm.nih.gov/medlineplus/ency/article/003137.htm hyperactive bowel sounds AE 肠鸣音亢进 10048720 bowel sounds increased AE UMLS CUI: C0232694 OAE:0004216 a bowel sounds abnormal AE that shows a decreased amount of bowel sounds. QL, YH WEB: https://www.nlm.nih.gov/medlineplus/ency/article/003137.htm hypoactive bowel sounds AE 肠鸣音减弱 bowel sounds decreased AE UMLS CUI: C0232695 OAE:0004217 a gastrointestinal disorder AE that shows an abnormal amount of bowel sounds. QL, YH WEB: https://www.nlm.nih.gov/medlineplus/ency/article/003137.htm 肠鸣音异常 bowel sounds abnormal AE UMLS CUI: C0159060 OAE:0004218 a bowel sounds abnormal AE that shows an cesssation of any bowel sounds. QL, YH WEB: https://www.nlm.nih.gov/medlineplus/ency/article/003137.htm 肠鸣音停止 肠鸣音消失 cessation of bowel sounds AE UMLS CUI: C0857330 OAE:0004219 a migraine AE which shows a migraine preceded or accompanied by sensory warning signs or symptoms, such as flashes of light, blind spots, or tingling in your hand or face. SJ, YH WEB: http://www.mayoclinic.org/diseases-conditions/migraine-with-aura/basics/definition/con-20030404 10027607 migraine with aura AE OAE:0004220 a hearing disorder AE with an abnormally disproportionate increase in the sensation of loudness in response to auditory stimuli of normal volume QL, YH WEB: https://en.wikipedia.org/wiki/Hyperacusis 听觉过敏 10052526 hyperacusia AE OAE:0004221 a back pain AE that occurs at the low back QL, YH low back pain AE WEB: https://en.wikipedia.org/wiki/Low_back_pain 下背痛 腰痛 lumbago AE OAE:0004222 a paralysis AE which occurs in a single limb, usually an arm SJ, YH WEB: http://en.wikipedia.org/wiki/Monoplegia 10027926 monoplegia AE OAE:0004223 a behavior and neurological AE which results in abnormal, disturbed or impaired functioning of a muscle, nerve, or center that affects or produces movement SJ, YH WEB: http://connection.ebscohost.com/c/reference-entries/23076155/motor-dysfunction 10061296 motor dysfunction AE OAE:0004224 a discomfort AE that occurs at the musculoskeletal level and results in musculoskeletal pain that affects the bones, muscles, ligaments, tendons, and nerves SJ, YH musculoskeletal pain AE WEB: http://my.clevelandclinic.org/health/diseases_conditions/hic_musculoskeletal_pain 10053156 musculoskeletal discomfort AE OAE:0004225 a musculoskeletal and connective tissue AE which results in a disease or abnormal condition of the musculoskeletal system SJ, YH 10048592 musculoskeletal disorder AE OAE:0004226 a urinary system AE which shows reduced excretion of urine SJ, YH WEB: http://c.merriam-webster.com/medlineplus/oliguria 10030302 oliguria AE OAE:0004227 a hypotension AE that happens during a medical procedure SJ, YH WEB: http://www.mayoclinic.org/diseases-conditions/low-blood-pressure/basics/definition/con-20032298 10062300 procedural hypotension AE OAE:0004228 a digestive system AE that occurs at esophagus YH, MW 食道副作用 esophagus AE OAE:0004229 a digestive system AE that occurs at anus YH, MW anus AE OAE:0004230 a digestive system AE that occurs at duodenum MW, YH duodenum AE OAE:0004231 QL, YH URL http://howshealth.com/kidney-pain-location-causes-symptoms-treatment/#percussion 肾区叩击痛 a renal pain AE that shows the pain in the kidney area identified by a percussion procedure. kidney area percussion pain AE OAE:0004234 a urine analysis result abnomal AE that shows cylindrical structures produced by the kidney and present in the urine. QL, YH urinary casts present AE WEB: http://medical-dictionary.thefreedictionary.com/cylindruria 管型尿 10011730 10067534 cylindruria AE OAE:0004235 a hepatitis AE that resutls in a hepatitis A viral infection. JX, YH hepatitis A AE WEB: https://en.wikipedia.org/wiki/Hepatitis_A 10019719 hepatitis A AE OAE:0004236 a connective tissue disorder AE that shows an inflammation of the fascia, the connective tissue surrounding muscles, blood vessels, and nerves. JX, YH WEB: https://en.wikipedia.org/wiki/Fasciitis 筋膜炎 10016228 fasciitis AE OAE:0004237 A tendon disorder AE that led to the formation of fibrous tissue in the tendon area JX, YH WEB: http://study.com/academy/lesson/fibrous-connective-tissue-function-types.html 10016662 fibrosis tendinous AE OAE:0004238 a fasciitis AE that shows an inflammation of the muscle fascia, the connective tissue surrounding muscles. JX, YH WEB: https://en.wikipedia.org/wiki/Fasciitis 肌筋膜炎 10052443 myofascitis AE OAE:0004239 an eye disorder AE that causes visual disturbance and interfere with normal sight. JX, YH WEB: http://www.healthline.com/symptom/visual-disturbance 10047543 visual disturbance AE OAE:0004240 a cognitive disturbance AE that has mild cognitive disability; not interfering with work/school/life performance; specialized educational services/devices not indicated MW, YH Grade 1 cognitive disturbance AE CTCAE: E12618 OAE:0004241 a cognitive disturbance AE that has moderate cognitive disability; interfering with work/school/life performance but capable of independent living; specialized resources on part time basis indicated MW, YH Grade 2 cognitive disturbance AE CTCAE: E12619 OAE:0004242 a cognitive disturbance AE that has severe cognitive disability; significant impairment of work/school/life performance MW, YH Grade 3 cognitive disturbance AE CTCAE: E12620 OAE:0004243 an abortion AE that results in a retention of dead products of conception in utero for more than 8 weeks. JX, YH WEB: http://medical-dictionary.thefreedictionary.com/missed+abortion 10000230 abortion missed AE OAE:0004244 an edema AE that has an outcome of swelling in the eye. JX, YH 10052139 eye edema AE OAE:0004245 Oral discomfort AE is a discomfort AE that shows an uncomfortable feeling in the oral. JX, YH 口腔不适 10030973 oral discomfort AE OAE:0004246 a female reproductive system AE that has an outcome of the presence of a fluid-filled sac within a patient's ovary. JX, YH WEB: https://en.wikipedia.org/wiki/Ovarian_cyst 10033132 ovarian cyst AE OAE:0004247 a female reproductive system AE that occurs in the placental area. JX, YH WEB: https://en.wikipedia.org/wiki/Placental_disease 10035132 placental disorder AE OAE:0004248 an inflammation AE that occurs at the central nervous system. JX, YH WEB: https://en.wikipedia.org/wiki/Central_nervous_system_disease 中枢神经系统炎症 central nervous system inflammation AE OAE:0004249 a nervous system AE that has outcome of lesion in the area of central nervous system. JX, YH WEB: http://www.emedicinehealth.com/brain_lesions_lesions_on_the_brain/article_em.htm 10051290 central nervous system lesion AE OAE:0004250 a behavioral and neurological AE is characterized by motor coordination problems with daily activities. JX, YH WEB: http://www.healthline.com/symptom/clumsiness 10009696 clumsiness AE OAE:0004251 a behavioral and neurological AE is a deficiency in the ability to write, primarily handwriting, but also coherence. JX, YH WEB: https://en.wikipedia.org/wiki/Dysgraphia 10058319 dysgraphia AE OAE:0004252 a sensory neuropathy AE than is the medical term for a sensation that exactly resembles that of small insects crawling on (or under) the skin. JX, YH WEB: https://en.wikipedia.org/wiki/Formication 10017062 formication AE OAE:0004253 a paresis AE that shows muscle weakness of the entire left or right side of the body. JX, YH WEB: https://en.wikipedia.org/wiki/Hemiparesis 轻偏瘫 10019465 hemiparesis AE OAE:0004254 an immunology and allergy investigation result abnormal AE that results in an increased level of an immunoglobulin. JX, YH WEB: http://www.webmd.com/a-to-z-guides/immunoglobulins immunoglobulin increased AE OAE:0004255 a urinary system AE that shows abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE. JX, YH WEB: http://sideeffects.embl.de/se/C0042035/pt 10027561 micturition disorder AE OAE:0004256 a muscle twitch AE that has an outcome of contractions involuntary of muscle. JX, YH 肌肉不自觉收缩 10028293 muscle contractions involuntary AE OAE:0004257 a nervous system AE that describes any neurologic deficit related to the spinal cord. JX, YH WEB: https://en.wikipedia.org/wiki/Myelopathy 脊髓病 10028570 myelopathy AE OAE:0004258 a optic neuritis AE that has outcome of optic neuritis in retrobulbar. JX, YH WEB: https://en.wikipedia.org/wiki/Optic_neuritis 球后视神经炎 10030945 optic neuritis retrobulbar AE OAE:0004259 a eye AE that is an area of partial alteration in the field of vision consisting of a partially diminished or entirely degenerated visual acuity that is surrounded by a field of normal – or relatively well-preserved – vision. JX, YH WEB: https://en.wikipedia.org/wiki/Scotoma 暗点 10039729 scotoma AE OAE:0004260 A thyroiditis AE where the body interprets the thyroid glands and its hormone products T3, T4 and TSH as threats, therefore producing special antibodies that target the thyroid’s cells, thereby destroying it. JX, YH https://en.wikipedia.org/wiki/Autoimmune_thyroiditis 自我免疫性甲状腺炎 10049046 autoimmune thyroiditis AE OAE:0004261 a colitis AE that is a disease that causes inflammation and sores (ulcers) in the lining of the large intestine. JX, YH ulcerative colitis AE WEB: http://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/ulcerative-colitis-topic-overview 溃疡性结肠炎 10009900 colitis ulcerative AE OAE:0004262 an abnormal stool AE that shows pale or clay-colored stool. JX, YH faeces pale AE WEB: http://www.healthline.com/symptom/pale-stools 大便苍白 10016102 feces pale AE OAE:0004263 a tumor AE that is a group of blood cell tumors that develop from lymphatic cells. JX, YH WEB: https://en.wikipedia.org/wiki/Lymphoma 淋巴瘤 10025310 lymphoma AE OAE:0004264 a paresis AE that affects a single limb, usually an arm. JX, YH WEB: https://en.wikipedia.org/wiki/Monoplegia 单肢轻瘫 10027925 monoparesis AE OAE:0004265 a eye AE that refers to weakness (-paresis) or paralysis (-plegia) of one or more extraocular muscles which are responsible for eye movements. JX, YH WEB: https://en.wikipedia.org/wiki/Ophthalmoparesis 眼肌麻痹 10030875 ophthalmoplegia AE OAE:0004266 a eye AE that has outcome of slight differences in pupil size. JX, YH WEB: https://www.nlm.nih.gov/medlineplus/ency/article/003314.htm 瞳孔不等 10037538 pupils unequal AE OAE:0004267 quadriplegia AE is paralysis caused by illness or injury that results in the partial or total loss of use of all four limbs and torso. JX, YH Tetraplegia WEB: https://en.wikipedia.org/wiki/Tetraplegia 四肢麻痹 10037714 quadriplegia AE OAE:0004268 a CSF white blood cell count increased AE with more than the normal number of lymphocytes in cerebrospinal fluid (CSF). JX, YH 脑脊液细胞增多 10035551 pleocytosis AE OAE:0004269 a behavior and neurological AE that shows an decreased preformance JX, YH WEB: https://en.wikipedia.org/wiki/Performance_status 体能下降 10048919 performance status decreased AE OAE:0004270 a skin AS that shows a mass at the skin. JX, YH skin tumor AE 10067868 skin mass AE OAE:0004271 an abnormal stool AE that shows an abnomal color in the feces. JX, YH faeces discoloured AE WEB: http://www.buzzle.com/articles/stool-colors-and-what-they-mean.html 10016100 feces discolored AE OAE:0004272 an investigation result abnormal AE that shows an abnormal ultrasound scan result. JX, YH WEB: http://www.nhs.uk/conditions/ultrasound-scan/Pages/Introduction.aspx 10061606 ultrasound scan abnormal AE OAE:0004273 an injection site AE that shows some substance release from an injection site. JX, YH 10065600 injection site discharge AE OAE:0004274 a tumor AE that has an outcome of the presense of a mass that arises from the axillary. JX, YH WEB: http://www.rightdiagnosis.com/sym/axillary_mass.htm 腋窝肿块 10049021 axillary mass AE OAE:0004275 a behavioral and neurological AE that involves a slowing-down of thought and a reduction of physical movements in an individual. JX, YH motormental retardation AE psychomotor impairment AE WEB: https://en.wikipedia.org/wiki/Psychomotor_retardation 精神运动性阻滞 10037213 psychomotor retardation AE OAE:0004276 an abscess AE that occurs at an injection-site. Note that an abscess is a collection of pus that has built up within a tissue of the body. JX, YH WEB: https://en.wikipedia.org/wiki/Abscess 10022044 injection site abscess AE OAE:0004277 an ulcer AE that occurs at an injection-site. JX, YH WEB: https://en.wikipedia.org/wiki/Ulcer 10022105 injection site ulcer AE OAE:0004278 a viral infection AE that is caused by a disseminated Bacillus Calmette-Guerin bacterial infection. JX, YH disseminated Bacillus Calmette-Guerin infection AE 10069636 disseminated BCG infection AE OAE:0004279 a paresis AE that shows a muscular weakness affecting all four extremities. JX, YH quadriparesis AE WEB: http://www.medilexicon.com/medicaldictionary.php?t=91062 tetraparesis AE OAE:0004280 a menstrual disorder AE that shows an extremely light menstrual blood flow QL, YH hypomenorrhoea AE WEB: https://en.wikipedia.org/wiki/Hypomenorrhea 月经减少 10021032 hypomenorrhea AE OAE:0004281 a menstrual disorder AE that shows a menstrual period with abnormally heavy flow and falls under the larger category of abnormal uterine bleeding (AUB) QL, YH hypermenorrhea AE WEB: https://en.wikipedia.org/wiki/Menorrhagia menorrhagia AE OAE:0004282 a male reproductive system AE in which spermatozoa in seminal fluid are dead or motionless QL, YH WEB: https://en.wikipedia.org/wiki/Necrospermia 死精 10074729 necrospermia AE MP: MP_0009325 OAE:0004283 a reproductive system AE that results in diminished ability to produce live offspring JX, LW, YH WEB: https://en.wikipedia.org/wiki/Infertility 生育能力下降 10042391 subfertility AE MP: MP_0001921 OAE:0004284 a reproductive system AE that results in an inability to conceive for at least one year after trying and having unprotected sex. QL, YH WEB: http://www.mayoclinic.org/diseases-conditions/infertility/basics/definition/con-20034770 不孕不育 10021926 infertility AE MP: MP_0001921 OAE:0004285 an endocrine investigation result abnormal AE that is characterized by a lower than normal level of estrogen, the primary sex hormone in women QL, YH estrogen deficiency AE hypoestrogenism AE WEB: http://www.md-health.com/Low-Estrogen.html WEB: https://en.wikipedia.org/wiki/Hypoestrogenism 性激素水平下降 10015519 low estrogen level AE OAE:0004286 a hemorrhage AE that occurs at the uterus, but it is not related to menstruation. The irregular and unpredictable bleeding usually comes from a dysfunctional endometrium. QL, YH WEB: http://emedicine.medscape.com/article/257007-overview 功能性子宫出血 10013908 dysfunctional uterine bleeding AE MESH: D008796 OAE:0004287 a testicular disorder AE that has a loss of testicular volume QL, YH WEB: https://en.wikipedia.org/wiki/Testicular_atrophy 睾丸萎缩 10043298 testicular atrophy AE OAE:0004288 an aplastic anemia AE that results in the suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. QL, YH PRCA AE red-cell aplasia, pure WEB: http://emedicine.medscape.com/article/205695-overview 纯红再障性贫血 pure red cell aplasia AE MESH: D012010 OAE:0004289 a paralysis AE that shows an impairment in motor or sensory function of the lower extremities. YH, JX WEB: https://en.wikipedia.org/wiki/Paraplegia 10033892 paraplegia AE OAE:0004290 a cutaneous vasculitis AE that results in inflammation of small blood vessels, characterized clinically by palpable purpura, which is a slightly elevated purpuric rash over one or more areas of the kin. QL, YH WEB: https://www.nlm.nih.gov/medlineplus/ency/article/000874.htm 皮肤变应性血管炎 allergic cutaneous vasculitis AE DO: DOID_11450 OAE:0004291 a skin hyperpigmentation AE that shows the occurrence of pigmented patches on the tongue and buccal mucousmembranes. QL, YH WEB: http://www.medilexicon.com/medicaldictionary.php?t=53725 皮肤黑斑病 melanoplakia AE SNOMEDCT: 84647002 OAE:0004292 an erythema AE that showns an erythematous eruption characterized by inflammatory nodules that are usually tender, multiple, and bilateral. Such a symptom is commonly associated with drug reactions or infection. QL, YH erythemanodosum AE WEB: https://en.wikipedia.org/wiki/Erythema_nodosum 结节性红斑 10015226 erythema nodosum AE HPO: HP_0012219 MeSH: D004893 OAE:0004293 a muscle spasm AE that occurs when the contraction of a spasm is sustained or continuing. Such a spasm is generally severe because is is often caused by diseases that affect the central nervous system or brain, such as tetanus, rabies, and cerebral palsy. QL, YH WEB: http://medical-dictionary.thefreedictionary.com/tonic+spasm 强直性痉挛 tonic spasm AE OAE:0004294 a menstrual disorder AE that results in frequent menses amd the menstrual cycles lasting less than 21 days. QL, YH 月经频繁 10070501 polymenorrhea AE HP: HP_0400007 OAE:0004295 a menstrual disorder AE that shows an outcome of a shortened time of menstrual period QL, YH short menstrual period AE WEB: http://www.everydayhealth.com/pms/short-periods.aspx 经期缩短 shortened menstrual period AE OAE:0004296 a menstrual disorder AE that shows an outcome of a prolonged duration of menstrual period QL, YH prolonged menstruation AE WEB: http://www.healthline.com/symptom/menstrual-irregularity 经期延长 prolonged menstrual period AE OAE:0004297 musculoskeletal stiffness AE that occurs at the neck and is typically characterized by soreness and difficulty moving the neck, especially when trying to turn the head to the side. QL, YH stiff neck AE WEB: http://www.spine-health.com/conditions/neck-pain/stiff-neck-causes-symptoms-and-treatment 颈项强直 10028843 neck stiffness AE stiffness of the neck AE OAE:0004298 a female reproductive system AE that occurs at the ovaries where ovaries do not produce estrogen despite high levels of circulating gonadotropins in women under 40. QL, YH primary ovarian insufficiency AE WEB: http://www.mayoclinic.org/diseases-conditions/premature-ovarian-failure/basics/definition/con-20028351 WEB: https://www.nlm.nih.gov/medlineplus/prematureovarianfailure.html 卵巢早衰 premature ovarian failure AE DO: DOID_5426 OAE:0004299 a skin adverse event that has an outcome of a discontinuity of the skin exhibiting incomplete loss of the epidermis, a lesion that is moist, circumscribed, and usually depressed. QL, YH 10040840 skin erosion AE HP: HP_0200041 OAE:0004300 a hematopoietic system AE that has an outcome of an arrest of the formation of blood cellular components. QL, YH WEB: https://en.wikipedia.org/wiki/Haematopoiesis 造血功能障碍 arrest of hematopoiesis AE OAE:0004301 an arrest of hematopoiesis AE that occurs quickly QL, YH WEB: https://en.wikipedia.org/wiki/Haematopoiesis 急性造血功能障碍 acute arrest of hematopoiesis AE OAE:0004302 an ulcer AE that occurs at the scrotum QL, YH 阴囊破溃 scrotum ulcer AE SNOMEDCT: 9750001 OAE:0004303 a skin adverse event that inherited chronic noninflammatory skin disease manifested by vesicles, large bullae (blisters), and skin erosions which often result from trauma. QL, YH epidermolysis bullosa type eruption AE WEB: http://www.mayoclinic.org/diseases-conditions/epidermolysis-bullosa/basics/definition/con-20032497 大疱性表皮坏死松解症 10014989 epidermolysis bullosa AE OAE:0004304 a female reproductive system AE that occurs in the uterus JX, YH WEB: https://en.wikipedia.org/wiki/Uterus uterine AE OAE:0004305 a reproduction system inflammation AE that occurs in the endometrium, the inner lining of the uterus. MW, YH WEB: https://en.wikipedia.org/wiki/Endometritis 子宫内膜炎 10014791 endometritis AE OAE:0004306 an inflammation AE which occurs in the female reproduction system YH, JX female reproduction system inflammation AE OAE:0004307 a reproduction system inflammation AE that occurs in the placenta. JX, YH WEB: https://en.wikipedia.org/wiki/Placenta 胎盘炎 10014791 placentitis AE OAE:0004308 a female reproductive system AE that occurs when the baby does not exit the pelvis during childbirth due to being physically blocked, even though the uterus is contracting normally. JX, YH obstructed labor AE obstructed labour AE WEB: https://en.wikipedia.org/wiki/Obstructed_labour 难产 dystocia AE OAE:0004309 a pneumonia AE that is caused by a mycotic infection JX, YH WEB: https://en.wikipedia.org/wiki/Fungal_pneumonia 真菌性肺炎 mycotic pneumonia AE OAE:0004310 an inflammation AE that refers to inflammation of the serous tissues of the body, the tissues lining the lungs (pleura), heart (pericardium), and the inner lining of the abdomen (peritoneum) and organs within. JX, YH WEB: https://en.wikipedia.org/wiki/Serositis 浆膜炎 10058556 serositis AE OAE:0004311 a female reproduction system inflammation AE that occurs in the wall of the uterus. JX, YH WEB: https://en.wikipedia.org/wiki/Metritis 子宫炎 10066270 metritis AE OAE:0004312 an abscess AE where the abscess is filled with pus. Note: based on the website: https://www.quora.com/What-is-a-purulent-abscess, it appears that the words purulent abscess are actually redundant. Purulent means pus. Abscess is a space or pocket in the body filled with pus. JX, YH 化脓性脓肿 purulent abscess AE OAE:0004313 a clostridial infection AE that results in muscle spasms. JX, YH lockjaw AE WEB: https://en.wikipedia.org/wiki/Tetanus 破伤风 10043376 tetanus AE OAE:0004314 a abscess AE that shows a collection of pus found near the rectum. JX, YH WEB: http://www.webmd.com/a-to-z-guides/anal-abscess 直肠脓肿 10048947 rectal abscess AE OAE:0004315 a brucellosis AE that shows an acute disease stage. JX, YH WEB: https://en.wikipedia.org/wiki/Brucellosis 急性布氏杆菌病 acute brucellosis AE OAE:0004316 a lymphadenopathy AE where the lymphadenopathy occurs in the supraclavicular lymph nodes. JX, YH WEB: https://en.wikipedia.org/wiki/Lymphadenopathy 锁骨上淋巴结病 supraclavicular lymphadenopathy AE OAE:0004317 a pain AE that shows a person with generalized aches and pains in multiple areas of the body. JX, YH WEB: http://www.everydayhealth.com/symptom-checker/body-aches 体痛 body ache AE OAE:0004318 an inflammation AE that occurs in the kidney tissue, calyces, and renal pelvis. JX, YH WEB: https://en.wikipedia.org/wiki/Pyelonephritis 肾盂肾炎 10037596 pyelonephritis AE OAE:0004319 a bacterial infection AE that is caused by the infection with Brucella, a Gram-negative bacterium. The infected animals can be human or a variety of mammal animals. JX, YH Bang's disease AE Crimean fever AE Gibraltar fever AE Malta fever AE Maltese fever AE Mediterranean fever AE rock fever AE undulant fever AE WEB: https://en.wikipedia.org/wiki/Brucellosis 布氏杆菌病 brucellosis AE OAE:0004320 an infection AE that is caused by a parasite. YH, JX WEB: https://en.wikipedia.org/wiki/Parasitic_disease parasitic infection AE OAE:0004321 a parasitic infection AE that is caused by a heminth, i.e., a parasitic worm, in the location of intestine. JX, YH WEB: https://en.wikipedia.org/wiki/Helminthiasis 肠道蠕虫病 intestinal helminthiasis AE OAE:0004322 a liver AE that has an outcome of the diffusion or accumulation of substances in the liver. JX, YH PubMed: http://www.ncbi.nlm.nih.gov/pubmed/20806348 WEB: https://en.wikipedia.org/wiki/Infiltration_(medical) 肝脏浸润 liver infiltration AE OAE:0004323 an epididymitis AE where the epidiymis is filled up with lymphocytes and plasma cells. JX, YH WEB: http://www.merriam-webster.com/medical/lymphoplasmacytic WEB: https://en.wikipedia.org/wiki/Epididymitis 淋巴浆细胞性附睾炎 lymphoplasmacytic epididymitis AE OAE:0004324 a testicular disorder AE that results in a discomfort or pain of the epidiymis, a curved structure at the back of the testicle in which sperm matures and is stored. JX, YH WEB: https://en.wikipedia.org/wiki/Epididymitis epididymitis AE OAE:0004325 a pneumonia AE that results in the dissemination of histiocytes in the lung. JX, YH PubMed: http://www.ncbi.nlm.nih.gov/pubmed/17882900 WEB: https://en.wikipedia.org/wiki/Pneumonia 弥漫性组织细胞性肺炎 disseminated histiocytic pneumonia AE OAE:0004326 a myocarditis AE where the heart muscle is filled with lymphocytes and plasma cells that are not normally seen. JX, YH WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001204/ 淋巴浆细胞性心肌炎 lymphoplasmacytic myocarditis AE OAE:0004327 a syndrome AE in which the immune system begins to recover from an immunosuppression or AIDS, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse. JX, YH IRIS AE immune recovery syndrome AE WEB: https://en.wikipedia.org/wiki/Immune_reconstitution_inflammatory_syndrome 10065042 immune reconstitution inflammatory syndrome AE OAE:0004329 a diarrhea AE that occurs when the bile acids are not reabsorbed into the bloodstream and enter the large bowel (colon), which causes abnormally high levels of water and salts in the large bowel and the formation of watery diarrhoea. YH bile acid malabsorption AE WEB: http://patient.info/health/bile-acid-malabsorptiondiarrhoea-leaflet WEB: https://en.wikipedia.org/wiki/Bile_acid_malabsorption WEB: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002596/ 10069703 bile acid diarrhoea AE OAE:0004330 an adverse event that has an outcome of nutrition disorder, which can be caused by an insufficient intake of food or of certain nutrients, by an inability of the body to absorb and use nutrients, or by overconsumption of certain foods. YH nutrition disorder AE WEB: http://www.who.int/topics/nutrition_disorders/en/ 营养失调 nutritional disorder AE OAE:0004331 a nutrional disorder AE that has an outcome of malnutrition, a condition resulting from insufficient nutrients in the body. YH WEB: https://medlineplus.gov/ency/article/000404.htm 营养不良 malnutrition AE OAE:0004332 a gastrointestinal disorder AE that has an outcome of the presence of very large numbers of bacteria growing in the small intestine YH BLS AE BOS AE SIBO AE bacterial overgrowth syndrome AE blind loop syndrome AE small bowel bacterial overgrowth AE WEB: https://en.wikipedia.org/wiki/Blind_loop_syndrome WEB: https://medlineplus.gov/ency/article/000222.htm small intestinal bacterial overgrowth AE OAE:0004333 an edema face AE where the face has gradually swollen into a rounded shape YH WEB: http://www.webmd.com/a-to-z-guides/moon-facies moon face AE OAE:0004335 a behavioral and neurological AE that has an outcome of impaired daily self care activities. KY, YH ADL impaired AE WEB: https://en.wikipedia.org/wiki/Activities_of_daily_living 10050954 activities of daily living impaired AE OAE:0004336 a hematology investigation result abnormal AE that is characterized by an abnomalty in the antibody level in the blood YH, KY antibody test abnormal AE OAE:0004337 an antibody test abnormal AE that shows positive antinuclear antibody, which often attack a person's own cell nucleus. YH, KY ANA test abnormal AE URL: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-20014566 In most cases, a positive ANA test indicates that your immune system has launched a misdirected attack on your own tissue — in other words, an autoimmune reaction. But some people have positive ANA tests even when they're healthy. Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-20014566 antinuclear antibody positive AE OAE:0004338 A nervous system AE which refers to an imbalance problem in the part of the nervous system that controls involuntary actions KY, YH https://medlineplus.gov/autonomicnervoussystemdisorders.html#cat59 10003840 autonomic nervous system imbalance AE OAE:0004339 A CSF test result abnormal AE with high glucose levels in the cerebrospinal fluid. KY, YH https://en.wikipedia.org/wiki/CSF_glucose 10050763 CSF glucose increased AE OAE:0004340 A CSF test result abnormal AE with high immunoglobin levels in the cerebrospinal fluid. KY, YH https://labtestsonline.org/understanding/conditions/multiplesclerosis/start/2/ 10064338 CSF immunoglobulin increased AE OAE:0004341 A palsy AE with temporary or permanent weakness of the facial muscles on one or both sides of the face. KY, YH http://www.facialpalsy.org.uk/about-facial-palsy/what-is-facial-palsy/1395/ 10016060 facial palsy AE OAE:0004342 A bone AE that refers to structural failure in a disc and advanced signs of aging. KY, YH https://www.ncbi.nlm.nih.gov/pubmed/16915105 10061246 intervertebral disc degeneration AE OAE:0004343 A behavioral and neurological test abnormal AE result that has an abnormal outcome in lumbar puncture involving pain or numbness to the legs, lower back pain, headaches, risk of infection, or risk of bleeding in the spinal canal. KY, YH http://www.hopkinsmedicine.org/healthlibrary/test_procedures/neurological/lumbar_puncture_lp_92,p07666/ 10025000 lumbar puncture abnormal AE OAE:0004344 A paralysis AE accompanied by involuntary tremors. KY, YH WEB: https://en.oxforddictionaries.com/definition/palsy WEB: https://en.wikipedia.org/wiki/Palsy 麻痹 palsy AE OAE:0004345 A behavioral and neurological test abnormal AE that involves an abnormal outcome in the series of simple questions and noninvasive tests in a neurological examination that provides crucial information about the nervous system. KY, YH http://www.healthcommunities.com/brain-nerve-tests/what-is-a-neuro-exam.shtml 10056832 neurological examination abnormal AE OAE:0004346 A paralysis AE characterized by extreme muscle weakness and loss of muscle tone. KY, YH http://www.brainandspinalcord.org/flaccid-paralysis/ 弛缓性麻痹 10033809 paralysis flaccid AE OAE:0004347 A paralysis AE on the peroneal nerve leading to loss of movement or sensation on the foot and leg and may lead to complete weakness or paralysis of the foot or leg. KY, YH https://medlineplus.gov/ency/article/000791.htm 10034701 peroneal nerve palsy AE OAE:0004348 A hyperaesthesia AE that occurs at the optic area, reflected by an abnormal sensitivity to light. YH, Jiahao Wang WEB: http://medical-dictionary.thefreedictionary.com/optic+hyperesthesia 光过敏 optic hyperesthesia AE OAE:0004349 An abnormal respiration AE that shows a severely deficient supply of oxygen to the body that arises from abnormal breathing. YH, Jiahao Wang asphyxiation AE WEB: https://en.wikipedia.org/wiki/Asphyxia 窒息 10003497 10003502 asphyxia AE OAE:0004350 An muscle AE showing delayed relaxation (prolonged contraction) of the skeletal muscles after voluntary contraction or electrical stimulation YH, Jiahao Wang WEB: https://en.wikipedia.org/wiki/Myotonia 肌强直 10061533 myotonia AE OAE:0004351 An myotonia AE that occurs in the neck. YH, Jiahao Wang WEB: https://en.wikipedia.org/wiki/Myotonia 颈项强直 neck myotonia AE OAE:0004352 a behavioral and neurological AE that refers to any pain or discomfort in the abdomen. NG, YH https://en.wikipedia.org/wiki/Distress_(medicine) 10000062 abdominal distress AE OAE:0004353 A blindness AE that refers to the reduced ability to distinguish between colors that are obvious to the rest of the population NG, YH https://en.wikipedia.org/wiki/Color_blindness 10010016 color blindness AE OAE:0004354 a behavioral and neurological AE that is characterized by involuntary muscle contractions that cause abnormal posture and slow, repetitive movements NG, YH http://www.webmd.com/brain/dystonia-causes-types-symptoms-and-treatments#1 10013983 dystonia AE OAE:0004355 a behavioral and neurological AE that is characterized by potentially impulsive or poorly controlled activity NG, YH 10015627 exciteness AE OAE:0004356 a dizziness AE that creates a feeling of a light head caused by a temporary decrease in blood to the brain NG, YH https://en.wikipedia.org/wiki/Lightheadedness 10024492 lightheadedness AE OAE:0004357 a psychiatric disorder AE that is characterized by an elevation or lowering of a person's mood NG, YH mood problem https://en.wikipedia.org/wiki/Mood_disorder 10027952 mood disorder AE OAE:0004358 a menstrual disorder AE that is characterized by infrequent menstrual periods NG, YH https://en.wikipedia.org/wiki/Oligomenorrhea 10030294 oligomenorrhea AE OAE:0004359 an ear AE that refers to ear poisoning resulting from exposure to drugs or chemicals that damage the inner ear NG, YH https://en.wikipedia.org/wiki/Ototoxicity 10033109 ototoxicity AE OAE:0004360 an inflammation AE that leads to swelling around the blood vessel wall NG, YH http://medical-dictionary.thefreedictionary.com/periarteritis 10034462 periarteritis AE OAE:0004361 a tumor AE that is benign and characterized by a small wart-like growth on the skin NG, YH https://en.wikipedia.org/wiki/Papilloma 10033722 skin papilloma AE OAE:0004362 a paresthesia AE characterized by unusual prickling sensations in any part of the body NG, YH http://www.mayoclinic.org/symptom-checker/numbness-or-tingling-in-hands-adult/related-factors/itt-20009075 10043876 tingling AE OAE:0004363 a diarrhea AE that has 4 stools per day over baseline; mild increase in ostomy output compared to baseline. MW, EO Grade 1 diarrhea AE CTCAE: E10573 OAE:0004364 a diarrhea AE that has increased of 4 - 6 stools per day over baseline; moderate increase in ostomy output compared to baseline. MW, EO Grade 2 diarrhea AE CTCAE: E10574 OAE:0004365 a diarrhea AE that has increased of >=7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self care ADL MW, EO Grade 3 diarrhea AE CTCAE: E10575 OAE:0004366 An epileptic seizure AE that is a complex autosomal dominant disorder usually caused by mutations in SCN1A (a voltage-gated sodium channel). One third of patients have febrile seizures only; two thirds have a variety of epilepsy syndromes, both focal and generalized. GEFS+ AE https://www.ncbi.nlm.nih.gov/pubmed/25917466 BY, YH genetic epilepsy with febrile seizures plus AE OAE:0004367 MW, EO a nausea AE that has Loss of appetite without alteration in eating habits Grade 1 nausea AE CTCAE: E10879 OAE:0004368 MW, EO a nausea AE that has oral intake decreased without significant weight loss, dehydration or malnutrition Grade 2 nausea AE CTCAE: E10880 OAE:0004369 MW, EO a nausea AE that has inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated Grade 3 nausea AE CTCAE: E10881 OAE:0004370 A bacterial infection AE that is induced by the bacterium Bordetella pertussis, which causes an acute respiratory infection marked by severe, spasmodic coughing episodes during the paroxysmal phase. https://www.ncbi.nlm.nih.gov/books/NBK7813/ BY, YH Bordetella pertussis infection AE OAE:0004371 A thyroiditis AE that is caused by an infection with a pathogen (e.g., bacterium or virus). YH https://en.wikipedia.org/wiki/Thyroiditis 10071250 infectious thyroiditis AE OAE:0004373 A neurotoxicity that occurs at the central nervous system. This type of neurotoxity manifests as altered thought content resulting in psychosis or confusion. BY, YH https://www.ncbi.nlm.nih.gov/pubmed/24275175 10071215 central nervous system toxicity AE OAE:0004374 A paralysis AE that results from infection with any one of the three related poliovirus types (referred to as types P1, P2, and P3) and that attacks the body's nervous system. infantile paralysis AE polio AE http://www.who.int/biologicals/areas/vaccines/polio/en/ 10036012 BY, YH poliomyelitis AE OAE:0004375 An immune system AE where a transplant recipient's immune system attacks the transplanted organ or tissue. transplant rejection AE https://medlineplus.gov/ency/article/000815.htm 10018650 BY, YH graft rejection AE OAE:0004376 A vasculitis AE that affects medium-sized and small muscular arteries, resulting in microaneurysm formation, aneurysmal rupture with hemorrhage, thrombosis, and, consequently, organ ischemia or infarction. panarteritis nodosa AE polyarteritis nodosa AE http://emedicine.medscape.com/article/330717-overview 10034462 BY, YH periarteritis nodosa AE OAE:0004377 An abnormal reflex AE characterized by episodes of shaking or exaggerated shivering which can occur with a high fever. http://patient.info/doctor/rigors 10039177 BY, YH rigors AE OAE:0004378 An immunology AE in which cells of the lymphatic system grow excessively. It is a AE of the lymphoid cells and of cells from the reticuloendothelial system that usually occur in people with compromised immune systems. http://www.medicinenet.com/script/main/art.asp?articlekey=7859 10061232 BY. YH lymphoproliferative disorder AE OAE:0004379 A rash AE where the rash is present on only one area of the body, which is usually caused by cellulitis, contat dermatitis, and poison ivy. http://www.everydayhealth.com/symptom-checker/localized-rash 10062705 BY, YH localized rash AE OAE:0004380 A neuropathy AE that is characterized by recurrent episodes of numbness, tingling, and loss of muscle function in the region associated with the affected nerve, usually an arm, hand, leg, or foot. HNPP AE https://ghr.nlm.nih.gov/condition/hereditary-neuropathy-with-liability-to-pressure-palsies 10069382 BY, YH hereditary neuropathy with liability to pressure palsies AE OAE:0004381 A viral infection AE that is caused by a Rubella virus. This contagious AE leads to symptoms that can include a low-grade fever, sore throat, and a red rash that starts on the face and spreads to the rest of the body. german measles AE three-day measles AE http://bodyandhealth.canada.com/channel/childhood-vaccinations/related-conditions/rubella 10018206 BY, YH Rubella infection AE OAE:0004382 A poliomyelitis AE that is associated with oral poliovirus vaccine (OPV) that occurs among healthy OPV recipients and their contacts. It is clinically indistinguishable from poliomyelitis caused by wild-type polio virus, which causes temporary or permanent paralysis. VAPP AE https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321898/ 10076716 BY, YH vaccine-associated paralytic poliomyelitis AE OAE:0004383 A seizure AE that is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. SMEI AE dravet syndrome AE https://www.dravetfoundation.org/what-is-dravet-syndrome/ 10073677 BY, YH severe myoclonic epilepsy of infancy AE OAE:0004384 A bacterial infection AE that is caused by exposure to environmental sources of nontuberculous mycobacteria (NTM), which leads to NTM entering the lungs, causing inflammation in the respiratory system. This AE can lead to progressive lung infection characterized by cough, shortness of breath, fatigue, and weight loss. NTM infection AE http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/nontuberculosis-mycobacteria/learn-about-ntm.html BY. YH nontuberculous mycobacteria infection AE OAE:0004385 An immunodeficiency AE that affects the immune system and results in the lack of the ability for the body to generate mature B cells, which manifests as a complete or near-complete lack of proteins called gamma globulins, including antibodies, in their bloodstream. This AE occurs almost exclusively in males. This AE also increases susceptibility to infections. Bruton’s Agammaglobulinemia AE Congenital Agammaglobulinemia AE XLA AE http://primaryimmune.org/about-primary-immunodeficiencies/specific-disease-types/agammaglobulinemia-x-linked-autosomal-recessive/ https://en.wikipedia.org/wiki/X-linked_agammaglobulinemia https://ghr.nlm.nih.gov/condition/x-linked-agammaglobulinemia BY. YH X-linked agammaglobulinemia AE OAE:0004386 A multi-organ failure AE that is associated with administration of a Yellow Fever vaccine. This happens when vaccine virus proliferates in multiple organs, causing multiple organ dysfunction syndrome or multiorgan failure and death. https://www.cdc.gov/travel-training/local/HistoryEpidemiologyandVaccination/page27412.html 10069197 BY, YH Yellow Fever vaccine-associated viscerotropic disease AE OAE:0004387 A duodenal ulcer AE that alters GI function and requiresTPN indicated; elective operative or endoscopic intervention indicated; limiting self care ADL. Grade 3 duodenal ulcer AE CTCAE: E10614 OAE:0004388 An anus AE that bleed from the anal region. 10055226 anal hemorrhage AE CTCAE: E10470 NCIt: C78168 OAE:0004389 An anal hemorrhage AE that has moderate symptoms; medical intervention or minor cauterization indicated. Grade 2 anal hemorrhage AE CTCAE: E10472 OAE:0004390 A thyroiditis AE where the thyroiditis inflammation has an acute process. YH https://en.wikipedia.org/wiki/Thyroiditis 10043780 acute thyroiditis AE OAE:0004391 An anal hemorrhage AE that has transfusion, radiologic, endoscopic, or elective operative intervention indicated. Grade 3 anal hemorrhage AE CTCAE: E10473 OAE:0004392 A gastrointestinal disorder AE that has a narrowing of the lumen of the colon. 10010004 colonic stenosis AE CTCAE: E10550 NCIt: C78243 OAE:0004393 A colonic stenosis AE that altered GI function. Grade 2 colonic stenosis AE CTCAE: E10552 OAE:0004394 A colonic stenosis AE that alters GI function and requires tube feeding or hospitalization. Grade 3 colonic stenosis AE CTCAE: E10553 OAE:0004395 An esophagus AE that has a rupture in the wall of the esophagus. 10055472 esophageal perforation AE CTCAE: E10665 NCIt: C50693 OAE:0004396 A mucosal inflammation AE that has moderate pain which is not interfering with oral intake but modified diet indicated. Grade 2 mucosal inflammation AE CTCAE: E10874 OAE:0004397 A mucosal inflammation AE that is interfering with oral intake. Grade 3 mucosal inflammation AE CTCAE: E10875 OAE:0004398 A dysesthesia AE that has burning or tingling sensation on the lips, tongue or entire mouth. 10054520 oral dysesthesia AE CTCAE: E10894 NCIt: C62545 OAE:0004399 An oral dysesthesia AE that has disabling pain, requires tube feeding and TPN. Grade 3 Oral dysesthesia AE CTCAE: E10897 OAE:0004400 An oral dysesthesia AE that has m oderate pain and is interfering with oral intake. Grade 2 Oral dysesthesia AE CTCAE: E10896 OAE:0004401 An oral dysesthesia AE that has mild discomfort but is not interfering with oral intake. Grade 1 Oral dysesthesia AE CTCAE: E10895 OAE:0004402 A periodontal disease AE that has spontaneous bleeding, severe bone loss with or without tooth loss and osteonecrosis of maxilla or mandible. Grade 3 periodontal disease AE CTCAE: E10938 OAE:0004403 A periodontal disease AE that has moderate gingival recession or gingivitis, multiple sites of bleeding on probing and moderate bone loss. Grade 2 periodontal disease AE CTCAE: E10937 OAE:0004404 A periodontal disease AE that has gingival recession or gingivitis, limited bleeding on probing and mild local bone loss. Grade 1 periodontal disease AE CTCAE: E10936 OAE:0004405 A necrosis AE that there the ecrotic process occurring in the rectal wall. 10065709 rectal necrosis AE CTCAE: E10967 NCIt: C78585 OAE:0004406 A rectal necrosis AE that requires tube feeding or TPN indicated; radiologic, endoscopic, or operative intervention indicated. Grade 3 rectal necrosis AE CTCAE: E10968 OAE:0004407 An inflammation AE that has inflammation of the salivary duct. 10056681 salivary duct inflammation AE CTCAE: E10470 NCIt: C78600 OAE:0004408 A salivary duct inflammation AE that has acute salivary gland necrosis; severe secretion-induced symptoms (e.g., thick saliva/oral secretions or gagging); tube feeding or TPN indicated; limiting self care ADL; disabling Grade 3 salivary duct inflammation AE CTCAE: E11006 OAE:0004409 A salivary duct inflammation AE that has thick, ropy, sticky saliva; markedly altered taste; alteration in diet indicated; secretion-induced symptoms; limiting instrumental ADL Grade 2 salivary duct inflammation AE CTCAE: E11005 OAE:0004410 A salivary duct inflammation AE that has slightly thickened saliva; slightly altered taste (e.g., metallic) Grade 1 salivary duct inflammation AE CTCAE: E11004 OAE:0004411 An inflammation AE that has inflammation of the mucous membrane of the small intestine. 10065710 small intestinal mucositis AE CTCAE: E11015 NCIt: C78613 OAE:0004412 A small intestinal mucositis AE that has severe pain and is interfering with oral intake; tube feeding, TPN or hospitalization indicated. Grade 3 small intestinal mucositis AE CTCAE: E11018 OAE:0004413 A small intestine ulcer AE that has altered GI function, requires TPN indicated. Elective operative or endoscopic intervention indicated; limiting self care ADL; disablingoperative intervention Grade 3 small intestine ulcer AE CTCAE: E11041 OAE:0004414 A small intestine ulcer AE that has altered GI function. Grade 2 small intestine ulcer AE CTCAE: E11040 OAE:0004415 A tooth disorder AE that has a pathological process of the teeth occurring during tooth development. 10044030 tooth development disorder AE CTCAE: E11048 NCIt: C35596 OAE:0004416 A tooth development disorder AE that has maldevelopment with impairment not surgically correctable. Grade 3 tooth development disorder AE CTCAE: E11051 OAE:0004417 A tooth development disorder AE that has impairment correctable with oral surgery Grade 2 tooth development disorder AE CTCAE: E11050 OAE:0004418 A tooth development disorder AE that has hypoplasia of tooth or enamel. Grade 1 tooth development disorder AE CTCAE: E11049 OAE:0004419 A digestive system AE that has abdominal pain, fever, change in bowel habits with ileus and peritoneal signs. Grade 3 cecitis AE CTCAE: E11059 OAE:0004420 A thyroiditis AE where the thyroiditis inflammation has a chronic process. YH https://en.wikipedia.org/wiki/Thyroiditis 10043781 chronic thyroiditis AE OAE:0004421 A chronic thyroiditis AE that shows a lot of dense fibrous tissue. YH Riedel goiter AE Riedel's thyroiditis AE chronic sclerosing thyroiditis AE chronic thyroiditis wood AE fibrous chronic thyroiditis AE invasive fibrous thyroiditis AE http://www.healthfrom.com/Disease/view-3435.html 10043782 chronic fibrous thyroiditis AE OAE:0004424 An acute thyroiditis AE that shows a form of painful, acute thyroiditis resulting from radioactive therapy to treat hyperthyroidism or from radiation to treat head and neck cancer or lymphoma. YH https://en.wikipedia.org/wiki/Radiation-induced_thyroiditis 10063885 radition thyroiditis AE OAE:0004425 An autoimmune thyroiditis AE where the thyroid gland is gradually destroyed. JX, YH Hashimoto's disease AE chronic lymphocytic thyroiditis AE https://en.wikipedia.org/wiki/Autoimmune_thyroiditis 10069432 Hashimoto's thyroiditis AE OAE:0004426 An autoimmune thyroiditis AE that shows an organ-specific autoimmune disease characterized by thyroid autoantibodies, functional hypothyroidism, and absence of goiter. YH https://link.springer.com/chapter/10.1007%2F978-1-60327-285-8_42 10077172 atrophic thyroiditis AE OAE:0004427 A thyroiditis AE that occurs after pregnancy and may involve hyperthyroidism, hypothyroidism or the two sequentially. YH https://en.wikipedia.org/wiki/Postpartum_thyroiditis postpartum thyroiditis AE OAE:0004428 An adverse event of hematoma in the subcapsular space of the kidney. This event occurs after a medical intervention, and may be caused by a tumor, trauma, vasculitis, renal infarction, or other disease process. YH, EO https://medical-dictionary.thefreedictionary.com/subcapsular+hematoma subcapsular hematoma subcapsular hematoma AE OAE:0004429 An adverse event of hematoma occurring around the kidney. YH, EO perinephric hematoma perinephric hematoma AE OAE:0004430 YH, EO arteriovenous fistulae arteriovenous fistula arteriovenous fistula AE OAE:0004431 An adverse event of surgery that leads to the puncturing of an adjacent organ. For example, a needle to the kidney may puncture the adjacent organs. Jennifer Schaub, Oliver He puncturing of adjacent organs https://www.ncbi.nlm.nih.gov/books/NBK493205/ puncturing of adjacent organ AE OAE:0004432 A renal failure AE that is characterized by abnormally high levels of nitrogen-containing compounds (such as urea, creatinine, various body waste compounds, and other nitrogen-rich compounds) in the blood. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Azotemia 10003885 azotaemia AE OAE:0004433 An adverse event with the IgA nephropathy, a form of glomerulonephritis (an inflammation of the glomeruli of the kidney), primarily characterized by deposition of the IgA antibody in the glomerulus. YH Berger's disease IgA nephritis IgAN synpharyngitic glomerulonephritis https://en.wikipedia.org/wiki/IgA_nephropathy IgA nephropathy AE OAE:0004434 An adverse event with the IgM nephropathy, a form of glomerulonephritis (an inflammation of the glomeruli of the kidney), primarily characterized by deposition of the IgM antibody in the glomerulus. YH https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/other-glomerular-diseases/igm-nephropathy/ IgM nephropathy AE OAE:0004435 A urine abnormality AE that is characterized by dark colored urine resulting from abormally high blood levels of conjugated bilirubin. David Ameriguian, Oliver He https://meded.ucsd.edu/clinicalimg/genital_urine_bili.htm 10004710 bilirubinuria AE OAE:0004436 A bladder cancer AE that is characterized by a benign or malignant, primary or metastatic neoplasm of the bladder. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/medgen/594 10005056 bladder neoplasm AE OAE:0004437 A urine abnormality AE that is characterized by the presence of bile in urine. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Choluria 10008684 choluria AE OAE:0004438 A urine abnormality AE that is characterized by when one passes blood sugar (blood glucose) into urine. David Ameriguian, Oliver He https://www.healthline.com/healthy/glycosuria 10018473 glycosuria AE OAE:0004439 A urine abnormality AE that is characterized by an abnormally low urinary specific gravity, i.e., reduced concentration of solutes in the urine. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/publications/dictionaries/cancer-terms/def/hydroureter 10021096 hyposthenuria AE OAE:0004440 A urine abnormality AE that is characterized by a medical condition in which ketone bodies are present in the urine. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Ketonuria 10023388 ketonuria AE OAE:0004441 A urine abnormality AE that is characterized by an abnormal pathologic state in which an excessive amount of myoglobin is found in the urine, imparting a cola-like hue, usually in association with myonecrosis and a clinical picture of weakness, myalgias, edema. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/10658177 10028629 myoglobinuria AE OAE:0004443 A kidney AE that is characterized by disease or damage of the kidney, which can eventually result in kidney failure David Ameriguian, Oliver He https://www.news-medical.net/health/What-is-Nephropathy.aspx 10029151 nephropathy AE OAE:0004444 A nephropathy AE that is characterized by any adverse functional or structural changes in the kidney due to the effect of a chemical or biological product that is inhaled, ingested, injected, or otherwise absorbed, or that yields toxic metabolites with an identifiable adverse effect on the kidneys. David Ameriguian, Oliver He https://jamanetwork.com/journals/jama/fullarticle/655056 10029155 nephropathy toxic AE OAE:0004445 A congenital AE that is characterized by a birth defect and inherited condition that affects the urinary tract (kidneys, ureters, and bladder) or the genital tract (reproductive organs). David Ameriguian, Oliver He https://umiamihealth.org/treatments-and-services/nephrology/congenital-urogenital-abnormalities 10062334 congenital genitourinary abnormality AE OAE:0004446 A urinary system AE that is characterized by the abnormal enlargement of the ureter caused by any blockage that prevents urine from draining into the bladder. David Ameriguian, Oliver He https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hydroureter 10020533 hydroureter AE OAE:0004447 A urinary system AE that is characterized by a condition in which the nephrons, the functional units of the kidneys, become inflamed. David Ameriguian, Oliver He https://www.medicalnewstoday.com/articles/312579.php 10029117 nephritis AE OAE:0004448 A kidney AE that is characterized by a progressive disease of the kidneys that results from sclerosis (hardening) of the small blood vessels in the kidneys. David Ameriguian, Oliver He https://www.medicinenet.com/script/main/art.asp?articlekey=4533 10029159 nephrosclerosis AE OAE:0004451 A pain AE that is characterized by pain from disease or injury to a kidney David Ameriguian, Oliver He kidney pain AE https://www.mayoclinic.org/symptoms/kidney-pain/basics/definition/sym-20050902 10039490 renal pain AE OAE:0004452 A kidney AE that is characterized by a very heterogeneous group of hereditary and acquired diseases that involve singular or complex dysfunctions of transporters and channels in the renal tubular system David Ameriguian, Oliver He https://www.amboss.com/us/knowledge/Renal_tubular_disorders 10038537 renal tubular disorder AE OAE:0004453 A renal tubular disorder AE that is characterized by acute kidney injury in the renal category involving damage to the tubule cells of the kidneys, which can lead to acute kidney failure David Ameriguian, Oliver He https://medlineplus.gov/ency/article/000512.htm 10038540 renal tubular necrosis AE OAE:0004454 A kidney AE that is characterized by vessel wall leukocyte infiltration, often with necrosis affecting the kidney David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/19891303 10038546 renal vasculitis AE OAE:0004455 A urinary system AE that is characterized by when a person has trouble starting or maintaining a urine stream David Ameriguian, Oliver He https://www.medicalnewstoday.com/articles/321087.php 10046542 urinary hesitation AE OAE:0004456 A urinary system AE that is characterized by any disorder that affects your urinary tract, which is the body's drainage system for removing urine David Ameriguian, Oliver He https://www.niddk.nih.gov/health-information/urologic-diseases 10046566 urinary tract disorder AE OAE:0004457 A uninary system AE that occurs in bladder David Ameriguian, Oliver He bladder disorder AE 10005037 10056655 bladder AE OAE:0004458 A urine abnormality AE that is characterized by the presence of porphyrins in the urine David Ameriguian, Oliver He https://en.wiktionary.org/wiki/porphyrinuria 10036193 porphyrinuria AE OAE:0004459 An abscess AE that is characterized by an infection that has gotten into the kidneys caused by bacteria. David Ameriguian, Oliver He https://www.urologyhealth.org/urologic-conditions/kidney-(renal)-abscess 10038351 renal abscess AE OAE:0004460 A kidney AE that is characterized by a kidney disorder where the kidneys are relatively small in comparison to the gender, age, and body weight of the patient. David Ameriguian, Oliver He https://www.novusbio.com/diseases/congenital-renal-atrophy 10038381 renal atrophy AE OAE:0004461 A kidney AE that is characterized by a sac of fluid that forms in the kidney. David Ameriguian, Oliver He https://www.radiologyinfo.org/en/info.cfm?pg=renal-cyst 10038423 renal cyst AE OAE:0004462 A bladder AE that is characterized by complete absence, or agenesis, of the urinary bladder David Ameriguian, Oliver He https://jamanetwork.com/journals/jama/fullarticle/325825 10056655 bladder agenesis AE OAE:0004463 A bladder AE that is characterized by a pouch in the bladder wall that a person may either be born with or get later. David Ameriguian, Oliver He https://www.urologyhealth.org/urologic-conditions/bladder-diverticulum 10005038 bladder diverticulum AE OAE:0004464 A bladder AE that is characterized by scarring and hardening of the tissue in the bladder. David Ameriguian, Oliver He https://www.oncolink.org/support/side-effects/genitourinary-side-effects/bladder-fibrosis 10005042 bladder fibrosis AE OAE:0004465 A bladder AE that is characterized by tumor-like formations, projecting above the level of the mucous membrane of the efferent urinary passages, and consisting of granulation tissue. David Ameriguian, Oliver He https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1464-410X.1937.tb06608.x 10005043 bladder granuloma AE OAE:0004466 A bladder AE that is characterized by an enlarged bladder where the bladder walls become thicker and then grow because they are overstretched. David Ameriguian, Oliver He enlarged bladder AE https://www.healthline.com/health/enlarged-bladder 10063408 bladder hypertrophy AE OAE:0004467 A bladder AE that is characterized by external bladder injuries that are caused by either blunt or penetrating trauma to the lower abdomen, pelvis, or perineum. David Ameriguian, Oliver He https://www.merckmanuals.com/professional/injuries-poisoning/genitourinary-tract-trauma/bladder-trauma 10061698 bladder injury AE OAE:0004468 A bladder AE that is characterized by squamous metaplasia of the transitional epithelium and keratinization; it is a rare condition. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/1949238 10051257 bladder leukoplakia AE OAE:0004469 A bladder AE that is characterized by acute or chronic changes in the uterine shape or position; this can occur in women prior to labor, during labor, or postpartum. David Ameriguian, Oliver He https://emedicine.medscape.com/article/272497-overview 10049716 bladder malposition acquired AE OAE:0004470 A bladder AE that is characterized by an overly distended bladder with flattened urothelium. David Ameriguian, Oliver He https://ntp.niehs.nih.gov/nnl/urinary/urinary_bladder/dilation/urinary_bladder-dilation_508.pdf 10005033 bladder dilatation AE OAE:0004471 A bladder AE that is characterized by being the putative precursor of urothelial carcinoma in situ (CIS) and invasive urothelial carcinoma of the urinary tract. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/10199474 10069448 bladder dysplasia AE OAE:0004472 A bladder AE that is characterized by a number of urinary conditions in people who lack bladder control due to a brain, spinal cord, or nerve problem. David Ameriguian, Oliver He https://www.urologyhealth.org/urologic-conditions/neurogenic-bladder 10029279 neurogenic bladder AE OAE:0004473 A urinary system AE that is characterized by a problem that affects the urinary and genital tracts (reproductive organs) This term may need to move to a higher level. More work need to be done. David Ameriguian, Oliver He https://intermountainhealthcare.org/services/pediatrics/services/urology/urogenital-disorders/ 10046694 urogenital disorder AE OAE:0004474 A procedural complication AE that occurs after a blood transfusion YH blood transfusion reaction AE OAE:0004475 A kidney AE that is characterized by a reversible form of acute renal dysfunction; it encompasses several different conditions that vary considerably. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895370/ 10001017 acute prerenal failure AE OAE:0004476 A urinary system AE that is characterized by an abnormal amount of amino acids in the urine. David Ameriguian, Oliver He https://www.ucsfbenioffchildrens.org/tests/003366.html 10001939 aminoaciduria AE OAE:0004477 A congenital AE that is characterized by a wide range of kidney disease that are from birth; cystic disease may involve one or both kidneys and may or may not occur in the presence of other anomalies. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Cystic_kidney_disease 10010428 congenital cystic kidney disease AE OAE:0004478 A bladder AE that is characterized by a bladder whose muscles do not fully contract. This makes it hard to urinate. David Ameriguian, Oliver He flaccid bladder, acontracile bladder https://www.healthline.com/health/atonic-bladder 10003629 atonic urinary bladder AE OAE:0004479 A kidney AE that is characterized by a disease that causes abnormal blood clots to form in small blood vessels in the kidneys. David Ameriguian, Oliver He atypical hemolytic uremic syndrome https://rarediseases.info.nih.gov/diseases/8702/atypical-hemolytic-uremic-syndrome 10079840 atypical haemolytic uraemic syndrome AE OAE:0004480 A urinary tract infection AE that is characterized by a type of urinary tract infection caused by bacteria where one or both kidneys become infected. David Ameriguian, Oliver He https://www.urologyhealth.org/urologic-conditions/kidney-(renal)-infection-pyelonephritis 10059517 bacterial pyelonephritis AE OAE:0004481 A urinary system AE that is characterized by the presence of bacteria in urine. It is often accompanied by symptoms is a urinary tract infection while that without is known as asymptomatic bacteriuria. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Bacteriuria 10004056 bacteriuria AE OAE:0004482 A bladder neoplasm AE that is characterized by a non-cancerous tumor of the bladder that does not spread (metastasize) to other parts of the body. David Ameriguian, Oliver He http://www.cancer.ca/en/cancer-information/cancer-type/bladder/bladder-cancer/non-cancerous-tumours/?region=on 10004302 benign neoplasm of bladder AE OAE:0004483 A bladder cancer AE that is characterized by cancer that has returned following initial treatment with surgery, radiation, chemotherapy, and immunotherapy. recurrent bladder cancer https://www.texasoncology.com/types-of-cancer/bladder-cancer/recurrent-bladder-cancer 10005005 bladder cancer recurrent AE OAE:0004484 A bladder AE that is characterized by problems with urination. This may include urgency of urination, frequency of urination, ability to "hold" urine during day or night, urinary incontinence, infrequent voiding, constipation, or other diagnoses. David Ameriguian, Oliver He https://www.choc.org/programs-services/urology/dysfunctional-bladder/ 10069632 bladder dysfunction AE OAE:0004485 A bladder AE that is characterized by a blockage at the base or neck of the bladder. Such a blockage reduces or stops the flow of urine into the urethra, which carries urine from the body. David Ameriguian, Oliver He https://my.clevelandclinic.org/health/diseases/15181-bladder-outlet-obstruction- 10005060 bladder obstruction AE OAE:0004486 A bladder AE that is characterized by a narrowing that can cause bladder obstruction that leads to incomplete bladder emptying. David Ameriguian, Oliver He https://urobop.co.nz/our-services/id/62 10005082 bladder stenosis AE OAE:0004487 A bladder cancer AE that is characterized by cancer that starts in the urothelial cells that line the inside of the bladder. It is the most common type of bladder cancer. David Ameriguian, Oliver He urothelial carcinoma https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html 10005084 bladder transitional cell carcinoma AE OAE:0004488 A urinary system AE that is characterized by yeast in the urine which can range from procurement contamination to a sign of a life-threatening, opportunistic fungal infection. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/11095903 10050762 candiduria AE OAE:0004489 A bladder AE that is characterized by a severe and long-standing reduction in bladder capacity. David Ameriguian, Oliver He https://www.auajournals.org/article/S0022-5347(17)70833-6/pdf 10010814 contracted bladder AE OAE:0004490 A kidney AE that is characterized by a medical test in which pain is elicited by percussion of the area of the back overlying the kidney (the costovertebral angle, an angle made by the vertebral column and the costal margin). David Ameriguian, Oliver He CVA tenderness, Murphy's punch sign, Pasternacki's sign, Goldflam's sign https://en.wikipedia.org/wiki/Costovertebral _angle_tenderness costovertebral angle tenderness AE OAE:0004491 A kidney AE that is characterized by a major shock and renal failure after a crushing injury to skeletal muscle. David Ameriguian, Oliver He Traumatic rhabdomyolysis, Bywaters' syndrome https://en.wikipedia.org/wiki/Crush_syndrome 10050702 crush syndrome AE OAE:0004492 A urinary system AE thta is characterized by cloudy urine when the cause of cloudiness is due to crystals found in the urine when performing a urine test. It is considered often as a benign condition. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Crystalluria 10011509 crystalluria AE OAE:0004493 A cystitis AE that is characterized by a strong, persistent urge to urinate; a burning sensation when urinating; passing ferquent, small amounts of urine; blood in the urine (hematuria); passing cloudy or strong-smelling urine; pelvic discomfort; a feeling of pressure in the lower abdomen; and a low-grade fever. David Ameriguian, Oliver He https://ww.mayoclinic.org/diseases-conditions/cystits/symptoms-causes/syc-20371306 10050687 cystitis-like symptom AE OAE:0004494 A kidney AE that is characterized by a birth defect in which a kidney is located below, above, or on the opposite side of its usual position; about one in 900 people has an ectopic kidney. David Ameriguian, Oliver He https://www.niddk.nih.gov/health-information/kidney-disease/children/ectopic-kidney 10063044 ectopic kidney AE OAE:0004495 A kidney AE that is characterized by two ureters coming from a single kidney. David Ameriguian, Oliver He https://www.chop.edu/conditions-diseases/duplex-kidney 10023416 kidney duplex AE OAE:0004496 A kidney AE that is characterized by a mixed bag of developmental abberations, all of which involve anatomical or major structural anomalies. David Ameriguian, Oliver He https://adc.bmj.com/content/77/6/471 10023430 kidney malformation AE OAE:0004497 A kidney AE that is characterized by either partial or complete fusion of the two kidneys. David Ameriguian, Oliver He https://www.omicsonline.org/open-access/renal-fusion-anomalies-a-review-of-surgical-anatomy-2161-0940-S5-001.php?aid=57809 10068033 renal fusion anomaly AE OAE:0004498 A urinary system AE that is characterized by either an anterior or posterior situation; the second type is the most common obstructive congenital malformation of the urethra. The condition presents with abnormal posterior urethral folds or membranes that prevent urine evacuation from the bladder. David Ameriguian, Oliver He https://www.sciencedirect.com/topics/medicine-and-dentistry/urethral-valves 10046479 urethral valves AE OAE:0004499 A bladder AE that is characterized by the urodynamic description of bladder outlet obstruction from detrusor muscle contraction with concomitant involuntary urethral sphincter activation. David Ameriguian, Oliver He https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739973 10012660 detrusor sphincter dyssynergia AE OAE:0004500 A kidney AE that is characterized by the most advanced stage of kidney disease. David Ameriguian, Oliver He https://www.heart.org/en/health-topics/diabetes/why-diabetes-matters/kidney-disease--diabetes 10012660 diabetic end stage renal disease AE OAE:0004501 A kidney AE that is characterized by a serious kidney-related complication of type 1 diabetes and type 2 diabetes. David Ameriguian, Oliver He diabetic kidney disease https://www.mayoclinic.org/diseases-conditions/diabetic-nephropathy/symptoms-causes/syc-20354556 10061835 diabetic nephropathy AE OAE:0004502 A kidney AE that is characterized by a rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. David Ameriguian, Oliver He https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/ 10067757 focal segmental glomerulosclerosis AE OAE:0004503 A urinary system AE that is characterized by urinary retention in young women; the problem is caused by the sphincter's failure to relax to allow urine to be passed. David Ameriguian, Oliver He https://www.bladderandbowel.org/bladder/bladder-conditions-and-symptoms/fowlers-syndrome/ 10071718 fowler's syndrome AE OAE:0004504 A urinary system AE that is characterized by any symptom related to the urinary and genital organs. David Ameriguian, Oliver He https://www.stanfordchildrens.org/en/topic/default?id=overview-of-genitourinary-disorders-90-P03103 10075537 genitourinary symptom AE OAE:0004505 A kidney AE that is characterized by inflammation and subsequent damage of the glomeruli leading to hematuria, proteinuria, and azotemia; it may be caused by primary renal disease or systemic conditions. Acute glomerulonephritis is the third most common cause of end-stage renal disease. David Ameriguian, Oliver He https://emedicine.medscape.com/article/777272-overview 10018366 glomerulonephritis acute AE OAE:0004506 A kidney AE that is characterized by glomerulonephritis that develops silently (without symptoms) over several years, leading, often, to complete kidney failure. David Ameriguian, Oliver He https://www.kidney.org/atoz/content/glomerul 10018367 glomerulonephritis chronic AE OAE:0004507 A kidney AE that is characterized by a type of glomerulonephritis caused by deposits in the kidney glomerular mesangium and basement membrane thickening. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Membranoproliferative_glomerulonephritis 10018370 glomerulonephritis membranoproliferative AE OAE:0004508 A kidney AE that is characterized by a specific type of glomerulonephritis that develops when inflammation of your kidney structures causes problems with the functioning of your kidney. David Ameriguian, Oliver He https://www.healthline.com/health/membranous-nephropathy 10018372 glomerulonephritis membranous AE OAE:0004509 A kidney AE that is characterized by a disease affecting the kidneys which causes a nephrotic syndrome. David Ameriguian, Oliver He minimal change disease https://en.wikipedia.org/wiki/Minimal_change_disease 10018374 glomerulonephritis minimal lesion AE OAE:0004510 A kidney AE that is characterized by an increased number of cells in the glomerulus. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Glomerulonephritis 10018376 glomerulonephritis proliferative AE OAE:0004511 A kidney AE that is characterized by any disease of renal glomeruli. David Ameriguian, Oliver He 10018620 glomerulonephropathy AE OAE:0004512 An autoimmune disorder AE that is characterized by a rare autoimmune disease in which antibodies attack the basement membrane in lungs and kidneys, leading to bleeding from the lungs and kidney failure. David Ameriguian, Oliver He goodpasture syndrome https://en.wikipedia.org/wiki/Goodpasture_syndrome 10018620 goodpasture's syndrome AE OAE:0004513 A urinary system AE that is characterized by bleeding of the urinary tract that can happen without a clear cause or as a result of an injury. David Ameriguian, Oliver He hemorrhage urinary tract https://www.hog.org/handbook/article/3/33/urinary-tract-bleeds 10055847 haemorrhage urinary tract AE OAE:0004514 A kidney AE that is characterized by a rare kidney disease leading to chronic kidney disease in a non-negligible percentage of patients. David Ameriguian, Oliver He https://cjasn.asnjournals.org/content/6/3/679 10069440 henoch-schonlein purpura nephritis AE OAE:0004515 A urinary system AE that is characterized by when hemoglobin is released from RBCs into the bloodstream in excess of the binding capacity of haptoglobin. It occurs with chronic introvascular hemolysis and is called "brown urine." David Ameriguian, Oliver He hemosiderinuria https://en.wikipedia.org/wiki/Hemosiderinuria 10069395 haemosiderinuria AE OAE:0004516 A kidney AE that is characterized by rapid deterioration in kidney function in individuals with cirrhosis or fulminant liver failure. It is a life-threatening medical condition. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Hepatorenal_syndrome 10019846 hepatorenal syndrome AE OAE:0004517 A urinary system AE that is characterized by an excessive urinary excretion of oxalate. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Hyperoxaluria 10020703 hyperoxaluria AE OAE:0004518 A nephropathy AE that is characterized by a disease of the kidneys where the vasculature of the kidneys is damaged with an increase in blood pressure (high blood pressure). David Ameriguian, Oliver He https://www.myvmc.com/diseases/hypertensive-nephropathy/ 10055171 hypertensive nephropathy AE OAE:0004519 A urinary system AE that is characterized by low urinary-citrate excretion (defined as less than 320 mg/day), which can cause kidney stones in up to 2/3 of cases. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Kidney_stone_disease#Hypocitraturia 10070871 hypocitraturia AE OAE:0004520 A congenital AE that is characterized by a congenital disorder of the urethra where the urinary opening is not at the usual location on the head of the penis. David Ameriguian, Oliver He https://en.wikipedia.org/wiki/Hypospadias 10021093 hypospadias AE OAE:0004521 A bladder AE that is characterized by the hypotonic bladder muscle failing to squeeze hard enough to completely empty the bladder. David Ameriguian, Oliver He http://urologygroup.com/conditions-we-treat/urinary-retention/ 10058914 hypotonic urinary bladder AE OAE:0004522 An AE with the fragmentation of the nucleus Anthony Huffman, Oliver He https://en.wikipedia.org/wiki/Karyorrhexis https://jvi.asm.org/content/78/22/12672.long https://www.nature.com/articles/43591 10063393 karyorrhexis AE OAE:0004523 A cardiac disorder AE that shows a disorder of the heart's electrical activity, which can cause sudden, uncontrollable, dangerous arrhythmias in response to exercise or stress. The term "long QT" refers to an abnormal pattern seen on an EKG (electrocardiogram), a test that detects and records the heart's electrical activity. Madison Kalter, Jamie Ngai, Beccca Racz, Oliver He LQTS AE https://en.wikipedia.org/wiki/Long_QT_syndrome https://www.nhlbi.nih.gov/health-topics/long-qt-syndrome long QT syndrome AE OAE:0004524 an injection-site AE that displays erythema at the injection site. Liwei Wang, Oliver He injection site erythema AE OAE:0004525 an adverse event that occurs immediately after an injection Liwei Wang, Oliver He immediate post-injection reaction AE OAE:0004526 an adverse event that displays swelling at the injection site Liwei Wang, Oliver He Injection site swelling AE OAE:0004527 Jessica DeGuise, Oliver He 1003880 axillary vein thrombosis AE OAE:0004528 Jessica DeGuise, Oliver He 10063093 basilar artery thrombosis AE OAE:0004529 Jessica DeGuise, Oliver He 10062573 brain stem thrombosis AE OAE:0004530 Jessica DeGuise, Oliver He 10053994 cardiac ventricular thrombosis AE OAE:0004531 Jessica DeGuise, Oliver He 10079523 catheter site thrombosis AE OAE:0004532 Jessica DeGuise, Oliver He 10007830 cavernous sinus thrombosis AE OAE:0004533 Jessica DeGuise, Oliver He 10063176 prosthetic cardiac valve thrombosis AE OAE:0004534 An adverse event with the outcome of the cerebral venous sinus thrombosis (CVST), which occurs when a blood clot forms in the brain’s venous sinuses. CVST prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage. Jessica DeGuise, Oliver He https://www.hopkinsmedicine.org/health/conditions-and-diseases/cerebral-venous-sinus-thrombosis 10083037 CVST cerebral venous sinus thrombosis AE OAE:0004535 Jessica DeGuise, Oliver He 10072240 foetal placental thrombosis AE OAE:0004536 Jessica DeGuise, Oliver He 10019636 hepatic artery thrombosis AE OAE:0004537 Jessica DeGuise, Oliver He 10019713 hepatic vein thrombosis AE OAE:0004538 Jessica DeGuise, Oliver He 10027397 mesenteric artery thrombosis AE OAE:0004539 Jessica DeGuise, Oliver He 10072564 peripheral artery thrombosis AE OAE:0004540 An adverse event in any patient presenting with both acute venous or arterial thrombosis AND new onset thrombocytopenia after a medical intervention such as vaccination. Oliver He, Jessica DeGuise TTS https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v9.0-April-16-202115853.pdf thrombosis with thrombocytopenia syndrome AE OAE:0004541 Jessica DeGuise, Oliver He 10077022 postpartum thrombosis AE OAE:0004542 Jessica DeGuise, Oliver He 10036300 postpartum venous thrombosis AE OAE:0004543 Jessica DeGuise, Oliver He 10037459 pulmonary venous thrombosis AE OAE:0004544 Jessica DeGuise, Oliver He 10038380 renal artery thrombosis AE OAE:0004545 Jessica DeGuise, Oliver He 10062108 retinal vascular thrombosis AE OAE:0004546 Jessica DeGuise, Oliver He 10071316 spinal artery thrombosis AE OAE:0004547 Jessica DeGuise, Oliver He 10074600 splenic artery thrombosis AE OAE:0004548 Jessica DeGuise, Oliver He 10041659 splenic vein thrombosis AE OAE:0004549 Jessica DeGuise, Oliver He 10043634 thrombosis prophylaxis AE OAE:0004550 Jessica DeGuise, Oliver He 10063934 vascular stent thrombosis AE OAE:0004551 Jessica DeGuise, Oliver He 10078675 vascular access site thrombosis AE OAE:0004552 Jessica DeGuise, Oliver He 10069922 vascular graft thrombosis AE OAE:0004553 Jessica DeGuise, Oliver He 10063363 brachiocephalic vein thrombosis AE OAE:0004554 Jessica DeGuise, Oliver He 10057777 vertebral artery thrombosis AE OAE:0004555 Jessica DeGuise, Oliver He 10077623 portosplenomesenteric venous thrombosis AE OAE:0004556 Jessica DeGuise, Oliver He 10058568 arteriovenous fistula thrombosis AE OAE:0004557 Jessica DeGuise, Oliver He 10074494 hepatic vascular thrombosis AE OAE:0004558 Jessica DeGuise, Oliver He 10069550 intrapericardial thrombosis AE OAE:0004559 Jessica DeGuise, Oliver He 10081144 ophthalmic artery thrombosis AE OAE:0004560 Jessica DeGuise, Oliver He 10074349 ophthalmic vein thrombosis AE OAE:0004561 an arterial embolism AE that results in the blockage of the main artery of a lung or one of its branches by a substance that has travelled from elsewhere in the body through the bloodstream [SS] moved by relation 'SubclassOf' from lung disorder AE to arterial embolism on 01/07/14 SZ, SS, YH, JD WEB: http://www.ncbi.nlm.nih.gov/pubmed/23299609 10037437 pulmonary thrombosis AE HPO: HP_0002204 SIDER: C0034065 OAE:0004562 Jessica DeGuise, Oliver He 10038518 renal vein thrombosis AE OAE:0004563 Jessica DeGuise, Oliver He 10038831 retinal artery thrombosis AE OAE:0004564 Jessica DeGuise, Oliver He 10074601 splenic thrombosis AE OAE:0004565 Jessica DeGuise, Oliver He 10042334 subclavian artery thrombosis AE OAE:0004566 Jessica DeGuise, Oliver He 10043626 thrombosis mesenteric vessel AE OAE:0004567 Jessica DeGuise, Oliver He 10044457 transverse sinus thrombosis AE OAE:0004568 Jessica DeGuise, Oliver He 10076190 vaccination site thrombosis AE OAE:0004569 Jessica DeGuise, Oliver He ophthalmic thrombosis AE OAE:0004570 Jessica DeGuise, Oliver He hepatic thrombosis AE OAE:0004571 Jessica DeGuise, Oliver He renal thrombosis AE OAE:0004572 Jessica DeGuise, Oliver He 10062108 retinal thrombosis AE OAE:0004573 Jessica DeGuise, Oliver He brain thrombosis AE OAE:0004574 cardiac thrombosis AE OAE:0004575 Jessica DeGuise, Oliver He 10019713 visceral venous thrombosis AE OAE:0004576 A definit case of TTS Oliver He, Jessica DeGuise Level 1 thrombosis with thrombocytopenia syndrome AE https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v9.0-April-16-202115853.pdf Level 1 TTS AE OAE:0004577 A probable case of TTS Oliver He, Jessica DeGuise Level 2 thrombosis with thrombocytopenia syndrome AE https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v9.0-April-16-202115853.pdf Level 2 TTS AE OAE:0004578 A possible case TTS Oliver He, Jessica DeGuise Level 3 thrombosis with thrombocytopenia syndrome AE https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v9.0-April-16-202115853.pdf Level 3 TTS AE OAE:0004579 A reported case as TTS but there is insufficient evidence to meet any level of the case. Oliver He, Jessica DeGuise Level 4 thrombosis with thrombocytopenia syndrome AE https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v9.0-April-16-202115853.pdf Level 4 TTS AE OAE:0004580 most likely not a case of TTS Oliver He, Jessica DeGuise Level 5 thrombosis with thrombocytopenia syndrome AE https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v9.0-April-16-202115853.pdf Level 5 TTS AE OAE:0004581 an arterial embolism AE that results in the blockage of the main artery of a lung or one of its branches by a substance that has travelled from elsewhere in the body through the bloodstream [SS] moved by relation 'SubclassOf' from lung disorder AE to arterial embolism on 01/07/14 SZ, SS, YH, JD WEB: http://www.ncbi.nlm.nih.gov/pubmed/23299609 10037340 pulmonary artery thrombosis AE HPO: HP_0002204 SIDER: C0034065 OAE:0004582 a thrombosis AE that occurs in subclavian vein. Among patients with effort-induced thrombosis with subclavian vein stenosis, the thrombosis occurs in the dominant arm in 80% of cases. SS WEB: http://emedicine.medscape.com/article/424777-overview#showall 10049446 subclavian thrombosis AE OAE:0004583 Jessica DeGuise, Oliver He 10027397 mesenteric thrombosis AE OAE:0004584 This is an AE which is the most common manifestation of abdominal tuberculosis. QY, JX, HY http://en.volupedia.org/wiki/Abdominal_tuberculosis 腹部淋巴结病 10073485 abdominal lymphadenopathy AE OAE:0004585 This is an AE which is any localized enlargement or swelling in the human abdomen. QY, JX, HY http://en.volupedia.org/wiki/Abdominal_mass 腹部肿块 10000077 abdominal mass AE OAE:0004586 This is an AE which is a disorder primarily of children which presents with episodes of abdominal pain without an accompanying headache. QY, JX, HY http://en.volupedia.org/wiki/Abdominal_migraine 腹型偏头痛 10049714 abdominal migraine AE OAE:0004587 This is an AE which is a type of abnormal and excessive growth of abdominal tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 腹部肿瘤 10060925 abdominal neoplasm AE OAE:0004588 This is an AE which is a clinical sign in which there is pain upon removal of pressure rather than application of pressure to the abdomen. QY, JX, HY http://en.volupedia.org/wiki/Blumberg_sign 腹部反弹压痛 10052489 abdominal rebound tenderness AE OAE:0004589 This is an AE which is the tensing of the abdominal wall muscles to guard inflamed organs within the abdomen from the pain of pressure upon them. QY, JX, HY http://en.volupedia.org/wiki/Abdominal_guarding 腹部僵硬 10000090 abdominal rigidity AE OAE:0004590 This is an AE which is the observed or detectable abdominal signs, and experienced symptoms of an illness, injury, or condition . QY, JX, HY http://en.volupedia.org/wiki/Signs_and_symptoms 腹部疾病 10060926 abdominal symptom AE OAE:0004591 This is an AE which is pain or discomfort when an affected abdominal area is touched. QY, JX, HY http://en.volupedia.org/wiki/Tenderness_(medicine) 腹部压痛 10000097 abdominal tenderness AE OAE:0004592 This is an AE which is a closed sac, having a distinct envelope and division compared with the abdominal wall. QY, JX, HY http://en.volupedia.org/wiki/Cyst 腹壁囊肿 10051634 abdominal wall cyst AE OAE:0004593 This is an AE which a functional abnormality or disturbance occurs on the abdominal. QY, JX, HY http://en.volupedia.org/wiki/Disorder 腹壁疾病 10059625 abdominal wall disorder AE OAE:0004594 This is an AE which is a abdominal wall bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken abdominal wall capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 腹壁血肿 10067383 abdominal wall hematoma AE OAE:0004595 This is an AE which was unencapsulated and had no distinct borders and was infiltrative and composed of bundles and sheets of densely packed fusiform cells on the abdominal wall. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24442574/ 腹壁肿块 10063005 abdominal wall mass AE OAE:0004596 This is an AE which is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of abdominal wall . QY, JX, HY http://en.volupedia.org/wiki/Cancer 恶性腹壁肿瘤 10071023 abdominal wall neoplasm malignant AE OAE:0004597 This is an AE which is the build-up of fluid in the abdominal wall. QY, JX, HY http://en.volupedia.org/wiki/Edema 腹壁水肿 10082609 abdominal wall edema AE OAE:0004598 This is an AE which is a surgical complication in which a abdominal wound ruptures along a surgical incision. QY, JX, HY http://en.volupedia.org/wiki/Wound_dehiscence 腹部伤口裂开 10066337 abdominal wound dehiscence AE OAE:0004599 This is an AE which is a intra-abdominal bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 腹腔血肿 10056457 intra-abdominal hematoma AE OAE:0004600 This is an AE which refers to a sudden, severe abdominal pain and it is in many cases a medical emergency, requiring urgent and specific diagnosis. QY, JX, HY http://en.volupedia.org/wiki/Acute_abdomen 急腹症 10000647 acute abdomen AE OAE:0004601 This is an AE which is the condition of having at least three loose, liquid, or watery bowel movements each day and causes by bacterial. QY, JX, HY http://en.volupedia.org/wiki/Diarrhea 细菌性腹泻 10004016 bacterial diarrhea AE OAE:0004602 This is an AE which is a rare condition characterized by abdominal pain attributed to compression of the celiac artery and the celiac ganglia by the median arcuate ligament. QY, JX, HY http://en.volupedia.org/wiki/Median_arcuate_ligament_syndrome 腹腔动脉压迫综合征 10009838 coeliac artery compression syndrome AE OAE:0004603 This is an AE which is an abnormal narrowing in a blood vessel or other tubular organ or structure such as foramina and canals occured on coeliac artery . QY, JX, HY http://en.volupedia.org/wiki/Stenosis 腹腔动脉狭窄 10067325 coeliac artery stenosis AE OAE:0004604 This is an AE which is a protrusion of abdominal-cavity contents through the inguinal canal and it is congenital. QY, JX, HY http://en.volupedia.org/wiki/Inguinal_hernia 先天性腹股沟疝 10068321 congenital inguinal hernia AE OAE:0004605 This is an AE which is the condition of having at least three loose, liquid, or watery bowel movements each day and occurs on the neonatal. QY, JX, HY http://en.volupedia.org/wiki/Diarrhea 新生儿腹泻 10012743 diarrhea neonatal AE OAE:0004606 This is an AE which is defined as a gap of about 2.7 cm or greater between the two sides of the rectus abdominis muscle. QY, JX, HY http://en.volupedia.org/wiki/Diastasis_recti 腹直肌分离 10073169 diastasis recti abdominis AE OAE:0004607 This is an AE which is inflammation of the focal peritoneum, the lining of the inner wall of the abdomen and cover of the abdominal organs. QY, JX, HY http://en.volupedia.org/wiki/Peritonitis 局灶性腹膜炎 10084697 focal peritonitis AE OAE:0004608 This is an AE which is a birth defect in which the baby's intestines extend outside of the abdomen through a hole next to the belly button. QY, JX, HY http://en.volupedia.org/wiki/Gastroschisis 腹裂 10018046 gastroschisis AE OAE:0004609 This is an AE which is the condition of having at least three loose, liquid, or watery bowel movements each day and causes by the viral. QY, JX, HY http://en.volupedia.org/wiki/Diarrhea 病毒性腹泻 10051511 viral diarrhea AE OAE:0004610 This is an AE which is the formation of a blood clot inside a truncus coeliacus blood vessel, obstructing the flow of blood through the circulatory system. QY, JX, HY http://en.volupedia.org/wiki/Thrombosis 腹腔干血栓形成 10062363 truncus coeliacus thrombosis AE OAE:0004611 This is an AE which is the part of the body between the thorax (chest) and pelvis, in humans and in other vertebrates. QY, JX, HY http://en.volupedia.org/wiki/Abdomen#Human_abdomen 舟状腹 10078474 scaphoid abdomen AE OAE:0004612 This is an AE which is a collection of pus that has built up within the tissue of the retroperitoneal body. QY, JX, HY http://en.volupedia.org/wiki/Abscess 腹膜后脓肿 10038975 retroperitoneal abscess AE OAE:0004613 This is an AE which refers to accumulation of fluid in an retroperitoneal space, usually without loculation. QY, JX, HY http://en.volupedia.org/wiki/Effusion 腹膜后积液 10063637 retroperitoneal effusion AE OAE:0004614 This is an AE which is a disease featuring the proliferation of fibrous tissue in the retroperitoneum, the compartment of the body containing the kidneys, aorta, renal tract, and various other structures. QY, JX, HY http://en.volupedia.org/wiki/Retroperitoneal_fibrosis 腹膜后纤维化 10038979 retroperitoneal fibrosis AE OAE:0004615 This is an AE which is an accumulation of blood in the retroperitoneal space. QY, JX, HY http://en.volupedia.org/wiki/Retroperitoneal_bleeding 腹膜后血肿 10058360 retroperitoneal hematoma AE OAE:0004616 This is an AE which is a disease of the lymph nodes, in which retroperitoneal are abnormal in size or consistency. QY, JX, HY http://en.volupedia.org/wiki/Lymphadenopathy 腹膜后淋巴结肿大 10067015 retroperitoneal lymphadenopathy AE OAE:0004617 This is an AE which is a mass in the posterior of the peritoneum. QY, JX, HY http://en.volupedia.org/wiki/Abdominal_mass 腹膜后肿块 10071732 retroperitoneal mass AE OAE:0004618 This is an AE which refers fluid retention, dropsy, hydropsy and swelling, is the build-up of fluid in the retroperitoneal. QY, JX, HY http://en.volupedia.org/wiki/Edema 腹膜后水肿 10038983 retroperitoneal edema AE OAE:0004619 This is an AE which is a collection of pus that has built up within the tissue of the peritoneal. QY, JX, HY http://en.volupedia.org/wiki/Abscess 腹腔脓肿 10034649 peritoneal abscess AE OAE:0004620 This is an AE which is fibrous bands that form between peritoneal tissues and organs, often as a result of injury during surgery. QY, JX, HY http://en.volupedia.org/wiki/Adhesion_(medicine) 腹膜粘连 10034650 peritoneal adhesions AE OAE:0004622 This is an AE which is a rare serious complication typically caused by peritoneal dialysis. QY, JX, HY http://en.volupedia.org/wiki/Encapsulating_peritoneal_sclerosis 腹膜透析并发症 10067594 peritoneal dialysis complication AE OAE:0004623 This is an AE which is a functional abnormality or disturbance on the peritoneal. QY, JX, HY http://en.volupedia.org/wiki/Disorder 腹膜疾病 10061343 peritoneal disorder AE OAE:0004624 This is an AE which is blood escaping from the circulatory system from damaged peritoneal blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 腹膜出血 10034666 peritoneal hemorrhage AE OAE:0004626 This is an AE which is a hyperplasia of peritoneal mesothelial cells in serous membranes . QY, JX, HY http://en.volupedia.org/wiki/Mesothelial_hyperplasia 腹膜间皮增生 10072853 peritoneal mesothelial hyperplasia AE OAE:0004627 This is an AE which is inflammation of the peritoneum caused by virus. QY, JX, HY http://en.volupedia.org/wiki/Peritonitis 细菌性腹膜炎 10062070 peritonitis bacterial AE OAE:0004628 This is an AE which is a relatively uncommon manifestation of Streptococcus pneumoniae infection , but nonetheless, a potentially life-threatening one that requires prompt medical attention and treatment with antibiotics and, in some cases, surgery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21358876/ 腹膜炎肺炎球菌 10034681 peritonitis pneumococcal AE OAE:0004629 This is an AE which is a protrusion of abdominal-cavity contents through the inguinal canal. QY, JX, HY http://en.volupedia.org/wiki/Inguinal_hernia 腹股沟疝 10022016 inguinal hernia AE OAE:0004630 This is an AE which is a protrusion of abdominal-cavity contents through the inguinal canal caused obstructive. QY, JX, HY http://en.volupedia.org/wiki/Inguinal_hernia 阻塞性腹股沟疝 10022021 inguinal hernia, obstructive AE OAE:0004631 This is an AE which is the abnormal exit of inguinal tissue or an organ, such as the bowel, through the wall of the cavity in which it normally resides. QY, JX, HY http://en.volupedia.org/wiki/Hernia 腹股沟肿块 10053217 inguinal mass AE OAE:0004632 This is an AE which is the name given to a common and aberrant immune response to infection with virus. QY, JX, HY http://en.volupedia.org/wiki/Feline_infectious_peritonitis 传染性腹膜炎 10071647 infectious peritonitis AE OAE:0004633 This is an AE which is a protrusion of abdominal-cavity contents through the inguinal canal and incarcerated. QY, JX, HY http://en.volupedia.org/wiki/Inguinal_hernia 嵌顿性腹股沟疝 10021613 incarcerated inguinal hernia AE OAE:0004634 This is an AE which is pneumatosis (abnormal presence of air or other gas) in the peritoneal cavity, a potential space within the abdominal cavity. QY, JX, HY http://en.volupedia.org/wiki/Pneumoperitoneum 气腹 10048299 pneumoperitoneum AE OAE:0004635 This is an AE which is a collection of pus that has built up within the tissue of the groin. QY, JX, HY http://en.volupedia.org/wiki/Abscess 腹股沟脓肿 10050269 groin abscess AE OAE:0004636 This is an AE which is the invasion of an organism's groin tissues by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 腹股沟感染 10050821 groin infection AE OAE:0004637 This is an AE which occurs when there is protrusion of an internal organ into a retroperitoneal fossa or a foramen (congenital or acquired) in the abdominal cavity. QY, JX, HY http://en.volupedia.org/wiki/Internal_hernia 内部疝 10051989 internal hernia AE OAE:0004638 This is an AE which innervates the serratus anterior muscle and function gets injuried. QY, JX, HY http://en.volupedia.org/wiki/Long_thoracic_nerve 胸神经根损伤 10029187 nerve root injury thoracic AE OAE:0004639 This is an AE which occurs in most hospitalized Covid-19 patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33016619/ 神经系统感染 10051295 neurological infection AE OAE:0004640 This is an AE which is any disorder of the nervous system. Structural, biochemical or electrical abnormalities in the brain, spinal cord or other nerves can result in a range of symptoms. QY, JX, HY http://en.volupedia.org/wiki/Neurological_disorder 神经症状 10060860 neurological symptom AE OAE:0004641 This is an AE which is a class of functional mental disorders of childhood involving chronic distress, but neither delusions nor hallucinations. QY, JX, HY http://en.volupedia.org/wiki/Neurosis 儿童神经性障碍 10029343 neurotic disorder of childhood AE OAE:0004642 This is an AE which is a term describing neuropathies with both sensory and motor involvement in a length dependant distribution where neurophysiology reveals axonal damage. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26961897/ 多发性神经病变 10036111 polyneuropathy idiopathic progressive AE OAE:0004643 This is an AE which is a rare, fluid-filled neuroglial cavity within the spinal cord (syringomyelia), in the brain stem (syringobulbia), or in the nerves of the elbow, usually in a young age. QY, JX, HY http://en.volupedia.org/wiki/Syrinx_(medicine) 先天性中枢神经系统异常 10010411 congenital central nervous system anomaly AE OAE:0004644 This is an AE which refers to types of paralysis and occurs on cranial nerve caused by multiple reasons. QY, JX, HY http://en.volupedia.org/wiki/Palsy 颅神经多发性麻痹 10011314 cranial nerve palsies multiple AE OAE:0004645 This is an AE which is any loss of nerve supply regardless of the cause. QY, JX, HY http://en.volupedia.org/wiki/Denervation 去神经萎缩 10049643 denervation atrophy AE OAE:0004646 This is an AE which is a condition typified by a weakness of voluntary movement, or by partial loss of voluntary movement or by impaired movement and its occurs on IVth nerve. QY, JX, HY http://en.volupedia.org/wiki/Paresis ivth神经麻痹性痴呆 10054201 ivth nerve paresis AE OAE:0004647 This is an AE which refers to long thoracic nerve of paralysis, often accompanied by weakness and the loss of feeling and uncontrolled body movements such as shaking. QY, JX, HY http://en.volupedia.org/wiki/Palsy 胸长神经麻痹 10067925 long thoracic nerve palsy AE OAE:0004648 This is an AE which is paralysis caused by illness or injury that results in the partial or total loss of use of all four limbs and torso; paraplegia is similar but does not affect the arms. QY, JX, HY http://en.volupedia.org/wiki/Tetraplegia 颈脊髓麻痹 10057276 cervical spinal cord paralysis AE OAE:0004649 This is an AE which is a localized bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries and it is spontaneous. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 自发性血肿 10065304 spontaneous hematoma AE OAE:0004650 This is an AE which is a symptom related to a spectrum of disorders characterized by unintentional and purposeless motions and restlessness, often but not always accompanied by emotional distress. QY, JX, HY http://en.volupedia.org/wiki/Psychomotor_agitation 精神运动过度活跃 10037211 psychomotor hyperactivity AE OAE:0004651 This is an AE which is any deliberate interruption of signals traveling along a nerve, often for the purpose of pain relief. QY, JX, HY http://en.volupedia.org/wiki/Nerve_block 神经阻滞 10029173 nerve block AE OAE:0004652 This is an AE which is deterioration in the medical sense and it is the change from a higher to a lower form nerve. QY, JX, HY http://en.volupedia.org/wiki/Degeneration_(medical) 神经变性 10056677 nerve degeneration AE OAE:0004653 This is an AE which is injury to nervous tissue. QY, JX, HY http://en.volupedia.org/wiki/Nerve_injury 神经损伤 10052897 nerve injury AE OAE:0004654 This is an AE which will produce functional disability. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28453446/ 神经根损伤 10061310 nerve root injury AE OAE:0004655 This is an AE which is a disease of the cervical spine and a space-occupying lesion that occurs because of pathological problems with cervical nerve roots. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28453446/ 颈神经根损伤 10029183 nerve root injury cervical AE OAE:0004656 This is an AE which refers to a small class of medical conditions affecting the nervous system. QY, JX, HY http://en.volupedia.org/wiki/Nervous_system_disease 神经系统紊乱 10029202 nervous system disorder AE OAE:0004657 This is an AE which is injury to nervous tissue. QY, JX, HY http://en.volupedia.org/wiki/Nerve_injury 神经系统损伤 10080898 nervous system injury AE OAE:0004658 This is an AE which are a group of birth defects in which an opening in the spine or cranium remains from early in human development. QY, JX, HY http://en.volupedia.org/wiki/Neural_tube_defect 神经管缺陷 10052046 neural tube defect AE OAE:0004659 This is an AE which is a syndrome of unknown cause; although many specific risk factors have been identified (such as; post-operatively, post-infectious, post-traumatic or post-vaccination), the cause is still unknown. QY, JX, HY http://en.volupedia.org/wiki/Parsonage%E2%80%93Turner_syndrome 神经性肌萎缩 10029229 neuralgic amyotrophy AE OAE:0004660 This is an AE which is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce the insulating myelin sheath covering peripheral nerves. QY, JX, HY http://en.volupedia.org/wiki/Schwannoma 神经膜瘤 10029234 neurilemmoma AE OAE:0004661 This is an AE which is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce the insulating myelin sheath covering peripheral nerves. QY, JX, HY http://en.volupedia.org/wiki/Schwannoma 良性神经膜瘤 10029235 neurilemmoma benign AE OAE:0004662 This is an AE which is inflammation of a cranial nerveor the general inflammation of the peripheral nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neuritis 神经炎颅 10029244 neuritis cranial AE OAE:0004663 This is an AE which is a type of cancer that forms in certain types of nerve tissue. QY, JX, HY http://en.volupedia.org/wiki/Neuroblastoma 神经母细胞瘤 10029260 neuroblastoma AE OAE:0004664 This is an AE which is the progressive loss of structure or function of neurons, which may ultimately involve cell death. QY, JX, HY http://en.volupedia.org/wiki/Neurodegeneration 神经退行性疾病 10053643 neurodegenerative disorder AE OAE:0004665 This is an AE which is a skin disorder characterized by chronic itching and scratching. QY, JX, HY http://en.volupedia.org/wiki/Lichen_simplex_chronicus 神经性皮炎 10029263 neurodermatitis AE OAE:0004666 This is an AE which is a group of disorders that affect the development of the nervous system, leading to abnormal brain function which may affect emotion, learning ability, self-control, and memory. QY, JX, HY http://en.volupedia.org/wiki/Neurodevelopmental_disorder 神经发育障碍 10064062 neuro developmental disorder AE OAE:0004667 This is an AE which are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. QY, JX, HY http://en.volupedia.org/wiki/Neuroendocrine_tumor 神经内分泌肿瘤 10052399 neuroendocrine tumor AE OAE:0004668 This is an AE which is a benign nerve-sheath tumor in the peripheral nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neurofibroma 神经纤维瘤 10029267 neurofibroma AE OAE:0004669 This is an AE which is a group of three conditions in which tumors grow in the nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neurofibromatosis 神经纤维瘤病 10029268 neurofibromatosis AE OAE:0004670 This is an AE which is the inability to control defecation due to a deterioration of or injury to the nervous system, resulting in faecal incontinence or constipation. QY, JX, HY http://en.volupedia.org/wiki/Neurogenic_bowel_dysfunction 神经源性肠 10048657 neurogenic bowel AE OAE:0004671 This is an AE which is a distributive type of shock resulting in hypotension (low blood pressure), often with bradycardia (slowed heart rate), caused by disruption of autonomic nervous system pathways. QY, JX, HY http://en.volupedia.org/wiki/Neurogenic_shock 神经源性休克 10058119 neurogenic shock AE OAE:0004672 This is an AE which is a neuropsychological condition in which, after damage to one hemisphere of the brain is sustained, a deficit in attention to and awareness of one side of the field of vision is observed. QY, JX, HY http://en.volupedia.org/wiki/Hemispatial_neglect 神经系统忽视综合症 10029289 neurologic neglect syndrome AE OAE:0004673 This is an AE which is any mental neurologic disorder that manifests as physical symptoms that suggest illness or injury, but cannot be explained fully by a general medical condition or by the direct effect of a substance, and are not attributable to another mental disorder. QY, JX, HY http://en.volupedia.org/wiki/Somatic_symptom_disorder 神经躯体症状障碍 10078080 neurologic somatic symptom disorder AE OAE:0004674 This is an AE which is a drooping or falling of the upper eyelid caused by neurological disorder. QY, JX, HY http://en.volupedia.org/wiki/Ptosis_(eyelid) 眼睑神经障碍 10061312 neurological eyelid disorder AE OAE:0004675 This is an AE which block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. QY, JX, HY http://en.volupedia.org/wiki/Neuromuscular-blocking_drug 神经肌肉阻滞 10029315 neuromuscular blockade AE OAE:0004676 This is an AE which ailments that impair the functioning of the muscles, either directly, being pathologies of the voluntary muscle, or indirectly, being pathologies of nerves or neuromuscular junctions and it will cause pain. QY, JX, HY http://en.volupedia.org/wiki/Neuromuscular_disease 神经肌肉疼痛 10074313 neuromuscular pain AE OAE:0004677 This is an AE which is the degree to which a chemical substance or a particular mixture of substances can damage neuromuscular. QY, JX, HY http://en.volupedia.org/wiki/Toxicity 神经肌肉毒性 10062284 neuromuscular toxicity AE OAE:0004678 This is an AE which is a form of peripheral nerve hyperexcitability that causes spontaneous muscular activity resulting from repetitive motor unit action potentials of peripheral origin. QY, JX, HY http://en.volupedia.org/wiki/Neuromyotonia 神经性肌强直 10072359 neuromyotonia AE OAE:0004679 This is an AE which refers to progressive degeneration of a weight-bearing joint and musclar , a process marked by bony destruction, bone resorption, and eventual deformity due to loss of sensation. QY, JX, HY http://en.volupedia.org/wiki/Neuropathic_arthropathy 神经性肌肉萎缩 10075469 neuropathic muscular atrophy AE OAE:0004680 This is an AE which is a general term describing disease affecting the peripheral nerves, meaning nerves beyond the brain and spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Peripheral_neuropathy 周围神经病变 10029331 neuropathy peripheral AE OAE:0004681 This is an AE which refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. QY, JX, HY http://en.volupedia.org/wiki/Neuropsychiatric_systemic_lupus_erythematosus 神经精神狼疮 10063663 neuropsychiatric lupus AE OAE:0004682 This is an AE which are the observed or detectable signs, and experienced symptoms of an illness, injury, or condition. QY, JX, HY http://en.volupedia.org/wiki/Signs_and_symptoms#Neuropsychiatric 神经精神症状 10078497 neuropsychiatric symptoms AE OAE:0004683 This is an AE which refers to a type of sarcoidosis, a condition of unknown cause featuring granulomas in various tissues, in this type involving the central nervous system (brain and spinal cord). QY, JX, HY http://en.volupedia.org/wiki/Neurosarcoidosis 神经类肉瘤病 10078011 neurosarcoidosis AE OAE:0004684 This is an AE which is a partial or total inability to hear caused by neurosensory. QY, JX, HY http://en.volupedia.org/wiki/Hearing_loss 感觉神经的听觉迟钝 10067587 neurosensory hypoacusis AE OAE:0004685 This is an AE which is a class of functional mental disorders involving chronic distress, but neither delusions nor hallucinations. QY, JX, HY http://en.volupedia.org/wiki/Neurosis 神经衰弱症 10029333 neurosis AE OAE:0004686 This is an AE which refers to infection of the central nervous system in a patient with syphilis. QY, JX, HY http://en.volupedia.org/wiki/Neurosyphilis 神经性梅毒 10029339 neurosyphilis AE OAE:0004687 This is an AE which is a form of toxicity in which a biological, chemical, or physical agent produces an adverse effect on the structure or function of the central and/or peripheral nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neurotoxicity 神经毒性 10029350 neurotoxicity AE OAE:0004688 This is an AE which refers to a condition where corneal epitheliopathy leading to frank epithelial defect with or without stromal ulceration (melting) is associated with reduced or absent corneal sensations. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29698813/ 向神经角膜病 10069732 neurotrophic keratopathy AE OAE:0004689 This is an AE which is a painful condition affecting the posterior head in the distributions of the greater occipital nerve (GON), lesser occipital nerve (LON), third occipital nerve (TON), or a combination of the three. QY, JX, HY http://en.volupedia.org/wiki/Occipital_neuralgia 枕神经痛 10068106 occipital neuralgia AE OAE:0004690 This is an AE which is the name of a dystonic reaction to certain drugs or medical conditions characterized by a prolonged involuntary upward deviation of the eyes. QY, JX, HY http://en.volupedia.org/wiki/Oculogyric_crisis 动眼神经危象 10030071 oculogyric crisis AE OAE:0004691 This is an AE which is a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell. QY, JX, HY http://en.volupedia.org/wiki/Oligodendroglioma 少突神经胶质瘤 10030286 oligodendroglioma AE OAE:0004692 This is an AE which is associated with typical vascular risk factors and with one systemic disease in particular: giant cell arteritis (GCA). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31584535/ 光学缺血性神经病变 10030924 optic ischemic neuropathy AE OAE:0004693 This is an AE which can be defined as remote effects of cancer that are not caused by the tumor and its metastasis, or by infection, ischemia or metabolic disruptions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17480225/ 多种神经综合症 10072106 paraneoplastic neurological syndrome AE OAE:0004694 This is an AE which resulting from a lesion involving the cisternal portion of the nerve prior to its anatomical bifurcation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16682550/ 麻痹性痴呆脑神经 10061911 paresis cranial nerve AE OAE:0004695 This is an AE which is a syndrome that causes episodes of increased activity of the sympathetic nervous system. QY, JX, HY http://en.volupedia.org/wiki/Paroxysmal_sympathetic_hyperactivity 阵发性交感神经过度活跃 10078476 paroxysmal sympathetic hyperactivity AE OAE:0004696 This is an AE which is a progressively worsening condition where muscles in the extremities gradually weaken. QY, JX, HY http://en.volupedia.org/wiki/Multifocal_motor_neuropathy 多病灶的运动神经病变 10065579 multifocal motor neuropathy AE OAE:0004697 This is an AE which is a closed sac, having a distinct envelope and division compared with the nearby perineurial tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 神经束膜囊肿 10051766 perineurial cyst AE OAE:0004698 This is an AE which is a medical condition caused by dissolved gases emerging from solution as bubbles inside the peripheral nerve tissues during decompression. QY, JX, HY http://en.volupedia.org/wiki/Decompression_sickness 周围神经减压 10057610 peripheral nerve decompression AE OAE:0004699 This is an AE which refers to damage to peripheral nerve beyond the capability to repair. QY, JX, HY http://en.volupedia.org/wiki/Destruction 周围神经损伤 10034584 peripheral nerve destruction AE OAE:0004700 This is an AE which resulting from trauma can be severe and permanently debilitating. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30187777/ 周围神经损伤 10034586 peripheral nerve injury AE OAE:0004701 This is an AE which is any damage or abnormal change in the tissue of an peripheral nerve , usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 周围神经病变 10067633 peripheral nerve lesion AE OAE:0004702 This is an AE which is the purposeful modulation of the nervous system's activity using invasive or non-invasive means on the peripheral nerve. QY, JX, HY http://en.volupedia.org/wiki/Neurostimulation 周围神经神经刺激 10034587 peripheral nerve neurostimulation AE OAE:0004703 This is an AE which is a paralysis on common fibular nerve that affects patient’s ability to lift the foot at the ankle. QY, JX, HY http://en.volupedia.org/wiki/Peroneal_nerve_paralysis 外周神经麻痹 10058530 peripheral nerve palsy AE OAE:0004704 This is an AE which is a paralysis on common fibular nerve that affects patient’s ability to lift the foot at the ankle. QY, JX, HY http://en.volupedia.org/wiki/Peroneal_nerve_paralysis 外周神经麻痹性痴呆 10071663 peripheral nerve paresis AE OAE:0004705 This is an AE which is a nerve in the lower leg that provides sensation over the posteriolateral part of the leg and the knee joint. QY, JX, HY http://en.volupedia.org/wiki/Common_peroneal_nerve 腓神经损伤 10034700 peroneal nerve injury AE OAE:0004706 This is an AE which is a chronic disabling condition of the peripheral nerves, characterized by symmetrical distal numbness and paresthesia, often accompanied with pain and weakness. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26700499/ 慢性多发性神经病 10064135 polyneuropathy chronic AE OAE:0004707 This is an AE which is damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain in malignant disease. QY, JX, HY http://en.volupedia.org/wiki/Polyneuropathy 恶性疾病中的多神经病变 10036115 polyneuropathy in malignant disease AE OAE:0004708 This is an AE which is neuropathic pain that occurs due to damage to a peripheral nerve caused by the reactivation of the varicella zoster virus (herpes zoster, also known as shingles). QY, JX, HY http://en.volupedia.org/wiki/Postherpetic_neuralgia 后疱疹的神经痛 10036376 post herpetic neuralgia AE OAE:0004709 This is an AE which is a nerve in the human body that supplies the posterior portion of the upper limb and its funtion get injury. QY, JX, HY http://en.volupedia.org/wiki/Radial_nerve 桡神经损伤 10037749 radial nerve injury AE OAE:0004710 This is an AE whichis a problem associated with the radial nerve resulting from injury consisting of acute trauma to the radial nerve. QY, JX, HY http://en.volupedia.org/wiki/Radial_nerve_dysfunction 桡神经麻痹 10037749 radial nerve palsy AE OAE:0004711 This is an AE which is pain "radiated" along the dermatome (sensory distribution) of a nerve due to inflammation or other irritation of the nerve root (radiculopathy) at its connection to the spinal column. QY, JX, HY http://en.volupedia.org/wiki/Radicular_pain 神经根痛 10059604 radicular pain AE OAE:0004712 This is an AE which refers to a set of conditions in which one or more nerves are affected and do not work properly (a neuropathy). QY, JX, HY http://en.volupedia.org/wiki/Radiculopathy 神经根综合征 10052442 radicular syndrome AE OAE:0004713 This is an AE which is pain "radiated" along the dermatome (sensory distribution) of a brachial nerve due to inflammation or other irritation of the nerve root (radiculopathy) at its connection to the spinal column. QY, JX, HY http://en.volupedia.org/wiki/Radicular_pain 臂神经根炎 10037778 radiculitis brachial AE OAE:0004714 This is an AE which is a relatively common neurological disorder resulting from nerve root dysfunction, which is often due to mechanical compression. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25985461/ 颈神经根炎 10050092 radiculitis cervical AE OAE:0004715 This is an AE which is one of the most common disorders evaluated by neurologists and is a leading referral diagnosis for the performance of electromyography. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17445735/ 腰骶神经根炎 10050085 radiculitis lumbosacral AE OAE:0004716 This is an AE which refers to a set of conditions in which one or more nerves are affected and do not work properly (a neuropathy). QY, JX, HY http://en.volupedia.org/wiki/Radiculopathy 神经根病 10037779 radiculopathy AE OAE:0004717 This is an AE which a condition affecting the nerves of the peripheral sciatic nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neuropathy_(disambiguation) 坐骨神经神经病 10048950 sciatic nerve neuropathy AE OAE:0004718 This is an AE which is a large nerve in humans and other vertebrate animals which is the largest branch of the sacral plexus and runs alongside the hip joint and down the lower limb and it maybe palsy. QY, JX, HY http://en.volupedia.org/wiki/Sciatic_nerve 坐骨神经麻痹 10039672 sciatic nerve palsy AE OAE:0004719 This is an AE which has been traditionally considered presenting with symptoms reflecting the length-dependent impairment of unmyelinated C and thinly myelinated A@ fibres, most commonly reported as burning feet. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28665811/ 小纤维神经病 10073928 small fibre neuropathy AE OAE:0004720 This is an AE which is a rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system. QY, JX, HY http://en.volupedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome#Clinical_subtypes 亚急性炎性脱髓鞘性多发性神经病 10081726 subacute inflammatory demyelinating polyneuropathy AE OAE:0004721 This is an AE which refers to damage to sympathetic nerve beyond the capability to repair. QY, JX, HY http://en.volupedia.org/wiki/Destruction 交感神经破坏 10042740 sympathetic nerve destruction AE OAE:0004722 This is an AE which is one of two divisions of the autonomic nervous system, along with the parasympathetic nervous system. QY, JX, HY http://en.volupedia.org/wiki/Sympathetic_nervous_system#Sympathicotonia 交感神经症 10051691 sympathicotonia AE OAE:0004723 This is an AE which includes those caused by industrial toxins (organic solvents and organophosphates), heavy metals (arsenic, thallium, and lead), drugs and alcohol. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21897232/ 中毒性神经病 10067722 toxic neuropathy AE OAE:0004724 This is an AE which is a condition typified by a weakness of voluntary movement, or by partial loss of voluntary movement or by impaired movement caused by trigeminal nerve. QY, JX, HY http://en.volupedia.org/wiki/Paresis 三叉神经麻痹 10068008 trigeminal nerve paresis AE OAE:0004725 This is an AE which refers to various types of paralysis, often accompanied by weakness and the loss of feeling and uncontrolled body movements such as shaking and occurs on trigeminal. QY, JX, HY http://en.volupedia.org/wiki/Palsy 三叉神经麻痹 10049788 trigeminal palsy AE OAE:0004726 This is an AE which takes three clinical forms: meningitis (TBM), intracranial tuberculoma, and spinal arachnoiditis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28281443/ 中枢神经系统结核 10061391 tuberculosis of central nervous system AE OAE:0004727 This is an AE which result in both sensory and motor deficits within the hand. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25442770/ 尺神经损伤 10045378 ulnar nerve injury AE OAE:0004728 This is an AE which is a chronic clinical condition characterized by a delayed onset ulnar neuropathy after an injury to the elbow. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30939566/ 尺神经麻痹 10059790 ulnar nerve palsy AE OAE:0004729 This is an AE which is inflammation of a ulnar nerve or the general inflammation of the peripheral ulnar nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neuritis 尺神经炎 10045380 ulnar neuritis AE OAE:0004730 This is an AE which Is an injury or abnormality that occurs in the neural pathway above the anterior horn cell of the spinal cord or motor nuclei of the cranial nerves. QY, JX, HY http://en.volupedia.org/wiki/Upper_motor_neuron_lesion 上运动神经元损伤 10046298 upper motor neurone lesion AE OAE:0004731 This is an AE which is the tenth cranial nerve or CN X, and interfaces with the parasympathetic control of the heart, lungs, and digestive tract and its function gets disorder. QY, JX, HY http://en.volupedia.org/wiki/Vagus_nerve 迷走神经紊乱 10061403 vagus nerve disorder AE OAE:0004732 This is an AE which is damage to the viiith nerve caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 第八神经损伤 10047409 viiith nerve injury AE OAE:0004733 This is an AE which is any damage or abnormal change in the tissue of viiith nerve , usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 第八神经病变 10062177 viiith nerve lesion AE OAE:0004734 This is an AE which is a loss of motor function in one or more muscles occured viith nerve . QY, JX, HY http://en.volupedia.org/wiki/Paralysis 颅神经麻痹 10050040 viith nerve paralysis AE OAE:0004735 This is an AE which refers to a functional abnormality or disturbance on VIIth nerve. QY, JX, HY http://en.volupedia.org/wiki/Disorder 颅神经紊乱 10053646 vith nerve disorder AE OAE:0004736 This is an AE which is a loss of motor function in one or more muscles occured vith nerve . QY, JX, HY http://en.volupedia.org/wiki/Paralysis 颅神经麻痹 10071044 vith nerve paresis AE OAE:0004737 This is an AE which is a nerve responsible for sensation in the face and motor functions which get injury. QY, JX, HY http://en.volupedia.org/wiki/Trigeminal_nerve 第五神经损伤 10047723 vth nerve injury AE OAE:0004738 This is an AE which is an injury to the spinal accessory nerve which results in diminished or absent function of the sternocleidomastoid muscle and upper portion of the trapezius muscle. QY, JX, HY http://en.volupedia.org/wiki/Accessory_nerve_disorder 副神经障碍 10060929 accessory nerve disorder AE OAE:0004739 This is an AE which is a benign tumor that develops on the vestibulocochlear nerve that passes from the inner ear to the brain. QY, JX, HY http://en.volupedia.org/wiki/Vestibular_schwannoma 听神经瘤 10000523 acoustic neuroma AE OAE:0004740 This is an AE which is a variant of Guillain–Barré syndrome. It is characterized by acute paralysis and loss of reflexes without sensory loss. QY, JX, HY http://en.volupedia.org/wiki/Acute_motor_axonal_neuropathy 急性运动轴突神经病 10076658 acute motor axonal neuropathy AE OAE:0004741 This is an AE which is a variant of Guillain–Barré syndrome. It is characterized by acute paralysis and loss of reflexes without sensory loss. QY, JX, HY http://en.volupedia.org/wiki/Acute_motor_axonal_neuropathy 急性运动感觉轴突神经病 10076657 acute motor-sensory axonal neuropathy AE OAE:0004742 This is an AE which is acute damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain. QY, JX, HY http://en.volupedia.org/wiki/Polyneuropathy 急性多神经病 10066699 acute polyneuropathy AE OAE:0004743 This is an AE which is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Angioedema 血管神经性水肿 10002473 angioneurotic edema AE OAE:0004744 This is an AE which is an eating disorder characterized by low weight, food restriction, body image disturbance, fear of gaining weight, and an overpowering desire to be thin. QY, JX, HY http://en.volupedia.org/wiki/Anorexia_nervosa 神经性厌食症 10002649 anorexia nervosa AE OAE:0004745 This is an AE which sometimes called autoimmune neuritis, may be a forme fruste of systemic lupus erythematosus (SLE) associated neuropathy. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_optic_neuropathy 自身免疫性神经病变 10070439 autoimmune neuropathy AE OAE:0004746 This is an AE which is a single autonomic seizure lasting between 2+ to 5+ minutes or two or more seizures within a five-minute period without the person returning to normal between them. QY, JX, HY http://en.volupedia.org/wiki/Status_epilepticus 自主神经发作 10049612 autonomic seizure AE OAE:0004747 This is an AE which is a nerve of the human body, that originates from the brachial plexus (upper trunk, posterior division, posterior cord) at the level of the axilla (armpit) and carries nerve fibers from C5 and C6 which it maybe get injury. QY, JX, HY http://en.volupedia.org/wiki/Axillary_nerve 腋神经损伤 10003879 axillary nerve injury AE OAE:0004748 This is an AE which is damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the axonal and demyelinating body, featuring weakness, numbness, and burning pain. QY, JX, HY http://en.volupedia.org/wiki/Polyneuropathy 轴突和脱髓鞘性多发性神经病 10084153 axonal and demyelinating polyneuropathy AE OAE:0004749 This is an AE which is a rare, autosomal recessive[1] neurological disorder that causes disorganization of neurofilaments. QY, JX, HY http://en.volupedia.org/wiki/Giant_axonal_neuropathy 轴突神经病变 10003882 axonal neuropathy AE OAE:0004750 This is an AE which is a collection of pus that has built up within the tissue of the central nervous system caused by bacterial. QY, JX, HY http://en.volupedia.org/wiki/Abscess 中枢神经系统细菌性脓肿 10004015 bacterial abscess central nervous system AE OAE:0004751 This is an AE which is a group of physical problems that occur when the group of nuclei in the brain known as the basal ganglia fail to properly suppress unwanted movements or to properly prime upper motor neuron circuits to initiate motor function and a type of symptom is haematoma. QY, JX, HY http://en.volupedia.org/wiki/Basal_ganglia_disease 基底神经节血肿 10077031 basal ganglia hematoma AE OAE:0004752 This is an AE which is a group of physical problems that occur when the group of nuclei in the brain known as the basal ganglia fail to properly suppress unwanted movements or to properly prime upper motor neuron circuits to initiate motor function and a type of symptom is stroke. QY, JX, HY http://en.volupedia.org/wiki/Basal_ganglia_disease 基底神经节中风 10071043 basal ganglia stroke AE OAE:0004753 This is an AE which is a group of subcortical nuclei, of varied origin, in the brains of vertebrates and it is begin degeneration. QY, JX, HY http://en.volupedia.org/wiki/Basal_ganglia 基底神经节变性 10004153 basal ganglion degeneration AE OAE:0004754 This is an AE which is an outmoded term for a condition now designated as a form of conversion disorder. QY, JX, HY http://en.volupedia.org/wiki/Hysterical_Blindness 神经性失明 10005179 blindness hysterical AE OAE:0004755 This is an AE which is a cancerous glioma tumor in the brainstem. QY, JX, HY http://en.volupedia.org/wiki/Brainstem_glioma 脑干神经胶质瘤 10006143 brain stem glioma AE OAE:0004756 This is an AE which is an eating disorder characterized by binge eating followed by purging; and excessive concern with body shape and weight. QY, JX, HY http://en.volupedia.org/wiki/Bulimia_nervosa 神经性暴食症 10006550 bulimia nervosa AE OAE:0004757 This is an AE which is a psychiatric syndrome which presents a set of symptoms similar to those of heart disease. QY, JX, HY http://en.volupedia.org/wiki/Da_Costa%27s_syndrome 心脏神经综合症 10007592 cardiac neurosis AE OAE:0004758 This is an AE which is a collection of pus that has built up within the tissue of the central nervous system. QY, JX, HY http://en.volupedia.org/wiki/Abscess 中枢神经系统脓肿 10061044 central nervous system abscess AE OAE:0004759 This is an AE which is the part of the nervous system consisting primarily of the brain and spinal cord which is got injury. QY, JX, HY http://en.volupedia.org/wiki/Central_nervous_system 中枢神经系统损伤 10081266 central nervous system injury AE OAE:0004760 This is an AE which is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells and occurs on central nervous system. QY, JX, HY http://en.volupedia.org/wiki/Leukemia 中枢神经系统白血病 10066231 central nervous system leukaemia AE OAE:0004761 This is an AE which is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the central nervous system body. QY, JX, HY http://en.volupedia.org/wiki/Lupus 中枢神经系统狼疮 10076328 central nervous system lupus AE OAE:0004762 This is an AE which is the part of the nervous system consisting primarily of the brain and spinal cord and it has mass. QY, JX, HY http://en.volupedia.org/wiki/Central_nervous_system 中枢神经系统肿块 10054937 central nervous system mass AE OAE:0004763 This is an AE which is a tumor affecting the cental nervous system. QY, JX, HY http://en.volupedia.org/wiki/Nervous_system_neoplasm 中枢神经系统肿瘤 10007958 central nervous system neoplasm AE OAE:0004764 This is an AE which is group of disorders that destroy blood vessels by inflammation and occurs on central nervous system. QY, JX, HY http://en.volupedia.org/wiki/Vasculitis 中枢神经系统刺激 10061444 central nervous system stimulation AE OAE:0004765 This is an AE which refers to virus infections usually begin in the peripheral tissues, and can invade the mammalian system by spreading into the peripheral nervous system and more rarely the CNS. QY, JX, HY http://en.volupedia.org/wiki/Central_nervous_system_viral_disease 中枢神经系统血管炎 10081778 central nervous system vasculitis AE OAE:0004766 This is an AE which is caused by viruses that attack the CNS. QY, JX, HY http://en.volupedia.org/wiki/Central_nervous_system_viral_disease 中枢神经系统病毒感染 10061037 central nervous system viral infection AE OAE:0004767 This is an AE which is any disorder of the nervous system and occurs on congenital time. QY, JX, HY http://en.volupedia.org/wiki/Neurological_disorder 先天性神经障碍 10062345 congenital neurological disorder AE OAE:0004768 This is an AE which is an impaired functioning of one of the twelve cranial nerves. QY, JX, HY http://en.volupedia.org/wiki/Cranial_nerve_disease 颅神经疾病 10061093 cranial nerve disorder AE OAE:0004769 This is an AE which are the nerves that emerge directly from the brain (including the brainstem) and get injury. QY, JX, HY http://en.volupedia.org/wiki/Cranial_nerves 颅神经损伤 10061094 cranial nerve injury AE OAE:0004770 This is an AE which is a loss of motor function in one or more muscles and occurs on cranial nerve. QY, JX, HY http://en.volupedia.org/wiki/Paralysis 颅神经麻痹 10061908 cranial nerve paralysis AE OAE:0004771 This is an AE which is a paralysis of the arm caused by injury to the upper group of the arm's main nerves, specifically the severing of the upper trunk C5–C6 nerves. QY, JX, HY http://en.volupedia.org/wiki/Erb%27s_palsy ERB麻痹 10015113 erb's palsy AE OAE:0004772 This is an AE which is pain in the distribution of a nerve or nerves, as in intercostal neuralgia, trigeminal neuralgia, and glossopharyngeal neuralgia. QY, JX, HY http://en.volupedia.org/wiki/Neuralgia 面部神经痛 10061594 facial neuralgia AE OAE:0004773 This is an AE which is a nerve in the thigh that supplies skin on the upper thigh and inner leg, and the muscles that extend the knee injury. QY, JX, HY http://en.volupedia.org/wiki/Femoral_nerve 股神经损伤 10016451 femoral nerve injury AE OAE:0004774 This is an AE which refers to various types of paralysis,often accompanied by weakness and the loss of feeling and uncontrolled body movements such as shaking and occurs on femoral nerve. QY, JX, HY http://en.volupedia.org/wiki/Palsy 股神经麻痹 10049789 femoral nerve palsy AE OAE:0004775 This is an AE which is a variant of neuroblastoma that is surrounded by ganglion cells. QY, JX, HY http://en.volupedia.org/wiki/Ganglioneuroblastoma 节细胞神经母细胞瘤 10017708 ganglioneuroblastoma AE OAE:0004776 This is an AE which is a rare and benign tumor of the autonomic nerve fibers arising from neural crest sympathogonia, which are completely undifferentiated cells of the sympathetic nervous system. QY, JX, HY http://en.volupedia.org/wiki/Ganglioneuroma 神经节细胞瘤 10017709 ganglioneuroma AE OAE:0004777 This is an AE which is a type of tumor that starts in the glial cells of the brain or the spine. QY, JX, HY http://en.volupedia.org/wiki/Glioma 神经胶质瘤 10018338 glioma AE OAE:0004778 This is an AE which is a nonspecific reactive change of glial cells in response to damage to the central nervous system (CNS). QY, JX, HY http://en.volupedia.org/wiki/Gliosis 神经胶质增生症 10018341 gliosis AE OAE:0004779 This is an AE which is a loss of motor function in one or more muscles and occurs on glossopharyngeal nerve. QY, JX, HY http://en.volupedia.org/wiki/Paralysis 舌咽神经瘫痪 10051270 glossopharyngeal nerve paralysis AE OAE:0004780 This is an AE which is pain in the distribution of a nerve or nerves, as in intercostal neuralgia, trigeminal neuralgia, and glossopharyngeal neuralgia. QY, JX, HY http://en.volupedia.org/wiki/Neuralgia#Glossopharyngeal 舌咽神经神经痛 10018391 glossopharyngeal neuralgia AE OAE:0004781 This is an AE which is a viral disease characterized by a painful skin rash with blisters in a localized area infection neurological. QY, JX, HY http://en.volupedia.org/wiki/Shingles 神经带状疱疹感染 10061208 herpes zoster infection neurological AE OAE:0004782 This is an AE which is frequently involved in head and neck afflictions as a result of its long course. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2698526/ 舌下神经麻痹 10069450 hypoglossal nerve paralysis AE OAE:0004783 This is an AE which refers to IIIrd nerve functional abnormality or disturbance. QY, JX, HY http://en.volupedia.org/wiki/Disorder iiird神经障碍 10053644 iiird nerve disorder AE OAE:0004784 This is an AE which is damage to the body caused by an external force and occurs on iiird nerve. QY, JX, HY http://en.volupedia.org/wiki/Injury iiird神经损伤 10021281 iiird nerve injury AE OAE:0004785 This is an AE which is a loss of motor function in one or more muscles and occurs on IIIrd nerve. QY, JX, HY http://en.volupedia.org/wiki/Paralysis iiird神经麻痹 10021283 iiird nerve paralysis AE OAE:0004786 This is an AE which is a condition typified by a weakness of voluntary movement, or by partial loss of voluntary movement or by impaired movement and occurs on IIIrd nerve. QY, JX, HY http://en.volupedia.org/wiki/Paresis iiird神经麻痹性痴呆 10054202 iiird nerve paresis AE OAE:0004787 This is an AE which is association with other neurological deficits. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16705532/ ivth神经麻痹 10023110 ivth nerve paralysis AE OAE:0004788 This is an AE which is a lesion which affects nerve fibers traveling from the lower motor neuron(s) in the anterior horn/anterior grey column of the spinal cord, or in the motor nuclei of the cranial nerves, to the relevant muscle(s). QY, JX, HY http://en.volupedia.org/wiki/Lower_motor_neuron_lesion 下运动神经元损伤 10024962 lower motor neurone lesion AE OAE:0004789 This is an AE which is pain going down the leg from the lower back. QY, JX, HY http://en.volupedia.org/wiki/Sciatica 腰椎神经根病 10050219 lumbar radiculopathy AE OAE:0004790 This is an AE which is a disorder of the network of nerves in the lumbosacral plexus. QY, JX, HY http://en.volupedia.org/wiki/Plexopathy 腰荐神经丛病变 10075478 lumbosacral plexopathy AE OAE:0004791 This is an AE which refers injuries to the lumbosacral plexus are predominantly witnessed as bone injuries. QY, JX, HY http://en.volupedia.org/wiki/Lumbosacral_plexus 腰骶神经丛损伤 10025015 lumbosacral plexus injury AE OAE:0004792 This is an AE which depends on what portion of the plexus gets involved in the disease process. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25299286/ 腰骶神经丛病变 10025016 lumbosacral plexus lesion AE OAE:0004793 This is an AE which is pain going down the leg from the lower back. QY, JX, HY http://en.volupedia.org/wiki/Sciatica 腰骶神经根病 10076578 lumbosacral radiculopathy AE OAE:0004794 This is an AE which is a nerve in humans and other animals in the upper limb and is injuried of median nerve at different levels causes different syndromes with varying motor and sensory deficits. QY, JX, HY http://en.volupedia.org/wiki/Median_nerve#Injury 正中神经损伤 10027067 median nerve injury AE OAE:0004795 This is an AE which is a common type of primary brain cancer in children. QY, JX, HY http://en.volupedia.org/wiki/Medulloblastoma 成神经管细胞瘤 10027107 medulloblastoma AE OAE:0004796 This is an AE which is a neurologic symptoms of neuroborreliosis. QY, JX, HY http://en.volupedia.org/wiki/Neuroborreliosis 脑膜神经根炎 10050169 meningoradiculitis AE OAE:0004797 This is an AE which is a general term describing disease affecting the peripheral nerves, meaning nerves beyond the brain and spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Peripheral_neuropathy 单神经病多路复用 10027918 mononeuropathy multiplex AE OAE:0004798 This is an AE which is a benign neuroma of an intermetatarsal plantar nerve, most commonly of the second and third intermetatarsal spaces (between the second/third and third/fourth metatarsal heads; the first is of the big toe), which results in the entrapment of the affected nerve. QY, JX, HY http://en.volupedia.org/wiki/Morton%27s_neuroma 神经瘤 10049691 morton's neuroma AE OAE:0004799 This is an AE which is the inflammation of the ventricles in the cns brain. QY, JX, HY http://en.volupedia.org/wiki/Ventriculitis 中枢神经系统脑室炎 10009719 cns ventriculitis AE OAE:0004800 This is an AE which is to act in a way that is likely to elicit attention, usually to elicit validation from others. QY, JX, HY http://en.volupedia.org/wiki/Attention_seeking 寻求注意行为 10003739 attention-seeking behaviour AE OAE:0004801 This is an AE which refers to a set of brief unconscious behaviors. QY, JX, HY http://en.volupedia.org/wiki/Automatism_(medicine) 无意识行为 10003830 automatism AE OAE:0004802 This is an AE which repetitive unconscious gestures, such as lip smacking, in certain types of epilepsy. QY, JX, HY http://en.volupedia.org/wiki/Automatism 无意识癫痫行为 10003831 automatism epileptic AE OAE:0004803 This is an AE which is romantic attraction, sexual attraction or sexual behavior between persons of the opposite sex or gender. QY, JX, HY http://en.volupedia.org/wiki/Heterosexuality 异性恋 10061108 heterosexuality AE OAE:0004804 This is an AE which is the description of the activity that will increase the probability that a person engaging in sexual activity with another person infected with a sexually transmitted infection will be infected or become pregnant, or make a partner pregnant. QY, JX, HY http://en.volupedia.org/wiki/Risky_sexual_behavior 高危性行为 10020082 high risk sexual behaviour AE OAE:0004805 This is an AE which is a tendency to act on a whim, displaying behavior characterized by little or no forethought, reflection, or consideration of the consequences. QY, JX, HY http://en.volupedia.org/wiki/Impulsivity 冲动行为 10021567 impulsive behaviour AE OAE:0004806 This is an AE which is a sleep disorder in which people act out their dreams. QY, JX, HY http://en.volupedia.org/wiki/Rapid_eye_movement_sleep_behavior_disorder 快速眼动睡眠行为障碍 10077299 rapid eye movement sleep behaviour disorder AE OAE:0004807 This is an AE which significantly interferes with social engagement and characterises various psychopathologies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32633192/ 社交回避行为 10041243 social avoidant behaviour AE OAE:0004808 This is an AE which is a disorder of the myelin sheath, which is a primary actor in the central nervous system and it also has herpes zoster. QY, JX, HY http://en.volupedia.org/wiki/Meningococcal_myelitis 带状疱疹脊髓脊膜炎 10074251 herpes zoster meningomyelitis AE OAE:0004809 This is an AE which is a generic term referring to a disorder in which a cyst or cavity forms within the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Syringomyelia 脊髓积水 10020523 hydromyelia AE OAE:0004810 This is an AE which is an infectious disease occured post vaccine transmitted by fecal-oral contamination with lymphatic replication . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32644370/ 脊髓灰质炎疫苗后 10057226 poliomyelitis post vaccine AE OAE:0004811 This is an AE which is a group of latent symptoms of poliomyelitis (polio), occurring at about a 25–40% rate (latest data greater than 80%). QY, JX, HY http://en.volupedia.org/wiki/Post-polio_syndrome 脊髓灰质炎后综合征 10036239 post polio syndrome AE OAE:0004812 This is an AE which is a common disease that most primary care doctors encounter . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29605415/ 脊髓疾病 10061367 spinal cord disorder AE OAE:0004813 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 脊髓出血 10048992 spinal cord hemorrhage AE OAE:0004814 This is an AE which is rarely caused by vertebral artery dissection (VAD), which is an important cause of posterior circulation stroke in young and middle-aged patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31830940/ 脊髓梗塞 10058571 spinal cord infarction AE OAE:0004815 This is an AE which is spinal cord tissue death (necrosis) due to inadequate blood supply to the affected area. QY, JX, HY http://en.volupedia.org/wiki/Infarction 脊髓感染 10049654 spinal cord infection AE OAE:0004816 This is an AE which is damage to the spinal cord that causes temporary or permanent changes in its function. QY, JX, HY http://en.volupedia.org/wiki/Spinal_cord_injury?wprov=srpw1_0 脊髓损伤 10041552 spinal cord injury AE OAE:0004817 This is an AE which is damage to the cervical spinal cord that causes temporary or permanent changes in its function. QY, JX, HY http://en.volupedia.org/wiki/Spinal_cord_injury?wprov=srpw1_0 脊髓损伤颈椎 10041553 spinal cord injury cervical AE OAE:0004818 This is an AE which is damage to the lumbar spinal cord that causes temporary or permanent changes in its function. QY, JX, HY http://en.volupedia.org/wiki/Spinal_cord_injury?wprov=srpw1_0 脊髓损伤腰椎 10041555 spinal cord injury lumbar AE OAE:0004819 This is an AE which is a benign tumor made of fat tissue on the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Lipoma 脊髓脂肪瘤 10064898 spinal cord lipoma AE OAE:0004820 This is an AE which is the build-up of fluid in the spinal cord tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 脊髓水肿 10063036 spinal cord edema AE OAE:0004821 This is an AE which is a loss of motor function in one or more spinal cord muscles. QY, JX, HY http://en.volupedia.org/wiki/Paralysis 脊髓麻痹 10057268 spinal cord paralysis AE OAE:0004822 This is an AE which is a non-surgical procedure intended to relieve pressure on the spinal cord or on one or more compressed nerve roots passing through or exiting the spinal column. QY, JX, HY http://en.volupedia.org/wiki/Spinal_decompression 脊柱减压 10041563 spinal decompression AE OAE:0004823 This is an AE which refers to a condition impairing the backbone. QY, JX, HY http://en.volupedia.org/wiki/Spinal_disease 脊柱畸形 10058907 spinal deformity AE OAE:0004824 This is an AE which refers to a condition impairing the backbone. QY, JX, HY http://en.volupedia.org/wiki/Spinal_disease 脊椎病 10061368 spinal disorder AE OAE:0004825 This is an AE which is a rare condition that usually presents with acute, severe pain at the location of the hemorrhage, with radiation to the extremities. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20675642/ 脊髓硬膜外血肿 10050162 spinal epidural hematoma AE OAE:0004827 This is an AE which is a rare neuromuscular disorder that results in the loss of motor neurons and progressive muscle wasting. QY, JX, HY http://en.volupedia.org/wiki/Spinal_muscular_atrophy 脊髓性肌萎缩 10041582 spinal muscular atrophy AE OAE:0004829 This is an AE which was first explored by Whytt in 1750 as a loss of sensation accompanied by motor paralysis with initial loss but gradual recovery of reflexes, following a spinal cord injury (SCI) – most often a complete transection. QY, JX, HY http://en.volupedia.org/wiki/Spinal_shock 脊髓休克 10049679 spinal shock AE OAE:0004830 This is an AE which is a generic term referring to a disorder in which a cyst or cavity forms within the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Syringomyelia 脊髓空洞症 10042928 syringomyelia AE OAE:0004831 This is an AE which is inflammation caused by the viral of the spinal cord which can disrupt the normal responses from the brain to the rest of the body, and from the rest of the body to the brain. Inflammation in the spinal cord, can cause the myelin and axon to be damaged resulting in symptoms such as paralysis and sensory loss. QY, JX, HY http://en.volupedia.org/wiki/Myelitis 病毒性脊髓炎 10071763 viral myelitis AE OAE:0004832 This is an AE which is a serious condition of the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Acute_flaccid_myelitis 急性弛缓性脊髓炎 10082097 acute flaccid myelitis AE OAE:0004833 This is an AE which is a neurodegenerative disease[a] that results in the progressive loss of motor neurons that control voluntary muscles. QY, JX, HY http://en.volupedia.org/wiki/Amyotrophic_lateral_sclerosis 肌萎缩性脊髓侧索硬化症 10002026 amyotrophic lateral sclerosis AE OAE:0004834 This is an AE which is a mass of cells (tumor) that lacks the ability to either invade neighboring tissue or metastasize (spread throughout the body) such as benign tumor of spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Benign_tumor 脊髓良性肿瘤 10004406 benign neoplasm of spinal cord AE OAE:0004835 This is an AE which is caused by damage to one half of the spinal cord, i.e. hemisection of the spinal cord resulting in paralysis and loss of proprioception on the same (or ipsilateral) side as the injury or lesion, and loss of pain and temperature sensation on the opposite (or contralateral) side as the lesion. QY, JX, HY http://en.volupedia.org/wiki/Brown-S%C3%A9quard_syndrome 脊髓半侧横断综合征 10006491 brown-sequard syndrome AE OAE:0004836 This is an AE which is the most common form of cervical spinal cord injury. QY, JX, HY http://en.volupedia.org/wiki/Central_cord_syndrome 中枢脊髓综合征 10054839 central cord syndrome AE OAE:0004837 This is an AE which describes any neurologic deficit related to the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Myelopathy 颈锥脊髓病 10008289 cervical myelopathy AE OAE:0004838 This is an AE which is a term used to describe a constellation of early-appearing social communication deficits and repetitive sensory-motor behaviours associated with a strong genetic component as well as other causes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30078460/ 自闭症谱系障碍 10063844 autism spectrum disorder AE OAE:0004839 This is an AE which is a condition which persists for more than 6 weeks in duration and occurs in the absence of an identifiable provoking factor. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30984191/ 自发慢性荨麻疹 10072757 chronic spontaneous urticaria AE OAE:0004840 This is an AE which is the experience in which an individual perceives the surrounding environment from a different perspective, from a position outside of their own body. QY, JX, HY http://en.volupedia.org/wiki/Autoscopy 自窥症；自见幻觉 10074080 autoscopy AE OAE:0004841 This is an AE which refers loss of the ability to read due to cerebral disorder. QY, JX, HY http://en.volupedia.org/wiki/Alexia 失读症 10001663 alexia AE OAE:0004842 This is an AE which is the inability to process sensory information. QY, JX, HY http://en.volupedia.org/wiki/Agnosia 失认症 10048663 agnosia AE OAE:0004843 This is an AE which is an acquired neurological disorder causing a loss in the ability to communicate through writing, either due to some form of motor dysfunction or an inability to spell. QY, JX, HY http://en.volupedia.org/wiki/Agraphia 失写症 10001508 agraphia AE OAE:0004844 This is an AE which is a deficit in memory caused by brain damage or disease, but it can also be caused temporarily by the use of various sedatives and hypnotic drugs. QY, JX, HY http://en.volupedia.org/wiki/Amnesia 失忆症 10061423 amnestic disorder AE OAE:0004845 This is an AE which is a mood disorder characterized by periods of depression and periods of abnormally-elevated mood that last from days to weeks each. QY, JX, HY http://en.volupedia.org/wiki/Bipolar_disorder 双相情感障碍 10057667 bipolar disorder AE OAE:0004846 This is an AE which is a bipolar spectrum disorder characterized by at least one episode of hypomania and at least one episode of major depression. QY, JX, HY http://en.volupedia.org/wiki/Bipolar_II_disorder 双相情感障碍ii型 10004940 bipolar ii disorder AE OAE:0004847 This is an AE which is a type of bipolar spectrum disorder characterized by the occurrence of at least one manic episode, with or without mixed or psychotic features. QY, JX, HY http://en.volupedia.org/wiki/Bipolar_I_disorder 双相情感障碍i型 10004939 bipolar i disorder AE OAE:0004848 This is an AE which is a condition of abnormally deep sleep or a stupor from which it is difficult to rouse. QY, JX, HY http://en.volupedia.org/wiki/Sopor_(sleep) 迷睡 10058709 sopor AE OAE:0004849 This is an AE which is the cumulative effect of not getting enough sleep. QY, JX, HY http://en.volupedia.org/wiki/Sleep_debt 睡眠不足 10080881 sleep deficit AE OAE:0004850 This is an AE which is a rare form of circadian rhythm sleep disorder. QY, JX, HY http://en.volupedia.org/wiki/Irregular_sleep%E2%80%93wake_rhythm 睡眠节律紊乱 10080301 irregular sleep wake rhythm disorder AE OAE:0004851 This is an AE which is a state, during waking up or falling asleep, in which a person is aware but unable to move or speak. QY, JX, HY http://en.volupedia.org/wiki/Sleep_paralysis 睡眠麻痹 10041002 sleep paralysis AE OAE:0004852 This is an AE which is a broad classification of sleeping disorders involving difficulty getting to sleep, remaining asleep, or of excessive sleepiness. QY, JX, HY http://en.volupedia.org/wiki/Dyssomnia 睡眠障碍 10061827 dyssomnia AE OAE:0004853 This is an AE which is characterized by reduced exercise capacity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31584302/ 慢性左心室衰竭 10063083 chronic left ventricular failure AE OAE:0004854 This is an AE which refers a chronic condition due to mental or physical impairments arising before adulthood. QY, JX, HY http://en.volupedia.org/wiki/Mental_disability 精神残疾 10027353 mental disability AE OAE:0004855 This is an AE which is a mental disorder characterized by continuous or relapsing episodes of psychosis. QY, JX, HY http://en.volupedia.org/wiki/Schizophrenia 精神分裂症 10039626 schizophrenia AE OAE:0004856 This is an AE which is a mental disorder diagnosed when symptoms of schizophrenia are present for a significant portion of time (at least a month), but signs of disturbance are not present for the full six months required for the diagnosis of schizophrenia. QY, JX, HY http://en.volupedia.org/wiki/Schizophreniform_disorder 精神分裂症 10039647 schizophreniform disorder AE OAE:0004857 This is an AE which is classified as “partial awakenings in which the state of consciousness remains impaired for several minutes without any accompanying major behavioural disorders or severe autonomic responses”. QY, JX, HY http://en.volupedia.org/wiki/Confusional_arousals 精神混乱的冲动 10067494 confusional arousal AE OAE:0004858 This is an AE which is an organically caused decline from a previous baseline mental functioning, that develops over a short period of time, typically hours to days. QY, JX, HY http://en.volupedia.org/wiki/Delirium 精神混乱的状态 10010305 confusional state AE OAE:0004859 This is an AE which is a behavioral or mental pattern that causes significant distress or impairment of personal functioning. QY, JX, HY http://en.volupedia.org/wiki/Mental_disorder 精神疾病 10061284 mental disorder AE OAE:0004860 This is an AE which is a temporary inability to maintain optimal cognitive performance. QY, JX, HY http://en.volupedia.org/wiki/Fatigue#Mental 精神疲劳 10076757 mental fatigue AE OAE:0004861 This is an AE which is characterized by backward disequilibrium in a sitting and standing position, reactional hypertonia, an alteration of postural reactions, gait modifications, and fear of falling. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15152732/ 精神运动不适应综合征 10080662 psychomotor disadaptation syndrome AE OAE:0004862 This is an AE which is a chronic disorder of the nervous system characterized by recurrent, unprovoked focal seizures that originate in the temporal lobe of the brain and last about one or two minutes. QY, JX, HY http://en.volupedia.org/wiki/Temporal_lobe_epilepsy 精神运动性癫痫发作 10037214 psychomotor seizures AE OAE:0004863 This is an AE which is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning. QY, JX, HY http://en.volupedia.org/wiki/Intellectual_disability 精神障碍 10027374 mental impairment AE OAE:0004864 This is an AE which is an abnormal condition of the mind that results in difficulties determining what is real and what is not real. QY, JX, HY http://en.volupedia.org/wiki/Psychosis 精神症状 10079254 psychotic symptom AE OAE:0004865 This is an AE which is the action of violently shaking one's head in rhythm with music. QY, JX, HY http://en.volupedia.org/wiki/Headbanging 头部撞击 10019191 head banging AE OAE:0004866 This is an Ae which is a cutaneous fungal infection (dermatophytosis) of the scalp. QY, JX, HY http://en.volupedia.org/wiki/Tinea_capitis 头癣 10043866 tinea capitis AE OAE:0004867 This is an AE which may be a clinical manifestation of autonomic nervous system dysregulation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/12172243/ 头晕劳累型 10013576 dizziness exertional AE OAE:0004868 This is an AE which is characterized by having difficulty returning to sleep after waking up during the night or very early in the morning. QY, JX, HY http://en.volupedia.org/wiki/Middle-of-the-night_insomnia 中期失眠症 10027590 middle insomnia AE OAE:0004869 This is an AE which is a state of tiredness, weariness, fatigue, or lack of energy. QY, JX, HY http://en.volupedia.org/wiki/Lethargy 呆滞 10041052 sluggishness AE OAE:0004870 This is an AE which is a rare neurodegenerative disorder characterized by autonomic dysfunction, tremors, slow movement, muscle rigidity, and postural instability (collectively known as parkinsonism) and ataxia. QY, JX, HY http://en.volupedia.org/wiki/Multiple_system_atrophy 多系统萎缩 10064060 multiple system atrophy AE OAE:0004871 This is an AE which encompasses several types of dementia involving the frontal and temporal lobes.[3] FTDs are broadly presented as behavioral or language disorders. QY, JX, HY http://en.volupedia.org/wiki/Frontotemporal_dementia 额颞叶痴呆 10068968 frontotemporal dementia AE OAE:0004872 This is an AE which is an anxiety disorder in which an individual experiences excessive anxiety regarding separation from home and/or from people to whom the individual has a strong emotional attachment (e.g., a parent, caregiver, significant other, or siblings). QY, JX, HY http://en.volupedia.org/wiki/Separation_anxiety_disorder 分离焦虑症 10040045 separation anxiety disorder AE OAE:0004873 This is an AE which is a neurological examination finding elicited by a reflex test which can help verify the presence or absence of issues arising from the corticospinal tract. QY, JX, HY http://en.volupedia.org/wiki/Hoffmann%27s_reflex 霍夫曼氏征 10058444 hoffmann's sign AE OAE:0004874 This is an AE which is a type of dementia characterized by changes in sleep, behavior, cognition, movement, and regulation of automatic bodily functions. QY, JX, HY http://en.volupedia.org/wiki/Dementia_with_Lewy_bodies 路易体痴呆 10067889 dementia with lewy bodies AE OAE:0004875 This is an AE which is a disorder of the central nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neuroborreliosis 螺旋体病 10052057 neuroborreliosis AE OAE:0004876 This is an AE which is a common neurodevelopmental disorder that begins in childhood or adolescence. QY, JX, HY http://en.volupedia.org/wiki/Tourette_syndrome 图雷特氏症 10044126 tourette's disorder AE OAE:0004877 QY, JX, HY 感觉神经节炎 10066196 sensory ganglionitis AE OAE:0004878 QY, JX, HY 血管病性神经病变 10079036 angiopathic neuropathy AE OAE:0004879 QY, JX, HY 脊柱扁平化 10077756 spinal flattening AE OAE:0004880 QY, JX, HY 睡眠期节律紊乱 10041003 sleep phase rhythm disturbance AE OAE:0004881 QY, JX, HY 精神运动技能受损 10049215 psychomotor skills impaired AE OAE:0004882 This is an AE which is a disease characterized by a weeks-long course of thunderclap headaches, sometimes focal neurologic signs, and occasionally seizures. QY, JX, HY http://en.volupedia.org/wiki/Reversible_cerebral_vasoconstriction_syndrome 大脑血管收缩 10059109 cerebral vasoconstriction AE OAE:0004883 This is an AE which is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease with bacteraemia. QY, JX, HY http://en.volupedia.org/wiki/Neisseria_meningitidis 脑膜炎球菌菌血症 10058858 meningococcal bacteremia AE OAE:0004884 This is an AE which is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease with carditis. QY, JX, HY http://en.volupedia.org/wiki/Neisseria_meningitidis 脑膜炎球菌性心炎 10027270 meningococcal carditis AE OAE:0004885 This is an AE which is a medical condition in which poor spinal blood flow to the brain causes cell death. QY, JX, HY http://en.volupedia.org/wiki/Stroke 脊柱中风 10082031 spinal stroke AE OAE:0004886 This is an AE which is a neurological condition in which the cerebellum is smaller than usual or not completely developed. QY, JX, HY http://en.volupedia.org/wiki/Cerebellar_hypoplasia_(non-human) 继发性小脑变性 10074943 secondary cerebellar degeneration AE OAE:0004887 This is an AE which is a perceptual disturbance experienced by some with epilepsy or migraine. QY, JX, HY http://en.volupedia.org/wiki/Aura_(symptom) 癫痫先兆 10015049 epileptic aura AE OAE:0004888 This is an AE which is a rare form of chronic, progressive brain inflammation caused by slow infection with certain defective strains of hypermutated measles virus. QY, JX, HY http://en.volupedia.org/wiki/Subacute_sclerosing_panencephalitis 全脑炎 10056332 panencephalitis AE OAE:0004889 This is an AE which is a relatively frequent occurrence in significant head trauma, and their detection is important, as even linear nondisplaced fractures can be associated with critical complications. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25086806/ 颅底骨折 10040960 skull fractured base AE OAE:0004890 This is an AE which is achieved in this model by injecting particles like blood clots (thrombembolic MCAO) or artificial spheres into the carotid artery of animals as an animal model of ischemic stroke. QY, JX, HY http://en.volupedia.org/wiki/Animal_model_of_ischemic_stroke#Embolic_middle_cerebral_artery_occlusion 脑动脉闭塞 10008089 cerebral artery occlusion AE OAE:0004891 This is an AE which is an abnormal narrowing in a cerebrovascular blood vessel or other tubular organ or structure such as foramina and canals. QY, JX, HY http://en.volupedia.org/wiki/Stenosis 脑血管狭窄 10061751 cerebrovascular stenosis AE OAE:0004892 This is an AE which is an acute inflammation of the protective membranes covering the brain and spinal cord caused by staphylococcal. QY, JX, HY http://en.volupedia.org/wiki/Meningitis 葡萄球菌脑膜炎 10027255 meningitis staphylococcal AE OAE:0004893 This is an AE which is an important and common complication of chimeric antigen receptor-T cell therapies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30387077/ 中毒性脑炎 10014607 encephalitis toxic AE OAE:0004894 This is an AE which is associated with infectious complications, whereas emerging treatments, including anakinra and tocilizumab, may also result in increased susceptibility to certain infections. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31021956/ 免疫介导性脑炎 10083074 immune-mediated encephalitis AE OAE:0004895 This is an AE which is characterized by macrocephaly and typical neuroimaging findings, is considered as a self-limiting condition and is therefore rarely treated in infants. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21647596/ 外部性脑积水 10076670 external hydrocephalus AE OAE:0004896 This is an AE which is defined as inflammation of the meninges, in almost all cases identified by an abnormal number of white blood cells in the cerebrospinal fluid and specific clinical signs/symptoms. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23958365/ 脑膜病 10061281 meningeal disorder AE OAE:0004897 This is an AE which is five main reasons for bacterial, viral, fungal, protozoal, and prionic. QY, JX, HY http://en.volupedia.org/wiki/List_of_infections_of_the_central_nervous_system 颅内感染 10082062 intracranial infection AE OAE:0004898 This is an AE which is inflammation with haemorrhagic of the brain. QY, JX, HY http://en.volupedia.org/wiki/Encephalitis 脑炎出血 10014589 encephalitis haemorrhagic AE OAE:0004899 This is an AE which is inflammation and allergy of the brain. QY, JX, HY http://en.volupedia.org/wiki/Encephalitis 脑炎过敏 10056387 encephalitis allergic AE OAE:0004900 This is an AE which is inflammation and infection of the brain. QY, JX, HY http://en.volupedia.org/wiki/Encephalitis 脑炎的感染 10058805 encephalitis infection AE OAE:0004901 This is an AE which is inflammation of the brain caused by meningococcal. QY, JX, HY http://en.volupedia.org/wiki/Encephalitis 脑膜炎球菌脑炎 10014597 encephalitis meningococcal AE OAE:0004902 This is an AE which is recognised as a central factor in the development of many neurological disorders, but much less is known about the role of the blood-brain barrier in psychiatric disorders. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28781208/ 血脑屏障缺陷 10057361 blood brain barrier defect AE OAE:0004903 This is an AE which is the effect of a intracranial growing mass that results in secondary pathological effects by pushing on or displacing surrounding tissue. QY, JX, HY http://en.volupedia.org/wiki/Mass_effect_(medicine) 颅内肿块 10077667 intracranial mass AE OAE:0004904 This is an AE which may refer to an abnormal growth that usually appears on a baby's neck or head. QY, JX, HY http://en.volupedia.org/wiki/Cystic_hygroma 脑水囊瘤 10052370 cerebral hygroma AE OAE:0004905 This is an AE which means any allergic disorder or disease of the brain, especially chronic degenerative conditions. QY, JX, HY http://en.volupedia.org/wiki/Encephalopathy 过敏性脑病 10014627 encephalopathy allergic AE OAE:0004906 This is an AE which presents with symptoms of nausea, vomiting, and dizziness and thus mimics benign conditions such as viral gastroenteritis or labyrinthitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25439292/ 栓塞性小脑梗死 10084072 embolic cerebellar infarction AE OAE:0004907 This is an AE which refers a protein encoded by the gene NODAL and responsible for left-right asymmetry. QY, JX, HY http://en.volupedia.org/wiki/Nodal 结性节律 10029470 nodal rhythm AE OAE:0004908 This is an AE which refers to head was lacking in comfort. QY, JX, HY http://en.volupedia.org/wiki/Comfort 头部不适 10019194 head discomfort AE OAE:0004909 This is an AE which which occurs a few weeks after recovery from influenza is thought to be an autoimmune process associated with demyelination and vasculopathy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9316161/ 流感性脑炎 10058094 encephalitis influenzal AE OAE:0004910 This is an AE which is the thickening, hardening, and loss of elasticity of the walls of arteries. QY, JX, HY http://en.volupedia.org/wiki/Arteriosclerosis 脑部动脉硬化 10065559 cerebral arterio sclerosis AE OAE:0004911 This is an AE whichis vasculitis (inflammation of the blood vessel wall) involving the brain and occasionally the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_vasculitis 脑部动脉炎 10008087 cerebral arteritis AE OAE:0004912 This is an AE which is an abnormal narrowing in a cerebral artery blood vessel or other tubular organ or structure such as foramina and canals. QY, JX, HY http://en.volupedia.org/wiki/Stenosis 脑部动脉狭窄 10063648 cerebral artery stenosis AE OAE:0004913 This is an AE which is a neurological sign consisting of lack of voluntary coordination of muscle movements that can include gait abnormality, speech changes, and abnormalities in eye movements. QY, JX, HY http://en.volupedia.org/wiki/Ataxia 脑性共济失调 10050389 cerebral ataxia AE OAE:0004914 This is an AE which is a common feature of many of the diseases that affect the brain. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_atrophy 脑部萎缩 10008096 cerebral atrophy AE OAE:0004915 This is an AE which is the accumulation of calcium salts in a cerebral body tissue. QY, JX, HY http://en.volupedia.org/wiki/Calcification 脑部钙化 10066296 cerebral calcification AE OAE:0004916 This is an AE which is defined as a general or specific failure of the circulation, either cardiac. QY, JX, HY http://en.volupedia.org/wiki/Circulatory_collapse 脑部循环衰竭 10008097 cerebral circulatory failure AE OAE:0004917 This is an AE which may refer to heart failure resulting in congestion in one or more organs. QY, JX, HY http://en.volupedia.org/wiki/Congestion 脑部堵塞 10076929 cerebral congestion AE OAE:0004918 This is an AE which is a cerebral closed sac, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 脑部囊肿 10061445 cerebral cyst AE OAE:0004919 This is an AE which is a medical condition caused by dissolved gases emerging from solution as bubbles inside the cerebral body tissues during decompression. QY, JX, HY http://en.volupedia.org/wiki/Decompression_sickness 大脑减压 10052940 cerebral decompression AE OAE:0004920 This is an AE which may refer to relating to the brain disease. QY, JX, HY http://en.volupedia.org/wiki/Cerebral 脑部疾病 10054938 cerebral disorder AE OAE:0004921 This is an AE which is a form of dysgenesis in adults that alters the size and shape of their cells that lead to abnormal development. QY, JX, HY http://en.volupedia.org/wiki/Dysgenesis_(embryology) 脑发育不全 10056467 cerebral dysgenesis AE OAE:0004922 This is an AE which is a localized bleeding outside of cerebral blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 脑部血肿 10053942 cerebral hematoma AE OAE:0004923 This is an AE which is a sudden bleeding into the tissues of the brain, into its ventricles, or into both. QY, JX, HY http://en.volupedia.org/wiki/Intracerebral_hemorrhage 脑出血 10008111 cerebral hemorrhage AE OAE:0004924 This is an AE which is a sudden bleeding into the tissues of the brain occured on foetal, into its ventricles, or into both. QY, JX, HY http://en.volupedia.org/wiki/Intracerebral_hemorrhage 脑出血胎儿 10050157 cerebral hemorrhage foetal AE OAE:0004925 This is an AE which is a form of hypoxia (reduced supply of oxygen), specifically involving the brain; when the brain is completely deprived of oxygen, it is called cerebral anoxia. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_hypoxia 脑灌注不足 10065384 cerebral hypoperfusion AE OAE:0004926 This is an AE which is mainly found in patients with Alzheimer's disease and lacunar infarction, and becomes one of the main reasons of death and disability in diabetic patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28822176/ 脑微血管病 10067466 cerebral microangiopathy AE OAE:0004927 This is an AE which is abnormal differences seen in magnetic resonance imaging of the brain of Alzheimer's disease patients, associated with amyloid-modifying therapies, particularly human monoclonal antibodies. QY, JX, HY http://en.volupedia.org/wiki/Amyloid-related_imaging_abnormalities 脑微出血 10067277 cerebral microhemorrhage AE OAE:0004928 This is an AE which refers to a group of pathological processes with various aetiologies that affect the small arteries, arterioles, venules, and capillaries of the brain with ischaemic. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20610345/ 脑小血管缺血性疾病 10070878 cerebral small vessel ischemic disease AE OAE:0004929 This is an AE which is the final product of the blood coagulation step in hemostasis on cerebral. QY, JX, HY http://en.volupedia.org/wiki/Thrombus 脑血栓形成 10008132 cerebral thrombosis AE OAE:0004930 This is an AE which is a parasitic disease caused by Toxoplasma gondii, an apicomplexan. QY, JX, HY http://en.volupedia.org/wiki/Toxoplasmosis 脑弓形体病 10057854 cerebral toxoplasmosis AE OAE:0004931 This is an AE which is the presence of a blood clot in the dural venous sinuses (which drain blood from the brain), the cerebral veins, or both. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_venous_sinus_thrombosis 脑静脉窦血栓形成 10083037 cerebral venous sinus thrombosis AE OAE:0004932 This is an AE which can refer to various forms of transient loss of consciousness caused by cerebral ventricle such as syncope, or loss of postural muscle tone without loss of consciousness . QY, JX, HY http://en.volupedia.org/wiki/Collapse 脑心室塌陷 10073706 cerebral ventricle collapse AE OAE:0004933 This is an AE which is defined as dilation of the fetal cerebral ventricles and is a relatively common finding on prenatal ultrasound. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29705191/ 脑室扩张 10048824 cerebral ventricle dilatation AE OAE:0004934 This is an AE which is a rare congenital disorder characterized by the reduction or absence of functional peroxisomes in the cells of an individual. QY, JX, HY http://en.volupedia.org/wiki/Zellweger_syndrome 脑肝肾综合征 10053684 cerebrohepatorenal syndrome AE OAE:0004935 This is an AE which is a medical condition in which poor blood flow to the brain causes cell death. QY, JX, HY http://en.volupedia.org/wiki/Stroke 脑血管中风 10008190 cerebrovascular accident AE OAE:0004936 This is an AE which is an abnormal cerebrovascular connection between arteries and veins, bypassing the capillary system. QY, JX, HY http://en.volupedia.org/wiki/Arteriovenous_malformation 脑血管动静脉畸形 10056371 cerebrovascular arteriovenous malformation AE OAE:0004937 This is an AE which includes a variety of medical conditions that affect the blood vessels of the brain and the cerebral circulation. QY, JX, HY http://en.volupedia.org/wiki/Cerebrovascular_disease 脑血管疾病 10008196 cerebrovascular disorder AE OAE:0004938 This is an AE which includes a variety of medical conditions that affect the blood vessels of the brain and the cerebral circulation. QY, JX, HY http://en.volupedia.org/wiki/Cerebrovascular_disease 脑血管机能不全 10058842 cerebrovascular insufficiency AE OAE:0004939 This is an AE which is a common CNS manifestation of mitochondrial disorders (MIDs) and has been reported in specific and non-specific MIDs. QY, JX, HY https://link.springer.com/article/10.1007%2Fs11011-018-0238-y 小脑萎缩 10008027 cerebellar atrophy AE OAE:0004940 This is an AE which is the lodging of an embolus, a blockage-causing piece of material, inside a cerebellar blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Embolism 小脑栓塞 10067167 cerebellar embolism AE OAE:0004941 This is an AE which accounts for 5-10% of all intracerebral haemorrhages and leads to severe, long-lasting functional deficits. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28318366/ 小脑出血 10008030 cerebellar hemorrhage AE OAE:0004942 This is an AE which is characterized by reduced cerebellar volume, even though cerebellar shape is (near) normal. QY, JX, HY http://en.volupedia.org/wiki/Cerebellar_hypoplasia 小脑发育不全 10008033 cerebellar hypoplasia AE OAE:0004943 This is an AE which is an important cause of stroke that often presents with common and non-specific symptoms such as dizziness, nausea and vomiting, unsteady gait, and headache. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18848314/ 小脑梗死 10008034 cerebellar infarction AE OAE:0004944 This is an AE which may present in a completely different way from common stroke syndromes in the anterior cerebral circulation and can initially mimic benign vestibular neuritis and may later deteriorate into a life-threatening neurologic state. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29891068/ 小脑卒中 10079062 cerebellar stroke AE OAE:0004945 This is an AE which is a type of abnormal and excessive growth of cerebellar tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 小脑肿瘤 10061750 cerebellar tumor AE OAE:0004946 This is an AE which is an abscess caused by inflammation and collection of infected material, coming from local (ear infection, dental abscess, infection of paranasal sinuses, infection of the mastoid air cells of the temporal bone, epidural abscess) or remote (lung, heart, kidney etc.) infectious sources, within the brain tissue. QY, JX, HY http://en.volupedia.org/wiki/Brain_abscess 脑脓肿 10006105 brain abscess AE OAE:0004947 This is an AE which is a bruise of the brain tissue and can be associated with multiple microhemorrhages, small blood vessel leaks into brain tissue. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_contusion 脑挫伤 10052346 brain contusion AE OAE:0004948 This is an AE which is a form of hypoxia (reduced supply of oxygen), specifically involving the brain; when the brain is completely deprived of oxygen, it is called cerebral anoxia. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_hypoxia 大脑缺氧 10006127 brain hypoxia AE OAE:0004949 This is an AE which is an abnormality of the structure of brain. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 大脑畸形 10048409 brain malformation AE OAE:0004950 This is an AE which is an important feature that can be measured using various imaging modalities including X-ray, ultrasound, computed tomography, and magnetic resonance imaging. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29849536/ 大脑中线移位 10069551 brain midline shift AE OAE:0004951 This is an AE which occurs when abnormal cells form within the brain. QY, JX, HY http://en.volupedia.org/wiki/Brain_tumor 脑部肿瘤 10061019 brain neoplasm AE OAE:0004952 This is an AE which is a mass of brain cells (tumor) that lacks the ability to either invade neighboring tissue or metastasize (spread throughout the body). QY, JX, HY http://en.volupedia.org/wiki/Benign_tumor 良性大脑肿瘤 10006129 brain neoplasm benign AE OAE:0004953 This is an AE which is commonly called brain cancer and they invade and destroy the surrounding tissue, may form metastases and, if untreated or unresponsive to treatment, will generally prove fatal. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 恶性大脑肿瘤 10006131 brain neoplasm malignant AE OAE:0004954 This is an AE which is excess accumulation of fluid (edema) in the intracellular or extracellular spaces of the brain. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_edema 脑部水肿 10048962 brain edema AE OAE:0004955 This is an AE which is an auditory evoked potential extracted from ongoing electrical activity in the brain and recorded via electrodes placed on the scalp. QY, JX, HY http://en.volupedia.org/wiki/Auditory_brainstem_response 脑干听觉诱发反应 10049507 brain stem auditory evoked response AE OAE:0004956 This is an AE which falls under the broader category of stroke syndromes, or specific symptoms caused by vascular injury to an area of brain (for example, the lacunar syndromes). QY, JX, HY http://en.volupedia.org/wiki/Brainstem_stroke_syndrome 脑干中风 10068644 brain stem stroke AE OAE:0004957 This is an AE which is most commonly due to occlusion of the posterior circulation or mass effect from intrinsic space-occupying lesions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31283463/ 脑干综合症 10063292 brain stem syndrome AE OAE:0004958 This is an AE which is a hemorrhage of blood between the skull and the periosteum of any age human, including a newborn baby secondary to rupture of blood vessels crossing the periosteum. QY, JX, HY http://en.volupedia.org/wiki/Cephalohematoma 头颅血肿 10008014 cephal hematoma AE OAE:0004959 This is an AE which is a major abnormality in the shape of head compared to the normal shape of that part. QY, JX, HY http://en.volupedia.org/wiki/Deformity 头畸形 10061199 head deformity AE OAE:0004960 This is an AE which is related to medical factors and early neurobehavior, but it may not be a good predictor of outcome when used in isolation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26709421/ 头滞后 10057870 head lag AE OAE:0004961 This is an AE which is tremor of the head and is of cerebellar origin. QY, JX, HY http://en.volupedia.org/wiki/Tremor#Titubation 摇头 10064950 head titubation AE OAE:0004962 This is an AE which is a condition in which circumference of the human head is abnormally large. QY, JX, HY http://en.volupedia.org/wiki/Macrocephaly 大头畸形 10050183 macrocephaly AE OAE:0004963 This is an AE which is a medical condition involving a smaller-than-normal head and may be present at birth or it may develop in the first few years of life. QY, JX, HY http://en.volupedia.org/wiki/Microcephaly 小脑症 10068320 microencephaly AE OAE:0004964 This is an AE which is a medical condition involving a smaller-than-normal head and may be present at birth or it may develop in the first few years of life. QY, JX, HY http://en.volupedia.org/wiki/Microcephaly 小头畸形 10027534 microcephaly AE OAE:0004965 This is an AE which is a condition characterized by an asymmetrical distortion (flattening of one side) of the skull. QY, JX, HY http://en.volupedia.org/wiki/Plagiocephaly 斜头畸形 10048586 plagiocephaly AE OAE:0004966 This is an AE which is an asymmetric deformation of skull due to various reasons; first birth, assisted labor, multiple pregnancy, prematurity, congenital muscular torticollis and position of head. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32380806/ 位置斜头畸形 10068711 positional plagiocephaly AE OAE:0004967 This is an AE which is a condition that affects the development of the human brain by multiple small gyri (microgyri) creating excessive folding of the brain leading to an abnormally thick cortex. QY, JX, HY http://en.volupedia.org/wiki/Polymicrogyria 多小脑回 10073489 polymicrogyria AE OAE:0004968 This is an AE which is a progressive, degenerative, genetic disease with multiple types, each of which could be considered a neurological condition in its own right. QY, JX, HY 脊髓小脑性共济失调 10057660 spino cerebellar ataxia AE OAE:0004969 This is an AE whichis a diverse group of rare, slowly progressive, neurological diseases, often inherited but of incompletely understood pathophysiology, which affect the cerebellum and its related pathways. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/14521474/ 脊髓小脑疾病 10061551 spino cerebellar disorder AE OAE:0004970 This is an AE which is a rare childhood neurological syndrome and is characterized by the sudden or gradual development of aphasia (the inability to understand or express language) and an abnormal electroencephalogram (EEG). QY, JX, HY http://en.volupedia.org/wiki/Landau%E2%80%93Kleffner_syndrome 获得性癫痫性失语 10052075 acquired epileptic aphasia AE OAE:0004971 This is an AE which is an inability to comprehend or formulate language because of damage to specific brain regions. QY, JX, HY http://en.volupedia.org/wiki/Aphasia 失语症 10002948 aphasia AE OAE:0004972 This is an AE which is a type of severe heat illness that results in a body temperature greater than 40.0 °C (104.0 °F). QY, JX, HY http://en.volupedia.org/wiki/Heat_stroke 热射病 10019345 heat stroke AE OAE:0004973 This is an AE which is the most common type of ischaemic stroke, resulting from the occlusion of small penetrating arteries that provide blood to the brain's deep structures. QY, JX, HY http://en.volupedia.org/wiki/Lacunar_stroke 腔隙性中风 10076994 lacunar stroke AE OAE:0004974 This is an AE which is sudden damage to the brain caused by a blow or jolt and it has one of the highest mortality and disability rates in the world. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607269/ 颅脑损伤 10070976 craniocerebral injury AE OAE:0004975 This is an AE which is a condition in which one or more of the fibrous sutures in a young infant's skull prematurely fuses by turning into bone (ossification), thereby changing the growth pattern of the skull. QY, JX, HY http://en.volupedia.org/wiki/Craniosynostosis 颅缝早闭 10049889 craniosynostosis AE OAE:0004976 This is an AE which is a break in one or more of the eight bones that form the cranial portion of the skull, usually occurring as a result of blunt force trauma. QY, JX, HY http://en.volupedia.org/wiki/Skull_fracture 颅骨骨折 10061365 skull fracture AE OAE:0004977 This is an AE which is bicoronal craniosynostosis is characterized by a wide, short skull. QY, JX, HY http://en.volupedia.org/wiki/Carpenter_syndrome 颅骨畸形 10062348 skull malformation AE OAE:0004978 This is an AE which is encephalitis due to herpes simplex virus. QY, JX, HY http://en.volupedia.org/wiki/Herpesviral_encephalitis 单纯疱疹性脑炎 10019953 herpes simplex encephalitis AE OAE:0004979 This is an AE which is meningitis associated with herpes simplex virus (HSV). QY, JX, HY http://en.volupedia.org/wiki/Herpesviral_meningitis 单纯疱疹性脑膜炎 10019956 herpes simplex meningitis AE OAE:0004980 This is an AE which is a medical condition that simultaneously resembles both meningitis, which is an infection or inflammation of the meninges, and encephalitis, which is an infection or inflammation of the brain. QY, JX, HY http://en.volupedia.org/wiki/Meningoencephalitis 单纯疱疹性脑膜脑炎 10074247 herpes simplex meningo encephalitis AE OAE:0004981 This is an AE which is characterized by recurrent clinical seizures and prominent interictal epileptiform discharges seen during the early infantile period. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26271793/ 癫痫性脑病 10077380 epileptic encephalopathy AE OAE:0004982 This is an AE which is a type of meningitis due to a herprs zoster infection. QY, JX, HY http://en.volupedia.org/wiki/Viral_meningitis 带状疱疹脑膜炎 10074259 herpes zoster meningitis AE OAE:0004983 This is an AE which is a medical condition that simultaneously resembles both meningitis, which is an infection or inflammation of the meninges, and encephalitis, which is an infection or inflammation of the brain. QY, JX, HY http://en.volupedia.org/wiki/Meningoencephalitis 带状疱疹脑膜脑炎 10074248 herpes zoster meningo encephalitis AE OAE:0004984 This is an AE which is tissue death (necrosis) due to inadequate blood supply to the affected area. QY, JX, HY http://en.volupedia.org/wiki/Infarction 脑梗死 10061216 infarction AE OAE:0004985 This is an AE which is a particular abnormal change in appearance of white matter near the lateral ventricles. QY, JX, HY http://en.volupedia.org/wiki/Leukoaraiosis 脑白质疏松症 10051765 leukoaraiosis AE OAE:0004986 This is an AE which is a group of usually inherited disorders characterized by degeneration of the white matter in the brain. QY, JX, HY http://en.volupedia.org/wiki/Leukodystrophy 脑白质营养不良 10024381 leukodystrophy AE OAE:0004987 This is an AE which is a form of encephalitis, a disease characterized by inflammation of the brain. QY, JX, HY http://en.volupedia.org/wiki/Limbic_encephalitis 边缘脑炎 10078012 limbic encephalitis AE OAE:0004988 This is an AE which is the three membranes that envelop the brain and spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Meninges 脑膜肿瘤 10061282 meningeal neoplasm AE OAE:0004989 This is an AE which is typically a slow-growing tumor that forms from the meninges, the membranous layers surrounding the brain and spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Meningioma 脑膜瘤 10027191 meningioma AE OAE:0004990 This is an AE which is a set of symptoms similar to those of meningitis but not caused by meningitis. QY, JX, HY http://en.volupedia.org/wiki/Meningism 假性脑膜炎 10027192 meningism AE OAE:0004991 This is an AE which is usually lethal unless appropriate antibiotics that cross the blood-brain barrier are given. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30273239/ 细菌性脑膜炎 10027202 meningitis bacterial AE OAE:0004992 This is an AE which is a potentially fatal fungal infection of mainly the lungs, presenting as a pneumonia, and brain, where it appears as a meningitis. QY, JX, HY http://en.volupedia.org/wiki/Cryptococcosis 隐球菌脑膜炎 10027209 meningitis cryptococcal AE OAE:0004993 This is an AE which is a form of bacterial meningitis caused by the Haemophilus influenzae bacteria. QY, JX, HY http://en.volupedia.org/wiki/Haemophilus_meningitis 嗜血杆菌脑膜炎 10027241 meningitis haemophilus AE OAE:0004994 This is an AE which is an acute inflammation of the protective membranes covering the brain and spinal cord caused by herps. QY, JX, HY http://en.volupedia.org/wiki/Meningitis 脑膜炎疱疹 10027242 meningitis herpes AE OAE:0004995 This is an AE which is a form of bacterial meningitis. QY, JX, HY http://en.volupedia.org/wiki/Meningococcal_disease#Meningitis 脑膜炎球菌性脑膜炎 10027249 meningitis meningococcal AE OAE:0004996 This is an AE which is a viral disease caused by the mumps virus and complications include deafness and a wide range of inflammatory conditions, of which inflammation of the meninges. QY, JX, HY http://en.volupedia.org/wiki/Mumps 脑膜炎腮腺炎 10027250 meningitis mumps AE OAE:0004997 This is an AE which is a serious medical condition in infants that is rapidly fatal if untreated. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_meningitis 新生儿脑膜炎 10058780 meningitis neonatal AE OAE:0004998 This is an AE which continues to be associated with high rates of mortality and long-term neurological sequelae and the most common route of infection starts by nasopharyngeal colonization by Streptococcus pneumoniae, which must avoid mucosal entrapment and evade the host immune system after local activation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21734248/ 肺炎球菌脑膜炎 10027253 meningitis pneumococcal AE OAE:0004999 This is an AE which is a symptomatic meningitis infection caused by bacteria of the Salmonella type . QY, JX, HY http://en.volupedia.org/wiki/Salmonellosis 沙门氏菌脑膜炎 10027254 meningitis salmonella AE OAE:0005000 This is an AE which is a specific type of bacterial meningitis caused by the Mycobacterium tuberculosis infection of the meninges—the system of membranes which envelop the central nervous system. QY, JX, HY http://en.volupedia.org/wiki/Tuberculous_meningitis 结核性脑膜炎 10027259 meningitis tuberculous AE OAE:0005001 This is an AE which is a type of meningitis due to a viral infection and it results in inflammation of the meninges. QY, JX, HY http://en.volupedia.org/wiki/Viral_meningitis 病毒性脑膜炎 10027260 meningitis viral AE OAE:0005002 This is an AE which is a birth defect in which there is incomplete closing of the spine and the membranes around the spinal cord during early development in pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Spina_bifida 脑脊膜突出 10027266 meningocele AE OAE:0005003 This is an AE which is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia, a life-threatening sepsis. QY, JX, HY http://en.volupedia.org/wiki/Neisseria_meningitidis 脑膜炎球菌感染 10027274 meningococcal infection AE OAE:0005004 This is an AE which describes infections caused by the bacterium Neisseria meningitidis. QY, JX, HY http://en.volupedia.org/wiki/Meningococcal_disease 脑膜炎球菌败血症 10027280 meningococcal sepsis AE OAE:0005005 This is an AE which is meningitis associated with herpes simplex virus (HSV). QY, JX, HY http://en.volupedia.org/wiki/Herpesviral_meningitis 脑膜脑炎疱疹 10027285 meningo encephalitis herpetic AE OAE:0005006 This is an AE which is a birth defect in which there is incomplete closing of the spine and the membranes around the spinal cord during early development in pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Spina_bifida 脑脊膜脊髓膨出 10027287 meningomyelocele AE OAE:0005007 This is an AE which is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of sphingolipids. QY, JX, HY http://en.volupedia.org/wiki/Metachromatic_leukodystrophy 异染性脑白质营养不良 10067609 metachromatic leukodystrophy AE OAE:0005008 This is an AE which refers to any syndrome or disorder of mental function whose cause is alleged to be known as organic (physiologic) rather than purely of the mind. QY, JX, HY http://en.volupedia.org/wiki/Organic_brain_syndrome 器质性脑综合征 10031077 organic brain syndrome AE OAE:0005009 This is an AE which is a fibrosing and inflammatory process, which involves the dura mater. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28413094/ 硬脑膜炎 10053658 pachymeningitis AE OAE:0005010 This is an AE which is a form of encephalomyopathy that is associated with a mitochondrial disease. QY, JX, HY http://en.volupedia.org/wiki/Mitochondrial_encephalomyopathy 线粒体脑肌病 10058799 mitochondrial encephalomyopathy AE OAE:0005011 This is an AE which represents a syndrome of temporary or permanent disturbance of brain functions that occurs in different diseases and varies in clinical presentation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28084256/ 代谢脑病 10062190 metabolic encephalopathy AE OAE:0005012 This is an AE which is a hyperacute and frequently fatal form of ADEM. QY, JX, HY http://en.volupedia.org/wiki/Acute_disseminated_encephalomyelitis#Acute_hemorrhagic_leukoencephalitis 白质脑脊髓炎 10048999 leuko encephalo myelitis AE OAE:0005013 This is an AE which is a form of hypoxia (reduced supply of oxygen), specifically involving the brain; when the brain is completely deprived of oxygen, it is called cerebral anoxia. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_hypoxia 缺氧性脑病变 10021147 hypoxic encephalopathy AE OAE:0005014 This is an AE which is a neural tube defect characterized by sac-like protrusions of the brain and the membranes that cover it through openings in the skull. QY, JX, HY http://en.volupedia.org/wiki/Encephalocele 脑膨出 10014617 encephalo cele AE OAE:0005015 This is an AE which is a localized softening of the substance of the brain, due to bleeding or inflammation. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_softening 脑软化 10051818 encephalo malacia AE OAE:0005016 This is an AE which is inflammation of the brain and spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Encephalomyelitis 脑脊髓炎 10014619 encephalo myelitis AE OAE:0005017 This is an AE which is defined by signs and symptoms of abnormal neurological function in the first few days of life in an infant born at term. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_encephalopathy 脑病新生儿 10014633 encephalopathy neonatal AE OAE:0005018 This is an AE which is a type of encephalitis that can result from a number of autoimmune diseases. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_encephalitis 自身免疫性脑炎 10072378 encephalitis autoimmune AE OAE:0005019 This is an AE which defines as an illness characterized by myoclonus, ataxia, nystagmus, oculomotor palsies, and bulbar palsy in various combinations, with or without neuroimaging. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22956971/ 脑干脑炎 10048997 encephalitis brain stem AE OAE:0005020 This is an AE which is discovered in Kern County, California and causes encephalitis in humans. QY, JX, HY http://en.volupedia.org/wiki/California_encephalitis_orthobunyavirus 加州脑炎 10014584 encephalitis california AE OAE:0005021 This is an AE which is an important opportunistic infection in HIV-infected patients but is rarely recognized in other groups. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/8815757/ 脑炎巨细胞病毒 10014586 encephalitis cytomegalovirus AE OAE:0005022 This is an AE which is defined by the presence of an inflammatory process of the brain in association with clinical evidence of neurologic dysfunction caused by enteroviral. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25175874/ 肠病毒性脑炎 10063946 encephalitis enteroviral AE OAE:0005023 This is an AE which is encephalitis due to herpes simplex virus. QY, JX, HY http://en.volupedia.org/wiki/Herpesviral_encephalitis 脑炎疱疹 10014590 encephalitis herpes AE OAE:0005024 This is an AE which is an infection of the brain caused by the Japanese encephalitis virus (JEV). QY, JX, HY http://en.volupedia.org/wiki/Japanese_encephalitis 日本乙型脑炎 10014596 encephalitis japanese b AE OAE:0005025 This is an AE which is an atypical form of encephalitis. QY, JX, HY http://en.volupedia.org/wiki/Encephalitis_lethargica 埃科诺莫氏病 10052369 encephalitis lethargica AE OAE:0005026 This is an AE which is a viral disease caused by the mumps virus and may occur encephalitis. QY, JX, HY http://en.volupedia.org/wiki/Mumps 脑炎流行性腮腺炎 10014598 encephalitis mumps AE OAE:0005027 This is an AE which is inflammation of the brain parenchyma, called encephalitis, by a virus. QY, JX, HY http://en.volupedia.org/wiki/Viral_encephalitis 病毒性脑炎 10014612 encephalitis viral AE OAE:0005028 This is an AE which is a brain injury in which scattered lesions occur over a widespread area in white matter tracts as well as grey matter. QY, JX, HY http://en.volupedia.org/wiki/Diffuse_axonal_injury 脑弥漫性轴索损伤 10066213 diffuse axonal injury AE OAE:0005029 This is an AE which is a rare endocrine condition featuring a low blood sodium concentration and dehydration in response to injury (trauma) or the presence of tumors in or surrounding the brain. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_salt-wasting_syndrome 脑性盐耗综合征 10078827 csws syndrome AE OAE:0005030 This is an AE which is a head injury that temporarily affects brain functioning. QY, JX, HY http://en.volupedia.org/wiki/Concussion 脑震荡 10010254 concussion AE OAE:0005031 This is an AE which is the pathologic process that results in an area of necrotic tissue in the brain (cerebral infarct) with embolic. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_infarction 栓塞性脑梗死 10060839 embolic cerebral infarction AE OAE:0005032 This is an AE which is a neurological condition characterized by encephalopathy, thyroid autoimmunity, and good clinical response to corticosteroids. QY, JX, HY http://en.volupedia.org/wiki/Hashimoto%27s_encephalopathy 桥本脑病 10069432 hashimoto's encephalopathy AE OAE:0005033 This is an AE which is a cephalic disorder in which the prosencephalon (the forebrain of the embryo) fails to develop into two hemispheres. QY, JX, HY http://en.volupedia.org/wiki/Holoprosencephaly 前脑无裂畸形 10056304 holoprosencephaly AE OAE:0005034 This is an AE which is the common collective name for human betaherpesvirus 6A (HHV-6A) and human betaherpesvirus 6B (HHV-6B) and can be associated with encephalitis in the case of immunocompromised patients. QY, JX, HY http://en.volupedia.org/wiki/Human_herpesvirus_6 人疱疹病毒脑炎 10081897 human herpesvirus 6 encephalitis AE OAE:0005035 This is an AE which is a syndrome (a set of signs and symptoms) with encephalomyelitis that is the consequence of cancer in the body, specifically due to the production of chemical signaling molecules (such as hormones or cytokines) by tumor cells or by an immune response against the tumor. QY, JX, HY http://en.volupedia.org/wiki/Paraneoplastic_syndrome 脑脊髓脑炎 10069587 paraneoplastic encephalomyelitis AE OAE:0005036 This is an AE which can result from neonatal encephalopathy and perinatal arterial ischaemic stroke, usually at term, but also in preterm infants. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25686754/ 围产期脑损伤 10056392 perinatal brain damage AE OAE:0005037 This is an AE which is a form of white-matter brain injury, characterized by the necrosis (more often coagulation) of white matter near the lateral ventricles. QY, JX, HY http://en.volupedia.org/wiki/Periventricular_leukomalacia 室周的脑栓塞 10052594 periventricular leukomalacia AE OAE:0005038 This is an AE which is a set of symptoms that may continue for weeks, months, or a year or more after a concussion – a mild form of traumatic brain injury (TBI). QY, JX, HY http://en.volupedia.org/wiki/Post-concussion_syndrome 脑震荡综合征 10057230 post concussion syndrome AE OAE:0005039 This is an AE which is a neurologic disorder caused by exposure to neurotoxic organic solvents such as toluene, following exposure to heavy metals such as manganese, as a side effect of melarsoprol treatment for African trypanosomiasis, adverse effects to prescription drugs, or exposure to extreme concentrations of any natural toxin such as cyanotoxins found in shellfish or freshwater cyanobacteria crusts. QY, JX, HY http://en.volupedia.org/wiki/Toxic_encephalopathy 中毒性脑病 10044221 toxic encephalopathy AE OAE:0005040 This is an AE which is a rare condition that is characterized by progressive damage (-pathy) to white matter (-leuko-) in the brain (-encephalo-), particularly myelin, due to causes such as exposure to substance use, environmental toxins, or chemotherapeutic drugs. QY, JX, HY http://en.volupedia.org/wiki/Toxic_leukoencephalopathy 中毒性白质脑病 10075528 toxic leukoencephalopathy AE OAE:0005041 This is an AE which is a hyperacute and frequently fatal form of acute disseminated encephalomyelitis(ADEM). QY, JX, HY http://en.volupedia.org/wiki/Acute_disseminated_encephalomyelitis#Acute_hemorrhagic_leukoencephalitis 急性出血性白细胞脑炎 10058994 acute haemorrhagic leukoencephalitis AE OAE:0005042 This is an AE which is an acute inflammation of the protective membranes covering the brain and spinal cord caused by adenoviral. QY, JX, HY http://en.volupedia.org/wiki/Meningitis 腺病毒性脑膜炎 10080442 adenoviral meningitis AE OAE:0005043 This is an AE which is rare but well recognised entity usually manifesting 1-4 weeks after anoxic exposure and characteristic subcortical white matter demyelination with necrosis of globus pallidus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7644404/ 缺氧脑病 10050750 anoxic encephalopathy AE OAE:0005044 This is an AE which is a structural defect in the cerebellum, characterized by a downward displacement of one or both cerebellar tonsils through the foramen magnum (the opening at the base of the skull). QY, JX, HY http://en.volupedia.org/wiki/Chiari_malformation 阿－基氏脑畸形 1003101 arnold-chiari malformation AE OAE:0005045 This is an AE which is a motor disorder caused by damage to the brain (specifically the posterior parietal cortex or corpus callosum) which causes difficulty with motor planning to perform tasks or movements. QY, JX, HY http://en.volupedia.org/wiki/Apraxia 失用症 10003062 apraxia AE OAE:0005046 This is an AE which represents a complex category of disease with diverse immunologic associations, clinical manifestations, and therapeutic outcomes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21590620/ 自身免疫性脑病 10075691 autoimmune encephalopathy AE OAE:0005047 This is an AE which is a rare inflammatory disorder of the central nervous system,It may also affect the peripheral nervous system, and has features in common with both Miller Fisher syndrome and Guillain Barré syndrome. QY, JX, HY http://en.volupedia.org/wiki/Bickerstaff_brainstem_encephalitis 比克斯塔夫脑炎 10076985 bickerstaff's encephalitis AE OAE:0005048 This is an AE which is a rare and fatal autosomal recessive degenerative disorder that causes progressive damage to nerve cells and loss of white matter in the brain. QY, JX, HY http://en.volupedia.org/wiki/Canavan_disease 海绵状脑白质营养不良症 10067608 canavan disease AE OAE:0005049 This is an AE which is a rodent-borne viral infectious disease that presents as aseptic meningitis, encephalitis or meningoencephalitis. QY, JX, HY http://en.volupedia.org/wiki/Lymphocytic_choriomeningitis 淋巴细胞性脉络丛脑膜炎 10008761 chorio meningitis lymphocytic AE OAE:0005050 This is an AE which is an extremely rare cephalic disorder involving encephalomalacia. QY, JX, HY http://en.volupedia.org/wiki/Porencephaly 脑穿通畸形 10036172 porencephaly AE OAE:0005051 This is an AE which is a rare condition in which parts of the brain are affected by swelling, usually as a result of an underlying cause. QY, JX, HY http://en.volupedia.org/wiki/Posterior_reversible_encephalopathy_syndrome 后部可逆性脑病综合征 10071066 posterior reversible encephalopathy syndrome AE OAE:0005052 This is an AE which is commonly associated with significant morbidity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/?term=postresuscitation+encephalopathy 复苏后脑病 10068191 postresuscitation encephalopathy AE OAE:0005053 This is an AE which is a rare and often fatal viral disease characterized by progressive damage (-pathy) or inflammation of the white matter (leuko-) of the brain (-encephalo-) at multiple locations (multifocal). QY, JX, HY http://en.volupedia.org/wiki/Progressive_multifocal_leukoencephalopathy 进行性多灶性白质脑病 10036807 progressive multifocal leukoencephalopathy AE OAE:0005054 This is an AE which is a rare inflammatory neurological disease, characterized by frequent and severe seizures, loss of motor skills and speech, hemiparesis (weakness on one side of the body), encephalitis (inflammation of the brain), and dementia. QY, JX, HY http://en.volupedia.org/wiki/Rasmussen%27s_encephalitis 拉斯姆森脑炎 10071141 rasmussen encephalitis AE OAE:0005055 This is an AE which is a common complication in septic patients and clinical presentation may range from mild confusion and disorientation to convulsions and deep coma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30280261/ 败血性脑病 10069141 septic encephalopathy AE OAE:0005056 This is an AE which is a rare benign disease that can cause myelopathy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26585731/ 脊髓脑膜囊肿 10067375 spinal meningeal cyst AE OAE:0005057 This is an AE which is either caused by trauma including that arising from medical interventions or spontaneously sometimes in those with predisposing conditions. QY, JX, HY http://en.volupedia.org/wiki/Cerebrospinal_fluid_leak 自发性脑脊液漏综合征 10073081 spontaneous cerebrospinal fluid leak syndrome AE OAE:0005058 This is an AE which is a rare form of chronic, progressive brain inflammation caused by slow infection with certain defective strains of hypermutated measles virus. QY, JX, HY http://en.volupedia.org/wiki/Subacute_sclerosing_panencephalitis 亚急性硬化性全脑炎 10042297 subacute sclerosing panencephalitis AE OAE:0005059 This is an AE which can present with a variety of sensory deficits that can be difficult to diagnose clinically because of their seemingly disconnected manifestations. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23269103/ 丘脑梗塞 10064961 thalamic infarction AE OAE:0005060 This is an AE which is an injury to the brain caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Traumatic_brain_injury 创伤性脑损伤 10060690 traumatic brain injury AE OAE:0005061 This is an AE which is a disease linked to the X chromosome and is a result of fatty acid buildup caused by a defect in the very long chain of fatty acids transporter in peroxisomes, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. QY, JX, HY http://en.volupedia.org/wiki/Adrenoleukodystrophy 肾上腺脑白质营养不良 10051260 adrenoleukodystrophy AE OAE:0005062 This is an AE which means any disorder or disease of the brain caused by AIDs, especially chronic degenerative conditions. QY, JX, HY http://en.volupedia.org/wiki/Encephalopathy 艾滋病脑病 10049072 aids encephalopathy AE OAE:0005063 This is an AE which is a communication disorder resulting in incoherent talkativeness. QY, JX, HY http://en.volupedia.org/wiki/Logorrhea 多语症，速语症 10024796 logorrhoea AE OAE:0005064 This is an AE which is a closed sac on the pituitary, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 垂体囊肿 10051687 pituitary cyst AE OAE:0005065 This is an AE which is the increase in the volume of pituitary tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 垂体增大 10048675 pituitary enlargement AE OAE:0005066 This is an AE which is tumors that occur in the pituitary gland. QY, JX, HY http://en.volupedia.org/wiki/Pituitary_adenoma 垂体肿瘤 10035104 pituitary tumor AE OAE:0005067 This is an AE which is a pituitary mass of cells (tumor) that lacks the ability to either invade neighboring tissue or metastasize (spread throughout the body). QY, JX, HY http://en.volupedia.org/wiki/Benign_tumor 良性垂体肿瘤 10061538 pituitary tumor benign AE OAE:0005068 This is an AE which is characterized by the absence of a subjacent cerebral lesion and neurological or intellectual deficit. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11785036/ 特发性局灶性癫痫 10076552 idiopathic partial epilepsy AE OAE:0005069 This is an AE which is seizures which affect initially only one hemisphere of the brain. QY, JX, HY http://en.volupedia.org/wiki/Focal_seizure 部分癫痫发作 10061334 partial seizures AE OAE:0005070 This is an AE which is a group of non-communicable neurological disorders characterized by recurrent epileptic seizures. QY, JX, HY http://en.volupedia.org/wiki/Epilepsy 癫痫 10015037 epilepsy AE OAE:0005071 This is an AE which is a single seizure lasting more than 5 minutes or two or more seizures within a five-minute period without the person returning to normal between them. QY, JX, HY http://en.volupedia.org/wiki/Status_epilepticus 癫痫持续状态 10041962 status epilepticus AE OAE:0005072 This is an AE which is common, particularly in the setting of medically refractory epilepsy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25695133/ 癫痫发作群 10071350 seizure cluster AE OAE:0005073 This is an AE which is primarily a disorder of childhood. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/414604/ 癫痫小发作癫痫 10034759 petit mal epilepsy AE OAE:0005074 This is an AE which is a neurological disorder that is characterized by brief, recurring seizures that arise in the frontal lobes of the brain, often while the patient is sleeping. QY, JX, HY http://en.volupedia.org/wiki/Frontal_lobe_epilepsy 额叶癫痫 10049424 frontal lobe epilepsy AE OAE:0005075 This is an AE which should be recognized as a discrete epileptic syndrome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21093732/ 非典型良性部分癫痫 10056699 atypical benign partial epilepsy AE OAE:0005076 This is an AE which is a period of symptoms due to abnormally excessive or synchronous neuronal activity in the brain caused by hyperglycaemic . QY, JX, HY http://en.volupedia.org/wiki/Seizure 高血糖癫痫发作 10071394 hyperglycaemic seizure AE OAE:0005077 This is an AE which is divided into simple and dyscognitive, with the latter resulting in the alteration of consciousness. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28362654/ 局灶性认知障碍癫痫发作 10079424 focal dyscognitive seizures AE OAE:0005078 This is an AE which is the most common epilepsy syndrome in childhood. QY, JX, HY http://en.volupedia.org/wiki/Rolandic_epilepsy 良性中央癫痫 10070530 benign rolandic epilepsy AE OAE:0005079 This is an AE which is subdivided into syndromes based on clinical and EEG features. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17223580/ 特发性全身性癫痫 10071081 idiopathic generalised epilepsy AE OAE:0005080 This is an AE which is a type of seizure that consists of partial or complete loss of muscle tone that is caused by temporary alterations in brain function. QY, JX, HY http://en.volupedia.org/wiki/Atonic_seizure 无源性癫痫发作 10003628 atonic seizures AE OAE:0005081 This is an AE which is a period of symptoms due to abnormally excessive or synchronous neuronal activity in the brain and is psychogenic . QY, JX, HY http://en.volupedia.org/wiki/Seizure 心因性癫痫发作 10058895 psychogenic seizure AE OAE:0005082 This is an AE which is condition that affects one side of the body. QY, JX, HY http://en.volupedia.org/wiki/Hemiplegic_migraine 偏瘫型偏头痛 10019476 hemiplegic migraine AE OAE:0005083 This is an AE which is a complication of migraine (with or without aura), representing an attack that lasts for more than 72 h. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30198804/ 偏头痛状态 10052945 status migrainosus AE OAE:0005084 This is an AE which is a neurological disorder characterized by recurrent severe headaches on one side of the head, typically around the eye. QY, JX, HY http://en.volupedia.org/wiki/Cluster_headache 丛集性头痛 10059133 cluster headache AE OAE:0005085 This is an AE which is the decreased (hypo) secretion of one or more of the eight hormones normally produced by the pituitary gland at the base of the brain. QY, JX, HY http://en.volupedia.org/wiki/Hypopituitarism 垂体机能减退 10021067 hypopituitarism AE OAE:0005086 This is an AE which is a particular abnormal change in appearance of white matter near the lateral ventricles. QY, JX, HY http://en.volupedia.org/wiki/Leukoaraiosis 白质病变 10072731 white matter lesion AE OAE:0005087 This is an AE which is basal ganglia tissue death (necrosis) due to inadequate blood supply to the affected area. QY, JX, HY http://en.volupedia.org/wiki/Infarction 基底节梗塞 10069020 basal ganglia infarction AE OAE:0005088 This is an AE which is a primary headache disorder characterized by recurrent headaches that are moderate to severe. QY, JX, HY http://en.volupedia.org/wiki/Migraine 基底性偏头痛 10050258 basilar migraine AE OAE:0005089 This is an AE which is an anatomical feature of the infant human skull comprising soft membranous gaps (sutures) between the cranial bones that make up the calvaria of a fetus or an infant and it is depressed. QY, JX, HY http://en.volupedia.org/wiki/Fontanelle 囟门凹陷 10053214 fontanelle depressed AE OAE:0005090 This is an AE which case as a patient with a bulging fontanelle, normal neuroimaging and cerebrospinal fluid analysis, and absence of a depressed level of consciousness, focal neurologic findings, or identified cause. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16291356/ 囟门膨大 10016945 fontanelle bulging AE OAE:0005091 This is an AE which includes achondroplasia, hypothyroidism, Down syndrome, increased intracranial pressure, and rickets. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/12825844/ 囟门延迟关闭 10054034 delayed fontanelle closure AE OAE:0005092 This is an AE which has itself since been replaced by other terms QY, JX, HY http://en.volupedia.org/wiki/Intellectual_disability#Terminology 严重智力低下 10036791 profound mental retardation AE OAE:0005093 This is an AE which is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomata. QY, JX, HY http://en.volupedia.org/wiki/Sarcoidosis 结节病 10039486 sarcoidosis AE OAE:0005094 This is an AE which is any of three medical signs, all of which may occur in meningitis or meningism. QY, JX, HY http://en.volupedia.org/wiki/Brudzi%C5%84ski%27s_sign 布鲁金斯基征 10064010 brudzinski's sign AE OAE:0005095 This is an AE which is the yellowish appearance of cerebrospinal fluid that occurs several hours after bleeding into the subarachnoid space caused by certain medical conditions, most commonly subarachnoid hemorrhage. QY, JX, HY http://en.volupedia.org/wiki/Xanthochromia 黄变症 10048213 xanthochromia AE OAE:0005096 This is an AE which is a fatal degenerative brain disorder. QY, JX, HY http://en.volupedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease 克雅二氏症 10011384 creutzfeldt-jakob disease AE OAE:0005097 This is an AE which is a potentially fatal disturbance in brain functions that results when the normal balance of electrolytes in the body is pushed outside safe limits by excessive water intake. QY, JX, HY http://en.volupedia.org/wiki/Water_intoxication 水中毒 10047837 water intoxication AE OAE:0005098 QY, JX, HY 脑硬化 10059150 cerebrosclerosis AE OAE:0005099 QY, JX, HY 下丘脑-垂体疾病 10021111 hypothalamo-pituitary disorder AE OAE:0005100 QY, JX, HY 非感染性脑炎 10074712 noninfective encephalitis AE OAE:0005101 QY, JX, HY 脑炎后免疫 10014602 encephalitis post immunisation AE OAE:0005102 QY, JX, HY 脑炎后麻疹 10014604 encephalitis post measles AE OAE:0005103 QY, JX, HY 脑炎后水痘 10014603 encephalitis post varicella AE OAE:0005104 QY, JX, HY 癫痫样现象 10071048 seizure like phenomena AE OAE:0005105 QY, JX, HY 偏瘫 10078746 hemiparaesthesia AE OAE:0005106 QY, JX, HY 偏头痛 10067040 hemicephalalgia AE OAE:0005107 This is an AE which is an unfavorable result of a disease, health condition, or treatment and its maybe lead atrial fibrillation. QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine)#Cardiovascular_complications 心脏手术并发症 10057461 cardiac procedure complication AE OAE:0005108 This is an AE which is any cardiovascular disease process involving one or more of the four valves of the heart (the aortic and mitral valves on the left side of heart and the pulmonic and tricuspid valves on the right side of heart). QY, JX, HY http://en.volupedia.org/wiki/Valvular_heart_disease 心脏瓣膜赘生物 10057651 cardiac valve vegetation AE OAE:0005109 This is an AE which are systemic diseases frequently affecting the heart and vessels. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32883041/ 风湿性心包炎 10034496 pericarditis rheumatic AE OAE:0005110 This is an AE which can be measured locoregionally to produce a map of systolic activity that reproduces the complex way in which the ventricle contracts. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31005299/ 心肌劳损 10066954 myocardial strain AE OAE:0005111 This is an AE which during thoracic surgery can have profound hemodynamic consequences and lead to devastating neurologic injury. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27871599/ 上腔静脉阻塞 10058988 superior vena caval occlusion AE OAE:0005112 This is an AE which is a devastating neurological disease for which there is no effective therapy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/1434509/ 高血糖症 10080883 hyperglycinaemia AE OAE:0005113 This is an AE which is a fluid-filled space surrounding certain blood vessels in several organs, including the brain,potentially having an immunological function, but more broadly a dispersive role for neural and blood-derived messengers. QY, JX, HY http://en.volupedia.org/wiki/Perivascular_space 大脑血管周围间隙扩大 10068734 enlarged cerebral perivascular spaces AE OAE:0005114 This is an AE which is a group of disorders that destroy blood vessels by inflammation and it is diffuse. QY, JX, HY http://en.volupedia.org/wiki/Vasculitis 弥散性血管炎 10012978 diffuse vasculitis AE OAE:0005115 This is an AE which is a group of disorders with with necrotising that destroy blood vessels by inflammation . QY, JX, HY http://en.volupedia.org/wiki/Vasculitis 血管炎坏死 10047124 vasculitis necrotising AE OAE:0005116 This is an AE which is a mechanical occlusion of the extracranial vertebral artery(VA)due to physiological movement of the head and neck. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33353881/ 椎动脉闭塞 10048965 vertebral artery occlusion AE OAE:0005117 This is an AE which is a medical condition in which injury to the large or small intestine occurs due to not enough blood supply. QY, JX, HY http://en.volupedia.org/wiki/Intestinal_ischemia 血管功能不全 10054880 vascular insufficiency AE OAE:0005118 This is an AE which is a muscular organ in most animals, which pumps blood through the blood vessels of the circulatory system and heart is feel discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Heart 心脏不舒服 10054211 cardiac discomfort AE OAE:0005119 This is an AE which is a pathological wound healing in which connective tissue replaces normal arterial parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis 动脉纤维化 10054793 arterial fibrosis AE OAE:0005120 This is an AE which is a rare complication in angiosarcoma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23542097/ 心房破裂 10048761 atrial rupture AE OAE:0005121 This is an AE which is a syndrome defined as the new onset (de novo heart failure (HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of HF, mostly related to systemic congestion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32139695/ 急性左心室衰竭 10063081 acute left ventricular failure AE OAE:0005122 This is an AE which is a type of respiratory failure characterized. QY, JX, HY http://en.volupedia.org/wiki/Acute_respiratory_distress_syndrome 呼吸窘迫 10049874 cardio-respiratory distress AE OAE:0005123 This is an AE which is a usually benign vascular tumor derived from blood liver vessel cell types. QY, JX, HY http://en.volupedia.org/wiki/Hemangioma 肝血管瘤 10018821 haemangioma of liver AE OAE:0005124 This is an AE which is a usually benign vascular tumor derived from bone blood vessel cell types. QY, JX, HY http://en.volupedia.org/wiki/Hemangioma 骨血管瘤 10072572 haemangioma of bone AE OAE:0005125 This is an AE which is an abnormal connection or passageway between an artery and a vein and the connection or passageway may be occlusion. QY, JX, HY http://en.volupedia.org/wiki/Arteriovenous_fistula 动静脉瘘闭塞 10058562 arteriovenous fistula occlusion AE OAE:0005126 This is an AE which is an abnormal connection or passageway between an artery and a vein. QY, JX, HY http://en.volupedia.org/wiki/Arteriovenous_fistula 动静脉瘘动脉瘤 10066916 arteriovenous fistula aneurysm AE OAE:0005127 This is an AE which is an abnormally dilated vessel occured on splenic with a tortuous course and haemorrhagic. QY, JX, HY http://en.volupedia.org/wiki/Varices 脾静脉曲张出血 10068662 splenic varices hemorrhage AE OAE:0005128 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 妊娠出血 10018981 hemorrhage in pregnancy AE OAE:0005129 This is an AE which is blood escaping from the circulatory system from damaged blood vessels occured on subcutaneous. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 皮下出血 10018999 hemorrhage subcutaneous AE OAE:0005130 This is an AE which is blood escaping from the circulatory system from damaged blood vessels occured on subepidermal. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 表皮下出血 10019001 hemorrhage subepidermal AE OAE:0005131 This is an AE which is characterized by various clinical manifestations and immunologic abnormalities. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28675998/ 心包炎红斑狼疮 10058149 pericarditis lupus AE OAE:0005132 This is an AE which is inflammation of the pleuro pericardium (the fibrous sac surrounding the heart). QY, JX, HY http://en.volupedia.org/wiki/Pericarditis 胸膜心包炎 10059361 pleuro pericarditis AE OAE:0005133 This is an AE which is the formation of a pulmonary artery blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. QY, JX, HY http://en.volupedia.org/wiki/Thrombosis 肺动脉血栓形成 10037340 pulmonary artery thrombosis AE OAE:0005134 This is an AE which is usually refers drug withdrawal such as clonidine. QY, JX, HY http://en.volupedia.org/wiki/Clonidine#Drug_withdrawal 戒断性高血压 10048007 withdrawal hypertension AE OAE:0005135 This is an AE which is very high blood pressure with potentially life-threatening symptoms and signs of acute damage to one or more organ systems especially kidneys. QY, JX, HY http://en.volupedia.org/wiki/Hypertensive_emergency 恶性高血压肾 10026674 malignant renal hypertension AE OAE:0005136 This is an AE which it is a condition characterized by abnormally low levels of platelets with haemangioma. QY, JX, HY http://en.volupedia.org/wiki/Thrombocytopenia 血管瘤-血小板减少综合征 10058423 haemangioma-thrombocytopenia syndrome AE OAE:0005137 This is an AE which refers to a blood pressure measurements and is out of the range of 60-80mmHg at adults. QY, JX, HY http://en.volupedia.org/wiki/Hypertension 舒张期高血压 10012758 diastolic hypertension AE OAE:0005138 This is an AE which is a class of diseases that involve the heart or blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Cardiovascular_disease 心血管疾病 10007649 cardiovascular disorder AE OAE:0005139 This is an AE which is characterized by excessive thoughts, feelings, and behaviors associated with physical symptoms with cardiovascular. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30578985/ 心血管症状障碍 10078078 cardiovascular somatic symptom disorder AE OAE:0005140 This is an AE which is a perceptual disturbance experienced by some with epilepsy or migraine with cardiovascular. QY, JX, HY http://en.volupedia.org/wiki/Aura_(symptom) 心血管征兆 10075534 cardiovascular symptom AE OAE:0005141 This is an AE which is a medical procedure by which an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia is converted to a normal rhythm using electricity or drugs. QY, JX, HY http://en.volupedia.org/wiki/Cardioversion 心脏复律 10007661 cardioversion AE OAE:0005142 This is an AE which is the inflammation of the heart. QY, JX, HY http://en.volupedia.org/wiki/Carditis 心脏炎，心肌炎 10062746 carditis AE OAE:0005143 This is an AE which is a sudden loss of blood flow resulting from the failure of the heart to pump effectively occured on neonatal. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_arrest 新生儿心脏骤停 10007516 cardiac arrest neonatal AE OAE:0005144 This is an AE which is a medical diagnosis of wheezing, coughing, dyspnea, bloody sputum, or shortness of breath due to congestive heart failure. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_asthma 心病性哮喘 10007522 cardiac asthma AE OAE:0005145 This is an AE which is an injury to the heart as the result of blunt trauma, typically to the anterior chest wall. QY, JX, HY http://en.volupedia.org/wiki/Blunt_cardiac_injury 心源性挫伤 10073356 cardiac contusion AE OAE:0005146 This is an AE which is a set of manifestations caused by the failure of the heart's function as a pump supporting the blood flow through the body; its signs and symptoms result from a structural and/or functional abnormality of the heart, that disrupts its filling with blood or its ejecting of it during each heart beat QY, JX, HY http://en.volupedia.org/wiki/Heart_failure 心脏功能障碍 10079751 cardiac dysfunction AE OAE:0005147 This is an AE which is a syndrome defined as the new onset (de novo heart failure (HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of HF, mostly related to systemic congestion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32139695/ 急性心力衰竭 10007556 cardiac failure acute AE OAE:0005148 This is an AE which is a long-term condition, usually kept stable by the treatment of symptoms. QY, JX, HY http://en.volupedia.org/wiki/Heart_failure#Classification_2 慢性心脏衰竭 10007558 cardiac failure chronic AE OAE:0005149 This is an AE which is an irregular and uncoordinated contraction of the cardiac muscle of atria. QY, JX, HY http://en.volupedia.org/wiki/Fibrillation 心脏颤动 10061592 cardiac fibrillation AE OAE:0005150 This is an AE which a common abnormal heart rhythm. QY, JX, HY http://en.volupedia.org/wiki/Flutter 心脏扑动 10052840 cardiac flutter AE OAE:0005151 This is an Ae which is thickening of the walls of a ventricle (lower chamber) of the heart. QY, JX, HY http://en.volupedia.org/wiki/Ventricular_hypertrophy 心脏肥大 10007572 cardiac hypertrophy AE OAE:0005152 This is an AE which refers to an abnormal intrathoracic position of the heart. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21861958/ 心脏错位 10007585 cardiac malposition AE OAE:0005153 This is an AE which is a heart murmur that is primarily due to physiologic conditions outside the heart, as opposed to structural defects in the heart itself. QY, JX, HY http://en.volupedia.org/wiki/Functional_murmur 心脏有杂音 10007587 cardiac murmur functional AE OAE:0005154 This is an AE which is a term used in cardiac physiology that describes the volume of blood being pumped by the heart, by the left and right ventricle, per unit time. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_output 心输出量 10007594 cardiac output AE OAE:0005155 This is an AE which is a defect in the structure of the heart or great vessels. QY, JX, HY http://en.volupedia.org/wiki/Congenital_heart_defect 心脏间隔缺损 10064021 cardiac septal defect AE OAE:0005156 This is an AE which is a condition in which the heart becomes thickened without an obvious cause. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophic_cardiomyopathy 心脏中隔肥大 10057576 cardiac septal hypertrophy AE OAE:0005157 This is an AE which is the narrowing of the exit of the left ventricle of the heart (where the aorta begins), such that problems result. QY, JX, HY http://en.volupedia.org/wiki/Aortic_stenosis 心脏瓣膜硬化症 10061082 cardiac valve sclerosis AE OAE:0005158 This is an AE which is a medical emergency resulting from inadequate blood flow due to the dysfunction of the ventricles of the heart. QY, JX, HY http://en.volupedia.org/wiki/Cardiogenic_shock 心原性休克 10007625 cardiogenic shock AE OAE:0005159 This is an AE which refers to a cluster of related risk factors for cardiovascular disease that includes abdominal obesity, diabetes, hypertension, and elevated cholesterol. QY, JX, HY http://en.volupedia.org/wiki/Epidemiology_of_metabolic_syndrome 心血管代谢疾病综合症 10082306 cardio metabolic syndrome AE OAE:0005161 This is an AE which is a sudden loss of blood flow resulting from the failure of the heart to pump effectively. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_arrest 心肺骤停 10007617 cardio-respiratory arrest AE OAE:0005162 This is an AE which is a sudden loss of blood flow resulting from the failure of the heart to pump effectively at neonatal. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_arrest 新生儿心肺骤停 10007618 cardio-respiratory arrest neonatal AE OAE:0005163 This is an AE which is a failure of smooth muscle fibers to relax, which can cause the lower esophageal sphincter to remain closed. QY, JX, HY http://en.volupedia.org/wiki/Esophageal_achalasia 贲门痉挛 10007645 cardiospasm AE OAE:0005164 This is an AE which has been a useful index of cardiac dilatation, and a value of 50% is generally considered to indicate the upper limit of normal cardiac size. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7666345/ 心胸比率 10068336 cardiothoracic ratio AE OAE:0005165 This is an AE which is a congenital malformation in which the heart is abnormally located either partially or totally outside of the thorax. QY, JX, HY http://en.volupedia.org/wiki/Ectopia_cordis 心脏异位 10014144 ectopia cordis AE OAE:0005166 This is an AE which is some of the commonest congenital disorders seen in prenatal life and they can be anatomical or functional and can develop de novo or as a consequence of either maternal or fetal disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29716424/ 胎儿心脏疾病 10052088 foetal cardiac disorder AE OAE:0005167 This is an AE which occurs when transplanted heart is rejected by the recipient's immune system, which destroys the transplanted heart . QY, JX, HY http://en.volupedia.org/wiki/Transplant_rejection 心脏移植排斥反应 10019315 heart transplant rejection AE OAE:0005168 This is an AE which is a one-way valve that normally allows blood to flow in only one direction through the heart and its functions are incompleted. QY, JX, HY http://en.volupedia.org/wiki/Heart_valve 心脏瓣膜功能不全 10067660 heart valve incompetence AE OAE:0005169 This is an AE which is a type of complications of high blood pressure that affect the heart. QY, JX, HY http://en.volupedia.org/wiki/Hypertensive_heart_disease 高血压心脏肥大 10020801 hypertensive cardiomegaly AE OAE:0005170 This is an AE which includes a variety of medical conditions that affect the blood vessels of the brain and the cerebral circulation caused by hypertensive. QY, JX, HY http://en.volupedia.org/wiki/Cerebrovascular_disease 高血压脑血管疾病 10077000 hypertensive cerebrovascular disease AE OAE:0005171 This is an AE which is very high blood pressure with potentially life-threatening symptoms and signs of acute damage to one or more organ systems (especially brain, eyes, heart, aorta, or kidneys). QY, JX, HY http://en.volupedia.org/wiki/Hypertensive_emergency 高血压急症 10058179 hypertensive emergency AE OAE:0005172 This is an AE which is general brain dysfunction due to significantly high blood pressure. QY, JX, HY http://en.volupedia.org/wiki/Hypertensive_encephalopathy 高血压脑病 10020803 hypertensive encephalopathy AE OAE:0005173 This is an AE which includes a number of complications of high blood pressure that affect the heart. QY, JX, HY http://en.volupedia.org/wiki/Hypertensive_heart_disease 高血压心脏病 10020823 hypertensive heart disease AE OAE:0005174 This is an AE which is a clinical situation in which blood pressure is very high (e.g., 220/125 mmHg) with minimal or no symptoms, and no signs or symptoms indicating acute organ damage. QY, JX, HY http://en.volupedia.org/wiki/Hypertensive_urgency 高血压急症 10058181 hypertensive urgency AE OAE:0005175 This is an AE which refers to valvular heart disease resulting from rheumatic fever. QY, JX, HY http://en.volupedia.org/wiki/Valvular_heart_disease#Inflammatory_disorders 风湿性心脏病 10062110 rheumatic heart disease AE OAE:0005176 This is an AE which moved from hearts with only one ventricle connected with atria [double inlet ventricle or absent atrioventricular (AV) connection] to hearts not amenable to biventricular repair, namely hearts with two ventricles unable to sustain separately pulmonary and systemic circulations in sequence. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25072035/ 单心室心脏 10045545 univentricular heart AE OAE:0005177 This is an AE which is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease when other medical or surgical treatments have failed and the surgical appear complications. QY, JX, HY http://en.volupedia.org/wiki/Heart_transplantation 移植心脏并发症 10010184 complications of transplanted heart AE OAE:0005178 This is an AE which is when bleeding occurs between the tough outer membrane covering the brain (dura mater) and the skull. QY, JX, HY http://en.volupedia.org/wiki/Epidural_hematoma 硬膜外血肿 10015769 extradural hematoma AE OAE:0005179 This is an AE which is an abnormal connection between arteries and veins, bypassing the capillary system with haemorrhagic. QY, JX, HY http://en.volupedia.org/wiki/Arteriovenous_malformation 出血热动静脉畸形 10064595 haemorrhagic arteriovenous malformation AE OAE:0005180 This is an AE which is bleeding within the skull. QY, JX, HY http://en.volupedia.org/wiki/Intracranial_hemorrhage 颅内出血 10018985 hemorrhage intracranial AE OAE:0005181 This is an AE which is a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood or a lowered ability of the blood to carry oxygen caused by haemorrhagic. QY, JX, HY http://en.volupedia.org/wiki/Anemia 出血性贫血 10052293 haemorrhagic anemia AE OAE:0005182 This is an AE which is the pathologic process that results in an area of necrotic tissue in the brain (cerebral infarct) with haemorrhagic. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_infarction 出血性脑梗死 10019005 haemorrhagic cerebral infarction AE OAE:0005183 This is an AE which having a distinct envelope and division compared with the nearby tissue and haemorrhagic . QY, JX, HY http://en.volupedia.org/wiki/Cyst 出血性囊肿 10059189 haemorrhagic cyst AE OAE:0005184 This is an AE which is a rare form of bleeding disorder that affects newborns and young infants due to low stores of vitamin K at birth. QY, JX, HY http://en.volupedia.org/wiki/Vitamin_K_deficiency_bleeding 新生儿出血症 10019008 haemorrhagic disease of newborn AE OAE:0005185 This is an AE which is the consequences of haemostasis dysfunction or defects. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26165091/ 出血性疾病 10019009 haemorrhagic disorder AE OAE:0005186 This is an AE which is tissue death (necrosis) due to inadequate blood with haemorrhagic supply to the affected area . QY, JX, HY http://en.volupedia.org/wiki/Infarction 出血性梗死 10019013 haemorrhagic infarction AE OAE:0005187 This is an AE which appears as a complex cystic mass arising from an ovary, with a reticular pattern of internal echoes representing internal fibrin strands. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30309168/ 出血性卵巢囊肿 10060781 haemorrhagic ovarian cyst AE OAE:0005188 This is an AE which is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli with haemorrhagic . QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 出血性肺炎 10077933 haemorrhagic pneumonia AE OAE:0005189 This is an AE which is a sudden bleeding into the tissues of the brain, into its ventricles, or into both. QY, JX, HY http://en.volupedia.org/wiki/Intracerebral_hemorrhage 出血性中风 10019016 haemorrhagic stroke AE OAE:0005190 This is an AE which is part of the natural history of some forms of ischaemic infarction, especially cerebral embolism, but it can be precipitated or enhanced by therapeutic interventions used in the acute phase of ischaemic stroke. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23726850/ 出血性转换中风 10055677 haemorrhagic transformation stroke AE OAE:0005191 This is an AE which is a kind of skin rash with red, raised, itchy bumps with haemorrhagic. QY, JX, HY http://en.volupedia.org/wiki/Hives 出血性热荨麻疹 10059499 haemorrhagic urticaria AE OAE:0005192 This is an AE which is a group of disorders that destroy blood vessels by inflammation with haemorrhagic . QY, JX, HY http://en.volupedia.org/wiki/Vasculitis 出血性血管炎 10071252 haemorrhagic vasculitis AE OAE:0005193 This is an AE which is cushions of submucosal vascular tissue located in the anal canal starting just distal to the dentate line and the anal canal is with haemorrhage. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19445775/ 直肠出血 10054787 haemorrhoidal hemorrhage AE OAE:0005194 This is an AE which is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. QY, JX, HY http://en.volupedia.org/wiki/Haemophilia 血友病 10061992 haemophilia AE OAE:0005195 This is an AE which is a condition of unrecognized origin which can become extremely serious and whose diagnosis is often made during perinatal autopsy and is often characterised by nonspecific clinical manifestations and a long delay before biological presentation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28748016/ 肝出血 10019677 hepatic hemorrhage AE OAE:0005196 This is an AE which is a condition that occurs when blood enters the front (anterior) chamber of the eye between the iris and the cornea. QY, JX, HY http://en.volupedia.org/wiki/Hyphema 眼前房出血 10020923 hyphaema AE OAE:0005197 This is an AE which is a loss of blood from a blood vessel that collects inside the body. QY, JX, HY http://en.volupedia.org/wiki/Internal_bleeding 内部出血 10075192 internal hemorrhage AE OAE:0005198 This is an AE which is a bleeding into the brain's ventricular system, where the cerebrospinal fluid is produced and circulates through towards the subarachnoid space. QY, JX, HY http://en.volupedia.org/wiki/Intraventricular_hemorrhage 脑室出血 10022840 intraventricular hemorrhage AE OAE:0005199 This is an AE which is a devastating cause of stroke and is a devastating injury for which prompt, effective treatment can impact meaningful survival. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25498578/ 颅内血肿 10059491 intracranial hematoma AE OAE:0005200 This is an AE which is a bleeding into the brain's ventricular system, where the cerebrospinal fluid is produced and circulates through towards the subarachnoid space occurs on neonatal. QY, JX, HY http://en.volupedia.org/wiki/Intraventricular_hemorrhage 新生儿脑室出血 10022841 intraventricular hemorrhage neonatal AE OAE:0005201 This is an AE which refers to a part of the eye with haemorrhage. QY, JX, HY http://en.volupedia.org/wiki/Iris 虹膜出血 10057418 iris hemorrhage AE OAE:0005202 This is an AE which is a membrane that lines various cavities in the body and covers the surface of internal organs and the membrane is haemorrhage. QY, JX, HY http://en.volupedia.org/wiki/Mucous_membrane 粘膜出血 10061298 mucosal hemorrhage AE OAE:0005203 This is an AE which is a membrane that lines various cavities in the body and covers the surface of internal organs and the membrane is hyperaemia. QY, JX, HY http://en.volupedia.org/wiki/Mucous_membrane 粘膜充血 10065334 mucosal hyperemia AE OAE:0005204 This is an AE which can cause complications such as nerve injury, compartment syndrome, myositis ossificans, pseudotumour, and even infection (abscess). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24914744/ 肌肉出血 10028309 muscle hemorrhage AE OAE:0005205 This is an AE which is an organ in vertebrates through which food passes, aided by peristaltic contractions, from the pharynx to the stomach and the organ is haemorrhage. QY, JX, HY http://en.volupedia.org/wiki/Esophagus 食管大出血 10030172 esophageal hemorrhage AE OAE:0005206 This is an AE which is a sudden inflammation of the pancreas with hemorrhagic. QY, JX, HY http://en.volupedia.org/wiki/Acute_pancreatitis 胰腺炎出血 10033650 pancreatitis haemorrhagic AE OAE:0005207 This is an AE which is an abnormal accumulation of fluid in the pericardial cavity with haemorrhage. QY, JX, HY http://en.volupedia.org/wiki/Pericardial_effusion 心包出血 10034476 pericardial hemorrhage AE OAE:0005208 This is an AE which is often associated with high morbidity and mortality and serves as an important clinical predictor of poor outcomes after intracranial haemorrhage (ICH). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28716276/ 出血后脑积水 10079859 posthaemorrhagic hydrocephalus AE OAE:0005209 This is an AE which is an inflammation of the anus and the lining of the rectum with haemorrhagic, affecting only the last 6 inches of the rectum. QY, JX, HY http://en.volupedia.org/wiki/Proctitis 出血性直肠炎 10036778 proctitis haemorrhagic AE OAE:0005210 This is an AE which is all the tissue in the body that is not hardened by the processes of ossification or calcification with haemorrhage. QY, JX, HY http://en.volupedia.org/wiki/Soft_tissue 软组织出血 10051297 soft tissue hemorrhage AE OAE:0005211 This is an AE which is blood escaping from the circulatory system from damaged blood vessels occured on splenic. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 脾出血 10041647 splenic hemorrhage AE OAE:0005212 This is an AE which is a recognized characteristic physical sign of endocarditis and other systemic conditions associated with splinter haemorrhages include systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, peptic ulcer disease, malignancies, use of the oral contraceptive pill, pregnancy and psoriasis . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24273777/ 碎片出血 10041663 splinter hemorrhages AE OAE:0005213 This is an AE which is bleeding into the subarachnoid space the neonatal area between the arachnoid membrane and the pia mater surrounding the brain. QY, JX, HY http://en.volupedia.org/wiki/Subarachnoid_hemorrhage 新生儿蛛网膜下腔出血 10042317 subarachnoid hemorrhage neonatal AE OAE:0005214 This is an AE which is bleeding beneath the chorion membranes that enclose the embryo in the uterus and appears to occur due to partial detachment of the chorion membranes from the wall of the uterus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32644443/ 绒毛膜下血肿 10072596 subchorionic hematoma AE OAE:0005215 This is an AE which is bleeding beneath the chorion membranes that enclose the embryo in the uterus and appears to occur due to partial detachment of the chorion membranes from the wall of the uterus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32644443/ 绒毛膜下出血 10071010 subchorionic hemorrhage AE OAE:0005216 This is an AE which is a type of bleeding in which a collection of blood—usually associated with a traumatic brain injury—gathers between the inner layer of the dura mater and the arachnoid mater of the meninges surrounding the brain. QY, JX, HY http://en.volupedia.org/wiki/Subdural_hematoma 硬膜下出血 10042364 subdural hemorrhage AE OAE:0005217 This is an AE which is usually considered a single entity although the thalamus is composed of anatomically as well as functionally discrete subregions receiving blood from different arteries. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9009994/ 丘脑出血 10058939 thalamus hemorrhage AE OAE:0005218 This is an AE which is a condition characterized by increased intracranial pressure (pressure around the brain) without a detectable cause. QY, JX, HY http://en.volupedia.org/wiki/Idiopathic_intracranial_hypertension 良性颅内高血压 10004277 benign intracranial hypertension AE OAE:0005219 This is an AE which is the pressure of circulating blood against the walls of blood vessels and the data is fluctuation. QY, JX, HY http://en.volupedia.org/wiki/Blood_pressure 血压波动 10005746 blood pressure fluctuation AE OAE:0005220 This is an AE which is the form of hypertension that by definition has no identifiable secondary cause. QY, JX, HY http://en.volupedia.org/wiki/Essential_hypertension 原发性高血压 10015488 essential hypertension AE OAE:0005221 This is an AE which is the development of new hypertension in a pregnant woman after 20 weeks' gestation without the presence of protein in the urine or other signs of pre-eclampsia. QY, JX, HY http://en.volupedia.org/wiki/Gestational_hypertension 妊娠期高血压 10070538 gestational hypertension AE OAE:0005222 This is an AE which is a condition characterized by increased intracranial pressure (pressure around the brain) without a detectable cause. QY, JX, HY http://en.volupedia.org/wiki/Idiopathic_intracranial_hypertension 特发性颅内高血压 10078904 idiopathic intracranial hypertension AE OAE:0005223 This is an AE which is very high blood pressure with potentially life-threatening symptoms and signs of acute damage to one or more organ systems (especially brain, eyes, heart, aorta, or kidneys). QY, JX, HY http://en.volupedia.org/wiki/Hypertensive_emergency 恶性高血压 10025600 malignant hypertension AE OAE:0005224 This is an AE which is defined as systolic and/or diastolic BPs persistently equal to or greater than the 95th percentile for age, gender, and height. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29808264/ 新生儿低血压 10049223 neonatal hypotension AE OAE:0005225 This is an AE which is a medical condition consisting of a sudden and abrupt increase in blood pressure (BP) when a person stands up. QY, JX, HY http://en.volupedia.org/wiki/Orthostatic_hypertension 直立性高血压 10065508 orthostatic hypertension AE OAE:0005226 This is an AE which is defined by the coexistence of portal and pulmonary hypertension and is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from cirrhosis. QY, JX, HY http://en.volupedia.org/wiki/Portopulmonary_hypertension 肺移植性高血压 10067281 portopulmonary hypertension AE OAE:0005227 This is an AE which is the development of new hypertension in a pregnant woman after 20 weeks' gestation without the presence of protein in the urine or other signs of pre-eclampsia. QY, JX, HY http://en.volupedia.org/wiki/Gestational_hypertension 妊娠高血压 10036563 pregnancy induced hypertension AE OAE:0005228 This is an AE which is a condition in which high blood pressure is caused by the kidneys' hormonal response to narrowing of the arteries supplying the kidneys. QY, JX, HY http://en.volupedia.org/wiki/Renovascular_hypertension 肾性高血压 10038464 renal hypertension AE OAE:0005229 This is an AE which is defined as an elevated systolic blood pressure (SBP). QY, JX, HY http://en.volupedia.org/wiki/Systolic_hypertension 收缩期高血压 10042957 systolic hypertension AE OAE:0005230 This is an AE which is a form of labile hypertension in which people exhibit a blood pressure level above the normal range, in a clinical setting, although they do not exhibit it in other settings. QY, JX, HY http://en.volupedia.org/wiki/White_coat_hypertension 白大衣高血压 10051581 white coat hypertension AE OAE:0005231 This is an AE which is a usually benign vascular tumor occurs on intracranialderived from blood vessel cell types . QY, JX, HY http://en.volupedia.org/wiki/Hemangioma 颅内血管瘤 10022759 intracranial haemangioma AE OAE:0005232 This is an AE which occurs when there are unexpected changes in blood pressure. QY, JX, HY http://en.volupedia.org/wiki/Labile_hypertension 血压不稳定 10023533 labile blood pressure AE OAE:0005233 This is an AE which occurs when there are unexpected changes in blood pressure. QY, JX, HY http://en.volupedia.org/wiki/Labile_hypertension 高血压不稳定 10049079 labile hypertension AE OAE:0005234 This is an AE which is an ultrasound (US) visible lesion of the brain, which appears as echogenic streaks or spots in the arteries of thalamus and basal ganglia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21648326/ 连状纹状体血管病变 10073774 lenticulostriatal vasculopathy AE OAE:0005235 This is an AE which is inflammation of small blood vessels (usually post-capillary venules in the dermis), characterized by palpable purpura and it is the most common vasculitis seen in clinical practice. QY, JX, HY http://en.volupedia.org/wiki/Cutaneous_small-vessel_vasculitis 白细胞性血管炎 10024377 leukocytoclastic vasculitis AE OAE:0005236 This is an AE which is a medical condition in which injury to the large or small intestine occurs due to not enough blood supply. QY, JX, HY http://en.volupedia.org/wiki/Intestinal_ischemia 肠系膜血管机能不全 10027401 mesenteric vascular insufficiency AE OAE:0005237 This is an AE which refers to the subset of disorders affecting the structure and function of the coronary microcirculation, is prevalent in patients across a broad spectrum of cardiovascular risk factors, and is associated with an increased risk of adverse events. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30466521/ 微血管冠状动脉疾病 10072685 microvascular coronary artery disease AE OAE:0005238 This is an AE which is a cutaneous condition that presents as slowly growing, multiple, discrete but grouped, red to violaceous papules. QY, JX, HY http://en.volupedia.org/wiki/Multinucleate_cell_angiohistiocytoma 多核细胞血管组织细胞瘤 10077003 multinucleate cell angiohistiocytoma AE OAE:0005239 This is an AE which constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33153227/ 新生血管老年性黄斑变性 10071129 neovascular age-related macular degeneration AE OAE:0005240 This is an AE which is the natural formation of new blood vessels (neo- + vascular + -ization), usually in the form of functional microvascular networks, capable of perfusion by red blood cells, that form to serve as collateral circulation in response to local poor perfusion or ischemia. QY, JX, HY http://en.volupedia.org/wiki/Neovascularization 新血管化 10029113 neovascularisation AE OAE:0005241 This is an AE which is a skin condition characterized by crops of small, tender, erythematous nodules on the legs, mostly on the calves and shins. QY, JX, HY http://en.volupedia.org/wiki/Nodular_vasculitis 结节性血管炎 10029491 nodular vasculitis AE OAE:0005242 This is an AE which encompass a large and diverse group of underlying pathologies ranging from venous thromboembolism to congenital malformations to inflammatory vasculitides. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26024602/ 肺血管疾病 10061474 pulmonary vascular disorder AE OAE:0005243 This is an AE which encompasses inflammation in the pulmonary vasculature with involved vessels varying in caliber from large elastic arteries to capillaries. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25836645/ 肺血管炎 10037457 pulmonary vasculitis AE OAE:0005244 This is an AE which is a disease characterized by a weeks-long course of thunderclap headaches, sometimes focal neurologic signs, and occasionally seizures. QY, JX, HY http://en.volupedia.org/wiki/Reversible_cerebral_vasoconstriction_syndrome 可逆性脑血管收缩综合征 10073240 reversible cerebral vasoconstriction syndrome AE OAE:0005245 This is an AE which is skin condition that is a typical feature of rheumatoid arthritis, presenting as peripheral vascular lesions that are localized purpura, cutaneous ulceration, and gangrene of the distal parts of the extremities. QY, JX, HY http://en.volupedia.org/wiki/Rheumatoid_vasculitis 类风湿性血管炎 10048628 rheumatoid vasculitis AE OAE:0005246 This is an AE which is an area of swelling (edema) of the lower layer of small bowel tissue just under the skin or mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Angioedema 小肠血管性水肿 10051401 small bowel angiedema AE OAE:0005247 This is an AE which are rare and constitute only 1% to 2% of all vascular neurologic pathologies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17493539/ 脊髓血管疾病 10061369 spinal vascular disorder AE OAE:0005248 This is an AE which is a form of dysautonomia characterized by an inappropriate drop in blood pressure while in the upright position. QY, JX, HY http://en.volupedia.org/wiki/Hypotension#Vasovagal_syncope 迷走性晕厥血管 10042777 syncope vasovagal AE OAE:0005249 This is an AE which refers to a recognized group of birth defects which tend to co-occur (see below). QY, JX, HY http://en.volupedia.org/wiki/VACTERL_association 血管综合征 10066022 vacterl syndrome AE OAE:0005250 This is an AE which is a skin condition characterized by fixed urticarial lesions that appear histologically as a vasculitis. QY, JX, HY http://en.volupedia.org/wiki/Urticarial_vasculitis 荨麻疹性血管炎 10048820 urticarial vasculitis AE OAE:0005251 This is an AE which is any of a range of lesions from a simple birthmark to a large tumor that may be disfiguring. QY, JX, HY http://en.volupedia.org/wiki/Vascular_anomaly 血管异常 10047050 vascular anomaly AE OAE:0005252 This is an AE which is a complex and highly regulated process that involves activation of cellular signaling pathways, circulating inhibitors of calcification, genetic factors, and hormones. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25435520/ 血管钙化 10051753 vascular calcification AE OAE:0005253 This is an AE which means any disorder or disease of the brain vascular , especially chronic degenerative conditions. QY, JX, HY http://en.volupedia.org/wiki/Encephalopathy 血管性脑病 10063661 vascular encephalopathy AE OAE:0005255 This is an AE which is the use of transplanted or prosthetic blood vessels in surgical procedures and after surgical appears complication. QY, JX, HY http://en.volupedia.org/wiki/Graft_(surgery) 血管移植并发症 10064252 vascular graft complication AE OAE:0005256 This is an AE which is an outdated term to describe certain types of headache which were thought to be related to blood vessel swelling and hyperemia as cause of pain. QY, JX, HY http://en.volupedia.org/wiki/Vascular_headache 血管性头痛 10047077 vascular headache AE OAE:0005257 This is an AE which is a devastating complication of acute knee dislocation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24554457/ 血管损伤 10047080 vascular injury AE OAE:0005258 This is an AE which is a blood vessel or lymph vessel abnormality. Vascular malformations are one of the classifications of vascular anomalies, the other grouping is vascular tumors. QY, JX, HY http://en.volupedia.org/wiki/Vascular_malformation 血管畸形 10074979 vascular malformation AE OAE:0005259 This is an AE which is a tumor of vascular origin; a soft tissue growth that can be either benign or malignant, formed from blood vessels or lymph vessels. QY, JX, HY http://en.volupedia.org/wiki/Vascular_tumor 血管肿瘤 10055031 vascular neoplasm AE OAE:0005260 This is an AE which is when there is a local hematoma being contained by the surrounding tissue around an vascular artery. QY, JX, HY http://en.volupedia.org/wiki/Pseudoaneurysm 血管假性动脉瘤 10048975 vascular pseudoaneurysm AE OAE:0005261 This is an AE which is a condition of red or purple discolored spots on the skin that do not blanch on applying pressure. QY, JX, HY http://en.volupedia.org/wiki/Purpura 血管性紫癜 10047097 vascular purpura AE OAE:0005262 This is an AE which is a change of the human skin which affects its color, appearance, or texture and causes by vascular disease. QY, JX, HY http://en.volupedia.org/wiki/Rash 血管炎性皮疹 10047111 vasculitic rash AE OAE:0005263 This is an AE which is vasculitis (inflammation of the blood vessel wall) involving the brain and occasionally the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_vasculitis 脑血管炎 10047119 vasculitis cerebral AE OAE:0005264 This is an AE which is the narrowing of the blood vessels resulting from contraction of the muscular wall of the vessels, in particular the large arteries and small arterioles. QY, JX, HY http://en.volupedia.org/wiki/Vasoconstriction 血管收缩 10047139 vasoconstriction AE OAE:0005265 This is an AE which is excess accumulation of fluid (edema) in the intracellular or extracellular spaces of the vasogenic brain. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_edema 血管源性脑水肿 10067275 vasogenic cerebral edema AE OAE:0005266 This is an AE which is inflammation of the inner part of the nose that is not caused by an allergy. QY, JX, HY http://en.volupedia.org/wiki/Nonallergic_rhinitis 血管运动性鼻炎 10047145 vasomotor rhinitis AE OAE:0005267 This is an AE which is a postperfusion syndrome characterized by low systemic vascular resistance and a high cardiac output. QY, JX, HY http://en.volupedia.org/wiki/Vasoplegic_syndrome 血管麻痹综合征 10067080 vasoplegia syndrome AE OAE:0005268 This is an AE which refers to a condition in which an arterial spasm leads to vasoconstriction. QY, JX, HY http://en.volupedia.org/wiki/Vasospasm 血管痉挛 10047163 vasospasm AE OAE:0005269 This is an AE which is a type of arrhythmia. QY, JX, HY http://en.volupedia.org/wiki/Arrhythmia#Ventricular_arrhythmia 室性心律失常 10047281 ventricular arrhythmia AE OAE:0005271 This is an AE which refers to a condition where the left atrium or right atrium of the heart is larger than would be expected. It can also affect both atria. QY, JX, HY http://en.volupedia.org/wiki/Atrial_enlargement 心室扩大 10079339 ventricular enlargement AE OAE:0005272 This is an AE which is a set of manifestations caused by the failure of the heart's function as a pump supporting the blood flow through the body; its signs and symptoms result from a structural and/or functional abnormality of the heart, that disrupts its filling with blood or its ejecting of it during each heart beat. QY, JX, HY http://en.volupedia.org/wiki/Heart_failure 心室衰竭 10060953 ventricular failure AE OAE:0005273 This is an AE which is an arrhythmia, more specifically a tachycardia affecting the ventricles with a rate over 250-350 beats/min, and one of the most indiscernible. QY, JX, HY http://en.volupedia.org/wiki/Ventricular_flutter 心室扑动 10047294 ventricular flutter AE OAE:0005274 This is an AE which is thickening of the walls of a ventricle (lower chamber) of the heart. QY, JX, HY http://en.volupedia.org/wiki/Ventricular_hypertrophy 心室肥大 10047295 ventricular hypertrophy AE OAE:0005275 This is an AE which is one of the classifications of movement disorders causes by ventricular disease, and refers to decreased bodily movement . QY, JX, HY http://en.volupedia.org/wiki/Hypokinesia 心室运动减退 10050510 ventricular hypokinesia AE OAE:0005276 This is an AE which is a defect in the ventricular septum, the wall dividing the left and right ventricles of the heart. QY, JX, HY http://en.volupedia.org/wiki/Ventricular_septal_defect 室间隔缺损 10047298 ventricular septal defect AE OAE:0005277 This is an AE which consists of multiple, radially oriented dilated medullary veins that drain into a transparenchymal venous stem. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/1442406/ 脑静脉血管瘤 10053485 venous angioma of brain AE OAE:0005278 This is an AE which is a group of disorders that destroy blood vessels by inflammation caused by viral. QY, JX, HY http://en.volupedia.org/wiki/Vasculitis 病毒性血管炎 10056281 viral vasculitis AE OAE:0005279 This is an AE which is a rare hemorrhagic diathesis, with clinical symptoms similar to those associated with the inherited form von Willebrand disease and syndrome is characterized by a lack of previous bleeding symptoms, negative familial history, and occurrence in a relatively older age. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28028990/ 获得性血管性血友病 10069495 acquired von willebrand's disease AE OAE:0005280 This is an AE which is small, reddish brown or even flesh-colored, smooth, shiny, 0.1 to 0.3 cm papules present over the sides of the nose and the medial portions of the cheeks. QY, JX, HY http://en.volupedia.org/wiki/Angiofibroma 血管纤维瘤 10002429 angiofibroma AE OAE:0005281 This is an AE which is a mature T-cell lymphoma of blood or lymph vessel immunoblasts characterized by a polymorphous lymph node infiltrate showing a marked increase in follicular dendritic cells (FDCs) and high endothelial venules (HEVs) and systemic involvement. QY, JX, HY http://en.volupedia.org/wiki/Angioimmunoblastic_T-cell_lymphoma 血管免疫母细胞性t细胞淋巴瘤 10002449 angioimmunoblastic t-cell lymphoma AE OAE:0005282 This is an AE which is the most common benign tumour of the kidney. QY, JX, HY http://en.volupedia.org/wiki/Angiomyolipoma 血管肌脂肪瘤 10051810 angiomyolipoma AE OAE:0005283 This is an AE which is a rare and aggressive cancer that starts in the endothelial cells that line the walls of blood vessels or lymphatic vessels. QY, JX, HY http://en.volupedia.org/wiki/Angiosarcoma 恶性血管皮内细胞瘤 10002476 angiosarcoma AE OAE:0005284 This is an AE which is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. QY, JX, HY http://en.volupedia.org/wiki/Angiotensin-converting_enzyme 血管紧张素转换酶 10050289 angiotensin converting enzyme AE OAE:0005285 This is an AE which is the creation of new blood vessels in the choroid layer of the eye. QY, JX, HY http://en.volupedia.org/wiki/Choroidal_neovascularization 脉络膜新生血管形成 10060823 choroidal neovascularisation AE OAE:0005286 This is an AE which is any disease that has the connective tissues of the body as a target of pathology. QY, JX, HY http://en.volupedia.org/wiki/Connective_tissue_disease 胶原血管病 10009905 collagen-vascular disease AE OAE:0005287 This is an AE which can be arbitrarily divided into micro- and macrovascular complications, the major microvascular complications being nephropathy, retinopathy and neuropathy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9315387/ 糖尿病性血管疾病 10061815 diabetic vascular disorder AE OAE:0005288 This is an AE which is an extremely rare autoimmune condition that causes inflammation of small and medium-sized blood vessels (vasculitis) in persons with a history of airway allergic hypersensitivity (atopy). QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_granulomatosis_with_polyangiitis 嗜酸性肉芽肿伴多血管炎 10078117 eosinophilic granulomatosis with polyangiitis AE OAE:0005289 This is an AE which is the rupturing (lysis) of intravascular red blood cells (erythrocytes) and the release of their contents (cytoplasm) into surrounding fluid (e.g. blood plasma) . QY, JX, HY http://en.volupedia.org/wiki/Hemolysis 血管内溶血 10022822 intravascular haemolysis AE OAE:0005290 This is an AE which is a rare, benign tumor. It may mimic an angiosarcoma, with lesions that are red or purplish 5-mm to 5-cm papules and deep nodules on the head, neck, or upper extremities. QY, JX, HY http://en.volupedia.org/wiki/Intravascular_papillary_endothelial_hyperplasia 血管内乳头状内皮增生 10060711 intravascular papillary endothelial hyperplasia AE OAE:0005291 This is an AE which is the natural formation of new iris blood vessels (neo- + vascular + -ization), usually in the form of functional microvascular networks, capable of perfusion by red blood cells, that form to serve as collateral circulation in response to local poor perfusion or ischemia. QY, JX, HY http://en.volupedia.org/wiki/Neovascularization 虹膜新生血管化 10065630 iris neovascularisation AE OAE:0005292 This is an AE which is a rare anatomical variant in which the aortic arch is on the right side rather than on the left. During normal embryonic development, the aortic arch is formed by the left fourth aortic arch and the left dorsal aorta. QY, JX, HY http://en.volupedia.org/wiki/Right-sided_aortic_arch 右主动脉弓 10067407 right aortic arch AE OAE:0005293 This is an AE which occurs late after the modified Fontan procedure is frequently associated with low output states, supraventricular arrhythmias, and atrial thrombus formation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9240287/ 右心房扩张 10067282 right atrial dilatation AE OAE:0005294 This is an AE which is a form of cardiomegaly, or heart enlargement. QY, JX, HY http://en.volupedia.org/wiki/Right_atrial_enlargement 右心房扩大 10058227 right atrial enlargement AE OAE:0005295 This is an AE which may can result in a lack of emotional prosody or intonation when speaking. Right hemisphere damage also has grave effects on understanding discourse and have a reduced ability to generate inferences, comprehend and produce main concepts, and a reduced ability to manage alternative meanings. QY, JX, HY http://en.volupedia.org/wiki/Lateralization_of_brain_function#Hemisphere_damage 右半球缺陷综合征 10075037 right hemisphere deficit syndrome AE OAE:0005297 This is an AE which is an accepted indication of ASD closure and several studies have reported that transcatheter ASD closure results in RV remodeling and exercise capacity improvement . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32410917/ 右心室扩张 10074222 right ventricular dilatation AE OAE:0005298 This is an AE which is a form of cardiomegaly, or heart enlargement. QY, JX, HY http://en.volupedia.org/wiki/Right_atrial_enlargement 右心室增大 10050582 right ventricular enlargement AE OAE:0005299 This is an AE which is a condition defined by an abnormal enlargement of the cardiac muscle surrounding the right ventricle. QY, JX, HY http://en.volupedia.org/wiki/Right_ventricular_hypertrophy 右心室肥大 10050326 right ventricular hypertrophy AE OAE:0005300 This is an AE which is an abnormal, congenital heart murmur caused by subaortic stenosis (SAS). QY, JX, HY http://en.volupedia.org/wiki/Subvalvular_aortic_stenosis_(canine) 瓣下主动脉瓣狭窄 10042431 subvalvular aortic stenosis AE OAE:0005301 This is an AE which is a congenital obstructive narrowing of the aorta just above the aortic valve and is the least common type of aortic stenosis. QY, JX, HY http://en.volupedia.org/wiki/Supravalvular_aortic_stenosis 瓣上主动脉瓣狭窄 10042598 supravalvular aortic stenosis AE OAE:0005302 This is an AE which has been defined by Abbot as a condition in which the arterial vessels in the greater circulation remain abnormally small. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/13617202/ 主动脉发育不全 10049209 aorta hypoplasia AE OAE:0005303 This is an AE which is the thickening, hardening, and loss of elasticity of the walls of arteries on aortic. QY, JX, HY http://en.volupedia.org/wiki/Arteriosclerosis 主动脉硬化 10065558 aortic arteriosclerosis AE OAE:0005304 This is an AE which is the abnormal sound generated by turbulent flow of blood in an aortic artery due to either an area of partial obstruction or a localized high rate of blood flow through an unobstructed aortic bruit artery. QY, JX, HY http://en.volupedia.org/wiki/Bruit 主动脉杂音 10051832 aortic bruit AE OAE:0005305 This is an AE which refers to the widening of luminal diameter in aortic blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Dilation 主动脉扩张 10057453 aortic dilatation AE OAE:0005306 This is an AE which could interfere with the classification of TEVAR complications. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32069982/ 主动脉延长 10065510 aortic elongation AE OAE:0005307 This is an AE which clotted blood which lines most aortic aneurysms can break off and result in an embolus. QY, JX, HY http://en.volupedia.org/wiki/Aortic_aneurysm 主动脉栓塞 10002897 aortic embolus AE OAE:0005308 This is an AE which due to aortic thrombosis is a rare condition which is often life-threatening. and occurs most commonly in individuals who are predisposed to cardiovascular diseases. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31079271/ 主动脉闭塞 10058178 aortic occlusion AE OAE:0005309 This is an AE which is the rupture or breakage of the aorta, the largest artery in the body. QY, JX, HY http://en.volupedia.org/wiki/Aortic_rupture 主动脉破裂 10060874 aortic rupture AE OAE:0005310 This is an AE which is the narrowing of the exit of the left ventricle of the heart (where the aorta begins), such that problems result. QY, JX, HY http://en.volupedia.org/wiki/Aortic_stenosis 主动脉瓣狭窄 10002906 aortic stenosis AE OAE:0005311 This is an AE which refers to the calcification in and around the aortic valve can progress and extend to involve the electrical conduction system of the heart in calcific aortic stenosis. QY, JX, HY http://en.volupedia.org/wiki/Aortic_stenosis 主动脉瓣钙化 10002918 aortic valve calcification AE OAE:0005312 This is an AE which is the increase in the volume of anaortic wall due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 主动脉壁肥大 10066243 aortic wall hypertrophy AE OAE:0005313 This is an AE which is the inflammation of the aortic walland the disorder is potentially life-threatening and rare. QY, JX, HY http://en.volupedia.org/wiki/Aortitis 主动脉炎 10002921 aortitis AE OAE:0005314 This is an AE which is a congenital condition whereby the aorta is narrow, usually in the area where the ductus arteriosus (ligamentum arteriosum after regression) inserts. QY, JX, HY http://en.volupedia.org/wiki/Coarctation_of_the_aorta 主动脉狭窄 10009807 coarctation of the aorta AE OAE:0005315 This is an AE which is where the capillaries, usually of the legs or lungs, are inflamed. QY, JX, HY http://en.volupedia.org/wiki/Capillaritis 毛细管炎 10068406 capillaritis AE OAE:0005316 This is an AE which is a small blood vessel from 5 to 10 micrometres (μm) in diameter, and having a wall one endothelial cell thick and its may become disorder. QY, JX, HY http://en.volupedia.org/wiki/Capillary 毛细管障碍 10007189 capillary disorder AE OAE:0005317 This is an AE which might be a useful clinical sign for screening Zika virus infection. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28532852/ 毛细血管变脆 10007191 capillary fragility AE OAE:0005318 This is an AE which is a combination of both myocarditis and pericarditis appearing in a single individual, namely inflammation of both the pericardium and the heart muscle. QY, JX, HY http://en.volupedia.org/wiki/Myopericarditis 心肌心包炎 10028650 myopericarditis AE OAE:0005319 This is an AE which is an abnormal dilatation of pericardium of the heart. QY, JX, HY http://en.volupedia.org/wiki/Pericardial_cyst 心包囊肿 10051730 pericardial cyst AE OAE:0005320 This is an AE which is a pathological wound healing on the pericardial in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis 心包纤维化 10048724 pericardial fibrosis AE OAE:0005321 This is an AE which is a medical condition characterized by a thickened, fibrotic pericardium, limiting the heart's ability to function normally. QY, JX, HY http://en.volupedia.org/wiki/Constrictive_pericarditis 紧缩性心包炎 10034487 pericarditis constrictive AE OAE:0005322 This is an AE which is inflammation of the pericardium (the fibrous sac surrounding the heart)and may be caused by viral, bacterial, or fungal infection. QY, JX, HY http://en.volupedia.org/wiki/Pericarditis#Infectious 感染性心包炎 10062491 pericarditis infective AE OAE:0005323 This is an AE which is inflammation of the pericardium (the fibrous sac surrounding the heart)caused by meningococcal. QY, JX, HY http://en.volupedia.org/wiki/Pericarditis 脑膜炎球菌心包炎 10034492 pericarditis meningococcal AE OAE:0005324 This is an AE which is a form of pericarditis and caused by tuberculosis is difficult to diagnose, because definitive diagnosis requires culturing Mycobacterium tuberculosis from aspirated pericardial fluid or pericardial biopsy, which requires high technical skill and is often not diagnostic (the yield from culture is low even with optimum specimens). QY, JX, HY http://en.volupedia.org/wiki/Tuberculous_pericarditis 结核性心包炎 10055069 pericarditis tuberculous AE OAE:0005325 This is an AE which is a localised infection of the pericardial space associated with purulent pericardial fluid. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18214575/ 化脓性心包炎 10051071 purulent pericarditis AE OAE:0005326 This is an AE which is inflammation of the pericardium (the fibrous sac surrounding the heart). QY, JX, HY http://en.volupedia.org/wiki/Pericarditis#Infectuous 病毒性心包炎 10047472 viral pericarditis AE OAE:0005327 This is an AE which occurs by direct infection during trauma, thoracic surgery, or catheter drainage, by spread from an intrathoracic, myocardial, or subdiaphragmatic focus, and by hematogenous dissemination. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15725041/ 细菌心包炎 10004050 bacterial pericarditis AE OAE:0005328 This is an AE which is a restriction in blood supply to brain stem tissues, causing a shortage of oxygen that is needed for cellular metabolism (to keep tissue alive). QY, JX, HY http://en.volupedia.org/wiki/Ischemia 脑干缺血 10006148 brain stem ischaemia AE OAE:0005329 This is an AE which is a medical condition in which inflammation and injury of the large intestine result from inadequate blood supply. QY, JX, HY http://en.volupedia.org/wiki/Ischemic_colitis 缺血性结肠炎 10009895 colitis ischemic AE OAE:0005330 This is an AE which is a form of hypoxia (reduced supply of oxygen), specifically involving the brain; when the brain is completely deprived of oxygen, it is called cerebral anoxia. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_hypoxia 缺氧缺血性脑病 10070511 hypoxic-ischemic encephalopathy AE OAE:0005331 This is an AE which is the pathologic process that results in an area of necrotic tissue in the ischaemic brain (cerebral infarct). QY, JX, HY http://en.volupedia.org/wiki/Cerebral_infarction 缺血性脑梗死 10060840 ischemic cerebral infarction AE OAE:0005332 This is an AE which is a recognized complication of prolonged periods of interruption of the coronary circulation during open-heart surgery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/1186287/ 左心室缺血挛缩 10070589 ischemic contracture of the left ventricle AE OAE:0005333 This is an AE which is a clinical syndrome frequently encountered in critically ill patients that represents a complication of underlying cardiac, circulatory, or respiratory failure. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28346236/ 缺血性肝炎 10023025 ischemic hepatitis AE OAE:0005334 This is an AE which is a dangerous condition, most often caused by diminished tissue perfusion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29742040/ 缺血性四肢疼痛 10062610 ischemic limb pain AE OAE:0005335 This is an AE which is a devastating complication after open or endovascular aortic repair for thoracoabdominal aortic disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30507678/ 脊髓缺血 10050209 spinal cord ischaemia AE OAE:0005336 This is an AE which is a congenital heart defect in which the septal and posterior leaflets of the tricuspid valve are displaced towards the apex of the right ventricle of the heart. QY, JX, HY http://en.volupedia.org/wiki/Ebstein%27s_anomaly 三尖瓣下移畸形 10014075 ebstein's anomaly AE OAE:0005337 This is an AE which is a congenital malformation of the pulmonary artery valve in which the valve orifice fails to develop . QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_atresia 肺动脉闭锁 10037337 pulmonary artery atresia AE OAE:0005338 This is an AE which can occur from many causes, including abnormal pulmonary hemodynamics, hypoxemia, trauma, and vasculitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32022665/ 肺动脉扩张 10058491 pulmonary artery dilatation AE OAE:0005339 This is an AE which is not a rare condition, is mostly asymptomatic in the absence of a peripheral VA, is strongly associated with diabetes and is promoted by long TCC carriage. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29893920/ 上腔静脉狭窄 10064771 superior vena cava stenosis AE OAE:0005340 This is an AE which is the most common variation of the thoracic venous system. QY, JX, HY http://en.volupedia.org/wiki/Persistent_left_superior_vena_cava 持续性左上腔静脉 10064193 persistent left superior vena cava AE OAE:0005341 This is an AE which refers to enlargement of the left atrium (LA) of the heart, and is a form of cardiomegaly. QY, JX, HY http://en.volupedia.org/wiki/Left_atrial_enlargement 左心室增大 10051860 left atrial enlargement AE OAE:0005342 This is an AE which is thickening of the heart muscle of the left ventricle of the heart, that is, left-sided ventricular hypertrophy. QY, JX, HY http://en.volupedia.org/wiki/Left_ventricular_hypertrophy 左心室扩张 10050043 left ventricular dilatation AE OAE:0005343 This is an AE which is the most common and the most serious complication and is associated with increased morbidity, short- and long-term mortality, and healthcare resource utilization. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27671216/ 心输出量低综合征 10024899 low cardiac output syndrome AE OAE:0005344 This is an AE which commonly refers to the excess deposition of extracellular matrix in the cardiac muscle, but the term may also refer to an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_fibrosis 心肌纤维化 10028594 myocardial fibrosis AE OAE:0005345 This is an AE which is defined as a myocardial:skeletal signal intensity ratio >1.9. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30143429/ 心肌水肿 10064966 myocardial edema AE OAE:0005346 This is an AE which is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). QY, JX, HY http://en.volupedia.org/wiki/Reperfusion_injury 心肌再灌注损伤 10051624 myocardial reperfusion injury AE OAE:0005347 This is an AE which is an uncommon cause of infectious myocarditis and is usually seen in the context of overwhelming sepsis or as part of a specific bacterial syndrome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17613408/ 细菌性心肌炎 10065218 myocarditis bacterial AE OAE:0005348 This is an AE which is the result of an immune response to a microbial infection of the heart. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29536322/ 心肌炎传染性 10066857 myocarditis infectious AE OAE:0005349 This is an AE which is inflammation of the heart muscle with septic. QY, JX, HY http://en.volupedia.org/wiki/Myocarditis 脓毒性心肌炎 10028615 myocarditis septic AE OAE:0005350 This is an AE which is a sudden loss of blood flow resulting from the failure of the heart to pump effectively. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_arrest 心源性猝死 10049418 sudden cardiac death AE OAE:0005351 This is an AE which is a heart rate that exceeds the normal resting rate occurs on foetal. QY, JX, HY http://en.volupedia.org/wiki/Tachycardia 胎儿心动过速 10043074 tachycardia foetal AE OAE:0005352 This is an AE which is a heart rate that exceeds the normal resting rate. QY, JX, HY http://en.volupedia.org/wiki/Tachycardia 心动过速 10064805 tachyphrenia AE OAE:0005353 This is an AE which can range from nonspecific symptoms of fatigue and shortness of breath to more aggressive symptoms that mimic acute coronary syndrome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32127272/ 病毒性心肌炎 10047470 viral myocarditis AE OAE:0005354 This is an AE which is the most severe form of hypertension, defined clinically by very high blood pressure (diastolic above 130 mm Hg) accompanied by bilateral retinal hemorrhages and/or exudates, with or without papilledema. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28200072/ 急进性高血压 10000358 accelerated hypertension AE OAE:0005355 This is an AE which is a ventricular rhythm with a rate of between 40 and 120 beats per minute. QY, JX, HY http://en.volupedia.org/wiki/Accelerated_idioventricular_rhythm 加速的心室节律 10049003 accelerated idioventricular rhythm AE OAE:0005356 This is an AE which is defined as abnormal heart rates in the neonatal period and they may occur as a result of various cardiovascular, systemic and metabolic problems. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26037725/ 新生儿心律不齐 10003124 arrhythmia neonatal AE OAE:0005357 This is an AE which is one of the main causes of medical consultation and they may also be the clinical presentation of various cardiovascular diseases and a marker of sudden death. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28055994/ 室上性心律失常 10003130 arrhythmia supraventricular AE OAE:0005358 This is an AE which refers to a condition where the left atrium or right atrium of the heart is larger than would be expected. It can also affect both atria. QY, JX, HY http://en.volupedia.org/wiki/Atrial_enlargement 心房扩大 10079340 atrial enlargement AE OAE:0005359 This is an AE which is a congenital heart defect in which blood flows between the atria (upper chambers) of the heart. QY, JX, HY http://en.volupedia.org/wiki/Atrial_septal_defect 心房中隔缺损 10003664 atrial septal defect AE OAE:0005360 This is an AE which a relatively uncommon arrhythmia that is nonetheless increasingly seen in elderly people of developed countries, due to the increase in life expectancy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22897386/ 完全房室传导阻滞 10003673 atrioventricular block complete AE OAE:0005361 This is an AE which is characterized by a deficiency of the atrioventricular septum of the heart. QY, JX, HY http://en.volupedia.org/wiki/Atrioventricular_septal_defect 房室中隔缺损 10063836 atrioventricular septal defect AE OAE:0005362 This is an AE which comprise a group of abnormalities seen on the electrocardiogram (ECG) that often confuse clinicians and may conceal potentially lethal disease entities, such as acute myocardial infarction (MI). Cardiac impulses normally originate in the sinoatrial (SA) node and then are conducted through atrial tissue to the atrioventricular (AV) node and into the bundle of His. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16308112/ 心室传导缺陷 10012118 defect conduction intraventricular AE OAE:0005363 This is an AE which is thickening of the walls of a ventricle (lower chamber) of the heart and shows up on the ECG . QY, JX, HY http://en.volupedia.org/wiki/Ventricular_hypertrophy 心室肥大迹象 10050998 ecg signs of ventricular hypertrophy AE OAE:0005364 This is an AE which is a rare heart disorder usually occurring in children two years old and younger. QY, JX, HY http://en.volupedia.org/wiki/Endocardial_fibroelastosis 心内膜弹力纤维增生症 10014663 endocardial fibroelastosis AE OAE:0005365 This is an AE which refers to the excess deposition of extracellular matrix in the cardiac muscle, but the term may also refer to an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. QY, JX, HY http://en.volupedia.org/wiki/Cardiac_fibrosis 心内膜心肌纤维化 10014664 endocardial fibrosis AE OAE:0005366 This is an AE which is an inflammation of the inner layer of the heart, the endocardium caused by viral. QY, JX, HY http://en.volupedia.org/wiki/Endocarditis 心内膜炎病毒 10061837 endocarditis viral AE OAE:0005367 This is an AE which is inflammation in the heart muscle that is caused by the infiltration and destructive activity of a type of white blood cell, the eosinophil. QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_myocarditis 嗜酸性心肌炎 10014961 eosinophilic myocarditis AE OAE:0005368 This is an AE which is an abnormal narrowing of arteries other than those that supply the heart or brain. QY, JX, HY http://en.volupedia.org/wiki/Peripheral_artery_disease 动脉闭塞性疾病 10062599 arterial occlusive disease AE OAE:0005369 This is an AE which refers to a condition in which an arterial spasm leads to vasoconstriction. QY, JX, HY http://en.volupedia.org/wiki/Vasospasm 动脉痉挛 10003175 arterial spasm AE OAE:0005370 This is an AE which is an abnormal narrowing in a arterial blood vessel or other tubular organ or structure. QY, JX, HY http://en.volupedia.org/wiki/Stenosis 动脉狭窄 10060965 arterial stenosis AE OAE:0005371 This is an AE which is the increase in the volume of an arterial wall due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 动脉壁肥大 10072809 arterial wall hypertrophy AE OAE:0005372 This is an AE which defined by a severe reversible diffuse or focal vasoconstriction is the most common diagnosis among INOCA (ischemia with no obstructive coronary artery disease) patients irrespective to racial, genetic, and geographic variations. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32508542/ 冠状动脉痉挛 10003225 arterio spasm coronary AE OAE:0005373 This is an AE which is an abnormal connection between arteries and veins, bypassing the capillary system. QY, JX, HY http://en.volupedia.org/wiki/Arteriovenous_malformation 动静脉畸形 10003193 arteriovenous malformation AE OAE:0005374 This is an AE which is responsible for stenosis, occlusion or aneurysms, and occur in the coronary artery, causing myocardial infarction. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28691733/ 冠状动脉炎 10003232 arteritis coronary AE OAE:0005375 This is an AE which is an abnormal enlargement of the pampiniform venous plexus in the scrotum. QY, JX, HY http://en.volupedia.org/wiki/Varicocele 精索静脉曲张 10046986 varicocele AE OAE:0005376 This is an AE which is a common disease in the medical practice of dermatologists and phlebologists. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21057915/ 曲张静脉炎 10056717 varicophlebitis AE OAE:0005377 This is an AE which is a medical condition in which superficial veins become enlarged and twisted. QY, JX, HY http://en.volupedia.org/wiki/Varicose_veins 静脉曲张 10046986 varicose vein AE OAE:0005378 This is an AE which is a common injury that results from repeated use of intravenous injections. QY, JX, HY http://en.volupedia.org/wiki/Collapsed_vein 静脉塌陷 10074621 vein collapse AE OAE:0005379 This is an AE which is a class of disease involving veins of the circulatory system. QY, JX, HY http://en.volupedia.org/wiki/Vein_disorders 静脉疾病 10047184 vein disorder AE OAE:0005380 This is an AE which is a distressing feeling on vein often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 静脉痛 10047187 vein pain AE OAE:0005381 This is an AE which is all in the cylindric axis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2321136/ 静脉破裂 10077110 vein rupture AE OAE:0005382 This is an AE which is the lodging of an embolus, a blockage-causing piece of material, inside a vena cava blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Embolism 腔静脉栓塞 10047193 vena cava embolism AE OAE:0005383 This is an AE which is damage to the vena cava caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 下腔静脉损伤 10047194 vena cava injury AE OAE:0005385 This is an AE which is the rare congenital disorders but the parotid gland VLMs are the rarest. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32584007/ 静脉淋巴管畸形 10079880 venolymphatic malformation AE OAE:0005386 This is an AE which is a potentially life-threatening condition in which some of the small veins in the liver are obstructed. QY, JX, HY http://en.volupedia.org/wiki/Hepatic_veno-occlusive_disease 静脉闭塞性疾病 10062173 venoocclusive disease AE OAE:0005387 This is an AE which is a benign phenomenon. QY, JX, HY http://en.volupedia.org/wiki/Venous_hum 静脉杂音 10065565 venous bruit AE OAE:0005388 This is an AE which is blood escaping from the circulatory system from damaged venous blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 静脉出血 10065441 venous hemorrhage AE OAE:0005389 This is an AE which can refer to varicose veins ,chronic venous insufficiency and venous stasis. QY, JX, HY http://en.volupedia.org/wiki/Venous_insufficiency 静脉功能不全 10057320 venous insufficiency AE OAE:0005390 This is an AE which is a generally solitary, soft, compressible, dark blue to violaceous, 0.2- to 1-cm papule commonly found on sun-exposed surfaces of the vermilion border of the lip, face and ears. QY, JX, HY http://en.volupedia.org/wiki/Venous_lake 静脉湖 10051510 venous lake AE OAE:0005391 This is an AE which is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. QY, JX, HY http://en.volupedia.org/wiki/Thrombosis 静脉闭塞 10058990 venous occlusion AE OAE:0005392 This is an AE which is a condition of slow blood flow in the veins, usually of the legs. QY, JX, HY http://en.volupedia.org/wiki/Venous_stasis 静脉淤滞 10047245 venous stasis AE OAE:0005393 This is an AE which is observed within 20 mm of the junction to the adjacent draining sinus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31323417/ 静脉狭窄 10048671 venous stenosis AE OAE:0005395 This is an AE which may contribute to posterior circulation ischemic events, especially when other risk factors coexist. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23816871/ 椎动脉发育不全 10066907 vertebral artery hypoplasia AE OAE:0005396 This is an AE which describes a temporary set of symptoms due to decreased blood flow (ischemia) in the posterior circulation of the brain. QY, JX, HY http://en.volupedia.org/wiki/Vertebrobasilar_insufficiency 椎基底动脉供血不足 10047334 vertebrobasilar insufficiency AE OAE:0005397 This is an AE which is syndrome caused by ischemia of the anterior spinal artery, resulting in loss of function of the anterior two-thirds of the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Anterior_spinal_artery_syndrome 脊髓前动脉综合征 10002703 anterior spinal artery syndrome AE OAE:0005398 This is an AE which is associated with a high risk of disability and mortality. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32568658/ 基底动脉阻塞 10048963 basilar artery occlusion AE OAE:0005399 This is an AE which is an outward bulging, likened to a bubble or balloon, caused by a localized, abnormal, weak spot on a carotid blood vessel wall but it is ruptured. QY, JX, HY http://en.volupedia.org/wiki/Aneurysm 颈动脉动脉瘤破裂 10051328 carotid aneurysm rupture AE OAE:0005400 This is an AE which is an outward bulging, likened to a bubble or balloon, caused by a localized, abnormal, weak spot on a carotid artery blood vessel wall. QY, JX, HY http://en.volupedia.org/wiki/Aneurysm 颈动脉动脉瘤 10007686 carotid artery aneurysm AE OAE:0005401 This is an AE which is often implicated in primary ischemic stroke secondary to thrombosis or embolism and may indicate concurrent cardiovascular disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7919691/ 颈动脉疾病 10061744 carotid artery disease AE OAE:0005402 This is an AE which refers blockage of a carotid artery blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Occlusion 颈动脉闭塞 10048964 carotid artery occlusion AE OAE:0005403 This is an AE which is a long lasting and continuously evolving disease with multiple clinical manifestations ranging from asymptomatic to stable angina, acute coronary syndrome (ACS), heart failure (HF) and sudden cardiac death (SCD). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27091673/ 冠状动脉动脉粥样硬化 10011076 coronary artery atherosclerosis AE OAE:0005404 This is an AE which is a surgical procedure to restore normal blood flow to an obstructed coronary artery. QY, JX, HY http://en.volupedia.org/wiki/Coronary_artery_bypass_surgery 冠状动脉搭桥 10011077 coronary artery bypass AE OAE:0005405 This is an AE which is an abnormal dilatation of part of the coronary artery. QY, JX, HY http://en.volupedia.org/wiki/Coronary_artery_aneurysm 冠状动脉扩张 10065420 coronary artery dilatation AE OAE:0005406 This is an AE which occurs when blood flow decreases or stops to the coronary artery of the heart, causing damage to the heart muscle. QY, JX, HY http://en.volupedia.org/wiki/Myocardial_infarction 冠状动脉闭塞 10011086 coronary artery occlusion AE OAE:0005407 This is an AE which involves the reduction of blood flow to the heart muscle due to build-up of plaque (atherosclerosis) in the arteries of the heart. QY, JX, HY http://en.volupedia.org/wiki/Coronary_artery_disease 冠状动脉狭窄 10011089 coronary artery stenosis AE OAE:0005408 This is an AE which occurs when an injury to the innermost layer of the coronary aorta allows blood to flow between the layers of the aortic wall, forcing the layers apart. QY, JX, HY http://en.volupedia.org/wiki/Aortic_dissection 解剖冠状动脉瘤 10013428 dissecting coronary artery aneurysm AE OAE:0005409 This is an AE which is the lodging of an embolus, a blockage-causing piece of material, inside a femoral artery blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Embolism 股动脉栓塞 10068365 femoral artery embolism AE OAE:0005410 This is an AE which refers blockage of a femoral artery blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Occlusion 股动脉闭塞 10052019 femoral artery occlusion AE OAE:0005411 This is an AE which is an inflammatory autoimmune disease of large blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Giant_cell_arteritis 巨细胞动脉炎 10018250 giant cell arteritis AE OAE:0005412 This is an AE which refers blockage of a iliac vein blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Occlusion 髂静脉阻塞 10058992 iliac vein occlusion AE OAE:0005413 This is an AE which is an abnormal narrowing of arteries other than those that supply the heart or brain. QY, JX, HY http://en.volupedia.org/wiki/Peripheral_artery_disease 周围动脉闭塞性疾病 10062585 peripheral arterial occlusive disease AE OAE:0005414 This is an AE which refers blockage of a peripheral artery blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Occlusion 外周动脉闭塞 10057525 peripheral artery occlusion AE OAE:0005415 This is an AE which refers blockage of a peripheral vein blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Occlusion 外周静脉阻塞 10083103 peripheral vein occlusion AE OAE:0005416 This is an AE which is the inflammation of a vein, usually in the legs. QY, JX, HY http://en.volupedia.org/wiki/Phlebitis 静脉周炎 10057267 periphlebitis AE OAE:0005417 This is an AE which presents in the umbilical cord. QY, JX, HY http://en.volupedia.org/wiki/Single_umbilical_artery 单脐动脉 10049807 single umbilical artery AE OAE:0005418 This is an AE which is a significant form of peripheral artery disease, which may be a marker of diffuse atherosclerosis and increased risk for cardiovascular events. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25051137/ 锁骨下动脉狭窄 10050180 subclavian artery stenosis AE OAE:0005419 This is an AE which is a form of large vessel granulomatous vasculitis with massive intimal fibrosis and vascular narrowing, most commonly affecting young or middle-age women of Asian descent, though anyone can be affected. QY, JX, HY http://en.volupedia.org/wiki/Takayasu%27s_arteritis 高安动脉炎 10043097 takayasu's arteritis AE OAE:0005420 This is an AE which is an inflammatory autoimmune disease of large blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Giant_cell_arteritis 颞动脉炎 10043207 temporal arteritis AE OAE:0005421 This is an AE which is a rare form of congenital heart disease that presents at birth. QY, JX, HY http://en.volupedia.org/wiki/Persistent_truncus_arteriosus 永存动脉干 10044703 truncus arteriosus persistent AE OAE:0005422 This is an AE which is a congenital defect of the pulmonary veins. QY, JX, HY http://en.volupedia.org/wiki/Anomalous_pulmonary_venous_connection 肺静脉连接异常 10058079 anomalous pulmonary venous connection AE OAE:0005423 This is an AE which is the catheter site inflammation of a vein, usually in the legs. QY, JX, HY http://en.volupedia.org/wiki/Phlebitis 导管部位静脉炎 10052269 catheter site phlebitis AE OAE:0005424 This is an AE which is a frequent finding in patients with cirrhosis and portal hypertension, and may be produced by various mechanisms. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9421656/ 下腔静脉扩张 10069111 inferior vena cava dilatation AE OAE:0005425 This is an AE which is an abnormal narrowing in a blood vessel or other tubular organ such as inferior vena cava or structure such as foramina and canals. QY, JX, HY http://en.volupedia.org/wiki/Stenosis 下腔静脉狭窄 10074639 inferior vena cava stenosis AE OAE:0005426 This is an AE which is the indirectly observed pressure over the venous system via visualization of the internal jugular vein. QY, JX, HY http://en.volupedia.org/wiki/Jugular_venous_pressure 颈静脉扩张 10059865 jugular vein distension AE OAE:0005427 This is an AE which is the most common type of congenital vascular malformation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29784122/ 畸形静脉 10025532 malformation venous AE OAE:0005428 This is an AE which may be an ocular complication of Buerger's disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29398225/ 乳头状静脉炎 10065373 papillophlebitis AE OAE:0005429 This is an AE which is the inflammation of a vein and is deep. QY, JX, HY http://en.volupedia.org/wiki/Phlebitis 深静脉炎 10034897 phlebitis deep AE OAE:0005430 This is an AE which is a small local, usually rounded, calcification within a vein. QY, JX, HY http://en.volupedia.org/wiki/Phlebolith 静脉结石 10051474 phlebolith AE OAE:0005431 This is an AE which is part of the complex biological response of portal tract tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 门静脉呼吸道炎症 10075331 portal tract inflammation AE OAE:0005432 This is an AE which is a rare finding on radiological exams. QY, JX, HY http://en.volupedia.org/wiki/Portal_vein#Clinical_significance 门静脉积气 10064711 portal venous gas AE OAE:0005433 This is an AE which results in venous hypertension with the formation of intra- and extrarenal collaterals and/or the development of gonadal vein reflux. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16374539/ 肾静脉压迫 10074386 renal vein compression AE OAE:0005434 This is an AE which is the lodging of an renal vein embolus, a blockage-causing piece of material, inside a blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Embolism 肾静脉栓塞 10038547 renal vein embolism AE OAE:0005435 This is an AE which has been often reported to be associated with acute decompensated heart failure and, to our knowledge. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33038002/ 肾静脉充血 10072109 renal venous congestion AE OAE:0005436 This is an AE which is characterized clinically by a local syndrome in an arm, the chest or a leg, by an irregular temperature (toothsaw curve), by blood cultures that are simultaneously or successively positive for one or several pathogenic microorganisms, by repeated, multiple infected embolism and by the possibility of endocarditis as a complication. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/866444/ 化脓性静脉炎 10056518 septic phlebitis AE OAE:0005437 This is an AE which is a vein that is close to the surface of the body and is prominent. QY, JX, HY http://en.volupedia.org/wiki/Superficial_vein 浅静脉突出 10068717 superficial vein prominence AE OAE:0005438 This is an AE which is important features of advanced heart failure. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33018978/ 内脏充血 10066397 visceral congestion AE OAE:0005439 This is an AE which is the build-up of fluid in the visceral tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 内脏水肿 10065768 visceral edema AE OAE:0005440 This is an AE which is pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera (organs). QY, JX, HY http://en.volupedia.org/wiki/Visceral_pain 内脏痛 10065385 visceral pain AE OAE:0005441 This is an AE which is a prolapse or a sinking of the abdominal viscera (internal organs) below their natural position. QY, JX, HY http://en.volupedia.org/wiki/Visceroptosis 内脏下垂 10063840 visceroptosis AE OAE:0005442 This is an AE which is a group of abnormal heart rhythms (arrhythmias) usually caused by a malfunction of the sinus node, the heart's primary pacemaker. QY, JX, HY http://en.volupedia.org/wiki/Sinus_node_dysfunction 窦房结功能障碍 10075889 sinus node dysfunction AE OAE:0005443 This is an AE which is an abnormal growth of sinus tissue projecting from a mucous membrane. QY, JX, HY http://en.volupedia.org/wiki/Polyp_(medicine) 窦性息肉 10040749 sinus polyp AE OAE:0005444 This is an AE which is any cardiac rhythm in which depolarisation of the cardiac muscle begins at the sinus node. QY, JX, HY http://en.volupedia.org/wiki/Sinus_rhythm 窦性心律 10048815 sinus rhythm AE OAE:0005445 This is an AE which is a commonly encountered variation of normal sinus rhythm. QY, JX, HY http://en.volupedia.org/wiki/Sinus_arrhythmia 窦性心律不齐 10040739 sinus arrhythmia AE OAE:0005446 This is an AE which is a form of iron overload disorder resulting in the accumulation of hemosiderin. QY, JX, HY http://en.volupedia.org/wiki/Hemosiderosis 含铁血黄素沉着病 10019024 haemosiderosis AE OAE:0005447 This is an AE which indicates accumulation of iron in the body from any cause. QY, JX, HY http://en.volupedia.org/wiki/Iron_overload 血色病 10018872 haemochromatosis AE OAE:0005448 This is an AE which maternal IgG antibodies with specificity for the ABO blood group system pass through the placenta to the fetal circulation where they can cause hemolysis of fetal red blood cells which can lead to fetal anemia and HDN. QY, JX, HY http://en.volupedia.org/wiki/Hemolytic_disease_of_the_newborn_(ABO) ABO血型不相容 10000206 abo incompatibility AE OAE:0005449 This is an AE which is a condition of the mucous membranes characterized by the sudden appearance of one or more blood blisters within the oral cavity. QY, JX, HY http://en.volupedia.org/wiki/Angina_bullosa_haemorrhagica 大疱性心绞痛出血 10064223 angina bullosa haemorrhagica AE OAE:0005450 This is an AE which frequently results in death, prompt treatment may result in full recovery . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3071324/ 低血糖昏迷 10021000 hypoglycaemic coma AE OAE:0005451 This is an AE which can damage the internal capsule and lead to high rates of disability and mortality. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31449206/ 基底节出血 10067057 basal ganglia hemorrhage AE OAE:0005452 This is an AE which is a type of prediabetes, in which a person's blood sugar levels during fasting are consistently above the normal range, but below the diagnostic cut-off for a formal diagnosis of diabetes mellitus. QY, JX, HY http://en.volupedia.org/wiki/Impaired_fasting_glucose 空腹血糖受损 10056997 impaired fasting glucose AE OAE:0005453 This is an AE which is the vomiting of blood. QY, JX, HY http://en.volupedia.org/wiki/Hematemesis 吐血 10018830 haematemesis AE OAE:0005454 This is an AE which is blood escaping from the circulatory system from damaged blood vessels and is traumatic . QY, JX, HY http://en.volupedia.org/wiki/Bleeding 外伤性出血 10053476 traumatic hemorrhage AE OAE:0005455 This is an AE which is the leakage of a fluid out of its container into the surrounding area, especially blood or blood cells from vessels. QY, JX, HY http://en.volupedia.org/wiki/Extravasation 外渗血 10015867 extravasation blood AE OAE:0005456 This is an AE which refers a generic term for the presence of toxins in the blood caused by bacterial. QY, JX, HY http://en.volupedia.org/wiki/Toxemia 细菌血毒症 10004053 bacterial toxaemia AE OAE:0005457 This is an AE which is a fall in blood sugar to levels below normal. QY, JX, HY http://en.volupedia.org/wiki/Hypoglycemia 休克性低血糖 10040576 shock hypoglycaemic AE OAE:0005458 This is an AE which is inflammation of the perivascular skin, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 血管周的皮炎 10064986 perivascular dermatitis AE OAE:0005459 This is an AE which related to renal replacement therapy (HIRRT) is a frequent complication of all renal replacement therapy (RRT) modalities commonly used in the intensive care unit. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31407042/ 血流动力不稳定 10052076 haemodynamic instability AE OAE:0005460 This is an AE which is a type of blister that forms when subdermal tissues and blood vessels are damaged without piercing the skin. QY, JX, HY http://en.volupedia.org/wiki/Blood_blister 血疱 10005372 blood blister AE OAE:0005461 This is an AE which is a common manifestation of plasma cell disease, and it is sometimes caused by autoimmune diseases (AIDs). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31550956/ 血球蛋白过多 10020633 hyperglobulinaemia AE OAE:0005462 This is an AE which is a disease caused by parasitic flatworms called schistosomes. QY, JX, HY http://en.volupedia.org/wiki/Schistosomiasis 血吸虫病 10039603 schistosomiasis AE OAE:0005465 This is an AE which is a rare congenital defect in which the major visceral organs are distributed abnormally within the chest and abdomen. QY, JX, HY http://en.volupedia.org/wiki/Situs_ambiguus 内脏异位 10067265 heterotaxia AE OAE:0005466 This is an AE which is a variant of asystole and is usually ventricular in origin. QY, JX, HY http://en.volupedia.org/wiki/Agonal_heart_rhythm 垂死心室律 10054015 agonal rhythm AE OAE:0005467 This is an AE which resulting from dysfunction of the heart. QY, JX, HY http://en.volupedia.org/wiki/Shock 休克症状 10040560 shock symptom AE OAE:0005468 This is an AE which is the lodging of an embolus, a blockage-causing piece of material, inside a blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Embolism 小栓塞 10073734 microembolism AE OAE:0005469 This is an AE which is a medical condition in which abnormal distribution of blood flow in the smallest blood vessels results in inadequate supply of blood to the body's tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Distributive_shock 分布性休克 10070559 distributive shock AE OAE:0005470 This is an AE which is a type of tissue death caused by a lack of blood supply. QY, JX, HY http://en.volupedia.org/wiki/Gangrene 坏疽 10017711 gangrene AE OAE:0005471 This is an AE which is a medical condition in which the spasm of small arteries causes episodes of reduced blood flow to end arterioles. QY, JX, HY http://en.volupedia.org/wiki/Raynaud_syndrome 雷诺现象 10037912 raynaud's phenomenon AE OAE:0005472 This is an AE which is the most common type of ischemic stroke, resulting from the occlusion of small penetrating arteries that provide blood to the brain's deep structures. QY, JX, HY http://en.volupedia.org/wiki/Lacunar_stroke 腔隙性梗死 10051078 lacunar infarction AE OAE:0005473 This is an AE which is a congenital heart defect where the left atrium (cor triatriatum sinistrum) or right atrium (cor triatriatum dextrum) is subdivided by a thin membrane, resulting in three atrial chambers (hence the name). QY, JX, HY http://en.volupedia.org/wiki/Cor_triatriatum 三房心 10010972 cor triatriatum AE OAE:0005474 This is an AE which is a defect of the bundle branches or fascicles in the electrical conduction system of the heart. QY, JX, HY http://en.volupedia.org/wiki/Bundle_branch_block 束支传导阻滞 10006578 bundle branch block AE OAE:0005476 This is an AE which refers to cardiac arrest in which the electrocardiogram shows a heart rhythm that should produce a pulse, but does not. Pulseless electrical activity is found initially in about 55% of people in cardiac arrest. QY, JX, HY http://en.volupedia.org/wiki/Pulseless_electrical_activity 无脉电活动 10058151 pulseless electrical activity AE OAE:0005477 QY, JX, HY 心血管机能不全 10065929 cardiovascular insufficiency AE OAE:0005478 QY, JX, HY 心脏感染 10054212 cardiac infection AE OAE:0005479 QY, JX, HY 心肺衰竭 10051093 cardiopulmonary failure AE OAE:0005480 QY, JX, HY 血肿肌肉 10055890 hematoma muscle AE OAE:0005481 QY, JX, HY 血压控制不足 10051128 blood pressure inadequately controlled AE OAE:0005482 QY, JX, HY 血管破裂 10053649 vascular rupture AE OAE:0005483 QY, JX, HY 非典型分枝杆菌心包炎 10055036 atypical mycobacterium pericarditis AE OAE:0005484 QY, JX, HY 缺血性坏死 10028862 necrosis ischemic AE OAE:0005485 QY, JX, HY 肺动脉病 10067284 pulmonary arteriopathy AE OAE:0005486 QY, JX, HY 心脏交替 10058155 heart alternation AE OAE:0005487 QY, JX, HY 髂动脉疾病 10077115 iliac artery disease AE OAE:0005488 QY, JX, HY 外周静脉疾病 10075049 peripheral venous disease AE OAE:0005490 This is an AE which is the space in the skull within the neurocranium, occupied by the brain and the is imperfectly composed in newborns, to allow the large human head to pass through the birth canal. QY, JX, HY http://en.volupedia.org/wiki/Cranial_vault 先天性颅穹窿缺失 10010318 congenital absence of cranial vault AE OAE:0005491 This is an AE which is the organs of the reproductive system and the urinary system and the organs are congenital malformation. QY, JX, HY http://en.volupedia.org/wiki/Genitourinary_system 先天性生殖器畸形 10062333 congenital genital malformation AE OAE:0005492 This is an AE which is a spectrum of conditions which is congenital caused by infection with the human immunodeficiency virus (HIV) , a retrovirus. QY, JX, HY http://en.volupedia.org/wiki/HIV/AIDS 先天性感染艾滋病毒 10010504 congenital hiv infection AE OAE:0005493 This is an AE which is syphilis present in utero and at birth, and occurs when a child is born to a mother with syphilis and osteochondritis. QY, JX, HY http://en.volupedia.org/wiki/Congenital_syphilis 先天性梅毒的骨软骨炎 10054002 congenital syphilitic osteochondritis AE OAE:0005494 This is an AE which is a condition thymus present at birth regardless of its cause. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect 先天性胸腺缺失 10048801 congenital thymus absence AE OAE:0005495 This is an AE which is a family of birth defects of the ureter, the bladder, and the urethra. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23408557/ 先天性输尿管膀胱交界异常 10068133 congenital ureterovesical junction anomaly AE OAE:0005496 This is an AE which is a defect in the structure of the heart or great vessels that is present at birth. QY, JX, HY http://en.volupedia.org/wiki/Congenital_heart_defect 先天性心脏瓣膜病 10064086 congenital heart valve disorder AE OAE:0005497 This is an AE which is a missing, extra, or irregular portion of chromosomal DNA. QY, JX, HY http://en.volupedia.org/wiki/Chromosome_abnormality x连锁染色体病 10056554 x-linked chromosomal disorder AE OAE:0005498 This is an Ae which is an organism's response to a stressor such as an environmental condition. QY, JX, HY http://en.volupedia.org/wiki/Stress_(biology) 家族性应激 10016215 family stress AE OAE:0005499 This is an AE which is an extremely rare developmental anomaly with right and left hepatic ducts draining directly into the gallbladder (GB). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27279403/ 先天性缺乏胆管 10010317 congenital absence of bile ducts AE OAE:0005500 This is an AE which is a rare cause of primary adrenocortical failure which involved a broad spectrum of cellular and physiologic processes, including metabolism, nuclear protein import, oxidative stress defense-mechanisms, and regulation of cell cycle. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25905355/ 先天性肾上腺发育不全 10049057 congenital adrenal gland hypoplasia AE OAE:0005501 This is an AE which is a condition present at birth regardless of its cause and may result in disabilities that may be physical, intellectual, or developmental. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect 先天性畸形 10010356 congenital anomaly AE OAE:0005502 This is an AE which is usually congenital and belong to the RASopathies and the genetic transmission patterns of AVMs are incomplete, but there are known genetic mutations (for instance in the epithelial line, tumor suppressor PTEN gene) which can lead to an increased occurrence throughout the body. QY, JX, HY http://en.volupedia.org/wiki/Arteriovenous_malformation 先天性动脉畸形 10062325 congenital arterial malformation AE OAE:0005503 This is an AE which can have devastating clinical consequences and they can lead to oligohydramnios with subsequent lung hypoplasia and neonatal death. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23832138/ 先天性膀胱异常 10061053 congenital bladder anomaly AE OAE:0005504 This is an AE which is the destruction or degeneration of brain cells which was congenital. QY, JX, HY http://en.volupedia.org/wiki/Brain_damage 先天性脑损伤 10010390 congenital brain damage AE OAE:0005505 This is an AE which is a rare condition in which a brain develops without the cerebellum. QY, JX, HY http://en.volupedia.org/wiki/Cerebellar_agenesis 先天性小脑发育不全 10010390 congenital cerebellar agenesis AE OAE:0005506 This is an AE which is papillary neoplasms of neuroectodermal origin arising from the choroid plexus epithelium of the cerebral ventricles. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30953158/ 先天性脉络丛囊肿 10048785 congenital choroid plexus cyst AE OAE:0005507 This is an AE which can be categorized into those with a lack of origin or ostial atresia, an abnormal origin such as an anomalous origin off the pulmonary artery or off an abnormal aortic sinus, or an anomalous course (such as a single coronary coursing between the pulmonary artery and aorta) or a coronary artery fistula. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27490623/ 先天性冠状动脉畸形 10061060 congenital coronary artery malformation AE OAE:0005508 This is an AE which is a congenital closed sac, having a distinct envelope and division compared with the nearby tissue . QY, JX, HY http://en.volupedia.org/wiki/Cyst 先天性囊肿 10062328 congenital cyst AE OAE:0005509 This is an AE which comprise a spectrum of anomalies that include pulmonary sequestrations, congenital lobar emphysema, bronchogenic cysts, and congenital cystic adenomatoid malformations. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25448785/ 先天性囊性肺 10010429 congenital cystic lung AE OAE:0005510 This is an AE which refers to a condition where cytomegalovirus is transmitted in the prenatal period. QY, JX, HY http://en.volupedia.org/wiki/Congenital_cytomegalovirus_infection 先天性巨细胞病毒感染 10010430 congenital cytomegalovirus infection AE OAE:0005511 This is an AE which is rare and is a tumor that originates in the connective fibrous tissue found at the ends of long bones and then spreads to other surrounding soft tissues. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29099410/ 先天性纤维肉瘤 10065859 congenital fibrosarcoma AE OAE:0005512 This is an AE which is a physical anomaly that is deleterious, i.e. foot defect perceived as a problem. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 先天性足畸形 10062332 congenital foot malformation AE OAE:0005513 This is an AE which is an autosomal-recessive disorder characterized by generalized lack of adipose tissue either at birth or within the first year of life. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590232/ 先天性普遍脂肪代谢障碍 10053547 congenital generalised lipodystrophy AE OAE:0005514 This is an AE which is frequent, usually isolated anomalies, but may exist as part of a syndrome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22585196/ 先天性手畸形 10062335 congenital hand malformation AE OAE:0005515 This is an AE which is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver;it is a type of congenital viral hepatitis. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis_B 先天性乙型肝炎感染 10010496 congenital hepatitis b infection AE OAE:0005516 This is an AE which is rare, with congenital HSV infection by intrauterine infection accounting for <5% of cases of HSV infection in the perinatal period. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32001045/ 先天性单纯疱疹感染 10019949 congenital herpes simplex infection AE OAE:0005517 This is an AE which is a type of hernia in which abdominal organs (typically the stomach) slip through the diaphragm into the middle compartment of the chest. QY, JX, HY http://en.volupedia.org/wiki/Hiatal_hernia 先天性食管裂孔疝 10010501 congenital hiatus hernia AE OAE:0005518 This is an AE which is a condition in which an accumulation of cerebrospinal fluid (CSF) occurs within the brain. QY, JX, HY http://en.volupedia.org/wiki/Hydrocephalus 先天性脑积水 10010506 congenital hydrocephalus AE OAE:0005519 This is an AE which defined as congenital dilatation of one or more components of the renal collecting system, is detected in 1-2% of all pregnancies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23052658/ 先天性肾盂积水 10050975 congenital hydronephrosis AE OAE:0005520 This is an AE which is thyroid hormone deficiency present at birth. QY, JX, HY http://en.volupedia.org/wiki/Congenital_hypothyroidism 先天性甲状腺功能减退 10010510 congenital hypothyroidism AE OAE:0005521 This is an AE which is an abnormality of the structure of jaw. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 先天性颌畸形 10062336 congenital jaw malformation AE OAE:0005522 This is an AE which is a widely used term for a congenital malformation, i.e. a congenital, physical anomaly such as joint and is recognizable at birth, and which is significant enough to be considered a problem. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 先天性关节畸形 10062337 congenital joint malformation AE OAE:0005523 This is an AE which is an indication for complete evaluation to establish the cause of the airway obstruction. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23988376/ 先天性喉喘鸣 10010527 congenital laryngeal stridor AE OAE:0005524 This is an AE which is a birth defect in which nerves are missing from parts of the intestine. QY, JX, HY http://en.volupedia.org/wiki/Hirschsprung%27s_disease 先天性巨结肠 10010539 congenital megacolon AE OAE:0005525 This is an AE which is a relatively rare and highly complex cardiac disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29425524/ 先天性二尖瓣关闭不全 10010547 congenital mitral valve incompetence AE OAE:0005526 This is an AE which is a complex, etiologically diverse, clinical descriptor identified in a variety of diagnoses characterized by multiple congenital joint contractures. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32674167/ 先天性多路关节弯曲 10051643 congenital multiplex arthrogryposis AE OAE:0005527 This is an AE which is an abnormality of the structure of a body musculoskeletal part. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect 先天性肌肉骨骼异常 10062344 congenital musculoskeletal anomaly AE OAE:0005528 This is an AE which is a type of melanocytic nevus (or mole) found in infants at birth. QY, JX, HY http://en.volupedia.org/wiki/Congenital_melanocytic_nevus 先天性痣 10067248 congenital naevus AE OAE:0005529 This is an AE which may be overt or subtle and can occasionally cause life-threatening emergencies at birth. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17346563/ 先天性鼻畸形 10062347 congenital nose malformation AE OAE:0005530 This is an AE which is an inflammatory condition of the lung primarily at birth affecting the small air sacs known as alveoli . QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 先天性肺炎 10010594 congenital pneumonia AE OAE:0005531 This is an AE which represent a diverse group of abnormalities, ranging from asymptomatic incidental findings to causes of sudden cardiac death. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30102560/ 先天性肺动脉异常 10061074 congenital pulmonary artery anomaly AE OAE:0005532 This is an AE which is a condition of increased blood pressure within the arteries of the lungs at birth. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_hypertension 先天性肺动脉高压 10050701 congenital pulmonary hypertension AE OAE:0005533 This is an AE which is often the result of congenital malformations and is observed in isolation or as part of a larger pathologic process, as in Tetralogy of Fallot, Noonan syndrome, and congenital rubella syndrome. QY, JX, HY http://en.volupedia.org/wiki/Valvular_heart_disease#Pulmonary_and_tricuspid_valve_disorders 先天性肺瓣膜病 10061075 congenital pulmonary valve disorder AE OAE:0005534 This is an AE which is often the result of congenital malformations and is observed in isolation or as part of a larger pathologic process, as in Tetralogy of Fallot, Noonan syndrome, and congenital rubella syndrome. QY, JX, HY http://en.volupedia.org/wiki/Valvular_heart_disease#Pulmonary_and_tricuspid_valve_disorders 先天性肾盂扩张 10049938 congenital pyelocaliectasis AE OAE:0005535 This is an AE which is a condition present at birth regardless of its cause which occured on renal. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect 先天性肾疾病 10066875 congenital renal disorder AE OAE:0005536 This is an AE which can occur in a developing fetus of a pregnant woman who has contracted rubella, usually in the first trimester. QY, JX, HY http://en.volupedia.org/wiki/Congenital_rubella_syndrome 先天性风疹感染 10010619 congenital rubella infection AE OAE:0005537 This is an AE which is syphilis present in utero and at birth, and occurs when a child is born to a mother with syphilis. QY, JX, HY http://en.volupedia.org/wiki/Congenital_syphilis 先天性梅毒 10010641 congenital syphilis AE OAE:0005538 This is an AE which is a neoplasm containing tissues foreign to the site of origin or containing more than one embryonic germ cell layer. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22902845/ 先天性畸胎瘤 10052012 congenital teratoma AE OAE:0005539 This is an AE which can occurs spontaneous and excessive bleeding. QY, JX, HY http://en.volupedia.org/wiki/Platelet 先天性血小板障碍 10058896 congenital thrombocyte disorder AE OAE:0005540 This is an AE which is a genetically and clinically heterogeneous group of platelet disorders that are characterized by thrombocytopenia since birth. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29973458/ 先天性血小板减少症 10077833 congenital thrombocytopenia AE OAE:0005541 This is an AE which is a rare occurrence and associates with cleft palate may be considered as evidence of close interrelation of embryogenesis of the tongue and palate. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24066710/ 先天性舌头异常 10061077 congenital tongue anomaly AE OAE:0005542 This is an AE which is defined as a contracture or fibrosis of the Sternocleidomastoid muscle, on one side, leading to a homolateral inclination and contralateral rotation of the face and chin. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31747185/ 先天性斜颈 10010650 congenital torticollis AE OAE:0005543 This is an AE which is a type of congenital valvular heart disease in which the tricuspid valve of the heart, located between the right atrium and right ventricle, does not close completely when the right ventricle contracts (systole). QY, JX, HY http://en.volupedia.org/wiki/Tricuspid_insufficiency 先天性三尖瓣不全 10067887 congenital tricuspid valve incompetence AE OAE:0005544 This is an AE which is a health condition where the abdominal wall behind the navel is congenital damaged. QY, JX, HY http://en.volupedia.org/wiki/Umbilical_hernia 先天性脐疝 10010658 congenital umbilical hernia AE OAE:0005545 This is an AE which might be associated with a detrimental effect on the probability of pregnancy achievement, spontaneous abortion and on the obstetric outcome of each pregnancy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25444500/ 先天性子宫畸形 10061079 congenital uterine anomaly AE OAE:0005546 This is an AE which is a congenital condition in which urine flows retrograde, or backward, from the bladder into one or both ureters and then to the renal calyx or kidneys. QY, JX, HY http://en.volupedia.org/wiki/Vesicoureteral_reflux 先天性膀胱输尿管回流 10010672 congenital vesicoureteric reflux AE OAE:0005547 This is an AE which is a defect in the structure of the heart or great vessels that is present at birth. QY, JX, HY http://en.volupedia.org/wiki/Congenital_heart_defect 先天性心脏病 10019273 heart disease congenital AE OAE:0005548 This is an AE which is small dilated blood vessels that can occur near the surface of the skin or mucous membranes, measuring between 0.5 and 1 millimeter in diameter and is congenital. . QY, JX, HY http://en.volupedia.org/wiki/Telangiectasia 先天性毛细血管扩张症 10061575 telangiectasia congenital AE OAE:0005549 This is an AE which is often associated with abnormal PA hemodynamics including increased pressure drop (Δp) and reduced asymmetric flow (Q), which may result in right ventricular dysfunction. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30293825/ 先天性肺动脉狭窄 10037339 pulmonary artery stenosis congenital AE OAE:0005550 This is an AE which is a congenital heart valve disorder. Blood going from the heart to the lungs goes through the pulmonary valve, whose purpose is to prevent blood from flowing back to the heart. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_valve_stenosis 先天性肺动脉瓣狭窄 10037451 pulmonary valve stenosis congenital AE OAE:0005551 This is an AE which is the arrangement of digits (fingers and toes) on the hands, feet, or sometimes wings of a tetrapod animal. QY, JX, HY http://en.volupedia.org/wiki/Dactyly 先天性无指或无趾 10049207 adactyly AE OAE:0005552 This is an AE which is a congenital oral anomaly that may decrease the mobility of the tongue tip and is caused by an unusually short, thick lingual frenulum, a membrane connecting the underside of the tongue to the floor of the mouth. QY, JX, HY http://en.volupedia.org/wiki/Ankyloglossia 先天性舌系带短缩 10049244 ankyloglossia congenital AE OAE:0005553 This is an AE which is a rare disorder characterized by congenital absence of skin. QY, JX, HY http://en.volupedia.org/wiki/Aplasia_cutis_congenita 先天性表皮发育不全 10002963 aplasia cutis congenita AE OAE:0005554 This is an AE which refers to a lens opacity which is present at birth. QY, JX, HY http://en.volupedia.org/wiki/Congenital_cataract 先天性白内障 10007747 cataract congenital AE OAE:0005555 This is an AE which may occur both as a unilateral and as a bilateral form with a family disposition for dacryostenosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20645229/ 先天性泪管狭窄 10011850 dacryostenosis congenital AE OAE:0005556 This is an AE which is an abnormal difference in body structure. QY, JX, HY http://en.volupedia.org/wiki/Dysmorphic_feature 先天性畸形 10066054 dysmorphism AE OAE:0005557 This is an AE which is a group of non-communicableepilepsy congenital disorders characterized by recurrent epileptic seizures. QY, JX, HY http://en.volupedia.org/wiki/Epilepsy 癫痫先天性 10015039 epilepsy congenital AE OAE:0005558 This is an AE which is an abnormal difference in body structure and it can be related to a congenital disorder, genetic syndrome or birth defect. QY, JX, HY http://en.volupedia.org/wiki/Dysmorphic_feature 面部先天性畸形 10016045 facial dysmorphism AE OAE:0005559 This is an AE which is the heart block that is diagnosed in fetus (in utero) or within the first 28 days after birth (neonatal period), some studies also include the diagnosis during early childhood to the definition of CHB. QY, JX, HY http://en.volupedia.org/wiki/Congenital_heart_block 心传导阻滞先天性 10019263 heart block congenital AE OAE:0005560 This is an AE which is the congenital abnormal exit of tissue or an organ, such as the bowel, through the wall of the cavity in which it normally resides. QY, JX, HY http://en.volupedia.org/wiki/Hernia 先天性疝 10019912 hernia congenital AE OAE:0005561 This is an AE which may refer to an eye diseases :Vitelliform macular dystrophy, an irregular autosomal dominant eye disorder. QY, JX, HY http://en.volupedia.org/wiki/Macular_dystrophy 黄斑营养不良先天性 10025412 macular dystrophy congenital AE OAE:0005562 This is an AE which as a pilonidal variety that is of no neurosurgical significance and a deep version with extension to the central nervous system. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/1590721/ 先天性藏毛囊肿 10054019 pilonidal cyst congenital AE OAE:0005563 This is an AE which the hair loss typically presents itself as either a receding front hairline, loss of hair on the crown (vertex) of the scalp, or a combination of both. QY, JX, HY http://en.volupedia.org/wiki/Pattern_hair_loss 雄性遗传脱发 10068168 androgenetic alopecia AE OAE:0005564 This is an AE which is a disorder that results in recurrent attacks of severe swelling. QY, JX, HY http://en.volupedia.org/wiki/Hereditary_angioedema 遗传性血管性水肿 10019860 hereditary angiedema AE OAE:0005565 This is an AE which is a health problem caused by one or more abnormalities in the genome. QY, JX, HY http://en.volupedia.org/wiki/Genetic_disorder 遗传性疾病 10061205 hereditary disorder AE OAE:0005566 This is an AE which is a genetic disorder characterized by excessive intestinal absorption of dietary iron, resulting in a pathological increase in total body iron stores. QY, JX, HY http://en.volupedia.org/wiki/Hereditary_haemochromatosis 遗传性血色素沉着症 10057873 hereditary haemochromatosis AE OAE:0005567 This is an AE which is an abnormality of red blood cells, or erythrocytes and is a chronic disease with no cure. QY, JX, HY http://en.volupedia.org/wiki/Hereditary_spherocytosis 遗传性球形红细胞症 10019904 hereditary spherocytosis AE OAE:0005568 This is an AE which is a set of rare brain disorders where the whole or parts of the surface of the brain appear smooth. QY, JX, HY http://en.volupedia.org/wiki/Lissencephaly 无脑回 10048911 lissencephaly AE OAE:0005569 This is an AE which is the absence of a major portion of the brain, skull, and scalp that occurs during embryonic development. QY, JX, HY http://en.volupedia.org/wiki/Anencephaly 先天无脑畸形 10002320 anencephaly AE OAE:0005570 This is an AE which is a common feature of many of the diseases that affect the brain and is congenital. QY, JX, HY http://en.volupedia.org/wiki/Cerebral_atrophy 先天性脑萎缩 10052236 cerebral atrophy congenital AE OAE:0005571 This is an AE which forms a large class of genetic diseases involving congenital disorders of enzyme activities. QY, JX, HY http://en.volupedia.org/wiki/Inborn_errors_of_metabolism 先天代谢错误 10062018 inborn error of metabolism AE OAE:0005572 This is an AE which is the most common type of migraine, has great impacts on quality of life for migraineurs. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30007828/ 先兆型偏头痛 10052787 migraine without aura AE OAE:0005573 This is an AE which is a disorder of pregnancy characterized by the onset of high blood pressure and often a significant amount of protein in the urine. QY, JX, HY http://en.volupedia.org/wiki/Pre-eclampsia 先兆子痫 10036485 pre-eclampsia AE OAE:0005574 This is an AE which is a genetic disorder that results in the destruction of nerve cells in the brain and spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Tay%E2%80%93Sachs_disease 黑蒙性先天白痴 10061888 amaurotic familial idiocy AE OAE:0005575 This is an AE which is a severe, complex malformation of monozygotic twinning. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22002952/ 无心畸形 10075721 acardia AE OAE:0005576 This is an AE which is the slowness of thought common to many disorders of the brain. QY, JX, HY http://en.volupedia.org/wiki/Bradyphrenia 智力迟钝 10050012 bradyphrenia AE OAE:0005577 This is an AE which is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning. QY, JX, HY http://en.volupedia.org/wiki/Intellectual_disability 智力疾病 10067989 intellectual disability AE OAE:0005578 This is an AE which occurs when an organism is exceptionally small. QY, JX, HY http://en.volupedia.org/wiki/Dwarfism 侏儒症 10013883 dwarfism AE OAE:0005579 This is an AE which is a neurodegenerative disease that results in the progressive loss of motor neurons that control voluntary muscles. QY, JX, HY http://en.volupedia.org/wiki/Amyotrophic_lateral_sclerosis 家族性肌萎缩侧索硬化症 10077024 familial amyotrophic lateral sclerosis AE OAE:0005580 This is an AE which is a hereditary inflammatory disorder and is an autoinflammatory disease caused by mutations in Mediterranean fever gene, which encodes a 781 amino acid protein called pyrin. QY, JX, HY http://en.volupedia.org/wiki/Familial_Mediterranean_fever 家族性地中海热 10016207 familial mediterranean fever AE OAE:0005581 This is an AE which is a group of rare genetic diseases that lead to weakness or paralysis from common triggers such as cold, heat, high carbohydrate meals, not eating, stress or excitement and physical activity of any kind. QY, JX, HY http://en.volupedia.org/wiki/Periodic_paralysis 家族性周期性麻痹 10016208 familial periodic paralysis AE OAE:0005582 This is an AE which is a medical condition characterized by involuntary rhythmic contractions and relaxations (oscillations or twitching movements) of certain muscle groups in one or more body parts of unknown cause. QY, JX, HY http://en.volupedia.org/wiki/Essential_tremor 家族性震颤 10016212 familial tremor AE OAE:0005583 This is an AE which is an uncommon form of Alzheimer's disease that usually strikes earlier in life, defined as before the age of 65 (usually between 30 and 60 years of age) and is inherited in an autosomal dominant fashion, identified by genetics and other characteristics such as the age of onset. QY, JX, HY http://en.volupedia.org/wiki/Early-onset_Alzheimer%27s_disease#Familial_Alzheimer's_disease 早发性家族性阿尔茨海默病 10078036 early onset familial alzheimer's disease AE OAE:0005584 This is an AE which is an alteration in the nucleotide sequence of the genome of an organism, virus, or extrachromosomal DNA. QY, JX, HY http://en.volupedia.org/wiki/Mutation 基因突变 10064571 gene mutation AE OAE:0005585 This is an AE which is the process of determining the nucleic acid sequence – the order of nucleotides in DNA. QY, JX, HY http://en.volupedia.org/wiki/DNA_sequencing 基因测序 10069604 gene sequencing AE OAE:0005586 This is an AE which is caused by errors in fatty acid metabolism. QY, JX, HY http://en.volupedia.org/wiki/Inborn_error_of_lipid_metabolism 先天脂质代谢错误 10072272 inborn error of lipid metabolism AE OAE:0005587 This is an AE which is inherited blood disorders characterized by decreased hemoglobin production. QY, JX, HY http://en.volupedia.org/wiki/Thalassemia 地中海贫血 10043388 thalassaemia AE OAE:0005588 This is an AE which is the inflammation, with effusion, of different serous membranes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29761620/ 多浆膜炎 10036141 polyserositis AE OAE:0005589 This is an AE which is a rare genetic disease that can affect many parts of the body, including the kidneys, heart, and skin. QY, JX, HY http://en.volupedia.org/wiki/Fabry_disease 法布瑞氏症 10016016 fabry's disease AE OAE:0005590 This is an AE which is a congenital heart defect characterized by four specific cardiac defects. QY, JX, HY http://en.volupedia.org/wiki/Tetralogy_of_Fallot 法乐氏四联症 10016193 fallot's tetralogy AE OAE:0005591 This is an AE which is the most common hereditary blood-clotting disorder in humans. QY, JX, HY http://en.volupedia.org/wiki/Von_Willebrand_disease 冯维勒布兰德病 10047715 von willebrand's disease AE OAE:0005592 This is an AE which is an autosomal-recessive genetic disease that causes difficulty walking, a loss of sensation in the arms and legs, and impaired speech that worsens over time. QY, JX, HY http://en.volupedia.org/wiki/Friedreich%27s_ataxia 弗里德希氏共济失调 10017374 friedreich's ataxia AE OAE:0005593 This is an AE which is a genetic disorder in which glucocerebroside (a sphingolipid, also known as glucosylceramide) accumulates in cells and certain organs. QY, JX, HY http://en.volupedia.org/wiki/Gaucher%27s_disease 高歇氏病 10018048 gaucher's disease AE OAE:0005594 This is an AE which is a rare genetic disorder in which large sugar molecules called glycosaminoglycans (or GAGs or mucopolysaccharides) build up in body tissues. QY, JX, HY http://en.volupedia.org/wiki/Hunter_syndrome 黏多糖病二期 10056889 mucopolysaccharidosis ii AE OAE:0005595 QY, JX, HY 特殊感觉先天异常 10041420 special senses congenital anomaly AE OAE:0005596 This is an AE which is a common source for life-threatening infections,so it often feels discomfortable. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23830659/ 尿路不适 10076568 urinary tract discomfort AE OAE:0005597 This is an AE which associated with ulcerative colitis (GDUC) is rare. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479559/ 胃十二指肠炎 10048714 gastroduodenitis AE OAE:0005598 This is an AE which is a disease of a joint. QY, JX, HY http://en.volupedia.org/wiki/Arthropathy 肠病发性脊柱炎 10076549 enteropathic spondylitis AE OAE:0005599 This is an AE which is a group of diseases involving rectosigmoid abnormal cell growth with the potential to invade or spread to other parts of the body. QY, JX, HY http://en.volupedia.org/wiki/Cancer 直肠乙状结肠癌 10038086 rectosigmoid cancer AE OAE:0005600 This is an AE which is a medical condition in which injury to the large or small intestine occurs due to not enough blood supply. QY, JX, HY http://en.volupedia.org/wiki/Intestinal_ischemia 肠系膜闭塞 10027399 mesenteric occlusion AE OAE:0005601 This is an AE which is a medical disorder consisting of weak muscular contractions (peristalsis) of the stomach, resulting in food and liquid remaining in the stomach for a prolonged period of time. QY, JX, HY http://en.volupedia.org/wiki/Gastroparesis 胃排空减少 10021518 impaired gastric emptying AE OAE:0005602 This is an AE which is a rare non-neoplastic disorder characterized by fat necrosis, chronic inflammation, and fibrosis typically of the small bowel mesentery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30829677/ 肠系膜炎 10069665 mesenteritis AE OAE:0005603 This is an AE which is an autoimmune disease of the liver. QY, JX, HY http://en.volupedia.org/wiki/Primary_biliary_cholangitis 胆汁性肝硬化 10004659 biliary cirrhosis AE OAE:0005604 This is an AE which is an inflammation of the colon and is autoimmune. QY, JX, HY http://en.volupedia.org/wiki/Colitis 自身免疫性结肠炎 10075761 autoimmune colitis AE OAE:0005605 This is an AE which is an outward bulging on the mesenteric artery wall, likened to a bubble or balloon, caused by a localized, abnormal, weak spot on a blood vessel wall. QY, JX, HY http://en.volupedia.org/wiki/Aneurysm 肠系膜动脉动脉瘤 10079556 mesenteric artery aneurysm AE OAE:0005606 This is an AE which is an unfavorable result of a disease, health condition, or treatment on the urinary tract . QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine) 泌尿道手术并发症 10081331 urinary tract procedural complication AE OAE:0005607 This is an AE which is an unfavorable result of a disease, health condition, or treatment on the urinary tract stoma. QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine) 泌尿道造口并发症 10074942 urinary tract stoma complication AE OAE:0005608 This is an AE which is defined as the involuntary retrograde passage of gastric contents into the esophagus with or without regurgitation or vomiting. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23322552/ 胃食管括约肌功能不全 10062879 gastresophageal sphincter insufficiency AE OAE:0005609 This is an AE which is the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose and is discoloured. QY, JX, HY http://en.volupedia.org/wiki/Vomiting 变色呕吐物 10079120 discolored vomit AE OAE:0005610 This is an AE which is the presence of gallstones in the common bile duct (CBD) (thus choledocho- + lithiasis). QY, JX, HY http://en.volupedia.org/wiki/Common_bile_duct_stone 胆管结石 10004637 bile duct stone AE OAE:0005611 This is an AE which is thin membranes occurring anywhere along the esophagus. QY, JX, HY http://en.volupedia.org/wiki/Esophageal_web 获得性食管网 10052820 acquired esophageal web AE OAE:0005612 This is an AE which occurs because of involuntary contractions of the bladder smooth muscle after urinary catheterization. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32304405/ 膀胱不适 10005034 bladder discomfort AE OAE:0005613 This is an AE which refers to a mass of lymphoid tissue in the pharynx. QY, JX, HY http://en.volupedia.org/wiki/Pharyngeal 咽部肿块 10049270 pharyngeal mass AE OAE:0005614 This is an AE which is the final act of digestion become disorder, by which organisms eliminate a solid, semisolid, or liquid waste material known as feces from the digestive tract via the anus. QY, JX, HY http://en.volupedia.org/wiki/Defecation 通便障碍 10079938 defecation disorder AE OAE:0005615 This is an AE which is the final act of digestion and it is urgency, by which organisms eliminate a solid, semisolid, or liquid waste material known as feces from the digestive tract via the anus. QY, JX, HY http://en.volupedia.org/wiki/Defecation 紧急通便 10012110 defecation urgency AE OAE:0005616 This is an AE which is a lack of control over defecation, leading to involuntary loss of bowel contents, both liquid stool elements and mucus, or solid feces. QY, JX, HY http://en.volupedia.org/wiki/Fecal_incontinence 粪便尿失禁 10016092 faecal incontinence AE OAE:0005617 This is an AE which is a more extreme form of fecal impaction, giving the accumulation an appearance of a tumor. QY, JX, HY http://en.volupedia.org/wiki/Fecal_impaction#Fecaloma 粪便瘤 10056325 faecaloma AE OAE:0005618 This is an AE which is the solid or semisolid remains of food that could not be digested or absorbed in the small intestine of humans, but has been further broken down by bacteria in the large intestine. QY, JX, HY http://en.volupedia.org/wiki/Human_feces 粪便硬 10016101 faeces hard AE OAE:0005619 This is an AE which is the passage of fresh blood through the anus, usually in or with stools (contrast with melena). QY, JX, HY http://en.volupedia.org/wiki/Hematochezia 便血 10018836 haematochezia AE OAE:0005620 This is an AE which determined by self-report, was defined as difficulty in passing stool, hard stool, straining for more than 15 min, or incomplete evacuation, occurring at least weekly. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18340532/ 阻塞性排便 10076953 obstructive defecation AE OAE:0005621 This is an AE which is defined as the infrequent passage of stools or difficulty with evacuation of stools. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30228729/ 排便困难 10055664 painful defecation AE OAE:0005622 This is an AE which is defined as the infrequent passage of stools or difficulty with evacuation of stools after post procedural. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30228729/ 术后便秘 10068620 post procedural constipation AE OAE:0005623 This is an AE which refres to stool has pus. QY, JX, HY http://en.volupedia.org/wiki/Stool 大便有脓 10064830 pus in stool AE OAE:0005624 This is an AE which should be used to determine if an acute episode of diarrhea is invasive. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1070939/ 白细胞大便 10047961 white blood cells stool AE OAE:0005625 This is an AE which refers to the presence of white blood cells within or upon casts strongly suggests pyelonephritis, a direct infection of the kidney. QY, JX, HY http://en.volupedia.org/wiki/Urinary_cast 白细胞尿 10050663 white blood cells urine AE OAE:0005626 This is an AE which refers to bowel movements that are infrequent or hard to pass. QY, JX, HY http://en.volupedia.org/wiki/Constipation 大便困难 10051244 dyschezia AE OAE:0005627 This is an AE which is voluntary or involuntary passage of feces outside of toilet trained contexts (fecal soiling) in children who are four years or older and after an organic cause has been excluded. QY, JX, HY http://en.volupedia.org/wiki/Encopresis 大便失禁 10014643 encopresis AE OAE:0005628 This is an AE which is food or drug administration via the human gastrointestinal tract. QY, JX, HY http://en.volupedia.org/wiki/Enteral_administration 肠内营养 10052591 enteral nutrition AE OAE:0005629 This is an AE which infectious enteritis are caused by four pathogens, Norovirus, Rotavirus, Campylobacter and Salmonella. QY, JX, HY http://en.volupedia.org/wiki/Enteritis 传染性肠炎 10058839 enteritis infectious AE OAE:0005630 This is an AE which is a segmental necrotizing infection of the jejunum and ileum caused by Clostridium perfringens, Type C. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11796843/ 坏死性肠炎 10014878 enteritis necroticans AE OAE:0005631 This is an AE which is a infection of a genus of common Gram-negative, facultatively anaerobic, rod-shaped, non-spore-forming bacteria of the family Enterobacteriaceae. QY, JX, HY http://en.volupedia.org/wiki/Enterobacter 肠杆菌属感染 10051910 enterobacter infection AE OAE:0005632 This is an AE which is a life-threatening condition caused by enterobacter that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 肠杆菌败血症 10054219 enterobacter sepsis AE OAE:0005633 This is an AE which is a human parasitic disease caused by the pinworm. QY, JX, HY http://en.volupedia.org/wiki/Pinworm_infection 蛲虫病 10014881 enterobiasis AE OAE:0005634 This is an AE which is associated with large burdens of morbidity and mortality, particularly among fragile and immunosuppressed patients presenting complicated bacteraemia due to multidrug-resistant enterococci. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33152537/ 肠球菌菌血症 10014885 enterococcal bacteremia AE OAE:0005635 This is an AE which is a infection caused by a large genus of lactic acid bacteria of the phylum Firmicutes. QY, JX, HY http://en.volupedia.org/wiki/Enterococcus 肠球菌感染 10061124 enterococcal infection AE OAE:0005636 This is an AE which include bacteremias when the infections are bacterial such as enterococcal when the infections are infections present in the blood. QY, JX, HY http://en.volupedia.org/wiki/Bloodstream_infections 肠球菌脓毒症 10054221 enterococcal sepsis AE OAE:0005637 This is an AE which is an inflammation of the digestive tract caused by bacterial, involving enteritis of the small intestine and colitis of the colon. QY, JX, HY http://en.volupedia.org/wiki/Enterocolitis 细菌性小肠结肠炎 10065206 enterocolitis bacterial AE OAE:0005638 This is an AE which is an inflammation of the digestive tract with haemorrhagic, involving enteritis of the small intestine and colitis of the colon. QY, JX, HY http://en.volupedia.org/wiki/Enterocolitis 小肠结肠炎出血 10014896 enterocolitis haemorrhagic AE OAE:0005639 This is an AE which is an inflammation of the digestive tract caused by viral, involving enteritis of the small intestine and colitis of the colon. QY, JX, HY http://en.volupedia.org/wiki/Enterocolitis 病毒性小肠结肠炎 10061841 enterocolitis viral AE OAE:0005640 This is an AE which is an abnormal communication between the small or large bowel and the skin that allows the contents of the stomach or intestines to leak through an opening in the skin. QY, JX, HY http://en.volupedia.org/wiki/Enterocutaneous_fistula 肠皮瘘 10051425 enterocutaneous fistula AE OAE:0005641 This is an AE which refers to range from mild to severe acute infections concerning several organ systems and are also associated with chronic diseases. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30106324/ 肠道病毒感染 10014909 enterovirus infection AE OAE:0005642 This is an AE which refers to a disorder involving the attachment of a tendon or ligament to a bone. QY, JX, HY http://en.volupedia.org/wiki/Enthesopathy 末端病 10014910 enthesopathy AE OAE:0005643 This is an AE which is a repeated inability to control urination. QY, JX, HY http://en.volupedia.org/wiki/Enuresis 遗尿症 10014928 enuresis AE OAE:0005644 This is an AE which is a rare entity characterized by the presence of a high eosinophilic infiltrate into the colonic wall in symptomatic patients, more often presenting with abdominal pain or diarrhea. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31122823/ 嗜酸性结肠炎 10057271 eosinophilic colitis AE OAE:0005645 This is an AE which presents either with a chronic feeling of difficulty swallowing, with food moving slowly through the oesophagus, or as an acute food bolus obstruction requiring emergency attention. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30860925/ 嗜酸性食管炎 10064212 eosinophilic esophagitis AE OAE:0005646 This is an AE which refers to the infections are bacterial such as escherichia when the infections are infections present in the blood. QY, JX, HY http://en.volupedia.org/wiki/Bloodstream_infections 大肠杆菌菌血症 10054258 escherichia bacteremia AE OAE:0005647 This is an AE whcih is inflammation of the kidney, typically due to a bacterial such as escherichia infection. QY, JX, HY http://en.volupedia.org/wiki/Pyelonephritis 大肠肾盂肾炎 10074409 escherichia pyelonephritis AE OAE:0005648 This is an AE which is a life-threatening condition caused by escherichia that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 大肠杆菌败血症 10015296 escherichia sepsis AE OAE:0005649 This is an AE which is defined in the medical literature as "flatus expelled through the anus" or the "quality or state of being flatulent", which is defined in turn as "marked by or affected with gases generated in the intestine or stomach; likely to cause digestive flatulence". QY, JX, HY http://en.volupedia.org/wiki/Flatulence 肠胃气胀 10016766 flatulence AE OAE:0005650 This is an AE which refers absence of stomach muscle tone. QY, JX, HY http://en.volupedia.org/wiki/Glossary_of_medicine 胃弛缓 10017753 gastric atony AE OAE:0005651 This is an AE which is a medical condition that affects dogs in which the stomach becomes overstretched and rotated by excessive gas content. QY, JX, HY http://en.volupedia.org/wiki/Gastric_dilatation_volvulus 胃扩张 10017779 gastric dilatation AE OAE:0005652 This is an AE which as been positively associated with the development of gastric ulceration in nonequine species, and reduction of hypermotility may be protective against their development. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31864457/ 胃运动过强 10052406 gastric hypermotility AE OAE:0005653 This is an AE which characterized by delayed gastric emptying in the absence of an obstructing structural lesion in the stomach manifested as abdominal bloating. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28434448/ 胃运动减弱 10052405 gastric hypomotility AE OAE:0005654 This is an AE which is a muscular, hollow organ in the gastrointestinal tract of humans and many other animals, including several invertebrates and it has infection. QY, JX, HY http://en.volupedia.org/wiki/Stomach 胃感染 10056663 gastric infection AE OAE:0005655 This is an AE which is the mucous membrane layer of the stomach and it has erythema, which contains the glands and the gastric pits. QY, JX, HY http://en.volupedia.org/wiki/Gastric_mucosa 胃粘膜红斑 10070994 gastric mucosa erythema AE OAE:0005656 This is an AE which will lead Ménétrier disease that is a very rare chronic gastric disorder. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26825202/ 胃粘膜肥大 10017807 gastric mucosal hypertrophy AE OAE:0005657 This is an AE which is hyperplastic polyps (HPs). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22414211/ 胃息肉 10017817 gastric polyps AE OAE:0005658 This is an AE which is a break in the inner lining with haemorrhage of the stomach, the first part of the small intestine, or sometimes the lower esophagus. QY, JX, HY http://en.volupedia.org/wiki/Peptic_ulcer_disease 胃溃疡出血 10017826 gastric ulcer hemorrhage AE OAE:0005660 This is an AE which is a twisting of all or part of the stomach by more than 180 degrees with obstruction of the flow of material through the stomach, variable loss of blood supply and possible tissue death. QY, JX, HY http://en.volupedia.org/wiki/Gastric_volvulus 胃肠扭结 10052541 gastric volvulus AE OAE:0005661 This is an AE which is an important cause of upper gastrointestinal bleeding, accounting for approximately one fourth of UGI bleeding in endoscopic studies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7905865/ 胃炎出血 10017866 gastritis haemorrhagic AE OAE:0005662 This is an AE which is inflammation of the lining of the stomach caused by viral. QY, JX, HY http://en.volupedia.org/wiki/Gastritis 病毒性胃炎 10051791 gastritis viral AE OAE:0005663 This is an AE which was a medical syndrome first coined by Ludwig von Roemheld (1871–1938) describing a cluster of cardiovascular symptoms stimulated by gastrointestinal changes. QY, JX, HY http://en.volupedia.org/wiki/Roemheld_syndrome 胃心综合征 10059360 gastrocardiac syndrome AE OAE:0005664 This is an AE which is inflammation of the gastrointestinal tract caused by astroviral. QY, JX, HY http://en.volupedia.org/wiki/Gastroenteritis 胃肠炎星形病毒 10017893 gastroenteritis astroviral AE OAE:0005665 This is an AE which is self-limiting, identification of an etiological agent by bacterial stool culture is required for the management of patients with severe or prolonged diarrhea, symptoms consistent with invasive disease, or a history that may predict a complicated course of disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25567220/ 细菌性胃肠炎 10061166 gastroenteritis bacterial AE OAE:0005666 This is an AE which is inflammation of the gastrointestinal tract caused by clostridial. QY, JX, HY http://en.volupedia.org/wiki/Gastroenteritis 梭状肠炎 10017898 gastroenteritis clostridial AE OAE:0005667 This is an AE which is a protozoan parasite of medical and veterinary importance that causes gastroenteritis in a variety of vertebrate hosts. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23297262/ 隐孢子虫胃肠炎 10017899 gastroenteritis cryptosporidial AE OAE:0005668 This is an AE which is an eosinophilic gastrointestinal disease (EGID) a chronic inflammatory condition characterized by gastrointestinal symptoms and infiltration of the esophageal and/or GI mucosa by eosinophils and mast cells . QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_gastroenteritis 嗜酸性胃肠炎 10017902 gastroenteritis eosinophilic AE OAE:0005669 This is an AE which is a leading cause of foodborne disease worldwide and may cause to gastroenteritis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29208344/ 轮状病毒肠胃炎 10017914 gastroenteritis salmonella AE OAE:0005670 This is an AE which is a disruption of the normal propulsive ability of the intestine with spastic. QY, JX, HY http://en.volupedia.org/wiki/Ileus 回肠痉挛 10021335 ileus spastic AE OAE:0005671 This is an AE which is a group of inflammatory conditions of the colon and small intestine, Crohn's disease and ulcerative colitis being the principal types. QY, JX, HY http://en.volupedia.org/wiki/Inflammatory_bowel_disease 炎症性肠病 10021972 inflammatory bowel disease AE OAE:0005672 This is an AE which includes excessive straining, a sense of incomplete evacuation, failed or lengthy attempts to defecate, use of digital manoeuvres for evacuation of stool, abdominal bloating, and hard consistency of stools. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28185025/ 不常见的肠道运动 10059158 infrequent bowel movements AE OAE:0005673 This is an AE which is a functional gastrointestinal disorder characterized by a group of symptoms accompanied together that include abdominal pain and changes in the consistency of bowel movements. QY, JX, HY http://en.volupedia.org/wiki/Irritable_bowel_syndrome 肠易激综合症 10023003 irritable bowel syndrome AE OAE:0005674 This is an AE which is a rare and poorly understood cause of abdominal pain in patients with systemic lupus erythematosus (SLE). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23642042/ 狼疮肠炎 10067738 lupus enteritis AE OAE:0005675 This is an AE which may have a congenital cause such as malrotation with volvulus or a persistent omphalomesenteric duct. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26443112/ 机械性肠梗阻 10051399 mechanical ileus AE OAE:0005676 This is an AE which is a disorder of pigmentation of the wall of the colon, often identified at the time of colonoscopy. QY, JX, HY http://en.volupedia.org/wiki/Melanosis_coli 结肠黑变病 10027158 melanosis coli AE OAE:0005677 This is an AE which is a heterogeneic group of clinically significant illnesses because of the more common imaging of the intestinal circulation when studying both vascular and nonvascular diseases of the abdomen. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/12472047/ 肠系膜动脉阻塞 10027394 mesenteric arterial occlusion AE OAE:0005678 This is an AE which is a cyst in the mesenterium, and is one of the rarest abdominal tumors. QY, JX, HY http://en.volupedia.org/wiki/Mesenteric_cyst 肠系膜囊肿 10079196 mesenteric cyst AE OAE:0005679 This is an AE which is a disease of the mesenteric lymph nodes, in which they are abnormal in size or consistency. QY, JX, HY http://en.volupedia.org/wiki/Lymphadenopathy 肠系膜淋巴结病 10071450 mesenteric lymphadenopathy AE OAE:0005680 This is an AE which is a condition characterized by chronic nonspecific inflammation of the mesentery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26971978/ 肠系膜脂膜炎 10063031 mesenteric panniculitis AE OAE:0005681 This is an AE which is an inflammation of the colon with necrotising . QY, JX, HY http://en.volupedia.org/wiki/Colitis 坏死性结肠炎 10051606 necrotising colitis AE OAE:0005682 This is an AE which is a devastating intestinal disease occured on neonatal that affects premature or very low birth weight infants. QY, JX, HY http://en.volupedia.org/wiki/Necrotizing_enterocolitis 坏死性小肠结肠炎 10055667 necrotising enterocolitis neonatal AE OAE:0005683 This is an AE which is inflammation of the gastrointestinal tract caused by parasitic QY, JX, HY http://en.volupedia.org/wiki/Gastroenteritis 寄生肠胃炎 10067720 parasitic gastroenteritis AE OAE:0005684 This is an AE which is a bacterial infection caused by one of the three types of Salmonella enterica. QY, JX, HY http://en.volupedia.org/wiki/Paratyphoid_fever 副肠热病 10033971 paratyphoid fever AE OAE:0005685 This is an AE which occurs in the dorsal portion of the perirectal tissues. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32514469/ 直肠周围脓肿 10052814 perirectal abscess AE OAE:0005686 This is an AE which is an inflammatory condition caused by escherichia of the lung primarily affecting the small air sacs known as alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 大肠杆菌肺炎 10035699 pneumonia escherichia AE OAE:0005687 This is an AE which is a polyp (fleshy growth) occurring on the lining of the colon or rectum. QY, JX, HY http://en.volupedia.org/wiki/Colorectal_polyp 息肉结直肠 10048646 polyp colorectal AE OAE:0005688 This is an AE which is a disruption of the normal propulsive ability of the intestine. QY, JX, HY http://en.volupedia.org/wiki/Ileus 术后肠梗阻 10054048 postoperative ileus AE OAE:0005689 This is an AE which is inflammation of the ileal pouch, an artificial rectum surgically created out of ileal gut tissue in patients who have undergone a colectomy. QY, JX, HY http://en.volupedia.org/wiki/Pouchitis 结肠袋炎 10036463 pouchitis AE OAE:0005690 This is an AE which is considered one of the initial manifestations of ulcerative colitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29393142/ 溃疡性直肠炎 10036783 proctitis ulcerative AE OAE:0005691 This is an AE which is a general term for inflammation of the rectum and colon. QY, JX, HY http://en.volupedia.org/wiki/Proctocolitis 直肠结肠炎 10036784 proctocolitis AE OAE:0005692 This is an AE which is the development of cancer from the colon or rectum (parts of the large intestine). QY, JX, HY http://en.volupedia.org/wiki/Colorectal_cancer 直肠癌 10038038 rectal cancer AE OAE:0005693 This is an AE which is intermittent or continuous expression of liquid from the anus (per rectum). QY, JX, HY http://en.volupedia.org/wiki/Rectal_discharge 直肠分泌物 10049101 rectal discharge AE OAE:0005694 This is an AE which is a break or tear in the skin of the anal canal. QY, JX, HY http://en.volupedia.org/wiki/Anal_fissure 直肠裂 10064993 rectal fissure AE OAE:0005695 This is an AE which is the development of cancer from the colon or rectum (parts of the large intestine). QY, JX, HY http://en.volupedia.org/wiki/Colorectal_cancer 直肠肿瘤 10062099 rectal neoplasm AE OAE:0005696 This is an AE which is when the rectal walls have prolapsed to a degree where they protrude out the anus and are visible outside the body. QY, JX, HY http://en.volupedia.org/wiki/Rectal_prolapse 直肠脱垂 10038077 rectal prolapse AE OAE:0005697 This is an AE which is a sudden involuntary contraction of a muscle, a group of muscles, or a hollow organ such as the rectal. QY, JX, HY http://en.volupedia.org/wiki/Spasm 直肠痉挛 10057011 rectal spasm AE OAE:0005698 This is an AE which is a feeling of incomplete defecation. QY, JX, HY http://en.volupedia.org/wiki/Rectal_tenesmus 直肠下坠 10057071 rectal tenesmus AE OAE:0005699 This is an AE which causes the rectum herniates into or forms a bulge in the vagina. QY, JX, HY http://en.volupedia.org/wiki/Rectocele 直肠前突 10038084 rectocele AE OAE:0005700 This is an AE which is a rare malabsorption disorder caused by a lack of functional small intestine. QY, JX, HY http://en.volupedia.org/wiki/Short_bowel_syndrome 短肠综合征 10049416 short-bowel syndrome AE OAE:0005701 This is an AE which is a disruption of the normal propulsive ability of the intestine. QY, JX, HY http://en.volupedia.org/wiki/Ileus 副肠梗阻 10050396 subileus AE OAE:0005702 This is an AE which is a gastro-vascular disorder in which the third and final portion of the duodenum is compressed between the abdominal aorta (AA) and the overlying superior mesenteric artery. QY, JX, HY http://en.volupedia.org/wiki/Superior_mesenteric_artery_syndrome 肠系膜上动脉综合征 10054156 superior mesenteric artery syndrome AE OAE:0005703 This is an AE which is when a loop of small bowel twists around itself and the mesentery that supports it, resulting in a bowel obstruction. QY, JX, HY http://en.volupedia.org/wiki/Volvulus 小肠扭转 10065666 volvulus of small bowel AE OAE:0005704 This is an AE which is an autosomal recessive metabolic disorder affecting the uptake of zinc through the inner lining of the bowel, the mucous membrane. QY, JX, HY http://en.volupedia.org/wiki/Acrodermatitis_enteropathica 肠病性肢端皮炎 10000596 acrodermatitis enteropathica AE OAE:0005705 This is an AE which is the development of cancer from the colon or rectum (parts of the large intestine). QY, JX, HY http://en.volupedia.org/wiki/Colorectal_cancer 结肠腺癌 10001167 adenocarcinoma of colon AE OAE:0005706 This is an AE which is an inflammation with allergic of the colon. QY, JX, HY http://en.volupedia.org/wiki/Colitis 过敏性结肠炎 10059447 allergic colitis AE OAE:0005707 This is an AE which is inflammation of the gastrointestinal tract with allergic. QY, JX, HY http://en.volupedia.org/wiki/Gastroenteritis 过敏性肠胃炎 10075308 allergic gastroenteritis AE OAE:0005708 This is an AE which is an abscess adjacent to the anus. QY, JX, HY http://en.volupedia.org/wiki/Anorectal_abscess 肛门脓肿 10048946 anal abscess AE OAE:0005709 This is an AE which is a cancer which arises from the anus, the distal opening of the gastrointestinal tract. QY, JX, HY http://en.volupedia.org/wiki/Anal_cancer 肛门癌 10061424 anal cancer AE OAE:0005710 This is an AE which is a anal fungal infection due to any type of Candida (a type of yeast). QY, JX, HY http://en.volupedia.org/wiki/Candidiasis 肛门念珠菌病 10002140 anal candidiasis AE OAE:0005711 This is an AE which is defined as localized mucous membrane tissue impairments of the anal canal caused by corrosive fecal enzymes and/or indwelling devices. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25945826/ 肛门侵蚀 10067272 anal erosion AE OAE:0005712 This is an AE which is redness of the skin or mucous membranes such as anal, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 肛门红斑 10084122 anal erythema AE OAE:0005713 This is an AE which is a common side effect of various medical conditions on the anal which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 肛门触觉减退 10075521 anal hypoesthesia AE OAE:0005714 This is an AE which is a lack of control over defecation, leading to involuntary loss of bowel contents, both liquid stool elements and mucus, or solid feces. QY, JX, HY http://en.volupedia.org/wiki/Fecal_incontinence 肛门失禁 10077605 anal incontinence AE OAE:0005715 This is an AE which is the invasion of anal by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 肛门感染 10061628 anal infection AE OAE:0005716 This is an AE which is part of the complex biological response of anal to harmful stimuli, such as pathogens, damaged cells, or irritants,and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 肛门发炎 10050247 anal inflammation AE OAE:0005717 This is an AE which is an abnormal growth of tissue projecting from a anal mucous membrane. QY, JX, HY http://en.volupedia.org/wiki/Polyp_(medicine) 肛门息肉 10002168 anal polyp AE OAE:0005718 This is an AE which is when the rectal walls have prolapsed to a degree where they protrude out the anus and are visible outside the body. QY, JX, HY http://en.volupedia.org/wiki/Rectal_prolapse 肛门脱垂 10065360 anal prolapse AE OAE:0005719 This is an AE which is the irritation of the skin at the exit of the rectum, known as the anus, causing the desire to scratch. QY, JX, HY http://en.volupedia.org/wiki/Pruritus_ani 肛门瘙痒 10068172 anal pruritus AE OAE:0005720 This is an AE which is a severe, episodic pain in the regions of the rectum and anus. QY, JX, HY http://en.volupedia.org/wiki/Proctalgia_fugax 肛门痉挛 10002173 anal spasm AE OAE:0005721 This is an AE which refers absence of anal sphincter muscle tone. QY, JX, HY http://en.volupedia.org/wiki/Glossary_of_medicine 肛门括约肌弛缓 10049823 anal sphincter atony AE OAE:0005722 This is an AE which is an increase in the muscle's resistance to passive stretching. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32636059/ 肛门括约肌张力亢进 10066894 anal sphincter hypertonia AE OAE:0005723 This is an AE which is a pre-cancerous condition which occurs when the lining of the anal canal undergoes abnormal changes. QY, JX, HY http://en.volupedia.org/wiki/Anal_dysplasia 肛门-生殖器发育不良 10051999 anogenital dysplasia AE OAE:0005724 This is an AE which is a sexually transmitted infection caused by certain types of human papillomavirus (HPV). QY, JX, HY http://en.volupedia.org/wiki/Genital_wart 肛门-生殖器疣 10059313 anogenital warts AE OAE:0005725 This is an AE which refers to acute or subacute arthritis in association with, or as a reaction to, an enteric (usually colonic) inflammatory condition. QY, JX, HY http://en.volupedia.org/wiki/Enteropathic_arthropathy 关节炎肠病 10003253 arthritis enteropathic AE OAE:0005726 This is an AE which refer to a transient abnormal enlargement of a body part or area such as anorectal not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 肛门直肠的肿胀 10074526 anorectal swelling AE OAE:0005727 This is an AE which is a rare disorder of the immune system condition that affects infants, young children and (rarely) adults causing severe diarrhea, vomiting, and other morbidities of the digestive tract. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_enteropathy 自身免疫性肠病 10081456 autoimmune enteropathy AE OAE:0005728 This is an AE which is a mass often found trapped in the gastrointestinal system,though it can occur in other locations. QY, JX, HY http://en.volupedia.org/wiki/Bezoar 胃肠石 10004542 bezoar AE OAE:0005729 This is an AE which is inflammation of the gastrointestinal tract caused by campylobacter . QY, JX, HY http://en.volupedia.org/wiki/Gastroenteritis 弯曲杆菌肠胃炎 10007048 campylobacter gastroenteritis AE OAE:0005730 This is an AE which is an inflammatory bowel disease affecting the colon specifically with peak incidence in the 5th decade of life, affecting women more than men. QY, JX, HY http://en.volupedia.org/wiki/Collagenous_colitis 胶原性结肠炎 10048928 colitis collagenous AE OAE:0005731 This is an AE which is a benign tumor of epithelial tissue colon with glandular origin, glandular characteristics, or both. QY, JX, HY http://en.volupedia.org/wiki/Adenoma 结肠腺瘤 10048832 colon adenoma AE OAE:0005732 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) and/or organs (macroscopic scale) such as colon. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 结肠发育不良 10071161 colon dysplasia AE OAE:0005733 This is an AE which is the second most commonly injured intra-abdominal organ in penetrating trauma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23336650/ 结肠损伤 10057669 colon injury AE OAE:0005734 This is an AE which used this technique in infants with intestinal obstruction due to anorectal malformations, intestinal atresias, and post-NEC strictures, to good effect. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15243777/ 结肠灌洗 10074741 colonic lavage AE OAE:0005735 This is an AE which is a polyp (fleshy growth) occurring on the lining of the colon or rectum. QY, JX, HY http://en.volupedia.org/wiki/Colorectal_polyp 结肠息肉 10010003 colonic polyp AE OAE:0005736 This is an AE which is an infection that affects part of the urinary tract caused by escherichia. QY, JX, HY http://en.volupedia.org/wiki/Urinary_tract_infection 膀胱炎大肠 10011790 cystitis escherichia AE OAE:0005738 This is an AE which is uncommonly found on upper endoscopy and can be categorized as subepithelial or mucosally-based. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26811610/ 十二指肠息肉 10013833 duodenal polyp AE OAE:0005739 This is an AE which is inflammation of the duodenum and may persist acutely or chronically. QY, JX, HY http://en.volupedia.org/wiki/Duodenitis 十二指肠炎 10013864 duodenitis AE OAE:0005740 This is an AE which is inflammation of the duodenum with haemorrhagic. QY, JX, HY http://en.volupedia.org/wiki/Duodenitis 十二指肠炎出血 10013865 duodenitis hemorrhagic AE OAE:0005741 This is an AE which consists of retrograde passage of alkaline duodenal contents into the stomach; it may occur due to antroduodenal motility disorder (primary DGR) or may arise following surgical alteration of gastoduodenal anatomy or because of biliary pathology (secondary DGR). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17285081/ 十二指肠胃反流 10060865 duodenogastric reflux AE OAE:0005742 This is an AE which is uncommon disease caused by Herpes simplex virus (HSV). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33054791/ 疱疹食管炎 10052330 herpes esophagitis AE OAE:0005743 This is an AE which is the second most common cause of infectious esophagitis and it occurs in both immunocompromised and immunocompetent patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31106821/ 单纯疱疹食管炎 10074242 herpes simplex esophagitis AE OAE:0005744 This is an AE which refers to bleeding from a laceration in the mucosa at the junction of the stomach and esophagus. QY, JX, HY http://en.volupedia.org/wiki/Mallory%E2%80%93Weiss_syndrome 食管贲门粘膜撕裂综合征 10026712 mallory-weiss syndrome AE OAE:0005745 This is an AE which is a failure of smooth muscle fibers to relax, which can cause the lower esophageal sphincter to remain closed. QY, JX, HY http://en.volupedia.org/wiki/Esophageal_achalasia 食管失弛缓性 10030136 esophageal achalasia AE OAE:0005746 This is an AE which is the most common type of infectious esophagitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31772927/ 食管念珠菌病 10030154 esophageal candidiasis AE OAE:0005747 This is an AE which is a malignancy that develops from oesophageal epithelial cells. QY, JX, HY http://en.volupedia.org/wiki/Carcinoma 食管癌 10030155 esophageal carcinoma AE OAE:0005748 This is an AE which includs a spectrum of disorders affecting the oesophagus. QY, JX, HY http://en.volupedia.org/wiki/Gastrointestinal_disease 食管疾病 10061318 esophageal disorder AE OAE:0005749 This is an AE which is the ability of oesophageal to move independently, using metabolic energy QY, JX, HY http://en.volupedia.org/wiki/Motility 食管运动减弱 10067752 esophageal hypomotility AE OAE:0005750 This is an AE which can cause chest pain, heartburn, or dysphagia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32866357/ 食管运动障碍 10072419 esophageal motility disorder AE OAE:0005751 This is an AE which is the build-up of fluid in the oesophageal tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 食管的水肿 10064342 esophageal edema AE OAE:0005752 This is an AE which is an uncommon disease that does not appear to predispose to esophageal cancer. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11555097/ 食管乳头状瘤 10071192 esophageal papilloma AE OAE:0005753 This is an AE which is a rupture of the esophageal wall. QY, JX, HY http://en.volupedia.org/wiki/Esophageal_rupture 食管破裂 10052211 esophageal rupture AE OAE:0005754 This is an AE which is a disorder of motility of the esophagus. QY, JX, HY http://en.volupedia.org/wiki/Esophageal_spasm 食管痉挛 10030184 esophageal spasm AE OAE:0005755 This is an AE which is a predictor of poor prognosis in patients with oesophageal cancer. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29617789/ 食管狭窄 10030194 esophageal stenosis AE OAE:0005756 This is an AE which occur mainly as a result of gastro-oesophageal reflux disease (GERD). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17465462/ 食管溃疡 10030201 esophageal ulcer AE OAE:0005757 This is an AE which is a chronic condition in which stomach contents rise up into the esophagus, resulting in either symptoms or complications. QY, JX, HY http://en.volupedia.org/wiki/Gastroesophageal_reflux_disease 反流性食管炎 10038263 reflux esophagitis AE OAE:0005758 This is an AE which is an abnormal connection (fistula) between the esophagus and the trachea. QY, JX, HY http://en.volupedia.org/wiki/Tracheoesophageal_fistula 气管食管瘘 10044310 tracheo-esophageal fistula AE OAE:0005759 This is an AE which is rare and the most common causes are tuberculosis and malignancy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/8737559/ 获得性气管食管瘘 10000582 acquired tracheo-esophageal fistula AE OAE:0005760 This is an AE which is a condition in which there is an abnormal (metaplastic) change in the mucosal cells lining the lower portion of the esophagus, from normal stratified squamous epithelium to simple columnar epithelium with interspersed goblet cells that are normally present only in the small intestine and large intestine. QY, JX, HY http://en.volupedia.org/wiki/Barrett%27s_esophagus 巴雷特食管 10004137 barrett's oesophagus AE OAE:0005761 This is an AE which is a disease characterized by inflammation with erosive of the esophagus. QY, JX, HY http://en.volupedia.org/wiki/Esophagitis 侵蚀性食管炎 10063655 erosive esophagitis AE OAE:0005762 This is an AE which refers to the state in the stomach where gastric acid levels are higher than the reference range. QY, JX, HY http://en.volupedia.org/wiki/Hyperchlorhydria 胃酸过多症 10020601 hyperchlorhydria AE OAE:0005763 This is an AE which is an abnormality in the stomach caused by chemicals, e.g. bile, alcohol, and characteristically has minimal inflammation. QY, JX, HY http://en.volupedia.org/wiki/Reactive_gastropathy 反应性胃病 10075425 reactive gastropathy AE OAE:0005764 This is an AE which refer to states where the production of hydrochloric acid in gastric secretions of the stomach and other digestive organs is absent or low, respectively. QY, JX, HY http://en.volupedia.org/wiki/Achlorhydria 胃酸缺乏症 10000451 achlorhydria AE OAE:0005765 This is an AE which refers to a wide range of problems of the gastric tissues. QY, JX, HY http://en.volupedia.org/wiki/Gastritis#Chronic 慢性胃炎 10008882 chronic gastritis AE OAE:0005766 This is an AE which remains a common and potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HCT). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25398933/ 慢性移植物抗宿主病 10066261 chronic graft versus host disease AE OAE:0005767 This is an AE which is inflammation of the lining of the stomach caused by helicobacter. QY, JX, HY http://en.volupedia.org/wiki/Gastritis 幽门螺杆菌胃炎 10054272 helicobacter gastritis AE OAE:0005768 This is an AE which is a genus of Gram-negative bacteria possessing a characteristic helical shape and causes infection. QY, JX, HY http://en.volupedia.org/wiki/Helicobacter 幽门螺杆菌感染 10054263 helicobacter infection AE OAE:0005769 This is an AE which is a painful mouth infection caused by coxsackieviruses. QY, JX, HY http://en.volupedia.org/wiki/Herpangina 疱疹性咽峡炎 10019936 herpangina AE OAE:0005770 This is an AE which is inflammation caused by herpes of the back of the throat. QY, JX, HY http://en.volupedia.org/wiki/Pharyngitis 疱疹咽炎 10066888 herpes pharyngitis AE OAE:0005771 This is an AE which is inflammation caused by herpes zoster of the back of the throat. QY, JX, HY http://en.volupedia.org/wiki/Pharyngitis 带状疱疹咽炎 10074245 herpes zoster pharyngitis AE OAE:0005772 This is an AE which is the part of the throat behind the mouth and nasal cavity, and above the oesophagus and trachea (the tubes going down to the stomach and the lungs) and it has blistering. QY, JX, HY http://en.volupedia.org/wiki/Pharynx 口咽部水疱 10067950 oropharyngeal blistering AE OAE:0005773 This is an AE which is the part of the throat behind the mouth and nasal cavity, and above the oesophagus and trachea (the tubes going down to the stomach and the lungs) and feels it discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Pharynx 口咽不适 10068318 oropharyngeal discomfort AE OAE:0005774 This is an AE which may impede tracheal intubation or laryngeal mask airway insertion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29634531/ 口咽伤疤 10070837 oropharyngeal scar AE OAE:0005775 This is an AE which can manifest as a rare complication after surgery for obstructive sleep apnea or tonsillectomy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29634531/ 口咽狭窄 10084375 oropharyngeal stenosis AE OAE:0005776 This is an AE which is the part of the throat behind the mouth and nasal cavity and it is swelling. QY, JX, HY http://en.volupedia.org/wiki/Pharynx 口咽肿胀 10031118 oropharyngeal swelling AE OAE:0005777 This is an AE which is a collection of pus that has built up within the tissue of the pharyngeal. QY, JX, HY http://en.volupedia.org/wiki/Abscess 咽脓肿 10067781 pharyngeal abscess AE OAE:0005778 This is an AE which is diverse and can include developmental, traumatic, immune-mediated, infectious, metabolic, endocrine, neurologic, neoplastic, and inflammatory etiologies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7817488/ 咽疾病 10067353 pharyngeal disorder AE OAE:0005779 This is an AE which is a rash (small spots) on the pharyngeal mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Enanthem 咽黏膜疹 10073741 pharyngeal enanthema AE OAE:0005780 This is an AE which is redness of the pharyngeal skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 咽红斑 10057009 pharyngeal erythema AE OAE:0005781 This is an AE which is a fluid emitted by an organism pharyngeal through pores or a wound. QY, JX, HY http://en.volupedia.org/wiki/Exudate 咽分泌物 10072369 pharyngeal exudate AE OAE:0005782 This is an AE which causing partial airway obstruction. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33653857/ 咽血肿 10068121 pharyngeal hematoma AE OAE:0005783 This is an AE which is the increase in the volume of pharyngeal tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 咽肥大 10057344 pharyngeal hypertrophy AE OAE:0005784 This is an AE which can be quantified with sensory testing using LSR and can cause dysphagia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31381234/ 咽触觉减退 10059923 pharyngeal hypoesthesia AE OAE:0005785 This is an AE which is the part of the throat behind the mouth and nasal cavity, and above the oesophagus and trachea (the tubes going down to the stomach and the lungs) and is injury. QY, JX, HY http://en.volupedia.org/wiki/Pharynx 咽受伤 10061555 pharyngeal injury AE OAE:0005786 This is an AE which is any damage or abnormal change in the tissue of pharyngeal , usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 咽病变 10054826 pharyngeal lesion AE OAE:0005787 This is an AE which is a firmly attached white patch on pharyngeal mucous membrane which is associated with increased risk of cancer. QY, JX, HY http://en.volupedia.org/wiki/Leukoplakia 咽黏膜白斑病 10051731 pharyngeal leukoplakia AE OAE:0005788 This is an AE which is the build-up of fluid in the pharyngeal tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 咽部水肿 10034829 pharyngeal edema AE OAE:0005789 This is an AE which is related to low pressure of lower esophageal sphincter(LES ) and high pressure of upper esophageal sphincter (UES). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26647543/ 咽部感觉异常 10076737 pharyngeal paraesthesia AE OAE:0005790 This is an AE which refers a transient abnormal enlargement of pharyngeal part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 咽肿胀 10082270 pharyngeal swelling AE OAE:0005791 This is an AE which caused by CMV infection, related to immune reconstitution inflammatory syndrome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33691621/ 咽部溃疡 10034834 pharyngeal ulceration AE OAE:0005792 This is an AE which is inflammation of the back of the throat caused by bacterial. QY, JX, HY http://en.volupedia.org/wiki/Pharyngitis 咽炎细菌 10057869 pharyngitis bacterial AE OAE:0005793 This is an AE which is an infection of the back of the throat including the tonsils caused by group A streptococcus (GAS). QY, JX, HY http://en.volupedia.org/wiki/Streptococcal_pharyngitis 咽炎链球菌 10034839 pharyngitis streptococcal AE OAE:0005794 This is an AE which is a significant complication following the use of laryngeal mask airway (LMA). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24226490/ 咽喉不适 10065968 pharyngolaryngeal discomfort AE OAE:0005795 This is an AE which develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses or the skin of the face. QY, JX, HY http://en.volupedia.org/wiki/Head_and_neck_cancer 咽喉癌 10043515 throat cancer AE OAE:0005796 This is an AE which is inflammation of the back of the throat caused by viral. QY, JX, HY http://en.volupedia.org/wiki/Pharyngitis 病毒性咽炎 10047473 viral pharyngitis AE OAE:0005797 This is an AE which is a bacterial infection involving the inner layers of the pharyngeal skin. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 蜂窝织炎咽 10007920 cellulitis pharyngeal AE OAE:0005798 This is an AE which is a sound made at the back of the throat by tightly constricting the laryngopharyngeal tissues and vibrating the palatoglossal arch and the vocal folds while exhaling through the nose. QY, JX, HY http://en.volupedia.org/wiki/Throat-clear 慢性咽喉清 10075070 chronic throat clearing AE OAE:0005799 This is an AE which is a tube that links the nasopharynx to the middle ear, of which it is also a part and its functions become disorder . QY, JX, HY http://en.volupedia.org/wiki/Eustachian_tube 咽鼓管疾病 10061462 eustachian tube disorder AE OAE:0005800 This is an AE which is defined as pressure abnormalities in the middle ear which result in symptoms. QY, JX, HY http://en.volupedia.org/wiki/Eustachian_tube_dysfunction 咽鼓管功能障碍 10015543 eustachian tube dysfunction AE OAE:0005801 This is an AE which is a tube that links the nasopharynx to the middle ear, of which it is also a part and becomes obstruction. QY, JX, HY http://en.volupedia.org/wiki/Eustachian_tube 咽鼓管梗阻 10015544 eustachian tube obstruction AE OAE:0005802 This is an AE which is the name of a physical disorder where the Eustachian tube, which is normally closed, instead stays intermittently open. QY, JX, HY http://en.volupedia.org/wiki/Patulous_Eustachian_tube 咽鼓管扩展 10015546 eustachian tube patulous AE OAE:0005803 This is an AE which is the irritation of the skin at the exit of the rectum, known as the anus, causing the desire to scratch. QY, JX, HY http://en.volupedia.org/wiki/Pruritus_ani 肛门瘙痒症 10037089 pruritus ani AE OAE:0005804 This is an AE which is the increase in the volume of anal papilla tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 肥厚性肛门乳头 10058442 hypertrophic anal papilla AE OAE:0005805 This is an AE which is a anal sphincter condition typified by a weakness of voluntary movement, or by partial loss of voluntary movement or by impaired movement. QY, JX, HY http://en.volupedia.org/wiki/Paresis 麻痹性痴呆肛门括约肌 10050373 paresis anal sphincter AE OAE:0005806 This is an AE which is a calcification of the gallbladder believed to be brought on by excessive gallstones, although the exact cause is not clear. QY, JX, HY http://en.volupedia.org/wiki/Porcelain_gallbladder 瓷样胆囊 10050899 porcelain gallbladder AE OAE:0005807 This is an AE which is a type of cancer that forms in the bile ducts. QY, JX, HY http://en.volupedia.org/wiki/Cholangiocarcinoma 胆管癌 10008593 cholangiocarcinoma AE OAE:0005808 This is an AE which is any inflammation with infective of the biliary tree. QY, JX, HY http://en.volupedia.org/wiki/Cholangitis_(disambiguation) 感染性胆管炎 10075445 cholangitis infective AE OAE:0005809 This is an AE which is defined as a condition with progressive stenosis and destruction of the bile ducts due to diffuse inflammation and fibrosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30205418/ 硬化性胆管炎 10008609 cholangitis sclerosing AE OAE:0005810 This is an AE which is defined as inflammation of the gallbladder and is usually caused by obstruction of the cystic duct. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24679431/ 急性胆囊炎 10008614 cholecystitis acute AE OAE:0005811 This is an AE which occurs after repeated episodes of acute cholecystitis and is almost always due to gallstones and may be asymptomatic, may present as a more severe case of acute cholecystitis, or may lead to a number of complications such as gangrene, perforation, or fistula formation. QY, JX, HY http://en.volupedia.org/wiki/Cholecystitis#Chronic_cholecystitis 慢性胆囊炎 10008617 cholecystitis chronic AE OAE:0005812 This is an AE which is inflammation with infective of the gallbladder. QY, JX, HY http://en.volupedia.org/wiki/Cholecystitis 感染性胆囊炎 10062631 cholecystitis infective AE OAE:0005813 This is an AE which encompass a wide breadth of diseases that vary in severity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33478678/ 胆囊疾病 10017626 gallbladder disorder AE OAE:0005814 This is an AE which is a small hollow organ where bile is stored and concentrated before it is released into the small intestine and becomes hypofunction. QY, JX, HY http://en.volupedia.org/wiki/Gallbladder 胆囊功能不良 10080936 gallbladder hypofunction AE OAE:0005815 This is an AE which leads to cicatricial and adhesive processes in its wall and surrounding tissues that significantly complicates cholecystectomy and increases the risk of bile ducts trauma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29460879/ 胆囊无功能 10080936 gallbladder non-functioning AE OAE:0005816 This is an AE which is the build-up of fluid in the gallbladder tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 胆囊水肿 10017637 gallbladder edema AE OAE:0005817 This is an AE which is extremely rare, majority of ruptures occur secondary to traumatic injuries. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30611267/ 胆囊破裂 10081151 gallbladder rupture AE OAE:0005818 This is an AE which is defined by acute distension of the gallbladder. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17402689/ 胆囊积水 10056972 hydrocholecystis AE OAE:0005819 This is an AE which is a cause of several gut-related problems, the main one being chronic diarrhea. QY, JX, HY http://en.volupedia.org/wiki/Bile_acid_malabsorption 胆汁酸吸收不良 10069703 bile acid malabsorption AE OAE:0005820 This is an AE which is an autoimmune disease of the liver. QY, JX, HY http://en.volupedia.org/wiki/Primary_biliary_cholangitis 原发性胆汁性肝硬化 10004661 biliary cirrhosis primary AE OAE:0005821 This is an AE which is rare dilatations of different parts of a biliary tract. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23002354/ 胆道囊肿 10052384 biliary cyst AE OAE:0005822 This is an AE which is a type of abnormal and excessive growth of neoplasm tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 胆道肿瘤 10004668 biliary neoplasm AE OAE:0005823 This is an AE which is any of a number of long tube-like structures that carry bile, and is present in most vertebrates. QY, JX, HY http://en.volupedia.org/wiki/Bile_duct#Clinical_significance 胆道梗阻 10084247 biliary obstruction AE OAE:0005824 This is an AE which refers to the liver, gall bladder and bile ducts, and how they work together to make, store and secrete bile and its function gets disorder. QY, JX, HY http://en.volupedia.org/wiki/Biliary_tract 胆道疾病 10061008 biliary tract disorder AE OAE:0005825 This is an AE which is a medical condition in which cholestasis occurs during pregnancy and typically presents with itching and can lead to complications for both mother and baby. QY, JX, HY http://en.volupedia.org/wiki/Intrahepatic_cholestasis_of_pregnancy 妊娠胆汁淤积 10049055 cholestasis of pregnancy AE OAE:0005826 This is an AE which is a destructive and expanding growth consisting of keratinizing squamous epithelium in the middle ear and/or mastoid process. QY, JX, HY http://en.volupedia.org/wiki/Cholesteatoma 胆脂瘤 10008642 cholesteatoma AE OAE:0005827 This is an AE which is an over-stimulation at a neuromuscular junction due to an excess of acetylcholine (ACh), as a result of the inactivity of the AChE enzyme, which normally breaks down acetylcholine. QY, JX, HY http://en.volupedia.org/wiki/Cholinergic_crisis 胆碱能综合症 10008674 cholinergic syndrome AE OAE:0005828 This is an AE which defines persisting conjugated hyperbilirubinemia in the newborn with conjugated bilirubin levels exceeding 15% (5.0 mg/dL) of total bilirubin level. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_cholestasis 新生儿胆汁淤积 10056528 neonatal cholestasis AE OAE:0005829 This is an AE which is an autoimmune disease of the liver. QY, JX, HY http://en.volupedia.org/wiki/Primary_biliary_cholangitis 原发性胆汁性胆管炎 10080429 primary biliary cholangitis AE OAE:0005830 This is an AE which is a hollow muscular organ in humans and other vertebrates that stores urine from the kidneys before disposal by urination and the organ is haemorrhage. QY, JX, HY http://en.volupedia.org/wiki/Urinary_bladder 膀胱出血 10046528 urinary bladder hemorrhage AE OAE:0005831 This is an AE which may occur if the bladder is overfilled and not emptied. QY, JX, HY http://en.volupedia.org/wiki/Urinary_bladder_disease 膀胱破裂 10046530 urinary bladder rupture AE OAE:0005832 This is an AE which is microscopic cylindrical structures produced by the kidney and present in the urine in certain disease states. QY, JX, HY http://en.volupedia.org/wiki/Urinary_cast 尿沉渣 10080828 urinary sediment AE OAE:0005833 This is an AE which includes urinary incontinence, urgency and nocturia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28937771/ 排尿困难 10069648 urinary straining AE OAE:0005834 This is an AE which is an infection that affects part of the urinary tract and children the only symptom of a urinary tract infection (UTI) may be a fever . QY, JX, HY http://en.volupedia.org/wiki/Urinary_tract_infection 新生儿尿路感染 10046573 urinary tract infection neonatal AE OAE:0005835 This is an AE which is part of the complex biological response of urinary tract tissues to harmful stimuli. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 泌尿道炎症 10064921 urinary tract inflammation AE OAE:0005836 This is an AE which is a condition in which urine flows retrograde, or backward, from the bladder into one or both ureters and then to the renal calyx or kidneys. QY, JX, HY http://en.volupedia.org/wiki/Vesicoureteral_reflux 膀胱输尿管反流 10047370 vesicoureteric reflux AE OAE:0005837 This is an AE which includes urinary bladder inflammation such as cystitis, bladder rupture and bladder obstruction (tamponade). QY, JX, HY http://en.volupedia.org/wiki/Urinary_bladder_disease 膀胱疾病 10061011 bladder disorder AE OAE:0005838 This is an AE which can treat with optional fulguration of Hunner lesions, improved IC symptoms. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26208131/ 膀胱积水 10066923 bladder hydrodistension AE OAE:0005839 This is an AE which is a bladder state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 膀胱刺激 10005052 bladder irritation AE OAE:0005840 This is an AE which refers absence of bladder sphincter muscle tone. QY, JX, HY http://en.volupedia.org/wiki/Glossary_of_medicine#Atony 膀胱括约肌弛缓 10005073 bladder sphincter atony AE OAE:0005841 This is an AE which is a chronic functional condition of unknown pathogenesis. QY, JX, HY http://en.volupedia.org/wiki/Cyclic_vomiting_syndrome 周期性呕吐综合征 10062937 cyclic vomiting syndrome AE OAE:0005842 This is an AE which is the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose occured on the infantile. QY, JX, HY http://en.volupedia.org/wiki/Vomiting 小儿呕吐 10075315 infantile vomiting AE OAE:0005843 This is an AE which is the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose after post-tussive . QY, JX, HY http://en.volupedia.org/wiki/Vomiting 咳嗽后呕吐 10066220 post-tussive vomiting AE OAE:0005844 This is an AE which is the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose after procedural . QY, JX, HY http://en.volupedia.org/wiki/Vomiting 手术后呕吐 10066963 procedural vomiting AE OAE:0005845 This is an AE which is a symptom of pregnancy that involves nausea or vomiting. QY, JX, HY http://en.volupedia.org/wiki/Morning_sickness 怀孕呕吐 10047704 vomiting in pregnancy AE OAE:0005846 This is an AE which is the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose occured on the neonatal. QY, JX, HY http://en.volupedia.org/wiki/Vomiting 呕吐新生儿 10047705 vomiting neonatal AE OAE:0005847 This is an AE which is an intense form of vomiting, sometimes seen in infants, that may include vomit exiting out the nostrils. QY, JX, HY http://en.volupedia.org/wiki/Vomiting 喷射型呕吐 10047708 vomiting projectile AE OAE:0005848 This is an AE which is a diffuse sensation of unease and discomfort, often perceived as an urge to vomit and it occured after the procedural . QY, JX, HY http://en.volupedia.org/wiki/Nausea 手术后恶心 10066962 procedural nausea AE OAE:0005849 This is an AE which is tumours that form in the tissues of salivary glands. QY, JX, HY http://en.volupedia.org/wiki/Salivary_gland_tumour 涎腺脓肿 10000305 abscess of salivary gland AE OAE:0005850 This is an AE which is inflammation with noninfective of salivary glands, usually the major ones, the most common being the parotid gland, followed by submandibular and sublingual glands. QY, JX, HY http://en.volupedia.org/wiki/Sialadenitis 非感染性涎腺炎 10075243 noninfective sialoadenitis AE OAE:0005851 This is an AE which is a collection of pus that has built up within the tissue of the appendiceal. QY, JX, HY http://en.volupedia.org/wiki/Abscess 阑尾的脓肿 10049764 appendiceal abscess AE OAE:0005852 This is an AE which is a stone made of feces when it occurs in the appendix and is sometimes concomitant with appendicitis. QY, JX, HY http://en.volupedia.org/wiki/Fecalith 阑尾石 10074458 appendicolith AE OAE:0005853 This is an AE which is very rare cancers of the vermiform appendix. QY, JX, HY http://en.volupedia.org/wiki/Appendix_cancer 阑尾癌 10073360 appendix cancer AE OAE:0005854 This is an AE which is a finger-like, blind-ended tube connected to the cecum and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Appendix_(anatomy) 阑尾疾病 10060960 appendix disorder AE OAE:0005855 This is an AE which is normally observed within the first 10 to 100 days post-transplant, and is a major challenge to transplants owing to associated morbidity and mortality. QY, JX, HY http://en.volupedia.org/wiki/Graft-versus-host_disease#Acute 急性移植抗宿主病 10066260 acute graft versus host disease AE OAE:0005856 This is an AE which is an extracellular fluid produced and secreted by salivary glands in the mouth and it becomes discolouration. QY, JX, HY http://en.volupedia.org/wiki/Saliva 唾液变色 10049069 saliva discoloration AE OAE:0005857 This is an AE which is tumours that form in the tissues of salivary glands. QY, JX, HY http://en.volupedia.org/wiki/Salivary_gland_tumour 唾液腺腺瘤 10051636 salivary gland adenoma AE OAE:0005858 This is an AE which is a concretion of material, usually mineral salts, that forms in an organ or duct of the salivary gland. QY, JX, HY http://en.volupedia.org/wiki/Calculus_(medicine) 唾液腺结石 10039394 salivary gland calculus AE OAE:0005859 This is an AE which is a type of salivary gland diseases. QY, JX, HY http://en.volupedia.org/wiki/Salivary_gland_disease 唾液腺肿大 10039408 salivary gland enlargement AE OAE:0005860 This is an AE which is tumours that form in the tissues of salivary glands. QY, JX, HY http://en.volupedia.org/wiki/Salivary_gland_tumour 唾液腺肿瘤 10061497 salivary gland neoplasm AE OAE:0005861 This is an AE which is exocrine glands that produce saliva through a system of ducts and feels pain. QY, JX, HY http://en.volupedia.org/wiki/Salivary_gland 唾液腺疼痛 10039421 salivary gland pain AE OAE:0005862 This is an AE which is the movement of material from one point to another, such as a secreted chemical substance from a salivary gland. QY, JX, HY http://en.volupedia.org/wiki/Secretion 唾液分泌过多 10039424 salivary hypersecretion AE OAE:0005863 This is an AE which is a break in the inner lining of the stomach, the first part of the small intestine, or sometimes the lower esophagus. QY, JX, HY http://en.volupedia.org/wiki/Peptic_ulcer_disease 消化性溃疡 10034341 peptic ulcer AE OAE:0005864 This is an AE which is an infection of a genus of anaerobic, Gram-positive, non-spore forming bacteria . QY, JX, HY http://en.volupedia.org/wiki/Peptostreptococcus 消化链球菌属感染 10054124 peptostreptococcus infection AE OAE:0005865 This is an AE which is a condition in which an untreated ulcer has burned through the mucosal wall in a segment of the gastrointestinal tract (e.g., the stomach or colon) allowing gastric contents to leak into the abdominal cavity. QY, JX, HY http://en.volupedia.org/wiki/Perforated_ulcer 穿孔性溃疡 10062065 perforated ulcer AE OAE:0005866 This is an AE which is an abscess adjacent to the anus. QY, JX, HY http://en.volupedia.org/wiki/Anorectal_abscess 肛周脓肿 10034447 perianal abscess AE OAE:0005867 This is an AE which is redness of the perianal skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 肛周的红斑 10056273 perianal erythema AE OAE:0005868 This is an AE which is a chronic motility disorder characterized by effortless regurgitation of most meals following consumption, due to the involuntary contraction of the muscles around the abdomen. QY, JX, HY http://en.volupedia.org/wiki/Rumination_syndrome 反刍 10027387 merycism AE OAE:0005869 This is an AE which is the expulsion of material from the pharynx, or esophagus, usually characterized by the presence of undigested food or blood. QY, JX, HY http://en.volupedia.org/wiki/Regurgitation_(digestion) 反流 10067171 regurgitation AE OAE:0005870 This is an AE which can present with sonographic findings similar to hypertrophic pyloric stenosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26835566/ 幽门痉挛 10037628 pylorospasm AE OAE:0005871 This is an AE which is a narrowing of the opening from the stomach to the first part of the small intestine (the pylorus). QY, JX, HY http://en.volupedia.org/wiki/Pyloric_stenosis 幽门狭窄 10037621 pyloric stenosis AE OAE:0005872 This is an AE which causes pulmonary atelectasis, secondary pneumonia, and respiratory failure is a frequent complication particularly in patients recovering from abdominal and thoracic surgery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/1519152/ 痰液潴留 10059685 sputum retention AE OAE:0005873 This is an AE which is mucus with purulent that is coughed up from the lower airways (the trachea and bronchi). QY, JX, HY http://en.volupedia.org/wiki/Sputum 痰中带脓 10050090 sputum purulent AE OAE:0005874 This is an AE which is complicated inflammation of the appendix. QY, JX, HY http://en.volupedia.org/wiki/Appendicitis 复杂性阑尾炎 10081534 complicated appendicitis AE OAE:0005875 This is an AE which is having more body fat than is optimally healthy. QY, JX, HY http://en.volupedia.org/wiki/Overweight 超重 10033307 overweight AE OAE:0005876 This is an AE which is a symptom of pregnancy that involves nausea or vomiting. QY, JX, HY http://en.volupedia.org/wiki/Morning_sickness 晨吐 10047704 morning sickness AE OAE:0005877 This is an AE which is the inflammation of the epiglottis—the flap at the base of the tongue that prevents food entering the trachea (windpipe). QY, JX, HY http://en.volupedia.org/wiki/Epiglottitis 会厌炎 10015030 epiglottitis AE OAE:0005878 This is an AE which is defined as a condition in which a person does not have the physical or financial capability to eat sufficient food to meet basic nutritional needs for a sustained period. QY, JX, HY http://en.volupedia.org/wiki/Hunger 饥饿 10020466 hunger AE OAE:0005879 This is an AE which is a severe deficiency in caloric energy intake, below the level needed to maintain an organism's life. QY, JX, HY http://en.volupedia.org/wiki/Starvation 饥饿 10041954 starvation AE OAE:0005880 This is an AE which is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus. QY, JX, HY http://en.volupedia.org/wiki/Crohn%27s_disease 克罗恩氏病 10011401 crohn's disease AE OAE:0005881 This is an AE which is a slight bulge in the small intestine present at birth and a vestigial remnant of the omphalomesenteric duct (also called the vitelline duct or yolk stalk). QY, JX, HY http://en.volupedia.org/wiki/Meckel%27s_diverticulum 憩室炎氏 10013542 diverticulitis meckel's AE OAE:0005882 This is an AE which is a person whose body weight is considered too low to be healthy. QY, JX, HY http://en.volupedia.org/wiki/Underweight 体重过轻 10048828 underweight AE OAE:0005883 This is an AE which is a condition of excessive air swallowing, which goes to the stomach. QY, JX, HY http://en.volupedia.org/wiki/Aerophagia 吞气症 10052813 aerophagia AE OAE:0005884 This is an AE which is vascular structures in the anal canal. QY, JX, HY http://en.volupedia.org/wiki/Hemorrhoid 痔核 10019022 haemorrhoids AE OAE:0005885 This is an AE which is a type of gastroenteritis that results in bloody diarrhea. QY, JX, HY http://en.volupedia.org/wiki/Dysentery 痢疾 10051402 dysentery AE OAE:0005886 This is an AE which is when a loop of intestine twists around itself and the mesentery that supports it, resulting in a bowel obstruction. QY, JX, HY http://en.volupedia.org/wiki/Volvulus 扭转 10047697 volvulus AE OAE:0005887 QY, JX, HY 粪便呕吐 10064670 faecal vomiting AE OAE:0005888 QY, JX, HY 胃粘膜病变 10061164 gastric mucosal lesion AE OAE:0005889 QY, JX, HY 蛋白丢失性胃肠病 10059344 protein-losing gastroenteropathy AE OAE:0005890 QY, JX, HY 肛门不适 10052811 anal discomfort AE OAE:0005891 QY, JX, HY 肛门损伤 10055023 anal injury AE OAE:0005892 QY, JX, HY 肛门直肠不适 10068286 anorectal discomfort AE OAE:0005893 QY, JX, HY 肠运动不规则 10063541 bowel movement irregularity AE OAE:0005894 QY, JX, HY 食管不适 10053634 esophageal discomfort AE OAE:0005895 QY, JX, HY 食管损伤 10058522 esophageal injury AE OAE:0005896 QY, JX, HY 食管刺激 10070818 esophageal irritation AE OAE:0005897 QY, JX, HY 食管梗阻 10030178 esophageal obstruction AE OAE:0005898 QY, JX, HY 食管炎溃疡性 10049098 esophagitis ulcerative AE OAE:0005899 QY, JX, HY 食管烧伤 10006707 burn esophageal AE OAE:0005900 QY, JX, HY 口腔损伤 10049294 mouth injury AE OAE:0005901 QY, JX, HY 口腔粘膜喷发 10030997 oral mucosal eruption AE OAE:0005902 QY, JX, HY 口腔粘膜表皮脱落 10064487 oral mucosal exfoliation AE OAE:0005903 QY, JX, HY 胃肿块 10066792 stomach mass AE OAE:0005904 QY, JX, HY 口腔球菌感染 10068385 stomatococcal infection AE OAE:0005905 QY, JX, HY 口腔烧伤 10075532 burn oral cavity AE OAE:0005906 QY, JX, HY 醋酸性呕吐 10058938 acetonaemic vomiting AE OAE:0005907 QY, JX, HY 口咽斑块 10067721 oropharyngeal plaque AE OAE:0005908 QY, JX, HY 咽侵蚀 10062773 pharyngeal erosion AE OAE:0005909 QY, JX, HY 胆汁分泌不足 10071634 deficiency of bile secretion AE OAE:0005910 This is an AE which blockage of the ear canal due to swelling of the eardrum. QY, JX, HY http://en.volupedia.org/wiki/Congestion 耳朵堵塞 10052136 ear congestion AE OAE:0005911 This is an AE which a transient abnormal enlargement of ear not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 耳肿胀 10003800 auricular swelling AE OAE:0005912 This is an AE which due to neurological damage is hearing loss that precludes a person from understanding spoken language, an audiological condition. QY, JX, HY http://en.volupedia.org/wiki/Deafness 神经感觉性耳聋 10011891 deafness neurosensory AE OAE:0005913 This is an AE which is permanently hearing loss that precludes a person from understanding spoken language, an audiological condition. QY, JX, HY http://en.volupedia.org/wiki/Deafness 永久性耳聋 10011894 deafness permanent AE OAE:0005914 This is an AE which is temporarily hearing loss that precludes a person from understanding spoken language, an audiological condition. QY, JX, HY http://en.volupedia.org/wiki/Deafness 暂时性耳聋 10011900 deafness transitory AE OAE:0005915 This is an AE which is a group of inflammatory noninfective diseases of the middle ear. QY, JX, HY http://en.volupedia.org/wiki/Otitis_media 非感染性鼓膜炎 10078830 noninfective myringitis AE OAE:0005916 This is an AE which is a group of inflammatory diseases of the middle ear. QY, JX, HY http://en.volupedia.org/wiki/Otitis_media 鼓膜疾病 10062218 tympanic membrane disorder AE OAE:0005917 This is an AE which is an injury to the auditory nerve. QY, JX, HY http://en.volupedia.org/wiki/Accessory_nerve_disorder 听觉神经障碍 10078794 auditory nerve disorder AE OAE:0005918 This is an AE which is the process of scuffing, scratching, wearing down, marring, or rubbing away on the ear. QY, JX, HY http://en.volupedia.org/wiki/Abrasion_(mechanical) 耳磨损 10061828 ear abrasion AE OAE:0005919 This is an AE which is redness of the ear canal membranes, caused by hyperemia in superficial capillaries . QY, JX, HY http://en.volupedia.org/wiki/Erythema 耳道红斑 10052135 ear canal erythema AE OAE:0005920 This is an AE which occurs fairly frequently and can leave minor to major deformity. QY, JX, HY http://en.volupedia.org/wiki/Ear#Injury 耳道伤 10056319 ear canal injury AE OAE:0005921 This is an AE which is a functional abnormality or disturbance on the ear. QY, JX, HY http://en.volupedia.org/wiki/Disease#Disorder 耳部疾病 10014004 ear disorder AE OAE:0005922 This is an AE which is blood escaping from the circulatory system from damaged blood vessels and occurs on the ear . QY, JX, HY http://en.volupedia.org/wiki/Bleeding 耳朵出血 10014009 ear hemorrhage AE OAE:0005923 This is an AE which is a general term for inflammation or infection of the ear, in both humans and other animals. QY, JX, HY http://en.volupedia.org/wiki/Otitis 耳炎 10014011 ear infection AE OAE:0005924 This is an AE which is the invasion of ear tissues by disease-causing bacterial. QY, JX, HY http://en.volupedia.org/wiki/Infection 耳朵细菌感染 10067046 ear infection bacterial AE OAE:0005925 This is an AE which a superficial mycotic infection of the outer ear canal. QY, JX, HY http://en.volupedia.org/wiki/Otomycosis 耳朵真菌感染 10068630 ear infection fungal AE OAE:0005926 This is an AE which is an ear infection caused by members of the Staphylococcus genus of bacteria . QY, JX, HY http://en.volupedia.org/wiki/Staphylococcal_infection 耳朵葡萄球菌感染 10057347 ear infection staphylococcal AE OAE:0005927 This is an AE which occurs when ear is invaded by pathogenic viruses, and infectious virus particles (virions) attach to and enter susceptible cells. QY, JX, HY http://en.volupedia.org/wiki/Viral_disease 耳朵病毒感染 10061830 ear infection viral AE OAE:0005928 This is an AE which including outer ear injury, middle ear injury, inner ear injury and tinnitus. QY, JX, HY http://en.volupedia.org/wiki/Ear#Injury 耳朵受伤 10057446 ear injury AE OAE:0005929 This is an AE which is the invasion of an organism's ear lobe by disease-causing agents, their multiplication, and the reaction of ear tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 耳垂感染 10014014 ear lobe infection AE OAE:0005930 This is an AE which are seen with the shape of a ear part and functional disorders in which problems exist with how a ear part works. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 耳畸形 10014016 ear malformation AE OAE:0005931 This is an AE which is a sensation that causes the desire or reflex to scratch on ear. QY, JX, HY http://en.volupedia.org/wiki/Itch 耳朵瘙痒 10052138 ear pruritus AE OAE:0005932 This is an AE which is a transient abnormal enlargement of ear part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 耳肿胀 10014025 ear swelling AE OAE:0005933 This is an AE which is a superficial infection of the ear that may be precipitated by trauma, an insect bite, or ear piercing. QY, JX, HY http://en.volupedia.org/wiki/Ear_pain#External_ear 外耳蜂窝织炎 10015729 external ear cellulitis AE OAE:0005934 This is an AE which occur fairly frequently and can leave minor to major deformity. QY, JX, HY http://en.volupedia.org/wiki/Ear#Outer_ear_2 外耳疾病 10061456 external ear disorder AE OAE:0005935 This is an AE which can cause hearing loss, tinnitus, vertigo and imbalance. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23648600/ 内耳疾病 10061524 inner ear disorder AE OAE:0005936 This is an AE which is part of the complex biological response of inner ear to harmful stimuli, such as pathogens, damaged cells, or irritants QY, JX, HY http://en.volupedia.org/wiki/Inflammation 内耳炎 10066966 inner ear inflammation AE OAE:0005937 This is an AE which is suddenly a partial or total inability to hear and may occur in one or both ears. QY, JX, HY http://en.volupedia.org/wiki/Hearing_loss 突发性听力损失 10061373 sudden hearing loss AE OAE:0005938 This is an AE which is a group of inflammatory diseases of the middle ear. QY, JX, HY http://en.volupedia.org/wiki/Otitis_media 中耳疾病 10061290 middle ear disorder AE OAE:0005939 This is an AE which is fluid accumulation that can occur in the middle ear and mastoid air cells due to negative pressure produced by dysfunction of the Eustachian tube. QY, JX, HY http://en.volupedia.org/wiki/Otitis_media#Otitis_media_with_effusion 中耳积液 10062545 middle ear effusion AE OAE:0005940 This is an AE which is an abnormal sensation of the ear skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 耳朵感觉异常 10052433 paraesthesia ear AE OAE:0005941 This is an AE which is an abnormality of the structure of external ear. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect 先天性外耳异常 10062339 anomaly of external ear congenital AE OAE:0005942 This is an AE which describes a rare congenital deformity that involves the complete absence of the pinna, the outer projected portion of the ear, and narrowing or absence of the ear canal. QY, JX, HY http://en.volupedia.org/wiki/Anotia 无耳 10002654 anotia AE OAE:0005943 This is an AE which is physical damage to body tissues caused by a difference in pressure between a gas space inside, or in contact with, the body, and the surrounding gas or fluid. QY, JX, HY http://en.volupedia.org/wiki/Barotrauma 气压性中耳炎 10004129 barotitis media AE OAE:0005944 This is an AE which is a rare disorder characterized by recurrent inflammation of the front of the eye (the cornea) and often fever, fatigue, and weight loss, episodes of vertigo (dizziness), tinnitus (ringing in the ears) and hearing loss. QY, JX, HY http://en.volupedia.org/wiki/Cogan_syndrome 耳蜗前庭综合征 10056667 cogan's syndrome AE OAE:0005945 This is an AE which occurs when there is a problem transferring sound waves anywhere along the pathway through the outer ear, tympanic membrane (eardrum), or middle ear (ossicles). QY, JX, HY http://en.volupedia.org/wiki/Conductive_hearing_loss 传导性耳聋 10010280 conductive deafness AE OAE:0005946 This is an AE which it develops on the face anterior to the ascending limb of the helix, followed by the inferior portion of the ascending limb itself. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33829886/ 先天性耳瘘 10054215 congenital aural fistula AE OAE:0005947 This is an AE which is total inability to hear. QY, JX, HY http://en.volupedia.org/wiki/Hearing_loss 双侧耳聋 10052556 deafness bilateral AE OAE:0005948 This is an AE which is defined as the hearing loss which is present at birth. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22538062/ 先天性耳聋 10011882 deafness congenital AE OAE:0005949 This is an AE which is a partial inability to hear. QY, JX, HY http://en.volupedia.org/wiki/Hearing_loss 单侧耳聋 10048812 deafness unilateral AE OAE:0005950 This is an AE which is a disorder of the inner ear that is characterized by episodes of vertigo, tinnitus, hearing loss, and a fullness in the ear. QY, JX, HY http://en.volupedia.org/wiki/M%C3%A9ni%C3%A8re%27s_disease 内耳眩晕病 10027183 meniere's disease AE OAE:0005951 This is an AE which is a congenital deformity where the pinna (external ear) is underdeveloped. QY, JX, HY http://en.volupedia.org/wiki/Microtia 小耳症 10027555 microtia AE OAE:0005952 This is an AE which isolated from the middle ear in AOM are Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis,and Staphylococcus aureus. QY, JX, HY http://en.volupedia.org/wiki/Otitis_media#Acute_otitis_media 急性中耳炎 10033079 otitis media acute AE OAE:0005953 This is an AE which is predominantly, nontypeable Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis caused middle ear infection. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15755616/ 细菌性中耳炎 10065176 otitis media bacterial AE OAE:0005954 This is an AE which is a chronic inflammation of the middle ear and mastoid cavity that is characterised by discharge from the middle ear through a perforated tympanic membrane for at least 6 weeks. QY, JX, HY http://en.volupedia.org/wiki/Otitis_media#Chronic_suppurative_otitis_media 慢性中耳炎 10033081 otitis media chronic AE OAE:0005955 This is an AE which starts when the tympanic membrane perforates. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21602234/ 耳漏 10033101 otorrhoea AE OAE:0005956 This is an AE which designate a distinct pathologic phenomenon. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/13605716/ 耳咽鼓管炎 10033102 otosalpingitis AE OAE:0005957 This is an AE which is a condition of the middle ear where one or more foci of irregularly laid spongy bone replace part of normally dense enchondral layer of bony otic capsule in the bony labyrinth. QY, JX, HY http://en.volupedia.org/wiki/Otosclerosis 耳硬化症 10033103 otosclerosis AE OAE:0005958 This is an AE which can cause a permanent hearing loss in rare cases. QY, JX, HY http://en.volupedia.org/wiki/Labyrinthitis?wprov=srpw1_0 病毒性迷路炎 10047466 viral labyrinthitis AE OAE:0005959 This is an AE which is the inflammation of the inner ear. QY, JX, HY http://en.volupedia.org/wiki/Labyrinthitis 迷路炎 10023567 labyrinthitis AE OAE:0005960 This is an AE which a group of inflammatory diseases of the middle ear. QY, JX, HY http://en.volupedia.org/wiki/Otitis_media#myringitis 鼓膜炎 10061302 myringitis AE OAE:0005961 This is an AE which is a thin, cone-shaped membrane that separates the external ear from the middle ear and the process of membrane hyperaemia . QY, JX, HY http://en.volupedia.org/wiki/Eardrum 鼓膜充血 10052154 tympanic membrane hyperemia AE OAE:0005962 This is an AE which developed in consistent patterns in the postero-superior quadrant of the pars tensa. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18792316/ 鼓膜瘢痕 10063604 tympanic membrane scarring AE OAE:0005963 This is an AE which is inflammation of a acoustic nerve or the general inflammation of the peripheral nervous system. QY, JX, HY http://en.volupedia.org/wiki/Neuritis 听觉神经炎 10063162 acoustic neuritis AE OAE:0005964 This is an AE which is an umbrella term for a variety of disorders that affect the way the brain processes auditory information. QY, JX, HY http://en.volupedia.org/wiki/Auditory_processing_disorder 听觉障碍 10003778 auditory disorder AE OAE:0005965 This is an AE which defines by the presence of normal or near-normal otoacoustic emissions (OAEs) but the absence of normal middle ear reflexes and severely abnormal or completely absent auditory brainstem response (ABRs). QY, JX, HY http://en.volupedia.org/wiki/Auditory_neuropathy_spectrum_disorder 听觉神经病谱系障碍 10072198 auditory neuropathy spectrum disorder AE OAE:0005966 This is an AE which is a mastoid collection of pus that has built up within the tissue of the body. QY, JX, HY http://en.volupedia.org/wiki/Abscess 乳突脓肿 10061276 mastoid abscess AE OAE:0005967 This is an AE which refers the mastoiditis that is the result of an infection that extends to the air cells of the skull behind the ear. QY, JX, HY http://en.volupedia.org/wiki/Mastoiditis 乳突障碍 10061277 mastoid disorder AE OAE:0005968 This is an AE which increases the risks for bacterial otitis and mastoiditis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33115615/ 乳突积液 10069008 mastoid effusion AE OAE:0005969 This is an AE which is the result of an infection that extends to the air cells of the skull behind the ear. QY, JX, HY http://en.volupedia.org/wiki/Mastoiditis 乳突炎 10026900 mastoiditis AE OAE:0005970 This is an AE which is a form of hallucination that involves perceiving sounds without auditory stimulus. QY, JX, HY http://en.volupedia.org/wiki/Auditory_hallucination 听觉幻觉 10019070 hallucination, auditory AE OAE:0005971 This is an AE which is a partial or total inability to hear. QY, JX, HY http://en.volupedia.org/wiki/Hearing_loss 听力残疾 10053194 hearing disability AE OAE:0005972 This is an AE which is a hearing impairment characterized by difficulty in processing details of sound due to distortion in frequency or intensity rather than primarily a loss of the ability to perceive sound. QY, JX, HY http://en.volupedia.org/wiki/Dysacusis 听力减退 10049712 dysacusis AE OAE:0005973 This is an AE which may be present at birth or acquired at any time afterwards. QY, JX, HY http://en.volupedia.org/wiki/Hearing_loss 听力受损 10019245 hearing impaired AE OAE:0005974 This is an AE which is an abnormal opening in the inner ear. QY, JX, HY http://en.volupedia.org/wiki/Labyrinthine_fistula 迷宫状瘘 10023563 labyrinthine fistula AE OAE:0005975 This is an AE which is a type of hearing disorder that is the perception of a single auditory stimulus as sounds of a different pitch in the two ears. QY, JX, HY http://en.volupedia.org/wiki/Diplacusis 复听 10013032 diplacusis AE OAE:0005976 This is an AE which is the obstruction of the nasolacrimal duct and may be acquired. QY, JX, HY http://en.volupedia.org/wiki/Nasolacrimal_duct_obstruction 泪管狭窄 10053990 dacryostenosis acquired AE OAE:0005977 This is an AE which are due to either an acidic or alkali substance getting in the eye. QY, JX, HY http://en.volupedia.org/wiki/Chemical_eye_injury 眼部化学灼伤 10008422 chemical burns of eye AE OAE:0005978 This is an AE which can be visually devastating caused by herpes zoster. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26084658/ 带状疱疹坏死性视网膜病变 10074253 herpes zoster necrotising retinopathy AE OAE:0005979 This is an AE which forms the outer blood⁻retina barrier and facilitates the transepithelial transport of glucose into the outer retina via GLUT1. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30754662/ 视网膜色素沉着 10038894 retinal pigmentation AE OAE:0005980 This is an AE which in contact lens wearers appears to be more common in patients wearing extended wear soft contact lenses. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/8719670/ 角膜浸润 10011022 corneal infiltrates AE OAE:0005981 This is an AE which is a benign inflammatory condition usually confined to the orbit. This may involve single or multiple intraorbital structures. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21546008/ 眼眶假瘤 10069692 orbital pseudotumor AE OAE:0005982 This is an AE which is a bodily function; it is a semi-autonomic rapid closing of the eyelid. QY, JX, HY http://en.volupedia.org/wiki/Blinking 过度眨眼 10065166 excessive eye blinking AE OAE:0005983 This is an AE which is a change of the human eyelid skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 眼睑皮疹 10074620 eyelid rash AE OAE:0005984 This is an AE which is a common side effect of various medical conditions which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 触觉减退的眼睛 10020939 hypoesthesia eye AE OAE:0005985 This is an AE which is a disorder of sight in which the brain fails to process inputs from one eye and over time favors the other eye. QY, JX, HY http://en.volupedia.org/wiki/Amblyopia 弱视，斜视 10001912 amblyopia strabismic AE OAE:0005986 This is an AE which is a tissue that lines the inside of the eyelids and covers the sclera (the white of the eye) and its become discouration process. QY, JX, HY http://en.volupedia.org/wiki/Conjunctiva 结膜变色 10010712 conjunctival discoloration AE OAE:0005987 This is an AE which is a type of rentinal detachment disease caused by macular. QY, JX, HY http://en.volupedia.org/wiki/Eye_disease#H35_Other_retinal_disorders 黄斑视网膜色素上皮脱落 10071004 detachment of macular retinal pigment epithelium AE OAE:0005988 This is an AE which is a viral syndrome characterized by a panuveitis with necrotizing retinitis that may be complicated by retinal detachment, vaso-occlusion, optic neuropathy, and other causes of decreased visual acuity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26035758/ 坏死性视网膜炎 10064997 necrotising retinitis AE OAE:0005989 This is an AE which is an autoimmune inflammatory disorder of the orbit and periorbital tissues, characterized by upper eyelid retraction, lid lag, swelling, redness (erythema), conjunctivitis, and bulging eyes (exophthalmos). QY, JX, HY http://en.volupedia.org/wiki/Graves%27_ophthalmopathy 内分泌眼病 10060742 endocrine ophthalmopathy AE OAE:0005990 This is an AE which is an uncommon neurological condition in which the affected individuals see white or black dots or transparent dots in part or the whole of their visual fields. QY, JX, HY http://en.volupedia.org/wiki/Visual_snow 视觉雪症候群 10079450 visual snow syndrome AE OAE:0005991 This is an AE which is organs of the visual system and its functions get disorder. QY, JX, HY http://en.volupedia.org/wiki/Eye 眼睛疾病 10015916 eye disorder AE OAE:0005992 This is an AE which is the ability to interpret the surrounding environment through color vision, scotopic vision, and mesopic vision, using light in the visible spectrum reflected by the objects in the environment and its gets alter. QY, JX, HY http://en.volupedia.org/wiki/Visual_perception 视深度知觉改变 10053549 altered visual depth perception AE OAE:0005993 This is an AE which is the dilation of the pupil, usually having a non-physiological cause, or sometimes a physiological pupillary response. QY, JX, HY http://en.volupedia.org/wiki/Mydriasis 瞳孔固定 10037515 pupil fixed AE OAE:0005994 This is an AE which is the invasion of an eye tissues by toxoplasmal, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 眼部感染弓形虫 10015939 eye infection toxoplasmal AE OAE:0005995 This is an AE which is a clinical syndrome characterized by attacks of acute optic neuritis and transverse myelitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33093467/ 视神经脊髓炎 10029322 neuromyelitis optica AE OAE:0005996 This is an Ae which is an etiologically heterogeneous syndrome predominantly characterized by acute inflammation of the optic nerve (optic neuritis, ON) and the spinal cord (myelitis). QY, JX, HY http://en.volupedia.org/wiki/Neuromyelitis_optica_spectrum_disorder 视神经脊髓炎谱系障碍 10077875 neuromyelitis optica spectrum disorder AE OAE:0005997 This is an AE which is the point of exit for ganglion cell axons leaving the eye and its function gets disorder. QY, JX, HY http://en.volupedia.org/wiki/Optic_disc 视神经盘障碍 10061321 optic disc disorder AE OAE:0005998 This is an AE which is globules of mucoproteins and mucopolysaccharides that progressively calcify in the optic disc and they are thought to be the remnants of the axonal transport system of degenerated retinal ganglion cells. QY, JX, HY http://en.volupedia.org/wiki/Optic_disc_drusen 视盘玻璃膜疣 10030617 optic disc drusen AE OAE:0005999 This is an AE which is strongly associated with the development and progression of glaucoma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31023711/ 视神经盘出血 10030919 optic disc hemorrhage AE OAE:0006000 This is an AE which is the increase of blood flow to different tissues in the optic disc. QY, JX, HY http://en.volupedia.org/wiki/Hyperaemia 视神经盘充血 10071196 optic disc hyperemia AE OAE:0006001 This is an AE which blurring of an image due to incorrect focus occurs on optic discs. QY, JX, HY http://en.volupedia.org/wiki/Blurred 视神经盘模糊 10030923 optic discs blurred AE OAE:0006002 This is an AE which refers a form of glioma which affects the optic nerve, is often one of the central nervous system manifestations of neurofibromatosis . QY, JX, HY http://en.volupedia.org/wiki/Optic_nerve_glioma 视神经胶质瘤 10030935 optic nerve glioma AE OAE:0006003 This is an AE which is a medical condition arising from the underdevelopment of the optic nerve(s). QY, JX, HY http://en.volupedia.org/wiki/Optic_nerve_hypoplasia 视神经发育不全 10062942 optic nerve hypoplasia AE OAE:0006004 This is an AE which is optic nerve death (necrosis) due to inadequate blood supply to the affected area. QY, JX, HY http://en.volupedia.org/wiki/Infarction 视神经梗塞 10030936 optic nerve infarction AE OAE:0006005 This is an AE which maybe causes permanent and potentially severe loss of vision, as well as an abnormal pupillary reflex. QY, JX, HY http://en.volupedia.org/wiki/Optic_nerve 视神经损伤 10030938 optic nerve injury AE OAE:0006006 This is an AE which is blood escaping from the circulatory system from damaged blood optic nerve sheath vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 视神经鞘出血 10030941 optic nerve sheath hemorrhage AE OAE:0006007 This is an AE which is an inflammation of a papilla. QY, JX, HY http://en.volupedia.org/wiki/Papillitis 视神经乳头炎 10033708 papillitis AE OAE:0006008 This is an AE which is a rare congenital malformation syndrome that features a combination of the underdevelopment of the optic nerve, pituitary gland dysfunction, and absence of the septum pellucidum (a midline part of the brain). QY, JX, HY http://en.volupedia.org/wiki/Septo-optic_dysplasia 视神经发育不良 10067159 septo-optic dysplasia AE OAE:0006009 This is an AE which is the total or partial loss of vision in a normal-appearing eye caused by damage to the brain's occipital cortex and can be acquired or congenital, and may also be transient in certain instances. QY, JX, HY http://en.volupedia.org/wiki/Cortical_blindness 皮质性盲 10005177 blindness cortical AE OAE:0006010 This is an AE which is an acute episode of ischemic origin in which one eye has profound visual loss, followed by full recovery within one hour. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29776764/ 一过性单眼盲 10005184 blindness transient AE OAE:0006011 This is an AE which is a decreased ability to see to a degree that causes problems not fixable by usual means occurd on unilateral eye. QY, JX, HY http://en.volupedia.org/wiki/Visual_impairment 单侧失明 10005186 blindness unilateral AE OAE:0006012 This is an AE which is the decreased ability to see color or differences in color. QY, JX, HY http://en.volupedia.org/wiki/Color_blindness 色盲 10010050 color blindness AE OAE:0006013 This is an AE which causes by diseases, drugs , and chemicals or organic solventsmay cause color blindness. QY, JX, HY http://en.volupedia.org/wiki/Color_blindness 获得性色盲 10010051 color blindness acquired AE OAE:0006014 This is an AE which is a loss of vision or blindness (anopsia) in half the visual field, usually on one side of the vertical midline. QY, JX, HY http://en.volupedia.org/wiki/Hemianopsia 偏盲 10019452 hemianopia AE OAE:0006015 This is an AE which is the loss of half of the visual field on different sides in both eyes. QY, JX, HY http://en.volupedia.org/wiki/Hemianopsia 异侧偏盲 10019455 hemianopia heteronymous AE OAE:0006016 This is an AE which is hemianopic visual field loss on the same side of both eyes. QY, JX, HY http://en.volupedia.org/wiki/Homonymous_hemianopsia 同侧偏盲 10019456 hemianopia homonymous AE OAE:0006017 This is an AE which refers to an anopia affecting a quarter of the field of vision and associated with a lesion of an optic radiation. QY, JX, HY http://en.volupedia.org/wiki/Quadrantanopia 象限盲 10077820 quadrantanopia AE OAE:0006018 This is an AE which is an impairment in recognition of visually presented objects and it is not due to a deficit in vision (acuity, visual field, and scanning), language, memory, or intellect. QY, JX, HY http://en.volupedia.org/wiki/Visual_agnosia 视觉失认症 10077168 visual agnosia AE OAE:0006019 This is an AE which is a decreased ability to see to a degree that causes problems not fixable by usual means, such as glasses. QY, JX, HY http://en.volupedia.org/wiki/Visual_impairment 视力障碍 10047471 visual impairment AE OAE:0006020 This is an AE which is a form of visual impairment that is caused by a brain problem rather than an eye problem. QY, JX, HY http://en.volupedia.org/wiki/Cortical_visual_impairment 大脑皮层视觉缺陷 10076660 cortical visual impairment AE OAE:0006021 This is an AE which is hallucinations accompanied by delusions. QY, JX, HY http://en.volupedia.org/wiki/Visual_hallucinations_in_psychosis 视觉幻觉 10019075 hallucination, visual AE OAE:0006022 This is an AE which deficiencies in earliest stages of Parkinson disease (PD), plausibly associated with alpha-synuclein deposits in the inner retinal layers. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31992401/ 视觉对比度敏感度的丧失 10064133 loss of visual contrast sensitivity AE OAE:0006023 This is an AE which is a sudden loss of the ability to see. QY, JX, HY http://en.volupedia.org/wiki/Acute_visual_loss 突然失明 10042441 sudden visual loss AE OAE:0006024 This is an AE which refers to a group of diseases and conditions occurring in childhood or early adolescence of below 16 years old, which, if left untreated, result in blindness or severe visual impairment that are likely to be permanent blindness later in life. QY, JX, HY http://en.volupedia.org/wiki/Congenital_Blindness_Gene_Therapy 先天性失明 10005176 blindness congenital AE OAE:0006025 This is an AE which is a type of glaucoma. QY, JX, HY http://en.volupedia.org/wiki/List_of_ICD-9_codes_320%E2%80%93389:_diseases_of_the_nervous_system_and_sense_organs 边缘型青光眼 10006027 borderline glaucoma AE OAE:0006026 This is an AE which is due to either an acidic or alkali substance getting in the eye. QY, JX, HY http://en.volupedia.org/wiki/Chemical_eye_injury 化学性眼睛受伤 10055116 chemical eye injury AE OAE:0006027 This is an AE which may be affected by congenital malformation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/12713104/ 先天性眼部疾病 10059159 congenital eye disorder AE OAE:0006028 This is an AE which is a condition of involuntary (or voluntary, in some cases) eye movement and it is congenital. QY, JX, HY http://en.volupedia.org/wiki/Nystagmus 先天性眼球震颤 10010562 congenital nystagmus AE OAE:0006029 This is an AE which refers the relative darkening of lower eyelid skin and can impart a fatigued and less youthful appearance to the face. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25440739/ 黑眼圈 10064729 dark circles under eyes AE OAE:0006030 This is an AE which is a group of eye diseases which result in damage to the optic nerve (or retina) and cause vision loss. QY, JX, HY http://en.volupedia.org/wiki/Glaucoma#Developmental_glaucoma 发育性青光眼 10012565 developmental glaucoma AE OAE:0006031 This is an AE which is one of the main organs affected by this disease, being diabetic retinopathy the most well-known microvascular complication and the leading. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25817504/ 糖尿病眼病 10012661 diabetic eye disease AE OAE:0006032 This is an AE which is inflammation of the skin, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 湿疹眼睑 10014194 eczema eyelids AE OAE:0006033 This is an AE which is inflammation of the interior cavity of the eye, usually caused by infection. QY, JX, HY http://en.volupedia.org/wiki/Endophthalmitis 眼内炎 10014801 endophthalmitis AE OAE:0006034 This is an AE which is the posterior displacement of the eyeball within the orbit due to changes in the volume of the orbit (bone) relative to its contents (the eyeball and orbital fat), or loss of function of the orbitalis muscle. QY, JX, HY http://en.volupedia.org/wiki/Enophthalmos 眼球内陷 10014853 enophthalmos AE OAE:0006035 This is an AE which is the seven extrinsic muscles of the human eye and its function gets disorder. QY, JX, HY http://en.volupedia.org/wiki/Extraocular_muscles 眼外肌疾病 10053635 extraocular muscle disorder AE OAE:0006036 This is an AE which refers to weakness (-paresis) or paralysis (-plegia) of one or more extraocular muscles which are responsible for eye movements. QY, JX, HY http://en.volupedia.org/wiki/Ophthalmoparesis 眼外肌轻度瘫痪 10015829 extraocular muscle paresis AE OAE:0006037 This is an AE which is a collection of pus that has built up within the tissue of the eye. QY, JX, HY http://en.volupedia.org/wiki/Abscess 眼睛脓肿 10015905 eye abscess AE OAE:0006038 This is an AE which is a number of conditions caused by hypersensitivity of the immune system of the eyes to typically harmless substances in the environment. QY, JX, HY http://en.volupedia.org/wiki/Allergy 眼睛过敏 10015907 eye allergy AE OAE:0006039 This is an AE which during early childhood, puberty, pregnancy, and sometimes after serious trauma (like heterochromia) do represent cause for a plausible argument stating that some eyes can or do change, based on chemical reactions and hormonal changes within the body. QY, JX, HY http://en.volupedia.org/wiki/Eye_color 眼睛颜色变化 10072289 eye color change AE OAE:0006040 This is an AE which is a type of hematoma of eye. QY, JX, HY http://en.volupedia.org/wiki/Bruise 眼部挫伤 10073354 eye contusion AE OAE:0006041 This is an AE which is a eye localized bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 眼睛血肿 10079891 eye hematoma AE OAE:0006042 This is an AE which can cause a nonexudative but persistent conjunctivitis without much redness. QY, JX, HY http://en.volupedia.org/wiki/Conjunctivitis#Bacterial 眼部细菌感染 10015930 eye infection bacterial AE OAE:0006043 This is an AE which may cause responsible for nonacute bacterial conjunctivitis. QY, JX, HY http://en.volupedia.org/wiki/Conjunctivitis#Bacterial 眼部葡萄球菌感染 10015937 eye infection staphylococcal AE OAE:0006044 This is an AE which occurs when an organism's eye is invaded by pathogenic viruses,[not verified in body] and infectious virus particles (virions) attach to and enter susceptible cells. QY, JX, HY http://en.volupedia.org/wiki/Viral_disease 眼部病毒感染 10015940 eye infection viral AE OAE:0006045 This is an AE which refers to physical or chemical injuries of the eye can be a serious threat to vision if not treated appropriately and in a timely fashion. QY, JX, HY http://en.volupedia.org/wiki/Eye_injury 眼睛受伤 10061128 eye injury AE OAE:0006046 This is an AE which is a bulging of the eye anteriorly out of the orbit. Exophthalmos can be either bilateral (as is often seen in Graves' disease) or unilateral (as is often seen in an orbital tumor). QY, JX, HY http://en.volupedia.org/wiki/Exophthalmos 眼球脱臼 10015948 eye luxation AE OAE:0006047 This is an AE which includes the voluntary or involuntary movement of the eyes, helping in acquiring, fixating and tracking visual stimuli. A special type of eye movement, rapid eye movement, occurs during REM sleep. QY, JX, HY http://en.volupedia.org/wiki/Eye_movement#Disorders 眼球运动障碍 10061129 eye movement disorder AE OAE:0006048 This is an AE which is a nonspecific medical term for a visible, circumscribed, chronic lesion of the eye skin or mucosa. QY, JX, HY http://en.volupedia.org/wiki/Nevus 眼睛痣 10051045 eye naevus AE OAE:0006049 This is an AE which means loss of normal transparency of cornea. QY, JX, HY http://en.volupedia.org/wiki/Corneal_opacity 眼睛混浊 10078394 eye opacity AE OAE:0006050 This is an AE which is an abnormal sensation of the eye skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 眼睛感觉异常 10076569 eye paraesthesia AE OAE:0006051 This is an AE which injury that occurs when an object pierces the skin and enters a tissue of the eye. QY, JX, HY http://en.volupedia.org/wiki/Penetration 穿透眼睛 10015960 eye penetration AE OAE:0006052 This is an AE which is a gesture in which a person briefly turns their eyes upward, often in an arcing motion from one side to the other. In the Anglosphere, it has been identified as a passive-aggressive response to an undesirable situation or person, or exasperation. QY, JX, HY http://en.volupedia.org/wiki/Eye-rolling 翻白眼 10015964 eye rolling AE OAE:0006053 This is an AE which is the observed or detectable signs, and experienced symptoms of an eye illness, injury, or condition. QY, JX, HY http://en.volupedia.org/wiki/Signs_and_symptoms 眼部疾病 10075536 eye symptom AE OAE:0006054 This is an AE which is a discontinuity or break in a bodily membrane that impedes normal function of the affected eye. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 眼溃疡 10073423 eye ulcer AE OAE:0006055 This is an AE which is an injury in which a eyeball structure is torn off by either trauma or surgery. QY, JX, HY http://en.volupedia.org/wiki/Avulsion_injury 眼球撕脱 10015971 eyeball avulsion AE OAE:0006056 This is an AE which is blood escaping from the circulatory system from damaged eyelid blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 眼睑出血 10053196 eyelid bleeding AE OAE:0006057 This is an AE which is a type of hematoma of eyelid tissue,the most common cause being capillaries damaged by trauma, causing localized bleeding that extravasates into the surrounding interstitial tissues. QY, JX, HY http://en.volupedia.org/wiki/Bruise 眼睑挫伤 10075018 eyelid contusion AE OAE:0006058 This is an AE which an eye disease. QY, JX, HY http://en.volupedia.org/wiki/Exfoliation 眼睑剥落 10064580 eyelid exfoliation AE OAE:0006059 This is an AE which is a localized bleeding outside of eyelid blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 眼睑血肿 10064976 eyelid hematoma AE OAE:0006060 This is an AE which is a thin fold of skin that covers and protects an eye and the skin is susceptible to infection. QY, JX, HY http://en.volupedia.org/wiki/Eyelid 眼睑感染 10015988 eyelid infection AE OAE:0006061 This is an AE which is a thin fold of skin that covers and protects an eye and its is injury. QY, JX, HY http://en.volupedia.org/wiki/Eyelid 眼睑受伤 10069200 eyelid injury AE OAE:0006062 This is an AE which is a state of inflammation or painful reaction to allergy or eyelid cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 眼睑刺激 10057385 eyelid irritation AE OAE:0006063 This is an AE which is a brief, involuntary, irregular (lacking rhythm) twitching (different from clonus, which is rhythmic/ regular) of a muscle or a group of muscles and its occurs on eyelid. QY, JX, HY http://en.volupedia.org/wiki/Myoclonus 眼睑肌阵挛 10076060 eyelid myoclonus AE OAE:0006064 This is an AE which is a distressing feeling often caused by intense or damaging stimuli and its occurs on eyelid. QY, JX, HY http://en.volupedia.org/wiki/Pain 眼睑疼痛 10059208 eyelid pain AE OAE:0006065 This is an AE which presents within the first year of life either in isolation or as a part of many different ocular or systemic disorders. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24657037/ 先天性眼睑下垂 10015996 eyelid ptosis congenital AE OAE:0006066 This is an AE which is usually secondary to thyroid disorders, trauma, proptosis, seventh nerve palsy, or neurological abnormalities affecting the third nerve. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2393644/ 眼睑收缩 10015997 eyelid retraction AE OAE:0006067 This is an AE which is a sensation that causes the desire or reflex to scratch on the eyelids. QY, JX, HY http://en.volupedia.org/wiki/Itch 眼睑瘙痒 10051627 eyelids pruritus AE OAE:0006068 This is an AE which is a cosmetic problem that results in an older and unnatural appearance. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29632789/ 眼睛凹陷 10016013 eyes sunken AE OAE:0006070 This is an AE which is a group of eye diseases which result in damage to the optic nerve (or retina) and cause vision loss with traumatic. QY, JX, HY http://en.volupedia.org/wiki/Glaucoma 创伤性青光眼 10018330 glaucoma traumatic AE OAE:0006071 This is an AE which is the coordinated control of eye movement with hand movement and the processing of visual input to guide reaching and grasping along with the use of proprioception of the hands to guide the eyes. QY, JX, HY http://en.volupedia.org/wiki/Eye%E2%80%93hand_coordination 手眼协调能力受损 10072649 hand-eye coordination impaired AE OAE:0006072 This is an AE which is a form of ophthalmic caused by recurrent herpes simplex virus (HSV) infection in the cornea. QY, JX, HY http://en.volupedia.org/wiki/Herpes_simplex_keratitis 眼部单纯疱疹 10019958 herpes simplex ophthalmic AE OAE:0006073 This is an AE which occurs due to reactivation of the varicella zoster virus in the ophthalmic branch of the fifth cranial nerve. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27644149/ 眼部带状疱疹 10019983 herpes zoster ophthalmic AE OAE:0006074 This is an AE which is an eye condition in which the directions that the eyes are pointing at rest position, when not performing binocular fusion, are not the same as each other, or, "not straight". QY, JX, HY http://en.volupedia.org/wiki/Heterophoria 隐斜视 10020015 heterophoria AE OAE:0006075 This is an AE which is a medical condition involving inflammatory cells in the anterior chamber of the eye. QY, JX, HY http://en.volupedia.org/wiki/Hypopyon 眼前房积脓 10021086 hypopyon AE OAE:0006076 This is an AE which is an infrequent, yet potentially vision-threatening, entity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31029581/ 眼压减低 10021124 hypotony of eye AE OAE:0006077 This is an AE which is the inability to close the eyelids completely. QY, JX, HY http://en.volupedia.org/wiki/Lagophthalmos 兔眼症 10023683 lagophthalmos AE OAE:0006078 This is an AE which is blood escaping from the circulatory system from damaged lacrimal blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 泪腺出血 10069930 lacrimal hemorrhage AE OAE:0006079 This is an AE which is a developmental disorder of the eye in which one (unilateral microphthalmia) or both (bilateral microphthalmia) eyes are abnormally small and have anatomic malformations. QY, JX, HY http://en.volupedia.org/wiki/Microphthalmia 小眼 10027548 microphthalmos AE OAE:0006080 This is an AE which is a condition of involuntary (or voluntary, in some cases) eye movement. QY, JX, HY http://en.volupedia.org/wiki/Nystagmus 眼球震颤 10029864 nystagmus AE OAE:0006081 This is an AE which may be objectively quantifiable, independent of subjective expressions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30267090/ 眼部不适 10052143 ocular discomfort AE OAE:0006082 This is an AE which is a form of dysmetria that involves the constant under- or over-shooting of the eyes when attempting to focus gaze on something. QY, JX, HY http://en.volupedia.org/wiki/Ocular_dysmetria 眼部屈光不正 10063534 ocular dysmetria AE OAE:0006083 This is an AE which is the presence of elevated fluid pressure inside the eye (intraocular pressure), usually with no optic nerve damage or visual field loss. QY, JX, HY http://en.volupedia.org/wiki/Ocular_hypertension 眼高血压 10030043 ocular hypertension AE OAE:0006084 This is an AE which is a disorder of ocular function that occurs subsequent to the stenosis of the carotid artery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32809550/ 眼部缺血性综合症 10069385 ocular ischemic syndrome AE OAE:0006085 This is an AE which is a form of myasthenia gravis in which weakness is restricted to the ocular muscles and may produce significant visual disability. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29655447/ 眼部肌无力 10049168 ocular myasthenia AE OAE:0006086 This is an AE which can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). QY, JX, HY http://en.volupedia.org/wiki/Eye_neoplasm 眼部肿瘤 10052448 ocular neoplasm AE OAE:0006087 This is an AE which is a potentially blinding consequence of craniofacial trauma, but timely ophthalmic evaluation is difficult to obtain in some settings and clear standards for canthotomy/cantholysis are lacking. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32546417/ 眼眼球后的出血 10057571 ocular retrobulbar hemorrhage AE OAE:0006088 This is an AE which is a manifestation of rosacea that affects the eyes and eyelids. QY, JX, HY http://en.volupedia.org/wiki/Ocular_rosacea 眼部酒渣鼻 10072139 ocular rosacea AE OAE:0006089 This is an AE which constitute the most common cause of visual disability. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24769221/ 眼部血管疾病 10052896 ocular vascular disorder AE OAE:0006090 This is an AE which is the inflammation of blood vessels that leads to loss of perfusion and ischemia with necrosis and when this occurs in the orbit, the consequences are typically very conspicuous and can be devastating with decreased quality of life and loss of vision. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23888364/ 眼部血管炎 10066926 ocular vasculitis AE OAE:0006091 This is an AE which is a loss of motor function in one or more muscles of oculofacial. QY, JX, HY http://en.volupedia.org/wiki/Paralysis 眼面麻痹 10030069 oculofacial paralysis AE OAE:0006092 This is an AE which is characterized by keratoconjunctivitis sicca and by scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva. QY, JX, HY http://en.volupedia.org/wiki/Oculomucocutaneous_syndrome 眼-粘膜-皮肤综合征 10030081 oculomucocutaneous syndrome AE OAE:0006093 This is an AE which is a usually transient condition characterized by bilateral conjunctivitis, facial edema, and upper respiratory symptoms following influenza immunization. QY, JX, HY http://en.volupedia.org/wiki/Oculo-respiratory_syndrome 眼呼吸综合征 10067317 oculo-respiratory syndrome AE OAE:0006094 This is an AE which is a form of conjunctivitis (inflammation of the outer eye) which affects newborn babies following birth. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_conjunctivitis 新生儿眼炎 10030861 ophthalmia neonatorum AE OAE:0006095 This is an AE which is the formation of a blood clot inside a ophthalmic artery blood vessel, obstructing the flow of blood through the circulatory system. QY, JX, HY http://en.volupedia.org/wiki/Thrombosis 眼动脉血栓形成 10081144 ophthalmic artery thrombosis AE OAE:0006096 This is an AE which is a viral ophthalmic infection caused by the herpes simplex virus . QY, JX, HY http://en.volupedia.org/wiki/Herpes_simplex 眼部单纯疱疹 10073938 ophthalmic herpes simplex AE OAE:0006097 This is an AE which is shingles involving the eye or the surrounding area. QY, JX, HY http://en.volupedia.org/wiki/Herpes_zoster_ophthalmicus 眼部带状疱疹 10030865 ophthalmic herpes zoster AE OAE:0006098 This is an AE which is a rare neurological disorder of unknown cause which appears to be the result of an autoimmune process involving the nervous system. QY, JX, HY http://en.volupedia.org/wiki/Opsoclonus_myoclonus_syndrome 斜视眼阵挛肌阵挛 10053854 opsoclonus myoclonus AE OAE:0006099 This is an AE which is a collection of cranial nerve deficits associated with a mass lesion near the apex of the orbit of the eye. QY, JX, HY http://en.volupedia.org/wiki/Orbital_apex_syndrome 眶尖综合征 10066383 orbital apex syndrome AE OAE:0006100 This is an AE which is the invasion of orbital tissue by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 眼眶感染 10064915 orbital infection AE OAE:0006101 This is an AE which typically occurs in an idiopathic acute form, with painful diplopia due to inflammation in 1 or more extraocular muscles of young adult females, which usually responds to a course of oral corticosteroids. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31261163/ 眼眶肌炎 10031050 orbital myositis AE OAE:0006102 This is an AE which is the build-up of fluid in the orbital tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 眼眶水肿 10031051 orbital edema AE OAE:0006103 This is an AE which is the inflammation of all coats of the animal eye including intraocular structures. QY, JX, HY http://en.volupedia.org/wiki/Panophthalmitis 全眼球炎 10033683 panophthalmitis AE OAE:0006104 This is an AE which is the inability to close the eyelids completely with paralytic feel. QY, JX, HY http://en.volupedia.org/wiki/Lagophthalmos 麻痹性兔眼 10033842 paralytic lagophthalmos AE OAE:0006105 This is an AE which is the appearance of swelling in the tissues around the eyes, called the orbits. QY, JX, HY http://en.volupedia.org/wiki/Periorbital_puffiness 眼睑肿胀 10042690 swelling of eyelid AE OAE:0006106 This is an AE which is a group of eye diseases which result in damage to the optic nerve (or retina[5]) and cause vision loss. QY, JX, HY http://en.volupedia.org/wiki/Glaucoma 闭角型青光眼 10002500 angle closure glaucoma AE OAE:0006107 This is an AE which is an eye condition that manifests through non-specific symptoms such as fatigue, pain in or around the eyes, blurred vision, headache, and occasional double vision. QY, JX, HY http://en.volupedia.org/wiki/Eye_strain 眼疲劳 10003552 asthenopia AE OAE:0006108 This is an AE which is the partial or complete wasting away of a part of eye globe. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 眼球萎缩 10065684 atrophy of globe AE OAE:0006109 This is an AE which is an autoimmune disease that affects the thyroid and it frequently results in and is the most common cause of hyperthyroidism. QY, JX, HY http://en.volupedia.org/wiki/Graves%27_disease 突眼性甲状腺肿 10004161 basedow's disease AE OAE:0006110 This is an AE which is a common finding especially in pediatric strabismus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27388203/ 过度的眼部融合 10053693 excessive ocular convergence AE OAE:0006111 This is an AE which is a bulging of the eye anteriorly out of the orbit. Exophthalmos can be either bilateral (as is often seen in Graves' disease) or unilateral (as is often seen in an orbital tumor). QY, JX, HY http://en.volupedia.org/wiki/Exophthalmos 眼球突出 10015683 exophthalmos AE OAE:0006112 This is an AE which is a condition of the eye where distant objects are seen clearly but near objects appear blurred. QY, JX, HY http://en.volupedia.org/wiki/Far-sightedness 远视 10020675 hypermetropia AE OAE:0006113 This is an AE which is a type of distorted vision in which a grid of straight lines appears wavy and parts of the grid may appear blank. QY, JX, HY http://en.volupedia.org/wiki/Metamorphopsia 视物变形症 10063341 metamorphopsia AE OAE:0006114 This is an AE which is an eye disorder where light focuses in front of, instead of on, the retina. QY, JX, HY http://en.volupedia.org/wiki/Myopia 近视 10028651 myopia AE OAE:0006115 This is an AE which is a group of uncommon posterior segment complications of herpetic viral aetiology caused by members of Herpesviridae. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26084658/ 坏死性疱疹的视网膜病变 10065119 necrotising herpetic retinopathy AE OAE:0006116 This is an AE which is an outward bulging, likened to a bubble or balloon, caused by a localized, abnormal, weak retinal spot on a blood vessel wall. QY, JX, HY http://en.volupedia.org/wiki/Aneurysm 视网膜动脉瘤 10064145 retinal aneurysm AE OAE:0006117 This is an AE which is the lodging of an embolus, a blockage-causing piece of material, inside a retinal artery blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Embolism 视网膜动脉栓塞 10038826 retinal artery embolism AE OAE:0006118 This is an AE which is the constellation of ocular signs and symptoms secondary to severe, chronic arterial hypoperfusion to the eye. QY, JX, HY http://en.volupedia.org/wiki/Ocular_ischemic_syndrome 视网膜动脉阻塞 10038827 retinal artery occlusion AE OAE:0006119 This is an AE which is a sudden involuntary contraction of retinal artery. QY, JX, HY http://en.volupedia.org/wiki/Spasm 视网膜动脉痉挛 10038829 retinal artery spasm AE OAE:0006120 This is an AE which is the formation of a blood clot inside a retinal artery vessel, obstructing the flow of blood through the circulatory system. QY, JX, HY http://en.volupedia.org/wiki/Thrombosis 视网膜动脉血栓形成 10038831 retinal artery thrombosis AE OAE:0006121 This is an AE which may refer to retinopathy that one of several eye diseases or eye disorders in humans. QY, JX, HY http://en.volupedia.org/wiki/Retinal_degeneration 视网膜变性 10038845 retinal degeneration AE OAE:0006122 This is an AE which is the lightening of the skin or loss of pigment on the oculocutaneous. QY, JX, HY http://en.volupedia.org/wiki/Depigmentation 视网膜色素脱失 10038846 retinal depigmentation AE OAE:0006123 This is an AE which is the innermost, light-sensitive layer of tissue of the eye of most vertebrates and some molluscs. QY, JX, HY http://en.volupedia.org/wiki/Retina#Diseases_and_disorders 视网膜病变 10038853 retinal disorder AE OAE:0006124 This is an AE which from the German word for node or geode (singular, "Druse"), are tiny yellow or white accumulations of extracellular material that build up between Bruch's membrane and the retinal pigment epithelium of the eye. QY, JX, HY http://en.volupedia.org/wiki/Drusen 视网膜玻璃疣 10062776 retinal drusen AE OAE:0006125 This is an AE which is the degeneration of rentinal tissue, due to disease or malnutrition, most likely due to heredity. QY, JX, HY http://en.volupedia.org/wiki/Dystrophy 视网膜营养不良 10038857 retinal dystrophy AE OAE:0006126 This is an AE which is a fluid emitted by an rentinal through pores or a wound. QY, JX, HY http://en.volupedia.org/wiki/Exudate 视网膜渗出液 10038862 retinal exudates AE OAE:0006127 This is an AE which an infarction can occur to the central retinal artery which supplies the retina causing sudden visual loss. QY, JX, HY http://en.volupedia.org/wiki/Infarction 视网膜梗塞 10051742 retinal infarction AE OAE:0006128 This is an AE which Physical or chemical injuries of the rentinal can be a serious threat to vision. QY, JX, HY http://en.volupedia.org/wiki/Eye_injury 视网膜损伤 10057430 retinal injury AE OAE:0006129 This is an AE which is a major cause of vision loss and impairment and a common underlying mechanism associated with diseases such as glaucoma, diabetic retinopathy, and central retinal artery occlusion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30654160/ 视网膜缺血 10038871 retinal ischaemia AE OAE:0006130 This is an AE which is a retinal disease often accompanied by migraine headache and typically affects only one eye. QY, JX, HY http://en.volupedia.org/wiki/Retinal_migraine 视网膜性偏头痛 10052784 retinal migraine AE OAE:0006131 This is an AE which occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell (edema). QY, JX, HY http://en.volupedia.org/wiki/Macular_edema 视网膜水肿 10038886 retinal edema AE OAE:0006132 This is an AE which is a pale color of the skin that can be caused by illness, emotional shock or stress, stimulant use, or anemia, and is the result of a reduced amount of oxyhaemoglobin and may also be visible as pallor of the conjunctivae of the eyes on physical examination. QY, JX, HY http://en.volupedia.org/wiki/Pallor 视网膜发白 10038891 retinal pallor AE OAE:0006133 This is an AE which is a relatively novel concept describing a phenotype characterized by attenuation of the choriocapillaris overlying dilated choroidal veins, and associated with progressive retinal pigment epithelium dysfunction and neovascularization. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29995841/ 视网膜色素上皮病 10038893 retinal pigment epitheliopathy AE OAE:0006134 This is an AE which is confined to inner retinal layers . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32779075/ 视网膜增厚 10077890 retinal thickening AE OAE:0006135 This is an AE which is the constellation of ocular signs and symptoms secondary to severe, chronic arterial hypoperfusion to the eye. QY, JX, HY http://en.volupedia.org/wiki/Ocular_ischemic_syndrome 视网膜血管阻塞 10038903 retinal vascular occlusion AE OAE:0006136 This is an AE which is inflammation of the vascular branches of the retinal artery, caused either by primary ocular disease processes, or as a specific presentation of any systemic form of vasculitis such as Behçet's disease, sarcoidosis, multiple sclerosis, or any form of systemic necrotizing vasculitis such as temporal arteritis, polyarteritis nodosa, and granulomatosis with polyangiitis, or due to lupus erythematosus, or rheumatoid arthritis. QY, JX, HY http://en.volupedia.org/wiki/Retinal_vasculitis 视网膜血管炎 10038905 retinal vasculitis AE OAE:0006137 This is an AE which is inflammation of the retina in the eye, which can permanently damage the retina and lead to blindness. QY, JX, HY http://en.volupedia.org/wiki/Retinitis 视网膜炎 10038910 retinitis AE OAE:0006138 This is an AE which is a genetic disorder of the eyes that causes loss of vision and symptoms include trouble seeing at night and decreased peripheral vision (side vision). QY, JX, HY http://en.volupedia.org/wiki/Retinitis_pigmentosa 视网膜色素变性 10038914 retinitis pigmentosa AE OAE:0006139 This is an AE which is a rare disease that implies involvement of Herpesviridae, a family of double-stranded DNA viruses characterised by latency within the host's cells after primary infection. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30859706/ 病毒性视网膜炎 10038915 retinitis viral AE OAE:0006140 This is an AE which is an eye disease characterized by the abnormal splitting of the retina's neurosensory layers, usually in the outer plexiform layer. QY, JX, HY http://en.volupedia.org/wiki/Retinoschisis 视网膜劈裂 10061492 retinoschisis AE OAE:0006141 This is an AE which typically presents with the perception of light flashes, floaters, or a "dark curtain." QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24565273/ 孔源性视网膜脱离 10065569 rhegmatogenous retinal detachment AE OAE:0006142 This is an AE which with hypertensive choroidopathy presented with choroidal thickening that decreased after resolution, but the residual flow defects observed in the choriocapillaris on OCTA confirmed the long-hypothesized notion that ischemia is a mechanism underlying hypertensive choroidopathy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31089238/ 浆液性视网膜脱离 10040114 serous retinal detachment AE OAE:0006143 This is an AE which is a result of a wound healing response that follows choroidal neovascularization in neovascular age-related macular degeneration (nAMD). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25773985/ 视网膜下纤维化 10062958 subretinal fibrosis AE OAE:0006144 This is an AE which observed in association with choroidal neovascularization and to distinguish SHE from other forms of subretinal hyperreflective material (SHM) seen in patients with age-related macular degeneration and other macular disorders. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24695062/ 视网膜下高反射性渗出 10082240 subretinal hyperreflective exudation AE OAE:0006145 This is an AE which an anomalous posterior vitreous detachment (APVD) with persistant symptomatic vitreoretinal adhesion is seen. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23842874/ 玻璃体视网膜牵引综合征 10071181 vitreoretinal traction syndrome AE OAE:0006146 This is an AE which is a rare retinal condition that features the sudden onset of bilateral central scotomata, which may be preceded by a viral prodrome in some patients. QY, JX, HY https://sci-hub.se/10.1001/archophthalmol.2011.22 急性黄斑外视网膜病变 10079367 acute macular outer retinopathy AE OAE:0006147 This is an AE which is an inflammatory retinopathy in the category of white dot syndromes typified by acute loss of one or more zones of outer retinal function associated with photopsia, minimal funduscopic changes and abnormal electroretinography findings. QY, JX, HY http://en.volupedia.org/wiki/Acute_zonal_occult_outer_retinopathy 急性带状隐匿性外视网膜病变 10074444 acute zonal occult outer retinopathy AE OAE:0006148 This is an AE which is a rare disease in which the patient's immune system attacks proteins in the retina, leading to loss of eyesight. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_retinopathy 自身免疫性视网膜病变 10071578 autoimmune retinopathy AE OAE:0006149 This is an AE which can be partially compensated by increased use of peripheral vision. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32965480/ 中心视力丧失 10081186 central vision loss AE OAE:0006150 This is an AE which is the partial or complete wasting away of a part of the chorioretinal body. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 视网膜脉络膜萎缩 10008762 chorioretinal atrophy AE OAE:0006151 This is an AE which is the vascular layer of the eye, containing connective tissues, and lying between the retina and the sclera that is gets disorder. QY, JX, HY http://en.volupedia.org/wiki/Choroid 视网膜脉络膜疾病 10061763 chorioretinal disorder AE OAE:0006152 This is an AE which is an area of fibrous tissue that replaces normal chorioretinal skin after an injury. QY, JX, HY http://en.volupedia.org/wiki/Scar 视网膜脉络膜疤痕 10008766 chorioretinal scar AE OAE:0006153 This is an AE which is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. QY, JX, HY http://en.volupedia.org/wiki/Chorioretinitis 绒毛膜视网膜炎 10008769 chorioretinitis AE OAE:0006154 This is an AE which is a posterior segment disease characterized by localized and limited serous detachments of the neurosensory retina often associated with focal detachments of an altered retinal pigment epithelium. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26026923/ 视网膜脉络膜视网膜病 10063118 chorioretinopathy AE OAE:0006155 This is an AE which is an impairment of the sense of vision. QY, JX, HY http://en.volupedia.org/wiki/Vision_disorder 色视症 10008795 chromatopsia AE OAE:0006156 This is an AE which refers to a risk for myopia may be inherited from one's parents. QY, JX, HY http://en.volupedia.org/wiki/Myopia#Genetics 先天性近视 10069153 congenital myopia AE OAE:0006157 This is an AE which is a medical term for seeing everything tinted with blue. QY, JX, HY http://en.volupedia.org/wiki/Cyanopsia 蓝视症 10051819 cyanopsia AE OAE:0006158 This is an AE which is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye caused by cytomegalovirus . QY, JX, HY http://en.volupedia.org/wiki/Chorioretinitis 巨细胞病毒脉络膜视网膜炎 10048843 cytomegalovirus chorioretinitis AE OAE:0006159 This is an AE which is a medical condition in which damage occurs to the retina due to diabetes mellitus. QY, JX, HY http://en.volupedia.org/wiki/Diabetic_retinopathy 糖尿病性视网膜病变 10012689 diabetic retinopathy AE OAE:0006160 This is an AE which is the simultaneous perception of two images of a single object that may be displaced horizontally or vertically in relation to each other. QY, JX, HY http://en.volupedia.org/wiki/Diplopia 复视 10013036 diplopia AE OAE:0006161 This is an AE which is a lack of coordination of movement typified by the undershoot or overshoot of intended position with the hand, arm, leg, or eye. It is a type of ataxia. QY, JX, HY http://en.volupedia.org/wiki/Dysmetria 辨距不良 10013936 dysmetria AE OAE:0006162 This is an AE which is a neuropsychological condition that causes a distortion of perception. QY, JX, HY http://en.volupedia.org/wiki/Alice_in_Wonderland_syndrome 视物大小不对称症 10067557 dysmetropsia AE OAE:0006163 This is an AE which is less common but nonetheless a possible reason as to why a patient may fail the 4 PRT. QY, JX, HY http://en.volupedia.org/wiki/Four_prism_dioptre_reflex_test#Abnormal_response:_eccentric_fixation 假黄斑注视 10070917 eccentric fixation AE OAE:0006164 This is an AE which may be a manifestation of a variety of isolated ocular or systemic diseases in children. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30170046/ 渗出性视网膜病变 10015901 exudative retinopathy AE OAE:0006165 This is an AE which is a visual disturbance in which objects appear with a red hue, is a recognized phenomenon after surgical excision of the natural lens. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17321412/ 红视症 10015290 erythropsia AE OAE:0006166 This is an AE which is sometimes visible deposits within the eye's vitreous humour ("the vitreous"), which is normally transparent, or between the vitreous and retina. QY, JX, HY http://en.volupedia.org/wiki/Floater 飞蝇症 10028623 myodesopsia AE OAE:0006167 This is an AE which is a visual disturbance in which objects in the visual field appear to oscillate. QY, JX, HY http://en.volupedia.org/wiki/Oscillopsia 振动幻视 10052087 oscillopsia AE OAE:0006168 This is an AE which is the phenomenon of seeing light without light entering the eye. QY, JX, HY http://en.volupedia.org/wiki/Phosphene 光幻视 10034936 phosphenes AE OAE:0006169 This is an AE which is a scratch to the surface of the cornea of the eye. QY, JX, HY http://en.volupedia.org/wiki/Corneal_abrasion 角膜擦伤 10010984 corneal abrasion AE OAE:0006170 This is an AE which is a collection of pus that has built up within the tissue of the corneal. QY, JX, HY http://en.volupedia.org/wiki/Abscess 角膜脓肿 10010985 corneal abscess AE OAE:0006171 This is an AE which is severe enough to require corneal transplantation is a rare complication of uveitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31906778/ 角膜失代偿 10052117 corneal decompensation AE OAE:0006172 This is an AE which is deterioration in the medical sense on the corneal. QY, JX, HY http://en.volupedia.org/wiki/Degeneration_(medicine) 角膜退化 10010996 corneal degeneration AE OAE:0006173 This is an AE which is the transparent front part of the eye that covers the iris, pupil, and anterior chamber. QY, JX, HY http://en.volupedia.org/wiki/Cornea 角膜沉积物 10011000 corneal deposits AE OAE:0006174 This is an AE which refers to anything that interferes with the cornea's stromal architecture, contributes to blood vessel migration, increases corneal pigmentation, or predisposes to corneal edema, disrupts the corneas transparency. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15948422/ 角膜疾病 10061453 corneal disorder AE OAE:0006175 This is an AE which is a group of rare hereditary disorders characterised by bilateral abnormal deposition of substances in the transparent front part of the eye called the cornea. QY, JX, HY http://en.volupedia.org/wiki/Corneal_dystrophy 角膜营养不良 10011005 corneal dystrophy AE OAE:0006176 This is an AE which is a single layer of endothelial cells on the inner surface of the cornea. QY, JX, HY http://en.volupedia.org/wiki/Corneal_endothelium 角膜内皮炎 10062621 corneal endotheliitis AE OAE:0006177 This is an AE which is made up of epithelial tissue and covers the front of the cornea and acts as a barrier to protect the cornea, resisting the free flow of fluids from the tears, and prevents bacteria from entering the epithelium and corneal stroma. QY, JX, HY http://en.volupedia.org/wiki/Corneal_epithelium 角膜上皮缺损 10011010 corneal epithelium defect AE OAE:0006178 This is an AE which is a disorder of the eyes characterized by the failure of the cornea's outermost layer of epithelial cells to attach to the underlying basement membrane (Bowman's layer). QY, JX, HY http://en.volupedia.org/wiki/Recurrent_corneal_erosion 角膜糜烂 10011013 corneal erosion AE OAE:0006179 This is an AE which is an age-related disease in which abnormal fibrillar extracellular material is produced and accumulates in many ocular tissues. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11166342/ 角膜脱落 10064489 corneal exfoliation AE OAE:0006180 This is an AE which comprises a sequence of complex immune responses that involves the recognition of the foreign histocompatibility antigens of the corneal graft by the host's immune system, leading to the initiation of the immune response cascade. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17574064/ 角膜移植排斥反应 10011017 corneal graft rejection AE OAE:0006181 This is an AE which is any damage or abnormal change in the corneal tissue of an organism, usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 角膜损伤 10011026 corneal lesion AE OAE:0006182 This is an AE which is the in-growth of new blood vessels from the pericorneal plexus into avascular corneal tissue as a result of oxygen deprivation. QY, JX, HY http://en.volupedia.org/wiki/Corneal_neovascularization 角膜新血管化 10055665 corneal neovascularisation AE OAE:0006183 This is an AE which is a common sign of acute or protracted corneal disease of various aetiologies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23679934/ 角膜水肿 10011033 corneal edema AE OAE:0006184 This is an AE which is a transparent membrane which allows light to pass through it. QY, JX, HY http://en.volupedia.org/wiki/Corneal_opacity 角膜透明度 10011035 corneal opacity AE OAE:0006185 This is an AE which accumulate in reaction to inflammatory responses and remain permanently in corneal stroma, and conventionally correctable only by donor corneal transplantation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32979396/ 角膜疤痕 10011044 corneal scar AE OAE:0006186 This is an AE which is the transparent front part of the eye that covers the iris, pupil, and anterior chamber and its is a process of becoming thin. QY, JX, HY http://en.volupedia.org/wiki/Cornea 角膜变薄 10054760 corneal thinning AE OAE:0006187 This is an AE which is a type of anterior uveitis and inflammation of iris and the ciliary body with inflammation predominantly confined to ciliary body. QY, JX, HY http://en.volupedia.org/wiki/Uveitis#Classification 虹膜睫状体炎 10022941 iridocyclitis AE OAE:0006188 This is an AE which is fibrous bands that form between iris tissues and organs,often as a result of injury during surgery. QY, JX, HY http://en.volupedia.org/wiki/Adhesion_(medicine) 虹膜粘连 10022945 iris adhesions AE OAE:0006189 This is an AE which is a hole in one of the structures of the eye, such as the iris. QY, JX, HY http://en.volupedia.org/wiki/Coloboma 虹膜孔 10052642 iris coloboma AE OAE:0006190 This is an AE which is part of the eye and its functiuon gets disorder. QY, JX, HY http://en.volupedia.org/wiki/Iris 虹膜障碍 10061254 iris disorder AE OAE:0006191 This is an AE which is characterized specifically as an area of iris skin becoming lighter than the baseline skin color, but not completely devoid of pigment. QY, JX, HY http://en.volupedia.org/wiki/Hypopigmentation 虹膜色素减退 10063694 iris hypopigmentation AE OAE:0006192 This is an AE which is damage to the iris caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 虹膜损伤 10057413 iris injury AE OAE:0006193 This is an AE which is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. QY, JX, HY http://en.volupedia.org/wiki/Uveitis 虹膜炎 10022955 iritis AE OAE:0006194 This is an AE which is due to the lens cortex (outer layer) becoming opaque and they occur when changes in the fluid contained in the periphery of the lens causes fissuring. QY, JX, HY http://en.volupedia.org/wiki/Cataract 皮质性白内障 10007748 cataract cortical AE OAE:0006195 This is an AE which is the most common type of cataract, and involves the central or 'nuclear' part of the lens. QY, JX, HY http://en.volupedia.org/wiki/Cataract 核性白内障 10007759 cataract nuclear AE OAE:0006196 This is an AE which is cloudy at the back of the lens adjacent to the capsule (or bag) in which the lens sits and because light becomes more focused toward the back of the lens, they can cause disproportionate symptoms for their size. QY, JX, HY http://en.volupedia.org/wiki/Cataract 囊下白内障 10007764 cataract subcapsular AE OAE:0006197 This is an AE which is a tissue that lines the inside of the eyelids and covers the sclera (the white of the eye) and it has deposit. QY, JX, HY http://en.volupedia.org/wiki/Conjunctiva 结膜沉积物 10010708 conjunctival deposit AE OAE:0006198 This is an AE which refers to a small spherical group of cells containing a cavity on the conjunctival. QY, JX, HY http://en.volupedia.org/wiki/Follicle 结膜囊 10010717 conjunctival follicles AE OAE:0006199 This is an AE which is the increase of blood flow to different tissues in the conjunctial tissue. QY, JX, HY http://en.volupedia.org/wiki/Hyperaemia 结膜充血 10051625 conjunctival hyperemia AE OAE:0006200 This is an AE which is a conjunctival state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 结膜刺激 10010725 conjunctival irritation AE OAE:0006201 This is an AE which is the swelling (or edema) of the conjunctiva. QY, JX, HY http://en.volupedia.org/wiki/Chemosis 结膜水肿 10010726 conjunctival edema AE OAE:0006202 This is an AE which is a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood or a lowered ability of the blood to carry oxygen. QY, JX, HY http://en.volupedia.org/wiki/Anemia 结膜苍白 10068819 conjunctival pallor AE OAE:0006203 This is an AE which is an eye finding occurring early in leptospirosis, which is caused by Leptospira interrogans. QY, JX, HY http://en.volupedia.org/wiki/Conjunctival_suffusion 结膜弥漫 10084034 conjunctival suffusion AE OAE:0006204 This is an AE which is an inflammatory or, more seriously, infective condition of the cornea involving disruption of its epithelial layer with involvement of the corneal stroma. QY, JX, HY http://en.volupedia.org/wiki/Corneal_ulcer 结膜溃疡 10010736 conjunctival ulcer AE OAE:0006205 This is an AE which is inflammation of the conjunctiva (the membrane covering the white part of the eye) due to allergy. QY, JX, HY http://en.volupedia.org/wiki/Allergic_conjunctivitis 结膜炎过敏 10010744 conjunctivitis allergic AE OAE:0006206 This is an AE which causes the rapid onset of conjunctival redness, swelling of the eyelid, and a sticky discharge. QY, JX, HY http://en.volupedia.org/wiki/Conjunctivitis#Bacterial_3 细菌性结膜炎 10061784 conjunctivitis bacterial AE OAE:0006207 This is an AE which is often associated with an infection of the upper respiratory tract, a common cold, or a sore throat. QY, JX, HY http://en.volupedia.org/wiki/Conjunctivitis#Viral 病毒性结膜炎 10010755 conjunctivitis viral AE OAE:0006208 This is an AE which is a common eye surface condition characterized by the presence of excess folds of the conjunctiva located between the globe of the eye and the eyelid margin. QY, JX, HY http://en.volupedia.org/wiki/Conjunctivochalasis 结膜松弛 10064132 conjunctivochalasis AE OAE:0006209 This is an AE which is a derivative of the highly contagious conjunctivitis virus, otherwise known as pink eye. QY, JX, HY http://en.volupedia.org/wiki/Acute_hemorrhagic_conjunctivitis 急性出血性结膜炎 10067817 acute haemorrhagic conjunctivitis AE OAE:0006210 This is an AE which is the type of viral conjunctivitis and the most common cause of it. QY, JX, HY http://en.volupedia.org/wiki/Conjunctivitis#Viral 腺病毒性结膜炎 10001257 adenoviral conjunctivitis AE OAE:0006211 This is an AE which is an inflammatory cellular deposit seen on corneal endothelium. QY, JX, HY http://en.volupedia.org/wiki/Keratic_precipitate 角膜炎沉淀性 10053703 keratic precipitates AE OAE:0006212 This is an AE which is a condition with herpetic in which the eye's cornea, the clear dome on the front surface of the eye, becomes inflamed. QY, JX, HY http://en.volupedia.org/wiki/Keratitis 角膜炎疱疹 10023334 keratitis herpetic AE OAE:0006213 This is an AE which is corneal scarring due to chronic inflammation of the corneal stroma. QY, JX, HY http://en.volupedia.org/wiki/Interstitial_keratitis 间质性角膜炎 10023335 keratitis interstitial AE OAE:0006214 This is an AE which is a condition in which the eye's cornea, the clear dome on the front surface of the eye, becomes inflamed caused by viral. QY, JX, HY http://en.volupedia.org/wiki/Keratitis 病毒性角膜炎 10062029 keratitis viral AE OAE:0006215 This is an AE which is a disorder of the eye that results in progressive thinning of the cornea. QY, JX, HY http://en.volupedia.org/wiki/Keratoconus 圆锥形角膜 10023353 keratoconus AE OAE:0006216 This is an AE which is a palmoplantar eruption of air-filled bullae on an erythematous base, which results in lamellar peeling with hallmark superficial collarettes of scale. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26990340/ 角质溶解获得性剥离 10052291 keratolysis exfoliativa acquired AE OAE:0006217 This is an AE which refers a disease of the human eye. QY, JX, HY http://en.volupedia.org/wiki/Keratopathy 角膜病 10023365 keratopathy AE OAE:0006218 This is an AE which refers early manifestation of herpes zoster ophthalmicus . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32309125/ 角膜葡萄膜炎 10078693 keratouveitis AE OAE:0006219 This is an AE which is an inflammation and infection of the eyelid and portions of skin around the eye anterior to the orbital septum. QY, JX, HY http://en.volupedia.org/wiki/Periorbital_cellulitis 眶周蜂窝织炎 10057182 periorbital cellulitis AE OAE:0006220 This is an AE which is a type of hematoma of periorbital tissue, the most common cause being capillaries damaged by trauma, causing localized bleeding that extravasates into the surrounding interstitial tissues. QY, JX, HY http://en.volupedia.org/wiki/Bruise 眶周挫伤 10062515 periorbital contusion AE OAE:0006221 This is an AE which refers specifically to the layer of tissue surrounding the orbit that consists of periosteum feel discomfortable and may refer to anything that is around the orbit. QY, JX, HY http://en.volupedia.org/wiki/Periorbita 眶周疾病 10057425 periorbital disorder AE OAE:0006222 This is an AE which is a localized bleeding outside of periorbital blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 眶周血肿 10034544 periorbital hematoma AE OAE:0006223 This is an AE which is blood escaping from the circulatory system from damaged periorbital blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 眶周出血 10071697 periorbital hemorrhage AE OAE:0006224 This is an AE which is part of the complex biological response of periorbital tissues to harmful stimuli, such as pathogens, damaged cells, or irritants,and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 眶周炎症 10080722 periorbital inflammation AE OAE:0006225 This is an AE which is the build-up of fluid in the periorbital tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 眶周水肿 10034545 periorbital edema AE OAE:0006226 This is an AE which is a periorbital distressing feeling often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 眶周疼痛 10034546 periorbital pain AE OAE:0006227 This is an AE which refers a transient abnormal enlargement of periorbital area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 眶周肿胀 10056647 periorbital swelling AE OAE:0006228 This is an AE which is a condition with herpetic caused by viral in which the eye's cornea, the clear dome on the front surface of the eye, becomes inflamed. QY, JX, HY http://en.volupedia.org/wiki/Keratitis 病毒性角膜炎 10078694 viral keratouveitis AE OAE:0006229 This is an AE which is paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. QY, JX, HY http://en.volupedia.org/wiki/Cycloplegia 睫状肌麻痹 10011719 cycloplegia AE OAE:0006231 This is an AE which is a pathology affecting the cornea. QY, JX, HY http://en.volupedia.org/wiki/Punctate_epithelial_erosions 点状角膜炎 10037508 punctate keratitis AE OAE:0006232 This is an AE which is a rare, benign yet relapsing pustular dermatosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27349653/ 角膜下脓疱性皮肤病 10042342 subcorneal pustular dermatosis AE OAE:0006233 This is an AE which is a condition with varicella in which the eye's cornea, the clear dome on the front surface of the eye, becomes inflamed. QY, JX, HY http://en.volupedia.org/wiki/Keratitis 水痘角膜炎 10077496 varicella keratitis AE OAE:0006234 This is an AE which can be a serious threat to vision if not treated appropriately and in a timely fashion. QY, JX, HY http://en.volupedia.org/wiki/Eye_injury 角膜损伤 10022120 injury corneal AE OAE:0006235 This is an AE which is a condition that results in the loss of eyelashes, and sometimes eyebrows. QY, JX, HY http://en.volupedia.org/wiki/Madarosis 睫毛脱落 10051235 madarosis AE OAE:0006236 This is an AE which is a medical term for abnormally positioned eyelashes that grow back toward the eye, touching the cornea or conjunctiva. QY, JX, HY http://en.volupedia.org/wiki/Trichiasis 倒睫 10044604 trichiasis AE OAE:0006237 This is an AE which is a part of the eye that includes the ciliary muscle, which controls the shape of the lens, and the ciliary epithelium, which produces the aqueous humor and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Ciliary_body 睫状体病症 10057415 ciliary body disorder AE OAE:0006238 This is an AE which is the increase of blood flow to different tissues in the ciliary. QY, JX, HY http://en.volupedia.org/wiki/Hyperaemia 纤毛性高血症 10052129 ciliary hyperemia AE OAE:0006239 This is an AE which is a sudden involuntary contraction of ciliary muscle muscle. QY, JX, HY http://en.volupedia.org/wiki/Spasm 睫状肌痉挛 10009185 ciliary muscle spasm AE OAE:0006240 This is an AE which is one of the hairs that grows at the edge of the eyelids. QY, JX, HY http://en.volupedia.org/wiki/Eyelash 睫毛生长 10048462 growth of eyelashes AE OAE:0006241 This is an AE which is a rare, ciliopathic, autosomal recessive genetic disorder that causes defects in the action of cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear), fallopian tube, and flagellum of sperm cells. QY, JX, HY http://en.volupedia.org/wiki/Primary_ciliary_dyskinesia 不动纤毛综合征 10060882 immotile cilia syndrome AE OAE:0006242 This is an AE which has also been observed in normal aging eyes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18418998/ 玻璃体变性 10047649 vitreous degeneration AE OAE:0006243 This is an AE which is a condition of the eye in which the vitreous membrane separates from the retina. QY, JX, HY http://en.volupedia.org/wiki/Posterior_vitreous_detachment 玻璃体脱离 10047650 vitreous detachment AE OAE:0006244 This is an AE which refers a clear gel that fills the space between the lens and the retina in vertebrate eyes and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Vitreous 玻璃体疾病 10047651 vitreous disorder AE OAE:0006245 This is an AE which is sometimes visible deposits within the eye's vitreous humour ("the vitreous"), which is normally transparent, or between the vitreous and retina. QY, JX, HY http://en.volupedia.org/wiki/Floater 玻璃体漂浮物 10047654 vitreous floaters AE OAE:0006246 This is an AE which refers a layer of collagen separating the vitreous body from the rest of the eye and it is haze. QY, JX, HY http://en.volupedia.org/wiki/Vitreous 玻璃状混浊 10077514 vitreous haze AE OAE:0006247 This is an AE which can be classified according to their aetiology as: genetic; inflammatory non-infectious; inflammatory infectious; inflammatory iatrogenic; degenerative, traumatic; neoplastic and idiopathic. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18344965/ 玻璃体混浊 10047658 vitreous opacities AE OAE:0006248 This is an AE which refers carries tears from the lacrimal sac of the eye into the nasal cavity and it is swelling. QY, JX, HY http://en.volupedia.org/wiki/Nasolacrimal_duct 泪管肿胀 10051209 swollen tear duct AE OAE:0006249 This is an AE which is a common and reliable finding of brain herniation, ischaemia, and acute brain injury in critically ill patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32035804/ 瞳孔畸形 10057426 pupillary deformity AE OAE:0006250 This is an AE which refers the diagnosis of an afferent or efferent it is crucial in the acquisition of a broad range of diseases of the brain or the peripheral nervous system. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30999363/ 瞳孔紊乱 10037521 pupillary disorder AE OAE:0006251 This is an AE which is determined using dynamic pupillometry and is impaired. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33551108/ 瞳孔反射受损 10037532 pupillary reflex impaired AE OAE:0006252 This is an AE which is blood escaping from the circulatory system from damaged scleral blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 巩膜出血 10050508 scleral hemorrhage AE OAE:0006253 This is an AE which is the build-up of fluid in the scleral tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 巩膜水肿 10057431 scleral edema AE OAE:0006254 This is an AE which is a benign, self-limiting inflammatory disease affecting part of the eye called the episclera. QY, JX, HY http://en.volupedia.org/wiki/Episcleritis 巩膜外层炎 10015084 episcleritis AE OAE:0006255 This is an AE which is a serious inflammatory disease that affects the white outer coating of the eye, known as the sclera. QY, JX, HY http://en.volupedia.org/wiki/Scleritis 巩膜炎 10039705 scleritis AE OAE:0006256 This is an AE which consisted of cortical dots of various shapes that increased in number with the age of the carriers in older obligate carriers, subcapsular plaques were common. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3763152/ 晶状体混浊 10024214 lenticular opacities AE OAE:0006257 This is an AE which is a sudden involuntary contraction of a muscle when nictitating. QY, JX, HY http://en.volupedia.org/wiki/Spasm 瞬目痉挛；瞬颤 10078741 nictitating spasm AE OAE:0006258 This is an AE which is a fold or line in the skin below the lower eyelid. QY, JX, HY http://en.volupedia.org/wiki/Dennie%E2%80%93Morgan_fold 眶下皱襞 10062918 dennie-morgan fold AE OAE:0006259 This is an AE which is typical manifestations of systemic diseases (e. g. Graves' disease) or typical complications of diseases in the vicinity of the orbit (e. g. orbital complications from inflammatory or tumorous sinus diseases). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33307575/ 眶病症 10054717 disorder of orbit AE OAE:0006260 This is an AE which is the product of a mismatch between the axial length of the eye and its optical power, creating blurred vision. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31525141/ 屈光不正 10038264 refraction disorder AE OAE:0006261 This is an AE which is vision loss or weakness that occurs without an apparent lesion affecting the eye. QY, JX, HY http://en.volupedia.org/wiki/Amaurosis 黑内障，黑朦 10001902 amaurosis AE OAE:0006262 This is an AE which is the aqueous humor-filled space inside the eye between the iris and the cornea's innermost surface, the endothelium. QY, JX, HY http://en.volupedia.org/wiki/Anterior_chamber_of_eyeball 前房细胞 10053781 anterior chamber cell AE OAE:0006263 This is an AE which is the aqueous humor-filled space inside the eye between the iris and the cornea's innermost surface and it has inflammation. QY, JX, HY http://en.volupedia.org/wiki/Anterior_chamber_of_eyeball 前房炎症 10054765 anterior chamber inflammation AE OAE:0006264 This is an AE which is a rare, late complication of cataract surgery, associated with impairment of visual function. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33425382/ 前囊收缩 10054045 anterior capsule contraction AE OAE:0006265 This is an AE which is a type of refractive error due to rotational asymmetry in the eye's refractive power. QY, JX, HY http://en.volupedia.org/wiki/Astigmatism 散光 10003569 astigmatism AE OAE:0006266 This is an AE which refers difficulty seeing in the presence of very bright light. QY, JX, HY http://en.volupedia.org/wiki/Glare 眩光 10052128 glare AE OAE:0006267 This is an AE which is the most common complication after cataract surgery, with an incidence of 30%. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25455552/ 后发性白内障 10036346 posterior capsule opacification AE OAE:0006268 This is an AE which is a rare benign neuroepithelial intraventricular WHO grade I lesion found in the choroid plexus. QY, JX, HY http://en.volupedia.org/wiki/Choroid_plexus_papilloma 脉络丛乳头状瘤 10008777 choroid plexus papilloma AE OAE:0006269 This is an AE which is a prevalent and potentially vision-threatening complication following glaucoma surgery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25325867/ 脉络膜的积液 10063970 choroidal effusion AE OAE:0006270 This is an AE which is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. QY, JX, HY http://en.volupedia.org/wiki/Chorioretinitis 脉络膜炎 10008792 choroiditis AE OAE:0006271 This is an AE which is a closed macular sac, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 黄斑囊肿 10025407 macular cyst AE OAE:0006272 This is an AE which is formation of the fibrous tissue in place of the normal retinal tissue on the macular area of the retina which provides the sharpest vision in the eyes. QY, JX, HY http://en.volupedia.org/wiki/Macular_scarring 黄斑脱离 10075873 macular detachment AE OAE:0006273 This is an AE which is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue such as macular fibrosis. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis 黄斑纤维化 10071392 macular fibrosis AE OAE:0006274 This is an AE which is a small break in the macula, located in the center of the eye's light-sensitive tissue called the retina. QY, JX, HY http://en.volupedia.org/wiki/Macular_hole 黄斑孔 10051058 macular hole AE OAE:0006275 This is an AE which occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell (edema). QY, JX, HY http://en.volupedia.org/wiki/Macular_edema 黄斑水肿 10025415 macular edema AE OAE:0006276 This is an AE which is a polygenic phenotypic character determined by two distinct factors: the pigmentation of the eye's iris and the frequency-dependence of the scattering of light by the turbid medium in the stroma of the iris. QY, JX, HY http://en.volupedia.org/wiki/Eye_color 黄斑色素沉着 10071041 macular pigmentation AE OAE:0006277 This is an AE which is supposed to be different from that of macular lamellar hole (LMH) and is thought to be caused by centripetal contraction of previously present epiretinal membrane. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20703497/ 黄斑假孔 10060815 macular pseudohole AE OAE:0006278 This is an AE which is any pathological condition of the macula, an area at the centre of the retina that is associated with highly sensitive, accurate vision. QY, JX, HY http://en.volupedia.org/wiki/Maculopathy 黄斑病变 10025425 maculopathy AE OAE:0006279 This is an AE which is the presence of perceived flashes of light in the field of vision. QY, JX, HY http://en.volupedia.org/wiki/Photopsia 闪光幻觉 10034962 photopsia AE OAE:0006280 This is an AE which is a form of uveitis localized to the vitreous and peripheral retina. QY, JX, HY http://en.volupedia.org/wiki/Intermediate_uveitis 中度葡萄膜炎 10022557 intermediate uveitis AE OAE:0006281 QY, JX, HY 视力暂时下降 10047532 visual acuity reduced transiently AE OAE:0006282 QY, JX, HY 视觉通路紊乱 10061411 visual pathway disorder AE OAE:0006283 QY, JX, HY 心因性视觉障碍 10076241 psychogenic visual disorder AE OAE:0006284 QY, JX, HY 设备相关的眼部并发症 10069837 eye complication associated with device AE OAE:0006285 QY, JX, HY 眼睑侵蚀 10060762 eyelid erosion AE OAE:0006286 QY, JX, HY 眼睑感觉障碍 10015999 eyelid sensory disorder AE OAE:0006287 QY, JX, HY 眼睑增厚 10072719 eyelid thickening AE OAE:0006288 QY, JX, HY 眼神呆滞 10072465 glassy eyes AE OAE:0006289 QY, JX, HY 眼部疱疹 10062004 herpes ophthalmic AE OAE:0006290 QY, JX, HY 泪腺紊乱 10061525 lacrimal disorder AE OAE:0006291 QY, JX, HY 眼周炎 10059407 parophthalmia AE OAE:0006292 QY, JX, HY 眼睛表面损伤 10042530 superficial injury of eye AE OAE:0006293 QY, JX, HY 眼睑的乳头状瘤 10057885 blepharal papilloma AE OAE:0006294 QY, JX, HY 视网膜沉积 10038847 retinal deposits AE OAE:0006295 QY, JX, HY 视网膜下液 10069356 subretinal fluid AE OAE:0006296 QY, JX, HY 动脉硬化性视网膜病变 10063452 arteriosclerotic retinopathy AE OAE:0006297 QY, JX, HY 彩视 10019099 halo vision AE OAE:0006298 QY, JX, HY 结膜侵蚀 10010716 conjunctival erosion AE OAE:0006299 QY, JX, HY 结膜瘢痕 10010733 conjunctival scar AE OAE:0006300 QY, JX, HY 眶周的不适 10082879 periorbital discomfort AE OAE:0006301 QY, JX, HY 眶畸形 10012141 deformity of orbit AE OAE:0006302 This is an AE whcih is a condition of the nasal septum in which there is a collection of pus between the mucoperichondrium and septal cartilage. QY, JX, HY http://en.volupedia.org/wiki/Nasal_septal_abscess 鼻脓肿 10028720 nasal abscess AE OAE:0006303 This is an AE which is a neurological disorder of excessive time spent sleeping or excessive sleepiness. QY, JX, HY http://en.volupedia.org/wiki/Hypersomnia 睡眠过度-食欲过盛综合征 10053712 hypersomnia-bulimia syndrome AE OAE:0006304 This is an AE which is a large, air-filled space above and behind the nose in the middle of the face and there is a mass. QY, JX, HY http://en.volupedia.org/wiki/Nasal_cavity 鼻腔肿块 10062771 nasal cavity mass AE OAE:0006305 This is an AE which is a rare sinonasal tumor that mainly occurs in adults during the 5th decade. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27053431/ 鼻窦乳头状瘤 10071665 sinonasal papilloma AE OAE:0006306 This is an AE which is a subtype of eosinophilic chronic rhinosinusitis (CRS) characterized by type I hypersensitivity, nasal polyposis, characteristic computed tomography scan findings, eosinophilic mucus, and the presence of fungus on surgical specimens without evidence of tissue invasion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22588040/ 过敏性鼻窦炎 10049153 allergic sinusitis AE OAE:0006307 This is an AE which is caused by one or more volatilized chemical compounds that are generally found in low concentrations that humans and animals can perceive by their sense of smell. QY, JX, HY http://en.volupedia.org/wiki/Odor 鼻腔气味 10051181 nasal odour AE OAE:0006308 This is an AE which is contents found in the human nose. It is a result of drying of the normally viscous colloidal mucus. QY, JX, HY http://en.volupedia.org/wiki/Dried_nasal_mucus 鼻腔干燥 10028740 nasal dryness AE OAE:0006309 This is an AE which is the movement of material from one point to another, such as a secreted chemical substance from a paranasal sinus cell . QY, JX, HY http://en.volupedia.org/wiki/Secretion 副鼻窦分泌过多 10057392 paranasal sinus hypersecretion AE OAE:0006310 This is an AE which might be beneficial in the management of sprue. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/13133068/ 无麦饮食 10047919 wheat-free diet AE OAE:0006311 This is an AE which is disabling, deadly, and costly mental disorders that considerably impair physical health and disrupt psychosocial functioning. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32171414/ 食欲障碍 10060961 appetite disorder AE OAE:0006312 This is an AE which is a mental disorder defined by abnormal eating behaviors that negatively affect a person's physical or mental health. QY, JX, HY http://en.volupedia.org/wiki/Eating_disorder 饮食失调症状 10061832 eating disorder symptom AE OAE:0006313 This is an AE which is a child's refusal to eat certain food groups, textures, solids or liquids for a period of at least one month, which causes the child to not gain enough weight, grow naturally or cause any developmental delays. QY, JX, HY http://en.volupedia.org/wiki/Feeding_disorder 进食障碍 10061148 feeding disorder AE OAE:0006314 This is an AE which in infancy or early childhood, is a child's refusal to eat certain food groups, textures, solids or liquids for a period of at least one month, which causes the child to not gain enough weight, grow naturally or cause any developmental delays.[1] Feeding disorders resemble failure to thrive, except that at times in feeding disorder there is no medical or physiological condition that can explain the very small amount of food the children consume or their lack of growth. QY, JX, HY http://en.volupedia.org/wiki/Feeding_disorder 进食障碍新生儿 10016316 feeding disorder neonatal AE OAE:0006315 This is an AE which is an abnormal immune response to food. QY, JX, HY http://en.volupedia.org/wiki/Food_allergy 食物过敏 10016946 food allergy AE OAE:0006316 This is an AE which is acquired as a result of unpleasant experiences with foods represent a potent defense mechanism against poisoning. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10336144/ 食物的厌恶 10049238 food aversion AE OAE:0006317 This is an AE which is an intense desire to consume a specific food, and is different from normal hunger. QY, JX, HY http://en.volupedia.org/wiki/Food_craving 饮食冲动 10056465 food craving AE OAE:0006318 This is an AE which is a behavior where people or animals accumulate food. QY, JX, HY http://en.volupedia.org/wiki/Hoarding 食物中毒 10016947 food hoarding AE OAE:0006319 This is an AE which is defined as alterations of pharmacokinetics or pharmacodynamics of a drug or nutritional element or a compromise in nutritional status as a result of the addition of a drug. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18382075/ 食物囤积 10016948 food interaction AE OAE:0006320 This is an AE which is a detrimental reaction, often delayed, to a food, beverage, food additive, or compound found in foods that produces symptoms in one or more body organs and systems, but generally refers to reactions other than food allergy. QY, JX, HY http://en.volupedia.org/wiki/Food_intolerance 食物不耐受 10061958 food intolerance AE OAE:0006321 This is an AE which is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that contaminate food, as well as prions (the agents of mad cow disease), and toxins such as aflatoxins in peanuts, poisonous mushrooms, and various species of beans that have not been boiled for at least 10 minutes. QY, JX, HY http://en.volupedia.org/wiki/Foodborne_illness 食物中毒 10016952 food poisoning AE OAE:0006322 This is an AE which is primarily associated with physical and ethical aspects and with end-of-life. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32271841/ 拒食 10080283 food refusal AE OAE:0006323 This is an AE which is a high-fat, adequate-protein, low-carbohydrate diet that in medicine is used mainly to treat hard-to-control (refractory) epilepsy in children. QY, JX, HY http://en.volupedia.org/wiki/Ketogenic_diet 生酮膳食 10073855 ketogenic diet AE OAE:0006324 This is an AE which refers an abnormal appetite for earth and other non-foods. QY, JX, HY http://en.volupedia.org/wiki/Pica 异食癖 10035001 pica AE OAE:0006325 This is an AE which is a type of eating disorder in which people eat only within an extremely narrow repertoire of foods. QY, JX, HY http://en.volupedia.org/wiki/Avoidant/restrictive_food_intake_disorder 选择性进食障碍 10078069 selective eating disorder AE OAE:0006326 This is an AE which is a collection of pus that has built up within the tissue of the oral. QY, JX, HY http://en.volupedia.org/wiki/Abscess 口腔脓肿 10000311 abscess oral AE OAE:0006327 This is an AE which is a common side effect of various medical conditions which manifests as a reduced sense of oral touch or sensation, or a partial loss of sensitivity to sensory stimuli. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 口腔触觉减退 10057371 hypoesthesia oral AE OAE:0006328 This is an AE which refers an unfavorable evolution of a disease, health condition or medical treatment such as oral administration drug. QY, JX, HY http://en.volupedia.org/wiki/Complication 口腔并发症 10062611 oral administration complication AE OAE:0006329 This is an AE which is a type of food allergy classified by a cluster of allergic reactions in the mouth and throat in response to eating certain (usually fresh) fruits, nuts, and vegetables that typically develops in adults with hay fever. QY, JX, HY http://en.volupedia.org/wiki/Oral_allergy_syndrome 口腔过敏综合症 10068355 oral allergy syndrome AE OAE:0006330 This is an AE which is a type of blister that forms when oral subdermal tissues and blood vessels are damaged without piercing the skin. QY, JX, HY http://en.volupedia.org/wiki/Blood_blister 口腔血疱 10076590 oral blood blister AE OAE:0006331 This is an AE which is a type of hematoma of tissue, the most common cause being capillaries damaged by trauma, causing oral localized bleeding that extravasates into the surrounding interstitial tissues. QY, JX, HY http://en.volupedia.org/wiki/Bruise 口腔挫伤 10078170 oral contusion AE OAE:0006332 This is an AE which is any medical condition that affects the oral integumentary system . QY, JX, HY http://en.volupedia.org/wiki/Skin_condition 口腔脓疱 10056674 oral pustule AE OAE:0006333 This is an AE which occurs when an organism's body oral is invaded by pathogenic viruses,not verified in body] and infectious virus particles (virions) attach to and enter susceptible cells. QY, JX, HY http://en.volupedia.org/wiki/Viral_disease 口腔病毒感染 10065234 oral viral infection AE OAE:0006334 This is an AE which is a condition of abnormally high storage levels of vitamins, which can lead to various symptoms as over excitement, irritability, or even toxicity. QY, JX, HY http://en.volupedia.org/wiki/Hypervitaminosis 维生素过多症 10020915 hypervitaminosis AE OAE:0006335 This is an AE which causing extensive neurological, ophthalmological, and hematological deficits. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10586628/ 多种维生素缺乏症 10028155 multi-vitamin deficiency AE OAE:0006336 This is an AE which is a distortion of the sense of taste. Dysgeusia is also often associated with ageusia, which is the complete lack of taste, and hypogeusia, which is a decrease in taste sensitivity. QY, JX, HY http://en.volupedia.org/wiki/Dysgeusia 味觉障碍 10082490 taste disorder AE OAE:0006337 This is an AE which is a common, morbid, and costly malady, often complicated by otitis media, sinusitis, and asthma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11892040/ 病毒性鼻炎 10064948 viral rhinitis AE OAE:0006338 This is an AE which is inflammation of the mucous membranes caused by viral that line the sinuses resulting in symptoms that may include thick nasal mucus, a plugged nose, and facial pain. QY, JX, HY http://en.volupedia.org/wiki/Sinusitis 病毒性鼻窦炎 10051513 viral sinusitis AE OAE:0006339 This is an AE which is usually precipitated by an earlier upper respiratory tract infection, generally of viral origin, mostly caused by rhinoviruses (with RVA and RVC giving more severe infection than RVB), coronaviruses, and influenza viruses, others caused by adenoviruses, human parainfluenza viruses, human respiratory syncytial virus, enteroviruses other than rhinoviruses, and metapneumovirus. QY, JX, HY http://en.volupedia.org/wiki/Sinusitis#Acute 急性鼻窦炎 10001076 acute sinusitis AE OAE:0006340 This is an AE which is a medical practice or technique of burning a part of a body such as nose to remove or close off a part of it. QY, JX, HY http://en.volupedia.org/wiki/Cauterization 鼻子烧伤 10007829 cautery to nose AE OAE:0006341 This is an AE which is bleeding from the nose. QY, JX, HY http://en.volupedia.org/wiki/Nosebleed 鼻出血 10015090 epistaxis AE OAE:0006342 This is an AE which is a common side effect of various medical conditions which manifests as a reduced sense of intranasal touch or sensation, or a partial loss of sensitivity to sensory stimuli. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 鼻内触觉减退 10067068 intranasal hypoesthesia AE OAE:0006343 This is an AE which is frequently used after septoplasty and some complications caused by nasal packing are unavoidable. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31076882/ 鼻腔填充 10028733 nasal cavity packing AE OAE:0006344 This is an AE which often manifests as nasal discharge with or without other nasal signs. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24268334/ 鼻部疾病 10062209 nasal disorder AE OAE:0006345 This is an AE which is determined by the nasal bones and the nasal cartilages, including the nasal septum which separates the nostrils and divides the nasal cavity into two. QY, JX, HY http://en.volupedia.org/wiki/Human_nose#Related_medical_conditions 鼻翼张开 10052319 nasal flaring AE OAE:0006346 This is an AE which is a viral nasal infection caused by the herpes virus. QY, JX, HY http://en.volupedia.org/wiki/Herpes_simplex 鼻翼疱疹 10074936 nasal herpes AE OAE:0006347 This is an AE which causes a loss of olfactory sensory neurons (OSNs) and atrophy of the olfactory bulb (OB), which recovers when inflammation subsides. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32220858/ 鼻腔炎症 10028741 nasal inflammation AE OAE:0006348 This is an AE which caused by various traumas including blunt, and penetrating trauma and trauma caused by blast injury. QY, JX, HY http://en.volupedia.org/wiki/Rhinoplasty#Nasal_reconstruction 鼻部损伤 10078651 nasal injury AE OAE:0006349 This is an AE which is a personal hygiene practice in which the nasal cavity is washed to flush out mucus and debris from the nose and sinuses, in order to enhance nasal breathing or can also refer to the use of saline nasal spray or nebulizers to moisten the mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Nasal_irrigation 鼻腔冲洗 10069202 nasal irrigation AE OAE:0006350 This is an AE which can be measured objectively with RGB analysis to aid the diagnosis of allergic rhinitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32238199/ 鼻黏膜变色 10057537 nasal mucosal discoloration AE OAE:0006351 This is an AE which is the increase in the volume of nasal mucosal due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 鼻黏膜肥大 10057358 nasal mucosal hypertrophy AE OAE:0006352 This is an AE which is a discontinuity or break in a bodily membrane such as nasal mucosal that impedes normal function of the affected organ. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 鼻粘膜溃疡 10065546 nasal mucosal ulcer AE OAE:0006353 This is an AE which is the blockage of nasal breathing usually due to membranes lining the nose becoming swollen from inflamed blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Nasal_congestion 鼻塞 10028748 nasal obstruction AE OAE:0006354 This is an AE which is the build-up of fluid in the body's tissue such as nasal. QY, JX, HY http://en.volupedia.org/wiki/Edema 鼻腔水肿 10028750 nasal edema AE OAE:0006355 This is an AE which is noncancerous growths within the nose or sinuses. QY, JX, HY http://en.volupedia.org/wiki/Nasal_polyp 鼻息肉 10028756 nasal polyps AE OAE:0006356 This is an AE which is a sensation that causes the desire or reflex to scratch occurs on the nasal . QY, JX, HY http://en.volupedia.org/wiki/Itch 鼻瘙痒 10076406 nasal pruritus AE OAE:0006357 This is an AE which is a physical disorder of the nose, involving a displacement of the nasal septum. QY, JX, HY http://en.volupedia.org/wiki/Nasal_septum_deviation 鼻中隔偏曲 10028762 nasal septum deviation AE OAE:0006358 This is an AE which separates the left and right airways of the nasal cavity and it is disorder. QY, JX, HY http://en.volupedia.org/wiki/Nasal_septum 鼻中隔疾病 10028763 nasal septum disorder AE OAE:0006359 This is an AE which is the increase in the volume of an organ or tissue due such as nasal turbinate to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 鼻甲状肌肥厚 10028779 nasal turbinate hypertrophy AE OAE:0006360 This is an AE which is a discontinuity or break in a bodily membrane such as nasal that impedes normal function of the affected organ. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 鼻溃疡 10028780 nasal ulcer AE OAE:0006361 This is an AE which has multiple causes, including congenital, traumatic, and, unfortunately, iatrogenic. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30017094/ 鼻瓣塌陷 10077240 nasal valve collapse AE OAE:0006363 This is an AE which is a closed sac on the paranasal, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 鼻侧的囊肿 10062321 paranasal cyst AE OAE:0006364 This is an AE which is blood escaping from the circulatory system from damaged paranasal sinus blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 副鼻窦出血 10080108 paranasal sinus hemorrhage AE OAE:0006365 This is an AE which is part of the complex biological response of body tissues to harmful stimuli such as paranasal sinus. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 副鼻窦炎症 10083836 paranasal sinus inflammation AE OAE:0006366 This is an AE which identified in divers suggests that diving may cause changes in the paranasal sinus mucosa. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21961405/ 鼻窦黏膜肥大 10067998 paranasal sinus mucosal hypertrophy AE OAE:0006367 This is an AE which can be managed in the emergency department, particularly if the patient offers a history consistent with foreign body and is calm and compliant with the examination and removal attempts. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30454775/ 从鼻子中取出异物 10038332 removal of foreign body from nose AE OAE:0006368 This is an AE which seem specific pain syndromes with a distinctive location in the nose. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26198298/ 鼻痛 10051496 rhinalgia AE OAE:0006369 This is an AE which is a type of inflammation in the nose that occurs when the immune system overreacts to allergens in the air. QY, JX, HY http://en.volupedia.org/wiki/Allergic_rhinitis 过敏性鼻炎 10039085 rhinitis allergic AE OAE:0006370 This is an AE which is irritation and inflammation of the mucous membrane inside the nose and is perennial. QY, JX, HY http://en.volupedia.org/wiki/Rhinitis 常年性鼻炎 10039094 rhinitis perennial AE OAE:0006371 This is an AE which is irritation and inflammation of the mucous membrane inside the nose and is seasonal. QY, JX, HY http://en.volupedia.org/wiki/Rhinitis 季节性鼻炎 10039095 rhinitis seasonal AE OAE:0006372 This is an AE which is a chronic granulomatous bacterial disease of the nose that can sometimes infect the upper respiratory tract. QY, JX, HY http://en.volupedia.org/wiki/Rhinoscleroma 鼻硬化 10039102 rhinoscleroma AE OAE:0006373 This is an AE which is an upper respiratory or pulmonary infection of cats caused by Felid alphaherpesvirus 1 (FeHV-1), of the family Herpesviridae. QY, JX, HY http://en.volupedia.org/wiki/Feline_viral_rhinotracheitis 鼻气管炎 10051497 rhinotracheitis AE OAE:0006374 This is an AE which is the most common viral infectious agent in humans and is the predominant cause of the common cold. QY, JX, HY http://en.volupedia.org/wiki/Rhinovirus 鼻病毒感染 10061494 rhinovirus infection AE OAE:0006375 This is an AE which is a long-term skin condition that typically affects the face. QY, JX, HY http://en.volupedia.org/wiki/Rosacea 酒渣鼻 10039218 rosacea AE OAE:0006376 This is an AE which is a common presenting symptom to clinicians and affects up to one-third of the population. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29941182/ 鼻窦阻塞 10080545 sinonasal obstruction AE OAE:0006377 This is an AE which is a reduced ability to smell and to detect odors. QY, JX, HY http://en.volupedia.org/wiki/Hyposmia 嗅觉减退 10050515 hyposmia AE OAE:0006378 This is an AE which refers to a fear, aversion, or psychological hypersensitivity to odors. QY, JX, HY http://en.volupedia.org/wiki/Osmophobia 气味恐怖 10060765 osmophobia AE OAE:0006379 This is an AE which is a form of severe malnutrition characterized by energy deficiency. QY, JX, HY http://en.volupedia.org/wiki/Marasmus 消瘦症 10026820 marasmus AE OAE:0006380 This is an AE which is often present in gastroparesis, but the importance of these symptoms in gastroparesis has not been well-described. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27781342/ 早饱 10059186 early satiety AE OAE:0006381 This is an AE which is a noise generated by the disturbance of the air flow passing through the nose. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21132253/ 鼾声 10076712 stertor AE OAE:0006382 QY, JX, HY 奶牛无奶饮食 10011244 cows milk free diet AE OAE:0006383 QY, JX, HY 饮食不规律 10072373 diet noncompliance AE OAE:0006384 QY, JX, HY 鼻结结痂 10076524 nasal crusting AE OAE:0006385 QY, JX, HY 鼻涕变色 10071553 nasal discharge discoloration AE OAE:0006386 QY, JX, HY 鼻粘膜水泡 10082185 nasal mucosal blistering AE OAE:0006387 QY, JX, HY 鼻粘膜疾病 10061305 nasal mucosal disorder AE OAE:0006388 QY, JX, HY 鼻粘膜侵蚀 10076585 nasal mucosal erosion AE OAE:0006389 QY, JX, HY 副鼻窦不适 10052438 paranasal sinus discomfort AE OAE:0006390 QY, JX, HY 副鼻窦分泌不足 10080046 paranasal sinus hyposecretion AE OAE:0006391 This is an AE which comprises lightening/greying, darkening, or even a complete hair colour change, which may involve the scalp and/or all body hair. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27545142/ 头发颜色变化 10019030 hair color changes AE OAE:0006392 This is an AE which is disorders primarily associated with the follicles of the hair. QY, JX, HY http://en.volupedia.org/wiki/Hair_disease 头发疾病 10019037 hair disorder AE OAE:0006393 This is an AE which can appear as firm, dome-shaped cutaneous or subcutaneous masses with alopecia. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155888/ 良性毛囊肿瘤 10019043 hair follicle tumor benign AE OAE:0006394 This is an AE which is damage to the hair caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 头发损伤 10074924 hair injury AE OAE:0006395 This is an AE which is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. QY, JX, HY http://en.volupedia.org/wiki/Hairy_cell_leukemia 毛细胞白血病 10019053 hairy cell leukaemia AE OAE:0006396 This is an AE which is a condition where a hair curls back or grows sideways into the skin. QY, JX, HY http://en.volupedia.org/wiki/Ingrown_hair 向内生毛 10052899 ingrown hair AE OAE:0006397 This is an AE which is a condition of the tongue in which the small bumps on the tongue elongate with black or brown discoloration, giving a black and hairy appearance. QY, JX, HY http://en.volupedia.org/wiki/Black_hairy_tongue 黑毛舌 10043941 tongue black hairy(black hairy tongue) AE OAE:0006398 This is an AE which is a common, autosomal-dominant, genetic condition of the skin's hair follicles characterized by the appearance of possibly itchy, small, gooseflesh-like bumps, with varying degrees of reddening or inflammation. QY, JX, HY http://en.volupedia.org/wiki/Keratosis_pilaris 毛发角化病 10066295 keratosis pilaris AE OAE:0006399 This is an AE which is an abnormal descent of the brow from its anatomical position to the point that a patient becomes uncomfortable with the brow's appearance or visual field deficits develop. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32809597/ 额头上睑下垂，眉毛下垂 10059001 brow ptosis AE OAE:0006400 This is an AE which is an acute headache of short duration brought on by some forms of activity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27409752/ 劳累型头痛 10068614 exertional headache AE OAE:0006401 This is an AE which is a form of brief pain or headache commonly associated with consumption (particularly quick consumption) of cold beverages or foods such as ice cream, Popsicles, and snow cones. QY, JX, HY http://en.volupedia.org/wiki/Cold-stimulus_headache 冷刺激性头痛 10071151 cold-stimulus headache AE OAE:0006402 This is an AE which is an imprecise term that can refer to a sense of disorientation in space, vertigo, or lightheadedness . QY, JX, HY http://en.volupedia.org/wiki/Dizziness 体位性头晕 10013578 dizziness postural AE OAE:0006403 This is an AE which is a primary headache syndrome which can mimic chronic migraine and chronic tension-type headache. QY, JX, HY http://en.volupedia.org/wiki/New_daily_persistent_headache 新的每日持续性头痛 10076678 new daily persistent headache AE OAE:0006404 This is an AE which is a cluster of boils caused by bacterial infection, most commonly with Staphylococcus aureus or Streptococcus pyogenes. QY, JX, HY http://en.volupedia.org/wiki/Carbuncle 痈 10007247 carbuncle AE OAE:0006405 This is an AE which is an inflammatory, primary cicatricial alopecia with several different patterns of hair loss. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29262050/ 毛发扁平苔癣 10081142 lichen planopilaris AE OAE:0006406 This is an AE which is a mental disorder characterized by a long-term urge that results in the pulling out of one's own hair. QY, JX, HY http://en.volupedia.org/wiki/Trichotillomania 拔毛癖 10044629 trichotillomania AE OAE:0006407 This is an AE which includes trichorrhexis invaginata and trichorrhexis nodosa. QY, JX, HY http://en.volupedia.org/wiki/Trichorrhexis 掉毛 10044625 trichorrhexis AE OAE:0006408 This is an AE which can be an early sign of skin aging and are a significant cosmetic concern. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25647394/ 扩张毛孔 10076249 dilated pores AE OAE:0006409 This is an AE which is a parasitic disease caused by Giardia duodenalis. QY, JX, HY http://en.volupedia.org/wiki/Giardiasis 梨形鞭毛虫病 10018262 giardiasis AE OAE:0006410 This is an AE which is the bumps on a person's skin at the base of body hairs which may involuntarily develop when a person is tickled, cold or experiencing strong emotions such as fear, euphoria or sexual arousal. QY, JX, HY http://en.volupedia.org/wiki/Goose_bumps 立毛 10035039 piloerection AE OAE:0006411 This is an AE which is the infection and inflammation of one or more hair follicles. QY, JX, HY http://en.volupedia.org/wiki/Folliculitis 毛囊炎 10016936 folliculitis AE OAE:0006412 This is an AE which is a medical condition involving the loss of all body hair, including eyebrows, eyelashes, chest hair, armpit hair, and pubic hair. QY, JX, HY http://en.volupedia.org/wiki/Alopecia_universalis 普秃 10001767 alopecia universalis AE OAE:0006413 This is an AE which is a condition of abnormal hair patterns, predominantly loss or reduction. QY, JX, HY http://en.volupedia.org/wiki/Hair_loss#Hypotrichosis 少毛症 10021126 hypotrichosis AE OAE:0006414 This is an AE which is a persistent irritation caused by shaving. QY, JX, HY http://en.volupedia.org/wiki/Pseudofolliculitis_barbae 须须假毛囊炎 10037120 pseudofolliculitis barbae AE OAE:0006415 This is an AE which is a clinical entity with a diversified aetiology, that allows to distinguish from circumscribed or cicatricial alopecia or male baldness. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/8048976/ 弥散性脱发 10073736 diffuse alopecia AE OAE:0006416 This is an AE which refers to a loss of hair from part of the head or body with effluvium. QY, JX, HY http://en.volupedia.org/wiki/Hair_loss 恶臭性脱发 10001762 alopecia effluvium AE OAE:0006417 This is an AE which has been largely considered a neurological catastrophe. With conventional treatment, only around 20% of patients achieve functional independence. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21129593/ 基底动脉血栓形成 10063093 basilar artery thrombosis AE OAE:0006418 This is an AE which include neuromuscular irritability, tetany, and seizures, which are rapidly resolved with intravenous administration of calcium gluconate. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30449546/ 低钙血症癫痫 10072456 hypocalcaemic seizure AE OAE:0006419 This is an AE which is a decrease in the total amount of neurogenic red blood cells (RBCs) or hemoglobin in the blood or a lowered ability of the blood to carry oxygen. QY, JX, HY http://en.volupedia.org/wiki/Anemia 肾原性的贫血 10058116 nephrogenic anemia AE OAE:0006420 This is an AE which is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. QY, JX, HY http://en.volupedia.org/wiki/Multiple_myeloma 骨髓瘤复发 10051381 myeloma recurrence AE OAE:0006421 This is an AE which is a global health concern affecting children, women and the elderly, whilst also being a common comorbidity in multiple medical conditions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31665543/ 缺乏性贫血 10061101 deficiency anemia AE OAE:0006422 This is an AE which is a group of blood disorders typically inherited from a person's parents. QY, JX, HY http://en.volupedia.org/wiki/Sickle_cell_disease 镰状细胞性贫血 10040641 sickle cell anemia AE OAE:0006423 This is an AE which is a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. QY, JX, HY http://en.volupedia.org/wiki/Myeloproliferative_neoplasm 骨髓增生障碍 10028576 myeloproliferative disorder AE OAE:0006424 This is an AE which is a life-threatening condition caused by haemophilus that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 嗜血杆菌败血症 10058875 haemophilus sepsis AE OAE:0006425 This is an AE which is a process with hyperchloraemic causing increased acidity in the blood and other body tissues . QY, JX, HY http://en.volupedia.org/wiki/Acidosis 酸中毒高氯血症 10000489 acidosis hyperchloraemic AE OAE:0006426 This is an AE which is an acquired autoimmune disorder resulting in the production of antibodies directed against red blood cell antigens causing shortened erythrocyte survival. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28189175/ 温热型溶血性贫血 10047822 warm type hemolytic anemia AE OAE:0006427 This is an AE which is an acquired autoimmune disorder resulting in the production of antibodies directed against red blood cell antigens causing shortened erythrocyte survival. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28189175/ 冷型溶血性贫血 10009868 cold type hemolytic anemia AE OAE:0006428 This is an AE which is infections present in the blood caused by bacillus. QY, JX, HY http://en.volupedia.org/wiki/Bloodstream_infections 芽孢杆菌菌血症 10074184 bacillus bacteremia AE OAE:0006429 This is an AE which is infections present in the blood caused by corynebacterium. QY, JX, HY http://en.volupedia.org/wiki/Bloodstream_infections 棒状杆菌属菌血症 10077106 corynebacterium bacteremia AE OAE:0006430 This is an AE which is infections present in the blood caused by haemophilus. QY, JX, HY http://en.volupedia.org/wiki/Bloodstream_infections 嗜血杆菌菌血症 10058922 haemophilus bacteremia AE OAE:0006431 This is an AE which is the cells of the immune system that are involved in protecting the body against both infectious disease and foreign invaders . QY, JX, HY http://en.volupedia.org/wiki/White_blood_cell 白细胞紊乱 10061414 white blood cell disorder AE OAE:0006432 This is an AE which is the formation of a blood clot inside a haemorrhoids blood vessel, obstructing the flow of blood through the circulatory system. QY, JX, HY http://en.volupedia.org/wiki/Thrombosis 痔疮血栓 10019023 haemorrhoids thrombosed AE OAE:0006433 This is an AE which is well recognized and not infrequent findings in hyperthyroidism in adults. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15469538/ 高转氨血症 10068237 hypertransaminasaemia AE OAE:0006434 This is an AE which occurs when a blood clot forms in the artery that provides blood flow to the peripheral. QY, JX, HY http://en.volupedia.org/wiki/Hepatic_artery_thrombosis 外周动脉血栓形成 10072564 peripheral artery thrombosis AE OAE:0006435 This is an AE which refers to a term for the presence of toxins in the blood caused by staphylococcal. QY, JX, HY http://en.volupedia.org/wiki/Toxemia 葡萄球菌毒血症 10041932 staphylococcal toxaemia AE OAE:0006436 This is an AE which is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs), either in the blood vessels (intravascular hemolysis) or elsewhere in the human body (extravascular). QY, JX, HY http://en.volupedia.org/wiki/Hemolytic_anemia 溶血性贫血 10018916 hemolytic anemia AE OAE:0006437 This is an AE which is a group of blood disorders characterized by low red blood cells, acute kidney failure, and low platelets. QY, JX, HY http://en.volupedia.org/wiki/Hemolytic%E2%80%93uremic_syndrome 溶血性尿毒综合征 10018932 hemolytic uraemic syndrome AE OAE:0006438 This is an AE which is a common cause of infection among acute myeloid leukemia (AML) patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10784625/ 溶血性链球菌感染 10054265 alpha hemolytic streptococcal infection AE OAE:0006439 This is an AE which is a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood or a lowered ability of the blood to carry oxygen. QY, JX, HY http://en.volupedia.org/wiki/Anemia 贫血 10002034 anemia AE OAE:0006440 This is an AE which occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_hemolytic_anemia 溶血性贫血自身免疫性 10002046 anemia hemolytic autoimmune AE OAE:0006441 This is an AE which is a type of macrocytic anemia. An anemia is a red blood cell defect that can lead to an undersupply of oxygen. QY, JX, HY http://en.volupedia.org/wiki/Megaloblastic_anemia 巨幼红细胞贫血 10002065 anemia megaloblastic AE OAE:0006442 This is an AE which can be due to blood loss, decreased RBC production, or increased destruction of erythrocytes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18411074/ 新生儿贫血 10002068 anemia neonatal AE OAE:0006443 This is an AE which is a form of anemia seen in chronic infection, chronic immune activation, and malignancy. QY, JX, HY http://en.volupedia.org/wiki/Anemia_of_chronic_disease 慢性贫血 10002073 anemia of chronic disease AE OAE:0006444 This is an AE which is a decrease in the total red blood cells (RBCs) or hemoglobin in the blood during pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Anemia_in_pregnancy 妊娠贫血 10066468 anemia of pregnancy AE OAE:0006445 This is an AE which occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_hemolytic_anemia 自身免疫性溶血性贫血 10073785 autoimmune hemolytic anemia AE OAE:0006446 This is an AE which is a type of streptococcus infection and beta-hemolytic is a complete lysis of red cells in the media around and under the colonies: the area appears lightened (yellow) and transparent. QY, JX, HY http://en.volupedia.org/wiki/Streptococcus 溶血性链球菌感染 10052100 beta hemolytic streptococcal infection AE OAE:0006447 This is an AE which is a condition in which the white cell (leukocyte count) is above the normal range in the blood. QY, JX, HY http://en.volupedia.org/wiki/Leukocytosis 高白细胞血症 10078862 hyperleukocytosis AE OAE:0006448 This is an AE which is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. QY, JX, HY http://en.volupedia.org/wiki/Leukemia 白血病 10024288 leukaemia AE OAE:0006449 This is an AE which is a condition in which the white cell (leukocyte count) is above the normal range in the blood. QY, JX, HY http://en.volupedia.org/wiki/Leukocytosis 白细胞增多症 10024378 leukocytosis AE OAE:0006450 This is an AE which is a long-term skin condition characterized by patches of the skin losing their pigment. QY, JX, HY http://en.volupedia.org/wiki/Vitiligo 白癜风 10024380 leukoderma AE OAE:0006451 This is an AE which is a medical emergency most commonly seen in patients with acute myeloid leukemia. QY, JX, HY http://en.volupedia.org/wiki/Leukostasis 白细胞平衡综合征 10074608 leukostasis syndrome AE OAE:0006452 This is an AE which is a rare autosomal recessive disorder that arises from a mutation of a lysosomal trafficking regulator protein,which leads to a decrease in phagocytosis. QY, JX, HY http://en.volupedia.org/wiki/Ch%C3%A9diak%E2%80%93Higashi_syndrome 白细胞异常色素减退综合征 10008415 chediak-higashi syndrome AE OAE:0006453 This is an AE which is a skin condition, a variant of acrocyanosis caused by chronic exposure to cold. QY, JX, HY http://en.volupedia.org/wiki/Erythrocyanosis_crurum 红细胞发绀 10048995 erythrocyanosis AE OAE:0006454 This is an AE which is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the myeloproliferation is of erythroblastic precursors. QY, JX, HY http://en.volupedia.org/wiki/Acute_erythroid_leukemia#M6a_(Erythroleukemia) 红白血病 10015281 erythroleukaemia AE OAE:0006455 This is an AE which is a fairly disabling microvascular phenomenon. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/545362/ 造红细胞组织增殖，皮肤红变 10056474 erythrosis AE OAE:0006456 This is an AE which is variation in cell shape: poikilocytes may be oval, teardrop-shaped, sickle-shaped or irregularly contracted. QY, JX, HY http://en.volupedia.org/wiki/Poikilocytosis 异形红细胞症 10035774 poikilocytosis AE OAE:0006457 This is an AE which is a disease state in which the hematocrit (the volume percentage of red blood cells in the blood) and/or hemoglobin concentration are elevated in peripheral blood. QY, JX, HY http://en.volupedia.org/wiki/Polycythemia 多血性贫血 10036051 polycythaemia AE OAE:0006458 This is an AE which is the medical term for an abnormal decrease of reticulocytes in the body. QY, JX, HY http://en.volupedia.org/wiki/Reticulocytopenia 网织红细胞减少症 10038795 reticulocytopenia AE OAE:0006459 This is an AE which is a condition where there is an increase in reticulocytes, immature red blood cells. QY, JX, HY http://en.volupedia.org/wiki/Reticulocytosis 网织红细胞增多症 10038796 reticulocytosis AE OAE:0006460 This is an AE which is a common inherited disorder that is characterised by anaemia, jaundice, and splenomegaly. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18940465/ 球形红细胞性贫血 10041509 spherocytic anemia AE OAE:0006461 This is an AE which refers to a type of aplastic anemia affecting the precursors to red blood cells but usually not to white blood cells. QY, JX, HY http://en.volupedia.org/wiki/Pure_red_cell_aplasia 发育不全纯红细胞 10002965 aplasia pure red cell AE OAE:0006462 This is an AE which is a type of thrombocytopenic purpura defined as an isolated low platelet count with a normal bone marrow in the absence of other causes of low platelets. QY, JX, HY http://en.volupedia.org/wiki/Immune_thrombocytopenic_purpura 自身免疫性血小板减少症 10050245 autoimmune thrombocytopenia AE OAE:0006463 This is an AE which is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow. QY, JX, HY http://en.volupedia.org/wiki/Essential_thrombocythemia 原发性血小板血症 10015493 essential thrombocythaemia AE OAE:0006464 This is an AE which is the development of thrombocytopenia (a low platelet count), due to the administration of various forms of heparin, an anticoagulant. QY, JX, HY http://en.volupedia.org/wiki/Heparin-induced_thrombocytopenia 肝素诱发的血小板减少症 10062506 heparin-induced thrombocytopenia AE OAE:0006465 This is an AE which is a type of thrombocytopenic purpura defined as an isolated low platelet count with a normal bone marrow in the absence of other causes of low platelets. QY, JX, HY http://en.volupedia.org/wiki/Immune_thrombocytopenic_purpura 免疫性血小板减少症 10083842 immune thrombocytopenia AE OAE:0006466 This is an AE which is a type of thrombocytopenic purpura defined as an isolated low platelet count with a normal bone marrow in the absence of other causes of low platelets. QY, JX, HY http://en.volupedia.org/wiki/Immune_thrombocytopenic_purpura 免疫性血小板减少性紫癜 10074667 immune thrombocytopenic purpura AE OAE:0006467 This is an AE which is a disease that affects babies in which the platelet count is decreased because the mother's immune system attacks her fetus' or newborn's platelets. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_alloimmune_thrombocytopenia 新生儿同种免疫性血小板减少症 10075149 neonatal alloimmune thrombocytopenia AE OAE:0006468 This is an AE which is a medical term meaning that a patient's red blood cells(such as platelet ) are of unequal size. QY, JX, HY http://en.volupedia.org/wiki/Anisocytosis 血小板异体细胞增多症 10066294 platelet anisocytosis AE OAE:0006469 This is an AE which is a component of blood whose function (along with the coagulation factors) is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot and its function is disorder. QY, JX, HY http://en.volupedia.org/wiki/Platelet 血小板疾病 10035532 platelet disorder AE OAE:0006470 This is an AE which is deeply involved in the pathogenesis of psoriasis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32349003/ 血小板功能障碍 10073391 platelet dysfunction AE OAE:0006471 This is an AE which is a condition of high platelet (thrombocyte) count in the blood. QY, JX, HY http://en.volupedia.org/wiki/Thrombocythemia#Causes 继发性血小板增多症 10083158 secondary thrombocytosis AE OAE:0006472 This is an AE which is a condition characterized by abnormally low levels of platelets occurs on the neonatal, also known as thrombocytes, in the blood. QY, JX, HY http://en.volupedia.org/wiki/Thrombocytopenia 新生儿血小板减少症 10043557 thrombocytopenia neonatal AE OAE:0006473 This is an AE which is a condition of high platelet (thrombocyte) count in the blood. QY, JX, HY http://en.volupedia.org/wiki/Thrombocythemia 血小板增多症 10043563 thrombocytosis AE OAE:0006474 This is an AE which is a crisis disease caused by production of abnormal hemoglobin, which binds with other abnormal hemoglobin molecules within the red blood cell to cause rigid deformation of the cell. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11452073/ 镰状细胞性贫血伴危象 10040642 sickle cell anemia with crisis AE OAE:0006475 This is an AE which is a group of blood disorders typically inherited from a person's parents. QY, JX, HY http://en.volupedia.org/wiki/Sickle_cell_disease 镰状细胞性贫血症 10040644 sickle cell disease AE OAE:0006476 This is an AE which describes a condition in which a person has one abnormal allele of the hemoglobin beta gene (is heterozygous), but does not display the severe symptoms of sickle cell disease that occur in a person who has two copies of that allele (is homozygous). QY, JX, HY http://en.volupedia.org/wiki/Sickle_cell_trait 镰状细胞性状 10040650 sickle cell trait AE OAE:0006477 This is an AE which is associated with a poor prognosis, and liver transplant is the only definitive management. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33139258/ 细胞性贫血 10052483 spur cell anemia AE OAE:0006478 This is an AE which is a form of thalassemia involving the genes HBA1 and HBA2. QY, JX, HY http://en.volupedia.org/wiki/Alpha-thalassemia α地中海贫血 10043390 thalassaemia alpha AE OAE:0006479 This is an AE which is without achylia or the Addisonian symptoms of glossitis, flatulent dyspepsia, diarrhoea, paraesthesiae, or neurological symptoms is seen in achrestic anaemia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/13160478/ 嗜铬性贫血，高色性贫血 10020605 hyperchromic anemia AE OAE:0006480 This is an AE which is a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood or a lowered ability of the blood to carry oxygen. QY, JX, HY http://en.volupedia.org/wiki/Anemia 发育不良性贫血 10021074 hypoplastic anemia AE OAE:0006481 This is an AE which is any of several types of anaemia characterized by small red blood cells (called microcytes). QY, JX, HY http://en.volupedia.org/wiki/Microcytic_anemia 小细胞性贫血 10027538 microcytic anemia AE OAE:0006482 This is an AE which is a condition in which red blood cells are unusually small as measured by their mean corpuscular volume. QY, JX, HY http://en.volupedia.org/wiki/Microcytosis 小细胞增多症 10027540 microcytosis AE OAE:0006483 This is an AE which appear to be the outcome of the impaired production of RBCs. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33351438/ 正常色素的贫血 10029782 normochromic anemia AE OAE:0006484 This is an AE which is a common complication in chronic kidney disease and is associated with many adverse clinical consequences. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26372086/ 正色素性正细胞性贫血 10029783 normochromic normocytic anemia AE OAE:0006485 This is an AE which may be caused by chronic disease, hemolysis, or bone marrow disorders. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20540485/ 正常红血球的贫血 10029784 normocytic anemia AE OAE:0006486 This is an AE which is a disease in which not enough red blood cells are produced due to a deficiency of vitamin B12. QY, JX, HY http://en.volupedia.org/wiki/Vitamin_B12_deficiency_anemia 恶性贫血 10034695 pernicious anemia AE OAE:0006487 This is an AE which is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. QY, JX, HY http://en.volupedia.org/wiki/Multiple_myeloma 浆细胞骨髓瘤 10035226 plasma cell myeloma AE OAE:0006488 This is an AE which is one of the most common serious bacterial infections worldwide. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21371655/ 葡萄球菌菌血症 10051017 staphylococcal bacteremia AE OAE:0006489 This is an AE which is an inflammatory bone disease that is caused by an infecting microorganism such as staphylococcal and leads to progressive bone destruction and loss. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29444953/ 葡萄球菌性骨髓炎 10064250 staphylococcal osteomyelitis AE OAE:0006490 This is an AE which is a life-threatening condition caused by staphylococcal that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 葡萄球菌败血症 10056430 staphylococcal sepsis AE OAE:0006491 This is an AE which is a family of serious medical conditions relating to an original diagnosis of leukemia. QY, JX, HY http://en.volupedia.org/wiki/Acute_leukemia 急性白血病 10000830 acute leukaemia AE OAE:0006492 This is an AE which is a rare condition (1:1,000,000), in which the bones have lesions, inflammation, and pain. QY, JX, HY http://en.volupedia.org/wiki/Chronic_recurrent_multifocal_osteomyelitis 慢性复发性多发性骨髓炎 10071530 chronic recurrent multifocal osteomyelitis AE OAE:0006493 This is an AE which is a rare malignancy affecting megakaryocytes, platelet-producing cells that reside in the bone marrow. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31548219/ 急性巨核细胞白血病 10000860 acute megakaryocytic leukaemia AE OAE:0006494 This is an AE which is a type of acute myeloid leukemia. In AML-M5 >80% of the leukemic cells are of monocytic lineage. QY, JX, HY http://en.volupedia.org/wiki/Acute_monocytic_leukemia 急性单核细胞的白血病 10000871 acute monocytic leukaemia AE OAE:0006495 This is an AE which is usually associated with determined recurrent cytogenetic aberrations like inv(16), t(v;11) (MLL gene rearrangement), and t(8;16). QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843787/ 急性骨髓单核细胞白血病 10000890 acute myelomonocytic leukaemia AE OAE:0006496 This is an AE which is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. QY, JX, HY http://en.volupedia.org/wiki/Multiple_myeloma 多发性骨髓瘤 10028228 multiple myeloma AE OAE:0006497 This is an AE which is a subtype of acute myeloid leukemia (AML), a cancer of the white blood cells. QY, JX, HY http://en.volupedia.org/wiki/Acute_promyelocytic_leukemia 急性早幼粒细胞白血病 10001019 acute promyelocytic leukaemia AE OAE:0006498 This is an AE which is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood. QY, JX, HY http://en.volupedia.org/wiki/Hematopoietic_stem_cell_transplantation 骨髓移植 10051410 bone marrow harvest AE OAE:0006499 This is an AE which is an uncommon and self-limited syndrome characterized by extremity pain of unknown etiology. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27587374/ 骨髓水肿 10051763 bone marrow edema AE OAE:0006500 This is an AE which is a type of leukemia affecting myeloid tissue. QY, JX, HY http://en.volupedia.org/wiki/Myeloid_leukemia 髓样白血病 10028549 myeloid leukaemia AE OAE:0006501 This is an AE which is a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. QY, JX, HY http://en.volupedia.org/wiki/Myeloproliferative_neoplasm 骨髓增殖性肿瘤 10077465 myeloproliferative neoplasm AE OAE:0006502 This is an AE which occurs in children who are otherwise healthy because of rich blood supply to the growing bones. QY, JX, HY http://en.volupedia.org/wiki/Osteomyelitis 急性骨髓炎 10031253 osteomyelitis acute AE OAE:0006503 This is an AE which is an infection of bone caused by bacterial infection, but rarely can be a fungal infection. QY, JX, HY http://en.volupedia.org/wiki/Osteomyelitis 细菌骨髓炎 10065237 osteomyelitis bacterial AE OAE:0006504 This is an AE which is a form of upper extremity deep vein thrombosis (DVT), a medical condition in which blood clots form in the deep veins of the arms. QY, JX, HY http://en.volupedia.org/wiki/Paget%E2%80%93Schroetter_disease 佩-施二氏综合征 10050216 paget-schroetter syndrome AE OAE:0006505 This is an AE which is a medical condition that may occur as a long-term complication of deep vein thrombosis (DVT). QY, JX, HY http://en.volupedia.org/wiki/Post-thrombotic_syndrome 后血栓性综合症 10048591 post thrombotic syndrome AE OAE:0006506 This is an AE which is the breakdown (lysis) of blood clots formed in blood vessels, using medication. QY, JX, HY http://en.volupedia.org/wiki/Thrombolysis 溶栓 10043568 thrombolysis AE OAE:0006507 This is an AE which is a thrombosis and inflammation of superficial veins which presents as a painful induration with erythema, often in a linear or branching configuration forming cords. QY, JX, HY http://en.volupedia.org/wiki/Superficial_thrombophlebitis 血栓性浅静脉炎 10043595 thrombophlebitis superficial AE OAE:0006508 This is an AE which occurs more frequently than thrombosis of one or both umbilical arteries, but poor fetal outcome is more likely with arterial thrombosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3041394/ 脐带血栓 10071652 umbilical cord thrombosis AE OAE:0006509 This is an AE which is a rare surgical complication which may cause serious leg damage and may occasionally be fatal. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30219778/ 髂动脉血栓形成 10021340 iliac artery thrombosis AE OAE:0006510 This is an AE which is a group of leukemias affecting circulating lymphocytes, a type of white blood cell. QY, JX, HY http://en.volupedia.org/wiki/Lymphoid_leukemia 淋巴细胞性白血病 10025270 lymphocytic leukaemia AE OAE:0006511 This is an AE which is a form of lymphoid leukemia and lymphoma in which too many T-cell lymphoblasts (immature white blood cells) are found in the blood, bone marrow, and tissues, particularly mediastinal lymph nodes. QY, JX, HY http://en.volupedia.org/wiki/T-lymphoblastic_leukemia/lymphoma 前体T淋巴细胞淋巴瘤/白血病 10036543 precursor t-lymphoblastic lymphoma/leukaemia AE OAE:0006512 This is an AE which is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin involvement. QY, JX, HY http://en.volupedia.org/wiki/T-cell_prolymphocytic_leukemia T细胞幼淋巴细胞白血病 10042985 t-cell prolymphocytic leukaemia AE OAE:0006513 This is an AE which is an aggressive malignancy that has historically been associated with a very poor prognosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31738819/ T细胞型急性白血病 10042987 t-cell type acute leukaemia AE OAE:0006514 This is an AE which is an increase of abnormal white blood cells and differs from acute leukemia, and is categorized as myelogenous or lymphocytic. QY, JX, HY http://en.volupedia.org/wiki/Chronic_leukemia 慢性白血病 10008943 chronic leukaemia AE OAE:0006515 This is an AE which is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). QY, JX, HY http://en.volupedia.org/wiki/Chronic_lymphocytic_leukemia 慢性淋巴细胞白血病 10008958 chronic lymphocytic leukaemia AE OAE:0006516 This is an AE which is a serious secondary disease that alters the events in the clotting cascade. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30567917/ 新生儿弥散性血管内凝血 10013443 disseminated intravascular coagulation in newborn AE OAE:0006517 This is an AE which is a common feature of several tumors to the extent that individuals with coagulation defects often present with occult visceral cancers. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27876232/ 凝血异常 10020608 hypercoagulation AE OAE:0006518 This is an AE which is a metabolic disorder that occurs in cattle when energy demand exceeds energy intake and results in a negative energy balance. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31896507/ 丙酮血症 10000410 acetonaemia AE OAE:0006519 This is an AE which is an abnormal protein that forms precipitate only in plasma and can be detected both in healthy persons and patients with autoimmune diseases, cancer and infections. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27789759/ 冷纤维蛋白原血症 10051229 cryofibrinogenaemia AE OAE:0006520 This is an AE which is a medical condition in which the blood contains large amounts of pathological cold sensitive antibodies called cryoglobulins – proteins (mostly immunoglobulins themselves) that become insoluble at reduced temperatures. QY, JX, HY http://en.volupedia.org/wiki/Cryoglobulinemia 冷球蛋白血症 10011474 cryoglobulinaemia AE OAE:0006521 This is an AE which is a medical condition caused by cytomegalovirus where cytomegalovirus enter the bloodstream and hence have access to the rest of the body. QY, JX, HY http://en.volupedia.org/wiki/Viremia 巨细胞病毒病毒血症 10058854 cytomegalovirus viraemia AE OAE:0006522 This is an AE which is a reduction in the number of mature blood cells. QY, JX, HY http://en.volupedia.org/wiki/Cytopenia 血球减少 10066274 cytopenia AE OAE:0006523 This is an AE which is present in the systemic circulation; in septicaemia, whole microbes invade normally sterile parts of the body. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27452161/ 内毒素血症 10067410 endotoxaemia AE OAE:0006524 This is an AE which is severe complications after hematopoietic stem cell transplantation (HSCT). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29949208/ 巴尔病毒血症 10065110 epstein-barr viraemia AE OAE:0006525 This is an AE which is a life-threatening condition caused by fungal that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 真菌败血症 10058872 fungal sepsis AE OAE:0006526 This is an AE which is a rare disorder that occurs in adults in whom hypogammaglobulinemia, deficient cell-mediated immunity, and thymoma (usually benign) may develop almost simultaneously. QY, JX, HY http://en.volupedia.org/wiki/Thymoma_with_immunodeficiency 胸腺瘤合并无丙种球蛋白血症 10079838 good syndrome AE OAE:0006527 This is an AE which is a type of neonatal infection caused by group b streptococcusand specifically refers to the presence in a newborn baby of a bacterial blood stream infection (BSI) (such as meningitis, pneumonia, pyelonephritis, or gastroenteritis) in the setting of fever. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_sepsis b组新生儿链球菌败血症 10053588 group b streptococcus neonatal sepsis AE OAE:0006528 This is an AE which is an acquired clonal disorder of the hemopoietic stem cell that is characterized by chronic intravascular hemolysis, as indicated by the grossly elevated levels of LDH in almost all patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15811985/ 血红蛋白血症 10018901 hemoglobinaemia AE OAE:0006529 This is an AE which is an uncommon hematologic disorder seen more often in children than in adults. QY, JX, HY http://en.volupedia.org/wiki/Hemophagocytic_lymphohistiocytosis 噬血细胞性淋巴组织细胞增多症 10071583 haemophagocytic lymphohistiocytosis AE OAE:0006530 This is an AE which is a genus of Gram-negative, pleomorphic, coccobacilli bacteria belonging to the family Pasteurellaceae. QY, JX, HY http://en.volupedia.org/wiki/Haemophilus 嗜血杆菌感染 10061190 haemophilus infection AE OAE:0006531 This is an AE which is the coughing up of blood or blood-stained mucus from the bronchi, larynx, trachea, or lungs. QY, JX, HY http://en.volupedia.org/wiki/Hemoptysis 咯血 10018964 hemoptysis AE OAE:0006532 This is an AE which is an inherited disease of vitamin B12 metabolism with a wide spectrum of clinical manifestations. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32443968/ 同型半胱氨酸血症 10048707 homocystinaemia AE OAE:0006533 This is an AE which is a metabolic disturbance characterised by an excess of ammonia in the blood. QY, JX, HY http://en.volupedia.org/wiki/Hyperammonemia 高氨血症 10020575 hyperammonaemia AE OAE:0006534 This is an AE which may also be due to an increase in the amylase content within the lung tissues; possibly the carcinoma provokes an inflammatory response resulting in release of amylase into the circulation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24194585/ 高淀粉酶血症 10062770 hyperamylasaemia AE OAE:0006535 This is an AE which is abnormally elevated levels of any or all lipids (fats, cholesterol, or triglycerides) or lipoproteins in the blood. QY, JX, HY http://en.volupedia.org/wiki/Hyperlipidemia 其他高脂血症 10020606 hyperchylomicronaemia AE OAE:0006536 This is an AE which would arise as a consequence of increased cysteine synthesis associated with the provision of protective substances (glutathione and/or taurine). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/14520508/ 高肌酸血症 10675350 hypercreatinaemia AE OAE:0006537 This is an AE which is a well-known feature of liver and testicular toxicity and we have recently proposed that hepatotoxin-induced hypercreatinuria would arise as a consequence of increased cysteine synthesis associated with the provision of protective substances (glutathione and/or taurine). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/14520508/ 高肌酐血症 10062747 hypercreatininaemia AE OAE:0006538 This is an AE which is a universal intracellular protein that stores iron and releases it in a controlled fashion. QY, JX, HY http://en.volupedia.org/wiki/Ferritin#Excess 高铁血症 10075046 hyperferritinaemia AE OAE:0006539 This is an AE which results in vascular remodelling, and fibrinogen (Fg) and amyloid β (Aβ) complex formation is a hallmark of Alzheimer's disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27121987/ 高纤维蛋白原血症 10051124 hyperfibrinogenaemia AE OAE:0006540 This is an AE which is considered important prognostic markers, with the monitoring of lactate blood levels being very important in critical patients, like those admitted to the intensive care units. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23704442/ 高乳酸血症 10020660 hyperlactacidaemia AE OAE:0006541 This is an AE which may cause subcutaneous fat necrosis progression, with subsequent sterile 'abscess' formation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7670790/ 高脂肪血症 10067725 hyperlipasaemia AE OAE:0006542 This is an AE which is abnormally elevated levels of any or all lipids (fats, cholesterol, or triglycerides) or lipoproteins in the blood. QY, JX, HY http://en.volupedia.org/wiki/Hyperlipidemia 高脂血症 10062060 hyperlipidaemia AE OAE:0006543 this is an AE which is an electrolyte disorder in which there is an elevated level of phosphate in the blood. QY, JX, HY http://en.volupedia.org/wiki/Hyperphosphatemia 高磷酸血症 10020711 hyperphosphataemia AE OAE:0006544 This is an AE which is closely associated with systemic expression and adverse outcomes (lymphoma development and death) in patients with primary SS. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15381790/ 低补体血症 10020974 hypocomplementaemia AE OAE:0006545 This is an AE which is characterized by an acute hemorrhagic state brought about by inability of the blood to clot, with massive hemorrhages into the skin producing blackish, purplish swellings and sloughing. QY, JX, HY http://en.volupedia.org/wiki/Fibrinolysis_syndrome 低纤维蛋白血症 10051125 hypofibrinogenaemia AE OAE:0006546 This is an AE which is a problem with the immune system in which not enough gamma globulins are produced in the blood (thus hypo- + gamma + globulin + -emia). QY, JX, HY http://en.volupedia.org/wiki/Hypogammaglobulinemia 低丙种球蛋白血症 10020983 hypogammaglobulinaemia AE OAE:0006547 This is an AE which is associated with chronic or severe illnesses, and limited nutritional intake, but similar medical problems were absent in the acromegalic patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/955558/ 低球蛋白血症 10058002 hypoglobulinaemia AE OAE:0006548 This is an AE which is the medical condition where there is too much fluid in the blood. QY, JX, HY http://en.volupedia.org/wiki/Hypervolemia 高容量血症 10020919 hypervolaemia AE OAE:0006549 This is an AE which is a rare condition and it can be caused by a genetic alteration or secondary factors. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32430154/ 低脂血症 10021024 hypolipidaemia AE OAE:0006550 This is an AE which is a condition where there is an abnormally low level of protein in the blood. QY, JX, HY http://en.volupedia.org/wiki/Hypoproteinemia 低蛋白血症 10021083 hypoproteinaemia AE OAE:0006551 This is an AE which may be the result of a low-grade, chronic inflammatory process with an abnormal excessive production of myelosuppressive cytokines in a study conducted in the island of Crete. QY, JX, HY http://en.volupedia.org/wiki/Neutropenia?wprov=srpw1_0#Pathophysiology 特发性嗜中性白血球减少症 10051645 idiopathic neutropenia AE OAE:0006552 This is an AE which is a biological role of human leucocyte lactotransferrin. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2390069/ 低铁血症 10053782 hyposideraemia AE OAE:0006553 This is an AE which is a life-threatening condition caused by klebsiella bacteria that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 克雷伯氏菌败血症 10054160 klebsiella sepsis AE OAE:0006554 This is an AE which is a complex of little prolactin and an immunoglobulin G antibody and the weight of the complex is more than 150 kDa. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20712249/ 巨泌乳素血症 10078846 macroprolactinaemia AE OAE:0006555 This is an AE which is infections present in the blood caused by pneumococcal. QY, JX, HY http://en.volupedia.org/wiki/Bloodstream_infections 肺炎球菌菌血症 10058859 pneumococcal bacteremia AE OAE:0006556 This is an AE which is a life-threatening condition caused by stenotrophomonas that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 狭养单胞菌败血症 10054137 stenotrophomonas sepsis AE OAE:0006557 This is an AE which caused by the Streptococcus pneumoniae bacteria, has been reported to cause autosplenectomy but is a very rare and poorly understood complication of the infection. QY, JX, HY http://en.volupedia.org/wiki/Autosplenectomy#Pneumococcal_sepsis 肺炎球菌败血症 10054047 pneumococcal sepsis AE OAE:0006558 This is an AE which is infections present in the blood caused by pseudomonal. QY, JX, HY http://en.volupedia.org/wiki/Bloodstream_infections 假单胞菌菌血症 10058923 pseudomonal bacteremia AE OAE:0006559 This is an AE which is a life-threatening condition caused by pseudomonal that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 败血症假单胞菌 10058877 pseudomonal sepsis AE OAE:0006560 This is an AE which is a common, and frequently fatal, cause of bacteraemia in children and HIVinfected adults in sub-Saharan Africa. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29523850/ 沙门氏菌菌血症 10058924 salmonella bacteremia AE OAE:0006561 This is an AE which is a rare cause of neonatal sepsis and can present with life threating complications, thus leading to increase in neonatal mortality and morbidity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31043097/ 沙门氏菌败血症 10058878 salmonella sepsis AE OAE:0006562 This is an AE which is a type of neonatal infection and specifically refers to the presence in a newborn baby of a bacterial blood stream infection (BSI) (such as meningitis, pneumonia, pyelonephritis, or gastroenteritis) in the setting of fever. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_sepsis 新生儿败血症 10040049 sepsis neonatal AE OAE:0006563 This is an AE which including fever, leukocytosis, elevated cardiac output, and reduced systemic vascular resistance has been associated with severe infection (i.e., sepsis). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10695741/ 败血症综合征 10053879 sepsis syndrome AE OAE:0006564 This is an AE which is frequent in neutropenic patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7783538/ 链球菌菌血症 10051018 streptococcal bacteremia AE OAE:0006565 This is an AE which is a form of hypogammaglobulinemia appearing after birth, leading to a reduction in the level of IgG, and also sometimes IgA and IgM. QY, JX, HY http://en.volupedia.org/wiki/Transient_hypogammaglobulinemia_of_infancy 婴儿暂时性低丙种球蛋白血症 10044388 transient hypogammaglobulinaemia of infancy AE OAE:0006566 This is an AE which refers to most common presenting symptoms or signs were of skin rash, cellulitis or abscess. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30287447/ 链球菌败血症 10048960 streptococcal sepsis AE OAE:0006567 This is an AE which is an error of metabolism, usually inborn, in which the body cannot effectively break down the amino acid tyrosine. QY, JX, HY http://en.volupedia.org/wiki/Tyrosinemia 酪氨酸血症 10063443 tyrosinaemia AE OAE:0006568 This is an AE which is a medical condition where viruses enter the bloodstream and hence have access to the rest of the body and is similar to bacteremia, a condition where bacteria enter the bloodstream. QY, JX, HY http://en.volupedia.org/wiki/Viremia 病毒血症 10058874 viraemia AE OAE:0006569 This is an AE which is caused by many viruses and is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 病毒性败血症 10071362 viral sepsis AE OAE:0006570 This is an AE which is a type of cancer affecting two types of B cells: lymphoplasmacytoid cells and plasma cells. QY, JX, HY http://en.volupedia.org/wiki/Waldenstr%C3%B6m%27s_macroglobulinemia 瓦尔登斯特伦巨球蛋白血症 10047801 waldenstrom's macroglobulinaemia AE OAE:0006571 This is an AE which is a life-threatening condition occued on post procedural that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 手术后败血症 10066593 post procedural sepsis AE OAE:0006572 This is an AE which is a rare malignancy derived from plasmacyoid dendritic cells . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30350260/ 母细胞浆细胞样树突状细胞瘤 10075460 blastic plasmacytoid dendritic cell neoplasia AE OAE:0006573 QY, JX, HY 幼淋巴细胞白血病 10036888 prolymphocytic leukaemia AE OAE:0006574 QY, JX, HY B前体型急性白血病 10003890 b precursor type acute leukaemia AE OAE:0006575 QY, JX, HY 冷球蛋白血症 10062714 dysglobulinaemia AE OAE:0006576 QY, JX, HY 低钠血症 10077515 hyponatriuria AE OAE:0006577 QY, JX, HY 黑色素血症，血色沉着病 10054978 melanemia AE OAE:0006578 This is an AE which is a rare complication after endoscopic retrograde cholangiopancreatography (ERCP). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27158211/ 肝血肿 10019676 hepatic hematoma AE OAE:0006579 This is an AE which is a yellowish or greenish pigmentation of the skin and whites of the eyes due to high bilirubin levels and is acholuric. QY, JX, HY http://en.volupedia.org/wiki/Jaundice 无胆色素尿性黄疸 10023128 jaundice acholuric AE OAE:0006580 This is an AE which is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver on the perinatal . QY, JX, HY http://en.volupedia.org/wiki/Hepatitis_B 围产期乙型肝炎病毒感染 10075233 perinatal hbv infection AE OAE:0006581 This is an AE which is the process of using one's hands to check the body such as liver, especially while perceiving/diagnosing a disease or illness. QY, JX, HY http://en.volupedia.org/wiki/Palpation 肝脏可触及 10075895 liver palpable AE OAE:0006582 This is an AE which management aims to control viral replication, which is correlated with progression of disease. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis#Hepatitis_B_4 慢性乙型肝炎 10008910 chronic hepatitis b AE OAE:0006583 This is an AE which is believed to be an autosomal dominant condition in which multiple lipomas are present on the body such as pancreas lipomatosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/?term=pancreas+lipomatosis 胰腺脂肪瘤 10050831 pancreas lipomatosis AE OAE:0006585 This is an AE which arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. QY, JX, HY http://en.volupedia.org/wiki/Pancreatic_cancer 胰脏癌 10033609 pancreatic carcinoma AE OAE:0006586 This is an AE which is a fluid filled sac within the pancreas. QY, JX, HY http://en.volupedia.org/wiki/Pancreatic_cyst 胰腺囊肿 10033615 pancreatic cyst AE OAE:0006587 This is an AE which occurs in patients of every age. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11977935/ 胰腺疾病 10033616 pancreatic disorder AE OAE:0006588 This is an AE which is reported to induce pancreatic fibrosis and this type of pancreatic change was classified as a special type of CP, obstructive CP. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/13678692/ 胰管梗阻 10052765 pancreatic duct obstruction AE OAE:0006589 This is an AE which is some form of trauma sustained by the pancreas. QY, JX, HY http://en.volupedia.org/wiki/Pancreatic_injury 胰腺损伤 10033627 pancreatic injury AE OAE:0006590 This is an AE which is the inability to properly digest food due to a lack of digestive enzymes made by the pancreas. QY, JX, HY http://en.volupedia.org/wiki/Exocrine_pancreatic_insufficiency 胰腺功能不全 10033628 pancreatic insufficiency AE OAE:0006591 This is an AE which is a type of abnormal and excessive growth of pancreatic tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 胰腺肿瘤 10061902 pancreatic neoplasm AE OAE:0006592 This is an AE which is a circumscribed collection of fluid rich in pancreatic enzymes, blood, and necrotic tissue, typically located in the lesser sac of the abdomen. QY, JX, HY http://en.volupedia.org/wiki/Pancreatic_pseudocyst 胰腺假性囊肿 10033635 pancreatic pseudocyst AE OAE:0006593 This is an AE which describes a disease ranging from infiltration of fat in the pancreas to pancreatic inflammation, and development of pancreatic fibrosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32490903/ 胰腺脂肪变性 10072787 pancreatic steatosis AE OAE:0006594 This is an AE which is a long-standing inflammation of the pancreas that alters the organ's normal structure and functions. QY, JX, HY http://en.volupedia.org/wiki/Chronic_pancreatitis 慢性胰腺炎 10033649 pancreatitis chronic AE OAE:0006595 This is an AE which is a condition with mumps characterized by inflammation of the pancreas. QY, JX, HY http://en.volupedia.org/wiki/Pancreatitis 胰腺炎腮腺炎 10033653 pancreatitis mumps AE OAE:0006596 This is an AE which is the most dreadful evolution associated to a poor prognosis: mortality is approximately 15% and up to 30-39% in case of infected necrosis, which is the major cause of death. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26708848/ 坏死性胰腺炎 10033654 pancreatitis necrotising AE OAE:0006597 This is an AE which is a condition caused by viral characterized by inflammation of the pancreas. QY, JX, HY http://en.volupedia.org/wiki/Pancreatitis 病毒性胰腺炎 10065192 pancreatitis viral AE OAE:0006599 This is an AE which is a type of damage to or disease of the liver. QY, JX, HY http://en.volupedia.org/wiki/Liver_disease 肝脏疾病 10024670 liver disorder AE OAE:0006600 This is an AE which is some form of trauma sustained to the liver. QY, JX, HY http://en.volupedia.org/wiki/Liver_injury 肝损伤 10067125 liver injury AE OAE:0006601 This is an AE which is the process of using one's hands to check theliver palpable subcostal, especially while perceiving/diagnosing a disease or illness. QY, JX, HY http://en.volupedia.org/wiki/Palpation 肝脏可触及的肋下 10024704 liver palpable subcostal AE OAE:0006602 This is an AE which refers pain or discomfort when an affected liver is touched. QY, JX, HY http://en.volupedia.org/wiki/Tenderness 肝压痛 10024712 liver tenderness AE OAE:0006603 This is an AE which occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue such as liver transplant rejection. QY, JX, HY http://en.volupedia.org/wiki/Transplant_rejection 肝移植排斥反应 10024715 liver transplant rejection AE OAE:0006604 This is an AE which is the most common reason for abdominal surgery in the elderly population. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/8165472/ 肝胆管的疾病 10062000 hepatobiliary disease AE OAE:0006605 This is an AE which is a malignant liver cancer occurring in infants and children and composed of tissue resembling fetal liver cells, mature liver cells, or bile duct cells. QY, JX, HY http://en.volupedia.org/wiki/Hepatoblastoma 肝母细胞癌 10062001 hepatoblastoma AE OAE:0006606 This is an AE which is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. QY, JX, HY http://en.volupedia.org/wiki/Hepatocellular_carcinoma 肝细胞癌 10073071 hepatocellular carcinoma AE OAE:0006607 This is an AE which is damage to the hepatocellular caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 肝细胞损伤 10019837 hepatocellular injury AE OAE:0006608 This is an AE which is a syndrome of shortness of breath and hypoxemia (low oxygen levels in the blood of the arteries) caused by vasodilation (broadening of the blood vessels) in the lungs of patients with liver disease. QY, JX, HY http://en.volupedia.org/wiki/Hepatopulmonary_syndrome 肝肺综合征 10052274 hepatopulmonary syndrome AE OAE:0006609 This is an AE which is a rare form of lymphoma that is generally incurable, except in the case of an allogeneic stem cell transplant. QY, JX, HY http://en.volupedia.org/wiki/Hepatosplenic_T-cell_lymphoma 肝脾t细胞淋巴瘤 10066957 hepatosplenic t-cell lymphoma AE OAE:0006610 This is an AE which is the abnormal exit of tissue or an organ, such as the bowel, through the wall of the cavity in which it normally resides. QY, JX, HY http://en.volupedia.org/wiki/Hernia 疝 10019909 hernia AE OAE:0006611 This is an AE which is the abnormal exit of tissue or an organ, such as the bowel, through the wall of the cavity in which it normally resides and feel it pain. QY, JX, HY http://en.volupedia.org/wiki/Hernia 疝痛 10049077 hernia pain AE OAE:0006612 This is an AE which is a rare, benign liver tumor and most commonly occurs in people with elevated systemic levels of estrogen, classically in women taking estrogen-containing oral contraceptive medication. QY, JX, HY http://en.volupedia.org/wiki/Hepatocellular_adenoma 肝腺瘤 10019629 hepatic adenoma AE OAE:0006613 This is an AE which is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. QY, JX, HY http://en.volupedia.org/wiki/Hepatocellular_carcinoma 肝癌症 10073069 hepatic cancer AE OAE:0006614 This is an AE which is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis and is metastatic. QY, JX, HY http://en.volupedia.org/wiki/Hepatocellular_carcinoma 肝癌转移 10055110 hepatic cancer metastatic AE OAE:0006615 This is an AE which refers abnormal accumulation of fluid in the hepatic interstitium, manifesting as swelling. QY, JX, HY http://en.volupedia.org/wiki/Congestion 肝充血 10019645 hepatic congestion AE OAE:0006616 This is an AE which is common benign liver lesions that usually have no malignant capability and is generally asymptomatic and are often found incidentally by abdominal imaging procedures. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30145861/ 肝囊肿 10019646 hepatic cyst AE OAE:0006617 This is an AE which refers to the passage and lodging of an embolus within the bloodstream on the hepatic. QY, JX, HY http://en.volupedia.org/wiki/Embolization 肝栓塞 10056203 hepatic embolisation AE OAE:0006618 This is an AE which is the impaired liver function caused by the formation of scar tissue known as fibrosis due to damage caused by liver disease. QY, JX, HY http://en.volupedia.org/wiki/Cirrhosis 肝纤维化 10019668 hepatic fibrosis AE OAE:0006619 This is an AE which is the increase in the volume of hepatic tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 肝肥大 10076254 hepatic hypertrophy AE OAE:0006620 This is an AE which is the invasion of an organism's body tissues by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce such as hepatic infection. QY, JX, HY http://en.volupedia.org/wiki/Infection 肝病毒感染 10056522 hepatic infection AE OAE:0006621 This is an AE which is disease caused by fungi on the hepatic. QY, JX, HY http://en.volupedia.org/wiki/Fungal_infection 肝真菌感染 10065217 hepatic infection fungal AE OAE:0006622 This is an AE which occurs in the setting of chronic liver inflammation, and is most closely linked to chronic viral hepatitis infection (hepatitis B or C) or exposure to toxins such as alcohol, aflatoxin, or pyrrolizidine alkaloids and is malignant. QY, JX, HY http://en.volupedia.org/wiki/Hepatocellular_carcinoma 恶性肝肿瘤 10019697 hepatic neoplasm malignant AE OAE:0006623 This is an AE which is a species of virus in the order Picornavirales, family Picornaviridae, genus Hepatovirus. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis_A#Virology 甲肝病毒 10052551 hepatitis a virus AE OAE:0006624 This is an AE which can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis 急性肝炎 10019727 hepatitis acute AE OAE:0006625 This is an AE which is a partially double-stranded DNA virus, a species of the genus Orthohepadnavirus and a member of the Hepadnaviridae family of viruses. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis_B_virus 乙型病毒性肝炎 10052552 hepatitis b virus AE OAE:0006626 This is an AE which is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis_C_virus 丙型病毒性肝炎 10019751 hepatitis c virus AE OAE:0006627 This is an AE which is a condition where bile cannot flow from the liver to the duodenum. QY, JX, HY http://en.volupedia.org/wiki/Cholestasis 淤胆型肝炎 10019754 hepatitis cholestatic AE OAE:0006628 This is an AE which is often asymptomatic early in its course and is detected only by liver laboratory studies for screening purposes or to evaluate non-specific symptoms. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis#Chronic_hepatitis 慢性活动型肝炎 10019755 hepatitis chronic active AE OAE:0006629 This is an AE which is a type of viral hepatitis caused by the hepatitis delta virus (HDV). QY, JX, HY http://en.volupedia.org/wiki/Hepatitis_D d型肝炎 10019762 hepatitis d AE OAE:0006630 This is an AE which is inflammation of the liver caused by infection with the hepatitis E virus (HEV);it is a type of viral hepatitis. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis_E e型肝炎 10019768 hepatitis e AE OAE:0006631 This is an AE which is a rare and life-threatening complication of acute hepatitis that can occur in cases of hepatitis B, D, and E, in addition to drug-induced and autoimmune hepatitis. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis#Fulminant_hepatitis 暴发性肝炎 10019772 hepatitis fulminant AE OAE:0006632 This is an AE which is inflammation of the liver tissue and is infective. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis 传染性肝炎 10019780 hepatitis infectious AE OAE:0006633 This is an AE which is an infection usually caused by the Epstein Barr virus (EBV) on the hepatitis. QY, JX, HY http://en.volupedia.org/wiki/Infectious_mononucleosis 肝炎传染性单核细胞增多 10019781 hepatitis infectious mononucleosis AE OAE:0006634 This is an AE which develops in approximately 7% of blood recipients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/6987932/ 输血后肝炎 10019791 hepatitis post transfusion AE OAE:0006635 This is an AE which implies chemical-driven liver damage. QY, JX, HY 毒性肝炎 10019795 hepatitis toxic AE OAE:0006636 This is an AE which is the appearance of severe complications rapidly after the first signs (such as jaundice) of liver disease, and indicates that the liver has sustained severe damage (loss of function of 80–90% of liver cells). QY, JX, HY http://en.volupedia.org/wiki/Acute_liver_failure 急性肝衰竭 10000804 acute hepatic failure AE OAE:0006637 This is an AE whichis defined as the discrete onset of symptoms, the presence of jaundice or elevated serum alanine transaminase levels, and test results showing hepatitis B surface antigen and hepatitis B core antigen. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30811163/ 急性乙型肝炎 10059193 acute hepatitis b AE OAE:0006638 This is an AE which refers infection is typically defined as the initial 6 months following exposure to the virus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24477864/ 急性丙型肝炎 10065051 acute hepatitis c AE OAE:0006639 This is an AE which presents with tiny very itchy wheals and small bumps on a reddish background. QY, JX, HY http://en.volupedia.org/wiki/Cholinergic_urticaria 荨麻疹胆碱能 10046740 urticaria cholinergic AE OAE:0006640 This is an AE which is a group of substances that blocks the action of the neurotransmitter called acetylcholine (ACh) at synapses in the central and peripheral nervous system. QY, JX, HY http://en.volupedia.org/wiki/Anticholinergic#Effects 抗胆碱能综合症 10002757 anticholinergic syndrome AE OAE:0006641 This is an AE which is a yellowish or greenish pigmentation of the skin and whites of the eyes due to high bilirubin levels. QY, JX, HY http://en.volupedia.org/wiki/Jaundice 高胆红素血症 10020578 hyperbilirubinaemia AE OAE:0006642 This is an AE which is the presence of high levels of cholesterol in the blood. QY, JX, HY http://en.volupedia.org/wiki/Hypercholesterolemia 血胆固醇过多 10020603 hypercholesterolaemia AE OAE:0006643 This is an AE which is due to significant damage to liver function → hepatic cell death and necrosis occur → impaired bilirubin transport across hepatocytes. QY, JX, HY http://en.volupedia.org/wiki/Jaundice 黄疸肝细胞 10023136 jaundice hepatocellular AE OAE:0006644 This is an AE which can then lead to complications such as cirrhosis and hepatocellular carcinoma. QY, JX, HY http://en.volupedia.org/wiki/Non-alcoholic_fatty_liver_disease 非酒精性脂肪性肝炎 10053219 non-alcoholic steatohepatitis AE OAE:0006645 This is an AE which is an uncommon vascular condition characterised by multiple, randomly distributed, blood-filled cavities throughout the liver. QY, JX, HY http://en.volupedia.org/wiki/Peliosis_hepatis 肝紫癜症 10034229 peliosis hepatis AE OAE:0006646 This is an AE which is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. QY, JX, HY http://en.volupedia.org/wiki/Steatohepatitis 脂肪性肝炎 10076331 steatohepatitis AE OAE:0006647 This is an AE which is some form of trauma sustained to the liver. QY, JX, HY http://en.volupedia.org/wiki/Liver_injury 外伤性肝损伤 10067979 traumatic liver injury AE OAE:0006648 This is an AE which may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer. QY, JX, HY http://en.volupedia.org/wiki/Hepatitis#Chronic 慢性肝炎 10008909 chronic hepatitis AE OAE:0006649 This is an AE which is one of the leading causes of liver cirrhosis and hepatocellular carcinoma and has become a curable disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27788732/ 慢性丙型肝炎 10008912 chronic hepatitis c AE OAE:0006650 This is an AE which is induced by immunocompetent alloreactive T lymphocytes in the donor graft responding to polymorphic and non-polymorphic host antigens and causing inflammation in primarily the liver. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33054103/ 急性肝移植抗宿主病 10066263 acute graft versus host disease in liver AE OAE:0006651 This is an AE which represents the terminal stage of alcoholic liver disease (ALD) and one of the main causes of death among alcohol abusers. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19389182/ 酒精性肝硬化 10009208 cirrhosis alcoholic AE OAE:0006652 This is an AE which is an altered level of consciousness as a result of liver failure. QY, JX, HY http://en.volupedia.org/wiki/Hepatic_encephalopathy 肝昏迷 10010075 coma hepatic AE OAE:0006653 This is an AE which is a cause of acute and chronic liver disease caused specifically by medications. QY, JX, HY http://en.volupedia.org/wiki/Hepatotoxicity 药物性肝损害 10072268 drug-induced liver injury AE OAE:0006654 This is an AE which is an aggregation on the liver of macrophages that forms in response to chronic inflammation. QY, JX, HY http://en.volupedia.org/wiki/Granuloma 肉芽肿性肝病 10018704 granulomatous liver disease AE OAE:0006655 This is an AE which is generally asymptomatic or rarely can lead to severe complications in immunocompetent hosts. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28081328/ 巨细胞病毒肝炎 10011830 cytomegalovirus hepatitis AE OAE:0006656 This is an AE which is the most common primary malignancy of the pancreas. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29038855/ 胰腺导管腺癌 10073364 ductal adenocarcinoma of pancreas AE OAE:0006657 This is an AE which is a condition with oedematous characterized by inflammation of the pancreas. QY, JX, HY http://en.volupedia.org/wiki/Pancreatitis 水肿性胰腺炎 10052400 edematous pancreatitis AE OAE:0006658 This is an AE which is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and pancreatic. QY, JX, HY http://en.volupedia.org/wiki/Cystic_fibrosis 囊性纤维化胰腺 10011766 cystic fibrosis pancreatic AE OAE:0006659 This is an AE which is a type of cancerous tumor that can occur in several parts of the body. QY, JX, HY http://en.volupedia.org/wiki/Adenocarcinoma 腺癌 10001141 adenocarcinoma AE OAE:0006660 This is an AE which manifests with several symptoms such as bilateral nasal obstruction, rhinorrhea, cough, snoring, hyponasal speech, hypopnea, and sleep apnea. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20199384/ 腺样体肥大 10001229 adenoidal hypertrophy AE OAE:0006661 This is an AE which is the inflammation of the adenoid tissue usually caused by an infection. QY, JX, HY http://en.volupedia.org/wiki/Adenoiditis 增殖腺炎 10051223 adenoiditis AE OAE:0006662 This is an AE which is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or both. QY, JX, HY http://en.volupedia.org/wiki/Adenoma 腺瘤良性 10001233 adenoma benign AE OAE:0006663 This is an AE which is a protein that in humans is encoded by the APC gene. QY, JX, HY http://en.volupedia.org/wiki/Adenomatous_polyposis_coli 腺瘤息肉病杆菌 10056981 adenomatous polyposis coli AE OAE:0006664 This is an AE which is a metabolic disorder that causes immunodeficiency. QY, JX, HY http://en.volupedia.org/wiki/Adenosine_deaminase_deficiency 腺苷脱氨酶缺乏症 10066367 adenosine deaminase deficiency AE OAE:0006665 This is an AE which is a group of liver disorders in which substances called porphyrins build up in the body, negatively affecting the skin or nervous system. QY, JX, HY http://en.volupedia.org/wiki/Porphyria 卟啉症 10036181 porphyria AE OAE:0006666 This is an AE which describes the presence of multiple cysts scattered throughout normal liver tissue. QY, JX, HY http://en.volupedia.org/wiki/Polycystic_liver_disease 多囊肝病 10048834 polycystic liver disease AE OAE:0006667 This is an AE which is the physiological or medicinal removal of toxic substances from a living organism, including the human body, which is mainly carried out by the liver. QY, JX, HY http://en.volupedia.org/wiki/Detoxification 排毒 10061814 detoxification AE OAE:0006668 QY, JX, HY 胰腺肿大 10055024 pancreatic enlargement AE OAE:0006669 QY, JX, HY 肝脏硬化 10052550 liver induration AE OAE:0006670 QY, JX, HY 肝细胞损伤 10019831 hepatocellular damage AE OAE:0006671 QY, JX, HY 肝部肿块 10057110 hepatic mass AE OAE:0006672 QY, JX, HY 不可切除的恶性肝肿瘤 10019698 hepatic neoplasm malignant non-resectable AE OAE:0006673 QY, JX, HY 获得性肝内导管扩张 10052383 dilatation intrahepatic duct acquired AE OAE:0006674 QY, JX, HY 腺样疾病 10057449 adenoidal disorder AE OAE:0006675 QY, JX, HY 肝肾功能衰竭 10019845 hepatorenal failure AE OAE:0006676 This is an AE which is a kidney-shaped organ of the lymphatic system, and the adaptive immune system and it is palpable. QY, JX, HY http://en.volupedia.org/wiki/Lymph_node 摸到淋巴结 10057470 lymph node palpable AE OAE:0006677 This is an AE whcih is an uncommon disease with a relatively high rate of associated morbidity and mortality. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20060254/ 硬膜外脓肿 10061846 extradural abscess AE OAE:0006678 This is an AE which is a clinical diagnosis made in patients with adverse reactions to two or more structurally unrelated drugs with an underlying immune-mediated mechanism causing the reaction. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24801461/ 多重过敏 10028164 multiple allergies AE OAE:0006679 This is an AE which is a heterogeneous group of lymphomas that derive from the malignant transformation of marginal zone B-cells. QY, JX, HY http://en.volupedia.org/wiki/Marginal_zone_B-cell_lymphoma 结外边缘区b细胞麦芽型淋巴瘤 10061850 extranodal marginal zone b-cell malt type lymphoma AE OAE:0006680 This is an AE which is a rare condition, but is associated with high mortality. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18186551/ 脾切除术后综合征 10075117 postsplenectomy syndrome AE OAE:0006681 This is an AE which is a type of abnormal and excessive growth of lymph node tissue and is benign. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 良性淋巴结肿瘤 10060997 benign lymph node neoplasm AE OAE:0006682 This is an AE which is an extremely rare infection of the central nervous system. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33246901/ 脊髓脓肿 10076050 spinal cord abscess AE OAE:0006683 This is an AE which is an infection usually caused by the Epstein–Barr virus (EBV). QY, JX, HY http://en.volupedia.org/wiki/Infectious_mononucleosis 单核细胞增多综合征 10027924 mononucleosis syndrome AE OAE:0006684 This is an AE which is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27370174/ 淋巴细胞性淋巴瘤 10052178 lymphocytic lymphoma AE OAE:0006685 This is an AE which is now a rare condition, the causes of which in child are more or less different from adult. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28395496/ 扁桃体出血 10057450 tonsillar hemorrhage AE OAE:0006686 This is an AE which is often associated with an acute decline in renal function and may be associated with permanent renal insufficiency. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29493948/ 肾炎过敏性 10029120 nephritis allergic AE OAE:0006687 This is an AE which is the process of using one's hands to check the spleen, especially while perceiving/diagnosing a disease or illness. QY, JX, HY http://en.volupedia.org/wiki/Palpation 脾可触及 10057471 spleen palpable AE OAE:0006688 This is an AE which represent a group of diseases, that develop in susceptible individuals after repeated exposure to usually organic inhalation antigen. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29303282/ 牙槽炎过敏 10001890 alveolitis allergic AE OAE:0006689 This is an AE which is a spectrum of progressively more severe monoclonal gammopathies in which a clone or multiple clones of pre-malignant or malignant plasma cells (sometimes in association with lymphoplasmacytoid cells or B lymphocytes) over-produce and secrete into the blood stream a myeloma protein, i.e. an abnormal monoclonal antibody or portion thereof. QY, JX, HY http://en.volupedia.org/wiki/Plasma_cell_dyscrasias 浆细胞疾病 10062081 plasma cell disorder AE OAE:0006690 This is an AE which is an inflammatory disease of the breast parenchyma, rare in males. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27815454/ 浆细胞乳腺炎 10066170 plasma cell mastitis AE OAE:0006691 This is an AE which is a disorder that negatively alters the body's processing and distribution of macronutrients such as proteins(such as plasma protein), fats, and carbohydrates . QY, JX, HY http://en.volupedia.org/wiki/Metabolic_disorder 血浆蛋白代谢紊乱 10061350 plasma protein metabolism disorder AE OAE:0006692 This is an AE which is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within the axial skeleton. QY, JX, HY http://en.volupedia.org/wiki/Plasmacytoma 浆细胞瘤 10035484 plasmacytoma AE OAE:0006693 This is an AE which is a condition in which there is an unusually large proportion of plasma cells in tissues, exudates, or blood. QY, JX, HY http://en.volupedia.org/wiki/Plasmacytosis 浆细胞增多 10035485 plasmacytosis AE OAE:0006694 This is an AE which is a collection of pus that has built up within the tissue of the lymph node . QY, JX, HY http://en.volupedia.org/wiki/Abscess 淋巴结脓肿 10050167 lymph node abscess AE OAE:0006695 This is an AE which refers to result from prior granulomatous infections, especially tuberculosis and histoplasmosis. Other, less common, causes are sarcoidosis, silicosis, amyloidosis, and calcifications secondary to the treatment of lymphomas (radiation therapy or chemotherapy). QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044648/ 淋巴结钙化 10056284 lymph node calcification AE OAE:0006696 This is an AE which is a pathological wound healing in which connective tissue replaces normal lymph node parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis 淋巴结纤维化 10025180 lymph node fibrosis AE OAE:0006697 This is an AE which is a kidney-shaped organ of the lymphatic system, and the adaptive immune system and some of it is rupture. QY, JX, HY http://en.volupedia.org/wiki/Lymph_node 淋巴结破裂 10082725 lymph node rupture AE OAE:0006698 This is an AE which is an infectious disease on the lymph node usually caused by Mycobacterium tuberculosis (MTB) bacteria. QY, JX, HY http://en.volupedia.org/wiki/Tuberculosis 淋巴结结核病 10025183 lymph node tuberculosis AE OAE:0006699 This is an AE which is a disease caused by bacterial of the lymph nodes, in which they are abnormal in size or consistency. QY, JX, HY http://en.volupedia.org/wiki/Lymphadenopathy 细菌性淋巴腺炎 10065224 lymphadenitis bacterial AE OAE:0006700 This is an AE which is a disease caused by viral of the lymph nodes, in which they are abnormal in size or consistency. QY, JX, HY http://en.volupedia.org/wiki/Lymphadenopathy 病毒性淋巴腺炎 10065209 lymphadenitis viral AE OAE:0006701 This is an AE which is an enlargement of the mediastinal lymph nodes. QY, JX, HY http://en.volupedia.org/wiki/Mediastinal_lymphadenopathy 淋巴结病纵隔 10025205 lymphadenopathy mediastinal AE OAE:0006702 This is an AE which is malformations of the lymphatic system characterized by lesions that are thin-walled cysts; these cysts can be macroscopic, as in a cystic hygroma, or microscopic. QY, JX, HY http://en.volupedia.org/wiki/Lymphangioma 淋巴管瘤 10025219 lymphangioma AE OAE:0006703 This is an AE which can occur in any age group, in symptomatic or asymptomatic patients, and in a single site or at multiple sites. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10907389/ 淋巴管病 10061231 lymphangiopathy AE OAE:0006704 This is an AE which is a class of disorders which directly affect the components of the lymphatic system. QY, JX, HY http://en.volupedia.org/wiki/Lymphatic_disease 淋巴疾病 10052314 lymphatic disorder AE OAE:0006705 This is an AE which is a type of abnormal and excessive growth of lymphatic system tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 淋巴系统肿瘤 10062044 lymphatic system neoplasm AE OAE:0006706 This is an AE which is defined as inflammation of the pituitary gland due to autoimmunity. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_hypophysitis 淋巴细胞下垂体炎 10063685 lymphocytic hypophysitis AE OAE:0006707 This is an AE which is an excessive number of lymphohistiocytes(tissue macrophages), and the term is also often used to refer to a group of rare diseases which share this sign as a characteristic. QY, JX, HY http://en.volupedia.org/wiki/Histiocytosis 淋巴组织细胞增多症 10049646 lymphohistiocytosis AE OAE:0006708 This is an AE which is the rapid proliferation of normal appendix lymphocytic cells that resemble lymph tissue which may occur with bacterial or viral infections. QY, JX, HY http://en.volupedia.org/wiki/Lymphoid_hyperplasia 阑尾淋巴样增生 10025298 lymphoid hyperplasia of appendix AE OAE:0006709 This is an AE which is the rapid proliferation of normal lymphocytic cells that resemble lymph tissue which may occur with bacterial or viral infections. QY, JX, HY http://en.volupedia.org/wiki/Lymphoid_hyperplasia 淋巴组织增生 10051808 lymphoid tissue hyperplasia AE OAE:0006710 This is an AE which is a rare skin disorder and can appear very similar to anaplastic large cell lymphoma. QY, JX, HY http://en.volupedia.org/wiki/Lymphomatoid_papulosis 淋巴瘤样丘疹病 10056670 lymphomatoid papulosis AE OAE:0006711 This is an AE which is a condition seen in some cases of AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse. QY, JX, HY http://en.volupedia.org/wiki/Immune_reconstitution_inflammatory_syndrome 免疫重建综合症 10054014 immune reconstitution syndrome AE OAE:0006712 This is an AE which is a condition arising from an abnormal immune response to a functioning body part. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_disease 免疫系统紊乱 10021425 immune system disorder AE OAE:0006713 This is an AE which is a state of unresponsiveness of the immune system to substances or tissue that have the capacity to elicit an immune response in a given organism. QY, JX, HY http://en.volupedia.org/wiki/Immune_tolerance 免疫耐受诱导 10070581 immune tolerance induction AE OAE:0006714 This is an AE which is immune-mediated inflammation or swelling of the muscles. QY, JX, HY http://en.volupedia.org/wiki/Myositis 免疫介导性肌炎 10083073 immune-mediated myositis AE OAE:0006715 This is an AE which is a type of autoimmune myopathy characterized by relatively severe proximal weakness, myofiber necrosis with minimal inflammatory cell infiltrate on muscle biopsy, and infrequent extra-muscular involvement. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29582188/ 免疫介导性坏死性肌病 10072155 immune-mediated necrotising myopathy AE OAE:0006716 This is an AE which describes general immune-mediated inflammation of lung tissue. QY, JX, HY http://en.volupedia.org/wiki/Pneumonitis 免疫介导性肺炎 10082452 immune-mediated pneumonitis AE OAE:0006717 This is an AE which is an immune disorder characterized by recurrent infections and low antibody levels, specifically in immunoglobulin (Ig) types IgG, IgM and IgA. QY, JX, HY http://en.volupedia.org/wiki/Common_variable_immunodeficiency 普通变化型免疫缺陷病 10021449 immunodeficiency common variable AE OAE:0006718 This is an AE which is a rare, benign and self-limited disease, affecting mainly young women and presenting with localised lymphadenopathy, fever and leucopenia in the majority of the reported cases. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011493/ 组织细胞的坏死性淋巴结炎 10069070 histiocytic necrotising lymphadenitis AE OAE:0006719 This is an AE which is types of lymphoma affecting B cells. QY, JX, HY http://en.volupedia.org/wiki/B-cell_lymphoma b细胞淋巴瘤 10003899 b-cell lymphoma AE OAE:0006720 This is an AE which is types of lymphoma affecting B cells and it is recurrent. QY, JX, HY http://en.volupedia.org/wiki/B-cell_lymphoma b细胞淋巴瘤复发 10003902 b-cell lymphoma recurrent AE OAE:0006721 This is an AE which is a long-term autoimmune disorder that primarily affects joints. QY, JX, HY http://en.volupedia.org/wiki/Rheumatoid_arthritis 自身免疫性关节炎 10071155 autoimmune arthritis AE OAE:0006722 This is an AE which may present with a clinical pattern of vesicles indistinguishable from dermatitis herpetiformis, or with vesicles and bullae in a bullous pemphigoid-like appearance. QY, JX, HY http://en.volupedia.org/wiki/Linear_IgA_bullous_dermatosis 自身免疫性水泡性疾病 10083961 autoimmune blistering disease AE OAE:0006723 This is an AE which is autoimmune diseases which primarily affect the body system. QY, JX, HY http://en.volupedia.org/wiki/CNS_demyelinating_autoimmune_diseases 自身免疫性脱髓鞘疾病 10075688 autoimmune demyelinating disease AE OAE:0006724 This is an AE which is a condition arising from an abnormal immune response to a functioning endocrine part. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_disease 自身免疫内分泌紊乱 10078953 autoimmune endocrine disorder AE OAE:0006725 This is an AE which is a chronic disease in which the body interprets the thyroid glands and its hormone products T3, T4 and TSH as threats, therefore producing special antibodies that target the thyroid's cells, thereby destroying it. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_thyroiditis 自身免疫性甲状腺功能减退 10076644 autoimmune hypothyroidism AE OAE:0006726 This is an AE which is autoimmune inflammation of the kidneys and may involve the glomeruli, tubules, or interstitial tissue surrounding the glomeruli and tubules. QY, JX, HY http://en.volupedia.org/wiki/Nephritis 自身免疫性肾炎 10077087 autoimmune nephritis AE OAE:0006727 This is an AE which is an increasingly recognized type of chronic pancreatitis that can be difficult to distinguish from pancreatic carcinoma but which responds to treatment with corticosteroids, particularly prednisone. QY, JX, HY http://en.volupedia.org/wiki/Autoimmune_pancreatitis 自身免疫性胰腺炎 10069002 autoimmune pancreatitis AE OAE:0006728 This is an AE which is the most frequent cause of acquired thyroid dysfunction, most commonly presenting either as Hashimoto's thyroiditis or Graves' Disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32973676/ 自身免疫性甲状腺疾病 10079165 autoimmune thyroid disorder AE OAE:0006729 This is an AE which refers not produce autoantibodies or antigen-specific T or B cells and can be characterized by errors in the innate immune system. QY, JX, HY http://en.volupedia.org/wiki/Periodic_fever_syndrome 自身炎症性疾病 10072220 autoinflammatory disease AE OAE:0006730 This is an AE which is a rare form of cancerous lymphoma affecting T-cells. QY, JX, HY http://en.volupedia.org/wiki/T-cell_lymphoma T细胞淋巴瘤 10042971 t-cell lymphoma AE OAE:0006731 This is an AE which is a disease of the lymph nodes on the vaccination site , in which they are abnormal in size or consistency. QY, JX, HY http://en.volupedia.org/wiki/Lymphadenopathy 接种部位淋巴结肿大 10069480 vaccination site lymphadenopathy AE OAE:0006732 This is an AE which refers to a group of non-Hodgkin lymphomas in which aberrant T cells proliferate uncontrollably. QY, JX, HY http://en.volupedia.org/wiki/Anaplastic_large-cell_lymphoma 间变性大细胞淋巴瘤 10073478 anaplastic large-cell lymphoma AE OAE:0006733 This is an AE which is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal center. QY, JX, HY http://en.volupedia.org/wiki/Burkitt_lymphoma 伯基特淋巴瘤 10006595 burkitt's lymphoma AE OAE:0006734 This is an AE which is malformations of the lymphatic system characterized by lesions that are thin-walled cysts; these cysts can be macroscopic, as in a cystic hygroma, or microscopic. QY, JX, HY http://en.volupedia.org/wiki/Lymphangioma 囊性淋巴管瘤 10058949 cystic lymphangioma AE OAE:0006735 This is an AE which is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies. QY, JX, HY http://en.volupedia.org/wiki/Diffuse_large_B-cell_lymphoma 弥漫大b细胞淋巴瘤 10012818 diffuse large b-cell lymphoma AE OAE:0006736 This is an AE which may arise as a consequence of the transformation of the underlying indolent lymphoma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28600333/ 淋巴瘤 10080202 double hit lymphoma AE OAE:0006737 This is an AE which can be classified as noninfectious GLA and infectious GLA, noninfectious GLA includes sarcoidosis and sarcoid-like reaction and infectious GLA can be classified as suppurative lymphadenitis (LA) and nonsuppurative LA. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22706525/ 肉芽肿性淋巴腺炎 10078494 granulomatous lymphadenitis AE OAE:0006738 This is an AE which is a disease of the lymph nodes on the injection site, in which they are abnormal in size or consistency. QY, JX, HY http://en.volupedia.org/wiki/Lymphadenopathy 注射部位淋巴结病 10057665 injection site lymphadenopathy AE OAE:0006739 This is an AE which is a heterogeneous group of lymphomas that derive from the malignant transformation of marginal zone B-cells. QY, JX, HY http://en.volupedia.org/wiki/Marginal_zone_B-cell_lymphoma 边缘带淋巴瘤 10076596 marginal zone lymphoma AE OAE:0006740 This is an AE which represents a group of diseases characterized by non-granulomatous inflammation and necrosis of the lymph node, caused by a variety of infective and inflammatory diseases, most common being Kikuchi-Fujimoto disease, acute Epstein Barr viral infection and systemic lupus erythematosis . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32031124/ 坏死性肉芽肿性淋巴腺炎 10058540 necrotising granulomatous lymphadenitis AE OAE:0006741 This is an AE which is irregularities in the heartbeat, including when it is too fast or too slow and is nodal. QY, JX, HY http://en.volupedia.org/wiki/Arrhythmia 淋巴性心律失常 10029458 nodal arrhythmia AE OAE:0006742 This is an AE which is a group of clinically indolent B-cell lymphomas postulated to derive from memory B lymphocytes in the 'marginal zone' of secondary lymphoid tissue. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31757436/ 淋巴结边缘区b细胞淋巴瘤 10029460 nodal marginal zone b-cell lymphoma AE OAE:0006743 This is an AE which is a type of nodal osteoarthritis degenerative joint disease that results from breakdown of joint cartilage and underlying bone. QY, JX, HY http://en.volupedia.org/wiki/Osteoarthritis 淋巴结骨关节炎 10029469 nodal osteoarthritis AE OAE:0006744 This is an AE which is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas. QY, JX, HY http://en.volupedia.org/wiki/Non-Hodgkin_lymphoma 非霍奇金淋巴瘤 10029547 non-hodgkin's lymphoma AE OAE:0006745 This is an AE which is a heterogeneous group of clinically aggressive diseases associated with poor outcome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29674443/ 未指明外周t细胞淋巴瘤 10034623 peripheral t-cell lymphoma unspecified AE OAE:0006746 This is an AE which is a reactive lymphadenitis affecting HIV-positive patients; furthermore, PGL is often a prodrome of AIDS-related complex and AIDS. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2192430/ 持续性全身淋巴结肿大 10049025 persistent generalised lymphadenopathy AE OAE:0006747 This is an AE which is a high-grade neoplasm arising from precursor lymphocytes of B-cell lineage. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23840980/ 前体 B 淋巴母细胞淋巴瘤 10036523 precursor b-lymphoblastic lymphoma AE OAE:0006748 This is an AE which is inherited defects of the innate or adaptive arms of the immune system that lead to an increase in the incidence, frequency, or severity of infections and/or immune dysregulation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31690396/ 原发性免疫缺陷综合征 10064859 primary immunodeficiency syndrome AE OAE:0006749 This is an AE which is a rare type of lymphoma that forms in the mediastinum (the space in between the lungs) and predominantly affects young adults. QY, JX, HY http://en.volupedia.org/wiki/Primary_mediastinal_B-cell_lymphoma 原发性纵隔大 B 细胞淋巴瘤 10036710 primary mediastinal large b-cell lymphoma AE OAE:0006750 This is an AE which is a benign lymphocytic infiltrate that resembles cutaneous lymphoma histologically, clinically, or both. QY, JX, HY http://en.volupedia.org/wiki/Pseudolymphoma 假性淋巴瘤 10037127 pseudolymphoma AE OAE:0006751 This is an AE which is a genetic immunodeficiency, a type of hypogammaglobulinemia. QY, JX, HY http://en.volupedia.org/wiki/Selective_immunoglobulin_A_deficiency 选择性iga免疫缺陷 10039915 selective iga immunodeficiency AE OAE:0006752 This is an AE which is frequent, both as an apparently isolated defect (about one fourth of patients suffering otherwise unexplained repeated infections) and in association with a number of primary and required immunodeficiency states. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2223061/ 选择性igg亚类缺乏症 10057863 selective igg subclass deficiency AE OAE:0006753 This is an AE which is a poorly defined dysgammaglobulinemia characterized by decreased levels of IgM while levels of other immunoglobulins are normal. QY, JX, HY http://en.volupedia.org/wiki/Isolated_primary_immunoglobulin_M_deficiency 选择性igm免疫缺陷 10039916 selective igm immunodeficiency AE OAE:0006754 This is an AE which is one that affects a number of organs and tissues, or affects the body as a whole. QY, JX, HY http://en.volupedia.org/wiki/Systemic_disease 全身感染 10077116 systemic infection AE OAE:0006755 This is an AE which is an inflammatory state affecting the whole body. QY, JX, HY http://en.volupedia.org/wiki/Systemic_inflammatory_response_syndrome 全身炎症反应综合征 10051379 systemic inflammatory response syndrome AE OAE:0006756 This is an AE which is a highly heterogeneous disorder, characterized by differences in autoantibody profile, serum cytokines, and a multi-system involvement commonly affecting the skin, renal, musculoskeletal, and hematopoetic systems clinical manifestations involving. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29775752/ 系统性红斑狼疮皮疹 10042946 systemic lupus erythematosus rash AE OAE:0006757 This is an AE which is a type of mast cell disease, is a rare disorder affecting both children and adults caused by the accumulation of functionally defective mast cells (also called mastocytes) and CD34+ mast cell precursors. QY, JX, HY http://en.volupedia.org/wiki/Mastocytosis 系统性肥大细胞增多症 10042949 systemic mastocytosis AE OAE:0006758 This is an AE which is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII. QY, JX, HY http://en.volupedia.org/wiki/Acquired_haemophilia 获得性血友病 10053745 acquired haemophilia AE OAE:0006759 This is an AE which is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV), a retrovirus. QY, JX, HY http://en.volupedia.org/wiki/HIV/AIDS 获得性免疫缺陷综合征 10000565 acquired immunodeficiency syndrome AE OAE:0006760 This is an AE which is a generic term referring to a disorder in which a cyst or cavity forms within the spinal cord . QY, JX, HY http://en.volupedia.org/wiki/Syringomyelia 获得性脊髓空洞症 10072631 acquired syringomyelia AE OAE:0006761 This is an AE which is an established treatment modality for a variety of hematologic malignancies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15253164/ 同种异体造血干细胞移植 10067859 allogenic stem cell transplantation AE OAE:0006762 This is an AE which is an immune response to nonself antigens from members of the same species, which are called alloantigens or isoantigens. QY, JX, HY http://en.volupedia.org/wiki/Alloimmunity 同种免疫 100060935 alloimmunisation AE OAE:0006763 This is an AE which is the lack of those reactions which may be transferred by lymphoid cells but not by serum. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/5539788/ 细胞介导免疫缺陷 10007877 cell-mediated immune deficiency AE OAE:0006764 This is an AE which is conditions which cause impairment of humoral immunity, which can lead to immunodeficiency. QY, JX, HY http://en.volupedia.org/wiki/Humoral_immune_deficiency 体液免疫缺陷 10020464 humoral immune defect AE OAE:0006765 This is an AE which is a state with infecion in which the immune system's ability to fight infectious diseases and cancer is compromised or entirely absent. QY, JX, HY http://en.volupedia.org/wiki/Immunodeficiency 免疫缺陷宿主的感染 10021818 infection in an immunocompromised host AE OAE:0006766 This is an AE which is a form of diabetes that exhibits clinical features similar to both type 1 diabetes (T1D) and type 2 diabetes (T2D). QY, JX, HY http://en.volupedia.org/wiki/Latent_autoimmune_diabetes_in_adults 成人潜伏性自身免疫性糖尿病 10066389 latent autoimmune diabetes in adults AE OAE:0006767 This is an AE which is a form of leukopenia associated with a deficiency of monocytes. QY, JX, HY http://en.volupedia.org/wiki/Monocytopenia 单核细胞减少症 10027905 monocytopenia AE OAE:0006768 This is an AE which is a state in which the immune system's ability to fight infectious diseases and cancer is compromised or entirely absent. QY, JX, HY http://en.volupedia.org/wiki/Immunodeficiency 继发性免疫缺陷 10054979 secondary immunodeficiency AE OAE:0006769 This is an AE which is an acute condition involving a severe and dangerous lowered white blood cell count (leukopenia, most commonly of neutrophils) and thus causing a neutropenia in the circulating blood. QY, JX, HY http://en.volupedia.org/wiki/Agranulocytosis 粒细胞减少症 10001507 agranulocytosis AE OAE:0006770 This is an AE which is a rare WHO grade III type of astrocytoma, which is a type of cancer of the brain. QY, JX, HY http://en.volupedia.org/wiki/Anaplastic_astrocytoma 间变型星形细胞瘤 10002224 anaplastic astrocytoma AE OAE:0006771 This is an AE which is integral to the treatment of various malignant haematological conditions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29933906/ 自体造血干细胞移植 10081347 autologous haematopoietic stem cell transplant AE OAE:0006772 This is an AE which is the condition of having greater than 200 basophils/μL in the venous blood. QY, JX, HY http://en.volupedia.org/wiki/Basophilia 嗜碱细胞增多症 10004173 basophilia AE OAE:0006773 This is an AE which is a relatively uncommon tumor of the bone. It is characterized by the presence of multinucleated giant cells (osteoclast-like cells). QY, JX, HY http://en.volupedia.org/wiki/Giant-cell_tumor_of_bone 骨巨细胞瘤 10005969 bone giant cell tumor AE OAE:0006774 This is an AE which is the tapered, lower end of the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Conus_medullaris 髓母细胞综合征 10053778 conus medullaris syndrome AE OAE:0006775 This is an AE which occurs predominantly in immunocompromised hosts. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2554845/ 播散性巨细胞病毒感染 10049075 disseminated cytomegaloviral infection AE OAE:0006776 This is an AE which is the enlargement of red blood cells with near-constant hemoglobin concentration, and is defined by a mean corpuscular volume (MCV) of greater than 100 femtolitres (the precise criterion varies between laboratories). QY, JX, HY http://en.volupedia.org/wiki/Macrocytosis 巨细胞增生症 10025382 macrocytosis AE OAE:0006777 This is an AE which is the medical term for an unusually large tongue. QY, JX, HY http://en.volupedia.org/wiki/Macroglossia 巨舌 10025391 macroglossia AE OAE:0006778 This is an AE which is a type of white blood cell of the immune system that engulfs and digests anything that does not have, on its surface, proteins that are specific to healthy body cells and is active. QY, JX, HY http://en.volupedia.org/wiki/Macrophage#Types 巨噬细胞活化 10050206 macrophage activation AE OAE:0006779 This is an AE which is one type of mast cell activation disorder (MCAD), and is an immunological condition in which mast cells inappropriately and excessively release chemical mediators, resulting in a range of chronic symptoms, sometimes including anaphylaxis or near-anaphylaxis attacks. QY, JX, HY http://en.volupedia.org/wiki/Mast_cell_activation_syndrome 肥大细胞激活综合征 10075217 mast cell activation syndrome AE OAE:0006780 This is an AE which is a type of round-cell tumor consisting of mast cells. QY, JX, HY http://en.volupedia.org/wiki/Mastocytoma 肥大细胞瘤 10026890 mastocytoma AE OAE:0006781 This is an AE which refers a type of mast cell disease, is a rare disorder affecting both children and adults caused by the accumulation of functionally defective mast cells (also called mastocytes) and CD34+ mast cell precursors. QY, JX, HY http://en.volupedia.org/wiki/Mastocytosis 肥大细胞增多症 10026891 mastocytosis AE OAE:0006782 This is an AE which is a large bone marrow cell with a lobated nucleus responsible for the production of blood thrombocytes (platelets), which are necessary for normal blood clotting. QY, JX, HY http://en.volupedia.org/wiki/Megakaryocyte 巨核细胞 10050922 megakaryocytes AE OAE:0006783 This is an AE which is the most common demyelinating disease,in which the insulating covers of nerve cells in the brain and spinal cord are damaged. QY, JX, HY http://en.volupedia.org/wiki/Multiple_sclerosis#Types_and_variants 原发性进行性多发性硬化 10063401 primary progressive multiple sclerosis AE OAE:0006784 This is an AE which is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27889191/ 进行性多发性硬化 10053395 progressive multiple sclerosis AE OAE:0006785 This is an AE which is the most common demyelinating disease and is progressive relapsing, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. QY, JX, HY http://en.volupedia.org/wiki/Multiple_sclerosis 进行性复发性多发性硬化 10067063 progressive relapsing multiple sclerosis AE OAE:0006786 This is an AE which is the most common demyelinating disease and can relapsing, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. QY, JX, HY http://en.volupedia.org/wiki/Multiple_sclerosis 复发性多发性硬化症 10080700 relapsing multiple sclerosis AE OAE:0006787 This is an AE which begins with a clinically isolated syndrome (CIS). QY, JX, HY http://en.volupedia.org/wiki/Multiple_sclerosis#Types_and_variants 复发缓解型多发性硬化症 10063399 relapsing-remitting multiple sclerosis AE OAE:0006788 This is an AE which occurs in around 65% of those with initial relapsing-remitting MS, who eventually have progressive neurologic decline between acute attacks without any definite periods of remission. QY, JX, HY http://en.volupedia.org/wiki/Multiple_sclerosis#Types_and_variants 继发性进行性多发性硬化 10063400 secondary progressive multiple sclerosis AE OAE:0006789 This is an AE which is considered one of the multiple sclerosis borderline diseases, which is a collection of diseases classified by some as MS variants and by others as different diseases. QY, JX, HY http://en.volupedia.org/wiki/Marburg_acute_multiple_sclerosis 马尔堡型多发性硬化症 10067067 marburg's variant multiple sclerosis AE OAE:0006790 This is an AE which is a bacterial infection involving the inner layers of the skin on the infusion site. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 输注部位蜂窝织炎 10065455 infusion site cellulitis AE OAE:0006791 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on the infusion site . QY, JX, HY http://en.volupedia.org/wiki/Bleeding 输液部位出血 10065464 infusion site hemorrhage AE OAE:0006792 This is an AE which is a distressing feeling often caused by intense or damaging stimuli on the infusion site. QY, JX, HY http://en.volupedia.org/wiki/Pain 输液部位疼痛 10053483 infusion site pain AE OAE:0006793 This is an AE which refers a transient abnormal enlargement of infusion site not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 输液部位肿胀 10053505 infusion site swelling AE OAE:0006794 This is an AE which refers a somewhat high temperature on the infusion site. QY, JX, HY http://en.volupedia.org/wiki/Warm 输液部位发热 10053484 infusion site warmth AE OAE:0006795 This is an AE which is an iatrogenic infection occurring as an isolated case or as cluster outbreak. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17643000/ 注射部位无菌脓肿 10022045 injection site abscess sterile AE OAE:0006796 This is an AE which is a type of hematoma of injection site tissue, the most common cause being capillaries damaged by trauma, causing localized bleeding that extravasates into the surrounding interstitial tissues. QY, JX, HY http://en.volupedia.org/wiki/Bruise 注射部位瘀伤 10022052 injection site bruising AE OAE:0006797 This is an AE which is the accumulation of calcium salts in injection site tissue. QY, JX, HY http://en.volupedia.org/wiki/Calcification 注射部位钙化 10054812 injection site calcification AE OAE:0006798 This is an AE which is a closed sac on the injection site, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 注射部位囊肿 10022055 injection site cyst AE OAE:0006799 This is an AE which is a harmful mutation or other deformation in injection site. QY, JX, HY http://en.volupedia.org/wiki/Deformation 注射部位变形 10079275 injection site deformation AE OAE:0006800 This is an AE which is inflammation of the skin on the injection site, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 注射部位皮肤炎 10022056 injection site dermatitis AE OAE:0006801 This is an AE which is the shedding of the outermost membrane or layer of a tissue, such as injection site skin. QY, JX, HY http://en.volupedia.org/wiki/Desquamation 注射部位脱屑 10059007 injection site desquamation AE OAE:0006802 This is an AE which is a medical condition in which there is local or more generalized decrease in normal lubrication of the skin or mucous membranes such in the injection site. QY, JX, HY http://en.volupedia.org/wiki/Dryness_(medical) 注射部位干燥 10067252 injection site dryness AE OAE:0006803 This is an AE which means "abnormal sensation" on the injection site. QY, JX, HY http://en.volupedia.org/wiki/Dysesthesia 注射部位感觉不良 10069124 injection site dysaesthesia AE OAE:0006804 This is an AE which is a chronic, relapsing, and remitting disease on the injection site that can affect patients from infancy through adulthood. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31563186/ 注射部位湿疹 10066221 injection site eczema AE OAE:0006805 This is an AE which removes dead injection site skin from the body and face. QY, JX, HY http://en.volupedia.org/wiki/Exfoliation 注射部位表皮脱落 10068689 injection site exfoliation AE OAE:0006807 This is an AE which is a pathological wound healing on the injection site in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis 注射部位纤维化 10022064 injection site fibrosis AE OAE:0006808 This is an AE which is an aggregation of macrophages that forms in response to chronic inflammation on the injection site. QY, JX, HY http://en.volupedia.org/wiki/Granuloma 注射部位肉芽肿 10022065 injection site granuloma AE OAE:0006809 This is an AE which is a condition on the injection site that involves an abnormal increase in sensitivity to stimuli of the sense. QY, JX, HY http://en.volupedia.org/wiki/Hyperesthesia 注射部位感觉过敏 10073418 injection site hyperesthesia AE OAE:0006810 This is an AE which is an abnormal amount of hair growth over the injection site tissue. QY, JX, HY http://en.volupedia.org/wiki/Hypertrichosis 注射部位多毛症 10075313 injection site hypertrichosis AE OAE:0006811 This is an AE which is the increase in the volume of injection site tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 注射部位肥大 10022072 injection site hypertrophy AE OAE:0006812 This is an AE which is a common side effect on the injection site of various medical conditions which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 注射部位触觉减退 10074586 injection site hypoesthesia AE OAE:0006813 This is an AE which is damage to the injection site caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 注射部位受伤 10066083 injection site injury AE OAE:0006814 This is an AE which is a injection site state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 注射部位疼痛 10022079 injection site irritation AE OAE:0006815 This is an AE which refers to accumulation of fluid in an anatomic injection site joint space, usually without loculation. QY, JX, HY http://en.volupedia.org/wiki/Effusion 注射部位关节积液 10064494 injection site joint effusion AE OAE:0006816 This is an AE which is redness of the injection site joint skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 注射部位关节红斑 10076327 injection site joint erythema AE OAE:0006817 This is an AE which is a procedure used in the treatment of inflammatory joint conditions, such as rheumatoid arthritis, psoriatic arthritis, gout, tendinitis, bursitis, Carpal Tunnel Syndrome, and occasionally osteoarthritis. QY, JX, HY http://en.volupedia.org/wiki/Joint_injection 注射部位关节感染 10074703 injection site joint infection AE OAE:0006818 This is an AE which is part of the complex biological response of injection site joint tissues to harmful stimuli, such as pathogens, damaged cells, or irritants,and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 注射部位关节炎症 10064111 injection site joint inflammation AE OAE:0006819 This is an AE which is a distressing feeling on the injection site joint often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 注射部位关节痛 10049261 injection site joint pain AE OAE:0006820 This is an AE which refers a transient abnormal enlargement of injection site joint area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 注射部位关节肿胀 10049260 injection site joint swelling AE OAE:0006821 This is an AE which refers a somewhat high temperature on the injection site joint. QY, JX, HY http://en.volupedia.org/wiki/Warm 注射部位关节发热 10049262 injection site joint warmth AE OAE:0006822 This is an AE which is a type of injury which happens relatively quickly such as in the injection site in which skin is torn, cut, or punctured (an open wound), or where blunt force trauma causes a contusion (a closed wound). QY, JX, HY http://en.volupedia.org/wiki/Wound 注射部位撕裂 10067253 injection site laceration AE OAE:0006823 This is an AE which is a lack of muscle strength in the injection site. QY, JX, HY http://en.volupedia.org/wiki/Muscle_weakness 注射部位肌无力 10084588 injection site muscle weakness AE OAE:0006824 This is an AE which is a form of cell injury in the injection site which results in the premature death of cells in living tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 注射部位坏死 10022082 injection site necrosis AE OAE:0006825 This is an AE which is injury to nervous tissue in the injection site. QY, JX, HY http://en.volupedia.org/wiki/Nerve_injury 注射部位神经损伤 10022083 injection site nerve damage AE OAE:0006826 This is an AE which refers a small aggregation of cells in the injection site. QY, JX, HY http://en.volupedia.org/wiki/Nodule 注射部位结节 10057880 injection site nodule AE OAE:0006827 This is an AE which is the build-up of fluid in the injection site tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 注射部位水肿 10022085 injection site edema AE OAE:0006828 This is an AE which is a pale color of the injection site skin. QY, JX, HY http://en.volupedia.org/wiki/Pallor 注射部位苍白 10066041 injection site pallor AE OAE:0006829 This is an AE which is a small, well-defined bump in the injection site skin. QY, JX, HY http://en.volupedia.org/wiki/Papule 注射部位丘疹 10066044 injection site papule AE OAE:0006830 This is an AE which is an abnormal sensation of the injection site skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 注射部位感觉异常 10022088 injection site paraesthesia AE OAE:0006831 This is an AE which refers a type of cutaneous condition in the injection site . QY, JX, HY http://en.volupedia.org/wiki/Plaque 注射部位斑块 10073174 injection site plaque AE OAE:0006832 This is an AE which is any medical condition that affects the integumentary system in the injection site . QY, JX, HY http://en.volupedia.org/wiki/Skin_condition 注射部位脓疱 10054994 injection site pustule AE OAE:0006833 This is an AE which is an area of fibrous tissue that replaces normal skin after an injury in the injection site tissue. QY, JX, HY http://en.volupedia.org/wiki/Scar 注射部位的疤痕 10059009 injection site scar AE OAE:0006834 This is an AE which is small dilated blood vessels that can occur near the surface of the injection site skin or mucous membranes, measuring between 0.5 and 1 millimeter in diameter. QY, JX, HY http://en.volupedia.org/wiki/Telangiectasia 注射部位毛细管扩张 10079124 injection site telangiectasia AE OAE:0006835 This is an AE which is a group of disorders that destroy blood vessels by inflammation on the injection site. QY, JX, HY http://en.volupedia.org/wiki/Vasculitis 注射部位血管炎 10067995 injection site vasculitis AE OAE:0006836 This is an AE which is redness of the instillation site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 滴注部位红斑 10063762 instillation site erythema AE OAE:0006837 This is an AE which is an abnormal sensation of the instillation site skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 滴注部位感觉异常 10073558 instillation site paraesthesia AE OAE:0006838 This is an AE which refers a liquid-filled cavity under the instillation site epidermis, commonly called a blister. QY, JX, HY http://en.volupedia.org/wiki/Vesicle 滴注部位囊泡 10073628 instillation site vesicles AE OAE:0006839 This is an AE which is a collection of pus that has built up within the tissue of the joint. QY, JX, HY http://en.volupedia.org/wiki/Abscess 关节脓肿 10058981 joint abscess AE OAE:0006840 This is an AE which is a collection of pus that has built up within the tissue of the muscle. QY, JX, HY http://en.volupedia.org/wiki/Abscess 肌脓肿 10049206 muscle abscess AE OAE:0006841 This is an AE which is a rare complication of acute parotitis in children. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26527073/ 腮腺脓肿 10034019 parotid abscess AE OAE:0006842 This is an AE which refers an abscess in the psoas muscle of the abdomen may be caused by lumbar tuberculosis. QY, JX, HY http://en.volupedia.org/wiki/Psoas_muscle_abscess 腰大肌脓肿 10056517 psoas abscess AE OAE:0006843 This is an AE which is the most common symptom is fever, followed by abdominal pain and a tender mass on palpation of the left upper quadrant of the abdomen. QY, JX, HY http://en.volupedia.org/wiki/Spleen_pain#Splenic_abscess 脾脓肿 10041643 splenic abscess AE OAE:0006844 This is an AE which is an abscess located in the subcutaneous tissue (also hypodermis). QY, JX, HY http://en.volupedia.org/wiki/Subcutaneous_abscess 皮下脓肿 10042343 subcutaneous abscess AE OAE:0006845 This is an AE which is a collection of pus that has built up within the tissue of the body caused by streptococcal. QY, JX, HY http://en.volupedia.org/wiki/Abscess 链球菌脓肿 10042176 streptococcal abscess AE OAE:0006846 This is an AE which is a collection of pus that has built up within the tissue of the subdural. QY, JX, HY http://en.volupedia.org/wiki/Abscess 硬膜下脓肿 10083083 subdural abscess AE OAE:0006847 This is an AE which is a condition that typically presents as collection of pus in the space between the periorbital and the lamina papyracea as a result of the migration and spread of an infection, such as sinusitis and ethmoiditis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30871969/ 骨膜下脓肿 10075118 subperiosteal abscess AE OAE:0006848 This is an AE which is a neoplasm or tumor of the thyroid. QY, JX, HY http://en.volupedia.org/wiki/Thyroid_neoplasm 甲状腺肿瘤 10043744 thyroid neoplasm AE OAE:0006849 This is an AE which is an unfavorable result of a disease, health condition, or treatment such after vaccination. QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine) 接种并发症 10046861 vaccination complication AE OAE:0006850 This is an AE which is a collection of pus that has built up within the tissue of the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Abscess 接种部位脓肿 10069556 vaccination site abscess AE OAE:0006851 This is an AE which is a vaccination site state of controlled, temporary loss of sensation or awareness that is induced for medical purposes. QY, JX, HY http://en.volupedia.org/wiki/Anesthesia 接种部位麻醉 10076192 vaccination site anaesthesia AE OAE:0006852 This is an AE which is the partial or complete wasting away of a part of the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 接种部位萎缩 10076155 vaccination site atrophy AE OAE:0006853 This is an AE which is a type of hematoma of vaccination site, the most common cause being capillaries damaged by trauma, causing localized bleeding that extravasates into the surrounding interstitial tissues. QY, JX, HY http://en.volupedia.org/wiki/Bruise 接种部位淤青 10069484 vaccination site bruising AE OAE:0006854 This is an AE which is a bacterial infection involving the inner layers of the vaccination site skin. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 接种部位蜂窝织炎 10069559 vaccination site cellulitis AE OAE:0006855 This is an AE which is a closed sac on the vaccination site, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 接种部位囊肿 10076158 vaccination site cyst AE OAE:0006856 This is an AE which is a medical condition in which there is local or more generalized decrease in normal lubrication of the vaccination site skin or mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Dryness_(medical) 接种部位干燥 10076159 vaccination site dryness AE OAE:0006857 This is an AE which defines as an unpleasant, abnormal sense of touch on the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Dysesthesia 接种部位感觉迟钝 10076160 vaccination site dysaesthesia AE OAE:0006858 This is an AE which refers to a broad range of conditions that begin as spongiotic dermatitis and may progress to a lichenified stage on the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/List_of_skin_conditions#Eczema 接种部位湿疹 10076161 vaccination site eczema AE OAE:0006859 This is an AE which is redness of the vaccination site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 接种部位红斑 10059079 vaccination site erythema AE OAE:0006860 This is an AE which is a slough or piece of dead tissue that is cast off from the surface of the vaccination site skin. QY, JX, HY http://en.volupedia.org/wiki/Eschar 接种部位焦痂 10069561 vaccination site eschar AE OAE:0006861 This is an AE which aims to remove dead skin from the vaccination site tissue. QY, JX, HY http://en.volupedia.org/wiki/Exfoliation 接种部位去角质 10069489 vaccination site exfoliation AE OAE:0006863 This is an AE which is an aggregation of macrophages that forms in response to chronic inflammation on the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Granuloma 接种部位肉芽肿 10069562 vaccination site granuloma AE OAE:0006864 This is an AE which is a vaccination site bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 接种部位血肿 10069472 vaccination site hematoma AE OAE:0006865 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on the vaccination site . QY, JX, HY http://en.volupedia.org/wiki/Bleeding 接种部位出血 10069475 vaccination site hemorrhage AE OAE:0006866 This is an AE which refers to undesirable reactions on the vaccination site produced by the normal immune system, including allergies and autoimmunity. QY, JX, HY http://en.volupedia.org/wiki/Hypersensitivity 接种部位过敏 10068880 vaccination site hypersensitivity AE OAE:0006867 This is an AE which is an abnormal amount of hair growth over the vaccination site tissue. QY, JX, HY http://en.volupedia.org/wiki/Hypertrichosis 接种部位多毛症 10076166 vaccination site hypertrichosis AE OAE:0006868 This is an AE which is the increase in the volume of vaccination site tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 接种部位肥大 10076167 vaccination site hypertrophy AE OAE:0006869 This is an AE which is a common side effect of vaccination site which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 接种部位感觉减退 10076168 vaccination site hypoesthesia AE OAE:0006870 This is an AE which is dermal thickening causing the cutaneous vaccination site surface to feel thicker and firmer. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 接种部位硬结 10065117 vaccination site induration AE OAE:0006871 This is an AE which is the invasion of vaccination site tissues by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 接种部位感染 10068877 vaccination site infection AE OAE:0006872 This is an AE which is part of the complex biological response of vaccination site tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 接种部位炎症 10068878 vaccination site inflammation AE OAE:0006873 This is an AE which is damage to the vaccination site caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 接种部位损伤 10076169 vaccination site injury AE OAE:0006874 This is an AE which is a vaccination site state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 接种部位刺激 10069479 vaccination site irritation AE OAE:0006875 This is an AE which is the presence of increased intra-articular fluid on the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Joint_effusion 接种部位关节积液 10076172 vaccination site joint effusion AE OAE:0006876 This is an AE which is redness of the vaccination site joint skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 接种部位关节红斑 10076177 vaccination site joint erythema AE OAE:0006877 This is an AE which is the invasion of a joint by an infectious agent resulting in joint inflammation on the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Septic_arthritis 接种部位关节感染 10076173 vaccination site joint infection AE OAE:0006878 This is an AE which is a vaccination site symptom of injury, infection, illness (in particular arthritis), or an allergic reaction to medication. QY, JX, HY http://en.volupedia.org/wiki/Arthralgia 接种部位关节痛 10076176 vaccination site joint pain AE OAE:0006879 This is an AE which refers a transient abnormal enlargement of vaccination site joint not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 接种部位关节肿胀 10076178 vaccination site joint swelling AE OAE:0006880 This is an AE which refers irregular tear-like wounds caused by some blunt trauma on the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Wound#Open 接种部位裂伤 10076180 vaccination site laceration AE OAE:0006881 This is an AE which is a change in vaccination site surface color, without elevation or depression, so nonpalpable, well or ill-defined, variously sized, but generally considered less than either 5 or 10 mm in diameter at the widest point. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Primary_lesions 接种部位黄斑 10076181 vaccination site macule AE OAE:0006882 This is an AE which is a form of cell injury on the vaccination site which results in the premature death of cells in living tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 接种部位坏死 10069625 vaccination site necrosis AE OAE:0006883 This is an AE which is injury to vaccination site nervous tissue. QY, JX, HY http://en.volupedia.org/wiki/Nerve_injury 接种部位神经损伤 10076184 vaccination site nerve damage AE OAE:0006884 This is an AE which refers a small aggregation of cells on the vaccination site. QY, JX, HY http://en.volupedia.org/wiki/Nodule 接种部位结节 10069616 vaccination site nodule AE OAE:0006885 This is an AE which is the build-up of fluid in thevaccination site tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 接种部位水肿 10069617 vaccination site edema AE OAE:0006886 This is an AE which is a distressing feeling on the vaccination site often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 接种部位疼痛 10068879 vaccination site pain AE OAE:0006887 This is an AE which is a pale color of the vaccination site skin that can be caused by illness, emotional shock or stress, stimulant use, or anemia, and is the result of a reduced amount of oxyhaemoglobin and may also be visible as pallor of the conjunctivae of the eyes on physical examination. QY, JX, HY http://en.volupedia.org/wiki/Pallor 疫苗接种部位发白 10066045 vaccination site pallor AE OAE:0006888 This is an AE which is a small, well-defined bump in the vaccination site skin. QY, JX, HY http://en.volupedia.org/wiki/Papule 接种部位丘疹 10066046 vaccination site papule AE OAE:0006889 This is an AE which is an abnormal sensation of the vaccination site skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 接种部位感觉异常 10069481 vaccination site paraesthesia AE OAE:0006890 This is an AE which refers a type of cutaneous vaccination site condition. QY, JX, HY http://en.volupedia.org/wiki/Plaque 接种点斑点 10076187 vaccination site plaque AE OAE:0006891 This is an AE which is a vaccination site sensation that causes the desire or reflex to scratch. QY, JX, HY http://en.volupedia.org/wiki/Itch 接种部位瘙痒 10068881 vaccination site pruritus AE OAE:0006892 This is an AE which is a small elevation of the vaccination site skin containing cloudy or purulent material (pus) usually consisting of necrotic inflammatory cells. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Pustule 接种部位脓疱 10066047 vaccination site pustule AE OAE:0006893 This is an AE which is a change of the vaccination site skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 接种部位皮疹 10069482 vaccination site rash AE OAE:0006894 This is an AE which refers a hard coating on the vaccination site skin formed during the wound healing reconstruction phase. QY, JX, HY http://en.volupedia.org/wiki/Scab 接种部位结痂 10069618 vaccination site scab AE OAE:0006895 This is an AE which is an area of fibrous tissue that replaces vaccination site skin after an injury. QY, JX, HY http://en.volupedia.org/wiki/Scar 接种部位疤痕 10069619 vaccination site scar AE OAE:0006896 This is an AE which is a discontinuity or break in avaccination site membrane that impedes normal function of the affected organ. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 接种部位溃疡 10069621 vaccination site ulcer AE OAE:0006897 This is an AE which is a kind of vaccination site skin rash with red, raised, itchy bumps. QY, JX, HY http://en.volupedia.org/wiki/Hives 接种部位荨麻疹 10069622 vaccination site urticaria AE OAE:0006898 This is an AE which is a collection of pus that has built up within the tissue of the wound. QY, JX, HY http://en.volupedia.org/wiki/Abscess 伤口脓肿 10058042 wound abscess AE OAE:0006899 This is an AE which is a collection of pus that has built up within the tissue of the body caused by the bacterial. QY, JX, HY http://en.volupedia.org/wiki/Abscess 脓肿细菌 10000272 abscess bacterial AE OAE:0006900 This is an AE which is a cost and clinically effective technique. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/8564178/ 脓肿引流 10000279 abscess drainage AE OAE:0006901 This is an AE which is a collection of pus that has built up within the tissue of the limb. QY, JX, HY http://en.volupedia.org/wiki/Abscess 肢体脓肿 10050473 abscess limb AE OAE:0006902 This is an AE which is a collection of pus that has built up within the tissue of the neck. QY, JX, HY http://en.volupedia.org/wiki/Abscess 颈部脓肿 10053576 abscess neck AE OAE:0006903 This is an AE which is the main and most serious complication which determines hemodynamic instability or septic state. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28027808/ 脓肿破裂 10064878 abscess rupture AE OAE:0006904 This is an AE which is a collection of pus that has built up within the tissue of the soft tissue. QY, JX, HY http://en.volupedia.org/wiki/Abscess 软组织脓肿 10050474 abscess soft tissue AE OAE:0006905 This is an AE which is a collection of pus that has built up within the tissue of the administration site. QY, JX, HY http://en.volupedia.org/wiki/Abscess 给药部位脓肿 10068791 administration site abscess AE OAE:0006906 This is an AE which occurs when a Bartholin's gland within the labia becomes blocked. QY, JX, HY http://en.volupedia.org/wiki/Bartholin%27s_cyst 巴多林氏脓肿 10004138 bartholin's abscess AE OAE:0006907 This is an AE which is a collection of pus that has built up within the tissue of the bone. QY, JX, HY http://en.volupedia.org/wiki/Abscess 骨脓肿 10068653 bone abscess AE OAE:0006908 This is an AE which is the inflammation of the thyroid gland and is acute. QY, JX, HY http://en.volupedia.org/wiki/Thyroiditis 急性甲状腺炎 10043780 thyroiditis acute AE OAE:0006909 This is an AE which is an uncommon systemic vasculitis, which involves small blood vessels of the lungs, peripheral nerves, skin, and, less frequently, the heart and gastrointestinal tract. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/14625818/ 过敏性肉芽肿性 10048594 allergic granulomatous angiitis AE OAE:0006910 This is an AE which is the build-up of fluid in the body's tissue and can cause allergic. QY, JX, HY http://en.volupedia.org/wiki/Edema 脉管炎过敏水肿 10060934 allergic edema AE OAE:0006911 This is an AE which is a number of conditions caused by hypersensitivity of the immune system to vaccine. QY, JX, HY http://en.volupedia.org/wiki/Allergy 对疫苗过敏 10055048 allergy to vaccine AE OAE:0006912 This is an AE which is a serious allergic reaction that is rapid in onset and may cause shock. QY, JX, HY http://en.volupedia.org/wiki/Anaphylaxis 过敏样休克 10063119 anaphylactoid shock AE OAE:0006913 This is an AE which is a widespread, proinflammatory, anaphylactic-like reaction that can occur when amniotic fluid enters the maternal blood circulation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30738557/ 妊娠类过敏综合征 10067010 anaphylactoid syndrome of pregnancy AE OAE:0006914 This is an AE which is a term often used to mean any disorder that affects joints caused by allergic. QY, JX, HY http://en.volupedia.org/wiki/Arthritis 关节炎过敏 10061430 arthritis allergic AE OAE:0006915 This is an AE which is a number of conditions caused by hypersensitivity of the immune system to typically caffeine substances in the environment. QY, JX, HY http://en.volupedia.org/wiki/Allergy 咖啡因过敏 10074895 caffeine allergy AE OAE:0006916 This is an AE which is a number of conditions caused by hypersensitivity of the immune system to contrast media substances in the environment. QY, JX, HY http://en.volupedia.org/wiki/Allergy 造影剂过敏 10066973 contrast media allergy AE OAE:0006917 This is an AE which is a number of conditions caused by hypersensitivity of the immune system to typically harmless substances such as dust in the environment. QY, JX, HY http://en.volupedia.org/wiki/Allergy 灰尘过敏 10077439 dust allergy AE OAE:0006918 This is an AE which is a number of conditions caused by hypersensitivity of the immune system to typically harmless substances such as dust in the house. QY, JX, HY http://en.volupedia.org/wiki/Allergy 房子灰尘过敏 10057631 house dust allergy AE OAE:0006919 This is an AE which is a teeth condition that involves an abnormal increase in sensitivity to stimuli of the sense. QY, JX, HY http://en.volupedia.org/wiki/Hyperesthesia 牙齿过敏 10082426 hyperesthesia teeth AE OAE:0006920 This is an AE which is inflammation of small blood vessels (usually post-capillary venules in the dermis), characterized by palpable purpura. QY, JX, HY http://en.volupedia.org/wiki/Cutaneous_small-vessel_vasculitis 高敏感性脉管炎 10020764 hypersensitivity vasculitis AE OAE:0006921 This is an AE which is not well-known in clinical practice and it might be combined with the adverse reactions of intravascular contrast media which contain iodine. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16573176/ 碘过敏 10052098 iodine allergy AE OAE:0006922 This is an AE which is a medical term encompassing a range of allergic reactions to the proteins present in natural rubber latex. QY, JX, HY http://en.volupedia.org/wiki/Latex_allergy 乳胶过敏 10056435 latex allergy AE OAE:0006923 This is an AE which is an adverse immune reaction to one or more proteins in cow's milk. QY, JX, HY http://en.volupedia.org/wiki/Milk_allergy 牛奶过敏 10027633 milk allergy AE OAE:0006924 This is an AE which is a number of conditions caused by hypersensitivity of the immune system to typically substances such as mite in the environment. QY, JX, HY http://en.volupedia.org/wiki/Allergy 螨过敏 10077290 mite allergy AE OAE:0006925 This is an AE which is a collection of pus that has built up within the tissue of the application site. QY, JX, HY http://en.volupedia.org/wiki/Abscess 用药部位脓肿 10057881 application site abscess AE OAE:0006926 This is an AE which is a number of conditions caused by hypersensitivity of the immune system to typically substances such as mycotic in the environment. QY, JX, HY http://en.volupedia.org/wiki/Allergy 对霉菌过敏 10052758 mycotic allergy AE OAE:0006927 This is an AE which is a sensation that causes the desire or reflex to scratch caused by allergic. QY, JX, HY http://en.volupedia.org/wiki/Itch 瘙痒过敏 10063438 pruritus allergic AE OAE:0006928 This is an AE which is a glycoprotein enzyme encoded in humans by the KLK3 gene and is free . QY, JX, HY http://en.volupedia.org/wiki/Prostate-specific_antigen 游离前列腺特异性抗原 10053837 free prostate-specific antigen AE OAE:0006929 This is an AE which occurs when transplanted kidney tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. QY, JX, HY http://en.volupedia.org/wiki/Transplant_rejection 肾移植排斥反应 10023439 kidney transplant rejection AE OAE:0006930 This is an AE which occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. QY, JX, HY http://en.volupedia.org/wiki/Transplant_rejection 移植排斥 10044439 transplant rejection AE OAE:0006931 This is an AE which refers an unfavorable evolution of a disease, health condition or medical treatment after transplantation. QY, JX, HY http://en.volupedia.org/wiki/Complication 移植并发症 10074555 transplantation complication AE OAE:0006932 This is an AE which is a kidney disorder which is the leading cause of kidney transplant failure, occurring months to years after the transplant. QY, JX, HY http://en.volupedia.org/wiki/Chronic_allograft_nephropathy 慢性同种异体移植物肾病 10063209 chronic allograft nephropathy AE OAE:0006933 This is an AE which is the organ transplant of a kidney into a patient with end-stage kidney disease (ESRD) and occurs complications. QY, JX, HY http://en.volupedia.org/wiki/Kidney_transplantation 移植肾并发症 10010185 complications of transplanted kidney AE OAE:0006934 This is an AE which is characterized by a significant reduction in one or more of the cellular elements of the blood in the presence of normocellular or hypercellular bone marrow and splenomegaly. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23454561/ 脾功能亢进 10020769 hypersplenism AE OAE:0006935 This is an AE which is associated with autoimmune diseases, inflammatory bowel disease, severe celiac disease, autoimmune thyroiditis, untreated HIV infection and chronic graft-versus-host disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32563569/ 脾功能减退症 10079831 hyposplenism AE OAE:0006936 This is an AE which is a non-surgical procedure developed to treat hypersplenism as a result of hepatic disease and thus avoid the disadvantages of splenectomy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18034810/ 部分脾栓塞 10081995 partial splenic embolisation AE OAE:0006937 This is an AE which refers abnormal accumulation of fluid in the interstitium on the spleen, manifesting as swelling. QY, JX, HY http://en.volupedia.org/wiki/Congestion 脾淤血 10050294 spleen congestion AE OAE:0006938 This is an AE which is the accumulation of calcium salts in a splenic tissue. QY, JX, HY http://en.volupedia.org/wiki/Calcification 脾钙化 10068608 splenic calcification AE OAE:0006939 This is an AE which is most commonly due to endemic parasites or congenital (epithelial) cysts in children. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27403673/ 脾囊肿 10051169 splenic cyst AE OAE:0006940 This is an AE which is an aggregation of macrophages that forms in response to chronic inflammation on the splenic. QY, JX, HY http://en.volupedia.org/wiki/Granuloma 脾肉芽肿 10064249 splenic granuloma AE OAE:0006941 This is an AE which is a splenic localized bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 脾血肿 10041646 splenic hematoma AE OAE:0006942 This is an AE which is a condition in which blood flow supply to the spleen is compromised,leading to partial or complete infarction (tissue death due to oxygen shortage) in the organ. QY, JX, HY http://en.volupedia.org/wiki/Splenic_infarction 脾梗塞 10041648 splenic infarction AE OAE:0006943 This is an AE which includes a ruptured spleen, is any injury to the spleen. QY, JX, HY http://en.volupedia.org/wiki/Splenic_injury 脾脏损伤 10041649 splenic injury AE OAE:0006944 This is an AE which is any damage or abnormal change in the tissue of splenic, usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 脾脏病变 10054829 splenic lesion AE OAE:0006945 This is an AE which is any injury to the spleen and the rupture of a normal spleen can be caused by trauma. QY, JX, HY http://en.volupedia.org/wiki/Splenic_injury 脾破裂 10041658 splenic rupture AE OAE:0006946 This is an AE which is an enlargement of the spleen. QY, JX, HY http://en.volupedia.org/wiki/Splenomegaly 脾炎 10058339 splenitis AE OAE:0006947 This is an AE which is the result of spleen tissue breaking off the main organ and implanting at another site inside the body. QY, JX, HY http://en.volupedia.org/wiki/Splenosis 脾组织移植 10050357 splenosis AE OAE:0006948 This is an AE which refers to the absence of normal spleen function and is associated with some serious infection risks. QY, JX, HY http://en.volupedia.org/wiki/Asplenia 无脾 10053622 asplenia AE OAE:0006949 This is an AE which is inflammation of the tonsils in the upper part of the throat. QY, JX, HY http://en.volupedia.org/wiki/Tonsillitis 慢性扁桃体炎 10009152 chronic tonsillitis AE OAE:0006950 This is an AE which encompasses both cellulitis and abscess. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3460043/ 扁桃体周炎 10049592 peritonsillitis AE OAE:0006951 This is an AE which is the partial or complete wasting away of a part of the tonsillar. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 扁桃体萎缩 10051502 tonsillar atrophy AE OAE:0006952 This is an AE which can recurre after marsupialization via microlaryngeal approach and finally it was resected successfully through a lateral cervical approach with concomitant tracheotomy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17129695/ 扁桃体囊肿 10057451 tonsillar cyst AE OAE:0006953 This is an AE which is redness of the tonsillar skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 扁桃体红斑 10078256 tonsillar erythema AE OAE:0006954 This is an AE which is a fluid emitted by an organism through tonsillar pores or a wound. QY, JX, HY http://en.volupedia.org/wiki/Exudate 扁桃体渗出液 10078257 tonsillar exudate AE OAE:0006955 This is an AE which is part of the complex biological response of tonsillar tissues to harmful stimuli. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 扁桃体发炎 10065169 tonsillar inflammation AE OAE:0006956 This is an AE which is a type of abnormal and excessive growth of tonsillar tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 扁桃体肿瘤 10062131 tonsillar neoplasm AE OAE:0006957 This is an AE which is a discontinuity or break in a tonsillar membrane that impedes normal function of the affected tonsillar . QY, JX, HY http://en.volupedia.org/wiki/Ulcer 扁桃体溃疡 10050211 tonsillar ulcer AE OAE:0006958 This is an AE which is inflammation of the tonsils in the upper part of the throat caused by viral. QY, JX, HY http://en.volupedia.org/wiki/Tonsillitis 病毒性扁桃体炎 10047480 viral tonsillitis AE OAE:0006959 This is an AE which is an inflammatory process of the tonsillar tissues and is usually infectious in nature. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22338587/ 急性扁桃体炎 10001093 acute tonsillitis AE OAE:0006960 This is an AE which is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease. QY, JX, HY http://en.volupedia.org/wiki/Lupus_nephritis 狼疮肾炎 10025140 lupus nephritis AE OAE:0006961 This is an AE which is a type of lymphoma, in which cancer originates from a specific type of white blood cells called lymphocytes, where multinucleated Reed–Sternberg cells (RS cells) are present in the patient's lymph nodes. QY, JX, HY http://en.volupedia.org/wiki/Hodgkin_lymphoma 霍奇金氏病 10020206 hodgkin's disease AE OAE:0006962 This is an AE which is the presence of an increased number of granulocytes in the peripheral blood. QY, JX, HY http://en.volupedia.org/wiki/Granulocytosis 粒细胞增多 10018690 granulocytosis AE OAE:0006963 This is an AE which is the presence of excessive amounts of myeloma protein or monoclonal gamma globulin in the blood. QY, JX, HY http://en.volupedia.org/wiki/Monoclonal_gammopathy 单克隆丙种球蛋白病 10060880 monoclonal gammopathy AE OAE:0006964 This is an AE which is a multisystem disease of presumed autoimmune cause that affects pigmented tissues, which have melanin. QY, JX, HY http://en.volupedia.org/wiki/Vogt%E2%80%93Koyanagi%E2%80%93Harada_disease vogt-小柳-原田病 10082001 vogt-koyanagi-harada disease AE OAE:0006965 This is an AE which is an extremely rare disease characterized by the abnormal multiplication of a specific type of white blood cells called histiocytes, or tissue macrophages (technically, this disease is termed a non-Langerhans-cell histiocytosis). QY, JX, HY http://en.volupedia.org/wiki/Erdheim%E2%80%93Chester_disease 埃尔德海姆-切斯特病 10060801 erdheim-chester disease AE OAE:0006966 This is an AE which is antibodies, typically immunoglobulin M (IgM), that are acquainted with and then binding the antigens on red blood cells, typically antigens "I" or "i" on the RBC surface. QY, JX, HY http://en.volupedia.org/wiki/Cold_sensitive_antibodies#Cold_agglutinin_antibodies 寒冷的凝集素 10050523 cold agglutinins AE OAE:0006967 This is an AE which is a rare adverse event following immunization (AEFI). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30808246/ 皮下结节 10042348 subcutaneous nodule AE OAE:0006968 This is an AE which is a long-term autoimmune disorder, primarily affecting the small intestine, where individuals develop intolerance to gluten, present in foods such as wheat, rye and barley. QY, JX, HY http://en.volupedia.org/wiki/Coeliac_disease 乳糜泄 10009839 coeliac disease AE OAE:0006969 This is an AE which associates with lamotrigine. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23011169/ 狼疮样综合征 10050551 lupus-like syndrome AE OAE:0006970 QY, JX, HY 淋巴阻塞 10052315 lymphatic obstruction AE OAE:0006971 QY, JX, HY 滤泡中心淋巴瘤弥漫性小细胞淋巴瘤 10061957 follicle centre lymphoma diffuse small cell lymphoma AE OAE:0006972 QY, JX, HY 假性单核细胞增多症 10058008 pseudomononucleosis AE OAE:0006973 QY, JX, HY 免疫接种后不良事件 10069520 adverse event following immunisation AE OAE:0006974 QY, JX, HY 输液部位关节运动障碍 10076075 infusion site joint movement impairment AE OAE:0006975 QY, JX, HY 注射部位发冷 10050082 injection site coldness AE OAE:0006976 QY, JX, HY 注射部位变色 10051572 injection site discoloration AE OAE:0006977 QY, JX, HY 注射部位不舒服 10054266 injection site discomfort AE OAE:0006978 QY, JX, HY 注射部位侵蚀 10022059 injection site erosion AE OAE:0006979 QY, JX, HY 注射部位压痕 10079277 injection site indentation AE OAE:0006980 QY, JX, HY 注射部位关节不适 10073459 injection site joint discomfort AE OAE:0006981 QY, JX, HY 注射部位关节运动障碍 10053979 injection site joint movement impairment AE OAE:0006982 QY, JX, HY 注射部位关节发红 10049263 injection site joint redness AE OAE:0006983 QY, JX, HY 注射部位运动障碍 10056250 injection site movement impairment AE OAE:0006984 QY, JX, HY 灌注部位异物感 10063771 instillation site foreign body sensation AE OAE:0006985 QY, JX, HY 接种部位脓肿无菌 10069476 vaccination site abscess sterile AE OAE:0006986 QY, JX, HY 接种部位发冷 10076157 vaccination site coldness AE OAE:0006987 QY, JX, HY 接种点分泌物 10069560 vaccination site discharge AE OAE:0006988 QY, JX, HY 接种部位变色 10069474 vaccination site discoloration AE OAE:0006989 QY, JX, HY 接种部位不适 10069478 vaccination site discomfort AE OAE:0006990 QY, JX, HY 接种部位关节运动障碍 10076175 vaccination site joint movement impairment AE OAE:0006991 QY, JX, HY 接种部位肿块 10076182 vaccination site mass AE OAE:0006992 QY, JX, HY 接种部位运动障碍 10076183 vaccination site movement impairment AE OAE:0006993 QY, JX, HY 脓肿无菌 10000317 abscess sterile AE OAE:0006994 QY, JX, HY 给药部位脓肿无菌 10075922 administration site abscess sterile AE OAE:0006995 QY, JX, HY 热感觉过敏 10068011 thermohyperesthesia AE OAE:0006996 QY, JX, HY 隐球菌抗原 10068337 cryptococcus antigen AE OAE:0006997 QY, JX, HY 移植的并发症 10058060 graft complication AE OAE:0006998 QY, JX, HY 肾移植感染 10078229 renal graft infection AE OAE:0006999 QY, JX, HY 恶性脾肿瘤 10026702 malignant splenic neoplasm AE OAE:0007000 QY, JX, HY 扁桃体疾病 10053477 tonsillar disorder AE OAE:0007001 This is an AE which is caused by substances derived from microbial plaque accumulating at or near the gingival sulcus; all other suspected local and systemic etiologic factors either enhance plaque accumulation or retention, or enhance the susceptibility of the gingival tissue to microbial attack. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3522644/ 牙龈感染 10058802 gingival infection AE OAE:0007002 This is an AE which might be underestimated due to its asymptomatic and non-specific mild infection, and the lack of simple standardized laboratory diagnostics in hospitals, especially in the developing countries. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19736383/ 汉坦病毒感染 10061198 hantaviral infection AE OAE:0007003 This is an AE which is large macroparasites caused infection; adults can generally be seen with the naked eye. QY, JX, HY http://en.volupedia.org/wiki/Parasitic_worm 蠕虫感染 10061201 helminthic infection AE OAE:0007004 This is an AE which is a histological technique used to visualize acid-fast bacilli using fluorescence microscopy, notably species in the Mycobacterium genus and it can cause infection. QY, JX, HY http://en.volupedia.org/wiki/Auramine%E2%80%93rhodamine_stain 抗酸杆菌感染 10054204 acid fast bacilli infection AE OAE:0007005 This is an AE which include skin infections such as cellulitis, pustules, and furuncles. QY, JX, HY http://en.volupedia.org/wiki/Aeromonas_infection 气单胞菌属感染 10054205 aeromonas infection AE OAE:0007006 This is an AE which is the closed sac between the embryo and the amnion, containing the amniotic fluid and is infected. QY, JX, HY http://en.volupedia.org/wiki/Amniotic_sac 羊膜腔感染 10060937 amniotic cavity infection AE OAE:0007007 This is an AE which is the invasion of an administration site by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce . QY, JX, HY http://en.volupedia.org/wiki/Infection 给药部位感染 10066214 administration site infection AE OAE:0007008 This is an AE which is a genus consisting of a few hundred mold species found in various climates worldwide and it can cause infection. QY, JX, HY http://en.volupedia.org/wiki/Aspergillus 曲霉属真菌感染 10074171 aspergillus infection AE OAE:0007009 This is an AE which is uncommon and characterized by a chronic, indolent course before diagnosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28344532/ 非典型性分枝杆菌感染 10061663 atypical mycobacterial infection AE OAE:0007010 This is an AE which is a genus of Gram-positive, rod-shaped bacteria, a member of the phylum Firmicutes, with 266 named species and it caused infection. QY, JX, HY http://en.volupedia.org/wiki/Bacillus 芽孢杆菌感染 10060976 bacillus infection AE OAE:0007011 This is an AE which is one of the common complications after hematopoietic stem cell transplantation(HSCT), which is also one of the reasons of the hemorrhagic cystitis． QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30501736/ 多瘤病毒感染 10055181 bk virus infection AE OAE:0007012 This is an AE which is a genus of single-celled heterokont parasites belonging to a group of organisms that are known as the Stramenopiles (also called Heterokonts) that includes algae, diatoms, and water molds and it can cause infection. QY, JX, HY http://en.volupedia.org/wiki/Blastocystis 人芽囊原虫感染，囊胚感染 10005092 blastocystis infection AE OAE:0007013 This is an AE which is a small pocket of body fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection. QY, JX, HY http://en.volupedia.org/wiki/Blister 水泡感染 10005192 blister infected AE OAE:0007014 This is an AE which is a genus of small (0.2 0.7 m), gram-negative coccobacilli of the phylum Proteobacteria. Bordetella species, with the exception of B. petrii, are obligate aerobes, as well as highly fastidious, or difficult to culture and all species can infect humans. QY, JX, HY http://en.volupedia.org/wiki/Bordetella 博代氏杆菌属感染 10052307 bordetella infection AE OAE:0007015 This is an AE which is an etiological factor which should be considered in patients suffering from vertigo especially if positional nystagmus is present. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3421091/ 博氏菌感染 10061591 borrelia infection AE OAE:0007016 This is an AE which is an emerging pathogen causes life-threatening infections in cystic fibrosis patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30012345/ 洋葱伯克霍尔德氏菌复杂感染 10069657 burkholderia cepacia complex infection AE OAE:0007017 This is an AE which is the inflammation of one or more bursae (fluid filled sacs) of synovial fluid in the body and is infective. QY, JX, HY http://en.volupedia.org/wiki/Bursitis 滑囊炎感染 10061022 bursitis infective AE OAE:0007018 This is an AE which is an infection by the Campylobacter bacterium, most commonly C. jejuni. QY, JX, HY http://en.volupedia.org/wiki/Campylobacteriosis 弯曲杆菌感染 10051226 campylobacter infection AE OAE:0007019 This is an AE which is a fungal infection due to any type of Candida (a type of yeast) , when it affects the mouth, in some countries it is commonly called thrush. QY, JX, HY http://en.volupedia.org/wiki/Candidiasis 念珠菌感染 100741710 candida infection AE OAE:0007020 This is an AE which refers a reemerging arbovirus, causes a crippling musculoskeletal inflammatory disease in humans characterized by fever, polyarthralgia, myalgia, rash, and headache. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28248203/ 基孔肯雅病毒感染 10067256 chikungunya virus infection AE OAE:0007021 This is an AE which is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis. QY, JX, HY http://en.volupedia.org/wiki/Chlamydia 衣原体感染 10061041 chlamydial infection AE OAE:0007022 This is an AE which is a genus of Gram-negative coliform bacteria in the family Enterobacteriaceae and it causes infection. QY, JX, HY http://en.volupedia.org/wiki/Citrobacter 枸橼酸杆菌属感染，柠檬酸杆菌感染 10051904 citrobacter infection AE OAE:0007023 This is an AE which is a group of related RNA viruses that cause diseases in mammals and birds and it caused infection. QY, JX, HY http://en.volupedia.org/wiki/Coronavirus 冠状病毒感染 10053983 corona virus infection AE OAE:0007024 This is an AE which is a group of related RNA viruses that cause diseases in mammals and birds and it caused infection. QY, JX, HY http://en.volupedia.org/wiki/Coronavirus 冠状病毒感染 10051905 coronavirus infection AE OAE:0007025 This is an AE which is a genus of bacteria that are Gram-positive and most are aerobic and it caused infection. QY, JX, HY http://en.volupedia.org/wiki/Corynebacterium 棒状杆菌属感染 10061092 corynebacterium infection AE OAE:0007026 This is an AE which is a mainstay of adjunctive therapy for superficial bladder cancer that increases length of disease progression-free survival and it usually well tolerated, moderate to severe local and systemic infectious complications can occur with this immunotherapy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31711964/ 播散性卡介苗杆菌感染 10076666 disseminated bacillus calmette-guerin infection AE OAE:0007027 This is an AE which is a polyphyletic group of viruses associated with enteric disease in humans and it caused infection. QY, JX, HY http://en.volupedia.org/wiki/Echovirus ECHO病毒感染 10061113 echo virus infection AE OAE:0007028 This is an AE which is inflammation of the skin, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 湿疹感染 10014199 eczema infected AE OAE:0007029 This is an AE which include asymptomatic infections, the primary infection, infectious mononucleosis, and the progression of asymptomatic or primary infections . QY, JX, HY http://en.volupedia.org/wiki/Epstein%E2%80%93Barr_virus_infection 埃普斯坦-巴尔病毒感染 10015108 epstein-barr virus infection AE OAE:0007030 This is an AE which is an epilepsy syndrome in which new-onset refractory status epilepticus (NORSE) is preceded by febrile illness 24 hours to 2 weeks prior to the onset of seizures. QY, JX, HY http://en.volupedia.org/wiki/Febrile_infection-related_epilepsy_syndrome 发热性感染相关癫痫综合征 10079438 febrile infection-related epilepsy syndrome AE OAE:0007031 This is an AE which is a infection caused by genus of Gram-variable-staining facultative anaerobic bacteria of which Gardnerella vaginalis is the only species. QY, JX, HY http://en.volupedia.org/wiki/Gardnerella_vaginalis 加德纳菌属感染 10017728 gardnerella infection AE OAE:0007032 This is an AE which is an infection by a type of intestinal parasite known as a hookworm. QY, JX, HY http://en.volupedia.org/wiki/Hookworm_infection 钩虫感染 10020376 hookworm infection AE OAE:0007033 This is an AE which is the name given to all viruses in the genus Bocaparvovirus of virus family Parvoviridae that are known to infect humans. QY, JX, HY http://en.volupedia.org/wiki/Human_bocavirus 人类博卡病毒感染 10077391 human bocavirus infection AE OAE:0007034 This is an AE which has been associated with different epilepsy syndromes, including febrile seizures and status epilepticus, acute symptomatic seizures secondary to encephalitis and temporal lobe epilepsy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30953871/ 人类疱疹病毒6感染 10020431 human herpesvirus 6 infection AE OAE:0007035 This is an AE which is an infectious disease caused by certain types of human herpes viruses. QY, JX, HY http://en.volupedia.org/wiki/Roseola 人类疱疹病毒7感染 10063571 human herpesvirus 7 infection AE OAE:0007036 This is an AE which is a family of viruses whose natural hosts are primarily mammals such as human. QY, JX, HY http://en.volupedia.org/wiki/Polyomaviridae 人类多瘤病毒感染 10057366 human polyomavirus infection AE OAE:0007037 This is an AE which is the causation of a disease, a harmful complication, or other ill effect by any medical activity, including diagnosis, intervention, error, or negligence. QY, JX, HY http://en.volupedia.org/wiki/Iatrogenesis 医源性感染 10064091 iatrogenic infection AE OAE:0007038 This is an AE which is the invasion of an implant site by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 植入部位感染 10059650 implant site infection AE OAE:0007039 This is an AE which is defined as infections occurring up to 30 days after surgery (or up to one year after surgery in patients receiving implants) and affecting either the incision or deep tissue at the operation site. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19022115/ 切口部位感染 10065616 incision site infection AE OAE:0007040 This is an AE which is the passing of a pathogen causing communicable disease from an infected host individual or group to a particular individual or group, regardless of whether the other individual was previously infected such as indirect infection. QY, JX, HY http://en.volupedia.org/wiki/Transmission_(medicine) 间接感染传播 10021714 indirect infection transmission AE OAE:0007041 This is an AE which is a wound received from the mouth of an animal or human and can caused infection. QY, JX, HY http://en.volupedia.org/wiki/Bite_(disambiguation) 被感染的叮咬 10076911 infected bite AE OAE:0007042 This is an AE which is a closed infected sac , having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 受感染的囊肿 10058015 infected cyst AE OAE:0007043 This is an AE which has been widely documented in marine mammals and may cause morbidity and mortality at levels that result in population level effects. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27667806/ 原生动物的感染 10021859 infection protozoal AE OAE:0007044 This is an AE which is the invasion of an organism's body tissues by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce such as via vaccinee. QY, JX, HY http://en.volupedia.org/wiki/Infection 通过接种疫苗感染 10021875 infection via vaccinee AE OAE:0007045 This is an AE which is an infection usually caused by the Epstein–Barr virus (EBV). QY, JX, HY http://en.volupedia.org/wiki/Infectious_mononucleosis 传染性单核细胞增多 10021914 infectious mononucleosis AE OAE:0007046 This is an AE which is the inflammation with infective of the fluid-filled sheath (called the synovium) that surrounds a tendon, typically leading to joint pain, swelling, and stiffness. QY, JX, HY http://en.volupedia.org/wiki/Tenosynovitis 感染性腱鞘炎 10057619 infective tenosynovitis AE OAE:0007047 This is an AE which refers a member of polyomaviridae family, has been described as a cause of the progressive multifocal leukoencephalopathy (PML) and it is a potentially fatal, disabling demyelinating infection of the brain occurring mostly in the setting of immunosuppression. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31142409/ jc病毒感染 10023163 jc virus infection AE OAE:0007048 This is an AE which is a genus of pathogenic Gram-negative bacteria that includes the species L. pneumophila, causing legionellosis (all illnesses caused by Legionella) including a pneumonia-type illness called Legionnaires' disease and a mild flu-like illness called Pontiac fever. QY, JX, HY http://en.volupedia.org/wiki/Legionella 军团菌感染 10061266 legionella infection AE OAE:0007049 This is an AE which is an atypical mycobacterial infection, i.e. one with nontuberculous mycobacteria or NTM, caused by Mycobacterium avium complex (MAC), which is made of two Mycobacterium species, M. avium and M. intracellulare. QY, JX, HY http://en.volupedia.org/wiki/Mycobacterium_avium-intracellulare_infection 禽分枝杆菌复合感染 10058806 mycobacterium avium complex infection AE OAE:0007050 This is an AE which occur after traumatic injuries, minor skin lesions, nonpenetrating injuries, natural childbirth, and in postsurgical and immunocompromised patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33303335/ 软组织坏死感染 10076637 necrotising soft tissue infection AE OAE:0007051 This is an AE which is an infection caused by large genus of bacteria that colonize the mucosal surfaces of many animals. QY, JX, HY http://en.volupedia.org/wiki/Neisseria 奈瑟氏菌属感染 10062212 neisseria infection AE OAE:0007052 This is an AE which is associated with high mortality and morbidity and is transmitted by direct and indirect contact. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22071827/ 新生儿念珠菌感染 10028924 neonatal candida infection AE OAE:0007053 This is an AE which is infections of the neonate (newborn) acquired during prenatal development or in the first four weeks of life (neonatal period). QY, JX, HY http://en.volupedia.org/wiki/Neonatal_infection 新生儿感染 10061308 neonatal infection AE OAE:0007054 This is an AE which is inflammation with noninfective of the outermost layer of the white part of the eye and the inner surface of the eyelid. QY, JX, HY http://en.volupedia.org/wiki/Conjunctivitis 非感染性结膜炎 10074701 noninfective conjunctivitis AE OAE:0007055 This is an AE which is a non-destructive and noninfective disease that causes inflammation of the gums. QY, JX, HY http://en.volupedia.org/wiki/Gingivitis 非感染性牙龈炎 10074863 noninfective gingivitis AE OAE:0007056 This is an AE which is serologically cross-reactive and cross-protective, and after the cessation of smallpox vaccination, CPXV and other OPV infections represent an emerging threat to human health. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21453121/ 正痘病毒感染 10069586 orthopox virus infection AE OAE:0007057 This is an AE which is involved in both juvenile and adult laryngeal papilloma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23273988/ 乳头状瘤病毒感染 10061331 papilloma viral infection AE OAE:0007058 This is an AE which is a common cause of seasonal upper respiratory tract infections in children and adults. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/12603206/ 副流感嗜血杆菌病毒感染 10061907 parainfluenzae virus infection AE OAE:0007059 This is an AE which is an important emerging infection in young infants, able to cause sepsis-like disease and meningoencephalitis, especially in newborns. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32656569/ 甲状病毒感染 10071449 parechovirus infection AE OAE:0007060 This is an AE which may cause significant fetal damage, and in rare cases, brain anomalies and neurodevelopmental insults, especially if infection occurs in the first 20 weeks of pregnancy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28398685/ 细小病毒b19感染 10034099 parvovirus b19 infection AE OAE:0007061 This is an AE which is an infection caused by viruses have linear, single-stranded DNA (ssDNA) genomes that typically contain two genes encoding for a replication initiator protein, called NS1, and the protein the viral capsid is made of. QY, JX, HY http://en.volupedia.org/wiki/Parvoviridae 细小病毒感染 10057343 parvovirus infection AE OAE:0007062 This is an AE which is an infection caused by species of parasitic protozoa that causes tertian malaria in humans. QY, JX, HY http://en.volupedia.org/wiki/Plasmodium_ovale 卵圆形疟原虫感染 10035502 plasmodium ovale infection AE OAE:0007063 This is an AE which is one of the most common causes of acute glomerulonephritis in children. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28891413/ 感染后肾炎 10074480 post infection glomerulonephritis AE OAE:0007064 This is an AE which is the invasion of post procedural tissue by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 手术后感染 10067268 post procedural infection AE OAE:0007065 This is an AE which is considered surgical site infection. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28790284/ 术后伤口感染 10036410 postoperative wound infection AE OAE:0007066 This is an AE which is an infection caused by a gram-positive, anaerobic, rod-shaped genus of bacteria . QY, JX, HY 丙酸杆菌感染 10051946 propionibacterium infection AE OAE:0007067 This is an AE which is a genus of Gram-negative Proteobacteria caused infection. QY, JX, HY http://en.volupedia.org/wiki/Proteus_(bacterium) 变形杆菌感染 10061470 proteus infection AE OAE:0007068 This is an AE which is the invasion of puncture site tissues by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 穿刺部位感染 10063677 puncture site infection AE OAE:0007069 This is an AE which is an infection caused by a type of virus that inserts a copy of its RNA genome into the DNA of a host cell that it invades, thus changing the genome of that cell. QY, JX, HY http://en.volupedia.org/wiki/Retrovirus 逆转录病毒感染 10061493 retroviral infection AE OAE:0007070 This is an AE which is a leading cause of severe, dehydrating gastroenteritis in children <5 years of age. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29119972/ 轮状病毒感染 10067470 rotavirus infection AE OAE:0007071 This is an AE which is an infection caused by the species of rod-shaped, Gram-negative bacteria in the family Yersiniaceae. QY, JX, HY http://en.volupedia.org/wiki/Serratia_marcescens 沙雷氏菌感染 10061512 serratia infection AE OAE:0007072 This is an AE which is a severe invasive infection caused by genus of gram-positive coccus (plural cocci) or spherical bacteria that belongs to the family Streptococcaceae, within the order Lactobacillales (lactic acid bacteria), in the phylum Firmicutes. QY, JX, HY http://en.volupedia.org/wiki/Streptococcus 严重侵袭性链球菌感染 10072839 severe invasive streptococcal infection AE OAE:0007073 This is an AE which is an infection caused by a strictly aerobic Gram-negative bacterium that has a single polar flagellum with slow motility. QY, JX, HY http://en.volupedia.org/wiki/Sphingomonas_paucimobilis 鞘氨醇单胞菌感染 10069639 sphingomonas paucimobilis infection AE OAE:0007074 This is an AE which is an infection caused by that contains distinctive diderm (double-membrane) gram-negative bacteria, most of which have long, helically coiled (corkscrew-shaped or spiraled) cells. QY, JX, HY http://en.volupedia.org/wiki/Spirochaete 螺旋体感染 10061370 spirochaetal infection AE OAE:0007075 This is an AE which is an infection caused by a genus of Gram-negative bacteria,comprising at least ten species. QY, JX, HY http://en.volupedia.org/wiki/Stenotrophomonas 狭养单胞菌感染 10054138 stenotrophomonas infection AE OAE:0007076 This is an AE which is an infection caused by a genus of gram-positive coccus (plural cocci) or spherical bacteria that belongs to the family Streptococcaceae, within the order Lactobacillales (lactic acid bacteria), in the phylum Firmicutes. QY, JX, HY http://en.volupedia.org/wiki/Streptococcus 链球菌感染 10061372 streptococcal infection AE OAE:0007077 This is an AE which is an infection caused by small tubular structures of the skin that produce sweat. QY, JX, HY http://en.volupedia.org/wiki/Sweat_gland 汗腺感染 10055027 sweat gland infection AE OAE:0007078 This is an AE which is the invasion of an systemic body tissues by disease-causing agents such as bacterial, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 全身细菌感染 10078415 systemic bacterial infection AE OAE:0007079 This is an AE which occurs in allogeneic hematopoietic stem cell transplantation, but data in children receiving chemotherapy for acute leukemia are scarce. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32918533/ 全身病毒感染 10078452 systemic viral infection AE OAE:0007080 This is an AE which is a fungal infection of the skin. QY, JX, HY http://en.volupedia.org/wiki/Dermatophytosis 癣感染 10060889 tinea infection AE OAE:0007081 This is an AE which is a case of illness in which a vaccinated individual becomes sick from the same illness that the vaccine is meant to prevent. QY, JX, HY http://en.volupedia.org/wiki/Breakthrough_infection 疫苗突破感染 10067923 vaccine breakthrough infection AE OAE:0007082 This is an AE which is an infection caused by a large, complex, enveloped virus belonging to the poxvirus family. QY, JX, HY http://en.volupedia.org/wiki/Vaccinia 痘苗病毒感染 10046865 vaccinia virus infection AE OAE:0007083 This is an AE which causes varicella (chickenpox), which can be severe in immunocompromised individuals, infants and adults. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27188665/ 水痘带状疱疹病毒感染 10075611 varicella zoster virus infection AE OAE:0007084 This is an AE which is the major route of HCV infection in children. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26350018/ 垂直感染传播 10047337 vertical infection transmission AE OAE:0007085 This is an AE which is an infection caused by a single-stranded RNA virus that causes West Nile fever. QY, JX, HY http://en.volupedia.org/wiki/West_Nile_virus 西尼罗河病毒感染 10057293 west nile viral infection AE OAE:0007086 This is an AE which is an infection caused by a genus of bacteria in the family Yersiniaceae. QY, JX, HY http://en.volupedia.org/wiki/Yersinia 耶尔森氏菌感染 10061416 yersinia infection AE OAE:0007087 This is an AE which is an infection aggregation of macrophages that forms in response to chronic inflammation with septic on infantile . QY, JX, HY http://en.volupedia.org/wiki/Granuloma 小儿感染性肉芽肿病 10048708 infantile septic granulomatosis AE OAE:0007088 This is an AE which is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning and is severe. QY, JX, HY http://en.volupedia.org/wiki/Intellectual_disability#Terminology 严重侵袭性链球菌感染 10040443 severe mental retardation AE OAE:0007089 This is an AE which refers a result of severe infection. QY, JX, HY http://en.volupedia.org/wiki/Shock 休克 10040560 shock AE OAE:0007090 This is an AE which is a viral infection of the skin that results in small raised pink lesions with a dimple in the center. QY, JX, HY http://en.volupedia.org/wiki/Molluscum_contagiosum 接触传染性软疣 10027807 molluscum contagiosum AE OAE:0007091 This is an AE which is a bacterial infection involving the inner layers of the skin. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 蜂窝织炎 10007882 cellulitis AE OAE:0007092 This is an AE which is inflammation of eye tissues behind the orbital septum. QY, JX, HY http://en.volupedia.org/wiki/Orbital_cellulitis 眼眶蜂窝织炎 10007918 cellulitis orbital AE OAE:0007093 This is an AE which describes an uncomplicated inflammation of the dermis and hypodermis from a noninfectious etiology. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32301203/ 假性蜂窝织炎 10074969 pseudocellulitis AE OAE:0007094 This is an AE which is characterized as a disruption to the microbiota homeostasis caused by an imbalance in the microflora, changes in their functional composition and metabolic activities, or a shift in their local distribution. QY, JX, HY http://en.volupedia.org/wiki/Dysbiosis 菌群失调 10064389 dysbacteriosis AE OAE:0007095 This is an AE which is a bacterial infection most commonly caused by Listeria monocytogenes,although L. ivanovii and L. grayi have been reported in certain cases. QY, JX, HY http://en.volupedia.org/wiki/Listeriosis 李氏杆菌病 10024641 listeriosis AE OAE:0007096 This is an AE which is a serious fungal infection, usually in people who are immunocompromised. QY, JX, HY http://en.volupedia.org/wiki/Mucormycosis 毛霉菌病 10028098 mucormycosis AE OAE:0007097 This is an AE which is an infectious disease affecting either the lungs (pulmonary nocardiosis) or the whole body (systemic nocardiosis). QY, JX, HY http://en.volupedia.org/wiki/Nocardiosis 诺卡氏菌病 10029444 nocardiosis AE OAE:0007098 This is an AE which is a mammalian fungal disease caused by Coccidioides immitis or Coccidioides posadasii. QY, JX, HY http://en.volupedia.org/wiki/Coccidioidomycosis 球孢子菌病 10009825 coccidioidomycosis AE OAE:0007099 This is an AE which is a symptomatic infection caused by bacteria of the Salmonella type. QY, JX, HY http://en.volupedia.org/wiki/Salmonellosis 沙门氏菌病 10039447 salmonellosis AE OAE:0007100 This is an AE which is localized redness, heat, swelling and pain. QY, JX, HY http://en.volupedia.org/wiki/Infection 细菌性疾病载体 10004017 bacterial disease carrier AE OAE:0007101 This is an AE which is the most common form of cutaneous T-cell lymphoma. QY, JX, HY http://en.volupedia.org/wiki/Mycosis_fungoides 蕈样真菌病 10028483 mycosis fungoides AE OAE:0007102 This is an AE which is a potentially fatal fungal infection of mainly the lungs, presenting as a pneumonia, and brain, where it appears as a meningitis. QY, JX, HY http://en.volupedia.org/wiki/Cryptococcosis 隐球菌病 10011490 cryptococcosis AE OAE:0007103 This is an AE which is disease caused by fungi. QY, JX, HY http://en.volupedia.org/wiki/Fungal_infection 真菌疾病载体 10080548 fungal disease carrier AE OAE:0007104 This is an AE which remains a rare disease occurring mostly in patients with predisposing host conditions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24126720/ 真菌性心内膜炎 10017529 fungal endocarditis AE OAE:0007105 This is an AE which is a fungal infection caused by Histoplasma capsulatum. QY, JX, HY http://en.volupedia.org/wiki/Histoplasmosis 组织胞浆菌病 10020141 histoplasmosis AE OAE:0007106 This is an AE which is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. QY, JX, HY http://en.volupedia.org/wiki/Uveitis 病毒性葡萄膜炎 10071005 viral uveitis AE OAE:0007107 This is an AE which is an infectious disease caused by one of two virus variants, Variola major and Variola minor. QY, JX, HY http://en.volupedia.org/wiki/Smallpox 天花 10041197 smallpox AE OAE:0007108 This is an AE which is a infection caused by a cytolytic Coxsackievirus of the Picornaviridae family, an enterovirus (a group containing the polioviruses, coxsackieviruses, and echoviruses). QY, JX, HY http://en.volupedia.org/wiki/Coxsackie_A_virus 柯萨基病毒感染 10011261 coxsackie viral infection AE OAE:0007109 This is an AE which causes clinically significant illness during acute and recurrent infection accompanied by robust innate and acquired immune responses. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30247598/ 播散性水痘带状疱疹疫苗病毒感染 10076667 disseminated varicella zoster vaccine virus infection AE OAE:0007110 This is an AE which causes clinically significant illness during acute and recurrent infection accompanied by robust innate and acquired immune responses. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30247598/ 播散性水痘带状疱疹病毒感染 10084396 disseminated varicella zoster virus infection AE OAE:0007111 This is an AE which is acute febrile tick-borne infectious diseases caused by members from the genera Ehrlichia and Anaplasma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28457353/ 人埃利希体病 10020429 human ehrlichiosis AE OAE:0007112 This is an AE which is an infection caused by any of the amoebae of the Entamoeba genus. QY, JX, HY http://en.volupedia.org/wiki/Amoebiasis 阿米巴疾病 10001980 amoebiasis AE OAE:0007113 This is an AE which is an infection caused by any of the amoebae of the Entamoeba genus. QY, JX, HY http://en.volupedia.org/wiki/Amoebiasis 阿米巴痢疾 10001986 amoebic dysentery AE OAE:0007114 This is an AE which is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. QY, JX, HY http://en.volupedia.org/wiki/Ebola 埃博拉病 10014071 ebola disease AE OAE:0007115 This is an AE which is a malaria-like parasitic disease caused by infection with a eukaryotic parasite in the order Piroplasmida, typically a Babesia or Theileria, in the phylum Apicomplexa. QY, JX, HY http://en.volupedia.org/wiki/Babesiosis 巴贝西虫病 10003965 babesiosis AE OAE:0007116 This is an AE which is an infectious disease produced by bacteria of the genus Bartonella. QY, JX, HY http://en.volupedia.org/wiki/Bartonellosis 巴尔通体病 10004145 bartonellosis AE OAE:0007117 This is an AE which is a food-borne parasitic infection caused by the lung fluke, most commonly Paragonimus westermani. QY, JX, HY http://en.volupedia.org/wiki/Paragonimiasis 并殖吸虫病 10033794 paragonimiasis AE OAE:0007118 This is an AE which was a mysterious and contagious disease that struck England and later continental Europe in a series of epidemics beginning in 1485. QY, JX, HY http://en.volupedia.org/wiki/Sweating_sickness 出汗发热 10042666 sweating fever AE OAE:0007119 This is an AE which is a mosquito-borne tropical disease caused by the dengue virus. QY, JX, HY http://en.volupedia.org/wiki/Dengue_fever 登革热 10012310 dengue fever AE OAE:0007120 This is an AE which is an infectious disease caused by the parasite Trichomonas vaginalis. QY, JX, HY http://en.volupedia.org/wiki/Trichomoniasis 滴虫病 10044620 trichomoniasis AE OAE:0007121 This is an AE which is a disease caused by infection with Coxiella burnetii, a bacterium that affects humans and other animals. QY, JX, HY http://en.volupedia.org/wiki/Q_fever 发烧 10037688 q fever AE OAE:0007122 This is an AE which is an insect-borne parasitic infection of humans and other animals. QY, JX, HY http://en.volupedia.org/wiki/African_trypanosomiasis 非洲锥虫病 10001461 african trypanosomiasis AE OAE:0007123 This is an AE which is a blood infection caused by the bacteria Leptospira. QY, JX, HY http://en.volupedia.org/wiki/Leptospirosis 钩端螺旋体病 10024238 leptospirosis AE OAE:0007124 This is an AE which is a vector-borne disease caused by infection with certain bacteria in the genus Borrelia, which is transmitted through the bites of lice or soft-bodied ticks (genus Ornithodoros). QY, JX, HY http://en.volupedia.org/wiki/Relapsing_fever 回归热 10038300 relapsing fever AE OAE:0007125 This is an AE which is an infection of the small intestine by some strains of the bacterium Vibrio cholerae. QY, JX, HY http://en.volupedia.org/wiki/Cholera 霍乱 10008631 cholera AE OAE:0007126 This is an AE which is a near-cosmopolitan zoonosis caused by adult or larval stages of cestodes belonging to the genus Echinococcus (family Taeniidae). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/14575976/ 棘球虫幼病，包虫病 10014096 echinococciasis AE OAE:0007127 This is an AE which is a tick-borne viral haemorrhagic fever endemic to South-western part of India. QY, JX, HY http://en.volupedia.org/wiki/Kyasanur_Forest_disease 夸赛纳森林病 10023505 kyasanur forest disease AE OAE:0007128 This is an AE which can cause an indolent cellulitis, more commonly in individuals who handle fish and raw meat. QY, JX, HY http://en.volupedia.org/wiki/Erysipeloid 类丹毒 10015146 erysipeloid AE OAE:0007129 This is an AE which is a human parasitic disease caused by the nematode called Strongyloides stercoralis, or sometimes the closely related S. QY, JX, HY http://en.volupedia.org/wiki/Strongyloidiasis 类圆线虫病 10042254 strongyloidiasis AE OAE:0007130 This is an AE which is a disease caused by intracellular bacteria. QY, JX, HY http://en.volupedia.org/wiki/Rickettsiosis 立克次体病 10061495 rickettsiosis AE OAE:0007131 This is an AE which is a viral disease of humans and livestock that can cause mild to severe symptoms. QY, JX, HY http://en.volupedia.org/wiki/Rift_Valley_fever 裂谷热 10039143 rift valley fever AE OAE:0007132 This is an AE which is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. QY, JX, HY http://en.volupedia.org/wiki/Gonorrhea 淋病 10018612 gonorrhoea AE OAE:0007133 This is an AE which is an infectious disease that most often results from a scratch or bite of a cat. QY, JX, HY http://en.volupedia.org/wiki/Cat-scratch_disease 猫抓热 10007729 cat scratch disease AE OAE:0007134 This is an AE which is a tropical parasitic disease caused by Trypanosoma cruzi. QY, JX, HY http://en.volupedia.org/wiki/Chagas_disease 美洲锥虫病 10001935 american trypanosomiasis AE OAE:0007135 This is an AE which is a rickettsial disease of sheep and cattle characterised by high fever and severe leucopaenia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/6349107/ 蜱传热 10043841 tick-borne fever AE OAE:0007136 This is an AE which is a bacterial infection that produces tissue gas in gangrene. QY, JX, HY http://en.volupedia.org/wiki/Gas_gangrene 气性坏疽 10017737 gas gangrene AE OAE:0007137 This is an AE which is when a person is infected with Mycobacterium tuberculosis, but does not have active tuberculosis. QY, JX, HY http://en.volupedia.org/wiki/Latent_tuberculosis 潜伏性结核 10065048 latent tuberculosis AE OAE:0007138 This is an AE which is a variety of influenza caused by viruses adapted to birds. QY, JX, HY http://en.volupedia.org/wiki/Avian_influenza 禽流感 10064097 avian influenza AE OAE:0007139 This is an AE which is a tick-borne, infectious disease caused by Anaplasma phagocytophilum, an obligate intracellular bacterium that is typically transmitted to humans by ticks of the Ixodes ricinus species complex, including Ixodes scapularis and Ixodes pacificus in North America. QY, JX, HY http://en.volupedia.org/wiki/Human_granulocytic_anaplasmosis 人类边虫病 10071038 human anaplasmosis AE OAE:0007140 This is an AE which caused by avian paramyxovirus serotype 1 (APMV-1) viruses, is included in List A of the Office International des Epizooties. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10935273/ 新城疫 10029393 newcastle disease AE OAE:0007141 This is an AE which is a disease resulting from a group A streptococcus (group A strep) infection. QY, JX, HY http://en.volupedia.org/wiki/Scarlet_fever 猩红热 10039587 scarlet fever AE OAE:0007142 This is an AE which is a form of typhus caused by the intracellular parasite Orientia tsutsugamushi, a Gram-negative α-proteobacterium of family Rickettsiaceae first isolated and identified in 1930 in Japan. QY, JX, HY http://en.volupedia.org/wiki/Scrub_typhus 恙虫病 10039766 scrub typhus AE OAE:0007143 This is an AE which is an infection caused by any one of several types of swine influenza viruses. QY, JX, HY http://en.volupedia.org/wiki/Swine_influenza 猪流感 10069500 swine influenza AE OAE:0007144 This is an AE which is an infestation of lice (blood-feeding ectoparasitic insects of the order Phthiraptera). QY, JX, HY http://en.volupedia.org/wiki/Pediculosis 虱病 10024424 lice infestation AE OAE:0007145 QY, JX, HY 感染再激活 10070891 infection reactivation AE OAE:0007146 This is an AE which is damage to the body internal tissue caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 内部损伤 10061245 internal injury AE OAE:0007147 This is an AE which results from damage, wear, or trauma to the bones, muscles, or other tissues of the back. QY, JX, HY http://en.volupedia.org/wiki/Back_injury 背部损伤 10003986 back injury AE OAE:0007148 This is an AE which is damage to the bursa caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 囊损伤 10057602 bursa injury AE OAE:0007149 This is an AE which is two rounded portions of the exterior anatomy of most mammals, located on the posterior of the pelvic region and is injury. QY, JX, HY http://en.volupedia.org/wiki/Buttocks 臀部损伤 10078480 buttock injury AE OAE:0007150 This is an AE which is a resilient and smooth elastic tissue but is injury, rubber-like padding that covers and protects the ends of long bones at the joints and nerves, and is a structural component of the rib cage, the ear, the nose, the bronchial tubes, the intervertebral discs, and many other body components. QY, JX, HY http://en.volupedia.org/wiki/Cartilage 软骨损伤 10007710 cartilage injury AE OAE:0007151 This is an AE which comprises nonfreezing injuries that include chilblain (aka pernio) and trench, or immersion, foot, as well as freezing injuries that affect core body tissues resulting in hypothermia of peripheral tissues, causing frostnip or frostbite. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19056919/ 冷暴露损伤 10009856 cold exposure injury AE OAE:0007152 This is an AE which is injury by an object that causes compression of the body. QY, JX, HY http://en.volupedia.org/wiki/Crush_injury 挤压伤 10061097 crush injury AE OAE:0007153 This is an AE which is injury on the consist of the mucosal tissue that lies over the mandible and maxilla inside the mouth. QY, JX, HY http://en.volupedia.org/wiki/Gums 牙龈损伤 10049300 gingival injury AE OAE:0007154 This is an AE which is a preventable adverse effect of care ("iatrogenesis"), whether or not it is evident or harmful to the patient. QY, JX, HY http://en.volupedia.org/wiki/Medical_error 医源性损伤 10061213 iatrogenic injury AE OAE:0007155 This is an AE which is injury lies on between adjacent vertebrae in the vertebral column. QY, JX, HY http://en.volupedia.org/wiki/Intervertebral_disc 椎间盘损伤 10055040 intervertebral disc injury AE OAE:0007156 This is an AE which is injury on the connection made between bones in the body which link the skeletal system into a functional whole. QY, JX, HY http://en.volupedia.org/wiki/Joint 关节损伤 10060820 joint injury AE OAE:0007157 This is an AE which is injury on the fibrous connective tissue that connects bones to other bones. QY, JX, HY http://en.volupedia.org/wiki/Ligament 韧带损伤 10061223 ligament injury AE OAE:0007158 This is an AE which is injury on a visible body part at the mouth of many animals, including humans. QY, JX, HY http://en.volupedia.org/wiki/Lip 嘴唇受伤 10055082 lip injury AE OAE:0007159 This is an AE which is injury on crescent-shaped fibrocartilaginous structure that partly divides a joint cavity. QY, JX, HY http://en.volupedia.org/wiki/Meniscus 半月板损伤 10072970 meniscus injury AE OAE:0007160 This is an AE which refers to damage of muscular or skeletal systems, which is usually due to a strenuous activity. QY, JX, HY http://en.volupedia.org/wiki/Musculoskeletal_injury 肌肉骨骼损伤 10073713 musculoskeletal injury AE OAE:0007161 This is an AE which is a common source of pain and has a great deal of functionality but is also subject to a lot of stress. QY, JX, HY http://en.volupedia.org/wiki/Neck#Clinical_significance 脖子受伤 10062211 neck injury AE OAE:0007162 This is an AE which is a medical condition in which the kidneys are functioning at less than 15% of normal levels. QY, JX, HY http://en.volupedia.org/wiki/Kidney_failure 肾损伤,肾衰竭 10061481 renal injury AE OAE:0007163 This is an AE which plays a key role in deterioration of renal function in both chronic kidney disease (CKD) and acute kidney injury (AKI). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29550485/ 肾小管损伤 10078933 renal tubular injury AE OAE:0007164 This is an AE which is an injury to part of the musculoskeletal or nervous system caused by repetitive use, vibrations, compression or long periods in a fixed position. QY, JX, HY http://en.volupedia.org/wiki/Repetitive_strain_injury 重复性劳损 10038584 repetitive strain injury AE OAE:0007165 This is an AE which is injury on a structural frame that supports an animal body. QY, JX, HY http://en.volupedia.org/wiki/Skeleton 骨骼损伤 10061363 skeletal injury AE OAE:0007166 This is an AE which is damage to the spinal cord that causes temporary or permanent changes in its function. QY, JX, HY http://en.volupedia.org/wiki/Spinal_cord_injury 脊柱损伤 10069689 spinal column injury AE OAE:0007167 This is an AE which is injuries that occur during sport, athletic activities, or exercising. QY, JX, HY http://en.volupedia.org/wiki/Sports_injury 运动损伤 10041738 sports injury AE OAE:0007168 This is an AE which is injury on a tough, high-tensile-strength band of dense fibrous connective tissue that connects muscle to bone. QY, JX, HY http://en.volupedia.org/wiki/Tendon 肌腱损伤 10043242 tendon injury AE OAE:0007169 This is an AE which is injury on a muscular organ in the mouth of a typical vertebrate. QY, JX, HY http://en.volupedia.org/wiki/Tongue 舌头受伤 10059924 tongue injury AE OAE:0007170 This is an AE which refers to trauma (injury) to the teeth and/or periodontium (gums, periodontal ligament, alveolar bone), and nearby soft tissues such as the lips, tongue, etc. QY, JX, HY http://en.volupedia.org/wiki/Dental_trauma 牙齿损伤 10044043 tooth injury AE OAE:0007171 This is an AE which is a non-medical term describing a range of injuries to the neck caused by or related to a sudden distortion of the neck associated with extension, although the exact injury mechanisms remain unknown. QY, JX, HY http://en.volupedia.org/wiki/Whiplash_(medicine) 挥鞭伤 10047929 whiplash injury AE OAE:0007172 This is an AE which occurs when living tissue is exposed to a corrosive substance (such as a strong acid, base or oxidizer) or a cytotoxic agent (such as mustard gas, lewisite or arsine). QY, JX, HY http://en.volupedia.org/wiki/Chemical_burn 化学烧伤 10008420 chemical burn AE OAE:0007173 This is an AE which refers macrophages present dysfunctional efferocytosis and abnormal phenotypes, which could result in excessive neutrophil accumulation and prolonged inflammation, thereby eventually hindering wound repair. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32856346/ 糖尿病伤口 10081558 diabetic wound AE OAE:0007174 This is an AE which is part of the complex biological response of wound tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 伤口炎症 10054923 inflammation of wound AE OAE:0007175 This is an AE which is a type of injury which happens relatively quickly in which skin is torn, cut, or punctured (an open wound). QY, JX, HY http://en.volupedia.org/wiki/Wound#Open 开放性伤口 10058834 open wound AE OAE:0007176 This is an AE which is those wounds acquired during surgical procedures. QY, JX, HY http://en.volupedia.org/wiki/Postoperative_wounds 术后伤口并发症 10061468 postoperative wound complication AE OAE:0007177 This is an AE which refers associating anterograde amnesia persisting for fifteen years, with temporal disorientation, false recognitions, initially intense transitory confabulation and secondarily bursts of confabulation, intact remote memory and persistence of old learnings. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11865559/ 创伤后癫痫 10036309 post-traumatic amnestic disorder AE OAE:0007178 This is an AE which is a form of acquired epilepsy that results from brain damage caused by physical trauma to the brain (traumatic brain injury, abbreviated TBI). QY, JX, HY http://en.volupedia.org/wiki/Post-traumatic_epilepsy 颈部创伤后综合症 10036312 post-traumatic epilepsy AE OAE:0007179 This is an AE which is a rare disorder occured on post-traumatic that is associated with neck pain and tingling/numbness of the tongue. QY, JX, HY http://en.volupedia.org/wiki/Neck-tongue_syndrome 创伤后疼痛 10071366 post-traumatic neck syndrome AE OAE:0007180 This is an AE which is a distressing feeling on the post-traumatic often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 创伤后压力心理障碍症 10065016 post-traumatic pain AE OAE:0007181 This is an AE which is a mental and behavioral disorder that can develop because of exposure to a traumatic event, such as sexual assault, warfare, traffic collisions, child abuse, domestic violence or other threats on a person's life. QY, JX, HY http://en.volupedia.org/wiki/Post-traumatic_stress_disorder 创伤后精神失调 10036316 post-traumatic stress disorder AE OAE:0007182 This is an AE which is a type of injury which happens relatively quickly in which skin is torn, cut, where blunt force trauma causes a contusion (a closed wound). QY, JX, HY http://en.volupedia.org/wiki/Wound#Closure 闭合性伤口 10057679 wound closure AE OAE:0007183 This is an AE which usually resulting from accidental injury; there are pathogenic organisms and foreign bodies in the wound. QY, JX, HY http://en.volupedia.org/wiki/Wound 伤口污染 10068796 wound contamination AE OAE:0007184 This is an AE which is a localized wound bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 伤口血肿 10071504 wound hematoma AE OAE:0007185 This is an AE which is blood escaping from the circulatory system from damaged wound haemorrhage blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 伤口出血 10051373 wound hemorrhage AE OAE:0007186 This is an AE which is a form of cell injury which results in the premature death of cells in living tissue by autolysis occured on the wound. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 伤口坏死 10053716 wound necrosis AE OAE:0007187 This is an AE which is a type of application site injury which happens relatively quickly in which skin is torn, cut, or punctured (an open wound), or where blunt force trauma causes a contusion (a closed wound) . QY, JX, HY http://en.volupedia.org/wiki/Wound 用药部位有伤口 10078380 application site wound AE OAE:0007188 This is an AE which is a small pocket of body fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection and is rupture. QY, JX, HY http://en.volupedia.org/wiki/Blister 水泡破裂 10073385 blister rupture AE OAE:0007189 This is an AE which is a closed sac, having a distinct envelope and division compared with the nearby tissue and is rupture. QY, JX, HY http://en.volupedia.org/wiki/Cyst 囊肿破裂 10061803 cyst rupture AE OAE:0007190 This is an AE which is a rare injury that occurs primarily during strength training. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33876275/ 肌肉破裂 10028331 muscle rupture AE OAE:0007191 This is an AE which is breakage of the amniotic sac before the onset of labor. QY, JX, HY http://en.volupedia.org/wiki/Prelabor_rupture_of_membranes 膜破裂时间延长 10073027 prolonged rupture of membranes AE OAE:0007192 This is an AE which is a common complication of chronic knee arthritis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19390451/ 滑膜破裂 10042862 synovial rupture AE OAE:0007193 This is an AE which is a type of abnormal and excessive growth of tissue and is rupture. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 肿瘤破裂 10070627 tumor rupture AE OAE:0007194 This is an AE which is a specific form of penetrating trauma to the skin that results from a knife or a similar pointed object. QY, JX, HY http://en.volupedia.org/wiki/Stab_wound 刀伤 10041899 stab wound AE OAE:0007195 This is an AE which is a wound, usually a puncture or laceration, caused by the teeth. QY, JX, HY http://en.volupedia.org/wiki/Animal_bite 动物咬伤 10002515 animal bite AE OAE:0007196 This is an AE which is a skin injury that occurs when exposed to extreme low temperatures, causing the freezing of the skin or other tissues, commonly affecting the fingers, toes, nose, ears, cheeks and chin areas. QY, JX, HY http://en.volupedia.org/wiki/Frostbite 冻伤 10017382 frostbite AE OAE:0007197 This is an AE which is a medical condition in which damage occurs to capillary beds in the skin, most often in the hands or feet, when blood perfuses into the nearby tissue resulting in redness, itching, inflammation, and possibly blisters. QY, JX, HY http://en.volupedia.org/wiki/Chilblains 冻疮 10008528 chillblains AE OAE:0007198 This is an AE which is substances that can cause death, injury or harm to organs, tissues, cells, and DNA usually by chemical reactions , when an organism is exposed to a sufficient quantity. QY, JX, HY http://en.volupedia.org/wiki/Poison 化学中毒 10008428 chemical poisoning AE OAE:0007199 This is an AE which is a mark of abrasion on a surface. QY, JX, HY http://en.volupedia.org/wiki/Scratch 划痕 10039737 scratch AE OAE:0007200 This is an AE which is a slough or piece of dead tissue that is cast off from the surface of the skin, particularly after a burn injury, but also seen in gangrene, ulcer, fungal infections, necrotizing spider bite wounds, tick bites associated with spotted fevers and exposure to cutaneous anthrax. QY, JX, HY http://en.volupedia.org/wiki/Eschar 焦痂 10051814 eschar AE OAE:0007201 This is an AE which is the toxic effect of certain metals in certain forms and doses on life. QY, JX, HY http://en.volupedia.org/wiki/Metal_toxicity 金属中毒 10027439 metal poisoning AE OAE:0007202 This is an AE which is the negative behavior and physical effects caused by a recent consumption of alcohol. QY, JX, HY http://en.volupedia.org/wiki/Alcohol_intoxication 酒精中毒 10001605 alcohol poisoning AE OAE:0007203 This is an AE which refers irregular tear-like wounds caused by some blunt trauma. QY, JX, HY http://en.volupedia.org/wiki/Laceration 撕裂伤 10023572 laceration AE OAE:0007204 This is an AE which is physical damage to body tissues caused by a difference in pressure between a gas space inside, or in contact with, the body, and the surrounding gas or fluid. QY, JX, HY http://en.volupedia.org/wiki/Barotrauma 气压伤 10061688 barotrauma AE OAE:0007205 This is an AE which is a sensation that causes the desire or reflex to scratch scar. QY, JX, HY http://en.volupedia.org/wiki/Itch 伤疤瘙痒 10050818 itching scar AE OAE:0007206 This is an AE which prior to lenvatinib administration prevented hyperammonemia and hepatic encephalopathy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32782972/ 分流闭塞 10040621 shunt occlusion AE OAE:0007207 This is an AE which is a type of hematoma of administration site tissue, the most common cause being capillaries damaged by trauma, causing localized bleeding that extravasates into the surrounding interstitial tissues. QY, JX, HY http://en.volupedia.org/wiki/Bruise 给药部位擦伤 10075094 administration site bruise AE OAE:0007208 This is an AE which is a bacterial infection involving the inner layers of the administration site skin. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 给药部位蜂窝织炎 10075095 administration site cellulitis AE OAE:0007209 This is an AE which is redness of the administration site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 给药部位红斑 10074796 administration site erythema AE OAE:0007210 This is an AE which is a localized bleeding such as administration site outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 给药部位血肿 10075100 administration site hematoma AE OAE:0007211 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on the administration site. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 给药部位出血 10075101 administration site hemorrhage AE OAE:0007212 This is an AE which is a common side effect of various medical conditions which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli on the administration site. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 给药部位感觉触觉减退 10075938 administration site hypoesthesia AE OAE:0007213 This is an AE which is dermal thickening on the administration site causing the cutaneous surface to feel thicker and firmer. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 给药部位硬化 10075939 administration site induration AE OAE:0007214 This is an AE which is part of the complex biological response of administration site tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 给药部位炎症 10074704 administration site inflammation AE OAE:0007215 This is an AE which is a administration site state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 给药部位刺激 10075941 administration site irritation AE OAE:0007216 This is an AE which is a administration site joint distressing feeling often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 给药部位关节疼痛 10075948 administration site joint pain AE OAE:0007217 This is an AE which is a form of cell injury which results in the premature death of cells in administration site tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 给药部位坏死 10075956 administration site necrosis AE OAE:0007218 This is an AE which is injury to administration site nervous tissue. QY, JX, HY http://en.volupedia.org/wiki/Nerve_injury 给药部位神经损伤 10075957 administration site nerve damage AE OAE:0007219 This is an AE which refers a small aggregation of cells on the administration site. QY, JX, HY http://en.volupedia.org/wiki/Nodule 给药部位结节 10075765 administration site nodule AE OAE:0007220 This is an AE which is the build-up of fluid in the administration site tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 给药部位水肿 10075104 administration site edema AE OAE:0007221 This is an AE which is a administration site distressing feeling often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 给药部位疼痛 10058049 administration site pain AE OAE:0007222 This is an AE which is a administration site sensation that causes the desire or reflex to scratch. QY, JX, HY http://en.volupedia.org/wiki/Itch 给药部位瘙痒 10075106 administration site pruritus AE OAE:0007223 This is an AE which is a change of the administration site skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 给药部位皮疹 10071156 administration site rash AE OAE:0007224 This is an AE which refers a transient abnormal enlargement of administration site not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 给药部位肿胀 10075107 administration site swelling AE OAE:0007225 This is an AE which is membrane-bound extracellular vesicles (EVs) on the administration site that are produced in the endosomal compartment of most eukaryotic cells. QY, JX, HY http://en.volupedia.org/wiki/Exosome_(vesicle) 给药部位起小囊泡 10075970 administration site vesicles AE OAE:0007226 This is an AE which refers a somewhat high temperature on the administration site. QY, JX, HY http://en.volupedia.org/wiki/Warm 给药部位发热 10075971 administration site warmth AE OAE:0007227 This is an AE which refers a pustule is a small elevation of the application site skin containing cloudy or purulent material (pus) usually consisting of necrotic inflammatory cells. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Nodule 用药部位长脓疱 10049144 application site pustules AE OAE:0007228 This is an AE which refers a hard coating on the application site skin formed during the wound healing reconstruction phase. QY, JX, HY http://en.volupedia.org/wiki/Scab 用药部位结痂 10066209 application site scab AE OAE:0007229 This is an AE which is an area of fibrous tissue that replaces normal skin after an injury such as application site scar. QY, JX, HY http://en.volupedia.org/wiki/Scar 用药部位留下疤痕 10059008 application site scar AE OAE:0007230 This is an AE which refers a transient abnormal enlargement of application site not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 用药部位肿胀 10053424 application site swelling AE OAE:0007231 This is an AE which is membrane-bound extracellular vesicles (EVs) on the application site that are produced in the endosomal compartment of most eukaryotic cells. QY, JX, HY http://en.volupedia.org/wiki/Exosome_(vesicle) 用药部位起水泡 10048941 application site vesicles AE OAE:0007232 This is an AE which refers a somewhat high temperature on application site . QY, JX, HY http://en.volupedia.org/wiki/Warm 用药部位发热 10003060 application site warmth AE OAE:0007233 This is an AE which is redness of the catheter site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 导管部位红斑 10052264 catheter site erythema AE OAE:0007234 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on catheter site. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 导管部位出血 10051099 catheter site hemorrhage AE OAE:0007235 This is an AE which is a distressing feeling on catheter site often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 导管部位疼痛 10052268 catheter site pain AE OAE:0007236 This is an AE which refers a transient abnormal enlargement of implant site not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 植入部位肿胀 10063867 implant site swelling AE OAE:0007237 This is an AE which is a bacterial infection involving the inner layers of the incision site skin. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 切口部位蜂窝织炎 10064109 incision site cellulitis AE OAE:0007238 This is an AE which refers the emission or secretion of fluid containing mucus and pus on incision site. QY, JX, HY http://en.volupedia.org/wiki/Discharge 切口部位分泌物 10082296 incision site discharge AE OAE:0007239 This is an AE which is redness of the incision site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 切口部位红斑 10065615 incision site erythema AE OAE:0007240 This is an AE which is a distressing feeling on incision site often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 切口部位疼痛 10058043 incision site pain AE OAE:0007241 This is an AE which is a incision site sensation that causes the desire or reflex to scratch. QY, JX, HY http://en.volupedia.org/wiki/Itch 切口部位瘙痒 10059386 incision site pruritus AE OAE:0007242 This is an AE which refers a transient abnormal enlargement of incision site not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 切口部位肿胀 10074758 incision site swelling AE OAE:0007243 This is an AE which is redness of the puncture site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 穿刺部位红斑 10074759 puncture site erythema AE OAE:0007244 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on puncture site . QY, JX, HY http://en.volupedia.org/wiki/Bleeding 穿刺部位出血 10051101 puncture site hemorrhage AE OAE:0007245 This is an AE which is dermal thickening on puncture site causing the cutaneous surface to feel thicker and firmer. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 穿刺部位硬结 10067681 puncture site induration AE OAE:0007246 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on post procedural. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 手术后出血 10051077 post procedural hemorrhage AE OAE:0007247 This is an AE which is a postoperative medical condition in which the kidneys are functioning at less than 15% of normal levels. QY, JX, HY http://en.volupedia.org/wiki/Kidney_failure 手术后肾功能衰竭 10056675 postoperative renal failure AE OAE:0007248 This is an AE which is a localized bleeding outside of blood vessels, due topost procedural and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 手术后血肿 10063188 post procedural hematoma AE OAE:0007249 This is an AE which is a post procedural medical condition in which poor blood flow to the brain causes cell death. QY, JX, HY http://en.volupedia.org/wiki/Stroke 手术后中风 10066591 post procedural stroke AE OAE:0007250 This is an AE which is an unfavorable result of a disease, health condition, or post procedural. QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine) 术后并发症 10058046 post procedural complication AE OAE:0007251 This is an AE which is a type of fistula occured on post procedural in which bile flows along an abnormal connection from the bile ducts into nearby hollow structure. QY, JX, HY http://en.volupedia.org/wiki/Biliary_fistula 术后胆漏 10057586 post procedural bile leak AE OAE:0007252 This is an AE which is an abnormal connection between two hollow spaces (technically, two epithelialized surfaces) on post procedural, such as blood vessels, intestines, or other hollow organs. QY, JX, HY http://en.volupedia.org/wiki/Fistula 术后瘘管 10061489 post procedural fistula AE OAE:0007253 This is an AE which is the excitatory ability that living organisms have to respond postvaccinal. QY, JX, HY http://en.volupedia.org/wiki/Irritability 接种后易怒 10057224 irritability postvaccinal AE OAE:0007254 This is an AE which is an acute vigorous local inflammatory reaction following vaccination. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29796310/ 接种疫苗的肢体广泛肿胀 10065106 extensive swelling of vaccinated limb AE OAE:0007255 This is an AE which is procedural condition of blood escaping from the circulatory system from damaged blood vessels . QY, JX, HY http://en.volupedia.org/wiki/Bleeding 手术性出血 10071229 procedural hemorrhage AE OAE:0007256 This is an AE which is often underestimated and neglected because of various myths, beliefs, and difficulties in its evaluation and treatment. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30486427/ 手术性疼痛 10064882 procedural pain AE OAE:0007257 This is an AE which is the symptom of pain in the face, head, or neck and is procedural . QY, JX, HY http://en.volupedia.org/wiki/Headache 手术性头痛 10066965 procedural headache AE OAE:0007258 This is an AE which is an imprecise term that can refer to a sense of disorientation in space, vertigo, or lightheadedness and is procedural . QY, JX, HY http://en.volupedia.org/wiki/Dizziness 手术性眩晕 10066964 procedural dizziness AE OAE:0007259 This is an AE which is a transient hyperthyroidism caused by inflammation associated with Hashimoto's thyroiditis disturbing the thyroid follicles, resulting in excess release of thyroid hormone. QY, JX, HY http://en.volupedia.org/wiki/Hashitoxicosis 积霉菌病 10067873 hashitoxicosis AE OAE:0007260 This is an AE which is an aids related unfavorable result of a disease, health condition, or treatment . QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine) 艾滋病相关并发症 10061624 aids related complication AE OAE:0007262 This is an AE which is the stream of consciousness that detaches from current, external tasks when attention drifts to a more personal and internal direction. QY, JX, HY http://en.volupedia.org/wiki/Daydream 做白日梦 10057315 daydreaming AE OAE:0007263 This is an AE which is a change in the action or side effects of a drug caused by concomitant administration with a food, beverage, supplement, or another drug. QY, JX, HY http://en.volupedia.org/wiki/Drug_interaction 药物相互作用 10064381 drug-disease interaction AE OAE:0007264 This is an AE which is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 给予额外剂量 10064366 extra dose administered AE OAE:0007265 This is an AE which is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 导管脓毒症 10053212 catheter sepsis AE OAE:0007266 This is an AE which is an extra administration of a vaccine after an earlier (primer) dose but it is missed. QY, JX, HY http://en.volupedia.org/wiki/Booster_dose 辅助剂量漏掉 10073205 booster dose missed AE OAE:0007267 This is an AE which is a staining method used to detect polysaccharides such as glycogen, and mucosubstances such as glycoproteins, glycolipids and mucins in tissues. QY, JX, HY http://en.volupedia.org/wiki/Periodic_acid%E2%80%93Schiff_stain 周期性酸性席夫染色 10076035 periodic acid schiff stain AE OAE:0007268 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) and/or organs (macroscopic scale), and/or the abnormal histology or anatomical structure presumably resulting from such growth. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 高色素沉着 10050808 hyperchromasia AE OAE:0007271 This is an AE which is the build-up of fluid in the puncture site . QY, JX, HY http://en.volupedia.org/wiki/Edema 穿刺部位水肿 10074069 puncture site edema AE OAE:0007272 This is an AE which is a distressing feeling on puncture site often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 穿刺部位疼痛 10065599 puncture site pain AE OAE:0007273 This is an AE which refers a transient abnormal enlargement of puncture site not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 穿刺部位肿胀 10072161 puncture site swelling AE OAE:0007274 This is an AE which is redness of the stoma site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 造口部位红斑 10074514 stoma site erythema AE OAE:0007275 This is an AE which is redness of the vessel puncture site skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 血管穿刺部位红斑 10074760 vessel puncture site erythema AE OAE:0007276 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on vessel puncture site. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 血管穿刺部位出血 10054092 vessel puncture site hemorrhage AE OAE:0007277 This is an AE which is an suture related unfavorable result of a disease. QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine) 缝合相关并发症 10059059 suture related complication AE OAE:0007278 This is an AE which is the medical term for using a machine called a ventilator to fully or partially provide artificial ventilation and it appears an unfavorable result of a disease. QY, JX, HY http://en.volupedia.org/wiki/Mechanical_ventilation 机械通气并发症 10066821 mechanical ventilation complication AE OAE:0007279 This is an AE which is an anaesthetic unfavorable result of a disease, health condition, or treatment. QY, JX, HY http://en.volupedia.org/wiki/Complication_(medicine) 麻醉并发症 10060938 anaesthetic complication AE OAE:0007280 This is an AE which is among the most devastating consequences of gastrointestinal surgery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32524361/ 吻合口并发症 10058059 anastomotic complication AE OAE:0007281 This is an AE which is a delayed adverse reaction to a blood transfusion or platelet transfusion that occurs when the body has produced alloantibodies to the allogeneic transfused platelets' antigens. QY, JX, HY http://en.volupedia.org/wiki/Post-transfusion_purpura 输血后紫癜 10072265 post transfusion purpura AE OAE:0007282 This is an AE which is a wheel and flare reaction occurring within 30 to 60 minutes after skin and mucosal contact. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3066278/ 接触性荨麻疹 10046742 urticaria contact AE OAE:0007283 This is an AE which is a way to detect irritated nerves. QY, JX, HY http://en.volupedia.org/wiki/Tinel%27s_sign tinel特征 10052492 tinel's sign AE OAE:0007284 This is an AE which is a series of radiographs used to examine the gastrointestinal tract for abnormalities. QY, JX, HY http://en.volupedia.org/wiki/Upper_gastrointestinal_series 钡餐 10004124 barium swallow AE OAE:0007285 This is an AE which is a infestation of insects from the genus Cimex that feed on human blood, usually at night. QY, JX, HY http://en.volupedia.org/wiki/Bed_bug 床臭虫侵染 10004194 bed bug infestation AE OAE:0007286 This is an AE which is defined as sudden onset of poor muscle tone, reduced consciousness, and pale or bluish skin occurring within 48 hours after vaccination, most commonly pertussis vaccination. QY, JX, HY http://en.volupedia.org/wiki/Hypotonic-hyporesponsive_episode 低反应性发作 10021121 hypotonic-hyporesponsive episode AE OAE:0007287 This is an AE which is a type of severe reaction that occurs in response to particular medications used during general anesthesia, among those who are susceptible. QY, JX, HY http://en.volupedia.org/wiki/Malignant_hyperthermia 恶性高热 10020844 hyperthermia malignant AE OAE:0007289 This is an AE which is a system to assess the severity of coma. QY, JX, HY http://en.volupedia.org/wiki/Coma_scale 昏迷评分 10069708 coma scale AE OAE:0007291 This is an AE which is a technique for noninvasive stimulation of the human brain. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17640522/ 经颅磁刺激 10051505 transcranial magnetic stimulation AE OAE:0007292 This is an AE which is a temporary means of pacing a patient's heart during a medical emergency. QY, JX, HY http://en.volupedia.org/wiki/Transcutaneous_pacing 经皮起搏 10083519 transcutaneous pacing AE OAE:0007294 This is an AE which is a form of viral shedding following a viral infection caused by a statistically insignificant number[citation needed] of administrations of attenuated (or "live virus") vaccines, which is a specific vaccine technology that uses an attenuated form of a live virus. QY, JX, HY http://en.volupedia.org/wiki/Vaccine_shedding 疫苗病毒脱落 10070583 vaccine virus shedding AE OAE:0007296 QY, JX, HY 给药部位关节运动障碍 10075947 administration site joint movement impairment AE OAE:0007297 QY, JX, HY 给药部位运动障碍 10075955 administration site movement impairment AE OAE:0007298 QY, JX, HY 植入部位变色 10063874 implant site discoloration AE OAE:0007299 QY, JX, HY 接种后挑战菌株脱落 10081989 post vaccination challenge strain shedding AE OAE:0007300 QY, JX, HY 分流血流量过多 10066111 shunt blood flow excessive AE OAE:0007301 QY, JX, HY 药物戒断抽搐 10013752 drug withdrawal convulsions AE OAE:0007302 This is an AE which is an abnormal condition of the mind that results in difficulties determining what is real and what is not real and it is transient. QY, JX, HY http://en.volupedia.org/wiki/Psychosis 短暂的精神病 10056326 transient psychosis AE OAE:0007303 This is an AE which is a very specific syndrome in relation to seizure activity: a clear temporal relationship exists between the psychotic state of sudden onset and a precipitating bout of complex partial or generalized seizures, with a characteristic lucid interval which lasts from two to 120h. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19683323/ 发作后精神病 10070669 postictal psychosis AE OAE:0007304 This is an AE which is a behavioral disorder characterized by explosive outbursts of anger and/or violence, often to the point of rage, that are disproportionate to the situation at hand (e.g., impulsive shouting, screaming or excessive reprimanding triggered by relatively inconsequential events). QY, JX, HY http://en.volupedia.org/wiki/Intermittent_explosive_disorder 间歇性暴发性精神障碍 10022568 intermittent explosive disorder AE OAE:0007305 This is an AE which is a mental and behavioral disorder, specifically a disorder primarily of mood, consisting of the same cognitive and physical problems as depression, but with longer-lasting symptoms. QY, JX, HY http://en.volupedia.org/wiki/Dysthymia 精神抑郁症 10013982 dysthymic disorder AE OAE:0007306 This is an AE which is a form of psychosis that is attributed to substance use. QY, JX, HY http://en.volupedia.org/wiki/Substance-induced_psychosis 物质诱发的精神障碍 10072388 substance-induced psychotic disorder AE OAE:0007307 This is an AE which is a lipid-rich (fatty) substance that surrounds nerve cell axons (the nervous system's "wires") to insulate them and increase the rate at which electrical impulses (called action potentials) are passed along the axon. QY, JX, HY http://en.volupedia.org/wiki/Myelin 髓鞘形成障碍 10067601 dysmyelination AE OAE:0007308 This is an AE which is a personality disorder characterized by a long-term pattern of unstable interpersonal relationships, distorted sense of self, and strong emotional reactions. QY, JX, HY http://en.volupedia.org/wiki/Borderline_personality_disorder 边缘型人格障碍 10006034 borderline personality disorder AE OAE:0007309 This is an AE which is a communication disorder in which there are difficulties with verbal and written expression. QY, JX, HY http://en.volupedia.org/wiki/Expressive_language_disorder 表达性语言障碍 10015715 expressive language disorder AE OAE:0007310 This is an AE which is a class of psychiatric disorders characterized by impulsivity – failure to resist a temptation, an urge, or an impulse; or having the inability to not speak on a thought. QY, JX, HY http://en.volupedia.org/wiki/Impulse-control_disorder 冲动控制障碍 10061215 impulse-control disorder AE OAE:0007311 This is an AE which is one of several chronic circadian rhythm sleep disorders (CRSDs). QY, JX, HY http://en.volupedia.org/wiki/Non-24-hour_sleep%E2%80%93wake_disorder 非24小时睡眠-觉醒障碍 10078086 non-24-hour sleep-wake disorder AE OAE:0007312 This is an AE which is a mental disorder characterized by abnormal thought processes and an unstable mood. QY, JX, HY http://en.volupedia.org/wiki/Schizoaffective_disorder 分裂情感障碍 10039621 schizoaffective disorder AE OAE:0007313 This is an AE which is a mental and behavioural disorder. QY, JX, HY http://en.volupedia.org/wiki/Schizotypal_personality_disorder 分裂型人格障碍 10039651 schizotypal personality disorder AE OAE:0007314 This is an AE which is a personality disorder characterized by a lack of interest in social relationships, a tendency toward a solitary or sheltered lifestyle, secretiveness, emotional coldness, detachment and apathy. QY, JX, HY http://en.volupedia.org/wiki/Schizoid_personality_disorder 精神分裂样人格障碍 10039624 schizoid personality disorder AE OAE:0007315 This is an AE which is a condition in which multisensory input is not adequately processed in order to provide appropriate responses to the demands of the environment. QY, JX, HY http://en.volupedia.org/wiki/Sensory_processing_disorder 感觉处理障碍 10077516 sensory processing disorder AE OAE:0007316 This is an AE which is a condition in which multisensory input is not adequately processed in order to provide appropriate responses to the demands of the environment. QY, JX, HY http://en.volupedia.org/wiki/Sensory_processing_disorder 感觉统合功能障碍 10048871 sensory integrative dysfunction AE OAE:0007317 This is an AE which is the large posterior area of the human body, rising from the top of the buttocks to the back of the neck and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Human_back 背部疾病 10003983 back disorder AE OAE:0007318 This is an AE which is a diagnostic category defining patients who have both anxiety and depressive symptoms of limited and equal intensity accompanied by at least some autonomic features. QY, JX, HY http://en.volupedia.org/wiki/Mixed_anxiety%E2%80%93depressive_disorder 混合焦虑和抑郁障碍 10080836 mixed anxiety and depressive disorder AE OAE:0007319 This is an AE which is a communication disorder in which both the receptive and expressive areas of communication may be affected in any degree, from mild to severe. QY, JX, HY http://en.volupedia.org/wiki/Mixed_receptive-expressive_language_disorder 混合接受-表达语言障碍 10027778 mixed receptive-expressive language disorder AE OAE:0007320 This is an AE which is a psychological response to a terrifying, traumatic, or surprising experience. QY, JX, HY http://en.volupedia.org/wiki/Acute_stress_disorder 急性应激障碍 10001084 acute stress disorder AE OAE:0007321 This is an AE which is a disability resulting in difficulty learning or comprehending arithmetic, such as difficulty in understanding numbers, learning how to manipulate numbers, performing mathematical calculations and learning facts in mathematics. QY, JX, HY http://en.volupedia.org/wiki/Dyscalculia 计算障碍 10049669 dyscalculia AE OAE:0007322 This is an AE which is any disease that has the connective tissues of the body as a target of pathology. QY, JX, HY http://en.volupedia.org/wiki/Connective_tissue_disease 胶原蛋白疾病 10009903 collagen disorder AE OAE:0007323 This is an AE which is a mental and behavioral disorder with anxiety, which is a maladaptive response to a psychosocial stressor that occurs when an individual has significant difficulty adjusting to or coping with a stressful psychosocial event. QY, JX, HY http://en.volupedia.org/wiki/Adjustment_disorder 焦虑性适应障碍 10001296 adjustment disorder with anxiety AE OAE:0007324 This is an AE which is a cluster of mental disorders characterized by significant and uncontrollable feelings of anxiety and fear such that a person's social, occupational, and personal function are significantly impaired. QY, JX, HY http://en.volupedia.org/wiki/Anxiety_disorder 焦虑性障碍 10057666 anxiety disorder AE OAE:0007325 This is an AE which is conditions that involve disruptions or breakdowns of memory, awareness, identity, or perception. QY, JX, HY http://en.volupedia.org/wiki/Dissociative_disorder 解离性障碍 10013462 dissociative disorder AE OAE:0007326 This is an AE which is the process by which food is crushed and ground by teeth and the process becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Chewing 咀嚼障碍 10026882 mastication disorder AE OAE:0007327 This is an AE which is a cluster C personality disorder marked by an excessive need for orderliness, neatness, and perfectionism. QY, JX, HY http://en.volupedia.org/wiki/Obsessive%E2%80%93compulsive_personality_disorder 强迫性人格障碍 10029901 obsessive-compulsive personality disorder AE OAE:0007328 This is an AE which is a group of conditions of mental and behavioral disorder where a disturbance in the person's mood is the main underlying feature. QY, JX, HY http://en.volupedia.org/wiki/Mood_disorder 情感障碍 10001443 affective disorder AE OAE:0007329 This is an AE which refers to frequent and persistent detachment from bodily self and disengagement from the outside world. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32846163/ 人格解体/现实感丧失障碍 10077805 depersonalisation/derealisation disorder AE OAE:0007330 This is an AE which is the decreased ability to see color or differences in color. QY, JX, HY http://en.volupedia.org/wiki/Color_blindness 色觉障碍 10013892 dyschromatopsia AE OAE:0007331 This is an AE which is a disorder where individuals have difficulties with verbal and nonverbal social communication. QY, JX, HY http://en.volupedia.org/wiki/Social_(pragmatic)_communication_disorder 社交沟通障碍 10078320 social (pragmatic) communication disorder AE OAE:0007332 This is an AE which is the most abundant type of granulocytes and make up 40% to 70% of all white blood cells in humans but it becomes function disorder. QY, JX, HY http://en.volupedia.org/wiki/Neutrophil 嗜中性粒细胞功能障碍 10061314 neutrophil function disorder AE OAE:0007333 This is an AE which is clinically associated with left ventricular failure in the presence of marked cardiomegaly, while diastolic dysfunction is accompanied by pulmonary congestion together with a normal or only slightly enlarged ventricle. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7713107/ 收缩功能障碍 10071436 systolic dysfunction AE OAE:0007334 This is an AE which is a mental disorder characterized by the obsessive idea that some aspect of one's own body part or appearance is severely flawed and therefore warrants exceptional measures to hide or fix it. QY, JX, HY http://en.volupedia.org/wiki/Body_dysmorphic_disorder 躯体变形障碍 10052793 body dysmorphic disorder AE OAE:0007335 This is an AE which is physical pain that is caused, increased, or prolonged by mental, emotional, or behavioral factors. QY, JX, HY http://en.volupedia.org/wiki/Psychogenic_pain 心因性疼痛障碍 10037198 psychogenic pain disorder AE OAE:0007336 This is an AE which is a condition in the brain that causes difficulties comprehending or processing information and can be caused by several different factors. QY, JX, HY http://en.volupedia.org/wiki/Learning_disability 学习能力障碍 10061265 learning disorder AE OAE:0007337 This is an AE which is a condition in the brain that causes difficulties comprehending or processing information and can be caused by several different factors. QY, JX, HY http://en.volupedia.org/wiki/Learning_disability 学习障碍 10024092 learning disability AE OAE:0007338 This is an AE which is a speech disorder in which some sounds (phonemes) are not produced or used correctly. QY, JX, HY http://en.volupedia.org/wiki/Speech_sound_disorder 言语声音障碍 10077803 speech sound disorder AE OAE:0007339 This is an AE which is disorders that involve the processing of linguistic information. QY, JX, HY http://en.volupedia.org/wiki/Language_disorder 语言障碍 10074869 language disorder AE OAE:0007340 This is an AE which is a condition in which a sufferer displays difficulty reading. QY, JX, HY http://en.volupedia.org/wiki/Reading_disability 阅读障碍 10037999 reading disorder AE OAE:0007341 This is an AE which is a neurodevelopmental disorder characterized by impaired coordination of physical movements as a result of brain messages not being accurately transmitted to the body. QY, JX, HY http://en.volupedia.org/wiki/Developmental_coordination_disorder 运动障碍 10013976 dyspraxia AE OAE:0007342 This is an AE which is probably a different disease than chronic tic disorders including Gilles de la Tourette syndrome. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850871/ 暂时性抽动障碍 10076694 provisional tic disorder AE OAE:0007343 This is an AE which is a rare disorder whose most notable features are pain in the mandibular, ocular and rectal areas as well as flushing. QY, JX, HY http://en.volupedia.org/wiki/Paroxysmal_extreme_pain_disorder 阵发性极度疼痛障碍 10081856 paroxysmal extreme pain disorder AE OAE:0007344 This is an AE which is a disruption to the efficacy of the executive functions, which is a group of cognitive processes that regulate, control, and manage other cognitive processes. QY, JX, HY http://en.volupedia.org/wiki/Executive_dysfunction 执行功能障碍 10070246 executive dysfunction AE OAE:0007345 This is an AE which is a neurodevelopmental disorder affecting the way the brain processes auditory information. QY, JX, HY http://en.volupedia.org/wiki/Auditory_processing_disorder 中枢性听觉处理障碍 10065165 central auditory processing disorder AE OAE:0007346 This is an AE which is a family of sleep disorders which affect the timing of sleep. QY, JX, HY http://en.volupedia.org/wiki/Circadian_rhythm_sleep_disorder 昼夜节律睡眠障碍 10009191 circadian rhythm sleep disorder AE OAE:0007347 This is an AE which is a condition in which a person has difficulties sitting or is unable to do so at all; usually due to pain. QY, JX, HY http://en.volupedia.org/wiki/Sitting_disability 坐姿障碍 10081807 sitting disability AE OAE:0007348 This is an AE which is the false perception of tactile sensory input that creates a hallucinatory sensation of physical contact with an imaginary object. QY, JX, HY http://en.volupedia.org/wiki/Tactile_hallucination 触觉幻觉 10019074 hallucination, tactile AE OAE:0007349 This is an AE which is a common side effect of various medical conditions which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli such as teeth hypoesthesia. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 牙齿触觉减退 10051780 hypoesthesia teeth AE OAE:0007350 This is an AE which is a common side effect of various medical conditions which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli such as hypoaesthesia facial. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 面部触觉减退 10065312 hypoesthesia facial AE OAE:0007351 This is an AE which is a common clinical condition characterized by difficulty initiating or maintaining sleep, accompanied by symptoms such as irritability or fatigue during wakefulness. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23423416/ 初始性失眠 10022035 initial insomnia AE OAE:0007352 This is an AE which is a neurodegenerative disease that usually starts slowly and progressively worsens. QY, JX, HY http://en.volupedia.org/wiki/Alzheimer%27s_disease 痴呆症阿尔茨海默氏型 10012271 dementia alzheimer's type AE OAE:0007353 This is an AE which is a sleep disorder in which people have trouble sleeping. QY, JX, HY http://en.volupedia.org/wiki/Insomnia 不眠症 10067530 hyposomnia AE OAE:0007354 This is an AE which is a mental and behavioral disorder in which a person has intrusive thoughts (called "obsessions") and/or feels the need to perform certain routines repeatedly (called "compulsions") to an extent where it induces distress or impairs one's general functioning. QY, JX, HY http://en.volupedia.org/wiki/Obsessive%E2%80%93compulsive_disorder 强迫思维 10029897 obsessive thoughts AE OAE:0007355 This is an AE which is an umbrella name for impulse control behaviors involving compulsively damaging one's physical appearance or causing physical injury. QY, JX, HY http://en.volupedia.org/wiki/Body-focused_repetitive_behavior 强迫性咬唇 10066241 compulsive lip biting AE OAE:0007356 This is an AE which is a mental and behavioral disorder in which a person has intrusive thoughts (called "obsessions") and/or feels the need to perform certain routines repeatedly (called "compulsions") to an extent where it induces distress or impairs one's general functioning. QY, JX, HY http://en.volupedia.org/wiki/Obsessive%E2%80%93compulsive_disorder 强迫性症状 10077894 obsessive-compulsive symptom AE OAE:0007357 This is an AE which is a mental and behavioral disorder in which a person has intrusive thoughts (called "obsessions") and/or feels the need to perform certain routines repeatedly (called "compulsions") to an extent where it induces distress or impairs one's general functioning. QY, JX, HY http://en.volupedia.org/wiki/Obsessive%E2%80%93compulsive_disorder 强迫症 10029898 obsessive-compulsive disorder AE OAE:0007358 This is an AE which refers a toxic condition in which neurological symptoms arise without a definable organic cause. QY, JX, HY http://en.volupedia.org/wiki/Conversion 强直性惊厥 10043994 tonic convulsion AE OAE:0007359 This is an AE which is the act of cleaning one's hands with soap and water to remove viruses/bacteria/microorganisms, dirt, grease, or other harmful and unwanted substances stuck to the hands and is compulsive . QY, JX, HY http://en.volupedia.org/wiki/Hand_washing 强制洗手 10071263 compulsive handwashing AE OAE:0007360 This is an AE which is a condition of reduced emotional reactivity in an individual. QY, JX, HY http://en.volupedia.org/wiki/Reduced_affect_display 情感迟钝 10005885 blunted affect AE OAE:0007361 This is an AE which is an extreme or rapid change in mood. QY, JX, HY http://en.volupedia.org/wiki/Mood_swing 情绪波动 10027951 mood swings AE OAE:0007362 This is an AE which is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. QY, JX, HY http://en.volupedia.org/wiki/Major_depressive_disorder 重度抑郁症 10057840 major depression AE OAE:0007363 This is an AE which is a mental and behavioral disorder, specifically a disorder primarily of mood, consisting of the same cognitive and physical problems as depression, but with longer-lasting symptoms. QY, JX, HY http://en.volupedia.org/wiki/Dysthymia 持续的抑郁症 10077804 persistent depressive disorder AE OAE:0007364 This is an AE which is the repetition of a particular response (such as a word, phrase, or gesture) regardless of the absence or cessation of a stimulus. QY, JX, HY http://en.volupedia.org/wiki/Perseveration 持续言语 10034703 perseveration AE OAE:0007365 This is an AE which is a state of low mood and aversion to activity. QY, JX, HY http://en.volupedia.org/wiki/Depressive_symptoms?wprov=srpw1_0 抑郁症状 10054089 depressive symptom AE OAE:0007366 This is an AE which is the act of intentionally causing one's own death caused by depression. QY, JX, HY http://en.volupedia.org/wiki/Suicide 抑郁症自杀 10012397 depression suicidal AE OAE:0007367 This is an AE which means difficulties in talking due to structural defects in speech organs, such as sigmatism (defective pronunciation of sibilant sounds, for example "S" pronounced as "TH") and rhotacism, in which the letter "R" pronounced as "I or Y". QY, JX, HY http://en.volupedia.org/wiki/Dyslalia 言语困难 10013931 dyslalia AE OAE:0007368 This is an AE which describes excessive speech at a rapid rate that involves causal association between ideas. QY, JX, HY http://en.volupedia.org/wiki/Glossary_of_psychiatry#flight_of_ideas 意念飞跃 10016777 flight of ideas AE OAE:0007369 This is an AE which is a state which occurs when the ability to maintain an awareness of self and environment is lost. QY, JX, HY http://en.volupedia.org/wiki/Unconsciousness 意识丧失 10024855 loss of consciousness AE OAE:0007370 This is an AE which refers to a lack of will or initiative and can be seen as a disorder of diminished motivation (DDM). QY, JX, HY http://en.volupedia.org/wiki/Abulia 意志力丧失 10050013 abulia AE OAE:0007371 This is an AE which is human vocal communication using language and it is slow. QY, JX, HY http://en.volupedia.org/wiki/Speech 语速缓慢 10071299 slow speech AE OAE:0007372 This is an AE which is sudden periods of intense fear and discomfort that may include palpitations, sweating, chest pain, shaking, shortness of breath, numbness, or a feeling of impending doom or of losing control. QY, JX, HY http://en.volupedia.org/wiki/Panic_attack 预期性焦虑 10002758 anticipatory anxiety AE OAE:0007373 This is an AE which is an anxiety disorder characterized by sentiments of fear and anxiety in social situations, causing considerable distress and impaired ability to function in at least some aspects of daily life. QY, JX, HY http://en.volupedia.org/wiki/Social_anxiety_disorder 社交焦虑症 10041242 social anxiety disorder AE OAE:0007374 This is an AE which is an intensely unpleasant emotion in response to perceiving or recognizing a danger or threat such as social communication. QY, JX, HY http://en.volupedia.org/wiki/Fear 社交恐惧 10041247 social fear AE OAE:0007375 This is an AE which is an anxiety disorder characterized by sentiments of fear and anxiety in social situations, causing considerable distress and impaired ability to function in at least some aspects of daily life. QY, JX, HY http://en.volupedia.org/wiki/Social_anxiety_disorder 社交恐惧症 10041250 social phobia AE OAE:0007376 This is an AE which is a category of sleep disorders that involve abnormal movements, behaviors, emotions, perceptions, and dreams that occur while falling asleep, sleeping, between sleep stages, or during arousal from sleep. QY, JX, HY http://en.volupedia.org/wiki/Parasomnia 深眠状态 10061910 parasomnia AE OAE:0007377 This is an AE which is a phenomenon of combined sleep and wakefulness. QY, JX, HY http://en.volupedia.org/wiki/Sleepwalking 梦游 10041012 sleep walking AE OAE:0007378 This is an AE which is closely related to emotion, and usually refers to the conscious subjective experience of emotions such as jittery. QY, JX, HY http://en.volupedia.org/wiki/Feeling 感到紧张不安 10016338 feeling jittery AE OAE:0007379 This is an AE which is defined as an unpleasant, abnormal sense of touch. QY, JX, HY http://en.volupedia.org/wiki/Dysesthesia 感觉不良 10013886 dysaesthesia AE OAE:0007380 This is an AE which occurs when one or more of the body's senses experiences over-stimulation from the environment. QY, JX, HY http://en.volupedia.org/wiki/Sensory_overload 感觉超负荷 10079780 sensory overload AE OAE:0007381 This is an AE which is an abnormal sensation of the mucosal skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 感觉异常黏膜 10033780 paraesthesia mucosal AE OAE:0007382 This is an AE which is numbness or pain in the outer thigh not caused by injury to the thigh, but by injury to a nerve that extends from the spinal column to the thigh. QY, JX, HY http://en.volupedia.org/wiki/Meralgia_paraesthetica 感应异常性股痛 10027385 meralgia paraesthetica AE OAE:0007387 This is an AE which is a state of low mood and aversion to activity. QY, JX, HY http://en.volupedia.org/wiki/Depression_(mood) 情感低落 10012374 depressed mood AE OAE:0007388 This is an AE which is a condition in which a person with a disability is cognitively unaware of having it due to an underlying physical condition. QY, JX, HY http://en.volupedia.org/wiki/Anosognosia 病感失认症 10068346 anosognosia AE OAE:0007389 This is an AE which is an instinct or thought process that is believed to be heavily influenced by anxiety or fear, often to the point of delusion and irrationality. QY, JX, HY http://en.volupedia.org/wiki/Paranoia 偏执狂 10033864 paranoia AE OAE:0007390 This is an AE which is a set of delusional conditions in which the affected persons believe they are being persecuted, despite a lack of evidence. QY, JX, HY http://en.volupedia.org/wiki/Persecutory_delusion 迫害妄想 10034702 persecutory delusion AE OAE:0007391 This is an AE which is transitory pain that comes on suddenly and is not alleviated by the patient's regular pain management. QY, JX, HY http://en.volupedia.org/wiki/Pain#Breakthrough_pain 爆发性疼痛 10064556 breakthrough pain AE OAE:0007392 This is an AE which is suggested to be similar to classic migraines, with cortical spreading depression leading to aura formation but without an associated headache. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30225597/ 复杂性偏头痛 10056236 complicated migraine AE OAE:0007393 This is an AE which is memory-based delusion or confabulation, or an inability to distinguish between real and fantasy memories. QY, JX, HY http://en.volupedia.org/wiki/Paramnesia 副失忆症 10033848 paramnesia AE OAE:0007394 This is an AE which is a neurodevelopmental disorder characterized by significant difficulties in social interaction and nonverbal communication, along with restricted and repetitive patterns of behavior and interests. QY, JX, HY http://en.volupedia.org/wiki/Asperger_syndrome 孤独症 10003484 asperger's disorder AE OAE:0007395 This is an AE which is a borrowed French word expressing the feeling that one has lived through the present situation before. QY, JX, HY http://en.volupedia.org/wiki/D%C3%A9j%C3%A0_vu 幻觉记忆 10012177 deja vu AE OAE:0007396 This is an AE which is a memory disorder characterized by sudden retrograde episodic memory loss, said to occur for a period of time ranging from hours to years to decades. QY, JX, HY http://en.volupedia.org/wiki/Psychogenic_amnesia 解离性失忆 10013461 dissociative amnesia AE OAE:0007397 This is an AE which is the most common type of primary headache. QY, JX, HY http://en.volupedia.org/wiki/Tension_headache 紧张性头痛 10043269 tension headache AE OAE:0007398 This is an AE which is an extreme or irrational fear or phobia of heights, especially when one is not particularly high up. QY, JX, HY http://en.volupedia.org/wiki/Acrophobia 恐高症 10000605 acrophobia AE OAE:0007399 This is an AE which is a mental and behavioral disorder, specifically an anxiety disorder characterized by reoccurring unexpected panic attacks. QY, JX, HY http://en.volupedia.org/wiki/Panic_disorder 恐慌症 10033666 panic disorder AE OAE:0007400 This is an AE which is a mixed perception in the absence of an external stimulus that has the qualities of a real perception. QY, JX, HY http://en.volupedia.org/wiki/Hallucination 混合幻觉 10019079 hallucinations, mixed AE OAE:0007401 This is an AE which is human vocal communication using language and is disorganised. QY, JX, HY http://en.volupedia.org/wiki/Speech 说话方式慌乱 10076227 disorganised speech AE OAE:0007402 This is an AE which is a cortical development malformation that is commonly associated with refractory epilepsy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31559780/ 室管膜下结节性异位 10071150 subependymal nodular heterotopia AE OAE:0007403 This is an AE which is neurological disorders caused by clumps of gray matter (nodules of neurons) located in the wrong part of the brain. QY, JX, HY http://en.volupedia.org/wiki/Gray_matter_heterotopia 室旁结节性异位 10066854 periventricular nodular heterotopia AE OAE:0007404 This is an AE which refers to an inflammation of the pituitary gland and is rare . QY, JX, HY http://en.volupedia.org/wiki/Hypophysitis 下垂体炎 10062767 hypophysitis AE OAE:0007405 This is an AE which is characterized by persistent antisocial behavior, impaired empathy and remorse, and bold, disinhibited, and egotistical traits. QY, JX, HY http://en.volupedia.org/wiki/Psychopathy 心理变态人格 10037218 psychopathic personality AE OAE:0007406 This is an AE which is damage to a person's mind as a result of one or more events that cause overwhelming amounts of stress that exceed the person's ability to cope or integrate the emotions involved, eventually leading to serious, long-term negative consequences. QY, JX, HY http://en.volupedia.org/wiki/Psychological_trauma 心理创伤 10071368 psychological trauma AE OAE:0007407 This is an AE which is a neurological disorder whose key defining characteristic is a temporary but almost total disruption of short-term memory with a range of problems accessing older memories. QY, JX, HY http://en.volupedia.org/wiki/Transient_global_amnesia 暂时性全球健忘症 10044380 transient global amnesia AE OAE:0007408 This is an AE which is the fear of confined spaces. QY, JX, HY http://en.volupedia.org/wiki/Claustrophobia 幽闭恐怖症 10009244 claustrophobia AE OAE:0007409 This is an AE which is a key component in all modern etiological models of insomnia disorder. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30046255/ 反应过度 10080831 hyperarousal AE OAE:0007410 This is an AE which refers to the property of a vaccine of being able to produce common, "expected" adverse reactions, especially excessive immunological responses and associated signs and symptoms, including fever and sore arm at the injection site. QY, JX, HY http://en.volupedia.org/wiki/Reactogenicity 反应原性事件 10065109 reactogenicity event AE OAE:0007411 This is an AE which is a fear of being on an airplane, or other flying vehicle, such as a helicopter, while in flight. QY, JX, HY http://en.volupedia.org/wiki/Fear_of_flying 飞行恐惧症 10034914 phobia of flying AE OAE:0007412 This is an AE which is the specific phobia of isolation; a morbid fear of being egotistical, or a dread of being alone or isolated. QY, JX, HY http://en.volupedia.org/wiki/Autophobia 独处恐惧症 10071070 autophobia AE OAE:0007413 This is an AE which is the experience of the transitional state from wakefulness to sleep: the hypnagogic state of consciousness, during the onset of sleep. QY, JX, HY http://en.volupedia.org/wiki/Hypnagogia 入睡前幻觉 10020927 hypnagogic hallucination AE OAE:0007414 This is an AE which is a common disabling condition following brain damage to the right hemisphere. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27103056/ 半感觉性忽视 10067022 hemisensory neglect AE OAE:0007415 This is an AE which is a distortion of the senses, which can reveal how the human brain normally organizes and interprets sensory stimulation. QY, JX, HY http://en.volupedia.org/wiki/Illusion 错觉 10021403 illusion AE OAE:0007416 This is an AE which refers a memory is suddenly and unexpectedly revisited. QY, JX, HY http://en.volupedia.org/wiki/Flashback 迷幻药效幻觉重现 10016754 flashback AE OAE:0007417 This is an AE which is a cognitive disorder of face perception in which the ability to recognize familiar faces, including one's own face (self-recognition), is impaired, while other aspects of visual processing (e.g., object discrimination) and intellectual functioning (e.g., decision-making) remain intact. QY, JX, HY http://en.volupedia.org/wiki/Prosopagnosia 面容失认症 10073980 prosopagnosia AE OAE:0007418 This is an AE which is an alteration in the perception of the external world, causing sufferers to perceive it as unreal, distant, distorted or falsified. QY, JX, HY http://en.volupedia.org/wiki/Derealization 现实感丧失 10012422 derealisation AE OAE:0007419 This is an AE which is an intrinsic feature of a living matter. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31756587/ 兴奋性 10015622 excitability AE OAE:0007420 This is an AE which is a hypnopompic perception in the absence of an external stimulus that has the qualities of a real perception. QY, JX, HY http://en.volupedia.org/wiki/Hallucination 醒前幻觉 10020928 hypnopompic hallucination AE OAE:0007421 This is an AE which is a fixed belief that is not amenable to change in light of conflicting evidence. QY, JX, HY http://en.volupedia.org/wiki/Delusion 妄想性知觉 10012258 delusional perception AE OAE:0007422 This is an AE which is a mental and behavioral disorder classified as a Dissociative disorder and a Dissociative [conversion] disorder. QY, JX, HY http://en.volupedia.org/wiki/Fugue_state 分离性神游症 10013466 dissociative fugue AE OAE:0007423 This is an AE which occurs due to a difference between actual and expected motion. QY, JX, HY http://en.volupedia.org/wiki/Motion_sickness 晕动病 10027990 motion sickness AE OAE:0007425 This is an AE which is the process of diverting the attention of an individual or group from a desired area of focus and thereby blocking or diminishing the reception of desired information. QY, JX, HY http://en.volupedia.org/wiki/Distraction 注意力分散性 10013486 distractibility AE OAE:0007426 This is an AE which is a subtype of delusion that occur in patients suffering from a wide range of psychiatric diseases, including two-thirds of patients in manic state of bipolar disorder, half of those with schizophrenia, patients with the grandiose subtype of delusional disorder, and a substantial portion of those with substance abuse disorders. QY, JX, HY http://en.volupedia.org/wiki/Grandiose_delusions 夸大妄想 10012241 delusion of grandeur AE OAE:0007427 This is an AE which is a mental and behavioral disorder,specifically an anxiety disorder characterized by symptoms of anxiety in situations where the person perceives their environment to be unsafe with no easy way to escape. QY, JX, HY http://en.volupedia.org/wiki/Agoraphobia 惧旷症 10001502 agoraphobia AE OAE:0007428 This is an AE which is an emotional and occasionally psychological state experienced when an individual is left without anything in particular to do, is not interested in their surroundings, or feels that a day or period is dull or tedious. QY, JX, HY http://en.volupedia.org/wiki/Boredom 倦怠 10024642 listless AE OAE:0007429 This is an AE which is the focused attention on the symptoms of one's distress, and on its possible causes and consequences, as opposed to its solutions, according to the Response Styles Theory proposed by Nolen-Hoeksema (1998). QY, JX, HY http://en.volupedia.org/wiki/Rumination_(psychology) 强迫性的沉思 10056264 obsessive rumination AE OAE:0007430 This is an AE which is a loose connective tissue composed mostly of adipocytes. QY, JX, HY http://en.volupedia.org/wiki/Adipose_tissue 身体脂肪症 10055164 body fat disorder AE OAE:0007431 This is an AE which is sudden periods of intense fear and discomfort that may include palpitations, sweating, chest pain, shaking, shortness of breath, numbness, or a feeling of impending doom or of losing control. QY, JX, HY http://en.volupedia.org/wiki/Panic_attack 惊恐发作 10033664 panic attack AE OAE:0007432 This is an AE which is the dropping of tears (or welling of tears in the eyes) in response to an emotional state, or pain. QY, JX, HY http://en.volupedia.org/wiki/Crying 哭泣 10011469 crying AE OAE:0007433 This is an AE which refers a psychological fear of water. QY, JX, HY http://en.volupedia.org/wiki/Hydrophobia 狂犬病 10053317 hydrophobia AE OAE:0007434 This is an AE which is the unsolicited repetition of vocalizations made by another person (when repeated by the same person, it is called palilalia). QY, JX, HY http://en.volupedia.org/wiki/Echolalia 模仿言语 10014127 echolalia AE OAE:0007435 This is an AE which is a state of low mood and aversion to activity. QY, JX, HY http://en.volupedia.org/wiki/Depression_(mood) 沮丧 10084257 discouragement AE OAE:0007436 This is an AE which is a state of tiredness, weariness, fatigue, or lack of energy. QY, JX, HY http://en.volupedia.org/wiki/Lethargy 嗜睡 10024264 lethargy AE OAE:0007437 This is an AE which is a loss of the ability to create new memories after the event that caused amnesia, leading to a partial or complete inability to recall the recent past, while long-term memories from before the event remain intact. QY, JX, HY http://en.volupedia.org/wiki/Anterograde_amnesia 顺行性遗忘 10002711 anterograde amnesia AE OAE:0007438 This is an AE which is an anxiety disorder in which a person who is otherwise capable of speech becomes unable to speak when exposed to specific situations, specific places, or to specific people, one or multiple of which serving as triggers. QY, JX, HY http://en.volupedia.org/wiki/Selective_mutism 选择性缄默 10039917 selective mutism AE OAE:0007439 This is an AE which is a sleep disorder causing feelings of panic or dread and typically occurring during the first hours of stage 3 4 non-rapid eye movement (NREM) sleep and lasting for 1 to 10 minutes. QY, JX, HY http://en.volupedia.org/wiki/Night_terror 夜惊 10041010 sleep terror AE OAE:0007440 This is an AE which is a non-associative learning process in which repeated administration of a stimulus results in the progressive amplification of a response. QY, JX, HY http://en.volupedia.org/wiki/Sensitization 致敏 10070834 sensitisation AE OAE:0007441 This is an AE which is a common fear or phobia among children and, to a varying degree, adults. QY, JX, HY http://en.volupedia.org/wiki/Fear_of_the_dark 黑夜恐怖症 10057946 noctiphobia AE OAE:0007442 QY, JX, HY 情感贫乏 10014557 emotional poverty AE OAE:0007443 QY, JX, HY 梦样状态 10013634 dreamy state AE OAE:0007444 QY, JX, HY 感觉忽冷忽热 10016335 feeling hot and cold AE OAE:0007445 QY, JX, HY 感觉体温变化 10061458 feeling of body temperature change AE OAE:0007446 QY, JX, HY 感觉醉 10016330 feeling drunk AE OAE:0007447 QY, JX, HY 室管膜炎 10014965 ependymitis AE OAE:0007449 QY, JX, HY 中性粒细胞中毒性颗粒 10029378 neutrophil toxic granulation present AE OAE:0007450 QY, JX, HY 感觉运动障碍 10062162 sensorimotor disorder AE OAE:0007451 This is an AE which is commonly described as a benign neoplasm emerging from the cells that comprise the adrenal cortex. QY, JX, HY http://en.volupedia.org/wiki/Adrenocortical_adenoma 肾上腺腺瘤 10001323 adrenal adenoma AE OAE:0007452 This is an AE which is the partial or complete wasting away of a part of the adrenal. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 肾上腺萎缩 10001324 adrenal atrophy AE OAE:0007453 This is an AE which is a form of adrenal cortex cell injury which results in the premature death of cells in living tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 肾上腺皮质坏死 10001337 adrenal cortex necrosis AE OAE:0007454 This is an AE which is conditions that interfere with the normal functioning of the adrenal glands. QY, JX, HY http://en.volupedia.org/wiki/Adrenal_gland_disorder 肾上腺疾病 10001347 adrenal disorder AE OAE:0007455 This is an AE which describes an acute blood loss from a ruptured blood vessel connecting to adrenal glands above kidneys. QY, JX, HY http://en.volupedia.org/wiki/Adrenal_haemorrhage 肾上腺出血 10001361 adrenal hemorrhage AE OAE:0007456 This is an AE which is any benign or malignant neoplasms of the adrenal gland, several of which are notable for their tendency to overproduce endocrine hormones. QY, JX, HY http://en.volupedia.org/wiki/Adrenal_tumor 肾上腺肿块 10053235 adrenal mass AE OAE:0007457 This is an AE which is disorders of the endocrine system such as adrenal medulla. QY, JX, HY http://en.volupedia.org/wiki/Endocrine_disease 肾上腺髓质机能亢进 10001371 adrenal medulla hyperfunction AE OAE:0007458 This is an AE which is a type of abnormal and excessive growth of adrenal tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 肾上腺肿瘤 10061588 adrenal neoplasm AE OAE:0007459 This is an AE which is a condition in which the adrenal glands do not produce adequate amounts of steroid hormones, primarily cortisol; but may also include impaired production of aldosterone (a mineralocorticoid), which regulates sodium conservation, potassium secretion, and water retention. QY, JX, HY http://en.volupedia.org/wiki/Adrenal_insufficiency 肾上腺抑制 10001382 adrenal suppression AE OAE:0007460 This is an AE which is a critical care emergency characterized by hemodynamic instability, lethargy, and cardiovascular collapse. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17456730/ 急性肾上腺皮质机能不全 10001389 acute adrenocortical insufficiency AE OAE:0007461 This is an AE which is a rare long-term endocrine disorder characterized by inadequate production of the steroid hormones cortisol and aldosterone by the two outer layers of the cells of the adrenal glands (adrenal cortex), causing adrenal insufficiency. QY, JX, HY http://en.volupedia.org/wiki/Addison%27s_disease 慢性肾上腺皮质机能不全 10001390 chronic adrenocortical insufficiency AE OAE:0007462 This is an AE which is a group of autosomal recessive disorders characterized by impaired cortisol synthesis. QY, JX, HY http://en.volupedia.org/wiki/Congenital_adrenal_hyperplasia 肾上腺综合症 10061630 adrenogenital syndrome AE OAE:0007463 This is an AE which indicates insufficient weight gain or absence of appropriate physical growth in children. QY, JX, HY http://en.volupedia.org/wiki/Failure_to_thrive 成人发育不良 10077257 adult failure to thrive AE OAE:0007464 This is an AE which is a bacterial infection that results in the death of parts of the body's soft tissue. QY, JX, HY http://en.volupedia.org/wiki/Necrotizing_fasciitis 新生儿坏死性筋膜炎 10028885 necrotising fasciitis AE OAE:0007465 This is an AE which is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. QY, JX, HY http://en.volupedia.org/wiki/Dyslipidemia 脂代谢紊乱 10058108 dyslipidaemia AE OAE:0007466 This is an AE which is believed to be an autosomal dominant condition in which multiple lipomas are present on the body. QY, JX, HY http://en.volupedia.org/wiki/Lipomatosis 脂肪过多症 10061228 lipomatosis AE OAE:0007467 This is an AE which is a benign tumor made of fat tissue. QY, JX, HY http://en.volupedia.org/wiki/Lipoma 脂肪瘤 10024612 lipoma AE OAE:0007468 This is an AE which is a condition that is almost exclusively found in women and results in enlargement of both legs due to deposits of fat under the skin. QY, JX, HY http://en.volupedia.org/wiki/Lipedema 脂肪水肿 10063955 lipedema AE OAE:0007469 This is an AE which is a group of diseases whose hallmark is inflammation of subcutaneous adipose tissue (the fatty layer under the skin – panniculus adiposus). QY, JX, HY http://en.volupedia.org/wiki/Panniculitis 脂膜炎 10033675 panniculitis AE OAE:0007470 This is an AE which is a panniculitis on the back of the calves. QY, JX, HY http://en.volupedia.org/wiki/Panniculitis#Lobular 脂膜炎小叶 10033678 panniculitis lobular AE OAE:0007471 This is an AE which is a non-cancerous (benign) skin tumour that originates from cells in the outer layer of the skin. QY, JX, HY http://en.volupedia.org/wiki/Seborrheic_keratosis 脂溢性角化病 10039796 seborrhoeic keratosis AE OAE:0007472 This is an AE which is a long-term skin disorder. QY, JX, HY http://en.volupedia.org/wiki/Seborrhoeic_dermatitis 脂溢性皮炎 10039793 seborrhoeic dermatitis AE OAE:0007473 This is an AE which is illnesses where trouble occurs in breaking down or synthesizing fats (or fat-like substances). QY, JX, HY http://en.volupedia.org/wiki/Lipid_metabolism#Lipid_metabolism_disorders 脂质代谢障碍 10061227 lipid metabolism disorder AE OAE:0007474 This is an AE which is the term describing the localized loss of fat tissue. QY, JX, HY http://en.volupedia.org/wiki/Lipoatrophy 脂质脂肪萎缩 10024604 lipoatrophy AE OAE:0007475 This is an AE which is the development of symptoms when standing upright that are relieved when reclining. QY, JX, HY http://en.volupedia.org/wiki/Orthostatic_intolerance 直立性不耐受 10063927 orthostatic intolerance AE OAE:0007476 This is an AE which is a condition in which the mitochondria of a body's cells become damaged or decline significantly in number. QY, JX, HY http://en.volupedia.org/wiki/Mitochondrial_toxicity 线粒体毒性 10053961 mitochondrial toxicity AE OAE:0007477 This is an AE which is a lack of something such as mitochondrial enzyme. QY, JX, HY http://en.volupedia.org/wiki/Deficiency 线粒体酶缺乏症 10067729 mitochondrial enzyme deficiency AE OAE:0007478 This is an AE which is a group of disorders caused by mitochondrial dysfunction. QY, JX, HY http://en.volupedia.org/wiki/Mitochondrial_disease 线粒体细胞病 10050029 mitochondrial cytopathy AE OAE:0007479 This is an AE which is a rare immune-mediated blistering skin disease frequently associated with medication exposure, especially vancomycin, with men and women being equally affected. QY, JX, HY http://en.volupedia.org/wiki/Linear_IgA_bullous_dermatosis 线性iga疾病 10024515 linear iga disease AE OAE:0007480 This is an AE which causes renal calculi. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26132002/ 缺乏腺嘌呤磷酸核糖转移酶 10072609 adenine phosphoribosyl transferase deficiency AE OAE:0007481 This is an AE which is used to describe the condition where a child does not reach one of these stages at the expected age. QY, JX, HY http://en.volupedia.org/wiki/Delayed_milestone 生长迟缓 10053759 growth retardation AE OAE:0007482 This is an AE which is a medical condition resulting from not enough growth hormone (GH). QY, JX, HY http://en.volupedia.org/wiki/Growth_hormone_deficiency 生长激素缺乏症 10056438 growth hormone deficiency AE OAE:0007483 This is an AE which is one of the fundamental processes of adolescent development and the process becomes disorder. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29464228/ 生长障碍 10081945 growth disorder AE OAE:0007484 This is an AE which is a collection of signs and symptoms due to prolonged exposure to glucocorticoids such as cortisol. QY, JX, HY http://en.volupedia.org/wiki/Cushing%27s_syndrome 肾上腺机能亢进 10020562 hyperadrenalism AE OAE:0007485 This is an AE which is a hormone and medication which is involved in regulating visceral functions (e.g., respiration). QY, JX, HY http://en.volupedia.org/wiki/Adrenaline 肾上腺素 10015060 epinephrine AE OAE:0007486 This is an AE which is a group of cancers that starts in the kidney. QY, JX, HY http://en.volupedia.org/wiki/Kidney_cancer 肾癌 10038389 renal cancer AE OAE:0007487 This is an AE which is two reddish-brown bean-shaped organs found in vertebrates and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Kidney 肾病 10038428 renal disorder AE OAE:0007488 This is an AE which is a syndrome comprising signs of nephritis, which is kidney disease involving inflammation. QY, JX, HY http://en.volupedia.org/wiki/Nephritic_syndrome 肾病综合症 10065673 nephritic syndrome AE OAE:0007489 This is an AE which is a type of hematoma of kidney tissue, the most common cause being capillaries damaged by trauma, causing localized bleeding that extravasates into the surrounding interstitial tissues. QY, JX, HY http://en.volupedia.org/wiki/Bruise 肾挫伤 10023413 kidney contusion AE OAE:0007490 This is an AE which in humans is associated with RET mutations. QY, JX, HY http://en.volupedia.org/wiki/Renal_agenesis 肾发育不全 10064655 renal aplasia AE OAE:0007491 This is an AE which is an abnormality that a person is born with in which one or both of the kidneys are smaller than normal (hypoplastic) but with normal structure. QY, JX, HY http://en.volupedia.org/wiki/Renal_hypoplasia 肾发育不全 10049102 renal hypoplasia AE OAE:0007492 This is an AE which is an arterial vascular event that may cause irreversible damage to kidney tissues. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23204242/ 肾梗塞 10038470 renal infarct AE OAE:0007493 This is an AE which is a medical condition in which the kidneys are functioning at less than 15% of normal levels on neonatal. QY, JX, HY http://en.volupedia.org/wiki/Kidney_failure 肾功能衰竭新生儿 10038447 renal failure neonatal AE OAE:0007494 This is an AE which is a rare side effect of cisplatin that manifests with polyuria, hypovolemia, and hyponatremia, and, because of similarities in clinical settings and laboratory values, it is frequently misdiagnosed as a syndrome of inappropriate antidiuretic hormone. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20622742/ 肾耗盐综合征 10062550 renal salt-wasting syndrome AE OAE:0007495 This is an AE which is a form of renal cell injury which results in the premature death of cells in living tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 肾坏死 10038481 renal necrosis AE OAE:0007496 This is an AE which is an important contributor to graft loss in chronic renal allograft injury. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28209809/ 肾间质纤维化 10038475 renal interstitial fibrosis AE OAE:0007497 This is an AE which is when a solid piece of material (kidney stone) develops in the urinary tract. QY, JX, HY http://en.volupedia.org/wiki/Kidney_stone_disease 肾结石 10029148 nephrolithiasis AE OAE:0007498 This is an AE which is a cancer of the kidneys that typically occurs in children, rarely in adults. QY, JX, HY http://en.volupedia.org/wiki/Nephroblastoma 肾胚细胞瘤 10029145 nephroblastoma AE OAE:0007499 This is an AE which is a rare cause of acute kidney failure. QY, JX, HY http://en.volupedia.org/wiki/Renal_cortical_necrosis 肾皮质坏死 10038422 renal cortical necrosis AE OAE:0007500 This is an AE which is a medical condition in which the kidneys are functioning at less than 15% of normal levels. QY, JX, HY http://en.volupedia.org/wiki/Kidney_failure 肾前性衰竭 10072370 prerenal failure AE OAE:0007501 This is an AE which is an accumulation of serous fluid in a renal cavity. QY, JX, HY http://en.volupedia.org/wiki/Hydrocele 肾鞘膜积液 10062854 renal hydrocele AE OAE:0007502 This is an AE which is the lodging of an embolus, a blockage-causing piece of material, inside a renal blood vessel. QY, JX, HY http://en.volupedia.org/wiki/Embolism 肾栓塞 10063544 renal embolism AE OAE:0007503 This is an AE which continues to be a difficult malignancy to treat because of its ability to spread asymptomatically and its inherent resistance to conventional chemotherapy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11981272/ 肾细胞癌 10067946 renal cell carcinoma AE OAE:0007504 This is an AE which is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue such as kidney fibrosis. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis#Kidney 肾纤维化 10023421 kidney fibrosis AE OAE:0007505 This is an AE which is two reddish-brown bean-shaped organs found in vertebrates and is small. QY, JX, HY http://en.volupedia.org/wiki/Kidney 小肾 10023435 kidney small AE OAE:0007506 This is an AE which is a medical condition involving the death of tubular epithelial cells that form the renal tubules of the kidneys. QY, JX, HY http://en.volupedia.org/wiki/Acute_tubular_necrosis 肾小管坏死 10038540 renal tubular necrosis AE OAE:0007507 This is an AE which is inflammation of the area of the kidney known as the renal interstitium, which consists of a collection of cells, extracellular matrix, and fluid surrounding the renal tubules. QY, JX, HY http://en.volupedia.org/wiki/Interstitial_nephritis 肾小管间质性肾炎 10048302 tubulointerstitial nephritis AE OAE:0007508 This is an AE which is a rare medical condition in which there is uveitis (inflammation of the uvea in the eye) together with tubulointerstitial nephritis (inflammation of the tubules inside the kidney). QY, JX, HY http://en.volupedia.org/wiki/Tubulointerstitial_nephritis_and_uveitis 肾小管间质性肾炎和葡萄膜炎综合征 10069034 tubulointerstitial nephritis and uveitis syndrome AE OAE:0007509 This is an AE which is a medical condition that involves an accumulation of acid in the body due to a failure of the kidneys to appropriately acidify the urine. QY, JX, HY http://en.volupedia.org/wiki/Renal_tubular_acidosis 肾小管酸中毒 10038535 renal tubular acidosis AE OAE:0007510 This is an AE which is a term used to refer to several kidney diseases (usually affecting both kidneys). QY, JX, HY http://en.volupedia.org/wiki/Glomerulonephritis 肾小球肾炎焦 10018369 glomerulonephritis focal AE OAE:0007511 This is an AE which is a syndrome of the kidney that is characterized by a rapid loss of kidney function, (usually a 50% decline in the glomerular filtration rate (GFR) within 3 months) with glomerular crescent formation seen in at least 50% or 75% of glomeruli seen on kidney biopsies. QY, JX, HY http://en.volupedia.org/wiki/Rapidly_progressive_glomerulonephritis 急性肾小球肾炎 10018378 glomerulonephritis rapidly progressive AE OAE:0007512 This is an AE which is a network of small blood vessels (capillaries) known as a tuft, located at the beginning of a nephron in the kidney and its vascular becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Glomerulus_(kidney) 肾小球血管障碍 10018362 glomerular vascular disorder AE OAE:0007513 This is an AE which is hardening of the glomeruli in the kidney. QY, JX, HY http://en.volupedia.org/wiki/Glomerulosclerosis 肾小球硬化症 10061989 glomerulosclerosis AE OAE:0007514 This is an AE which is a localized renal bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 肾血肿 10038459 renal hematoma AE OAE:0007515 This is an AE which is inflammation of the area of the kidney known as the renal interstitium, which consists of a collection of cells, extracellular matrix, and fluid surrounding the renal tubules. QY, JX, HY http://en.volupedia.org/wiki/Interstitial_nephritis 肾炎间质 10029134 nephritis interstitial AE OAE:0007516 This is an AE which is inflammation of the kidney, typically due to a bacterial infection. QY, JX, HY http://en.volupedia.org/wiki/Pyelonephritis 肾盂炎 10037584 pyelitis AE OAE:0007517 This is an AE which is a form of diabetes insipidus primarily due to pathology of the kidney. QY, JX, HY http://en.volupedia.org/wiki/Nephrogenic_diabetes_insipidus 肾原性的尿崩症 10029147 nephrogenic diabetes insipidus AE OAE:0007518 This is an AE which is tumours, or growths, on or in the kidney. QY, JX, HY http://en.volupedia.org/wiki/Kidney_tumour 肾脏肿块 10062104 renal mass AE OAE:0007519 This is an AE which is damage to or disease of a kidney. QY, JX, HY http://en.volupedia.org/wiki/Kidney_disease 肾肿大 10048469 kidney enlargement AE OAE:0007520 This is an AE which is a group of cancers that starts in the kidney. QY, JX, HY http://en.volupedia.org/wiki/Kidney_neoplasm?wprov=srpw1_1 肾肿瘤 10061482 renal neoplasm AE OAE:0007521 This is an AE which refers to accumulation of fluid in an anatomic space such as perinephric. QY, JX, HY http://en.volupedia.org/wiki/Effusion 肾周的积液 10053550 perinephric effusion AE OAE:0007522 This is an AE which is determined by measuring plasma glucose levels 2 hours after glucose loading in the oral glucose tolerance test. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15799213/ 糖耐量降低 10018429 glucose tolerance impaired AE OAE:0007523 This is an AE which include problems that develop rapidly (acute) or over time (chronic) and may affect many organ systems. QY, JX, HY http://en.volupedia.org/wiki/Complications_of_diabetes 糖尿病的并发症 10061104 diabetic complication AE OAE:0007524 This is an AE which occurs predominantly after the age of 50 years but is not easy to distinguish from late onset insulin-dependent diabetes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9158288/ 糖尿病非胰岛素依赖 10012613 diabetes mellitus non-insulin-dependent AE OAE:0007525 This is an AE which is a reversible form of coma found in people with diabetes mellitus. QY, JX, HY http://en.volupedia.org/wiki/Diabetic_coma 糖尿病昏迷 10012650 diabetic coma AE OAE:0007526 This is an AE which is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time and it is inadequate control. QY, JX, HY http://en.volupedia.org/wiki/Diabetes 糖尿病控制不足 10012607 diabetes mellitus inadequate control AE OAE:0007527 This is an AE which is of interest due to their remarkable resistance to heal; severe thermal burns are addressed due to critical need for effective therapies for the prevention shock and improvement in scarring. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27412677/ 糖尿病溃疡 10056340 diabetic ulcer AE OAE:0007528 This is an AE which is a group of metabolic disorders with foetopathy characterized by a high blood sugar level over a prolonged period of time. QY, JX, HY http://en.volupedia.org/wiki/Diabetes 糖尿病胎儿病 10059116 diabetic foetopathy AE OAE:0007529 This is an AE which is a potentially life-threatening complication of diabetes mellitus. QY, JX, HY http://en.volupedia.org/wiki/Diabetic_ketoacidosis 糖尿病酮症 10012673 diabetic ketosis AE OAE:0007530 This is an AE which is a serious and potentially life-threatening acute complication of diabetes mellitus with hyperglycaemic. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30150107/ 糖尿病酮症酸中毒高血糖昏迷 10012672 diabetic ketoacidotic hyperglycaemic coma AE OAE:0007531 This is an AE which results from failure of the pancreas to produce enough insulin due to loss of beta cells. QY, JX, HY http://en.volupedia.org/wiki/Diabetes 糖尿病胰岛素依赖型 10012608 diabetes mellitus insulin-dependent AE OAE:0007532 This is an AE which is a necrotising skin condition that usually occurs in patients with diabetes mellitus but can also be associated with rheumatoid arthritis. QY, JX, HY http://en.volupedia.org/wiki/Necrobiosis_lipoidica 糖尿病脂质坏死病 10056969 necrobiosis lipoidica diabeticorum AE OAE:0007533 This is an AE which is any pathology that results directly from peripheral arterial disease (PAD) and/or sensory neuropathy affecting the feet in diabetes mellitus; it is a long-term (or "chronic") complication of diabetes mellitus. QY, JX, HY http://en.volupedia.org/wiki/Diabetic_foot 糖尿病足 10060734 diabetic foot AE OAE:0007534 This is an AE which may involve a number of genes including HFE and TFR2. QY, JX, HY http://en.volupedia.org/wiki/Iron_metabolism_disorder 铁代谢障碍 10022983 iron metabolism disorder AE OAE:0007535 This is an AE which is a rare condition characterized by late onset of developmental delays—or severe and sudden reversals—in language, social function, and motor skills. QY, JX, HY http://en.volupedia.org/wiki/Childhood_disintegrative_disorder 童年分解性障碍 10008522 childhood disintegrative disorder AE OAE:0007536 This is an AE which is a metabolic state caused by uncontrolled production of ketone bodies that cause a metabolic acidosis. QY, JX, HY http://en.volupedia.org/wiki/Ketoacidosis 酮酸中毒 10023379 ketoacidosis AE OAE:0007537 This is an AE which is a metabolic state characterized by elevated levels of ketone bodies in the blood or urine. QY, JX, HY http://en.volupedia.org/wiki/Ketosis 酮症 10023391 ketosis AE OAE:0007538 This is an AE which is a medical condition characterized by the buildup of lactate (especially L-lactate) in the body, with formation of an excessively low pH in the bloodstream. QY, JX, HY http://en.volupedia.org/wiki/Lactic_acidosis 乳酸酸中毒 10023676 lactic acidosis AE OAE:0007539 This is an AE which is a common condition caused by a decreased ability to digest lactose, a sugar found in dairy products. QY, JX, HY http://en.volupedia.org/wiki/Lactose_intolerance 乳糖不耐受 10023981 lactose intolerance AE OAE:0007540 This is an AE which is the most common type of thyroid cancer, representing 75 percent to 85 percent of all thyroid cancer cases. QY, JX, HY http://en.volupedia.org/wiki/Papillary_thyroid_cancer 乳头状甲状腺癌 10033701 papillary thyroid cancer AE OAE:0007541 This is an AE which is a benign epithelial tumor growing exophytically (outwardly projecting) in nipple-like and often finger-like fronds. QY, JX, HY http://en.volupedia.org/wiki/Papilloma 乳头状瘤 10033713 papilloma AE OAE:0007542 This is an AE which is an acquired benign squamous cell tumor that can present at any age, but most frequently in the third and fourth decades of life. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31236424/ 乳头状瘤结膜 10067127 papilloma conjunctival AE OAE:0007543 This is an AE which is a common condition caused by a decreased ability to digest lactose, a sugar found in dairy products. QY, JX, HY http://en.volupedia.org/wiki/Lactose_intolerance 乳制品不耐受性 10011852 dairy intolerance AE OAE:0007544 This is an AE which is an endocrinological disorder characterized by decreased levels of the hormone aldosterone. QY, JX, HY http://en.volupedia.org/wiki/Hypoaldosteronism 醛固酮减少症 10020944 hypoaldosteronism AE OAE:0007545 This is an AE which is the main mineralocorticoid steroid hormone produced by the zona glomerulosa of the adrenal cortex in the adrenal gland on the urine. QY, JX, HY http://en.volupedia.org/wiki/Aldosterone 醛固酮尿 10001649 aldosterone urine AE OAE:0007546 This is an AE which is a lack of the trace element iodine, an essential nutrient in the diet. QY, JX, HY http://en.volupedia.org/wiki/Iodine_deficiency 缺碘 10067997 iodine deficiency AE OAE:0007547 This is an AE which motivates the consumption of food. QY, JX, HY http://en.volupedia.org/wiki/Hunger_(physiology) 缺乏饱腹感 10064720 lack of satiety AE OAE:0007548 This is an AE which is lack of the heterodimer of two chains: IFNGR1 and IFNGR2. It binds interferon-γ, the sole member of interferon type II. QY, JX, HY http://en.volupedia.org/wiki/Interferon-gamma_receptor 缺乏干扰素受体 10057605 interferon gamma receptor deficiency AE OAE:0007549 This is an AE which is the state in which a body lacks enough iron to supply its needs. QY, JX, HY http://en.volupedia.org/wiki/Iron_deficiency 缺铁 10022970 iron deficiency AE OAE:0007550 This is an AE which is defined either as insufficient copper to meet the needs of the body, or as a serum copper level below the normal range. QY, JX, HY http://en.volupedia.org/wiki/Copper_deficiency 缺铜症 10010957 copper deficiency AE OAE:0007551 This is an AE which means a total depletion in the level of oxygen, an extreme form of hypoxia or "low oxygen". QY, JX, HY http://en.volupedia.org/wiki/Anoxia 缺氧 10002660 anoxia AE OAE:0007552 This is an AE which is a human health condition or disease that is persistent or otherwise long-lasting in its effects or a disease that comes with time. QY, JX, HY http://en.volupedia.org/wiki/Chronic_condition 慢性疾病 10076311 chronic disease AE OAE:0007553 This is an AE which defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) based on type (motor or phonic) and duration of tics (sudden, rapid, nonrhythmic movements). QY, JX, HY http://en.volupedia.org/wiki/Tic_disorder 慢性疾病 10076661 chronic tic disorder AE OAE:0007554 This is an AE which is the inflammation of the thyroid gland and is chronic. QY, JX, HY http://en.volupedia.org/wiki/Thyroiditis 慢性甲状腺炎 10043781 thyroiditis chronic AE OAE:0007555 This is an AE which is a complex, fatiguing, long-term medical condition diagnosed by required primary symptoms and criteria, and often involves a broad range of symptoms. QY, JX, HY http://en.volupedia.org/wiki/Chronic_fatigue_syndrome 慢性疲劳综合症 10008874 chronic fatigue syndrome AE OAE:0007556 This is an AE which is a diverse group of hereditary diseases in which certain cells of the immune system have difficulty forming the reactive oxygen compounds (most importantly the superoxide radical due to defective phagocyte NADPH oxidase) used to kill certain ingested pathogens. QY, JX, HY http://en.volupedia.org/wiki/Chronic_granulomatous_disease 慢性肉芽肿性疾病 10008906 chronic granulomatous disease AE OAE:0007557 This is an AE which consists of pigmented macular lesions, predominantly involving the lower extremities. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3677535/ 慢性色素紫癜 10072726 chronic pigmented purpura AE OAE:0007558 This is an AE which is a syndrome of progressive loss of renal function that results in loss of urinary concentrating ability, retention of nitrogenous and other metabolic end products, alterations in electrolyte and acid-base status, and dysfunction of several hormone systems. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18061852/ 慢性肾功能衰竭 10038444 renal failure chronic AE OAE:0007559 This is an AE which is defined as hives, typically occurring daily, for greater than 6 weeks duration. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24305753/ 慢性荨麻疹 10052568 urticaria chronic AE OAE:0007561 This is an AE which is an autosomal recessive metabolic disorder that disrupts the biosynthesis of cholesterol and isoprenoids. QY, JX, HY http://en.volupedia.org/wiki/Mevalonate_kinase_deficiency 甲羟戊酸激酶缺乏症 10072221 mevalonate kinase deficiency AE OAE:0007562 This is an AE which is a metabolite such as urine of epinephrine (adrenaline) created by action of catechol-O-methyl transferase on epinephrine. QY, JX, HY http://en.volupedia.org/wiki/Metanephrine 甲肾上腺素尿 10059217 metanephrine urine AE OAE:0007563 This is an AE which most commonly present with abnormalities of serum calcium. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23944728/ 甲状旁腺疾病 10033942 parathyroid disorder AE OAE:0007564 This is an AE which is small endocrine glands in the neck of humans and it is not normal enlargemet. QY, JX, HY http://en.volupedia.org/wiki/Parathyroid_gland 甲状旁腺肿大 10051653 parathyroid gland enlargement AE OAE:0007565 This is an AE which represent an elusive endocrine neoplasia, which lead to primary hyperparathyroidism, pHPT, a common endocrine calcium disorder characterized by hypercalcemia and normal-high parathormone secretion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30477753/ 甲状旁腺肿瘤 10033963 parathyroid tumor AE OAE:0007566 This is an AE which is a fibrous cyst that forms from a persistent thyroglossal duct. QY, JX, HY http://en.volupedia.org/wiki/Thyroglossal_cyst 甲状舌囊肿 10051320 thyroglossal cyst AE OAE:0007567 This is an AE which is cancer that develops from the tissues of the thyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Thyroid_cancer 甲状腺癌 10066474 thyroid cancer AE OAE:0007568 This is an AE which is cancer that develops from the tissues of the thyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Thyroid_cancer 甲状腺癌 10043738 thyroid gland cancer AE OAE:0007569 This is an AE which is a rare but severe and potentially life-threatening complication of hyperthyroidism (overactivity of the thyroid gland). QY, JX, HY http://en.volupedia.org/wiki/Thyroid_storm 甲状腺毒性危象 10043786 thyrotoxic crisis AE OAE:0007570 This is an AE which is mainly present in classical papillary thyroid carcinoma (PTC) and in medullary thyroid carcinoma (MTC), despite being described in benign lesions and in other subtypes of thyroid carcinomas. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33086487/ 甲状腺钙化 10078379 thyroid calcification AE OAE:0007571 This is an AE which is a swelling with hypothyroidic in the neck resulting from an enlarged thyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Goitre 甲状腺功能减退甲状腺肿 10059844 hypothyroidic goitre AE OAE:0007572 This is an AE which is a medical condition that affects the function of the thyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Thyroid_disease 甲状腺疾病 10043709 thyroid disorder AE OAE:0007573 This is an AE which is a neoplasm or tumor of the thyroid and can be a benign tumor such as thyroid adenoma. QY, JX, HY http://en.volupedia.org/wiki/Thyroid_neoplasm 甲状腺良性肿瘤 10004412 benign neoplasm of thyroid gland AE OAE:0007574 This is an AE which is nodules (raised areas of tissue or fluid) which commonly arise within an otherwise normal thyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Thyroid_nodule#Presentation 甲状腺囊肿 10043706 thyroid cyst AE OAE:0007575 This is an AE which is a collection of pus that has built up within the tissue of thethyroid gland . QY, JX, HY http://en.volupedia.org/wiki/Abscess 甲状腺脓肿 10051878 thyroid gland abscess AE OAE:0007576 This is an AE which is an endocrine gland in vertebrates and feel it pain. QY, JX, HY http://en.volupedia.org/wiki/Thyroid 甲状腺痛 10043757 thyroid pain AE OAE:0007577 This is an AE which is a swelling in the neck resulting from an enlarged thyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Goitre 甲状腺肿 10018498 goitre AE OAE:0007578 This is an AE which is a common complication of critical illness affecting between 30 and 60% of critically ill patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21989699/ 急性肾功能衰竭 10038436 renal failure acute AE OAE:0007579 This is an AE which the patient experiences high fever, abdominal pain and pain while passing urine. QY, JX, HY http://en.volupedia.org/wiki/Excretory_system#Acute_Pyelonephritis 急性肾盂肾炎 10037597 pyelonephritis acute AE OAE:0007580 This is an AE which is a tumor of the pancreas that is derived from beta cells and secretes insulin. QY, JX, HY http://en.volupedia.org/wiki/Insulinoma 胰岛瘤 10022498 insulinoma AE OAE:0007581 This is an AE which is a form of diabetes that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. QY, JX, HY http://en.volupedia.org/wiki/Type_2_diabetes 胰岛素抵抗糖尿病 10022491 insulin resistant diabetes AE OAE:0007582 This is an AE which refers to an above normal level of insulin in the blood of a person or animal. QY, JX, HY http://en.volupedia.org/wiki/Hyperinsulinism 胰岛素过多 10061211 hyperinsulinism AE OAE:0007583 This is an AE which is the condition that occurs due to excessive production of thyroid hormones by the thyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Hyperthyroidism 原发性甲亢 10075899 primary hyperthyroidism AE OAE:0007584 This is an AE which is usually caused by a tumor within the parathyroid gland. QY, JX, HY http://en.volupedia.org/wiki/Primary_hyperparathyroidism 原发性甲状旁腺功能亢进症 10020707 hyperparathyroidism primary AE OAE:0007585 This is an AE which is a common endocrinological process, characterized by chronic elevation of serum concentrations of calcium and parathyroid hormone (PTH). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28992983/ 原发性甲状腺功能减退症 10036697 primary hypothyroidism AE OAE:0007586 This is an AE which refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels and high blood pressure. QY, JX, HY http://en.volupedia.org/wiki/Primary_aldosteronism 原发性醛固酮增多症 10036692 primary hyperaldosteronism AE OAE:0007587 This is an AE which is a rare long-term endocrine disorder characterized by inadequate production of the steroid hormones cortisol and aldosterone by the two outer layers of the cells of the adrenal glands (adrenal cortex), causing adrenal insufficiency. QY, JX, HY http://en.volupedia.org/wiki/Addison%27s_disease 原发性肾上腺皮质功能不全 10052381 primary adrenal insufficiency AE OAE:0007588 This is an AE which is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes and is idiopathic . QY, JX, HY http://en.volupedia.org/wiki/Angioedema 原发性血管性水肿 10073257 idiopathic angiedema AE OAE:0007589 This is an AE which is a medical condition characterized by involuntary rhythmic contractions and relaxations (oscillations or twitching movements) of certain muscle groups in one or more body parts of unknown cause. QY, JX, HY http://en.volupedia.org/wiki/Essential_tremor 原发性震颤 10015496 essential tremor AE OAE:0007590 This is an AE which is a form of thyroiditis that can be a cause of both thyrotoxicosis and hypothyroidism. QY, JX, HY http://en.volupedia.org/wiki/Subacute_thyroiditis 亚急性甲状腺炎 10043784 thyroiditis subacute AE OAE:0007591 This is an AE which is an over-accumulation of dietary histamine in the human body. QY, JX, HY http://en.volupedia.org/wiki/Histamine_intolerance 组胺不耐受 10068652 histamine intolerance AE OAE:0007592 This is an AE which refers a hereditary condition caused by a deficiency of liver enzymes that metabolise fructose. QY, JX, HY http://en.volupedia.org/wiki/Fructose_intolerance 果糖不耐受 10072104 fructose intolerance AE OAE:0007593 This is an AE which is a common condition caused by a decreased ability to digest lactose, a sugar found in dairy products. QY, JX, HY http://en.volupedia.org/wiki/Lactose_intolerance 牛奶不耐受 10011241 cow's milk intolerance AE OAE:0007594 This is an AE which is a rare condition in which the cells lining the intestine cannot take in the sugars glucose and galactose, which prevents proper digestion of these molecules and larger molecules made from them. QY, JX, HY http://en.volupedia.org/wiki/Glucose-galactose_malabsorption 碳水化合物不耐受 10071200 carbohydrate intolerance AE OAE:0007595 This is an AE which is the condition in which sucrase-isomaltase, an enzyme needed for proper metabolism of sucrose (sugar) and starch (e.g., grains), is not produced or the enzyme produced is either partially functional or non-functional in the small intestine. QY, JX, HY http://en.volupedia.org/wiki/Sucrose_intolerance 蔗糖不耐受 10042432 sucrose intolerance AE OAE:0007596 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) or organs (macroscopic scale), and the abnormal histology or anatomical structure resulting from such growth. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 发育不良 10058314 dysplasia AE OAE:0007597 This is an AE which is when a child who has reached a certain developmental stage begins to lose previously acquired milestones. QY, JX, HY http://en.volupedia.org/wiki/Developmental_regression 发育退化 10076709 developmental regression AE OAE:0007598 This is an AE which is a congenital abnormality of brain development where the neurons in an area of the brain failed to migrate in the proper formation in utero. QY, JX, HY http://en.volupedia.org/wiki/Focal_cortical_dysplasia 皮质发育不良 10070666 cortical dysplasia AE OAE:0007599 This is an AE which incidence rate was equal to 5.96/1,000 infants, which would result in 2.0 IQ points loss in 34.31% of the newborns. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30427427/ 轻度精神发育迟滞 10027618 mild mental retardation AE OAE:0007600 This is an AE which comprise a group of psychiatric conditions originating in childhood that involve serious impairment in different areas such as speech disorder developmental. QY, JX, HY http://en.volupedia.org/wiki/Developmental_disorder 言语障碍发育 10041467 speech disorder developmental AE OAE:0007601 This is an AE which is a skin disorder that generally presents, but not exclusively, as erythematous plaques or flat patches without hair primarily on the scalp, neck and face. QY, JX, HY http://en.volupedia.org/wiki/Alopecia_mucinosa 毛囊皮脂腺粘蛋白沉积症 10056506 follicular mucinosis AE OAE:0007602 This is an AE which is an inflammation caused by viral of one or both parotid glands, the major salivary glands located on either side of the face, in humans. QY, JX, HY http://en.volupedia.org/wiki/Parotitis 病毒性腮腺炎 10072589 viral parotitis AE OAE:0007603 This is an AE which is small tubular structures of the skin that produce sweat and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Sweat_gland 汗腺疾病 10042653 sweat gland disorder AE OAE:0007604 This is an AE which is the leading cause of evaporative dry eye disease and is one of the most common conditions encountered by eye care providers. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31494111/ 睑板腺功能障碍 10065062 meibomian gland dysfunction AE OAE:0007605 This is an AE which is a bacterial infection of an oil gland in the eyelid. QY, JX, HY http://en.volupedia.org/wiki/Stye 睑腺炎 10020377 hordeolum AE OAE:0007606 This is an AE which is a viral disease caused by the mumps virus. QY, JX, HY http://en.volupedia.org/wiki/Mumps 流行性腮腺炎 10028257 mumps AE OAE:0007607 This is an AE which is a microscopic exocrine gland in the skin that opens into a hair follicle to secrete an oily or waxy matter and it is overactivity. QY, JX, HY http://en.volupedia.org/wiki/Sebaceous_gland 皮脂腺过度活跃 10039784 sebaceous glands overactivity AE OAE:0007608 This is an AE which is a microscopic exocrine gland in the skin that opens into a hair follicle to secrete an oily or waxy matter and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Sebaceous_gland 皮脂腺疾病 10061511 sebaceous gland disorder AE OAE:0007609 This is an AE which is a inflammation of major salivary gland in human. QY, JX, HY http://en.volupedia.org/wiki/Parotid_gland 腮腺炎症 10067789 parotid gland inflammation AE OAE:0007610 This is an AE which is an increasingly recognized cause of transient thyrotoxicosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/3760800/ 无症状性甲状腺炎 10079012 silent thyroiditis AE OAE:0007611 This is an AE which is an inflammation caused by bacterial of one or both parotid glands, the major salivary glands located on either side of the face, in humans. QY, JX, HY http://en.volupedia.org/wiki/Parotitis 细菌性腮腺炎 10077487 bacterial parotitis AE OAE:0007612 This is an AE which characterized by decreased brain glucose consumption, is a common feature of many neurodegenerative diseases. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28463438/ 代谢减退 10021034 hypometabolism AE OAE:0007613 This is an AE which is a metabolic condition in which the pH of tissue is elevated beyond the normal range (7.35–7.45). QY, JX, HY http://en.volupedia.org/wiki/Metabolic_alkalosis 代谢性碱中毒 10027423 metabolic alkalosis AE OAE:0007614 This is an AE which is the sugar formed when two monosaccharides are joined by glycosidic linkage and its metabolism becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Disaccharide 二糖代谢障碍 10061107 disaccharide metabolism disorder AE OAE:0007615 This is an AE which occur when the body has too little or too much calcium. QY, JX, HY http://en.volupedia.org/wiki/Disorders_of_calcium_metabolism 钙代谢障碍 10006974 calcium metabolism disorder AE OAE:0007616 This is an AE which is defined as an elevated resting energy expenditure (REE) > 110% of predicted REE. QY, JX, HY http://en.volupedia.org/wiki/Hypermetabolism 高代谢反应 10020674 hypermetabolism AE OAE:0007617 This is an AE which is a rare genetic disorder caused by pathogenic variants in the gene CDKL5. QY, JX, HY http://en.volupedia.org/wiki/CDKL5_deficiency_disorder cdkl5缺乏症 10083005 cdkl5 deficiency disorder AE OAE:0007618 This is an AE which is an immunodeficiency of absent or suboptimal functioning of one of the complement system proteins. QY, JX, HY http://en.volupedia.org/wiki/Complement_deficiency 补体缺乏症 10075551 complement deficiency disease AE OAE:0007619 This is an AE which is not epileptic seizures or epilepsy. QY, JX, HY http://en.volupedia.org/wiki/Reflex_asystolic_syncope 癫痫发作缺氧 10039907 seizure anoxic AE OAE:0007620 This is an AE which appears to predispose to severe respiratory tract infection. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20375630/ 甘露糖结合凝集素缺乏症 10083190 mannose-binding lectin deficiency AE OAE:0007621 This is an AE which is a major abnormality in the shape of a body part or organ compared to the normal shape of that part. QY, JX, HY http://en.volupedia.org/wiki/Deformity 畸形 10061619 deformity AE OAE:0007622 This is an AE which risk factors were found to be low birth weight (2500 g or less) and threatened abortion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/8474950/ 减少肢体缺陷 10024503 limb reduction defect AE OAE:0007623 This is an AE which is a diverse array of deficits in hedonic function, including reduced motivation or ability to experience pleasure. QY, JX, HY http://en.volupedia.org/wiki/Anhedonia 快感缺乏症 10002511 anhedonia AE OAE:0007624 This is an AE which is a lack of the dietary minerals, the micronutrients that are needed for an organism's proper health. QY, JX, HY http://en.volupedia.org/wiki/Mineral_deficiency 矿物质缺乏症 10061291 mineral deficiency AE OAE:0007625 This is an AE which is an electrolyte disturbance in which there is a low level of magnesium in the body. QY, JX, HY http://en.volupedia.org/wiki/Magnesium_deficiency 镁缺乏 10025433 magnesium deficiency AE OAE:0007626 This is an AE which is a condition of reduced emotional reactivity in an individual. QY, JX, HY http://en.volupedia.org/wiki/Reduced_affect_display 情感缺乏 10016759 flat affect AE OAE:0007627 This is an AE which occurs when an organism lacks the required levels of selenium, a critical nutrient in many species. QY, JX, HY http://en.volupedia.org/wiki/Selenium_deficiency 硒缺乏 10039921 selenium deficiency AE OAE:0007628 This is an AE which is defined either as insufficient zinc to meet the needs of the body, or as a serum zinc level below the normal range. QY, JX, HY http://en.volupedia.org/wiki/Zinc_deficiency 锌缺乏症 10048259 zinc deficiency AE OAE:0007629 This is an AE which is a low level of folate and derivatives in the body. QY, JX, HY http://en.volupedia.org/wiki/Folate_deficiency 叶酸缺乏 10016880 folate deficiency AE OAE:0007630 This is an AE which is a behavioral and neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, which are pervasive, impairing, and otherwise age inappropriate. QY, JX, HY http://en.volupedia.org/wiki/Attention_deficit_hyperactivity_disorder 注意力缺陷/多动症 10003736 attention deficit/hyperactivity disorder AE OAE:0007631 This is an AE which is the result of a process reducing hydrogen ion concentration of arterial blood plasma (alkalemia). QY, JX, HY http://en.volupedia.org/wiki/Alkalosis 碱毒症 10001680 alkalosis AE OAE:0007632 This is an AE which refers to the act of suppressing lactation by medication or other non pharmaceutical means. QY, JX, HY http://en.volupedia.org/wiki/Lactation_suppression 抑制泌乳 10042576 suppressed lactation AE OAE:0007633 This is an AE which is also lost from the plasma in hypovolemia, the body's need for salt proportionately increases in addition to thirst in such cases. QY, JX, HY http://en.volupedia.org/wiki/Thirst#Salt_craving 盐的渴望 10067951 salt craving AE OAE:0007634 This is an AE which may be prone to a combined cow's milk and soy protein allergy. QY, JX, HY http://en.volupedia.org/wiki/Milk_allergy 奶大豆蛋白不耐症 10071754 milk soy protein intolerance AE OAE:0007635 This is an AE which is an excessive number of histiocytes (tissue macrophages), and the term is also often used to refer to a group of rare diseases which share this sign as a characteristic. QY, JX, HY http://en.volupedia.org/wiki/Histiocytosis 组织细胞增生症 10020117 histiocytosis AE OAE:0007636 This is an AE which is a medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets. QY, JX, HY http://en.volupedia.org/wiki/Pancytopenia 双细胞减少症 10058956 bicytopenia AE OAE:0007637 This is an AE which is an abnormal clonal proliferation of Langerhans cells, abnormal cells deriving from bone marrow and capable of migrating from skin to lymph nodes. QY, JX, HY http://en.volupedia.org/wiki/Langerhans_cell_histiocytosis 朗格汉斯细胞组织细胞增生症 10069698 langerhans' cell histiocytosis AE OAE:0007638 This is an AE which is "a clinical entity induced by the ingestion of gluten leading to intestinal and/or extraintestinal symptoms that improve once the gluten-containing foodstuff is removed from the diet, and celiac disease and wheat allergy have been excluded". QY, JX, HY http://en.volupedia.org/wiki/Non-celiac_gluten_sensitivity 谷蛋白敏感性 10076493 gluten sensitivity AE OAE:0007639 This is an AE which contribute to function and stability of surfactant film. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33839914/ 表面活性蛋白 10073028 surfactant protein AE OAE:0007640 This is an AE which is a class of globulins, identified by their position after serum protein electrophoresis. QY, JX, HY http://en.volupedia.org/wiki/Gamma_globulin 丙种球蛋白病 10061964 gammopathy AE OAE:0007641 This is an AE which is a collective term for blood tests used to check the function of the thyroid. QY, JX, HY http://en.volupedia.org/wiki/Thyroid_function_tests 不含甲状腺素 10055157 thyroxine free AE OAE:0007642 This is an AE which is the functional deterioration of a structure or system that had been previously working with the help of allostatic compensation such as diabetic metabolic decompensation. QY, JX, HY http://en.volupedia.org/wiki/Decompensation 糖尿病代谢代谢失调 10074309 diabetic metabolic decompensation AE OAE:0007643 This is an AE which is a lysosomal storage disorder characterized by the excess accumulation of phospholipids in tissues. QY, JX, HY http://en.volupedia.org/wiki/Phospholipidosis 磷脂质病 10074564 phospholipidosis AE OAE:0007644 This is an AE which is a rare long-term endocrine disorder characterized by inadequate production of the steroid hormones cortisol and aldosterone by the two outer layers of the cells of the adrenal glands (adrenal cortex), causing adrenal insufficiency. QY, JX, HY http://en.volupedia.org/wiki/Addison%27s_disease 阿狄森氏病 10001130 addison's disease AE OAE:0007645 This is an AE which is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. QY, JX, HY http://en.volupedia.org/wiki/Krabbe_disease 克腊伯氏病 10023492 krabbe's disease AE OAE:0007646 This is an AE which is characterized as a disruption to the microbiota homeostasis caused by an imbalance in the microflora, changes in their functional composition and metabolic activities, or a shift in their local distribution. QY, JX, HY http://en.volupedia.org/wiki/Dysbiosis 菌群失调 10082129 dysbiosis AE OAE:0007647 This is an AE which is an abnormality of the human body's normal balance of acids and bases that causes the plasma pH to deviate out of the normal range (7.35 to 7.45). QY, JX, HY http://en.volupedia.org/wiki/Acid%E2%80%93base_disorder 酸碱平衡失调混合 10000483 acid-base balance disorder mixed AE OAE:0007648 QY, JX, HY 肾旋转不良 10067877 kidney malrotation AE OAE:0007649 QY, JX, HY 乳液积滞 10060710 galactostasis AE OAE:0007650 QY, JX, HY 湿度不耐受 10072791 humidity intolerance AE OAE:0007651 QY, JX, HY 偏侧感觉缺失 10077170 hemianaesthesia AE OAE:0007652 QY, JX, HY 认知语言缺陷 10078970 cognitive linguistic deficit AE OAE:0007653 QY, JX, HY 病原体耐药性 10034133 pathogen resistance AE OAE:0007654 QY, JX, HY 肾上腺素综合征 10001387 adrenergic syndrome AE OAE:0007655 QY, JX, HY 肾上腺肿大 10051896 adrenomegaly AE OAE:0007656 QY, JX, HY 运动发育迟缓 10070302 motor developmental delay AE OAE:0007657 QY, JX, HY 中度精神发育迟滞 10027791 moderate mental retardation AE OAE:0007658 QY, JX, HY 腮腺导管阻塞 10034021 parotid duct obstruction AE OAE:0007659 This is an AE which is a pain of responsible for adduction of the jaw, and one (the lateral pterygoid) helps to abduct it. QY, JX, HY http://en.volupedia.org/wiki/Muscles_of_mastication 肌痛 10077030 masticatory pain AE OAE:0007660 This is an AE which is a pathology affecting the vocal folds (commonly referred to as the vocal cords) characterized by full or partial vocal fold closure causing difficulty and distress during respiration, especially during inhalation. QY, JX, HY http://en.volupedia.org/wiki/Vocal_cord_dysfunction 声带收肌无力 10001136 adductor vocal cord weakness AE OAE:0007661 This is an AE which is a rare autoimmune disorder characterized by muscle weakness of the limbs. QY, JX, HY http://en.volupedia.org/wiki/Lambert%E2%80%93Eaton_myasthenic_syndrome 肌无力综合征 10028424 myasthenic syndrome AE OAE:0007662 This is an AE which is organs of the vertebrate muscular system that are mostly attached by tendons to bones of the skeleton. QY, JX, HY http://en.volupedia.org/wiki/Skeletal_muscle 肌肉肿块 10056720 muscle mass AE OAE:0007663 This is an AE which is the partial or complete wasting away of a part of the bone. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 骨萎缩 10068975 bone atrophy AE OAE:0007664 This is an AE which is an abnormal growth of tissue in bone, traditionally classified as noncancerous (benign) or cancerous (malignant). QY, JX, HY http://en.volupedia.org/wiki/Bone_tumor 骨癌 10005949 bone cancer AE OAE:0007665 This is an AE which is characterized by a diffuse or localized pattern of low signal intensity on T1-weighted images without a defined fracture. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7803074/ 骨挫伤 10066251 bone contusion AE OAE:0007666 This is an AE which is the softening of bones due to the removal of calcium ions, and can be performed as a histological technique to study bones and extract DNA. QY, JX, HY http://en.volupedia.org/wiki/Bone_decalcification 骨脱钙 10070817 bone decalcification AE OAE:0007667 This is an AE which is rare diseases and about 1 in 5,000 babies are born with some type of skeletal dysplasia. QY, JX, HY http://en.volupedia.org/wiki/Osteochondrodysplasia 骨骼畸形 10070918 bone deformity AE OAE:0007668 This is an AE which refers to the medical conditions which affect the bone. QY, JX, HY http://en.volupedia.org/wiki/Bone_disease 骨疾病 10005956 bone disorder AE OAE:0007669 This is an AE which is the loss of bone from disease processes. QY, JX, HY http://en.volupedia.org/wiki/Bone_erosion 骨侵蚀 10051728 bone erosion AE OAE:0007670 This is an AE which is sorted by size and the proportional weights of each size category were compared to isolate any differences in fragmentation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23756520/ 骨头碎片 10064211 bone fragmentation AE OAE:0007671 This is an AE which is the darkening of an area of skin or nails or bone caused by increased melanin. QY, JX, HY http://en.volupedia.org/wiki/Hyperpigmentation 骨色素沉着过度 10070598 bone hyperpigmentation AE OAE:0007672 This is an AE which is the loss of skeletal muscle mass. QY, JX, HY http://en.volupedia.org/wiki/Muscle_atrophy 肌肉萎缩 10028289 muscle atrophy AE OAE:0007673 This is an AE which is second only to strain as the leading cause of morbidity from sports-related injuries. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11476532/ 肌肉挫伤 10070757 muscle contusion AE OAE:0007674 This is an AE which is injuries or pain in the human musculoskeletal system, including the joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck and back. QY, JX, HY http://en.volupedia.org/wiki/Musculoskeletal_disorder 肌肉疾病 10028300 muscle disorder AE OAE:0007675 This is an AE which is a condition in which the muscle of the body is deprived of adequate oxygen supply at the tissue level. QY, JX, HY http://en.volupedia.org/wiki/Hypoxia_(medical) 肌肉缺氧 10078053 muscle hypoxia AE OAE:0007676 This is an AE which is a form of muscle cell injury which results in the premature death of cells in living tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 肌肉坏死 10028320 muscle necrosis AE OAE:0007677 This is an AE which is a type of abnormal and excessive growth of muscle tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 肌肉瘤 10061692 muscle neoplasm AE OAE:0007678 This is an AE which is the build-up of fluid in the muscle tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 肌肉水肿 10071759 muscle edema AE OAE:0007679 This is an AE which refers a transient abnormal enlargement of the muscle not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 肌肉肿胀 10064470 muscle swelling AE OAE:0007680 This is an AE which is a highly aggressive form of cancer that develops from mesenchymal cells that have failed to fully differentiate into myocytes of skeletal muscle. QY, JX, HY http://en.volupedia.org/wiki/Rhabdomyosarcoma 横纹肌肉瘤 10039022 rhabdomyosarcoma AE OAE:0007681 This is an AE which is a type of muscle loss (muscle atrophy) that occurs with aging and/or immobility. QY, JX, HY http://en.volupedia.org/wiki/Sarcopenia 肌肉减少症 10063024 sarcopenia AE OAE:0007682 This is an AE which is benign tumors that are composed of fibrous or connective tissue. QY, JX, HY http://en.volupedia.org/wiki/Fibroma 纤维瘤 10016629 fibroma AE OAE:0007683 This is an AE which is a non-atherosclerotic, non-inflammatory disease of the blood vessels that causes abnormal growth within the wall of an artery. QY, JX, HY http://en.volupedia.org/wiki/Fibromuscular_dysplasia 纤维肌性的发育不良 10054794 fibromuscular dysplasia AE OAE:0007684 This is an AE which is a medical condition characterized by chronic widespread pain and a heightened pain response to pressure. QY, JX, HY http://en.volupedia.org/wiki/Fibromyalgia 纤维肌痛症 10048439 fibromyalgia AE OAE:0007685 This is an AE which is a malignant mesenchymal tumour derived from fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern. QY, JX, HY http://en.volupedia.org/wiki/Fibrosarcoma 纤维肉瘤 10016632 fibrosarcoma AE OAE:0007686 This is an AE which is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis 纤维化 10016642 fibrosis AE OAE:0007687 This is an AE which is a pathological wound healing in which connective tissue replaces normal tendinous parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue. QY, JX, HY http://en.volupedia.org/wiki/Fibrosis 纤维化腱 10016662 fibrosis tendinous AE OAE:0007688 This is an AE which is a benign, non-neoplastic proliferative process that is relatively common in the long bones of skeletally immature adolescents. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20692185/ 纤维皮质缺损 10052753 fibrous cortical defect AE OAE:0007689 This is an AE which is a benign skin growth. QY, JX, HY http://en.volupedia.org/wiki/Dermatofibroma 纤维组织细胞瘤 10053717 fibrous histiocytoma AE OAE:0007690 This is an AE which is a fracture of the lower legs bones meaning either or both of the tibia and fibula. QY, JX, HY http://en.volupedia.org/wiki/Crus_fracture 腓骨骨折 10016667 fibula fracture AE OAE:0007691 This is an AE which is an inability or impairment of an individual to perform tasks that require a degree of manual dexterity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33085413/ 精细动作延迟 10066088 fine motor delay AE OAE:0007692 This is an AE which is a function that involves specific movements of the bodies muscles to perform a certain task but it has dysfunction. QY, JX, HY http://en.volupedia.org/wiki/Motor_skill 精细运动技能障碍 10076288 fine motor skill dysfunction AE OAE:0007693 This is an AE which is a permanent shortening of a extremity muscle or joint. QY, JX, HY http://en.volupedia.org/wiki/Contracture 肢体挛缩 10050732 extremity contracture AE OAE:0007694 This is an AE which is a form of extremity cell injury which results in the premature death of cells in living tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 肢体坏死 10059385 extremity necrosis AE OAE:0007696 This is an AE which is a medical condition in which damage to the anterior interosseous nerve (AIN), a distal motor and sensory branch of the median nerve, classically with severe weakness of the pincer movement of the thumb and index finger, and can cause transient pain in the wrist (the terminal, sensory branch of the AIN innervates the bones of the carpal tunnel). QY, JX, HY http://en.volupedia.org/wiki/Anterior_interosseous_syndrome 前骨间的综合症 10065536 anterior interosseous syndrome AE OAE:0007697 This is an AE which is a bone fracture which occurs when a fragment of bone tears away from the main mass of bone as a result of physical trauma. QY, JX, HY http://en.volupedia.org/wiki/Avulsion_fracture 撕裂骨折 10066184 avulsion fracture AE OAE:0007698 This is an AE which is a resilient and smooth elastic tissue and its development is disorder. QY, JX, HY http://en.volupedia.org/wiki/Cartilage 软骨发育障碍 10061745 cartilage development disorder AE OAE:0007699 This is an AE which exists when the capacity of the pelvis is inadequate to allow the fetus to negotiate the birth canal. QY, JX, HY http://en.volupedia.org/wiki/Cephalopelvic_disproportion 头骨盆不成比例 10008020 cephalo-pelvic disproportion AE OAE:0007700 This is an AE which is a fracture of any of the seven cervical vertebrae in the neck. QY, JX, HY http://en.volupedia.org/wiki/Cervical_fracture 颈椎骨折 10049946 cervical vertebral fracture AE OAE:0007701 This is an AE which is inflammation of cartilage. QY, JX, HY http://en.volupedia.org/wiki/Chondritis 软骨炎 10008685 chondritis AE OAE:0007702 This is an AE which is calcification (accumulation of calcium salts) in hyaline cartilage and/or fibrocartilage. QY, JX, HY http://en.volupedia.org/wiki/Chondrocalcinosis 软骨钙化沉着病 10061761 chondrocalcinosis AE OAE:0007703 This is an AE which refers to a skeletal disorder caused by one of myriad genetic mutations that can affect the development of cartilage. QY, JX, HY http://en.volupedia.org/wiki/Chondrodystrophy 软骨营养不良 10008723 chondrodystrophy AE OAE:0007704 This is an AE which is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. QY, JX, HY http://en.volupedia.org/wiki/Chondrosarcoma 软骨肉瘤 10008734 chondrosarcoma AE OAE:0007705 This is an AE which is a bone fracture of the clavicle. QY, JX, HY http://en.volupedia.org/wiki/Clavicle_fracture 锁骨骨折 10009245 clavicle fracture AE OAE:0007706 This is an AE which is a medical term meaning pain in the coccyx or tailbone area, often brought on by a fall onto the coccyx or by persistent irritation usually from sitting. QY, JX, HY http://en.volupedia.org/wiki/Coccydynia 尾骨痛 10009829 coccydynia AE OAE:0007707 This is an AE which refers a fracture in which the bone has broken into several pieces. QY, JX, HY http://en.volupedia.org/wiki/Bone_fracture#Fragments 粉碎性骨折 10052614 comminuted fracture AE OAE:0007708 This is an AE which is a collapse of a vertebra. It may be due to trauma or due to a weakening of the vertebra (compare with burst fracture). QY, JX, HY http://en.volupedia.org/wiki/Vertebral_compression_fracture 压缩性骨折 10010214 compression fracture AE OAE:0007709 This is an AE which is a benign inflammatory condition affecting the upper costochondral junctions and costosternal joints. QY, JX, HY http://en.volupedia.org/wiki/Costochondritis 肋软骨炎 10011219 costochondritis AE OAE:0007710 This is an AE which refers the bone remodeling is the process of laying down new bone material by cells named osteoblasts. QY, JX, HY http://en.volupedia.org/wiki/Ossification 骨骼外骨形成 10049811 extraskeletal ossification AE OAE:0007711 This is an AE which represents a relatively uncommon injury in the non-elderly population often resulting from high-energy trauma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31203740/ 股骨颈骨折 10016450 femoral neck fracture AE OAE:0007712 This is an AE which is a bone fracture that involves the femur. QY, JX, HY http://en.volupedia.org/wiki/Femoral_fracture 股骨骨折 10016454 femur fracture AE OAE:0007713 This is an AE which is a disorder of the foot that can be congenital or acquired. QY, JX, HY http://en.volupedia.org/wiki/Foot_deformity 脚骨折 10061159 foot deformity AE OAE:0007714 This is an AE which includes lisfranc fracture,Jones fracture , march fracture , calcaneal fracture, broken toe and cuneiform fracture. QY, JX, HY http://en.volupedia.org/wiki/Foot#fracture 脚骨伤 10016970 foot fracture AE OAE:0007715 This is an AE which is one of the serious neurological complications in ACH. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27767902/ 枕骨大孔狭窄 10064157 foramen magnum stenosis AE OAE:0007716 This is an AE which is the region of the upper limb between the elbow and the wrist which is fracture. QY, JX, HY http://en.volupedia.org/wiki/Forearm#Fracture 前臂骨折 10016997 forearm fracture AE OAE:0007717 This is an AE which is when a fractured bone does not heal properly. QY, JX, HY http://en.volupedia.org/wiki/Malunion 骨折畸形愈合 10017085 fracture malunion AE OAE:0007718 This is an AE which is broadly classified as surgical or conservative, the latter basically referring to any non-surgical procedure, such as pain management, immobilization or other non-surgical stabilization. QY, JX, HY http://en.volupedia.org/wiki/Bone_fracture#Treatment 骨折的治疗 10061959 fracture treatment AE OAE:0007719 This is an AE which is a fracture of the coccyx. QY, JX, HY http://en.volupedia.org/wiki/Coccyx_fracture 尾骨骨折 10049164 fractured coccyx AE OAE:0007720 This is an AE which is a scaphoid fracture—a fracture of the scaphoid bone, one of the carpal bones. QY, JX, HY http://en.volupedia.org/wiki/Hand#fracture 手骨折 10019114 hand fracture AE OAE:0007721 This is an AE which is a break of the humerus bone in the upper arm. QY, JX, HY http://en.volupedia.org/wiki/Humerus_fracture 肱骨骨折 10020462 humerus fracture AE OAE:0007722 This is an AE which is a medical condition combining clubbing and periostitis of the small hand joints, especially the distal interphalangeal joints and the metacarpophalangeal joints. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophic_osteoarthropathy 肥厚性骨关节病 10020877 hypertrophic osteoarthropathy AE OAE:0007723 This is an AE which is the second most common knee injury caused by inflammation located on the lateral aspect of the knee due to friction between the iliotibial band and the lateral epicondyle of the femur. QY, JX, HY http://en.volupedia.org/wiki/Iliotibial_band_syndrome 髂胫骨带综合征 10060813 iliotibial band syndrome AE OAE:0007724 This is an AE which is the separation of ilium into two or more pieces under the action of stress. QY, JX, HY http://en.volupedia.org/wiki/Fracture 髂骨骨折 10021343 ilium fracture AE OAE:0007725 This is an AE which is the separation of limb into two or more pieces under the action of stress. QY, JX, HY http://en.volupedia.org/wiki/Fracture 四肢骨折 10074551 limb fracture AE OAE:0007726 This is an AE which is the separation of lower limb into two or more pieces under the action of stress. QY, JX, HY http://en.volupedia.org/wiki/Fracture 下肢骨折 10061599 lower limb fracture AE OAE:0007727 This is an AE which can directly produce massive RPH leading to hemorrhagic death. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29368084/ 腰骨伤 10049947 lumbar vertebral fracture AE OAE:0007728 This is an AE which is pain along the inside edge of the shinbone (tibia) due to inflammation of tissue in the area. QY, JX, HY http://en.volupedia.org/wiki/Shin_splints 内侧胫骨应力综合征 10065303 medial tibial stress syndrome AE OAE:0007729 This is an AE which is any painful foot condition affecting the metatarsal region of the foot. QY, JX, HY http://en.volupedia.org/wiki/Metatarsalgia 跖骨痛 10027487 metatarsalgia AE OAE:0007730 This is an AE which is a rare genetic disorder (dominant form: 1 in 10,000 births) that affects the growing ends of bones. QY, JX, HY http://en.volupedia.org/wiki/Multiple_epiphyseal_dysplasia 多发性骨骺发育不良 10028197 multiple epiphyseal dysplasia AE OAE:0007731 This is an AE which is of high clinical relevance, as a significant increase in mortality rate has been described. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30747275/ 多发性骨折 10028200 multiple fractures AE OAE:0007732 This is an AE which comprises two syndromes characterized by heterotopic ossification (calcification) of muscle. QY, JX, HY http://en.volupedia.org/wiki/Myositis_ossificans 骨化性肌炎 10048618 myositis ossificans AE OAE:0007733 This is an AE which is a noninflammatory condition of an uncertain etiology, characterized by sclerotic bone lesions located mainly in the iliac region of the sacroiliac joints. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32328707/ 致密性骨炎 10031150 osteitis condensans AE OAE:0007734 This is an AE which is a painful type of osteochondrosis where the cartilage or bone in a joint is inflamed. QY, JX, HY http://en.volupedia.org/wiki/Osteochondritis 骨软骨炎 10031230 osteochondritis AE OAE:0007735 This is an AE which is the most common benign tumors of the bones. QY, JX, HY http://en.volupedia.org/wiki/Osteochondroma 骨软骨瘤 10059587 osteochondroma AE OAE:0007736 This is an AE which is a family of orthopedic diseases of the joint that occur in children, adolescents and rapidly growing animals, particularly pigs, horses, dogs, and broiler chickens. QY, JX, HY http://en.volupedia.org/wiki/Osteochondrosis 骨软骨病 10031233 osteochondrosis AE OAE:0007737 This is an AE which is a group of genetic disorders that all result in bone that breaks easily.[9][1]: 85  The range of symptoms—on the skeleton as well as on the body's other organs—may be mild to severe. QY, JX, HY http://en.volupedia.org/wiki/Osteogenesis_imperfecta 成骨不全症 10031243 osteogenesis imperfecta AE OAE:0007738 This is an AE which is a new piece of bone usually growing on another piece of bone, typically the skull. QY, JX, HY http://en.volupedia.org/wiki/Osteoma 骨瘤 10031249 osteoma AE OAE:0007739 This is an AE which is a disease characterized by the softening of the bones caused by impaired bone metabolism primarily due to inadequate levels of available phosphate, calcium, and vitamin D, or because of resorption of calcium. QY, JX, HY http://en.volupedia.org/wiki/Osteomalacia 骨软化 10031250 osteomalacia AE OAE:0007740 This is an AE which is an extremely rare inherited disorder whereby the bones harden, becoming denser, in contrast to more prevalent conditions like osteoporosis, in which the bones become less dense and more brittle, or osteomalacia, in which the bones soften. Osteopetrosis can cause bones to dissolve and break. QY, JX, HY http://en.volupedia.org/wiki/Osteopetrosis 骨硬化病 10031280 osteopetrosis AE OAE:0007741 This is an AE which is a bone fracture caused by weakness of the bone structure that leads to decrease mechanical resistance to normal mechanical loads. QY, JX, HY http://en.volupedia.org/wiki/Pathologic_fracture 骨质疏松性骨折 10031290 osteoporotic fracture AE OAE:0007742 This is an AE which is a cancerous tumor in a bone. QY, JX, HY http://en.volupedia.org/wiki/Osteosarcoma 骨肉瘤 10031291 osteosarcoma AE OAE:0007743 This is an AE which is a break of the kneecap. QY, JX, HY http://en.volupedia.org/wiki/Patella_fracture 髌骨骨折 10034122 patella fracture AE OAE:0007744 This is an AE which is a bone fracture caused by weakness of the bone structure that leads to decrease mechanical resistance to normal mechanical loads. QY, JX, HY http://en.volupedia.org/wiki/Pathologic_fracture 病理性骨折 10034156 pathological fracture AE OAE:0007745 This is an AE which is fibrous bands that form between joint tissues and organs, often as a result of injury during surgery. QY, JX, HY http://en.volupedia.org/wiki/Adhesion_(medicine) 关节粘连 10058031 joint adhesion AE OAE:0007746 This is an AE which is a stiffness of a joint due to abnormal adhesion and rigidity of the bones of the joint, which may be the result of injury or disease. QY, JX, HY http://en.volupedia.org/wiki/Ankylosis 关节僵硬 10023198 joint ankylosis AE OAE:0007747 This is an AE which is a permanent shortening of a muscle or joint. QY, JX, HY http://en.volupedia.org/wiki/Contracture 关节挛缩 10023201 joint contracture AE OAE:0007748 This is an AE which refers a crunching sensation felt in certain medical problems on joint. QY, JX, HY http://en.volupedia.org/wiki/Crepitation 关节爆裂声 10051374 joint crepitation AE OAE:0007749 This is an AE which refers to damage to joint (physical vandalism) beyond the capability to repair. QY, JX, HY http://en.volupedia.org/wiki/Destruction 关节破坏 10023203 joint destruction AE OAE:0007750 This is an AE which occurs when there is an abnormal separation in the joint, where two or more bones meet. QY, JX, HY http://en.volupedia.org/wiki/Joint_dislocation?wprov=srpw1_0 减少关节脱位 10052988 joint dislocation reduction AE OAE:0007751 This is an AE which is a deformity in the knee joint, so that the knee bends backwards. QY, JX, HY http://en.volupedia.org/wiki/Genu_recurvatum 关节过伸 10062310 joint hyperextension AE OAE:0007752 This is an AE which refers to the resistance offered by various musculoskeletal tissues that surround a skeletal joint which is instability. QY, JX, HY http://en.volupedia.org/wiki/Joint_stability 关节不稳定 10064931 joint instability AE OAE:0007754 This is an AE which has been implicated in ankle sprains, anterior cruciate ligament injury, shoulder instability, and osteoarthritis of the hand. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21807914/ 关节松弛 10070874 joint laxity AE OAE:0007755 This is an AE which is a common symptom that often leads to outpatient clinic visits. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29564040/ 关节噪声 10074329 joint noise AE OAE:0007756 This is an AE which is considered an important physical sign of joint dysfunction and/or joint pathology. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19697644/ 关节振动 10074327 joint vibration AE OAE:0007757 This is an AE which refers a somewhat high temperature on joint. QY, JX, HY http://en.volupedia.org/wiki/Warm 关节发热 10054106 joint warmth AE OAE:0007758 This is an AE which is any form of chronic arthritis or chronic arthritis-related conditions which affects individuals under the age of 16. QY, JX, HY http://en.volupedia.org/wiki/Childhood_arthritis 少年关节炎 10059177 juvenile arthritis AE OAE:0007759 This is an AE which is the most common, chronic rheumatic disease of childhood, affecting approximately one per 1,000 children. QY, JX, HY http://en.volupedia.org/wiki/Juvenile_idiopathic_arthritis 青少年特发性关节炎 10059176 juvenile idiopathic arthritis AE OAE:0007760 This is an AE which is a fairly common form of generalized epilepsy of presumed genetic origin (previously known an idiopathic generalized epilepsy), representing 5-10% of all epilepsy cases. QY, JX, HY http://en.volupedia.org/wiki/Juvenile_myoclonic_epilepsy 青少年肌阵挛性癫痫 10071082 juvenile myoclonic epilepsy AE OAE:0007761 This is an AE which is thought to be important regulators of disc cell metabolism. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17978649/ 椎间盘压迫 10055039 intervertebral disc compression AE OAE:0007762 This is an AE which refers anything arising from the intervertebral disc may be termed discogenic in particular when referring to associated pain as discogenic pain. QY, JX, HY http://en.volupedia.org/wiki/Intervertebral_disc#Clinical_significance 椎间盘疾病 10061521 intervertebral disc disorder AE OAE:0007763 This is an AE which is an injury to the cushioning and connective tissue between vertebrae, usually caused by excessive strain or trauma to the spine. QY, JX, HY http://en.volupedia.org/wiki/Spinal_disc_herniation 椎间盘移位 10022636 intervertebral disc displacement AE OAE:0007764 This is an AE which associated strongly with the enhancement (Pearson's correlation coefficient 0.46, P < 0.001). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18949498/ 椎间盘间隙变窄 10055041 intervertebral disc space narrowing AE OAE:0007765 This is an AE which is a rare disorder which is easily missed and presents with non-specific symptoms such as irritability, abdominal pain, decreased appetite and limping. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27649709/ 椎间关节盘炎 10060738 intervertebral discitis AE OAE:0007766 This is an AE which is a very rare neurologic disorder classically characterised by pronounced startle responses to tactile or acoustic stimuli and hypertonia. QY, JX, HY http://en.volupedia.org/wiki/Hyperekplexia 肌张力过度 10058271 hyperexplexia AE OAE:0007767 This is an AE which is a rare, sometimes fatal neurological condition linked to the ingestion of the dietary supplement L-tryptophan. QY, JX, HY http://en.volupedia.org/wiki/Eosinophilia%E2%80%93myalgia_syndrome 嗜酸细胞增多性肌痛综合征 10014952 eosinophilia myalgia syndrome AE OAE:0007768 This is an AE which refers to a group of functional disorders leading to abdominal pain due to dysfunction of the Sphincter of Oddi: functional biliary sphincter of Oddi and functional pancreatic sphincter of Oddi disorder. QY, JX, HY http://en.volupedia.org/wiki/Sphincter_of_Oddi_dysfunction 奥迪括约肌功能障碍 10066424 sphincter of oddi dysfunction AE OAE:0007769 This is an AE which is the most common inflammatory muscle disease in older adults. QY, JX, HY http://en.volupedia.org/wiki/Inclusion_body_myositis 包涵体肌炎 10066407 inclusion body myositis AE OAE:0007770 This is an AE which is a complication after a viral infection mainly caused by Influenza A and B viruses. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31560498/ 病毒性肌炎 10051512 viral myositis AE OAE:0007771 This is an AE which is a relatively common infectious condition characterized by bullae or vesicles on the tympanic membrane (TM), without affecting the contents of the external or middle ear. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31971705/ 大疱性肌炎 10028659 myringitis bullous AE OAE:0007772 This is an AE which is myopathies that result from defects in biochemical metabolism that primarily affect muscle. QY, JX, HY http://en.volupedia.org/wiki/Metabolic_myopathy 代谢性肌病 10068836 metabolic myopathy AE OAE:0007773 This is an AE which symptoms usually appear about two years after adolescent growth spurt and is significantly more common in males (average age of onset, 15- to 25-year-old). QY, JX, HY http://en.volupedia.org/wiki/Monomelic_amyotrophy 单肢肌萎缩 10069681 monomelic amyotrophy AE OAE:0007774 This is an AE which is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. QY, JX, HY http://en.volupedia.org/wiki/Polymyositis 多肌炎 10036102 polymyositis AE OAE:0007775 This is an AE which is a form of dilated cardiomyopathy that is defined as a deterioration in cardiac function presenting typically between the last month of pregnancy and up to six months postpartum. QY, JX, HY http://en.volupedia.org/wiki/Peripartum_cardiomyopathy 分娩前后心肌病 10049430 peripartum cardiomyopathy AE OAE:0007776 This is an AE which is a birth defect where diaphragmatic tissue is wholly or largely absent. QY, JX, HY http://en.volupedia.org/wiki/Aplasia 膈肌发育不全 10012711 diaphragmatic aplasia AE OAE:0007777 This is an AE which is a disorder of a sheet of internal skeletal muscle in humans and other mammals that extends across the bottom of the thoracic cavity . QY, JX, HY http://en.volupedia.org/wiki/Thoracic_diaphragm 膈肌疾病 10061106 diaphragmatic disorder AE OAE:0007778 This is an AE which is an intense itching sensation of the arm usually between the wrist and elbow of either or both arms. QY, JX, HY http://en.volupedia.org/wiki/Brachioradial_pruritus 肱桡肌瘙痒 10071443 brachioradial pruritus AE OAE:0007779 This is an AE which could result from external carotid artery (ECA) occlusive disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21397442/ 颌肌跛行 10009243 claudication of jaw muscles AE OAE:0007780 This is an AE which is a benign tumor of striated muscle. QY, JX, HY http://en.volupedia.org/wiki/Rhabdomyoma 横纹肌瘤 10039021 rhabdomyoma AE OAE:0007781 This is an AE which is a bacterial infection of the skeletal muscles which results in an abscess. QY, JX, HY http://en.volupedia.org/wiki/Pyomyositis 化脓性肌炎 10037652 pyomyositis AE OAE:0007782 This is an AE which is a disease of the muscle in which the muscle fibers do not function properly. QY, JX, HY http://en.volupedia.org/wiki/Myopathy 肌病 10028641 myopathy AE OAE:0007783 This is an AE which is a tough, high-tensile-strength band of dense fibrous connective tissue that connects muscle to bone and feel it discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Tendon 肌腱不适 10074599 tendon discomfort AE OAE:0007784 This is an AE which is a painful shoulder disorder characterised by either single or multiple deposits in the rotator cuff tendon. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26163832/ 肌腱钙化 10057888 tendon calcification AE OAE:0007785 This is an AE which is a form of tendon cell injury which results in the premature death of cells in living tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 肌腱坏死 10069650 tendon necrosis AE OAE:0007786 This is an AE which is a permanent shortening of a tendinous muscle or joint. QY, JX, HY http://en.volupedia.org/wiki/Contracture 肌腱挛缩 10043233 tendinous contracture AE OAE:0007787 This is an AE which is a tough, high-tensile-strength band of dense fibrous connective tissue that connects muscle to bone and feel it pain. QY, JX, HY http://en.volupedia.org/wiki/Tendon 肌腱痛 10066371 tendon pain AE OAE:0007788 This is an AE which is a sudden involuntary contraction of myofascial tissue. QY, JX, HY http://en.volupedia.org/wiki/Spasm 肌筋膜痉挛 10051378 myofascial spasm AE OAE:0007789 This is an AE which is a syndrome characterized by chronic pain in multiple myofascial trigger points ("knots") and fascial (connective tissue) constrictions. QY, JX, HY http://en.volupedia.org/wiki/Myofascial_pain_syndrome 肌筋膜疼痛综合征 10048780 myofascial pain syndrome AE OAE:0007790 This is an AE which main cause of the disease is aseptic inflammation of local muscles and connective tissues such as myofascial, which can be manifested as paralysis, distension, and other discomfort, local muscle stiffness, spasm or palpable strain-like nodules. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/34114979/ 肌筋膜炎 10052443 myofascitis AE OAE:0007791 This is an AE which is a type of muscular dystrophy, a group of genetic disorders that cause progressive muscle loss and weakness. QY, JX, HY http://en.volupedia.org/wiki/Myotonic_dystrophy 肌强直性营养不良 10068871 myotonic dystrophy AE OAE:0007792 This is an AE which is the medical term for intercostal muscle pain. QY, JX, HY http://en.volupedia.org/wiki/Myalgia 肌痛肋间 10028413 myalgia intercostal AE OAE:0007793 This is an AE which is progressive wasting of muscle tissues. QY, JX, HY http://en.volupedia.org/wiki/Amyotrophy 肌萎缩 10002027 amyotrophy AE OAE:0007794 This is an AE which is an involuntary, spontaneous, localized quivering of a few muscles, or bundles within a muscle, but which are insufficient to move a joint. QY, JX, HY http://en.volupedia.org/wiki/Myokymia 肌纤维颤搐 10028632 myokymia AE OAE:0007795 This is an AE which occurs in individuals of all ages who are affected by dystonia, a movement disorder in which sustained involuntary muscle contractions cause twisting and repetitive motions or painful and abnormal postures or positions. QY, JX, HY http://en.volupedia.org/wiki/Tremor#Types 肌张力异常性颤抖 10073210 dystonic tremor AE OAE:0007796 This is an AE which is a disorder of the continuous and passive partial contraction of the muscles, or the muscle's resistance to passive stretch during resting state. QY, JX, HY http://en.volupedia.org/wiki/Muscle_tone 肌张力障碍 10072889 muscle tone disorder AE OAE:0007797 This is an AE which is a brief, involuntary, irregular (lacking rhythm) twitching (different from clonus, which is rhythmic/ regular) of a muscle or a group of muscles. QY, JX, HY http://en.volupedia.org/wiki/Myoclonus 肌阵挛 10028622 myoclonus AE OAE:0007798 This is an AE which refers to a family of epilepsies that present with myoclonus. QY, JX, HY http://en.volupedia.org/wiki/Myoclonic_epilepsy 肌阵挛性癫痫 10054859 myoclonic epilepsy AE OAE:0007799 This is an AE which is a benign, soft tissue tumor composed of myofibroblasts (i.e. immature cells that contain features of myocytes and fibroblasts) that typically occurs in subcutaneous tissue (i.e. lowermost layer of the skin), fascia (i.e. band of connective tissue just beneath the skin), and/or muscles. QY, JX, HY http://en.volupedia.org/wiki/Nodular_fasciitis 结节性筋膜炎 10065988 nodular fasciitis AE OAE:0007800 This is an AE which is a skin disease that presents with painful, red, raised, and warm patches of skin. QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_cellulitis 嗜酸性蜂窝织炎 10053776 eosinophilic cellulitis AE OAE:0007801 This is an AE which is an inflammatory disease that affects the fascia, other connective tissues, surrounding muscles, blood vessels and nerves. QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_fasciitis 嗜酸性筋膜炎 10014954 eosinophilic fasciitis AE OAE:0007802 This is an AE which is an infectious and sometimes fatal viral disease that affects cloven-hoofed animals, including domestic and wild bovids. QY, JX, HY http://en.volupedia.org/wiki/Foot-and-mouth_disease 口蹄疫 10016961 foot and mouth disease AE OAE:0007803 This is an AE which is primarily a disorder of healthy children and young adults, characterized by lesions that are primarily painful, subcutaneous nodules on the plantar surface, resembling erythema nodosum. QY, JX, HY http://en.volupedia.org/wiki/Recurrent_palmoplantar_hidradenitis 足底红斑 10051170 plantar erythema AE OAE:0007804 This is an AE which is a disorder of the plantar fascia, which is the connective tissue which supports the arch of the foot. QY, JX, HY http://en.volupedia.org/wiki/Plantar_fasciitis 足底筋膜炎 10035155 plantar fasciitis AE OAE:0007805 This is an AE which is a common skin infection of the feet caused by fungus. QY, JX, HY http://en.volupedia.org/wiki/Athlete%27s_foot 足癣 10043873 tinea pedis AE OAE:0007806 This is an AE which is an abnormal narrowing of the spinal canal or neural foramen that results in pressure on the spinal cord or nerve roots. QY, JX, HY http://en.volupedia.org/wiki/Spinal_stenosis 椎管狭窄 10082214 spinal stenosis AE OAE:0007807 This is an AE which is an abnormal narrowing in a blood vessel or other tubular organ or structure such as vertebral foraminal . QY, JX, HY http://en.volupedia.org/wiki/Stenosis 椎间孔狭窄 10069690 vertebral foraminal stenosis AE OAE:0007808 This is an AE which is a defect or stress fracture in the pars interarticularis of the vertebral arch. QY, JX, HY http://en.volupedia.org/wiki/Spondylolysis 椎间盘突出症 10052013 spondylolysis AE OAE:0007809 This is an AE which is an abnormal narrowing in a blood vessel or other tubular organ or structure such as vertebral lateral recess. QY, JX, HY http://en.volupedia.org/wiki/Stenosis 椎体侧隐窝狭窄 10081612 vertebral lateral recess stenosis AE OAE:0007810 This is an AE which is a dislocation of an irregular bone with a complex structure composed of bone and some hyaline cartilage, the proportions of which vary according to the segment of the backbone and the species of vertebrate. QY, JX, HY http://en.volupedia.org/wiki/Vertebra 椎体脱位，腰椎脱位 10013183 dislocation of vertebra AE OAE:0007811 This is an AE which refers to any clinical syndrome with either an excess of movement or a paucity of voluntary and involuntary movements, unrelated to weakness or spasticity. QY, JX, HY http://en.volupedia.org/wiki/Movement_disorder 锥体外系疾病 10015832 extrapyramidal disorder AE OAE:0007812 This is an AE which is the absence of, or a violation of, symmetry such as limb asymmetry. QY, JX, HY http://en.volupedia.org/wiki/Asymmetry#Asymmetry_in_biology 肢体不对称 10070670 limb asymmetry AE OAE:0007813 This is an AE which is congenital musculoskeletal disorders which primarily affect the upper and lower limbs. QY, JX, HY http://en.volupedia.org/wiki/Congenital_limb_deformities 肢体畸形 10053652 limb deformity AE OAE:0007814 This is an AE which is a physical anomaly that is deleterious, i.e. a structural defect perceived as a problem such as limb malformation. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 肢体畸形 10024500 limb malformation AE OAE:0007815 This is an AE which is a mass on appendage of a human . QY, JX, HY http://en.volupedia.org/wiki/Limb 肢体肿块 10078503 limb mass AE OAE:0007817 This is an AE which is a rare condition and should be considered a rare differential diagnosis to unexplained back pain. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20334799/ 腰疝 10024995 lumbar hernia AE OAE:0007818 This is an AE which is a medical condition in which the spinal canal narrows and compresses the nerves and blood vessels at the level of the lumbar vertebrae. QY, JX, HY http://en.volupedia.org/wiki/Lumbar_spinal_stenosis 腰椎管狭窄症 10025005 lumbar spinal stenosis AE OAE:0007819 This is an AE which is the displacement of one spinal vertebra compared to another. QY, JX, HY http://en.volupedia.org/wiki/Spondylolisthesis 脊柱滑脱 10063550 spondylolisthesis AE OAE:0007820 This is an AE which is flattening of the five vertebrae between the rib cage and the pelvis. QY, JX, HY http://en.volupedia.org/wiki/Lumbar_vertebrae 腰椎扁平化 10051823 lumbar spine flattening AE OAE:0007821 This is an AE which is a syndrome in which the facet joints (synovial diarthroses, from L2 to S1) cause painful symptoms. QY, JX, HY http://en.volupedia.org/wiki/Facet_syndrome 小关节综合征 10054813 facet joint syndrome AE OAE:0007822 This is an AE which is a disorder of the hand that can be congenital or acquired. QY, JX, HY http://en.volupedia.org/wiki/Hand_deformity 手畸形 10061194 hand deformity AE OAE:0007823 This is an AE which in older people is common following treatment for a wrist fracture, particularly after non-surgical treatment. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32197641/ 手腕畸形 10061415 wrist deformity AE OAE:0007824 This is an AE which presents with hyperkeratotic, fissure-prone, erythematous areas of the middle or proximal palm, and the volar surfaces of the fingers may also be involved. QY, JX, HY http://en.volupedia.org/wiki/Hyperkeratotic_hand_dermatitis 手性皮炎 10058898 hand dermatitis AE OAE:0007825 This is an AE which is a fungal infection of the hand, mostly a type of dermatophytosis, often part of two feet-one hand syndrome. QY, JX, HY http://en.volupedia.org/wiki/Tinea_manuum 手癣 10067197 tinea manuum AE OAE:0007826 This is an AE which is a common infection caused by a group of enteroviruses. QY, JX, HY http://en.volupedia.org/wiki/Hand,_foot,_and_mouth_disease 手足口病 10019113 hand-foot-and-mouth disease AE OAE:0007827 This is an AE which is a symptom characterized by slow, involuntary, convoluted, writhing movements of the fingers, hands, toes, and feet and in some cases, arms, legs, neck and tongue. QY, JX, HY http://en.volupedia.org/wiki/Athetosis 手足徐动症 10003620 athetosis AE OAE:0007828 This is an AE which is a small benign tumor that forms primarily in areas where the skin forms creases (or rubs together), such as the neck, armpit and groin. QY, JX, HY http://en.volupedia.org/wiki/Skin_tag 软垂疣 10000591 acrochordon AE OAE:0007829 This is an AE which is a heritable connective tissue disorder that affects joints and ligaments. QY, JX, HY http://en.volupedia.org/wiki/Hypermobility_spectrum_disorder 软筋症候群 10020677 hypermobility syndrome AE OAE:0007830 This is an AE which is medical conditions affecting soft tissue. QY, JX, HY http://en.volupedia.org/wiki/Soft_tissue#Disorders 软组织疾病 10061366 soft tissue disorder AE OAE:0007831 This is an AE which is a mass of all the tissue in the body that is not hardened by the processes of ossification or calcification such as bones and teeth. QY, JX, HY http://en.volupedia.org/wiki/Soft_tissue 软组织块 10071051 soft tissue mass AE OAE:0007832 This is an AE which is a malignant tumour, a type of cancer, that develops in soft tissue. QY, JX, HY http://en.volupedia.org/wiki/Soft-tissue_sarcoma 软组织肉瘤 10075333 soft tissue sarcoma AE OAE:0007833 This is an AE which is the partial or complete wasting away of a part of the soft tissue. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 软组织萎缩 10068548 soft tissue atrophy AE OAE:0007834 This is an AE which is part of the complex biological response of soft tissue to harmful stimuli. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 软组织炎症 10041290 soft tissue inflammation AE OAE:0007835 This is an AE which is a type of abnormal and excessive growth of soft tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 软组织肿瘤 10068771 soft tissue neoplasm AE OAE:0007836 This is an AE which refers a transient abnormal enlargement of soft tissue not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 软组织肿胀 10076991 soft tissue swelling AE OAE:0007837 This is an AE which is rupture of the fibrous connective tissue that connects bones to other bones. QY, JX, HY http://en.volupedia.org/wiki/Ligament 韧带断裂 10065433 ligament rupture AE OAE:0007838 This is an AE which is the stretching or tearing of ligaments within a joint, often caused by an injury abruptly forcing the joint beyond its functional range of motion. QY, JX, HY http://en.volupedia.org/wiki/Sprain 韧带扭伤 10024453 ligament sprain AE OAE:0007839 This is an AE which is a cause of chronic body pain characterized by loose ligaments. QY, JX, HY http://en.volupedia.org/wiki/Ligamentous_laxity 韧带松弛 10024452 ligament laxity AE OAE:0007840 This is an AE which is a disorder of the fibrous connective tissue that connects bones to other bones. QY, JX, HY http://en.volupedia.org/wiki/Ligament 韧带障碍 10061222 ligament disorder AE OAE:0007841 This is an AE which is any disease that has the connective tissues of the body as a target of pathology. QY, JX, HY http://en.volupedia.org/wiki/Connective_tissue_disease?wprov=srpw1_0 结缔组织炎症 10057254 connective tissue inflammation AE OAE:0007842 This is an AE which refers to any joint disease of the vertebral column. QY, JX, HY http://en.volupedia.org/wiki/Spondyloarthropathy 脊柱关节病 10051265 spondyloarthropathy AE OAE:0007843 This is an AE which is a spinal of posterior displacement of one vertebral body with respect to the subjacent vertebra to a degree less than a luxation (dislocation). QY, JX, HY http://en.volupedia.org/wiki/Retrolisthesis 脊柱后滑脱 10081602 spinal retrolisthesis AE OAE:0007844 This is an AE which is a physical anomaly that is deleterious, i.e. a structural defect perceived as a problem such as spine malformation. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 脊柱畸形 10041611 spine malformation AE OAE:0007845 This is an AE which is a birth defect in which there is incomplete closing of the spine and the membranes around the spinal cord during early development in pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Spina_bifida 脊柱裂 10041524 spina bifida AE OAE:0007846 This is an AE which is a mass on the part of the axial skeleton. QY, JX, HY http://en.volupedia.org/wiki/Vertebral_column 脊柱肿块 10054820 vertebral column mass AE OAE:0007847 This is an AE which feels pain of a small membranous protrusion from a neuron's dendrite. QY, JX, HY http://en.volupedia.org/wiki/Spine 脊椎痛 10072005 spinal pain AE OAE:0007848 This is an AE which is an inflammation of the vertebrae. QY, JX, HY http://en.volupedia.org/wiki/Spondylitis 脊椎炎 10061371 spondylitis AE OAE:0007849 This is an AE which is a form of gait abnormality. QY, JX, HY http://en.volupedia.org/wiki/Spastic_gait 步态痉挛性 10017585 gait spastic AE OAE:0007850 This is an AE which is nominally referred to as any variation of standard human gait, typically manifesting as a coping mechanism in response to an anatomical impairment. QY, JX, HY http://en.volupedia.org/wiki/Gait_deviations 步态偏差 10054197 gait deviation AE OAE:0007851 This is an AE which is characterised by an inability to initiate the process of walking, despite the power and coordination of the legs being normal when tested in the seated or lying position. QY, JX, HY http://en.volupedia.org/wiki/Bruns_apraxia 步态失用症 10070635 gait apraxia AE OAE:0007852 This is an AE which is nominally referred to as any variation of standard human gait, typically manifesting as a coping mechanism in response to an anatomical impairment. QY, JX, HY http://en.volupedia.org/wiki/Gait_deviations 步态障碍 10017577 gait disturbance AE OAE:0007853 This is an AE which is the inflammation of the fluid-filled sheath (called the synovium) that surrounds a tendon, typically leading to joint pain, swelling, and stiffness. QY, JX, HY http://en.volupedia.org/wiki/Tenosynovitis 腱鞘炎 10043261 tenosynovitis AE OAE:0007854 This is an AE which can occur in apparently healthy subjects having no atypical appearance and who may be unaware of carrying risk. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20207434/ 腱索断裂 10008745 chordae tendinae rupture AE OAE:0007855 This is an AE which is a rare neurologic disorder of unclear cause characterized by progressive rigidity and stiffness. QY, JX, HY http://en.volupedia.org/wiki/Stiff-person_syndrome 僵人综合症 10072148 stiff person syndrome AE OAE:0007856 This is an AE which is an uncommon focal variant of the stiff person syndrome and is characterized by stiffness and painful spasms of the lower limbs, with no axial involvement. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27000980/ 僵腿综合症 10079359 stiff leg syndrome AE OAE:0007857 This is an AE which is defined as arthritis affecting two to four joints during the first six months of disease. QY, JX, HY http://en.volupedia.org/wiki/Oligoarthritis 少关节炎 10082100 oligoarthritis AE OAE:0007858 This is an AE which refers to a height of a human which is below typical. QY, JX, HY http://en.volupedia.org/wiki/Short_stature 身材矮小 10040600 short stature AE OAE:0007859 This is an AE which is a limitation on a person's physical functioning, mobility, dexterity or stamina. QY, JX, HY http://en.volupedia.org/wiki/Physical_disability 身体残疾 10048624 physical disability AE OAE:0007860 This is an AE which is any intentional act causing injury or trauma to another person or animal by way of bodily contact. QY, JX, HY http://en.volupedia.org/wiki/Physical_abuse 虐待身体 10034982 physical abuse AE OAE:0007861 This is an AE which is the removal of a leg by trauma, medical illness, or surgery. QY, JX, HY http://en.volupedia.org/wiki/Amputation 腿部截肢 10024124 leg amputation AE OAE:0007862 This is an AE which is a deviation from normal walking (gait). QY, JX, HY http://en.volupedia.org/wiki/Gait_abnormality 行走困难 10012794 difficulty in walking AE OAE:0007863 This is an AE which is one of the most widespread and impactful consequences of multiple sclerosis (MS). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29772185/ 行走障碍 10053204 walking disability AE OAE:0007864 This is an AE which is a condition in which one or more fingers become permanently bent in a flexed position. QY, JX, HY http://en.volupedia.org/wiki/Dupuytren%27s_contracture 掌腱膜挛缩 10013872 dupuytren's contracture AE OAE:0007865 This is an AE which is a heterogeneous group of disorders characterized by abnormal thickening of the stratum corneum of the palms and soles. QY, JX, HY http://en.volupedia.org/wiki/Palmoplantar_keratoderma 掌跖角化病 10033554 palmoplantar keratoderma AE OAE:0007866 This is an AE which is a bleeding into joint spaces. It is a common feature of hemophilia. QY, JX, HY http://en.volupedia.org/wiki/Hemarthrosis 关节积血 10018829 haemarthrosis AE OAE:0007867 This is an AE which is very frequent and usually self limited to a few weeks. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16604875/ 病毒性关节炎 10003274 arthritis viral AE OAE:0007868 This is an AE which is a form of osteoarthritis following an injury to a joint. QY, JX, HY http://en.volupedia.org/wiki/Post-traumatic_arthritis 创伤性关节炎 10048873 traumatic arthritis AE OAE:0007869 This is an AE which should be regarded as infectious until proved otherwise. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9217557/ 单关节炎 10027811 monarthritis AE OAE:0007870 This is an AE which is inflammation within the sacroiliac joint. QY, JX, HY http://en.volupedia.org/wiki/Sacroiliitis 骶髂关节炎 10039361 sacroiliitis AE OAE:0007871 This is an AE which is recurring pain symptoms that are relatively common in children ages 3 to 12. QY, JX, HY http://en.volupedia.org/wiki/Growing_pains 发育期痛 10018745 growing pains AE OAE:0007872 This is an AE which is an abnormality of the hip joint where the socket portion does not fully cover the ball portion, resulting in an increased risk for joint dislocation. QY, JX, HY http://en.volupedia.org/wiki/Hip_dysplasia 发育性髋关节发育不良 10073767 developmental hip dysplasia AE OAE:0007873 This is an AE which is an infection with arthritis caused by the rubella virus. QY, JX, HY http://en.volupedia.org/wiki/Rubella 关节炎风疹 10003270 arthritis rubella AE OAE:0007874 This is an AE which is the invasion of a joint by an infectious agent streptococcal resulting in joint inflammation. QY, JX, HY http://en.volupedia.org/wiki/Septic_arthritis 链球菌化脓性关节炎 10067323 septic arthritis streptococcal AE OAE:0007875 This is an AE which is the invasion of a joint by an infectious agent haemophilus resulting in joint inflammation. QY, JX, HY http://en.volupedia.org/wiki/Septic_arthritis 嗜血杆菌化脓性关节炎 10040059 septic arthritis haemophilus AE OAE:0007876 This is an AE which is associated with conditions such as clubfoot, cerebral palsy, and myelodysplasia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32398628/ 踝关节畸形 10071050 ankle deformity AE OAE:0007877 This is an AE which is a class of joint disorder (called arthropathy) that is characterized by accumulation of tiny crystals in one or more joints. QY, JX, HY http://en.volupedia.org/wiki/Crystal_arthropathy 晶体关节病 10061419 crystal arthropathy AE OAE:0007878 This is an AE which is an abnormality of the hip joint where the socket portion does not fully cover the ball portion, resulting in an increased risk for joint dislocation. QY, JX, HY http://en.volupedia.org/wiki/Hip_dysplasia 髋关节发育不良 10063175 hip dysplasia AE OAE:0007879 This is an AE which is a major abnormality in the shape of hip compared to the normal shape of that part. QY, JX, HY http://en.volupedia.org/wiki/Deformity 髋关节畸形 10061209 hip deformity AE OAE:0007880 This is an AE which is a disease in which the body mistakenly attacks its own tissues. QY, JX, HY http://en.volupedia.org/wiki/Undifferentiated_connective_tissue_disease 未分化结缔组织病 10071575 undifferentiated connective tissue disease AE OAE:0007881 This is an AE which is an autoimmune disease characterized by the presence of elevated blood levels of a specific autoantibody, now called anti-U1 ribonucleoprotein (RNP) together with a mix of symptoms of systemic lupus erythematosus (SLE), scleroderma, and polymyositis. QY, JX, HY http://en.volupedia.org/wiki/Mixed_connective_tissue_disease 混合性结缔组织病 10027754 mixed connective tissue disease AE OAE:0007882 This is an AE which is a type of arthritis in which there is a long-term inflammation of the joints of the spine. QY, JX, HY http://en.volupedia.org/wiki/Ankylosing_spondylitis 强直性脊柱炎 10002556 ankylosing spondylitis AE OAE:0007883 This is an AE which is paralysis caused by illness or injury that results in the partial or total loss of use of all four limbs and torso; paraplegia is similar but does not affect the arms. QY, JX, HY http://en.volupedia.org/wiki/Tetraplegia 四肢瘫痪 10049680 quadriparesis AE OAE:0007884 This is an AE which is a sleep disorder where the patient moves limbs involuntarily and periodically during sleep, and has symptoms or problems related to the movement. QY, JX, HY http://en.volupedia.org/wiki/Periodic_limb_movement_disorder 周期性肢体运动障碍 10064600 periodic limb movement disorder AE OAE:0007885 This is an AE which is a stump pain of the removal of a limb by trauma, medical illness, or surgery. QY, JX, HY http://en.volupedia.org/wiki/Amputation 截肢残肢疼痛 10069724 amputation stump pain AE OAE:0007886 This is an AE which is frequently associated with other cerebral malformations. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11826610/ 透明隔发育不全 10062267 septum pellucidum agenesis AE OAE:0007887 This is an AE which is inflammation of the tissues in the mid-chest, or mediastinum. QY, JX, HY http://en.volupedia.org/wiki/Mediastinitis 纵隔炎 10027082 mediastinitis AE OAE:0007888 This is an AE which refers a consequence of diaphragm dysfunction and atrophy, is common in the ICU and associated with serious clinical consequences. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31876624/ 横膈轻瘫 10012708 diaphragm muscle weakness AE OAE:0007889 This is an AE which is a major abnormality in the shape of shoulder compared to the normal shape of that part. QY, JX, HY http://en.volupedia.org/wiki/Deformity 肩部畸形 10062241 shoulder deformity AE OAE:0007890 This is an AE which is typically a symptom-limiting condition that resolves spontaneously. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23370373/ 肩周炎 10034464 periarthritis AE OAE:0007891 This is an AE which is a major abnormality in the shape of neck compared to the normal shape of that part. QY, JX, HY http://en.volupedia.org/wiki/Deformity 颈部畸形 10061307 neck deformity AE OAE:0007892 This is an AE which is any damage or abnormal change in the tissue of cervical plexus, usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 颈丛病变 10067785 cervical plexus lesion AE OAE:0007893 This is an AE which is a cervical root distressing feeling often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 颈根疼痛 10008303 cervical root pain AE OAE:0007894 This is an AE which is flattening of the vertebrae of the neck, immediately below the skull. QY, JX, HY http://en.volupedia.org/wiki/Cervical_vertebrae 颈椎扁平化 10051824 cervical spine flattening AE OAE:0007895 This is an AE which is a medical condition of pregnancy in which the cervix begins to dilate (widen) and efface (thin) before the pregnancy has reached term. QY, JX, HY http://en.volupedia.org/wiki/Cervical_weakness 颈锥功能不全 10008267 cervical incompetence AE OAE:0007897 This is an AE which is a disorder in which the muscles that generate a person's voice go into periods of spasm. QY, JX, HY http://en.volupedia.org/wiki/Spasmodic_dysphonia 喉肌痉挛症 10067672 spasmodic dysphonia AE OAE:0007898 This is an AE which is a group of inherited diseases whose main feature is a progressive gait disorder. QY, JX, HY http://en.volupedia.org/wiki/Hereditary_spastic_paraplegia 痉挛性截瘫 10048792 spastic paraplegia AE OAE:0007899 This is an AE which is a feature of altered skeletal muscle performance with a combination of paralysis, increased tendon reflex activity, and hypertonia. QY, JX, HY http://en.volupedia.org/wiki/Spasticity 痉挛性麻痹 10041415 spastic paralysis AE OAE:0007900 This is an AE which is a highly characteristic, abnormal, sustained spasm of the facial muscles that appears to produce grinning. QY, JX, HY http://en.volupedia.org/wiki/Risus_sardonicus 痉笑 10039198 risus sardonicus AE OAE:0007901 This is an AE which is a behavioral characteristic assigned to those with conditions that are regarded as rare or dysfunctional such as somatic dysfunction. QY, JX, HY http://en.volupedia.org/wiki/Abnormality_(behavior) 躯体功能障碍 10077554 somatic dysfunction AE OAE:0007902 This is an AE which is a mental and behavioral disorder characterized by recurring, multiple, and current, clinically significant complaints about somatic symptoms. QY, JX, HY http://en.volupedia.org/wiki/Somatization_disorder 躯体化障碍 10041318 somatisation disorder AE OAE:0007903 This is an AE which is a perception in the absence of an external stimulus that has the qualities of a real perception. QY, JX, HY http://en.volupedia.org/wiki/Hallucination 躯体幻觉 10062684 somatic hallucination AE OAE:0007904 This is an AE which is a fixed belief that is not amenable to change in light of conflicting evidence. QY, JX, HY http://en.volupedia.org/wiki/Delusion 躯体妄想 10041317 somatic delusion AE OAE:0007907 This is an AE which is a method of medication administration in which a medicine is injected into the epidural space around the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Epidural_administration 硬膜外镇痛 10054891 epidural analgesia AE OAE:0007908 This is an AE which is a form of empyema – a collection of pus, in the subdural space. QY, JX, HY http://en.volupedia.org/wiki/Subdural_empyema 硬膜下积脓 10042360 subdural empyema AE OAE:0007909 This is an AE which refers to an effusion in the subdural space, usually of cerebrospinal fluid. QY, JX, HY http://en.volupedia.org/wiki/Subdural_effusion 硬膜下积液 10054797 subdural effusion AE OAE:0007910 This is an AE which is postictal process of a loss of motor function in one or more muscles. QY, JX, HY http://en.volupedia.org/wiki/Paralysis 发作后麻痹 10052469 postictal paralysis AE OAE:0007911 This is an AE which has a variable definition in the literature without consideration of degree or substratification of other confounders such as the presence of arthritis or pain. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28526423/ 假性麻痹 10056300 pseudoparalysis AE OAE:0007912 This is an AE which is a disorder of viscous, non-Newtonian fluid found in the cavities of synovial joints. QY, JX, HY http://en.volupedia.org/wiki/Synovial_fluid 滑膜病 10061374 synovial disorder AE OAE:0007913 This is an AE which is the medical term for inflammation of the synovial membrane. QY, JX, HY http://en.volupedia.org/wiki/Synovitis 滑膜炎 10042868 synovitis AE OAE:0007914 This is an AE which is crystal of viscous, non-Newtonian fluid found in the cavities of synovial joints. QY, JX, HY http://en.volupedia.org/wiki/Synovial_fluid 滑液结晶 10063369 synovial fluid crystal AE OAE:0007915 This is an AE which is a group of diseases with necrotising whose hallmark is inflammation of subcutaneous adipose tissue (the fatty layer under the skin panniculus adiposus). QY, JX, HY http://en.volupedia.org/wiki/Panniculitis 坏死性脂膜炎 10062579 necrotising panniculitis AE OAE:0007916 This is an AE which is a collection or gathering of pus within a naturally existing anatomical cavity. QY, JX, HY http://en.volupedia.org/wiki/Empyema 积脓症 10014568 empyema AE OAE:0007917 This is an AE which is an accumulation of serous fluid in a body cavity. QY, JX, HY http://en.volupedia.org/wiki/Hydrocele 积水 10020488 hydrocele AE OAE:0007918 This is an AE which is conditions causing chronic, often intermittent pain affecting the joints or connective tissue. QY, JX, HY http://en.volupedia.org/wiki/Rheumatism 风湿病 10072736 rheumatic disorder AE OAE:0007919 This is an AE which is an inflammatory disease that can involve the heart, joints, skin, and brain. QY, JX, HY http://en.volupedia.org/wiki/Rheumatic_fever 风湿热 10039054 rheumatic fever AE OAE:0007920 This is an AE which is a syndrome characterised by recurrent, self-resolving inflammatory attacks in and around the joints, consists of arthritis or periarticular soft tissue inflammation. QY, JX, HY http://en.volupedia.org/wiki/Palindromic_rheumatism 复发性风湿病 10033534 palindromic rheumatism AE OAE:0007921 This is an AE which is a neurodegenerative disease that is mostly inherited. QY, JX, HY http://en.volupedia.org/wiki/Huntington%27s_disease 亨廷顿氏舞蹈症 10070668 huntington's disease AE OAE:0007922 This is an AE which is the occurrence of involuntary movements in a combination of chorea (irregular migrating contractions) and athetosis (twisting and writhing). QY, JX, HY http://en.volupedia.org/wiki/Choreoathetosis 舞蹈手足徐动症 10008754 choreoathetosis AE OAE:0007923 This is an AE which is crystal of viscous, non-Newtonian fluid found in the cavities of synovial joints. QY, JX, HY http://en.volupedia.org/wiki/Synovial_fluid 存在滑液结晶 10057112 synovial fluid crystal present AE OAE:0007924 This is an AE which is a basal ganglia syndrome resulting from damage to the subthalamic nucleus in the basal ganglia. QY, JX, HY http://en.volupedia.org/wiki/Hemiballismus 颤搐 10058504 ballismus AE OAE:0007925 This is an AE which is a medical sign consisting of the involuntary contraction of muscles, which may be caused by disorders that increase the action potential frequency of muscle cells or the nerves that innervate them. QY, JX, HY http://en.volupedia.org/wiki/Tetany 抽搐 10043380 tetany AE OAE:0007926 This is an AE which is a medical condition where local body muscles contract and relax rapidly and repeatedly, resulting in uncontrolled shaking. QY, JX, HY http://en.volupedia.org/wiki/Convulsion 局部抽搐 10010920 convulsions local AE OAE:0007927 This is an AE which is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations or twitching movements of one or more body parts. QY, JX, HY http://en.volupedia.org/wiki/Tremor 静止性震颤 10071390 resting tremor AE OAE:0007928 This is an AE which is a medical sign observed in patients with low calcium. QY, JX, HY http://en.volupedia.org/wiki/Trousseau_sign_of_latent_tetany 潜在性手足搐搦 10052067 latent tetany AE OAE:0007929 This is an AE which is any damage or abnormal change in the tissue of meniscus , usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 半月板损伤 10053777 meniscus lesion AE OAE:0007930 This is an AE which is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and swollen joint. QY, JX, HY http://en.volupedia.org/wiki/Gout 痛风 10018627 gout AE OAE:0007931 This is an AE which is a disorder characterized by catching or locking of the involved finger. QY, JX, HY http://en.volupedia.org/wiki/Trigger_finger 狭窄性腱鞘炎 10056698 tenosynovitis stenosans AE OAE:0007932 This is an AE which is a disorder characterized by rapid, uncoordinated jerking movements primarily affecting the face, hands and feet. QY, JX, HY http://en.volupedia.org/wiki/Sydenham%27s_chorea 西德纳姆舞蹈病 10042732 sydenham's chorea AE OAE:0007933 This is an AE which is a medical condition where body muscles contract and relax rapidly and repeatedly, resulting in uncontrolled shaking and is clonic. QY, JX, HY http://en.volupedia.org/wiki/Convulsion 阵发性痉挛 10053398 clonic convulsion AE OAE:0007934 This is an AE which is a medical condition characterized by involuntary rhythmic contractions and relaxations (oscillations or twitching movements) of certain muscle groups in one or more body parts of unknown cause. QY, JX, HY http://en.volupedia.org/wiki/Essential_tremor 姿势震颤 10073211 postural tremor AE OAE:0007935 This is an AE which preceding convulsion has been observed in sports injuries at the moment of impact where extension and flexion of opposite arms occur despite body position or gravity. QY, JX, HY http://en.volupedia.org/wiki/Fencing_response 强直姿势 10075125 tonic posturing AE OAE:0007936 This is an AE which results in avascular necrosis. QY, JX, HY http://en.volupedia.org/wiki/Infarction 骨梗死 10049824 bone infarction AE OAE:0007937 This is an AE which may refer to a number of entities: Osteoporosis, a condition in which overall bone density decreases Periodontitis, a condition in which the supporting bone around teeth exhibits resorption. QY, JX, HY http://en.volupedia.org/wiki/Bone_loss 骨质流失 10065687 bone loss AE OAE:0007938 This is an AE which is an abnormal growth of tissue in bone, traditionally classified as noncancerous (benign) or cancerous (malignant). QY, JX, HY http://en.volupedia.org/wiki/Bone_tumor 骨肿瘤 10005995 bone neoplasm AE OAE:0007939 This is an AE which the primary symptom of is pain, which often occurs at rest or at night. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18399615/ 恶性骨肿瘤 10053650 bone neoplasm malignant AE OAE:0007940 This is an AE which is a primary malignant bone tumour, a type of sarcoma that starts in the bones. QY, JX, HY http://en.volupedia.org/wiki/Bone_sarcoma 骨肉瘤 10006007 bone sarcoma AE OAE:0007941 This is an AE which is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. QY, JX, HY http://en.volupedia.org/wiki/Tuberculosis 骨结核病 10056377 bone tuberculosis AE OAE:0007942 This is an AE which is a medical condition in which there is a partial or complete break in the continuity of a facial bone. QY, JX, HY http://en.volupedia.org/wiki/Bone_fracture 面部骨骼断裂 10016042 facial bones fracture AE OAE:0007943 This is an AE which is a subtype of the rhabdomyosarcoma soft tissue cancer family whose lineage is from mesenchymal cells and are related to skeletal muscle cells. QY, JX, HY http://en.volupedia.org/wiki/Alveolar_rhabdomyosarcoma 腺泡状横纹肌肉瘤 10065867 alveolar rhabdomyosarcoma AE OAE:0007944 This is an AE which is pain syndromes where excessive, acute and chronic pain are observed for which no overt primary cause can be found or surmised. QY, JX, HY http://en.volupedia.org/wiki/Amplified_musculoskeletal_pain_syndromes 放大肌肉骨骼疼痛综合征 10082375 amplified musculoskeletal pain syndrome AE OAE:0007945 This is an AE which is a mass of muscle cells (tumor) that lacks the ability to either invade neighboring tissue or metastasize (spread throughout the body). QY, JX, HY http://en.volupedia.org/wiki/Benign_tumor 良性肌肉肿瘤 10061692 benign muscle neoplasm AE OAE:0007946 This is an AE which is the accumulation of calcium salts in a body muscle tissue. QY, JX, HY http://en.volupedia.org/wiki/Calcification 肌肉钙化 10049797 calcification of muscle AE OAE:0007947 This is an AE which is a malignant (cancerous) smooth muscle tumor. QY, JX, HY http://en.volupedia.org/wiki/Leiomyosarcoma 平滑肌肉瘤 10024189 leiomyosarcoma AE OAE:0007948 This is an AE which is a medical condition characterized by the inability to control facial movements (such as chewing and speaking) and caused by a variety of neurological disorders. QY, JX, HY http://en.volupedia.org/wiki/Pseudobulbar_palsy 假性球麻痹 10037114 pseudobulbar palsy AE OAE:0007949 This is an AE which is a medical condition. It belongs to a group of disorders known as motor neuron diseases. QY, JX, HY http://en.volupedia.org/wiki/Progressive_bulbar_palsy 进行性延髓麻痹 10036800 progressive bulbar palsy AE OAE:0007950 This is an AE which refers to a range of different signs and symptoms linked to impairment of function of the glossopharyngeal nerve (CN IX), the vagus nerve (CN X), the accessory nerve (CN XI), and the hypoglossal nerve (CN XII). QY, JX, HY http://en.volupedia.org/wiki/Bulbar_palsy 延髓性麻痹 10006542 bulbar palsy AE OAE:0007951 This is an AE which is any mental disorder that manifests as physical symptoms that suggest illness or injury, but cannot be explained fully by a general medical condition or by the direct effect of a substance, and are not attributable to another mental disorder (e.g., panic disorder). QY, JX, HY http://en.volupedia.org/wiki/Somatic_symptom_disorder 躯体症状障碍 10078076 somatic symptom disorder AE OAE:0007952 This is an AE which is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and swollen joint. QY, JX, HY http://en.volupedia.org/wiki/Gout 痛风性关节炎 10018634 gouty arthritis AE OAE:0007953 This is an AE which is a term often used to mean any disorder that affects joints caused by bacterial. QY, JX, HY http://en.volupedia.org/wiki/Arthritis 细菌性关节炎 10053555 arthritis bacterial AE OAE:0007954 This is an AE which is a long-term inflammatory arthritis that occurs in people affected by the autoimmune disease psoriasis. QY, JX, HY http://en.volupedia.org/wiki/Psoriatic_arthritis 银屑病关节病 10037162 psoriatic arthropathy AE OAE:0007955 This is an AE which is a chronic, autoinflammatory disease predominantly affecting the axial skeleton (sacroiliac joints and spine). QY, JX, HY http://en.volupedia.org/wiki/Axial_spondyloarthritis 轴向脊椎关节炎 10071400 axial spondyloarthritis AE OAE:0007956 This is an AE which is a major abnormality in the shape of elbow compared to the normal shape of that part. QY, JX, HY http://en.volupedia.org/wiki/Deformity 肘关节畸形 10061833 elbow deformity AE OAE:0007957 This is an AE which is a complex, rare, and severe childhood-onset epilepsy. QY, JX, HY http://en.volupedia.org/wiki/Lennox%E2%80%93Gastaut_syndrome 伦诺克斯-胃肠综合征 10048816 lennox-gastaut syndrome AE OAE:0007958 This is an AE which is a paralytic illness that resembles poliomyelitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31503131/ 急性哮喘后肌萎缩症 10066224 acute post asthmatic amyotrophy AE OAE:0007959 This is an AE which is a condition which is believed to result from compression of the sciatic nerve by the piriformis muscle. QY, JX, HY http://en.volupedia.org/wiki/Piriformis_syndrome 梨状肌综合症 10049433 piriformis syndrome AE OAE:0007960 This is an AE which is a benign smooth muscle tumor that very rarely becomes cancer (0.1%). QY, JX, HY http://en.volupedia.org/wiki/Leiomyoma 平滑肌瘤 10024184 leiomyoma AE OAE:0007961 This is an AE which is a rare, but catastrophic mechanical complication of acute myocardial infarction (AMI). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15362545/ 乳头状肌断裂 10033698 papillary muscle rupture AE OAE:0007962 This is an AE which is a crisis of a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. QY, JX, HY http://en.volupedia.org/wiki/Myasthenia_gravis 重症肌无力危象 10062758 myasthenia gravis crisis AE OAE:0007963 This is an AE which occurs when blood flow decreases or stops to the coronary artery of the heart, causing damage to the heart muscle and it is silent. QY, JX, HY http://en.volupedia.org/wiki/Myocardial_infarction 无症状心肌梗塞 10049768 silent myocardial infarction AE OAE:0007964 This is an AE which is a form of focal dystonia affecting the mouth, jaw and tongue, and in this disease it is hard to speak. QY, JX, HY http://en.volupedia.org/wiki/Oromandibular_dystonia 下颌肌张力障碍 10067954 oromandibular dystonia AE OAE:0007965 This is an AE which is types of myopathies associated with mitochondrial disease. QY, JX, HY http://en.volupedia.org/wiki/Mitochondrial_myopathy 线粒体肌病 10027710 mitochondrial myopathy AE OAE:0007966 This is an AE which is an injury where one or more of the tendons or muscles of the rotator cuff of the shoulder get torn. QY, JX, HY http://en.volupedia.org/wiki/Rotator_cuff_tear 旋转肌综合症 10039227 rotator cuff syndrome AE OAE:0007967 This is an AE which is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. QY, JX, HY http://en.volupedia.org/wiki/Myasthenia_gravis 重症肌无力 10028417 myasthenia gravis AE OAE:0007968 This is an AE which is inflammation of the perichondrium, a layer of connective tissue which surrounds cartilage. QY, JX, HY http://en.volupedia.org/wiki/Perichondritis 软骨膜炎 10062067 perichondritis AE OAE:0007969 This is an AE which is a medical condition caused by inflammation of the periosteum, a layer of connective tissue that surrounds bone. QY, JX, HY http://en.volupedia.org/wiki/Periostitis 骨膜炎 10034551 periostitis AE OAE:0007970 This is an AE which is a hereditary motor and sensory neuropathy of the peripheral nervous system characterized by progressive loss of muscle tissue and touch sensation across various parts of the body. QY, JX, HY http://en.volupedia.org/wiki/Charcot%E2%80%93Marie%E2%80%93Tooth_disease 腓骨肌萎缩症 10034699 peroneal muscular atrophy AE OAE:0007971 This is an AE which is a multi-systemic condition characterized by repeated episodes of inflammation and deterioration of cartilage. QY, JX, HY http://en.volupedia.org/wiki/Relapsing_polychondritis 多软骨炎 10065159 polychondritis AE OAE:0007972 This is an AE which is the most forward-facing (ventral and anterior) of the three main bones making up the pelvis and feel it pain. QY, JX, HY http://en.volupedia.org/wiki/Pubis_(bone) 耻骨痛 10049747 pubic pain AE OAE:0007973 This is an AE which is the ventral and anterior of the three parts forming the hip bone and has fracture. QY, JX, HY http://en.volupedia.org/wiki/Hip_bone#Pubis 耻骨骨折 10070286 pubis fracture AE OAE:0007974 This is an AE which is one of the most commonly treated fractures in the United States. The highest rates are seen among the elderly, second only to hip fractures. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29499822/ 桡骨骨折 10037802 radius fracture AE OAE:0007975 This is an AE which is a break in a rib bone. QY, JX, HY http://en.volupedia.org/wiki/Rib_fracture 肋骨骨折 10039117 rib fracture AE OAE:0007976 This is an AE which is different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. QY, JX, HY http://en.volupedia.org/wiki/Senile_osteoporosis 老年性骨质疏松症 10039984 senile osteoporosis AE OAE:0007977 This is an AE which is a general term for a disorder of the development (dysplasia) of bone ("osteo") and cartilage ("chondro"). QY, JX, HY http://en.volupedia.org/wiki/Osteochondrodysplasia 骨骼发育不良 10072610 skeletal dysplasia AE OAE:0007978 This is an AE which is a fatigue-induced bone fracture caused by repeated stress over time. QY, JX, HY http://en.volupedia.org/wiki/Stress_fracture 应力性骨折 10042212 stress fracture AE OAE:0007979 This is an AE which is a region of the abdomen located below the umbilical region and feels pain. QY, JX, HY http://en.volupedia.org/wiki/Hypogastrium 耻骨上痛 10050822 suprapubic pain AE OAE:0007980 This is an AE which can be classified according to the involved bone into: femoral fracture (in the upper leg) and crus fracture (in the lower leg). QY, JX, HY http://en.volupedia.org/wiki/Human_leg#Fracture 胫骨骨折 10043827 tibia fracture AE OAE:0007981 This is an AE which is a break in the ulna bone, one of the two bones in the forearm. QY, JX, HY http://en.volupedia.org/wiki/Ulna_fracture 尺骨骨折 10045357 ulna fracture AE OAE:0007982 This is an AE which is caused by entrapment of the ulnar nerve in the Guyon canal as it passes through the wrist. QY, JX, HY http://en.volupedia.org/wiki/Ulnar_tunnel_syndrome 尺骨隧道症候群 10058942 ulnar tunnel syndrome AE OAE:0007983 This is an AE which is a break of the humerus bone in the upper arm. QY, JX, HY http://en.volupedia.org/wiki/Humerus_fracture 上肢骨折 10061394 upper limb fracture AE OAE:0007984 This is an AE which is any damage or abnormal change in the tissue of vertebral , usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 椎骨病变 10048877 vertebral lesion AE OAE:0007985 This is an AE which is related to anatomical structures adjacent to the spinal column. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20383671/ 椎骨骨赘 10055042 vertebral osteophyte AE OAE:0007986 This is an AE which is characterized by presence of a very rigid foot deformity. QY, JX, HY http://en.volupedia.org/wiki/Rocker_bottom_foot 垂直距骨 10066242 vertical talus AE OAE:0007987 This is an AE which is a skeletal medical condition in which the shoulder blade protrudes from a person's back in an abnormal position. QY, JX, HY http://en.volupedia.org/wiki/Winged_scapula 翼状肩胛骨 10067628 winged scapula AE OAE:0007988 This is an AE which is pain that results from touching the region inside of the costovertebral angle. QY, JX, HY http://en.volupedia.org/wiki/Costovertebral_angle_tenderness 肋椎角压痛 10051704 costovertebral angle tenderness AE OAE:0007989 This is an AE which is characterised by focal thickening of the skin of the hands and feet and is associated with a very high lifetime risk of developing squamous cell carcinoma of the oesophagus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26419362/ 掌跖角化过度 10052573 hyperkeratosis palmaris and plantaris AE OAE:0007990 This is an AE which occurs when an organism is exceptionally small. QY, JX, HY http://en.volupedia.org/wiki/Dwarfism 矮小体型 10071034 microsomia AE OAE:0007991 This is an AE which is any condition that makes it more difficult for a person to do certain activities or effectively interact with the world around them (socially or materially). QY, JX, HY http://en.volupedia.org/wiki/Disability 残疾 10013050 disability AE OAE:0007992 This is an AE which refers slowness of initiation of voluntary movement with a progressive reduction in speed and range of repetitive actions, such as voluntary finger-tapping. QY, JX, HY http://en.volupedia.org/wiki/Hypokinesia#Bradykinesia 动作迟缓 10006100 bradykinesia AE OAE:0007993 This is an AE which is a seizure associated with a high body temperature but without any serious underlying health issue. QY, JX, HY http://en.volupedia.org/wiki/Febrile_seizure 高热惊厥 10016284 febrile convulsion AE OAE:0007994 This is an AE which is a bony growth originating inside a ligament, commonly seen in the ligaments of the spine, specifically the ligaments in the intervertebral joints leading to fusion of vertebrae. QY, JX, HY http://en.volupedia.org/wiki/Syndesmophyte 合生体 10057603 syndesmophyte AE OAE:0007995 This is an AE which is a symptom that describes muscle pain on mild exertion (ache, cramp, numbness or sense of fatigue), classically in the calf muscle, which occurs during exercise, such as walking, and is relieved by a short period of rest. QY, JX, HY http://en.volupedia.org/wiki/Intermittent_claudication 间歇性跛行 10022562 intermittent claudication AE OAE:0007996 This is an AE which refers a small aggregation of cells. QY, JX, HY http://en.volupedia.org/wiki/Nodule 结节 10054107 nodule AE OAE:0007997 This is an AE which is a lump of tissue, or an area of swelling, that appear on the exterior of the skin usually around the olecranon (tip of the elbow) or the interphalangeal joints (finger knuckles), but can appear in other areas. QY, JX, HY http://en.volupedia.org/wiki/Rheumatoid_nodule 类风湿结节 10048694 rheumatoid nodule AE OAE:0007998 This is an AE which is a deformity of the joint connecting the big toe to the foot. QY, JX, HY http://en.volupedia.org/wiki/Bunion 姆囊炎 10006585 bunion AE OAE:0007999 This is an AE which is a childhood hip disorder initiated by a disruption of blood flow to the head of the femur. QY, JX, HY http://en.volupedia.org/wiki/Legg%E2%80%93Calv%C3%A9%E2%80%93Perthes_disease 佩尔特斯疾病 10034735 perthes disease AE OAE:0008000 This is an AE which is a condition in which one side of the body or a part of one side of the body is larger than the other to an extent considered greater than the normal variation. QY, JX, HY http://en.volupedia.org/wiki/Hemihypertrophy 偏侧肥大 10019463 hemihypertrophy AE OAE:0008001 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) or organs (macroscopic scale), and the abnormal histology or anatomical structure resulting from such growth. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 起立困难 10050256 dysstasia AE OAE:0008002 This is an AE which is a radially symmetrical contraction and relaxation of muscles that propagates in a wave down a tube, in an anterograde direction and is visible. QY, JX, HY http://en.volupedia.org/wiki/Peristalsis 蠕动可见 10034647 peristalsis visible AE OAE:0008003 This is an AE which is a dystonic condition defined by an abnormal, asymmetrical head or neck position, which may be due to a variety of causes. QY, JX, HY http://en.volupedia.org/wiki/Torticollis 斜颈 10044074 torticollis AE OAE:0008004 This is an AE which is the placement of the body in a reverentially or submissively prone position as a gesture. QY, JX, HY http://en.volupedia.org/wiki/Prostration 虚脱 10036985 prostration AE OAE:0008005 QY, JX, HY 肌肉不适 10028299 muscle discomfort AE OAE:0008006 QY, JX, HY 浮游髌骨 10065564 floating patella AE OAE:0008008 QY, JX, HY 骨关节病 10031173 osteoarthropathy AE OAE:0008009 QY, JX, HY 关节沉积 10023202 joint deposit AE OAE:0008010 QY, JX, HY 关节硬化 10060788 joint stabilisation AE OAE:0008011 QY, JX, HY 判断力减退 10023236 judgement impaired AE OAE:0008012 QY, JX, HY 肌腱松弛 10074443 tendon laxity AE OAE:0008013 QY, JX, HY 肌硬化症 10064584 myosclerosis AE OAE:0008015 QY, JX, HY 腰椎间盘突出症 10063410 lumbarisation AE OAE:0008016 QY, JX, HY 韧带炎 10064804 ligamentitis AE OAE:0008017 QY, JX, HY 类固醇依赖性 10082986 steroid dependence AE OAE:0008018 QY, JX, HY 关节处身体松动 10024829 loose body in joint AE OAE:0008019 QY, JX, HY 关节周围疾病 10048745 periarticular disorder AE OAE:0008020 QY, JX, HY 四肢结节 10050690 nodule on extremity AE OAE:0008021 QY, JX, HY 膈痛 10052749 diaphragmalgia AE OAE:0008024 QY, JX, HY 肋间收缩 10022533 intercostal retraction AE OAE:0008025 This is an AE which is a disorder characterized by catching or locking of the involved finger. QY, JX, HY http://en.volupedia.org/wiki/Trigger_finger 扳机指 10044654 trigger finger AE OAE:0008026 This is an AE whcih is a very rare medical syndrome that includes pleural effusions, lymphedema (due to under development of the lymphatic vessels) and yellow dystrophic nails. QY, JX, HY http://en.volupedia.org/wiki/Yellow_nail_syndrome 黄指甲综合征 10048244 yellow nail syndrome AE OAE:0008027 This is an AE which is a medical condition that causes one or more fingers to be permanently bent and is acquired. QY, JX, HY http://en.volupedia.org/wiki/Camptodactyly 屈曲指收购 10049132 camptodactyly acquired AE OAE:0008028 This is an AE which refers to a congenital deformity involving one foot or both , a relatively short and round thumb with an accompanying wide nail bed or a deformity of the fingers and fingernails. QY, JX, HY http://en.volupedia.org/wiki/Clubbing 杵状指 10009691 clubbing AE OAE:0008029 This is an AE which is inflammation of an entire digit (a finger or toe),and can be painful. QY, JX, HY http://en.volupedia.org/wiki/Dactylitis 指炎 10064769 dactylitis AE OAE:0008032 This is an AE which is a major abnormality in the shape of a body part or organ compared to the normal shape of that part such as finger. QY, JX, HY http://en.volupedia.org/wiki/Deformity 手指畸形 10061156 finger deformity AE OAE:0008033 This is an AE which is a disorder of the bones and is a rare disease in which the outer part of the shafts of long bones is thinner than normal and there is an increased chance of fractures. QY, JX, HY http://en.volupedia.org/wiki/Metaphyseal_dysplasia 口指面骨发育不全 10066147 metaphyseal dysplasia AE OAE:0008034 This is an AE which is the partial or complete wasting away of a part of the nail. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 指甲萎缩 10068058 nail atrophy AE OAE:0008035 This is an AE which is a collection of blood (hematoma) underneath a toenail or fingernail (subungal hematoma). QY, JX, HY http://en.volupedia.org/wiki/Subungual_hematoma 甲床出血 10048891 nail bed bleeding AE OAE:0008036 This is an AE which refers to the skin beneath the nail plate is disorder. QY, JX, HY http://en.volupedia.org/wiki/Nail_bed 甲床疾病 10070533 nail bed disorder AE OAE:0008037 This is an AE which refers onychomycosis or tinea unguium, is a fungal infection of the nail. QY, JX, HY http://en.volupedia.org/wiki/Onychomycosis 甲床感染 10067867 nail bed infection fungal AE OAE:0008038 This is an AE which is a disease or deformity of the nail. QY, JX, HY http://en.volupedia.org/wiki/Nail_disease 甲营养不良 10028698 nail dystrophy AE OAE:0008039 This is an AE which occurs by alteration of shape, partial loss, or absence of the nail, resulting in loss of the nail fold physiological limit. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/34604327/ 指甲肥大 10028700 nail hypertrophy AE OAE:0008040 This is an AE which can cause the nail plate to be torn from the nail bed. QY, JX, HY http://en.volupedia.org/wiki/Avulsion_injury 指甲受伤 10068655 nail injury AE OAE:0008041 This is an AE which is a much less frequent cause of brown-black nail color than other melanocytic and nonmelanocytic pigmentations, which include subungual hematoma, exogenous pigmentations, and melanonychia due to benign conditions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25828711/ 指甲色素沉着 10058455 nail pigmentation AE OAE:0008042 This is an AE which is a form of extremely localized corrosion that leads to the creation of small holes in the metal on the nail. QY, JX, HY http://en.volupedia.org/wiki/Pitting_corrosion 指甲凹陷 10028702 nail pitting AE OAE:0008043 This is an AE which is an anomaly in humans and animals resulting in supernumerary fingers and/or toes. QY, JX, HY http://en.volupedia.org/wiki/Polydactyly 多指多趾 10036063 polydactyly AE OAE:0008044 This is an AE which is a nail disease that can be a sign of hypochromic anemia, especially iron-deficiency anemia. QY, JX, HY http://en.volupedia.org/wiki/Koilonychia 凹甲 10054999 koilonychia AE OAE:0008045 This is an AE which is less common and typically more severe than hammer toe. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30309185/ 获得性爪趾 10057689 acquired claw toe AE OAE:0008047 This is an AE which refers to a condition where a person walks on their toes without putting much or any weight on the heel or any other part of the foot. QY, JX, HY http://en.volupedia.org/wiki/Toe_walking 脚趾走路 10068872 toe walking AE OAE:0008048 QY, JX, HY 指甲不舒服 10028693 nail discomfort AE OAE:0008049 This is an AE which is a visible body part at the mouth of humans and it has desease. QY, JX, HY http://en.volupedia.org/wiki/Lip 唇部疾病 10048470 lip disorder AE OAE:0008050 This is an AE which is a group of conditions that includes cleft lip, cleft palate, and both together. QY, JX, HY http://en.volupedia.org/wiki/Cleft_lip_and_cleft_palate 唇腭裂 10009260 cleft lip and palate AE OAE:0008051 This is an AE which is inflammation of one or both corners of the mouth. QY, JX, HY http://en.volupedia.org/wiki/Angular_cheilitis 唇炎 10008418 cheilosis AE OAE:0008052 This is an AE which is redness of the lip skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 唇红斑 10080124 lip erythema AE OAE:0008053 This is an AE which is a group of conditions that includes cleft lip, cleft palate, and both together. QY, JX, HY http://en.volupedia.org/wiki/Cleft_lip_and_cleft_palate 唇裂 10009259 cleft lip AE OAE:0008054 This is an AE which is a sensation that causes the desire or reflex to scratch lip. QY, JX, HY http://en.volupedia.org/wiki/Itch 唇瘙痒 10070721 lip pruritus AE OAE:0008055 This is an AE which is the build-up of fluid in the body's tissue such as lip oedema. QY, JX, HY http://en.volupedia.org/wiki/Edema 唇水肿 10024558 lip edema AE OAE:0008056 This is an AE which is a localized bleeding outside of lip blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 唇血肿 10066304 lip hematoma AE OAE:0008057 This is an AE which is a medical condition characterized by inflammation of the lips. QY, JX, HY http://en.volupedia.org/wiki/Cheilitis 唇炎 10008417 cheilitis AE OAE:0008058 This is an AE which is the roof of the mouth in humans and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Palate 腭部疾病 10052453 palatal disorder AE OAE:0008060 This is an AE which is a group of conditions that includes cleft lip, cleft palate, and both together. QY, JX, HY http://en.volupedia.org/wiki/Cleft_lip_and_cleft_palate 腭裂 10009269 cleft palate AE OAE:0008061 This is an AE which is a medical term which refers to various types of paralysis, often accompanied by weakness and the loss of feeling and uncontrolled body movements such as palatal palsy. QY, JX, HY http://en.volupedia.org/wiki/Palsy 腭麻痹 10072012 palatal palsy AE OAE:0008062 This is an AE which is the build-up of fluid in the palatal tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 腭水肿 10056998 palatal edema AE OAE:0008063 This is an AE which the most frequent known interstitial deletion identified in man, is associated with chromosomal microdeletions in the q11 band of chromosome 22. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15877762/ 腭心面综合征 10066430 velo-cardio-facial syndrome AE OAE:0008064 This is an AE which is a malfunction of a velopharyngeal mechanism which is responsible for directing the transmission of sound energy and air pressure in both the oral cavity and the nasal cavity. QY, JX, HY http://en.volupedia.org/wiki/Velopharyngeal_inadequacy 腭咽功能不全 10066790 velopharyngeal incompetence AE OAE:0008065 This is an AE which refers a transient abnormal enlargement of palatal part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 腭肿胀 10074403 palatal swelling AE OAE:0008066 This is an AE which is a colored material that is completely or nearly insoluble in water adhere the lip. QY, JX, HY http://en.volupedia.org/wiki/Pigment 嘴唇色素沉着 10035025 pigmentation lip AE OAE:0008067 This is an AE which is a pseudo-pathological name of what is either considered a normal adaptive lip seal mechanism, whereby normal nasal breathing or normal swallowing can occur. QY, JX, HY http://en.volupedia.org/wiki/Tongue_thrust 舌刺 10082545 tongue thrust AE OAE:0008068 This is an AE which is a medical condition and abnormality which involves the downward displacement or retraction of the tongue. QY, JX, HY http://en.volupedia.org/wiki/Glossoptosis 舌下垂 10059138 glossoptosis AE OAE:0008069 This is an AE which is a loss of motor function in one or more tongue muscles. QY, JX, HY http://en.volupedia.org/wiki/Paralysis 舌麻痹 10043972 tongue paralysis AE OAE:0008070 This is an AE which is a closed sac on the tongue, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 舌囊肿 10051879 tongue cyst AE OAE:0008071 This is an AE which is the increase in the volume of of tongue papillae tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 舌乳头肥大 10020893 hypertrophy of tongue papillae AE OAE:0008072 This is an AE which is the partial or complete wasting away of a part of tongue papillae. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 舌乳头萎缩 10003712 atrophy of tongue papillae AE OAE:0008073 This is an AE which is the build-up of fluid in the tongue tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 舌水肿 10043967 tongue edema AE OAE:0008074 This is an AE which refers a grayish-white deposit on the tongue, is the main cause of intra-oral halitosis (IOH), a socially unacceptable condition. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29269592/ 舌苔 10043945 tongue coated AE OAE:0008075 This is an AE which is blood escaping from the circulatory system from damaged tongue blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 舌头出血 10049870 tongue hemorrhage AE OAE:0008076 This is an AE which is a condition of the mucous membrane of the tongue, usually on the dorsal surface. QY, JX, HY http://en.volupedia.org/wiki/Geographic_tongue 地图舌 10043957 tongue geographic AE OAE:0008077 This is an AE which is a muscular organ in the mouth of a typical vertebrate and is feel dry. QY, JX, HY http://en.volupedia.org/wiki/Tongue 舌头干燥 10049713 tongue dry AE OAE:0008078 This is an AE which is redness of the tongue skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 舌头红斑 10079075 tongue erythema AE OAE:0008079 This is an AE which is a sudden involuntary contraction of a muscle, a group of muscles, or a hollow organ such as the tongue. QY, JX, HY http://en.volupedia.org/wiki/Spasm 舌头痉挛 10043981 tongue spasm AE OAE:0008080 This is an AE which is a small pocket of body fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the tongue skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection. QY, JX, HY http://en.volupedia.org/wiki/Blister 舌头起泡 10043942 tongue blistering AE OAE:0008081 This is an AE which refers a cosmetic technique that aims to remove dead skin from the tongue . QY, JX, HY http://en.volupedia.org/wiki/Exfoliation 舌头去角质 10064488 tongue exfoliation AE OAE:0008082 This is an AE which is a sensation that causes the desire or reflex to scratch tongue. QY, JX, HY http://en.volupedia.org/wiki/Itch 舌头瘙痒 10070072 tongue pruritus AE OAE:0008083 This is an AE which is a colored material that is completely or nearly insoluble in water adhere the tongue . QY, JX, HY http://en.volupedia.org/wiki/Pigment 舌头色素沉着 10069164 tongue pigmentation AE OAE:0008084 This is an AE which is the partial or complete wasting away of a part of the tongue. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 舌头萎缩 10055028 tongue atrophy AE OAE:0008085 This is an AE which is regularly investigated for the death caused by strangulation or hanging, whilst seems to be overlooked in case of charred remains as the significance of this sign is still discussed. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31187740/ 舌突出 10037076 protrusion tongue AE OAE:0008086 This is an AE which is blood escaping from the circulatory system from damaged tooth socket blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 牙槽出血 10064946 tooth socket hemorrhage AE OAE:0008087 This is an AE which is an inflammation of the airspaces (alveoli). QY, JX, HY http://en.volupedia.org/wiki/Hypersensitivity_pneumonitis 牙槽炎 10001889 alveolitis AE OAE:0008088 This is an AE which is a hard, calcified structure found in the jaws (or mouths) of many vertebrates and used to break down food and it has deposit. QY, JX, HY http://en.volupedia.org/wiki/Tooth 牙齿沉积 10044029 tooth deposit AE OAE:0008089 This is an AE which is underdevelopment or incomplete development of tooth . QY, JX, HY http://en.volupedia.org/wiki/Hypoplasia 牙齿发育不全 10044041 tooth hypoplasia AE OAE:0008090 This is an AE which is an abnormal sensation of the skin or tooth (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 牙齿感觉异常 10078276 dental paraesthesia AE OAE:0008091 This is an AE which is a physical anomaly that is deleterious on tooth. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 牙齿畸形 10044046 tooth malformation AE OAE:0008092 This is an AE which is dental pain which is sharp in character and of short duration, arising from exposed dentin surfaces in response to stimuli, typically thermal, evaporative, tactile, osmotic, chemical or electrical; and which cannot be ascribed to any other dental disease. QY, JX, HY http://en.volupedia.org/wiki/Dentin_hypersensitivity 牙齿敏感 10040012 sensitivity of teeth AE OAE:0008093 This is an AE which is the complete displacement of a tooth from its socket in alveolar bone owing to trauma. QY, JX, HY http://en.volupedia.org/wiki/Dental_avulsion 牙齿撕脱 10065953 tooth avulsion AE OAE:0008094 This is an AE which is the horizontal or vertical displacement of a tooth beyond its normal physiological boundaries around the gingival area, i.e. the medical term for a loose tooth. QY, JX, HY http://en.volupedia.org/wiki/Tooth_mobility 牙齿松动 10065612 loose tooth AE OAE:0008095 This is an AE which is one that fails to erupt into the dental arch within the expected developmental window. QY, JX, HY http://en.volupedia.org/wiki/Tooth_impaction 牙齿阻生 10044042 tooth impacted AE OAE:0008096 This is an AE which is a type of tissue death caused by a lack of blood supply occured on dental. QY, JX, HY http://en.volupedia.org/wiki/Gangrene 牙科坏疽 10063066 dental gangrene AE OAE:0008097 This is an AE which is inflammation of dental pulp tissue. QY, JX, HY http://en.volupedia.org/wiki/Pulpitis 牙髓炎 10037464 pulpitis dental AE OAE:0008098 This is an AE which is the process of lightening the color of human teeth. QY, JX, HY http://en.volupedia.org/wiki/Tooth_whitening 牙龈变色 10018278 gingival discoloration AE OAE:0008099 This is an AE which consist of the mucosal tissue that lies over the mandible and maxilla inside the mouth and feel it discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Gums 牙龈不适 10077854 gingival discomfort AE OAE:0008100 This is an AE which is a non-destructive disease that causes inflammation of the gums. QY, JX, HY http://en.volupedia.org/wiki/Gingivitis 牙龈发炎 10072575 gingival inflammation AE OAE:0008101 This is an AE which is an increase in the size of the gingiva (gums). QY, JX, HY http://en.volupedia.org/wiki/Gingival_enlargement 牙龈肥大 10018284 gingival hypertrophy AE OAE:0008102 This is an AE which is the term given to any disorder primarily affecting the gingiva. QY, JX, HY http://en.volupedia.org/wiki/Gingival_disease 牙龈疾病 10018280 gingival disorder AE OAE:0008103 This is an AE which is a discontinuity or break in gingival membrane that impedes normal function of the affected organ. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 牙龈溃疡 10049398 gingival ulceration AE OAE:0008104 This is an AE which is a type of cysts of the jaws that originates from the dental lamina and is found in the mouth parts. QY, JX, HY http://en.volupedia.org/wiki/Gingival_cyst 牙龈囊肿 10055018 gingival cyst AE OAE:0008105 This is an AE which is a small pocket of body fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the gingival skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection. QY, JX, HY http://en.volupedia.org/wiki/Blister 牙龈泡 10049304 gingival blister AE OAE:0008106 This is an AE which is a gingival sensation that causes the desire or reflex to scratch. QY, JX, HY http://en.volupedia.org/wiki/Itch 牙龈瘙痒 10049306 gingival pruritus AE OAE:0008107 This is an AE which is the build-up of fluid in the gingival tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 牙龈水肿 10049305 gingival edema AE OAE:0008108 This is an AE which is the exposure in the roots of the teeth caused by a loss of gum tissue and/or retraction of the gingival margin from the crown of the teeth. QY, JX, HY http://en.volupedia.org/wiki/Gingival_recession 牙龈萎缩 10018290 gingival recession AE OAE:0008109 This is an AE which is a non-destructive disease that causes inflammation of the gums. QY, JX, HY http://en.volupedia.org/wiki/Gingivitis 牙龈炎 10018292 gingivitis AE OAE:0008110 This is an AE which is a typical adverse reaction of certain drugs (phenytoin, calcium antagonists and cyclosporine). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20131672/ 牙龈增生 10018283 gingival hyperplasia AE OAE:0008111 This is an AE which is a viral disease that causes inflammation of the brain in humans and other mammals. QY, JX, HY http://en.volupedia.org/wiki/Rabies 嘴部发泡 10062654 foaming at mouth AE OAE:0008112 This is an AE which is a visible body part at the mouth of humans and it is discolouration. QY, JX, HY http://en.volupedia.org/wiki/Lip 嘴唇变色 10024549 lip discoloration AE OAE:0008113 This is an AE which involves the removal of the oldest dead skin cells from the lip skin's surface. QY, JX, HY http://en.volupedia.org/wiki/Exfoliation_(cosmetology) 嘴唇表皮脱落 10064482 lip exfoliation AE OAE:0008114 This is an AE which is blood escaping from the circulatory system from damaged lip blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 嘴唇出血 10049297 lip hemorrhage AE OAE:0008115 This is an AE which refers constant licking of the lips causes drying and irritation, and eventually the mucosa splits or cracks. QY, JX, HY http://en.volupedia.org/wiki/Cheilitis#Cheilitis_simplex_(chapped_lips) 嘴唇干裂 10024552 lip dry AE OAE:0008116 This is an AE which is an ulcer that occurs on the mucous membrane of the oral cavity. QY, JX, HY http://en.volupedia.org/wiki/Mouth_ulcer 嘴唇溃疡 10024572 lip ulceration AE OAE:0008117 This is an AE which is a small pocket of body fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the lip skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection. QY, JX, HY http://en.volupedia.org/wiki/Blister 嘴唇起泡 10049307 lip blister AE OAE:0008118 This is an AE which is the process by which an infant's first teeth (the deciduous teeth, often called "baby teeth" or "milk teeth") sequentially appear by emerging through the gums, typically arriving in pairs. QY, JX, HY http://en.volupedia.org/wiki/Teething 出牙 10043183 teething AE OAE:0008119 This is an AE which is a small pocket of body fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the lip skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection. QY, JX, HY http://en.volupedia.org/wiki/Stuttering 口吃 10054964 dysphemia AE OAE:0008120 This is an AE which is inflammation of the mouth and lips and is allergic. QY, JX, HY http://en.volupedia.org/wiki/Stomatitis 变应性口炎 10079554 allergic stomatitis AE OAE:0008121 This is an AE which is a common type of skin rash. Symptoms include multiple small (1–2 mm) bumps and blisters sometimes with background redness and scale, localized to the skin around the mouth and nostrils. QY, JX, HY http://en.volupedia.org/wiki/Perioral_dermatitis 口周的皮炎 10034541 perioral dermatitis AE OAE:0008122 This is an AE which is the flow of saliva outside the mouth. Drooling can be caused by excess production of saliva, inability to retain saliva within the mouth (incontinence of saliva), or problems with swallowing (dysphagia or odynophagia). QY, JX, HY http://en.volupedia.org/wiki/Drooling 流口水 10013642 drooling AE OAE:0008123 This is an AE which is glossitis which manifests with hyperplastic (enlarged) fungiform papillae, giving the appearance of a strawberry. QY, JX, HY http://en.volupedia.org/wiki/Glossitis#Strawberry_tongue 草莓舌 10051495 strawberry tongue AE OAE:0008124 This is an AE which is considered as a possible clinical finding of obstructive sleep apnoea (OSA). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28548303/ 扇贝舌 10074686 scalloped tongue AE OAE:0008125 This is an AE which is a common zoological behavior involving the active, rapid closing of the jaw around an object. QY, JX, HY http://en.volupedia.org/wiki/Biting 咬 10004966 bite AE OAE:0008126 This is an AE which is also an age appropriate behavior and reaction for human children 30 months and younger. QY, JX, HY http://en.volupedia.org/wiki/Biting#In_humans 咬人 10020428 human bite AE OAE:0008127 This is an AE which may occur both in seizures and in psychogenic non-epileptic events (PNEEs). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23041172/ 咬舌头 10050467 tongue biting AE OAE:0008128 This is an AE which is the increase in the volume of mucosal tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 粘膜肥大 10079674 mucosal hypertrophy AE OAE:0008129 This is an AE which is a membrane that lines various cavities in the body and covers the surface of internal organs and it is dryness. QY, JX, HY http://en.volupedia.org/wiki/Mucous_membrane 粘膜干燥 10028111 mucosal dryness AE OAE:0008130 This is an AE which is a colored material on the mucosal that is completely or nearly insoluble in water. QY, JX, HY http://en.volupedia.org/wiki/Pigment 粘膜色素沉着 10067724 mucosal pigmentation AE OAE:0008131 This is an AE which is an exudate of inflamed mucous membranes in one of the airways or cavities of the body,usually with reference to the throat and paranasal sinuses. QY, JX, HY http://en.volupedia.org/wiki/Catarrh 粘膜炎 10007774 catarrh AE OAE:0008132 This is an AE which is a burning sensation in the mouth with no underlying known dental or medical cause. QY, JX, HY http://en.volupedia.org/wiki/Burning_mouth_syndrome 灼烧感黏膜 10006789 burning sensation mucosal AE OAE:0008133 This is an AE which is inflammation of one or both corners of the mouth. QY, JX, HY http://en.volupedia.org/wiki/Angular_cheilitis 角唇炎 10002509 angular cheilitis AE OAE:0008134 This is an AE which is a mode of keratinization characterized by the retention of nuclei in the stratum corneum. QY, JX, HY http://en.volupedia.org/wiki/Parakeratosis 角化不全 10058318 parakeratosis AE OAE:0008135 This is an AE which is excessive teeth grinding or jaw clenching. QY, JX, HY http://en.volupedia.org/wiki/Bruxism 磨牙症 10006514 bruxism AE OAE:0008136 This is an AE which is a membrane that lines various cavities in the body and covers the surface of internal organs and it is discolouration. QY, JX, HY http://en.volupedia.org/wiki/Mucous_membrane 黏膜变色 10054877 mucosal discoloration AE OAE:0008137 This is an AE which refers a supramolecular assembly of lipid molecules, like a cell membrane. QY, JX, HY http://en.volupedia.org/wiki/Vesicle 黏膜囊泡 10028103 mucosa vesicle AE OAE:0008138 This is an AE which is a misalignment or incorrect relation between the teeth of the upper and lower dental arches when they approach each other as the jaws close. QY, JX, HY http://en.volupedia.org/wiki/Malocclusion 错位咬合 10061274 malocclusion AE OAE:0008139 This is an AE which is one of the criteria for the diagnosis of idiopathic Parkinson disease and is often an early sign of the disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15883274/ 齿轮刚性 10009848 cogwheel rigidity AE OAE:0008140 This is an AE which is inflammation of the alveolar bone (i.e., the alveolar process of the maxilla or mandible). QY, JX, HY http://en.volupedia.org/wiki/Alveolar_osteitis 牙槽骨炎 10066995 alveolar osteitis AE OAE:0008141 This is an AE which is a cellular aggregation seen in a developing tooth and it lies above the dental papilla. QY, JX, HY http://en.volupedia.org/wiki/Enamel_organ 牙釉质异常 10014576 enamel anomaly AE OAE:0008142 This is an AE which is a hard, calcified structure found in the jaws (or mouths) of many vertebrates and used to break down food and feel it discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Tooth 牙齿不舒服 10054217 dental discomfort AE OAE:0008143 This is an AE which is a hard, calcified structure found in the jaws (or mouths) of many vertebrates and used to break down food and it becomes brittle. QY, JX, HY http://en.volupedia.org/wiki/Tooth 牙齿变脆 10043173 teeth brittle AE OAE:0008144 This is an AE which is a muscular organ in the mouth of a typical vertebrate and is feel discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Tongue 舌头不适 10077855 tongue discomfort AE OAE:0008145 This is an AE which is any condition of the teeth that can be congenital or acquired. QY, JX, HY http://en.volupedia.org/wiki/Tooth_pathology 牙齿状况差 10059184 poor dental condition AE OAE:0008146 This is an AE which is the horizontal or vertical displacement of a tooth beyond its normal physiological boundariesaround the gingival area, i.e. the medical term for a loose tooth. QY, JX, HY http://en.volupedia.org/wiki/Tooth_mobility 外伤性牙齿移位 10071180 traumatic tooth displacement AE OAE:0008147 This is an AE which is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer. QY, JX, HY http://en.volupedia.org/wiki/Mucositis 粘膜紊乱 10082268 mucosal disorder AE OAE:0008148 This is an AE which is a periodontal disorder diagnosed based on distinct clinical characteristics. QY, JX, HY http://en.volupedia.org/wiki/Linear_gingival_erythema 牙龈红斑 10067419 gingival erythema AE OAE:0008149 This is an AE which defined as a type of groove along the free edge of the vocal fold, disrupts the normal, pliable vocal fold cover, causing alterations in the intrinsic mucosal wave. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31088694/ 声带沟 10077497 sulcus vocalis AE OAE:0008150 This is an AE which is defined as a white oral lesion not related to another disease process. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28916027/ 口腔白斑 10024396 leukoplakia oral AE OAE:0008151 This is an AE which is cancer of the lining of the lips, mouth, or upper throat. QY, JX, HY http://en.volupedia.org/wiki/Oral_cancer 唇癌或口腔癌 10061523 lip and/or oral cavity cancer AE OAE:0008152 This is an AE which is a closed sac on the mouth, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 口囊肿 10028020 mouth cyst AE OAE:0008153 This is an AE which is a biofilm of microorganisms (mostly bacteria, but also fungi) that grows on surfaces within the mouth. QY, JX, HY http://en.volupedia.org/wiki/Dental_plaque 口腔菌斑 10028032 mouth plaque AE OAE:0008154 This is an AE which refres to the most frequent causes are lithiathesis and neoplasm. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9487738/ 嘴巴肿胀 10075203 mouth swelling AE OAE:0008155 This is an AE which is a group of infections that occur around the oral cavity. QY, JX, HY http://en.volupedia.org/wiki/Mouth_infection 口腔感染 10048685 oral infection AE OAE:0008156 This is an AE which is a chronic inflammatory and immune-mediated disease that affects the skin, nails, hair, and mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Lichen_planus 口腔扁平苔癣 10030983 oral lichen planus AE OAE:0008157 This is an AE which is the mucous membrane lining the inside of the mouth and the membrane has haematoma. QY, JX, HY http://en.volupedia.org/wiki/Oral_mucosa 口腔黏膜血肿 10074779 oral mucosa hematoma AE OAE:0008158 This is an AE which is the mucous membrane with blistering lining the inside of the mouth. QY, JX, HY http://en.volupedia.org/wiki/Oral_mucosa 口腔粘膜引起水泡 10030995 oral mucosal blistering AE OAE:0008159 This is an AE which can occur due to a multitude of non-neoplastic causes because black and brown pigmentation . Endogenous or exogenous pigments may be responsible for oral discoloration which can range from innocuous to life-threatening in nature. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30671761/ 口腔黏膜变色 10030996 oral mucosal discoloration AE OAE:0008160 This is an AE which is the increase in the volume of oral mucosal due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 口腔粘膜肥大 10062956 oral mucosal hypertrophy AE OAE:0008161 This is an AE which is a small (1- 2 mm) red or purple spot on the oral mucosal, caused by a minor bleed from broken capillary blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Petechia 口腔粘膜瘀点 10030998 oral mucosal petechiae AE OAE:0008162 This is an AE which is a hard coating on the skin formed during the wound healing reconstruction phase on the oral mucosal. QY, JX, HY http://en.volupedia.org/wiki/Scab 口腔粘膜痂 10082769 oral mucosal scab AE OAE:0008163 This is an AE which is a benign epithelial oral tumor growing exophytically (outwardly projecting) in nipple-like and often finger-like fronds. QY, JX, HY http://en.volupedia.org/wiki/Papilloma 口腔乳头状瘤 10068322 oral papilloma AE OAE:0008164 This is an AE which is a small, well-defined bump in the oral skin. QY, JX, HY http://en.volupedia.org/wiki/Papule 口腔丘疹 10031010 oral papule AE OAE:0008165 This is an AE which is a sensation that causes the desire or reflex to scratch on the oral. QY, JX, HY http://en.volupedia.org/wiki/Itch 口腔瘙痒 10052894 oral pruritus AE OAE:0008166 This is an AE which is the invasion of an organism's oral tissues by disease-causing agents such as bacterial, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection#Bacterial_or_viral 口腔细菌感染 10065233 oral bacterial infection AE OAE:0008167 This is an AE which is oral disease caused by fungi . QY, JX, HY http://en.volupedia.org/wiki/Fungal_infection 口腔真菌感染 10061324 oral fungal infection AE OAE:0008168 This is an AE which is an abnormal sensation of the oral skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. QY, JX, HY http://en.volupedia.org/wiki/Paresthesia 感觉异常口腔 10057372 paraesthesia oral AE OAE:0008169 This is an AE which refers to comprise a number of different types of oral cancer that result from squamous cells . QY, JX, HY http://en.volupedia.org/wiki/Squamous_cell_carcinoma 口腔鳞状细胞癌 10041857 squamous cell carcinoma of the oral cavity AE OAE:0008170 This is an AE which is inflammation with haemorrhagic of the mouth and lips. QY, JX, HY http://en.volupedia.org/wiki/Stomatitis 出血性口炎 10042132 stomatitis haemorrhagic AE OAE:0008171 This is an AE which is inflammation of the mouth and lips and sometimes can lead with necrotising. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/?term=stomatitis+necrotising 口炎坏死 10042135 stomatitis necrotising AE OAE:0008172 This is an AE which is a common condition characterized by the repeated formation of benign and non-contagious mouth ulcers (aphthae) in otherwise healthy individuals. QY, JX, HY http://en.volupedia.org/wiki/Aphthous_stomatitis 口腔炎 10002958 aphthous stomatitis AE OAE:0008174 This is an AE which is a burning sensation in the mouth with no underlying known dental or medical cause. QY, JX, HY http://en.volupedia.org/wiki/Burning_mouth_syndrome 灼烧口腔综合征 10068065 burning mouth syndrome AE OAE:0008175 This is an AE which is the build-up of fluid in the circumoral tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 口腔周围水肿 10052250 circumoral edema AE OAE:0008176 This is an AE which refers to a transient abnormal enlargement of circumoral tissue not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 口腔周围肿胀 10081703 circumoral swelling AE OAE:0008177 This is an AE which is a disorder that is caused by the reactivation of varicella zoster virus in the geniculate ganglion, a nerve cell bundle of the facial nerve. QY, JX, HY http://en.volupedia.org/wiki/Ramsay_Hunt_syndrome_type_2 口腔带状疱疹 10063491 herpes zoster oticus AE OAE:0008178 QY, JX, HY 舌头变色 10043949 tongue discoloration AE OAE:0008179 QY, JX, HY 吐舌 10052002 tongue eruption AE OAE:0008180 QY, JX, HY 牙龈侵蚀 10018282 gingival erosion AE OAE:0008181 QY, JX, HY 毛舌症 10080276 trichoglossia AE OAE:0008182 QY, JX, HY 粘膜糜烂 10061297 mucosal erosion AE OAE:0008183 QY, JX, HY 舌头运动障碍 10043963 tongue movement disturbance AE OAE:0008184 This is an AE which is a seizure in a baby younger than 4 weeks old. Seizures are abnormally excessive or synchronous neuronal activity in the brain. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_seizure 新生儿癫痫发作 10082067 neonatal seizure AE OAE:0008185 This is an AE which is defined as having a temperature above the normal range due to an increase in the body's temperature set point occured on the neonatal. QY, JX, HY http://en.volupedia.org/wiki/Fever 新生儿发烧 10016562 fever neonatal AE OAE:0008186 This is an AE which is a rare but serious, even fatal, side effect that occurs in newborn infants (especially premature babies) following the accumulation of antibiotic chloramphenicol. QY, JX, HY http://en.volupedia.org/wiki/Gray_baby_syndrome 灰婴综合征 10018723 grey syndrome neonatal AE OAE:0008187 This is an AE which is different from the disorder affecting older children and adults. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29345589/ 新生儿疾病 10028934 neonatal disorder AE OAE:0008188 This is an AE which is a medical condition where neonatal body muscles contract and relax rapidly and repeatedly, resulting in uncontrolled shaking. QY, JX, HY http://en.volupedia.org/wiki/Convulsion 新生儿惊厥 10010911 convulsion neonatal AE OAE:0008189 This is an AE which is a bacterial tetanus neonatorum infection characterized by muscle spasms. QY, JX, HY http://en.volupedia.org/wiki/Tetanus 新生儿破伤风 10043378 tetanus neonatorum AE OAE:0008190 This is an AE which is a condition in which the neonatal body or a region of the body is deprived of adequate oxygen supply at the tissue level. QY, JX, HY http://en.volupedia.org/wiki/Hypoxia_(medical) 新生儿缺氧 10050081 neonatal hypoxia AE OAE:0008191 This is an AE which is a neonatal state of strong desire for sleep, or sleeping for unusually long periods (compare hypersomnia). QY, JX, HY http://en.volupedia.org/wiki/Somnolence 新生儿嗜睡 10041350 somnolence neonatal AE OAE:0008192 This is an AE which due to renal tubular dysgenesis, secondary to the use of angiotensin converting enzyme inhibitor (ACEI) during pregnancy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/12657763/ 新生儿无尿症 10049778 neonatal anuria AE OAE:0008193 This is an AE which is the group of neonatal symptoms that occur upon the abrupt discontinuation or decrease in the intake of medicational or recreational drugs. QY, JX, HY http://en.volupedia.org/wiki/Drug_withdrawal 新生儿药物戒断综合征 10013756 drug withdrawal syndrome neonatal AE OAE:0008194 This is an AE which is a complex task, as in newborns hypotonia can be the presenting sign of different underlying causes, including peripheral and central nervous system involvement and genetic and metabolic diseases. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31324324/ 新生儿张力减退 10021119 hypotonia neonatal AE OAE:0008195 This is an AE which is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations or twitching movements of one or more neonatal body parts. QY, JX, HY http://en.volupedia.org/wiki/Tremor 新生儿震颤 10044575 tremor neonatal AE OAE:0008196 This is an AE which is the sudden unexplained death of a child of less than one year of age. QY, JX, HY http://en.volupedia.org/wiki/Sudden_infant_death_syndrome 婴儿猝死综合症 10042440 sudden infant death syndrome AE OAE:0008197 This is an AE which is characterized by the rapid onset of annular purpuric lesions associated with initially localized edemas affecting the extremities. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31692802/ 婴儿急性出血性水肿 10070599 acute haemorrhagic edema of infancy AE OAE:0008198 This is an AE which is an uncommon-to-rare epileptic disorder in infants, children and adults. QY, JX, HY http://en.volupedia.org/wiki/Epileptic_spasms 婴儿痉挛症 10021750 infantile spasms AE OAE:0008199 This is an AE which is described in clinical literature as a severe and relatively uncommon disorder that can affect children. QY, JX, HY http://en.volupedia.org/wiki/Reactive_attachment_disorder 婴儿期或幼儿期的反应性依恋障碍 10037996 reactive attachment disorder of infancy or early childhood AE OAE:0008200 This is an AE which is a infantile condition in which stomach contents rise up into the esophagus, resulting in either symptoms or complications. QY, JX, HY http://en.volupedia.org/wiki/Gastroesophageal_reflux_disease 婴儿吐奶 10063338 infantile spitting up AE OAE:0008201 This is an AE which due to appearance, is a type of benign vascular tumor or anomaly that affects babies. QY, JX, HY http://en.volupedia.org/wiki/Infantile_hemangioma 婴儿血管瘤 10075378 infantile haemangioma AE OAE:0008202 This is an AE which is the excitatory ability that infants have to respond to changes in their environment. QY, JX, HY http://en.volupedia.org/wiki/Irritability 婴儿易怒 10082189 infant irritability AE OAE:0008203 This is an AE which is defined as episodes of crying for more than three hours a day, for more than three days a week, for three weeks in an otherwise healthy child. QY, JX, HY http://en.volupedia.org/wiki/Baby_colic 小儿疝气 10021746 infantile colic AE OAE:0008204 This is an AE which is a long-term inflammatory infantile disease of the airways of the lungs. QY, JX, HY http://en.volupedia.org/wiki/Asthma 小儿哮喘 10049585 infantile asthma AE OAE:0008205 This is an AE which is an foetal abnormality of the structure of a body part. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 胎儿畸形 10060919 foetal malformation AE OAE:0008206 This is an AE which is a condition during pregnancy or labor in which the fetus shows signs of inadequate oxygenation. QY, JX, HY http://en.volupedia.org/wiki/Fetal_distress 胎儿窘迫综合征 10016855 foetal distress syndrome AE OAE:0008207 This is an AE which is defined as birth weight >4000 g and is associated with several maternal and fetal complications such as maternal birth canal trauma, shoulder dystocia, and perinatal asphyxia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27727018/ 胎儿巨大胎儿 10053700 foetal macrosomia AE OAE:0008208 This is an AE which is a rare disease that is identified by an abnormally large or distended bladder. QY, JX, HY http://en.volupedia.org/wiki/Megacystis_(fetal) 胎儿巨囊肿 10073660 foetal megacystis AE OAE:0008209 This is an AE which is the loss of fetal blood cells into the maternal circulation. QY, JX, HY http://en.volupedia.org/wiki/Fetal-maternal_haemorrhage 胎儿-母体出血 10016871 foetal-maternal hemorrhage AE OAE:0008210 This is an AE which is an abnormal growth that usually appears on a baby's neck or head. QY, JX, HY http://en.volupedia.org/wiki/Cystic_hygroma 胎儿囊性水囊瘤 10052011 foetal cystic hygroma AE OAE:0008211 This is an AE which is a common complication of pregnancy that has been associated with a variety of adverse perinatal outcomes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30681542/ 胎儿生长受限 10070531 foetal growth restriction AE OAE:0008212 This is an AE which is damage to the foetal body caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 胎儿损伤 10016852 foetal damage AE OAE:0008213 This is an AE which leads to greater risk of cesarean delivery, prolonged labor, and increased perinatal morbidity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25851845/ 胎儿胎位不正 10016863 foetal malposition AE OAE:0008214 This is an AE which is irregular positions of the crown of the fetal head in relation to the mother's pelvis (the fetus is in an abnormal position). QY, JX, HY http://en.volupedia.org/wiki/Prolonged_labor#Fetal_malpresentations_%5B9%5D 胎儿先露异常 10058013 foetal malpresentation AE OAE:0008215 This is an AE which is defined as a heart rate less than 100 BPM (normal is around 120–160 BPM). QY, JX, HY http://en.volupedia.org/wiki/Bradycardia#Infantile 胎儿心动过缓 10006094 bradycardia foetal AE OAE:0008216 This is an AE which is non-reassuring fetal heart rate characteristics, which do not uniformly predict poor fetal outcome but can prompt obstetricians to proceed with cesarean delivery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32839938/ 胎儿心率减慢 10058322 foetal heart rate deceleration AE OAE:0008217 This is an AE which encompasses a broad spectrum of disorders, united by impaired movement in utero. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29959180/ 胎儿运动功能减退 10068461 foetal hypokinesia AE OAE:0008218 This is an AE which refers to any clinical foetal syndrome with either an excess of movement or a paucity of voluntary and involuntary movements, unrelated to weakness or spasticity. QY, JX, HY http://en.volupedia.org/wiki/Movement_disorder 胎儿运动障碍 10077576 foetal movement disorder AE OAE:0008219 This is an AE which is the earliest stool of a mammalian infant resulting from defecation and is stain. QY, JX, HY http://en.volupedia.org/wiki/Meconium 胎粪染色 10057028 meconium stain AE OAE:0008220 This is an AE which is breakage of the amniotic sac before the onset of labor. QY, JX, HY http://en.volupedia.org/wiki/Prelabor_rupture_of_membranes 胎膜早破 10036603 premature rupture of membranes AE OAE:0008221 This is an AE which defined as rupture of fetal membranes prior to 28 weeks of gestation, complicates approximately 0.4%-0.7% of all pregnancies. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28710882/ 胎膜早破 10073024 preterm premature rupture of membranes AE OAE:0008222 This is an AE which is when the placenta separates early from the uterus, in other words separates before childbirth. QY, JX, HY http://en.volupedia.org/wiki/Placental_abruption 胎盘过早分离 10036608 premature separation of placenta AE OAE:0008223 This is an AE which is often defined as the loss of more than 500 ml or 1,000 ml of blood within the first 24 hours following childbirth. QY, JX, HY http://en.volupedia.org/wiki/Postpartum_bleeding 产后出血 10036417 postpartum hemorrhage AE OAE:0008224 This is an AE which is among the leading causes of preventable maternal morbidity and mortality not only in developing countries but in developed countries as well. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17511893/ 产后发热 10037294 puerperal pyrexia AE OAE:0008225 This is an AE which is a type of mood disorder associated with childbirth, which can affect both sexes. QY, JX, HY http://en.volupedia.org/wiki/Postpartum_depression 产后抑郁症 10056393 postpartum depression AE OAE:0008226 This is an AE which refers psychological trauma to the mother following childbirth. QY, JX, HY http://en.volupedia.org/wiki/Birth_trauma 产伤 10004954 birth trauma AE OAE:0008227 This is an AE which is the culmination of one multiple pregnancy, wherein the mother gives birth to two or more offspring. QY, JX, HY http://en.volupedia.org/wiki/Multiple_birth 多胎妊娠 10028243 multiple pregnancy AE OAE:0008228 This is an AE which is a medical condition where children body muscles contract and relax rapidly and repeatedly, resulting in uncontrolled shaking. QY, JX, HY http://en.volupedia.org/wiki/Convulsion 小儿抽搐 10052391 convulsion in childhood AE OAE:0008229 This is an AE which is an abnormal condition of the children mind that results in difficulties determining what is real and what is not real. QY, JX, HY http://en.volupedia.org/wiki/Psychosis 儿童精神病 10061040 childhood psychosis AE OAE:0008230 This is an AE which is a class of mental children disorders characterized by enduring maladaptive patterns of behavior, cognition, and inner experience, exhibited across many contexts and deviating from those accepted by the individual's culture. QY, JX, HY http://en.volupedia.org/wiki/Personality_disorder 儿童人格障碍 10034723 personality disorder of childhood AE OAE:0008231 This is an AE which is a children long-term inflammatory disease of the airways of the lungs. QY, JX, HY http://en.volupedia.org/wiki/Asthma 儿童哮喘 10081274 childhood asthma AE OAE:0008232 This is an AE which is the ending of pregnancy where one or more babies leaves the uterus by passing through the vagina or by Caesarean section. QY, JX, HY http://en.volupedia.org/wiki/Childbirth 分娩 10067647 delivery AE OAE:0008233 This is an AE which includes obstructed labour,eclampsia and so on. QY, JX, HY http://en.volupedia.org/wiki/Childbirth#Labour_and_delivery_complications 分娩并发症 10061781 complication of delivery AE OAE:0008234 This is an AE which includes obstructed labour,eclampsia and so on. QY, JX, HY http://en.volupedia.org/wiki/Childbirth#Labour_and_delivery_complications 分娩合并症 10061050 labour complication AE OAE:0008235 This is an AE which is normally the most painful event in a woman's lifetime. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28648158/ 分娩疼痛 10059204 labour pain AE OAE:0008236 This is an AE which is an infection caused by the rubella virus in pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Rubella 怀孕期间风疹 10039264 rubella in pregnancy AE OAE:0008237 This is an AE which is a term used to describe infants that are born with an abnormally high weight, specifically in the 90th percentile or above, compared to other babies of the same developmental age. QY, JX, HY http://en.volupedia.org/wiki/Large_for_gestational_age 巨大胎儿 10025394 macrosomia AE OAE:0008238 This is an AE which is a condition characterized by excessive growth and height significantly above average. QY, JX, HY http://en.volupedia.org/wiki/Gigantism 巨人症 10018265 gigantism AE OAE:0008239 This is an AE which is associated with adverse pregnancy outcomes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29746025/ 脐带短 10045453 umbilical cord short AE OAE:0008240 This is an AE which is when the umbilical cord becomes wrapped around the fetus's neck. QY, JX, HY http://en.volupedia.org/wiki/Nuchal_cord 脐带绕脖 10045447 umbilical cord around neck AE OAE:0008241 This is an AE which is when the umbilical cord comes out of the uterus with or before the presenting part of the baby. QY, JX, HY http://en.volupedia.org/wiki/Umbilical_cord_prolapse 脐带脱垂 10045452 umbilical cord prolapse AE OAE:0008242 This is an AE which is the obstruction of blood flow through the umbilical cord secondary to pressure from an external object or misalignment of the cord itself. QY, JX, HY http://en.volupedia.org/wiki/Umbilical_cord_compression 压缩性脐带 10045451 umbilical cord compression AE OAE:0008243 This is an AE which is inflammation of the connective tissue of the umbilical cord that occurs with chorioamnionitis. QY, JX, HY http://en.volupedia.org/wiki/Funisitis 脐带炎 10064502 funisitis AE OAE:0008244 This is an AE which is the most common umbilical abnormality in neonates, causing inflammation and drainage. QY, JX, HY http://en.volupedia.org/wiki/Umbilical_granuloma 脐肉芽肿 10067731 umbilical granuloma AE OAE:0008245 This is an AE which is a health condition where the abdominal wall behind the navel is damaged. QY, JX, HY http://en.volupedia.org/wiki/Umbilical_hernia 脐疝 10045458 umbilical hernia AE OAE:0008246 This is an AE which is a rare abdominal wall defect. QY, JX, HY http://en.volupedia.org/wiki/Omphalocele 脐突出 10015677 exomphalos AE OAE:0008247 This is an AE which is the medical term for inflammation of the umbilical cord stump in the neonatal newborn period, most commonly attributed to a bacterial infection. QY, JX, HY http://en.volupedia.org/wiki/Omphalitis_of_newborn 脐炎 10030306 omphalitis AE OAE:0008248 This is an AE which is health problems that are related to pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Complications_of_pregnancy 妊娠并发症 10061452 complication of pregnancy AE OAE:0008249 This is an AE which is a chronic hives-like rash that strikes some women during pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Pruritic_urticarial_papules_and_plaques_of_pregnancy 妊娠多形性爆发 10066100 polymorphic eruption of pregnancy AE OAE:0008250 This is an AE which is a pregnancy complication that is characterized by severe nausea, vomiting, weight loss, and possibly dehydration. QY, JX, HY http://en.volupedia.org/wiki/Hyperemesis_gravidarum 妊娠剧吐 10020614 hyperemesis gravidarum AE OAE:0008251 This is an AE which is when a woman has not yet delivered her baby after 42 weeks of gestation, two weeks beyond the typical 40-week duration of pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Postterm_pregnancy 妊娠期延长 10036877 prolonged pregnancy AE OAE:0008252 This is an AE which is inflammation of the fetal membranes (amnion and chorion), usually due to bacterial infection. QY, JX, HY http://en.volupedia.org/wiki/Chorioamnionitis 绒毛膜羊膜炎 10008755 chorioamnionitis AE OAE:0008253 This is an AE which is two offspring produced by the same pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Twin 双胎妊娠 10045188 twin pregnancy AE OAE:0008254 This is an AE which is when a baby is born bottom first instead of head first, as is normal. QY, JX, HY http://en.volupedia.org/wiki/Breech_birth 臀位分娩 10006346 breech delivery AE OAE:0008255 This is an AE which is when a baby is born bottom first instead of head first, as is normal. QY, JX, HY http://en.volupedia.org/wiki/Breech_birth 后肢先产 10006356 breech presentation AE OAE:0008256 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on the peripartum. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 围产期出血 10072693 peripartum hemorrhage AE OAE:0008257 This is an AE which includes major and minor depressive episodes that occur during pregnancy or in the first 12 months after delivery, is one of the most common medical complications during pregnancy and the postpartum period, affecting one in seven women. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30629567/ 围产期抑郁症 10078366 perinatal depression AE OAE:0008258 This is an AE which is a congenital disorder with unknown cause. QY, JX, HY http://en.volupedia.org/wiki/Constriction_ring_syndrome 羊膜带综合征 10064100 amniotic band syndrome AE OAE:0008259 This is an AE which containing the amniotic fluid and the embryo and its becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Amniotic_sac 羊膜腔疾病 10060936 amniotic cavity disorder AE OAE:0008260 This is an AE which is a medical condition describing an excess of amniotic fluid in the amniotic sac. QY, JX, HY http://en.volupedia.org/wiki/Polyhydramnios 羊水过多 10036079 polyhydramnios AE OAE:0008261 This is an AE which is a medical condition in pregnancy characterized by a deficiency of amniotic fluid, the fluid that surrounds the fetus in the abdomen, in the amniotic sac. QY, JX, HY http://en.volupedia.org/wiki/Oligohydramnios 羊水过少 10030289 oligohydramnios AE OAE:0008262 This is an AE which is a complication of pregnancy in which the embryo attaches outside the uterus. QY, JX, HY http://en.volupedia.org/wiki/Ectopic_pregnancy 异位妊娠 10014166 ectopic pregnancy AE OAE:0008263 This is an AE which is the birth of a baby at fewer than 37 weeks gestational age, as opposed to full-term delivery at approximately 40 weeks but the baby is dead. QY, JX, HY http://en.volupedia.org/wiki/Preterm_birth 早产儿死亡 10076700 premature baby death AE OAE:0008264 This is an AE which is the termination of a pregnancy by removal or expulsion of an embryo or fetus. QY, JX, HY http://en.volupedia.org/wiki/Abortion 早期流产 10052846 abortion early AE OAE:0008265 This is an AE which is the natural loss of an embryo or fetus before it is able to survive independently. QY, JX, HY http://en.volupedia.org/wiki/Miscarriage 终止妊娠 10000209 aborted pregnancy AE OAE:0008266 This is an AE which is typically defined as fetal death at or after 20 or 28 weeks of pregnancy, depending on the source. QY, JX, HY http://en.volupedia.org/wiki/Stillbirth 死胎 10042062 stillbirth AE OAE:0008267 This is an AE which is used for describing children presenting with muscle hypotonia at or shortly after birth. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26573950/ 松软婴儿 10051004 floppy infant AE OAE:0008268 This is an AE which is considered an important contributor to neonatal morbidity and mortality in low-resource settings. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21094417/ 低体温新生儿 10050080 hypothermia neonatal AE OAE:0008269 This is an AE which is the inmature liver storage of glucose seen in preterms or children born intrauterine growth retarded. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32741157/ 低血糖新生儿 10020994 hypoglycaemia neonatal AE OAE:0008270 This is an AE which is a yellowish discoloration of the white part of the eyes and skin in a newborn baby due to high bilirubin levels. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_jaundice 黄疸新生儿 10023138 jaundice neonatal AE OAE:0008271 This is an AE which is a long-term type of inflammation of the skin (dermatitis). QY, JX, HY http://en.volupedia.org/wiki/Atopic_dermatitis 湿疹婴儿 10014198 eczema infantile AE OAE:0008272 This is an AE which can be part of a mental illness or a side effect of anti-psychotic medication on neonatal. QY, JX, HY http://en.volupedia.org/wiki/Agitation 躁动新生儿 10001500 agitation neonatal AE OAE:0008273 This is an AE which is pregnancies that are mistimed, unplanned or unwanted at the time of conception. QY, JX, HY http://en.volupedia.org/wiki/Unintended_pregnancy 意外怀孕 10046267 unwanted pregnancy AE OAE:0008274 This is an AE which occurs when a fetus, whatever its gestational age, exits the maternal body and subsequently shows any sign of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord, for however brief a time and regardless of whether the umbilical cord or placenta are intact. QY, JX, HY http://en.volupedia.org/wiki/Live_birth_(human) 活产 10049550 live birth AE OAE:0008275 This is an AE which is related to the appearance of postpartum haemorrhage due to posterior uterine atony. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28765661/ 急产 10036519 precipitate labour AE OAE:0008276 This is an AE which is when, after vaginal delivery of the head, the baby's anterior shoulder gets caught above the mother's pubic bone. QY, JX, HY http://en.volupedia.org/wiki/Shoulder_dystocia 肩难产 10040613 shoulder dystocia AE OAE:0008277 This is an AE which is when the baby does not exit the pelvis during childbirth due to being physically blocked, despite the uterus contracting normally. QY, JX, HY http://en.volupedia.org/wiki/Obstructed_labour 难产 10029934 obstructed labour AE OAE:0008278 This is an AE which is a situation at childbirth where the fetus is in a longitudinal lie and the head enters the pelvis first; the most common form of cephalic presentation is the vertex presentation, where the occiput is the leading part (the part that first enters the birth canal). QY, JX, HY http://en.volupedia.org/wiki/Cephalic_presentation 额先露 10052848 brow presentation AE OAE:0008279 This is an AE which is one where the mother or the fetus has an increased risk of adverse outcomes compared to uncomplicated pregnancies. QY, JX, HY http://en.volupedia.org/wiki/High-risk_pregnancy 高危妊娠 10052744 high risk pregnancy AE OAE:0008280 This is an AE which is a health condition where the abdominal wall behind the navel is damaged and is also incarcerated. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/?term=incarcerated+umbilical+hernia 嵌顿性脐疝 10064492 incarcerated umbilical hernia AE OAE:0008281 This is an AE which is a rare genetic disorder of the small intestine that is inherited in an autosomal recessive pattern. QY, JX, HY http://en.volupedia.org/wiki/Microvillous_inclusion_disease 微绒毛包涵体疾病 10068494 microvillous inclusion disease AE OAE:0008282 This is an AE which make it difficult to initiate breastfeeding for these high-risk infants. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22301537/ 吸吮反射差 10058605 poor sucking reflex AE OAE:0008283 This is an AE which is the ending of pregnancy where one or more babies leaves the uterus by passing through the vagina or by Caesarean section and is traumatic . QY, JX, HY http://en.volupedia.org/wiki/Childbirth 创伤性分娩 10044520 traumatic delivery AE OAE:0008284 This is an AE which is designed to allow the remaining fetus(es) to develop after premature expulsion of the first twin in the second trimester of pregnancy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33235650/ 延迟分娩 10012186 delayed delivery AE OAE:0008285 This is an AE which is a common complication of pregnancy that has been associated with a variety of adverse perinatal outcomes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30681542/ 胎儿生长迟缓 10016857 foetal growth retardation AE OAE:0008286 This is an AE which refer to a disability classification used in educational settings that allows educational institutions to provide special education and related services to students who have displayed poor social and/or academic progress. QY, JX, HY http://en.volupedia.org/wiki/Emotional_and_behavioral_disorders 儿童情绪障碍 10014552 emotional disorder of childhood AE OAE:0008287 This is an AE which is an effect of kernicterus. QY, JX, HY http://en.volupedia.org/wiki/Neonatal_jaundice 哭泣的声音尖锐 10052286 high-pitched crying AE OAE:0008288 QY, JX, HY 婴儿背拱起 10077276 infantile back arching AE OAE:0008289 QY, JX, HY 胎儿不下 10059107 missed labour AE OAE:0008290 QY, JX, HY 胎儿心率紊乱 10061158 foetal heart rate disorder AE OAE:0008291 QY, JX, HY 怀孕期间胎儿暴露 10071404 foetal exposure during pregnancy AE OAE:0008292 QY, JX, HY 羊水过多 10066470 amniorrhoea AE OAE:0008293 QY, JX, HY 大号婴儿 10023789 large for dates baby AE OAE:0008294 QY, JX, HY 斜产位 10052849 oblique presentation AE OAE:0008295 This is an AE which corresponds to an impairment of urinary transport that can lead to renal dysfunction if not treated. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29302903/ 输尿管梗阻 10034232 pelvi-ureteric obstruction AE OAE:0008296 This is an AE which is a potential emergency. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7855946/ 阴囊肿胀 10039759 scrotal swelling AE OAE:0008297 This is an AE which is any part of an animal or plant that is involved in sexual reproduction and is enlarged. QY, JX, HY http://en.volupedia.org/wiki/Sex_organ 生殖器增大 10073740 genitals enlarged AE OAE:0008298 This is an AE which is cancer that develops from breast tissue and occurs invasive ductal. QY, JX, HY http://en.volupedia.org/wiki/Breast_cancer 浸润性导管乳腺癌 10073095 invasive ductal breast carcinoma AE OAE:0008299 This is an AE which is cancer that develops from breast tissuec and is hormone refractory . QY, JX, HY http://en.volupedia.org/wiki/Breast_cancer 激素难治性乳腺癌 10076935 hormone refractory breast cancer AE OAE:0008300 This is an AE which is defined as an endometrium of > 5 mm discovered on ultrasound in a postmenopausal woman who is not bleeding. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29731210/ 子宫内膜增厚 10056432 endometrial thickening AE OAE:0008301 This is an AE which is the medical use of probes called sounds to increase the inner diameter of the urethra and to locate obstructions in it. QY, JX, HY http://en.volupedia.org/wiki/Urethral_sounding 尿道扩张 10046442 urethral dilatation AE OAE:0008302 This is an AE which is the partial or total loss of reproductive and hormonal function of the ovaries before age 40 because of folliclular (egg producing area) dysfunction or early loss of eggs. QY, JX, HY http://en.volupedia.org/wiki/Primary_ovarian_insufficiency 卵巢衰竭 10033165 ovarian failure AE OAE:0008303 This is an AE which refers a band of coagulative necrosis at the choriodecidual interphase, is a histologic lesion of unclear pathogenesis that has been reported in placentas from preeclampsia, preterm premature rupture of membranes, and preterm abruption. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15702362/ 胎盘坏死 10035139 placental necrosis AE OAE:0008304 This is an AE which is a collection of pus that has built up within the tissue of the vaginal. QY, JX, HY http://en.volupedia.org/wiki/Abscess 阴道脓肿 10049573 vaginal abscess AE OAE:0008305 This is an AE which might accurately reflect an acidotic state in the vaginal synapses and perineural space. QY, JX, HY http://en.volupedia.org/wiki/Dysesthesia 阴道灼热感 10050023 vaginal burning sensation AE OAE:0008306 This is an AE which is an extraordinarily rare form of cancer that develops in the tissue of the vagina. QY, JX, HY http://en.volupedia.org/wiki/Vaginal_cancer 阴道癌 10046885 vaginal cancer AE OAE:0008307 This is an AE which is excessive growth of yeast in the vagina that results in irritation. QY, JX, HY http://en.volupedia.org/wiki/Vaginal_yeast_infection 阴道念珠菌病 10046898 vaginal candidiasis AE OAE:0008308 This is an AE which is a pathological condition that affects part or all of the vagina. QY, JX, HY http://en.volupedia.org/wiki/Vaginal_disease 阴道紊乱 10061402 vaginal disorder AE OAE:0008309 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) and/or organs (macroscopic scale), and/or the abnormal histology or anatomical structure presumably resulting from such growth such as vaginal dysplasia. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 阴道发育不良 10046905 vaginal dysplasia AE OAE:0008310 This is an AE which is an emission or expulsion of air from the vagina. QY, JX, HY http://en.volupedia.org/wiki/Vaginal_flatulence 阴道胀气 10064227 vaginal flatulence AE OAE:0008311 This is an AE which refers irregular tear-like wounds caused by some blunt trauma on the vaginal . QY, JX, HY http://en.volupedia.org/wiki/Wound#Open 阴道撕裂伤 10046919 vaginal laceration AE OAE:0008312 This is an AE which is any damage or abnormal change in the tissue of vaginal , usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 阴道病变 10048937 vaginal lesion AE OAE:0008313 This is an AE which is a cancer of the vulva, the outer portion of the female genitals. QY, JX, HY http://en.volupedia.org/wiki/Vulvar_cancer 阴道肿瘤 10062165 vaginal neoplasm AE OAE:0008314 This is an AE which is caused by one or more volatilized chemical compounds on the vaginal that are generally found in low concentrations . QY, JX, HY http://en.volupedia.org/wiki/Odor 阴道异味 10046935 vaginal odour AE OAE:0008315 This is an AE which is the build-up of fluid in the vaginal tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 阴道水肿 10063818 vaginal edema AE OAE:0008316 This is an AE which refers a transient abnormal enlargement of a vaginal part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 阴道肿胀 10055049 vaginal swelling AE OAE:0008317 This is an AE which occurs when the normal lactobacilli of the vagina are replaced by mostly anaerobic bacteria. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21524046/ 阴道溃疡 10046943 vaginal ulceration AE OAE:0008318 This is an AE which is inflammation of the vagina and vulva caused by bacterial. QY, JX, HY http://en.volupedia.org/wiki/Vaginitis 细菌性阴道炎 10062167 vaginitis bacterial AE OAE:0008319 This is an AE which is a facultatively anaerobic Gram-variable rod that is involved, together with many other bacteria, mostly anaerobic, in bacterial vaginosis in some women as a result of a disruption in the normal vaginal microflora. QY, JX, HY http://en.volupedia.org/wiki/Gardnerella_vaginalis 阴道炎加德纳菌 10046957 vaginitis gardnerella AE OAE:0008320 This is an AE which is a closed sac on the vulva, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 外阴囊肿 10050475 vulva cyst AE OAE:0008321 This is an AE which is a cancer of the vulva, the outer portion of the female genitals. QY, JX, HY http://en.volupedia.org/wiki/Vulvar_cancer 外阴癌 10047741 vulval cancer AE OAE:0008322 This is an AE which is a closed sac on the vulva, having a distinct envelope and division compared with the nearby tissue and it become disorder. QY, JX, HY http://en.volupedia.org/wiki/Vulva 外阴疾病 10047754 vulval disorder AE OAE:0008323 This is an AE which is blood escaping from the circulatory system from damaged vulval blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 外阴出血 10063816 vulval hemorrhage AE OAE:0008324 This is an AE which refers irregular tear-like wounds caused by some blunt trauma. Lacerations and incisions may appear linear (regular) or stellate (irregular) such as vulval lacerations. QY, JX, HY http://en.volupedia.org/wiki/Wound#Open 外阴撕裂伤 10047759 vulval laceration AE OAE:0008325 This is an AE which is an open sore located on the genital area, which includes the vulva, penis, perianal region, or anus. QY, JX, HY http://en.volupedia.org/wiki/Genital_ulcer 外阴溃疡 10047768 vulval ulceration AE OAE:0008326 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) and/or organs (macroscopic scale), and/or the abnormal histology or anatomical structure presumably resulting from such growth such as vulvar dysplasia. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 外阴发育不良 10054932 vulvar dysplasia AE OAE:0008327 This is an AE which is inflammation of the vulva, the external female mammalian genitalia that include the labia majora, labia minora, clitoris, and introitus (the entrance to the vagina). QY, JX, HY http://en.volupedia.org/wiki/Vulvitis 外阴炎 10047780 vulvitis AE OAE:0008328 This is an AE which is related to neuropathic pain and associated to various degrees of vulvar mucosal hypersensitivity (mostly in the vestibular area), pelvic floor muscles dysfunction, a disorder of general perception of pain and/or various complex regional pain syndromes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23972919/ 外阴阴道灼热感 10067641 vulvovaginal burning sensation AE OAE:0008329 This is an AE which is excessive growth of yeast in the vagina that results in irritation. QY, JX, HY http://en.volupedia.org/wiki/Vaginal_yeast_infection 外阴阴道念珠菌病 10047784 vulvovaginal candidiasis AE OAE:0008330 This is an AE which refers frequently or always decreased interest in sex or ability to have sex . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31108226/ 外阴阴道不适 10047786 vulvovaginal discomfort AE OAE:0008331 This is an AE which includes yeast infection, vaginitis, sexually transmitted infections (STIs) and cancer. QY, JX, HY http://en.volupedia.org/wiki/Vagina#Clinical_significance 外阴阴道疾病 10047787 vulvovaginal disorder AE OAE:0008332 This is an AE which is a common condition that is particularly prevalent during and after the menopause, and is one of the symptoms of vulvovaginal atrophy/genitourinary syndrome of menopause. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26707589/ 外阴阴道干燥 10047791 vulvovaginal dryness AE OAE:0008333 This is an AE which is redness of the vulvovaginal skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 外阴阴道红斑 10070437 vulvovaginal erythema AE OAE:0008334 This is an AE which is an vulvovaginal infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family. QY, JX, HY http://en.volupedia.org/wiki/Human_papillomavirus_infection 外阴阴道人乳头瘤病毒感染 10066416 vulvovaginal human papilloma virus infection AE OAE:0008335 This is an AE which is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators such as vulvovaginal inflammmation. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 外阴阴道炎症 10079372 vulvovaginal inflammation AE OAE:0008336 This is an AE which is vulvovaginal disease caused by fungi . QY, JX, HY http://en.volupedia.org/wiki/Fungal_infection 外阴阴道真菌感染 10064899 vulvovaginal mycotic infection AE OAE:0008337 This is an AE which is major health concerns in women of childbearing age. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25104563/ 外阴阴道痛 10069055 vulvovaginal pain AE OAE:0008338 This is an AE which thought to be attributable to autoimmune progesterone dermatitis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16891434/ 外阴阴道瘙痒 10056530 vulvovaginal pruritus AE OAE:0008339 This is an AE which is a change of the vulvovaginal skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 外阴阴道皮疹 10071588 vulvovaginal rash AE OAE:0008340 This is an AE which refers a transient abnormal enlargement of a vulvovaginal part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 外阴阴道肿胀 10071211 vulvovaginal swelling AE OAE:0008341 This is an AE which is a discontinuity or break in a bodily membrane that impedes normal function of the affected organ such as vulvovaginal . QY, JX, HY http://en.volupedia.org/wiki/Ulcer 外阴阴道溃疡 10050181 vulvovaginal ulceration AE OAE:0008342 This is an AE which is the most common mucosal human papillomavirus (HPV) infection encountered by the dermatologists. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33817597/ 外阴阴道疣 10047793 vulvovaginal warts AE OAE:0008343 This is an AE which is inflammation of the vagina and vulva. QY, JX, HY http://en.volupedia.org/wiki/Vaginitis 外阴阴道炎 10047794 vulvovaginitis AE OAE:0008344 This is an AE which is inflammation caused by trichomonal of the vagina and vulva. QY, JX, HY http://en.volupedia.org/wiki/Vaginitis 外阴滴虫性阴道炎 10047799 vulvovaginitis trichomonal AE OAE:0008345 This is an AE which is a collection of pus that has built up within the tissue of the uterine. QY, JX, HY http://en.volupedia.org/wiki/Abscess 子宫脓肿 10063012 uterine abscess AE OAE:0008346 This is an AE which is the failure of the uterus to contract adequately following delivery. QY, JX, HY http://en.volupedia.org/wiki/Uterine_atony 子宫收缩乏力 10046763 uterine atony AE OAE:0008347 This is an AE which includes two types of cancer that develop from the tissues of the uterus. QY, JX, HY http://en.volupedia.org/wiki/Uterine_cancer 子宫癌 10046766 uterine cancer AE OAE:0008348 This is an AE which is a condition in which the cells from the 'inside' of the cervical canal, known as glandular cells (or columnar epithelium), are present on the 'outside' of the vaginal portion of the cervix. QY, JX, HY http://en.volupedia.org/wiki/Cervical_ectropion 子宫颈糜烂 10008264 uterine cervical erosion AE OAE:0008349 This is an AE which is a distressing feeling on the uterine cervical often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 子宫颈痛 10058704 uterine cervical pain AE OAE:0008350 This is an AE which is a benign non-cancerous change (metaplasia) of surfacing lining cells (epithelium) to a squamous morphology on the uterine cervical . QY, JX, HY http://en.volupedia.org/wiki/Squamous_metaplasia 子宫颈鳞状上皮化生 10062663 uterine cervical squamous metaplasia AE OAE:0008351 This is an AE which is a discontinuity or break in a uterine cervix membrane that impedes normal function of the affected organ. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 子宫颈溃疡 10051960 uterine cervix ulcer AE OAE:0008352 This is an AE which is a closed uterine sac, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 子宫囊肿 10048931 uterine cyst AE OAE:0008353 This is an AE which is a less severe condition in which there is only incomplete separation of the old scar. QY, JX, HY http://en.volupedia.org/wiki/Uterine_rupture 子宫裂开 10070301 uterine dehiscence AE OAE:0008354 This is an AE which is the main female hormone-responsive, secondary sex organ of the reproductive system in humans and most other mammals and its function become disorder. QY, JX, HY http://en.volupedia.org/wiki/Uterus#Clinical_significance 子宫疾病 10046779 uterine disorder AE OAE:0008355 This is an AE which is a medical symptom in which the volume and size of the uterus in a female is abnormally high. QY, JX, HY http://en.volupedia.org/wiki/Uterine_hyperplasia 子宫增大 10046782 uterine enlargement AE OAE:0008356 This is an AE which is a localized bleeding outside of uterine blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 子宫血肿 10063875 uterine hematoma AE OAE:0008357 This is an AE which associated with fundal placenta causing depression of the uterine fundus in case of inappropriate maneuvers (pulling on the umbilical cord, uterine expression). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29875980/ 子宫低渗 10046792 uterine hypotonus AE OAE:0008358 This is an AE which is often equated to the physiological response to injury or infection on uterine . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32471078/ 子宫炎症 10046793 uterine inflammation AE OAE:0008359 This is an AE which is damage to the uterine caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 子宫损伤 10061401 uterine injury AE OAE:0008360 This is an AE which is when the uterus turns inside out, usually following childbirth. QY, JX, HY http://en.volupedia.org/wiki/Uterine_inversion 子宫内翻 10046796 uterine inversion AE OAE:0008361 This is an AE which is the most common benign tumor of the uterus found in women of reproductive age. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29186429/ 子宫肌瘤 10046798 uterine leiomyoma AE OAE:0008362 This is an AE which is a uterus that is oriented posteriorly, towards the back of the body. QY, JX, HY http://en.volupedia.org/wiki/Retroverted_uterus 子宫错位 10046800 uterine malposition AE OAE:0008363 This is an AE which is one of the rarest complications following pelvic arterial embolization for postpartum hemorrhage (PPH). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23932304/ 子宫坏死 10072333 uterine necrosis AE OAE:0008364 This is an AE which is a type of abnormal and excessive growth of uterine . QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 子宫肿瘤 10046803 uterine neoplasm AE OAE:0008365 This is an AE which is a mass in the inner lining of the uterus. QY, JX, HY http://en.volupedia.org/wiki/Endometrial_polyp 子宫息肉 10046811 uterine polyp AE OAE:0008366 This is an AE which is when the muscular wall of the uterus tears during pregnancy or childbirth. QY, JX, HY http://en.volupedia.org/wiki/Uterine_rupture 子宫破裂 10046820 uterine rupture AE OAE:0008367 This is an AE which is a sudden involuntary contraction of a muscle, a group of muscles, or a hollow organ such as the uterine tissue. QY, JX, HY http://en.volupedia.org/wiki/Spasm 子宫痉挛 10046823 uterine spasm AE OAE:0008368 This is an AE which refers pain or discomfort when an affected uterine area is touched. QY, JX, HY http://en.volupedia.org/wiki/Tenderness 子宫压痛 10046827 uterine tenderness AE OAE:0008369 This is an AE which is a type of bacteria that can cause infection of the urinary tract and vagina. QY, JX, HY http://en.volupedia.org/wiki/Ureaplasma_urealyticum_infection 解脲支原体感染 10059640 ureaplasma infection AE OAE:0008370 This is an AE which is a common and salvaging complications after renal transplantation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33138801/ 输尿管狭窄 10046411 ureteric stenosis AE OAE:0008371 This is an AE which is a medical condition of the ureter that involves inflammation. QY, JX, HY http://en.volupedia.org/wiki/Ureteritis 输尿管炎 10051250 ureteritis AE OAE:0008372 This is an AE which is when a solid piece of material (kidney stone) develops in the urinary tract. QY, JX, HY http://en.volupedia.org/wiki/Kidney_stone_disease 输尿管结石 10077989 ureterolithiasis AE OAE:0008373 This is an AE which is a common presentation of sexually transmitted infection (STI) in men and known pathogens include Neisseria gonorrhoeae and Chlamydia trachomatis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25331311/ 尿道分泌物 10046443 urethral discharge AE OAE:0008374 This is an AE which is a tube that connects the urinary bladder to the urinary meatus for the removal of urine from the body of both females and males and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Urethra 尿道疾病 10046445 urethral disorder AE OAE:0008375 This is an AE which is blood escaping from the circulatory system from damaged urethral blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 尿道出血 10049710 urethral hemorrhage AE OAE:0008376 This is an AE which in major trauma is infrequent, with complex problems of diagnosis and treatment. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30857738/ 尿道损伤 10046454 urethral injury AE OAE:0008377 This is an AE which is an imprecise diagnosis, which continues to be defined by a low pressure urethra. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19444119/ 尿道内源性括约肌功能障碍 10046456 urethral intrinsic sphincter deficiency AE OAE:0008378 This is an AE which is an abnormal narrowing in a blood vessel or other tubular organ or structure such as foramina and canals such as urethral meatus stenosis. QY, JX, HY http://en.volupedia.org/wiki/Stenosis 尿道口狭窄 10058463 urethral meatus stenosis AE OAE:0008379 This is an AE which is a symptom complex including dysuria, urinary urgency and frequency, nocturia and persistent or intermittent urethral and/or pelvic pain in the absence of proven infection. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26337167/ 尿道痛 10046461 urethral pain AE OAE:0008380 This is an AE which is a sudden involuntary contraction of a muscle, a group of muscles, or a hollow organ such as the bladder such as urethral spasm. QY, JX, HY http://en.volupedia.org/wiki/Spasm 尿道痉挛 10046464 urethral spasm AE OAE:0008381 This is an AE which is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. QY, JX, HY http://en.volupedia.org/wiki/Gonorrhea 淋球菌性尿道炎 10046483 urethritis gonococcal AE OAE:0008382 This is an AE which is the inflammation of the urethra and is noninfective. QY, JX, HY http://en.volupedia.org/wiki/Urethritis 非感染性尿道炎 10062903 urethritis noninfective AE OAE:0008383 This is an AE which comprises a number of different types of cancer that result from squamous cells on the cervix. QY, JX, HY http://en.volupedia.org/wiki/Squamous_cell_carcinoma 宫颈鳞状细胞癌 10041848 squamous cell carcinoma of the cervix AE OAE:0008384 This is an AE which is a physiological phenomenon in which the penis becomes firm, engorged, enlarged and is spontaneous. QY, JX, HY http://en.volupedia.org/wiki/Erection 自发性阴茎勃起 10049118 spontaneous penile erection AE OAE:0008385 This is an AE which is infections that are spread by sexual activity, especially vaginal intercourse, anal sex and oral sex. QY, JX, HY http://en.volupedia.org/wiki/Sexually_transmitted_infection 性抑制 10040488 sexual transmission of infection AE OAE:0008386 This is an AE which is a cutaneous condition characterized by calcification of the skin resulting from the deposition of calcium and phosphorus occurring on the scrotum. QY, JX, HY http://en.volupedia.org/wiki/Idiopathic_scrotal_calcinosis 阴囊囊肿 10065670 scrotal cyst AE OAE:0008387 This is an AE which is not considered a separate disease entity and is usually considered a condition similar to the contact dermatitis occurring elsewhere. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24044054/ 阴囊皮炎 10083260 scrotal dermatitis AE OAE:0008388 This is an AE which is reactive scrotal skin conditions in which there is blanchable redness. QY, JX, HY http://en.volupedia.org/wiki/List_of_skin_conditions#Erythemas 阴囊红斑 10054950 scrotal erythema AE OAE:0008389 This is an AE which is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or both on the prostatic. QY, JX, HY http://en.volupedia.org/wiki/Adenoma 前列腺腺瘤 10036940 prostatic adenoma AE OAE:0008390 This is an AE which is commonly observed while performing transrectal ultrasonography (TRUS), yet its significance is poorly understood. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25530382/ 前列腺钙化 10066880 prostatic calcification AE OAE:0008391 This is an AE which is a closed sac on the prostatic, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 前列腺囊肿 10067640 prostatic cyst AE OAE:0008392 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) and/or organs (macroscopic scale), and/or the abnormal histology or anatomical structure presumably resulting from such growth such as prostatic dysplasia. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 前列腺发育不良 10071019 prostatic dysplasia AE OAE:0008393 This is an AE which is inflammation of the prostate gland and is classified into acute, chronic, asymptomatic inflammatory prostatitis, and chronic pelvic pain syndrome. QY, JX, HY http://en.volupedia.org/wiki/Prostatitis 前列腺炎 10036978 prostatitis AE OAE:0008394 This is an AE which is a noncancerous increase in size of the prostate gland. QY, JX, HY http://en.volupedia.org/wiki/Benign_prostatic_hyperplasia 前列腺肿大 10051482 prostatomegaly AE OAE:0008395 This is an AE which is when the placenta attaches inside the uterus but in an abnormal position near or over the cervical opening. QY, JX, HY http://en.volupedia.org/wiki/Placenta_praevia 前置胎盘 10035119 placenta praevia AE OAE:0008396 This is an AE which is the most common cause of antepartum haemorrhage. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31622483/ 前置胎盘出血 10035121 placenta praevia hemorrhage AE OAE:0008397 This is an AE which is a common pathologic condition in obstetrics and identified nanobacteria in placental calcification indicated that nanobacteria infection is related to placental calcification. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22559042/ 胎盘钙化 10082008 placental calcification AE OAE:0008398 This is an AE which is the failure of the placenta to deliver sufficient nutrients to the fetus during pregnancy, and is often a result of insufficient blood flow to the placenta. QY, JX, HY http://en.volupedia.org/wiki/Placental_insufficiency 胎盘机能不全 10035138 placental insufficiency AE OAE:0008399 This is an AE which is a collection of pus that has built up within the tissue of the perineal. QY, JX, HY http://en.volupedia.org/wiki/Abscess 会阴脓肿 10052457 perineal abscess AE OAE:0008400 This is an AE which is a closed sac on the perineal, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 会阴囊肿 10066058 perineal cyst AE OAE:0008401 This is an AE which is an unusual condition that presents 2–3 days after a throat infection as a fine diffuse macular erythema of the perineal region. QY, JX, HY http://en.volupedia.org/wiki/Recurrent_toxin-mediated_perineal_erythema 会阴红斑 10070707 perineal erythema AE OAE:0008402 This is an AE which refers the region of the body between the pubic arch and the tail bone and it has infection. QY, JX, HY http://en.volupedia.org/wiki/Perineal 会阴感染 10066876 perineal infection AE OAE:0008403 This is an AE which is a laceration of the skin and other soft tissue structures which, in women, separate the vagina from the anus. QY, JX, HY http://en.volupedia.org/wiki/Perineal_tear 会阴撕裂 10034521 perineal laceration AE OAE:0008404 This is an AE which is a discontinuity or break in a bodily membrane that impedes normal function of the affected organ such as perineal ulceration. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 会阴部溃疡 10069679 perineal ulceration AE OAE:0008405 This is an AE which is a relatively common complication of obstetric and colorectal surgery , and can also occur in diseases such as Crohn’s disease, diverticulitis, ischemic colitis, pelvic inflammatory disease, or endocarditis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25159523/ 盆腔脓肿 10034236 pelvic abscess AE OAE:0008406 This is an AE which is a long term condition in women believed to be due to enlarged veins in the lower abdomen. QY, JX, HY http://en.volupedia.org/wiki/Pelvic_congestion_syndrome 盆腔充血 10034240 pelvic congestion AE OAE:0008407 This is an AE which is a break of the bony structure of the pelvis. QY, JX, HY http://en.volupedia.org/wiki/Pelvic_fracture 骨盆骨折 10061161 pelvic fracture AE OAE:0008408 This is an AE which can be described as a pregnancy discomfort for some women and a severe disability for others. PGP can cause pain, instability and limitation of mobility and functioning in any of the three pelvic joints. QY, JX, HY http://en.volupedia.org/wiki/Pelvic_girdle_pain 骨盆带疼痛 10083336 pelvic girdle pain AE OAE:0008409 This is an AE which is a common finding following hysterectomy which at times may become infected causing substantial morbidity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33298036/ 盆腔血肿 10054974 pelvic hematoma AE OAE:0008410 This is an AE which is blood escaping from the circulatory system from damaged pelvic blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 盆腔出血 10063678 pelvic hemorrhage AE OAE:0008411 This is an AE which is an infection of the upper part of the female reproductive system, namely the uterus, fallopian tubes, and ovaries, and inside of the pelvis. QY, JX, HY http://en.volupedia.org/wiki/Pelvic_inflammatory_disease 盆腔炎性疾病 10034254 pelvic inflammatory disease AE OAE:0008412 This is an AE which is damage to the pelvic organ caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 盆腔器官损伤 10061405 pelvic organ injury AE OAE:0008414 This is an AE which is characterized by descent of pelvic organs from their normal positions. QY, JX, HY http://en.volupedia.org/wiki/Pelvic_organ_prolapse 盆腔脱垂 10034268 pelvic prolapse AE OAE:0008415 This is an AE which is a group of rare autoimmune blistering diseases of the skin, and mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Pemphigoid 类天疱疮 10034277 pemphigoid AE OAE:0008416 This is an AE which is a small pocket of body fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the penile skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection. QY, JX, HY http://en.volupedia.org/wiki/Blister 阴茎泡 10052898 penile blister AE OAE:0008417 This is an AE which is redness of the penile skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 阴茎红斑 10070655 penile erythema AE OAE:0008418 This is an AE which is blood escaping from the circulatory system from damaged penile blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 阴茎出血 10034305 penile hemorrhage AE OAE:0008419 This is an AE which is the build-up of fluid in the penile tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 阴茎水肿 10066774 penile edema AE OAE:0008420 This is an AE which is a change of the penile skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 阴茎皮疹 10082571 penile rash AE OAE:0008421 This is an AE which refers a transient abnormal enlargement of a penile part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 阴茎肿胀 10034319 penile swelling AE OAE:0008422 This is an AE which is an open sore located on the genital area, which includes the vulva, penis, perianal region, or anus. QY, JX, HY http://en.volupedia.org/wiki/Genital_ulcer 阴茎溃疡 10034322 penile ulceration AE OAE:0008423 This is an AE which is typically small, rough, hard growths on the penile that are similar in color to the rest of the skin. QY, JX, HY http://en.volupedia.org/wiki/Wart 阴茎疣 10034325 penile wart AE OAE:0008424 This is an AE which is the process of combining two or more distinct entities into a new whole such as penoscrotal fusion. QY, JX, HY http://en.volupedia.org/wiki/Fusion 阴囊融合 10064951 penoscrotal fusion AE OAE:0008425 This is an AE which is classified as menstrual disorders and include oligoovulation and anovulation. QY, JX, HY http://en.volupedia.org/wiki/Ovulation#Disorders 排卵障碍 10067490 ovulation disorder AE OAE:0008426 This is an AE which is a physiological phenomenon in which the penis becomes firm, engorged, and enlarged. QY, JX, HY http://en.volupedia.org/wiki/Erection 勃起困难 10056303 painful erection AE OAE:0008427 This is an AE which is a collection of pus that has built up within the tissue of the ovarian. QY, JX, HY http://en.volupedia.org/wiki/Abscess 卵巢脓肿 10033119 ovarian abscess AE OAE:0008428 This is an AE which is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or both such as ovarian adenoma. QY, JX, HY http://en.volupedia.org/wiki/Adenoma 卵巢腺瘤 10048991 ovarian adenoma AE OAE:0008429 This is an AE which is the partial or complete wasting away of a part of the body such as ovarian atrophy. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 卵巢萎缩 10033122 ovarian atrophy AE OAE:0008430 This is an AE which is a fluid-filled sac within the ovary and the sac is ruptured. QY, JX, HY http://en.volupedia.org/wiki/Ovarian_cyst 卵巢囊肿破裂 10033136 ovarian cyst ruptured AE OAE:0008431 This is an AE which may refer to diseases primarily affecting, or centered on, the ovaries. QY, JX, HY http://en.volupedia.org/wiki/Ovarian_disorders 卵巢疾病 10033139 ovarian disorder AE OAE:0008432 This is an AE which is any of various types of abnormal growth or development of cells (microscopic scale) and/or organs (macroscopic scale), and/or the abnormal histology or anatomical structure presumably resulting from such growth such as ovarian dyspasia. QY, JX, HY http://en.volupedia.org/wiki/Dysplasia 卵巢发育不良 10080570 ovarian dysplasia AE OAE:0008433 This is an AE which is a tumor made up of several different types of tissue, such as ovarian germ cell . QY, JX, HY http://en.volupedia.org/wiki/Teratoma 卵巢生殖细胞畸胎瘤 10073265 ovarian germ cell teratoma AE OAE:0008434 This is an AE which is a tumor made up of several different types of tissue, such as ovarian germ cell and is benign. QY, JX, HY http://en.volupedia.org/wiki/Teratoma 卵巢生殖细胞良性畸胎瘤 10033236 ovarian germ cell teratoma benign AE OAE:0008435 This is an AE which is a histologically diverse group of neoplasms with a common origin in the primitive germ cell. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31097117/ 卵巢生殖细胞瘤 10075812 ovarian germ cell tumor AE OAE:0008436 This is an AE which is tumours that arise from ovarian granulosa cells. QY, JX, HY http://en.volupedia.org/wiki/Granulosa_cell_tumour 卵巢颗粒细胞瘤 10073260 ovarian granulosa cell tumor AE OAE:0008437 This is an AE which is damage to the ovarian caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 卵巢损伤 10079330 ovarian injury AE OAE:0008438 This is an AE which is a form of cell injury which results in the premature death of cells in living tissue by autolysis such as ovarian necrosis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 卵巢坏死 10033270 ovarian necrosis AE OAE:0008439 This is an AE which is a type of abnormal and excessive growth of ovarian tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 卵巢肿瘤 10061535 ovarian neoplasm AE OAE:0008440 This is an AE which is a condition in which organs fall down or slip out of place such as ovarian prolapse. QY, JX, HY http://en.volupedia.org/wiki/Prolapse 子宫脱垂 10033277 ovarian prolapse AE OAE:0008441 This is an AE which is when an ovary twists on its attachment to other structures, such that blood flow is decreased. QY, JX, HY http://en.volupedia.org/wiki/Ovarian_torsion 卵巢扭转 10033280 ovarian torsion AE OAE:0008442 This is an AE which is listed in the DSM-5 under Disruptive, impulse-control, and conduct disorders and defined as "a pattern of angry/irritable mood, argumentative/defiant behavior, or vindictiveness". QY, JX, HY http://en.volupedia.org/wiki/Oppositional_defiant_disorder 对立违抗性障碍 10056440 oppositional defiant disorder AE OAE:0008443 This is an AE which occurs in young adult men, and leads to pain and swelling of the testis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33815357/ 睾丸炎流行性腮腺炎 10031068 orchitis mumps AE OAE:0008444 This is an AE which is inflammation of the testes and is noninfective. QY, JX, HY http://en.volupedia.org/wiki/Orchitis 非感染性睾丸炎 10058461 orchitis noninfective AE OAE:0008445 This is an AE which is an inflammation of the ovaries. QY, JX, HY http://en.volupedia.org/wiki/Oophoritis 卵巢炎 10030345 oophoritis AE OAE:0008446 This is an AE which may be an aetiological factor in the development of urinary incontinence in women. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23076892/ 雌激素缺乏 10030247 oestrogen deficiency AE OAE:0008447 This is an AE which is an inflammation of the ovaries and is noninfective. QY, JX, HY http://en.volupedia.org/wiki/Oophoritis 非感染性卵巢 10074436 noninfective oophoritis AE OAE:0008448 This is an AE which is a type of abnormal and excessive growth of prostate tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 前列腺肿瘤 10029096 neoplasm prostate AE OAE:0008449 This is an AE which is inflammation of the kidneys and may involve the glomeruli, tubules, or interstitial tissue surrounding the glomeruli and tubules. QY, JX, HY http://en.volupedia.org/wiki/Nephritis 性肾炎 10029117 nephritis AE OAE:0008450 This is an AE which is a condition in which prolonged or excessive uterine bleeding occurs irregularly and more frequently than normal. QY, JX, HY http://en.volupedia.org/wiki/Menometrorrhagia 月经过多 10027295 menometrorrhagia AE OAE:0008451 This is an AE which is the time in women's lives when menstrual periods stop permanently, and they are no longer able to bear children. QY, JX, HY http://en.volupedia.org/wiki/Menopause#Signs_and_symptoms 更年期症状 10027304 menopausal symptoms AE OAE:0008452 This is an AE which is the regular discharge of blood and mucosal tissue from the inner lining of the uterus through the vagina feel discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Menstruation#Cramps 经期不适 10056344 menstrual discomfort AE OAE:0008453 This is an AE which is the regular discharge of blood and mucosal tissue from the inner lining of the uterus through the vagina and it is delayed. QY, JX, HY http://en.volupedia.org/wiki/Menstruation 月经推迟 10027336 menstruation delayed AE OAE:0008454 This is an AE which the lower end of the uterus, the cervix, opens into the vagina, while the upper end, the fundus, is connected to the fallopian tubes and is infected. QY, JX, HY http://en.volupedia.org/wiki/Uterus 宫内感染 10056254 intrauterine infection AE OAE:0008455 This is an AE which is a medical condition characterized by high levels of androgens in women and, less commonly, in men. QY, JX, HY http://en.volupedia.org/wiki/Hyperandrogenism 雄激素过多症 10065597 hyperandrogenism AE OAE:0008456 This is an AE which is a collection of pus that has built up within the tissue of the genital. QY, JX, HY http://en.volupedia.org/wiki/Abscess 生殖器脓肿 10062316 genital abscess AE OAE:0008457 This is an AE which is a small pocket of genital fluid (lymph, serum, plasma, blood, or pus) within the upper layers of the skin, usually caused by forceful rubbing (friction), burning, freezing, chemical exposure or infection. QY, JX, HY http://en.volupedia.org/wiki/Blister 生殖器疱 10074995 genital blister AE OAE:0008458 This is an AE which is defined as an unpleasant, abnormal sense of touch on the genital. QY, JX, HY http://en.volupedia.org/wiki/Dysesthesia 外阴烧灼感 10054815 genital burning sensation AE OAE:0008459 This is an AE which is a closed sac on the genital, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 生殖器囊肿 10053178 genital cyst AE OAE:0008460 This is an AE which is a condition that affects the female reproductive system. QY, JX, HY http://en.volupedia.org/wiki/Female_genital_disease 女性生殖障碍 10061176 genital disorder female AE OAE:0008461 This is an AE which is a condition that affects the male reproductive system. QY, JX, HY http://en.volupedia.org/wiki/Male_genital_disease 男性生殖障碍 10061177 genital disorder male AE OAE:0008462 This is an AE which is redness of the genital skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 生殖器红斑 10054816 genital erythema AE OAE:0008463 This is an AE which is blood escaping from the circulatory system from damaged genital blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 生殖器出血 10061178 genital hemorrhage AE OAE:0008464 This is an AE which is an infection by the herpes simplex virus (HSV) of the genitals. QY, JX, HY http://en.volupedia.org/wiki/Genital_herpes 生殖器疱疹 10018150 genital herpes AE OAE:0008465 This is an AE which is a viral infection caused by the herpes simplex virus. QY, JX, HY http://en.volupedia.org/wiki/Herpes_simplex 生殖器单纯疱疹 10073931 genital herpes simplex AE OAE:0008466 This is an AE which is a viral genital disease characterized by a painful skin rash with blisters in a localized genital area. QY, JX, HY http://en.volupedia.org/wiki/Shingles 生殖器带状疱疹 10072210 genital herpes zoster AE OAE:0008467 This is an AE which is a common side effect of various medical conditions which manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli such as genital hypoesthesia. QY, JX, HY http://en.volupedia.org/wiki/Hypoesthesia 生殖器触觉减退 10068912 genital hypoesthesia AE OAE:0008468 This is an AE which is the invasion of an organism's body tissues by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce such as genital infection. QY, JX, HY http://en.volupedia.org/wiki/Infection 生殖器感染 10048461 genital infection AE OAE:0008469 This is an AE which is the invasion of an organism's genital tissues by disease-causing agents such as bactarial, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 生殖器细菌感染 10061179 genital infection bacterial AE OAE:0008470 This is an AE which is the invasion of an organism's genital  tissues by disease-causing agents such as fungal, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. QY, JX, HY http://en.volupedia.org/wiki/Infection 生殖器真菌感染 10061180 genital infection fungal AE OAE:0008471 This is an AE which is trauma to the genitalia. QY, JX, HY http://en.volupedia.org/wiki/Genital_trauma 生殖器损伤 10063630 genital injury AE OAE:0008472 This is an AE which is defined as complete or partial fusion of the labia minora in the midline through flimsy or dense adhesions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30488271/ 生殖器唇粘连 10064162 genital labial adhesions AE OAE:0008473 This is an AE which is uncommon and may occur in cases of generalized porokeratosis with genital involvement or be localized to the genital area. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18358198/ 生殖器病变 10061978 genital lesion AE OAE:0008474 This is an AE which is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body such as female genital malignant neoplasm. QY, JX, HY http://en.volupedia.org/wiki/Cancer 女性生殖道恶性肿瘤 10018160 genital neoplasm malignant female AE OAE:0008475 This is an AE which can arise from a variety of conditions, crimes, trauma, medical treatments, physical diseases, mental illness and infections. QY, JX, HY http://en.volupedia.org/wiki/List_of_causes_of_genital_pain 生殖器疼痛 10061979 genital pain AE OAE:0008476 This is an AE which is a sensation on the female genital that causes the desire or reflex to scratch. QY, JX, HY http://en.volupedia.org/wiki/Itch 女性生殖器瘙痒 10018172 genital pruritus female AE OAE:0008477 This is an AE which is a change of the human genital skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 生殖器皮疹 10018175 genital rash AE OAE:0008478 This is an AE which is for a long time suspected of inducing sterility in the male. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16126436/ 生殖道炎症 10058821 genital tract inflammation AE OAE:0008479 This is an AE which is a genitalia external distressing feeling often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 生殖器外部疼痛 10018184 genitalia external painful AE OAE:0008480 This is an AE which is the most common bacterial infection in children and can be the early clinical manifestation of congenital anomalies of the kidney and urinary tract (CAKUT) or be related to bladder dysfunctions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31783012/ 泌尿生殖系统感染 10061182 genitourinary tract infection AE OAE:0008481 This is an AE which is a type of abnormal and excessive growth of germ cell . QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 感染生殖细胞肿瘤 10075292 germ cell neoplasm AE OAE:0008482 This is an AE which is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. QY, JX, HY http://en.volupedia.org/wiki/Gestational_diabetes 妊娠期糖尿病 10018209 gestational diabetes AE OAE:0008483 This is an AE which is a term used for a group of pregnancy-related tumours. QY, JX, HY http://en.volupedia.org/wiki/Gestational_trophoblastic_disease 妊娠滋养层肿瘤 10061988 gestational trophoblastic tumor AE OAE:0008484 This is an AE which is a malignant neoplasm that originates from the fallopian tube. QY, JX, HY http://en.volupedia.org/wiki/Fallopian_tube_cancer 输卵管癌 10016180 fallopian tube cancer AE OAE:0008485 This is an AE which is a closed sac on the fallopian tube, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 输卵管囊肿 10050697 fallopian tube cyst AE OAE:0008486 This is an AE which is tubes that stretch from the ovaries to the uterus, in the human female reproductive system and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Fallopian_tube 输卵管紊乱 10052094 fallopian tube disorder AE OAE:0008487 This is an AE which is disorders of the endocrine system. QY, JX, HY http://en.volupedia.org/wiki/Endocrine_disease 内分泌紊乱 10014695 endocrine disorder AE OAE:0008488 This is an AE which is a surgical procedure that is used to remove (ablate) or destroy the endometrial lining of the uterus in people with uteruses who have heavy menstrual bleeding. QY, JX, HY http://en.volupedia.org/wiki/Endometrial_ablation 子宫内膜消融 10051908 endometrial ablation AE OAE:0008489 This is an AE which is a cancer that arises from the endometrium (the lining of the uterus or womb). QY, JX, HY http://en.volupedia.org/wiki/Endometrial_cancer 子宫内膜癌 10014733 endometrial cancer AE OAE:0008490 This is an AE which is the inner epithelial layer, along with its mucous membrane, of the mammalian uterus and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Endometrium 子宫内膜症 10014753 endometrial disorder AE OAE:0008491 This is an AE which is the increase in the volume of an organ or tissue due to the enlargement of its component cells such as endometrial hypertrophy. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 子宫内膜肥厚 10014756 endometrial hypertrophy AE OAE:0008492 This is an AE which is a disease of the female reproductive system in which cells similar to those in the endometrium, the layer of tissue that normally covers the inside of the uterus, grow outside the uterus. QY, JX, HY http://en.volupedia.org/wiki/Endometriosis 子宫内膜异位 10014778 endometriosis AE OAE:0008493 This is an AE which is inflammation of the inner lining of the uterus (endometrium). QY, JX, HY http://en.volupedia.org/wiki/Endometritis 子宫内膜炎 10014791 endometritis AE OAE:0008494 This is an AE which is inflammation of the inner lining of the uterus (endometrium) with decidual. QY, JX, HY http://en.volupedia.org/wiki/Endometritis 子宫内膜炎蜕膜 10014792 endometritis decidual AE OAE:0008495 This is an AE which is a systemic pathological state of the endothelium. QY, JX, HY http://en.volupedia.org/wiki/Endothelial_dysfunction 内皮功能障碍 10048554 endothelial dysfunction AE OAE:0008496 This is an AE which is a commonly used method for securing airway and is considered to be safe but it can still lead to some complications of the airway. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31985591/ 气管插管并发症 10063349 endotracheal intubation complication AE OAE:0008497 This is an AE which is a female sex organ present in mammals, ostriches and a limited number of other animals and is become enlarged. QY, JX, HY http://en.volupedia.org/wiki/Clitoris 阴蒂增大 10014838 enlarged clitoris AE OAE:0008498 This is an AE that caused difficulty in swallowing and speech after it had been damaged by intubation or suction of the throat. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18242802/ 外阴增大 10066192 enlarged uvula AE OAE:0008499 This is an AE which is inflammation of the uterine cervix. QY, JX, HY http://en.volupedia.org/wiki/Cervicitis 宫颈炎 10008323 cervicitis AE OAE:0008500 This is an AE which is inflammation of the uterine cervix caused by human papilloma virus. QY, JX, HY http://en.volupedia.org/wiki/Cervicitis 宫颈炎人乳头瘤病毒 10051800 cervicitis human papilloma virus AE OAE:0008501 This is an AE which is a type of headache characterised by chronic hemicranial pain referred to the head from either the cervical spine or soft tissues within the neck. QY, JX, HY http://en.volupedia.org/wiki/Cervicogenic_headache 宫颈源性头痛 10064888 cervicogenic headache AE OAE:0008502 This is an AE which is a condition where a person has the sensation of movement or of surrounding objects moving when they are not and it is cervicogenic. QY, JX, HY http://en.volupedia.org/wiki/Vertigo 宫颈源性眩晕 10075760 cervicogenic vertigo AE OAE:0008503 This is an AE which is a cancer arising from the cervix and is metastatic. QY, JX, HY http://en.volupedia.org/wiki/Cervical_cancer 宫颈癌症转移 10055094 cervix cancer metastatic AE OAE:0008504 This is an AE which is a cancer arising from the cervix. QY, JX, HY http://en.volupedia.org/wiki/Cervical_cancer 子宫颈癌 10008342 cervix carcinoma AE OAE:0008505 This is an AE which is a cancer arising from the cervix and is recurrent. QY, JX, HY http://en.volupedia.org/wiki/Cervical_cancer 宫颈复发癌 10008344 cervix carcinoma recurrent AE OAE:0008506 This is an AE which is the lower part of the uterus (womb) in the human female reproductive system and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Cervix 宫颈疾病 10008351 cervix disorder AE OAE:0008507 This is an AE which is blood escaping from the circulatory system from damaged uterine cervix blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 宫颈出血子宫 10050022 cervix hemorrhage uterine AE OAE:0008508 This is an AE which is the inflammation of the cervix that can cause cervicitis . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30630634/ 宫颈炎症 10068402 cervix inflammation AE OAE:0008509 This is an AE which is damage to the cervix caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 子宫颈损伤 10078266 cervix injury AE OAE:0008510 This is an AE which is a type of abnormal and excessive growth of cervix tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 宫颈肿瘤 10008354 cervix neoplasm AE OAE:0008511 This is an AE which is the build-up of fluid in the cervix tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 宫颈水肿 10063817 cervix edema AE OAE:0008512 This is an AE which is any form of physical injury to the chest including the ribs, heart and lungs. QY, JX, HY http://en.volupedia.org/wiki/Chest_injury 胸部受伤 10061386 chest injury AE OAE:0008513 This is an AE which is a collection of pus that has built up within the tissue of the chest wall. QY, JX, HY http://en.volupedia.org/wiki/Abscess 胸壁脓肿 10051568 chest wall abscess AE OAE:0008514 This is an AE which is a common benign polyp or tumour on the surface of the cervical canal. QY, JX, HY http://en.volupedia.org/wiki/Cervical_polyp 宫颈息肉 10008297 cervical polyp AE OAE:0008515 This is an AE which is a cyst as a swelling in the upper part of neck anterior to sternocleidomastoid. QY, JX, HY http://en.volupedia.org/wiki/Branchial_cleft_cyst 宫颈囊肿 10008254 cervical cyst AE OAE:0008516 This is an AE which is a collection of pus that develops in the breast with various causes. QY, JX, HY http://en.volupedia.org/wiki/Mastitis#Breast_abscess 乳房脓肿 10006171 breast abscess AE OAE:0008517 This is an AE which is a common mammographic finding, present on 86% of images. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23547207/ 乳房钙化 10048782 breast calcifications AE OAE:0008518 This is an AE which is cancer that develops from breast tissue on female. QY, JX, HY http://en.volupedia.org/wiki/Breast_cancer 女性乳腺癌 10057654 breast cancer female AE OAE:0008519 This is an AE which is a pre-cancerous or non-invasive cancerous lesion of the breast. QY, JX, HY http://en.volupedia.org/wiki/Ductal_carcinoma_in_situ 原位乳腺癌 10006189 breast cancer in situ AE OAE:0008520 This is an AE which is when a person's cancer returns after treatment such as breast cancer recurrence. QY, JX, HY http://en.volupedia.org/wiki/Cancer_recurrence 乳腺癌复发 10006198 breast cancer recurrent AE OAE:0008521 This is an AE which is a bacterial infection involving the inner layers of the breast skin. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 乳房蜂窝织炎 10006217 breast cellulitis AE OAE:0008522 This is an AE which is a fluid-filled sac within the breast. QY, JX, HY http://en.volupedia.org/wiki/Breast_cyst 乳腺囊肿 10006220 breast cyst AE OAE:0008523 This is an AE which is fluid from the nipple caused infection, with or without squeezing the breast. QY, JX, HY http://en.volupedia.org/wiki/Nipple_discharge 乳腺分泌物感染 10006225 breast discharge infected AE OAE:0008524 This is an AE which is a constellation of symptoms involving the breasts. QY, JX, HY http://en.volupedia.org/wiki/Breast_tension 乳房不适 10049872 breast discomfort AE OAE:0008525 This is an AE which the most common symptoms are a breast mass, breast pain, and nipple discharge. QY, JX, HY http://en.volupedia.org/wiki/Breast_disease 女性乳房疾病 10006229 breast disorder female AE OAE:0008526 This is an AE which is benign, although malignancies can also occur such gynecomastia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29708282/ 男性乳房疾病 10006230 breast disorder male AE OAE:0008527 This is an AE which is the enlargement of the breasts. QY, JX, HY http://en.volupedia.org/wiki/Breast_enlargement 乳房增大 10006242 breast enlargement AE OAE:0008528 This is an AE which can range from small mammographically-detected hematomas to large clinically significant hematomas that can cause severe discomfort to patients. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409600/ 乳腺出血 10006254 breast hemorrhage AE OAE:0008529 This is an AE which is dermal thickening causing the breast cutaneous surface to feel thicker and firmer. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 乳房硬结 10006258 breast induration AE OAE:0008530 This is an AE which is inflammation of the breast or udder, usually associated with breastfeeding. QY, JX, HY http://en.volupedia.org/wiki/Mastitis 乳腺炎症 10006262 breast inflammation AE OAE:0008531 This is an AE which is damage to the breast caused by an external force. QY, JX, HY http://en.volupedia.org/wiki/Injury 乳房受伤 10059391 breast injury AE OAE:0008532 This is an AE which is deformities of the breast contour involving the inferior breast pole. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/9354603/ 乳房畸形 10006271 breast malformation AE OAE:0008533 This is an AE which is a localized swelling that feel different from the surrounding tissue. QY, JX, HY http://en.volupedia.org/wiki/Breast_mass 乳腺肿块 10006272 breast mass AE OAE:0008534 This is an AE which is one of the important imaging features of early breast cancer and are a key to early breast cancer diagnosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31137184/ 乳房微钙化 10049791 breast microcalcification AE OAE:0008535 This is an AE which is milk produced by mammary glands, located in the breast of a human female and is discolouration . QY, JX, HY http://en.volupedia.org/wiki/Breast_milk 母乳变色 10058665 breast milk discoloration AE OAE:0008536 This is an AE which is a manufactured food designed and marketed for feeding to babies and infants under 12 months of age, usually prepared for bottle-feeding or cup-feeding from powder (mixed with water) or liquid (with or without additional water) but is intolerance. QY, JX, HY 母乳替代品不耐受 10072187 breast milk substitute intolerance AE OAE:0008537 This is an AE which is an abnormal mass of tissue in the breast as a result of neoplasia. QY, JX, HY http://en.volupedia.org/wiki/Breast_disease#Neoplasms 乳腺肿瘤 10006279 breast neoplasm AE OAE:0008538 This is an AE which clinically using signs which include; increase in breast size, peau d'orange, skin erythema, hyperpigmented skin pores and positive pitting sign, as well as symptoms of breast pain and the sensation of heaviness in the breast. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28527396/ 乳房水肿 10006294 breast edema AE OAE:0008539 This is an AE which is a discontinuity or break in a breast membrane that impedes normal function of the affected organ. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 乳腺溃疡 10073419 breast ulceration AE OAE:0008540 This is an AE which is an abnormal mass of tissue in the breast as a result of neoplasia is benign. QY, JX, HY http://en.volupedia.org/wiki/Breast_disease 良性乳腺肿瘤 10004243 benign breast neoplasm AE OAE:0008541 This is an AE which is a medical condition characterized by not enough androgenic activity in the body. QY, JX, HY http://en.volupedia.org/wiki/Androgen_deficiency 缺乏雄激素 10002261 androgen deficiency AE OAE:0008542 This is an AE which is a pregnancy in which the embryo never develops or develops and is reabsorbed. QY, JX, HY http://en.volupedia.org/wiki/Blighted_ovum 无胚胎妊娠 10079814 anembryonic gestation AE OAE:0008543 This is an AE which is a type of cancerous tumor that can occur in several parts of the body such as cervix. QY, JX, HY http://en.volupedia.org/wiki/Adenocarcinoma 宫颈腺癌 10001197 adenocarcinoma of the cervix AE OAE:0008544 This is an AE which is any form of physical injury to the chest including the ribs, heart and lungs. QY, JX, HY http://en.volupedia.org/wiki/Chest_injury 外伤性肺损伤 10069363 traumatic lung injury AE OAE:0008545 This is an AE which is part of the female genitalia; they are the major externally visible portions of the vulva and it is enlarged. QY, JX, HY http://en.volupedia.org/wiki/Labia 阴唇大 10023527 labia enlarged AE OAE:0008546 This is an AE which is an unusually small penis. QY, JX, HY http://en.volupedia.org/wiki/Micropenis 小阴茎 10071706 micropenis AE OAE:0008547 This is an AE which is normal small bumps on the human penis. QY, JX, HY http://en.volupedia.org/wiki/Pearly_penile_papules 珍珠阴茎丘疹 10075021 pearly penile papules AE OAE:0008548 This is an AE which is a disease of the vagina caused by excessive growth of bacteria. QY, JX, HY http://en.volupedia.org/wiki/Bacterial_vaginosis 细菌性阴道病 10004055 bacterial vaginosis AE OAE:0008549 This is an AE which is inflammation caused by bacterial of the vagina and vulva. QY, JX, HY http://en.volupedia.org/wiki/Vaginitis 细菌性外阴阴道炎 10079528 bacterial vulvovaginitis AE OAE:0008550 This is an AE which is inflammation caused by candida of the glans penis. QY, JX, HY http://en.volupedia.org/wiki/Balanitis 念珠菌炎 10004074 balanitis candida AE OAE:0008551 This is an AE which is an inflammation that affects both the glans penis and prepuce. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31971711/ 阴茎头包皮炎 10004078 balanoposthitis AE OAE:0008552 This is an AE which may be associated with an inability to void, sexual dysfunction, and recurrent infection. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30544206/ 隐性阴茎综合征 10067131 buried penis syndrome AE OAE:0008553 This is an AE which is a condition in which the head of the penis curves downward or upward, at the junction of the head and shaft of the penis. QY, JX, HY http://en.volupedia.org/wiki/Chordee 痛性阴茎勃起 10008746 chordee AE OAE:0008554 This is an AE which is a common cause of a benign breast lump in premenopausal women. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11270760/ 纤维腺瘤的乳房 10016613 fibroadenoma of breast AE OAE:0008555 This is an AE which is a condition of the breasts where there may be pain, breast cysts, and breast masses. QY, JX, HY http://en.volupedia.org/wiki/Fibrocystic_breast_changes 乳腺纤维囊性乳腺病 10016621 fibrocystic breast disease AE OAE:0008556 This is an AE which is defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, as a persistent or recurrent delay in, or absence of, orgasm following a 'normal' sexual excitement phase. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22005203/ 女性性高潮障碍 10016405 female orgasmic disorder AE OAE:0008557 This is an AE which is a rare medical condition of the breast connective tissues in which the breasts become excessively large. QY, JX, HY http://en.volupedia.org/wiki/Breast_hypertrophy 肥大的乳房 10020881 hypertrophy breast AE OAE:0008558 This is an AE which is one of the most aggressive forms of breast cancer and can occur at any age (and, extremely rarely, in men). QY, JX, HY http://en.volupedia.org/wiki/Inflammatory_breast_cancer 乳腺炎性癌 10021980 inflammatory carcinoma of the breast AE OAE:0008559 This is an AE which refers to infertility in women. QY, JX, HY http://en.volupedia.org/wiki/Female_infertility 不孕女性 10021928 infertility female AE OAE:0008560 This is an AE which refers to a sexually mature male's inability to impregnate a fertile female. QY, JX, HY http://en.volupedia.org/wiki/Male_infertility 男性不育 10021929 infertility male AE OAE:0008561 This is an AE which is a type of tumor that can occur within the cells of the pancreatic duct. QY, JX, HY http://en.volupedia.org/wiki/Intraductal_papillary_mucinous_neoplasm 导管内乳头状黏液性肿瘤 10070999 intraductal papillary mucinous neoplasm AE OAE:0008562 This is an AE which including usual ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) are associated with increased risk, albeit of greatly different magnitudes, for the subsequent development of invasive carcinoma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27498697/ 乳腺导管内增生性病变 10073094 intraductal proliferative breast lesion AE OAE:0008563 This is an AE which is the most common 'special' morphological subtype of breast cancer, comprising up to 15% of all cases. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25849106/ 浸润性小叶乳腺癌 10073096 invasive lobular breast carcinoma AE OAE:0008564 This is an AE which is a risk factor and a nonobligate precursor of breast carcinoma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29413653/ 原位小叶性乳腺癌 10073099 lobular breast carcinoma in situ AE OAE:0008565 This is an AE which is inflammation of the breast or udder, usually associated with breastfeeding. QY, JX, HY http://en.volupedia.org/wiki/Mastitis 乳腺炎 10026883 mastitis AE OAE:0008566 This is an AE which is a raised region of tissue on the surface of the breast from which , in females, milk leaves the breast through the lactiferous ducts to feed an infant; meantime,its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Nipple 乳头紊乱 10029417 nipple disorder AE OAE:0008567 This is an AE which is one of the most common reasons given by mothers for ceasing exclusive breastfeeding. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26426034/ 乳头疼痛 10029421 nipple pain AE OAE:0008568 This is an AE which refers a transient abnormal enlargement of a nipple part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 乳头肿胀 10058680 nipple swelling AE OAE:0008569 This is an AE which is the lower part of the uterus (womb) in the human female reproductive system and is shortened. QY, JX, HY http://en.volupedia.org/wiki/Cervix 缩短的子宫颈 10067726 shortened cervix AE OAE:0008570 This is an AE which is a closed sac on the adnexa uteri, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 附件子宫囊肿 10050203 adnexa uteri cyst AE OAE:0008571 This is an AE which is the structures most closely related structurally and functionally to the uterus and it has mass. QY, JX, HY http://en.volupedia.org/wiki/Uterine_appendages 附件子宫肿块 10058897 adnexa uteri mass AE OAE:0008572 This is an AE which is the structures most closely related structurally and functionally to the uterus and it feel pain. QY, JX, HY http://en.volupedia.org/wiki/Uterine_appendages 附件子宫痛 10058841 adnexa uteri pain AE OAE:0008573 This is an AE which is a person's overall sexual drive or desire for sexual activity that is became disorder. QY, JX, HY http://en.volupedia.org/wiki/Libido 性欲障碍 10061221 libido disorder AE OAE:0008574 This is an AE which is a noncancerous increase in size of the prostate gland. QY, JX, HY http://en.volupedia.org/wiki/Benign_prostatic_hyperplasia 良性前列腺增生 10004446 benign prostatic hyperplasia AE OAE:0008575 This is an AE which is non-cyclic uterine bleeding characterized by irregular, prolonged, and often heavy menstruation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31747180/ 无排卵性出血 10005104 bleeding anovulatory AE OAE:0008576 This is an AE which is the ending of pregnancy where one or more babies leaves the uterus by passing through the vagina or by Caesarean section with bleeding. QY, JX, HY http://en.volupedia.org/wiki/Childbirth 围产期出血 10048607 bleeding peripartum AE OAE:0008577 This is an AE which is a bacterial infection involving the inner layers of the skin of male external genital organ. QY, JX, HY http://en.volupedia.org/wiki/Cellulitis 男性外生殖器蜂窝组织炎 10064929 cellulitis of male external genital organ AE OAE:0008578 This is an AE which is a sexual activity typically involving the insertion and thrusting of the penis into the vagina for sexual pleasure, reproduction, or both and can bleeding sometimes. QY, JX, HY http://en.volupedia.org/wiki/Sexual_intercourse 性交出血 10065019 coital bleeding AE OAE:0008579 This is an AE which means diminished functional activity of the gonads—the testes or the ovaries—that may result in diminished production of sex hormones. QY, JX, HY http://en.volupedia.org/wiki/Hypogonadism 性腺机能减退 10058359 hypogonadism AE OAE:0008580 This is an AE which means diminished functional activity of the gonads the testes or the ovaries that may result in diminished production of sex hormones occurs on male. QY, JX, HY http://en.volupedia.org/wiki/Hypogonadism#Men 男性性腺机能减退 10021011 hypogonadism male AE OAE:0008581 This is an AE which is extremely heavy menstrual blood flow. QY, JX, HY http://en.volupedia.org/wiki/Hypomenorrhea 月经过多 10021033 hypomenorrhoea AE OAE:0008582 This is an AE which is a common disorder that appears to be a consequence of a wide range of physical and psychological conditions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27681645/ 男性性功能障碍 10057672 male sexual dysfunction AE OAE:0008583 This is an AE which is a type of abnormal and excessive growth of malignant nipple tissue on the female. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 女性恶性乳头肿瘤 10053129 malignant nipple neoplasm female AE OAE:0008584 This is an AE which occurs when semen which would be ejaculated via the urethra is redirected to the urinary bladder. QY, JX, HY http://en.volupedia.org/wiki/Retrograde_ejaculation 逆行性射精 10038967 retrograde ejaculation AE OAE:0008585 This is an AE which is a localized bleeding outside of retroplacental blood vessels, due to either disease or trauma including injury or surgery[1] and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 胎盘后血肿 10054798 retroplacental hematoma AE OAE:0008586 This is an AE which can be seen on the oocyte retrieval day which might cause the cancelation of oocyte retrieval procedure. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31350169/ 射精失败 10014328 ejaculation failure AE OAE:0008587 This is an AE which is pain during menstruation. QY, JX, HY http://en.volupedia.org/wiki/Dysmenorrhea 痛经 10013935 dysmenorrhoea AE OAE:0008588 This is an AE which is an infection and inflammation in the Fallopian tubes (salpinges). QY, JX, HY http://en.volupedia.org/wiki/Salpingitis 输卵管炎 10039453 salpingitis AE OAE:0008589 This is an AE which is an inflammation of the ovaries with salpingo. QY, JX, HY http://en.volupedia.org/wiki/Oophoritis 输卵管卵巢炎 10049677 salpingo-oophoritis AE OAE:0008590 This is an AE which is still common cause of maternal morbidity and mortality, and is still a major challenge in gynaecological practice. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28718242/ 输卵管破裂 10067553 tubal rupture AE OAE:0008591 This is an AE which is the most common endocrine disorder in women of reproductive age. QY, JX, HY http://en.volupedia.org/wiki/Polycystic_ovary_syndrome 多囊卵巢 10036049 polycystic ovaries AE OAE:0008592 This is an AE which is defined as having serologic proof of infection without symptoms of disease. QY, JX, HY http://en.volupedia.org/wiki/Syphilis#Latent 潜伏梅毒 10070738 latent syphilis AE OAE:0008593 This is an AE which is due to problems with either the hypothalamus or pituitary gland affecting the hypothalamic-pituitary-gonadal axis (HPG axis). QY, JX, HY http://en.volupedia.org/wiki/Hypogonadotropic_hypogonadism 继发性性腺机能减退 10059594 secondary hypogonadism AE OAE:0008594 This is an AE which is a sexually transmitted infection caused by the bacterium Treponema pallidum subspecies pallidum. QY, JX, HY http://en.volupedia.org/wiki/Syphilis 梅毒 10062120 syphilis AE OAE:0008595 This is an AE which is a pregnancy in which the embryo never develops or develops and is reabsorbed. QY, JX, HY http://en.volupedia.org/wiki/Blighted_ovum 萎亡孕卵 10005160 blighted ovum AE OAE:0008596 This is an AE which is the type of sexual dysfunction in which the penis fails to become or stay erect during sexual activity. QY, JX, HY http://en.volupedia.org/wiki/Erectile_dysfunction 器质性勃起功能障碍 10052004 organic erectile dysfunction AE OAE:0008597 This is an AE which is blood escaping from the circulatory system from damaged blood vessels on postmenopausal. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 绝经后出血 10055870 postmenopausal hemorrhage AE OAE:0008598 This is an AE which is a severe and disabling form of premenstrual syndrome affecting 1.8–5.8% of menstruating women. QY, JX, HY http://en.volupedia.org/wiki/Premenstrual_dysphoric_disorder 经前综合症 10051537 premenstrual dysphoric disorder AE OAE:0008599 This is an AE which is the symptom of pain in the face, head, or neck on the premenstrual . QY, JX, HY http://en.volupedia.org/wiki/Headache 经前头痛 10049122 premenstrual headache AE OAE:0008600 This is an AE which refers to emotional and physical symptoms that regularly occur in the one to two weeks before the start of each menstrual period. QY, JX, HY http://en.volupedia.org/wiki/Premenstrual_syndrome 经前综合症 10036618 premenstrual syndrome AE OAE:0008601 This is an AE which occurs when a man expels semen (and most likely experiences orgasm) soon after beginning sexual activity, and with minimal penile stimulation. QY, JX, HY http://en.volupedia.org/wiki/Premature_ejaculation 早泄 10036596 premature ejaculation AE OAE:0008602 This is an AE which occurs when a man expels semen (and most likely experiences orgasm) soon after beginning sexual activity, and with minimal penile stimulation. QY, JX, HY http://en.volupedia.org/wiki/Premature_ejaculation 包含结膜炎 10021629 inclusion conjunctivitis AE OAE:0008603 This is an AE which is a condition in which the ridged band of the akroposthion of the foreskin of the penis cannot stretch to allow it to be pulled back past the glans. QY, JX, HY http://en.volupedia.org/wiki/Phimosis 包皮过长 10034878 phimosis AE OAE:0008604 This is an AE which a condition in which the glans is completely exposed. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30280224/ 包皮连帽 10072135 hooded prepuce AE OAE:0008605 This is an AE which is the presence of blood in ejaculation. QY, JX, HY http://en.volupedia.org/wiki/Hematospermia 血精症 10018866 haematospermia AE OAE:0008606 This is an AE which is any disease of the reproductive system. QY, JX, HY http://en.volupedia.org/wiki/Reproductive_system_disease 生殖道疾病 10061483 reproductive tract disorder AE OAE:0008607 This is an AE which is a spontaneous orgasm during sleep that includes ejaculation for a male, or vaginal wetness or an orgasm (or both) for a female. QY, JX, HY http://en.volupedia.org/wiki/Nocturnal_emission 遗精 10041497 spermatorrhoea AE OAE:0008608 This is an AE which is the cord-like structure in males formed by the vas deferens (ductus deferens) and surrounding tissue that runs from the deep inguinal ring down to each testicle and its become disorder. QY, JX, HY http://en.volupedia.org/wiki/Spermatic_cord 精索疾病 10056348 spermatic cord disorder AE OAE:0008609 This is an AE which is a germ cell tumor of the testicle or, more rarely, the mediastinum or other extra-gonadal locations. QY, JX, HY http://en.volupedia.org/wiki/Seminoma 精原细胞瘤 10039956 seminoma AE OAE:0008610 This is an AE which is a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. QY, JX, HY http://en.volupedia.org/wiki/Peyronie%27s_disease 佩罗尼氏病 10034765 peyronie's disease AE OAE:0008611 QY, JX, HY 阴道糜烂 10062558 vaginal erosion AE OAE:0008612 QY, JX, HY 阴道粘膜起泡 10048904 vaginal mucosal blistering AE OAE:0008613 QY, JX, HY 子宫肿块 10062662 uterine mass AE OAE:0008614 QY, JX, HY 输尿管疾病 10062220 ureteral disorder AE OAE:0008615 QY, JX, HY 阴囊疾病 10062155 scrotal disorder AE OAE:0008616 QY, JX, HY 胎盘输血综合症 10035146 placental transfusion syndrome AE OAE:0008617 QY, JX, HY 盆腔不适 10064229 pelvic discomfort AE OAE:0008618 QY, JX, HY 盆腔肿块 10034260 pelvic mass AE OAE:0008619 QY, JX, HY 阴茎尺寸减小 10034311 penile size reduced AE OAE:0008620 QY, JX, HY 阴茎血管障碍 10034323 penile vascular disorder AE OAE:0008621 QY, JX, HY 生殖器排泄物 10056740 genital discharge AE OAE:0008622 QY, JX, HY 生殖器不适 10066887 genital discomfort AE OAE:0008623 QY, JX, HY 生殖器侵蚀 10063802 genital erosion AE OAE:0008624 QY, JX, HY 子宫颈扩张 10057209 cervix enlargement AE OAE:0008625 QY, JX, HY 胸部压碎 10008468 chest crushing AE OAE:0008626 QY, JX, HY 胸壁肿块 10063004 chest wall mass AE OAE:0008627 QY, JX, HY 会阴损伤 10073329 perineal injury AE OAE:0008628 This is an AE which is defined as the elevation of end- expiratory lung volume above its predicted value, with no increase in end-expiratory alveolar pressure, which remains equal to atmospheric pressure. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19107020/ 肺恶性通货膨胀 10059487 lung hyperinflation AE OAE:0008629 This is an AE which comprise a group of anatomical abnormalities of the respiratory tree including congenital cystic malformations, bronchopulmonary sequestrations, bronchogenic cyst, bronchial atresia, and congenital lobar emphysema. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29110827/ 肺畸形 10037419 pulmonary malformation AE OAE:0008630 This is an AE which describes tumour cell microemboli with occlusive fibrointimal remodelling in small pulmonary arteries, veins and lymphatics. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27387102/ 肺微栓子 10037421 pulmonary microemboli AE OAE:0008631 This is an AE which is a cartilaginous tube that connects the larynx to the bronchi of the lungs, allowing the passage of air, and so is present in almost all air-breathing animals with lungs and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Trachea 气管疾病 10053490 tracheal disorder AE OAE:0008632 This is an AE which is a disease characterized by eosinophilic infiltration of the lung and bronchial mucosa, as demonstrated by examination of bronchoalveolar lavage fluid cytologic preparations or histologic examination of the bronchial mucosa. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17693206/ 支气管肺病 10053582 bronchopneumopathy AE OAE:0008633 This is an AE which is a disorder at the respiratory tract organ level that is due to problems with tissue development. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect#congenital_malformation 呼吸道畸形 10038733 respiratory tract malformation AE OAE:0008634 This is an AE which is an important opportunistic invasive mycosis in immunocompromised patients, but it is also increasingly seen in immunocompetent patients. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30329097/ 肺真菌病 10037422 pulmonary mycosis AE OAE:0008635 This is an AE which is common and radiological investigation of pleural effusion, thickening, masses, and pneumothorax is key in diagnosing and determining management. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28233652/ 胸膜疾病 10035595 pleural disorder AE OAE:0008636 This is an AE which is induced experimentally by adding high external resistances to breathing. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/1546280/ 呼吸疲劳 10068733 respiratory fatigue AE OAE:0008637 This is an AE which is one of two potentially fatal syndromes of zoonotic origin caused by species of hantavirus. QY, JX, HY http://en.volupedia.org/wiki/Hantavirus_pulmonary_syndrome 汉坦病毒肺感染 10019143 hantavirus pulmonary infection AE OAE:0008638 This is an AE which is pathological conditions with allergic affecting the organs and tissues that make gas exchange difficult in air-breathing animals. QY, JX, HY http://en.volupedia.org/wiki/Respiratory_disease 过敏性呼吸道症状 10063527 allergic respiratory symptom AE OAE:0008639 This is an AE which is the process by which gases move passively by diffusion across a surface on respiratory process occured problem . QY, JX, HY http://en.volupedia.org/wiki/Gas_exchange 呼吸气体交换障碍 10062105 respiratory gas exchange disorder AE OAE:0008640 This is an AE which is a clinical sign that results from unequal intrathoracic pressure within the chest cavity. QY, JX, HY http://en.volupedia.org/wiki/Tracheal_deviation 气管偏斜 10044287 tracheal deviation AE OAE:0008641 This is an AE which is known as tracheitis, usually due to an infection. QY, JX, HY http://en.volupedia.org/wiki/Trachea#Inflammation_and_infection 气管炎症 10065899 tracheal inflammation AE OAE:0008642 This is an AE which is a distressing feeling on the tracheal often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 气管痛 10051955 tracheal pain AE OAE:0008643 This is an AE which is a discontinuity or break in a bodily membrane that impedes normal function of the tracheal . QY, JX, HY http://en.volupedia.org/wiki/Ulcer 气管溃疡 10044299 tracheal ulcer AE OAE:0008644 This is an AE which is a condition or incident where the cartilage that keeps the airway (trachea) open is soft such that the trachea partly collapses especially during increased airflow. QY, JX, HY http://en.volupedia.org/wiki/Tracheomalacia 气管软化 10056397 tracheomalacia AE OAE:0008645 This is an AE which is a surgical procedure infection which consists of making an incision (cut) on the anterior aspect (front) of the neck and opening a direct airway through an incision in the trachea (windpipe) . QY, JX, HY http://en.volupedia.org/wiki/Tracheotomy 气管切开感染 10066335 tracheostomy infection AE OAE:0008646 This is an AE which is a surgical procedure which consists of making an incision (cut) on the anterior aspect (front) of the neck and opening a direct airway through an incision in the trachea (windpipe) and the surgical procedure results are malfunction. QY, JX, HY http://en.volupedia.org/wiki/Tracheotomy 气管切开术功能障碍 10044322 tracheostomy malfunction AE OAE:0008647 This is an AE which is a condition in which there is compression of the nerves, arteries, or veins in the passageway from the lower neck to the armpit. QY, JX, HY http://en.volupedia.org/wiki/Thoracic_outlet_syndrome 胸廓出口综合征 10048627 thoracic outlet syndrome AE OAE:0008648 This is an AE which is a marker of bone fragility on the thoracic and is associated with a downward spiral of recurrent fractures known as the vertebral fracture cascade. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26363627/ 胸椎骨折 10049948 thoracic vertebral fracture AE OAE:0008649 This is an AE which is any damage or abnormal change in the throat tissue of an organism, usually caused by disease or trauma. QY, JX, HY http://en.volupedia.org/wiki/Lesion 喉咙病变 10054830 throat lesion AE OAE:0008650 This is an AE which is a headache that is severe and has a sudden onset and is defined as a severe headache that takes seconds to minutes to reach maximum intensity. QY, JX, HY http://en.volupedia.org/wiki/Thunderclap_headache 霹雳性头痛 10075481 thunderclap headache AE OAE:0008651 This is an AE which is a tumor originating from the epithelial cells of the thymus that is considered a rare malignancy. QY, JX, HY http://en.volupedia.org/wiki/Thymoma 胸腺瘤 10043670 thymoma AE OAE:0008652 This is an AE which is rare indolent tumours of the anterior superior mediastinum. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10772969/ 胸腺瘤恶性 10061031 thymoma malignant AE OAE:0008653 This is an AE which is a specialized primary lymphoid organ of the immune system and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Thymus 胸腺疾病 10061381 thymus disorder AE OAE:0008654 This is an AE which refers to an enlargement ("hyperplasia") of the thymus and is not always a disease state. QY, JX, HY http://en.volupedia.org/wiki/Thymus_hyperplasia 胸腺增大 10065588 thymus enlargement AE OAE:0008655 This is an AE which is the increase in the volume of thymus tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 胸腺肥大 10043682 thymus hypertrophy AE OAE:0008656 This is an AE which is a condition where the thymus is underdeveloped or involuted. QY, JX, HY http://en.volupedia.org/wiki/Thymic_hypoplasia 胸腺发育不全 10052645 thymus hypoplasia AE OAE:0008657 This is an AE which is a medical condition in which increased respiration elevates the blood pH beyond the normal range (7.35–7.45) with a concurrent reduction in arterial levels of carbon dioxide. QY, JX, HY http://en.volupedia.org/wiki/Respiratory_alkalosis 呼吸性碱中毒 10038664 respiratory alkalosis AE OAE:0008658 This is an AE which is caused by apnea (cessation of breathing) or respiratory dysfunction severe enough it will not sustain the body (such as agonal breathing). QY, JX, HY http://en.volupedia.org/wiki/Respiratory_arrest 呼吸骤停 10038669 respiratory arrest AE OAE:0008659 This is an AE which occurs when ventilation is inadequate to perform needed respiratory gas exchange. QY, JX, HY http://en.volupedia.org/wiki/Hypoventilation 呼吸抑制 10038678 respiratory depression AE OAE:0008660 This is an AE which is pathological conditions affecting the organs and tissues that make gas exchange difficult in neonatal . QY, JX, HY http://en.volupedia.org/wiki/Respiratory_disease 呼吸系统疾病新生儿 10061484 respiratory disorder neonatal AE OAE:0008661 This is an AE which results from inadequate gas exchange by the respiratory system, meaning that the arterial oxygen, carbon dioxide, or both cannot be kept at normal levels. QY, JX, HY http://en.volupedia.org/wiki/Respiratory_failure 呼吸衰竭 10038695 respiratory failure AE OAE:0008662 This is an AE which refers the two reasons is neuromuscular disorders and respiratory muscle fatigue may lead to respiratory muscle weakness. QY, JX, HY http://en.volupedia.org/wiki/Respiratory_arrest 呼吸肌无力 10070833 respiratory muscle weakness AE OAE:0008663 This is an AE which is a benign epithelial tumor on the respiratory growing exophytically (outwardly projecting) in nipple-like and often finger-like fronds. QY, JX, HY http://en.volupedia.org/wiki/Papilloma 呼吸道乳头状瘤 10038707 respiratory papilloma AE OAE:0008664 This is an AE which results from inadequate gas exchange by the respiratory system, meaning that the arterial oxygen, carbon dioxide, or both cannot be kept at normal levels. QY, JX, HY http://en.volupedia.org/wiki/Respiratory_failure 呼吸麻痹 10038708 respiratory paralysis AE OAE:0008665 This is an AE which is blockage of the small airways in the lungs caused by respiratory syncytial virus. QY, JX, HY http://en.volupedia.org/wiki/Bronchiolitis 呼吸道合胞病毒性毛细支气管炎 10038718 respiratory syncytial virus bronchiolitis AE OAE:0008666 This is an AE which is inflammation of the bronchi (large and medium-sized airways) in the lungs that causes coughing caused by respiratory syncytial virus . QY, JX, HY http://en.volupedia.org/wiki/Bronchitis 呼吸道合胞病毒性支气管炎 10069811 respiratory syncytial virus bronchitis AE OAE:0008667 This is an AE which is a very common, contagious virus that causes infections of the respiratory tract. QY, JX, HY http://en.volupedia.org/wiki/Respiratory_syncytial_virus 呼吸道合胞病毒感染 10061603 respiratory syncytial virus infection AE OAE:0008668 This is an AE which is part of the complex biological response of respiratory tract tissues to harmful stimuli and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 呼吸道炎症 10068956 respiratory tract inflammation AE OAE:0008669 This is an AE which is a respiratory tract state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 呼吸道刺激 10038731 respiratory tract irritation AE OAE:0008670 This is an AE which is the build-up of fluid in the respiratory tract tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 呼吸道水肿 10070774 respiratory tract edema AE OAE:0008671 This is an AE which is an acute bleeding from the lung, from the upper respiratory tract and the trachea, and the alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_hemorrhage 肺泡出血 10037313 pulmonary alveolar hemorrhage AE OAE:0008672 This is an AE which is the complete absence of lung tissue, including bronchial tree, lung parenchyma, and supporting vasculatures. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_agenesis 肺发育不全 10037322 pulmonary aplasia AE OAE:0008673 This is an AE which is a common asymptomatic finding, usually discovered on routine chest X-ray or at autopsy and is caused mainly by two mechanisms: the dystrophic form and the metastatic form. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10783928/ 肺钙化 10051200 pulmonary calcification AE OAE:0008674 This is an AE which is an enclosed pocket of air or gas in the lung and includes blebs, bullae, pulmonary cysts, and lung cavities and has a wall thickness of more than 4 mm. QY, JX, HY http://en.volupedia.org/wiki/Focal_lung_pneumatosis 肺空化 10051738 pulmonary cavitation AE OAE:0008675 This is an AE which is a bruise of the lung, caused by chest trauma. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_contusion 肺挫伤 10037370 pulmonary contusion AE OAE:0008676 This is an AE which is an aggregation on the pulmonary of macrophages that forms in response to chronic inflammation. QY, JX, HY http://en.volupedia.org/wiki/Granuloma 肺肉芽肿 10037391 pulmonary granuloma AE OAE:0008677 This is an AE which results from recurrent bleeding into alveolar spaces and interstitial lung tissue. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16473816/ 肺含铁血黄素沉着症 10037396 pulmonary haemosiderosis AE OAE:0008678 This is an AE which is a group of structures that emerge at the hilum of each lung, just above the middle of the mediastinal surface and behind the cardiac impression of the lung and it has mass. QY, JX, HY http://en.volupedia.org/wiki/Root_of_the_lung 肺门肿块 10058563 pulmonary hilum mass AE OAE:0008679 This is an AE which is incomplete development of the lungs, resulting in an abnormally low number or size of bronchopulmonary segments or alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_hypoplasia 肺发育不全 10037407 pulmonary hypoplasia AE OAE:0008680 This is an AE which occurs when an artery to the lung becomes blocked and part of the lung dies. QY, JX, HY http://en.volupedia.org/wiki/Lung_infarction 肺梗塞 10037410 pulmonary infarction AE OAE:0008681 This is an AE which is a form of pulmonary cell injury which results in the premature death of cells in living pulmonary tissue by autolysis. QY, JX, HY http://en.volupedia.org/wiki/Necrosis 肺坏死 10058824 pulmonary necrosis AE OAE:0008682 This is an AE which is a rare condition often diagnosed by either surgery or postmortem examination. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25316886/ 肺骨化 10070310 pulmonary ossification AE OAE:0008683 This is an AE which is a distressing pulmonary feeling often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 肺痛 10074693 pulmonary pain AE OAE:0008684 This is an AE which refers to as pseudocysts in the literature, are air-filled thin-walled cysts that are formed in lung interstitium and can be single but are more often multiple. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32310606/ 肺积气 10063749 pulmonary pneumatocele AE OAE:0008685 This is an AE which is a rare medical syndrome in which respiratory failure involving bleeding in the lungs and kidney failure (glomerulonephritis) occur. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary-renal_syndrome 肺肾综合征 10068513 pulmonary renal syndrome AE OAE:0008686 This is an AE which can be asymptomatic or result in impairment in quality of life and end-stage, severe, and/or life-threatening disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33059834/ 肺结节病 10037430 pulmonary sarcoidosis AE OAE:0008687 This is an AE which is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs such as pulmonary sepsis. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 肺脓毒症 10051739 pulmonary sepsis AE OAE:0008688 This is an AE which is the medical name for side effects on the lungs. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_toxicity 肺毒性 10061924 pulmonary toxicity AE OAE:0008689 This is an AE which is defined as the spontaneously occurring presence of air in the pleural space in patients without clinically apparent underlying lung disease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20956196/ 自发性气胸 10035763 pneumothorax spontaneous AE OAE:0008690 This is an AE which is a life threatening condition requiring emergent intervention. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30509377/ 气胸自发性张力 10035764 pneumothorax spontaneous tension AE OAE:0008691 This is an AE which result from fibrothorax, secondary to hemothorax, thoracic empyema, tuberculous pleural effusion, or even exposure to asbestos fibers. QY, JX, HY https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459740/ 胸膜钙化 10035592 pleural calcification AE OAE:0008692 This is an AE which is a medical procedure involving the surgical removal of the surface layer, membrane, or fibrous cover of an organ such as pleural. QY, JX, HY http://en.volupedia.org/wiki/Decortication 胸膜剥外皮 10066322 pleural decortication AE OAE:0008693 This is an AE which can result from a variety of inflammatory processes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16716812/ 胸膜纤维化 10035600 pleural fibrosis AE OAE:0008694 This is an AE which is a type of cancer that develops from the thin layer of pleural tissue that covers many of the internal organs (known as the mesothelium). QY, JX, HY http://en.volupedia.org/wiki/Mesothelioma 胸膜间皮瘤 10035603 pleural mesothelioma AE OAE:0008695 This is an AE which is an audible medical sign present in some patients with pleurisy and other conditions affecting the chest cavity. QY, JX, HY http://en.volupedia.org/wiki/Pleural_friction_rub 胸膜擦伤 10035615 pleural rub AE OAE:0008696 This is an AE which is an increase in the bulkiness of one or both of the pulmonary pleurae. QY, JX, HY http://en.volupedia.org/wiki/Pleural_thickening 胸膜增厚 10035616 pleural thickening AE OAE:0008697 This is an AE which is inflammation caused by viral of the membranes that surround the lungs and line the chest cavity (pleurae). QY, JX, HY http://en.volupedia.org/wiki/Pleurisy 病毒性胸膜炎 10052761 pleurisy viral AE OAE:0008698 This is an AE which is the abnormal presence of air or other gas within tissues. QY, JX, HY http://en.volupedia.org/wiki/Pneumatosis 肺气肿 10051986 pneumatosis AE OAE:0008699 This is an AE which is the general term for a class of interstitial lung diseases where inhalation of dust has caused interstitial fibrosis. QY, JX, HY http://en.volupedia.org/wiki/Pneumoconiosis 尘肺 10035653 pneumoconiosis AE OAE:0008700 This is an AE which is a group of diseases involving respiratory tract abnormal cell growth with the potential to invade or spread to other parts of the body. QY, JX, HY http://en.volupedia.org/wiki/Cancer 恶性呼吸道肿瘤 10061270 malignant respiratory tract neoplasm AE OAE:0008701 This is an AE which is an infection caused by the bacterium Streptococcus pneumoniae, which is also called the pneumococcus. QY, JX, HY http://en.volupedia.org/wiki/Pneumococcal_infection 肺炎球菌感染 10061353 pneumococcal infection AE OAE:0008702 This is an AE which is a yeast-like fungus of the genus Pneumocystis caused infection. QY, JX, HY http://en.volupedia.org/wiki/Pneumocystis_jirovecii 耶氏肺孢子菌感染 10064107 pneumocystis jiroveci infection AE OAE:0008703 This is an AE which is a yeast-like fungus of the genus Pneumocystis caused infection. QY, JX, HY http://en.volupedia.org/wiki/Pneumocystis_jirovecii 卡式肺感染 10073756 pneumocystis jirovecii infection AE OAE:0008704 This is an AE which is a form of pneumonia that is caused by the yeast-like fungus Pneumocystis jirovecii. QY, JX, HY http://en.volupedia.org/wiki/Pneumocystis_pneumonia 卡式肺孢子菌肺炎 10073755 pneumocystis jirovecii pneumonia AE OAE:0008705 This is an AE which is pneumatosis (abnormal presence of air or other gas) in the mediastinum. QY, JX, HY http://en.volupedia.org/wiki/Pneumomediastinum 纵隔气肿 10050184 pneumomediastinum AE OAE:0008706 This is an AE which is a fungal infection caused by Cryptococcus neoformans predominantly in immunosuppressed individuals and rarely in the immunocompetent population. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30363287/ 隐球菌肺炎 10067565 pneumonia cryptococcal AE OAE:0008707 This is an AE which is an inflammatory condition caused by haemophilus of the lung primarily affecting the small air sacs known as alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 嗜血杆菌肺炎 10035702 pneumonia haemophilus AE OAE:0008708 This is an AE which is an inflammatory condition with influenzal of the lung primarily affecting the small air sacs known as alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 流感肺炎 10035714 pneumonia influenzal AE OAE:0008709 This is an AE which is a recognised but rare cause of rhabdomyolysis and can be further complicated with renal impairment. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31227570/ 军团菌肺炎 10035718 pneumonia legionella AE OAE:0008710 This is an AE which is a highly contagious infectious disease caused by measles virus and can cause pneumonia. QY, JX, HY http://en.volupedia.org/wiki/Measles 肺炎麻疹 10035722 pneumonia measles AE OAE:0008711 This is an AE which refers to the development of necrosis, liquefication, and cavitation of the lung parenchyma from an infectious pathogen. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28192581/ 坏死性肺炎 10055672 pneumonia necrotising AE OAE:0008712 This is an AE which is a type of bacterial pneumonia that is caused by Streptococcus pneumoniae (which is also called pneumococcus). QY, JX, HY http://en.volupedia.org/wiki/Pneumococcal_pneumonia 肺炎球菌肺炎 10035728 pneumonia pneumococcal AE OAE:0008713 This is an AE which is an inflammatory condition caused by pseudomonal of the lung primarily affecting the small air sacs known as alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 假性肺炎 10035731 pneumonia pseudomonal AE OAE:0008714 This is an AE which is rare, has a high mortality and morbidity rate, and occurs commonly during influenza epidemics (airborne) or during the course of right sided bacterial endocarditis in drug addicts (blood borne). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/7460648/ 葡萄球菌肺炎 10035734 pneumonia staphylococcal AE OAE:0008715 This is an AE which is a severe lung infection caused by the bacterium Yersinia pestis. QY, JX, HY http://en.volupedia.org/wiki/Pneumonic_plague 肺鼠疫 10053026 pneumonic plague AE OAE:0008716 This is an AE which is a type of liquefactive necrosis of the lung tissue and formation of cavities (more than 2 cm)containing necrotic debris or fluid caused by microbial infection. QY, JX, HY http://en.volupedia.org/wiki/Lung_abscess 肺脓肿 10025028 lung abscess AE OAE:0008717 This is an AE which is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. QY, JX, HY http://en.volupedia.org/wiki/Adenocarcinoma_of_the_lung 肺腺癌 10025031 lung adenocarcinoma AE OAE:0008718 This is an AE which is a region of normally compressible lung tissue that has filled with liquid instead of air. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_consolidation 肺实变 10025080 lung consolidation AE OAE:0008719 This is an AE which has a wall thickness of up to 4 mm. QY, JX, HY http://en.volupedia.org/wiki/Focal_lung_pneumatosis 肺囊肿 10068749 lung cyst AE OAE:0008720 This is an AE which is dermal thickening causing the lung cutaneous surface to feel thicker and firmer. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 肺硬化 10057261 lung induration AE OAE:0008721 This is an AE which is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body such as lung neoplasm malignant. QY, JX, HY http://en.volupedia.org/wiki/Cancer 恶性肺肿瘤 10058467 lung neoplasm malignant AE OAE:0008722 This is an AE which refers abnormal accumulation of fluid in the interstitium, manifesting as swelling on the lower respiratory tract. QY, JX, HY http://en.volupedia.org/wiki/Congestion 下呼吸道充血 10075565 lower respiratory tract congestion AE OAE:0008723 This is an AE which is a term often used as a synonym for pneumonia but can also be applied to other types of infection caused by bacterial including lung abscess and acute bronchitis. QY, JX, HY http://en.volupedia.org/wiki/Lower_respiratory_tract_infection 下呼吸道细菌感染 10063890 lower respiratory tract infection bacterial AE OAE:0008724 This is an AE which is a term often used as a synonym for pneumonia but can also be applied to other types of infection caused by fungal including lung abscess and acute bronchitis. QY, JX, HY http://en.volupedia.org/wiki/Lower_respiratory_tract_infection 下呼吸道真菌感染 10065187 lower respiratory tract infection fungal AE OAE:0008725 This is an AE which is a term often used as a synonym for pneumonia but can also be applied to other types of infection caused by viral including lung abscess and acute bronchitis. QY, JX, HY http://en.volupedia.org/wiki/Lower_respiratory_tract_infection 下呼吸道病毒感染 10065188 lower respiratory tract infection viral AE OAE:0008726 This is an AE which is part of the complex biological response of lower respiratory tract tissues to harmful stimuli, such as pathogens, damaged cells, or irritants,and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 下呼吸道炎症 10057260 lower respiratory tract inflammation AE OAE:0008727 This is an AE which is mostly squamous-cell carcinomas, reflecting their origin from the epithelium of the larynx. QY, JX, HY http://en.volupedia.org/wiki/Laryngeal_cancer 喉癌 10023825 laryngeal cancer AE OAE:0008728 This is an AE which is cysts involving the larynx or more frequently supraglottic locations, such as epiglottis and vallecula. QY, JX, HY http://en.volupedia.org/wiki/Laryngeal_cyst 喉囊肿 10051848 laryngeal cyst AE OAE:0008729 This is an AE which refers to the larynx and feel discomfortable. QY, JX, HY http://en.volupedia.org/wiki/Laryngeal 喉不舒服 10054115 laryngeal discomfort AE OAE:0008730 This is an AE which is manifested by obstructive breathing patterns reflecting functional or mechanical upper airway obstruction. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31882166/ 喉症 10061263 laryngeal disorder AE OAE:0008731 This is an AE which is a feeling on the laryngeal of not being able to breathe well enough. QY, JX, HY http://en.volupedia.org/wiki/Shortness_of_breath 喉呼吸困难 10052390 laryngeal dyspnoea AE OAE:0008732 This is an AE which is redness of the laryngeal skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries. QY, JX, HY http://en.volupedia.org/wiki/Erythema 喉红斑 10051706 laryngeal erythema AE OAE:0008733 This is an AE which is the increase in the volume of laryngeal tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 喉肥大 10068840 laryngeal hypertrophy AE OAE:0008734 This is an AE which may be a cause of ABD in preterm newborns and it may arise from oesophageal reflux and/or presence of the feeding tube. It can be diagnosed by atraumatic fiberoptic fibroscopy and successfully treated with corticosteroids. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/15814221/ 喉水肿 10023845 laryngeal edema AE OAE:0008735 This is an AE which is a distressing laryngeal feeling often caused by intense or damaging stimuli. QY, JX, HY http://en.volupedia.org/wiki/Pain 喉痛 10023848 laryngeal pain AE OAE:0008736 This is an AE which is a rare medical condition in which benign tumors (papilloma) form along the aerodigestive tract. QY, JX, HY http://en.volupedia.org/wiki/Laryngeal_papillomatosis 喉乳头状瘤 10023849 laryngeal papilloma AE OAE:0008737 This is an AE which is a complex disorder of intralaryngeal and extralaryngeal movement. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/20798566/ 喉头颤抖 10078751 laryngeal tremor AE OAE:0008738 This is an AE which is inflammation of the larynx (voice box) and is allergic. QY, JX, HY http://en.volupedia.org/wiki/Laryngitis 过敏性喉炎 10064866 laryngitis allergic AE OAE:0008739 This is an AE which is inflammation of the larynx (voice box) caused by bacterial. QY, JX, HY http://en.volupedia.org/wiki/Laryngitis 细菌性喉炎 10063070 laryngitis bacterial AE OAE:0008740 This is an AE which is inflammation of the larynx (voice box) caused by viral. QY, JX, HY http://en.volupedia.org/wiki/Laryngitis 病毒性喉炎 10023880 laryngitis viral AE OAE:0008741 This is an AE which is the most common cause of chronic stridor in infancy, in which the soft, immature cartilage of the upper larynx collapses inward during inhalation, causing airway obstruction. QY, JX, HY http://en.volupedia.org/wiki/Laryngomalacia 喉软骨软化病 10060786 laryngomalacia AE OAE:0008742 This is an AE which is the build-up of fluid in the laryngotracheal tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 喉气管的水肿 10023893 laryngotracheal edema AE OAE:0008743 This is an AE which is a larynx state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 喉部刺激 10058670 larynx irritation AE OAE:0008744 This is an AE which is the enlargement and failure of the right ventricle of the heart as a response to increased vascular resistance (such as from pulmonic stenosis) or high blood pressure in the lungs. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_heart_disease 肺心病 10010968 cor pulmonale AE OAE:0008745 This is an AE which is the enlargement and failure of the right ventricle of the heart as a response to increased vascular resistance (such as from pulmonic stenosis) or high blood pressure in the lungs and is acute. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_heart_disease 急性肺心病 10010969 cor pulmonale acute AE OAE:0008746 This is an AE which results in right ventricular hypertrophy (RVH), whereas acute pulmonary heart disease usually results in dilatation. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_heart_disease 慢性肺心病 10010970 cor pulmonale chronic AE OAE:0008747 This is an AE which is an abnormal pattern of breathing characterized by progressively deeper, and sometimes faster, breathing followed by a gradual decrease that results in a temporary stop in breathing called an apnea. QY, JX, HY http://en.volupedia.org/wiki/Cheyne%E2%80%93Stokes_respiration 呼吸节律异常 10008501 cheyne-stokes respiration AE OAE:0008748 This is an AE which is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. QY, JX, HY http://en.volupedia.org/wiki/Lung_cancer 支气管癌 10006417 bronchial carcinoma AE OAE:0008749 This is an AE which is a passage or airway in the respiratory system that conducts air into the lungs and its function becomes disorder. QY, JX, HY http://en.volupedia.org/wiki/Bronchus 支气管疾病 10064913 bronchial disorder AE OAE:0008750 This is an AE which is a state characterised by easily triggered bronchospasm (contraction of the bronchioles or small airways). QY, JX, HY http://en.volupedia.org/wiki/Bronchial_hyperresponsiveness 支气管高反应性 10066091 bronchial hyperreactivity AE OAE:0008751 This is an AE which is a bronchial state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 支气管发炎 10006438 bronchial irritation AE OAE:0008752 This is an AE which is a radiologic sign which occurs when excess fluid or mucus buildup in the small airway passages of the lung causes localized patches of atelectasis (lung collapse). QY, JX, HY http://en.volupedia.org/wiki/Peribronchial_cuffing 支气管壁增厚 10067182 bronchial wall thickening AE OAE:0008753 This is an AE which is a disease in which there is permanent enlargement of parts of the airways of the lung. QY, JX, HY http://en.volupedia.org/wiki/Bronchiectasis 支气管扩张 10006445 bronchiectasis AE OAE:0008754 This is an AE which is inflammation of the bronchi (large and medium-sized airways) in the lungs that causes coughing. QY, JX, HY http://en.volupedia.org/wiki/Bronchitis 支气管炎 10006451 bronchitis AE OAE:0008755 This is an AE which is short-term bronchitis – inflammation of the bronchi (large and medium-sized airways) of the lungs. QY, JX, HY http://en.volupedia.org/wiki/Acute_bronchitis 急性支气管炎 10006452 bronchitis acute AE OAE:0008756 This is an AE which is inflammation caused by bacterial of the bronchi (large and medium-sized airways) in the lungs that causes coughing. QY, JX, HY http://en.volupedia.org/wiki/Bronchitis 细菌性支气管炎 10061736 bronchitis bacterial AE OAE:0008757 This is an AE which is a lower respiratory tract disease, defined by a productive cough that lasts for three months or more per year for at least two years. QY, JX, HY http://en.volupedia.org/wiki/Bronchitis#Chronic_bronchitis 慢性支气管炎 10006458 bronchitis chronic AE OAE:0008758 This is an AE which is inflammation of the bronchi (large and medium-sized airways) in the lungs that causes coughing because pneumococcal infection. QY, JX, HY http://en.volupedia.org/wiki/Bronchitis 肺炎球菌支气管炎 10062487 bronchitis pneumococcal AE OAE:0008759 This is an AE which is short term inflammation of the bronchi of the lungs and the cause is a viral infection. QY, JX, HY http://en.volupedia.org/wiki/Bronchitis 病毒性支气管炎 10053160 bronchitis viral AE OAE:0008760 This is an AE which is a term for weak cartilage in the walls of the bronchial tubes, often occurring in children under a day. QY, JX, HY http://en.volupedia.org/wiki/Bronchomalacia 支气管软化 10053421 bronchomalacia AE OAE:0008761 This is an AE which is a chronic lung disease in which premature infants, usually those who were treated with supplemental oxygen, require long-term oxygen. QY, JX, HY http://en.volupedia.org/wiki/Bronchopulmonary_dysplasia 支气管肺发育不良 10006475 bronchopulmonary dysplasia AE OAE:0008762 This is an AE which is a known complication of endobronchial tuberculosis though most patients with endobronchial stenosis do not develop severe bronchostenosis or occlusion. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33614322/ 支气管狭窄 10006487 bronchostenosis AE OAE:0008763 This is an AE which is abnormally slow breathing. QY, JX, HY http://en.volupedia.org/wiki/Bradypnea 呼吸徐缓 10006102 bradypnoea AE OAE:0008764 This is an AE which is a mass of cells (tumor) that lacks the ability to either invade neighboring tissue or metastasize (spread throughout the body) such as benign lung neoplasm. QY, JX, HY http://en.volupedia.org/wiki/Benign_tumor 良性肺肿瘤 10004280 benign lung neoplasm AE OAE:0008765 This is an AE which is the cessation of breathing. QY, JX, HY http://en.volupedia.org/wiki/Apnea 憋气 10006322 breath holding AE OAE:0008766 This is an AE which is a sleep disorder in which abnormalities in breathing occur during sleep that may or may not be present while awake. QY, JX, HY http://en.volupedia.org/wiki/Sleep-related_breathing_disorder 与呼吸相关的睡眠障碍 10006344 breathing-related sleep disorder AE OAE:0008767 This is an AE which is the partial or complete wasting away of a part of the vocal cord. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 声带萎缩 10050201 vocal cord atrophy AE OAE:0008768 This is an AE which is a pathology affecting the vocal folds (commonly referred to as the vocal cords)characterized by full or partial vocal fold closure causing difficulty and distress during respiration, especially during inhalation. QY, JX, HY http://en.volupedia.org/wiki/Vocal_cord_dysfunction 声带功能障碍 10061581 vocal cord dysfunction AE OAE:0008769 This is an AE which is part of the complex biological response of vocal cord tissues to harmful stimuli. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 声带炎症 10057295 vocal cord inflammation AE OAE:0008770 This is an AE which is an injury to one or both recurrent laryngeal nerves (RLNs), which control all muscles of the larynx except for the cricothyroid muscle. QY, JX, HY http://en.volupedia.org/wiki/Vocal_cord_paresis 声带麻痹 10047674 vocal cord paralysis AE OAE:0008771 This is an AE which is an injury to one or both recurrent laryngeal nerves (RLNs), which control all muscles of the larynx except for the cricothyroid muscle. QY, JX, HY http://en.volupedia.org/wiki/Vocal_cord_paresis 声带麻痹 10049234 vocal cord paresis AE OAE:0008772 This is an AE which is bilaterally symmetrical benign white masses that form at the midpoint of the vocal folds. QY, JX, HY http://en.volupedia.org/wiki/Vocal_cord_nodule 声带息肉 10047675 vocal cord polyp AE OAE:0008773 This is an AE which is an illness caused by an acute bacterial infection, which involves the upper respiratory tract, including the nose, sinuses, pharynx, larynx or trachea. QY, JX, HY http://en.volupedia.org/wiki/Upper_respiratory_tract_infection 上呼吸道细菌性感染 10057868 upper respiratory tract infection bacterial AE OAE:0008774 This is an AE which is part of the complex biological response of body tissues to harmful stimuli such as upper respiratory tract inflammation. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 上呼吸道炎症 10049590 upper respiratory tract inflammation AE OAE:0008775 This is an AE which is a upper respiratory tract state of inflammation or painful reaction to allergy or cell-lining damage. QY, JX, HY http://en.volupedia.org/wiki/Irritation 上呼吸道刺激 10070841 upper respiratory tract irritation AE OAE:0008776 This is an AE which occurs when excessive mucus is produced by the nasal mucosa. QY, JX, HY http://en.volupedia.org/wiki/Post-nasal_drip 上呼吸道咳嗽综合征 10070488 upper-airway cough syndrome AE OAE:0008777 This is an AE which is an illness caused by an acute viral infection, which involves the upper respiratory tract, including the nose, sinuses, pharynx, larynx or trachea. QY, JX, HY http://en.volupedia.org/wiki/Upper_respiratory_tract_infection 病毒性上呼吸道感染 10047482 viral upper respiratory tract infection AE OAE:0008778 This is an AE which is pathological conditions affecting the organs and tissues that make gas exchange difficult in air-breathing animals and is allergic. QY, JX, HY http://en.volupedia.org/wiki/Respiratory_disease 过敏性呼吸道疾病 10063532 allergic respiratory disease AE OAE:0008779 This is an AE which is defined as cessation of breathing with implicit pathophysiology. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23714577/ 呼吸暂停症 10002974 apnoea AE OAE:0008780 This is an AE which is the cessation of breathing on the neonatal. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23714577/ 新生儿呼吸暂停 10002976 apnoea neonatal AE OAE:0008781 This is an AE which is a quarterly peer-reviewed medical journal that covers research in the field of respiratory disease, including chronic obstructive pulmonary disease, respiratory failure, and obstructive sleep apnea. QY, JX, HY http://en.volupedia.org/wiki/Chronic_Respiratory_Disease 慢性呼吸道疾病 10061768 chronic respiratory disease AE OAE:0008782 This is an AE which is a feeling of not being able to breathe well enough at rest. QY, JX, HY http://en.volupedia.org/wiki/Shortness_of_breath 休息时呼吸困难 10013969 dyspnoea at rest AE OAE:0008783 This is an AE which is an attack of severe shortness of breath and coughing that generally occurs at night. QY, JX, HY http://en.volupedia.org/wiki/Paroxysmal_nocturnal_dyspnoea 呼吸困难阵发性夜间 10013974 dyspnoea paroxysmal nocturnal AE OAE:0008784 This is an AE which is overly shallow breathing or an abnormally low respiratory rate. QY, JX, HY http://en.volupedia.org/wiki/Hypopnea 呼吸功能不全 10021079 hypopnoea AE OAE:0008785 This is an AE which is the cessation of breathing on infantile. QY, JX, HY http://en.volupedia.org/wiki/Apnea 小儿呼吸暂停 10077321 infantile apnoea AE OAE:0008786 This is an AE which is a disease in which there is permanent enlargement of parts of the airways of the lung and is infective exacerbation. QY, JX, HY http://en.volupedia.org/wiki/Bronchiectasis 支气管扩张的感染性加重 10070295 infective exacerbation of bronchiectasis AE OAE:0008787 This is an AE which is the medical condition resulting from deprivation of oxygen to a newborn infant that lasts long enough during the birth process to cause physical harm, usually to the brain. QY, JX, HY http://en.volupedia.org/wiki/Perinatal_asphyxia 新生儿窒息 10028923 neonatal asphyxia AE OAE:0008788 This is an AE which associates neonatal case fatality, and morbidity prevalence are high. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21949140/ 新生儿呼吸衰竭 10028970 neonatal respiratory depression AE OAE:0008789 This is an AE which is a syndrome in premature infants caused by developmental insufficiency of pulmonary surfactant production and structural immaturity in the lungs. QY, JX, HY http://en.volupedia.org/wiki/Infant_respiratory_distress_syndrome 新生儿呼吸窘迫综合征 10028974 neonatal respiratory distress syndrome AE OAE:0008790 This is an AE which is a respiratory rate greater than normal at neonatal, resulting in abnormally rapid breathing. QY, JX, HY http://en.volupedia.org/wiki/Tachypnea 新生儿呼吸急促 10057183 neonatal tachypnoea AE OAE:0008791 This is an AE which is a feeling of not being able to breathe well enough on postoperative. QY, JX, HY http://en.volupedia.org/wiki/Shortness_of_breath 术后呼吸窘迫 10054809 postoperative respiratory distress AE OAE:0008792 This is an AE which is a viral respiratory disease of zoonotic origin caused by severe acute respiratory syndrome coronavirus (SARS-CoV or SARS-CoV-1), the first identified strain of the SARS coronavirus species severe acute respiratory syndrome–related coronavirus (SARSr-CoV). QY, JX, HY http://en.volupedia.org/wiki/Severe_acute_respiratory_syndrome 严重急性呼吸综合征 10061982 severe acute respiratory syndrome AE OAE:0008793 This is an AE which is a sleep disorder in which pauses in breathing or periods of shallow breathing during sleep occur more often than normal. QY, JX, HY http://en.volupedia.org/wiki/Sleep_apnea 睡眠呼吸暂停综合征 10040979 sleep apnoea syndrome AE OAE:0008794 This is an AE which is an accumulation of air in the chest causing the lung to separate from the chest wall. QY, JX, HY http://en.volupedia.org/wiki/Collapsed_lung_(disambiguation) 肺萎陷 10009913 collapse of lung AE OAE:0008795 This is an AE which is inflammation of the bronchi fibrinous (large and medium-sized airways) in the lungs that causes coughing. QY, JX, HY http://en.volupedia.org/wiki/Bronchitis 纤维素性支气管炎 10051011 fibrinous bronchitis AE OAE:0008796 This is an AE which is inflammation of the bronchi (large and medium-sized airways) in the lungs that causes coughing and is allergic. QY, JX, HY http://en.volupedia.org/wiki/Bronchitis 过敏性支气管炎 10052613 allergic bronchitis AE OAE:0008797 This is an AE which is a sudden expulsion of air through the large breathing passages that can help clear them of fluids, irritants, foreign particles and microbes and is allergic. QY, JX, HY http://en.volupedia.org/wiki/Cough 过敏性咳嗽 10053779 allergic cough AE OAE:0008798 This is an AE which is a bacterial infection of the trachea and is capable of producing airway obstruction. QY, JX, HY http://en.volupedia.org/wiki/Tracheitis#Bacterial_tracheitis 细菌气管炎 10066798 bacterial tracheitis AE OAE:0008799 This is an AE which is a disease that results in obstruction of the smallest airways of the lungs (bronchioles) due to inflammation. QY, JX, HY http://en.volupedia.org/wiki/Bronchiolitis_obliterans 闭塞性细支气管炎 10029888 obliterative bronchiolitis AE OAE:0008800 This is an AE which is a disease of the lymph nodes at paratracheal, in which they are abnormal in size or consistency. QY, JX, HY http://en.volupedia.org/wiki/Lymphadenopathy 气管旁淋巴结病 10033969 paratracheal lymphadenopathy AE OAE:0008801 This is an AE which is significant both because of the clinical problems that it can create and because its pathogenesis can be defined. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2916958/ 心因性呼吸窘迫 10072630 psychogenic respiratory distress AE OAE:0008802 This is an AE which occurs also during sleep. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23816600/ 呼吸不规则 10076213 irregular breathing AE OAE:0008803 This is an AE which is a deep and labored breathing pattern often associated with severe metabolic acidosis, particularly diabetic ketoacidosis (DKA) but also kidney failure. QY, JX, HY http://en.volupedia.org/wiki/Kussmaul_breathing 库斯莫尔呼吸 10023499 kussmaul respiration AE OAE:0008804 This is an AE which is believed to be caused by retrograde flow of gastric contents (particularly acid and pepsin) that affect pharyngeal and laryngeal mucosa by direct contact or by a secondary mechanism. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23769008/ 反流性喉炎 10067869 reflux laryngitis AE OAE:0008805 This is an AE which is potentially a life-threatening condition with sudden onset and dramatic clinical presentation demanding prompt management and airway preservation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25921270/ 声门下喉炎 10076988 subglottic laryngitis AE OAE:0008806 This is an AE which is an infection caused by the bacterium Corynebacterium diphtheriae. QY, JX, HY http://en.volupedia.org/wiki/Diphtheria 白喉 10013023 diphtheria AE OAE:0008807 This is an AE which is closely related to sighing, and the inhalation characterizing a gasp induced by shock or surprise may be released as a sigh if the event causing the initial emotional reaction is determined to be less shocking or surprising than the observer first believed. QY, JX, HY http://en.volupedia.org/wiki/Paralanguage#Gasps 喘息综合症 10069162 gasping syndrome AE OAE:0008808 This is an AE which is a disease of the hilar lymph nodes, in which they are abnormal in size or consistency. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32771058/ 肺门淋巴结病 10020094 hilar lymphadenopathy AE OAE:0008809 This is an AE which is a rare, progressive illness of the respiratory system, characterized by the thickening and stiffening of lung tissue, associated with the formation of scar tissue. QY, JX, HY http://en.volupedia.org/wiki/Idiopathic_pulmonary_fibrosis 特发性肺纤维化 10021240 idiopathic pulmonary fibrosis AE OAE:0008810 This is an AE which is a heterogeneous group of undifferentiated malignant neoplasms that lack the cytologic and architectural features of small cell carcinoma and glandular or squamous differentiation. QY, JX, HY http://en.volupedia.org/wiki/Large-cell_lung_carcinoma 大细胞肺癌 10023774 large cell lung cancer AE OAE:0008811 This is an AE which is mainly caused by bacteria, group B streptococcus, Escherichia coli and listeria being the most frequently involved; Herpes simplex is the main viral agent. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10223164/ 新生儿肺炎 10053584 neonatal pneumonia AE OAE:0008812 This is an AE which is a category of extrapulmonary, pleural, or parenchymal respiratory diseases that restrict lung expansion, resulting in a decreased lung volume, an increased work of breathing, and inadequate ventilation and/or oxygenation. QY, JX, HY http://en.volupedia.org/wiki/Restrictive_lung_disease 限制性肺病 10048667 restrictive pulmonary disease AE OAE:0008813 This is an AE which is an inflammatory condition caused by varicella zoster of the lung primarily affecting the small air sacs known as alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 水痘带状疱疹肺炎 10074254 varicella zoster pneumonia AE OAE:0008814 This is an AE which is a rare, severe lung disease that usually affects otherwise healthy individuals. QY, JX, HY http://en.volupedia.org/wiki/Acute_interstitial_pneumonitis 急性间质性肺炎 10066728 acute interstitial pneumonitis AE OAE:0008815 This is an AE which is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. QY, JX, HY http://en.volupedia.org/wiki/Acute_respiratory_distress_syndrome 急性肺损伤 10069351 acute lung injury AE OAE:0008816 This is an AE which is a group of diseases that mainly affect the alveoli of the lungs. QY, JX, HY http://en.volupedia.org/wiki/Alveolar_lung_disease 肺泡肺部疾病 10073344 alveolar lung disease AE OAE:0008817 This is an AE which is a rare lung disorder characterized by an abnormal accumulation of surfactant-derived lipoprotein compounds within the alveoli of the lung. QY, JX, HY http://en.volupedia.org/wiki/Pulmonary_alveolar_proteinosis 肺泡蛋白质沉积症 10001881 alveolar proteinosis AE OAE:0008818 This is an AE which is a rare immune system disorder that affects the lungs and is fibrosing. QY, JX, HY http://en.volupedia.org/wiki/Hypersensitivity_pneumonitis 纤维性肺泡炎 10001892 alveolitis fibrosing AE OAE:0008819 This is an AE which is the collapse or closure of a lung resulting in reduced or absent gas exchange at neonatal. QY, JX, HY http://en.volupedia.org/wiki/Atelectasis 新生儿肺不张 10003599 atelectasis neonatal AE OAE:0008820 This is an AE which is an inflammatory condition caused by candida of the lung primarily affecting the small air sacs known as alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pneumonia 念珠菌肺炎 10053158 candida pneumonia AE OAE:0008821 This is an AE which is a surgical procedure in which one or both lungs are replaced by lungs from a donor and after the surgical procedure occurs complications . QY, JX, HY http://en.volupedia.org/wiki/Lung_transplantation#Transplant_requirements 肺移植并发症 10010187 complications of transplanted lung AE OAE:0008822 This is an AE which is an inflammatory condition caused by covid-19 of the lung primarily affecting the small air sacs known as alveoli. QY, JX, HY http://en.volupedia.org/wiki/Pneumonia covid-19肺炎 10084380 covid-19 pneumonia AE OAE:0008823 This is an AE which is a genetic disorder that affects mostly the lungs. QY, JX, HY http://en.volupedia.org/wiki/Cystic_fibrosis 肺囊性纤维化 10011763 cystic fibrosis lung AE OAE:0008824 This is an AE which is a histologic term used to describe specific changes that occur to the structure of the lungs during injury or disease. QY, JX, HY http://en.volupedia.org/wiki/Diffuse_alveolar_damage 弥漫性肺泡损伤 10060902 diffuse alveolar damage AE OAE:0008825 This is an AE which is a lower respiratory tract disease, characterised by air-filled spaces (pneumatoses) in the lung, that can vary in size and may be very large. QY, JX, HY http://en.volupedia.org/wiki/Emphysema 肺气肿 10014561 emphysema AE OAE:0008826 This is an AE which is a disease in which an eosinophil, a type of white blood cell, accumulates in the lungs. QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_pneumonia 嗜酸性肺炎 10014962 eosinophilic pneumonia AE OAE:0008827 This is an AE which is a chronic disease in which an eosinophil, a type of white blood cell, accumulates in the lungs . QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_pneumonia 慢性嗜酸性肺炎 10052833 eosinophilic pneumonia chronic AE OAE:0008828 This is an AE which is tuberculosis (TB) within a location in the body other than the lungs. QY, JX, HY http://en.volupedia.org/wiki/Extrapulmonary_tuberculosis 肺外结核 10064445 extrapulmonary tuberculosis AE OAE:0008829 This is an AE which causes viral pneumonia which can become life-threatening if the virus spreads to the lungs. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32423043/ 肺炎病毒感染 10066226 metapneumovirus infection AE OAE:0008830 This is an AE which is a disease of the lung associated with RA, rheumatoid arthritis. QY, JX, HY http://en.volupedia.org/wiki/Rheumatoid_lung_disease 类风湿肺 10039081 rheumatoid lung AE OAE:0008831 This is an AE which is more common in men than in women and it is closely correlated with a history of tobacco smoking, more so than most other types of lung cancer. QY, JX, HY http://en.volupedia.org/wiki/Non-small-cell_lung_carcinoma#Squamous-cell_lung_carcinoma 肺鳞状细胞癌 10041826 squamous cell carcinoma of lung AE OAE:0008832 This is an AE which is any type of pneumonia not caused by one of the pathogens most commonly associated with the disease. QY, JX, HY http://en.volupedia.org/wiki/Atypical_pneumonia 非典型性肺炎 10003757 atypical pneumonia AE OAE:0008833 This is an AE which is damage to the spinal cord that causes temporary or permanent changes in its function. QY, JX, HY http://en.volupedia.org/wiki/Spinal_cord_injury 脊髓损伤胸 10041558 spinal cord injury thoracic AE OAE:0008834 This is an AE which is a long flat bone located in the central part of the chest is injury. QY, JX, HY http://en.volupedia.org/wiki/Sternum 胸骨损伤 10056287 sternal injury AE OAE:0008835 This is an AE which is one the most common extrapulmonary tuberculosis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32501259/ 结核性胸膜炎 10045104 tuberculous pleurisy AE OAE:0008836 This is an AE which is a vaso-occlusive crisis of the pulmonary vasculature commonly seen in people with sickle cell anemia. QY, JX, HY http://en.volupedia.org/wiki/Acute_chest_syndrome 急性胸部综合症 10051895 acute chest syndrome AE OAE:0008837 This is an AE which generally refers to a broad, deep chest found on a patient. QY, JX, HY http://en.volupedia.org/wiki/Barrel_chest 桶状胸 10004133 barrel chest AE OAE:0008838 This is an AE which is a major abnormality in the shape of a body part or organ compared to the normal shape of that part such as thorax part. QY, JX, HY http://en.volupedia.org/wiki/Deformity 畸形胸 10061810 deformity thorax AE OAE:0008839 This is an AE which is a life-threatening medical condition that occurs when a segment of the rib cage breaks due to trauma and becomes detached from the rest of the chest wall. QY, JX, HY http://en.volupedia.org/wiki/Flail_chest 连枷胸 10016747 flail chest AE OAE:0008840 This is an AE which is an accumulation of blood within the pleural cavity. QY, JX, HY http://en.volupedia.org/wiki/Hemothorax 血胸 10019027 haemothorax AE OAE:0008841 This is an AE which is accumulation of excessive fluid in the pleural space, the potential space that surrounds each lung. QY, JX, HY http://en.volupedia.org/wiki/Pleural_effusion#Transudative 胸膜积水 10048612 hydrothorax AE OAE:0008842 This is an AE which is accumulation of excessive fluid in the pleural space, the potential space that surrounds each lung and is infectious. QY, JX, HY http://en.volupedia.org/wiki/Pleural_effusion 传染性胸膜积液 10071699 infectious pleural effusion AE OAE:0008843 This is an AE which is a structural deformity of the anterior thoracic wall in which the sternum and rib cage are shaped abnormally. QY, JX, HY http://en.volupedia.org/wiki/Pectus_excavatum 漏斗胸 10034204 pectus excavatum AE OAE:0008844 This is an AE which is a collection of pus in the pleural cavity caused by microorganisms, usually bacteria. QY, JX, HY http://en.volupedia.org/wiki/Pleural_empyema 胸膜积脓 10037658 pyothorax AE OAE:0008845 This is an AE which is a rare and potentially limb- and life-threatening injury, that results from high-energy trauma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31046412/ 肩胸分离 10070073 scapulothoracic dissociation AE OAE:0008846 This is an AE which is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators (inhalers) and corticosteroids. QY, JX, HY http://en.volupedia.org/wiki/Acute_severe_asthma 哮喘持续状态 10041961 status asthmaticus AE OAE:0008847 This is an AE which is a long-term inflammatory disease of the airways of the lungs and is crisis. QY, JX, HY http://en.volupedia.org/wiki/Asthma 哮喘危机 10064823 asthmatic crisis AE OAE:0008848 This is an AE which occurs when breathing is impeded by a constricted or obstructed throat or windpipe. QY, JX, HY http://en.volupedia.org/wiki/Choking 气哽 10008590 choking sensation AE OAE:0008849 This is an AE which is a feeling of deficient supply of oxygen to the body that arises from abnormal breathing. QY, JX, HY http://en.volupedia.org/wiki/Asphyxia 窒息感 10042444 suffocation feeling AE OAE:0008850 This is an AE which is a blockage of respiration in the airway that hinders the free flow of air and is reversible. QY, JX, HY http://en.volupedia.org/wiki/Airway_obstruction 可逆性气道阻塞 10062109 reversible airways obstruction AE OAE:0008851 This is an AE which is the vibration of respiratory structures and the resulting sound due to obstructed air movement during breathing while sleeping. QY, JX, HY http://en.volupedia.org/wiki/Snoring 打鼾 10041235 snoring AE OAE:0008852 This is an AE which is a type of respiratory infection that is usually caused by a virus. QY, JX, HY http://en.volupedia.org/wiki/Croup 危重疾病 10077264 critical illness AE OAE:0008853 QY, JX, HY 肺门增大 10065291 pulmonary hilar enlargement AE OAE:0008854 QY, JX, HY 肺低通货膨胀 10076905 lung hypoinflation AE OAE:0008855 QY, JX, HY 肺浑浊 10081792 lung opacity AE OAE:0008856 QY, JX, HY 喉部肿块 10057439 laryngeal mass AE OAE:0008857 QY, JX, HY 支气管肺的疾病 10053420 bronchopulmonary disease AE OAE:0008858 QY, JX, HY 声带障碍 10061581 vocal cord disorder AE OAE:0008859 QY, JX, HY 呼吸暂停发作 10002977 apnoeic attack AE OAE:0008860 QY, JX, HY 婴儿呼吸暂停发作 10065422 infantile apnoeic attack AE OAE:0008861 QY, JX, HY 新生儿呼吸暂停发作 10028922 neonatal apnoeic attack AE OAE:0008862 QY, JX, HY 副鼻窦支气管炎 10048979 sinobronchitis AE OAE:0008863 This is an AE which is a chronic, inflammatory skin disease of unknown cause which can affect any body part of any person but has a strong preference for the genitals (penis, vulva) and is also known as balanitis xerotica obliterans (BXO) when it affects the penis. QY, JX, HY http://en.volupedia.org/wiki/Lichen_sclerosus 硬化性苔癣 10024434 lichen sclerosus AE OAE:0008864 This is an AE which is the most common demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged and it has plaque. QY, JX, HY http://en.volupedia.org/wiki/Multiple_sclerosis 多发性硬化斑块 10078558 multiple sclerosis plaque AE OAE:0008865 This is an AE which is a neuropathological condition with severe neuronal cell loss and gliosis in the hippocampus, specifically in the CA-1 (Cornu Ammonis area 1) and subiculum of the hippocampus. QY, JX, HY http://en.volupedia.org/wiki/Hippocampal_sclerosis 海马硬化 10063629 hippocampal sclerosis AE OAE:0008866 This is an AE which is a form of Hodgkin's lymphoma that is the most common subtype of HL in developed countries. QY, JX, HY http://en.volupedia.org/wiki/Nodular_sclerosis 霍奇金氏病结节性硬化 10020244 hodgkin's disease nodular sclerosis AE OAE:0008867 This is an AE which is a genetic multisystem disorder characterised by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18722871/ 结节性硬化症 10045138 tuberous sclerosis AE OAE:0008868 This is an AE which refers epidermal thickening characterized by visible and palpable thickening of the skin with accentuated skin markings. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 苔藓样硬化 10024438 lichenification AE OAE:0008869 This is an AE which is a disease in which the white matter of the brain appears damaged in concentric layers, leaving the axis cylinder intact. QY, JX, HY http://en.volupedia.org/wiki/Balo_concentric_sclerosis 向心性硬化 10010252 concentric sclerosis AE OAE:0008870 This is an AE which is dermal thickening causing the cutaneous surface to feel thicker and firmer. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 硬化 10060708 induration AE OAE:0008871 This ia an AE which is a eyelid skin condition characterized by excessively dry skin. QY, JX, HY http://en.volupedia.org/wiki/Xeroderma 眼睑皮肤干燥 10071717 eyelid skin dryness AE OAE:0008872 This is an AE which pressure is placed on the skin, the skin is damaged and is unable to be repaired due to the lack of blood perfusing the tissue. QY, JX, HY http://en.volupedia.org/wiki/Arterial_insufficiency_ulcer 缺血性皮肤溃疡 10077408 ischemic skin ulcer AE OAE:0008873 This is an AE which is the condition of dissimilar particles or surfaces to cling to one another on the skin. QY, JX, HY http://en.volupedia.org/wiki/Adhesion 皮肤粘连 10074976 skin adhesion AE OAE:0008874 This is an AE which is a skin condition present at birth regardless of its cause. QY, JX, HY http://en.volupedia.org/wiki/Birth_defect 先天性皮肤病 10067769 congenital skin disorder AE OAE:0008875 This is an AE which is a small elevation of the skin containing cloudy or purulent material (pus) usually consisting of necrotic inflammatory cells. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Pustule 脓包 10037578 pustule AE OAE:0008876 This is an AE which is an enlargement of skin tissue caused by an increase in the amount of organic tissue that results from cell proliferation. QY, JX, HY http://en.volupedia.org/wiki/Hyperplasia 皮肤增生 10074507 skin hyperplasia AE OAE:0008877 This is an AE which is the degeneration of skin tissue, due to disease or malnutrition, most likely due to heredity. QY, JX, HY http://en.volupedia.org/wiki/Dystrophy 皮肤营养不良 10040836 skin dystrophy AE OAE:0008878 This is an Ae which is the increase in the volume of skin tissue due to the enlargement of its component cells. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophy 皮肤肥大 10040867 skin hypertrophy AE OAE:0008879 This is an AE which is the result of a continuous process based on degenerative skin cell changes, affecting tissues or organs, which will increasingly deteriorate over time. QY, JX, HY http://en.volupedia.org/wiki/Degenerative_disease 皮肤退化性疾病 10061531 skin degenerative disorder AE OAE:0008880 This is an AE which is underdevelopment or incomplete development of a skin tissue . QY, JX, HY http://en.volupedia.org/wiki/Hypoplasia 皮肤发育不良 10040869 skin hypoplasia AE OAE:0008881 This is an AE which is a mass of cells that lacks the ability to either invade neighboring tissue or metastasize and occurs on the skin. QY, JX, HY http://en.volupedia.org/wiki/Benign_tumor 皮肤良性肿瘤 10004398 benign neoplasm of skin AE OAE:0008882 This is an AE which is a small cutaneous depressions that can be noted on any part of the body and may be caused by traumatic, mechanical, metabolic, and genetic factors as well as by exposure to infections or drugs. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31602696/ 先天性皮肤酒窝 10072978 congenital skin dimples AE OAE:0008883 This is an AE which may present as either a superficial or deep infection of the skin, hair, and/or nails. QY, JX, HY http://en.volupedia.org/wiki/Skin_infection 真菌性皮肤感染 10017543 fungal skin infection AE OAE:0008884 This is an AE which is the most frequent and potentially fatal complication of an allogeneic hematopoietic progenitor cell transplantation on the skin. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30309668/ 皮肤移植抗宿主病 10064675 graft versus host disease in skin AE OAE:0008885 This is an AE which is a heterogeneous group of diseases, characterized by a skin inflammatory reaction triggered by a wide variety of stimuli, including infections, foreign bodies, malignancy, metabolites, and chemicals. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29352388/ 皮肤肉芽肿 10018698 granuloma skin AE OAE:0008886 This is an AE which is a usually benign vascular skin tumor derived from blood vessel cell types. QY, JX, HY http://en.volupedia.org/wiki/Hemangioma 皮肤血管瘤 10018823 haemangioma of skin AE OAE:0008887 This is an AE which is a sore on the skin or a mucous membrane, accompanied by the disintegration of tissue. QY, JX, HY http://en.volupedia.org/wiki/Ulcer_(dermatology) 感染性皮肤溃疡 10021784 infected skin ulcer AE OAE:0008888 This is an AE which is a type of abnormal and excessive growth of skin tissue . QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 肿瘤皮肤 10029098 neoplasm skin AE OAE:0008889 This is an AE which is skin neoplasms that arise from cells of the endocrine and nervous systems . QY, JX, HY http://en.volupedia.org/wiki/Neuroendocrine_tumor 皮肤神经内分泌肿瘤 10029266 neuroendocrine carcinoma of the skin AE OAE:0008890 This is an AE which refers to skin lesions with a degree of risk of progression to squamous cell carcinoma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/27658688/ 癌前皮肤病变 10049422 precancerous skin lesion AE OAE:0008891 This is an AE which is most commonly caused by infection by the bacterium Staphylococcus aureus, resulting in a painful swollen area on the skin caused by an accumulation of pus and dead tissue，meantime it often recurs. QY, JX, HY http://en.volupedia.org/wiki/Boil 复发性皮肤疖子 10038143 recurring skin boils AE OAE:0008892 This is an AE which is a skin condition in which skin is prone to itching and irritation experienced as a subjective sensation when using cosmetics and toiletries. QY, JX, HY http://en.volupedia.org/wiki/Sensitive_skin 敏感型皮肤 10081765 sensitive skin AE OAE:0008893 This is an AE which bacterial skin infections include Cellulitis, Erysipelas,Folliculitis and Impetigo. QY, JX, HY http://en.volupedia.org/wiki/Skin_infection 皮肤细菌感染 10052891 skin bacterial infection AE OAE:0008894 This is an AE which is kind of cancers that arise from the skin and they are due to the development of abnormal cells that have the ability to invade or spread to other parts of the body. QY, JX, HY http://en.volupedia.org/wiki/Skin_cancer 皮肤癌 10040808 skin cancer AE OAE:0008895 This is an AE which is located on most of mucosal surfaces and mainly the skin and candida are almost universal in low numbers on healthy adult skin. QY, JX, HY http://en.volupedia.org/wiki/Candida_(fungus) 皮肤念珠菌 10054152 skin candida AE OAE:0008896 This is an AE which is defined as necrotic lesions that should have required additional resection after breast reconstruction. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30426185/ 皮瓣坏死 10068774 skin flap necrosis AE OAE:0008897 This is an AE which is a cutaneous condition characterized by trauma-induced blisters and erosions. QY, JX, HY http://en.volupedia.org/wiki/Skin_fragility_syndrome 皮肤脆弱症 10040851 skin fragility AE OAE:0008898 This is an AE which refers to cause an indentation in the skin. QY, JX, HY http://en.volupedia.org/wiki/Wedding_ring 皮肤压痕 10079274 skin indentation AE OAE:0008899 This is an AE which is part of the complex biological response of skin tissues to harmful stimuli, such as pathogens, damaged cells, or irritants,and is a protective response involving immune cells, blood vessels, and molecular mediators. QY, JX, HY http://en.volupedia.org/wiki/Inflammation 皮肤炎症 10062249 skin inflammation AE OAE:0008900 This is an AE which specifically refers to a sharp injury which damages the dermis of the skin in pathology. QY, JX, HY http://en.volupedia.org/wiki/Injury 皮肤损伤 10061364 skin injury AE OAE:0008901 This is an AE which is defined as the softening and breaking down of skin resulting from prolonged exposure to moisture. QY, JX, HY http://en.volupedia.org/wiki/Skin_maceration 皮肤浸渍 10048625 skin maceration AE OAE:0008902 This is an AE which is an area of edema of the lower layer of skin under the skin. QY, JX, HY http://en.volupedia.org/wiki/Angioedema 皮肤水肿 10058679 skin edema AE OAE:0008903 This is an AE which has been described as a broad papule, or confluence of papules equal to or greater than 10 mm, or alternatively as an elevated, plateau-like lesion that is greater in its diameter than in its depth on the skin. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Primary_lesions 皮肤斑 10067723 skin plaque AE OAE:0008904 This is an AE which specifically refers to a sharp injury which damages the epidermis of the skin in pathology . QY, JX, HY http://en.volupedia.org/wiki/Wound 皮肤伤口 10072170 skin wound AE OAE:0008905 This is an AE which is a rare genetic condition characterized by sagging, wrinkled skin, low skin elasticity, and delayed fontanel (soft spot) closure along with a range of other symptoms. QY, JX, HY http://en.volupedia.org/wiki/Wrinkly_skin_syndrome 皮肤皱纹 10040954 skin wrinkling AE OAE:0008906 This is an AE which comprises a number of different types of cancer that result from squamous cells that form on the surface of the skin. QY, JX, HY http://en.volupedia.org/wiki/Squamous_cell_carcinoma 皮肤鳞状细胞癌 10041834 squamous cell carcinoma of skin AE OAE:0008907 This is an AE which is a dermatological condition caused by Staphylococcus aureus. QY, JX, HY http://en.volupedia.org/wiki/Staphylococcal_scalded_skin_syndrome 葡萄球菌性烫伤样皮肤综合征 10041929 staphylococcal scalded skin syndrome AE OAE:0008908 This is an AE which is an skin infection caused by members of the Staphylococcus genus of bacteria . QY, JX, HY http://en.volupedia.org/wiki/Staphylococcal_infection 葡萄球菌皮肤感染 10066409 staphylococcal skin infection AE OAE:0008909 This is an AE which is a popular name for an alleged ability of some people to attract objects to their skin. QY, JX, HY http://en.volupedia.org/wiki/Human_magnetism 粘性皮肤 10051788 sticky skin AE OAE:0008910 This is an AE which is a rash with central clearing in dermatology . QY, JX, HY http://en.volupedia.org/wiki/Target_lesion 皮肤靶样病变 10081998 target skin lesion AE OAE:0008911 This is an AE which refers to Virus-related cutaneous conditions caused by these obligate intracellular agents derive from both DNA and RNA viruses. QY, JX, HY http://en.volupedia.org/wiki/Skin_infection 病毒性皮肤感染 10065173 viral skin infection AE OAE:0008912 This is an AE which is a yellowish or greenish pigmentation of the skin and whites of the eyes due to high bilirubin levels. QY, JX, HY http://en.volupedia.org/wiki/Jaundice 黄疸 10048245 yellow skin AE OAE:0008913 This is an AE which is the loss of intercellular connections, such as desmosomes, resulting in loss of cohesion between keratinocytes, seen in diseases such as pemphigus vulgaris. QY, JX, HY http://en.volupedia.org/wiki/Acantholysis 皮肤棘层松解 10058820 acantholysis AE OAE:0008914 This is an AE which is a skin neoplasm composed of squamous or epidermal cells. QY, JX, HY http://en.volupedia.org/wiki/Acanthoma 棘皮瘤 10059394 acanthoma AE OAE:0008915 This is an AE which is diffuse epidermal hyperplasia (thickening of the skin, and not to be confused with acanthocytes). QY, JX, HY http://en.volupedia.org/wiki/Epidermis#Hyperplasia 棘皮症 10000349 acanthosis AE OAE:0008916 This ia an AE which is a childhood form of dermatitis selectively affecting the hands and feet and may be accompanied by mild symptoms of fever and malaise. QY, JX, HY http://en.volupedia.org/wiki/Acrodermatitis 螨性皮炎 10063409 acarodermatitis AE OAE:0008917 This is an AE which is a highly inflammatory disease presenting with comedones, nodules, abscesses, and draining sinus tracts. QY, JX, HY http://en.volupedia.org/wiki/Acne_conglobata 聚合型痤疮 10000501 acne conglobata AE OAE:0008918 This ia an AE which refers an inflammatory nodule with or without an associated epidermoid inclusion cyst. QY, JX, HY http://en.volupedia.org/wiki/Cyst 囊性痤疮 10000503 acne cystic AE OAE:0008919 This is an AE which is a form of acneiform eruption that occurs in infants from 6 weeks to 1 year of age. QY, JX, HY http://en.volupedia.org/wiki/Infantile_acne 婴儿痤疮 10000507 acne infantile AE OAE:0008920 This is an AE which is a long-term skin condition with pustular that occurs when dead skin cells and oil from the skin clog hair follicles. QY, JX, HY http://en.volupedia.org/wiki/Acne 脓疱性痤疮 10000513 acne pustular AE OAE:0008921 This is an AE which is a rare condition consisting of follicular vesicopustules, sometimes occurring as solitary lesions that are usually very itchy. QY, JX, HY http://en.volupedia.org/wiki/Acne_miliaris_necrotica 痘疱样痤疮 10000518 acne varioliformis AE OAE:0008922 This is an AE which is a chronic subepidermal blistering disease associated with autoimmunity to type VII collagen within anchoring fibril structures that are located at the dermoepidermal junction. QY, JX, HY http://en.volupedia.org/wiki/Epidermolysis_bullosa_acquisita 后天性大疱性表皮松解 10056508 acquired epidermolysis bullosa AE OAE:0008923 This is an AE which is a childhood form of dermatitis selectively affecting the hands and feet and may be accompanied by mild symptoms of fever and malaise. QY, JX, HY http://en.volupedia.org/wiki/Acrodermatitis 肢皮炎 10000593 acrodermatitis AE OAE:0008924 This is an AE which is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. QY, JX, HY http://en.volupedia.org/wiki/Acrodermatitis_chronica_atrophicans 慢性萎缩性肢皮炎 10000594 acrodermatitis chronica atrophicans AE OAE:0008925 This is an AE which is a skin disease characterized by the sudden onset of fever, an elevated white blood cell count, and tender, red, well-demarcated papules and plaques that show dense infiltrates by neutrophil granulocytes on histologic examination. QY, JX, HY http://en.volupedia.org/wiki/Febrile_neutrophilic_dermatosis 急性发热性中性粒细胞性皮肤病 10000748 acute febrile neutrophilic dermatosis AE OAE:0008926 This is an AE which is a change of the application site skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 用药部位皮疹 10003054 application site rash AE OAE:0008927 This is an AE which is a rare, cutaneous condition that causes dermal atrophy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30085611/ 帕西尼和皮耶尼氏萎缩皮病 10066406 atrophoderma of pasini and pierini AE OAE:0008928 This is an AE which is the partial or complete wasting away of a part of the body. QY, JX, HY http://en.volupedia.org/wiki/Atrophy 萎缩 10003694 atrophy AE OAE:0008929 This is an AE which is inflammation of the skin, typically characterized by itchiness, redness and a rash and it is autoimmune. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 自身免疫性皮炎 10075689 autoimmune dermatitis AE OAE:0008930 This is an AE which induced by heparin is a rare and benign side effect . QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32005507/ 大疱性出血性皮肤病 10083809 bullous haemorrhagic dermatosis AE OAE:0008931 This is an AE which is an cryptococcal infection of the skin in humans and other animals, that can also affect the associated soft tissues such as loose connective tissue and mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Skin_infection 隐球菌皮肤感染 10054216 cryptococcal cutaneous infection AE OAE:0008932 This is an AE which is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. QY, JX, HY http://en.volupedia.org/wiki/Lupus_erythematosus 皮肤红斑狼疮 10056509 cutaneous lupus erythematosus AE OAE:0008933 This is an AE which is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomata. QY, JX, HY http://en.volupedia.org/wiki/Sarcoidosis 皮肤结节病 10011674 cutaneous sarcoidosis AE OAE:0008934 This is an AE which is the layer of usually soft, flexible outer tissue covering the body of a vertebrate animal, with three main functions: protection, regulation, and sensation. QY, JX, HY http://en.volupedia.org/wiki/Skin 皮肤的症状 10075531 cutaneous symptom AE OAE:0008935 This is an AE which is a group of rare connective tissue disorders in which the skin becomes inelastic and hangs loosely in folds. QY, JX, HY http://en.volupedia.org/wiki/Cutis_laxa 皮肤松弛 10011692 cutis laxa AE OAE:0008936 This is an AE which is a skin condition of the posterior neck, characterized by deep furrowing of the skin. QY, JX, HY http://en.volupedia.org/wiki/Cutis_rhomboidalis_nuchae 菱形皮肤 10059441 cutis rhomboidalis nuchae AE OAE:0008937 This is an AE which is a generalized bluish discoloration of the body and the visible mucous membranes, which occurs due to inadequate oxygenation secondary to conditions that lead to an increase in deoxygenated hemoglobin or presence of abnormal hemoglobin. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32644593/ 中枢性紫绀 10011704 cyanosis central AE OAE:0008938 This is an AE which is the change of neonatal body tissue color to a bluish-purple hue as a result of having decreased amounts of oxygen bound to the hemoglobin in the red blood cells of the capillary bed. QY, JX, HY http://en.volupedia.org/wiki/Cyanosis 新生儿紫绀 10011705 cyanosis neonatal AE OAE:0008939 This is an AE which is a closed dermal sac, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 真皮囊肿 10012426 dermal cyst AE OAE:0008940 This is an AE which is a sac or cavity in any organ or tissue, or an abnormal cavity or passage caused by the destruction of tissue. QY, JX, HY http://en.volupedia.org/wiki/Sinus_(anatomy) 皮肤窦 10012428 dermal sinus AE OAE:0008941 This is an AE which is a rare disease that seldom affects the genitals. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29463978/ 皮肤病 10065701 dermatillomania AE OAE:0008942 This is an AE which is a chronic inflammatory skin disease that is characterised by intense itching and recurrent eczematous lesions. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26377142/ 过敏性皮炎 10012434 dermatitis allergic AE OAE:0008943 This is an AE which is a long-term type of inflammation of the skin (dermatitis). QY, JX, HY http://en.volupedia.org/wiki/Atopic_dermatitis 特应性皮炎 10012438 dermatitis atopic AE OAE:0008944 This is an AE which is a type of inflammation of the skin. QY, JX, HY http://en.volupedia.org/wiki/Contact_dermatitis 接触性皮炎 10012442 dermatitis contact AE OAE:0008945 This is an AE which is one of the most common skin conditions that infants suffer from and their caregivers manage in the first months post-birth. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29596731/ 皮炎尿布 10012444 dermatitis diaper AE OAE:0008946 This is an AE which is an uncommon but serious skin disorder that family physicians must be able to recognize and treat appropriately. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10029788/ 皮炎剥脱性全身性 10012456 dermatitis exfoliative generalised AE OAE:0008947 This is an AE which is a chronic autoimmune blistering skin condition, characterised by intensely itchy blisters filled with a watery fluid. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis_herpetiformis 疱疹样皮炎 10012468 dermatitis herpetiformis AE OAE:0008948 This is an AE which is inflammation of the skin, typically characterized by itchiness, redness and a rash and is infected. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 皮炎感染 10012470 dermatitis infected AE OAE:0008949 This is an AE which is inflammation with psoriasiform of the skin, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 银屑病形皮炎 10058675 dermatitis psoriasiform AE OAE:0008950 This is an AE which is a medical condition, defined as an excess of skin in the upper or lower eyelid. QY, JX, HY http://en.volupedia.org/wiki/Dermatochalasis 皮肤松垂 10012493 dermatochalasis AE OAE:0008951 This is an AE which is a rare locally aggressive malignant cutaneous soft-tissue sarcoma. QY, JX, HY http://en.volupedia.org/wiki/Dermatofibrosarcoma_protuberans 皮肤纤维肉瘤 10057043 dermatofibrosarcoma AE OAE:0008952 This is an AE which is a rare locally aggressive malignant cutaneous soft-tissue sarcoma. QY, JX, HY http://en.volupedia.org/wiki/Dermatofibrosarcoma_protuberans 隆凸性皮肤纤维肉瘤 10057043 dermatofibrosarcoma protuberans AE OAE:0008953 This is an AE which refers to the making of naturally occurring ridges on certain body parts, namely palms, fingers, soles, and toes and it is anomal. QY, JX, HY http://en.volupedia.org/wiki/Dermatoglyphics 皮肤多态异常 10061455 dermatoglyphic anomaly AE OAE:0008954 This is an AE which is lymph node pathology due to skin disease. QY, JX, HY http://en.volupedia.org/wiki/Dermatopathic_lymphadenopathy 皮肤淋巴结病 10074339 dermatopathic lymphadenopathy AE OAE:0008955 This is an AE which has diffuse involvement in which the entire integument may be thickened and infiltrated with mast cells to produce a peculiar orange color, giving rise to the term "homme orange." QY, JX, HY http://en.volupedia.org/wiki/Mastocytosis#Classification 弥漫性皮肤肥大细胞增多症 10012812 diffuse cutaneous mastocytosis AE OAE:0008956 This is an AE which is any medical condition that affects the integumentary system—the organ system that encloses the body and includes skin, hair, nails, and related muscle and glands. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition 皮肤病 10048768 dermatosis AE OAE:0008957 This is an AE which is a teratoma of a cystic nature that contains an array of developmentally mature, solid tissues. QY, JX, HY http://en.volupedia.org/wiki/Dermoid_cyst 皮样囊肿 10012522 dermoid cyst AE OAE:0008958 This is an AE which refers a neurophysiologic factor in functional disorders. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/4231964/ 皮层运动区活动障碍 10065699 dysponesis AE OAE:0008959 This is an AE which is the enlargement and hardening of limbs or body parts due to tissue swelling. QY, JX, HY http://en.volupedia.org/wiki/Elephantiasis 象皮病 10014472 elephantiasis AE OAE:0008960 This is an AE which is a iatrogenic cutaneous reaction that occurs immediately after a drug injection. QY, JX, HY http://en.volupedia.org/wiki/Livedoid_dermatitis 药物性皮肤栓塞 10058729 embolia cutis medicamentosa AE OAE:0008961 This is an AE which refers a punctate or linear abrasion produced by mechanical means (often scratching), usually involving only the epidermis, but commonly reaching the papillary dermis. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 表皮脱落 10049796 excoriation AE OAE:0008962 This is an AE which is a change of the human skin which affects its color, appearance, or texture and is exfoliative. QY, JX, HY http://en.volupedia.org/wiki/Rash 表皮剥脱的皮疹 10064579 exfoliative rash AE OAE:0008963 This is an AE which is immune-mediated inflammation of the skin, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 免疫介导性皮炎 10083156 immune-mediated dermatitis AE OAE:0008964 This is an AE which refers a punctate or linear abrasion produced by mechanical means (often scratching), usually involving only the mucosal epidermis, but commonly reaching the papillary dermis. QY, JX, HY http://en.volupedia.org/wiki/Skin_condition#Secondary_lesions 粘膜表皮脱落 10059490 mucosal excoriation AE OAE:0008965 This is an AE which is a change of the incision site skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 切口部位皮疹 10073411 incision site rash AE OAE:0008966 This is an AE which is an immune disorder of T cells, it is characterized by chronic infections with Candida that are limited to mucosal surfaces, skin, and nails. QY, JX, HY http://en.volupedia.org/wiki/Chronic_mucocutaneous_candidiasis 黏膜与皮肤的念珠菌病 10028080 mucocutaneous candidiasis AE OAE:0008967 This is an AE which is blood escaping from the circulatory system from damaged mucocutaneous blood vessels. QY, JX, HY http://en.volupedia.org/wiki/Bleeding 黏膜与皮肤的出血 10076048 mucocutaneous hemorrhage AE OAE:0008968 This is an AE which is a change of the mucocutaneous skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 黏膜与皮肤的皮疹 10056671 mucocutaneous rash AE OAE:0008969 This is an AE which is an inflammatory skin condition related to Sweet syndrome that responds to corticosteroids. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28941785/ 中性皮肤病 10058105 neutrophilic dermatosis AE OAE:0008970 This is an AE which is a change of the nodular skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 结节性皮疹 10075807 nodular rash AE OAE:0008971 This is an AE which refers a small spherical group of cells containing a cavity on the skin. QY, JX, HY http://en.volupedia.org/wiki/Follicle 皮疹滤泡 10037857 rash follicular AE OAE:0008972 This is an AE which is a change of the neonatal skin which affects its color, appearance, or texture. QY, JX, HY http://en.volupedia.org/wiki/Rash 新生儿皮疹 10037871 rash neonatal AE OAE:0008973 This is an AE which is a condition which presents with both papules and scales, or both scaly papules and plaques. QY, JX, HY http://en.volupedia.org/wiki/Papulosquamous_disorder 皮疹丘疹鳞状 10037879 rash papulosquamous AE OAE:0008974 This is an AE which is a disease resulting from a group A streptococcus (group A strep) infection. QY, JX, HY http://en.volupedia.org/wiki/Scarlet_fever 猩红热皮疹 10037890 rash scarlatiniform AE OAE:0008975 This is an AE which is inflammation of the vaccination site skin, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 接种部位皮炎 10069477 vaccination site dermatitis AE OAE:0008976 This is an AE which is an acute, often fatal, thrombotic disorder which manifests as blood spots, bruising and discolouration of the skin resulting from coagulation in small blood vessels within the skin and rapidly leads to skin necrosis and disseminated intravascular coagulation. QY, JX, HY http://en.volupedia.org/wiki/Purpura_fulminans 暴发性紫癜 10037556 purpura fulminans AE OAE:0008977 This is an AE which is a neonatal condition of red or purple discolored spots on the skin that do not blanch on applying pressure. QY, JX, HY http://en.volupedia.org/wiki/Purpura 新生儿紫癜 10037557 purpura neonatal AE OAE:0008978 This is an AE which is a characterized of henoch-Schonlein purpura (HSP). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30428889/ 非血小板减少性紫癜 10057739 purpura non-thrombocytopenic AE OAE:0008979 This is an AE which commonly refers to flaking (or scaling) of the skin. QY, JX, HY http://en.volupedia.org/wiki/Pityriasis 蛇皮癣 10035110 pityriasis AE OAE:0008980 This is an AE which is a disease of the immune system and is the more severe version of pityriasis lichenoides chronica. QY, JX, HY http://en.volupedia.org/wiki/Pityriasis_lichenoides_et_varioliformis_acuta 地衣糠秕孢子虫病 10048895 pityriasis lichenoides et varioliformis acuta AE OAE:0008981 This is an AE which is a type of skin rash. QY, JX, HY http://en.volupedia.org/wiki/Pityriasis_rosea 玫瑰糠疹 10035114 pityriasis rosea AE OAE:0008982 This is an AE which refers to a group of chronic disorders characterized by reddish orange, scaling plaques and keratotic follicular papules. QY, JX, HY http://en.volupedia.org/wiki/Pityriasis_rubra_pilaris 毛发红糠疹 10035116 pityriasis rubra pilaris AE OAE:0008983 This is an AE which is a type of melanocytic tumor that contains nevus cells. QY, JX, HY http://en.volupedia.org/wiki/Melanocytic_nevus 黑素细胞痣 10027145 melanocytic naevus AE OAE:0008984 This is an AE which is a genus of two species of white rot poroid fungi in the family Polyporaceae. QY, JX, HY http://en.volupedia.org/wiki/Melanoderma 黑皮病 10027146 melanoderma AE OAE:0008985 This is an AE which correspond to epidermal hypermelanocytosis (an increased number of melanocytes) or epidermal hypermelanosis (an increase in the quantity of melanin in the epidermis with no modification of the number of melanocytes). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23260521/ 白斑病 10027147 melanodermia AE OAE:0008986 This is an AE which is a form of hyperpigmentation associated with increased melanin. QY, JX, HY http://en.volupedia.org/wiki/Melanosis 黑变病 10027157 melanosis AE OAE:0008987 This is an AE which is a skin condition caused by long-term exposure to heat (infrared radiation). QY, JX, HY http://en.volupedia.org/wiki/Erythema_ab_igne 火激红斑 10015152 erythema ab igne AE OAE:0008988 This is an AE which is a descriptive term for a class of skin lesion presenting redness (erythema) in a ring form (anulare) that spreads from a center (centrifugum). QY, JX, HY http://en.volupedia.org/wiki/Erythema_annulare_centrifugum 环形红斑 10015153 erythema annulare AE OAE:0008989 This is an AE which is a form of vasculitis and has been described as a paraneoplastic syndrome. QY, JX, HY http://en.volupedia.org/wiki/Erythema_elevatum_diutinum 持久性隆起性红斑 10056968 erythema elevatum diutinum AE OAE:0008990 This is an AE which is a panniculitis on the calves and it occurs mainly in women, but it is very rare now. QY, JX, HY http://en.volupedia.org/wiki/Erythema_induratum 硬结性红斑 10015213 erythema induratum AE OAE:0008991 This is an AE which is one of several possible manifestations of infection by parvovirus B19. QY, JX, HY http://en.volupedia.org/wiki/Fifth_disease 传染性红斑 10015214 erythema infectiosum AE OAE:0008992 This is an AE which is a type of erythema (redness of the skin or mucous membranes) involving pink rings on the torso and inner surfaces of the limbs which come and go for as long as several months. QY, JX, HY http://en.volupedia.org/wiki/Erythema_marginatum 边缘性红斑 10015216 erythema marginatum AE OAE:0008993 This is an AE which is an expanding rash often seen in the early stage of Lyme disease, and can also (but less commonly) be caused by southern tick-associated rash illness (STARI). QY, JX, HY http://en.volupedia.org/wiki/Erythema_migrans 游走性红斑 10062488 erythema migrans AE OAE:0008994 This is an AE which is a common, non-threatening rash in newborns. QY, JX, HY http://en.volupedia.org/wiki/Erythema_toxicum_neonatorum 新生儿中毒性红斑 10056274 erythema toxicum neonatorum AE OAE:0008995 This is an AE which is a superficial skin infection that causes brown, scaly skin patches. QY, JX, HY http://en.volupedia.org/wiki/Erythrasma 红癣 10015248 erythrasma AE OAE:0008996 This is an AE which is an infectious disease caused by certain types of human herpes viruses. QY, JX, HY http://en.volupedia.org/wiki/Roseola 婴儿玫瑰疹 10015586 exanthema subitum AE OAE:0008997 This is an AE which is a tan or dark skin discoloration. QY, JX, HY http://en.volupedia.org/wiki/Melasma 黄褐斑 10008570 chloasma AE OAE:0008998 This is an AE which describes anatomy with the appearance and hair follicles get buried in the oedema and resemble an orange peel. QY, JX, HY http://en.volupedia.org/wiki/Peau_d%27orange 桔皮性皮肤 10049752 peau d'orange AE OAE:0008999 This is an AE which is a disorder where hives (urticaria) or large red welts form on the skin after exposure to a cold stimulus. QY, JX, HY http://en.volupedia.org/wiki/Cold_urticaria 寒冷性荨麻疹 10009869 cold urticaria AE OAE:0009000 This is an AE which is the physical urticarias where wheals are elicited via specific physical (mechanical, temperature, radiation) stimuli. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/22760346/ 机械荨麻疹 10068773 mechanical urticaria AE OAE:0009001 This is an AE which is a rare condition in which exposure to ultraviolet or UV radiation, or sometimes even visible light, induces a case of urticaria or hives that can appear in both covered and uncovered areas of the skin. QY, JX, HY http://en.volupedia.org/wiki/Solar_urticaria 日光性荨麻疹 10041307 solar urticaria AE OAE:0009002 This is an AE which is the most common form of cutaneous mastocytosis. QY, JX, HY http://en.volupedia.org/wiki/Urticaria_pigmentosa 色素性荨麻疹 10046752 urticaria pigmentosa AE OAE:0009003 This is an AE which is a rare form of physical urticaria in which hives develop on the skin after contact with water, regardless of its temperature. QY, JX, HY http://en.volupedia.org/wiki/Aquagenic_urticaria 水源性荨麻疹 10046739 urticaria aquagenic AE OAE:0009004 This is an AE which is a kind of skin rash with red, raised, itchy bumps. QY, JX, HY http://en.volupedia.org/wiki/Hives 特发性荨麻疹 10021247 idiopathic urticaria AE OAE:0009005 This is an AE which is a kind of skin rash with red, raised, itchy bumps. QY, JX, HY http://en.volupedia.org/wiki/Hives 荨麻疹热 10061399 urticaria thermal AE OAE:0009006 This is an AE which is a physical urticaria caused by pressure applied to the skin, and is characterized by the development of swelling and pain that usually occurs 3 to 12 hours after local pressure has been applied. QY, JX, HY http://en.volupedia.org/wiki/Pressure_urticaria 压力性荨麻疹 10052572 urticaria pressure AE OAE:0009007 This is an AE which is a non-life-threatening and potentially distressing skin condition that is triggered by sunlight and artificial UV exposure in a genetically susceptible person, particularly in temperate climates during the spring and early summer. QY, JX, HY http://en.volupedia.org/wiki/Polymorphous_light_eruption 多形日光疹 10036087 polymorphic light eruption AE OAE:0009008 This is an AE which is a group of infectious diseases that include epidemic typhus, scrub typhus, and murine typhus. QY, JX, HY http://en.volupedia.org/wiki/Typhus 斑疹伤寒 10061393 typhus AE OAE:0009009 This is an AE which is a widespread rash occurring on the outside of the body and usually occurring in children. QY, JX, HY http://en.volupedia.org/wiki/Exanthem 病毒性皮疹 10047476 viral rash AE OAE:0009010 This is an AE which is a viral disease characterized by a painful skin rash with blisters in a localized area. QY, JX, HY http://en.volupedia.org/wiki/Shingles 带状疱疹 10019974 herpes zoster AE OAE:0009011 This is an AE which is a viral disease characterized by a painful skin rash with blisters in a localized area and is multi-dermatomal. QY, JX, HY http://en.volupedia.org/wiki/Shingles 多皮节性带状疱疹 10058428 herpes zoster multi-dermatomal AE OAE:0009012 This is an AE which is defined as more than twenty skin lesions appearing outside either the primarily affected dermatome or dermatomes directly adjacent to it. QY, JX, HY http://en.volupedia.org/wiki/Shingles#Disseminated_shingles 带状疱疹传播 10065038 herpes zoster disseminated AE OAE:0009013 This is an AE which is a medical sign consisting of a characteristic form of facial rash. QY, JX, HY http://en.volupedia.org/wiki/Malar_rash 蝶形皮疹 10067982 butterfly rash AE OAE:0009014 This is an AE which is an infection caused by the rubella virus. QY, JX, HY http://en.volupedia.org/wiki/Rubella 风疹 10039252 rubella AE OAE:0009015 This is an AE which is an infectious disease caused by certain types of human herpes viruses. QY, JX, HY http://en.volupedia.org/wiki/Roseola 红疹 10039222 roseola AE OAE:0009016 This is an AE which can refer to both beneficial medical procedures (e.g. vaccination) as well as non-beneficial or harmful natural processes (e.g. infection or disease). QY, JX, HY http://en.volupedia.org/wiki/Autoinoculation 后接种疱疹 10066043 post vaccination autoinoculation AE OAE:0009017 This is an AE which is a change of the human skin which affects its color, appearance, or texture and is septic. QY, JX, HY http://en.volupedia.org/wiki/Rash 化脓性皮疹 10062657 septic rash AE OAE:0009018 This is an AE which is a skin disease marked by small and itchy rashes due to sweat trapped under the skin by clogged sweat gland ducts. QY, JX, HY http://en.volupedia.org/wiki/Miliaria 栗疹 10027627 miliaria AE OAE:0009019 This is an AE which is a bacterial disease spread by ticks. QY, JX, HY http://en.volupedia.org/wiki/Rocky_Mountain_spotted_fever 落基山斑疹热 10039207 rocky mountain spotted fever AE OAE:0009020 This is an AE which is a rash (small spots) on the mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Enanthem 黏膜疹 10014579 enanthema AE OAE:0009021 This is an AE which is a rare severe adverse reaction to smallpox vaccination. QY, JX, HY http://en.volupedia.org/wiki/Eczema_vaccinatum 牛痘性湿疹 10066042 eczema vaccinatum AE OAE:0009022 This is an AE which is a life-threatening condition with herpes that arises when the body's response to infection causes injury to its own tissues and organs. QY, JX, HY http://en.volupedia.org/wiki/Sepsis 疱疹脓毒症 10058876 herpes sepsis AE OAE:0009023 This is an AE which is a chronic autoimmune blistering skin condition, characterised by intensely itchy blisters filled with a watery fluid. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis_herpetiformis 疱疹性皮炎 10062639 herpes dermatitis AE OAE:0009024 This is an AE which is a rare but severe disseminated infection that generally occurs at sites of skin damage produced by, for example, atopic dermatitis, burns, long-term usage of topical steroids or eczema. QY, JX, HY http://en.volupedia.org/wiki/Eczema_herpeticum 疱疹性湿疹 10014197 eczema herpeticum AE OAE:0009025 This is an AE which is inflammation of the skin, typically characterized by itchiness, redness and a rash. QY, JX, HY http://en.volupedia.org/wiki/Dermatitis 湿疹型哭泣 10055182 eczema weeping AE OAE:0009026 This is an AE which is a common type of pruritic dermatitis and can also be known as xerosis, which is dry skin. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31747214/ 湿疹性脂肪变性 10014190 eczema asteatotic AE OAE:0009027 This is an AE which is a form of typhus transmitted by fleas (Xenopsylla cheopis), usually on rats, in contrast to epidemic typhus which is usually transmitted by lice. QY, JX, HY http://en.volupedia.org/wiki/Murine_typhus 鼠斑疹伤寒 10028282 murine typhus AE OAE:0009028 This is an AE which is a clog of the eccrine sweat gland. QY, JX, HY http://en.volupedia.org/wiki/Milium_(dermatology) 粟丘疹 10027626 milia AE OAE:0009029 This is an AE which is an itchy eruption of the skin. QY, JX, HY http://en.volupedia.org/wiki/Prurigo 痒疹 10037083 prurigo AE OAE:0009030 This is an AE which may mimic diseases that present with annular configuration and the differential diagnosis is broad. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32778043/ 圆形湿疹 10014201 eczema nummular AE OAE:0009031 This is an AE which is an infectious disease caused by the cowpox virus. QY, JX, HY http://en.volupedia.org/wiki/Cowpox 牛痘 10011238 cow pox AE OAE:0009032 This is an AE which is a large, complex, enveloped virus belonging to the poxvirus family. QY, JX, HY http://en.volupedia.org/wiki/Vaccinia 牛痘 10066048 vaccinia AE OAE:0009033 This is an AE which is a slow-growing (16- to 20-hour generation time) aerobic bacterium and the causative agent of tuberculosis in cattle (known as bovine TB). QY, JX, HY http://en.volupedia.org/wiki/Mycobacterium_bovis 牛结核病 10006049 bovine tuberculosis AE OAE:0009034 This is an AE which is flat, hyperpigmented birthmarks. QY, JX, HY http://en.volupedia.org/wiki/Caf%C3%A9_au_lait_spot 牛奶咖啡斑 10006926 cafe au lait spots AE OAE:0009035 This is an AE which is clusters of concentrated melaninized cells which are most easily visible on people with a fair complexion. QY, JX, HY http://en.volupedia.org/wiki/Freckle 雀斑 10014970 ephelis AE OAE:0009036 This is an AE which is a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin. QY, JX, HY http://en.volupedia.org/wiki/Lentigo 雀斑 10024217 lentigo AE OAE:0009037 This is an AE which is a skin condition characterized by excessively dry skin. QY, JX, HY http://en.volupedia.org/wiki/Xeroderma 干皮病 10048218 xeroderma AE OAE:0009038 This is an AE which is a skin condition characterized by excessively dry skin. QY, JX, HY http://en.volupedia.org/wiki/Xeroderma 干燥症 10048222 xerosis AE OAE:0009039 This is an AE which is a discoloration of the human skin caused by a vascular anomaly (a capillary malformation in the skin). QY, JX, HY http://en.volupedia.org/wiki/Port-wine_stain 鲜红斑痣 10067193 naevus flammeus AE OAE:0009040 This is an AE which is a condition in which hair is lost from some or all areas of the body. QY, JX, HY http://en.volupedia.org/wiki/Alopecia_areata 斑秃 10001761 alopecia areata AE OAE:0009041 This is an AE which is a condition characterized by a skin eruption on the trunk and proximal extremities. QY, JX, HY http://en.volupedia.org/wiki/Tinea_versicolor 花斑癣 10056131 tinea versicolor AE OAE:0009042 This is an AE which is redness of the skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries and it is epiglottic. QY, JX, HY http://en.volupedia.org/wiki/Erythema 会厌性红斑 10067486 epiglottic erythema AE OAE:0009043 This is an AE which is a common type of conjunctival stromal degeneration in the eye. QY, JX, HY http://en.volupedia.org/wiki/Pinguecula 结膜黄斑 10035060 pinguecula AE OAE:0009044 This is an AE which is a medical condition which may result in blurred or no vision in the center of the visual field. QY, JX, HY http://en.volupedia.org/wiki/Macular_degeneration 年龄相关性黄斑变性 10064930 age-related macular degeneration AE OAE:0009045 This is an AE which is a firmly attached white patch on a mucous membrane which is associated with increased risk of cancer. QY, JX, HY http://en.volupedia.org/wiki/Leukoplakia 黏膜白斑病 10062037 leukoplakia AE OAE:0009046 This is an AE which is a form of radiation burn that affects living tissue, such as skin, that results from an overexposure to ultraviolet (UV) radiation, usually from the Sun. QY, JX, HY http://en.volupedia.org/wiki/Sunburn 晒斑 10042496 sunburn AE OAE:0009047 This is an AE which is blemishes on the skin associated with aging and exposure to ultraviolet radiation from the sun. QY, JX, HY http://en.volupedia.org/wiki/Liver_spot 太阳斑 10064127 solar lentigo AE OAE:0009048 This is an AE which is a form of scleroderma that involves isolated patches of hardened skin on the face, hands, and feet, or anywhere else on the body, with no internal organ involvement. QY, JX, HY http://en.volupedia.org/wiki/Morphea 硬斑病 10027982 morphoea AE OAE:0009049 This is an AE which is a microscopic exocrine gland in the skin that opens into a hair follicle to secrete an oily or waxy matter, called sebum, which lubricates the hair and skin of mammals. QY, JX, HY http://en.volupedia.org/wiki/Sebaceous_gland 皮脂溢 10039792 seborrhoea AE OAE:0009050 This is an AE which is the (uncontrolled) death of cells in the (cerebral) cortex of the brain in a band-like pattern,with a relative preservation of cells immediately adjacent to the meninges. QY, JX, HY http://en.volupedia.org/wiki/Cortical_pseudolaminar_necrosis 皮质层状坏死 10051990 cortical laminar necrosis AE OAE:0009051 This is an AE which is a rare neurodegenerative disease involving the cerebral cortex and the basal ganglia. QY, JX, HY http://en.volupedia.org/wiki/Corticobasal_degeneration 皮质基底节变性 10078208 corticobasal degeneration AE OAE:0009052 This is an AE which is one specific measure of bodily symmetry. QY, JX, HY http://en.volupedia.org/wiki/Facial_symmetry 面部不对称 10068737 facial asymmetry AE OAE:0009053 This is an AE which is feel discomfortable of a family of skin care treatments for the face, including steam, exfoliation (physical and chemical), extraction, creams, lotions, facial masks, peels, and massage. QY, JX, HY http://en.volupedia.org/wiki/Facial 面部不适 10083537 facial discomfort AE OAE:0009054 This is an AE which is a rare neuromuscular disease characterized by irregular, involuntary muscle contractions (spasms) on one side (hemi-) of the face (-facial). QY, JX, HY http://en.volupedia.org/wiki/Hemifacial_spasm 面部痉挛 10063006 facial spasm AE OAE:0009055 This is an AE which is sensitivity of a powder made by grinding raw grains, roots, beans, nuts, or seeds. QY, JX, HY http://en.volupedia.org/wiki/Flour 面粉敏感性 10016788 flour sensitivity AE OAE:0009056 This is an AE which is a bacterial infection that involves the superficial skin. QY, JX, HY http://en.volupedia.org/wiki/Impetigo 脓疱病 10021531 impetigo AE OAE:0009057 This is an AE which is used for a heterogeneous group of diseases that share pustular skin characteristics. QY, JX, HY http://en.volupedia.org/wiki/Pustular_psoriasis 脓疱型银屑病 10037575 pustular psoriasis AE OAE:0009058 This is an AE which is a chronic inflammatory and immune-mediated disease that affects the skin, nails, hair, and mucous membranes. QY, JX, HY http://en.volupedia.org/wiki/Lichen_planus 苔藓样角化病 10064000 lichenoid keratosis AE OAE:0009059 This is an AE which is highly inflammatory skin condition resulting in large fluid-filled blister-like areas - pustules and it is eosinophilic . QY, JX, HY http://en.volupedia.org/wiki/Pustulosis 嗜酸性脓疱病 10049172 eosinophilic pustulosis AE OAE:0009060 This is an AE which is an itchy rash with an unknown cause that is most common among individuals with HIV, though it can occur in HIV-negative individuals where it is known by the eponym Ofuji disease. QY, JX, HY http://en.volupedia.org/wiki/Eosinophilic_folliculitis 嗜酸性脓疱的毛囊炎 10052834 eosinophilic pustular folliculitis AE OAE:0009061 This is an AE which is a cutaneous condition characterized by deposits of excessive amounts of collagen which gives rise to a raised scar, but not to the degree observed with keloids. QY, JX, HY http://en.volupedia.org/wiki/Hypertrophic_scar 肥厚性疤痕 10020879 hypertrophic scar AE OAE:0009062 This is an AE which refers to one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying cause. QY, JX, HY http://en.volupedia.org/wiki/Parapsoriasis 类银屑病 10033898 parapsoriasis AE OAE:0009063 This is an AE which is a family of genetic skin disorders characterized by dry, thickened, scaly skin. QY, JX, HY http://en.volupedia.org/wiki/Ichthyosis 鱼鳞癣 10021198 ichthyosis AE OAE:0009064 This is an AE which is a polymorphic, pruritic, papulovesicular dermatosis characterized histologically by acantholysis with or without dyskeratosis. QY, JX, HY http://en.volupedia.org/wiki/Transient_acantholytic_dermatosis 一过性棘层松解性皮肤病 10051446 transient acantholytic dermatosis AE OAE:0009065 This is an AE which is a condition where purpura, which constitutes visible non-blanching hemorrhages, are raised and able to be touched or felt upon palpation. QY, JX, HY http://en.volupedia.org/wiki/Palpable_purpura 可触及紫癜 10056872 palpable purpura AE OAE:0009066 This is an AE which implies that this nevus exists as a distinct and defined entity of potential detriment to its host. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26037217/ 异常增生痣 10062805 dysplastic naevus AE OAE:0009067 This is an AE which is a type of telangiectasis (swollen blood vessels) found slightly beneath the skin surface, often containing a central red spot and deep reddish extensions (see Blood color) which radiate outwards like a spider's web or a spider's legs. QY, JX, HY http://en.volupedia.org/wiki/Spider_angioma 蜘蛛痣 10041519 spider naevus AE OAE:0009068 This is an AE which is a deep folliculitis on eyelid, infection of the hair follicle. QY, JX, HY http://en.volupedia.org/wiki/Boil 睑疖 10015980 eyelid boil AE OAE:0009069 This is an AE which is a common type of contagious, superficial fungal infection of the groin region, which occurs predominantly but not exclusively in men and in hot-humid climates. QY, JX, HY http://en.volupedia.org/wiki/Tinea_cruris 股癣 10043868 tinea cruris AE OAE:0009070 This is an AE which is a bacterial skin infection caused by Staphylococcus aureus that results in the formation of large blisters called bullae, usually in areas with skin folds like the armpit, groin, between the fingers or toes, beneath the breast, and between the buttocks. It accounts for 30% of cases of impetigo, the other 70% being non-bullous impetigo. QY, JX, HY http://en.volupedia.org/wiki/Bullous_impetigo 大疱性脓疱病 10006563 bullous impetigo AE OAE:0009071 This is an AE which is a type of dermatitis that is characterized by itchy blisters on the palms of the hands and bottoms of the feet. QY, JX, HY http://en.volupedia.org/wiki/Dyshidrosis 汗疱 10013913 dyshidrotic eczema AE OAE:0009072 This is an AE which is a chronic recurrent pustular dermatosis (that is, a pustulosis or pustular psoriasis) localized on the palms and soles only, characterized histologically by intraepidermal pustules filled with neutrophils. QY, JX, HY http://en.volupedia.org/wiki/Pustulosis_palmaris_et_plantaris 掌跖脓疱病 10050185 palmoplantar pustulosis AE OAE:0009073 This is an AE which attributed to Heinrich Köbner, is the appearance of skin lesions on lines of trauma. QY, JX, HY http://en.volupedia.org/wiki/Koebner_phenomenon koebner现象 10048649 koebner phenomenon AE OAE:0009074 This is an AE which involves a neuropathic component is often of mild intensity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30394066/ 疤痕痛 10049002 scar pain AE OAE:0009075 This is an AE which is the formation of a type of scar which, depending on its maturity, is composed mainly of either type III (early) or type I (late) collagen. QY, JX, HY http://en.volupedia.org/wiki/Keloid 瘢痕疙瘩 10023330 keloid scar AE OAE:0009076 This is an AE which is a cutaneous condition characterized by rough, yellow-brown keratotic, flat-topped papules. QY, JX, HY http://en.volupedia.org/wiki/Hyperkeratosis#Other 持久性豆状角化过度病 10071311 hyperkeratosis lenticularis perstans AE OAE:0009077 This is an AE which is a deep folliculitis, infection of the hair follicle. QY, JX, HY http://en.volupedia.org/wiki/Boil 疔疮 10017553 furuncle AE OAE:0009078 This is an AE which is largely dermatological conditions, which present clinically as cutaneous photosensitivity. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2194599/ 非急性卟啉症 10036186 porphyria non-acute AE OAE:0009079 This is an AE which is a skin disease marked by small and itchy rashes due to sweat trapped under the skin by clogged sweat gland ducts. QY, JX, HY http://en.volupedia.org/wiki/Miliaria 痱子 10019343 heat rash AE OAE:0009080 This is an AE which is a specific disorder of keratinization that is characterized histologically by the presence of a cornoid lamella, a thin column of closely stacked, parakeratotic cells extending through the stratum corneum with a thin or absent granular layer. QY, JX, HY http://en.volupedia.org/wiki/Porokeratosis 汗孔角化病 10036175 porokeratosis AE OAE:0009081 This is an AE which is a rare, inflammatory skin disease where painful pustules or nodules become ulcers that progressively grow. QY, JX, HY http://en.volupedia.org/wiki/Pyoderma_gangrenosum 坏疽性脓皮病 10037635 pyoderma gangrenosum AE OAE:0009082 This is an AE which is a fungal infection of the skin. QY, JX, HY http://en.volupedia.org/wiki/Dermatophytosis 脚气 10012504 dermatophytosis AE OAE:0009083 This is an AE which is a clinical dermatological sign, named after Pyotr Nikolsky. QY, JX, HY http://en.volupedia.org/wiki/Nikolsky%27s_sign 尼氏征 10029415 nikolsky's sign AE OAE:0009084 This is an AE which is a form of allergic contact dermatitis in which the allergen must be activated by light to sensitize the allergic response, and to cause a rash or other systemic effects on subsequent exposure. QY, JX, HY http://en.volupedia.org/wiki/Photodermatitis 日光性皮炎 10041303 solar dermatitis AE OAE:0009085 This is an AE which is a chronic discoloration of the skin found in people of all ages, usually only affecting the feet, legs or thighs or a combination. QY, JX, HY http://en.volupedia.org/wiki/Schamberg_disease 尚伯格病 10039593 schamberg's disease AE OAE:0009086 This is an AE which a medical sign, is a reduced degree of facial expression. QY, JX, HY http://en.volupedia.org/wiki/Hypomimia 假面 10026863 masked facies AE OAE:0009087 QY, JX, HY 皮肤不适 10040830 skin discomfort AE OAE:0009088 QY, JX, HY 皮肤过敏 10070835 skin sensitisation AE OAE:0009089 QY, JX, HY 出血性皮肤溃疡 10050377 skin ulcer hemorrhage AE OAE:0009090 QY, JX, HY 皮下炎 10065259 dermo-hypodermitis AE OAE:0009091 QY, JX, HY 皮疹泛化 10037858 rash generalised AE OAE:0009092 QY, JX, HY 皮疹黄斑囊泡 10050004 rash maculovesicular AE OAE:0009093 QY, JX, HY 皮疹银屑病 10037885 rash psoriaform AE OAE:0009094 QY, JX, HY 风疹样皮疹 10057984 rash rubelliform AE OAE:0009095 QY, JX, HY 水疱性荨麻疹 10046755 urticaria vesiculosa AE OAE:0009096 QY, JX, HY 带状疱疹皮肤传播 10074297 herpes zoster cutaneous disseminated AE OAE:0009097 QY, JX, HY 脓疱性湿疹 10051890 eczema impetiginous AE OAE:0009098 QY, JX, HY 皮炎 10051504 thelitis AE OAE:0009099 QY, JX, HY 面部消瘦 10056866 facial wasting AE OAE:0009100 QY, JX, HY 体癣 10005913 body tinea AE OAE:0009101 This is an AE which is a complication of pregnancy; the acronym stands for Hemolysis, Elevated Liver enzymes, and Low Platelet count. QY, JX, HY http://en.volupedia.org/wiki/HELLP_syndrome HELLP综合征 10049058 hellp syndrome AE OAE:0009102 This is an AE which is a state of adaptation or dysregulation of thyrotropic feedback control wherein the levels of T3 and/or T4 are abnormal, but the thyroid gland does not appear to be dysfunctional. QY, JX, HY http://en.volupedia.org/wiki/Euthyroid_sick_syndrome 甲状腺机能正常的病态综合征 10015549 euthyroid sick syndrome AE OAE:0009103 This is an AE which is a vascular occlusion in humans in the region of the ulna. QY, JX, HY http://en.volupedia.org/wiki/Hypothenar_hammer_syndrome 下丘脑锤打综合征 10063518 hypothenar hammer syndrome AE OAE:0009104 This is an AE which is a rare congenital brain malformation in which the part joining the two hemispheres of the cerebellum (the cerebellar vermis) does not fully form, and the fourth ventricle and space behind the cerebellum (the posterior fossa) are enlarged with cerebrospinal fluid. QY, JX, HY http://en.volupedia.org/wiki/Dandy%E2%80%93Walker_malformation dandy-walker综合症 10048411 dandy-walker syndrome AE OAE:0009105 This is an AE which is a reaction of the skin to a viral infection. QY, JX, HY http://en.volupedia.org/wiki/Gianotti%E2%80%93Crosti_syndrome gianotti-crosti综合症 10053842 gianotti-crosti syndrome AE OAE:0009106 This is an AE which is an autosomal recessive kidney tubule disorder characterized by low blood levels of potassium and magnesium, decreased excretion of calcium in the urine, and elevated blood pH. QY, JX, HY http://en.volupedia.org/wiki/Gitelman_syndrome gitelman综合征 10062906 gitelman's syndrome AE OAE:0009107 This is an AE which is a postulated disorder of vision or image-processing in the brain. QY, JX, HY http://en.volupedia.org/wiki/Irlen_syndrome irlen综合症 10074972 irlen syndrome AE OAE:0009108 This is an AE which is a rare congenital medical condition in which blood vessels and/or lymph vessels fail to form properly. QY, JX, HY http://en.volupedia.org/wiki/Klippel%E2%80%93Tr%C3%A9naunay_syndrome klippel-trenaunay综合症 10051452 klippel-trenaunay syndrome AE OAE:0009109 This is an AE which is defined as acute coronary syndrome (symptoms such as chest pain relating to reduced blood flow to the heart) caused by an allergic reaction or a strong immune reaction to a drug or other substance. QY, JX, HY http://en.volupedia.org/wiki/Kounis_syndrome kounis综合症 10069167 kounis syndrome AE OAE:0009110 This is an AE which represents the asymmetric variant of chronic inflammatory demyelinating polyneuropathy (CIDP). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/19145651/ lewis-sumner综合症 10065580 lewis-sumner syndrome AE OAE:0009111 This is an AE which is a condition in which compression of the common venous outflow tract of the left lower extremity may cause discomfort, swelling, pain or clots (deep venous thrombosis) in the iliofemoral veins. QY, JX, HY http://en.volupedia.org/wiki/May%E2%80%93Thurner_syndrome may-thurner综合症 10069727 may-thurner syndrome AE OAE:0009112 This is an AE which is a type of dystonia and is actually a combination of two forms of dystonia, blepharospasm and oromandibular dystonia (OMD). QY, JX, HY http://en.volupedia.org/wiki/Meige%27s_syndrome meige综合征 10027138 meige's syndrome AE OAE:0009113 This is an AE which is a medical condition, typically starting in young children, in which high fever occurs periodically at intervals of about 3-5 weeks, frequently accompanied by aphthous-like ulcers, pharyngitis and/or cervical adenitis (cervical lymphadenopathy). QY, JX, HY http://en.volupedia.org/wiki/Periodic_fever,_aphthous_stomatitis,_pharyngitis_and_adenitis pfapa综合症 10070594 pfapa syndrome AE OAE:0009114 This is an AE which is a severe endocrine disease caused by a corticotroph pituitary tumor and associated with increased morbidity and mortality. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/26067718/ pituitary-dependent库兴氏综合征 10035109 pituitary-dependent cushing's syndrome AE OAE:0009115 This is an AE which is a rare disorder of unknown cause that is characterized by abundant histiocytes in the lymph nodes or other locations throughout the body. QY, JX, HY http://en.volupedia.org/wiki/Rosai%E2%80%93Dorfman_disease rosai-dorfman综合症 10063397 rosai-dorfman syndrome AE OAE:0009116 This is an AE which is a rare disorder characterized by severe and unilateral headaches with orbital pain, along with weakness and paralysis (ophthalmoplegia) of certain eye muscles (extraocular palsies). QY, JX, HY http://en.volupedia.org/wiki/Tolosa%E2%80%93Hunt_syndrome tolosa-hunt综合征 10051526 tolosa-hunt syndrome AE OAE:0009117 This is an AE which is a multisystem disease of presumed autoimmune cause that affects pigmented tissues, which have melanin. QY, JX, HY http://en.volupedia.org/wiki/Vogt%E2%80%93Koyanagi%E2%80%93Harada_disease vogt-小柳-原田综合征 10047680 vogt-koyanagi-harada syndrome AE OAE:0009118 This is an AE which is a chromosomal deletion syndrome resulting from a partial deletion on the short arm of chromosome 4 (del(4p16.3)). QY, JX, HY http://en.volupedia.org/wiki/Wolf%E2%80%93Hirschhorn_syndrome wolf-hirschhorn综合征 10050365 wolf-hirschhorn syndrome AE OAE:0009119 This is an AE which is a rare genetic malformation syndrome characterized by the partial or complete absence of a key structure in the brain called the corpus callosum, the presence of retinal abnormalities, and seizures in the form of infantile spasms. QY, JX, HY http://en.volupedia.org/wiki/Aicardi_syndrome 阿卡迪综合征 10054935 aicardi's syndrome AE OAE:0009120 This is an AE which is a group of thirteen genetic connective-tissue disorders that are in the current classification, with a fourteenth type discovered in 2018. QY, JX, HY http://en.volupedia.org/wiki/Ehlers%E2%80%93Danlos_syndromes 埃勒斯－当洛二氏综合征 10014316 ehlers-danlos syndrome AE OAE:0009121 This is an AE which is an autoimmune disease in which an individual's immune system attacks their own red blood cells and platelets, the syndrome can include immune neutropenia. QY, JX, HY http://en.volupedia.org/wiki/Evans_syndrome 埃文斯综合症 10053873 evans syndrome AE OAE:0009122 This is an AE which is a neuropsychological condition that causes a distortion of perception. QY, JX, HY http://en.volupedia.org/wiki/Alice_in_Wonderland_syndrome 爱丽丝梦游仙境综合症 10001666 alice in wonderland syndrome AE OAE:0009123 This is an AE which is a type of psychophysical visual disturbance in which a person with partial or severe blindness experiences visual hallucinations. QY, JX, HY http://en.volupedia.org/wiki/Visual_release_hallucinations 邦纳症候群 10063354 charles bonnet syndrome AE OAE:0009124 This is an AE which is an abnormal sensory perception during sleep in which a person experiences unreal noises that are loud and of short duration when falling asleep or waking up. QY, JX, HY http://en.volupedia.org/wiki/Exploding_head_syndrome 爆炸头综合征 10080684 exploding head syndrome AE OAE:0009125 This is an AE which is a type of inflammatory disorder which affects multiple parts of the body. QY, JX, HY http://en.volupedia.org/wiki/Beh%C3%A7et%27s_disease 贝赫切特综合征 10004213 behcet's syndrome AE OAE:0009126 This is an AE which is possible to argue that motor competence can be understood as the person s ability to carry out different motor skills and is become disorder. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16355603/ 笨挫儿童综合征 10009697 clumsy child syndrome AE OAE:0009127 This is an AE which is a condition in which a patient is aware but cannot move or communicate verbally due to complete paralysis of nearly all voluntary muscles in the body except for vertical eye movements and blinking. QY, JX, HY http://en.volupedia.org/wiki/Locked-in_syndrome 闭锁综合症 10024792 locked-in syndrome AE OAE:0009128 This is an AE which is knee pain as a result of problems between the kneecap and the femur. QY, JX, HY http://en.volupedia.org/wiki/Patellofemoral_pain_syndrome 髌股疼痛综合征 10049143 patellofemoral pain syndrome AE OAE:0009129 This is an AE which is a complex, fatiguing, long-term medical condition diagnosed by required primary symptoms and criteria, and often involves a broad range of symptoms. QY, JX, HY http://en.volupedia.org/wiki/Chronic_fatigue_syndrome 病毒后疲劳综合征 10057244 post viral fatigue syndrome AE OAE:0009130 This is an AE which is a condition in which people in a building suffer from symptoms of illness or become infected with chronic disease from the building in which they work or reside. QY, JX, HY http://en.volupedia.org/wiki/Sick_building_syndrome 病态建筑综合症 10040634 sick building syndrome AE OAE:0009131 This is an AE which is generally a long-term disorder that causes a strong urge to move one's legs. QY, JX, HY http://en.volupedia.org/wiki/Restless_legs_syndrome 不安腿综合征 10058920 restless legs syndrome AE OAE:0009132 This is an AE which is a rare X-linked dominant genetic disorder that affects the skin, hair, teeth, nails and central nervous system. QY, JX, HY http://en.volupedia.org/wiki/Incontinentia_pigmenti 布洛克，色素失调症 10077624 bloch-sulzberger syndrome AE OAE:0009133 This is an AE which is a neurological disorder causing a range of symptoms due to ischemia in the lateral part of the medulla oblongata in the brainstem. QY, JX, HY http://en.volupedia.org/wiki/Lateral_medullary_syndrome 侧髓综合症 10024033 lateral medullary syndrome AE OAE:0009134 This is an AE which is a hereditary autoinflammatory syndrome caused by mutations in the mevalonate kinase gene. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/25990874/ 超级igd综合症 10072010 hyper igd syndrome AE OAE:0009135 This is an AE which is a heterogeneous group of immune disorders. QY, JX, HY http://en.volupedia.org/wiki/Hyperimmunoglobulin_E_syndrome 超级ige综合症 10051040 hyper ige syndrome AE OAE:0009136 This is an AE which is a genetic disorder characterized by mild-to-moderate intellectual disability. QY, JX, HY http://en.volupedia.org/wiki/Fragile_X_syndrome 脆性x综合征 10017324 fragile x syndrome AE OAE:0009137 This is an AE which is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). QY, JX, HY http://en.volupedia.org/wiki/Metabolic_syndrome 代谢综合征 10052066 metabolic syndrome AE OAE:0009138 This is an AE which is a medical condition characterized by a snapping sensation felt when the hip is flexed and extended. QY, JX, HY http://en.volupedia.org/wiki/Snapping_hip_syndrome 弹响髋综合征 10080832 snapping hip syndrome AE OAE:0009139 This is an AE which is a syndrome caused by a microdeletion on the long arm of chromosome 22. QY, JX, HY http://en.volupedia.org/wiki/DiGeorge_syndrome 迪格奥尔格综合征 10012979 digeorge's syndrome AE OAE:0009140 This is an AE which is a congenital rare type of strabismus most commonly characterized by the inability of the eye to move outward. QY, JX, HY http://en.volupedia.org/wiki/Duane_syndrome 杜安综合征 10013799 duane's syndrome AE OAE:0009141 This is an AE which is part of a group called Ras/MAPK pathway syndromes, is a rare autosomal dominant,multisystem disease caused by a mutation in the protein tyrosine phosphatase, non-receptor type 11 gene (PTPN11). QY, JX, HY http://en.volupedia.org/wiki/Noonan_syndrome_with_multiple_lentigines 多发性雀斑综合征 10062901 multiple lentigines syndrome AE OAE:0009142 This is an AE which is altered organ function in an acutely ill patient requiring medical intervention to achieve homeostasis. QY, JX, HY http://en.volupedia.org/wiki/Multiple_organ_dysfunction_syndrome 多器官功能障碍综合征 10077361 multiple organ dysfunction syndrome AE OAE:0009143 This is an AE which is an informal label that physicians apply to patients with symptoms similar to those of asthma. QY, JX, HY http://en.volupedia.org/wiki/Reactive_airway_disease 反应性气道功能障碍综合征 10070832 reactive airways dysfunction syndrome AE OAE:0009144 This is an AE which is a compression neuropathy and painful foot condition in which the tibial nerve is compressed as it travels through the tarsal tunnel. QY, JX, HY http://en.volupedia.org/wiki/Tarsal_tunnel_syndrome 跗管综合征 10043121 tarsal tunnel syndrome AE OAE:0009145 This is an AE which is a rare syndrome caused by a genetic disorder. QY, JX, HY http://en.volupedia.org/wiki/CHARGE_syndrome 联合畸形 10064043 charge syndrome AE OAE:0009146 This is an AE which is a long-term autoimmune disease that affects the body's moisture-producing (lacrimal and salivary) glands, and often seriously affects other organ systems, such as the lungs, kidneys, and nervous system. QY, JX, HY http://en.volupedia.org/wiki/Sj%C3%B6gren_syndrome 干燥综合征 10040633 sicca syndrome AE OAE:0009147 This is an AE which is a complication of otitis media and mastoiditis involving the apex of the petrous temporal bone. QY, JX, HY http://en.volupedia.org/wiki/Gradenigo%27s_syndrome 格拉代尼果氏综合征 10063095 gradenigo's syndrome AE OAE:0009148 This is an AE which is a chronic and multi-symptomatic disorder affecting returning military veterans of the 1990–1991 Persian Gulf War. QY, JX, HY http://en.volupedia.org/wiki/Gulf_War_syndrome 海湾战争综合症 10056557 gulf war syndrome AE OAE:0009149 This is an AE which is the sensation that an amputated or missing limb is still attached. QY, JX, HY http://en.volupedia.org/wiki/Phantom_limb 幻肢综合症 10082544 phantom limb syndrome AE OAE:0009150 This is an AE which is a combination of symptoms that arises when a group of nerves known as the sympathetic trunk is damaged. QY, JX, HY http://en.volupedia.org/wiki/Horner%27s_syndrome 霍纳氏综合征 10020392 horner's syndrome AE OAE:0009151 This is an AE which is a medical condition of decreased mobility due to disorders of the locomotor system. QY, JX, HY http://en.volupedia.org/wiki/Locomotive_syndrome 机车综合症 10077495 locomotive syndrome AE OAE:0009152 This is an AE which is a mild liver disorder in which the liver does not properly process bilirubin. QY, JX, HY http://en.volupedia.org/wiki/Gilbert%27s_syndrome 吉尔伯特的综合症 10018267 gilbert's syndrome AE OAE:0009153 This is an AE which is a syndrome involving tendonitis (inflammation of tendons) of the rotator cuff muscles as they pass through the subacromial space, the passage beneath the acromion. QY, JX, HY http://en.volupedia.org/wiki/Shoulder_impingement_syndrome 肩撞击综合征 10063932 impingement syndrome AE OAE:0009154 This is an AE which is the group of symptoms that occur upon the abrupt discontinuation or decrease in the intake of medicational or recreational drugs. QY, JX, HY http://en.volupedia.org/wiki/Drug_withdrawal 戒断综合症 10048010 withdrawal syndrome AE OAE:0009155 This is an AE which is an autoimmune disease associated with interstitial lung disease, dermatomyositis, and polymyositis. QY, JX, HY http://en.volupedia.org/wiki/Antisynthetase_syndrome 抗合成酶综合征 10068801 antisynthetase syndrome AE OAE:0009156 This is an AE which is an autoimmune, hypercoagulable state caused by antiphospholipid antibodies. QY, JX, HY http://en.volupedia.org/wiki/Antiphospholipid_syndrome 抗磷脂综合征 10002817 antiphospholipid syndrome AE OAE:0009157 This is an AE which is a collection of signs and symptoms due to prolonged exposure to glucocorticoids such as cortisol. QY, JX, HY http://en.volupedia.org/wiki/Cushing%27s_syndrome 库兴氏综合征 10011652 cushing's syndrome AE OAE:0009158 This is an AE which is a rapidly worsening brain disease. QY, JX, HY http://en.volupedia.org/wiki/Reye_syndrome 雷氏综合症 10039012 reye's syndrome AE OAE:0009159 This is an AE which is a group of rare, heterogeneous autoinflammatory disease characterized by interleukin 1β-mediated systemic inflammation and clinical symptoms involving skin, joints, central nervous system, and eyes. QY, JX, HY http://en.volupedia.org/wiki/Cryopyrin-associated_periodic_syndrome 冷卟啉相关周期性综合征 10068850 cryopyrin associated periodic syndrome AE OAE:0009160 This is an AE which is a rare progressive disorder of presumed autoimmune cause, characterized by painful muscle spasms, alopecia, diarrhea, endocrinopathy with amenorrhoea and secondary skeletal abnormalities. QY, JX, HY http://en.volupedia.org/wiki/Satoyoshi_syndrome 里吉综合征 10070579 satoyoshi syndrome AE OAE:0009161 This is an AE which is a clinical situation of an individual's first neurological episode, caused by inflammation or demyelination of nerve tissue. QY, JX, HY http://en.volupedia.org/wiki/Clinically_isolated_syndrome 临床孤立综合征 10071068 clinically isolated syndrome AE OAE:0009162 This is an AE which mostly occurs in congenital ptosis patients, is characterized by jaw movement evoking ptotic eyelid retraction, followed by collapse. Inverted, bilateral and acquired MGS were also reported. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/33254517/ 马库斯·甘恩综合症 10064583 marcus gunn syndrome AE OAE:0009163 This is an AE which is the triad of ascites, pleural effusion, and benign ovarian tumor (ovarian fibroma, fibrothecoma, Brenner tumour, and occasionally granulosa cell tumour). QY, JX, HY http://en.volupedia.org/wiki/Meigs%27s_syndrome 梅格斯氏综合征 10027139 meigs' syndrome AE OAE:0009164 This is an AE which is a form of chemical pneumonitis or aspiration pneumonitis caused by aspiration of stomach contents (principally gastric acid) during anaesthesia in childbirth. QY, JX, HY http://en.volupedia.org/wiki/Mendelson%27s_syndrome 门德尔松综合征 10049783 mendelson's syndrome AE OAE:0009165 This is an AE which is one of the family of mitochondrial diseases, which also include MERRF syndrome, and Leber's hereditary optic neuropathy. QY, JX, HY http://en.volupedia.org/wiki/MELAS_syndrome 米拉斯综合症 10053872 melas syndrome AE OAE:0009166 This is an AE which is a rare variant of Guillain-Barré's syndrome characterized by the acute development of ataxia, ophthalmoparesis, and areflexia. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/23677659/ 米勒费雪症候群 10049567 miller fisher syndrome AE OAE:0009167 This is an AE which is an umbrella term covering pain and dysfunction of the muscles of mastication (the muscles that move the jaw) and the temporomandibular joints (the joints which connect the mandible to the skull). QY, JX, HY http://en.volupedia.org/wiki/Temporomandibular_joint_dysfunction 颞下颌关节综合征 10043220 temporomandibular joint syndrome AE OAE:0009168 This is an AE which is a genetic disorder that may present with mildly unusual facial features, short height, congenital heart disease, bleeding problems, and skeletal malformations. QY, JX, HY http://en.volupedia.org/wiki/Noonan_syndrome 努南综合症 10029748 noonan syndrome AE OAE:0009169 This is an AE which is a congenital defect observed in humans which is characterized by facial abnormalities. QY, JX, HY http://en.volupedia.org/wiki/Pierre_Robin_sequence 皮埃尔·罗宾综合症 10035009 pierre robin syndrome AE OAE:0009170 This is an AE which is a common and important problem among health professionals that also has adverse effects on people's daily life, especially increasing the incidence of infection and trauma. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31800896/ 疲劳综合征 10065369 burnout syndrome AE OAE:0009171 This is an AE which is a genetic disorder caused by a loss of function of specific genes on chromosome 15. QY, JX, HY http://en.volupedia.org/wiki/Prader%E2%80%93Willi_syndrome 普拉德-威利综合征 10036476 prader-willi syndrome AE OAE:0009172 This is an AE which is a rare condition that encompasses a combination of syndromes such as bronchiectasis, rhinosinusitis and reduced male fertility. QY, JX, HY http://en.volupedia.org/wiki/Young%27s_syndrome 青年综合症 10063689 young's syndrome AE OAE:0009173 This is an AE which occurs when food, especially sugar, moves too quickly from the stomach to the duodenum—the first part of the small intestine—in the upper gastrointestinal (GI) tract. QY, JX, HY http://en.volupedia.org/wiki/Dumping_syndrome 倾倒综合征 10013810 dumping syndrome AE OAE:0009174 This is an AE which refers to as calcium-alkali syndrome, is the third most common cause of hypercalcemia and is characterized by elevated blood calcium levels, metabolic alkalosis, and acute kidney injury. QY, JX, HY http://en.volupedia.org/wiki/Milk-alkali_syndrome 乳碱综合征 10027635 milk-alkali syndrome AE OAE:0009175 This is an AE which is a form of inflammatory arthritis that develops in response to an infection in another part of the body (cross-reactivity). QY, JX, HY http://en.volupedia.org/wiki/Reactive_arthritis 瑞特综合征 10038294 reiter's syndrome AE OAE:0009176 This is an AE which is an eponymous paediatric medical disorder, characterised by gastrointestinal symptoms and associated neurological features. QY, JX, HY http://en.volupedia.org/wiki/Sandifer_syndrome 桑迪夫综合症 10066142 sandifer's syndrome AE OAE:0009177 This is an AE which is a rare headache disorder that belongs to the group of headaches called trigeminal autonomic cephalalgia (TACs). QY, JX, HY http://en.volupedia.org/wiki/SUNCT_syndrome 桑克综合征 10061981 sunct syndrome AE OAE:0009178 This is an AE which is the term used for both central pontine myelinolysis and extrapontine myelinolysis. QY, JX, HY http://en.volupedia.org/wiki/Central_pontine_myelinolysis 渗透性脱髓鞘综合征 10069350 osmotic demyelination syndrome AE OAE:0009179 This is an AE which refers to a group of neurological disorders that relate to malformations of the spinal cord. QY, JX, HY http://en.volupedia.org/wiki/Tethered_spinal_cord_syndrome 绳索综合征 10066334 tethered cord syndrome AE OAE:0009180 This is an AE which is a type of severe skin reaction. QY, JX, HY http://en.volupedia.org/wiki/Stevens%E2%80%93Johnson_syndrome 史蒂文斯-约翰逊综合征 10042033 stevens-johnson syndrome AE OAE:0009181 This is an AE which is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. QY, JX, HY http://en.volupedia.org/wiki/Hypereosinophilic_syndrome 嗜酸细胞增多综合征 10048643 hypereosinophilic syndrome AE OAE:0009182 This is an AE which is a syndrome resulting from bilateral lesions of the medial temporal lobe (including amygdaloid nucleus). QY, JX, HY http://en.volupedia.org/wiki/Kl%C3%BCver%E2%80%93Bucy_syndrome 双侧颞叶切除综合征 10066431 kluver-bucy syndrome AE OAE:0009183 This is an AE which is seen exclusively in women; men with a mutation of the related gene (called XLIS or DCX) usually die in utero or have a much more severe brain anomaly. QY, JX, HY http://en.volupedia.org/wiki/Gray_matter_heterotopia 双皮质综合征 10073490 double cortex syndrome AE OAE:0009184 This is an AE which is a genetic condition in which a female is partially or completely missing an X chromosome. QY, JX, HY http://en.volupedia.org/wiki/Turner_syndrome 特纳综合征 10045181 turner's syndrome AE OAE:0009185 This is an AE which is a condition in which a change from lying to standing causes an abnormally large (or higher than normal) increase in heart beat rate. QY, JX, HY http://en.volupedia.org/wiki/Postural_orthostatic_tachycardia_syndrome 体位性直立性心动过速综合征 10063080 postural orthostatic tachycardia syndrome AE OAE:0009186 This is an AE which is a genetic disorder that mainly affects the nervous system. QY, JX, HY http://en.volupedia.org/wiki/Angelman_syndrome 天使综合症 10049004 angelman's syndrome AE OAE:0009187 This is an AE which is a group of disorders with diverse etiologies involving different anatomical components of the neck, ultimately resulting in a debilitating, flexible, anterior curvature of the cervical spine. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32105239/ 头部综合征下降 10072442 dropped head syndrome AE OAE:0009188 This is an AE which is a category of conditions in which a person experiences their limbs acting seemingly on their own, without conscious control over the actions. QY, JX, HY http://en.volupedia.org/wiki/Alien_hand_syndrome 异手综合征 10070883 alien limb syndrome AE OAE:0009189 This is an AE which is a genetic disorder that affects many parts of the body. QY, JX, HY http://en.volupedia.org/wiki/Williams_syndrome 威廉姆斯综合症 10049644 williams syndrome AE OAE:0009190 This is an AE which is the combined presence of Wernicke encephalopathy (WE) and Korsakoff syndrome. QY, JX, HY http://en.volupedia.org/wiki/Wernicke%E2%80%93Korsakoff_syndrome 韦尼克-科萨科夫综合征 10047913 wernicke-korsakoff syndrome AE OAE:0009191 This is an AE which is defined as adrenal gland failure due to bleeding into the adrenal glands, commonly caused by severe bacterial infection. QY, JX, HY http://en.volupedia.org/wiki/Waterhouse%E2%80%93Friderichsen_syndrome 沃特豪斯-弗里德里希森综合征 10047847 waterhouse-friderichsen syndrome AE OAE:0009192 This is an AE which is a fetus in a multigestation pregnancy that dies in utero and is then partially or completely reabsorbed. QY, JX, HY http://en.volupedia.org/wiki/Vanishing_twin 消失双胞胎综合症 10071398 vanishing twin syndrome AE OAE:0009193 This is an AE which is a group of symptoms that may occur with the use of certain serotonergic medications or drugs. QY, JX, HY http://en.volupedia.org/wiki/Serotonin_syndrome 血清素综合征 10040108 serotonin syndrome AE OAE:0009194 This is an AE which is a rare congenital growth disorder. QY, JX, HY http://en.volupedia.org/wiki/Silver%E2%80%93Russell_syndrome 银罗素综合征 10062282 silver-russell syndrome AE OAE:0009195 This is an AE which is a condition caused by bacterial toxins. QY, JX, HY http://en.volupedia.org/wiki/Toxic_shock_syndrome 中毒性休克综合征 10044248 toxic shock syndrome AE OAE:0009196 This is an AE which is a neurological condition consisting of constant, moderate to severe pain due to damage to the central nervous system (CNS) which causes a sensitization of the pain system. QY, JX, HY http://en.volupedia.org/wiki/Central_pain_syndrome 中央疼痛综合征 10064012 central pain syndrome AE OAE:0009197 This is an AE which is a medical condition which shares features of at least two more widely recognised disorders. QY, JX, HY http://en.volupedia.org/wiki/Overlap_syndrome 重叠综合征 10068786 overlap syndrome AE OAE:0009198 This is an AE which is the second most common peripheral nerve compression syndrome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/21547883/ 肘管综合征 10056473 cubital tunnel syndrome AE OAE:0009199 This is an AE which is a medical condition that causes severe burning and aching of the feet, hyperesthesia, and vasomotor changes of the feet that lead to excessive sweating. QY, JX, HY http://en.volupedia.org/wiki/Burning_feet_syndrome 灼烧脚综合征 10070237 burning feet syndrome AE OAE:0009200 This is an AE which is a genetic disorder that affects primarily the liver and the heart. QY, JX, HY http://en.volupedia.org/wiki/Alagille_syndrome 阿拉吉欧征候群 10053870 alagille syndrome AE OAE:0009201 This is an AE which means living with two or more chronic illnesses. QY, JX, HY http://en.volupedia.org/wiki/Multimorbidity 多发病性 10063914 multimorbidity AE OAE:0009202 This is an AE which is an unrecognized and controversial diagnosis characterized by chronic symptoms attributed to exposure to low levels of commonly used chemicals. QY, JX, HY http://en.volupedia.org/wiki/Multiple_chemical_sensitivity 多重化学敏感性 10057865 multiple chemical sensitivity AE OAE:0009203 This is an AE which is a condition that results in weak or soft bones in children. QY, JX, HY http://en.volupedia.org/wiki/Rickets 佝偻 10039119 rickets AE OAE:0009204 This is an AE which is a parasitic disease caused by Toxoplasma gondii, an apicomplexan. QY, JX, HY http://en.volupedia.org/wiki/Toxoplasmosis 弓形体病 10044272 toxoplasmosis AE OAE:0009205 This is an AE which is a viral disease of typically short duration. QY, JX, HY http://en.volupedia.org/wiki/Yellow_fever 黄热病 10048240 yellow fever AE OAE:0009206 This is an AE which is a viral disease that causes inflammation of the brain in humans and other mammals. QY, JX, HY http://en.volupedia.org/wiki/Rabies 狂犬病 10037742 rabies AE OAE:0009207 This is an AE which is a genetic disorder that typically becomes apparent after 6–18 months of age in females. QY, JX, HY http://en.volupedia.org/wiki/Rett_syndrome 雷特氏症 10039000 rett's disorder AE OAE:0009208 This is an AE which is a clinical syndrome characterized by tremor, bradykinesia (slowed movements), rigidity and postural instability. QY, JX, HY http://en.volupedia.org/wiki/Parkinsonism 帕金森症 10034010 parkinsonism AE OAE:0009209 This is an AE which is a condition where an organ does not perform its expected function. QY, JX, HY http://en.volupedia.org/wiki/Organ_dysfunction 器官衰竭 10053159 organ failure AE OAE:0009210 This is an AE which is a spectrum of disorders due to environmental exposure to heat. QY, JX, HY http://en.volupedia.org/wiki/Heat_illness 热病 10068188 heat illness AE OAE:0009211 This is an AE which is a parasomnia that refers to talking aloud while asleep. QY, JX, HY http://en.volupedia.org/wiki/Sleep-talking 说梦话 10041009 sleep talking AE OAE:0009212 This is an AE which refers to systemic-onset juvenile idiopathic arthritis and adult-onset Still's disease. QY, JX, HY http://en.volupedia.org/wiki/Still%27s_disease 尚病 10042061 still's disease AE OAE:0009213 This is an AE which is a form of Still's disease, a rare systemic autoinflammatory disease characterized by the classic triad of fevers, joint pain, and a distinctive salmon-colored bumpy rash. QY, JX, HY http://en.volupedia.org/wiki/Adult-onset_Still%27s_disease 尚病成人发病型 10064056 still's disease adult onset AE OAE:0009214 This is an AE which is a condition in which organs fall down or slip out of place. QY, JX, HY http://en.volupedia.org/wiki/Prolapse 脱垂 10076708 prolapse AE OAE:0009215 This is an AE which is a disorder in which a person exhibits diminished sweating in response to appropriate stimuli. QY, JX, HY http://en.volupedia.org/wiki/Hypohidrosis 无汗症 10002512 anhidrosis AE OAE:0009216 This is an AE which is a chronic dysregulation of a person's circadian rhythm (biological clock), compared to those of the general population and societal norms. QY, JX, HY http://en.volupedia.org/wiki/Delayed_sleep_phase_disorder 延迟睡眠阶段 10012209 delayed sleep phase AE OAE:0009217 This is an AE which refers to any winglike triangular membrane occurring in the neck, eyes, knees, elbows, ankles or digits. QY, JX, HY http://en.volupedia.org/wiki/Pterygium 翼状胬肉 10037263 pterygium AE OAE:0009218 This is an AE which is the harmful effect that occurs when too much of that substance has been taken. QY, JX, HY http://en.volupedia.org/wiki/Poisoning 中毒 10061355 poisoning AE OAE:0009219 This is an AE which is a severe form of heat illness. QY, JX, HY http://en.volupedia.org/wiki/Heat_exhaustion 中暑衰竭 10019332 heat exhaustion AE OAE:0009220 This is an AE which is defined as an absence of speech while conserving or maintaining the ability to hear the speech of others. QY, JX, HY http://en.volupedia.org/wiki/Muteness 缄默症 10028403 mutism AE OAE:0009221 This is an AE which is a medical condition caused by dissolved gases emerging from solution as bubbles inside the body tissues during decompression. QY, JX, HY http://en.volupedia.org/wiki/Decompression_sickness 减压病 10011951 decompression sickness AE OAE:0009222 QY, JX, HY 废弃综合征 10066871 disuse syndrome AE OAE:0009223 QY, JX, HY buccoglossal综合症 10006532 buccoglossal syndrome AE OAE:0009224 QY, JX, HY 高力心综合征 10058177 hyperkinetic heart syndrome AE OAE:0009225 QY, JX, HY 后接种综合症 10036242 post vaccination syndrome AE OAE:0009226 QY, JX, HY 雷诺氏综合症 10070953 reynold's syndrome AE OAE:0009227 This is an AE which is a genus of yeasts and is the most common cause of fungal infections worldwide. QY, JX, HY http://en.volupedia.org/wiki/Candida_(fungus) 系统性念珠菌 10042938 systemic candida AE OAE:0009228 This is an AE which is an autoimmune rheumatic disease characterised by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs and by injuries to small arteries. QY, JX, HY http://en.volupedia.org/wiki/Systemic_scleroderma 系统性硬化症 10042953 systemic sclerosis AE OAE:0009229 This is an AE which is an autoimmune rheumatic disease characterised by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs and by injuries to small arteries. QY, JX, HY http://en.volupedia.org/wiki/Systemic_scleroderma 系统性硬皮病 10078638 systemic scleroderma AE OAE:0009230 This is an AE which is disease caused by fungi. QY, JX, HY http://en.volupedia.org/wiki/Fungal_infection 系统性真菌病 10052366 systemic mycosis AE OAE:0009231 This is an AE which is a neurological disorder whose key defining characteristic is a temporary but almost total disruption of short-term memory with a range of problems accessing older memories. QY, JX, HY http://en.volupedia.org/wiki/Transient_global_amnesia 全局性失忆 10058669 global amnesia AE OAE:0009232 This is an AE which is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents. QY, JX, HY http://en.volupedia.org/wiki/General_anaesthesia 全身麻醉 10018060 general anaesthesia AE OAE:0009233 This is an AE which is defined as a seizure that has a tonic phase followed by clonic muscle contractions and is non-motor. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32119383/ 非运动性全身性发作 10083376 generalised onset non-motor seizure AE OAE:0009234 This is an AE which is redness of the skin or mucous membranes, caused by hyperemia (increased blood flow) in superficial capillaries and is generalised . QY, JX, HY http://en.volupedia.org/wiki/Erythema 全身性红斑 10051576 generalised erythema AE OAE:0009235 This is an AE which is a mental and behavioral disorder, specifically an anxiety disorder characterized by excessive, uncontrollable and often irrational worry about events or activities. QY, JX, HY http://en.volupedia.org/wiki/Generalized_anxiety_disorder 全身性焦虑障碍 10018075 generalised anxiety disorder AE OAE:0009236 This is an AE which is a large, complex, enveloped virus belonging to the poxvirus family and is generalised desease. QY, JX, HY http://en.volupedia.org/wiki/Vaccinia 全身性牛痘 10069540 generalised vaccinia AE OAE:0009237 This is an AE which is associated with poorer sleep quality, with Pittsburgh Sleep Quality Index score above 6. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32580764/ 全身性瘙痒 10052576 pruritus generalised AE OAE:0009238 This is an AE which is described as pruritic erythematous, raised, circumscribed lesions with central pallor that blanch with pressure and is generalised desease. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31690389/ 全身性荨麻疹 10052569 urticaria generalised AE OAE:0009239 This is an AE which is the loss of all skull and facial hair and its causes are unclear, but believed to be autoimmune. QY, JX, HY http://en.volupedia.org/wiki/Alopecia_totalis 全秃 10001766 alopecia totalis AE OAE:0009240 QY, JX, HY 全身症状 10060891 general symptom AE OAE:0009241 This is an AE which can be spread over a large area it does not obstruct venous return. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/5085940/ 重力性水肿 10018713 gravitational edema AE OAE:0009242 This is an AE which is a benign growth on the pituitary gland in the brain, specifically a mucin-filled cyst in the posterior portion of the anterior pituitary gland. QY, JX, HY http://en.volupedia.org/wiki/Rathke%27s_cleft_cyst Rathke裂囊肿 10058969 rathke's cleft cyst AE OAE:0009243 This is an AE which is a closed sac, having a distinct envelope and division compared with the nearby tissue. QY, JX, HY http://en.volupedia.org/wiki/Cyst 囊肿 10011732 cyst AE OAE:0009244 This is an AE which is a collection of cerebrospinal fluid (CSF), without blood, located under the dural membrane of the brain. QY, JX, HY http://en.volupedia.org/wiki/Subdural_hygroma 硬膜下水瘤 10048626 subdural hygroma AE OAE:0009245 This is an AE which is a common, sometimes chronic skin condition which presents as reddish bumps on the skin arranged in a circle or ring. QY, JX, HY http://en.volupedia.org/wiki/Granuloma_annulare 环状肉芽肿 10018692 granuloma annulare AE OAE:0009246 This is an AE which is a condition in the fetus characterized by an accumulation of fluid, or edema, in at least two fetal compartments. QY, JX, HY http://en.volupedia.org/wiki/Hydrops_fetalis 胎儿水肿 10020529 hydrops foetalis AE OAE:0009247 This is an AE which is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). QY, JX, HY http://en.volupedia.org/wiki/Tumefactive_multiple_sclerosis 肿瘤性多发性硬化症 10078556 tumefactive multiple sclerosis AE OAE:0009248 This is an AE which is a condition or lesion involving abnormal cells which are associated with an increased risk of developing into cancer. QY, JX, HY http://en.volupedia.org/wiki/Precancerous_condition 癌前病变 10083553 precancerous condition AE OAE:0009249 This is an AE which is a cutaneous condition characterized by dependent edema from vasodilatory pooling. QY, JX, HY http://en.volupedia.org/wiki/Heat_edema 热水肿 10019340 heat edema AE OAE:0009250 This is an AE which is a cutaneous condition that develop in patients with an acute exacerbation of chronic edema, particularly of the lower extremities, and in the setting of anasarca. QY, JX, HY http://en.volupedia.org/wiki/Edema_blister 水肿泡 10080039 edema blister AE OAE:0009251 This is an AE which is a cyst in the eyelid usually due to a blocked meibomian gland,typically in the middle of the eyelid, red, and not painful. QY, JX, HY http://en.volupedia.org/wiki/Chalazion 睑板腺囊肿 10008388 chalazion AE OAE:0009252 This is an AE which is a deposition of yellowish cholesterol-rich material that can appear anywhere in the body in various disease states. QY, JX, HY http://en.volupedia.org/wiki/Xanthoma 黄瘤 10048214 xanthoma AE OAE:0009253 This is an AE which is a fluid-filled bump associated with a joint or tendon sheath. QY, JX, HY http://en.volupedia.org/wiki/Ganglion_cyst 滑膜囊肿 10042858 synovial cyst AE OAE:0009254 This is an AE which is a group of abnormal cells. QY, JX, HY http://en.volupedia.org/wiki/Carcinoma_in_situ 原位癌 10061450 carcinoma in situ AE OAE:0009255 This is an AE which is a localized bleeding outside of subcutaneous blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. QY, JX, HY http://en.volupedia.org/wiki/Hematoma 皮下血肿 10042345 subcutaneous hematoma AE OAE:0009256 This is an AE which is a malignant and aggressive neoplasm with unclear molecular etiology. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32166375/ 基底鳞状癌 10004178 basosquamous carcinoma AE OAE:0009257 This is an AE which is a malignant tumor in the mediastinum, the cavity that separates the lungs from the rest of the chest. QY, JX, HY http://en.volupedia.org/wiki/Mediastinal_tumors 恶性纵隔肿瘤 10061241 malignant mediastinal neoplasm AE OAE:0009258 This is an AE which is a malignant tumor, a type of cancer that arises from transformed cells of mesenchymal (connective tissue) origin. QY, JX, HY http://en.volupedia.org/wiki/Sarcoma 肉瘤 10039491 sarcoma AE OAE:0009259 This is an AE which is a mass of cells (tumor) that lacks the ability to either invade neighboring tissue or metastasize (spread throughout the body). QY, JX, HY http://en.volupedia.org/wiki/Benign_tumor 良性肿瘤 10060999 benign neoplasm AE OAE:0009260 This is an AE which is a pre-cancerous area of thick, scaly, or crusty skin. QY, JX, HY http://en.volupedia.org/wiki/Actinic_keratosis 光线性角化病 10000614 actinic keratosis AE OAE:0009261 This is an AE which is a primary cause of reduced vision following both cataract and successful vitreoretinal surgery. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28351047/ 囊状的黄斑水肿 10058202 cystoid macular edema AE OAE:0009262 This is an AE which is a rare clinical condition characterised by diffuse woody induration of skin commonly associated with diabetes mellitus,infections and monoclonal gammopathy. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32539033/ 硬化病 10055953 scleredema AE OAE:0009263 This is an AE which is a rare condition. Desmoid tumors arise from cells called fibroblasts, which are found throughout the body and provide structural support, protection to the vital organs, and play a critical role in wound healing. QY, JX, HY http://en.volupedia.org/wiki/Aggressive_fibromatosis 硬纤维瘤 10059352 desmoid tumor AE OAE:0009264 This is an AE which is a rare disorder defined as a pathological overgrowth of normal epidural fat. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/10745936/ 硬膜外脂肪瘤病 10067599 epidural lipomatosis AE OAE:0009265 This is an AE which is a rare skin disorder that primarily affects children under one year of age but can also be found in older children and adults. QY, JX, HY http://en.volupedia.org/wiki/Juvenile_xanthogranuloma 黄色肉芽肿 10051251 xanthogranuloma AE OAE:0009266 This is an AE which is a rare tumor of the adrenal medulla composed of chromaffin cells, also known as pheochromocytes. QY, JX, HY http://en.volupedia.org/wiki/Pheochromocytoma 嗜铬细胞瘤 10034800 phaeochromocytoma AE OAE:0009267 This is an AE which is a serious long-term complication in cancer survivors. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28373478/ 第二原发恶性肿瘤 10039801 second primary malignancy AE OAE:0009268 This is an AE which is a sharply demarcated yellowish deposit of cholesterol underneath the skin. QY, JX, HY http://en.volupedia.org/wiki/Xanthelasma 黄瘤 10048211 xanthelasma AE OAE:0009269 This is an AE which is a skin condition that most commonly presents with symmetrical round-to-oval red or violet plaques on the flanks, armpits, inner thighs, and lower abdomen. QY, JX, HY http://en.volupedia.org/wiki/Interstitial_granulomatous_dermatitis_with_arthritis 间质性肉芽肿性皮炎 10067972 interstitial granulomatous dermatitis AE OAE:0009270 This is an AE which is a syndrome (a set of signs and symptoms) that is the consequence of cancer in the body, specifically due to the production of chemical signaling molecules (such as hormones or cytokines) by tumor cells or by an immune response against the tumor. QY, JX, HY http://en.volupedia.org/wiki/Paraneoplastic_syndrome 副肿瘤综合征 10059420 paraneoplastic syndrome AE OAE:0009271 This is an AE which is a term used synonymously with severe hypothyroidism. QY, JX, HY http://en.volupedia.org/wiki/Myxedema 粘液性水肿 10028665 myxedema AE OAE:0009272 This is an AE which is a tumor in the mediastinum, the cavity that separates the lungs from the rest of the chest. QY, JX, HY http://en.volupedia.org/wiki/Mediastinal_tumors 纵隔肿块 10027076 mediastinal mass AE OAE:0009273 This is an AE which is a tumor in the mediastinum, the cavity that separates the lungs from the rest of the chest. It contains the heart, esophagus, trachea, thymus, and aorta. QY, JX, HY http://en.volupedia.org/wiki/Mediastinal_tumors 纵隔肿瘤 10027086 mediastinum neoplasm AE OAE:0009274 This is an AE which is a tumor made up of several different types of tissue, such as hair, muscle, teeth, or bone. QY, JX, HY http://en.volupedia.org/wiki/Teratoma 畸胎瘤 10043276 teratoma AE OAE:0009275 This is an AE which is a tumor that arises from the ependyma, a tissue of the central nervous system. QY, JX, HY http://en.volupedia.org/wiki/Ependymoma 室管膜瘤 10014967 ependymoma AE OAE:0009276 This is an AE which is a tumor that can develop on any skin or mucosal surface, but occurs on the tongue 40% of the time. QY, JX, HY http://en.volupedia.org/wiki/Granular_cell_tumor 颗粒细胞瘤 10060980 granular cell tumor AE OAE:0009277 This is an AE which is a type of abnormal and excessive growth of tissue. QY, JX, HY http://en.volupedia.org/wiki/Neoplasm 肿瘤 10028980 neoplasm AE OAE:0009278 This is an AE which is a type of cancer that can form masses in the skin, in lymph nodes, in the mouth, or in other organs. QY, JX, HY http://en.volupedia.org/wiki/Kaposi%27s_sarcoma 卡波济氏肉瘤 10023284 kaposi's sarcoma AE OAE:0009279 This is an AE which is a type of cancer that may be a bone sarcoma or a soft-tissue sarcoma. QY, JX, HY http://en.volupedia.org/wiki/Ewing%27s_sarcoma 尤文氏肉瘤 10015560 ewing's sarcoma AE OAE:0009280 This is an AE which is a type of connective tissue cancer in which the cells are spindle-shaped when examined under a microscope. QY, JX, HY http://en.volupedia.org/wiki/Spindle_cell_sarcoma 梭形细胞肉瘤 10049067 spindle cell sarcoma AE OAE:0009281 This is an AE which is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. QY, JX, HY http://en.volupedia.org/wiki/Small-cell_carcinoma 小细胞癌 10041056 small cell carcinoma AE OAE:0009282 This is an AE which is a type of skin cancer that develops from the pigment-producing cells known as melanocytes in situ. QY, JX, HY http://en.volupedia.org/wiki/Melanoma 原位恶性黑色素瘤 10025652 malignant melanoma in situ AE OAE:0009283 This is an AE which is a type of skin cancer that develops from the pigment-producing cells known as melanocytes. QY, JX, HY http://en.volupedia.org/wiki/Melanoma 恶性黑色素瘤 10025650 malignant melanoma AE OAE:0009284 This is an AE which is a type of skin infection which typically occurs as a cyst between the cheeks of the buttocks and often at the upper end. QY, JX, HY http://en.volupedia.org/wiki/Pilonidal_disease 藏毛囊肿 10035043 pilonidal cyst AE OAE:0009285 This is an AE which is a usually benign (non-malignant) cyst in the pineal gland, a small endocrine gland in the brain. QY, JX, HY http://en.volupedia.org/wiki/Pineal_gland_cyst 松果体囊肿 10068650 pineal gland cyst AE OAE:0009286 This is an AE which is a vascular tumor that occurs on both mucosa and skin, and appears as an overgrowth of tissue due to irritation, physical trauma, or hormonal factors. QY, JX, HY http://en.volupedia.org/wiki/Pyogenic_granuloma 化脓性肉芽肿 10037649 pyogenic granuloma AE OAE:0009287 This is an AE which is an abnormal growth of tissue projecting from a mucous membrane. QY, JX, HY http://en.volupedia.org/wiki/Polyp_(medicine) 息肉 10061529 polyp AE OAE:0009288 This is an AE which is an ambiguous mass found in the neck area. QY, JX, HY http://en.volupedia.org/wiki/Neck_mass 脖子上有肿块 10049146 neck mass AE OAE:0009289 This is an AE which is an extremely rare long-term systemic disorder that involves the formation of granulomas and inflammation of blood vessels (vasculitis). QY, JX, HY http://en.volupedia.org/wiki/Granulomatosis_with_polyangiitis 肉芽肿性多血管炎 10072579 granulomatosis with polyangiitis AE OAE:0009290 This is an AE which is an extremely rare long-term systemic disorder that involves the formation of granulomas and inflammation of blood vessels (vasculitis). QY, JX, HY http://en.volupedia.org/wiki/Granulomatosis_with_polyangiitis 韦格纳肉芽肿 10047888 wegener's granulomatosis AE OAE:0009291 This is an AE which is an uncommon but distinctive acquired ichthyosiform dermatosis characterized by persistent dark, scaly, papules and plaques that tend to be localized predominantly on the central trunk. QY, JX, HY http://en.volupedia.org/wiki/Confluent_and_reticulated_papillomatosis 融合和网状乳头状瘤病 10069414 confluent and reticulate papillomatosis AE OAE:0009292 This is an AE which is edema (accumulation of fluid causing swelling) in tissues perfused by the peripheral vascular system, usually in the lower limbs. QY, JX, HY http://en.volupedia.org/wiki/Peripheral_edema 外围肿胀 10048959 peripheral swelling AE OAE:0009293 This is an AE which is edema (accumulation of fluid causing swelling) in tissues perfused by the peripheral vascular system, usually in the lower limbs. QY, JX, HY http://en.volupedia.org/wiki/Peripheral_edema 外周性水肿 10030124 edema peripheral AE OAE:0009294 This is an AE which is palpated and computed tomography examination revealed entire bone proliferation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30012929/ 下颌肿块 10079878 mandibular mass AE OAE:0009295 This is an AE which is the build-up of fluid in the face tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 脸部水肿 10016029 face edema AE OAE:0009296 This is an AE which is the medical term for an unusually large tongue. QY, JX, HY http://en.volupedia.org/wiki/Macroglossia 舌头肿胀 10042727 swollen tongue AE OAE:0009297 This is an AE which is the most aggressive form of melanoma. QY, JX, HY http://en.volupedia.org/wiki/Nodular_melanoma 结节性黑素瘤 10029488 nodular melanoma AE OAE:0009298 This is an AE which is the most aggressive type of cancer that begins within the brain. QY, JX, HY http://en.volupedia.org/wiki/Glioblastoma 多形性成胶质细胞瘤 10018337 glioblastoma multiforme AE OAE:0009299 This is an AE which is the most aggressive type of cancer that begins within the brain. QY, JX, HY http://en.volupedia.org/wiki/Glioblastoma 胶质母细胞瘤 10018336 glioblastoma AE OAE:0009300 This is an AE which is the term used for a group of rare syndromes involving structures arising from the embryonic ectoderm. QY, JX, HY http://en.volupedia.org/wiki/Phakomatosis 脂肪瘤病 10048734 phakomatosis AE OAE:0009301 This is an AE which is tumors that affect the blood, bone marrow, lymph, and lymphatic system. QY, JX, HY http://en.volupedia.org/wiki/Tumors_of_the_hematopoietic_and_lymphoid_tissues 血液系统恶性肿瘤 10066476 haematological malignancy AE OAE:0009302 This is an AE which is when a person's cancer returns after treatment. QY, JX, HY http://en.volupedia.org/wiki/Cancer_recurrence 癌症复发 10038111 recurrent cancer AE OAE:0009303 This is an AE which may amplify bronchial responsiveness by increasing epithelial permeability, by altering airway mechanics, or by stimulating neural pathways. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/2679603/ 粘膜水肿 10030111 edema mucosal AE OAE:0009306 This is an AE which presents as skin-colored to erythematous papules symmetrically distributed on extensor extremities. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30921008/ 帕利萨脱型中性粒细胞性肉芽肿性皮炎 10068809 palisaded neutrophilic granulomatous dermatitis AE OAE:0009307 This is an AE which refers a transient abnormal enlargement of a body part or area not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 肿胀 10042674 swelling AE OAE:0009308 This is an AE which refers a transient abnormal enlargement of face not caused by a tumor. QY, JX, HY http://en.volupedia.org/wiki/Swelling 脸肿胀 10042682 swelling face AE OAE:0009309 QY, JX, HY 良性软组织肿瘤 10061004 benign soft tissue neoplasm AE OAE:0009310 QY, JX, HY 颌下腺肿大 10042419 submaxillary gland enlargement AE OAE:0009311 QY, JX, HY 朗格汉斯细胞肉芽肿病 10023688 langerhans' cell granulomatosis AE OAE:0009313 QY, JX, HY 肉芽肿性皮炎 10074954 granulomatous dermatitis AE OAE:0009314 QY, JX, HY 上肢肿块 10048698 upper extremity mass AE OAE:0009315 QY, JX, HY 外伤性血肿 10044522 traumatic hematoma AE OAE:0009316 QY, JX, HY 心内肿块 10066087 intracardiac mass AE OAE:0009317 QY, JX, HY 凹陷性水肿 10035076 pitting edema AE OAE:0009318 QY, JX, HY 会厌性水肿 10015029 epiglottic edema AE OAE:0009319 QY, JX, HY 假性视乳头水肿 10037141 pseudopapilledema AE OAE:0009320 QY, JX, HY 全身性水肿 10018092 generalised edema AE OAE:0009321 QY, JX, HY 粘膜癌前病变 10068367 precancerous mucosal lesion AE OAE:0009322 This is an AE which is a non-destructive disease that causes inflammation with ulcerative of the gums. QY, JX, HY http://en.volupedia.org/wiki/Gingivitis 齿龈炎溃疡性 10010296 gingivitis ulcerative AE OAE:0009323 This is an AE which is extensive, yet the rare nature of this disease means that there is a lack of good quality research available. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/28761942/ 坏死性溃疡性龈口炎 10055670 necrotising ulcerative gingivostomatitis AE OAE:0009324 This is an AE which is a discontinuity or break in a bodily membrane with haemorrhage that impedes normal function of the affected organ. QY, JX, HY http://en.volupedia.org/wiki/Ulcer 溃疡出血 10061577 ulcer hemorrhage AE OAE:0009328 This is an AE which is an autosomal recessive metabolic disorder affecting amino acid transport. QY, JX, HY http://en.volupedia.org/wiki/Lysinuric_protein_intolerance 赖氨酸尿性蛋白耐受不良 10058300 lysinuric protein intolerance AE OAE:0009329 This is an AE which is a component of MHC class I molecules, MHC class I molecules have α1, α2, and α3 proteins which are present on all nucleated cells (excludes red blood cells). QY, JX, HY http://en.volupedia.org/wiki/Beta-2_microglobulin β2微球蛋白尿 10073223 beta 2 microglobulin urine AE OAE:0009330 This is an AE which characterized by rapid and almost complete destruction of pancreatic β-cells, is a newly identified subtype of type 1 diabetes mellitus. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/30203124/ 暴发性1型糖尿病 10072628 fulminant type 1 diabetes mellitus AE OAE:0009331 This is an AE which is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. QY, JX, HY http://en.volupedia.org/wiki/Phenylketonuria 苯丙酮酸尿 10034872 phenylketonuria AE OAE:0009332 This is an AE which is abnormal, characterization of the chromatogram is facilitated by calculation of uroporphyrin-to-heptacarboxylate porphyrin (uro/hepta) and uroporphyrin-to-isocoproporphyrin (uro/iso) ratios. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11508829/ 卟啉尿 10059910 porphyrins urine AE OAE:0009333 This is an AE which is an inability to completely empty the bladder. QY, JX, HY http://en.volupedia.org/wiki/Urinary_retention 残尿 10060695 residual urine AE OAE:0009334 This is an AE which is a possible adverse effect of selective sodium-glucose cotransporter inhibitors 2 (isGLT2) in patients with diabetes. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/31734176/ 常血糖性糖尿病酮症酸中毒 10080061 euglycaemic diabetic ketoacidosis AE OAE:0009335 This is an AE which is a monoamine neurotransmitter, an organic compound that has a catechol (benzene with two hydroxyl side groups next to each other) and a side-chain amine and it appears on urine. QY, JX, HY http://en.volupedia.org/wiki/Catecholamine 儿茶酚胺尿 10062277 catecholamines urine AE OAE:0009336 This is an AE which is a highly polar chiral carboxylic acid on the urine that is usually not detected during routine organic acid analysis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/11920944/ 甘油酸尿 10060757 glyceric acid urine AE OAE:0009337 This is an AE which is a reversible form of coma found in people with diabetes mellitus. QY, JX, HY http://en.volupedia.org/wiki/Diabetic_coma 高渗透压性糖尿病 10012631 diabetes with hyperosmolarity AE OAE:0009338 This is an AE which is a generic term applied to skin rashes in the diaper area that are caused by various skin disorders and/or irritants. QY, JX, HY http://en.volupedia.org/wiki/Irritant_diaper_dermatitis 念珠菌尿布疹 10007135 candida nappy rash AE OAE:0009339 This is an AE which is a liquid by-product of metabolism in humans and in many other animals and is crystal. QY, JX, HY http://en.volupedia.org/wiki/Urine 晶体尿 10053114 crystal urine AE OAE:0009340 This is an AE which is characterized by excessive unsuppressible release of antidiuretic hormone (ADH) either from the posterior pituitary gland, or an abnormal non-pituitary source. QY, JX, HY http://en.volupedia.org/wiki/Syndrome_of_inappropriate_antidiuretic_hormone_secretion 抗利尿激素分泌不当 10053198 inappropriate antidiuretic hormone secretion AE OAE:0009341 This is an AE which is diabetes specifically caused by cystic fibrosis, a genetic condition. QY, JX, HY http://en.volupedia.org/wiki/Cystic_fibrosis%E2%80%93related_diabetes 囊性纤维化相关性糖尿病 10068271 cystic fibrosis related diabetes AE OAE:0009342 This is an AE which is a condition characterized by large amounts of dilute urine and increased thirst. QY, JX, HY http://en.volupedia.org/wiki/Diabetes_insipidus 尿崩症 10012599 diabetes insipidus AE OAE:0009343 This is an AE which is the low output of urine specifically more than 80 ml/day but less than 100ml/day. QY, JX, HY http://en.volupedia.org/wiki/Oliguria 尿过少 10030302 oliguria AE OAE:0009344 This is an AE which is when a solid piece of material (kidney stone) develops in the urinary tract. QY, JX, HY http://en.volupedia.org/wiki/Kidney_stone_disease 尿路结石 10007027 calculus urinary AE OAE:0009345 This is an AE which refers the involuntary excretion of urine. QY, JX, HY http://en.volupedia.org/wiki/Incontinence 尿失禁 10021639 incontinence AE OAE:0009346 This is an AE which is the release of urine from the urinary bladder through the urethra to the outside of the body and the process is urgency. QY, JX, HY http://en.volupedia.org/wiki/Urination 排尿急症 10027566 micturition urgency AE OAE:0009347 This is an AE which is infrequent (or, in occasional usage, very light) menstruation. QY, JX, HY http://en.volupedia.org/wiki/Oligomenorrhea 少尿症 10030295 oligomenorrhoea AE OAE:0009348 This is an AE which was found in a variety of kidney diseases besides AIN. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/24052222/ 嗜酸性粒细胞尿 10058391 eosinophils urine AE OAE:0009349 This is an AE which is when a solid piece of material (kidney stone) develops in the urinary tract. QY, JX, HY http://en.volupedia.org/wiki/Kidney_stone_disease 输尿管结石 10007025 calculus ureteric AE OAE:0009350 This is an AE which is urine which contains white blood cells while appearing sterile by standard culturing techniques. QY, JX, HY http://en.volupedia.org/wiki/Pyuria 无菌性脓尿 10042010 sterile pyuria AE OAE:0009351 This is an AE which analysis by HPLC gave a positive predictive value of 81% for Cushing's syndrome. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/17022883/ 无皮质醇尿液 10011199 cortisol free urine AE OAE:0009352 This is an AE which is bacteriuria without accompanying symptoms of a urinary tract infection. QY, JX, HY http://en.volupedia.org/wiki/Bacteriuria 无症状菌尿 10056396 asymptomatic bacteriuria AE OAE:0009353 This is an AE which is a chemical intermediate in the synthesis of artificial vanilla flavorings and is an end-stage metabolite of the catecholamines (dopamine, epinephrine, and norepinephrine) and it appears on the urine . QY, JX, HY http://en.volupedia.org/wiki/Vanillylmandelic_acid 香草扁桃酸尿 10050833 vanillyl mandelic acid urine AE OAE:0009354 This is an AE which is a condition in which the oxygen transport protein hemoglobin is found in abnormally high concentrations in the urine. QY, JX, HY http://en.volupedia.org/wiki/Hemoglobinuria 血红素尿 10018906 hemoglobinuria AE OAE:0009355 This is an AE which is defined as the presence of blood or red blood cells in the urine. QY, JX, HY http://en.volupedia.org/wiki/Hematuria 血尿症 10018867 haematuria AE OAE:0009356 This is an AE which is a form of urinary incontinence. QY, JX, HY http://en.volupedia.org/wiki/Stress_incontinence 压力性尿失禁 10066218 stress urinary incontinence AE OAE:0009357 This is an AE which is associated urinary tract infections (UTIs). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32430571/ 亚硝酸盐尿 10059220 nitrite urine AE OAE:0009358 This is an AE which consists 10% of the total renal biopsy of glomerulonephritis. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/18723953/ 膜增生性肾小球肾炎 10066453 mesangioproliferative glomerulonephritis AE OAE:0009359 This is an AE which occurs with unilateral renal agenesis (URA) in 1/2000 live births - or after uninephrectomy for tumor, trauma, uncontrolled infections or hypertension and post-kidney donation. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/29374876/ 单功能肾 10063530 single functional kidney AE OAE:0009360 This is an AE which is a major complication of kidney transplantation. Many centers respond to PVAN by reducing immunosuppression. QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/16734632/ 多瘤病毒相关性肾病 10065381 polyomavirus-associated nephropathy AE OAE:0009361 This is an AE which is kidney damage (nephropathy) due to urine flowing backward (reflux) from the bladder toward the kidneys; the latter is called vesicoureteral reflux (VUR). QY, JX, HY http://en.volupedia.org/wiki/Reflux_nephropathy 反流性肾病 10065427 reflux nephropathy AE OAE:0009362 This is an AE which is a secondary condition in which the adrenal glands do not produce adequate amounts of steroid hormones, primarily cortisol; but may also include impaired production of aldosterone (a mineralocorticoid), which regulates sodium conservation, potassium secretion, and water retention. QY, JX, HY http://en.volupedia.org/wiki/Adrenal_insufficiency 继发性肾上腺皮质功能不全 10039807 secondary adrenocortical insufficiency AE OAE:0009363 This is an AE which is a disorder of the small blood vessels of the kidney. QY, JX, HY http://en.volupedia.org/wiki/Acute_proliferative_glomerulonephritis 链球菌后肾小球肾炎 10036303 post streptococcal glomerulonephritis AE OAE:0009364 This is an AE which is a group of clinically similar illnesses caused by the Puumala virus. QY, JX, HY http://en.volupedia.org/wiki/Hantavirus_hemorrhagic_fever_with_renal_syndrome 流行性肾病 10062522 epidemic nephropathy AE OAE:0009365 This is an AE which is the build-up of fluid in the kidney tissue. QY, JX, HY http://en.volupedia.org/wiki/Edema 肾脏水肿 10073381 edematous kidney AE OAE:0009366 This is an AE which is a medical condition in which the kidneys are functioning at less than 15% of normal levels. QY, JX, HY http://en.volupedia.org/wiki/Kidney_failure 终末期肾病 10077512 end stage renal disease AE OAE:0009367 This is an AE which is hallmarks of the uremic phenotype and contribute to impaired health status, reduced quality of life, and premature mortality in chronic kidney disease (CKD). QY, JX, HY https://pubmed.ncbi.nlm.nih.gov/32260373/ 过早衰老 10063493 premature ageing AE OAE:0009368 渴感过少 10053141 oligodipsia AE OAE:0009369 小结石病 10062199 microlithiasis AE OAE:0009370 音响过弱 10051233 hypophonesis AE OAE:0009371 roux循环转换 10039245 roux loop conversion AE OAE:0009372 做鬼脸 10061991 grimacing AE OAE:0009373 伴随疾病恶化 10010253 concomitant disease aggravated AE OAE:0009374 跌倒发作 10013643 drop attacks AE OAE:0009375 动物抓痕 10002519 animal scratch AE OAE:0009376 冻结现象 10060904 freezing phenomenon AE OAE:0009377 多发性损伤 10028224 multiple injuries AE OAE:0009378 多器官疾病 10058092 multi-organ disorder AE OAE:0009379 发低沉的咕噜声 10018762 grunting AE OAE:0009380 囊液积聚 10072833 bursal fluid accumulation AE OAE:0009381 滑囊疾病 10056337 bursa disorder AE OAE:0009382 产生过量的耵聍 10076897 excessive cerumen production AE OAE:0009383 汗水变色 10042652 sweat discoloration AE OAE:0009385 昏迷酸中毒的 10049037 coma acidotic AE OAE:0009386 获得结节病 10049243 ankyloglossia acquired AE OAE:0009387 颊粘膜粗化 10048479 buccal mucosal roughening AE OAE:0009388 惊厥阈值降低 10010927 convulsive threshold lowered AE OAE:0009390 期外收缩 10015856 extrasystoles AE OAE:0009391 热感觉减退 10068009 thermohypoesthesia AE OAE:0009393 双杂合子镰状病 10013609 double heterozygous sickling disorders AE OAE:0009394 畸形足 10043101 talipes AE OAE:0009395 特伦德伦堡的症状 10050051 trendelenburg's symptom AE OAE:0009396 晶状体色素沉着 10024216 lenticular pigmentation AE OAE:0009397 外围瘫痪 10054808 peripheral paralysis AE OAE:0009398 外周循环衰竭 10034567 peripheral circulatory failure AE OAE:0009399 网状内皮系统刺激 10038802 reticuloendothelial system stimulated AE OAE:0009400 假臀部 10050187 pseudocroup AE OAE:0009401 无法爬行 10050740 inability to crawl AE OAE:0009402 无症状covid-19 10084459 asymptomatic covid-19 AE OAE:0009403 线虫病 10062701 nematodiasis AE OAE:0009404 香水过敏 10034434 perfume sensitivity AE OAE:0009405 橡胶过敏 10039251 rubber sensitivity AE OAE:0009406 悬雍膜炎 10051962 uvulitis AE OAE:0009407 髓鞘推迟形成 10076456 delayed myelination AE OAE:0009408 炎症后色素沉着改变 10036229 post inflammatory pigmentation change AE OAE:0009409 炎症性疼痛 10065390 inflammatory pain AE OAE:0009410 面部压伤 10016023 face crushing AE OBA:2001000 The age at which Alzheimer disease manifestations first appear. true age Alzheimer disease symptoms begin age at onset of Alzheimer disease age of onset of Alzheimer disease OBA:2001001 The age at which asthma manifestations first appear. true age asthma symptoms begin age at onset of asthma age of onset of asthma OBA:2001002 The age at which urinary bladder carcinoma manifestations first appear. age at onset of urinary bladder carcinoma age urinary bladder carcinoma symptoms begin age of onset of urinary bladder carcinoma OBA:2001004 The age at which cataract manifestations first appear. true age at onset of cataract age cataract symptoms begin age of onset of cataract OBA:2001007 The age at which hyperlipidemia manifestations first appear. age at onset of hyperlipidemia age hyperlipidemia symptoms begin age of onset of hyperlipidemia OBA:2001008 The age at which osteoarthritis manifestations first appear. true age at onset of osteoarthritis age osteoarthritis symptoms begin age of onset of osteoarthritis OBA:2001009 The age at which Parkinson disease manifestations first appear. true age Parkinson disease symptoms begin age at onset of Parkinson disease age of onset of Parkinson disease OBA:2001010 The age at which essential hypertension manifestations first appear. age at onset of essential hypertension age essential hypertension symptoms begin age of onset of essential hypertension OBA:2001011 The age at which schizophrenia manifestations first appear. true age at onset of schizophrenia age schizophrenia symptoms begin age of onset of schizophrenia OBA:2001012 The age at which type 1 diabetes mellitus manifestations first appear. true age at onset of type 1 diabetes mellitus age type 1 diabetes mellitus symptoms begin age of onset of type 1 diabetes mellitus OBA:2001013 The age at which type 2 diabetes mellitus manifestations first appear. true age at onset of type 2 diabetes mellitus age type 2 diabetes mellitus symptoms begin age of onset of type 2 diabetes mellitus OBA:2001015 The age at which childhood onset asthma manifestations first appear. true age at onset of childhood onset asthma age childhood onset asthma symptoms begin age of onset of childhood onset asthma OBA:2001016 The age at which alcohol dependence manifestations first appear. true age alcohol dependence symptoms begin age at onset of alcohol dependence age of onset of alcohol dependence OBA:2001017 The age at which allergic disease manifestations first appear. true age allergic disease symptoms begin age at onset of allergic disease age of onset of allergic disease OBA:2001018 The age at which amyotrophic lateral sclerosis manifestations first appear. true age amyotrophic lateral sclerosis symptoms begin age at onset of amyotrophic lateral sclerosis age of onset of amyotrophic lateral sclerosis OBA:2001019 The age at which bipolar disorder manifestations first appear. true age at onset of bipolar disorder age bipolar disorder symptoms begin age of onset of bipolar disorder OBA:2001020 The age at which Buruli ulcer disease manifestations first appear. true age Buruli ulcer disease symptoms begin age at onset of Buruli ulcer disease age of onset of Buruli ulcer disease OBA:2001022 The age at which frontotemporal dementia manifestations first appear. true age at onset of frontotemporal dementia age frontotemporal dementia symptoms begin age of onset of frontotemporal dementia OBA:2001024 The age at which Huntington disease manifestations first appear. true age Huntington disease symptoms begin age at onset of Huntington disease age of onset of Huntington disease OBA:2001026 The age at which migraine disorder manifestations first appear. true age at onset of migraine disorder age migraine disorder symptoms begin age of onset of migraine disorder OBA:2001027 The age at which migraine with aura manifestations first appear. true age at onset of migraine with aura age migraine with aura symptoms begin age of onset of migraine with aura OBA:2001028 The age at which migraine without aura manifestations first appear. true age at onset of migraine without aura age migraine without aura symptoms begin age of onset of migraine without aura OBA:2001029 The age at which multiple sclerosis manifestations first appear. true age at onset of multiple sclerosis age multiple sclerosis symptoms begin age of onset of multiple sclerosis OBA:2001030 The age at which myopia manifestations first appear. true age at onset of myopia age myopia symptoms begin age of onset of myopia OBA:2001031 The age at which refractive error manifestations first appear. age at onset of refractive error age refractive error symptoms begin age of onset of refractive error OBA:2001032 The age at which narcolepsy-cataplexy syndrome manifestations first appear. true age at onset of narcolepsy-cataplexy syndrome age narcolepsy-cataplexy syndrome symptoms begin age of onset of narcolepsy-cataplexy syndrome OBA:2001033 The age at which coronary atherosclerosis manifestations first appear. age at onset of coronary atherosclerosis age coronary atherosclerosis symptoms begin age of onset of coronary atherosclerosis OBA:2040153 The age at which cancer manifestations first appear. age at onset of cancer age cancer symptoms begin age of onset of cancer OBA:2040154 The age at which glaucoma manifestations first appear. age at onset of glaucoma age glaucoma symptoms begin age of onset of glaucoma OBA:2040155 The age at which stroke disorder manifestations first appear. age at onset of stroke disorder age stroke disorder symptoms begin age of onset of stroke disorder OBA:2040156 The age at which coronary stenosis manifestations first appear. age at onset of coronary stenosis age coronary stenosis symptoms begin age of onset of coronary stenosis OBA:2040157 The age at which glioblastoma manifestations first appear. age at onset of glioblastoma age glioblastoma symptoms begin age of onset of glioblastoma OBA:2040158 The age at which systemic lupus erythematosus manifestations first appear. age at onset of systemic lupus erythematosus age systemic lupus erythematosus symptoms begin age of onset of systemic lupus erythematosus OBA:2040159 The age at which hypertensive disorder manifestations first appear. age at onset of hypertensive disorder age hypertensive disorder symptoms begin age of onset of hypertensive disorder OBA:2040160 The age at which Machado-Joseph disease manifestations first appear. age Machado-Joseph disease symptoms begin age at onset of Machado-Joseph disease age of onset of Machado-Joseph disease OBA:2040161 The age at which major depressive disorder manifestations first appear. age at onset of major depressive disorder age major depressive disorder symptoms begin age of onset of major depressive disorder OBA:2040165 The age at which cognitive disorder manifestations first appear. true age at onset of cognitive disorder age cognitive disorder symptoms begin age of onset of cognitive disorder OBA:2040166 The age at which depressive disorder manifestations first appear. true age at onset of depressive disorder age depressive disorder symptoms begin age of onset of depressive disorder OBA:2040167 The age at which cervical dystonia manifestations first appear. true age at onset of cervical dystonia age cervical dystonia symptoms begin age of onset of cervical dystonia OBA:2050099 The age at which anorexia nervosa manifestations first appear. true age anorexia nervosa symptoms begin age at onset of anorexia nervosa age of onset of anorexia nervosa OBCS:0000003 A continuous probability distribution that is associated with the f statistic. Yongqun He Fisher-Snedecor distribution WEB: http://stattrek.com/probability-distributions/f-distribution.aspx STATO_0000204 F distribution OBCS:0000004 A continuous probability distribution that is a two-parameter family of continuous probability distributions. Yongqun He WEB: http://en.wikipedia.org/wiki/Gamma_distribution STATO_0000268 gamma distribution OBCS:0000005 A continuous probability distribution that has a symmetrical curve, whose position and shape is determined by its location and scale parameters, the mean and standard deviation respectively. Yongqun He Gaussian distribution WEB: http://en.wikipedia.org/wiki/Normal_distribution STATO_0000227 normal distribution OBCS:0000006 A continuous probability distribution that is is used to estimate population parameters when the sample size is small and/or when the population variance is unknown. Yongqun He t-distribution WEB: http://stattrek.com/probability-distributions/t-distribution.aspx STATO_0000059 Student's t distribution OBCS:0000007 A continuous probability distribution of two variables that has the traditional bell shape and the distribution of one variable is normal to each and every value of the other variable. Marcy Harris bivariate normality WEB: SAS users guide bivariate normal distribution OBCS:0000008 A continuous probability that is the distribution of a random variable X if ln(X) is normally distributed Marcy Harris log normal, lognormal WEB: http://www.statistics.com log-normal distribution OBCS:0000010 An information content entity that refers to a distribution of a random variable that can be described using a mathematical formula. Yongqun He, Jie Zheng WEB: http://en.wikipedia.org/wiki/Probability_distribution probability distribution OBCS:0000011 An information content entity that represents a type of scale on which a variable is measured, including nominal, ordinal, interval, ratio. Marcy Harris level of measurement scale of measure WEB: http://en.wikipedia.org/wiki/Level_of_measurement measurement scale OBCS:0000044 A discrete probability distribution that has the number of successes in a sequence of n independent yes/no experiments, each of which yields success with probability p. Such a success/failure experiment is also called a Bernoulli experiment or Bernoulli trial. Yongqun He WEB: http://en.wikipedia.org/wiki/Binomial_distribution binomial distribution OBCS:0000045 A discrete probability distribution that expresses the probability of a given number of events occurring in a fixed interval of time and/or space if these events occur with a known average rate and independently of the time since the last event. The Poisson distribution can also be used for the number of events in other specified intervals such as distance, area or volume. Yongqun He WEB: http://en.wikipedia.org/wiki/Poisson_distribution Poisson distribution OBCS:0000066 A probability distribution that is associated with continuous variables and has a probability density function. Yongqun He WEB: http://en.wikipedia.org/wiki/Continuous_probability_distribution#Continuous_probability_distribution continuous probability distribution OBCS:0000067 A probability distribution that is associated with discrete variables and is characterized by a probability mass function. Yongqun He WEB: http://en.wikipedia.org/wiki/Continuous_probability_distribution#Discrete_probability_distribution discrete probability distribution OBCS:0000068 A tabular summary of a set of data showing the number of items in each of several non-overlapping classes or groupings Marcy Harris WEB: http://statistics.com frequency distribution OBCS:0000090 A measurement scale consisting of equal-sized units; the distance between any two positions is of known size. Marcy Harris WEB: SAS Users Guide WEB: WEB: http://en.wikipedia.org/wiki/Level_of_measurement interval scale OBCS:0000091 A measurement scale that placing of data into categories, without any order or structure (see related OBI term of categorical measurement datum). Marcy Harris http://en.wikipedia.org/wiki/Nominal_scale#Nominal_scale nominal scale OBCS:0000092 A measurement scale that rankings on which data can be sorted however the size or magnitude of differences between any data points in a class is unknown, just that one ranking is greater than the other Marcy Harris WEB: http://en.wikipedia.org/wiki/Nominal_scale#Ordinal_scale ordinal scale OBCS:0000093 A measurement scale that is similar to an interval scale, i.e. a magnitude of a continuous quantity and a unit magnitude of the same kind; the distinguishing feature of a ratio scale is a meaningful zero value that means the absence of whatever is measured. Marcy Harris WEB: http://en.wikipedia.org/wiki/Nominal_scale#Ratio_scale ratio scale OBCS:0000119 A probability distribution that with k degrees of freedom is the distribution of a sum of the squares of k independent standard normal random variables. Yongqun He WEB: http://en.wikipedia.org/wiki/Chi-square_distribution STATO_0000229 chi-square distribution OBCS:0000125 A continuous probability distribution that describes the time between events in a Poisson process, i.e. a process in which events occur continuously and independently at a constant average rate. Yongqun He WEB: http://en.wikipedia.org/wiki/Exponential_distribution STATO_0000160 exponential distribution OBCS:0000210 A probability distribution that represents the probability distribution corresponding to a histogram of data values. Yongqun He, Jie Zheng WEB: https://reference.wolfram.com/language/ref/HistogramDistribution.html histogram distribution OBCS:0000211 A normal distribution that is the distribution of a random variable X for which the Box–Cox transformation on X follows a truncated normal distribution. Yongqun He Gaussian distribution power-normal distribution WEB: http://en.wikipedia.org/wiki/Normal_distribution Box-Cox distribution OBI:0000070 assay Assay the wavelength of light emitted by excited Neon atoms. Count of geese flying over a house. A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies. A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies. 12/3/12: BP: the reference to the 'physical examination' is included to point out that a prediction is not an assay, as that does not require physical examiniation. PlanAndPlannedProcess Branch measuring scientific observation OBI branch derived study assay any method CHMO:0000000 CHMO:0001133 measurement method OBI:0000070 assay assay OBI:0000070 A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies. obi:pppb OBI:0000117 Bernoulli trial An assay where the output data is a datum with one of two values denoting success and failure. PlanAndPlannedProcess Branch OBI branch derived Bernoulli trial OBI:0000182 NMR 3D molecular structure determination assay Determining the binding of epitope-specific nanobody cAb-HuL5 to wild type human lysozyme by chemical shift perturbations in NMR spectra (Erwin De Genst, J Phys Chem B 2013). A 3D molecular structure determination assay that uses magnetic properties of atomic nuclei to determine the 3D structure and dynamics of molecules in the input sample. IEDB PlanAndPlannedProcess Branch IEDB NMR 3D molecular structure determination assay OBI:0000185 imaging assay An assay that produces a picture of an entity. PlanAndPlannedProcess Branch OBI branch derived imaging assay OBI:0000201 radioactivity detection Placing the evaluant input material close to a scintillation counter which emits light upon being hit with alpha/beta/gamma radiation and counting the frequency of light blasts to determine the radioactivity of the input material. An assay that measures the amount of radiation in the radioactive spectrum (alpha, beta or gamma rays) emitted from an input material. IEDB PlanAndPlannedProcess Branch IEDB radioactivity detection OBI:0000251 cluster Cluster of the lymphocytes population. A data set which is a subset of data that are a similar to each other in some way. person:Allyson person:Chris Stoeckert group:OBI cluster OBI:0000272 protocol PCR protocol, has objective specification, amplify DNA fragment of interest, and has action specification describes the amounts of experimental reagents used (e..g. buffers, dNTPS, enzyme), and the temperature and cycle time settings for running the PCR. A plan specification which has sufficient level of detail and quantitative information to communicate it between investigation agents, so that different investigation agents will reliably be able to independently reproduce the process. PlanAndPlannedProcess Branch OBI branch derived + wikipedia (http://en.wikipedia.org/wiki/Protocol_%28natural_sciences%29) study protocol protocol OBI:0000288 protein-protein interaction detection assay An assay that determines interactions between proteins, such as protein-protein binding. protein-protein interaction detection assay OBI:0000291 transcription factor binding site assay Transcription factor binding site identification in yeast: a comparison of high-density oligonucleotide and PCR-based microarray platforms. An assay tthat determines DNA regions specifically recognized by proteins that function as transcription factors Philippe Rocca-Serra TF binding OBI https://sourceforge.net/p/obi/obi-terms/767/ transcription factor binding site assay OBI:0000366 metabolite profiling assay Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008 Sep 18;7(1):72. PMID: 18799019 An assay that detects and identifies chemical entities resulting from biochemical and cellular metabolism Philippe Rocca-Serra metabolite assay metabolomic assay OBI metabolite profiling assay OBI:0000418 measuring glucose concentration in blood serum assay Measuring glucose concentration in blood from a mouse. See Figure 2 of the 2016 OBI paper, PMID: 27128319. An assay that determines the concentration of glucose molecules in a blood serum sample Bjoern Peters OBI measuring glucose concentration in blood serum assay OBI:0000424 transcription profiling assay Whole genome transcription profiling of Anaplasma phagocytophilum in human and tick host cells by tiling array analysis. BMC Genomics. 2008 Jul 31;9:364. PMID: 18671858 An assay that determines gene expression and transcription activity using ribonucleic acids collected from a material entity. This term should encompass transcription and post-transcription, but before translation into protein. So 'gene expression' itself is too broad, and we use 'transcription profiling identification objective' to constrain the scope of this term. Philippe Rocca-Serra gene expression profiling transcription profiling OBI transcription profiling assay OBI:0000433 DNA sequence feature detection assay genotyping using an Affymetrix chip An assay with the objective to determine a sequence feature of DNA Bjoern Peters Philippe Rocca-Serra OBI DNA sequence feature detection assay OBI:0000435 genotyping assay High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem. 2008 Jan;54(1):86-92. Epub 2007 Nov 2.PMID: 17981923 An assay which generates data about a genotype from a specimen of genomic DNA. A variety of techniques and instruments can be used to produce information about sequence variation at particular genomic positions. Philippe Rocca-Serra SNP analysis genotype profiling OBI Biomaterial genotyping assay OBI:0000438 DNA sequence variation detection assay Capturing genomic signatures of DNA sequence variation using a standard anonymous microarray platform. Nucleic Acids Res. 2006;34(18):e121. PMID: 17000641 An assay that measures changes (expansion, amplification, deletion, mutation) in the sequence of a DNA molecule. Philippe Rocca-Serra OBI Biomaterial DNA sequence variation detection assay OBI:0000443 analyte assay example of usage: In lab test for blood glucose, the test is the assay, the blood bears evaluant_role and glucose bears the analyte role. The evaluant is considered an input to the assay and the information entity that records the measurement of glucose concentration the output An assay with the objective to capture information about the presence, concentration, or amount of an analyte in an evaluant. Alan Ruttenberg Bjoern Peters Helen Parkinson Philippe Rocca-Serra Alan Ruttenberg Bjoern Peters Helen Parkinson OBI Planned process branch Philippe Rocca-Serra analyte assay OBI:0000445 mass measurement assay The patients was weighed and mass was determined to be 47 kilograms An assay that determines the mass of an evaluant Helen Parkinson OBI mass measurement assay OBI:0000447 intracellular electrophysiology recording assay An electrophysiology assay where the recording location of the electrode is intracellular. Frank Gibson Frank Gibson intracellular electrophysiology recording assay OBI:0000454 extracellular electrophysiology recording assay The recording of a spike train in the caudate nucleus of a monkey where the electrodes are extra cellular, i.e. not in the neuron An electrophysiology assay where the recording location of the electrode is extracellular. Frank Gibson Helen Parkinson Frank Gibson extracellular electrophysiology recording assay OBI:0000470 mass spectrometry assay Identification of a proteins cut out from a 2D gel by cleaving it into peptides using trypsin digestion using electrospray ionizatino to ensure the peptides are charged, and accelerating them with an electro magnetic field in which the flight path is determined by the mass / charge ratio of the peptides. Comparing the mass/charge ratio of peptides in the proteins with databases of protein sequences allows to identify which protein gave rise to the peptides. An assay that identifies the amount and type of material entities present in a sample by fragmenting the sample and measuring the mass-to-charge ratio of the resulting particles. Philippe Rocca-Serra Philippe Rocca-Serra mass spectrometry assay OBI:0000520 clinical chemistry assay Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters. An analyte assay which uses analytical methods to produce measurements and data on the concentration of chemical parameters (analytes) present in a bodily fluid collected from an organism. Philippe Rocca-Serra chemical pathology detection of analyte in blood sample url:https://en.wikipedia.org/wiki/Clinical_chemistry clinical chemistry assay OBI:0000537 copy number variation profiling assay Profiling of copy number variations (CNVs) in healthy individuals from three ethnic groups using a human genome 32 K BAC-clone-based array. PMID:18058796 An assay that determines lost or amplified genomic regions of DNA by comparing genomic DNA originating from tissues from the same or different individuals using specific techniques such as CGH, array CGH, SNP genotyping Philippe Rocca-Serra CNV analysis copy number variation profiling assay OBI:0000615 protein expression profiling assay Protein Expression Profiling During Chick Retinal Maturation: A Proteomics-based approach. PMID:19077203 An assay that determines protein expression and translation activity using protein extracts collected from a material entity. Phlippe Rocca-Serra proteomic analysis OBI branch derived protein expression profiling assay OBI:0000623 NMR spectroscopy assay Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y. Toxicol Appl Pharmacol. 2008 Nov 25. PMID: 19073202 An assay that exploits the magnetic properties of certain nuclei (those with a spin) to resonate when placed in particular magnetic field conditions. Instruments recording NMR spectrum and sets of analysis can be used to deduce identity of chemical as well as composition of complex chemical mixtures. Philippe Rocca-Serra Nuclear magnetic resonance spectroscopy url:https://en.wikipedia.org/wiki/Nuclear_magnetic_resonance_spectroscopy NMR spectroscopy assay OBI:0000626 DNA sequencing assay Illumina (Solexa) sequencing is an example of DNA sequencing A sequencing assay which determines information on the sequence of a DNA molecule. Philippe Rocca-Serra nucleotide sequencing url:https://en.wikipedia.org/wiki/DNA_sequencing DNA sequencing assay OBI:0000630 hematology assay Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology._PMID:18702943 An assay that studies blood and blood producing organs using a variety of techniques and instruments Philippe Rocca-Serra blood analysis haematology OBI branch derived hematology assay OBI:0000634 DNA methylation profiling assay Genome-wide, high-resolution DNA methylation profiling using bisulfite-mediated cytosine conversion. Reinders J, Delucinge Vivier C, Theiler G, Chollet D, Descombes P, Paszkowski J._PMID:18218979 An assay that measures the state of methylation of DNA molecules using genomic DNA collected from a material entity using a range of techniques and instrument such as DNA sequencers and often relying on treatment with bisulfites to ensure cytosine conversion. Philippe Rocca-Serra DNA methylation profiling OBI branch derived DNA methylation profiling assay OBI:0000661 enzyme-linked immunosorbent assay 1) Detection of IL-2 (analyte) in a cell supernatant (evaluant), using plate bound anti IL-2 antibodies, and a reporter enzyme-linked reporter antibody. 2) Measurement of IgG antibody (analyte) titer in a serum sample (evaluant) using plate bound antigen and a reporter anti-IgG antibody. An analyte assay where binding of an enzyme linked antibody to a material entity that is immobilized on solid support is detected utilizing a chemiluminescent reaction. Depending on the setup, the enzyme-linked antibody could be binding directly to the analyte, or it serves as a secondary antibody detecting binding of the primary antibody to the analyte. IEDB ELISA IEDB enzyme-linked immunosorbent assay OBI:0000664 BrdU incorporation assay The measurement of T cell proliferation as a response to a viral peptide by culturing T cells stimulated with APCs and peptide in the presence of BrdU. A cell proliferation assay in which cells are cultured in the presence of BrdU which is incorporated into newly synthesized DNA of replicating cells (during the S phase of the cell cycle), substituting for thymidine during DNA replication, which can be quantified by BrdU specific antibodies. IEDB IEDB BrdU incorporation assay OBI:0000669 tritiated thymidine incorporation assay The measurement of T cell proliferation as a response to a viral peptide by culturing T cells stimulated with APCs and peptide in the presence of tritiated thymidine, and using a scintillation counter to detect the radioactivity. A cell proliferation assay in which cells are cultured in the presence of tritiated thymidine which is incorporated into newly synthesized DNA of replicating cells (during the S phase of the cell cycle). The radioactivity of tritiated thymidine in a cell is a proxy for cells that were actively replicating. IEDB IEDB tritiated thymidine incorporation assay OBI:0000693 MeDIP-seq assay PMID: 18612301. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Gr�_f S, Johnson N, Herrero J, Tomazou EM, Thorne NP, B�_ckdahl L, Herberth M, Howe KL, Jackson DK, Miretti MM, Marioni JC, Birney E, Hubbard TJ, Durbin R, Tavar�� S, Beck S. Nat Biotechnol. 2008 Jul;26(7):779-85. A DNA methylation profiling assay that identifies methylated sites in genomic DNA and determines the methylation pattern that affect gene transcription using immunoprecipitation of methylated genomic DNA, creation of a library of corresponding DNA fragments (either single or paired-end fragments) and subsequent sequencing using parallelized sequencing methods. Philippe Rocca-Serra Methylated DNA immunoprecipitation sequencing assay url:https://en.wikipedia.org/wiki/Methylated_DNA_immunoprecipitation MeDIP-seq assay OBI:0000695 chain termination sequencing assay PMID: 271968. DNA sequencing with chain-terminating inhibitors. A DNA sequencing assay which rely on the use of dideoxynucleotides used in 4 distinct sequencing reaction on the same DNA sample. The dideoxynucleotides, once incorporated in the complementary DNA strand being synthesized by the DNA polymerase prevent any further chain elongation. The newly generated sequences are resolved on a polyacrylamide gel using electrophoresis and labels (either fluorochrome or radioactivity) are used to determine the nucleotide present at a given position Philippe Rocca-Serra Sanger sequencing dye terminator sequencing url:https://en.wikipedia.org/wiki/Sanger_sequencing chain termination sequencing assay OBI:0000697 Helicos sequencing assay PMID: 18388294. Single-molecule DNA sequencing of a viral genome. A DNA sequencing by synthesis assay that identifiies the sequnece of billions of DNA molecules immobilized to a surface using DNA polymerase and fluorescently labeled nucleotides added one at a time. The sequencing process does not require an amplification step and is typically able to produce reads of 25 base pair length. Philippe Rocca-Serra true single molecule sequencing url:https://en.wikipedia.org/wiki/Helicos_single_molecule_fluorescent_sequencing Helicos sequencing assay OBI:0000699 survival assessment assay An assay that measures the occurrence of death events in one or more organisms over time survival assessment assay OBI:0000705 Edman degradation Determination of the amino acid sequence of a peptide eluted from HLA-DRB1*04:01 to be VYPEVTVYPAKT. A sequencing assay in which the amino acid sequence of input peptides or proteins is determined by iteratively cleaving of the amino-terminal (N-terminal) residue without disrupting the peptide bonds and identifying it by e.g. chromatography or electropheresis. IEDB IEDB Edman degradation OBI:0000706 SOLiD sequencing assay PMID: 19119315. High-resolution analysis of the 5'-end transcriptome using a next generation DNA sequencer. Hashimoto S, Qu W, Ahsan B, Ogoshi K, Sasaki A, Nakatani Y, Lee Y, Ogawa M, Ametani A, Suzuki Y, Sugano S, Lee CC, Nutter RC, Morishita S, Matsushima K. PLoS One. 2009;4(1):e4108. A DNA sequencing by ligation assay that identifies sequence information using primers to hybridize to the P1 adapter sequence within the library template, fluorescently labeled di-base probes to compete for ligation to the sequencing primer, multiple cycles of ligation, detection and cleavage to determine the eventual read length, following a series of ligation cycles, the extension product is removed and the template is reset with a primer complementary to the n-1 position for a second round of ligation cycles. Philippe Rocca-Serra url:https://en.wikipedia.org/wiki/ABI_Solid_Sequencing SOLiD sequencing assay OBI:0000716 ChIP-seq assay PMID: 19275939 An assay in which chromatin is immunoprecipitated and subsequently analyzed using a DNA sequencing step to identify which parts of DNA are part of the isolated chromatin Bjoern Peters Philippe Rocca-Serra chromatin immunoprecipitation sequencing assay url:https://en.wikipedia.org/wiki/ChIP-sequencing ChIP-seq assay OBI:0000721 glucose tolerance test PMID: 19527607 An assay that measures glucose clearance from blood over time by repeated glucose measurement in blood serum or plasma after the administration of a glucose bolus in-vivo. This assay can be used to evaluate the severity of insulin resistance or the efficiency of glucose clearance. Philippe Rocca-Serra NuGO OBI plan branch glucose tolerance test OBI:0000723 DNA sequencing by ligation assay ABI Solid Sequencing uses the ligation-based DNA sequencing technology (https://en.wikipedia.org/wiki/ABI_Solid_Sequencing). A DNA sequencing assay that performs chain extension during the sequencing reaction step using DNA ligase Philippe Rocca-Serra url:https://en.wikipedia.org/wiki/Sequencing_by_ligation DNA sequencing by ligation assay OBI:0000724 Solexa sequencing assay PMID: 18987734 A DNA sequencing by synthesis assay that identifies sequence information using DNA polymerase and reversible terminator, requiring immobilization of genomic DNA fragments onto a surface and a specific clonal amplification step known as bridge PCR. Reliance on a reversible terminator allows cycles of DNA chain extension by DNA polymerase and imaging without the need of electrophoretic separation of newly synthesized DNA fragment as with Sanger sequencing. Philippe Rocca-Serra reversible terminator sequencing Solexa web site (SS_DNAsequencing.pdf document available on july 2009) Solexa sequencing assay OBI:0000730 pyrosequencing assay Pyrosequencing sheds light on DNA sequencing. PMID:1115661 A DNA sequencing by synthesis assay which sequences a single strand of DNA by synthesizing the complementary strand along it, one base pair at a time, and detecting which base was actually added at each step. The template DNA is immobilized, and solutions of A, C, G, and T nucleotides are added and removed after the reaction, sequentially. Light is produced only when the nucleotide solution complements the first unpaired base of the template. The sequence of solutions which produce chemiluminescent signals allows the determination of the sequence of the template. ssDNA template is hybridized to a sequencing primer and incubated with the enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase, and with the substrates adenosine 5-prime phosphosulfate (APS) and luciferin. Philippe Rocca-Serra url:http://en.wikipedia.org/wiki/Pyrosequencing pyrosequencing assay OBI:0000734 DNA sequencing by synthesis assay Roche-454 pyrosequencing and Illumina (Solexa) sequencing use synthesis-based method for DNA sequencing A DNA sequencing assay that relies on DNA polymerase activity to perform chain extension during the sequencing reaction step. Philippe Rocca-Serra url:https://www.illumina.com/technology/next-generation-sequencing/sequencing-technology.html DNA sequencing by synthesis assay OBI:0000743 immune response assay Measuring if a Hepacivirus C (HCV) infected patient has an antibody response to HCV core protein by ELISA. An assay that determines information about an immune response Bjoern Peters Randi Vita IEDB immune response assay OBI:0000748 bisulfite sequencing assay PMID: 19581485. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Hodges E, Smith A, Kendall J, Xuan Z, Ravi K, Rooks M, Zhang M, Ye K, Battacharjee A, Brizuela L, McCombie WR, Wigler M, Hannon GJ, Hicks J. A DNA methylation profiling assay which determines the methylation status of genomic DNA using DNA sequencing techniques preceded by a bisulfite based chemical modification of genomic DNA at CpG island location. Philippe Rocca-Serra Sagar Jain url:https://en.wikipedia.org/wiki/Bisulfite_sequencing bisulfite sequencing assay OBI:0000787 human antithrombin-III in blood assay PMID:19696660#The antithrombin-III (AT-III) was determined using a Berichrom(r) Antithrombin-III (A) kit. An assay that measures the amount of antithrombin III in blood. Alan Ruttenberg AT-III assay url:http://www.muschealth.com/lab/content.aspx?id=150006@2009/08/06 human antithrombin-III in blood assay OBI:0000802 prothrombin time assay PMID:19696660#The prothrombin time (PT) was quantitatively determined using RecombiPlasTin (Instrumentation Laboratory Company, Lexington, Massachusetts, USA). An assay that measures the prothrombin ratio, which is the prothrombin time for a patient, divided by the result for control plasma. Most commonly the test is preformed using blood plasma. Blood is drawn into a test tube containing liquid citrate, which acts as an anticoagulant. An excess of calcium is added to enable the blood to clot again.Tissue factor (also known as factor III or thromboplastin) is added, and the time the sample takes to clot is measured optically as the prothrombin time, which is compared to a control sample. Alan Ruttenberg url:http://en.wikipedia.org/wiki/Prothrombin_time@2009/10/06 prothrombin time assay OBI:0000805 antithrombin-III berichrome assay An antithrombin-III (AT-III) assay in which exogenous bovine thrombin and heparin are added to test plasma to form a thrombin-heparin-AT complex. The residual thrombin not bound then hydrolyzes the p-nitroalanine substrate to produce a yellow color, which is read at 405 nm. The intensity of color produced is inversely proportional to the AT present. A calibration is done with standard human plasma reagent and results for a given specimen are reported as a percentage relative to the standard AT-III assay url:http://www.clinchem.org/cgi/content/full/43/9/1783@2009/08/06 antithrombin-III berichrome assay OBI:0000808 spectrolyse heparin antifactor-Xa assay PMID:19696660#Antifactor-Xa (anti-Xa) was determined using spectrolyse heparin (Xa) (Trinity Biotech plc, Bray, County Wicklow, Ireland). An assay that quantitatively measures heparin in human plasma using Factor Xa and Antithrombin III in excess, where the rate of Factor Xa inhibition is directly proportional to the heparin concentration. The residual Factor Xa activity, measured with a Factor Xa-specific chromogenic substrate, is inversely proportional to the heparin concentration. Alan Ruttenberg url:http://www.kordia.nl/en/product/hemostasis/specialty_kits__reagens/598/spectrolyse_heparin_anti_xa@2009/08/06 spectrolyse heparin antifactor-Xa assay OBI:0000812 measuring neural activity in the caudate nucleus assay An SU micro-electrode was used to measure neural activity in the form of spike trains in the caudate nucleus of monkeys in response to a flashing light stimulus An assay that measures neural activity in the caudate nucleus Helen Parkinson Dirk Derom, OBI Jessica Turner, NIF measuring neural activity in the caudate nucleus assay OBI:0000820 activated partial thromboplastin time assay The activated partial thromboplastin time (aPTT) was determined using Dade Actin FSL activated PTT reagent (PMID:19696660) An assay that evaluates blood coagulation by measuring the time required for the appearance of fibrin strands following the mixing blood or plasma with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of blood coaguation . It is used as a screening test and to monitor heparin therapy. There is also the 'partial thromboplastin assay', which some people use synonymously to aPPT, but historically was done slightly differently (without adding a coagulant). Alan Ruttenberg OBI call aPTT assay url:http://www.ebi.ac.uk/ols/ontologies/efo/terms?short_form=EFO_0004310 activated partial thromboplastin time assay OBI:0000823 thrombin time assay PMID:19696660#The thrombin time was determined using thromboclotin assay kit. An assay that measures the time between the addition of the thrombin and the clot formation in plasma. Alan Ruttenberg url:http://en.wikipedia.org/wiki/Thrombin_time@2009/10/06 thrombin time assay OBI:0000854 western blot assay Running a cell lysate on an acrylamide gel in a western blot aparatus to separate the constituent proteins, followed by transfer of the proteins from the gel to a nitrocellulose membrane. Staining this membrane with specific antibodies to detect the presence of specific proteins of interest. An analyte assay that detects specific peptides in an input material by separating it using gel electrophoresis, transfering the separated molecules to a membrane, and staining them with_ antibodies specific to the analyte molecules. IEDB Philippe Rocca-Serra IEDB Philippe Rocca-Serra western blot assay OBI:0000860 northern blot assay The level of actin mRNA levels in normal and diseased tiisue was measured using a northern blot assay. An assay that determines the presence of gene transcripts by hybridizing labeled RNA or DNA probes against messenger RNAs isolated from tissue or cell cultures, resolved on denaturing gel, transfered by a blotting procedure to a solid support. Detection of hybridization signals is carried out by immunofluorescence or radioactivity measurements using photographic films or digital imaging devices such as Phosphor Imager. Philippe Rocca-Serra Richard Scheuermann northern blot northern blot assay OBI:0000865 96-well neutralization assay A serum neutralization of viral infectivity assay which is performed in a 96-well plate. Bjoern Peters Melanie Courtot microneutralization assay 96-well neutralization assay OBI:0000870 single-nucleotide-resolution nucleic acid structure mapping assay An assay that provides information about the secondary structure of nucleic acids using chemical or enzymatic probing to establish the extent of base-pairing or solvent accessiblity. Philippe Rocca-Serra RNAO single-nucleotide-resolution nucleic acid structure mapping assay OBI:0000871 viral hemagglutination assay Determining the viral titer of a virus infected human by measuring the presence of hemagglutination when dilutions of serum samples are added to a known quantity of red blood cells. An assay that quantifies viruses by their hemagglutination activity. Bjoern Peters Melanie Courtot Randi Vita HA HI viral haemagglutinin assay url:http://en.wikipedia.org/wiki/Hemagglutination_assay viral hemagglutination assay OBI:0000872 serum neutralization of viral infectivity assay An analyte assay that measures virus-neutralizing abilities of different sera. Different dilutions of serum are mixed with virus and used to infect cells. At the lower dilutions, antibodies will block infection, but at higher dilutions, there will be too few antibodies to have an effect.The neutralization titer is expressed as the reciprocal of the highest dilution at which virus infection is blocked. Bjoern Peters Melanie Courtot influenza neutralization assay url:http://www.virology.ws/2009/05/28/influenza-microneutralization-assay/ serum neutralization of viral infectivity assay OBI:0000874 detection of specific nucleic acid polymers with complementary probes Primer based PCR assay, Norther blot, Southern Blot, and RNAse protection assays. An analyte assay in which a specified input material (the evaluant) is examined for the presence or quantity of specified nucleic acid polymers, which are identified based on the use of complementary nucleic acid probes. IEDB IEDB detection of specific nucleic acid polymers with complementary probes OBI:0000875 viral hemagglutination inhibition assay Examining the ability of a monoclonal antibody to inhibit hemagglutination by Influenza A virus by comparing the levels of hemagglutination with and without the presence of the antibody. An assay that measures the ability of an evaluant to inhibit hemagglutination by a virus. Hemagglutinin is a viral protein which binds to sialic acid receptors on cells or to erythrocytes, causing the cells to clump. Loss of clumping indicates that the evaluant blocks binding of hemagglutinin to sialic acid receptors. Bjoern Peters Melanie Courtot Randi Vita HAI HIA biological activity hemagglutination inhibition viral haemagglutinin inhibition assay OBI branch derived viral hemagglutination inhibition assay OBI:0000882 cell-cell killing assay Autologous EBV-transformed B-LCL were used as target cells for the influenza virus-specific CTL assays. Equal volumes of target and effector cells were added to tissue culture plates, and 1:2 serial dilutions of effectors were made. After a 4-h incubation of the effector cells with the target cells, supernatants were collected and counted with the LKB 1272 Clinigamma counter. Percent specific killing was determined with the following equation: (experimental 51Cr release - spontaneous 51Cr release)/(maximum 51Cr release - spontaneous 51Cr release) x 100. A cytometry assay that monitors a cell population to track how many are killed by other cells. IEDB IEDB cell-cell killing assay OBI:0000883 in vivo cell killing assay Labeling two populations of cells with different levels of CFSE, pusling one population with an influenza peptide, injecting the cells into a mouse, and recoving cells 24 hours later. By comparing the recovery rate of cells with different CFSE labeling, it is possible to determine if there was specific killing of peptide pulsed target cells. A cell killing assay that measures if and how many target cells are killed within an organism. IEDB IEDB in vivo cell killing assay OBI:0000891 cell proliferation assay Measuring the amount of tritiated thymidine incorporated by dividing cells as a proxy for cell proliferation. A cytometry assay which measures the degreee to which input cells are replicating. IEDB IEDB cell proliferation assay OBI:0000892 Southern blot assay PMID: 9452032. Germline mutations detected in the von Hippel-Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing. An analyte assay that detects the presence of a specific sequence in a DNA sample, which has been digested by restriction enzymes, resolved by gel electrophoresis, and blotted to a solid support, followed by hybridization of a probe raised against a specific sequence and detected with fluorescence or radioactivity. Marcus Chibucos Philippe Rocca-Serra Southern blot OBI Southern blot assay OBI:0000893 real time polymerase chain reaction assay An assay, based on the PCR, that amplifies and simultaneously quantifies a specific DNA molecule based on the use of complementary probes/primers. It enables both detection and quantification (as absolute number of copies or relative amount when normalized to DNA input or additional normalizing genes) of one or more specific sequences in a DNA sample. Bjoern Peters Melanie Courtot Q-PCR kinetic polymerase chain reaction qPCR quantitative real time polymerase chain reaction url:http://en.wikipedia.org/wiki/Real-time_polymerase_chain_reaction real time polymerase chain reaction assay OBI:0000897 DEPC structure mapping assay PMID:2446263. Probing the structure of RNAs in solution. Nucleic Acids Res. 1987 Nov 25;15(22):9109-28. A single-nucleotide-resolution nucleic acid structure mapping assay which determines nucleic acid secondary structure at a nucleotide resolution scale using DEPC as reagent and chemical probe Philippe Rocca-Serra RNA ontology DEPC structure mapping assay OBI:0000903 in vitro cell killing assay Autologous EBV-transformed B-LCL were used as target cells for the influenza virus-specific CTL assays. Equal volumes of target and effector cells were added to tissue culture plates, and 1:2 serial dilutions of effectors were made. After a 4-h incubation of the effector cells with the target cells, supernatants were collected and counted with the LKB 1272 Clinigamma counter. Percent specific killing was determined with the following equation: (experimental 51Cr release - spontaneous 51Cr release)/(maximum 51Cr release - spontaneous 51Cr release) x 100. A cell killing assay that measures if and how many target cells are actively killed by other cells in a cell culture. IEDB IEDB in vitro cell killing assay OBI:0000904 reporter cell line analyte detection bioassay CTLL-2 cells were grown in the presence of hybridoma supernatants and their growth was monitored by a 3H-thymidine incorporation cell proliferation assay in order to detect IL-2 in the hybridoma supernatant. An analyte assay in which a cell line whose growth is known to be affected by the presence of a specific type of material (the anlyte) is cultured in the presence of an input material (the evaluant) in order to detect presence of the analyte in the evaluant. IEDB IEDB reporter cell line analyte detection bioassay OBI:0000910 radio immuno assay To evaluate the specificity of antibody binding to 35S-labeled IA-2(256-760) in comparison with 35S-labeled IA-2IC construct, the mutual inhibition activity of different concentrations of unlabeled IA-2IC and/or IA-2(256-760) fragments were tested. Unlabeled recombinant IA-2(256-760) and/or IA-2IC (0.5-, 1-, 2-, and 4-fold the amount of 35S-labeled protein) were added to each tube and incubated overnight at 4C with patient sera. The following day, after incubation with radiolabeled 35 IA-2(256-760) or 35S IA-2IC proteins, samples were processed with the usual radioimmunoprecipitation assay. An assay in which a radioactive labeled antigen or antibody is used to determine the interaction between an antigen and its receptor. This can be used to detect the presence of an antigen of interest in an input sample or determine the specificity of an input antibody. IEDB IEDB radio immuno assay OBI:0000911 real time reverse-transcription polymerase chain reaction assay An assay that uses a reverse transcription step (an RNA strand is reverse transcribed into its DNA complement using the enzyme reverse transcriptase) before a PCR assay. Bjoern Peters Melanie Courtot RRT-PCR RT-rt PCR qRT-PCR real time reverse-transcription polymerase chain reaction assay OBI:0000912 X-ray crystallography 3D molecular structure determination assay Crystallizing an antibody:antigen complex, and recording the diffraction pattern of a synchrotron beam, and assembling the 3d complex structure based on homologous complexes. A 3D molecular structure determination assay in which the diffraction of pattern of X-ray beams in a crystal of purified material entities is used to resolve the 3-dimensional structure of the material entity of interest. IEDB IEDB X-ray crystallography 3D molecular structure determination assay OBI:0000913 promoter activity detection by reporter gene assay A T cell hybridoma in which the beta-galactosidase gene (lacZ) was inserted under the control of the IL-2 promoter, is detected by adding the X-gal substrate which when cleaved by lacZ results in detectable blue color. An assay in which the activity of a promoter in a cell is monitored by using a reporter gene that was inserted in a genomic location under control of the promoter and whose expression can be easily detected based on qualities or functions of the gene. IEDB IEDB promoter activity detection by reporter gene assay OBI:0000916 flow cytometry assay Using a flow cytometer to quantitate the percent of CD3 positive cells in a population by labeling them with a FITC tagged anti-CD3 antibody. A cytometry assay in which an input cell population is put in solution, is passed by a laser, and optical sensors are used to detect scattering of the laser light and/or fluorescence of specific markers to count and characterize the particles in solution. IEDB FACS IEDB flow cytometry assay OBI:0000920 cytometric bead array assay Using a Luminex machine to detect IFN-gamma and IL-10 in the supernatant of a cell culture. An analyte assay in which a series of beads coated with antibodies, antigens, or other small molecules are used to detect an analyte of interest. IEDB Luminex assay IEDB cytometric bead array assay OBI:0000923 surface plasmon resonance binding assay Running a Biacore instrument to measure the affinity, on and off rates of binding of a plate bound antibody to a antigen passing by in flow. A binding assay that uses the detection of electromagnetic waves in a surface to detect material entities adsorbed to the surface, which change the local optical index of refraction. IEDB IEDB surface plasmon resonance binding assay OBI:0000944 handedness assay The Edinburgh handedness assay is a specific method of determing handedness An assay that measures the unequal distribution of fine motor skill between the left and right hands typically in human subjects by means of some questionnaire and scoring procedure. Helen Parkinson handedness test url:http://en.wikipedia.org/wiki/Handedness handedness assay OBI:0000957 self reported handedness assessment An assay where a person makes a statement that indicates what handedness he has from a choice of different categories. self reported handedness assessment OBI:0000964 in live cell assay An assay in which a measurement is made by observing entities located in a live cell. in live cell assay OBI:0000966 in live organism assay Measuring the rate in which cells that are pulsed with a peptide are killed inside a mouse by peptide specific cytotoxic T cells. An assay in which a measurement is made by observing entities located in an organism. Bjoern Peters in vivo assay in live organism assay OBI:0000975 cell-cell binding detection by flow cytometry assay Staining a B cell with PE and staining a T cell with FITC, incubating them together with a peptide, and counting the number of co-stained conjugates. A binding assay which uses a flow cytometer to detect pairs of cells that are bound to each other by staining them with different fluorescent labels. IEDB IEDB cell-cell binding detection by flow cytometry assay OBI:0000978 in container assay An assay in which a measurement is made by observing entities located in a container. in container assay OBI:0001001 Edinburgh handedness assay Verdino (1998) Perceptual and Motor Skills. 86 (2): 476_8. (PMID: 9638746) uses this measure in an experimental study: "Individuals of extreme handedness based on the Edinburgh Handedness Inventory (laterality Quotients of +90 to +100 and -100 and +54; 50 each)" An assay that uses a set of questions (the Edinburgh Handedness inventory) to generate a score that can be used to assess the dominance of a person's right or left hand in everyday activities. The inventory can be used by an observer assessing the person, or by a person self-reporting hand use. The latter method tends to be less reliable due to a person over-attributing tasks to the dominant hand. Alan Ruttenberg Gully Burns (orcid:0000-0003-1493-865X) Jessica Turner PMID:5146491 url:http://en.wikipedia.org/wiki/Edinburgh_Handedness_Inventory Edinburgh handedness assay OBI:0001005 RNASE CL3 structure mapping assay PMID:16453415 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAse CL3 as reagent and enzymatic probe. Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse CL3 RNA ontology RNASE CL3 structure mapping assay OBI:0001006 CMCT structure mapping assay PMID:2422386 and PMID:2446263 A single-nucleotide-resolution nucleic acid structure mapping assay which uses CMCT as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure Philippe Rocca-Serra single nucleotide resolution mapping assay using CMCT probe RNA ontology CMCT structure mapping assay OBI:0001008 MPE-Fe(II) structure mapping assay PMID:6209709 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at the nucleotide resolution scale using Fe-MP as reagent and chemical probe. Philippe Rocca-Serra single nucleotide resolution mapping assay using Fe-MP probe RNA ontology MPE-Fe(II) structure mapping assay OBI:0001011 ENU structure mapping assay PMID:7002606 and PMID:2446263 A single-nucleotide-resolution nucleic acid structure mapping assay that determines the secondary structure of a nucleic acid at the nucleotide resolution scale which uses ENU as reagent and chemical probe Philippe Rocca-Serra single nucleotide resolution mapping assay using ENU probe RNA ontology ENU structure mapping assay OBI:0001012 RNASE V1 structure mapping assay PMID:7031604 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAse V1 as reagent and enzymatic probe Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse V1 RNA ontology RNASE V1 structure mapping assay OBI:0001013 kethoxal structure mapping assay single nucleotide resolution mapping assay using Kethoxal probe A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at nucleotide resolution scale using kethoxal as reagent and chemical probe Philippe Rocca-Serra RNA ontology kethoxal structure mapping assay OBI:0001014 single-nucleotide-resolution nucleic acid structure mapping assay using enzymatic probing A single-nucleotide-resolution nucleic acid structure mapping assay that determines structural information about the RNA species under study using proteins acting as enzymatic probes. Philippe Rocca-Serra RNAO and OBI https://github.com/obi-ontology/obi/issues/808 single-nucleotide-resolution nucleic acid structure mapping assay using enzymatic probing OBI:0001015 DMS structure mapping assay PMID:6159633 and PMID:2446263 A single-nucleotide-resolution nucleic acid structure mapping assay which determins nucleic acid secondary structure at a nucleotide resolution scale using DMS as reagent and chemical probe Philippe Rocca-Serra single nucleotide resolution mapping assay using DMS probe RNA Ontology DMS structure mapping assay OBI:0001016 DNASE 1 structure mapping assay PMID:3773731 A single-nucleotide-resolution deoxyribonucleic acid structure mapping assay which uses DNAse 1 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure Philippe Rocca-Serra DNAse footprinting assay single nucleotide resolution mapping assay using DNAse I RNA ontology DNASE 1 structure mapping assay OBI:0001017 single-nucleotide-resolution nucleic acid structure mapping assay using chemical probing A single-nucleotide-resolution nucleic acid structure mapping assay that determines structural information about the RNA species under study using small chemical compounds acting as chemical probes. Philippe Rocca-Serra RNAO and OBI single-nucleotide-resolution nucleic acid structure mapping assay using chemical probing OBI:0001018 Rhodium DNA structure mapping assay PMID:2843807 A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using Rhodium as reagent and chemical probe. Philippe Rocca-Serra single nucleotide resolution mapping assay using Rhodium probe RNA ontology Rhodium DNA structure mapping assay OBI:0001019 RNA ADA I RNA structure mapping assay PMID:7527340 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNA adenosine deaminase I as reagent and enzymatic probe. Philippe Rocca-Serra single nucleotide resolution mapping assay using RNA adenosine deaminase I RNA ontology RNA ADA I RNA structure mapping assay OBI:0001020 Lead structure mapping assay PMID:2686708 A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at nucleotide resolution scale using lead as reagent and chemical probe Philippe Rocca-Serra single nucleotide resolution mapping assay using Lead probe RNA ontology Lead structure mapping assay OBI:0001021 RNASE T2 structure mapping assay PMID:6207483 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAse T2 as reagent and enzymatic probe Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse T2 RNA ontology RNASE T2 structure mapping assay OBI:0001022 gene dosage assay An assay that measures changes in phenotype due to increased or decreased dosage of a single allele of a gene. Bjoern Peters David Osumi Sutherland gene dosage assay OBI:0001023 Fe-BABE RNA structure mapping assay PMID: 7862644 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic secondary structure at a nucleotide resolution scale using Fe-BABE as reagent and chemical probe. Philippe Rocca-Serra single nucleotide resolution mapping assay using Fe-BABE probe RNA ontology Fe-BABE RNA structure mapping assay OBI:0001024 RNASE U2 structure mapping assay PMID:409999 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAase U2 as reagent and enzymatic probe Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse U2 RNA ontology RNASE U2 structure mapping assay OBI:0001025 binding constant determination assay Determination of KD value for an antibody binding a protein using a BIACORE assay. A binding assay where the specified output is a binding constant Bjoern Peters Jason Greenbaum Randi Vita IEDB binding constant determination assay OBI:0001026 NMIA RNA structure mapping assay PMID: 15796531 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at the nucleotide resolution scale using NMIA as reagent and chemical probe Philippe Rocca-Serra SHAPE mapping assay single nucleotide resolution mapping assay using NMIA probe RNA ontology NMIA RNA structure mapping assay OBI:0001027 Terbium RNA structure mapping assay PMID:10772868 A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using Terbium as reagent and chemical probe Philippe Rocca-Serra single nucleotide resolution mapping assay using Terbium probe RNA ontology Terbium RNA structure mapping assay OBI:0001029 OH-radical structure mapping assay PMID:2501870 A single-nucleotide-resolution nucleic acid structure mapping assay hat determines nucleic acid secondary structure at a nucleotide resolution scale using hydroxyl radical as reagent and chemical probe Philippe Rocca-Serra MOHCA assay OH footprinting assay single nucleotide resolution mapping assay using OH-radical probe RNA ontology OH-radical structure mapping assay OBI:0001030 RNASE T1 structure mapping assay PMID:114514 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale uses RNAse T1 as reagent and enzymatic probe. Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse T1 RNA ontology RNASE T1 structure mapping assay OBI:0001035 Nuclease S1 structure mapping assay PMID:363143 A single-nucleotide-resolution deoxyribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using DNAse 1 as reagent and enzymatic probe. Philippe Rocca-Serra single nucleotide resolution mapping assay using Nuclease S1 RNA ontology Nuclease S1 structure mapping assay OBI:0001038 Ruthenium structure mapping assay PMID:3016894 A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using Rhutenium as reagent and chemical probe Philippe Rocca-Serra RNA Ontology Ruthenium structure mapping assay OBI:0001039 inline probing RNA structure mapping assay PMID:10573122 and PMID: 18369975 A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at nucleotide resolution scale using intromolecular reactivity Philippe Rocca-Serra RNA ontology inline probing RNA structure mapping assay OBI:0001145 3D structure determination of bound molecular complex assay Determination of a 3D structure of an antibody binding a protein by X-Ray crystallography, which identifies the specific binding site of the antibody. A 3D molecular structure determination assay in which a complex of 2 or more molecular enties is characterized which provides information on their binding configuration. IEDB IEDB 3D structure determination of bound molecular complex assay OBI:0001146 binding assay Determination of KD value for an antibody binding a protein using a BIACORE assay. Using plate bound antigen in an ELISA to determine if a mixture of serum antibodies bind the antigen. The following are NOT binding assays, as the desired output is not binding data: RNA microarray experiments to determine levels of gene expression. ChIP experiments to determine where in DNA a transcription factor binds. Using an IL-2 antibody on an ELISA plate to determine presence of IL-2 after stimulating a T cell culture. An assay with the objective to characterize the disposition of two or more material entities to form a complex. Bjoern Peters Jason Greenbaum Randi Vita binding assay OBI:0001158 age determination assay An assay that determines the duration of part of the life of an organism, where the initial time point is the beginning of some transitional state (such as birth or when planted). This assay measures time not developmental stage. we recognize that development takes different time periods under different conditions such as media / temperature. For example, age measurement assay of fly age, the output likes 28 days but not mid-life of age at room temperature. Alan Ruttenberg age measurement assay OBI group age determination assay OBI:0001170 reverse transcription polymerase chain reaction assay An assay that determines the concentration of RNA in a sample in which an RNA strand is first reverse transcribed into its DNA complement (complementary DNA, or cDNA) using the enzyme reverse transcriptase, and the resulting cDNA is amplified using traditional or real-time PCR. Chris Stoeckert Jie Zheng Penn Group reverse transcription polymerase chain reaction assay OBI:0001177 RNA sequencing assay An assay that determines the sequence of an RNA molecule. Bjoern Peters Bjoern Peters RNA sequencing assay OBI:0001178 efficacy of epitope intervention experiment An assay that tests if inducing an epitope specific immune response in an organism has an effect, such as the ability to prevent, treat or exacerbate diseases in the organism. Bjoern Peters efficacy of in vivo intervention efficacy of epitope intervention experiment OBI:0001179 epitope protection from infectious challenge experiment An epitope protection experiment in which the ability of the epitope to protect the host from an infection is assessed. Bjoern Peters protection from infectious challenge epitope protection from infectious challenge experiment OBI:0001183 epitope protection from tumor challenge experiment An epitope protection experiment in which the ability of the epitope to protect the host from developing tumors is assessed. Bjoern Peters protection from tumor challenge epitope protection from tumor challenge experiment OBI:0001184 epitope protection experiment An efficacy of epitope intervention experiment that tests the efficacy of inducing an immune epitope response to prevent disease in a host. Bjoern Peters protection from challenge epitope protection experiment OBI:0001186 epitope protection from infectious challenge experiment based on pathogen burden An epitope protection from infectious challenge experiment in which the readout is a reduction in the presence of pathogens in the host compared to controls. Bjoern Peters burden after infectious challenge epitope protection from infectious challenge experiment based on pathogen burden OBI:0001187 infectious agent detection assay Culturing a sputum sample on agar medium to detect bacterial growth; Stain slices of liver from a mouse to count presence of infectious centers; PCR amplification using primers specific for influenza virus. An assay that measures the presence or amount of an infectious agent in an evaluant Bjoern Peters Jason Greenbaum Randi Vita Richard Scheuermann infectious agent detection assay OBI:0001188 epitope disease exacerbation experiment An efficacy of epitope intervention experiment that tests the ability of inducing an epitope immune response to increase the severity of an existing disease in the host. Bjoern Peters exacerbation assay epitope disease exacerbation experiment OBI:0001189 epitope protection experiment based on survival An epitope protection experiment that determines the success of the epitope intervention based on increased survival of the host. Bjoern Peters host survival after challenge epitope protection experiment based on survival OBI:0001190 epitope treatment experiment An epitope intervention experiment that tests the ability of inducing an epitope immune response to treat an existing disease in the host. Bjoern Peters decreased disease symptoms after treatment epitope treatment experiment OBI:0001194 ELISPOT assay measuring epitope specific transforming growth factor-beta production by T cells An enzyme-linked immunospot assay that detects transforming growth factor-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TGFb release|ELISPOT ELISPOT assay measuring epitope specific transforming growth factor-beta production by T cells OBI:0001196 cytometric bead array assay measuring epitope specific IP-10 production by T cells A cytometric bead array assay that detects IP-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL10/IP-10 release|cytometric bead array cytometric bead array assay measuring epitope specific IP-10 production by T cells OBI:0001198 assay measuring epitope specific interleukin-27 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-27 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-27 release|biological activity assay measuring epitope specific interleukin-27 production by T cells OBI:0001203 detection of specific nucleic acids with complementary probes assay measuring epitope specific transforming growth factor-beta production by T cells A detection of specific nucleic acid polymers with complementary probes that detects transforming growth factor-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TGFb release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific transforming growth factor-beta production by T cells OBI:0001206 ELISPOT assay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells An enzyme-linked immunospot assay that detects granulocyte macrophage colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB GM-CSF release|ELISPOT ELISPOT assay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells OBI:0001209 assay measuring epitope specific interleukin-10 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-10 release|biological activity assay measuring epitope specific interleukin-10 production by T cells OBI:0001210 cytometric bead array assay measuring epitope specific transforming growth factor-beta production by T cells A cytometric bead array assay that detects transforming growth factor-beta production by T cells PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TGFb release|cytometric bead array cytometric bead array assay measuring epitope specific transforming growth factor-beta production by T cells OBI:0001215 intracellular material detection assay measuring epitope specific perforin release A flow cytometry assay that detects epitope specific perforin release by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB perforin release|intracellular staining intracellular material detection assay measuring epitope specific perforin release OBI:0001216 cell culture analyte detection bioassay measuring epitope specific interleukin-2 production by T cells A reporter cell line analyte detection bioassay that detects interleukin-2 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-2 release|bioassay cell culture analyte detection bioassay measuring epitope specific interleukin-2 production by T cells OBI:0001217 assay measuring epitope specific interleukin-22 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-22 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-22 release|biological activity assay measuring epitope specific interleukin-22 production by T cells OBI:0001218 assay measuring epitope specific interleukin-8 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-8 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-8 release|biological activity assay measuring epitope specific interleukin-8 production by T cells OBI:0001220 cell culture analyte detection bioassay measuring epitope specific interleukin-10 production by T cells A reporter cell line analyte detection bioassay that detects interleukin-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-10 release|bioassay cell culture analyte detection bioassay measuring epitope specific interleukin-10 production by T cells OBI:0001221 ChIP-chip by SNP array assay A ChIP-ChIP assay in which immunoprecipitated chromatin is run on a SNP array to detect polymorphism specific DNA elements in the isolated chromatin ArrayExpress production team EFO:0002764 ChIP-chip by SNP array assay OBI:0001222 ELISA measuring epitope specific RANTES production by T cells An enzyme-linked immunosorbent assay that detects RANTES production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL5/RANTES release|ELISA ELISA measuring epitope specific RANTES production by T cells OBI:0001223 cytometric bead array assay measuring epitope specific interleukin-1 beta production by T cells A cytometric bead array assay that detects interleukin-1 beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1b release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-1 beta production by T cells OBI:0001227 ELISPOT assay measuring epitope specific interleukin-6 production by T cells An enzyme-linked immunospot assay that detects interleukin-6 production by T cells PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-6 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-6 production by T cells OBI:0001228 in vivo assay measuring epitope specific helper T cell enhancement of a B cell mediated immune response A T cell epitope specific helper activity assay that detects the ability of a T cell epitope to enhance an antibody response. IEDB IEDB antibody help|in vivo assay in vivo assay measuring epitope specific helper T cell enhancement of a B cell mediated immune response OBI:0001229 plasmon resonance assay measuring the dissociation constant [KD] of a T cell epitope:MHC:TCR complex A surface plasmon resonance binding assay that measures the dissociation constant [KD] of an epitope:MHC complex binding with a T cell receptor. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|surface plasmon resonance (SPR)|nM plasmon resonance assay measuring the dissociation constant [KD] of a T cell epitope:MHC:TCR complex OBI:0001230 assay measuring epitope specific interleukin-5 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-5 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-5 release|biological activity assay measuring epitope specific interleukin-5 production by T cells OBI:0001231 ELISA measuring epitope specific transforming growth factor-beta production by T cells An enzyme-linked immunosorbent assay that detects transforming growth factor-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TGFb release|ELISA ELISA measuring epitope specific transforming growth factor-beta production by T cells OBI:0001232 assay measuring epitope specific RANTES production by T cells A T cell epitope specific cytokine production assay that detects RANTES production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL5/RANTES release|biological activity assay measuring epitope specific RANTES production by T cells OBI:0001233 assay measuring epitope specific granulocyte macrophage colony stimulating factor production by T cells A T cell epitope specific cytokine production assay that detects granulocyte macrophage colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB GM-CSF release|biological activity assay measuring epitope specific granulocyte macrophage colony stimulating factor production by T cells OBI:0001235 transcription profiling by tiling array assay A transcription profiling by array assay that uses a tiling path array. James Malone EFO:0002769 transcription profiling by tiling array assay OBI:0001236 ELISA measuring epitope specific interleukin-22 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-22 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-22 release|ELISA ELISA measuring epitope specific interleukin-22 production by T cells OBI:0001237 assay measuring epitope specific interleukin-21 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-21 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-21 release|biological activity assay measuring epitope specific interleukin-21 production by T cells OBI:0001238 ELISA measuring epitope specific interleukin-9 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-9 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-9 release|ELISA ELISA measuring epitope specific interleukin-9 production by T cells OBI:0001240 intracellular cytokine staining assay measuring epitope specific interleukin-6 production by T cells A flow cytometry assay that detects interleukin-6 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-6 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-6 production by T cells OBI:0001241 cell culture analyte detection bioassay measuring epitope specific interleukin-4 production by T cells A reporter cell line analyte detection bioassay that detects interleukin-4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-4 release|bioassay cell culture analyte detection bioassay measuring epitope specific interleukin-4 production by T cells OBI:0001242 detection of specific nucleic acids with complementary probes assay measuring epitope specific tumor necrosis factor alpha production by T cells A detection of specific nucleic acid polymers with complementary probes that detects tumor necrosis factor alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNFa release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific tumor necrosis factor alpha production by T cells OBI:0001243 cytometric bead array assay measuring epitope specific monocyte chemotactic protein-1 production by T cells A cytometric bead array assay that detects monocyte chemotactic protein-1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL2/MCP-1 release|cytometric bead array cytometric bead array assay measuring epitope specific monocyte chemotactic protein-1 production by T cells OBI:0001244 ELISA measuring epitope specific interleukin-23 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-23 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-23 release|ELISA ELISA measuring epitope specific interleukin-23 production by T cells OBI:0001245 detection of specific nucleic acids with complementary probes assay measuring epitope specific perforin release A detection of specific nucleic acids with complementary probes assay that detects epitope specific perforin release by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB perforin release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific perforin release OBI:0001246 ELISA measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells An enzyme-linked immunosorbent assay that detects tumor necrosis factor superfamily cytokine production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNF release|ELISA ELISA measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells OBI:0001247 genotyping by high throughput sequencing assay A genotyping assay that uses a high througput sequencer James Malone EFO:0002771 genotyping by high throughput sequencing assay OBI:0001248 ChIP-chip assay An assay in which chromatin is immunoprecipitated and subsequently analyzed using a DNA microarray to identify which parts of DNA are part of the isolated chromatin Bjoern Petesr James Malone ChIP-on-chip assay url:http://en.wikipedia.org/wiki/ChIP-on-chip ChIP-chip assay OBI:0001251 assay measuring epitope specific interleukin-13 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-13 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-13 release|biological activity assay measuring epitope specific interleukin-13 production by T cells OBI:0001253 assay measuring interleukin-9 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-9 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-9 release|biological activity assay measuring interleukin-9 production by T cells OBI:0001255 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-5 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-5 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-5 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-5 production by T cells OBI:0001260 ELISA measuring epitope specific interleukin-3 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-3 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-3 release|ELISA ELISA measuring epitope specific interleukin-3 production by T cells OBI:0001261 ELISA measuring epitope specific interleukin-1 alpha production by T cells An enzyme-linked immunosorbent assay that detects interleukin-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1a release|ELISA ELISA measuring epitope specific interleukin-1 alpha production by T cells OBI:0001263 in vivo assay measuring epitope specific helper T cell enhancement of a T cell mediated immune response A T cell epitope specific helper activity assay that detects the ability of a T cell epitope to enhance a T cell response. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB T cell help|in vivo assay in vivo assay measuring epitope specific helper T cell enhancement of a T cell mediated immune response OBI:0001264 assay measuring epitope specific transforming growth factor-beta production by T cells A T cell epitope specific cytokine production assay that detects transforming growth factor-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TGFb release|biological activity assay measuring epitope specific transforming growth factor-beta production by T cells OBI:0001266 DNA methylation profiling by high throughput sequencing assay A DNA methylation profiling assay in which the methylation state of DNA is determined and can be compared between samples using sequencing based technology ArrayExpress production team Helen Parkinson James Malone EFO:0002761 DNA methylation profiling by high throughput sequencing assay OBI:0001268 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-12 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-12 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-12 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-12 production by T cells OBI:0001269 assay measuring epitope specific cytotoxic T cell degranulation A T cell epitope dependent biological activity assay that detects cytotoxic T cell degranulation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB degranulation|biological activity assay measuring epitope specific cytotoxic T cell degranulation OBI:0001270 cell culture analyte detection bioassay measuring epitope specific transforming growth factor-beta production by T cells A reporter cell line analyte detection bioassay that detects transforming growth factor-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TGFb release|bioassay cell culture analyte detection bioassay measuring epitope specific transforming growth factor-beta production by T cells OBI:0001271 RNA-seq assay An RNA sequencing assay that determines an RNA sequence by analyzing the transcibed regions of the genome and or to quantitate transcript abundance. James Malone transcription profiling by high throughput sequencing EFO:0002770 RNA-seq assay OBI:0001272 ELISPOT assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells An enzyme-linked immunospot assay that detects tumor necrosis factor superfamily cytokine production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNF release|ELISPOT ELISPOT assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells OBI:0001273 cell culture analyte detection bioassay measuring epitope specific interleukin-5 production by T cells A reporter cell line analyte detection bioassay that detects interleukin-5 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-5 release|bioassay cell culture analyte detection bioassay measuring epitope specific interleukin-5 production by T cells OBI:0001274 genotyping by array assay A genotyping assay that uses an array ArrayExpress production team EFO:0002767 genotyping by array assay OBI:0001276 assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells A T cell epitope specific cytokine production assay that detects production of chemokine (C-C motif) ligand 1 by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL1/TCA-3 release|biological activity assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells OBI:0001277 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-2 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-2 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-2 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-2 production by T cells OBI:0001279 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-22 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-22 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-22 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-22 production by T cells OBI:0001280 assay measuring epitope specific interleukin-16 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-16 release|biological activity assay measuring epitope specific interleukin-16 production by T cells OBI:0001281 ELISA measuring epitope specific IP-10 production by T cells An enzyme-linked immunosorbent assay that detects IP-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL10/IP-10 release|ELISA ELISA measuring epitope specific IP-10 production by T cells OBI:0001282 translation profiling assay An assay in which surface-bound, translationally competent ribosome complexes are used to generate a translation profile for mRNA, which mRNA may be a single molecular species, or a combination of species, including complex mixtures such as those found in the set of mRNAs isolated from a cell or tissue. One or more components of the surface-bound ribosome complex may be labeled at specific positions to permit analysis of multiple or single molecules for determination of ribosomal conformational changes and translation kinetics. Translation profiles are used as the basis for comparison of an mRNA or set of mRNA species. The translation profile can be used to determine such characteristics as kinetics of initiation, kinetic of elongation, identity of the polypeptide product, and the like. Analysis of translation profiles may be used to determine differential gene expression, optimization of mRNA sequences for expression, screening drug candidates for an effect on translation. James Malone EFO:0001033 translation profiling assay OBI:0001283 ELISA measuring epitope specific interleukin-15 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-15 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-15 release|ELISA ELISA measuring epitope specific interleukin-15 production by T cells OBI:0001284 cytometric bead array assay measuring epitope specific interleukin-12 production by T cells A cytometric bead array assay that detects interleukin-12 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-12 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-12 production by T cells OBI:0001288 ELISA measuring epitope specific lymphotoxin A production by T cells An enzyme-linked immunosorbent assay that detects lymphotoxin A production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB lymphotoxin A/TNFb release|ELISA ELISA measuring epitope specific lymphotoxin A production by T cells OBI:0001289 cytometric bead array assay measuring epitope specific interleukin-5 production by T cells A cytometric bead array assay that detects interleukin-5 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-5 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-5 production by T cells OBI:0001291 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-17 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-17 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-17 production by T cells OBI:0001292 assay measuring epitope specific interleukin-15 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-15 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-15 release|biological activity assay measuring epitope specific interleukin-15 production by T cells OBI:0001295 assay measuring epitope specific interleukin-17 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-17 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17 release|biological activity assay measuring epitope specific interleukin-17 production by T cells OBI:0001296 cytometric bead array assay measuring epitope specific interleukin-17 production by T cells A cytometric bead array assay that detects interleukin-17 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-17 production by T cells OBI:0001297 cytometric bead array assay measuring epitope specific interleukin-10 production by T cells A cytometric bead array assay that detects interleukin-10 production by T cells. IEDB IEDB IL-10 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-10 production by T cells OBI:0001298 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-21 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-21 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-21 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-21 production by T cells OBI:0001299 intracellular cytokine staining assay measuring epitope specific interleukin-5 production by T cells A flow cytometry assay that detects interleukin-5 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-5 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-5 production by T cells OBI:0001300 cytometric bead array assay measuring epitope specific interleukin-2 production by T cells A cytometric bead array assay that detects interleukin-2 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-2 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-2 production by T cells OBI:0001301 cell culture analyte detection bioassay measuring epitope specific interleukin-16 production by T cells A reporter cell line analyte detection bioassay that detects interleukin-16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-16 release|bioassay cell culture analyte detection bioassay measuring epitope specific interleukin-16 production by T cells OBI:0001302 ELISA measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells An enzyme-linked immunosorbent assay that detects macrophage inflammatory protein-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL3/MIP-1a release|ELISA ELISA measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells OBI:0001303 intracellular cytokine staining assay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells A flow cytometry assay that detects granulocyte macrophage colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB GM-CSF release|ICS intracellular cytokine staining assay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells OBI:0001304 RNAi profiling by array assay An assay in which double stranded RNA is synthesized with a sequence complementary to a gene(s) of interest and introduced into a cell or organism, where it is recognized as exogenous genetic material and activates the RNAi pathway resulting in knockdown of the transcripts and providing a means to study downstream changes in gene expression. James Malone EFO:0001030 RNAi profiling by array assay OBI:0001308 assay measuring epitope specific IP-10 production by T cells A T cell epitope specific cytokine production assay that detects IP-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL10/IP-10 release|biological activity assay measuring epitope specific IP-10 production by T cells OBI:0001309 intracellular cytokine staining assay measuring epitope specific interleukin-13 production by T cells A flow cytometry assay that detects interleukin-13 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-13 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-13 production by T cells OBI:0001311 X-ray crystallography assay determining the 3D structure of a T cell epitope:MHC:TCR complex A X-ray crystallography 3D molecular structure determination assay that characterizes the 3-dimensional molecular structure of a T cell epitope:MHC:TCR complex. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 3D structure|x-ray crystallography|angstroms X-ray crystallography assay determining the 3D structure of a T cell epitope:MHC:TCR complex OBI:0001315 ELISA measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells An enzyme-linked immunosorbent assay that detects chemokine (C-C motif) ligand 1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL1/TCA-3 release|ELISA ELISA measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells OBI:0001317 flow cytometry assay measuring cell-cell binding of a T cell epitope:MHC:TCR complex A flow cytometry assay that measures the cell-cell binding of an epitope:MHC complex binding with a T cell receptor. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB T cell- APC binding|binding assay flow cytometry assay measuring cell-cell binding of a T cell epitope:MHC:TCR complex OBI:0001318 proteomic profiling by array assay An assay that detects proteins in a sample (quantified or otherwise analyzed), e.g. antibody profiling using an array based technology. James Malone EFO:0002765 proteomic profiling by array assay OBI:0001319 cell culture analyte detection bioassay measuring epitope specific interferon-gamma production by T cells A reporter cell line analyte detection bioassay that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|bioassay cell culture analyte detection bioassay measuring epitope specific interferon-gamma production by T cells OBI:0001322 ELISPOT assay measuring epitope specific granzyme B release by T cells An enzyme-linked immunospot assay that detects epitope specific granzyme B release by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB granzyme B release|ELISPOT ELISPOT assay measuring epitope specific granzyme B release by T cells OBI:0001324 in vivo assay measuring T cell epitope specific tolerance induction An efficacy of T cell epitope intervention experiment that uses a tolerance induction intervention experiment. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB tolerance|in vivo assay in vivo assay measuring T cell epitope specific tolerance induction OBI:0001325 detection of specific nucleic acids with complementary probes assay measuring epitope specific RANTES production by T cells A detection of specific nucleic acid polymers with complementary probes that detects RANTES production by T cells. IEDB IEDB CCL5/RANTES release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific RANTES production by T cells OBI:0001326 cytometric bead array assay measuring epitope specific interleukin-4 production by T cells A cytometric bead array assay that detects interleukin-4 production by T cells PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-4 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-4 production by T cells OBI:0001327 assay measuring epitope specific lymphotoxin A production by T cells A T cell epitope specific cytokine production assay that detects lymphotoxin A production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB lymphotoxin A/TNFb release|biological activity assay measuring epitope specific lymphotoxin A production by T cells OBI:0001330 ELISA measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells An enzyme-linked immunosorbent assay that detects chemokine (C-X-C motif) ligand 9 production by T cells. IEDB IEDB CXCL9/MIG release|ELISA ELISA measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells OBI:0001332 DNA methylation profiling by array assay A DNA methylation profiling assay in which the methylation state of DNA is determined and can be compared between samples using array technology James Malone EFO:0002759 DNA methylation profiling by array assay OBI:0001333 assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells A T cell epitope specific cytokine production assay that detects macrophage inflammatory protein-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL3/MIP-1a release|biological activity assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells OBI:0001335 microRNA profiling by array assay An assay that analyses the microRNA component of the transcriptome using a microRNA array. James Malone EFO:0000753 microRNA profiling by array assay OBI:0001339 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-4 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-4 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-4 production by T cells OBI:0001341 cell culture analyte detection bioassay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells A reporter cell line analyte detection bioassay that detects granulocyte macrophage colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB GM-CSF release|bioassay cell culture analyte detection bioassay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells OBI:0001342 intracellular cytokine staining assay measuring epitope specific interleukin-21 production by T cells A flow cytometry assay that detects interleukin-21 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-21 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-21 production by T cells OBI:0001343 detection of specific nucleic acids with complementary probes assay measuring epitope specific monocyte chemotactic protein-1 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects monocyte chemotactic protein-1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL2/MCP-1 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific monocyte chemotactic protein-1 production by T cells OBI:0001344 ELISA measuring epitope specific monocyte chemotactic protein-1 production by T cells An enzyme-linked immunosorbent assay that detects monocyte chemotactic protein-1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL2/MCP-1 release|ELISA ELISA measuring epitope specific monocyte chemotactic protein-1 production by T cells OBI:0001345 assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-C motif) ligand 4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL4/MIP-1b release|biological activity assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells OBI:0001346 ELISA measuring epitope specific interleukin-21 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-21 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-21 release|ELISA ELISA measuring epitope specific interleukin-21 production by T cells OBI:0001348 in vivo skin test assay measuring T cell epitope specific type IV hypersensitivity An efficacy of T cell epitope intervention experiment that detects epitope specific type IV hypersensitivity. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB type IV hypersensitivity (DTH)|in vivo skin test in vivo skin test assay measuring T cell epitope specific type IV hypersensitivity OBI:0001349 cytometric bead array assay measuring epitope specific interleukin-13 production by T cells A cytometric bead array assay that detects interleukin-13 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-13 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-13 production by T cells OBI:0001350 detection of specific nucleic acids with complementary probes assay measuring epitope specific interferon-gamma production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interferon-gamma production by T cells OBI:0001353 cytometric bead array assay measuring epitope specific tumor necrosis factor alpha production by T cells A cytometric bead array assay that detects tumor necrosis factor alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNFa release|cytometric bead array cytometric bead array assay measuring epitope specific tumor necrosis factor alpha production by T cells OBI:0001354 ELISPOT assay measuring epitope specific interleukin-17 production by T cells An enzyme-linked immunospot assay that detects interleukin-17 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-17 production by T cells OBI:0001356 detection of specific nucleic acids with complementary probes assay measuring epitope specific interferon-beta production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interferon-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNb release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interferon-beta production by T cells OBI:0001357 detection of specific nucleic acids with complementary probes assay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells A detection of specific nucleic acid polymers with complementary probes that detects granulocyte macrophage colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB GM-CSF release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells OBI:0001359 ELISA measuring epitope specific interleukin-8 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-8 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-8 release|ELISA ELISA measuring epitope specific interleukin-8 production by T cells OBI:0001360 cytometric bead array assay measuring epitope specific interleukin-6 production by T cells A cytometric bead array assay that detects interleukin-6 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-6 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-6 production by T cells OBI:0001361 transcription profiling by RT-PCR assay A transcription profiling assay that uses reverse transcription PCR (RT-PCR). Anna Farne EFO:0002943 transcription profiling by RT-PCR assay OBI:0001363 assay measuring epitope specific interleukin-23 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-23 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-23 release|biological activity assay measuring epitope specific interleukin-23 production by T cells OBI:0001367 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-10 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-10 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-10 production by T cells OBI:0001368 cytometric bead array assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells A cytometric bead array assay that detects tumor necrosis factor superfamily cytokine production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNF release|cytometric bead array cytometric bead array assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells OBI:0001370 intracellular cytokine staining assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells A flow cytometry assay that detects chemokine (C-C motif) ligand 4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL4/MIP-1b release|ICS intracellular cytokine staining assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells OBI:0001376 intracellular cytokine staining assay measuring epitope specific interleukin-3 production by T cells A flow cytometry assay that detects interleukin-3 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-3 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-3 production by T cells OBI:0001378 ELISA measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells An enzyme-linked immunosorbent assay that detects chemokine (C-C motif) ligand 4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL4/MIP-1b release|ELISA ELISA measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells OBI:0001379 cytometric bead array assay measuring epitope specific interferon-gamma production by T cells A cytometric bead array assay that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|cytometric bead array cytometric bead array assay measuring epitope specific interferon-gamma production by T cells OBI:0001380 assay measuring epitope specific interleukin-18 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-18 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-18 release|biological activity assay measuring epitope specific interleukin-18 production by T cells OBI:0001382 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-27 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-27 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-27 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-27 production by T cells OBI:0001383 detection of specific nucleic acids with complementary probes assay measuring epitope specific IP-10 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects IP-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL10/IP-10 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific IP-10 production by T cells OBI:0001384 cell culture analyte detection bioassay measuring epitope specific interleukin-3 production by T cells A reporter cell line analyte detection bioassay that detects interleukin-3 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-3 release|bioassay cell culture analyte detection bioassay measuring epitope specific interleukin-3 production by T cells OBI:0001385 intracellular cytokine staining assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells A flow cytometry assay that detects tumor necrosis factor superfamily cytokine production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNF release|ICS intracellular cytokine staining assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells OBI:0001388 assay measuring epitope specific interleukin-1 alpha production by T cells A T cell epitope specific cytokine production assay that detects interleukin-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1a release|biological activity assay measuring epitope specific interleukin-1 alpha production by T cells OBI:0001389 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-6 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-6 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-6 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-6 production by T cells OBI:0001390 assay measuring epitope specific interferon-beta production by T cells A T cell epitope specific cytokine production assay that detects interferon-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNb release|biological activity assay measuring epitope specific interferon-beta production by T cells OBI:0001391 assay measuring epitope specific interleukin-12 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-12 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-12 release|biological activity assay measuring epitope specific interleukin-12 production by T cells OBI:0001392 in vivo assay measuring epitope specific T cell killing An in vivo cell killing assay that measures the killing of antigen presenting cells (APC) by T cells whose TCR recognizes an epitope presented by the APC. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB cytotoxicity|in vivo assay in vivo assay measuring epitope specific T cell killing OBI:0001393 comparative genomic hybridization by array assay An assay that measures changes in DNA sequence copy number using a microarray. For example the analysis of LOH in tumor cells vs a non diseased sample or the comparison of clinical isolated of disease causing bacteria. James Malone array CGH EFO:0000749 comparative genomic hybridization by array assay OBI:0001395 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-23 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-23 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-23 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-23 production by T cells OBI:0001397 cytometric bead array assay measuring epitope specific granulocyte colony stimulating factor production by T cells A cytometric bead array assay that detects granulocyte colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB G-CSF release|cytometric bead array cytometric bead array assay measuring epitope specific granulocyte colony stimulating factor production by T cells OBI:0001400 assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells A T cell epitope specific cytokine production assay that detects tumor necrosis factor superfamily cytokine production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNF release|biological activity assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells OBI:0001402 promoter activity detection by reporter gene assay measuring epitope specific interleukin-2 production by T cells A promoter activity detection by reporter gene assay that detects interleukin-2 production by T cells. IEDB IEDB IL-2 release|reporter gene assay promoter activity detection by reporter gene assay measuring epitope specific interleukin-2 production by T cells OBI:0001405 cytometric bead array assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells A cytometric bead array assay that detects macrophage inflammatory protein-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL3/MIP-1a release|cytometric bead array cytometric bead array assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells OBI:0001406 assay measuring epitope specific interleukin-3 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-3 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-3 release|biological activity assay measuring epitope specific interleukin-3 production by T cells OBI:0001407 assay measuring epitope specific T cell activation A T cell epitope dependent biological activity assay that detects T cell activation. IEDB IEDB activation|biological activity assay measuring epitope specific T cell activation OBI:0001412 cytometric bead array assay measuring epitope specific RANTES production by T cells A cytometric bead array assay that detects RANTES production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL5/RANTES release|cytometric bead array cytometric bead array assay measuring epitope specific RANTES production by T cells OBI:0001413 cell culture analyte detection bioassay measuring epitope specific interleukin-6 production by T cells A reporter cell line analyte detection bioassay that detects interleukin-6 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-6 release|bioassay cell culture analyte detection bioassay measuring epitope specific interleukin-6 production by T cells OBI:0001414 assay measuring epitope specific interferon-gamma production by T cells A T cell epitope specific cytokine production assay that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|biological activity assay measuring epitope specific interferon-gamma production by T cells OBI:0001416 assay measuring epitope specific tumor necrosis factor alpha production by T cells An assay of epitope specific tumor necrosis factor alpha production by T cells that detects tumor necrosis factor production. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNFa release|biological activity assay measuring epitope specific tumor necrosis factor alpha production by T cells OBI:0001419 ChIP-chip by tiling array assay A ChIP-ChIP assay in which immunoprecipitated chromatin is run on a tiling array that covers stretches of DNA to to detect which elements in those stretches are present in the isolated chromatin ArrayExpress production team EFO:0002762 ChIP-chip by tiling array assay OBI:0001423 intracellular material detection measuring epitope specific granzyme B release by T cells A flow cytometry assay that detects epitope specific granzyme B release by T cells PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB granzyme B release|intracellular staining intracellular material detection measuring epitope specific granzyme B release by T cells OBI:0001433 radio immuno assay measuring epitope specific interferon-gamma production by T cells A radio immuno assay that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|radio immuno assay (RIA) radio immuno assay measuring epitope specific interferon-gamma production by T cells OBI:0001436 assay measuring epitope specific granzyme B release by T cells A T cell epitope specific cytotoxic T cell degranulation assay that detects granzyme B release by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB granzyme B release|biological activity assay measuring epitope specific granzyme B release by T cells OBI:0001437 intracellular cytokine staining assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells A flow cytometry assay that detects chemokine (C-X-C motif) ligand 9 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL9/MIG release|ICS intracellular cytokine staining assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells OBI:0001438 ELISA measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells An enzyme-linked immunosorbent assay that detects macrophage inflammatory protein-1 gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL9/MIP-1g release|ELISA ELISA measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells OBI:0001445 assay measuring epitope specific interleukin-2 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-2 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-2 release|biological activity assay measuring epitope specific interleukin-2 production by T cells OBI:0001449 assay measuring epitope specific interleukin-1 beta production by T cells A T cell epitope specific cytokine production assay that detects interleukin-1 beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1b release|biological activity assay measuring epitope specific interleukin-1 beta production by T cells OBI:0001450 assay measuring epitope specific interleukin-4 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-4 release|biological activity assay measuring epitope specific interleukin-4 production by T cells OBI:0001451 assay measuring epitope specific interleukin-6 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-6 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-6 release|biological activity assay measuring epitope specific interleukin-6 production by T cells OBI:0001452 cell culture analyte detection bioassay measuring epitope specific tumor necrosis factor alpha production by T cells A reporter cell line analyte detection bioassay that detects tumor necrosis factor alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNFa release|bioassay cell culture analyte detection bioassay measuring epitope specific tumor necrosis factor alpha production by T cells OBI:0001453 intracellular cytokine staining assay measuring epitope specific lymphotoxin A production by T cells A flow cytometry assay that detects lymphotoxin A production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB lymphotoxin A/TNFb release|ICS intracellular cytokine staining assay measuring epitope specific lymphotoxin A production by T cells OBI:0001455 ELISPOT assay measuring epitope specific interleukin-5 production by T cells An enzyme-linked immunospot assay that detects interleukin-5 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-5 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-5 production by T cells OBI:0001456 assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells A T cell epitope specific cytokine production assay that detects macrophage inflammatory protein-1 gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL9/MIP-1g release|biological activity assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells OBI:0001457 cytometric bead array assay measuring epitope specific interleukin-8 production by T cells A cytometric bead array assay that detects interleukin-8 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-8 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-8 production by T cells OBI:0001459 assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-X-C motif) ligand 9 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL9/MIG release|biological activity assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells OBI:0001461 ELISA measuring epitope specific granzyme B release by T cells An enzyme-linked immunosorbent assay that detects epitope specific granzyme B release by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB granzyme B release|ELISA ELISA measuring epitope specific granzyme B release by T cells OBI:0001463 transcription profiling by array assay A transcription profiling assay that uses array technology. James Malone RNA profiling by array assay EFO:0002768 https://sourceforge.net/p/obi/obi-terms/757/ transcription profiling by array assay OBI:0001465 assay measuring epitope specific monocyte chemotactic protein-1 production by T cells A T cell epitope specific cytokine production assay that detects monocyte chemotactic protein-1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL2/MCP-1 release|biological activity assay measuring epitope specific monocyte chemotactic protein-1 production by T cells OBI:0001466 intracellular cytokine staining assay measuring epitope specific interleukin-12 production by T cells A flow cytometry assay that detects interleukin-12 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-12 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-12 production by T cells OBI:0001467 in vivo assay measuring T cell epitope specific disease exacerbation An efficacy of T cell epitope intervention experiment that uses a disease exacerbation in vivo intervention experiment. IEDB IEDB disease exacerbation|in vivo assay in vivo assay measuring T cell epitope specific disease exacerbation OBI:0001469 monospecific T cell recognition assay measuring MHC ligand processing and presentation A MHC ligand processing and presentation assay in which the presence of a specific ligand in an eluate is detected using the response of T cells that are known to be monospecific for that ligand as a readout. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB ligand presentation|T cell recognition monospecific T cell recognition assay measuring MHC ligand processing and presentation OBI:0001473 in vivo assay measuring T cell epitope specific protection after tumor burden challenge An in vivo assay measuring T cell epitope specific protection from tumor challenge using tumor burden. IEDB IEDB tumor burden after challenge|in vivo assay in vivo assay measuring T cell epitope specific protection after tumor burden challenge OBI:0001475 in vivo assay measuring T cell epitope specific protection from infectious challenge based on pathogen burden An in vivo assay measuring T cell epitope specific protection from pathogen challenge using pathogen burden. IEDB IEDB pathogen burden after challenge|in vivo assay in vivo assay measuring T cell epitope specific protection from infectious challenge based on pathogen burden OBI:0001476 phage display binding assay Using a commercial library of phages that produce random peptide sequences to infect E coli cells, and screening them for binding to a selecting antibody of unknown specificity. By iteratively using phages from selected E coli cells and repeating this process, phages encoding high affinity peptides for the antibody are selected, sequenced, and thereby the specificity of the antibody is elucidated. A binding assay in which a collection of phages expressing a library of different peptides or protein fragnments is used to infect cells, followed by screening for cells that bind a protein of interest, and identifiying the sequence of infecting phages to determine a suitable binding partner. IEDB IEDB phage display binding assay OBI:0001478 mass spectrometry assay measuring MHC ligand processing and presentation A MHC ligand processing and presentation assay that uses a mass spectrometry assay to identify eluted ligands IEDB IEDB ligand presentation|mass spectrometry mass spectrometry assay measuring MHC ligand processing and presentation OBI:0001482 intracellular cytokine staining assay measuring epitope specific transforming growth factor-beta production by T cells A flow cytometry assay that detects transforming growth factor-beta production by T cells. IEDB IEDB TGFb release|ICS intracellular cytokine staining assay measuring epitope specific transforming growth factor-beta production by T cells OBI:0001484 assay measuring T cell epitope specific in vivo activity A T cell epitope dependent biological activity determination assay that uses an in vivo intervention experiment. IEDB IEDB in vivo activity|biological activity assay measuring T cell epitope specific in vivo activity OBI:0001488 epitope tolerance induction experiment An efficacy of epitope intervention experiment that tests the ability of the intervention to decrease an existing immune response IEDB tolerance induction IEDB epitope tolerance induction experiment OBI:0001489 mass spectrometry assay measuring MHC ligand processing and presentation of MHC ligands eluted from cellular MHC A mass spectrometry of MHC ligands assay that identifies eluted ligands from cell bound MHC. IEDB IEDB ligand presentation|cellular MHC/mass spectrometry mass spectrometry assay measuring MHC ligand processing and presentation of MHC ligands eluted from cellular MHC OBI:0001490 cytometric bead array measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells A cytometric bead array assay that detects granulocyte macrophage colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB GM-CSF release|cytometric bead array cytometric bead array measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells OBI:0001491 binding assay using radioactivity detection A binding assay that uses radioactivity detection as an indicator of binding. Bjoern Peters Randi Vita IEDB binding assay using radioactivity detection OBI:0001492 in vivo assay measuring T cell epitope specific protection based on survival An in vivo assay measuring T cell epitope specific protection from other challenge using survival. IEDB IEDB survival from challenge|in vivo assay in vivo assay measuring T cell epitope specific protection based on survival OBI:0001493 cell bound MHC competitive binding assay of a MHC:ligand complex using T cell epitope recognition A cell bound MHC binding assay that uses a T cell epitope recognition assay. IEDB IEDB qualitative binding|cellular MHC/T cell inhibition cell bound MHC competitive binding assay of a MHC:ligand complex using T cell epitope recognition OBI:0001495 in vivo assay measuring epitope specific T cell helper activity A T cell epitope dependent biological activity assay that detects the ability of epitope specific helper T cells to enhance either B cell or T cell adaptive immune response function. IEDB IEDB helper response|in vivo assay in vivo assay measuring epitope specific T cell helper activity OBI:0001496 intracellular cytokine staining assay measuring epitope specific interleukin-22 production by T cells A flow cytometry assay that detects interleukin-22 production by T cells. IEDB IEDB IL-22 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-22 production by T cells OBI:0001497 assay measuring epitope specific perforin release by T cells A T cell epitope specific cytotoxic T cell degranulation assay that detects perforin release by T cells. IEDB IEDB perforin release|biological activity assay measuring epitope specific perforin release by T cells OBI:0001499 binding assay using fluorescence detection A binding assay that uses fluorescence detection as an indicator of binding. Bjoern Peters Randi Vita IEDB binding assay using fluorescence detection OBI:0001500 coelution assay measuring MHC ligand processing and presentation using T cell recognition of HPLC fractionated eluate compared to synthetic ligand A MHC ligand processing and presentation assay in which an HPL chromatography is run to separate an input mixture of ligands eluted from MHC into fractions. These fractions are tested for recognition by T cells and compared to the recognition of a synthetic ligand that is presumed to be the recognized epitope. Identical HPLC fractionation and T cell recognition patterns confirm that the specific ligand was presented by MHC molecules. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB ligand presentation|coelution coelution assay measuring MHC ligand processing and presentation using T cell recognition of HPLC fractionated eluate compared to synthetic ligand OBI:0001501 fluorescence detection assay Using a laser to stimulate a cell culture that was previously labeled with fluorescent antibodies to detect light emmission at a different wavelength in order to determine the presence of surface markers the antibodies are specific for. An assay in which a material's fluorescence is determined. IEDB IEDB fluorescence detection assay OBI:0001507 in vivo assay measuring T cell epitope specific treatment of disease An efficacy of T cell epitope intervention experiment that detects a decrease in disease. IEDB IEDB decreased disease|in vivo assay in vivo assay measuring T cell epitope specific treatment of disease OBI:0001509 Edman degradation assay measuring MHC ligand processing and presentation A MHC ligand processing and presentation assay that uses Edman degradation to identify the eluted ligands PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB ligand presentation|Edman degradation Edman degradation assay measuring MHC ligand processing and presentation OBI:0001510 mass spectrometry assay measuring MHC ligand processing and presentation of MHC ligands eluted from secreted MHC A mass spectrometry of MHC ligands that identifies eluted ligands from secreted MHC. IEDB IEDB ligand presentation|secreted MHC/mass spectrometry mass spectrometry assay measuring MHC ligand processing and presentation of MHC ligands eluted from secreted MHC OBI:0001512 cytometric bead array assay measuring epitope specific interleukin-17A production by T cells A cytometric bead array assay that detects interleukin-17A production by T cells. IEDB IEDB IL-17A release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-17A production by T cells OBI:0001513 radioactivity detection assay measuring competitive binding of a purified-MHC:ligand complex A radioactivity detection assay that detects loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|purified MHC/competitive/radioactivity radioactivity detection assay measuring competitive binding of a purified-MHC:ligand complex OBI:0001516 radioactivity detection assay measuring half maximal effective concentration [EC50] to determine direct binding of a cell-lysate-MHC:ligand complex A radioactivity detection assay that measures half maximal effective concentration (EC50) to detect the direct binding of a cell-lysate-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half maximal effective concentration (EC50)|lysate MHC/direct/radioactivity|nM radioactivity detection assay measuring half maximal effective concentration [EC50] to determine direct binding of a cell-lysate-MHC:ligand complex OBI:0001517 radioactivity detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a cell-bound-MHC:ligand complex A radioactivity detection assay that measures half maximal inhibitory concentration (IC50) to detect the loss of binding of a known reference ligand to cell-bound-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half maximal inhibitory concentration (IC50)|cellular MHC/competitive/radioactivity|nM radioactivity detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a cell-bound-MHC:ligand complex OBI:0001519 fluorescence detection assay measuring direct binding of a cell-lysate-MHC:ligand complex A fluorescence detection assay that detects direct binding of a cell-lysate-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|lysate MHC/direct/fluorescence fluorescence detection assay measuring direct binding of a cell-lysate-MHC:ligand complex OBI:0001520 fluorescence detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that measures half maximal inhibitory concentration (IC50) to detect the loss of binding of a known reference ligand to cell-bound-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half maximal inhibitory concentration (IC50)|cellular MHC/competitive/fluorescence|nM fluorescence detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a cell-bound-MHC:ligand complex OBI:0001521 ELISA measuring epitope specific granulocyte colony stimulating factor production by T cells An enzyme-linked immunosorbent assay that detects granulocyte colony stimulating factor production by T cells. IEDB IEDB G-CSF release|ELISA ELISA measuring epitope specific granulocyte colony stimulating factor production by T cells OBI:0001523 cytometric bead array assay measuring epitope specific interleukin-17F production by T cells A cytometric bead array assay that detects interleukin-17F production by T cells. IEDB IEDB IL-17F release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-17F production by T cells OBI:0001524 fluorescence detection assay measuring equilibrium association constant [KA] to determine direct binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that measures equilibrium association constant (KA) to detect the direct binding of a cell-bound-MHC molecule with a ligand. IEDB IEDB association constant KA|cellular MHC/direct/fluorescence|1/M fluorescence detection assay measuring equilibrium association constant [KA] to determine direct binding of a cell-bound-MHC:ligand complex OBI:0001531 fluorescence detection assay measuring half life to determine direct binding of a purified-MHC:ligand complex A fluorescence detection assay that measures half life to detect the direct binding of a purified-MHC molecule with a ligand. IEDB IEDB half life|purified MHC/direct/fluorescence|min fluorescence detection assay measuring half life to determine direct binding of a purified-MHC:ligand complex OBI:0001532 cytometric bead array assay measuring epitope specific interleukin-9 production by T cells A cytometric bead array assay that detects interleukin-9 production by T cells. IEDB IEDB IL-9 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-9 production by T cells OBI:0001534 fluorescence detection assay measuring competitive binding of a purified-MHC:ligand complex A fluorescence detection assay that detects loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation. IEDB IEDB qualitative binding|purified MHC/competitive/fluorescence fluorescence detection assay measuring competitive binding of a purified-MHC:ligand complex OBI:0001537 fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex A fluorescence detection assay that measures equilibrium dissociation constant (KD) to detect the loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|purified MHC/competitive/fluorescence|nM fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex OBI:0001539 fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that measures equilibrium dissociation constant (KD) to detect the loss of binding of a known reference ligand to cell-bound-MHC due to competition by the ligand under investigation. IEDB IEDB dissociation constant KD|cellular MHC/competitive/fluorescence|nM fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a cell-bound-MHC:ligand complex OBI:0001541 fluorescence detection assay measuring binding on rate [kon] to determine direct binding of a purified-MHC:ligand complex A fluorescence detection assay measuring binding on rate (kon) to detect direct binding of a purified-MHC:ligand complex. IEDB IEDB on rate|purified MHC/direct/fluorescence|nM^-1s^-1 fluorescence detection assay measuring binding on rate [kon] to determine direct binding of a purified-MHC:ligand complex OBI:0001542 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-13 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-13 production by T cells. IEDB IEDB IL-13 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-13 production by T cells OBI:0001543 fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine direct binding of a purified-MHC:ligand complex approximated by EC50 A fluorescence detection assay that measures equilibrium dissociation constant (KD) to detect direct binding of a purified-MHC molecule with a ligand and provides EC50 values determined under assay conditions where the EC50 approximates a KD value. IEDB IEDB dissociation constant KD (~EC50)|purified MHC/direct/fluorescence|nM fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine direct binding of a purified-MHC:ligand complex approximated by EC50 OBI:0001544 radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a cell-lysate-MHC:ligand complex A radioactivity detection assay that measures equilibrium dissociation constant (KD) to detect the loss of binding of a known reference ligand to cell-lysate-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|lysate MHC/competitive/radioactivity|nM radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a cell-lysate-MHC:ligand complex OBI:0001545 intracellular cytokine staining assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells A flow cytometry assay that detects macrophage inflammatory protein-1 alpha production by T cells. IEDB IEDB CCL3/MIP-1a release|ICS intracellular cytokine staining assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells OBI:0001549 radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a cell-bound-MHC:ligand complex A radioactivity detection assay that measures equilibrium dissociation constant (KD) to detect the loss of binding of a known reference ligand to cell-bound-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|cellular MHC/competitive/radioactivity|nM radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a cell-bound-MHC:ligand complex OBI:0001550 assay measuring binding of a cell-bound-MHC:ligand complex A qualitative binding assay that detects the binding of a cell-bound-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|cellular MHC assay measuring binding of a cell-bound-MHC:ligand complex OBI:0001552 intracellular cytokine staining assay measuring epitope specific tumor necrosis factor (ligand) superfamily member 11 production by T cells A flow cytometry assay that detects tumor necrosis factor (ligand) superfamily member 11 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNFSF11/RANKL release|ICS intracellular cytokine staining assay measuring epitope specific tumor necrosis factor (ligand) superfamily member 11 production by T cells OBI:0001553 assay measuring a binding constant of a MHC:ligand complex A MHC:ligand binding assay that measures a binding constant. IEDB IEDB binding constant|binding assay assay measuring a binding constant of a MHC:ligand complex OBI:0001555 assay measuring binding of a purified-MHC:ligand complex A qualitative binding assay that detects the binding of a purified-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|purified MHC assay measuring binding of a purified-MHC:ligand complex OBI:0001556 radioactivity detection assay measuring direct binding of a cell-lysate-MHC:ligand complex A radioactivity detection assay that detects direct binding of a cell-lysate-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|lysate MHC/direct/radioactivity radioactivity detection assay measuring direct binding of a cell-lysate-MHC:ligand complex OBI:0001558 radioactivity detection assay measuring half life to determine direct binding of a cell-bound-MHC:ligand complex A radioactivity detection assay that measures half life to detect the direct binding of a cell-bound-MHC molecule with a ligand. IEDB IEDB half life|cellular MHC/direct/radioactivity|min radioactivity detection assay measuring half life to determine direct binding of a cell-bound-MHC:ligand complex OBI:0001559 fluorescence detection assay measuring half life to determine direct binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that measures half life to detect the direct binding of a cell-bound-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half life|cellular MHC/direct/fluorescence|min fluorescence detection assay measuring half life to determine direct binding of a cell-bound-MHC:ligand complex OBI:0001561 fluorescence detection assay measuring half maximal effective concentration [EC50] to determine direct binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that measures half maximal effective concentration (EC50) to detect direct binding of a cell-bound-MHC molecule with a ligand. IEDB IEDB half maximal effective concentration (EC50)|cellular MHC/direct/fluorescence|nM fluorescence detection assay measuring half maximal effective concentration [EC50] to determine direct binding of a cell-bound-MHC:ligand complex OBI:0001562 intracellular cytokine staining assay measuring epitope specific interleukin-17F production by T cells A flow cytometry assay that detects interleukin-17F production by T cells. IEDB IEDB IL-17F release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-17F production by T cells OBI:0001564 radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex approximated by IC50 A radioactivity detection assay that measures equilibrium dissociation constant (KD) to detect the loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation and provides IC50 values determined under assay conditions where the IC50 approximates a KD value. IEDB IEDB dissociation constant KD (~IC50)|purified MHC/competitive/radioactivity|nM radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex approximated by IC50 OBI:0001565 radioactivity detection assay measuring half life to determine direct binding of a cell-lysate-MHC:ligand complex A radioactivity detection assay that measures half life to detect the direct binding of a cell-lysate-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half life|lysate MHC/direct/radioactivity|min radioactivity detection assay measuring half life to determine direct binding of a cell-lysate-MHC:ligand complex OBI:0001567 radioactivity detection assay measuring binding off rate [koff] to determine direct binding of a cell-lysate-MHC:ligand complex A radioactivity detection assay that measures binding off rate [koff] to detect direct binding of a cell-lysate-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB off rate|lysate MHC/direct/radioactivity|1/s radioactivity detection assay measuring binding off rate [koff] to determine direct binding of a cell-lysate-MHC:ligand complex OBI:0001568 radioactivity detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a purified-MHC:ligand complex A radioactivity detection assay that measures half maximal inhibitory concentration (IC50) to detect the loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half maximal inhibitory concentration (IC50)|purified MHC/competitive/radioactivity|nM radioactivity detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a purified-MHC:ligand complex OBI:0001569 fluorescence detection assay measuring binding off rate [koff] to determine direct binding of a purified-MHC:ligand complex A fluorescence detection assay that measures binding off rate [koff] to detect direct binding of a purified-MHC molecule with a ligand. IEDB IEDB off rate|purified MHC/direct/fluorescence|1/s fluorescence detection assay measuring binding off rate [koff] to determine direct binding of a purified-MHC:ligand complex OBI:0001570 assay measuring epitope specific vascular endothelial growth factor production by T cells A T cell epitope specific cytokine production assay that detects vascular endothelial growth factor production by T cells. IEDB IEDB VEGF release|biological activity assay measuring epitope specific vascular endothelial growth factor production by T cells OBI:0001577 cytometric bead array assay measuring epitope specific intracellular cytokine staining (ICS) IL-22 production by T cells A cytometric bead array assay that detects interleukin-22 production by T cells. IEDB IEDB IL-22 release|cytometric bead array cytometric bead array assay measuring epitope specific intracellular cytokine staining (ICS) IL-22 production by T cells OBI:0001578 ELISA measuring epitope specific vascular endothelial growth factor production by T cells An enzyme-linked immunosorbent assay that detects vascular endothelial growth factor production by T cells. IEDB IEDB VEGF release|ELISA ELISA measuring epitope specific vascular endothelial growth factor production by T cells OBI:0001579 assay measuring binding of a cell-lysate-MHC:ligand complex A qualitative binding assay that detects the binding of a cell-lysate-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|lysate MHC assay measuring binding of a cell-lysate-MHC:ligand complex OBI:0001584 phage display binding assay measuring binding of a purified-MHC:ligand complex A phage display binding assay that detects direct binding of a purified-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|purified MHC/direct/phage display phage display binding assay measuring binding of a purified-MHC:ligand complex OBI:0001585 cytometric bead array assay measuring epitope specific interleukin-7 production by T cells A cytometric bead array assay that detects interleukin-7 production by T cells. IEDB IEDB IL-7 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-7 production by T cells OBI:0001586 radioactivity detection assay measuring half life to determine direct binding of a purified-MHC:ligand complex A radioactivity detection assay that measures half life to detect the direct binding of a purified-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half life|purified MHC/direct/radioactivity|min radioactivity detection assay measuring half life to determine direct binding of a purified-MHC:ligand complex OBI:0001587 assay measuring epitope specific interleukin-7 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-7 production by T cells. IEDB IEDB IL-7 release|biological activity assay measuring epitope specific interleukin-7 production by T cells OBI:0001589 intracellular cytokine staining assay measuring epitope specific interleukin-17A production by T cells A flow cytometry assay that detects interleukin-17A production by T cells. IEDB IEDB IL-17A release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-17A production by T cells OBI:0001590 fluorescence detection assay measuring direct binding of a purified-MHC:ligand complex A fluorescence detection assay that detects direct binding of a purified-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|purified MHC/direct/fluorescence fluorescence detection assay measuring direct binding of a purified-MHC:ligand complex OBI:0001591 direct binding assay Detecting the binding of a fluorescently labeled antibody to a peptide bound to the bottom of an ELISA plate, by incubating the antibody in the well, washing the plate, and detecing fluorescence which is a proxy for the presence of the bound antibody._ A binding assay that measures the formation or disassociation of a complex of 2 material entities directly without use of a competitve ligand. Bjoern Peters Randi Vita IEDB direct binding assay OBI:0001592 fluorescence detection assay measuring half maximal effective concentration [EC50] to determine direct binding of a purified-MHC:ligand complex A fluorescence detection assay that measures half maximal effective concentration (EC50) to detect direct binding of a purified-MHC molecule with a ligand. IEDB IEDB half maximal effective concentration (EC50)|purified MHC/direct/fluorescence|nM fluorescence detection assay measuring half maximal effective concentration [EC50] to determine direct binding of a purified-MHC:ligand complex OBI:0001593 competitive inhibition of binding assay Detecting the inhibition of binding of a fluorescently labeled antibody to its known protein ligand bound to the bottom of an ELISA plate, by incubating the antibody in the presence of a peptide of interest, adding it to the plate, washing the plate, and detecing fluorescence which is a proxy for the presence of the bound antibody. Reduction in binding due to the presence of the peptide indicates that the antibody binds the peptide._ A binding assay that detects the inhibition of binding between 2 material entities known to form a complex by the addition of a third material entity of interest. Inhibition of binding between the 2 materials reflects binding by the third material. IEDB IEDB competitive inhibition of binding assay OBI:0001594 fluorescence detection assay measuring competitive binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that detects loss of binding of a known reference ligand to cell-bound-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|cellular MHC/competitive/fluorescence fluorescence detection assay measuring competitive binding of a cell-bound-MHC:ligand complex OBI:0001595 X-ray crystallography assay determining the 3D structure of a MHC:ligand complex A X-ray crystallography 3D molecular structure determination assay that characterizes the 3-dimensional molecular structure of a MHC:ligand complex. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 3D structure|x-ray crystallography|angstroms X-ray crystallography assay determining the 3D structure of a MHC:ligand complex OBI:0001597 cell bound MHC competitive binding assay measuring half maximal inhibitory concentration [IC50] of a MHC:ligand complex using T cell epitope recognition A cell bound MHC ligand binding half maximal inhibitory concentration (IC50) determination assay that uses a T cell epitope recognition assay to measure ligand binding. IEDB IEDB half maximal inhibitory concentration (IC50)|cellular MHC/T cell inhibition|nM cell bound MHC competitive binding assay measuring half maximal inhibitory concentration [IC50] of a MHC:ligand complex using T cell epitope recognition OBI:0001599 radioactivity detection assay measuring competitive binding of a cell-bound-MHC:ligand complex A radioactivity detection assay that detects loss of binding of a known reference ligand to cell-bound-MHC due to competition by the ligand under investigation. IEDB IEDB qualitative binding|cellular MHC/competitive/radioactivity radioactivity detection assay measuring competitive binding of a cell-bound-MHC:ligand complex OBI:0001600 assay measuring epitope specific granulocyte colony stimulating factor production by T cells A T cell epitope specific cytokine production assay that detects granulocyte colony stimulating factor production by T cells. IEDB IEDB G-CSF release|biological activity assay measuring epitope specific granulocyte colony stimulating factor production by T cells OBI:0001601 cytometric bead array assay measuring epitope specific intracellular cytokine staining (ICS) IL-21 production by T cells A cytometric bead array assay that detects interleukin-21 production by T cells. IEDB IEDB IL-21 release|cytometric bead array cytometric bead array assay measuring epitope specific intracellular cytokine staining (ICS) IL-21 production by T cells OBI:0001602 radioactivity detection assay measuring direct binding of a cell-bound-MHC:ligand complex A radioactivity detection assay that detects direct binding of a cell-bound-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|cellular MHC/direct/radioactivity radioactivity detection assay measuring direct binding of a cell-bound-MHC:ligand complex OBI:0001604 fluorescence detection assay measuring 50% dissociation of binding temperature [Tm] of a purified-MHC:ligand complex A fluorescence detection assay that measures the 50% dissociation of binding temperature of a purified-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 50% dissociation temperature|purified MHC/direct/fluorescence|°C fluorescence detection assay measuring 50% dissociation of binding temperature [Tm] of a purified-MHC:ligand complex OBI:0001606 fluorescence detection assay measuring direct binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that detects direct binding of a cell-bound-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|cellular MHC/direct/fluorescence fluorescence detection assay measuring direct binding of a cell-bound-MHC:ligand complex OBI:0001607 assay measuring epitope specific tumor necrosis factor (ligand) superfamily member 11 production by T cells An assay of epitope specific tumor necrosis factor (ligand) superfamily member 11 production by T cells that detects tumor necrosis factor production. IEDB IEDB TNFSF11/RANKL release|biological activity assay measuring epitope specific tumor necrosis factor (ligand) superfamily member 11 production by T cells OBI:0001608 radioactivity detection assay measuring direct binding of a purified-MHC:ligand complex A radioactivity detection assay that detects direct binding of a purified-MHC molecule with a ligand. IEDB IEDB qualitative binding|purified MHC/direct/radioactivity radioactivity detection assay measuring direct binding of a purified-MHC:ligand complex OBI:0001609 intracellular cytokine staining assay measuring epitope specific interleukin-8 production by T cells A flow cytometry assay that detects interleukin-8 production by T cells. IEDB IEDB IL-8 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-8 production by T cells OBI:0001610 cytometric bead array assay measuring epitope specific intracellular cytokine staining (ICS) IL-23 production by T cells A cytometric bead array assay that detects interleukin-23 production by T cells. IEDB IEDB IL-23 release|cytometric bead array cytometric bead array assay measuring epitope specific intracellular cytokine staining (ICS) IL-23 production by T cells OBI:0001613 fluorescence detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a purified-MHC:ligand complex A fluorescence detection assay that measures half maximal inhibitory concentration (IC50) to detect the loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB half maximal inhibitory concentration (IC50)|purified MHC/competitive/fluorescence|nM fluorescence detection assay measuring half maximal inhibitory concentration [IC50] to determine competitive binding of a purified-MHC:ligand complex OBI:0001620 latitude coordinate measurement datum A measurement datum that is the measure of the latitude coordinate of a site. A measurement that is the measure of the latitude coordinate of a site. Chris Stoeckert Jie Zheng Person: Chris Stoeckert, Jie Zheng latitude NIAID GSCID-BRC metadata working group Specimen Collection Location - Latitude NIAID GSCID-BRC NCIt:C68642 latitude latitude coordinate measurement datum OBI:0001621 longitude coordinate measurement datum A measurement datum that is the measure of the longitude coordinate of a site. A measurement that is the measure of the longitude coordinate of a site. Chris Stoeckert Jie Zheng Person: Chris Stoeckert, Jie Zheng longitude NIAID GSCID-BRC metadata working group Specimen Collection Location - Longitude NIAID GSCID-BRC NCIt:C68643 longitude longitude coordinate measurement datum OBI:0001624 organism species detection assay An organism detection assay that identifies the organism species in a specimen. Chris Stoeckert Jie Zheng organism identification assay NIAID GSCID-BRC metadata working group organism species detection assay OBI:0001630 analytical chromatography Detection of the presence of blood group A specific antibodies by passing a serum sample through an affinity column containing blood group A carbohydrate, and quantifying the protein content eluted from the column. An analyte assay that uses a biomaterial's preferential affinity for either the mobile phase or the stationary phase to separate it from other materials and thereby detect its presence in an input material. IEDB IEDB analytical chromatography OBI:0001631 electron microscopy imaging assay Using gold labeled antibodies to stain a mouse brain slice and use electron microscopy to generate an image that shows the location of the antibodies within the tissue structure. An imaging assay in which an electrons are used to probe the density, shape and composition of an input material which are detected in an electron microscope and utilized to produce an image of the material. IEDB IEDB electron microscopy imaging assay OBI:0001632 immuno staining assay Detection of the presence of VCAM molecules on the surface of cells in a histology slide using an enzyme-linked antibody followed by enzyme activation to release a dye. A assay detecting a molecular label assay in which the label is attached to an antibody so that substances are marked based on the antibody's binding specificity. IEDB IEDB immuno staining assay OBI:0001634 calorimetric binding assay A solution of a proteins is titrated into a solution containing a specific antibody. The heat released upon their interaction (delta H) is monitored over time where each peak represents a heat change associated with the injection of a small volume of sample into the reaction cell. As successive amounts of the ligand are titrated into the cell, the quantity of heat absorbed or released is in direct proportion to the amount of binding. As the system reaches saturation, the heat signal diminishes until only heats of dilution are observed. A binding curve is then obtained from a plot of the heats from each injection against the ratio of protein and antibody in the cell ._ A binding assay in which the heat generated or absorbed during a binding event is measured, which allows determination of binding constants, reaction stoichiometry, enthalpy and entropy. IEDB IEDB calorimetric binding assay OBI:0001635 antibody binding detection by fluorescence quenching The binding affinity of Fab 4-4-20 for the fluorescein molecule was determined using the fluorescence quenching assay, by placing the Fab and the fluorescein together in a well and measuring the fluorescence after each addition of increasing concentrations of the Fab (PMID: 8637844). A binding assay in which affinity is measured by detecting a change in fluorescence (usually quenching) that occurs upon binding of the antibody to the ligand. The fluorescent signal that is affected by binding is either from an exogenous fluorophore attached to the ligand, or is the intrisic fluorescence of aromatic (tryptophan) residues on the binding site of the antibody (no conjugated fluorophore necessary) or, less commonly, on the ligand binding region (epitope). IEDB IEDB antibody binding detection by fluorescence quenching OBI:0001638 antigen inhibition assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex approximated by IC50 A B cell epitope equilibrium dissociation constant (KD) assay that provides IC50 values determined under assay conditions where the IC50 approximates a KD value using a B cell epitope antigen inhibition of binding assay. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|inhibition by antigen (~ IC50)|nM antigen inhibition assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex approximated by IC50 OBI:0001639 assay measuring epitope specific Ig-mediated histamine release A B cell epitope specific activation of additional immune response assay that detects histamine release in vitro. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB histamine release|biological activity assay measuring epitope specific Ig-mediated histamine release OBI:0001640 assay measuring epitope specific immunoglobulin-mediated antigen activation A B cell epitope dependent biological activity determination assay that detects antigen activation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB antigen activation|biological activity assay measuring epitope specific immunoglobulin-mediated antigen activation OBI:0001641 assay measuring epitope specific complement-dependent cytotoxicity A B cell epitope specific activation of additional immune response assay that detects complement-dependent cytotoxicity in vitro . PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB complement-dependent cytotoxicity|biological activity assay measuring epitope specific complement-dependent cytotoxicity OBI:0001642 assay measuring epitope specific antibody-dependent cellular cytotoxicity A B cell epitope specific activation of additional immune response assay that detects antibody-dependent cellular cytotoxicity in vitro. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB antibody-dependent cellular cytotoxicity|biological activity assay measuring epitope specific antibody-dependent cellular cytotoxicity OBI:0001643 assay measuring epitope specific immunoglobulin-mediated neutralization A B cell epitope dependent biological activity determination assay that detects neutralization of the antigen. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB neutralization |biological activity assay measuring epitope specific immunoglobulin-mediated neutralization OBI:0001644 assay measuring epitope specific opsonization A B cell epitope specific activation of additional immune response assay that detects opsonization in vitro . PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB opsonization|biological activity assay measuring epitope specific opsonization OBI:0001645 calorimetry assay measuring binding of a B cell epitope:antibody complex A calorimetric binding assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|calorimetry calorimetry assay measuring binding of a B cell epitope:antibody complex OBI:0001646 electron microscopy assay determining the 3D structure of a B cell epitope:antibody complex An electron-microscopy 3D molecular structure determination assay that characterizes the 3-dimensional molecular structrue of a B cell epitope:antibody complex PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 3D structure|electron microscopy electron microscopy assay determining the 3D structure of a B cell epitope:antibody complex OBI:0001647 NMR assay determining the 3D structure of a B cell epitope:antibody complex A nuclear magnetic resonance 3D molecular structure determination assay that characterizes the 3-dimensional structure of a B cell epitope:antibody complex. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 3D structure|nuclear magnetic resonance (NMR) NMR assay determining the 3D structure of a B cell epitope:antibody complex OBI:0001648 cross blocking assay measuring binding of a B cell epitope:antibody complex A cross-blocking assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|cross blocking cross blocking assay measuring binding of a B cell epitope:antibody complex OBI:0001649 RIA measuring binding of a B cell epitope:antibody complex A radio immuno assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|radio immuno assay (RIA) RIA measuring binding of a B cell epitope:antibody complex OBI:0001650 immunoblot assay measuring binding of a B cell epitope:antibody complex An immunoblot assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|western blot immunoblot assay measuring binding of a B cell epitope:antibody complex OBI:0001651 plasmon resonance assay measuring binding of a B cell epitope:antibody complex A surface plasmon resonance binding assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|surface plasmon resonance (SPR) plasmon resonance assay measuring binding of a B cell epitope:antibody complex OBI:0001652 immuno staining assay measuring binding of a B cell epitope:antibody complex An immuno staining assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|immuno staining immuno staining assay measuring binding of a B cell epitope:antibody complex OBI:0001653 immunoprecipitation assay measuring binding of a B cell epitope:antibody complex An immunoprecipitation assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|immunoprecipitation immunoprecipitation assay measuring binding of a B cell epitope:antibody complex OBI:0001654 mass spectrometry assay measuring binding of a B cell epitope:antibody complex A mass spectrometry assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|mass spectrometry mass spectrometry assay measuring binding of a B cell epitope:antibody complex OBI:0001655 phage display assay measuring binding of a B cell epitope:antibody complex A phage display binding assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|phage display phage display assay measuring binding of a B cell epitope:antibody complex OBI:0001656 electron microscopy assay measuring binding of a B cell epitope:antibody complex An electron microscopy imaging assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|electron microscopy electron microscopy assay measuring binding of a B cell epitope:antibody complex OBI:0001657 ELISA measuring binding of a B cell epitope:antibody complex An enzyme-linked immunosorbent assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|ELISA ELISA measuring binding of a B cell epitope:antibody complex OBI:0001658 ELISPOT assay measuring binding of a B cell epitope:antibody complex An enzyme-linked immunospot assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|ELISPOT ELISPOT assay measuring binding of a B cell epitope:antibody complex OBI:0001659 flow cytometry assay measuring binding of a B cell epitope:antibody complex A flow cytometry assay that detects the binding of an antigen with an antibody. IEDB IEDB qualitative binding|flow cytometry flow cytometry assay measuring binding of a B cell epitope:antibody complex OBI:0001660 intracellular material detection assay measuring epitope specific granzyme A release by T cells A flow cytometry assay that detects epitope specific granzyme A release by T cells. IEDB IEDB granzyme A release|intracellular staining intracellular material detection assay measuring epitope specific granzyme A release by T cells OBI:0001661 chromatography assay measuring binding of a B cell epitope:antibody complex An analytical chromatography assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|chromatography chromatography assay measuring binding of a B cell epitope:antibody complex OBI:0001662 NMR assay measuring binding of a B cell epitope:antibody complex A B cell epitope qualitative binding to antibody assay that uses a nuclear magnetic resonance assay. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|nuclear magnetic resonance (NMR) NMR assay measuring binding of a B cell epitope:antibody complex OBI:0001663 ELISA measuring epitope specific granulysin release by T cells An enzyme-linked immunosorbent assay that detects epitope specific granulysin release by T cells. IEDB IEDB granulysin release|ELISA ELISA measuring epitope specific granulysin release by T cells OBI:0001664 intracellular material detection assay measuring epitope specific granulysin release by T cells A flow cytometry assay that detects epitope specific granulysin release by T cells. IEDB IEDB granulysin release|intracellular staining intracellular material detection assay measuring epitope specific granulysin release by T cells OBI:0001665 fluorescence detection assay measuring binding off rate [koff] to determine direct binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that measures binding off rate [koff] to detect direct binding of a cell-bound-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB off rate|cellular MHC/direct/fluorescence|1/s fluorescence detection assay measuring binding off rate [koff] to determine direct binding of a cell-bound-MHC:ligand complex OBI:0001666 fluorescence detection assay measuring binding on rate [kon] to determine direct binding of a cell-bound-MHC:ligand complex A fluorescence detection assay that measures binding on rate (kon) to detect direct binding of a cell-bound-MHC molecule with a ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB on rate|cellular MHC/direct/fluorescence|nM^-1s^-1 fluorescence detection assay measuring binding on rate [kon] to determine direct binding of a cell-bound-MHC:ligand complex OBI:0001667 fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex approximated by IC50 A fluorescence detection assay that measures equilibrium dissociation constant (KD) to detect the loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation and provides IC50 values determined under assay conditions where the IC50 approximates a KD value. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD (~IC50)|purified MHC/competitive/fluorescence|nM fluorescence detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex approximated by IC50 OBI:0001668 split-ubiquitin assay Split-ubiquitin two-hybrid assay to analyze protein-protein interactions at the endosome: application to Saccharomyces cerevisiae Bro1 interacting with ESCRT complexes, the Doa4 ubiquitin hydrolase, and the Rsp5 ubiquitin ligase. PMID:17513562 A binding assay that screens membrane soluble proteins by fusion of two integral membrane proteins (bait and prey) to two different ubiquitin moieties. One moiety is also fused to a transcription factor (TF) that can be cleaved off by ubiquitin specific proteases. Upon bait and prey interaction, Nub and Cub-moieties assemble, reconstituting the split-ubiquitin. The reconstituted split-ubiquitin molecule is recognized by ubiquitin specific proteases, which cleave off the reporter protein, allowing it to induce the transcription of reporter genes. Marcus Chibucos Philippe Rocca-Serra url:https://en.wikipedia.org/wiki/Two-hybrid_screening split-ubiquitin assay OBI:0001669 far-western blot assay Studying protein-protein interactions via blot overlay or Far Western blot. PMID:15064457 An assay that measures protein-protein interactions by separating target proteins on an SDS-PAGE gel, transfering them to a solid substrate, hybridizing with a protein probe and visualizing bound proteins using a probe-directed antibody. This is a adaptation on the western blot assay. Marcus Chibucos Philippe Rocca-Serra PMID:18079728 far-western blot assay OBI:0001670 RNA protection assay Absolute concentrations of mRNA for type I and type VI collagen in the canine meniscus in normal and ACL-deficient knee joints obtained by RNase protection assay. PMID:11518275 An assay that determines the presence and estimates abundance of transcript species by first creating an homo or heteroduplex by adding a specific, complementary sequence to the sequence of interest and then exposing the mixture of ribonuclease, which will degrade only single stranded molecules. A detection step will reveal if the sample contained a sequence of interest. Marcus Chibucos Philippe Rocca-Serra RNAse protection assay RPA PMID:16491611 RNA protection assay OBI:0001671 electrophoretic mobility shift assay Electrophoretic mobility shift assay reveals a novel recognition sequence for Setaria italica NAC protein. PMID:21918373 An assay that measures information about Protein-DNA or Protein-RNA interactions using gel electrophoresis and relying on the fact the molecular interactions will cause the heterodimer to be retarded on the gel when compared to controls corresponding to protein extract alone and protein extract + neutral nucleic acid. Marcus Chibucos Philippe Rocca-Serra EMSA band shift assay gel mobility shift assay gel retardation assay gel shift assay PMID:6269071 electrophoretic mobility shift assay OBI:0001672 gene knock-down assay An assay which transiently disrupts gene transcripts by expressing antisense RNA constructs or delivering RNA interfering molecules in cells. Marcus Chibucos Philippe Rocca-Serra PMID:17430206 gene knock-down assay OBI:0001673 nano-cap analysis of gene expression assay Linking promoters to functional transcripts in small samples with nanoCAGE and CAGEscan._PMID:20543846 A transcription profiling assay that is performed using a very low amount (nanogram scale) of mRNA samples using Cap analysis gene expression (CAGE). Marcus Chibucos Philippe Rocca-Serra nano-CAGE PMID:20543846 nano-cap analysis of gene expression assay OBI:0001674 cap analysis of gene expression assay 5' end-centered expression profiling using cap-analysis gene expression and next-generation sequencing. PMID:22362160 A transcription profiling assay which measures RNA transcript abundances in biological samples by extracting 5' ends of capped transcripts, RTPCR and sequence those. Copy numbers of CAGE tags provide a way of quantification and provide a measure of expression of the transcriptome Marcus Chibucos Philippe Rocca-Serra CAGE PMID:14663149 cap analysis of gene expression assay OBI:0001675 ELISA measuring epitope specific interleukin-17A production by T cells An enzyme-linked immunosorbent assay that detects interleukin-17A production by T cells. IEDB IEDB IL-17A release|ELISA ELISA measuring epitope specific interleukin-17A production by T cells OBI:0001676 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-7 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-7 production by T cells. IEDB IEDB IL-7 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-7 production by T cells OBI:0001679 yeast 2-hybrid assay Strong FANCA/FANCG but weak FANCA/FANCC interaction in the yeast 2-hybrid system. PMID:10627486 An assay that detects protein protein interactions and protein DNA interactions by testing for physical interactions (such as binding) between two proteins or a single protein and a DNA molecule, respectively. The premise behind the test is the activation of downstream reporter gene(s) by the binding of a transcription factor onto an upstream activating sequence (UAS). For two-hybrid screening, the transcription factor is split into two separate fragments, called the binding domain (BD) and activating domain (AD). The BD is the domain responsible for binding to the UAS and the AD is the domain responsible for the activation of transcription. The Y2H is thus a protein-fragment complementation assay. Marcus Chibucos Philippe Rocca-Serra Y2H url:https://en.wikipedia.org/wiki/Two-hybrid_screening yeast 2-hybrid assay OBI:0001680 Sos-recruitment assay The Sos-recruitment system as a tool to analyze cellular localization of plant proteins: membrane localization of Arabidopsis thaliana PEPINO/PASTICCINO2. PMID:20300944 A binding assay that detects interacting proteins for a targeted domain where mammalian guanyl nucleotide exchange factor (GEF) Sos is recruited to the Saccharomyces cerevisiae plasma membrane harboring a temperature-sensitive Ras GEF, Cdc25-2, allowing growth at the nonpermissive temperature using the Sos recruitment system, a kind of yeast 2 hybrid system. Marcus Chibucos Philippe Rocca-Serra SRS PMID:9154808 Sos-recruitment assay OBI:0001681 yeast one-hybrid assay Yeast one-hybrid assays for gene-centered human gene regulatory network mapping. PMID:22037702 An assay that determines protein DNA interactions using a single fusion protein in which the activating domain is linked directly to the binding domain. Marcus Chibucos Philippe Rocca-Serra Y1H PMID:22218861 yeast one-hybrid assay OBI:0001682 bacterial one-hybrid assay A systematic characterization of factors that regulate Drosophila segmentation via a bacterial one-hybrid system. PMID:18332042 An assay that identifies the sequence-specific target site of a DNA-binding domain. In this system, a given transcription factor (TF) is expressed as a fusion to a subunit of RNA polymerase. In parallel, a library of randomized oligonucleotides representing potential TF target sequences, is cloned into a separate vector containing the selectable genes HIS3 and URA3. If the DNA-binding domain (bait) binds a potential DNA target site (prey) in vivo, it will recruit RNA polymerase to the promoter and activate transcription of the reporter genes in that clone. The two reporter genes, HIS3 and URA3, allow for positive and negative selections, respectively. At the end of the process, positive clones are sequenced and examined with motif-finding tools in order to resolve the favoured DNA target sequence Marcus Chibucos Philippe Rocca-Serra B1H url:http://en.wikipedia.org/wiki/Bacterial_one-hybrid_system bacterial one-hybrid assay OBI:0001683 chromosome organization assay by fluorescence in-situ hybridization Duplication of intrachromosomal insertion segments 4q32__�q35 confirmed by comparative genomic hybridization and fluorescent in situ hybridization. PMID:22384449 An in-situ hybridization assay that uses fluorescence to detect chromosomal integrity Marcus Chibucos Philippe Rocca-Serra https://github.com/obi-ontology/obi/issues/788| chromosome organization assay by fluorescence in-situ hybridization OBI:0001684 methylation-specific polymerase chain reaction assay Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. PMID:18219662 An assay that uses initial modification of DNA by sodium bisulfite, converting all unmethylated, but not methylated, cytosines to uracil, and subsequent amplification with primers specific for methylated versus unmethylated DNA. Marcus Chibucos Philippe Rocca-Serra MSP PMID:8790415 methylation-specific polymerase chain reaction assay OBI:0001685 amplification of intermethylated sites assay Analysis of DNA methylation by amplification of intermethylated sites (AIMS). PMID:18987810 An assay that estimates genome-wide DNA methylation and measures methylation of DNA sequences. AIMS is based on the differential enzymatic digestion of genomic DNA with methylation-sensitive and methylation-insensitive isoschizomers followed by restrained PCR amplification of methylated sequences. Marcus Chibucos Philippe Rocca-Serra AIMS assay intermethylated site amplification PMID:18987810 amplification of intermethylated sites assay OBI:0001686 in-situ hybridization assay Use of in situ hybridization to examine gene expression in the embryonic, neonatal, and adult urogenital system. PMID:22639265 An assay that localizes a specific DNA or RNA sequence within a portion or section of tissue using artificially induced nucleic hybridization. Marcus Chibucos Philippe Rocca-Serra ISH in situ hybridization PMID:9021518 in-situ hybridization assay OBI:0001689 cytochalasin-induced inhibition of actin polymerization assay An assay which uses compound cytochalasin (CHEBI: 23528) to block actin polymerization-dependent cell motility (GO:0070358) and actin filament polymerization (GO:0030041). Marcus Chibucos Philippe Rocca-Serra cytochalasin-induced inhibition of actin polymerization assay OBI:0001692 in vivo assay measuring B cell epitope specific protection from fertility An efficacy of B cell epitope intervention experiment that uses a epitope protection experiment based on reduction of fertility. PERSON:Randi Vita, James Overton, Bjoern Peters IEDB protection from fertility|in vivo assay in vivo assay measuring B cell epitope specific protection from fertility OBI:0001693 in vivo assay measuring B cell epitope specific tolerance induction An efficacy of B cell epitope intervention experiment that uses a tolerance induction intervention experiment. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB tolerance|in vivo assay in vivo assay measuring B cell epitope specific tolerance induction OBI:0001694 in vivo assay measuring B cell epitope specific induction of hypersensitivity An efficacy of B cell epitope intervention experiment that detects a hypersensitivity response by monitoring skin reactions. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB hypersensitivity|in vivo assay in vivo assay measuring B cell epitope specific induction of hypersensitivity OBI:0001695 assay measuring epitope specific immune complex formation A B cell epitope specific activation of additional immune response assay that detects agglutination in vitro. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB agglutination|biological activity assay measuring epitope specific immune complex formation OBI:0001696 in vivo assay measuring B cell epitope specific protection based on survival An in vivo assay measuring B cell epitope specific protection from other challenge using survival. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB survival from challenge|in vivo assay in vivo assay measuring B cell epitope specific protection based on survival OBI:0001697 in vivo assay measuring B cell epitope specific treatment of disease An efficacy of B cell epitope intervention experiment that detects a decrease in disease. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB decreased disease|in vivo assay in vivo assay measuring B cell epitope specific treatment of disease OBI:0001698 assay measuring B cell epitope specific in vivo activity A B cell epitope dependent biological activity determination assay that uses an in vivo intervention experiment. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB in vivo activity|biological activity assay measuring B cell epitope specific in vivo activity OBI:0001699 antibody cross-blocking assay Testing two antibodies that bind the HBV core protein for the ability of one antibody pre-incubated with the protein in solution to inhibit binding to the other antibody which is plate-bound in an ELISA format. A competitive inhibition of binding assay in which two antibodies that are known to bind the same antigen are tested for the ability of one antibody to inhibit binding of the other antibody to the antigen, thereby determining if they have overlapping binding sites. IEDB antibody inhibition of antibody binding IEDB antibody cross-blocking assay OBI:0001700 immunoprecipitation assay Determining if a cell is producing a protein using a protein specific antibody to immunoprecipitate the cell lysate. Determining if the serum of a patient contains antibodies against HBV core protein by immunoprecipitating purified HBV core protein with the patients serum. An analyte assay in which an input material is mixed with antibodies and bound antigen:antibody complexes are separated out using immunoprecipitation. Either the antibody has known specificy, and the antigen mixture is tested for the presence of a specific antigen, or the antigen solution is well defined and the antibody solution is tested for the presence of antigen specific antibodies. IEDB IEDB immunoprecipitation assay OBI:0001701 antigen inhibition assay measuring binding of a B cell epitope:antibody complex A B cell epitope qualitative binding to antibody assay that measures the ability of an antigen to inhibit antibody binding to a known ligand. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|inhibition by antigen antigen inhibition assay measuring binding of a B cell epitope:antibody complex OBI:0001703 assay measuring qualitative binding of a B cell epitope:antibody complex An assay that detects the binding of an antigen with an antibody, and produces a qualitative measurement of the binding as an output. IEDB IEDB qualitative binding|binding assay assay measuring qualitative binding of a B cell epitope:antibody complex OBI:0001704 assay measuring epitope specific activation of additional immune response in vitro A B cell epitope dependent biological activity determination assay that detects secondary in vitro activity. IEDB IEDB secondary in vitro activity|biological activity assay measuring epitope specific activation of additional immune response in vitro OBI:0001705 assay measuring epitope specific antigen inhibition of antibody activity A B cell epitope dependent biological activity determination assay that detects inhibition of the antibody's activity by the antigen. IEDB IEDB antibody activity inhibition|biological activity assay measuring epitope specific antigen inhibition of antibody activity OBI:0001706 assay measuring biological activity resulting from B cell epitope:antibody binding A B cell epitope assay that measures the immune response process resulting from the binding of an antibody receptor to epitope or recognition of the epitope. IEDB IEDB biological activity|any method assay measuring biological activity resulting from B cell epitope:antibody binding OBI:0001708 assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex A B cell epitope binding constant determination assay that measures the dissociation constant KD. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|binding assay|nM assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0001709 assay measuring a binding constant of a B cell epitope:antibody complex A B cell epitope recognition assay that quantitavely characterizes the binding of an antibody / BCR with a ligand by determining a binding constant. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB binding constant|binding assay assay measuring a binding constant of a B cell epitope:antibody complex OBI:0001710 in vivo assay measuring B cell epitope specific protection from challenge An efficacy of B cell epitope intervention experiment that uses a epitope protection experiment. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB protection from challenge|in vivo assay in vivo assay measuring B cell epitope specific protection from challenge OBI:0001711 in vivo assay measuring B cell epitope specific disease exacerbation An efficacy of B cell epitope intervention experiment that uses a disease exacerbation in vivo intervention experiment. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB disease exacerbation|in vivo assay in vivo assay measuring B cell epitope specific disease exacerbation OBI:0001718 assay measuring the on rate [kon] of a B cell epitope:antibody complex A B cell epitope binding constant determination assay that measures the on rate. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB on rate|binding assay|M^-1s^-1 assay measuring the on rate [kon] of a B cell epitope:antibody complex OBI:0001719 assay measuring the association constant [KA] of a B cell epitope:antibody complex A B cell epitope binding constant determination assay that measures the association constant KA. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|binding assay|1/nM assay measuring the association constant [KA] of a B cell epitope:antibody complex OBI:0001721 3D molecular structure determination assay of an antigen:antibody complex A 3D structure determination of bound molecular complex assay that characterizes the 3-dimensional structure of an antigen:antobody complex. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 3D structure|any method 3D molecular structure determination assay of an antigen:antibody complex OBI:0001723 assay measuring the off rate [koff] of a B cell epitope:antibody complex A B cell epitope binding constant determination assay that measures the off rate. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB off rate|binding assay|1/s assay measuring the off rate [koff] of a B cell epitope:antibody complex OBI:0001724 viral hemagglutination inhibition assay measuring binding of a B cell epitope:antibody complex A viral hemagglutination inhibition assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding| hemagglutination inhibition viral hemagglutination inhibition assay measuring binding of a B cell epitope:antibody complex OBI:0001726 quenching assay measuring binding of a B cell epitope:antibody complex A fluorescence quenching assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|quenching quenching assay measuring binding of a B cell epitope:antibody complex OBI:0001727 RIA measuring the dissociation constant [KD] of a B cell epitope:antibody complex A radio immuno assay that measures the dissociation constant [KD] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|radio immuno assay (RIA)|nM RIA measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0001728 ELISA measuring the dissociation constant [KD] of a B cell epitope:antibody complex An enzyme-linked immunosorbent assay that measures the dissociation constant [KD] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|ELISA|nM ELISA measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0001729 quenching assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex A fluorescence quenching assay that measures the dissociation constant [KD] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|quenching|nM quenching assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0001730 surface plasmon resonance assay measuring the association constant [KA] of a B cell epitope:antibody complex A surface plasmon resonance binding assay that measures the association constant [KA] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|surface plasmon resonance (SPR)|1/nM surface plasmon resonance assay measuring the association constant [KA] of a B cell epitope:antibody complex OBI:0001731 surface plasmon resonance assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex A surface plasmon resonance binding assay that measures the dissociation constant [KD] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|surface plasmon resonance (SPR)|nM surface plasmon resonance assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0001732 quenching assay measuring the association constant [KA] of a B cell epitope:antibody complex A fluorescence quenching assay that measures the association constant [KA] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|quenching|1/nM quenching assay measuring the association constant [KA] of a B cell epitope:antibody complex OBI:0001733 calorimetry assay measuring the association constant [KA] of a B cell epitope:antibody complex A calorimetric binding assay that measures the association constant [KA] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|calorimetry|1/nM calorimetry assay measuring the association constant [KA] of a B cell epitope:antibody complex OBI:0001734 calorimetry assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex A calorimetric binding assay that measures the dissociation constant [KD] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|calorimetry|nM calorimetry assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0001735 ELISA measuring the association constant [KA] of a B cell epitope:antibody complex An enzyme-linked immunosorbent assay that measures the association constant [KA] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|ELISA|1/nM ELISA measuring the association constant [KA] of a B cell epitope:antibody complex OBI:0001736 RIA measuring the association constant [KA] of a B cell epitope:antibody complex A radio immuno assay that measures the association constant [KA] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|radio immuno assay (RIA)|1/nM RIA measuring the association constant [KA] of a B cell epitope:antibody complex OBI:0001738 X-ray crystallography assay determining the 3D structure of a B cell epitope:antibody complex A X-ray crystallography 3D molecular structure determination assay that characterizes the 3-dimensional molecular structrue of a B cell epitope:antibody complex. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 3D structure|x-ray crystallography|angstroms X-ray crystallography assay determining the 3D structure of a B cell epitope:antibody complex OBI:0001739 surface plasmon resonance assay measuring the off rate [koff] of a B cell epitope:antibody complex A surface plasmon resonance binding assay that measures the off rate [koff] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB off rate|surface plasmon resonance (SPR)|1/s surface plasmon resonance assay measuring the off rate [koff] of a B cell epitope:antibody complex OBI:0001740 quenching assay measuring the off rate [koff] of a B cell epitope:antibody complex A fluorescence quenching assay that measures the off rate [koff] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB off rate|quenching|1/s quenching assay measuring the off rate [koff] of a B cell epitope:antibody complex OBI:0001741 surface plasmon resonance assay measuring the on rate [kon] of a B cell epitope:antibody complex A surface plasmon resonance binding assay that measures the on rate [kon] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB on rate|surface plasmon resonance (SPR)|M^-1s^-1 surface plasmon resonance assay measuring the on rate [kon] of a B cell epitope:antibody complex OBI:0001742 quenching assay measuring the on rate [kon] of a B cell epitope:antibody complex A fluorescence quenching assay that measures the on rate [kon] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB on rate|quenching|M^-1s^-1 quenching assay measuring the on rate [kon] of a B cell epitope:antibody complex OBI:0001743 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-1 beta production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-1 beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1b release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-1 beta production by T cells OBI:0001744 intracellular cytokine staining assay measuring epitope specific interleukin-1 alpha production by T cells A flow cytometry assay that detects interleukin-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1a release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-1 alpha production by T cells OBI:0001745 ELISPOT assay measuring epitope specific interleukin-1 alpha production by T cells An enzyme-linked immunospot assay that detects interleukin-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1a release|ELISPOT ELISPOT assay measuring epitope specific interleukin-1 alpha production by T cells OBI:0001746 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-1 alpha production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1a release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-1 alpha production by T cells OBI:0001747 cytometric bead array assay measuring epitope specific interleukin-1 alpha production by T cells A cytometric bead array assay that detects interleukin-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1a release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-1 alpha production by T cells OBI:0001748 ELISPOT assay measuring epitope specific interferon-beta production by T cells An enzyme-linked immunospot assay that detects interferon-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNb release|ELISPOT ELISPOT assay measuring epitope specific interferon-beta production by T cells OBI:0001749 intracellular cytokine staining assay measuring epitope specific interferon-beta production by T cells A flow cytometry assay that detects interferon-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNb release|ICS intracellular cytokine staining assay measuring epitope specific interferon-beta production by T cells OBI:0001750 intracellular cytokine staining assay measuring epitope specific granulocyte colony stimulating factor production by T cells A flow cytometry assay that detects granulocyte colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB G-CSF release|ICS intracellular cytokine staining assay measuring epitope specific granulocyte colony stimulating factor production by T cells OBI:0001751 ELISA measuring epitope specific interferon-beta production by T cells An enzyme-linked immunosorbent assay that detects interferon-beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNb release|ELISA ELISA measuring epitope specific interferon-beta production by T cells OBI:0001752 detection of specific nucleic acids with complementary probes assay measuring epitope specific granulocyte colony stimulating factor production by T cells A detection of specific nucleic acid polymers with complementary probes that detects granulocyte colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB G-CSF release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific granulocyte colony stimulating factor production by T cells OBI:0001753 ELISPOT assay measuring epitope specific granulocyte colony stimulating factor production by T cells An enzyme-linked immunospot assay that detects granulocyte colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB G-CSF release|ELISPOT ELISPOT assay measuring epitope specific granulocyte colony stimulating factor production by T cells OBI:0001754 cytometric bead array assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells A cytometric bead array assay that detects chemokine (C-X-C motif) ligand 9 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL9/MIG release|cytometric bead array cytometric bead array assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells OBI:0001756 ELISPOT assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells An enzyme-linked immunospot assay that detects chemokine (C-X-C motif) ligand 9 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL9/MIG release|ELISPOT ELISPOT assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells OBI:0001757 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-X-C motif) ligand 9 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL9/MIG release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 9 production by T cells OBI:0001758 ELISPOT assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells An enzyme-linked immunospot assay that detects chemokine (C-C motif) ligand 4 production by T cells. IEDB IEDB CCL4/MIP-1b release|ELISPOT ELISPOT assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells OBI:0001759 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 12 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-X-C motif) ligand 12 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL12/SDF-1 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 12 production by T cells OBI:0001760 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 13 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-X-C motif) ligand 13 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL13/BLC release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 13 production by T cells OBI:0001761 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 16 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-X-C motif) ligand 16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL16 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-X-C motif) ligand 16 production by T cells OBI:0001762 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 21 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-C motif) ligand 21 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL21/SLC release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 21 production by T cells OBI:0001763 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 22 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-C motif) ligand 22 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL22/MDC release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 22 production by T cells OBI:0001764 cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells A cytometric bead array assay that detects chemokine (C-C motif) ligand 4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL4/MIP-1b release|cytometric bead array cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells OBI:0001765 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-C motif) ligand 4 production by T cells. IEDB IEDB CCL4/MIP-1b release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 4 production by T cells OBI:0001766 detection of specific nucleic acids with complementary probes assay measuring epitope specific vascular endothelial growth factor production by T cells A detection of specific nucleic acid polymers with complementary probes that detects vascular endothelial growth factor production by T cells. IEDB IEDB VEGF release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific vascular endothelial growth factor production by T cells OBI:0001767 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 19 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-C motif) ligand 19 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL19/MIP-3b release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 19 production by T cells OBI:0001768 intracellular cytokine staining assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells A flow cytometry assay that detects chemokine (C-C motif) ligand 1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL1/TCA-3 release|ICS intracellular cytokine staining assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells OBI:0001770 intracellular cytokine staining assay measuring epitope specific vascular endothelial growth factor production by T cells A flow cytometry assay that detects vascular endothelial growth factor production by T cells. IEDB IEDB VEGF release|ICS intracellular cytokine staining assay measuring epitope specific vascular endothelial growth factor production by T cells OBI:0001771 ELISPOT assay measuring epitope specific vascular endothelial growth factor production by T cells An enzyme-linked immunospot assay that detects vascular endothelial growth factor production by T cells. IEDB IEDB VEGF release|ELISPOT ELISPOT assay measuring epitope specific vascular endothelial growth factor production by T cells OBI:0001772 assay measuring epitope specific interleukin-17F production by T cells An assay of epitope specific interleukin-17 production by T cells that detects interleukin-17F production. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17F release|biological activity assay measuring epitope specific interleukin-17F production by T cells OBI:0001773 assay measuring epitope specific interleukin-17A production by T cells An assay of epitope specific interleukin-17 production by T cells that detects interleukin-17A production. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17A release|biological activity assay measuring epitope specific interleukin-17A production by T cells OBI:0001774 assay measuring epitope specific chemokine (C-C motif) ligand 21 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-C motif) ligand 21 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL21/SLC release|biological activity assay measuring epitope specific chemokine (C-C motif) ligand 21 production by T cells OBI:0001775 assay measuring epitope specific chemokine (C-C motif) ligand 19 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-C motif) ligand 19 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL19/MIP-3b release|biological activity assay measuring epitope specific chemokine (C-C motif) ligand 19 production by T cells OBI:0001776 assay measuring epitope specific chemokine (C-X-C motif) ligand 12 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-X-C motif) ligand 12 production by T cells. IEDB IEDB CXCL12/SDF-1 release|biological activity assay measuring epitope specific chemokine (C-X-C motif) ligand 12 production by T cells OBI:0001777 assay measuring epitope specific chemokine (C-C motif) ligand 22 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-C motif) ligand 22 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL22/MDC release|biological activity assay measuring epitope specific chemokine (C-C motif) ligand 22 production by T cells OBI:0001778 assay measuring epitope specific chemokine (C-X-C motif) ligand 16 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-X-C motif) ligand 16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL16 release|biological activity assay measuring epitope specific chemokine (C-X-C motif) ligand 16 production by T cells OBI:0001779 assay measuring epitope specific chemokine (C-X-C motif) ligand 13 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-X-C motif) ligand 13 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL13/BLC release|biological activity assay measuring epitope specific chemokine (C-X-C motif) ligand 13 production by T cells OBI:0001780 ELISPOT assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells An enzyme-linked immunospot assay that detects macrophage inflammatory protein-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL3/MIP-1a release|ELISPOT ELISPOT assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells OBI:0001781 cytometric bead array assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells A cytometric bead array assay that detects macrophage inflammatory protein-1 gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL9/MIP-1g release|cytometric bead array cytometric bead array assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells OBI:0001782 detection of specific nucleic acids with complementary probes assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells A detection of specific nucleic acid polymers with complementary probes that detects macrophage inflammatory protein-1 gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL9/MIP-1g release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells OBI:0001783 intracellular cytokine staining assay measuring epitope specific monocyte chemotactic protein-1 production by T cells A flow cytometry assay that detects monocyte chemotactic protein-1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL2/MCP-1 release|ICS intracellular cytokine staining assay measuring epitope specific monocyte chemotactic protein-1 production by T cells OBI:0001784 ELISPOT assay measuring epitope specific monocyte chemotactic protein-1 production by T cells An enzyme-linked immunospot assay that detects monocyte chemotactic protein-1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL2/MCP-1 release|ELISPOT ELISPOT assay measuring epitope specific monocyte chemotactic protein-1 production by T cells OBI:0001785 intracellular cytokine staining assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells A flow cytometry assay that detects macrophage inflammatory protein-1 gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL9/MIP-1g release|ICS intracellular cytokine staining assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells OBI:0001786 ELISPOT assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells An enzyme-linked immunospot assay that detects inflammatory protein-1 gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL9/MIP-1g release|ELISPOT ELISPOT assay measuring epitope specific macrophage inflammatory protein-1 gamma production by T cells OBI:0001787 cytometric bead array assay measuring epitope specific vascular endothelial growth factor production by T cells A cytometric bead array assay that detects vascular endothelial growth factor production by T cells. IEDB IEDB VEGF release|cytometric bead array cytometric bead array assay measuring epitope specific vascular endothelial growth factor production by T cells OBI:0001788 detection of specific nucleic acids with complementary probes assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells A detection of specific nucleic acid polymers with complementary probes that detects tumor necrosis factor superfamily cytokine production by T cells. IEDB IEDB TNF release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells OBI:0001789 intracellular cytokine staining assay measuring epitope specific RANTES production by T cells A flow cytometry assay that detects RANTES production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL5/RANTES release|ICS intracellular cytokine staining assay measuring epitope specific RANTES production by T cells OBI:0001790 ELISPOT assay measuring epitope specific RANTES production by T cells An enzyme-linked immunospot assay that detects RANTES production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL5/RANTES release|ELISPOT ELISPOT assay measuring epitope specific RANTES production by T cells OBI:0001791 ELISPOT assay measuring epitope specific lymphotoxin A production by T cells An enzyme-linked immunospot assay that detects lymphotoxin A production by T cells. IEDB IEDB lymphotoxin A/TNFb release|ELISPOT ELISPOT assay measuring epitope specific lymphotoxin A production by T cells OBI:0001792 detection of specific nucleic acids with complementary probes assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells A detection of specific nucleic acid polymers with complementary probes that detects macrophage inflammatory protein-1 alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL3/MIP-1a release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific macrophage inflammatory protein-1 alpha production by T cells OBI:0001793 cytometric bead array assay measuring epitope specific lymphotoxin A production by T cells A cytometric bead array assay that detects lymphotoxin A production by T cells. IEDB IEDB lymphotoxin A/TNFb release|cytometric bead array cytometric bead array assay measuring epitope specific lymphotoxin A production by T cells OBI:0001794 detection of specific nucleic acids with complementary probes assay measuring epitope specific lymphotoxin A production by T cells A detection of specific nucleic acid polymers with complementary probes that detects lymphotoxin A production by T cells. IEDB IEDB lymphotoxin A/TNFb release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific lymphotoxin A production by T cells OBI:0001795 ELISPOT assay measuring epitope specific IP-10 production by T cells An enzyme-linked immunospot assay that detects IP-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL10/IP-10 release|ELISPOT ELISPOT assay measuring epitope specific IP-10 production by T cells OBI:0001796 intracellular cytokine staining assay measuring epitope specific IP-10 production by T cells A flow cytometry assay that detects IP-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CXCL10/IP-10 release|ICS intracellular cytokine staining assay measuring epitope specific IP-10 production by T cells OBI:0001797 ELISPOT assay measuring epitope specific interleukin-9 production by T cells An enzyme-linked immunospot assay that detects interleukin-9 production by T cells. IEDB IEDB IL-9 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-9 production by T cells OBI:0001798 intracellular cytokine staining assay measuring epitope specific interleukin-9 production by T cells A flow cytometry assay that detects interleukin-9 production by T cells. IEDB IEDB IL-9 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-9 production by T cells OBI:0001799 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-9 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-9 production by T cells. IEDB IEDB IL-9 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-9 production by T cells OBI:0001800 ELISPOT assay measuring epitope specific interleukin-8 production by T cells An enzyme-linked immunospot assay that detects interleukin-8 production by T cells. IEDB IEDB IL-8 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-8 production by T cells OBI:0001801 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-8 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-8 production by T cells. IEDB IEDB IL-8 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-8 production by T cells OBI:0001802 ELISPOT assay measuring epitope specific interleukin-3 production by T cells An enzyme-linked immunospot assay that detects interleukin-3 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-3 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-3 production by T cells OBI:0001803 ELISA measuring epitope specific interleukin-7 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-7 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-7 release|ELISA ELISA measuring epitope specific interleukin-7 production by T cells OBI:0001804 ELISPOT assay measuring epitope specific interleukin-7 production by T cells An enzyme-linked immunospot assay that detects interleukin-7 production by T cells. IEDB IEDB IL-7 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-7 production by T cells OBI:0001805 intracellular cytokine staining assay measuring epitope specific interleukin-7 production by T cells A flow cytometry assay that detects interleukin-7 production by T cells. IEDB IEDB IL-7 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-7 production by T cells OBI:0001806 intracellular cytokine staining assay measuring epitope specific interleukin-27 production by T cells A flow cytometry assay that detects interleukin-27 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-27 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-27 production by T cells OBI:0001807 cytometric bead array assay measuring epitope specific interleukin-3 production by T cells A cytometric bead array assay that detects interleukin-3 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-3 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-3 production by T cells OBI:0001808 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-3 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-3 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-3 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-3 production by T cells OBI:0001809 assay measuring epitope specific granzyme A release by T cells A T cell epitope specific cytotoxic T cell degranulation assay that detects granzyme A release by T cells. IEDB IEDB granzyme A release|biological activity assay measuring epitope specific granzyme A release by T cells OBI:0001810 assay measuring epitope specific granulysin release by T cells A T cell epitope specific cytotoxic T cell degranulation assay that detects granulysin release by T cells. IEDB IEDB granulysin release|biological activity assay measuring epitope specific granulysin release by T cells OBI:0001811 cytometric bead array assay measuring epitope specific interleukin-27 production by T cells A cytometric bead array assay that detects interleukin-27 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-27 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-27 production by T cells OBI:0001812 intracellular cytokine staining assay measuring epitope specific interleukin-23 production by T cells A flow cytometry assay that detects interleukin-23 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-23 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-23 production by T cells OBI:0001813 ELISPOT assay measuring epitope specific interleukin-27 production by T cells An enzyme-linked immunospot assay that detects interleukin-27 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-27 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-27 production by T cells OBI:0001814 ELISA measuring epitope specific interleukin-27 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-27 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-27 release|ELISA ELISA measuring epitope specific interleukin-27 production by T cells OBI:0001815 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-18 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-18 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-18 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-18 production by T cells OBI:0001817 ELISPOT assay measuring epitope specific interleukin-18 production by T cells An enzyme-linked immunospot assay that detects interleukin-18 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-18 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-18 production by T cells OBI:0001821 ELISPOT assay measuring epitope specific interleukin-22 production by T cells An enzyme-linked immunospot assay that detects interleukin-22 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-22 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-22 production by T cells OBI:0001822 ELISPOT assay measuring epitope specific interleukin-23 production by T cells An enzyme-linked immunospot assay that detects interleukin-23 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-23 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-23 production by T cells OBI:0001824 intracellular cytokine staining assay measuring epitope specific interleukin-18 production by T cells A flow cytometry assay that detects interleukin-18 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-18 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-18 production by T cells OBI:0001826 ELISPOT assay measuring epitope specific interleukin-21 production by T cells An enzyme-linked immunospot assay that detects interleukin-21 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-21 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-21 production by T cells OBI:0001827 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-C motif) ligand 1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL1/TCA-3 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells OBI:0001828 cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells A cytometric bead array assay that detects chemokine (C-C motif) ligand 1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL1/TCA-3 release|cytometric bead array cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells OBI:0001829 ELISPOT assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells An enzyme-linked immunospot assay that detects chemokine (C-C motif) ligand 1 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB CCL1/TCA-3 release|ELISPOT ELISPOT assay measuring epitope specific chemokine (C-C motif) ligand 1 production by T cells OBI:0001830 ELISPOT assay measuring epitope specific interleukin-17F production by T cells An enzyme-linked immunospot assay that detects interleukin-17F production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17F release|ELISPOT ELISPOT assay measuring epitope specific interleukin-17F production by T cells OBI:0001831 ELISA measuring epitope specific interleukin-17F production by T cells An enzyme-linked immunosorbent assay that detects interleukin-17F production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17F release|ELISA ELISA measuring epitope specific interleukin-17F production by T cells OBI:0001832 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-17F production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-17F production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17F release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-17F production by T cells OBI:0001833 ELISPOT assay measuring epitope specific interleukin-17A production by T cells An enzyme-linked immunospot assay that detects interleukin-17A production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17A release|ELISPOT ELISPOT assay measuring epitope specific interleukin-17A production by T cells OBI:0001835 cytometric bead array assay measuring epitope specific interleukin-18 production by T cells A cytometric bead array assay that detects interleukin-18 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-18 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-18 production by T cells OBI:0001836 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-16 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-16 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-16 production by T cells OBI:0001837 ELISA measuring epitope specific interleukin-16 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-16 release|ELISA ELISA measuring epitope specific interleukin-16 production by T cells OBI:0001838 ELISPOT assay measuring epitope specific interleukin-16 production by T cells An enzyme-linked immunospot assay that detects interleukin-16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-16 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-16 production by T cells OBI:0001839 intracellular cytokine staining assay measuring epitope specific interleukin-16 production by T cells A flow cytometry assay that detects interleukin-16 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-16 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-16 production by T cells OBI:0001840 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-17A production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-17A production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17A release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-17A production by T cells OBI:0001841 intracellular cytokine staining assay measuring epitope specific interleukin-1 beta production by T cells A flow cytometry assay that detects interleukin-1 beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1b release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-1 beta production by T cells OBI:0001842 ELISPOT assay measuring epitope specific interleukin-1 beta production by T cells An enzyme-linked immunospot assay that detects interleukin-1 beta production by T cells. IEDB IEDB IL-1b release|ELISPOT ELISPOT assay measuring epitope specific interleukin-1 beta production by T cells OBI:0001843 detection of specific nucleic acids with complementary probes measuring epitope specific interleukin-15 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-15 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-15 release|RNA/DNA detection detection of specific nucleic acids with complementary probes measuring epitope specific interleukin-15 production by T cells OBI:0001844 ELISPOT assay measuring epitope specific interleukin-12 production by T cells An enzyme-linked immunospot assay that detects interleukin-12 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-12 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-12 production by T cells OBI:0001845 intracellular cytokine staining assay measuring epitope specific interleukin-15 production by T cells A flow cytometry assay that detects interleukin-15 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-15 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-15 production by T cells OBI:0001846 ELISPOT assay measuring epitope specific interleukin-15 production by T cells An enzyme-linked immunospot assay that detects interleukin-15 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-15 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-15 production by T cells OBI:0001848 chromatin interaction analysis by paired-end tag sequencing assay Zhang, et al. ChIA-PET analysis of transcriptional chromatin interactions. Methods. 2012 Nov;58(3):289-99. [PMID:22926262] An assay that incorporates chromatin immunoprecipitation (ChIP)-based enrichment, chromatin proximity ligation, Paired-End Tags, and high-throughput sequencing to determine de novo long-range chromatin interactions genome-wide. Chris Stoeckert Jie Zheng Venkat Malladi ChIA-PET ChIA-PET assay url:http://en.wikipedia.org/wiki/ChIA-PET chromatin interaction analysis by paired-end tag sequencing assay OBI:0001849 structural analysis by paired-end tag sequencing assay Yao, et al. Long Span DNA Paired-End-Tag (DNA-PET) Sequencing Strategy for the Interrogation of Genomic Structural Mutations and Fusion-Point-Guided Reconstruction of Amplicons. PLoS One. 2012;7(9):e46152 [PMID:23029419] An assay that incorporates Paired-End Tags and sequencing technology to determine structural variants. Chris Stoeckert Jie Zheng Venkat Malladi DNA-PET DNA-PET assay PMID:23029419 structural analysis by paired-end tag sequencing assay OBI:0001850 transcript analysis by paired-end tag sequencing assay Ruan, et al. Genome wide full-length transcript analysis using 5' and 3' paired-end-tag next generation sequencing (RNA-PET). Methods Mol Biol. 2012;809:535-62. [PMID:22113299] A transcription profiling assay that determines transcripts, gene structures, and gene expressions using Paired-End Tags and sequencing technology. Chris Stoeckert Jie Zheng Venkat Malladi RNA-PET RNA-PET assay PMID:22113299 transcript analysis by paired-end tag sequencing assay OBI:0001853 DNase I hypersensitive sites sequencing assay Sabo, et al. Discovery of functional noncoding elements by digital analysis of chromatin structure. Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16837-42. [PMID:15550541] An assay that identifies the location of regulatory regions, based on the genome-wide sequencing of regions super sensitive to cleavage by DNase I. Chris Stoeckert Jie Zheng Venkat Malladi url:http://en.wikipedia.org/wiki/DNase-Seq DNase I hypersensitive sites sequencing assay OBI:0001857 RNP (ribonuclear particle) immunoprecipitation high- throughput sequencing assay Zhao et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Molecular Cell (2010) vol. 40 (6) pp. 939-53 [PMID:21172659] An analyte assay that combines immunoprecipitation of an RNA-binding protein and RNA-seq to identify mRNAs associated with selected RNA binding proteins (RBPs). Chris Stoeckert Jie Zheng Venkat Malladi RIP-seq RIP-seq assay PMID:21172659 RNP (ribonuclear particle) immunoprecipitation high- throughput sequencing assay OBI:0001858 cross-linking immunoprecipitation high-throughput sequencing assay Heulga et al. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012 Feb 23;1(2):167-78. [PMID:22574288] An analyte assay that employs UV-crosslinking between RNA and a protein, followed by immunoprecipitation with antibodies for the protein, fragmentation, and high-throughput screening for RNA sequences that interact with a particular RNA-binding protein. Chris Stoeckert Jie Zheng Venkat Malladi CLIP-seq CLIP-seq assay HITS-CLIP PMID:18978773 cross-linking immunoprecipitation high-throughput sequencing assay OBI:0001859 formaldehyde-assisted isolation of regulatory elements assay Giresi, et al. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Research 17 (6): 877_�_85. [PMID:17179217] An assay to determine the sequences of those DNA regions in the genome associated with regulatory activity. Chris Stoeckert Jie Zheng Venkat Malladi FAIRE-seq FAIRE-seq assay url:http://en.wikipedia.org/wiki/FAIRE-Seq formaldehyde-assisted isolation of regulatory elements assay OBI:0001861 methylation-sensitive restriction enzyme sequencing assay Maunakea et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010 Jul 8;466(7303):253-7. [PMID:20613842] An assay that identifies unmethylated CpGs using methylation sensitive restriction enzymes to fragment DNA. Chris Stoeckert Jie Zheng Venkat Malladi MRE-seq MRE-seq assay PMID:20613842 methylation-sensitive restriction enzyme sequencing assay OBI:0001862 reduced representation bisulfite sequencing assay Meissner et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005; 33(18): 5868_�_5877. [PMCID: PMC1258174] A bisulfite sequencing assay that identifies genomic methylation patterns using a bisulfite based protocol that enriches CG-rich parts of the genome. Chris Stoeckert Jie Zheng Venkat Malladi RRBS RRBS assay reduced representation bisulfite-seq PMC:1258174 reduced representation bisulfite sequencing assay OBI:0001863 shotgun bisulfite-seq assay Cokus et al. Shotgun bisulfite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008 Mar 13;452(7184):215-9. [PMID:18278030]. A bisulfite sequencing assay that identifies methylated cytosines across the genome using high throughput sequencing. Chris Stoeckert Jie Zheng Venkat Malladi Shotgun bisulfite sequencing WGBS WGSBS whole genome bisulfite sequencing whole-genome shotgun bisulfite sequencing PMID:18278030 shotgun bisulfite-seq assay OBI:0001864 RNA Annotation and Mapping of Promoters for the Analysis of Gene Expression assay Batut et al. High-fidelity promoter profiling reveals widespread alternative promoter usage and transposon-driven developmental gene expression. Genome Research. 2013 Jan;23(1):169-80. [PMID:22936248] An transcription profiling assay that identifies transcription start sites (TSS), the quantification of their expression and the characterization of their transcripts using high throughput sequencing. Chris Stoeckert Jie Zheng Venkat Malladi RAMPAGE PMID:22936248 RNA Annotation and Mapping of Promoters for the Analysis of Gene Expression assay OBI:0001915 DNA replication timing by array assay Hiranti et al. Global reorganization of replication domains during embryonic stem cell differentiation. PLoS Biol. 2008 October 7;6(10):e245 [PMID:18842067] An assay which quantifies the timing of DNA replication as a function of genome position using array technology. Chris Stoeckert Jie Zheng Venkat Malladi Repli-chip Repli-chip assay PMID:18842067 DNA replication timing by array assay OBI:0001918 RNA-binding protein immunoprecipitation array profiling assay Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] An assay that combines immunoprecipitation of an RNA-binding protein and array technology to identify mRNAs associated with selected RNA binding proteins (RBPs). Chris Stoeckert Jie Zheng Venkat Malladi RIP-chip RIP-chip assay PMID:21125495 RNA-binding protein immunoprecipitation array profiling assay OBI:0001919 Carbon-copy chromosome conformation capture assay van Berkum et al. Determining spatial chromatin organization of large genomic regions using 5C technology. Methods Mol Biol (2009) vol. 567 pp. 189-213 [PMID:19588094] An assay that measures the organization of chromosomes at the genome-wide scale. Chris Stoeckert Jie Zheng Venkat Malladi 5C 5C assay PMID:16954542 Carbon-copy chromosome conformation capture assay OBI:0001920 DNA replication timing by sequencing assay Hansen et al. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. Proc Natl Acad Sci U S A. 2010 January 5; 107(1): 139_�_144. [PMID:19966280] An assay in which timing of DNA replication is quantified as a function of genome position based on genome-wide sequencing. Chris Stoeckert Jie Zheng Venkat Malladi Repli-seq Repli-seq assay PMID:19966280 DNA replication timing by sequencing assay OBI:0001921 RNA-binding protein immunoprecipitation tiling array profiling assay Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] An RNA-binding protein immunoprecipitation array profiling assay that combines immunoprecipitation of an RNA-binding protein and RNA tiling array to identify mRNAs associated with selected RNA binding proteins (RBPs). Chris Stoeckert Jie Zheng Venkat Malladi PMID:21125495 RNA-binding protein immunoprecipitation tiling array profiling assay OBI:0001922 microRNA profiling by high throughput sequencing assay Juhlia et al. MicroRNA expression profiling reveals miRNA families regulating_specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. 2011;6(6). PMID: 21731767 A microRNA profiling assay that analyzes the microRNA component of the transcriptome using high throughput sequencing technology. Chris Stoeckert Jie Zheng Venkat Malladi miRNA-HTS miRNA-seq microRNA-seq microRNA-seq assay url:http://www.ebi.ac.uk/efo/EFO_0002896 microRNA profiling by high throughput sequencing assay OBI:0001923 protein sequencing by tandem mass spectrometry assay Taylor et al.Implementation and uses of automated de novo peptide sequencing by tandem mass spectrometry. Anal Chem. 2001 Jun;73(11):2594-604. [PMID:11403305] A sequencing assay that detremines amino acid sequences of proteins using multiple rounds of mass spectrometry and molecule fragmentation. Chris Stoeckert Jie Zheng Venkat Malladi PMID:3462691 protein sequencing by tandem mass spectrometry assay OBI:0001924 micrococcal nuclease digestion followed by high throughput sequencing assay Cui et al.Genome-wide approaches to determining nucleosome occupancy in metazoans using MNase-Seq. Methods Mol Biol. 2012;833:413-9. [PMID:22183607] An assay that identifies nucleosome positioning by genome wide sequencing of regions sensitive to digestion by micrococal nuclease Chris Stoeckert Jie Zheng Venkat Malladi MNase-seq MNase-seq assay PMID:17038564 micrococcal nuclease digestion followed by high throughput sequencing assay OBI:0001925 chromatin immunoprecipitation with exonuclease sequencing assay Rhee et al. Comprehensive Genome-wide Protein-DNA Interactions Detected at Single-Nucleotide Resolution. Cell. 2011 Dec;147(6):1408-19. [PMID:22153082] A ChIP-seq assay which uses immunoprecipitation to isolate protein bound DNA followed by an exonuclease step to degrade DNA that is not protein bound to provide greater resolution of the DNA binding site Bjoern Peters Chris Stoeckert Jie Zheng Venkat Malladi ChIP-exo assay PMID:22153082 chromatin immunoprecipitation with exonuclease sequencing assay OBI:0001926 microRNA profiling assay A transcription profiling assay that quantifies the microRNA species within a biological sample. Chris Stoeckert Jie Zheng Venkat Malladi miRNA expression assay microRNA expression assay PMID: 23382819 microRNA profiling assay OBI:0001954 ChIP assay PMID: 6379641 An assay in which portions of chromatin, the ordered and organized complex of DNA and its interaction partners that make up a chormosome, is extracted and purified by immunoprecipitation with antibodies or tags, and subsequently analyzed Bjoern Peters Philippe Rocca-Serra chromatin immunoprecipitation assay url:https://en.wikipedia.org/wiki/Chromatin_immunoprecipitation ChIP assay OBI:0001956 assay using chromatin immunoprecipitation http://www.lifetechnologies.com/uk/en/home/life-science/epigenetics-noncoding-rna-research/chromatin-remodeling/chromatin-immunoprecipitation-chip.html An assay that produces data about protein-DNA interaction or DNA epigenetic modification using immunoprecipitation Philippe Rocca-Serra http://sourceforge.net/p/obi/obi-terms/707/ assay using chromatin immunoprecipitation OBI:0001960 taxonomic diversity assessment by targeted gene survey PMID:20679230 PMID:25367129 An assay that dteremines taxonomic and community diversity information by sequencing specific genomic regions used as marker of identity or diversity. Philippe Rocca-Serra environmental gene survey targeted gene survey targeted gene survey DNA barcoding OBI taxonomic diversity assessment by targeted gene survey OBI:0001976 hydrogen/deuterium exchange footprinting assay Performing deuterium exchange on a protein by itself and in the presence of a binding partner, degrading the protein into peptide segments and identifying where deuterium exchange occurred by detecting the peptides in Mass Spectrometry. Peptides that have a modified deuteration pattern when the protein was bound to a partner are expected to be part of the binding interface. A footprinting assay that uses a chemical reaction whereby a covalently bonded hydrogen atom is replaced by a deuterium atom, or vice versa in order to gather information about the solvent accessibility of parts of a molecule and thus its tertiary structure. IEDB IEDB hydrogen/deuterium exchange footprinting assay OBI:0001977 cytometry assay An intracellular material detection by flow cytometry assay measuring peforin inside a culture of T cells. An assay that counts and/or measures characteristics of cells. IEDB IEDB cytometry assay OBI:0001978 immunoblot assay An analyte assay that detects specific molecules in an input material by separating it using gel electrophoresis, transfering the separated molecules to a membrane, and staining them with_ antibodies specific to the analyte molecules. IEDB IEDB immunoblot assay OBI:0001979 fluorescence quenching binding assay A binding assay in which the proximity of two entities is monitored by measuring a fluorescent signal of one of the entities that gets reduced if the two entities are cliose to each other. IEDB IEDB fluorescence quenching binding assay OBI:0001980 in vivo intervention experiment Comparing the level of allergy symptoms in humans before and post allergy immunotherapy. Testing if injection of a chemical compound into mice will lead to decreased survival. An assay in which the effect of a targeted process (the intervention) on an organism is tested. The intervention in an experiment should be modeled accordingly to the intevention carried out in a human cllinical trial, which is currently modeled as 'study intervention'. This touches the boundaries of study vs. assay. IEDB IEDB in vivo intervention experiment OBI:0001981 disease exacerbation in vivo intervention experiment Injecting a set of mice with a peptide and measuring symtoms to determine if their disease course was more severe than the disease course of a set of mice that were not injected with the same peptide. An in vivo intervention experiment that tests the ability of the intervention to increase the severity of a disease in the host. Should have data about disease severity as readout; could just use disease for now IEDB IEDB disease exacerbation in vivo intervention experiment OBI:0001982 protection from challenge in vivo intervention experiment Injecting a set of mice with a peptide and measuring symtoms to determine if their disease course was less severe than the disease course of a set of mice that were not injected with the same peptide. An in vivo intervention experiment that tests the ability of the intervention to prevent occurrence of a disease in a host. should have challenge as intervention IEDB IEDB protection from challenge in vivo intervention experiment OBI:0001983 tolerance induction intervention experiment Injecting a set of mice with a Der p 2 peptide and measuring the IL-2 response of T cells from those mice when exposed to the Der p 2 protein in vitro to determine if those T cells made less IL-2 than cells taken from mice which were not injected with the same Der p 2 peptide. An in vivo intervention experiment that tests the ability of the intervention to decrease an immune response. should have tolerance induction as intervention IEDB IEDB tolerance induction intervention experiment OBI:0001984 treatment intervention experiment Testing if administering oral histamine-blockers will reduce the number of emergency room visits in severely asthmatic individuals. An in vivo intervention experiment in which the ability of the intervention to reduce or cure the effects of a disease are tested. should have treatment as intervention IEDB IEDB treatment intervention experiment OBI:0001985 microarray assay Measuring if sera from an influenza A virus immunizedmouse binds to Hemagglutinin protein that is immobilized on a microarray. An analyte assay where binding of the analyte to immobilized matrix is measured. IEDB IEDB microarray assay OBI:0001986 immunohistochemistry Staining a brain tissue sample from an Alzheimer's disease patient with antibodies to amyloid beta to identify amyloid plaques. An immunostaining assay to detect and potentially localize antigens within the cells of a tissue section. IEDB IEDB immunohistochemistry OBI:0001987 assay measuring the association constant [KA] of a MHC:ligand complex A MHC binding constant determination assay measuring equilibrium association constant (KA). IEDB IEDB association constant KA|binding assay|1/M assay measuring the association constant [KA] of a MHC:ligand complex OBI:0001988 assay measuring the dissociation constant [KD] of a MHC:ligand complex A MHC binding constant determination assay measuring equilibrium dissociation constant (KD). IEDB IEDB dissociation constant KD|binding assay|nM assay measuring the dissociation constant [KD] of a MHC:ligand complex OBI:0001989 radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex A radioactivity detection assay that measures equilibrium dissociation constant (KD) to detect the loss of binding of a known reference ligand to purified-MHC due to competition by the ligand under investigation. IEDB IEDB dissociation constant KD|purified MHC/direct/radioactivity|nM radioactivity detection assay measuring equilibrium dissociation constant [KD] to determine competitive binding of a purified-MHC:ligand complex OBI:0001990 assay measuring the half life of a MHC:ligand complex A MHC binding constant determination assay measuring half life of binding. IEDB IEDB half life|binding assay|min assay measuring the half life of a MHC:ligand complex OBI:0001991 assay measuring the half maximal effective concentration [EC50] of a MHC:ligand complex A MHC binding constant determination assay measuring half maximal effective concentration (EC50). IEDB IEDB half maximal effective concentration (EC50)|binding assay|nM assay measuring the half maximal effective concentration [EC50] of a MHC:ligand complex OBI:0001992 assay measuring the half maximal inhibitory concentration [IC50] of a MHC:ligand complex A MHC binding constant determination assay measuring half maximal inhibitory concentration (IC50). IEDB IEDB half maximal inhibitory concentration (IC50)|binding assay|nM assay measuring the half maximal inhibitory concentration [IC50] of a MHC:ligand complex OBI:0001993 assay measuring the off rate measurement [koff] of a MHC:ligand complex A MHC binding constant determination assay measuring binding off rate measurement data item (koff). IEDB IEDB off rate|binding assay|1/s assay measuring the off rate measurement [koff] of a MHC:ligand complex OBI:0001994 assay measuring the MHC ligand binding on rate [kon] of a MHC:ligand complex A MHC binding constant determination assay measuring binding on rate (kon). IEDB IEDB on rate|binding assay|nM^-1s^-1 assay measuring the MHC ligand binding on rate [kon] of a MHC:ligand complex OBI:0001995 chromatography assay measuring the association constant [KA] of a B cell epitope:antibody complex An analytical chromatography assay that measures the association constant [KA] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|chromatography|1/nM chromatography assay measuring the association constant [KA] of a B cell epitope:antibody complex OBI:0001996 chromatography assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex An analytical chromatography assay that measures the dissociation constant [KD] of an antigen binding with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|chromatography|nM chromatography assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0001997 hydrogen/deuterium exchange footprinting assay measuring binding of a B cell epitope:antibody complex A hydrogen/deuterium exchange footprinting assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, James Overton, Bjoern Peters IEDB qualitative binding|hydrogen/deuterium exchange footprinting assay hydrogen/deuterium exchange footprinting assay measuring binding of a B cell epitope:antibody complex OBI:0001998 immunohistochemistry assay measuring binding of a B cell epitope:antibody complex A immunohistochemistry assay that detects the binding of an antigen with an antibody. IEDB IEDB qualitative binding|immunohistochemistry immunohistochemistry assay measuring binding of a B cell epitope:antibody complex OBI:0001999 3D molecular structure determination assay of a T cell epitope:MHC:TCR complex A 3D structure determination of bound molecular complex assay that characterizes the 3-dimensional structure of a T cell epitope:MHC:TCR complex. IEDB IEDB 3D structure|any method 3D molecular structure determination assay of a T cell epitope:MHC:TCR complex OBI:0002014 DNA methylation profiling by ChIP-chip assay An epigenetic modification assay that identifies sites of DNA methylation using ChIP-chip technologies. Chris Stoeckert Jie Zheng DNA methylation ChIP-chip Penn group DNA methylation profiling by ChIP-chip assay OBI:0002015 transcription profiling by MPSS assay A transcription profiling assay that uses Massive Parallel Signature Sequencing (MPSS). Chris Stoeckert Jie Zheng expression MPSS url:http://en.wikipedia.org/wiki/Massively_parallel_signature_sequencing transcription profiling by MPSS assay OBI:0002016 histone modification identification by ChIP-chip assay An epigenetic modification assay that identifies regions containing specific histones and their modifications using ChIP-chip techniques. Chris Stoeckert Jie Zheng histone modification ChIP-chip Penn group histone modification identification by ChIP-chip assay OBI:0002017 histone modification identification by ChIP-Seq assay An epigenetic modification assay that identifies regions containing specific histones and their modifications using ChIP-Seq techniques. Chris Stoeckert Jie Zheng histone modification ChIP-Seq Penn group histone modification identification by ChIP-Seq assay OBI:0002018 transcription factor binding site identification by ChIP-chip assay A transcription factor binding site assay that utilizes ChIP-chip technology. Chris Stoeckert Jie Zheng TF Binding ChIP-chip Penn group transcription factor binding site identification by ChIP-chip assay OBI:0002019 transcription factor binding site identification by ChIP-Seq assay A transcription factor binding site assay that utilizes ChIP-seq technology. Chris Stoeckert Jie Zheng TF Binding ChIP-Seq Penn group transcription factor binding site identification by ChIP-Seq assay OBI:0002020 epigenetic modification assay An assay that identifies epigenetic modifications including histone modifications, open chromatin, and DNA methylation. Chris Stoeckert Jie Zheng Penn group epigenetic modification assay OBI:0002029 serial analysis of gene expression assay PMID:15905473 A transcription profiling assay that quantifies RNA through creating short signature tags of the messages and ligating them into a larger molecule than was sequenced. Chris Stoeckert Janos Demeter Jie Zheng SAGE PMID:7570003 https://sourceforge.net/p/obi/obi-terms/720/ serial analysis of gene expression assay OBI:0002030 genotyping by tiling array assay PMID:19521816 A genotyping by array assay that uses tiling array technology. Chris Stoeckert Janos Demeter Jie Zheng DNA sequence variation detection by tiling array PMID:19521816 https://sourceforge.net/p/obi/obi-terms/720/ genotyping by tiling array assay OBI:0002031 genotyping by SNP array assay PMID:20080586 A genotyping by array assay that uses SNP array technology. Chris Stoeckert Janos Demeter Jie Zheng DNA sequence variation detection by snp array PMID:20393561 https://sourceforge.net/p/obi/obi-terms/720/ genotyping by SNP array assay OBI:0002032 parallel analysis of RNA structure assay pmid:20811459 A single-nucleotide-resolution nucleic acid structure mapping assay that performs simultaneous in vitro profiling of the secondary structure of thousands of RNA species at single nucleotide resolution using enzymatic probing based on deep sequencing fragments of RNAs that were treated with structure-specific enzymes Chris Stoeckert Janos Demeter PARS PMID:20811459 https://sourceforge.net/p/obi/obi-terms/725/ parallel analysis of RNA structure assay OBI:0002033 translation-associated transcript leader sequencing assay pmid:23580730 An RNA-seq assay that combines TL-seq with polysome fractionation Chris Stoeckert Janos Demeter TATL-seq PMID:23580730 https://sourceforge.net/p/obi/obi-terms/725/ translation-associated transcript leader sequencing assay OBI:0002034 transcript leader sequencing assay pmid:23580730 An RNA-seq assay that combines enzymatic capture of m(7)G-capped mRNA 5' ends with high-throughput sequencing. Chris Stoeckert Janos Demeter TL-seq PMID:23580730 https://sourceforge.net/p/obi/obi-terms/725/ transcript leader sequencing assay OBI:0002035 peptide mass fingerprinting assay A mass spectrometry assay that measures the absolute mass of the cleaved peptides derived from an unknown protein of interest. These masses are then compared to values for known protein sequences to identify the unknown protein. Chris Stoeckert Janos Demeter PMF protein fingerprinting ERO:0001668 url:http://en.wikipedia.org/wiki/Peptide_mass_fingerprinting https://sourceforge.net/p/obi/obi-terms/725/ peptide mass fingerprinting assay OBI:0002036 array based nucleic acid structure mapping assay pmid:23580730 An assay which aims to provide information about the in vivo organization/structure of nucleic acids using chemical or enzymatic probes using a microarray. Chris Stoeckert Janos Demeter OBI:0000870 https://sourceforge.net/p/obi/obi-terms/725/ array based nucleic acid structure mapping assay OBI:0002037 micrococcal nuclease digestion followed by tiling array assay pmid:17873876 An array based nucleic acid structure mapping assay that identifies nucleosome positions genome wide, by detection of regions protected by nucleosomes from digestion by micrococal nuclease using tiling array assays Chris Stoeckert Janos Demeter https://sourceforge.net/p/obi/obi-terms/725/ micrococcal nuclease digestion followed by tiling array assay OBI:0002038 ribosomal profiling by sequencing assay Aspden et al., (August 2014). "Extensive translation of small open reading frames revealed by poly-ribo-seq." eLIFE 2014;3:e03528 A RNA-seq assay that sequences only mRNA protected by the ribosome during translation. Chris Stoeckert Jie Zheng Venkat Malladi Ribo-seq Ribo-seq assay ribosomal profiling PMID:24468696 ribosomal profiling by sequencing assay OBI:0002039 assay for transposase-accessible chromatin using sequencing Kasinathan et al., (February 2014). "High-resolution mapping of transcription factor binding sites on natitve chromatin." Nat Methods 11(2):203-9. doi: 10.1038/nmeth.2766. An assay to capture the location of open chromatin, DNA-binding proteins, individual nucleosomes and chromatin compaction at nucleotide resolution by Tn5 transposase insertion. Chris Stoeckert Jie Zheng Venkat Malladi ATAC-seq ATAC-seq assay PMID:24097267 assay for transposase-accessible chromatin using sequencing OBI:0002040 chromatin isolation by RNA purification sequencing assay Csorba et al., (November 2014). "Antisense COOLAIR mediates the coordinated switching of chromatin states at FLC during vernalization." Proc Natl Acad Sci 111(45):16160-5. doi: 10.1073/pnas.1419030111. A detection of specific nucleic acids with complementary probes assay that measures regions of the genome which are bound by a specific RNA (or a by a ribonucleoprotein containing the RNA of interest) using high-throughput sequencing. Chris Stoeckert Jie Zheng Venkat Malladi ChIRP-seq ChIRP-seq assay Chromatin Isolation by RNA purification PMID:21963238 chromatin isolation by RNA purification sequencing assay OBI:0002041 self-transcribing active regulatory region sequencing assay Bohla et al., (September 2014). "A functional insulator screen identifies NURF and dREAM components to be required for enhancer-blocking." PLoS One 9(9):e107765. doi: 10.1371/journal.pone.0107765. An RNA-seq assay that identifies the sequences that act as transcriptional enhancers in a direct, quantitative, and genome-wide manner from sheared genomic DNA. Chris Stoeckert Jie Zheng Venkat Malladi STARR-seq STARR-seq assay self-transcribing active regulatory region sequencing PMID:23328393 self-transcribing active regulatory region sequencing assay OBI:0002042 carbon-copy chromosome conformation capture assay followed by sequencing assay Fudenberg et al., (November 2014). "High order chromatin architecture shapes the landscape of chromosomal alterations in cancer." Nat Biotechol 29(12):1109-13. doi: 10.1038/nbt.2049. A carbon-copy chromosome conformation capture assay to analyze the organization of chromosomes in an unbiased, genome-wide manner using high throughput sequening following carbon-copy chromosome conformation capture. Chris Stoeckert Jie Zheng Venkat Malladi Carbon-copy chromosome conformation capture assay followed by sequencing HiC HiC assay PMID:19815776 carbon-copy chromosome conformation capture assay followed by sequencing assay OBI:0002043 individual-nucleotide resolution cross-linking and immunoprecipitation sequencing assay Protein-RNA interactions: new genomic technologies and perspectives. Nature Reviews Genetics 13 (2): 77-83. doi:10.1038/nrg3141 A cross-linking immunoprecipitation high-throughput sequencing assay that identifies protein-RNA interactions using UV light to covalently bind proteins and RNA molecules, allowing for a very stringent purification of the linked protein-RNA complexes. Chris Stoeckert Jie Zheng Venkat Malladi iCLIP iCLIP assay individual-nucleotide resolution cross-linking and immunoprecipitation doi:10.1016/j.ymeth.2013.10.011 individual-nucleotide resolution cross-linking and immunoprecipitation sequencing assay OBI:0002044 RNA Bind-n-Seq assay An RNA-seq assay that comprehensively characterizes sequence and structural specificity of RNA binding proteins (RBPs). Chris Stoeckert Jie Zheng Venkat Malladi RBNS RNA Bind-n-Seq RNBS assay doi: 10.1016/j.molcel.2014.04.016 RNA Bind-n-Seq assay OBI:0002045 polyA-site sequencing assay Wu et al., (July 2014). "Genome-wide determination of poly(A) sites in Medicago truncatula: evolutionary conservation of alternative poly(A) site choice. BMC Genomics. 2014 Jul 21;15:615. doi: 10.1186/1471-2164-15-615. A RNA-seq assay that quantitatively profiles RNA polyadenylation at the transcriptome level. Chris Stoeckert Jie Zheng Venkat Malladi PAS-seq PAS-seq assay Poly(A)-site sequencing poly(A)-site sequencing assay doi: 10.1261/rna.2581711 polyA-site sequencing assay OBI:0002050 3D molecular structure determination assay of a MHC:ligand complex A 3D structure determination of bound molecular complex assay that characterizes the 3-dimensional structure of a MHC:ligand complex. IEDB IEDB 3D structure|any method 3D molecular structure determination assay of a MHC:ligand complex OBI:0002051 in vivo assay measuring B cell epitope specific protection from infectious challenge based on pathogen burden An in vivo assay measuring B cell epitope specific protection from pathogen challenge using pathogen burden. IEDB IEDB pathogen burden after challenge|in vivo assay in vivo assay measuring B cell epitope specific protection from infectious challenge based on pathogen burden OBI:0002052 in vivo assay measuring B cell epitope specific protection after tumor burden challenge An in vivo assay measuring B cell epitope specific protection from tumor challenge using tumor burden. IEDB IEDB tumor burden after challenge|in vivo assay in vivo assay measuring B cell epitope specific protection after tumor burden challenge OBI:0002053 microarray assay measuring binding of a B cell epitope:antibody complex A microarray assay that detects the binding of an antigen with an antibody. IEDB IEDB qualitative binding|microarray microarray assay measuring binding of a B cell epitope:antibody complex OBI:0002054 NMR assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex A B cell epitope equilibrium dissociation constant (KD) determination assay that uses a nuclear magnetic resonance assay. IEDB IEDB dissociation constant KD|nuclear magnetic resonance (NMR)|nM NMR assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0002055 assay measuring biological activity resulting from T cell epitope:MHC:TCR binding A T cell epitope recognition assay that measures the immune response process resulting from the binding of a T cell receptor to epitope or the recongition of the epitope. IEDB IEDB biological activity|any method assay measuring biological activity resulting from T cell epitope:MHC:TCR binding OBI:0002056 assay measuring epitope specific chemokine (C-C motif) ligand 17 production by T cells A T cell epitope specific cytokine production assay that detects production of chemokine (C-C motif) ligand 17 production by T cells. IEDB IEDB CCL17/TARC release|biological activity assay measuring epitope specific chemokine (C-C motif) ligand 17 production by T cells OBI:0002057 assay measuring epitope specific macrophage migration inhibitory factor (MIF) production by T cells A T cell epitope specific cytokine production assay that detects macrophage migration inhibitory factor (MIF) production by T cells. IEDB IEDB MIF release|biological activity assay measuring epitope specific macrophage migration inhibitory factor (MIF) production by T cells OBI:0002058 assay measuring epitope specific oncostatin M production by T cells A T cell epitope specific cytokine production assay that detects oncostatin M production by T cells. IEDB IEDB oncostatin M release|biological activity assay measuring epitope specific oncostatin M production by T cells OBI:0002059 assay measuring a binding constant of a T cell epitope:MHC:TCR complex A T cell epitope recognition assay that quantitavely characterizes the binding of a TCR with a ligand by determining a binding constant. IEDB IEDB binding constant|binding assay assay measuring a binding constant of a T cell epitope:MHC:TCR complex OBI:0002060 detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 17 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects chemokine (C-C motif) ligand 17 production by T cells. IEDB IEDB CCL17/TARC release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific chemokine (C-C motif) ligand 17 production by T cells OBI:0002061 cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 22 production by T cells A cytometric bead array assay that detects chemokine (C-C motif) ligand 22 production by T cells. IEDB IEDB CCL22/MDC release|cytometric bead array cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 22 production by T cells OBI:0002062 in vitro assay measuring epitope specific T cell killing An in vitro cell killing assay that measures the killing of antigen presenting cells (APC) by T cells whose TCR recognizes an epitope presented by the APC. IEDB IEDB cytotoxicity|in vitro assay in vitro assay measuring epitope specific T cell killing OBI:0002063 cytometric bead array assay measuring epitope specific granzyme A release by T cells A cytometric bead array assay that detects epitope specific granzyme A release by T cells. IEDB IEDB granzyme A release|cytometric bead array cytometric bead array assay measuring epitope specific granzyme A release by T cells OBI:0002064 detection of specific nucleic acids with complementary probes assay measuring epitope specific granzyme A release by T cells A detection of specific nucleic acids with complementary probes assay that detects epitope specific granzyme A release by T cells. IEDB IEDB granzyme A release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific granzyme A release by T cells OBI:0002065 cytometric bead array assay measuring epitope specific granzyme B release by T cells A cytometric bead array assay that detects epitope specific granzyme B release by T cells. IEDB IEDB granzyme B release|cytometric bead array cytometric bead array assay measuring epitope specific granzyme B release by T cells OBI:0002066 detection of specific nucleic acids with complementary probes assay measuring epitope specific granzyme B release by T cells A detection of specific nucleic acids with complementary probes assay that detects epitope specific granzyme B release by T cells IEDB IEDB granzyme B release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific granzyme B release by T cells OBI:0002067 cytometric bead array assay measuring epitope specific macrophage migration inhibitory factor (MIF) production by T cells A cytometric bead array assay that detects macrophage migration inhibitory factor (MIF) production by T cells. IEDB IEDB MIF release|cytometric bead array cytometric bead array assay measuring epitope specific macrophage migration inhibitory factor (MIF) production by T cells OBI:0002068 cytometric bead array assay measuring epitope specific oncostatin M production by T cells A cytometric bead array assay that detects oncostatin M production by T cells. IEDB IEDB oncostatin M release|cytometric bead array cytometric bead array assay measuring epitope specific oncostatin M production by T cells OBI:0002069 ELISPOT assay measuring epitope specific perforin release by T cells An enzyme-linked immunospot assay that detects epitope specific perforin release by T cells. IEDB IEDB perforin release|ELISPOT ELISPOT assay measuring epitope specific perforin release by T cells OBI:0002070 in vivo assay measuring epitope specific proliferation of T cells A T cell epitope specific proliferation assay that is performed in vivo. IEDB IEDB proliferation|in vivo assay in vivo assay measuring epitope specific proliferation of T cells OBI:0002071 in vitro assay measuring epitope specific proliferation of T cells A T cell epitope specific proliferation assay that is performed on cells in vitro. IEDB IEDB proliferation|in vitro assay in vitro assay measuring epitope specific proliferation of T cells OBI:0002072 assay measuring qualitative binding of a MHC:ligand complex An assay that detects the binding of a MHC molecule with a ligand, and produces a qualitative measurement of the binding as an output. IEDB IEDB qualitative binding|binding assay assay measuring qualitative binding of a MHC:ligand complex OBI:0002073 in vivo assay measuring T cell epitope specific protection from challenge An efficacy of T cell epitope intervention experiment that uses a epitope protection experiment. IEDB IEDB protection from challenge|in vivo assay in vivo assay measuring T cell epitope specific protection from challenge OBI:0002074 assay measuring T cell epitope specific suppression in vitro T cell epitope dependent biological activity assay that detects suppression of an in vitro response. PERSON:Randi Vita, James Overton, Bjoern Peters IEDB suppression|in vitro assay assay measuring T cell epitope specific suppression in vitro OBI:0002075 MHC ligand assay An immune epitope assay that characterizes the structrue of a MHC-ligand complex, or detects the processing and presentation of a ligand by an antigen presenting cell, or the binding of a ligand to an MHC molecule. IEDB IEDB MHC ligand assay|any method MHC ligand assay OBI:0002082 reporter gene assay An assay that detects expression of a reporter gene that was inserted under the control of a regulatory sequence of interest. Chris Stoeckert Paul D. Thomas reporter gene detection assay Paul D. Thomas, Yang Chai; FaceBase https://github.com/obi-ontology/obi/issues/781 reporter gene assay OBI:0002083 enhancer activity detection by reporter gene assay PMID 19268701: "we experimentally concatenated up to four enhancers from different genes and used a transgenic mouse assay to compare the in vivo activity of these compound elements with that of the single modules" A reporter gene assay that detects expression of a reporter gene that was inserted under the control of an enhancer of interest. Paul D. Thomas Yang Chai enhancer reporter gene assay FaceBase PMID 24614317 https://github.com/obi-ontology/obi/issues/781 enhancer activity detection by reporter gene assay OBI:0002084 transcription cofactor activity region identification by ChIP-Seq assay PMID 19212405: "we present the results of chromatin immunoprecipitation with the enhancer-associated protein p300 followed by massively parallel sequencing, and map several thousand in vivo binding sites of p300 in mouse embryonic forebrain, midbrain and limb tissue" A ChIP-seq assay that identifies regions of chromatin bound to a chromatin modifying protein, e.g. a histone acetyltransferase. Paul D. Thomas Yang Chai chromatin modifier binding site identification by ChIP-Seq assay PMID:19212405 https://github.com/obi-ontology/obi/issues/782 transcription cofactor activity region identification by ChIP-Seq assay OBI:0002085 transcript expression location detection by hybridization chain reaction assay PMID 25977364: "Multiplexed imaging of mRNA expression using fluorescent hybridization chain reaction (HCR) quantitatively confirmed the expression profiles of lead cells" An in situ hybridization assay in which the location (e.g. anatomical/tissue) of a transcript is detected by a multiplexed fluorescent in situ hybridization, based on orthogonal amplification with hybridization chain reactions (HCR). RNA probes complementary to mRNA targets trigger chain reactions in which fluorophore-labeled RNA hairpins self-assemble into tethered fluorescent amplification polymers. Paul D. Thomas Yang Chai transcript expression location detection by fluorescent HCR. PMID:21037591 https://github.com/obi-ontology/obi/issues/783 transcript expression location detection by hybridization chain reaction assay OBI:0002086 Tet-assisted bisulfite sequencing assay A bisulfite sequencing assay that identifies genomic methylation patterns by using a bisulfite based protocol with the Tet enzyme to differentiate 5-hydroxylmethylcytosine (5hmC) from 5-methylcytosine (5mC) through a step-wise oxidative demethylation of 5mC, converting it to 5-carboxylcytosine (5caC) while keeping 5hmC protected. Bjoern Peters Chris Stoeckert Jason Hilton OBI TAB-seq Tet-assisted bisulfite sequencing PMID:23196972 http://sourceforge.net/p/obi/obi-terms/789/ Tet-assisted bisulfite sequencing assay OBI:0002094 MethylC-Capture sequencing assay MethylC-Capture Sequencing approach was introduced as a cost-effective and customizable alternative method for large-scale interrogation of functionally-active methylomes while simultaneously providing genetic variation information in a proof-of-concept epigenome-wide association study of 72 obese individuals, identifying novel disease-associated variants. A bisulfite sequencing assay in which a whole-genome sequencing library is prepared, bisulfite converted and amplified, followed by a capture enriching for targeted bisulfite-converted DNA fragments that are are subsequently identified by DNA sequencing. Chris Stoeckert David Bujold Capture Methylome MCC-Seq MethylC-Capture Sequencing PMID:26021296 MethylC-Capture sequencing assay OBI:0002096 carboxyfluorescein succinimidyl ester staining assay measuring epitope specific proliferation of T cells A CFSE assay that detects T cell epitope specific proliferation in vitro. IEDB IEDB proliferation|CFSE carboxyfluorescein succinimidyl ester staining assay measuring epitope specific proliferation of T cells OBI:0002097 assay measuring the dissociation constant [KD] of a T cell epitope:MHC:TCR complex A T cell epitope binding constant determination assay that measures the dissociation constant KD. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB dissociation constant KD|binding assay|nM assay measuring the dissociation constant [KD] of a T cell epitope:MHC:TCR complex OBI:0002098 assay measuring the on rate [kon] of a T cell epitope:MHC:TCR complex A T cell epitope binding constant determination assay that measures the on rate. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB on rate|binding assay|M^-1s^-1 assay measuring the on rate [kon] of a T cell epitope:MHC:TCR complex OBI:0002099 assay measuring the off rate [koff] of a T cell epitope:MHC:TCR complex A T cell epitope binding constant determination assay that measures the off rate. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB off rate|binding assay|1/s assay measuring the off rate [koff] of a T cell epitope:MHC:TCR complex OBI:0002100 assay measuring the association constant [KA] of a T cell epitope:MHC:TCR complex A T cell epitope binding constant determination assay that measures the association constant KA. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB association constant KA|binding assay|1/nM assay measuring the association constant [KA] of a T cell epitope:MHC:TCR complex OBI:0002101 small-angle scattering assay determining the 3D structure of a B cell epitope:antibody complex A small-angle scattering 3D molecular structure determination assay that characterizes the 3-dimensional molecular structure of a B cell epitope:antibody complex PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB 3D structure|small-angle scattering assay small-angle scattering assay determining the 3D structure of a B cell epitope:antibody complex OBI:0002102 bio-layer interferometry assay measuring the on rate [kon] of a B cell epitope:antibody complex A bio-layer interferometry assay that measures the on rate of an antigen with an antibody. IEDB IEDB on rate|bio-layer interferometry assay|M^-1s^-1 bio-layer interferometry assay measuring the on rate [kon] of a B cell epitope:antibody complex OBI:0002103 bio-layer interferometry assay measuring the off rate [koff] of a B cell epitope:antibody complex A bio-layer interferometry assay that measures the off rate of an antigen with an antibody. IEDB IEDB off rate|bio-layer interferometry assay|1/s bio-layer interferometry assay measuring the off rate [koff] of a B cell epitope:antibody complex OBI:0002104 bio-layer interferometry assay measuring binding of a B cell epitope:antibody complex A bio-layer interferometry assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|bio-layer interferometry assay bio-layer interferometry assay measuring binding of a B cell epitope:antibody complex OBI:0002105 bio-layer interferometry assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex A bio-layer interferometry assay that measures the dissociation constant [KD] of an antigen with an antibody. IEDB IEDB dissociation constant KD|bio-layer interferometry assay|nM bio-layer interferometry assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex OBI:0002106 carboxyfluorescein succinimidyl ester staining assay Measuring T cell proliferation based on the progressive halving of CFSE fluorescence within daughter cells following each cell division. a assay detecting a molecular label assay where the amount of carboxyfluorescein succinimidyl ester is measured using fluorescence detection. IEDB CFSE assay IEDB carboxyfluorescein succinimidyl ester staining assay OBI:0002107 bio-layer interferometry assay Detecting the presence of an antibody in a cell culture supernatant by detecting a shift in the interference pattern reflected from a layer of immobilized protein to which the antibody binds. A binding assay that detects a shift in the interference pattern reflected from a layer of immobilized material on the biosensor tip to measure binding to- or dissociating from the material on the biosensor. IEDB biolayer interferometry, BLI IEDB bio-layer interferometry assay OBI:0002108 small-angle scattering 3D molecular structure determination assay Targeting a solution of antibody bound to a protein with a neutron beam to determine the binding site of the antibody on the protein A 3D molecular structure determination assay in which the scattering pattern of a neutron or x-ray beam targeted at a material entity is recorded at small angles relative to the incident beam to determine the size, shape and structure of the material entity examined. IEDB SAXS IEDB small-angle scattering 3D molecular structure determination assay OBI:0002110 digital object identifier The doi symbol: "10.1109/5.771073" resolves to ieee website: http://ieeexplore.ieee.org/xpl/articleDetails.jsp?reload=true&arnumber=771073 A centrally registered identifier symbol used to uniquely identify objects given by International DOI Foundation. The DOI system is particularly used for electronic documents such as journal articles. Discussed on Aug 22, 2016 OBI dev call. Details see tracker: https://sourceforge.net/p/obi/obi-terms/818/ OBI developers DOI https://en.wikipedia.org/wiki/Digital_object_identifier https://www.doi.org/ digital object identifier OBI:0002111 enhanced cross-linking immunoprecipitation high-throughput sequencing assay An iCLIP assay that is enhanced to robustly identify protein-RNA interactions with high efficiency through improvements in library preparation of RNA fragments. Chris Stoeckert Jason Hilton eCLIP PMID:27018577 enhanced cross-linking immunoprecipitation high-throughput sequencing assay OBI:0002112 small RNA sequencing assay An RNA-seq assay which is targeting small RNA (< 200 bp) sequences such as, but not exclusive to, miRNAs using, for example, small RNA library preparation kits. Chris Stoeckert Jason Hilton Mark A. Miller short RNA-seq small RNA-seq url:http://science.sciencemag.org/content/316/5830/1484.full url:http://www.illumina.com/techniques/sequencing/rna-sequencing/small-rna-seq.html https://github.com/obi-ontology/obi/issues/859 small RNA sequencing assay OBI:0002113 bromouridine labeling and sequencing assay An RNA-seq assay to identify spans of nascent transcription in the genome through isolation of recent bromouridine (Bru) labelled RNAs. Chris Stoeckert Jason Hilton Bru-seq PMC:4009065 bromouridine labeling and sequencing assay OBI:0002114 bromouridine pulse-chase and sequencing assay An RNA-seq assay to identify RNA populations of specific ages through isolation of RNAs first labelled with bromouridine (Bru) followed by chasing in uridine for different periods of time. Chris Stoeckert Jason Hilton BruChase-seq PMC:4009065 bromouridine pulse-chase and sequencing assay OBI:0002115 cytometry time of flight assay Whole human blood samples were incubated with lipopolysaccharide (LPS) to examine dose-dependent signaling responses within the toll-like receptor 4 (TLR4) pathway. After LPS stimulation, rare earth metal tagged antibodies against phenotypic markers were used to stain the blood sample (Nd143-CD45RA, Nd145-CD4, Er170-CD3, Sm152-TCR__, Pr141-CD7, Nd146-CD8, Nd142-CD19). A Fluidigm CyTOF version 1 instrument equipped with CyTOF software version 5.1.648 was used to measure and analyze the levels of antibody staining reflective of the level of expression of those surface receptors. A cytometry assay in which the presence of molecules of interest on or in cells is indicated by binding of antibodies labeled with rare earth element tags which are detected by time-of-flight mass spectrometry. ImmPort CyTOF mass cytometry assay PMID:26190063 cytometry time of flight assay OBI:0002116 high performance liquid chromotography assay On-line coupled immunoaffinity chromatography-reversed-phase high-performance liquid chromatography (IAC-HPLC) with detection by quadrupole ion trap mass spectrometry using a particle beam interface has been developed for the determination of the steroids, dexamethasone and flumethasone. HEMA (polyhydroxyethylmethacrylate) was evaluated as a support material for the anti-dexamethasone antibodies used in IAC. Antibody cross-reactivity and non-specific binding have been investigated for the HEMA bound anti-dexamethasone IAC column. The on-line IAC-HPLC-MS determination of dexamethasone and flumethasone in post-administration equine urine samples showed precisions (R.S.D.) of 8.0 and 7.1%, respectively, with limits of detection in the range 3-4 ng/ml. An analytical chromatography assay that utilizes a high performance liquid chromatography instrument for separation of compounts in a solution. ImmPort HPLC PMID:9491555 high performance liquid chromotography assay OBI:0002117 whole genome sequencing assay WGS permits comprehensive sequencing of introns and exons, whereas whole exome sequencing (WES) allows deeper sequencing of exonic regions at a lower cost. Due to the large number of genetic variants found in each genome, it is necessary to use filtering approaches to distinguish deleterious from benign variants. WES has been used successfully to identify novel genetic causes of primary immunodeficiency. Complex structural variations and non-Mendelian disorders remain challenges for WGS. A DNA sequencing assay that intends to provide information about the sequence of an entire genome of an organism. Genotyping assays should ideally identify which part of the genome the information is about. We do not currently have a good way to do this. That information should be added later. ImmPort WGS PMID:23095910 PMID:25827230 whole genome sequencing assay OBI:0002118 exome sequencing assay DNA was extracted from the Ficoll pellet of blood taken from congenital asplenia patients. Unamplified, high-molecular weight, RNase-treated genomic DNA (4_6 _g) was used for whole exome sequencing (WES) with the use of Agilent 71 Mb (V4 + UTR) singlesample capture and an Illumina HiSeq 2000. Sequencing was carried out so as to obtain 30_ coverage from 2 _ 100-bp paired-end reads. We used the Annovar tool (25) to annotate the resulting highquality (HQ) variants. In the regions targeted by WES capture (81.5% of the consensus coding genome), the mean numbers of single-nucleotide variants (SNVs) and small insertions/deletions (indels) detected per sample were 84,192 and13,325, respectively. After filtering, a mean of 74,398 (95.3%) high-quality (HQ) SNVs and 9,033 (70.6%) HQ indels were called. A mean of 105 coding HQ SNVs and 32 indels was identified. A DNA sequencing assay that intends to provide information about the sequence of the protein coding components of a genome (exons). ImmPort WES PMID:25827230 exome sequencing assay OBI:0002119 microscopy assay Lung, liver, and spleen tissue samples were collected from female BALB/c mice and fixed in 100% formalin solution, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The stained samples were examined for signs of pathological changes under light microscopy. An imaging assay that utilizes a microscope to magnify features of the visualized material of interest that are not visible to naked eye. ImmPort PMID:21685355 microscopy assay OBI:0002120 mixed lymphocyte reaction assay T cells were separated from PBL of laboratory volunteers and used as responder cells (R). Mitomycin C-treated allogeneic mAPC enriched populations were used as stimulators (S), incubated for 5 days, pulsed with 3H-thymidine (3H-TdR) for 16 hours, harvested, and radioactivity counted using a beta scintillation counter to measure proliferation of the 3H-thymidine labeled cells. A cytometry assay where lymphocytes from two individuals are co-cultured with the lymphocytes from one of the allogeneic individuals (Responders) being labeled (with 3H Thymidine or BrdU) and the proliferation of the labeled cells is measured, which is thought to reflect recognition of histocompatibility antigens on the unlabeled cells (stimulators). ImmPort MLR PMID:14969764 mixed lymphocyte reaction assay OBI:0002121 killer cell immunoglobulin-like receptor typing assay DNA was isolated from PBMCs from healthy donors.The single-nucleotide polymorphism (SNP) assay was performed on an HT7900 Sequence Detection System (Applied Biosystems) following the allelic discrimination assay protocol provided by the manufacturer. Primers for the assay were designed in such a way that they amplified all the alleles of a particular HLA type (HLA-B or HLA-C) as well as the amplicon containing the polymorphic region of interest. Two probes were designed with a single mismatch between them. Each probe bound only one group of alleles and was labeled with either 6FAM or VIC fluorescent dye at its 5_ end. The 3_ end of the probes contained a quencher. For KIR2DL1 functional allele typing, the probe was designed based on a single-nucleotide mismatch at amino acid position 245 in the mature protein. A universal primer was designed that could specifically amplify all the alleles of KIR2DL1.The SNP assay was run on the HT7900 using the same protocol as described for KIR ligand typing. Results showed that 20 individuals had only arginine at amino acid position 245 of KIR2DL1, 5 were heterozygous for arginine and cysteine, and 1 had only cysteine in that position.Thus, this approach was useful not only for the identification of functional groups of KIR alleles, but also for determining the presence of the KIR gene itself. A genotyping assay in which the alleles of genes encoding for killer cell immunoglobulin-like receptors are determined. Genotyping assays should ideally identify which part of the genome the information is about. We do not currently have a good way to do this. That information should be added later. ImmPort KIR typing PMID:21239231 killer cell immunoglobulin-like receptor typing assay OBI:0002122 major histocompatibility typing assay Blood samples from Holstein-Friesian heifer calves were used to isolate white blood cell (WBC) pellets, from which total RNA was extracted using Tri-reagent and cDNA generated using a Reverse Transcription Kit, both_ according to the manufacturers? instructions. An alignment of sequences of known bovine MHCI gene cDNAs, as presented in the IPD-MHC database (May 2014), was used to design a series of 3_ (for) and 5_ (rev) pan-MHCI primers. cDNA from individual animals was subject to PCR amplification in two separate reactions using either the For1/Rev2 or the For3/Rev1 primer pairs. For each sample primers using a unique combination of MID tags were used to allow subsequent de-multiplexing of the sequence data. PCRs were conducted using the Phusion High-Fidelity PCR kit. Following amplification, 5?_l of PCR products from each sample were pooled, purified using Agencourt AMPure XP Beads and run on a 1.5?% agarose gel. Bands of the appropriate size_ were extracted and purified using the Qiagen Gel extraction kit. Libraries were submitted to Edinburgh Genomics where after standard quality control procedures they underwent 300 base paired-end sequencing on an Illumina MiSeq v3. Data were separated into reads generated from For1Rev2 and For3Rev1 primer pairs, generating separate datasets for up to 192 samples. Within each sample, reads were clustered into unique variants which were subsequently compared using BLAST against a database of the previously identified bovine MHCI sequences. This process identified >140 novel classical MHCI genes and defined 62 novel MHCI haplotypes, dramatically expanding the known bovine MHCI repertoire. A genotyping assay in which the alleles of genes encoding for major histocompatibility complex molecules are determined. Genotyping assays should ideally identify which part of the genome the information is about. We do not currently have a good way to do this. That information should be added later. IEDB MHC typing, HLA typing PMC:2628004 PMID:27516207 major histocompatibility typing assay OBI:0002132 pulse stable isotope labeling by amino acids in cell culture An assay that detects differences in protein abundance using samples that have been metabolically labeled in vivo with a stable non-radioactive heavy isotope containing amino acid for a short period of time. After diluting the pulsed cells into growth media without label, high resolution mass spectrometry-based proteomics is used to analyze the time-dependent decay and determine protein stability. Rob Nash dynamic SILAC pulse SILAC pulsed SILAC PMID:18954100 PMID:19053139 pulse stable isotope labeling by amino acids in cell culture OBI:0002133 cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells A cytometric bead array assay that detects chemokine (C-C motif) ligand 20 production by T cells. PERSON:Randi Vita, James Overton, Bjoern Peters IEDB CCL20/MIP-3a release|cytometric bead array cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells OBI:0002134 assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells A T cell epitope specific cytokine production assay that detects chemokine (C-C motif) ligand 20 production by T cells. PERSON:Randi Vita, James Overton, Bjoern Peters IEDB CCL20/MIP-3a release|biological activity assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells OBI:0002140 temperature measurement assay An assay to determine the temperature of an evaluant. Bjoern Peters Chris Stoeckert OBI temperature measurement assay OBI:0002141 volume measurement assay An assay to determine the volume of an evaluant. Bjoern Peters Chris Stoeckert OBI volume measurement assay OBI:0002142 Nanostring nCounter miRNA expression assay A microRNA profiling assay using digital molecular barcoding technology to quantify target microRNA molecules without the need for amplification. Chris Stoeckert Jason Hilton microRNA counts PMID:26729350 url:http://www.nanostring.com/applications/technology https://github.com/obi-ontology/obi/issues/806 ENCODE DCC Nanostring nCounter miRNA expression assay OBI:0002143 bromouride labeling and sequencing after UV exposure An RNA-seq assay to identify transcription start sites and active enhancer elements through isolation of bromouridine (Bru) labelled RNAs after UV light exposure introduces transcription-blocking lesions. Chris Stoeckert Jason Hilton BruUV-seq PMC:4675984 https://github.com/obi-ontology/obi/issues/827 ENCODE DCC bromouride labeling and sequencing after UV exposure OBI:0002144 extrachromosomal circular DNA sequencing assay An assay which aims at identifying the endogenous population of extrachromosomal circular DNA originating from a subset of genomic loci and potentially having profound consequences on the regulatory and coding capabilities of these regions. The assay includes creation of a library out of the circular DNA molecules and subsequent sequencing using parallelized sequencing methods. Chris Stoeckert Jason Hilton circulome-seq eccDNA-seq url:http://biorxiv.org/content/early/2017/04/19/128686 https://github.com/obi-ontology/obi/issues/830 ENCODE DCC extrachromosomal circular DNA sequencing assay OBI:0002145 antigen specific antibodies assay Test performed using antibodies produced by human B-cells that bind with human immunodeficiency virus (HIV) antigens An analyte assay that measures the presence or amount of antibodies to a specified antigen. Bjoern Peters Chris Stoeckert James Overton Randi Vita OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB antigen specific antibodies assay OBI:0002146 HIV antibody assay An antigen specific antibodies assay that is meant to detect antibodies that bind to human immunodeficiency virus (HIV) antigens. HIV-1 and HIV-2 are two different viruses (http://i-base.info/qa/36) Bjoern Peters Chris Stoeckert James Overton Randi Vita HIV I/II Ab assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB HIV antibody assay OBI:0002147 HIV group O antibody assay An antigen specific antibodies assay that is meant to detect antibodies that bind to human immunodeficiency virus (HIV) group O antigens. https://www.cdc.gov/mmwr/preview/mmwrhtml/00042810.htm Bjoern Peters Chris Stoeckert James Overton Randi Vita HIV I/II Plus O assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB HIV group O antibody assay OBI:0002148 surface HBV antibody assay An antigen specific antibodies assay that is meant to detect antibodies that bind to hepatitis B virus (HBV) surface antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita HBsAb assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB surface HBV antibody assay OBI:0002149 core HBV antibody assay An antigen specific antibodies assay that is meant to detect antibodies that bind to hepatitis B virus (HBV) core antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita HBcAb assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB core HBV antibody assay OBI:0002150 core HBV IgM antibody assay An antigen specific antibodies assay that is meant to detectimmunoglobulin M (IgM) antibodies that bind to hepatitis B virus (HBV) core antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita HBcAb-IgM assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB core HBV IgM antibody assay OBI:0002151 HCV antibody assay An antigen specific antibodies assay that is meant to detect antibodies that bind to Hepacivirus C (HCV) antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita HCV Ab assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB HCV antibody assay OBI:0002152 EBV IgG antibody assay An antigen specific antibodies assay that is meant to detect immunoglobulin G (IgG) antibodies that bind to Epstein-Barr virus (EBV) antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita EBV IgG Ab assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB EBV IgG antibody assay OBI:0002153 EBV IgM antibody assay An antigen specific antibodies assay that is meant to detect immunoglobulin M (IgM) antibodies that bind to Epstein-Barr virus (EBV) antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita EBV IgM Ab assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB EBV IgM antibody assay OBI:0002154 CMV antibody assay An antigen specific antibodies assay that is meant to detect antibodies that bind to cytomegalovirus (CMV) antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita CMV Ab assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB CMV antibody assay OBI:0002155 venereal disease research laboratory test An analyte assay that is meant to detect general antibodies that react with substances that are produced by cellular damage caused by Treponema pallidum indicating a syphilis infection. VDRL tests require a microscope and can be done on cerebrospinal fluid as well as blood. Bjoern Peters Chris Stoeckert James Overton Randi Vita VDRL test OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB venereal disease research laboratory test OBI:0002156 rapid plasma reagin test An analyte assay that is meant to detect with the aid of carbon or charcoal particles general antibodies that react with substances that are produced by cellular damage caused by Treponema pallidum indicating a syphilis infection. RPR tests can be done without a microscope. Bjoern Peters Chris Stoeckert James Overton Randi Vita RPR assay url:http://www.differencebetween.net/science/health/difference-between-vdlr-and-rpr/ https://github.com/obi-ontology/obi/issues/825 NCI BBRB rapid plasma reagin test OBI:0002157 HBV surface antigen assay An analyte assay that is meant to detect hepatitis B virus (HBV) surface antigens. Bjoern Peters Chris Stoeckert James Overton Randi Vita HBsAg assay OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB HBV surface antigen assay OBI:0002158 HIV-1 nucleic acid testing An analyte assay that is meant to detect human immunodeficiency virus (HIV-1) nucleic acids. Bjoern Peters Chris Stoeckert James Overton Randi Vita HIV-1 NAT OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB HIV-1 nucleic acid testing OBI:0002159 HCV nucleic acid testing An analyte assay that is meant to detect hepatitis C virus (HCV) nucleic acids. Bjoern Peters Chris Stoeckert James Overton Randi Vita HCV NAT OBI https://github.com/obi-ontology/obi/issues/825 NCI BBRB HCV nucleic acid testing OBI:0002160 multiplexed indexed T7 ChIP-seq assay A ChIP-seq assay which leverages T7 promoter amplification to allow low sample input and chromatin barcoding and pool-and-split multiplexing for high-throughput, quantitative profiling of chromatin states. Chris Stoeckert Jason Hilton Mint-ChIP Mint-ChIP-seq url:http://www.cell.com/molecular-cell/abstract/S1097-2765(15)00863-1 https://github.com/obi-ontology/obi/issues/829 ENCODE DCC multiplexed indexed T7 ChIP-seq assay OBI:0002161 systematic evolution of ligands by exponential enrichment assay A binding assay that identifies protein-binding sites on nucleic acids by selecting high-affinity target ligands from a randomized pool. The process is repeated in rounds, then the bound nucleic acids are separated from the unbound nucleic acids and amplified by PCR._ Rebecca Jackson SELEX PMID:21720957 systematic evolution of ligands by exponential enrichment assay OBI:0002162 footprinting assay An assay that measures ligand binding and conformational changes by the solvent accessibility of the backbone, bases, or side-chain structures of macromolecules through their sensitivity to chemical or enzymatic cleavage or modification reactions. Bjoern Peters doi:10.1002/3527600906.mcb.200300025 footprinting assay OBI:0002163 DNAse footprinting assay An enzymatic footprinting assay that determines protein-binding sites on DNA by identifying bound fragments that are protected from DNAse I-catalyzed hydrolysis Rebecca Jackson OBI development call DNAse footprinting assay OBI:0002164 mammalian 2-hybrid assay A binding assay that increases the expression of a reporter gene in mammalian cells by proteins of interest attached to two portions of the transcriptional activator, bringing those portions closer together. Rebecca Jackson ECO:0001095 PMID:9043710 mammalian 2-hybrid assay OBI:0002165 protein localization assay An assay that determines the specific location of a protein. Subcellular localization is distinguished from tissue-based localization based on the type of microscopy applied. Rebecca Jackson OBI development call protein localization assay OBI:0002166 tissue-based protein localization assay A protein localization assay that determines the specific location of a protein in a living tissue sample. Rebecca Jackson PMID:14686950 tissue-based protein localization assay OBI:0002167 subcellular protein localization assay A protein localization assay that determines the specific subcellular location of a protein. The location is visualized through electron microscopy. Rebecca Jackson ECO subcellular protein localization assay OBI:0002168 subcellular protein immunohistochemistry assay An immunohistochemistry assay that uses antibodies to display the specific subcellular location of proteins. Rebecca Jackson ECO subcellular protein immunohistochemistry assay OBI:0002169 ChIP-qPCR assay A ChIP assay that uses quantitative PCR to determine levels of specific DNA in immunoprecipitated samples. Chris Stoeckert PMID:18388953 ChIP-qPCR assay OBI:0002170 genomic SELEX A systematic evolution of ligands by exponential enrichment assay that starts with a library derived from genomic DNA instead of synthetically derived random DNA molecules. Chris Stoeckert PMID:20541015 genomic SELEX OBI:0002171 dot blot assay An analyte assay that detects molecules in a mixture dotted on a membrane using DNA probes or antibodies. Bjoern Peters dot blot analysis PMID:10473518 dot blot assay OBI:0002172 Northwestern blot assay A direct binding assay that detects interactions of labeled RNA with immobilized protein on a membrane. Bjoern Peters Northwestern analysis Northwestern assay PMID:26965261 Northwestern blot assay OBI:0002173 Southwestern blot assay A direct binding assay that detects interactions of labeled DNA with immobilized protein on a membrane. Bjoern Peters PMID:26404144 Southwestern blot assay OBI:0002174 immunocytochemistry An immuno staining assay in which samples of intact cells are examined that have had most, if not all, of their surrounding extracellular matrix removed Bjoern Peters immunocytochemistry OBI:0002175 ATP bioluminescence assay An analyte assay that detects ATP concentration through light intensity when luciferase catalyzes the oxidation of luciferin in the presence of ATP, magnesium ions, and molecular oxygen. Rebecca Jackson ATP quantitation assay cell viability ATP quantitation assay ECO ATP bioluminescence assay OBI:0002176 electrophysiology assay An assay that measures the electrical properties of biological cells or tissues. Typically, this assay will generate measurements of voltage changes or electric current (or other associated variables such as impedence or capacitance). Note that electrophysiological manipulations also exist which involve processes that alter the electrophysiological properties of cells and tissues. Gully Burns url:https://en.wikipedia.org/wiki/Electrophysiology electrophysiology assay OBI:0002177 patch clamp assay An intracellular electrophysiology assay where a glass micropipette is sealed to the surface of the cell membrane as a recording electrode to study ion channel activity. The key distinction of this technique is the electrical resistance of the seal between the cell membrane and the pipette is of the order 10-100 gigaohms, permitting high-resolution current measurements over the cell membrane in several different standard configurations. Gully Burns ECO:0006012 url:http://www.annualreviews.org/doi/pdf/10.1146/annurev.ph.46.030184.002323 url:https://en.wikipedia.org/wiki/Patch_clamp patch clamp assay OBI:0002178 whole-cell patch clamp assay A patch-clamp assay where the electrode is left in place on the cell, as in cell-attached recordings, but the membrane patch has been perforated, providing access from the interior of the pipette to the intracellular space of the cell. Measurements made with this technique involve recording currents through multiple channels simultaneously, over the membrane of the entire cell. Gully Burns ECO:0006015 url:https://en.wikipedia.org/wiki/Patch_clamp#Whole-cell_recording_or_whole-cell_patch whole-cell patch clamp assay OBI:0002179 cell-attached patch clamp assay A patch-clamp assay where the electrode is left in place on the cell, and the membrane patch has been left intact been perforated. This maintains the separation of the interior of the pipette to the intracellular space of the cell. Measurements made with this technique involve recording currents through multiple channels simultaneously, over the membrane of the entire cell. Gully Burns url:https://en.wikipedia.org/wiki/Patch_clamp#Cell-attached_patch cell-attached patch clamp assay OBI:0002180 inside-out patch clamp assay A patch-clamp assay where a patch of the membrane is attached to the patch pipette, detached from the rest of the cell, and the cytosolic surface of the membrane is exposed to the external media, or bath. This provides the experimenter has access to the intracellular surface of the membrane via the bath and can manipulate the environment at the intracellular surface of single ion channels. For example, channels that are activated by intracellular ligands can then be studied through a range of ligand concentrations. Gully Burns url:http://www.leica-microsystems.com/science-lab/the-patch-clamp-technique/ url:https://en.wikipedia.org/wiki/Patch_clamp#Inside-out_patch inside-out patch clamp assay OBI:0002181 outside-out patch clamp assay A patch-clamp assay where a patch of the membrane is attached to the patch pipette. In this configuration, the external surface of the cell membrane is exposed as the outside of the membrane patch relative to the patch electrode. An outside-out patch starts with a gigaohm seal in a whole-cell recording configuration. The electrode is slowly withdrawn from the cell, until a fragment of membrane bulges away from the cell, which detaches and reforms as a convex membrane on the end of the electrode, with the original external surface of the membrane facing outward from the electrode. This provides the experimenter with access to the extracellular surface of the membrane via the bath and can manipulate the environment at the extracellular surface of single ion channels. Gully Burns url:http://www.leica-microsystems.com/science-lab/the-patch-clamp-technique/ url:https://en.wikipedia.org/wiki/Patch_clamp#Outside-out_patch outside-out patch clamp assay OBI:0002182 voltage clamp assay An cellular electrophysiology assay where the membrane potential of a cell is controlled by the experimentalist. This is accomplished through a feedback mechanism where any change in membrane potential is countered by permitting electrical current to flow into or out of the cell. Gully Burns url:https://en.wikipedia.org/wiki/Voltage_clamp voltage clamp assay OBI:0002183 two electrode voltage clamp assay The two electrode voltage clamp (TEVC) method utilizes two low-resistance pipettes, one sensing voltage and the other injecting current. The microelectrodes are filled with conductive solution and inserted into the cell to artificially control membrane potential. The membrane acts as a dielectric as well as a resistor, while the fluids on either side of the membrane function as capacitors.[9] The microelectrodes compare the membrane potential against a command voltage, giving an accurate reproduction of the currents flowing across the membrane. Current readings can be used to analyze the electrical response of the cell to different applications. This technique is mainly used in the Oocyte preparation. Gully Burns TEVC url:https://en.wikipedia.org/wiki/Voltage_clamp#Two-electrode_voltage_clamp_using_microelectrodes two electrode voltage clamp assay OBI:0002184 cut open oocyte voltage clamp assay The cut-open oocyte Vaseline gap (COVG) voltage-clamp technique is designed to solve weaknesses in the two elextrode voltage clamp by maximizing the benefits of the Xenopus oocyte expression system by improving on clamp speed, signal-to-noise ratio, and ability to effectively perfuse the oocyte. In this way, it was possible to combine the most popular transient expression system, and the associated benefits of molecular cloning and site-directed mutagenesis, with the superior voltage-clamp properties of cut-open cell techniques. Gully Burns COVG PMID:9711615 cut open oocyte voltage clamp assay OBI:0002185 current clamp assay The current clamp technique records the membrane potential by injecting current into a cell through the recording electrode. Unlike in the voltage clamp mode, where the membrane potential is held at a level determined by the experimenter, in "current clamp" mode the membrane potential is free to vary, and the amplifier records whatever voltage the cell generates on its own or as a result of stimulation. This technique is used to study how a cell responds when electric current enters a cell; this is important for instance for understanding how neurons respond to neurotransmitters that act by opening membrane ion channels. Gully Burns url:https://en.wikipedia.org/wiki/Electrophysiology#Current_clamp current clamp assay OBI:0002186 electroencephalography An extracellular electrophysiology assay where electrodes are mounted outside the brain (either on the surface of the scalp on onto the brain surface itself during surgery) to measure the electrical field over the external surface. Gully Burns EEG electroencephalography OBI:0002187 single-unit recording An extracellular electrophysiology assay where a single microelectrode is placed in close proximity to a single neuron to measure voltage and current changes over time. This is the technicque used by Hubel and Wiesel to measure firing properties of primary visual cortex neurons in the 1950s in their original Nobel-prize winning study. A classic, old technique. Can be used on any cell, not just neurons. Gully Burns url:http://www.thieme.com/media/samples/pubid-80418214.pdf single-unit recording OBI:0002188 multi-unit recording An extracellular electrophysiology assay where a collection of microelectrodes (often in an 'array' configuration) is placed into neural tissue to measure the distribution of voltage and current changes for a population of cells over time. Gully Burns multi-unit recording OBI:0002189 local field potential recording An extracellular electrophysiology assay where a microelectrode is placed in the extracellular space of brain tissue to measure action potential and compared to an electrode either outside or inside that tissue. Gully Burns doi:10.1007/978-1-4614-7320-6_723-1 local field potential recording OBI:0002436 RNA interactome capture An assay that identifies RNA binding proteins by cross-linking RNA and proteins with UV light, then purifying the bound complexes by oligo(dT) capture. Finally, the complexes are analyzed by mass spectrometry. Rebecca Jackson PMID:26463381 RNA interactome capture OBI:0002437 widefield microscopy assay A fluorescence microscopy technique where the specimen under investigation is fully bathed in light, as opposed to confocal microscopy in which only a small portion of the specimen is illuminated. Jie Zheng WFM url:http://bitesizebio.com/19409/the-many-flavors-of-widefield-microscopy/ url:https://svi.nl/WideFieldMicroscope widefield microscopy assay OBI:0002438 nuclear ligation assay An assay that detects the proximity of chromosomal DNA through the use of a ligation reaction in isolated nuclei. Chris S PMID:8327891 nuclear ligation assay OBI:0002439 chromosome conformation capture assay A nuclear ligation assay that detects chromosomal interactions between any two genomic loci. Chromatin segments are cross-linked, cut by restriction enzymes, ligated, and finally analyzed by PCR. Chris S 3C assay PMID:11847345 url:http://www.nature.com/nprot/journal/v2/n7/full/nprot.2007.243.html chromosome conformation capture assay OBI:0002440 Hi-C assay A chromosome conformation capture assay that detects genome-wide chromosomal interactions. High-throughput techniques are used to sequence the ligated fragments after cross-linking and cutting with restriction enzymes. Chris S PMID:20461051 Hi-C assay OBI:0002441 physical examination of individual An assay that produces a description of the qualities of an entity that has not been transformed, through observation and physical, non-invasive techniques. physical examination of individual OBI:0002442 hydroxyl-radical footprinting assay A footprinting assay that uses the reaction of hydroxyl radicals with side-chain sites in molecules (proteins, DNA, etc)_ with the resultant mass shift demonstrating the site of modification, used to_ to asses the accessibility of that site. Jie Zheng PMID:21770468 hydroxyl-radical footprinting assay OBI:0002443 methidiumpropyl-EDTA-iron(II) footprinting assay A footprinting assay that determines protein-binding sites on DNA by partial cleavage of ligand-protected DNA restriction fragments with methidium-propyl-EDTA (MPE). MPE-Fe(II) in the presence of oxygen efficiently catalyzes the non-specific clevage of DNA. Jie Zheng MPE-Fe(II) footprinting PMID:6225070 PMID:6435669 methidiumpropyl-EDTA-iron(II) footprinting assay OBI:0002445 transcription start site mapping by primer extension assay A transcription profiling assay in which the transcription start site for a gene is determined by identifying the 5' end of mRNA. A radio-labeled primer is annealed to a complementary mRNA sequence near the 3' end, then cDNA is synthesized until the 5' end is reached. Rebecca Jackson PMID:23378648 url:https://en.wikipedia.org/wiki/Primer_extension transcription start site mapping by primer extension assay OBI:0002449 footprinting assay measuring binding of a B cell epitope:antibody complex A footprinting assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, James Overton, Bjoern Peters IEDB qualitative binding|footprinting assay footprinting assay measuring binding of a B cell epitope:antibody complex OBI:0002450 hydroxyl-radical footprinting assay measuring binding of a B cell epitope:antibody complex A hydroxyl-radical footprinting assay that detects the binding of an antigen with an antibody. PERSON:Randi Vita, James Overton, Bjoern Peters IEDB qualitative binding|hydroxyl-radical footprinting assay hydroxyl-radical footprinting assay measuring binding of a B cell epitope:antibody complex OBI:0002451 ELISA measuring epitope specific interferon-alpha production by T cells An enzyme-linked immunosorbent assay that detects interferon-alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNa release|ELISA ELISA measuring epitope specific interferon-alpha production by T cells OBI:0002452 assay measuring epitope specific interferon-alpha production by T cells A T cell epitope specific cytokine production assay that detects interferon-alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNa release|biological activity assay measuring epitope specific interferon-alpha production by T cells OBI:0002457 precision nuclear run-on sequencing assay An RNA-seq assay that maps the genome-wide distribution of transcriptionally-engaged Pol II at base-pair resolution by using biotin-labeled ribonucleotide triphosphate analogs (biotin-NTP) for nuclear run-on reactions, allowing the efficient affinity purification of nascent RNAs for high throughput sequencing from their 3' ends. Rebecca Jackson PRO-Seq precision nuclear run-on and sequencing assay PMID:23430654 https://github.com/obi-ontology/obi/issues/876 precision nuclear run-on sequencing assay OBI:0002458 chromosome conformation capture-on-chip assay A nuclear ligation assay which uses cross-linking of proteins to proteins and DNA, followed by two rounds of digestion and ligation, inverse PCR, and characterization by microarray or DNA sequencing. This enables unbiased genome-wide screens for DNA contacts made by single genomic sites of interest. Rebecca Jackson 4C assay circularized chromosome conformation capture assay url:http://www.sciencedirect.com/science/article/pii/B9780123919380000045 https://github.com/obi-ontology/obi/issues/875 chromosome conformation capture-on-chip assay OBI:0002459 genotype phasing by Hi-C assay A genotyping assay in which carbon-copy chromosome conformation is used to detect polymorphism in DNA samples. Rebecca Jackson haplotype reconstruction by Hi-C assay PMID:19815776 url:https://www.nature.com/articles/nbt.2728 https://github.com/obi-ontology/obi/issues/828 genotype phasing by Hi-C assay OBI:0002485 transcript analysis by single-end sequencing assay A sequencing assay that incorporates single-end reads and sequencing technology to determine transcripts, gene structures, and gene expressions. Dan Berrios Junhyong Kim Stephen A. Fisher transcript analysis by single-end sequencing url:https://www.illumina.com/science/technology/next-generation-sequencing/paired-end-vs-single-read-sequencing.html transcript analysis by single-end sequencing assay OBI:0002488 pipette A device that is a laboratory tool commonly used in chemistry, biology and medicine to transport a measured volume of liquid, often as a media dispenser. Stephen A. Fisher, Junhyong Kim, Dan Berrios https://en.wikipedia.org/wiki/Pipette pipette OBI:0002489 differential medium assay An organism detection assay that uses a differential medium to achieve its objective. John Judkins EuPathDB, https://www.uwyo.edu/molb2210_lab/info/biochemical_tests.htm differential medium assay OBI:0002564 histopathology assay A histological assay that is intended to check for the presence or level of a specific disease. OBI histopathology assay OBI:0002571 polyA-selected RNA sequencing assay An RNA-seq assay to study transcriptomes through the enrichment of polyadenylated transcripts or removal of ribosomal RNA prior to high-throughput sequencing. Jason Hilton Mark A. Miller mRNA-seq url:https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-15-419 ENCODE polyA-selected RNA sequencing assay OBI:0002572 polyA-depleted RNA sequencing assay An RNA-seq assay to study non-polyadenylated transcripts, such as, but not exclusive to unspliced and circular isoforms, through the depletion of polyadenylated transcripts prior to high-throughput sequencing. Jason Hilton Mark A. Miller polyA-depleted RNA-seq url:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030733 url:http://www.tandfonline.com/doi/full/10.1080/15476286.2015.1110676 ENCODE polyA-depleted RNA sequencing assay OBI:0002575 isoform sequencing Novel transcript forms were assessed by isoform sequencing. A method for sequencing isoforms by enriching a cDNA library for full-length reads spanning entire transcript isoforms. ISO-seq url:http://www.pacb.com/blog/intro-to-iso-seq-method-full-leng/ isoform sequencing OBI:0002597 chromosome conformation capture sequencing assay A chromosome conformation capture-on-chip assay quantitates the products with multiplexed high-throughput sequencing. Rebecca Jackson 3C-seq assay PMID:23411633 https://github.com/obi-ontology/obi/issues/939 chromosome conformation capture sequencing assay OBI:0002621 reconstitution assay "In an attempt to define the mechanism of insulin-regulated glucose transporter 4 (Glut4) translocation, we have developed an in vitro reconstitution assay... insulin-induced Glut4 translocation can be reconstituted in vitro to a limited extent by using isolated membranes." (PMID:10611313) An assay in which a cellular process is replicated from the bottom-up using isolated components in order to observe how the components work together. Rebecca Jackson reconstitution experiment url:https://jcs.biologists.org/content/132/4/jcs227488 https://github.com/obi-ontology/obi/issues/1059 reconstitution assay OBI:0002622 in vitro transcription reconstitution assay An in vitro reconstituted mouse transcription system helped identify an NF-Y interacting promoter as essential for high-level expression from the R2 promoter. (PMID:11502214) A reconstitution assay in which RNA synthesis is investigated using RNA polymerase II transcription systems replicated in vitro from their base components. Rebecca Jackson PMID:9237163 https://github.com/obi-ontology/obi/issues/1059 in vitro transcription reconstitution assay OBI:0002623 whole metagenome sequencing assay A DNA sequencing assay that intends to provide information on the DNA sequences of multiple genomes (a metagenome) from different organisms present in the same input sample. Whole metagenome sequencing has been used to explore the composition and metabolic capability of communities of microbes found in the environment (e.g. in soil, water, etc.) and in humans and other species (e.g. in the gut, oral cavity, etc.). Rebecca Jackson WMS Bjoern Peters Michelle Giglio https://github.com/obi-ontology/obi/issues/1056 whole metagenome sequencing assay OBI:0002628 RNAi knockdown assay "Here, we described the development of RNAi by micro-injection of double-stranded RNA (dsRNA) in the pea aphid Acyrthosiphon pisum. Injection of dsRNA into whole aphid body induced the silencing of two marker genes with different expression patterns: the ubiquitously expressed Ap-crt genes encoding a calreticulin and the gut specific Ap-cath-L gene encoding a cathepsin-L." (PMID:17903251) A gene knockdown assay in which RNAi gene knockdown is used to disrupt gene transcripts. Rebecca Jackson RNA interference knockdown assay RNAi gene knockdown assay Rebecca Jackson https://github.com/obi-ontology/obi/issues/1057 RNAi knockdown assay OBI:0002629 direct RNA sequencing assay An assay to study transcription through direct RNA sequence determination, without prior conversion of RNA molecules to cDNA. Dan Berrios DRS direct RNA-seq url:https://www.nature.com/articles/nature08390 https://github.com/obi-ontology/obi/issues/874 jahilton direct RNA sequencing assay OBI:0002631 single-cell RNA sequencing assay Single-cell RNA sequencing (scRNA-seq) assays provide the expression profiles of individual cells. An RNA sequencing assay that uses RNA extracts as input that can be traced to a single cell of origin. Dan Berrios scRNA-seq Anna Maria Masci single-cell RNA sequencing assay OBI:0002634 in vivo assay measuring B cell epitope specific disease exacerbation resulting from the adoptive transfer of epitope specific antibodies or B cells An efficacy of B cell epitope intervention experiment that uses a disease exacerbation in vivo intervention experiment after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB disease exacerbation after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific disease exacerbation resulting from the adoptive transfer of epitope specific antibodies or B cells OBI:0002635 in vivo assay measuring T cell epitope specific disease reduction resulting from the adoptive transfer of epitope specific T cells An efficacy of T cell epitope intervention experiment that detects a decrease in disease after adoptive transfer of epitope specfic T cells. IEDB IEDB decreased disease after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific disease reduction resulting from the adoptive transfer of epitope specific T cells OBI:0002636 in vivo assay measuring B cell epitope specific disease reduction resulting from adoptive transfer of epitope specific antibodies or B cells An efficacy of B cell epitope intervention experiment that detects a decrease in disease after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB decreased disease after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific disease reduction resulting from adoptive transfer of epitope specific antibodies or B cells OBI:0002637 in vivo assay measuring T cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific T cells An efficacy of T cell epitope intervention experiment that uses a epitope protection experiment after adoptive transfer of epitope specfic T cells. IEDB IEDB protection from challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific T cells OBI:0002638 in vivo assay measuring B cell epitope specific protection from challenge resulting from adoptive transfer of epitope specific antibodies or B cells An efficacy of B cell epitope intervention experiment that uses a epitope protection experiment after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB protection from challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from challenge resulting from adoptive transfer of epitope specific antibodies or B cells OBI:0002639 in vivo assay measuring T cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific T cells based on pathogen burden An in vivo assay measuring T cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific antibodies or B cells using pathogen burden. IEDB IEDB pathogen burden after challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific T cells based on pathogen burden OBI:0002640 in vivo assay measuring B cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on pathogen burden An in vivo assay measuring B cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific antibodies or B cells using pathogen burden. IEDB IEDB pathogen burden after challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on pathogen burden OBI:0002641 in vivo assay measuring T cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific T cells based on survival An in vivo assay measuring T cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific T cells using survival. IEDB IEDB survival from other challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific T cells based on survival OBI:0002642 in vivo assay measuring B cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on survival An in vivo assay measuring B cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific antibodies or B cells using survival. IEDB IEDB survival from other challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on survival OBI:0002643 in vivo assay measuring T cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific T cells based on tumor burden An in vivo assay measuring T cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific T cells using tumor burden. IEDB IEDB tumor burden after challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific T cells based on tumor burden OBI:0002644 in vivo assay measuring B cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on tumor burden An in vivo assay measuring B cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific antibodies or B cells using tumor burden. IEDB IEDB tumor burden after challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on tumor burden OBI:0002645 in vivo assay measuring T cell epitope specific tolerance induction resulting from the adoptive transfer of epitope specific T cells An efficacy of T cell epitope intervention experiment that uses a tolerance induction intervention experiment after adoptive transfer of epitope specfic T cells. IEDB IEDB tolerance after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific tolerance induction resulting from the adoptive transfer of epitope specific T cells OBI:0002646 in vivo assay measuring B cell epitope specific tolerance induction resulting from the adoptive transfer of epitope specific antibodies or B cells An efficacy of B cell epitope intervention experiment that uses a tolerance induction intervention experiment after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB tolerance after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific tolerance induction resulting from the adoptive transfer of epitope specific antibodies or B cells OBI:0002647 Giemsa stain assay Cytogenetics; the histopathological diagnosis of malaria and other parasites; differentiate nuclear and cytoplasmic morphology of the various blood cells like platelets, RBCs, WBCs An assay that uses a Giemsa stain to characterize cells. Chris Stoeckert Jie Zheng https://github.com/obi-ontology/obi/issues/1093 VEuPathDB Giemsa stain assay OBI:0002649 blood microbiology assay An organism detection assay that detects microorganisms in a blood specimen. John Judkins https://github.com/obi-ontology/obi/issues/1064 blood microbiology assay OBI:0002664 cytometric bead array assay measuring epitope specific interleukin-15 production by T cells A cytometric bead array assay that detects interleukin-15 production by T cells. IEDB IEDB IL-15 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-15 production by T cells OBI:0002665 cytometric bead array assay measuring epitope specific interleukin-16 production by T cells A cytometric bead array assay that detects interleukin-16 production by T cells. IEDB IEDB IL-16 release|cytometric bead array cytometric bead array assay measuring epitope specific interleukin-16 production by T cells OBI:0002666 in vivo assay measuring B cell epitope specific induction of hypersensitivity resulting from the adoptive transfer of epitope specific antibodies or B cells An efficacy of B cell epitope intervention experiment that detects a hypersensitivity response by monitoring skin reactions after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB hypersensitivity after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific induction of hypersensitivity resulting from the adoptive transfer of epitope specific antibodies or B cells OBI:0002667 in vivo skin test assay measuring T cell epitope specific type IV hypersensitivity resulting from the adoptive transfer of epitope specific T cells An efficacy of T cell epitope intervention experiment that detects epitope specific type IV hypersensitivity after adoptive transfer of epitope specfic T cells. IEDB IEDB type IV hypersensitivity (DTH) after adoptive transfer|in vivo skin test in vivo skin test assay measuring T cell epitope specific type IV hypersensitivity resulting from the adoptive transfer of epitope specific T cells OBI:0002668 in vivo assay measuring epitope specific proliferation of T cells resulting from the adoptive transfer of epitope specific T cells A T cell epitope specific proliferation assay that is performed in vivo after adoptive transfer of epitope specfic T cells. IEDB IEDB proliferation after adoptive transfer|in vivo assay in vivo assay measuring epitope specific proliferation of T cells resulting from the adoptive transfer of epitope specific T cells OBI:0002669 assay measuring epitope specific helper T cell enhancement of a B cell mediated immune response resulting from the adoptive transfer of epitope specific T cells A T cell epitope specific helper activity assay that detects the ability of a T cell epitope to enhance an antibody response after adoptive transfer of epitope specfic T cells. IEDB IEDB antibody help after adoptive transfer|in vivo assay assay measuring epitope specific helper T cell enhancement of a B cell mediated immune response resulting from the adoptive transfer of epitope specific T cells OBI:0002670 assay measuring epitope specific helper T cell enhancement of a T cell mediated immune response resulting from the adoptive transfer of epitope specific T cells A T cell epitope specific helper activity assay that detects the ability of a T cell epitope to enhance a T cell response after adoptive transfer of epitope specfic T cells. IEDB IEDB T cell help after adoptive transfer|in vivo assay assay measuring epitope specific helper T cell enhancement of a T cell mediated immune response resulting from the adoptive transfer of epitope specific T cells OBI:0002671 in vivo assay measuring epitope specific T cell killing resulting from the adoptive transfer of epitope specific T cells An in vivo cell killing assay that detects the killing of an antigen presenting cell (APC) by a T cell whose TCR recognizes an epitope presented by the APC after adoptive transfer of epitope specific T cells. IEDB IEDB cytotoxicity after adoptive transfer|in vivo assay in vivo assay measuring epitope specific T cell killing resulting from the adoptive transfer of epitope specific T cells OBI:0002672 ELISA measuring epitope specific perforin release by T cells An enzyme-linked immunosorbent assay that detects epitope specific perforin release by T cells. IEDB IEDB perforin release|ELISA ELISA measuring epitope specific perforin release by T cells OBI:0002675 massively parallel reporter assay An assay in which multiplexing the construction and interrogation of larger libraries of reporter constructs allows measurement of the transcriptional regulatory activities of thousands to hundreds of thousands of DNA sequences. Damion Dooley MPRA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364389/ massively parallel reporter assay OBI:0002676 in vivo assay measuring a T cell epitope specific response after adoptive transfer of epitope specific T cells An efficacy of T cell epitope intervention experiment that is performed after adoptive transfer of epitope specfic T cells. IEDB IEDB in vivo response after adoptive transfer|in vivo assay in vivo assay measuring a T cell epitope specific response after adoptive transfer of epitope specific T cells OBI:0002677 in vivo assay measuring a B cell epitope specific response after adoptive transfer of epitope specific antibodies or B cells An efficacy of B cell epitope intervention experiment that is performed after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB in vivo response after adoptive transfer|in vivo assay in vivo assay measuring a B cell epitope specific response after adoptive transfer of epitope specific antibodies or B cells OBI:0002678 in vivo assay measuring T cell epitope specific disease exacerbation resulting from the adoptive transfer of epitope specific T cells An efficacy of T cell epitope intervention experiment that uses a disease exacerbation in vivo intervention experiment after adoptive transfer of epitope specfic T cells. IEDB IEDB disease exacerbation after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific disease exacerbation resulting from the adoptive transfer of epitope specific T cells OBI:0002680 pseudovirus entry assay “Inhibition of MERS-CoV-spike-mediated pseudovirus entry by the HKU4 S1 domain “ (from https://doi.org/10.1073/pnas.1405889111); “protease treatment did not enhance pseudotype entry in the absence of host receptor “; “bat-derived cell lines derived from other species were infected with VSV-reporter particles pseudotyped with chimeric spikes and luciferase was measured as readout for cell entry” (from https://doi.org/10.1038/s41564-020-0688-y) ; “teicoplanin could inhibit the entry of HIV-1-2019-nCoV-S pseudoviruses with the IC50 value of 1.66 uM” (from https://doi.org/10.1101/2020.02.05.935387) An assay that measures the entry in target cells of reporter viral particles that express an envelope protein of a different virus of interest. Thomas Lemberger pseudotype cell entry pseudotype entry pseudotyped particle cell entry assay pseudovirus cell entry Figure 1c in https://doi.org/10.1038/s41564-020-0688-y or Materials & Method in https://www.pnas.org/content/111/34/12516 pseudovirus entry assay OBI:0002692 polymerase chain reaction assay An assay that uses polymerase chain reaction technique to amplify DNA. VEuPathDB VEuPathDB https://github.com/obi-ontology/obi/issues/1117 VEuPathDB polymerase chain reaction assay OBI:0002693 restriction fragment length polymorphism assay An assay that uses digestion of DNA with specific restriction enzymes followed by gel electropheresis to detect differences in the sizes of the generated fragments that are due to genetic differences (polymorphisms) in homologous sequences. VEuPathDB RFLP restriction fragment length polymorphism restriction fragment length polymorphism analysis https://en.wikipedia.org/wiki/Restriction_fragment_length_polymorphism https://github.com/obi-ontology/obi/issues/1117 VEuPathDB restriction fragment length polymorphism assay OBI:0002694 DNA fingerprinting assay An assay to identify a specific individual organism from a DNA specimen by looking at unique patterns in their DNA. VEuPathDB DNA finger printing DNA fingerprint DNA fingerprinting DNA profiling VEuPathDB https://github.com/obi-ontology/obi/issues/1117 VEuPathDB DNA fingerprinting assay OBI:0002695 insecticide resistance assay An assay that aims to detect the presence and/or frequency of resistance to insecticides in an organism or organism population. VEuPathDB resistance identification/monitoring MIRO:20000001 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance assay OBI:0002696 insecticide resistance by monitoring known mutations assay An insecticide resistance assay that detects, in a population, presence and frequency of mutant alleles for previously characterized mutations with insecticide resistance phenotypes. VEuPathDB monitoring known mutations MIRO:20000096 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by monitoring known mutations assay OBI:0002697 insecticide resistance by detecting enzyme activity assay An insecticide resistance assay that is based on determination the catalytic activity of an enzyme associated with insecticide resistance phenotypes. VEuPathDB metabolic resistance assay MIRO:20000003 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by detecting enzyme activity assay OBI:0002698 insecticide resistance bioassay An insecticide resistance assay that is typically conducted to measure the effects of a substance on a living organism. VEuPathDB bioassay MIRO:20000058 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance bioassay OBI:0002699 insecticide resistance by detecting alpha esterase activity assay An insecticide resistance by detecting enzyme activity assay that measures activity of alpha esterase. VEuPathDB alpha esterase activity assay IRO:0000149 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by detecting alpha esterase activity assay OBI:0002700 insecticide resistance by detecting beta esterase activity assay An insecticide resistance by detecting enzyme activity assay that measures activity of beta esterase. VEuPathDB beta esterase activity assay IRO:0000150 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by detecting beta esterase activity assay OBI:0002701 insecticide resistance by detecting acetylcholinesterase activity assay An insecticide resistance by detecting enzyme activity assay that measures activity of acetylcholinesterase. VEuPathDB AChE activity assay AChE assay acetylcholinesterase assay MIRO:20000010 MIRO:20000084 MIRO:20000086 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by detecting acetylcholinesterase activity assay OBI:0002702 insecticide resistance by detecting glutathione S-transferase activity assay An insecticide resistance by detecting enzyme activity assay that measures activity of glutathione S-transferase (GST). VEuPathDB GST related assay MIRO:20000083 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by detecting glutathione S-transferase activity assay OBI:0002703 insecticide resistance by detecting carboxylic ester hydrolase activity assay An insecticide resistance by detecting enzyme activity assay that measures activity of carboxylic ester hydrolase using p-nitrophenyl acetate as a substrate. VEuPathDB pNPA assay MIRO:20000019 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by detecting carboxylic ester hydrolase activity assay OBI:0002704 insecticide resistance by detecting mixed-function oxidase assay An insecticide resistance by detecting enzyme activity assay that measures whether mixed-function oxidase activity present. VEuPathDB mixed-function oxidase assay MIRO:20000062 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by detecting mixed-function oxidase assay OBI:0002705 direct insecticide resistance bioassay An insecticide resistance bioassay without the use of any synergist. VEuPathDB direct bioassay MIRO:20000044 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB direct insecticide resistance bioassay OBI:0002706 topical application insecticide resistance bioassay An insecticide resistance bioassay by adding insecticide directly to the thorax of the insect. VEuPathDB topical application assay IRO:0000155 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB topical application insecticide resistance bioassay OBI:0002707 direct insecticide resistance diagnostic assay A direct insecticide resistance assay that at preset insecticide dosage scoring mortality to determine resistance of a population. VEuPathDB diagnostic test MIRO:20000075 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB direct insecticide resistance diagnostic assay OBI:0002708 insecticide resistance dose response assay A direct insecticide resistance assay in which an insect population is exposed to a range of insecticide dosage scoring mortality to determine resistance. VEuPathDB dose response test MIRO:20000076 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance dose response assay OBI:0002709 insecticide resistance time response assay A direct insecticide resistance assay to determine resistance as a consequence of the time of exposure to insecticide. VEuPathDB time response test MIRO:20000013 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance time response assay OBI:0002710 Centre for Disease Control and Prevention bottle bioassay A direct insecticide resistance diagnostic assay performs in a glass bottle coated with insecticides for detecting resistance to insecticides in vector populations. VEuPathDB CDC bottle bioassay MIRO:20000009 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB Centre for Disease Control and Prevention bottle bioassay OBI:0002711 WHO cone kit diagnostic assay A direct insecticide resistance diagnostic assay uses WHO cone kit. VEuPathDB cone DT MIRO:20000039 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB WHO cone kit diagnostic assay OBI:0002712 WHO paper kit diagnostic assay A direct insecticide resistance diagnostic assay uses WHO paper kit. VEuPathDB WHO paper kit DT MIRO:20000041 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB WHO paper kit diagnostic assay OBI:0002713 WHO larvicide diagnostic assay A direct insecticide resistance diagnostic assay tests survival of larvae in a medium supplemented with insecticide. VEuPathDB WHO larvicide DT MIRO:20000049 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB WHO larvicide diagnostic assay OBI:0002714 insecticide resistance dose response by bottle assay An insecticide resistance dose response assay that performs in a glass bottle coated with insecticides. VEuPathDB bottle bioassay DR test MIRO:20000011 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance dose response by bottle assay OBI:0002715 insecticide resistance dose response by survival of larvae assay An insecticide resistance dose response assay that tests survival of larvae in a medium supplemented with insecticide. VEuPathDB WHO larvicide DR test MIRO:20000050 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance dose response by survival of larvae assay OBI:0002716 insecticide resistance dose response by WHO paper kit assay An insecticide resistance dose response assay using WHO paper kit. VEuPathDB WHO paper kit DR test MIRO:20000048 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance dose response by WHO paper kit assay OBI:0002717 insecticide resistance time response by bottle assay An insecticide resistance time response assay that is performed in a glass bottle coated with insecticides, with the presence of a synergist. VEuPathDB bottle bioassay TR test MIRO:20000030 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance time response by bottle assay OBI:0002718 insecticide resistance time response by WHO paper kit assay An insecticide resistance time response assay using WHO paper kit, with the presence of a synergist. VEuPathDB WHO paper kit TR test MIRO:20000036 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance time response by WHO paper kit assay OBI:0002719 insecticide resistance by amplification refractory mutation system assay An insecticide resistance by monitoring known mutations assay that detects any mutation involving single base changes or small deletions using amplification refractory mutation system (ARMS). The ARMS is based on the use of sequence-specific PCR primers that allow amplification of test DNA only when the target allele is contained within the sample. Following an ARMS reaction the presence or absence of a PCR product is diagnostic for the presence or absence of the target allele. It can be used to analyze human genomic DNA for one or more mutations. VEuPathDB ARMS Amplification Refractory Mutation System IRO:0000006 PMID: 18428319 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by amplification refractory mutation system assay OBI:0002720 insecticide resistance by primer introduced restriction analysis PCR assay An insecticide resistance by monitoring known mutations assay that detects Single Nucleotide Polymorphisms (SNPs) using PCR technique and mismatched primers that is close to the mutation of interest and digested the PCR productions using restriction enzymes. VEuPathDB PIRA-PCR Primer Introduced Restriction Analysis PCR polymerase chain reaction-primer-introduced restriction analysis IRO:0000007 PMID: 8339229 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by primer introduced restriction analysis PCR assay OBI:0002721 insecticide resistance by nested polymerase chain reaction assay An insecticide resistance by monitoring known mutations assay that detects gene mutation based on nested polymerase chain reaction technique. VEuPathDB gene mutation detection by nested PCR IRO:0000127 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by nested polymerase chain reaction assay OBI:0002722 insecticide resistance by ligase detection reaction assay An insecticide resistance assay that is based on monitoring known mutations using ligase detection reaction exquisitely discriminate between a mismatched and complementary DNA helix. VEuPathDB MIRO:20000103 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by ligase detection reaction assay OBI:0002723 insecticide resistance by ligase detection reaction-fluorescent microsphere assay An insecticide resistance by ligase detection reaction assay that uses fluorescently labeled conserved probes in ligase detection reaction. VEuPathDB gene mutation detection by LDR-FMA ligase detection reaction-fluorescent microsphere assay IRO:0000151 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by ligase detection reaction-fluorescent microsphere assay OBI:0002724 insecticide resistance by PCR amplification of specific alleles assay An insecticide resistance assay that is based on monitoring known mutations by PCR amplification of specific alleles to detect polymorphic or mutant alleles. VEuPathDB PASA PCR amplification of specific alleles allele-specific amplification and amplification refractory mutation system PMID: 1734929 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by PCR amplification of specific alleles assay OBI:0002725 insecticide resistance by fluorogenic PCR assay An insecticide resistance assay that is based on monitoring known mutations by PCR technique that uses target specific probes labeled with fluorogenic chromophores to detect gene mutation. VEuPathDB MIRO:20000102 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by fluorogenic PCR assay OBI:0002726 insecticide resistance by PCR-RFLP assay An insecticide resistance by monitoring known mutations assay based on restriction fragment length polymorphism assay. VEuPathDB PCR-RFLP MIRO:20000113 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by PCR-RFLP assay OBI:0002727 insecticide resistance by short interspersed elements PCR assay An insecticide resistance assay that is based on monitoring known mutations by PCR amplification of short interspersed elements (SINEs). VEuPathDB Short Interspersed Elements PCR IRO:0000013 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB insecticide resistance by short interspersed elements PCR assay OBI:0002728 pathogen detection assay An organism detection assay that detects pathogens. VEuPathDB pathogen detection method IRO:0000137 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB pathogen detection assay OBI:0002729 VectorTest assay A pathogen detection assay that identifies the presence or absence of specific peptide epitopes of circumsporozoite (CS) protein of the most important Plasmodium falciparum and two strains (variants 210 and 247) of the more widespread Plasmodium vivax using a dipstick wicking test strip. VEuPathDB VectorTest IRO:0000138 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB VectorTest assay OBI:0002730 pathogen detection by Rapid Analyte Measurement Platform assay A pathogen detection assay that is based on Rapid Analyte Measurement Platform (RAMP) technology to quantify immunologically active substances. VEuPathDB Rapid Analyte Measurement Platform IRO:0000164 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB pathogen detection by Rapid Analyte Measurement Platform assay OBI:0002731 pathogen detection by loop-mediated isothermal amplification assay A pathogen detection assay that is based on loop-mediated isothermal amplification. VEuPathDB Loop-mediated isothermal amplification IRO:0000165 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB pathogen detection by loop-mediated isothermal amplification assay OBI:0002732 blood meal assay An assay that analyzes the specimen taken from blood meal fed organism, such as insect. VEuPathDB blood meal analysis IRO:0000135 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB blood meal assay OBI:0002733 blood meal by counter current immunoelectrophoresis assay A blood meal assay that uses a counter current immunoelectrophoresis technique. VEuPathDB CIE countercurrent immunoelectrophoresis IRO:0000136 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB blood meal by counter current immunoelectrophoresis assay OBI:0002734 DNA based blood meal finger printing assay A DNA fingerprinting assay that uses DNA extracted from blood meal fed organism, such as insect. VEuPathDB DNA based blood meal finger printing VEuPathDB VSMO:0001307 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB DNA based blood meal finger printing assay OBI:0002735 organism detection by size assay An organism detection assay that is based on the size of organism. VEuPathDB by size IRO:0000145 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by size assay OBI:0002736 organism detection by cross mating assay An organism detection assay that is based on genetic crossings between specimens collected in the field to determine whether fertile progeny is produced. VEuPathDB cross mating experiment MIRO:30000036 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by cross mating assay OBI:0002737 organism detection by cytological chromosome examination assay An organism detection assay that is based on analysis of polytene chromosomes through cytological examination of the banding pattern of the species. VEuPathDB cytological chromosome examination MIRO:30000037 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by cytological chromosome examination assay OBI:0002738 organism detection by isoenzyme electrophoresis assay An organism detection assay that is based on electrophoresis to determine the isozymes that are present in a specific population to determine the species. VEuPathDB isoenzyme electrophoresis MIRO:30000038 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by isoenzyme electrophoresis assay OBI:0002739 organism detection by morphological examination assay An organism detection assay that is based on examination of morphology and the use of specific taxonomic keys to determine the species of the specimen. VEuPathDB morphological examination MIRO:30000039 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by morphological examination assay OBI:0002740 organism detection by PCR assay An organism detection assay that is based on PCR. VEuPathDB PCR-based species identification MIRO:30000040 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by PCR assay OBI:0002741 organism detection by specific DNA hybridization assay An organism detection assay that is based on DNA hybrdization. VEuPathDB species specific DNA hybridization MIRO:30000041 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by specific DNA hybridization assay OBI:0002742 organism detection by salinity tolerance assay An organism detection assay of mosquito species that is on the basis of mosquito survival depending on the salt concentration in the water used to lay their eggs to differentiate between morphologically very similar species. VEuPathDB salinity tolerance tests MIRO:30000042 https://github.com/obi-ontology/obi/issues/1117 VEuPathDB organism detection by salinity tolerance assay OBI:0002753 PRO-cap Precision nuclear run-on and sequencing to detect Pol II initiation sites Bonita Lam PRO-CAP https://github.com/obi-ontology/obi/issues/1102 PRO-cap OBI:0002759 ribosomal RNA-depleted RNA sequencing assay An RNA-seq assay in which highly abundant ribosomal RNAs are removed from total RNA before sequencing, resulting in more efficient transcript/gene detection. Michelle Giglio Rebecca Jackson Suvarna Nadendla rRNA-deleted RNA sequencing assay PMID:29556074 CFDE ribosomal RNA-depleted RNA sequencing assay OBI:0002760 metatranscriptome sequencing assay An RNA-seq assay that determines the RNA sequence of microbial transcripts from a microbioal community of mixed species from a given microbiome. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:31450270 CFDE metatranscriptome sequencing assay OBI:0002761 lipid profiling assay An analyte assay assay that detects and identifies lipids resulting from biochemical and cellular metabolism. Michelle Giglio Rebecca Jackson Suvarna Nadendla lipidomic assay OBI metabolite profiling assay CFDE lipid profiling assay OBI:0002762 single-nucleus ATAC-seq snATAC-seq can be used to dissect heterogeneity and delineate gene regulatory sequences in complex tissues, and uncover both the cell types and the regulatory elements in each cell type without prior knowledge. An ATAC-seq assay in which single nuclei are isolated from frozen tissue samples, through a protocol designed to maximally preserve nucleus integrity during sample processing and optimize transposase-mediated fragmentation of chromatin in individual nuclei. Mark Andrew Miller, ORCID:0000-0001-9076-6066 snATAC-seq http://www.biorxiv.org/content/early/2017/07/06/159137 https://github.com/obi-ontology/obi/issues/864 ENCODE single-nucleus ATAC-seq OBI:0002763 16s ribosomal gene sequencing assay An amplicon sequencing assay in which the amplicon is derived from universal primers used to amplify the 16S ribosomal RNA gene from isolate bacterial genomic DNA or metagenomic DNA from a microbioal community. Resulting sequences are compared to reference 16S sequence databases to identify or classify bacteria present within a given sample. Michelle Giglio Rebecca Jackson Suvarna Nadendla 16S rRNA sequencing assay PMID:31450270 CFDE 16s ribosomal gene sequencing assay OBI:0002764 single-cell ATAC-seq An ATAC assay designed to robustly map the accessible genome of individual cells, using sequencing integrated into a programmable microfluidics platform, in order to provide insights into cell-to-cell variation in accessibility profiles. Mark Andrew Miller, ORCID:0000-0001-9076-6066 scATAC-seq http://www.nature.com/nature/journal/v523/n7561/full/nature14590.html https://github.com/obi-ontology/obi/issues/864 ENCODE single-cell ATAC-seq OBI:0002765 microbiome protein expression profiling assay A protein expression profiling assay of microbial proteins extracted from a microbioal community of mixed species from a given microbiome. Michelle Giglio Rebecca Jackson Suvarna Nadendla metaproteomic assay PMID:31450270 CFDE microbiome protein expression profiling assay OBI:0002766 cytokine assay An analyte assay to study presence, concentration, or amount of cytokines. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:23603216 CFDE cytokine assay OBI:0002767 amplicon sequencing assay A sequencing assay in which a DNA or RNA input molecule is amplified by PCR and the product sequenced. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:29628929 PMID:31450270 CFDE amplicon sequencing assay OBI:0002768 whole virome sequencing assay A whole metagenome sequencing assay that intends to provide information on multiple genome sequences from different viruses present in the same input sample. Michelle Giglio Rebecca Jackson Suvarna Nadendla OBI:0002623 CFDE whole virome sequencing assay OBI:0002773 single-value binding of antibody with reporter to antigen assay Detection of SARS-CoV-2 IgG antibodies by an immunoassay method, such as enzyme-linked immunosorbent assay. This test is used in conjunction with SARS-CoV-2 IgA and IgM to aid in the diagnosis of COVID-19 and in the identification of individuals infected with SARS-CoV-2. An assay that detects the linking of antigens and antibodies via special signaling mechanisms, such as EIA, ELISA, chemiluminescence, etc. that produces one measure (quantitative or qualitative) of the analyte of interest LOINC indicates that this class would not include flow cytometry or any technique that can determine the localization of an analyte, such as peroxidase immune staining or indirect immunofluorescence (IFA) Mark Andrew Miller, ORCID:0000-0001-9076-6066 IA immunoassay LOINC User's Guide, Version 2.68, PUBLISHED JUNE 2020, page 47 https://github.com/obi-ontology/obi/issues/1203 single-value binding of antibody with reporter to antigen assay OBI:0002946 fluorescence imaging-based apoptosis assay A type of cytometry assay in which fluorescent dyes are used to label and detect proteins or structures associated with molecular processes of apoptosis. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:http://lincsportal.ccs.miami.edu/beta/assays/1 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging-based apoptosis assay OBI:0002947 fluorescence imaging-based cell proliferation assay A type of cell proliferation assay in which fluorescent dyes are ued to label and detect proteins or structures that can be used to count cells. Michelle Giglio Rebecca Jackson Suvarna Nadendla fluroescence imaging-based cell count assay url:http://lincsportal.ccs.miami.edu/beta/assays/31 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging-based cell proliferation assay OBI:0002948 fluroescence imaging-based cell cycle state assay A type of cytometry assay in which fluorescent dyes are used to label and detect proteins or structures associated with particular cell cycle states. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:http://lincsportal.ccs.miami.edu/beta/assays/10 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluroescence imaging-based cell cycle state assay OBI:0002949 fluorescence imaging-based cell viability assay A type of cytometry assay in which fluorescent dyes are used to label and detect proteins or structures associated with cell viability. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:http://lincsportal.ccs.miami.edu/beta/assays/27 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging-based cell viability assay OBI:0002950 fluorescence imaging-based drug synergy assay A type of cytometry assay in which fluorescent dyes are used to label and detect proteins or structures to determine if drugs applied to cells in combination have a greater effect together than the sum of their separate effects. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:http://lincsportal.ccs.miami.edu/beta/assays/7 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging-based drug synergy assay OBI:0002951 fluorescence imaging-based cell morphology assay A type of cytometry assay in which fluorescent dyes are used to label and detect proteins or structures in order to determine cell morphology. Michelle Giglio Rebecca Jackson Suvarna Nadendla CFDE Michelle Giglio Suvarna Nadendla https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging-based cell morphology assay OBI:0002952 fluorescence imaging multiplex cytological profiling A type of cytometry assay in which fluorescent dyes are used to stain seven major cellular components followed by automatic image capture and analysis which extracts shape, texture, and intensity parameters. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:http://lincsportal.ccs.miami.edu/beta/assays/8 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging multiplex cytological profiling OBI:0002953 protein state assay A type of assay that measures the quantity and/or identity of proteins in their modficied and unmodified states where modifications include phosphorylation, methylation, acetylation, etc. Michelle Giglio Rebecca Jackson Suvarna Nadendla CFDE Michelle Giglio Suvarna Nadendla https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS protein state assay OBI:0002954 fluorescence imaging-based protein phosphorylation state assay A type of protein state assay that employs high-throughput microscopy to measure levels of proteins in different phosphorylation states. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:http://lincsportal.ccs.miami.edu/beta/assays/15 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging-based protein phosphorylation state assay OBI:0002955 mass spectrometry-based protein state assay A type of protein state assay that employs mass spectrometry to measure levels of proteins in different phosphorylation states. Michelle Giglio Rebecca Jackson Suvarna Nadendla CFDE Michelle Giglio Suvarna Nadendla https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS mass spectrometry-based protein state assay OBI:0002956 targeted, drug-modulated, mass spectrometry-based protein phoshporylation-state assay A type of mass spectrometry protein state assay that measures levels of a targeted set of proteins in different phosphorylation states in response to drug perturbations. Michelle Giglio Rebecca Jackson Suvarna Nadendla P100 phosphoprotein quantification assay PMID:26912667 PMID:29655704 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS targeted, drug-modulated, mass spectrometry-based protein phoshporylation-state assay OBI:0002957 reverse phase protein array profiling assay A type of protein state assay where tissue or cell samples are lysed and then spotted onto a slide which is probed with antibodies specific to proteins with and without post-translational modifications. Michelle Giglio Rebecca Jackson Suvarna Nadendla RPLA assay RPPA assay reverse phase lysate array profiling assay PMID: 17041095 PMID:31820393 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS reverse phase protein array profiling assay OBI:0002958 SWATH-MS protein profiling assay A type of mass spectrometry assay using a data-independent acquisition method to identify target peptides. Michelle Giglio Rebecca Jackson Suvarna Nadendla sequential window acquisition of all theoretical mass spectra protein profiling assay PMID:30104418 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS SWATH-MS protein profiling assay OBI:0002959 tandem mass tag mass spectrometry assay A type of tandem mass spectrometry where isotopomer labels are employed for accurate quantification and identification of specific proteins. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:12713048 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS tandem mass tag mass spectrometry assay OBI:0002960 fluorescence imaging-based reporter gene assay A type of reporter gene assay that employs fluorescence imaging to detect a reporter gene's expression. Michelle Giglio Rebecca Jackson Suvarna Nadendla CFDE Michelle Giglio Suvarna Nadendla https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS fluorescence imaging-based reporter gene assay OBI:0002961 global chromatin profiling by mass spectrometry assay A type of epigenetic modification assay that employs targeted quantitative mass spectrometry to profile modifications of the core histones of chromatin. Michelle Giglio Rebecca Jackson Suvarna Nadendla GCP global chromatin epigenetic profiling global chromatin profiling PMID:25448295 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS global chromatin profiling by mass spectrometry assay OBI:0002962 kinase inhibitor assay A type of assay that identifies compounds that inhibit the activity of kinases. Michelle Giglio Rebecca Jackson Suvarna Nadendla CFDE Michelle Giglio Suvarna Nadendla https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS kinase inhibitor assay OBI:0002963 KINOMEscan assay A type of proprietary kinase inhibitor assay that and employs a panel of kinases against which one can test compounds for their selectivity and potency in interactions with kinases, without the need to add ATP to the reactions. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:https://www.discoverx.com/technologies-platforms/competitive-binding-technology/kinomescan-technology-platform https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS KINOMEscan assay OBI:0002964 KiNativ assay A type of proprietary in situ kinase inhibitor assay that employs biotinylated acyl phosphates of ATP and ADP. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:https://www.kinativ.com/technology.html https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS KiNativ assay OBI:0002965 landmark transcript profiling assay A type of transcription profiling assay in which a set of landmark transcripts that have been determined to provide a comprehensive profile of cell activity, plus numerous steady-state controls, are assayed via ligation-mediated amplification followed by capture on fluorescently labeled microspheres followed by detection of fluorescence. Michelle Giglio Rebecca Jackson Suvarna Nadendla L1000 mRNA profiling assay PMID:29195078 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS landmark transcript profiling assay OBI:0002966 microenvironment microarray assay A type of cytometry assay where cells are incubated for three days with a standardized set of extracellular matrix proteins in combination with various ligands creating varying microenvironment perterbations for the cells. Immunofluorescent imaging of cells is used to measure features such as morphology, metabolism, cell cycle, and nuclear activity. Michelle Giglio Rebecca Jackson Suvarna Nadendla MEMA assay PMID:29199020 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS microenvironment microarray assay OBI:0002967 microwestern meso-scale quantitative western blot assay A western blot assay that provides a high-throughput, sensitive, and quantitative measurement of proteins from numerous samples via an array of small western blots on a single sheet of nitrocellulose. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:28092050 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS microwestern meso-scale quantitative western blot assay OBI:0002968 positive/negative ion switching metabolite profiling assay A type of metabolic profiling assay which employs a hybrid dual quadrupole linear ion trap mass spectrometer for steady-state profiling of endogenous polar metabolites from organic extractions from biological samples. Michelle Giglio Rebecca Jackson Suvarna Nadendla positive/negative ion switching metabolomic assay PMID:22498707 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS positive/negative ion switching metabolite profiling assay OBI:0002969 cyclic immunoflouroescence assay A type of microscopy assay resulting in highly multiplexed immunofluorescence imaging through sequential rounds of imaging followed by fluorophore inactivation. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:27925668 PMID:29993362 https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS cyclic immunoflouroescence assay OBI:0002970 multiplex bead-based protein state immunoassay A type of protein state assay in which antibodies attached to different colored beads and fluorescent reporter dye labels are used in a multiplexed mixture to assay for proteins in specific states. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:https://www.bio-rad.com/en-us/applications-technologies/multiplex-immunoassays?ID=LUSM0E8UU https://github.com/obi-ontology/obi/issues/1243 CFDE-LINCS multiplex bead-based protein state immunoassay OBI:0002984 capture Hi-C assay PMID:29979818 Chromosome conformation capture (3C), coupled with next-generation sequencing (Hi-C), provides a means for deciphering not only the principles underlying genome folding and architecture, but more broadly, the role 3D chromatin structure plays in gene regulation and the replication and repair of DNA. A Hi-C assay in which a selection step is performed on ligated fragments in order to enrich for ligation products containing specific regions of interest. Bonita Lam cHi-C PMID:29979818 https://github.com/obi-ontology/obi/issues/1251 capture Hi-C assay OBI:0002985 magnetic resonance imaging assay An imaging assay in which nuclear magnetic resonance is used to produce information about the interior structure and composition of an input material entity. Alexander D. Bartnik, ORCID:0000-0001-9676-7377 Alexander D. Diehl, ORCID:0000-0001-9990-8331 Lauren M. Wishnie, ORCID:0000-0002-7245-3450 Lucas M. Serra, ORCID:0000-0002-2104-0568 Mackenzie T. Smith, ORCID:0000-0002-9821-4132 Rebecca Jackson William D. Duncan, ORCID:0000-0001-9625-1899 MRI url:https://en.wikipedia.org/wiki/Magnetic_resonance_imaging https://github.com/obi-ontology/obi/issues/1290 magnetic resonance imaging assay OBI:0002986 computed tomography imaging assay An imaging assay that uses a series of X-ray images to produce information about the interior structure and composition of an input material entity. Rebecca Jackson CAT scan CT scan computed tomography scan url:https://www.mayoclinic.org/tests-procedures/ct-scan/about/pac-20393675 https://github.com/obi-ontology/obi/issues/1290 computed tomography imaging assay OBI:0002987 positron emission tomography imaging assay An imaging assay in which positron-emitting radionuclides are used to visualize functional processes of an input material entity. Rebecca Jackson PET scan positron emission tomography scan url:https://en.wikipedia.org/wiki/Positron_emission_tomography https://github.com/obi-ontology/obi/issues/1290 positron emission tomography imaging assay OBI:0002990 T cell receptor repertoire sequencing assay A sequencing assay that determines the sequences of DNA or RNA molecules that encode the repertoire of T cell receptors within an input sample. Rebecca Jackson TCR repertoire sequencing assay doi:10.1186/s12896-017-0379-9 https://github.com/obi-ontology/obi/issues/1307 T cell receptor repertoire sequencing assay OBI:0002991 B cell receptor repertoire sequencing assay A sequencing assay that determines the sequence of a DNA or RNA molecules that encode the repertoire of B cell receptors within an input sample. Rebecca Jackson Antibody repertoire sequencing assay BCR repertoire sequencing assay doi:10.1186/s12896-017-0379-9 https://github.com/obi-ontology/obi/issues/1307 B cell receptor repertoire sequencing assay OBI:0003009 ferritin assay An assay that measures ferritin James A. Overton, ORCID:0000-0001-5139-5557 OBI ferritin assay OBI:0003010 fibrinogen assay An assay that measures fibrinogen James A. Overton, ORCID:0000-0001-5139-5558 OBI fibrinogen assay OBI:0003011 iron assay An analyte assay that measures the abundance of iron James A. Overton, ORCID:0000-0001-5139-5559 OBI iron assay OBI:0003012 ionized calcium assay An analyte assay that measures the abundance of ionized calcium James A. Overton, ORCID:0000-0001-5139-5561 OBI ionized calcium assay OBI:0003013 transferrin assay An analyte assay that measures the abundance of transferrin James A. Overton, ORCID:0000-0001-5139-5562 OBI transferrin assay OBI:0003014 uric acid assay An analyte assay that measures the abundance of uric acid James A. Overton, ORCID:0000-0001-5139-5563 OBI uric acid assay OBI:0003015 globulin assay An analyte assay that measures the abundance of globulin James A. Overton, ORCID:0000-0001-5139-5564 OBI globulin assay OBI:0003016 myelocyte assay A cytometry assay that measures the abundance and/or characteristics of myelocytes James A. Overton, ORCID:0000-0001-5139-5565 OBI myelocyte assay OBI:0003017 metamyelocyte assay A cytometry assay that measures the abundance and/or characteristics of metamyelocytes James A. Overton, ORCID:0000-0001-5139-5566 OBI metamyelocyte assay OBI:0003018 hematocrit assay A cytometry assay that measures the proportion of red blood cells James A. Overton, ORCID:0000-0001-5139-5567 OBI hematocrit assay OBI:0003019 promyelocyte assay A cytometry assay that measures the abundance and/or characteristics of promyelocytes James A. Overton, ORCID:0000-0001-5139-5568 OBI promyelocyte assay OBI:0003021 basophil assay A cytometry assay that measures the abundance and/or characteristics of basophils James A. Overton, ORCID:0000-0001-5139-5569 OBI basophil assay OBI:0003022 neutrophil assay A cytometry assay that measures the abundance and/or characteristics of neutrophils James A. Overton, ORCID:0000-0001-5139-5570 OBI neutrophil assay OBI:0003023 eosinophil assay A cytometry assay that measures the abundance and/or characteristics of eosinophils James A. Overton, ORCID:0000-0001-5139-5571 OBI eosinophil assay OBI:0003024 lymphocyte assay A cytometry assay that measures the abundance and/or characteristics of lymphocytes James A. Overton, ORCID:0000-0001-5139-5572 OBI lymphocyte assay OBI:0003025 monocyte assay A cytometry assay that measures the abundance and/or characteristics of monocytes James A. Overton, ORCID:0000-0001-5139-5573 OBI monocyte assay OBI:0003026 reticulocyte assay A cytometry assay that measures the abundance and/or characteristics of reticulocytes James A. Overton, ORCID:0000-0001-5139-5574 OBI reticulocyte assay OBI:0003027 macrophage assay A cytometry assay that measures the abundance and/or characteristics of macrophages James A. Overton, ORCID:0000-0001-5139-5577 OBI macrophage assay OBI:0003028 platelet assay A cytometry assay that measures the abundance and/or characteristics of platelets James A. Overton, ORCID:0000-0001-5139-5578 OBI platelet assay OBI:0003031 fluorogenic PCR assay A polymerase chain reaction assay that uses target specific probes labeled with fluorogenic chromophores. John Judkins TaqMan MIRO:20000102 https://github.com/obi-ontology/obi/issues/1320 fluorogenic PCR assay OBI:0003032 genotyping by PCR assay genotyping by PCR assay to identify microsatellites, chromosomal inversions and targeted assays of known resistance loci. A genotyping assay that uses polymerase chain reaction. Chris Stoeckert, ORCID:0000-0002-5714-991X Jie Zheng, ORCID:0000-0002-2999-0103 VEuPathDB https://github.com/obi-ontology/obi/issues/1348 VEuPathDB genotyping by PCR assay OBI:0003033 cleavage under targets and release using nuclease assay A type of DNA sequencing assay employing in situ chromatin profiling in which antibody-targeted controlled cleavage by micrococcal nuclease releases specific protein-DNA complexes into the the supernatant for sequencing. Michelle Giglio Rebecca Jackson Suvarna Nadendla CUT&RUN assay url:https://elifesciences.org/articles/21856 https://github.com/obi-ontology/obi/issues/1192 bonitalam cleavage under targets and release using nuclease assay OBI:0003034 cleavage under targets and tagmentation A type of DNA sequencing assay employing in situ chromatin profiling in which a chromatin protein is bound in situ by a specific antibody, which then tethers to a protein A-Tn5 hyperactive transposase fusion protein (pA-Tn5) loaded with sequence adapters. Activation of pA-Tn5 results in factor-targeted tagmentation, generating fragments ready for PCR enrichment and DNA sequencing. Michelle Giglio Rebecca Jackson Suvarna Nadendla CUT&Tag assay url:https://www.nature.com/articles/s41467-019-09982-5 https://github.com/obi-ontology/obi/issues/1192 bonitalam cleavage under targets and tagmentation OBI:0003035 coma severity assay Examining a patient and grading their coma status on the Blantyre or Glasgow coma scale. A physical examination of individual that has the objective to determine the severity of coma in a patient. John Judkins https://github.com/obi-ontology/obi/issues/1357 John Judkins coma severity assay OBI:0003036 Plasmodium gametocyte detection assay An assay that detects Plasmodium gametocytes in a specimen. Chris Stoeckert Jie Zheng John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1322 Plasmodium gametocyte detection assay OBI:0003037 malaria rapid diagnosis assay An assay that is quick and easy in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. Chris Stoeckert Jie Zheng malaria rapid diagnosis test VEuPathDB https://github.com/obi-ontology/obi/issues/1322 malaria rapid diagnosis assay OBI:0003038 parasite detection assay An assay that detects parasite in a specimen. Chris Stoeckert Jie Zheng VEuPathDB https://github.com/obi-ontology/obi/issues/1322 parasite detection assay OBI:0003039 feces microbiology assay An organism detection assay that detects microorganisms in a feces specimen. John Judkins stool test for microorganisms VEuPathDB https://github.com/obi-ontology/obi/issues/1322 feces microbiology assay OBI:0003040 blood assay An assay that has a blood specimen as evaulant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1322 blood assay OBI:0003041 falcivax rapid diagnostic test A parasite detection assay that can quickly establish the diagnosis of P. falciparum or P. vivax malaria infection by detecting the antigens in a person's blood. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1322 falcivax rapid diagnostic test OBI:0003042 optimal-IT rapid diagnostic test A parasite detection assay that is rapid, sensitive, and able to differentiate between P. falciparum and other malaria parasites. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1322 optimal-IT rapid diagnostic test OBI:0003043 urine assay An assay that has a urine specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1322 urine assay OBI:0003044 parasite species identification by PCR assay A parasite detection by PCR assay that identifies the species of parasite. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1322 parasite species identification by PCR assay OBI:0003045 parasite detection by PCR assay A parasite detection assay that uses PCR. Chris Stoeckert Jie Zheng VEuPathDB https://github.com/obi-ontology/obi/issues/1322 parasite detection by PCR assay OBI:0003080 organismal body temperature measurement assay An assay that detects body temperature of an organism. Chris Stoeckert Jie Zheng VEuPathDB https://github.com/obi-ontology/obi/issues/1322 organismal body temperature measurement assay OBI:0003087 autofluorescence assay A fluorescence detection assay in which the light that is naturally emitted by a sample is visualized after excitation of the sample with light at a suitable wavelength. Michelle Giglio Rebecca Jackson Suvarna Nadendla intrinsic fluorescence assay PMID:25578980 url:https://en.wikipedia.org/wiki/Autofluorescence https://github.com/obi-ontology/obi/issues/1393 CFDE autofluorescence assay OBI:0003088 autofluorescence microscopy assay An autofluorescence assay in which the light that is naturally emitted by a sample is visualized via microscopy after excitation of the sample with light at a suitable wavelength. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:25578980 url:https://en.wikipedia.org/wiki/Autofluorescence https://github.com/obi-ontology/obi/issues/1394 CFDE autofluorescence microscopy assay OBI:0003089 bulk assay for transposase-accessible chromatin using sequencing An assay for transposase-accessible chromatin using sequencing in which the sample that is sequenced is derived from a collection of cells, such as a tissue sample or entire cell culture, and therefore provides results representative of the aggregate of sample cells. Michelle Giglio Rebecca Jackson Suvarna Nadendla bulk ATAC-seq PMID:24097267 https://github.com/obi-ontology/obi/issues/1395 CFDE bulk assay for transposase-accessible chromatin using sequencing OBI:0003090 bulk RNA-seq assay An RNA-seq assay in which the sample that is sequenced is derived from a collection of cells, such as a tissue sample or entire cell culture, and therefore provides results representative of the aggregate of sample cells. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:https://www.biostars.org/p/458516/ https://github.com/obi-ontology/obi/issues/1396 CFDE bulk RNA-seq assay OBI:0003091 multiplexed fluorescent antibody imaging assay An imaging assay in which multiple cycles consisting of fluorescent labeling, imaging, and fluorophor deactivation are used to detect multiple proteins and their locations in a given sample of tissues or cells. Michelle Giglio Rebecca Jackson Suvarna Nadendla PMID:29993362 https://github.com/obi-ontology/obi/issues/1397 CFDE multiplexed fluorescent antibody imaging assay OBI:0003092 Cell DIVE multiplexed imaging assay A multiplexed fluorescent antibody imaging assay that involves an iterative staining, imaging and dye inactivation workflow for over 60 biomarkers on a single fixed tissue section. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:https://cancerres.aacrjournals.org/content/80/16_Supplement/1448 url:https://www.cytivalifesciences.co.kr/wp-content/uploads/2020/07/Cell-DIVE-Tech-Info-Sheet-CY11898-09Apr20-DF.pdf https://github.com/obi-ontology/obi/issues/1398 CFDE Cell DIVE multiplexed imaging assay OBI:0003093 co-detection by indexing assay A multiplexed fluorescent antibody imaging assay that involves a highly multiplexed analysis of up to 40 proteins in a tissue using cyclic detection of DNA-indexed antibody panels. Michelle Giglio Rebecca Jackson Suvarna Nadendla CODEX url:https://www.scilifelab.se/facilities/co-detection-by-indexing-codex/ https://github.com/obi-ontology/obi/issues/1399 CFDE co-detection by indexing assay OBI:0003094 fluorescence in-situ hybridization assay An in-situ hybridization assay in which fluorescently labeled molecules are used to localize specific DNA or RNA sequences. Michelle Giglio Rebecca Jackson Suvarna Nadendla FISH url:https://en.wikipedia.org/wiki/Fluorescence_in_situ_hybridization https://github.com/obi-ontology/obi/issues/1400 CFDE fluorescence in-situ hybridization assay OBI:0003095 decoding amplified targeted transcripts with fluorescence in situ hybridization assay A fluorescence in-situ hybridization assay which involves multiplex in situ digital quantification of targeted RNA transcripts in fresh or frozen tissue providing an understanding of the spatial organization of different cell types. Michelle Giglio Rebecca Jackson Suvarna Nadendla DARTFISH url:http://genome-tech.ucsd.edu/ZhangLab/index.php/data/tech-dev/ url:http://www.weizmann.ac.il/conferences/SCG2015/sites/conferences.SCG2015/files/scg_2015_abstractbook_online_version.pdf url:https://escholarship.org/uc/item/5bq3128f https://github.com/obi-ontology/obi/issues/1401 CFDE decoding amplified targeted transcripts with fluorescence in situ hybridization assay OBI:0003096 imaging mass cytometry assay A cytometry time of flight assay in which molecules of interest on or in cells are imaged through a system in which samples are labeled with multiple different rare-earth tagged antibodies. The sample is then ablated with a laser and the labeled material is detected by cytometry time of flight mass spectrometry. Michelle Giglio Rebecca Jackson Suvarna Nadendla IMC imaging CyTOF PMID:31798587 https://github.com/obi-ontology/obi/issues/1403 CFDE imaging mass cytometry assay OBI:0003097 liquid chromatography mass spectrometry assay A mass spectrometry assay where a sample mixture is first separated by liquid chromatography before being converted into ions which are characterized by using mass spectrometry based on their mass-to-charge ratio and relative abundance. Michelle Giglio Rebecca Jackson Suvarna Nadendla LC-MS CHMO:0000524 https://github.com/obi-ontology/obi/issues/1404 CFDE liquid chromatography mass spectrometry assay OBI:0003098 lightsheet fluorescence microscopy assay A fluorescence microscopy that involves capturing of photons emitted by fluorophores excited with a thin sheet of laser light in a sample only in a relatively narrow plane by a detection objective oriented perpendicularly to the light sheet and imaged onto a detection device such as a CCD camera. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/light-sheet-fluorescence-microscopy https://github.com/obi-ontology/obi/issues/1405 CFDE lightsheet fluorescence microscopy assay OBI:0003099 matrix assisted laser desorption ionization imaging mass spectrometry assay A mass spectrometry assay that involves collection of spatially resolved mass spectra of a sample during microscopy where a pulse laser is used to produce both ionisation and vaporization. The sample is held in a matrix (such as dihydrobenzoic acid) to protect it from direct laser illumination and to separate the sample molecules. The spectra are used to visualise the spatial distribution of biomolecules by their molecular masses. Michelle Giglio Rebecca Jackson Suvarna Nadendla MALDI-IMS url:http://purl.obolibrary.org/obo/CHMO_0000054 https://github.com/obi-ontology/obi/issues/1406 CFDE matrix assisted laser desorption ionization imaging mass spectrometry assay OBI:0003100 multiplexed ion beam imaging assay A cytometry time of flight assay in which molecules of interest on or in cells are imaged through a system in which samples are labeled with multiple different rare-earth tagged antibodies. A primary ion beam is ued to rasterize sections under vacuum, releasing showers of secondary ions detected by cytometry time of flight mass spectrometry. Michelle Giglio Rebecca Jackson Suvarna Nadendla MIBI url:https://www.nature.com/articles/s41374-020-0417-4 https://github.com/obi-ontology/obi/issues/1407 CFDE multiplexed ion beam imaging assay OBI:0003101 nanospray desorption electrospray ionization assay A mass spectrometry assay that analyzes organic and biological molecules on a substrate by desorption of an analyte into a solvent bridge formed between two capillaries and the analysis surface. One capillary supplies solvent to create and maintain the bridge, while the second capillary transports the dissolved analyte from the bridge to the mass spectrometer. A high voltage applied between the inlet of mass spectrometer and the primary capillary creates a self-aspirating nanospray. Michelle Giglio Rebecca Jackson Suvarna Nadendla NanoDESI url:https://pubmed.ncbi.nlm.nih.gov/20593081/ https://github.com/obi-ontology/obi/issues/1408 CFDE nanospray desorption electrospray ionization assay OBI:0003102 nanodroplet processing in one pot for trace samples assay A protein expression profiling assay in which proteomics sample processing is performed in nanoliter volumes. Flow cytometry or laser microdissection is employed to isolate a small population or single cells into a nanoPOTS chip. Then, liquid chromatography mass spectrometry is used to measure the global protein expression. Michelle Giglio Rebecca Jackson Suvarna Nadendla NanoPOTS url:https://www.emsl.pnnl.gov/science/related-instrument/nanodroplet-processing-in-one-pot-for-trace-samples--nanopots-/1806 https://github.com/obi-ontology/obi/issues/1409 CFDE nanodroplet processing in one pot for trace samples assay OBI:0003103 periodic acid-Schiff staining assay A histological assay which is used on tissue samples to demonstrate the presence of carbohydrates and carbohydrate compounds such as polysaccharides, mucin, glycogen, or fungal cell wall components. Michelle Giglio Rebecca Jackson Suvarna Nadendla PAS staining url:https://microbenotes.com/periodic-acid-schiff-pas-staining/ https://github.com/obi-ontology/obi/issues/1410 CFDE periodic acid-Schiff staining assay OBI:0003104 single cell combinatorial indexing assay for transposase-accessessable chromatin using sequencing An assay for transposase-accessible chromatin that uses sequencing which involves single cell combinatorial indexing ('sci-') strategy where nucleic acids from each of many cells are uniquely tagged through several rounds of split-pool barcoding which enables identification of single cells without single cell isolation. Michelle Giglio Rebecca Jackson Suvarna Nadendla sciATACseq url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158300/ https://github.com/obi-ontology/obi/issues/1411 CFDE single cell combinatorial indexing assay for transposase-accessessable chromatin using sequencing OBI:0003105 single-cell combinatorial indexing RNA sequencing assay A single-cell RNA sequencing assay that involves single cell combinatorial indexing ('sci-') strategy to profile the transcriptomes of single cells or nuclei without single cell isolation. Michelle Giglio Rebecca Jackson Suvarna Nadendla sciRNAseq url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894354/ https://github.com/obi-ontology/obi/issues/1412 CFDE single-cell combinatorial indexing RNA sequencing assay OBI:0003106 sequential fluorescence in-situ hybridization assay A fluorescence in-situ hybridization assay that involves ultra-resolution imaging of cell activity by targetting thousands of single molecules with fluorescent probes which find and hybridize with complementary DNA or RNA sequences in the tissue sample, thus enabling identification of those molecules directly in single cells with their spatial context preserved. Michelle Giglio Rebecca Jackson Suvarna Nadendla seqFISH url:https://spatial.caltech.edu/seqfish/ https://github.com/obi-ontology/obi/issues/1413 CFDE sequential fluorescence in-situ hybridization assay OBI:0003107 slide-seq assay An RNA-seq assay that involves transfer of RNA from tissue sections onto a surface covered in DNA-barcoded beads with known positions, allowing the locations of the RNA to be inferred by sequencing. Michelle Giglio Rebecca Jackson Suvarna Nadendla url:https://science.sciencemag.org/content/363/6434/1463 https://github.com/obi-ontology/obi/issues/1414 CFDE slide-seq assay OBI:0003108 single-nucleus chromatin accessibility and mRNA expression sequencing assay A single-nucleus RNA sequencing assay that involves joint profiling of accessible chromatin and RNA within the same cells which enables direct matching of transcriptional regulation to its outputs. Michelle Giglio Rebecca Jackson Suvarna Nadendla SNARE-seq SNAREseq url:https://www.nature.com/articles/s41587-019-0290-0 https://github.com/obi-ontology/obi/issues/1416 CFDE single-nucleus chromatin accessibility and mRNA expression sequencing assay OBI:0003109 single-nucleus RNA sequencing assay A RNA-seq assay that is used for profiling gene expression in individual nuclei with optimized next generation sequencing (NGS) technologies. This allows the RNA-seq profiling of cell types that are more vulnerable to the tissue dissociation process, and that are therefore underrepresented in the final data set in single cell sequencing. Michelle Giglio Rebecca Jackson Suvarna Nadendla sNuc-seq single nuclei RNA sequencing snRNA-seq EFO:0009809 url:https://www.biocompare.com/Editorial-Articles/557506-Advantages-of-Single-Nucleus-RNA-Sequencing/ https://github.com/obi-ontology/obi/issues/1415 CFDE single-nucleus RNA sequencing assay OBI:0003110 gas chromatography mass spectrometry assay A mass spectrometry assay combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determination of compounds. Michelle Giglio Rebecca Jackson Suvarna Nadendla GC-MS url:http://purl.bioontology.org/ontology/MESH/D008401 https://github.com/obi-ontology/obi/issues/1417 CFDE gas chromatography mass spectrometry assay OBI:0003111 SOMAscan assay An analyte assay that uses aptamers to detect protein analytes in serum. Bjoern Peters Randi Vita Rohloff JC, et al. Nucleic acid ligands with protein-like side chains: modified aptamers and their uses as diagnostic and therapeutic agents. Mol Ther Nucleic Acids. 2014;3:e201. https://github.com/obi-ontology/obi/issues/1308 ImmPort SOMAscan assay OBI:0003112 Olink assay A proximity extension assay that uses quantitative polymerase chain reaction (qPCR) technology to determine the concentration/presence of proteins using a high-multiplex, high-throughput protein biomarker platform. The assay utilizes two distinct oligonucleotide-labeled antibodies (‘probes’) that bind at different sites for each detected protein. When the two probes are in close proximity, a new PCR target sequence is formed by a proximity-dependent DNA polymerization event. The resulting sequence is subsequently detected and quantified using standard real-time PCR. Bjoern Peters Hector Guzman-Orozco Randi Vita https://www.olink.com/ https://github.com/obi-ontology/obi/issues/1308 ImmPort Olink assay OBI:0003113 proximity extension assay An analyte assay that uses quantitative polymerase chain reaction (qPCR) technology to determine the concentration/presence of an analyte or analyte complex. Bjoern Peters Hector Guzman-Orozco Randi Vita Bjoern Peters https://github.com/obi-ontology/obi/issues/1308 ImmPort proximity extension assay OBI:0003115 antigen detection by cytometric bead array assay A cytometric bead array assay in which a series of beads are coated with antibodies specific to antigens of interest. Antigens of interest attach to antibodies on the beads. Fluorescent labeled secondary antibodies are used to detect the antigens of interest. CMI-PB CMI-PB https://github.com/obi-ontology/obi/issues/1399 antigen detection by cytometric bead array assay OBI:0003116 antibody detection by cytometric bead array assay A cytometric bead array assay that detects antigen-specific antibodies. In the assay a series of beads are coated with antigens which capture antibodies specific to the antigens. Fluorescent labeled secondary antibodies are used to detect the antibodies of interest. CMI-PB CMI-PB https://github.com/obi-ontology/obi/issues/1399 antibody detection by cytometric bead array assay OBI:0003117 3D molecular structure determination assay An assay that determines the 3-dimensional configuration of a molecular entity or molecular complex. Bjoern Peters Hector Guzman-Orozco IEDB https://github.com/obi-ontology/obi/issues/1380 3D molecular structure determination assay OBI:0003118 electron-microscopy 3D molecular structure determination assay A 3D molecular structure determination assay that uses electron microscopy imaging. Bjoern Peters Hector Guzman-Orozco IEDB https://github.com/obi-ontology/obi/issues/1380 electron-microscopy 3D molecular structure determination assay OBI:0003122 3D cell structure determination assay A 3D structure determination assay that determines the 3-dimensional configuration of a cell. Hector Guzman-Orozco Patrick Ray Hector Guzman-Orozco Patrick Ray https://github.com/obi-ontology/obi/issues/1364 3D cell structure determination assay OBI:0003123 3D neural cell structure determination assay A 3D cell structure determination assay that determines the 3-dimensional configuration of a neural cell. Hector Guzman-Orozco Patrick Ray Hector Guzman-Orozco Patrick Ray https://github.com/obi-ontology/obi/issues/1364 Allen Institute for Brain Science 3D neural cell structure determination assay OBI:0003124 neuron morphology assay A 3D neural cell structure determination assay that determines the 3-dimensional configuration of a neuron. Hector Guzman-Orozco Patrick Ray Patrick Ray https://github.com/obi-ontology/obi/issues/1364 Allen Institute for Brain Science neuron morphology assay OBI:0003125 mosaicism with repeat frameshift genetic sparse labeling A 3D neural cell structure determination assay where sparse and stochastic methods are used to label genetically-defined neurons. Patrick Ray MORF genetic sparse labeling https://biccn.org/teams/u01-yang https://doi.org/10.1016/j.neuron.2020.07.019 https://github.com/obi-ontology/obi/issues/1364 Allen Institute for Brain Science mosaicism with repeat frameshift genetic sparse labeling OBI:0003126 neuron morphology reconstruction assay A neuron morphology assay where the morphology or structure of a neuron is represented. Often, this assay is a combination of different assays (sparse labelling, fluorescent labeling, fMOST). The representation of the morphology (3D structure) of a neuron can be a summary of various measurements relating to the dimensions of the neuron in question. Hector Guzman-Orozco Patrick Ray http://doi.org/10.1101/675280 https://github.com/obi-ontology/obi/issues/1364 Allen Institute for Brain Science neuron morphology reconstruction assay OBI:0003127 B cell epitope assay An immune epitope assay that characterizes the structrue of an antibody-epitope complex, or measures the binding of an antibody receptor to epitope, or the immune response process resulting from such a binding event or the recognition of the epitope. IEDB IEDB B cell assay|any method B cell epitope assay OBI:0003128 T cell epitope assay An immune epitope assay that characterizes the structrue of an epitope-T cell receptor complex, or measures the binding of a T cell receptor to epitope, or the immune response process resulting from such a binding event or the recognition of the epitope. IEDB IEDB T cell assay|any method T cell epitope assay OBI:0003145 assay measuring quantitative binding of a MHC:ligand complex An assay that detects the binding of a MHC molecule with a ligand, and produces a quantitative measurement of the binding as an output. IEDB IEDB quantitative binding|binding assay assay measuring quantitative binding of a MHC:ligand complex OBI:0003146 assay measuring quantitative binding of an antigen:antibody complex An assay that detects the binding of an antigen with an antibody, and produces a quantitative measurement of the binding as an output. IEDB IEDB quantitative binding|binding assay assay measuring quantitative binding of an antigen:antibody complex OBI:0003147 assay measuring quantitative binding of an epitope:MHC:TCR complex An assay that detects the binding of a MHC:epitope complex with a T cell receptor, and produces a quantitative measurement of the binding as an output. IEDB IEDB quantitative binding|binding assay assay measuring quantitative binding of an epitope:MHC:TCR complex OBI:0003148 albumin concentration assay An albumin assay that measures the concentration of albumin in a specimen. James A. Overton albumin concentration assay OBI:0003149 basophil percentage assay A basophil assay that measures the percentage of basophils in a specimen. James A. Overton basophil percentage assay OBI:0003150 calcium cation concentration assay A calcium cation assay that measures the concentration of calcium cations in a specimen. James A. Overton calcium cation concentration assay OBI:0003151 chloride concentration assay A chloride assay that measures the concentration of chloride in a specimen. James A. Overton chloride concentration assay OBI:0003152 cholesterol concentration assay A cholesterol assay that measures the concentration of cholesterol in a specimen. James A. Overton cholesterol concentration assay OBI:0003153 creatinine concentration assay A creatinine assay that measures the concentration of creatinine in a specimen. James A. Overton creatinine concentration assay OBI:0003154 eosinophil percentage assay An eosinophil assay that measures the percentage of eosinophils in a specimen. James A. Overton eosinophil percentage assay OBI:0003155 globulin concentration assay A globulin assay that measures the concentration of globulin in a specimen. James A. Overton globulin concentration assay OBI:0003156 hemoglobin concentration assay A hemoglobin assay that measures the amount of hemoglobin in a specimen. James A. Overton hemoglobin concentration assay OBI:0003157 high-density lipoprotein cholesterol concentration assay A high-density lipoprotein cholesterol assay that measures the concentration of high-density lipoprotein cholesterol in a specimen. James A. Overton high-density lipoprotein cholesterol concentration assay OBI:0003158 iron concentration assay An iron assay that measures the concentration of iron cation in a specimen. James A. Overton iron concentration assay OBI:0003159 low-density lipoprotein cholesterol concentration assay A low-density lipoprotein cholesterol assay that measures the concentration of low-density lipoprotein cholesterol in a specimen. James A. Overton low-density lipoprotein cholesterol concentration assay OBI:0003160 lymphocyte percentage assay A lymphocyte assay that measures the percentage of lymphocytes in a specimen. James A. Overton lymphocyte percentage assay OBI:0003161 metamyelocyte count assay A metamyelocyte assay that measures the number of metamyelocytes in a specimen. James A. Overton metamyelocyte count assay OBI:0003162 metamyelocyte percentage assay A metamyelocyte assay that measures the percentage of metamyelocytes in a specimen. James A. Overton metamyelocyte percentage assay OBI:0003163 methemoglobin percentage assay A methemoglobin assay that measures the percentage of methemoglobin in a specimen. James A. Overton methemoglobin percentage assay OBI:0003164 monocyte percentage assay A monocyte assay that measures the percentage of monocytes in a specimen. James A. Overton monocyte percentage assay OBI:0003165 myelocyte count assay A myelocyte assay that measures the number of myelocytes in a specimen. James A. Overton myelocyte count assay OBI:0003166 neutrophil percentage assay A neutrophil assay that measures the percentage of neutrophils in a specimen. James A. Overton neutrophil percentage assay OBI:0003167 phosphate ion concentration assay A phosphate ion assay that measures the concentration of phosphate ions in a specimen. James A. Overton phosphate ion concentration assay OBI:0003168 potassium(1+) concentration assay A potassium(1+) assay that measures the concentration of potassium(1+) in a specimen. James A. Overton potassium(1+) concentration assay OBI:0003170 reticulocyte percentage assay A reticulocyte assay that measures the percentage of reticulocytes in a specimen. James A. Overton reticulocyte percentage assay OBI:0003171 sodium(1+) concentration assay A sodium(1+) assay that measures the concentration of sodium(1+) in a specimen. James A. Overton sodium(1+) concentration assay OBI:0003172 thyroid stimulating hormone concentration assay A thyroid stimulating hormone assay that measures the concentration of thyroid stimulating hormone in a specimen. James A. Overton thyroid stimulating hormone concentration assay OBI:0003173 triglyceride concentration assay A triglyceride assay that measures the concentration of triglycerides in a specimen. James A. Overton triglyceride concentration assay OBI:0003174 3,3',5'-triiodothyronine concentration assay A 3,3',5'-triiodothyronine assay that measures the concentration of 3,3',5'-triiodothyronine in a specimen. James A. Overton 3,3',5'-triiodothyronine concentration assay OBI:0003175 fibrinogen concentration assay A fibrinogen assay that measures the concentration of fibrinogen in a specimen. James A. Overton fibrinogen concentration assay OBI:0003176 free thyroxine concentration assay A thyroxine assay that measures the concentration of free thyroxine in a specimen. James A. Overton free thyroxine concentration assay OBI:0003177 total thyroxine concentration assay A thyroxine assay that measures the concentration of total thyroxine in a specimen. James A. Overton total thyroxine concentration assay OBI:0003180 direct bilirubin concentration assay A bilirubin IXalpha assay that measures the concentration of direct bilirubin in a specimen. James A. Overton direct bilirubin concentration assay OBI:0003181 indirect bilirubin concentration assay A bilirubin IXalpha assay that measures the concentration of indirect bilirubin in a specimen. James A. Overton indirect bilirubin concentration assay OBI:0003182 total bilirubin concentration assay A bilirubin IXalpha assay that measures the concentration of total bilirubin in a specimen. James A. Overton total bilirubin concentration assay OBI:0003183 mean cell hemoglobin assay A hemoglobin assay that measures the average concentration of hemoglobin in a population of erythrocytes. James A. Overton mean cell hemoglobin assay OBI:0003184 mean cell hemoglobin concentration assay A hemoglobin assay that measures the concentration of hemoglobin in a specimen. James A. Overton mean cell hemoglobin concentration assay OBI:0003185 mean platelet volume assay A platelet assay that measures the average volume of platelets in a specimen. James A. Overton mean platelet volume assay OBI:0003186 immature neutrophil count assay A neutrophil assay that measures the number of immature neutrophils in a specimen. James A. Overton immature neutrophil count assay OBI:0003187 immature neutrophil percentage assay An neutrophil assay that measures the percentage of immature neutrophils in a specimen. James A. Overton immature neutrophil percentage assay OBI:0003188 nucleated erythrocyte percentage assay An erythrocyte assay that measures the percentage of nucleated erythrocytes in a specimen. James A. Overton nucleated erythrocyte percentage assay OBI:0003189 mean cell volume assay An erythrocyte assay that measures the average volume of erythrocytes in a specimen. James A. Overton mean cell volume assay OBI:0003190 erythrocyte assay A cytometry assay that measures the abundance and/or characteristics of erythrocytes. James A. Overton erythrocyte assay OBI:0003191 manual hematocrit assay A hematocrit assay that measures the percentage of erythrocytes in a specimen by manual processes. James A. Overton manual hematocrit assay OBI:0003192 adiponectin assay An analyte assay that measures the abundance of adiponectin James A. Overton adiponectin assay OBI:0003193 adiponectin concentration assay An adiponectin assay that measures the concentration of adiponectin in a specimen. James A. Overton adiponectin concentration assay OBI:0003194 creatine assay An analyte assay that measures the abundance of creatine James A. Overton creatine assay OBI:0003195 creatine concentration assay A creatine assay that measures the concentration of creatine in a specimen. James A. Overton creatine concentration assay OBI:0003196 estradiol assay An analyte assay that measures the abundance of estradiol James A. Overton estradiol assay OBI:0003197 estradiol concentration assay An estradiol assay that measures the concentration of estradiol in a specimen. James A. Overton estradiol concentration assay OBI:0003202 leptin assay An analyte assay that measures the abundance of leptin James A. Overton leptin assay OBI:0003203 leptin concentration assay An leptin assay that measures the concentration of leptin in a specimen. James A. Overton leptin concentration assay OBI:0003204 lipoprotein concentration assay An analyte assay that measures the abundance of lipoprotein James A. Overton lipoprotein concentration assay OBI:0003205 high-density lipoprotein concentration assay A lipoprotein concentration assay that measures the concentration of high-density lipoprotein in a specimen. James A. Overton high-density lipoprotein concentration assay OBI:0003206 low-density lipoprotein concentration assay A lipoprotein concentration assay that measures the concentration of low-density lipoprotein in a specimen. James A. Overton low-density lipoprotein concentration assay OBI:0003207 very-low-density lipoprotein concentration assay A lipoprotein concentration assay that measures the concentration of very-low-density lipoprotein in a specimen. James A. Overton very-low-density lipoprotein concentration assay OBI:0003208 luteinizing hormone assay An analyte assay that measures the abundance of luteinizing hormone James A. Overton luteinizing hormone assay OBI:0003209 luteinizing hormone concentration assay A luteinizing hormone assay that measures the concentration of luteinizing hormone in a specimen. James A. Overton luteinizing hormone concentration assay OBI:0003210 nitrite assay An analyte assay that measures the abundance of nitrite James A. Overton nitrite assay OBI:0003211 nitrite concentration assay A nitrite assay that measures the concentration of nitrite in a specimen. James A. Overton nitrite concentration assay OBI:0003212 phospholipid assay An analyte assay that measures the abundance of phospholipid James A. Overton phospholipid assay OBI:0003213 phospholipid concentration assay A phospholipid assay that measures the concentration of phospholipids in a specimen. James A. Overton phospholipid concentration assay OBI:0003214 progesterone assay An analyte assay that measures the abundance of progesterone James A. Overton progesterone assay OBI:0003215 progesterone concentration assay A progesterone assay that measures the concentration of progesterone in a specimen. James A. Overton progesterone concentration assay OBI:0003216 testosterone assay An analyte assay that measures the abundance of testosterone James A. Overton testosterone assay OBI:0003217 testosterone concentration assay A testosterone assay that measures the concentration of testosterone in a specimen. James A. Overton testosterone concentration assay OBI:0003218 bile salt assay An analyte assay that measures the abundance of bile salt James A. Overton bile salt assay OBI:0003219 bile salt concentration assay A bile salt assay that measures the concentration of bile salt in a specimen. James A. Overton bile salt concentration assay OBI:0003220 fatty acid assay An analyte assay that measures the abundance of fatty acid James A. Overton fatty acid assay OBI:0003221 free fatty acid concentration assay A fatty acid assay that measures the concentration of free fatty acids in a specimen. James A. Overton free fatty acid concentration assay OBI:0003222 insulin assay An analyte assay that measures the abundance of insulin James A. Overton insulin assay OBI:0003223 insulin concentration assay A insulin assay that measures the concentration of insulin in a specimen. James A. Overton insulin concentration assay OBI:0003224 follicle stimulating hormone assay An analyte assay that measures the abundance of follicle stimulating hormone James A. Overton follicle stimulating hormone assay OBI:0003225 follicle stimulating hormone concentration assay A follicle stimulating hormone assay that measures the concentration of follicle stimulating hormone in a specimen. James A. Overton follicle stimulating hormone concentration assay OBI:0003226 total lymphocyte count assay A lymphocyte assay that measures the number of lymphocytes and large unstained cells in a specimen. James A. Overton total lymphocyte count assay OBI:0003227 total lymphocyte percentage assay A lymphocyte assay that measures the percentage of lymphocytes and large unstained cells in a specimen. James A. Overton total lymphocyte percentage assay OBI:0003228 fluorescent immunospot assay A cytometry assay that detects the presence of cells that secrete a material of interest (analyte). In the assay, a plate is coated with an antibody specific to the analyte of interest. These antibodies capture the analytes secreted by the cells. The analytes are then detected using fluorescent labeled secondary antibodies. Hector Guzman-Orozco FLUOROSPOT https://en.wikipedia.org/wiki/ELISpot#Mechanism_of_FluoroSpot https://github.com/obi-ontology/obi/issues/1414 CMI-PB fluorescent immunospot assay OBI:0003229 plasma proteomics assay A proteomics profiling assay that detects proteins in a blood plasma specimen. Hector Guzman-Orozco CMI-PB https://github.com/obi-ontology/obi/issues/1414 CMI-PB plasma proteomics assay OBI:0003230 T cell activation induced marker assay A flow cytometry assay that detects the presence/amount of antigen-specific T cells without the need to identify their cytokine production. Instead, antigen-specific T cells are detected on the basis of upregulation of TCR stimulation-induced surface markers. Hector Guzman-Orozco https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955771/ https://github.com/obi-ontology/obi/issues/1414 CMI-PB T cell activation induced marker assay OBI:0003232 cerebrospinal fluid assay An assay that has a cerebrospinal fluid specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 cerebrospinal fluid assay OBI:0003233 endotracheal aspirate assay An assay that has an endotracheal aspirate specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 endotracheal aspirate assay OBI:0003234 induced sputum assay An assay that has an induced sputum specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 induced sputum assay OBI:0003235 lung assay An assay that has a lung specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 lung assay OBI:0003236 milk assay An assay that has a milk specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 milk assay OBI:0003237 feces assay An assay that has a feces specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 feces assay OBI:0003238 umbilical cord blood assay An assay that has an umbilical cord blood specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 umbilical cord blood assay OBI:0003239 saliva assay An assay that has a saliva specimen as evaluant. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 saliva assay OBI:0003240 cerebrospinal fluid microbiology assay An organism detection assay that detects microorganisms in a cerebrospinal fluid specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 cerebrospinal fluid microbiology assay OBI:0003241 endotracheal tube aspirate microbiology assay An organism detection assay that detects microorganisms in an endotracheal aspirate specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 endotracheal tube aspirate microbiology assay OBI:0003242 induced sputum microbiology assay An organism detection assay that detects microorganisms in an induced sputum specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 induced sputum microbiology assay OBI:0003282 lung microbiology assay An organism detection assay that detects microorganisms in a lung specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 lung microbiology assay OBI:0003283 pleural fluid microbiology assay An organism detection assay that detects microorganisms in a pleural fluid specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 pleural fluid microbiology assay OBI:0003284 umbilical cord blood microbiology assay An organism detection assay that detects microorganisms in an umbilical cord blood specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 umbilical cord blood microbiology assay OBI:0003285 nasopharyngeal or oropharyngeal swab microbiology assay An organism detection assay that detects microorganisms in a nasopharyngeal or oropharyngeal swab specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 nasopharyngeal or oropharyngeal swab microbiology assay OBI:0003286 urine microbiology assay An organism detection assay that detects microorganisms in a urine specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1429 urine microbiology assay OBI:0003287 multiplex real time polymerase chain reaction assay A real time polymerase chain reaction assay in which multiple DNA sequences are amplified in a single cycle. John Judkins multiplexed real time polymerase chain reaction assay VEuPathDB https://github.com/obi-ontology/obi/issues/1431 multiplex real time polymerase chain reaction assay OBI:0003288 multiplex real time reverse-transcription polymerase chain reaction assay A real time reverse-transcription polymerase chain reaction assay in which multiple DNA sequences are amplified in a single cycle. John Judkins multiplexed real time reverse-transcription polymerase chain reaction assay VEuPathDB https://github.com/obi-ontology/obi/issues/1431 multiplex real time reverse-transcription polymerase chain reaction assay OBI:0003290 mosquito membrane feeding assay Testing the effectiveness of drugs or antibodies against parasite transmission. An assay that evaluates host-to-mosquito transmission of a parasite organism by feeding a specimen of host blood infected with the parasite organism to a collection of mosquitoes through a mosquito membrane feeding device and, after a given time, dissecting the mosquitoes and counting the number of parasite organisms within them. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1439 mosquito membrane feeding assay OBI:0003292 cytometric bead array assay measuring epitope specific granulysin release by T cells A cytometric bead array assay that detects epitope specific granulysin release by T cells. IEDB IEDB granulysin release|cytometric bead array cytometric bead array assay measuring epitope specific granulysin release by T cells OBI:0003293 cytometric bead array assay measuring epitope specific perforin release by T cells A cytometric bead array assay that detects epitope specific perforin release by T cells. IEDB IEDB perforin release|cytometric bead array cytometric bead array assay measuring epitope specific perforin release by T cells OBI:0003294 modified acid-fast stain microscopy assay A microscopy assay that uses staining to identify acid-fast organisms in a specimen and does not require heating. John Judkins NCIT:C85736 https://www.cdc.gov/dpdx/diagnosticprocedures/stool/staining.html https://github.com/obi-ontology/obi/issues/1444 modified acid-fast stain microscopy assay OBI:0003296 antibodies from lymphocyte secretions assay PMID: 11329444.Clin Diagn Lab Immunol. 2001 May. Development of a Novel In Vitro Assay (ALS Assay) for Evaluation of Vaccine-Induced Antibody Secretion from Circulating Mucosal Lymphocytes. An assay that evaluates a blood specimen for antibodies currently being produced by lymphocytes in the specimen, by separating peripheral blood mononuclear cells, culturing them, and then collecting the supernatant containing the antibodies secreted from those cells. John Judkins ALS assay antibodies from lymphocyte supernatant assay OBI VEuPathDB https://github.com/obi-ontology/obi/issues/1443 antibodies from lymphocyte secretions assay OBI:0003297 tyramide signal amplification sequencing assay A DNA sequencing assay that uses tyramide signal amplification (TSA) to assess distance of DNA regions to a targeted nuclear compartment or protein, typically on a scale of 100-1000 nm. Michelle Giglio Suvarna Nadendla TSA-seq EFO:0009971 PMID:30154186 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN tyramide signal amplification sequencing assay OBI:0003298 DNA adenine methyltransferase identification assay An assay for identifying DNA binding sites for a protein by fusing it to Dam methylase, and expressing it so that bound DNA gets methylated. The methylated DNA can then be isolated and analyzed. Michelle Giglio Suvarna Nadendla DamID assay EFO:0008704 PMID:17545983 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN DNA adenine methyltransferase identification assay OBI:0003299 DamID-seq A DNA adenine methyltransferase identification (DamID) assay in which DamID-generated DNA fragments undergo high-throughput sequencing to determine a protein's DNA-binding site. Michelle Giglio Suvarna Nadendla 4DN DCIC https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN DamID-seq OBI:0003300 nucleolus-associated domain sequencing assay A DNA sequencing assay in which nucleoli are isolated and the DNA associated with them is sequenced to identify nucleoli-associating domains. Michelle Giglio Suvarna Nadendla NAD-seq EFO:0009972 PMID:31201210 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN nucleolus-associated domain sequencing assay OBI:0003301 DNase Hi-C assay A Hi-C assay in which DNase I is used for digesting DNA fragments rather than a restriction enzyme, which can result in a higher resolution of mapped chromosome contacts. Michelle Giglio Suvarna Nadendla EFO:0009976 PMID:27685100 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN DNase Hi-C assay OBI:0003302 micro-C assay A Hi-C assay which uses micrococcal nuclease digestion in place of the restriction enzyme digestion step. Michelle Giglio Suvarna Nadendla EFO:0008808 PMID:26119342 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN micro-C assay OBI:0003303 single cell combinatorial indexing Hi-C assay A Hi-C assay performed on massively multiplexed single-cell samples. Michelle Giglio Suvarna Nadendla sci-Hi-C EFO:0009977 PMID:28135255 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN single cell combinatorial indexing Hi-C assay OBI:0003304 single nucleus Hi-C assay A Hi-C assay performed on isolated nuclei. Michelle Giglio Suvarna Nadendla sn-Hi-C EFO:0009978 PMID:28355183 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN single nucleus Hi-C assay OBI:0003305 single cell Hi-C assay A Hi-C assay performed on a single cell. Michelle Giglio Suvarna Nadendla EFO:0009979 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN single cell Hi-C assay OBI:0003306 bulk Hi-C assay A Hi-C assay in which the sample that is sequenced is derived from a collection of cells, such as a tissue sample or entire cell culture, and therefore provides results representative of the aggregate of sample cells. Michelle Giglio Suvarna Nadendla 4DN DCIC https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN bulk Hi-C assay OBI:0003307 multi-contact Hi-C assay A Hi-C assay that assesses interactions between multiple DNA fragments rather than only pairwise interactions as in traditional Hi-C. The experimental procedure of cross-linking, digestion, and ligation is performed similarly to traditional Hi-C, but after DNA is purified a long-read library is produced in which many ligated fragments may be contained in a single molecule. The library is then sequenced on a long read sequencer. Michelle Giglio Suvarna Nadendla MC-3C MC-HI-C The 4D Nucleome Network https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN multi-contact Hi-C assay OBI:0003309 transposase-mediated analysis of chromatin looping assay A DNA sequencing assay designed to detect interacting genomic regions. Rather than the traditional Hi-C approach of digestion and proximity ligation, the procedure involves transposase-mediated insertion of an oligonucleotide linker between the pair of interacting regions. Michelle Giglio Suvarna Nadendla TrAC-Loop EFO:0009982 PMID:30150754 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN transposase-mediated analysis of chromatin looping assay OBI:0003310 split-pool recognition of interactions and tag extension assay A sequencing assay designed to detect multi-way interactions between nucleic acids. The procedure involves crosslinking nuclei, and then splitting the lysate among wells in a 96-well or other multi-well plate. A different barcode is ligated to the fragments in each well, and the lysates are pooled together again. This sequence of splitting, tagging, and re-combining is repeated several times so that fragments with the same sequences of barcodes represent fragments that have co-associated throughout the experiment. Finally, a sequencing library is constructed and high-throughput sequencing is performed. Michelle Giglio Suvarna Nadendla SPRITE EFO:0009984 PMID:29887377 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN split-pool recognition of interactions and tag extension assay OBI:0003311 DNA split-pool recognition of interactions and tag extension assay A split-pool recognition of interactions and tag extension (SPRITE) assay that only assays interactions between regions of genomic DNA. Michelle Giglio Suvarna Nadendla DNA SPRITE EFO:0009985 PMID:29887377 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN DNA split-pool recognition of interactions and tag extension assay OBI:0003312 RNA-DNA split-pool recognition of interactions and tag extension assay A split-pool recognition of interactions and tag extension (SPRITE) assay in which RNA in the cross-linked complexes is converted to cDNA before the initial splitting step, allowing analysis of RNA-DNA interactions. Michelle Giglio Suvarna Nadendla RNA-DNA SPRITE EFO:0009986 PMID:29887377 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN RNA-DNA split-pool recognition of interactions and tag extension assay OBI:0003313 genome architecture mapping assay A DNA sequencing assay designed to analyze 3D chromatin structure without relying on digestion and ligation. The procedure involves cryosectioning samples in random orientation, and then single nuclear profiles are isolated by laser microdissection. Each nuclear profile then undergoes high-throughput sequencing, and subsequent analysis can generate a matrix of inferred proximity between genomic regions. Michelle Giglio Suvarna Nadendla GAM EFO:0009987 PMID:28273065 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN genome architecture mapping assay OBI:0003314 mapping RNA-genome interactions assay A nuclear ligation assay for probing RNA-DNA interactions in the nucleus. Nuclei are crosslinked, and RNA fragments are ligated to proximal DNA fragments via a special linker molecule. After reverse transcription, high-throughput sequencing is performed. Michelle Giglio Suvarna Nadendla MARGI EFO:0009988 PMID:28132817 https://github.com/obi-ontology/obi/issues/1472 CFDE-4DN mapping RNA-genome interactions assay OBI:0003315 assay measuring epitope specific amphiregulin production by T cells A T cell epitope specific cytokine production assay that detects amphiregulin production by T cells. IEDB IEDB amphiregulin release|biological activity assay measuring epitope specific amphiregulin production by T cells OBI:0003316 ELISA measuring epitope specific amphiregulin production by T cells An enzyme-linked immunosorbent assay that detects amphiregulin production by T cells. IEDB IEDB amphiregulin release|ELISA ELISA measuring epitope specific amphiregulin production by T cells OBI:0003321 venous blood microbiology assay A blood microbiology assay that detects a microorganism in a venous blood specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1491 venous blood microbiology assay OBI:0003323 high throughput multiplexed assay measuring binding of a B cell epitope:antibody complex Next-generation high-density peptide microarrays measuring antibody responses to overlapping peptides: PMID:25922409. A B cell epitope assay that measures the binding of an antibody receptor to an epitope using a high throughput multiplexed assay. IEDB IEDB antibody binding|High throughput multiplexed assay high throughput multiplexed assay measuring binding of a B cell epitope:antibody complex OBI:0003324 high throughput multiplexed assay measuring binding of a T cell epitope:MHC:TCR complex Adaptive Biotech multiplexed TCR sequencing assays: PMID:32793919. A T cell epitope assay that measures the binding of T cell receptor to an epitope using a high throughput multiplexed assay. IEDB IEDB T cell binding|High throughput multiplexed assay high throughput multiplexed assay measuring binding of a T cell epitope:MHC:TCR complex OBI:0003325 high throughput multiplexed assay measuring binding of a MHC:ligand complex Peptide microarray with fluorescence detection for millions of MHC binding measurements: PMID: 33705522. A MHC ligand assay that detects the binding of a ligand to an MHC molecule using a high throughput multiplexed assay. IEDB IEDB MHC binding|High throughput multiplexed assay high throughput multiplexed assay measuring binding of a MHC:ligand complex OBI:0003326 high throughput multiplexed assay measuring MHC ligand processing and presentation Mass spectrometry identified 35,367 and 28,132 HLA-class I ligands witth a false discovery rate: PMID: 29789417. A MHC ligand assay that determines what ligands are processed and loaded onto MHC molecules by eluting ligands and identifying them using a high throughput multiplexed assay. IEDB IEDB ligand presentation|High throughput multiplexed assay high throughput multiplexed assay measuring MHC ligand processing and presentation OBI:0003368 detection technique Using a radioactivity detection assay as part of a tritiated thymidine incorporation assay to determine the degree to which cells are replicating by detecting radioactivity of tritiated thymidine, where radioactivity of tritiated thymidine in a cell is a proxy for cells that were actively replicating. An assay (A) that is part of another assay (B), where the target entities of A and B are disjoint, and the target entity of A is a proxy for the target of assay B. Bjoern Peters Hector Guzman-Orozco OBI https://github.com/obi-ontology/obi/issues/1488 detection technique OBI:0003372 assay measuring epitope specific lymphotactin production by T cells A T cell epitope specific cytokine production assay that detects lymphotactin production by T cells. IEDB IEDB lymphotactin release|biological activity assay measuring epitope specific lymphotactin production by T cells OBI:0003373 ELISA measuring epitope specific lymphotactin production by T cells An enzyme-linked immunosorbent assay that detects lymphotactin production by T cells. IEDB IEDB lymphotactin release|ELISA ELISA measuring epitope specific lymphotactin production by T cells OBI:0003381 placental blood microbiology assay A blood microbiology assay that detects microorganisms in a placental blood specimen. John Judkins VEuPathDB https://github.com/obi-ontology/obi/issues/1297 placental blood microbiology assay OBI:0003418 antigen specific antibodies in blood assay An antigen specific antibodies assay that has a blood specimen as evaluant. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1526 VEuPathDB antigen specific antibodies in blood assay OBI:0003419 antigen specific antibodies in milk assay An antigen specific antibodies assay that has a milk specimen as evaluant. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1526 VEuPathDB antigen specific antibodies in milk assay OBI:0003422 enzymatic activity level assay An assay in which the level of catalytic activity of an enzyme is determined. James A. Overton enzymatic activity level assay OBI:0003423 5'-nucleotidase activity level assay An enzymatic activity level assay that measures the activity of 5'-nucleotidase in a sample. James A. Overton 5'-nucleotidase activity level assay OBI:0003424 alanine aminotransferase activity level assay An enzymatic activity level assay that measures the activity of alanine aminotransferase in a sample. James A. Overton alanine aminotransferase activity level assay OBI:0003425 alkaline phosphatase activity level assay An enzymatic activity level assay that measures the activity of alkaline phosphatase in a sample. James A. Overton alkaline phosphatase activity level assay OBI:0003426 amylase activity level assay An enzymatic activity level assay that measures the activity of amylase in a sample. James A. Overton amylase activity level assay OBI:0003427 aspartate aminotransferase activity level assay An enzymatic activity level assay that measures the activity of aspartate aminotransferase in a sample. James A. Overton aspartate aminotransferase activity level assay OBI:0003428 cholinesterase activity level assay An enzymatic activity level assay that measures the activity of cholinesterase in a sample. James A. Overton cholinesterase activity level assay OBI:0003429 creatine kinase activity level assay An enzymatic activity level assay that measures the activity of creatine kinase in a sample. James A. Overton creatine kinase activity level assay OBI:0003430 gamma-glutamyltransferase activity level assay An enzymatic activity level assay that measures the activity of gamma-glutamyltransferase in a sample. James A. Overton gamma-glutamyltransferase activity level assay OBI:0003431 glutamate dehydrogenase activity level assay An enzymatic activity level assay that measures the activity of glutamate dehydrogenase in a sample. James A. Overton glutamate dehydrogenase activity level assay OBI:0003432 isocitrate dehydrogenase activity level assay An enzymatic activity level assay that measures the activity of isocitrate dehydrogenase in a sample. James A. Overton isocitrate dehydrogenase activity level assay OBI:0003433 lactate dehydrogenase activity level assay An enzymatic activity level assay that measures the activity of lactate dehydrogenase in a sample. James A. Overton lactate dehydrogenase activity level assay OBI:0003434 sorbitol dehydrogenase activity level assay An enzymatic activity level assay that measures the activity of sorbitol dehydrogenase in a sample. James A. Overton sorbitol dehydrogenase activity level assay OBI:0003435 acyl-CoA oxidase activity level assay An enzymatic activity level assay that measures the activity of Acyl-CoA oxidase in a sample. James A. Overton acyl-CoA oxidase activity level assay OBI:0003436 N-acetyl-beta-glucosaminidase activity level assay An enzymatic activity level assay that measures the activity of N-acetyl-beta-glucosaminidase in a sample. James A. Overton N-acetyl-beta-glucosaminidase activity level assay OBI:0003437 ribonuclease activity level assay An enzymatic activity level assay that measures the activity of ribonuclease in a sample. James A. Overton ribonuclease activity level assay OBI:0003438 galactosidase activity level assay An enzymatic activity level assay that measures the activity of galactosidase in a sample. James A. Overton galactosidase activity level assay OBI:0003457 epitope protection from infectious challenge experiment based on survival An epitope protection from infectious challenge experiment that determines the success of the epitope intervention based on increased survival of the host compared to controls. Hector Guzman-Orozco survival after infectious challenge IEDB https://github.com/obi-ontology/obi/issues/1594 epitope protection from infectious challenge experiment based on survival OBI:0003458 epitope protection from tumor challenge experiment based on burden An epitope protection from tumor challenge experiment in which the readout is a reduction in the presence of malignant cells in the host compared to controls. Hector Guzman-Orozco burden after tumor challenge IEDB https://github.com/obi-ontology/obi/issues/1594 epitope protection from tumor challenge experiment based on burden OBI:0003459 epitope protection from tumor challenge experiment based on survival An epitope protection from tumor challenge experiment that determines the success of the epitope intervention based on increased survival of the host compared to controls. Hector Guzman-Orozco survival after tumor challenge IEDB https://github.com/obi-ontology/obi/issues/1594 epitope protection from tumor challenge experiment based on survival OBI:0003460 in vivo assay measuring T cell epitope specific protection from pathogen challenge An in vivo assay measuring T cell epitope specific protection from pathogen challenge. IEDB IEDB protection from pathogen challenge|in vivo assay in vivo assay measuring T cell epitope specific protection from pathogen challenge OBI:0003461 in vivo assay measuring T cell epitope specific protection from tumor challenge An in vivo assay measuring T cell epitope specific protection from tumor challenge. IEDB IEDB protection from tumor challenge|in vivo assay in vivo assay measuring T cell epitope specific protection from tumor challenge OBI:0003462 in vivo assay measuring T cell epitope specific protection from other challenge An in vivo assay measuring T cell epitope specific protection from a challenge other than pathogen, infection, or tumor. IEDB IEDB protection from other challenge|in vivo assay in vivo assay measuring T cell epitope specific protection from other challenge OBI:0003463 in vivo assay measuring T cell epitope specific survival after tumor challenge An in vivo assay measuring T cell epitope specific protection from tumor challenge using survival. IEDB IEDB survival from tumor challenge|in vivo assay in vivo assay measuring T cell epitope specific survival after tumor challenge OBI:0003464 in vivo assay measuring T cell epitope specific survival after pathogen challenge An in vivo assay measuring T cell epitope specific protection from pathogen challenge using survival. IEDB IEDB survival from pathogen challenge|in vivo assay in vivo assay measuring T cell epitope specific survival after pathogen challenge OBI:0003465 in vivo assay measuring B cell epitope specific protection from pathogen challenge An in vivo assay measuring B cell epitope specific protection from pathogen challenge. IEDB IEDB protection from pathogen challenge|in vivo assay in vivo assay measuring B cell epitope specific protection from pathogen challenge OBI:0003466 in vivo assay measuring B cell epitope specific protection from tumor challenge An in vivo assay measuring B cell epitope specific protection from tumor challenge. IEDB IEDB protection from tumor challenge|in vivo assay in vivo assay measuring B cell epitope specific protection from tumor challenge OBI:0003467 in vivo assay measuring B cell epitope specific protection from other challenge An in vivo assay measuring B cell epitope specific protection from a challenge other than pathogen, infection, or tumor. IEDB IEDB protection from other challenge|in vivo assay in vivo assay measuring B cell epitope specific protection from other challenge OBI:0003468 in vivo assay measuring B cell epitope specific survival after pathogen challenge An in vivo assay measuring B cell epitope specific protection from pathogen challenge using survival. IEDB IEDB survival from pathogen challenge|in vivo assay in vivo assay measuring B cell epitope specific survival after pathogen challenge OBI:0003469 in vivo assay measuring B cell epitope specific survival after tumor challenge An in vivo assay measuring B cell epitope specific protection from tumor challenge using survival. IEDB IEDB survival from tumor challenge|in vivo assay in vivo assay measuring B cell epitope specific survival after tumor challenge OBI:0003470 in vivo assay measuring T cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific T cells An in vivo assay measuring a T cell epitope specific protection from a pathogen challenge after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB protection from pathogen challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific T cells OBI:0003471 in vivo assay measuring T cell epitope specific pathogen protection from challenge resulting from the adoptive transfer of epitope specific T cells based on survival An in vivo assay measuring T cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific T cells using survival. IEDB IEDB survival after pathogen challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific pathogen protection from challenge resulting from the adoptive transfer of epitope specific T cells based on survival OBI:0003472 in vivo assay measuring T cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific T cells An in vivo assay measuring a T cell epitope specific protection from a tumor challenge after adoptive transfer of epitope specific T cells. IEDB IEDB protection from tumor challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific T cells OBI:0003473 in vivo assay measuring T cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific T cells based on survival An in vivo assay measuring T cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific T cells using survival. IEDB IEDB survival after tumor challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific T cells based on survival OBI:0003474 in vivo assay measuring T cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific T cells An in vivo assay measuring a T cell epitope specific protection from other challenge after adoptive transfer of epitope specific T cells. IEDB IEDB protection from other challenge after adoptive transfer|in vivo assay in vivo assay measuring T cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific T cells OBI:0003475 in vivo assay measuring B cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific antibodies or B cells An in vivo assay measuring a B cell epitope specific protection from a pathogen challenge after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB protection from pathogen challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific antibodies or B cells OBI:0003476 in vivo assay measuring B cell epitope specific pathogen protection from challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on survival An in vivo assay measuring B cell epitope specific protection from pathogen challenge resulting from the adoptive transfer of epitope specific antibodies or B cells using survival. IEDB IEDB survival after pathogen challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific pathogen protection from challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on survival OBI:0003477 in vivo assay measuring B cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific antibodies or B cells An in vivo assay measuring a B cell epitope specific protection from a tumor challenge after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB protection from tumor challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific antibodies or B cells OBI:0003478 in vivo assay measuring B cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on survival An in vivo assay measuring B cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific antibodies or B cells using survival. IEDB IEDB survival after tumor challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from tumor challenge resulting from the adoptive transfer of epitope specific antibodies or B cells based on survival OBI:0003479 in vivo assay measuring B cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific antibodies or B cells An in vivo assay measuring a B cell epitope specific protection from other challenge after adoptive transfer of epitope specific antibodies or B cells. IEDB IEDB protection from other challenge after adoptive transfer|in vivo assay in vivo assay measuring B cell epitope specific protection from other challenge resulting from the adoptive transfer of epitope specific antibodies or B cells OBI:0003480 Gram stain assay An organism detection assay that identifies bacteria based on the differential retention of a crystal violet-iodine complex within the cell wall. Gram-positive bacteria retain the violet stain whereas gram-negative bacteria do not. John Judkins ORCID:0000-0001-6595-0902 American Heritage Medical Dictionary NCI https://github.com/obi-ontology/obi/issues/1603 Gram stain assay OBI:0003484 assay measuring epitope specific interleukin-25 production by T cells A T cell epitope specific cytokine production assay that detects interleukin-25 production by T cells. IEDB IEDB IL-25 release|biological activity assay measuring epitope specific interleukin-25 production by T cells OBI:0003485 detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-25 production by T cells A detection of specific nucleic acid polymers with complementary probes that detects interleukin-25 production by T cells. IEDB IEDB IL-25 release|RNA/DNA detection detection of specific nucleic acids with complementary probes assay measuring epitope specific interleukin-25 production by T cells OBI:0003486 intracellular cytokine staining assay measuring epitope specific interleukin-25 production by T cells A flow cytometry assay that detects interleukin-25 production by T cells. IEDB IEDB IL-25 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-25 production by T cells OBI:0003487 ELISA measuring epitope specific interleukin-25 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-25 production by T cells. IEDB IEDB IL-25 release|ELISA ELISA measuring epitope specific interleukin-25 production by T cells OBI:0003488 cell culture analyte detection bioassay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells A reporter cell line analyte detection bioassay that detects tumor necrosis factor superfamily cytokine production by T cells. IEDB IEDB TNF release|bioassay cell culture analyte detection bioassay measuring epitope specific tumor necrosis factor superfamily cytokine production by T cells OBI:0003498 organism detection assay An assay that detects a type of organism and/or the quantity of individuals of a type of organism. This term is a generalized version of the term previously known as 'organism identification assay', to include classification other than species and to include quantities as outputs. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1633 organism detection assay OBI:0003501 functional assessment of individual A physical examination of an individual's ability to perform functional activities. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 functional assessment of individual OBI:0003502 facial atrophy assessment An observational assessment of the loss of facial muscle tissue due to inactivity or disease. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 facial atrophy assessment OBI:0003503 tongue atrophy assessment An observational assessment of the loss of muscle tissue related to tongue movement due to inactivity or disease. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 tongue atrophy assessment OBI:0003504 forced cough assessment A functional assessment of an individual's ability to cough forcefully. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 forced cough assessment OBI:0003505 speech test assessment A functional assessment of an individual's ability to understandably repeat spoken sentences. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 speech test assessment OBI:0003506 finger to finger assessment A functional assessment of an individual's ability to touch index fingers together in front of the sternum without oscillation for a specified duration of time Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 finger to finger assessment OBI:0003507 nose to finger assessment A functional assessment of an individual's ability to touch their own nose and then touch an examiners finger in front of them and then touch their own nose once more. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 nose to finger assessment OBI:0003508 dysmetria assessment A functional assessment of an individual's ability to accurately touch a moving target with their finger and then touch their own chin a number of times in a row. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 dysmetria assessment OBI:0003509 rapid alternating hands assessment A functional assessment of an individual's ability to alternate the forearm between pronation and suppination as quickly as possible during a specified duration of time Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 rapid alternating hands assessment OBI:0003510 finger taps assessment A functional assessment of an individual's ability to touch their finger-tip to thumb as many times as possible during a specified duration of time. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 finger taps assessment OBI:0003511 heel along shin assessment A functional assessment of an individual's ability to slide their heel back and forth along their contralateral tibia from the patella to the ankle with the contralateral leg extended. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 heel along shin assessment OBI:0003512 heel to shin assessment A functional assessment of an individual's ability to tap their heel to the midpoint of the contralateral shin a number of times. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 heel to shin assessment OBI:0003513 muscle atrophy assessment An observational assesment of an individual's muscle tissue loss due to inactivity or disease. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 muscle atrophy assessment OBI:0003514 muscle weakness assessment A functional assessment of an individual's ability to perform muscle movement to overcome gravity or physical resistence. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 muscle weakness assessment OBI:0003515 vibratory sense assessment A functional assessment of an individual's ability to sense vibration. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 vibratory sense assessment OBI:0003516 position sense assessment A functional assessment of an individual's ability to sense the position of a finger or toe that has been manipulated by minimal random movements. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 position sense assessment OBI:0003517 deep tendon reflex assessment A functional assessment of an individual's muscle contraction when a muscle is triggered by a signal from a muscle spindle in response to a stimulus applied to a specific trigger point on the body. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 deep tendon reflex assessment OBI:0003518 limits of stability assessment The functional assessment of an individual's ability to maintain balance, posture or upright stability. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 limits of stability assessment OBI:0003519 sitting posture assessment A limits of stability assessment designed to assess an individual's ability to maintain unsupported posture while sitting over a given time period. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 sitting posture assessment OBI:0003520 stance feet apart assessment A limits of stability assessment designed to assess an individual's ability to maintain a stable stance with feet 20 cm apart. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 stance feet apart assessment OBI:0003521 stance feet apart assessment, with eyes closed A limits of stability assessment designed to assess an individual's ability to maintain a stable stance with their eyes closed. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 stance feet apart assessment, with eyes closed OBI:0003522 stance feet together assessment A limits of stability assessment designed to assess an individual's ability to maintain a stable stance with feet together. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 stance feet together assessment OBI:0003523 stance feet together assessment, with eyes closed A limits of stability assessment designed to assess an individual's ability to maintain a stable stance with feet together and eyes closed. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 stance feet together assessment, with eyes closed OBI:0003524 tandem stance assessment A limits of stability assessment designed to assess an individual's ability to maintain a stable stance with feet in tandem placement. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 tandem stance assessment OBI:0003525 stance on one foot assessment A limits of stability assessment designed to assess an individual's ability to maintain a stable stance on one foot. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 stance on one foot assessment OBI:0003526 tandem walk assessment A limits of stability assessment designed to assess an individual's ability to maintain balance while walking in a straight line placing steps in tandem. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 tandem walk assessment OBI:0003527 gait assessment A limits of stability assessment designed to assess an individual's manner or pattern of walking. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 gait assessment OBI:0003528 bulbar assessment A functional assessment of an individual's lower cranial nerve function via proxy of facial muscle performance. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 bulbar assessment OBI:0003529 spontaneous speech assessment A functional assessment of an individual's ability to articulate spoken words. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 spontaneous speech assessment OBI:0003530 limb coordination assessment A functional assessment of an individual's ability to coordinate limb movement. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 limb coordination assessment OBI:0003531 upper limb coordination assessment A limb coordination assessment designed to assess an individual's ability to coordinate upper limb movement. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 upper limb coordination assessment OBI:0003532 lower limb coordination assessment A limb coordination assessment designed to assess an individual's ability to coordinate lower limb movement. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 lower limb coordination assessment OBI:0003533 nervous system functionality assessment A functional assesment of an individual's nerve performance. Specifically the nerves connecting the sensory and motor structures with the central nervous system. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 nervous system functionality assessment OBI:0003534 upright stability assessment A functional assessment of an individual's ability to maintain upright body posture. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 upright stability assessment OBI:0003535 deep tendon reflex assessment of the knee joint A deep tendon reflex assessment of an individual's reaction to stimulus applied to a knee joint. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 deep tendon reflex assessment of the knee joint OBI:0003536 observational assessment of individual A physical examination of an individual through visual assesment. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 observational assessment of individual OBI:0003537 deep tendon reflex assessment of the ankle joint A deep tendon reflex assessment of an individual's reaction to stimulus applied to an ankle joint. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 deep tendon reflex assessment of the ankle joint OBI:0003538 deep tendon reflex assessment of the tendon of biceps brachii A deep tendon reflex assessment of an individual's reaction to stimulus applied to a tendon of biceps brachii. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 deep tendon reflex assessment of the tendon of biceps brachii OBI:0003539 deep tendon reflex assessment of the brachioradialis A deep tendon reflex assessment of an individual's reaction to stimulus applied to a brachioradialis. Daniel Olson, ORCID: 0000-0002-8134-1207 Critical Path Institute https://github.com/obi-ontology/obi/issues/1637 deep tendon reflex assessment of the brachioradialis OBI:0003540 tandem mass spectrometry assay A precursor ion is selected in the first stage, allowed to fragment and then all resultant masses are scanned in the second mass analyzer and detected in the detector that is positioned after the second mass analyzer. This experiment is commonly performed to identify transitions used for quantification by tandem MS. A mass spectrometry assay that uses two or more analyzers separated by a region in which ions can be induced to fragment by transfer of energy (frequently by collision with other molecules). Discussed on the OBI developer call 2022-03-07: 'tandem mass spectrometry' OBI:0200198 is under 'data transformation' but is actually defined like an assay. Moving OBI:0200198 from 'data transformation' to 'assay' is a major logical change, so the OBI development team supports obsoleting 'tandem mass spectrometry' OBI:0200198 and replacing it with ‘tandem mass spectrometry assay’ OBI:0003540. Hector Guzman-Orozco, ORCID:0000-0003-3430-8997 http://purl.obolibrary.org/obo/OBI_0200198 https://github.com/obi-ontology/obi/issues/1506 tandem mass spectrometry assay OBI:0003541 ELISA measuring Orientia tsutsugamushi IgM antibody An enzyme-linked immunosorbent assay that detects the IgM antibody that binds Orientia tsutsugamushi. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1456 ELISA measuring Orientia tsutsugamushi IgM antibody OBI:0003542 microarray assay measuring Dengue IgM antibody A microarray assay that detects the IgM antibody that binds Dengue. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1456 microarray assay measuring Dengue IgM antibody OBI:0003543 microarray assay measuring NS1 A microarray assay that detects NS1. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1456 microarray assay measuring NS1 OBI:0003544 analytical chromatography measuring Chikungunya IgM antibody Analytical chromatography that detects the IgM antibody that binds Chikungunya. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1456 analytical chromatography measuring Chikungunya IgM antibody OBI:0003545 ELISA measuring Chikungunya IgM antibody An enzyme-linked immunosorbent assay that detects the IgM antibody that binds Chikungunya. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1456 ELISA measuring Chikungunya IgM antibody OBI:0003546 microarray ELISA measuring Chikungunya IgM antibody An enzyme-linked immunosorbent assay that uses a microarray as the solid support and detects the IgM antibody that binds Chikungunya. John Judkins ORCID:0000-0001-6595-0902 VEuPathDB https://github.com/obi-ontology/obi/issues/1456 microarray ELISA measuring Chikungunya IgM antibody OBI:0100026 organism animal fungus plant virus A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') 13-02-2009: OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. This issue is outside the scope of OBI. GROUP: OBI Biomaterial Branch WEB: http://en.wikipedia.org/wiki/Organism organism OBI:0302736 comet assay PMID: 18326531.Mutagenesis. 2008 Mar 6.Recommendations for design of the rat comet assay. An assay that measures DNA damage (DNA breakage) in eucaryotic cells exposed to a challenge by determining the size and shape of DNA migration by detecting fluorescently labeled DNA from a cell placed in an electric field using gel electrophoresis Philippe Rocca-Serra SCGE assay single cell gel electrophoresis assay PMID:7686265 comet assay OBI:0302737 PCR-SSCP assay PMID: 17334176.Hum Exp Toxicol. 2007 Jan;26(1):9-18.Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? An assay that identifies DNA sequence variation (mutation, deletion, insertions) in target DNA sequences amplified using polymerase chain reaction using gel electrophoresis and denaturating conditions Philippe Rocca-Serra polymerase chain reaction-single strand conformation polymorphism assay PMID:18219595 PCR-SSCP assay OBI:0600002 tumor grading An assay that determines the grade (severity/stage) of a tumor sample, used in cancer biology to describe abnormalities/qualities of tumor cells or tissues. Values can be described by terms from NCI Thesaurus. Compiled by Helen Parkinson for Transcriptomics thanks to Adam Witney grading of tumor OBI branch derived; submitted by MO tumor grading OBI:0600017 assay detecting a molecular label Determination of the amount of phycoerytherin label present in a cell population stained with anti-CD8-PE in order to determine the percentage of CD8+ T cells present An assay that detects the presence or a quality of a molecular label which is a proxy for the detection of the molecular target to which the label is attached Matthew Brush OBI developer call, 3-12-12 assay detecting a molecular label OBI:0600020 histological assay the counting of the number of cells with fluorescent label at their surface to determine the percentage of the population which was activated An assay that uses visual examination of cells or tissue (or images of them) to make an assessment regarding a quality of the cells or tissue. This assay can include steps of staining, imaging, and judgement. Adam Witney Helen Parkinson histology histopathology OBI branch derived histological assay OBI:0600025 substance detection assay the detection of phycoerytherin by means of flow cytometry An assay that detects a specified substance Kevin Clancy OBI branch derived substance detection assay OBI:0600026 longitudinal mass measurement assay The comparison of the weight of vaccinated and non-vaccinated mice after infection with influenza A over 6 weeks post-infection An assay that measures the mass of a material at two or more time points Helen Parkinson OBI branch derived longitudinal mass measurement assay OBI:0600031 enzyme-linked immunospot assay Determination of the frequency of cells producing IFN-gamma in response to viral peptides by placing effector cells on a anti IFN-gamma coated plate, and adding antigen presenting cells pulsed with a peptide. After washing, the bound IFN-gamma is detected with a secondary antibody linked to a dye that visualizes as one spot per cell. A cytometry assay in which cells are cultured on a surface coated with a capture antibody binding a secretory material of interest which subsequently gets stained resulting in a spot for each cell producing the secretory material of interest. IEDB ELISPOT assay IEDB enzyme-linked immunospot assay OBI:0600045 3D structure determination assay The use of X-ray crystallography to determine the 3D coordinates of atoms in a protein. An assay that determines the 3-dimensional configuration of an input material. IEDB IEDB 3D structure determination assay OBI:0600047 sequencing assay The use of the Sanger method of DNA sequencing to determine the order of the nucleotides in a DNA template An assay the uses chemical or biochemical means to infer the sequence of a biomaterial PlanAndPlannedProcess Branch OBI branch derived sequencing assay OBI:1110013 ELISPOT assay measuring epitope specific interleukin-2 production by T cells An enzyme-linked immunospot assay that detects interleukin-2 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-2 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-2 production by T cells OBI:1110037 assay measuring binding of a T cell epitope:MHC:TCR complex A T cell epitope assay that measures the binding of T cell receptor to an epitope. IEDB IEDB T cell binding|any method assay measuring binding of a T cell epitope:MHC:TCR complex OBI:1110059 ELISPOT assay measuring epitope specific interferon-gamma production by T cells An enzyme-linked immunospot assay that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|ELISPOT ELISPOT assay measuring epitope specific interferon-gamma production by T cells OBI:1110124 assay measuring qualitative binding of a T cell epitope:MHC:TCR complex An assay that detects the binding of a MHC:epitope complex with a T cell receptor, and produces a qualitative measurement of the binding as an output. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|binding assay assay measuring qualitative binding of a T cell epitope:MHC:TCR complex OBI:1110125 assay measuring MHC ligand processing and presentation A MHC ligand assay that determines what ligands are processed and loaded onto MHC molecules by eluting ligands and identifying them. IEDB IEDB ligand presentation|any method assay measuring MHC ligand processing and presentation OBI:1110126 assay measuring binding of a MHC:ligand complex A MHC ligand assay that detects the binding of a ligand to an MHC molecule. IEDB IEDB MHC binding|any method assay measuring binding of a MHC:ligand complex OBI:1110127 assay measuring binding of a B cell epitope:antibody complex A B cell epitope assay that measures the binding of an antibody receptor to an epitope. IEDB IEDB antibody binding|any method assay measuring binding of a B cell epitope:antibody complex OBI:1110128 immune epitope assay An assay that detects the binding of an epitope to an adaptive immune receptor, or an immune process resulting from such a binding event, or characterizes the structrue of the complex resulting from such a binding event. IEDB IEDB immune epitope assay immune epitope assay OBI:1110129 assay measuring epitope specific cytokine production by T cells A T cell epitope assay that detects cytokine production by T cells. IEDB IEDB cytokine release|biological activity assay measuring epitope specific cytokine production by T cells OBI:1110130 assay measuring epitope specific T cell killing A T cell epitope dependent biological activity assay that detects the killing of an antigen presenting cell (APC) by a T cell whose TCR recognizes an epitope presented by the APC. IEDB IEDB cytotoxicity|biological activity assay measuring epitope specific T cell killing OBI:1110131 assay measuring epitope specific proliferation of T cells A T cell epitope dependent biological activity assay that detects T cell proliferation. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB proliferation|biological activity assay measuring epitope specific proliferation of T cells OBI:1110150 51 chromium assay measuring epitope specific T cell killing A chromium release assay that detects the killing of an antigen presenting cell (APC) by a T cell whose TCR recognizes an epitope presented by the APC. IEDB IEDB cytotoxicity|51 chromium 51 chromium assay measuring epitope specific T cell killing OBI:1110151 ELISA measuring epitope specific interferon-gamma production by T cells An enzyme-linked immunosorbent assay that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|ELISA ELISA measuring epitope specific interferon-gamma production by T cells OBI:1110152 ELISA measuring epitope specific interleukin-2 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-2 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-2 release|ELISA ELISA measuring epitope specific interleukin-2 production by T cells OBI:1110153 ELISA measuring epitope specific interleukin-4 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-4 release|ELISA ELISA measuring epitope specific interleukin-4 production by T cells OBI:1110154 ELISA measuring epitope specific interleukin-5 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-5 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-5 release|ELISA ELISA measuring epitope specific interleukin-5 production by T cells OBI:1110155 ELISA measuring epitope specific tumor necrosis factor alpha production by T cells An enzyme-linked immunosorbent assay that detects tumor necrosis factor alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNFa release|ELISA ELISA measuring epitope specific tumor necrosis factor alpha production by T cells OBI:1110156 ELISA measuring epitope specific interleukin-10 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-10 release|ELISA ELISA measuring epitope specific interleukin-10 production by T cells OBI:1110157 ELISA measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells An enzyme-linked immunosorbent assay that detects granulocyte macrophage colony stimulating factor production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB GM-CSF release|ELISA ELISA measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells OBI:1110158 ELISA measuring epitope specific interleukin-6 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-6 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-6 release|ELISA ELISA measuring epitope specific interleukin-6 production by T cells OBI:1110159 ELISA measuring epitope specific interleukin-13 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-13 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-13 release|ELISA ELISA measuring epitope specific interleukin-13 production by T cells OBI:1110160 ELISA measuring epitope specific interleukin-12 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-12 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-12 release|ELISA ELISA measuring epitope specific interleukin-12 production by T cells OBI:1110161 ELISA measuring epitope specific interleukin-1 beta production by T cells An enzyme-linked immunosorbent assay that detects interleukin-1 beta production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-1b release|ELISA ELISA measuring epitope specific interleukin-1 beta production by T cells OBI:1110162 ELISA measuring epitope specific interleukin-17 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-17 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17 release|ELISA ELISA measuring epitope specific interleukin-17 production by T cells OBI:1110163 ELISA measuring epitope specific interleukin-18 production by T cells An enzyme-linked immunosorbent assay that detects interleukin-18 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-18 release|ELISA ELISA measuring epitope specific interleukin-18 production by T cells OBI:1110167 ELISPOT assay measuring epitope specific interleukin-4 production by T cells An enzyme-linked immunospot assay that detects interleukin-4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-4 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-4 production by T cells OBI:1110168 ELISPOT assay measuring epitope specific tumor necrosis factor alpha production by T cells An enzyme-linked immunospot assay that detects tumor necrosis factor alpha production by T cells IEDB IEDB TNFa release|ELISPOT ELISPOT assay measuring epitope specific tumor necrosis factor alpha production by T cells OBI:1110170 ELISPOT assay measuring epitope specific interleukin-10 production by T cells An enzyme-linked immunospot assay that detects interleukin-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-10 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-10 production by T cells OBI:1110171 ELISPOT assay measuring epitope specific interleukin-13 production by T cells An enzyme-linked immunospot assay that detects interleukin-13 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-13 release|ELISPOT ELISPOT assay measuring epitope specific interleukin-13 production by T cells OBI:1110172 intracellular cytokine staining assay measuring epitope specific interferon-gamma production by T cells A flow cytometry assay that detects interferon-gamma production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IFNg release|ICS intracellular cytokine staining assay measuring epitope specific interferon-gamma production by T cells OBI:1110173 intracellular cytokine staining assay measuring epitope specific interleukin-2 production by T cells A flow cytometry assay that detects interleukin-2 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-2 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-2 production by T cells OBI:1110174 intracellular cytokine staining assay measuring epitope specific tumor necrosis factor alpha production by T cells A flow cytometry assay that detects tumor necrosis factor alpha production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB TNFa release|ICS intracellular cytokine staining assay measuring epitope specific tumor necrosis factor alpha production by T cells OBI:1110175 intracellular cytokine staining assay measuring epitope specific interleukin-4 production by T cells A flow cytometry assay that detects interleukin-4 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-4 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-4 production by T cells OBI:1110177 intracellular cytokine staining assay measuring epitope specific interleukin-10 production by T cells A flow cytometry assay that detects interleukin-10 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-10 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-10 production by T cells OBI:1110178 intracellular cytokine staining assay measuring epitope specific interleukin-17 production by T cells A flow cytometry assay that detects interleukin-17 production by T cells. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IL-17 release|ICS intracellular cytokine staining assay measuring epitope specific interleukin-17 production by T cells OBI:1110179 MHC tetramer/multimer assay measuring binding of a T cell epitope:MHC:TCR complex A MHC tetramer/multimer assay that measures the binding of an epitope:MHC complex binding with a T cell receptor. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB qualitative binding|multimer/tetramer MHC tetramer/multimer assay measuring binding of a T cell epitope:MHC:TCR complex OBI:1110180 3H-thymidine assay measuring epitope specific proliferation of T cells A tritiated thymidine incorporation assay that detects T cell epitope specific proliferation in vitro. IEDB IEDB proliferation|3H-thymidine 3H-thymidine assay measuring epitope specific proliferation of T cells OBI:1110181 BrdU assay measuring epitope specific proliferation of T cells A BrdU incorporation assay that detects T cell epitope specific proliferation in vitro. IEDB IEDB proliferation|BrdU BrdU assay measuring epitope specific proliferation of T cells OBI:1110207 assay detecting IFN-gamma production An IFN-g ELISPOT is an assay detecting ifn-gamma production An assay that determines information about the production of the cytokine interferon gamma Bjoern Peters IFNg release IEDB assay detecting IFN-gamma production OBI:2100001 carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 carbon dioxide assay OBI:2100002 sodium(1+) assay An analyte assay that measures the abundance of sodium(1+) Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 sodium(1+) assay OBI:2100003 creatinine assay An analyte assay that measures the abundance of creatinine Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 creatinine assay OBI:2100004 potassium(1+) assay An analyte assay that measures the abundance of potassium(1+) Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 potassium(1+) assay OBI:2100005 basophil count assay A cytometry assay that measures the count of basophils Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basophil count assay OBI:2100006 neutrophil count assay A cytometry assay that measures the count of neutrophils Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 neutrophil count assay OBI:2100007 eosinophil count assay A cytometry assay that measures the count of eosinophils Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 eosinophil count assay OBI:2100008 lymphocyte count assay A cytometry assay that measures the count of lymphocytes Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lymphocyte count assay OBI:2100009 monocyte count assay A cytometry assay that measures the count of monocytes Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 monocyte count assay OBI:2100010 chloride assay An analyte assay that measures the abundance of chloride Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chloride assay OBI:2100011 erythrocyte count assay A cytometry assay that measures the count of erythrocytes Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 erythrocyte count assay OBI:2100012 platelet count assay A cytometry assay that measures the count of platelets Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 platelet count assay OBI:2100013 leukocyte count assay A cytometry assay that measures the count of leukocytes Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 leukocyte count assay OBI:2100014 hemoglobin assay An analyte assay that measures the abundance of hemoglobin Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hemoglobin assay OBI:2100015 phosphate ion assay An analyte assay that measures the abundance of phosphate ion Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 phosphate ion assay OBI:2100016 alanine aminotransferase assay An analyte assay that measures the abundance of alanine aminotransferase Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 alanine aminotransferase assay OBI:2100017 alkaline phosphatase (human) assay An analyte assay that measures the abundance of alkaline phosphatase (human) Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 alkaline phosphatase (human) assay OBI:2100018 bilirubin IXalpha assay An analyte assay that measures the abundance of bilirubin IXalpha Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bilirubin IXalpha assay OBI:2100019 aspartate aminotransferase (human) assay An analyte assay that measures the abundance of aspartate aminotransferase (human) Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 aspartate aminotransferase (human) assay OBI:2100020 glucose assay An analyte assay that measures the abundance of glucose Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 glucose assay OBI:2100021 magnesium cation assay An analyte assay that measures the abundance of magnesium cation Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 magnesium cation assay OBI:2100022 albumin assay An analyte assay that measures the abundance of albumin Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 albumin assay OBI:2100023 protein assay An analyte assay that measures the abundance of protein Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 protein assay OBI:2100024 calcium cation assay An analyte assay that measures the abundance of calcium cation Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 calcium cation assay OBI:2100025 creatine kinase assay An analyte assay that measures the abundance of creatine kinase Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 creatine kinase assay OBI:2100026 nucleate erythrocyte count assay A cytometry assay that measures the count of nucleate erythrocytes Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 nucleate erythrocyte count assay OBI:2100027 segmented neutrophil of bone marrow count assay A cytometry assay that measures the count of segmented neutrophil of bone marrows Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 segmented neutrophil of bone marrow count assay OBI:2100028 lactate dehydrogenase complex assay An assay that measures lactate dehydrogenase complex Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lactate dehydrogenase complex assay OBI:2100029 triglyceride assay An analyte assay that measures the abundance of triglyceride Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 triglyceride assay OBI:2100030 high-density lipoprotein cholesterol assay An analyte assay that measures the abundance of high-density lipoprotein cholesterol Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 high-density lipoprotein cholesterol assay OBI:2100031 cholesterol assay An analyte assay that measures the abundance of cholesterol Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cholesterol assay OBI:2100032 low-density lipoprotein cholesterol assay An analyte assay that measures the abundance of low-density lipoprotein cholesterol Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 low-density lipoprotein cholesterol assay OBI:2100033 thyroid stimulating hormone assay An analyte assay that measures the abundance of thyroid stimulating hormone Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 thyroid stimulating hormone assay OBI:2100034 prostate-specific antigen assay An analyte assay that measures the abundance of prostate-specific antigen Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 prostate-specific antigen assay OBI:2100035 thyroxine assay An analyte assay that measures the abundance of thyroxine Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 thyroxine assay OBI:2100036 elemental oxygen assay An analyte assay that measures the abundance of elemental oxygen Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 elemental oxygen assay OBI:2100037 folic acids assay An analyte assay that measures the abundance of folic acids Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 folic acids assay OBI:2100038 reticulocyte count assay A cytometry assay that measures the count of reticulocytes Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 reticulocyte count assay OBI:2100039 osmolality assay An assay that measures osmolality Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 osmolality assay OBI:2100040 methemoglobin assay An analyte assay that measures the abundance of methemoglobin Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 methemoglobin assay OBI:2100041 cytosolic creatine kinase complex, MB-type assay An assay that measures cytosolic creatine kinase complex, MB-type Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cytosolic creatine kinase complex, MB-type assay OBI:2100042 rac-lactic acid assay An assay that measures rac-lactic acid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 rac-lactic acid assay OBI:2100043 hydrogencarbonate assay An analyte assay that measures the abundance of hydrogencarbonate Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hydrogencarbonate assay OBI:2100044 vancomycin assay An analyte assay that measures the abundance of vancomycin Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 vancomycin assay OBI:2100045 tobramycin assay An analyte assay that measures the abundance of tobramycin Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 tobramycin assay OBI:2100046 3,3',5'-triiodothyronine assay An analyte assay that measures the abundance of 3,3',5'-triiodothyronine Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 3,3',5'-triiodothyronine assay OBI:2100047 C-reactive protein assay An analyte assay that measures the abundance of C-reactive protein Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 C-reactive protein assay OBI:2100048 megakaryocyte count assay A cytometry assay that measures the count of megakaryocytes Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 megakaryocyte count assay OBI:2100049 mesothelial cell count assay A cytometry assay that measures the count of mesothelial cells Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 mesothelial cell count assay OBI:2100050 macrophage count assay A cytometry assay that measures the count of macrophages Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 macrophage count assay OBI:2100051 3-hydroxybutyric acid assay An analyte assay that measures the abundance of 3-hydroxybutyric acid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 3-hydroxybutyric acid assay OBI:2100052 panel5 venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a panel5 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 panel5 venous blood carbon dioxide assay OBI:2100053 panel5 venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a panel5 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 panel5 venous blood sodium assay OBI:2100054 panel5 venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood as part of a panel5 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 panel5 venous blood creatinine assay OBI:2100055 panel5 venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a panel5 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 panel5 venous blood potassium assay OBI:2100056 automated differential venous blood basophil count assay A cytometry assay that measures the count of basophils in venous blood as part of a automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 automated differential venous blood basophil count assay OBI:2100057 automated differential venous blood neutrophil count assay A cytometry assay that measures the count of neutrophils in venous blood as part of a automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 automated differential venous blood neutrophil count assay OBI:2100058 automated differential venous blood eosinophil count assay A cytometry assay that measures the count of eosinophils in venous blood as part of a automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 automated differential venous blood eosinophil count assay OBI:2100059 automated differential venous blood lymphocyte count assay A cytometry assay that measures the count of lymphocytes in venous blood as part of a automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 automated differential venous blood lymphocyte count assay OBI:2100060 automated differential venous blood monocyte count assay A cytometry assay that measures the count of monocytes in venous blood as part of a automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 automated differential venous blood monocyte count assay OBI:2100061 venous blood chloride assay An analyte assay that measures the abundance of chloride in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood chloride assay OBI:2100062 CBC with automated differential venous blood RBC count assay A cytometry assay that measures the count of RBCs in venous blood as part of a CBC with automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with automated differential venous blood RBC count assay OBI:2100063 CBC with automated differential venous blood platelet count assay A cytometry assay that measures the count of platelets in venous blood as part of a CBC with automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with automated differential venous blood platelet count assay OBI:2100064 CBC with automated differential venous blood WBC count assay A cytometry assay that measures the count of WBCs in venous blood as part of a CBC with automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with automated differential venous blood WBC count assay OBI:2100065 CBC with automated differential venous blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in venous blood as part of a CBC with automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with automated differential venous blood hematocrit assay OBI:2100066 CBC with automated differential venous blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in venous blood as part of a CBC with automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with automated differential venous blood hemoglobin assay OBI:2100067 venous blood phosphate assay An analyte assay that measures the abundance of phosphate in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood phosphate assay OBI:2100068 liver injury venous blood alanine aminotransferase assay An analyte assay that measures the abundance of alanine aminotransferase in venous blood as part of a liver injury order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver injury venous blood alanine aminotransferase assay OBI:2100069 liver injury venous blood human alkaline phosphatase assay An analyte assay that measures the abundance of human alkaline phosphatase in venous blood as part of a liver injury order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver injury venous blood human alkaline phosphatase assay OBI:2100070 liver injury venous blood bilirubin assay An analyte assay that measures the abundance of bilirubin in venous blood as part of a liver injury order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver injury venous blood bilirubin assay OBI:2100071 liver injury venous blood human aspartate aminotransferase assay An analyte assay that measures the abundance of human aspartate aminotransferase in venous blood as part of a liver injury order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver injury venous blood human aspartate aminotransferase assay OBI:2100072 venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood glucose assay OBI:2100073 venous blood magnesium assay An analyte assay that measures the abundance of magnesium in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood magnesium assay OBI:2100074 CBC venous blood RBC count assay A cytometry assay that measures the count of RBCs in venous blood as part of a CBC order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC venous blood RBC count assay OBI:2100075 CBC venous blood WBC count assay A cytometry assay that measures the count of WBCs in venous blood as part of a CBC order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC venous blood WBC count assay OBI:2100076 CBC venous blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in venous blood as part of a CBC order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC venous blood hematocrit assay OBI:2100077 CBC venous blood platelet count assay A cytometry assay that measures the count of platelets in venous blood as part of a CBC order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC venous blood platelet count assay OBI:2100078 CBC venous blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in venous blood as part of a CBC order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC venous blood hemoglobin assay OBI:2100079 corrected venous blood leukocyte count assay A cytometry assay that measures the count of leukocytes in venous blood as part of a corrected order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 corrected venous blood leukocyte count assay OBI:2100080 liver evaluation venous blood bilirubin assay An analyte assay that measures the abundance of bilirubin in venous blood as part of a liver evaluation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver evaluation venous blood bilirubin assay OBI:2100081 liver evaluation venous blood globulin assay An analyte assay that measures the abundance of globulin in venous blood as part of a liver evaluation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver evaluation venous blood globulin assay OBI:2100082 liver evaluation venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a liver evaluation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver evaluation venous blood albumin assay OBI:2100083 liver evaluation venous blood human aspartate aminotransferase assay An analyte assay that measures the abundance of human aspartate aminotransferase in venous blood as part of a liver evaluation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver evaluation venous blood human aspartate aminotransferase assay OBI:2100084 liver evaluation venous blood alanine aminotransferase assay An analyte assay that measures the abundance of alanine aminotransferase in venous blood as part of a liver evaluation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver evaluation venous blood alanine aminotransferase assay OBI:2100085 liver evaluation venous blood human alkaline phosphatase assay An analyte assay that measures the abundance of human alkaline phosphatase in venous blood as part of a liver evaluation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver evaluation venous blood human alkaline phosphatase assay OBI:2100086 liver evaluation venous blood protein assay An analyte assay that measures the abundance of protein in venous blood as part of a liver evaluation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver evaluation venous blood protein assay OBI:2100087 basic metabolic panel venous blood chloride assay An analyte assay that measures the abundance of chloride in venous blood as part of a basic metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basic metabolic panel venous blood chloride assay OBI:2100088 basic metabolic panel venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a basic metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basic metabolic panel venous blood potassium assay OBI:2100089 basic metabolic panel venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a basic metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basic metabolic panel venous blood sodium assay OBI:2100090 basic metabolic panel venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood as part of a basic metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basic metabolic panel venous blood creatinine assay OBI:2100091 basic metabolic panel venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood as part of a basic metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basic metabolic panel venous blood glucose assay OBI:2100092 basic metabolic panel venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood as part of a basic metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basic metabolic panel venous blood calcium assay OBI:2100093 basic metabolic panel venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a basic metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 basic metabolic panel venous blood carbon dioxide assay OBI:2100094 venous blood creatine kinase assay An analyte assay that measures the abundance of creatine kinase in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood creatine kinase assay OBI:2100095 venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood calcium assay OBI:2100096 venous blood ferritin assay An assay that measures ferritin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood ferritin assay OBI:2100097 total venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total venous blood calcium assay OBI:2100098 venous blood iron assay An analyte assay that measures the abundance of iron in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood iron assay OBI:2100099 CBC with manual differential venous blood band neutrophil count assay A cytometry assay that measures the count of band neutrophils in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood band neutrophil count assay OBI:2100100 CBC with manual differential venous blood WBC count assay A cytometry assay that measures the count of WBCs in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood WBC count assay OBI:2100101 CBC with manual differential venous blood eosinophil count assay A cytometry assay that measures the count of eosinophils in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood eosinophil count assay OBI:2100102 CBC with manual differential venous blood lymphocyte count assay A cytometry assay that measures the count of lymphocytes in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood lymphocyte count assay OBI:2100103 CBC with manual differential venous blood nucleated RBC count assay A cytometry assay that measures the count of nucleated RBCs in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood nucleated RBC count assay OBI:2100104 CBC with manual differential venous blood monocyte count assay A cytometry assay that measures the count of monocytes in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood monocyte count assay OBI:2100105 CBC with manual differential venous blood segmented neutrophil count assay A cytometry assay that measures the count of segmented neutrophils in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood segmented neutrophil count assay OBI:2100106 CBC with manual differential venous blood basophil count assay A cytometry assay that measures the count of basophils in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood basophil count assay OBI:2100107 venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood albumin assay OBI:2100108 cardiac enzymes venous blood creatine kinase assay An analyte assay that measures the abundance of creatine kinase in venous blood as part of a cardiac enzymes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cardiac enzymes venous blood creatine kinase assay OBI:2100109 venous blood haptoglobin assay An analyte assay that measures the abundance of haptoglobin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood haptoglobin assay OBI:2100110 venous blood lactate dehydrogenase assay An assay that measures lactate dehydrogenase in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood lactate dehydrogenase assay OBI:2100111 venous blood prealbunin assay An analyte assay that measures the abundance of prealbunin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood prealbunin assay OBI:2100112 lipid panel venous blood triglyceride assay An analyte assay that measures the abundance of triglyceride in venous blood as part of a lipid panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel venous blood triglyceride assay OBI:2100113 lipid panel venous blood high density lipoprotein assay An analyte assay that measures the abundance of high density lipoprotein in venous blood as part of a lipid panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel venous blood high density lipoprotein assay OBI:2100114 lipid panel venous blood cholesterol assay An analyte assay that measures the abundance of cholesterol in venous blood as part of a lipid panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel venous blood cholesterol assay OBI:2100115 lipid panel venous blood low density lipoprotein assay An analyte assay that measures the abundance of low density lipoprotein in venous blood as part of a lipid panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel venous blood low density lipoprotein assay OBI:2100116 venous blood hemoglobin A1c assay An assay that measures hemoglobin A1c in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood hemoglobin A1c assay OBI:2100117 venous blood uric acid assay An analyte assay that measures the abundance of uric acid in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood uric acid assay OBI:2100118 total venous blood protein assay An analyte assay that measures the abundance of protein in venous blood as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total venous blood protein assay OBI:2100119 venous blood thyroid stimulating hormone assay An analyte assay that measures the abundance of thyroid stimulating hormone in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood thyroid stimulating hormone assay OBI:2100120 venous blood prostate specific antigen assay An analyte assay that measures the abundance of prostate specific antigen in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood prostate specific antigen assay OBI:2100121 24 hour total urine volume assay An assay that measures volume in urine as part of a 24 hour total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 24 hour total urine volume assay OBI:2100122 T4 uptake venous blood T4 assay An analyte assay that measures the abundance of T4 in venous blood as part of a T4 uptake order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 T4 uptake venous blood T4 assay OBI:2100123 arterial blood glucose assay An analyte assay that measures the abundance of glucose in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood glucose assay OBI:2100124 CBC with manual differential venous blood cell count assay A cytometry assay that measures the count of cells in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood cell count assay OBI:2100125 hemoglobin oxygen saturation arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a hemoglobin oxygen saturation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hemoglobin oxygen saturation arterial blood oxygen assay OBI:2100126 hemoglobin oxygen saturation arterial blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in arterial blood as part of a hemoglobin oxygen saturation order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hemoglobin oxygen saturation arterial blood hemoglobin assay OBI:2100127 inpatient profile venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a inpatient profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 inpatient profile venous blood sodium assay OBI:2100128 inpatient profile venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood as part of a inpatient profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 inpatient profile venous blood creatinine assay OBI:2100129 inpatient profile venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a inpatient profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 inpatient profile venous blood potassium assay OBI:2100130 inpatient profile venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a inpatient profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 inpatient profile venous blood carbon dioxide assay OBI:2100131 venous blood folic acid assay An analyte assay that measures the abundance of folic acid in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood folic acid assay OBI:2100132 count venous blood reticulocyte count assay A cytometry assay that measures the count of reticulocytes in venous blood as part of a count order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 count venous blood reticulocyte count assay OBI:2100133 venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood potassium assay OBI:2100134 venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood carbon dioxide assay OBI:2100135 venous blood transferrin assay An analyte assay that measures the abundance of transferrin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood transferrin assay OBI:2100136 venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood sodium assay OBI:2100137 random electrolytes urine sodium assay An analyte assay that measures the abundance of sodium in urine as part of a random electrolytes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 random electrolytes urine sodium assay OBI:2100138 random electrolytes urine potassium assay An analyte assay that measures the abundance of potassium in urine as part of a random electrolytes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 random electrolytes urine potassium assay OBI:2100139 urine creatinine assay An analyte assay that measures the abundance of creatinine in urine Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 urine creatinine assay OBI:2100140 urine osmolality assay An assay that measures osmolality in urine Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 urine osmolality assay OBI:2100141 cooximitery arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a cooximitery order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cooximitery arterial blood oxygen assay OBI:2100142 cooximitery arterial blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in arterial blood as part of a cooximitery order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cooximitery arterial blood hemoglobin assay OBI:2100143 cooximitery arterial blood methemoglobin assay An analyte assay that measures the abundance of methemoglobin in arterial blood as part of a cooximitery order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cooximitery arterial blood methemoglobin assay OBI:2100144 electrolytes urine sodium assay An analyte assay that measures the abundance of sodium in urine as part of a electrolytes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 electrolytes urine sodium assay OBI:2100145 electrolytes urine potassium assay An analyte assay that measures the abundance of potassium in urine as part of a electrolytes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 electrolytes urine potassium assay OBI:2100146 Biosite cardiac panel arterial blood creatine kinase MB assay An assay that measures creatine kinase MB in arterial blood as part of a Biosite cardiac panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 Biosite cardiac panel arterial blood creatine kinase MB assay OBI:2100147 venous blood fibrinogen assay An assay that measures fibrinogen in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood fibrinogen assay OBI:2100148 comprehensive metabolic panel venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood carbon dioxide assay OBI:2100149 comprehensive metabolic panel venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood calcium assay OBI:2100150 comprehensive metabolic panel venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood potassium assay OBI:2100151 comprehensive metabolic panel venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood sodium assay OBI:2100152 comprehensive metabolic panel venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood glucose assay OBI:2100153 comprehensive metabolic panel venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood albumin assay OBI:2100154 comprehensive metabolic panel venous blood human alkaline phosphatase assay An analyte assay that measures the abundance of human alkaline phosphatase in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood human alkaline phosphatase assay OBI:2100155 comprehensive metabolic panel venous blood bilirubin assay An analyte assay that measures the abundance of bilirubin in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood bilirubin assay OBI:2100156 comprehensive metabolic panel venous blood chloride assay An analyte assay that measures the abundance of chloride in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood chloride assay OBI:2100157 comprehensive metabolic panel venous blood human aspartate aminotransferase assay An analyte assay that measures the abundance of human aspartate aminotransferase in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood human aspartate aminotransferase assay OBI:2100158 comprehensive metabolic panel venous blood protein assay An analyte assay that measures the abundance of protein in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood protein assay OBI:2100159 comprehensive metabolic panel venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood creatinine assay OBI:2100160 comprehensive metabolic panel venous blood alanine aminotransferase assay An analyte assay that measures the abundance of alanine aminotransferase in venous blood as part of a comprehensive metabolic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 comprehensive metabolic panel venous blood alanine aminotransferase assay OBI:2100161 venous blood LDH assay An assay that measures LDH in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood LDH assay OBI:2100162 venous blood creatine kinase MB assay An assay that measures creatine kinase MB in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood creatine kinase MB assay OBI:2100163 venous blood lactic acid assay An assay that measures lactic acid in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood lactic acid assay OBI:2100164 venous blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood hematocrit assay OBI:2100165 venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood creatinine assay OBI:2100166 blood gas venous blood oxygen assay An analyte assay that measures the abundance of oxygen in venous blood as part of a blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 blood gas venous blood oxygen assay OBI:2100167 ionized venous blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in venous blood as part of a ionized order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ionized venous blood ionized calcium assay OBI:2100168 blood gas venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 blood gas venous blood carbon dioxide assay OBI:2100169 blood gas venous blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in venous blood as part of a blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 blood gas venous blood bicarbonate assay OBI:2100170 arterial blood creatinine assay An analyte assay that measures the abundance of creatinine in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood creatinine assay OBI:2100171 venous blood tacrolimus assay An analyte assay that measures the abundance of tacrolimus in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood tacrolimus assay OBI:2100172 random venous blood vancomycin assay An analyte assay that measures the abundance of vancomycin in venous blood as part of a random order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 random venous blood vancomycin assay OBI:2100173 venous blood mycophenolic acid assay An analyte assay that measures the abundance of mycophenolic acid in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood mycophenolic acid assay OBI:2100174 non-vented blood gas arterial blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in arterial blood as part of a non-vented blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 non-vented blood gas arterial blood carbon dioxide assay OBI:2100175 non-vented blood gas arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a non-vented blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 non-vented blood gas arterial blood oxygen assay OBI:2100176 non-vented blood gas arterial blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in arterial blood as part of a non-vented blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 non-vented blood gas arterial blood bicarbonate assay OBI:2100177 quantitative venous blood IgG assay An assay that measures IgG in venous blood as part of a quantitative order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 quantitative venous blood IgG assay OBI:2100178 quantitative venous blood IgM assay An assay that measures IgM in venous blood as part of a quantitative order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 quantitative venous blood IgM assay OBI:2100179 quantitative venous blood IgA assay An assay that measures IgA in venous blood as part of a quantitative order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 quantitative venous blood IgA assay OBI:2100180 arterial blood sodium assay An analyte assay that measures the abundance of sodium in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood sodium assay OBI:2100181 arterial blood potassium assay An analyte assay that measures the abundance of potassium in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood potassium assay OBI:2100182 ionized arterial blood calcium assay An analyte assay that measures the abundance of calcium in arterial blood as part of a ionized order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ionized arterial blood calcium assay OBI:2100183 vented blood gas arterial blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in arterial blood as part of a vented blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 vented blood gas arterial blood bicarbonate assay OBI:2100184 vented blood gas arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a vented blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 vented blood gas arterial blood oxygen assay OBI:2100185 vented blood gas arterial blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in arterial blood as part of a vented blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 vented blood gas arterial blood carbon dioxide assay OBI:2100186 arterial blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood hematocrit assay OBI:2100187 arterial blood chloride assay An analyte assay that measures the abundance of chloride in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood chloride assay OBI:2100188 arterial blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood hemoglobin assay OBI:2100189 GEM premier blood gas venous blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood hematocrit assay OBI:2100190 GEM premier blood gas venous blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood ionized calcium assay OBI:2100191 GEM premier blood gas venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood potassium assay OBI:2100192 GEM premier blood gas venous blood oxygen assay An analyte assay that measures the abundance of oxygen in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood oxygen assay OBI:2100193 GEM premier blood gas venous blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood hemoglobin assay OBI:2100194 GEM premier blood gas venous blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood bicarbonate assay OBI:2100195 GEM premier blood gas venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood glucose assay OBI:2100196 GEM premier blood gas venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood sodium assay OBI:2100197 GEM premier blood gas venous blood lactic acid assay An assay that measures lactic acid in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood lactic acid assay OBI:2100198 GEM premier blood gas venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a GEM premier blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM premier blood gas venous blood carbon dioxide assay OBI:2100199 trough venous blood tobramycin assay An analyte assay that measures the abundance of tobramycin in venous blood as part of a trough order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 trough venous blood tobramycin assay OBI:2100200 random venous blood tobramycin assay An analyte assay that measures the abundance of tobramycin in venous blood as part of a random order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 random venous blood tobramycin assay OBI:2100201 CBC with manual differential venous blood metamyelocyte count assay A cytometry assay that measures the count of metamyelocytes in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood metamyelocyte count assay OBI:2100202 arterial blood lactic acid assay An assay that measures lactic acid in arterial blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 arterial blood lactic acid assay OBI:2100203 venous blood 25-hydroxyvitamin D2 assay An analyte assay that measures the abundance of 25-hydroxyvitamin D2 in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood 25-hydroxyvitamin D2 assay OBI:2100204 venous blood digoxin assay An analyte assay that measures the abundance of digoxin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood digoxin assay OBI:2100205 urine protein assay An analyte assay that measures the abundance of protein in urine Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 urine protein assay OBI:2100206 venous blood tobramycin assay An analyte assay that measures the abundance of tobramycin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood tobramycin assay OBI:2100207 CBC with manual differential venous blood myelocyte count assay A cytometry assay that measures the count of myelocytes in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood myelocyte count assay OBI:2100208 SPEP protein electrophoresis venous blood beta-globin assay An analyte assay that measures the abundance of beta-globin in venous blood as part of a SPEP protein electrophoresis order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 SPEP protein electrophoresis venous blood beta-globin assay OBI:2100209 SPEP protein electrophoresis venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a SPEP protein electrophoresis order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 SPEP protein electrophoresis venous blood albumin assay OBI:2100210 SPEP protein electrophoresis venous blood protein assay An analyte assay that measures the abundance of protein in venous blood as part of a SPEP protein electrophoresis order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 SPEP protein electrophoresis venous blood protein assay OBI:2100211 trough venous blood vancomycin assay An analyte assay that measures the abundance of vancomycin in venous blood as part of a trough order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 trough venous blood vancomycin assay OBI:2100212 hepatic panel venous blood protein assay An analyte assay that measures the abundance of protein in venous blood as part of a hepatic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hepatic panel venous blood protein assay OBI:2100213 hepatic panel venous blood bilirubin assay An analyte assay that measures the abundance of bilirubin in venous blood as part of a hepatic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hepatic panel venous blood bilirubin assay OBI:2100214 hepatic panel venous blood alanine aminotransferase assay An analyte assay that measures the abundance of alanine aminotransferase in venous blood as part of a hepatic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hepatic panel venous blood alanine aminotransferase assay OBI:2100215 hepatic panel venous blood human aspartate aminotransferase assay An analyte assay that measures the abundance of human aspartate aminotransferase in venous blood as part of a hepatic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hepatic panel venous blood human aspartate aminotransferase assay OBI:2100216 hepatic panel venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a hepatic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hepatic panel venous blood albumin assay OBI:2100217 hepatic panel venous blood human alkaline phosphatase assay An analyte assay that measures the abundance of human alkaline phosphatase in venous blood as part of a hepatic panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hepatic panel venous blood human alkaline phosphatase assay OBI:2100218 estimated venous blood glomerular filtration assay An assay that measures glomerular filtration in venous blood as part of a estimated order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 estimated venous blood glomerular filtration assay OBI:2100219 DT60 venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood as part of a DT60 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 DT60 venous blood creatinine assay OBI:2100220 fasting venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood as part of a fasting order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 fasting venous blood glucose assay OBI:2100221 random venous blood amikacin assay An analyte assay that measures the abundance of amikacin in venous blood as part of a random order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 random venous blood amikacin assay OBI:2100222 venous blood ammonia assay An analyte assay that measures the abundance of ammonia in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood ammonia assay OBI:2100223 venous blood GGT assay An analyte assay that measures the abundance of GGT in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood GGT assay OBI:2100224 chem11 venous blood phosphate assay An analyte assay that measures the abundance of phosphate in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood phosphate assay OBI:2100225 chem11 venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood potassium assay OBI:2100226 chem11 venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood calcium assay OBI:2100227 chem11 venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood glucose assay OBI:2100228 chem11 venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood carbon dioxide assay OBI:2100229 chem11 venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood albumin assay OBI:2100230 chem11 venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood sodium assay OBI:2100231 chem11 venous blood magnesium assay An analyte assay that measures the abundance of magnesium in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood magnesium assay OBI:2100232 chem11 venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood creatinine assay OBI:2100233 chem11 venous blood chloride assay An analyte assay that measures the abundance of chloride in venous blood as part of a chem11 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem11 venous blood chloride assay OBI:2100234 total venous blood IgE assay An assay that measures IgE in venous blood as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total venous blood IgE assay OBI:2100235 chem16 venous blood human aspartate aminotransferase assay An analyte assay that measures the abundance of human aspartate aminotransferase in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood human aspartate aminotransferase assay OBI:2100236 chem16 venous blood creatinine assay An analyte assay that measures the abundance of creatinine in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood creatinine assay OBI:2100237 chem16 venous blood magnesium assay An analyte assay that measures the abundance of magnesium in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood magnesium assay OBI:2100238 chem16 venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood carbon dioxide assay OBI:2100239 chem16 venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood glucose assay OBI:2100240 chem16 venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood calcium assay OBI:2100241 chem16 venous blood triglyceride assay An analyte assay that measures the abundance of triglyceride in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood triglyceride assay OBI:2100242 chem16 venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood sodium assay OBI:2100243 chem16 venous blood phosphate assay An analyte assay that measures the abundance of phosphate in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood phosphate assay OBI:2100244 chem16 venous blood human alkaline phosphatase assay An analyte assay that measures the abundance of human alkaline phosphatase in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood human alkaline phosphatase assay OBI:2100245 chem16 venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood albumin assay OBI:2100246 chem16 venous blood bilirubin assay An analyte assay that measures the abundance of bilirubin in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood bilirubin assay OBI:2100247 chem16 venous blood chloride assay An analyte assay that measures the abundance of chloride in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood chloride assay OBI:2100248 chem16 venous blood alanine aminotransferase assay An analyte assay that measures the abundance of alanine aminotransferase in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood alanine aminotransferase assay OBI:2100249 chem16 venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a chem16 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 chem16 venous blood potassium assay OBI:2100250 POC chem8 arterial blood glucose assay An analyte assay that measures the abundance of glucose in arterial blood as part of a POC chem8 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC chem8 arterial blood glucose assay OBI:2100251 POC chem8 arterial blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in arterial blood as part of a POC chem8 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC chem8 arterial blood ionized calcium assay OBI:2100252 POC chem8 arterial blood potassium assay An analyte assay that measures the abundance of potassium in arterial blood as part of a POC chem8 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC chem8 arterial blood potassium assay OBI:2100253 POC chem8 arterial blood sodium assay An analyte assay that measures the abundance of sodium in arterial blood as part of a POC chem8 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC chem8 arterial blood sodium assay OBI:2100254 POC chem8 arterial blood creatinine assay An analyte assay that measures the abundance of creatinine in arterial blood as part of a POC chem8 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC chem8 arterial blood creatinine assay OBI:2100255 POC chem8 arterial blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in arterial blood as part of a POC chem8 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC chem8 arterial blood hematocrit assay OBI:2100256 POC chem8 arterial blood chloride assay An analyte assay that measures the abundance of chloride in arterial blood as part of a POC chem8 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC chem8 arterial blood chloride assay OBI:2100257 peak venous blood tobramycin assay An analyte assay that measures the abundance of tobramycin in venous blood as part of a peak order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 peak venous blood tobramycin assay OBI:2100258 24 hour urine creatinine assay An analyte assay that measures the abundance of creatinine in urine as part of a 24 hour order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 24 hour urine creatinine assay OBI:2100259 intact venous blood PTH assay An analyte assay that measures the abundance of PTH in venous blood as part of a intact order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 intact venous blood PTH assay OBI:2100260 total venous blood PSA assay An analyte assay that measures the abundance of PSA in venous blood as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total venous blood PSA assay OBI:2100261 total venous blood T3 assay An analyte assay that measures the abundance of T3 in venous blood as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total venous blood T3 assay OBI:2100262 24 hour urine protein assay An analyte assay that measures the abundance of protein in urine as part of a 24 hour order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 24 hour urine protein assay OBI:2100263 total venous blood cholesterol assay An analyte assay that measures the abundance of cholesterol in venous blood as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total venous blood cholesterol assay OBI:2100264 venous blood triglyceride assay An analyte assay that measures the abundance of triglyceride in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood triglyceride assay OBI:2100265 tube 4 count cerebrospinal fluid cell count assay A cytometry assay that measures the count of cells in cerebrospinal fluid as part of a tube 4 count order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 tube 4 count cerebrospinal fluid cell count assay OBI:2100266 cerebrospinal fluid protein assay An analyte assay that measures the abundance of protein in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid protein assay OBI:2100267 cerebrospinal fluid glucose assay An analyte assay that measures the abundance of glucose in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid glucose assay OBI:2100268 tube 1 count cerebrospinal fluid cell count assay A cytometry assay that measures the count of cells in cerebrospinal fluid as part of a tube 1 count order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 tube 1 count cerebrospinal fluid cell count assay OBI:2100269 venous blood dehydroepiandrosterone assay An analyte assay that measures the abundance of dehydroepiandrosterone in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood dehydroepiandrosterone assay OBI:2100270 venous blood cortisol assay An analyte assay that measures the abundance of cortisol in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood cortisol assay OBI:2100271 ABL90 panel arterial blood sodium assay An analyte assay that measures the abundance of sodium in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood sodium assay OBI:2100272 ABL90 panel arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood oxygen assay OBI:2100273 ABL90 panel arterial blood glucose assay An analyte assay that measures the abundance of glucose in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood glucose assay OBI:2100274 ABL90 panel arterial blood lactic acid assay An assay that measures lactic acid in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood lactic acid assay OBI:2100275 ABL90 panel arterial blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood hemoglobin assay OBI:2100276 ABL90 panel arterial blood chloride assay An analyte assay that measures the abundance of chloride in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood chloride assay OBI:2100277 ABL90 panel arterial blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood carbon dioxide assay OBI:2100278 ABL90 panel arterial blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood hematocrit assay OBI:2100279 ABL90 panel arterial blood calcium assay An analyte assay that measures the abundance of calcium in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood calcium assay OBI:2100280 ABL90 panel arterial blood temperature assay An assay that measures temperature in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood temperature assay OBI:2100281 ABL90 panel arterial blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood bicarbonate assay OBI:2100282 ABL90 panel arterial blood potassium assay An analyte assay that measures the abundance of potassium in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood potassium assay OBI:2100283 CBC with manual differential venous blood promyelocyte count assay A cytometry assay that measures the count of promyelocytes in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood promyelocyte count assay OBI:2100284 ABL90 panel venous blood glucose assay An analyte assay that measures the abundance of glucose in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood glucose assay OBI:2100285 ABL90 panel venous blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood hemoglobin assay OBI:2100286 ABL90 panel venous blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood ionized calcium assay OBI:2100287 ABL90 panel venous blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood carbon dioxide assay OBI:2100288 ABL90 panel venous blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood hematocrit assay OBI:2100289 ABL90 panel venous blood sodium assay An analyte assay that measures the abundance of sodium in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood sodium assay OBI:2100290 ABL90 panel venous blood oxygen assay An analyte assay that measures the abundance of oxygen in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood oxygen assay OBI:2100291 ABL90 panel venous blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood bicarbonate assay OBI:2100292 ABL90 panel venous blood lactic acid assay An assay that measures lactic acid in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood lactic acid assay OBI:2100293 ABL90 panel venous blood chloride assay An analyte assay that measures the abundance of chloride in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood chloride assay OBI:2100294 venous blood T4 assay An analyte assay that measures the abundance of T4 in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood T4 assay OBI:2100295 free venous blood T4 assay An analyte assay that measures the abundance of T4 in venous blood as part of a free order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 free venous blood T4 assay OBI:2100296 ABL90 panel venous blood potassium assay An analyte assay that measures the abundance of potassium in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood potassium assay OBI:2100297 urine sodium assay An analyte assay that measures the abundance of sodium in urine Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 urine sodium assay OBI:2100298 bone profile venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a bone profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bone profile venous blood albumin assay OBI:2100299 bone profile venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood as part of a bone profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bone profile venous blood calcium assay OBI:2100300 bone profile venous blood human alkaline phosphatase assay An analyte assay that measures the abundance of human alkaline phosphatase in venous blood as part of a bone profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bone profile venous blood human alkaline phosphatase assay OBI:2100301 bone profile venous blood protein assay An analyte assay that measures the abundance of protein in venous blood as part of a bone profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bone profile venous blood protein assay OBI:2100302 bone profile venous blood phosphate assay An analyte assay that measures the abundance of phosphate in venous blood as part of a bone profile order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bone profile venous blood phosphate assay OBI:2100303 ABG/electrolytes arterial blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in arterial blood as part of a ABG/electrolytes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABG/electrolytes arterial blood carbon dioxide assay OBI:2100304 ABG/electrolytes arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a ABG/electrolytes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABG/electrolytes arterial blood oxygen assay OBI:2100305 ABG/electrolytes arterial blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in arterial blood as part of a ABG/electrolytes order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABG/electrolytes arterial blood ionized calcium assay OBI:2100306 CBC with automated differential venous blood nucleated RBC count assay A cytometry assay that measures the count of nucleated RBCs in venous blood as part of a CBC with automated differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with automated differential venous blood nucleated RBC count assay OBI:2100307 ABL90 panel venous blood methemoglobin assay An analyte assay that measures the abundance of methemoglobin in venous blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel venous blood methemoglobin assay OBI:2100308 ABL90 panel arterial blood methemoglobin assay An analyte assay that measures the abundance of methemoglobin in arterial blood as part of a ABL90 panel order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ABL90 panel arterial blood methemoglobin assay OBI:2100309 venous blood valproic acid assay An analyte assay that measures the abundance of valproic acid in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood valproic acid assay OBI:2100310 high sensitivity cardiac/neonatal venous blood c-reactive protein assay An analyte assay that measures the abundance of c-reactive protein in venous blood as part of a high sensitivity cardiac/neonatal order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 high sensitivity cardiac/neonatal venous blood c-reactive protein assay OBI:2100311 POC arterial blood creatinine assay An analyte assay that measures the abundance of creatinine in arterial blood as part of a POC order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 POC arterial blood creatinine assay OBI:2100312 GEM4000 ANLCOOX arterial blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood bicarbonate assay OBI:2100313 GEM4000 ANLCOOX arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood oxygen assay OBI:2100314 GEM4000 ANLCOOX arterial blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood hematocrit assay OBI:2100315 GEM4000 ANLCOOX arterial blood temperature assay An assay that measures temperature in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood temperature assay OBI:2100316 GEM4000 ANLCOOX arterial blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood hemoglobin assay OBI:2100317 GEM4000 ANLCOOX arterial blood potassium assay An analyte assay that measures the abundance of potassium in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood potassium assay OBI:2100318 GEM4000 ANLCOOX arterial blood glucose assay An analyte assay that measures the abundance of glucose in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood glucose assay OBI:2100319 GEM4000 ANLCOOX arterial blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood ionized calcium assay OBI:2100320 GEM4000 ANLCOOX arterial blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood carbon dioxide assay OBI:2100321 GEM4000 ANLCOOX arterial blood sodium assay An analyte assay that measures the abundance of sodium in arterial blood as part of a GEM4000 ANLCOOX order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4000 ANLCOOX arterial blood sodium assay OBI:2100322 ionized venous blood calcium assay An analyte assay that measures the abundance of calcium in venous blood as part of a ionized order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 ionized venous blood calcium assay OBI:2100323 venous blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood hemoglobin assay OBI:2100324 CBC with manual differential venous blood megakaryocyte count assay A cytometry assay that measures the count of megakaryocytes in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood megakaryocyte count assay OBI:2100325 non-cardiac venous blood c-reactive protein assay An analyte assay that measures the abundance of c-reactive protein in venous blood as part of a non-cardiac order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 non-cardiac venous blood c-reactive protein assay OBI:2100326 intraoperative venous blood PTH assay An analyte assay that measures the abundance of PTH in venous blood as part of a intraoperative order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 intraoperative venous blood PTH assay OBI:2100327 venous blood parathyroid hormone assay An analyte assay that measures the abundance of parathyroid hormone in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood parathyroid hormone assay OBI:2100328 total bodily fluid protein assay An analyte assay that measures the abundance of protein in bodily fluid as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total bodily fluid protein assay OBI:2100329 bodily fluid glucose assay An analyte assay that measures the abundance of glucose in bodily fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bodily fluid glucose assay OBI:2100330 count bodily fluid cell count assay A cytometry assay that measures the count of cells in bodily fluid as part of a count order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 count bodily fluid cell count assay OBI:2100331 manual differential bodily fluid segmented neutrophil count assay A cytometry assay that measures the count of segmented neutrophils in bodily fluid as part of a manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 manual differential bodily fluid segmented neutrophil count assay OBI:2100332 manual differential bodily fluid mesothelial cell count assay A cytometry assay that measures the count of mesothelial cells in bodily fluid as part of a manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 manual differential bodily fluid mesothelial cell count assay OBI:2100333 manual differential bodily fluid monocyte count assay A cytometry assay that measures the count of monocytes in bodily fluid as part of a manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 manual differential bodily fluid monocyte count assay OBI:2100334 manual differential bodily fluid lymphocyte count assay A cytometry assay that measures the count of lymphocytes in bodily fluid as part of a manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 manual differential bodily fluid lymphocyte count assay OBI:2100335 manual differential bodily fluid macrophage count assay A cytometry assay that measures the count of macrophages in bodily fluid as part of a manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 manual differential bodily fluid macrophage count assay OBI:2100336 manual differential bodily fluid basophil count assay A cytometry assay that measures the count of basophils in bodily fluid as part of a manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 manual differential bodily fluid basophil count assay OBI:2100337 manual differential bodily fluid eosinophil count assay A cytometry assay that measures the count of eosinophils in bodily fluid as part of a manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 manual differential bodily fluid eosinophil count assay OBI:2100338 liver function venous blood bilirubin assay An analyte assay that measures the abundance of bilirubin in venous blood as part of a liver function order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver function venous blood bilirubin assay OBI:2100339 liver function venous blood alanine aminotransferase assay An analyte assay that measures the abundance of alanine aminotransferase in venous blood as part of a liver function order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver function venous blood alanine aminotransferase assay OBI:2100340 liver function venous blood human aspartate aminotransferase assay An analyte assay that measures the abundance of human aspartate aminotransferase in venous blood as part of a liver function order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver function venous blood human aspartate aminotransferase assay OBI:2100341 liver function venous blood albumin assay An analyte assay that measures the abundance of albumin in venous blood as part of a liver function order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver function venous blood albumin assay OBI:2100342 liver function venous blood protein assay An analyte assay that measures the abundance of protein in venous blood as part of a liver function order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver function venous blood protein assay OBI:2100343 liver function venous blood human alkaline phosphatase assay An analyte assay that measures the abundance of human alkaline phosphatase in venous blood as part of a liver function order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver function venous blood human alkaline phosphatase assay OBI:2100344 vitamin B12 and Folate venous blood folic acid assay An analyte assay that measures the abundance of folic acid in venous blood as part of a vitamin B12 and Folate order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 vitamin B12 and Folate venous blood folic acid assay OBI:2100345 bodily fluid cell count assay A cytometry assay that measures the count of cells in bodily fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bodily fluid cell count assay OBI:2100346 venous blood reticulocyte count assay A cytometry assay that measures the count of reticulocytes in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood reticulocyte count assay OBI:2100347 bodily fluid cholesterol assay An analyte assay that measures the abundance of cholesterol in bodily fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bodily fluid cholesterol assay OBI:2100348 TSH reflex Free T4 venous blood thyroid stimulating hormone assay An analyte assay that measures the abundance of thyroid stimulating hormone in venous blood as part of a TSH reflex Free T4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 TSH reflex Free T4 venous blood thyroid stimulating hormone assay OBI:2100349 direct venous blood bilirubin assay An analyte assay that measures the abundance of bilirubin in venous blood as part of a direct order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 direct venous blood bilirubin assay OBI:2100350 free venous blood T3 assay An analyte assay that measures the abundance of T3 in venous blood as part of a free order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 free venous blood T3 assay OBI:2100351 bodily fluid albumin assay An analyte assay that measures the abundance of albumin in bodily fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bodily fluid albumin assay OBI:2100352 bodily fluid triglyceride assay An analyte assay that measures the abundance of triglyceride in bodily fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 bodily fluid triglyceride assay OBI:2100353 hemoglobin and hematocrit venous blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in venous blood as part of a hemoglobin and hematocrit order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hemoglobin and hematocrit venous blood hematocrit assay OBI:2100354 hemoglobin and hematocrit venous blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in venous blood as part of a hemoglobin and hematocrit order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 hemoglobin and hematocrit venous blood hemoglobin assay OBI:2100355 venous blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood ionized calcium assay OBI:2100356 venous blood temperature assay An assay that measures temperature in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood temperature assay OBI:2100357 venous blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood bicarbonate assay OBI:2100358 venous blood oxygen assay An analyte assay that measures the abundance of oxygen in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood oxygen assay OBI:2100359 venous blood osmolality assay An assay that measures osmolality in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood osmolality assay OBI:2100360 liver fibrosis (chronic viral hepatitis) venous blood platelet count assay A cytometry assay that measures the count of platelets in venous blood as part of a liver fibrosis (chronic viral hepatitis) order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver fibrosis (chronic viral hepatitis) venous blood platelet count assay OBI:2100361 venous blood T3 assay An analyte assay that measures the abundance of T3 in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood T3 assay OBI:2100362 CBC with manual differential venous blood neutrophil count assay A cytometry assay that measures the count of neutrophils in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood neutrophil count assay OBI:2100363 creatinine clearance urine creatinine assay An analyte assay that measures the abundance of creatinine in urine as part of a creatinine clearance order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 creatinine clearance urine creatinine assay OBI:2100364 venous blood beta hydroxybutryic acid assay An analyte assay that measures the abundance of beta hydroxybutryic acid in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood beta hydroxybutryic acid assay OBI:2100365 venous blood megakaryocyte count assay A cytometry assay that measures the count of megakaryocytes in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood megakaryocyte count assay OBI:2100366 venous blood nucleated RBC count assay A cytometry assay that measures the count of nucleated RBCs in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood nucleated RBC count assay OBI:2100367 venous blood WBC count assay A cytometry assay that measures the count of WBCs in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood WBC count assay OBI:2100368 automated count venous blood reticulocyte count assay A cytometry assay that measures the count of reticulocytes in venous blood as part of a automated count order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 automated count venous blood reticulocyte count assay OBI:2100369 total venous blood homocysteine assay An analyte assay that measures the abundance of homocysteine in venous blood as part of a total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 total venous blood homocysteine assay OBI:2100370 venous blood Ceruloplasmin assay An analyte assay that measures the abundance of Ceruloplasmin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood Ceruloplasmin assay OBI:2100371 GEM4 arterial blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood bicarbonate assay OBI:2100372 GEM4 arterial blood lactic acid assay An assay that measures lactic acid in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood lactic acid assay OBI:2100373 GEM4 arterial blood hemoglobin assay An analyte assay that measures the abundance of hemoglobin in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood hemoglobin assay OBI:2100374 GEM4 arterial blood sodium assay An analyte assay that measures the abundance of sodium in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood sodium assay OBI:2100375 GEM4 arterial blood potassium assay An analyte assay that measures the abundance of potassium in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood potassium assay OBI:2100376 GEM4 arterial blood temperature assay An assay that measures temperature in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood temperature assay OBI:2100377 GEM4 arterial blood glucose assay An analyte assay that measures the abundance of glucose in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood glucose assay OBI:2100378 GEM4 arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood oxygen assay OBI:2100379 GEM4 arterial blood hematocrit assay A cytometry assay that measures the proportion of red blood cells in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood hematocrit assay OBI:2100380 GEM4 arterial blood ionized calcium assay An analyte assay that measures the abundance of ionized calcium in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood ionized calcium assay OBI:2100381 GEM4 arterial blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in arterial blood as part of a GEM4 order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 GEM4 arterial blood carbon dioxide assay OBI:2100382 liver fibrosis (NAFLD) venous blood platelet count assay A cytometry assay that measures the count of platelets in venous blood as part of a liver fibrosis (NAFLD) order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 liver fibrosis (NAFLD) venous blood platelet count assay OBI:2100383 venous blood beta hydroxybutric acid assay An analyte assay that measures the abundance of beta hydroxybutric acid in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood beta hydroxybutric acid assay OBI:2100384 CBC with manual differential venous blood plasma cell count assay A cytometry assay that measures the count of plasma cells in venous blood as part of a CBC with manual differential order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 CBC with manual differential venous blood plasma cell count assay OBI:2100385 venous blood erythropoietin assay An analyte assay that measures the abundance of erythropoietin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood erythropoietin assay OBI:2100386 blood gas arterial blood oxygen assay An analyte assay that measures the abundance of oxygen in arterial blood as part of a blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 blood gas arterial blood oxygen assay OBI:2100387 blood gas arterial blood bicarbonate assay An analyte assay that measures the abundance of bicarbonate in arterial blood as part of a blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 blood gas arterial blood bicarbonate assay OBI:2100388 blood gas arterial blood carbon dioxide assay An analyte assay that measures the abundance of carbon dioxide in arterial blood as part of a blood gas order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 blood gas arterial blood carbon dioxide assay OBI:2100389 free/total venous blood PSA assay An analyte assay that measures the abundance of PSA in venous blood as part of a free/total order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 free/total venous blood PSA assay OBI:2100390 cerebrospinal fluid lymphocyte count assay A cytometry assay that measures the count of lymphocytes in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid lymphocyte count assay OBI:2100391 cerebrospinal fluid segmented neutrophil count assay A cytometry assay that measures the count of segmented neutrophils in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid segmented neutrophil count assay OBI:2100392 cerebrospinal fluid mesothelial cell count assay A cytometry assay that measures the count of mesothelial cells in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid mesothelial cell count assay OBI:2100393 cerebrospinal fluid macrophage count assay A cytometry assay that measures the count of macrophages in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid macrophage count assay OBI:2100394 cerebrospinal fluid basophil count assay A cytometry assay that measures the count of basophils in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid basophil count assay OBI:2100395 cerebrospinal fluid monocyte count assay A cytometry assay that measures the count of monocytes in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid monocyte count assay OBI:2100396 cerebrospinal fluid eosinophil count assay A cytometry assay that measures the count of eosinophils in cerebrospinal fluid Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 cerebrospinal fluid eosinophil count assay OBI:2100397 venous blood beta-2-microglobulin assay An analyte assay that measures the abundance of beta-2-microglobulin in venous blood Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 venous blood beta-2-microglobulin assay OBI:2100398 lipid panel reflex direct venous blood low density lipoprotein assay An analyte assay that measures the abundance of low density lipoprotein in venous blood as part of a Lipid panel reflex direct order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel reflex direct venous blood low density lipoprotein assay OBI:2100399 lipid panel reflex direct venous blood triglyceride assay An analyte assay that measures the abundance of triglyceride in venous blood as part of a Lipid panel reflex direct order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel reflex direct venous blood triglyceride assay OBI:2100400 lipid panel reflex direct venous blood cholesterol assay An analyte assay that measures the abundance of cholesterol in venous blood as part of a Lipid panel reflex direct order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel reflex direct venous blood cholesterol assay OBI:2100401 lipid panel reflex direct venous blood high density lipoprotein assay An analyte assay that measures the abundance of high density lipoprotein in venous blood as part of a Lipid panel reflex direct order Mark A. Miller, ORCID:0000-0001-9076-6066 & Chris Stoeckert, ORCID ORCID:0000-0002-5714-991X PennTURBO team https://github.com/obi-ontology/obi/issues/1253 lipid panel reflex direct venous blood high density lipoprotein assay OBI:2100402 pooled clone sequencing assay Although a similar pooled clone sequencing method has recently been described by others for metagenome-derived medium-insert plasmids and large-insert fosmids, to our knowledge, we are the first to report the pooled strategy for sequencing of large-insert metagenomic clones while also critically evaluating the performance of this pooled strategy by comparing the results to barcoded reference sequences of the same clones. A DNA sequencing assay in which the DNA input is derived from pooled clones (for example BACs and Fosmids) is sequenced. Dan Berrios, ORCID: 0000-0003-4312-9552 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049660/ https://github.com/obi-ontology/obi/issues/1106 Bonita Lam pooled clone sequencing assay OBI:9999994 chromium release assay Autologous EBV-transformed B-LCL were used as target cells for the influenza virus-specific CTL assays. Equal volumes of target and effector cells were added to triplicate wells of 96-well tissue culture plates, and 1:2 serial dilutions of effectors were made, producing effector-to-target (E:T) ratios of 100:1, 50:1, 25:1, and 12.5:1. After a 4-h incubation of the effector cells with the target cells, supernatants were collected following brief centrifugation and transferred to polystyrene tubes to be counted with the LKB 1272 Clinigamma counter (Wallac). Percent specific killing was determined with the following equation: (experimental 51Cr release - spontaneous 51Cr release)/(maximum 51Cr release - spontaneous 51Cr release) x 100. An in vitro cell killing assay in which radioactive chromium is absorbed by cells and released into supernatant when the cells die. The amount of radioactivity measured in the supernatant is a proxy for the number of cells that have died. IEDB PlanAndPlannedProcess Branch chromium release assay A time quality inhering in a bearer by virtue of how long the bearer has existed. quality PATO:0000011 age PATO:0000011 A time quality inhering in a bearer by virtue of how long the bearer has existed. WordNet:WordNet PATO:0000033 A quality inhering in a substance by virtue of the amount of the bearer's there is mixed with another substance. concentration quality PATO:0000033 concentration of PATO:0000033 A quality inhering in a substance by virtue of the amount of the bearer's there is mixed with another substance. Wikipedia:http://en.wikipedia.org/wiki/concentration A physical quality which inheres in a bearer by virtue of the number of the bearer's repetitive actions in a particular time. quality PATO:0000044 frequency PATO:0000044 A physical quality which inheres in a bearer by virtue of the number of the bearer's repetitive actions in a particular time. Wikipedia:http://en.wikipedia.org/wiki/frequency A quality inhering in a bearer by virtue of the bearer's possessing or displaying a distinctive feature in type or degree or effect or force. quality PATO:0000049 intensity PATO:0000049 A quality inhering in a bearer by virtue of the bearer's possessing or displaying a distinctive feature in type or degree or effect or force. PATOC:GVG quality PATO:0000068 TODO: define this or obsolete it and move children somewhere else. qualitative PATO:0000068 PATO:0000117 A morphology quality inhering in a bearer by virtue of the bearer's physical magnitude. quality PATO:0000117 size PATO:0000117 A morphology quality inhering in a bearer by virtue of the bearer's physical magnitude. WordNet:WordNet A 1-D extent quality inhering in a bearer by virtue of the bearer's vertical dimension of extension. quality PATO:0000119 height PATO:0000119 A 1-D extent quality inhering in a bearer by virtue of the bearer's vertical dimension of extension. PATOC:GVG A 1-D extent quality which is equal to the distance between two points. https://github.com/pato-ontology/pato/issues/337 quality PATO:0000122 Length often refers to the longer or longest dimension of an object, however, this is not always true. See https://github.com/pato-ontology/pato/issues/337 for full discussion. length PATO:0000122 A 1-D extent quality which is equal to the distance between two points. PATOC:GVG A physical quality that inheres in a bearer by virtue of the proportion of the bearer's amount of matter. quality PATO:0000125 For any biological use of PATO, the concept that should be used is 'mass' and not 'weight'. For example, increased weight of an organism. mass PATO:0000125 A physical quality that inheres in a bearer by virtue of the proportion of the bearer's amount of matter. PATOC:GVG A physical quality of the thermal energy of a system. quality PATO:0000146 temperature PATO:0000146 A physical quality of the thermal energy of a system. PATOC:GVG A morphologic quality inhering in a bearer by virtue of the bearer's relative size, organization and distribution of its surface elements or the representation or invention of the appearance of its surface; visual and tactile surface characteristics. quality PATO:0000150 texture PATO:0000150 A morphologic quality inhering in a bearer by virtue of the bearer's relative size, organization and distribution of its surface elements or the representation or invention of the appearance of its surface; visual and tactile surface characteristics. PATOC:GVG PATO:0000161 A quality of a single process inhering in a bearer by virtue of the bearer's occurrence per unit time. quality PATO:0000161 rate PATO:0000161 A quality of a single process inhering in a bearer by virtue of the bearer's occurrence per unit time. PATOC:melissa A quality of a single physical entity which is held by a bearer when the latter exhibits a state of growth, differentiation, or development. quality PATO:0000261 maturity PATO:0000261 A quality of a single physical entity which is held by a bearer when the latter exhibits a state of growth, differentiation, or development. Merriam-Webster:Merriam-Webster quality PATO:0000371 obsolete distance value true PATO:0000371 A frequency which is relatively high. high frequency quality frequent PATO:0000380 increased frequency PATO:0000380 A frequency which is relatively high. PATOC:GVG A frequency which is relatively low. low frequency quality infrequent PATO:0000381 decreased frequency PATO:0000381 A frequency which is relatively low. PATOC:GVG A height which is relatively low. quality short PATO:0000569 decreased height PATO:0000569 A height which is relatively low. PATOC:GVG A height which is relatively high. quality tall PATO:0000570 increased height PATO:0000570 A height which is relatively high. PATOC:GVG A length quality which is relatively large. long quality PATO:0000573 increased length PATO:0000573 A length quality which is relatively large. PATOC:GVG A length quality which is relatively small. short quality shortened stubby PATO:0000574 decreased length PATO:0000574 A length quality which is relatively small. PATOC:GVG An increased size quality inhering in a bearer by virtue of the bearer's exhibiting enlargement of a cell or constituent group of cells (for example, organ). hypertrophy quality PATO:0000584 hypertrophic PATO:0000584 An increased size quality inhering in a bearer by virtue of the bearer's exhibiting enlargement of a cell or constituent group of cells (for example, organ). PATOC:MAH A decreased size quality inhering in a bearer by virtue of the bearer's exhibiting reduced size of a cell or constituent group of cells (for example, organ). PATO:0000412 shrunken quality PATO:0000585 hypotrophic PATO:0000585 A decreased size quality inhering in a bearer by virtue of the bearer's exhibiting reduced size of a cell or constituent group of cells (for example, organ). PATOC:MAH A size quality which is relatively high. PATO:0001202 quality big enlarged expanded great large PATO:0000586 increased size PATO:0000586 A size quality which is relatively high. PATOC:GVG A size quality which is relatively low. hypoplasia underdeveloped quality reduced small tiny PATO:0000587 decreased size PATO:0000587 A size quality which is relatively low. PATOC:GVG A thickness which is relatively high. high thickness stout thickened quality thick PATO:0000591 increased thickness PATO:0000591 A thickness which is relatively high. PATOC:GVG A thickness which is relatively low. low thickness quality slender thin PATO:0000592 decreased thickness PATO:0000592 A thickness which is relatively low. PATOC:GVG A volume which is relatively high. high volume quality large volume PATO:0000595 increased volume PATO:0000595 A volume which is relatively high. PATOC:GVG A volume which is relatively low. low volume quality small volume PATO:0000596 decreased volume PATO:0000596 A volume which is relatively low. PATOC:GVG A width which is relatively small. quality narrow PATO:0000599 decreased width PATO:0000599 A width which is relatively small. PATOC:GVG A width which is relatively large. quality broad wide wide/broad PATO:0000600 increased width PATO:0000600 A width which is relatively large. PATOC:GVG A rate which is relatively low. slow rate quality PATO:0000911 decreased rate PATO:0000911 A rate which is relatively low. PATO:GVG A rate which is relatively high. fast rate high rate quality PATO:0000912 increased rate PATO:0000912 A rate which is relatively high. PATO:GVG A 1-D extent quality which is equal to the dimension through an object as opposed to its length or width. https://github.com/pato-ontology/pato/issues/337 quality PATO:0000915 Thickness often refers to the smallest 1-D extent compared to the other two orthogonal dimensions, however, this is not always true. See https://github.com/pato-ontology/pato/issues/337 for full discussion. thickness PATO:0000915 A 1-D extent quality which is equal to the dimension through an object as opposed to its length or width. WordNet:WordNet A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies. quality PATO:0000918 volume PATO:0000918 A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies. PATOC:GVG A 1-D extent quality which is equal to the distance from one side of an object to another side which is opposite. https://github.com/pato-ontology/pato/issues/337 quality breadth PATO:0000921 Width often refers to the dimension that is greater than the extent in only one of the other two orthogonal dimensions, however, this is not always true. See https://github.com/pato-ontology/pato/issues/337 for full discussion. width PATO:0000921 A 1-D extent quality which is equal to the distance from one side of an object to another side which is opposite. PATOC:GVG A size quality inhering in a bearer by virtue of the bearer's being abnormally small. dwarfed quality PATO:0000969 dwarf-like PATO:0000969 A size quality inhering in a bearer by virtue of the bearer's being abnormally small. Answers.com:Answers.com PATO:0000973 A structure quality inhering in a bearer by virtue of the bearer's disposition to admit the passage of gas or liquid through pores or interstices. quality PATO:0000973 porosity PATO:0000973 A structure quality inhering in a bearer by virtue of the bearer's disposition to admit the passage of gas or liquid through pores or interstices. PATOC:GVG A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities. PATO:0002079 Wikipedia:Physical_property relational physical quality quality PATO:0001018 physical quality PATO:0001018 A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities. PATOC:GVG A physical quality which inheres in a bearer by virtue of some influence is exerted by the bearer's mass per unit size. quality density PATO:0001019 mass density PATO:0001019 A physical quality which inheres in a bearer by virtue of some influence is exerted by the bearer's mass per unit size. WordNet:WordNet A physical quality which inheres in a bearer by virtue of the bearer's exhibiting density. quality PATO:0001164 dense PATO:0001164 A physical quality which inheres in a bearer by virtue of the bearer's exhibiting density. PATOC:GVG A maturity quality inhering in a bearer by virtue the bearer's being not fully grown or developed. quality PATO:0001190 juvenile PATO:0001190 A maturity quality inhering in a bearer by virtue the bearer's being not fully grown or developed. thefreedictionary.com:thefreedictionary.com A quality which inheres in a continuant. PATO:0001237 PATO:0001238 snap:Quality monadic quality of a continuant multiply inhering quality of a physical entity quality of a continuant quality of a single physical entity quality of an object quality of continuant monadic quality of an object monadic quality of continuant quality PATO:0001241 Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles. physical object quality PATO:0001241 A quality which inheres in a continuant. PATOC:GVG A 2-D extent quality inhering in a bearer by virtue of the bearer's two dimensional extent. quality PATO:0001323 area PATO:0001323 A 2-D extent quality inhering in a bearer by virtue of the bearer's two dimensional extent. Wikipedia:http://en.wikipedia.org/wiki/Area A length quality which is equal to the length of any straight line segment that passes through the center of a circle and whose endpoints are on the circular boundary. quality PATO:0001334 diameter PATO:0001334 A length quality which is equal to the length of any straight line segment that passes through the center of a circle and whose endpoints are on the circular boundary. Wikipedia:http://en.wikipedia.org/wiki/Diameter A density quality which inheres in a bearer by virtue of some influence exerted by the bearer's mass on a given area. quality PATO:0001351 area density PATO:0001351 A density quality which inheres in a bearer by virtue of some influence exerted by the bearer's mass on a given area. Wikipedia:http://en.wikipedia.org/wiki/Area_density A density quality which is equal to the mass exerting an influence on a one-dimensional object. quality PATO:0001352 linear density PATO:0001352 A density quality which is equal to the mass exerting an influence on a one-dimensional object. Wikipedia:http://en.wikipedia.org/wiki/Linear_density A density quality which inheres in a bearer by virtue of some influence exerted by the bearer's mass on a given volume. quality PATO:0001353 volumetric density PATO:0001353 A density quality which inheres in a bearer by virtue of some influence exerted by the bearer's mass on a given volume. Wikipedia:http://en.wikipedia.org/wiki/Mass_density A quality that is equal to the potential energy per unit charge associated with a static (time-invariant) electric field, also called the electrostatic potential. quality PATO:0001464 electric potential PATO:0001464 A quality that is equal to the potential energy per unit charge associated with a static (time-invariant) electric field, also called the electrostatic potential. Wikipedia:http://en.wikipedia.org/wiki/Electric_potential A depth which is relatively low. PATO:0001692 low depth shallow quality PATO:0001472 decreased depth PATO:0001472 A depth which is relatively low. PATOC:GVG The rate or speed of the change in size of an individual entity or change in number of a population. quality PATO:0001492 growth rate PATO:0001492 The rate or speed of the change in size of an individual entity or change in number of a population. https://orcid.org/0000-0002-9900-7880 https://orcid.org/0000-0003-4606-0597 quality PATO:0001493 This term will be obsoleted; Use GO:growth and PATO:rate. hypertrophic growth PATO:0001493 quality PATO:0001494 This term will be obsoleted; Use GO:growth and PATO:rate. hypotrophic growth PATO:0001494 The frequency of transmitted vibrations. quality PATO:0001520 sound frequency PATO:0001520 The frequency of transmitted vibrations. thefreedictionary.com:thefreedictionary.com A sound frequency in the range of 0-20 Hz. quality PATO:0001524 intrasonic PATO:0001524 A sound frequency in the range of 0-20 Hz. studyphysics:studyphysics A sound frequency in the range of 20 to 20.000 Hz. quality PATO:0001525 sonic PATO:0001525 A sound frequency in the range of 20 to 20.000 Hz. url:http://www.studyphysics.ca/ A sound frequency in the range of 20 000 + Hz. quality PATO:0001526 ultrasonic PATO:0001526 A sound frequency in the range of 20 000 + Hz. studyphysics:studyphysics A molecular quality that inheres in a molecular entity by virtue of the bearer's disposition to dissolve in a liquid. quality PATO:0001536 solubility PATO:0001536 A molecular quality that inheres in a molecular entity by virtue of the bearer's disposition to dissolve in a liquid. edp:edp A solubility quality inhering in a substance by virtue of the bearer's disposition to dissolve in a liquid. soluble quality PATO:0001537 soluble in PATO:0001537 A solubility quality inhering in a substance by virtue of the bearer's disposition to dissolve in a liquid. edp:edp A solubility quality inhering in a substance by virtue of the bearer's inability of a substance to dissolve in a liquid. insoluble quality PATO:0001538 insoluble in PATO:0001538 A solubility quality inhering in a substance by virtue of the bearer's inability of a substance to dissolve in a liquid. edp:edp The number of parts of a particular type that the bearer entity has. This is a relational quality, and thus holds between two entities: the bearer of the quality, and the type of parts. OBO_REL:has_part extra or missing physical or functional parts has or lacks parts of type mereological quality number of quality cardinality number PATO:0001555 has number of PATO:0001555 The number of parts of a particular type that the bearer entity has. This is a relational quality, and thus holds between two entities: the bearer of the quality, and the type of parts. PATOC:CJM A size quality inhering in a bearer by virtue of the bearer's being made wider or larger in all dimensions. quality PATO:0001571 dilated PATO:0001571 A size quality inhering in a bearer by virtue of the bearer's being made wider or larger in all dimensions. WordNet:WordNet A physical quality inhering in a bearer by virtue of the bearer's disposition to transmit of an entity through a medium. quality PATO:0001585 Examples could be heat or electricity or sound. conductivity PATO:0001585 A physical quality inhering in a bearer by virtue of the bearer's disposition to transmit of an entity through a medium. PATOC:GVG A 1-D extent quality inhering in a bearer by virtue of the bearer's downward or backward or inward dimension. quality PATO:0001595 depth PATO:0001595 A 1-D extent quality inhering in a bearer by virtue of the bearer's downward or backward or inward dimension. WordNet:WordNet A depth quality which is relatively high. PATO:0001666 deep quality PATO:0001596 increased depth PATO:0001596 A depth quality which is relatively high. PATO:GVG A size quality inhering in a bearer by virtue of the bearer's being abnormally expanded or increased in size. quality expanded PATO:0001602 distended PATO:0001602 A size quality inhering in a bearer by virtue of the bearer's being abnormally expanded or increased in size. WordNet:WordNet A size quality inhering in a bearer by virtue of a part or parts of the bearer's being decreased in size due to reduction in tissue mass through wasting. atrophic quality PATO:0001623 atrophied PATO:0001623 A size quality inhering in a bearer by virtue of a part or parts of the bearer's being decreased in size due to reduction in tissue mass through wasting. Wiikipedia:Wasting Wikipedia:Atrophy An 1-D extent quality which is equal to the length of the closed curve of a circle. quality PATO:0001648 circumference PATO:0001648 An 1-D extent quality which is equal to the length of the closed curve of a circle. WordNet:WordNet A solubility which is relatively high. high solubility quality PATO:0001663 increased solubility PATO:0001663 A solubility which is relatively high. PATO:GVG A solubility which is relatively low. low solubility quality PATO:0001664 decreased solubility PATO:0001664 A solubility which is relatively low. PATO:GVG A volume quality inhering in a mass of substance by virtue of the amount of 3-dimensional space it occupies. quality PATO:0001679 The reciprocal of density. specific volume PATO:0001679 A volume quality inhering in a mass of substance by virtue of the amount of 3-dimensional space it occupies. Wikipedia:http://en.wikipedia.org/wiki/Specific_volume A volume quality inhering in a homogeneous substance containing 6.02 x 1023 atoms or molecules by virtue of the amount of 3-dimensional space it occupies. quality PATO:0001680 molar volume PATO:0001680 A volume quality inhering in a homogeneous substance containing 6.02 x 1023 atoms or molecules by virtue of the amount of 3-dimensional space it occupies. Wikipedia:http://en.wikipedia.org/wiki/Molar_volume A size quality inhering in an bearer by virtue of the bearer's extension in one dimension. 1-D size quality PATO:0001708 1-D extent PATO:0001708 A size quality inhering in an bearer by virtue of the bearer's extension in one dimension. PATOC:GVG A size quality inhering in an bearer by virtue of the bearer's extension in two dimensions. 2-D size quality PATO:0001709 2-D extent PATO:0001709 A size quality inhering in an bearer by virtue of the bearer's extension in two dimensions. PATOC:GVG A size quality inhering in an bearer by virtue of the bearer's extension in three dimensions. 3D size quality PATO:0001710 3-D extent PATO:0001710 A size quality inhering in an bearer by virtue of the bearer's extension in three dimensions. PATOC:GVG An 1-D extent quality inhering in two-dimensional bearer by virtue of being equal to the distance around it. quality PATO:0001711 perimeter PATO:0001711 An 1-D extent quality inhering in two-dimensional bearer by virtue of being equal to the distance around it. Wikipedia:http://en.wikipedia.org/wiki/Perimeter A perimeter which is relatively high. quality PATO:0001712 increased perimeter PATO:0001712 A perimeter which is relatively high. PATOC:GVG A perimeter which is relatively low. quality PATO:0001713 decreased perimeter PATO:0001713 A perimeter which is relatively low. PATOC:GVG A diameter which is relatively large. quality PATO:0001714 increased diameter PATO:0001714 A diameter which is relatively large. PATOC:GVG A diameter which is relatively small. quality PATO:0001715 decreased diameter PATO:0001715 A diameter which is relatively small. PATOC:GVG A size quality inhering in a bearer by virtue of the bearer's being abnormally developed, usually due to malnutrition. dystrophied quality dystrophy PATO:0001780 dystrophic PATO:0001780 A size quality inhering in a bearer by virtue of the bearer's being abnormally developed, usually due to malnutrition. Wiikipedia:Wiikipedia A thickness quality which lacks pattern. quality PATO:0001781 irregular thickness PATO:0001781 A thickness quality which lacks pattern. PATOC:GVG A density which is higher relative to the normal or average. high density quality PATO:0001788 increased mass density PATO:0001788 A density which is higher relative to the normal or average. PATOC:GVG A density which is lower relative to the normal or average. low density quality PATO:0001790 decreased mass density PATO:0001790 A density which is lower relative to the normal or average. PATOC:GVG A circumference which is relatively high. quality PATO:0001898 increased circumference PATO:0001898 A circumference which is relatively high. PATOC:GVG A circumference which is relatively low. quality PATO:0001899 decreased circumference PATO:0001899 A circumference which is relatively low. PATOC:GVG A size quality inhering in a bearer by virtue of the bearer's being many folds greater relative to the normal average. giant quality PATO:0001940 gigantic PATO:0001940 A size quality inhering in a bearer by virtue of the bearer's being many folds greater relative to the normal average. PATOC:UMH A quality inhering in a bearer by virtue of the bearer's passing into solution. quality PATO:0001986 dissolved PATO:0001986 A quality inhering in a bearer by virtue of the bearer's passing into solution. PATOC:GVG A texture quality that exists through a liquid cover on the surface of the bearer. quality PATO:0002012 coating PATO:0002012 A texture quality that exists through a liquid cover on the surface of the bearer. Wikipedia:Wikipedia A diameter that is along the anterior-posterior axis. quality PATO:0002041 anterior-posterior diameter PATO:0002041 A diameter that is along the anterior-posterior axis. PATOC:GVG An anterior-posterior diameter quality which is relatively small. low anterior-posterior diameter quality PATO:0002042 decreased anterior-posterior diameter PATO:0002042 An anterior-posterior diameter quality which is relatively small. PATOC:GVG An anterior-posterior diameter quality which is relatively large. high anterior-posterior diameter quality PATO:0002043 increased anterior-posterior diameter PATO:0002043 An anterior-posterior diameter quality which is relatively large. PATOC:GVG An area which is relatively high. 2009-03-30T04:11:43Z quality PATO:0002057 increased area PATO:0002057 An area which is relatively high. PATOC:GVG An area which is relatively low. 2009-03-30T04:12:11Z quality PATO:0002058 decreased area PATO:0002058 An area which is relatively low. PATOC:GVG A volume quality inhering in a degenerating cell by virtue of the bearer's exhibiting an increase in volume associated with cytoplasmic abnormalities. 2009-10-05T12:01:13Z quality PATO:0002093 ballooning PATO:0002093 A volume quality inhering in a degenerating cell by virtue of the bearer's exhibiting an increase in volume associated with cytoplasmic abnormalities. PATOC:GVG A density quality which lacks pattern. 2009-10-28T01:57:53Z quality PATO:0002141 irregular density PATO:0002141 A density quality which lacks pattern. PATOC:GVG A quality inhering in a bearer by virtue of the bearer exhibiting increased density resulting in exhibiting increased degree of radiopacity (in X-rays). 2009-11-03T02:59:08Z quality PATO:0002149 ivory PATO:0002149 A quality inhering in a bearer by virtue of the bearer exhibiting increased density resulting in exhibiting increased degree of radiopacity (in X-rays). PATOC:GVG PATO:0002390 A length quality which is equal to the length of any straight line segment that passes from the center of a circle to any endpoint on the circular boundary. The radius is half of the diameter. 2012-11-15T05:17:15Z quality PATO:0002390 radius PATO:0002390 A length quality which is equal to the length of any straight line segment that passes from the center of a circle to any endpoint on the circular boundary. The radius is half of the diameter. PATO:DS A quality in which the effect or outcome is not primary or the focus of the observation. 2014-05-26T13:17:45Z quality PATO:0002632 secondary PATO:0002632 A quality in which the effect or outcome is not primary or the focus of the observation. PATO:MAH A size quality inhering in an entity or set of entities in which size increases or decreases along the extent of the entity or set. 2014-09-25T15:17:51Z gradient of size quality PATO:0005015 tapered size PATO:0005015 A size quality inhering in an entity or set of entities in which size increases or decreases along the extent of the entity or set. PATOC:WD A diameter that remains constant throughout the extent of an entity. 2014-10-17T14:15:59Z quality PATO:0005022 uniform diameter PATO:0005022 A diameter that remains constant throughout the extent of an entity. PATOC:WD A width and length quality which is relatively small, where both width and length are decreased. quality PATO:0040030 decreased width and length PATO:0040030 A width and length quality that is relatively large, where both width and length are increased. quality PATO:0040031 increased width and length PATO:0040031 The rate or speed of the change in in number of a population. http://orcid.org/0000-0001-5208-3432 quality PATO:0040045 population growth rate PATO:0040045 The rate or speed of the change in in number of a population. https://orcid.org/0000-0002-9900-7880 https://orcid.org/0000-0003-4606-0597 A rate which is relatively normal. quality PATO:0045000 normal rate PATO:0045000 A density which is relatively normal or average. 2017-12-22T14:16:43Z quality PATO:0045031 normal mass density PATO:0045031 A size quality which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045050 normal size PATO:0045050 An area which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045051 normal area PATO:0045051 A depth quality which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045052 normal depth PATO:0045052 A height which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045053 normal height PATO:0045053 A length quality which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045054 normal length PATO:0045054 A diameter which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045055 normal diameter PATO:0045055 An anterior-posterior diameter which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045056 normal anterior-posterior diameter PATO:0045056 A perimeter which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045057 normal perimeter PATO:0045057 A circumference which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045058 normal circumference PATO:0045058 A thickness which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045059 normal thickness PATO:0045059 A volume which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045060 normal volume PATO:0045060 A width which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045061 normal width PATO:0045061 A solubility which is relatively normal or average 2017-12-22T14:16:43Z quality PATO:0045062 normal solubility PATO:0045062 A frequency which is relatively normal. quality PATO:0045087 normal frequency PATO:0045087 The number of repeated events per unit time, occurring in a repeating series. (e.g. the number of heart beats occurring over 1 minute) quality PATO:0050000 rate of occurence PATO:0050000 The number of repeated events per unit time, occurring in a repeating series. (e.g. the number of heart beats occurring over 1 minute) https://orcid.org/0000-0002-9943-9018 PATO:0050001 The rate of output of a continuous process. Example include: growth rate, cell migration rate, enzyme reaction rate. quality PATO:0050001 rate of continuous process PATO:0050001 The rate of output of a continuous process. Example include: growth rate, cell migration rate, enzyme reaction rate. https://orcid.org/0000-0002-9943-9018 A rate of occurrence that is relatively high. 2020-08-19T09:23:19Z quality PATO:0055003 increased rate of occurrence PATO:0055003 A rate of occurrence that is relatively high. https://orcid.org/0000-0003-4148-4606 A rate of occurrence that is relatively low. 2020-08-19T09:24:35Z quality PATO:0055004 decreased rate of occurrence PATO:0055004 A rate of occurrence that is relatively low. https://orcid.org/0000-0003-4148-4606 A rate of output of a continuous process that is relatively high. 2020-08-19T09:24:56Z quality PATO:0055005 increased rate of continuous process PATO:0055005 A rate of output of a continuous process that is relatively high. https://orcid.org/0000-0003-4148-4606 A rate of output of a continuous process that is relatively low. 2020-08-19T09:25:07Z quality PATO:0055006 decreased rate of continuous process PATO:0055006 A rate of output of a continuous process that is relatively low. https://orcid.org/0000-0003-4148-4606 A 3-D extent quality inhering in a bearer by virtue of the spatial region that is defined by the maximal span of the bearer's dendritic arbor. quality PATO:0070064 dendritic field size PATO:0070064 A 3-D extent quality inhering in a bearer by virtue of the spatial region that is defined by the maximal span of the bearer's dendritic arbor. https://orcid.org/0000-0001-7258-9596 https://orcid.org/0000-0002-1373-1705 https://orcid.org/0000-0002-5260-9315 STATO:0000017 Wilks' lambda distribution (named for Samuel S. Wilks), is a probability distribution used in multivariate hypothesis testing, especially with regard to the likelihood-ratio test and Multivariate analysis of variance. It is a multivariate generalization of the univariate F-distribution, and generalizes the F-distribution in the same way that the Hotelling's T-squared distribution generalizes Student's t-distribution. Wilk's lambda distribution STATO:0000023 The studentized range (q) distribution is a probability distribution used by the Tukey Honestly Significant Difference test. The distribution of the statistic [x̄(k)- x̄(1)]/(s/√n) where random samples of size n have been taken from k independent and identically distributed normal populations, with x̄(1) and x̄(k) being, respectively, the smallest and largest of the k sample means, and s2 being the pooled estimate of the common variance. This statistic is particularly used in multiple comparison tests. studentized range distribution STATO:0000060 hypergeometric distribution is a probability distribution that describes the probability of k successes in n draws from a finite population of size N containing K successes without replacement hypergeometric distribution STATO:0000103 the multinomial distribution is a probability distribution which gives the probability of any particular combination of numbers of successes for various categories defined in the context of n independent trials each of which leads to a success for exactly one of k categories, with each category having a given fixed success probability. multinomial distribution STATO:0000132 Hotelling T squared distribution is a probability distribution used in multivariate hypothesis testing, which is a univariate distribution proportional to the F-distribution and arises importantly as the distribution of a set of statistics which are natural generalizations of the statistics underlying Student's t-distribution. In particular, the distribution arises in multivariate statistics in undertaking tests of the differences between the (multivariate) means of different populations, where tests for univariate problems would make use of a t-test. The distribution is named for Harold Hotelling, who developed it[1] as a generalization of Student's t-distribution. This distribution is commonly used to describe the sample Mahalanobis distance between two populations. Hotelling T2 distribution STATO:0000145 the geometric distribution is a negative binomial distribution where r is 1. It is useful for modeling the runs of consecutive successes (or failures) in repeated independent trials of a system. The geometric distribution models the number of successes before one failure in an independent succession of tests where each test results in success or failure. The geometric distribution with prob = p has density p(x) = p (1-p)^x for x = 0, 1, 2, …, 0 < p ≤ 1. If an element of x is not integer, the result of dgeom is zero, with a warning. The quantile is defined as the smallest value x such that F(x) ≥ p, where F is the distribution function. geometric distribution STATO:0000177 the beta distribution is a continuous probability distributions defined on the interval [0, 1] parametrized by two positive shape parameters, denoted by α and β, that appear as exponents of the random variable and control the shape of the distribution beta distribution STATO:0000180 standard normal distribution is a normal distribution with variance = 1 and mean=0 standard normal distribution STATO:0000262 Bernoulli distribution is a binomial distribution where the number of trials is equal to 1. notation: B(1,p) The mean is p The variance is p*q Bernoulli distribution STATO:0000283 negative binomial probability distribution is a discrete probability distribution of the number of successes in a sequence of Bernoulli trials before a specified (non-random) number of failures (denoted r) occur. The negative binomial distribution, also known as the Pascal distribution or Pólya distribution, gives the probability of r-1 successes and x failures in x+r-1 trials, and success on the (x+r)th trial. negative binomial distribution UBERON:0000062 Anatomical structure that performs a specific function or group of functions [WP]. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions. CARO v1 does not include a generic 'organ' class, only simple and compound organ. CARO v2 may include organ, see https://github.com/obophenotype/caro/issues/4 BIRNLEX:4 CARO:0020004 EFO:0000634 EMAPA:35949 ENVO:01000162 FMA:67498 MA:0003001 NCIT:C13018 SCTID:272625005 UMLS:C0178784 WBbt:0003760 Wikipedia:Organ_(anatomy) uberon anatomical unit body organ element UBERON:0000062 organ UBERON:0000062 Anatomical structure that performs a specific function or group of functions [WP]. Wikipedia:Organ_(anatomy) Wikipedia Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions. GO:0048513 UMLS:C0178784 ncithesaurus:Organ element http://orcid.org/0000-0002-6601-2165 Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation. changed label and definition to reflect CARO2 AAO:0000607 AAO:0010054 AEO:0000043 BILA:0000043 BIRNLEX:19 CALOHA:TS-2090 CARO:0000043 EHDAA2:0003043 EMAPA:35868 FBbt:00007003 FMA:9637 HAO:0000043 MA:0003002 MESH:D014024 NCIT:C12801 TAO:0001477 TGMA:0001844 UMLS:C0040300 VHOG:0001757 WBbt:0005729 XAO:0003040 ZFA:0001477 galen:Tissue portion of tissue tissue portion simple tissue uberon UBERON:0000479 tissue UBERON:0000479 Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation. CARO:0000043 UMLS:C0040300 ncithesaurus:Tissue portion of tissue CARO:0000043 simple tissue AEO:0000043 Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. AAO:0010841 AEO:0000000 BILA:0000000 BIRNLEX:6 CARO:0000000 EHDAA2:0002229 FBbt:10000000 FMA:62955 HAO:0000000 MA:0000001 NCIT:C12219 TAO:0100000 TGMA:0001822 UMLS:C1515976 WBbt:0000100 XAO:0000000 ZFA:0100000 uberon UBERON:0001062 anatomical entity UBERON:0001062 Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. FMA:62955 http://orcid.org/0000-0001-9114-8737 UMLS:C1515976 ncithesaurus:Anatomic_Structure_System_or_Substance An organ that functions as a secretory or excretory organ. glandular AAO:0000212 AEO:0000096 BTO:0000522 EFO:0000797 EHDAA2:0003096 EHDAA:2161 EHDAA:4475 EHDAA:6522 EMAPA:18425 FBbt:00100317 FMA:7146 FMA:86294 HAO:0000375 MA:0003038 MAT:0000021 MIAA:0000021 NCIT:C13319 SCTID:134358001 UMLS:C1285092 Wikipedia:Gland WikipediaCategory:Glands galen:Gland glandular organ uberon Druese glandula UBERON:0002530 gland UBERON:0002530 http://upload.wikimedia.org/wikipedia/commons/a/a1/Gray1026.png An organ that functions as a secretory or excretory organ. MGI:csmith MP:0002163 UMLS:C1285092 ncithesaurus:Gland glandular organ http://orcid.org/0000-0002-6601-2165 Druese BTO:0000522 glandula BTO:0000522 Wikipedia:Gland Any gland that is part of the digestive system. AAO:0000130 BTO:0000345 uberon digestive gland UBERON:0006925 digestive system gland UBERON:0006925 Any gland that is part of the digestive system. UBERON:cjm digestive gland BTO:0000345 UO:0000000 "A unit of measurement is a standardized quantity of a physical quality." [Wikipedia:Wikipedia] unit "A unit which is a standard measure of the distance between two points." [Wikipedia:Wikipedia] length unit "A unit which is a standard measure of the amount of matter/energy of a physical object." [Wikipedia:Wikipedia] mass unit time derived unit "A unit which is a standard measure of the dimension in which events occur in sequence." [Wikipedia:Wikipedia] time unit "A unit which is a standard measure of the flow of electric charge." [Wikipedia:Wikipedia] electric current unit temperature derived unit "A unit which is a standard measure of the average kinetic energy of the particles in a sample of matter." [Wikipedia:Wikipedia] temperature unit "A unit which is a standardised quantity of an element or compound with uniform composition." [Wikipedia:Wikipedia] substance unit "A unit which is a standard measure of the wavelength-weighted power emitted by a light source in a particular direction." [Wikipedia:Wikipedia] luminous intensity unit "A unit which is one of a particular measure to which all measures of that type can be related." [NIST:NIST] base unit "A unit which is a standard measure of the amount of a 2-dimensional flat surface." [UOC:GVG] area unit "A unit which is a standard measure of the rate of change of velocity in either speed or direction." [Wikipedia:Wikipedia] acceleration unit "A unit which is a standard measure of the rate of angular movement about an axis; the angle rotated in a given time." [Wikipedia:Wikipedia] angular velocity unit "A unit which is a standard measure of the rate of change of angular velocity." [Wikipedia:Wikipedia] angular acceleration unit "A unit which represents a standard measurement of how much of a given substance there is mixed with another substance." [UOC:GVG] concentration unit mass per unit volume "A density unit which is a standard measure of the mass of a substance in a given volume." [UOC:GVG] mass density unit "A unit which is a standard measure of the luminous intensity impinging on a given area." [Wikipedia:Wikipedia] luminance unit UO:0000054 mass per unit area unit "A density unit which is a standard measure of the mass exerting an influence on a given area." [Wikipedia:Wikipedia] area density unit "A unit which is a standard measure of the mass of a homogeneous substance containing 6.02 x 1023 atoms or molecules." [Wikipedia:Wikipedia] molar mass unit "A unit which is a standard measure of the volume of a homogeneous substance containing 6.02 x 1023 atoms or molecules." [Wikipedia:Wikipedia] molar volume unit "A unit which is a standard measure of the quantity of motion measured by the product of mass and velocity." [Wikipedia:Wikipedia] momentum unit "A unit which is a standard measure of the number of rotations in a given time." [NIST:NIST] rotational frequency unit "A unit which is a standard measure of the volume of a given mass of substance (the reciprocal of density)." [Wikipedia:Wikipedia] specific volume unit "A unit which is a standard measure of the rate of movement. Speed is measured in the same physical units of measurement as velocity, but does not contain the element of direction that velocity has. Speed is thus the magnitude component of velocity." [Wikipedia:Wikipedia] speed/velocity unit "A concentration unit which is a standard measure of the number of moles of a given substance per liter of solution." [UOC:GVG] unit of molarity "A concentration unit which is a standard measure of the number of moles of a given substance per kilogram of solvent." [UOC:GVG] unit of molality "A unit of concentration which highlights the chemical nature of salts." [Wikipedia:Wikipedia] unit of normality "A unit which is a standard measure of the amount of space occupied by any substance, whether solid, liquid, or gas." [NIST:NIST] volume unit "A unit which is a standard measure of the number of repetitive actions in a particular time." [NIST:NIST] frequency unit "A unit which is a standard measure of the force is applied when a mass is accelerated." [NIST:NIST] force unit "A unit which is a standard measure of the force applied to a given area." [NIST:NIST] pressure unit "A unit which is a standard measure of the work done by a certain force (gravitational, electric, magnetic, force of inertia, etc)." [NIST:NIST] energy unit "A unit which is a standard measure power or the rate of doing work." [NIST:NIST] power unit "A unit which is a standard measure of the luminous flux incident on a unit area." [Wikipedia:Wikipedia] illuminance unit "A unit which is a standard measure of the flow of radiant energy." [Wikipedia:Wikipedia] luminous flux unit "A unit which is a standard measure of the amount of the action of a catalyst." [NIST:NIST] catalytic activity unit "A unit which is a standard measure of the figure or space formed by the junction of two lines or planes." [Wikipedia:Wikipedia] angle unit "A unit which is a standard measure of the angle formed by two straight lines in the same plane." [Wikipedia:Wikipedia] plane angle unit "A unit which is a standard measure of the angle formed by three or more planes intersecting at a common point." [Wikipedia:Wikipedia] solid angle unit "A unit which is a standard measure of the amount of radiation emitted by a given radiation source as well as the amount of radiation absorbed or deposited in a specific material by a radiation source." [OCRBS:OCRBS] radiation unit "A unit which is a standard measure of the transformation (disintegration) rate of a radioactive substance." [DEFRA:DEFRA] activity (of a radionuclide) unit "A unit which is a standard measure of the energy imparted by ionizing radiation to unit mass of matter such as tissue." [DEFRA:DEFRA] absorbed dose unit "A unit which is a standard measure of the expression of dose in terms of its biological effect." [ORCBS:ORCBS] dose equivalent unit "A unit which is a standard measure of the quantity that expresses the ability of radiation to ionize air and thereby create electric charges which can be collected and measured." [ORCBS:ORCBS] exposure unit "A unit which is a standard measure of the power of electromagnetic radiation at a surface, per unit area." [Wikipedia:Wikipedia] irradiance unit "A unit which is a standard measure of the intensity of light." [NIST:NIST] light unit "A unit which is a standard measure of the intensity of electromagnetic radiation." [Wikipedia:Wikipedia] radiant intensity unit "A unit which is a standard measure of the power of electromagnetic radiation through space or through a material medium in the form of electromagnetic waves." [Wikipedia:Wikipedia] radiance unit "A dimensionless concentration notation which describes the amount of one substance in another. It is the ratio of the amount of the substance of interest to the amount of that substance plus the amount of the substance." [Wikipedia:Wikipedia] parts per notation unit "A concentration unit which is a standard measure of the number of units, as an agreed arbitrary amount, of a given substance per a specific volume of solution." [Webmd:Webmd] unit per volume unit "A unit which is a standard measure of the influence exerted by some mass." [Wikipedia:Wikipedia] density unit "A density unit which is a standard measure of the mass exerting an influence on a one-dimensional object." [Wikipedia:Wikipedia] linear density unit "A unit which is a standard measure of physical quantity consisting of only a numerical number without any units." [Wikipedia:Wikipedia] dimensionless unit % "A dimensionless ratio unit which denotes numbers as fractions of 100." [Wikipedia:Wikipedia] percent count "A dimensionless unit which denotes a simple count of things." [MGED:MGED] count unit "A dimensionless unit which denotes an amount or magnitude of one quantity relative to another." [Wikipedia:Wikipedia] ratio unit "A dimensionless ratio unit which relates the part (the numerator) to the whole (the denominator)." [Wikipedia:Wikipedia] fraction "A concentration unit which denotes the average cell number in a given volume." [Bioedonline:Bioedonline] cell concentration unit "A concentration unit which is a standard measure of the amount of the action of a catalyst in a given volume." [UOC:GVG] catalytic (activity) concentration unit "A dimensionless concentration unit which denotes the given volume of the solute in the total volume of the resulting solution." [NIST:NIST] volume per unit volume "A concentration unit which a measure of plaque forming units in a given volume." [UOC:GVG] plaque forming unit per volume "A unit which is a standard measure of the work done per unit charge as a charge is moved between two points in an electric field." [Wikipedia:Wikipedia] electric potential difference unit "A unit which is a standard measure of the quantity of unbalanced electricity in a body (either positive or negative) and construed as an excess or deficiency of electrons." [WordNet:WordNet] electric charge "A unit which is a standard measure of quantity of magnetism, taking account of the strength and the extent of a magnetic field." [Wikipedia:Wikipedia] magnetic flux unit B "A unit which is a standard measure of the strength of a magnetic field." [allnet:allnet] magnetic flux density unit "A unit which is a standard measure of the amount of information." [Wikipedia:Wikipedia] information unit "An information unit which is a standard measure of the detail an image holds." [Wikipedia:Wikipedia] image resolution unit "An image resolution unit which is a standard measure of the way luminance and chrominance may be sampled at different levels." [Wikipedia:Wikipedia] spatial resolution unit "A unit which is a standard measure of the ability of a liguid to attraction of molecules at its surface as a result of unbalanced molecular cohesive forces." [NIST:NIST] surface tension unit "A unit which is a standard measure of the internal resistance of fluids to flow." [UOC:GVG] viscosity unit "A unit which represents a standard measurement of the transmission of an entity through a medium." [UOC:GVG] conduction unit "A unit which represents a standard measurement of the movement of electrically charged particles through a transmission medium (electrical conductor)." [UOC:GVG] electrical conduction unit "A unit which represents a standard measurement of the spontaneous transfer of thermal energy through matter, from a region of higher temperature to a region of lower temperature." [Wikipedia:Wikipedia] heat conduction unit E-field strength "The electric field strength is a unit which is a measure of the potential difference between two points some distance apart." [Wikipedia:http\://en.wikipedia.org/wiki/Electric_field] electric field strength unit "A unit which is a standard measure of the volume of fluid which passes through a given surface per unit time ." [Wikipedia:Wikipedia] volumetric flow rate unit "A concentration unit which is a standard measure of the amount of a substance in a given container." [UOC:GVG] amount per container "A unit which is equal to one microgram per disk, where a disk is some physical surface/container upon which the substance is deposited." [UOC:MD] ug/disk "A unit which is equal to one nanomole per disk, where a disk is some physical surface/container upon which the substance is deposited." [UOC:MD] nmole/disk "A unit which represents a standard measurement occurrence of a process per unit time." [UOC:GVG] rate unit "A concentration unit which is a standard measure of the amount of a toxic or pharmaceutical substance administered to a recipient subject, expressed in terms of the size of the subject." [UO:PC] dose unit "A unit used to indicate the clarity of water or other solutions or suspensions, as measured by the ability of the solution or suspension to scatter light of a defined wavelength range." [UO:PC] turbidity unit cells per microlitre cells per ul "A unit of cell concentration which is equal to one cell in a volume of 1 microliter." [UO:GVG] cells per microliter "A unit of cell concentration which is equal to 1 cell in a well or discrete container of arbitrary volume." [UO:PC] cells per well FNU "1000 formazin turbidity units (FNU) on the empirical formazin turbidity scale represents reflectance of insol. reaction products of 0.0725 g hydrazine sulfate with 0.7250 g hexamethylenetetramine diluted to 1 L." [AOAC:192] formazin nephelometric unit "A concentration unit which is a standard measure of the amount of radioactivity in a given volume." [UO:GVG] radioactivity concentration curie per litre "A unit of radioactivity concentration which is equal to one curie in a volume of 1 liter." [UO:GVG] curie per liter microcurie per millilitre "A unit of radioactivity concentration which is equal to one micro curie in a volume of 1 liter." [UO:GVG] microcurie per milliliter "A unit that is the ratio of concentration of two solutions of interest, typically with one solution derived from the other by the addition of solvent." [UO:PC] fold dilution "An area density unit which is equal to the mass of an object in tons divided by the surface area in hectares." [UO:GVG] ton per hectare A^[2] "An area unit which is equal to an area enclosed by a square with sides each 1 angstrom long." [UOC:GVG] square angstrom kbp kilobasepair "A unit equal to one thousand base pairs." [UOC:GVG] kilo base pair GB "An information unit which is equal to 1000000000 bytes." [UO:GVG] gigabyte TB "An information unit which is equal to 1000 gigabytes." [UO:GVG] terabyte "A dimensionless ratio unit which, given a pair of quantities a and b, for which b is a multiple of a, denotes b by giving the multiplier (coefficient) c for a to result in b." [UOB:LKSR] ratio Vs/cm^2 volt-second per square centimetre "An electrical mobility unit which is equal to one volt second per square centimeter." [UOB:LKSR] volt-second per square centimeter us customary teaspoon "A United States customary units teaspoon is a unit of measurement of volume widely used in cooking recipes and pharmaceutic prescriptions in America. It equals a 4.93 mL volume." [Wikipedia:https://en.wikipedia.org/wiki/United_States_customary_units#Cooking_measures] united states customary teaspoon metric tablespoon tbsp "A metric tablespoon is a unit of measurement of volume widely used in cooking recipes and pharmaceutic prescriptions. It equals a 15mL volume." [Wikipedia:https://en.wikipedia.org/wiki/Tablespoon] tablespoon "An Australian metric tablespoon is a unit of measurement of volume used in Australia for cooking recipes and pharmaceutic prescriptions. It equals a 20mL volume." [Wikipedia:https://en.wikipedia.org/wiki/Tablespoon] australian metric tablespoon us customary tablespoon "A United States customary units tablespoon is a unit of measurement of volume widely used in cooking recipes and pharmaceutic prescriptions in America. It equals a 14.79 mL volume." [Wikipedia:https://en.wikipedia.org/wiki/United_States_customary_units#Cooking_measures] united states customary tablespoon C "A metric cup is a unit of measurement of volume widely used in cooking recipes and pharmaceutic prescriptions. It equals a 250mL volume." [Wikipedia:https://en.wikipedia.org/wiki/Cooking_weights_and_measures] metric cup us customary cup "A United States customary units cup is a unit of measurement of volume widely used in cooking recipes and pharmaceutic prescriptions in America. It equals a 236.59 mL volume." [Wikipedia:https://en.wikipedia.org/wiki/United_States_customary_units#Cooking_measures] united states customary cup us fda cup "A United States FDA cup is a unit of measurement of volume used by the US Federal Department of Agriculture as a nutritional serving measure. It equals a 240 mL volume." [Wikipedia:https://en.wikipedia.org/wiki/United_States_customary_units#Cooking_measures] united states fda cup lbf/in^[2] psi "A pressure unit which is equal to 6894.757 pascal." [Wikipedia:Wikipedia] pounds per square inch meter based unit second based unit ampere based unit kelvin based unit mole based unit candela based unit angstrom based unit gram based unit degree Celsius based unit minute based unit hour based unit day based unit week based unit month based unit year based unit molar based unit molal based unit normal based unit mole fraction based unit meter per second per second based unit radian per second per second based unit radian per second based unit square meter based unit square centimeter based unit square millimeter based unit gram per cubic centimeter based unit candela per square meter based unit gram per mole based unit cubic meter per mole based unit cubic centimeter per mole based unit turns per second based unit cubic meter per kilogram based unit meter per second based unit cubic meter based unit cubic centimeter based unit liter based unit cubic decimeter based unit hertz based unit newton based unit pascal based unit joule based unit watt based unit lux based unit lumen based unit katal based unit radian based unit steradian based unit becquerel based unit curie based unit gray based unit rad based unit roentgen based unit sievert based unit Roentgen equivalent man based unit disintegrations per minute based unit counts per minute based unit century based unit half life based unit foot candle based unit watt per square meter based unit einstein per square meter per second based unit watt per steradian per square meter based unit watt per steradian based unit mass percentage based unit mass volume percentage based unit volume percentage based unit parts per hundred based unit parts per thousand based unit parts per million based unit parts per billion based unit parts per trillion based unit parts per quadrillion based unit gram per milliliter based unit gram per liter based unit unit per milliliter based unit unit per liter based unit mass per unit volume based unit enzyme unit based unit degree based unit pi based unit molecule count based unit purity percentage based unit confluence percentage based unit degree Fahrenheit based unit pH based unit liter per kilogram based unit cells per milliliter based unit katal per cubic meter based unit katal per liter based unit gram per deciliter based unit colony forming unit based unit plaque forming unit based unit colony forming unit per milliliter based unit plaque forming unit per milliliter based unit disintegrations per second based unit volt based unit coulomb based unit dalton based unit watt-hour based unit weber based unit tesla based unit volt-hour based unit bit based unit byte based unit chroma sampling unit based unit dynamic range unit based unit dots per inch based unit pixels per inch based unit pixels per millimeter based unit base pair based unit kibibyte based unit mebibyte based unit newton per meter based unit dyne per cm based unit pascal second based unit poise based unit effective dose unit based unit siemens based unit watt per meter kelvin based unit electronvolt based unit volt per meter based unit absorbance unit based unit count per nanomolar second based unit count per molar second based unit count per nanomolar based unit count per molar based unit dosage unit based unit relative light unit based unit relative luminescence unit based unit relative fluorescence unit based unit square micrometer based unit hectare based unit inch based unit thou based unit foot based unit yard based unit chain based unit furlong based unit mile based unit league based unit maritime length unit based unit fathom based unit cable based unit nautical mile based unit perch based unit rood based unit acre based unit fluid ounce based unit gill based unit pint based unit quart based unit gallon based unit grain based unit drachm based unit ounce based unit pound based unit stone based unit quarter based unit hundredweight based unit ton based unit slug based unit teaspoon based unit gram per square meter based unit large calorie based unit gray per minute based unit NPO_1473 FIX:0000015 infrared spectroscopy IR spectroscopy The technique is based on the fact that molecules have specific frequencies at which they rotate or vibrate corresponding to discrete energy levels (vibrational modes). infrared spectroscopy NPO_1475 FIX:0000016 ultraviolet/visible spectroscopy UV-Vis spectroscopy ultraviolet/visible spectroscopy NPO_1471 FIX:0000041 NCIT:C78871 x-ray photoelectron spectroscopy ESCA Electron Spectroscopy for Chemical Analysis XPS Photoelectrons are collected and analyzed by the XPS instrument to produce a spectrum of emission intensity versus electron binding energy. Since each element has a unique set of binding energies, XPS can be used to identify the elements on the surface. Also, peak areas at nominal binding energies can be used to quantify concentration of the elements. Small shifts in these binding energies (chemical shifts) provide powerful information about sample chemical states and short-range chemistry . [definition: based on NCIT, http://encyclopedia.thefreedictionary.com, http://www.chem.umd.edu/facility/xps.php] x-ray photoelectron spectroscopy NPO_1458 FIX:0000053 chromatography [definition adapted from NCIT, WordNet, http://encyclopedia.thefreedictionary.com/chromatography] chromatography NPO_1472 FIX:0000058 NCIT:C17157 Raman spectroscopy [definition: adapted from http://epsc.wustl.edu/haskin-group/Raman/faqs.htm, http://encyclopedia.thefreedictionary.com] Raman spectroscopy NPO_1460 FIX:0000098 gas chromatography gas chromatography NPO_1448 FIX:0000116 contact atomic force microscopy contact AFM [definition: adapted from http://en.wikipedia.org, http://www.nanoscience.com/education/AFM.html] contact atomic force microscopy NPO_1449 FIX:0000117 non contact atomic force micrsocopy NC-AFM non contact atomic force micrsocopy NPO_1450 FIX:0000118 magnetic force microscopy magnetic force microscopy NPO_1474 FIX:0000321 near-infrared spectroscopy NIR spectroscopy near-infrared spectroscopy NPO_1466 FIX:0000402 NCIT:C62323 light scattering light scattering technique [definition: adapted from NCIT] light scattering NPO_1459 FIX:0000607 chromatography by mobile phase state chromatography by physical state of the mobile phase chromatography by mobile phase state NPO_1461 FIX:0000608 liquid chromatography LC liquid chromatography NPO_1463 FIX:0000610 chromatography by separation mechanism chromatography by separation mechanism NPO_1464 FIX:0000626 NCIT:C16433 size-exclusion chromatography GPC SEC gel filtration chromatography gel permeation chromatography size-exclusion chromatography NPO_1462 FIX:0000630 NCIT: C16434 high pressure liquid chromatography HPLC high performance liquid chromatography high pressure liquid chromatography NPO_1457 FIX:0000836 NCIT:C17637 capillary electrophoresis capillary electrophoresis NPO_1346 PATO:0001242 wavelength wavelength NPO_1352 PATO:0001522 speed of sound wave speed of sound velocity of sound speed of sound wave NPO_1353 PATO:0001523 wavelength of sound wavelength of sound A particular published volume of a journal, comprising one or more journal issues. journal volume Molar refractviity is a measure of the total polarizability of a mole of a substance and is dependent on the temperature, the index of refraction, and the pressure. Molar refractviity is a measure of the total polarizability of a mole of a substance and is dependent on the temperature, the index of refraction, and the pressure. molar refractivity atomic polarizability sum is the sum of the atomic polarizabilities (including implicit hydrogens). atomic polarizability sum is the sum of the atomic polarizabilities (including implicit hydrogens). atomic polarizability sum sum of surface area on positive parts of molecule sum of surface area on positive parts of molecule PPSA-1 partial positive surface area partial positive surface area * total positive charge on the molecule partial positive surface area * total positive charge on the molecule PPSA-2 PPSA-2 RS stereochemical descriptor R stereochemical descriptor A canonical SMILES descriptor is a SMILES descriptor that is produced using a canonicalization algorithm which results in one special generic SMILES among all valid possibilities. A canonical SMILES descriptor is a SMILES descriptor that is produced using a canonicalization algorithm which results in one special generic SMILES among all valid possibilities. canonical SMILES descriptor charge weighted partial positive surface area charge weighted partial positive surface area PPSA-3 charge weighted partial positive surface area Atomic order is an atomic descriptor that specifies the ordinal position of an atom. Atomic order is an atomic descriptor that specifies the ordinal position of an atom. atomic order sum of surface area on negative parts of molecule sum of surface area on negative parts of molecule PNSA-1 partial negative surface area Chirality is a molecular entity quality which inheres in a molecular entity by virtue of the existence of another molecular entity which is the mirror image of the first one, yet non-superposable on it. Chirality is a molecular entity quality which inheres in a molecular entity by virtue of the existence of another molecular entity which is the mirror image of the first one, yet non-superposable on it. chirality A chemical entity information format specification is an information content entity which specifies a format in which information about a molecular entity should be encoded. A chemical entity information format specification is an information content entity which specifies a format in which information about a molecular entity should be encoded. chemical entity information format specification partial negative surface area * total negative charge on the molecule partial negative surface area * total negative charge on the molecule PNSA-2 PNSA-2 An energetic descriptor is a chemical descriptor which captures information about some aspect of the energetic behaviour of a chemical entity. An energetic descriptor is a chemical descriptor which captures information about some aspect of the energetic behaviour of a chemical entity. energetic descriptor A SMILES descriptor is a structure descriptor that denotes a molecular structure as a graph. A SMILES descriptor is a structure descriptor that denotes a molecular structure as a graph. SMILES descriptor A SMARTS descriptor is a molecular structure descriptor that conforms to the SMARTS specification. A SMARTS descriptor is a molecular structure descriptor that conforms to the SMARTS specification. SMARTS descriptor The simplified molecular input line entry specification (SMILES) is a specification for unambiguously describing the structure of chemical molecules using short ASCII strings. SMILES strings can be imported by most molecule editors for conversion back into two-dimensional drawings or three-dimensional models of the molecules (source:wikipedia). The simplified molecular input line entry specification (SMILES) is a specification for unambiguously describing the structure of chemical molecules using short ASCII strings. SMILES strings can be imported by most molecule editors for conversion back into two-dimensional drawings or three-dimensional models of the molecules (source:wikipedia). SMILES format specification Smiles ARbitrary Target Specification (SMARTS) is a language for specifying substructural patterns in molecules. The SMARTS line notation is expressive and allows extremely precise and transparent substructural specification and atom typing (source:Wikipedia) Smiles ARbitrary Target Specification (SMARTS) is a language for specifying substructural patterns in molecules. The SMARTS line notation is expressive and allows extremely precise and transparent substructural specification and atom typing (source:Wikipedia) SMARTS format specification A molecular structure encoding format specification is a molecular entity format specification which specifies a format in which a molecular structure information entity may be encoded. A molecular structure encoding format specification is a molecular entity format specification which specifies a format in which a molecular structure information entity may be encoded. molecular structure encoding format specification A molecular stereochemistry format specification is a molecular structure format specification that specifies how to encode the stereochemical aspects of a molecular structure. A molecular stereochemistry format specification is a molecular structure format specification that specifies how to encode the stereochemical aspects of a molecular structure. molecular stereochemistry format specification RS stereochemistry specification A physical descriptor is a chemical descriptor which describes some physical property (quality or disposition) of a chemical entity. A physical descriptor is a chemical descriptor which describes some physical property (quality or disposition) of a chemical entity. physical descriptor DL stereochemistry specification A stereochemical descriptor is a chemical descriptor which describes some aspect of the three dimensional structure of a chemical entity. A stereochemical descriptor is a chemical descriptor which describes some aspect of the three dimensional structure of a chemical entity. stereochemical descriptor A specification of stereochemistry by configuration specifies a format in which the stereochemistry of a molecule should be encoded with reference to the configuration of attachments around the stereogenic centre. A specification of stereochemistry by configuration specifies a format in which the stereochemistry of a molecule should be encoded with reference to the configuration of attachments around the stereogenic centre. specification of stereochemistry by configuration A specification of stereochemistry by optical activity specifies a format by which the stereochemistry of a molecule should be encoded by reference to the observable optical activity of a chiral molecule. A specification of stereochemistry by optical activity specifies a format by which the stereochemistry of a molecule should be encoded by reference to the observable optical activity of a chiral molecule. specification of stereochemistry by optical activity +/- stereochemistry specification A molecular entity quality is a quality which inheres in a molecular entity. A molecular entity quality is a quality which inheres in a molecular entity. molecular entity quality an isomeric SMILES descriptor is a SMILES descriptor that written with isotopic and chiral specifications. an isomeric SMILES descriptor is a SMILES descriptor that written with isotopic and chiral specifications. isomeric SMILES descriptor Molecular structure is a molecular entity quality that inheres in a molecule by virtue of its shape - the way in which the atoms which constitute the molecule are bonded together and the shape which they therefore form. Molecular structure is a molecular entity quality that inheres in a molecule by virtue of its shape - the way in which the atoms which constitute the molecule are bonded together and the shape which they therefore form. molecular structure S stereochemical descriptor An atomic connectivity molecular structure encoding format specification is a molecular structure encoding format specification which specifies a format in which the connectivity of atoms within a molecule may be specified. An atomic connectivity molecular structure encoding format specification is a molecular structure encoding format specification which specifies a format in which the connectivity of atoms within a molecule may be specified. atomic connectivity molecular structure encoding format specification A molecular composition format specification is a molecular entity information format specification which specifies a format in which a molecular composition may be encoded. A molecular composition format specification is a molecular entity information format specification which specifies a format in which a molecular composition may be encoded. molecular composition format specification IUPAC chemical formula The IUPAC International Chemical Identifier (InChI) is a textual identifier for chemical substances, designed to provide a standard and human-readable way to encode molecular information and to facilitate the search for such information in databases and on the web. Developed by IUPAC and NIST during 2000-2005, the format and algorithms are non-proprietary and the software is freely available under the open source LGPL license (though the term "InChI" is a trademark of IUPAC). [source: Wikipedia, http://en.wikipedia.org/wiki/International_Chemical_Identifier] The IUPAC International Chemical Identifier (InChI) is a textual identifier for chemical substances, designed to provide a standard and human-readable way to encode molecular information and to facilitate the search for such information in databases and on the web. Developed by IUPAC and NIST during 2000-2005, the format and algorithms are non-proprietary and the software is freely available under the open source LGPL license (though the term "InChI" is a trademark of IUPAC). [source: Wikipedia, http://en.wikipedia.org/wiki/International_Chemical_Identifier] InChI format specification A molecular entity name format specification is a molecular entity information format specification which specifies a format in which a molecular entity name may be encoded. A molecular entity name format specification is a molecular entity information format specification which specifies a format in which a molecular entity name may be encoded. molecular entity name format specification http://www.iupac.org/web/ins/2001-043-1-800 Preferred IUPAC Name for Organic Compounds A positional descriptor is a chemical descriptor which describes some aspect of the position, or location of a chemical entity, or of the relative parts of a chemical entity with respct to one another. A positional descriptor is a chemical descriptor which describes some aspect of the position, or location of a chemical entity, or of the relative parts of a chemical entity with respct to one another. positional descriptor A molecular formula is a structure descriptor which identifies each constituent element by its chemical symbol and indicates the number of atoms of each element found in each discrete molecule of that compound. A molecular formula is a structure descriptor which identifies each constituent element by its chemical symbol and indicates the number of atoms of each element found in each discrete molecule of that compound. molecular formula An information entity about a molecular entity which serves to name that molecular entity. An information entity about a molecular entity which serves to name that molecular entity. molecular entity name A preferred name is a molecular entity name which is preferred, or recommended, for usage in textual annotations referring to that molecular entity. A preferred name is a molecular entity name which is preferred, or recommended, for usage in textual annotations referring to that molecular entity. preferred name http://www.iupac.org/web/ins/2006-038-1-800 Preferred IUPAC Name for Inorganic Compounds The sum of the squared atom degrees of all heavy atoms. The sum of the squared atom degrees of all heavy atoms. zagreb index +/- stereochemical descriptor + stereochemical descriptor - stereochemical descriptor DL stereochemical descriptor D stereochemical descriptor L stereochemical descriptor Molecular composition is a molecular entity quality that inheres in a molecule by virtue of the atoms which constitute the molecule. Molecular composition is a molecular entity quality that inheres in a molecule by virtue of the atoms which constitute the molecule. molecular composition A chemical connectivity table is a structure descriptor which consists of a connection table representing bonds between atoms in a molecular entity. A chemical connectivity table is a structure descriptor which consists of a connection table representing bonds between atoms in a molecular entity. chemical connectivity table An aromaticity descriptor is a chemical descriptor which indicates the aromaticity of a molecular entity. An aromaticity descriptor is a chemical descriptor which indicates the aromaticity of a molecular entity. aromaticity descriptor InChIKey A dimensional extent descriptor is a physical property descriptor which describes some measurable length, area or volume aspect of a chemical entity. A dimensional extent descriptor is a physical property descriptor which describes some measurable length, area or volume aspect of a chemical entity. dimensional extent descriptor An identifying descriptor is a chemical descriptor which provides an identifier for the chemical entity it is about, which in most cases should aim to be unique and easy to use as an unambiguous reference for the chemical entity. An identifying descriptor is a chemical descriptor which provides an identifier for the chemical entity it is about, which in most cases should aim to be unique and easy to use as an unambiguous reference for the chemical entity. identifying descriptor A bond order descriptor is a descriptor associated with a bond in a chemical entity which indicates the order of the bond (single, double or triple). A bond order descriptor is a descriptor associated with a bond in a chemical entity which indicates the order of the bond (single, double or triple). bond order descriptor A Quantitative Structure Activity Relationship (QSAR) descriptor is a chemical descriptor which gives a numeric, quantitative value which is believed to be associated with some aspect of the chemical or biological activity of the chemical entity. A Quantitative Structure Activity Relationship (QSAR) descriptor is a chemical descriptor which gives a numeric, quantitative value which is believed to be associated with some aspect of the chemical or biological activity of the chemical entity. BODO:Descriptor NOTE: QSAR descriptors are often just called 'chemical descriptor' or 'molecular descriptor' in the cheminformatics community. QSAR descriptor cyclicity is a quality that inheres in a molecular entity by virtue of the presence of cycles in the connection of the atoms within the molecular entity. cyclicity is a quality that inheres in a molecular entity by virtue of the presence of cycles in the connection of the atoms within the molecular entity. cyclicity A functional group descriptor is a structural descriptor which describes specific groups of atoms within molecules that are responsible for the characteristic chemical reactions of those molecules. A functional group descriptor is a structural descriptor which describes specific groups of atoms within molecules that are responsible for the characteristic chemical reactions of those molecules. functional group descriptor Polarity is a quality that inheres in a molecular entity by virtue of whether or not the molecular entity has a separation of electric charge which leads to the molecule having an electric dipole. Polarity is a quality that inheres in a molecular entity by virtue of whether or not the molecular entity has a separation of electric charge which leads to the molecule having an electric dipole. polarity Polar polarity is a quality that inheres in a molecular entity when the molecular entity is polar, i.e. does possess an electric dipole. Polar polarity is a quality that inheres in a molecular entity when the molecular entity is polar, i.e. does possess an electric dipole. polar Nonpolar polarity is a quality which inheres in a molecular entity when the molecular entity does not possess an electrical dipole. Nonpolar polarity is a quality which inheres in a molecular entity when the molecular entity does not possess an electrical dipole. nonpolar Cyclic cyclicity inheres in a molecule when the atoms of the molecule do contain at least one cycle in the atom-atom connection paths (through bonds). Cyclic cyclicity inheres in a molecule when the atoms of the molecule do contain at least one cycle in the atom-atom connection paths (through bonds). cyclic Acyclic cyclicity inheres in a molecule when the atoms within the molecule do not contain at least one cycle in the atom-atom connection paths (through the bonds). Acyclic cyclicity inheres in a molecule when the atoms within the molecule do not contain at least one cycle in the atom-atom connection paths (through the bonds). acyclic chiral achiral Aromatic aromaticity is a quality that inheres in a molecular entity when it possesses at least one ring that is aromatic. Aromatic aromaticity is a quality that inheres in a molecular entity when it possesses at least one ring that is aromatic. aromatic Non aromatic aromaticity is a quality that inheres in a molecular entity by virtue of the molecule possessing no rings that are aromatic. Non aromatic aromaticity is a quality that inheres in a molecular entity by virtue of the molecule possessing no rings that are aromatic. non-aromatic The (integer) number of neutrons in the atoms nucleus. The (integer) number of neutrons in the atoms nucleus. neutron count The (integer) number of protons in the atoms nucleus. The (integer) number of protons in the atoms nucleus. proton count Descriptors which show the relationship between two ligands attached to separate atoms that are connected by a double bond or are contained in a ring. The two ligands are said to be located cis to each other if they lie on the same side of a plane. If they are on opposite sides, their relative position is described as trans. The appropriate reference plane of a double bond is perpendicular to that of the relevant s-bonds and passes through the double bond.[source:IUPAC Gold Book - http://goldbook.iupac.org/C01092.html] cis-trans stereochemical descriptor cis stereochemical descriptor trans stereochemical descriptor mass descriptor atomic mass descriptor A structural descriptor is a chemical descriptor which is about some aspect of the molecular structure (composition) of a chemical entity. A structural descriptor is a chemical descriptor which is about some aspect of the molecular structure (composition) of a chemical entity. structural descriptor electronic descriptor The mass of a molecule calculated according to some assumption about the isotopic identity of the atoms constituting it. Person: Colin Batchelor molecular mass descriptor The integer number of non-H substituents of an atom. The integer number of non-H substituents of an atom. atomic degree The quality of an atom that reflects the combination of its atomic orbitals to create bonding orbitals. The quality of an atom that reflects the combination of its atomic orbitals to create bonding orbitals. hybridization A topological descriptor is a chemical descriptor which pertains to spatial properties of a geometric object that are preserved under continuous deformations of objects, for example, deformations that involve stretching. A topological descriptor is a chemical descriptor which pertains to spatial properties of a geometric object that are preserved under continuous deformations of objects, for example, deformations that involve stretching. topological descriptor A geometric descriptor is a descriptor that concerns information about size, shape, and relative position. A geometric descriptor is a descriptor that concerns information about size, shape, and relative position. geometric descriptor charge delocalization descriptor A hybridization descriptor is a chemical descriptor that is about the hybridization of atomic orbitals in a molecular entity. A hybridization descriptor is a chemical descriptor that is about the hybridization of atomic orbitals in a molecular entity. hybridization descriptor Atomic valence is an atomic descriptor that specifies the maximum number of univalent atoms (originally hydrogen or chlorine atoms) which may combine with an atom of the element under consideration, or with a fragment, or for which an atom of this element can be substituted [source: IUPAC Gold Book - http://goldbook.iupac.org/V06588.html] Atomic valence is an atomic descriptor that specifies the maximum number of univalent atoms (originally hydrogen or chlorine atoms) which may combine with an atom of the element under consideration, or with a fragment, or for which an atom of this element can be substituted [source: IUPAC Gold Book - http://goldbook.iupac.org/V06588.html] atomic valence An atomic hardness descriptor is an atomic descriptor that estimates the difference between the ionization potential and the electron affinity of a given atom. An atomic hardness descriptor is an atomic descriptor that estimates the difference between the ionization potential and the electron affinity of a given atom. atomic hardness descriptor Valency is an atomic quality of the number of chemical bonds formed by the atom. Valency is an atomic quality of the number of chemical bonds formed by the atom. valency An atomic softness descriptor is an atomic descriptor which is about the charge delocalizing ability of a given atom. An atomic softness descriptor is an atomic descriptor which is about the charge delocalizing ability of a given atom. atomic softness descriptor The MOLfile atomic connectivity molecular structure encoding format specification may be found described at http://en.wikipedia.org/wiki/Chemical_table_file#Molfiles. It is composed primarily of a connection table (atoms and bonds); hydrogen may be implicit or explicit. The MOLfile atomic connectivity molecular structure encoding format specification may be found described at http://en.wikipedia.org/wiki/Chemical_table_file#Molfiles. It is composed primarily of a connection table (atoms and bonds); hydrogen may be implicit or explicit. MOLfile format specification A chemical substance quality is a quality that inheres in an aggregate molecular substance, such as a portion of solid or liquid matter. A chemical substance quality is a quality that inheres in an aggregate molecular substance, such as a portion of solid or liquid matter. chemical substance quality A crystal structure is a chemical substance quality which inheres in a crystalline solid or liquid crystal substance by virtue of the way the molecules are ordered within the crystal. A crystal structure is a chemical substance quality which inheres in a crystalline solid or liquid crystal substance by virtue of the way the molecules are ordered within the crystal. crystal structure A molecular QSAR descriptor is a OSAR descriptor which gives a quantitative value to some aspect of a molecular entity. A molecular QSAR descriptor is a OSAR descriptor which gives a quantitative value to some aspect of a molecular entity. molecular QSAR descriptor The cycle basis of a molecular structure is the smallest set of cycles (closed paths) formed in the graph representation of the structure, from which all other cycles can be computed. The cycle basis of a molecular structure is the smallest set of cycles (closed paths) formed in the graph representation of the structure, from which all other cycles can be computed. cycle basis A systematic name is a molecular entity name which is formulated systematically from the structure of the molecular entity. A systematic name is a molecular entity name which is formulated systematically from the structure of the molecular entity. systematic name An IUPAC name is a systematic name which is formulated according to the rules and recommendations for chemical nomenclature set out by the International Union of Pure and Applied Chemistry (IUPAC). An IUPAC name is a systematic name which is formulated according to the rules and recommendations for chemical nomenclature set out by the International Union of Pure and Applied Chemistry (IUPAC). IUPAC name An atomic quality is a molecular entity quality which inheres in an atom. An atomic quality is a molecular entity quality which inheres in an atom. atomic quality A trivial name is a molecular entity name that is in common public use and may not be related to the structure of the molecular entity. A trivial name is a molecular entity name that is in common public use and may not be related to the structure of the molecular entity. trivial name The fused cycles in a molecular structure are those cycles from the cycle basis which share at least one bond. The fused cycles in a molecular structure are those cycles from the cycle basis which share at least one bond. fused cycles A CML (Chemical Markup Language) file is an XML-based representation of the atomic connectivity of a molecular entity. A CML (Chemical Markup Language) file is an XML-based representation of the atomic connectivity of a molecular entity. CML format specification An atomic QSAR descriptor is a QSAR descriptor which gives a quantitative value to some aspect of an atom which is part of a molecular entity. An atomic QSAR descriptor is a QSAR descriptor which gives a quantitative value to some aspect of an atom which is part of a molecular entity. atomic QSAR descriptor An InChI descriptor is a structure descriptor which conforms to the InChI format specification. An InChI descriptor is a structure descriptor which conforms to the InChI format specification. InChI descriptor A MOLfile descriptor is a structure descriptor which conforms to the MOLfile format specification. A MOLfile descriptor is a structure descriptor which conforms to the MOLfile format specification. MOLfile descriptor Aromaticity is a molecular entity quality that inheres in a conjugated ring of unsaturated bonds, lone pairs, or empty orbitals that exhibit a stabilization stronger than would be expected by the stabilization of conjugation alone. Aromaticity is a molecular entity quality that inheres in a conjugated ring of unsaturated bonds, lone pairs, or empty orbitals that exhibit a stabilization stronger than would be expected by the stabilization of conjugation alone. aromaticity An atomic connectivity index is an atomic descriptor that is a measure of atomic connectivity, which can take various forms (e.g. zero-order, or first-order). An atomic connectivity index is an atomic descriptor that is a measure of atomic connectivity, which can take various forms (e.g. zero-order, or first-order). atomic connectivity index Half the sum of all the distance matrix entries, topological index of atom-atom distances. Half the sum of all the distance matrix entries, topological index of atom-atom distances. Wiener path number The formal charge gives the charge assigned to an atom in a molecule, assuming that electrons in a chemical bond are shared equally between atoms, regardless of relative electronegativity. The formal charge of any atom in a molecule can be calculated by the following equation: FC = number of valence electrons of the atom in isolation (atom in ground state) - number of non-bonding electrons on this atom in the molecule - half the total number of electrons shared in covalent bonds with other atoms in the molecule. [source:wikipedia] The formal charge gives the charge assigned to an atom in a molecule, assuming that electrons in a chemical bond are shared equally between atoms, regardless of relative electronegativity. The formal charge of any atom in a molecule can be calculated by the following equation: FC = number of valence electrons of the atom in isolation (atom in ground state) - number of non-bonding electrons on this atom in the molecule - half the total number of electrons shared in covalent bonds with other atoms in the molecule. [source:wikipedia] formal charge descriptor A partial charge descriptor gives the charge with an absolute value of less than one elementary charge unit (that is, smaller than the charge of the electron). [source:wikipedia] A partial charge descriptor gives the charge with an absolute value of less than one elementary charge unit (that is, smaller than the charge of the electron). [source:wikipedia] partial charge descriptor Charge is a quality that inheres in a molecular entity by virtue of the overall electric charge of the molecule, which is due to a comparison between the total number of electrons and the total number of protons. Charge is a quality that inheres in a molecular entity by virtue of the overall electric charge of the molecule, which is due to a comparison between the total number of electrons and the total number of protons. charge An electronegativity descriptor is a chemical descriptor that is about the electronegativity quality of an atom. An electronegativity descriptor is a chemical descriptor that is about the electronegativity quality of an atom. electronegativity descriptor A chemical descriptor is a data item (quantity or value) about a chemical entity that conforms to a specification for how it is calculated, measured or recorded. A chemical descriptor is a data item (quantity or value) about a chemical entity that conforms to a specification for how it is calculated, measured or recorded. chemical descriptor Atomic radius is the 1D extent of the electron cloud surrounding the atom. atomic radius ionic radius van der Waals radius covalent radius Bond multiplicity is the extent to which participating electrons are localized in the bonding orbitals. Bond multiplicity is the extent to which participating electrons are localized in the bonding orbitals. bond multiplicity A bond multiplicity descriptor is a chemical descriptor that in primitive cases is defined as half of the difference between the number of bonding and antibonding electrons in a particular system, but may also be defined with relation to the strength of a single bond. A bond multiplicity descriptor is a chemical descriptor that in primitive cases is defined as half of the difference between the number of bonding and antibonding electrons in a particular system, but may also be defined with relation to the strength of a single bond. bond multiplicity descriptor A charge descriptor is a chemical descriptor which indicates the charge of a chemical entity. A charge descriptor is a chemical descriptor which indicates the charge of a chemical entity. charge descriptor A bond length descriptor is a dimensional extent descriptor which gives the measured or predicted (idealised) length of an atom to atom bond within a chemical entity. A bond length descriptor is a dimensional extent descriptor which gives the measured or predicted (idealised) length of an atom to atom bond within a chemical entity. bond length descriptor The quality of an atom in which the 2s orbital mixes with only one of the three p-orbitals resulting in two sp orbitals and two remaining unchanged p orbitals. spsp overlap between two atoms form a s bond and two additional p bonds formed by pp overlap. The quality of an atom in which the 2s orbital mixes with only one of the three p-orbitals resulting in two sp orbitals and two remaining unchanged p orbitals. spsp overlap between two atoms form a s bond and two additional p bonds formed by pp overlap. sp hybridized sp2 hybridized sp3 hybridized constitutional descriptor Half the sum of all the distance matrix entries with a value of 3 Half the sum of all the distance matrix entries with a value of 3 Wiener polarity number descriptor PubChem compound identifier (CID) PubChem substance identifier (SID) topological surface area descriptor a generic SMILES descriptor is a SMILES descriptor that denotes only the labeled molecular graph (i.e. atoms and bonds, but no chiral or isotopic information). a generic SMILES descriptor is a SMILES descriptor that denotes only the labeled molecular graph (i.e. atoms and bonds, but no chiral or isotopic information). generic SMILES descriptor isomeric SMILES format specification canonical SMILES format specification topological polar surface area descriptor charge weighted partial negative surface area charge weighted partial negative surface area PNSA-3 charge weighted partial negative surface area difference of PPSA-1 and PNSA-1 difference of PPSA-1 and PNSA-1 DPSA-1 DPSA-1 difference of FPSA-2 and PNSA-2 difference of FPSA-2 and PNSA-2 DPSA-2 DPSA-2 difference of PPSA-3 and PNSA-3 difference of PPSA-3 and PNSA-3 DPSA-3 DPSA-3 PPSA-1 / total molecular surface area PPSA-1 / total molecular surface area FPSA-1 FPSA-1 PPSA-2 / total molecular surface area PPSA-2 / total molecular surface area FPSA-2 FPSA-2 PPSA-3 / total molecular surface area PPSA-3 / total molecular surface area FPSA-3 FPSA-3 PNSA-1 / total molecular surface area PNSA-1 / total molecular surface area FNSA-1 FNSA-1 PNSA-2 / total molecular surface area PNSA-2 / total molecular surface area FNSA-2 FNSA-2 PNSA-3 / total molecular surface area PNSA-3 / total molecular surface area FNSA-3 FNSA-3 PPSA-1 * total molecular surface area / 1000 PPSA-1 * total molecular surface area / 1000 WPSA-1 WPSA-1 PPSA-2 * total molecular surface area /1000 PPSA-2 * total molecular surface area /1000 WPSA-2 WPSA-2 PPSA-3 * total molecular surface area /1000 PPSA-3 * total molecular surface area /1000 WPSA-3 WPSA-3 PNSA-1 * total molecular surface area /1000 PNSA-1 * total molecular surface area /1000 WNSA-1 WNSA-1 PNSA-2 * total molecular surface area /1000 PNSA-2 * total molecular surface area /1000 WNSA-2 WNSA-2 PNSA-3 * total molecular surface area /1000 PNSA-3 * total molecular surface area /1000 WNSA-3 WNSA-3 most positive charge / total positive charge most positive charge / total positive charge RPCG relative positive charge most negative charge / total negative charge most negative charge / total negative charge RNCG relative negative charge most positive surface area * RPCG most positive surface area * RPCG RPCS relative positive charge surface area most negative surface area * RNCG most negative surface area * RNCG RNCS relative negative charge surface area sum of solvent accessible surface areas of atoms with absolute value of partial charges less than 0.2 sum of solvent accessible surface areas of atoms with absolute value of partial charges less than 0.2 THSA THSA sum of solvent accessible surface areas of atoms with absolute value of partial charges greater than or equal 0.2 sum of solvent accessible surface areas of atoms with absolute value of partial charges greater than or equal 0.2 TPSA TPSA THSA / total molecular surface area THSA / total molecular surface area RHSA RHSA TPSA / total molecular surface area TPSA / total molecular surface area RPSA RPSA collection of 3D coordinates collection of 3D atomic coordinates Sum of the absolute value of the difference between atomic polarizabilities of all bonded atoms in the molecule (including implicit hydrogens) Sum of the absolute value of the difference between atomic polarizabilities of all bonded atoms in the molecule (including implicit hydrogens) BPol molecular polarizability defined as @cdk.cite{Nilakantan06} defined as @cdk.cite{Nilakantan06} FragmentComplexity fragment complexity descriptor vertex adjacency matrix descriptor A measure of the anisotropy in a molecule (as per Petitjean et al) A measure of the anisotropy in a molecule (as per Petitjean et al) Petitjean Topological Shape Index A measure of the anisotropy in a molecule (as per Bath et al) A measure of the anisotropy in a molecule (as per Bath et al) Petitjean Geometric Shape Index the eccentricity of a vertex corresponds to the distance from that vertex to the most remote vertex in the graph. The distance is obtained from the distance matrix as the count of edges between the two vertices. If r i is the largest matrix entry in row i of the distance matrix D, then the radius is defined as the smallest of the r i . The graph diameter D is defined as the largest vertex eccentricity in the graph. Petitjean Number is the value of ( diameter - radius ) diameter . the eccentricity of a vertex corresponds to the distance from that vertex to the most remote vertex in the graph. The distance is obtained from the distance matrix as the count of edges between the two vertices. If r i is the largest matrix entry in row i of the distance matrix D, then the radius is defined as the smallest of the r i . The graph diameter D is defined as the largest vertex eccentricity in the graph. Petitjean Number is the value of ( diameter - radius ) diameter . petitjeanNumber Petitjean number A measure of the anisotropy in a molecule A measure of the anisotropy in a molecule petitjeanShapeIndex Petitjean Shape Index A LogP descriptor based on the atom-type method described in Wang, R., Fu, Y., and Lai, L.. A New Atom-Additive Method for Calculating Partition Coefficients, Journal of Chemical Information and Computer Sciences. vol. 37. 1997, pp. 615-621. A LogP descriptor based on the atom-type method described in Wang, R., Fu, Y., and Lai, L.. A New Atom-Additive Method for Calculating Partition Coefficients, Journal of Chemical Information and Computer Sciences. vol. 37. 1997, pp. 615-621. XLogP XLogP descriptor A LogP descriptor based on a simple equation using the number of carbons and hetero atoms. A LogP descriptor based on a simple equation using the number of carbons and hetero atoms. MannholdLogP MLogP descriptor maximal ratio of length to breadth descriptor A descriptor characterizing the ratio of the length to the breadth of a given entity. ratio of length to breadth descriptor minimal ratio of length to breadth descriptor An ionization energy descriptor is a descriptor that describes the minimum amount of energy required to remove an electron (to an infinite distance) from an atom or molecule in a gaseous state. X + energy → X+ + e- The term 'ionization potential' has historically been used but is now no longer recommended. ionization energy ionization enthalpy ionization potential ionization energy descriptor EccentricConnectivityIndex eccentric connectivity index descriptor equilibrium constant the acid dissociation constant, Ka, is quantitative measure of the strength of an acid in solution. It is the equilibrium constant for a chemical reaction known as dissociation in the context of acid-base reactions. the acid dissociation constant, Ka, is quantitative measure of the strength of an acid in solution. It is the equilibrium constant for a chemical reaction known as dissociation in the context of acid-base reactions. Ka acid dissociation constant the logarithmic measure of the acid dissociation constant (Ka) the logarithmic measure of the acid dissociation constant (Ka) pKa pKa A molecular weight descriptor calculated by a relevant module of the Pipeline Pilot software tool. molecular weight calculated by pipeline pilot An absolute SMILES descriptor is an isomeric SMILES descriptor that is produced using a canonicalization algorithm. An absolute SMILES descriptor is an isomeric SMILES descriptor that is produced using a canonicalization algorithm. absolute SMILES descriptor a count descriptor that denotes the number of tautomers. a count descriptor that denotes the number of tautomers. tautomer count stereocenter count atom stereocenter count defined atom stereocenter count A formation energy descriptor is an energetic descriptor which gives the value for the energy of formation of a chemical entity. A formation energy descriptor is an energetic descriptor which gives the value for the energy of formation of a chemical entity. formation energy descriptor A solvation energy descriptor is a chemical descriptor which gives the value for the energy of dissolving a particular chemical entity in a solvent. A solvation energy descriptor is a chemical descriptor which gives the value for the energy of dissolving a particular chemical entity in a solvent. solvation energy descriptor A count descriptor is a chemical descriptor which is calculated by counting the number of features of a certain kind which are present in the chemical entity. A count descriptor is a chemical descriptor which is calculated by counting the number of features of a certain kind which are present in the chemical entity. count descriptor A dissociation energy descriptor is an energetic descriptor which gives a value for the dissociation energy for a chemical entity. A dissociation energy descriptor is an energetic descriptor which gives a value for the dissociation energy for a chemical entity. dissociation energy descriptor undefined atom stereocenter count bond stereocenter count defined bond stereocenter count undefined bond stereocenter count The mass of a molecule calculated using the average mass of each element weighted for its natural isotopic abundance. E.g., Carbon has two natural isotopes 12 and 13 with relative abundances of 98.9% and 1.1% to yield an average mass of 12.011 g/mol The mass of a molecule calculated using the average mass of each element weighted for its natural isotopic abundance. E.g., Carbon has two natural isotopes 12 and 13 with relative abundances of 98.9% and 1.1% to yield an average mass of 12.011 g/mol average molecular weight descriptor an exact mass descriptor corresponds to the mass of the most intense molecule/ion peak in an MS spec, and when calculated denotes the mass of an ion or a molecule containing most likely isotopic composition for a single random molecule. an exact mass descriptor corresponds to the mass of the most intense molecule/ion peak in an MS spec, and when calculated denotes the mass of an ion or a molecule containing most likely isotopic composition for a single random molecule. exact mass descriptor The mass of a molecule calculated using the mass of the most abundant isotope of each element. E.g., Carbon has a monoisotopic mass of 12.000 g/mol. The mass of a molecule calculated using the mass of the most abundant isotope of each element. E.g., Carbon has a monoisotopic mass of 12.000 g/mol. monoisotopic mass descriptor A complexity descriptor denotes the how complicated a structure is, seen from both the point of view of the elements contained and its structural features . A complexity descriptor denotes the how complicated a structure is, seen from both the point of view of the elements contained and its structural features . complexity descriptor cis-trans stereochemistry specification The integer number of atoms in a pi-orbital system. The integer number of atoms in a pi-orbital system. LargestPiSystem pi-system size Bond dissociation Gibbs energy descriptor captures the Gibbs energy associated with the process of breaking the bond in question. This could be measured or calculated in vacuo or in a specific Solvent, at a given temperature and pressure. Depends on molecular conformation. Bond dissociation Gibbs energy descriptor captures the Gibbs energy associated with the process of breaking the bond in question. This could be measured or calculated in vacuo or in a specific Solvent, at a given temperature and pressure. Depends on molecular conformation. bond dissociation Gibbs energy descriptor The molecular entity solvation Gibbs energy descriptor reflects the Gibbs energy associated with the solvation of the molecular entity in question. This could be measured or calculated in vacuo or in a specific solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. The molecular entity solvation Gibbs energy descriptor reflects the Gibbs energy associated with the solvation of the molecular entity in question. This could be measured or calculated in vacuo or in a specific solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. solvation Gibbs energy descriptor bond charge density descriptor A surface area descriptor is a descriptor which describes a measure or calculation of the surface area of a chemical entity. A surface area descriptor is a descriptor which describes a measure or calculation of the surface area of a chemical entity. surface area descriptor From PATO. composition A charge density descriptor is a chemical entity descriptor which indicates the distribution of the electric charge over the volume of the chemical entity. A charge density descriptor is a chemical entity descriptor which indicates the distribution of the electric charge over the volume of the chemical entity. charge density descriptor A descriptor that provides the integer count of aromatic atoms in a given molecular entity. A descriptor that provides the integer count of aromatic atoms in a given molecular entity. aromatic atom count A descriptor that specifies the integer count of bonds in a given molecular entity. A descriptor that specifies the integer count of bonds in a given molecular entity. bond count PubChem conformer identifier The linear, surface, or volume charge density is the amount of electric charge in a line, surface, or volume respectively. [source: Wikipedia, http://en.wikipedia.org/wiki/Charge_density] The linear, surface, or volume charge density is the amount of electric charge in a line, surface, or volume respectively. [source: Wikipedia, http://en.wikipedia.org/wiki/Charge_density] charge density A bond aromaticity descriptor is an aromaticity descriptor associated with a bond within a chemical entity which indicates whether that bond belongs to an aromatic system. A bond aromaticity descriptor is an aromaticity descriptor associated with a bond within a chemical entity which indicates whether that bond belongs to an aromatic system. bond aromaticity descriptor The formation Gibbs energy descriptor captures the Gibbs energy associated with the formation of a molecular entity, relative to the standard state of constituent atoms. This can be measured, calculated in vacuo, or calculated with respect to a specific solvent, at a particular temperature and pressure. When calculated, the formation Gibbs energy value depends on the molecular conformation. The formation Gibbs energy descriptor captures the Gibbs energy associated with the formation of a molecular entity, relative to the standard state of constituent atoms. This can be measured, calculated in vacuo, or calculated with respect to a specific solvent, at a particular temperature and pressure. When calculated, the formation Gibbs energy value depends on the molecular conformation. formation Gibbs energy descriptor The largest aliphatic chain size descriptor is a count descriptor that gives the integer length (number of atoms) in the largest unbranched chain of atoms that does not contain aromatic atoms, within a given molecular entity. The largest aliphatic chain size descriptor is a count descriptor that gives the integer length (number of atoms) in the largest unbranched chain of atoms that does not contain aromatic atoms, within a given molecular entity. size of largest aliphatic chain Molecular entity formation enthaply descriptor captures the enthalpy associated with the formation of the molecular entity in question, relative to the standard state of constituent atoms. This could be measured or calculated in vacuo or in a specific Solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. enthalpy of formation heat of formation Molecular entity formation enthaply descriptor captures the enthalpy associated with the formation of the molecular entity in question, relative to the standard state of constituent atoms. This could be measured or calculated in vacuo or in a specific Solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. formation enthalpy descriptor A volume descriptor is a descriptor which describes a measure or calculation of the volume of a chemical entity. A volume descriptor is a descriptor which describes a measure or calculation of the volume of a chemical entity. volume descriptor A descriptor that provides the integer count of aromatic bonds in a given molecular entity. A descriptor that provides the integer count of aromatic bonds in a given molecular entity. aromatic bond count A descriptor that reflects the integer number of hydrogen bond donors in a given molecular entity, as determined by a given method. In highly simplified terms, this is usually the count of all negatively or partially negatively charged heteroatoms (e.g. alcohol oxygen) that have covalently attached to them partially positively charged hydrogen atoms that are capable of participating in a hydrogen bond. A descriptor that reflects the integer number of hydrogen bond donors in a given molecular entity, as determined by a given method. In highly simplified terms, this is usually the count of all negatively or partially negatively charged heteroatoms (e.g. alcohol oxygen) that have covalently attached to them partially positively charged hydrogen atoms that are capable of participating in a hydrogen bond. hydrogen bond donor count A descriptor that reflects the integer number of hydrogen bond acceptors in a given molecular entity, as determined by a given method. In highly simplified terms, this is usually the count of all negatively or partially negatively charged heteroatoms (e.g. alcohol oxygen) capable of accepting a hydrogen bond. A descriptor that reflects the integer number of hydrogen bond acceptors in a given molecular entity, as determined by a given method. In highly simplified terms, this is usually the count of all negatively or partially negatively charged heteroatoms (e.g. alcohol oxygen) capable of accepting a hydrogen bond. hydrogen bond acceptor count The largest chain size descriptor is a count descriptor that gives the integer length (number of atoms) in the largest chain in a molecular entity. The largest chain size descriptor is a count descriptor that gives the integer length (number of atoms) in the largest chain in a molecular entity. size of largest chain surface area The molecular entity solvation entropy descriptor reflects the entropy associated with the solvation of the molecular entity in question. This could be measured or calculated in vacuo or in a specific solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. The molecular entity solvation entropy descriptor reflects the entropy associated with the solvation of the molecular entity in question. This could be measured or calculated in vacuo or in a specific solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. solvation entropy descriptor The molecular entity solvation enthalpy descriptor reflects the enthalpy associated with the solvation of the molecular entity in question. This could be measured or calculated in vacuo or in a specific solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. The molecular entity solvation enthalpy descriptor reflects the enthalpy associated with the solvation of the molecular entity in question. This could be measured or calculated in vacuo or in a specific solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. solvation enthalpy descriptor The logarithm of octanol-water partition coefficient, which is the ratio of the molecules dissolved in octanol to those dissolved in pure un-ionized water upon mixture equilibration. This can be measured or predicted. The value is dimensionless. May depend on molecular conformation when computed. The logarithm of octanol-water partition coefficient, which is the ratio of the molecules dissolved in octanol to those dissolved in pure un-ionized water upon mixture equilibration. This can be measured or predicted. The value is dimensionless. May depend on molecular conformation when computed. logP descriptor Bond dissociation enthalpy descriptor captures the enthalpy associated with the process of breaking the bond in question. This could be measured or calculated in vacuo or in a specific Solvent, at a given temperature and pressure. Depends on molecular conformation. Bond dissociation enthalpy descriptor captures the enthalpy associated with the process of breaking the bond in question. This could be measured or calculated in vacuo or in a specific Solvent, at a given temperature and pressure. Depends on molecular conformation. bond dissociation enthalpy descriptor Chemical substance refractive index descriptor is a unitless descriptor that specifies the ratio of the speed of light in vacuum to that in a given chemical substance. [IUPAC: http://goldbook.iupac.org/R05240.html] Chemical substance refractive index descriptor is a unitless descriptor that specifies the ratio of the speed of light in vacuum to that in a given chemical substance. [IUPAC: http://goldbook.iupac.org/R05240.html] refractive index descriptor a bond count that denotes the integer number of rotors in the molecule, generally single bonds torsion around which produces non-identical geometric molecular configurations. a bond count that denotes the integer number of rotors in the molecule, generally single bonds torsion around which produces non-identical geometric molecular configurations. RotatableBondsCount rotatable bond count Melting point descriptor specifies the temperature at which a chemical substance undergoes the transition from solid to liquid state under standard conditions. melting point descriptor The boiling point descriptor indicates the temperature at which a chemical substance undergoes a state transition from liquid to gas, at standard conditions. boiling point descriptor Molecular entity formaiton entropy descriptor captures the entropy associated with the formation of the molecular entity in question, relative to the standard state of constituent atoms. This could be measured or calculated in vacuo or in a specific Solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. Molecular entity formaiton entropy descriptor captures the entropy associated with the formation of the molecular entity in question, relative to the standard state of constituent atoms. This could be measured or calculated in vacuo or in a specific Solvent, at a particular temperature and pressure. Depends on molecular conformation when computed. formation entropy descriptor The relative permittivity descriptor specifies the ratio of the electric field strength in vacuum to that in a given medium. It was formerly called the dielectric constant. [IUPAC Gold Book: http://goldbook.iupac.org/R05273.html ] The relative permittivity descriptor specifies the ratio of the electric field strength in vacuum to that in a given medium. It was formerly called the dielectric constant. [IUPAC Gold Book: http://goldbook.iupac.org/R05273.html ] relative permittivity descriptor A descriptor that specifies the integer count of atoms in a given molecular entity. A descriptor that specifies the integer count of atoms in a given molecular entity. atom count atomic charge density descriptor Bond dissociation entropy descriptor captures the entropy associated with the process of breaking the bond in question. This could be measured or calculated in vacuo or in a specific Solvent, at a given temperature and pressure. Depends on molecular conformation. Bond dissociation entropy descriptor captures the entropy associated with the process of breaking the bond in question. This could be measured or calculated in vacuo or in a specific Solvent, at a given temperature and pressure. Depends on molecular conformation. bond dissociation entropy descriptor A count descriptor that takes into account flexibility of rings and rotatable bonds. A count descriptor that takes into account flexibility of rings and rotatable bonds. effective rotor count A charge descriptor that gives the total charge for a molecule A charge descriptor that gives the total charge for a molecule total formal charge descriptor conformer volume descriptor a count of the number of amino acid residues. a count of the number of amino acid residues. amino acid count alanine count arginine count asparagine count aspartate count cysteine count phenylalanine count glutamate count glutamine count glycine count The number of covalent units (molecule / ion) in a chemical structure The number of covalent units (molecule / ion) in a chemical structure covalent unit count histidine count isoleucine count proline count leucine count lysine count methionine count serine count threonine count tyrosine count valine count tryptophan count A descriptor that the energy of the highest occupied 'molecular' orbital of the chemical entity. A descriptor that the energy of the highest occupied 'molecular' orbital of the chemical entity. Highest Occupied Molecular Orbital Energy A descriptor that the energy of the lowest unoccupied 'molecular' orbital of the chemical entity. A descriptor that the energy of the lowest unoccupied 'molecular' orbital of the chemical entity. Lowest Unoccupied Molecular Orbital Energy A descriptor that specifies the integer count of acidic groups in a given molecular entity. A descriptor that specifies the integer count of acidic groups in a given molecular entity. acidic group count A descriptor that specifies the integer count of basic groups in a given molecular entity. A descriptor that specifies the integer count of basic groups in a given molecular entity. basic group count The ALogP descriptor described by Ghose and Crippen in 1986 and 1987. The ALogP descriptor described by Ghose and Crippen in 1986 and 1987. ALogP ALogP descriptor hybridization descriptor (VSEPR) inductive atomic hardness TPSA (fragments) VABC volume descriptor The number of non-hydrogen atoms The number of non-hydrogen atoms heavy atom count The sum of all atoms enriched with respect to a particular atom isotope The sum of all atoms enriched with respect to a particular atom isotope isotope atom count PubChem Identifier GenBank Protein Identifier GenBank Nucleotide Identifier ALogP calculated by Pipeline Pilot polar surface area descriptor polar surface area descriptor calculated by Pipeline Pilot hydrogen bond acceptor count calculated by pipeline pilot hydrogen bond donor count calculated by pipeline pilot rotatable bond count calculated by pipeline pilot Number of properties defined in Lipinski’s Rule of 5 (RO5) that the compound fails. Conditions which violate the RO5 are: Molecular weight>=500 AlogP>=5 HBD>=5 HBA>=10 rule of five violations descriptor rule of five violations calculated by pipeline pilot Rule of 3 passes. It is suggested that compounds that pass all these criteria are more likely to be hits in fragment screening. molecular weight <=300, number of hydrogen bond donors <=3, number of hydrogen bond acceptors <=3 AlogP <=3. RTB <=3 PSA<=60 rule of three passes descriptor rule of three passes calculated by pipeline pilot MedChem Friendly These are functional groups that may not be desirable from a medicinal chemistry perspective. For example reactive groups will be flagged as “N” (not MedChem Friendly). Molecules which do not contain any of these groups will be flagged as “Y” (MedChem Friendly). The groups are defined by the following list of SMARTS: [N+]([O-])=O [C;!R](-[C;!R]=O)=[C;!R] C(-N)=S P O-N=C OS(=O)=O O1-CC-O-C-1 C(-N)=C [C;H2]-[C;H2]-[C;H2]-[C;H2]-[C;H2]-[C;H2]-[C;H2] OC1OCC(O)C1 C=N-C(-O) [N;H]-[C;H]-[N;H] [C;!R]=[C;!R]-N-[C;D1&H3,D2&H2,D3&H1,D4] [S;!R]-[C;!R]-[O;!R] [O;D2]-[C;!H0](([F,Br,I,Cl])([F,Br,I,Cl])([!F,!Br,!I,!Cl])) CC([O;!R])([O;!R]) C1-C-O1 C(=O)-S-C(=S) [S;H] SC#N medchem friendly descriptor medchem friendly descriptor calculated by pipeline pilot logP calculated by ACD/Labs PhysChem software octanol-water distribution coefficient calculated at a given pH. logD descriptor ACD_LogD(pH7.4) Distribution Coefficient calculated at pH7.4 logD calculated at pH 7.4 by ACD/Labs PhysChem software Most acidic pKa of the molecule most acidic pKa calculated by ACD/Labs PhysChem software library Most basic pKa of the molecule most basic pKa calculated by ACD/Labs PhysChem software library Molecular Species is a description of the predominant form of the molecule at pH7.4. molecular species at pH 7.4 descriptor These are defined according to the definitions: Acid(A) ACD_MOST_ApKa <6.5 and ACD_MOST_BpKa<8.5 Bas (B) ACD_MOST_ApKa >6.5 and ACD_MOST_BpKa>8.5 Neutral (N) ACD_MOST_ApKa >6.5 and ACD_MOST_BpKa<8.5 Zwitterion (ZW) ACD_MOST_ApKa <6.5 and ACD_MOST_BpKa>8.5 molecular species at pH 7.4 calculated by ACD/Labs PhysChem software molecular weight calculated by the pubchem software library molecular formula calculated by the pubchem software library total formal charge calculated by the pubchem software library monoisotopic mass calculated by the pubchem software library exact mass calculated by pubchem software library A molecular entity name that has been supplied by a depositor to the PubChem database. This is just a molecular entity name with additional provenance associated. pubchem depositor-supplied molecular entity name Octanol-water distribution coefficient calculated at pH 5.5 by ACD/Labs PhysChem software library version 12.01. Octanol-water distribution coefficient calculated at pH 5.5 by ACD/Labs PhysChem software library version 12.01. logD calculated at pH 5.5 by ACD/Labs PhysChem software library version 12.01 Hydrogen bond acceptor count that has been calculated by ACD/Labs PhysChem software library version 12.01. Hydrogen bond acceptor count that has been calculated by ACD/Labs PhysChem software library version 12.01. hydrogen bond acceptor count calculated by ACD/Labs PhysChem software library version 12.01 Hydrogen bond donor count that has been calculated by ACD/Labs PhysChem software library version 12.01. Hydrogen bond donor count that has been calculated by ACD/Labs PhysChem software library version 12.01. hydrogen bond donor count calculated by ACD/Labs PhysChem software library version 12.01 The boiling point of a substance at 760 mmHg pressure that has been calculated by ACD/Labs PhysChem software library version 12.01. The boiling point of a substance at 760 mmHg pressure that has been calculated by ACD/Labs PhysChem software library version 12.01. Boiling point at 760 mmHg pressure calculated by ACD/Labs PhysChem software library version 12.01 Number of freely rotating bonds that has been calculated by ACD/Labs PhysChem software library version 12.01. Number of freely rotating bonds that has been calculated by ACD/Labs PhysChem software library version 12.01. number of freely rotating bonds calculated by ACD/Labs PhysChem software library version 12.01 Polar surface area that has been calculated by ACD/Labs PhysChem software library version 12.01. Polar surface area that has been calculated by ACD/Labs PhysChem software library version 12.01. polar surface area calculated by ACD/Labs PhysChem software library version 12.01 The molecular weight for the free base chemical structure matching this chemical structure. The molecular weight for the free base chemical structure matching this chemical structure. molecular weight of the corresponding free base Molar refractivity that has been calculated by ACD/Labs PhysChem software library version 12.01. Molar refractivity that has been calculated by ACD/Labs PhysChem software library version 12.01. molar refractivity calculated by ACD/Labs PhysChem software library version 12.01 Index of refraction that has been calculated by ACD/Labs PhysChem software library version 12.01. Index of refraction that has been calculated by ACD/Labs PhysChem software library version 12.01. index of refraction calculated by ACD/Labs PhysChem software library version 12.01 Molar volume that has been calculated by ACD/Labs PhysChem software library version 12.01. Molar volume that has been calculated by ACD/Labs PhysChem software library version 12.01. molar volume calculated by ACD/Labs PhysChem software library version 12.01 Density that has been calculated by ACD/Labs PhysChem software library version 12.01. Density that has been calculated by ACD/Labs PhysChem software library version 12.01. density calculated by ACD/Labs PhysChem software library version 12.01 Flash point that has been calculated by ACD/Labs PhysChem software library version 12.01. Flash point that has been calculated by ACD/Labs PhysChem software library version 12.01. flash point calculated by ACD/Labs PhysChem software library version 12.01 Enthalpy of vaporization that has been calculated by ACD/Labs PhysChem software library version 12.01. Enthalpy of vaporization that has been calculated by ACD/Labs PhysChem software library version 12.01. enthalpy of vaporization calculated by ACD/Labs PhysChem software library version 12.01 Vapour pressure that has been calculated by ACD/Labs PhysChem software library version 12.01. Vapour pressure that has been calculated by ACD/Labs PhysChem software library version 12.01. vapour pressure calculated by ACD/Labs PhysChem software library version 12.01 Organic carbon adsorption coefficient at pH 5.5 that has been calculated by ACD/Labs PhysChem software library version 12.01. Organic carbon adsorption coefficient at pH 5.5 that has been calculated by ACD/Labs PhysChem software library version 12.01. organic carbon adsorption coefficient at pH 5.5 calculated by ACD/Labs PhysChem software library version 12.01 Organic carbon adsorption coefficient at pH 7.4 that has been calculated by ACD/Labs PhysChem software library version 12.01. Organic carbon adsorption coefficient at pH 7.4 that has been calculated by ACD/Labs PhysChem software library version 12.01. organic carbon adsorption coefficient at pH 7.4 calculated by ACD/Labs PhysChem software library version 12.01 Bioconcentration factor at pH 7.4 that has been calculated by ACD/Labs PhysChem software library version 12.01. Bioconcentration factor at pH 7.4 that has been calculated by ACD/Labs PhysChem software library version 12.01. bioconcentration factor at pH 5.5 calculated by ACD/Labs PhysChem software library version 12.01 Bioconcentration factor at pH 7.4 that has been calculated by ACD/Labs PhysChem software library version 12.01. Bioconcentration factor at pH 7.4 that has been calculated by ACD/Labs PhysChem software library version 12.01. bioconcentration factor at pH 7.4 calculated by ACD/Labs PhysChem software library version 12.01 Number of rule of five violations for a chemical structure that has been calculated by ACD/Labs PhysChem software library version 12.01. Number of rule of five violations for a chemical structure that has been calculated by ACD/Labs PhysChem software library version 12.01. number of rule of five violations calculated by ACD/Labs PhysChem software library version 12.01 Surface tension, in dyne per centimetre, that has been calculated by ACD/Labs PhysChem software library version 12.01. Surface tension, in dyne per centimetre, that has been calculated by ACD/Labs PhysChem software library version 12.01. surface tension calculated by ACD/Labs PhysChem software library version 12.01 covalent unit count generated by pubchem software library defined atom stereocenter count generated by the pubchem software library defined bond stereocenter count generated by pubchem software library isotope atom count generated by pubchem software library heavy atom count generated by pubchem software library undefined atom stereocenter count generated by the pubchem software library undefined bond stereocenter count generated by the pubchem software library canonical smiles generated by OEChem isomeric SMILES generated by OEChem A descriptor that specifies the integer count of cycles in a given molecular entity. cycle count A descriptor that specifies the integer count of aromatic cycles in a given molecular entity. aromatic rings aromatic cycle count IUPAC Name generated by LexiChem hydrogen bond donor count calculated by cactvs hydrogen bond acceptor count calculated by cactvs rotatable bond count calculated by cactvs structure complexity calculated by cactvs tautomer count calculated by cactvs TPSA calculated by cactvs xlogp3 calculated by the xlogp3 software InChI calculated by library version 1.0.4 InChIKey generated by software version 1.0.4 A chemical graph is a structural descriptor in which the connectivity and constitution of the chemical entity are described in terms of a mathematical graph, usually with atoms as vertices and bonds as edges, but other variants exist. A chemical graph is a structural descriptor in which the connectivity and constitution of the chemical entity are described in terms of a mathematical graph, usually with atoms as vertices and bonds as edges, but other variants exist. chemical graph Neutral charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing the same amount of electrons overall as protons, thus having an overall neutral charge. Neutral charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing the same amount of electrons overall as protons, thus having an overall neutral charge. neutral charge Positive charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing more protons overall than electrons, thus having an overall positive charge. Positive charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing more protons overall than electrons, thus having an overall positive charge. positive charge Negative charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing more electrons overall than protons, thus having an overall negative charge. Negative charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing more electrons overall than protons, thus having an overall negative charge. negative charge Database identifier used by ChemSpider. Database identifier used by ChemSpider. ChemSpider identifier Database identifier used by DrugBank. Database identifier used by DrugBank. DrugBank identifier Database identifier used by ChEBI. Database identifier used by ChEBI. ChEBI identifier Database identifier used by Human Metabolome Database. Database identifier used by Human Metabolome Database. HMDB identifier Database identifier used by KEGG. Database identifier used by KEGG. KEGG identifier Database identifier used by Reactome. Database identifier used by Reactome. Reactome identifier Identifier used by the ChEMBL database for compounds, assays, target, etc. Identifier used by the ChEMBL database for compounds, assays, target, etc. ChEMBL identifier A descriptor of the ratio of the amount of a given chemical substance adsorbed per unit weight of organic carbon in soil or sediment to the concentration of the chemical substance in solution at equilibrium. Colin Batchelor A descriptor of the ratio of the amount of a given chemical substance adsorbed per unit weight of organic carbon in soil or sediment to the concentration of the chemical substance in solution at equilibrium. organic carbon adsorption descriptor A descriptor of the ratio of the concentration of a chemical substance in an organism immersed in water to that in the surrounding water at equilibrium. Colin Batchelor A descriptor of the ratio of the concentration of a chemical substance in an organism immersed in water to that in the surrounding water at equilibrium. bioconcentration factor descriptor A descriptor of the volume occupied by one mole of the given substance at a given temperature and pressure. Colin Batchelor A descriptor of the volume occupied by one mole of the given substance at a given temperature and pressure. molar volume descriptor A descriptor of the density of a given substance at a given temperature and pressure. Colin Batchelor A descriptor of the density of a given substance at a given temperature and pressure. density descriptor A descriptor of the flash point of a substance at a given pressure. The flash point is the minimum temperature at which a mixture of the substance with air can be ignited, within its explosive range. Colin Batchelor A descriptor of the flash point of a substance at a given pressure. The flash point is the minimum temperature at which a mixture of the substance with air can be ignited, within its explosive range. flash point descriptor A descriptor of the energy taken in by a chemical substance on vaporization at a given temperature and pressure. Colin Batchelor A descriptor of the energy taken in by a chemical substance on vaporization at a given temperature and pressure. enthalpy of vaporization descriptor A descriptor of the pressure exerted by the vapour phase of a chemical substance on its condensed phase at a given temperature and pressure. Colin Batchelor A descriptor of the pressure exerted by the vapour phase of a chemical substance on its condensed phase at a given temperature and pressure. vapour pressure descriptor A descriptor of the disposition of a portion of liquid to resist a force. Colin Batchelor A descriptor of the disposition of a portion of liquid to resist a force. surface tension descriptor The number of structural alerts, that is, unwanted features as defined according to the procedure followed in Brenk et al., 2008. Brenk R, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. Chem Med Chem. 2008;3:435–444. structural alert count A descriptor which gives a quantitative estimate of drug likeness according to the procedure outlined in Bickerton et al., 2012. http://www.ncbi.nlm.nih.gov/pubmed/22270643 Nat Chem. 2012 Jan 24;4(2):90-8. doi: 10.1038/nchem.1243. Quantifying the chemical beauty of drugs. Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL. QED weighted weighted quantitative estimate of drug-likeness A descriptor that indicates the temperature at which a chemical substance undergoes a state transition from gas or liquid to solid, under standard conditions. A descriptor that indicates the temperature at which a chemical substance undergoes a state transition from gas or liquid to solid, under standard conditions. freezing point descriptor Henry's law, formulated by William Henry in 1803, states "At a constant temperature, the amount of a given gas that dissolves in a given type and volume of liquid is directly proportional to the partial pressure of that gas in equilibrium with that liquid." Henry's law can be put into mathematical terms (at constant temperature) as p = kHc where p is the partial pressure of the solute in the gas above the solution, c is the concentration of the solute and kH is a constant with the dimensions of pressure divided by concentration. The constant, known as the Henry's law constant, depends on the solute, the solvent and the temperature. Henry's law, formulated by William Henry in 1803, states "At a constant temperature, the amount of a given gas that dissolves in a given type and volume of liquid is directly proportional to the partial pressure of that gas in equilibrium with that liquid." Henry's law can be put into mathematical terms (at constant temperature) as p = kHc where p is the partial pressure of the solute in the gas above the solution, c is the concentration of the solute and kH is a constant with the dimensions of pressure divided by concentration. The constant, known as the Henry's law constant, depends on the solute, the solvent and the temperature. Henry's Law constant A physical descriptor for the rate constant of a reaction of a chemical entity with OH. This is used to describe the atmospheric behaviour (i.e. stability) of the entity. A physical descriptor for the rate constant of a reaction of a chemical entity with OH. This is used to describe the atmospheric behaviour (i.e. stability) of the entity. atmospheric OH rate constant A physical descriptor for the upper explosive limit of the entity in air as a percentage by volume at room temperature. A physical descriptor for the upper explosive limit of the entity in air as a percentage by volume at room temperature. upper explosive limit descriptor A physical descriptor for the lower explosive limit in air as a percentage by volume at room temperature A physical descriptor for the lower explosive limit in air as a percentage by volume at room temperature lower explosive limit descriptor A physical descriptor for the minimum explosive concentration. A physical descriptor for the minimum explosive concentration. minimum explosive concentration descriptor A physical descriptor of the ratio of the density of chemical substance to the density of a reference substance. The reference substance is usually water for liquids or air for gases. A physical descriptor of the ratio of the density of chemical substance to the density of a reference substance. The reference substance is usually water for liquids or air for gases. specific gravity descriptor A descriptor of the relative density of gases referenced to air as 1, which indicates how many times a gas is heavier than air at the same temperature. A descriptor of the relative density of gases referenced to air as 1, which indicates how many times a gas is heavier than air at the same temperature. relative density descriptor A descriptor of the density of a vapour in relation in that of hydrogen, defined as the mass of a certain volume of the given substance divided by the mass of the same volume of hydrogen. A descriptor of the density of a vapour in relation in that of hydrogen, defined as the mass of a certain volume of the given substance divided by the mass of the same volume of hydrogen. vapor density descriptor A physical descriptor for the lowest concentration of an odorant chemical entity that is perceivable by the human sense of smell. A physical descriptor for the lowest concentration of an odorant chemical entity that is perceivable by the human sense of smell. odor detection threshold descriptor A physical descriptor which gives a measure of the acidity or basicity of an aqueous solution, defined as the decimal logarithm of the reciprocal of the hydrogen ion activity in a solution. A physical descriptor which gives a measure of the acidity or basicity of an aqueous solution, defined as the decimal logarithm of the reciprocal of the hydrogen ion activity in a solution. pH descriptor A physical descriptor of the rate of evaporation of a liquid under standard conditions. A physical descriptor of the rate of evaporation of a liquid under standard conditions. evaporation rate descriptor A physical descriptor of the lowest temperature at a substance will spontaneously ignite in a normal atmosphere without an external source of ignition. kindling point A physical descriptor of the lowest temperature at a substance will spontaneously ignite in a normal atmosphere without an external source of ignition. autoignition temperature descriptor A physical descriptor for the time it takes for half of a portion of substance of a given type to decompose in soil under standard conditions. A physical descriptor for the time it takes for half of a portion of substance of a given type to decompose in soil under standard conditions. soil half-life descriptor Identifier used by the Chemical Abstracts Service database. Identifier used by the Chemical Abstracts Service database. CAS registry number A seven-digit identifier for chemical substances for regulatory purposes within the European Union. A seven-digit identifier for chemical substances for regulatory purposes within the European Union. EC number EINECS No European Community number A descriptor that specifies the integer count of metal atoms in a given chemical entity. metal atom count A descriptor that specifies the integer count of oxygen atoms in a given chemical entity. oxygen atom count An identifying descriptor which is used within a particular database system to identify a chemical system. Person: Colin Batchelor chemical database identifier A preferred name in ChemSpider by virtue of having been validated by a curator. Person: Colin Batchelor ChemSpider validated synonym A molecular entity name in the ChemSpider database which has not been validated by a curator. Person: Colin Batchelor ChemSpider unvalidated synonym A chemical database identifier which has been validated by a curator. Person: Colin Batchelor validated chemical database identifier A ChemSpider validated synonym that has been identified as a title by the ChemSpider software. ChemSpider title Person: Colin Batchelor average molecular weight descriptor calculated by ACD/Labs PhysChem software library version 12.01 Person: Colin Batchelor monoisotopic molecular weight descriptor calculated by ACD/Labs PhysChem software library version 12.01 A descriptor that describes the energy range in a solid where no electron states can exist. In graphs of the electron band structure of solids, the band gap generally refers to the energy difference (in electron volts) between the top of the valence band and the bottom of the conduction band in insulators and semiconductors. [http://en.wikipedia.org/wiki/Band_gap] band gap energy gap energy band gap A descriptor describing the mass of the metal element component of a composite substance. metal element mass metal element mass descriptor Molecular formula for a chemical structure as calculated by ACD/Labs PhysChem software library version 12.01. Molecular formula for a chemical structure as calculated by ACD/Labs PhysChem software library version 12.01. molecular formula calculated by ACD/Labs PhysChem software library version 12.01 The ratio of a dissolved substance in a two-phase system, giving a measure of the difference in solubility of the substance in the two phases. partition coefficient numeric chemical descriptor textual chemical descriptor chemical substance descriptor A property of solids which is the total surface area of a material per unit of mass, solid or bulk volume, or cross-sectional area. specific surface area Descriptor that returns the group in the periodic table of a given atom. Descriptor that returns the group in the periodic table of a given atom. group of an atom An InChI-like descriptor for nanomaterials. An InChI-like descriptor for nanomaterials. NInChI descriptor TUCAN is an identifier based on a canonicalization and serialization algorithm that is independent of domain-specific concepts of structure and bonding. TUCAN is an identifier based on a canonicalization and serialization algorithm that is independent of domain-specific concepts of structure and bonding. TUCAN descriptor The spatial arrangement of the atoms of a chiral molecular entity (or group) and its stereochemical description e.g. R or S. 2022-07-11T08:01:45Z The spatial arrangement of the atoms of a chiral molecular entity (or group) and its stereochemical description e.g. R or S. https://doi.org/10.1351/goldbook.A00020 absolute configuration stereochemical descriptor The configuration of any stereogenic (asymmetric) centre with respect to any other stereogenic centre contained within the same molecular entity. Unlike absolute configuration, relative configuration is reflection-invariant. Relative configuration, distinguishing diastereoisomers, may be denoted by the configurational descriptors R*, R* (or l) and R*, S* (or u) meaning, respectively, that the two centres have identical or opposite configurations. For molecules with more than two asymmetric centres the prefix rel- may be used in front of the name of one enantiomer where R and S have been used. If any centres have known absolute configuration then only R* and S* can be used for the relative configuration. 2022-07-11T08:04:08Z The configuration of any stereogenic (asymmetric) centre with respect to any other stereogenic centre contained within the same molecular entity. Unlike absolute configuration, relative configuration is reflection-invariant. Relative configuration, distinguishing diastereoisomers, may be denoted by the configurational descriptors R*, R* (or l) and R*, S* (or u) meaning, respectively, that the two centres have identical or opposite configurations. For molecules with more than two asymmetric centres the prefix rel- may be used in front of the name of one enantiomer where R and S have been used. If any centres have known absolute configuration then only R* and S* can be used for the relative configuration. https://doi.org/10.1351/goldbook.R05260 relative configuration stereochemical descriptor The number of molecules of H2 that would have to be added to a molecule to convert all pi bonds to single bonds, and all rings to acyclic structures. DBE, degree/level of unsaturation, unsaturation index, index of hydrogen deficiency (IHD) 2022-07-11T08:07:03Z The number of molecules of H2 that would have to be added to a molecule to convert all pi bonds to single bonds, and all rings to acyclic structures. http://www.chem.ucla.edu/~harding/IGOC/D/double_bond_equivalent.html double bond equivalent The Smallest Set of Smallest Rings (SSSR) is a subset of cycles within a molecular graph (ring). SSSR was the first widely-used cycle set to classify cyclic molecules in cheminformatics. It offers a limited solution to the problem of molecular cycle perception. Unlike the set of all cycles, an SSSR can filter useless or interfering envelope cycles, but offers no guarantee of uniqueness. A given molecular graph can produce multiple SSSRs with no constraints on which one will be obtained. SSSR 2022-07-11T08:18:30Z The Smallest Set of Smallest Rings (SSSR) is a subset of cycles within a molecular graph (ring). SSSR was the first widely-used cycle set to classify cyclic molecules in cheminformatics. It offers a limited solution to the problem of molecular cycle perception. Unlike the set of all cycles, an SSSR can filter useless or interfering envelope cycles, but offers no guarantee of uniqueness. A given molecular graph can produce multiple SSSRs with no constraints on which one will be obtained. https://depth-first.com/articles/2020/08/31/a-smallest-set-of-smallest-rings/ smallest set of smallest rings A molecular entity name that represents the name of a molecular structure determined by the naming algorithms developed by ACD/Labs. index name 2022-07-11T08:20:10Z A molecular entity name that represents the name of a molecular structure determined by the naming algorithms developed by ACD/Labs. https://www.acdlabs.com/products/name/ ACD/Labs index name An InChI descriptor that is not the standard and that is created with the fixedH layer option. The fixedH layer is appended to the standard InChI and lists the exact position of the tautomeric hydrogen atoms. It is useful when one wants to represent a specific tautomer of a given structure, because if the InChIs for the tautomers were created without the fixedH layer option, the normalization performed by the InChI generation program would result in these InChIs being identical. 2022-07-11T08:22:02Z An InChI descriptor that is not the standard and that is created with the fixedH layer option. The fixedH layer is appended to the standard InChI and lists the exact position of the tautomeric hydrogen atoms. It is useful when one wants to represent a specific tautomer of a given structure, because if the InChIs for the tautomers were created without the fixedH layer option, the normalization performed by the InChI generation program would result in these InChIs being identical. https://doi.org/10.1186%2Fs13321-015-0068-4 InChI with fixedH layer A ChEBI name is a preferred name annotated by the ChEBI database. The ChEBI name has the additional feature that it is unique within the ChEBI dataset. ChEBI name Trade name of a drug compound. drug trade name International Non-proprietary Name, defined by the WHO. INN International Non-proprietary Name Identifier used by the USA Food and Drug Administration. Identifier used by the USA Food and Drug Administration. UNII Unique Ingredient Identifier Identifier used by the LipidMaps database, http://www.lipidmaps.org/. Identifier used by the LipidMaps database, http://www.lipidmaps.org/. LipidMaps identifier Identifier used by the Cancer Chemotherapy National Service Center. Identifier used by the Cancer Chemotherapy National Service Center. NSC number National Service Center number Identifier used by the RTECS database (http://www.cdc.gov/niosh/rtecs/). Identifier used by the RTECS database (http://www.cdc.gov/niosh/rtecs/). RTECS identifier Identifier used by the European Registry of Materials (https://nanocommons.github.io/identifiers/). Identifier used by the European Registry of Materials (https://nanocommons.github.io/identifiers/). European Registry of Materials identifier SwissLipids identifier MolMeDB identifier PDB ligand identifier PDB identifier PDB structure identifier number of rule of five violations calculated by RDKit software library version 2015_09_2 hydrogen bond acceptor count calculated by RDKit software library version 2015_09_2 hydrogen bond donor count calculated by RDKit software library version 2015_09_2 logP descriptor calculated by RDKit software library version 2015_09_2 molecular formula calculated by RDKit software library version 2015_09_2 average molecular weight calculated by RDKit software library version 2015_09_2 total polar surface area calculated by RDKit software library version 2015_09_2 Descriptor that calculates the sum of the absolute value of the difference between atomic polarizabilities of all bonded atoms in the molecule (including implicit hydrogens). Descriptor that calculates the sum of the absolute value of the difference between atomic polarizabilities of all bonded atoms in the molecule (including implicit hydrogens). Bond Polarizabilities Eigenvalue based descriptor noted for its utility in chemical diversity. Eigenvalue based descriptor noted for its utility in chemical diversity. http://dx.doi.org/10.1021/ci980137x BCUT BCUT Descriptor that calculates bond-pi Partial charge of a bond by determining the difference the Partial Pi Charge on atoms A and B of a bond (based in Gasteiger Charge). Descriptor that calculates bond-pi Partial charge of a bond by determining the difference the Partial Pi Charge on atoms A and B of a bond (based in Gasteiger Charge). bondPartialPiCharge bond partial pi charge Descriptor that calculates bond-sigma Partial charge of a bond. Descriptor that calculates bond-sigma Partial charge of a bond. bondPartialSigmaCharge bond partial sigma charge Descriptor that calculates bond-total Partial charge of a bond. Descriptor that calculates bond-total Partial charge of a bond. bondPartialTCharge bond partial total charge Descriptor that calculates of bond-Polarizability of a bond by determining the difference the Sigma electronegativity on atoms A and B of a bond. Descriptor that calculates of bond-Polarizability of a bond by determining the difference the Sigma electronegativity on atoms A and B of a bond. bondSigmaElectronegativity bond sigma electronegativity Descriptor based on the number of bonds on the shortest path between two atoms (topological distance). Descriptor based on the number of bonds on the shortest path between two atoms (topological distance). bondsToAtom This is the shortest distance between a pair of atoms in a graph, defined as the number of edges in the shortest path between the atom pair in the molecular graph. bonds to Atom Evluates the simple and valence chi chain descriptors (Kier and Hall) of orders 3, 4, 5, 6 and 7. Evluates the simple and valence chi chain descriptors (Kier and Hall) of orders 3, 4, 5, 6 and 7. chiChain It utilizes the graph isomorphism code of the CDK to find fragments matching SMILES strings representing the fragments corresponding to each type of chain. chi chain indices Evluates the simple and valence chi cluster descriptors (Kier and Hall) of orders 3, 4,5 and 6. Evluates the simple and valence chi cluster descriptors (Kier and Hall) of orders 3, 4,5 and 6. chiCluster It utilizes the graph isomorphism code of the CDK to find fragments matching SMILES strings representing the fragments corresponding to each type of chain. chi cluster indices Evaluates the Kier and Hall Chi path indices of orders 0,1,2,3,4,5,6 and 7. Evaluates the Kier and Hall Chi path indices of orders 0,1,2,3,4,5,6 and 7. chiPath It utilizes the graph isomorphism code of the CDK to find fragments matching SMILES strings representing the fragments corresponding to each type of chain. chi path indices Evaluates the Kier and Hall Chi path cluster indices of orders 4,5 and 6. Evaluates the Kier and Hall Chi path cluster indices of orders 4,5 and 6. chiPathCluster It utilizes the graph isomorphism code of the CDK to find fragments matching SMILES strings representing the fragments corresponding to each type of chain. chi path-cluster indices Descriptor characterizing the mass distribution of the molecule. Descriptor characterizing the mass distribution of the molecule. http://dx.doi.org/10.1021/jp953224q gravitationalIndex gravitational index Descriptor characterizing the mass distribution of the molecule as the square or cube root of the gravitational index. Descriptor characterizing the mass distribution of the molecule as the square or cube root of the gravitational index. http://dx.doi.org/10.1021/ci980029a gravitationalIndex_SquareAndCubeRoots gravitational index (square and cube roots) Counts the number of acceptor field atoms for a carbonyl oxygen probe using force field based definition. Counts the number of acceptor field atoms for a carbonyl oxygen probe using force field based definition. http://dx.doi.org/10.1021/jm011039x hBondAcceptorsBoehmKlebe acceptor field atoms (Boehm,Klebe) Descriptor that calculates the number of hydrogen bond acceptors (by Daylight). Descriptor that calculates the number of hydrogen bond acceptors (by Daylight). hBondacceptorsDaylight SMILES on-line tutorial, http://www.daylight.com/dayhtml_tutorials/languages/smarts/smarts_examples.html) hydrogen bond acceptors (Daylight) Counts the number of acceptor/donor field atoms for a carbonyl oxygen or amino hydrogen probe. Counts the number of acceptor/donor field atoms for a carbonyl oxygen or amino hydrogen probe. http://dx.doi.org/10.1021/jm011039x hBondAcceptorsDonorsBoehmKlebe acceptors or donors field atoms (Boehm,Klebe) Counts the number of donor field atoms for an amino hydrogen probe. Counts the number of donor field atoms for an amino hydrogen probe. http://dx.doi.org/10.1021/jm011039x hBondDonorsBoehmKlebe donor field atoms (Boehm,Klebe) Descriptor that calculates the number of hydrogen bond donors (by Daylight). Descriptor that calculates the number of hydrogen bond donors (by Daylight). hBondDonorsDaylight SMILES on-line tutorial, http://www.daylight.com/dayhtml_tutorials/languages/smarts/smarts_examples.html) hydrogen bond donors (Daylight) Descriptor returns 1 if the protons is directly bonded to an aromatic system, it returns 2 if the distance between aromatic system and proton is 2 bonds, and it return 0 for other positions. Descriptor returns 1 if the protons is directly bonded to an aromatic system, it returns 2 if the distance between aromatic system and proton is 2 bonds, and it return 0 for other positions. isProtonInAromaticSystem proton belonging to an aromatic system Descriptor returns true if the protons is directly bonded to a pi system. Descriptor returns true if the protons is directly bonded to a pi system. isProtonInConjugatedPiSystem proton belonging to a pi-system Counts the number of occurrences of the E-state fragments. Counts the number of occurrences of the E-state fragments. http://dx.doi.org/10.3390/91201004 kierHallSmarts Kier Hall SMARTS Evaluate molecular distance edge descriptors for C, N and O. Evaluate molecular distance edge descriptors for C, N and O. http://dx.doi.org/10.1021/ci970109z mde molecular distance edge Descriptor that calculates the principal moments of inertia and ratios of the principal moments. Als calculates the radius of gyration. Descriptor that calculates the principal moments of inertia and ratios of the principal moments. Als calculates the radius of gyration. momentOfInertia moments of inertia Descriptor that calculates total partial charges of an heavy atom. Descriptor that calculates total partial charges of an heavy atom. partialTChargeMMFF94 partial total charge (MMFF94) Descriptor that returns the period in the periodic table of an atom belonging to an atom container. Descriptor that returns the period in the periodic table of an atom belonging to an atom container. period period of an atom Descriptor that check if two atoms have pi-contact (this is true when there is one and the same conjugated pi-system which contains both atoms, or directly linked neighboors of the atoms). Descriptor that check if two atoms have pi-contact (this is true when there is one and the same conjugated pi-system which contains both atoms, or directly linked neighboors of the atoms). piContact pi-contact of two atoms Descriptor that calculates partial charges of an heavy atom and its protons based on Gasteiger Marsili (PEOE). Descriptor that calculates partial charges of an heavy atom and its protons based on Gasteiger Marsili (PEOE). protonPartialCharge proton total partial charge Calculation of RDF proton descriptor. Calculation of RDF proton descriptor. http://dx.doi.org/10.1021/ac010737m rdfProtonCalculatedValues This is a mixed descriptor: topological, geometrical and electronic descriptor. RDF proton descriptor Descriptors are derived from pre-calculated quantum mechanical parameters by using the paramaters for amino acids and evaluating a set of 147 descriptors for peptide sequences. Descriptors are derived from pre-calculated quantum mechanical parameters by using the paramaters for amino acids and evaluating a set of 147 descriptors for peptide sequences. http://dx.doi.org/10.1016/0097-8485(94)00052-G taeAminoAcid {@cdk.cite BREN1995} {@cdk.cite BREN1997} {@cdk.cite WHITE2003} TAE RECON descriptors for amino acid sequences The weighted path (molecular ID) descriptors were described by Randic and they characterize molecular branching. The weighted path (molecular ID) descriptors were described by Randic and they characterize molecular branching. weightedPath weighted path Holistic descriptors described by Todeschini et al. Holistic descriptors described by Todeschini et al. WHIM Todeschini, R. and Gramatica, P.. New 3D Molecular Descriptors: The WHIM theory and QAR Applications, Persepectives in Drug Discovery and Design. 1998, pp. 355-380. Mixed descriptors: molecular size, shape, symmetry, and atom distribution and density. Uses 3D coordinates, PCA and it calculates 10 descriptors. WHIM The Moreau-Broto autocorrelation descriptors using partial charges. The Moreau-Broto autocorrelation descriptors using partial charges. autoCorrelationCharge ATSc1 - ATSc5 Moreau-Broto Autocorrelation (charge) descriptors The Moreau-Broto autocorrelation descriptors using atomic weight. The Moreau-Broto autocorrelation descriptors using atomic weight. autoCorrelationMass ATSm1 - ATSm5 Moreau-Broto autocorrelation (mass) descriptors The Moreau-Broto autocorrelation descriptors using polarizability. The Moreau-Broto autocorrelation descriptors using polarizability. autoCorrelationPolarizability ATSp1 - ATSp5 Moreau-Broto autocorrelation (polarizability) descriptors Characterizes the carbon connectivity in terms of hybridization Characterizes the carbon connectivity in terms of hybridization carbonTypes C1SP1, C2SP1, C1SP2, C2SP2, C3SP2, C1SP3, C2SP3, C3SP3, C4SP3 carbon types Descriptor that calculates the carbon connectivity index (order 0). Descriptor that calculates the carbon connectivity index (order 0). chi0C carbon connectivity index (order 0) Descriptor that calculates atomic valence connectivity index (order 0). Descriptor that calculates atomic valence connectivity index (order 0). chi0v valence connectivity index (order 0) Descriptor that calculates carbon valence connectivity index (order 0). Descriptor that calculates carbon valence connectivity index (order 0). chi0vC valence carbon connectivity index (order 0) Descriptor that calculates carbon connectivity index (order 1). Descriptor that calculates carbon connectivity index (order 1). chi1C carbon connectivity index (order 1) Descriptor that calculates atomic valence connectivity index (order 1). Descriptor that calculates atomic valence connectivity index (order 1). chi1v valence connectivity index (order 1) Descriptor that calculates carbon valence connectivity index (order 1). Descriptor that calculates carbon valence connectivity index (order 1). chi1vC valence carbon connectivity index (order 1) Descriptor that calculates the 3D distance between two atoms. Descriptor that calculates the 3D distance between two atoms. distanceToAtom distance to atom Descriptor that calculates the effective polarizability of a given heavy atom. Descriptor that calculates the effective polarizability of a given heavy atom. effectivePolarizability EffectiveAtomPolarizabilityDescriptor, effAtomPol effective polarizability Characterizes molecular complexity in terms of carbon hybridization states. Characterizes molecular complexity in terms of carbon hybridization states. hybratio It reports the fraction of sp3 carbons to sp2 carbons as Nsp3/ (Nsp3 + Nsp2). The original form of the descriptor (i.e., simple ratio) has been used to characterize molecular complexity, especially in the are of natural products , which usually have a high value of the sp3 to sp2 ratio. Other short names: HybridizationRatio, HybRatio. hybridization ratio Descriptor that calculates Kier and Hall kappa molecular shape indices. Descriptor that calculates Kier and Hall kappa molecular shape indices. kierValues Kier and Hall kappa molecular shape indices compare the molecular graph with minimal and maximal molecular graphs. First kappa shape index is given by n ( n - 1 ) 2 m 2 , second kappa shape index is given by ( n - 1 ) ( n - 2 ) 2 p 2 2 and third kappa shape index is given by ( n - 1 ) ( n - 3 ) 2 p 3 2 for odd n and ( n - 3 ) ( n - 2 ) 2 p 3 2 for enev n, where n denotes the number of atoms in the hydrogen suppressed graph, m is the number of bonds in the hydrogen suppressed graph. Also, let p2 denote the number of paths of length 2 and let p3 denote the number of paths of length 3. Other short names: KappaShapeIndices, Kier1, Kier2, Kier3. Kier and Hall kappa molecular shape indices Descriptor that calculates pi partial charges in pi-bonded systems of an heavy atom based on based on Gasteiger H.Saller (PEPE). Descriptor that calculates pi partial charges in pi-bonded systems of an heavy atom based on based on Gasteiger H.Saller (PEPE). http://dx.doi.org/10.1002/ange.19850970818 partialPiCharge Other short_name: pepe. partial pi charge Descriptor that calculates sigma partial charges in sigma-bonded systems (PEOE) of an heavy atom based on Gasteiger Marsili. Descriptor that calculates sigma partial charges in sigma-bonded systems (PEOE) of an heavy atom based on Gasteiger Marsili. http://dx.doi.org/10.1016/0040-4020(80)80168-2 partialSigmaCharge partial sigma charge Descriptor that returns the pi electronegativity for a given atom. Descriptor that returns the pi electronegativity for a given atom. piElectronegativity Pi electronegativity is given by X = a + b q + c ( q 2 ) , where a, b and c are Gasteiger Marsili parameters, and q is the sigma charge. Other short_name: elecPiA. pi electronegativity resource:SIO_000769 The uncertainty value (margin of error) of a measurement is a range of values likely to enclose the true value. uncertainty value resource:SIO_000770 A standard deviation (represented by the symbol σ) is the quantity of variation from the average (mean, or expected value). standard deviation resource:SIO_001113 min A minimal value is smallest value of an attribute for the entities in the defined set. minimal value resource:SIO_001114 max A maximal value is largest value of an attribute for the entities in the defined set. maximal value resource:SIO_001379 A protein domain is a part of a protein that maintains its structure and function independently of the rest of the protein. A protein domain is a part of a protein that maintains its structure and function independently of the rest of the protein. protein domain resource:SIO_001393 a post-translational modification is a part of a protein that was added, removed, or modified as a result of a chemical reaction after synthesis. a post-translational modification is a part of a protein that was added, removed, or modified as a result of a chemical reaction after synthesis. post-translational modification resource:SIO_010055 A strain is a genetic variant or kind of microorganism. strain resource:SIO_010074 An amino acid residue is a submolecule of an amino acid that is part of a larger molecule. amino acid residue resource:SIO_010468 An alpha helix is structural region of a protein that is characterized by 3.6 residues per turn, a translation of 1.5 angstroms along the helical axis in which backbone N-H groups form a hydrogen bond to the backbone carboxyl group of the amino acid four residues prior. alpha helix resource:SIO_010469 A beta strand is structural region of a protein that is characterized by a roughly planar sequence of amino acid residues forming hydrogen bonds between the N-O and the C=O of another part of the peptide and having their side chains perpendicular to the planar axis. beta strand resource:SIO_010471 An amino acid polymer submolecule is a submolecule of an amino acid polymer. amino acid polymer submolecule It is a measure of the number of dead cells in a culture well. We consider it as a subclass of 'percent inhibition', because cell death is induced by inhibition of vital cellular processes and percent cytotoxicity increases as the number of dead cells increases. It can be estimated in the compound treated wells in comparison to vehicle-treated control wells and is expressed as a percent. The compound treatment is preferably performed in a short window of time to avoid masking the effect due to cell proliferation. Compound cytotoxicity is an important parameter to measure when developing potential human therapeutics. Cytotoxicity is determined as a measure of radioisotope (3H thymidine or 51Cr) release, lactate dehydrogenase release from damaged cells, tetrazolium salt and alamar blue reduction, fluorescent dyes that selectively stain live or dead cells, and decrease in ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls indicate proliferation and cultures with ATP concentrations lower than controls indicate cytotoxicity. Percent cytotoxicity = 100-percent viability % cytotoxicity percent cytotoxicity Categorization of bioassays based on the property or process that the assay is interrogating, e.g. ADMET, functional, etc. bioassay type A set of instructions, methodology, operations, required reagents, instruments to carry out experiments for the purpose of testing the effect of a perturbing agent in a biological model system, measuring one or multiple effect(s) of the agent facilitated by an assay design method translate the perturbation into a detectable signal to arrive at one or multiple endpoint(s) that quantify or qualify the extent of the perturbation. Bioassay is described by multiple bioassay components: assay format, biology (biological participants in various role and processes), design method, physical detection method / technology, screened entity, and endpoint. Bioassay includes one or multiple measure groups to describe panel, profiling, multiparametric (or multiplexed) assays (assays that measure more than one effect of the perturbagen on the system that is screened). bioassay They are used to express the binding interactions between labeled or unlabeled ligands with protein receptors and include Bmax, Kd, etc. protein substrate and ligand constant Description of an experiment carried out for the purpose of screening a perturbing agent in a biological system, measuring the effect of the agents using specified technology, and arriving at endpoints that satisfy particular criteria. bioassay specification It is the amount of drug required to saturate a population of receptors and a measure of the number of receptors present in the sample. It is derived from Scatchard plot of binding data. It is analogous to Vmax in enzyme kinetics. The units of Bmax include cpm, sites/cell or fmol/mg. http://graphpad.com/curvefit/fitting_specific_binding_.htm Bmax Kd – is the equilibrium dissociation constant for a drug. It describes the affinity between a ligand (L) (such as a drug) and a protein (P). Ligand-protein affinities are influenced by non-covalent intermolecular interactions between the two molecules such as hydrogen bonding, electrostatic interactions, hydrophobic and Van der Waals forces. Kd = ([P] [L]) / [PL] The dissociation constant has molar units (M), which corresponds to the concentration of ligand [L] at which the binding site on a particular protein is half occupied, i.e. the concentration of ligand, at which the concentration of protein with ligand bound [PL], equals the concentration of protein with no ligand bound [P]. The smaller the dissociation constant, the more tightly bound the ligand is, or the higher the affinity between ligand and protein. http://www.graphpad.com/curvefit/law_of_mass_action.htm Kd Cue Signal Response assay Percent increase or decrease of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. % response percent response % growth reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. % growth inhibition percent growth inhibition The concentration of a perturbagen used in an assay to elicit the biological effect or perturbation. This typically assumes uniform / equal distribution of the perturbagen / compound in the assay system (typically a screening well). screening concentration It is an interaction between a protein (e.g., receptor, transcription factor) and small molecule (e.g., hormone, organic compound with a low molecular weight (<800 Da)). protein-small molecule interaction assay Percent control is the response relative to a reference state, typically to a high control. For example it can describe (remaining) activity of a kinase (or e.g. kinase bound to substrate). Percent control could also quantify an inhibitory action depending on control and assay method. percent control Metal ions such as copper, iron, magnesium and zinc are transported between different cellular compartments to bring about specific functions. This is regulated by their influx and efflux across membranes, which could occur either by passive diffusion or active transport. metal ion redistribution assay The endpoint is a quantitive or qualitative interpretable standardized representation of a perturbation (a change from a defined reference state of a "closed" model system) that is measured by the bioassay. An endpoint consists of a series of data points, one for each perturbing agent (screened entity) tested the assay. endpoint result It can refer to the screening concentration (for example in a primary assay) or it can be a concentration at which the perturbagen mediates a defined response, such as IC50 or EC50. It always has one value and a concentration unit. concentration endpoint Reporting the extent / magnitude of the perturbation (induced by the perturbagen) such as percent inhibition. Response-type endpoints would typically be obtained from a single concentration perturbagen measurement. response endpoint The effective concentration of a perturbagen, which produces 50% of the maximal possible response, which could mean either activation (EC50) or inhibition (IC50) for that perturbagen. Potency AC50 The effective concentration of a cytotoxic compound, which produces 50% of the maximum possible cell death for that compound. Although the cytotoxic compound induces cell death, we define CC50 as subclass of IC50, because critical cellular processes are inhibited and CC50 is often used as a more specific description of IC50 for cell toxicity assays. Compound cytotoxicity is an important parameter to measure when developing potential human therapeutics. Cytotoxicity can be determined for example as a measure of radioisotope (3H thymidine or 51Cr) release, lactate dehydrogenase release from damaged cells, tetrazolium salt and alamar blue reduction, fluorescent dyes that selectively stain live or dead cells, or decrease in ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls (untreated cells) indicate proliferation and cultures with ATP concentrations lower than controls indicate cytotoxicity. CC50 The effective concentration of an agonist, which produces 50% of the maximum possible response for that agonist. EC50 The effective concentration of a growth inhibitor, which produces 50% of the maximum possible response for that inhibitor. GI50 is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, where Tz is absorbance at time zero, Ti is absorbance in the presence of test drug, and C is absorbance in the control (untreated cells). As a measure of viable or proliferating cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), expression of proliferation associated antigens (by immunostaining for Ki-67), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement). growth inhibition by 50% GI50 The effective concentration of an inhibitor, which produces 50% of the maximum possible response for that inhibitor. IC50 The effective concentration of an inhibitor, which produces 80% of the maximum possible response for that inhibitor. IC80 Ki is the equilibrium inhibitor dissociation constant, the concentration of the competing inhibitor that results in binding to half the enzymes sites at equilibrium in the absence of substrate or other competitors. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([L]/Kd)) relates IC50 to Ki under conditions of competitive binding; Kd equilibrium dissociation constant of the (labeled) ligand, [L] ligand concentration. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([S]/Km)) relates IC50 to Ki under conditions of competitive inhibition; Ki equilibrium enzyme inhibitor dissociation constant; Km Michaelis-Menton constant, [S] substrate concentration. Ki It is the ratio of biological activity in the presence of an exogenous substance to that in its absence. The fold change is useful when comparing test compounds evaluated across multiple functional assays because varying levels of efficacy can be observed amongst the different or same reference agonists. fold change TGI is total growth inhibition, which is the effective concentration of a growth inhibitor, which produces 0% relative growth for that inhibitor. Thus TGI signifies a cytostatic effect. tgi is calculated from [(Ti-Tz)/(C-Tz)] x 100 =0, where Ti = Tz and Tz is absorbance at time zero, Ti is absorbance in the presence of test drug, and C is absorbance in the control (untreated cells). As a measure of viable cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement). total growth inhibition TGI Absolute IC50 (calculated from the curve-fit function) is the concentration corresponding to exactly 50 percent inhibition. It is obtained from the curve fit function (back-calculated IC50) and can also be extrapolated. Commonly the relative IC50 is reported; however in cell proliferation assays absolute IC50 is often used. The absolute IC50 can be more reproducible. IC50 absolute The concentration of a test substance that produces an inhibitory effect corresponding to 50% of the activity of that particular substance (i.e. 50% of the difference between top and bottom of fitted curve). It can also be described as the concentration corresponding to the inflection point of the curve. IC50 relative pIC50 is -log IC50, where IC50 is the effective concentration of an inhibitor, which produces 50% of the maximum possible response for that inhibitor. -log IC50 pIC50 Percent increase of a measureable response relative to some baseline. Unit of Measure is always % when normalized to the dynamic range of the assay. Percent activity measures the increased activity vs. an unperturbed state, i.e. percent activation := percent activity - 100; e.g. an agonist that results in twice the activity would have percent activity = 200 and percent activation = 100. % activation percent activation Percent decrease of a measureable response as a consequence of compound treatment. Unit of Measure is always % when normalized to the dynamic range of the assay. Percent inhibition is expressed relative to a positive control (which results in total inhibition). percent inhibition It is a measure of living cells in a culture well. Unit of Measure is always % when normalized to the dynamic range of the assay. It can be estimated in the compound treated wells in comparison to vehicle-treated control wells and is expressed as a percent. Viability is determined by measuring tetrazolium salt and alamar blue reduction, staining with selective fluorescent dyes, or ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls indicate proliferation and cultures with ATP concentrations lower than controls indicates cytotoxicity. Percent viability = 100-percent cytotoxicity % viability percent cell viability 50% increase of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% activation 50 percent activation 50% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% inhibition 50 percent inhibition 80% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 80% inhibition 80 percent inhibition Assay has 50% living cells. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% viability 50 percent cell viability The ratio of biological activity in the presence of an exogenous substance to that in its absence. This result type is used exclusively with single point (screening concentration) assays. fold activation The ratio of biological activity in the absence of an exogenous substance to that in its presence. This result type is used exclusively with single point (screening concentration) assays. fold inhibition Cellular signaling can bring about the movement of proteins in cells. Upon receiving a cue, proteins undergo posttranslational modifications, e.g. phosphorylation, dephosphorylation, etc, which results in their activation and migration to different compartments, often to the nucleus, where they regulate gene expression. Add a relation between this class and immunoassay using a new object property 'is detected by'. protein redistribution assay Second messengers relay signals from the receptors to the cell interior as part of a signaling event. In the process, they amplify the signal. Examples include cAMP, cGMP, calcium, nitric oxide, diacylglycerol, etc, which play important roles in different physiological processes. second messenger redistribution assay The comment deposited by the assay provider, which summarizes the screening campaign with respect to the identification of lead compounds and chemical probes. summary comment Protein-nucleotide interaction protein-nucleotide interaction assay ITC is a thermodynamic technique that can directly measure the heat released or absorbed during a biomolecular binding event. It can measure the binding affinity (Ka), reaction stoichiometry (n), enthalpy (∆H) and entropy (ΔS) of the interaction between two or more molecules in solution.</obo:IAO_0000115> ITC isothermal titration calorimetry The B score is an analog of the Z score, but is more resistant to the presence of outliers and to differences in the measurement error distributions of the compounds. It is calculated by first computing a two-way median to account for row and column effects of the plate, which is then divided by their median absolute deviation to standardize for plate-to-plate variability. B-score Random and systematic error can induce either underestimation (false negatives) or overestimation (false positives) of measured signals. Z score indicates how many standard deviations an observation is above or below the mean. For calculating this, the average of the plate values is subtracted from individual raw values and the difference divided by the standard deviation estimated from all measurements of the plate. Z-score The Hill equation is commonly used to estimate the number of ligand molecules that are required to bind to a receptor to produce a functional effect. The Hill coefficient can be considered as an interaction coefficient, reflecting the extent of cooperativity among multiple ligand binding sites. Hill equation The concentration of substrate at ½ Vmax, according to the Henri-Michaelis-Menten kinetic model. km The off-rate associated with the release of inhibitor from an enzyme-inhibitor complex. koff The on-rate associated with the formation of an enzyme-inhibitor complex. kon Turnover number representing the maximum number of substrate molecules converted to products per active site per unit time. kcat Describe kinetics of enzyme-catalyzed reactions. It includes the enzyme kinetic constants namely, Km and Vmax, which help to model the time course of disappearance of substrate and the production of product. enzyme kinetic constant This includes the different pieces of information about a PubChem bioassay that is available at the PubChem website, namely, the assay title, assay protocol, assay description, assay provider, endpoint name, etc. assay description The name of a bioassay which is associated with each assay ID (AID). It contains information about the target tested, the stage of the assay (primary or confirmatory), the assay format (biochemical or cell based), etc. assay title This contains the background information and rationale for performing a bioassay and is found on the PubChem website associated with each assay ID (AID). It also includes the assay design and some information on the related bioassays. assay narrative This includes the methodology used to perform a particular bioassay and is found on the PubChem website associated with each assay ID (AID). It includes the assay components and the order in which they were added, the incubation times, detection method and the kit used, etc. use cito: citesForInformation or citeAsSourceData some DOI or PMID assay protocol This is the PubChem assay remark that can be assigned by depositors to a bioassay. assay comment Cuvettes are used to measure absorbance or fluorescence in a spectrophotometer or fluorimeter, respectively using either plastic, glass or quartz cuvettes. cuvette Tm is defined as the midpoint temperatuere of the protein unfolding transition. It is determined by generating a thermal denaturation curve for the target molecule and taking the midpoint temperature between folding and unfolding state of the protein. In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA strands and its perfect complement are in duplex. melting temperature Tm Raw or qualitative data are reported as endpoints in an assay, e.g., luminescence counts, fluorescence intensity, etc. raw activity The types of endpoints that report changes in temperature as a measure of a biological reaction, e.g. tm. temperature endpoint Vmax is defined as the maximum initial velocity of an enzyme catalyzed reaction under the given conditions, and it is measured in units of quantity of substrate transformed per unit time for a given concentration of enzyme. vmax This endpoint type describes the bonding affinity between two molecules at equilibrium, e.g., drug-receptor interaction. binding constant The perturbagen mediated 50% of cells to die in an assay. 50 percent cytotoxicity DNA-RNA interaction deoxyribonucleic acid-ribonucleic acid DNA-RNA interaction assay Protein-DNA interaction protein-deoxyribonucleic acid protein-DNA interaction assay Protein-RNA interaction protein-ribonucleic acid protein-RNA interaction assay The effective concentration of an agonist, which produces 30% of the maximum possible response for that agonist. EC30 It is the term that describes an endpoint or result of a bioassay, which is deposited at PubChem. PubChem endpoint name A mathematical model / equation to which the data is fitted (using the curve fit method / algorithm). curve fit model 3 parameter Hill equation 4 parameter Hill equation Calcium functions as second messenger in cell signaling. calcium redistribution assay Cyclic AMP (cAMP) functions as second messenger in cell signaling. cAMP cAMP redistribution assay Cyclic GMP (cGMP) functions as second messenger in cell signaling. cGMP cGMP redistribution assay Dye redistribution is used to study flux of molecules across membranes, e.g. calcein AM, ethidium homodimer-1, etc. dye redistribution assay The maximum response that can be achieved with the perturbagen as percentage of the positive control. Efficacy efficacy ViewLux ultraHTS Microplate Imager Tecan Infinite F200 is a multifunctional microplate filter-based reader with injector option, that provides high performance for the vast majority of microplate applications and research. It has been designed as a general purpose laboratory instrument for professional use, supporting common 6 to 384-well microplates. (Manufacturer description) Infinite F200 The names of equipment used for measurement/readout from an assay, e.g. FLIPR, ViewLux plate reader, PHERAstar, etc. detection instrument 8453 UV-Visible Spectrophotometer Analyst HT ELx808 Absorbance Microplate Reader EnVision Multilabel Reader FLx800 Fluorescence Microplate Reader HTFC Screening System PHERAstar Plus SpectraMax M5 Multi-Mode Microplate Reader VICTOR X2 Multilabel Plate Reader VP-ITC Isothermal Titration Calorimeter The name of the screening center organization that is affiliated with an assay or an experiment; for example the assay was developed by an individual affiliated with that organization or an assay experiment (screen) was performed by a group / in lab affiliated with that research organization. research institute It is a specialized chemistry center of MLPCN. vanderbilt screening center for gpcrs, ion channels and transporters Packard Fusion Microplate Reader Infinite PF200 Monolight 2010 Luminometer It is a specialized screening center of MLPCN. southern research institute Maximum inhibition of an antagonist or inhibitor (relative an efficacious positive control) maximal inhibition The maximum percent activation of an agonist maximal activation It is an MLSCN (pilot phase) screening center. MLSCN center at columbia university Radiolabeled flux assays to study ion channel activity by chemically initiating the opening of channels in the presence of a fixed amount of radiolabeled cation or anion, and a potential ion channel modulator compound. ion redistribution assay API 4000 LC/MS/MS System AxioVert 200M Fluorescence Light Microscope It is an MLPCN comprehensive screening center. broad institute It is an MLPCN comprehensive screening center. burnham center for chemical genomics CCD Luminometer It is an MLSCN (pilot phase) screening center. emory university molecular libraries screening center FDSS6000 FDSS7000 FlexStation II Microplate Reader FLIPR TETRA Fluorometer HyperCyt High Throughput Flow Cytometry System It is a specialized screening center of MLPCN. john hopkins ion channel center Mx3005P qPCR System It is an MLPCN comprehensive screening center. NCGC NIH chemical genomics center It is a specialized screening center of MLPCN. new mexico molecular libraries screening center Odyssey Infrared Imager Opera QEHS It is an MLSCN (pilot phase) screening center. the penn center for molecular discovery SGC Oxford the structural genomics consortium SpectraMax 190 Microplate Reader It is an MLPCN comprehensive screening center. the scripps research institute molecular screening center TopCount NXT Microplate Scintillation Luminescence Counter It is an MLSCN (pilot phase) screening center. university of pittsburgh molecular libraries screening center VICTOR X3 Multilabel Plate Reader ViewLux CCD Imager Wallac MicroBeta Liquid Scintillation Counter Percent activity is the response relative to an unperturbed state; in case of inhibition the interpretation is that of remaining activity, i.e. percent inhibition := 100 - percent activity. percent activity 50 percent growth inhibition 100 percent growth inhibition IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC20 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC150 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC90 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 IC95 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MIC80 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MIC90 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED25 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED30 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED90 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 LD10 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ID50 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MinED IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MTD IRI prefix change from BAO_02000 to BAO_00012 in January 2017 TD50 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 maximal effect IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Increase IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent change IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent growth IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent protection IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent remaining IRI prefix change from BAO_02000 to BAO_00012 in January 2017 uptake IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Kinactivation IRI prefix change from BAO_02000 to BAO_00012 in January 2017 residence time IRI prefix change from BAO_02000 to BAO_00012 in January 2017 T IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED80 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC10 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC25 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 IC75 kinase activity panel kinase assay kinase panel kinase profiling kinase screen kinase activity assay The percentage of cells in an assay that show the hallmarks of 'programmed cell death' or apoptosis, namely, membrane asymmetry, caspase activation, nuclear fragmentation, etc. percent apoptotic cells This represents the percentage of cells in a cell population that are in the M phase of the cell cycle. The cells in this phase can be detected using various markers, one of which is the characteristic phosphorylation of certain proteins that stain positive with MPM2 antibody. percent mitotic cells endpoints: percent proliferation percent interphase percent mitosis percent G2-M arrested percent non-arrested cell cycle assay This represents the percentage of cells in a cell population that are preparing for cell division and that exist in either G1, S or G2 phases of the cell cycle. This is calculated by subtracting from the total cell number, the number of cells in the M phase, apoptotic and dead cells in an assay plate. 'has marker' some (not ('DEVD-NucView 488' or 'LysoTracker Red' or 'Hoechst 33342')) percent interphase cells programmed cell death apoptosis assay This represents the percentage of cells in a cell population that have undergone the S phase (completed DNA replication) in preparation for mitosis, as indicated by staining positive for EdU. percent DNA replicated cells The percentage of cells in an assay that are no longer alive (viable), and show the characteristic features, such as staining with propidium iodide, blurry staining with DAPI, etc. 'has marker' some ('Hoechst 33342' and not ('DEVD-NucView 488' or 'LysoTracker Red') ) percent dead cells This represents the percentage of cells in a cell population that have undergone the DNA synthesis in the S phase as indicated by staining positive for EdU, but have not undergone the M phase as they stained negative for MDM2. In other words, these cells were arrested in the G2/M cell cycle check-points after treatment with the respective perturbagen in the assay. percent G2 arrested cells This represents the percentage of cells in a cell population that have completed the mitotic cell cycle, and that have stained positive for both S phase (EdU) and M phase (MDM2) markers. In other words, these cells were not arrested in any of the cell cycle check-points after treatment with the respective perturbagen in the assay. percent non-arrested cells cell growth assay An endpoint defined by a length in time at which a desired effect or observation occurs. time endpoint Half-life of drug is the time taken for the concentration of the drug to decrease by half. T1/2 An endpoint defined an effect seen in animals at a particular dosage, typically defined as a ratio of treatment to animal mass (e.g., mg/kg). dosage endpoint The median lethal dose is the dose required to kill (produce lethality) in 50% of tested population. lethal dose 50% LD50 An endpoint derived from calculus-based analysis of graphical measures. graphical calculation endpoint The maximal concentration of a drug achieved following administration (maximum point of a concentration-time curve). Cmax It is the area under the drug concentration-time curve (AUC) following a single dose or at steady state, and is expressed as weight*time/volume. area under curve AUC Slope is described as the ratio of the change in y-axis divided by the change in x-axis between two points on a line or a curve. m= y2-y1 / x2-x1 slope Endpoint values derived from an exponential growth curve, such as in a PCR reaction. amplification curve calculated endpoint Crossing point- In an exponential amplification curve (i.e., qPCR amplification) the value in number of amplification cycles at which the signal enters log phase, as determined by the maximal second derivative of the curve. crossing point Cp Quantificatoin cycle; general term, whether defined by Cp or Ct, for the value of interest determined from an exponential amplification curve (such as number of cycles in a PCR reaction). quantificatoin cycle Cq Crossing threshold; in an exponential amplification curve (i.e., qPCR amplification) the value in number of amplification cycles at which the signal crosses a defined threshold. threshold cycle Ct Endpoint values determined by a statistical measurement of the signal relative to the populations of signals observed. statistical endpoint The number of median absolute deviations outside the median of control or compound wells. MAD score An endpoint defined by a set of measurements from a multiparametric assay. The set of measurements may be aggregated to an overall profile score, weighting each measurment in the profile relative to a desired outcome. profile endpoint computational profile endpoint gene-expression profile endpoint panel-assay profile endpoint The effective concentration of an inhibitor, which produces 90% of the maximum possible response for that inhibitor. IC90 It is 50% lethal concentration (the concentration that kills 50% of treated cells). LC50 The lowest concentration of an inhibitor (antimicrobial agent) required to inhibit the growth of a microorganism. minimum inhibitory concentration MIC It is a measure of the amount of radioligand that binds to its receptor in a competitive binding assay. It is the ratio of the bound to the total bound, where bound refers to the reading obtained from a binding reaction involving radioligand, receptor and a cold competitor ligand, while total bound is the reading obtained in the absence of any added competitor. percent bound In a purification assay, percent recovery is the ratio of mass of the entity obtained after the affinity purification to the mass of the unpurified entity originally added in the assay, multiplied by 100. percent recovery concentration response endpoint genotoxicity assay oxidative stress assay oxidative phosphorylation assay ADME assay ADME assay PK PK assay PK study pharmacokinetic assay pharmacokinetic studies pharmacokinetic study pharmacokinetics pharmacokinetic assay pharmacodynamic assay QT interval study QT interval assay DDI FDA RPS Pharmacokinetics: Drug Interactions drug-drug interaction drug-drug interaction assay drug-drug interactions drug interaction assay toxicity assay mitochondrial membrane potential assay plasma membrane potential assay nuclear membrane potential assay localization assay bioavailability study bioavailability assay non-specific protein binding assay FDA RPS Pharmacokinetics: Distribution distribution assay drug distribution drug tissue exposure organ distribution tissue distribution tissue drug distribution tissue exposure tissue distribution assay safety pharmacology assay safety pharmacology assay drug abuse assay metastasis assay ICRM12000 atomic absorption spectrometer Sector imager 6000 LabChip EZ Reader Cellomics ArrayScan IN Cell Analyzer Epic reader Applied biosystems 8200 AlphaQuest reader LJL reader IonWorks Quattro RapidFire Mass Spec Tecan Ultra pEC50 is -logEC50, where EC50 is the effective concentration of an agonist, which produces 50% of the maximum possible response for that agonist. -log EC50 pEC50 'involves biological process' some 'mitotic cell cycle arrest' 'involves biological process' some 'mitotic cell cycle arrest' and 'apoptotic process' mitotic cell cycle state assay meiotic cell cycle state assay luciferase reporter gene assay 90% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 90% inhibition 90 percent inhibition Avance III CyAn Flow Cytometer MSD SECTOR instrument AMINCO-Bowman Series 2 Luminescence Spectrometer HPLC System luciferase enzyme activity assay cytochrome P450 enzyme activity assay Measured / detected concentration of the perturbagen / compound in the assay or a subsystem (locally) in the assay. For example measured absolute concentration in the brain. This is in contrast to screening concentration, which is the (final assumed) concentration of a compound added to the assay. measured concentration volume endpoint Clearance is the volume of plasma from which the drug is completely removed per unit time, or, alternatively, the volume of plasma that would have to lose all of the drug that it contains within a unit of time to account for an observed rate of drug elimination. Drug clearance CL chaperone activity assay phosphatase activity assay platelet activation assay protease activity assay organism behavior assay The time taken for the concentration of the drug in a particular tissue or blood plasma to decrease by half. T1/2(in vivo) The time taken for the concentration of the drug in an in-vitro system (e.g., liver microsomes) to decrease by half. T1/2(in vitro) The area under the drug concentration-time curve following an oral dose. AUC(oral) The area under the drug concentration-time curve following an intravenous dose. AUC(iv) Clearance of the drug due to renal excretion. CL(renal) Clearance of the drug due to hepatic enzyme activity and biliary excretion. CL(hepatic) The ability of a chemical substance to dissolve in water. aqueous solubility radioligand binding assay beta galactosidase enzyme activity assay cell permeability assay protein unfolding assay IP1 redistribution assay This assay quantifies the expression level of the entire gene pool in a cell or a subpopulation (e.g. tissue-specific gene expression, kinases) using either microarray, bead method, RNASeq, or reporter gene method. gene expression assay gene expression assay cell cycle state assay hydrolase activity assay oxidoreductase activity assay lyase activity assay isomerase activity assay transferase activity assay fold increase fold decrease neurite outgrowth assay protein stability assay generic hydrolase enzyme activity assay percent mitotic arrested cells Ka physicochemical The concentration of compound that elicits an extension of circadian period length by 5 hours. EC 5 hour The compound concentration at which the fitted curve passes activity threshold 1000. AC1000 absolute The compound concentration at which the fitted curve passes activity threshold 10. AC10 absolute The compound concentration at which the fitted curve passes activity threshold 26. AC26 absolute The compound concentration at which the fitted curve passes activity threshold 35. AC35 absolute The compound concentration at which the fitted curve passes activity threshold 40. AC40 absolute The compound concentration at which the fitted curve passes activity threshold 500. AC500 absolute The compound concentration whereupon perceived activity reaches the maximum value observed (with a positive control). ECMax The compound concentration whereupon perceived activity (change in Tm) reaches the maximum value observed (with a positive control). ECMax_Tm The agonist concentration whereupon perceived activity reaches the maximum value observed (with a positive control). ECMax_Agonist The compound concentration whereupon perceived activity (fold increase) reaches the maximum value observed (with a positive control). ECMax_fold increase The compound concentration whereupon perceived activity (percent inhibition) reaches the maximum value observed (with a positive control). ECMax_percent inhibition KiNativ assay automated cytometer Hypercyt An imageing cytometer is an instrument for image-based study or measurement of cells. (definition from OBI) imaging cytometer Intelligent Imaging Innovations www.intelligent-imaging.com 3i Marianas TTP LabTech http://www.ttplabtech.com/products/acumen/index.html Acumen Thermo Fisher Scientific www.cellomics.com ArrayScan VTI HCS Reader BD Biosciences http://www.bdbiosciences.com/instruments/pathway/index.jsp BD Pathway 435 BD Biosciences http://www.bdbiosciences.com/instruments/pathway/index.jsp BD Pathway 855 FLUXION http://www.fluxionbio.com/products/bioflux-live-cell-imaging-with-flow/ BioFlux 1000 Brooks Life Science Systems http://www.brooks.com/products/life-science-systems/instruments-and-devices/celigo-cytometer Celigo S Imaging Cell Cytometer Yokogawa http://www.yokogawa.com/scanner/products/cv1000e.htm Cell Voyager 1000 Yokogawa http://www.yokogawa.com/hca/product/cv6000.htm Cell Voyager 6000 Yokogawa http://www.yokogawa.com/hca/product/cv7000.htm Cell Voyager 7000 Amnis https://www.amnis.com/documents/brochures/FS_Brochure_Final.pdf FlowSight CompuCyte http://www.compucyte.com/icyte.htm iCyte Automated Imaging Cytometer Amnis https://www.amnis.com/documents/brochures/ISX-MKII%20Brochure_Final_Web.pdf ImageStreamX Mark II Imaging Flow Cytometer Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html ImageXpress Micro Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html ImageXpress Ultra formerly known as: isocyte cytometer Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html ImageXpress Velos Laser Scanning Cytometer GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 2000 GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 6000 Perkin Elmer http://www.perkinelmer.com/pages/020/cellularimaging/products/opera.xhtml Opera Perkin Elmer http://www.perkinelmer.com/pages/020/cellularimaging/products/operetta.xhtml Operetta life technologies http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cell-Analysis/Cellular-Imaging/imaging-cytometry/Tali-Image-Cytometer/Tali-Image-Cytometer-Specifications.html Tali Image Cytometer It is performed to quantify the interactions between two molecules, e.g. small molecule-protein, protein-protein, protein-DNA, etc. ligand binding ligand binding assay binding assay It is performed to quantify the interactions between two protein molecules, using methods such as protein fragment complementation assay, immunoassay, radioligand binding, etc. protein-protein interaction assay It reports the size and shape of cells and organelles (phenotype). These are detected by microscopy. cell morphology assay It is performed to measure the movement of cells and organelles (phenotype). These are detected by microscopy. cell motility assay cytotox assay cytotoxic activity in vitro cytotoxic activity cytotoxicity assay It is used to measure the effect of a perturbagen on the enzyme activity, which can be measured either directly or coupled to a secondary signal. enzymatic activities enzyme activity assay This assay quantifies the expression level of the entire gene pool in a cell or a subpopulation (e.g. tissue-specific gene expression, kinases) using a bead-based method. transcriptional profile transcriptional profiling transcriptomic profiling transcriptional profiling assay This reports the membrane potential of a cell by using electrophysiological techniques or by staining with dyes whose binding is dependent on the membrane potential. membrane potential assay Ion channel assays are performed in electrically active cells: neurons, muscle, and endocrine cells. ion channel assay This assay quantifies the protein folding/conformation using technologies, such as nuclear magnetic resonance, circular dichroism are used to determine the protein folding/conformation. protein folding assay It is performed to measure the redistribution of organelles and molecules within the cell (proteins, second messengers, metal ions, dyes, etc. ). This is visualized by microscopy. redistribution assay This assay quantifies the amount of a mature transcript that is produced after splicing. Splicing is a modification of an mRNA intermediate after transcription, in which introns are removed and exons are joined. It can be detected by several methods, namely, the use of a reporter gene, RNA-Seq, specialiez microarrays, etc. rna splicing assay This assay allows the identification of new drugs that sensitize or desensitize the sensitivity of a cell to its signaling molecule (e.g calcium, light). The perturbagen has the role 'sensitizer' in this assay. sensitizer assay This assay measures one of the series of events that are downstream to the receipt of a chemical signal at the cell cell signaling cell signaling assay cell signalling cell signalling assay signal transduction assay It measures the types and amounts of cytokines that are released as the consequence of a signaling event. Cytokines can be quantitated using ELISA-based kits, PCR array, etc. cytokine release cytokine release assay cytokine secretion assay This assay quantifies the modification that a protein can undergo after it is synthesized by translation. E.g. phosphorylation, acetylation, etc. The modification status is detected by one of several methods such as using modification specific antibodies followed by western blotting, imaging; mass spectrometry, etc. posttranslation modification assay This assay quantifies the phosphorylation levels of a protein. The phosphorylation status is detected by one of several methods: using phosphorylation specific antibodies followed by western blotting or imaging, mass spectrometry, etc. kinase phosphorylation protein phosphorylation assay detect some (protein phosphorilation and ('catalyzed by' some kinase)) phosphorylation assay Reporter gene assay measures the gene expression from a reporter gene. The reporter gene is inserted under the control of a foreign promoter or an artificial regulatory element of interest. Reporters include luciferase, beta galactosidase, beta lactamase, chloramphenicol acetyl transferase, or a fluorescent protein. reporter assay reporter assays reporter gene assays reports some ('gene expression' and ('has part' some 'reporter gene')) needs clean up to say has part gene with role of reporter. reporter gene assay This assay quantifies the second messengers (calcium, cAMP, cGMP) produced in the cell as a result of a signaling event. second messenger assay This assay quantifies the activity of a transporter that carries proteins, cofactors, ions, drugs, etc. across the cell membranes. Fluorescence-conjugated dyes or radiolabeled ligands are used to quantitate the various molecular entities that are being transported. drug transporter assay transporter assay This assay type measures the cellular state of living or dying by measuring an indicator of life or death. Cell life indicators include ATP content, cell number, dehydrogenase activity, DNA content, esterase activity, mitochondrial membrane potential, membrane integrity, and protease activity. Cell death indicators include caspase activity, chromatin condensation, and phospholipid redistribution. viability assay viability assays BAO_0003009 cell viability assay This assay quantifies the protein turnover, which is a natural phenomenon in healthy cells, but becomes aberrant in diseased cells. The protein that is needed to be degraded first undergoes ubiquitinated. Ubiquitinated proteins are degraded in the proteasome complex. The protein degradation is quantitated by using reporters, such as green fluorescent protein as proteasome substrates. protein-turnover assay KINOMEScan assay fluorescent protein reporter gene assay beta galactosidase reporter gene assay beta lactamase reporter gene assay chloramphenicol acetyltransferase reporter gene assay The lowest concentration of an antimicrobial agent required to inhibit the growth of 50% of organisms. MIC50 It is the dose that produces an effect in 50% of the tested population, or the dose required to produce half-maximal response. ED50 The time required for a drug to reach maximum concentration in plasma (Cmax) following administration. Tmax The negative logarithm (log10) of the molar concentration of antagonist which requires the agonist concentration to be doubled in order to achieve the original response. pA2 In the disk diffusion susceptibility test, the zone of inhibition is the clear area surrounding an antimicrobial disk where bacterial growth is inhibited, usually measured as a diameter. The diameter of the zone of inhibition is proportional to the susceptibility of the organism tested. Inhibition zone IZ Volume of Distribution is defined as the theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma. Measured as the total amount of drug in the body divided by the concentration of drug in the plasma. Volume of distribution Vd The theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma at steady state i.e when the rate of change of amount of drug in the body is zero. VdSS is proportional to the amount of drug in the body versus the plasma concentration of the drug at steady state (pseudo-equilibrium). Volume of distribution at steady state Vdss Bioavailability is a subcategory of absorption and is the fraction (or %) of unchanged drug that reaches the systemic circulation, thereby accessing the site of action. It is usually determined as the ratio of AUC(oral)/AUC(iv). BA Bioavailability F ICR 8000 Ion Channel Reader MicroBeta TriLux SpectraMax Plus384 LabChip 3000 Safire Infinite F500 Infinite M1000 LEADseeker Imaging system Harward Medical School HMS cell viability ATP quantitation assay 2 color apoptosis assay 3 color apoptosis assay mitosis/apoptosis assay single cell protein secretion microfluidic assay A common in vitro ADME assay that tests the stability of compounds when incubated with liver microsomes (subcellular fractions which contain membrane-bound drug-metabolizing enzymes). Assay is used to measure in vitro intrinsic clearance or to identify metabolites formed. Typically liver microsomes from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed to understand differences in metabolism. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). Date from BAE: 6/6/2016 liver microsomal stability liver microsome stability metabolic stability in liver microsomes microsomal stability microsome stability microsome stability assay PubChem AID: 504610 microsomal stability assay A common in vitro ADME assay that tests the stability of compounds when incubated with plasma. Assay is used to measure stability of new chemical entities in plasma, as compounds that rapidly degrade in plasma generally show poor in vivo efficacy. Typically lplasma from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). Date from BAE: 6/6/2016 plasma stability PubChem AID: 504605 plasma stability assay A common in vitro ADME assay that uses the Caco-2 cell line (derived from human colon carcinoma) to assess transport in both directions (apical to basolateral (A-B) and basolateral to apical (B-A)) across the cell monolayer), to predict the in vivo absorption of drugs across the gut wall and to investigate drug efflux. Date from BAE: 6/6/2016 Caco-2 permeability PubChem AID: 504629 Caco-2 permeability assay Physicochemical assays measure inherent properties of molecules, and include turbidimetric and thermodynamic solubility (in water or PBS), chemical stability, pKa, and lipophilicity (logP and logD) Date from BAE: 6/6/2016 physicochemical assay PubChem AID: 504606 physicochemical assay A physicochemical assay that measures the maximum solubility of a molecule in a particular solvent (typically water or PBS). Date from BAE: 6/6/2016 solubility assay PubChem AID: 504606 solubility assay An in vivo efficacy assay is a study perfromed in a whole, living organism (usually an animal such as a mouse or rat) to test the effects of a treatment on a specific disease modeled in this animal. Date from BAE: 9/30/2016 efficacy assessed efficacy comparison efficacy study evaluate the efficacy evaluation of efficacy evaluation of the efficacies in vivo efficacies in vivo efficacy in vivo efficacy study PubChem AID: 687012 in vivo efficacy assay Polyacrylamide gel electrophoresis (PAGE), describes a technique to separate biological macromolecules, usually proteins or nucleic acids, according to their electrophoretic mobility. Mobility is a function of the length, conformation and charge of the molecule. Gels can be native or denaturing (urea for nucleic acids, SDS for proteins). A low-throughput method. Date from BAE: 6/2/2016 PubChem AID: 449751 PAGE Protein profiling assays can be used to identify and quantify proteins together with their post-translational modifications protein profiling protein quantification assay protein quantification assay protein profiling assay An assay that is used to identify in a data-dependent mode proteins by combining the HPLC and MS methods. It is also known as liquid chromatography-coupled tandem mass spectrometry (LC-MS) shotgun MS protein profiling assay Sequential window acquisition of all theoretical mass spectra (SWATH) MS is a mass spectrometrical method thatcouples data-independent acquisition is coupled with peptide spectral library match SWATH MS protein profiling assay A targeted phosphoproteomic assay that uses a data-driven approach to identify and quantify a set of 96 phosphopeptide probes P100 protein profiling assay Reverse phase protein array (RPPA) is a an assay that measures multiple protein expression levels in a large number of biological samples simultaneously using high quality antibodies RPPA protein profiling assay Epigenetic assays that can be used to identify epigenome modifications together with the epigenetic enzymes that regulate it. The epigenetic assays are split in two categories: targeted epigenetic assays and epigenetic profiling assays depending on whether they are used to identify a modifications on a global scale or only measure and identify a predetermined list of targets epigenetic assay Assays that measure a targeted and predetermined subset of the epigenetic modifications in a cell targeted epigenetic assay An assay that quantifies the levels of the acetylated histones in a cell. Acetylated histones are involved in the regulation of chromatin structure and thetranscription factor recruitment acetylated histone assay An assay that quantifies the levels of the methylated histones in a cell methylated histone assay An assay that identifies genome-wide DNA binding sites for transcription factors and other proteins ChIP-seq assay Assays that are used to capture the genome-wide epigenetic modifications in a cell epigenetic profiling assay An assay that is used to determine themethylation marks in a cells genome Bisulfite Sequencing assay ATAC-seq (assay for transposase-accessible chromatin using sequencing) is an assay that identifies open-chromatin sites on the whole genome level by using theTn5 transposase, which inserts sequencing adapters into accessible regions of chromatin ATAC-seq epigenetic profiling assay A mass spectrometry-based assay that is used to identify and quantify post-translational modifications on histone proteins from bulk chromatin global chromatin epigenetic profiling assay Assays that identify and quantify cell metabolites (metabolic analytes) metabolomic assay targeted metabolomic assay Assays that profile key metabolomic parameters metabolomic profiling assay A high throughput live-cell microarray screening assay that is used to detect metabolic analytes such as oxygen, pH and glucose at the single-cell level Cellarium metabolomic profiling assay Assays that quantify the expression of a predetermined RNA transcript / set of transcripts RNA expression targeted transcriptional assay An assay that uses NGS (Next Generation Sequencing) to quantify the expression of the entire RNA transcripts in a cell / cell population RNA-seq gene expression profiling assay RNA-seq gene expression profiling assay L1000 is a bead-based, high-throughput gene expression assay in which cultured cells are treated with various chemical and genetic perturbations and the corresponding transcriptional responses are measured L1000 mRNA profiling assay An assay that uses barcoded hybridization probes to quantify the expression of RNA transcripts Nanostring An array based method that simultaneously measures the expression of tens of thousands of RNA transcripts Microarray Microwestern Bead-based immunoassay for protein state ELISA protein secretion profiling assay ELISA protein state assay Fluorescence imaging apoptosis assay Fluorescence imaging cell cycle state assay Fluorescence imaging cell growth inhibition assay Fluorescence imaging morphology assay Fluorescence imaging multiplex cytological profiling assay Fluorescence imaging protein state assay MEMA cell growth assay MS protein quantification assay MS protein state assay P100 phosphoprotein quantification assay RPPA protein state assay SWATH-MS protein quantification assay A variant of the BRET assay utilizing Nanoluc luciferace, providing higher stability, smaller size, greater separation of donor and acceptor wavelengths, and higher fluorescence intensity, enabling more accurate and precise quantification of protein-protein interactions Protein-Protein NanoBRET Assay A variant of the BRET assay utilizing Nanoluc luciferace, providing higher stability, smaller size, greater separation of donor and acceptor wavelengths, and higher fluorescence intensity, enabling more accurate and precise quantification of protein-small molecule interactions Protein-Small Molecule NanoBRET Assay A specific application of protein-small molecule NanoBRET examining the interaction of small molecules with specific kinases Kinase NanoBRET Assay Tandem Mass Tag (TMT) MS Protein Quantification Liquid Chromatography/Mass Spectroscopy (LC/MS) protein quantification A method which determines the permeability of substances from a donor compartment, through a lipid-infused artificial membrane into an acceptor compartment. At the beginning of the test, the drug is added to the donor compartment, and the acceptor compartment is drug-free. After an incubation period the amount of drug is measured in each compartment. Mass balance allows calculation of drug that remains in the membrane. It is used as an in vitro model of passive, transcellular permeation to predict oral absorption. PAMPA is an alternative to the cell-based Caco-2 permeability assay PAMPA parallel artificial membrane permeability assay low throughput screening GPCR assay GPCR functional assay GPCR pharmacology GPCR profiling GPCR screening assay GPCR signaling assay GPCR Signaling A variant of a BRET assay wherein fluorescently tagged beta-arrestin2 is detected when in proximity of a G-protein coupled receptor with an Rluc C-terminal tag. Arrestin2 recruitment assay Beta-arrestin2 fused to the TEV protease liberates a tTA molecule fused to the C-terminus of a target G-protein coupled receptor when in close proximity, resulting in a tTA-driven expression of RLuc from a genomic TETO7-RLuc locus. PRESTO-TANGO Measure release of the heterotrimeric G-protein complex from G-protein coupled receptors (GPCRs). When activated GPCRs catalyze the exchange of GDP for GTP in the G-alpha subunit of the Galpha-beta-gamma heterotrimeric complex, resulting in the disassociation of these subunits from the GPCR of interest. Heterotrimeric G-protein dissassociation assay Measures heterotrimer G-protein disassociation using BRET between alpha and gamma subunits. TRUPath drug absorption assay SEED Project - Pistoia Alliance drug absorption assay assessment of permeability bidirectional assay bidirectional assays drug permeability permeability study permeabillity studies SEED Project - Pistoia Alliance permeability assay Ussing chamber assay Ussing chamber permeability SEED Project - Pistoia Alliance Ussing chamber permeability assay BCRP assessment of permeability BCRP permeability assay BCRP-MDCK permeability SEED Project - Pistoia Alliance MDCK-BCRP permeability assay MDCK assay MDCK permeability SEED Project - Pistoia Alliance MDCK permeability assay RRCK assay RRCK permeability Ralph Russ Canine Kidney (RRCK) assay Ralph Russ Canine Kidney assay SEED Project - Pistoia Alliance RRCK permeability assay LLCPK1 assay LLCPK1 monolayer assay LLCPK1 monolayer bidirectional permeability LLCPK1 monolayer permeability bidirectional permeability across LLCPK1 monolayers SEED Project - Pistoia Alliance LLCPK1 monolayer permeability assay MDCKII assay MDCKII monolayer assay MDCKII monolayer bidirectional permeability MDCKII monolayer permeability MDCKII permeability bidirectional permeability across MDCKII monolayers SEED Project - Pistoia Alliance MDCKII monolayer permeability assay FDA RPS Pharmacokinetics: Metabolism Pharmacokinetics: Metabolism In Vitro drug metabolism in vitro metabolism metabolic study metabolism - in vitro metabolism in vitro SEED Project - Pistoia Alliance drug metabolism assay Met Id MetId biotransformation metabolite Id metabolite identification and profiling SEED Project - Pistoia Alliance metabolite identification and profiling assay TMDD TMDD PK TMDD PK model TMDD PK modeling TMDD PK profile TMDD determination TMDD model TMDD modeling drug induced TMDD target mediated drug disposition target mediated drug disposition determination SEED Project - Pistoia Alliance target mediated drug dispositioning receptor internalization SEED Project - Pistoia Alliance receptor internalization assay portal vein study SEED Project - Pistoia Alliance portal vein study Met Stab Metab metabolic stability SEED Project - Pistoia Alliance metabolic stability assay cytosol stability cytosolic stability SEED Project - Pistoia Alliance cytosol stability assay S9 fraction stability S9 metabolic stability S9 stability SEED Project - Pistoia Alliance S9 stability assay blood stability blood stability assay whole blood stability SEED Project - Pistoia Alliance whole blood stability assay plasma stability with inhibitor SEED Project - Pistoia Alliance plasma stability with inhibitors hepatocyte clearance assay hepatocyte stability metabolic stability in hepatocytes SEED Project - Pistoia Alliance hepatocyte stability assay low clearance assay low clearance hepatocyte stability low clearance relay low intrinsic clearance assay SEED Project - Pistoia Alliance hepatocyte low clearance relay assay co-culture low clearance low clearance hepatocyte co-culture SEED Project - Pistoia Alliance hepatocyte co-culture low clearance assay ex vivo gastric fluid stabiliy gastric fluid stability stabiity in gastric fluids SEED Project - Pistoia Alliance gastric fluid stability assay simulated gastric fluid stability SEED Project - Pistoia Alliance simulated gastric fluid stability assay enzymatic simulated gastric fluid stability simulated gastric fluid stability (enzymatic) stability in simulated gastric fluids with enzymes SEED Project - Pistoia Alliance simulated gastric fluid stability assay (with enzymes) ex vivo intestinal fluid stability intestinal fluid stability SEED Project - Pistoia Alliance intestinal fluid stability assay enzymatic simulated intestinal fluid stability SEED Project - Pistoia Alliance simulated intestinal fluid stability assay (with enzymes) simulated intestinal fluid stability SEED Project - Pistoia Alliance simulated intestinal fluid stability assay ex-vivo interstitial fluid stability interstitial fluid stability SEED Project - Pistoia Alliance interstitial fluid stability assay simulated interstitial fluid simulated interstitial fluid stability stability in simulated interstitial fluid SEED Project - Pistoia Alliance simulated interstitial fluid stability assay stability in tissue homogenate tissue homogenate stability SEED Project - Pistoia Alliance tissue homogenate stability assay cell culture homogenate stability cell homogenate stability metabolic stability in cell homogenate SEED Project - Pistoia Alliance cell homogenate stability assay enzymatic stability metabolic stability in enzymes SEED Project - Pistoia Alliance enzymatic stability assay reaction phenotyping SEED Project - Pistoia Alliance enzyme reaction phenotyping AOX reaction phenotyping AOX stability aldehyde oxidase reaction phenotyping aldehyde oxidase stability in vitro liver cytosol stability for aldehyde oxidase substrates SEED Project - Pistoia Alliance AOX reaction phenotyping FMO 1 stability FMO 3 stability FMO 5 stability FMO stability flavin monooxygenases reaction phenotyping flavin-containing monooxygenase (fmo3): screening for substrates SEED Project - Pistoia Alliance FMO reaction phenotyping MAO stability MAOA reaction phenotyping MAOA stability MAOB reaction phenotyping MAOB stability monoamine oxidase reaction phenotyping monoamine oxidase stability SEED Project - Pistoia Alliance MAO reaction phenotyping hepatocyte relay with inhibitors SEED Project - Pistoia Alliance hepatocyte relay with inhibitors CES stability carboxylesterase reaction phenotyping carboxylesterase stability carboxylesterases (ces1 and ces2): screening for substrate and inhibitor SEED Project - Pistoia Alliance CES reaction phenotyping esterase chemical inhibitor esterase chemical inhibitors SEED Project - Pistoia Alliance esterase chemical inhibition esterase metabolite formation kinetics SEED Project - Pistoia Alliance esterase metabolite formation kinetics recombinant esterases SEED Project - Pistoia Alliance recombinant esterases CYP identification CYP phenotyping CYP450 reaction phenotyping Cytochrome P450 phenotyping Cytochrome P450 reaction phenotyping SEED Project - Pistoia Alliance CYP reaction phenotyping CYP chemical inhibition phenotyping CYP chemical inhibition reaction phenotyping CYP phenotyping - chem inhib CYP phenotyping- chemical inhibition SEED Project - Pistoia Alliance CYP chemical inhibition CYP metabolite formation kinetics SEED Project - Pistoia Alliance CYP metabolite formation kinetics CYP recombinant enzymes CYP recombinant enzymes phenotyping phenotyping with recombinant CYPs phenotyping – rCYP rCYP recation phenotyping rCYPs phenotyping rCYPs recation phenotyping recombinant CYP phenotyping recombinant CYPs reaction phenotyping SEED Project - Pistoia Alliance recombinant CYP reaction phenotyping CYP immuno inhibition CYP monoclocal antibody inhibition CYP phenotyping - mAb inhib CYP phenotyping - monoclocal antibody inhibition CYP phenotyping- immuno inhibition mAb inhibition of CYP mAb inhibitors of CYP monoclonal antibody inhibitors of CYP SEED Project - Pistoia Alliance CYP mAb inhibition UGT phenotyping UGT substrate identification SEED Project - Pistoia Alliance UGT reaction phenotyping UGT chem inhib UGT chemical inhibition phenotyping UGT chemical inhibition reaction phenotyping UGT phenotyping- chemical inhibition SEED Project - Pistoia Alliance UGT chemical inhibition UGT metabolite formation kinetics SEED Project - Pistoia Alliance UGT metabolite formation kinetics UGT recombinant enzymes phenotyping – rUGT rUGT phenotyping rUGT reaction phenotyping rUGTs phenotyping rUGTs reaction phenotyping recombinant UGT phenotyping recombinant UGTs reaction phenotyping SEED Project - Pistoia Alliance recombinant UGT reaction phenotyping B/P assay RBC partitioning blood partitioning blood plasma distribution blood plasma partitioning blood to plasma partitioning blood/plasma ratio assay red blood cell partitioning SEED Project - Pistoia Alliance blood to plasma ratio assay tissue binding tissue protein binding tissue protein binding assay SEED Project - Pistoia Alliance tissue binding assay Placental transfer studies Placental transfer study SEED Project - Pistoia Alliance placental transfer assay plasma protein binding plasma protein binding (equilibrium dialysis) SEED Project - Pistoia Alliance plasma protein binding assay binding to in vitro media in vitro free fraction in vitro media binding induction media binding media binding stability in induction stability in induction media SEED Project - Pistoia Alliance media binding assay 2% BSA binding BSA binding binding to BSA binding to bovine serum albumin bovine serum albumin binding SEED Project - Pistoia Alliance BSA binding asssay microsomal protein binding assay microsome binding microsome binding assay microsome protein binding assay SEED Project - Pistoia Alliance microsomal binding assay FDA RPS Pharmacokinetics: Excretion SEED Project - Pistoia Alliance drug excretion assay excretion balance excretion balance study mass balance mass balance study SEED Project - Pistoia Alliance mass balance assay biliary elimination biliary excretion excretion into bile SEED Project - Pistoia Alliance biliary excretion assay excretion in milk excretion into milk SEED Project - Pistoia Alliance milk excretion assay renal elimination renal excretion renal excretion study SEED Project - Pistoia Alliance renal excretion assay receptor induction SEED Project - Pistoia Alliance receptor induction assay Fc/FcRn assay Fc/FcRn induction FcRn induction SEED Project - Pistoia Alliance Fc/FcRN induction assay definitive induction SEED Project - Pistoia Alliance enzyme induction assay CYP induction screen SEED Project - Pistoia Alliance CYP induction screen UGT induction assay SEED Project - Pistoia Alliance UGT induction assay CYP Induction in human hepatocytes CYP induction CYP mRNA Induction CYP450 induction Cytochrome P450 Induction Induction of CYP Induction of CYP450 Induction of cytochrome P450 SEED Project - Pistoia Alliance CYP induction assay CYP1A2 induction definitive CYP1A2 induction definitive CYP1A2 induction assay SEED Project - Pistoia Alliance CYP1A2 induction assay CYP2B6 induction definitive CYP2B6 induction assay SEED Project - Pistoia Alliance CYP2B6 induction assay CYP2C19 induction definitive CYP2C19 induction definitive CYP2C19 induction assay SEED Project - Pistoia Alliance CYP2C19 induction assay CYP2C8 induction definitive CYP2C8 induction definitive CYP2C8 induction assay SEED Project - Pistoia Alliance CYP2C8 induction assay CYP2C9 induction definitive CYP2C9 induction definitive CYP2C9 induction assay SEED Project - Pistoia Alliance CYP2C9 induction assay CYP3A4 induction definitive CYP3A4 induction definitive CYP3A4 induction assay SEED Project - Pistoia Alliance CYP3A4 induction assay 3A4 Relative Induction Score CYP Induction in human hepatocytes - 3A4 Relative Induction Score (RIS) CYP Induction prediction CYP Relative Induction Score RIS determination RIS evaluation Relative Induction Score evaluation prediction of CYP induction SEED Project - Pistoia Alliance Relative Induction Score determination enzyme inhibition assay SEED Project - Pistoia Alliance enzyme inhibition assay MAO Inhibition inhibition MAO inhibition of MAO inhibition of monoamine oxidase SEED Project - Pistoia Alliance monoamine oxidase inhibition CYP reversible inhibition CYP reversible inhibition assay CYP450 Inhibition CYP450 direct inhibition CYP450 reversible inhibition Cytochrome P450 Inhibition Cytochrome P450 reversible inhibition DDI- reversible Definitive DDI cytochrome P450 direct inhibition cytochrome P450 reversible inhibition inhibition of CYP inhibition of CYP450 inhibition of cytochrome P450 SEED Project - Pistoia Alliance CYP inhibition assay CYP1A2 inhibition SEED Project - Pistoia Alliance CYP1A2 inhibition assay CYP2B6 inhibition SEED Project - Pistoia Alliance CYP2B6 inhibition assay CYP2C19 inhibition SEED Project - Pistoia Alliance CYP2C19 inhibition assay CYP2C8 inhibition SEED Project - Pistoia Alliance CYP2C8 inhibition assay CYP2C9 inhibition SEED Project - Pistoia Alliance CYP2C9 inhibition assay CYP3A4 inhibition SEED Project - Pistoia Alliance CYP3A4 inhibition assay CYP IC50 cocktail SEED Project - Pistoia Alliance CYP cocktail IC50 CYP single point inhibition SEED Project - Pistoia Alliance CYP single point inhibition definitive CYP IC50 SEED Project - Pistoia Alliance definitive CYP IC50 CYP time-dependent Inhibition DDI- TDI DDI- TDI Cocktail DDI-MBI Definitive TDI mechanism-based CYP inhibition mechanism-based inhibition time-dependent CYP450 Inhibition time-dependent Inhibition of CYP time-dependent Inhibition of CYP450 SEED Project - Pistoia Alliance CYP time-dependent inhibition CYP IC50-shift assay CYP time-dependent Inhibition (IC50 shift) CYP time-dependent Inhibition shifted IC50 CYP450 time-dependent Inhibition IC50 shift Cytochrome P450 time-dependent Inhibition IC50 shift TDI IC50 shift SEED Project - Pistoia Alliance CYP time dependent inhibition IC50 shift CYP time-dependent Inhibition (Ki/kinact) CYP time-dependent Inhibition (kinact/Ki) CYP450 time-dependent Inhibition (kinact/Ki) Cytochrome P450 time-dependent Inhibition (kinact/Ki) Ki & Kinact (TDI) SEED Project - Pistoia Alliance CYP time dependent inhibition Ki/kinact CYP time-dependent Inhibition (single point) TDI single point single point TDI single-point time dependent inhibiton time dependent inhibition single point SEED Project - Pistoia Alliance CYP time dependent inhibition single point UGT inhibition SEED Project - Pistoia Alliance UGT inhibition UGT1A1 with BSA SEED Project - Pistoia Alliance UGT1A1 with BSA UGT1A1 without BSA SEED Project - Pistoia Alliance UGT1A1 without BSA UGT1A4 with BSA SEED Project - Pistoia Alliance UGT1A4 with BSA UGT1A4 without BSA SEED Project - Pistoia Alliance UGT1A4 without BSA UGT1A6 with BSA SEED Project - Pistoia Alliance UGT1A6 with BSA UGT1A6 without BSA SEED Project - Pistoia Alliance UGT1A6 without BSA UGT1A9 with BSA SEED Project - Pistoia Alliance UGT1A9 with BSA UGT1A9 without BSA SEED Project - Pistoia Alliance UGT1A9 without BSA UGT2B15 with BSA SEED Project - Pistoia Alliance UGT2B15 with BSA UGT2B15 without BSA SEED Project - Pistoia Alliance UGT2B15 without BSA UGT2B7 with BSA SEED Project - Pistoia Alliance UGT2B7 with BSA UGT2B7 without BSA SEED Project - Pistoia Alliance UGT2B7 without BSA induction of transport proteins SEED Project - Pistoia Alliance transporter induction assay ABCB1 induction MDR1 induction P-glycoprotein (P-gp) induction assay P-glycoprotein induction assay P-gp induction multi-drug resistance 1 induction SEED Project - Pistoia Alliance p-gp induction assay transporter inhibition assay SEED Project - Pistoia Alliance transporter inhibition assay efflux transporter inhibition assay SEED Project - Pistoia Alliance efflux transporter inhibition assay ABCB11 inhibition BSEP inhibition SEED Project - Pistoia Alliance BSEP inhibition assay ABCG2 inhibition BCRP inhibition inhibition of BCRP SEED Project - Pistoia Alliance BCRP inhibition assay ABCC2 inhibition MRP2 inhibition SEED Project - Pistoia Alliance MRP2 inhibition assay ABCB1 inhibition MDR1 inhibition P-glycoprotein (P-gp) inhibition assay P-glycoprotein inhibition assay P-gp inhibition multi-drug resistance 1 inhibition SEED Project - Pistoia Alliance P-gp inhibition assay MATE1 inhibition SLC47A1 inhibition SEED Project - Pistoia Alliance MATE1 inhibition assay MATE2 inhibition MATE2-K inhibition SLC47A2 inhibition SEED Project - Pistoia Alliance MATE2 inhibition assay uptake transporter inhibition SEED Project - Pistoia Alliance uptake transporter inhibition assay OAT1 inhibition SLC22A6 inhibition SEED Project - Pistoia Alliance OAT1 inhibition assay OAT2 inhibition SLC22A7 inhibition SEED Project - Pistoia Alliance OAT2 inhibition assay OAT3 inhibition SLC22A8 inhibition SEED Project - Pistoia Alliance OAT3 inhibition assay OATP1B1 inhibition SLCO1B1 inhibition SEED Project - Pistoia Alliance OATP1B1 inhibition assay OATP1B3 inhibition SLCO1B3 inhibition SEED Project - Pistoia Alliance OATP1B3 inhibition assay OCT1 inhibition SLC22A1 inhibition SEED Project - Pistoia Alliance OCT1 inhibition assay OCT2 inhibition SLC22A inhibition SEED Project - Pistoia Alliance OCT2 inhibition assay transporter substrate assay transporter substrate identification SEED Project - Pistoia Alliance transporter substrate assay efflux transporter substrate identification SEED Project - Pistoia Alliance efflux transporter substrate assay ABCB1 substrate ABCB1 substrate identification MDR1 substrate P-glycoprotein (P-gp) substrate assay P-gp substrate P-gp substrate assay P-gp substrate identification P-gp substrate identification assay SEED Project - Pistoia Alliance P-gp substrate assay ABCC2 substrate MRP2 substrate SEED Project - Pistoia Alliance MRP2 substrate assay ABCG2 substrate BCRP substrate BCRP substrate assessment BCRP substrate identification BCRP substrate identification assay SEED Project - Pistoia Alliance BCRP substrate assay MATE1 substrate SLC47A1 substrate SEED Project - Pistoia Alliance MATE1 substrate assay MATE2 substrate MATE2-K substrate SLC47A2 substrate SEED Project - Pistoia Alliance MATE2 substrate assay uptake transporter substrate identification SEED Project - Pistoia Alliance uptake transporter substrate assay OAT1 substrate OAT1 substrate assessment OAT1 substrate identification SLC22A6 substrate SEED Project - Pistoia Alliance OAT1 substrate assay OAT2 substrate SLC22A7 substrate SEED Project - Pistoia Alliance OAT2 substrate assay OAT3 substrate OAT3 substrate assessment OAT3 substrate identification SLC22A8 substrate SEED Project - Pistoia Alliance OAT3 substrate assay OATP1B1 substrate SLCO1B1 substrate SEED Project - Pistoia Alliance OATP1B1 substrate assay OATP1B3 substrate SLCO1B3 substrate SEED Project - Pistoia Alliance OATP1B3 substrate assay OCT1 substrate SLC22A1 substrate SEED Project - Pistoia Alliance OCT1 substrate assay OCT2 substrate OCT2 substrate identification SLC22A substrate SEED Project - Pistoia Alliance OCT2 substrate assay OATP2B1 substrate SLCO2B1 substrate SEED Project - Pistoia Alliance OATP2B1 substrate assay hepatic uptake hepatic uptake assay hepatocyte uptake SEED Project - Pistoia Alliance hepatocyte uptake assay SCHH assay sandwich-cultured fresh hepatocytes sandwich-cultured hepatocytes sandwich-cultured human cryopreserved hepatocyte sandwich-cultured human hepatocytes SEED Project - Pistoia Alliance sandwich cultured human hepatocyte assay plated human hepatocyte clearance plated human hepatocyte clearance assay plated human hepatocytes plated primary human hepatocytes SEED Project - Pistoia Alliance plated human hepatocytes assay PK modeling in silico pharmacometrics pharmacometrics pharmacometrics and modeling SEED Project - Pistoia Alliance pharmacometrics PBPK PBPK model PBPK models PBPK simulations Physiologically based pharmacokinetic modeling Physiologically based pharmacokinetic modelling pharmacokinetic (PBPK) modeling physiologically based pharmacokinetic (PBPK) model SEED Project - Pistoia Alliance PBPK modeling methods of analysis SEED Project - Pistoia Alliance method development and validation other pharmacokinetic studies SEED Project - Pistoia Alliance other pharmacokinetic studies PK non-rodent SEED Project - Pistoia Alliance non-rodent PK non-rodent urinary excretion SEED Project - Pistoia Alliance non-rodent excretion in urine non-rodent IV clearance SEED Project - Pistoia Alliance non-rodent IV clearance non-rodent IV half-life SEED Project - Pistoia Alliance non-rodent IV half-life non-rodent % F non-rodent % bioavailability non-rodent %F non-rodent (%F) non-rodent F SEED Project - Pistoia Alliance non-rodent oral bioavailability non-rodent oral half-life SEED Project - Pistoia Alliance non-rodent oral half-life non-rodent Vdss SEED Project - Pistoia Alliance non-rodent Vdss PK rodent SEED Project - Pistoia Alliance rodent PK rodent urinary excretion SEED Project - Pistoia Alliance rodent excretion in urine rodent IV clearance SEED Project - Pistoia Alliance rodent IV clearance rodent IV half-life SEED Project - Pistoia Alliance rodent IV half-life rodent % F rodent % bioavailability rodent %F rodent (%F) rodent F SEED Project - Pistoia Alliance rodent oral bioavailability rodent oral half-life SEED Project - Pistoia Alliance rodent oral half-life rodent Vdss SEED Project - Pistoia Alliance rodent Vdss Lipophilicity Lipophilicity assay LogD Shake Flask LogD assay LogD/LogP LogD/LogP assay LogD7.4 Shake Flask LogP/D SEED Project - Pistoia Alliance lipophilicity assay measuring pKa values pKa assay pKa measurement SEED Project - Pistoia Alliance pKa determination chemical stability SEED Project - Pistoia Alliance chemical stability assay stability-pH profile SEED Project - Pistoia Alliance pH stability assay GSH trapping GSH-adducts formation of GSH adduct formation of GSH adducts SEED Project - Pistoia Alliance GSH adduct formation thermodynamic (equilibrium) solubility thermodynamic solubility SEED Project - Pistoia Alliance thermodynamic solubility assay turbidimetric solubility SEED Project - Pistoia Alliance turbidimetric solubility assay kinome assay kinome panel kinome profiling kinome scannning kinome screen SEED Project - Pistoia Alliance kinome activity assay CRISPR CRISPR editing CRISPR-Cas9 CRISPR-Cas9 editing CRISPR-Cas9-mediated gene editing CRISPR/Cas9 CRISPR/Cas9 gene editing SEED Project - Pistoia Alliance CRISPR/Cas9 method cell binding SEED Project - Pistoia Alliance cell binding assay biological pathway assay pathway activity pathway assay pathway biology SEED Project - Pistoia Alliance signaling pathway assay protein expression assay SEED Project - Pistoia Alliance protein expression assay T cell - tumor cell co-culture assay T cell activation T cell proliferation assay T-cell functional activity T-cell proliferation tumor cell - T cell co-culture assay SEED Project - Pistoia Alliance T-cell activation assay mouse syngeneic mouse syngeneic tumor models syngeneic syngeneic model syngeneic models syngeneic mouse model syngeneic mouse tumor model syngeneic tumor models SEED Project - Pistoia Alliance syngeneic tumor model T-cell engraftment T-cell graft SEED Project - Pistoia Alliance T-cell engraftment PK/PD PK/PD analysis PK/PD assays PK/PD model PK/PD models PK/PD study pharmacokinetics and pharmacodynamics pharmacokinetics and pharmacodynamics study pharmacokinetics, pharmacodynamics pharmocokinetic/pharmocodynamic SEED Project - Pistoia Alliance in vivo PK/PD assay Dahl rat model Dahl rat models Dahl salt-sensitive (DSS) rat Dahl salt-sensitive rat SEED Project - Pistoia Alliance Dahl salt-sensitive rat model concentration response concentration response assay concentration response determination concentration response relationship SEED Project - Pistoia Alliance concentration response assay receptor occupancy assay target occupancy assay SEED Project - Pistoia Alliance target engagement assay delayed type hypersensitivity (DTH) in mice delayed-type hypersensitivity mouse model model of delayed type hypersensitivity SEED Project - Pistoia Alliance delayed-type hypersensitivity model thermofluor assay thermofluor studies thermofluor study SEED Project - Pistoia Alliance thermal shift assay T-cell cytotoxicity T-cell cytotoxicity mediated killing assay immune cell killing assay in vitro hepatocyte killing tumor cell killing SEED Project - Pistoia Alliance T-cell cytotoxicity assay CEREP CEREP profiling CEREP screen CEREP screening assay SEED Project - Pistoia Alliance CEREP assay biosensor assay SEED Project - Pistoia Alliance biosensor method Annexin V FITC apoptosis assay Annexin V FITC apoptosis detection Annexin V staining Annexin V-FITC FITC Annexin V apoptosis detection SEED Project - Pistoia Alliance Annexin V apoptosis assay Epitope Mapping SEED Project - Pistoia Alliance Epitope Mapping drug-protein equilibrium dialysis equilibrium dialysis equilibrium dialysis for protein binding protein binding equilibrium dialysis SEED Project - Pistoia Alliance equilibrium assay orthotopic model orthotopic mouse model orthotopic tumor models SEED Project - Pistoia Alliance orthotopic tumor model chemotaxis assay SEED Project - Pistoia Alliance chemotaxis assay biomarker assay biomarker assessment biomarker identification SEED Project - Pistoia Alliance PD biomarker assay MET and pMET immunoassay pMET immunoassay SEED Project - Pistoia Alliance MET immunoassay Poly(ADP-Ribose) assay Poly(ADP-Ribose) immunoassay SEED Project - Pistoia Alliance PAR Immunoassay γH2AX, pNBS1, and β-catenin γH2AX, pNBS1, and β-catenin immuno assay SEED Project - Pistoia Alliance γH2AX, pNBS1, and β-catenin Multiplex Immunofluorescence Assay Phosphorylated H2Ax Assay Total H2AX assay γH2Ax immunofluoresence assay SEED Project - Pistoia Alliance γH2Ax immunoassay HIF-1α assay Hypoxia Inducible Factor 1-alpha assay SEED Project - Pistoia Alliance HIF1-alpha assay TOP1 Immunoassay Topoisomerase I Immunoassay SEED Project - Pistoia Alliance Total Topoisomerase I assay DiscoverX G protein coupled receptor (GPCR)max pharmacology panel DiscoverX gpcrMAX assay GPCRmax pharmacology panel gpcrMAX SEED Project - Pistoia Alliance gpcrMAX℠ GPCR Assay Panel The effective concentration of an inhibitor, which produces 20% of the maximum possible response for that inhibitor. IC20 The effective concentration of an inhibitor, which produces 25% of the maximum possible response for that inhibitor. IC25 The effective concentration of an inhibitor, which produces 30% of the maximum possible response for that inhibitor. IC30 FPKM fragments per kilobase of exon per million mapped reads percent neurite outgrowth percent neurite count percent neurite branch point The concentration of compound required to kill 50% of a cell population (i.e., 50% inhibitory concentration in a cytotoxicity assay). Date from BAE: 6/22/2016 PubChem AID: 2649 TC50 50% Tissue Culture Infective Dose (TCID50) is the measure of infectious virus titer. This endpoint dilution assay quantifies the amount of virus required to kill 50% of infected hosts or to produce a cytopathic effect in 50% of inoculated tissue culture cells. Date from BAE: 7/21/2016 PubChem AID: 2024 TCID50 Any result reported as a simple binary assessment, such as 'active/ inactive', 'true/ false', etc. Date from BAE: 5/30/2016 PubChem AID: 449752 binary endpoint protein level true quantified endpoint metabaloid profile Cell Painting Profile epigenetic profile cell profile The Transfluor assay employs a a beta-arrestin-GFP fusion protein to detect activation of GPCRs: Upon ligand binding the GPCR, cytosolic arrestin-GFP quickly translocates to the cell membrane and then to endocytic vesicles, where it 'clusters' and can be detected by fluorescent image analysis. (Developed / commercialized by Norak, then Molecular Devices) beta-arrestin clustering assay The property values are divided by the average value for the positive control wells and multiplied by 100: X' = 100*(X/PosAvg) % positive control percent postive control perturbagen / positive control ratio endpoint Maximum induction effect (dimensionless) Emax The maximum observed fold increase. max fold increase Count of cells as an endpoint cell count A ratio endpoint is the relative relation between two quantitative results (a/b) ratio endpoint The ratio of the concentration of molecule in whole blood (i.e. contains both red blood cells and plasma) to the concentration of molecule in plasma, namely CB/CP. blood to plasma ratio Ratio of AC50 values AC50 Ratio A categorical endpoint is any result that can take one of a limited number of possible values. categorical endpoint GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 2200 GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 3000 CellWoRx HCS Reader Thermo Fisher Scientific www.cellomics.com CellInsight NXT HCS Platform Thermo Fisher Scientific Cellomics ArrayScan II HCS Reader Thermo Fisher Scientific Cellomics ArrayScan 3.1 HCS Reader Thermo Fisher Scientific Cellomics ArrayScan 4.0 HCS Reader Cellomics http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf KineticScan HCS Reader microscope optical microscope confocal microscope laser scanning confocal microscope spinning-disk confocal microscope laser capture microdissection microscope scanning force microscope wide-field microscope Automated patch clamp systems for ion channel research Date from BAE: 6/26/2016 PubChem AID: 2581 https://www.moleculardevices.com/systems/automated-electrophysiology IonWorks automated electrophysiology system (Molecular Devices) Assay development system (plate-reader) with four modes: fluorescence, luminescence, absorbance, and Epi-absorbance (Molecular Devices) Date from BAE: 6/25/2016 PubChem AID: 463184 Analyst AD (Molecular Devices) An instument for single-channel recoding and whole-cell voltage-clamp recording (Axon Instruments/ Molecular Devices) Date from BAE: 6/26/2016 PubChem AID: 504828 https://www.moleculardevices.com/systems/axon-conventional-patch-clamp/axopatch-200b-amplifier Axopatch 200B amplifier (Molecular Devices) The BD LSRII FACS is an air-cooled multi-laser benchtop flow cytometer. Date from BAE: 5/11/2016 PubChem AID: 652043 Becton Dickinson (BD) LSRII FACS The Synergy 2 Multi-Mode Plate Reader's (BioTek) detection modes include fluorescence intensity, fluorescence polarization, time-resolved fluorescence, AlphaScreen, luminescence and UV-visible absorbance. Date from BAE: 6/18/2016 PubChem AID: 652216 http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html Synergy 2 Multi-Mode Reader (BioTek) BMG PHERAstar is a multi-mode benchtop plate reader; FSX and other models (BMG Labtech) Date from BAE: 6/2/2016 PubChem AID: 435018 http://www.bmglabtech.com/en/products/pherastar-fsx/#tab-product-detail BMG PHERAstar FSX plate reader (BMG Labtech, Cary NC) An automated cell counting device: Countess; Countes II FL has fluorescence capabilites (Invitrogen/ ThermoFisher) Date from BAE: 6/1/2016 PubChem AID: 588370 https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-instruments/automated-cell-counters/countess-ii-fl-automated-cell-counter.html Countess automatic cell counter A flow cell_based benchtop cytometer (Becton Dickinson (BD)) Date from BAE: 6/24/2016 PubChem AID: 1758 FacSCAN flow cytometer A filter-based absorbance platereader for kinetic and endpoint assays (Molecualr Devices) Date from BAE: 6/22/2016 PubChem AID: 2649 https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers Molecular Devices Vmax plate reader Several models of UV-visible absorbance microplate readers: SpectraMax 190; SpectraMax Plus 384; SpectraMax 340PC384 (Molecular Devices) Date from BAE: 6/22/2016 PubChem AID: 504388 https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers Molecular Devices SpectraMax Plate reader Several models of automated patch clamp systems for studying ion channels: QPatch8, QPAtch16, QpatchHT (Biolin Scientific) Date from BAE: 5/13/2016 PubChem AID: 623915 http://www.biolinscientific.com/product/qpatch-88x/ Qpatch automated patch clamp system (Biolin) One of several models of a plate-based real-time PCR device (Roche ) Date from BAE: 6/15/2016 PubChem AID: 651770, 720492 https://lifescience.roche.com/shop/products/lightcycler14301-480-instrument-ii LightCycler 480 Real-Time PCR detection instrument The Agilent Mx3005P QPCR System, a benchtop RT-PCR plate reader, has been replaced with the AriaMx system (Agilent Technologies) Date from BAE: 6/7/2016 PubChem AID: 2427 http://www.genomics.agilent.com/en/Mx3005P-Mx3000P-qPCR-Instruments-Software/Mx3005P-qPCR-System/?cid=AG-PT-199&tabId=AG-PR-1127 Mx3005P RT-PCR instrument (Agilent Technologies) The Synergy HT (or HTX) is a Multi-Mode Plate Reader (BioTek) is a single-channel absorbance, fluorescence and luminescence microplate reader. Date from BAE: 6/25/2016 PubChem AID: 504653 http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html Synergy HT Multi-Mode Reader (BioTek) One of several models of luminometer, either single-tube to multiple plate readers (Promega). Some models are multimode and can also read fluorescence or absorbance in addition to luminescence ) Date from BAE: 6/1/2016 PubChem AID: 624302 GloMax luminometer (Promega) A mass spectrometer Date from BAE: 6/30/2016 PubChem AID: 602339 LTQ-Orbitrap Velos (Thermo Scientific) Encompasses various models--ABI-9300, ABI-7500, and QuantStudio. Date from BAE: 7/22/2016 PubChem AID: 540282 Appled Biosystems Real-Time PCR System (ThermoFisher) A mass spectrometer Date from BAE: 6/30/2016 PubChem AID: 602415 Agilent 1100 series LC-MSD SL Date from BAE: 7/4/2016 PubChem AID: 2692 VE-2 whole-cell patch clamp amplifier (Alembic Instruments) A microplate spectrophotometer Date from BAE: 7/10/2016 PubChem AID: 624061 micro-Quant Plate Reader (BioTek) Date from BAE: 7/11/2016 PubChem AID: 651896 SpectraMax Gemini XS microplate fluorometer (Molecular Devices) Date from BAE: 7/1/2016 PubChem AID: 602172 Typhoon FLA 9000 laser scanner (GE Healthcare) Date from BAE: 7/12/2016 PubChem AID: 720723 Fluoroskan Ascent FL Microplate Fluorometer and Luminometer (ThermoFisher) Date from BAE: 7/4/2016 PubChem AID: 2719 iMIC platform/ Polychrome V imaging system, (TILL Photonics/ FEI Munic GmbH) Date from BAE: 7/2/2016 PubChem AID: 602457 Infinte M200 plate reader (Tecan) Date from BAE: 7/12/2016 PubChem AID: 720722 Multiskan EX plate reader (Thermo Scientific) Date from BAE: 7/18/2016 PubChem AID: 1061 Wallac 1420 (Victor2) Microplate reader (PerkinElmer) Date from BAE: 7/20/2016 PubChem AID: 1745 SpectraFluor Plus Microplate Reader (Tecan) Date from BAE: 7/8/2016 PubChem AID: 602143 TSQ Quantum Triple Quadrupole LC-MS (Thermo Scientific) A laser-based scanner that produces digital images of radioactive, fluorescent, or chemiluminescent samples Date from BAE: 7/19/2016 PubChem AID: 623937 Typhoon Trio variable-mode imager (Amersham/ GE LifeSciences) Date from BAE: 7/15/2016 PubChem AID: 456 https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/1314742967685/litdoc28402704_20110831020220.pdf IN Cell Analyzer 1000 The xCELLigence RTCA DP instrument uses noninvasive electrical impedance monitoring to quantify cell proliferation, morphology change, and attachment quality in a label-free, real-time manner. Date from BAE: 7/22/2016 PubChem AID: 602291 http://www.aceabio.com/product/rtca-dp/ xCELLigence RTCA DP cellular impedance instrument (Acea Biosciences) Date from BAE: 9/30/2016 PubChem AID: 720665 BD FACSAria flow cytometer (BD Biosciences) One of several models of surface plasmon resonance (SPR) instruments. Date from BAE: 9/30/2016 PubChem AID: 651876 Biacore 3000 SPR System (GE Healthcare) Imaging system based on CCD high-resolution detection, supports multiple detection methods including fluorescence, colorimetry, densitometry, chemiluminescence, and chemifluorescence. Date from BAE: 9/30/2016 PubChem AID: 652251 ChemiDoc XRS Imaging System (BioRad) 9Date from BAE: /30/2016 PubChem AID: 720663 FACScalibur flow cytometer (BD Biosciences) Date from BAE: 9/30/2016 PubChem AID: 623961 FLUOstar Omega microplate reader (BMG Labtech) Date from BAE: 9/30/2016 PubChem AID: 623974 Pico patch clamp amplifier (Tecella) An imaging system for blots, gels, etc, to replace use of film; can be used for autoradiography, fluorescence, and chemifluorescence imaging. Date from BAE: 9/30/2016 PubChem AID: 2704 Storm PhosphorImager (Molecular Dynamics/ GE) Date from BAE: 9/30/2016 PubChem AID: 623970 Varioskan LUX multimode microplate reader (ThermoFisher) Velos-MS NGS Instrument Odyssey Plate Reader The Luminex 100/200 System is the combination of three core xMAP® Technologies. The first is xMAP microspheres, a family of fluorescently dyed micron-sized polystyrene microspheres that act as both the identifier and the solid surface to build the assay. The second is a flow cytometry-based instrument, the Luminex 100/200 analyzer, which integrates key xMAP detection components, such as lasers, optics, fluidics, and high-speed digital signal processors. The third component is the xPONENT® software, which is designed for protocol-based data acquisition with robust data regression analysis. From https://www.luminexcorp.com/research-luminex-100200/ Luminex 200 Flow Cytometer The Luminex 200 system is a compact analyzer that performs up to 100 immunoassays simultaneously using a single drop of fluid. Luminex 200 Flow Cytometer The FlexStation 3 Multi-Mode Microplate Reader measures absorbance, fluorescence intensity, fluorescence polarization, luminescence, and time-resolved fluorescence for biochemical and cell-based assays. The reader adds up to three transfers of assay reagents from a 96- or 384-well source plate to enhance assay design using integrated fluidics. FlexStation 3 FlexStation III Microplate Reader IN Cell Analyzer 2500HS is a widefield high-content imaging system equipped with deconvolution. IN Cell Analyzer 2500 IN Cell Analyzer 6500HS is a laser-based high-content imaging system featuring IRIS confocal technology. IN Cell Analyzer 6500 efo:EFO_0000001 An experimental factor in Array Express which are essentially the variable aspects of an experiment design which can be used to describe an experiment, or set of experiments, in an increasingly detailed manner. This upper level class is really used to give a root class from which applications can rely on and not be tied to upper ontology classses which do change. Helen Parkinson James Malone Jie Zheng Tomasz Adamusiak true Helen Parkinson James Malone Tomasz Adamusiak MO:10 ExperimentalFactor Concept naming convention is lower case natural naming with spaces, when necessary captials should be used, for example disease factor, HIV, breast carcinoma, Ewing's sarcoma experimental factor efo:EFO_0000246 3 days post planting A temporal measurement of the time period elapsed since an identifiable point in the life cycle of an organism. If a developmental stage is specified, the identifiable point would be the beginning of that stage. Otherwise the identifiable point must be specified such as planting (e.g. 3 days post planting). James Malone Jie Zheng Tomasz Adamusiak MO:467 NCIt:C25150 SNOMEDCT:397669002 age efo:EFO_0000287 A biopsy number is an information entity about the numerical label given to a partciular biopsy obtained. James Malone biopsy number efo:EFO_0000388 The measure of movement of electrical charges in a conductor measured in milliamperes. James Malone NCIt:C48434 Formerly class "current milliamperes" electrical current efo:EFO_0000391 by a caterpillar on a plant leaf A measurement of physical damage, e.g. by a caterpillar on a plant leaf James Malone damage intensity efo:EFO_0000399 A developmental stage is spatiotemporal region encompassing some part of the life cycle of an organism, e.g. blastula stage James Malone Jie Zheng Tomasz Adamusiak true MO:878 NCIt:C43531 development stage developmental_stage life cycle stage This branch will be replaced by, and if necessary merged with an Uberon import in future. developmental stage efo:EFO_0000409 A temporal measurement of the period after successful treatment in which there is no appearance of the symptoms or effects of the disease. James Malone true MeSH:D018572 Disease-Free Survival morbidity-free survival disease free survival efo:EFO_0000412 Is a temporal measure from a defined start point e.g. diagnosis, or treatment of the period to appearance of a distant metastasis. A distant metastasis refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes. Also known as distant cancer. Helen Parkinson http://www.cancer.gov/dictionary?cdrid=415317 event distant metastases time to development of distant metastases distant metastasis free survival efo:EFO_0000428 The total quantity or strength of a substance administered at one time. James Malone NCIt:C25488 dose efo:EFO_0000433 60 seconds duration of centrifugation A temporal measurement of the time between two specified points. James Malone Tomasz Adamusiak NCIt:C25330 NIFSTD:birnlex_2052 SNOMEDCT:103335007 duration efo:EFO_0000480 An event that has caused the permanent cessation of all vital functions; the end of life. Can be applied to a whole organism or to a part of an organism. James Malone true event death efo:EFO_0000482 Is the survival of a subject (or group of subjects) measured from the date of diagnosis until locoregional or systemic recurrence, second malignancy, or death from any cause or disease progression or relapse, institution of new unplanned anticancer treatment, or death from any cause. James Malone http://en.wikibooks.org/wiki/Radiation_Oncology/Survival_curve_terminology true event free survival time efo:EFO_0000487 exposure to cigarette smoke The act of subjecting someone or something to an influencing experience. E.g. exposure to cigarette smoke James Malone ICD10:Z58 NCIt:C17941 exposure efo:EFO_0000513 The total sum of the genetic information of an organism that is known and relevant to the experiment being performed, including chromosomal, plasmid, viral or other genetic material which has been introduced into the organism either prior to or during the experiment. James Malone Jie Zheng Tomasz Adamusiak MO:51 MeSH:D005838 NCIt:C16631 NIFSTD:birnlex_2023 Information, making the distinction between the actual physical material (e.g. a cell) and the information about the genetic content (genotype). genotype efo:EFO_0000627 The scalar number of injections administered to a material or organism. James Malone number of injections efo:EFO_0000633 A measurement of the effects of different investigators, laboratories, or organizations on experimental results are studied. James Malone MO:38 OperatorVariation operator variation efo:EFO_0000638 A measurement of the survival rate for a group of individuals suffering from a disease. James Malone true overall survival efo:EFO_0000648 James Malone period of infection efo:EFO_0000686 The probability that an event will occur generally with unfavorable outcome. James Malone risk status efo:EFO_0000689 James Malone Jie Zheng Tomasz Adamusiak true MO:866 sampling_time_point sampling time efo:EFO_0000714 Time of survival is an information entity which is about the length of time a material entity has survived after some adverse event, such as infection from a disease. James Malone true MeSH:D013534 NCIt:C17177 PERSON: James Malone SNOMEDCT:445320007 survival time of survival survival time efo:EFO_0000718 The temperature that a material is exposed to. James Malone exposure temperature efo:EFO_0000719 The life of an organism, a surgical operation as processual context for a nosocomical infection, the spatiotemporal context occupied by a process of cellular meiosis, the spatiotemporal region occupied by the development of a cancer tumor. A temporal entity is an entity that has temporal parts and that happens, unfolds or develops through time. An occurrent is something which exists over time, rather than existing completely at many times James Malone temporal measurement efo:EFO_0000721 James Malone MeSH:D013995 NCIt:C25207 SNOMEDCT:410669006 SNOMEDCT:410670007 SNOMEDCT:900000000000475002 time efo:EFO_0000724 Time point at which a sample or observation is made or taken from a biomaterial as measured from some reference point. James Malone Jie Zheng Tomasz Adamusiak MO:738 NCIt:C68568 timepoint efo:EFO_0001080 A 267b1 ki ras is a cell line. A 267b1 ki ras derives from a prostate. James Malone Natural Language Generator 8th April 2010 267B1 efo:EFO_0001081 James Malone 267B1 Ki-ras efo:EFO_0001082 James Malone 293T efo:EFO_0001083 James Malone 293TsiLL efo:EFO_0001084 James Malone https://www.atcc.org/products/all/CL-173.aspx 3T3-L1 efo:EFO_0001085 James Malone 600MPE efo:EFO_0001087 James Malone AU565 efo:EFO_0001089 James Malone Beas2B BEAS-2B efo:EFO_0001090 James Malone BJABK3 efo:EFO_0001091 James Malone BL41K3 efo:EFO_0001092 A cell line derived from epithelial cells of human breast carcinoma. James Malone Natural Language Generator 8th April 2010 BT20 efo:EFO_0001093 James Malone BT474 efo:EFO_0001095 James Malone BT483 efo:EFO_0001096 James Malone BT549 efo:EFO_0001098 James Malone https://www.atcc.org/Products/All/CRL-1772.aspx C2C12 efo:EFO_0001099 James Malone Caco2 Caco-2 efo:EFO_0001100 James Malone CAMA1 efo:EFO_0001101 James Malone CC531 efo:EFO_0001102 James Malone CFT-2 efo:EFO_0001103 James Malone CSBwt-rescued fibroblasts efo:EFO_0001107 James Malone GM06985 efo:EFO_0001108 James Malone GM06993 efo:EFO_0001109 James Malone GM06994 efo:EFO_0001110 James Malone GM07000 efo:EFO_0001111 James Malone GM07022 efo:EFO_0001112 James Malone GM07034 efo:EFO_0001113 James Malone GM07055 efo:EFO_0001114 James Malone GM07056 efo:EFO_0001115 James Malone GM07345 efo:EFO_0001116 James Malone GM07357 efo:EFO_0001117 James Malone GM11829 efo:EFO_0001118 James Malone GM11830 efo:EFO_0001119 James Malone GM11831 efo:EFO_0001120 James Malone GM11832 efo:EFO_0001121 James Malone GM11839 efo:EFO_0001122 James Malone GM11881 efo:EFO_0001123 James Malone GM11882 efo:EFO_0001124 James Malone true GM11992 efo:EFO_0001125 James Malone GM11993 efo:EFO_0001126 James Malone GM11994 efo:EFO_0001127 James Malone GM11995 efo:EFO_0001128 James Malone GM12003 efo:EFO_0001129 James Malone GM12004 efo:EFO_0001130 James Malone GM12005 efo:EFO_0001131 James Malone GM12006 efo:EFO_0001132 James Malone GM12043 efo:EFO_0001133 James Malone GM12044 efo:EFO_0001134 James Malone GM12056 efo:EFO_0001135 James Malone GM12057 efo:EFO_0001136 James Malone GM12144 efo:EFO_0001137 James Malone GM12145 efo:EFO_0001138 James Malone GM12146 efo:EFO_0001139 James Malone GM12154 efo:EFO_0001140 James Malone GM12155 efo:EFO_0001141 James Malone GM12156 efo:EFO_0001142 James Malone GM12234 efo:EFO_0001143 James Malone GM12236 efo:EFO_0001144 James Malone GM12239 efo:EFO_0001145 James Malone GM12248 efo:EFO_0001146 James Malone GM12249 efo:EFO_0001147 James Malone GM12716 efo:EFO_0001148 James Malone GM12717 efo:EFO_0001149 A lymphoblastoid cell line derived from CEPH/UTAH PEDIGREE 1444. James Malone GM12750 efo:EFO_0001150 James Malone GM12751 efo:EFO_0001151 James Malone GM12760 efo:EFO_0001152 James Malone GM12761 efo:EFO_0001153 James Malone GM12762 efo:EFO_0001154 James Malone GM12763 efo:EFO_0001155 James Malone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12812&product=CC GM12812 efo:EFO_0001156 James Malone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12813&Product=CC GM12813 efo:EFO_0001157 James Malone GM12814 efo:EFO_0001158 James Malone GM12815 efo:EFO_0001159 James Malone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12872&Product=CC GM12872 efo:EFO_0001160 James Malone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12873&Product=CC GM12873 efo:EFO_0001161 James Malone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12874&Product=CC GM12874 efo:EFO_0001162 James Malone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12875&Product=CC GM12875 efo:EFO_0001166 James Malone H720 efo:EFO_0001167 James Malone HBL100 efo:EFO_0001168 A cell line derived from epithelial cells of human breast carcinoma. James Malone Natural Language Generator 8th April 2010 HCC-1007 HCC1007 efo:EFO_0001169 James Malone HCC-1143 HCC1143 efo:EFO_0001170 James Malone HCC-1187 HCC1187 efo:EFO_0001171 James Malone HCC-1428 HCC1428 efo:EFO_0001172 James Malone HCC-1500 HCC1500 efo:EFO_0001173 James Malone HCC-1569 HCC1569 efo:EFO_0001174 James Malone HCC-1937 HCC1937 efo:EFO_0001175 James Malone HCC-1954 HCC1954 efo:EFO_0001176 James Malone HCC-202 HCC202 efo:EFO_0001177 James Malone HCC-2157 HCC2157 efo:EFO_0001178 James Malone HCC-2185 HCC2185 efo:EFO_0001179 James Malone HCC-3153 HCC3153 efo:EFO_0001180 James Malone HCC-38 HCC38 efo:EFO_0001181 James Malone HCC-70 HCC70 efo:EFO_0001182 James Malone BTO:0000007 MCC:0000006 human embryonic kidney cell HEK293 efo:EFO_0001183 James Malone HEK-293H efo:EFO_0001184 James Malone HEK293T efo:EFO_0001185 A cell line derived from epithelial cells of human cervical carcinoma. James Malone Natural Language Generator 8th April 2010 BTO:0000567 NCIt:C20226 HeLa efo:EFO_0001186 James Malone HepaRG efo:EFO_0001187 James Malone Hep-G2 HepG2 cell HepG2 efo:EFO_0001188 James Malone HMEC efo:EFO_0001189 James Malone HMEC S1 efo:EFO_0001190 James Malone HMEC184 efo:EFO_0001191 James Malone HMT3522S1 efo:EFO_0001192 James Malone HS578T efo:EFO_0001193 James Malone HT-29 efo:EFO_0001194 James Malone IB3-1 efo:EFO_0001195 A cell line derived from vertebrate neuroblastoma. James Malone Natural Language Generator 8th April 2010 IMR-32 efo:EFO_0001196 Human Fetal Lung Fibroblast cell line James Malone IMR90 IMR-90 efo:EFO_0001197 James Malone Kin-S49 efo:EFO_0001198 James Malone L3055 efo:EFO_0001199 A cell line derived from epithelial cells of a breast carcinoma. James Malone Natural Language Generator 8th April 2010 LY2 efo:EFO_0001200 James Malone MCF 10A efo:EFO_0001202 James Malone MCF12A efo:EFO_0001203 Human breast adenocarcinoma, established from the pleural effusion of a 69-year-old caucasian woman with metastatic mammary carcinoma (after radio- and hormone therapy) in 1970; cells were described of being positive for cytoplasmic estrogen receptors and having the capability to form domes. James Malone BTO:0000093 MCC:0000307 NCIt:C18096 MCF-7 cell MCF7 MCF7 cell MCF-7 efo:EFO_0001205 James Malone MDA-MB-134VI MDAMB134VI efo:EFO_0001206 James Malone MDA-MB-157 MDAMB-157 MDAMB157 efo:EFO_0001208 James Malone MDA-MB-175VII MDAMB175VII efo:EFO_0001209 James Malone MDA-MB-231 MDAMB231 efo:EFO_0001211 James Malone MDA-MB-361 MDAMB361 efo:EFO_0001212 James Malone MDA-MB-415 MDAMB415 efo:EFO_0001213 James Malone NCIt:C117184 MDA-MB-435 Was originally considered to be a breast cancer cell line but has since been identified as a melanoma cell line. MDAMB435 efo:EFO_0001214 James Malone MDA-MB-436 MDAMB436 efo:EFO_0001215 James Malone MDA-MB-453 MDAMB453 efo:EFO_0001216 James Malone NCIt:C117224 MDA-MB-468 MDAMB468 efo:EFO_0001218 James Malone Met5A efo:EFO_0001219 James Malone MM1 efo:EFO_0001220 James Malone NCIt:C117119 MOLT4 MOLT-4 efo:EFO_0001221 A cell line derived from bone marrow multiple myeloma B cells. James Malone Natural Language Generator 8th April 2010 NCI-H929 efo:EFO_0001222 James Malone https://www.atcc.org/products/all/CRL-1658.aspx CLO:0008172 NIH-3T3 NIH/3T3 NIH3T3 efo:EFO_0001223 James Malone NIH3T3-L1 efo:EFO_0001224 James Malone PAC2 efo:EFO_0001225 James Malone PC12 efo:EFO_0001226 James Malone R18 efo:EFO_0001227 James Malone R28 efo:EFO_0001228 James Malone R43 efo:EFO_0001229 James Malone R46 efo:EFO_0001230 James Malone R8 efo:EFO_0001231 James Malone RAW264.7 efo:EFO_0001232 James Malone RKO efo:EFO_0001233 Insect - fruitfly (Drosophila melanogaster) cell line, established from the late embryo of a Drosophila melanogaster (fruitfly) in 1972; originally the cells were diploid with 5-10% XY, currently the cell line has only XX cells that are now 60-80% tetraploid. James Malone BTO:0001677 NCIt:C111071 S-2 cell S2 cell SCHNEIDER S2 Cell SCHNEIDER-2 cell SL2 SL2 cell Schneider Schneider cell Schneider's Line S2 cell S2 efo:EFO_0001234 James Malone SchneiderSL2 S49 efo:EFO_0001236 A cell line derived from epithelial cells of human breast carcinoma. James Malone Natural Language Generator 8th April 2010 SKBR3 efo:EFO_0001237 James Malone SKGT4 efo:EFO_0001239 James Malone SUM1315MO2 efo:EFO_0001240 James Malone Sirarat Sarntivijai PMID:10604729 PMID:10718481 SUM 149 SUM 149PT SUM-149 SUM-149PT SUM149 SUM149PT efo:EFO_0001241 James Malone Sirarat Sarntivijai PMID:10604729 PMID:10718481 SUM 159 SUM 159PT SUM-159 SUM-159PT SUM159 SUM159PT efo:EFO_0001242 James Malone Sirarat Sarntivijai PMID:10604729 PMID:10718481 SUM 185 SUM 185PE SUM-185 SUM-185PE SUM185 SUM185PE efo:EFO_0001243 James Malone Sirarat Sarntivijai PMID:10604729 PMID:10718481 SUM 190 SUM 190PT SUM-190 SUM-190PT SUM190 SUM190PT efo:EFO_0001244 James Malone Sirarat Sarntivijai PMID:10604729 PMID:10718481 SUM 225 SUM 225CWN SUM-225 SUM-225CWN SUM225 SUM225CWN efo:EFO_0001245 James Malone Sirarat Sarntivijai PMID:10604729 PMID:10718481 SUM 44 SUM 44PE SUM-44 SUM-44PE SUM44 SUM44PE efo:EFO_0001246 James Malone Sirarat Sarntivijai PMID:10604729 PMID:10718481 SUM 52 SUM 52PE SUM-52 SUM-52PE SUM52 SUM52PE efo:EFO_0001247 James Malone T47D efo:EFO_0001249 A TERV is a cell line. A TERV derives from a kidney. James Malone Natural Language Generator 8th April 2010 TERV efo:EFO_0001250 James Malone TERV-AntiSenseB56 efo:EFO_0001251 James Malone TERV-ST efo:EFO_0001252 James Malone TERV-ST110 efo:EFO_0001253 A human cell line derived from peripheral blood monocytes. The patient was a 1-year-old male infant with acute monocytic leukemia. James Malone https://www.atcc.org/products/all/TIB-202.aspx THP1 THP-1 efo:EFO_0001254 James Malone U-266 U266B1 U266 efo:EFO_0001255 James Malone U373 efo:EFO_0001257 James Malone U937 efo:EFO_0001258 James Malone UACC812 efo:EFO_0001259 James Malone An organ of corti derived cell line UBOC-1 UBOC1 efo:EFO_0001260 James Malone WI38 efo:EFO_0001261 James Malone ZF4 efo:EFO_0001262 James Malone ZR751 efo:EFO_0001263 James Malone ZR7530 efo:EFO_0001264 James Malone ZR75B efo:EFO_0001272 A maturity quality inhering in an individual by virtue of the individual having attained sexual maturity and full growth James Malone OntologyMappingImporter following MAT:0000403 Tomasz Adamusiak EV:0300070 EVM:2990028 FBdv:00005369 MAT:0000403 MeSH:D000328 NCIt:C17600 NIFSTD:birnlex_228 NIFSTD:birnlex_681 SNOMEDCT:133936004 WBls:0000041 XAO:1000009 adult stage adult efo:EFO_0001444 A measurement is an information entity that is a recording of the output of a measurement such as produced by an instrument. James Malone Jie Zheng Tomasz Adamusiak true MO:144 NCIt:C25209 NIFSTD:sao279801585 SNOMEDCT:122869004 measurement efo:EFO_0001639 A cancer cell line is defined as something that is bearer of a cancer. A cancer cell line is a cell line. James Malone Natural Language Generator 8th April 2010 cancer cell line efo:EFO_0001640 B cell derived cell line efo:EFO_0001641 An epithelial cell derived cell line is defined as something that derives from an epithelial cell. James Malone Natural Language Generator 8th April 2010 epithelial cell derived cell line efo:EFO_0001643 kidney derived cell line efo:EFO_0001667 James Malone atcc:CRL-2265 CEM-c1 CEM/C1 efo:EFO_0002009 fibroblast derived cell line efo:EFO_0002032 An Ara-C-resistant murine leukemia is a cell line. A b117h, and a b140h are kinds of Ara-C-resistant murine leukemias. James Malone Natural Language Generator 8th April 2010 Ara-C-resistant murine leukemia efo:EFO_0002033 Ara-C-sensitive parental cell line efo:EFO_0002034 A GATA-1-null erythroblast is a cell line. A g1e er4 is a GATA-1-null erythroblast. Natural Language Generator 8th April 2010 PMID:12832487 GATA-1-null erythroblast cell line G1E efo:EFO_0002035 murine neuroblastoma cholinergic cell line efo:EFO_0002037 Ele Holloway James Malone 4T1 efo:EFO_0002038 Ele Holloway James Malone 66cl4 efo:EFO_0002039 Ele Holloway James Malone 67NR efo:EFO_0002040 A b117h is an ara c resistant murine leukemia. Ele Holloway James Malone Natural Language Generator 8th April 2010 B117H efo:EFO_0002041 Ele Holloway James Malone B117P efo:EFO_0002042 AB140H is an Ara-C-resistant murine leukemia. Ele Holloway James Malone Natural Language Generator 8th April 2010 B140H efo:EFO_0002043 Ele Holloway James Malone B140P efo:EFO_0002044 Ele Holloway James Malone BC1 BC-1 efo:EFO_0002045 Ele Holloway James Malone BC-2 efo:EFO_0002046 Ele Holloway James Malone BC-3 efo:EFO_0002047 Ele Holloway James Malone BC-5 efo:EFO_0002048 Ele Holloway James Malone BCBL-1 efo:EFO_0002049 Ele Holloway James Malone BCKN-1 efo:EFO_0002050 Ele Holloway James Malone BeWo efo:EFO_0002051 Ele Holloway James Malone D4 D4 glioblastoma derived primary cell line efo:EFO_0002052 Ele Holloway James Malone EcR-RKO/KLF4 efo:EFO_0002053 Ele Holloway James Malone F9 Mouse cell line F9 mouse embryonal carcinoma cell line efo:EFO_0002054 Ele Holloway James Malone Fu97 efo:EFO_0002055 A g1e er4 is a GATA-1-null erythroblast. Ele Holloway James Malone Natural Language Generator 8th April 2010 PMID:12832487 G1E-ER4 efo:EFO_0002056 Ele Holloway James Malone HaCaT efo:EFO_0002057 Ele Holloway James Malone HCC-1008 HCC1008 efo:EFO_0002059 Ele Holloway James Malone https://www.atcc.org/Products/All/CCL-121.aspx HT1080 efo:EFO_0002060 Ele Holloway James Malone IBL4 efo:EFO_0002061 Ele Holloway James Malone ITM efo:EFO_0002062 Ele Holloway James Malone ITM-E6E7 efo:EFO_0002063 Ele Holloway James Malone ITM-E6E7-ST efo:EFO_0002064 Ele Holloway James Malone ITM-ST efo:EFO_0002065 Ele Holloway James Malone ITV efo:EFO_0002066 Ele Holloway James Malone JEG3 efo:EFO_0002067 Human chronic myeloid leukemia in blast crisis established from the pleural effusion of a 53-year-old woman with chronic myeloid leukemia (CML) in blast crisis in 1970; cells can be used as highly sensitive targets in in-vitro natural killer assays; cells produce hemoglobin; cells carry the Philadelphia chromosome with a b3-a2 fusion gene. Ele Holloway James Malone https://www.sigmaaldrich.com/catalog/product/sigma/cb_89121407?lang=en&region=US&gclid=EAIaIQobChMIjriUsZWq3wIVEh6tBh01pwF_EAAYASAAEgLhBPD_BwE BTO:0000664 NCIt:C19437 K-562 K-562 cell K562 cell K562 efo:EFO_0002068 A Kc is a cell line. A Kc derives from a drosophila melanogaster. Ele Holloway James Malone Natural Language Generator 8th April 2010 Kc efo:EFO_0002069 A cell line derived from human neuroblastoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 KELLY efo:EFO_0002070 A cell line derived from murine pituitary gland. Ele Holloway James Malone Natural Language Generator 8th April 2010 MCC:0000292 LbetaT2 efo:EFO_0002071 Human prostate carcinoma, established from the left supraclavicular lymph node metastasis from a 50-year-old man with prostate carcinoma in 1977; cells were described to be androgen-sensitive. Ele Holloway James Malone BTO:0001321 MCC:0000290 LNCAP cell LNCAP efo:EFO_0002072 Ele Holloway James Malone MCF-7aro efo:EFO_0002073 Ele Holloway James Malone MCC:0000500 mIMCD3 mIMCD-3 efo:EFO_0002074 Human prostate carcinoma cell line; established from the bone marrow metastasis isolated post-mortem from a 62-year-old Caucasian man with grade IV prostate cancer, poorly differentiated adenocarcinoma, after androgen suppression therapy; described to form tumors in nude mice, to grow in soft agar, and to be unresponsive to androgen treatment. Ele Holloway James Malone BTO:0001061 MCC:0000380 NCIt:C117219 SNOMEDCT:272976006 https://www.atcc.org/products/all/CRL-1435.aspx PC-3 cell PC3 PC3 cell PC-3 efo:EFO_0002075 PEL-5 is a human primary effusion lymphoma cell line Ele Holloway James Malone PEL-5 efo:EFO_0002076 R1 is a mouse embryonic stem cell line. Ele Holloway James Malone R1 efo:EFO_0002077 Ramos cell line is an EBV-negative, HLA class 1 positive B-lymphoblastoid cell line derived from a Burkitt lymphoma Ele Holloway James Malone Ramos efo:EFO_0002078 Ele Holloway James Malone https://dgrc.bio.indiana.edu/product/View?product=9 NCIt:C111070 S1 efo:EFO_0002079 Ele Holloway James Malone NCIt:C117188 SK-MEL-2 efo:EFO_0002081 Ele Holloway James Malone SN56.B5.G4 efo:EFO_0002083 Ele Holloway James Malone https://www.atcc.org/Products/All/CCL-228.aspx SW480 efo:EFO_0002084 Ele Holloway James Malone T84 efo:EFO_0002085 Human, Caucasian, glioblastoma cell line. Ele Holloway James Malone BTO:0001583 MCC:0000457 T-98G cell T98G cell T98G efo:EFO_0002086 TIVE is a human cell line. Ele Holloway James Malone TIVE efo:EFO_0002094 Ele Holloway James Malone 1A2 efo:EFO_0002095 A cell line derived from human prostate carcinoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 22Rv1 efo:EFO_0002096 Ele Holloway James Malone 5637 efo:EFO_0002097 Ele Holloway James Malone 639V efo:EFO_0002098 Ele Holloway James Malone 647V efo:EFO_0002099 Ele Holloway James Malone 769P efo:EFO_0002100 A cell line derived from human skin melanoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 A101D efo:EFO_0002101 Ele Holloway James Malone A172 efo:EFO_0002102 Ele Holloway James Malone A204 efo:EFO_0002103 Ele Holloway James Malone A375 efo:EFO_0002104 Ele Holloway James Malone A427 efo:EFO_0002105 Ele Holloway James Malone NCIt:C117212 A498 efo:EFO_0002106 Ele Holloway James Malone A673 efo:EFO_0002107 Ele Holloway James Malone A7 efo:EFO_0002108 Ele Holloway James Malone NCIt:C117213 ACHN efo:EFO_0002109 Ele Holloway James Malone AGS efo:EFO_0002110 Ele Holloway James Malone AN3CA efo:EFO_0002111 A cell line derived from a lymphatic system plasma cell neoplasm. Ele Holloway James Malone Natural Language Generator 8th April 2010 ARH77 efo:EFO_0002112 Ele Holloway James Malone AsPC1 efo:EFO_0002113 A cell line derived from human acute myeloid leukemia. Ele Holloway James Malone Natural Language Generator 8th April 2010 BDCM efo:EFO_0002115 Ele Holloway James Malone BFTC905 efo:EFO_0002116 Ele Holloway James Malone BHT101 efo:EFO_0002117 A cell line derived from human prostate carcinoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 BM1604 efo:EFO_0002118 Ele Holloway James Malone BV173 efo:EFO_0002119 Ele Holloway James Malone C32TG efo:EFO_0002120 Ele Holloway James Malone C33A efo:EFO_0002121 Ele Holloway James Malone C3A efo:EFO_0002122 Ele Holloway James Malone C4I efo:EFO_0002123 Ele Holloway James Malone C4II efo:EFO_0002124 Ele Holloway James Malone CA46 efo:EFO_0002125 Ele Holloway James Malone CAL-54 CAL54 efo:EFO_0002126 Ele Holloway James Malone CAL-62 CAL62 efo:EFO_0002127 Ele Holloway James Malone CCFSTTG1 efo:EFO_0002128 Ele Holloway James Malone CCRFCEM efo:EFO_0002130 Ele Holloway James Malone CESS efo:EFO_0002131 Ele Holloway James Malone CGTHW1 efo:EFO_0002132 Ele Holloway James Malone CHL1 efo:EFO_0002133 Ele Holloway James Malone CHP212 efo:EFO_0002134 Ele Holloway James Malone CMLT1 efo:EFO_0002135 Ele Holloway James Malone COLO201 efo:EFO_0002136 Ele Holloway James Malone COLO320DM efo:EFO_0002137 Ele Holloway James Malone COLO320HSR efo:EFO_0002138 Ele Holloway James Malone COLO668 efo:EFO_0002139 Ele Holloway James Malone COLO-704 COLO704 efo:EFO_0002140 Ele Holloway James Malone COLO-829 COLO829 efo:EFO_0002141 Ele Holloway James Malone CORL-105 CORL105 efo:EFO_0002142 Ele Holloway James Malone CORL-23 CORL23 efo:EFO_0002143 Ele Holloway James Malone CORL279 efo:EFO_0002144 Ele Holloway James Malone CORL88 efo:EFO_0002145 Ele Holloway James Malone CROAP-2 CROAP2 efo:EFO_0002146 Ele Holloway James Malone CROAP-5 CROAP5 efo:EFO_0002147 Ele Holloway James Malone CaHPV10 efo:EFO_0002148 Ele Holloway James Malone CaOv3 efo:EFO_0002149 Ele Holloway James Malone NCIt:C117214 Caki-1 Caki1 efo:EFO_0002150 Ele Holloway James Malone https://www.atcc.org/Products/All/HTB-47.aspx Caki-2 Caki2 efo:EFO_0002151 Ele Holloway James Malone Calu-1 Calu1 efo:EFO_0002152 Ele Holloway James Malone Calu-6 Calu6 efo:EFO_0002153 Ele Holloway James Malone Capan-1 Capan1 efo:EFO_0002154 Ele Holloway James Malone Capan-2 Capan2 efo:EFO_0002155 Ele Holloway James Malone ChaGoK1 efo:EFO_0002156 Ele Holloway James Malone HTB-185 D283Med efo:EFO_0002157 Ele Holloway James Malone https://www.atcc.org/en/Products/Cells_and_Microorganisms/By_Tissue/Brain/HTB-187.aspx D341Med efo:EFO_0002158 Ele Holloway James Malone SNOMEDCT:259042002 DB efo:EFO_0002159 DBTRG-05MG James Malone DBTRG05MG efo:EFO_0002160 Ele Holloway James Malone DG75 efo:EFO_0002161 Ele Holloway James Malone DKMG efo:EFO_0002162 Ele Holloway James Malone DMS 114 DMS114 efo:EFO_0002163 Ele Holloway James Malone DMS153 efo:EFO_0002164 Ele Holloway James Malone DMS273 efo:EFO_0002165 Ele Holloway James Malone DMS-53 DMS53 efo:EFO_0002166 Ele Holloway James Malone DMS-79 DMS79 efo:EFO_0002167 Ele Holloway James Malone https://www.dsmz.de/catalogues/details/culture/ACC-47.html DOHH2 efo:EFO_0002168 Ele Holloway James Malone DU4475 efo:EFO_0002169 A Daudi Burkitt's lymphoma cell line is a cell line. A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymphoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 Daudi efo:EFO_0002170 Ele Holloway James Malone Detroit 562 Detroit562 efo:EFO_0002171 Ele Holloway James Malone DoTc2 4510 DoTc2 efo:EFO_0002172 Ele Holloway James Malone EB1 efo:EFO_0002173 Ele Holloway James Malone EB2 efo:EFO_0002174 Ele Holloway James Malone EB3 efo:EFO_0002175 Ele Holloway James Malone EMF-19 EFM19 efo:EFO_0002176 Ele Holloway James Malone EM-2 EM2 efo:EFO_0002177 Ele Holloway James Malone ES2 efo:EFO_0002178 Ele Holloway James Malone Cell line derived from squamous cell carcinoma of the hypopharynx. FaDu efo:EFO_0002179 A human cell line derived from a pediatric patient initially classified as Wilm's tumor, reclassified as deriving from a rhabdoid tumor of the kidney. Ele Holloway James Malone https://www.atcc.org/Products/All/CRL-1441.aspx G-401 G401 efo:EFO_0002180 A human cell line derived from some renal leiomyeloblastoma Ele Holloway James Malone G402 efo:EFO_0002181 Ele Holloway James Malone GA10 efo:EFO_0002182 A Giant Cell Tumor (GCT) cell line derived from a human fibrous histiocytoma lung metastasis Ele Holloway James Malone GCT efo:EFO_0002183 A cell line derived from a human patient with Philadelphia chromosome negative myeloproliferative disorder, after transformation to acute myelomonoblastic leukemia.http://www.ncbi.nlm.nih.gov/pubmed/6296552 Ele Holloway James Malone GDM 1 GDM1 efo:EFO_0002184 A cell line of epithelial morphology derived from adult human brain. Ele Holloway James Malone https://www.atcc.org/products/all/HTB-148.aspx#generalinformation H4 efo:EFO_0002185 Ele Holloway James Malone HCC-1395 HCC1395 efo:EFO_0002186 Ele Holloway James Malone HCC-1599 HCC1599 efo:EFO_0002187 Ele Holloway James Malone HCC-2218 HCC2218 efo:EFO_0002188 Ele Holloway James Malone NCIt:C117163 HCT-15 HCT15 efo:EFO_0002189 Ele Holloway James Malone HCT-8 HCT8 efo:EFO_0002190 Ele Holloway James Malone HDMYZ efo:EFO_0002191 Ele Holloway James Malone HEC-1A HEC1A efo:EFO_0002192 Ele Holloway James Malone HEC-1-B HEC1B efo:EFO_0002193 Ele Holloway James Malone HEL9217 efo:EFO_0002194 Ele Holloway James Malone HH efo:EFO_0002195 Ele Holloway James Malone HMCB efo:EFO_0002196 Ele Holloway James Malone HOS efo:EFO_0002197 Ele Holloway James Malone HPAC efo:EFO_0002198 Ele Holloway James Malone HPAFII efo:EFO_0002199 Ele Holloway James Malone HSSultan efo:EFO_0002200 Ele Holloway James Malone HT efo:EFO_0002202 Ele Holloway James Malone HT-1197 HT1197 efo:EFO_0002203 Ele Holloway James Malone HT-1376 HT1376 efo:EFO_0002204 Ele Holloway James Malone SNOMEDCT:272850005 HT-3 HT3 efo:EFO_0002205 Ele Holloway James Malone Hep-3B Hep3B efo:EFO_0002207 Ele Holloway James Malone HuNS-1 HuNS1 efo:EFO_0002208 Ele Holloway James Malone HuPT4 efo:EFO_0002209 Ele Holloway James Malone HuT78 efo:EFO_0002210 Ele Holloway James Malone J82 efo:EFO_0002211 Ele Holloway James Malone NCIt:C43195 SNOMEDCT:705586008 JAR efo:EFO_0002212 Ele Holloway James Malone JM1 efo:EFO_0002213 Ele Holloway James Malone JRT3T35 efo:EFO_0002214 Ele Holloway James Malone JVM3 efo:EFO_0002215 A Jiyoye is a cell line. A Jiyoye is bearer of a Burkitt's lymphoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 Jiyoye efo:EFO_0002217 Ele Holloway James Malone KATOIII efo:EFO_0002218 Ele Holloway James Malone KG1 efo:EFO_0002219 Ele Holloway James Malone KHOS240S efo:EFO_0002220 Ele Holloway James Malone KLE efo:EFO_0002221 Ele Holloway James Malone KPL1 efo:EFO_0002222 Ele Holloway James Malone KU812 efo:EFO_0002223 Ele Holloway James Malone KYSE30 efo:EFO_0002224 Ele Holloway James Malone Kasumi2 efo:EFO_0002225 Ele Holloway James Malone L428 efo:EFO_0002226 Ele Holloway James Malone LS1034 efo:EFO_0002227 Ele Holloway James Malone LS174T efo:EFO_0002228 Ele Holloway James Malone MC116 efo:EFO_0002229 Ele Holloway James Malone MCCAR efo:EFO_0002230 Ele Holloway James Malone MCIXC efo:EFO_0002231 Ele Holloway James Malone MEC1 efo:EFO_0002232 Ele Holloway James Malone MEG01 efo:EFO_0002233 Ele Holloway James Malone MESSA efo:EFO_0002234 Ele Holloway James Malone MG63 efo:EFO_0002235 Ele Holloway James Malone MHHPREB1 efo:EFO_0002236 Ele Holloway James Malone MIA Paca-2 efo:EFO_0002237 Ele Holloway James Malone SNOMEDCT:258787002 MJ efo:EFO_0002238 Ele Holloway James Malone ML2 efo:EFO_0002239 Ele Holloway James Malone MOLT16 efo:EFO_0002241 Ele Holloway James Malone MT3 efo:EFO_0002242 Ele Holloway James Malone MV4II efo:EFO_0002243 Ele Holloway James Malone Malme3M efo:EFO_0002244 Ele Holloway James Malone NALM1 efo:EFO_0002245 Ele Holloway James Malone NALM6 efo:EFO_0002246 Ele Holloway James Malone https://www.atcc.org/products/all/CRL-1432.aspx#generalinformation https://www.sigmaaldrich.com/catalog/product/sigma/cb_87060801?lang=en&region=US&gclid=EAIaIQobChMIjPy10Jiq3wIVcyCtBh1y0wk_EAMYASAAEgLz8fD_BwE NAMALWA efo:EFO_0002247 Ele Holloway James Malone NC37 efo:EFO_0002248 Ele Holloway James Malone NCI-H1048 efo:EFO_0002249 Ele Holloway James Malone NCI-H1092 efo:EFO_0002250 Ele Holloway James Malone NCI-H1155 efo:EFO_0002251 Ele Holloway James Malone NCI-H1355 efo:EFO_0002252 Ele Holloway James Malone NCI-H1395 efo:EFO_0002253 Ele Holloway James Malone NCI-H1436 efo:EFO_0002254 Ele Holloway James Malone NCI-H1437 efo:EFO_0002255 Ele Holloway James Malone NCI-H1563 efo:EFO_0002256 Ele Holloway James Malone NCI-H1573 efo:EFO_0002257 Ele Holloway James Malone NCI-H1581 efo:EFO_0002258 Ele Holloway James Malone NCI-H1618 efo:EFO_0002259 Ele Holloway James Malone NCI-H1623 efo:EFO_0002260 Ele Holloway James Malone NCI-H1650 efo:EFO_0002261 Ele Holloway James Malone NCI-H1651 efo:EFO_0002262 Ele Holloway James Malone NCI-H1666 efo:EFO_0002263 Ele Holloway James Malone NCI-H1694 efo:EFO_0002264 Ele Holloway James Malone NCI-H1703 efo:EFO_0002265 Ele Holloway James Malone NCI-H1770 efo:EFO_0002266 Ele Holloway James Malone NCI-H1792 efo:EFO_0002267 Ele Holloway James Malone NCI-H1793 efo:EFO_0002268 Ele Holloway James Malone NCI-H1838 efo:EFO_0002269 Ele Holloway James Malone NCI-H187 efo:EFO_0002270 Ele Holloway James Malone NCI-H1930 efo:EFO_0002271 Ele Holloway James Malone NCI-H1975 efo:EFO_0002272 Ele Holloway James Malone NCI-H1993 efo:EFO_0002273 Ele Holloway James Malone NCI-H2009 efo:EFO_0002274 Ele Holloway James Malone NCI-H2030 efo:EFO_0002275 Ele Holloway James Malone NCI-H2052 efo:EFO_0002276 Ele Holloway James Malone NCI-H2081 efo:EFO_0002277 Ele Holloway James Malone NCI-H2087 efo:EFO_0002278 Ele Holloway James Malone NCI-H2107 efo:EFO_0002279 Ele Holloway James Malone NCI-H2122 efo:EFO_0002280 Ele Holloway James Malone NCI-H2126 efo:EFO_0002281 Ele Holloway James Malone NCI-H2170 efo:EFO_0002282 Ele Holloway James Malone NCI-H2171 efo:EFO_0002283 Ele Holloway James Malone NCI-H2195 efo:EFO_0002284 Ele Holloway James Malone NCI-H2228 efo:EFO_0002285 Ele Holloway James Malone NCIt:C117137 NCI-H226 efo:EFO_0002286 Ele Holloway James Malone NCIt:C117141 NCI-H23 efo:EFO_0002287 Ele Holloway James Malone NCI-H2347 efo:EFO_0002288 Ele Holloway James Malone NCI-H2405 efo:EFO_0002289 Ele Holloway James Malone NCI-H295R efo:EFO_0002291 Ele Holloway James Malone NCI-H358 efo:EFO_0002292 Ele Holloway James Malone NCI-H441 efo:EFO_0002293 Ele Holloway James Malone NCI-H446 efo:EFO_0002294 Ele Holloway James Malone NCI-H508 efo:EFO_0002295 Ele Holloway James Malone NCIt:C117158 NCI-H522 efo:EFO_0002296 Ele Holloway James Malone NCI-H524 efo:EFO_0002297 Ele Holloway James Malone NCI-H630 efo:EFO_0002298 Ele Holloway James Malone NCI-H650 efo:EFO_0002299 Ele Holloway James Malone NCI-H661 efo:EFO_0002300 Human Caucasian lung small cell carcinoma cell line. Ele Holloway James Malone Sirarat Sarntivijai HTB-119 BTO:0000679 H69 H69 cell Merged definition and description based on now-obsolete EFO_0002823 that refers to ATCC call number: HTB-119 and http://www.lgcstandards-atcc.org/products/all/HTB-119.aspx?geo_country=gb NCI-H69 efo:EFO_0002301 Ele Holloway James Malone NCI-H716 efo:EFO_0002302 Ele Holloway James Malone NCI-H720 efo:EFO_0002303 Ele Holloway James Malone NCI-H747 efo:EFO_0002304 Ele Holloway James Malone NCI-H748 efo:EFO_0002305 Ele Holloway James Malone NCI-H810 efo:EFO_0002306 Ele Holloway James Malone NCI-H82 efo:EFO_0002307 Ele Holloway James Malone NCI-H838 efo:EFO_0002308 Ele Holloway James Malone OE19 efo:EFO_0002309 Ele Holloway James Malone OE21 efo:EFO_0002310 Ele Holloway James Malone OE33 efo:EFO_0002311 Ele Holloway James Malone OV90 efo:EFO_0002312 Ele Holloway James Malone P3HR1 efo:EFO_0002313 Ele Holloway James Malone PLB985 efo:EFO_0002314 Ele Holloway James Malone RCHACV efo:EFO_0002315 Ele Holloway James Malone RD efo:EFO_0002316 Ele Holloway James Malone RDES efo:EFO_0002317 Ele Holloway James Malone REC1 efo:EFO_0002318 Ele Holloway James Malone RKOE6 efo:EFO_0002319 Ele Holloway James Malone RL efo:EFO_0002320 Ele Holloway James Malone RL952 efo:EFO_0002321 Ele Holloway James Malone RPMI6666 efo:EFO_0002322 Ele Holloway James Malone https://www.atcc.org/Products/All/CCL-155.aspx RPMI8226 efo:EFO_0002323 Epithelial cells derived from the peripheral zone of a histologically normal adult human prostate were transfected with a single copy of the human papilloma virus 18 (HPV-18) to establish the RWPE-1 (ATCC CRL-11609) cell line. [PMID:9214605]. Ele Holloway James Malone http://www.atcc.org/products/all/CRL-11609.aspx#characteristics CRL-11609 RWPE 1 RWPE_1 RWPE1 efo:EFO_0002324 Ele Holloway James Malone https://www.atcc.org/Products/All/CCL-86.aspx Raji efo:EFO_0002325 Ele Holloway James Malone SCaBER efo:EFO_0002326 Ele Holloway James Malone SEM efo:EFO_0002327 Ele Holloway James Malone SH4 efo:EFO_0002328 Ele Holloway James Malone SHP77 efo:EFO_0002329 Ele Holloway James Malone SJRH30 efo:EFO_0002330 Ele Holloway James Malone SJSA1 efo:EFO_0002331 Ele Holloway James Malone SKLMS1 efo:EFO_0002332 Ele Holloway James Malone SKMEL1 efo:EFO_0002333 Ele Holloway James Malone SKMEL3 efo:EFO_0002334 Ele Holloway James Malone SKMES1 efo:EFO_0002337 SKNEP1 is a human kidney cell line derived from a patient with Nephroblastoma. Ele Holloway James Malone SKNEP1 efo:EFO_0002338 Ele Holloway James Malone Sirarat Sarntivijai SK-N-F1 SKNF1 SKNFI efo:EFO_0002339 Ele Holloway James Malone SKO007 efo:EFO_0002340 Ele Holloway James Malone SKOV3 efo:EFO_0002341 Ele Holloway James Malone SKUT1 efo:EFO_0002342 Ele Holloway James Malone Tomasz Adamusiak MCC:0000434 NCIt:C117176 SNB-19 SNB19 efo:EFO_0002343 Ele Holloway James Malone SNU1 efo:EFO_0002344 Ele Holloway James Malone SNU16 efo:EFO_0002345 Ele Holloway James Malone SNU182 efo:EFO_0002346 Ele Holloway James Malone SNU387 efo:EFO_0002347 Ele Holloway James Malone SNU398 efo:EFO_0002348 Ele Holloway James Malone SNU423 efo:EFO_0002349 Ele Holloway James Malone SNU449 efo:EFO_0002350 Ele Holloway James Malone SNU475 efo:EFO_0002351 Ele Holloway James Malone SNU5 efo:EFO_0002352 Ele Holloway James Malone NCIt:C117126 SR efo:EFO_0002353 Ele Holloway James Malone ST486 efo:EFO_0002354 Ele Holloway James Malone SU-DHL-10 SUDHL10 efo:EFO_0002355 Ele Holloway James Malone SU-DHL-16 SUDHL16 efo:EFO_0002356 Ele Holloway James Malone SU-DHL-5 SUDHL5 efo:EFO_0002357 Ele Holloway James Malone https://www.atcc.org/products/all/CRL-2959.aspx SU-DHL-6 SUDHL6 efo:EFO_0002358 Ele Holloway James Malone SW1088 efo:EFO_0002359 Ele Holloway James Malone SW1116 efo:EFO_0002360 Ele Holloway James Malone SW1353 efo:EFO_0002361 Ele Holloway James Malone SW1417 efo:EFO_0002362 Ele Holloway James Malone SW1463 efo:EFO_0002363 Ele Holloway James Malone SW1573 efo:EFO_0002364 Ele Holloway James Malone SW1783 efo:EFO_0002365 Ele Holloway James Malone SW1990 efo:EFO_0002366 Ele Holloway James Malone SW403 efo:EFO_0002367 Ele Holloway James Malone SW48 efo:EFO_0002368 Ele Holloway James Malone SW620 efo:EFO_0002369 Ele Holloway James Malone SW684 efo:EFO_0002370 Ele Holloway James Malone SW756 efo:EFO_0002371 Ele Holloway James Malone SW780 efo:EFO_0002372 Ele Holloway James Malone SW837 efo:EFO_0002373 Ele Holloway James Malone SW872 efo:EFO_0002374 Ele Holloway James Malone SW900 efo:EFO_0002375 Ele Holloway James Malone SW948 efo:EFO_0002376 Ele Holloway James Malone SW954 efo:EFO_0002377 Ele Holloway James Malone SW962 efo:EFO_0002378 Ele Holloway James Malone SW982 efo:EFO_0002379 Ele Holloway James Malone SiHa efo:EFO_0002380 Ele Holloway James Malone TANOUE efo:EFO_0002382 Ele Holloway James Malone TT efo:EFO_0002383 Ele Holloway James Malone Toledo efo:EFO_0002385 Ele Holloway James Malone UACC893 efo:EFO_0002386 Ele Holloway James Malone UMC11 efo:EFO_0002389 Ele Holloway James Malone WIDR efo:EFO_0002390 Ele Holloway James Malone WM115 efo:EFO_0002392 Ele Holloway James Malone Y79 efo:EFO_0002394 Cell lines derived from ovarian cancer tissue. ovarian cancer cell lines efo:EFO_0002529 Pancreatic beta -cell line of rat origin. Jie Zheng Tomasz Adamusiak BTO:0002135 MCC:0000246 INS-1 cell INS-1 efo:EFO_0002659 MDCC-MSB1 efo:EFO_0002694 A process performed as part of an experiment or wider study, i.e. intentionally designed. NCIt:C42790 NIFSTD:birnlex_2117 Experiment experimental process efo:EFO_0002705 Catherine Leroy Ele Holloway James Malone PMID:9354455 HPL1B efo:EFO_0002706 Ele Holloway James Malone SM1 efo:EFO_0002707 Ele Holloway James Malone NT-1 efo:EFO_0002708 A cell line derived from rat suprachiasmatic nucleus. Ele Holloway James Malone Natural Language Generator 8th April 2010 SCN2.2 efo:EFO_0002709 Human pancreatic adenocarcinoma cell line, established from a 61 year old human female. Ele Holloway James Malone HTL96012 BTO:0001861 Bx-PC3 cell BxPC-3 cell BxPC3 BxPC3 cell BxPC-3 efo:EFO_0002710 Ele Holloway James Malone COLO357 efo:EFO_0002711 Ele Holloway James Malone Normal pancreatic cell line F13 efo:EFO_0002712 A normal pancreas cell line. Ele Holloway James Malone Sirarat Sarntivijai Kif-5 While it is used in studies where pancreatic cell lines are also used, Kif-5 (the preferred name) are foreskin fibroblast. As described in: RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; "Foreskin-derived fibroblasts (Kif-5) were used for coculture experiments. This fibroblast cell line was established previously in our laboratory." (FGPTO-736) KIF5 efo:EFO_0002713 PANC-1 is a human pancreatic cancer cell line isolated from a pancreatic carcinoma of ductal cell origin in a 56-year-old male. Ele Holloway James Malone https://www.sigmaaldrich.com/catalog/product/sigma/cb_87092802?lang=en&region=US PMID:1140870 Wikipedia:PANC-1 PANC-1 Panc1 efo:EFO_0002714 Ele Holloway James Malone T3M4 Panc89 efo:EFO_0002715 Ele Holloway James Malone PancTu-I PancTUI efo:EFO_0002716 Ele Holloway James Malone Pt45P1 efo:EFO_0002717 Ele Holloway James Malone CRL-2266 https://www.atcc.org/Products/All/CRL-2266.aspx SH-SY5Y efo:EFO_0002776 H0287 is a cell line derived from normal lymphoblastoid cells H0287 efo:EFO_0002777 NHA is a cell line derived from normal (healthy) human astrocyte cells. James Malone NHA Normal Human Astrocytes efo:EFO_0002778 BG02ES is a cell line dervied from human embryonic stem cells. James Malone NCIt:C20234 BG02 BG02ES efo:EFO_0002779 https://www.atcc.org/products/all/CRL-2522 BJ efo:EFO_0002781 A chorion cell line is a cell line that is derived from the chorion. chorion cell line efo:EFO_0002782 Glioblastoma H54 is a cell line derived from http://genome.ucsc.edu/ENCODE/protocols/cell/human/D54_Crawford_protocol.pdf https://cansar.icr.ac.uk/cansar/cell-lines/D54/ H54 glioblastoma H54 efo:EFO_0002783 GM06990 is a cell line derived from some lymphoblastoid cells from a CEPH familiy of UTAH/MORMON ethnicity. It is supplied by Corriell under catalogue number GM06990. https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM06990 GM06990 efo:EFO_0002784 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12878&Product=CC GM12878 efo:EFO_0002785 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12891&Product=CC GM12891 efo:EFO_0002786 A cell line derived from human female B cells. James Malone Natural Language Generator 8th April 2010 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM12892&Product=CC GM12892 efo:EFO_0002787 A cell line derived from human male lymphoblasts. James Malone Natural Language Generator 8th April 2010 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM18507&product=CC GM18507 efo:EFO_0002788 A cell line derived from human female B cells. James Malone Natural Language Generator 8th April 2010 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM19238&Product=CC GM19238 efo:EFO_0002789 A cell line derived from human male B cells. James Malone Natural Language Generator 8th April 2010 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM19239&Product=CC GM19239 efo:EFO_0002790 A cell line derived from human female B cells. James Malone Natural Language Generator 8th April 2010 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM19240&Product=CC GM19240 efo:EFO_0002791 https://atcc.org/Products/All/CCL-2.2.aspx?slp=1 HeLa-S3 efo:EFO_0002792 A cell line derived from human normal fibroblasts. James Malone Natural Language Generator 8th April 2010 Human Gingival Fibroblasts HGF efo:EFO_0002793 HL-60 is a cell line which is the bearer of human acute myeloid leukemia established from the peripheral blood of a 35-year-old woman with acute myeloid leukemia (AML FAB M2) in 1976. Human acute myeloid leukemia established from the peripheral blood of a 35-year-old woman with acute myeloid leukemia (AML FAB M2) in 1976. https://www.sigmaaldrich.com/catalog/product/sigma/cb_98070106?lang=en&region=US&gclid=EAIaIQobChMIw-Pa7aCq3wIVEMRkCh2bGA2iEAAYAiAAEgKrzPD_BwE BTO:0000738 NCIt:C19433 HL-60 cell HL60 HL60 cell HL-60 efo:EFO_0002794 Human Renal Epithelial cell line HRE efo:EFO_0002795 HUVEC cell line efo:EFO_0002796 A cell line derived from human T cell acute lymphoblastic leukemia. Human T cell leukemia, established from the peripheral blood of a 14-year-old boy with acute lymphoblastic leukemia (ALL) at first relapse in 1976; often this cell line is called "JM (JURKAT and JM are derived from the same patient and are sister clones), occasionally JM may be a subclone with somewhat divergent features. Human T cell leukemia, established from the peripheral blood of a 14-year-old boy with acute lymphoblastic leukemia (ALL) at first relapse in 1976; often this cell line is called JM (JURKAT and JM are derived from the same patient and are sister clones), occasionally JM may be a subclone with somewhat divergent features. Ele Holloway James Malone Natural Language Generator 8th April 2010 BTO:0000661 JM JM cell JURKAT cell Jurkat efo:EFO_0002797 LHSR is a cell line in which human prostate epithelial cells (PrEC) were infected with amphotropic retroviruses encoding the SV40 large T antigen (L), the telomerase catalytic subunit hTERT (H), the SV40 small T antigen (S) and an oncogenic allele of H-ras (R) to create LHSR cells. James Malone LHSR efo:EFO_0002798 https://www.dsmz.de/catalogues/details/culture/ACC-207.html NB4 efo:EFO_0002799 NHEK efo:EFO_0002800 SAEC is a cell line derived from Small Airway Epithelial Cells SAEC efo:EFO_0002801 Human Skeletal Muscle Cells SKMC efo:EFO_0002802 neuroblastoma cell line differentiated w/ retinoic acid SK-N-SH_RA efo:EFO_0002803 TH-1 efo:EFO_0002804 TH-2 efo:EFO_0002807 Ele Holloway James Malone 4470 efo:EFO_0002808 Ele Holloway James Malone 4475 efo:EFO_0002809 Ele Holloway James Malone 4483 efo:EFO_0002810 A cell line derived from human melanoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 1205-Lu efo:EFO_0002811 Preadipocyte cell line. Ele Holloway James Malone BTO:0001169 3T3-F442A cell F442A F442A cell 3T3-F442A efo:EFO_0002812 A cell line derived from murine embryonic stem cells. Ele Holloway James Malone Natural Language Generator 8th April 2010 AB2.2 efo:EFO_0002813 Ele Holloway James Malone JCRB0815 ABC-1 efo:EFO_0002814 Ele Holloway James Malone JCRB0061 AZ521 AZ-521 efo:EFO_0002815 The malignant human B-cell-line BJAB is a EBV-negative Burkitt-like lymphoma cell line. Ele Holloway James Malone BTO:0001931 BJAB cell BJAB efo:EFO_0002816 Ele Holloway James Malone https://www.atcc.org/Products/All/CCL-226.aspx C3H10T1/2 efo:EFO_0002817 Ele Holloway James Malone Caco-2/TC7 efo:EFO_0002818 A cell line derived from human 39 s sarcoma. Ele Holloway James Malone CADO ES1 efo:EFO_0002819 Ele Holloway James Malone Calu3 efo:EFO_0002820 A cell line derived from murine embryonic stem cells. Ele Holloway James Malone Natural Language Generator 8th April 2010 CM7-1 efo:EFO_0002821 Mouse, C57BL/6, T-lymphocyte cell line. Ele Holloway James Malone BTO:0001482 CTLL-2 cell CTLL-2 efo:EFO_0002822 Ele Holloway James Malone D10.G4.1 efo:EFO_0002824 Human colon carcinoma cell line; established from the primary colon carcinoma of an adult man. Ele Holloway James Malone https://www.atcc.org/products/all/CCL-247.aspx BTO:0002254 HCT-116 cell HCT116 cell HCT116 efo:EFO_0002826 A KS-IMM is a cell line. A KS-IMM is bearer of a Kaposi's sarcoma. The tumorigenic KS IMM cell line derives from Kaposi's sarcoma (KS), a highly angiogenic tumor. Ele Holloway James Malone BTO:0002070 KS IMM cell KS-IMM cell KSIMM cell KS-IMM efo:EFO_0002827 A cell line derived from human squamous cell lung carcinoma. Ele Holloway James Malone Natural Language Generator 8th April 2010 LC-1F efo:EFO_0002828 Ele Holloway James Malone JCRB0170 Lu-135 Lu135 efo:EFO_0002829 A MIN6 is a cell line. A MIN6 derives from a mus musculus. The murine MIN6 cell line derived from in vivo immortalized insulin-secreting pancreatic beta cells. Ele Holloway James Malone Natural Language Generator 8th April 2010 BTO:0002284 MIN-6 cell MIN6 cell MIN6 efo:EFO_0002830 Human gastric adenosquamous carcinoma cell line. Ele Holloway James Malone JCRB0252 BTO:0002384 MKN-1 MKN-1 cell MKN1 cell MKN1 efo:EFO_0002831 Well differentiated human gastric adenocarcinoma cell line. Ele Holloway James Malone JCRB0253 BTO:0002381 MKN-28 MKN-28 cell MKN28 cell MKN28 efo:EFO_0002832 Human gastric adenocarcinoma, established from the poorly differentiated adenocarcinoma of the stomach (medullary type) of a 62-year-old woman. Ele Holloway James Malone JCRB0254 BTO:0001225 MKN-45 MKN-45 cell MKN45 cell MKN45 efo:EFO_0002834 Well differentiated human gastric adenocarcinoma cell line. Ele Holloway James Malone JCRB0255 BTO:0002383 MKN-74 MKN-74 cell MKN74 cell MKN74 efo:EFO_0002835 Homo sapiens (human) lung; fibroblast; normal cell line. The MRC-5 cell line was derived from normal lung tissue of a 14-week-old male fetus by J.P. Jacobs in September of 1966. Ele Holloway James Malone BTO:0001590 MRC-5 MRC-5 cell MRC-V cell MRC5 cell MRC5 efo:EFO_0002836 Ele Holloway James Malone JCRB1081 MS-1-L MS-1 efo:EFO_0002837 Ele Holloway James Malone MS428 efo:EFO_0002838 Ele Holloway James Malone MS589 efo:EFO_0002839 Human mesothelioma cell line; established from the pleural effusion of a 62-year-old Caucasian man with mesothelioma (malignant biphasic) who did not have any prior therapy. Ele Holloway James Malone CRL-2081 BTO:0002425 211H cell MSTO-211 H cell MSTO-211H cell MSTO-211H efo:EFO_0002840 Ele Holloway James Malone N231 efo:EFO_0002841 Ele Holloway James Malone NCI-N87 efo:EFO_0002842 Ele Holloway James Malone PC-1 efo:EFO_0002843 Ele Holloway James Malone PC-10 efo:EFO_0002844 Ele Holloway James Malone PC-14 efo:EFO_0002845 Ele Holloway James Malone PC-6 efo:EFO_0002846 Ele Holloway James Malone PC-7 efo:EFO_0002847 Ele Holloway James Malone https://www.sigmaaldrich.com/catalog/product/sigma/cb_90071810?lang=en&region=US PC-9 efo:EFO_0002848 Ele Holloway James Malone QG56 efo:EFO_0002849 Ele Holloway James Malone R11 efo:EFO_0002850 Ele Holloway James Malone RERF-LC-AI efo:EFO_0002851 Ele Holloway James Malone JCRB0137 RERF-LC-KJ efo:EFO_0002852 Ele Holloway James Malone JCRB0081 RERF-LC-MS efo:EFO_0002853 A cell line derived from human 39 s sarcoma. Ele Holloway James Malone RM82 RM 82 efo:EFO_0002854 A cell line derived from human small cell lung carcinoma. Ele Holloway James Malone JCRB0818 SBC-3 efo:EFO_0002855 Ele Holloway James Malone JCRB0819 SBC-5 efo:EFO_0002856 Ele Holloway James Malone SCH efo:EFO_0002857 Ele Holloway James Malone SHEP-SF efo:EFO_0002858 Ele Holloway James Malone SK ES1 SK-ES-1 efo:EFO_0002859 Ele Holloway James Malone SKNAS SK-N-AS efo:EFO_0002860 Ele Holloway James Malone HB-10 https://www.atcc.org/products/all/HTB-10.aspx SKNMc SK-N-MC efo:EFO_0002861 Ele Holloway James Malone SQ-5 efo:EFO_0002862 Ele Holloway James Malone STA ET1 STA-ET-1 efo:EFO_0002863 Ele Holloway James Malone STA ET2.1 STA-ET-2.1 efo:EFO_0002864 Ele Holloway James Malone T24 efo:EFO_0002865 Ele Holloway James Malone TC71 efo:EFO_0002866 Ele Holloway James Malone TE85 efo:EFO_0002867 Ele Holloway James Malone TMK1 efo:EFO_0002868 Ele Holloway James Malone TT3E efo:EFO_0002869 Ele Holloway James Malone https://www.atcc.org/Products/All/HTB-96.aspx U2-OS U2OS efo:EFO_0002870 Ele Holloway James Malone VH-64 efo:EFO_0002871 Ele Holloway James Malone WB-F344 efo:EFO_0002872 Ele Holloway James Malone WE-68 efo:EFO_0002873 Ele Holloway James Malone WM793 efo:EFO_0002874 Ele Holloway James Malone WM793-P1N1 efo:EFO_0002875 Ele Holloway James Malone WM793-P2N1 efo:EFO_0002876 Ele Holloway James Malone YCC1 efo:EFO_0002877 Ele Holloway James Malone YCC10 efo:EFO_0002878 Ele Holloway James Malone YCC11 efo:EFO_0002879 Ele Holloway James Malone YCC16 efo:EFO_0002880 Ele Holloway James Malone YCC3 efo:EFO_0002881 Ele Holloway James Malone YCC6 efo:EFO_0002882 Ele Holloway James Malone YCC7 efo:EFO_0002883 Cell lines that are part of the haemopoietic system. hemopoietic system cell line haemopoietic system cell line efo:EFO_0002884 mammary gland cell line efo:EFO_0002885 breast cancer cell line efo:EFO_0002886 Cell lines derived from stem cells. stem cell derived cell line efo:EFO_0002887 Cell lines derived from mice. NCIt:C20220 mouse cell line efo:EFO_0002888 Homo sapiens cell line efo:EFO_0002891 Any cell line that is derived from the prostate. James Malone prostate derived cell line efo:EFO_0002895 Well differentiated human gastric adenocarcinoma cell line. Ele Holloway James Malone JCRB1025 BTO:0002382 MKN-7 MKN-7 cell MKN7 cell MKN7 efo:EFO_0002922 normal cell line efo:EFO_0002926 ENCODE cell line efo:EFO_0002933 Cell lines used in experiments under the HapMap Project HapMap cell line efo:EFO_0002934 lung cancer cell line efo:EFO_0002935 Drosophila melanogaster cell line efo:EFO_0002936 Cell lines derived from rats. NCIt:C20222 rat cell line efo:EFO_0002937 lymphoma or leukaemia cell line efo:EFO_0002940 zebrafish cell line efo:EFO_0002957 2102ep is an embryonal cell line 2102Ep efo:EFO_0002959 A human embryonal carcinoma (EC) stem cell line used as a model system for the study of neuronal differentiation NTera2 efo:EFO_0002960 A human embryonic stem cell line NCIt:C20235 BG03 efo:EFO_0002961 A human embryonal carcinoma (EC) stem cell line used as a model system for the study of neuronal differentiation and differentiated into neuronal like cells NTera2 derived dopaminergic neuronal like cells efo:EFO_0003037 Tomasz Adamusiak https://www.ncbi.nlm.nih.gov/pubmed/2665839 MCC:0000105 CMK efo:EFO_0003039 The EAhy 926 cell is a hybridoma line derived from human endothelium and A549/8 cells. They display stable endothelial characteristics and may provide an indication of how endothelial cells respond to photodynamic therapy. Tomasz Adamusiak BTO:0000396 EA.hy926 cell EAhy 926 cell efo:EFO_0003040 Tomasz Adamusiak BTO:0000669 embryonic cell line efo:EFO_0003042 H1 human embryonic stem cell line, usually called H1-hESC and on occasion just H1 Tomasz Adamusiak PMID:18564034 H1 H1-hESC efo:EFO_0003043 Tomasz Adamusiak MCC:0000352 NCI-H1299 efo:EFO_0003044 Tomasz Adamusiak https://www.atcc.org/Products/All/HTB-177.aspx MCC:0000356 NCIt:C117157 NCI-H460 efo:EFO_0003045 This human ES cell line expresses cell surface markers specific to undifferentiated nonhuman primate ES and human EC cells: stage-specific embryonic antigen (SSEA)–3, SSEA-4, TRA-l-60, TRA-1- 81, and alkaline phosphatase. It has a normal 46, XX karyotype. Teratomas are formed upon cell injection into SCID mice. These teratomas include cells from all three germ layers. Isolation & Growth Conditions This cell line can be cultured using feeder cells or in a feeder-free protocol. When using feeder cells, human ESC culture medium should be compreised of Advanced DMEM/F12 supplemented with knockout serum replacement (20%), non-essential amino acids (1x), L-glutamine (1x), penicillin/streptomycin (1x), β-mercaptoethanol (1x) and FGF-2 (4 ng/ml). Maintain the human ESCs on Matrigel using hESC medium conditioned by mouse embryonic fibroblasts. Olamidipupo Ajigboye Tomasz Adamusiak PMID:18564034 H9 efo:EFO_0003048 Tomasz Adamusiak PMID:10748519 HES-2 HES2 efo:EFO_0003055 Tomasz Adamusiak PMID:2784066 lp-1 LP1 efo:EFO_0003056 The human melanoma cell line M14 has been established from surgically removed melanoma metastases. Tomasz Adamusiak BTO:0002805 NCIt:C117183 M14 cell M14 efo:EFO_0003061 Tomasz Adamusiak https://www.atcc.org/Products/All/HTB-161.aspx MCC:0000363 OVCAR3 efo:EFO_0003064 Tomasz Adamusiak primary cell line efo:EFO_0003072 James Malone Tomasz Adamusiak http://www.atcc.org/products/all/HTB-11.aspx MCC:0000430 SKNSH SK-N-SH efo:EFO_0003074 Mouse embryonic stem cell line Mikkelsen et al. (2007). Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-560 NCIt:C20232 ES cell line efo:EFO_0003081 Tomasz Adamusiak MCC:0000426 NCIt:C117189 SK-MEL-28 efo:EFO_0003082 Tomasz Adamusiak MCC:0000107 COLO205 efo:EFO_0003115 James Malone EBC-1 efo:EFO_0003116 H125 NCI-H125 efo:EFO_0003117 James Malone H1334 NCI-H1334 efo:EFO_0003118 James Malone H157 NCI-H157 efo:EFO_0003119 James Malone H1648 NCI-H1648 efo:EFO_0003120 James Malone H2279 NCI-H2279 efo:EFO_0003121 James Malone H2882 NCI-H2882 efo:EFO_0003122 James Malone H2287 NCI-H2287 efo:EFO_0003123 James Malone H3255 NCI-H3255 efo:EFO_0003124 James Malone H520 NCI-H520 efo:EFO_0003125 James Malone H820 NCI-H820 efo:EFO_0003126 James Malone HCC-1171 HCC1171 efo:EFO_0003127 James Malone HCC-1159 HCC1159 efo:EFO_0003128 James Malone HCC-1359 HCC1359 efo:EFO_0003129 James Malone HCC-15 HCC15 efo:EFO_0003130 James Malone HCC-193 HCC193 efo:EFO_0003131 James Malone HCC-366 HCC366 efo:EFO_0003132 James Malone HCC-4006 HCC4006 efo:EFO_0003133 James Malone HCC-44 HCC44 efo:EFO_0003134 James Malone HCC-461 HCC461 efo:EFO_0003135 James Malone HCC-515 HCC515 efo:EFO_0003136 HCC-78 HCC78 efo:EFO_0003137 HCC-827 HCC827 efo:EFO_0003138 James Malone HCC-95 HCC95 efo:EFO_0003139 James Malone HCjE efo:EFO_0003140 James Malone LC2/AD efo:EFO_0003141 James Malone LK-2 efo:EFO_0003142 James Malone Lu130 efo:EFO_0003892 Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Tomasz Adamusiak true MeSH:D012129 NCIt:C38081 FUNCTION TEST PULM FUNCTION TESTS PULM Function Test, Lung Function Test, Pulmonary Function Test, Respiratory Function Tests, Lung Function Tests, Pulmonary Function Tests, Respiratory Lung Function Test Lung Function Tests PULM FUNCTION TEST PULM FUNCTION TESTS Pulmonary Function Tests Respiratory Function Test Respiratory Function Tests TEST PULM FUNCTION TESTS PULM FUNCTION Test, Lung Function Test, Pulmonary Function Test, Respiratory Function Tests, Lung Function Tests, Pulmonary Function Tests, Respiratory Function pulmonary function test pulmonary function measurement efo:EFO_0003912 An alternative to the ankle-brachial index. Comparison of the BLOOD PRESSURE between the BRACHIAL ARTERY and the POSTERIOR TIBIAL ARTERY. It is a predictor of PERIPHERAL ARTERIAL DISEASE. Tomasz Adamusiak true MeSH:D055109 MedDRA:10062762 NCIt:C87304 SNOMEDCT:401221002 SNOMEDCT:446841001 ABPI Ankle Brachial Indices Ankle Brachial Pressure Index (ABPI) Ankle-Brachial Index Ankle-Brachial Indices Brachial Index, Ankle Brachial Index, Toe Brachial Indices, Ankle Brachial Indices, Toe Index, Ankle Brachial Index, Ankle-Brachial Index, Toe Brachial Index, Toe-Brachial Indices, Ankle Brachial Indices, Ankle-Brachial Indices, Toe Brachial Indices, Toe-Brachial Toe Brachial Index Toe Brachial Indices Toe-Brachial Index Toe-Brachial Indices ankle brachial pressure index ankle brachial index efo:EFO_0003923 The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Tomasz Adamusiak true ICD10:M85 MeSH:D015519 NCIt:C96950 BMD Bone Densities Bone Mineral Densities Bone Mineral Density Density, Bone Density, Bone Mineral aBMD areal bone mineral density bone density efo:EFO_0003926 Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Tomasz Adamusiak true MeSH:D009483 MedDRA:10065432 Aphasia Test Aphasia Tests Memory for Designs Test NEUROPSYCHOL TEST NEUROPSYCHOL TESTS Neuropsychologic Test Neuropsychologic Tests Neuropsychological Tests TEST NEUROPSYCHOL TESTS NEUROPSYCHOL Test, Aphasia Test, Neuropsychologic Test, Neuropsychological Tests, Aphasia Tests, Neuropsychologic Tests, Neuropsychological cognitive performance cognitive performance test cognitive test performance neuropsychological test efo:EFO_0003960 A computed tomography scan (CT scan) is the output of an imaging technology which produces a 3D iimage of the subject. Tomasz Adamusiak NCIt:C17204 CT scan computed tomography scan computed tomography efo:EFO_0003962 Echocardiography applying the Doppler effect, with velocity detection combined with range discrimination. Short bursts of ultrasound are transmitted at regular intervals and the echoes are demodulated as they return. Tomasz Adamusiak MeSH:D018619 DOPPLER ECHOCARDIOGR PULSED DOPPLER PULSED ECHOCARDIOGR Doppler Echocardiography, Pulsed Doppler Pulsed Echocardiography ECHOCARDIOGR DOPPLER PULSED ECHOCARDIOGR PULSED DOPPLER Echocardiography, Doppler Pulsed Echocardiography, Doppler, Pulsed Echocardiography, Pulsed Doppler PULSED DOPPLER ECHOCARDIOGR PULSED ECHOCARDIOGR DOPPLER Pulsed Echocardiography, Doppler pulsed doppler echocardiography efo:EFO_0003965 An infant whose weight at birth is less than 1500 grams (3.3 lbs), regardless of gestational age. Tomasz Adamusiak MeSH:D019102 MedDRA:10004958 NCIt:C114935 SNOMEDCT:276611006 INFANT VLBW Infant, Very Low Birth Weight Infant, Very-Low-Birth-Weight Infants, Very-Low-Birth-Weight VLBW INFANT Very Low Birth Weight Very Low Birth Weight Infant Very-Low-Birth-Weight Infant Very-Low-Birth-Weight Infants very low birth weight infant efo:EFO_0003971 https://www.ncbi.nlm.nih.gov/pubmed/21416373 MEL Mouse Erythroleukemia cell line MEL cell line efo:EFO_0003972 A mouse embryonic stem cell hybrid cell line Mikkelsen et al. (2007). Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-560 ESHyb efo:EFO_0004037 Mouse embryonic fibroblast cell line James Malone MEF cell line efo:EFO_0004041 Mouse Neural Progenitor cell line James Malone Mouse Neural Progenitor cell line NPC efo:EFO_0004134 The physical size of a tumor. James Malone NCIt:C120284 SNOMEDCT:263605001 size of tumor tumor size efo:EFO_0004297 A clinical laboratory measurement is a measurement of some entity e.g. erythrocyte count or metabolite panel which is used in the process of clinical diagnosis in human patients Dani Welter true clinical laboratory techniques clinical laboratory measurement efo:EFO_0004298 A cardiovascular measurement is a measurement of some part of the cardiovascular system and is typically used in the process of disease diagnosis in human patients. Dani Welter true MeSH:D003935 SNOMEDCT:113021009 Diagnostic Techniques, Cardiovascular cardiovascular diagnostic technique cardiovascular measurement efo:EFO_0004299 Based on known statistical data, the number of years which any person of a given age may reasonably be expected to live. Dani Welter MeSH:D008017 life expectancy efo:EFO_0004300 The length of time of an organism's life. Dani Welter true MeSH:D008136 SNOMEDCT:111951006 length of life Combine with age, or move? longevity efo:EFO_0004301 The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA. Dani Welter true MeSH:D001809 SNOMEDCT:85015001 blood viscosity efo:EFO_0004302 Anthropometry is a measurement of the size, weight, and proportions of the human or other primate body. Dani Welter true MeSH:D000886 anthropometric traits anthropometry anthropometric measurement efo:EFO_0004303 The signs of life that may be monitored or measured, namely pulse rate, respiratory rate, body temperature, and blood pressure. Dani Welter MeSH:D055986 SNOMEDCT:46680005 vital signs efo:EFO_0004304 Measurement of rate of settling of erythrocytes in anticoagulated blood. Dani Welter true MeSH:D001799 SNOMEDCT:416560009 erythrocyte sedimentation erythrocyte sedimentation rate blood sedimentation efo:EFO_0004305 The number of red blood cells per unit volume in a sample of venous blood. Dani Welter true MeSH:D004906 NCIt:C51946 SNOMEDCT:14089001 RBC erythrocyte number red blood cell count erythrocyte count efo:EFO_0004306 ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC). Dani Welter http://www.nlm.nih.gov/medlineplus/ency/article/003644.htm http://www.nlm.nih.gov/medlineplus/ency/article/003648.htm true MeSH:D004909 RBC count erythrocyte index erythrocyte indexes erythrocyte size determination red cell index red cell indices erythrocyte indices efo:EFO_0004307 A test to determine the ability of an individual to maintain homeostatis of blood glucose. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Dani Welter true MeSH:D005951 MedDRA:10018432 NCIt:C45946 SNOMEDCT:113076002 glucose tolerance test efo:EFO_0004308 The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Dani Welter http://www.nlm.nih.gov/medlineplus/ency/article/003643.htm true MeSH:D007958 MedDRA:10080703 NCIt:C51948 SNOMEDCT:767002 WBC white blood cell count white cell count leukocyte count efo:EFO_0004309 The number of PLATELETS per unit volume in a sample of venous BLOOD. Dani Welter http://www.nlm.nih.gov/medlineplus/ency/article/003647.htm true MeSH:D010976 MedDRA:10035525 NCIt:C51951 SNOMEDCT:61928009 blood platelet number platelet count efo:EFO_0004310 The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Dani Welter http://www.nlm.nih.gov/medlineplus/ency/article/003653.htm true MeSH:D010314 NCIt:C38462 Cephalin-Kaolin coagulation time activated partial thromboplastin time partial thromboplastin time efo:EFO_0004311 A heart function measurement is a measurement of some heart function or process typically used to establish normal heart function or in process of diagnosis Dani Welter true MeSH:D006334 cardiac function tests heart function tests heart function measurement efo:EFO_0004312 The volume of air that is exhaled by a maximal expiration following a maximal inspiration. Dani Welter true MeSH:D014797 MedDRA:10047579 NCIt:C111361 SNOMEDCT:268379003 FVC forced vital capacity vital capacity efo:EFO_0004313 Measurement of rate of airflow over the middle half of a FORCED VITAL CAPACITY determination (from the 25 percent level to the 75 percent level). Common abbreviations are MMFR and FEF 25%-75%. Dani Welter true MeSH:D008450 FEF25-75% maximal midexpiratory flow rate efo:EFO_0004314 Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Dani Welter true MeSH:D005541 MedDRA:10016984 NCIt:C120933 FEV1 FEVt timed vital capacity forced expiratory volume efo:EFO_0004324 Measurements of the height, weight, length, area, etc., of the human and animal body or its parts. Dani Welter true MeSH:D001837 body measures body weights and measures efo:EFO_0004325 PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Dani Welter true MeSH:D001794 MedDRA:10005727 NCIt:C54706 SNOMEDCT:75367002 blood pressure efo:EFO_0004326 The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Dani Welter true MeSH:D006339 MedDRA:10019299 NCIt:C49677 SNOMEDCT:364075005 cardiac chronotropy pulse rate heart rate efo:EFO_0004327 Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. Dani Welter true ICD9:89.52 MeSH:D004562 NCIt:C38053 EKG electrocardiogram electrocardiography efo:EFO_0004328 Controlled physical activity, more strenuous than at rest, which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used. The intensity of exercise is often graded, using criteria such as rate of work done, oxygen consumption, and heart rate. Dani Welter http://www.nlm.nih.gov/medlineplus/ency/article/003878.htm true MeSH:D005080 MedDRA:10015652 stress test exercise test efo:EFO_0004338 The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Dani Welter true MeSH:D001835 NCIt:C81328 SNOMEDCT:27113001 weight body weight efo:EFO_0004339 The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Dani Welter true MeSH:D001827 MedDRA:10005891 NCIt:C25347 height body height efo:EFO_0004340 An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention) Dani Welter https://en.wikipedia.org/wiki/Body_mass_index true ICD9:V85-V85.99 MeSH:D015992 MedDRA:10005894 NCIt:C16358 SNOMEDCT:60621009 BMI Quetelet's Index body mass index efo:EFO_0004341 Deposits of ADIPOSE TISSUE throughout the body. The pattern of fat deposits in the body regions is an indicator of health status. Excess ABDOMINAL FAT increases health risks more than excess fat around the hips or thighs, therefore, WAIST-HIP RATIO is often used to determine health risks. Dani Welter true MeSH:D050218 body fat patterning body fat distribution efo:EFO_0004342 The measurement around the body at the level of the ABDOMEN and just above the hip bone. The measurement is usually taken immediately after exhalation. Dani Welter true MeSH:D055105 MedDRA:10074998 NCIt:C100948 SNOMEDCT:276361009 waist circumference efo:EFO_0004343 The waist circumference measurement divided by the hip circumference measurement. For both men and women, a waist-to-hip ratio (WHR) of 1.0 or higher is considered "at risk" for undesirable health consequences, such as heart disease and ailments associated with OVERWEIGHT. A healthy WHR is 0.90 or less for men, and 0.80 or less for women. (National Center for Chronic Disease Prevention and Health Promotion, 2004) Dani Welter true MeSH:D049629 NCIt:C17651 waist-hip ratio efo:EFO_0004344 The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms. Dani Welter true MeSH:D001724 NCIt:C76325 SNOMEDCT:364589006 birthweight birth weight efo:EFO_0004345 The measurement of curvature and shape of the anterior surface of the cornea using techniques such as keratometry, keratoscopy, photokeratoscopy, profile photography, computer-assisted image processing and videokeratography. This measurement is often applied in the fitting of contact lenses and in diagnosing corneal diseases or corneal changes including keratoconus, which occur after keratotomy and keratoplasty. Dani Welter true MeSH:D019781 MedDRA:10011052 SNOMEDCT:252830007 videokeratography corneal topography efo:EFO_0004346 Non-invasive methods of visualizing and measuring the CENTRAL NERVOUS SYSTEM, especially the brain, by various imaging modalities e.g. CT scan Dani Welter true brain imaging is about MeSH:D059906 neuroimaging measurement efo:EFO_0004348 The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Dani Welter http://www.nlm.nih.gov/medlineplus/ency/article/003646.htm true MeSH:D006400 MedDRA:10019422 Ht packed erythrocyte volume packed red-cell volume hematocrit efo:EFO_0004351 quantification of the number of times the heart beats in a given time interval, usually a minute, while the body is at rest Dani Welter true SNOMEDCT:444981005 resting heart rate efo:EFO_0004352 Quantification of the number of deaths in a population. Dani Welter true MeSH:D009026 MeSH:Q000401 NCIt:C16880 SNOMEDCT:409651001 mortality measurement mortality rate mortality efo:EFO_0004357 Am electroencephalogram measurement measures the wave-like oscillations of electric potential between parts of the brain. Dani Welter true MeSH:D058256 brain oscillations brain waves brainwaves electroencephalogram traits electroencephalogram measurement efo:EFO_0004358 The measurement of wave-like oscillations of electric potential between parts of the brain recorded by EEG that are the result of a specific stimulus Dani Welter true PERSON: Dani Welter event-related brain oscillations event-related brain oscillation efo:EFO_0004389 Human chordoma cell line. James Malone https://www.atcc.org/Products/All/CRL-3217.aspx UCH-1 efo:EFO_0004425 The first time point measured at the start of some process. James Malone initial timepoint initial time point efo:EFO_0004458 C-reactive protein (CRP) measurement is a measurement of the level of C-reactive protein in the blood. Levels are known to rise in response to inflammation, CRP is therefore used as a clinical measure of inflammation. The measurement is used in the process of clinical diagnosis as high levels of CRP are associated with cardiovascular disease, diabetes and hypertension and in some cancers. Helen Parkinson true NCIt:C64548 SNOMEDCT:55235003 C-reactive protein level is about MeSH:D002097 C-reactive protein measurement efo:EFO_0004459 A ferritin measurement a is measurement of ferritin level in serum as an indicator of iron metabolism Helen Parkinson true NCIt:C74737 SNOMEDCT:489004 ferritin level ferritin measurement efo:EFO_0004460 A soluble transferrin receptor measurement (sTfR) is a measure of the level of the Soluble transferrin receptor protein in blood as a measure of iron metabolism. Helen Parkinson true NCIt:C100438 sTfR level soluble transferrin receptor level soluble transferrin receptor measurement efo:EFO_0004461 An iron biomarker measurement is a measurement of some molecule e.g. protein or metabolite which is used as a measure of iron metabolism Helen Parkinson true iron biomarker level iron status biomarkers iron biomarker measurement efo:EFO_0004462 A PR interval is an electrocardiography measurement which measures from the beginning of the P wave to the beginning of the QRS complex in the heart's electrical cycle Helen Parkinson https://en.wikipedia.org/wiki/PR_interval true NCIt:C83502 https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=22330 PQ interval PR interval efo:EFO_0004463 ACE activity level An angiotensin converting enzyme (ACE) activity measurement measures the ACE activity in the blood. ACE mediates extracellular volume by participation in the renin-angiotensin system and is a therefore target for ACE inhibitors which aim to reduce blood pressure. Variants in the ACE gene are associated with ischemic stroke, intracerebral hemorrhage, tubular dygenesis and microvascular complications of diabetes. angiotensin converting ezyme activity level Helen Parkinson http://www.nlm.nih.gov/medlineplus/ency/article/003567.htm http://www.uniprot.org/uniprot/J3KRQ0 https://en.wikipedia.org/wiki/Angiotensin-converting_enzyme true ACE activity measurement Angiotensin-converting enzyme activity angiotensin converting enzyme activity measurement efo:EFO_0004464 true brain measurement efo:EFO_0004465 An fasting blood glucose measurement is a measurement of glucose in the blood of a patient at some defined time point after eating. Helen Parkinson true SNOMEDCT:271062006 fasting blood glucose level fasting glucose-related traits fasting plasma glucose fasting blood glucose measurement efo:EFO_0004466 A fasting blood insulin measurement is a measurement of insulin in the blood at a predetermined point after the patient has fasted true fasting blood insulin fasting blood insulin level fasting insulin-related traits fasting blood insulin measurement efo:EFO_0004467 An insulin measurement is a measure of insulin typically performed in the diagnosis of patients Helen Parkinson true NCIt:C74788 SNOMEDCT:16890009 insulin level insulin measurement efo:EFO_0004468 Is any quantification of glucose. Helen Parkinson true ICD10:R73 NCIt:C105585 SNOMEDCT:36048009 glucose level glucose measurement efo:EFO_0004469 The HOMA-B measurement employs the homeostatic model assessment (HOMA) to quantify beta-cell function. Helen Parkinson https://en.wikipedia.org/wiki/Homeostatic_model_assessment true homeostasis model assessment B cell function HOMA-B efo:EFO_0004471 An insulin sensitivity measurement is a measurement of insulin metabolism, which can be measured in a number of ways, for example using the HOMA model or via a glucose tolerance test. Helen Parkinson true insulin sensitivity test insulin sensitivity measurement efo:EFO_0004501 The HOMA-IR measurement employs the homeostatic model assessment (HOMA) to quantify insulin resistance. Helen Parkinson true homeostasis model assessment insulin resistance HOMA-IR efo:EFO_0004502 Adiponectin measurement is a measurement of the circulating hormone adiponectin in serum. Adiponectin regulated modulates glucose regulation and fatty acid catabolism. Low circulating adiponectin concentrations (hypoadiponectinemia; <4 μg/mL) are associated with a variety of diseases, including dysmetabolism (type 2 diabetes, insulin resistance, hypertension, dyslipidemia, metabolic syndrome, hyperuricemia), atherosclerosis (coronary artery disease, stroke, peripheral artery disease), sleep apnea, non-alcoholic fatty liver disease, gastritis and gastro-esophageal reflux disease, inflammatory bowel diseases, pancreatitis, osteoporosis, and cancer (endometrial cancer, postmenopausal breast cancer, leukemia, colon cancer, gastric cancer, prostate cancer). Hyperadiponectinemia is associated with cardiac, renal and pulmonary diseases. Helen Parkinson http://www.sciencedirect.com/science/article/pii/S1521690X13001188 true NCIt:C74839 adiponectin levels adiponectin measurement efo:EFO_0004503 A measurement quantifying some blood cell, or component. Helen Parkinson true hematological measurement efo:EFO_0004504 A serum hepcidin measurement is a measurement of the peptide hormone hepcidin. Hepcidin is secreted by the liver and regulates iron metabolism. Helen Parkinson true hepcidin levels serum hepcidin serum hepcidin measurement efo:EFO_0004505 A measurement of telomere length measures the number of TTAGGG repeats at the end of the chromosome. As cell division proceeds telomeres shorten, telomere length is measure of cellular aging. Helen Parkinson http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370421/ true telomere length efo:EFO_0004506 A monocyte early outgrowth colony forming unit measurement is the result of a cell culture assay in which monocytes are plated on fibronectin plates and morphology and growth assessed in an assay which correlates circulating cells and vascular function. The output of the assay is a measure of how many colonies were formed, at what point and their morphology. http://www.stemcell.com/~/media/Technical%20Resources/3/29012_CFUHill_3_0_1.ashx true early outgrowth endothelial progenitor cell colony forming units monocyte early outgrowth colony forming units monocyte early outgrowth colony forming unit efo:EFO_0004507 A D dimer measurement is a quantification of a fibrinogen degradation product in blood used in the diagnosis of thrombosis. Helen Parkinson http://en.wikipedia.org/wiki/D-dimer true D-dimer levels fibrin D-dimer levels plasma D-dimer levels D dimer measurement efo:EFO_0004508 Spine bone size is a measurement of the dimensions of the spine. Helen Parkinson true spine bone size efo:EFO_0004509 Hemoglobin measurement is a measure of the quantity of the metallo protein hemoglobin in blood often used in the diagnosis of anaemia. hemoglobin levels Helen Parkinson true NCIt:C64848 Hb haemoglobin measurement hemoglobin count hemoglobin measurement efo:EFO_0004510 HPV seropositivity is the result of a measurement of circulating human papilloma virus specific antibodies used in the diagnosis of HPV infection. Helen Parkinson true HPV seropositivity efo:EFO_0004511 Femoral neck bone geometry is the quantification of the dimensions of the femoral neck bone of the femur. Femoral neck bone geometry is used in determining risk of hip fracture. Helen Parkinson true femoral neck bone geometry efo:EFO_0004512 true bone measurement efo:EFO_0004513 Bone geometry is the measure of the dimensions of some bone. Bone geometry is used as a predictive indicator of fracture risk. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/16822403 bone geometry efo:EFO_0004514 A bone quantitative ultrasound measurement is the output of a an ultrasound process in which bones are assayed using ultrasound and information about bone density, cortical thickness, elasticity and microarchitecture may be returned. Helen Parkinson true bone quantitative ultrasound broadband ultrasound attenuation bone quantitative ultrasound measurement efo:EFO_0004515 A muscle mass measurement is the quantification of the mass of a muscle e.g. skeletal muscle for an individual. Helen Parkinson true muscle mass muscle mass measurement muscle measurement efo:EFO_0004516 A fracture related measurement is a measure of some bone or muscular entity which collectively are used to determine the risk of bone fracture e.g. bone density, muscle mass etc. Helen Parkinson true fracture-related traits bone fracture related measurement efo:EFO_0004517 An Arterial stiffness measurement is the information output of a non invasive pulse wave velocity assay. Arterial stiffness is a predictor of cardiovascular mortality Helen Parkinson true arterial stiffness arterial stiffness measurement efo:EFO_0004518 A creatinine measurement is a measure of the metabolite creatinine in a sample. For example, in the serum, where it can be used in assessment of kidney function. Elliot Sollis Helen Parkinson http://labtestsonline.org.uk/understanding/analytes/creatinine/ true NCIt:C61023 creatinine levels serum creatinine levels serum creatinine measurement creatinine measurement efo:EFO_0004519 The measurement of the soluble component of the P-selectin adhesion molecule. Soluble P-selection is associated with adverse cardiovascular events. Alternative terms include: CD62 antigen-like family member P Granule membrane protein 140 GMP-140 Leukocyte-endothelial cell adhesion molecule 3 LECAM3 Platelet activation dependent granule-external membrane protein PADGEM Helen Parkinson true NCIt:C120650 sP-selectin soluble P-selectin level soluble P-selectin measurement efo:EFO_0004520 A soluble ICAM-1 measurement is the quantification of the ICAM-1 protein. ICAM-1 levels are associated with adverse cardiovascular events. Helen Parkinson https://en.wikipedia.org/wiki/ICAM-1 true sICAM-1 soluble ICAM1 measurement soluble intercellular adhesion molecule-1 ICAM-1 measurement efo:EFO_0004522 A soluble adhesion molecule measurement is a quantification of the soluble compoment (as opposed to membrane bound) a molecule known to participate in the process of adhesion, levels of which may be implicated in cardiovascular adverse events. true soluble adhesion molecule measurement adhesion molecule measurement efo:EFO_0004526 A mean corpuscular volume is the result of calculation of the mean volume of erythrocytes in a blood sample. Helen Parkinson true MedDRA:10027008 MCV mean cell volume mean corpuscular volume efo:EFO_0004527 The MCH is the average mass of hemoglobin per red blood cell in a sample of blood and is calculated by dividing the total mass of hemoglobin by the RBC count true MedDRA:10055624 MCH mean corpuscular haemoglobin mean corpuscular hemoglobin efo:EFO_0004528 The mean corpuscular hemoglobin concentration is a measure of the concentration of hemoglobin in a given volume of packed red blood cell Helen Parkinson true NCIt:C139067 CHCM Corpuscular HGB Concentration Mean Corpuscular Hemoglobin Concentration Mean Erythrocyte Corpuscular Hemoglobin Concentration Mean MCHC mean corpuscular haemoglobin concentration mean corpuscular hemoglobin concentration efo:EFO_0004529 A measure of circulating lipid Helen Parkinson true NCIt:C74949 lipid measurement efo:EFO_0004530 A triglyceride measurement is a quantification of triglycerides in some body fluid, used as a biomarker for cardiovascular disease. Helen Parkinson true NCIt:C64812 triglyceride levels triglyceride measurement efo:EFO_0004531 A urate measurement is the quantification of some urate in body fluid Helen Parkinson true NCIt:C64814 urate levels urate measurement efo:EFO_0004532 Serum gamma-glutamyl transferase level measurement is the quantification of gamma-glutamyl transferase in blood. Gamma-glutamyl transferase is used as a marker for liver/bile duct problems and alcohol abuse. Helen Parkinson true SNOMEDCT:313849004 GGT measurement Gamma gluatamyl transferase levels Gamma glutamyl transpeptidase levels gamma glutamyl transferase measurement serum gamma-glutamyl transferase measurement efo:EFO_0004533 Alkaline phosphatase measurement is a quantification of alkaline phosphatase in blood. AP is a marker for bone and liver disease. Helen Parkinson http://www.nlm.nih.gov/medlineplus/ency/article/003470.htm true NCIt:C64432 SNOMEDCT:88810008 AP alkaline phosphatase measurement efo:EFO_0004534 A creatine kinase measurement is a quantification of creatine kinase in blood. Creatine kinase is a marker for tissue damage and is assayed in blood tests as a marker of myocardial infarction (heart attack), rhabdomyolysis (severe muscle breakdown), muscular dystrophy, the autoimmune myositides and in acute renal failure. Helen Parkinson true NCIt:C64489 SNOMEDCT:397798009 creatine kinase measurement efo:EFO_0004535 An albumin measurement is a quantification of albumin in blood. Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca2+, Na+, K+, fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc. Low levels of albumin in the blood may indicate liver disease. Helen Parkinson http://en.wikipedia.org/wiki/Serum_albumin http://labtestsonline.org.uk/understanding/analytes/albumin/tab/test/ http://www.uniprot.org/uniprot/P02768 true NCIt:C61015 blood albumin serum albumin measurement efo:EFO_0004536 A total blood protein measurement is a quantification of protein in a blood sample. It is used as a marker for disease and nutrition. It is performed in the liquid portion of blood and typically measures albumin and globulin. true TBP serum total protein total blood protein measurement efo:EFO_0004541 A quantification of glycated A1c hemoglobin in blood used as an index for blood glucose level over several months. Glycated hemoglobin is preferred over glycosylated hemoglobin to reflect the correct (non-enyzmatic) process. Early literature often used glycosylated as it was unclear which process was involved until further research was performed. The terms are still sometimes used interchangeably in English language literature. (See https://en.wikipedia.org/wiki/Glycated_hemoglobin) Helen Parkinson Zoe May Pendlington true NCIt:C64849 A1C measurement A1c measurement Glycosylated Hemoglobin Glycosylated Hemoglobin Measurement HBA1C HbA1c levels Hemoglobin A1C glycated hemoglobin levels glycosylated Haemoglobin A level glycosylated Hemoglobin A level HbA1c measurement efo:EFO_0004550 Is the quantification of amygdala response to stimulus using MRI. The amygdala is implicated in many mental and behavioual disorders. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/22856363 true amygdala reactivity measurement efo:EFO_0004554 Is a quantification of some aspect of the genome, e.g. copy number variation at some locus. Helen Parkinson genomic measurement efo:EFO_0004555 Is the quantification of some glycoprotein. Helen Parkinson true glycoprotein measurement efo:EFO_0004556 Is the quantification of some antibody Helen Parkinson true SNOMEDCT:3527003 antibody measurement efo:EFO_0004557 Is the quantification of some measureable quality of a population e.g. birth rate. Helen Parkinson population measurement efo:EFO_0004565 A serum immunoglobulin G measurement is the measurement of the IgG antibody isotype produced by plasma cells in response to an immunogen and which function as antibodies, measured in serum http://labtestsonline.org.uk/understanding/analytes/immunoglobulins/tab/test/ true IgG level immunoglobulin G level serum IgG measurement efo:EFO_0004568 The measurement of the non-albumin portion of blood protein (globulin) in serum Helen Parkinson true serum non-albumin protein measurement efo:EFO_0004569 A serotonin transported measurement is the quantification of serotonin transporter. Serotonin transporter regulates the levels of extracellular serotonin. The 5-HTT levels in brain can be measured using PET. Helen Parkinson true 5-HTT brain serotonin transporter levels brain serotonin transporter measurement efo:EFO_0004570 A bilirubin measurement is a quantification of bilirubin typically measured in serum. Helen Parkinson true SNOMEDCT:302787001 bilirubin levels bilirubin measurement efo:EFO_0004571 A butyrylcholinesterase measurement is a quanitification of butyrylcholinesterase a non-specific cholinesterase enzyme that hydrolyses many different choline esters. It is found in liver in humans. Helen Parkinson http://en.wikipedia.org/wiki/Butyrylcholinesterase true NCIt:C111142 butyrylcholinesterase levels butyrylcholinesterase measurement efo:EFO_0004572 A C4BP measurement is the quantification of C4BP, it controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component. (Uniprot defintion). Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thrombosis based on GWAS and gene expression studies. Helen Parkinson http://en.wikipedia.org/wiki/C4b-binding_protein true C4b binding protein levels C4b-binding protein levels C4b-binding protein measurement C4BP measurement efo:EFO_0004573 A chemerin measurement is a quantification of chemerin typically in serum. Chemerin is an adipokine with important regulatory roles in adipogenesis. In humans, serum total chemerin (i.e. prochemerin plus chemerin) levels are positively associated with body mass index and metabolic syndrome (http://www.ncbi.nlm.nih.gov/pubmed/20363880) true RAR-responsive protein TIG2 measurement Retinoic acid receptor responder protein 2 measurement Tazarotene-induced gene 2 protein measurement chemerin levels chemerin measurement efo:EFO_0004574 A total cholesterol measurement is the quantification of cholesterol in blood, total cholesterol is defined as the sum of HDL, LDL, and VLDL. Helen Parkinson true SNOMEDCT:121868005 cholesterol, total total cholesterol levels total cholesterol measurement efo:EFO_0004575 An e-selectin measurement is the quantification of e-selectin typically measured in serum. E-selectin is a cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. In humans. It is also used as a cancer biomarker. Helen Parkinson doi:10.1093/jjco/hyq095. PMID 20576794. http://en.wikipedia.org/wiki/E-selectin true CD62 antigen-like family member E measurement E-selectin levels endothelial-leukocyte adhesion molecule 1measurement eukocyte-endothelial cell adhesion molecule 2 measurement soluble e-selectin levels e-selectin measurement efo:EFO_0004576 A fetal hemoglobin measurement is the quantification of fetal hemoglobin typically measured in the blood of children for diagnosis of congenital disease. Helen Parkinson true NCIt:C92262 UMLS:C0200695 Fetal Hemoglobin HGBF HbF levels Hemoglobin F fetal haemoglobin measurement fetal hemoglobin levels fetal hemoglobin measurement efo:EFO_0004577 The infant head circumference is the measurement of the diameter of the head and is a routine measure made during human development as a broad indicator of child development. It can be used as a proxy for brain development true infant head circumference efo:EFO_0004578 A homocysteine measurement is the quantification of homocsyteine in blood or urine and is used in the diagnosis of B12 and/or folate deficiency, and as part of a cardiac risk assessment. Helen Parkinson true SNOMEDCT:104733005 homocysteine levels homocysteine measurement efo:EFO_0004579 A serum immunoglobulin E measurement is the measurement of the IgE antibody isotype produced by plasma cells in response to an immunogen and which function as antibodies, measured in serum. IgE's main function is immunity to parasites such as parasitic worms and it plays an essential role in the allergy disorder, and is especially associated with type I hypersensitivity. Helen Parkinson http://en.wikipedia.org/wiki/IgE http://labtestsonline.org.uk/understanding/analytes/immunoglobulins/tab/test/ true IgE levels serum IgE measurement efo:EFO_0004581 An IL-18 measurement is the quantification of IL-18, typically in blood. Helen Parkinson true NCIt:C74814 IL-18 levels IL-18 measurement Interleukin-18 levels interleukin 18 measurement efo:EFO_0004582 A quantification of liver enzymes, typically in blood, used by clinicians to determine liver injury, disease and function. Helen Parkinson http://en.wikipedia.org/wiki/Liver_enzyme true liver enzyme levels liver enzyme measurement efo:EFO_0004584 A measurement of mean platelet volume is a machine-calculated measurement of the average size of platelets found in blood Helen Parkinson http://en.wikipedia.org/wiki/Mean_platelet_volume http://www.ncbi.nlm.nih.gov/pubmed/11280550 true MeSH:D063847 MedDRA:10050539 mean platelet volume efo:EFO_0004585 A quantification of the naphthyl-keratin adduct levels. naphthyl-keratin adduct is used as a marker for exposure to the xenobiotic napthalene. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/22391508 true naphthyl-keratin adduct levels naphthyl-keratin adduct measurement efo:EFO_0004586 A complete blood cell count quantifies specific blood components. http://en.wikipedia.org/wiki/Complete_blood_cell_count true NCIt:C28133 UMLS:C0005771 CBC Complete Blood Count FBC Full Blood Count blood cell count full blood count complete blood cell count efo:EFO_0004587 A quantification of lymphocytes in blood. Helen Parkinson http://www.nlm.nih.gov/medlineplus/ency/article/003657.htm true MeSH:D018655 MedDRA:10025251 NCIt:C51949 SNOMEDCT:74765001 lymphocyte counts lymphocyte count true efo:EFO_0004589 bachial circumference (BC) is a measurement of the diameter of the upper arm and can be used as an indicator of muscle mass and fat tissue. Helen Parkinson true mid arm circumference upper arm circumference brachial circumference efo:EFO_0004611 The measurement of LDL cholesterol in blood used as a risk indicator for heart disease. Helen Parkinson true NCIt:C105588 SNOMEDCT:113079009 LDL measurement low density lipoprotein cholesterol measurement efo:EFO_0004612 The measurement of HDL cholesterol in blood used as a risk indicator for heart disease. true MedDRA:10020060 NCIt:C105587 SNOMEDCT:28036006 HDL measurement high density lipoprotein cholesterol measurement efo:EFO_0004614 Is a quantification of apolipoprotein A 1 in a sample. It is encoded in humans by the APOA1 gene and is the major protein component of high density lipoprotein (HDL) in plasma. Apolipoprotein A 1 relates to lower observational risk of coronary artery disease. Helen Parkinson true https://www.uniprot.org/uniprotkb/P02647/entry apo-AI levels apoA-I levels apolipoprotein A-1 levels apolipoprotein A-I levels apolipoprotein A1 levels apolipoprotein A 1 measurement Is a quantification of apolipoprotein A 1 in a sample. It is encoded in humans by the APOA1 gene and is the major protein component of high density lipoprotein (HDL) in plasma. Apolipoprotein A 1 relates to lower observational risk of coronary artery disease. PMID:32113648 efo:EFO_0004615 The measurement of ApoB in blood. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor, and is upregulated in response to enterovirus 71. Helen Parkinson http://www.uniprot.org/uniprot/P04114 true NCIt:C74734 apolipoprotein B measurement efo:EFO_0004617 is a quantification of serum cystatin C C (formerly gamma trace, post-gamma-globulin or neuroendocrine basic polypeptide),[1] a protein encoded by the CST3 gene, is mainly used as a biomarker of kidney function and kidney disease. Helen Parkinson true NCIt:C92290 cystatin C measurement efo:EFO_0004618 is a quantification of Vitamin K or Phylloquinone, a polycyclic aromatic ketone, based on 2-methyl-1,4-naphthoquinone, with a 3-phytyl substituent. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants, particularly leaves, since it functions as an electron acceptor during photosynthesis, forming part of the electron transport chain of Photosystem I. Helen Parkinson true NCIt:C74907 SNOMEDCT:105030006 phylloquinone measurement vitamin K measurement efo:EFO_0004619 Is a quantification of factor VII in serum, (formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme (EC 3.4.21.21) of the serine protease class. Abnormal measurements of factor VII may be associated with congenital deficiency of factor VII, disseminated intravascular coagulation (DIC), fat malabsorption, liver disease (such as cirrhosis). Vitamin K deficiency, Warfarin (Coumadin) use. http://www.nlm.nih.gov/medlineplus/ency/article/003676.htm true NCIt:C81960 factor VII measurement efo:EFO_0004620 is a quantification of Vitamin B12, vitamin B12 or vitamin B-12, is a water-solublevitamin with a key role in the normal functioning of the brain and nervous system, and for the formation of blood. It is one of the eight B vitamins. It is normally involved in themetabolism of every cell of the human body, especially affecting DNA synthesis and regulation, but also fatty acid synthesis and energy production. It is the largest and most structurally complicated vitamin and can be produced industrially only through bacterial fermentation-synthesis. Helen Parkinson http://en.wikipedia.org/wiki/Vitamin_B12 true NCIt:C64817 SNOMEDCT:14598005 vitamin B12 levels vitamin B12 measurement efo:EFO_0004621 is a quantification of Vitamin B6 a water soluble vitamin Helen Parkinson http://en.wikipedia.org/wiki/Vitamin_B12 true NCIt:C74901 SNOMEDCT:11829003 vitamin B6 levels vitamin B6 measurement efo:EFO_0004622 Is a quantification of sphingolipids - molecules playing a role in signal transmission. Helen Parkinson true Sphingolipid assay sphingolipid measurement efo:EFO_0004623 is a quantification of circulating fibrinogen (factor I) is a soluble plasma glycoprotein, synthesised by the liver, that is converted by thrombin into fibrin during blood coagulation. Helen Parkinson true NCIt:C64606 SNOMEDCT:250346004 fibrinogen levels fibrinogen measurement efo:EFO_0004624 A PSA measurement is the quantification of prostate specific antigen typically in blood used in the diagnosis of prostate cancer. Helen Parkinson true NCIt:C17634 SNOMEDCT:63476009 PSA levels PSA measurement prostate specific antigen levels prostate specific antigen measurement efo:EFO_0004625 A progranulin measurement is a quantification of progranulin, typically in blood. Progranulins are secreted glycosylated peptides implicated in frontotemporal disease, and low levels of progranulin are a risk factor for frontotemporal disease Helen Parkinson true progranulin levels progranulin measurement efo:EFO_0004626 Is the quantification of IGFBP-3, a member of the insulin-like growth factor-binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. Decreased IIGFBP3 protein levels are used as a biomarker for prostate cancer progression. Helen Parkinson true Insulin-Like Growth Factor Binding Protein 3 levels IGFBP-3 measurement efo:EFO_0004627 Is the quantification of Insulin-like growth factor 1 (IGF-1), also called somatomedin C. IGF-1 is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. Levels of IGF-1 are known to increase in some cancers. Helen Parkinson http://en.wikipedia.org/wiki/IGF-1 true Insulin-Like Growth Factor 1 levels IGF-1 measurement efo:EFO_0004628 Is a quantification of any of the insulin like growth factors Helen Parkinson n.wikipedia.org/wiki/Insulin-like_growth_factor true insulin like growth factor measurement efo:EFO_0004629 Is a quantification of von Willebrand factor (vWF) is a blood glycoprotein involved in hemostasis. It is deficient or defective in von Willebrand disease and is involved in a large number of other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic-uremic syndrome.[1] Increased plasma levels in a large number of cardiovascular, neoplastic, and connective tissue diseases are presumed to arise from adverse changes to the endothelium, and may contribute to an increased risk of thrombosis. http://en.wikipedia.org/wiki/Von_Willebrand_factor true NCIt:C98799 vWF von Willebrand factor levels von Willebrand factor measurement efo:EFO_0004630 Is a quantification of factor VIII in serum, Factor VIII (FVIII) is an essential blood clotting protein, also known as anti-hemophilic factor (AHF). In humans, Factor VIII is encoded by the F8 gene.[1][2] Defects in this gene results in hemophilia A. http://en.wikipedia.org/wiki/Factor_viii true NCIt:C81961 factor VIII levels factor VIII measurement efo:EFO_0004631 A quantification of Vitamin D levels, typically in blood. Vitamin D includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE (MeSH). 25-hydroxyvitamin D or calcifediol, a prehormone precursor of vitamin D, is widely used as a proxy to quanitfy vitamin D levels in blood. Helen Parkinson true NCIt:C84818 SNOMEDCT:83729008 is about MeSH:D014807 vitamin D measurement efo:EFO_0004632 A nevus count is the quantification of nevi on the skin. Helen Parkinson https://labtestsonline.org/understanding/analytes/differential/tab/test true nevus count efo:EFO_0004633 Is a quantification of Protein C, also known as autoprothrombin IIA and blood coagulation factor XIV,] is a zymogenic (inactive) protein, the activated form of which plays an important role in regulating blood clotting, inflammation, cell death and maintaining the permeability of blood vessel walls in humans and other animals. http://en.wikipedia.org/wiki/Protein_c true coagulation factor XIV protein C measurement efo:EFO_0004634 A coagulation factor measurement is the quantification of any of the entities involved in the process of coagulation or regulation of coagulation. Abnormal coagulation may result in thrombosis or hemorrhage. true coagulation factor measurement efo:EFO_0004635 is a quantification of circulating soluble leptin receptor levels, these are inversely associated with diabetes risk factors, including adiposity and insulin resistance, and highly correlated with the expression levels of leptin receptor. Variations in the leptin receptor gene are reported to be associated with obesity. Helen Parkinson true leptin receptor levels soluble leptin receptor levels leptin receptor measurement efo:EFO_0004637 is a quantification of protein S, a vitamin K-dependent plasma glycoprotein synthesized in the endothelium involved in anticoagulation and used in the diagnosis of thrombosis. http://en.wikipedia.org/wiki/Protein_s true NCIt:C100436 protein S measurement efo:EFO_0004639 Is a quantification of phospholipids, typically in blood used as a biomarker in diet studies. Helen Parkinson true NCIt:C96623 SNOMEDCT:18284006 plasma phospholipid levels phospholipid measurement efo:EFO_0004640 Helen Parkinson Is a quantifictaion of blood haptoglobin. This test is used as in the diagnosis of tranfusion reaction and haemolytic anaemia. http://www.nlm.nih.gov/medlineplus/ency/article/003634.htm true haptoglobin levels haptoglobin measurement efo:EFO_0004641 White matter integrity is a measure of brain white matter using brain imaging and quantification techniques. White matter integrity is used as a measure of CNS function. Helen Parkinson true white matter integrity efo:EFO_0004642 iI a quantification of secreted cortisol, typically in the blood. Some studies report increased cortisol in depressive patients. Helen Parkinson true cortisol secretion measurement efo:EFO_0004644 Is a measurement of the T-peak to T-end (TPE) interval on an electrocardiogram, is a measure of myocardial dispersion of repolarization and is associated with an increased risk of ventricular arrhythmias. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/22342860 true TPE interval measurement efo:EFO_0004670 Is the quantification of Beta-amyloid 1-42 in cerebrospinal fluid typically used as a biomarker for Alzheimer's Disease true CSF AB1-42 levels CSF Aβ1-42 levels amyloid-beta 1-42 measurement beta-amyloid 1-42 measurement efo:EFO_0004682 The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle http://en.wikipedia.org/wiki/QT_interval true MedDRA:10037701 NCIt:C83501 QT interval efo:EFO_0004684 Is a quantification of tumor necrosis factor-alpha, a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by other cell types as well. The measurement is used as a biomarker for inflammation and is typically performed on a blood sample. true tumor necrosis factor-alpha measurement efo:EFO_0004685 Measurements of the hip. true hip geometry efo:EFO_0004694 Is a quantification of Factor XI, typically in blood. Factor Xi is a serine protease involved in the process of coagulation. Helen Parkinson http://en.wikipedia.org/wiki/Factor_XI true factor XI measurement efo:EFO_0004695 Is a quantification of intraocular pressure. Increased intraocular pressure is a heritable risk factor for primary open angle glaucoma. Helen Parkinson true intraocular pressure measurement efo:EFO_0004696 Is a quantification of sex hormone binding globulin. In men the test is used in when investigating testosterone deficiency. The SHBG glycoprotein binds to circulating estradiol and testosterone, low levels of SHBG may be implicated in breast cancer etiology. Helen Parkinson http://labtestsonline.org.uk/understanding/analytes/shbg/tab/test/ http://www.ncbi.nlm.nih.gov/pubmed/22675492 true SHBG level SHBG levels sex hormone-binding globulin measurement efo:EFO_0004697 Is a quantification of circulating estradiol a circulating steriod sex hormone. true NCIt:C74782 SNOMEDCT:37538009 estradiol levels oestrogen level oestrogen levels estradiol measurement efo:EFO_0004703 The age of onset of (human) menarche, the beginning of the first menstrual cycle in an individual Helen Parkinson true NCIt:C19666 SNOMEDCT:398700009 age at menarche efo:EFO_0004704 The age of onset of (human) menopause, the beginning of the first menstrual cycle in an individual Helen Parkinson true NCIt:C106497 age at menopause efo:EFO_0004713 Helen Parkinson Is the measurement of the ratio of forced expiratory volume (FEV) to forced vital capacity (FCV), used as a measure of pulmonary function. true FEV/FVC FEV1/FVC FEV/FEC ratio efo:EFO_0004724 Carotid-femoral pulse wave velocity (CFPWV) is a heritable measure of aortic stiffness that is strongly associated with increased risk for major cardiovascular disease events. Helen Parkinson https://www.google.com/calendar/render?tab=mc true carotid-femoral pulse wave velocity efo:EFO_0004725 The quantification of some metabolite. This is an annotation class for metabolite measurements where the exact metabolite measurements are unknown. Do not annotate to this class. Helen Parkinson true metabolite levels metabolite traits metabolite measurement efo:EFO_0004728 Is the quantification of serum amyloid A protein in serum and is a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma. Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs). Helen Parkinson http://en.wikipedia.org/wiki/Amyloid_A http://www.ncbi.nlm.nih.gov/pubmed/22593464 true serum amyloid A protein measurement efo:EFO_0004729 The quantification of some vitamin, typically from a body fluid such as blood. A vitamin is an organic compound required by an organism as a vital nutrient in limited amounts. An organic chemical compound (or related set of compounds) is called a vitamin when it cannot be synthesized in sufficient quantities by an organism, and must be obtained from the diet. http://en.wikipedia.org/wiki/Vitamin true NCIt:C74803 SNOMEDCT:122446006 vitamin levels vitamin measurement efo:EFO_0004730 The determination of the amount of hormone present in a sample. true NCIt:C74742 SNOMEDCT:122445005 hormone measurement efo:EFO_0004731 Is a quantification of some eye structure or property of an eye structure, such as corneal thickness. Helen Parkinson true eye measurement efo:EFO_0004732 Is the quantification of some lipoprotein Helen Parkinson true lipoprotein measurement efo:EFO_0004733 Is a quantification of anti-cyclic citrullinated peptide antibody, these are associated with rheumatoid arthritis. Helen Parkinson true anti-cyclic citrullinated peptide antibody measurement efo:EFO_0004735 Is a quantification of serum alanine aminotransferase, most commonly found in liver, the test is used in ascertainment of liver function. Helen Parkinson http://labtestsonline.org.uk/understanding/analytes/alt/tab/test/ true NCIt:C61017 SNOMEDCT:34608000 alanine aminotransferase measurement alanine transaminase measurement serum alanine aminotransferase measurement efo:EFO_0004736 Is a quantification of aspartate aminotransferase, and is commonly used as a marker for liver function. http://en.wikipedia.org/wiki/Aspartate_transaminase true NCIt:C64467 SNOMEDCT:45896001 Aspartate transaminase measurement aspartate aminotransferase measurement efo:EFO_0004737 Is a quantification of some carotenoid, typically in blood. These are lipid based compounds derived from chloroplasts and chromoplasts of plants and some other photosynthetic organisms. Consumption of a diet rich in carotenoids is reported to have health benefits for human populations. http://en.wikipedia.org/wiki/Carotenoid true carotenoid measurement efo:EFO_0004738 Is a quantification of some tocopherol, typically in blood. Some tocopherols have Vitamin E function (note that tocotrienols also have vitamin E function). Helen Parkinson true tocopherol measurement efo:EFO_0004739 Is a quantification of circulating cell free DNA measured in blood used as an indicator of cell death and as an indicator of disease, for example some tumour types release this. http://www.ncbi.nlm.nih.gov/pubmed/21990379 http://www.ncbi.nlm.nih.gov/pubmed/22511988 http://www.ncbi.nlm.nih.gov/pubmed/24553385 true circulating cell free DNA level circulating cell free DNA levels circulating cell free DNA measurement efo:EFO_0004741 Is a quantification of blood urea nitrogen used in the measure of renal function. Helen Parkinson true NCIt:C61019 SNOMEDCT:105011006 blood urea nitrogen measurement efo:EFO_0004742 Is a quantification of some renal system biomarker Helen Parkinson true renal system measurement efo:EFO_0004744 Is a quantification of matrix metalloproteinases, Collectively, they are capable of degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine/cytokine in/activation.[3] MMPs are also thought to play a major role on cell behaviors such as cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense. Helen Parkinson http://en.wikipedia.org/wiki/Matrix_metalloproteinase true matrix metalloproteinase measurement efo:EFO_0004745 Is a quantification of NT-proBNP (N-terminal prohormone of brain natriuretic peptide) which is associated with acute congestive heart failure. Helen Parkinson http://en.wikipedia.org/wiki/NT-proBNP true NT-proBNP measurement efo:EFO_0004746 Is a quantification of Lipoprotein-associated phospholipase A(2). It is involved in the process of arthrosclerosis and is a cardiovascular disease biomarker. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/20442857 true Lipoprotein-associated phospholipase A(2) level Lipoprotein-associated phospholipase A(2) levels lipoprotein-associated phospholipase A(2) measurement efo:EFO_0004747 Is a quantification of some protein, typically obtained from an individual with the intention of using the measurement in some diagnostic process. This is a general class for any measurement of a protein. Do not annotate to this class, request a more specific child term. Helen Parkinson true SNOMEDCT:74040009 protein levels protein measurement efo:EFO_0004748 Is a quantification of thyroid-stimulating hormone, a glycoprotein and hormone secreted from the pituitary which regulates the thryoid. Helen Parkinson http://en.wikipedia.org/wiki/Thyrotropin http://labtestsonline.org.uk/understanding/analytes/tsh/tab/test/ true NCIt:C64813 SNOMEDCT:61167004 thyroid stimulating hormone level thyroid stimulating hormone levels thyrotropin measurement thyroid stimulating hormone measurement efo:EFO_0004749 Is the quantification of Chemokine (C-C motif) ligand 2, involved in response to infection and inflammation. Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. CCL2 is reported to be associated with Alzheimer's disease e.g. http://www.ncbi.nlm.nih.gov/pubmed/22303443 and http://europepmc.org/abstract/MED/25340798 Helen Parkinson http://en.wikipedia.org/wiki/CCL2 http://www.uniprot.org/uniprot/P13500 true MCP-1 measurement MCP1 measurement chemokine CCL2 level chemokine CCL2 levels monocyte chemoattractant protein-1 measurement monocyte chemotactic protein-1 level monocyte chemotactic protein-1 levels monocyte chemotactic protein-1 measurement CCL2 measurement efo:EFO_0004750 Is a quantification of interleukin 10, typically in blood. Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells. interleukin 10 levels Helen Parkinson http://www.uniprot.org/uniprot/P22301 true NCIt:C74806 interleukin 10 measurement efo:EFO_0004751 Is the quantification of Chemokine (C-C motif) ligand 4, involved in response to infection and inflammation, chemoattractant for natural killer cells, monocytes and a variety of other immune cells. http://en.wikipedia.org/wiki/CCL4 true Chemokine (C-C motif) ligand 4 level Chemokine (C-C motif) ligand 4 levels Chemokine (C-C motif) ligand 4 measurement macrophage inflammatory protein-1b CCL4 measurement efo:EFO_0004752 Is the quantification of parathyroid hormone, typically in blood. The protein encoded by this gene is a hormone secreted by parathyroid cells. This hormone elevates blood Ca2+ level by dissolving the salts in bone and preventing their renal excretion. Defects in this gene are a cause of familial isolated hypoparathyroidism (FIH) (RefSeq), High level s of parathyroid hormone are also used in the diagnostics for hypo and hyper calcemia, primary and secondary hyper parathyroidism. Low values are used in the diagnostics of hypoparathyroidism. Helen Parkinson http://www.acb.org.uk/Nat%20Lab%20Med%20Hbk/Parathyroid%20hormone.pdf http://www.ncbi.nlm.nih.gov/nuccore/NM_000315.2 true SNOMEDCT:3352000 parathyroid hormone measurement efo:EFO_0004753 Is a quantification of interleukin 12. Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. Helen Parkinson http://en.wikipedia.org/wiki/Interleukin_12 true NCIt:C74808 interleukin 12 measurement efo:EFO_0004754 Is a quantification of Interleukin 1 Receptor Antagonist (IL1-RA). Inhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure Helen Parkinson http://www.uniprot.org/uniprot/P18510 true NCIt:C112324 interleukin 1 receptor antagonist measurement efo:EFO_0004760 Is a quantification of total tau protein, a biomarker for Alzheimer's disease. Helen Parkinson true t-tau measurement efo:EFO_0004761 Is a quantification of uric acid, typically in blood. Uric acid is associated with gout, insulin resistance and cardivascular disease. Helen Parkinson http://labtestsonline.org.uk/understanding/analytes/uric-acid/tab/test true SNOMEDCT:86228006 uric acid level uric acid levels uric acid measurement efo:EFO_0004762 Is a quantification of VEGF, a growth factor involved in angiogenesis and a biomarker for cancer. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813747/ true NCIt:C92514 vascular endothelial growth factor measurement efo:EFO_0004763 Is a quantification of phosphorylated tau protein, used as a biomarker for Alzheimer's disease. Helen Parkinson true p-tau measurement efo:EFO_0004764 Is a quantification of some aspect of adipose tissue, for example used in the diagnosis and research into obesity. Helen Parkinson true adipose tissue measurement efo:EFO_0004765 Is a quantification of a particular location of adipose tissue. Helen Parkinson true visceral adipose tissue measurement efo:EFO_0004766 Is a quantification of adipose tissue located beneath the skin. Helen Parkinson true subcutaneous adipose tissue measurement efo:EFO_0004767 Is a quantification of visceral to subcutaneous adipose tissue. Helen Parkinson true visceral:subcutaneous adipose tissue ratio efo:EFO_0004768 Is a quantification of follicle stimulating hormone. ollicle-stimulating hormone (FSH) is a hormone found in humans and other animals. It is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the body. FSH and luteinizing hormone (LH) act synergistically in reproduction. Specifically, an increase in FSH secretion by the anterior pituitary causes ovulation. FSH measurements are used as a biomarker of oocyte reserve. Helen Parkinson http://en.wikipedia.org/wiki/Follicle-stimulating_hormone true NCIt:C74783 SNOMEDCT:31003009 FSH level FSH levels follicle stimulating hormone level follicle stimulating hormone levels follicle stimulating hormone measurement efo:EFO_0004769 Is a quantification of anti_Mullerian hormone, and is used as a biomarker of ovarian reserve. The AMH is produced by the granulosa cells of the early developing antral follicles. These are the immature eggs that wake up from their dormant state and develop into mature eggs. As the number of oocytes decline, the number of small antral follicles decline in number and the serum Anti-Mullerian hormone level falls. Helen Parkinson http://www.repromed.com.au/custom/files/AMH%20Information%20Sheet%20for%20Doctors%203.4.09.pdf true NCIt:C120625 anti-Mullerian hormone level anti-Mullerian hormone levels anti-Mullerian hormone measurement efo:EFO_0004770 Ovarian reserve is a term that is used to determine the capacity of the ovary to provide oocytes that are capable of fertilization resulting in a healthy and successful pregnancy. Ovarian reserve is correlated with levels of FSH and anti-Mullerian hormones. Helen Parkinson http://en.wikipedia.org/wiki/Ovarian_reserve true MeSH:D065851 ovarian reserve efo:EFO_0004771 quantification of the surface area of the visual cortex. The visual cortex is located in the occipital lobe at the back of the brain. It is variable and heritable, and is correlated with visual acuity and visual perception. true PMID:22343285 visual cortical surface area measurement efo:EFO_0004779 The CHAOS (Confusion, Hubbub and Order) scale is a questionnaire filled out by parents that is designed to assess the level of confusion and disorganization in the child’s home environment. Helen Parkinson CHAOS scale http://www.acf.hhs.gov/programs/opre/ehs/perf_measures/reports/resources_measuring/res_meas_phih.html true CHAOS score CHAOS measure efo:EFO_0004780 Helen Parkinson A measure of social behaviour used in behavioral studies to examine autistic like traits. DSM-IV-based social scale efo:EFO_0004781 A measure of non social behaviour used in behavioral studies to examine autistic like traits. Helen Parkinson http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797846/? DSM-IV-based non-social scale efo:EFO_0004782 Measurements used to quantify, or assess individual or population behaviour or disorderd behaviours, e.g. by adminsistration of a questionaire. Helen Parkinson true behavior or behavioral disorder measurement efo:EFO_0004783 Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A). The TEMPS-A is designed to assess lifelong, milder aspects of bipolar symptomatology and defines five temperaments: hyperthymic, dysthymic, cyclothymic, irritable, and anxious. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/22365631 true TEMPS-A questionnaire efo:EFO_0004784 A measure of educational progress reported using a questionnaire based approach, often used as a proxy for cognitive performance as the two are correlated. Helen Parkinson true self reported educational attainment efo:EFO_0004785 The South Texas Assessment of Neurocognition (STAN) is a 90-min primarily computerized battery of standard and experimental neuropsychological tests. The STAN combines software developed for psychological experimentation (E-Prime) and database software (Microsoft ACCESS) with a user interface developed in visual basic to provide a fully automated testing environment which logs subject information, administers tests in a pre-defined order and databases subject performance at the completion of each test. Helen Parkinson http://www.glahngroup.org/research/neuropsychology/ true South Texas Assessment of Neurocognition efo:EFO_0004786 The Mini-international neuropsychiatric interview is a short structured clinical interview which enables researchers to make diagnoses of psychiatric disorders according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) or ICD-10. The administration time of the interview is approximately 15 minutes and was designed for epidemiological studies and multicenter clinical trials. Helen Parkinson http://en.wikipedia.org/wiki/Mini-international_neuropsychiatric_interview Mini-International Neuropsychiatric Interview efo:EFO_0004789 Is a quantification of the 126-amino acid C-terminal fragment of the ANP precursor, an approximately 150-amino acid polypeptide in a number of species. It is formed by the removal of the N-terminal signal sequence ANP (1-24). This prohormone contains various active ANF sequences. ANF is is a powerful vasodilator, and a protein (polypeptide) hormone secreted by heart muscle cells.[1][2][3] It is involved in the homeostatic control of body water, sodium, potassium and fat (adipose tissue). Increased levels of ANP are associated with heart failure. Helen Parkinson http://en.wikipedia.org/wiki/Atrial_natriuretic_factor true is about MeSH:D017461 atrial natriuretic factor measurement efo:EFO_0004790 Is a quantification of CD40 ligand, primarily expressed on activated CD4+ T lymphocytes. Protein function - mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching.1 Publication Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway. Helen Parkinson D023201 http://en.wikipedia.org/wiki/CD40_ligand http://www.uniprot.org/uniprot/P29965 true NCIt:C82007 CD154 ligand measurement CD40 ligand measurement efo:EFO_0004791 Is a quantification of tissue plasminogen activator, an enzyme which converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration. Helen Parkinson http://europepmc.org/abstract/MED/24578379 http://www.uniprot.org/uniprot/P00750 true tissue plasminogen activator measurement efo:EFO_0004792 Is a quantification of plasminogen activator inhibitor 1 a serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis Helen Parkinson http://www.uniprot.org/uniprot/P05121 true PAI-1 measurement PAI1 measurement plasminogen activator inhibitor 1 measurement efo:EFO_0004798 A quantification of a genomic variation that increases or decreases the copy number of a given region. Helen Parkinson http://purl.org/obo/owl/SO#SO_0001019 copy number variation efo:EFO_0004800 Is a quantification of frontal theta event related oscillations, determined by target processing in an oddball paradigm. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/22554406 true frontal theta oscillation measurement efo:EFO_0004802 Is a quantification of family size, also used as a measure of male fertility. Helen Parkinson true family size efo:EFO_0004804 Is a quantification of birth rate, te ratio of live births in an area to the population of that area, expressed per 1000 people in the population per year. Also used as a measure of male fertility Helen Parkinson true MeSH:D001723 NCIt:C53345 birth rate efo:EFO_0004806 Is a quantification of some asbestos exposure, Helen Parkinson http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Asbestos_Exposure true asbestos exposure measurement efo:EFO_0004807 Is a quantification of sleep time in humans where average sleep time was less than five hours. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/22322875 true short sleep efo:EFO_0004808 Is a quantification of L lactate dehydrodgenase, typically measured in serum, used as a marker of tissue breakdown as LDH is abundant in red blood cells and can function as a marker for hemolysis Helen Parkinson http://en.wikipedia.org/wiki/Lactate_dehydrogenase true L lactate dehydrogenase measurement efo:EFO_0004809 Is a quantification of Fructose-Bisphosphate Aldolase,is an enzyme catalyzing a reversible reaction that splits the aldol, fructose 1,6-bisphosphate, into the triose phosphates dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (GAP). Helen Parkinson http://en.wikipedia.org/wiki/Fructose-bisphosphate_aldolase true SNOMEDCT:104670006 fructose-bisphosphate aldolase measurement efo:EFO_0004810 Is a quantification of interleukin-6, a pro-inflammatory and anti-inflammatory cytokine. Helen Parkinson http://en.wikipedia.org/wiki/Interleukin-6 true IL-6 level IL-6 levels IL-6 measurement interleukin-6 measurement efo:EFO_0004811 Is a quantification of interleukin-8, is a chemokine produced by macrophages and other cell types such as epithelial cells. It is also synthesized by endothelial cells, which store IL-8 in their storage vesicles, the Weibel-Palade bodies. IL-8 is secreted and is an important mediator of the immune reaction in the innate immune system response. Helen Parkinson http://en.wikipedia.org/wiki/Interleukin_8 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893518/ true IL-8 level IL-8 levels IL-8 measurement interleukin-8 measurement efo:EFO_0004812 Is a quantification of interleukin-1 beta, an IL-1 cytokine family protein, secreted by macrophages and a mediator of inflammatory response. Helen Parkinson http://en.wikipedia.org/wiki/Interleukin-1_beta true interleukin 1 beta measurement interleukin-1 beta measurement efo:EFO_0004813 Is a quantification of any of the alpha globulin class of proteins, typically in serum. Helen Parkinson true This is a container class for the alpha globulins, which will be child terms of it. E.g. haptoglobin, see also: α1-antitrypsin Alpha 1-antichymotrypsin Orosomucoid (acid glycoprotein) Serum amyloid A Alpha 1-lipoprotein [edit]Alpha 2 globulins Haptoglobin Alpha-2u globulin α2-macroglobulin Ceruloplasmin Thyroxine-binding globulin Alpha 2-antiplasmin Protein C Alpha 2-lipoprotein Angiotensinogen is about MeSH:D000510 alpha globulin measurement efo:EFO_0004814 Is a quantification of the IL-6 receptor (CD126), activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis. Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation. Helen Parkinson http://en.wikipedia.org/wiki/Interleukin-6_receptor http://www.uniprot.org/uniprot/P05231 http://www.uniprot.org/uniprot/P08887 true interleukin-6 receptor measurement efo:EFO_0004815 Is a quantification of alphamacroglobulins 1 and/or 2, glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters. Chronic kidney disease can result in the leakage of alphamacroglobulins into the blood. Helen Parkinson http://en.wikipedia.org/wiki/Alpha-macroglobulin true alpha macroglobulin measurement efo:EFO_0004818 Is a quantification of any of the TF1b isoforms, TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of oncogenesis. Helen Parkinson http://en.wikipedia.org/wiki/Transforming_growth_factor_beta true transforming growth factor beta measurement efo:EFO_0004819 Is a quantification of resistin, a cytokine secreted by immune and epithelial cells in human and associated with obseity and type II diabetes by some studies Helen Parkinson http://www.uniprot.org/uniprot/Q9HD89 true NCIt:C80205 resistin level resistin levels resistin measurement efo:EFO_0004820 The number of males per 100 females, usually counted for live births but sometimes applied at a later life stage Helen Parkinson true MeSH:D012744 sex ratio efo:EFO_0004825 An inventory for personality traits devised by Cloninger et al. Traits scored include: Novelty Seeking (NS) Harm Avoidance (HA) Reward Dependence (RD) Persistence (PS) Self-Directedness (SD) Cooperativeness (CO) Self-Transcendence (ST) Helen Parkinson true temperament and character inventory efo:EFO_0004828 The genetic variation of individuals in a population. Helen Parkinson true MeSH:D014644 NCIt:C17248 SNOMEDCT:64195000 genetic variation efo:EFO_0004830 The volume of the caudate nucleus, a brain structure implicated in many common neurological and psychiatric disorders Helen Parkinson true caudate nucleus volume efo:EFO_0004831 A RR interval is an electrocardiography measurement - R wave to R wave interval (RR interval) and is the inverse of the heart rate. Helen Parkinson https://en.wikipedia.org/wiki/Heart_rate#Electronic_measurement true RR interval efo:EFO_0004832 Is a quantification of the optic disk size Helen Parkinson true optic disc size measurement efo:EFO_0004833 Is a quantification of neutrophils in blood. The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. Helen Parkinson true CMO:0000030 MedDRA:10029363 NCIt:C51950 SNOMEDCT:30630007 blood neutrophil count neutrophil count efo:EFO_0004838 Is a quantification of calcium, typically in serum. Calcium (Ca2+) plays a pivotal role in the physiology and biochemistry of organisms and the cell. It plays an important role in signal transduction pathways, where it acts as a second messenger, in neurotransmitter release from neurons, contraction of all muscle cell types, and fertilization. Many enzymes require calcium ions as a cofactor, those of the blood-clotting cascade being notable examples. Extracellular calcium is also important for maintaining the potential difference across excitable cell membranes, as well as proper bone formation. Helen Parkinson http://en.wikipedia.org/wiki/Blood_calcium#Measurement true NCIt:C64488 SNOMEDCT:71878006 calcium levels calcium measurement efo:EFO_0004839 Is the ratio of CD4 vs. CD8 lymphocytes, abormal ratios may reflect an infection such as HIV and the measurement may be used as an indicator of disease progression. Helen Parkinson http://europepmc.org/abstract/MED/26130226 true CD4:CD8 lymphocyte ratio efo:EFO_0004840 Is a quantification of the thickness of brain cortex, e.g. measured by MRI, used in the diagnosis of Alzheimer's disease and other neurological conditions Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/21810643 true cortical thickness efo:EFO_0004841 Is the ratio of 2D:4D used a a marker for prenatal androgen exposure. Helen Parkinson http://www.ncbi.nlm.nih.gov/pubmed/20303062 true digit length ratio efo:EFO_0004842 Is a quantification of eosinphils in blood. The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. Helen Parkinson true CMO:0000033 MedDRA:10014941 NCIt:C64550 SNOMEDCT:71960002 blood eosinophil count eosinophil count efo:EFO_0004843 Is a quantification of any or all of the B vitamins Helen Parkinson true vitamin B measurement efo:EFO_0004844 Is a quantification of the size of a human hip bone. Helen Parkinson true hip bone size efo:EFO_0004845 Is a quantification of magnesium in serum. Helen Parkinson true NCIt:C64840 SNOMEDCT:38151008 magnesium measurement efo:EFO_0004846 Is the quantification of circulating serotonin (5HT), a monoamine neurotransmitter Helen Parkinson https://labtestsonline.org/understanding/analytes/serotonin/tab/test true NCIt:C74872 SNOMEDCT:50880007 serotonin measurement efo:EFO_0004847 The age at which some process, or disease started in a human individual. Helen Parkinson true age at onset efo:EFO_0004857 Is the quantification of any vitamin A compound. Helen Parkinson true NCIt:C74895 SNOMEDCT:76609004 vitamin A measurement efo:EFO_0004860 Is a quantification of the common carotid intimal medial thickness. Helen Parkinson true common carotid intimal medial thickness efo:EFO_0004861 Is the quantification of serum phosphorus used in the diagnosis of hyper or hypophosphatemia, and used in the diagnosis of disease. Helen Parkinson http://www.nlm.nih.gov/medlineplus/ency/article/003478.htm true SNOMEDCT:8364005 phosphorus measurement efo:EFO_0004862 Is the quantification of phytosterol, plant derived cholesterol like compounds. Helen Parkinson true phytosterol measurement efo:EFO_0004863 Is the genome wide recombination rate. Helen Parkinson true recombination rate efo:EFO_0004864 Is the quantification of adipose tissue located in the renal sinus(es), correlated with chronic kidney disease and obesity. Helen Parkinson true renal sinus adipose tissue measurement efo:EFO_0004865 Is a quantification of the volume of the thyroid. Helen Parkinson true thyroid volume efo:EFO_0004866 Is a quantification of an autoantibody, an antibody produced by the immune system and directed against an individual's own protein. e.g. anti-islet autoantibodies. Helen Parkinson http://en.wikipedia.org/wiki/Autoantibody http://www.ncbi.nlm.nih.gov/pubmed/21829393 true SNOMEDCT:314067002 autoantibody measurement efo:EFO_0004867 Is a quantification of vitamin E. Helen Parkinson true NCIt:C74906 SNOMEDCT:7557006 vitamin E measurement efo:EFO_0004868 Is a quantification of brain volume using magnetic resonance imaging. Helen Parkinson true volumetric brain MRI efo:EFO_0004869 Is a quantification of the secreted glycoprotein YKL-40 (Chitinase-3-like protein 1) YKL-40 has been associated with asthma, inflammatory disease and cancer progression. Helen Parkinson http://en.wikipedia.org/wiki/CHI3L1 http://europepmc.org/abstract/MED/25592985 true CHI3L1 levels CHI3L1 measurement Chitinase-3-like protein 1 levels Chitinase-3-like protein 1 measurement YKL-40 levels YKL40 measurement efo:EFO_0004870 Is a quantification of some sleep parameter. Helen Parkinson true sleep measurement efo:EFO_0004872 Is a quantification of any molecule involved in the process of inflammatory response. Helen Parkinson true inflammatory marker measurement A container class for inflammatory biomarker measurements, populated by selecting all human proteins annotated with inflammatory response, or a child term, and including measurements of these proteins in this class. Only protein-GO term associations with a curated evidence code were considered, so IEA for e.g. were excluded. inflammatory biomarker measurement efo:EFO_0004873 Is a quantification of some cytokine, secreted cell signalling molecules. Helen Parkinson true NCIt:C74804 cytokine measurement efo:EFO_0004874 Is a quantification of a subject's activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. Memory performance is typically assessed by some clinical memory test and is used in the diagnosis of diseases such as Alzheimer's disease. Helen Parkinson http://purl.bioontology.org/ontology/SNOMEDCT/363888004 true SNOMEDCT:363888004 memory performance efo:EFO_0004880 Is the quantification of arsenic urine. Helen Parkinson true urinary arsenic measurement efo:EFO_0004884 Is a quantification of some aspect of breast size Helen Parkinson true SNOMEDCT:248808008 mammary gland size breast size efo:EFO_0004885 Early repolarization pattern (ERP) is a common ECG variant, characterized by J point elevation manifested either as terminal QRS slurring (the transition from the QRS segment to the ST segment) or notching (a positive deflection inscribed on terminal QRS complex) associated with concave upward ST-segment elevation and prominent T waves in at least two contiguous leads. Helen Parkinson http://circ.ahajournals.org/content/124/20/2185 true early cardiac repolarization measurement efo:EFO_0004886 Is a quantification of intracranial volume. Helen Parkinson true intra cranial volume measurement intracranial volume measurement efo:EFO_0004887 Is the quantification of is the maximum capacity of an individual's body to transport and use oxygen during incremental exercise, and is used as an indicator of physical fitness Helen Parkinson true VO2 max maximal aerobic capacity maximal oxygen consumption maximal oxygen uptake peak oxygen uptake maximal oxygen uptake measurement efo:EFO_0004902 European HapMap cell line efo:EFO_0004908 is a quantification of testosterone, typically in serum. Testosterone is a steroid hormone.Testosterone measurement is used in the diagnosis of precocious or delayed puberty, infertility (in men and women), ovarian tumours, adrenal tumours and pituitary disorders. http://labtestsonline.org.uk/understanding/analytes/testosterone/tab/test/ true NCIt:C75378 SNOMEDCT:104957004 testosterone level testosterone levels testosterone measurement efo:EFO_0004909 is a quantification of dihydrotestosterone (DHT), typically in serum. Dihydrotestosterone is a steroid hormone, a small percentage of testosterone is reduced to DHT which has a greater affinity for androgen receptors. true NCIt:C74853 dihydrotestosterone levels dihydrotestosterone measurement efo:EFO_0004910 is a quantification of cytochrome P450 3A4 activity. CP4503A4 is a heme-thiolate monooxygenases induced in response to drugs, pesticides and carcinogens (Uniprot definition). http://www.uniprot.org/uniprot/P08684 true CYP3A4 enzyme activity. CYP3A4 activity efo:EFO_0004912 Is a quantification of immunoglobulin A, an antibody with a role in mucosal immunity. Reduced levels of IgA may indicate a congenital deficiency and increased levels may indicate multiple myeloma. http://labtestsonline.org.uk/understanding/analytes/immunoglobulins/tab/test/ true IgA levels serum immunoglobulin A measurement serum IgA measurement efo:EFO_0004913 Is a quantification of the lentiform nucleus (or lenticular nucleus) volume, typically by MRI. Deficits in lentiform nucleus volume and morphometry are implicated in a number of genetically influenced disorders, including Parkinson’s disease, schizophrenia, and ADH. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779070/ true lenticular nucleus measurement lentiform nucleus volume lentiform nucleus measurement efo:EFO_0004914 Is a quantification of the ability of humans to process different facial expressions, measured by MRI. true facial neural processing efo:EFO_0004915 Is a quantification of vaspin, commonly termed Serpin A12 (visceral adipose tissue-derived serine protease inhibitor) , typically in serum an adipokine which may modulate insulin activity in white adipose tissue (Uniprot). http://www.ncbi.nlm.nih.gov/pubmed/22139797 true Serpin A12 measurement vaspin levels vaspin measurement efo:EFO_0004918 The age, measured from some defined time point e.g. birth at which a subject (e.g. a human patient) is diagnosed with some disease e.g. breast cancer. Helen Parkinson http://purl.bioontology.org/ontology/SNOMEDCT/423493009 true SNOMEDCT:423493009 age at diagnosis efo:EFO_0004919 The percentage of subjects in a study who have survived without cancer spread for a defined period of time. Usually reported as time since diagnosis or treatment. Can be reported for an individual or a study population. Helen Parkinson www.oncura.net/glossary.php metastasis free survival time metastasis free survival efo:EFO_0004920 Progression free survival is a measurement from a defined time point e.g. diagnosis and indicates that the disease did not progress i.e. tumours did not increase in size and new incidences did not occur. PFS is usually used in analyzing results of treatment for advanced disease. Helen Parkinson http://cancerguide.org/scurve_basic.html true time before disease progression progression free survival efo:EFO_0004921 Apparently health human non-fetal tissue. James Malone http://ccr.coriell.org/Sections/Search/Sample_Detail.aspx?Ref=GM00038&PgId=166 GM00038 efo:EFO_0004922 ATAXIA-TELANGIECTASIA; AT OMIM:208900 GM00719 cell GM00719 efo:EFO_0004949 A temporal measurement related to disease progression Helen Parkinson clinical event clinical temporal measurement efo:EFO_0004950 The point in time at which an individual was born. Helen Parkinson SNOMEDCT:184099003 date of birth efo:EFO_0004951 A clinical temporal measurement indicating that the subject is alive at the end of the clinical investigation. Helen Parkinson alive at endpoint efo:EFO_0004952 The recurrence of a disease after treatment Helen Parkinson true MedDRA:10061819 relapse disease recurrence efo:EFO_0004953 The point at which a clinical diagnosis is made. Helen Parkinson true SNOMEDCT:432213005 date of diagnosis efo:EFO_0004955 The measurement in millimeters of the vertical thickness of primary cutaneous melanoma. Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells. It is used in staging of melanoma. (NCI) http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Breslow_Thickness true NCIt:C25734 Breslow's thickness Breslow thickness efo:EFO_0004972 The total sum of the genetic information of an organism's somatic cells Helen Parkinson somatic genotype efo:EFO_0004973 The total sum of the genetic information of an organism's germline Helen Parkinson germline genotype efo:EFO_0004979 Compressive strength index (CSI) is a predictive measure for hip fracture risk that integrates multiple parameters including hip BMD, femur neck area, and weight. Helen Parkinson http://www.sciencedirect.com/science/article/pii/S8756328212011635 true comprehensive strength index efo:EFO_0004980 Appendicular lean mass is a measurement of skeletal strength of lower limbs and is used as a predictive measure of hip fracture. Helen Parkinson http://www.sciencedirect.com/science/article/pii/S8756328212011635 true appendicular lean mass efo:EFO_0004983 Complement C3 measurement is a quantification of the C3 glycoprotein typically in serum, that is central in both the classical and the alternative pathway of complement activation . Complement activation, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes. Helen Parkinson http://www.nlm.nih.gov/medlineplus/ency/article/003539.htm true NCIt:C80174 complement C3 levels complement C3 measurement efo:EFO_0004984 Complement C4 measurement is a quantification of the C4 glycoprotein, typically in serum, that is central in both the classical and the alternative pathway of complement activation . Complement activation, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes. Helen Parkinson true NCIt:C80177 complement C4 levels complement C4 measurement efo:EFO_0004985 A platelet reactivity measurement is the quantification of platelet reactivity e.g. by measuring platelet induced agglutination. High levels of platelet reactivity are reported to be associated with cardiovascular events. Helen Parkinson true platelet reactivity measurement efo:EFO_0004990 J1 is an embryonic cell line. SNOMEDCT:260248003 J1 efo:EFO_0004993 Is a quantification of immunoglobulin M, an antibody produced by B cells. IgM measurements are useful for detecting or monitoring of monoclonal gammopathies and immune deficiencies. James Malone http://labtestsonline.org.uk/understanding/analytes/immunoglobulins/tab/test/ true IgM levels serum IgM measurement efo:EFO_0004995 The weight of all organs and tissue in an individual less the weight of the individual's body fat. James Malone true NCIt:C71258 SNOMEDCT:248362003 lean body mass efo:EFO_0004998 The quantification of some carbohydrate, typically obtained from an individual with the intention of using the measurement in some diagnostic process. Dani Welter true SNOMEDCT:5638008 carbohydrate measurement efo:EFO_0004999 The quantification of N-glycans in a plasma sample. Dani Welter true N-glycan level N-glycan measurement efo:EFO_0005000 Quantification of leptin, a hormone made by adipocytes with a role in the regulation of energy balance. https://en.wikipedia.org/wiki/Leptin true NCIt:C74866 SNOMEDCT:117694008 leptin measurement efo:EFO_0005001 The quantification of some phenylalanine, typically obtained from an individual with the intention of using the measurement in some diagnostic process. For example in the diagnosis of phenylkenonuria (PKU) Dani Welter true NCIt:C81280 SNOMEDCT:76819007 phenylalanine measurement efo:EFO_0005002 The quantification of some lysine, typically obtained from an individual with the intention of using the measurement in some diagnostic process. Dani Welter true SNOMEDCT:104796004 lysine measurement efo:EFO_0005020 The latitude at which a sample was obtained. For example a sea water sample. Helen Parkinson collection latitude efo:EFO_0005021 The longitude at which a sample was obtained. For example a sea water sample. Helen Parkinson collection longitude efo:EFO_0005035 Measurement of the volume of the hippocampus Dani Welter true hippocampal volume efo:EFO_0005036 A measurement quantifying some platelet Dani Welter true platelet measurement efo:EFO_0005037 The aortic root size is the size of the part of the ascending aorta beginning at the aortic annulus and extending to the sinotubular junction Dani Welter true aortic root size efo:EFO_0005043 Is a quantification of cardiac troponin T, typically measured in blood. Cardiac troponin T measurements are used as a marker of cardiac muscle damage and used in the diagnosis of myocardial infarction. true cardiac troponin T level cardiac troponin T levels hs-cTnT levels cardiac troponin T measurement efo:EFO_0005047 Is a quantification of some aspect of erythrocyte function, quantity, or composition. Helen Parkinson true red blood cell measurement erythrocyte measurement efo:EFO_0005052 nervous system measurement efo:EFO_0005053 Is a quantification of the internal carotid intimal medial thickness. Dani Welter true internal carotid intimal medial thickness efo:EFO_0005054 A QRS complex is a combination of the three electrocardiographical measurements of the Q, R and S waves in the heart's electrical cycle. It corresponds to the depolarization of the right and left ventricles of the human heart. The QRS complex can be further classified into a set of parameters, including QRS duration, QRS amplitude and ventricular activation time (VAT). Dani Welter https://en.wikipedia.org/wiki/QRS_complex true MedDRA:10037693 MedDRA:10058099 NCIt:C41329 QRS complex efo:EFO_0005055 QRS duration is a measurement of the combined duration of the Q, R and S waves of the human heart's electric cycle Dani Welter true QRS interval QRS duration efo:EFO_0005056 The age at which death occurs. Dani Welter true age at death efo:EFO_0005057 The determination of the amount of myoglobin present in a sample, usually blood Dani Welter true NCIt:C79436 SNOMEDCT:33606006 myoglobin measurement efo:EFO_0005058 The quantification of some tyrosine, typically obtained from an individual with the intention of using the measurement in some diagnostic process. Dani Welter true SNOMEDCT:84796003 tyrosine measurement efo:EFO_0005059 The quantification of some acylcarnitine, typically obtained from the blood of an individual with the intention of using the measurement in some diagnostic process. The test is used in the diagnosis of iherited fatty acid metabolic disorders. Dani Welter http://www.ncbi.nlm.nih.gov/pubmed/21207283 true SNOMEDCT:104465009 acylcarnitine measurement efo:EFO_0005080 Quantification of the pneumoprotein CC16 or clara cell secreted protein . CC16 plays an important protective role in the respiratory tract against oxidative stress and inflammatory response. CC16 is used peripheral lung marker for assessing the cellular integrity or the permeability of the lung epithelium and serum CC16 is increased serum in acute or chronic lung disorders characterized by an increased airways permeability. Dani Welter true Clara cell secretory protein CC16 measurement efo:EFO_0005081 quantification of the pneumoprotein surfactant protein D. This protein is an innate immune protein and plays a role in pulmonary host defence and the modulation of allergic responses. Several human lung diseases are characterized by decreased levels of bronchoalveolar SP-D. Dani Welter true NCIt:C111322 SP-D measurement surfactant protein D measurement efo:EFO_0005089 quantification of the total volume of the brain Dani Welter true whole-brain volume efo:EFO_0005090 The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. quantification of basophils in the blood Dani Welter true CMO:0000034 CMO:0000111 MedDRA:10049695 SNOMEDCT:42351005 blood basophil count basophil count efo:EFO_0005091 quantification of monocytes in the blood Dani Welter http://www.nlm.nih.gov/medlineplus/ency/article/003657.htm true MedDRA:10027876 NCIt:C64823 SNOMEDCT:67776007 monocyte count efo:EFO_0005092 quantification of the volume of the entorhinal cortex Dani Welter true entorhinal cortical volume efo:EFO_0005093 circumferential measurement of the largest part of the hip Dani Welter true NCIt:C100947 SNOMEDCT:284472007 hip circumference efo:EFO_0005094 measurement of the time from start to finish of the P wave, in the electrocardiograph illustrating the initial deflection of the cardiac cycle, representing the excitation of the atria. Dani Welter https://en.wikipedia.org/wiki/P_wave_(electrocardiography) true SNOMEDCT:251204004 P wave duration efo:EFO_0005095 measurement of the interval from the offset of the P wave to the onset of the QRS wave complex Dani Welter true PR segment efo:EFO_0005105 quantification of some lipid or lipoprotein Dani Welter true lipid or lipoprotein measurement efo:EFO_0005106 measurement of the percentages of fat, bone and muscle in human bodies Dani Welter true body composition measurement efo:EFO_0005108 Distance between the tips of the longest fingers with the arms maximally outstretched laterally. Dani Welter true arm span efo:EFO_0005110 The determination of the amount of fatty acids present in a sample. Dani Welter true NCIt:C80157 SNOMEDCT:313406008 fatty acid measurement efo:EFO_0005111 A measurement of the folic acid in a biological sample Dani Welter true NCIt:C74676 SNOMEDCT:104660009 folate measurement vitamin B9 measurement folic acid measurement efo:EFO_0005112 The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated as the time from the last day of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization. Dani Welter true MeSH:D005865 gestational age efo:EFO_0005114 A circumferential measurement of the head at the widest point, which is traditionally above the eyebrow Dani Welter true MedDRA:10060025 NCIt:C81255 SNOMEDCT:363812007 head circumference efo:EFO_0005115 a quantification of metabolic rate Dani Welter true metabolic rate measurement efo:EFO_0005116 quantification of some metabolite in urine Dani Welter true urinary metabolite measurement efo:EFO_0005117 Is the quantification of Chemokine (C-C motif) ligand 5. CCL5 is a Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils (PubMed:16791620, PubMed:1380064, PubMed:8525373, PubMed:9516414, PubMed:15923218). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:23979485). Dani Welter http://www.uniprot.org/uniprot/P13501 true RANTES Regulated on Activation, Normal T cell Expressed and Secreted CCL5 measurement efo:EFO_0005118 IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Promotes cell migration. Dani Welter http://www.uniprot.org/uniprot/P08833 true IGFBP-1 measurement efo:EFO_0005119 quantification of some antioxidant in a biological sample Dani Welter true antioxidant measurement efo:EFO_0005126 quantification of the activity of enzymes from the arylesterase family. Low measurements have been associated with cardiovascular risk - http://europepmc.org/abstract/MED/22982463 Dani Welter true paraoxonase enzyme measurement arylesterase enzyme measurement efo:EFO_0005127 cancer biomarkers, such as cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein, are used as indicators for cancer screening and as predictors for therapeutic responses and prognoses in cancer patient Dani Welter true cancer biomarker measurement efo:EFO_0005128 quantification of the ratio of the protein albumin to globulin in the blood serum Aoife McMahon Dani Welter true PMID:29403010 http://www.ebi.ac.uk/efo/EFO_0005128 ALBGLOB Albumin to Globulin Ratio Measurement Albumin/Globulin albumin-globulin ratio measurement albumin:globulin ratio measurement efo:EFO_0005130 quantification of the thyroid hormone thyroxine (T4) in the blood, usually as an indicator of thyroid function Dani Welter true SNOMEDCT:72765002 FT4 levels thyroxine measurement efo:EFO_0005131 quantification of homovanillic acid (HVA) in cerebrospinal fluid. HVA/5-HIAA ratios may be used as biomarkers for suicidial behavior. quantification of homovanillic acid in cerebrospinal fluid Dani Welter true HVA measurement efo:EFO_0005132 quantification of 5-hydroxyindoleacetic acid in cerebrospinal fluid or urine. 5-HIAA is a metabolite of serotonin. This measurement is performed during diagnosis of serotonin secreting neuroendocrine tumours. Low levels of 5-HIAA in the cerebrospinal fluid have been associated with aggressive behavior and suicide by violent means, correlating with diminished serotonin levels. Elevated serotonin (hyperserotonemia) is one of the most common biological findings in autism[3] and 5-HIAA may be elevated in patients with autistic spectrum disorders. Dani Welter, Helen Parkinson https://en.wikipedia.org/wiki/5-Hydroxyindoleacetic_acid www.ncbi.nlm.nih.gov/pubmed/25140149 true NCIt:C112217 SNOMEDCT:104741005 5-Hydroxyindoleacetic acid measurement 5-HIAA measurement efo:EFO_0005133 quantification of 3-methoxy-4-hydroxyphenylglycol in measured in urine, plasma or cerebrospinal fluid. MHPG is reported to be associated with neuropsychiatric disorders. Dani Welter http://www.ncbi.nlm.nih.gov/pubmed/25709459 true MHPG measurement efo:EFO_0005134 quantification of some amino acid in a biological assay Dani Welter true NCIt:C81183 amino acid measurement efo:EFO_0005139 Quantification of some ceruloplasmin in the blood. Quantification of some ceruloplasmin in the blood. Ceruloplasmin is a copper containing enzyme synthesized in tge liver that plays a role in iron metabolism and Copper ion transport. It is measured in combination with copper tests in the diagnosis of Wilson's disease. Ceruloplasmin is a copper containing enzyme that plays a role in iron metabolism measured in combination with copper tests in the diagnosis of Wilson's disease. Dani Welter http://labtestsonline.org.uk/understanding/analytes/caeruloplasmin true SNOMEDCT:270975004 serum ceruloplasmin levels serum ceruloplasmin measurement efo:EFO_0005168 wild type genotype efo:EFO_0005187 A measurement of the connecting peptide, or C-peptide - a short 31-amino-acid polypeptide that connects insulin's A-chain to its B-chain in the proinsulin molecule. C-peptide measurements may be made for clinical diagnostics. As a means of distinguishing type 1 diabetes from type 2 diabetes or Maturity onset diabetes of the young (MODY). To determine how much of their own natural insulin a person is producing as C-peptide is secreted in equimolar amounts to insulin. C-peptide may be used for determining the possibility of gastrinomas associated with Multiple Endocrine Neoplasm syndromes. C-peptide levels may be checked in women with Polycystic Ovarian Syndrome (PCOS) to help determine degree of insulin resistance Dani Welter, Helen Parkinson https://en.wikipedia.org/wiki/C-peptide true NCIt:C74736 C-peptide measurement efo:EFO_0005188 A quantification of C-C motif chemokine 11, also known as Eotaxin, Eosinophil chemotactic protein and Small-inducible cytokine A11. In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. Binds to CCR3 Dani Welter http://www.uniprot.org/uniprot/P51671 true CCL11 measurement efo:EFO_0005189 The respiratory quotient (or RQ or respiratory coefficient), is a dimensionless number used in calculations of basal metabolic rate (BMR) when estimated from carbon dioxide production. Such measurements, like measurements of oxygen uptake, are forms of indirect calorimetry. Dani Welter https://en.wikipedia.org/wiki/Respiratory_quotient true SNOMEDCT:74427007 respiratory quotient efo:EFO_0005190 Dani Welter true urinary nitrogen measurement efo:EFO_0005191 A quantification of the waist-height WHtR - a measurement of body fat distribution. Dani Welter true waist height ratio efo:EFO_0005192 measure of the variation of red blood cell (RBC) volume Dani Welter erthrocyte distribution width https://en.wikipedia.org/wiki/Red_blood_cell_distribution_width true RDW red blood cell distribution width efo:EFO_0005193 quantification of N-linked IgG glycans in a serum sample Dani Welter true serum IgG glycosylation measurement efo:EFO_0005194 quantification of the amyloid-beta, either in a sample of cerebro-spinal fluid or via PET scan, used as a biomarker for Alzheimer's disease Dani Welter https://en.wikipedia.org/wiki/Amyloid_beta true Ab measurement cortical Ab measurement amyloid-beta measurement efo:EFO_0005196 quantification of some peptide with a vasodilating or vasoconstricting effect in a blood sample, usually as an indicator of cardiovascular disease Dani Welter http://europepmc.org/abstract/MED/23381795 true vasoactive peptide measurement efo:EFO_0005197 A quantification of the MHC component beta-2 microglobulin, typically in a blood sample. Used as progostic indicator in multiple myeloma, and diseases associated with increased cell turnover. Levels are also elevated in several benign conditions such as chronic inflammation, liver disease, renal dysfunction, some acute viral infections, and a number of malignancies, especially hematologic malignancies associated with the B-lymphocyte lineage. Dani Welter http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/9234 true NCIt:C81980 beta-2 microglobulin measurement efo:EFO_0005198 Dani Welter true ICD10:T86 ICD10:Z94 transplant outcome measurement efo:EFO_0005199 quantification of the outcome of a kidney transplant Dani Welter true renal transplant outcome measurement efo:EFO_0005200 Quantification of antiphospholipid antibodies in a biological sample, usually a blood sample. Antiphospholipid antibodies include anticardiolipin antibodies (ACL), lupus anticoagulant (LAC), and anti- β 2 glycoprotein I antibodies (anti- β 2GPI).They can be an indicator of antiphospholipid syndrome Dani Welter true NCIt:C102258 SNOMEDCT:82886000 antiphospholipid antibody measurement efo:EFO_0005201 growth is measured as the difference in body height between two time points Dani Welter true height growth measurement efo:EFO_0005206 detection or quantification of bands of immunoglobulins in blood serum or cerebrospinal fluid, usually as an indicator of central nervous system disorders such as multiple sclerosis, Lyme disease, systemic lupus erythematosus or neurosarcoidosis Dani Welter https://en.wikipedia.org/wiki/Oligoclonal_band true oligoclonal band measurement efo:EFO_0005208 measurement of the flow rate of filtered fluid through the kidney, calculated either by comparative measurements of substances in the blood and urine, or estimated from a blood test Dani Welter true MeSH:D005919 MedDRA:10018355 NCIt:C90505 SNOMEDCT:80274001 GFR glomerular filtration rate efo:EFO_0005210 quantification of the pattern of links between distinct units within a nervous system through neuroimaging techniques such a MRI Dani Welter true brain connectivity measurement efo:EFO_0005211 quantification of the rate of hydrolysis of aspirin in blood as an indicator of the therapeutic effectiveness of aspirin Dani Welter true aspirin hydrolysis measurement efo:EFO_0005213 A measure of the corneal thickness (CCT). This can be measured by contact e.g. ultrasound, confocal microscpy or non contact methods e.g. biometry. Reduced central corneal thickness is used as an indicator for glaucoma. Helen Parkinson true SNOMEDCT:422162007 central corneal thickness efo:EFO_0005214 A cell line which is a model for neuroblastoma. neuroblastoma cell line efo:EFO_0005215 A cell line which is a model for breast adenocarcinoma. breast adenocarcinoma cell line efo:EFO_0005216 A cell line used as model for hepatocellular carcinoma. hepatoma cell line efo:EFO_0005217 A cell line used as a model for cervical adenocarcinoma. cervical adenocarcinoma cell line efo:EFO_0005218 A cell line which is used as a model for cervical carcinoma. cervical carcinoma cell line efo:EFO_0005231 An established epithelial cell line derived from an adenocarcinoma of human endometrial lining. BTO_0005365 ECC-1 cell ECC-1 efo:EFO_0005233 The CH12.LX B cell line derived from the murine CH12 B cell lymphoma. BTO_0002493 CH12.LX cell CH12.LX efo:EFO_0005234 Neuroectodermal cell line derived from a cerebral brain tumor. [PMID: 1316433] [CLO:0008425] PFSK-1 cell PFSK-1 efo:EFO_0005236 The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line. Derived from metastatic site: lung [BTO:0000946] NT2/D1 cell NTERA-2 cl.D1 cell NT2/D1 efo:EFO_0005237 A human epithelial cell derived from subject with grade IV glioblastoma; astrocytoma. U-87 MG cell U-87 cell U-87-MG cell U-87MG cell U87 U87 cell U87-MG cell U87MG cell U-87 MG efo:EFO_0005241 quantification of an individual's occupation, both in terms of employment vs unemployment and in terms of nature of employment, eg self-employment Dani Welter true SNOMEDCT:224362002 employment status efo:EFO_0005243 quantification of the enzyme myeloperoxidase in the blood, for example as an indicator of coronary artery disease Dani Welter true NCIt:C80198 myeloperoxidase measurement efo:EFO_0005247 measurement of the IgG antibody isotype produced by plasma cells in response to a Heliobacter pylori infection Dani Welter true anti-Helicobacter pylori serum IgG measurement efo:EFO_0005263 TOV-112D is a human epithelial cell line initiated in October of 1992 from a patient with early onset ovarian cancer. The patient was of French-Canadian descent with an unknown family history of ovarian cancer. http://www.lgcstandards-atcc.org/products/all/CRL-11731.aspx?geo_country=gb#characteristics TOV112D TOV-112D efo:EFO_0005264 The ectocervical Ect1/E6E7 (ATCC CRL-2614) and endocervical End1/E6E7 (ATCC CRL-2615) cell lines were established in 1996 from normal epithelial tissue taken from a premenopausal woman undergoing hysterectomy for endometriosis. http://www.lgcstandards-atcc.org/products/all/CRL-2614.aspx?geo_country=gb#characteristics Ect1 efo:EFO_0005265 MOLT-3 is a male human malignant T-lymphoblastic cell line. MOLT3 MOLT-3 efo:EFO_0005266 quantification of selenium in blood Dani Welter true SNOMEDCT:166759002 serum selenium measurement efo:EFO_0005267 quantification of copper in blood used in the diagnosis of Wilson's disease (in combination with ceruloplasmin measurement) or copper deficiences. Low levels may indicate Wilson's disease, high levels may indicate liver disease. Dani Welter http://labtestsonline.org.uk/understanding/analytes/copper/ true serum copper measurement efo:EFO_0005268 quantification of zinc in blood Dani Welter https://en.wikipedia.org/wiki/Zinc_deficiency https://ods.od.nih.gov/factsheets/Zinc-Consumer/#h6 true SNOMEDCT:273975003 serum zinc measurement efo:EFO_0005271 duration of sleep, measured either via a self-reporting questionnaire, interview or through obversation in a sleep lab Dani Welter true sleep duration efo:EFO_0005272 quantification of some aspect of sleep quality, such as number of awakenings during a sleep interval or time taken to get to sleep. Sleep quality can be evaluated either through self-reporting, observation in a sleep lab or using a sleep monitoring device Dani Welter true NCIt:C121705 sleep quality efo:EFO_0005273 self-reported assessment of how difficult an individual is to wake Dani Welter true sleep depth efo:EFO_0005274 measurement of the time at which sleep begins Dani Welter true sleep time efo:EFO_0005275 the quantification of dihydroxy docosatrienoic acid, a metabolite significantly associated with increased risk of heart failure Dani Welter true dihydroxy docosatrienoic acid measurement efo:EFO_0005276 the quantification of hydroxy-leucine, a metabolite significantly associated with increased risk of heart failure Dani Welter true X-11787 measurement hydroxy-isoleucine measurement hydroxy-leucine measurement efo:EFO_0005278 cardiovascular disease biomarkers, such as ST2 cardiac biomarker and C-reactive protein, are used as indicators for cardiovascular disease and as predictors for therapeutic responses Dani Welter true cardiovascular disease biomarker measurement efo:EFO_0005280 amount of time, usually recorded in minutes, between going to bed and falling asleep Dani Welter true sleep latency efo:EFO_0005282 Established from human bone marrow stromal cells transformed by HPV-16 E6/E7. https://www.atcc.org/Products/All/CRL-11882.aspx HS-5 cell HS-5 efo:EFO_0005283 Established from human bone marrow stromal cells transformed by HPV-16 E6/E7. https://www.atcc.org/products/all/CRL-2496.aspx HS-27A cell HS-27A efo:EFO_0005284 Mouse lymphocytic leukemia established from the methylcholanthrene-induced tumor in a DBA strain mouse (subline 212, 8-month-old female) in 1949; the cells were propagated by heterotransplantation into DBA/2 mice; an in-vitro suspension culture was first reported in 1966; cells are used for cytotoxicity studies.[BTO:0000702] L-1210 cell L1210 L1210 cell L-1210 efo:EFO_0005285 Murine B-lymphoma cell line. PMID: 14738152 [BTO:0001930] A-20 A20 cell A20 efo:EFO_0005292 lymphoblastoid cell line efo:EFO_0005294 chronic myelogenous leukemia cell line efo:EFO_0005298 quantification of allergic sensitization status, for example through measurement of allergen-specific IgE in the blood or skin reaction after puncture of skin through a droplet of allergen extract (skin prick test) Dani Welter http://europepmc.org/abstract/MED/23817571 true allergic sensitization measurement efo:EFO_0005318 quantification of the distance between the anterior surface of the cornea and the fovea, usually measured by A-scan ultrasonography or optical coherence biometry Dani Welter true SNOMEDCT:251692002 AL axial length ocular axial length axial length measurement efo:EFO_0005332 GM18505 efo:EFO_0005333 GM08714 efo:EFO_0005334 GM10248 efo:EFO_0005335 GM10266 efo:EFO_0005336 GM10847 efo:EFO_0005337 GM12864 efo:EFO_0005338 GM12865 efo:EFO_0005339 GM12866 efo:EFO_0005340 GM12867 efo:EFO_0005341 GM12868 efo:EFO_0005342 GM12869 efo:EFO_0005343 GM12870 efo:EFO_0005344 GM12871 efo:EFO_0005345 GM13976 efo:EFO_0005346 GM13977 efo:EFO_0005347 GM15510 efo:EFO_0005348 GM18526 efo:EFO_0005349 GM18951 efo:EFO_0005350 GM19099 efo:EFO_0005351 GM19193 efo:EFO_0005352 GM20000 efo:EFO_0005353 GM12801 efo:EFO_0005355 A human embryonic stem cell line Dani Welter HUES-1 HUES1 efo:EFO_0005356 Dani Welter CAL-120 CAL120 efo:EFO_0005357 Dani Welter CAL-148 CAL148 efo:EFO_0005358 Dani Welter CAL-51 CAL51 efo:EFO_0005359 Dani Welter CAL-85-1 CAL851 efo:EFO_0005360 Dani Welter http://www.lgcstandards-atcc.org/products/all/CCL-202.aspx CCD-11Lu efo:EFO_0005361 Dani Welter http://www.lgcstandards-atcc.org/products/all/CCL-200.aspx CCD-13Lu efo:EFO_0005362 Dani Welter http://www.lgcstandards-atcc.org/products/all/CCL-204.aspx CCD-16Lu efo:EFO_0005363 Dani Welter http://www.lgcstandards-atcc.org/products/all/CCL-210.aspx CCD-19Lu efo:EFO_0005364 Dani Welter http://www.lgcstandards-atcc.org/products/all/CCL-215.aspx CCD-25Lu efo:EFO_0005365 Dani Welter http://www.lgcstandards-atcc.org/products/all/CRL-1478.aspx CCD-29Lu efo:EFO_0005366 Dani Welter http://www.lgcstandards-atcc.org/products/all/CRL-1490.aspx CCD-33Lu efo:EFO_0005367 Dani Welter http://www.lgcstandards-atcc.org/products/all/CCL-201.aspx CCD-8Lu efo:EFO_0005368 Dani Welter CCL-153 HFL1 efo:EFO_0005369 Dani Welter Granta-519 efo:EFO_0005370 Dani Welter NCIt:C117160 HCC-2998 HCC2998 efo:EFO_0005371 Dani Welter HCC-1195 HCC1195 efo:EFO_0005372 Dani Welter HCC-1419 HCC1419 efo:EFO_0005373 Dani Welter HCC-1806 HCC1806 efo:EFO_0005374 Dani Welter PMID:10353731 PMID:20679594 PMID:25485619 HCC-2279 HCC227 efo:EFO_0005375 Dani Welter HCC-2935 HCC2935 efo:EFO_0005376 Dani Welter NCIt:C117191 UACC.257 UACC-257 efo:EFO_0005377 Dani Welter NCIt:C117192 UACC.62 UACC-62 efo:EFO_0005382 HepG3 efo:EFO_0005383 HMEC-1 Hmec-1 HMEC1 efo:EFO_0005384 HuH-7 is a well differentiated hepatocyte derived cellular carcinoma cell line that was originally taken from a liver tumor in a 57-year-old Japanese male in 1982. The line was established by Nakabayshi, H. and Sato, J. HuH-7 is an immortal cell line of epithelial-like tumorigenic cells. It usually grow in 2D monolayers. http://cellbank.nibio.go.jp/legacy/celldata/jcrb0403.htm BTO:0001950 Huh-7 Huh7 HuH-7 efo:EFO_0005385 Igrov-1 IGROV-1 efo:EFO_0005386 INA-6 efo:EFO_0005387 JEKO-1 JeKo-1 efo:EFO_0005388 Source : Pleural effusion, Ductal breast cancer (grade 3 invasive, T2N1M0) Karyotype : Highly rearranged hyperdiploid karyotype with 6% polyploidy Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drugs Sirarat Sarntivijai http://bioinfoweb.com/CLDB-JIMT-1.htm http://www.broadinstitute.org/ccle/cell%20lines/JIMT1_BREAST JIMT1 JIMT-1 efo:EFO_0005389 KARPAS-231 Karpas-231 KARPAS 231 efo:EFO_0005390 KARPAS-299 Karpas-299 KARPAS 299 efo:EFO_0005391 LAN-1 LAN1 LA-N-1 efo:EFO_0005392 LAPC4 LAPC-4 efo:EFO_0005393 LAPC9 LAPC-9 efo:EFO_0005394 MLO-Y4 efo:EFO_0005395 MUTZ-3 efo:EFO_0005408 the quantification of pyroglutamine, a metabolite significantly associated with increased risk of heart failure Dani Welter true pyroglutamine measurement efo:EFO_0005409 The weight of the individual's body fat. Dani Welter true total body fat measurement fat body mass efo:EFO_0005412 quantification of the effect of persistent interference in daily life activities and role performance by psychiatric conditions or related symptoms, usually established through a combination of medical assessments and questionnaires Dani Welter true functional impairment measurement efo:EFO_0005413 quantification of the level of joint damage, eg through radiological analysis Dani Welter true joint damage measurement efo:EFO_0005415 quantification of the protease inhibitor alpha-1-antitrypsin in the blood. The test is used in the diagnosis of early onset emphysema and liver disease. Dani Welter http://labtestsonline.org.uk/understanding/analytes/alpha1-antitrypsin/ true serum AAT measurement serum alpha-1-antitrypsin measurement efo:EFO_0005416 A soluble ST2 measurement is the quantification of the ST2 protein, also known as Interleukin-1 receptor-like 1 or IL1RL1. The protein ST2 levels are associated with adverse cardiovascular events. IL1Rl1 measurement http://europepmc.org/abstract/MED/25802475 http://europepmc.org/abstract/MED/25949827 http://www.uniprot.org/uniprot/Q01638 https://en.wikipedia.org/wiki/ST2_cardiac_biomarker true sST2 measurement soluble ST2 measurement soluble suppression of tumorigenicity 2 measurement serum ST2 measurement efo:EFO_0005418 quantification of symmetric or asymmetric dimethylarginine in the blood Dani Welter true serum dimethylarginine measurement efo:EFO_0005419 quantificiation of ability to detect sharp boundaries (stimuli) and to detect slight changes in luminance at regions without distinct contours. Psychophysical measurements of this visual function are used to evaluate visual acuity and to detect eye disease. Dani Welter true contrast sensitivity measurement efo:EFO_0005420 quantification of the volume of grey matter in the brain, usuallly through an MRI scan. Grey matter volume is associated with schizophrenia. Dani Welter true grey matter volume measurement efo:EFO_0005421 quantification of the amino acid derivate homoarginine in the blood. Low levels are associated with cardiovascular disease risk and for stroke in patients undergoing coronoary angiograpahy and decreased kidney function Dani Welter http://www.ncbi.nlm.nih.gov/pubmed/21311067 http://www.ncbi.nlm.nih.gov/pubmed/24398889 true serum homoarginine levels serum homoarginine measurement efo:EFO_0005441 A cell line derived from human prostate carcinoma. The patient was a 69-year-old male, and the sample was derived from brain metastasis. NCIt:C93036 https://www.atcc.org/products/all/HTB-81.aspx DU-145 DU145 DU 145 efo:EFO_0005442 NCIt:C117206 OVCAR-4 OVCAR.4 OVCAR4 efo:EFO_0005443 NCIt:C117207 OVCAR-5 OVCAR.5 OVCAR5 efo:EFO_0005444 NCIt:C117208 OVCAR-8 OVCAR.8 OVCAR8 efo:EFO_0005445 PEO1 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated serous adenocarcinoma. The patient previously received cisplatin, 5-fluorouracil and chlorambucil treatment. PEO1 is tumourigenic in immunologically-deprived CBA mice. PEO1 exhibits good growth in semi-solid medium (agar). PEO1 is from the same patient as the PEO4 and PEO6 cell lines (Sigma Catalogue numbers 10032309 & 10032310).This cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages) available at ECACC which provides a model system for research into the mechanism of oestrogen action on ovarian adenocarcinoma tumour cells, and for the study of efficacy and toxicity of oestrogen protagonists. (Sigma-Aldrich catalog number 10032308) http://www.sigmaaldrich.com/catalog/product/sigma/10032308 PE01 PEO1 efo:EFO_0005446 PEO14 efo:EFO_0005447 PEO23 efo:EFO_0005448 PEO4 efo:EFO_0005449 PEO6 efo:EFO_0005450 SF-126 SF126 efo:EFO_0005451 NCIt:C117169 SF-268 SF268 efo:EFO_0005452 NCIt:C117170 SF-295 SF295 efo:EFO_0005453 NCIt:C117174 SF-539 SF539 efo:EFO_0005454 SHEF1 Shef-1 SHEF-1 efo:EFO_0005455 SHEF3 Shef-3 SHEF-3 efo:EFO_0005456 SHEP-2 efo:EFO_0005457 SKMM1 SK-MM-1 efo:EFO_0005458 SKMM2 SK-MM-2 efo:EFO_0005460 SKI-DCLC efo:EFO_0005461 SU-DHL-1 SUDHL-1 SUDHL1 efo:EFO_0005462 SW 527 SW-527 SW527 efo:EFO_0005475 BL-2 efo:EFO_0005476 JVM-2 efo:EFO_0005479 Z-138 efo:EFO_0005480 This is a mouse suspension cell line derived from MEL cells by stable transfection with a GATA-1-ER fusion protein construct as described by Choe et al., 2003 (Cancer Res 63, 6363–6369, 2003). These cells can be terminally differentiated into mature erythroid cells with β-estradiol treatment, while GATA-1 alone can induce MEL cells to differentiate and to lose their tumorigenic properties. [PMID: 14559825] PMID:14559825 MEL-GATA-1-ER efo:EFO_0005481 Mouse Embryonic Kidney Fibroblast. As described in Lingenfelter et al., 1998 (Nat Genet. 1998 18:212-3) and Yang et al., 2010 (Genome Res. 2010 20:614-22), PATSKI is a female interspecific mouse fibroblast that was derived from the embryonic kidney of an M.spretus x C57BL/6J hybrid mouse such that the C57Bl/6J X chromosome (maternal) is always the inactive X. This is an adherent cell line. Patski efo:EFO_0005482 Mouse hematopoietic suspension cell line positive for CD34. The cells have a diploid complement of chromosomes, are non-tumorigenic and bipotential (can be induced to differentiate in vivo into two distinct haematopoietic lineages), and which in appropriate circumstances protect mice from potentially lethal radiation. [PMID: 763330] PMID:763330 416B efo:EFO_0005483 An embryonic cell line isolated from C57BL/6 mouse strain. Injection of Bruce4 cells into C57BL/6 blastocysts will produce agouti chimeras. ES-Bruce4 efo:EFO_0005484 46C is an embryonic stem cell line, constructed in the laboratory of Austin Smith, in which a drug resistance gene is placed under the control of a Sox1 promoter. Cells were isolated from the 129a mouse strain. [PMID: 12524553] PMID:12524553 46C efo:EFO_0005485 ES-cells isolated from C57BL/6xCBA TT2 efo:EFO_0005486 Fetal myoblast Desmin+ J185a efo:EFO_0005512 quantification of the level of estrogen receptors in a tumor Dani Welter true ICD9:V86 ICD9:V86-V86.99 NCIt:C16150 estrogen receptor status efo:EFO_0005513 quantification of progesterone receptors in breast cancer. PR status is used in the classification of breast cancers. Dani Welter NCIt:C16149 progesterone receptor status efo:EFO_0005514 quantification of the level of human epidermal growth factor receptor 2 (HER2) in a tumor. Amplification or overexpression of the HER2 oncogene plays a role in the development and progression of some breast cancers. Dani Welter true HER2 status efo:EFO_0005527 quantification of the volumetric fraction of blood pumped out of the left and right ventricle with each heartbeat or cardiac cycle Dani Welter true ejection fraction measurement efo:EFO_0005528 quantification of the content of parasites in the blood, used as a measurement of parasite load in the organism and an indication of the degree of an active parasitic infection Dani Welter true parasitemia measurement efo:EFO_0005530 Trypanosoma cruzi seropositivity is the result of a measurement of circulating T. cruzi specific antibodies Dani Welter true Trypanosoma cruzi seropositivity efo:EFO_0005536 Quantification of the fraction of nitric oxide in the total exhalation volume, used as a non-invasive biomarker of eosinophilic airway inflammation. Higher Feno values are associated with childhood asthma symptoms, exacerbations, physician-diagnosed asthma and atopy. Dani Welter https://en.wikipedia.org/wiki/Nitric_oxide true FENO fraction of exhaled nitric oxide nitric oxide exhalation measurement efo:EFO_0005538 quantification of the capacity of a given individual to generate thrombin, measured in plasma and shown to associate with thrombotic disorders Dani Welter http://europepmc.org/abstract/MED/24357727 true TGP measurement thrombin generation potential measurement efo:EFO_0005602 Helen Parkinson The age at which an alcohol diagnosis was made in a human patient age at alcohol diagnosis efo:EFO_0005603 Helen Parkinson The age at which a breast cancer diagnosis was made in a human patient age at breast cancer diagnosis efo:EFO_0005608 A measure of cortical opacity used in the diagnosis of cataract. Helen Parkinson cortical opacity measurement efo:EFO_0005648 This line was haploid when it was established. Like other lines, it may go back in forth in ploidy (by factors of two), depending on the growth conditions and the general health of the cells. FBtc0000177 PMID:21177962 PMID:98714 1180 4H 11824H 1182-4H efo:EFO_0005650 Cells are from the ventral leg imaginal disc of the third instar larval stage. Transcriptome analysis suggests similarity to cells in the tibia or femur region of a leg disc (Cherbas et al., 2011). CME-L1 efo:EFO_0005653 quantification of some metabolite in serum Dani Welter true serum metabolite measurement efo:EFO_0005654 quantification of the speed at which sound travels through bone as an indicator of the physical and structural properties of the bone Dani Welter true velocity of sound measurement efo:EFO_0005659 Is the quantification of Beta-amyloid 1-40 in plasma, typically used as a biomarker for Alzheimer's Disease Dani Welter https://en.wikipedia.org/wiki/Amyloid_beta true plasma beta-amyloid 1-40 measurement efo:EFO_0005660 Is the quantification of Beta-amyloid 1-42 in plasma, typically used as a biomarker for Alzheimer's Disease Dani Welter true plasma beta-amyloid 1-42 measurement efo:EFO_0005661 The CBCL is a widely used checklist of between 100 and 120 questions (depending on target age group) for identifying problem behaviour in children. Dani Welter true CBCL Child Behaviour Checklist assessment efo:EFO_0005663 quantification of the glycoprotein uromodulin in urine Dani Welter true urinary Tamm-Horsfall glycoprotein measurement urinary uromodulin measurement efo:EFO_0005664 quantification of some metabolite in blood Dani Welter true blood metabolite measurement efo:EFO_0005665 quantification of white matter hyperintensity, usually measured by MRI Dani Welter true white matter hyperintensity measurement efo:EFO_0005666 quantification of the antibodies to the enzyme thyroid peroxidase in blood, usually as an indicator for autoimmune thyroid disease Dani Welter true thyroid peroxidase antibody measurement efo:EFO_0005667 quantification of the amount of albumin excreted in urine, measured as an indicator for kidney malfunctions such as diabetic nephropathy Dani Welter true urinary albumin excretion rate efo:EFO_0005668 quantification of the depth of the anterior chamber of the eye as an indicator for eye disease such as primary angle closure glaucoma Dani Welter true anterior chamber depth measurement efo:EFO_0005671 the quantification of some smoking or smoking-related behaviour, usually self-reported via a questionnaire Dani Welter true smoking behaviour measurement efo:EFO_0005674 quantification of the microstructre of the white matter of the brain Dani Welter true white matter microstructure measurement efo:EFO_0005675 the quantification of vitamin D-binding protein in blood as a biomarker for vitamin D-related diseases such as osteoporosis, arthritis, cardiovascular disease and cancer Dani Welter true vitamin D-binding protein measurement efo:EFO_0005677 quantification of the onset of puberty in human males and females through a series of proxy measurements such as genital enlargement (males) or breast development (females). These characteristics are assessed based on pre-defined scales either through self-reporting or through assessment by a medical professional. Dani Welter true puberty onset measurement efo:EFO_0005680 The determination of the amount of omega-6 polyunsaturated fatty acids present in a sample. Dani Welter true omega-6 polyunsaturated fatty acid measurement efo:EFO_0005682 quantification of the relative amount of oxygen that is dissolved or carried in a given medium Dani Welter true NCIt:C60832 SNOMEDCT:104847001 oxygen saturation measurement efo:EFO_0005689 The quantification of NHDL cholesterol in blood, calculated by subtracting the amount of cholesterol in the HDL fraction from total cholesterol and used as an indicator for cardiovascular disease risk Dani Welter true NCIt:C116204 NHDL cholesterol measurement non-high density lipoprotein cholesterol measurement efo:EFO_0005691 The quantification in blood of trimethylamine N-oxide, a product of gut microbiome and hepatic-mediated metabolism of dietary choline and L-carnitine Dani Welter true TMAO measurement plasma trimethylamine N-oxide measurement efo:EFO_0005694 KMS-11 cell line was derived from four patients with multiple myeloma. These cells represent a later stage of B-cell differentiation, and shows characteristics of plasma cells by secreting surface kappa chain immunoglobulins. http://www.ncbi.nlm.nih.gov/pubmed/2768132 PMID:2519219 KMS11 KMS_11 KMS-11 efo:EFO_0005696 Medulloblastoma (aka D721), surgical resection from a patient with medulloblastoma as described by Darrell Bigner (1997) http://cellfinder.org/ontology?id=CELDA_00006808 D-721 D-721 Med D-721Med D721 D721Med efo:EFO_0005697 M059J cells were isolated from a tumor specimen taken from a 33 year old male with untreated malignant glioblastoma. The cells were isolated concurrently from the same tumor specimen as M059K (see CRL-2365). http://www.atcc.org/products/all/CRL-2366.aspx#generalinformation CRL_2366 M059J efo:EFO_0005698 The Daoy cell line was established in 1985 by P. F Jacobsen of the Royal Perth Hospital in Western Australia. The line was derived from biopsy material taken from a tumor in the posterior fossa of a 4 year old boy. http://www.atcc.org/Products/All/HTB-186.aspx HTB186 Daoy efo:EFO_0005700 This is an adherent cell line derived from a hepatic rhabdoid tumor. Hepatic rhabdoid tumors are extremely rare. This cell line has a large deletion on 22q, which indicates numerous genes in addition to SNF5 are deleted. http://www.ncbi.nlm.nih.gov/pubmed/12973738 https://genome.ucsc.edu/ENCODE/protocols/cell/human/MRTTTC549_Crawford_protocol.pdf MRTTTC549 TTC549 efo:EFO_0005702 A malignant rhabdoid tumor diploid cell population cloned from the A204 ATCC cell line. [PMID: 16897758] http://www.atcc.org/products/all/HTB-82.aspx http://www.jbc.org/content/257/15/9016.full.pdf A204.1 efo:EFO_0005703 This is an adherent cell line that represents the prototypical renal rhabdoid tumor [PMID: 16897758]. G401.6 is a diploid, 6-thioguanine-resistant clonal variant of the G401 cell line isolated by Weissman et al., Science, 236:175-180 (1986). The parental cell line, G401, can be ordered from the ATCC (CRL1441). http://genome.ucsc.edu/ENCODE/protocols/cell/human/MRTG401.6_Crawford_protocol.pdf MRT_G401.6 G401.6 efo:EFO_0005704 HuH-7 is a well differentiated hepatocyte derived cellular carcinoma cell line that was originally taken from a liver tumor in a 57-year-old Japanese male in 1982. The line was established by Nakabayshi, H. and Sato, J. HuH-7 is an immortal cell line of epithelial-like tumorigenic cells. It usually grow in 2D monolayers. HuH7.5 developed from HuH7. BTO:0004126 HuH-7.5 efo:EFO_0005705 Nasal biopsies were collected from volunteer donors as an outpatient procedure as described (Feron et al., 1998). This was done by a registered otolaryngologist via an endoscopic procedure to ensure biopsy samples were taken from the superior, posterior region of the nasal septum close to the cribriform plate. Pieces of olfactory mucosa were obtained which contain stem cells in the olfactory epithelium. The stem cell population derived from human olfactory mucosa has been described as ecto-mesenchymal (Delorme et al., 2010) because it has characteristics of both neural and mesenchymal stem cells, suggesting a neural crest origin. olfactory neurosphere cell line efo:EFO_0005706 in the Surgery Branch of the NCI.">This cell line was from a melanoma metastasis tumor taken from the subcutaneous shoulder of an individual. Cell line was derived by Dr. Yardena Samuels (samuelsy[at]mail.nih.gov) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947167/ BTO:0000849 Mel 2183 Mel_2183 Melanoma Mel-2183 Mel-2183 efo:EFO_0005707 This line was derived from a primary clear cell adenocarcinoma. The karyotype is hypertriploid; Y was present in 60% the cells examined. The cells display both microvilli and desmosomes, and can be grown in soft agar. The cells produce a PTH like peptides that is identical to peptides produced by breast and lung tumors. http://www.ncbi.nlm.nih.gov/pubmed?cmd=Retrieve&list_uids=721102&dopt=AbstractPlus NCIt:C117211 786_0 CRL-1932 RCC 7860 RCC7860 RCC_7860 786-0 efo:EFO_0005709 First trimester human trophoblast cells established by immortalizing a physiologic extravillous trophoblast cell via transfection with a plasmid containing the simian virus 40 large T antigen (SV40) (see Graham et al., 1993). Cells are a thin layer of ectoderm that forms the wall of many mammalian blastulas and functions in the nutrition and implantation of the embryo. http://www.sciencedirect.com/science/article/pii/S0014482783711390# HTR-8-SVNEO HTR-8/SVneo HTR8-SVNEO htr_8_svneo HTR8/SVneo efo:EFO_0005710 This is an adherent cell line. HFF-Myc are human foreskin fibroblasts containing a virally integrated vector expressing the canine cMyc gene. Cells were received from Dr. Beverly Torok-Storb, Fred Hutchison Cancer Research Center, Seattle, WA. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0005951 HFF Myc HFF cMyc HFF-cMyc HFF_Myc HFF_cMyc HFF-Myc efo:EFO_0005711 Normal benign adult human pancreatic duct cells immortalized with E6E7 gene of HPV-16. HPDE6-E6E7 cells demonstrated a near normal genotype and phenotype of pancreatic duct epithelial cells. [PMC1861644] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885733/ BTO:0002362 HPDE-6/E6E7 HPDE-6E6E7 HPDE-6_E6E7 HPDE6-E6E7-HPV Pancreatic duct cells E6E7 HPDE6-E6E7 efo:EFO_0005712 Human skin malignant melanoma cells that can be ordered from ATCC. This is a hyperdiploid human cell line with the modal chromosome number of 49, occurring in 24% of cells. Polyploid cells occurred at 22%, which is high. Cells are adherent, and were first harvested in 1971 from a metastatic site in a lymph node. BTO:0003508 RPMI 7951 RPMI7951 RPMI_7951 RPMI-7951 efo:EFO_0005713 Human pancreas adenocarcinoma (PA-TU-8988T), "established in 1985 from the liver metastasis of a primary pancreatic adenocarcinoma from a 64-year-old woman; sister cell line of PA-TU-8988S" - DSMZ. Laura Huerta http://www.ncbi.nlm.nih.gov/pubmed/1348891 BTO:0001521 8988 T 8988-T ACC 162 PA-TU-8988T 8988T efo:EFO_0005714 Skeletal myoblasts derived from satellite cells from the pectoralis major muscle of a 41 year old caucasian heart transplant donor, immortalized with lox-hygro-hTERT (LH), and Cdk4-neo (CN), Zhu et al. (2007) in Aging Cell, vol. 6, pp 515-523. M2 is an extremely well-differentiating subclone of LHCN (thus "LHCN-M2"). http://www.ncbi.nlm.nih.gov/pubmed/17559502 BTO:0000023 BTO:0005046 LHCN M2 LHCNM2 LHCN-M2 efo:EFO_0005715 The WERI-Rb-1 line is one of two human retinoblastoma cell lines established in 1974 by R.M. McFall and T.W. Sery. This is a near diploid line. The modal chromosome number is 47 occurring at 38%, and the rate of polyploidy is 9%. Cells are grape-like clusters of round cells in suspension. BTO:0001178 PMID:844036 WERI Rb 1 WERI_Rb_1 WERI-Rb-1 efo:EFO_0005718 "The cell line Ishikawa was established from an endometrial adenocarcinoma of a 39 year old woman. Cells can be commercially obtained from Sigma (99040201-1VL). However, it should be noted that the original source of these cells (M. Nashide, Japan) can spontaneously lose the progesterone and estrogen receptor. For details, see Nishida M., The Ishikawa cells from birth to the present. Hum Cell. 2002 Sep;15(3):104-17." BTO:0003041 Ishikawa cell Ishikawa efo:EFO_0005719 Established from a pleural effusion of 73 year-old woman diagnosed with B-cell non-Hodgkin lymphoma (intra-abdominal, diffuse large cell lymphoma, refractory, terminal). Cells are available from Dr Abraham Karpas, Department of Haematology, University of Cambridge, and are round and polygonal, growing in suspension. [PMID: 2297573] https://ximbio.com/reagent/152419/karpas-422-cell-line Karpas 422 cell Karpas-422 Karpas 422 efo:EFO_0005720 This melanoma cell line was derived from a metastatic axillary node of the skin of a 24 year old female. It is a hyperpentaploid human cell line with the modal chromosome number of 120, occurring in 9% of cells. [PMID: 1067619] NCIt:C117190 PMID:12828737 Mel-5 SK MEL 5 SK-MEL-5 cell SKMEL5 SK_MEL_5 SK-MEL-5 efo:EFO_0005721 SK-N-DZ is a neuroblastoma cell line derived in 1978 from a bone marrow metastasis from a child with poorly differentiated embryonal neuroblastoma. http://cancerres.aacrjournals.org/content/47/20/5433.full.pdf SK N DZ SK-N-DZ cell SKNDZ SK_N_DZ SK-N-DZ efo:EFO_0005722 The line was established from cells from the bone marrow of a child with rhabdomyosarcoma. Derived from a metastatic site of the bone marrow. The cells show ultrastructural elements of primitive skeletal muscle differentiation. https://www.encodeproject.org/documents/f714cd44-747e-4a56-9c0f-ae7ea5715783/@@download/attachment/SJCRH30_SOP_V1.pdf CRL-2061 RMS 13 SJCRH30 efo:EFO_0005723 Fibroblasts taken from a skin punch of the arm http://wiki.encodedcc.org/index.php/Scenario_9:_Personal_Genomes#PGP1_Fibroblasts.2C_iPSC_and_Derived_Samples http://cellfinder.de/ontology?id=CF_193910 https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM23248&product=CC GM23248 cell GM23248 efo:EFO_0005724 MM.1S is a B lymphoblast cell line derived in 1986. The parent cell line, MM.1, was established from peripheral blood of a multiple myeloma patient who had become resistant to steroid-based therapy. provide critical information about disease progression and the development of drug resistance. This cell line represents a valuable tool for elucidating the mechanisms of action of glucocorticoids and the development of new therapeutics. [PMID: 2926241] https://www.atcc.org/Products/All/CRL-2974.aspx PMID:12691914 MM.1 S MM.1-S MM.1S cell MM.1S efo:EFO_0005725 BE(2)-C is a clone of the SK-N-BE(2) neuroblastoma cell line (ATCC CRL-2271) that was established in November of 1972 from a bone marrow biopsy taken from child with disseminated neuroblastoma after repeated courses of chemotherapy and radiotherapy. The cells grow as clusters of flattened neuroblastic cells with occasional fine cell processes (neurites). Unlike the parent line, they generally do not detach and float. BTO:0000932 PMID:PMC1531688 BE(2) C BE(2)-C cell BE(2)_C BE2-C BE2C BE2_C BE(2)-C efo:EFO_0005726 LNCaP clone FGC was isolated in 1977 by J.S. Horoszewicz, et al., from a needle aspiration biopsy of the left supraclavicular lymph node of a 50-year-old Caucasian male (blood type B+) with confirmed diagnosis of metastatic prostate carcinoma. This is a hypotetraploid human cell line. The modal chromosome number was 84, occurring in 22% of cells. However, cells with chromosome counts of 86 (20%) and 87 (18%) also occurred at high frequencies. These cells are responsive to 5-alpha-dihydrotestosterone (growth modulation and acid phosphatase production). PMID:2660395 CRL-1740 LNCaP clone FGC cell LNCaP-FGC LNCaP_FGC LNCaP clone FGC efo:EFO_0005728 A cell line derived from airway epithelial cells. Catherine Leroy Sirarat Sarntivijai BTO:0002022 Wikipedia:Bronchiole small airway epithelial cell derived cell line bronchial epithelial cell derived cell line efo:EFO_0005730 An endothelial cell derived cell line is defined as a cell line that derives from an endothelial cell. Catherine Leroy Sirarat Sarntivijai BTO:0001519 CLO:0000091 endothelial cell derived cell line efo:EFO_0005731 A cardiac myocyte cell derived cell line is defined as a cell lineage that derives from cardiac myocyte cell Catherine Leroy Sirarat Sarntivijai BTO:0003265 cardiac muscle cell line heart muscle cell line cardiac myocyte cell derived cell line efo:EFO_0005734 This cell line refers to a model cell line derived from muscle cells Sirarat Sarntivijai CLO:0000076 muscle cell derived cell line efo:EFO_0005735 A cell line that derives from smooth muscle cell Sirarat Sarntivijai BTO:0004576 CLO:0000078 smooth muscle cell derived cell line efo:EFO_0005736 A cell line that derives from bronchial smooth muscle cell Sirarat Sarntivijai BTO:0004402 bronchial smooth muscle cell derived cell line efo:EFO_0005738 ESC derived cell line is a cell line that derives from an embryonic stem cell. Sirarat Sarntivijai ESC cell line embryonic stem cell derived cell line "To date, human embryonic stem cell (hESC) lines have been obtained from fresh and frozen embryos of varying quality at morula and blastocyst stages of development (Hoffman and Carpenter, 2005a)." Differences between human embryonic stem cell lines C.Allergrucci and L.E.Young Hum. Reprod. Update (March/April 2007) 13 (2): 103-120. doi: 10.1093/humupd/dml041 First published online: August 26, 2006 http://humupd.oxfordjournals.org/content/13/2/103.full ESC derived cell line efo:EFO_0005740 iPSC derived cell line is a cell line that derives from iPS cells (induced pluripotent stem cell). Sirarat Sarntivijai induced pluripotent stem cell derived cell line iPSC derived cell line efo:EFO_0005742 lung fibroblast derived cell line efo:EFO_0005743 This cell line was cloned from CME W1 in the Milner lab. The line was derived from L3 dorsal mesothoracic disc (Currie et al., 1988). Transcriptome analysis suggests similarity to cells along the A/P boundary of the wing blade primordium, possibly at the D/V boundary (Cherbas et al., 2011). The sex is male, based on roX expression - (L. Cherbas). CME W1 cl.8+ CME-W1-cl.8+ CME_W1_Cl.8+ CME_W1_Cl.8plus Cl.8 cl.8+ clone8 FBtc:FBtc0000151 PMID:21177962 PMID:25262759 http://flybase.org/reports/FBtc0000151.html CME W1 CME-W1-Cl.8+ efo:EFO_0005744 The line was made from L3 prothoracic leg discs in the Milner lab (Currie et al., 1988). FBtc:FBtc0000155 PMID:21177962 PMID:25262759 http://flybase.org/reports/FBtc0000155.html CME W2 CME_W2 W2 CME-W2 efo:EFO_0005745 This stable cell line is a mix of female germ-line stem cells/ovarian somatic sheet, which contains both germ-line and somatic cells. FBtc:FBtc0000191 PMID:17056713 http://flybase.org/reports/FBtc0000191.html fGS.OSS fGS_OSS fGS/OSS efo:EFO_0005746 Cells are made by W. Gehring from 6-10 hr embryos of cross y w f x In(3LR)C269, e mwh PMID:24985917 G2 efo:EFO_0005747 Cells are of embryonic line made by Mosna and Dolfini. GM2 line was characterized by XO cells showing two “new” telocentric chromosomes while an autosome of the II pair was missing (Mosna and Dolfini, 1972). XO Drosophila are sterile males (http://www.ncbi.nlm.nih.gov/books/NBK10025/). PMID:21177962 GM2 efo:EFO_0005760 Quantification of carcinoembryonic antigen in serum. Carcinoembryonic antigen is a cancer-specific antigen associated with both tumors and the developing fetus. The main use of this antigen is as a tumor marker, especially with respect to intestinal cancers. Production of the antigen ceases shortly before birth, but may reappear in people who develop certain types of cancer. Dani Welter http://labtestsonline.org.uk/understanding/analytes/cea/tab/test/ true serum carcinoembryonic antigen measurement efo:EFO_0005763 quantification of the difference between systolic blood pressure and diastolic blood pressure. Higher PP is associated with left ventricle hypertrophy and the increased intimal thickness of the carotid artery, which represent early target organ damage in cardiovascular diseases Dani Welter true pulse pressure measurement efo:EFO_0005766 quantification of the level of fluorescence of the skin, measured by spectromemeter and used as a non-invasive marker of advanced glycation end product (AGE) accumulation. Skin fluorescence (SF) is a non-invasive marker of AGEs and is associated with the long-term complications of diabetes. SF increases with age and is also greater among individuals with diabetes Dani Welter http://europepmc.org/abstract/MED/24934506 true skin fluorescence measurement efo:EFO_0005767 quantification of rheumatoid factors, antibodies in the serum of individuals with rheumatoid arthritis that react with antigenic determinants or immunoglobulins that enhance agglutination of suspended particles coated with pooled human gamma -globulin. Rheumatoid factors also occur in other autoimmune and certain infectious diseases. Dani Welter NCIt:C805 https://en.wikipedia.org/wiki/Rheumatoid_factor true NCIt:C74717 SNOMEDCT:54921001 rheumatoid factor measurement efo:EFO_0005819 Kc line established from 6-12 hr embryos of cross se x e. Clone 167 isolated in Goldschmitt-Clermont laboratory. Selected for growth in high-pH medium by Bourouis and Jarry. Restored to normal medium in Cherbas laboratory Kc line established from 6-12 hr embryos of cross se x e. Clone 167 isolated in Goldschmitt-Clermont laboratory. Selected for growth in high-pH medium by Bourouis and Jarry. Restored to normal medium in Cherbas laboratory. Karytopye information revealed XO-haplo-IV pseudodiploid (Cherbas lab, unpublished). Cells have e/se genotype and are female, by criterion of dsx splicing (Lynch and Maniatis, 1996). Transcriptome analysis suggests plasmatocyte-like properties for Kc167 cells (Cherbas et al., 2011) https://dgrc.cgb.indiana.edu/product/View?product=1 PMID:21177962 PMID:25262759 Kc167 efo:EFO_0005820 A tumorous blood cell line made from flies homozygous for the malignant blood neoplasm mutation l(2)mbn (Gateff, 1980). PMID:21177962 mbn2 efo:EFO_0005821 This cell line was made from the L3 (y v f mal) central nervous system (Ui et al., 1994).). Cells were cloned from their parent line ML-DmBG1 in the Miyake lab. PMID:21177962 BG1 c1 BG1-c1 DmBG1-c1 DmBG1_c1 ML DmBG1 c1 ML_DmBG1_c1 ML-DmBG1-c1 efo:EFO_0005822 This cell line was made from the L3 (y v f mal) central nervous system (Ui et al., 1994).) and was cloned from their parent line ML-DmBG2 in the Miyake lab. Cells are male, by criterion of roX1 and roX2 expression (DGRC unpublished). They express acetylcholine, substance P, proctolin, and somatostatin, and stains with anti-HRP (Ui-Tei et al., 1994, 1995). PMID:21177962 BG1 c2 BG1-c2 DmBG2-c2 DmBG2_c2 ML DmBG2 c2 ML_DmBG2_c2 ML-DmBG2-c2 efo:EFO_0005823 ML-DmBG3-c2 cells were made from the brain ventral ganglion of late L3 (y v f mal). Cloned from their parent line ML-DMBG3 in the Miyake lab. PMID:21177962 PMID:25262759 BG3 c2 BG3-c2 DmBG3-c2 DmBG3_c2 ML DmBG3 c2 ML_DmBG3_c2 ML-DmBG3-c2 efo:EFO_0005824 These cells are from the third instar larval stage, made from eye-antenna discs of late L3 (y v f mal) in the Miyake lab. PMID:21177962 D11 DmD11 ML_DmD11 ML-DmD11 efo:EFO_0005825 The line was derived from L3 wing discs (Ui et al., 1987). Transcriptome analysis suggests similarity to cells in the notal region, but not to adepithelial cells (Cherbas et al., 2011). Cells are also female, by criterion of Rox expression. PMID:21177962 PMID:25262759 D16-c3 DmD16-c3 DmD16_c3 ML DmD16 c3 ML_DmD16_c3 ML-DmD16-c3 efo:EFO_0005826 This cell line was derived from the third instar larval stage (y v f mal) of dorsal metathoracic discs. Originated from the Miyake lab and cloned from its parent ML-DMD17 cell line. PMID:21177962 PMID:25262759 D17-c3 DmD17-c3 DmD17_c3 ML DmD17 c3 ML_DmD17_c3 ML-DmD17-c3 efo:EFO_0005827 This cell line was derived from the third instar larval stage (y v f mal) of antennal discs. Originated from the Miyake lab and cloned from its parent ML-DMD20 cell line. Cells are male, by criterion of roX expression. PMID:21177962 PMID:25262759 D20-c2 DmD20-c2 DmD20_c2 ML DmD20 c2 ML_DmD20_c2 ML-DmD20-c2 efo:EFO_0005828 This cell line was derived from the third instar larval stage (y v f mal) of antennal discs. Originated from the Miyake lab and cloned from its parent ML-DMD20 cell line. Cells are male, by criterion of roX expression. PMID:21177962 PMID:25262759 D20-c5 DmD20-c5 DmD20_c5 ML DmD20 c5 ML_DmD20_c5 ML-DmD20-c5 efo:EFO_0005829 This cell line was derived from the third instar larval stage (y v f mal) of dorsal mesothoracic discs. The cells originated from the Miyake lab, and are male by criterion of roX expression (DGRC, unpublished). PMID:21177962 D21 DmD21 ML DmD21 ML_DmD21 ML-DmD21 efo:EFO_0005830 This cell line was derived from the third instar larval stage (y v f mal) of dorsal mesothoracic discs. Originated from the Miyake lab. PMID:21177962 D32 DmD32 ML DmD32 ML_DmD32 ML-DmD32 efo:EFO_0005831 This cell line was derived from the third instar larval stage (y v f mal) of imaginal discs. Originated from the Miyake lab and cloned from its parent ML-DMD4 cell line. PMID:21177962 PMID:25262759 D4-c1 DmD4-c1 DmD4_c1 ML DmD4 c1 ML_DmD4_c1 ML-DmD4-c1 efo:EFO_0005832 This cell line was derived from the third instar larval stage (y v f mal) of dorsal mesothoracic discs. Originated from the Miyake lab. PMID:21177962 PMID:25262759 D8 DmD8 ML DmD8 ML_DmD8 ML-DmD8 efo:EFO_0005833 This cell line was derived from the third instar larval stage (y v f mal) of dorsal mesothoracic discs. Originated from the Miyake lab. PMID:21177962 PMID:25262759 D9 DmD9 ML DmD9 ML_DmD9 ML-DmD9 efo:EFO_0005834 Ovarian somatic adult stage cells originated in the Siomi lab. PMID:19812547 Ovarian somatic cells OSC efo:EFO_0005835 This cell line comes from removing the stem cells from its parent fGS/OSS (female germ-line stem cells/ovarian somatic sheet), which contains both germ-line and somatic cells. Since stem cells express the Vasa protein, selected subpopulations consisting of only somatic cells was checked for vas-Egfp expression to ensure homogeneity. Cells show cytoplasmic processes like epithelial cells. This OSS line would be very useful as a cell feeder layer for culturing various types of genetically marked germ-line cells including primordial germ cells. PMID:17056713 SNOMEDCT:258333005 ovarian somatic sheet cells OSS efo:EFO_0005836 This S2 isolate is the one routinely used for RNAi screens at the DRSC; it is referred to at the DRSC as "S2". Its relationship to the line we call "S2" (catalog #006) is not known. NCIt:C111071 PMID:21177962 PMID:25262759 S2 S2_DRSC SL2 Schneider's 2 Schneider's line 2 S2-DRSC efo:EFO_0005837 An isolate of S2 cells that was found in the Miyake laboratory freezer. It was contributed to the Miyake lab by Imogene Schneider and is likely to be very similar to the original S2 line. an isolate of S2 that has receptors for wg signalling. PMID:21177962 PMID:25262759 S2 receptor plus S2Rplus S2R+ efo:EFO_0005838 These cells were made from Oregon R embryos on the verge of hatching in the late embryonic stage. Originated in the Schneider lab. NCIt:C111072 PMID:21177962 PMID:25262759 S3 efo:EFO_0005839 Clone of S2. Differs from the S2 cell distributed by the DGRC in many transcriptional properties, among them a higher expression of Abd-B in Sg4, and a much higher expression of defensins in S2. PMID:21177962 PMID:25262759 SG4 Sg4 efo:EFO_0005843 quantification of the hormone cortisol in blood or urine Dani Welter true NCIt:C74781 SNOMEDCT:62037009 cortisol measurement efo:EFO_0005845 Hemoglobin A2 measurement is a measure of the quantity of the metallo protein hemoglobin A2, a tetramer of alpha- and delta-globin chains, in blood The determination of the amount of hemoglobin A2 present in a sample. [ NCI ] Dani Welter Zoe May Pendlington https://en.wikipedia.org/wiki/Hemoglobin_A2 true NCIt:C92259 SNOMEDCT:269822005 UMLS:C0474543 HGBA2 HbA2 levels Hemoglobin A2 hemoglobin A2 levels hemoglobin A2 measurement efo:EFO_0005849 quantification of some lipase activity in blood. It is used as a diagnostic test for pancreatitis, pancreatic cancer and and in the diagnosis and monitoring of coelic disease, Chrohn's disease and cystic fibrosis. Dani Welter http://labtestsonline.org.uk/understanding/analytes/lipase/tab/test/ http://www.nlm.nih.gov/medlineplus/ency/article/000221.htm https://en.wikipedia.org/wiki/Lipase true serum lipase activity measurement efo:EFO_0005850 quantification by computed tomography scans of distinct pathologic patterns in the lungs that occur in emphysema Dani Welter true emphysema pattern measurement efo:EFO_0005851 height-adjusted version of BMI calculated as BMI[x] = weight(kg)/height(m)^x), where x is derived to give the lowest Pearson's correlation coefficient of BMI[x] with height within a study cohort Dani Welter true height-adjusted BMI height-adjusted body mass index efo:EFO_0005852 quantification of the morphology (eg thickness and surface area) of Heschl's gyrus, a core region of the auditory cortex with highly variable morphology Dani Welter http://europepmc.org/abstract/MED/25130324 true Heschl's gyrus morphology measurement efo:EFO_0005890 osteoarthritis biomarkers, such as serum cartilage oligomeric protein (sCOMP) and urinary C-telopeptide of type II collagen (uCTX-II), are used as indicators for osteoarthritis screening and as predictors for therapeutic responses and prognoses in patients Dani Welter true osteoarthritis biomarker measurement efo:EFO_0005901 Human embryonic stem cell line ELF-1 was derived from a human embryo in the Ellison Stem Cell Core at the University of Washington, Seattle, WA. Catherine Leroy https://www.wicell.org/home/stem-cells/catalog-of-stem-cell-lines/elf1.cmsx?closable=true ELF-1 cell ELF-1 efo:EFO_0005903 KBM-7 cells were derived from a 39-year-old man with chronic myeloid leukemia in blast crisis. The original cell line contained both near haploid and hyperdiploid clones. Subsequent subcloning yielded a pure near-haploid cell line.Genome analysis has revealed that besides the disomic chromosome 8 also a 30 megabase fragment of chromosome 15 is present in two copies. Like other CML cells lines (e.g., K562) KBM-7 cells are positive for the Philadelphia chromosome harboring the BCR-ABL oncogenic fusion. KBM-7 cells have been reprogrammed to yield the HAP1 cell line which is also haploid for chromosome 8. Catherine Leroy PMID:3466682 KBM-7 efo:EFO_0005904 Undifferentiated embryonic stem cells Catherine Leroy NCIt:C20309 PMID:9804556 SNOMEDCT:264834000 https://www.wicell.org/home/stem-cells/catalog-of-stem-cell-lines/wa07.cmsx?closable=true H7 H7 cell H7-ES WA07 H7-hESC efo:EFO_0005906 non-Hodgkin lymphoma derived cell lines Catherine Leroy B-cell non-Hodgkin lymphoma cell line efo:EFO_0005907 Established from the bone marrow of a 44-year-old man with B-cell Non-Hodgkin lymphoma (B-NHL; diffuse large cell), stage 4B at relapse in 1983. Catherine Leroy PMID:11807979 OCI-LY1 efo:EFO_0005909 Dermal fibroblasts from an 8 year old male with Hutchinson-Gilford progeria syndrome (cell line HGPS, HGADFN167, progeria research foundation). Catherine Leroy PMID:23027899 HGADFN167 cell HGPS HGPS cell HGADFN167 efo:EFO_0005910 The clonal embryonic stem cell line ES-D3 was derived from blastocysts of a male 129S2/SvPas strain mouse. The cells spontaneously differentiate into embryonic structures in the absence of a feeder layer or conditioned medium. Catherine Leroy ATCC:CRL-1934 PMID: 3897439 ATCC CRL-1934 D3 D3 cell ES-D3 cell ES-D3 efo:EFO_0005912 An immortalized cell line from hTERT-infected myometrial cells (hTERT-HM). Cells were isolated from myometrial tissue obtained from women undergoing hysterectomy, and retroviral infection was used to express the catalytic subunit of telomerase in myometrial cells. PMID:12135889 myometrial cells hTERT-HM efo:EFO_0005913 Primary ureter cell culture of urothelial cells derived from a 12 year-old girl and immortalized by transfection with a temperature-sensitive SV-40 large T antigen gene. Catherine Leroy PMCID: PMC1240407 NCIt:C33841 PMID: 8788275 UROtsa cell human ureter cell urothelial cell urothelium cell line efo:EFO_0005914 ZHBTc4 undifferentiated mouse embryonic stem cells originated from a male mouse of the 129/Ola strain, and received as frozen ampoules from D. Levasseur (University of Iowa). These cells lack functional endogenous Oct4 alleles and harbor a regulatable Oct4 transgene. Catherine Leroy PMCID:PMC2259027 http://genome.ucsc.edu/ENCODE/protocols/cell/mouse/ZhBTc4_Stam_protocol.pdf ZHBTc4 ZHBTc4 ES ZHBTc4 ES cell ZHBTc4 cell ZHBTc4-mESC efo:EFO_0005915 Embryonic stem cells isolated from mix of ~20% C57/B6J, ~75% 129/Sv and ~5% SJL all male strains. Catherine Leroy PMID:7638196 WW6 cell WW6 efo:EFO_0005916 Undifferentiated embryonic stem cells were originally isolated from 129S1/SVImJ strain mice by Swiatek PJ et al. in 1993. Catherine Leroy PMID:8224839 http://genome.ucsc.edu/ENCODE/protocols/cell/mouse/ES-CJ7_Stam_protocol.pdf CJ7 cell ES-CJ7 cell ES-CJ7 efo:EFO_0005918 quantification of osteoprotegerin in a sample Dani Welter http://atvb.ahajournals.org/content/30/9/1684.full http://europepmc.org/abstract/MED/25080503 true NCIt:C116206 OPG measurement Osteoclastogenesis Inhibitory Factor measurement TNFRS11B measurement Tumor Necrosis Factor Receptor Superfamily Member 11b measurement osteoprotegerin measurement efo:EFO_0005919 quantification of any recombination-related factor, such as hotspot usage, African enchrichment and recombination rate Dani Welter true recombination measurement efo:EFO_0005921 quantification of the rate of change in FEV of an individual over the course of time, used as an indicator of improvement or decay of pulmonary function Dani Welter true FEV1 change measurement FEV change measurement efo:EFO_0005935 quantification of weight/height relationships above a certain threshold that classes an individual as overweight. This threshold may vary based on an individual's ethnicity but is commonly considered to correspond in European populations to a 25<BMI<30 Dani Welter true overweight BMI status overweight body mass index status efo:EFO_0005936 quantification of weight/height relationships below a certain threshold that classes an individual as underweight. This threshold may vary based on an individual's ethnicity but is commonly considered in European populations to correspond to a BMI < 18 Dani Welter true underweight BMI status underweight body mass index status efo:EFO_0005937 quantification of the variation in body mass index over time Dani Welter true body mass index change measurement longitudinal BMI measurement efo:EFO_0005939 quantification of the effect of the parental genotype, usually the maternal genotype on the development of a child, for example to determine its influence on congenital abnormalities Dani Welter true parental genotype effect measurement efo:EFO_0005941 quantification of the density of breast tissue from a mammogram, used as an indicator of breast cancer risk Dani Welter true mammographic density measurement efo:EFO_0005949 A measurement of the antinuclear antibodies (antibodies that attack the body's own tissue) in a biological specimen. The determination of the amount of antinuclear antibodies present in a sample. true NCIt:C74916 ANA levels antinuclear antibody measurement efo:EFO_0006266 quantification of skinfold thickness as a proxy for measuring the amount of adipose tissue Dani Welter true sum of skinfolds efo:EFO_0006268 The epidermoid carcinoma cell line A-431, derived from an 85-year-old female, is one of a series of cell lines established from solid tumors by D.J. Giard, et al. This is a hypertriploid human cell line. The modal chromosome number was 74 occurring in 36% of cells. The rate of cells with higher ploidies was 1.0%. http://www.lgcstandards-atcc.org/products/all/CRL-1555.aspx ATCC:CRL-1555 A-431 A431 efo:EFO_0006269 Cell line was established by fusion of primary human first trimester trophoblasts (week 12 of gestation) with a human choriocarcinoma cell line (AC1-1). Hiden et al (2007) BMC Developmental Biology 7:137 ACH-3P efo:EFO_0006270 The culture was initiated on 5/20/80 from explants of minced lung tissue taken from a therapeutically aborted fetus of 12 weeks gestational age. The cell morphology is fibroblast-like. The karyotype is 46,XY; normal diploid male. A matched skin-derived fibroblast culture from same fetus is AG04449. https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG04450 AG04450 efo:EFO_0006271 ARPE-19 is a spontaneously arising retinal pigment epithelia (RPE) cell line derived in 1986 by Amy Aotaki-Keen from the normal eyes of a 19-year-old male who died from head trauma in a motor vehicle accident. http://www.lgcstandards-atcc.org/products/all/CRL-2302.aspx ATCC:CRL-2302 ARPE-19 efo:EFO_0006273 The germ-line competent cell line CGR8 was established from the inner cell mass of a 3.5 day male pre-implantation mouse embryo (Mus musculus, strain 129). These pluripotent cells retain the ability to participate in normal embryonic development. Differentiation of CGR8 cells is inhibited by the pleiotropic cytokine Differentiation Inhibiting Activity (DIA) which is identical to Leukaemia Inhibiting Factor (LIF). Addition of DIA/LIF is essential and allows culture of CGR8 without the use of feeder layers. Cells are small and tightly packed. http://www.phe-culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=07032901&collection=ecacc_gc CGR8 efo:EFO_0006274 The DT40 chicken B cell line is derived from an avian leukosis virus (ALV)-induced bursal lymphoma. The ALV was injected intravenously into Hyline SC chickens and a resulting tumor was twice transplanted in vivo prior to cell culturing (Baba and Humphries, 1984; Baba et al., 1985). The DT40 cells are small, approximately 10 μm in diameter, and have a high nucleus to cytoplasm ratio (Fig. 1). They carry IgM on the surface, and although Baba et al. (1985) did not find evidence of secreted IgM, others have (Takagaki et al., 1996; Takami et al., 1999). DT40 cells do release ALV into the surroundings, but in negligible amounts (Baba et al., 1985). In keeping with the observation that nearly 85% of all ALV-induced tumors are disrupted in the c-myc locus, the DT40 cells have integrated the 3′ viral long terminal repeat (LTR) upstream of the c-myc gene ( Hayward et al., 1981). The 3′ LTR is in the same orientation as c-myc, elevating the transcription levels 100-fold in this cell line compared with normal avian bursal cells ( Baba et al., 1985). Whereas Baba et al. (1985) detected a normal and an altered c-myc allele, Kim et al. (1990) reported a possible mitotic recombination event among the parental alleles, as they describe the loss of the normal c-myc allele and instead find two copies of the altered c-myc gene. DT40 cells continue to undergo gene conversion, as seen by testing for the presence or absence of various restriction sites within the light chain variable region ( Thompson et al., 1987). Although the DT40 cell line may best be characterized as being a bursal B cell line, the ongoing gene conversion and the fact that v-myc transformed cells can reconstitute an ablated bursa of Fabricius suggests, that the DT40 cell line is arrested at a bursal stem cell stage of differentiation ( Baba et al., 1985; Thompson et al., 1987; McCormack et al., 1991). Winding and Berchtold (2001) Journal of Immunological Methods 249:1-16 DT40 efo:EFO_0006275 This is a derivative of one of several mouse embryonal stem cell (ES) lines developed by M. Hooper in 1987. Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-1821.aspx ATCC:CRL-1821 ES-E14TG2a efo:EFO_0006276 Clinically affected; ataxia; scoliosis; hypertrophic cardiomyopathy; slurred speech; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 650 and 1030 repeats; brother of GM15849 and GM15851, son of GM15847 and GM15848. https://catalog.coriell.org GM15850 efo:EFO_0006277 Clinically unaffected;has two FRDA alleles in the normal range of GAA trinucleotide repeats;brother of an affected individual (GM15850). https://catalog.coriell.org GM15851 efo:EFO_0006278 GM5659 primary fibroblasts were established from a skin biopsy of an apparently healthy donor Duarte et al (2009) Free Radical Biology and Medicine 46:78-87 GM-5659 GM5659 efo:EFO_0006279 Cell line is derived from the normal human parotid gland. The cell lines are propagated in serum-free medium comprised of keratinocyte basal medium supplemented with insulin (5 micrograms/ml), hydrocortisone (0.5 micrograms/ml),epidermal growth factor (EGF, 10 ng/ml), bovine pituitary extract (25 micrograms/ml), and antibiotics. Normal diploid karyotypes, lack transformed phenotypes and non-tumorigenic in nude mice. Produces tissue-specific proteins, i.e. α-amylase 1, basic proline-rich protein, and cystatins; and expressed the corresponding genes as determined by RT-PCR analyses. Chopra et al (1995) Differentiation 58:241-251 HPAF1 efo:EFO_0006280 Cell line is derived from the normal human parotid gland. The cell lines are propagated in serum-free medium comprised of keratinocyte basal medium supplemented with insulin (5 micrograms/ml), hydrocortisone (0.5 micrograms/ml),epidermal growth factor (EGF, 10 ng/ml), bovine pituitary extract (25 micrograms/ml), and antibiotics. Normal diploid karyotypes, lack transformed phenotypes and non-tumorigenic in nude mice. Produces tissue-specific proteins, i.e. α-amylase 1, basic proline-rich protein, and cystatins; and expressed the corresponding genes as determined by RT-PCR analyses. Chopra et al (1995) Differentiation 58:241-251 HPAM1 efo:EFO_0006281 CD47-deficient T cell line derived from Jurkat cells (JinB8) Barazi et al (2002) The Journal of Biological Chemistry 277:42859-42866 JinB8 efo:EFO_0006282 KM12 is one of the cell lines of the NCI-60 panel which represents different cancer types and has been widely utilized for drug screening and molecular target identification. http://ezbiosystems.com/view2.asp?d_id=318 NCIt:C117165 KM-12|KM.12 KM12 efo:EFO_0006283 KOPTK1 KOPT-K1 efo:EFO_0006284 LOX-IMVI is one of the cell lines of the NCI-60 panel which represents different cancer types and has been widely utilized for drug screening and molecular target identification. http://ezbiosystems.com/view2.asp?d_id=336 NCIt:C117181 LOX IMVI LOX-IMVI LOXIMVI efo:EFO_0006285 Cell line grew spontaneously on two subsequent occasions from the peripheral blood (PB) of a patient with B-chronic lymphocytic leukemia (B-CLL) in prolymphocytoid transformation. The patient was EBV-seropositive, his leukemic cells were EBNA negative, but the spontaneously grown cell lines are EBNA-2 positive. MEC2 cells do not adhere and form large clumps. The doubling time of MEC2 is 31h. Stacchini et al (1999) Leukemia Research 23:127-136 MEC-2 MEC2 efo:EFO_0006286 MGC803 MGC-803 efo:EFO_0006287 A monocytic cell line, termed Mono Mac, was established from peripheral blood of a patient with monoblastic leukemia. Two clones, designated Mono Mac I and Mono Mac 6, were isolated and both were assigned to the monocyte lineage on the basis of morphological, cytochemical and immunological criteria. Most importantly, the clones express NaF-sensitive non-specific-esterase, produce reactive oxygen and stain with MAb My4. Mono Mac 6, in addition, constitutively exhibits phagocytosis of antibody-coated erythrocytes in 80% of the cells and reacts with a panel of MAbs that are specific for mature monocytes, i.e., M42, LeuM3, 63D3, Mo2 and UCHMI. By contrast, the monoblastic cell lines U937 and THP-I are negative for all these markers. Only expression of My4 could be detected after differentiation induced by interferon-gamma (IFN-gamma). Similar treatment of Mono Mac I, however, resulted in staining with all the monocyte-specific MAbs mentioned above, while IFN-gamma treatment of Mono Mac 6 enhanced antigen expression. In addition, the cells showed an increased frequency of multinucleated cells with a rise from 4.8% to 21.9%. Mono Mac 6 appears to be the only one of the cell lines studied to constitutively express phenotypic and functional features of mature monocytes. Ziegler-Heitbrock et al (1988) International Journal of Cancer 41:456-461 MM6 Mono-Mac 6 Mono Mac 6 efo:EFO_0006288 90-8TL NF90-8 efo:EFO_0006289 established from the peripheral blood of a 57-year-old man with acute myeloid leukemia (AML FAB M4) at diagnosis in 1987; cells carry an NPM1 gene mutation (type A) and the DNMT3A R882C mutation. http://www.dsmz.de/catalogues/details/culture/ACC-582.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-AML3 efo:EFO_0006291 A continuously growing cell line has been established from autopsy material taken from a primary liver carcinoma, a cancer which has a high incidence in Southern Africa. The cell line was initiated from multifocal areas of outgrowth in the primary culture, and adaptation to in vitro conditions was completed after 18 months. The cells resemble hepatocytes in culture, have a doubling time of 35 - 40 hours and a plating efficiency of 40 - 50%. No virus particles have been found in the cells by ultrastructural examination. The isozyme pattern and the karyology of the cells are human. The chromosome pattern is heteroploid (mean number 56) and there are marker chromosomes. Alexander et al (1976) SA Medical Journal 50:2124-2128 Alexander cell PLC/PRF/5 efo:EFO_0006292 S462 efo:EFO_0006293 Human gastric cancer cell line (SGC-7901) was established by Wang Long-Bao et al in cooperation with Shanghai No.6 People's hospital and other institutions in China. The cells were isolated from surgically resected metastatic lymph node from a female patient with stage 4 gastric cancer with remarkable peritoneal invasion. The shape was Borrman stage 3-4. Long-Bao et al (1993) Recent Advances in Management of Digestive Cancers, pp 416-418 SGC-7901 efo:EFO_0006294 SH-EP is derived from SK-N-SH cell line. Cells of SH-EP are flattened in shape and do not have neuritic processes. Ross et al (1983) Journal of the National Cancer Institute 71:741-747 SH-EP Shep shep SHEP efo:EFO_0006295 ST88-14 efo:EFO_0006296 STS26T cells were derived from a sporadic MPNST and have functional neurofibromin Sun et al (2012) Translational Oncogenomics 5:1-7 STS26T efo:EFO_0006297 derived from Swiss3T3 fibroblasts http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss19 efo:EFO_0006298 derived from Swiss3T3 fibroblasts http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss2 efo:EFO_0006299 derived from Swiss3T3 fibroblasts http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss22 efo:EFO_0006300 derived from Swiss3T3 fibroblasts http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss3 efo:EFO_0006301 derived from Swiss3T3 fibroblasts http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss5 efo:EFO_0006302 derived from Swiss3T3 fibroblasts http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss8 efo:EFO_0006303 derived from Swiss3T3 fibroblasts http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss9 efo:EFO_0006304 The T265 cell line is widely used for cell culture studies of Schwann cells in MPNSTs. This cell line has characteristics consistent with Schwann cells that have been transformed into a malignant phenotype because of the loss of neurofibromin in the auto-somal-dominant condition NF1 Lee at al (2004) Neuron Glia Biology 1:135-147 T265 efo:EFO_0006305 T87 efo:EFO_0006306 TUBO cells are a cloned line established in vitro from a BALB-neuT mouse mammary carcinoma. They display membrane class I H-2dMHC glycoproteins and rp185neu proteins. In BALB/c mice, r-p185 is a xenogeneic Ag that differs from mouse rp185 in <6% of the amino residues. Despite these differences, a challenge of 1 x 105 TUBO cells grew progressively in all BALB/c mice and gave rise to lobular carcinomas histologically similar to those that appear in BALB-neuT-transgenic mice. The reactive cell infiltrate associated with TUBO cell growth was marginal. No anti-TUBO cell CTL, nor IFN-gama, nor GM-CSF release were found when Spc from BALB/c mice bearing 3- or 10-mm mean TUBO tumors were tested immediately or after 6 days in in vitro restimulation with TUBO cells. Moreover, no anti-rp185 Ab were detected in the sera of tumor bearing mice. Despite their high membrane expression of the xenogeneic rp185, growing TUBO cells appear to trigger a marginal or no immune reaction in BALB/c mice. https://cancermodels.nci.nih.gov/camod/ViewModelAction.do?unprotected_method=populateCellLines&aModelID=448 TUBO efo:EFO_0006307 Cell line was established from a patient with essential thrombocytosis that transformed into acute leukemia. The patient's initial clinical presentation included skin and lymph node infiltrations that were taken for an angiosarcoma due to positivity for CD34, CD31, and von Willebrand factor on immunohistology. In addition to hematopoietic markers, leukemic cells expressed endothelial antigens such as CD62E, CD105, and bound Ulex europäeus lectin-1. Immunocytochemistry revealed positive staining for vascular endothelial growth factor receptor type 2 (KDR), Tie-2/Tek, the angiopoietin receptor, and vascular endothelial cadherin. These results were confirmed by PCR analysis. Simultaneous staining for CD62E and FISH analysis showed that cells with endothelial characteristics belonged to the leukemia. FISH analysis of histologic sections of the lymph node infiltration confirmed this manifestation as part of the leukemic process. The derived cell line, UKE-1, forms colonies in soft agar and is tumorigenic in SCID mice. Fiedler et al (2000) Cancer 88:344-351 UKE-1 UKE1 efo:EFO_0006308 Mouse embryonic stem cells from a male mouse embryo http://www.novusbio.com/v65-Mouse-embryonic-stem-cells-_NBP1-41162.html V6.5 efo:EFO_0006309 quantification of the protein plasminogen in a plasma sample Dani Welter true plasma plasminogen measurement efo:EFO_0006312 quantification of mitochondrial DNA in a sample, usually through genetic amplification of target genes by quantifiative real-time PCR Dani Welter true mtDNA measurement mitochondrial DNA measurement efo:EFO_0006319 plasma HIV1 RNA levels at a specific point in time, eg before or after initiation of anti-retroviral therapy Dani Welter true HIV viral set point measurement efo:EFO_0006331 quantification of selenium in a sample Dani Welter true SNOMEDCT:37188009 selenium measurement efo:EFO_0006332 quantification of the amount of iron in a blood sample used in the diagnosis of familial hemochromatosis Dani Welter true SNOMEDCT:250216004 serum iron measurement efo:EFO_0006333 The determination of the iron bound to transferrin in a sample. true NCIt:C98792 transferrin saturation measurement efo:EFO_0006334 The determination of the saturation of iron binding sites on serum transferrin proteins. true MedDRA:10044089 NCIt:C74718 SNOMEDCT:117173006 total iron binding capacity efo:EFO_0006335 The blood pressure during the contraction of the left ventricle of the heart. Dani Welter true MedDRA:10042955 NCIt:C25298 SNOMEDCT:271649006 SYSBP systolic pressure systolic blood pressure efo:EFO_0006336 The blood pressure after the contraction of the heart while the chambers of the heart refill with blood. Dani Welter true MedDRA:10012751 NCIt:C25299 SNOMEDCT:271650006 DIABP diastolic pressure diastolic blood pressure efo:EFO_0006340 The mean pressure of the blood within the arterial circulation. The arterial pressure may be directly measured by insertion of an intra-arterial catheter connected to a transducer. The mean arterial pressure (MAP) can be calculated by subsequent analysis of the waveform. MAP can be approximated without an invasive procedure using the following formula: diastolic pressure plus 1/3 of the pulse pressure, where pulse pressure is systolic pressure - diastolic pressure. Dani Welter true MedDRA:10026982 NCIt:C49679 MAP mean arterial pressure efo:EFO_0006341 The determination of the amount of transferrin present in a sample. true NCIt:C82037 SNOMEDCT:359982005 transferrin measurement efo:EFO_0006348 The ratio of the diameter of the pulmonary artery to the diameter of the aorta (PA/A) as measured using CT. Dani Welter PMID:25101718 PA/A pulmonary artery-aorta diameter ratio measurement efo:EFO_0006354 Human chondrosarcoma cell line. PMID: 2045389 105KC efo:EFO_0006355 Human osteosarcoma cell line. ATCC catalog number CRL-8308 http://www.atcc.org/products/all/CRL-8303.aspx 143B efo:EFO_0006356 Human melanoma cell line PMID: 25485619 mel501a 501A efo:EFO_0006357 Human melanoma cell line PMID: 25485619 537-mel 537 MEL efo:EFO_0006358 Human ovarian carcinoma cell line. (Sigma-Aldrich catalog number 89081802) http://www.sigmaaldrich.com/catalog/product/sigma/89081802 59M efo:EFO_0006359 Human melanoma cell line PMID: 25485619 624-mel 624 mel efo:EFO_0006360 Human melanoma cell line PMID: 25485619 928-mel 928 mel efo:EFO_0006361 Human melanoma cell line from 43-year-old male patient. ATCC catalog number CRL-11147. http://www.atcc.org/products/all/CRL-11147.aspx A2058 efo:EFO_0006362 Human ovarian carcinoma cell line. (Sigma-Aldrich catalog number 93112519) http://www.sigmaaldrich.com/catalog/product/sigma/93112519 A2780 efo:EFO_0006363 Human colorectal carcinoma cell line PMID: 25485619 C170 efo:EFO_0006364 Human melanoma cell line. ATCC catalog number CRL-1585 http://www.atcc.org/products/all/CRL-1585.aspx C32 efo:EFO_0006365 Human prostate cancer cell line derived from subcutaneous LNCaP xenografts in castrated nude mice. PMID: 8169003 C4-2B efo:EFO_0006366 Human squamous cell carcinoma cell line http://www.atcc.org/products/all/CRL-2095.aspx CAL 27 efo:EFO_0006367 Human non-Hodgkin's lymphoma cell line (DSMZ catalog number ACC 570) http://www.dsmz.de/catalogues/details/culture/ACC-570.html CI-1 efo:EFO_0006368 Human colon carcinoma cell line (DSMZ catalog number ACC 467) http://www.dsmz.de/catalogues/details/culture/ACC-467.html CL-11 efo:EFO_0006369 Human colon carcinoma cell line (DSMZ catalog number ACC 520) http://www.dsmz.de/catalogues/details/culture/ACC-520.html CL-34 efo:EFO_0006370 Human colon carcinoma cell line (DSMZ catalog number ACC 535) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-535.html CL-40 efo:EFO_0006371 Human colon carcinoma cell line (DSMZ catalog number ACC 194) http://www.dsmz.de/catalogues/details/culture/ACC-194.html COLO-678 COLO 678 efo:EFO_0006372 Human melanoma cell line (Sigma-Aldrich catalog number 87061210) http://www.sigmaaldrich.com/catalog/product/sigma/87061210 COLO-679 COLO 679 efo:EFO_0006373 Human squamous cell carcinoma cell line (DSMZ catalog number ACC 182) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-182.html COLO-680N COLO 680N efo:EFO_0006374 Human lung adenocarcinoma cell line (DSMZ catalog number ACC196) http://www.dsmz.de/catalogues/details/culture/ACC-196.html COLO-699 COLO 699 efo:EFO_0006375 Derived from a pelvic wall metastasis of a 69 year old female with colon carcinoma. (Sigma-Aldrich catalog number 93052621) http://www.sigmaaldrich.com/catalog/product/sigma/93052621 COLO-783 COLO 741 efo:EFO_0006376 Human melanoma cell line (DSMZ catalog number ACC257) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-257.html COLO-783 COLO 783 efo:EFO_0006377 Derived from a brain metastasis of a 62 year old male with melanoma. The cells bleb during culture. (Sigma-Aldrich catalog number 93052616) http://www.sigmaaldrich.com/catalog/product/sigma/93052616 COLO-792 COLO 792 efo:EFO_0006378 Derived from a subcutaneous nodule of a tumour from a 14-year-old male. Cells display remarkable blebbing. (Sigma-Aldrich catalog number 93051123) http://en.wikipedia.org/wiki/List_of_contaminated_cell_lines http://www.sigmaaldrich.com/catalog/product/sigma/93051123 COLO 818 COLO-800 COLO-818 COLO 800 efo:EFO_0006379 derived in 1992 from right axillary lymph nodes of a 43-year-old Caucasian man with metastatic maligant melanoma (DSMZ catalog number ACC 216) http://www.dsmz.de/catalogues/details/culture/ACC-216.html COLO-849 COLO 849 efo:EFO_0006380 Derived from the right axilla lymph node of a 43 year old male with melanoma. (Sigma-Aldrich catalog number 93052606) http://www.sigmaaldrich.com/catalog/product/sigma/93052606 COLO-853 COLO 853 efo:EFO_0006381 Derived from a right axilla lymph node of a 43 year old male with melanoma. The biopsy material was obtained post chemotherapy. (Sigma-Aldrich catalog number 93051120) http://www.sigmaaldrich.com/catalog/product/sigma/93051120 COLO-857 COLO 857 efo:EFO_0006382 A human ovarian epithelial-serous carcinoma cell line established from a peritoneal ascites. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071903) http://www.sigmaaldrich.com/catalog/product/sigma/07071903 COV318 efo:EFO_0006383 A human ovarian epithelial-endometroid carcinoma cell line established from a pleural effusion. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071910) http://www.sigmaaldrich.com/catalog/product/sigma/07071910 COV362 efo:EFO_0006384 Human ovarian granulosa tumour cell line established from a solid primary tumour (Sigma-Aldrich catalog number 07071909) http://www.sigmaaldrich.com/catalog/product/sigma/07071909 COV434 efo:EFO_0006385 A human ovarian epithelial-serous carcinoma cell line established from a pleural effusion. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071902) http://www.sigmaaldrich.com/catalog/product/sigma/07071902 COV504 efo:EFO_0006386 Human ovarian epithelial-mucinous carcinoma cell line established from a solid primary tumour. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071908) http://www.sigmaaldrich.com/catalog/product/sigma/07071908 COV644 efo:EFO_0006389 Dukes' Type C, Colorectal Adenocarcinoma cell line. ATCC catalog number CCL-221 http://www.atcc.org/Products/All/CCL-221.aspx DLD-1 DLD1 efo:EFO_0006390 The small cell carcinoma DMS 454 was isolated in 1981 from lung tissue of a male patient at time of autopsy. (Sigma-Aldrich catalog number 95062832) http://www.sigmaaldrich.com/catalog/product/sigma/95062832 DMS 454 efo:EFO_0006392 A woman with exocrine pancreatic cancer presented a syndrome of humoral hypercalcemia of malignancy. Supraclavicular lymph node was biopsied. The fragments of the biopsied specimen were transplanted and grown in athymic nude mice for several generations before being extracted and cultured. PMID: 2543550 FA-6 FA6 efo:EFO_0006393 The Farage cell line was adapted to culture in 1990 from a lymph node biopsy of a patient with diffuse large cell non-Hodgkin's lymphoma (DLCL). (ATCC catalog number CRL-2630) http://www.atcc.org/products/all/CRL-2630.aspx Farage efo:EFO_0006394 Human malignant melanoma cell line (ATCC catalog number CRL-1424) http://www.atcc.org/products/all/CRL-1424.aspx G-361 efo:EFO_0006395 Human glioma cell line PMID: 25485619 G111 efo:EFO_0006396 Human glioma cell line PMID: 25485619 G112 efo:EFO_0006397 Human glioma cell line PMID: 25485619 G118 efo:EFO_0006398 Human glioma cell line PMID: 25485619 G120 efo:EFO_0006399 Human glioma cell line PMID: 25485619 G121 efo:EFO_0006400 Human glioma cell line PMID: 25485619 G122 efo:EFO_0006401 Human glioma cell line PMID: 25485619 G124 efo:EFO_0006402 Human glioma cell line PMID: 25485619 G130 efo:EFO_0006403 Human glioma cell line PMID: 25485619 G140 efo:EFO_0006404 Human glioma cell line PMID: 25485619 G141 efo:EFO_0006405 Human glioma cell line PMID: 25485619 G142 efo:EFO_0006406 Human glioma cell line PMID: 25485619 G22 efo:EFO_0006407 Human glioma cell line PMID: 25485619 G28T efo:EFO_0006408 Human glioma cell line PMID: 25485619 G44 efo:EFO_0006409 Human glioma cell line PMID: 25485619 G59 efo:EFO_0006410 Human glioma cell line PMID: 25485619 G61 efo:EFO_0006411 Human glioma cell line PMID: 25485619 G84 efo:EFO_0006412 Human glioma cell line PMID: 25485619 G96 efo:EFO_0006414 a prolactin (PRL) responsive clone of the COMMA-1D mouse (Balb/c) mammary epithelial cell line PMID: 19523745 HC-11 HC11 efo:EFO_0006415 The human colon cancer cell line, HCA-7 Colony 29 expresses Cox-2. An interesting feature of this cell line is that it forms polarised epithelial sheets which allows examination of the trafficking and release of biomolecules in vitro. Cyclooxygenases (COXs) are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. It has been found that colonic polyps and cancers overexpress Cox-2 and that the inhibition of this enzyme by nonsteroidal anti-inflammatory drugs decreases the risk of colonic neoplasia. This cell line is useful for studying the role of Cox-2 in cancer cell biology and the investigation of colorectal epithelial cell polarity. Imperial College Innovations has stated that this cell line is not to be supplied to commercial organisations. (Sigma-Aldrich catalog number 02091238) http://www.sigmaaldrich.com/catalog/product/sigma/02091238 HCA-7 efo:EFO_0006416 Human renal cell carcinoma cell line from 45-year-old female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC12 HCC0012 efo:EFO_0006417 Human small cell lung carcinoma cell line from a 53-year-old Caucasian male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC33 HCC0033 efo:EFO_0006418 Human cystoadenocarcinoma cell line from a 26-year-old Black female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC60 HCC0060 efo:EFO_0006419 Human renal cell carcinoma cell line from a 64-year-old Caucasian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC89 HCC0089 efo:EFO_0006420 Human lung adenocarcinoma cell line from a 76-year-old male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC364 HCC0364 efo:EFO_0006421 Human ovarian carcinoma cell line from a 32-year-old Hispanic female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC630 HCC0630 efo:EFO_0006422 Human cystic renal cell carcinoma cell line from 37-year-old Hispanic male http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1011 efo:EFO_0006423 Human uterine adenocarcinoma cell line from 48-year-old Black female http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1162 efo:EFO_0006424 Human colorectal adenocarcinoma cell line from 20-year-old Black female http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1263 efo:EFO_0006425 Human renal cell carcinoma cell line from 68-year-old Caucasian male http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1319 efo:EFO_0006426 Human uterine adenocarcinoma cell line from 62-year-old Caucasian female http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1482 efo:EFO_0006427 Human breast adenocarcinoma cell line from 43-year-old male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1493 efo:EFO_0006428 Human lung adenocarcinoma cell line http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1534 efo:EFO_0006429 Human adrenal gland tumour cell line http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1576 efo:EFO_0006430 Human lung adenocarcinoma cell line from 64-year-old Caucasian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2270 efo:EFO_0006431 Human lung adenocarcinoma cell line from 52-year-old Asian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2279 efo:EFO_0006432 Human lung adenocarcinoma cell line http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2302 efo:EFO_0006433 Human breast ductal carcinoma cell line from a female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2688 efo:EFO_0006434 Human non small cell lung carcinoma cell line http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2885 efo:EFO_0006435 Human breast carcinoma cell line PMID: 25485619 HCC2911 efo:EFO_0006436 Human lung adenocarcinoma cell line from a 53-year-old Caucasian male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC4011 efo:EFO_0006437 Human non small cell lung carcinoma cell line from a 62-year-old Caucasian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC4017 efo:EFO_0006438 Cells of this line contain HeLa marker chromosomes, and were derived via HeLa contamination. This line was originally thought to be derived from an epidermoid carcinoma of the larynx, but was subsequently found, based on isoenzyme analysis, HeLa marker chromosomes, and DNA fingerprinting, to have been established via HeLa cell contamination. The cells are positive for keratin by immunoperoxidase staining. ATCC confirmed this cell line is positive for the presence of human papilloma viral DNA sequences via PCR. http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HEp-2 efo:EFO_0006439 Human non small cell lung carcinoma cell line PMID: 25485619 HOP62 efo:EFO_0006440 Human large cell carcinoma cell line PMID: 25485619 HOP92 efo:EFO_0006441 Human glioma cell line (ATCC catalog number HTB-138) http://www.atcc.org/products/all/HTB-138.aspx Hs 683 efo:EFO_0006442 Human colon carcinoma cell line. Cells possess Ca antigen as defined by the Ca1 antibody. The Ca antigen has been shown to be absent in non-malignant human cell strains and is considered to be a marker linked with malignancy. Island cell growth will degenerate if left more than 9 days between passages. (Sigma-Aldrich catalog number 85061104) http://www.sigmaaldrich.com/catalog/product/sigma/85061104 HT-115 HT115 efo:EFO_0006443 Human malignant melanoma cell line derived from metastatis in subcutaneous tissue from a 29-year-old male Caucasian patient. (ATCC catalog number HTB-63) http://www.atcc.org/products/all/HTB-63.aspx HT-144 HT144 efo:EFO_0006444 Human colon carcinoma cell line (Sigma-Aldrich catalog number 85061105) http://www.sigmaaldrich.com/catalog/product/sigma/85061105 HT-55 HT55 efo:EFO_0006445 Human hepatocellular carcinoma cell line http://lincs.hms.harvard.edu/db/cells/50256/ huH-1 efo:EFO_0006446 Human adenocarcinoma cell line from a 63-year-old Japanese male patient with moderately differentiated adenocarcinoma of the stomach http://cellbank.nibio.go.jp/legacy/celldata/jcrb1075.0.htm IM95 IM-95 efo:EFO_0006447 Human melanoma cell line established from the primary tumor (right cervical) of a 64-year-old woman with cutaneous melanoma. (DSMZ catalog number ACC 251) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-251.html IPC298 IPC-298 efo:EFO_0006448 Human malignant epithelioid mesothelioma cell line established from the untreated malignant epithelioid mesothelioma of the pleura of a 54-year-old man with asbestos cancer in 2003 (DSMZ catalog number ACC 596) http://www.dsmz.de/catalogues/details/culture/ACC-596.html JL1 JL-1 efo:EFO_0006449 human plasma cell leukemia established from the peripheral blood of a 77-year-old woman at diagnosis of plasma cell leukemia (IgGkappa) in 1987; plasma cell leukemia is related to multiple myeloma confirmed as human by cytogenetics http://www.cabri.org/CABRI/srs-bin/wgetz?-newId+-e+-page+qResult+[DSMZ_MUTZ-id:%27ACC%20514%27] KARPAS-620 Karpas 620 KARPAS-620 efo:EFO_0006450 human plasma cell leukemia cell line established from the peripheral blood of a 36-year-old woman with plasma cell leukemia (IgG) in 1977; cells were described to be EBNA-negative and to express mRNA for proto-oncogene BCL2; plasma cell leukemia is related to multiple myeloma. (DSMZ catalog number ACC 49) http://www.dsmz.de/catalogues/details/culture/ACC-49.html L-363 efo:EFO_0006451 M059K cells were isolated from a tumor specimen from a 33 year-old male patient with untreated glioblastoma. (ATCC catalog number CRL-2365) http://www.atcc.org/products/all/CRL-2365.aspx M059K efo:EFO_0006453 Human ovarian adenocarcinoma cell line PMID: 25485619 MCAS efo:EFO_0006454 Human breast carcinoma cell line (ATCC catalog number HTB-127) http://www.atcc.org/products/all/HTB-127.aspx MDA-MB-330 efo:EFO_0006455 Model of a dopaminergic cell, generated by somatic cell fusion of primary neurons from mouse embryonic Day 14 rostral mesencephalic tegmentum and the neuroblastoma cell line, N18TG2. PMID: 1913182 MN9D efo:EFO_0006456 Human cervical epidermoid carcinoma cell line derived from metastatis in lymph node (ATCC catalog number HTB-34) http://www.atcc.org/products/all/HTB-34.aspx MS751 efo:EFO_0006457 Human breast carcinoma cell line PMID: 25485619 MX-1 efo:EFO_0006458 The OV56 cell line was established from ascitic fluid derived from a 46-year-old female patient diagnosed with ovarian cancer. The tumour was characterised as stage IV, poorly differentiated. Immunocytochemical staining of the cells was reported to show strong staining for cytokeratin (CK), weak staining for carcinoembryonic antigen (CEA) and strong staining for human milk fat globulin (HMFG-2). Production of vascular endothelial growth factor (VEGF) has been detected by ELISA. The patient had received sequential treatment with cisplatin and cyclophosphamide, cisplatin and etoposide and subsequently tamoxifen. (Sigma-Aldrich catalog number 96020759) http://www.sigmaaldrich.com/catalog/product/sigma/96020759?lang=en&region=GB OV56 efo:EFO_0006459 The OV7 cell line was established from solid ovarian tumour tissue taken from a 78-year-old female patient. The tumour was characterised as stage III, mixed tumour type and poorly differentiated. Immunocytochemical staining of the cells was reported to show strong staining for cytokeratin (CK), no staining for carcinoembryonic antigen (CEA) and strong staining for human milk fat globulin (HMFG-2). Detection of mRNA expression of vascular endothelial growth factor (VEGF) and its receptors flt and KDR has been reported. The patient had received treatment with chlorambucil. (Sigma-Aldrich catalog number 96020764) http://www.sigmaaldrich.com/catalog/product/sigma/96020764 OV7 efo:EFO_0006465 Human ovarian teratocarcinoma cell line derived from metastasis in ascites (ATCC catalog number CRL-1572) http://www.atcc.org/products/all/CRL-1572.aspx PA1 PA-1 efo:EFO_0006466 Panc 02.03 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. (ATCC catalog number CRL-2553) http://www.atcc.org/products/all/CRL-2553.aspx Panc 02.03 efo:EFO_0006467 Panc 03.27 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. (ATCC catalog number CRL-2549) http://www.atcc.org/products/all/CRL-2549.aspx Panc 03.27 efo:EFO_0006468 Panc 04.03 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. (ATCC catalog number CRL-2555) http://www.atcc.org/products/all/CRL-2555.aspx Panc 04.03 efo:EFO_0006469 Panc 05.04 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. (ATCC catalog number CRL-2557) http://www.atcc.org/products/all/CRL-2557.aspx Panc 05.04 efo:EFO_0006470 Panc 08.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. (ATCC catalog number CRL-2551) http://www.atcc.org/products/all/CRL-2551.aspx Panc 08.13 efo:EFO_0006472 The Pfeiffer cell line was established in 1992 from a patient in the leukemic phase of diffuse large cell lymphoma (DLCL) with cleaved and non-cleaved nuclei. (ATCC catalog number CRL-2632) http://www.atcc.org/products/all/CRL-2632.aspx Pfeiffer efo:EFO_0006473 Human acute myeloid leukemia cell line established from the peripheral blood of a 24-year-old man with refractory acute promyelocytic leukemia after mediastinal granulocytic sarcoma. (DSMZ catalog number ACC 536) http://www.dsmz.de/catalogues/details/culture/ACC-536.html PL-21 efo:EFO_0006474 PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin. (ATCC catalog number CRL-2558) http://www.atcc.org/products/all/CRL-2558.aspx PL45 efo:EFO_0006476 Human colorectal adenocarcinoma cell line PMID: 25485619 RCM-1 efo:EFO_0006477 Human lymphoma cell line established from the peripheral blood of a 57-year-old woman with B-cell non-Hodgkin lymphoma (B-NHL, lymphocytic, small cell type progressing to large non-convoluted cell type) in the refractory terminal stage in 1977; assigned to ABC-like lymphoma subtype (activated B-cell); cell line also known as Riva. (DSMZ catalog number ACC 585) http://www.dsmz.de/catalogues/details/culture/ACC-585.htm Riva RI-1 efo:EFO_0006478 Human squamous cell carcinoma derived from metastatis in pleural effusion (ATCC catalog number CCL-30) http://www.atcc.org/products/all/CCL-30.aspx RPMI 2650 efo:EFO_0006479 Human carcinoma cell line established from the transitional cell carcinoma (histological grade G2) excised from a woman (age unknown) with untreated primary urinary bladder carcinoma in 1973; described to form tumors in nude mice (DSMZ catalog number ACC 418) http://www.dsmz.de/catalogues/details/culture/ACC-418.html RT-112 efo:EFO_0006480 Human transitional cell papilloma cell line (ATCC catalog number HTB-2) http://www.atcc.org/products/all/HTB-2.aspx RT4 efo:EFO_0006481 Human B-cell lymphoma cell line from a 67-year-old male patient PMID: 25485619 SC-1 efo:EFO_0006482 Human squamous cell carcinoma cell line from the tongue of a 55-year-old male patient. (ATCC catalog number CRL-1623) http://www.atcc.org/products/all/CRL-1623.aspx SCC-15 efo:EFO_0006483 Human squamous cell carcinoma cell line from the tongue of a 70-year-old male patient. (ATCC catalog number CRL-1628) http://www.atcc.org/products/all/CRL-1628.aspx SCC-25 efo:EFO_0006484 Human non-Hodgkin's lymphoma cell line. PMID: 3095281 SCC-3 efo:EFO_0006485 Human squamous cell carcinoma cell line from the tongue of a 25-year-old male patient. (ATCC catalog number CRL-1629) http://www.atcc.org/products/all/CRL-1629.aspx SCC-9 efo:EFO_0006486 Human essential thrombocythemia cell line established from the peripheral blood of a 71-year-old woman with essential thrombocythemia at megakaryoblastic leukemic transformation in 1995. (DSMZ catalog number ACC 608) http://www.dsmz.de/catalogues/details/culture/ACC-608.html SET-2 efo:EFO_0006487 Human melanoma cell line derived from metastasis in lymph node (ATCC catalog number HTB-71) http://www.atcc.org/products/all/HTB-71.aspx SK-MEL-24 efo:EFO_0006488 Human melanoma cell line derived from tumor tissue (subcutis metastasis) of a 67-year-old Caucasian man with malignant melanoma in 1975 (DSMZ catalog number ACC 151) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-151.html SK-MEL-30 efo:EFO_0006489 Human melanoma cell line derived from a female patient with malignant melanoma (ATCC catalog number HTB-73) http://www.atcc.org/products/all/HTB-73.aspx SK-MEL-31 efo:EFO_0006490 Human melanoma cell line PMID: 25485619 SK23-mel SK23 efo:EFO_0006491 Human anaplastic large T cell lymphoma cell line established from the pleural effusion an 11-year-old boy with CD30+ (Ki-1) large T cell lymphoma in 1983 (also described as "SR"); described to express the NPM1-ALK (NPM-ALK) fusion gene (DSMZ catalog number ACC 369) http://www.dsmz.de/catalogues/details/culture/ACC-369.html SR-786 efo:EFO_0006492 Human lymphoma cell line isolated from peritoneal effusion in a 38-year-old male Caucasian patient. (ATCC catalog number CRL-2957) ATCC:CRL-2957 SU-DHL-4 efo:EFO_0006493 Human large cell lymphoma cel line derived from peritoneal effusion in a 59-year-old male Caucasian patient (ATCC catalog number CRL-2961). http://www.atcc.org/products/all/CRL-2961.aspx SU-DHL-8 efo:EFO_0006494 Human pancreatic ductal carcinoma derived from metastasis in liver. (ATCC catalog number CRL-1837) http://www.atcc.org/products/all/CRL-1837.aspx SU.86.86 efo:EFO_0006495 Human pancreatic tubular adenocarcinoma derived from metastasis in the liver of a 73-year-old male Japanese patient. PMID: 25485619 SUIT-2 efo:EFO_0006496 Human diffuse large B cell lymphoma cell line derived from a 62-year-old male patient. PMID: 25485619 TMD8 efo:EFO_0006498 Human glioblastoma cell line (Sigma-Aldrich catalog number 09063001) http://www.sigmaaldrich.com/catalog/product/sigma/09063001 U-251 MG efo:EFO_0006499 Human diffuse large B cell lymphoma cell line established in 1996 from the ascites of a 29-year-old woman with diffuse large B cell lymphoma, who 16 years earlier was diagnosed with advanced stage Hodgkin lymphoma, and relapsed several times after multiple chemo- and radiotharapy regimens to complete remissions; cells were described to overexpress BCL2, BCL6 and p53; assigned to ABC-like lymphoma subtype (activated B-cell) (DSMZ catalog number ACC 633) http://www.dsmz.de/catalogues/details/culture/ACC-633.html U-2932 efo:EFO_0006501 quantification of the build-up of atheroscleortic plaque, expressed as the sum of plaque areas over the segments in common and internal carotid arteries and bifurcation Dani Welter true PMID:24954085 CPB carotid plaque burden carotid plaque build efo:EFO_0006502 proportion of the total breast area that is dense Dani Welter true PMID:25342443 mammographic density percentage efo:EFO_0006503 quantification of the area of the breast tissue that is dense, expressed in cm2 Dani Welter true PMID:25342443 dense area measurement efo:EFO_0006504 quantification of the area of the breast tissue that is non-dense, expressed in cm2 Dani Welter true PMID:25342443 non-dense area measurement efo:EFO_0006506 quantification of the lipid content of the liver, through medical imaging or from histological samples Dani Welter true hepatic lipid content measurement efo:EFO_0006507 quantification of nicotine metabolisation via the glucuronidation pathway, usually via analysis of a urine sample Dani Welter true nicotine glucuronidation measurement efo:EFO_0006508 quantification of cotinine metabolisation via the glucuronidation pathway, usually via analysis of a urine sample Dani Welter true cotinine glucuronidation measurement efo:EFO_0006512 quantification of some heart-related structural phenotype via the medical imaging technique of angiography, for example to determine the number or type of coronary artery lesions in coronary artery disease Dani Welter true angiographic measurement efo:EFO_0006514 Alzheimer's disease biomarkers are used as indicators for Alzheimer's disease screening and as predictors for therapeutic responses and prognoses in Alzheimer patients Dani Welter true Alzheimer's disease biomarker measurement efo:EFO_0006515 quantification of the amount of angiotension-converting enzyme in a sample, eg in cerebro-spinal fluid or blood Dani Welter https://en.wikipedia.org/wiki/Angiotensin-converting_enzyme true ACE measurement angiotensin-converting enzyme measurement efo:EFO_0006516 quantification of the volume of grey matter in the superior frontal gyrus, usuallly through an MRI scan Dani Welter true superior frontal gyrus grey matter volume measurement efo:EFO_0006517 quantification of interferon alpha in a sample Dani Welter true NCIt:C81994 interferon alpha measurement efo:EFO_0006520 Quantification of the amount of carbon monoxide in a person's exhalation, usually measured using a breath CO monitor. Breath CO can be used for evaluation of smoking status or assessment of carbon monoxide poisoning Dani Welter true breath carbon monoxide measurement carbon monoxide exhalation measurement efo:EFO_0006521 Quantification of the amount of calcium consumed from dietary and supplemental sources Dani Welter true calcium intake measurement efo:EFO_0006522 quantification of the amount of asymmetrical dimethylarginine in blood. Asymmetric dimethylarginine (ADMA) is an independent risk factor for coronary heart disease in patients with heart disease, type II diabetes or kidney disease. ADMA inhibits nitric oxide (NO) synthesis and is elevated in diseases related to endothelial dysfunction including hypertension, hyperlipidemia, and type-II diabetes mellitus. Elevation in ADMA and subsequent NO synthesis inhibition leads to vasoconstriction, reduced peripheral blood flow, and reduced cardiac output. Dani Welter https://en.wikipedia.org/wiki/Asymmetric_dimethylarginine true ADMA measurement asymmetrical dimethylarginine measurement efo:EFO_0006523 quantification of the amount of asymmetrical dimethylarginine in blood. It is a structural isomer of asymmetric dimethyl argigine. It has been reported to be a marker for kidney disease, often used a predictor of all-cause mortality after ischemic stroke Dani Welter http://europepmc.org/abstract/MED/25245031 http://jasn.asnjournals.org/content/17/4/1128.abstract true SDMA measurement symmetrical dimethylarginine measurement efo:EFO_0006524 quantification of the amount of L-arginine in a sample, eg in blood Dani Welter true L-arginine measurement efo:EFO_0006525 the quantification of the number of cigarettes that a subject smoked on average per day Dani Welter true CPD measurement cigarettes per day measurement efo:EFO_0006526 the quantification of the average number of packs smoked per day times the total number of years a subject smoked during his/ her lifetime Dani Welter true pack-years measurement efo:EFO_0006527 self-reported binary measure, used to denote whether an individual is currently or has ever been a smoker Dani Welter true smoking status measurement efo:EFO_0006528 human gastric adenocarcinoma cell line established from the primary tumor of a 72-year-old man with gastric adenocarcinoma in 1987 confirmed as human with IEF of AST, MDH Laura Huerta http://www.cabri.org/CABRI/srs-bin/wgetz?-newId+-e+-page+qResult+[DSMZ_MUTZ-id:%27ACC%20201%27] 23132/87 efo:EFO_0006529 mouse embryonic stem cells derived from 129/01a male mouse. Feeder-free cell line Laura Huerta https://database.riken.jp/sw/en/2TS22C/cria322s1ria322u400000000125i/ 2TS22C efo:EFO_0006530 mouse multiple myeloma cell line Laura Huerta PMID: 11920212 5T33MM efo:EFO_0006531 human melanoma cell line designated 888-mel has been developed from the resected tumor of a 26-year old Caucasian female (patient 888) diagnosed with metastatic melanoma - See more at: https://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=34826089312#sthash.to7UCByK.dpuf Laura Huerta https://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=34826089312 888-mel efo:EFO_0006532 human lymphoma cell line from a 68 year old female Japanese patient with stomach cancer and lymphoma Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0101.htm A3/KAW efo:EFO_0006533 human lymphoma cell line from a 52 year old female Japanese patient with malignant melanoma Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0097.htm A4/Fuk efo:EFO_0006534 human plasmacytoma cell line from a 64 year old female patient (DSMZ catalog number ACC 583) Laura Huerta http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-538.html AMO-1 efo:EFO_0006535 human colorectal carcinoma cell line from an adult male patient (ATCC CRL-2780) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-2780.aspx?geo_country=gb ATRFLOX efo:EFO_0006537 human carcinoma cell line established from the supraclavicular tumor cells-containing lymph node of a 71-year-old man with poorly differentiated carcinoma of the lung (DSMZ calatog number: ACC 254) Laura Huerta http://www.cabri.org/CABRI/srs-bin/wgetz?-newId+-e+-page+qResult+[DSMZ_MUTZ-id:'ACC%20254'] BEN efo:EFO_0006538 human cell carcinoma established from the sarcomatoid component of a grade III transitional cell carcinoma of the renal pelvis of a 64-year-old man in 1990; patient lived in a blackfoot disease endemic area in Taiwan (DSMZ catalog number ACC 367) Laura Huerta http://purl.obolibrary.org/obo/CLO_0001949 http://www.dsmz.de/catalogues/details/culture/ACC-367.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 BFTC-909 efo:EFO_0006539 human oral squamous cell carcinoma established from the tumor of a 52-year-old Japanese man with highly differentiated squamous cell carcinoma of the lower alveolus which was highly invasive to the mandibular bone and the muscle layer of the oral floor (DSMZ catalog number ACC 404) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-404.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 BHY efo:EFO_0006540 human recurrent squamous cell carcinoma of the buccal mucosa of a Caucasian female (Sigma catalog number 04072103) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/04072103?lang=en&region= BICR 10 efo:EFO_0006541 human cell line derived from a lymph node metastasis squamous cell carcinoma of the tongue of a Caucasian male (Sigma catalog number 04072106) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/04072106?lang=en&region= BICR 22 efo:EFO_0006542 human cell line derived from a lymph node metastasis squamous cell carcinoma of the tongue of a Caucasian male (Sigma catalog number 04072107) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/04072107?lang=en&region= BICR 31 efo:EFO_0006543 human cell line derived from a squamous cell carcinoma of the oral alveolus of a Caucasian male (Sigma catalog number 04072111) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/04072111?lang=en&region= BICR 78 efo:EFO_0006546 human colorectal carcinoma cell line from a 72 year old male patient (ATCC CRL-2102) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-2102.aspx?geo_country=gb C2BBe1 efo:EFO_0006547 human cell lung carcinoma line established from a male patient with a non-small cell lung carcinoma in 1981 (DSMZ catalog number ACC 443) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-443.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 CAL-12T efo:EFO_0006548 human rectal carcinoma cell line establish from a metastatic lymph node of a 70-year-old male patient with primary rectal adenocarcinoma Laura Huerta PMID: 2253219 http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb0207 CaR-1 efo:EFO_0006549 human cervical epidermoid carcinoma cell line from a 40 year old female Caucasian patient (ATCC CRL-1550) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-1550.aspx?geo_country=gb ATCC:CRL-1550 CaSki efo:EFO_0006550 human lymphoma cell line from a 11.5 year old male Caucasian patient (ATCC CCL-120) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CCL-120.aspx?geo_country=gb ATCC:CCL-120 CCRF-SB efo:EFO_0006551 human ductal pancreatic adenocarcinoma derived by differential trypsinisation of explant cultures from a metastatic lesion in the liver of a 26 year old caucasian male with cystic fibrosis (Sigma catalog number 91112501) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/91112501?lang=en&region= CFPAC-1 efo:EFO_0006552 human myeloma cell line derived from a peritoneal effusion of a patient with refractory myeloma Laura Huerta PMID: 16266902 CMA-03 efo:EFO_0006553 human myeloma cell line derived from CMA03 Laura Huerta PMID: 24327544 CMA-03/06 efo:EFO_0006554 human colon adenocarcinoma cell line established from the ascites fluid obtained from a 70-year-old male patient with adenocarcinoma of the colon (Sigma catalog number 93052620) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/93052620?lang=en&region=GB COLO 206F efo:EFO_0006555 human large cell lung cancer bone marrow aspirate derived cell line established from a female patient (Sigma catalog number 96020740) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/96020740?lang=en&region=GB COR-L26 efo:EFO_0006556 human lung cancer cell line derived from the bone marrow aspirate of a 67-year-old Caucasian male suffering from small cell lung carcinoma (Sigma catalog number 92031915) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/92031915?lang=en&region=GB COR-L47 efo:EFO_0006557 human ovarian epithelial-serous carcinoma cell line established from a metastasis of the sigmoid colon (Sigma catalog number 07071905) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/07071905?lang=en&region=GB COV413A efo:EFO_0006558 human ovarian epithelial-serous carcinoma cell line established from an intraperitoneal metastasis of the bladder dome (Sigma catalog number 07071906) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/07071906?lang=en&region=GB COV413B efo:EFO_0006559 human small lung carcinoma cell line established from the pleural effusion metastasis of a patient with small cell lung carcinoma in 1987 (DSMZ catalog number ACC 306) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-306.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 CPC-N efo:EFO_0006560 human colon carcinoma cell line Laura Huerta https://database.riken.jp/sw/en/CW-2/cria322s1ria322u100000000778i/ CW-2 efo:EFO_0006561 human colon adenocarcinoma cell line established from the tumor tissue of a 44-year-old woman with well-differentiated colon adenocarcinoma in 1984 (DSMZ catalog number ACC 129) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-129.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 CX-1 efo:EFO_0006562 human pancreas carcinoma cell line established from a human individual with pancreas carcinoma in 1985 (DSMZ catalog number ACC 249) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-249.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 DAN-G efo:EFO_0006563 human malignant melanoma cell line established from the heel lesion of a 59-year-old Japanese man Laura Huerta PMID: 17547717 DEOC-1 efo:EFO_0006564 human dysplastic oral keratinocyte cell line isolated from a piece of dorsal tongue from a 57 year old Caucasian man (Sigma catalog number 94122104) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/94122104?lang=en&region=GB DOK efo:EFO_0006565 human lung adenocarcinoma established from the pleural effusion of a stage IV lung adenocarcinoma Laura Huerta PMID: 7839470 DV-90 efo:EFO_0006568 human breast carcinoma cell line established from the pleural effusion of the left side (14 days after EFM-192A) of a 46-year-old Caucasian woman with breast adenocarcinoma (DSMZ catalog number ACC 311) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-311.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFM-192A efo:EFO_0006569 human breast carcinoma cell line established from the pleural effusion of the left side (14 days after EFM-192A) of a 46-year-old Caucasian woman with breast adenocarcinoma (DSMZ catalog number ACC 308) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-308.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFM-192B efo:EFO_0006570 human breast carcinoma cell line human breast carcinoma cell line established from the pleural effusion of the left side from a 46-year-old Caucasian woman with metastasizing breast adenocarcinoma in 1985 (DSMZ catalog number ACC 258) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-258.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFM-192C efo:EFO_0006571 human ovarian adenocarcinoma cell line established from the solid omental metastasis of a mucinous papillary adenocarcinoma of the ovary of a 36-year-old woman in 1979 (DSMZ catalog number ACC 191) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-191.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFO-27 efo:EFO_0006572 human multiple myeloma cell line established from the peritoneal fluid of a 58-year-old woman with IgG lambda myeloma in 1988 at her terminal refractory stage (DSMZ catalog number ACC 560) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-560.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EJM efo:EFO_0006573 human lung adenocarcinoma cell line established from a surgical lung specimen of a 57-year-old Caucasian man who underwent surgery for undifferentiated squamous cell carcinoma of the lung (without having received prior radiation or chemotherapy) in 1986 (DSMZ catalog number ACC 383) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-383.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EPLC-272H efo:EFO_0006574 human breast carcinoma cell line established from the malignant ascitic effusion from a woman with metastatic breast carcinoma; described as being estrogen receptor-negative and progesterone receptor-positive (DSMZ catalog number ACC 433) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-433.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EVSA-T efo:EFO_0006575 human colon adenocarcinoma cell line derived from a local recurrence of Duke′s grade B, poorly differentiated carcinoma of the colon from a 71 year old female at surgical resection (SIgma catalog number 95090714) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/95090714?lang=en&region=GB GP2d efo:EFO_0006576 human colon adenocarcinoma cell line derived from a local recurrence of Duke′s grade B, poorly differentiated carcinoma of the colon from a 71 year old female at surgical resection (SIgma catalog number 95090715) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/95090715?lang=en&region=GB GP5d efo:EFO_0006577 human melanoma obtained from the thorax of a 36 year old male with skin metastases having received no treatment at the time of the biopsy (Sigma catalog number 95032301) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/95032301?lang=en&region=GB GR-M efo:EFO_0006578 human gastric carcinoma cell line with amplification of the MET oncogene (Motoyama et al., 1986) Laura Huerta PMID: 3962675 GTL-16 efo:EFO_0006579 human erythroleukemia cell line derived from peripheral blood of a patient with Hodgkin's disease who later developed erythroleukemia Laura Huerta PMID: 6177045 HEL efo:EFO_0006580 human ovarian carcinoma cell line was derived from a human ovarian cancer xenograft (HX-62) originally grown from a peritoneal deposit of a patient with moderately differentiated papillary cystadenocarcinoma of the ovary (catalog number AKR-205) Laura Huerta http://www.cellbiolabs.com/sites/default/files/AKR-205-gfp-hey-cell-line.pdf HEY efo:EFO_0006581 human gastric carcinoma cell line established by culture of the metastatic lymph node from a gastric cancer patient diagnosed histologically as undifferentiated carcinoma Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/94042256?lang=en&region=GB HGC-27 efo:EFO_0006582 human melanoma cell line established from metastasised lymph node of a 62 year old Japanese man Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1018.htm HMY-1 efo:EFO_0006583 human acute myeloid leukemia cell line established in 1994 from the peripheral blood of a 47-year-old woman with acute myeloid leukemia (AML FAB M4) secondary to previous myelodysplastic syndromes (MDS), specifically chronic myelomonocytic leukemia (CMML) (DSMZ catalog number ACC-600) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-600.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 HNT-34 efo:EFO_0006584 human colon adenocarcinoma cell line from a 46 year old Caucasian woman (ATCC CRL-7213) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-7213.aspx?geo_country=gb Hs 255.T efo:EFO_0006585 human melanoma cell line from a 56 year old Caucasian male (ATCC HTB-140) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/HTB-140.aspx Hs 294T efo:EFO_0006586 human ovarian teratoma cell line from a female (ATCC CRL-7826) Laura Huerta http://purl.obolibrary.org/obo/CLO_0003936 http://www.lgcstandards-atcc.org/Products/All/CRL-7826.aspx Hs 38.T efo:EFO_0006587 human colorectal cancer cell line from a Caucasian male (ATCC CRL-7400) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-7400.aspx Hs 675.T efo:EFO_0006588 human melanoma cell line from a 26 year old Caucasian male (ATCC HTB-137) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/HTB-137.aspx Hs 695T efo:EFO_0006589 human gastric carcinoma cell line from a 74 year old Caucasian male (ATCC HTB-135) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/HTB-135.aspx Hs 746T efo:EFO_0006590 human pancreatic carcinoma from a 46 year old Caucasian male (ATCC HTB-134) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/HTB-134.aspx Hs 766T efo:EFO_0006591 human melanoma cell line from a 42 year old Caucasian female (ATCC CRL-7572) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-7572.aspx Hs 839.T efo:EFO_0006592 human melanoma cell line from a 53 year old Asian male (ATCC CRL-7585) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-7585.aspx Hs 852.T efo:EFO_0006593 human melanoma cell line from a 48 year old Caucasian female (ATCC CRL-7637) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-7637.aspx Hs 895.T efo:EFO_0006594 human melanoma cell line from a male (ATCC CRL-7686) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-7686_FL.aspx Hs 936.T efo:EFO_0006595 human melanoma cell line from a 57 year old Caucasian male (ATCC CRL-7691) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-7691.aspx Hs 940.T efo:EFO_0006596 human pancreatic adenocarcinoma cell line derived from an ascites sample taken from a 66 year old Japanese male with a poorly differentiated pancreatic adenocarcinoma (Sigma catlaog number 93121055) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/93121055?lang=en&region=GB HuP-T3 efo:EFO_0006597 human melanoma established from the lymph node metastasis (groin) of a 26-year-old man with malignant melanoma (primary tumor histology: SSM level IV) (DSMZ catalog number ACC 237) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-237.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 IGR-37 efo:EFO_0006598 human stomach adenocarcinoma cell line from a 63 year old Japanese male with moderately differentiated adenocarcinoma of stomach Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1075.1.htm IM95m efo:EFO_0006599 human hepatocellular carcinoma cell line from a 50 year old Japanese male with complication of hepatic cirrhosis and hepatocellular carcinoma Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1062.htm JHH-1 efo:EFO_0006600 human hepatocellular carcinoma cell line from a 57 year old Japanese male with hepatocellular carcinoma Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1028.htm JHH-2 efo:EFO_0006601 human hepatocellular carcinoma cell line from a 51 year old Japanese male with hepatocellular carcinoma Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0435.htm JHH-4 efo:EFO_0006602 human hepatocellular carcinoma cell line from a 50 year old male with small liver cancer observed in the chronic hepatitis Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1029.htm JHH-5 efo:EFO_0006603 human hepatocellular carcinoma cell line from a 53 year old male with HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1031.htm JHH-7 efo:EFO_0006604 human chondrosarcoma cell line Laura Huerta PMID: 25485619 JJ012 efo:EFO_0006605 human leukemia cell line established from the bone marrow of a 57-year-old woman with plasma cell leukemia (IgA1kappa) at diagnosis in 1987 (DSMZ catalog number ACC 541) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-541.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 JJN-3 efo:EFO_0006606 human B-cell lymphoma cell line established from a pleural effusion of a 23 year old women with mediastinal lymphoblastic B-cell non-Hodgkin′s lymphoma (Sigma catalog number 06072607) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/06072607?lang=en&region=GB KARPAS 1106P efo:EFO_0006607 human acute myeloid leukemia cell line established from the peripheral blood of a 7-year-old Japanese boy with acute myeloid leukemia (AML FAB M2) (in 2nd relapse after bone marrow transplantation) in 1989 (DSMZ catalog number AAC 2200 Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-220.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 Kasumi-1 efo:EFO_0006608 human pancreatic adenocarcinoma cell line from the moderately differentiated adenocarcinoma of the head of the pancreas from a 74-year-old African-American man in 1996 (DSMZ catalog number ACC 498) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-498.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KCI-MOH1 efo:EFO_0006609 human multiple myeloma cell line established from a pleural effusion of a 53 year old man with IgA lambda multiple myeloma with hyperamylasemia Laura Huerta http://bioinfoweb.com/CLDB-KHM-1B.htm KHM-1B efo:EFO_0006610 human pancreatic carcinoma cell line Laura Huerta https://database.riken.jp/sw/en/KLM-1/cria322s1ria322u100000002138i/ KLM-1 efo:EFO_0006611 human multiple myeloma cell line from a 62 year old Japanese male Laura Huerta http://bioinfoweb.com/CLDB-KMM-1.htm KMM-1 efo:EFO_0006612 human multiple myeloma cell line established from the bone marrow of a 64-year-old woman with multiple myeloma in 1988 (DSMZ catalog number ACC 551) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-551.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KMS-12-BM efo:EFO_0006613 human multiple myeloma cell line established from the bone marrow of a 64-year-old woman with multiple myeloma in 1988 Laura Huerta PMID: 2479409 KMS-12-PE efo:EFO_0006614 human multiple myeloma cell line from a 62 year old Japanese male Laura Huerta http://bioinfoweb.com/CLDB-KMS-21BM.htm KMS-21-BM efo:EFO_0006615 human multiple myeloma cell line from a 50 year old Japanese male Laura Huerta http://bioinfoweb.com/CLDB-KMS-26.htm KMS-26 efo:EFO_0006616 human multiple myeloma cell line from a 52 year old Japanese male Laura Huerta http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb1188 KMS-27 efo:EFO_0006617 human multiple myeloma cell line from a 77 year old female Laura Huerta http://bioinfoweb.com/CLDB-KMS-28BM.htm KMS-28BM efo:EFO_0006618 human multiple myeloma cell line from a 77 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb1191 KMS-28PE efo:EFO_0006619 human multiple myeloma cell line from a 60 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb1195 KMS-34 efo:EFO_0006620 human non-small cell lung carcinoma line established from a 49 year old male patient with a non-small cell lung carcinoma Laura Huerta PMID: 25485619 KNS-62 efo:EFO_0006621 human pancreatic carcinoma cell line established from a 50 year old Japanese male with pancreatic ductal cell carcinoma Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0182.htm KP-2 efo:EFO_0006622 human pancreatic adenosquamous carcinoma cell line from a 75 year old Japanese male Laura Huerta PMID: 25485618 KP-3 efo:EFO_0006623 human pancreatic ductal carcinoma cell line from a 50 year old Japanese male Laura Huerta http://bioinfoweb.com/CLDB-KP-4.htm KP-4 efo:EFO_0006624 human breast ductal adenocarcinoma cell line from a 52 year old Japanese female Laura Huerta PMID: 25485619 KPL-4 efo:EFO_0006625 human ovarian carcinoma from a Japanese female with ovarian cancer, undifferentiated carcinoma Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0098.htm KURAMOCHI efo:EFO_0006626 human esophageal squamous carcinoma cell line derived from the moderately differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 54-year-old Japanese man prior to treatment (DSMZ catalog number ACC 348) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-348.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-140 efo:EFO_0006627 human esophageal squamous carcinoma cell line established from the poorly differentiated esophageal squamous cell carcinoma resected from upper (cervical) esophagus of a 49-year-old Japanese woman after receiving radiotherapy (DSMZ catalog number ACC 375) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-375.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-150 efo:EFO_0006628 human esophageal squamous carcinoma cell line established from the well differentiated esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 53-year-old Japanese man prior to treatment (DSMZ catalog number ACC 379) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-379.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-180 efo:EFO_0006629 human esophageal squamous carcinoma cell line derived from well differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 79-year-old Japanese man prior to treatment (DSMZ catalog number ACC 380) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-380.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-270 efo:EFO_0006630 human esophageal squamous carcinoma cell line established from the well differentiated invasive eosphageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 59-year-old Japanese man prior to treatment (DSMZ catalog number ACC 387) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-387.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-450 efo:EFO_0006631 human esophageal squamous carcinoma cell line established from the well-differentiated eosphageal squamous cell carcinoma with moderate invasion of the adventitia resected from cervical esophagus of a 67-year-old Japanese woman after cisplatin and radiotherapy (DSMZ catalog number ACC 374) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-374.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-510 efo:EFO_0006632 human esophageal squamous carcinoma cell line established from the moderately differentiated invasive eosphageal squamous cell carcinoma resected from lower intra-thoracic esophagus of a 58-year-old Japanese woman prior to treatment (DSMZ catalog number ACC 371) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-371.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-520 efo:EFO_0006633 human esophageal squamous carcinoma cell line established from the poorly differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 77-year-old Japanese man prior to treatment (DSMZ catalog number ACC 363) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-363.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-70 efo:EFO_0006634 human large cell lung carcinoma cell line established from the pleural effusion of a 61-year-old Caucasian man with large cell lung carcinoma with giant cells who had received chemo- and radiotherapy (DSMZ catalog number ACC 384) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-384.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LCLC-103H efo:EFO_0006635 human large cell lung carcinoma cell line that represents the xenotransplant of a primary tumor which was obtained from a 44-year-old Caucasian man with large cell lung carcinoma who did not have any prior therapy (DSMZ catalog number ACC 388) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-388.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LCLC-97TM1 efo:EFO_0006636 human brain glioblastoma cell line from a 65 year old male of white ethnicity (ATCC CRL-2610) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-2610.aspx?geo_country=gb LN-18 efo:EFO_0006637 human brain glioblastoma cell line from a 60 year old female of white ethnicity (ATCC CRL-2611) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-2611.aspx LN-229 efo:EFO_0006638 human lung squamous carcinoma cell line established from the lower right lung lobe removed two months after diagnosis of highly differentiated squamous cell lung carcinoma with metastasis to one lymph node (no visceral involvement) in a 64-year-old woman (DSMZ catalog number ACC 393) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-393.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LOU-NH91 efo:EFO_0006639 human colorectal adenocarcinoma cell line established from the metastatic nodule resected from a 56-year-old Caucasian man with colon adenocarcinoma in 1972 (DSMZ catalog number ACC 350) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-350.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LoVo efo:EFO_0006640 human colorectal adenocarcinoma cell line from a 58 year old Caucasian female (ATCC CL-187) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CL-187.aspx?geo_country=gb LS 180 efo:EFO_0006641 human lung adenocarcinoma established from the lung adenocarcinoma of a 63 year old male (DSMZ catalog number ACC 265) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-265.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LXF-289 efo:EFO_0006642 human non-small cell lung carcinoma cell line Laura Huerta PMID: 25485619 LXFL529 efo:EFO_0006643 clonal breast cancer cell line derived from a xenograft originating from premalignant MCF10AT cells Laura Huerta PMID: 23401782 MCF10DCIS.COM efo:EFO_0006644 human colon carcinoma cell line establlished from human colorectal tumor explants (Sigma catalog number 99011801) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/99011801?lang=en&region=GB MDST8 efo:EFO_0006645 human acute myeloid leukemia cell line established from the peripheral blood of a 40-year-old Japanese man with acute myeloid leukemia (AML) FAB M4eo at second relapse in 1988 (DSMZ catalog number ACC 357) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-537.html ME-1 efo:EFO_0006646 human epidermoid carcinoma cell line from a 66 year old Caucasian female (ATCC HTB-33) Laura Huerta http://www.lgcstandards-atcc.org/products/all/HTB-33.aspx?geo_country=gb ME-180 efo:EFO_0006647 human skin melanoma cell line established from the primary tumor of a woman with melanoma in 1976 (DSMZ catalog number ACC 62) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-62.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MEL-HO efo:EFO_0006648 human skin melanoma cell line from a 78 year old Caucasian male Laura Huerta http://www.lgcstandards-atcc.org/products/all/HTB-65.aspx?geo_country=gb MeWo efo:EFO_0006649 human mammary carcinoma cell line obtained from the pleural effusion of a postmenopausal breast cancer patient (Sigma catalog number 98050130) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/98050130?lang=en&region=GB MFM-223 efo:EFO_0006650 human Ewings' sarcoma cell line established from the ascites of a 12-year-old Turkish boy with Ewing's sarcoma of the left pelvis (with peritoneal metastasis) (DSMZ catalog number ACC 167) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-167.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MHH-ES-1 efo:EFO_0006651 human brain neuroblastoma cell line established from a neuroblastoma metastasis at an adrenal site of a 4-year-old white boy in 1986 (DSMZ catalog number ACC 157) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-157.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MHH-NB-11 efo:EFO_0006652 human acute myeloid leukemia cell line established in 1999 from the peripheral blood of a 77-year-old Japanese woman at relapse of acute myeloid leukemia (DSMZ catalog number ACC 555) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-555.html MOLM-16 efo:EFO_0006653 human multiple myeloma cell line established from the peripheral blood of a 55-year-old man with IgD lambda type multiple myeloma in 1991 (DSMZ catalog number ACC 607) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-607.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MOLP-2 efo:EFO_0006654 human multiple myeloma cell line established from the peripheral blood of a 52-year-old Japanese man with multiple myeloma (stage IIIA, type IgD lambda) in 2002 (DSMZ catalog number ACC 569) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-569.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MOLP-8 efo:EFO_0006655 human lung adenocarcinoma cell line (Sigma catalog number 84112312) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/84112312?lang=en&region=GB MOR efo:EFO_0006656 mouse cell line produced from pancreatic islets isolated from juvenile but not aging adult mice, when infected with a retrovirus carrying polyomavirus middle T oncogene Laura Huerta PMID: 7521578 http://purl.obolibrary.org/obo/BCGO_0000121 mPAC L20 efo:EFO_0006657 human lung adenocarcinoma cell line from a 56 year old African male Laura Huerta PMID: 25485619 NCI-H1373 efo:EFO_0006658 human non-small cell lung carcinoma cell line from a 35 year old female (ATCC CRL-5870) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-5870.aspx?geo_country=gb ATCC:CRL-5870 NCI-H1435 efo:EFO_0006659 human small cell lung carcinoma cell line established from a 59 year old Caucasian male (ATCC HTB-173) Laura Huerta http://www.lgcstandards-atcc.org/products/all/HTB-173.aspx?geo_country=gb ATCC:HTB-173 NCI-H146 efo:EFO_0006660 human non-small cell lung carcinoma cell line from a 48 year old Caucasian female (ATCC CRL-5876) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5876.aspx ATCC:CRL-5876 NCI-H1568 efo:EFO_0006661 human non-small cell lung carcinoma cell line from a 55 year old Caucasian female (ATCC CRL-5887) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5887.aspx ATCC:CRL-5887 NCI-H1693 efo:EFO_0006662 human non-small cell lung carcinoma cell line from a 56 year old female (ATCC CRL-5891) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5891.aspx ATCC:CRL-5891 NCI-H1734 efo:EFO_0006663 human lung adenocarcinoma cell line from a 66 year old Caucasian female (ATCC CRL-5894) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5894.aspx ATCC:CRL-5894 NCI-H1781 efo:EFO_0006664 human non-small cell lung carcinoma cell line from a 58 year old Caucasian male ATCC CRL-5900) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5900.aspx ATCC:CRL-5900 NCI-H1869 efo:EFO_0006665 human small cell lung carcinoma cell line from a 59 year old Caucasian male (ATCC CRL-5903) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5903.aspx ATCC:CRL-5903 NCI-H1882 efo:EFO_0006666 human non-small cell lung carcinoma cell line from a 61 year old Caucasian female (ATCC CRL-5904) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5904.aspx ATCC:CRL-5904 NCI-H1915 efo:EFO_0006667 human non-small cell lung carcinoma cell line from a 62 year old Caucasian female (ATCC CRL-5907) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5907.aspx ATCC:CRL-5907 NCI-H1944 efo:EFO_0006668 human small cell lung carcinoma cell line from a 68 year old Caucasian male (ATCC CRL-5823) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5823.aspx ATCC:CRL-5823 NCI-H196 efo:EFO_0006669 human non-small cell lung carcinoma cell line from a 26 year old Caucasian male (ATCC CRL-5912) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5912.aspx ATCC:CRL-5912 NCI-H2023 efo:EFO_0006670 human lung adenocarcinoma cell line from a 47 year old Caucasian female (ATCC CRL-5918) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5918.aspx ATCC:CRL-5918 NCI-H2073 efo:EFO_0006671 human small cell lung carcinoma cell line from a Caucasian male (ATCC HTB-172) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/HTB-172.aspx ATCC:HTB-172 H209 NCI-H209 efo:EFO_0006672 human non-small cell lung carcinoma cell line from a 58 year old Caucasian male (ATCC CRL-5923) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5923.aspx ATCC:CRL-5923 NCI-H2106 efo:EFO_0006673 human non-small cell lung carcinoma cell line (ATCC CRL-5924) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5924.aspx ATCC:CRL-5924 NCI-H2110 efo:EFO_0006674 human non-small cell lung carcinoma cell line (ATCC CRL-5926) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5926.aspx ATCC:CRL-5926 NCI-H2135 efo:EFO_0006675 human non-small cell lung carcinoma cell line established from a female (ATCC CRL-5930) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5930.aspx ATCC:CRL-5930 NCI-H2172 efo:EFO_0006676 human small cell lung carcinoma cell line from a 67 year old Caucasian male (ATCC CRL-5932) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5932.aspx ATCC:CRL-5932 NCI-H2196 efo:EFO_0006677 human small cell lung carcinoma cell line from a 67 year old Caucasian male (ATCC CRL-5933) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5933.aspx ATCC:CRL-5933 NCI-H2198 efo:EFO_0006678 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2369 efo:EFO_0006679 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2373 efo:EFO_0006680 human lung mesothelioma cell line (ATCC CRL-5946) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-5946.aspx?geo_country=gb NCI-H2452 efo:EFO_0006681 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2461 efo:EFO_0006682 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2595 efo:EFO_0006683 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2596 efo:EFO_0006684 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2722 efo:EFO_0006685 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2795 efo:EFO_0006686 human lung mesothelioma cell line from a 48 year old Caucasian male (ATCC CRL-5820) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-5820.aspx?geo_country=gb ATCC:CRL-5820 NCI-H28 efo:EFO_0006687 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2803 efo:EFO_0006688 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2804 efo:EFO_0006689 human lung mesothelioma cell line Laura Huerta PMID: 25485619 NCI-H2810 efo:EFO_0006690 human pulmonary mucoepidermoid carcinoma cell line derived from a cervical node metastasis of a pulmonary mucoepidermoid carcinoma from a 32 year old female (SIGMA catalog number 91091815) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/91091815?lang=en&region=GB NCI-H292 efo:EFO_0006691 human non-small cell lung carcinoma cell line Laura Huerta PMID: 25485619 H322T NCI-H322 NCI-H322T efo:EFO_0006692 human small cell lung carcinoma cell line from a 64 year old Caucasian male (ATCC HTB-180) Laura Huerta http://www.lgcstandards-atcc.org/products/all/HTB-180.aspx?geo_country=gb NCI-H345 efo:EFO_0006693 human small cell lung carcinoma cell line from a 56 year old Caucasian male (ATCC HTB-184) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/HTB-184.aspx ATCC:HTB-184 NCI-H510A efo:EFO_0006694 human adenosquamous lung carcinoma cell line from a 73 year old Caucasian male (ATCC HTB-178) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/HTB-178.aspx ATCC:HTB-178 NCI-H596 efo:EFO_0006695 human non-small cell lung carcinoma cell line from the lung of a 65 year old Caucasian female with a non-small cell lung carcinoma, prior to treatment (SIGMA catalog number 94060303) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/94060303?lang=en&region=GB NCI-H727 efo:EFO_0006696 human small cell lung carcinoma cell line from a 63 year old Caucasian male (ATCC CRL-5846) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5846.aspx ATCC:CRL-5846 NCI-H847 efo:EFO_0006697 human small cell lung carcinoma cell line from a 69 year old Caucasian female (ATCC CRL-5817) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5817.aspx ATCC:CRL-5817 NCI-H889 efo:EFO_0006698 human non-small cell lung carcinoma cell line from a 43 year old Caucasian male (ATCC CRL-5850) Laura Huerta http://www.lgcstandards-atcc.org/Products/All/CRL-5850.aspx ATCC:CRL-5850 NCI-H920 efo:EFO_0006699 human normal ovarian fibroblast cell line Laura Huerta PMID: 17060621 NOF151 efo:EFO_0006700 human B-cell non-Hodgkin lymphoma cell line established in 1982 from the cerebrospinal fluid of a 43-year-old Caucasian man with B-cell non-Hodgkin lymphoma (DSMZ catalog number ACC 579) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-579.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 NU-DUL-1 efo:EFO_0006701 human stomach adenocarcinoma cell line from a 56 year old female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0821.htm NUGC-2 efo:EFO_0006702 human stomach adenocarcinoma cell line from a 72 year old male Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0822.htm NUGC-3 efo:EFO_0006703 human stomach adenocarcinoma cell line from a 35 year old female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0834.htm NUGC-4 efo:EFO_0006704 human ovarian serous cystadenocarcinoma cell line from an ascites of patient with ovarian cystadenocarcinoma (Sigma catalog number 85101601) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/85101601?lang=en&region=GB OAW28 efo:EFO_0006705 human ovarian serous cystadenocarcinoma cell line from an ascites of patient with ovarian cystadenocarcinoma (Sigma catalog number 85073102) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/85073102?lang=en&region=GB OAW42 efo:EFO_0006706 human acute myeloid leukemia cell line established from the peripheral blood of a 65-year-old man with acute myeloid leukemia (AML FAB M4) in 1986 (DSMZ catalog number ACC 99) Laura Huerta http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-99.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-AML2 efo:EFO_0006707 human acute myeloid leukemia cell line established from the peripheral blood of a 77-year-old man with acute myeloid leukemia (AML M4) in relapse in 1990 (DSMZ catalog number ACC 247) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-247.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-AML5 efo:EFO_0006708 human B-cell non-Hodgkin lymphoma cell line established from the bone marrow of a 44-year-old man with B-cell non-Hodgkin lymphoma (B-NHL; diffuse large cell), stage 4B at relapse in 1983 (DSMZ catalog number ACC 722) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-722.html OCI-LY10 efo:EFO_0006709 human B-cell non-Hodgkin lymphoma cell line established from the bone marrow of a 27-year-old woman with B-cell non-Hodgkin lymphoma (B-NHL) in 1987 (DSMZ catalog number ACC 528) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-528.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-LY19 efo:EFO_0006710 human B-cell non-Hodgkin lymphoma cell line established in 1983 from the bone marrow sample of a 52-year-old man with B-cell non-Hodgkin lymphoma (DSMZ catalog number Acc 761) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-761.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 PMID:11807979 Oci-Ly-3 Oci-Ly-3 cell OCI-LY3 efo:EFO_0006711 human B-cell non-Hodgkin lymphoma cell line established from the peripheral blood sample of a 48-year-old man with B-cell non-Hodgkin lymphoma in 1984 (DSMZ catalog number ACC 688) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-688.html https://www.dsmz.de/catalogues/details/culture/ACC-688.html PMID:11807979 OCI-LY7 efo:EFO_0006712 human acute myeloid leukemia cell line established from erythroleukemia blasts (AML M6) of a 62-year-old patient following a 7-year chlorambucil treatment for chronic lymphocytic leukemia (DSMZ catalog number ACC 529) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-529.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-M1 efo:EFO_0006713 human acute myeloid leukemia cell line established in 1984 from the leukemic cells of a 56-year-old patient with erythroleukemia (DSMZ catalog number ACC 619) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-619.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-M2 efo:EFO_0006714 human stomach adenocarcinoma cell line from a 38 year old Japanese adult Laura Huerta PMID: 25485619 OCUM-1 efo:EFO_0006715 human stomach adenocarcinoma cell line Laura Huerta PMID: 25485619 Okajima efo:EFO_0006716 human multiple myeloma cell line established from the peripheral blood of a 56-year-old woman with multiple myeloma (IgG lambda) in leukemic phase (relapse, terminal) in 1982 (DSMZ catalog number ACC 50) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-50.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OPM-2 efo:EFO_0006717 human colon adenocarcinoma cell line established from a male Laura Huerta PMID: 25485619 OUMS-23 efo:EFO_0006720 human ovarian carcinoma cell line established from a female Laura Huerta PMID: 25485619 OVCA420 efo:EFO_0006721 human ovarian adenocarcinoma cell line established from a female Laura Huerta PMID: 25485619 OVCA429 efo:EFO_0006722 human ovarian carcinoma cell line established from a female Laura Huerta PMID: 25485619 OVCA432 efo:EFO_0006723 human ovarian carcinoma cell line Laura Huerta PMCID: PMC370929 PMID:25485619 OVCAR433 OVCA433 efo:EFO_0006724 human ovarian carcinoma cell line from a 40 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1043.htm OVISE efo:EFO_0006725 human ovarian adenocarcinoma cell line from a 40 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1044.htm OVKATE efo:EFO_0006726 human ovarian adenocarcinoma cell line from a 51 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1045.htm OVMANA efo:EFO_0006727 human ovarian adenocarcinoma cell line from a 56 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1046.htm OVSAHO efo:EFO_0006728 human ovarian adenocarcinoma cell line from a 78 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb1048.htm OVTOKO efo:EFO_0006729 human pancreatic adenocarcinoma cell line Laura Huerta PMID: 25485619 PA-TU-8902 efo:EFO_0006730 human pancreatic adenocarcinoma cell line from a 64 year old female Laura Huerta PMID: 25485619 PA-TU-8988S efo:EFO_0006733 human oral squamous carcinoma cell line established from tongue tissue of a 45 year old male patient with oral squamous cell carcinoma (Sigma catalog number 96121230) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/96121230?lang=en&region=GB PE/CA-PJ15 efo:EFO_0006734 human pancreatic carcinoma cell line Laura Huerta PMID: 25485619 PK-45H efo:EFO_0006735 human pancreatic carcinoma cell line Laura Huerta http://www2.idac.tohoku.ac.jp/dep/ccr/TKGdate/TKGvo104/0493.html PK-45P efo:EFO_0006736 human pancreatic carcinoma cell line Laura Huerta http://www2.idac.tohoku.ac.jp/dep/ccr/TKGdate/TKGvo104/0492.html PK-59 efo:EFO_0006737 human pancreatic carcinoma cell line Laura Huerta PMID: 25485619 PK-8 efo:EFO_0006739 human pancreatic adenocarcinoma cell line (Sigma catalog number 94060601) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/94060601?lang=en&region=GB PSN1 efo:EFO_0006741 human pancreatic carcinoma cell line of islet cell origin Laura Huerta PMID: 25485619 QGP-1 efo:EFO_0006742 human B-cell lymphoma cell line established from the peritoneal effusion of a patient with lymphoma, described at the time as true histiocytic lymphoma, in 1984 (DSMZ catalog number ACC 561) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-561.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 RC-K8 efo:EFO_0006743 human stomach carcinoma cell line from a 41 year old Japanese male Laura Huerta PMID: 25485619 RERF-GC-1B efo:EFO_0006744 human lung adenocarcinoma cell line Laura Huerta PMID: 25485619 RERF-LC-OK efo:EFO_0006745 human ovarian leiomyosarcoma from a 45 year old Japanese female Laura Huerta PMID: 25485619 RKN efo:EFO_0006746 human ovarian mesonephroid adenocarcinoma cell line from a 34 year old Japanese female Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0172.htm RMG-I efo:EFO_0006747 human ovarian adenocarcinoma cell line from a 62 year old Japanese female Laura Huerta PMID: 25485619 RMUG-S efo:EFO_0006748 spontaneously immortalised human epidermal keratinocytes Laura Huerta PMID: 8221669 RTS3b efo:EFO_0006749 human small cell lung carcinoma cell line established from the pleural effusion of a 46-year-old Caucasian man with small cell lung carcinoma (DSMZ catalog number ACC 372) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-372.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SCLC-21H efo:EFO_0006750 human small cell lung carcinoma cell line established from the pericardial effusion of a 46-year-old Caucasian man with small cell lung carcinoma (DSMZ catalog number ACC 373) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-373.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SCLC-22H efo:EFO_0006751 human acute myeloid leukemia cell line established in 1995 from the bone marrow of a 63-year-old man with acute myeloid leukemia of monocytic origin (DSMZ ACC 468) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-468.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SIG-M5 efo:EFO_0006752 human colorectal adenocarcinoma from a 65 year old Caucasian male (ATCC HTB-39) Laura Huerta http://www.lgcstandards-atcc.org/products/all/HTB-39.aspx?geo_country=gb ATCC:HTB-39 SK-CO-1 efo:EFO_0006753 human myelodysplasic cell line established from the peripheral blood of a 76-year-old Japanese man with acute monoblastic leukemia (AML M5) in 1989 following myelodysplastic syndromes (DSMZ catalog number ACC 547) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-547.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SKM-1 efo:EFO_0006754 human stomach carcinoma cell line from a 46 year old female Laura Huerta PMID: 25485619 SNU-216 efo:EFO_0006755 human stomach carcinoma cell line from a 53 year old male Laura Huerta PMID: 25485619 SNU-484 efo:EFO_0006756 human stomach carcinoma cell line from a 34 year old male Laura Huerta PMID: 25485619 SNU-601 efo:EFO_0006757 human stomach carcinoma cell line from a 59 year old female Laura Huerta PMID: 25485619 SNU-620 efo:EFO_0006758 human stomach carcinoma cell line from a 48 year old male Laura Huerta PMID: 25485619 SNU-638 efo:EFO_0006759 human stomach carcinoma cell line from a 68 year old male Laura Huerta PMID: 25485619 SNU-668 efo:EFO_0006760 human stomach carcinoma cell line from a 53 year old male Laura Huerta PMID: 25485619 SNU-719 efo:EFO_0006761 human colon adenocarcinoma cell line from a 71 year old Asian male (ATCC CRL-5972) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-5972.aspx?geo_country=gb ATCC:CRL-5972 SNU-C1 efo:EFO_0006762 human breast carcinoma cell line established from a female Laura Huerta Sirarat Sarntivijai PMID:10604729 PMID:10718481 PMID:25485619 SUM 229 SUM 229PE SUM-229 SUM-229PE SUM229 SUM229PE efo:EFO_0006763 human acute lymphoblastic leukemia cell line from a 8 year old Caucasian boy (ATCC CRL-1929) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-1929.aspx?geo_country=gb ATCC:CRL-1929 SUP-B15 efo:EFO_0006764 human pancreatic carcinoma cell line from a 68 year old Japanese female Laura Huerta PMID: 25485619 TCC-PAN2 efo:EFO_0006765 human carcinoma cell line from kidney of a 46 year old male Laura Huerta PMID: 25485619 NCIt:C117217 TK-10 efo:EFO_0006766 human ovarian carcinoma cell line Laura Huerta PMID: 25485619 TYK-nu efo:EFO_0006767 human undifferentiated carcinoma cell line Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0234.1.htm TYK-nu.CP-r efo:EFO_0006768 human B-cell lymphoma cell line established from the involved tonsil of a 7-year-old boy with lymphoblastic lymphoma at diagnosis prior to therapy in 1972 (DSMZ catalog number ACC 4) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-4.html U-698-M efo:EFO_0006769 human skin melanoma cell line Laura Huerta PMID: 25485619 UCSD-242l efo:EFO_0006770 human bladder transitional carcinoma cell line derived from a bladder cancer metastasis of a black male (Sigma catalog number 06080301) Laura Huerta http://www.sigmaaldrich.com/catalog/product/sigma/06080301?lang=en&region=GB UM-UC-1 efo:EFO_0006771 human bladder transitional carcinoma cell line from the urinary bladder of a male (ATCC CRL-1749) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-1749.aspx?geo_country=gb UMUC3 UM-UC-3 efo:EFO_0006773 human lung adenocarcinoma cell line from a male Laura Huerta http://cellbank.nibio.go.jp/legacy/celldata/jcrb0814.htm VMRC-LCD efo:EFO_0006774 human skin melanoma cell line from a 58 year old female (ATCC CRL-1676) Laura Huerta http://www.lgcstandards-atcc.org/products/all/CRL-1676.aspx?geo_country=gb ATCC:CRL-1676 WM-266-4 efo:EFO_0006775 human B-cell lymphoma cell line derived from the pleural effusion of a 41-year-old Caucasian man with B-cell non-Hodgkin lymphoma (DSMZ catalog number ACC 575) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-575 WSU-DLCL2 efo:EFO_0006776 human B-cell lymphoma cell line established from the peripheral blood of a 37-year-old white man with low-grade follicular small cleaved cell lymphoma (DSMZ catalog number ACC 612) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-612.html WSU-FSCCL efo:EFO_0006777 human B-cell lymphoma cell line established from the pleural effusion of a 46-year-old woman with nodular histiocytic lymphoma (refractory, progressive) in 1986 (DSMZ ACC 58) Laura Huerta http://www.dsmz.de/catalogues/details/culture/ACC-58.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 WSU-NHL efo:EFO_0006778 human pancreatic carcinoma cell line from a 43 year old Japanese male Laura Huerta PMID: 25485619 YAPC efo:EFO_0006779 human breast carcinoma cell line from a 55 year old female Laura Huerta PMID: 25485619 YMB-1 efo:EFO_0006780 human breast carcinoma cell line from a 55 year old female Laura Huerta PMID: 25485619 YMB-1-E efo:EFO_0006781 the quantification of some coffee consumption or coffee consumption-related behaviour, usually self-reported via a questionnaire Dani Welter true coffee consumption measurement efo:EFO_0006782 the quantification of the number of cups of coffee that a subject consumes on average per day Dani Welter true cups of coffee per day measurement efo:EFO_0006783 the quantification of psychosocial stress factors such as financial strain, marital problems, work-related difficulties or health problems, usually assessed through self-reporting via standardised questionnaires. Dani Welter true ICD10:F43 psychosocial stress measurement efo:EFO_0006784 The distance from the sole to the crown of the head of a newborn right after birth Dani Welter true SNOMEDCT:169886007 birth length body height at birth efo:EFO_0006785 The distance from the sole to the crown of the head of an infant, which can be used as a proxy for skeletal growth in early life true SNOMEDCT:276351002 infant length infant body height efo:EFO_0006786 Laura Huerta Sirarat Sarntivijai NCIt:C117131 PMID:22355448 EKVX efo:EFO_0006787 human colon adenocarcinoma cell line Laura Huerta Sirarat Sarntivijai PMID:25485619 HM7 efo:EFO_0006793 quantification of the volume of the left inferior lateral ventricle, usuallly through an MRI scan Dani Welter true left inferior lateral ventricle volume measurement efo:EFO_0006794 A cerebrospinal fluid biomarker measurement is a quantification in cerebrospinal fluid of some molecule e.g. protein or metabolite that acts as a biomarker for some disease, eg Alzheimer's disease true cerebrospinal fluid biomarker measurement efo:EFO_0006795 quantification in blood of the transmembrane receptor tyrosine kinase VEGFR2, expressed by endothelial cells. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC (Uniprot). Variations in this gene are associated with Hemangioma, capillary infantile (OMIM label). Dani Welter http://www.uniprot.org/uniprot/P35968 true serum VEGFR2 concentration measurement efo:EFO_0006796 The determination of the amount of very long-chain saturated fatty acids present in a sample. VLSFAs are fatty acids with 20 or more carbons. Dani Welter true very long-chain saturated fatty acid measurement efo:EFO_0006797 quantification of the presence and amount of neurofibrillary tangles, pathological protein aggregates formed by hyperphosphorylation of a microtubule-associated protein known as tau Dani Welter true neurofibrillary tangles measurement efo:EFO_0006798 quantification of neuritic (senile) plaques in the brain, Senile plaques (also known as neuritic plaques, senile druse and braindruse) are extracellular deposits of amyloid beta in the grey matter of the brain.[1][2] Degenerative neural structures and an abundance of microglia and astrocytes can be associated with senile plaque deposits. These deposits can also be a byproduct of senescence (ageing). However, large numbers of senile plaques and neurofibrillary tangles are characteristic features of Alzheimer's disease. Abnormal neurites in senile plaques are composed primarily of paired helical filaments, a component of neurofibrillary tangles.[3] The plaques are variable in shape and size, but are on average 50 µm in size.[4] In Alzheimer's disease they are primarily composed of amyloid beta peptides. Dani Welter https://en.wikipedia.org/wiki/Senile_plaques true senile plaque measurement neuritic plaque measurement efo:EFO_0006799 quantification of the amount and location of Lewy bodies in patients with symptoms of Lewy body dementia Dani Welter https://en.wikipedia.org/wiki/Dementia_with_Lewy_bodies true Lewy body dementia measurement efo:EFO_0006800 quantification of the location and the amount of injuries to the blood vessels of the brain Dani Welter true vascular brain injury measurement efo:EFO_0006805 Word list delayed recall is a verabl declarative memory test using visually or verbally presented word lists, with or without semantic relatedness between words, with articipants being asked to remember as many words as possible after a specified delay interval, The test is used to quanitfy memory performance. Dani Welter true word list delayed recall measurement efo:EFO_0006806 Paragraph delayed recall is a verabl declarative memory test using one or two verbally presented stories, with articipants being asked to remember as many paragraph elements as possible after a specified delay interval, The test is used to quanitfy memory performance. Dani Welter true paragraph delayed recall measurement efo:EFO_0006807 The determination of the amount of linoleic acid present in a sample. Dani Welter true linoleic acid measurement efo:EFO_0006808 The determination of the amount of arachidonic acid present in a sample. Dani Welter true NCIt:C102259 SNOMEDCT:430749000 arachidonic acid measurement efo:EFO_0006809 The determination of the amount of docosapentaenoic acid present in a sample. Dani Welter true docosapentaenoic acid measurement efo:EFO_0006810 The determination of the amount of oleic acid present in a sample. Dani Welter true oleic acid measurement efo:EFO_0006811 The determination of the amount of linolenic acid present in a sample. Dani Welter true linolenic acid measurement efo:EFO_0006821 The determination of the amount of trans fatty acids, a kind of unsaturated fatty acids, present in a sample. Dani Welter http://www.nejm.org/doi/full/10.1056/NEJMra054035 true trans fatty acid measurement efo:EFO_0006822 The determination of the amount of trans fatty acids with 16 carbons and 1 double bond at the seventh N-terminal carbon present in a sample. Dani Welter true trans-16:1n-7 fatty acid measurement efo:EFO_0006823 The determination of the amount of trans fatty acids with 18 carbons and 1 double bond present in a sample. Dani Welter true total trans-18:1 fatty acid measurement efo:EFO_0006824 The determination of the amount of trans fatty acids with 18 carbons and 2 double bonds, with the first one in cis configuration and the 2nd one in trans configuration, present in a sample. Dani Welter true cis/trans-18:2 fatty acid measurement efo:EFO_0006825 The determination of the amount of fatty acids with 18 carbons and 2 double bonds, with the first one in trans configuration and the 2nd one in cis configuration, present in a sample. Dani Welter true trans/cis-18:2 fatty acid measurement efo:EFO_0006826 The determination of the amount of trans fatty acids with 18 carbons and 2 double bonds, both of which are in trans configuration, present in a sample. Dani Welter true trans/trans-18:2 fatty acid measurement efo:EFO_0006827 quantification of some part of the renin-angiotensin-aldosterone system (RAAS), a central pathway in cardiovascular and renal physiology, critical for regulation of blood pressure and fluid balance and influencing cardiovascular remodeling Dani Welter RAAS measurement renin–angiotensin–aldosterone system measurement efo:EFO_0006828 Quantification of the activity of the enzyme renin in the blood. Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE, the angiotensin-converting enzyme primarily within the capillaries of the lungs. Dani Welter true plasma renin activity measurement efo:EFO_0006829 A quantification of the variation in an individual's glomerular filtration rate (GFR) over a period of time used in assessment of kidney function and diagnosis of kidney disease. Dani Welter true GFR change measurement efo:EFO_0006830 quantification of the rate at which insulin is cleared from some part of the metabolism, eg from the blood Dani Welter true insulin metabolic clearance rate measurement efo:EFO_0006831 quantification of insulin release in response to a controlled glucose intake, generally calculated as the increase in insulin concentrations at 2–8 min above the basal (fasting) insulin level after the bolus glucose injection at 0–1 min Dani Welter http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2128254/ true acute insulin response measurement efo:EFO_0006832 quantification of the disposition index, the product of measures of insulin sensitivity and firstphase insulin secretion, shown to predict conversion to diabetes Dani Welter true insulin disposition index measurement disposition index measurement efo:EFO_0006833 quantification of glucose effectiveness, the capacity of glucose to enhance its own cellular uptake and to suppress endogenous glucose production Dani Welter true glucose effectiveness measurement efo:EFO_0006841 The quantitation of a biomarker used in the measurement of lung fuction used in diagnosis or management of a clinical condition. Helen Parkinson respiratory disease biomarker efo:EFO_0006842 Helen Parkinson The quantification of a biomarker used in the diagnosis or management of diabetes mellitus true diabetes mellitus biomarker efo:EFO_0006843 A quantification of some biomarker used in the diagnosis or management of infectious disease. Helen Parkinson infectious disease biomarker efo:EFO_0006845 The quantification of biomarkers used in the diagnosis or management of liver disease Helen Parkinson true liver disease biomarker efo:EFO_0006846 Is a quantification of some substance or anatomical feature used as an indicator of biological state Helen Parkinson autoimmune disease biomarker efo:EFO_0006848 Is the quantification of some marker used in the diagnosis or clinical management of some mental or behavioural disorder. Helen Parkinson mental or behavioural disorder biomarker efo:EFO_0006864 breastfeeding duration is a measurement of the mean number of months each mother breastfed each child, averaged across all live births and standardized to a Z-score Dani Welter true PMID:25475840 breastfeeding duration efo:EFO_0006866 quantification of the change in the heat and electricity passed through the skin by nerves and sweat. Skin conduction increases in certain emotional states and during hot flashes that happen with menopause. Dani Welter true PMID:25387706 galvanic skin response measurement electrodermal activity measurement efo:EFO_0006867 The skin conductance level is a baseline measure that changes slowly with altered arousal state. SCL is measured as the median response during a 5-min relaxation period. Dani Welter true PMID:25387706 skin conductance level efo:EFO_0006868 quantification of the difference in microsiemens between peak and baseline of the change in skin conductance that occurs in response to a discrete stimulus Dani Welter true PMID:25387706 skin conductance response amplitude efo:EFO_0006869 quantification of the number of valid skin conductance change responses, used to gauge an individual's resistance to habituation Dani Welter true PMID:25387706 skin conductance response frequency efo:EFO_0006870 quantification of the wave-like oscillations in the alpha band (8-13 Hz) of electric potential between parts of the brain Dani Welter true PMID:25387704 alpha wave measurement efo:EFO_0006871 quantification of the wave-like oscillations in the beta band (13-30 Hz) of electric potential between parts of the brain Dani Welter true PMID:25387704 beta wave measurement efo:EFO_0006872 quantification of the wave-like oscillations in the delta band (0.1-4 Hz) of electric potential between parts of the brain Dani Welter true PMID:25387704 delta wave measurement efo:EFO_0006873 quantification of the wave-like oscillations in the theta band (4-8 Hz) of electric potential between parts of the brain Dani Welter true PMID:25387704 theta wave measurement efo:EFO_0006874 Quantification of the error rate reflecting the proportion of trials in an antisaccade task that resulted in a prosaccade response. An antisaccade task invovles the suppression of the involuntary saccade towards a stimulus (prosaccade response) following a period of fixation on a motionless target. Dani Welter true PMID:25387707 antisaccade response measurement efo:EFO_0006875 quantification of an individual's eye blink response to a startling acoustic stimulus, measured via electrodes placed on the orbicularis oculi muscle Dani Welter true PMID:25387708 acoustic startle blink response measurement efo:EFO_0006876 Quantification of the seasonal changes in mood and behaviour, usually evaluated through a questionnaire such as the "Seasonal Pattern Assessment Questionnaire" (SPAQ). The resulting score is used as an indictaor to determine the potential presence of seasonal affective disorder SAD. Dani Welter true PMID:25562672 seasonality measurement efo:EFO_0006882 quantification of some aspect of suicide behaviour, eg suicide behaviour severity, assessed via a self-reported questionnaire or semi-structured interview Dani Welter true PMID:25917933 suicide behaviour measurement efo:EFO_0006883 quantification of the dominant frequency of the alpha band Dani Welter true PMID:25387704 alpha peak frequency measurement efo:EFO_0006896 quantification of some aspect of glucose homeostasis Dani Welter true PMID:25524916 glucose homeostasis measurement efo:EFO_0006897 quantification of airway responsiveness, calculated as the concentration of methacholine at which a greater than 20% decresase in FEV1 is achieved during a bronchial challenge test Dani Welter true PMID:25514360 airway responsiveness measurement efo:EFO_0006898 Quantification of the thickness of the walls of different parts of the respiratory tract, calculated from cross-sectional CT images. This measure can be used as an indicator of airway obstruction severity in COPD. Dani Welter true PMID:25517131 airway wall thickness measurement efo:EFO_0006899 quantification of PCSK9 protein in the blood Dani Welter true PMID:25089948 PCSK9 protein measurement efo:EFO_0006900 quantification of some circulating endothelial growth factor in blood Dani Welter true PMID:25552591 endothelial growth factor measurement efo:EFO_0006901 quantification of circulating angiotensin-2 in blood Dani Welter true PMID:25552591 angiopoietin-2 measurement efo:EFO_0006902 quantification of circulating angiopoietin-2 receptor in blood Dani Welter true PMID:25552591 sTie-2 measurement soluble receptor Tie-2 measurement angiopoietin-2 receptor measurement efo:EFO_0006903 quantification of circulating hepatocyte growth factor in blood Dani Welter true PMID:25552591 HGF measurement hepatocyte growth factor measurement efo:EFO_0006906 quantification of the change in viral disease status in response to treatment Dani Welter true PMID:25461247 virologic response measurement efo:EFO_0006907 PMID:9354455 HPL1A efo:EFO_0006908 Catherine Leroy PMID:9354455 HPL1C efo:EFO_0006909 Catherine Leroy PMID:9354455 HPL1D efo:EFO_0006910 Catherine Leroy PMID:9354455 HPL1E efo:EFO_0006913 quantification of the cytoarchitecture, ie the cellular composition, of the prefrontal cortex of the brain Dani Welter true prefrontal cortex cytoarchtiectural measurement efo:EFO_0006919 quantification of some cardiovascular event such as nonfatal myocardial infarction or atherothrombotic stroke Dani Welter PMID:25583994 true cardiovascular event measurement efo:EFO_0006920 quantification of B-type natriuretic peptide in a sample, eg in blood Dani Welter PMID:25581431 true B-type natriuretic peptide measurement brain natriuretic peptide measurement BNP measurement efo:EFO_0006921 quantification of some aspect of birth, eg whether it preterm or full term Dani Welter PMID:25599974 true birth measurement efo:EFO_0006922 quantification of some aspect of delivery, eg whether it occured preterm or at full term Dani Welter PMID:25599974 true delivery measurement efo:EFO_0006923 quantification of some aspect of fertility, eg number of children or number of births Dani Welter PMID:25742292 true fertility measurement efo:EFO_0006924 quantification of some aspect of air pollution in the home, eg from coal burning for cooking and heating, used as an environmental risk factor for lung cancer Dani Welter PMID:25566987 true household air pollution measurement efo:EFO_0006925 quantification of some lipoprotein A in a sample Dani Welter PMID:25575512 true Lp(a) measurement lipoprotein A measurement efo:EFO_0006929 the IgG index (or CSF index) is the cerebrospinal fluid (CSF) IgG to CSF albumin ration compared to the serum IgG to serum albumin ratio. It is an indicator of the relative amount IgG in CSF compared to serum Dani Welter true IgG index efo:EFO_0006930 quantification of the volume of the brain or of a part of the brain Dani Welter true brain volume measurement efo:EFO_0006931 quantification of the volume of the nucleus accumbens, a region of the basal forebrain rostral to the preoptic area of the hypothalamus and which together with the olfactory tubercle forms the ventral striatum Dani Welter true nucleus accumbens volume efo:EFO_0006932 quantification of the volume of the putamen, a round structure located at the base of the forebrain Dani Welter true putamen volume efo:EFO_0006933 quantification of the volume of the pallidum or globus pallidus, a sub-cortical structure of the brain that is part of the telencephalon Dani Welter true pallidum volume efo:EFO_0006934 quantification of the volume of the amygdala, an almond-shaped group of nuclei located deep and medially within each temporal lobe of the brain Dani Welter true amygdala volume efo:EFO_0006935 quantification of the volume of the thalamus, a midline symmetrical structure of two halves, within the vertebrate brain, situated between the cerebral cortex and the midbrain Dani Welter true thalamus volume efo:EFO_0006936 Is a quantification of some aspect of the optic disk optic nerve head measurement Dani Welter true optic disc measurement efo:EFO_0006937 Is a quantification of the area of the optic disc Dani Welter true optic disc area measurement efo:EFO_0006938 Is a quantification of the rim of the optic disc Dani Welter optic rim area measurement efo:EFO_0006939 Is a quantification of the ratio between optic cup and optic disc, used in the diagnosis of glaucoma Dani Welter true cup-to-disc ratio measurement efo:EFO_0006940 Is a quantification of the area of the optic cup Dani Welter true optic cup area measurement efo:EFO_0006941 quantification of the force applied by the hand to pull on or suspend from objects Dani Welter true grip strength measurement efo:EFO_0006942 quantification of some aspect of facial pigmentation, such as the number, size or location of pigmentation spots Dani Welter true facial pigmentation measurement efo:EFO_0006943 quantification of any change in an indiviual's blood pressure, for example in response to treatment with a antihypertensive agent Dani Welter true blood pressure change measurement efo:EFO_0006944 quantification of any change in an indiviual's systolic blood pressure Dani Welter true systolic blood pressure change measurement efo:EFO_0006945 quantification of any change in an indiviual's diastolic blood pressure Dani Welter true diastolic blood pressure change measurement efo:EFO_0006946 quantification of some aspect of behavioural disinhibition, including risky and impulsive behaviours. Behavioural disinhibition can be a marker for certain kinds of mental or behavioural disorders. Dani Welter true behavioural disinhibition measurement efo:EFO_0006947 quantification of an individual's appreciation of red wine Dani Welter true red wine liking measurement efo:EFO_0006948 quantification of an individual's appreciation of white wine Dani Welter true white wine liking measurement efo:EFO_0006949 quantification of an individual's appreciation of wine Dani Welter wine liking measurement efo:EFO_0006952 quantification of some aspect of cytotoxity such as survival time or cell viability Dani Welter true cytotoxicity measurement efo:EFO_0006953 A reported family history of lung cancer in one or more family members. true family history of lung carcinoma lung cancer family history family history of lung cancer efo:EFO_0006955 quantification of the activity of the von Willebrand factor-cleaving protease ADAMTS13 Dani Welter true PMID:25934476 disintegrin and metalloproteinase with thrombospondin motifs 13 activity measurement ADAMTS13 activity measurement efo:EFO_0006956 quantification of the difference in intraocular pressure between two time points Dani Welter true PMID:25813999 intraocular pressure change measurement efo:EFO_0006957 quantification of the unknown substance X12063 in blood Dani Welter true PMID:25898920 X12063 measurement efo:EFO_0006958 quantification of mannose in a sample Dani Welter true PMID:25898920 mannose measurement efo:EFO_0006959 quantification of the amount of DNA methylation in a target gene Dani Welter true PMID:25713168 gene methylation measurement efo:EFO_0006999 quantification of the agressiveness of a (usually malignant) cancer Dani Welter true cancer aggressiveness measurement efo:EFO_0007000 Quantification of the cytoarchitecture of a prostate cancer sample, used in the evaluation of cancer prognosis. Cancers with a higher Gleason score are generally more aggressive and have a worse prognosis. Dani Welter true Gleason score measurement efo:EFO_0007001 Quantification of dehydroepiandrosterone sulfate (DHEA-S) in a sample. DHEA-S is a metabolite of dehydroepiandrosterone (DHEA), the most abundant circulating steroid hormone in humans. Dani Welter true DHEA-S measurement dehydroepiandrosterone sulphate measurement efo:EFO_0007002 Quantification of luteinizing hormone (LH) in a sample. In females, an acute rise of LH ("LH surge") triggers ovulation and development of the corpus luteum. In males, where LH had also been called interstitial cell–stimulating hormone (ICSH), it stimulates Leydig cell production of testosterone. It acts synergistically with FSH. Dani Welter true LH measurement luteinizing hormone measurement efo:EFO_0007003 quantification of prolactin in a sample Dani Welter true prolactin measurement efo:EFO_0007004 quantification of progesterone in a sample Dani Welter true progesterone measurement efo:EFO_0007005 Quantification of abnormal androgen status in humans, calculated as the ratio of the total level of testosterone divided by the SHBG level, multiplied by a constant (usually 100) Dani Welter true MedDRA:10073182 free androgen index efo:EFO_0007006 quantification of the existence and severity of depressive symptoms, usually via a questionnaire such as the Center for Epidemiological Studies Depression Scale (CES-D) Dani Welter true depressive symptom measurement efo:EFO_0007007 Quantification of the amount of ticagrelor in a sample. Ticagrelor is a platelet aggregation inhibitor used for the prevention of thrombotic events in people with acute coronary syndrome or myocardial infarction with ST elevation. Dani Welter true ticagrelor measurement efo:EFO_0007008 quantification of some aspect of an allergy, for example whether an allergy is present or its severity. Allergies are commonly quantified through measurement of allergen-specific IgE in the blood or skin reaction after puncture of skin through a droplet of allergen extract (skin prick test) Dani Welter allergy measurement efo:EFO_0007009 quantification of some aspect of skin pigmentation, such as saturation, darkness or skin sensitivity to sun Dani Welter true skin pigmentation measurement efo:EFO_0007010 quantification of some aspect of drug use, such as whether drug use occured, over what period of time it occured and what dosage was used Dani Welter true drug use measurement efo:EFO_0007011 quantification of some aspect of SSRI use Dani Welter true selective serotonin reuptake inhibitor use measurement SSRI use measurement efo:EFO_0007012 quantification of some aspect of NSAID use Dani Welter true non-steroid anti-inflammatory drug use measurement NSAID use measurement efo:EFO_0007013 quantification of some aspect of aspirin use Dani Welter true aspirin use measurement efo:EFO_0007014 quantification in a urine sample of 3-hydroxypropylmercapturic acid, one of the main metabolites of acrolein, an important constituent of cigarette smoke with well documented toxic effects Dani Welter true 3-HPMA measurement 3-hydroxypropylmercapturic acid measurement efo:EFO_0007015 quantification in a urine sample of 3-hydroxy-1-methylpropylmercapturic acid, one of the main metabolites of crotonaldehyde, an important constituent of cigarette smoke with well documented toxic effects Dani Welter true HMPMA measurement 3-hydroxy-1-methylpropylmercapturic acid measurement efo:EFO_0007016 quantification of the presence or severity of an allergy to some food Dani Welter true food allergy measurement efo:EFO_0007017 quantification of the presence or severity of an allergy to peanuts Dani Welter true peanut allergy measurement efo:EFO_0007018 quantification of the presence or severity of an allergy to eggs Dani Welter true egg allergy measurement efo:EFO_0007019 quantification of the presence or severity of an allergy to milk or other dairy products Dani Welter true milk allergy measurement efo:EFO_0007020 Quantification of the amount of AR-C124910XX in a sample. AR-C124910XX is the active metabolite of ticagrelor formed by O-deethylation. Dani Welter true AR-C124910XX measurement efo:EFO_0007021 quantification of the amount and location of Lewy bodies in a brain biopsy sample Dani Welter true Lewy body measurement efo:EFO_0007034 a seropositivity measurement is the quantification of an individual's exposure to a certain pathogen through the presence or absence in blood of pathogen specific circulating antibodies Dani Welter true seropositivity measurement efo:EFO_0007035 Chlamydia pneumoniae seropositivity is the result of a measurement of circulating C. pneumoniae specific antibodies Dani Welter true Chlamydia pneumoniae seropositivity efo:EFO_0007036 herpes virus seropositivity is the result of a measurement of circulating herpes virus specific antibodies Dani Welter true herpes virus seropositivity efo:EFO_0007037 cytomegalovirus seropositivity is the result of a measurement of circulating cytomegalovirus specific antibodies Dani Welter true cytomegalovirus seropositivity efo:EFO_0007038 Influenza A seropositivity is the result of a measurement of circulating Influenza A specific antibodies Dani Welter true Influenza A seropositivity efo:EFO_0007039 human herpesvirus 8 seropositivity is the result of a measurement of circulating human herpesvirus 8 specific antibodies Dani Welter true human herpesvirus 8 seropositivity efo:EFO_0007040 Quantification of lead in a blood sample Dani Welter true blood lead measurement efo:EFO_0007041 quantification of weight/height relationships above a certain threshold that classes an individual as overweight. This threshold may vary based on an individual's ethnicity but is commonly considered to correspond in European populations to a BMI > 30. Dani Welter true obese BMI status obese body mass index status efo:EFO_0007042 quantification in a sample of some polychlorinated biphenyls, a group of man-made environmental pollutants which accumulate in humans with adverse health effects Dani Welter true polychlorinated biphenyls measurement efo:EFO_0007047 Toxoplasma gondii seropositivity is the result of a measurement of circulating T. gondii specific antibodies. T. gondii is a parasitic protozoan that causes toxoplasmosis Dani Welter true Toxoplasma gondii seropositivity efo:EFO_0007048 human herpesvirus 6 seropositivity is the result of a measurement of circulating human herpesvirus 6 specific antibodies Dani Welter true human herpesvirus 6 seropositivity efo:EFO_0007049 gliadim seropositivity is the result of a measurement of circulating antibodies specific to the food antigen gliadin Dani Welter gliadin seropositivity efo:EFO_0007050 HSV1 seropositivity is the result of a measurement of circulating herpes simplex virus type 1 specific antibodies Dani Welter true herpes simplex type 1 seropositivity HSV1 seropositivity efo:EFO_0007052 quantification of some aspect of adult antisocial behaviour (AAB), a form of disordered behaviour that is moderately heritable, relatively common and has adverse consequences for individuals and society. AAB is generally measured via questionnaires and psychological assessments, e.g. using a count of the number of Antisocial Personality Disorder criteria endorsed under criterion A from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Dani Welter true PMID:25918995 adult antisocial behaviour measurement antisocial behaviour measurement efo:EFO_0007054 quantification of microsatellite instability Dani Welter true microsatellite instability measurement efo:EFO_0007057 A measure of how fast cancer cells are dividing and growing. To find the mitotic rate, the number of cells dividing in a certain amount of cancer tissue is counted. Mitotic rate is used to help find the stage of melanoma (a type of skin cancer) and other types of cancer. Higher mitotic rates are linked with lower survival rates. Catherine Leroy MR Definition taken from : http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=681122 miotic rate efo:EFO_0007058 The date or time of the last check of a patient by a medical professional. Catherine Leroy last follow up efo:EFO_0007061 The number of times a cell culture has been passaged (sub-cultured or split). Catherine Leroy passage number efo:EFO_0007069 Mouse 3134 is a murine mammary adenocarcinoma cell line generated in Dr. Gordon Hager’s laboratory at the National Institutes of Health, Bethesda, MD. https://genome.ucsc.edu/ENCODE/protocols/cell/mouse/3134_Stam_protocol.pdf 3134 efo:EFO_0007070 ACC112 was established from a salivary glad tumor of a 70-year-old male. Adenoid cystic carcinoma cell line supplied by Lurdes Queimado, M.D., Ph.D. Phone: 405-271-4232 (office); 405-271-4279 (lab); cells immortalized by infection with a retrovirus expressing HPV16 E6 and E7 http://www.ncbi.nlm.nih.gov/pubmed/10328235 UTSW-ACC112 ACC112 efo:EFO_0007071 The hES line BG01 with a normal 46XY karyotype was derived from fibroblasts of an embryonic male human. http://www.iscr-admin.com/Default.aspx?Action=viewsc&StemCellLine=62&StemCelName=BG01 BG01 efo:EFO_0007072 A B-lymphoblastoid cell line derived from a randomly selected Caucasian blood donor whose parents and grandparents were born in the UK or Ireland. The cell line was generated by Epstein-Barr Virus (EBV) transformation of peripheral blood lymphocytes. This cell line is part of the European Collection of Cell Cultures (ECACC) Human Random Control (HRC) collection. http://www.sigmaaldrich.com/catalog/product/sigma/94060845?lang=en&region=US C0202 efo:EFO_0007073 This hESC line was isolated using human feeder cells under good manufacturing process (GMP) conditions. NIH registration: 0041. http://discovery.lifemapsc.com/stem-cell-differentiation/in-vitro-cells/inner-cell-mass-homo-sapiens-cyt49-viacyte-novocell-san-diego-ca CyT49 efo:EFO_0007074 DND-41 was established from the peripheral blood of 13-year-old boy with T-acute lymphoblastic leukemia (T-ALL; type III cortical) in 1977; described to carry CDKN2B (p15INK4B) and CDKN2A (p16INK4A) deletions and TP53 (p53)mutation. https://www.dsmz.de/catalogues/details/culture/ACC-525.html ACC525 DND-41 efo:EFO_0007075 Mouse embryonic stem cell line E14. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1014154 ES-E14 efo:EFO_0007076 The I3 stem cell line was derived from donated blastocysts by removal of the trophoblast layer and further culturing of the intact inner cell mass on mitotically inactivated mouse embryonic fibroblast (MEF) feeder cells. Following injection into SCID mice, the I3 line formed teratomas that contained tissues from all three embryonic germ layers. This line exhibits a normal XX karyotype. These cells were provided by Alex Meissner and maintained in mTeSR medium. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM537624 ES-I3 efo:EFO_0007077 Lymphoblastoid cells taken from the blood of a female human. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM659931 GM06999 efo:EFO_0007078 Human embryonic stem cell line with a normal 46XY karyotype, pluripotency tested in vitro and in vivo. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. [DOI: 10.1056/NEJMsr040330]. Cells were provided by Harvard University and maintained on 10% KOSR (Invitrogen) medium. http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES13 efo:EFO_0007079 Human embryonic stem cell line with a normal 46XX karyotype, pluripotency tested in vivo (teratoma). The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. [PMCID: PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES28 efo:EFO_0007080 Human embryonic stem cell line with a normal 46XY karyotype, pluripotency tested in vitro and in vivo. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. [DOI: 10.1056/NEJMsr040330]. Cells were provided by Harvard University and maintained on KSR medium. http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES3 efo:EFO_0007081 Human embryonic stem cell line derived from human blastocysts. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on 10% KOSR (Invitrogen) medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES44 efo:EFO_0007082 Human embryonic stem cell line derived from human blastocysts. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on 10% KOSR (Invitrogen) medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES45 efo:EFO_0007083 Human embryonic stem cell line with a normal 46XX karyotype. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, NANOG, and TRA-1-81. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES48 efo:EFO_0007084 Human embryonic stem cell line with a normal 46XX karyotype. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, and NANOG. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES49 efo:EFO_0007085 Human embryonic stem cell line with a normal 46XY karyotype. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, TRA1-60, TRA1-81 and NANOG. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES53 efo:EFO_0007086 Human embryonic stem cell line with a normal 46XX karyotype, pluripotency tested in vitro and in vivo. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. [DOI: 10.1056/NEJMsr040330]. Cells were provided by Harvard University and maintained on KSR medium. http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES6 efo:EFO_0007087 Human embryonic stem cell line with a normal 46XX karyotype. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, and NANOG. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES62 efo:EFO_0007088 Human embryonic stem cell line with a normal 46XY karyotype. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, and NANOG. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES63 efo:EFO_0007089 Human embryonic stem cell line with a normal 46XY karyotype. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, and NANOG. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES64 efo:EFO_0007090 HUES64 cells were differentiated into CD184+ endothelial cells in feeder free conditions, using RPMI containing 100ng/mL of Activin A and 50ng/mL of Wnt3a, for 5 days. On day 5, the CD184 positive population was sorted via FACS. Cells come from a healthy male embryo provided by Harvard University. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM772725 HUES64-derived CD184+ efo:EFO_0007091 Human embryonic stem cell line with a normal 46XY karyotype. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, and NANOG. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES65 efo:EFO_0007092 Human embryonic stem cell line derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including OCT4, NANOG, and TRA-1-60. [PMCID:PMC3335201]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES66 efo:EFO_0007093 Human embryonic stem cell line with a normal 46XY karyotype, pluripotency tested in vitro and in vivo. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. [DOI: 10.1056/NEJMsr040330]. Cells were provided by Harvard University and maintained on KSR medium. http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES8 efo:EFO_0007094 Human embryonic stem cell line with an abnormal 46XX, Inv9 karyotype, pluripotency tested in vitro and in vivo. The stem cells were derived from human blastocysts and are strongly positive for a number of molecular markers of undifferentiated pluripotent human stem cells, including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. [DOI: 10.1056/NEJMsr040330]. Cells were provided by Harvard University and maintained on KSR medium. http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES9 efo:EFO_0007095 IPS DF 19.7 cell line is an induced pluripotent stem cell line, derived from newborn foreskin fibroblasts. Cells were received from the James Thomson laboratory, who originally reprogrammed the cells from fibroblasts provided by ATCC (Cat# CRL-2097TM). The first set of numbers before the period refer to different clones, the number after the period indicates the sub-clone. The differentiation method is described here: http://www.sciencemag.org/cgi/content/full/324/5928/797?rss=1 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM665800 PMID:19325077 iPS DF 19.7 efo:EFO_0007096 Human induced pluripotent stem cell line line derived from foreskin fibroblasts, isolated as described by Yu, J. et al. Human induced pluripotent stem cell lines free of vector and transgene sequences. Science 324, 797-801 (2009). Cells were received from the James Thomson laboratory, who originally reprogrammed the cells from fibroblasts provided by ATCC. The first set of numbers before the period refer to different clones, the number after the period indicates the sub-clone. Cells were maintained on mTeSR medium. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM752965 PMID:19325077 iPS DF 19.11 efo:EFO_0007097 IPS DF 4.7 cell line is an induced pluripotent stem cell line, derived from newborn foreskin fibroblasts. Cells were received from the James Thomson laboratory, who originally reprogrammed the cells from fibroblasts provided by ATCC (Cat# CRL-2097TM). The first set of numbers before the period refer to different clones, the number after the period indicates the sub-clone. The differentiation method is described here: http://www.sciencemag.org/cgi/content/full/324/5928/797?rss=1 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM665803 PMID:19325077 iPS DF 4.7 efo:EFO_0007098 Human induced pluripotent stem cell line line derived from foreskin fibroblasts, isolated as described by Yu, J. et al. Human induced pluripotent stem cell lines free of vector and transgene sequences. Science 324, 797-801 (2009). Cells were received from the James Thomson laboratory, who originally reprogrammed the cells from fibroblasts provided by ATCC. The first set of numbers before the period refer to different clones, the number after the period indicates the sub-clone. Cells were maintained on mTeSR medium. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM706073 PMID:19325077 iPS DF 6.9 efo:EFO_0007099 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: normal, 46XY [90%]; abnormal, extra marker chr [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4. [PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-11a efo:EFO_0007100 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: normal, 46XY [95%]; abnormal, 47XY +1 [5%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4. [PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-11b efo:EFO_0007101 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: normal, 46XY [75%]; abnormal, 46 XY del in chr 2 [25%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on 10% KOSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-11c efo:EFO_0007102 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX [55%]; Abnormal, +(1)(q25.3) [40%]; trisomy X, +(1)(q25.3) [5%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-15b efo:EFO_0007103 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4. [PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-17a efo:EFO_0007104 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-17b efo:EFO_0007105 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX [90%]; Abnormal, 45XO [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-18a efo:EFO_0007106 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-18b efo:EFO_0007107 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-18c efo:EFO_0007108 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XY [90%]; Abnormal, non clonal tetraploid [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-20b efo:EFO_0007109 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Abnormal, 47XX +17, addition to 9 [80%]; Normal, 46XX [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on 10% KOSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-27b efo:EFO_0007110 Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX [95%]; Abnormal, 47XX +17 [5%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on 10% KOSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-27e efo:EFO_0007111 This induced pluripotent stem cell (iPSC) line was generated from dermal fibroblasts, by viral transduction of OCT4, SOX2, KLF4, MYC, hTERT, and SV40 large T (hTERT and SV40 large T did not integrate). http://discovery.lifemapsc.com/stem-cell-differentiation/in-vitro-cells/inner-cell-mass-homo-sapiens-ips5-childrens-hospital-corporationboston' iPS-5 efo:EFO_0007112 Loucy was established in 1987 from the peripheral blood of a 38-year-old female patient with T-cell acute lymphoblastic leukemia (T-ALL) obtained two months prior to her death. May be of value in evaluating the role of t(16;20) in the etiology of T-ALL. http://www.ncbi.nlm.nih.gov/pubmed?cmd=Retrieve&list_uids=2208060 Loucy efo:EFO_0007113 This cell line was derived from the third instar larval stage of dorsal mesothoracic discs. Originated from the Mikyake lab. https://dgrc.bio.indiana.edu/product/View?product=121 D23 DmD23 ML DmD23 ML_DmD23 ML-DmD23 efo:EFO_0007114 This cell line was cloned from ML-DmD23 cell line, which was derived from the third instar larval stage of dorsal mesothoracic discs. ML-DmD23-C4 cells are male, by criteria of roX gene expression and Sxl splicing (Stoiber et al., 2016, G3, in press). Originated from the Mikyake lab. https://dgrc.bio.indiana.edu/product/View?product=89 D23-c4 DmD23-c4 DmD_c4 ML DmD23 c4 ML_DmD23_c4 ML-DmD23-c4 efo:EFO_0007115 Human B-lymphoblastoid cells established from peripheral blood lymphocytes of a 27-year-old white Caucasian woman by Epstein-Barr virus (EBV) transformation in 1990; suitable normal control cell line for toxicity or radiosensitivity assays confirmed as human with IEF of AST, NP. http://bioinformatics.hsanmartino.it/cldb/cl3650.html ACC120 NC-NC efo:EFO_0007116 The hESC line UCSF4 with a normal 46XX karyotype was derived from a blastocyst-stage embryo on human foreskin fibroblasts. http://grants.nih.gov/stem_cells/registry/current.htm?id=200 UCSF-4 UCSF4 efo:EFO_0007117 quantification of the thickness of tunica intima and tunica media, the innermost two layers of the wall of the carotid artery, usually by carotid ultrasound Dani Welter true carotid artery intima media thickness efo:EFO_0007118 ratio of sitting height to total body height Dani Welter true sitting height ratio efo:EFO_0007574 Quantification of toxic metal in a blood sample Dani Welter blood toxic metal measurement efo:EFO_0007575 Quantification of aluminium in a blood sample Dani Welter true blood aluminium measurement efo:EFO_0007576 Quantification of cadmium in a blood sample Dani Welter true blood cadmium measurement efo:EFO_0007577 Quantification of cobalt in a blood sample Dani Welter true blood cobalt measurement efo:EFO_0007578 Quantification of copper in a blood sample Dani Welter true blood copper measurement efo:EFO_0007579 Quantification of chromium in a blood sample Dani Welter true blood chromium measurement efo:EFO_0007580 Quantification of mercury in a blood sample Dani Welter true blood mercury measurement efo:EFO_0007581 Quantification of manganese in a blood sample Dani Welter true blood manganese measurement efo:EFO_0007582 Quantification of molybdenum in a blood sample Dani Welter true blood molybdenum measurement efo:EFO_0007583 Quantification of nickel in a blood sample Dani Welter true blood nickel measurement efo:EFO_0007584 Quantification of zinc in a blood sample Dani Welter true blood zinc measurement efo:EFO_0007591 quantification of the accruel of bone mineral density over time Dani Welter true BMA measurement bone density increase measurement bone mineral density change measurement bone mineral accretion measurement efo:EFO_0007593 Quantification of the level of DNA strand breaks in a cell, for example induced by an antineoplastic agent such a bleomycin. Chromatid breaks can be assessed under the microscope in dividing cells during metaphase. Dani Welter true chromatid break measurement efo:EFO_0007598 HAP1 is a near-haploid human cell line that was derived from the male chronic myelogenous leukemia (CML) cell line KBM-7. HAP1 cells are adherent with fibroblast-like morphology. https://www.horizondiscovery.com/knowledge-base/faqs-hap1-knockout-cell-lines#B PMID:3466682 HAP1 HAP-1 efo:EFO_0007599 L1-S8 is a partially reprogrammed cell line generated from human bone marrow mononuclear cells (BMMCs) after prestimulation with early cytokines (TPO, FL, SCF, IL-3) and transduced with Sendai viruses expressing the four factors OCT4, SOX2, KLF4 and cMYC. It originated from a single colony manually picked and clonal expanded. https://www.encodeproject.org/biosamples/ENCBS259CUZ/ L1-S8 efo:EFO_0007600 L1-S8R is a human iPSC line derived from L1-S8 after transduction with lentiviral vector pLM-fSV2A (Papapetrou et al NBT 2011) expressing OCT4, SOX2, KLF4 and cMYC. https://www.encodeproject.org/biosamples/ENCBS023FES/ L1-S8R efo:EFO_0007601 MN1 is a cholinergic motor neuron cell line derived from a fusion of N18TG2 with embryonic mouse spinal cord motor neurons (clone 2F1.10.14.7) http://www.jbc.org/content/271/52/33358.full MN1 efo:EFO_0007602 quantification of the total volume of a brain's four ventricles, usuallly through an MRI scan Dani Welter true total ventricular volume measurement efo:EFO_0007610 RWPE-2 cells were derived from RWPE-1 cells (ATCC CRL-11609) by transformation with Ki-ras using the Kirsten murine sarcoma virus (Ki-MuSV). ATCC:CRL-11610 CRL-11610 RWPE 2 RWPE_2 RWPE2 efo:EFO_0007611 Human anaplastic large cell lymphoma cell line, established from the pleural effusion of a 73-year-old female. Most of these cells were hyperdiploid, with a sharp modal number of 51 chromosomes; occasional cells in the hypertetraploid range were also seen. A minute marker chromosome was consistently observed, and increased numbers of chromosomes were seen in the A, B, C, and F groups Sirarat Sarntivijai ATCC:CRL-2956 CRL-2956 SUDHL-2 SU-DHL-2 efo:EFO_0007614 quantification of acute asthma exacerbations in an individual, generally defined by short courses of treatment with medication such as oral steroids. Dani Welter true PMID:26073756 asthma exacerbation measurement efo:EFO_0007615 quantification of some aspect of thrombus formation, ie the formation of a blood clot inside a blood vessel through the aggregation of platelets and fibrin Dani Welter true PMID:22550155 thrombus formation measurement efo:EFO_0007616 quantification of some aspect of hearing Dani Welter true hearing measurement efo:EFO_0007617 quantification of an individual's hearing thresholds through exposure to pure tone stimuli Dani Welter true pure tone audiometry pure tone hearing measurement efo:EFO_0007618 quantification of the highest and/or lowest frequency of sound perceived by an individual Dani Welter true hearing threshold measurement efo:EFO_0007619 quantification of suicide ideation Dani Welter true suicide ideation measurement efo:EFO_0007620 quantification of the mineral mass per unit volume of bone, generally expressed in grams per cubic centimeter or per ml. This is not to be confused with bone mineral density as calculated per unit area of bone (grams per square centimeter), which is the definition most commonly used in clinical practice. Dani Welter true volumetric bone mineral density efo:EFO_0007621 quantification of the form or content of one or more of the mineral components of bone Dani Welter true BMC measurement bone mineral content measurement efo:EFO_0007622 quantification in a plasma sample of the levels of soluble Receptor for Advanced Glycation End-products (sRAGE). sRAGE is a strong markers of vascular outcomes Dani Welter true soluble receptor for advanced glycation end-products measurement sRAGE measurement efo:EFO_0007626 Quantification of some aspect, eg the presence/absence or severity of emphysema through the use of imaging techniques such as CT scans Dani Welter true emphysema imaging measurement efo:EFO_0007627 Quantification of the size of or level of damage to a person's airways using medical imaging techniques such as CT scans. This approach is used in the diagnosis and assessment of respiratory disorders such as COPD and emphysema Dani Welter true airway imaging measurement efo:EFO_0007628 Quantification of the amount of air that is abnormally retained in the lungs at the end of an exhalation. Dani Welter true gas trapping measurement efo:EFO_0007629 Hemoglobin A1 measurement is a measure of the quantity of the metallo protein hemoglobin A. Hemoglobin A (HbA), also known as adult hemoglobin or a2b2, is the most common human hemoglobin tetramer, comprising over 97% of the total red blood cell hemoglobin. It consists of two alpha chains and two beta chains. Dani Welter https://en.wikipedia.org/wiki/Hemoglobin_A true NCIt:C92258 SNOMEDCT:313995005 HbA levels HbA1 levels hemoglobin A measurement hemoglobin A1 levels hemoglobin A1 measurement efo:EFO_0007630 Is a quantification, typically in blood, of glycerophospholipids, a group of glycerol-based phospholipids Dani Welter true glycerophospholipid measurement efo:EFO_0007631 Is a quantification of the monosaccharide hexose in a sample, typically in blood Dani Welter true hexose measurement efo:EFO_0007635 Quantification of the metabolism rate of drugs such as psychotropic drugs, defined as the quotient of a drug's serum concentration (in nmol/L) by its prescribed daily dosage (in mg/day). This measure can also be standardised to allow comparison across multiple drugs by dividing individual CDR values by a reference CDR for the specific drug. Dani Welter true PMID:25944848 CDR measurement concentration dose ratio efo:EFO_0007636 quantification of an individual's attention function through administration of one or more standardised tests such as the Connors Continuous Performance Test-II (CPT-II) Dani Welter true attention function measurement efo:EFO_0007639 quantification of an individual's sensitity to UV radiation, defined as the shortest exposure to ultraviolet radiation that produces reddening of the skin within 1 to 6 hr and disappears in 24 hr Dani Welter true MED minimal erythema dose efo:EFO_0007645 quantification of some aspect of alcohol consumption over a long period of time (typically several years) Dani Welter true PMID:26081443 longitudinal alcohol consumption measurement efo:EFO_0007646 quantification of accumulation of amyloid plaques in the brain over a long period of time (typically several years), measured by using PET scan imaging technology. The accumulation of amyloid plaques can be a biomarker for Alzheimer's disease Dani Welter true PMID:26268530 amyloid plaque accumulation rate efo:EFO_0007648 quantification of the lowest concentration of vancomycin in a patient's blood during the course of treatment. Trough measurements are used to calculate the rate of absorption of the drug and determine the optimum time for administering the next dose Dani Welter true vancomycin trough measurement efo:EFO_0007649 quantification of the rate at which the kidneys eliminate a substance from the blood stream Dani Welter true renal elimination rate measurement efo:EFO_0007650 quantification of the amount of soluble interleukin-2 receptor subunit alpha in a sample Dani Welter true sIL-2Ra measurement soluble interleukin-2 receptor subunit alpha measurement efo:EFO_0007651 quantification in a urine sample of S-phenylmercapturic acid, a specific biomarker of benzene uptake in smokers Dani Welter true urinary SPMA measurement urinary S-phenylmercapturic acid measurement efo:EFO_0007655 quantification of the amount of the glycoprotein clusterin in a sample. Clusterin is also known as apolipoprotein J and plays a role in several cellular processes including apoptosis, proliferation, and clearance of misfolded proteins Dani Welter true CLU measurement apolipoprotein J measurement clusterin measurement efo:EFO_0007656 quantification of the amount of the clusterin in a sample of blood plasma Dani Welter true plasma clusterin measurement efo:EFO_0007657 quantification of the amount of the clusterin in a sample of cerebrospinal fluid Dani Welter true CSF clusterin measurement cerebrospinal fluid clusterin measurement efo:EFO_0007658 quantification of the presence or absence of a marker, eg a gene or a substance, in a sample Dani Welter true carrier status efo:EFO_0007659 quantification of the presence or absence of apolipoprotein E (APOE) in an individual Dani Welter true APOE carrier status efo:EFO_0007660 Quantification of some aspect of neuroticism or neurotic behaviour, such as severity or frequency of neurotic behaviour. This is usually assessed via a standardised questionnaire. Dani Welter true neuroticism measurement efo:EFO_0007663 quantification of some aspect of aggressive behaviour during childhood, usually assessed through the use of standardised questionnaires. Childhood aggressive behaviour is a criterion for disruptive behavior disorders such as oppositional defiant disorder (ODD) and conduct disorder (CD) [American Psychiatric Association, 2013]. Aggressive behavior is also implicated in neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) [Hamshere et al., 2013], autism spectrum disorder (ASD) [Mandy et al., 2013], dysregulated behavior [Pope and Bierman, 1999], substance use disorders [White et al., 2013], antisocial personality disorder [Schaeffer et al., 2003], and schizophrenia [Volavka, 2013] later in life. Dani Welter true PMID:26087016 childhood aggressive behaviour measurement efo:EFO_0007675 quantification of some aspect of cancer metastases, incl presence/abscence, size, location or origin Dani Welter true metastasis measurement efo:EFO_0007677 peak distance between two specified opposite points on the periphery of blood-derived low-density lipoprotein (LDL) particles Dani Welter true low density lipoprotein peak particle diameter measurement LDL peak particle diameter measurement efo:EFO_0007678 quantification of the total amount of dietary fat consumed by an individual Dani Welter true total fat intake measurement efo:EFO_0007679 quantification of some aspect of oppositional defiant disorder such as irritability or number of temper tantrums, usually assessed by means of standardised questionnaires Dani Welter true oppositional defiant disorder measurement efo:EFO_0007680 quantification of some aspect of a person's gait such as rhythm, variability or step length Dani Welter true gait measurement efo:EFO_0007681 quantification of the change in triglyceride levels in an individual over time, eg over the course of several hours after a high-fat meal Dani Welter true triglyceride change measurement efo:EFO_0007697 quantification of the volume of grey matter in the left superior temporal gyrus, usuallly through an MRI scan Dani Welter left superior temporal gyrus grey matter volume measurement efo:EFO_0007698 quantification of the presence or absence of a mutation in the gene for Glucocerebrosidase (GBA) in an individual Dani Welter GBA carrier status efo:EFO_0007699 quantification of some aspect of eye movement Dani Welter true eye movement measurement efo:EFO_0007700 quantification of a participant’s eye tracking while viewing stationary S-shaped figures Dani Welter true exploratory eye movement measurement efo:EFO_0007701 mineral density of the spine bones Dani Welter true spine bone mineral density efo:EFO_0007702 mineral density of the hip bone Dani Welter true hip bone mineral density efo:EFO_0007703 quantification in a sample of autoantibodies against hystidil-tRNA synthetase, an enzyme which in humans is encoded by the HARS gene Dani Welter Jo-1 autoantibody measurement hystidil-tRNA synthetase autoantibody measurement efo:EFO_0007704 quantification of some aspect, eg frequency or severity, of depressive episodes in patients with mental or behavioural disorders such as bipolar disorder or clinical depression Dani Welter true depressive episode measurement efo:EFO_0007705 quantification of some aspect, eg frequency or severity, of manic episodes in patients with bipolar disorder Dani Welter true manic episode measurement efo:EFO_0007707 quantification by PET scan imaging or other techniques of the deposition of amyloid proteins in any part of the cerebral cortex Dani Welter true PMID:26252872 cerebral amyloid deposition measurement efo:EFO_0007708 quantification of the ratio of t-tau protein to beta-amyloid 1-42 protein in a sample Dani Welter true PMID:26252872 t-tau:beta-amyloid 1-42 ratio measurement efo:EFO_0007709 quantification of the ratio of p-tau protein to beta-amyloid 1-42 protein in a sample Dani Welter true PMID:26252872 p-tau:beta-amyloid 1-42 ratio measurement efo:EFO_0007710 quantification of some aspect of cognitive decline such as the rate at which it occurs or its severity, for example in patients with dementia or Alzheimer's disease. Cognitive decline is ususally assessed using a structured-interview protocol covering a number of standardised areas. Dani Welter true cognitive decline measurement efo:EFO_0007716 Quantification of some aspect of the carotid artery, eg its size, diameter or stiffness Dani Welter carotid artery measurement efo:EFO_0007717 Quantification of some aspect of the carotid artery geometry Dani Welter carotid artery geometry measurement efo:EFO_0007718 Quantification of the stiffness of the carotid artery Dani Welter true PMID:26160806 carotid artery stiffness measurement efo:EFO_0007719 Quantification of the external diameter of the carotid artery Dani Welter true PMID:26160806 carotid artery external diameter measurement efo:EFO_0007720 Quantification of the internal diameter of the carotid artery Dani Welter true PMID:26160806 carotid artery internal diameter measurement efo:EFO_0007721 Quantification of the central pulse pressure in the carotid artery Dani Welter true PMID:26160806 carotid artery central pulse pressure measurement efo:EFO_0007722 Quantification of the area of a cross section of the carotid artery's wall Dani Welter true PMID:26160806 carotid artery wall cross sectional area measurement efo:EFO_0007723 Quantification of mean blood pressure in the carotid artery Dani Welter true PMID:26160806 carotid artery mean blood pressure measurement efo:EFO_0007724 Quantification of the circumferential wall stress of the carotid artery, an indicator for carotid artery stiffness Dani Welter true PMID:26160806 carotid artery circumferential wall stress measurement efo:EFO_0007737 Adiponection measurement that has been adjusted by subjects’ body mass index by performing linear regressions for adiponectin against BMI Dani Welter true PMID:26299439 BMI-adjusted adiponectin measurement efo:EFO_0007738 quantification of some aspect of the cingulate cortex, a part of the brain situated in the medial aspect of the cerebral cortex Dani Welter true cingulate cortex measurement efo:EFO_0007739 quantification of the thickness of the grey matter in the left superior temporal gyrus Dani Welter true left superior temporal gyrus thickness measurement efo:EFO_0007740 The magnitude of the S wave, the downward deflection of the QRS complex following the R wave representing late depolarization of the ventricles as illustrated in an electrocardiograph. Dani Welter true CMO:0000272 S wave amplitude efo:EFO_0007741 The magnitude of the R wave, which is the initial upward deflection of the QRS complex following the Q wave representing early depolarization of the ventricles as illustrated by an electrocardiograph. Dani Welter true CMO:0000270 R wave amplitude efo:EFO_0007742 The magnitude of the portion of the electrocardiograph comprising the Q, R, and S waves which together represent ventricular depolarization. Dani Welter true CMO:0000268 QRS amplitude efo:EFO_0007743 quantification of the severity of an infection with the influenza type A virus Dani Welter true PMID:26379185 influenza A severity measurement efo:EFO_0007744 quantification of the severity of lung disease, eg cystic fibrosis, through comparison of an individual's FEV1 score to the average age-specific percentile values of FEV1 for each patient in a study Dani Welter true PMID:26417704 lung disease severity measurement efo:EFO_0007745 quantification of lactate in a sample Dani Welter true lactate measurement efo:EFO_0007746 quantification of the progression of lesions in white matter of the brain using magnetic resonance imaging Dani Welter true white matter lesion progression measurement efo:EFO_0007747 quantification of the severity of hypertrophic scarring in burn patients, usually using the Vancouver Scar Scale (VSS) Dani Welter true postburn hypertrophic scarring severity measurement efo:EFO_0007748 Non-transformed BJ cells expressing hTERT and SV40 early region. https://www.atcc.org/Products/All/CRL-2522, http://www.sciencedirect.com/science/article/pii/S1535610810000693 BJ-EH, BJ EH EH efo:EFO_0007749 Non-transformed BJ cells expressing hTERT. https://www.atcc.org/Products/All/CRL-2522, http://www.sciencedirect.com/science/article/pii/S1535610810000693 BJ-EL, BJ EL EL efo:EFO_0007750 Transformed BJ cells expressing hTERT, SV40 early region and RAS. http://mcb.asm.org/content/25/15/6464.full, https://www.atcc.org/Products/All/CRL-2522 BJ-ELR, BJ ELR ELR efo:EFO_0007751 Feeder free cell line derived from E14TG2a. https://www.mmrrc.org/catalog/cellLineSDS.php?mmrrc_id=15890 E14TG2a.4 ES-E14TG2a.4 efo:EFO_0007752 Human prostate cancer cell line. https://www.atcc.org/products/all/CRL-2876.aspx#generalinformation VCaP efo:EFO_0007753 quantification of some aspect of the seasonal variation in the micrbiome of the gut Dani Welter true seasonal gut microbiome measurement efo:EFO_0007756 quantification of the presence or absence of Staphylococcus aureus colonies in an individual. Positive carrier status should not be equated with infection. Dani Welter Staphylococcus aureus carrier status efo:EFO_0007757 quantification of the consistent presence or absence of Staphylococcus aureus colonies in an individual at at least two separate points in time Dani Welter true persistent Staphylococcus aureus carrier status efo:EFO_0007758 quantification of the change in presence or absence of Staphylococcus aureus colonies in an individual at two different points in time, from positive to negative or negative to positve Dani Welter true intermittent Staphylococcus aureus carrier status efo:EFO_0007759 The determination of the amount of alpha-linolenic acid present in a sample. Dani Welter true alpha-linolenic acid measurement efo:EFO_0007760 The determination of the amount of eicosapentaenoic acid present in a sample. Dani Welter true icosapentaenoic acid measurement eicosapentaenoic acid measurement efo:EFO_0007761 The determination of the amount of docosahexaenoic acid present in a sample. Dani Welter true docosahexaenoic acid measurement efo:EFO_0007762 The determination of the amount of gamma-linolenic acid present in a sample. Dani Welter true gamma-linolenic acid measurement efo:EFO_0007763 The determination of the amount of dihomo-gamma-linolenic acid present in a sample. Dani Welter true dihomo-gamma-linolenic acid measurement efo:EFO_0007764 The determination of the amount of delta-5 desaturase in a sample, generally estimated as the ratio of arachidonic acid:diohomo-gamma-linolenic acid Dani Welter true delta-5 desaturase measurement efo:EFO_0007765 The determination of the amount of delta-5 desaturase in a sample, generally estimated as the ratio of diohomo-gamma-linolenic acid:linolenic acid Dani Welter true delta-6 desaturase measurement efo:EFO_0007769 quantification of the ratio of thoracic circumference to hip circumference, used as an indicator of type 2 diabetes risk Dani Welter true thoracic-to-hip circumference ratio measurement efo:EFO_0007770 quantification of the amount of fentanyl, an opiate, consumed within the first 24hrs after a surgical intervention Dani Welter true post-operative fentanyl consumption measurement efo:EFO_0007771 quantification of the absence of residual invasive disease in the breast and in the axillary lymph nodes at the completion of the neoadjuvant treatment Dani Welter true pathologic complete response measurement efo:EFO_0007772 bone quantitiave ultrasound of the main bone in the heel, recognized as a non-invasive method for evaluation of bone strength and prediction of osteoporotic fracture Dani Welter true calcaneal bone quantitative ultrasound measurement efo:EFO_0007773 quantification of the presence or absence of psoriatic arthritis in patients with psoriasis vulgaris Dani Welter true cutaneous psoriasis measurement efo:EFO_0007774 quantification of the amount of thrombomodulin in a sample Dani Welter true thrombomodulin measurement efo:EFO_0007775 quantification of the amount of thrombin-antithrombin complex in a sample Dani Welter true thrombin-antithrombin complex measurement efo:EFO_0007776 quantification of the amount of prothrombin fragments F1+2 in a sample Dani Welter true coagulation factor II measurement prothrombin fragments F1+2 measurement efo:EFO_0007777 quantification of an individual's base metabolic rate, the minimum amount of energy required to sustain life while at complete rest, including the body being in a post-absorptive state (ie the digestive system is inactive). BMR differs from RMR because BMR measurements must meet total physiological equilibrium whereas RMR conditions of measurement can be altered and defined by the contextual limitations. Dani Welter true BMR measurement basal metabolic rate measurement base metabolic rate measurement efo:EFO_0007778 quantification of the ratio of albumin to creatinine in a urine sample Dani Welter true urinary albumin to creatinine ratio efo:EFO_0007780 quantification of some aspect of periodontitis or periodontal examinations, including acute vs chronic status, interproximal clincial attachement level and others Dani Welter true PMID:27601451 periodontal measurement efo:EFO_0007781 Quantification of some aspect of stressful life events, such as the presence or absence thereof, the severity of the event or their impact on general health or pre-existing conditions. Data is generally captured via questionnaires and interviews by qualified mental health care professionals. Dani Welter true stressful life event measurement efo:EFO_0007783 Dani Welter true mosaic loss of chromosome Y measurement efo:EFO_0007784 quantification of some aspect of muscle function deterioration such as the rate at which it occurs or its severity, for example in patients with neurodegenerative conditions such as ALS. Functional decline is ususally assessed using a combination of physical exams and structured-interview protocols covering a number of standardised areas. Dani Welter true functional decline measurement efo:EFO_0007785 mineral density of the neck of the femur, the region just below the ball of the hip joint Dani Welter true femoral neck bone mineral density efo:EFO_0007786 quantification of some aspect's of a female's menstrual cycle such as its length Dani Welter true menstrual cycle measurement efo:EFO_0007787 quantification in a plasma sample of betaine, an amino acid derived from glycine. Betaine has been identified as a potential biomarker for coronary artery disease Dani Welter true plasma N,N,N-Trimethylglycine measurement plasma glycine betaine measurement plasma trimethylaminoacetate measurement plasma trimethylammonioacetate measurement plasma betaine measurement efo:EFO_0007788 waist-hip ratio that has been adjusted by subjects’ body mass index Dani Welter true PMID:26785701 BMI-adjusted waist-hip ratio efo:EFO_0007789 waist circumference measurement that has been adjusted by subjects’ body mass index Dani Welter true PMID:26785701 BMI-adjusted waist circumference efo:EFO_0007790 measurement of the IgG antibody isotype produced by plasma cells in response to an Epstein Barr virus infection, specifically to the Epstein–Barr virus nuclear antigen 1 Dani Welter true EBNA1 IgG measurement Epstein Barr virus nuclear antigen 1 IgG measurement efo:EFO_0007791 rheumatoid factor seropositivity is the result of a measurement of circulating autoantibodies called rheumatoid factors that contribute to a number of autoimmune diseases including rheumatoid arthritis Dani Welter true rheumatoid factor seropositivity measurement efo:EFO_0007792 quantification of some aspect of antipsychotic drug use such as drug dosage Dani Welter true antipsychotic drug use measurement efo:EFO_0007793 leptin measurement that has been adjusted for subjects' body mass index Dani Welter true PMID:26833098 BMI-adjusted leptin measurement efo:EFO_0007794 quantification of the ratio of 3’-trans-hydroxycotinine to cotinine in a sample, typically in a urine or blood sample Dani Welter true PMID:26921259 nicotine metabolite ratio efo:EFO_0007795 quantification of some aspect of anxiety disorder such as its presence or absence in an individual or its severity Dani Welter true anxiety disorder measurement efo:EFO_0007796 length of an individual's parents' life, either taken individually (paternal or maternal longevity) or in combination and sometimes used as an indicator of an individual longevity Dani Welter true parental longevity efo:EFO_0007797 quantification of some aspect of language or language development Dani Welter true language measurement efo:EFO_0007798 quantification of an individual's linguistic error rate, generally through the administration of standardised tests or the analysis of language samples by a specialist Dani Welter true linguistic error measurement efo:EFO_0007799 quantification of an individual's ability to form syntactically complex language constructs, generally through the administration of standardised tests or the analysis of language samples by a specialist Dani Welter true syntactic complexity measurement efo:EFO_0007800 Quantification of the amount of body fat as a percentage of total body mass, calculated as either total mass of fat divided by total body mass or one of a number of more complex weighted equations. Body fat includes essential body fat and storage body fat. Dani Welter true body fat percentage efo:EFO_0007801 quantification in a sample (eg blood) of lycopene, a bright red carotene and carotenoid pigment and phytochemical found in tomatoes and other red fruits and vegetables, such as red carrots, watermelons and papayas Dani Welter true lycopene measurement efo:EFO_0007802 quantification of some aspect of obsessive-compulsive symptoms, such as their existence and severity, usually via a standardised questionnaire or interview with a qualified mental health professional Dani Welter true obsessive-compulsive symptom measurement efo:EFO_0007803 quantification of some aspect of emotional problem symptoms, such as their existence and severity, usually via a standardised questionnaire such as the emotional symptoms subscale of the Strengths and Difficulties Questionnaire or interview with a qualified mental health professional Dani Welter true emotional symptom measurement efo:EFO_0007804 quantification of the change in LDL cholesterol levels in an individual over time, eg over the course of several hours after a high-fat meal or following treatment with a cholesterol-lowering drug Dani Welter true LDL cholesterol change measurement efo:EFO_0007805 quantification of the change in HDL cholesterol levels in an individual over time, eg over the course of several hours after a high-fat meal or following treatment with a cholesterol-lowering drug Dani Welter true HDL cholesterol change measurement efo:EFO_0007806 quantification of the change in total cholesterol levels in an individual over time, eg over the course of several hours after a high-fat meal or following treatment with a cholesterol-lowering drug Dani Welter true total cholesterol change measurement efo:EFO_0007807 Quantification of the amount of cadmium present in erythrocytes. Cadmium in erythrocytes is a valid biomarker of exposure and body burden of cadmium, a non-essential toxic metal with multiple adverse health effects Dani Welter true PMID:27005419 erythrocyte cadmium measurement efo:EFO_0007810 measurement of the IgG1 antibody isotype produced by plasma cells in response to a Plasmodium falciparum infection Dani Welter true Plasmodium falciparum antigen IgG1 measurement efo:EFO_0007811 measurement of the IgG3 antibody isotype produced by plasma cells in response to a Plasmodium falciparum infection Dani Welter true Plasmodium falciparum antigen IgG3 measurement efo:EFO_0007812 measurement of the IgG antibody isotype produced by plasma cells in response to a Plasmodium falciparum infection Dani Welter true Plasmodium falciparum antigen IgG measurement efo:EFO_0007813 quantification of cotinine in a sample Dani Welter true cotinine measurement efo:EFO_0007814 quantification of some aspect of refractive errors, which occur when the shape of the eye prevents light from focusing directly on the retina. The length of the eyeball (longer or shorter), changes in the shape of the cornea, or aging of the lens can cause refractive errors. Quantification of an individual's refractive error allows the establishemnt of a number of corrective parameters such as spherical equivalent, lens decentration and transposition Dani Welter refractive error measurement efo:EFO_0007817 quantification of some aspect of obstructive sleep apnea, such as oxygen desaturation levels during an apnea event or severity, duration or frequency of apnea events Dani Welter true sleep apnea measurement efo:EFO_0007818 quantification of some aspect of athletic endurance Dani Welter true athletic endurance measurement efo:EFO_0007819 quantification in a sample of advanced glycation end-products (AGEs), a diverse group of molecules produced by the non-enzymatic addition of glucose to proteins, lipids, and nucleic acids, possibly associated with hyperglycemia and diabetic complications Dani Welter true AGE measurement advanced glycation end-product measurement efo:EFO_0007821 quantification of some aspect of hair morphology such as hair density, colour, thickness or growth pattern Dani Welter true PMID:26926045 hair morphology measurement efo:EFO_0007822 quantification of some aspect of hair colour, such as whether greying occurs, how advanced greying is or qualification to what colour family hair belongs Dani Welter true PMID:26926045 hair colour measurement efo:EFO_0007823 quantification of the thickness or density of facial air, including beards and eyebrows Dani Welter true PMID:26926045 facial hair thickness measurement efo:EFO_0007824 quantification of some aspect of hair shape, eg whether it is curly or straight Dani Welter true PMID:26926045 hair shape measurement efo:EFO_0007825 quantification of the amount of balding in an individual Dani Welter true PMID:26926045 balding measurement efo:EFO_0007826 quantification of some aspect of aggressive behaviour Dani Welter true aggressive behaviour measurement efo:EFO_0007827 quantification of some aspect of nighttime rest such as duration or quality Dani Welter true PMID:27126917 nighttime rest measurement efo:EFO_0007828 quantification of some aspect of daytime rest such as duration, frequency or quality Dani Welter true PMID:27126917 daytime rest measurement efo:EFO_0007830 quantification of some aspect of food addiction such as presence or absence or severity of symptoms, usually assessed through a standarised questionnaire or structured interview with a mental health professional Dani Welter true food addiction measurement efo:EFO_0007835 quantification of some aspect of alcohol dependence or misuse, eg using a cummulative symptom score to determine the severity of a case of alcohol dependence Dani Welter true PMID:27151647 alcohol misuse measurement alcohol dependence measurement efo:EFO_0007836 quantification in a sample of the amount of coenzyme Q10, a lipophilic redox molecule that is present in membranes of almost all cells in human tissues, is essential for the respiratory transport chain and is a modulator of inflammatory processes and gene expression Dani Welter true PMID:27149984 CoQ10 measurement coenzyme Q10 measurement efo:EFO_0007837 anti-citrullinated protein antibody seropositivity is the result of a measurement of circulating anti-cyclic citrullinated peptide antibodies Dani Welter true anti-citrullinated protein antibody seropositivity efo:EFO_0007840 quantification of some aspect of pesticide exposure such as frequency, duration or severity Dani Welter true pesticide exposure measurement efo:EFO_0007841 quantification of some aspect of facial morphology such as lip thickness, forehead height or chin protrusion Dani Welter true PMID:27193062 facial morphology measurement efo:EFO_0007842 quantification of some aspect of chin morphology such as chin shape or chin protrusion Dani Welter true PMID:27193062 chin morphology measurement efo:EFO_0007843 quantification of some aspect of nose morphology such as nose wing breadth, nose tip shape or nose profile Dani Welter true PMID:27193062 nose morphology measurement efo:EFO_0007844 quantification of some aspect of forehead morphology such as forehead profile, forehead height or brow-ridge protrusion Dani Welter true PMID:27193062 forehead morphology measurement efo:EFO_0007845 quantification of some aspect of lip morphology such as upper lip or lower lip thickness or lip curvature Dani Welter true PMID:27193062 lip morphology measurement efo:EFO_0007847 quantification of some aspect of cheekbone morphology such as cheekbone protrusion Dani Welter true PMID:27193062 cheekbone morphology measurement efo:EFO_0007848 quantification of serum lipoprotein A-IV. Apolipoprotein A-IV, encoded in humans by the APOA4 gene, a 376-residue mature O-linked glycoprotein. Dani Welter true lipoprotein A-IV levels apolipoprotein A-IV measurement efo:EFO_0007849 quantification of brain function, usually via functional magnetic resonance imaging (MRI), for example using blood-oxygen-level dependent contrast imaging (BOLD), often measured in response to a stimulus such as performing a task or exposure to images, sounds or smells Dani Welter true brain activation measurement functional brain measurement efo:EFO_0007850 quantification of the amount or severity of solar lentigines, flat tan to brown spots sometimes called liver spots, on an individual's skin. Lentigines are associated with skin aging and sun exposure Dani Welter true solar lentigines measurement efo:EFO_0007852 quantification of the activity of the enzyme thiopurine methyltransferase in a sample Dani Welter true thiopurine methyltransferase activity measurement efo:EFO_0007854 quantification of peak torque values of the knee flexor muscles Dani Welter true knee peak torque measurement efo:EFO_0007855 quantification of some aspect of facial width, such a the cranial base width Dani Welter true PMID:27560520 facial width measurement efo:EFO_0007856 quantification of some aspect of facial height, such a the height of the entire face or the height of the upper half of the face Dani Welter true PMID:27560520 facial height measurement efo:EFO_0007857 quantification of some aspect of facial depth, such as the distance from the tip of the nose to the tip of the ear lobe Dani Welter true PMID:27560520 facial depth measurement efo:EFO_0007858 quantification of some aspect of eye morphology, such as the width of the eye socket Dani Welter true PMID:27560520 eye morphology measurement efo:EFO_0007860 quantification of some aspect of ADHD symptoms such as presence/absence or severity, usually through administration of standardised questionnaires or evaluation by a qualified professional Dani Welter true PMID:27663945 ADHD symptom measurement efo:EFO_0007861 quantification of the ratio between two body measures, eg waist-hip ratio Dani Welter body ratio measurement efo:EFO_0007862 quantification of some aspect of reproductive behaviour such as age at first birth or number of children Dani Welter PMID:27798627 reproductive behaviour measurement efo:EFO_0007863 quantification of the severity of a patient's illness, eg critical or mild Dani Welter true illness severity status efo:EFO_0007864 Quantification of the amount of sulfate, an inorganic polyatomic anion, in a sample. Sulfate is critical in many organisms in the biotransformation of multiple compounds via sulfotransferase-mediated sulfate conjugation (sulfation). Dani Welter true sulfate measurement efo:EFO_0007865 Quantification of some aspect of loneliness, such as severity or presence/absence, generally through administration of a standardised questionnaire such as the 3-Item Leave Behind Questionnaire (LBQ). Dani Welter true loneliness measurement efo:EFO_0007869 quantification of some aspect of wellbeing such as life satisfaction or emotional wellbeing, usually self-reported and quantified through the use of a structured questionnaire Dani Welter true PMID:27089181 wellbeing measurement efo:EFO_0007872 quantification of caffeine (1,3,7 trimethylxanthine) or any metabolite derived from caffeine, including paraxanthine (1,7 dimethylxanthine), theophylline (1,3 dimethylxanthine), and theobromine (3,7 dimethylxanthine) in a sample Dani Welter true PMID:27702941 caffeine metabolite measurement efo:EFO_0007873 Quantification of the thickness of cartilage in a joint, most commonly the hip joint, for example using minimal joint space width (mJSW) as a proxy measure. Cartilage thickness is an indicator of joint health, which makes it a suitable biomarker for osteoarthritis. Dani Welter true PMID:27701424 cartilage thickness measurement efo:EFO_0007874 quantification of some aspect of an individual's micrbiome of the gut Dani Welter true gut microbiome measurement efo:EFO_0007875 quantification of excessive daytime sleepiness such as how often it occurs and its severity Dani Welter true excessive daytime sleepiness measurement efo:EFO_0007876 quantification of insomnia such as how often it occurs and its severity Dani Welter true insomnia measurement efo:EFO_0007877 quantification of some aspect of risky sexual behaviour such as frequency of unprotected sexual intercourse and number of sexual partners within a given time frame Dani Welter true PMID:27531626 risky sexual behaviour measurement efo:EFO_0007878 quantification of some aspect of alcohol consumption such as frequency or quantity Dani Welter true PMID:26081443 alcohol consumption measurement efo:EFO_0007881 quantification of some aspect of job-related exhaustion such as severity or duration Dani Welter true PMID:27748236 job-related exhaustion measurement efo:EFO_0007882 quantification of some aspect of an individual's microbiome Dani Welter microbiome measurement efo:EFO_0007883 quantification of the taxonomic variation in a microbiome sample Dani Welter true taxonomic microbiome measurement efo:EFO_0007884 quantification of the functional variation in a microbiome Dani Welter functional microbiome measurement efo:EFO_0007885 measurement of the repolarisation phase of the heart's electrical cycle, defined as the difference between the duration of the QT interval and duration of the QRS interval Dani Welter true PMID:27958378 JT interval efo:EFO_0007886 quantification in a sample of the organochlorine pesticide dichlorodiphenyltrichloroethane (DDT) or any metabolite derived from DDT, eg 2, 2-bis (4-chlorophenyl)-1, 1-dichloroethene (p,p′-DDE) Dani Welter true PMID:27839851 DDT metabolite measurement efo:EFO_0007888 The age of onset of (human) voice drop, the deepening of the voice of adolescents as they reach puberty Dani Welter true age at voice drop efo:EFO_0007889 quantification of some aspect of dysmenorrheic pain (menstrual cramps), such as their severity or duration Dani Welter true PMID:27454463 dysmenorrheic pain measurement efo:EFO_0007890 quantification of adipose tissue located around the heart Dani Welter true pericardial adipose tissue measurement efo:EFO_0007891 quantification of epidermal permeability barrier status, for example using transepidermal water loss, the passive diffusion of water from the hydrated layers of the dermis and epidermis towards those layers with a lower water content Dani Welter true PMID:28011148 skin barrier function measurement efo:EFO_0007892 quantification of the effect of the donor genotype on the success of an organ or tissue transplant Dani Welter true PMID:27595289 donor genotype effect measurement efo:EFO_0007893 quantification in a sample (eg blood) of alpha-carotene, the second most common form of carotene, with a β-ionone ring at one end and an α-ionone ring at the opposite end Dani Welter true alpha-carotene measurement efo:EFO_0007894 quantification in a sample (eg blood) of beta-carotene, an organic, strongly colored red-orange pigment abundant in plants and fruits. Among the carotenes, β-carotene is distinguished by having beta-rings at both ends of the molecule. β-Carotene is biosynthesized from geranylgeranyl pyrophosphate. Dani Welter true beta-carotene measurement efo:EFO_0007895 quantification in a sample (eg blood) of lutein, a xanthophyll and one of 600 known naturally occurring carotenoids. Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots. Dani Welter true lutein measurement efo:EFO_0007896 quantification in a sample (eg blood) of zeaxanthin, one of the most common carotenoid alcohols found in nature and the pigment that gives paprika, corn, saffron, wolfberries, and many other plants and microbes their characteristic color Dani Welter true zeaxanthin measurement efo:EFO_0007897 quantification in a sample (eg blood) of cryptoxanthin, a carotenoid closely related in terms of structure to beta-carotene and that has been isolated from a variety of sources including the petals and flowers of plants in the genus Physalis, orange rind, papaya, egg yolk, butter, apples, and bovine blood serum Dani Welter true cryptoxanthin measurement efo:EFO_0007898 quantification in a sample of alpha-tocopherol, a form of vitamin E that is preferentially absorbed and accumulated in humans Dani Welter true alpha-tocopherol measurement efo:EFO_0007899 quantification in a sample of gamma-tocopherol Dani Welter true gamma-tocopherol measurement efo:EFO_0007900 quantification in a sample (eg blood) of retinol, a vitamin A retinoid synthesized from the breakdown of β-carotene Dani Welter true vitamin A1 measurement retinol measurement efo:EFO_0007901 quantification of the ratio of hepcidin to ferritin in a sample Dani Welter true hepcidin:ferritin ratio efo:EFO_0007902 quantification of the ratio of hepcidin to transferrin saturation, the amount of iron bound to transferrin, in a sample Dani Welter true hepcidin:transferrin saturation ratio efo:EFO_0007903 quantification of the ratio of magnesium to calcium in a sample, typically a urine sample, a proxy measure for the differential handling by the renal tubule and excretion of Ca2+ and Mg2+ Dani Welter true magnesium:calcium ratio efo:EFO_0007904 quantification of an individual's susceptibility to childhood ear infections, generally as a count of number of infections suffered or a binary scale of presence or absence of childhood ear infections Dani Welter true susceptibility to childhood ear infection measurement efo:EFO_0007905 quantification of the severity of joint hypermobility, for example using the Beighton score, a score ranging from 0 to 9 based on 9 different measurements regarding the hypermobility of finger, knee, elbow, thumb and hip hypermobility Dani Welter true joint hypermobility measurement efo:EFO_0007906 quantification of some aspect of unibrows, such as their presence or absence, or their severity Dani Welter true monobrow measurement unibrow measurement synophrys measurement efo:EFO_0007907 quantification of some aspect of methadone dosage Dani Welter true PMID:28115739 methadone dose measurement efo:EFO_0007908 quantification of some aspect of air pollution through traffic, such as annual average NO2 exposure estimates derived using land use regression modeling Dani Welter true PMID:27901618 traffic air pollution measurement efo:EFO_0007909 quantification of the amount of chromogranin A cleavage product in a sample Dani Welter true chromogranin A cleavage product measurement CHGA cleavage product measurement efo:EFO_0007910 quantification of the amount of chromogranin B cleavage product in a sample Dani Welter true chromogranin B cleavage product measurement CHGB cleavage product measurement efo:EFO_0007911 quantification of some aspect of personality traits, usually through administration of standardised questionnaire such as the Big Five Inventory (BFI) Dani Welter true personality trait measurement efo:EFO_0007912 quantification of conscientiousness, usually through administration of standardised questionnaire such as the Big Five Inventory (BFI) Dani Welter true PMID:27918536 conscientiousness measurement efo:EFO_0007913 quantification of extraversion, usually through administration of standardised questionnaire such as the Big Five Inventory (BFI) Dani Welter true PMID:27918536 extraversion measurement efo:EFO_0007914 quantification of openness, usually through administration of standardised questionnaire such as the Big Five Inventory (BFI) Dani Welter true PMID:27918536 openness measurement efo:EFO_0007915 quantification of agreeableness, usually through administration of standardised questionnaire such as the Big Five Inventory (BFI) Dani Welter true PMID:27918536 agreeableness measurement efo:EFO_0007924 Quantification an individual's risk of undergoing tonsillectomy. Some individuals experience recurrent, severe tonsillitis and massive hypertrophy of the tonsils in which case surgical removal of the tonsils may be considered. There are a number of genetic variants that may reduce the risk of tonsillectomy by conferring a protective effect. Dani Welter true PMID:27182965 tonsillectomy risk measurement efo:EFO_0007927 quantification of the severity of schizophrenia symptoms, for example as a result of treatment. Schizophrenia symptom severity can be evaluated via a range of measures, including the the Positive and Negative Syndrome Scale (PANSS), a medical scale used for measuring symptom severity of patients with schizophrenia, the PANSS sub-component PANSS positive Marder factor score and PANSS negative Marder factor score and the Clinical Global Impression – Severity scale (CGI-S), a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Dani Welter true PMID:27846195 schizophrenia symptom severity measurement efo:EFO_0007928 quantification in an electrocardiogram of the number of QRS complexes per minute Dani Welter true ventricular rate measurement efo:EFO_0007929 quantification of the ratio of triglyceride to HDL cholesterol in a sample Dani Welter true PMID:28046027 triglyceride:HDL cholesterol ratio efo:EFO_0007930 quantification of the ratio of LDL cholesterol to HDL cholesterol in a sample Dani Welter true PMID:28046027 LDL cholesterol:HDL cholesterol ratio efo:EFO_0007931 quantification of the ratio of non-HDL cholesterol to HDL cholesterol in a sample Dani Welter true PMID:28046027 non-HDL cholesterol:HDL cholesterol ratio efo:EFO_0007932 Quantification of the susceptibility of developing multiple keratinocyte carcinomas (mKC), which is defined as the presence of more than one basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). Dani Welter true PMID:28081215 multiple keratinocyte carcinoma susceptibility measurement efo:EFO_0007933 mineral density of the radial bone Dani Welter true radius bone mineral density efo:EFO_0007934 The clearance rate of creatinine, that is, the volume of plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance is calculated using the level of creatinine in a sample of urine, usually one collected over a period of 24 hours, the corresponding plasma creatinine level, and the volume of urine excreted. It is used as an approximation of the glomerular filtration rate (GFR). Dani Welter true CMO:0000765 creatinine clearance measurement efo:EFO_0007935 quantification of the ratio of uric acid to creatinine in a urine sample Dani Welter true urinary uric acid to creatinine ratio efo:EFO_0007936 quantification of some aspect of disease prognosis Dani Welter true PMID:28067912 disease prognosis measurement efo:EFO_0007937 quantification of the levels of some protein in a blood sample Dani Welter true blood protein measurement efo:EFO_0007938 Quantification of coronary atherosclerosis as the number of diseased coronary vessels at the time of a catheterization procedure. The variable describes the number (0–3) of vessels with significant (> 75%) blockage while taking into account the location of the vessels as well as the left or right dominance of the patient Dani Welter true PMID:28355232 coronary atherosclerosis measurement efo:EFO_0007939 quantification of the range and severity of respiratory symptoms, either through clinical examination or through a standardised questionnaire assessing variables such as presence and severity of cough, pleghm and dyspnea Dani Welter true PMID:28073367 respiratory symptom measurement efo:EFO_0007941 Quantification of the severity of sciatica symptoms in patients with lumbar disc herniation. In the case of persistent progressive severe sciatica symptoms, patients may require surgical intervention via microdiscectomy, a minimally invasive spinal surgery for removal of herniated lumbar disc tissue. Dani Welter true PMID:28223688 lumbar disc herniation-related sciatica symptom severity measurement LDH-related sciatica symptom severity measurement efo:EFO_0007942 Quantification of the hip osteoarthritis symptoms. In the case severe hip osteoarthritis, patients may require surgical intervention via a total hip replacement. Dani Welter true PMID:28319091 hip osteoarthritis symptom severity measurement efo:EFO_0007944 Quantification of an individual's level of exposure to an allergen such as a food allergen or dust mites. The level of exposure is defined as units of allergen in a sample, eg microgram of dust mites in a gram of dust. Dani Welter true allergen exposure measurement efo:EFO_0007945 quantification of some aspect of agoraphobia symptoms such as their frequency or severity, usually via a structured questionnaire such as the Agoraphobia Cognition Questionnaire (ACQ) Dani Welter true agoraphobia symptom measurement efo:EFO_0007946 Quantification an individual's level of tiredness, generally via a standardised questionnaire or structured interview. Dani Welter true PMID:28194004 tiredness measurement efo:EFO_0007947 Quantification of the galactose-deficient immunoglobulin A1, a form of immunoglobulin A1 deficient in the 3-6 O-glycans usually present in the hinge-region segments of the heavy chains of immunoglobulin A1. Galactose-deficient IgA1 (Gd-IgA1) glycoforms are significantly more abundant in individuals with IgA nephropathy than in healthy individuals. Dani Welter true serum galactose-deficient IgA1 measurement efo:EFO_0007950 Induced pluripotent stem cell line; Participant #1 (hu43860C) in the Personal Genome Project: http://www.personalgenomes.org Fibroblast culture from this same subject from which this cell line was made is GM23248and a matching lymphoblast line from this same subject is GM20431. https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM23338 GM23338 efo:EFO_0007951 This induced pluripotent stem cell (iPSC) line was generated from dermal fibroblasts, by viral transduction of OCT4, SOX2, KLF4, c-MYC, hTERT, and SV40 Large T antigen transgenes. Cells express pluripotent markers and have a normal karyotype, 46XY. https://discovery.lifemapsc.com/stem-cell-differentiation/in-vitro-cells/inner-cell-mass-homo-sapiens-ips4-childrens-hospital-corporationboston hFib2 iPS4 hFib2-iPS4 efo:EFO_0007952 Induced pluripotent stem cell line isolated from skin sample AG20443. http://www.sciencedirect.com/science/article/pii/S1873506112000888, https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG20443&PgId=166 iPS NIHi11 iPS-NIHi11 efo:EFO_0007953 Induced pluripotent stem cell line isolated from skin sample AG08395. http://www.sciencedirect.com/science/article/pii/S1873506112000888, https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG08395&PgId=166 iPS NIHi7 iPS-NIHi7 efo:EFO_0007955 quantification of some aspect of mouth morphology such as mouth width Dani Welter true PMID:28441456 mouth morphology measurement efo:EFO_0007956 quantification of the ratio between absolute monocyte count and absolute lymphocyte count Dani Welter true MLR monocyte:lymphocyte ratio efo:EFO_0007957 quantification in a urine sample of 1,3-butadiene, a metabolite found in tobacco smoke and which is known to have carcinogenic properties Dani Welter true urinary 1,3-butadiene measurement efo:EFO_0007958 quantification of the effect of an external genotype, eg from a parent/fetus during pregnancy or organ donor, on some aspect of an individual's metabolic processes Dani Welter genotype effect measurement efo:EFO_0007959 quantification of the effect of the fetal genotype on the metabolic processes of the mother during pregnancy Dani Welter true PMID:28235828 fetal genotype effect measurement efo:EFO_0007960 quantification of organochlorine pesticides or metabolites derived from organochloride pesticides in a sample Dani Welter true PMID:28235828 organochlorine pesticide measurement efo:EFO_0007961 quantification in a sample of some polybrominated biphenyls, a group of man-made environmental pollutants which accumulate in humans with adverse health effects Dani Welter true PMID:28235828 polybromobiphenyl measurement polybrominated biphenyl measurement efo:EFO_0007962 quantification in a sample of some polybrominated diphenyl ethers, a group of man-made environmental pollutants which accumulate in humans with adverse health effects Dani Welter true PMID:28235828 polybromodiphenyl ether measurement polybrominated diphenyl ether measurement efo:EFO_0007963 quantification of some aspect of Paneth cell abnormality, such as abnormal morphology or abnormal number of cells. Paneth cells, along with goblet cells, enterocytes, and enteroendocrine cells, represent the principal cell types of the epithelium of the small intestine. Dani Welter true PMID:28352666 abnormal paneth cell measurement efo:EFO_0007964 quantification of some chemical compound such as a metabolite or environmental pollutant in a serum sample taken from a women at some stage during pregnancy Dani Welter true PMID:28235828 gestational serum measurement efo:EFO_0007966 quantification of the activate metabolite of the platelet aggregation inhibitor clopidogrel in a sample Dani Welter true PMID:28207573 clopidogrel metabolite measurement efo:EFO_0007967 quantification of the concentration of ions in blood, often expressed as a function of sodium and glucose concentrations Dani Welter true PMID:28360221 blood osmolality measurement efo:EFO_0007968 quantification of the amount of tissue factor pathway inhibitor in a sample Dani Welter true PMID:28421636 tissue factor pathway inhibitor measurement efo:EFO_0007969 quantification of cognitive inhibition or executive inhibition in an individual with ADHD, measured for example using the Stroop test Dani Welter true PMID:28416812 executive inhibition measurement cognitive inhibition measurement efo:EFO_0007970 quantification of the amount of estrone in a sample Dani Welter true estrone measurement efo:EFO_0007971 quantification of the amount of estrone conjugates, such as sulphate and glucuronide conjugates, in a sample Dani Welter true estrone conjugate measurement efo:EFO_0007972 quantification of androstenedione in a sample Dani Welter true androstenedione measurement efo:EFO_0007973 The determination of the amount of palmitoleic acid present in a sample. Dani Welter true palmitoleic acid measurement efo:EFO_0007974 The determination of the amount of vaccenic acid present in a sample. Dani Welter true vaccenic acid measurement efo:EFO_0007975 The determination of the amount of gondoic acid present in a sample. Dani Welter true gondoic acid measurement efo:EFO_0007976 The determination of the amount of erucic acid present in a sample. Dani Welter true erucic acid measurement efo:EFO_0007977 The determination of the amount of nervonic acid present in a sample. Dani Welter true nervonic acid measurement efo:EFO_0007978 quantification of the density of a red blood cell (DRBC). DRBC is affected by the hydration level of the cell, with dehydrated cells being dense and deformed. Increased DRBC may be an indicator of disease severity in sickle cell anemia Dani Welter true PMID:28552477 red blood cell density measurement efo:EFO_0007979 quantification of some aspect of childhood trauma such as type, severity or duration. Childhood trauma can be reliably assessed through the Childhood Trauma Questionnaire (CTQ), a 28-item self-report inventory of early life adverse events. Dani Welter true PMID:28453389 childhood trauma measurement efo:EFO_0007980 quantification of the flow of blood through vessels in the brain, including flow rate and flow velocity through the vessel. Cerebral blood flow can be assessed using magnetic resonance imaging. Dani Welter true PMID:28627999 cerebral blood flow measurement efo:EFO_0007984 Measure of variation in platelet size. The determination of the amount of platelet shape changes present in a sample. [ NCI ] Dani Welter true CMO:0001350 NCIt:C111294 PCDW Platelet Component Distribution Width Measurement Platelet distribution width platelet component distribution width efo:EFO_0007985 The proportion of blood volume that is occupied by platelets, expressed as a percentage. Dani Welter true CMO:0001349 PCT platelet crit (PCT) plateletcrit plateletcrit (PCT) platelet crit efo:EFO_0007986 The number of reticulocytes per unit volume of blood. Reticulocytes are immature red blood cells and typically compose aoubt 1% of red blood cells in the human body. Dani Welter true MedDRA:10038787 reticulocyte count efo:EFO_0007987 The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. Dani Welter true CMO:0000111 MedDRA:10018678 blood granulocyte count granulocyte count efo:EFO_0007988 The number of myeloid leukocytes in a specified volume of blood, usually 1 cubic millimeter. Dani Welter true myeloid leukocyte count myeloid white cell count efo:EFO_0007989 A calculated measurement in which the number of monocytes in a specified sample of blood is divided by the total number of white blood cells in the sample, and the result presented as a ratio, fraction, quotient or percentage. Dani Welter true CMO:0000374 blood monocyte count to total leukocyte count ratio monocyte count as percentage of total white blood cells monocyte count to total WBC count ratio monocyte percentage monocyte percentage of white cells monocyte percentage of leukocytes efo:EFO_0007990 A calculated measurement in which the number of neutrophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. A neutrophil is, or is in the process of becoming, a granular leucocyte having a nucleus with three to five lobes connected by threads of chromatin, cytoplasm containing very fine granules, and which is readily stainable with neutral dyes. Dani Welter true CMO:0000370 blood neutrophil count to total leukocyte count ratio neutrophil count as percentage of total white blood cells neutrophil count to total WBC count ratio neutrophil percentage neutrophil percentage of white cells neutrophil percentage of leukocytes efo:EFO_0007991 A calculated measurement in which the number of eosinophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. An eosinophil is a granular leukocyte having a nucleus with two lobes connected by a thread of chromatin, and cytoplasm containing coarse, round granules of uniform size that stain readily with eosin and other acid dyes. Dani Welter true CMO:0000369 blood eosinophil count to total leukocyte count ratio eosinophil count as percentage of total white blood cells eosinophil count to total WBC count ratio eosinophil percentage eosinophil percentage of white cells eosinophil percentage of leukocytes efo:EFO_0007992 A calculated measurement in which the number of basophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. A basophil is a granular leukocyte with an irregularly shaped, relatively pale-staining nucleus that is partially constricted into two lobes, and with cytoplasm containing coarse granules of variable size that stain bluish-black when exposed to basic dyes. Dani Welter true CMO:0000368 basophil count as percentage of total white blood cells basophil count to total WBC count ratio basophil percentage basophil percentage of white cells blood basophil count to total leukocyte count ratio basophil percentage of leukocytes efo:EFO_0007993 A calculated measurement in which the number of lymphocytes in a specified sample of blood is divided by the total number of white blood cells in the sample, and the result presented as a ratio, fraction, quotient or percentage. Dani Welter true CMO:0000371 blood lymphocyte count to total leukocyte count ratio lymphocyte count as percentage of total white blood cells lymphocyte count to total WBC count ratio lymphocyte percentage lymphocyte percentage of white cells lymphocyte percentage of leukocytes efo:EFO_0007994 A calculated measurement in which the number of neutrophil granulocytes is divided by the number of all granulocytes in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. Dani Welter true neutrophil percentage of granulocytes efo:EFO_0007995 A calculated measurement in which the number of basophil granulocytes is divided by the number of all granulocytes in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. Dani Welter true basophil percentage of granulocytes efo:EFO_0007996 A calculated measurement in which the number of eosinophil granulocytes is divided by the number of all granulocytes in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. Dani Welter true eosinophil percentage of granulocytes efo:EFO_0007997 A calculated measurement in which the number of granulocytes is divided by the number of all myeloid white cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. Dani Welter true granulocyte percentage of myeloid white cells efo:EFO_0007998 quantification of some aspect of cognitive impairment such as its severity or rate of progression Dani Welter true cognitive impairment measurement efo:EFO_0007999 quantification of the force that can be exerted by the lower body Dani Welter true lower body strength measurement efo:EFO_0008000 quantification of the time point at which insulin secretion is highest Dani Welter true peak insulin response measurement efo:EFO_0008001 Measurement of compounds, generally C-peptide or mature insulin, whose levels quantify insulin secretion from the pancreas. Dani Welter true http://orcid.org/0000-0001-9043-693X insulin secretion rate measurement insulin secretion measurement efo:EFO_0008002 quantification of some aspect of physical activity such as frequency or intensity Dani Welter true physical activity measurement efo:EFO_0008003 Quantification of heart rate variability, the physiological phenomenon of variation in the time interval between heartbeats. Dani Welter true heart rate variability measurement efo:EFO_0008004 quantification of an individual's resting metabolic rate, the minimum amount of energy required to sustain life during a time period of steady resting conditions. RMR differs from BMR because BMR measurements must meet total physiological equilibrium whereas RMR conditions of measurement can be altered and defined by the contextual limitations. Dani Welter true RMR measurement resting metabolic rate measurement efo:EFO_0008005 quantification of an individual's energy expenditure, generally considered to be the sum of internal heat produced and external work through physical activity Dani Welter true energy expenditure measurement efo:EFO_0008006 quantification of some aspect of skin aging such as wrinkling or photoaging. Skin aging can be assessed using teh 6-point Beagley and Gibson (BG6) microtopography scoring system of skin patterning regularity and complexity Dani Welter true skin aging measurement efo:EFO_0008007 The age of an individual at the time an assessment takes place Dani Welter true PMID:20634892 age at assessment efo:EFO_0008009 quantification of the amount of 1,5 anydroglucitol in a sample Dani Welter true 1,5 anhydroglucitol measurement efo:EFO_0008010 quantification of the amount of [Pyruvate dehydrogenase acetyl-transferring] kinase isozyme 1, mitochondrial in a sample Dani Welter true [Pyruvate dehydrogenase acetyl-transferring] kinase isozyme 1, mitochondrial measurement efo:EFO_0008011 quantification of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 13 in a sample Dani Welter true ADAMTS-13 measurement a disintegrin and metalloproteinase with thrombospondin motifs 13 measurement efo:EFO_0008012 quantification of the amount of Abelson tyrosine-protein kinase 2 in a sample Dani Welter true Abelson tyrosine-protein kinase 2 measurement efo:EFO_0008013 quantification of the amount of acid sphingomyelinase-like phosphodiesterase 3a in a sample Dani Welter true acid sphingomyelinase-like phosphodiesterase 3a measurement efo:EFO_0008014 quantification of the amount of ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 in a sample Dani Welter true ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 measurement efo:EFO_0008015 quantification of the amount of afamin in a sample Dani Welter true afamin measurement efo:EFO_0008016 quantification of the amount of Agouti-related protein in a sample Dani Welter true Agouti-related protein measurement efo:EFO_0008017 quantification of the amount of alcohol dehydrogenase [NADP+] in a sample Dani Welter true alcohol dehydrogenase [NADP+] measurement efo:EFO_0008018 quantification of the amount of alpha-1-antichymotrypsin complex in a sample Dani Welter true alpha-1-antichymotrypsin complex measurement efo:EFO_0008019 quantification of the amount of alpha-1-antichymotrypsin in a sample Dani Welter true alpha-1-antichymotrypsin measurement efo:EFO_0008020 quantification of the amount of alpha-2-HS-glycoprotein in a sample Dani Welter true fetuin-A protein measurement alpha-2-HS-glycoprotein measurement efo:EFO_0008021 quantification of the amount of alpha-2-macroglobulin receptor-associated protein in a sample Dani Welter true alpha-2-macroglobulin receptor-associated protein measurement efo:EFO_0008022 quantification of the amount of angiogenin in a sample Dani Welter true angiogenin measurement efo:EFO_0008023 quantification of the amount of angiopoietin-1 receptor, soluble in a sample Dani Welter true angiopoietin-1 receptor, soluble measurement efo:EFO_0008024 quantification of the amount of angiostatin in a sample Dani Welter true angiostatin measurement efo:EFO_0008025 quantification of the amount of angiotensinogen in a sample Dani Welter true angiotensinogen measurement efo:EFO_0008026 quantification of the amount of annexin A1 in a sample Dani Welter true annexin A1 measurement efo:EFO_0008027 quantification of the amount of annexin A2 in a sample Dani Welter true annexin A2 measurement efo:EFO_0008028 quantification of the amount of apolipoprotein E isoform E2 in a sample Dani Welter true apolipoprotein E isoform E2 measurement efo:EFO_0008029 quantification of the amount of apolipoprotein E in a sample Dani Welter true apolipoprotein E measurement efo:EFO_0008030 quantification of the amount of arylsulfatase B in a sample Dani Welter true arylsulfatase B measurement efo:EFO_0008031 quantification of the amount of aspartate aminotransferase, cytoplasmic in a sample Dani Welter true aspartate aminotransferase, cytoplasmic measurement efo:EFO_0008032 quantification of the amount of basal Cell Adhesion Molecule in a sample Dani Welter true basal cell adhesion molecule measurement efo:EFO_0008033 quantification of the amount of beta-Ala-His dipeptidase in a sample Dani Welter true beta-Ala-His dipeptidase measurement efo:EFO_0008034 quantification of the amount of beta-endorphin in a sample Dani Welter true beta-endorphin measurement efo:EFO_0008035 quantification of the amount of beta-nerve growth factor in a sample Dani Welter true beta-nerve growth factor measurement efo:EFO_0008036 fasting blood glucose measurement that has been adjusted for subjects' body mass index Dani Welter true BMI-adjusted fasting blood glucose measurement efo:EFO_0008037 fasting insulin measurement that has been adjusted for subjects' body mass index Dani Welter true BMI-adjusted fasting blood insulin measurement efo:EFO_0008038 hip bone size measurement that has been adjusted for subjects' body mass index Dani Welter true BMI-adjusted hip bone size efo:EFO_0008039 hip circumference measurement that has been adjusted for subjects' body mass index Dani Welter true BMI-adjusted hip circumference efo:EFO_0008040 quantification of the amount of breast cancer anti-estrogen resistance protein 3 in a sample Dani Welter true breast cancer anti-estrogen resistance protein 3 measurement efo:EFO_0008041 quantification of the amount of C-C motif chemokine 1 in a sample Dani Welter true C-C motif chemokine 1 measurement efo:EFO_0008042 quantification of the amount of C-C motif chemokine 14 in a sample Dani Welter true C-C motif chemokine 14 measurement efo:EFO_0008043 quantification of the amount of C-C motif chemokine 15 in a sample Dani Welter true C-C motif chemokine 15 measurement efo:EFO_0008044 quantification of the amount of C-C motif chemokine 16 in a sample Dani Welter true chemokine CC-4 (HCC-4) measurement C-C motif chemokine 16 measurement efo:EFO_0008045 quantification of the amount of C-C motif chemokine 17 in a sample Dani Welter true C-C motif chemokine 17 measurement efo:EFO_0008046 quantification of the amount of C-C motif chemokine 18 in a sample Dani Welter true pulmonary and activation-regulated chemokine (PARC) measurement C-C motif chemokine 18 measurement efo:EFO_0008047 quantification of the amount of C-C motif chemokine 19 in a sample Dani Welter true C-C motif chemokine 19 measurement efo:EFO_0008048 quantification of the amount of C-C motif chemokine 21 in a sample Dani Welter true C-C motif chemokine 21 measurement efo:EFO_0008049 quantification of the amount of C-C motif chemokine 23 in a sample Dani Welter true C-C motif chemokine 23 measurement efo:EFO_0008050 quantification of the amount of C-C motif chemokine 25 in a sample Dani Welter true C-C motif chemokine 25 measurement efo:EFO_0008051 quantification of the amount of C-C motif chemokine 3 in a sample Dani Welter true C-C motif chemokine 3 measurement efo:EFO_0008052 quantification of the amount of C-C motif chemokine 3-like 1 in a sample Dani Welter true C-C motif chemokine 3-like 1 measurement efo:EFO_0008053 quantification of the amount of C-C motif chemokine 5 in a sample Dani Welter true C-C motif chemokine 5 measurement efo:EFO_0008054 quantification of the amount of C-C motif chemokine 7 in a sample Dani Welter true C-C motif chemokine 7 measurement efo:EFO_0008055 quantification of the amount of C-C motif chemokine 8 in a sample Dani Welter true C-C motif chemokine 8 measurement efo:EFO_0008056 quantification of the amount of C-X-C motif chemokine 10 in a sample Dani Welter true IP-10 measurement IP10 measurement Interferon gamma-induced protein 10 measurement C-X-C motif chemokine 10 measurement efo:EFO_0008057 quantification of the amount of C-X-C motif chemokine 11 in a sample Dani Welter true C-X-C motif chemokine 11 measurement efo:EFO_0008058 quantification of the amount of C-X-C motif chemokine 5 in a sample Dani Welter true C-X-C motif chemokine 5 measurement efo:EFO_0008059 quantification of the amount of C-X-C motif chemokine 6 in a sample Dani Welter true C-X-C motif chemokine 6 measurement efo:EFO_0008060 quantification of the amount of cadherin-5 in a sample Dani Welter true cadherin-5 measurement efo:EFO_0008061 quantification of the amount of calcineurin in a sample Dani Welter true calcineurin measurement efo:EFO_0008062 quantification of the amount of calcium/calmodulin-dependent protein kinase type 1 in a sample Dani Welter true calcium/calmodulin-dependent protein kinase type 1 measurement efo:EFO_0008063 quantification of the amount of calcium/calmodulin-dependent protein kinase type 1D in a sample Dani Welter true calcium/calmodulin-dependent protein kinase type 1D measurement efo:EFO_0008064 quantification of the amount of calpain I in a sample Dani Welter true calpain I measurement efo:EFO_0008065 quantification of the amount of calpastatin in a sample Dani Welter true calpastatin measurement efo:EFO_0008066 quantification of the amount of carbohydrate sulfotransferase 15 in a sample Dani Welter true carbohydrate sulfotransferase 15 measurement efo:EFO_0008067 quantification of the amount of carbonic anhydrase 13 in a sample Dani Welter true carbonic anhydrase 13 measurement efo:EFO_0008068 quantification of the amount of carbonic anhydrase 6 in a sample Dani Welter true carbonic anhydrase 6 measurement efo:EFO_0008069 quantification of the amount of carboxypeptidase B2 in a sample Dani Welter true carboxypeptidase B2 measurement efo:EFO_0008070 quantification of the amount of caspase-3 in a sample Dani Welter true caspase-3 measurement efo:EFO_0008071 quantification of the amount of catalase in a sample Dani Welter true catalase measurement efo:EFO_0008072 quantification of the amount of cathepsin B in a sample Dani Welter true cathepsin B measurement efo:EFO_0008073 quantification of the amount of cathepsin S in a sample Dani Welter true cathepsin S measurement efo:EFO_0008074 quantification of the amount of cathepsin Z in a sample Dani Welter true cathepsin Z measurement efo:EFO_0008075 quantification of the amount of cation-independent mannose-6-phosphate receptor in a sample Dani Welter true cation-independent mannose-6-phosphate receptor measurement efo:EFO_0008076 quantification of the amount of CD109 antigen in a sample Dani Welter true CD109 antigen measurement efo:EFO_0008077 quantification of the amount of CD209 antigen in a sample Dani Welter true CD209 antigen measurement efo:EFO_0008078 quantification of the amount of CD27 antigen in a sample Dani Welter true CD27 antigen measurement efo:EFO_0008079 quantification of the amount of cell adhesion molecule-related/down-regulated by oncogenes in a sample Dani Welter true cell adhesion molecule-related/down-regulated by oncogenes measurement efo:EFO_0008080 quantification of the volume of cerebrospinal fluid in the brain, usually through an MRI scan Dani Welter true cerebrospinal fluid volume measurement efo:EFO_0008081 quantification of the amount of cGMP-specific 3',5'-cyclic phosphodiesterase in a sample Dani Welter true cGMP-specific 3',5'-cyclic phosphodiesterase measurement efo:EFO_0008082 quantification of the amount of chemokine (C-C motif) ligand 27 in a sample Dani Welter true chemokine (C-C motif) ligand 27 measurement efo:EFO_0008083 quantification of the amount of chemokine (C-X-C motif) ligand 1 in a sample Dani Welter true chemokine (C-X-C motif) ligand 1 measurement efo:EFO_0008084 quantification of the amount of chitotriosidase-1 in a sample Dani Welter true chitotriosidase-1 measurement efo:EFO_0008085 quantification of the amount of Ck-beta-8-1 in a sample Dani Welter true Ck-beta-8-1 measurement efo:EFO_0008086 quantification of the amount of CMRF35-like molecule 6 in a sample Dani Welter true CMRF35-like molecule 6 measurement efo:EFO_0008087 quantification of the amount of coagulation Factor V in a sample Dani Welter true coagulation factor V measurement efo:EFO_0008088 quantification of the amount of collectin-11 in a sample Dani Welter true collectin-11 measurement efo:EFO_0008089 quantification of the amount of complement C1q subcomponent in a sample Dani Welter true complement C1q subcomponent measurement efo:EFO_0008090 quantification of the amount of complement C1r subcomponent in a sample Dani Welter true complement C1r subcomponent measurement efo:EFO_0008091 quantification of the amount of complement C1s subcomponent in a sample Dani Welter true complement C1s subcomponent measurement efo:EFO_0008092 quantification of the amount of complement C4b in a sample Dani Welter true complement C4b measurement efo:EFO_0008093 quantification of the amount of complement component C7 in a sample Dani Welter true complement component C7 measurement efo:EFO_0008094 quantification of the amount of complement component C8 in a sample Dani Welter true complement component C8 measurement efo:EFO_0008095 quantification of the amount of complement decay-accelerating factor in a sample Dani Welter true complement decay-accelerating factor measurement efo:EFO_0008096 quantification of the amount of complement factor B in a sample Dani Welter true complement factor B measurement efo:EFO_0008097 quantification of the amount of complement factor H in a sample Dani Welter true complement factor H measurement efo:EFO_0008098 quantification of the amount of complement factor H-related protein 5 in a sample Dani Welter true complement factor H-related protein 5 measurement efo:EFO_0008099 quantification of the amount of complement factor I in a sample Dani Welter true complement factor I measurement efo:EFO_0008100 quantification of the amount of contactin-2 in a sample Dani Welter true contactin-2 measurement efo:EFO_0008101 quantification of the amount of contactin-5 in a sample Dani Welter true contactin-5 measurement efo:EFO_0008102 quantification of the amount of copine-1 in a sample Dani Welter true copine-1 measurement efo:EFO_0008103 quantification of the amount of cystatin-D in a sample Dani Welter true cystatin-D measurement efo:EFO_0008104 quantification of the amount of cystatin-F in a sample Dani Welter true cystatin-F measurement efo:EFO_0008105 quantification of the amount of cystatin-SA in a sample Dani Welter true cystatin-SA measurement efo:EFO_0008106 quantification of the amount of cystatin-SN in a sample Dani Welter true cystatin-SN measurement efo:EFO_0008107 quantification of the amount of death-associated protein kinase 2 in a sample Dani Welter true death-associated protein kinase 2 measurement efo:EFO_0008108 quantification of the amount of dermatopontin in a sample Dani Welter true dermatopontin measurement efo:EFO_0008109 quantification of the amount of Dickkopf-related protein 3 in a sample Dani Welter true Dickkopf-related protein 3 measurement efo:EFO_0008110 quantification of the amount of Dickkopf-related protein 4 in a sample Dani Welter true Dickkopf-related protein 4 measurement efo:EFO_0008111 quantification of some aspect of diet, including diet patterns, balance of nutrient consumption and glycemic load Dani Welter true diet measurement efo:EFO_0008112 quantification of the amount of dual specificity mitogen-activated protein kinase kinase 2 in a sample Dani Welter true dual specificity mitogen-activated protein kinase kinase 2 measurement efo:EFO_0008113 quantification of the amount of dual specificity mitogen-activated protein kinase kinase 4 in a sample Dani Welter true dual specificity mitogen-activated protein kinase kinase 4 measurement efo:EFO_0008114 quantification of the amount of dynein light chain roadblock-type 1 in a sample Dani Welter true dynein light chain roadblock-type 1 measurement efo:EFO_0008115 quantification of the amount of ectonucleoside triphosphate diphosphohydrolase 5 in a sample Dani Welter true ectonucleoside triphosphate diphosphohydrolase 5 measurement efo:EFO_0008116 quantification of the amount of EGF-like module-containing mucin-like hormone receptor-like 2 in a sample Dani Welter true EGF-like module-containing mucin-like hormone receptor-like 2 measurement efo:EFO_0008117 quantification of the amount of elafin in a sample Dani Welter true elafin measurement efo:EFO_0008118 quantification of the amount of endoglin in a sample Dani Welter true endoglin measurement efo:EFO_0008119 quantification of the amount of endoplasmic reticulum aminopeptidase 1 in a sample Dani Welter true endoplasmic reticulum aminopeptidase 1 measurement efo:EFO_0008120 quantification of the amount of endothelial cell-selective adhesion molecule in a sample Dani Welter true endothelial cell-selective adhesion molecule measurement efo:EFO_0008121 quantification of the amount of endothelin-converting enzyme 1 in a sample Dani Welter true endothelin-converting enzyme 1 measurement efo:EFO_0008122 quantification of the amount of eotaxin in a sample Dani Welter true eotaxin measurement efo:EFO_0008123 quantification of the amount of ephrin type-A receptor 1 in a sample Dani Welter true ephrin type-A receptor 1 measurement efo:EFO_0008124 quantification of the amount of ephrin type-B receptor 2 in a sample Dani Welter true ephrin type-B receptor 2 measurement efo:EFO_0008125 quantification of the amount of estrogen receptor in a sample Dani Welter true estrogen receptor measurement efo:EFO_0008126 quantification of the amount of extracellular matrix protein 1 in a sample Dani Welter true extracellular matrix protein 1 measurement efo:EFO_0008127 quantification of the amount of Fc receptor-like protein 3 in a sample Dani Welter true Fc receptor-like protein 3 measurement efo:EFO_0008128 quantification of the amount of fetuin-B in a sample Dani Welter true fetuin-B measurement efo:EFO_0008129 quantification of the amount of fibroblast growth factor 2 in a sample Dani Welter true fibroblast growth factor 2 measurement efo:EFO_0008130 quantification of the amount of fibroblast growth factor basic in a sample Dani Welter true fibroblast growth factor basic measurement efo:EFO_0008131 quantification of the amount of fibronectin Fragment 3 in a sample Dani Welter true fibronectin fragment 3 measurement efo:EFO_0008132 quantification of the amount of fibronectin Fragment 4 in a sample Dani Welter true fibronectin fragment 4 measurement efo:EFO_0008133 quantification of the amount of fibronectin in a sample Dani Welter true fibronectin measurement efo:EFO_0008134 quantification of the amount of ficolin-1 in a sample Dani Welter true ficolin-1 measurement efo:EFO_0008135 quantification of the amount of ficolin-2 in a sample Dani Welter true ficolin-2 measurement efo:EFO_0008136 quantification of the amount of galactoside 34-L-fucosyltransferase in a sample Dani Welter true galactoside 34-L-fucosyltransferase measurement efo:EFO_0008137 quantification of the amount of galectin-3 in a sample Dani Welter true galectin-3 measurement efo:EFO_0008138 quantification of the amount of GDNF family receptor alpha-2 in a sample Dani Welter true GDNF family receptor alpha-2 measurement efo:EFO_0008139 quantification of the amount of glypican-5 in a sample Dani Welter true glypican-5 measurement efo:EFO_0008140 quantification of the amount of gp41 C34 peptide, HIV in a sample Dani Welter true gp41 C34 peptide, HIV measurement efo:EFO_0008141 quantification of the amount of granulins in a sample Dani Welter true granulins measurement efo:EFO_0008142 quantification of the amount of granulocyte colony-stimulating factor in a sample Dani Welter true granulocyte colony-stimulating factor measurement efo:EFO_0008144 quantification of the amount of granulysin in a sample Dani Welter true granulysin measurement efo:EFO_0008145 quantification of the amount of granzyme A in a sample Dani Welter true granzyme A measurement efo:EFO_0008146 quantification of the amount of growth-regulated alpha protein in a sample Dani Welter true growth-regulated alpha protein measurement efo:EFO_0008148 quantification of the amount of hemojuvelin in a sample Dani Welter true hemojuvelin measurement efo:EFO_0008149 quantification of the amount of hemopexin in a sample Dani Welter true hemopexin measurement efo:EFO_0008150 quantification of the amount of heparin cofactor 2 in a sample Dani Welter true heparin cofactor 2 measurement efo:EFO_0008151 quantification of the amount of hepatitis A virus cellular receptor 2 in a sample Dani Welter true hepatitis A virus cellular receptor 2 measurement efo:EFO_0008152 quantification of the amount of hepatocyte growth factor activator in a sample Dani Welter true hepatocyte growth factor activator measurement efo:EFO_0008153 quantification of the amount of hepatocyte growth factor receptor in a sample Dani Welter true hepatocyte growth factor receptor measurement efo:EFO_0008154 quantification of the amount of hepatocyte growth factor-like protein in a sample Dani Welter true macrophage-stimulating protein (MSP) measurement hepatocyte growth factor-like protein measurement efo:EFO_0008155 quantification of the amount of histidine-rich glycoprotein in a sample Dani Welter true histidine-rich glycoprotein measurement efo:EFO_0008156 quantification of the amount of human Chorionic Gonadotropin in a sample Dani Welter true human Chorionic Gonadotropin measurement efo:EFO_0008157 quantification of the amount of inorganic pyrophosphatase in a sample Dani Welter true inorganic pyrophosphatase measurement efo:EFO_0008158 quantification of the amount of inosine-5'-monophosphate dehydrogenase 1 in a sample Dani Welter true inosine-5'-monophosphate dehydrogenase 1 measurement efo:EFO_0008159 quantification of the amount of inosine-5'-monophosphate dehydrogenase 2 in a sample Dani Welter true inosine-5'-monophosphate dehydrogenase 2 measurement efo:EFO_0008160 quantification of the amount of insulin receptor in a sample Dani Welter true insulin receptor measurement efo:EFO_0008161 quantification of the amount of insulin-like growth factor-binding protein 7 in a sample Dani Welter true insulin-like growth factor-binding protein 7 measurement efo:EFO_0008162 quantification of the amount of integrin alpha-I: beta-1 complex in a sample Dani Welter true integrin alpha-I: beta-1 complex measurement efo:EFO_0008163 quantification of the amount of intercellular adhesion molecule 2 in a sample Dani Welter true intercellular adhesion molecule 2 measurement efo:EFO_0008164 quantification of the amount of intercellular adhesion molecule 5 in a sample Dani Welter true intercellular adhesion molecule 5 measurement efo:EFO_0008165 quantification of the amount of interferon gamma in a sample Dani Welter true interferon gamma measurement efo:EFO_0008167 quantification of the amount of interleukin 1 Receptor accessory protein in a sample Dani Welter true interleukin 1 Receptor accessory protein measurement efo:EFO_0008168 quantification of the amount of interleukin 1 receptor-like 1 in a sample Dani Welter true interleukin 1 receptor-like 1 measurement efo:EFO_0008169 quantification of the amount of interleukin 1 receptor-like 2 in a sample Dani Welter true interleukin 1 receptor-like 2 measurement efo:EFO_0008170 quantification of the amount of interleukin 12 receptor subunit beta-1 in a sample Dani Welter true interleukin 12 receptor subunit beta-1 measurement efo:EFO_0008171 quantification of the amount of interleukin 13 in a sample Dani Welter true interleukin 13 measurement efo:EFO_0008172 quantification of the amount of interleukin 15 receptor subunit alpha in a sample Dani Welter true interleukin 15 receptor subunit alpha measurement efo:EFO_0008173 quantification of the amount of interleukin 16 in a sample Dani Welter true interleukin 16 measurement efo:EFO_0008174 quantification of the amount of interleukin 17 in a sample Dani Welter true interleukin 17 measurement efo:EFO_0008175 quantification of the amount of interleukin 17 receptor A in a sample Dani Welter true interleukin 17 receptor A measurement efo:EFO_0008176 quantification of the amount of interleukin 17 receptor B in a sample Dani Welter true interleukin 17 receptor B measurement efo:EFO_0008177 quantification of the amount of interleukin 17 receptor D in a sample Dani Welter true interleukin 17 receptor D measurement efo:EFO_0008178 quantification of the amount of interleukin 18 receptor 1 in a sample Dani Welter true interleukin 18 receptor 1 measurement efo:EFO_0008179 quantification of the amount of interleukin 18 receptor accessory protein in a sample Dani Welter true interleukin 18 receptor accessory protein measurement efo:EFO_0008180 quantification of the amount of interleukin 19 in a sample Dani Welter true interleukin 19 measurement efo:EFO_0008181 quantification of the amount of interleukin 23 receptor in a sample Dani Welter true interleukin 23 receptor measurement efo:EFO_0008182 quantification of the amount of interleukin 25 in a sample Dani Welter true interleukin 25 measurement efo:EFO_0008183 quantification of the amount of interleukin 27 receptor subunit alpha in a sample Dani Welter true interleukin 27 receptor subunit alpha measurement efo:EFO_0008184 quantification of the amount of interleukin 4 in a sample Dani Welter true interleukin 4 measurement efo:EFO_0008185 quantification of the amount of interleukin 5 in a sample Dani Welter true interleukin 5 measurement efo:EFO_0008186 quantification of the amount of interleukin 5 receptor subunit alpha in a sample Dani Welter true interleukin 5 receptor subunit alpha measurement efo:EFO_0008187 quantification of the amount of interleukin 6 receptor subunit alpha in a sample Dani Welter true interleukin 6 receptor subunit alpha measurement efo:EFO_0008188 quantification of the amount of interleukin 6 receptor subunit beta in a sample Dani Welter true interleukin 6 receptor subunit beta measurement efo:EFO_0008189 quantification of the amount of interleukin 7 in a sample Dani Welter true interleukin 7 measurement efo:EFO_0008190 quantification of the amount of interleukin 7 receptor subunit alpha in a sample Dani Welter true interleukin 7 receptor subunit alpha measurement efo:EFO_0008191 quantification of the amount of interleukin 8 in a sample Dani Welter true interleukin 8 measurement efo:EFO_0008192 quantification of the amount of interleukin 9 in a sample Dani Welter true interleukin 9 measurement efo:EFO_0008193 quantification of the amount of interstitial collagenase in a sample Dani Welter true interstitial collagenase measurement efo:EFO_0008194 quantification of the amount of kallikrein-12 in a sample Dani Welter true kallikrein-12 measurement efo:EFO_0008195 quantification of the amount of kallikrein-7 in a sample Dani Welter true kallikrein-7 measurement efo:EFO_0008196 quantification of the amount of kallistatin in a sample Dani Welter true kallistatin measurement efo:EFO_0008197 quantification of the amount of killer cell immunoglobulin-like receptor 2DL4 in a sample Dani Welter true killer cell immunoglobulin-like receptor 2DL4 measurement efo:EFO_0008198 quantification of the amount of kininogen-1 in a sample Dani Welter true kininogen-1 measurement efo:EFO_0008199 quantification of the amount of Kunitz-type protease inhibitor 1 in a sample Dani Welter true Kunitz-type protease inhibitor 1 measurement efo:EFO_0008200 quantification of the amount of Kunitz-type protease inhibitor 2 in a sample Dani Welter true Kunitz-type protease inhibitor 2 measurement efo:EFO_0008201 quantification of the amount of kynureninase in a sample Dani Welter true kynureninase measurement efo:EFO_0008202 quantification of the amount of L-Selectin in a sample Dani Welter true L-Selectin measurement efo:EFO_0008203 quantification of the amount of lactadherin in a sample Dani Welter true lactadherin measurement efo:EFO_0008204 quantification of some aspect of the diastolic function of the left cardiac ventricle such as peak velocity of mitral waves, isovolumetric relaxation time or diastolic dysfunction with preserved ejection fraction Dani Welter true left ventricular diastolic function measurement efo:EFO_0008205 quantification of some aspect of the structure of the left cardiac ventricle such as wall thickness, mass or atrial atero-posterior diameter Dani Welter true left ventricular structural measurement efo:EFO_0008206 quantification of some aspect of the systolic function of the left cardiac ventricle such as ventricular fractional shortening or systolic dysfunction Dani Welter true left ventricular systolic function measurement efo:EFO_0008207 quantification of the amount of leucine carboxyl methyltransferase 1 in a sample Dani Welter true leucine carboxyl methyltransferase 1 measurement efo:EFO_0008208 quantification of the amount of leukocyte immunoglobulin-like receptor subfamily B member 1 in a sample Dani Welter true leukocyte immunoglobulin-like receptor subfamily B member 1 measurement efo:EFO_0008209 quantification of the amount of leukocyte immunoglobulin-like receptor subfamily B member 2 in a sample Dani Welter true leukocyte immunoglobulin-like receptor subfamily B member 2 measurement efo:EFO_0008210 quantification of the amount of low affinity immunoglobulin epsilon Fc receptor in a sample Dani Welter true low affinity immunoglobulin epsilon Fc receptor measurement efo:EFO_0008211 quantification of the amount of low affinity immunoglobulin gamma Fc region receptor II-a/b in a sample Dani Welter true low affinity immunoglobulin gamma Fc region receptor II-a/b measurement efo:EFO_0008212 quantification of the amount of low affinity immunoglobulin gamma Fc region receptor III-B in a sample Dani Welter true low affinity immunoglobulin gamma Fc region receptor III-B measurement efo:EFO_0008213 quantification of the amount of low molecular weight phosphotyrosine protein phosphatase in a sample Dani Welter true low molecular weight phosphotyrosine protein phosphatase measurement efo:EFO_0008214 quantification of the amount of lymphotactin in a sample Dani Welter true lymphotactin measurement efo:EFO_0008215 quantification of the amount of lysosomal protective protein in a sample Dani Welter true lysosomal protective protein measurement efo:EFO_0008216 quantification of the amount of lysozyme C in a sample Dani Welter true lysozyme C measurement efo:EFO_0008217 quantification of the amount of macrophage colony stimulating factor in a sample Dani Welter true macrophage colony stimulating factor measurement efo:EFO_0008218 quantification of the amount of macrophage inflammatory protein 1a in a sample Dani Welter true macrophage inflammatory protein 1a measurement efo:EFO_0008219 quantification of the amount of macrophage inflammatory protein 1b in a sample Dani Welter true macrophage inflammatory protein 1b measurement efo:EFO_0008220 quantification of the amount of macrophage metalloelastase in a sample Dani Welter true macrophage metalloelastase measurement efo:EFO_0008221 quantification of the amount of macrophage migration inhibitory factor in a sample Dani Welter true macrophage migration inhibitory factor measurement efo:EFO_0008222 quantification of the amount of macrophage scavenger receptor types I and II in a sample Dani Welter true macrophage scavenger receptor types I and II measurement efo:EFO_0008223 quantification of the amount of mannan-binding lectin serine protease 1 in a sample Dani Welter true mannan-binding lectin serine protease 1 measurement efo:EFO_0008224 quantification of the amount of mannose-binding protein C in a sample Dani Welter true mannose-binding protein C measurement efo:EFO_0008225 quantification of the amount of MAP kinase-activated protein kinase 2 in a sample Dani Welter true MAP kinase-activated protein kinase 2 measurement efo:EFO_0008226 quantification of the amount of MAP kinase-activated protein kinase 3 in a sample Dani Welter true MAP kinase-activated protein kinase 3 measurement efo:EFO_0008227 quantification of the amount of matrilysin in a sample Dani Welter true matrilysin measurement efo:EFO_0008228 quantification of the amount of mediator of RNA polymerase II transcription subunit 1 in a sample Dani Welter true mediator of RNA polymerase II transcription subunit 1 measurement efo:EFO_0008229 quantification of the amount of melanoma-derived growth regulatory protein in a sample Dani Welter true melanoma-derived growth regulatory protein measurement efo:EFO_0008230 quantification of some aspect of mental development, including cognition, expressive language and receptive language Dani Welter true mental development measurement efo:EFO_0008231 quantification of the amount of metalloproteinase inhibitor 3 in a sample Dani Welter true metalloproteinase inhibitor 3 measurement efo:EFO_0008232 quantification of the amount of methionine aminopeptidase 2 in a sample Dani Welter true methionine aminopeptidase 2 measurement efo:EFO_0008233 quantification of the amount of MHC class I polypeptide-related sequence A in a sample Dani Welter true MHC class I polypeptide-related sequence A measurement efo:EFO_0008234 quantification of the amount of MHC class I polypeptide-related sequence B in a sample Dani Welter true MHC class I polypeptide-related sequence B measurement efo:EFO_0008235 quantification of the amount of monocyte chemotactic protein 3 in a sample Dani Welter true CCL7 measurement monocyte chemotactic protein 3 measurement efo:EFO_0008236 quantification of the amount of monokine induced by gamma interferon in a sample Dani Welter true monokine induced by gamma interferon measurement efo:EFO_0008237 quantification of some aspect of motor development, including fine and gross motor skills Dani Welter true motor development measurement efo:EFO_0008238 quantification of the amount of myeloid cell surface antigen CD33 in a sample Dani Welter true myeloid cell surface antigen CD33 measurement efo:EFO_0008239 quantification of the amount of N-acetyl-D-glucosamine kinase in a sample Dani Welter true N-acetyl-D-glucosamine kinase measurement efo:EFO_0008240 quantification of the amount of N-acylethanolamine-hydrolyzing acid amidase in a sample Dani Welter true N-acylethanolamine-hydrolyzing acid amidase measurement efo:EFO_0008241 quantification of the amount of NAD-dependent protein deacetylase sirtuin-2 in a sample Dani Welter true NAD-dependent protein deacetylase sirtuin-2 measurement efo:EFO_0008242 quantification of the amount of NADPH--cytochrome P450 reductase in a sample Dani Welter true NADPH--cytochrome P450 reductase measurement efo:EFO_0008243 quantification of the amount of natural cytotoxicity triggering receptor 3 in a sample Dani Welter true natural cytotoxicity triggering receptor 3 measurement efo:EFO_0008244 quantification of the amount of neurexophilin-1 in a sample Dani Welter true neurexophilin-1 measurement efo:EFO_0008245 quantification of some aspect of neurodevelopment, such as language development or fine motor skills development. Neurodevelopment scores can used as an indicator of neurodevelopmental delays. Dani Welter neurodevelopmental measurement efo:EFO_0008246 quantification of the amount of neurogenic locus notch homolog protein 1 in a sample Dani Welter true neurogenic locus notch homolog protein 1 measurement efo:EFO_0008247 quantification of the amount of neutral ceramidase in a sample Dani Welter true neutral ceramidase measurement efo:EFO_0008248 quantification of the amount of neutrophil collagenase in a sample Dani Welter true neutrophil collagenase measurement efo:EFO_0008249 quantification of the amount of nidogen-1 in a sample Dani Welter true nidogen-1 measurement efo:EFO_0008250 quantification of the amount of NKG2-D type II integral membrane protein in a sample Dani Welter true NKG2-D type II integral membrane protein measurement efo:EFO_0008251 quantification of the amount of non-receptor tyrosine-protein kinase TYK2 in a sample Dani Welter true non-receptor tyrosine-protein kinase TYK2 measurement efo:EFO_0008252 quantification of the amount of OCIA domain-containing protein 1 in a sample Dani Welter true OCIA domain-containing protein 1 measurement efo:EFO_0008253 quantification of the amount of OX-2 membrane glycoprotein in a sample Dani Welter true OX-2 membrane glycoprotein measurement efo:EFO_0008254 quantification of the amount of P-Selectin in a sample Dani Welter true P-Selectin measurement efo:EFO_0008255 quantification of some aspect of particulate matter air pollution, such as daily levels of exposure Dani Welter true particulate matter air pollution measurement efo:EFO_0008256 quantification of the amount of peptidyl-prolyl cis-trans isomerase D in a sample Dani Welter true peptidyl-prolyl cis-trans isomerase D measurement efo:EFO_0008257 quantification of the amount of peptidyl-prolyl cis-trans isomerase E in a sample Dani Welter true peptidyl-prolyl cis-trans isomerase E measurement efo:EFO_0008258 quantification of the amount of persulfide dioxygenase ETHE1, mitochondrial in a sample Dani Welter true persulfide dioxygenase ETHE1, mitochondrial measurement efo:EFO_0008259 quantification of the amount of phospholipase A2, membrane associated in a sample Dani Welter true phospholipase A2, membrane associated measurement efo:EFO_0008260 quantification of the amount of plasma kallikrein in a sample Dani Welter true plasma kallikrein measurement efo:EFO_0008261 quantification of the amount of plasma protease C1 inhibitor in a sample Dani Welter true plasma protease C1 inhibitor measurement efo:EFO_0008262 quantification of the amount of platelet glycoprotein 4 in a sample Dani Welter true platelet glycoprotein 4 measurement efo:EFO_0008263 quantification of the amount of platelet glycoprotein VI in a sample Dani Welter true platelet glycoprotein VI measurement efo:EFO_0008264 quantification of the amount of platelet-derived growth factor BB in a sample Dani Welter true platelet-derived growth factor BB measurement efo:EFO_0008265 quantification of the amount of platelet-derived growth factor receptor beta in a sample Dani Welter true platelet-derived growth factor receptor beta measurement efo:EFO_0008266 quantification of the amount of plexin-C1 in a sample Dani Welter true plexin-C1 measurement efo:EFO_0008267 quantification of the amount of polymeric immunoglobulin receptor in a sample Dani Welter true polymeric immunoglobulin receptor measurement efo:EFO_0008268 quantification of the amount of programmed cell death 1 ligand 2 in a sample Dani Welter true programmed cell death 1 ligand 2 measurement efo:EFO_0008269 quantification of the amount of properdin in a sample Dani Welter true properdin measurement efo:EFO_0008270 quantification of the amount of proprotein convertase subtilisin/kexin type 7 in a sample Dani Welter true proprotein convertase subtilisin/kexin type 7 measurement efo:EFO_0008271 quantification of the amount of protein jagged-1 in a sample Dani Welter true protein jagged-1 measurement efo:EFO_0008272 quantification of the amount of proto-oncogene tyrosine-protein kinase receptor Ret in a sample Dani Welter true proto-oncogene tyrosine-protein kinase receptor Ret measurement efo:EFO_0008273 quantification of the amount of repulsive guidance molecule A in a sample Dani Welter true repulsive guidance molecule A measurement efo:EFO_0008274 quantification of the amount of retinoic acid receptor responder protein 2 in a sample Dani Welter true retinoic acid receptor responder protein 2 measurement efo:EFO_0008275 quantification of the amount of S-formylglutathione hydrolase in a sample Dani Welter true S-formylglutathione hydrolase measurement efo:EFO_0008276 quantification of the amount of scavenger receptor class F member 1 in a sample Dani Welter true scavenger receptor class F member 1 measurement efo:EFO_0008277 quantification of the amount of Secreted frizzled-related protein 3 in a sample Dani Welter true Secreted frizzled-related protein 3 measurement efo:EFO_0008278 quantification of the amount of semaphorin-3A in a sample Dani Welter true semaphorin-3A measurement efo:EFO_0008279 quantification of the amount of semaphorin-3E in a sample Dani Welter true semaphorin-3E measurement efo:EFO_0008280 quantification of the amount of serine protease 27 in a sample Dani Welter true serine protease 27 measurement efo:EFO_0008281 quantification of the amount of serine/threonine-protein kinase 17B in a sample Dani Welter true serine/threonine-protein kinase 17B measurement efo:EFO_0008282 quantification of the amount of serum amyloid A-1 protein in a sample Dani Welter true serum amyloid A-1 protein measurement efo:EFO_0008283 quantification of the amount of serum amyloid P-component in a sample Dani Welter true serum amyloid P-component measurement efo:EFO_0008284 quantification of the amount of sialic acid-binding Ig-like lectin 14 in a sample Dani Welter true sialic acid-binding Ig-like lectin 14 measurement efo:EFO_0008285 quantification of the amount of sialic acid-binding Ig-like lectin 6 in a sample Dani Welter true sialic acid-binding Ig-like lectin 6 measurement efo:EFO_0008286 quantification of the amount of sialic acid-binding Ig-like lectin 9 in a sample Dani Welter true sialic acid-binding Ig-like lectin 9 measurement efo:EFO_0008287 quantification of the amount of SLAM family member 7 in a sample Dani Welter true SLAM family member 7 measurement efo:EFO_0008288 quantification of the amount of small nuclear ribonucleoprotein F in a sample Dani Welter true small nuclear ribonucleoprotein F measurement efo:EFO_0008289 quantification of the amount of SPARC-like protein 1 in a sample Dani Welter true SPARC-like protein 1 measurement efo:EFO_0008290 quantification of the amount of spondin-1 in a sample Dani Welter true spondin-1 measurement efo:EFO_0008291 quantification of the amount of stem Cell Factor in a sample Dani Welter true stem Cell Factor measurement efo:EFO_0008292 quantification of the amount of stem Cell Growth Factor beta in a sample Dani Welter true stem Cell Growth Factor beta measurement efo:EFO_0008293 quantification of the amount of stromal cell-derived factor 1 alpha in a sample Dani Welter true stromal cell-derived factor 1 alpha measurement efo:EFO_0008294 quantification of the amount of superoxide dismutase [Mn], mitochondrial in a sample Dani Welter true superoxide dismutase [Mn], mitochondrial measurement efo:EFO_0008295 quantification of the amount of T-lymphocyte surface antigen Ly-9 in a sample Dani Welter true T-lymphocyte surface antigen Ly-9 measurement efo:EFO_0008296 quantification of the amount of tenascin in a sample Dani Welter true tenascin measurement efo:EFO_0008297 quantification of the amount of teratocarcinoma-derived growth factor 1 in a sample Dani Welter true teratocarcinoma-derived growth factor 1 measurement efo:EFO_0008298 quantification of the amount of thioredoxin domain-containing protein 12 in a sample Dani Welter true thioredoxin domain-containing protein 12 measurement efo:EFO_0008299 quantification of the amount of thrombospondin-2 in a sample Dani Welter true thrombospondin-2 measurement efo:EFO_0008300 quantification of the amount of TNF-related apoptosis-inducing ligand in a sample Dani Welter true TNF-related apoptosis-inducing ligand measurement efo:EFO_0008301 quantification of the amount of toll-like receptor 4:Lymphocyte antigen 96 complex in a sample Dani Welter true toll-like receptor 4:Lymphocyte antigen 96 complex measurement efo:EFO_0008302 quantification of the amount of transforming growth factor-beta-induced protein ig-h3 in a sample Dani Welter true transforming growth factor-beta-induced protein ig-h3 measurement efo:EFO_0008303 quantification of the amount of transmembrane glycoprotein NMB in a sample Dani Welter true transmembrane glycoprotein NMB measurement efo:EFO_0008304 quantification of the amount of trefoil factor 3 in a sample Dani Welter true trefoil factor 3 measurement efo:EFO_0008305 quantification of the amount of trypsin-2 in a sample Dani Welter true trypsin-2 measurement efo:EFO_0008306 quantification of the amount of tryptase beta-2 in a sample Dani Welter true tryptase beta-2 measurement efo:EFO_0008307 quantification of the severity of the skin reaction in response to the injection of TB antigen Dani Welter true TST reactivity measurement tuberculin skin test reactivity measurement efo:EFO_0008308 quantification of the amount of tumor necrosis factor beta in a sample Dani Welter true tumor necrosis factor beta measurement efo:EFO_0008309 quantification of the amount of tumor necrosis factor receptor superfamily member 19L in a sample Dani Welter true tumor necrosis factor receptor superfamily member 19L measurement efo:EFO_0008310 quantification of the amount of tumor necrosis factor receptor superfamily member EDAR in a sample Dani Welter true tumor necrosis factor receptor superfamily member EDAR measurement efo:EFO_0008311 quantification of the amount of tumor necrosis factor-inducible gene 6 protein in a sample Dani Welter true tumor necrosis factor-inducible gene 6 protein measurement efo:EFO_0008312 quantification of the amount of tyrosine-protein kinase receptor Tie-1, soluble in a sample Dani Welter true tyrosine-protein kinase receptor Tie-1, soluble measurement efo:EFO_0008313 quantification of the amount of UMP-CMP kinase in a sample Dani Welter true UMP-CMP kinase measurement efo:EFO_0008314 quantification of the amount of vascular endothelial growth factor receptor 2 in a sample Dani Welter true vascular endothelial growth factor receptor 2 measurement efo:EFO_0008315 quantification of the amount of vascular endothelial growth factor receptor 3 in a sample Dani Welter true vascular endothelial growth factor receptor 3 measurement efo:EFO_0008316 quantification of some aspect of vaso-occlusive pain, or vas-occlusive crises, such as severity or frequency of occurences Dani Welter true vaso-occlusive pain measurement efo:EFO_0008317 quantification of the amount of very low density lipoprotein cholesterol in a sample Dani Welter true vLDL cholesterol measurement very low density lipoprotein cholesterol measurement efo:EFO_0008318 quantification of the amount of vitamin K-dependent protein C in a sample Dani Welter true vitamin K-dependent protein C measurement efo:EFO_0008319 quantification of the amount of WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 in a sample Dani Welter true WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 measurement efo:EFO_0008320 quantification of the volume of white matter in the brain, usually through an MRI scan Dani Welter true white matter volume measurement efo:EFO_0008321 quantification of the amount of WNT1-inducible-signaling pathway protein 1 in a sample Dani Welter true WNT1-inducible-signaling pathway protein 1 measurement efo:EFO_0008326 quantification of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 5 in a sample Dani Welter true ADAMTS5 measurement a disintegrin and metalloproteinase with thrombospondin motifs 5 measurement efo:EFO_0008327 quantification of the amount of alpha-1-antitrypsin in a sample Dani Welter true alpha-1-antitrypsin measurement efo:EFO_0008328 quantification of some aspect of chronotype such as ease of getting up in the morning Dani Welter true chronotype measurement efo:EFO_0008329 quantification of some aspect of facial emotion recognition such as ability to differentiate between different emotions Dani Welter true facial emotion recognition measurement efo:EFO_0008330 quantification of some aspect of fear of pain, generallly through the use of a structured questionnaire Dani Welter true PMID:28701861 fear of pain measurement efo:EFO_0008331 quantification of the amount of interleukin 2 in a sample Dani Welter true interleukin 2 measurement efo:EFO_0008332 quantification of the amount of interleukin 2 receptor antagonist in a sample Dani Welter true interleukin 2 receptor antagonist measurement efo:EFO_0008333 quantification of the magnitude of the T wave, the part of the electrocardiograph that represents the repolarisation or recovery of the ventricles Dani Welter true T wave amplitude efo:EFO_0008334 quantification of the duration of the T wave from its peak to its end Dani Welter true T weave peak to T wave end measurement TpTe measurement efo:EFO_0008335 quantification of the duration of ventricular repolarisation or a change therein Dani Welter true ventricular repolarisation duration measurement efo:EFO_0008336 quantification of some aspect of disease progression such as speed or symptom variability. Disease progression can be quantified in a number of ways, for example as a correlated measure of progression scores from different symptom areas Dani Welter true PMID:28642124 disease progression measurement efo:EFO_0008337 quantification of the level of an individual's predisposition of a psychotic disorder, based on a range of psychometric measures such as Hypomanic Personality, Perceptual Aberration, Physical and Social Anhedonia (also known as Chapman’s Schizotypia scales), and Schizoidia scales. Dani Welter true PMID:28525603 psychosis predisposition measurement efo:EFO_0008338 quantification of some aspect of fear of severe pain, generallly assessed through the use of a structured questionnaire Dani Welter true PMID:28701861 fear of severe pain measurement efo:EFO_0008339 quantification of some aspect of fear of pain related to medical treatments such as dental treatments. FoP is generallly assessed through the use of a structured questionnaire Dani Welter true PMID:28701861 fear of medical pain measurement efo:EFO_0008340 quantification of some aspect of fear of minor pain, generally assessed through the use of a structured questionnaire Dani Welter true PMID:28701861 fear of minor pain measurement efo:EFO_0008341 quantification of some aspect of snoring such as frequency or severity Dani Welter true PMID:28604731 snoring measurement efo:EFO_0008342 quantification of some aspect parental emotion expression, such as the level of warmth expressed by a parent towards a child or the amount of criticism directed by a parent at a child. Emotion expression is evaluated by qualified professionals on the basis of parental responses during the clinical assessment Dani Welter true PMID:18846501 parental emotion expression measurmement efo:EFO_0008343 quantification of the interaction between some phenotype and biological sex Dani Welter true PMID:21253498 sex interaction measurement efo:EFO_0008350 quantification of the amount of alpha-linoleic acid in a sample Dani Welter true alpha-linoleic acid measurement efo:EFO_0008351 quantification of some aspect of the deposition of amyloid proteins in an organ Dani Welter amyloid deposition measurement efo:EFO_0008352 quantification of the presence or absence of C9orf72 mutations in a tissue sample or an individual Dani Welter C9orf72 mutation status efo:EFO_0008353 quantification of the amount cellular adhesion molecule in a sample Dani Welter true CAM measurement cellular adhesion molecule measurement efo:EFO_0008354 quantification of some aspect of cognitive function Dani Welter true cognitive function measurement efo:EFO_0008355 quantification of the amount of heme iron acquired through dietary intake Dani Welter true PMID:23386860 dietary heme iron intake measurement efo:EFO_0008356 quantification of the amount of dihomo-gamma-linoleic acid in a sample Dani Welter dihomo-gamma-linoleic acid measurement efo:EFO_0008357 quantification of the amount of docosatetranoic acid in a sample Dani Welter docosatetranoic acid measurement efo:EFO_0008358 quantification of the function of the dorsolateral prefrontal cortex, an area of the prefrontal cortex strongly implicated in schizophrenia. Dani Welter true dorsolateral prefrontal cortex functional measurement efo:EFO_0008359 quantification of the amount of eicosadienoic acid in a sample Dani Welter true eicosadienoic acid measurement efo:EFO_0008360 quantification of some aspect of exposure to an environmental factor such as pollutants Dani Welter true environmental exposure measurement efo:EFO_0008361 quantification of some aspect of environmental tobacco smoke exposure Dani Welter true PMID:28738859 second-hand tobacco smoke exposure measurement environmental tobacco smoke exposure measurement efo:EFO_0008362 quantification of some aspect of an individual's exposure to a farm environment such as frequeny or duration. Farm exposure may have a beneficial or protective effect against certain conditions such as asthma Dani Welter true PMID:21211648 farm exposure measurement efo:EFO_0008363 quantification of the amount of gamma-linoleic acid in a sample Dani Welter gamma-linoleic acid measurement efo:EFO_0008364 quantification of the effect of belonging to a specific generation on a genotype effect Dani Welter true PMID:23942779 generational effect measurement efo:EFO_0008365 quantification of some aspect of the deposition of amyloid proteins in the heart Dani Welter true PMID:28679651 heart amyloid deposition measurement efo:EFO_0008366 quantification of immunoglobulin G in a sample as light chain or heavy chain or kappy type or lambda type Dani Welter true PMID:28679651 IgG isotype profile measurement efo:EFO_0008367 quantification of the volume of cerebrospinal fluid in an infant's brain Dani Welter true PMID:28763065 infant cerebrospinal fluid volume measurement efo:EFO_0008368 quantification of the volume of grey matter in an infant's brain Dani Welter true PMID:28763065 infant grey matter volume measurement efo:EFO_0008369 quantification of an infant's intracranial volume Dani Welter true PMID:28763065 infant intracranial volume measurement efo:EFO_0008370 quantification of the volume of white matter in an infant's brain Dani Welter true PMID:28763065 infant white matter volume measurement efo:EFO_0008371 quantification of some aspect of the deposition of amyloid proteins in the kidney Dani Welter true PMID:28679651 kidney amyloid deposition measurement efo:EFO_0008372 quantification of some aspect of laterality such as scoring concepts as unilateral or bilateral Dani Welter true PMID:28775256 laterality measurement efo:EFO_0008373 quantification of the volumetric fraction of blood pumped out of the left ventricle Dani Welter true PMID:28763429 left ventricular ejection fraction measurement efo:EFO_0008374 quantification of some aspect of the deposition of amyloid proteins in the liver Dani Welter true PMID:28679651 liver amyloid deposition measurement efo:EFO_0008375 quantification of some aspect of the macula Dani Welter true PMID:28835685 macula measurement efo:EFO_0008376 quantification of some aspect of mosquito bites Dani Welter PMID:28199695 mosquito bite measurement efo:EFO_0008377 quanitifcation of the itch intensity of a mosquito bite reaction, generally through the use of a standardised questionnaire Dani Welter true PMID:28199695 mosquito bite reaction itch intensity measurement efo:EFO_0008378 quantification of the size of a mosquito bite reaction, generally through the use of a standardised questionnaire Dani Welter true PMID:28199695 mosquito bite reaction size measurement efo:EFO_0008379 quantification of P wave terminal force, the product of the duration and the amplitude of the terminal negative part of the P-wave Dani Welter true P wave terminal force measurement efo:EFO_0008380 quantification of an individual's perceived unattractiveness to mosquitos, generally through the use of a standardised questionnaire Dani Welter true PMID:28199695 perceived unattractiveness to mosquitos measurement efo:EFO_0008381 quantification of the surface area of the cerebral cortex, the largest region of the mammalian brain Dani Welter true PMID:22343285 total cortical area measurement efo:EFO_0008382 quantification of some aspect of TP53 mutation, such as the number of accummulated mutations, determined either through immunohistochemistry or DNA sequencing Dani Welter true PMID:28179588 TP53 mutation status efo:EFO_0008383 quantification of some treatment outcome Dani Welter true treatment outcome measurement efo:EFO_0008384 quantification of the amount of tumor necrosis factor receptor II in a sample Dani Welter true TNF-receptor-II measurement tumor necrosis factor receptor II measurement efo:EFO_0008385 quantification of visual acuity Dani Welter true PMID:28835685 visual acuity measurement efo:EFO_0008386 Quantification of body odor, a perceived unpleasant smell given off by the body Laura Harris true PMID:28753643 body odour measurement body odor measurement efo:EFO_0008387 Quantification of some aspect of the caudate nucleus, part of the basal ganglia of the brain, primarily associated with voluntary movement and reward. Laura Harris true PMID:28927378 Wikipedia:Caudate_nucleus caudate measurement caudate nucleus measurement efo:EFO_0008388 Quantification of the wave-like oscillations in the alpha band (8-13 Hz) of electric potential between parts of the brain Annalisa Buniello true PMID:28922980 gamma wave measurement efo:EFO_0008389 Quantification of some aspect of the putamen, part of the basal ganglia of the brain, primarily associated with voluntary movement and reward. Laura Harris true PMID:28927378 Wikipedia:Putamen putamen measurement efo:EFO_0008390 Quantification of the clotting tendency of blood plasma following the addition of tissue factor. Prothrombin time requires the presence of factors I, II, V, VII, and X. It measures the extrinsic pathway of coagulation and can be used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway. It is used as a screening test and can be affected by vitamin K deficiency, liver disease, warfarin therapy or intestinal problems. Laura Harris true PMID:22703881 Wikipedia:Prothrombin_time International normalized ratio of prothrombin time measurement PT/INR measurement ProTime INR measurement prothrombin time measurement efo:EFO_0008391 Quantification of the glycoprotein erythropoetin typically in the blood Laura Harris true PMID:18464913 erythropoetin measurement efo:EFO_0008392 Quantification of the thyroid hormone triiodothyronine (T3) typically in the blood, usually as an indicator of thyroid function Laura Harris true PMID:18464913 T3 measurement triiodothyronine measurement efo:EFO_0008393 In psychology, the quantification of the interval of time between the presentation of a stimulus to a subject and the beginning of the subject's response to that stimulus. Several categories of reaction time, such as simple reaction time and choice reaction time, have been established and studied in experimental psychology to assess general alertness and motor speed. Laura Harris true PMID:28746715 reaction time measurement efo:EFO_0008394 Quantification of verbal and/or numerical reasoning, typically based on a written or multiple choice test Laura Harris true PMID:28746715 verbal-numerical reasoning measurement efo:EFO_0008398 Quantification of the morphology of the T wave, the part of the electrocardiograph that represents the repolarisation or recovery of the ventricles Joannella Morales true PMID:28800628 T wave morphology measurement efo:EFO_0008399 quantification of some aspects of brain connectivity that can be derived from the diffusion tensor imaging (DTI) dataset. Annalisa Buniello true PMID:28924203 mean fractional anisotropy measurement efo:EFO_0008400 Quantification of an individual's susceptibility to chickenpox, resulting from results from primary Varicella zoster virus infection, typically occurring in childhood. Laura Harris true PMID:28928442 susceptibility to varicella zoster virus infection measurement susceptibility to chickenpox measurement efo:EFO_0008401 Quantification of an individual's susceptibility to shingles, a pinaful rash resultin from reactivation of latent Varicella zoster virus infection within a dorsal root ganglion, typically occuring in later life. Laura Harris true PMID:28928442 susceptibility to herpes zoster measurement susceptibility to shingles measurement efo:EFO_0008402 Quantification of an individual's susceptibility to cold sores, vesicular lesions of the lips and mouth caused by another member of the human herpesvirus family, herpes simplex virus type 1 (HSV-1) Laura Harris true PMID:28928442 susceptibility to cold sores measurement efo:EFO_0008403 Quantification of an individual's susceptibility to infectious mononucleosis, a syndrome of fever, tonsillitis, swollen lymph nodes, and persistent fatigue resulting from primary infection with the Epstein-Barr virus. Laura Harris true PMID:28928442 susceptibility to glandular fever measurement susceptibility to infectious mononucleosis measurement susceptibility to mononucleosis measurement efo:EFO_0008404 Quantification of an individual's susceptibility to mumps, a syndrome of low-grade fever, malaise, headache, and characteristic swelling of the parotid glands that is caused by the mumps virus Laura Harris true PMID:28928442 susceptibility to mumps measurement efo:EFO_0008405 Quantification of an individual's susceptibility to hepatitis B Laura Harris true PMID:28928442 susceptibility to hepatitis B infection measurement efo:EFO_0008406 Quantification of an individual's susceptibility to plantar warts Laura Harris true PMID:28928442 susceptibility to plantar warts measurement efo:EFO_0008407 Quantification of an individual's susceptibility to infection with Mycobacterium tuberculosis Laura Harris true PMID:28928442 susceptibility to Mycobacterium tuberculosis infection measurement efo:EFO_0008408 Quantification of an individual's susceptibility to throat symptoms and fever caused by Group A Streptococcal infection Laura Harris true PMID:28928442 susceptibility to strep throat measurement efo:EFO_0008409 Quantification of an individual's susceptibility to scarlet fever, a syndrome of rash, sore throat and fever caused by Group A Streptococcal infection Laura Harris true PMID:28928442 susceptibility to scarlet fever measurement efo:EFO_0008410 Quantification of an individual's susceptibility to pneumonia, an infection of the lung tissue, typically by bacteria or viruses Laura Harris true PMID:28928442 susceptibility to pneumonia measurement efo:EFO_0008411 Quantification of an individual's susceptibility to bacterial meningitis Laura Harris true PMID:28928442 susceptibility to bacterial meningitis measurement efo:EFO_0008412 Quantification of an individual's susceptibility to vaginal yeast infection or thrush, typically by Candida albicans or other Candida species. Laura Harris true PMID:28928442 susceptibility to Candida vulvovaginitis measurement susceptibility to thrush measurement susceptibility to vaginal yeast infection measurement efo:EFO_0008413 Quantification of an individual's susceptibility to infactions of the urinary tract, typically caused by Escherichia coli, Staphylococcus saprophyticus, or other fecal flora. Laura Harris true PMID:28928442 susceptibility to cystitis susceptibility to urinary tract infection measurement efo:EFO_0008414 Quantification of an individual's susceptibility to measles Laura Harris true PMID:28928442 susceptibility to measles measurement efo:EFO_0008415 Quantification of an individual's susceptibility to hepatitis A Laura Harris true PMID:28928442 susceptibility to hepatitis A infection measurement efo:EFO_0008416 Quantification of an individual's susceptibility to rheumatic fever, arising as a complication of primary infection with Group A Streptococcus Laura Harris true PMID:28928442 susceptibility to rheumatic fever measurement efo:EFO_0008417 Quantification of an individual's susceptibility to the common cold Laura Harris true PMID:28928442 susceptibility to common cold measurement efo:EFO_0008418 Quantification of an individual's susceptibility to shingles Laura Harris true PMID:28928442 susceptibility to rubella infection measurement efo:EFO_0008419 Quantification of an individual's susceptibility to chronic sinus infections, requiring surgery. Laura Harris true PMID:28928442 susceptibility to chronic sinus infection measurement efo:EFO_0008420 quantification of the parietal cortex, a part of the brain situated in the medial aspect of the cerebral cortex Annalisa Buniello true PMID:28924203 parietal cortex measurement efo:EFO_0008421 Quantification of the severity of non-alcoholic fatty liver disease, typically by a histological grading. Laura Harris true PMID:28918882 non-alcoholic fatty liver disease severity measurement efo:EFO_0008422 true susceptibility to infectious disease measurement efo:EFO_0008423 Quantification of monogalactosylated N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG mono-galactosylation measurement IgG monogalactosylation measurement efo:EFO_0008424 Quantification of digalactosylated N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG di-galactosylation measurement IgG digalactosylation measurement efo:EFO_0008425 Quantification of galactosylated N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG galactosylation measurement efo:EFO_0008426 Quantification of bisecting N-acetyl glucosamine-containing N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG GlcNAc measurement IgG bisecting N-acetyl glucosamine measurement efo:EFO_0008427 Quantification of fucosylated N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG fucosylation measurement efo:EFO_0008428 Quantification of sialylated N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG sialylation measurement efo:EFO_0008429 Quantification of disialylated N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG di-sialylation measurement IgG disialylation measurement efo:EFO_0008430 Quantification of monosialylated N-glycans of IgG in a biological sample, typically serum Laura Harris true PMID:28878392 IgG mono-sialylation measurement IgG monosialylation measurement efo:EFO_0008431 Qunatification of the maximum volume of air that an organism can breathe in and out during a specified period of time, often 1 minute. Annalisa Buniello true MedDRA:10026958 PMID:29095316 maximal voluntary ventilation efo:EFO_0008432 Quantification of the rate of change in lipoprotein-associated phospholipase A(2) over the course of time, used as an indicator of risk of cardiovascular events, and a target for certain cardiovascular drugs. Laura Harris true PMID:28753643 lipoprotein-associated phospholipase A(2) change measurement efo:EFO_0008433 Quantification of the accuracy of matching eye velocity to target velocity during sustained pursuit, typically measured using a video-based eye tracker. Abnormalities of this system have been observed in psychiatric disoreders such as aschizophrenia. Laura Harris true PMID:29064472 Wikipedia:Smooth_pursuit pursuit maintenance gain measurement efo:EFO_0008434 Quantification of the rate of change of eye velocity during the first 100ms of pursuit, typically measured using a video-based eye-tracker. Abnormalities of this sysmtem have been observed in psychiatric disorders such as schizophrenia. Laura Harris true PMID:29064472 Wikipedia:Smooth_pursuit initial pursuit acceleration efo:EFO_0008435 Quantification of the amount of weight gained by a woman during pregnancy. Laura Harris true PMID:28990592 gestational weight gain measurement efo:EFO_0008436 Quantification of the amount of weight gained by a woman during late pregnancy. Laura Harris true PMID:28990592 late gestational weight gain efo:EFO_0008437 Quantification of the amount of weight gained by a woman during early pregnancy. Laura Harris true PMID:28990592 early gestational weight gain efo:EFO_0008438 Quantification of the amount of growth hormone in a sample, typically blood. Laura Harris true PMID:29065906 growth hormone measurement efo:EFO_0008446 The ratio of platelet count to lymphocyte count, quantified in a blood sample. Both neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio have been proposed as biomarkers for the diagnosis or prognostic prediction of disease. Laura Harris true PMID:29066854 platelet:lymphocyte ratio platelet-to-lymphocyte ratio efo:EFO_0008447 The ratio of neutrophil count to lymphocyte count, quantified in a blood sample. Both neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio have been proposed as biomarkers for the diagnosis or prognostic prediction of disease. Laura Harris true PMID:29066854 neutrophil:lymphocyte ratio neutrophil-to-lymphocyte ratio efo:EFO_0008449 quantification of the ratio of magnesium to creatinine in a sample, typically a urine sample, a proxy measure for Mg2+ homeostasis Joannella Morales true PMID:29093028 magnesium:creatinine ratio measurement efo:EFO_0008450 quantification of fractional excretion of magnesium based on the calculation of serum and urinary levels of magneiusm and creatinine. Used as a marker of renal tubular function. Joannella Morales true PMID:29093028 FEMg fractional excretion of magnesium measurement efo:EFO_0008451 quantification of ability to perform daily living activities independently. A proxy to assess functional status in the elderly. Joannella Morales true PMID:29158487 ADL Katz ADL index activities of daily living score measurement efo:EFO_0008452 quatification of the muscle circumference of the mid arm. A proxy for muscle mass of the arm. Joannella Morales true PMID:29158487 MAMC mid-arm muscle circumference measurement efo:EFO_0008453 quatification of the muscle circumference of the calf. A proxy for muscle mass of the leg. Joannella Morales true PMID:29158487 CC calf circumference measurement efo:EFO_0008454 quantification of physical performance. A proxy to assess lower extremity function in the elderly. Joannella Morales true PMID:29158487 SPPB short physical performance battery score measurement efo:EFO_0008455 A pause in breathing or shallow breaths during REM sleep. true sleep apnea measurement during REM sleep efo:EFO_0008456 A pause in breathing or shallow breaths during non-REM sleep. true sleep apnea measurement during non-REM sleep efo:EFO_0008457 Quantification of the degree to which an individual is dependent on cannabis, for example based on the number of DSM-IV criteria met for cannabis dependence. Laura Harris true PMID:29112194 cannabis dependence measurement efo:EFO_0008458 Quantification of the amount of tacrolimus in a sample. Tacrolimus (TAC) is a common immunosuppressive agent that potently inhibits T-cell function and proliferation through inhibition of calcineurin by binding to FKB12. Aoife McMahon true PMID:29160300 tacrolimus hydrate measurement tacrolimus measurement efo:EFO_0008463 The quantification of glucagon, a hormone involved in glucose homeostasis. Joannella Morales true PMID:29093273 glucagon measurement efo:EFO_0008464 The quantification of glucose-dependent insulinotropic peptide, an incretin hormone secreted in response to nutrient stimulation that acts to increase insulin secretion. Joannella Morales true PMID:29093273 glucose-dependent insulinotropic peptide measurement efo:EFO_0008465 The quantification of glucagon-like peptide 1, an incretin hormone secreted in response to nutrient stimulation that acts to increase insulin secretion. Joannella Morales true PMID:29093273 glucagon-like peptide-1 measurement efo:EFO_0008466 The determination of the amount of matrix metalloproteinase 8 present in a sample Annalisa Buniello true NCIt:C80196 PMID:29212897 MMP8 matrix metalloproteinase 8 matrix metalloproteinase 8 measurement neutrophil collagenase matrix metalloproteinase 8 measurement efo:EFO_0008467 Some quantification of the ability to inhibit maladaptive or inappropriate behavior. Aoife McMahon true PMID:29251981 inhibitory control measurement behavioural inhibitory control measurement efo:EFO_0008468 Quantification of the levels of midregional pro atrial natriuretic peptide. Joannella Morales true PMID:29237677 MR-proANP midregional pro atrial natriuretic peptide measurement efo:EFO_0008469 Quantification of the ratio of B-type natriuretic levels to N-terminal pro B-type natriuretic peptide levels. Joannella Morales true PMID:29237677 BNP:NT-proBNP ratio B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio efo:EFO_0008470 Quatification of dietary potassium intake by measuring 24 hr urinary potassium levels. Joannella Morales true PMID:29212900 dietary potassium intake measurement efo:EFO_0008471 A measurement of some protein which is used as a measure of heart failure. Trish Whetzel cardiac stress biomarker measurement efo:EFO_0008473 Quantification of some aspect of insulin response, typically measuring insulin levels in the blood following a glucose challenge Laura Harris true PMID:24699409 insulin response measurement efo:EFO_0008474 Quantification of a change in mineral density of the spine bones Laura Harris true PMID:29266176 lumbar spine bone mineral density change measurement spine bone mineral density change measurement http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern efo:EFO_0008475 Quantifiication of some aspect of mood instability. Aoife McMahon true PMID:29187730 mood instability measurement efo:EFO_0008476 Quantification of some aspect of impulsivity related to the increased perceived value of immediate gratification as compared to a larger future reward. The more remote the future reward, the lower its perceived present value (the more it is discounted) and the less likely it is to be chosen. Aoife McMahon true PMID:29230059 delay discounting measurement delayed reward discounting measurement efo:EFO_0008487 Quantification of the volume of the lateral ventricle, the largest cavity of the ventricular system of the human brain which contains cerebrospinal fluid (CSF). Aoife McMahon true PMID:29187748 https://en.wikipedia.org/wiki/Lateral_ventricles lateral ventricle volume measurement efo:EFO_0008529 Quatification of plasma levels of kynurenine, a ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group. Joannella Morales true PMID:29317604 KYN kynurenine measurement efo:EFO_0008530 Quantification of the ration of kynurenine to tryptophan in plasma. Joannella Morales true PMID:29317604 KYN:TRP kynurenine:tryptophan ratio efo:EFO_0008531 Quantification of insulin release in response to stimulation with GLP-1, typically measured under hyperglycemic clamp. Laura Harris true PMID:29293525 glucagon-like-peptide-1-stimulated insulin response GLP-1-stimulated insulin response efo:EFO_0008534 Quantification of the levels of tryptophan in a sample, typically cerebrospinal fluid or blood Laura Harris true PMID:29395996 tryptophan measurement efo:EFO_0008535 Quantification of the severity of post-traumatic stress disorder symptoms, typically quantified as the sum score of items of a diagnostic instrument such as the Semi-Structured Assessment for the Genetics of Alcoholism Laura Harris true PMID:28262088 PTSD symptom measurement post-traumatic stress disorder symptom measurement efo:EFO_0008538 Quantification of some aspect of helping behavior, for example helping others without being paid. Helping behavior is an example of prosocial behavior. Aoife McMahon true PMID:29324852 helpfulness measurement helping behavior measurement efo:EFO_0008539 Quantification of dietary vitamin D intake. Joannella Morales true PMID:29343764 vitamin D dietary intake measurement efo:EFO_0008542 Quantification of the amount of complement C3d subcomponent in a blood sample. Annalisa buniello PMID:29398083 complement C3d subcomponent measurement efo:EFO_0008543 Quantification of the ratio of complement C3d to C3 in a blood sample. This measure is a biomarker for systemic complement activation. Annalisa buniello true PMID:29398083 c3d:C3 ratio efo:EFO_0008544 Quantification of the amount of analgesic drug required during a painful procedure such as surgery. Laura Harris true PMID:29207912 analgesia requirement measurement efo:EFO_0008578 Quantification of sperm motility, measured as the percentage of motile sperm in ejaculated sperms ([number of motile sperm in the ejaculate]/[number of sperm in the ejaculate])×100. Joannella Morales true PMID:29453196 sperm motility measurement efo:EFO_0008582 Quantification of the amount of the activation peptide of thrombin activatable fibrinolysis inhibitor in a blood sample, typically as a marker of the extent of TAFI activation. Cleavage of the activation peptide from the intact peptide makes the active site accesible to substrates. Laura Harris true PMID:29378355 TAFI activation peptide levels TAFI-AP levels carboxypeptidase B2 measurement thrombin activatable fibrinolysis inhibitor activation peptide measurement efo:EFO_0008589 Quantification of the amount of esterified cholesterol in a sample. Laura Harris true PMID:29084231 cholesterol ester measurement esterified cholesterol measurement efo:EFO_0008591 Quantification of the amount of free cholesterol in a sample. Laura Harris true PMID:29084231 free cholesterol measurement efo:EFO_0008592 Quantification of the size of HDL particles, typically their diameter. Laura Harris true PMID:29084231 HDL particle size measurement high density lipoprotein particle size measurement efo:EFO_0008593 Quantification of the size of LDL particles, typically their diameter. Laura Harris true PMID:29084231 LDL particle size measurement low density lipoprotein particle size measurement efo:EFO_0008594 Quantification of the size of VLDL particles, typically their diameter. Laura Harris true PMID:29084231 VLDL particle size measurement very low density lipoprotein particle size measurement efo:EFO_0008595 Quantification of the amount of intermediate density lipoprotein in a sample. Laura Harris true PMID:29084231 IDL measurement intermediate density lipoprotein measurement efo:EFO_0008596 Quantification of the amount of chylomicrons in a sample. Chylomicrons are lipoprotein particles that consist of triglycerides (85–92%), phospholipids (6–12%), cholesterol (1–3%), and proteins (1–2%). Laura Harris true PMID:29084231 Wikipedia:Chylomicron chylomicron measurement efo:EFO_0009010 Quantification of the severity of Herpes simplex virus-2 infection, typically by assessment of viral shedding Laura Harris true PMID:29535370 Herpes simplex virus-2 virologic severity measurement | HSV-2 virologic severity measurement HSV2 virologic severity measurement efo:EFO_0009092 A measurement of some aspect of breast milk. Aoife McMahon true PMID:29514873 breast milk measurement efo:EFO_0009095 A measurement of some aspect of human psychology. Aoife McMahon psychological measurement efo:EFO_0009096 A measurement of some aspect of psychological negative valence systems e.g. those responsible for responses to aversive situations or context, such as fear, anxiety and loss Aoife McMahon true negative domain measurement efo:EFO_0009097 A measurement of some aspect of psychological positive valence systems e.g. those responsible for responses to positive motivational situations or contexts, such as reward seeking, consummatory behavior, and reward/habit learning. Based on the NIH NIMH's research domain criteria (RDoC). https://www.nimh.nih.gov/research-priorities/rdoc/definitions-of-the-rdoc-domains-and-constructs.shtml Aoife McMahon true positive domain measurement efo:EFO_0009098 A measurement of some aspect of cognitive systems e.g. those responsible for various cognitive processes. Based on the NIH NIMH's research domain criteria (RDoC). https://www.nimh.nih.gov/research-priorities/rdoc/definitions-of-the-rdoc-domains-and-constructs.shtml Aoife McMahon true cognitive domain measurement efo:EFO_0009099 A measurement of some aspect of psychological arousal/regulatory systems e.g. those responsible for generating activation of neural systems as appropriate for various contexts, and providing appropriate homeostatic regulation of such systems as energy balance and sleep. Based on the NIH NIMH's research domain criteria (RDoC). https://www.nimh.nih.gov/research-priorities/rdoc/definitions-of-the-rdoc-domains-and-constructs.shtml Aoife McMahon true arousal domain measurement efo:EFO_0009100 A measurement of some aspect of psychological systems for social processes e.g. those that mediate responses in interpersonal settings of various types, including perception and interpretation of others’ actions. Based on the NIH NIMH's research domain criteria (RDoC). https://www.nimh.nih.gov/research-priorities/rdoc/definitions-of-the-rdoc-domains-and-constructs.shtml Aoife McMahon true social domain measurement efo:EFO_0009101 A measurement of the age at which a woman gave birth to her first live child Annalisa Buniello true age at first birth measurement efo:EFO_0009102 A measurement of the number of children born Annalisa Buniello true number of children ever born measurement efo:EFO_0009103 Quantification of theory of mind ability, defined as the ability to attribute mental states to one self and others and to use such mental state attribution to make sense of behaviour and predict it. Theory of mind can be quantified using the Emotional Triangles Task test ("Triangles task"). Joannella Morales true PMID:29472613 theory of mind measurement efo:EFO_0009113 Quantification of some aspect of alcohol exposure. Aoife McMahon true PMID:29535761 alcohol exposure measurement efo:EFO_0009114 Quantification of some aspect of the exposure of a fetus to an agent while in the womb. Aoife McMahon PMID:29535761 in utero exposure measurement efo:EFO_0009115 Quantification of some aspect of tobacco smoke exposure. Aoife McMahon true PMID:29535761 tobacco smoke exposure measurement efo:EFO_0009116 Quantification of some aspect of the consumption of dietry vitamin supplements. Aoife McMahon true PMID:29535761 vitamin use exposure measurement vitamin supplement exposure measurement efo:EFO_0009132 Quantification of cholesterol efflux capacity, a measure of HDL functionality that quantifies the ability of an individual’s HDL to extract cholesterol from cholesterol-loaded macrophages. Efflux capacity is considered to be a predictor of atherosclerotic burden. Laura Harris true PMID:29674289 cholesterol efflux capacity measurement efo:EFO_0009133 Quantification of the amount of cholestryl ester transfer protein in a sample, typically serum. Laura Harris true PMID:29728394 https://en.wikipedia.org/wiki/Cholesterylester_transfer_protein CETP plasma lipid transfer protein measurement cholesteryl ester transfer protein measurement efo:EFO_0009134 Quantification of trimethyllysine (N6,N6,N6-trimethyl-L-lysine) in the blood. Annalisa Buniello true https://pubchem.ncbi.nlm.nih.gov/compound/440120 trimethyllysine measurement efo:EFO_0009172 Is a quantification of thyroxine-binding globulin. Inherited abnormalities in the level of serum TBG have been classified as complete deficiency (TBG-CD), partial deficiency (TBG-PD), and excess (TBG-E). Patients are euthyroid (summary by Mori et al., 1995). Hannah McLaren true OMIM:300932 TBGQTL thyroxine-binding globulin QTL thyroxine-binding globulin excess thyroxine-binding globulin quantitative trait thyroxine-binding globulin measurement efo:EFO_0009176 Quantification of the suppression of adrenal gland function, typically following stimulation with adrenocorticotrophic hormone or a synthetic equivalent. Adrenal suppression may occur as a result of primary hypoadrenalism, or secondary to a number of other conditions including tuberculosis, or chronic exposure to corticosteroids. Laura Harris true PMID:29551627 adrenal suppression measurement efo:EFO_0009177 Quantification of the severity of myopic maculopathy Laura Harris true PMID:29725004 myopic macular degeneration severity measurement myopic maculopathy severity measurement efo:EFO_0009178 Quantification of the levels of neurofilament light chain, typically in blood or cerebrospinal fluid. Used as a marker of neurodegeneration, in Alzheimer's disease, Amyotrophic Lateral Sclerosis, multiple sclerosis and Huntington's disease. Laura Harris true PMID:29747637 NF-L measurement NFL measurement neurofilament light measurement neurofilament light chain measurement efo:EFO_0009179 Quantification of the amount of beta-secretase 1 in a sample, typicallly cerebrospinal fluid. Beta-secretase-1 is an aspartic-acid protease important in the formation of myelin sheaths in peripheral nerve cells, and is thought to have a role in Alzheimer's disease pathogenesis. Laura Harris true PMID:29751835 Wikipedia:Beta-secretase_1 ASP2 BACE1 aspartyl protease 2 beta-site APP cleaving enzyme 1 beta-site amyloid precursor protein cleaving enzyme 1 memapsin-2 membrane-associated aspartic protease 2 beta-secretase 1 measurement efo:EFO_0009180 Quantification of the severity of rosacea symptoms, based on a survey of facial, nose and ocular sympoms related to rosacea, a chronic inflammatory skin disease. Joannella Morales true PMID:29771307 rosacea severity measurement efo:EFO_0009181 Quantification of growth differentiation factor 15 in a biological sample. Annalisa Buniello true PMID:29628937 growth differentiation factor 15 levels growth differentiation factor 15 measurement efo:EFO_0009182 Quantification of some aspect of psychotic symptoms, such as their existence and severity, usually via a standardised questionnaire or interview with a qualified mental health professional. The symptoms can include paranoia, hallucinations, anhedonia, cognitive disorganisation. Annalisa Buniello true PMID:29603866 https://en.wikipedia.org/wiki/Psychosis psychotic symptom measurement efo:EFO_0009183 Quantification of some aspect of empathy, i.e. the ability to understand and share another person's experiences and emotions Laura Harris true PMID:29527006 empathy measurement efo:EFO_0009184 Quantification of heart rate during exercise. Joannella Morales true PMID:29769521 heart rate response to exercise efo:EFO_0009185 Quantification of heart rate during a recovery period following exercise. Joannella Morales true PMID:29769521 heart rate recovery post exercise heart rate response to recovery post exercise efo:EFO_0009186 Indicator of larger (> 12 fL) circulating platelets (percentage). true P-LCR Platelet larger cell ratio platelet larger cell ratio (P-LCR) platelet larger cell ratio efo:EFO_0009187 Percentage of immature platelets IPF immature platelet fraction efo:EFO_0009188 Red blood cell distribution width (RDW or RDW-CV or RCDW and RDW-SD) is a measure of the range of variation of red blood cell (RBC) volume that is reported as part of a standard complete blood count. Usually red blood cells are a standard size of about 6-8 μm in diameter. Certain disorders, however, cause a significant variation in cell size. Higher RDW values indicate greater variation in size. Normal reference range of RDW-CV in human red blood cells is 11.5-14.5%.[1] If anemia is observed, RDW test results are often used together with mean corpuscular volume (MCV) results to determine the possible causes of the anemia. It is mainly used to differentiate an anemia of mixed causes from an anemia of a single cause. Zoe May Pendlington true MedDRA:10051168 NCIt:C64800 Wikipedia:Red_blood_cell_distribution_width Erythrocyte Distribution Width Measurement RCDW RDW RDW-CV RDW-SD Red blood cell erythrocyte distribution width Red cell distribution width (RDW) blood test Red cell distribution width efo:EFO_0009202 The determination of the mean amount of hemoglobin per reticulocyte present in a sample. [ NCI ] Zoe May Pendlington NCIt:C117855 UMLS:C3897698 CHr High light scatter reticulocyte percentage Measurement of reticulocyte haemoglobin reticulocyte haemoglobin measurement reticulocyte hemoglobin content (CHr) Reticulocyte Mean Corpuscular Hemoglobin Measurement efo:EFO_0009203 The determination of the ratio of carboxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147355 Carboxyhemoglobin/Total Hemoglobin HBCOHGB Carboxyhemoglobin to Total Hemoglobin Ratio Measurement efo:EFO_0009204 A measurement of the standard deviation of hemoglobin concentrations in individual red blood cells, calculated as the standard deviation of hemoglobin content divided by the mean hemoglobin content. [ NCI ] Zoe May Pendlington NCIt:C139068 CHDW Corpuscular HGB Conc Distribution Width Erythrocyte Corpuscular Hemoglobin Concentration Distribution Width Corpuscular Hemoglobin Concentration Distribution Width efo:EFO_0009205 A measurement of the mean red blood cell hemoglobin content within an individual red blood cell, calculated as the product of cell volume and cell hemoglobin concentration. [ NCI ] Zoe May Pendlington NCIt:C139066 CH CHCNT Cellular Hemoglobin Content Erythrocyte Corpuscular Hemoglobin Content Corpuscular Hemoglobin Content efo:EFO_0009206 The determination of the amount of free hemoglobin present in a sample. [ NCI ] Zoe May Pendlington NCIt:C127617 HGBFR Hemoglobin, Free Free Hemoglobin Measurement efo:EFO_0009208 The determination of the amount of hemoglobin A present in a sample. [ NCI ] Zoe May Pendlington NCIt:C92258 UMLS:C1281911 HGBA Hemoglobin A Hemoglobin A Measurement efo:EFO_0009209 The determination of the ratio of Hemoglobin A compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C81276 UMLS:C2825554 HGBAHGB Hemoglobin A/Total Hemoglobin Percent Hemoglobin A Hemoglobin A to Total Hemoglobin Ratio Measurement efo:EFO_0009210 The determination of the ratio of hemoglobin A1 compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147363 HGBA1HGB Hemoglobin A1/Total Hemoglobin Hemoglobin A1 to Total Hemoglobin Ratio Measurement efo:EFO_0009211 The determination of the ratio of hemoglobin A2 prime compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147353 HBA2PHB Hemoglobin A2 Prime/Total Hemoglobin Hemoglobin A2 Prime to Total Hemoglobin Ratio Measurement efo:EFO_0009212 The determination of the ratio of Hemoglobin A2 compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C81277 UMLS:C2825555 HGBA2HGB Hemoglobin A2/Total Hemoglobin Percent Hemoglobin A2 Hemoglobin A2 to Total Hemoglobin Ratio Measurement efo:EFO_0009213 The determination of the amount of hemoglobin B present in a sample. [ NCI ] Zoe May Pendlington NCIt:C92260 UMLS:C2984939 HGBB Hemoglobin B Hemoglobin B Measurement efo:EFO_0009214 The determination of the ratio of hemoglobin Barts compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147354 HBBARTHB Hemoglobin Barts/Total Hemoglobin Hemoglobin Barts to Total Hemoglobin Ratio Measurement efo:EFO_0009215 The determination of the amount of hemoglobin C present in a sample. [ NCI ] Zoe May Pendlington NCIt:C92261 UMLS:C1275423 HGBC Hemoglobin C Measurement of Hemoglobin C Hemoglobin C Measurement efo:EFO_0009216 The determination of the ratio of Hemoglobin C compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C81278 UMLS:C2825556 HGBCHGB Hemoglobin C/Total Hemoglobin Percent Hemoglobin C Hemoglobin C to Total Hemoglobin Ratio Measurement efo:EFO_0009217 The determination of the ratio of hemoglobin D compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147364 HGBDHGB Hemoglobin D/Total Hemoglobin Hemoglobin D to Total Hemoglobin Ratio Measurement efo:EFO_0009218 The determination of the ratio of hemoglobin E compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147365 HGBEHGB Hemoglobin E/Total Hemoglobin Hemoglobin E to Total Hemoglobin Ratio Measurement efo:EFO_0009219 The determination of the ratio of hemoglobin F compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147366 HGBFHGB Hemoglobin F/Total Hemoglobin Hemoglobin F to Total Hemoglobin Ratio Measurement efo:EFO_0009220 The determination of the ratio of hemoglobin G compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147356 HBGCHTHB Hemoglobin G Coushatta/Total Hemoglobin Hemoglobin G Coushatta to Total Hemoglobin Ratio Measurement efo:EFO_0009221 The determination of the ratio of hemoglobin Lepore compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147357 HBLEPRHB Hemoglobin Lepore/Total Hemoglobin Hemoglobin Lepore to Total Hemoglobin Ratio Measurement efo:EFO_0009222 The determination of the ratio of hemoglobin O-Arab compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147358 HBOARBHB Hemoglobin O-Arab/Total Hemoglobin Hemoglobin O-Arab to Total Hemoglobin Ratio Measurement efo:EFO_0009223 The determination of the amount of hemoglobin S present in a sample. [ NCI ] Zoe May Pendlington NCIt:C122123 HGBS Hemoglobin S Sickle Hemoglobin Hemoglobin S Measurement efo:EFO_0009224 The determination of the ratio of Hemoglobin S compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C81279 UMLS:C2825557 HGBSHGB Hemoglobin S Measurement Hemoglobin S/Total Hemoglobin Percent Hemoglobin S Hemoglobin S to Total Hemoglobin Ratio Measurement efo:EFO_0009225 The determination of the amount of hemoglobin tetramer in a biological sample. [ NCI ] Zoe May Pendlington NCIt:C135425 HGBTET Hemoglobin Tetramer Hemoglobin Tetramer Measurement efo:EFO_0009226 The determination of the ratio of methemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147367 HGBMHGB Methemoglobin/Total Hemoglobin Methemoglobin to Total Hemoglobin Ratio Measurement efo:EFO_0009227 The determination of the ratio of oxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C147359 HBOXHGB Oxyhemoglobin/Total Hemoglobin Oxyhemoglobin to Total Hemoglobin Ratio Measurement efo:EFO_0009228 An indirect measurement of the average concentration of hemoglobin per reticulocyte in a biological specimen, calculated as the ratio of hemoglobin to hematocrit. [ NCI ] Zoe May Pendlington NCIt:C138970 CHCMR CHCMr Ret. Corpuscular HGB Concentration Mean Reticulocyte Corpuscular Hemoglobin Concentration Mean efo:EFO_0009229 The determination of the amount of hemoglobin in reticulocytes within a sample. [ NCI ] Zoe May Pendlington NCIt:C98776 UMLS:C3890034 CHr RETICH Ret. Corpuscular Hemoglobin Content Reticulocyte Cellular Hemoglobin Content Total Reticulocyte Corpuscular Hemoglobin Content Measurement Reticulocyte Corpuscular Hemoglobin Content efo:EFO_0009230 A measurement of the standard deviation of hemoglobin concentrations in reticulocytes, calculated as the standard deviation of hemoglobin content divided by the mean hemoglobin content. [ NCI ] Zoe May Pendlington NCIt:C139069 CHDWR Ret Corpuscular HGB Conc Distr Width Reticulocyte Corpuscular Hemoglobin Distribution Width efo:EFO_0009231 A measurement of the distribution of the hemoglobin concentration in reticulocytes. [ NCI ] Zoe May Pendlington NCIt:C139070 HDWR Ret Hemoglobin Distribution Width Reticulocyte Hemoglobin Concentration Distribution Width Reticulocyte Hemoglobin Distribution Width efo:EFO_0009232 The determination of the number of blast cells present in a blood sample. [ NCI ] Zoe May Pendlington NCIt:C74605 UMLS:C0523113 BLAST Blasts Blast Count efo:EFO_0009233 The determination of the ratio of one blood cell component lto another in a blood sample. The measurement may be expressed as either a ratio or a percentage. [ NCI ] Zoe May Pendlington NCIt:C67208 UMLS:C1879889 Blood Cell Count Ratio Measurement efo:EFO_0009234 A hematologic procedure to determine the number of red blood cells, white blood cells, and platelets, including the white cell differential count and red cell morphology, in a blood sample. [ NCI ] Zoe May Pendlington NCIt:C98494 UMLS:C0545131 CBC with Diff Blood Cell Count with Differential efo:EFO_0009235 The determination of the number of eosinophilic metamyelocytes in a blood sample. [ NCI ] Zoe May Pendlington NCIt:C84819 UMLS:C2827509 EOSMM Eosinophilic Metamyelocytes Eosinophilic Metamyelocyte Count efo:EFO_0009236 The determination of the number of eosinophilic myelocytes in a blood sample. [ NCI ] Zoe May Pendlington NCIt:C84821 UMLS:C2827510 EOSMYL Eosinophilic Myelocytes Eosinophilic Myelocyte Count efo:EFO_0009237 The estimated amount of platelets in a biological sample. [ NCI ] Zoe May Pendlington NCIt:C135440 UMLS:C0200642 Estimated PLATEST Platelets Estimated Platelets Measurement efo:EFO_0009238 The determination of the amount of immature plasma cells present in a sample. [ NCI ] Zoe May Pendlington NCIt:C96679 UMLS:C3272957 Immature Plasma Cells PLSIMCE Immature Plasma Cell Count efo:EFO_0009239 The determination of the number of mature plasma cells present in a sample. [ NCI ] Zoe May Pendlington NCIt:C74661 UMLS:C2698029 Mature Plasma Cells PLSMCE Plasmacytes Mature Plasma Cell Count efo:EFO_0009240 The determination of the amount of metarubricytes present in a sample. [ NCI ] Zoe May Pendlington NCIt:C128972 UMLS:C0029330 METARUB Metarubricyte Orthochromatophilic Normoblast Orthochromic Erythroblast Orthochromic Normoblast Metarubricyte Count efo:EFO_0009241 The determination of the ratio of monocytoid cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C120641 UMLS:C4054477 MOCYCELE Monocytoid Cells/Leukocytes Monocytoid Cells to Leukocytes Ratio Measurement efo:EFO_0009242 The determination of the number of myeloid progenitor cells in a sample. [ NCI ] Zoe May Pendlington NCIt:C130165 MYPC Myeloid Progenitor Cells Myeloid Progenitor Cell Count efo:EFO_0009243 The determination of the ratio of myeloid cells compared to erythroid cells present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI ] Zoe May Pendlington NCIt:C92242 UMLS:C2984931 MYPCERPC Myeloid/Erythroid Ratio Myeloid to Erythroid Ratio Measurement efo:EFO_0009244 The determination of the number of neutrophilic metamyelocytes in a blood sample. [ NCI ] Zoe May Pendlington NCIt:C84822 UMLS:C2827511 NEUTMM Neutrophilic Metamyelocytes Neutrophilic Metamyelocyte Count efo:EFO_0009245 The determination of the number of neutrophilic myelocytes in a blood sample. [ NCI ] Zoe May Pendlington NCIt:C84823 UMLS:C2827512 NEUTMY Neutrophilic Myelocytes Neutrophilic Myelocyte Count efo:EFO_0009246 The determination of the ratio of neutrophil band form compared to neutrophils present in a sample. The measurement may be expressed as a ratio or percentage. [ NCI] Zoe May Pendlington NCIt:C120642 UMLS:C4054355 NEUTBNE Neutrophils Band Form/ Neutrophils Neutrophils Band Form to Neutrophils Ratio Measurement efo:EFO_0009247 The determination of the amount of ovalocytes present in a sample. [ NCI ] Zoe May Pendlington NCIt:C142287 OVALCY Ovalocytes Ovalocyte Count efo:EFO_0009248 The determination of the amount of plasma cells present in a sample. [ NCI ] Zoe May Pendlington MedDRA:1005MedDRA:1006 NCIt:C128974 UMLS:C0581142 PLSTCE Total Plasma Cells Plasma Cell Count efo:EFO_0009249 The determination of the number of precursor plasma cells present in a sample. [ NCI ] Zoe May Pendlington NCIt:C74619 UMLS:C2698870 PLSPCE Plasmablast Precursor Plasma Cells Precursor Plasma Cell Count efo:EFO_0009250 The determination of the amount of prorubricytes present in a sample. [ NCI ] Zoe May Pendlington NCIt:C128976 Basophilic Erythroblast Basophilic Normoblast PRORUB Prorubricyte Prorubricyte Count efo:EFO_0009251 The determination of the amount of rubricytes present in a sample. [ NCI ] Zoe May Pendlington NCIt:C128978 Polychromatophilic Erythroblast Polychromatophilic Normoblast RUB Rubricyte Rubricyte Count efo:EFO_0009252 The determination of the ratio of segmented neutrophils compared to neutrophils present in a sample. The measurement may be expressed as a ratio or percentage. [NCI ] Zoe May Pendlington NCIt:C120643 UMLS:C4054040 NEUTSGNE Neutrophils Segmented/Neutrophils Segmented Neutrophils to Neutrophils Ratio Measurement efo:EFO_0009253 The determination of the ratio of immature reticulocytes to total reticulocytes present in a sample. [ NCI ] Zoe May Pendlington true NCIt:C102276 UMLS:C1446165 IRF Immature Reticulocyte Fraction Measurement of Immature Reticulocyte Fraction Immature Reticulocyte Fraction Measurement efo:EFO_0009256 Quantification of the intervals between normal heartbeats, expressed as standard deviation. Annalisa Buniello PMID:28613276 SDNN standard deviation of the normal-to-normal inter beat intervals efo:EFO_0009257 Quantification of the differences in intervals between heartbeats, expressed as root mean square. Annalisa Buniello PMID:28613276 RMSSD root mean square of the successive differences of inter beat intervals efo:EFO_0009258 Quantification of some aspects of sinus arrhythmia or high frequency power. Annalisa Buniello PMID:28613276 pvRSA/HF peak-valley respiratory sinus arrhythmia or high frequency power efo:EFO_0009262 Quantification of symptom associated with nicotine dependence. Joannella Morales true PMID:29532581 nicotine dependence symptom count efo:EFO_0009263 Quantification of symptom associated with nicotine withdrawal. Joannella Morales true PMID:29532581 nicotine withdrawal symptom count efo:EFO_0009264 Quantification of the maximum number of cigarettes that a subject smoked per day Joannella Morales true PMID:29532581 maximum cigarettes per day measurement efo:EFO_0009265 Aoife McMahon true PMID:29563502 Morning sickness severity measurement NVP severity measurement nausea and vomiting of pregnancy severity measurement efo:EFO_0009268 A reported family history of Alzheimer’s disease in one or more family members. true Alzheimer disease family history Alzheimer’s disease family history family history of Alzheimer disease family history of Alzheimer’s disease efo:EFO_0009269 Quantification of the levels of ADAMTS13 protein in a sample, typically blood plasma Laura Harris true PMID:29296746 disintegrin and metalloproteinase with thrombospondin motifs 13 measurement ADAMTS13 measurement efo:EFO_0009270 Quantification of the mineral density of the heel bone Joannella Morales true PMID:28869591 heel bone mineral density http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern efo:EFO_0009271 The result of a measurement of circulating Epstein Barr virus nuclear antigen-1 antibodies used in the diagnosis of latent Epstein-Barr virus infection Laura Harris true PMID:29868224 EBNA seropositivity EBNA-1 seropositivity Epstein Barr virus nuclear antigen-1 seropositivity efo:EFO_0009272 The result of a measurement of circulating Epstein Barr viral capsid antigen antibodies used in the diagnosis of Epstein-Barr virus infection Laura Harris true PMID:29868224 VCA seropositivity VCA-IgG seropositivity Epstein Barr viral capsid antigen seropositivity efo:EFO_0009273 Quantification of one or more antibodies to the Epstein-Barr virus, typically in serum Laura Harris true PMID:29868224 anti-EBV antibody measurement anti-Epstein Barr virus antibody measurement efo:EFO_0009274 Quantification of antibodies to the Epstein-Barr virus viral capsid antigen, typically in serum. Laura Harris true PMID:29868224 VCA-IgG measurement Epstein Barr viral capsid antigen IgG measurement efo:EFO_0009278 Quantification of any aspect of the morphology of the cranial vault, including shape, size, structure or pattern. The cranial vault is a region comprising interlocking flat bones surrounding the cerebral cortex. Laura Harris true PMID:29698431 cranial vault shape measurement cranial vault morphology measurement efo:EFO_0009281 Quantification of the thickness of the choroid, the vascular layer of the eye lying between the retina and the sclera. Laura Harris true PMID:29844195 choroidal thickness measurement efo:EFO_0009282 A quantitative measurement of the amount of sodium present in a sample. Aoife McMahon true PMID:29403010 Na measurement sodium levels sodium measurement efo:EFO_0009283 A quantitative measurement of the amount of potassium present in a sample. Aoife McMahon true PMID:29403010 K measurement potassium levels potassium measurement efo:EFO_0009284 A quantitative measurement of the amount of chloride present in a sample. Aoife McMahon true PMID:29403010 Cl measurement chloride levels chloride measurement efo:EFO_0009285 A calculated measurement corresponding to the ratio or percent reduction in heart chamber diameter between end-systole and end-diastole. Aoife McMahon true PMID:29403010 modelled on http://purl.obolibrary.org/obo/CMO_0001488 fractional shortening efo:EFO_0009286 A calculated measurement of heart wall geometry. It represents a measure of the wall thickness normalized to the size of the chamber lumen. Aoife McMahon true PMID:29403010 http://purl.obolibrary.org/obo/CMO_0000992 heart relative wall thickness efo:EFO_0009287 A quantitative measurement of the thickness of an interventricular septum. Aoife McMahon true PMID:29403010 http://purl.obolibrary.org/obo/OBA_0006021 interventricular septum thickness efo:EFO_0009288 A quantitative measurement of the thickness or depth of the dorsal/posterior wall of the heart. Aoife McMahon true PMID:29403010 http://purl.obolibrary.org/obo/CMO_0000238 posterior wall thickness efo:EFO_0009289 A quantitative measure calculated as the difference between the epicardium delimited volume and the left ventricular chamber volume Aoife McMahon true PMID:29403010 http://purl.obolibrary.org/obo/NCIT_C35462 LV mass left ventricular mass efo:EFO_0009290 The left ventricular mass divided by the subject's body surface area Aoife McMahon true PMID:29403010 http://purl.obolibrary.org/obo/NCIT_C142243 LV mass index left ventricular mass index efo:EFO_0009291 The E/A ratio is a marker of the function of the left ventricle of the heart. It represents the ratio of peak velocity blood flow from gravity in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial contraction (the A wave). Aoife McMahon true PMID:29403010 https://en.wikipedia.org/wiki/E/A_ratio E wave/A wave ratio E/A ratio efo:EFO_0009303 Quantification of levels of fructosamine present in a sample. Joannella Morales true NCIt:C74678 PMID:29844224 fructosamine measurement efo:EFO_0009304 Quantification of the percentage of serum albumin in a sample that is glycated. Joannella Morales true PMID:29844224 percent glycated albumin efo:EFO_0009305 Quantification of the total amount of glycated albumin in a sample. Joannella Morales true PMID:29844224 total glycated albumin efo:EFO_0009306 Quantification of the total amount of atazanavir, typically assayed in hair. This is used as a measure of exposure to the drug. Annalisa Buniello true PMID:29315502 atazanavir levels atazanavir measurement efo:EFO_0009307 The determination of the amount of glycated albumin related peptide present in a biological specimen. NCIt:C122092 glycated albumin measurement efo:EFO_0009312 Quantification of the amount of proprotein convertase subtilisin/kexin type 9 in plasma. Joannella Morales true PMID:29748315 PCSK9 measurement proprotein convertase subtilisin/kexin type 9 measurement efo:EFO_0009317 Lymphoblastoid cell line from B-lymphocyte of a Caucasian male as part of the Personal Genome Project. Zoe May Pendlington https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM20431&Product=CC GM20431 efo:EFO_0009318 Human foreskin fibroblast cell line immortalized by infection with retroviral constrcuts that expressed the hTERT open reading frame Zoe May Pendlington https://www.nature.com/articles/23962 HFF-hTERT clone 6 HFFc6 efo:EFO_0009319 Immortalized mouse embryonic stem cell line Zoe May Pendlington https://www.ncbi.nlm.nih.gov/pmc/articles/PMC196021/ F123 F123-CASTx129 efo:EFO_0009320 Human embryonic stem cell line from a female donor Zoe May Pendlington https://www.sciencedirect.com/science/article/pii/S1934590909003476?via%3Dihub RUES2 efo:EFO_0009323 Quantification of alpha synuclein levels in the cerebrospinal fluid. Joannella Morales true PMID:29959729 α-synuclein alpha synuclein measurement efo:EFO_0009324 Quantification of the presence of absence of the APOL1 risk genotype in an individual Laura Harris true PMID:29885931 APOL1 risk genotype carrier status http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern efo:EFO_0009325 Quantification of any aspect of growth of the basal ganglia during development Laura Harris true PMID:29682794 basal ganglia growth measurement efo:EFO_0009326 Quantification of any aspect of the growth of the brain during development Laura Harris PMID:29682794 brain growth measurement efo:EFO_0009327 Quantification of any aspect of the growth of the cerebellum during development Laura Harris true PMID:29682794 cerebellum growth measurement efo:EFO_0009328 Quantification of any aspect of growth of the cerebral cortex during development Laura Harris true PMID:29682794 cerebral cortex growth measurement efo:EFO_0009330 Chlamydia trachomatis seropositivity is the result of a measurement of circulating C. trachomatis specific antibodies Laura Harris true PMID:29967566 Chlamydia trachomatis seropositivity efo:EFO_0009331 Quantification of some aspect of erosive tooth wear. Erosive tooth wear is a condition where non-bacterial acids dissolve and soften the tooth surface, thus exposing the tooth to mechanical forces. Laura Harris true PMID:29898447 erosive tooth wear measurement efo:EFO_0009332 Quantification of executive function in an individual, for example using the Behavioural Rating Inventory of Executive Function (BRIEF). Tests of executive function may be performed as part of a more comprehensive assessment to diagnose neurological and psychiatric disorders. Laura Harris true PMID:29769613 executive function measurement efo:EFO_0009334 Quantification of any aspect of growth of the prefrontal cortex during development Laura Harris true PMID:29682794 prefrontal cortex growth measurement efo:EFO_0009335 Quantification of any aspect of growth of the white matter during development Laura Harris true PMID:29682794 white matter growth measurement efo:EFO_0009338 The result of a measurement of circulating Epstein-Barr virus early antigen-specific antibodies Laura Harris true PMID:30053915 EBV-EA seropositivity Epstein-Barr virus early antigen seropositivity efo:EFO_0009339 The result of a measurement of circulating Herpes simplex virus 2-specific antibodies Laura Harris true PMID:30053915 HSV2 seropositivity Herpes simplex virus 2 seropositivity efo:EFO_0009340 The result of a measurement of circulating Varicella zoster virus-specific antibodies Laura Harris true PMID:30053915 VZV seropositivity Varicella zoster virus seropositivity efo:EFO_0009341 The result of a measurement of circulating Helicobacter pylori-specific antibodies Laura Harris true PMID:30053915 Helicobacter pylori seropositivity efo:EFO_0009342 The result of a measurement of circulating Measles virus-specific antibodies Laura Harris true PMID:30053915 Measles virus seropositivity efo:EFO_0009343 The result of a measurement of circulating Mumps virus-specific antibodies Laura Harris true PMID:30053915 Mumps virus seropositivity efo:EFO_0009344 The result of a measurement of circulating Rubella virus-specific antibodies Laura Harris true PMID:30053915 Rubella virus seropositivity efo:EFO_0009345 The result of a measurement of circulating Hepatitis B virus surface antigen-specific antibodies Laura Harris true PMID:30053915 HBs seropositivity Hepatitis B virus surface antigen seropositivity efo:EFO_0009346 The result of a measurement of circulating Hepatitis B virus core antigen-specific antibodies Laura Harris true PMID:30053915 HBc seropositivity Hepatitis B virus core antigen seropositivity efo:EFO_0009347 Quantification of the IgG antibody isotype produced in response to cytomegalovirus infection Laura Harris true PMID:30053915 CMV IgG measurement Anti-cytomegalovirus IgG measurement efo:EFO_0009348 Quantification of antibodies to the Epstein-Barr virus early antigen Laura Harris true PMID:30053915 EBV-EA IgG measurement Anti-Epstein-Barr virus early antigen IgG measurement efo:EFO_0009349 Quantification of the IgG antibody isotype produced in response to herpes simplex virus 1 infection Laura Harris true PMID:30053915 HSV1 IgG measurement Anti-herpes simplex virus 1 IgG measurement efo:EFO_0009350 Quantification of the IgG antibody isotype produced in response to herpes simplex virus 2 infection Laura Harris true PMID:30053915 HSV2 IgG measurement Anti-herpes simplex virus 2 IgG measurement efo:EFO_0009351 Quantification of the IgG antibody isotype produced in response to varicella zoster virus infection Laura Harris true PMID:30053915 VZV IgG measurement Anti-varicella zoster virus IgG measurement efo:EFO_0009352 Quantification of the IgG antibody isotype produced in response to Helicobacter pylori infection Laura Harris true PMID:30053915 Anti-Helicobacter pylori IgG measurement efo:EFO_0009353 Quantification of the IgG antibody isotype produced in response to Toxoplasma gondii infection Laura Harris true PMID:30053915 Anti-Toxoplasma gondii IgG measurement efo:EFO_0009354 Quantification of the IgG antibody isotype produced in response to influenza A virus infection Laura Harris true PMID:30053915 Anti-influenza A virus IgG measurement efo:EFO_0009355 Quantification of the IgG antibody isotype produced in response to measles virus infection Laura Harris true PMID:30053915 Anti-measles virus IgG measurement efo:EFO_0009356 Quantification of the IgG antibody isotype produced in response to mumps virus infection Laura Harris true PMID:30053915 Anti-mumps virus IgG measurement efo:EFO_0009357 Quantification of the IgG antibody isotype produced in response to rubella virus infection Laura Harris true PMID:30053915 Anti-rubella virus IgG measurement efo:EFO_0009358 Quantification of antibodies to the hepatitis B virus surface antigen Laura Harris true PMID:30053915 HBs IgG measurement Anti-hepatitis B virus surface antigen IgG measurement efo:EFO_0009359 Quantification of antibodies to the hepatitis B virus core antigen Laura Harris true PMID:30053915 HBc IgG measurement Anti-hepatitis B virus core antigen IgG measurement efo:EFO_0009360 Quantification of the excess eyelid skin that generally occurs in middle-aged or elderly persons, or as a result of genetic disorder such as cutis laxa or Ehlers-Danlos syndrome. Quantification is typically a visual grading by a dermatologist. Laura Harris true PMID:29654602 blepharoptosis measurement dermatochalasis measurement eyelid sagging measurement efo:EFO_0009362 Quantification of measure of nicotine withdrwawal. Joannella Morales true PMID:29532581 nicotine withdrawal measurement efo:EFO_0009366 A measure to assess quality of life (QOL) based on how the individual has felt during the menstrual period. Annalisa Buniello true PMID:29855537 quality of life during menstruation measurement efo:EFO_0009367 Quantification of a glucose metabolic process. Annalisa Buniello true PMID:29130521 glucose metabolism measurement efo:EFO_0009368 Quantification of the amount of factor VII activating protease in a blood sample Laura Harris true PMID:30070759 FSAP measurement Factor seven-activating protease measurement Hepatocyte growth factor activator-like protein measurement Hyaluronan-binding protein 2 measurement Plasma hyaluronan-binding protein measurement factor VII activating protease measurement efo:EFO_0009369 A measurement of carbon monoxide (CO) transfer from inspired gas to pulmonary capillary blood. During the test, the subject inspires a gas containing CO and one or more tracer gases to allow determination of the gas exchanging capability of the lungs. Laura Harris true PMID:30049742 carbon monoxide diffusing capacity pulmonary diffusing capacity transfer factor of the lung for carbon monoxide diffusing capacity of the lung for carbon monoxide efo:EFO_0009370 Quantification of some aspect of exposure to radon gas Laura Harris true PMID:29971594 radon exposure measurement efo:EFO_0009374 Quantification of the energy intake of an individual, e.g. based on a food frequency questionnaire or seven-day food record and assessment of the calorific content of the food types and portion sizes recorded. Laura Harris true PMID:30071075 energy intake measurement efo:EFO_0009375 Telomerase-immortalized human breast epithelial cell line. paolaroncaglia 2018-10-17T10:28:42Z PMID:17395154 https://orcid.org/0000-0001-9203-6323 https://web.expasy.org/cellosaurus/CVCL_K053 184-hTERT efo:EFO_0009381 Quantification of the amount of fibroblast growth factor 23 in a sample Laura Harris true PMID:30217807 FGF23 measurement fibroblast growth factor 23 measurement efo:EFO_0009388 Sum of quantification of basophil and neutrophil in the blood. Annalisa Buniello true PMID:27863252 sum of basophil and neutrophil counts efo:EFO_0009389 Sum of quantification of eosinophil and basophil in the blood. Annalisa Buniello true PMID:27863252 sum of eosinophil and basophil counts efo:EFO_0009390 Sum of quantification of neutrophils and eosinophils in the blood. Annalisa Buniello true PMID:27863252 sum of neutrophil and eosinophil counts efo:EFO_0009392 quantification of a reduction in glucose metabolism. Maria Cerezo true glucose metabolism decline measurement efo:EFO_0009393 Change in pressure of the breast. Maria Cerezo true breast pressure measurement efo:EFO_0009394 Volume of hippocampal CA1, which is the part of hippocampus proper bounded by CA2 and the subiculum, characterized by pyramidal neurons that receive projections from pyramidal neurons of CA3 via the Schaffer collaterals. Maria Cerezo true hippocampal CA1 volume efo:EFO_0009395 Volume of hippocampal CA3, which is the part of hippocampus proper bounded by the hilus of the dentate gyrus and area CA2, characterized by large pyramidal cells and a dense projection from dentate gyrus granule cell mossy fibers. Maria Cerezo true hippocampal CA3 volume efo:EFO_0009396 Volume of hippocampal CA4. Maria Cerezo true hippocampal CA4 volume efo:EFO_0009397 Volume of hippocampus molecular layer. Maria Cerezo true hippocampus molecular layer volume efo:EFO_0009398 Volume of hippocampal tail. Maria Cerezo true hippocampal tail volume efo:EFO_0009399 Volume of subiculum region in hippocampus. Maria Cerezo true subiculum volume efo:EFO_0009400 Volume of subiculum region in hippocampus. Maria Cerezo true presubiculum volume efo:EFO_0009401 Volume of hippocampal amigdala transition area. Maria Cerezo true hippocampal amigdala transition area volume efo:EFO_0009402 Volume of hippocampus fimbria volume. Maria Cerezo true hippocampus fimbria volume efo:EFO_0009403 Volume of granule cell layer dentate gyrus volume. Maria Cerezo true granule cell layer dentate gyrus volume efo:EFO_0009404 Volume of hippocampal fissure volume. Maria Cerezo true hippocampal fissure volume efo:EFO_0009405 Volume of parasubiculum volume. Maria Cerezo true parasubiculum volume efo:EFO_0009410 Quantification of some aspect of uterine fibroids, such as the number, volume or dimensions. Laura Harris true PMID:30196971 uterine fibroid measurement efo:EFO_0009411 Quantification of the amount of CCL13 protein in a sample. Laura Harris true PMID:30134952 CC motif chemokine 13 measurement MCP4 measurement monocyte chemotactic protein-4 measurement CCL13 measurement efo:EFO_0009412 Quantification of the amount of interleukin 1-alpha protein in a sample. Laura Harris true PMID:30134952 IL-1A measurement interleukin 1 alpha measurement efo:EFO_0009413 Quantification of the amount of CCL15 protein in a sample. Laura Harris true PMID:30134952 CC motif chemokine 15 measurement MIP1D measurement macrophage inflammatory protein 1-delta measurement CCL15 measurement efo:EFO_0009414 Quantification of the amount of CCL17 protein in a sample. Laura Harris true PMID:30134952 CC motif chemokine 17 measurement TARC measurement thymus and activation regulated chemokine measurement CCL17 measurement efo:EFO_0009415 Quantification of the amount of CCL19 protein in a sample. Laura Harris true PMID:30134952 CC motif chemokine 19 measurement MIP3B measurement macrophage inflammatory protein 3 beta measurement CCL19 measurement efo:EFO_0009416 Quantification of the amount of CCL21 protein in a sample. Laura Harris true PMID:30134952 CC motif chemokine 21 measurement CCL21 measurement efo:EFO_0009417 Quantification of the amount of CCL23 protein in a sample. Laura Harris true PMID:30134952 CC motif chemokine 23 measurement MPIF1 measurement myeloid progenitor inhibitory factor 1 measurement CCL23 measurement efo:EFO_0009418 Quantification of the amount of CCL24 protein in a sample. Laura Harris true PMID:30134952 CC motif chemokine 24 measurement eotaxin-2 measurement CCL24 measurement efo:EFO_0009419 Quantification of the amount of CX3CL1 protein in a sample. Laura Harris true PMID:30134952 C-X3-C motif chemokine 1 measurement fractalkine measurement neurotactin measurement CX3CL1 measurement efo:EFO_0009420 Quantification of the amount of CXCL12 protein in a sample. Laura Harris true PMID:30134952 SDF-1 measurement stromal cell-derived factor 1 measurement CXCL12 measurement efo:EFO_0009421 Quantification of the amount of CXCL13 protein in a sample. Laura Harris true PMID:30134952 B cell-attracting chemokine 1 measurement BCA-1 measurement C-X-C motif chemokine 13 measurement CXCL13 measurement efo:EFO_0009422 Quantification of the amount of CXCL5 protein in a sample. Laura Harris true PMID:30134952 C-X-C motif chemokine 5 ENA78 measurement epithelial-derived neutrophil-activating peptide 78 measurement CXCL5 measurement efo:EFO_0009423 Quantification of the amount of CXCL6 protein in a sample. Laura Harris true PMID:30134952 C-X-C motif chemokine 6 GCP-5 measurement granulocyte chemotactic protein 2 measurement CXCL6 measurement efo:EFO_0009435 Quantification of the global severity of rheumatoid arthritis in a patient, based on a combination of several different specific measures, e.g. swollen 28-joint count, tender 28-joint count, erythrocyte sedimentation rate and patient global health assessment score. Laura Harris true PMID:30166627 DAS28 disease activity score arthritis disease activity score measurement efo:EFO_0009436 Quantification of the ability of an individual's offspring to survive or live successfully, e.g. the number of children surviving to a given age. Laura Harris true PMID:30188897 offspring survival measurement efo:EFO_0009437 Quantification of some aspect of the death of an individual's offspring, e.g. the number of children dying before a given age. Laura Harris true PMID:30188897 offspring mortality measurement efo:EFO_0009438 Quantification of the number of pregnancies a woman has Laura Harris true PMID:30188897 number of pregnancies measurement efo:EFO_0009439 Quantification of some aspect of multiple births, eg the number or proportion born to an individual. Laura Harris true PMID:30188897 multiple births measurement efo:EFO_0009440 A measurement of the age at which a woman became pregnant for the final time in her reproductive life. Laura Harris true PMID:30188897 age at last pregnancy measurement efo:EFO_0009458 A quantitative measure of alcohol use disorder, e.g. using the Alcohol Use Disorders Identification Test. Laura Harris true PMID:30336701 alcohol use disorder measurement efo:EFO_0009480 Quantification of some aspect of coping behaviour, such as emotional coping, behavioural coping, positive reappraisal, emotional support seeking or disengagement. Laura Harris true PMID:29665250 coping behaviour measurement efo:EFO_0009494 Cell line from olfactory neurosphere cells from a 59-year-old human male. PMID:26438696 https://www.encodeproject.org/documents/ca3a16d0-3a6b-4b1c-8bf2-fc470ae0f9d8/@@download/attachment/Olfneurosphere_Crawford_protocol.pdf C1 100 08 0002 C802 C1 100080002 efo:EFO_0009495 Cell line from olfactory neurosphere cells from a 66-year-old human female. PMID:26438696 https://www.encodeproject.org/documents/ca3a16d0-3a6b-4b1c-8bf2-fc470ae0f9d8/@@download/attachment/Olfneurosphere_Crawford_protocol.pdf C1 100 08 0003 C803 C1 100080003 efo:EFO_0009496 Cell line from olfactory neurosphere cells from a 64-year-old human male. PMID:26438696 https://www.encodeproject.org/documents/ca3a16d0-3a6b-4b1c-8bf2-fc470ae0f9d8/@@download/attachment/Olfneurosphere_Crawford_protocol.pdf C1 100 08 0013 C813 C1 100080013 efo:EFO_0009497 Lymphoblastoid cell line from a Caucasian male with type 2 diabetes, same donor as of MSiPS cell line. PMID:24136358 MSLCL efo:EFO_0009499 Cells isolated from colonic biopsy of 'patient 2' (Roig et al 2010), and immortalized by expression of Cdk4 and hTERT. PMID:19962984 HCEC 2CT efo:EFO_0009500 Cells isolated from colonic biopsy of 'patient 1' (Roig et al 2010), and immortalized by expression of Cdk4 and hTERT. PMID:19962984 HCEC 1CT efo:EFO_0009583 Quantification of some aspect of an individual's place of residence, such as population density or socioeconomic status. Laura Harris true PMID:29936532 place of residence measurement efo:EFO_0009586 Quantification of the degree of hydration of the superficial layers of the skin. Joannella Morales true PMID:30065583 skin capacitance skin hydration measurement efo:EFO_0009587 Quantification of levels of anhedonia, defined as the inability to experience pleasure in activities usually found enjoyable. Joannella Morales true PMID:30104601 anhedonia measurement efo:EFO_0009588 Quantification of whether an individual feels or felt "fed-up". Joannella Morales true PMID:29500382 feeling "fed-up" measurement efo:EFO_0009589 Quantification of whether an individual feels or felt worried. Joannella Morales true PMID:29500382 worry measurement efo:EFO_0009590 Quantification of an individual's ability to store and recall visual information. Joannella Morales true PMID:29907492 visual memory measurement efo:EFO_0009591 Quantification of an individual's ability to store and recall linguistic information. Joannella Morales true PMID:29907492 verbal memory measurement efo:EFO_0009592 Quantification, typically by a questionnaire, of some aspect of social interaction, such as engagement in social activities, or degree of contact with friends and family. Laura Harris true PMID:29970889 social interaction measurement efo:EFO_0009593 Quantification of whether an individual experiences changes in mood. Joannella Morales PMID:29500382 mood change measurement efo:EFO_0009594 Quantification of whether an individual feels or felt irritable. Joannella Morales true PMID:29500382 irritability measurement efo:EFO_0009595 Quantification of whether an individual feels or felt guilty. Joannella Morales true PMID:29500382 guilt measurement efo:EFO_0009596 Quantification of whether an individual feels or felt tense. Joannella Morales true PMID:29500382 feeling tense measurement efo:EFO_0009597 Quantification of whether an individual feels or felt nervous or "suffered from nerves". Joannella Morales true PMID:29500382 feeling nervous measurement efo:EFO_0009598 Quantification of whether an individual feels or felt miserable. Joannella Morales true PMID:29500382 feeling miserable measurement efo:EFO_0009599 Quantification of whether an individual feels or felt emotionally hurt. Joannella Morales true PMID:29500382 feeling emotionally hurt measurement efo:EFO_0009603 Quantification of the the degree of disability or dependence in the daily activities of people who have suffered a stroke, for example using the Modified Rankin Scale. Laura Harris true PMID:30582445 stroke outcome severity measurement efo:EFO_0009693 Quantification of the metabolites of thiopurine compounds. Laura Harris true PMID:30201983 thiopurine metabolite measurement efo:EFO_0009694 Quantification of the presence or severity of an allergy to beta-lactam, including beta-lactam antibiotics. Annalisa Buniello true PMID:25224099 http://www.antimicrobe.org/e35.asp beta-lactam allergy measurement efo:EFO_0009698 Quantification of glucose levels in the blood of a pregnant individual. Laura Harris true PMID:30324795 gestational blood glucose measurement efo:EFO_0009699 Quantification of foot muscle strength. Joannella Morales true PMID:30706531 foot muscle strength measurement efo:EFO_0009700 Quantification of some aspect of visual perception. Laura Harris true PMID:30242048 visual perception measurement efo:EFO_0009701 Quantification of visceral to total adipose tissue. Maria Cerezo true PMID:30363675 visceral:total adipose tissue ratio efo:EFO_0009702 Quantification of the variability in reaction time (the interval of time between the presentation of a stimulus to a subject and the beginning of the subject's response to that stimulus) of an individual, over successive tasks. An increase in intra-individual reaction time variability is a hallmark of neurocogintive disturbance in many neurological and psychiatric disorders, particularly ADHD. Laura Harris true PMID:30287865 IIRTV measurement intra-individual response time variability measurement intra-individual reaction time variability measurement efo:EFO_0009703 The determination of the concentration of folic acid present in a sample of red blood cells. Maria Cerezo true PMID:30339177 RBC Folate RBC Folate Status RBC Folic Acid Red Blood Cell Folate Red Blood Cell Folate Measurement Red Blood Cell Folate Status Red Cell Folate red blood cell folate measurement efo:EFO_0009712 The age of a person's father at which father's death occurred. true father's age at death efo:EFO_0009713 An individual's total number of brothers and sisters. [ NCI ] NCIt:C102469 number of siblings efo:EFO_0009716 The age of onset of first facial hair. true age at first facial hair efo:EFO_0009718 The maximum rate of gas flow, beginning at the point of peak inspiratory capacity, that can be sustained during forced exhalation for a defined period of time. The maximum rate of gas flow, beginning at the point of peak inspiratory capacity, that can be sustained during forced exhalation for a defined period of time. This test is most often used in combination with other studies of lung function to diagnose and monitor obstructive and restrictive lung disease(s). [ NCI ] Maria Cerezo true NCIt:C41372 PMID:30804560 PEF peak expiratory flow efo:EFO_0009720 A measurement indicating ability of an individual to hear what was said with hearing aids. true NCIt:C156149 able to hear with hearing aids efo:EFO_0009721 The age of a person's mother at which mother's death occurred. true mother's age at death efo:EFO_0009722 A measurement of the total number of birth events at which the fetus is of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, which is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes. [ NCI ] NCIt:C139267 number of stillbirths efo:EFO_0009723 Quantification of job satisfaction. true http://purl.obolibrary.org/obo/OMIT_0008700 work satisfaction job satisfaction measurement efo:EFO_0009724 Quantification of health satisfaction. true health satisfaction measurement efo:EFO_0009725 Quantification of friendship satisfaction. true friendship satisfaction measurement efo:EFO_0009726 Quantification of satisfaction with financial situation. true NCIt:C121821 financial situation satisfaction measurement efo:EFO_0009747 Induced pluripotent stem cell line derived from adult skin (leg) fibroblasts; subject clinically normal; wild-type; FISH test: 46, XY. https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM25256&Product=CC WTC-11 WTC11 GM25256 efo:EFO_0009749 A measurement of the age at which a person has the first sexual intercourse. Maria Cerezo true PMID:27089180 age at first sexual intercourse measurement efo:EFO_0009750 Quantification of some aspect of the psychological experience of dissociation. Dissociation in community samples is most commonly measured by the Dissociative Experiences Scale. The DSM-IV considers symptoms such as depersonalization, derealization and psychogenic amnesia to be core features of dissociative disorders. However, in the normal population, dissociative experiences that are not clinically significant are highly prevalent with 60% to 65% of the respondents indicating that they have had some dissociative experiences. The SCID-D is a structured interview used to assess and diagnose dissociation. Laura Harris true PMID:30552317 Wikipedia:Dissociation_(psychology) dissociative symptom measurement dissociation measurement efo:EFO_0009751 Quantification of assymetry of the face. Joannella Morales true PMID:30631343 facial asymmetry measurement efo:EFO_0009762 The period of a person's life during which they are generally healthy and free from serious or chronic illness. Laura Harris true PMID:30729179 health span health-span healthspan efo:EFO_0009764 The quantification of some aspect of eye colour, such as hue, saturation or brightness. Joannella Morales true PMID:30664655 eye colour measurement efo:EFO_0009765 Quantification of the amount of the amino acid alanine in a sample. Laura Harris true PMID:30659259 alanine measurement efo:EFO_0009766 Quantification of the amount of the amino acid asparagine in a sample. Laura Harris true PMID:30659259 asparagine measurement efo:EFO_0009767 Quantification of the amount of the amino acid glycine in a sample. Laura Harris true PMID:30659259 glycine measurement efo:EFO_0009768 Quantification of the amount of the amino acid glutamine in a sample. Laura Harris true PMID:30659259 glutamine measurement efo:EFO_0009769 Quantification of the amount of the amino acid histidine in a sample. Laura Harris true PMID:30659259 histidine measurement efo:EFO_0009770 Quantification of the amount of the amino acid leucine in a sample. Laura Harris true PMID:30659259 leucine measurement efo:EFO_0009771 Quantification of the amount of the amino acid methionine in a sample. Laura Harris true PMID:30659259 methionine measurement efo:EFO_0009773 Quantification of the amount of the amino acid proline in a sample. Laura Harris true PMID:30659259 proline measurement efo:EFO_0009774 Quantification of the amount of the amino acid serine in a sample. Laura Harris true PMID:30659259 serine measurement efo:EFO_0009775 Quantification of the amount of the amino acid threonine in a sample. Laura Harris true PMID:30659259 threonine measurement efo:EFO_0009776 Quantification of the amount of the amino acid ornithine in a sample. Laura Harris true PMID:30659259 ornithine measurement efo:EFO_0009777 Quantification of the amount of the amino acid citrulline in a sample. Laura Harris true PMID:30659259 citrulline measurement efo:EFO_0009778 Quantification of the thyroid hormone tri-iodothyronine (T3) in the blood, usually as an indicator of thyroid function. Maria Cerezo PMID:30824882 T3 measurement thyroid T3 measurement tri-iodothyronine measurement efo:EFO_0009779 Quantification of the thyroid hormone tri-iodothyronine (T3)/ thyroxine (T4) ratio in the blood, usually as an indicator of thyroid function. Maria Cerezo true PMID:30824882 T3/T4 ratio measurement thyroid T3/T4 ratio measurement tri-iodothyronine/thyroxine ratio measurement efo:EFO_0009790 Quantification of the activity of the enzyme asparaginase in a sample, following its administration as a medication. Asparaginase is typically used in the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma. Laura Harris true PMID:30450575 asparaginase activity measurement efo:EFO_0009791 Quantification of the amount of fatty acid desaturase enzyme activity. Joannella Morales true PMID:30453627 fatty acid desaturase enzyme activity measurement efo:EFO_0009792 Quantification of the amount of the amino acid valine in a sample. Laura Harris true PMID:30659259 valine measurement efo:EFO_0009793 Quantification of the amount of the amino acid isoleucine in a sample. Laura Harris true PMID:30659259 isoleucine measurement efo:EFO_0009794 Quantification of the amount of nuclear factor (erythroid-derived 2)-like 2 protein in a sample. Laura Harris true PMID:30767168 NFE2L2 measurement Nuclear factor (erythroid-derived 2)-like 2 measurement NRF2 measurement efo:EFO_0009795 Quantification of the amount of urea in serum. Aoife McMahon true PMID:30808845 urea measurement serum urea measurement efo:EFO_0009804 Quantification of some aspect of cardiovascular system; reflection index is a measure of reflection. A digital volume pulse can be considered to be the summation of a direct and a reflected component. The direct component is due to transmission of a pressure wave from the left ventricle to the finger via the most direct route. The reflected component is formed by pressure transmitted from the heart to the lower body where it is reflected back up the aorta and thence to the finger. If 'b' is the height of direct wave peak and 'a' is the height of reflected wave peak, the reflected index = (a/b) * 100%. true pulse wave reflection index measurement efo:EFO_0009805 The weight of an individual's body water, i.e. the water content of a body that is contained in the tissues, the blood, the bones and elsewhere. The percentages of body water contained in various fluid compartments add up to total body water (TBW). true Wikipedia:Body_water whole body water mass efo:EFO_0009814 A measurement of the number of children fathered by a male individual. number of children fathered measurement efo:EFO_0009815 CASCOT stands for Computer Assisted Structure COding Tool. This is used to translate free-text job descriptions into Standard Occupational Classification (SOC) 2000 codes. The CASCOT programme generates a confidence score (1-100%) for each job description, which represents the Bayesian probability that the computer-assigned SOC code is that which would be assigned manually by experts in job coding. http://biobank.ctsu.ox.ac.uk/crystal/docs/JobRecoding.pdf CASCOT confidence score measurement efo:EFO_0009860 Frequency of chromosomal aberrations in human peripheral blood. Joannella Morales true PMID:30368896 CA chromosomal aberration frequency efo:EFO_0009861 Frequency of chromosome-type chromosomal aberrations in human peripheral blood (typically resulting in damage to both chromatids). Joannella Morales true PMID:30368896 CSA chromosome-type aberration frequency efo:EFO_0009862 Frequency of chromatid-type chromosomal aberrations in human peripheral blood (typically resulting in damage to a single chromatid). Joannella Morales true PMID:30368896 CTA chromatid-type aberration frequency efo:EFO_0009863 Quantification of the level of a generalised feeling of anxiety experienced by an individual, typically measured via a questionnaire. Laura Harris true PMID:30867560 anxiety measurement efo:EFO_0009864 Quantification of some high level aspect of a metabolic network. Aoife McMahon true PMID:30852652 metabolic network measurement efo:EFO_0009865 Quantification of some aspect of the transcriptome. Aoife McMahon true PMID:30852652 transcriptome measurement efo:EFO_0009882 Quantification of the ratio of potassium to creatinine in a urine sample. Aoife McMahon true PMID:30910378 urinary potassium to creatinine ratio efo:EFO_0009883 Quantification of the ratio of sodium to creatinine in a urine sample. Aoife McMahon true PMID:30910378 urinary sodium to creatinine ratio efo:EFO_0009884 Quantification of the ratio of sodium to potassium in a urine sample. Aoife McMahon true PMID:30910378 urinary sodium to potassium ratio efo:EFO_0009885 Quantification of some aspect of frailty. Frailty is usually described as clinical state of heightened vulnerability to poor resolution of homeostasis after a stressor event, which thereby increases the risk of adverse outcomes, including falls, delirium, disability and mortality. Aoife McMahon true PMID:30475886 frailty measurement efo:EFO_0009890 Quantification of an individual's body fat mass that has been corrected for lean mass. Laura Harris true PMID:30944420 lean mass-adjusted fat body mass efo:EFO_0009891 Quantification of some metabolite of the anti-epileptic drug carbamazepine. Aoife McMahon true PMID:30868120 carbamazepine metabolite measurement efo:EFO_0009892 Quantiication of some aspect of facial attractiveness, typically via a rating scale. Laura Harris true PMID:30946739 facial attractiveness measurement efo:EFO_0009896 A quantification of antibodies against thyroglobulin, usually as an indicator of autoimmune thyroid disease. Aoife McMahon true PMID:30926877 TgAb measurement anti-thyroglobulin measurement anti-thyroglobulin antibody measurement efo:EFO_0009923 Quantification of some aspect of the use of drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD). Aoife McMahon true PMID:31015401 Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement efo:EFO_0009924 Quantification of some aspect of the use of drugs used in diabetes. Aoife McMahon true PMID:31015401 Drugs used in diabetes use measurement efo:EFO_0009925 Quantification of some aspect of the use of antithrombotic agents. Aoife McMahon true PMID:31015401 Antithrombotic agent use measurement efo:EFO_0009926 Quantification of some aspect of the use of vasodilators used in cardiac diseases. Aoife McMahon true PMID:31015401 Vasodilators used in cardiac diseases use measurement efo:EFO_0009927 Quantification of some aspect of the use of antihypertensives. Aoife McMahon true PMID:31015401 Antihypertensive use measurement efo:EFO_0009928 Quantification of some aspect of the use of diuretic drugs. Aoife McMahon true PMID:31015401 Diuretic use measurement efo:EFO_0009929 Quantification of some aspect of the use of beta blocking agents. Aoife McMahon true PMID:31015401 Beta blocking agent use measurement efo:EFO_0009930 Quantification of some aspect of the use of calcium channel blockers. Aoife McMahon true PMID:31015401 Calcium channel blocker use measurement efo:EFO_0009931 Quantification of some aspect of the use of agents acting on the renin-angiotensin system. Aoife McMahon true PMID:31015401 Agents acting on the renin-angiotensin system use measurement efo:EFO_0009932 Quantification of some aspect of the use of HMG CoA reductase inhibitors. Aoife McMahon true PMID:31015401 HMG CoA reductase inhibitor use measurement efo:EFO_0009933 Quantification of some aspect of the use of thyroid preparations. Aoife McMahon true PMID:31015401 Thyroid preparation use measurement efo:EFO_0009934 Quantification of some aspect of the use of immunosuppressant drugs. Aoife McMahon true PMID:31015401 Immunosuppressant use measurement efo:EFO_0009935 Quantification of some aspect of the use of non-steroidal anti-inflammatory and antirheumatic product. Aoife McMahon true PMID:31015401 Non-steroidal anti-inflammatory and antirheumatic product use measurement efo:EFO_0009936 Quantification of some aspect of the use of drugs affecting bone structure and mineralization. Aoife McMahon true PMID:31015401 Drugs affecting bone structure and mineralization use measurement efo:EFO_0009937 Quantification of some aspect of the use of opioid drugs. Aoife McMahon true PMID:31015401 Opioid use measurement efo:EFO_0009938 Quantification of some aspect of the use of anilide drugs. Aoife McMahon true PMID:31015401 Anilide use measurement efo:EFO_0009939 Quantification of some aspect of the use of antimigraine preparations. Aoife McMahon true PMID:31015401 Antimigraine preparation use measurement efo:EFO_0009940 Quantification of some aspect of the use of antidepressant drugs. Aoife McMahon true PMID:31015401 Antidepressant use measurement efo:EFO_0009941 Quantification of some aspect of the use of inhalant adrenergic drugs. Aoife McMahon true PMID:31015401 Inhalant adrenergic use measurement efo:EFO_0009942 Quantification of some aspect of the use of glucocorticoids. Aoife McMahon true PMID:31015401 Glucocorticoid use measurement efo:EFO_0009943 Quantification of some aspect of the use of antihistamines. Aoife McMahon true PMID:31015401 Antihistamine use measurement efo:EFO_0009944 Quantification of some aspect of the use of antiglaucoma preparations and miotics. Aoife McMahon true PMID:31015401 Antiglaucoma preparations and miotics use measurement efo:EFO_0009945 Quantification of the degree to which an individual is resilient to psychological stress, typically assessed via a questionnaire or clinical review of an individual's mental health before and after a stressful life event. Laura Harris true PMID:31081985 psychological resilience measurement efo:EFO_0009946 A quantification of triglycerides contained in low density lipoproteins. Elliot Sollis true PMID:30685440 LDL triglyceride measurement low density lipoprotein triglyceride measurement efo:EFO_0009947 A quantification of the amount of nucleoside diphosphate kinase A in a sample. Elliot Sollis true PMID:30662464 NDK A measurement NDP kinase A measurement NM23 measurement NME1 measurement nucleoside diphosphate kinase A measurement efo:EFO_0009949 Quantification of some aspect of the red cell antigen KANNO. Laura Harris true PMID:31020675 KANNO antigen measurement efo:EFO_0009961 Measure of first-phase insulin response to glucose challenge. Annalisa Buniello true PMID:23263489 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083884/ Insulinogenic index measurement efo:EFO_0010049 Quantification of some aspect of asthma symptoms. Aoife McMahon true PMID:30367910 asthma symptoms measurement efo:EFO_0010050 Quantification of the amount of the thyroglobulin in a sample. Joannella Morales true PMID:30929638 http://purl.obolibrary.org/obo/NCIT_C103446 thyroglobulin measurement efo:EFO_0010056 Quantification of the amount of iron in the liver. Elliot Sollis true PMID:31226389 liver iron measurement efo:EFO_0010057 Quantification of the amount of soluble vascular cell adhesion molecule-1 in a sample Laura Harris true PMID:31217265 Wikipedia:VCAM-1 VCAM-1 measurement VCAM1 measurement sVCAM-1 measurement soluble vascular cell adhesion molecule-1 measurement vascular cell adhesion molecule-1 measurement efo:EFO_0010066 A measure of the biomechanical properties of the cornea. Low corneal hysteresis may be indicative of keratoconus. Elliot Sollis true PMID:31246245 corneal hysteresis efo:EFO_0010067 A measure of the biomechanical properties of the cornea. Low corneal resistance factor may be indicative of keratoconus. Elliot Sollis true PMID:31246245 corneal resistance factor efo:EFO_0010068 Quantification of the rate of change in respiratory symptoms of an individual over the course of time (either through clinical examination or through a standardised questionnaire), used as an indicator of improvement or decay of respiratory function. Laura Harris true PMID:31299468 respiratory symptom change measurement efo:EFO_0010069 Quantification of the velocity of nerve conduction, often used to measure peripheral nerve function. Joannella Morales true PMID:30992453 nerve conduction velocity efo:EFO_0010070 Quantification of the amplitude of nerve conduction, often used to measure peripheral nerve function. Joannella Morales true PMID:30992453 nerve conduction amplitude efo:EFO_0010071 Quantification of cardiac troponin I, typically measured in blood. Cardiac troponin I measurements are used as a marker of cardiac muscle damage and used in the diagnosis of myocardial infarction. Joannella Morales true PMID:31014085 cardiac troponin I measurement efo:EFO_0010073 Quantification of the number of natural teeth an individual has Laura Harris true PMID:31235808 number of teeth measurement efo:EFO_0010074 Quantification of the size of the femoral trochanter. Elliot Sollis true PMID:31053729 femoral trochanter size trochanter size efo:EFO_0010075 Quantification of the size of the intertrochanteric region of the femur. Elliot Sollis true PMID:31053730 intertrochanteric region size efo:EFO_0010076 Quantification of the size of the femoral neck. Elliot Sollis true PMID:31053731 femoral neck size efo:EFO_0010079 Quantification of some aspect of corneal endothelial cells, such as their size, shape or density. Laura Harris true PMID:30894546 corneal endothelial cell measurement efo:EFO_0010080 Quantification of the growth of geographic atrophy lesions, a symptom of late-stage age-related macular degeneration. Elliot Sollis true PMID:31120506 geographic atrophy lesion growth efo:EFO_0010082 Quantification of any aspect of the act of transmitting electricty along a nerve. Joannella Morales PMID:30992453 nerve conduction measurement efo:EFO_0010083 Quantification of the volume of the dentate gyrus. Laura Harris true PMID:31155012 Wikipedia:Dentate_gyrus dentate gyrus volume measurement efo:EFO_0010084 Quantification of the IgG antibody isotype produced in response to meningococcal C exposure. Elliot Sollis true PMID:31189108 anti-meningococcal C IgG measurement efo:EFO_0010085 Quantification of the IgG antibody isotype produced in response to tetanus toxoid exposure. Elliot Sollis true PMID:31189108 anti-tetanus toxoid IgG measurement efo:EFO_0010086 Quantification of the IgG antibody isotype produced in response to Haemophilus influenzae type b polyribosylribitol phosphate exposure. Elliot Sollis true PMID:31189108 anti-Haemophilus influenzae type b polyribosylribitol phosphate IgG measurement efo:EFO_0010087 Quantification of serum bactericidal antibody produced in response to meningococcal C exposure. Elliot Sollis true PMID:31189108 anti-meningococcal C serum bactericidal antibody measurement efo:EFO_0010088 Quantification of some beverage consumption or beverage consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 beverage consumption measurement efo:EFO_0010089 Quantification of some bitter beverage consumption or bitter beverage consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 bitter beverage consumption measurement efo:EFO_0010090 Quantification of some sweet beverage consumption or sweet beverage consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 sweet beverage consumption measurement efo:EFO_0010091 Quantification of some tea consumption or tea consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 tea consumption measurement efo:EFO_0010092 Quantification of some bitter alcoholic beverage consumption or bitter alcoholic beverage consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 bitter alcoholic beverage consumption measurement efo:EFO_0010093 Quantification of some bitter non-alcoholic beverage consumption or bitter non-alcoholic beverage consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 bitter non-alcoholic beverage consumption measurement efo:EFO_0010094 Quantification of some grapefruit juice consumption or grapefruit juice consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 grapefruit juice consumption measurement efo:EFO_0010095 Quantification of some non-grapefruit juice consumption or non-grapefruit juice consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 non-grapefruit juice consumption measurement efo:EFO_0010096 Quantification of some artificially sweetened beverage consumption or artificially sweetened beverage consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 artificially sweetened beverage consumption measurement efo:EFO_0010097 Quantification of some sugar sweetened beverage consumption or sugar sweetened beverage consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31046077 sugar sweetened beverage consumption measurement efo:EFO_0010104 A measurement of the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. Aoife McMahon true PMID:31250787 health literacy measurement efo:EFO_0010105 A quantification of CD4-positive T-lymphocytes in blood. Annalisa Buniello true PMID:20045101 CD4-positive T-lymphocyte count efo:EFO_0010106 A quantification of CD3-positive T-lymphocytes in blood. Annalisa Buniello true PMID:20045101 CD3-positive T-lymphocyte count efo:EFO_0010107 A quantification of CD8-positive T-lymphocytes in blood. Annalisa Buniello true PMID:20045101 CD8-positive T-lymphocyte count efo:EFO_0010108 A quantification of CD19-positive B-lymphocytes in blood. Annalisa Buniello true PMID:20045101 CD19-positive B-lymphocyte count efo:EFO_0010109 A quantification of CD56-positive NK-lymphocytes in blood. Annalisa Buniello true PMID:20045101 CD56-positive NK-lymphocyte cell count efo:EFO_0010110 A quantification of ketone bodies in a sample. Aoife McMahon true PMID:31367044 ketone body measurement efo:EFO_0010111 A quantification of acetoacetate in a sample. Aoife McMahon true PMID:31367044 acetoacetate measurement efo:EFO_0010112 A quantification of acetate in a sample. Aoife McMahon true PMID:31367044 acetate measurement efo:EFO_0010113 A quantification of 3-hydroxybutyric acid in a sample. Aoife McMahon true PMID:31367044 beta-hydroxybutyric acid measurement 3-hydroxybutyric acid measurement efo:EFO_0010114 A quantification of citrate in a sample. Aoife McMahon true PMID:31367044 citrate measurement efo:EFO_0010115 A quantification of glycerol in a sample. Aoife McMahon true PMID:31367044 glycerol measurement efo:EFO_0010116 A quantification of choline in a sample. Aoife McMahon true PMID:31367044 choline measurement efo:EFO_0010117 A quantification of pyruvate in a sample. Aoife McMahon true PMID:31367044 pyruvate measurement efo:EFO_0010118 A quantification of sphingomyeline in a sample. Aoife McMahon true PMID:31367044 sphingomyelin measurement efo:EFO_0010119 A quantification of omega-3 fatty acid in a sample. Aoife McMahon true PMID:31367044 Omega-3 fatty acid measurement omega-3 polyunsaturated fatty acid measurement efo:EFO_0010120 A quantification of the change in fasting blood glucose measurements at different points in time. Elliot Sollis true PMID:31263163 fasting blood glucose change measurement efo:EFO_0010125 A measurement of the quantity of virus in a given volume of body fluid. Elliot Sollis true MedDRA:10062178 PMID:31260374 https://en.wikipedia.org/wiki/Viral_load viral burden viral titer viral titre viral load efo:EFO_0010126 Quantification of how soon after waking up an individual smokes their first cigarette of the day. Laura Harris true PMID:31294817 time to first cigarette measurement efo:EFO_0010127 Quantification of the amount of immunglobulin in a serum sample. Laura Harris true PMID:28628107 serum immunoglobulin measurement efo:EFO_0010128 Quantification of the switching of activated B cells from IgM biosynthesis to biosynthesis of other isotypes of immunoglobulin. Laura Harris true PMID:28628107 immunoglobulin isotype switching measurement efo:EFO_0010129 Quantification of the frequency which an individual omits to eat breakfast. Breakfast skipping is often considered as a sub-clinical eating disorder. Laura Harris true PMID:31190057 breakfast skipping measurement efo:EFO_0010135 Quantification of the concentration of particles in the urine. Joannella Morales true CMO:0000257 PMID:30476138 urine specific gravity measurement efo:EFO_0010136 Quantification of pH of an organism, typically in urine or blood. This measures the degree of acidity or alkalinity. Joannella Morales true PMID:30476138 urinary pH measurement efo:EFO_0010137 Quantification of the amount of leukocyte esterase present in a sample. Joannella Morales true NCIt:C64856 PMID:30476138 leukocyte esterase measurement efo:EFO_0010138 Quantification of the amount of nitrite present in a sample. Joannella Morales true NCIt:C64810 PMID:30476138 nitrite measurement efo:EFO_0010139 Quantification of some fish consumption or fish consumption-related behaviour, usually self-reported via a questionnaire. Joannella Morales true PMID:31320941 fish intake measurement fish consumption measurement efo:EFO_0010140 Quantification of the frequency and severity of overdoses as a result of opioid drug use in a person's lifetime. Elliot Sollis true PMID:31362332 opioid overdose severity measurement efo:EFO_0010144 Quantification of the volume of the frontal lobe of the brain. Elliot Sollis true PMID:31396565 frontal lobe volume measurement efo:EFO_0010145 Quantification of the volume of the occipital lobe of the brain. Elliot Sollis true PMID:31396565 occipital lobe volume measurement efo:EFO_0010146 Quantification of the volume of the parietal lobe of the brain. Elliot Sollis true PMID:31396565 parietal lobe volume measurement efo:EFO_0010147 Quantification of the volume of the temporal lobe of the brain. Elliot Sollis true PMID:31396565 temporal lobe volume measurement efo:EFO_0010148 Quantification of the amount of pepsinogen-I in a sample Laura Harris true PMID:30753327 pepsinogen-I measurement efo:EFO_0010149 Quantification of the ratio of pepsinogen I to pepsinogen II in a sample Laura Harris true PMID:30753327 pepsinogen I/II ratio efo:EFO_0010150 Quantification of antibodies against anoctamin 2. Joannella Morales true PMID:31375628 anti-ANO2 antibody anti-anoctamin 2 antibody measurement efo:EFO_0010151 Quantification of the amount of soluble TREM2 (triggering receptor expressed on myeloid cells 2) protein in a sample. Cerebrospinal fluid sTREM2 is used as a biomarker of disease pathogenesis in Alzheimer's disease. Laura Harris true PMID:31413141 sTREM2 measurement soluble triggering receptor expressed on myeloid cells 2 measurement efo:EFO_0010154 Quantification of platinum in a sample. Aoife McMahon true PMID:31296530 platinum measurement efo:EFO_0010155 Quantification of an individual's appreciation of a taste. Maria Cerezo true PMID:31005972 taste liking measurement efo:EFO_0010156 Quantification of an individual's appreciation of sweet. Maria Cerezo true PMID:31005972 sweet liking measurement efo:EFO_0010157 Quantification of an individual's appreciation of sucrose. Maria Cerezo true PMID:31005972 sucrose liking measurement efo:EFO_0010158 Quantification of some aspect of sugar consumption such as frequency or quantity. Maria Cerezo true PMID:31005972 sugar intake measurement sugar consumption measurement efo:EFO_0010162 Death in during childhood, defined here as between the ages of 2 and 10 years. Baron Koylass UMLS:C1843392 death in childhood efo:EFO_0010219 Quantification of the level of aldosterone in a sample Laura Harris true PMID:31169883 Wikipedia:Aldosterone aldosterone measurement efo:EFO_0010220 Quantification of the amount of 17-hydroxyprogesterone in a sample Laura Harris true PMID:31169883 Wikipedia:17α-Hydroxyprogesterone 17-hydroxyprogesterone measurement efo:EFO_0010221 Quantification of the drive to systemise, ie identifiy input-operation-output relationships in order to build, analyse or understand systems, typically quantified by administration of a standardised questionnaire such as the Systemising Quotient-Revised (SQ-R) Laura Harris true PMID:31508503 systemizing measurement systemising measurement efo:EFO_0010222 A quantification of ceramides. Elliot Sollis true PMID:31551469 ceramide measurement efo:EFO_0010223 A quantification of diglycerides. Elliot Sollis true PMID:31551469 diacylglyceride measurement diglyceride measurement efo:EFO_0010224 A quantification of lysophosphatidylcholines. Elliot Sollis true PMID:31551469 lysophosphatidylcholine measurement efo:EFO_0010225 A quantification of lysophosphatidylethanolamines. Elliot Sollis true PMID:31551469 lysophosphatidylethanolamine measurement efo:EFO_0010226 A quantification of phosphatidylcholines. Elliot Sollis true PMID:31551469 phosphatidylcholine measurement efo:EFO_0010227 A quantification of phosphatidylcholine ethers. Elliot Sollis true PMID:31551469 phosphatidylcholine ether measurement efo:EFO_0010228 A quantification of phosphatidylethanolamines. Elliot Sollis true PMID:31551469 phosphatidylethanolamine measurement efo:EFO_0010229 A quantification of phosphatidylethanolamine ethers. Elliot Sollis true PMID:31551469 phosphatidylethanolamine ether measurement efo:EFO_0010230 A quantification of phosphatidylinositols. Elliot Sollis true PMID:31551469 phosphatidylinositol measurement efo:EFO_0010231 A quantification of sterols. Elliot Sollis true PMID:31551469 sterol measurement efo:EFO_0010232 Quantification of the amount of osteocalcin in a sample Laura Harris true PMID:29875488 BGLAP measurement BGP measurement bone gamma-carboxyglutamic acid-containing protein measurement osteocalcin measurement efo:EFO_0010233 Quantification of some aspect of exposure to genotoxic compounds, i.e. compounds that may cause DNA damage. Elliot Sollis true PMID:31586183 genotoxic compound exposure measurement efo:EFO_0010234 Quantification of the presence or absence of a particular viral subtype in an individual. Aoife McMahon true PMID:31341412 virus type carrier status viral subtype carrier status efo:EFO_0010239 Quantification of the ratio of cortisol to dehydroepiandrosterone (DHEA) in a sample. Laura Harris true PMID:23696881 cortisol:dehydroepiandrosterone sulfate ratio measurement cortisol:dehydroepiandrosterone sulphate ratio measurement cortisol:DHEAS ratio measurement efo:EFO_0010240 Quantification of the amount of dehydroepiandrosterone (DHEA) in a sample. Laura Harris true PMID:23696881 DHEA measurement dehydroepiandrosterone measurement efo:EFO_0010241 Quantification of the amount of galectin-3-binding protein in a sample. Laura Harris true PMID:23696881 90K protein measurement mac-2-binding protein measurement tumor-asociated antigen 90K measurement galectin-3-binding protein measurement efo:EFO_0010242 Quantification of the amount of beta globulin in a sample. Laura Harris true PMID:23696881 beta globulin measurement efo:EFO_0010243 Quantification of the amount of an inorganic ion, such as magnesium, iron or calcium, in a sample Laura Harris true PMID:23696881 inorganic ion measurement efo:EFO_0010244 Quantification of the degree of severity of uveal melanoma, eg by TNM staging Laura Harris true PMID:31626034 uveal melanoma disease severity efo:EFO_0010245 Quantification of the amount of oxytocin in a sample. Elliot Sollis true PMID:31361301 oxytocin measurement efo:EFO_0010271 A measurement of the genotype of a bacterial pathogen in an infected individual. Elliot Sollis true PMID:31092817 bacterial pathogen genotype measurement efo:EFO_0010272 A quantification of the extent of calcification in the abdominal aorta. Elliot Sollis true PMID:31659325 abdominal aortic calcification measurement efo:EFO_0010273 A quantification of the extent of calcification in the thoracic aorta. Elliot Sollis true PMID:31659325 thoracic aortic calcification measurement efo:EFO_0010286 Quantification of the volume of the banks of the superior temporal sulcus. Joannella Morales true PMID:31530798 banks of the superior temporal sulcus volume measurement efo:EFO_0010287 Quantification of the volume of the brain cortex. Joannella Morales true PMID:31530798 brain cortex volume measurement efo:EFO_0010288 Quantification of the density of the brain. Joannella Morales PMID:31530798 brain density measurement efo:EFO_0010289 Quantification of the volume of the caudal anterior cingulate cortex. Joannella Morales true PMID:31530798 caudal anterior cingulate cortex volume measurement efo:EFO_0010290 Quantification of the volume of the caudal middle frontal gyrus. Joannella Morales true PMID:31530798 caudal middle frontal gyrus volume measurement efo:EFO_0010291 Quantification of the volume of the cerebellar cortex. Joannella Morales true PMID:31530798 cerebellum cortex volume measurement cerebellar cortex volume measurement efo:EFO_0010292 Quantification of the volume of the cerebral cortex. Joannella Morales PMID:31530798 cerebral cortex volume measurement efo:EFO_0010293 Quantification of the volume of the choroid plexus. Joannella Morales true PMID:31530798 choroid plexus volume measurement efo:EFO_0010294 Quantification of the volume of the cingulate cortex. Joannella Morales PMID:31530798 cingulate cortex volume measurement efo:EFO_0010295 Quantification of the volume of the corpus callosum anterior. Joannella Morales true PMID:31530798 corpus callosum anterior volume measurement efo:EFO_0010296 Quantification of the volume of the corpus callosum central. Joannella Morales true PMID:31530798 corpus callosum central volume measurement efo:EFO_0010297 Quantification of the volume of the corpus callosum mid-anterior. Joannella Morales true PMID:31530798 corpus callosum mid-anterior volume measurement efo:EFO_0010298 Quantification of the volume of the corpus callosum posterior. Joannella Morales true PMID:31530798 corpus callosum posterior volume measurement efo:EFO_0010299 Quantification of the volume of the corpus callosum. Joannella Morales PMID:31530798 corpus callosum volume measurement efo:EFO_0010300 Quantification of the volume of the corpus collosum mid-posterior. Joannella Morales true PMID:31530798 corpus collosum mid-posterior volume measurement efo:EFO_0010301 Quantification of the volume of the cuneus cortex. Joannella Morales true PMID:31530798 cuneus cortex volume measurement efo:EFO_0010302 Quantification of the volume of the entorhinal cortex. Joannella Morales true PMID:31530798 entorhinal cortex volume measurement efo:EFO_0010303 Quantification of the volume of the choroid plexus. Joannella Morales true PMID:31530798 fourth ventricle volume measurement efo:EFO_0010304 Quantification of the volume of the frontal pole. Joannella Morales true PMID:31530798 frontal pole volume measurement efo:EFO_0010305 Quantification of the volume of the fusiform gyrus. Joannella Morales true PMID:31530798 fusiform gyrus volume measurement efo:EFO_0010306 Quantification of the density of the grey matter of the brain or part of the brain. Joannella Morales true PMID:31530798 Grey matter density measurement efo:EFO_0010307 Quantification of the volume of the inferior parietal cortex. Joannella Morales true PMID:31530798 inferior parietal cortex volume measurement efo:EFO_0010308 Quantification of the volume of the inferior temporal gyrus. Joannella Morales true PMID:31530798 inferior temporal gyrus volume measurement efo:EFO_0010309 Quantification of the volume of the insular cortex. Joannella Morales true PMID:31530798 insular cortex volume measurement efo:EFO_0010310 Quantification of the volume of the isthmus of the cingulate cortex. Joannella Morales true PMID:31530798 isthmus cingulate cortex volume measurement efo:EFO_0010311 Quantification of the volume of the lateral occipital. Joannella Morales true PMID:31530798 lateral occipital cortex volume measurement efo:EFO_0010312 Quantification of the volume of the Lateral orbital frontal cortex. Joannella Morales true PMID:31530798 lateral orbital frontal cortex volume measurement efo:EFO_0010313 Quantification of the volume of the limbic lobe. Joannella Morales PMID:31530798 limbic lobe volume measurement efo:EFO_0010314 Quantification of the volume of the lingual gyrus. Joannella Morales true PMID:31530798 lingual gyrus volume measurement efo:EFO_0010315 Quantification of the volume of the medial orbital frontal cortex. Joannella Morales true PMID:31530798 medial orbital frontal cortex volume measurement efo:EFO_0010316 Quantification of the volume of the middle temporal gyrus. Joannella Morales true PMID:31530798 middle temporal gyrus volume measurement efo:EFO_0010317 Quantification of the volume of the paracentral lobule. Joannella Morales true PMID:31530798 paracentral lobule volume measurement efo:EFO_0010318 Quantification of the volume of the parahippocampal gyrus. Joannella Morales true PMID:31530798 parahippocampal gyrus volume measurement efo:EFO_0010319 Quantification of the volume of the pars opercularis. Joannella Morales true PMID:31530798 pars opercularis volume measurement efo:EFO_0010320 Quantification of the volume of the pars orbitalis. Joannella Morales true PMID:31530798 pars orbitalis volume measurement efo:EFO_0010321 Quantification of the volume of the pars triangularis. Joannella Morales true PMID:31530798 pars triangularis volume measurement efo:EFO_0010322 Quantification of the volume of the pericalcarine cortex. Joannella Morales true PMID:31530798 pericalcarine cortex volume measurement efo:EFO_0010323 Quantification of the volume of the postcentral gyrus. Joannella Morales true PMID:31530798 postcentral gyrus volume measurement efo:EFO_0010324 Quantification of the volume of the posterior cingulate cortex. Joannella Morales true PMID:31530798 posterior cingulate cortex volume measurement efo:EFO_0010325 Quantification of the volume of the precentral gyrus. Joannella Morales true PMID:31530798 precentral gyrus volume measurement efo:EFO_0010326 Quantification of the volume of the precuneus cortex. Joannella Morales true PMID:31530798 precuneus cortex volume measurement efo:EFO_0010327 Quantification of the volume of the rostral anterior cingulate cortex. Joannella Morales true PMID:31530798 rostral anterior cingulate cortex volume measurement efo:EFO_0010328 Quantification of the volume of the rostral middle frontal gyrus. Joannella Morales true PMID:31530798 rostral middle frontal gyrus volume measurement efo:EFO_0010329 Quantification of the volume of the superior frontal gyrus. Joannella Morales true PMID:31530798 superior frontal gyrus volume measurement efo:EFO_0010330 Quantification of the volume of the superior parietal cortex. Joannella Morales true PMID:31530798 superior parietal cortex volume measurement efo:EFO_0010331 Quantification of the volume of the superior temporal gyrus. Joannella Morales true PMID:31530798 superior temporal gyrus volume measurement efo:EFO_0010332 Quantification of the volume of the supramarginal gyrus. Joannella Morales true PMID:31530798 supramarginal gyrus volume measurement efo:EFO_0010333 Quantification of the volume of the choroid plexus. Joannella Morales true PMID:31530798 temporal horn of lateral ventricle volume measurement efo:EFO_0010334 Quantification of the volume of the temporal pole. Joannella Morales true PMID:31530798 temporal pole volume measurement efo:EFO_0010335 Quantification of the volume of the choroid plexus. Joannella Morales true PMID:31530798 third ventricle volume measurement efo:EFO_0010336 Quantification of the volume of the transverse temporal cortex. Joannella Morales true PMID:31530798 transverse temporal cortex volume measurement efo:EFO_0010337 Quantification of the volume of the ventral diencephalon. Joannella Morales true PMID:31530798 ventral diencephalon volume measurement efo:EFO_0010339 Quantification of the rate of change in forced vital capacity of an individual over the course of time, used as an indicator of improvement or decay of pulmonary function. Laura Harris true PMID:31557306 forced vital capacity change meaurement FVC change measurement efo:EFO_0010340 The quantification of cholesteryl ester 14:0 levels in a sample. Joannella Morales true PMID:23823483 CE 14:0 cholesteryl ester 14:0 measurement efo:EFO_0010341 The quantification of cholesteryl ester 16:0 levels in a sample. Joannella Morales true PMID:23823483 CE 16:0 cholesteryl ester 16:0 measurement efo:EFO_0010342 The quantification of cholesteryl ester 16:1 levels in a sample. Joannella Morales true PMID:23823483 CE 16:1 cholesteryl ester 16:1 measurement efo:EFO_0010343 The quantification of cholesteryl ester 18:0 levels in a sample. Joannella Morales true PMID:23823483 CE 18:0 cholesteryl ester 18:0 measurement efo:EFO_0010344 The quantification of cholesteryl ester 18:1 levels in a sample. Joannella Morales true PMID:23823483 CE 18:1 cholesteryl ester 18:1 measurement efo:EFO_0010345 The quantification of cholesteryl ester 18:2 levels in a sample. Joannella Morales true PMID:23823483 CE 18:2 cholesteryl ester 18:2 measurement efo:EFO_0010346 The quantification of cholesteryl ester 18:3 levels in a sample. Joannella Morales true PMID:23823483 CE 18:3 cholesteryl ester 18:3 measurement efo:EFO_0010347 The quantification of cholesteryl ester 20:3 levels in a sample. Joannella Morales true PMID:23823483 CE 20:3 cholesteryl ester 20:3 measurement efo:EFO_0010348 The quantification of cholesteryl ester 20:4 levels in a sample. Joannella Morales true PMID:23823483 CE 20:4 cholesteryl ester 20:4 measurement efo:EFO_0010349 The quantification of cholesteryl ester 20:5 levels in a sample. Joannella Morales true PMID:23823483 CE 20:5 cholesteryl ester 20:5 measurement efo:EFO_0010350 The quantification of cholesteryl ester 22:6 levels in a sample. Joannella Morales true PMID:23823483 CE 22:6 cholesteryl ester 22:6 measurement efo:EFO_0010351 The quantification of cholesteryl ester levels in a sample. Joannella Morales true PMID:23823483 CE cholesteryl ester measurement efo:EFO_0010352 The quantification of diacylglycerol 34:1 levels in a sample. Joannella Morales true PMID:23823483 DAG 34:1 diacylglycerol 34:1 measurement efo:EFO_0010353 The quantification of diacylglycerol 34:2 levels in a sample. Joannella Morales true PMID:23823483 DAG 34:2 diacylglycerol 34:2 measurement efo:EFO_0010354 The quantification of diacylglycerol 36:1 levels in a sample. Joannella Morales true PMID:23823483 DAG 36:1 diacylglycerol 36:1 measurement efo:EFO_0010355 The quantification of diacylglycerol 36:2 levels in a sample. Joannella Morales true PMID:23823483 DAG 36:2 diacylglycerol 36:2 measurement efo:EFO_0010356 The quantification of lysophosphatidylcholine 14:0 levels in a sample. Joannella Morales true PMID:23823483 LPC 14:0 lysophosphatidylcholine 14:0 measurement efo:EFO_0010357 The quantification of lysophosphatidylcholine 16:0 levels in a sample. Joannella Morales true PMID:23823483 LPC 16:0 lysophosphatidylcholine 16:0 measurement efo:EFO_0010358 The quantification of lysophosphatidylcholine 16:1 levels in a sample. Joannella Morales true PMID:23823483 LPC 16:1 lysophosphatidylcholine 16:1 measurement efo:EFO_0010359 The quantification of lysophosphatidylcholine 18:0 levels in a sample. Joannella Morales true PMID:23823483 LPC 18:0 lysophosphatidylcholine 18:0 measurement efo:EFO_0010360 The quantification of lysophosphatidylcholine 18:1 levels in a sample. Joannella Morales true PMID:23823483 LPC 18:1 lysophosphatidylcholine 18:1 measurement efo:EFO_0010361 The quantification of lysophosphatidylcholine 18:2 levels in a sample. Joannella Morales true PMID:23823483 LPC 18:2 lysophosphatidylcholine 18:2 measurement efo:EFO_0010362 The quantification of lysophosphatidylcholine 20:3 levels in a sample. Joannella Morales true PMID:23823483 LPC 20:3 lysophosphatidylcholine 20:3 measurement efo:EFO_0010363 The quantification of lysophosphatidylcholine 20:4 levels in a sample. Joannella Morales true PMID:23823483 LPC 20:4 lysophosphatidylcholine 20:4 measurement efo:EFO_0010364 The quantification of lysophosphatidylcholine 20:5 levels in a sample. Joannella Morales true PMID:23823483 LPC 20:5 lysophosphatidylcholine 20:5 measurement efo:EFO_0010365 The quantification of lysophosphatidylcholine 22:6 levels in a sample. Joannella Morales true PMID:23823483 LPC 22:6 lysophosphatidylcholine 22:6 measurement efo:EFO_0010366 The quantification of lysophosphatidylethanolamine 16:0 levels in a sample. Joannella Morales true PMID:23823483 LPE 16:0 lysophosphatidylethanolamine 16:0 measurement efo:EFO_0010367 The quantification of lysophosphatidylethanolamine 18:0 levels in a sample. Joannella Morales true PMID:23823483 LPE 18:0 lysophosphatidylethanolamine 18:0 measurement efo:EFO_0010368 The quantification of lysophosphatidylethanolamine 18:1 levels in a sample. Joannella Morales true PMID:23823483 LPE 18:1 lysophosphatidylethanolamine 18:1 measurement efo:EFO_0010369 The quantification of lysophosphatidylethanolamine 18:2 levels in a sample. Joannella Morales true PMID:23823483 LPE 18:2 lysophosphatidylethanolamine 18:2 measurement efo:EFO_0010370 The quantification of lysophosphatidylethanolamine 20:4 levels in a sample. Joannella Morales true PMID:23823483 LPE 20:4 lysophosphatidylethanolamine 20:4 measurement efo:EFO_0010371 The quantification of lysophosphatidylethanolamine 22:6 levels in a sample. Joannella Morales true PMID:23823483 LPE 22:6 lysophosphatidylethanolamine 22:6 measurement efo:EFO_0010372 The quantification of phosphatidylcholine 32:0 levels in a sample. Joannella Morales true PMID:23823483 PC 32:0 phosphatidylcholine 32:0 measurement efo:EFO_0010373 The quantification of phosphatidylcholine 32:1 levels in a sample. Joannella Morales true PMID:23823483 PC 32:1 phosphatidylcholine 32:1 measurement efo:EFO_0010374 The quantification of phosphatidylcholine 32:2 levels in a sample. Joannella Morales true PMID:23823483 PC 32:2 phosphatidylcholine 32:2 measurement efo:EFO_0010375 The quantification of phosphatidylcholine 34:1 levels in a sample. Joannella Morales true PMID:23823483 PC 34:1 phosphatidylcholine 34:1 measurement efo:EFO_0010376 The quantification of phosphatidylcholine 34:2 levels in a sample. Joannella Morales true PMID:23823483 PC 34:2 phosphatidylcholine 34:2 measurement efo:EFO_0010377 The quantification of phosphatidylcholine 34:3 levels in a sample. Joannella Morales true PMID:23823483 PC 34:3 phosphatidylcholine 34:3 measurement efo:EFO_0010378 The quantification of phosphatidylcholine 34:4 levels in a sample. Joannella Morales true PMID:23823483 PC 34:4 phosphatidylcholine 34:4 measurement efo:EFO_0010379 The quantification of phosphatidylcholine 36:1 levels in a sample. Joannella Morales true PMID:23823483 PC 36:1 phosphatidylcholine 36:1 measurement efo:EFO_0010380 The quantification of phosphatidylcholine 36:2 levels in a sample. Joannella Morales true PMID:23823483 PC 36:2 phosphatidylcholine 36:2 measurement efo:EFO_0010381 The quantification of phosphatidylcholine 36:3 levels in a sample. Joannella Morales true PMID:23823483 PC 36:3 phosphatidylcholine 36:3 measurement efo:EFO_0010382 The quantification of phosphatidylcholine 36:4 levels in a sample. Joannella Morales true PMID:23823483 PC 36:4 phosphatidylcholine 36:4 measurement efo:EFO_0010383 The quantification of phosphatidylcholine 36:5 levels in a sample. Joannella Morales true PMID:23823483 PC 36:5 phosphatidylcholine 36:5 measurement efo:EFO_0010384 The quantification of phosphatidylcholine 38:2 levels in a sample. Joannella Morales true PMID:23823483 PC 38:2 phosphatidylcholine 38:2 measurement efo:EFO_0010385 The quantification of phosphatidylcholine 38:3 levels in a sample. Joannella Morales true PMID:23823483 PC 38:3 phosphatidylcholine 38:3 measurement efo:EFO_0010386 The quantification of phosphatidylcholine 38:4 levels in a sample. Joannella Morales true PMID:23823483 PC 38:4 phosphatidylcholine 38:4 measurement efo:EFO_0010387 The quantification of phosphatidylcholine 38:5 levels in a sample. Joannella Morales true PMID:23823483 PC 38:5 phosphatidylcholine 38:5 measurement efo:EFO_0010388 The quantification of phosphatidylcholine 38:6 levels in a sample. Joannella Morales true PMID:23823483 PC 38:6 phosphatidylcholine 38:6 measurement efo:EFO_0010389 The quantification of phosphatidylcholine 40:6 levels in a sample. Joannella Morales true PMID:23823483 PC 40:6 phosphatidylcholine 40:6 measurement efo:EFO_0010390 The quantification of sphingomyelin 14:0 levels in a sample. Joannella Morales true PMID:23823483 SM 14:0 sphingomyelin 14:0 measurement efo:EFO_0010391 The quantification of sphingomyelin 16:0 levels in a sample. Joannella Morales true PMID:23823483 SM 16:0 sphingomyelin 16:0 measurement efo:EFO_0010392 The quantification of sphingomyelin 16:1 levels in a sample. Joannella Morales true PMID:23823483 SM 16:1 sphingomyelin 16:1 measurement efo:EFO_0010393 The quantification of sphingomyelin 18:0 levels in a sample. Joannella Morales true PMID:23823483 SM 18:0 sphingomyelin 18:0 measurement efo:EFO_0010394 The quantification of sphingomyelin 18:1 levels in a sample. Joannella Morales true PMID:23823483 SM 18:1 sphingomyelin 18:1 measurement efo:EFO_0010395 The quantification of sphingomyelin 22:0 levels in a sample. Joannella Morales true PMID:23823483 SM 22:0 sphingomyelin 22:0 measurement efo:EFO_0010396 The quantification of sphingomyelin 22:1 levels in a sample. Joannella Morales true PMID:23823483 SM 22:1 sphingomyelin 22:1 measurement efo:EFO_0010397 The quantification of sphingomyelin 24:0 levels in a sample. Joannella Morales true PMID:23823483 SM 24:0 sphingomyelin 24:0 measurement efo:EFO_0010398 The quantification of sphingomyelin 24:1 levels in a sample. Joannella Morales true PMID:23823483 SM 24:1 sphingomyelin 24:1 measurement efo:EFO_0010399 The quantification of triacylglycerol 44:1 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 44:1 triacylglycerol 44:1 measurement efo:EFO_0010400 The quantification of triacylglycerol 46:0 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 46:0 triacylglycerol 46:0 measurement efo:EFO_0010401 The quantification of triacylglycerol 46:1 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 46:1 triacylglycerol 46:1 measurement efo:EFO_0010402 The quantification of triacylglycerol 46:2 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 46:2 triacylglycerol 46:2 measurement efo:EFO_0010403 The quantification of triacylglycerol 48:0 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 48:0 triacylglycerol 48:0 measurement efo:EFO_0010404 The quantification of triacylglycerol 48:1 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 48:1 triacylglycerol 48:1 measurement efo:EFO_0010405 The quantification of triacylglycerol 48:2 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 48:2 triacylglycerol 48:2 measurement efo:EFO_0010406 The quantification of triacylglycerol 48:3 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 48:3 triacylglycerol 48:3 measurement efo:EFO_0010407 The quantification of triacylglycerol 48:4 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 48:4 triacylglycerol 48:4 measurement efo:EFO_0010408 The quantification of triacylglycerol 50:1 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 50:1 triacylglycerol 50:1 measurement efo:EFO_0010409 The quantification of triacylglycerol 50:2 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 50:2 triacylglycerol 50:2 measurement efo:EFO_0010410 The quantification of triacylglycerol 50:3 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 50:3 triacylglycerol 50:3 measurement efo:EFO_0010411 The quantification of triacylglycerol 50:4 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 50:4 triacylglycerol 50:4 measurement efo:EFO_0010412 The quantification of triacylglycerol 50:5 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 50:5 triacylglycerol 50:5 measurement efo:EFO_0010413 The quantification of triacylglycerol 52:1 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 52:1 triacylglycerol 52:1 measurement efo:EFO_0010414 The quantification of triacylglycerol 52:2 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 52:2 triacylglycerol 52:2 measurement efo:EFO_0010415 The quantification of triacylglycerol 52:3 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 52:3 triacylglycerol 52:3 measurement efo:EFO_0010416 The quantification of triacylglycerol 52:4 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 52:4 triacylglycerol 52:4 measurement efo:EFO_0010417 The quantification of triacylglycerol 52:5 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 52:5 triacylglycerol 52:5 measurement efo:EFO_0010418 The quantification of triacylglycerol 52:6 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 52:6 triacylglycerol 52:6 measurement efo:EFO_0010419 The quantification of triacylglycerol 54:1 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:1 triacylglycerol 54:1 measurement efo:EFO_0010420 The quantification of triacylglycerol 54:2 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:2 triacylglycerol 54:2 measurement efo:EFO_0010421 The quantification of triacylglycerol 54:3 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:3 triacylglycerol 54:3 measurement efo:EFO_0010422 The quantification of triacylglycerol 54:4 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:4 triacylglycerol 54:4 measurement efo:EFO_0010423 The quantification of triacylglycerol 54:5 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:5 triacylglycerol 54:5 measurement efo:EFO_0010424 The quantification of triacylglycerol 54:6 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:6 triacylglycerol 54:6 measurement efo:EFO_0010425 The quantification of triacylglycerol 54:7 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:7 triacylglycerol 54:7 measurement efo:EFO_0010426 The quantification of triacylglycerol 54:8 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:8 triacylglycerol 54:8 measurement efo:EFO_0010427 The quantification of triacylglycerol 54:9 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 54:9 triacylglycerol 54:9 measurement efo:EFO_0010428 The quantification of triacylglycerol 56:10 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:10 triacylglycerol 56:10 measurement efo:EFO_0010429 The quantification of triacylglycerol 56:2 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:2 triacylglycerol 56:2 measurement efo:EFO_0010430 The quantification of triacylglycerol 56:3 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:3 triacylglycerol 56:3 measurement efo:EFO_0010431 The quantification of triacylglycerol 56:4 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:4 triacylglycerol 56:4 measurement efo:EFO_0010432 The quantification of triacylglycerol 56:5 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:5 triacylglycerol 56:5 measurement efo:EFO_0010433 The quantification of triacylglycerol 56:6 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:6 triacylglycerol 56:6 measurement efo:EFO_0010434 The quantification of triacylglycerol 56:7 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:7 triacylglycerol 56:7 measurement efo:EFO_0010435 The quantification of triacylglycerol 56:8 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:8 triacylglycerol 56:8 measurement efo:EFO_0010436 The quantification of triacylglycerol 56:9 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 56:9 triacylglycerol 56:9 measurement efo:EFO_0010437 The quantification of triacylglycerol 58:10 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 58:10 triacylglycerol 58:10 measurement efo:EFO_0010438 The quantification of triacylglycerol 58:11 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 58:11 triacylglycerol 58:11 measurement efo:EFO_0010439 The quantification of triacylglycerol 58:12 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 58:12 triacylglycerol 58:12 measurement efo:EFO_0010440 The quantification of triacylglycerol 58:6 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 58:6 triacylglycerol 58:6 measurement efo:EFO_0010441 The quantification of triacylglycerol 58:7 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 58:7 triacylglycerol 58:7 measurement efo:EFO_0010442 The quantification of triacylglycerol 58:8 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 58:8 triacylglycerol 58:8 measurement efo:EFO_0010443 The quantification of triacylglycerol 58:9 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 58:9 triacylglycerol 58:9 measurement efo:EFO_0010444 The quantification of triacylglycerol 60:12 levels in some body fluid, used as a biomarker for disease. Joannella Morales true PMID:23823483 TAG 60:12 triacylglycerol 60:12 measurement efo:EFO_0010446 Quantification of 2-hydroxyglutaric acid levels in a sample. Joannella Morales true PMID:23823483 2-hydroxyglutaric acid measurement efo:EFO_0010447 Quantification of 3-hydroxyanthranilic acid levels in a sample. Joannella Morales true PMID:23823483 3-hydroxyanthranilic acid measurement efo:EFO_0010448 Quantification of 3-hydroxyphenylacetic acid levels in a sample. Joannella Morales true PMID:23823483 3-hydroxyphenylacetic acid measurement efo:EFO_0010449 Quantification of 3-methyladipic acid levels in a sample. Joannella Morales true PMID:23823483 3-methyladipic acid measurement efo:EFO_0010450 Quantification of 3-phosphoglyceric acid levels in a sample. Joannella Morales PMID:23823483 3-phosphoglyceric acid efo:EFO_0010451 Quantification of aconitate levels in a sample. Joannella Morales true PMID:23823483 aconitate measurement efo:EFO_0010452 Quantification of adenosine diphosphate levels in a sample. Joannella Morales true PMID:23823483 adenosine diphosphate measurement efo:EFO_0010453 Quantification of adenosine levels in a sample. Joannella Morales true PMID:23823483 adenosine measurement efo:EFO_0010454 Quantification of adenosine monophosphate levels in a sample. Joannella Morales true PMID:23823483 adenosine monophosphate measurement efo:EFO_0010455 Quantification of adipic acid levels in a sample. Joannella Morales true PMID:23823483 adipic acid mesurement efo:EFO_0010456 Quantification of allantoin levels in a sample. Joannella Morales true PMID:23823483 allantoin measurement efo:EFO_0010457 Quantification of alpha ketoglutarate levels in a sample. Joannella Morales true PMID:23823483 alpha ketoglutaric acid Alpha ketoglutarate measurement efo:EFO_0010458 Quantification of alpha-hydroxybutyric acid levels in a sample. Joannella Morales true PMID:23823483 2-hydroxybutyric acid alpha-hydroxybutyric acid measurement efo:EFO_0010459 Quantification of aminoadipic acid levels in a sample. Joannella Morales true PMID:23823483 aminoadipic acid measurement efo:EFO_0010460 Quantification of anthrallic acid levels in a sample. Joannella Morales true PMID:23823483 anthranilic acid measurement efo:EFO_0010461 Quantification of argininosuccinate levels in a sample. Joannella Morales true PMID:23823483 argininosuccinate measurement efo:EFO_0010462 Quantification of aspartate levels in a sample. Joannella Morales true PMID:23823483 aspartate measurement efo:EFO_0010463 Quantification of asymmetric dimethylarginine levels in a sample. Joannella Morales true PMID:23823483 asymmetric dimethylarginine measurement efo:EFO_0010464 Quantification of beta-aminoisobutyric acid levels in a sample. Joannella Morales true PMID:23823483 beta-aminoisobutyric acid measurement efo:EFO_0010465 Quantification of beta-hydroxybutyric acid levels in a sample. Joannella Morales true PMID:23823483 beta-hydroxybutyric acid measurement efo:EFO_0010466 Quantification of carboxamide levels in a sample. Joannella Morales PMID:23823483 carboxamide measurement efo:EFO_0010467 Quantification of carboxylic acid anion levels in a sample. Joannella Morales true PMID:23823483 carboxylic acid anion measurement efo:EFO_0010468 Quantification of carboxylic acid levels in a sample. Joannella Morales true PMID:23823483 carboxylic acid measurement efo:EFO_0010469 Quantification of carnitine levels in a sample. Joannella Morales true PMID:23823483 carnitine measurement efo:EFO_0010470 Quantification of carnosine levels in a sample. Joannella Morales true PMID:23823483 carnosine measurement efo:EFO_0010471 Quantification of chenodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 chenodeoxycholate measurement efo:EFO_0010472 Quantification of creatine levels in a sample. Joannella Morales true PMID:23823483 creatine measurement efo:EFO_0010473 Quantification of cyclic adenosine monophosphate levels in a sample. Joannella Morales true PMID:23823483 cyclic adenosine monophosphate measurement efo:EFO_0010474 Quantification of cystathionine levels in a sample. Joannella Morales true PMID:23823483 cystathionine measurement efo:EFO_0010475 Quantification of chenodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 deoxycholate measurement efo:EFO_0010476 Quantification of dimethylglycine levels in a sample. Joannella Morales true PMID:23823483 dimethylglycine measurement efo:EFO_0010477 Quantification of fructose levels in a sample. Joannella Morales true PMID:23823483 fructose measurement efo:EFO_0010478 Quantification of fructose-1-phosphate levels in a sample. Joannella Morales true PMID:23823483 fructose-1-phosphate measurement efo:EFO_0010479 Quantification of fructose-6-phosphate levels in a sample. Joannella Morales true PMID:23823483 fructose-6-phosphate measurement efo:EFO_0010480 Quantification of fumarate levels in a sample. Joannella Morales true PMID:23823483 fumarate measurement efo:EFO_0010481 Quantification of galactose levels in a sample. Joannella Morales true PMID:23823483 galactose measurement efo:EFO_0010482 Quantification of gamma-aminoisobutyric levels in a sample. Joannella Morales true PMID:23823483 gamma-aminoisobutyric acid measurement efo:EFO_0010483 Quantification of gentisic acid levels in a sample. Joannella Morales true PMID:23823483 gentisic acid measurement efo:EFO_0010484 Quantification of kglucose-1-phosphate levels in a sample. Joannella Morales true PMID:23823483 glucose-1-phosphate measurement efo:EFO_0010485 Quantification of glucose-6-phosphate levels in a sample. Joannella Morales true PMID:23823483 glucose-6-phosphate measurement efo:EFO_0010486 Quantification of glucuronate levels in a sample. Joannella Morales true PMID:23823483 glucuronate measurement efo:EFO_0010487 Quantification of glutamate levels in a sample. Joannella Morales true PMID:23823483 glutamate measurement efo:EFO_0010488 Quantification of glycerol-3-phosphate levels in a sample. Joannella Morales true PMID:23823483 glycerol-3-phosphate measurement efo:EFO_0010489 Quantification of glycerophosphocholine levels in a sample. Joannella Morales true PMID:23823483 glycerophosphocholine measurement efo:EFO_0010490 Quantification of glycochenodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 glycochenodeoxycholate measurement efo:EFO_0010491 Quantification of glycocholate levels in a sample. Joannella Morales true PMID:23823483 glycocholate measurement efo:EFO_0010492 Quantification of glycocholic acid levels in a sample. Joannella Morales true PMID:23823483 glycocholic acid measurement efo:EFO_0010493 Quantification of glycodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 glycodeoxycholate measurement efo:EFO_0010494 Quantification of guanosine diphosphate levels in a sample. Joannella Morales true PMID:23823483 guanosine diphosphate measurement efo:EFO_0010495 Quantification of guanosine monophosphate levels in a sample. Joannella Morales true PMID:23823483 guanosine monophosphate measurement efo:EFO_0010496 Quantification of hippuric acid levels in a sample. Joannella Morales true PMID:23823483 hippuric acid measurement efo:EFO_0010497 Quantification of hydroxide levels in a sample. Joannella Morales PMID:23823483 hydroxide measurement efo:EFO_0010498 Quantification of hydroxyproline levels in a sample. Joannella Morales true PMID:23823483 hydroxyproline measurement efo:EFO_0010499 Quantification of hyodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 hyodeoxycholate measurement efo:EFO_0010500 Quantification of hypoxanthine levels in a sample. Joannella Morales true PMID:23823483 hypoxanthine mesurement efo:EFO_0010501 Quantification of indole-3-propionate levels in a sample. Joannella Morales true PMID:23823483 indole-3-propionate measurement efo:EFO_0010502 Quantification of indoxyl sulfate levels in a sample. Joannella Morales true PMID:23823483 indoxyl sulfate measurement efo:EFO_0010503 Quantification of inosine levels in a sample. Joannella Morales true PMID:23823483 inosine measurement efo:EFO_0010504 Quantification of inositol levels in a sample. Joannella Morales true PMID:23823483 inositol measurement efo:EFO_0010505 Quantification of isocitrate levels in a sample. Joannella Morales true PMID:23823483 isocitrate measurement efo:EFO_0010506 Quantification of kynurenic acid levels in a sample. Joannella Morales true PMID:23823483 kynurenic acid measurement efo:EFO_0010507 Quantification of lactose levels in a sample. Joannella Morales true PMID:23823483 lactose measurement efo:EFO_0010508 Quantification of malate levels in a sample. Joannella Morales true PMID:23823483 malate measurement efo:EFO_0010509 Quantification of maleate levels in a sample. Joannella Morales true PMID:23823483 maleate measurement efo:EFO_0010510 Quantification of NG-monomethyl-arginine levels in a sample. Joannella Morales true PMID:23823483 NG-monomethyl-arginine measurement efo:EFO_0010511 Quantification of niacinamide levels in a sample. Joannella Morales true PMID:23823483 niacinamide measurement efo:EFO_0010512 Quantification of nucleoside levels in a sample. Joannella Morales true PMID:23823483 nucleoside measurement efo:EFO_0010513 Quantification of nucleotide levels in a sample. Joannella Morales true PMID:23823483 nucleotide measurement efo:EFO_0010514 Quantification of organic anion levels in a sample. Joannella Morales PMID:23823483 organic anion measurement efo:EFO_0010515 Quantification of organic cation levels in a sample. Joannella Morales PMID:23823483 organic cation measurement efo:EFO_0010516 Quantification of orotic acid levels in a sample. Joannella Morales true PMID:23823483 orotic acid measurement efo:EFO_0010517 Quantification of oxalate levels in a sample. Joannella Morales true PMID:23823483 oxalate measurement efo:EFO_0010518 Quantification of oxide levels in a sample. Joannella Morales PMID:23823483 oxide measurement efo:EFO_0010519 Quantification of pantothenic acid levels in a sample. Joannella Morales true PMID:23823483 pantothenic acid mesurement efo:EFO_0010520 Quantification of peptide levels in a sample. Joannella Morales true PMID:23823483 peptide measurement efo:EFO_0010521 Quantification of phosphocreatine levels in a sample. Joannella Morales true PMID:23823483 phosphocreatine measurement efo:EFO_0010522 Quantification of phosphoenolpyruvic acid levels in a sample. Joannella Morales true PMID:23823483 phosphoenolpyruvic acid measurement efo:EFO_0010523 Quantification of phosphoglyceric acid levels in a sample. Joannella Morales true PMID:23823483 phosphoglyceric acid measurement efo:EFO_0010524 Quantification of pimelic acid levels in a sample. Joannella Morales true PMID:23823483 pimelic acid measurement efo:EFO_0010525 Quantification of propionic acid levels in a sample. Joannella Morales true PMID:23823483 propionic acid measurement efo:EFO_0010526 Quantification of purine levels in a sample. Joannella Morales true PMID:23823483 purine measurement efo:EFO_0010527 Quantification of pyridoxate levels in a sample. Joannella Morales true PMID:23823483 pyridoxate measurement efo:EFO_0010528 Quantification of quinolinic acid levels in a sample. Joannella Morales true PMID:23823483 quinolinic acid measurement efo:EFO_0010529 Quantification of ribose-5-phosphate levels in a sample. Joannella Morales true PMID:23823483 ribose-5-phosphate measurement efo:EFO_0010530 Quantification of ribulose-5-phosphate levels in a sample. Joannella Morales true PMID:23823483 ribulose-5-phosphate measurement efo:EFO_0010531 Quantification of S-adenosylhomocysteine levels in a sample. Joannella Morales true PMID:23823483 S-adenosylhomocysteine measurement efo:EFO_0010532 Quantification of salicylurate levels in a sample. Joannella Morales true PMID:23823483 salicylurate measurement efo:EFO_0010533 Quantification of sorbitol levels in a sample. Joannella Morales true PMID:23823483 sorbitol measurement efo:EFO_0010534 Quantification of suberic acid levels in a sample. Joannella Morales true PMID:23823483 suberic acid measurement efo:EFO_0010535 Quantification of sucrose levels in a sample. Joannella Morales true PMID:23823483 sucrose measurement efo:EFO_0010536 Quantification of taurine levels in a sample. Joannella Morales true PMID:23823483 taurine measurement efo:EFO_0010537 Quantification of taurochenodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 taurochenodeoxycholate measurement efo:EFO_0010538 Quantification of taurocholate levels in a sample. Joannella Morales true PMID:23823483 taurocholate measurement efo:EFO_0010539 Quantification of taurodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 taurodeoxycholate measurement efo:EFO_0010540 Quantification of thiamine levels in a sample. Joannella Morales true PMID:23823483 thiamine measurement efo:EFO_0010541 Quantification of trimethylamine-N-oxide levels in a sample. Joannella Morales true PMID:23823483 trimethylamine-N-oxide measurement efo:EFO_0010542 Quantification of ureidopropionic acid levels in a sample. Joannella Morales true PMID:23823483 ureidopropionic acid measurement efo:EFO_0010543 Quantification of uridine diphosphate galactose levels in a sample. Joannella Morales true PMID:23823483 uridine diphosphate galactose measurement efo:EFO_0010544 Quantification of uridine diphosphate glucose levels in a sample. Joannella Morales true PMID:23823483 uridine diphosphate glucose measurement efo:EFO_0010545 Quantification of uridine diphosphate levels in a sample. Joannella Morales true PMID:23823483 uridine diphosphate measurement efo:EFO_0010546 Quantification of uridine levels in a sample. Joannella Morales true PMID:23823483 uridine measurement efo:EFO_0010547 Quantification of ursodeoxycholate levels in a sample. Joannella Morales true PMID:23823483 ursodeoxycholate measurement efo:EFO_0010548 Quantification of xanthine levels in a sample. Joannella Morales true PMID:23823483 xanthine measurement efo:EFO_0010549 Quantification of xanthosine levels in a sample. Joannella Morales true PMID:23823483 xanthosine measurement efo:EFO_0010551 Quantification of xanthurenate levels in a sample. Joannella Morales true PMID:23823483 xanthurenate measurement efo:EFO_0010552 A measurement of some aspect of an individual's social environment, including the people with whom they interact and the culture and behaviours to which they are exposed. Elliot Sollis true PMID:31490055 https://en.wikipedia.org/wiki/Social_environment social environment measurement efo:EFO_0010553 A quantification of some aspect of cocaine use Elliot Sollis true PMID:31591132 cocaine use measurement efo:EFO_0010554 A quantification of some aspect of the vasculature of the retina, for example retinal venular tortuousity. Aoife McMahon true retinal vasculature measurement efo:EFO_0010555 Quantification of the volume of blood pumped from the left ventricle of the heart with each beat, calculated by subtracting the volume of blood in the ventricle at the end of a beat (end-systolic volume) from the volume of blood just prior to the beat (end-diastolic volume). Laura Harris true PMID:31554410 left ventricular stroke volume measurement efo:EFO_0010556 Quantification of the ratio of left ventricular mass to end-diastolic volume. Elevated left ventricular mass/end-diastolic volume ratio has been associated with higher evidence of myocardial fibrosis and dysfunction in hypertensive patients Laura Harris true PMID:31554410 Left ventricular mass to end-diastolic volume ratio efo:EFO_0010557 A test to determine the ability of an individual to metabolise lactose, an estimate of lactase activity. It includes measuring fasting blood glucose levels before and after oral lactose intake. Laura Harris true MedDRA:10052986 PMID:31791255 lactose tolerance test efo:EFO_0010559 Quantification of the levels of antibodies against biotherapeutic agents. Such antibodies can reduce treatment efficacy by neutralizing circulating immune-biologicals and/or promoting their clearance. Laura Harris true PMID:31600487 anti-drug antibody measurement efo:EFO_0010570 A quantification of some aspect of the enlargement of the ventricles of the brain. Elliot Sollis true PMID:31711042 ventricular enlargement measurement efo:EFO_0010572 Quantification of the rate of growth of an organism, in terms of the change in body mass, height or other anthropometric measurement per unit of time Laura Harris true PMID:31840077 growth rate measurement efo:EFO_0010573 Quantification of the amount of kallikrein-11 in a sample. Annalisa Buniello true PMID:25147954 kallikrein-11 measurement efo:EFO_0010574 Quantification of the amount of epithelial cell adhesion molecule in a sample. Annalisa Buniello true PMID:25147954 epithelial cell adhesion molecule measurement efo:EFO_0010575 Quantification of the amount of Vascular Endothelial Growth Factor D in the sample. Annalisa Buniello true PMID:25147954 vascular endothelial growth factor D measurement efo:EFO_0010576 Quantification of the invasion of fibrous connective tissue into the liver, typically by histological assessment of biopsy samples. Laura Harris true PMID:31832568 liver fibrosis measurement efo:EFO_0010583 Quantification of the amount of alpha fetoprotein in a sample, typically serum Laura Harris true PMID:31666285 alpha-1-fetoprotein measurement alpha-fetoglobulin measurement alpha fetoprotein measurement efo:EFO_0010584 Quantification of the amount of cancer antigen 19.9 in a sample, typically serum. Laura Harris true PMID:31666285 cancer antigen 19.9 measurement efo:EFO_0010585 Quantification of the amount of cancer antigen 15.3 in a sample, typically serum. Laura Harris true PMID:31666285 cancer antigen 15.3 measurement efo:EFO_0010586 quantification of the amount of CD40 in a sample Elizabeth Lewis true PMID:28915241 CD40 CD40L receptor CD40 measurement efo:EFO_0010587 quantification of the amount of interleukin-2 receptor subunit alpha in a sample Elizabeth Lewis true PMID:28915241 IL2RA interleukin-2 receptor subunit alpha measurement efo:EFO_0010588 quantification of the amount of matrix metalloproteinase 1 in a sample Elizabeth Lewis true PMID:28915241 MMP-1 matrix metalloproteinase 1 measurement efo:EFO_0010589 quantification of the amount of matrix metalloproteinase 10 in a sample Elizabeth Lewis true PMID:28915241 MMP-10 matrix metalloproteinase 10 measurement efo:EFO_0010590 quantification of the amount of matrix metalloproteinase 12 in a sample Elizabeth Lewis true PMID:28915241 MMP-12 matrix metalloproteinase 12 measurement efo:EFO_0010591 quantification of the amount of matrix metalloproteinase 7 in a sample Elizabeth Lewis true PMID:28915241 MMP-7 matrix metalloproteinase 7 measurement efo:EFO_0010592 quantification of the amount of tumor necrosis factor ligand superfamily member 8 in a sample Elizabeth Lewis true PMID:28915241 CD30-L tumor necrosis factor ligand superfamily member 8 measurement efo:EFO_0010593 quantification of the amount of cystatin B in a sample Elizabeth Lewis true PMID:28915241 Cystatin B cystatin B measurement efo:EFO_0010594 quantification of the amount of Fms-related tyrosine kinase 3 ligand in a sample Elizabeth Lewis true PMID:28915241 Flt3L Fms-related tyrosine kinase 3 ligand measurement efo:EFO_0010595 quantification of the amount of heat shock protein beta-1 in a sample Elizabeth Lewis true PMID:28915241 HSP_27 heat shock protein beta-1 measurement efo:EFO_0010596 quantification of the amount of monocyte chemotactic protein 1 in a sample Elizabeth Lewis true PMID:28915241 MCP-1 monocyte chemotactic protein 1 measurement efo:EFO_0010597 quantification of the amount of NF-kappa-B essential modulator in a sample Elizabeth Lewis true PMID:28915241 NEMO NF-kappa-B essential modulator measurement efo:EFO_0010598 quantification of the amount of platelet endothelial cell adhesion molecule in a sample Elizabeth Lewis true PMID:28915241 PECAM-1 platelet endothelial cell adhesion molecule measurement efo:EFO_0010599 quantification of the amount of ST2 protein in a sample Elizabeth Lewis true PMID:28915241 ST2 ST2 protein measurement efo:EFO_0010600 quantification of the amount of angiopoietin-1 receptor in a sample Elizabeth Lewis true PMID:28915241 TIE2 angiopoietin-1 receptor measurement efo:EFO_0010601 quantification of the amount of hepatitis A virus cellular receptor 1 in a sample Elizabeth Lewis true PMID:28915241 TIM hepatitis A virus cellular receptor 1 measurement efo:EFO_0010602 Quantification or estimate of the age of the brain, e.g. as derived from brain MRI features. Elliot Sollis true PMID:31776335 brain age measurement efo:EFO_0010603 Quantification of the amount of cancer antigen 125 in a sample, typically serum. Laura Harris true PMID:31666285 cancer antigen 125 measurement efo:EFO_0010604 Quantification of the amount of urine voided Laura Harris true PMID:31993563 urinary volume measurement urine volume measurement efo:EFO_0010605 Quantification of the volume of the brainstem. Aoife McMahon true PMID: 31636452 brain stem volume measurement efo:EFO_0010606 Quantification of the amount of sclerostin in a sample. Elizabeth Lewis true PMID:31170332 sclerostin measurement efo:EFO_0010607 quantification of the amount of tumor necrosis factor receptor superfamily member 5 in a sample Annalisa Buniello true PMID:28369058 tumor necrosis factor, receptor superfamily, member 5 measurement efo:EFO_0010608 quantification of the amount of mucin 16 in a sample Annalisa Buniello true PMID:28369058 stromelysin‐1 measurement efo:EFO_0010609 quantification of the amount of stromelysin 1 in a sample Annalisa Buniello true PMID:28369058 mucin‐16 measurement efo:EFO_0010610 quantification of the amount of tumor necrosis factor receptor superfamily member 6 in a sample Annalisa Buniello true PMID:28369058 FAS ligand (FASLG) receptor measurement tumor necrosis factor receptor superfamily member 6 measurement efo:EFO_0010611 quantification of the amount of cathepsin D in a sample Annalisa Buniello true PMID:28369058 cathepsin D measurement efo:EFO_0010612 quantification of the amount of kit ligand in a sample Annalisa Buniello true PMID:28369058 kit ligand measurement efo:EFO_0010613 quantification of the amount of tumor necrosis factor receptor superfamily member 14 in a sample Annalisa Buniello true PMID:28369058 tumor necrosis factor ligand superfamily member 14 measurement efo:EFO_0010614 quantification of the amount of follistatin in a sample Annalisa Buniello true PMID:28369058 follistatin measurement efo:EFO_0010615 quantification of the amount of galanin peptides in a sample Annalisa Buniello true PMID:28369058 galanin peptides measurement efo:EFO_0010616 quantification of the amount of reninpeptides in a sample Annalisa Buniello true PMID:28369058 renin measurement efo:EFO_0010617 quantification of the amount of tumor necrosis factor receptor superfamily member 11 in a sample Annalisa Buniello true PMID:28369058 tumor necrosis factor ligand superfamily member 11 measurement efo:EFO_0010618 quantification of pappalysin 1 in a sample Annalisa Buniello true PMID:28369058 pappalysin‐1 measurement efo:EFO_0010619 quantification of cathepsin L1 in a sample Annalisa Buniello true PMID:28369058 cathepsin L1 measurement efo:EFO_0010620 quantification of dickkopf‐related protein 1 in a sample Annalisa Buniello true PMID:28369058 dickkopf‐related protein 1 measurement efo:EFO_0010621 quantification of stromelysin 2 in a sample Annalisa Buniello true PMID:28369058 stromelysin‐2 measurement efo:EFO_0010622 quantification of kallikrein 6 in a sample Annalisa Buniello true PMID:28369058 kallikrein‐6 measurement efo:EFO_0010623 quantification of tissue factor in a sample Annalisa Buniello true PMID:28369058 tissue factor measurement efo:EFO_0010624 quantification of tumor necrosis factor receptor superfamily member 1B in a sample Annalisa Buniello true PMID:28369058 tumor necrosis factor receptor superfamily member 1B measurement efo:EFO_0010625 quantification of xaa‐pro aminopeptidase 2 in a sample Annalisa Buniello true PMID:28369058 xaa‐pro aminopeptidase 2 measurement efo:EFO_0010626 quantification of placenta growth factor in a sample Annalisa Buniello true PMID:28369058 placenta growth factor measurement efo:EFO_0010627 quantification of pro‐adrenomedullin in a sample Annalisa Buniello true PMID:28369058 pro‐adrenomedullin measurement efo:EFO_0010628 quantification of natriuretic peptides B in a sample Annalisa Buniello true PMID:28369058 natriuretic peptides B measurement efo:EFO_0010629 quantification of pro‐interleukin 16 in a sample Annalisa Buniello true PMID:28369058 pro‐interleukin‐16 measurement efo:EFO_0010637 Quantification of some metabolite in saliva. Elliot Sollis PMID:31960908 true salivary metabolite measurement efo:EFO_0010639 Quantification of levels of pain. Joannella Morales PMID:31669095 true pain measurement efo:EFO_0010640 Quantification of pain that develops after a surgical procedure, and is present for at least 3 months after the procedure. Joannella Morales PMID:31669095 true chronic post-operative pain measurement efo:EFO_0010641 A quantification of the levels of 3-ureidopropionate in a sample. Elliot Sollis true HMDB:HMDB0000026 KEGG COMPOUND:C02642 PMID:31960908 N-carbamoyl-beta-alaninate measurement ureidopropionate measurement 3-ureidopropionate measurement efo:EFO_0010650 A quantification of an individual's creativity, i.e. capacity to produce new or original ideas, insights or inventions. Elliot Sollis true PMID:32133506 creativity measurement efo:EFO_0010696 Quantification of soluble gp130 in a sample. gp130 acts as a natural inhibitor of soluble interleukin-6 receptor. Annalisa Buniello true PMID:31932740 soluble glycoprotein 130 soluble gp130 measurement efo:EFO_0010699 Quantification of diffuse plaques in the brain. Diffuse plaques are diffuse collections of aggregated amyloid-β peptide without organized internal structure (e.g. not fibrillar) and that lack dystrophic neurites or glial reaction. Elliot Sollis true PMID:28322283 diffuse plaque measurement efo:EFO_0010700 A quantification of some aspect of reticulocyte function, quantity, or composition. Samuel Lambert true reticulocyte measurement efo:EFO_0010701 Mean volume of reticulocyte cells Samuel Lambert true mean reticulocyte volume efo:EFO_0010703 Quantification of some aspect of trauma exposure. Aoife McMahon true PMID:31969693 trauma measurement trauma exposure measurement efo:EFO_0010707 Quantification of the amount of 3'-hydroxydotinine in a sample. Elliot Sollis true PMID:32157176 trans-3-hydroxycotinine measurement efo:EFO_0010724 Quantification of some aspect of a subject's lifestyle. Aoife McMahon true PMID:32317632 lifestyle measurement efo:EFO_0010729 Quantification of some aspect of exposure to incident light from the sun. Aoife McMahon true PMID:25590795 sunlight exposure measurement sun exposure measurement efo:EFO_0010732 Quantification of the ratio of omega-6 polyunsaturated fatty acid to omega-3 polyunsaturated fatty acid. Elizabeth Lewis true PMID:31991592 omega-6:omega-3 polyunsaturated fatty acid ratio efo:EFO_0010733 The determination of the amount of polyunsaturated fatty acids present in a sample. Elizabeth Lewis true PMID:31991592 polyunsaturated fatty acid measurement efo:EFO_0010736 Quantification of the surface area of the cerebral cortex or parts thereof. Aoife McMahon true PMID:32193296 cortex surface area measurement cortical area measurement cortical surface area measurement efo:EFO_0010742 Quantification of the binding of a protein to another entity, usually another protein, for example using ELISA (enzyme-linked immunosorbent assay). Aoife McMahon true PMID:32321835 protein adhesion measurement protein binding measurement efo:EFO_0010743 Quantification of some aspect of sperm e.g. sperm density, total sperm count, total motile sperm count Aoife McMahon true PMID:32341457 sperm measurement efo:EFO_0010744 Quantification of the size of the testis Aoife McMahon true PMID:32341457 testis size efo:EFO_0010745 Quantification of some aspect of semen Aoife McMahon true PMID:32341457 seminal fluid measurement semen measurement efo:EFO_0010746 Quantification of amount of inhibin B in a sample. Aoife McMahon true PMID:32341457 Inhibin B measurement efo:EFO_0010749 Quantification of some aspect of motor function. Aoife McMahon true PMID: 32355309 motor control measurement motor function measurement efo:EFO_0010750 Quantification of amount of tau, in the form of paired helical filaments, in a sample Aoife McMahon true PMID:32450446 paired helical filament tau measurement PHF-tau measurement efo:EFO_0010756 HL-60/S4 is a subline of the HL-60 cell line. The HL-60/S4 cell line was established in 1992 and is supersensitive to retinoic acid. PMID:1737356 HL-60/S4 efo:EFO_0010758 Quantification of one or more antibodies to the Kaposi's sarcoma-associated herpesvirus, typically in serum Maria Cerezo true PMID:32737300 anti-Kaposi's sarcoma-associated herpesvirus antibody measurement efo:EFO_0010759 Quantification of some aspect of the male reproductive system Aoife McMahon PMID:32341457 male reproductive system measurement efo:EFO_0010760 Quantification of the amount of 4E-BP1 protein in a sample Annalisa Buniello true PMID:32641083 4E-BP1 measurement efo:EFO_0010761 Quantification of the amount of adenosine deaminase protein in a sample Annalisa Buniello true PMID:32641083 ADA adenosine deaminase measurement efo:EFO_0010762 Quantification of the amount of advanced glycosylation end product-specific receptor ligand in a sample Annalisa Buniello true PMID:32641083 EN-RAGE advanced glycosylation end product-specific receptor ligand measurement efo:EFO_0010763 Quantification of the amount of axin-1 in a sample Annalisa Buniello true PMID:32641083 axin-1 measurement efo:EFO_0010764 Quantification of the amount of caspase 8 protein in a sample Annalisa Buniello true PMID:32641083 CASP8 caspase-8 measurement efo:EFO_0010766 Quantification of the amount of CCL20 protein in a sample Annalisa Buniello true PMID:32641083 CCL20 measurement efo:EFO_0010768 Quantification of the amount of CCL25 protein in a sample Annalisa Buniello true PMID:32641083 CCL25 measurement efo:EFO_0010769 Quantification of the amount of CCL28 protein in a sample Annalisa Buniello true PMID:32641083 CCL28 measurement efo:EFO_0010770 Quantification of the amount of CCL3 protein in a sample Annalisa Buniello true PMID:32641083 CCL3 measurement efo:EFO_0010772 Quantification of the amount of CD244 protein in a sample Annalisa Buniello true PMID:32641083 CD244 measurement efo:EFO_0010773 Quantification of the amount of CD5 protein in a sample Annalisa Buniello true PMID:32641083 CD5 measurement efo:EFO_0010774 Quantification of the amount of CD6 protein in a sample Annalisa Buniello true PMID:32641083 CD6 measurement efo:EFO_0010775 Quantification of the amount of colony stimulating factor 1 in a sample Annalisa Buniello true PMID:32641083 CSF1 colony stimulating factor 1 measurement efo:EFO_0010776 Quantification of the amount of CUB domain containing protein 1 in a sample Annalisa Buniello true PMID:32641083 CDCP1 CUB domain containing protein 1 measurement efo:EFO_0010777 Quantification of the amount of CXCL1 protein in a sample Annalisa Buniello true PMID:32641083 CXCL1 measurement efo:EFO_0010778 Quantification of the amount of CXCL10 protein in a sample Annalisa Buniello true PMID:32641083 CXCL10 measurement efo:EFO_0010779 Quantification of the amount of CXCL11 protein in a sample Annalisa Buniello true PMID:32641083 CXCL11 measurement efo:EFO_0010780 Quantification of the amount of CXCL9 protein in a sample Annalisa Buniello true PMID:32641083 CXCL9 measurement efo:EFO_0010781 Quantification of the amount of delta/notch like EGF repeat containing protein in a sample Annalisa Buniello true PMID:32641083 DNER delta/notch like EGF Repeat Containing protein measurement efo:EFO_0010782 Quantification of the amount of fms related receptor tyrosine kinase 3 ligand in a sample Annalisa Buniello true PMID:32641083 fibroblast growth factor 19 measurement efo:EFO_0010783 Quantification of the amount of fibroblast growth factor 5 in a sample Annalisa Buniello true PMID:32641083 fibroblast growth factor 21 measurement efo:EFO_0010784 Quantification of the amount of fibroblast growth factor 21 in a sample Annalisa Buniello true PMID:32641083 fibroblast growth factor 5 measurement efo:EFO_0010785 Quantification of the amount of fibroblast growth factor 19 in a sample Annalisa Buniello true PMID:32641083 FLT3L fms related receptor tyrosine kinase-3 ligand measurement efo:EFO_0010786 Quantification of the amount of interleukin-10 receptor B in a sample Annalisa Buniello true PMID:32641083 IL10RB interleukin-10 receptor B measurement efo:EFO_0010787 Quantification of the amount of interleukin-12 subunit B in a sample Annalisa Buniello true PMID:32641083 IL12B interleukin-12 subunit B measurement efo:EFO_0010788 Quantification of the amount of leukemia inhibitory factor receptor in a sample Annalisa Buniello true PMID:32641083 LIFR leukemia inhibitory factor receptor measurement efo:EFO_0010789 Quantification of the amount of monocyte chemotactic protein-2 in a sample. Annalisa Buniello true PMID:32641083 MCP2 MPC-2 monocyte chemotactic protein 2 measurement monocyte chemotactic protein-2 measurement efo:EFO_0010790 Quantification of the amount of monocyte chemotactic protein-2 in a sample Annalisa Buniello true PMID:32641083 MCP4 monocyte chemotactic protein-4 measurement efo:EFO_0010791 Quantification of the amount of neurotrophin-3 in a sample Annalisa Buniello true PMID:32641083 NT3 neurotrophin-3 measurement efo:EFO_0010792 Quantification of the amount of oncostatin-M in a sample Annalisa Buniello true PMID:32641083 OSM oncostatin-M measurement efo:EFO_0010793 Quantification of the amount of programmed death-ligand 1 in a sample Annalisa Buniello true PMID:32641083 PDL1 programmed death-ligand 1 measurement efo:EFO_0010794 Quantification of the amount of signaling lymphocytic activation molecule 1 in a sample Annalisa Buniello true PMID:32641083 SLAMF1 signaling lymphocytic activation molecule 1 measurement efo:EFO_0010795 Quantification of the amount of sirtuin-2 in a sample Annalisa Buniello PMID:32641083 SIRT2 sirtuin-2 measurement efo:EFO_0010796 Quantification of the amount of STAM binding protein in a sample Annalisa Buniello true PMID:32641083 STAM binding protein measurement efo:EFO_0010797 Quantification of the amount of sulfotrasferase 1A1 in a sample Annalisa Buniello true PMID:32641083 ST1A1 sulfotrasferase 1A1 measurement efo:EFO_0010798 Quantification of the amount of transforming growth factor-alpha in a sample Annalisa Buniello true PMID:32641083 TGF-alpha transforming growth factor-alpha measurement efo:EFO_0010799 Quantification of the amount of transforming growth factor-beta in a sample Annalisa Buniello PMID:32641083 TGF-beta1 transforming growth factor-beta measurement efo:EFO_0010800 Quantification of the amount of tumor necrosis factor ligand receptor superfamily member 10 in a sample Annalisa Buniello true PMID:32641083 TRAIL tumor necrosis factor ligand superfamily member 10 measurement efo:EFO_0010801 Quantification of the amount of tumor necrosis factor ligand receptor superfamily member 12 in a sample Annalisa Buniello true PMID:32641083 TWEAK tumor necrosis factor ligand superfamily member 12 measurement efo:EFO_0010802 Quantification of the amount of tumor necrosis factor receptor superfamily member 9 in a sample Annalisa Buniello true PMID:32641083 TNFRSF9 tumor necrosis factor receptor superfamily member 9 measurement efo:EFO_0010803 Quantification of the amount of urokinase-type plasminogen activator in a sample Annalisa Buniello true PMID:32641083 uPA urokinase-type plasminogen activator measurement efo:EFO_0010804 Quantification of the amount of vascular endothelial growth factor A in a sample Annalisa Buniello true PMID:32641083 VEGFA vascular endothelial growth factor A measurement efo:EFO_0010807 A female embryonic stem cell derived by crossing male Mus musculus castaneus and female Mus musculus 129. paola https://data.4dnucleome.org/protocols/cb03c0c6-4ba6-4bbe-9210-c430ee4fdb2c/ F121-9-CASTx129 F121-9 efo:EFO_0010809 Quantification of the fat intake of an individual. Aoife McMahon true PMID:32393786 fat consumption measurement fat intake measurement efo:EFO_0010810 Quantification of the protein intake of an individual. Aoife McMahon true PMID:32393786 protein consumption measurement protein intake measurement efo:EFO_0010811 Quantification of the carbohydrate intake of an individual. Aoife McMahon true PMID:32393786 carbohydrate consumption measurement carbohydrate intake measurement efo:EFO_0010812 Quantification of the amount of T-cell immunoglobulin and mucin domain 1 protein in a sample. Annalisa Buniello true PMID:32460577 TIM-1 T-cell immunoglobulin and mucin domain 1 measurement efo:EFO_0010813 A measurement of serum C-peptide levels at a predetermined point after a patient has fasted. paola http://orcid.org/0000-0001-9043-693X fasting C-peptide measurement efo:EFO_0010814 Measurement of proinsulin, an insulin precursor that is processed into mature insulin and C-peptide. paola Wikipedia:Proinsulin http://orcid.org/0000-0001-9043-693X proinsulin measurement efo:EFO_0010815 Measurement of remnant cholesterol (remnant lipoprotein), which is an atherogenic lipoprotein composed primarily of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL). paola true Wikipedia:Remnant_cholesterol http://orcid.org/0000-0001-9043-693X remnant cholesterol measurement efo:EFO_0010816 Quantification of an individual's appreciation of lipids or fats in food or drink. Elliot Sollis true PMID:32516399 fat liking measurement dietary fat liking measurement efo:EFO_0010818 A measurement of some aspect of an individual's perception or recognition of the contents of food or drink. Elliot Sollis PMID:32516399 sensory perception of food content sensory perception of dietary content efo:EFO_0010821 A quantification of the fat content of the liver such as liver fat fraction, typically assessed by MRI. Aoife McMahon true PMID:32766472 liver fat measurement efo:EFO_0010834 The determination of the amount of tumor necrosis factor present in a sample. Jacqueline MacArthur PMID:32805626 true TNF measurement tumor necrosis factor measurement efo:EFO_0010835 Lymphoblastoid cell line from a Luhya female from Webuye, Kenya https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM19023&Product=CC GM19023 efo:EFO_0010836 Lymphoblastoid cell line from a Luhya male from Webuye, Kenya https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM19025&Product=CC GM19025 efo:EFO_0010837 Lymphoblastoid cell line from a Luhya male from Webuye, Kenya https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM19043&Product=CC GM19043 efo:EFO_0010838 Lymphoblastoid cell line from a Maasai male from Kinyawa, Kenya https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM21515&Product=CC GM21515 efo:EFO_0010839 Lymphoblastoid cell line from a Maasai male from Kinyawa, Kenya https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM21737&Product=CC GM21737 efo:EFO_0010840 Lymphoblastoid cell line from a Maasai female from Kinyawa, Kenya https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM21786&Product=CC GM21786 efo:EFO_0010841 Lymphoblastoid cell line from a Gambian female from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02571&Product=CC HG02571 efo:EFO_0010842 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02588&Product=CC HG02588 efo:EFO_0010843 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02610&Product=CC HG02610 efo:EFO_0010844 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03039&Product=CC HG02623 efo:EFO_0010845 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02642&Product=CC HG02642 efo:EFO_0010846 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02678&Product=CC HG02678 efo:EFO_0010847 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02759&Product=CC HG02759 efo:EFO_0010848 Lymphoblastoid cell line from a Gambian female from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02763&Product=CC HG02763 efo:EFO_0010849 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02798&Product=CC HG02798 efo:EFO_0010850 Lymphoblastoid cell line from a Gambian female from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02840&Product=CC HG02840 efo:EFO_0010851 Lymphoblastoid cell line from a Gambian female from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02852&Product=CC HG02852 efo:EFO_0010852 Lymphoblastoid cell line from a Gambian female from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02870&Product=CC HG02870 efo:EFO_0010853 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02884&Product=CC HG02884 efo:EFO_0010854 Lymphoblastoid cell line from a Gambian female from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02885&Product=CC HG02885 efo:EFO_0010855 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02938&Product=CC HG02938 efo:EFO_0010856 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02943&Product=CC HG02943 efo:EFO_0010857 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02970&Product=CC HG02970 efo:EFO_0010858 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02973&Product=CC HG02973 efo:EFO_0010859 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG02981&Product=CC HG02981 efo:EFO_0010860 Lymphoblastoid cell line from a Gambian female from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03025&Product=CC HG03025 efo:EFO_0010861 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03039&Product=CC HG03039 efo:EFO_0010862 Lymphoblastoid cell line from a Gambian male from the Western Division in the Gambia https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03045&Product=CC HG03045 efo:EFO_0010863 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03060&Product=CC HG03060 efo:EFO_0010864 Lymphoblastoid cell line from a Mende female from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03064&Product=CC HG03064 efo:EFO_0010865 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03066&Product=CC HG03066 efo:EFO_0010866 Lymphoblastoid cell line from a Mende female from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03095&Product=CC HG03095 efo:EFO_0010867 Lymphoblastoid cell line from a Mende female from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03097&Product=CC HG03097 efo:EFO_0010868 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03103&Product=CC HG03103 efo:EFO_0010869 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03108&Product=CC HG03108 efo:EFO_0010870 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03135&Product=CC HG03135 efo:EFO_0010871 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03139&Product=CC HG03139 efo:EFO_0010872 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03159&Product=CC HG03159 efo:EFO_0010873 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03175&Product=CC HG03175 efo:EFO_0010874 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03196&Product=CC HG03196 efo:EFO_0010875 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03280&Product=CC HG03280 efo:EFO_0010876 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03342&Product=CC HG03342 efo:EFO_0010877 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03354&Product=CC HG03354 efo:EFO_0010878 Lymphoblastoid cell line from a Mende female from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03378&Product=CC HG03378 efo:EFO_0010879 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03432&Product=CC HG03432 efo:EFO_0010880 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03439&Product=CC HG03439 efo:EFO_0010881 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03442&Product=CC HG03442 efo:EFO_0010882 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03457&Product=CC HG03457 efo:EFO_0010883 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03460&Product=CC HG03460 efo:EFO_0010884 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03469&Product=CC HG03469 efo:EFO_0010885 Lymphoblastoid cell line from an Esan female from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03520&Product=CC HG03520 efo:EFO_0010886 Lymphoblastoid cell line from an Esan male from Nigeria https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03521&Product=CC HG03521 efo:EFO_0010887 Lymphoblastoid cell line from a Mende female from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03558&Product=CC HG03558 efo:EFO_0010888 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03565&Product=CC HG03565 efo:EFO_0010889 Lymphoblastoid cell line from a Mende male from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03571&Product=CC HG03571 efo:EFO_0010890 Lymphoblastoid cell line from a Mende female from Sierra Leone https://www.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=HG03575&Product=CC HG03575 efo:EFO_0010899 Quantification of one or more antibodies to the Merkel-cell virus, typically in serum. Annalisa Buniello true PMID:33204752 anti-MCV measurement anti-merkel cell virus antibody measurement efo:EFO_0010900 Quantification of one or more antibodies to the polyomavirus 2, typically in serum. Annalisa Buniello true PMID:33204752 JCV anti-polyomavirus 2 antibody measurement efo:EFO_0010903 Quantification of one or more antibodies to the chlamydia trachomatis virus, typically in serum. Annalisa Buniello true PMID:33204752 anti-chlamydia trachomatis antibody measurement efo:EFO_0010904 Quantification of one or more antibodies to the BK polyomavirus, typically in serum. Annalisa Buniello true PMID:33204752 anti-BK polyomavirus antibody measurement efo:EFO_0010905 The result of a measurement of circulating BK polyomavirus-specific antibodies. Annalisa Buniello true PMID:33204752 BKV seropositivity BK polyomavirus seropositivity efo:EFO_0010906 The result of a measurement of circulating merkel cell virus-specific antibodies. Annalisa Buniello true PMID:33204752 MKV seropositivity merkel cell virus seropositivity efo:EFO_0010907 The result of a measurement of circulating polyomavirus 2-specific antibodies. Annalisa Buniello true PMID:33204752 JCV seropositivity polyomavirus 2 seropositivity efo:EFO_0010908 The result of a measurement of circulating Epstein-Barr virus-specific antibodies. Annalisa Buniello true PMID:33204752 Epstein-Barr virus seropositivity efo:EFO_0010909 Quantification of the amount of adrenomedullin in a sample Annalisa Buniello true PMID:33067605 adrenomedullin measurement efo:EFO_0010910 Quantification of the amount of C-C motif chemokine 20 in a sample Annalisa Buniello true PMID:33067605 C-C motif chemokine 20 measurement efo:EFO_0010911 Quantification of the amount of C-X-C motif chemokine 16 in a sample Annalisa Buniello true PMID:33067605 C-X-C motif chemokine 16 measurement efo:EFO_0010912 Quantification of the amount of endothelial cell-specific molecule 1 in a sample Annalisa Buniello true PMID:33067605 endothelial cell-specific molecule 1 measurement efo:EFO_0010913 Quantification of the amount of eosinophil cationic protein in a sample Annalisa Buniello true PMID:33067605 eosinophil cationic protein measurement efo:EFO_0010914 Quantification of the amount of fatty acid-binding protein, adipocyte in a sample Annalisa Buniello true PMID:33067605 fatty acid-binding protein, adipocyte measurement efo:EFO_0010915 Quantification of the amount of heat shock 27 kDa protein in a sample Annalisa Buniello true PMID:33067605 heat shock 27 kDa protein measurement efo:EFO_0010916 Quantification of the amount of interleukin-27 in a sample Annalisa Buniello true PMID:33067605 interleukin-27 measurement efo:EFO_0010917 Quantification of the amount of kidney injury molecule 1 in a sample Annalisa Buniello true PMID:33067605 kidney injury molecule 1 measurement efo:EFO_0010918 Quantification of the amount of lectin-like oxidized LDL receptor 1 in a sample Annalisa Buniello true PMID:33067605 lectin-like oxidized LDL receptor 1 measurement efo:EFO_0010919 Quantification of the amount of melusin in a sample Annalisa Buniello true PMID:33067605 melusin measurement efo:EFO_0010920 Quantification of the amount of membrane-bound aminopeptidase P in a sample Annalisa Buniello true PMID:33067605 membrane-bound aminopeptidase P measurement efo:EFO_0010921 Quantification of the amount of N-terminal prohormone brain natriuretic peptide in a sample Annalisa Buniello true PMID:33067605 N-terminal prohormone brain natriuretic peptide measurement efo:EFO_0010922 Quantification of the amount of P-selectin glycoprotein ligand 1 in a sample Annalisa Buniello true PMID:33067605 P-selectin glycoprotein ligand 1 measurement efo:EFO_0010923 Quantification of the amount of pentraxin-related protein PTX3 in a sample Annalisa Buniello true PMID:33067605 pentraxin-related protein PTX3 measurement efo:EFO_0010924 Quantification of the amount of proheparin-binding EGF-like growth factor in a sample Annalisa Buniello true PMID:33067605 proheparin-binding EGF-like growth factor measurement efo:EFO_0010925 Quantification of the amount of protein S100-A12 in a sample Annalisa Buniello true PMID:33067605 protein S100-A12 measurement efo:EFO_0010926 Quantification of the amount of proteinase-activated receptor 1 in a sample Annalisa Buniello true PMID:33067605 proteinase-activated receptor 1 measurement efo:EFO_0010927 Quantification of the amount of proto-oncogene tyrosine-protein kinase Src in a sample Annalisa Buniello true PMID:33067605 proto-oncogene tyrosine-protein kinase Src measurement efo:EFO_0010928 Quantification of the amount of SIR2-like protein 2 in a sample Annalisa Buniello true PMID:33067605 SIR2-like protein 2 measurement efo:EFO_0010929 Quantification of the amount of TNF-related activation-induced cytokine in a sample Annalisa Buniello true PMID:33067605 TNF-related activation-induced cytokine measurement efo:EFO_0010930 Quantification of the amount of TNF-related apoptosis-inducing ligand receptor 2 in a sample Annalisa Buniello true PMID:33067605 TNF-related apoptosis-inducing ligand receptor 2 measurement efo:EFO_0010931 Quantification of the amount of tumor necrosis factor receptor 1 in a sample Annalisa Buniello true PMID:33067605 tumor necrosis factor receptor 1 measurement efo:EFO_0010932 Quantification of the amount of urokinase plasminogen activator surface receptor in a sample Annalisa Buniello true PMID:33067605 urokinase plasminogen activator surface receptor measurement efo:EFO_0010934 The ratio between the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Elizabeth Lewis true PMID:33004991 AST:ALT ratio aspartate aminotransferase to alanine aminotransferase ratio efo:EFO_0010940 The quantification of the amount of activated migroglia in the brain. Elizabeth Lewis true PMID:30679421 proportion of activated microglia microglial activation measurement efo:EFO_0010947 The determination of the amount of epidermal growth factor present in a sample. Annalisa Buniello true PMID:33067605 EGF epidermal growth factor measurement efo:EFO_0010948 Quantification of some aspect of lower face morphology such as chin protrusion. Annalisa Buniello true PMID:33288918 lower face morphology measurement efo:EFO_0010949 Quantification of some aspect of upper face morphology such as forehead height. Annalisa Buniello true PMID:33288918 upper face morphology measurement efo:EFO_0010952 A quantitative measurement of the total amount of potassium present in a sample of urine. Sam Lambert true NCIt:C61047 ORCID:0000-0001-8222-008X PMID:33462484 urine potassium measurement urinary potassium measurement efo:EFO_0010966 Quantification of the severity of the symptoms of pneumonia, an inflammation of the lung parenchyma caused by an infection. Elliot Sollis true PMID:33357513 pneumonia severity measurement efo:EFO_0010967 The quantification of microalbumin in urine. Elizabeth Lewis true PMID:33462484 urinary microalbumin measurement efo:EFO_0010968 Quantification of phosphate levels in a sample. Elizabeth Lewis true PMID:33462484 phosphate measurement efo:EFO_0010972 The amount of phosphorus, measured as inorganic phosphate, in a specified sample of blood. Sam Lambert true ORCID:0000-0001-8222-008X PMID:33462484 Serum phosphate level blood phosphate level serum inorganic phosphate concentration serum inorganic phosphorus concentration blood phosphate measurement The amount of phosphorus, measured as inorganic phosphate, in a specified sample of blood. CMO:0000504 Serum phosphate level CMO:0000542 blood phosphate level CMO:0000504 serum inorganic phosphate concentration https://www.ncbi.nlm.nih.gov/books/NBK310/ serum inorganic phosphorus concentration https://www.ncbi.nlm.nih.gov/books/NBK310/ efo:EFO_0010973 A human cancer cell line, derived from ascites of a patient of peritonitis carcinomatosa. The patient was diagnosed with adenocarcinoma tubular ++, moderately differentiated. This cell line was composed of polygonal, spindle and round shaped cells. PMID:3154020 https://web.expasy.org/cellosaurus/CVCL_3079 NOZAWA NOZC-1 NOZ efo:EFO_0010976 Human induced pluripotent stem cell line, derived from a healthy white British male, with a normal karyotype. A subclone of WTSIi018-B. CLO:0102734 https://hpscreg.eu/cell-line/WTSIi018-B-1 https://web.expasy.org/cellosaurus/CVCL_9S58 HPSI0114i-kolf_2-C1 WTSIi018-B-1 KOLF2-C1 efo:EFO_0010978 Quantification of some aspect of cytotoxity such as survival time or cell viability, as a response to a chemotherapic drug. Annalisa Buniello true PMID:33575800 chemotherapy-induced cytotoxicity measurement efo:EFO_0010979 Quantification of 2-hydroxyisobutyrate in a sample. Elizabeth Lewis true PMID:33283231 2-hydroxyisobutyrate measurement efo:EFO_0010980 Quantification of 3-aminoisobutyrate in a sample. Elizabeth Lewis true PMID:33283231 3-aminoisobutyrate measurement efo:EFO_0010982 Quantification of 3-hydroxybutyrate in a sample. Elizabeth Lewis true PMID:33283231 3-hydroxybutyrate measurement efo:EFO_0010983 Quantification of 3-hydroxyisobutyrate in a sample. Elizabeth Lewis true PMID:33283231 3-hydroxyisobutyrate measurement efo:EFO_0010984 Quantification of 3-hydroxyisovalerate in a sample. Elizabeth Lewis true PMID:33283231 3-hydroxyisovalerate measurement efo:EFO_0010985 Quantification of 3-Indoxylsulfate in a sample. Elizabeth Lewis true PMID:33283231 3-Indoxylsulfate measurement efo:EFO_0010986 Quantification of 4-deoxyerythronic acid in a sample. Elizabeth Lewis true PMID:33283231 4-deoxyerythronic acid measurement efo:EFO_0010987 Quantification of 4-deoxythreonic acid in a sample. Elizabeth Lewis true PMID:33283231 4-deoxythreonic acid measurement efo:EFO_0010988 Quantification of 5-oxoproline in a sample. Elizabeth Lewis true PMID:33283231 5-oxoproline measurement efo:EFO_0010989 Quantification of acetone in a sample. Elizabeth Lewis true PMID:33283231 acetone measurement efo:EFO_0010990 Quantification of dimethylamine in a sample. Elizabeth Lewis true PMID:33283231 dimethylamine measurement efo:EFO_0010991 Quantification of formate in a sample. Elizabeth Lewis true PMID:33283231 formate measurement efo:EFO_0010992 Quantification of hippurate in a sample. Elizabeth Lewis true PMID:33283231 hippurate measurement efo:EFO_0010993 Quantification of n-acetyl neuraminic acid in a sample. Elizabeth Lewis true PMID:33283231 n-acetyl neuraminic acid measurement efo:EFO_0010994 Quantification of n-methyl-2-pyridone-5-carboxamide in a sample. Elizabeth Lewis true PMID:33283231 n-methyl-2-pyridone-5-carboxamide measurement efo:EFO_0010995 Quantification of n-methylnicotinic acid in a sample. Elizabeth Lewis true PMID:33283231 n-methylnicotinic acid measurement efo:EFO_0010996 Quantification of n-methylpicolinic acid in a sample. Elizabeth Lewis true PMID:33283231 n-methylpicolinic acid measurement efo:EFO_0010997 Quantification of n1-methyl-nicotinamide in a sample. Elizabeth Lewis true PMID:33283231 n1-methyl-nicotinamide measurement efo:EFO_0010998 Quantification of p-cresol sulfate in a sample. Elizabeth Lewis true PMID:33283231 p-cresol sulfate measurement efo:EFO_0010999 Quantification of p-hydroxyphenylacetate in a sample. Elizabeth Lewis true PMID:33283231 p-hydroxyphenylacetate measurement efo:EFO_0011000 Quantification of proline beatine in a sample. Elizabeth Lewis true PMID:33283231 proline betaine measurement efo:EFO_0011001 Quantification of scyllo-inositol in a sample. Elizabeth Lewis true PMID:33283231 scyllo-inositol measurement efo:EFO_0011002 Quantification of succinate in a sample. Elizabeth Lewis true PMID:33283231 succinate measurement efo:EFO_0011003 Quantification of trimethylamine in a sample. Elizabeth Lewis true PMID:33283231 trimethylamine measurement efo:EFO_0011004 Quantification of trimethylamine oxide in a sample. Elizabeth Lewis true PMID:33283231 trimethylamine oxide measurement efo:EFO_0011005 Quantification of urea in a sample. Elizabeth Lewis true PMID:33283231 urea measurement efo:EFO_0011007 Quantification of the levels of estrogen, or osetrogen, a category of sex hormone responsible for the development and regulation of the female reproductive system and secondary sex characteristics. There are three major endogenous estrogens that have estrogenic hormonal activity: estrone (E1), estradiol (E2), and estriol (E3). Another estrogen called estetrol (E4) is produced only during pregnancy Aoife McMahon true PMID:32701512 estrogen levels oestrogen levels oestrogen measurement estrogen measurement Quantification of the levels of estrogen, or osetrogen, a category of sex hormone responsible for the development and regulation of the female reproductive system and secondary sex characteristics. There are three major endogenous estrogens that have estrogenic hormonal activity: estrone (E1), estradiol (E2), and estriol (E3). Another estrogen called estetrol (E4) is produced only during pregnancy http://purl.obolibrary.org/obo/CHEBI_50114 https://en.wikipedia.org/wiki/Estrogen efo:EFO_0011008 The determination of the amount of a sex hormone present in a sample. true sex hormone measurement efo:EFO_0011009 Quantification of the amount of glycochenodeoxycholate 3-O-glucuronide in a sample. Elizabeth Lewis true PMID:32961594 GCDCA-3G glycochenodeoxycholate 3-O-glucuronide measurement efo:EFO_0011010 Quantification of the amount of glycodeoxycholate 3-O-glucuronide in a sample. Elizabeth Lewis true PMID:32961594 GDCA-3G glycodeoxycholate 3-O-glucuronide measurement efo:EFO_0011011 Quantification of some aspect of height, when assuming a sitting position. Annalisa Buniello true PMID:33623009 sitting height measurement efo:EFO_0011012 The determination of the amount of bicarbonate present in a blood sample. Annalisa Buniello true PMID:33623009 blood sodium bicarbonate measurement blood bicarbonate measurement efo:EFO_0011013 Quantification of some aspect of an individual's microbiome of the vagina. Aoife McMahon true PMID:32723796 vaginal flora measurement vaginal microbiota measurement vaginal microbiome measurement efo:EFO_0011014 A measure to assess health-related quality of life (HRQOL), which domains include physical health, emotional health, cognitive functioning, fatigue and pain. Elizabeth Lewis true PMID:33578652 HRQOL health-related quality of life measurement efo:EFO_0011015 A measure of academic performance through educational benchmarks such as national exams and curriculum assessments. Elizabeth Lewis true PMID:33594131 academic attainment educational attainment efo:EFO_0011018 Quantification of the amount of brain-derived neurotrophic factor present in a sample Elizabeth Lewis true PMID:33345186 http://purl.obolibrary.org/obo/NCIT_C82004 BDNF brain-derived neurotrophic factor measurement efo:EFO_0011021 Determination of the presence or absence of known harmful mutation(s) in the BRAC1 gene. BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents. BRCA1/BRCA2 germline mutations significantly increase the risk of breast and ovarian cancer. Elizabeth Lewis true PMID:33597508 BRCA1 carrier status BRCA1 mutation status BRCA1 mutation carier status Determination of the presence or absence of known harmful mutation(s) in the BRAC1 gene. BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents. BRCA1/BRCA2 germline mutations significantly increase the risk of breast and ovarian cancer. doi:10.1001/jama.2017.7112 efo:EFO_0011022 Determination of the presence or absence of known harmful mutation(s) in the BRAC2 gene. BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents. BRCA1/BRCA2 germline mutations significantly increase the risk of breast and ovarian cancer. Elizabeth Lewis true PMID:33597508 BRCA2 carrier status BRCA2 mutation status BRCA2 mutation carier statu Determination of the presence or absence of known harmful mutation(s) in the BRAC2 gene. BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents. BRCA1/BRCA2 germline mutations significantly increase the risk of breast and ovarian cancer. doi:10.1001/jama.2017.7112 efo:EFO_0011031 Quantification of the intestinal permeability barrier status, for example measured by the ratio of the fractional excretion of lactulose to mannitol (LacMan ratio) Annalisa Buniello true PMID:31251335 doi:10.1111/nmo.12871 gut permeability measurement intestinal permeability measurement efo:EFO_0011032 The gold standard for functional measurements of intestinal permeability in humans is the lactulose/ mannitol test, which measures urinary excretion of the two orally administered non-metabolized sugars over a 6 h period. Analysis by high pressure liquid chromatography or liquid chromatography in combination with mass spectrometry is usually performed on urine samples. Annalisa Buniello PMID:31251335 LacMan ratio lactulose mannitol test fractional excretion of lactulose to mannitol ratio The gold standard for functional measurements of intestinal permeability in humans is the lactulose/ mannitol test, which measures urinary excretion of the two orally administered non-metabolized sugars over a 6 h period. Analysis by high pressure liquid chromatography or liquid chromatography in combination with mass spectrometry is usually performed on urine samples. doi: 10.1111/nmo.12871 efo:EFO_0011033 Electrocardiography measurement of the duration from the end of the S wave to the start of the T wave Elliot Sollis true PMID:32602732 ST segment duration efo:EFO_0011034 Electrocardiography measurement of the duration from the start of the T wave to the end of the T wave. Elliot Sollis true PMID:32602732 T wave duration efo:EFO_0011035 Electrocardiography measurement of the duration from the end of the T wave to the start of the P wave. Elliot Sollis true PMID:32602732 TP segment duration efo:EFO_0011036 Quantification of matrix metalloproteinase-degraded type I collagen (also known as metabolite of type I collagen) in a sample. Elizabeth Lewis true PMID:33134509 MMP-mediated type I collagen degradation measurement matrix metalloproteinase (MMP)-degraded type I collagen (C1M) measurement type I collagen metabolite measurement matrix metalloproteinase–degraded type I collagen measurement efo:EFO_0011037 Quantification of the amount of antibody to human herpes virus 6 in a sample. Laura Harris true PMID:33204752 anti-human herpes virus 6 antibody measurement efo:EFO_0011038 Quantification of the amount of antibody to human herpes virus 7 in a sample. Laura Harris true PMID:33204752 anti-human herpes virus 7 antibody measurement efo:EFO_0011039 Quantification of myeloperoxidase (MPO)-DNA complex levels in a biological specimen. Plasma MPO-DNA complex levels typically measured by immunofluorescence or ELISA are used to detect neutrophil extracellular trap (NETs) formation. Annalisa Buniello true PMID:31172493 PMID:33717105 MPO-DNA complex myeloperoxidase (MPO)-DNA complex measurement efo:EFO_0011043 A circumferential measurement of the neck. Elizabeth Lewis true NCIT:C154891 PMID:33907307 neck circumference efo:EFO_0011044 A circumferential measurement of the neck that has been adjusted for subjects' body mass index. Elizabeth Lewis true PMID:33907307 BMI-adjusted neck circumference efo:EFO_0011045 The mass or quantity of heaviness of an fetus in utero. It is expressed by units of pounds or kilograms. Santhi Ramachandran true NCIT:C124479 PMID:32407400 fetal weight efo:EFO_0020004 CH12F3 is a B-lymphocyte cell line that is a subclone of the IgM+ CH12.LX lymphoma cell line. zmp 2021-09-13T08:04:38Z PMID:8671604 CH12F3 efo:EFO_0020007 Quantification of X-21467 levels in a sample. zmp 2021-10-26T11:17:42Z true PMID:34436474 X-21467 measurement Quantification of X-21467 levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020008 Quantification of the campesterol levels in a sample. Campesterol is a phytosterol (molecular formula C28H48O) whose chemical structure is similar to that of cholesterol. zmp 2021-10-26T11:22:09Z true PMID:11432711 campesterol measurement Quantification of the campesterol levels in a sample. Campesterol is a phytosterol (molecular formula C28H48O) whose chemical structure is similar to that of cholesterol. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020009 Quantification of ethylmalonate levels in a sample. zmp 2021-10-26T11:26:46Z true SNOMEDCT:104659004 ethylmalonate measurement Quantification of ethylmalonate levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020010 Quantification of butyrylcarnitine levels in a sample. zmp 2021-10-26T11:28:43Z true PMID:18500942 butyrylcarnitine measurement Quantification of butyrylcarnitine levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020011 Quantification of X-16964 levels in a sample. zmp 2021-10-26T11:30:41Z true X-16964 measurement Quantification of X-16964 levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020012 Quantification of indolelactate levels in a sample. zmp 2021-10-26T11:31:36Z true indolelactate measurement Quantification of indolelactate levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020013 Quantification of 5-methyluridine levels in a sample. zmp 2021-10-26T11:34:48Z true 5-methyluridine (ribothymidine) measurement Quantification of 5-methyluridine levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020014 Quantification of 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2) levels in a sample. zmp 2021-10-26T11:35:59Z true https://pubchem.ncbi.nlm.nih.gov/compound/122198213 1-(1-enyl-stearoyl)-2-linoleoyl-GPE measurement;GPE(P-18:0/18:2) measurement 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)* measurement Quantification of 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2) levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020015 Quantification of X-11593 levels in a sample. zmp 2021-10-26T11:38:06Z true PMID:23093944 X-11593 measurement Quantification of X-11593 levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020016 Quantification of X-21444 levels in a sample. zmp 2021-10-26T11:39:30Z X-21444 measurement Quantification of X-21444 levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020017 Quantification of 2-aminobutyrate levels in a sample. zmp 2021-10-26T11:40:12Z true SNOMEDCT:412904008 2-aminobutyrate measurement Quantification of 2-aminobutyrate levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020018 Quantification of glycerophosphorylcholine levels in a sample. zmp 2021-10-26T11:41:56Z true NCIt:C15826 GPC measurement glycerophosphorylcholine measurement Quantification of glycerophosphorylcholine levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020019 Quantification of isovalerylcarnitine levels in a sample. zmp 2021-10-26T11:43:56Z true SNOMEDCT:121799004 isovalerylcarnitine measurement Quantification of isovalerylcarnitine levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020020 Quantification of succinylcarnitine levels in a sample. zmp 2021-10-26T11:45:02Z true succinylcarnitine measurement Quantification of succinylcarnitine levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020021 Quantification of N-acetyltyrosine levels in a sample. zmp 2021-10-26T11:45:56Z true SNOMEDCT:121817007 N-Acetyl-L-tyrosine measurement N-acetyltyrosine measurement Quantification of N-acetyltyrosine levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020022 Quantification of N-acetylneuraminate levels in a sample. zmp 2021-10-26T11:47:38Z true PMID:1525488 NANA measurement Neu5Ac measurement N-acetylneuraminate measurement Quantification of N-acetylneuraminate levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020023 Quantification of N-acetyltaurine levels in a sample. zmp 2021-10-26T11:49:20Z true PMID:27520321 NAcT measurement N-acetyltaurine measurement Quantification of N-acetyltaurine levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020024 Quantification of X-15728 levels in a sample. zmp 2021-10-26T11:50:46Z true X-15728 measurement Quantification of X-15728 levels in a sample. https://orcid.org/0000-0002-2417-7324 efo:EFO_0020042 The determination of the amount of jasmonic acid present in a sample, typically blood Annalisa Buniello PMID:34503513 jasmonic acid measurement efo:EFO_0020043 The determination of the amount of octadecanoids present in a sample, typically blood Annalisa Buniello true PMID:34503513 octadecanoids measurement efo:EFO_0020044 The determination of the amount of eicosanoids present in a sample, typically blood Annalisa Buniello true PMID:34503513 ecosanoids measurement efo:EFO_0020045 The determination of the amount of prostaglandins present in a sample, typically blood PMID:34503513 prostaglandins measurement efo:EFO_0020046 The quantification of phosphatidylcholine 18:1 levels in a sample, typically blood Annalisa Buniello PMID:34503513 phosphatidylcholine 18:1 measurement efo:EFO_0020047 The quantification of phosphatidate levels in a sample, typically blood Annalisa Buniello true PMID:34503513 phosphatidate measurement efo:EFO_0020048 The quantification of lysophosphatidylserine levels in a sample, typically blood Annalisa Buniello true PMID:34503513 lysophosphatidylserine measurement efo:EFO_0020049 The quantification of phosphatidylserines levels in a sample, typically blood Annalisa Buniello true PMID:34503513 phosphatidylserines measurement efo:EFO_0020050 The quantification of diacylglycerol 30:1 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 bile acid measurement efo:EFO_0020051 The quantification of diacylglycerol 30:0 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 30:1 measurement efo:EFO_0020052 The quantification of diacylglycerol 30:1 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 30:0 measurement efo:EFO_0020053 The quantification of diacylglycerol 28:0 levels in a sample, typically blood Annalisa Buniello PMID:34503513 diacylglycerol 28:0 measurement efo:EFO_0020054 The quantification of diacylglycerol 32:0 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 32:0 measurement efo:EFO_0020055 The quantification of diacylglycerol 32:2 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 32.2 measurement efo:EFO_0020056 The quantification of diacylglycerol 33:1 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 33:1 measurement efo:EFO_0020057 The quantification of diacylglycerol 33:3 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 33:3 measurement efo:EFO_0020058 The quantification of diacylglycerol 34:0 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 34:0 measurement efo:EFO_0020059 The quantification of diacylglycerol 34:3 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 34:3 measurement efo:EFO_0020062 The quantification of diacylglycerol 36:3 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 36:3 measurement efo:EFO_0020063 The quantification of diacylglycerol 36:4 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 36:4 measurement efo:EFO_0020064 The quantification of diacylglycerol 36:5 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 36:5 measurement efo:EFO_0020065 The quantification of diacylglycerol 38:3 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 38:3 measurement efo:EFO_0020066 The quantification of diacylglycerol 38:4 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 38:4 measurement efo:EFO_0020067 The quantification of diacylglycerol 38:5 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 38:5 measurement efo:EFO_0020068 The quantification of diacylglycerol 42:7 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 42:7 measurement efo:EFO_0020069 The quantification of diacylglycerol 44:7 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 44:7 measurement efo:EFO_0020070 The quantification of diacylglycerol 44:6 levels in a sample, typically blood Annalisa Buniello true PMID:34503513 diacylglycerol 44:6 measurement efo:EFO_0020071 A measure of femoral head sphericity. Zoe May Pendlington 2023-03-14T15:22:48Z true alpha angle measurement A measure of femoral head sphericity. PMID:36662418 efo:EFO_0020072 Quantification of the circulating pattern recognition receptor CD163 in a sample such as blood plasma. Zoe May Pendlington 2023-03-14T15:47:02Z true https://www.uniprot.org/uniprotkb/Q86VB7/entry sCD163 measurement soluble cluster of differentiation 163 measurement soluble CD163 measurement Quantification of the circulating pattern recognition receptor CD163 in a sample such as blood plasma. PMID:36314488 efo:EFO_0020074 A measurement of the amount of protein in a urine sample. Santhi Ramachandran true urine protein measurement A measurement of the amount of protein in a urine sample. PMID:36777999 efo:EFO_0020075 A measurement of the amount of glucose in a urine sample. Santhi Ramachandran true urine glucose measurement A measurement of the amount of glucose in a urine sample. PMID:36777999 efo:EFO_0020076 A measurement of the amount of blood in a urine sample. Santhi Ramachandran true urine blood measurement A measurement of the amount of blood in a urine sample. PMID:36777999 efo:EFO_0020077 Quantification of dietary vitamin A intake. Santhi Ramachandran true dietary vitamin A intake measurement Quantification of dietary vitamin A intake. PMID:36777999 efo:EFO_0020078 Quantification of dietary vitamin B1 intake. Santhi Ramachandran true dietary vitamin B1 intake measurement Quantification of dietary vitamin B1 intake. PMID:36777999 efo:EFO_0020079 Quantification of dietary vitamin B1 intake. Santhi Ramachandran true dietary vitamin B2 intake measurement Quantification of dietary vitamin B1 intake. PMID:36777999 efo:EFO_0020080 Quantification of dietary sodium intake. Santhi Ramachandran true dietary sodium intake measurement Quantification of dietary sodium intake. PMID:36777999 efo:EFO_0020081 Quantification of dietary niacin intake. Santhi Ramachandran true dietary niacin intake measurement Quantification of dietary niacin intake. PMID:36777999 efo:EFO_0020082 Quantification of dietary vitamin C intake. Santhi Ramachandran true dietary vitamin C intake measurement Quantification of dietary vitamin C intake. PMID:36777999 efo:EFO_0020083 Quantification of dietary zinc intake. Santhi Ramachandran true dietary zinc intake measurement Quantification of dietary zinc intake. PMID:36777999 efo:EFO_0020084 Quantification of dietary vitamin B6 intake. Santhi Ramachandran true dietary vitamin B6 intake measurement Quantification of dietary vitamin B6 intake. PMID:36777999 efo:EFO_0020085 Quantification of dietary retinol intake. Santhi Ramachandran true dietary retinol intake measurement Quantification of dietary retinol intake. PMID:36777999 efo:EFO_0020086 Quantification of dietary carotene intake. Santhi Ramachandran true dietary carotene intake measurement Quantification of dietary carotene intake. PMID:36777999 efo:EFO_0020087 Quantification of dietary ash intake. Santhi Ramachandran true dietary ash intake measurement Quantification of dietary ash intake. PMID:36777999 efo:EFO_0020088 Quantification of dietary fiber intake. Santhi Ramachandran true dietary fiber intake measurement Quantification of dietary fiber intake. PMID:36777999 efo:EFO_0020089 Quantification of dietary vitamin E intake. Santhi Ramachandran true dietary vitamin E intake measurement Quantification of dietary vitamin E intake. PMID:36777999 efo:EFO_0020090 Quantification of dietary cholesterol intake. Santhi Ramachandran true dietary cholesterol intake measurement Quantification of dietary cholesterol intake. PMID:36777999 efo:EFO_0020091 Quantification of dietary phosphorus intake. Santhi Ramachandran true dietary phosphorus intake measurement Quantification of dietary phosphorus intake. PMID:36777999 efo:EFO_0020095 The mineral density of femoral trochanter. Zoe May Pendlington 2023-04-14T10:31:20Z true trochanter bone mineral density The mineral density of femoral trochanter. PMID:36228083 efo:EFO_0020096 Measurement of the diameter of the mitral valve annulus. Zoe May Pendlington 2023-04-14T10:53:35Z true mitral valve annular diameter Measurement of the diameter of the mitral valve annulus. PMID:35132965 efo:EFO_0020097 An electrocardiogram‐derived measure of the difference in mean vectors of depolarization and repolarization. Zoe May Pendlington 2023-04-14T11:41:27Z true QRS-T angle An electrocardiogram‐derived measure of the difference in mean vectors of depolarization and repolarization. PMID:36918541 efo:EFO_0020098 Quantification of abdominal fat ratio. Zoe May Pendlington 2023-04-14T12:00:57Z true abdominal fat ratio Quantification of abdominal fat ratio. PMID:36402844 efo:EFO_0020099 Quantification of weight to muscle ratio. Zoe May Pendlington 2023-04-14T12:01:34Z true weight-to-muscle ratio Quantification of weight to muscle ratio. PMID:36402844 efo:EFO_0020100 Quantification of some aspect of the thigh muscle. Zoe May Pendlington 2023-04-14T12:02:18Z thigh muscle measurement Quantification of some aspect of the thigh muscle. PMID:36402844 efo:EFO_0020102 Quantification of circulating alpha-Klotho in a sample. Elizabeth Lewis Zoe May Pendlington 2022-01-06T11:00:15Z true PMID:34542150 circulating alpha-Klotho measurement efo:EFO_0020104 Mineral density of the pelvis bone. Elizabeth Lewis Zoe May Pendlington 2022-01-14T10:00:47Z true PMID:33430342 pelvis bone mineral density efo:EFO_0020105 Mineral density of the trunk. Elizabeth Lewis Zoe May Pendlington 2022-01-14T10:02:24Z true PMID:33430342 trunk bone mineral density efo:EFO_0020107 Quantification of some aspect of thigh muscle volume. Zoe May Pendlington 2023-04-14T12:02:47Z true thigh muscle volume Quantification of some aspect of thigh muscle volume. PMID:36402844 efo:EFO_0020108 The determination of the amount of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 in a sample Annalisa Buniello true PMID:28240269 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 measurement efo:EFO_0020109 The determination of the amount of 14-3-3 protein family in a sample Annalisa Buniello true PMID:28240269 14-3-3 protein family measurement efo:EFO_0020110 The determination of the amount of 14-3-3 protein sigma in a sample Annalisa Buniello true PMID:28240269 14-3-3 protein sigma measurement efo:EFO_0020111 The determination of the amount of 15-hydroxyprostaglandin dehydrogenase [NAD(+)] in a sample Annalisa Buniello true PMID:28240269 15-hydroxyprostaglandin dehydrogenase [NAD(+)] measurement efo:EFO_0020112 The determination of the amount of 26s proteasome non-atpase regulatory subunit 7 in a sample Annalisa Buniello true PMID:28240269 26s proteasome non-atpase regulatory subunit 7 measurement efo:EFO_0020113 The determination of the amount of 3-hydroxy-3-methylglutaryl-coenzymeAreductase in a sample Annalisa Buniello true PMID:28240269 3-hydroxy-3-methylglutaryl-coenzymeAreductase measurement efo:EFO_0020114 The determination of the amount of 3-hydroxyacyl-coa dehydrogenase type-2 in a sample Annalisa Buniello true PMID:28240269 3-hydroxyacyl-coa dehydrogenase type-2 measurement efo:EFO_0020115 The determination of the amount of 3-hydroxyisobutyrate dehydrogenase, mitochondrial in a sample Annalisa Buniello true PMID:28240269 3-hydroxyisobutyrate dehydrogenase, mitochondrial measurement efo:EFO_0020116 The determination of the amount of 3-phosphoinositide-dependent protein kinase 1 in a sample Annalisa Buniello true PMID:28240269 3-phosphoinositide-dependent protein kinase 1 measurement efo:EFO_0020117 The determination of the amount of 40s ribosomal protein S3 in a sample Annalisa Buniello true PMID:28240269 40s ribosomal protein S3 measurement efo:EFO_0020118 The determination of the amount of 40s ribosomal protein S7 in a sample Annalisa Buniello true PMID:28240269 40s ribosomal protein S7 measurement efo:EFO_0020119 The determination of the amount of 40s ribosomal protein SA in a sample Annalisa Buniello true PMID:28240269 40s ribosomal protein SA measurement efo:EFO_0020120 The determination of the amount of 6-phosphogluconate dehydrogenase, decarboxylating in a sample Annalisa Buniello true PMID:28240269 6-phosphogluconate dehydrogenase, decarboxylating measurement efo:EFO_0020121 The determination of the amount of 60 kda heat shock protein, mitochondrial in a sample Annalisa Buniello true PMID:28240269 60 kda heat shock protein, mitochondrial measurement efo:EFO_0020122 The determination of the amount of 72 kda type IV collagenase in a sample Annalisa Buniello true PMID:28240269 72 kda type IV collagenase measurement efo:EFO_0020123 The determination of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 15 in a sample Annalisa Buniello true PMID:28240269 a disintegrin and metalloproteinase with thrombospondin motifs 15 measurement efo:EFO_0020124 The determination of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 4 in a sample Annalisa Buniello true PMID:28240269 a disintegrin and metalloproteinase with thrombospondin motifs 4 measurement efo:EFO_0020125 The determination of the amount of acidic leucine-rich nuclear phosphoprotein 32 family member b in a sample Annalisa Buniello true PMID:28240269 acidic leucine-rich nuclear phosphoprotein 32 family member b measurement efo:EFO_0020126 The determination of the amount of activated protein C in a sample Annalisa Buniello true PMID:28240269 activated protein C measurement efo:EFO_0020127 The determination of the amount of activin receptor type-1B in a sample Annalisa Buniello true PMID:28240269 activin receptor type-1B measurement efo:EFO_0020128 The determination of the amount of adapter molecule CRK in a sample Annalisa Buniello true PMID:28240269 adapter molecule CRK measurement efo:EFO_0020129 The determination of the amount of adenylate kinase isoenzyme 1 in a sample Annalisa Buniello true PMID:28240269 adenylate kinase isoenzyme 1 measurement efo:EFO_0020130 The determination of the amount of adenylosuccinate lyase in a sample Annalisa Buniello true PMID:28240269 adenylosuccinate lyase measurement efo:EFO_0020131 The determination of the amount of advanced glycosylation end product-specific receptor, soluble in a sample Annalisa Buniello true PMID:28240269 advanced glycosylation end product-specific receptor, soluble measurement efo:EFO_0020132 The determination of the amount of aflatoxin B1 aldehyde reductase member 2 in a sample Annalisa Buniello true PMID:28240269 aflatoxin B1 aldehyde reductase member 2 measurement efo:EFO_0020133 The determination of the amount of aggrecan core protein in a sample Annalisa Buniello true PMID:28240269 aggrecan core protein measurement efo:EFO_0020134 The determination of the amount of AH receptor-interacting protein in a sample Annalisa Buniello true PMID:28240269 AH receptor-interacting protein measurement efo:EFO_0020135 The determination of the amount of allograft inflammatory factor 1 in a sample Annalisa Buniello true PMID:28240269 allograft inflammatory factor 1 measurement efo:EFO_0020136 The determination of the amount of alpha-(1,3)-fucosyltransferase 5 in a sample Annalisa Buniello true PMID:28240269 alpha-(1,3)-fucosyltransferase 5 measurement efo:EFO_0020137 The determination of the amount of alpha-2-antiplasmin in a sample Annalisa Buniello true PMID:28240269 alpha-2-antiplasmin measurement efo:EFO_0020138 The determination of the amount of alpha-2-macroglobulin in a sample Annalisa Buniello true PMID:28240269 alpha-2-macroglobulin measurement efo:EFO_0020139 The determination of the amount of alpha-L-iduronidase in a sample Annalisa Buniello true PMID:28240269 alpha-L-iduronidase measurement efo:EFO_0020140 The determination of the amount of alpha-soluble NSF attachment protein in a sample Annalisa Buniello true PMID:28240269 alpha-soluble NSF attachment protein measurement efo:EFO_0020141 The determination of the amount of aminoacylase-1 in a sample Annalisa Buniello true PMID:28240269 aminoacylase-1 measurement efo:EFO_0020142 The determination of the amount of amp kinase (alpha1beta1gamma1) in a sample Annalisa Buniello true PMID:28240269 amp kinase (alpha1beta1gamma1) measurement efo:EFO_0020143 The determination of the amount of amp kinase (alpha2beta2gamma1) in a sample Annalisa Buniello true PMID:28240269 amp kinase (alpha2beta2gamma1) measurement efo:EFO_0020144 The determination of the amount of amphiregulin in a sample Annalisa Buniello true PMID:28240269 amphiregulin measurement efo:EFO_0020145 The determination of the amount of amyloid beta A4 protein in a sample Annalisa Buniello true PMID:28240269 amyloid beta A4 protein measurement efo:EFO_0020146 The determination of the amount of angiopoietin-1 in a sample Annalisa Buniello true PMID:28240269 angiopoietin-1 measurement efo:EFO_0020147 The determination of the amount of angiopoietin-4 in a sample Annalisa Buniello true PMID:28240269 angiopoietin-4 measurement efo:EFO_0020148 The determination of the amount of angiopoietin-related protein 3 in a sample Annalisa Buniello true PMID:28240269 angiopoietin-related protein 3 measurement efo:EFO_0020149 The determination of the amount of angiopoietin-related protein 4 in a sample Annalisa Buniello true PMID:28240269 angiopoietin-related protein 4 measurement efo:EFO_0020150 The determination of the amount of angiotensin-converting enzyme 2 in a sample Annalisa Buniello true PMID:28240269 angiotensin-converting enzyme 2 measurement efo:EFO_0020151 The determination of the amount of annexin A6 in a sample Annalisa Buniello true PMID:28240269 annexin A6 measurement efo:EFO_0020152 The determination of the amount of anterior gradient protein 2 homolog in a sample Annalisa Buniello true PMID:28240269 anterior gradient protein 2 homolog measurement efo:EFO_0020153 The determination of the amount of anti-muellerian hormone type-2 receptor in a sample Annalisa Buniello true PMID:28240269 anti-muellerian hormone type-2 receptor measurement efo:EFO_0020154 The determination of the amount of antileukoproteinase in a sample Annalisa Buniello true PMID:28240269 antileukoproteinase measurement efo:EFO_0020155 The determination of the amount of antithrombin-III in a sample Annalisa Buniello true PMID:28240269 antithrombin-III measurement efo:EFO_0020156 The determination of the amount of apolipoprotein D in a sample Annalisa Buniello true PMID:28240269 apolipoprotein D measurement efo:EFO_0020157 The determination of the amount of apolipoprotein E (isoform E3) in a sample Annalisa Buniello true PMID:28240269 apolipoprotein E (isoform E3) measurement efo:EFO_0020158 The determination of the amount of apolipoprotein E (isoform E4) in a sample Annalisa Buniello true PMID:28240269 apolipoprotein E (isoform E4) measurement efo:EFO_0020159 The determination of the amount of apoptosis regulator BCL-2 in a sample Annalisa Buniello true PMID:28240269 apoptosis regulator BCL-2 measurement efo:EFO_0020160 The determination of the amount of arginase-1 in a sample Annalisa Buniello true PMID:28240269 arginase-1 measurement efo:EFO_0020161 The determination of the amount of aromatic-l-amino-acid decarboxylase in a sample Annalisa Buniello true PMID:28240269 aromatic-l-amino-acid decarboxylase measurement efo:EFO_0020162 The determination of the amount of artemin in a sample Annalisa Buniello true PMID:28240269 artemin measurement efo:EFO_0020163 The determination of the amount of arylsulfatase A in a sample Annalisa Buniello true PMID:28240269 arylsulfatase A measurement efo:EFO_0020164 The determination of the amount of asialoglycoprotein receptor 1 in a sample Annalisa Buniello true PMID:28240269 asialoglycoprotein receptor 1 measurement efo:EFO_0020165 The determination of the amount of AT-rich interactive domain-containing protein 3A in a sample Annalisa Buniello true PMID:28240269 AT-rich interactive domain-containing protein 3A measurement efo:EFO_0020166 The determination of the amount of ATP synthase subunit beta, mitochondrial in a sample Annalisa Buniello true PMID:28240269 ATP synthase subunit beta, mitochondrial measurement efo:EFO_0020167 The determination of the amount of ATP-dependent rna helicase ddx19b in a sample Annalisa Buniello true PMID:28240269 ATP-dependent rna helicase ddx19b measurement efo:EFO_0020168 The determination of the amount of aurora kinase A in a sample Annalisa Buniello true PMID:28240269 aurora kinase A measurement efo:EFO_0020169 The determination of the amount of aurora kinase B in a sample Annalisa Buniello true PMID:28240269 aurora kinase B measurement efo:EFO_0020170 The determination of the amount of azurocidin in a sample Annalisa Buniello true PMID:28240269 azurocidin measurement efo:EFO_0020171 The determination of the amount of B-cell receptor CD22 in a sample Annalisa Buniello true PMID:28240269 B-cell receptor CD22 measurement efo:EFO_0020172 The determination of the amount of bactericidal permeability-increasing protein in a sample Annalisa Buniello true PMID:28240269 bactericidal permeability-increasing protein measurement efo:EFO_0020173 The determination of the amount of baculoviral IAP repeat-containing protein 3 in a sample Annalisa Buniello true PMID:28240269 baculoviral IAP repeat-containing protein 3 measurement efo:EFO_0020174 The determination of the amount of baculoviral IAP repeat-containing protein 5 in a sample Annalisa Buniello true PMID:28240269 baculoviral IAP repeat-containing protein 5 measurement efo:EFO_0020175 The determination of the amount of baculoviral IAP repeat-containing protein 7 isoform beta in a sample Annalisa Buniello true PMID:28240269 baculoviral IAP repeat-containing protein 7 isoform beta measurement efo:EFO_0020176 The determination of the amount of basigin in a sample Annalisa Buniello true PMID:28240269 basigin measurement efo:EFO_0020177 The determination of the amount of BCL-2-like protein 1 in a sample Annalisa Buniello true PMID:28240269 BCL-2-like protein 1 measurement efo:EFO_0020178 The determination of the amount of BCL-2-related protein A1 in a sample Annalisa Buniello true PMID:28240269 BCL-2-related protein A1 measurement efo:EFO_0020179 The determination of the amount of bdnf/nt-3 growth factors receptor in a sample Annalisa Buniello true PMID:28240269 bdnf/nt-3 growth factors receptor measurement efo:EFO_0020180 The determination of the amount of beta-2-microglobulin in a sample Annalisa Buniello true PMID:28240269 beta-2-microglobulin measurement efo:EFO_0020181 The determination of the amount of beta-adrenergic receptor kinase 1 in a sample Annalisa Buniello true PMID:28240269 beta-adrenergic receptor kinase 1 measurement efo:EFO_0020182 The determination of the amount of biglycan in a sample Annalisa Buniello true PMID:28240269 biglycan measurement efo:EFO_0020183 The determination of the amount of BMP-binding endothelial regulator protein in a sample Annalisa Buniello true PMID:28240269 BMP-binding endothelial regulator protein measurement efo:EFO_0020184 The determination of the amount of bone morphogenetic protein 1 in a sample Annalisa Buniello true PMID:28240269 bone morphogenetic protein 1 measurement efo:EFO_0020185 The determination of the amount of bone morphogenetic protein 10 in a sample Annalisa Buniello true PMID:28240269 bone morphogenetic protein 10 measurement efo:EFO_0020186 The determination of the amount of bone morphogenetic protein 6 in a sample Annalisa Buniello true PMID:28240269 bone morphogenetic protein 6 measurement efo:EFO_0020187 The determination of the amount of bone morphogenetic protein 7 in a sample Annalisa Buniello true PMID:28240269 bone morphogenetic protein 7 measurement efo:EFO_0020188 The determination of the amount of bone morphogenetic protein receptor type-1a in a sample Annalisa Buniello true PMID:28240269 bone morphogenetic protein receptor type-1a measurement efo:EFO_0020189 The determination of the amount of bone morphogenetic protein receptor type-2 in a sample Annalisa Buniello true PMID:28240269 bone morphogenetic protein receptor type-2 measurement efo:EFO_0020190 The determination of the amount of bone sialoprotein 2 in a sample Annalisa Buniello true PMID:28240269 bone sialoprotein 2 measurement efo:EFO_0020191 The determination of the amount of brain natriuretic peptide 32 in a sample Annalisa Buniello true PMID:28240269 brain natriuretic peptide 32 measurement efo:EFO_0020192 The determination of the amount of brain-specific serine protease 4 in a sample Annalisa Buniello true PMID:28240269 brain-specific serine protease 4 measurement efo:EFO_0020193 The determination of the amount of brevican core protein in a sample Annalisa Buniello true PMID:28240269 brevican core protein measurement efo:EFO_0020194 The determination of the amount of brother of CDO in a sample Annalisa Buniello true PMID:28240269 brother of CDO measurement efo:EFO_0020195 The determination of the amount of C-C motif chemokine 13 in a sample Annalisa Buniello true PMID:28240269 C-C motif chemokine 13 measurement efo:EFO_0020196 The determination of the amount of C-C motif chemokine 22 in a sample Annalisa Buniello true PMID:28240269 C-C motif chemokine 22 measurement efo:EFO_0020197 The determination of the amount of C-C motif chemokine 24 in a sample Annalisa Buniello true PMID:28240269 C-C motif chemokine 24 measurement efo:EFO_0020198 The determination of the amount of C-C motif chemokine 27 in a sample Annalisa Buniello true PMID:28240269 C-C motif chemokine 27 measurement efo:EFO_0020199 The determination of the amount of C-C motif chemokine 28 in a sample Annalisa Buniello true PMID:28240269 C-C motif chemokine 28 measurement efo:EFO_0020200 The determination of the amount of C-type lectin domain family 1 member B in a sample Annalisa Buniello true PMID:28240269 C-type lectin domain family 1 member B measurement efo:EFO_0020201 The determination of the amount of C-type lectin domain family 4 member K in a sample Annalisa Buniello true PMID:28240269 C-type lectin domain family 4 member K measurement efo:EFO_0020202 The determination of the amount of C-type lectin domain family 4 member M in a sample Annalisa Buniello true PMID:28240269 C-type lectin domain family 4 member M measurement efo:EFO_0020203 The determination of the amount of C-type lectin domain family 7 memberA in a sample Annalisa Buniello true PMID:28240269 C-type lectin domain family 7 memberAmeasurement efo:EFO_0020204 The determination of the amount of C-type mannose receptor 2 in a sample Annalisa Buniello true PMID:28240269 C-type mannose receptor 2 measurement efo:EFO_0020205 The determination of the amount of C-X-C motif chemokine 13 in a sample Annalisa Buniello true PMID:28240269 C-X-C motif chemokine 13 measurement efo:EFO_0020206 The determination of the amount of C3a anaphylatoxin des arginine in a sample Annalisa Buniello true PMID:28240269 C3a anaphylatoxin des arginine measurement efo:EFO_0020207 The determination of the amount of C3a anaphylatoxin in a sample Annalisa Buniello true PMID:28240269 C3a anaphylatoxin measurement efo:EFO_0020208 The determination of the amount of C5a anaphylatoxin in a sample Annalisa Buniello true PMID:28240269 C5a anaphylatoxin measurement efo:EFO_0020209 The determination of the amount of cadherin-1 in a sample Annalisa Buniello true PMID:28240269 cadherin-1 measurement efo:EFO_0020210 The determination of the amount of cadherin-12 in a sample Annalisa Buniello true PMID:28240269 cadherin-12 measurement efo:EFO_0020211 The determination of the amount of cadherin-15 in a sample Annalisa Buniello true PMID:28240269 cadherin-15 measurement efo:EFO_0020212 The determination of the amount of cadherin-2 in a sample Annalisa Buniello true PMID:28240269 cadherin-2 measurement efo:EFO_0020213 The determination of the amount of cadherin-3 in a sample Annalisa Buniello true PMID:28240269 cadherin-3 measurement efo:EFO_0020214 The determination of the amount of cadherin-6 in a sample Annalisa Buniello true PMID:28240269 cadherin-6 measurement efo:EFO_0020215 The determination of the amount of calcineurin subunit B type 1 in a sample Annalisa Buniello true PMID:28240269 calcineurin subunit B type 1 measurement efo:EFO_0020216 The determination of the amount of calcium-dependent phospholipase A2 in a sample Annalisa Buniello true PMID:28240269 calcium-dependent phospholipase A2 measurement efo:EFO_0020217 The determination of the amount of calcium/calmodulin-dependent protein kinase kinase 1 in a sample Annalisa Buniello true PMID:28240269 calcium/calmodulin-dependent protein kinase kinase 1 measurement efo:EFO_0020218 The determination of the amount of calcium/calmodulin-dependent protein kinase type II subunit alpha in a sample Annalisa Buniello true PMID:28240269 calcium/calmodulin-dependent protein kinase type II subunit alpha measurement efo:EFO_0020219 The determination of the amount of calcium/calmodulin-dependent protein kinase type II subunit beta in a sample Annalisa Buniello true PMID:28240269 calcium/calmodulin-dependent protein kinase type II subunit beta measurement efo:EFO_0020220 The determination of the amount of calcium/calmodulin-dependent protein kinase type II subunit delta in a sample Annalisa Buniello true PMID:28240269 calcium/calmodulin-dependent protein kinase type II subunit delta measurement efo:EFO_0020221 The determination of the amount of calreticulin in a sample Annalisa Buniello true PMID:28240269 calreticulin measurement efo:EFO_0020222 The determination of the amount of cAMP-dependent protein kinase catalytic subunit alpha in a sample Annalisa Buniello true PMID:28240269 cAMP-dependent protein kinase catalytic subunit alpha measurement efo:EFO_0020223 The determination of the amount of cAMP-regulated phosphoprotein 19 in a sample Annalisa Buniello true PMID:28240269 cAMP-regulated phosphoprotein 19 measurement efo:EFO_0020224 The determination of the amount of cAMP-specific 3',5'-cyclic phosphodiesterase 4D in a sample Annalisa Buniello true PMID:28240269 cAMP-specific 3',5'-cyclic phosphodiesterase 4D measurement efo:EFO_0020225 The determination of the amount of carbohydrate sulfotransferase 2 in a sample Annalisa Buniello true PMID:28240269 carbohydrate sulfotransferase 2 measurement efo:EFO_0020226 The determination of the amount of carbohydrate sulfotransferase 6 in a sample Annalisa Buniello true PMID:28240269 carbohydrate sulfotransferase 6 measurement efo:EFO_0020227 The determination of the amount of carbonic anhydrase 1 in a sample Annalisa Buniello true PMID:28240269 carbonic anhydrase 1 measurement efo:EFO_0020228 The determination of the amount of carbonic anhydrase 2 in a sample Annalisa Buniello true PMID:28240269 carbonic anhydrase 2 measurement efo:EFO_0020229 The determination of the amount of carbonic anhydrase 3 in a sample Annalisa Buniello true PMID:28240269 carbonic anhydrase 3 measurement efo:EFO_0020230 The determination of the amount of carbonic anhydrase 4 in a sample Annalisa Buniello true PMID:28240269 carbonic anhydrase 4 measurement efo:EFO_0020231 The determination of the amount of carbonic anhydrase 7 in a sample Annalisa Buniello true PMID:28240269 carbonic anhydrase 7 measurement efo:EFO_0020232 The determination of the amount of carbonic anhydrase 9 in a sample Annalisa Buniello true PMID:28240269 carbonic anhydrase 9 measurement efo:EFO_0020233 The determination of the amount of carbonic anhydrase-related protein 10 in a sample Annalisa Buniello true PMID:28240269 carbonic anhydrase-related protein 10 measurement efo:EFO_0020234 The determination of the amount of carboxypeptidase e in a sample Annalisa Buniello true PMID:28240269 carboxypeptidase e measurement efo:EFO_0020235 The determination of the amount of cardiotrophin-1 in a sample Annalisa Buniello true PMID:28240269 cardiotrophin-1 measurement efo:EFO_0020236 The determination of the amount of casein kinase II 2-alpha:2-beta heterotetramer in a sample Annalisa Buniello true PMID:28240269 casein kinase II 2-alpha:2-beta heterotetramer measurement efo:EFO_0020237 The determination of the amount of casein kinase II 2-alpha':2-beta heterotetramer in a sample Annalisa Buniello true PMID:28240269 casein kinase II 2-alpha':2-beta heterotetramer measurement efo:EFO_0020238 The determination of the amount of casein kinase II subunit alpha in a sample Annalisa Buniello true PMID:28240269 casein kinase II subunit alpha measurement efo:EFO_0020239 The determination of the amount of caspase-10 in a sample Annalisa Buniello true PMID:28240269 caspase-10 measurement efo:EFO_0020240 The determination of the amount of caspase-2 in a sample Annalisa Buniello true PMID:28240269 caspase-2 measurement efo:EFO_0020241 The determination of the amount of cathepsin E in a sample Annalisa Buniello true PMID:28240269 cathepsin E measurement efo:EFO_0020242 The determination of the amount of cathepsin G in a sample Annalisa Buniello true PMID:28240269 cathepsin G measurement efo:EFO_0020243 The determination of the amount of cathepsin H in a sample Annalisa Buniello true PMID:28240269 cathepsin H measurement efo:EFO_0020244 The determination of the amount of cathepsin L2 in a sample Annalisa Buniello true PMID:28240269 cathepsin L2 measurement efo:EFO_0020245 The determination of the amount of CD166 antigen in a sample Annalisa Buniello true PMID:28240269 CD166 antigen measurement efo:EFO_0020246 The determination of the amount of CD226 antigen in a sample Annalisa Buniello true PMID:28240269 CD226 antigen measurement efo:EFO_0020247 The determination of the amount of CD48 antigen in a sample Annalisa Buniello true PMID:28240269 CD48 antigen measurement efo:EFO_0020248 The determination of the amount of CD5 antigen-like in a sample Annalisa Buniello true PMID:28240269 CD5 antigen-like measurement efo:EFO_0020249 The determination of the amount of CD70 antigen in a sample Annalisa Buniello true PMID:28240269 CD70 antigen measurement efo:EFO_0020250 The determination of the amount of CD97 antigen in a sample Annalisa Buniello true PMID:28240269 CD97 antigen measurement efo:EFO_0020251 The determination of the amount of cell adhesion molecule 1 in a sample Annalisa Buniello true PMID:28240269 cell adhesion molecule 1 measurement efo:EFO_0020252 The determination of the amount of cell adhesion molecule 3 in a sample Annalisa Buniello true PMID:28240269 cell adhesion molecule 3 measurement efo:EFO_0020253 The determination of the amount of cell surface glycoprotein CD200 receptor 1 in a sample Annalisa Buniello true PMID:28240269 cell surface glycoprotein CD200 receptor 1 measurement efo:EFO_0020254 The determination of the amount of cerebral dopamine neurotrophic factor in a sample Annalisa Buniello true PMID:28240269 cerebral dopamine neurotrophic factor measurement efo:EFO_0020255 The determination of the amount of cGMP-inhibited 3',5'-cyclic phosphodiesterase A in a sample Annalisa Buniello true PMID:28240269 cGMP-inhibited 3',5'-cyclic phosphodiesterase A measurement efo:EFO_0020256 The determination of the amount of chloride intracellular channel protein 1 in a sample Annalisa Buniello true PMID:28240269 chloride intracellular channel protein 1 measurement efo:EFO_0020257 The determination of the amount of chordin-like protein 1 in a sample Annalisa Buniello true PMID:28240269 chordin-like protein 1 measurement efo:EFO_0020258 The determination of the amount of chromobox protein homolog 5 in a sample Annalisa Buniello true PMID:28240269 chromobox protein homolog 5 measurement efo:EFO_0020259 The determination of the amount of chymase in a sample Annalisa Buniello true PMID:28240269 chymase measurement efo:EFO_0020260 The determination of the amount of ciliary neurotrophic factor in a sample Annalisa Buniello true PMID:28240269 ciliary neurotrophic factor measurement efo:EFO_0020261 The determination of the amount of ciliary neurotrophic factor receptor subunit alpha in a sample Annalisa Buniello true PMID:28240269 ciliary neurotrophic factor receptor subunit alpha measurement efo:EFO_0020262 The determination of the amount of coactosin-like protein in a sample Annalisa Buniello true PMID:28240269 coactosin-like protein measurement efo:EFO_0020263 The determination of the amount of coagulation factor IX in a sample Annalisa Buniello true PMID:28240269 coagulation factor IX measurement efo:EFO_0020264 The determination of the amount of coagulation factor IXAB in a sample Annalisa Buniello true PMID:28240269 coagulation factor IXAB measurement efo:EFO_0020265 The determination of the amount of coagulation factor X in a sample Annalisa Buniello true PMID:28240269 coagulation factor X measurement efo:EFO_0020266 The determination of the amount of coagulation factor XA in a sample Annalisa Buniello true PMID:28240269 coagulation factor XA measurement efo:EFO_0020267 The determination of the amount of cofilin-1 in a sample Annalisa Buniello true PMID:28240269 cofilin-1 measurement efo:EFO_0020268 The determination of the amount of coiled-coil domain-containing protein 80 in a sample Annalisa Buniello true PMID:28240269 coiled-coil domain-containing protein 80 measurement efo:EFO_0020269 The determination of the amount of collagen alpha-1(VIII) chain in a sample Annalisa Buniello true PMID:28240269 collagen alpha-1(VIII) chain measurement efo:EFO_0020270 The determination of the amount of collagen alpha-1(XXIII) chain in a sample Annalisa Buniello true PMID:28240269 collagen alpha-1(XXIII) chain measurement efo:EFO_0020271 The determination of the amount of collagenase 3 in a sample Annalisa Buniello true PMID:28240269 collagenase 3 measurement efo:EFO_0020272 The determination of the amount of collectin-12 in a sample Annalisa Buniello true PMID:28240269 collectin-12 measurement efo:EFO_0020273 The determination of the amount of COMM domain-containing protein 7 in a sample Annalisa Buniello true PMID:28240269 COMM domain-containing protein 7 measurement efo:EFO_0020274 The determination of the amount of complement C2 in a sample Annalisa Buniello true PMID:28240269 complement C2 measurement efo:EFO_0020275 The determination of the amount of complement C3B in a sample Annalisa Buniello true PMID:28240269 complement C3B measurement efo:EFO_0020276 The determination of the amount of complement C3B, inactivated in a sample Annalisa Buniello true PMID:28240269 complement C3B, inactivated measurement efo:EFO_0020277 The determination of the amount of complement C3D fragment in a sample Annalisa Buniello true PMID:28240269 complement C3D fragment measurement efo:EFO_0020278 The determination of the amount of complement C5 in a sample Annalisa Buniello true PMID:28240269 complement C5 measurement efo:EFO_0020279 The determination of the amount of complement C5B-C6 complex in a sample Annalisa Buniello true PMID:28240269 complement C5B-C6 complex measurement efo:EFO_0020280 The determination of the amount of complement component 1 q subcomponent-binding protein, mitochondrial in a sample Annalisa Buniello true PMID:28240269 complement component 1 q subcomponent-binding protein, mitochondrial measurement efo:EFO_0020281 The determination of the amount of complement component C6 in a sample Annalisa Buniello true PMID:28240269 complement component C6 measurement efo:EFO_0020282 The determination of the amount of complement component C9 in a sample Annalisa Buniello true PMID:28240269 complement component C9 measurement efo:EFO_0020283 The determination of the amount of complement factor D in a sample Annalisa Buniello true PMID:28240269 complement factor D measurement efo:EFO_0020284 The determination of the amount of connective tissue growth factor in a sample Annalisa Buniello true PMID:28240269 connective tissue growth factor measurement efo:EFO_0020285 The determination of the amount of connective tissue-activating peptide III in a sample Annalisa Buniello true PMID:28240269 connective tissue-activating peptide III measurement efo:EFO_0020286 The determination of the amount of contactin-1 in a sample Annalisa Buniello true PMID:28240269 contactin-1 measurement efo:EFO_0020287 The determination of the amount of contactin-4 in a sample Annalisa Buniello true PMID:28240269 contactin-4 measurement efo:EFO_0020288 The determination of the amount of corticosteroid-binding globulin in a sample Annalisa Buniello true PMID:28240269 corticosteroid-binding globulin measurement efo:EFO_0020289 The determination of the amount of corticotropin in a sample Annalisa Buniello true PMID:28240269 corticotropin measurement efo:EFO_0020290 The determination of the amount of creatine kinase b-type in a sample Annalisa Buniello true PMID:28240269 creatine kinase b-type measurement efo:EFO_0020291 The determination of the amount of creatine kinase m-type in a sample Annalisa Buniello true PMID:28240269 creatine kinase m-type measurement efo:EFO_0020292 The determination of the amount of creatine kinase m-type:creatine kinase b-type heterodimer in a sample Annalisa Buniello true PMID:28240269 creatine kinase m-type:creatine kinase b-type heterodimer measurement efo:EFO_0020293 The determination of the amount of cryptic protein in a sample Annalisa Buniello true PMID:28240269 cryptic protein measurement efo:EFO_0020294 The determination of the amount of cyclin-dependent kinase 1:g2/mitotic-specific cyclin-B1 complex in a sample Annalisa Buniello true PMID:28240269 cyclin-dependent kinase 1:g2/mitotic-specific cyclin-B1 complex measurement efo:EFO_0020295 The determination of the amount of cyclin-dependent kinase 2:cyclin-A2 complex in a sample Annalisa Buniello true PMID:28240269 cyclin-dependent kinase 2:cyclin-A2 complex measurement efo:EFO_0020296 The determination of the amount of cyclin-dependent kinase 5:cyclin-dependent kinase 5 activator 1 complex in a sample Annalisa Buniello true PMID:28240269 cyclin-dependent kinase 5:cyclin-dependent kinase 5 activator 1 complex measurement efo:EFO_0020297 The determination of the amount of cyclin-dependent kinase 8:cyclin-c complex in a sample Annalisa Buniello true PMID:28240269 cyclin-dependent kinase 8:cyclin-c complex measurement efo:EFO_0020298 The determination of the amount of cyclin-dependent kinase inhibitor 1b in a sample Annalisa Buniello true PMID:28240269 cyclin-dependent kinase inhibitor 1b measurement efo:EFO_0020299 The determination of the amount of cystatin-M in a sample Annalisa Buniello true PMID:28240269 cystatin-M measurement efo:EFO_0020300 The determination of the amount of cystatin-S in a sample Annalisa Buniello true PMID:28240269 cystatin-S measurement efo:EFO_0020301 The determination of the amount of cysteine-rich secretory protein 3 in a sample Annalisa Buniello true PMID:28240269 cysteine-rich secretory protein 3 measurement efo:EFO_0020302 The determination of the amount of cytochrome C in a sample Annalisa Buniello true PMID:28240269 cytochrome C measurement efo:EFO_0020303 The determination of the amount of cytochrome p450 3a4 in a sample Annalisa Buniello true PMID:28240269 cytochrome p450 3a4 measurement efo:EFO_0020304 The determination of the amount of cytokine receptor common subunit gamma in a sample Annalisa Buniello true PMID:28240269 cytokine receptor common subunit gamma measurement efo:EFO_0020305 The determination of the amount of cytokine receptor-like factor 1:cardiotrophin-like cytokine factor 1 complex in a sample Annalisa Buniello true PMID:28240269 cytokine receptor-like factor 1:cardiotrophin-like cytokine factor 1 complex measurement efo:EFO_0020306 The determination of the amount of cytokine receptor-like factor 2 in a sample Annalisa Buniello true PMID:28240269 cytokine receptor-like factor 2 measurement efo:EFO_0020307 The determination of the amount of cytoplasmic protein NCK1 in a sample Annalisa Buniello true PMID:28240269 cytoplasmic protein NCK1 measurement efo:EFO_0020308 The determination of the amount of cytoplasmic tyrosine-protein kinase BMX in a sample Annalisa Buniello true PMID:28240269 cytoplasmic tyrosine-protein kinase BMX measurement efo:EFO_0020309 The determination of the amount of cytoskeleton-associated protein 2 in a sample Annalisa Buniello true PMID:28240269 cytoskeleton-associated protein 2 measurement efo:EFO_0020310 The determination of the amount of cytosolic non-specific dipeptidase in a sample Annalisa Buniello true PMID:28240269 cytosolic non-specific dipeptidase measurement efo:EFO_0020311 The determination of the amount of cytotoxic and regulatory t-cell molecule in a sample Annalisa Buniello true PMID:28240269 cytotoxic and regulatory t-cell molecule measurement efo:EFO_0020312 The determination of the amount of cytotoxic t-lymphocyte protein 4 in a sample Annalisa Buniello true PMID:28240269 cytotoxic t-lymphocyte protein 4 measurement efo:EFO_0020313 The determination of the amount of d-dimer in a sample Annalisa Buniello true PMID:28240269 d-dimer measurement efo:EFO_0020314 The determination of the amount of DCTP pyrophosphatase 1 in a sample Annalisa Buniello true PMID:28240269 DCTP pyrophosphatase 1 measurement efo:EFO_0020315 The determination of the amount of decorin in a sample Annalisa Buniello true PMID:28240269 decorin measurement efo:EFO_0020316 The determination of the amount of delta-like protein 1 in a sample Annalisa Buniello true PMID:28240269 delta-like protein 1 measurement efo:EFO_0020317 The determination of the amount of delta-like protein 4 in a sample Annalisa Buniello true PMID:28240269 delta-like protein 4 measurement efo:EFO_0020318 The determination of the amount of dentin matrix acidic phosphoprotein 1 in a sample Annalisa Buniello true PMID:28240269 dentin matrix acidic phosphoprotein 1 measurement efo:EFO_0020319 The determination of the amount of desert hedgehog protein n-product in a sample Annalisa Buniello true PMID:28240269 desert hedgehog protein n-product measurement efo:EFO_0020320 The determination of the amount of desmocollin-3 in a sample Annalisa Buniello true PMID:28240269 desmocollin-3 measurement efo:EFO_0020321 The determination of the amount of desmoglein-1 in a sample Annalisa Buniello true PMID:28240269 desmoglein-1 measurement efo:EFO_0020322 The determination of the amount of desmoglein-2 in a sample Annalisa Buniello true PMID:28240269 desmoglein-2 measurement efo:EFO_0020323 The determination of the amount of diablo homolog, mitochondrial in a sample Annalisa Buniello true PMID:28240269 diablo homolog, mitochondrial measurement efo:EFO_0020324 The determination of the amount of dickkopf-like protein 1 in a sample Annalisa Buniello true PMID:28240269 dickkopf-like protein 1 measurement efo:EFO_0020325 The determination of the amount of dipeptidyl peptidase 1 in a sample Annalisa Buniello true PMID:28240269 dipeptidyl peptidase 1 measurement efo:EFO_0020326 The determination of the amount of dipeptidyl peptidase 2 in a sample Annalisa Buniello true PMID:28240269 dipeptidyl peptidase 2 measurement efo:EFO_0020327 The determination of the amount of discoidin domain-containing receptor 2 in a sample Annalisa Buniello true PMID:28240269 discoidin domain-containing receptor 2 measurement efo:EFO_0020328 The determination of the amount of disintegrin and metalloproteinase domain-containing protein 12 in a sample Annalisa Buniello true PMID:28240269 disintegrin and metalloproteinase domain-containing protein 12 measurement efo:EFO_0020329 The determination of the amount of disintegrin and metalloproteinase domain-containing protein 9 in a sample Annalisa Buniello true PMID:28240269 disintegrin and metalloproteinase domain-containing protein 9 measurement efo:EFO_0020330 The determination of the amount of DNA repair protein rad51 homolog 1 in a sample Annalisa Buniello true PMID:28240269 DNA repair protein rad51 homolog 1 measurement efo:EFO_0020331 The determination of the amount of DNA topoisomerase 1 in a sample Annalisa Buniello true PMID:28240269 DNA topoisomerase 1 measurement efo:EFO_0020332 The determination of the amount of DNAj homolog subfamily b member 1 in a sample Annalisa Buniello true PMID:28240269 DNAj homolog subfamily b member 1 measurement efo:EFO_0020333 The determination of the amount of drebrin-like protein in a sample Annalisa Buniello true PMID:28240269 drebrin-like protein measurement efo:EFO_0020334 The determination of the amount of dual 3',5'-cyclic-amp and -gmp phosphodiesterase 11a in a sample Annalisa Buniello true PMID:28240269 dual 3',5'-cyclic-amp and -gmp phosphodiesterase 11a measurement efo:EFO_0020335 The determination of the amount of dual specificity mitogen-activated protein kinase kinase 1 in a sample Annalisa Buniello true PMID:28240269 dual specificity mitogen-activated protein kinase kinase 1 measurement efo:EFO_0020336 The determination of the amount of dual specificity protein phosphatase 3 in a sample Annalisa Buniello true PMID:28240269 dual specificity protein phosphatase 3 measurement efo:EFO_0020337 The determination of the amount of dual specificity tyrosine-phosphorylation-regulated kinase 3 in a sample Annalisa Buniello true PMID:28240269 dual specificity tyrosine-phosphorylation-regulated kinase 3 measurement efo:EFO_0020338 The determination of the amount of dynactin subunit 2 in a sample Annalisa Buniello true PMID:28240269 dynactin subunit 2 measurement efo:EFO_0020339 The determination of the amount of dynein light chain 1, cytoplasmic in a sample Annalisa Buniello true PMID:28240269 dynein light chain 1, cytoplasmic measurement efo:EFO_0020340 The determination of the amount of e3 ubiquitin-protein ligase mdm2 in a sample Annalisa Buniello true PMID:28240269 e3 ubiquitin-protein ligase mdm2 measurement efo:EFO_0020341 The determination of the amount of ectodysplasin-a, secreted form in a sample Annalisa Buniello true PMID:28240269 ectodysplasin-a, secreted form measurement efo:EFO_0020342 The determination of the amount of ectonucleoside triphosphate diphosphohydrolase 1 in a sample Annalisa Buniello true PMID:28240269 ectonucleoside triphosphate diphosphohydrolase 1 measurement efo:EFO_0020343 The determination of the amount of ectonucleoside triphosphate diphosphohydrolase 3 in a sample Annalisa Buniello true PMID:28240269 ectonucleoside triphosphate diphosphohydrolase 3 measurement efo:EFO_0020344 The determination of the amount of ectonucleotide pyrophosphatase/phosphodiesterase family member 7 in a sample Annalisa Buniello true PMID:28240269 ectonucleotide pyrophosphatase/phosphodiesterase family member 7 measurement efo:EFO_0020345 The determination of the amount of elongation factor 1-beta in a sample Annalisa Buniello true PMID:28240269 elongation factor 1-beta measurement efo:EFO_0020346 The determination of the amount of endoplasmic reticulum resident protein 29 in a sample Annalisa Buniello true PMID:28240269 endoplasmic reticulum resident protein 29 measurement efo:EFO_0020347 The determination of the amount of endostatin in a sample Annalisa Buniello true PMID:28240269 endostatin measurement efo:EFO_0020348 The determination of the amount of endothelial monocyte-activating polypeptide 2 in a sample Annalisa Buniello true PMID:28240269 endothelial monocyte-activating polypeptide 2 measurement efo:EFO_0020349 The determination of the amount of enteropeptidase in a sample Annalisa Buniello true PMID:28240269 enteropeptidase measurement efo:EFO_0020350 The determination of the amount of ephrin type-a receptor 10 in a sample Annalisa Buniello true PMID:28240269 ephrin type-a receptor 10 measurement efo:EFO_0020351 The determination of the amount of ephrin type-a receptor 2 in a sample Annalisa Buniello true PMID:28240269 ephrin type-a receptor 2 measurement efo:EFO_0020352 The determination of the amount of ephrin type-a receptor 3 in a sample Annalisa Buniello true PMID:28240269 ephrin type-a receptor 3 measurement efo:EFO_0020353 The determination of the amount of ephrin type-a receptor 5 in a sample Annalisa Buniello true PMID:28240269 ephrin type-a receptor 5 measurement efo:EFO_0020354 The determination of the amount of ephrin type-b receptor 4 in a sample Annalisa Buniello true PMID:28240269 ephrin type-b receptor 4 measurement efo:EFO_0020355 The determination of the amount of ephrin type-b receptor 6 in a sample Annalisa Buniello true PMID:28240269 ephrin type-b receptor 6 measurement efo:EFO_0020356 The determination of the amount of ephrin-A4 in a sample Annalisa Buniello true PMID:28240269 ephrin-A4 measurement efo:EFO_0020357 The determination of the amount of ephrin-A5 in a sample Annalisa Buniello true PMID:28240269 ephrin-A5 measurement efo:EFO_0020358 The determination of the amount of ephrin-B3 in a sample Annalisa Buniello true PMID:28240269 ephrin-B3 measurement efo:EFO_0020359 The determination of the amount of epidermal growth factor receptor in a sample Annalisa Buniello true PMID:28240269 epidermal growth factor receptor measurement efo:EFO_0020360 The determination of the amount of epidermal growth factor receptor substrate 15-like 1 in a sample Annalisa Buniello true PMID:28240269 epidermal growth factor receptor substrate 15-like 1 measurement efo:EFO_0020361 The determination of the amount of epiregulin in a sample Annalisa Buniello true PMID:28240269 epiregulin measurement efo:EFO_0020362 The determination of the amount of epithelial discoidin domain-containing receptor 1 in a sample Annalisa Buniello true PMID:28240269 epithelial discoidin domain-containing receptor 1 measurement efo:EFO_0020363 The determination of the amount of erythropoietin in a sample Annalisa Buniello true PMID:28240269 erythropoietin measurement efo:EFO_0020364 The determination of the amount of erythropoietin receptor in a sample Annalisa Buniello true PMID:28240269 erythropoietin receptor measurement efo:EFO_0020365 The determination of the amount of estradiol 17-beta-dehydrogenase 1 in a sample Annalisa Buniello true PMID:28240269 estradiol 17-beta-dehydrogenase 1 measurement efo:EFO_0020366 The determination of the amount of eukaryotic initiation factor 4a-III in a sample Annalisa Buniello true PMID:28240269 eukaryotic initiation factor 4a-III measurement efo:EFO_0020367 The determination of the amount of eukaryotic translation initiation factor 4 gamma 2 in a sample Annalisa Buniello true PMID:28240269 eukaryotic translation initiation factor 4 gamma 2 measurement efo:EFO_0020368 The determination of the amount of eukaryotic translation initiation factor 4E-binding protein 2 in a sample Annalisa Buniello true PMID:28240269 eukaryotic translation initiation factor 4E-binding protein 2 measurement efo:EFO_0020369 The determination of the amount of eukaryotic translation initiation factor 5 in a sample Annalisa Buniello true PMID:28240269 eukaryotic translation initiation factor 5 measurement efo:EFO_0020370 The determination of the amount of eukaryotic translation initiation factor 5A-1 in a sample Annalisa Buniello true PMID:28240269 eukaryotic translation initiation factor 5A-1 measurement efo:EFO_0020371 The determination of the amount of fact complex subunit ssrp1 in a sample Annalisa Buniello true PMID:28240269 fact complex subunit ssrp1 measurement efo:EFO_0020372 The determination of the amount of fatty acid-binding protein, epidermal in a sample Annalisa Buniello true PMID:28240269 fatty acid-binding protein, epidermal measurement efo:EFO_0020373 The determination of the amount of fatty acid-binding protein, heart in a sample Annalisa Buniello true PMID:28240269 fatty acid-binding protein, heart measurement efo:EFO_0020374 The determination of the amount of fibrinogen gamma chain in a sample Annalisa Buniello true PMID:28240269 fibrinogen gamma chain measurement efo:EFO_0020375 The determination of the amount of fibroblast growth factor 1 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 1 measurement efo:EFO_0020376 The determination of the amount of fibroblast growth factor 10 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 10 measurement efo:EFO_0020377 The determination of the amount of fibroblast growth factor 12 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 12 measurement efo:EFO_0020378 The determination of the amount of fibroblast growth factor 16 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 16 measurement efo:EFO_0020379 The determination of the amount of fibroblast growth factor 17 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 17 measurement efo:EFO_0020380 The determination of the amount of fibroblast growth factor 18 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 18 measurement efo:EFO_0020381 The determination of the amount of fibroblast growth factor 20 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 20 measurement efo:EFO_0020382 The determination of the amount of fibroblast growth factor 4 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 4 measurement efo:EFO_0020383 The determination of the amount of fibroblast growth factor 6 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 6 measurement efo:EFO_0020384 The determination of the amount of fibroblast growth factor 7 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 7 measurement efo:EFO_0020385 The determination of the amount of fibroblast growth factor 8 isoformA in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 8 isoform A measurement efo:EFO_0020386 The determination of the amount of fibroblast growth factor 8 isoform b in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 8 isoform b measurement efo:EFO_0020387 The determination of the amount of fibroblast growth factor 9 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor 9 measurement efo:EFO_0020388 The determination of the amount of fibroblast growth factor receptor 1 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor receptor 1 measurement efo:EFO_0020389 The determination of the amount of fibroblast growth factor receptor 2 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor receptor 2 measurement efo:EFO_0020390 The determination of the amount of fibroblast growth factor receptor 3 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor receptor 3 measurement efo:EFO_0020391 The determination of the amount of fibroblast growth factor receptor 4 in a sample Annalisa Buniello true PMID:28240269 fibroblast growth factor receptor 4 measurement efo:EFO_0020392 The determination of the amount of ficolin-3 in a sample Annalisa Buniello true PMID:28240269 ficolin-3 measurement efo:EFO_0020393 The determination of the amount of focal adhesion kinase 1 in a sample Annalisa Buniello true PMID:28240269 focal adhesion kinase 1 measurement efo:EFO_0020394 The determination of the amount of follistatin-related protein 3 in a sample Annalisa Buniello true PMID:28240269 follistatin-related protein 3 measurement efo:EFO_0020395 The determination of the amount of fractalkine in a sample Annalisa Buniello true PMID:28240269 fractalkine measurement efo:EFO_0020396 The determination of the amount of g2/mitotic-specific cyclin-B1 in a sample Annalisa Buniello true PMID:28240269 g2/mitotic-specific cyclin-B1 measurement efo:EFO_0020397 The determination of the amount of galectin-2 in a sample Annalisa Buniello true PMID:28240269 galectin-2 measurement efo:EFO_0020398 The determination of the amount of galectin-4 in a sample Annalisa Buniello true PMID:28240269 galectin-4 measurement efo:EFO_0020399 The determination of the amount of galectin-8 in a sample Annalisa Buniello true PMID:28240269 galectin-8 measurement efo:EFO_0020400 The determination of the amount of gdnf family receptor alpha-1 in a sample Annalisa Buniello true PMID:28240269 gdnf family receptor alpha-1 measurement efo:EFO_0020401 The determination of the amount of gdnf family receptor alpha-3 in a sample Annalisa Buniello true PMID:28240269 gdnf family receptor alpha-3 measurement efo:EFO_0020402 The determination of the amount of gelsolin in a sample Annalisa Buniello true PMID:28240269 gelsolin measurement efo:EFO_0020403 The determination of the amount of glia-derived nexin in a sample Annalisa Buniello true PMID:28240269 glia-derived nexin measurement efo:EFO_0020404 The determination of the amount of glial fibrillary acidic protein in a sample Annalisa Buniello true PMID:28240269 glial fibrillary acidic protein measurement efo:EFO_0020405 The determination of the amount of glucocorticoid receptor in a sample Annalisa Buniello true PMID:28240269 glucocorticoid receptor measurement efo:EFO_0020406 The determination of the amount of glucokinase regulatory protein in a sample Annalisa Buniello true PMID:28240269 glucokinase regulatory protein measurement efo:EFO_0020407 The determination of the amount of glucose-6-phosphate isomerase in a sample Annalisa Buniello true PMID:28240269 glucose-6-phosphate isomerase measurement efo:EFO_0020408 The determination of the amount of glutamate carboxypeptidase 2 in a sample Annalisa Buniello true PMID:28240269 glutamate carboxypeptidase 2 measurement efo:EFO_0020409 The determination of the amount of glutathione s-transferase a3 in a sample Annalisa Buniello true PMID:28240269 glutathione s-transferase a3 measurement efo:EFO_0020410 The determination of the amount of glutathione s-transferase p in a sample Annalisa Buniello true PMID:28240269 glutathione s-transferase p measurement efo:EFO_0020411 The determination of the amount of glyceraldehyde-3-phosphate dehydrogenase in a sample Annalisa Buniello true PMID:28240269 glyceraldehyde-3-phosphate dehydrogenase measurement efo:EFO_0020412 The determination of the amount of glycogen synthase kinase-3 alpha/beta in a sample Annalisa Buniello true PMID:28240269 glycogen synthase kinase-3 alpha/beta measurement efo:EFO_0020413 The determination of the amount of glycylpeptide n-tetradecanoyltransferase 1 in a sample Annalisa Buniello true PMID:28240269 glycylpeptide n-tetradecanoyltransferase 1 measurement efo:EFO_0020414 The determination of the amount of glypican-2 in a sample Annalisa Buniello true PMID:28240269 glypican-2 measurement efo:EFO_0020415 The determination of the amount of glypican-3 in a sample Annalisa Buniello true PMID:28240269 glypican-3 measurement efo:EFO_0020416 The determination of the amount of granulocyte colony-stimulating factor receptor in a sample Annalisa Buniello true PMID:28240269 granulocyte colony-stimulating factor receptor measurement efo:EFO_0020417 The determination of the amount of granulocyte-macrophage colony-stimulating factor in a sample Annalisa Buniello true PMID:28240269 granulocyte-macrophage colony-stimulating factor measurement efo:EFO_0020418 The determination of the amount of granzyme b in a sample Annalisa Buniello true PMID:28240269 granzyme b measurement efo:EFO_0020419 The determination of the amount of granzyme h in a sample Annalisa Buniello true PMID:28240269 granzyme h measurement efo:EFO_0020420 The determination of the amount of grb2-related adapter protein 2 in a sample Annalisa Buniello true PMID:28240269 grb2-related adapter protein 2 measurement efo:EFO_0020421 The determination of the amount of gremlin-1 in a sample Annalisa Buniello true PMID:28240269 gremlin-1 measurement efo:EFO_0020422 The determination of the amount of gro-beta/gamma in a sample Annalisa Buniello true PMID:28240269 gro-beta/gamma measurement efo:EFO_0020423 The determination of the amount of group 10 secretory phospholipase A2 in a sample Annalisa Buniello true PMID:28240269 group 10 secretory phospholipase A2 measurement efo:EFO_0020424 The determination of the amount of group IIe secretory phospholipase A2 in a sample Annalisa Buniello true PMID:28240269 group IIe secretory phospholipase A2 measurement efo:EFO_0020425 The determination of the amount of growth arrest-specific protein 1 in a sample Annalisa Buniello true PMID:28240269 growth arrest-specific protein 1 measurement efo:EFO_0020426 The determination of the amount of growth hormone receptor in a sample Annalisa Buniello true PMID:28240269 growth hormone receptor measurement efo:EFO_0020427 The determination of the amount of growth/differentiation factor 11 in a sample Annalisa Buniello true PMID:28240269 growth/differentiation factor 11 measurement efo:EFO_0020428 The determination of the amount of growth/differentiation factor 2 in a sample Annalisa Buniello true PMID:28240269 growth/differentiation factor 2 measurement efo:EFO_0020429 The determination of the amount of growth/differentiation factor 5 in a sample Annalisa Buniello true PMID:28240269 growth/differentiation factor 5 measurement efo:EFO_0020430 The determination of the amount of growth/differentiation factor 9 in a sample Annalisa Buniello true PMID:28240269 growth/differentiation factor 9 measurement efo:EFO_0020431 The determination of the amount of GTP-binding nuclear protein ran in a sample Annalisa Buniello true PMID:28240269 GTP-binding nuclear protein ran measurement efo:EFO_0020432 The determination of the amount of GTPase kras in a sample Annalisa Buniello true PMID:28240269 GTPase kras measurement efo:EFO_0020433 The determination of the amount of heat shock 70 kda protein 1a/1b in a sample Annalisa Buniello true PMID:28240269 heat shock 70 kda protein 1a/1b measurement efo:EFO_0020434 The determination of the amount of heat shock cognate 71 kda protein in a sample Annalisa Buniello true PMID:28240269 heat shock cognate 71 kda protein measurement efo:EFO_0020435 The determination of the amount of heat shock protein hsp 90-alpha/beta in a sample Annalisa Buniello true PMID:28240269 heat shock protein hsp 90-alpha/beta measurement efo:EFO_0020436 The determination of the amount of heme oxygenase 2 in a sample Annalisa Buniello true PMID:28240269 heme oxygenase 2 measurement efo:EFO_0020437 The determination of the amount of heparan-sulfate 6-o-sulfotransferase 1 in a sample Annalisa Buniello true PMID:28240269 heparan-sulfate 6-o-sulfotransferase 1 measurement efo:EFO_0020438 The determination of the amount of heparin-binding egf-like growth factor in a sample Annalisa Buniello true PMID:28240269 heparin-binding egf-like growth factor measurement efo:EFO_0020439 The determination of the amount of hepatoma-derived growth factor-related protein 2 in a sample Annalisa Buniello true PMID:28240269 hepatoma-derived growth factor-related protein 2 measurement efo:EFO_0020440 The determination of the amount of hepcidin in a sample Annalisa Buniello true PMID:28240269 hepcidin measurement efo:EFO_0020441 The determination of the amount of heterogeneous nuclear ribonucleoprotein a/b in a sample Annalisa Buniello true PMID:28240269 heterogeneous nuclear ribonucleoprotein a/b measurement efo:EFO_0020442 The determination of the amount of heterogeneous nuclear ribonucleoprotein k in a sample Annalisa Buniello true PMID:28240269 heterogeneous nuclear ribonucleoprotein k measurement efo:EFO_0020443 The determination of the amount of heterogeneous nuclear ribonucleoprotein q in a sample Annalisa Buniello true PMID:28240269 heterogeneous nuclear ribonucleoprotein q measurement efo:EFO_0020444 The determination of the amount of heterogeneous nuclear ribonucleoproteins A2/B1 in a sample Annalisa Buniello true PMID:28240269 heterogeneous nuclear ribonucleoproteins A2/B1 measurement efo:EFO_0020445 The determination of the amount of high affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7a in a sample Annalisa Buniello true PMID:28240269 high affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7a measurement efo:EFO_0020446 The determination of the amount of high affinity cgmp-specific 3',5'-cyclic phosphodiesterase 9a in a sample Annalisa Buniello true PMID:28240269 high affinity cgmp-specific 3',5'-cyclic phosphodiesterase 9a measurement efo:EFO_0020447 The determination of the amount of high affinity immunoglobulin gamma fc receptor i in a sample Annalisa Buniello true PMID:28240269 high affinity immunoglobulin gamma fc receptor i measurement efo:EFO_0020448 The determination of the amount of high affinity nerve growth factor receptor in a sample Annalisa Buniello true PMID:28240269 high affinity nerve growth factor receptor measurement efo:EFO_0020449 The determination of the amount of high mobility group protein B1 in a sample Annalisa Buniello true PMID:28240269 high mobility group protein B1 measurement efo:EFO_0020450 The determination of the amount of histidine triad nucleotide-binding protein 1 in a sample Annalisa Buniello true PMID:28240269 histidine triad nucleotide-binding protein 1 measurement efo:EFO_0020451 The determination of the amount of histone acetyltransferase kat6a in a sample Annalisa Buniello true PMID:28240269 histone acetyltransferase kat6a measurement efo:EFO_0020452 The determination of the amount of histone acetyltransferase type b catalytic subunit in a sample Annalisa Buniello true PMID:28240269 histone acetyltransferase type b catalytic subunit measurement efo:EFO_0020453 The determination of the amount of histone deacetylase 8 in a sample Annalisa Buniello true PMID:28240269 histone deacetylase 8 measurement efo:EFO_0020454 The determination of the amount of histone H2A.Z in a sample Annalisa Buniello true PMID:28240269 histone H2A.Z measurement efo:EFO_0020455 The determination of the amount of histone-lysine n-methyltransferase EHMT2 in a sample Annalisa Buniello true PMID:28240269 histone-lysine n-methyltransferase EHMT2 measurement efo:EFO_0020456 The determination of the amount of homeobox protein nanog in a sample Annalisa Buniello true PMID:28240269 homeobox protein nanog measurement efo:EFO_0020457 The determination of the amount of homeodomain-interacting protein kinase 3 in a sample Annalisa Buniello true PMID:28240269 homeodomain-interacting protein kinase 3 measurement efo:EFO_0020458 The determination of the amount of hsp90 co-chaperone CDC37 in a sample Annalisa Buniello true PMID:28240269 hsp90 co-chaperone CDC37 measurement efo:EFO_0020459 The determination of the amount of hyaluronan and proteoglycan link protein 1 in a sample Annalisa Buniello true PMID:28240269 hyaluronan and proteoglycan link protein 1 measurement efo:EFO_0020460 The determination of the amount of icos ligand in a sample Annalisa Buniello true PMID:28240269 icos ligand measurement efo:EFO_0020461 The determination of the amount of iduronate 2-sulfatase in a sample Annalisa Buniello true PMID:28240269 iduronate 2-sulfatase measurement efo:EFO_0020462 The determination of the amount of immunoglobulin alpha fc receptor in a sample Annalisa Buniello true PMID:28240269 immunoglobulin alpha fc receptor measurement efo:EFO_0020463 The determination of the amount of immunoglobulin D in a sample Annalisa Buniello true PMID:28240269 immunoglobulin D measurement efo:EFO_0020464 The determination of the amount of immunoglobulin E in a sample Annalisa Buniello true PMID:28240269 immunoglobulin E measurement efo:EFO_0020465 The determination of the amount of immunoglobulin G in a sample Annalisa Buniello true PMID:28240269 immunoglobulin G measurement efo:EFO_0020466 The determination of the amount of immunoglobulin M in a sample Annalisa Buniello true PMID:28240269 immunoglobulin M measurement efo:EFO_0020467 The determination of the amount of importin subunit alpha-1 in a sample Annalisa Buniello true PMID:28240269 importin subunit alpha-1 measurement efo:EFO_0020468 The determination of the amount of importin subunit beta-1 in a sample Annalisa Buniello true PMID:28240269 importin subunit beta-1 measurement efo:EFO_0020469 The determination of the amount of inhibin beta A chain in a sample Annalisa Buniello true PMID:28240269 inhibin beta A chain measurement efo:EFO_0020470 The determination of the amount of inhibin beta A chain:inhibin beta B chain heterodimer in a sample Annalisa Buniello true PMID:28240269 inhibin beta A chain:inhibin beta B chain heterodimer measurement efo:EFO_0020471 The determination of the amount of inhibitor of growth protein 1 in a sample Annalisa Buniello true PMID:28240269 inhibitor of growth protein 1 measurement efo:EFO_0020472 The determination of the amount of insulin-degrading enzyme in a sample Annalisa Buniello true PMID:28240269 insulin-degrading enzyme measurement efo:EFO_0020473 The determination of the amount of insulin-like growth factor 1 receptor in a sample Annalisa Buniello true PMID:28240269 insulin-like growth factor 1 receptor measurement efo:EFO_0020474 The determination of the amount of insulin-like growth factor-binding protein 1 in a sample Annalisa Buniello true PMID:28240269 insulin-like growth factor-binding protein 1 measurement efo:EFO_0020475 The determination of the amount of insulin-like growth factor-binding protein 2 in a sample Annalisa Buniello true PMID:28240269 insulin-like growth factor-binding protein 2 measurement efo:EFO_0020476 The determination of the amount of insulin-like growth factor-binding protein 4 in a sample Annalisa Buniello true PMID:28240269 insulin-like growth factor-binding protein 4 measurement efo:EFO_0020477 The determination of the amount of insulin-like growth factor-binding protein 5 in a sample Annalisa Buniello true PMID:28240269 insulin-like growth factor-binding protein 5 measurement efo:EFO_0020478 The determination of the amount of insulin-like growth factor-binding protein 6 in a sample Annalisa Buniello true PMID:28240269 insulin-like growth factor-binding protein 6 measurement efo:EFO_0020479 The determination of the amount of integrin alpha-IIb: beta-3 complex in a sample Annalisa Buniello true PMID:28240269 integrin alpha-IIb: beta-3 complex measurement efo:EFO_0020480 The determination of the amount of integrin alpha-V: beta-5 complex in a sample Annalisa Buniello true PMID:28240269 integrin alpha-V: beta-5 complex measurement efo:EFO_0020481 The determination of the amount of inter-alpha-trypsin inhibitor heavy chain h4 in a sample Annalisa Buniello true PMID:28240269 inter-alpha-trypsin inhibitor heavy chain h4 measurement efo:EFO_0020482 The determination of the amount of intercellular adhesion molecule 3 in a sample Annalisa Buniello true PMID:28240269 intercellular adhesion molecule 3 measurement efo:EFO_0020483 The determination of the amount of interferon alpha-2 in a sample Annalisa Buniello true PMID:28240269 interferon alpha-2 measurement efo:EFO_0020484 The determination of the amount of interferon gamma receptor 1 in a sample Annalisa Buniello true PMID:28240269 interferon gamma receptor 1 measurement efo:EFO_0020485 The determination of the amount of interferon lambda-1 in a sample Annalisa Buniello true PMID:28240269 interferon lambda-1 measurement efo:EFO_0020486 The determination of the amount of interferon lambda-2 in a sample Annalisa Buniello true PMID:28240269 interferon lambda-2 measurement efo:EFO_0020487 The determination of the amount of interleukin-1 receptor type 1 in a sample Annalisa Buniello true PMID:28240269 interleukin-1 receptor type 1 measurement efo:EFO_0020488 The determination of the amount of interleukin-10 in a sample Annalisa Buniello true PMID:28240269 interleukin-10 measurement efo:EFO_0020489 The determination of the amount of interleukin-10 receptor subunit beta in a sample Annalisa Buniello true PMID:28240269 interleukin-10 receptor subunit beta measurement efo:EFO_0020490 The determination of the amount of interleukin-11 in a sample Annalisa Buniello true PMID:28240269 interleukin-11 measurement efo:EFO_0020491 The determination of the amount of interleukin-11 receptor subunit alpha in a sample Annalisa Buniello true PMID:28240269 interleukin-11 receptor subunit alpha measurement efo:EFO_0020492 The determination of the amount of interleukin-12 receptor subunit beta-2 in a sample Annalisa Buniello true PMID:28240269 interleukin-12 receptor subunit beta-2 measurement efo:EFO_0020493 The determination of the amount of interleukin-13 receptor subunit alpha-1 in a sample Annalisa Buniello true PMID:28240269 interleukin-13 receptor subunit alpha-1 measurement efo:EFO_0020494 The determination of the amount of interleukin-17 receptor c in a sample Annalisa Buniello true PMID:28240269 interleukin-17 receptor c measurement efo:EFO_0020495 The determination of the amount of interleukin-18-binding protein in a sample Annalisa Buniello true PMID:28240269 interleukin-18-binding protein measurement efo:EFO_0020496 The determination of the amount of interleukin-20 in a sample Annalisa Buniello true PMID:28240269 interleukin-20 measurement efo:EFO_0020497 The determination of the amount of interleukin-20 receptor subunit alpha in a sample Annalisa Buniello true PMID:28240269 interleukin-20 receptor subunit alpha measurement efo:EFO_0020498 The determination of the amount of interleukin-22 in a sample Annalisa Buniello true PMID:28240269 interleukin-22 measurement efo:EFO_0020499 The determination of the amount of interleukin-22 receptor subunit alpha-1 in a sample Annalisa Buniello true PMID:28240269 interleukin-22 receptor subunit alpha-1 measurement efo:EFO_0020500 The determination of the amount of interleukin-22 receptor subunit alpha-2 in a sample Annalisa Buniello true PMID:28240269 interleukin-22 receptor subunit alpha-2 measurement efo:EFO_0020501 The determination of the amount of interleukin-23 in a sample Annalisa Buniello true PMID:28240269 interleukin-23 measurement efo:EFO_0020502 The determination of the amount of interleukin-24 in a sample Annalisa Buniello true PMID:28240269 interleukin-24 measurement efo:EFO_0020503 The determination of the amount of interleukin-3 in a sample Annalisa Buniello true PMID:28240269 interleukin-3 measurement efo:EFO_0020504 The determination of the amount of interleukin-3 receptor subunit alpha in a sample Annalisa Buniello true PMID:28240269 interleukin-3 receptor subunit alpha measurement efo:EFO_0020505 The determination of the amount of interleukin-34 in a sample Annalisa Buniello true PMID:28240269 interleukin-34 measurement efo:EFO_0020506 The determination of the amount of interleukin-37 in a sample Annalisa Buniello true PMID:28240269 interleukin-37 measurement efo:EFO_0020507 The determination of the amount of interleukin-4 receptor subunit alpha in a sample Annalisa Buniello true PMID:28240269 interleukin-4 receptor subunit alpha measurement efo:EFO_0020508 The determination of the amount of interleukin-7 receptor subunit alpha in a sample Annalisa Buniello true PMID:28240269 interleukin-7 receptor subunit alpha measurement efo:EFO_0020509 The determination of the amount of junctional adhesion molecule B in a sample Annalisa Buniello true PMID:28240269 junctional adhesion molecule B measurement efo:EFO_0020510 The determination of the amount of junctional adhesion molecule C in a sample Annalisa Buniello true PMID:28240269 junctional adhesion molecule C measurement efo:EFO_0020511 The determination of the amount of junctional adhesion molecule-like in a sample Annalisa Buniello true PMID:28240269 junctional adhesion molecule-like measurement efo:EFO_0020512 The determination of the amount of kallikrein-13 in a sample Annalisa Buniello true PMID:28240269 kallikrein-13 measurement efo:EFO_0020513 The determination of the amount of kallikrein-14 in a sample Annalisa Buniello true PMID:28240269 kallikrein-14 measurement efo:EFO_0020514 The determination of the amount of kallikrein-4 in a sample Annalisa Buniello true PMID:28240269 kallikrein-4 measurement efo:EFO_0020515 The determination of the amount of kallikrein-5 in a sample Annalisa Buniello true PMID:28240269 kallikrein-5 measurement efo:EFO_0020516 The determination of the amount of kallikrein-8 in a sample Annalisa Buniello true PMID:28240269 kallikrein-8 measurement efo:EFO_0020517 The determination of the amount of keratin, type I cytoskeletal 18 in a sample Annalisa Buniello true PMID:28240269 keratin, type I cytoskeletal 18 measurement efo:EFO_0020518 The determination of the amount of killer cell immunoglobulin-like receptor 3DL2 in a sample Annalisa Buniello true PMID:28240269 killer cell immunoglobulin-like receptor 3DL2 measurement efo:EFO_0020519 The determination of the amount of killer cell immunoglobulin-like receptor 3DS1 in a sample Annalisa Buniello true PMID:28240269 killer cell immunoglobulin-like receptor 3DS1 measurement efo:EFO_0020520 The determination of the amount of killer cell lectin-like receptor subfamily F member 1 in a sample Annalisa Buniello true PMID:28240269 killer cell lectin-like receptor subfamily F member 1 measurement efo:EFO_0020521 The determination of the amount of kin of IRRE-like protein 3 in a sample Annalisa Buniello true PMID:28240269 kin of IRRE-like protein 3 measurement efo:EFO_0020522 The determination of the amount of kinesin-like protein KIF23 in a sample Annalisa Buniello true PMID:28240269 kinesin-like protein KIF23 measurement efo:EFO_0020523 The determination of the amount of kremen protein 2 in a sample Annalisa Buniello true PMID:28240269 kremen protein 2 measurement efo:EFO_0020524 The determination of the amount of L-lactate dehydrogenase B chain in a sample Annalisa Buniello true PMID:28240269 L-lactate dehydrogenase B chain measurement efo:EFO_0020525 The determination of the amount of lactoperoxidase in a sample Annalisa Buniello true PMID:28240269 lactoperoxidase measurement efo:EFO_0020526 The determination of the amount of lactotransferrin in a sample Annalisa Buniello true PMID:28240269 lactotransferrin measurement efo:EFO_0020527 The determination of the amount of lamin-B1 in a sample Annalisa Buniello true PMID:28240269 lamin-B1 measurement efo:EFO_0020528 The determination of the amount of laminin in a sample Annalisa Buniello true PMID:28240269 laminin measurement efo:EFO_0020529 The determination of the amount of layilin in a sample Annalisa Buniello true PMID:28240269 layilin measurement efo:EFO_0020530 The determination of the amount of legumain in a sample Annalisa Buniello true PMID:28240269 legumain measurement efo:EFO_0020531 The determination of the amount of leucine-rich repeat transmembrane neuronal protein 1 in a sample Annalisa Buniello true PMID:28240269 leucine-rich repeat transmembrane neuronal protein 1 measurement efo:EFO_0020532 The determination of the amount of leucine-rich repeat transmembrane neuronal protein 3 in a sample Annalisa Buniello true PMID:28240269 leucine-rich repeat transmembrane neuronal protein 3 measurement efo:EFO_0020533 The determination of the amount of leucine-rich repeat transmembrane protein FLRT1 in a sample Annalisa Buniello true PMID:28240269 leucine-rich repeat transmembrane protein FLRT1 measurement efo:EFO_0020534 The determination of the amount of leucine-rich repeats and immunoglobulin-like domains protein 3 in a sample Annalisa Buniello true PMID:28240269 leucine-rich repeats and immunoglobulin-like domains protein 3 measurement efo:EFO_0020535 The determination of the amount of leukotriene a-4 hydrolase in a sample Annalisa Buniello true PMID:28240269 leukotriene a-4 hydrolase measurement efo:EFO_0020536 The determination of the amount of ligand-dependent nuclear receptor corepressor-like protein in a sample Annalisa Buniello true PMID:28240269 ligand-dependent nuclear receptor corepressor-like protein measurement efo:EFO_0020537 The determination of the amount of limbic system-associated membrane protein in a sample Annalisa Buniello true PMID:28240269 limbic system-associated membrane protein measurement efo:EFO_0020538 The determination of the amount of low-density lipoprotein receptor-related protein 8 in a sample Annalisa Buniello true PMID:28240269 low-density lipoprotein receptor-related protein 8 measurement efo:EFO_0020539 The determination of the amount of lymphatic vessel endothelial hyaluronic acid receptor 1 in a sample Annalisa Buniello true PMID:28240269 lymphatic vessel endothelial hyaluronic acid receptor 1 measurement efo:EFO_0020540 The determination of the amount of lymphocyte activation gene 3 protein in a sample Annalisa Buniello true PMID:28240269 lymphocyte activation gene 3 protein measurement efo:EFO_0020541 The determination of the amount of lymphocyte antigen 86 in a sample Annalisa Buniello true PMID:28240269 lymphocyte antigen 86 measurement efo:EFO_0020542 The determination of the amount of lymphotoxin alpha1:beta2 in a sample Annalisa Buniello true PMID:28240269 lymphotoxin alpha1:beta2 measurement efo:EFO_0020543 The determination of the amount of lymphotoxin alpha2:beta1 in a sample Annalisa Buniello true PMID:28240269 lymphotoxin alpha2:beta1 measurement efo:EFO_0020544 The determination of the amount of lymphotoxin-alpha in a sample Annalisa Buniello true PMID:28240269 lymphotoxin-alpha measurement efo:EFO_0020545 The determination of the amount of lysosome membrane protein 2 in a sample Annalisa Buniello true PMID:28240269 lysosome membrane protein 2 measurement efo:EFO_0020546 The determination of the amount of macrophage colony-stimulating factor 1 in a sample Annalisa Buniello true PMID:28240269 macrophage colony-stimulating factor 1 measurement efo:EFO_0020547 The determination of the amount of macrophage colony-stimulating factor 1 receptor in a sample Annalisa Buniello true PMID:28240269 macrophage colony-stimulating factor 1 receptor measurement efo:EFO_0020548 The determination of the amount of macrophage mannose receptor 1 in a sample Annalisa Buniello true PMID:28240269 macrophage mannose receptor 1 measurement efo:EFO_0020549 The determination of the amount of macrophage-capping protein in a sample Annalisa Buniello true PMID:28240269 macrophage-capping protein measurement efo:EFO_0020550 The determination of the amount of macrophage-stimulating protein receptor in a sample Annalisa Buniello true PMID:28240269 macrophage-stimulating protein receptor measurement efo:EFO_0020551 The determination of the amount of malate dehydrogenase, cytoplasmic in a sample Annalisa Buniello true PMID:28240269 malate dehydrogenase, cytoplasmic measurement efo:EFO_0020552 The determination of the amount of mammaglobin-b in a sample Annalisa Buniello true PMID:28240269 mammaglobin-b measurement efo:EFO_0020553 The determination of the amount of MAP kinase-activated protein kinase 5 in a sample Annalisa Buniello true PMID:28240269 MAP kinase-activated protein kinase 5 measurement efo:EFO_0020554 The determination of the amount of mast/stem cell growth factor receptor kit in a sample Annalisa Buniello true PMID:28240269 mast/stem cell growth factor receptor kit measurement efo:EFO_0020555 The determination of the amount of matrilin-2 in a sample Annalisa Buniello true PMID:28240269 matrilin-2 measurement efo:EFO_0020556 The determination of the amount of matrilin-3 in a sample Annalisa Buniello true PMID:28240269 matrilin-3 measurement efo:EFO_0020557 The determination of the amount of matrix extracellular phosphoglycoprotein in a sample Annalisa Buniello true PMID:28240269 matrix extracellular phosphoglycoprotein measurement efo:EFO_0020558 The determination of the amount of matrix metalloproteinase-14 in a sample Annalisa Buniello true PMID:28240269 matrix metalloproteinase-14 measurement efo:EFO_0020559 The determination of the amount of matrix metalloproteinase-16 in a sample Annalisa Buniello true PMID:28240269 matrix metalloproteinase-16 measurement efo:EFO_0020560 The determination of the amount of matrix metalloproteinase-17 in a sample Annalisa Buniello true PMID:28240269 matrix metalloproteinase-17 measurement efo:EFO_0020561 The determination of the amount of matrix metalloproteinase-9 in a sample Annalisa Buniello true PMID:28240269 matrix metalloproteinase-9 measurement efo:EFO_0020562 The determination of the amount of megakaryocyte-associated tyrosine-protein kinase in a sample Annalisa Buniello true PMID:28240269 megakaryocyte-associated tyrosine-protein kinase measurement efo:EFO_0020563 The determination of the amount of membrane frizzled-related protein in a sample Annalisa Buniello true PMID:28240269 membrane frizzled-related protein measurement efo:EFO_0020564 The determination of the amount of membrane metallo-endopeptidase-like 1 in a sample Annalisa Buniello true PMID:28240269 membrane metallo-endopeptidase-like 1 measurement efo:EFO_0020565 The determination of the amount of mesothelin in a sample Annalisa Buniello true PMID:28240269 mesothelin measurement efo:EFO_0020566 The determination of the amount of metalloproteinase inhibitor 1 in a sample Annalisa Buniello true PMID:28240269 metalloproteinase inhibitor 1 measurement efo:EFO_0020567 The determination of the amount of metalloproteinase inhibitor 2 in a sample Annalisa Buniello true PMID:28240269 metalloproteinase inhibitor 2 measurement efo:EFO_0020568 The determination of the amount of methionine aminopeptidase 1 in a sample Annalisa Buniello true PMID:28240269 methionine aminopeptidase 1 measurement efo:EFO_0020569 The determination of the amount of methyl-cpg-binding domain protein 4 in a sample Annalisa Buniello true PMID:28240269 methyl-cpg-binding domain protein 4 measurement efo:EFO_0020570 The determination of the amount of microtubule-associated protein tau in a sample Annalisa Buniello true PMID:28240269 microtubule-associated protein tau measurement efo:EFO_0020571 The determination of the amount of midkine in a sample Annalisa Buniello true PMID:28240269 midkine measurement efo:EFO_0020572 The determination of the amount of mitochondrial glutamate carrier 2 in a sample Annalisa Buniello true PMID:28240269 mitochondrial glutamate carrier 2 measurement efo:EFO_0020573 The determination of the amount of mitochondrial import inner membrane translocase subunit tim14 in a sample Annalisa Buniello true PMID:28240269 mitochondrial import inner membrane translocase subunit tim14 measurement efo:EFO_0020574 The determination of the amount of mitogen-activated protein kinase 1 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 1 measurement efo:EFO_0020575 The determination of the amount of mitogen-activated protein kinase 11 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 11 measurement efo:EFO_0020576 The determination of the amount of mitogen-activated protein kinase 12 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 12 measurement efo:EFO_0020577 The determination of the amount of mitogen-activated protein kinase 13 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 13 measurement efo:EFO_0020578 The determination of the amount of mitogen-activated protein kinase 14 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 14 measurement efo:EFO_0020579 The determination of the amount of mitogen-activated protein kinase 3 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 3 measurement efo:EFO_0020580 The determination of the amount of mitogen-activated protein kinase 8 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 8 measurement efo:EFO_0020581 The determination of the amount of mitogen-activated protein kinase 9 in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase 9 measurement efo:EFO_0020582 The determination of the amount of mitogen-activated protein kinase kinase kinase 7:tgf-beta-activated kinase 1 and map3k7-binding protein 1 fusion in a sample Annalisa Buniello true PMID:28240269 mitogen-activated protein kinase kinase kinase 7:tgf-beta-activated kinase 1 and map3k7-binding protein 1 fusion measurement efo:EFO_0020583 The determination of the amount of moesin in a sample Annalisa Buniello true PMID:28240269 moesin measurement efo:EFO_0020584 The determination of the amount of muellerian-inhibiting factor in a sample Annalisa Buniello true PMID:28240269 muellerian-inhibiting factor measurement efo:EFO_0020585 The determination of the amount of myeloblastin in a sample Annalisa Buniello true PMID:28240269 myeloblastin measurement efo:EFO_0020586 The determination of the amount of n-acetylglucosamine-6-sulfatase in a sample Annalisa Buniello true PMID:28240269 n-acetylglucosamine-6-sulfatase measurement efo:EFO_0020587 The determination of the amount of nascent polypeptide-associated complex subunit alpha in a sample Annalisa Buniello true PMID:28240269 nascent polypeptide-associated complex subunit alpha measurement efo:EFO_0020588 The determination of the amount of natural cytotoxicity triggering receptor 1 in a sample Annalisa Buniello true PMID:28240269 natural cytotoxicity triggering receptor 1 measurement efo:EFO_0020589 The determination of the amount of natural cytotoxicity triggering receptor 2 in a sample Annalisa Buniello true PMID:28240269 natural cytotoxicity triggering receptor 2 measurement efo:EFO_0020590 The determination of the amount of netrin receptor UNC5C in a sample Annalisa Buniello true PMID:28240269 netrin receptor UNC5C measurement efo:EFO_0020591 The determination of the amount of netrin receptor UNC5D in a sample Annalisa Buniello true PMID:28240269 netrin receptor UNC5D measurement efo:EFO_0020592 The determination of the amount of netrin-4 in a sample Annalisa Buniello true PMID:28240269 netrin-4 measurement efo:EFO_0020593 The determination of the amount of neural cell adhesion molecule 1, 120 kda isoform in a sample Annalisa Buniello true PMID:28240269 neural cell adhesion molecule 1, 120 kda isoform measurement efo:EFO_0020594 The determination of the amount of neural cell adhesion molecule L1 in a sample Annalisa Buniello true PMID:28240269 neural cell adhesion molecule L1 measurement efo:EFO_0020595 The determination of the amount of neural cell adhesion molecule l1-like protein in a sample Annalisa Buniello true PMID:28240269 neural cell adhesion molecule l1-like protein measurement efo:EFO_0020596 The determination of the amount of neurexin-1-beta in a sample Annalisa Buniello true PMID:28240269 neurexin-1-beta measurement efo:EFO_0020597 The determination of the amount of neurexin-3-beta in a sample Annalisa Buniello true PMID:28240269 neurexin-3-beta measurement efo:EFO_0020598 The determination of the amount of neuroblastoma suppressor of tumorigenicity 1 in a sample Annalisa Buniello true PMID:28240269 neuroblastoma suppressor of tumorigenicity 1 measurement efo:EFO_0020599 The determination of the amount of neurogenic locus notch homolog protein 2 in a sample Annalisa Buniello true PMID:28240269 neurogenic locus notch homolog protein 2 measurement efo:EFO_0020600 The determination of the amount of neurogenic locus notch homolog protein 3 in a sample Annalisa Buniello true PMID:28240269 neurogenic locus notch homolog protein 3 measurement efo:EFO_0020601 The determination of the amount of neuroligin-4, x-linked in a sample Annalisa Buniello true PMID:28240269 neuroligin-4, x-linked measurement efo:EFO_0020602 The determination of the amount of neuronal cell adhesion molecule in a sample Annalisa Buniello true PMID:28240269 neuronal cell adhesion molecule measurement efo:EFO_0020603 The determination of the amount of neuropilin-1 in a sample Annalisa Buniello true PMID:28240269 neuropilin-1 measurement efo:EFO_0020604 The determination of the amount of neurotrophin-4 in a sample Annalisa Buniello true PMID:28240269 neurotrophin-4 measurement efo:EFO_0020605 The determination of the amount of neutrophil elastase in a sample Annalisa Buniello true PMID:28240269 neutrophil elastase measurement efo:EFO_0020606 The determination of the amount of neutrophil-activating peptide 2 in a sample Annalisa Buniello true PMID:28240269 neutrophil-activating peptide 2 measurement efo:EFO_0020607 The determination of the amount of nicotinamide phosphoribosyltransferase in a sample Annalisa Buniello true PMID:28240269 nicotinamide phosphoribosyltransferase measurement efo:EFO_0020608 The determination of the amount of nidogen-2 in a sample Annalisa Buniello true PMID:28240269 nidogen-2 measurement efo:EFO_0020609 The determination of the amount of NKG2-D ligand 1 in a sample Annalisa Buniello true PMID:28240269 NKG2-D ligand 1 measurement efo:EFO_0020610 The determination of the amount of NKG2-D ligand 2 in a sample Annalisa Buniello true PMID:28240269 NKG2-D ligand 2 measurement efo:EFO_0020611 The determination of the amount of NKG2-D ligand 3 in a sample Annalisa Buniello true PMID:28240269 NKG2-D ligand 3 measurement efo:EFO_0020612 The determination of the amount of NFSL1 cofactor p47 in a sample Annalisa Buniello true PMID:28240269 NFSL1 cofactor p47 measurement efo:EFO_0020613 The determination of the amount of nt-3 growth factor receptor in a sample Annalisa Buniello true PMID:28240269 nt-3 growth factor receptor measurement efo:EFO_0020614 The determination of the amount of nuclear receptor subfamily 1 group d member 1 in a sample Annalisa Buniello true PMID:28240269 nuclear receptor subfamily 1 group d member 1 measurement efo:EFO_0020615 The determination of the amount of nucleoside diphosphate kinase B in a sample Annalisa Buniello true PMID:28240269 nucleoside diphosphate kinase B measurement efo:EFO_0020616 The determination of the amount of NudC domain-containing protein 3 in a sample. Annalisa Buniello true PMID:28240269 NudC domain-containing protein 3 measurement efo:EFO_0020617 The determination of the amount of olfactomedin-4 in a sample Annalisa Buniello true PMID:28240269 olfactomedin-4 measurement efo:EFO_0020618 The determination of the amount of opioid-binding protein/cell adhesion molecule in a sample Annalisa Buniello true PMID:28240269 opioid-binding protein/cell adhesion molecule measurement efo:EFO_0020619 The determination of the amount of osteomodulin in a sample Annalisa Buniello true PMID:28240269 osteomodulin measurement efo:EFO_0020620 The determination of the amount of oxidized low-density lipoprotein receptor 1 in a sample Annalisa Buniello true PMID:28240269 oxidized low-density lipoprotein receptor 1 measurement efo:EFO_0020621 The determination of the amount of pancreatic hormone in a sample Annalisa Buniello true PMID:28240269 pancreatic hormone measurement efo:EFO_0020622 The determination of the amount of parathyroid hormone-related protein in a sample Annalisa Buniello true PMID:28240269 parathyroid hormone-related protein measurement efo:EFO_0020623 The determination of the amount of peptide yy in a sample Annalisa Buniello true PMID:28240269 peptide yy measurement efo:EFO_0020624 The determination of the amount of peptidoglycan recognition protein 1 in a sample Annalisa Buniello true PMID:28240269 peptidoglycan recognition protein 1 measurement efo:EFO_0020625 The determination of the amount of peptidyl-prolyl cis-trans isomerase A in a sample Annalisa Buniello true PMID:28240269 peptidyl-prolyl cis-trans isomerase A measurement efo:EFO_0020626 The determination of the amount of peptidyl-prolyl cis-trans isomerase B in a sample Annalisa Buniello true PMID:28240269 peptidyl-prolyl cis-trans isomerase B measurement efo:EFO_0020627 The determination of the amount of peptidyl-prolyl cis-trans isomerase F, mitochondrial in a sample Annalisa Buniello true PMID:28240269 peptidyl-prolyl cis-trans isomerase F, mitochondrial measurement efo:EFO_0020628 The determination of the amount of periostin in a sample Annalisa Buniello true PMID:28240269 periostin measurement efo:EFO_0020629 The determination of the amount of peroxiredoxin-1 in a sample Annalisa Buniello true PMID:28240269 peroxiredoxin-1 measurement efo:EFO_0020630 The determination of the amount of peroxiredoxin-5, mitochondrial in a sample Annalisa Buniello true PMID:28240269 peroxiredoxin-5, mitochondrial measurement efo:EFO_0020631 The determination of the amount of peroxiredoxin-6 in a sample Annalisa Buniello true PMID:28240269 peroxiredoxin-6 measurement efo:EFO_0020632 The determination of the amount of persephin in a sample Annalisa Buniello true PMID:28240269 persephin measurement efo:EFO_0020633 The determination of the amount of pescadillo homolog in a sample Annalisa Buniello true PMID:28240269 pescadillo homolog measurement efo:EFO_0020634 The determination of the amount of phosphatidylethanolamine-binding protein 1 in a sample Annalisa Buniello true PMID:28240269 phosphatidylethanolamine-binding protein 1 measurement efo:EFO_0020635 The determination of the amount of phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase pten in a sample Annalisa Buniello true PMID:28240269 phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase pten measurement efo:EFO_0020636 The determination of the amount of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform:phosphatidylinositol 3-kinase regulatory subunit alpha complex in a sample Annalisa Buniello true PMID:28240269 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform:phosphatidylinositol 3-kinase regulatory subunit alpha complex measurement efo:EFO_0020637 The determination of the amount of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform in a sample Annalisa Buniello true PMID:28240269 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform measurement efo:EFO_0020638 The determination of the amount of phosphoglycerate kinase 1 in a sample Annalisa Buniello true PMID:28240269 phosphoglycerate kinase 1 measurement efo:EFO_0020639 The determination of the amount of phosphoglycerate mutase 1 in a sample Annalisa Buniello true PMID:28240269 phosphoglycerate mutase 1 measurement efo:EFO_0020640 The determination of the amount of pituitary adenylate cyclase-activating polypeptide 27 in a sample Annalisa Buniello true PMID:28240269 pituitary adenylate cyclase-activating polypeptide 27 measurement efo:EFO_0020641 The determination of the amount of pituitary adenylate cyclase-activating polypeptide 38 in a sample Annalisa Buniello true PMID:28240269 pituitary adenylate cyclase-activating polypeptide 38 measurement efo:EFO_0020642 The determination of the amount of plasma serine protease inhibitor in a sample Annalisa Buniello true PMID:28240269 plasma serine protease inhibitor measurement efo:EFO_0020643 The determination of the amount of plasmin in a sample Annalisa Buniello true PMID:28240269 plasmin measurement efo:EFO_0020644 The determination of the amount of platelet factor 4 in a sample Annalisa Buniello true PMID:28240269 platelet factor 4 measurement efo:EFO_0020645 The determination of the amount of platelet glycoprotein ib alpha chain in a sample Annalisa Buniello true PMID:28240269 platelet glycoprotein ib alpha chain measurement efo:EFO_0020646 The determination of the amount of platelet-activating factor acetylhydrolase ib subunit beta in a sample Annalisa Buniello true PMID:28240269 platelet-activating factor acetylhydrolase ib subunit beta measurement efo:EFO_0020647 The determination of the amount of platelet-activating factor acetylhydrolase in a sample Annalisa Buniello true PMID:28240269 platelet-activating factor acetylhydrolase measurement efo:EFO_0020648 The determination of the amount of platelet-derived growth factor c in a sample Annalisa Buniello true PMID:28240269 platelet-derived growth factor c measurement efo:EFO_0020649 The determination of the amount of platelet-derived growth factor subunitA in a sample Annalisa Buniello true PMID:28240269 platelet-derived growth factor subunitAmeasurement efo:EFO_0020650 The determination of the amount of platelet-derived growth factor subunit b in a sample Annalisa Buniello true PMID:28240269 platelet-derived growth factor subunit b measurement efo:EFO_0020651 The determination of the amount of pleiotrophin in a sample Annalisa Buniello true PMID:28240269 pleiotrophin measurement efo:EFO_0020652 The determination of the amount of prefoldin subunit 5 in a sample Annalisa Buniello true PMID:28240269 prefoldin subunit 5 measurement efo:EFO_0020653 The determination of the amount of probable g-protein coupled receptor 114 in a sample Annalisa Buniello true PMID:28240269 probable g-protein coupled receptor 114 measurement efo:EFO_0020654 The determination of the amount of programmed cell death 1 ligand 1 in a sample Annalisa Buniello true PMID:28240269 programmed cell death 1 ligand 1 measurement efo:EFO_0020655 The determination of the amount of prokineticin-1 in a sample Annalisa Buniello true PMID:28240269 prokineticin-1 measurement efo:EFO_0020656 The determination of the amount of prolactin receptor in a sample Annalisa Buniello true PMID:28240269 prolactin receptor measurement efo:EFO_0020657 The determination of the amount of proliferating cell nuclear antigen in a sample Annalisa Buniello true PMID:28240269 proliferating cell nuclear antigen measurement efo:EFO_0020658 The determination of the amount of proliferation-associated protein 2g4 in a sample Annalisa Buniello true PMID:28240269 proliferation-associated protein 2g4 measurement efo:EFO_0020659 The determination of the amount of prostaglandin g/h synthase 2 in a sample Annalisa Buniello true PMID:28240269 prostaglandin g/h synthase 2 measurement efo:EFO_0020660 The determination of the amount of prostate-specific antigen in a sample Annalisa Buniello true PMID:28240269 prostate-specific antigen measurement efo:EFO_0020661 The determination of the amount of proteasome activator complex subunit 1 in a sample Annalisa Buniello true PMID:28240269 proteasome activator complex subunit 1 measurement efo:EFO_0020662 The determination of the amount of proteasome activator complex subunit 3 in a sample Annalisa Buniello true PMID:28240269 proteasome activator complex subunit 3 measurement efo:EFO_0020663 The determination of the amount of proteasome subunit alpha type-1 in a sample Annalisa Buniello true PMID:28240269 proteasome subunit alpha type-1 measurement efo:EFO_0020664 The determination of the amount of proteasome subunit alpha type-2 in a sample Annalisa Buniello true PMID:28240269 proteasome subunit alpha type-2 measurement efo:EFO_0020665 The determination of the amount of proteasome subunit alpha type-6 in a sample Annalisa Buniello true PMID:28240269 proteasome subunit alpha type-6 measurement efo:EFO_0020666 The determination of the amount of protein 4.1 in a sample Annalisa Buniello true PMID:28240269 protein 4.1 measurement efo:EFO_0020667 The determination of the amount of protein amnionless in a sample Annalisa Buniello true PMID:28240269 protein amnionless measurement efo:EFO_0020668 The determination of the amount of protein disulfide-isomerase a3 in a sample Annalisa Buniello true PMID:28240269 protein disulfide-isomerase a3 measurement efo:EFO_0020669 The determination of the amount of protein disulfide-isomerase in a sample Annalisa Buniello true PMID:28240269 protein disulfide-isomerase measurement efo:EFO_0020670 The determination of the amount of protein dj-1 in a sample Annalisa Buniello true PMID:28240269 protein dj-1 measurement efo:EFO_0020671 The determination of the amount of protein e7_hpv16 in a sample Annalisa Buniello true PMID:28240269 protein e7_hpv16 measurement efo:EFO_0020672 The determination of the amount of protein e7_hpv18 in a sample Annalisa Buniello true PMID:28240269 protein e7_hpv18 measurement efo:EFO_0020673 The determination of the amount of protein fam107a in a sample Annalisa Buniello true PMID:28240269 protein fam107a measurement efo:EFO_0020674 The determination of the amount of protein fam107b in a sample Annalisa Buniello true PMID:28240269 protein fam107b measurement efo:EFO_0020675 The determination of the amount of protein jagged-2 in a sample Annalisa Buniello true PMID:28240269 protein jagged-2 measurement efo:EFO_0020676 The determination of the amount of protein kinase b alpha/beta/gamma in a sample Annalisa Buniello true PMID:28240269 protein kinase b alpha/beta/gamma measurement efo:EFO_0020677 The determination of the amount of protein kinase c alpha type in a sample Annalisa Buniello true PMID:28240269 protein kinase c alpha type measurement efo:EFO_0020678 The determination of the amount of protein kinase c beta type (splice variant beta-II) in a sample Annalisa Buniello true PMID:28240269 protein kinase c beta type (splice variant beta-II) measurement efo:EFO_0020679 The determination of the amount of protein kinase c delta type in a sample Annalisa Buniello true PMID:28240269 protein kinase c delta type measurement efo:EFO_0020680 The determination of the amount of protein kinase c gamma type in a sample Annalisa Buniello true PMID:28240269 protein kinase c gamma type measurement efo:EFO_0020681 The determination of the amount of protein kinase c iota type in a sample Annalisa Buniello true PMID:28240269 protein kinase c iota type measurement efo:EFO_0020682 The determination of the amount of protein kinase c theta type in a sample Annalisa Buniello true PMID:28240269 protein kinase c theta type measurement efo:EFO_0020683 The determination of the amount of protein kinase c zeta type in a sample Annalisa Buniello true PMID:28240269 protein kinase c zeta type measurement efo:EFO_0020685 The determination of the amount of protein nov homolog in a sample Annalisa Buniello true PMID:28240269 protein nov homolog measurement efo:EFO_0020686 The determination of the amount of protein rev_hv2be in a sample Annalisa Buniello true PMID:28240269 protein rev_hv2be measurement efo:EFO_0020687 The determination of the amount of protein s100-a9 in a sample Annalisa Buniello true PMID:28240269 protein s100-a9 measurement efo:EFO_0020688 The determination of the amount of protein set in a sample Annalisa Buniello true PMID:28240269 protein set measurement efo:EFO_0020689 The determination of the amount of protein wnt-7a in a sample Annalisa Buniello true PMID:28240269 protein wnt-7a measurement efo:EFO_0020690 The determination of the amount of protein-glutamine gamma-glutamyltransferase e in a sample Annalisa Buniello true PMID:28240269 protein-glutamine gamma-glutamyltransferase e measurement efo:EFO_0020691 The determination of the amount of protein-tyrosine kinase 6 in a sample Annalisa Buniello true PMID:28240269 protein-tyrosine kinase 6 measurement efo:EFO_0020692 The determination of the amount of prothrombin in a sample Annalisa Buniello true PMID:28240269 prothrombin measurement efo:EFO_0020693 The determination of the amount of pulmonary surfactant-associated protein d in a sample Annalisa Buniello true PMID:28240269 pulmonary surfactant-associated protein d measurement efo:EFO_0020694 The determination of the amount of pyridoxal phosphate phosphatase in a sample Annalisa Buniello true PMID:28240269 pyridoxal phosphate phosphatase measurement efo:EFO_0020695 The determination of the amount of pyruvate kinase pkm in a sample Annalisa Buniello true PMID:28240269 pyruvate kinase pkm measurement efo:EFO_0020696 The determination of the amount of r-spondin-2 in a sample Annalisa Buniello true PMID:28240269 r-spondin-2 measurement efo:EFO_0020697 The determination of the amount of rab gdp dissociation inhibitor beta in a sample Annalisa Buniello true PMID:28240269 rab gdp dissociation inhibitor beta measurement efo:EFO_0020698 The determination of the amount of ras GTPase-activating protein 1 in a sample Annalisa Buniello true PMID:28240269 ras GTPase-activating protein 1 measurement efo:EFO_0020699 The determination of the amount of ras-related c3 botulinum toxin substrate 1 in a sample Annalisa Buniello true PMID:28240269 ras-related c3 botulinum toxin substrate 1 measurement efo:EFO_0020700 The determination of the amount of receptor tyrosine-protein kinase erbb-2 in a sample Annalisa Buniello true PMID:28240269 receptor tyrosine-protein kinase erbb-2 measurement efo:EFO_0020701 The determination of the amount of receptor tyrosine-protein kinase erbb-3 in a sample Annalisa Buniello true PMID:28240269 receptor tyrosine-protein kinase erbb-3 measurement efo:EFO_0020702 The determination of the amount of receptor tyrosine-protein kinase erbb-4 in a sample Annalisa Buniello true PMID:28240269 receptor tyrosine-protein kinase erbb-4 measurement efo:EFO_0020703 The determination of the amount of receptor-type tyrosine-protein kinase flt3 in a sample Annalisa Buniello true PMID:28240269 receptor-type tyrosine-protein kinase flt3 measurement efo:EFO_0020704 The determination of the amount of reticulon-4 in a sample Annalisa Buniello true PMID:28240269 reticulon-4 measurement efo:EFO_0020705 The determination of the amount of reticulon-4 receptor in a sample Annalisa Buniello true PMID:28240269 reticulon-4 receptor measurement efo:EFO_0020706 The determination of the amount of retinoblastoma-associated protein in a sample Annalisa Buniello true PMID:28240269 retinoblastoma-associated protein measurement efo:EFO_0020707 The determination of the amount of retinol-binding protein 4 in a sample Annalisa Buniello true PMID:28240269 retinol-binding protein 4 measurement efo:EFO_0020708 The determination of the amount of rgm domain family member b in a sample Annalisa Buniello true PMID:28240269 rgm domain family member b measurement efo:EFO_0020709 The determination of the amount of ribosomal protein s6 kinase alpha-3 in a sample Annalisa Buniello true PMID:28240269 ribosomal protein s6 kinase alpha-3 measurement efo:EFO_0020710 The determination of the amount of ribosomal protein s6 kinase alpha-5 in a sample Annalisa Buniello true PMID:28240269 ribosomal protein s6 kinase alpha-5 measurement efo:EFO_0020711 The determination of the amount of ribosome maturation protein sbds in a sample Annalisa Buniello true PMID:28240269 ribosome maturation protein sbds measurement efo:EFO_0020712 The determination of the amount of rna-binding protein 39 in a sample Annalisa Buniello true PMID:28240269 rna-binding protein 39 measurement efo:EFO_0020713 The determination of the amount of roundabout homolog 2 in a sample Annalisa Buniello true PMID:28240269 roundabout homolog 2 measurement efo:EFO_0020714 The determination of the amount of roundabout homolog 3 in a sample Annalisa Buniello true PMID:28240269 roundabout homolog 3 measurement efo:EFO_0020715 The determination of the amount of s-phase kinase-associated protein 1 in a sample Annalisa Buniello true PMID:28240269 s-phase kinase-associated protein 1 measurement efo:EFO_0020716 The determination of the amount of scavenger receptor class F member 2 in a sample Annalisa Buniello true PMID:28240269 scavenger receptor class F member 2 measurement efo:EFO_0020717 The determination of the amount of scavenger receptor cysteine-rich type 1 protein m130 in a sample Annalisa Buniello true PMID:28240269 scavenger receptor cysteine-rich type 1 protein m130 measurement efo:EFO_0020718 The determination of the amount of secreted frizzled-related protein 1 in a sample Annalisa Buniello true PMID:28240269 secreted frizzled-related protein 1 measurement efo:EFO_0020719 The determination of the amount of secretin in a sample Annalisa Buniello true PMID:28240269 secretin measurement efo:EFO_0020720 The determination of the amount of seizure 6-like protein 2 in a sample Annalisa Buniello true PMID:28240269 seizure 6-like protein 2 measurement efo:EFO_0020721 The determination of the amount of semaphorin-6A in a sample Annalisa Buniello true PMID:28240269 semaphorin-6A measurement efo:EFO_0020722 The determination of the amount of seprase in a sample Annalisa Buniello true PMID:28240269 seprase measurement efo:EFO_0020723 The determination of the amount of serine protease HTRA2, mitochondrial in a sample Annalisa Buniello true PMID:28240269 serine protease HTRA2, mitochondrial measurement efo:EFO_0020724 The determination of the amount of serine/threonine-protein kinase 16 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase 16 measurement efo:EFO_0020725 The determination of the amount of serine/threonine-protein kinase CHK11 in a sample Annalisa Buniello PMID:28240269 serine/threonine-protein kinase CHK11 measurement efo:EFO_0020726 The determination of the amount of serine/threonine-protein kinase CHK2 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase CHK2 measurement efo:EFO_0020727 The determination of the amount of serine/threonine-protein kinase MRCK beta in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase MRCK beta measurement efo:EFO_0020728 The determination of the amount of serine/threonine-protein kinase PAK 3 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase PAK 3 measurement efo:EFO_0020729 The determination of the amount of serine/threonine-protein kinase PAK 6 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase PAK 6 measurement efo:EFO_0020730 The determination of the amount of serine/threonine-protein kinase PAK 7 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase PAK 7 measurement efo:EFO_0020731 The determination of the amount of serine/threonine-protein kinase PIM-1 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase PIM-1 measurement efo:EFO_0020732 The determination of the amount of serine/threonine-protein kinase PLK1 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase PLK1 measurement efo:EFO_0020733 The determination of the amount of serine/threonine-protein kinase receptor R3 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase receptor R3 measurement efo:EFO_0020734 The determination of the amount of serine/threonine-protein kinase TBK1 in a sample Annalisa Buniello true PMID:28240269 serine/threonine-protein kinase TBK1 measurement efo:EFO_0020735 The determination of the amount of serotransferrin in a sample Annalisa Buniello true PMID:28240269 serotransferrin measurement efo:EFO_0020736 The determination of the amount of serum paraoxonase/arylesterase 1 in a sample Annalisa Buniello true PMID:28240269 serum paraoxonase/arylesterase 1 measurement efo:EFO_0020737 The determination of the amount of sh2 domain-containing protein 1a in a sample Annalisa Buniello true PMID:28240269 sh2 domain-containing protein 1a measurement efo:EFO_0020738 The determination of the amount of shc-transforming protein 1 in a sample Annalisa Buniello true PMID:28240269 shc-transforming protein 1 measurement efo:EFO_0020739 The determination of the amount of sialic acid-binding ig-like lectin 7 in a sample Annalisa Buniello true PMID:28240269 sialic acid-binding ig-like lectin 7 measurement efo:EFO_0020740 The determination of the amount of sialoadhesin in a sample Annalisa Buniello true PMID:28240269 sialoadhesin measurement efo:EFO_0020741 The determination of the amount of SLAM family member 5 in a sample Annalisa Buniello true PMID:28240269 SLAM family member 5 measurement efo:EFO_0020742 The determination of the amount of SLAM family member 6 in a sample Annalisa Buniello true PMID:28240269 SLAM family member 6 measurement efo:EFO_0020743 The determination of the amount of slit and ntrk-like protein 5 in a sample Annalisa Buniello true PMID:28240269 slit and ntrk-like protein 5 measurement efo:EFO_0020744 The determination of the amount of small glutamine-rich tetratricopeptide repeat-containing protein alpha in a sample Annalisa Buniello true PMID:28240269 small glutamine-rich tetratricopeptide repeat-containing protein alpha measurement efo:EFO_0020745 The determination of the amount of somatostatin-28 in a sample Annalisa Buniello true PMID:28240269 somatostatin-28 measurement efo:EFO_0020746 The determination of the amount of sonic hedgehog protein in a sample Annalisa Buniello true PMID:28240269 sonic hedgehog protein measurement efo:EFO_0020747 The determination of the amount of sorting nexin-4 in a sample Annalisa Buniello true PMID:28240269 sorting nexin-4 measurement efo:EFO_0020748 The determination of the amount of SPARC in a sample Annalisa Buniello true PMID:28240269 SPARC measurement efo:EFO_0020749 The determination of the amount of spectrin alpha chain, non-erythrocytic 1 in a sample Annalisa Buniello true PMID:28240269 spectrin alpha chain, non-erythrocytic 1 measurement efo:EFO_0020750 The determination of the amount of sphingosine kinase 1 in a sample Annalisa Buniello true PMID:28240269 sphingosine kinase 1 measurement efo:EFO_0020751 The determination of the amount of sphingosine kinase 2 in a sample Annalisa Buniello true PMID:28240269 sphingosine kinase 2 measurement efo:EFO_0020752 The determination of the amount of stabilin-2 in a sample Annalisa Buniello true PMID:28240269 stabilin-2 measurement efo:EFO_0020753 The determination of the amount of stanniocalcin-1 in a sample Annalisa Buniello true PMID:28240269 stanniocalcin-1 measurement efo:EFO_0020754 The determination of the amount of stem cell growth factor-alpha in a sample Annalisa Buniello true PMID:28240269 stem cell growth factor-alpha measurement efo:EFO_0020755 The determination of the amount of stress-induced-phosphoprotein 1 in a sample Annalisa Buniello true PMID:28240269 stress-induced-phosphoprotein 1 measurement efo:EFO_0020756 The determination of the amount of stromal cell-derived factor 1 in a sample Annalisa Buniello true PMID:28240269 stromal cell-derived factor 1 measurement efo:EFO_0020757 The determination of the amount of sumo-conjugating enzyme UBC9 in a sample Annalisa Buniello true PMID:28240269 sumo-conjugating enzyme UBC9 measurement efo:EFO_0020758 The determination of the amount of superoxide dismutase [Cu-Zn] in a sample Annalisa Buniello true PMID:28240269 superoxide dismutase [Cu-Zn] measurement efo:EFO_0020759 The determination of the amount of syntaxin-1a in a sample Annalisa Buniello true PMID:28240269 syntaxin-1a measurement efo:EFO_0020760 The determination of the amount of t-cell surface glycoprotein CD4 in a sample Annalisa Buniello true PMID:28240269 t-cell surface glycoprotein CD4 measurement efo:EFO_0020761 The determination of the amount of t-lymphocyte activation antigen CD80 in a sample Annalisa Buniello true PMID:28240269 t-lymphocyte activation antigen CD80 measurement efo:EFO_0020762 The determination of the amount of t-lymphocyte activation antigen CD86 in a sample Annalisa Buniello true PMID:28240269 t-lymphocyte activation antigen CD86 measurement efo:EFO_0020763 The determination of the amount of tartrate-resistant acid phosphatase type 5 in a sample Annalisa Buniello true PMID:28240269 tartrate-resistant acid phosphatase type 5 measurement efo:EFO_0020764 The determination of the amount of tata-box-binding protein in a sample Annalisa Buniello true PMID:28240269 tata-box-binding protein measurement efo:EFO_0020765 The determination of the amount of testican-1 in a sample Annalisa Buniello true PMID:28240269 testican-1 measurement efo:EFO_0020766 The determination of the amount of testican-2 in a sample Annalisa Buniello true PMID:28240269 testican-2 measurement efo:EFO_0020767 The determination of the amount of tgf-beta receptor type-2 in a sample Annalisa Buniello true PMID:28240269 tgf-beta receptor type-2 measurement efo:EFO_0020768 The determination of the amount of thrombin in a sample Annalisa Buniello true PMID:28240269 thrombin measurement efo:EFO_0020769 The determination of the amount of thrombopoietin receptor in a sample Annalisa Buniello true PMID:28240269 thrombopoietin receptor measurement efo:EFO_0020770 The determination of the amount of thrombospondin-1 in a sample Annalisa Buniello true PMID:28240269 thrombospondin-1 measurement efo:EFO_0020771 The determination of the amount of thrombospondin-4 in a sample Annalisa Buniello true PMID:28240269 thrombospondin-4 measurement efo:EFO_0020772 The determination of the amount of thymic stromal lymphopoietin in a sample Annalisa Buniello true PMID:28240269 thymic stromal lymphopoietin measurement efo:EFO_0020773 The determination of the amount of thymidine kinase, cytosolic in a sample Annalisa Buniello true PMID:28240269 thymidine kinase, cytosolic measurement efo:EFO_0020774 The determination of the amount of thymidylate synthase in a sample Annalisa Buniello true PMID:28240269 thymidylate synthase measurement efo:EFO_0020775 The determination of the amount of thyroid peroxidase in a sample Annalisa Buniello true PMID:28240269 thyroid peroxidase measurement efo:EFO_0020776 The determination of the amount of tissue-type plasminogen activator in a sample Annalisa Buniello true PMID:28240269 tissue-type plasminogen activator measurement efo:EFO_0020777 The determination of the amount of toll-like receptor 2 in a sample Annalisa Buniello true PMID:28240269 toll-like receptor 2 measurement efo:EFO_0020778 The determination of the amount of transcription factor IIIb 90 kda subunit in a sample Annalisa Buniello true PMID:28240269 transcription factor IIIb 90 kda subunit measurement efo:EFO_0020779 The determination of the amount of transforming growth factor beta receptor type 3 in a sample Annalisa Buniello true PMID:28240269 transforming growth factor beta receptor type 3 measurement efo:EFO_0020780 The determination of the amount of transforming growth factor beta-1 in a sample Annalisa Buniello true PMID:28240269 transforming growth factor beta-1 measurement efo:EFO_0020781 The determination of the amount of transforming growth factor beta-2 in a sample Annalisa Buniello true PMID:28240269 transforming growth factor beta-2 measurement efo:EFO_0020782 The determination of the amount of transforming growth factor beta-3 in a sample Annalisa Buniello true PMID:28240269 transforming growth factor beta-3 measurement efo:EFO_0020783 The determination of the amount of transketolase in a sample Annalisa Buniello true PMID:28240269 transketolase measurement efo:EFO_0020784 The determination of the amount of translationally-controlled tumor protein in a sample Annalisa Buniello true PMID:28240269 translationally-controlled tumor protein measurement efo:EFO_0020785 The determination of the amount of triosephosphate isomerase in a sample Annalisa Buniello true PMID:28240269 triosephosphate isomerase measurement efo:EFO_0020786 The determination of the amount of tropomyosin alpha-1 chain in a sample Annalisa Buniello true PMID:28240269 tropomyosin alpha-1 chain measurement efo:EFO_0020787 The determination of the amount of tropomyosin beta chain in a sample Annalisa Buniello true PMID:28240269 tropomyosin beta chain measurement efo:EFO_0020788 The determination of the amount of troponin i, cardiac muscle in a sample Annalisa Buniello true PMID:28240269 troponin i, cardiac muscle measurement efo:EFO_0020789 The determination of the amount of troponin i, fast skeletal muscle in a sample Annalisa Buniello true PMID:28240269 troponin i, fast skeletal muscle measurement efo:EFO_0020790 The determination of the amount of trypsin-1 in a sample Annalisa Buniello true PMID:28240269 trypsin-1 measurement efo:EFO_0020791 The determination of the amount of trypsin-3 in a sample Annalisa Buniello true PMID:28240269 trypsin-3 measurement efo:EFO_0020792 The determination of the amount of tryptase gamma in a sample Annalisa Buniello true PMID:28240269 tryptase gamma measurement efo:EFO_0020793 The determination of the amount of tumor necrosis factor ligand superfamily member 13B in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor ligand superfamily member 13B measurement efo:EFO_0020794 The determination of the amount of tumor necrosis factor ligand superfamily member 15 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor ligand superfamily member 15 measurement efo:EFO_0020795 The determination of the amount of tumor necrosis factor ligand superfamily member 18 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor ligand superfamily member 18 measurement efo:EFO_0020796 The determination of the amount of tumor necrosis factor ligand superfamily member 4 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor ligand superfamily member 4 measurement efo:EFO_0020797 The determination of the amount of tumor necrosis factor ligand superfamily member 6, soluble form in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor ligand superfamily member 6, soluble form measurement efo:EFO_0020798 The determination of the amount of tumor necrosis factor ligand superfamily member 9 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor ligand superfamily member 9 measurement efo:EFO_0020799 The determination of the amount of tumor necrosis factor receptor superfamily member 10A in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 10A measurement efo:EFO_0020800 The determination of the amount of tumor necrosis factor receptor superfamily member 11A in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 11A measurement efo:EFO_0020801 The determination of the amount of tumor necrosis factor receptor superfamily member 11B in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 11B measurement efo:EFO_0020802 The determination of the amount of tumor necrosis factor receptor superfamily member 12A in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 12A measurement efo:EFO_0020803 The determination of the amount of tumor necrosis factor receptor superfamily member 13B in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 13B measurement efo:EFO_0020804 The determination of the amount of tumor necrosis factor receptor superfamily member 13C in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 13C measurement efo:EFO_0020805 The determination of the amount of tumor necrosis factor receptor superfamily member 14 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 14 measurement efo:EFO_0020806 The determination of the amount of tumor necrosis factor receptor superfamily member 17 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 17 measurement efo:EFO_0020807 The determination of the amount of tumor necrosis factor receptor superfamily member 18 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 18 measurement efo:EFO_0020808 The determination of the amount of tumor necrosis factor receptor superfamily member 19 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 19 measurement efo:EFO_0020809 The determination of the amount of tumor necrosis factor receptor superfamily member 1A in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 1Ameasurement efo:EFO_0020810 The determination of the amount of tumor necrosis factor receptor superfamily member 21 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 21 measurement efo:EFO_0020811 The determination of the amount of tumor necrosis factor receptor superfamily member 25 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 25 measurement efo:EFO_0020812 The determination of the amount of tumor necrosis factor receptor superfamily member 27 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 27 measurement efo:EFO_0020813 The determination of the amount of tumor necrosis factor receptor superfamily member 3 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 3 measurement efo:EFO_0020814 The determination of the amount of tumor necrosis factor receptor superfamily member 4 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 4 measurement efo:EFO_0020815 The determination of the amount of tumor necrosis factor receptor superfamily member 6B in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 6B measurement efo:EFO_0020816 The determination of the amount of tumor necrosis factor receptor superfamily member 8 in a sample Annalisa Buniello true PMID:28240269 tumor necrosis factor receptor superfamily member 8 measurement efo:EFO_0020817 The determination of the amount of tumor-associated calcium signal transducer 2 in a sample Annalisa Buniello true PMID:28240269 tumor-associated calcium signal transducer 2 measurement efo:EFO_0020818 The determination of the amount of tyrosine-protein kinase ABL1 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase ABL1 measurement efo:EFO_0020819 The determination of the amount of tyrosine-protein kinase BTK in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase BTK measurement efo:EFO_0020820 The determination of the amount of tyrosine-protein kinase CSK in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase CSK measurement efo:EFO_0020821 The determination of the amount of tyrosine-protein kinase FER in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase FER measurement efo:EFO_0020822 The determination of the amount of tyrosine-protein kinase FGR in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase FGR measurement efo:EFO_0020823 The determination of the amount of tyrosine-protein kinase FYN in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase FYN measurement efo:EFO_0020824 The determination of the amount of tyrosine-protein kinase HCK in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase HCK measurement efo:EFO_0020825 The determination of the amount of tyrosine-protein kinase JAK2 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase JAK2 measurement efo:EFO_0020826 The determination of the amount of tyrosine-protein kinase LCK in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase LCK measurement efo:EFO_0020827 The determination of the amount of tyrosine-protein kinase LYN in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase lyn measurement efo:EFO_0020828 The determination of the amount of tyrosine-protein kinase LYN, isoform b in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase LYN, isoform b measurement efo:EFO_0020829 The determination of the amount of tyrosine-protein kinase receptor TYRO3 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase receptor TYRO3 measurement efo:EFO_0020830 The determination of the amount of tyrosine-protein kinase TEC in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase TEC measurement efo:EFO_0020831 The determination of the amount of tyrosine-protein kinase transmembrane receptor ROR1 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase transmembrane receptor ROR1 measurement efo:EFO_0020832 The determination of the amount of tyrosine-protein kinase YES in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase YES measurement efo:EFO_0020833 The determination of the amount of tyrosine-protein kinase ZAP-70 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein kinase ZAP-70 measurement efo:EFO_0020834 The determination of the amount of tyrosine-protein phosphatase non-receptor type 1 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein phosphatase non-receptor type 1 measurement efo:EFO_0020835 The determination of the amount of tyrosine-protein phosphatase non-receptor type 11 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein phosphatase non-receptor type 11 measurement efo:EFO_0020836 The determination of the amount of tyrosine-protein phosphatase non-receptor type 2 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein phosphatase non-receptor type 2 measurement efo:EFO_0020837 The determination of the amount of tyrosine-protein phosphatase non-receptor type 6 in a sample Annalisa Buniello true PMID:28240269 tyrosine-protein phosphatase non-receptor type 6 measurement efo:EFO_0020838 The determination of the amount of ubiquitin carboxyl-terminal hydrolase isozyme L1 in a sample Annalisa Buniello true PMID:28240269 ubiquitin carboxyl-terminal hydrolase isozyme L1 measurement efo:EFO_0020839 The determination of the amount of ubiquitin in a sample Annalisa Buniello true PMID:28240269 ubiquitin measurement efo:EFO_0020840 The determination of the amount of ubiquitin-conjugating enzyme E2 L3 in a sample Annalisa Buniello true PMID:28240269 ubiquitin-conjugating enzyme E2 L3 measurement efo:EFO_0020841 The determination of the amount of ubiquitin-conjugating enzyme E2 N in a sample Annalisa Buniello true PMID:28240269 ubiquitin-conjugating enzyme E2 N measurement efo:EFO_0020842 The determination of the amount of ubiquitin-fold modifier 1 in a sample Annalisa Buniello true PMID:28240269 ubiquitin-fold modifier 1 measurement efo:EFO_0020843 The determination of the amount of ubiquitin-fold modifier-conjugating enzyme 1 in a sample Annalisa Buniello true PMID:28240269 ubiquitin-fold modifier-conjugating enzyme 1 measurement efo:EFO_0020844 The determination of the amount of ubiquitin+1, truncated mutation for UBB in a sample Annalisa Buniello true PMID:28240269 ubiquitin+1, truncated mutation for UBB measurement efo:EFO_0020845 The determination of the amount of vacuolar protein sorting-associated protein VTA1 homolog in a sample Annalisa Buniello true PMID:28240269 vacuolar protein sorting-associated protein VTA1 homolog measurement efo:EFO_0020846 The determination of the amount of vascular cell adhesion protein 1 in a sample Annalisa Buniello true PMID:28240269 vascular cell adhesion protein 1 measurement efo:EFO_0020847 The determination of the amount of vascular endothelial growth factor A, isoform 121 in a sample Annalisa Buniello true PMID:28240269 vascular endothelial growth factor A, isoform 121 measurement efo:EFO_0020848 The determination of the amount of vascular endothelial growth factor C in a sample Annalisa Buniello true PMID:28240269 vascular endothelial growth factor C measurement efo:EFO_0020849 The determination of the amount of vasoactive intestinal peptide in a sample Annalisa Buniello true PMID:28240269 vasoactive intestinal peptide measurement efo:EFO_0020850 The determination of the amount of vitamin k-dependent protein S in a sample Annalisa Buniello true PMID:28240269 vitamin k-dependent protein S measurement efo:EFO_0020851 The determination of the amount of vps10 domain-containing receptor sorcs2 in a sample Annalisa Buniello true PMID:28240269 vps10 domain-containing receptor sorcs2 measurement efo:EFO_0020852 The determination of the amount of wap, kazal, immunoglobulin, kunitz and ntr domain-containing protein 1 in a sample Annalisa Buniello true PMID:28240269 wap, kazal, immunoglobulin, kunitz and ntr domain-containing protein 1 measurement efo:EFO_0020853 The determination of the amount of wnt inhibitory factor 1 in a sample Annalisa Buniello true PMID:28240269 wnt inhibitory factor 1 measurement efo:EFO_0020854 The determination of the amount of x-linked interleukin-1 receptor accessory protein-like 2 in a sample Annalisa Buniello true PMID:28240269 x-linked interleukin-1 receptor accessory protein-like 2 measurement efo:EFO_0020855 The determination of the amount of x-ray repair cross-complementing protein 6 in a sample Annalisa Buniello true PMID:28240269 x-ray repair cross-complementing protein 6 measurement efo:EFO_0020856 The determination of the amount of xaa-pro aminopeptidase 1 in a sample Annalisa Buniello true PMID:28240269 xaa-pro aminopeptidase 1 measurement efo:EFO_0020857 Quantification of the change in very low density lipoprotein cholesterol levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 very low density lipoprotein cholesterol change measurement efo:EFO_0020859 Quantification of the change in lipid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 lipid change measurement efo:EFO_0020860 Quantification of the circulating pattern recognition receptor CD14 in a sample such as blood plasma. Elizabeth Lewis Zoe May Pendlington 2022-02-04T09:58:22Z true PMID:33910371 cluster of differentiation 14 sCD14 soluble CD14 measurement efo:EFO_0020861 Quantification of the levels of ANGPTL8 protein in a sample, typically blood plasma. Elliot Sollis Zoe May Pendlington 2022-02-04T10:00:08Z true PMID:33619548 ANGPTL8 measurement efo:EFO_0020863 Quantification of some major cardiovascular event such as cardiovascular death, myocardial infarction, atherothrombotic stroke and repeated revascularization. Annalisa Buniello Zoe May Pendlington 2022-02-04T10:02:48Z true PMID:34158603 MACE major adverse cardiovascular event measurement efo:EFO_0020864 Quantification of the volume of the cerebellum. Santhi Ramachandran Zoe May Pendlington 2022-02-14T09:18:56Z true PMID:35079123 cerebellar volume measurement efo:EFO_0020865 Measurement of some parts of the aorta, including ascending aorta distensibility and area. Annalisa Buniello Zoe May Pendlington 2022-02-14T09:22:02Z true aortic diagnostic technique aortic measurement efo:EFO_0020866 Quantification of the change in high density lipoprotein particle size levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 high density lipoprotein particle size change measurement efo:EFO_0020867 Quantification of the change in remnant cholesterol levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 remnant cholesterol change measurement efo:EFO_0020868 Quantification of the change in diglyceride levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 diglyceride change measurement efo:EFO_0020869 Quantification of the change in glycerophospholipid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 glycerophospholipid change measurement efo:EFO_0020870 Quantification of the change in choline levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 choline change measurement efo:EFO_0020871 Quantification of the change in phosphatidylcholine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 phosphatidylcholine change measurement efo:EFO_0020872 Quantification of the change in sphingomyelin levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 sphingomyelin change measurement efo:EFO_0020873 Quantification of the change in apolipoprotein A 1 levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 apolipoprotein A 1 change measurement efo:EFO_0020874 Quantification of the change in apolipoprotein B levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 apolipoprotein B change measurement efo:EFO_0020875 Quantification of the change in fatty acid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 fatty acid change measurement efo:EFO_0020876 Quantification of the change in docosahexaenoic acid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 docosahexaenoic acid change measurement efo:EFO_0020877 Quantification of the change in linoleic acid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 linoleic acid change measurement efo:EFO_0020878 Quantification of the change in omega-3 polyunsaturated fatty acid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 omega-3 polyunsaturated fatty acid change measurement efo:EFO_0020879 Quantification of the change in omega-6 polyunsaturated fatty acid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 omega-6 polyunsaturated fatty acid change measurement efo:EFO_0020880 Quantification of the change in polyunsaturated fatty acid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 polyunsaturated fatty acid change measurement efo:EFO_0020881 Quantification of the change in glucose levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 glucose change measurement efo:EFO_0020882 Quantification of the change in lactate levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 lactate change measurement efo:EFO_0020883 Quantification of the change in citrate levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 citrate change measurement efo:EFO_0020884 Quantification of the change in alanine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 alanine change measurement efo:EFO_0020885 Quantification of the change in glutamine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 glutamine change measurement efo:EFO_0020886 Quantification of the change in histidine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 histidine change measurement efo:EFO_0020887 Quantification of the change in isoleucine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 isoleucine change measurement efo:EFO_0020888 Quantification of the change in leucine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 leucine change measurement efo:EFO_0020889 Quantification of the change in valine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 valine change measurement efo:EFO_0020890 Quantification of the change in phenylalanine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 phenylalanine change measurement efo:EFO_0020891 Quantification of the change in tyrosine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 tyrosine change measurement efo:EFO_0020892 Quantification of the change in acetate levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 acetate change measurement efo:EFO_0020893 Quantification of the change in 3-hydroxybutyrate levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 3-hydroxybutyrate change measurement efo:EFO_0020894 Quantification of the change in creatinine levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 creatinine change measurement efo:EFO_0020895 Quantification of the change in serum albumin levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 serum albumin change measurement efo:EFO_0020896 Quantification of the change in glycoprotein levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 glycoprotein change measurement efo:EFO_0020897 Quantification of some aspect of citrus consumption such as frequency or quantity. Elizabeth Lewis Zoe May Pendlington 2022-03-02T10:38:53Z true citrus intake measurement efo:EFO_0020899 Quantification of the expression of FLG in a cell, tissue or sample. Elizabeth Lewis Zoe May Pendlington 2022-03-02T09:22:57Z true FLG gene expression measurement filaggrin gene expression measurement efo:EFO_0020900 Quantification of some aspect of thigh muscle fat infiltration. Zoe May Pendlington 2023-04-14T12:03:20Z thigh muscle fat infiltration measurement Quantification of some aspect of thigh muscle fat infiltration. PMID:36402844 efo:EFO_0020901 Quantification of the change in chylomicron levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 chylomicron change measurement efo:EFO_0020902 Two main types of recessive c phenotypes are recognized: (1) the nonsecretor classic Bombay type (h null and se (FUT2; 182100) null) with H deficiency of both red cells and saliva, and (2) the secretor Bombay type (h null, Se heterozygous) with H deficiency in red cells but normal ABH in secretions. The latter has been designated para-Bombay phenotype. Under this 2-locus model, the H blood group locus determines expression of the H antigen (as well as the A and/or B antigens) in the erythroid lineage, whereas the SE locus controls H expression (and thus A or B antigen expression) in a variety of secretory epithelia and in saliva. Bombay and para-Bombay individuals display no apparent deleterious phenotype except in circumstances requiring blood transfusion, wherein they are cross-match incompatible with all donors except other H-deficient individuals. Zoe May Pendlington 2022-01-31T14:31:44Z OMIM:616754 bombay phenotype efo:EFO_0020903 Quantification of the change in phospholipid levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 phospholipid change measurement efo:EFO_0020904 Quantification of the change in esterified cholesterol levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 esterified cholesterol change measurement efo:EFO_0020905 Quantification of the change in free cholesterol levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 free cholesterol change measurement efo:EFO_0020906 Quantification of the change in intermediate density lipoprotein levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 intermediate density lipoprotein change measurement efo:EFO_0020907 Quantification of the change in very low density lipoprotein particle size levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 very low density lipoprotein particle size change measurement efo:EFO_0020908 Quantification of the change in low density lipoprotein particle size levels in an individual over time, e.g. over the course of several hours after a high-fat meal. Santhi Ramachandran true PMID:34610981 low density lipoprotein particle size change measurement efo:EFO_0020929 Increased time for the interval between the beginning of the P wave to the beginning of the QRS complex as measured by electrocardiogram (EKG) Nicolas Bosc Zoe May Pendlington 2022-03-14T15:52:59Z MedDRA:10053657 electrocardiogram PR prolongation efo:EFO_0020931 Quantification of some aspect of the posterior thigh muscle volume. Zoe May Pendlington 2023-04-14T12:04:15Z true posterior thigh muscle volume Quantification of some aspect of the posterior thigh muscle volume. PMID:36402844 efo:EFO_0020932 Quantification of the amount of galectin-1 in a sample. Elizabeth Lewis Zoe May Pendlington 2022-03-21T09:44:17Z true PMID:34743218 galectin-1 measurement efo:EFO_0020933 A measurement of HIV reservoir in a sample. Elizabeth Lewis Zoe May Pendlington 2022-03-21T12:20:06Z true PMID:34781942 HIV resevoir measurement efo:EFO_0020934 Quantification of some aspect of the posterior thigh muscle fat infiltration. Zoe May Pendlington 2023-04-14T12:04:45Z true posterior thigh muscle fat infiltration measurement Quantification of some aspect of the posterior thigh muscle fat infiltration. PMID:36402844 efo:EFO_0020935 Quantification of some aspect of the anterior thigh muscle volume. Zoe May Pendlington 2023-04-14T12:05:29Z true anterior thigh muscle volume Quantification of some aspect of the anterior thigh muscle volume. PMID:36402844 efo:EFO_0020936 Quantification of some aspect of the anterior thigh muscle fat infiltration. Zoe May Pendlington 2023-04-14T12:05:54Z true anterior thigh muscle fat infiltration measurement Quantification of some aspect of the anterior thigh muscle fat infiltration. PMID:36402844 efo:EFO_0020938 The sphericity index is defined as the ratio of LV short axis length divided by LV long axis length. Zoe May Pendlington 2023-05-19T09:19:14Z left ventricle sphericity index The sphericity index is defined as the ratio of LV short axis length divided by LV long axis length. PMID:36996817 efo:EFO_0020940 An assay that measures the ability of platelets to aggregate and promote clotting in a sample of blood. Zoe May Pendlington 2022-04-14T09:01:21Z PMID:34904537 SNOMEDCT:80329005 platelet function test efo:EFO_0020941 The quantification of lysophosphatidylcholine 15:0 levels in a sample. Zoe May Pendlington 2022-04-14T09:05:42Z true PMID:34801968 LysoPC(15:0) lysophosphatidylcholine 15:0 measurement efo:EFO_0020942 Quantification of propionylcarnitine in a sample. Zoe May Pendlington 2022-04-14T09:09:15Z true PMID:34801968 propionylcarnitine measurement efo:EFO_0020943 Quantification of the ratio of cholesterol to total lipids in a sample. Elizabeth Lewis Zoe May Pendlington 2022-04-14T10:29:54Z true PMID:35213538 cholesterol:total lipids ratio efo:EFO_0020944 Quantification of the ratio of cholesteryl esters to total lipids in a sample. Elizabeth Lewis Zoe May Pendlington 2022-04-14T10:30:35Z true PMID:35213538 cholesteryl esters:total lipids ratio efo:EFO_0020945 Quantification of the ratio of free cholesterol to total lipids in a sample. Elizabeth Lewis Zoe May Pendlington 2022-04-14T10:31:59Z true PMID:35213538 free cholesterol:total lipids ratio efo:EFO_0020946 Quantification of the ratio of phospholipids to total lipids in a sample. Elizabeth Lewis Zoe May Pendlington 2022-04-14T10:32:37Z true PMID:35213538 phospholipids:total lipids ratio efo:EFO_0020947 Quantification of the ratio of triglycerides to total lipids in a sample. Elizabeth Lewis Zoe May Pendlington 2022-04-14T10:33:18Z true PMID:35213538 triglycerides:total lipids ratio efo:EFO_0020948 Quantification of the amount of salicylic acid in a sample. Zoe May Pendlington 2022-04-14T11:39:57Z true PMID:34836419 salicylic acid measurement efo:EFO_0020949 Quantification of the number of known clonal hematopoiesis mutations in a sample. Zoe May Pendlington 2022-04-14T12:06:26Z true PMID:34815255 clonal hematopoiesis mutation measurement efo:EFO_0020950 Quantification of the amount of apolipoprotein C in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:44:23Z true PMID:35264221 apolipoprotein C measurement efo:EFO_0020951 Quantification of the amount of apolipoprotein H in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:45:11Z true PMID:35264221 apolipoprotein H measurement efo:EFO_0020952 Quantification of the amount of dopamine beta-hydroxylase in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:46:42Z true PMID:35264221 DPH measurement dopamine beta-hydroxylase measurement efo:EFO_0020953 Quantification of the amount of omentin in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:53:08Z true PMID:35264221 intelectin-1 measurement omentin measurement efo:EFO_0020954 Quantification of the amount of pigement epithleium-derived factor in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:54:41Z true NCIT:C101645 PMID:35264221 pigement epithleium-derived factor (PEDF) measurement efo:EFO_0020955 Quantification of the amount of beta-microseminoprotein in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:55:20Z true PMID:35264221 PSP94 measurement beta-microseminoprotein measurement efo:EFO_0020956 Quantification of the amount of pancreatic secretory trypsin inhibitor protein in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:55:49Z true PMID:35264221 TATI measurement serine protease inhibitor Kazal-type 1 measurement pancreatic secretory trypsin inhibitor protein measurement efo:EFO_0020957 Quantification of the amount of tetranectin in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-14T16:56:45Z true PMID:35264221 C-type lectin domain family 3 member B measurement tetranectin measurement efo:EFO_0020958 Quantification of the amount of total brassicasterol in a sample. Brassicasterol is a phytosterol whose chemical structure is similar to that of cholesterol. Arwa Ibrahim Zoe May Pendlington 2022-04-16T13:18:27Z true PMID:35013273 total brassicasterol measurement efo:EFO_0020959 Quantification of the amount of free brassicasterol in a sample. Brassicasterol is a phytosterol whose chemical structure is similar to that of cholesterol. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:07:00Z true PMID:35013273 free brassicasterol measurement efo:EFO_0020960 Quantification of the amount of esterified brassicasterol in a sample. Brassicasterol is a phytosterol whose chemical structure is similar to that of cholesterol. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:08:13Z true PMID:35013273 esterified brassicasterol measurement efo:EFO_0020961 Quantification of the amount of free lanosterol in a sample. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:09:33Z true PMID:35013273 free lanosterol measurement efo:EFO_0020962 Quantification of the amount of total campesterol in a sample. Campesterol is a phytosterol (molecular formula C28H48O) whose chemical structure is similar to that of cholesterol. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:10:09Z true PMID:35013273 total campesterol measurement efo:EFO_0020963 Quantification of the amount of free campesterol in a sample. Campesterol is a phytosterol (molecular formula C28H48O) whose chemical structure is similar to that of cholesterol. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:10:46Z true PMID:35013273 free campesterol measurement efo:EFO_0020964 Quantification of the amount of esterified campesterol in a sample. Campesterol is a phytosterol (molecular formula C28H48O) whose chemical structure is similar to that of cholesterol. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:11:59Z true PMID:35013273 esterified campesterol measurement efo:EFO_0020965 Quantification of the amount of total sitosterol in a sample. Sitosterol is a member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:13:06Z true PMID:35013273 total sitosterol measurement efo:EFO_0020966 Quantification of the amount of free sitosterol in a sample. Sitosterol is a member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:13:31Z true PMID:35013273 free sitosterol measurement efo:EFO_0020967 Quantification of the amount of esterified sitosterol in a sample. Sitosterol is a member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:14:23Z true PMID:35013273 esterified sitosterol measurement efo:EFO_0020968 Quantification of the amount of total stigmasterol in a sample. Stigmasterol is a 3beta-sterol that consists of 3beta-hydroxystigmastane having double bonds at the 5,6- and 22,23-positions. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:15:01Z true PMID:35013273 total stigmasterol measurement efo:EFO_0020969 Quantification of the amount of free stigmasterol in a sample. Stigmasterol is a 3beta-sterol that consists of 3beta-hydroxystigmastane having double bonds at the 5,6- and 22,23-positions. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:15:43Z true PMID:35013273 free stigmasterol measurement efo:EFO_0020970 Quantification of the amount of esterified stigmasterol in a sample. Stigmasterol is a 3beta-sterol that consists of 3beta-hydroxystigmastane having double bonds at the 5,6- and 22,23-positions. Arwa Ibrahim Zoe May Pendlington 2022-04-19T08:16:07Z true PMID:35013273 esterified stigmasterol measurement efo:EFO_0020977 A measure of occupational attainment through eg. hierarchical categorisation using the Standard Occupational Classification (SOC) system. Zoe May Pendlington 2022-04-29T09:18:03Z true PMID:34613391 occupational attainment efo:EFO_0020980 Exposure to radioactive materials or ionizing radiation. Zoe May Pendlington 2022-04-29T13:45:14Z true ICD10:Z92.3 NCIT:C61398 radiation exposure efo:EFO_0020990 Quanitification of argininine levels in a sample. Zoe May Pendlington 2022-05-25T11:57:27Z true PMID:35016259 arginine measurement efo:EFO_0020991 Zoe May Pendlington 2022-05-25T12:00:29Z true PMID:35016259 Quantification of ethanolamine in a sample. ethanolamine measurement efo:EFO_0020992 Quantification of alpha-amino-N-butyric acid in a sample. Zoe May Pendlington 2022-05-25T12:01:08Z true PMID:35016259 alpha-amino-N-butyric acid measurement efo:EFO_0020994 Quantification of the amount of cancer antigen 50 in a sample, typically serum. Zoe May Pendlington 2022-05-25T15:23:23Z PMID:35144566 CA 50 measurement cancer antigen 50 measurement efo:EFO_0020995 Quantification of the amount of squamous cell carcinoma antigen in a sample. Zoe May Pendlington 2022-05-25T15:24:03Z PMID:35144566 SCCA measurement squamous cell carcinoma antigen measurement efo:EFO_0020999 Quantification of the amount of 2-hydroxybutyrate in a sample. Elizabeth Lewis true PMID:24816252 2-hydroxybutyrate measurement efo:EFO_0021000 Quantification of the amount of cysteine in a sample. Elizabeth Lewis true PMID:24816252 cysteine measurement efo:EFO_0021001 Quantification of the amount of cysteine-glutathione disulfide in a sample. Elizabeth Lewis true PMID:24816252 cysteine-glutathione disulfide measurement efo:EFO_0021002 Quantification of the amount of N-acetylglycine in a sample. Elizabeth Lewis true PMID:24816252 N-acetylglycine measurement efo:EFO_0021003 Quantification of the amount of 4-acetamidobutanoate in a sample. Elizabeth Lewis true PMID:24816252 4-acetamidobutanoate measurement efo:EFO_0021004 Quantification of the amount of 3-methylhistidine in a sample. Elizabeth Lewis true PMID:24816252 3-methylhistidine measurement efo:EFO_0021005 Quantification of the amount of glutaroyl carnitine in a sample. Elizabeth Lewis true PMID:24816252 glutaroyl carnitine measurement efo:EFO_0021006 Quantification of the amount of pipecolate in a sample. Elizabeth Lewis true PMID:24816252 pipecolate measurement efo:EFO_0021007 Quantification of the amount of 3-3-hydroxyphenylpropionate in a sample. Elizabeth Lewis true PMID:24816252 3-3-hydroxyphenylpropionate measurement efo:EFO_0021008 Quantification of the amount of 3- 4-hydroxyphenyl lactate in a sample. Elizabeth Lewis true PMID:24816252 3- 4-hydroxyphenyl lactate measurement efo:EFO_0021009 Quantification of the amount of 3-methoxytyrosine in a sample. Elizabeth Lewis true PMID:24816252 3-methoxytyrosine measurement efo:EFO_0021010 Quantification of the amount of 3-phenylpropionate hydrocinnamate in a sample. Elizabeth Lewis true PMID:24816252 3-phenylpropionate hydrocinnamate measurement efo:EFO_0021011 Quantification of the amount of phenol sulfate in a sample. Elizabeth Lewis true PMID:24816252 phenol sulfate measurement efo:EFO_0021012 Quantification of the amount of phenylacetate in a sample. Elizabeth Lewis true PMID:24816252 phenylacetate measurement efo:EFO_0021013 Quantification of the amount of phenylacetylglutamine in a sample. Elizabeth Lewis true PMID:24816252 phenylacetylglutamine measurement efo:EFO_0021014 Quantification of the amount of C-glycosyltryptophan in a sample. Elizabeth Lewis true PMID:24816252 C-glycosyltryptophan measurement efo:EFO_0021015 Quantification of the amount of indoleacetate in a sample. Elizabeth Lewis true PMID:24816252 indoleacetate measurement efo:EFO_0021016 Quantification of the amount of indolepropionate in a sample. Elizabeth Lewis true PMID:24816252 indolepropionate measurement efo:EFO_0021017 Quantification of the amount of tryptophan betaine in a sample. Elizabeth Lewis true PMID:24816252 tryptophan betaine measurement efo:EFO_0021018 Quantification of the amount of homocitrulline in a sample. Elizabeth Lewis true PMID:24816252 homocitrulline measurement efo:EFO_0021019 Quantification of the amount of 2-methylbutyroylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 2-methylbutyroylcarnitine measurement efo:EFO_0021020 Quantification of the amount of 3-methyl-2-oxobutyrate in a sample. Elizabeth Lewis true PMID:24816252 3-methyl-2-oxobutyrate measurement efo:EFO_0021021 Quantification of the amount of 3-methyl-2-oxovalerate in a sample. Elizabeth Lewis true PMID:24816252 3-methyl-2-oxovalerate measurement efo:EFO_0021022 Quantification of the amount of 4-methyl-2-oxopentanoate in a sample. Elizabeth Lewis true PMID:24816252 4-methyl-2-oxopentanoate measurement efo:EFO_0021023 Quantification of the amount of isobutyrylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 isobutyrylcarnitine measurement efo:EFO_0021024 Quantification of the amount of levulinate 4-oxovalerate in a sample. Elizabeth Lewis true PMID:24816252 levulinate 4-oxovalerate measurement efo:EFO_0021025 Quantification of the amount of erythronate in a sample. Elizabeth Lewis true PMID:24816252 erythronate measurement efo:EFO_0021026 Quantification of the amount of erythrose in a sample. Elizabeth Lewis true PMID:24816252 erythrose measurement efo:EFO_0021027 Quantification of the amount of mannitol in a sample. Elizabeth Lewis true PMID:24816252 mannitol measurement efo:EFO_0021028 Quantification of the amount of 1,6-anhydroglucose in a sample. Elizabeth Lewis true PMID:24816252 1,6-anhydroglucose measurement efo:EFO_0021029 Quantification of the amount of glycerate in a sample. Elizabeth Lewis true PMID:24816252 glycerate measurement efo:EFO_0021030 Quantification of the amount of arabinose in a sample. Elizabeth Lewis true PMID:24816252 arabinose measurement efo:EFO_0021031 Quantification of the amount of threitol in a sample. Elizabeth Lewis true PMID:24816252 threitol measurement efo:EFO_0021032 Quantification of the amount of threonate in a sample. Elizabeth Lewis true PMID:24816252 threonate measurement efo:EFO_0021033 Quantification of the amount of biliverdin in a sample. Elizabeth Lewis true PMID:24816252 biliverdin measurement efo:EFO_0021034 Quantification of the amount of pantothenate in a sample. Elizabeth Lewis true PMID:24816252 pantothenate measurement efo:EFO_0021035 Quantification of the amount of acetylphosphate in a sample. Elizabeth Lewis true PMID:24816252 acetylphosphate measurement efo:EFO_0021036 Quantification of the amount of taurolithocholate 3-sulfate in a sample. Elizabeth Lewis true PMID:24816252 taurolithocholate 3-sulfate measurement efo:EFO_0021037 Quantification of the amount of 3-dehydrocarnitine in a sample. Elizabeth Lewis true PMID:24816252 3-dehydrocarnitine measurement efo:EFO_0021038 Quantification of the amount of acetylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 acetylcarnitine measurement efo:EFO_0021039 Quantification of the amount of decanoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 decanoylcarnitine measurement efo:EFO_0021040 Quantification of the amount of hexanoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 hexanoylcarnitine measurement efo:EFO_0021041 Quantification of the amount of laurylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 laurylcarnitine measurement efo:EFO_0021042 Quantification of the amount of octanoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 octanoylcarnitine measurement efo:EFO_0021043 Quantification of the amount of oleoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 oleoylcarnitine measurement efo:EFO_0021044 Quantification of the amount of palmitoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 palmitoylcarnitine measurement efo:EFO_0021045 Quantification of the amount of stearoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 stearoylcarnitine measurement efo:EFO_0021046 Quantification of the amount of dihomo-linolenate 20:3n3 or n6 in a sample. Elizabeth Lewis true PMID:24816252 dihomo-linolenate 20:3n3 or n6 measurement efo:EFO_0021047 Quantification of the amount of docosahexaenoate DHA; 22:6n3 in a sample. Elizabeth Lewis true PMID:24816252 docosahexaenoate DHA; 22:6n3 measurement efo:EFO_0021048 Quantification of the amount of docosapentaenoate n3 DPA; 22:5n3 in a sample. Elizabeth Lewis true PMID:24816252 docosapentaenoate n3 DPA; 22:5n3 measurement efo:EFO_0021049 Quantification of the amount of eicosapentaenoate EPA; 20:5n3 in a sample. Elizabeth Lewis true PMID:24816252 eicosapentaenoate EPA; 20:5n3 measurement efo:EFO_0021050 Quantification of the amount of linolenate [alpha or gamma; 18:3n3 or 6] in a sample. Elizabeth Lewis true PMID:24816252 linolenate [alpha or gamma; 18:3n3 or 6] measurement efo:EFO_0021051 Quantification of the amount of isovalerate in a sample. Elizabeth Lewis true PMID:24816252 isovalerate measurement efo:EFO_0021052 Quantification of the amount of 15-methylpalmitate isobar with 2-methylpalmitate in a sample. Elizabeth Lewis true PMID:24816252 15-methylpalmitate isobar with 2-methylpalmitate measurement efo:EFO_0021053 Quantification of the amount of 3-carboxy-4-methyl-5-propyl-2-furanpropanoate CMPF in a sample. Elizabeth Lewis true PMID:24816252 3-carboxy-4-methyl-5-propyl-2-furanpropanoate CMPF measurement efo:EFO_0021054 Quantification of the amount of dodecanedioate in a sample. Elizabeth Lewis true PMID:24816252 dodecanedioate measurement efo:EFO_0021055 Quantification of the amount of hexadecanedioate in a sample. Elizabeth Lewis true PMID:24816252 hexadecanedioate measurement efo:EFO_0021056 Quantification of the amount of octadecanedioate in a sample. Elizabeth Lewis true PMID:24816252 octadecanedioate measurement efo:EFO_0021057 Quantification of the amount of tetradecanedioate in a sample. Elizabeth Lewis true PMID:24816252 tetradecanedioate measurement efo:EFO_0021058 Quantification of the amount of n-Butyl Oleate in a sample. Elizabeth Lewis true PMID:24816252 n-Butyl Oleate measurement efo:EFO_0021059 Quantification of the amount of 2-hydroxystearate in a sample. Elizabeth Lewis true PMID:24816252 2-hydroxystearate measurement efo:EFO_0021060 Quantification of the amount of 10-heptadecenoate 17:1n7 in a sample. Elizabeth Lewis true PMID:24816252 10-heptadecenoate 17:1n7 measurement efo:EFO_0021061 Quantification of the amount of 10-nonadecenoate 19:1n9 in a sample. Elizabeth Lewis true PMID:24816252 10-nonadecenoate 19:1n9 measurement efo:EFO_0021062 Quantification of the amount of adrenate 22:4n6 in a sample. Elizabeth Lewis true PMID:24816252 adrenate 22:4n6 measurement efo:EFO_0021063 Quantification of the amount of arachidonate 20:4n6 in a sample. Elizabeth Lewis true PMID:24816252 arachidonate 20:4n6 measurement efo:EFO_0021064 Quantification of the amount of dihomo-linoleate 20:2n6 in a sample. Elizabeth Lewis true PMID:24816252 dihomo-linoleate 20:2n6 measurement efo:EFO_0021065 Quantification of the amount of eicosenoate 20:1n9 or 11 in a sample. Elizabeth Lewis true PMID:24816252 eicosenoate 20:1n9 or 11 measurement efo:EFO_0021066 Quantification of the amount of margarate 17:0 in a sample. Elizabeth Lewis true PMID:24816252 margarate 17:0 measurement efo:EFO_0021067 Quantification of the amount of myristate 14:0 in a sample. Elizabeth Lewis true PMID:24816252 myristate 14:0 measurement efo:EFO_0021068 Quantification of the amount of myristoleate 14:1n5 in a sample. Elizabeth Lewis true PMID:24816252 myristoleate 14:1n5 measurement efo:EFO_0021069 Quantification of the amount of nonadecanoate 19:0 in a sample. Elizabeth Lewis true PMID:24816252 nonadecanoate 19:0 measurement efo:EFO_0021070 Quantification of the amount of oleate 18:1n9 in a sample. Elizabeth Lewis true PMID:24816252 oleate 18:1n9 measurement efo:EFO_0021071 Quantification of the amount of palmitate 16:0 in a sample. Elizabeth Lewis true PMID:24816252 palmitate 16:0 measurement efo:EFO_0021072 Quantification of the amount of palmitoleate 16:1n7 in a sample. Elizabeth Lewis true PMID:24816252 palmitoleate 16:1n7 measurement efo:EFO_0021073 Quantification of the amount of pentadecanoate 15:0 in a sample. Elizabeth Lewis true PMID:24816252 pentadecanoate 15:0 measurement efo:EFO_0021074 Quantification of the amount of stearate 18:0 in a sample. Elizabeth Lewis true PMID:24816252 stearate 18:0 measurement efo:EFO_0021075 Quantification of the amount of stearidonate 18:4n3 in a sample. Elizabeth Lewis true PMID:24816252 stearidonate 18:4n3 measurement efo:EFO_0021076 Quantification of the amount of 1-arachidonoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-arachidonoylglycerophosphocholine measurement efo:EFO_0021077 Quantification of the amount of 1-arachidonoylglycerophosphoethanolamine in a sample. Elizabeth Lewis true PMID:24816252 1-arachidonoylglycerophosphoethanolamine measurement efo:EFO_0021078 Quantification of the amount of 1-arachidonoylglycerophosphoinositol in a sample. Elizabeth Lewis true PMID:24816252 1-arachidonoylglycerophosphoinositol measurement efo:EFO_0021079 Quantification of the amount of 1-docosahexaenoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-docosahexaenoylglycerophosphocholine measurement efo:EFO_0021080 Quantification of the amount of 1-eicosadienoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-eicosadienoylglycerophosphocholine measurement efo:EFO_0021081 Quantification of the amount of 1-eicosatrienoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-eicosatrienoylglycerophosphocholine measurement efo:EFO_0021082 Quantification of the amount of 1-heptadecanoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-heptadecanoylglycerophosphocholine measurement efo:EFO_0021083 Quantification of the amount of 1-linoleoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-linoleoylglycerophosphocholine measurement efo:EFO_0021084 Quantification of the amount of 1-linoleoylglycerophosphoethanolamine in a sample. Elizabeth Lewis true PMID:24816252 1-linoleoylglycerophosphoethanolamine measurement efo:EFO_0021085 Quantification of the amount of 1-myristoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-myristoylglycerophosphocholine measurement efo:EFO_0021086 Quantification of the amount of 1-oleoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-oleoylglycerophosphocholine measurement efo:EFO_0021087 Quantification of the amount of 1-oleoylglycerophosphoethanolamine in a sample. Elizabeth Lewis true PMID:24816252 1-oleoylglycerophosphoethanolamine measurement efo:EFO_0021088 Quantification of the amount of 1-palmitoleoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-palmitoleoylglycerophosphocholine measurement efo:EFO_0021089 Quantification of the amount of 1-palmitoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-palmitoylglycerophosphocholine measurement efo:EFO_0021090 Quantification of the amount of 1-palmitoylglycerophosphoethanolamine in a sample. Elizabeth Lewis true PMID:24816252 1-palmitoylglycerophosphoethanolamine measurement efo:EFO_0021091 Quantification of the amount of 1-palmitoylglycerophosphoinositol in a sample. Elizabeth Lewis true PMID:24816252 1-palmitoylglycerophosphoinositol measurement efo:EFO_0021092 Quantification of the amount of 1-stearoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 1-stearoylglycerophosphocholine measurement efo:EFO_0021093 Quantification of the amount of 1-stearoylglycerophosphoethanolamine in a sample. Elizabeth Lewis true PMID:24816252 1-stearoylglycerophosphoethanolamine measurement efo:EFO_0021094 Quantification of the amount of 1-stearoylglycerophosphoinositol in a sample. Elizabeth Lewis true PMID:24816252 1-stearoylglycerophosphoinositol measurement efo:EFO_0021095 Quantification of the amount of 2-linoleoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 2-linoleoylglycerophosphocholine measurement efo:EFO_0021096 Quantification of the amount of 2-oleoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 2-oleoylglycerophosphocholine measurement efo:EFO_0021097 Quantification of the amount of 2-palmitoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 2-palmitoylglycerophosphocholine measurement efo:EFO_0021098 Quantification of the amount of 2-stearoylglycerophosphocholine in a sample. Elizabeth Lewis true PMID:24816252 2-stearoylglycerophosphocholine measurement efo:EFO_0021099 Quantification of the amount of 10-undecenoate 11:1n1 in a sample. Elizabeth Lewis true PMID:24816252 10-undecenoate 11:1n1 measurement efo:EFO_0021100 Quantification of the amount of 5-dodecenoate 12:1n7 in a sample. Elizabeth Lewis true PMID:24816252 5-dodecenoate 12:1n7 measurement efo:EFO_0021101 Quantification of the amount of caprate 10:0 in a sample. Elizabeth Lewis true PMID:24816252 caprate 10:0 measurement efo:EFO_0021102 Quantification of the amount of caproate 6:0 in a sample. Elizabeth Lewis true PMID:24816252 caproate 6:0 measurement efo:EFO_0021103 Quantification of the amount of caprylate 8:0 in a sample. Elizabeth Lewis true PMID:24816252 caprylate 8:0 measurement efo:EFO_0021104 Quantification of the amount of heptanoate 7:0 in a sample. Elizabeth Lewis true PMID:24816252 heptanoate 7:0 measurement efo:EFO_0021105 Quantification of the amount of laurate 12:0 in a sample. Elizabeth Lewis true PMID:24816252 laurate 12:0 measurement efo:EFO_0021106 Quantification of the amount of pelargonate 9:0 in a sample. Elizabeth Lewis true PMID:24816252 pelargonate 9:0 measurement efo:EFO_0021107 Quantification of the amount of undecanoate 11:0 in a sample. Elizabeth Lewis true PMID:24816252 undecanoate 11:0 measurement efo:EFO_0021108 Quantification of the amount of 1-linoleoylglycerol 1-monolinolein in a sample. Elizabeth Lewis true PMID:24816252 1-linoleoylglycerol 1-monolinolein measurement efo:EFO_0021109 Quantification of the amount of 1-oleoylglycerol 1-monoolein in a sample. Elizabeth Lewis true PMID:24816252 1-oleoylglycerol 1-monoolein measurement efo:EFO_0021110 Quantification of the amount of 1-palmitoylglycerol 1-monopalmitin in a sample. Elizabeth Lewis true PMID:24816252 1-palmitoylglycerol 1-monopalmitin measurement efo:EFO_0021111 Quantification of the amount of 1-stearoylglycerol 1-monostearin in a sample. Elizabeth Lewis true PMID:24816252 1-stearoylglycerol 1-monostearin measurement efo:EFO_0021112 Quantification of the amount of valerate in a sample. Elizabeth Lewis true PMID:24816252 valerate measurement efo:EFO_0021113 Quantification of the amount of 4-androsten-3beta,17beta-diol disulfate 1 in a sample. Elizabeth Lewis true PMID:24816252 4-androsten-3beta,17beta-diol disulfate 1 measurement efo:EFO_0021114 Quantification of the amount of 4-androsten-3beta,17beta-diol disulfate 2 in a sample. Elizabeth Lewis true PMID:24816252 4-androsten-3beta,17beta-diol disulfate 2 measurement efo:EFO_0021115 Quantification of the amount of 5alpha-androstan-3beta,17beta-diol disulfate in a sample. Elizabeth Lewis true PMID:24816252 5alpha-androstan-3beta,17beta-diol disulfate measurement efo:EFO_0021116 Quantification of the amount of 7-alpha-hydroxy-3-oxo-4-cholestenoate 7-Hoca in a sample. Elizabeth Lewis true PMID:24816252 7-alpha-hydroxy-3-oxo-4-cholestenoate 7-Hoca measurement efo:EFO_0021117 Quantification of the amount of androsterone sulfate in a sample. Elizabeth Lewis true PMID:24816252 androsterone sulfate measurement efo:EFO_0021118 Quantification of the amount of cortisone in a sample. Elizabeth Lewis true PMID:24816252 cortisone measurement efo:EFO_0021119 Quantification of the amount of dehydroisoandrosterone sulfate DHEA-S in a sample. Elizabeth Lewis true PMID:24816252 dehydroisoandrosterone sulfate DHEA-S measurement efo:EFO_0021120 Quantification of the amount of epiandrosterone sulfate in a sample. Elizabeth Lewis true PMID:24816252 epiandrosterone sulfate measurement efo:EFO_0021121 Quantification of the amount of lathosterol in a sample. Elizabeth Lewis true PMID:24816252 lathosterol measurement efo:EFO_0021122 Quantification of the amount of N1-methyladenosine in a sample. Elizabeth Lewis true PMID:24816252 N1-methyladenosine measurement efo:EFO_0021123 Quantification of the amount of 7-methylguanine in a sample. Elizabeth Lewis true PMID:24816252 7-methylguanine measurement efo:EFO_0021124 Quantification of the amount of guanosine in a sample. Elizabeth Lewis true PMID:24816252 guanosine measurement efo:EFO_0021125 Quantification of the amount of N2,N2-dimethylguanosine in a sample. Elizabeth Lewis true PMID:24816252 N2,N2-dimethylguanosine measurement efo:EFO_0021126 Quantification of the amount of pseudouridine in a sample. Elizabeth Lewis true PMID:24816252 pseudouridine measurement efo:EFO_0021127 Quantification of the amount of aspartylphenylalanine in a sample. Elizabeth Lewis true PMID:24816252 aspartylphenylalanine measurement efo:EFO_0021128 Quantification of the amount of cycloleu-pro in a sample. Elizabeth Lewis true PMID:24816252 cycloleu-pro measurement efo:EFO_0021129 Quantification of the amount of glycylvaline in a sample. Elizabeth Lewis true PMID:24816252 glycylvaline measurement efo:EFO_0021130 Quantification of the amount of leucylleucine in a sample. Elizabeth Lewis true PMID:24816252 leucylleucine measurement efo:EFO_0021131 Quantification of the amount of phenylalanylphenylalanine in a sample. Elizabeth Lewis true PMID:24816252 phenylalanylphenylalanine measurement efo:EFO_0021132 Quantification of the amount of pro-hydroxy-pro in a sample. Elizabeth Lewis true PMID:24816252 pro-hydroxy-pro measurement efo:EFO_0021133 Quantification of the amount of pyroglutamylglycine in a sample. Elizabeth Lewis true PMID:24816252 pyroglutamylglycine measurement efo:EFO_0021134 Quantification of the amount of ADpSGEGDFXAEGGGVR in a sample. Elizabeth Lewis true PMID:24816252 ADpSGEGDFXAEGGGVR measurement efo:EFO_0021135 Quantification of the amount of ADSGEGDFXAEGGGVR in a sample. Elizabeth Lewis true PMID:24816252 ADSGEGDFXAEGGGVR measurement efo:EFO_0021136 Quantification of the amount of DSGEGDFXAEGGGVR in a sample. Elizabeth Lewis true PMID:24816252 DSGEGDFXAEGGGVR measurement efo:EFO_0021137 Quantification of the amount of gamma-glutamylglutamate in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylglutamate measurement efo:EFO_0021138 Quantification of the amount of gamma-glutamylglutamine in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylglutamine measurement efo:EFO_0021139 Quantification of the amount of gamma-glutamylisoleucine in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylisoleucine measurement efo:EFO_0021140 Quantification of the amount of gamma-glutamylleucine in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylleucine measurement efo:EFO_0021141 Quantification of the amount of gamma-glutamylmethionine in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylmethionine measurement efo:EFO_0021142 Quantification of the amount of gamma-glutamylphenylalanine in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylphenylalanine measurement efo:EFO_0021143 Quantification of the amount of gamma-glutamylthreonine in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylthreonine measurement efo:EFO_0021144 Quantification of the amount of gamma-glutamyltyrosine in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamyltyrosine measurement efo:EFO_0021145 Quantification of the amount of gamma-glutamylvaline in a sample. Elizabeth Lewis true PMID:24816252 gamma-glutamylvaline measurement efo:EFO_0021146 Quantification of the amount of bradykinin, des-arg 9 in a sample. Elizabeth Lewis true PMID:24816252 bradykinin, des-arg 9 measurement efo:EFO_0021147 Quantification of the amount of HWESASXX in a sample. Elizabeth Lewis true PMID:24816252 HWESASXX measurement efo:EFO_0021148 Quantification of the amount of 4-ethylphenylsulfate in a sample. Elizabeth Lewis true PMID:24816252 4-ethylphenylsulfate measurement efo:EFO_0021149 Quantification of the amount of 4-vinylphenol sulfate in a sample. Elizabeth Lewis true PMID:24816252 4-vinylphenol sulfate measurement efo:EFO_0021150 Quantification of the amount of benzoate in a sample. Elizabeth Lewis true PMID:24816252 benzoate measurement efo:EFO_0021151 Quantification of the amount of catechol sulfate in a sample. Elizabeth Lewis true PMID:24816252 catechol sulfate measurement efo:EFO_0021152 Quantification of the amount of glycerol 2-phosphate in a sample. Elizabeth Lewis true PMID:24816252 glycerol 2-phosphate measurement efo:EFO_0021153 Quantification of the amount of 2-hydroxyacetaminophen sulfate in a sample. Elizabeth Lewis true PMID:24816252 2-hydroxyacetaminophen sulfate measurement efo:EFO_0021154 Quantification of the amount of 2-methoxyacetaminophen sulfate in a sample. Elizabeth Lewis true PMID:24816252 2-methoxyacetaminophen sulfate measurement efo:EFO_0021155 Quantification of the amount of 3-cystein-S-ylacetaminophen in a sample. Elizabeth Lewis true PMID:24816252 3-cystein-S-ylacetaminophen measurement efo:EFO_0021156 Quantification of the amount of 4-acetaminophen sulfate in a sample. Elizabeth Lewis true PMID:24816252 4-acetaminophen sulfate measurement efo:EFO_0021157 Quantification of the amount of hydroquinone sulfate in a sample. Elizabeth Lewis true PMID:24816252 hydroquinone sulfate measurement efo:EFO_0021158 Quantification of the amount of ibuprofen in a sample. Elizabeth Lewis true PMID:24816252 ibuprofen measurement efo:EFO_0021159 Quantification of the amount of metoprolol acid metabolite in a sample. Elizabeth Lewis true PMID:24816252 metoprolol acid metabolite measurement efo:EFO_0021160 Quantification of the amount of p-acetamidophenylglucuronide in a sample. Elizabeth Lewis true PMID:24816252 p-acetamidophenylglucuronide measurement efo:EFO_0021161 Quantification of the amount of salicylate in a sample. Elizabeth Lewis true PMID:24816252 salicylate measurement efo:EFO_0021162 Quantification of the amount of salicyluric glucuronide in a sample. Elizabeth Lewis true PMID:24816252 salicyluric glucuronide measurement efo:EFO_0021163 Quantification of the amount of ergothioneine in a sample. Elizabeth Lewis true PMID:24816252 ergothioneine measurement efo:EFO_0021164 Quantification of the amount of homostachydrine in a sample. Elizabeth Lewis true PMID:24816252 homostachydrine measurement efo:EFO_0021165 Quantification of the amount of N-2-furoylglycine in a sample. Elizabeth Lewis true PMID:24816252 N-2-furoylglycine measurement efo:EFO_0021166 Quantification of the amount of piperine in a sample. Elizabeth Lewis true PMID:24816252 piperine measurement efo:EFO_0021167 Quantification of the amount of quinate in a sample. Elizabeth Lewis true PMID:24816252 quinate measurement efo:EFO_0021168 Quantification of the amount of saccharin in a sample. Elizabeth Lewis true PMID:24816252 saccharin measurement efo:EFO_0021169 Quantification of the amount of stachydrine in a sample. Elizabeth Lewis true PMID:24816252 stachydrine measurement efo:EFO_0021170 Quantification of the amount of thymol sulfate in a sample. Elizabeth Lewis true PMID:24816252 thymol sulfate measurement efo:EFO_0021171 Quantification of the amount of erythritol in a sample. Elizabeth Lewis true PMID:24816252 erythritol measurement efo:EFO_0021172 Quantification of the amount of 1,3,7-trimethylurate in a sample. Elizabeth Lewis true PMID:24816252 1,3,7-trimethylurate measurement efo:EFO_0021173 Quantification of the amount of 1-methylurate in a sample. Elizabeth Lewis true PMID:24816252 1-methylurate measurement efo:EFO_0021174 Quantification of the amount of 1-methylxanthine in a sample. Elizabeth Lewis true PMID:24816252 1-methylxanthine measurement efo:EFO_0021175 Quantification of the amount of 3-methylxanthine in a sample. Elizabeth Lewis true PMID:24816252 3-methylxanthine measurement efo:EFO_0021176 Quantification of the amount of 7-methylxanthine in a sample. Elizabeth Lewis true PMID:24816252 7-methylxanthine measurement efo:EFO_0021177 Quantification of the amount of caffeine in a sample. Elizabeth Lewis true PMID:24816252 caffeine measurement efo:EFO_0021178 Quantification of the amount of paraxanthine in a sample. Elizabeth Lewis true PMID:24816252 paraxanthine measurement efo:EFO_0021179 Quantification of the amount of theobromine in a sample. Elizabeth Lewis true PMID:24816252 theobromine measurement efo:EFO_0021180 Quantification of the amount of theophylline in a sample. Elizabeth Lewis true PMID:24816252 theophylline measurement efo:EFO_0021181 Quantification of the amount of X-01911 in a sample. Elizabeth Lewis true PMID:24816252 X-01911 measurement efo:EFO_0021182 Quantification of the amount of X-02249 in a sample. Elizabeth Lewis true PMID:24816252 X-02249 measurement efo:EFO_0021183 Quantification of the amount of X-02269 in a sample. Elizabeth Lewis true PMID:24816252 X-02269 measurement efo:EFO_0021184 Quantification of the amount of X-02973 in a sample. Elizabeth Lewis true PMID:24816252 X-02973 measurement efo:EFO_0021185 Quantification of the amount of X-03003 in a sample. Elizabeth Lewis true PMID:24816252 X-03003 measurement efo:EFO_0021186 Quantification of the amount of X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide in a sample. Elizabeth Lewis true PMID:24816252 X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide measurement efo:EFO_0021187 Quantification of the amount of X-03088 in a sample. Elizabeth Lewis true PMID:24816252 X-03088 measurement efo:EFO_0021188 Quantification of the amount of X-03094 in a sample. Elizabeth Lewis true PMID:24816252 X-03094 measurement efo:EFO_0021189 Quantification of the amount of X-04357 in a sample. Elizabeth Lewis true PMID:24816252 X-04357 measurement efo:EFO_0021190 Quantification of the amount of X-04494 in a sample. Elizabeth Lewis true PMID:24816252 X-04494 measurement efo:EFO_0021191 Quantification of the amount of X-04495 in a sample. Elizabeth Lewis true PMID:24816252 X-04495 measurement efo:EFO_0021192 Quantification of the amount of X-04498 in a sample. Elizabeth Lewis true PMID:24816252 X-04498 measurement efo:EFO_0021193 Quantification of the amount of X-04499--3,4-dihydroxybutyrate in a sample. Elizabeth Lewis true PMID:24816252 X-04499--3,4-dihydroxybutyrate measurement efo:EFO_0021194 Quantification of the amount of X-04500 in a sample. Elizabeth Lewis true PMID:24816252 X-04500 measurement efo:EFO_0021195 Quantification of the amount of X-05426 in a sample. Elizabeth Lewis true PMID:24816252 X-05426 measurement efo:EFO_0021196 Quantification of the amount of X-05907 in a sample. Elizabeth Lewis true PMID:24816252 X-05907 measurement efo:EFO_0021197 Quantification of the amount of X-06126 in a sample. Elizabeth Lewis true PMID:24816252 X-06126 measurement efo:EFO_0021198 Quantification of the amount of X-06226 in a sample. Elizabeth Lewis true PMID:24816252 X-06226 measurement efo:EFO_0021199 Quantification of the amount of X-06246 in a sample. Elizabeth Lewis true PMID:24816252 X-06246 measurement efo:EFO_0021200 Quantification of the amount of X-06267 in a sample. Elizabeth Lewis true PMID:24816252 X-06267 measurement efo:EFO_0021201 Quantification of the amount of X-06307 in a sample. Elizabeth Lewis true PMID:24816252 X-06307 measurement efo:EFO_0021202 Quantification of the amount of X-06350 in a sample. Elizabeth Lewis true PMID:24816252 X-06350 measurement efo:EFO_0021203 Quantification of the amount of X-06351 in a sample. Elizabeth Lewis true PMID:24816252 X-06351 measurement efo:EFO_0021204 Quantification of the amount of X-07765 in a sample. Elizabeth Lewis true PMID:24816252 X-07765 measurement efo:EFO_0021205 Quantification of the amount of X-08402 in a sample. Elizabeth Lewis true PMID:24816252 X-08402 measurement efo:EFO_0021206 Quantification of the amount of X-08766 in a sample. Elizabeth Lewis true PMID:24816252 X-08766 measurement efo:EFO_0021207 Quantification of the amount of X-08988 in a sample. Elizabeth Lewis true PMID:24816252 X-08988 measurement efo:EFO_0021208 Quantification of the amount of X-09026 in a sample. Elizabeth Lewis true PMID:24816252 X-09026 measurement efo:EFO_0021209 Quantification of the amount of X-09108 in a sample. Elizabeth Lewis true PMID:24816252 X-09108 measurement efo:EFO_0021210 Quantification of the amount of X-09706 in a sample. Elizabeth Lewis true PMID:24816252 X-09706 measurement efo:EFO_0021211 Quantification of the amount of X-09789 in a sample. Elizabeth Lewis true PMID:24816252 X-09789 measurement efo:EFO_0021212 Quantification of the amount of X-10346 in a sample. Elizabeth Lewis true PMID:24816252 X-10346 measurement efo:EFO_0021213 Quantification of the amount of X-10395 in a sample. Elizabeth Lewis true PMID:24816252 X-10395 measurement efo:EFO_0021214 Quantification of the amount of X-10429 in a sample. Elizabeth Lewis true PMID:24816252 X-10429 measurement efo:EFO_0021215 Quantification of the amount of X-10500 in a sample. Elizabeth Lewis true PMID:24816252 X-10500 measurement efo:EFO_0021216 Quantification of the amount of X-10506 in a sample. Elizabeth Lewis true PMID:24816252 X-10506 measurement efo:EFO_0021217 Quantification of the amount of X-10510 in a sample. Elizabeth Lewis true PMID:24816252 X-10510 measurement efo:EFO_0021218 Quantification of the amount of X-10810 in a sample. Elizabeth Lewis true PMID:24816252 X-10810 measurement efo:EFO_0021219 Quantification of the amount of X-11204 in a sample. Elizabeth Lewis true PMID:24816252 X-11204 measurement efo:EFO_0021220 Quantification of the amount of X-11247 in a sample. Elizabeth Lewis true PMID:24816252 X-11247 measurement efo:EFO_0021221 Quantification of the amount of X-11261 in a sample. Elizabeth Lewis true PMID:24816252 X-11261 measurement efo:EFO_0021222 Quantification of the amount of X-11299 in a sample. Elizabeth Lewis true PMID:24816252 X-11299 measurement efo:EFO_0021223 Quantification of the amount of X-11315 in a sample. Elizabeth Lewis true PMID:24816252 X-11315 measurement efo:EFO_0021224 Quantification of the amount of X-11317 in a sample. Elizabeth Lewis true PMID:24816252 X-11317 measurement efo:EFO_0021225 Quantification of the amount of X-11327 in a sample. Elizabeth Lewis true PMID:24816252 X-11327 measurement efo:EFO_0021226 Quantification of the amount of X-11334 in a sample. Elizabeth Lewis true PMID:24816252 X-11334 measurement efo:EFO_0021227 Quantification of the amount of X-11374 in a sample. Elizabeth Lewis true PMID:24816252 X-11374 measurement efo:EFO_0021228 Quantification of the amount of X-11381 in a sample. Elizabeth Lewis true PMID:24816252 X-11381 measurement efo:EFO_0021229 Quantification of the amount of X-11412 in a sample. Elizabeth Lewis true PMID:24816252 X-11412 measurement efo:EFO_0021230 Quantification of the amount of X-11422--xanthine in a sample. Elizabeth Lewis true PMID:24816252 X-11422--xanthine measurement efo:EFO_0021231 Quantification of the amount of X-11423--O-sulfo-L-tyrosine in a sample. Elizabeth Lewis true PMID:24816252 X-11423--O-sulfo-L-tyrosine measurement efo:EFO_0021232 Quantification of the amount of X-11437 in a sample. Elizabeth Lewis true PMID:24816252 X-11437 measurement efo:EFO_0021233 Quantification of the amount of X-11438 in a sample. Elizabeth Lewis true PMID:24816252 X-11438 measurement efo:EFO_0021234 Quantification of the amount of X-11440 in a sample. Elizabeth Lewis true PMID:24816252 X-11440 measurement efo:EFO_0021235 Quantification of the amount of X-11441 in a sample. Elizabeth Lewis true PMID:24816252 X-11441 measurement efo:EFO_0021236 Quantification of the amount of X-11442 in a sample. Elizabeth Lewis true PMID:24816252 X-11442 measurement efo:EFO_0021237 Quantification of the amount of X-11444 in a sample. Elizabeth Lewis true PMID:24816252 X-11444 measurement efo:EFO_0021238 Quantification of the amount of X-11445--5-alpha-pregnan-3beta,20alpha-disulfate in a sample. Elizabeth Lewis true PMID:24816252 X-11445--5-alpha-pregnan-3beta,20alpha-disulfate measurement efo:EFO_0021239 Quantification of the amount of X-11452 in a sample. Elizabeth Lewis true PMID:24816252 X-11452 measurement efo:EFO_0021240 Quantification of the amount of X-11469 in a sample. Elizabeth Lewis true PMID:24816252 X-11469 measurement efo:EFO_0021241 Quantification of the amount of X-11470 in a sample. Elizabeth Lewis true PMID:24816252 X-11470 measurement efo:EFO_0021242 Quantification of the amount of X-11478 in a sample. Elizabeth Lewis true PMID:24816252 X-11478 measurement efo:EFO_0021243 Quantification of the amount of X-11483 in a sample. Elizabeth Lewis true PMID:24816252 X-11483 measurement efo:EFO_0021244 Quantification of the amount of X-11485 in a sample. Elizabeth Lewis true PMID:24816252 X-11485 measurement efo:EFO_0021245 Quantification of the amount of X-11491 in a sample. Elizabeth Lewis true PMID:24816252 X-11491 measurement efo:EFO_0021246 Quantification of the amount of X-11497 in a sample. Elizabeth Lewis true PMID:24816252 X-11497 measurement efo:EFO_0021247 Quantification of the amount of X-11521 in a sample. Elizabeth Lewis true PMID:24816252 X-11521 measurement efo:EFO_0021248 Quantification of the amount of X-11529 in a sample. Elizabeth Lewis true PMID:24816252 X-11529 measurement efo:EFO_0021249 Quantification of the amount of X-11530 in a sample. Elizabeth Lewis true PMID:24816252 X-11530 measurement efo:EFO_0021250 Quantification of the amount of X-11537 in a sample. Elizabeth Lewis true PMID:24816252 X-11537 measurement efo:EFO_0021251 Quantification of the amount of X-11538 in a sample. Elizabeth Lewis true PMID:24816252 X-11538 measurement efo:EFO_0021252 Quantification of the amount of X-11540 in a sample. Elizabeth Lewis true PMID:24816252 X-11540 measurement efo:EFO_0021253 Quantification of the amount of X-11546 in a sample. Elizabeth Lewis true PMID:24816252 X-11546 measurement efo:EFO_0021254 Quantification of the amount of X-11550 in a sample. Elizabeth Lewis true PMID:24816252 X-11550 measurement efo:EFO_0021255 Quantification of the amount of X-11552 in a sample. Elizabeth Lewis true PMID:24816252 X-11552 measurement efo:EFO_0021256 Quantification of the amount of X-11593--O-methylascorbate in a sample. Elizabeth Lewis PMID:24816252 X-11593--O-methylascorbate measurement efo:EFO_0021257 Quantification of the amount of X-11786--methylcysteine in a sample. Elizabeth Lewis true PMID:24816252 X-11786--methylcysteine measurement efo:EFO_0021258 Quantification of the amount of X-11787 in a sample. Elizabeth Lewis true PMID:24816252 X-11787 measurement efo:EFO_0021259 Quantification of the amount of X-11792 in a sample. Elizabeth Lewis true PMID:24816252 X-11792 measurement efo:EFO_0021260 Quantification of the amount of X-11793--oxidized bilirubin in a sample. Elizabeth Lewis true PMID:24816252 X-11793--oxidized bilirubin measurement efo:EFO_0021261 Quantification of the amount of X-11795 in a sample. Elizabeth Lewis true PMID:24816252 X-11795 measurement efo:EFO_0021262 Quantification of the amount of X-11799 in a sample. Elizabeth Lewis true PMID:24816252 X-11799 measurement efo:EFO_0021263 Quantification of the amount of X-11805 in a sample. Elizabeth Lewis true PMID:24816252 X-11805 measurement efo:EFO_0021264 Quantification of the amount of X-11818 in a sample. Elizabeth Lewis true PMID:24816252 X-11818 measurement efo:EFO_0021265 Quantification of the amount of X-11820 in a sample. Elizabeth Lewis true PMID:24816252 X-11820 measurement efo:EFO_0021266 Quantification of the amount of X-11843 in a sample. Elizabeth Lewis true PMID:24816252 X-11843 measurement efo:EFO_0021267 Quantification of the amount of X-11845 in a sample. Elizabeth Lewis true PMID:24816252 X-11845 measurement efo:EFO_0021268 Quantification of the amount of X-11847 in a sample. Elizabeth Lewis true PMID:24816252 X-11847 measurement efo:EFO_0021269 Quantification of the amount of X-11849 in a sample. Elizabeth Lewis true PMID:24816252 X-11849 measurement efo:EFO_0021270 Quantification of the amount of X-11850 in a sample. Elizabeth Lewis true PMID:24816252 X-11850 measurement efo:EFO_0021271 Quantification of the amount of X-11852 in a sample. Elizabeth Lewis true PMID:24816252 X-11852 measurement efo:EFO_0021272 Quantification of the amount of X-11858 in a sample. Elizabeth Lewis true PMID:24816252 X-11858 measurement efo:EFO_0021273 Quantification of the amount of X-11859 in a sample. Elizabeth Lewis true PMID:24816252 X-11859 measurement efo:EFO_0021274 Quantification of the amount of X-11876 in a sample. Elizabeth Lewis true PMID:24816252 X-11876 measurement efo:EFO_0021275 Quantification of the amount of X-11905 in a sample. Elizabeth Lewis true PMID:24816252 X-11905 measurement efo:EFO_0021276 Quantification of the amount of X-12007 in a sample. Elizabeth Lewis true PMID:24816252 X-12007 measurement efo:EFO_0021277 Quantification of the amount of X-12013 in a sample. Elizabeth Lewis true PMID:24816252 X-12013 measurement efo:EFO_0021278 Quantification of the amount of X-12029 in a sample. Elizabeth Lewis true PMID:24816252 X-12029 measurement efo:EFO_0021279 Quantification of the amount of X-12038 in a sample. Elizabeth Lewis true PMID:24816252 X-12038 measurement efo:EFO_0021280 Quantification of the amount of X-12039 in a sample. Elizabeth Lewis true PMID:24816252 X-12039 measurement efo:EFO_0021281 Quantification of the amount of X-12040 in a sample. Elizabeth Lewis true PMID:24816252 X-12040 measurement efo:EFO_0021282 Quantification of the amount of X-12056 in a sample. Elizabeth Lewis true PMID:24816252 X-12056 measurement efo:EFO_0021283 Quantification of the amount of X-12063 in a sample. Elizabeth Lewis true PMID:24816252 X-12063 measurement efo:EFO_0021284 Quantification of the amount of X-12092 in a sample. Elizabeth Lewis true PMID:24816252 X-12092 measurement efo:EFO_0021285 Quantification of the amount of X-12093 in a sample. Elizabeth Lewis true PMID:24816252 X-12093 measurement efo:EFO_0021286 Quantification of the amount of X-12094 in a sample. Elizabeth Lewis true PMID:24816252 X-12094 measurement efo:EFO_0021287 Quantification of the amount of X-12095--N1-methyl-3-pyridone-4-carboxamide in a sample. Elizabeth Lewis true PMID:24816252 X-12095--N1-methyl-3-pyridone-4-carboxamide measurement efo:EFO_0021288 Quantification of the amount of X-12100--hydroxytryptophan in a sample. Elizabeth Lewis true PMID:24816252 X-12100--hydroxytryptophan measurement efo:EFO_0021289 Quantification of the amount of X-12116 in a sample. Elizabeth Lewis true PMID:24816252 X-12116 measurement efo:EFO_0021290 Quantification of the amount of X-12188 in a sample. Elizabeth Lewis true PMID:24816252 X-12188 measurement efo:EFO_0021291 Quantification of the amount of X-12189 in a sample. Elizabeth Lewis true PMID:24816252 X-12189 measurement efo:EFO_0021292 Quantification of the amount of X-12206 in a sample. Elizabeth Lewis true PMID:24816252 X-12206 measurement efo:EFO_0021293 Quantification of the amount of X-12212 in a sample. Elizabeth Lewis true PMID:24816252 X-12212 measurement efo:EFO_0021294 Quantification of the amount of X-12216 in a sample. Elizabeth Lewis true PMID:24816252 X-12216 measurement efo:EFO_0021295 Quantification of the amount of X-12217 in a sample. Elizabeth Lewis true PMID:24816252 X-12217 measurement efo:EFO_0021296 Quantification of the amount of X-12230 in a sample. Elizabeth Lewis true PMID:24816252 X-12230 measurement efo:EFO_0021297 Quantification of the amount of X-12231 in a sample. Elizabeth Lewis true PMID:24816252 X-12231 measurement efo:EFO_0021298 Quantification of the amount of X-12236 in a sample. Elizabeth Lewis true PMID:24816252 X-12236 measurement efo:EFO_0021299 Quantification of the amount of X-12244--N-acetylcarnosine in a sample. Elizabeth Lewis true PMID:24816252 X-12244--N-acetylcarnosine measurement efo:EFO_0021300 Quantification of the amount of X-12253 in a sample. Elizabeth Lewis true PMID:24816252 X-12253 measurement efo:EFO_0021301 Quantification of the amount of X-12261 in a sample. Elizabeth Lewis true PMID:24816252 X-12261 measurement efo:EFO_0021302 Quantification of the amount of X-12329 in a sample. Elizabeth Lewis true PMID:24816252 X-12329 measurement efo:EFO_0021303 Quantification of the amount of X-12405 in a sample. Elizabeth Lewis true PMID:24816252 X-12405 measurement efo:EFO_0021304 Quantification of the amount of X-12407 in a sample. Elizabeth Lewis true PMID:24816252 X-12407 measurement efo:EFO_0021305 Quantification of the amount of X-12428 in a sample. Elizabeth Lewis true PMID:24816252 X-12428 measurement efo:EFO_0021306 Quantification of the amount of X-12435 in a sample. Elizabeth Lewis true PMID:24816252 X-12435 measurement efo:EFO_0021307 Quantification of the amount of X-12441--12-hydroxyeicosatetraenoate 12-HETE in a sample. Elizabeth Lewis true PMID:24816252 X-12441--12-hydroxyeicosatetraenoate 12-HETE measurement efo:EFO_0021308 Quantification of the amount of X12442--5,8-tetradecadienoate in a sample. Elizabeth Lewis true PMID:24816252 X12442--5,8-tetradecadienoate measurement efo:EFO_0021309 Quantification of the amount of X-12443 in a sample. Elizabeth Lewis true PMID:24816252 X-12443 measurement efo:EFO_0021310 Quantification of the amount of X-12450 in a sample. Elizabeth Lewis true PMID:24816252 X-12450 measurement efo:EFO_0021311 Quantification of the amount of X-12456 in a sample. Elizabeth Lewis true PMID:24816252 X-12456 measurement efo:EFO_0021312 Quantification of the amount of X-12465 in a sample. Elizabeth Lewis true PMID:24816252 X-12465 measurement efo:EFO_0021313 Quantification of the amount of X-12510--2-aminooctanoic acid in a sample. Elizabeth Lewis true PMID:24816252 X-12510--2-aminooctanoic acid measurement efo:EFO_0021314 Quantification of the amount of X-12524 in a sample. Elizabeth Lewis true PMID:24816252 X-12524 measurement efo:EFO_0021315 Quantification of the amount of X-12544 in a sample. Elizabeth Lewis true PMID:24816252 X-12544 measurement efo:EFO_0021316 Quantification of the amount of X-12556 in a sample. Elizabeth Lewis true PMID:24816252 X-12556 measurement efo:EFO_0021317 Quantification of the amount of X-12627 in a sample. Elizabeth Lewis true PMID:24816252 X-12627 measurement efo:EFO_0021318 Quantification of the amount of X-12644 in a sample. Elizabeth Lewis true PMID:24816252 X-12644 measurement efo:EFO_0021319 Quantification of the amount of X-12645 in a sample. Elizabeth Lewis true PMID:24816252 X-12645 measurement efo:EFO_0021320 Quantification of the amount of X-12680 in a sample. Elizabeth Lewis true PMID:24816252 X-12680 measurement efo:EFO_0021321 Quantification of the amount of X-12696 in a sample. Elizabeth Lewis true PMID:24816252 X-12696 measurement efo:EFO_0021322 Quantification of the amount of X-12704 in a sample. Elizabeth Lewis true PMID:24816252 X-12704 measurement efo:EFO_0021323 Quantification of the amount of X-12712 in a sample. Elizabeth Lewis true PMID:24816252 X-12712 measurement efo:EFO_0021324 Quantification of the amount of X-12717 in a sample. Elizabeth Lewis true PMID:24816252 X-12717 measurement efo:EFO_0021325 Quantification of the amount of X-12719 in a sample. Elizabeth Lewis true PMID:24816252 X-12719 measurement efo:EFO_0021326 Quantification of the amount of X-12726 in a sample. Elizabeth Lewis true PMID:24816252 X-12726 measurement efo:EFO_0021327 Quantification of the amount of X-12728 in a sample. Elizabeth Lewis true PMID:24816252 X-12728 measurement efo:EFO_0021328 Quantification of the amount of X-12729 in a sample. Elizabeth Lewis true PMID:24816252 X-12729 measurement efo:EFO_0021329 Quantification of the amount of X-12734 in a sample. Elizabeth Lewis true PMID:24816252 X-12734 measurement efo:EFO_0021330 Quantification of the amount of X-12740 in a sample. Elizabeth Lewis true PMID:24816252 X-12740 measurement efo:EFO_0021331 Quantification of the amount of X-12749 in a sample. Elizabeth Lewis true PMID:24816252 X-12749 measurement efo:EFO_0021332 Quantification of the amount of X-12771 in a sample. Elizabeth Lewis true PMID:24816252 X-12771 measurement efo:EFO_0021333 Quantification of the amount of X-12776 in a sample. Elizabeth Lewis true PMID:24816252 X-12776 measurement efo:EFO_0021334 Quantification of the amount of X-12786 in a sample. Elizabeth Lewis true PMID:24816252 X-12786 measurement efo:EFO_0021335 Quantification of the amount of X-12798 in a sample. Elizabeth Lewis true PMID:24816252 X-12798 measurement efo:EFO_0021336 Quantification of the amount of X-12816 in a sample. Elizabeth Lewis true PMID:24816252 X-12816 measurement efo:EFO_0021337 Quantification of the amount of X-12830 in a sample. Elizabeth Lewis true PMID:24816252 X-12830 measurement efo:EFO_0021338 Quantification of the amount of X-12833 in a sample. Elizabeth Lewis true PMID:24816252 X-12833 measurement efo:EFO_0021339 Quantification of the amount of X-12844 in a sample. Elizabeth Lewis true PMID:24816252 X-12844 measurement efo:EFO_0021340 Quantification of the amount of X-12847 in a sample. Elizabeth Lewis true PMID:24816252 X-12847 measurement efo:EFO_0021341 Quantification of the amount of X-12850 in a sample. Elizabeth Lewis true PMID:24816252 X-12850 measurement efo:EFO_0021342 Quantification of the amount of X-12851 in a sample. Elizabeth Lewis true PMID:24816252 X-12851 measurement efo:EFO_0021343 Quantification of the amount of X-12855 in a sample. Elizabeth Lewis true PMID:24816252 X-12855 measurement efo:EFO_0021344 Quantification of the amount of X-12990--docosapentaenoic acid n6-DPA in a sample. Elizabeth Lewis true PMID:24816252 X-12990--docosapentaenoic acid n6-DPA measurement efo:EFO_0021345 Quantification of the amount of X-13069 in a sample. Elizabeth Lewis true PMID:24816252 X-13069 measurement efo:EFO_0021346 Quantification of the amount of X-13183--stearamide in a sample. Elizabeth Lewis true PMID:24816252 X-13183--stearamide measurement efo:EFO_0021347 Quantification of the amount of X-13215 in a sample. Elizabeth Lewis true PMID:24816252 X-13215 measurement efo:EFO_0021348 Quantification of the amount of X-13429 in a sample. Elizabeth Lewis true PMID:24816252 X-13429 measurement efo:EFO_0021349 Quantification of the amount of X-13431--nonanoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 X-13431--nonanoylcarnitine measurement efo:EFO_0021350 Quantification of the amount of X-13435 in a sample. Elizabeth Lewis true PMID:24816252 X-13435 measurement efo:EFO_0021351 Quantification of the amount of X-13477 in a sample. Elizabeth Lewis true PMID:24816252 X-13477 measurement efo:EFO_0021352 Quantification of the amount of X-13496 in a sample. Elizabeth Lewis true PMID:24816252 X-13496 measurement efo:EFO_0021353 Quantification of the amount of X-13548 in a sample. Elizabeth Lewis true PMID:24816252 X-13548 measurement efo:EFO_0021354 Quantification of the amount of X-13549 in a sample. Elizabeth Lewis true PMID:24816252 X-13549 measurement efo:EFO_0021355 Quantification of the amount of X-13553 in a sample. Elizabeth Lewis true PMID:24816252 X-13553 measurement efo:EFO_0021356 Quantification of the amount of X-13619 in a sample. Elizabeth Lewis true PMID:24816252 X-13619 measurement efo:EFO_0021357 Quantification of the amount of X-13658 in a sample. Elizabeth Lewis true PMID:24816252 X-13658 measurement efo:EFO_0021358 Quantification of the amount of X-13671 in a sample. Elizabeth Lewis true PMID:24816252 X-13671 measurement efo:EFO_0021359 Quantification of the amount of X-13741 in a sample. Elizabeth Lewis true PMID:24816252 X-13741 measurement efo:EFO_0021360 Quantification of the amount of X-13859 in a sample. Elizabeth Lewis true PMID:24816252 X-13859 measurement efo:EFO_0021361 Quantification of the amount of X-14056 in a sample. Elizabeth Lewis true PMID:24816252 X-14056 measurement efo:EFO_0021362 Quantification of the amount of X-14057 in a sample. Elizabeth Lewis true PMID:24816252 X-14057 measurement efo:EFO_0021363 Quantification of the amount of X-14086 in a sample. Elizabeth Lewis true PMID:24816252 X-14086 measurement efo:EFO_0021364 Quantification of the amount of X-14189--leucylalanine in a sample. Elizabeth Lewis true PMID:24816252 X-14189--leucylalanine measurement efo:EFO_0021365 Quantification of the amount of X-14205--alpha-glutamyltyrosine in a sample. Elizabeth Lewis true PMID:24816252 X-14205--alpha-glutamyltyrosine measurement efo:EFO_0021366 Quantification of the amount of X-14208--phenylalanylserine in a sample. Elizabeth Lewis true PMID:24816252 X-14208--phenylalanylserine measurement efo:EFO_0021367 Quantification of the amount of X-14304--leucylalanine in a sample. Elizabeth Lewis true PMID:24816252 X-14304--leucylalanine measurement efo:EFO_0021368 Quantification of the amount of X-14374 in a sample. Elizabeth Lewis true PMID:24816252 X-14374 measurement efo:EFO_0021369 Quantification of the amount of X-14450--phenylalanylleucine in a sample. Elizabeth Lewis true PMID:24816252 X-14450--phenylalanylleucine measurement efo:EFO_0021370 Quantification of the amount of X-14473 in a sample. Elizabeth Lewis true PMID:24816252 X-14473 measurement efo:EFO_0021371 Quantification of the amount of X-14541 in a sample. Elizabeth Lewis true PMID:24816252 X-14541 measurement efo:EFO_0021372 Quantification of the amount of X-14588 in a sample. Elizabeth Lewis true PMID:24816252 X-14588 measurement efo:EFO_0021373 Quantification of the amount of X-14625 in a sample. Elizabeth Lewis true PMID:24816252 X-14625 measurement efo:EFO_0021374 Quantification of the amount of X-14626 in a sample. Elizabeth Lewis true PMID:24816252 X-14626 measurement efo:EFO_0021375 Quantification of the amount of X-14632 in a sample. Elizabeth Lewis true PMID:24816252 X-14632 measurement efo:EFO_0021376 Quantification of the amount of X-14658 in a sample. Elizabeth Lewis true PMID:24816252 X-14658 measurement efo:EFO_0021377 Quantification of the amount of X-14662 in a sample. Elizabeth Lewis true PMID:24816252 X-14662 measurement efo:EFO_0021378 Quantification of the amount of X-14745 in a sample. Elizabeth Lewis true PMID:24816252 X-14745 measurement efo:EFO_0021379 Quantification of the amount of X-14977--vanillin in a sample. Elizabeth Lewis true PMID:24816252 X-14977--vanillin measurement efo:EFO_0021380 Quantification of the amount of X-18601 in a sample. Elizabeth Lewis true PMID:24816252 X-18601 measurement efo:EFO_0021381 Quantification of the ratio of betaine to pyroglutamine in a sample. Elizabeth Lewis true PMID:24816252 betaine-to-pyroglutamine ratio efo:EFO_0021382 Quantification of the ratio of N-acetylornithine to myo-inositol in a sample. Elizabeth Lewis true PMID:24816252 N-acetylornithine-to-myo-inositol ratio efo:EFO_0021383 Quantification of the ratio of X-08402 to cholesterol in a sample. Elizabeth Lewis true PMID:24816252 X-08402-to-cholesterol ratio efo:EFO_0021384 Quantification of the ratio of phosphate to erythronate in a sample. Elizabeth Lewis true PMID:24816252 phosphate-to-erythronate ratio efo:EFO_0021385 Quantification of the ratio of propionylcarnitine to isovalerylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 propionylcarnitine-to-isovalerylcarnitine ratio efo:EFO_0021386 Quantification of the ratio of octanoylcarnitine to X-13435 in a sample. Elizabeth Lewis true PMID:24816252 octanoylcarnitine-to-X-13435 ratio efo:EFO_0021387 Quantification of the ratio of valine to isovalerylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 valine-to-isovalerylcarnitine ratio efo:EFO_0021388 Quantification of the ratio of X-12038 to bradykinin, des-arg 9 in a sample. Elizabeth Lewis true PMID:24816252 X-12038-to-bradykinin, des-arg 9 ratio efo:EFO_0021389 Quantification of the ratio of docosapentaenoate n3 DPA; 22:5n3 to X-12627 in a sample. Elizabeth Lewis true PMID:24816252 docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio efo:EFO_0021390 Quantification of the ratio of lysine to glutaroyl carnitine in a sample. Elizabeth Lewis true PMID:24816252 lysine-to-glutaroyl carnitine ratio efo:EFO_0021391 Quantification of the ratio of aspartylphenylalanine to X-14450--phenylalanylleucine in a sample. Elizabeth Lewis true PMID:24816252 aspartylphenylalanine-to-X-14450--phenylalanylleucine ratio efo:EFO_0021392 Quantification of the ratio of X-11820 to cholesterol in a sample. Elizabeth Lewis true PMID:24816252 X-11820-to-cholesterol ratio efo:EFO_0021393 Quantification of the ratio of X-11440 to 4-androsten-3beta,17beta-diol disulfate 2 in a sample. Elizabeth Lewis true PMID:24816252 X-11440-to-4-androsten-3beta,17beta-diol disulfate 2 ratio efo:EFO_0021394 Quantification of the ratio of ADSGEGDFXAEGGGVR to ADpSGEGDFXAEGGGVR in a sample. Elizabeth Lewis true PMID:24816252 ADSGEGDFXAEGGGVR-to-ADpSGEGDFXAEGGGVR ratio efo:EFO_0021395 Quantification of the ratio of DSGEGDFXAEGGGVR to ADpSGEGDFXAEGGGVR in a sample. Elizabeth Lewis true PMID:24816252 DSGEGDFXAEGGGVR-to-ADpSGEGDFXAEGGGVR ratio efo:EFO_0021396 Quantification of the ratio of indoleacetate to N2,N2-dimethylguanosine in a sample. Elizabeth Lewis true PMID:24816252 indoleacetate-to-N2,N2-dimethylguanosine ratio efo:EFO_0021397 Quantification of the ratio of arachidonate 20:4n6 to 1-arachidonoylglycerophosphoinositol in a sample. Elizabeth Lewis true PMID:24816252 arachidonate 20:4n6-to-1-arachidonoylglycerophosphoinositol ratio efo:EFO_0021398 Quantification of the ratio of X-10510 to palmitoyl sphingomyelin in a sample. Elizabeth Lewis true PMID:24816252 X-10510-to-palmitoyl sphingomyelin ratio efo:EFO_0021399 Quantification of the ratio of X-12095--N1-methyl-3-pyridone-4-carboxamide to X-12844 in a sample. Elizabeth Lewis true PMID:24816252 X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio efo:EFO_0021400 Quantification of the ratio of 4-acetamidobutanoate to X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide in a sample. Elizabeth Lewis true PMID:24816252 4-acetamidobutanoate-to-X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide ratio efo:EFO_0021401 Quantification of the ratio of ADpSGEGDFXAEGGGVR to X-14304--leucylalanine in a sample. Elizabeth Lewis true PMID:24816252 ADpSGEGDFXAEGGGVR-to-X-14304--leucylalanine ratio efo:EFO_0021402 Quantification of the ratio of 10-undecenoate 11:1n1 to X-11438 in a sample. Elizabeth Lewis true PMID:24816252 10-undecenoate 11:1n1-to-X-11438 ratio efo:EFO_0021403 Quantification of the ratio of carnitine to X-12798 in a sample. Elizabeth Lewis true PMID:24816252 carnitine-to-X-12798 ratio efo:EFO_0021404 Quantification of the ratio of glucose to mannose in a sample. Elizabeth Lewis true PMID:24816252 glucose-to-mannose ratio efo:EFO_0021405 Quantification of the ratio of X-11444 to X-12844 in a sample. Elizabeth Lewis true PMID:24816252 X-11444-to-X-12844 ratio efo:EFO_0021406 Quantification of the ratio of isoleucine to X-11529 in a sample. Elizabeth Lewis true PMID:24816252 isoleucine-to-X-11529 ratio efo:EFO_0021407 Quantification of the ratio of X-11315 to pyroglutamine in a sample. Elizabeth Lewis true PMID:24816252 X-11315-to-pyroglutamine ratio efo:EFO_0021408 Quantification of the ratio of X-13215 to X-13671 in a sample. Elizabeth Lewis true PMID:24816252 X-13215-to-X-13671 ratio efo:EFO_0021409 Quantification of the ratio of urate to histidine in a sample. Elizabeth Lewis true PMID:24816252 urate-to-histidine ratio efo:EFO_0021410 Quantification of the ratio of hexanoylcarnitine to octanoylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 hexanoylcarnitine-to-octanoylcarnitine ratio efo:EFO_0021411 Quantification of the ratio of DHEA-S to 4-androsten-3beta,17beta-diol disulfate 2 in a sample. Elizabeth Lewis true PMID:24816252 DHEA-S-to-4-androsten-3beta,17beta-diol disulfate 2 ratio efo:EFO_0021412 Quantification of the ratio of X-11444 to X-11470 in a sample. Elizabeth Lewis true PMID:24816252 X-11444-to-X-11470 ratio efo:EFO_0021413 Quantification of the ratio of androsterone sulfate to 4-androsten-3beta,17beta-diol disulfate 2 in a sample. Elizabeth Lewis true PMID:24816252 androsterone sulfate-to-4-androsten-3beta,17beta-diol disulfate 2 ratio efo:EFO_0021414 Quantification of the ratio of valine to proline in a sample. Elizabeth Lewis true PMID:24816252 valine-to-proline ratio efo:EFO_0021415 Quantification of the ratio of X-04499--3,4-dihydroxybutyrate to C-glycosyltryptophan in a sample. Elizabeth Lewis true PMID:24816252 X-04499--3,4-dihydroxybutyrate-to-C-glycosyltryptophan ratio efo:EFO_0021416 Quantification of the ratio of C-glycosyltryptophan to succinylcarnitine in a sample. Elizabeth Lewis true PMID:24816252 C-glycosyltryptophan-to-succinylcarnitine ratio efo:EFO_0021417 Quantification of the ratio of X-12798 to phenylalanine in a sample. Elizabeth Lewis true PMID:24816252 X-12798-to-phenylalanine ratio efo:EFO_0021418 Quantification of the ratio of 4-acetamidobutanoate to N1-methyladenosine in a sample. Elizabeth Lewis true PMID:24816252 4-acetamidobutanoate-to-N1-methyladenosine ratio efo:EFO_0021419 Quantification of the ratio of myristate 14:0 to myristoleate 14:1n5 in a sample. Elizabeth Lewis true PMID:24816252 myristate 14:0-to-myristoleate 14:1n5 ratio efo:EFO_0021420 Quantification of the ratio of glutamine to histidine in a sample. Elizabeth Lewis true PMID:24816252 glutamine-to-histidine ratio efo:EFO_0021421 Quantification of the amount of iron in the spleen. Zoe May Pendlington 2022-06-07T14:18:23Z true PMID:35568031 spleen iron measurement efo:EFO_0021427 Quantification of N-acetylmethionine levels in a sample. Zoe May Pendlington 2022-06-09T08:06:34Z true ORCID:0000-0002-2417-7324 N-acetylmethionine measurement Quantification of N-acetylmethionine levels in a sample. https://www.sciencedirect.com/topics/medicine-and-dentistry/n-acetylmethionine efo:EFO_0021428 Quantification of the N6-succinyladenosine levels in a sample. Zoe May Pendlington 2022-06-09T08:07:32Z true ORCID:0000-0002-2417-7324 succinyladenosine measurement N6-succinyladenosine measurement Quantification of the N6-succinyladenosine levels in a sample. https://www.medchemexpress.com/succinyladenosine.html efo:EFO_0021429 Quantification of N-acetylarginine levels in a sample. Zoe May Pendlington 2022-06-09T08:10:30Z true ORCID:0000-0002-2417-7324 N-Acetyl-L-arginine measurement N-acetylarginine measurement Quantification of N-acetylarginine levels in a sample. https://pubchem.ncbi.nlm.nih.gov/compound/N-Acetyl-L-arginine efo:EFO_0021430 Quantification of N-acetyl-beta-alanine levels in a sample. Zoe May Pendlington 2022-06-09T08:13:30Z true ORCID:0000-0002-2417-7324 N-acetyl-beta-alanine measurement efo:EFO_0021434 Quantification of cholesteryl ester 15:0 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 15:0 measurement efo:EFO_0021435 Quantification of cholesteryl ester 16:2 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 16:2 measurement efo:EFO_0021436 Quantification of cholesteryl ester 17:0 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 17:0 measurement efo:EFO_0021437 Quantification of cholesteryl ester 17:1 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 17:1 measurement efo:EFO_0021438 Quantification of cholesteryl ester 20:0 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 20:0 measurement efo:EFO_0021439 Quantification of cholesteryl ester 20:1 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 20:1 measurement efo:EFO_0021440 Quantification of cholesteryl ester 20:2 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 20:2 measurement efo:EFO_0021441 Quantification of cholesteryl ester 22:0 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 22:0 measurement efo:EFO_0021442 Quantification of cholesteryl ester 22:1 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 22:1 measurement efo:EFO_0021443 Quantification of cholesteryl ester 22:4 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 22:4 measurement efo:EFO_0021444 Quantification of cholesteryl ester 22:5 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 22:5 measurement efo:EFO_0021445 Quantification of cholesteryl ester 24:0 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 24:0 measurement efo:EFO_0021446 Quantification of cholesteryl ester 24:1 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 24:1 measurement efo:EFO_0021447 Quantification of cholesteryl ester 24:4 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 24:4 measurement efo:EFO_0021448 Quantification of cholesteryl ester 24:5 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 24:5 measurement efo:EFO_0021449 Quantification of cholesteryl ester 24:6 in a sample. Santhi Ramachandran true PMID:35668104 cholesteryl ester 24:6 measurement efo:EFO_0021450 Quantification of GM1 ganglioside in a sample. Santhi Ramachandran true PMID:35668104 GM1 ganglioside measurement efo:EFO_0021451 Quantification of GM3 ganglioside in a sample. Santhi Ramachandran true PMID:35668104 GM3 ganglioside measurement efo:EFO_0021452 Quantification of lysophosphatidylcholine 17:0 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 17:0 measurement efo:EFO_0021453 Quantification of lysophosphatidylcholine 17:1 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 17:1 measurement efo:EFO_0021454 Quantification of lysophosphatidylcholine 18:3 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 18:3 measurement efo:EFO_0021455 Quantification of lysophosphatidylcholine 19:0 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 19:0 measurement efo:EFO_0021456 Quantification of lysophosphatidylcholine 20:0 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 20:0 measurement efo:EFO_0021457 Quantification of lysophosphatidylcholine 20:1 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 20:1 measurement efo:EFO_0021458 Quantification of lysophosphatidylcholine 20:2 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 20:2 measurement efo:EFO_0021459 Quantification of lysophosphatidylcholine 22:0 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 22:0 measurement efo:EFO_0021460 Quantification of lysophosphatidylcholine 22:1 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 22:1 measurement efo:EFO_0021461 Quantification of lysophosphatidylcholine 22:4 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 22:4 measurement efo:EFO_0021462 Quantification of lysophosphatidylcholine 22:5 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 22:5 measurement efo:EFO_0021463 Quantification of lysophosphatidylcholine 24:0 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 24:0 measurement efo:EFO_0021464 Quantification of lysophosphatidylcholine 26:0 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylcholine 26:0 measurement efo:EFO_0021465 Quantification of lysophosphatidylethanolamine 17:0 in a sample. Santhi Ramachandran true PMID:35668104 lysophosphatidylethanolamine 17:0 measurement efo:EFO_0021466 Quantification of phosphatidylcholine 28:0 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 28:0 measurement efo:EFO_0021467 Quantification of phosphatidylcholine 31:0 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 31:0 measurement efo:EFO_0021468 Quantification of phosphatidylcholine 33:0 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 33:0 measurement efo:EFO_0021469 Quantification of phosphatidylcholine 33:1 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 33:1 measurement efo:EFO_0021470 Quantification of phosphatidylcholine 33:2 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 33:2 measurement efo:EFO_0021471 Quantification of phosphatidylcholine 34:5 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 34:5 measurement efo:EFO_0021472 Quantification of phosphatidylcholine 35:5 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 35:5 measurement efo:EFO_0021473 Quantification of phosphatidylcholine 36:0 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 36:0 measurement efo:EFO_0021474 Quantification of phosphatidylcholine 36:6 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 36:6 measurement efo:EFO_0021475 Quantification of phosphatidylcholine 38:7 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 38:7 measurement efo:EFO_0021476 Quantification of phosphatidylcholine 39:5 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 39:5 measurement efo:EFO_0021477 Quantification of phosphatidylcholine 40:7 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 40:7 measurement efo:EFO_0021478 Quantification of phosphatidylcholine 40:8 in a sample. Santhi Ramachandran true PMID:35668104 phosphatidylcholine 40:8 measurement efo:EFO_0021479 Quantification of triacylglycerol 49:1 in a sample. Santhi Ramachandran true PMID:35668104 triacylglycerol 49:1 measurement efo:EFO_0021480 Quantification of triacylglycerol 50:0 in a sample. Santhi Ramachandran true PMID:35668104 triacylglycerol 50:0 measurement efo:EFO_0021481 Quantification of triacylglycerol 51:0 in a sample. Santhi Ramachandran true PMID:35668104 triacylglycerol 51:0 measurement efo:EFO_0021482 Quantification of triacylglycerol 51:1 in a sample. Santhi Ramachandran true PMID:35668104 triacylglycerol 51:1 measurement efo:EFO_0021483 Quantification of triacylglycerol 51:2 in a sample. Santhi Ramachandran true PMID:35668104 triacylglycerol 51:2 measurement efo:EFO_0021484 Quantification of triacylglycerol 53:2 in a sample. Santhi Ramachandran true PMID:35668104 triacylglycerol 53:2 measurement efo:EFO_0021485 Quantification of triacylglycerol 54:0 in a sample. Santhi Ramachandran true PMID:35668104 triacylglycerol 54:0 measurement efo:EFO_0021486 Quantification of ubiquinone in a sample. Santhi Ramachandran true PMID:35668104 ubiquinone measurement efo:EFO_0021487 Quantification of disease-related phenotypic variability using qualitative symptom data. Zoe May Pendlington 2022-07-12T08:29:20Z true PMID:35760791 cryptic phenotype measurement efo:EFO_0021488 Quantification of the ratio of 6‑hydroxymelatonin sulfate to creatinine in a urine sample. Zoe May Pendlington 2022-07-12T08:54:42Z true PMID:35577822 urinary 6‑hydroxymelatonin sulfate to creatinine ratio efo:EFO_0021489 Quantification of some aspect of treprostinil dosage. Zoe May Pendlington 2022-07-12T10:18:20Z true PMID:35383711 treprostinil dose measurement efo:EFO_0021490 Quantification of the change in amygdala volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:40:28Z true PMID:35383335 amygdala volume change measurement efo:EFO_0021491 Quantification of the change in caudate volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:41:51Z true PMID:35383335 caudate volume change measurement efo:EFO_0021492 Quantification of the change in hippocampus volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:42:35Z true PMID:35383335 hippocampus volume change measurement efo:EFO_0021493 Quantification of the change in nucleus accumbens volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:43:17Z true PMID:35383335 nucleus accumbens volume change measurement efo:EFO_0021494 Quantification of the change in pallidum volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:46:10Z true PMID:35383335 pallidum volume change measurement efo:EFO_0021495 Quantification of the change in putamen volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:47:54Z true PMID:35383335 putamen volume change measurement efo:EFO_0021496 Quantification of the change in thalamus volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:49:23Z true PMID:35383335 thalamus volume change measurement efo:EFO_0021497 Quantification of the change in cerebellum cortex volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:52:52Z true PMID:35383335 cerebellum cortex volume change measurement efo:EFO_0021498 Quantification of the change in cerebellum white matter volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:54:26Z true PMID:35383335 cerebellum white matter volume change measurement efo:EFO_0021499 Quantification of the change in cerebral white matter volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:55:12Z true PMID:35383335 cerebral white matter volume change measurement efo:EFO_0021500 Quantification of the change in cortex volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:56:00Z true PMID:35383335 cortex volume change measurement efo:EFO_0021501 Quantification of the change in cortical thickness over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:56:28Z true PMID:35383335 cortical thickness change measurement efo:EFO_0021502 Quantification of the change in lateral ventricle volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:57:02Z true PMID:35383335 lateral ventricle volume change measurement efo:EFO_0021503 Quantification of the change in cortical surface area over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:57:32Z true PMID:35383335 cortical surface area change measurement efo:EFO_0021504 Quantification of the change in total brain volume over time. Elizabeth Lewis Zoe May Pendlington 2022-07-12T10:58:08Z true PMID:35383335 total brain volume change measurement efo:EFO_0021506 Quantification of the amount of 2-hydroxyglutarate measurement in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:36:47Z true PMID:24816252 2-hydroxyglutarate measurement efo:EFO_0021507 Quantification of the amount of 2-hydroxypalmitate measurement in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:37:13Z true PMID:24816252 2-hydroxypalmitate measurement efo:EFO_0021508 Quantification of the amount of 4-hydroxyhippurate measurement in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:37:25Z true PMID:24816252 4-hydroxyhippurate measurement efo:EFO_0021509 Quantification of the amount of cholate measurement in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:37:36Z true PMID:24816252 cholate measurement efo:EFO_0021510 Quantification of the amount of linoleate 18:2n6 measurement in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:37:48Z true PMID:24816252 linoleate 18:2n6 measurement efo:EFO_0021511 Quantification of the amount of phenyllactate measurement in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:38:04Z true PMID:24816252 phenyllactate measurement efo:EFO_0021512 Quantification of the amount of 1,7-dimethylurate measurement in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:38:15Z true PMID:24816252 1,7-dimethylurate measurement efo:EFO_0021513 Quantification of the ratio of 3-4-hydroxyphenyl lactate-to-alpha-hydroxyisovalerate ratio in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:38:27Z true PMID:24816252 3-4-hydroxyphenyl lactate-to-alpha-hydroxyisovalerate ratio efo:EFO_0021514 Quantification of the ratio of acetylcarnitine-to-hexanoylcarnitine ratio in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:38:39Z true PMID:24816252 acetylcarnitine-to-hexanoylcarnitine ratio efo:EFO_0021515 Quantification of the ratio of androsterone sulfate-to-epiandrosterone sulfate ratio in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:38:53Z true PMID:24816252 androsterone sulfate-to-epiandrosterone sulfate ratio efo:EFO_0021517 Quantification of the ratio of arachidonate 20:4n6-to-dihomo-linolenate 20:3n3 or n6 ratio in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:39:28Z true PMID:24816252 arachidonate 20:4n6-to-dihomo-linolenate 20:3n3 or n6 ratio efo:EFO_0021518 Quantification of the ratio of linoleate 18:2n6-to-dihomo-linolenate 20:3n3 or n6 ratio in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:39:39Z true PMID:24816252 linoleate 18:2n6-to-dihomo-linolenate 20:3n3 or n6 ratio efo:EFO_0021519 Quantification of the ratio of linoleate 18:2n6-to-X-12442-5,8-tetradecadienoate ratio in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:39:53Z true PMID:24816252 linoleate 18:2n6-to-X-12442-5,8-tetradecadienoate ratio efo:EFO_0021521 Quantification of the ratio of phenyllactate-to-phenylalanine ratio in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-12T11:40:15Z true PMID:24816252 phenyllactate-to-phenylalanine ratio efo:EFO_0021522 A quantitative measurement of the total amount of sodium present in a sample of urine. Zoe May Pendlington 2022-07-12T12:02:38Z https://orcid.org/0000-0002-2417-7324 true PMID:31085678 sodium in urine urinary sodium measurement efo:EFO_0021527 Quantification of arsenic in a blood sample. Elliot Sollis Zoe May Pendlington 2022-07-12T14:05:05Z true PMID:35501403 blood arsenic measurement efo:EFO_0021528 Quantification of barium in a blood sample. Elliot Sollis Zoe May Pendlington 2022-07-12T14:06:48Z true PMID:35501403 blood barium measurement efo:EFO_0021529 Quantification of rubidium in a blood sample. Elliot Sollis Zoe May Pendlington 2022-07-12T14:07:11Z true PMID:35501403 blood rubidium measurement efo:EFO_0021530 Quantification of tin in a blood sample. Elliot Sollis Zoe May Pendlington 2022-07-12T14:07:33Z true PMID:35501403 blood tin measurement efo:EFO_0021531 Quantification of strontium in a blood sample. Elliot Sollis Zoe May Pendlington 2022-07-12T14:07:50Z true PMID:35501403 blood strontium measurement efo:EFO_0021532 Quantification of titanium in a blood sample. Elliot Sollis Zoe May Pendlington 2022-07-12T14:08:16Z true PMID:35501403 blood titanium measurement efo:EFO_0021533 Quantification of vanadium in a blood sample. Elliot Sollis Zoe May Pendlington 2022-07-12T14:08:38Z true PMID:35501403 blood vanadium measurement efo:EFO_0021534 Quanitification of abdominal fat cells in a sample. Zoe May Pendlington 2022-07-12T16:31:59Z true PMID:35320353 abdominal fat cell number efo:EFO_0021536 Quantification of irritable bowel syndrome symptoms for instance using the IBS Symptom Severity Scale assessing pain frequency and intensity, bowel dysfunction or bloating. Zoe May Pendlington 2022-07-13T08:26:36Z true PMID:35401282 IBS symptom measurement irritable bowel syndrome symptom measurement efo:EFO_0021537 Quantification of N-linked transferrin glycans in a sample. Zoe May Pendlington 2022-07-13T08:46:48Z true PMID:35332118 transferrin glycosylation measurement efo:EFO_0021538 Quantification of the amount of N-acetylornithine in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-13T09:32:58Z PMID:27073872 N-acetylornithine measurement efo:EFO_0021539 Quantification of the amount of X-11244 in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-13T09:33:17Z PMID:27073872 X-11244 measurement efo:EFO_0021540 Quantification of the amount of X-11255 in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-13T09:33:30Z PMID:27073872 X-11255 measurement efo:EFO_0021541 Quantification of the amount of X-11421 in a sample. Elizabeth Lewis Zoe May Pendlington 2022-07-13T09:33:40Z PMID:27073872 X-11421 measurement efo:EFO_0021542 Quantification of the amount of (S)-(-)-2-Hydroxyisocaproic acid measurement in a sample. Elizabeth Lewis true PMID:33634981 (S)-(-)-2-Hydroxyisocaproic acid measurement efo:EFO_0021543 Quantification of the amount of 1-Methylhistidine measurement in a sample. Elizabeth Lewis true PMID:33634981 1-Methylhistidine measurement efo:EFO_0021544 Quantification of the amount of 1,3-Dimethyluric acid measurement in a sample. Elizabeth Lewis true PMID:33634981 1,3-Dimethyluric acid measurement efo:EFO_0021545 Quantification of the amount of 1,3,7-trimethyluric acid measurement in a sample. Elizabeth Lewis true PMID:33634981 1,3,7-trimethyluric acid measurement efo:EFO_0021546 Quantification of the amount of 1,4-dihydro-1-Methyl-4-oxo-3-pyridinecarboxamide measurement in a sample. Elizabeth Lewis true PMID:33634981 1,4-dihydro-1-Methyl-4-oxo-3-pyridinecarboxamide measurement efo:EFO_0021547 Quantification of the amount of 1,7-Dimethylxanthine in a sample. Elizabeth Lewis true PMID:33634981 1,7-Dimethylxanthine measurement efo:EFO_0021548 Quantification of the amount of 2-(dimethylamino) guanosine in a sample. Elizabeth Lewis true PMID:33634981 2-(dimethylamino) guanosine measurement efo:EFO_0021549 Quantification of the amount of 2-Aminoethanesulfonic acid in a sample. Elizabeth Lewis true PMID:33634981 2-Aminoethanesulfonic acid measurement efo:EFO_0021550 Quantification of the amount of 2-Hydroxybutanoic acid in a sample. Elizabeth Lewis true PMID:33634981 2-Hydroxybutanoic acid measurement efo:EFO_0021551 Quantification of the amount of 2-Hydroxyisocaproic acid in a sample. Elizabeth Lewis true PMID:33634981 2-Hydroxyisocaproic acid measurement efo:EFO_0021552 Quantification of the amount of 2-Methylsuccinic acid in a sample. Elizabeth Lewis true PMID:33634981 2-Methylsuccinic acid measurement efo:EFO_0021553 Quantification of the amount of 2-Picolinic acid in a sample. Elizabeth Lewis true PMID:33634981 2-Picolinic acid measurement efo:EFO_0021554 Quantification of the amount of 2,3-dimethylsuccinic acid in a sample. Elizabeth Lewis true PMID:33634981 2,3-dimethylsuccinic acid measurement efo:EFO_0021555 Quantification of the amount of 2,6-Diaminooimelic acid in a sample. Elizabeth Lewis true PMID:33634981 2,6-Diaminooimelic acid measurement efo:EFO_0021556 Quantification of the amount of 3-(3-hydroxyphenyl) propionate acid in a sample. Elizabeth Lewis true PMID:33634981 3-(3-hydroxyphenyl) propionate acid measurement efo:EFO_0021557 Quantification of the amount of 3-Hydroxy-3-methyl butyric acid in a sample. Elizabeth Lewis true PMID:33634981 3-Hydroxy-3-methyl butyric acid measurement efo:EFO_0021558 Quantification of the amount of 3-Hydroxyhippuric acid (m-Hydroxyhippuricacid) in a sample. Elizabeth Lewis true PMID:33634981 3-Hydroxyhippuric acid (m-Hydroxyhippuricacid) measurement efo:EFO_0021559 Quantification of the amount of 3-Indolebutyric acid in a sample. Elizabeth Lewis true PMID:33634981 3-Indolebutyric acid measurement efo:EFO_0021560 Quantification of the amount of 3-Indolepropionic acid in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid measurement efo:EFO_0021561 Quantification of the amount of 3-Methylcrotonyl glycine in a sample. Elizabeth Lewis true PMID:33634981 3-Methylcrotonyl glycine measurement efo:EFO_0021562 Quantification of the amount of 3-N-Methyl-L-histidine in a sample. Elizabeth Lewis true PMID:33634981 3-N-Methyl-L-histidine measurement efo:EFO_0021563 Quantification of the amount of 3,3',5-Triiodo-L-thyronine in a sample. Elizabeth Lewis true PMID:33634981 3,3',5-Triiodo-L-thyronine measurement efo:EFO_0021564 Quantification of the amount of 3,4,5-Trimethoxycinnamic acid in a sample. Elizabeth Lewis true PMID:33634981 3,4,5-Trimethoxycinnamic acid measurement efo:EFO_0021565 Quantification of the amount of 4-Acetamidobutyric acid in a sample. Elizabeth Lewis true PMID:33634981 4-Acetamidobutyric acid measurement efo:EFO_0021566 Quantification of the amount of 4-Guanidinobutyric acid in a sample. Elizabeth Lewis true PMID:33634981 4-Guanidinobutyric acid measurement efo:EFO_0021567 Quantification of the amount of 4-Hydroxybenzaldehyde in a sample. Elizabeth Lewis true PMID:33634981 4-Hydroxybenzaldehyde measurement efo:EFO_0021568 Quantification of the amount of 4-Nitrophenol in a sample. Elizabeth Lewis true PMID:33634981 4-Nitrophenol measurement efo:EFO_0021569 Quantification of the amount of 4-Pyridoxic acid in a sample. Elizabeth Lewis true PMID:33634981 4-Pyridoxic acid measurement efo:EFO_0021570 Quantification of the amount of 5-Methyluridine in a sample. Elizabeth Lewis true PMID:33634981 5-Methyluridine measurement efo:EFO_0021571 Quantification of the amount of 5'-Deoxy-5'-(methylthio) adenosine in a sample. Elizabeth Lewis true PMID:33634981 5'-Deoxy-5'-(methylthio) adenosine measurement efo:EFO_0021572 Quantification of the amount of 9,10-dihome in a sample. Elizabeth Lewis true PMID:33634981 9,10-dihome measurement efo:EFO_0021573 Quantification of the amount of Adenine in a sample. Elizabeth Lewis true PMID:33634981 Adenine measurement efo:EFO_0021574 Quantification of the amount of Adenosine 5'-monophosphate in a sample. Elizabeth Lewis true PMID:33634981 Adenosine 5'-monophosphate measurement efo:EFO_0021575 Quantification of the amount of Adipic acid in a sample. Elizabeth Lewis true PMID:33634981 Adipic acid measurement efo:EFO_0021576 Quantification of the amount of Asp-phe in a sample. Elizabeth Lewis true PMID:33634981 Asp-phe measurement efo:EFO_0021577 Quantification of the amount of Azelaic acid in a sample. Elizabeth Lewis true PMID:33634981 Azelaic acid measurement efo:EFO_0021578 Quantification of the amount of Caffeic acid in a sample. Elizabeth Lewis true PMID:33634981 Caffeic acid measurement efo:EFO_0021580 Quantification of the amount of Cyclic AMP in a sample. Elizabeth Lewis true PMID:33634981 Cyclic AMP measurement efo:EFO_0021581 Quantification of the amount of D-2-Aminobutyric acid in a sample. Elizabeth Lewis true PMID:33634981 D-2-Aminobutyric acid measurement efo:EFO_0021582 Quantification of the amount of D-Arabinose in a sample. Elizabeth Lewis true PMID:33634981 D-Arabinose measurement efo:EFO_0021583 Quantification of the amount of D-Erythronolactone in a sample. Elizabeth Lewis true PMID:33634981 D-Erythronolactone measurement efo:EFO_0021584 Quantification of the amount of D-Fructose in a sample. Elizabeth Lewis true PMID:33634981 D-Fructose measurement efo:EFO_0021585 Quantification of the amount of D-Glucopyranose in a sample. Elizabeth Lewis true PMID:33634981 D-Glucopyranose measurement efo:EFO_0021586 Quantification of the amount of D-Glucose in a sample. Elizabeth Lewis true PMID:33634981 D-Glucose measurement efo:EFO_0021587 Quantification of the amount of D-Lactic acid in a sample. Elizabeth Lewis true PMID:33634981 D-Lactic acid measurement efo:EFO_0021588 Quantification of the amount of D-Malic acid in a sample. Elizabeth Lewis true PMID:33634981 D-Malic acid measurement efo:EFO_0021589 Quantification of the amount of D-Mannose in a sample. Elizabeth Lewis true PMID:33634981 D-Mannose measurement efo:EFO_0021590 Quantification of the amount of D-Sorbitol in a sample. Elizabeth Lewis true PMID:33634981 D-Sorbitol measurement efo:EFO_0021591 Quantification of the amount of D-Sucrose in a sample. Elizabeth Lewis true PMID:33634981 D-Sucrose measurement efo:EFO_0021592 Quantification of the amount of D-Trehalose in a sample. Elizabeth Lewis true HMDB:HMDB0000975 KEGG COMPOUND:C01083 PMID:33634981 trehalose measurement D-Trehalose measurement efo:EFO_0021593 Quantification of the amount of Deoxycholic acid in a sample. Elizabeth Lewis true PMID:33634981 Deoxycholic acid measurement efo:EFO_0021594 Quantification of the amount of DL-P-hydroxyphenyllactic acid in a sample. Elizabeth Lewis true PMID:33634981 DL-P-hydroxyphenyllactic acid measurement efo:EFO_0021595 Quantification of the amount of Dodecanedioic aicd in a sample. Elizabeth Lewis true PMID:33634981 Dodecanedioic aicd measurement efo:EFO_0021596 Quantification of the amount of Dulcitol in a sample. Elizabeth Lewis true PMID:33634981 Dulcitol measurement efo:EFO_0021597 Quantification of the amount of Eudesmic acid (3,4,5-trimethoxybenzoic acid) in a sample. Elizabeth Lewis true PMID:33634981 Eudesmic acid (3,4,5-trimethoxybenzoic acid) measurement efo:EFO_0021598 Quantification of the amount of Gluconic acid in a sample. Elizabeth Lewis true PMID:33634981 Gluconic acid measurement efo:EFO_0021599 Quantification of the amount of Glycochenodeoxycholic acid in a sample. Elizabeth Lewis true PMID:33634981 Glycochenodeoxycholic acid measurement efo:EFO_0021600 Quantification of the amount of Glycoursodeoxycholic acid in a sample. Elizabeth Lewis true PMID:33634981 Glycoursodeoxycholic acid measurement efo:EFO_0021601 Quantification of the amount of Hexanoyl glycine in a sample. Elizabeth Lewis true PMID:33634981 Hexanoyl glycine measurement efo:EFO_0021602 Quantification of the amount of Homovanillic acid in a sample. Elizabeth Lewis true PMID:33634981 Homovanillic acid measurement efo:EFO_0021603 Quantification of the amount of Hydrocinnamic acid in a sample. Elizabeth Lewis true PMID:33634981 Hydrocinnamic acid measurement efo:EFO_0021604 Quantification of the amount of Hypoxanthine in a sample. Elizabeth Lewis true PMID:33634981 Hypoxanthine measurement efo:EFO_0021605 Quantification of the amount of Indole-5-carboxylic acid in a sample. Elizabeth Lewis true PMID:33634981 Indole-5-carboxylic acid measurement efo:EFO_0021607 Quantification of the amount of Isonicotinamide in a sample. Elizabeth Lewis true PMID:33634981 Isonicotinamide measurement efo:EFO_0021608 Quantification of the amount of L-2-Aminobutyric acid in a sample. Elizabeth Lewis true PMID:33634981 L-2-Aminobutyric acid measurement efo:EFO_0021609 Quantification of the amount of L-3-Phenyllactic acid in a sample. Elizabeth Lewis true PMID:33634981 L-3-Phenyllactic acid measurement efo:EFO_0021610 Quantification of the amount of L-Asparagine anhydrous in a sample. Elizabeth Lewis true PMID:33634981 L-Asparagine anhydrous measurement efo:EFO_0021611 Quantification of the amount of L-Aspartic acid in a sample. Elizabeth Lewis true PMID:33634981 L-Aspartic acid measurement efo:EFO_0021612 Quantification of the amount of L-Carnitine in a sample. Elizabeth Lewis true PMID:33634981 L-Carnitine measurement efo:EFO_0021613 Quantification of the amount of L-Citrulline in a sample. Elizabeth Lewis true PMID:33634981 L-Citrulline measurement efo:EFO_0021614 Quantification of the amount of L-Cysteine in a sample. Elizabeth Lewis true PMID:33634981 L-Cysteine measurement efo:EFO_0021615 Quantification of the amount of L-Cystine in a sample. Elizabeth Lewis true PMID:33634981 L-Cystine measurement efo:EFO_0021616 Quantification of the amount of L-Glutamic acid in a sample. Elizabeth Lewis true PMID:33634981 L-Glutamic acid measurement efo:EFO_0021617 Quantification of the amount of L-Glutamine in a sample. Elizabeth Lewis true PMID:33634981 L-Glutamine measurement efo:EFO_0021618 Quantification of the amount of L-Histidine in a sample. Elizabeth Lewis true PMID:33634981 L-Histidine measurement efo:EFO_0021619 Quantification of the amount of L-Isoleucine in a sample. Elizabeth Lewis true PMID:33634981 L-Isoleucine measurement efo:EFO_0021620 Quantification of the amount of L-Leucine in a sample. Elizabeth Lewis true PMID:33634981 L-Leucine measurement efo:EFO_0021621 Quantification of the amount of L-Lysine in a sample. Elizabeth Lewis true PMID:33634981 L-Lysine measurement efo:EFO_0021622 Quantification of the amount of L-Malic acid in a sample. Elizabeth Lewis true HMDB:HMDB0000156 KEGG COMPOUND:C00149 PMID:33634981 malic acid measurement L-Malic acid measurement efo:EFO_0021623 Quantification of the amount of L-Methionine in a sample. Elizabeth Lewis true PMID:33634981 L-Methionine measurement efo:EFO_0021624 Quantification of the amount of L-Ornithine in a sample. Elizabeth Lewis true PMID:33634981 L-Ornithine measurement efo:EFO_0021625 Quantification of the amount of L-Phenylalanine in a sample. Elizabeth Lewis true PMID:33634981 L-Phenylalanine measurement efo:EFO_0021626 Quantification of the amount of L-Pipecolic acid in a sample. Elizabeth Lewis true PMID:33634981 L-Pipecolic acid measurement efo:EFO_0021627 Quantification of the amount of L-Proline in a sample. Elizabeth Lewis true PMID:33634981 L-Proline measurement efo:EFO_0021628 Quantification of the amount of L-Pyroglutamic acid in a sample. Elizabeth Lewis true PMID:33634981 L-Pyroglutamic acid measurement efo:EFO_0021629 Quantification of the amount of L-Saccharopine in a sample. Elizabeth Lewis true PMID:33634981 L-Saccharopine measurement efo:EFO_0021630 Quantification of the amount of L-Serine in a sample. Elizabeth Lewis true PMID:33634981 L-Serine measurement efo:EFO_0021631 Quantification of the amount of L-Threonine in a sample. Elizabeth Lewis true PMID:33634981 L-Threonine measurement efo:EFO_0021632 Quantification of the amount of L-Thyroxine in a sample. Elizabeth Lewis true PMID:33634981 L-Thyroxine measurement efo:EFO_0021633 Quantification of the amount of L-Tryptophan in a sample. Elizabeth Lewis true PMID:33634981 L-Tryptophan measurement efo:EFO_0021634 Quantification of the amount of L-Tyrosine in a sample. Elizabeth Lewis true PMID:33634981 L-Tyrosine measurement efo:EFO_0021635 Quantification of the amount of L-Valine in a sample. Elizabeth Lewis true PMID:33634981 L-Valine measurement efo:EFO_0021636 Quantification of the amount of Lauric acid / Dodecanoic acid (C12:0) in a sample. Elizabeth Lewis true PMID:33634981 Dodecanoic acid measurement Lauric acid measurement efo:EFO_0021637 Quantification of the amount of LysoPA 16:0 in a sample. Elizabeth Lewis true PMID:33634981 LysoPA 16:0 measurement efo:EFO_0021638 Quantification of the amount of LysoPC 14:0 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 14:0 measurement efo:EFO_0021639 Quantification of the amount of LysoPC 16:0 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 16:0 measurement efo:EFO_0021640 Quantification of the amount of LysoPC 16:1 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 16:1 measurement efo:EFO_0021641 Quantification of the amount of LysoPC 18:0 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 18:0 measurement efo:EFO_0021642 Quantification of the amount of LysoPC 18:1 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 18:1 measurement efo:EFO_0021643 Quantification of the amount of LysoPC 20:0 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 20:0 measurement efo:EFO_0021644 Quantification of the amount of LysoPC 20:1 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 20:1 measurement efo:EFO_0021645 Quantification of the amount of LysoPC 20:2 in a sample. Elizabeth Lewis true PMID:33634981 LysoPC 20:2 measurement efo:EFO_0021646 Quantification of the amount of LysoPE 14:0 in a sample. Elizabeth Lewis true PMID:33634981 LysoPE 14:0 measurement efo:EFO_0021647 Quantification of the amount of LysoPE 16:0 in a sample. Elizabeth Lewis true PMID:33634981 LysoPE 16:0 measurement efo:EFO_0021648 Quantification of the amount of LysoPE 18:1 in a sample. Elizabeth Lewis true PMID:33634981 LysoPE 18:1 measurement efo:EFO_0021649 Quantification of the amount of Maltose in a sample. Elizabeth Lewis true PMID:33634981 Maltose measurement efo:EFO_0021650 Quantification of the amount of Methionine sulfoxide in a sample. Elizabeth Lewis true PMID:33634981 Methionine sulfoxide measurement efo:EFO_0021651 Quantification of the amount of Methylmalonic acid in a sample. Elizabeth Lewis true PMID:33634981 Methylmalonic acid measurement efo:EFO_0021652 Quantification of the amount of Myoinositol in a sample. Elizabeth Lewis true PMID:33634981 Myoinositol measurement efo:EFO_0021653 Quantification of the amount of N-acetyl-l-leucine in a sample. Elizabeth Lewis true PMID:33634981 N-acetyl-l-leucine measurement efo:EFO_0021654 Quantification of the amount of N-Acetyl-L-tyrosine in a sample. Elizabeth Lewis true PMID:33634981 N-Acetyl-L-tyrosine measurement efo:EFO_0021655 Quantification of the amount of N,N-Dimethylglycine in a sample. Elizabeth Lewis true PMID:33634981 N,N-Dimethylglycine measurement efo:EFO_0021656 Quantification of the amount of N6-Acetyl-L-lysine in a sample. Elizabeth Lewis true PMID:33634981 N6-Acetyl-L-lysine measurement efo:EFO_0021657 Quantification of the amount of N6-Succinyl adenosine in a sample. Elizabeth Lewis true PMID:33634981 N6-Succinyl adenosine measurement efo:EFO_0021658 Quantification of the amount of p-Hydroxyphenyl acetic acid in a sample. Elizabeth Lewis true PMID:33634981 p-Hydroxyphenyl acetic acid measurement efo:EFO_0021659 Quantification of the amount of Palmitaldehyde in a sample. Elizabeth Lewis true PMID:33634981 Palmitaldehyde measurement efo:EFO_0021660 Quantification of the amount of Palmitic acid / Hexadecanoic acid (C16:0) in a sample. Elizabeth Lewis true PMID:33634981 Hexadecanoic acid measurement Palmitic acid measurement efo:EFO_0021661 Quantification of the amount of Phenylacetyl-L-glutamine in a sample. Elizabeth Lewis true PMID:33634981 Phenylacetyl-L-glutamine measurement efo:EFO_0021662 Quantification of the amount of Phenyllactate (PLA) in a sample. Elizabeth Lewis true PMID:33634981 Phenyllactate (PLA) measurement efo:EFO_0021663 Quantification of the amount of Phenylpyruvic acid in a sample. Elizabeth Lewis true PMID:33634981 Phenylpyruvic acid measurement efo:EFO_0021664 Quantification of the amount of Pipecolinic acid in a sample. Elizabeth Lewis true PMID:33634981 Pipecolinic acid measurement efo:EFO_0021665 Quantification of the amount of Riboflavin in a sample. Elizabeth Lewis true PMID:33634981 Riboflavin measurement efo:EFO_0021666 Quantification of the amount of S-(5-Adenosy)-L-homocysteine in a sample. Elizabeth Lewis true PMID:33634981 S-(5-Adenosy)-L-homocysteine measurement efo:EFO_0021667 Quantification of the amount of S-Sulfo-L-cysteine in a sample. Elizabeth Lewis true PMID:33634981 S-Sulfo-L-cysteine measurement efo:EFO_0021668 Quantification of the amount of Sarcosine in a sample. Elizabeth Lewis true PMID:33634981 Sarcosine measurement efo:EFO_0021669 Quantification of the amount of Succinic acid in a sample. Elizabeth Lewis true PMID:33634981 Succinic acid measurement efo:EFO_0021670 Quantification of the amount of Taurochenodesoxycholic acid in a sample. Elizabeth Lewis true PMID:33634981 Taurochenodesoxycholic acid measurement efo:EFO_0021671 Quantification of the amount of Taurocholic acid sodium salt hydrate in a sample. Elizabeth Lewis true PMID:33634981 Taurocholic acid sodium salt hydrate measurement efo:EFO_0021672 Quantification of the amount of Tauroursodeoxycholic acid in a sample. Elizabeth Lewis true PMID:33634981 Tauroursodeoxycholic acid measurement efo:EFO_0021674 Quantification of the amount of trans,trans-Muconic acid in a sample. Elizabeth Lewis true PMID:33634981 trans,trans-Muconic acid measurement efo:EFO_0021675 Quantification of the amount of Uridine 5-monophosphate in a sample. Elizabeth Lewis true PMID:33634981 Uridine 5-monophosphate measurement efo:EFO_0021676 Quantification of the amount of Urocanic acid (RG) in a sample. Elizabeth Lewis true PMID:33634981 Urocanic acid (RG) measurement efo:EFO_0021677 Quantification of the amount of beta-Nicotinamide mononucleotide in a sample. Elizabeth Lewis true PMID:33634981 beta-Nicotinamide mononucleotide measurement efo:EFO_0021678 Quantification of the amount of beta-Pseudouridine in a sample. Elizabeth Lewis true PMID:33634981 beta-Pseudouridine measurement efo:EFO_0021679 Quantification of the ratio of L-Histidine to Uric acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Histidine to Uric acid ratio efo:EFO_0021680 Quantification of the ratio of Cis-5,8,11,14,17-eicosapentaenoic acid (C20:5n3) to LysoPC 20:2 ratio in a sample. Elizabeth Lewis true PMID:33634981 Cis-5,8,11,14,17-eicosapentaenoic acid (C20:5n3) to LysoPC 20:2 ratio efo:EFO_0021681 Quantification of the ratio of L-Tryptophan to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Tryptophan to 3-Indolepropionic acid ratio efo:EFO_0021682 Quantification of the ratio of 3-Indolepropionic acid to L-Lysine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Lysine ratio efo:EFO_0021683 Quantification of the ratio of 3-Indolepropionic acid to Uridine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Uridine ratio efo:EFO_0021684 Quantification of the ratio of 3-Indolepropionic acid to Adenine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Adenine ratio efo:EFO_0021685 Quantification of the ratio of 3-Indolepropionic acid to L-Methionine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Methionine ratio efo:EFO_0021686 Quantification of the ratio of L-Phenylalanine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Phenylalanine to 3-Indolepropionic acid ratio efo:EFO_0021687 Quantification of the ratio of 3-Indolepropionic acid to L-Tyrosine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Tyrosine ratio efo:EFO_0021688 Quantification of the ratio of 3-Indolepropionic acid to Phenylpyruvic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Phenylpyruvic acid ratio efo:EFO_0021689 Quantification of the ratio of 3-Indolepropionic acid to L-Ornithine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Ornithine ratio efo:EFO_0021690 Quantification of the ratio of L-Glutamine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Glutamine to 3-Indolepropionic acid ratio efo:EFO_0021691 Quantification of the ratio of 3-Indolepropionic acid to Taurocholic acid sodium salt hydrate ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Taurocholic acid sodium salt hydrate ratio efo:EFO_0021692 Quantification of the ratio of 3-Indolepropionic acid to L-Valine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Valine ratio efo:EFO_0021693 Quantification of the ratio of Asp-phe to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 Asp-phe to 3-Indolepropionic acid ratio efo:EFO_0021694 Quantification of the ratio of L-Histidine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Histidine to 3-Indolepropionic acid ratio efo:EFO_0021695 Quantification of the ratio of 3-Indolepropionic acid to 3,3',5-Triiodo-L-thyronine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 3,3',5-Triiodo-L-thyronine ratio efo:EFO_0021696 Quantification of the ratio of D-Arabinose to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 D-Arabinose to 3-Indolepropionic acid ratio efo:EFO_0021697 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 16:0 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 16:0 ratio efo:EFO_0021698 Quantification of the ratio of L-Threonine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Threonine to 3-Indolepropionic acid ratio efo:EFO_0021699 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 18:1 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 18:1 ratio efo:EFO_0021700 Quantification of the ratio of 3-Indolepropionic acid to N6-Acetyl-L-lysine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to N6-Acetyl-L-lysine ratio efo:EFO_0021701 Quantification of the ratio of L-Thyroxine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Thyroxine to 3-Indolepropionic acid ratio efo:EFO_0021702 Quantification of the ratio of L-Aspartic acid to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Aspartic acid to 3-Indolepropionic acid ratio efo:EFO_0021703 Quantification of the ratio of 3-Indolepropionic acid to Trimethylamine N-oxide ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Trimethylamine N-oxide ratio efo:EFO_0021704 Quantification of the ratio of 3-Indolepropionic acid to Uric acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Uric acid ratio efo:EFO_0021705 Quantification of the ratio of 3-Indolepropionic acid to D-Fructose ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to D-Fructose ratio efo:EFO_0021706 Quantification of the ratio of 3-Indolepropionic acid to Sarcosine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Sarcosine ratio efo:EFO_0021707 Quantification of the ratio of 3-Indolepropionic acid to Choline ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Choline ratio efo:EFO_0021708 Quantification of the ratio of L-Glutamic acid to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Glutamic acid to 3-Indolepropionic acid ratio efo:EFO_0021709 Quantification of the ratio of L-Serine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Serine to 3-Indolepropionic acid ratio efo:EFO_0021710 Quantification of the ratio of 3-Indolepropionic acid to S-(5-Adenosy) -L-homocysteine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to S-(5-Adenosy) -L-homocysteine ratio efo:EFO_0021711 Quantification of the ratio of 3-Indolepropionic acid to D-2-Aminobutyric acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to D-2-Aminobutyric acid ratio efo:EFO_0021712 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 16:1 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 16:1 ratio efo:EFO_0021713 Quantification of the ratio of 3-Indolepropionic acid to Hippuric acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Hippuric acid ratio efo:EFO_0021714 Quantification of the ratio of 3-Indolepropionic acid to Pipecolinic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Pipecolinic acid ratio efo:EFO_0021715 Quantification of the ratio of L-Citrulline to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Citrulline to 3-Indolepropionic acid ratio efo:EFO_0021716 Quantification of the ratio of 3-Indolepropionic acid to L-Saccharopine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Saccharopine ratio efo:EFO_0021717 Quantification of the ratio of 3-Indolepropionic acid to 5-oxoproline ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 5-oxoproline ratio efo:EFO_0021718 Quantification of the ratio of L-Asparagine Anhydrous to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Asparagine Anhydrous to 3-Indolepropionic acid ratio efo:EFO_0021719 Quantification of the ratio of 3-Indolepropionic acid to Kinurenine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Kinurenine ratio efo:EFO_0021720 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 18:0 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 18:0 ratio efo:EFO_0021721 Quantification of the ratio of 3-Indolepropionic acid to L-2-Aminobutyric acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-2-Aminobutyric acid ratio efo:EFO_0021722 Quantification of the ratio of 3-Indolepropionic acid to 2-Picolinic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 2-Picolinic acid ratio efo:EFO_0021723 Quantification of the ratio of 3-Indolepropionic acid to 2-Methylsuccinic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 2-Methylsuccinic acid ratio efo:EFO_0021724 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 20:2 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 20:2 ratio efo:EFO_0021725 Quantification of the ratio of 3-Indolepropionic acid to 4-Guanidinobutyric acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 4-Guanidinobutyric acid ratio efo:EFO_0021726 Quantification of the ratio of 3-Indolepropionic acid to Isonicotinamide ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Isonicotinamide ratio efo:EFO_0021727 Quantification of the ratio of 5-Methyluridine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 5-Methyluridine to 3-Indolepropionic acid ratio efo:EFO_0021728 Quantification of the ratio of 3-Indolepropionic acid to N-acetylglycine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to N-acetylglycine ratio efo:EFO_0021729 Quantification of the ratio of 3-Indolepropionic acid to N-Acetyl-L-tyrosine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to N-Acetyl-L-tyrosine ratio efo:EFO_0021730 Quantification of the ratio of L-Cystine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Cystine to 3-Indolepropionic acid ratio efo:EFO_0021731 Quantification of the ratio of 3-Indolepropionic acid to Cyclic AMP ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Cyclic AMP ratio efo:EFO_0021732 Quantification of the ratio of 3-Indolepropionic acid to L-Carnitine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Carnitine ratio efo:EFO_0021733 Quantification of the ratio of 3-Indolepropionic acid to 1,4-dihydro-1-Methyl-4-oxo-3-pyridinecarboxamide ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 1,4-dihydro-1-Methyl-4-oxo-3-pyridinecarboxamide ratio efo:EFO_0021734 Quantification of the ratio of 3-Indolepropionic acid to Creatine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Creatine ratio efo:EFO_0021735 Quantification of the ratio of 3-Indolepropionic acid to Dodecanedioic aicd ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Dodecanedioic aicd ratio efo:EFO_0021736 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 20:1 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 20:1 ratio efo:EFO_0021737 Quantification of the ratio of 3-Indolepropionic acid to L-Arginine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Arginine ratio efo:EFO_0021738 Quantification of the ratio of 3-Indolepropionic acid to Kynurenic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Kynurenic acid ratio efo:EFO_0021739 Quantification of the ratio of 3-Indolepropionic acid to 2-Hydroxyisocaproic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 2-Hydroxyisocaproic acid ratio efo:EFO_0021740 Quantification of the ratio of 3-Indolepropionic acid to 4-Pyridoxic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 4-Pyridoxic acid ratio efo:EFO_0021741 Quantification of the ratio of 3-Indolepropionic acid to L-Pipecolic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to L-Pipecolic acid ratio efo:EFO_0021742 Quantification of the ratio of 3-Indolepropionic acid to 3-Hydroxybutyrate ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 3-Hydroxybutyrate ratio efo:EFO_0021743 Quantification of the ratio of 3-Indolepropionic acid to (S)-(-)-2-Hydroxyisocaproic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to (S)-(-)-2-Hydroxyisocaproic acid ratio efo:EFO_0021744 Quantification of the ratio of 3-Indolepropionic acid to Creatinine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Creatinine ratio efo:EFO_0021745 Quantification of the ratio of L-Pyroglutamic acid to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Pyroglutamic acid to 3-Indolepropionic acid ratio efo:EFO_0021746 Quantification of the ratio of 3-Indolepropionic acid to gamma-Linolenic acid (C18:3n6) ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to gamma-Linolenic acid (C18:3n6) ratio efo:EFO_0021747 Quantification of the ratio of 3-Indolepropionic acid to N,N-Dimethylglycine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to N,N-Dimethylglycine ratio efo:EFO_0021748 Quantification of the ratio of 3-Indolepropionic acid to SubericAcid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to SubericAcid ratio efo:EFO_0021749 Quantification of the ratio of 3-Indolepropionic acid to 2-(dimethylamino) guanosine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 2-(dimethylamino) guanosine ratio efo:EFO_0021750 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 14:0 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 14:0 ratio efo:EFO_0021751 Quantification of the ratio of 3-Indolepropionic acid to 4-Hydroxybenzaldehyde ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 4-Hydroxybenzaldehyde ratio efo:EFO_0021752 Quantification of the ratio of 3-Indolepropionic acid to Azelaic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Azelaic acid ratio efo:EFO_0021753 Quantification of the ratio of 3-Indolepropionic acid to cis-5,8,11,14,17-Eicosapentaenoic acid C20:5n3) ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to cis-5,8,11,14,17-Eicosapentaenoic acid C20:5n3) ratio efo:EFO_0021754 Quantification of the ratio of 3-Indolepropionic acid to Hypoxanthine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Hypoxanthine ratio efo:EFO_0021755 Quantification of the ratio of L-Proline to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 L-Proline to 3-Indolepropionic acid ratio efo:EFO_0021756 Quantification of the ratio of D-Trehalose to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 D-Trehalose to 3-Indolepropionic acid ratio efo:EFO_0021757 Quantification of the ratio of 3-Indolepropionic acid to Methylmalonic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Methylmalonic acid ratio efo:EFO_0021758 Quantification of the ratio of 3-Indolepropionic acid to alpha-Linolenic acid (C18:3n3) ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to alpha-Linolenic acid (C18:3n3) ratio efo:EFO_0021759 Quantification of the ratio of 3-Indolepropionic acid to S-Sulfo-L-cysteine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to S-Sulfo-L-cysteine ratio efo:EFO_0021760 Quantification of the ratio of 3-Indolepropionic acid to LysoPC 20:0 ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to LysoPC 20:0 ratio efo:EFO_0021761 Quantification of the ratio of 3-Indolepropionic acid to beta-Pseudouridine ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to beta-Pseudouridine ratio efo:EFO_0021762 Quantification of the ratio of Dulcitol to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 Dulcitol to 3-Indolepropionic acid ratio efo:EFO_0021763 Quantification of the ratio of 3-Indolepropionic acid to 4-Nitrophenol ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to 4-Nitrophenol ratio efo:EFO_0021764 Quantification of the ratio of 3-Indolepropionic acid to Indole-5-carboxylic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Indole-5-carboxylic acid ratio efo:EFO_0021765 Quantification of the ratio of Pantothenate to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 Pantothenate to 3-Indolepropionic acid ratio efo:EFO_0021766 Quantification of the ratio of 3-Indolepropionic acid to Lauric acid/Dodecanoic acid (C12:0) ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Lauric acid ratio efo:EFO_0021767 Quantification of the ratio of 3-Indolepropionic acid to Homovanillic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Homovanillic acid ratio efo:EFO_0021768 Quantification of the ratio of N-acetyl-l-leucine to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 N-acetyl-l-leucine to 3-Indolepropionic acid ratio efo:EFO_0021769 Quantification of the ratio of 3-Indolepropionic acid to Myoinositol ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Myoinositol ratio efo:EFO_0021770 Quantification of the ratio of 3-Indolepropionic acid to Urocanic acid (RG) ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Urocanic acid (RG) ratio efo:EFO_0021771 Quantification of the ratio of Riboflavin to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 Riboflavin to 3-Indolepropionic acid ratio efo:EFO_0021772 Quantification of the ratio of 3-Indolepropionic acid to Maltose ratio in a sample. Elizabeth Lewis true PMID:33634981 3-Indolepropionic acid to Maltose ratio efo:EFO_0021773 Quantification of the ratio of D-Malic acid to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 D-Malic acid to 3-Indolepropionic acid ratio efo:EFO_0021774 Quantification of the ratio of D-Sucrose to 3-Indolepropionic acid ratio in a sample. Elizabeth Lewis true PMID:33634981 D-Sucrose to 3-Indolepropionic acid ratio efo:EFO_0021776 Quantification of the amount of osteopontin protein in a sample Arwa Ibrahim Zoe May Pendlington 2022-07-13T13:19:18Z true PMID:35385482 SPP-1 measurement bone sialoprotein 1 measurement nephropontin measurement secreted phosphoprotein 1 measurement urinary stone protein measurement uropontin measurement osteopontin measurement efo:EFO_0021777 Quantification of the ratio of serine to glycine in plasma. Zoe May Pendlington 2022-07-27T12:34:28Z true PMID:35460232 serine:glycine ratio efo:EFO_0021778 Quantification of circulating uromodulin. Elizabeth Lewis Zoe May Pendlington 2022-07-28T07:47:04Z true PMID:35446786 Kidney disease biomarker. uromodulin measurement efo:EFO_0021779 Age at initiation of a medical treatment, such as a drug, therapy or medical device. Zoe May Pendlington 2022-08-03T09:36:16Z NCIT:C124440 age at first treatment age at initiation of medical treatment age at initiation of treatment efo:EFO_0021780 Age at initiation of hormone replacement therapy, the therapeutic use of hormones to alleviate the effects of hormone deficiency. Zoe May Pendlington 2022-08-03T09:39:40Z age at initiation of hormone replacement therapy efo:EFO_0021781 Age at initiation of the use of corrective lenses, such as glasses or contact lenses, to treat an abnormality of the eye. Zoe May Pendlington 2022-08-03T09:40:43Z true age at initiation of corrective lens use efo:EFO_0021782 Age at initiation of the use of an oral contraceptive pill. Zoe May Pendlington 2022-08-03T09:41:19Z age at initiation of oral contraceptive pill use efo:EFO_0021783 Age at the time of a specific medical procedure or intervention intended to alter the course of a disease. Zoe May Pendlington 2022-08-03T09:45:18Z age at intervention age at medical intervention age at procedure age at medical procedure efo:EFO_0021784 Age of initation of the habit of smoking, the inhaling and exhaling of tobacco smoke. Zoe May Pendlington 2022-08-03T09:47:25Z true age at initiation of smoking efo:EFO_0021785 Age of initiation of the consumption of the drug cannabis. Zoe May Pendlington 2022-08-03T09:47:59Z age at initiation of cannabis consumption age at initiation of cannabis use efo:EFO_0021786 Measurement of the diameter of some part of the aorta. Zoe May Pendlington 2022-08-04T09:27:16Z PMID:34837083 aorta diameter aortic diameter efo:EFO_0021787 Measurement of the diameter of the ascending aorta. Zoe May Pendlington 2022-08-04T09:28:33Z true PMID:34837083 ascending aorta diameter ascending aortic diameter efo:EFO_0021788 Measurement of the diameter of the descending aorta. Zoe May Pendlington 2022-08-04T09:29:10Z true PMID:34837083 descending aorta diameter descending aortic diameter efo:EFO_0021789 Quantification of the volume of the cerebrum. Arwa Ibrahim Zoe May Pendlington 2022-08-05T12:40:47Z true PMID:35842455 cerebral volume measurement efo:EFO_0021790 Quantification of the volume of the subcortex. Arwa Ibrahim Zoe May Pendlington 2022-08-05T12:41:34Z true PMID:35842455 subcortical volume measurement efo:EFO_0021792 Quantification of the severity of the symptoms of preeclampsia. Zoe May Pendlington 2022-08-17T08:24:07Z true PMID:35588731 preeclampsia severity measurement efo:EFO_0021793 Quantification of oral motor skills, generally through the administration of standardised tests such as syllable repetition on single, double and multi-syllable sequences. Elizabeth Lewis Zoe May Pendlington 2022-08-17T13:20:36Z true PMID:34315907 oral motor function measurement efo:EFO_0021794 Quantification of the presence or absence of the CFTR mutation in an individual. Zoe May Pendlington 2022-08-18T08:00:08Z true PMID:35647563 CFTR mutation carrier status efo:EFO_0021802 Quantification of the amount of spermidine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:27:09Z true PMID:35888728 spermidine measurement efo:EFO_0021803 Quantification of the amount of decenoylcarnitine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:27:59Z true PMID:35888728 decenoylcarnitine measurement efo:EFO_0021804 Quantification of the amount of dodecanoylcarnitine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:29:42Z true PMID:35888728 dodecanoylcarnitine measurement efo:EFO_0021805 Quantification of the amount of hydroxyvalerylcarnitine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:31:20Z true PMID:35888728 hydroxyvalerylcarnitine measurement efo:EFO_0021806 Quantification of the amount of hexadecenoylcarnitine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:32:00Z true PMID:35888728 hexadecenoylcarnitine measurement efo:EFO_0021807 Quantification of the amount of hydroxyhexadecenoylcarnitine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:32:51Z true PMID:35888728 hydroxyhexadecanoylcarnitine measurement efo:EFO_0021808 Quantification of the amount of dodecenoylcarnitine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:33:39Z true PMID:35888728 dodecenoylcarnitine measurement efo:EFO_0021809 Quantification of the amount of tetradecenoylcarnitine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:34:20Z true PMID:35888728 tetradecenoylcarnitine meaasurement efo:EFO_0021810 Quantification of the amount of putrescine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:34:57Z true PMID:35888728 putrescine measurement efo:EFO_0021811 Quantification of the amount of lysophosphatidylcholine 26:1 levels in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-05T09:35:54Z true PMID:35888728 lysophosphatidylcholine 26:1 measurement efo:EFO_0021813 The lowest noxious stimulation intensity required to trigger a reflex motor response. Zoe May Pendlington 2022-09-05T13:30:01Z true RIII threshold nociceptive flexion reflex threshold efo:EFO_0021814 Quantification of some aspect of the diastolic function of the right cardiac ventricle. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:26:55Z true PMID:35697867 right ventricular diastolic volume measurement efo:EFO_0021815 Quantification of some aspect of the systolic function of the right cardiac ventricle. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:28:03Z true PMID:35697867 right ventricular systolic volume measurement efo:EFO_0021816 Quantification of the volumetric fraction of blood pumped out of the right ventricle. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:30:03Z true PMID:35697867 right ventricular ejection fraction measurement efo:EFO_0021817 Quantification of the volume of blood ejected from the right ventricle during one heart contraction. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:30:47Z true PMID:35697867 right ventricular stroke volume measurement Quantification of the volume of blood ejected from the right ventricle during one heart contraction. https://cardiacmri.com/analysis-guide/rv-volumes-and-global-function/volumes/ efo:EFO_0021818 The ratio of right ventricular diastolic volume to left ventricular diastolic volume. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:32:03Z PMID:35697867 right ventricular diastolic volume to left ventricular diastolic volume ratio efo:EFO_0021819 The ratio of right ventricular systolic volume to left ventricular systolic volume. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:33:27Z PMID:35697867 right ventricular systolic volume to left ventricular systolic volume ratio efo:EFO_0021820 The ratio of right ventricular ejection fraction to left ventricular ejection fraction. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:45:11Z PMID:35697867 right ventricular ejection fraction to left ventricular ejection fraction ratio efo:EFO_0021821 The ratio of right ventricular stroke volume to left ventricular stroke volume. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:46:04Z PMID:35697867 right ventricular stroke volume to left ventricular stroke volume ratio efo:EFO_0021822 Quantification of the maximum area of the right cardiac atrium. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:46:48Z PMID:35697867 right atrial maximum area measurement efo:EFO_0021823 Quantification of the minimum area of the right cardiac atrium. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:47:08Z PMID:35697867 right atrial minimum area measurement efo:EFO_0021824 The ratio of the change in area between the maximum and minimum area divided by the maximum area of the right cardiac atrium. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:47:32Z PMID:35697867 right atrial fractional area change measurement efo:EFO_0021825 Quantification of the diameter of the pulmonary artery root (the apical-most segment to the right ventricle) as measured by MRI. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:47:52Z PMID:35697867 pulmonary artery root diameter measurement efo:EFO_0021826 Quantification of the diameter of the proximal pulmonary artery (the distal-most segment of the main pulmonary artery) as measured by MRI. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:48:11Z PMID:35697867 proximal pulmonary artery diameter measurement efo:EFO_0021827 Quantification of pulmonary artery strain (change in diameter between systolic and diastolic diameter divided by diastolic diameter of the pulmonary artery) as measured by MRI. Arwa Ibrahim Zoe May Pendlington 2022-09-06T09:48:29Z PMID:35697867 pulmonary artery strain measurement efo:EFO_0021828 Quantification of the amount of 1-aminocyclopropane-1-carboxylic acid in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:29:52Z true PMID:35888748 1-aminocyclopropane-1-carboxylic acid meaaurement efo:EFO_0021829 Quantification of the amount of 1-methylnicotinamide in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:30:55Z true PMID:35888748 1-methylnicotinamide measurement efo:EFO_0021830 Quantification of the amount of 3-methyl-2-oxindole in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:31:43Z true PMID:35888748 3-methyl-2-oxindole measurement efo:EFO_0021831 Quantification of the amount of caprylic acid in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:32:13Z true HMDB:HMDB0304443 PMID:35888748 octanoate measurement caprylic acid measurement efo:EFO_0021832 Quantification of the amount of L-Gulonic acid gamma-lactone in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:33:52Z true PMID:35888748 L-Gulonic acid gamma-lactone measurement efo:EFO_0021833 Quantification of the amount of hypotaurine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:34:24Z true PMID:35888748 hypotaurine measurement efo:EFO_0021834 Quantification of the amount of L-arabitol in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:34:58Z true PMID:35888748 L-arabitol measurement efo:EFO_0021835 Quantification of the amount of melanin in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:35:20Z true PMID:35888748 melanin measurement efo:EFO_0021836 Quantification of the amount of N-acetyl-d-tryptophan in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:35:38Z true PMID:35888748 N-acetyl-d-tryptophan measurement efo:EFO_0021837 Quantification of the amount of pyridoxamine in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:35:56Z true PMID:35888748 pyridoxamine measurement efo:EFO_0021838 Quantification of the amount of sorbate in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:36:26Z true PMID:35888748 sorbate measurement efo:EFO_0021839 Quantification of the amount of cinnamaldehyde in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:37:41Z true PMID:35888748 cinnamaldehyde measurement efo:EFO_0021840 Quantification of the amount of glycerol-1-myristate in a sample. Santhi Ramachandran Zoe May Pendlington 2022-09-14T10:38:09Z true PMID:35888748 glycerol-1-myristate measurement efo:EFO_0021841 The determination of the amount of mucin-1 in a sample true PMID:34814699 mucin-1 measurement efo:EFO_0021842 The determination of the amount of interleukin-1 receptor type 2 in a sample true PMID:34814699 interleukin-1 receptor type 2 measurement efo:EFO_0021843 The determination of the amount of vitronectin in a sample true PMID:34814699 vitronectin measurement efo:EFO_0021844 The determination of the amount of platelet-derived growth factor receptor alpha in a sample true PMID:34814699 platelet-derived growth factor receptor alpha measurement efo:EFO_0021845 The determination of the amount of gamma-enolase in a sample true PMID:34814699 gamma-enolase measurement efo:EFO_0021846 The determination of the amount of trefoil factor 2 in a sample true PMID:34814699 trefoil factor 2 measurement efo:EFO_0021847 The determination of the amount of pigment epithelium-derived factor in a sample true PMID:34814699 pigment epithelium-derived factor measurement efo:EFO_0021848 The determination of the amount of C-C motif chemokine 4-like in a sample true PMID:34814699 C-C motif chemokine 4-like measurement efo:EFO_0021849 The determination of the amount of protein Z-dependent protease inhibitor in a sample true PMID:34814699 protein Z-dependent protease inhibitor measurement efo:EFO_0021850 The determination of the amount of interferon alpha/beta receptor 1 in a sample true PMID:34814699 interferon alpha/beta receptor 1 measurement efo:EFO_0021851 The determination of the amount of interleukin-36 alpha in a sample true PMID:34814699 interleukin-36 alpha measurement efo:EFO_0021852 The determination of the amount of secreted and transmembrane protein 1 in a sample true PMID:34814699 secreted and transmembrane protein 1 measurement efo:EFO_0021853 The determination of the amount of galactoside 3(4)-L-fucosyltransferase in a sample true PMID:34814699 galactoside 3(4)-L-fucosyltransferase measurement efo:EFO_0021854 The determination of the amount of apolipoprotein L1 in a sample true PMID:34814699 apolipoprotein L1 measurement efo:EFO_0021855 The determination of the amount of fatty acid-binding protein, liver in a sample true PMID:34814699 fatty acid-binding protein, liver measurement efo:EFO_0021856 The determination of the amount of prolyl endopeptidase FAP in a sample true PMID:34814699 prolyl endopeptidase FAP measurement efo:EFO_0021857 The determination of the amount of protein FAM3B in a sample true PMID:34814699 protein FAM3B measurement efo:EFO_0021858 The determination of the amount of synaptosomal-associated protein 25 in a sample true PMID:34814699 synaptosomal-associated protein 25 measurement efo:EFO_0021859 The determination of the amount of phosphoglucomutase-1 in a sample true PMID:34814699 phosphoglucomutase-1 measurement efo:EFO_0021860 The determination of the amount of leucine-rich repeat transmembrane protein FLRT2 in a sample true PMID:34814699 leucine-rich repeat transmembrane protein FLRT2 measurement efo:EFO_0021861 The determination of the amount of leucine-rich repeat transmembrane protein FLRT3 in a sample true PMID:34814699 leucine-rich repeat transmembrane protein FLRT3 measurement efo:EFO_0021862 The determination of the amount of 3-hydroxyanthranilate 3,4-dioxygenase in a sample true PMID:34814699 3-hydroxyanthranilate 3,4-dioxygenase measurement efo:EFO_0021863 The determination of the amount of galectin-9 in a sample true PMID:34814699 galectin-9 measurement efo:EFO_0021864 The determination of the amount of semaphorin-5A in a sample true PMID:34814699 semaphorin-5A measurement efo:EFO_0021865 The determination of the amount of trefoil factor 1 in a sample true PMID:34814699 trefoil factor 1 measurement efo:EFO_0021866 The determination of the amount of cD177 antigen in a sample true PMID:34814699 cD177 antigen measurement efo:EFO_0021867 The determination of the amount of plexin-B2 in a sample true PMID:34814699 plexin-B2 measurement efo:EFO_0021868 The determination of the amount of sPARC-related modular calcium-binding protein 1 in a sample true PMID:34814699 sPARC-related modular calcium-binding protein 1 measurement efo:EFO_0021869 The determination of the amount of protein FAM3D in a sample true PMID:34814699 protein FAM3D measurement efo:EFO_0021870 The determination of the amount of cysteine-rich with EGF-like domain protein 1 in a sample true PMID:34814699 cysteine-rich with EGF-like domain protein 1 measurement efo:EFO_0021871 The determination of the amount of glypican-6 in a sample true PMID:34814699 glypican-6 measurement efo:EFO_0021872 The determination of the amount of non-histone chromosomal protein HMG-14 in a sample true PMID:34814699 non-histone chromosomal protein HMG-14 measurement efo:EFO_0021873 The determination of the amount of low-density lipoprotein receptor-related protein 1B in a sample true PMID:34814699 low-density lipoprotein receptor-related protein 1B measurement efo:EFO_0021874 The determination of the amount of ankyrin-2 in a sample true PMID:34814699 ankyrin-2 measurement efo:EFO_0021875 The determination of the amount of ubiquitin-like protein ISG15 in a sample true PMID:34814699 ubiquitin-like protein ISG15 measurement efo:EFO_0021876 The determination of the amount of leucine-rich repeat serine/threonine-protein kinase 2 in a sample true PMID:34814699 leucine-rich repeat serine/threonine-protein kinase 2 measurement efo:EFO_0021877 The determination of the amount of platelet receptor Gi24 in a sample true PMID:34814699 platelet receptor Gi24 measurement efo:EFO_0021878 The determination of the amount of r-spondin-3 in a sample true PMID:34814699 r-spondin-3 measurement efo:EFO_0021879 The determination of the amount of immunoglobulin superfamily containing leucine-rich repeat protein 2 in a sample true PMID:34814699 immunoglobulin superfamily containing leucine-rich repeat protein 2 measurement efo:EFO_0021880 The determination of the amount of quinone oxidoreductase-like protein 1 in a sample true PMID:34814699 quinone oxidoreductase-like protein 1 measurement efo:EFO_0021881 The determination of the amount of ubiquitin carboxyl-terminal hydrolase 25 in a sample true PMID:34814699 ubiquitin carboxyl-terminal hydrolase 25 measurement efo:EFO_0021882 The determination of the amount of natural killer cell receptor 2B4 in a sample true PMID:34814699 natural killer cell receptor 2B4 measurement efo:EFO_0021883 The determination of the amount of betacellulin in a sample true PMID:34814699 betacellulin measurement efo:EFO_0021884 The determination of the amount of transgelin-2 in a sample true PMID:34814699 transgelin-2 measurement efo:EFO_0021885 The determination of the amount of semaphorin-6B in a sample true PMID:34814699 semaphorin-6B measurement efo:EFO_0021886 The determination of the amount of e3 ubiquitin-protein ligase RNF43 in a sample true PMID:34814699 e3 ubiquitin-protein ligase RNF43 measurement efo:EFO_0021887 The determination of the amount of glial cell line-derived neurotrophic factor in a sample true PMID:34814699 glial cell line-derived neurotrophic factor measurement efo:EFO_0021888 The determination of the amount of glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic in a sample true PMID:34814699 glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic measurement efo:EFO_0021889 The determination of the amount of lumican in a sample true PMID:34814699 lumican measurement efo:EFO_0021890 The determination of the amount of interleukin-10 receptor subunit alpha in a sample true PMID:34814699 interleukin-10 receptor subunit alpha measurement efo:EFO_0021891 The determination of the amount of hemK methyltransferase family member 2 in a sample true PMID:34814699 hemK methyltransferase family member 2 measurement efo:EFO_0021892 The determination of the amount of adhesion G protein-coupled receptor E2 in a sample true PMID:34814699 adhesion G protein-coupled receptor E2 measurement efo:EFO_0021893 The determination of the amount of protein S100-A4 in a sample true PMID:34814699 protein S100-A4 measurement efo:EFO_0021894 The determination of the amount of lipopolysaccharide-binding protein in a sample true PMID:34814699 lipopolysaccharide-binding protein measurement efo:EFO_0021895 The determination of the amount of formimidoyltransferase-cyclodeaminase in a sample true PMID:34814699 formimidoyltransferase-cyclodeaminase measurement efo:EFO_0021904 Quantification of the amount of E3 ubiquitin-protein ligase CHIP measurement in a sample. Elizabeth Lewis true PMID:36168886 E3 ubiquitin-protein ligase CHIP measurement efo:EFO_0021905 Quantification of the amount of CCAAT/enhancer-binding protein beta measurement in a sample. Elizabeth Lewis true PMID:36168886 CCAAT/enhancer-binding protein beta measurement efo:EFO_0021906 Quantification of the amount of E3 SUMO-protein ligase PIAS4 measurement in a sample. Elizabeth Lewis true PMID:36168886 E3 SUMO-protein ligase PIAS4 measurement efo:EFO_0021907 Quantification of the amount of signal transducer and activator of transcription 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 signal transducer and activator of transcription 3 measurement efo:EFO_0021908 Quantification of the amount of interferon regulatory factor 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 interferon regulatory factor 1 measurement efo:EFO_0021909 Quantification of the amount of transcription factor AP-1 measurement in a sample. Elizabeth Lewis true PMID:36168886 transcription factor AP-1 measurement efo:EFO_0021910 Quantification of the amount of induced myeloid leukemia cell differentiation protein Mcl-1 measurement in a sample. Elizabeth Lewis true PMID:36168886 induced myeloid leukemia cell differentiation protein Mcl-1 measurement efo:EFO_0021911 Quantification of the amount of 2'-5'-oligoadenylate synthase 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 2'-5'-oligoadenylate synthase 1 measurement efo:EFO_0021912 Quantification of the amount of myc proto-oncogene protein measurement in a sample. Elizabeth Lewis true PMID:36168886 myc proto-oncogene protein measurement efo:EFO_0021913 Quantification of the amount of mothers against decapentaplegic homolog 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 mothers against decapentaplegic homolog 3 measurement efo:EFO_0021914 Quantification of the amount of mothers against decapentaplegic homolog 2 measurement in a sample. Elizabeth Lewis true PMID:36168886 mothers against decapentaplegic homolog 2 measurement efo:EFO_0021915 Quantification of the amount of signal transducer and activator of transcription 1-alpha/beta measurement in a sample. Elizabeth Lewis true PMID:36168886 signal transducer and activator of transcription 1-alpha/beta measurement efo:EFO_0021916 Quantification of the amount of signal transducer and activator of transcription 6 measurement in a sample. Elizabeth Lewis true PMID:36168886 signal transducer and activator of transcription 6 measurement efo:EFO_0021917 Quantification of the amount of glycerol-3-phosphate dehydrogenase [NAD(+)]; cytoplasmic measurement in a sample. Elizabeth Lewis true PMID:36168886 glycerol-3-phosphate dehydrogenase [NAD(+)]; cytoplasmic measurement efo:EFO_0021918 Quantification of the amount of galectin-10 measurement in a sample. Elizabeth Lewis true PMID:36168886 galectin-10 measurement efo:EFO_0021919 Quantification of the amount of pyridoxal kinase measurement in a sample. Elizabeth Lewis true PMID:36168886 pyridoxal kinase measurement efo:EFO_0021920 Quantification of the amount of toll-like receptor 4 measurement in a sample. Elizabeth Lewis true PMID:36168886 toll-like receptor 4 measurement efo:EFO_0021921 Quantification of the amount of regenerating islet-derived protein 4 measurement in a sample. Elizabeth Lewis true PMID:36168886 regenerating islet-derived protein 4 measurement efo:EFO_0021922 Quantification of the amount of alpha-enolase measurement in a sample. Elizabeth Lewis true PMID:36168886 alpha-enolase measurement efo:EFO_0021923 Quantification of the amount of ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 measurement efo:EFO_0021924 Quantification of the amount of CD59 glycoprotein measurement in a sample. Elizabeth Lewis true PMID:36168886 CD59 glycoprotein measurement efo:EFO_0021925 Quantification of the amount of fatty acid-binding protein; liver measurement in a sample. Elizabeth Lewis true PMID:36168886 fatty acid-binding protein; liver measurement efo:EFO_0021926 Quantification of the amount of hypoxia-inducible factor 1-alpha measurement in a sample. Elizabeth Lewis true PMID:36168886 hypoxia-inducible factor 1-alpha measurement efo:EFO_0021927 Quantification of the amount of protein S100-A6 measurement in a sample. Elizabeth Lewis true PMID:36168886 protein S100-A6 measurement efo:EFO_0021928 Quantification of the amount of bcl-2-like protein 2 measurement in a sample. Elizabeth Lewis true PMID:36168886 bcl-2-like protein 2 measurement efo:EFO_0021929 Quantification of the amount of chorionic somatomammotropin hormone measurement in a sample. Elizabeth Lewis true PMID:36168886 chorionic somatomammotropin hormone measurement efo:EFO_0021930 Quantification of the amount of ephrin-B1 measurement in a sample. Elizabeth Lewis true PMID:36168886 ephrin-B1 measurement efo:EFO_0021931 Quantification of the amount of Ly6/PLAUR domain-containing protein 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 Ly6/PLAUR domain-containing protein 3 measurement efo:EFO_0021932 Quantification of the amount of neuronal growth regulator 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 neuronal growth regulator 1 measurement efo:EFO_0021933 Quantification of the amount of B-cell lymphoma 6 protein measurement in a sample. Elizabeth Lewis true PMID:36168886 B-cell lymphoma 6 protein measurement efo:EFO_0021934 Quantification of the amount of follistatin-related protein 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 follistatin-related protein 1 measurement efo:EFO_0021935 Quantification of the amount of choline/ethanolamine kinase measurement in a sample. Elizabeth Lewis true PMID:36168886 choline/ethanolamine kinase measurement efo:EFO_0021936 Quantification of the amount of desmocollin-2 measurement in a sample. Elizabeth Lewis true PMID:36168886 desmocollin-2 measurement efo:EFO_0021937 Quantification of the amount of low-density lipoprotein receptor measurement in a sample. Elizabeth Lewis true PMID:36168886 low-density lipoprotein receptor measurement efo:EFO_0021938 Quantification of the amount of hexokinase-2 measurement in a sample. Elizabeth Lewis true PMID:36168886 hexokinase-2 measurement efo:EFO_0021939 Quantification of the amount of hexokinase-1 measurement in a sample. Elizabeth Lewis true PMID:36168886 hexokinase-1 measurement efo:EFO_0021940 Quantification of the amount of latent-transforming growth factor beta-binding protein 4 measurement in a sample. Elizabeth Lewis true PMID:36168886 latent-transforming growth factor beta-binding protein 4 measurement efo:EFO_0021941 Quantification of the amount of PILR alpha-associated neural protein measurement in a sample. Elizabeth Lewis true PMID:36168886 PILR alpha-associated neural protein measurement efo:EFO_0021942 Quantification of the amount of tumor necrosis factor receptor superfamily member 10D measurement in a sample. Elizabeth Lewis true PMID:36168886 tumor necrosis factor receptor superfamily member 10D measurement efo:EFO_0021943 Quantification of the amount of E3 ubiquitin-protein ligase ZNRF3 measurement in a sample. Elizabeth Lewis true PMID:36168886 E3 ubiquitin-protein ligase ZNRF3 measurement efo:EFO_0021944 Quantification of the amount of ephrin-A2 measurement in a sample. Elizabeth Lewis true PMID:36168886 ephrin-A2 measurement efo:EFO_0021945 Quantification of the amount of apolipoprotein M measurement in a sample. Elizabeth Lewis true PMID:36168886 apolipoprotein M measurement efo:EFO_0021946 Quantification of the amount of interferon alpha-10 measurement in a sample. Elizabeth Lewis true PMID:36168886 interferon alpha-10 measurement efo:EFO_0021947 Quantification of the amount of interferon alpha-7 measurement in a sample. Elizabeth Lewis true PMID:36168886 interferon alpha-7 measurement efo:EFO_0021948 Quantification of the amount of HERV-H LTR-associating protein 2 measurement in a sample. Elizabeth Lewis true PMID:36168886 HERV-H LTR-associating protein 2 measurement efo:EFO_0021949 Quantification of the amount of amphoterin-induced protein 2 measurement in a sample. Elizabeth Lewis true PMID:36168886 amphoterin-induced protein 2 measurement efo:EFO_0021950 Quantification of the amount of relaxin receptor 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 relaxin receptor 1 measurement efo:EFO_0021951 Quantification of the amount of neuregulin-4 measurement in a sample. Elizabeth Lewis true PMID:36168886 neuregulin-4 measurement efo:EFO_0021952 Quantification of the amount of histone H2B type 2-E measurement in a sample. Elizabeth Lewis true PMID:36168886 histone H2B type 2-E measurement efo:EFO_0021953 Quantification of the amount of histone H2A type 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 histone H2A type 3 measurement efo:EFO_0021954 Quantification of the amount of histone H3.1 measurement in a sample. Elizabeth Lewis true PMID:36168886 histone H3.1 measurement efo:EFO_0021955 Quantification of the amount of interleukin-36 beta measurement in a sample. Elizabeth Lewis true PMID:36168886 interleukin-36 beta measurement efo:EFO_0021956 Quantification of the amount of ephrin-A3 measurement in a sample. Elizabeth Lewis true PMID:36168886 ephrin-A3 measurement efo:EFO_0021957 Quantification of the amount of 14-3-3 protein beta/alpha measurement in a sample. Elizabeth Lewis true PMID:36168886 14-3-3 protein beta/alpha measurement efo:EFO_0021958 Quantification of the amount of 14-3-3 protein epsilon measurement in a sample. Elizabeth Lewis true PMID:36168886 14-3-3 protein epsilon measurement efo:EFO_0021959 Quantification of the amount of annexin A5 measurement in a sample. Elizabeth Lewis true PMID:36168886 annexin A5 measurement efo:EFO_0021960 Quantification of the amount of growth/differentiation factor 8 measurement in a sample. Elizabeth Lewis true PMID:36168886 growth/differentiation factor 8 measurement efo:EFO_0021961 Quantification of the amount of C-C motif chemokine 2 measurement in a sample. Elizabeth Lewis true PMID:36168886 C-C motif chemokine 2 measurement efo:EFO_0021962 Quantification of the amount of growth/differentiation factor 11/8 measurement in a sample. Elizabeth Lewis true PMID:36168886 growth/differentiation factor 11/8 measurement efo:EFO_0021963 Quantification of the amount of interleukin-17F measurement in a sample. Elizabeth Lewis true PMID:36168886 interleukin-17F measurement efo:EFO_0021964 Quantification of the amount of neutrophil gelatinase-associated lipocalin measurement in a sample. Elizabeth Lewis true PMID:36168886 neutrophil gelatinase-associated lipocalin measurement efo:EFO_0021965 Quantification of the amount of serine/threonine-protein kinase Chk1 measurement in a sample. Elizabeth Lewis true PMID:36168886 serine/threonine-protein kinase Chk1 measurement efo:EFO_0021966 Quantification of the amount of histone H1.2 measurement in a sample. Elizabeth Lewis true PMID:36168886 histone H1.2 measurement efo:EFO_0021967 Quantification of the amount of inducible T-cell costimulator measurement in a sample. Elizabeth Lewis true PMID:36168886 inducible T-cell costimulator measurement efo:EFO_0021968 Quantification of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 a disintegrin and metalloproteinase with thrombospondin motifs 1 measurement efo:EFO_0021969 Quantification of the amount of low affinity immunoglobulin gamma Fc region receptor II-a measurement in a sample. Elizabeth Lewis true PMID:36168886 low affinity immunoglobulin gamma Fc region receptor II-a measurement efo:EFO_0021970 Quantification of the amount of low affinity immunoglobulin gamma Fc region receptor II-b measurement in a sample. Elizabeth Lewis true PMID:36168886 low affinity immunoglobulin gamma Fc region receptor II-b measurement efo:EFO_0021971 Quantification of the amount of PIK3CA/PIK3R1 measurement in a sample. Elizabeth Lewis true PMID:36168886 PIK3CA/PIK3R1 measurement efo:EFO_0021972 Quantification of the amount of RAC-alpha/beta/gamma serine/threonine-protein kinase measurement in a sample. Elizabeth Lewis true PMID:36168886 RAC-alpha/beta/gamma serine/threonine-protein kinase measurement efo:EFO_0021973 Quantification of the amount of interleukin-17B measurement in a sample. Elizabeth Lewis true PMID:36168886 interleukin-17B measurement efo:EFO_0021974 Quantification of the amount of SLIT and NTRK-like protein 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 SLIT and NTRK-like protein 1 measurement efo:EFO_0021975 Quantification of the amount of heat shock 70 kDa protein 1A measurement in a sample. Elizabeth Lewis true PMID:36168886 heat shock 70 kDa protein 1A measurement efo:EFO_0021976 Quantification of the amount of interleukin-17D measurement in a sample. Elizabeth Lewis true PMID:36168886 interleukin-17D measurement efo:EFO_0021977 Quantification of the amount of alcohol dehydrogenase [NADP(+)] measurement in a sample. Elizabeth Lewis true PMID:36168886 alcohol dehydrogenase [NADP(+)] measurement efo:EFO_0021978 Quantification of the amount of protein lin-7 homolog B measurement in a sample. Elizabeth Lewis true PMID:36168886 protein lin-7 homolog B measurement efo:EFO_0021979 Quantification of the amount of alpha-(1;3)-fucosyltransferase 5 measurement in a sample. Elizabeth Lewis true PMID:36168886 alpha-(1;3)-fucosyltransferase 5 measurement efo:EFO_0021980 Quantification of the amount of adhesion G-protein coupled receptor G5 measurement in a sample. Elizabeth Lewis true PMID:36168886 adhesion G-protein coupled receptor G5 measurement efo:EFO_0021981 Quantification of the amount of superoxide dismutase [Mn]; mitochondrial measurement in a sample. Elizabeth Lewis true PMID:36168886 superoxide dismutase [Mn]; mitochondrial measurement efo:EFO_0021982 Quantification of the amount of protein deglycase DJ-1 measurement in a sample. Elizabeth Lewis true PMID:36168886 protein deglycase DJ-1 measurement efo:EFO_0021983 Quantification of the amount of CD83 antigen measurement in a sample. Elizabeth Lewis true PMID:36168886 CD83 antigen measurement efo:EFO_0021984 Quantification of the amount of [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1; mitochondrial measurement in a sample. Elizabeth Lewis true PMID:36168886 [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1; mitochondrial measurement efo:EFO_0021985 Quantification of the amount of dual 3';5'-cyclic-AMP and -GMP phosphodiesterase 11A measurement in a sample. Elizabeth Lewis true PMID:36168886 dual 3';5'-cyclic-AMP and -GMP phosphodiesterase 11A measurement efo:EFO_0021986 Quantification of the amount of calcium/calmodulin-dependent 3';5'-cyclic nucleotide phosphodiesterase 1A measurement in a sample. Elizabeth Lewis true PMID:36168886 calcium/calmodulin-dependent 3';5'-cyclic nucleotide phosphodiesterase 1A measurement efo:EFO_0021987 Quantification of the amount of ras-related C3 botulinum toxin substrate 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 ras-related C3 botulinum toxin substrate 3 measurement efo:EFO_0021988 Quantification of the amount of proto-oncogene vav measurement in a sample. Elizabeth Lewis true PMID:36168886 proto-oncogene vav measurement efo:EFO_0021989 Quantification of the amount of RAC-beta serine/threonine-protein kinase measurement in a sample. Elizabeth Lewis true PMID:36168886 RAC-beta serine/threonine-protein kinase measurement efo:EFO_0021990 Quantification of the amount of growth factor receptor-bound protein 2 measurement in a sample. Elizabeth Lewis true PMID:36168886 growth factor receptor-bound protein 2 measurement efo:EFO_0021991 Quantification of the amount of heat shock protein HSP 90-beta measurement in a sample. Elizabeth Lewis true PMID:36168886 heat shock protein HSP 90-beta measurement efo:EFO_0021992 Quantification of the amount of serine/threonine-protein kinase WNK3 measurement in a sample. Elizabeth Lewis true PMID:36168886 serine/threonine-protein kinase WNK3 measurement efo:EFO_0021993 Quantification of the amount of tumor necrosis factor receptor superfamily member 10B measurement in a sample. Elizabeth Lewis true PMID:36168886 tumor necrosis factor receptor superfamily member 10B measurement efo:EFO_0021994 Quantification of the amount of BH3-interacting domain death agonist measurement in a sample. Elizabeth Lewis true PMID:36168886 BH3-interacting domain death agonist measurement efo:EFO_0021995 Quantification of the amount of noggin measurement in a sample. Elizabeth Lewis true PMID:36168886 noggin measurement efo:EFO_0021996 Quantification of the amount of 14-3-3 protein zeta/delta measurement in a sample. Elizabeth Lewis true PMID:36168886 14-3-3 protein zeta/delta measurement efo:EFO_0021997 Quantification of the amount of 3-hydroxyanthranilate 3;4-dioxygenase measurement in a sample. Elizabeth Lewis true PMID:36168886 3-hydroxyanthranilate 3;4-dioxygenase measurement efo:EFO_0021998 Quantification of the amount of bcl2-associated agonist of cell death measurement in a sample. Elizabeth Lewis true PMID:36168886 bcl2-associated agonist of cell death measurement efo:EFO_0021999 Quantification of the amount of eukaryotic translation initiation factor 4H measurement in a sample. Elizabeth Lewis true PMID:36168886 eukaryotic translation initiation factor 4H measurement efo:EFO_0022000 Quantification of the amount of gastrin-releasing peptide measurement in a sample. Elizabeth Lewis true PMID:36168886 gastrin-releasing peptide measurement efo:EFO_0022001 Quantification of the amount of peroxisomal targeting signal 1 receptor measurement in a sample. Elizabeth Lewis true PMID:36168886 peroxisomal targeting signal 1 receptor measurement efo:EFO_0022002 Quantification of the amount of protein S100-A7 measurement in a sample. Elizabeth Lewis true PMID:36168886 protein S100-A7 measurement efo:EFO_0022003 Quantification of the amount of WNT1-inducible-signaling pathway protein 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 WNT1-inducible-signaling pathway protein 3 measurement efo:EFO_0022004 Quantification of the amount of thrombopoietin measurement in a sample. Elizabeth Lewis true PMID:36168886 thrombopoietin measurement efo:EFO_0022005 Quantification of the amount of dual specificity mitogen-activated protein kinase kinase 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 dual specificity mitogen-activated protein kinase kinase 3 measurement efo:EFO_0022006 Quantification of the amount of cellular tumor antigen p53 measurement in a sample. Elizabeth Lewis true PMID:36168886 cellular tumor antigen p53 measurement efo:EFO_0022007 Quantification of the amount of polyUbiquitin K48-linked measurement in a sample. Elizabeth Lewis true PMID:36168886 polyUbiquitin K48-linked measurement efo:EFO_0022008 Quantification of the amount of polyUbiquitin K63-linked measurement in a sample. Elizabeth Lewis true PMID:36168886 polyUbiquitin K63-linked measurement efo:EFO_0022009 Quantification of the amount of netrin-1 measurement in a sample. Elizabeth Lewis true PMID:36168886 netrin-1 measurement efo:EFO_0022010 Quantification of the amount of leukocyte surface antigen CD47 measurement in a sample. Elizabeth Lewis true PMID:36168886 leukocyte surface antigen CD47 measurement efo:EFO_0022011 Quantification of the amount of 14-3-3 protein theta measurement in a sample. Elizabeth Lewis true PMID:36168886 14-3-3 protein theta measurement efo:EFO_0022012 Quantification of the amount of vesicular integral-membrane protein VIP36 measurement in a sample. Elizabeth Lewis true PMID:36168886 vesicular integral-membrane protein VIP36 measurement efo:EFO_0022013 Quantification of the amount of myosin-binding protein C; slow-type measurement in a sample. Elizabeth Lewis true PMID:36168886 myosin-binding protein C; slow-type measurement efo:EFO_0022014 Quantification of the amount of N-terminal pro-BNP measurement in a sample. Elizabeth Lewis true PMID:36168886 N-terminal pro-BNP measurement efo:EFO_0022015 Quantification of the amount of tropomyosin alpha-4 chain measurement in a sample. Elizabeth Lewis true PMID:36168886 tropomyosin alpha-4 chain measurement efo:EFO_0022016 Quantification of the amount of appetite-regulating hormone measurement in a sample. Elizabeth Lewis true PMID:36168886 appetite-regulating hormone measurement efo:EFO_0022017 Quantification of the amount of somatotropin measurement in a sample. Elizabeth Lewis true PMID:36168886 somatotropin measurement efo:EFO_0022018 Quantification of the amount of extracellular superoxide dismutase [Cu-Zn] measurement in a sample. Elizabeth Lewis true PMID:36168886 extracellular superoxide dismutase [Cu-Zn] measurement efo:EFO_0022019 Quantification of the amount of R-spondin-4 measurement in a sample. Elizabeth Lewis true PMID:36168886 R-spondin-4 measurement efo:EFO_0022020 Quantification of the amount of ribonuclease H1 measurement in a sample. Elizabeth Lewis true PMID:36168886 ribonuclease H1 measurement efo:EFO_0022021 Quantification of the amount of chromogranin-A measurement in a sample. Elizabeth Lewis true PMID:36168886 chromogranin-A measurement efo:EFO_0022022 Quantification of the amount of EGF-containing fibulin-like extracellular matrix protein 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 EGF-containing fibulin-like extracellular matrix protein 1 measurement efo:EFO_0022023 Quantification of the amount of kelch-like ECH-associated protein 1 measurement in a sample. Elizabeth Lewis true PMID:36168886 kelch-like ECH-associated protein 1 measurement efo:EFO_0022024 Quantification of the amount of C-C motif chemokine 26 measurement in a sample. Elizabeth Lewis true PMID:36168886 C-C motif chemokine 26 measurement efo:EFO_0022025 Quantification of the amount of small ubiquitin-related modifier 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 small ubiquitin-related modifier 3 measurement efo:EFO_0022026 Quantification of the amount of interleukin-17A measurement in a sample. Elizabeth Lewis true PMID:36168886 interleukin-17A measurement efo:EFO_0022027 Quantification of the amount of cysteine and glycine-rich protein 3 measurement in a sample. Elizabeth Lewis true PMID:36168886 cysteine and glycine-rich protein 3 measurement efo:EFO_0022028 Quantification of the amount of down syndrome cell adhesion molecule measurement in a sample. Elizabeth Lewis true PMID:36168886 down syndrome cell adhesion molecule measurement efo:EFO_0022029 Quantification of the amount of neuregulin-1 measurement in a sample. Elizabeth Lewis true PMID:36168886 neuregulin-1 measurement efo:EFO_0022030 Quantification of the amount of interferon gamma receptor 2 measurement in a sample. Elizabeth Lewis true PMID:36168886 interferon gamma receptor 2 measurement efo:EFO_0022031 Quantification of the amount of low-density lipoprotein receptor-related protein 1; soluble measurement in a sample. Elizabeth Lewis true PMID:36168886 low-density lipoprotein receptor-related protein 1; soluble measurement efo:EFO_0022032 Quantification of the amount of C-X-C motif chemokine 9 measurement in a sample. Elizabeth Lewis true PMID:36168886 C-X-C motif chemokine 9 measurement efo:EFO_0022033 Quantification of the amount of CD63 antigen measurement in a sample. Elizabeth Lewis true PMID:36168886 CD63 antigen measurement efo:EFO_0022034 Quantification of the amount of galectin-7 measurement in a sample. Elizabeth Lewis true PMID:36168886 galectin-7 measurement efo:EFO_0022035 Quantification of the amount of ubiquitin-conjugating enzyme E2 G2 measurement in a sample. Elizabeth Lewis true PMID:36168886 ubiquitin-conjugating enzyme E2 G2 measurement efo:EFO_0022036 Quantification of the amount of ATP synthase subunit O; mitochondrial measurement in a sample. Elizabeth Lewis true PMID:36168886 ATP synthase subunit O; mitochondrial measurement efo:EFO_0022037 Quantification of the amount of pro-opiomelanocortin measurement in a sample. Elizabeth Lewis true PMID:36168886 pro-opiomelanocortin measurement efo:EFO_0022038 Quantification of the amount of cathepsin F measurement in a sample. Elizabeth Lewis true PMID:36168886 cathepsin F measurement efo:EFO_0022042 The P-null phenotype, also referred to as the p phenotype (previously Tj[a-]), is rare, and is defined by the lack of P, P1, and Pk on red blood cells. Zoe May Pendlington 2022-11-30T11:13:58Z Tj[a-] p-null phenotype p phenotype The P-null phenotype, also referred to as the p phenotype (previously Tj[a-]), is rare, and is defined by the lack of P, P1, and Pk on red blood cells. PMID:34539318 efo:EFO_0022046 Sulcal opening was defined as the average distance between both banks of the pial surface. Santhi Ramachandran Zoe May Pendlington 2023-01-03T10:50:31Z true sulcal opening distance Sulcal opening was defined as the average distance between both banks of the pial surface. PMID:36442731 efo:EFO_0022047 Sulcal depth was defined as the average geodesic distance from the convex hull of the brain to the bottom line of the sulcus medial surface. Santhi Ramachandran Zoe May Pendlington 2023-01-03T10:51:15Z true sulcal depth Sulcal depth was defined as the average geodesic distance from the convex hull of the brain to the bottom line of the sulcus medial surface. PMID:36442731 efo:EFO_0022048 The determination of the amount of the eosinophil-derived neurotoxin in a sample. Zoe May Pendlington 2023-01-03T13:31:33Z true NCIt:C184644 eosinophil-derived neurotoxin measurement efo:EFO_0022052 Quantification of the amount of 2,4,5-trichlorophenol in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:44:26Z true PMID:36006120 2,4,5-trichlorophenol measurement efo:EFO_0022053 Quantification of the amount of 4,6-dinitro-o-cresol in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:45:21Z true PMID:36006120 4,6-dinitro-o-cresol measurement efo:EFO_0022054 Quantification of the amount of aldrin in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:45:51Z true PMID:36006120 aldrin measurement efo:EFO_0022055 Quantification of the amount of azinphos methyl in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:46:25Z true PMID:36006120 azinphos methyl measurement efo:EFO_0022056 Quantification of the amount of cadmium chloride in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:46:53Z true PMID:36006120 cadmium chloride measurement efo:EFO_0022057 Quantification of the amount of chlorpyrifos in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:47:33Z true PMID:36006120 chlorpyrifos measurement efo:EFO_0022058 Quantification of the amount of dibutyl phthalate in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:48:04Z true PMID:36006120 dibutyl phthalate measurement efo:EFO_0022059 Quantification of the amount of diazinon in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:49:12Z true PMID:36006120 diazinon measurement efo:EFO_0022060 Quantification of the amount of dicofol in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:49:41Z true PMID:36006120 dicofol measurement efo:EFO_0022061 Quantification of the amount of dieldrin in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:50:17Z true PMID:36006120 dieldrin measurement efo:EFO_0022062 Quantification of the amount of disulfoton in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:50:52Z true PMID:36006120 disulfoton measurement efo:EFO_0022063 Quantification of the amount of endosulfan in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:51:23Z true PMID:36006120 endosulfan measurement efo:EFO_0022064 Quantification of the amount of endrin in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:51:44Z true PMID:36006120 endrin measurement efo:EFO_0022065 Quantification of the amount of ethion in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:52:14Z true PMID:36006120 ethion measurement efo:EFO_0022066 Quantification of the amount of heptachlor in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:52:36Z true PMID:36006120 heptachlor measurement efo:EFO_0022067 Quantification of the amount of heptachlor epoxide in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:53:04Z true PMID:36006120 heptachlor epoxide measurement efo:EFO_0022068 Quantification of the amount of mercuric chloride in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:53:24Z true PMID:36006120 mercuric chloride measurement efo:EFO_0022069 Quantification of the amount of methoxychlor in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:53:42Z true PMID:36006120 methoxychlor measurement efo:EFO_0022070 Quantification of the amount of parathion in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:54:04Z true PMID:36006120 parathion measurement efo:EFO_0022071 Quantification of the amount of pentachlorophenol in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:54:25Z true PMID:36006120 pentachlorophenol measurement efo:EFO_0022072 Quantification of the amount of potassium chromate in a sample. Santhi Ramachandran Zoe May Pendlington 2023-01-04T08:54:44Z true PMID:36006120 potassium chromate measurement efo:EFO_0022073 Quantification of the amount of (S)-a-amino-omega-caprolactam (X-13737) in a sample. Santhi Ramachandran true PMID:35050183 (S)-a-amino-omega-caprolactam (X-13737) measurement efo:EFO_0022076 Quantification of the amount of 15-methylpalmitate in a sample. Santhi Ramachandran true PMID:35050183 15-methylpalmitate measurement efo:EFO_0022077 Quantification of the amount of 16-hydroxypalmitate in a sample. Santhi Ramachandran true PMID:35050183 16-hydroxypalmitate measurement efo:EFO_0022078 Quantification of the amount of 17-methylstearate in a sample. Santhi Ramachandran true PMID:35050183 17-methylstearate measurement efo:EFO_0022079 Quantification of the amount of 1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) in a sample. Santhi Ramachandran true PMID:35050183 1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) measurement efo:EFO_0022080 Quantification of the amount of 1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) in a sample. Santhi Ramachandran true PMID:35050183 1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) measurement efo:EFO_0022081 Quantification of the amount of 1-margaroyl-2-arachidonoyl-GPC (17:0/20:4) in a sample. Santhi Ramachandran true PMID:35050183 1-margaroyl-2-arachidonoyl-GPC (17:0/20:4) measurement efo:EFO_0022082 Quantification of the amount of 1-methylimidazoleacetate in a sample. Santhi Ramachandran true PMID:35050183 1-methylimidazoleacetate measurement efo:EFO_0022083 Quantification of the amount of 1-palmitoyl-2-eicosapentaenoyl-GPE (16:0/20:5) in a sample. Santhi Ramachandran true PMID:35050183 1-palmitoyl-2-eicosapentaenoyl-GPE (16:0/20:5) measurement efo:EFO_0022084 Quantification of the amount of 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) in a sample. Santhi Ramachandran true PMID:35050183 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) measurement efo:EFO_0022085 Quantification of the amount of 1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) in a sample. Santhi Ramachandran true PMID:35050183 1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) measurement efo:EFO_0022086 Quantification of the amount of 2-hydroxybutyrate/2-hydroxyisobutyrate in a sample. Santhi Ramachandran true PMID:35050183 2-hydroxybutyrate/2-hydroxyisobutyrate measurement efo:EFO_0022087 Quantification of the amount of 3-hydroxy-5-cholestenoic acid in a sample. Santhi Ramachandran true PMID:35050183 3-hydroxy-5-cholestenoic acid measurement efo:EFO_0022088 Quantification of the amount of 3-indoxyl sulfate in a sample. Santhi Ramachandran true PMID:35050183 3-indoxyl sulfate measurement efo:EFO_0022089 Quantification of the amount of 4-androsten-3alpha,17alpha-diol monosulfate (2) in a sample. Santhi Ramachandran true PMID:35050183 4-androsten-3alpha,17alpha-diol monosulfate (2) measurement efo:EFO_0022090 Quantification of the amount of 4-androsten-3alpha,17alpha-diol monosulfate (3) in a sample. Santhi Ramachandran true PMID:35050183 4-androsten-3alpha,17alpha-diol monosulfate (3) measurement efo:EFO_0022091 Quantification of the amount of Cis-4-decenoyl carnitine in a sample. Santhi Ramachandran true PMID:35050183 Cis-4-decenoyl carnitine measurement efo:EFO_0022092 Quantification of the amount of Cyclo(pro-val) in a sample. Santhi Ramachandran true PMID:35050183 Cyclo(pro-val) measurement efo:EFO_0022094 Quantification of the amount of Dopamine sulfate (2) in a sample. Santhi Ramachandran true PMID:35050183 Dopamine sulfate (2) measurement efo:EFO_0022095 Quantification of the amount of Eicosanodioate in a sample. Santhi Ramachandran true PMID:35050183 Eicosanodioate measurement efo:EFO_0022096 Quantification of the amount of Glutarate (pentanedioate) in a sample. Santhi Ramachandran true PMID:35050183 Glutarate (pentanedioate) measurement efo:EFO_0022097 Quantification of the amount of Glycochenodeoxycholate sulfate in a sample. Santhi Ramachandran true PMID:35050183 Glycochenodeoxycholate sulfate measurement efo:EFO_0022098 Quantification of the amount of Glycodeoxycholate sulfate in a sample. Santhi Ramachandran true PMID:35050183 Glycodeoxycholate sulfate measurement efo:EFO_0022099 Quantification of the amount of Hydantoin-5-propionic acid in a sample. Santhi Ramachandran true PMID:35050183 Hydantoin-5-propionic acid measurement efo:EFO_0022100 Quantification of the amount of Isoleucylleucine/leucylisoleucine in a sample. Santhi Ramachandran true PMID:35050183 Isoleucylleucine/leucylisoleucine measurement efo:EFO_0022101 Quantification of the amount of N-acetylcarnosine in a sample. Santhi Ramachandran true PMID:35050183 N-acetylcarnosine measurement efo:EFO_0022102 Quantification of the amount of O-methylcatechol sulfate in a sample. Santhi Ramachandran true PMID:35050183 O-methylcatechol sulfate measurement efo:EFO_0022103 Quantification of the amount of Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2] in a sample. Santhi Ramachandran true PMID:35050183 Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2] measurement efo:EFO_0022104 Quantification of the amount of Pregn steroid monosulfate in a sample. Santhi Ramachandran true PMID:35050183 Pregn steroid monosulfate measurement efo:EFO_0022105 Quantification of the amount of Sphingomyelin (d18:1/14:0, d16:1/16:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/14:0, d16:1/16:0) measurement efo:EFO_0022106 Quantification of the amount of Sphingomyelin (d18:1/15:0, d16:1/17:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/15:0, d16:1/17:0) measurement efo:EFO_0022107 Quantification of the amount of Sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0) measurement efo:EFO_0022108 Quantification of the amount of Sphingomyelin (d18:1/18:1, d18:2/18:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/18:1, d18:2/18:0) measurement efo:EFO_0022109 Quantification of the amount of Sphingomyelin (d18:1/20:0, d16:1/22:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/20:0, d16:1/22:0) measurement efo:EFO_0022110 Quantification of the amount of Sphingomyelin (d18:1/20:1, d18:2/20:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/20:1, d18:2/20:0) measurement efo:EFO_0022111 Quantification of the amount of Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0) measurement efo:EFO_0022112 Quantification of the amount of Sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1) measurement efo:EFO_0022113 Quantification of the amount of Sphingomyelin (d18:1/24:1, d18:2/24:0) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:1/24:1, d18:2/24:0) measurement efo:EFO_0022114 Quantification of the amount of Sphingomyelin (d18:2/14:0, d18:1/14:1) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:2/14:0, d18:1/14:1) measurement efo:EFO_0022115 Quantification of the amount of Sphingomyelin (d18:2/16:0, d18:1/16:1) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:2/16:0, d18:1/16:1) measurement efo:EFO_0022116 Quantification of the amount of Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1) measurement efo:EFO_0022117 Quantification of the amount of Sphingomyelin (d18:2/24:1, d18:1/24:2) in a sample. Santhi Ramachandran true PMID:35050183 Sphingomyelin (d18:2/24:1, d18:1/24:2) measurement efo:EFO_0022118 Quantification of the amount of Succinimide in a sample. Santhi Ramachandran true PMID:35050183 Succinimide measurement efo:EFO_0022119 Quantification of the amount of X-14568 in a sample. Santhi Ramachandran true PMID:35050183 X-14568 measurement efo:EFO_0022120 Quantification of the amount of X-21358 in a sample. Santhi Ramachandran true PMID:35050183 X-21358 measurement efo:EFO_0022121 Quantification of the amount of X-21658 in a sample. Santhi Ramachandran true PMID:35050183 X-21658 measurement efo:EFO_0022122 Quantification of the amount of X-22775 in a sample. Santhi Ramachandran true PMID:35050183 X-22775 measurement efo:EFO_0022123 Quantification of the amount of X-23637 in a sample. Santhi Ramachandran true PMID:35050183 X-23637 measurement efo:EFO_0022124 Quantification of the amount of X-23652 in a sample. Santhi Ramachandran true PMID:35050183 X-23652 measurement efo:EFO_0022125 Quantification of the amount of X-23749 in a sample. Santhi Ramachandran true PMID:35050183 X-23749 measurement efo:EFO_0022126 Quantification of the amount of X-23756 in a sample. Santhi Ramachandran true PMID:35050183 X-23756 measurement efo:EFO_0022127 Quantification of the amount of X-23765 in a sample. Santhi Ramachandran true PMID:35050183 X-23765 measurement efo:EFO_0022128 Quantification of the amount of X-24020 in a sample. Santhi Ramachandran true PMID:35050183 X-24020 measurement efo:EFO_0022129 Quantification of the amount of X-24027 in a sample. Santhi Ramachandran true PMID:35050183 X-24027 measurement efo:EFO_0022130 Quantification of the amount of X-24243 in a sample. Santhi Ramachandran true PMID:35050183 X-24243 measurement efo:EFO_0022131 Quantification of the amount of X-24452 in a sample. Santhi Ramachandran true PMID:35050183 X-24452 measurement efo:EFO_0022132 Quantification of the amount of X-24512 in a sample. Santhi Ramachandran true PMID:35050183 X-24512 measurement efo:EFO_0022133 Quantification of the amount of X-24513 in a sample. Santhi Ramachandran true PMID:35050183 X-24513 measurement efo:EFO_0022134 Quantification of the amount of X-24738 in a sample. Santhi Ramachandran true PMID:35050183 X-24738 measurement efo:EFO_0022135 Quantification of the amount of X-24747 in a sample. Santhi Ramachandran true PMID:35050183 X-24747 measurement efo:EFO_0022136 Quantification of the amount of X-24748 in a sample. Santhi Ramachandran true PMID:35050183 X-24748 measurement efo:EFO_0022137 Quantification of the amount of X-24765 in a sample. Santhi Ramachandran true PMID:35050183 X-24765 measurement efo:EFO_0022138 Quantification of the amount of X-24803 in a sample. Santhi Ramachandran true PMID:35050183 X-24803 measurement efo:EFO_0022139 Quantification of the amount of X-24804 in a sample. Santhi Ramachandran true PMID:35050183 X-24804 measurement efo:EFO_0022140 Quantification of the amount of X-24806 in a sample. Santhi Ramachandran true PMID:35050183 X-24806 measurement efo:EFO_0022141 Quantification of the amount of X-24813 in a sample. Santhi Ramachandran true PMID:35050183 X-24813 measurement efo:EFO_0022142 Quantification of the amount of X-24831 in a sample. Santhi Ramachandran true PMID:35050183 X-24831 measurement efo:EFO_0022143 Quantification of the amount of X-24870 in a sample. Santhi Ramachandran true PMID:35050183 X-24870 measurement efo:EFO_0022144 Quantification of triglycerides in very small VLDL. true triglycerides in very small VLDL measurement Quantification of triglycerides in very small VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022145 Quantification of triglycerides in small VLDL. true triglycerides in small VLDL measurement Quantification of triglycerides in small VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022146 Quantification of phospholipids in small VLDL. true phospholipids in small VLDL measurement Quantification of phospholipids in small VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022147 A lipoprotein concentration assay that measures the concentration of small very-low-density lipoprotein in a specimen. concentration of small VLDL particles A lipoprotein concentration assay that measures the concentration of small very-low-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022148 Quantification of total lipids in small VLDL. true total lipids in small VLDL Quantification of total lipids in small VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022149 Quantification of triglycerides in IDL. true triglycerides in IDL measurement Quantification of triglycerides in IDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022150 Quantification of phospholipids in very small VLDL. phospholipids in very small VLDL measurement Quantification of phospholipids in very small VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022151 A lipoprotein concentration assay that measures the concentration of very small very-low-density lipoprotein in a specimen. concentration of very small VLDL particles A lipoprotein concentration assay that measures the concentration of very small very-low-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022152 A lipoprotein concentration assay that measures the concentration of very-low-density lipoprotein in a specimen. concentration of medium VLDL particles A lipoprotein concentration assay that measures the concentration of very-low-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022153 Quantification of total lipids in medium VLDL. true total lipids in medium VLDL Quantification of total lipids in medium VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022154 Quantification of phospholipids in medium VLDL. true phospholipids in medium VLDL measurement Quantification of phospholipids in medium VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022155 Quantification of triglycerides in medium VLDL. true triglycerides in medium VLDL measurement Quantification of triglycerides in medium VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022156 Quantification of total lipids in very small VLDL. true total lipids in very small VLDL measurement Quantification of total lipids in very small VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022157 Quantification of free cholesterol contained in or bound to HDL. true free cholesterol in large HDL measurement Quantification of free cholesterol contained in or bound to HDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022158 Quantification of triglycerides in small HDL. true triglycerides in small HDL measurement Quantification of triglycerides in small HDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022159 Quantification of cholesterol esters contained in or bound to HDL. cholesterol esters in large HDL measurement Quantification of cholesterol esters contained in or bound to HDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022160 A lipoprotein concentration assay that measures the concentration of large low-density lipoprotein in a specimen. true concentration of large LDL particles measurement A lipoprotein concentration assay that measures the concentration of large low-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022161 Quantification of total lipids in IDL. true total lipids in IDL Quantification of total lipids in IDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022162 Quantification of total cholesterol in medium VLDL. total cholesterol in medium VLDL Quantification of total cholesterol in medium VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022163 Quantification of total lipids in large LDL. true total lipids in large LDL Quantification of total lipids in large LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022164 Quantification of phospholipids in IDL. true phospholipids in IDL measurement Quantification of phospholipids in IDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022165 Quantification of cholesterol esters contained in or bound to large LDL. cholesterol esters in large LDL measurement Quantification of cholesterol esters contained in or bound to large LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022166 A lipoprotein concentration assay that measures the concentration of small low-density lipoprotein in a specimen. concentration of small LDL particles measurement A lipoprotein concentration assay that measures the concentration of small low-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022167 Quantification of total cholesterol in large LDL. total cholesterol in large LDL Quantification of total cholesterol in large LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022168 Quantification of total lipids in small LDL. true total lipids in small LDL Quantification of total lipids in small LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022169 Quantification of phospholipids in large VLDL. true phospholipids in large VLDL measurement Quantification of phospholipids in large VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022170 Quantification of cholesterol esters contained in or bound to large VLDL. cholesterol esters in large VLDL measurement Quantification of cholesterol esters contained in or bound to large VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022171 Quantification of total cholesterol in small VLDL. total cholesterol in small VLDL Quantification of total cholesterol in small VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022172 A lipoprotein concentration assay that measures the concentration of medium low-density lipoprotein in a specimen. concentration of medium LDL particles measurement A lipoprotein concentration assay that measures the concentration of medium low-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022173 A lipoprotein concentration assay that measures the concentration of large very-low-density lipoprotein in a specimen. concentration of large VLDL particles measurement A lipoprotein concentration assay that measures the concentration of large very-low-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022174 Quantification of phospholipids in large LDL. true phospholipids in large LDL measurement Quantification of phospholipids in large LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022175 Quantification of total lipids in large VLDL. true total lipids in large VLDL Quantification of total lipids in large VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022176 Quantification of free cholesterol contained in or bound to LDL. true free cholesterol in large LDL measurement Quantification of free cholesterol contained in or bound to LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022177 Quantification of total cholesterol in large VLDL. total cholesterol in large VLDL Quantification of total cholesterol in large VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022178 Quantification of triglycerides in large VLDL. true triglycerides in large VLDL measurement Quantification of triglycerides in large VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022179 Quantification of total cholesterol in small LDL. total cholesterol in small LDL Quantification of total cholesterol in small LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022180 Quantification of total lipids in medium LDL. true total lipids in medium LDL Quantification of total lipids in medium LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022181 Quantification of free cholesterol contained in or bound to IDL. true free cholesterol in IDL measurement Quantification of free cholesterol contained in or bound to IDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022182 Quantification of cholesterol esters contained in or bound to medium VLDL. cholesterol esters in medium VLDL measurement Quantification of cholesterol esters contained in or bound to medium VLDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022183 Quantification of phospholipids in medium LDL. true phospholipids in medium LDL measurement Quantification of phospholipids in medium LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022184 Quantification of total cholesterol in IDL. total cholesterol in IDL Quantification of total cholesterol in IDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022185 Quantification of total cholesterol in medium LDL. total cholesterol in medium LDL Quantification of total cholesterol in medium LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022186 Quantification of cholesterol esters contained in or bound to medium LDL. cholesterol esters in medium LDL measurement Quantification of cholesterol esters contained in or bound to medium LDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022187 The determination of the amount of polyunsaturated fatty acids present in a sample. true monounsaturated fatty acids; 16:1, 18:1 measurement The determination of the amount of polyunsaturated fatty acids present in a sample. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022188 A lipoprotein concentration assay that measures the concentration of large high-density lipoprotein in a specimen. concentration of large HDL particles measurement A lipoprotein concentration assay that measures the concentration of large high-density lipoprotein in a specimen. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022189 Quantification of total lipids in large HDL. true total lipids in large HDL Quantification of total lipids in large HDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022190 Quantification of phospholipids in large HDL. true phospholipids in large HDL measurement Quantification of phospholipids in large HDL. PMID:32150548 https://orcid.org/0000-0002-2417-7324 efo:EFO_0022196 Quantification of the body's total surface area. Zoe May Pendlington 2023-02-13T10:01:32Z true NCIT:C25157 OMIT:0003188 body surface area Quantification of the body's total surface area. PMID:36502284 efo:EFO_0022197 The determination of the amount of 3-hydroxymyristate in a blood sample Santhi Ramachandran CAS:3422-31-9 PubChem:16064 blood 3-hydroxymyristate measurement The determination of the amount of 3-hydroxymyristate in a blood sample PMID:36635386 efo:EFO_0022198 The determination of the amount of citramalate in a blood sample Santhi Ramachandran CAS:1583915 KEGG COMPOUND:C00815 PubChem:1081 blood citramalate measurement The determination of the amount of citramalate in a blood sample PMID:36635386 efo:EFO_0022199 The determination of the amount of 2,3-dihydroxypyridine in a blood sample Santhi Ramachandran CAS:5466678 PubChem:28115 blood 2,3-dihydroxypyridine measurement The determination of the amount of 2,3-dihydroxypyridine in a blood sample PMID:36635386 efo:EFO_0022200 The determination of the amount of Glutaconic acid in a blood sample Santhi Ramachandran KEGG COMPOUND:C02226 PubChem:5280498 blood glutaconic acid measurement The determination of the amount of Glutaconic acid in a blood sample PMID:36635386 efo:EFO_0022201 The determination of the amount of Citraconic acid in a blood sample Santhi Ramachandran KEGG COMPOUND:C02214 PubChem:643798 blood Citraconic acid measurement The determination of the amount of Citraconic acid in a blood sample PMID:36635386 efo:EFO_0022202 The determination of the amount of N-acetyl-2-aminoadipate in a blood sample Santhi Ramachandran KEGG COMPOUND:C12986 PubChem:443992 blood N-acetyl-2-aminoadipate measurement The determination of the amount of N-acetyl-2-aminoadipate in a blood sample PMID:36635386 efo:EFO_0022203 The determination of the amount of N-carbamoylalanine in a blood sample Santhi Ramachandran CAS:77340-50-2 PubChem:426409 blood N-carbamoylalanine measurement The determination of the amount of N-carbamoylalanine in a blood sample PMID:36635386 efo:EFO_0022204 The determination of the amount of N(1)-acetylspermidine in a blood sample Santhi Ramachandran KEGG COMPOUND:C01029 PubChem:496 blood N(1)-acetylspermidine measurement The determination of the amount of N(1)-acetylspermidine in a blood sample PMID:36635386 efo:EFO_0022205 The determination of the amount of N(8)-acetylspermidine in a blood sample Santhi Ramachandran KEGG COMPOUND:C00612 PubChem:123689 blood N(8)-acetylspermidine measurement The determination of the amount of N(8)-acetylspermidine in a blood sample PMID:36635386 efo:EFO_0022206 The determination of the amount of N-acetylasparagine in a blood sample Santhi Ramachandran CAS:4033-40-3 PubChem:99715 blood N-acetylasparagine measurement The determination of the amount of N-acetylasparagine in a blood sample PMID:36635386 efo:EFO_0022207 The determination of the amount of N-acetylproline in a blood sample Santhi Ramachandran CAS:1074-79-9 PubChem:322640 blood N-acetylproline measurement The determination of the amount of N-acetylproline in a blood sample PMID:36635386 efo:EFO_0022208 The determination of the amount of 2,2'-Methylenebis(6-tert-butyl-p-cresol) in a blood sample Santhi Ramachandran CAS:119-47-1 PubChem:8398 blood 2,2'-Methylenebis(6-tert-butyl-p-cresol) measurement The determination of the amount of 2,2'-Methylenebis(6-tert-butyl-p-cresol) in a blood sample PMID:36635386 efo:EFO_0022209 The determination of the amount of ethylparaben sulfate in a blood sample Santhi Ramachandran CAS:162338-11-6 PubChem:22908099 blood ethylparaben sulfate measurement The determination of the amount of ethylparaben sulfate in a blood sample PMID:36635386 efo:EFO_0022210 The determination of the amount of pantoate in a blood sample Santhi Ramachandran CAS:470-29-1 KEGG COMPOUND:C00522 PubChem:5289105 blood pantoate measurement The determination of the amount of pantoate in a blood sample PMID:36635386 efo:EFO_0022211 The determination of the amount of succinimide in a blood sample Santhi Ramachandran CAS:123-56-8 KEGG COMPOUND:C07273 PubChem:11439 blood succinimide measurement The determination of the amount of succinimide in a blood sample PMID:36635386 efo:EFO_0022212 The determination of the amount of dibutyl sulfosuccinate in a blood sample Santhi Ramachandran CAS:5144-51-4 PubChem:423891 blood dibutyl sulfosuccinate measurement The determination of the amount of dibutyl sulfosuccinate in a blood sample PMID:36635386 efo:EFO_0022213 The determination of the amount of cytosine in a blood sample Santhi Ramachandran CAS:71-30-7 KEGG COMPOUND:C00380 PubChem:597 blood cytosine measurement The determination of the amount of cytosine in a blood sample PMID:36635386 efo:EFO_0022214 The determination of the amount of vanillic alcohol sulfate in a blood sample Santhi Ramachandran CAS:754920-02-0 blood vanillic alcohol sulfate measurement The determination of the amount of vanillic alcohol sulfate in a blood sample PMID:36635386 efo:EFO_0022215 The determination of the amount of 3,4-dihydroxybutyrate in a blood sample Santhi Ramachandran CAS:51267-44-8 PubChem:150929 blood 3,4-dihydroxybutyrate measurement The determination of the amount of 3,4-dihydroxybutyrate in a blood sample PMID:36635386 efo:EFO_0022216 The determination of the amount of 4-oxo-retinoic acid in a blood sample Santhi Ramachandran CAS:38030-57-8 PubChem:6437063 blood 4-oxo-retinoic acid measurement The determination of the amount of 4-oxo-retinoic acid in a blood sample PMID:36635386 efo:EFO_0022217 The determination of the amount of N-acetylcarnosine in a blood sample Santhi Ramachandran CAS:56353-15-2 PubChem:9903482 blood N-acetylcarnosine measurement The determination of the amount of N-acetylcarnosine in a blood sample PMID:36635386 efo:EFO_0022218 The determination of the amount of 1H-indole-7-acetic acid in a blood sample Santhi Ramachandran CAS:39689-63-9 PubChem:18356439 blood 1H-indole-7-acetic acid measurement The determination of the amount of 1H-indole-7-acetic acid in a blood sample PMID:36635386 efo:EFO_0022219 The determination of the amount of 2,3-dihydroxy-2-methylbutyrate in a blood sample Santhi Ramachandran CAS:14868-24-7 PubChem:301941 blood 2,3-dihydroxy-2-methylbutyrate measurement The determination of the amount of 2,3-dihydroxy-2-methylbutyrate in a blood sample PMID:36635386 efo:EFO_0022220 The determination of the amount of 3-hydroxyoctanoylcarnitine in a blood sample Santhi Ramachandran PubChem:86583357 blood 3-hydroxyoctanoylcarnitine The determination of the amount of 3-hydroxyoctanoylcarnitine in a blood sample PMID:36635386 efo:EFO_0022221 The determination of the amount of 2,4-di-tert-butylphenol in a blood sample Santhi Ramachandran CAS:96-76-4 PubChem:7311 blood 2,4-di-tert-butylphenol measurement The determination of the amount of 2,4-di-tert-butylphenol in a blood sample PMID:36635386 efo:EFO_0022222 The determination of the amount of pyridoxal in a blood sample Santhi Ramachandran CAS:65-22-5 KEGG COMPOUND:C00250 PubChem:1050 blood pyridoxal measurement The determination of the amount of pyridoxal in a blood sample PMID:36635386 efo:EFO_0022223 Quantification of the ratio of one metabolite to another Santhi Ramachandran metabolite ratio Quantification of the ratio of one metabolite to another PMID:36635386 efo:EFO_0030017 RCH-ACV cell line is a human B cell precursor leukemia cell line established from a bone marrow sample of a child with acute lymphoblastic leukemia. paola RCH BTO:0003376 RCHACV RCH-ACV RCH-ACV cell line is a human B cell precursor leukemia cell line established from a bone marrow sample of a child with acute lymphoblastic leukemia. PMID:3455845 efo:EFO_0030018 BLaER1 cell line is a tamoxifen-inducible subclone of the RCH-ACV B-cell leukemia cell line genetically modified using a retrovirus vector to express C/EBPα fused with the estrogen receptor hormone binding domain (ER) and GFP. paola B cell Leukemia C/EBPalphaER clone 1 BLaER1 BLaER1 cell line is a tamoxifen-inducible subclone of the RCH-ACV B-cell leukemia cell line genetically modified using a retrovirus vector to express C/EBPα fused with the estrogen receptor hormone binding domain (ER) and GFP. PMID:23545498 efo:EFO_0030082 An estimate of an individual’s genetic risk for some traits, obtained by aggregating and quantifying the effect of many common variants in the genome (usually defined as minor allele frequency ≥1%), each of which can have a small effect on a person’s genetic risk for a given disease or condition. paola true PRS genetic risk score polygenic score polygenic risk score An estimate of an individual’s genetic risk for some traits, obtained by aggregating and quantifying the effect of many common variants in the genome (usually defined as minor allele frequency ≥1%), each of which can have a small effect on a person’s genetic risk for a given disease or condition. http://orcid.org/0000-0002-7059-6378 efo:EFO_0600000 Quantification of the amount of sortilin in a sample. Santhi Ramachandran true PMID:33937362 sortilin measurement efo:EFO_0600001 Quantification of the amount of ghrelin present in a sample. Santhi Ramachandran true NCIT:C112286 PMID:33852427 ghrelin measurement efo:EFO_0600002 A measure of the thickness of one or more layers of the retina. It is measured with various imaging tools including ultrasound, optical coherence tomography (OCT), confocal microscopy, and biometry. Reduced retinal layer thickness is one of the biomarkers used for the diagnosis of glaucoma. Annalisa Buniello true PMID:33979322 retinal layer thickness measurement efo:EFO_0600003 Quantification of vitamin C levels in a sample. Elizabeth Lewis true NCIt:C74903 PMID:33203707 vitamin C measurement efo:EFO_0600004 A measure of the thickness of the retinal nerve fiber layer (RNFL). It is typically measured using optical imaging methods such as optical coherence tomography (OCT). The thickness of the ganglion cell complex (GCC), the collective name for the retinal nerve fibre layer and the ganglion cell inner plexiform layer, is one of the biomarkers used in the diagnosis of primary open angle glaucoma (POAG). Annalisa Buniello true PMID:33979322 RNFL thickness measurement peripapillary retinal nerve fiber layer thickness measurement retinal nerve fibre layer thickness measurement efo:EFO_0600005 A measure of the thickness of the ganglion cell inner plexiform layer (GCIPL). It is typically measured using optical imaging methods such as optical coherence tomography (OCT). The thickness of the ganglion cell complex (GCC), the collective name for the retinal nerve fibre layer and the ganglion cell inner plexiform layer, is one of the biomarkers used in the diagnosis of primary open angle glaucoma (POAG). Annalisa Buniello true PMID:33979322 GCIPL thickness measurement ganglion cell inner plexiform layer thickness measurement efo:EFO_0600006 human herpesvirus 7 seropositivity is the result of a measurement of circulating human herpesvirus 7 specific antibodies Laura Harris true PMID:33204752 human herpesvirus 7 seropositivity efo:EFO_0600007 Quantification of some aspect of an individual's exposure to fish oil supplementation. Elizabeth Lewis true PMID:33760818 fish oil supplement exposure measurement efo:EFO_0600008 A quantification of the degree of mitochondrial heteroplasmy, i.e. the presence of different mitochondrial DNA variants in different mitochondria within the same individual organism or cell. Heteroplasmy can be inherited through the maternal germ line, or arise through somatic mitochondrial mutations within an individual. Elliot Sollis true PMID:33731350 mitochondrial heteroplasmy measurement efo:EFO_0600010 Quantification of emodin metabolisation via the glucuronidation pathway. Santhi Ramachandran true PMID:32538071 emodin glucuronidation measurement efo:EFO_0600011 Quantification of some aspect of Parkinson's disease symptoms such as their frequency, severity or ratio. Elizabeth Lewis true PMID:33987465 Parkinson's disease symptom measurement efo:EFO_0600012 The quantification of S100 calcium-binding protein B in a sample. true NCIT:C127635 PMID:33227023 S100B measurement S100 calcium-binding protein B measurement efo:EFO_0600015 Quantification of some aspect of noise exposure, such as occupational levels. Elizabeth Lewis true PMID:33242228 noise exposure measurement efo:EFO_0600016 Quantification of the ratio of beta-amyloid 1-40 to 1-42 proteins in a sample of blood plasma. Annalisa Buniello true PMID:34002480 plasma beta-amyloid 1-40:1-42 ratio measurement efo:EFO_0600018 The trabecular bone score (TBS) is an analytical tool used to measure grey-level textures on lumbar spine (LS) dual X-ray absorptiometry (DXA) images. It is a measure of bone texture correlated with bone microarchitecture and is associated with the incidence of new fracture. Santhi Ramachandran true PMID:33232597 trabecular bone score efo:EFO_0600019 Quantification of some aspect of COVID-19 symptoms, such as severity or time to remission. Elizabeth Lewis true PMID:34035401 COVID-19 symptoms measurement efo:EFO_0600020 Quantification of time to remission of COVID-19 symptoms. Elizabeth Lewis true PMID:34035401 time to remission of COVID-19 symptoms efo:EFO_0600025 Quantification of the calcification of vascular smooth muscle cells derived from the aorta. Santhi Ramachandran true PMID:33040646 aortic VSMC calcification measurement aortic vascular smooth muscle cell calcification measurement efo:EFO_0600026 Quantification of the multiplication or reproduction of vascular smooth muscle cells derived from the aorta. Santhi Ramachandran true PMID:33040646 aortic VSMC proliferation measurement aortic vascular smooth muscle cell proliferation measurement efo:EFO_0600027 Quantification of the change in hemoglobin levels in an individual over time, eg over the course of several years after regular blood donation. Elizabeth Lewis true PMID:33491795 hemoglobin change measurement efo:EFO_0600028 Quantification of the levels of N-acylethanolamine in a sample. Elizabeth Lewis true PMID:33437986 N-acylethanolamine measurement efo:EFO_0600035 Quantification of the volume of or amount contained in the left upper chamber of the heart. Elizabeth Lewis true PMID:34338756 VT:0004063 heart left atrium capacity left atrial volume measurement efo:EFO_0600036 Quantification of a muscle fiber cross-sectional area by muscle biopsy. It is a microscopic measure of muscle fiber size and structure to assess skeletal muscle hypertrophy typically in the context of resistance training. Santhi Ramachandran true PMID:33891350 muscle fCSA muscle fiber cross-sectional area measurement efo:EFO_0600038 Quantification of the levels of clozapine in blood plasma. Clozapine is an antipsychotic drug used to treat schizophrenia. Elizabeth Lewis true PMID:30922102 plasma clozapine measurement efo:EFO_0600039 Quantification of the levels of N-desmethylclozapine, also known as norclozapine, in blood plasma. N-desmethylclozapine is a major active metabolite of clozapine, an antipsychotic drug used to treat schizophrenia. Elizabeth Lewis true PMID:30922102 plasma norclozapine measurement plasma N-desmethylclozapine measurement efo:EFO_0600040 Quantification of the ratio of clozapine to-N-desmethylclozapine, also known as norclozapine, in blood plasma. Clozapine is an antipsychotic drug used to treat schizophrenia and N-desmethylclozapine is a a major active metabolite of clozapine. Elizabeth Lewis true PMID:30922102 plasma clozapine-to-norclozapine ratio measurement plasma clozapine-to-N-desmethylclozapine ratio measurement efo:EFO_0600041 Quantification of the levels of clozapine in blood serum. Clozapine is an antipsychotic drug used to treat schizophrenia. Elizabeth Lewis true PMID:32555152 serum clozapine measurement efo:EFO_0600042 Quantification of the ratio of clozapine to-N-desmethylclozapine, also known as norclozapine, in blood serum. Clozapine is an antipsychotic drug used to treat schizophrenia and N-desmethylclozapine is a a major active metabolite of clozapine. true PMID:32555152 serum clozapine-to-norclozapine ratio measurement serum clozapine-to-N-desmethylclozapine ratio measurement efo:EFO_0600043 Quantification of the levels of N-desmethylclozapine, also known as norclozapine, in blood serum. N-desmethylclozapine is a a major active metabolite of clozapine, an antipsychotic drug used to treat schizophrenia. Elizabeth Lewis true PMID:32555152 serum norclozapine measurement serum N-desmethylclozapine measurement efo:EFO_0600044 Quantification of the volume of the kidney. Elizabeth Lewis true PMID:34128465 kidney volume efo:EFO_0600045 Quantification of the volume of the pancreas. Elizabeth Lewis true PMID:34128465 pancreas volume efo:EFO_0600046 Quantification of the volume of the lung. Elizabeth Lewis true PMID:34128465 lung volume efo:EFO_0600047 Quantification of the volume of the spleen. Elizabeth Lewis true PMID:34128465 spleen volume efo:EFO_0600048 Quantification of the volume of the liver. Elizabeth Lewis true PMID:34128465 liver volume efo:EFO_0600049 Quantification of the fat content of the pancreas. Elizabeth Lewis true PMID:34128465 pancreas fat measurement efo:EFO_0600050 Quantification of the levels of leucine rich alpha-2-glycoprotein 1 present in a sample. Elizabeth Lewis true NCIT:C165973 PMID:33889958 plasma LRG1 measurement plasma leucine rich alpha-2-glycoprotein 1 measurement efo:EFO_0600053 Quantification of the amount of complement factor H-related proteins in a sample. Annalisa Buniello PMID:34260947 FHR proteins measurement complement factor H-related proteins measurement efo:EFO_0600054 Quantification of the amount of complement factor H-related protein 1 in a sample. Annalisa Buniello true PMID:34260947 FHR-1 protein measurement complement factor H-related protein 1 measurement efo:EFO_0600055 Quantification of the amount of complement factor H-related protein 2 in a sample. Annalisa Buniello true PMID:34260947 FHR-2 protein measurement complement factor H-related protein 2 measurement efo:EFO_0600056 Quantification of the amount of complement factor H-related protein 3 in a sample. Annalisa Buniello true PMID:34260947 FHR-3 protein measurement complement factor H-related protein 3 measurement efo:EFO_0600057 Quantification of the amount of complement factor H-related protein 4A in a sample. Annalisa Buniello true PMID:34260947 FHR-4A protein measurement complement factor H-related protein 4A measurement efo:EFO_0600058 Any of the various types of human blood whose antigen characteristics determine compatibility in transfusion. While the ABO and Rhesus sytems are the most well known, there are in total about 300 different blood type antigens distributed across 34 different blood type systems. HP:0032223 PMID:26085552 blood group efo:EFO_0600059 The ABO system consists of A and B antigens and antibodies against these antigens. Santhi Ramachandran HP:0032223 PMID:34202464 ABO blood group efo:EFO_0600060 ABO phenotype A, corresponding to the genotype AO or AA. Santhi Ramachandran true HP:0032370 PMID:34202464 blood group A efo:EFO_0600061 ABO phenotype B, corresponding to the genotype BO or BB. Santhi Ramachandran true HP:0032440 PMID:34202464 blood group B efo:EFO_0600062 ABO phenotype AB, corresponding to the genotype AB. Santhi Ramachandran true HP:0032441 PMID:34202464 blood group AB efo:EFO_0600063 ABO phenotype O, corresponding to the genotype OO. Santhi Ramachandran true HP:0032442 PMID:34202464 blood group O efo:EFO_0600066 Quantification of some aspect of the consumption of dietary nutritional supplements. Elizabeth Lewis PMID:34025683 nutritional supplement exposure measurement efo:EFO_0600067 Quantification of some aspect of the consumption of mastiha, a natural nutritional supplement known to possess antioxidant and anti-inflammatory properties. Elizabeth Lewis true PMID:34025683 mastiha supplement exposure measurement efo:EFO_0600068 Quantification of the expression of a gene in a cell, tissue or sample. Elizabeth Lewis gene expression measurement efo:EFO_0600069 Quantification of the expression of the TNFA gene, which encodes tumor necrosis factor-alpha. Elizabeth Lewis true PMID:34025683 DIF gene expression measurement TNF gene expression measurement TNF superfamily, member 2 gene expression measurement TNF-α gene expression measurement TNFA gene expression measurement TNFSF2 gene expression measurement tumor necrosis factor gene expression measurement tumor necrosis factor alpha gene expression measurement efo:EFO_0600070 Quantification of the expression of IL-6 gene, encoding interleukin-6. Elizabeth Lewis true PMID:34025683 IL-6 gene expression measurement IL6 gene expression measurement interleukin 6 gene expression measurement interleukin-6 gene expression measurement efo:EFO_0600071 Quantification of glutathione peroxidase in a sample. true PMID:34025683 blood Gpx measurement blood glutathione peroxidase measurement efo:EFO_0600072 The result of a measurement of circulating human polyomavirus 6-specific antibodies. Elizabeth Lewis true PMID:34532061 human polyomavirus 6 seropositivity efo:EFO_0600073 Quantification of one or more antibodies to the WU polyomavirus, typically in serum. Elizabeth Lewis true PMID:34532061 anti-WU polyomavirus antibody measurement efo:EFO_0600074 Quantification of one or more antibodies to the human polyomavirus 6, typically in serum. Elizabeth Lewis true PMID:34532061 anti-human polyomavirus 6 antibody measurement efo:EFO_0600076 Quantification of some aspect of stimulant use, for instance in the treatment of ADHD. Elizabeth Lewis true PMID:34154395 stimulant use measurement efo:EFO_0600077 Quantification of the change in cardiac troponin I in an individual over time, typically measured in blood. Elizabeth Lewis true PMID:33961016 cTnI change measurement cardiac troponin I change measurement efo:EFO_0600079 Quantification of glucocorticoid receptor gene expression. Elizabeth Lewis true PMID:33002292 NR3C1 gene expression measurement glucocorticoid receptor gene expression measurement efo:EFO_0600081 Quantification of time an individual spends outside. 0000-0001-8222-008X true https://biobank.ndph.ox.ac.uk/crystal/field.cgi?id=1050 https://biobank.ndph.ox.ac.uk/crystal/field.cgi?id=1060 https://doi.org/10.1101/2021.09.02.21262942 time spent outdoors measurement efo:EFO_0600082 Quantification of some aspect of the use of insulin. 0000-0001-8222-008X https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=2986 https://doi.org/10.1101/2021.09.02.21262942 insulin use measurement efo:EFO_0600084 Number of times bowels opened per day. 0000-0001-8222-008X true SNOMEDCT:249521002 https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=21044 https://doi.org/10.1101/2021.09.02.21262942 average number of times bowels opened per day frequency of bowel action (observable entity) frequency of bowel movement frequency of stool number of times bowel opened bowel opening frequency efo:EFO_0600085 An interval measured from the onset of the P wave in one PQRST wave complex to the onset of the P wave in the following PQRST wave complex. 0000-0001-8222-008X true CMO:0000278 https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=22334 https://doi.org/10.1101/2021.09.02.21262942 PP interval efo:EFO_0600087 A narrow or occludable angle is when the angle of the eye is narrow or closed by the iris. Occludable anterior chamber angle is considered as a primary risk factor for primary angle closure glaucoma (PACG). Santhi Ramachandran PMID:34608871 SNOMEDCT:421324002 occludable anterior chamber of eye narrow occludable anterior chamber angle efo:EFO_0600088 Quantification of the ratio between absolute lymphocyte count and absolute monocyte count. Santhi Ramachandran true PMID:34469753 LMR lymphocyte-to-monocyte ratio lymphocyte:monocyte ratio efo:EFO_0600089 Quantification of the rate at which small molecules cross the peritoneal membrane typically measured as the ratio of the concentration of creatinine in the dialysate at 4 hours of a dwell of dialysate solution to that in the plasma (4-hr D/P creatinine). Santhi Ramachandran true PMID:34197840 SNOMEDCT:251875008 peritoneal transport rate peritoneal solute transfer rate efo:EFO_0600091 Quantification of the amount of complement factor H-related protein 4 in a sample. Elizabeth Lewis true PMID:34260948 PR:Q92496 CFHL4 protein measurement FHR-4 protein measurement FHR4 protein measurement complement factor H-related protein 4 measurement efo:EFO_0600092 Quantification of complement factor H-like 1 protein in a sample. Elizabeth Lewis true PMID:34260948 FHL-1 protein measurement complement factor H-like 1 protein measurement efo:EFO_0600094 Quantification of some aspect of skin roughness such as frequency or severity. Elizabeth Lewis true PMID:34265127 skin roughness measurement efo:EFO_0800000 Quantification of dietary folate intake. Elizabeth Lewis true PMID:34959947 vitamin B9 intake measurement folate intake measurement efo:EFO_0800002 Quantification of the amount of 5-hydroxylysine in a sample. Santhi Ramachandran true HMDB:HMDB0000450 KEGG COMPOUND:C16741 PMID:35347128 hydroxylysine measurement 5-hydroxylysine measurement efo:EFO_0800003 Quantification of the amount of 4-guanidinobutanoate in a sample. Santhi Ramachandran true PMID:35347128 4-guanidinobutanoate measurement efo:EFO_0800004 Quantification of the amount of imidazole lactate in a sample. Santhi Ramachandran true PMID:35347128 imidazole lactate measurement efo:EFO_0800005 Quantification of the amount of N-acetylglutamate in a sample. Santhi Ramachandran true PMID:35347128 N-acetylglutamate measurement efo:EFO_0800006 Quantification of the amount of N-alpha-acetylornithine in a sample. Santhi Ramachandran true PMID:35347128 N-alpha-acetylornithine measurement efo:EFO_0800007 Quantification of the amount of gentisate in a sample. Santhi Ramachandran true PMID:35347128 gentisate measurement efo:EFO_0800008 Quantification of the amount of 5-aminovalerate in a sample. Santhi Ramachandran true PMID:35347128 5-aminovalerate measurement efo:EFO_0800009 Quantification of the amount of alpha-hydroxyisocaproate in a sample. Santhi Ramachandran true PMID:35347128 alpha-hydroxyisocaproate measurement efo:EFO_0800010 Quantification of the amount of isovalerate (i5:0) in a sample. Santhi Ramachandran true PMID:35347128 isovalerate (i5:0) measurement efo:EFO_0800011 Quantification of the amount of 1-methylguanidine in a sample. Santhi Ramachandran true PMID:35347128 1-methylguanidine measurement efo:EFO_0800012 Quantification of the amount of N-acetylaspartate (NAA) in a sample. Santhi Ramachandran true PMID:35347128 N-acetylaspartate (NAA) measurement efo:EFO_0800013 Quantification of the amount of cysteine s-sulfate in a sample. Santhi Ramachandran true PMID:35347128 cysteine s-sulfate measurement efo:EFO_0800014 Quantification of the amount of 3-hydroxy-2-ethylpropionate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxy-2-ethylpropionate measurement efo:EFO_0800015 Quantification of the amount of 1-methyl-4-imidazoleacetate in a sample. Santhi Ramachandran true PMID:35347128 1-methyl-4-imidazoleacetate measurement efo:EFO_0800016 Quantification of the amount of guanidinosuccinate in a sample. Santhi Ramachandran true PMID:35347128 guanidinosuccinate measurement efo:EFO_0800017 Quantification of the amount of N-acetylglutamine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylglutamine measurement efo:EFO_0800018 Quantification of the amount of N-acetyltryptophan in a sample. Santhi Ramachandran true PMID:35347128 N-acetyltryptophan measurement efo:EFO_0800019 Quantification of the amount of N-acetylphenylalanine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylphenylalanine measurement efo:EFO_0800020 Quantification of the amount of N-acetylthreonine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylthreonine measurement efo:EFO_0800021 Quantification of the amount of N-acetylisoleucine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylisoleucine measurement efo:EFO_0800022 Quantification of the amount of N-acetylhistidine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylhistidine measurement efo:EFO_0800023 Quantification of the amount of alpha-hydroxyisovalerate in a sample. Santhi Ramachandran true PMID:35347128 alpha-hydroxyisovalerate measurement efo:EFO_0800024 Quantification of the amount of isovalerylcarnitine (C5) in a sample. Santhi Ramachandran true PMID:35347128 isovalerylcarnitine (C5) measurement efo:EFO_0800025 Quantification of the amount of isovalerylglycine in a sample. Santhi Ramachandran true PMID:35347128 isovalerylglycine measurement efo:EFO_0800026 Quantification of the amount of 2-methylbutyrylcarnitine (C5) in a sample. Santhi Ramachandran true PMID:35347128 2-methylbutyrylcarnitine (C5) measurement efo:EFO_0800027 Quantification of the amount of 2-hydroxy-3-methylvalerate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxy-3-methylvalerate measurement efo:EFO_0800028 Quantification of the amount of N-acetylcitrulline in a sample. Santhi Ramachandran true PMID:35347128 N-acetylcitrulline measurement efo:EFO_0800029 Quantification of the amount of isobutyrylglycine in a sample. Santhi Ramachandran true PMID:35347128 isobutyrylglycine measurement efo:EFO_0800030 Quantification of the amount of glutarylcarnitine (C5-DC) in a sample. Santhi Ramachandran true PMID:35347128 glutarylcarnitine (C5-DC) measurement efo:EFO_0800031 Quantification of the amount of beta-hydroxyisovaleroylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 beta-hydroxyisovaleroylcarnitine measurement efo:EFO_0800032 Quantification of the amount of tiglylcarnitine (C5:1-DC) in a sample. Santhi Ramachandran true PMID:35347128 tiglylcarnitine (C5:1-DC) measurement efo:EFO_0800033 Quantification of the amount of N-acetyl-aspartyl-glutamate (NAAG) in a sample. Santhi Ramachandran true PMID:35347128 N-acetyl-aspartyl-glutamate (NAAG) measurement efo:EFO_0800034 Quantification of the amount of 1-ribosyl-imidazoleacetate in a sample. Santhi Ramachandran true PMID:35347128 1-ribosyl-imidazoleacetate measurement efo:EFO_0800035 Quantification of the amount of indoleacetylglutamine in a sample. Santhi Ramachandran true PMID:35347128 indoleacetylglutamine measurement efo:EFO_0800036 Quantification of the amount of N6-acetyllysine in a sample. Santhi Ramachandran true PMID:35347128 N6-acetyllysine measurement efo:EFO_0800037 Quantification of the amount of dimethylarginine (SDMA + ADMA) in a sample. Santhi Ramachandran true PMID:35347128 dimethylarginine (SDMA + ADMA) measurement efo:EFO_0800038 Quantification of the amount of N-acetylserine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylserine measurement efo:EFO_0800039 Quantification of the amount of N-methylproline in a sample. Santhi Ramachandran true PMID:35347128 N-methylproline measurement efo:EFO_0800040 Quantification of the amount of 5-methylthioribose in a sample. Santhi Ramachandran true PMID:35347128 5-methylthioribose measurement efo:EFO_0800041 Quantification of the amount of cysteine sulfinic acid in a sample. Santhi Ramachandran true PMID:35347128 cysteine sulfinic acid measurement efo:EFO_0800042 Quantification of the amount of S-methylmethionine in a sample. Santhi Ramachandran true PMID:35347128 S-methylmethionine measurement efo:EFO_0800043 Quantification of the amount of indole-3-carboxylate in a sample. Santhi Ramachandran true PMID:35347128 indole-3-carboxylate measurement efo:EFO_0800044 Quantification of the amount of N-acetyl-3-methylhistidine in a sample. Santhi Ramachandran true PMID:35347128 N-acetyl-3-methylhistidine measurement efo:EFO_0800045 Quantification of the amount of N-acetyl-cadaverine in a sample. Santhi Ramachandran true PMID:35347128 N-acetyl-cadaverine measurement efo:EFO_0800046 Quantification of the amount of alpha-ketoglutaramate in a sample. Santhi Ramachandran true PMID:35347128 alpha-ketoglutaramate measurement efo:EFO_0800047 Quantification of the amount of 3-methylglutaconate in a sample. Santhi Ramachandran true PMID:35347128 3-methylglutaconate measurement efo:EFO_0800048 Quantification of the amount of 5-(galactosylhydroxy)-L-lysine in a sample. Santhi Ramachandran true PMID:35347128 5-(galactosylhydroxy)-L-lysine measurement efo:EFO_0800049 Quantification of the amount of cysteinylglycine disulfide in a sample. Santhi Ramachandran true PMID:35347128 cysteinylglycine disulfide measurement efo:EFO_0800050 Quantification of the amount of formiminoglutamate in a sample. Santhi Ramachandran true PMID:35347128 formiminoglutamate measurement efo:EFO_0800051 Quantification of the amount of hydantoin-5-propionate in a sample. Santhi Ramachandran true PMID:35347128 hydantoin-5-propionate measurement efo:EFO_0800052 Quantification of the amount of 4-hydroxyglutamate in a sample. Santhi Ramachandran true PMID:35347128 4-hydroxyglutamate measurement efo:EFO_0800053 Quantification of the amount of gamma-carboxyglutamate in a sample. Santhi Ramachandran true PMID:35347128 gamma-carboxyglutamate measurement efo:EFO_0800054 Quantification of the amount of S-methylcysteine in a sample. Santhi Ramachandran true PMID:35347128 S-methylcysteine measurement efo:EFO_0800055 Quantification of the amount of argininate in a sample. Santhi Ramachandran true PMID:35347128 argininate measurement efo:EFO_0800056 Quantification of the amount of 2-oxoarginine in a sample. Santhi Ramachandran true PMID:35347128 2-oxoarginine measurement efo:EFO_0800057 Quantification of the amount of 1-methyl-5-imidazoleacetate in a sample. Santhi Ramachandran true PMID:35347128 1-methyl-5-imidazoleacetate measurement efo:EFO_0800058 Quantification of the amount of S-methylcysteine sulfoxide in a sample. Santhi Ramachandran true PMID:35347128 S-methylcysteine sulfoxide measurement efo:EFO_0800059 Quantification of the amount of carboxyethyl-GABA in a sample. Santhi Ramachandran true PMID:35347128 carboxyethyl-GABA measurement efo:EFO_0800060 Quantification of the amount of beta-citrylglutamate in a sample. Santhi Ramachandran true PMID:35347128 beta-citrylglutamate measurement efo:EFO_0800061 Quantification of the amount of N6-methyllysine in a sample. Santhi Ramachandran true PMID:35347128 N6-methyllysine measurement efo:EFO_0800062 Quantification of the amount of imidazole propionate in a sample. Santhi Ramachandran true PMID:35347128 imidazole propionate measurement efo:EFO_0800063 Quantification of the amount of lanthionine in a sample. Santhi Ramachandran true PMID:35347128 lanthionine measurement efo:EFO_0800064 Quantification of the amount of N-methyltaurine in a sample. Santhi Ramachandran true PMID:35347128 N-methyltaurine measurement efo:EFO_0800065 Quantification of the amount of N-acetyl-1-methylhistidine in a sample. Santhi Ramachandran true PMID:35347128 N-acetyl-1-methylhistidine measurement efo:EFO_0800066 Quantification of the amount of 6-oxopiperidine-2-carboxylate in a sample. Santhi Ramachandran true PMID:35347128 6-oxopiperidine-2-carboxylate measurement efo:EFO_0800067 Quantification of the amount of N-delta-acetylornithine in a sample. Santhi Ramachandran true PMID:35347128 N-delta-acetylornithine measurement efo:EFO_0800068 Quantification of the amount of acisoga in a sample. Santhi Ramachandran true PMID:35347128 acisoga measurement efo:EFO_0800069 Quantification of the amount of N-formylanthranilic acid in a sample. Santhi Ramachandran true PMID:35347128 N-formylanthranilic acid measurement efo:EFO_0800070 Quantification of the amount of N2,N5-diacetylornithine in a sample. Santhi Ramachandran true PMID:35347128 N2,N5-diacetylornithine measurement efo:EFO_0800071 Quantification of the amount of 3-methoxytyramine sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-methoxytyramine sulfate measurement efo:EFO_0800072 Quantification of the amount of methionine sulfone in a sample. Santhi Ramachandran true PMID:35347128 methionine sulfone measurement efo:EFO_0800073 Quantification of the amount of fructosyllysine in a sample. Santhi Ramachandran true PMID:35347128 fructosyllysine measurement efo:EFO_0800074 Quantification of the amount of 3-methylglutarylcarnitine (2) in a sample. Santhi Ramachandran true PMID:35347128 3-methylglutarylcarnitine (2) measurement efo:EFO_0800075 Quantification of the amount of N-formylphenylalanine in a sample. Santhi Ramachandran true PMID:35347128 N-formylphenylalanine measurement efo:EFO_0800076 Quantification of the amount of tyramine O-sulfate in a sample. Santhi Ramachandran true PMID:35347128 tyramine O-sulfate measurement efo:EFO_0800077 Quantification of the amount of N-acetylhistamine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylhistamine measurement efo:EFO_0800078 Quantification of the amount of vanillactate in a sample. Santhi Ramachandran true PMID:35347128 vanillactate measurement efo:EFO_0800079 Quantification of the amount of p-cresol glucuronide in a sample. Santhi Ramachandran true PMID:35347128 p-cresol glucuronide measurement efo:EFO_0800080 Quantification of the amount of 4-methoxyphenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-methoxyphenol sulfate measurement efo:EFO_0800081 Quantification of the amount of dopamine 4-sulfate in a sample. Santhi Ramachandran true PMID:35347128 dopamine 4-sulfate measurement efo:EFO_0800082 Quantification of the amount of dopamine 3-O-sulfate in a sample. Santhi Ramachandran true PMID:35347128 dopamine 3-O-sulfate measurement efo:EFO_0800083 Quantification of the amount of N-acetylkynurenine (2) in a sample. Santhi Ramachandran true PMID:35347128 N-acetylkynurenine (2) measurement efo:EFO_0800084 Quantification of the amount of phenol glucuronide in a sample. Santhi Ramachandran true PMID:35347128 phenol glucuronide measurement efo:EFO_0800085 Quantification of the amount of 5-hydroxyindole sulfate in a sample. Santhi Ramachandran true PMID:35347128 5-hydroxyindole sulfate measurement efo:EFO_0800086 Quantification of the amount of 7-hydroxyindole sulfate in a sample. Santhi Ramachandran true PMID:35347128 7-hydroxyindole sulfate measurement efo:EFO_0800087 Quantification of the amount of 2-methylserine in a sample. Santhi Ramachandran true PMID:35347128 2-methylserine measurement efo:EFO_0800088 Quantification of the amount of catechol glucuronide in a sample. Santhi Ramachandran true PMID:35347128 catechol glucuronide measurement efo:EFO_0800089 Quantification of the amount of indolepropionylglycine in a sample. Santhi Ramachandran true PMID:35347128 indolepropionylglycine measurement efo:EFO_0800090 Quantification of the amount of N,N,N-trimethyl-5-aminovalerate in a sample. Santhi Ramachandran true PMID:35347128 N,N,N-trimethyl-5-aminovalerate measurement efo:EFO_0800091 Quantification of the amount of (N(1) + N(8))-acetylspermidine in a sample. Santhi Ramachandran true PMID:35347128 (N(1) + N(8))-acetylspermidine measurement efo:EFO_0800092 Quantification of the amount of hydroxyasparagine in a sample. Santhi Ramachandran true PMID:35347128 hydroxyasparagine measurement efo:EFO_0800093 Quantification of the amount of N-methylhydroxyproline in a sample. Santhi Ramachandran true PMID:35347128 N-methylhydroxyproline measurement efo:EFO_0800094 Quantification of the amount of N,N,N-trimethyl-alanylproline betaine (TMAP) in a sample. Santhi Ramachandran true PMID:35347128 N,N,N-trimethyl-alanylproline betaine (TMAP) measurement efo:EFO_0800095 Quantification of the amount of N-carbamoylvaline in a sample. Santhi Ramachandran true PMID:35347128 N-carbamoylvaline measurement efo:EFO_0800096 Quantification of the amount of 8-methoxykynurenate in a sample. Santhi Ramachandran true PMID:35347128 8-methoxykynurenate measurement efo:EFO_0800097 Quantification of the amount of 3-amino-2-piperidone in a sample. Santhi Ramachandran true PMID:35347128 3-amino-2-piperidone measurement efo:EFO_0800098 Quantification of the amount of N,N-dimethylalanine in a sample. Santhi Ramachandran true PMID:35347128 N,N-dimethylalanine measurement efo:EFO_0800099 Quantification of the amount of 6-bromotryptophan in a sample. Santhi Ramachandran true PMID:35347128 6-bromotryptophan measurement efo:EFO_0800100 Quantification of the amount of N6,N6-dimethyllysine in a sample. Santhi Ramachandran true PMID:35347128 N6,N6-dimethyllysine measurement efo:EFO_0800101 Quantification of the amount of 1-carboxyethylphenylalanine in a sample. Santhi Ramachandran true PMID:35347128 1-carboxyethylphenylalanine measurement efo:EFO_0800102 Quantification of the amount of 1-carboxyethyltyrosine in a sample. Santhi Ramachandran true PMID:35347128 1-carboxyethyltyrosine measurement efo:EFO_0800103 Quantification of the amount of 1-carboxyethylvaline in a sample. Santhi Ramachandran true PMID:35347128 1-carboxyethylvaline measurement efo:EFO_0800104 Quantification of the amount of 1-carboxyethylleucine in a sample. Santhi Ramachandran true PMID:35347128 1-carboxyethylleucine measurement efo:EFO_0800105 Quantification of the amount of 1-carboxyethylisoleucine in a sample. Santhi Ramachandran true PMID:35347128 1-carboxyethylisoleucine measurement efo:EFO_0800106 Quantification of the amount of indoleacetoylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 indoleacetoylcarnitine measurement efo:EFO_0800107 Quantification of the amount of N-acetyl-isoputreanine in a sample. Santhi Ramachandran true PMID:35347128 N-acetyl-isoputreanine measurement efo:EFO_0800108 Quantification of the amount of 5-hydroxyindole glucuronide in a sample. Santhi Ramachandran true PMID:35347128 5-hydroxyindole glucuronide measurement efo:EFO_0800109 Quantification of the amount of N2-acetyl,N6-methyllysine in a sample. Santhi Ramachandran true PMID:35347128 N2-acetyl,N6-methyllysine measurement efo:EFO_0800110 Quantification of the amount of 2-ketocaprylate in a sample. Santhi Ramachandran true PMID:35347128 2-ketocaprylate measurement efo:EFO_0800111 Quantification of the amount of 2,3-dihydroxy-5-methylthio-4-pentenoate (DMTPA) in a sample. Santhi Ramachandran true PMID:35347128 2,3-dihydroxy-5-methylthio-4-pentenoate (DMTPA) measurement efo:EFO_0800112 Quantification of the amount of hydroxy-N6,N6,N6-trimethyllysine in a sample. Santhi Ramachandran true PMID:35347128 hydroxy-N6,N6,N6-trimethyllysine measurement efo:EFO_0800113 Quantification of the amount of 2-hydroxy-4-(methylthio)butanoic acid in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxy-4-(methylthio)butanoic acid measurement efo:EFO_0800114 Quantification of the amount of trans-4-hydroxyproline in a sample. Santhi Ramachandran true PMID:35347128 trans-4-hydroxyproline measurement efo:EFO_0800115 Quantification of the amount of picolinate in a sample. Santhi Ramachandran true PMID:35347128 picolinate measurement efo:EFO_0800116 Quantification of the amount of N-acetylleucine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylleucine measurement efo:EFO_0800117 Quantification of the amount of N-acetylvaline in a sample. Santhi Ramachandran true PMID:35347128 N-acetylvaline measurement efo:EFO_0800118 Quantification of the amount of N-acetylalanine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylalanine measurement efo:EFO_0800119 Quantification of the amount of vanillylmandelate (VMA) in a sample. Santhi Ramachandran true PMID:35347128 vanillylmandelate (VMA) measurement efo:EFO_0800120 Quantification of the amount of 4-hydroxyphenylpyruvate in a sample. Santhi Ramachandran true PMID:35347128 4-hydroxyphenylpyruvate measurement efo:EFO_0800121 Quantification of the amount of tigloylglycine in a sample. Santhi Ramachandran true PMID:35347128 tigloylglycine measurement efo:EFO_0800122 Quantification of the amount of cys-gly, oxidized in a sample. Santhi Ramachandran true PMID:35347128 cys-gly, oxidized measurement efo:EFO_0800123 Quantification of the amount of anthranilate in a sample. Santhi Ramachandran true PMID:35347128 anthranilate measurement efo:EFO_0800124 Quantification of the amount of 4-hydroxyphenylacetate in a sample. Santhi Ramachandran true PMID:35347128 4-hydroxyphenylacetate measurement efo:EFO_0800125 Quantification of the amount of beta-hydroxyisovalerate in a sample. Santhi Ramachandran true PMID:35347128 beta-hydroxyisovalerate measurement efo:EFO_0800126 Quantification of the amount of N6,N6,N6-trimethyllysine in a sample. Santhi Ramachandran true PMID:35347128 N6,N6,N6-trimethyllysine measurement efo:EFO_0800127 Quantification of the amount of N-acetylputrescine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylputrescine measurement efo:EFO_0800128 Quantification of the amount of N-formylmethionine in a sample. Santhi Ramachandran true PMID:35347128 N-formylmethionine measurement efo:EFO_0800129 Quantification of the amount of methylsuccinate in a sample. Santhi Ramachandran true PMID:35347128 methylsuccinate measurement efo:EFO_0800130 Quantification of the amount of 5-methylthioadenosine (MTA) in a sample. Santhi Ramachandran true PMID:35347128 5-methylthioadenosine (MTA) measurement efo:EFO_0800131 Quantification of the amount of 2-hydroxyphenylacetate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxyphenylacetate measurement efo:EFO_0800132 Quantification of the amount of phenylpyruvate in a sample. Santhi Ramachandran true PMID:35347128 phenylpyruvate measurement efo:EFO_0800133 Quantification of the amount of cysteinylglycine in a sample. Santhi Ramachandran true PMID:35347128 cysteinylglycine measurement efo:EFO_0800134 Quantification of the amount of cystine in a sample. Santhi Ramachandran true PMID:35347128 cystine measurement efo:EFO_0800135 Quantification of the amount of guanidinoacetate in a sample. Santhi Ramachandran true PMID:35347128 guanidinoacetate measurement efo:EFO_0800136 Quantification of the amount of S-1-pyrroline-5-carboxylate in a sample. Santhi Ramachandran true PMID:35347128 S-1-pyrroline-5-carboxylate measurement efo:EFO_0800137 Quantification of the amount of 2-aminoadipate in a sample. Santhi Ramachandran true PMID:35347128 2-aminoadipate measurement efo:EFO_0800138 Quantification of the amount of trans-urocanate in a sample. Santhi Ramachandran true PMID:35347128 trans-urocanate measurement efo:EFO_0800139 Quantification of the amount of 5-hydroxyindoleacetate in a sample. Santhi Ramachandran true PMID:35347128 5-hydroxyindoleacetate measurement efo:EFO_0800140 Quantification of the amount of alpha-ketobutyrate in a sample. Santhi Ramachandran true PMID:35347128 alpha-ketobutyrate measurement efo:EFO_0800141 Quantification of the amount of kynurenate in a sample. Santhi Ramachandran true PMID:35347128 kynurenate measurement efo:EFO_0800142 Quantification of the amount of maltotriose in a sample. Santhi Ramachandran true PMID:35347128 maltotriose measurement efo:EFO_0800143 Quantification of the amount of ribitol in a sample. Santhi Ramachandran true PMID:35347128 ribitol measurement efo:EFO_0800144 Quantification of the amount of ribonate in a sample. Santhi Ramachandran true PMID:35347128 ribonate measurement efo:EFO_0800145 Quantification of the amount of galactonate in a sample. Santhi Ramachandran true PMID:35347128 galactonate measurement efo:EFO_0800146 Quantification of the amount of N6-carboxymethyllysine in a sample. Santhi Ramachandran true PMID:35347128 N6-carboxymethyllysine measurement efo:EFO_0800147 Quantification of the amount of xylonate in a sample. Santhi Ramachandran true PMID:35347128 xylonate measurement efo:EFO_0800148 Quantification of the amount of arabitol in a sample. Santhi Ramachandran true PMID:35347128 arabitol measurement efo:EFO_0800149 Quantification of the amount of N-acetylgalactosamine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylgalactosamine measurement efo:EFO_0800150 Quantification of the amount of lyxonate in a sample. Santhi Ramachandran true PMID:35347128 lyxonate measurement efo:EFO_0800151 Quantification of the amount of N-acetylglucosaminylasparagine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylglucosaminylasparagine measurement efo:EFO_0800152 Quantification of the amount of 3-phosphoglycerate in a sample. Santhi Ramachandran true PMID:35347128 3-phosphoglycerate measurement efo:EFO_0800153 Quantification of the amount of xylose in a sample. Santhi Ramachandran true PMID:35347128 xylose measurement efo:EFO_0800154 Quantification of the amount of trigonelline (N'-methylnicotinate) in a sample. Santhi Ramachandran true PMID:35347128 trigonelline (N'-methylnicotinate) measurement efo:EFO_0800155 Quantification of the amount of I-urobilinogen in a sample. Santhi Ramachandran true PMID:35347128 I-urobilinogen measurement efo:EFO_0800156 Quantification of the amount of nicotinamide riboside in a sample. Santhi Ramachandran true PMID:35347128 nicotinamide riboside measurement efo:EFO_0800157 Quantification of the amount of nicotinate ribonucleoside in a sample. Santhi Ramachandran true PMID:35347128 nicotinate ribonucleoside measurement efo:EFO_0800158 Quantification of the amount of heme in a sample. Santhi Ramachandran true PMID:35347128 heme measurement efo:EFO_0800159 Quantification of the amount of gulonate in a sample. Santhi Ramachandran true PMID:35347128 gulonate measurement efo:EFO_0800160 Quantification of the amount of gamma-CEHC in a sample. Santhi Ramachandran true PMID:35347128 gamma-CEHC measurement efo:EFO_0800161 Quantification of the amount of L-urobilin in a sample. Santhi Ramachandran true PMID:35347128 L-urobilin measurement efo:EFO_0800162 Quantification of the amount of astaxanthin in a sample. Santhi Ramachandran true PMID:35347128 astaxanthin measurement efo:EFO_0800163 Quantification of the amount of alpha-CEHC glucuronide in a sample. Santhi Ramachandran true PMID:35347128 alpha-CEHC glucuronide measurement efo:EFO_0800164 Quantification of the amount of 2-O-methylascorbic acid in a sample. Santhi Ramachandran true PMID:35347128 2-O-methylascorbic acid measurement efo:EFO_0800165 Quantification of the amount of gamma-CEHC glucuronide in a sample. Santhi Ramachandran true PMID:35347128 gamma-CEHC glucuronide measurement efo:EFO_0800166 Quantification of the amount of alpha-CEHC sulfate in a sample. Santhi Ramachandran true PMID:35347128 alpha-CEHC sulfate measurement efo:EFO_0800167 Quantification of the amount of alpha-CMBHC glucuronide in a sample. Santhi Ramachandran true PMID:35347128 alpha-CMBHC glucuronide measurement efo:EFO_0800168 Quantification of the amount of beta-tocopherol in a sample. Santhi Ramachandran true PMID:35347128 beta-tocopherol measurement efo:EFO_0800169 Quantification of the amount of ascorbic acid 2-sulfate in a sample. Santhi Ramachandran true PMID:35347128 ascorbic acid 2-sulfate measurement efo:EFO_0800170 Quantification of the amount of carotene diol (1) in a sample. Santhi Ramachandran true PMID:35347128 carotene diol (1) measurement efo:EFO_0800171 Quantification of the amount of carotene diol (2) in a sample. Santhi Ramachandran true PMID:35347128 carotene diol (2) measurement efo:EFO_0800172 Quantification of the amount of carotene diol (3) in a sample. Santhi Ramachandran true PMID:35347128 carotene diol (3) measurement efo:EFO_0800173 Quantification of the amount of ascorbic acid 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 ascorbic acid 3-sulfate measurement efo:EFO_0800174 Quantification of the amount of delta-CEHC in a sample. Santhi Ramachandran true PMID:35347128 delta-CEHC measurement efo:EFO_0800175 Quantification of the amount of quinolinate in a sample. Santhi Ramachandran true PMID:35347128 quinolinate measurement efo:EFO_0800176 Quantification of the amount of adenosine 5'-diphosphoribose (ADP-ribose) in a sample. Santhi Ramachandran true PMID:35347128 adenosine 5'-diphosphoribose (ADP-ribose) measurement efo:EFO_0800177 Quantification of the amount of flavin adenine dinucleotide (FAD) in a sample. Santhi Ramachandran true PMID:35347128 flavin adenine dinucleotide (FAD) measurement efo:EFO_0800178 Quantification of the amount of nicotinamide in a sample. Santhi Ramachandran true PMID:35347128 nicotinamide measurement efo:EFO_0800179 Quantification of the amount of homocitrate in a sample. Santhi Ramachandran true PMID:35347128 homocitrate measurement efo:EFO_0800180 Quantification of the amount of isocitric lactone in a sample. Santhi Ramachandran true PMID:35347128 isocitric lactone measurement efo:EFO_0800181 Quantification of the amount of suberate (C8-DC) in a sample. Santhi Ramachandran true PMID:35347128 suberate (C8-DC) measurement efo:EFO_0800182 Quantification of the amount of 2-arachidonoylglycerol (20:4) in a sample. Santhi Ramachandran true PMID:35347128 2-arachidonoylglycerol (20:4) measurement efo:EFO_0800183 Quantification of the amount of 1-palmityl-GPC (O-16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmityl-GPC (O-16:0) measurement efo:EFO_0800184 Quantification of the amount of 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) measurement efo:EFO_0800185 Quantification of the amount of sphingosine 1-phosphate in a sample. Santhi Ramachandran true PMID:35347128 sphingosine 1-phosphate measurement efo:EFO_0800186 Quantification of the amount of 1-oleoyl-GPS (18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-GPS (18:1) measurement efo:EFO_0800187 Quantification of the amount of 1-stearoyl-2-oleoyl-GPS (18:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-oleoyl-GPS (18:0/18:1) measurement efo:EFO_0800188 Quantification of the amount of 1-stearoyl-GPI (18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-GPI (18:0) measurement efo:EFO_0800189 Quantification of the amount of 1,2-dipalmitoyl-GPC (16:0/16:0) in a sample. Santhi Ramachandran true PMID:35347128 1,2-dipalmitoyl-GPC (16:0/16:0) measurement efo:EFO_0800190 Quantification of the amount of 1,2-distearoyl-GPC (18:0/18:0) in a sample. Santhi Ramachandran true PMID:35347128 1,2-distearoyl-GPC (18:0/18:0) measurement efo:EFO_0800191 Quantification of the amount of 1-myristoyl-2-palmitoyl-GPC (14:0/16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-myristoyl-2-palmitoyl-GPC (14:0/16:0) measurement efo:EFO_0800192 Quantification of the amount of 2-hydroxyoctanoate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxyoctanoate measurement efo:EFO_0800193 Quantification of the amount of 3-hydroxyoctanoate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyoctanoate measurement efo:EFO_0800194 Quantification of the amount of 1-palmitoylglycerol (16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoylglycerol (16:0) measurement efo:EFO_0800195 Quantification of the amount of 1-oleoylglycerol (18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoylglycerol (18:1) measurement efo:EFO_0800196 Quantification of the amount of 2-oleoylglycerol (18:1) in a sample. Santhi Ramachandran true PMID:35347128 2-oleoylglycerol (18:1) measurement efo:EFO_0800197 Quantification of the amount of 2-linoleoylglycerol (18:2) in a sample. Santhi Ramachandran true PMID:35347128 2-linoleoylglycerol (18:2) measurement efo:EFO_0800198 Quantification of the amount of 3-hydroxydecanoate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxydecanoate measurement efo:EFO_0800199 Quantification of the amount of 1-linoleoylglycerol (18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoylglycerol (18:2) measurement efo:EFO_0800200 Quantification of the amount of 2-palmitoylglycerol (16:0) in a sample. Santhi Ramachandran true PMID:35347128 2-palmitoylglycerol (16:0) measurement efo:EFO_0800201 Quantification of the amount of butyrylcarnitine (C4) in a sample. Santhi Ramachandran true PMID:35347128 butyrylcarnitine (C4) measurement efo:EFO_0800202 Quantification of the amount of 7-ketodeoxycholate in a sample. Santhi Ramachandran true PMID:35347128 7-ketodeoxycholate measurement efo:EFO_0800203 Quantification of the amount of glycolithocholate in a sample. Santhi Ramachandran true PMID:35347128 glycolithocholate measurement efo:EFO_0800204 Quantification of the amount of 3-hydroxylaurate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxylaurate measurement efo:EFO_0800205 Quantification of the amount of 3-hydroxysebacate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxysebacate measurement efo:EFO_0800206 Quantification of the amount of 5-hydroxyhexanoate in a sample. Santhi Ramachandran true PMID:35347128 5-hydroxyhexanoate measurement efo:EFO_0800207 Quantification of the amount of propionylglycine in a sample. Santhi Ramachandran true PMID:35347128 propionylglycine measurement efo:EFO_0800208 Quantification of the amount of butyrylglycine in a sample. Santhi Ramachandran true PMID:35347128 butyrylglycine measurement efo:EFO_0800209 Quantification of the amount of 2-hydroxyadipate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxyadipate measurement efo:EFO_0800210 Quantification of the amount of propionylcarnitine (C3) in a sample. Santhi Ramachandran true PMID:35347128 propionylcarnitine (C3) measurement efo:EFO_0800211 Quantification of the amount of docosadienoate (22:2n6) in a sample. Santhi Ramachandran true PMID:35347128 docosadienoate (22:2n6) measurement efo:EFO_0800212 Quantification of the amount of sebacate (C10-DC) in a sample. Santhi Ramachandran true PMID:35347128 sebacate (C10-DC) measurement efo:EFO_0800213 Quantification of the amount of tauro-beta-muricholate in a sample. Santhi Ramachandran true PMID:35347128 tauro-beta-muricholate measurement efo:EFO_0800214 Quantification of the amount of 1-palmitoyl-GPC (16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-GPC (16:0) measurement efo:EFO_0800215 Quantification of the amount of 1-margaroyl-GPC (17:0) in a sample. Santhi Ramachandran true PMID:35347128 1-margaroyl-GPC (17:0) measurement efo:EFO_0800216 Quantification of the amount of myristoylcarnitine (C14) in a sample. Santhi Ramachandran true PMID:35347128 myristoylcarnitine (C14) measurement efo:EFO_0800217 Quantification of the amount of 1-stearoyl-GPC (18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-GPC (18:0) measurement efo:EFO_0800218 Quantification of the amount of 1-oleoyl-GPC (18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-GPC (18:1) measurement efo:EFO_0800219 Quantification of the amount of hyocholate in a sample. Santhi Ramachandran true PMID:35347128 hyocholate measurement efo:EFO_0800220 Quantification of the amount of eicosenoate (20:1) in a sample. Santhi Ramachandran true PMID:35347128 eicosenoate (20:1) measurement efo:EFO_0800221 Quantification of the amount of 1-myristoyl-GPC (14:0) in a sample. Santhi Ramachandran true PMID:35347128 1-myristoyl-GPC (14:0) measurement efo:EFO_0800222 Quantification of the amount of 1-arachidoyl-GPC (20:0) in a sample. Santhi Ramachandran true PMID:35347128 1-arachidoyl-GPC (20:0) measurement efo:EFO_0800223 Quantification of the amount of 1-linoleoyl-GPC (18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-GPC (18:2) measurement efo:EFO_0800224 Quantification of the amount of 1-arachidonylglycerol (20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-arachidonylglycerol (20:4) measurement efo:EFO_0800225 Quantification of the amount of 1-linolenoylglycerol (18:3) in a sample. Santhi Ramachandran true PMID:35347128 1-linolenoylglycerol (18:3) measurement efo:EFO_0800226 Quantification of the amount of 3-hydroxydodecanedioate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxydodecanedioate measurement efo:EFO_0800227 Quantification of the amount of 1-stearoyl-GPE (18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-GPE (18:0) measurement efo:EFO_0800228 Quantification of the amount of 1-stearoyl-GPG (18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-GPG (18:0) measurement efo:EFO_0800229 Quantification of the amount of 1-docosahexaenoylglycerol (22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-docosahexaenoylglycerol (22:6) measurement efo:EFO_0800230 Quantification of the amount of 1-dihomo-linoleoylglycerol (20:2) in a sample. Santhi Ramachandran true PMID:35347128 1-dihomo-linoleoylglycerol (20:2) measurement efo:EFO_0800231 Quantification of the amount of 1-palmitoleoyl-GPC (16:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoleoyl-GPC (16:1) measurement efo:EFO_0800232 Quantification of the amount of malonylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 malonylcarnitine measurement efo:EFO_0800233 Quantification of the amount of hexanoylglycine in a sample. Santhi Ramachandran true PMID:35347128 hexanoylglycine measurement efo:EFO_0800234 Quantification of the amount of 1-arachidonoyl-GPC (20:4n6) in a sample. Santhi Ramachandran true PMID:35347128 1-arachidonoyl-GPC (20:4n6) measurement efo:EFO_0800235 Quantification of the amount of 1-dihomo-linolenoyl-GPC (20:3n3 or 6) in a sample. Santhi Ramachandran true PMID:35347128 1-dihomo-linolenoyl-GPC (20:3n3 or 6) measurement efo:EFO_0800236 Quantification of the amount of 1-dihomo-linoleoyl-GPC (20:2) in a sample. Santhi Ramachandran true PMID:35347128 1-dihomo-linoleoyl-GPC (20:2) measurement efo:EFO_0800237 Quantification of the amount of 2-arachidonoyl-GPC (20:4) in a sample. Santhi Ramachandran true PMID:35347128 2-arachidonoyl-GPC (20:4) measurement efo:EFO_0800238 Quantification of the amount of 2-oleoyl-GPC (18:1) in a sample. Santhi Ramachandran true PMID:35347128 2-oleoyl-GPC (18:1) measurement efo:EFO_0800239 Quantification of the amount of 2-linoleoyl-GPC (18:2) in a sample. Santhi Ramachandran true PMID:35347128 2-linoleoyl-GPC (18:2) measurement efo:EFO_0800240 Quantification of the amount of 2-palmitoleoyl-GPC (16:1) in a sample. Santhi Ramachandran true PMID:35347128 2-palmitoleoyl-GPC (16:1) measurement efo:EFO_0800241 Quantification of the amount of 2-palmitoyl-GPC (16:0) in a sample. Santhi Ramachandran true PMID:35347128 2-palmitoyl-GPC (16:0) measurement efo:EFO_0800242 Quantification of the amount of 2-myristoyl-GPC (14:0) in a sample. Santhi Ramachandran true PMID:35347128 2-myristoyl-GPC (14:0) measurement efo:EFO_0800243 Quantification of the amount of 2-docosahexaenoyl-GPC (22:6) in a sample. Santhi Ramachandran true PMID:35347128 2-docosahexaenoyl-GPC (22:6) measurement efo:EFO_0800244 Quantification of the amount of 1-docosahexaenoyl-GPC (22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-docosahexaenoyl-GPC (22:6) measurement efo:EFO_0800245 Quantification of the amount of 1-palmitoyl-GPE (16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-GPE (16:0) measurement efo:EFO_0800246 Quantification of the amount of 1-oleoyl-GPE (18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-GPE (18:1) measurement efo:EFO_0800247 Quantification of the amount of 1-linoleoyl-GPE (18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-GPE (18:2) measurement efo:EFO_0800248 Quantification of the amount of 1-arachidonoyl-GPE (20:4n6) in a sample. Santhi Ramachandran true PMID:35347128 1-arachidonoyl-GPE (20:4n6) measurement efo:EFO_0800249 Quantification of the amount of docosapentaenoate (n6 DPA; 22:5n6) in a sample. Santhi Ramachandran true PMID:35347128 docosapentaenoate (n6 DPA; 22:5n6) measurement efo:EFO_0800250 Quantification of the amount of 2-methylmalonylcarnitine (C4-DC) in a sample. Santhi Ramachandran true PMID:35347128 2-methylmalonylcarnitine (C4-DC) measurement efo:EFO_0800251 Quantification of the amount of 3beta,7alpha-dihydroxy-5-cholestenoate in a sample. Santhi Ramachandran true PMID:35347128 3beta,7alpha-dihydroxy-5-cholestenoate measurement efo:EFO_0800252 Quantification of the amount of 1-myristoylglycerol (14:0) in a sample. Santhi Ramachandran true PMID:35347128 1-myristoylglycerol (14:0) measurement efo:EFO_0800253 Quantification of the amount of glycerophosphoethanolamine in a sample. Santhi Ramachandran true PMID:35347128 glycerophosphoethanolamine measurement efo:EFO_0800254 Quantification of the amount of 2-oleoyl-GPE (18:1) in a sample. Santhi Ramachandran true PMID:35347128 2-oleoyl-GPE (18:1) measurement efo:EFO_0800255 Quantification of the amount of 2-palmitoyl-GPE (16:0) in a sample. Santhi Ramachandran true PMID:35347128 2-palmitoyl-GPE (16:0) measurement efo:EFO_0800256 Quantification of the amount of 1-arachidonoyl-GPI (20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-arachidonoyl-GPI (20:4) measurement efo:EFO_0800257 Quantification of the amount of 1-palmitoyl-GPI (16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-GPI (16:0) measurement efo:EFO_0800258 Quantification of the amount of glycolithocholate sulfate in a sample. Santhi Ramachandran true PMID:35347128 glycolithocholate sulfate measurement efo:EFO_0800259 Quantification of the amount of deoxycarnitine in a sample. Santhi Ramachandran true PMID:35347128 deoxycarnitine measurement efo:EFO_0800260 Quantification of the amount of 2-arachidonoyl-GPE (20:4) in a sample. Santhi Ramachandran true PMID:35347128 2-arachidonoyl-GPE (20:4) measurement efo:EFO_0800261 Quantification of the amount of alpha-hydroxycaproate in a sample. Santhi Ramachandran true PMID:35347128 alpha-hydroxycaproate measurement efo:EFO_0800262 Quantification of the amount of hexanoylglutamine in a sample. Santhi Ramachandran true PMID:35347128 hexanoylglutamine measurement efo:EFO_0800263 Quantification of the amount of 3-methyladipate in a sample. Santhi Ramachandran true PMID:35347128 3-methyladipate measurement efo:EFO_0800264 Quantification of the amount of 2-linoleoyl-GPE (18:2) in a sample. Santhi Ramachandran true PMID:35347128 2-linoleoyl-GPE (18:2) measurement efo:EFO_0800265 Quantification of the amount of 1-oleoyl-GPI (18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-GPI (18:1) measurement efo:EFO_0800266 Quantification of the amount of 1-linoleoyl-GPI (18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-GPI (18:2) measurement efo:EFO_0800267 Quantification of the amount of 1-palmitoleoyl-GPE (16:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoleoyl-GPE (16:1) measurement efo:EFO_0800268 Quantification of the amount of 1-palmitoleoyl-GPI (16:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoleoyl-GPI (16:1) measurement efo:EFO_0800269 Quantification of the amount of 1-stearoyl-2-oleoyl-GPE (18:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-oleoyl-GPE (18:0/18:1) measurement efo:EFO_0800270 Quantification of the amount of chiro-inositol in a sample. Santhi Ramachandran true PMID:35347128 chiro-inositol measurement efo:EFO_0800271 Quantification of the amount of 1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) measurement efo:EFO_0800272 Quantification of the amount of 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) measurement efo:EFO_0800273 Quantification of the amount of 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) measurement efo:EFO_0800274 Quantification of the amount of sphinganine-1-phosphate in a sample. Santhi Ramachandran true PMID:35347128 sphinganine-1-phosphate measurement efo:EFO_0800275 Quantification of the amount of glycosyl-N-stearoyl-sphingosine (d18:1/18:0) in a sample. Santhi Ramachandran true PMID:35347128 glycosyl-N-stearoyl-sphingosine (d18:1/18:0) measurement efo:EFO_0800276 Quantification of the amount of glycocholenate sulfate in a sample. Santhi Ramachandran true PMID:35347128 glycocholenate sulfate measurement efo:EFO_0800277 Quantification of the amount of taurocholenate sulfate in a sample. Santhi Ramachandran true PMID:35347128 taurocholenate sulfate measurement efo:EFO_0800278 Quantification of the amount of androstenediol (3beta,17beta) disulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 androstenediol (3beta,17beta) disulfate (1) measurement efo:EFO_0800279 Quantification of the amount of pregnenediol disulfate (C21H34O8S2) in a sample. Santhi Ramachandran true PMID:35347128 pregnenediol disulfate (C21H34O8S2) measurement efo:EFO_0800280 Quantification of the amount of androstenediol (3beta,17beta) disulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 androstenediol (3beta,17beta) disulfate (2) measurement efo:EFO_0800281 Quantification of the amount of 21-hydroxypregnenolone disulfate in a sample. Santhi Ramachandran true PMID:35347128 21-hydroxypregnenolone disulfate measurement efo:EFO_0800282 Quantification of the amount of 21-hydroxypregnenolone monosulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 21-hydroxypregnenolone monosulfate (1) measurement efo:EFO_0800283 Quantification of the amount of 5alpha-androstan-3alpha,17alpha-diol monosulfate in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3alpha,17alpha-diol monosulfate measurement efo:EFO_0800284 Quantification of the amount of 5alpha-pregnan-3beta,20beta-diol monosulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 5alpha-pregnan-3beta,20beta-diol monosulfate (1) measurement efo:EFO_0800285 Quantification of the amount of 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) measurement efo:EFO_0800286 Quantification of the amount of 5alpha-pregnan-diol disulfate in a sample. Santhi Ramachandran true PMID:35347128 5alpha-pregnan-diol disulfate measurement efo:EFO_0800287 Quantification of the amount of 5alpha-androstan-3alpha,17beta-diol disulfate in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3alpha,17beta-diol disulfate measurement efo:EFO_0800288 Quantification of the amount of 5alpha-androstan-3alpha,17beta-diol monosulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3alpha,17beta-diol monosulfate (1) measurement efo:EFO_0800289 Quantification of the amount of 5alpha-androstan-3beta,17alpha-diol disulfate in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3beta,17alpha-diol disulfate measurement efo:EFO_0800290 Quantification of the amount of 5alpha-androstan-3beta,17beta-diol monosulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3beta,17beta-diol monosulfate (1) measurement efo:EFO_0800291 Quantification of the amount of 5alpha-androstan-3beta,17beta-diol monosulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3beta,17beta-diol monosulfate (2) measurement efo:EFO_0800292 Quantification of the amount of androstenediol (3alpha, 17alpha) monosulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 androstenediol (3alpha, 17alpha) monosulfate (2) measurement efo:EFO_0800293 Quantification of the amount of androstenediol (3alpha, 17alpha) monosulfate (3) in a sample. Santhi Ramachandran true PMID:35347128 androstenediol (3alpha, 17alpha) monosulfate (3) measurement efo:EFO_0800294 Quantification of the amount of androstenediol (3beta,17beta) monosulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 androstenediol (3beta,17beta) monosulfate (1) measurement efo:EFO_0800295 Quantification of the amount of androstenediol (3beta,17beta) monosulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 androstenediol (3beta,17beta) monosulfate (2) measurement efo:EFO_0800296 Quantification of the amount of 1-docosahexaenoyl-GPE (22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-docosahexaenoyl-GPE (22:6) measurement efo:EFO_0800297 Quantification of the amount of 2-docosahexaenoyl-GPE (22:6) in a sample. Santhi Ramachandran true PMID:35347128 2-docosahexaenoyl-GPE (22:6) measurement efo:EFO_0800298 Quantification of the amount of 1-docosapentaenoyl-GPC (22:5n3) in a sample. Santhi Ramachandran true PMID:35347128 1-docosapentaenoyl-GPC (22:5n3) measurement efo:EFO_0800299 Quantification of the amount of pregnenediol sulfate (C21H34O5S) in a sample. Santhi Ramachandran true PMID:35347128 pregnenediol sulfate (C21H34O5S) measurement efo:EFO_0800300 Quantification of the amount of palmitoyl sphingomyelin (d18:1/16:0) in a sample. Santhi Ramachandran true PMID:35347128 palmitoyl sphingomyelin (d18:1/16:0) measurement efo:EFO_0800301 Quantification of the amount of 16a-hydroxy DHEA 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 16a-hydroxy DHEA 3-sulfate measurement efo:EFO_0800302 Quantification of the amount of 17alpha-hydroxypregnenolone 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 17alpha-hydroxypregnenolone 3-sulfate measurement efo:EFO_0800303 Quantification of the amount of pregnenolone sulfate in a sample. Santhi Ramachandran true PMID:35347128 pregnenolone sulfate measurement efo:EFO_0800304 Quantification of the amount of 5-HEPE in a sample. Santhi Ramachandran true PMID:35347128 5-HEPE measurement efo:EFO_0800305 Quantification of the amount of andro steroid monosulfate C19H28O6S (1) in a sample. Santhi Ramachandran true PMID:35347128 andro steroid monosulfate C19H28O6S (1) measurement efo:EFO_0800306 Quantification of the amount of 1-margaroyl-GPE (17:0) in a sample. Santhi Ramachandran true PMID:35347128 1-margaroyl-GPE (17:0) measurement efo:EFO_0800307 Quantification of the amount of 1-pentadecanoyl-GPC (15:0) in a sample. Santhi Ramachandran true PMID:35347128 1-pentadecanoyl-GPC (15:0) measurement efo:EFO_0800308 Quantification of the amount of 13-HODE + 9-HODE in a sample. Santhi Ramachandran true PMID:35347128 13-HODE + 9-HODE measurement efo:EFO_0800309 Quantification of the amount of tridecenedioate (C13:1-DC) in a sample. Santhi Ramachandran true PMID:35347128 tridecenedioate (C13:1-DC) measurement efo:EFO_0800310 Quantification of the amount of 4-cholesten-3-one in a sample. Santhi Ramachandran true PMID:35347128 4-cholesten-3-one measurement efo:EFO_0800311 Quantification of the amount of cis-4-decenoylcarnitine (C10:1) in a sample. Santhi Ramachandran true PMID:35347128 cis-4-decenoylcarnitine (C10:1) measurement efo:EFO_0800312 Quantification of the amount of 2s,3R-dihydroxybutyrate in a sample. Santhi Ramachandran true PMID:35347128 2s,3R-dihydroxybutyrate measurement efo:EFO_0800313 Quantification of the amount of (16 or 17)-methylstearate (a19:0 or i19:0) in a sample. Santhi Ramachandran true PMID:35347128 (16 or 17)-methylstearate (a19:0 or i19:0) measurement efo:EFO_0800314 Quantification of the amount of 2R,3R-dihydroxybutyrate in a sample. Santhi Ramachandran true PMID:35347128 2R,3R-dihydroxybutyrate measurement efo:EFO_0800315 Quantification of the amount of isoursodeoxycholate in a sample. Santhi Ramachandran true PMID:35347128 isoursodeoxycholate measurement efo:EFO_0800316 Quantification of the amount of 4-hydroxy-2-oxoglutaric acid in a sample. Santhi Ramachandran true PMID:35347128 4-hydroxy-2-oxoglutaric acid measurement efo:EFO_0800317 Quantification of the amount of androsterone glucuronide in a sample. Santhi Ramachandran true PMID:35347128 androsterone glucuronide measurement efo:EFO_0800318 Quantification of the amount of cis-4-decenoate (10:1n6) in a sample. Santhi Ramachandran true PMID:35347128 cis-4-decenoate (10:1n6) measurement efo:EFO_0800319 Quantification of the amount of 1-meadoyl-GPC (20:3n9) in a sample. Santhi Ramachandran true PMID:35347128 1-meadoyl-GPC (20:3n9) measurement efo:EFO_0800320 Quantification of the amount of 1-erucoyl-GPC (22:1) in a sample. Santhi Ramachandran true PMID:35347128 1-erucoyl-GPC (22:1) measurement efo:EFO_0800321 Quantification of the amount of 1-adrenoyl-GPC (22:4) in a sample. Santhi Ramachandran true PMID:35347128 1-adrenoyl-GPC (22:4) measurement efo:EFO_0800322 Quantification of the amount of 1-lignoceroyl-GPC (24:0) in a sample. Santhi Ramachandran true PMID:35347128 1-lignoceroyl-GPC (24:0) measurement efo:EFO_0800323 Quantification of the amount of 1-(1-enyl-palmitoyl)-GPC (P-16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-GPC (P-16:0) measurement efo:EFO_0800324 Quantification of the amount of 1-(1-enyl-oleoyl)-GPC (P-18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-oleoyl)-GPC (P-18:1) measurement efo:EFO_0800325 Quantification of the amount of 1-(1-enyl-stearoyl)-GPC (P-18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-GPC (P-18:0) measurement efo:EFO_0800326 Quantification of the amount of glycoursodeoxycholate in a sample. Santhi Ramachandran true PMID:35347128 glycoursodeoxycholate measurement efo:EFO_0800327 Quantification of the amount of tauroursodeoxycholate in a sample. Santhi Ramachandran true PMID:35347128 tauroursodeoxycholate measurement efo:EFO_0800328 Quantification of the amount of ursocholate in a sample. Santhi Ramachandran true PMID:35347128 ursocholate measurement efo:EFO_0800329 Quantification of the amount of (14 or 15)-methylpalmitate (a17:0 or i17:0) in a sample. Santhi Ramachandran true PMID:35347128 (14 or 15)-methylpalmitate (a17:0 or i17:0) measurement efo:EFO_0800330 Quantification of the amount of eicosanedioate (C20-DC) in a sample. Santhi Ramachandran true PMID:35347128 eicosanedioate (C20-DC) measurement efo:EFO_0800331 Quantification of the amount of docosadioate (C22-DC) in a sample. Santhi Ramachandran true PMID:35347128 docosadioate (C22-DC) measurement efo:EFO_0800332 Quantification of the amount of oleoyl-linoleoyl-glycerol (18:1/18:2) [1] in a sample. Santhi Ramachandran true PMID:35347128 oleoyl-linoleoyl-glycerol (18:1/18:2) [1] measurement efo:EFO_0800333 Quantification of the amount of oleoyl-linoleoyl-glycerol (18:1/18:2) [2] in a sample. Santhi Ramachandran true PMID:35347128 oleoyl-linoleoyl-glycerol (18:1/18:2) [2] measurement efo:EFO_0800334 Quantification of the amount of 1-(1-enyl-palmitoyl)-GPE (P-16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-GPE (P-16:0) measurement efo:EFO_0800335 Quantification of the amount of 1-(1-enyl-stearoyl)-GPE (P-18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-GPE (P-18:0) measurement efo:EFO_0800336 Quantification of the amount of 2-stearoyl-GPI (18:0) in a sample. Santhi Ramachandran true PMID:35347128 2-stearoyl-GPI (18:0) measurement efo:EFO_0800337 Quantification of the amount of N-oleoyltaurine in a sample. Santhi Ramachandran true PMID:35347128 N-oleoyltaurine measurement efo:EFO_0800338 Quantification of the amount of linoleoylcarnitine (C18:2) in a sample. Santhi Ramachandran true PMID:35347128 linoleoylcarnitine (C18:2) measurement efo:EFO_0800339 Quantification of the amount of N-palmitoyltaurine in a sample. Santhi Ramachandran true PMID:35347128 N-palmitoyltaurine measurement efo:EFO_0800340 Quantification of the amount of N-stearoyltaurine in a sample. Santhi Ramachandran true PMID:35347128 N-stearoyltaurine measurement efo:EFO_0800341 Quantification of the amount of pregnanediol-3-glucuronide in a sample. Santhi Ramachandran true PMID:35347128 pregnanediol-3-glucuronide measurement efo:EFO_0800342 Quantification of the amount of N-palmitoylglycine in a sample. Santhi Ramachandran true PMID:35347128 N-palmitoylglycine measurement efo:EFO_0800343 Quantification of the amount of 2-stearoyl-GPE (18:0) in a sample. Santhi Ramachandran true PMID:35347128 2-stearoyl-GPE (18:0) measurement efo:EFO_0800344 Quantification of the amount of (R)-3-hydroxybutyrylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 (R)-3-hydroxybutyrylcarnitine measurement efo:EFO_0800345 Quantification of the amount of margaroylcarnitine (C17) in a sample. Santhi Ramachandran true PMID:35347128 margaroylcarnitine (C17) measurement efo:EFO_0800346 Quantification of the amount of glycohyocholate in a sample. Santhi Ramachandran true PMID:35347128 glycohyocholate measurement efo:EFO_0800347 Quantification of the amount of 2-hydroxydecanoate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxydecanoate measurement efo:EFO_0800348 Quantification of the amount of 3b-hydroxy-5-cholenoic acid in a sample. Santhi Ramachandran true PMID:35347128 3b-hydroxy-5-cholenoic acid measurement efo:EFO_0800349 Quantification of the amount of 2-aminooctanoate in a sample. Santhi Ramachandran true PMID:35347128 2-aminooctanoate measurement efo:EFO_0800350 Quantification of the amount of 1-stearoyl-GPS (18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-GPS (18:0) measurement efo:EFO_0800351 Quantification of the amount of 3-hydroxyadipate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyadipate measurement efo:EFO_0800352 Quantification of the amount of 2-aminoheptanoate in a sample. Santhi Ramachandran true PMID:35347128 2-aminoheptanoate measurement efo:EFO_0800353 Quantification of the amount of 1-eicosapentaenoyl-GPE (20:5) in a sample. Santhi Ramachandran true PMID:35347128 1-eicosapentaenoyl-GPE (20:5) measurement efo:EFO_0800354 Quantification of the amount of 1-linolenoyl-GPC (18:3) in a sample. Santhi Ramachandran true PMID:35347128 1-linolenoyl-GPC (18:3) measurement efo:EFO_0800355 Quantification of the amount of 1-eicosapentaenoyl-GPC (20:5) in a sample. Santhi Ramachandran true PMID:35347128 1-eicosapentaenoyl-GPC (20:5) measurement efo:EFO_0800356 Quantification of the amount of 1-eicosenoyl-GPC (20:1) in a sample. Santhi Ramachandran true PMID:35347128 1-eicosenoyl-GPC (20:1) measurement efo:EFO_0800357 Quantification of the amount of 1-nonadecanoyl-GPC (19:0) in a sample. Santhi Ramachandran true PMID:35347128 1-nonadecanoyl-GPC (19:0) measurement efo:EFO_0800358 Quantification of the amount of 1-dihomo-linolenoyl-GPE (20:3n3 or 6) in a sample. Santhi Ramachandran true PMID:35347128 1-dihomo-linolenoyl-GPE (20:3n3 or 6) measurement efo:EFO_0800359 Quantification of the amount of 1-(1-enyl-oleoyl)-GPE (P-18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-oleoyl)-GPE (P-18:1) measurement efo:EFO_0800360 Quantification of the amount of 5alpha-androstan-3alpha,17beta-diol 17-glucuronide in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3alpha,17beta-diol 17-glucuronide measurement efo:EFO_0800361 Quantification of the amount of 11-ketoetiocholanolone glucuronide in a sample. Santhi Ramachandran true PMID:35347128 11-ketoetiocholanolone glucuronide measurement efo:EFO_0800362 Quantification of the amount of etiocholanolone glucuronide in a sample. Santhi Ramachandran true PMID:35347128 etiocholanolone glucuronide measurement efo:EFO_0800363 Quantification of the amount of 17alpha-hydroxypregnanolone glucuronide in a sample. Santhi Ramachandran true PMID:35347128 17alpha-hydroxypregnanolone glucuronide measurement efo:EFO_0800364 Quantification of the amount of 1-docosapentaenoyl-GPC (22:5n6) in a sample. Santhi Ramachandran true PMID:35347128 1-docosapentaenoyl-GPC (22:5n6) measurement efo:EFO_0800365 Quantification of the amount of 1-linolenoyl-GPE (18:3) in a sample. Santhi Ramachandran true PMID:35347128 1-linolenoyl-GPE (18:3) measurement efo:EFO_0800366 Quantification of the amount of 1-oleoyl-GPG (18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-GPG (18:1) measurement efo:EFO_0800367 Quantification of the amount of 1-palmitoyl-GPG (16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-GPG (16:0) measurement efo:EFO_0800368 Quantification of the amount of N-linoleoyltaurine in a sample. Santhi Ramachandran true PMID:35347128 N-linoleoyltaurine measurement efo:EFO_0800369 Quantification of the amount of 9-hydroxystearate in a sample. Santhi Ramachandran true PMID:35347128 9-hydroxystearate measurement efo:EFO_0800370 Quantification of the amount of octadecenedioylcarnitine (C18:1-DC) in a sample. Santhi Ramachandran true PMID:35347128 octadecenedioylcarnitine (C18:1-DC) measurement efo:EFO_0800371 Quantification of the amount of octadecanedioylcarnitine (C18-DC) in a sample. Santhi Ramachandran true PMID:35347128 octadecanedioylcarnitine (C18-DC) measurement efo:EFO_0800372 Quantification of the amount of 5alpha-androstan-3alpha,17beta-diol monosulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 5alpha-androstan-3alpha,17beta-diol monosulfate (2) measurement efo:EFO_0800373 Quantification of the amount of myristoleoylcarnitine (C14:1) in a sample. Santhi Ramachandran true PMID:35347128 myristoleoylcarnitine (C14:1) measurement efo:EFO_0800374 Quantification of the amount of 1-dihomo-linolenylglycerol (20:3) in a sample. Santhi Ramachandran true PMID:35347128 1-dihomo-linolenylglycerol (20:3) measurement efo:EFO_0800375 Quantification of the amount of pregnanolone sulfate in a sample. Santhi Ramachandran true PMID:35347128 pregnanolone sulfate measurement efo:EFO_0800376 Quantification of the amount of behenoyl sphingomyelin (d18:1/22:0) in a sample. Santhi Ramachandran true PMID:35347128 behenoyl sphingomyelin (d18:1/22:0) measurement efo:EFO_0800377 Quantification of the amount of lignoceroyl sphingomyelin (d18:1/24:0) in a sample. Santhi Ramachandran true PMID:35347128 lignoceroyl sphingomyelin (d18:1/24:0) measurement efo:EFO_0800378 Quantification of the amount of 3-hydroxyhexanoate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyhexanoate measurement efo:EFO_0800379 Quantification of the amount of 3beta-hydroxy-5-cholestenoate in a sample. Santhi Ramachandran true PMID:35347128 3beta-hydroxy-5-cholestenoate measurement efo:EFO_0800380 Quantification of the amount of adipoylcarnitine (C6-DC) in a sample. Santhi Ramachandran true PMID:35347128 adipoylcarnitine (C6-DC) measurement efo:EFO_0800381 Quantification of the amount of nonanoylcarnitine (C9) in a sample. Santhi Ramachandran true PMID:35347128 nonanoylcarnitine (C9) measurement efo:EFO_0800382 Quantification of the amount of suberoylcarnitine (C8-DC) in a sample. Santhi Ramachandran true PMID:35347128 suberoylcarnitine (C8-DC) measurement efo:EFO_0800383 Quantification of the amount of deoxycholic acid 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 deoxycholic acid 3-sulfate measurement efo:EFO_0800384 Quantification of the amount of glycochenodeoxycholate 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 glycochenodeoxycholate 3-sulfate measurement efo:EFO_0800385 Quantification of the amount of glycodeoxycholate 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 glycodeoxycholate 3-sulfate measurement efo:EFO_0800386 Quantification of the amount of taurodeoxycholic acid 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 taurodeoxycholic acid 3-sulfate measurement efo:EFO_0800387 Quantification of the amount of linoleoyl ethanolamide in a sample. Santhi Ramachandran true PMID:35347128 linoleoyl ethanolamide measurement efo:EFO_0800388 Quantification of the amount of 1,2-dilinoleoyl-GPC (18:2/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1,2-dilinoleoyl-GPC (18:2/18:2) measurement efo:EFO_0800389 Quantification of the amount of 1-stearoyl-2-oleoyl-GPC (18:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-oleoyl-GPC (18:0/18:1) measurement efo:EFO_0800390 Quantification of the amount of 1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) measurement efo:EFO_0800391 Quantification of the amount of 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) measurement efo:EFO_0800392 Quantification of the amount of 1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6) measurement efo:EFO_0800393 Quantification of the amount of 1-(1-enyl-stearoyl)-2-oleoyl-GPC (P-18:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-2-oleoyl-GPC (P-18:0/18:1) measurement efo:EFO_0800394 Quantification of the amount of 1-(1-enyl-stearoyl)-2-arachidonoyl-GPC (P-18:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-2-arachidonoyl-GPC (P-18:0/20:4) measurement efo:EFO_0800395 Quantification of the amount of 1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1) measurement efo:EFO_0800396 Quantification of the amount of 1-palmitoyl-2-stearoyl-GPC (16:0/18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-stearoyl-GPC (16:0/18:0) measurement efo:EFO_0800397 Quantification of the amount of vaccenate (18:1) in a sample. Santhi Ramachandran true PMID:35347128 vaccenate (18:1) measurement efo:EFO_0800398 Quantification of the amount of 1-palmitoleoylglycerol (16:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoleoylglycerol (16:1) measurement efo:EFO_0800399 Quantification of the amount of 2-palmitoleoylglycerol (16:1) in a sample. Santhi Ramachandran true PMID:35347128 2-palmitoleoylglycerol (16:1) measurement efo:EFO_0800400 Quantification of the amount of palmitoyl dihydrosphingomyelin (d18:0/16:0) in a sample. Santhi Ramachandran true PMID:35347128 palmitoyl dihydrosphingomyelin (d18:0/16:0) measurement efo:EFO_0800401 Quantification of the amount of tricosanoyl sphingomyelin (d18:1/23:0) in a sample. Santhi Ramachandran true PMID:35347128 tricosanoyl sphingomyelin (d18:1/23:0) measurement efo:EFO_0800402 Quantification of the amount of 1-stearoyl-2-linoleoyl-GPE (18:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-linoleoyl-GPE (18:0/18:2) measurement efo:EFO_0800403 Quantification of the amount of 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) measurement efo:EFO_0800404 Quantification of the amount of 1-stearoyl-2-linoleoyl-GPC (18:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-linoleoyl-GPC (18:0/18:2) measurement efo:EFO_0800405 Quantification of the amount of 1-oleoyl-2-linoleoyl-GPC (18:1/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-linoleoyl-GPC (18:1/18:2) measurement efo:EFO_0800406 Quantification of the amount of 1-palmitoyl-2-palmitoleoyl-GPC(16:0/16:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-palmitoleoyl-GPC(16:0/16:1) measurement efo:EFO_0800407 Quantification of the amount of 1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) measurement efo:EFO_0800408 Quantification of the amount of 1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) measurement efo:EFO_0800409 Quantification of the amount of 1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) measurement efo:EFO_0800410 Quantification of the amount of 1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6) measurement efo:EFO_0800411 Quantification of the amount of 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) measurement efo:EFO_0800412 Quantification of the amount of 1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) measurement efo:EFO_0800413 Quantification of the amount of 1-stearoyl-2-linoleoyl-GPI (18:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-linoleoyl-GPI (18:0/18:2) measurement efo:EFO_0800414 Quantification of the amount of 1-palmitoyl-2-palmitoleoyl-GPE (16:0/16:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-palmitoleoyl-GPE (16:0/16:1) measurement efo:EFO_0800415 Quantification of the amount of 1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) measurement efo:EFO_0800416 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (P-16:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (P-16:0/22:6) measurement efo:EFO_0800417 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4) measurement efo:EFO_0800418 Quantification of the amount of 1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (P-18:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (P-18:0/22:6) measurement efo:EFO_0800419 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1) measurement efo:EFO_0800420 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1) measurement efo:EFO_0800421 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (P-16:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (P-16:0/22:6) measurement efo:EFO_0800422 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) measurement efo:EFO_0800423 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) measurement efo:EFO_0800424 Quantification of the amount of 1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (P-18:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (P-18:0/22:6) measurement efo:EFO_0800425 Quantification of the amount of 1-palmityl-2-oleoyl-GPC (O-16:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmityl-2-oleoyl-GPC (O-16:0/18:1) measurement efo:EFO_0800426 Quantification of the amount of 1-palmityl-2-arachidonoyl-GPC (O-16:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-palmityl-2-arachidonoyl-GPC (O-16:0/20:4) measurement efo:EFO_0800427 Quantification of the amount of behenoyl dihydrosphingomyelin (d18:0/22:0) in a sample. Santhi Ramachandran true PMID:35347128 behenoyl dihydrosphingomyelin (d18:0/22:0) measurement efo:EFO_0800428 Quantification of the amount of N-palmitoyl-sphinganine (d18:0/16:0) in a sample. Santhi Ramachandran true PMID:35347128 N-palmitoyl-sphinganine (d18:0/16:0) measurement efo:EFO_0800429 Quantification of the amount of lactosyl-N-palmitoyl-sphingosine (d18:1/16:0) in a sample. Santhi Ramachandran true PMID:35347128 lactosyl-N-palmitoyl-sphingosine (d18:1/16:0) measurement efo:EFO_0800430 Quantification of the amount of 1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) measurement efo:EFO_0800431 Quantification of the amount of 1-margaroyl-2-oleoyl-GPC (17:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-margaroyl-2-oleoyl-GPC (17:0/18:1) measurement efo:EFO_0800432 Quantification of the amount of 1-margaroyl-2-linoleoyl-GPC (17:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-margaroyl-2-linoleoyl-GPC (17:0/18:2) measurement efo:EFO_0800433 Quantification of the amount of myristoyl dihydrosphingomyelin (d18:0/14:0) in a sample. Santhi Ramachandran true PMID:35347128 myristoyl dihydrosphingomyelin (d18:0/14:0) measurement efo:EFO_0800434 Quantification of the amount of 1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) measurement efo:EFO_0800435 Quantification of the amount of palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] in a sample. Santhi Ramachandran true PMID:35347128 palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] measurement efo:EFO_0800436 Quantification of the amount of palmitoleoyl-oleoyl-glycerol (16:1/18:1) [1] in a sample. Santhi Ramachandran true PMID:35347128 palmitoleoyl-oleoyl-glycerol (16:1/18:1) [1] measurement efo:EFO_0800437 Quantification of the amount of palmitoleoyl-oleoyl-glycerol (16:1/18:1) [2] in a sample. Santhi Ramachandran true PMID:35347128 palmitoleoyl-oleoyl-glycerol (16:1/18:1) [2] measurement efo:EFO_0800438 Quantification of the amount of palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] in a sample. Santhi Ramachandran true PMID:35347128 palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] measurement efo:EFO_0800439 Quantification of the amount of 1-palmitoyl-2-oleoyl-GPI (16:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-oleoyl-GPI (16:0/18:1) measurement efo:EFO_0800440 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2) measurement efo:EFO_0800441 Quantification of the amount of 1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) measurement efo:EFO_0800442 Quantification of the amount of 1-palmitoyl-2-alpha-linolenoyl-GPC (16:0/18:3n3) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-alpha-linolenoyl-GPC (16:0/18:3n3) measurement efo:EFO_0800443 Quantification of the amount of 1-oleoyl-2-linoleoyl-GPE (18:1/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-linoleoyl-GPE (18:1/18:2) measurement efo:EFO_0800444 Quantification of the amount of 1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) measurement efo:EFO_0800445 Quantification of the amount of 1-linoleoyl-GPA (18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-GPA (18:2) measurement efo:EFO_0800446 Quantification of the amount of 1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) measurement efo:EFO_0800447 Quantification of the amount of 1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) measurement efo:EFO_0800448 Quantification of the amount of 1-margaroyl-2-docosahexaenoyl-GPC (17:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-margaroyl-2-docosahexaenoyl-GPC (17:0/22:6) measurement efo:EFO_0800449 Quantification of the amount of 1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) measurement efo:EFO_0800450 Quantification of the amount of 1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) measurement efo:EFO_0800451 Quantification of the amount of 1-(1-enyl-stearoyl)-2-linoleoyl-GPC (P-18:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-stearoyl)-2-linoleoyl-GPC (P-18:0/18:2) measurement efo:EFO_0800452 Quantification of the amount of 1-myristoyl-2-linoleoyl-GPC (14:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-myristoyl-2-linoleoyl-GPC (14:0/18:2) measurement efo:EFO_0800453 Quantification of the amount of 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) measurement efo:EFO_0800454 Quantification of the amount of 1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) measurement efo:EFO_0800455 Quantification of the amount of 1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) measurement efo:EFO_0800456 Quantification of the amount of 1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6) measurement efo:EFO_0800457 Quantification of the amount of 1-palmitoyl-2-adrenoyl-GPC (16:0/22:4) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-adrenoyl-GPC (16:0/22:4) measurement efo:EFO_0800458 Quantification of the amount of 1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) measurement efo:EFO_0800459 Quantification of the amount of 1-stearoyl-2-adrenoyl-GPC (18:0/22:4) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-adrenoyl-GPC (18:0/22:4) measurement efo:EFO_0800460 Quantification of the amount of 1-stearyl-GPC (O-18:0) in a sample. Santhi Ramachandran true PMID:35347128 1-stearyl-GPC (O-18:0) measurement efo:EFO_0800461 Quantification of the amount of 1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) measurement efo:EFO_0800462 Quantification of the amount of 1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) measurement efo:EFO_0800463 Quantification of the amount of 1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) measurement efo:EFO_0800464 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) measurement efo:EFO_0800465 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-myristoyl-GPC (P-16:0/14:0) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-myristoyl-GPC (P-16:0/14:0) measurement efo:EFO_0800466 Quantification of the amount of 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) measurement efo:EFO_0800467 Quantification of the amount of phosphatidylcholine (16:0/22:5n3, 18:1/20:4) in a sample. Santhi Ramachandran true PMID:35347128 phosphatidylcholine (16:0/22:5n3, 18:1/20:4) measurement efo:EFO_0800468 Quantification of the amount of phosphatidylcholine (18:0/20:5, 16:0/22:5n6) in a sample. Santhi Ramachandran true PMID:35347128 phosphatidylcholine (18:0/20:5, 16:0/22:5n6) measurement efo:EFO_0800469 Quantification of the amount of 1-stearoyl-2-oleoyl-GPI (18:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-stearoyl-2-oleoyl-GPI (18:0/18:1) measurement efo:EFO_0800470 Quantification of the amount of 1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) measurement efo:EFO_0800471 Quantification of the amount of 1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) measurement efo:EFO_0800472 Quantification of the amount of 1-linoleoyl-GPG (18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-GPG (18:2) measurement efo:EFO_0800473 Quantification of the amount of palmitoylcholine in a sample. Santhi Ramachandran true PMID:35347128 palmitoylcholine measurement efo:EFO_0800474 Quantification of the amount of glycochenodeoxycholate glucuronide (1) in a sample. Santhi Ramachandran true PMID:35347128 glycochenodeoxycholate glucuronide (1) measurement efo:EFO_0800475 Quantification of the amount of (S)-3-hydroxybutyrylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 (S)-3-hydroxybutyrylcarnitine measurement efo:EFO_0800476 Quantification of the amount of glycosyl-N-palmitoyl-sphingosine (d18:1/16:0) in a sample. Santhi Ramachandran true PMID:35347128 glycosyl-N-palmitoyl-sphingosine (d18:1/16:0) measurement efo:EFO_0800477 Quantification of the amount of oleoylcholine in a sample. Santhi Ramachandran true PMID:35347128 oleoylcholine measurement efo:EFO_0800478 Quantification of the amount of arachidonoylcholine in a sample. Santhi Ramachandran true PMID:35347128 arachidonoylcholine measurement efo:EFO_0800479 Quantification of the amount of docosahexaenoylcholine in a sample. Santhi Ramachandran true PMID:35347128 docosahexaenoylcholine measurement efo:EFO_0800480 Quantification of the amount of palmitoloelycholine in a sample. Santhi Ramachandran true PMID:35347128 palmitoloelycholine measurement efo:EFO_0800481 Quantification of the amount of dihomo-linolenoyl-choline in a sample. Santhi Ramachandran true PMID:35347128 dihomo-linolenoyl-choline measurement efo:EFO_0800482 Quantification of the amount of eicosapentaenoylcholine in a sample. Santhi Ramachandran true PMID:35347128 eicosapentaenoylcholine measurement efo:EFO_0800483 Quantification of the amount of 1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) measurement efo:EFO_0800484 Quantification of the amount of 1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) measurement efo:EFO_0800485 Quantification of the amount of phosphatidylcholine (14:0/14:0, 16:0/12:0) in a sample. Santhi Ramachandran true PMID:35347128 phosphatidylcholine (14:0/14:0, 16:0/12:0) measurement efo:EFO_0800486 Quantification of the amount of phosphatidylcholine (15:0/18:1, 17:0/16:1, 16:0/17:1) in a sample. Santhi Ramachandran true PMID:35347128 phosphatidylcholine (15:0/18:1, 17:0/16:1, 16:0/17:1) measurement efo:EFO_0800487 Quantification of the amount of 1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) in a sample. Santhi Ramachandran true PMID:35347128 1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) measurement efo:EFO_0800488 Quantification of the amount of phosphatidylcholine (18:0/20:2, 20:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 phosphatidylcholine (18:0/20:2, 20:0/18:2) measurement efo:EFO_0800489 Quantification of the amount of 1-linoleoyl-2-docosapentaenyol-GPC (18:2/22:5n3) in a sample. Santhi Ramachandran true PMID:35347128 1-linoleoyl-2-docosapentaenyol-GPC (18:2/22:5n3) measurement efo:EFO_0800490 Quantification of the amount of 1-(1-enyl-oleoyl)-2-docosahexaenoyl-GPE (P-18:1/22:6) in a sample. Santhi Ramachandran true PMID:35347128 1-(1-enyl-oleoyl)-2-docosahexaenoyl-GPE (P-18:1/22:6) measurement efo:EFO_0800491 Quantification of the amount of hexadecadienoate (16:2n6) in a sample. Santhi Ramachandran true PMID:35347128 hexadecadienoate (16:2n6) measurement efo:EFO_0800492 Quantification of the amount of 1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) in a sample. Santhi Ramachandran true PMID:35347128 1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) measurement efo:EFO_0800493 Quantification of the amount of palmitoleoylcarnitine (C16:1) in a sample. Santhi Ramachandran true PMID:35347128 palmitoleoylcarnitine (C16:1) measurement efo:EFO_0800494 Quantification of the amount of pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) in a sample. Santhi Ramachandran true PMID:35347128 pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) measurement efo:EFO_0800495 Quantification of the amount of palmitoyl-oleoyl-glycerol (16:0/18:1) [1] in a sample. Santhi Ramachandran true PMID:35347128 palmitoyl-oleoyl-glycerol (16:0/18:1) [1] measurement efo:EFO_0800496 Quantification of the amount of palmitoyl-oleoyl-glycerol (16:0/18:1) [2] in a sample. Santhi Ramachandran true PMID:35347128 palmitoyl-oleoyl-glycerol (16:0/18:1) [2] measurement efo:EFO_0800497 Quantification of the amount of oleoyl-oleoyl-glycerol (18:1/18:1) [1] in a sample. Santhi Ramachandran true PMID:35347128 oleoyl-oleoyl-glycerol (18:1/18:1) [1] measurement efo:EFO_0800498 Quantification of the amount of oleoyl-oleoyl-glycerol (18:1/18:1) [2] in a sample. Santhi Ramachandran true PMID:35347128 oleoyl-oleoyl-glycerol (18:1/18:1) [2] measurement efo:EFO_0800499 Quantification of the amount of linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] in a sample. Santhi Ramachandran true PMID:35347128 linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] measurement efo:EFO_0800500 Quantification of the amount of linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] in a sample. Santhi Ramachandran true PMID:35347128 linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] measurement efo:EFO_0800501 Quantification of the amount of linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] in a sample. Santhi Ramachandran true PMID:35347128 linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] measurement efo:EFO_0800502 Quantification of the amount of linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) [1] in a sample. Santhi Ramachandran true PMID:35347128 linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) [1] measurement efo:EFO_0800503 Quantification of the amount of linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) [2] in a sample. Santhi Ramachandran true PMID:35347128 linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) [2] measurement efo:EFO_0800504 Quantification of the amount of palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1] in a sample. Santhi Ramachandran true PMID:35347128 palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1] measurement efo:EFO_0800505 Quantification of the amount of diacylglycerol (14:0/18:1, 16:0/16:1) [1] in a sample. Santhi Ramachandran true PMID:35347128 diacylglycerol (14:0/18:1, 16:0/16:1) [1] measurement efo:EFO_0800506 Quantification of the amount of diacylglycerol (14:0/18:1, 16:0/16:1) [2] in a sample. Santhi Ramachandran true PMID:35347128 diacylglycerol (14:0/18:1, 16:0/16:1) [2] measurement efo:EFO_0800507 Quantification of the amount of oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] in a sample. Santhi Ramachandran true PMID:35347128 oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] measurement efo:EFO_0800508 Quantification of the amount of oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] in a sample. Santhi Ramachandran true PMID:35347128 oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] measurement efo:EFO_0800509 Quantification of the amount of diacylglycerol (16:1/18:2 [2], 16:0/18:3 [1]) in a sample. Santhi Ramachandran true PMID:35347128 diacylglycerol (16:1/18:2 [2], 16:0/18:3 [1]) measurement efo:EFO_0800510 Quantification of the amount of linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] in a sample. Santhi Ramachandran true PMID:35347128 linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] measurement efo:EFO_0800511 Quantification of the amount of stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] in a sample. Santhi Ramachandran true PMID:35347128 stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] measurement efo:EFO_0800512 Quantification of the amount of diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [1] in a sample. Santhi Ramachandran true PMID:35347128 diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [1] measurement efo:EFO_0800513 Quantification of the amount of diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [2] in a sample. Santhi Ramachandran true PMID:35347128 diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [2] measurement efo:EFO_0800514 Quantification of the amount of 1-palmityl-GPE (O-16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmityl-GPE (O-16:0) measurement efo:EFO_0800515 Quantification of the amount of 1-palmityl-2-palmitoyl-GPC (O-16:0/16:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmityl-2-palmitoyl-GPC (O-16:0/16:0) measurement efo:EFO_0800516 Quantification of the amount of N-palmitoyl-sphingadienine (d18:2/16:0) in a sample. Santhi Ramachandran true PMID:35347128 N-palmitoyl-sphingadienine (d18:2/16:0) measurement efo:EFO_0800517 Quantification of the amount of lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) in a sample. Santhi Ramachandran true PMID:35347128 lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) measurement efo:EFO_0800518 Quantification of the amount of lactosyl-N-behenoyl-sphingosine (d18:1/22:0) in a sample. Santhi Ramachandran true PMID:35347128 lactosyl-N-behenoyl-sphingosine (d18:1/22:0) measurement efo:EFO_0800519 Quantification of the amount of N-behenoyl-sphingadienine (d18:2/22:0) in a sample. Santhi Ramachandran true PMID:35347128 N-behenoyl-sphingadienine (d18:2/22:0) measurement efo:EFO_0800520 Quantification of the amount of glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) in a sample. Santhi Ramachandran true PMID:35347128 glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) measurement efo:EFO_0800521 Quantification of the amount of N-stearoyl-sphingadienine (d18:2/18:0) in a sample. Santhi Ramachandran true PMID:35347128 N-stearoyl-sphingadienine (d18:2/18:0) measurement efo:EFO_0800522 Quantification of the amount of 2-hydroxybehenate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxybehenate measurement efo:EFO_0800523 Quantification of the amount of 2-hydroxynervonate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxynervonate measurement efo:EFO_0800524 Quantification of the amount of N-palmitoylserine in a sample. Santhi Ramachandran true PMID:35347128 N-palmitoylserine measurement efo:EFO_0800525 Quantification of the amount of N-oleoylserine in a sample. Santhi Ramachandran true PMID:35347128 N-oleoylserine measurement efo:EFO_0800526 Quantification of the amount of sphingadienine in a sample. Santhi Ramachandran true PMID:35347128 sphingadienine measurement efo:EFO_0800527 Quantification of the amount of myristoyl-linoleoyl-glycerol (14:0/18:2) [1] in a sample. Santhi Ramachandran true PMID:35347128 myristoyl-linoleoyl-glycerol (14:0/18:2) [1] measurement efo:EFO_0800528 Quantification of the amount of myristoyl-linoleoyl-glycerol (14:0/18:2) [2] in a sample. Santhi Ramachandran true PMID:35347128 myristoyl-linoleoyl-glycerol (14:0/18:2) [2] measurement efo:EFO_0800529 Quantification of the amount of hexadecasphingosine (d16:1) in a sample. Santhi Ramachandran true PMID:35347128 hexadecasphingosine (d16:1) measurement efo:EFO_0800530 Quantification of the amount of glycosyl ceramide (d16:1/24:1, d18:1/22:1) in a sample. Santhi Ramachandran true PMID:35347128 glycosyl ceramide (d16:1/24:1, d18:1/22:1) measurement efo:EFO_0800531 Quantification of the amount of N-palmitoyl-heptadecasphingosine (d17:1/16:0) in a sample. Santhi Ramachandran true PMID:35347128 N-palmitoyl-heptadecasphingosine (d17:1/16:0) measurement efo:EFO_0800532 Quantification of the amount of glycosyl ceramide (d18:2/24:1, d18:1/24:2) in a sample. Santhi Ramachandran true PMID:35347128 glycosyl ceramide (d18:2/24:1, d18:1/24:2) measurement efo:EFO_0800533 Quantification of the amount of glycosyl-N-(2-hydroxynervonoyl)-sphingosine (d18:1/24:1(2OH)) in a sample. Santhi Ramachandran true PMID:35347128 glycosyl-N-(2-hydroxynervonoyl)-sphingosine (d18:1/24:1(2OH)) measurement efo:EFO_0800534 Quantification of the amount of stearoylcholine in a sample. Santhi Ramachandran true PMID:35347128 stearoylcholine measurement efo:EFO_0800535 Quantification of the amount of linoleoylcholine in a sample. Santhi Ramachandran true PMID:35347128 linoleoylcholine measurement efo:EFO_0800536 Quantification of the amount of nisinate (24:6n3) in a sample. Santhi Ramachandran true PMID:35347128 nisinate (24:6n3) measurement efo:EFO_0800537 Quantification of the amount of heneicosapentaenoate (21:5n3) in a sample. Santhi Ramachandran true PMID:35347128 heneicosapentaenoate (21:5n3) measurement efo:EFO_0800538 Quantification of the amount of linolenoylcarnitine (C18:3) in a sample. Santhi Ramachandran true PMID:35347128 linolenoylcarnitine (C18:3) measurement efo:EFO_0800539 Quantification of the amount of behenoylcarnitine (C22) in a sample. Santhi Ramachandran true PMID:35347128 behenoylcarnitine (C22) measurement efo:EFO_0800540 Quantification of the amount of arachidoylcarnitine (C20) in a sample. Santhi Ramachandran true PMID:35347128 arachidoylcarnitine (C20) measurement efo:EFO_0800541 Quantification of the amount of lignoceroylcarnitine (C24) in a sample. Santhi Ramachandran true PMID:35347128 lignoceroylcarnitine (C24) measurement efo:EFO_0800542 Quantification of the amount of cerotoylcarnitine (C26) in a sample. Santhi Ramachandran true PMID:35347128 cerotoylcarnitine (C26) measurement efo:EFO_0800543 Quantification of the amount of ximenoylcarnitine (C26:1) in a sample. Santhi Ramachandran true PMID:35347128 ximenoylcarnitine (C26:1) measurement efo:EFO_0800544 Quantification of the amount of arachidonoylcarnitine (C20:4) in a sample. Santhi Ramachandran true PMID:35347128 arachidonoylcarnitine (C20:4) measurement efo:EFO_0800545 Quantification of the amount of eicosenoylcarnitine (C20:1) in a sample. Santhi Ramachandran true PMID:35347128 eicosenoylcarnitine (C20:1) measurement efo:EFO_0800546 Quantification of the amount of dihomo-linoleoylcarnitine (C20:2) in a sample. Santhi Ramachandran true PMID:35347128 dihomo-linoleoylcarnitine (C20:2) measurement efo:EFO_0800547 Quantification of the amount of dihomo-linolenoylcarnitine (C20:3n3 or 6) in a sample. Santhi Ramachandran true PMID:35347128 dihomo-linolenoylcarnitine (C20:3n3 or 6) measurement efo:EFO_0800548 Quantification of the amount of docosahexaenoylcarnitine (C22:6) in a sample. Santhi Ramachandran true PMID:35347128 docosahexaenoylcarnitine (C22:6) measurement efo:EFO_0800549 Quantification of the amount of nervonoylcarnitine (C24:1) in a sample. Santhi Ramachandran true PMID:35347128 nervonoylcarnitine (C24:1) measurement efo:EFO_0800550 Quantification of the amount of docosapentaenoylcarnitine (C22:5n3) in a sample. Santhi Ramachandran true PMID:35347128 docosapentaenoylcarnitine (C22:5n3) measurement efo:EFO_0800551 Quantification of the amount of glycosyl ceramide (d18:1/20:0, d16:1/22:0) in a sample. Santhi Ramachandran true PMID:35347128 glycosyl ceramide (d18:1/20:0, d16:1/22:0) measurement efo:EFO_0800552 Quantification of the amount of cortolone glucuronide (1) in a sample. Santhi Ramachandran true PMID:35347128 cortolone glucuronide (1) measurement efo:EFO_0800553 Quantification of the amount of phosphatidylcholine (O-18:1/20:4, O-16:0/22:5n3) in a sample. Santhi Ramachandran true PMID:35347128 phosphatidylcholine (O-18:1/20:4, O-16:0/22:5n3) measurement efo:EFO_0800554 Quantification of the amount of 1-palmitoyl-2-pentadecanoyl-GPC (16:0/15:0) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-pentadecanoyl-GPC (16:0/15:0) measurement efo:EFO_0800555 Quantification of the amount of 5-dodecenoylcarnitine (C12:1) in a sample. Santhi Ramachandran true PMID:35347128 5-dodecenoylcarnitine (C12:1) measurement efo:EFO_0800556 Quantification of the amount of 2-butenoylglycine in a sample. Santhi Ramachandran true PMID:35347128 2-butenoylglycine measurement efo:EFO_0800557 Quantification of the amount of hydroxy-CMPF in a sample. Santhi Ramachandran true PMID:35347128 hydroxy-CMPF measurement efo:EFO_0800558 Quantification of the amount of 2-hydroxyarachidate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxyarachidate measurement efo:EFO_0800559 Quantification of the amount of N-stearoylserine in a sample. Santhi Ramachandran true PMID:35347128 N-stearoylserine measurement efo:EFO_0800560 Quantification of the amount of 3-hydroxyoleate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyoleate measurement efo:EFO_0800561 Quantification of the amount of dodecenedioate (C12:1-DC) in a sample. Santhi Ramachandran true PMID:35347128 dodecenedioate (C12:1-DC) measurement efo:EFO_0800562 Quantification of the amount of hexadecenedioate (C16:1-DC) in a sample. Santhi Ramachandran true PMID:35347128 hexadecenedioate (C16:1-DC) measurement efo:EFO_0800563 Quantification of the amount of octadecenedioate (C18:1-DC) in a sample. Santhi Ramachandran true PMID:35347128 octadecenedioate (C18:1-DC) measurement efo:EFO_0800564 Quantification of the amount of heptenedioate (C7:1-DC) in a sample. Santhi Ramachandran true PMID:35347128 heptenedioate (C7:1-DC) measurement efo:EFO_0800565 Quantification of the amount of octadecadienedioate (C18:2-DC) in a sample. Santhi Ramachandran true PMID:35347128 octadecadienedioate (C18:2-DC) measurement efo:EFO_0800566 Quantification of the amount of 3-carboxy-4-methyl-5-pentyl-2-furanpropionate (3-CMPFP) in a sample. Santhi Ramachandran true PMID:35347128 3-carboxy-4-methyl-5-pentyl-2-furanpropionate (3-CMPFP) measurement efo:EFO_0800567 Quantification of the amount of N-acetyl-2-aminooctanoate in a sample. Santhi Ramachandran true PMID:35347128 N-acetyl-2-aminooctanoate measurement efo:EFO_0800568 Quantification of the amount of 3-hydroxybutyroylglycine in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxybutyroylglycine measurement efo:EFO_0800569 Quantification of the amount of glyco-beta-muricholate in a sample. Santhi Ramachandran true PMID:35347128 glyco-beta-muricholate measurement efo:EFO_0800570 Quantification of the amount of tetradecadienoate (14:2) in a sample. Santhi Ramachandran true PMID:35347128 tetradecadienoate (14:2) measurement efo:EFO_0800571 Quantification of the amount of 2-hydroxysebacate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxysebacate measurement efo:EFO_0800572 Quantification of the amount of dodecadienoate (12:2) in a sample. Santhi Ramachandran true PMID:35347128 dodecadienoate (12:2) measurement efo:EFO_0800573 Quantification of the amount of 11beta-hydroxyandrosterone glucuronide in a sample. Santhi Ramachandran true PMID:35347128 11beta-hydroxyandrosterone glucuronide measurement efo:EFO_0800574 Quantification of the amount of cholic acid glucuronide in a sample. Santhi Ramachandran true PMID:35347128 cholic acid glucuronide measurement efo:EFO_0800575 Quantification of the amount of deoxycholic acid glucuronide in a sample. Santhi Ramachandran true PMID:35347128 deoxycholic acid glucuronide measurement efo:EFO_0800576 Quantification of the amount of 4-methylhexanoylglutamine in a sample. Santhi Ramachandran true PMID:35347128 4-methylhexanoylglutamine measurement efo:EFO_0800577 Quantification of the amount of 1-nonadecenoyl-GPC (19:1) in a sample. Santhi Ramachandran true PMID:35347128 1-nonadecenoyl-GPC (19:1) measurement efo:EFO_0800578 Quantification of the amount of glycoursodeoxycholic acid sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 glycoursodeoxycholic acid sulfate (1) measurement efo:EFO_0800579 Quantification of the amount of lithocholate sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 lithocholate sulfate (1) measurement efo:EFO_0800580 Quantification of the amount of 3-hydroxyhexanoylcarnitine (1) in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyhexanoylcarnitine (1) measurement efo:EFO_0800581 Quantification of the amount of 3-hydroxyhexanoylcarnitine (2) in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyhexanoylcarnitine (2) measurement efo:EFO_0800582 Quantification of the amount of tetrahydrocortisol sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 tetrahydrocortisol sulfate (1) measurement efo:EFO_0800583 Quantification of the amount of hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) in a sample. Santhi Ramachandran true PMID:35347128 hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) measurement efo:EFO_0800584 Quantification of the amount of taurochenodeoxycholic acid 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 taurochenodeoxycholic acid 3-sulfate measurement efo:EFO_0800585 Quantification of the amount of tetradecadienedioate (C14:2-DC) in a sample. Santhi Ramachandran true PMID:35347128 tetradecadienedioate (C14:2-DC) measurement efo:EFO_0800586 Quantification of the amount of pregnenetriol sulfate in a sample. Santhi Ramachandran true PMID:35347128 pregnenetriol sulfate measurement efo:EFO_0800587 Quantification of the amount of pregnenetriol disulfate in a sample. Santhi Ramachandran true PMID:35347128 pregnenetriol disulfate measurement efo:EFO_0800588 Quantification of the amount of undecenoylcarnitine (C11:1) in a sample. Santhi Ramachandran true PMID:35347128 undecenoylcarnitine (C11:1) measurement efo:EFO_0800589 Quantification of the amount of 3-decenoylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 3-decenoylcarnitine measurement efo:EFO_0800590 Quantification of the amount of 3-hydroxydecanoylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxydecanoylcarnitine measurement efo:EFO_0800591 Quantification of the amount of palmitoyl-sphingosine-phosphoethanolamine (d18:1/16:0) in a sample. Santhi Ramachandran true PMID:35347128 palmitoyl-sphingosine-phosphoethanolamine (d18:1/16:0) measurement efo:EFO_0800592 Quantification of the amount of picolinoylglycine in a sample. Santhi Ramachandran true PMID:35347128 picolinoylglycine measurement efo:EFO_0800593 Quantification of the amount of branched chain 14:0 dicarboxylic acid in a sample. Santhi Ramachandran true PMID:35347128 branched chain 14:0 dicarboxylic acid measurement efo:EFO_0800594 Quantification of the amount of (2 or 3)-decenoate (10:1n7 or n8) in a sample. Santhi Ramachandran true PMID:35347128 (2 or 3)-decenoate (10:1n7 or n8) measurement efo:EFO_0800595 Quantification of the amount of isoursodeoxycholate sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 isoursodeoxycholate sulfate (1) measurement efo:EFO_0800596 Quantification of the amount of chenodeoxycholic acid sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 chenodeoxycholic acid sulfate (1) measurement efo:EFO_0800597 Quantification of the amount of chenodeoxycholic acid sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 chenodeoxycholic acid sulfate (2) measurement efo:EFO_0800598 Quantification of the amount of decadienedioic acid (C10:2-DC) in a sample. Santhi Ramachandran true PMID:35347128 decadienedioic acid (C10:2-DC) measurement efo:EFO_0800599 Quantification of the amount of deoxycholic acid (12 or 24)-sulfate in a sample. Santhi Ramachandran true PMID:35347128 deoxycholic acid (12 or 24)-sulfate measurement efo:EFO_0800600 Quantification of the amount of phosphoethanolamine in a sample. Santhi Ramachandran true PMID:35347128 phosphoethanolamine measurement efo:EFO_0800601 Quantification of the amount of erucate (22:1n9) in a sample. Santhi Ramachandran true PMID:35347128 erucate (22:1n9) measurement efo:EFO_0800602 Quantification of the amount of 3-hydroxy-3-methylglutarate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxy-3-methylglutarate measurement efo:EFO_0800603 Quantification of the amount of valerate (5:0) in a sample. Santhi Ramachandran true PMID:35347128 valerate (5:0) measurement efo:EFO_0800604 Quantification of the amount of oleoyl ethanolamide in a sample. Santhi Ramachandran true PMID:35347128 oleoyl ethanolamide measurement efo:EFO_0800605 Quantification of the amount of isobutyrate (4:0) in a sample. Santhi Ramachandran true PMID:35347128 isobutyrate (4:0) measurement efo:EFO_0800606 Quantification of the amount of estrone 3-sulfate in a sample. Santhi Ramachandran true PMID:35347128 estrone 3-sulfate measurement efo:EFO_0800607 Quantification of the amount of N-palmitoyl-sphingosine (d18:1/16:0) in a sample. Santhi Ramachandran true PMID:35347128 N-palmitoyl-sphingosine (d18:1/16:0) measurement efo:EFO_0800608 Quantification of the amount of 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) measurement efo:EFO_0800609 Quantification of the amount of 1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) measurement efo:EFO_0800610 Quantification of the amount of 1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) measurement efo:EFO_0800611 Quantification of the amount of stearoyl sphingomyelin (d18:1/18:0) in a sample. Santhi Ramachandran true PMID:35347128 stearoyl sphingomyelin (d18:1/18:0) measurement efo:EFO_0800612 Quantification of the amount of 1-palmitoyl-2-oleoyl-GPC (16:0/18:1) in a sample. Santhi Ramachandran true PMID:35347128 1-palmitoyl-2-oleoyl-GPC (16:0/18:1) measurement efo:EFO_0800613 Quantification of the amount of N-stearoyl-sphingosine (d18:1/18:0) in a sample. Santhi Ramachandran true PMID:35347128 N-stearoyl-sphingosine (d18:1/18:0) measurement efo:EFO_0800614 Quantification of the amount of linoleate (18:2n6) in a sample. Santhi Ramachandran true PMID:35347128 linoleate (18:2n6) measurement efo:EFO_0800615 Quantification of the amount of azelate (C9-DC) in a sample. Santhi Ramachandran true PMID:35347128 azelate (C9-DC) measurement efo:EFO_0800616 Quantification of the amount of eicosapentaenoate (EPA; 20:5n3) in a sample. Santhi Ramachandran true PMID:35347128 eicosapentaenoate (EPA; 20:5n3) measurement efo:EFO_0800617 Quantification of the amount of choline phosphate in a sample. Santhi Ramachandran true PMID:35347128 choline phosphate measurement efo:EFO_0800618 Quantification of the amount of sphingosine in a sample. Santhi Ramachandran true PMID:35347128 sphingosine measurement efo:EFO_0800619 Quantification of the amount of sphinganine in a sample. Santhi Ramachandran true PMID:35347128 sphinganine measurement efo:EFO_0800620 Quantification of the amount of glutarate (C5-DC) in a sample. Santhi Ramachandran true PMID:35347128 glutarate (C5-DC) measurement efo:EFO_0800621 Quantification of the amount of myo-inositol in a sample. Santhi Ramachandran true PMID:35347128 myo-inositol measurement efo:EFO_0800622 Quantification of the amount of methylmalonate (MMA) in a sample. Santhi Ramachandran true PMID:35347128 methylmalonate (MMA) measurement efo:EFO_0800623 Quantification of the amount of pristanate in a sample. Santhi Ramachandran true PMID:35347128 pristanate measurement efo:EFO_0800624 Quantification of the amount of 12,13-DiHOME in a sample. Santhi Ramachandran true PMID:35347128 12,13-DiHOME measurement efo:EFO_0800625 Quantification of the amount of arachidate (20:0) in a sample. Santhi Ramachandran true PMID:35347128 arachidate (20:0) measurement efo:EFO_0800626 Quantification of the amount of N-stearoyl-sphinganine (d18:0/18:0) in a sample. Santhi Ramachandran true PMID:35347128 N-stearoyl-sphinganine (d18:0/18:0) measurement efo:EFO_0800627 Quantification of the amount of N1-methylinosine in a sample. Santhi Ramachandran true PMID:35347128 N1-methylinosine measurement efo:EFO_0800628 Quantification of the amount of N4-acetylcytidine in a sample. Santhi Ramachandran true PMID:35347128 N4-acetylcytidine measurement efo:EFO_0800629 Quantification of the amount of N6-carbamoylthreonyladenosine in a sample. Santhi Ramachandran true PMID:35347128 N6-carbamoylthreonyladenosine measurement efo:EFO_0800630 Quantification of the amount of orotidine in a sample. Santhi Ramachandran true PMID:35347128 orotidine measurement efo:EFO_0800631 Quantification of the amount of 5,6-dihydrouridine in a sample. Santhi Ramachandran true PMID:35347128 5,6-dihydrouridine measurement efo:EFO_0800632 Quantification of the amount of 3-(3-amino-3-carboxypropyl)uridine in a sample. Santhi Ramachandran true PMID:35347128 3-(3-amino-3-carboxypropyl)uridine measurement efo:EFO_0800633 Quantification of the amount of 3-methylcytidine in a sample. Santhi Ramachandran true PMID:35347128 3-methylcytidine measurement efo:EFO_0800634 Quantification of the amount of N2-methylguanosine in a sample. Santhi Ramachandran true PMID:35347128 N2-methylguanosine measurement efo:EFO_0800635 Quantification of the amount of 2'-O-methylcytidine in a sample. Santhi Ramachandran true PMID:35347128 2'-O-methylcytidine measurement efo:EFO_0800636 Quantification of the amount of 2'-O-methyluridine in a sample. Santhi Ramachandran true PMID:35347128 2'-O-methyluridine measurement efo:EFO_0800637 Quantification of the amount of 5,6-dihydrouracil in a sample. Santhi Ramachandran true PMID:35347128 5,6-dihydrouracil measurement efo:EFO_0800638 Quantification of the amount of 5,6-dihydrothymine in a sample. Santhi Ramachandran true PMID:35347128 5,6-dihydrothymine measurement efo:EFO_0800639 Quantification of the amount of N6-methyladenosine in a sample. Santhi Ramachandran true PMID:35347128 N6-methyladenosine measurement efo:EFO_0800640 Quantification of the amount of beta-alanine in a sample. Santhi Ramachandran true PMID:35347128 beta-alanine measurement efo:EFO_0800641 Quantification of the amount of inosine 5'-monophosphate (IMP) in a sample. Santhi Ramachandran true PMID:35347128 inosine 5'-monophosphate (IMP) measurement efo:EFO_0800642 Quantification of the amount of orotate in a sample. Santhi Ramachandran true PMID:35347128 orotate measurement efo:EFO_0800643 Quantification of the amount of 2'-deoxyuridine in a sample. Santhi Ramachandran true PMID:35347128 2'-deoxyuridine measurement efo:EFO_0800644 Quantification of the amount of uracil in a sample. Santhi Ramachandran true PMID:35347128 uracil measurement efo:EFO_0800645 Quantification of the amount of cytidine in a sample. Santhi Ramachandran true PMID:35347128 cytidine measurement efo:EFO_0800646 Quantification of the amount of thymine in a sample. Santhi Ramachandran true PMID:35347128 thymine measurement efo:EFO_0800647 Quantification of the amount of dihydroorotate in a sample. Santhi Ramachandran true PMID:35347128 dihydroorotate measurement efo:EFO_0800648 Quantification of the amount of glucuronide of C19H28O4 (1) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of C19H28O4 (1) measurement efo:EFO_0800649 Quantification of the amount of glucuronide of C19H28O4 (2) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of C19H28O4 (2) measurement efo:EFO_0800650 Quantification of the amount of glucuronide of C10H18O2 (1) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of C10H18O2 (1) measurement efo:EFO_0800651 Quantification of the amount of glucuronide of C10H18O2 (4) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of C10H18O2 (4) measurement efo:EFO_0800652 Quantification of the amount of glucuronide of C10H18O2 (7) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of C10H18O2 (7) measurement efo:EFO_0800653 Quantification of the amount of glucuronide of C10H18O2 (8) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of C10H18O2 (8) measurement efo:EFO_0800654 Quantification of the amount of glycine conjugate of C10H12O2 in a sample. Santhi Ramachandran true PMID:35347128 glycine conjugate of C10H12O2 measurement efo:EFO_0800655 Quantification of the amount of glycine conjugate of C10H14O2 (1) in a sample. Santhi Ramachandran true PMID:35347128 glycine conjugate of C10H14O2 (1) measurement efo:EFO_0800656 Quantification of the amount of glutamine conjugate of C7H12O2 in a sample. Santhi Ramachandran true PMID:35347128 glutamine conjugate of C7H12O2 measurement efo:EFO_0800657 Quantification of the amount of glutamine conjugate of C6H10O2 (1) in a sample. Santhi Ramachandran true PMID:35347128 glutamine conjugate of C6H10O2 (1) measurement efo:EFO_0800658 Quantification of the amount of glutamine conjugate of C6H10O2 (2) in a sample. Santhi Ramachandran true PMID:35347128 glutamine conjugate of C6H10O2 (2) measurement efo:EFO_0800659 Quantification of the amount of metabolonic lactone sulfate in a sample. Santhi Ramachandran true PMID:35347128 metabolonic lactone sulfate measurement efo:EFO_0800660 Quantification of the amount of pentose acid in a sample. Santhi Ramachandran true PMID:35347128 pentose acid measurement efo:EFO_0800661 Quantification of the amount of branched-chain, straight-chain, or cyclopropyl 10:1 fatty acid (1) in a sample. Santhi Ramachandran true PMID:35347128 branched-chain, straight-chain, or cyclopropyl 10:1 fatty acid (1) measurement efo:EFO_0800662 Quantification of the amount of branched-chain, straight-chain, or cyclopropyl 12:1 fatty acid in a sample. Santhi Ramachandran true PMID:35347128 branched-chain, straight-chain, or cyclopropyl 12:1 fatty acid measurement efo:EFO_0800663 Quantification of the amount of GlcNAc sulfate conjugate of C21H34O2 steroid in a sample. Santhi Ramachandran true PMID:35347128 GlcNAc sulfate conjugate of C21H34O2 steroid measurement efo:EFO_0800664 Quantification of the amount of pyroglutamylglutamine in a sample. Santhi Ramachandran true PMID:35347128 pyroglutamylglutamine measurement efo:EFO_0800665 Quantification of the amount of bradykinin in a sample. Santhi Ramachandran true PMID:35347128 bradykinin measurement efo:EFO_0800666 Quantification of the amount of pyroglutamylvaline in a sample. Santhi Ramachandran true PMID:35347128 pyroglutamylvaline measurement efo:EFO_0800667 Quantification of the amount of gamma-glutamyl-epsilon-lysine in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamyl-epsilon-lysine measurement efo:EFO_0800668 Quantification of the amount of glycylphenylalanine in a sample. Santhi Ramachandran true PMID:35347128 glycylphenylalanine measurement efo:EFO_0800669 Quantification of the amount of HWESASLLR in a sample. Santhi Ramachandran true PMID:35347128 HWESASLLR measurement efo:EFO_0800670 Quantification of the amount of gamma-glutamylglycine in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamylglycine measurement efo:EFO_0800671 Quantification of the amount of gamma-glutamyltryptophan in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamyltryptophan measurement efo:EFO_0800672 Quantification of the amount of fibrinopeptide A in a sample. Santhi Ramachandran true PMID:35347128 fibrinopeptide A measurement efo:EFO_0800673 Quantification of the amount of fibrinopeptide A, des-ala(1) in a sample. Santhi Ramachandran true PMID:35347128 fibrinopeptide A, des-ala(1) measurement efo:EFO_0800674 Quantification of the amount of gamma-glutamyl-2-aminobutyrate in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamyl-2-aminobutyrate measurement efo:EFO_0800675 Quantification of the amount of gamma-glutamylalanine in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamylalanine measurement efo:EFO_0800676 Quantification of the amount of cyclo(leu-pro) in a sample. Santhi Ramachandran true PMID:35347128 cyclo(leu-pro) measurement efo:EFO_0800677 Quantification of the amount of isoleucylglycine in a sample. Santhi Ramachandran true PMID:35347128 isoleucylglycine measurement efo:EFO_0800678 Quantification of the amount of leucylglycine in a sample. Santhi Ramachandran true PMID:35347128 leucylglycine measurement efo:EFO_0800679 Quantification of the amount of phenylalanyltryptophan in a sample. Santhi Ramachandran true PMID:35347128 phenylalanyltryptophan measurement efo:EFO_0800680 Quantification of the amount of valylglycine in a sample. Santhi Ramachandran true PMID:35347128 valylglycine measurement efo:EFO_0800681 Quantification of the amount of valylphenylalanine in a sample. Santhi Ramachandran true PMID:35347128 valylphenylalanine measurement efo:EFO_0800682 Quantification of the amount of methionylalanine in a sample. Santhi Ramachandran true PMID:35347128 methionylalanine measurement efo:EFO_0800683 Quantification of the amount of prolylglycine in a sample. Santhi Ramachandran true PMID:35347128 prolylglycine measurement efo:EFO_0800684 Quantification of the amount of prolylproline in a sample. Santhi Ramachandran true PMID:35347128 prolylproline measurement efo:EFO_0800685 Quantification of the amount of prolylserine in a sample. Santhi Ramachandran true PMID:35347128 prolylserine measurement efo:EFO_0800686 Quantification of the amount of phenylacetylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 phenylacetylcarnitine measurement efo:EFO_0800687 Quantification of the amount of phenylacetylglutamate in a sample. Santhi Ramachandran true PMID:35347128 phenylacetylglutamate measurement efo:EFO_0800688 Quantification of the amount of 4-hydroxyphenylacetylglutamine in a sample. Santhi Ramachandran true PMID:35347128 4-hydroxyphenylacetylglutamine measurement efo:EFO_0800689 Quantification of the amount of gamma-glutamyl-alpha-lysine in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamyl-alpha-lysine measurement efo:EFO_0800690 Quantification of the amount of gamma-glutamylcitrulline in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamylcitrulline measurement efo:EFO_0800691 Quantification of the amount of gamma-glutamylhistidine in a sample. Santhi Ramachandran true PMID:35347128 gamma-glutamylhistidine measurement efo:EFO_0800692 Quantification of the amount of X-10458 in a sample. Santhi Ramachandran true PMID:35347128 X-10458 measurement efo:EFO_0800693 Quantification of the amount of X-11308 in a sample. Santhi Ramachandran true PMID:35347128 X-11308 measurement efo:EFO_0800694 Quantification of the amount of X-11372 in a sample. Santhi Ramachandran true PMID:35347128 X-11372 measurement efo:EFO_0800695 Quantification of the amount of X-11378 in a sample. Santhi Ramachandran true PMID:35347128 X-11378 measurement efo:EFO_0800696 Quantification of the amount of X-11522 in a sample. Santhi Ramachandran true PMID:35347128 X-11522 measurement efo:EFO_0800697 Quantification of the amount of X-11632 in a sample. Santhi Ramachandran true PMID:35347128 X-11632 measurement efo:EFO_0800698 Quantification of the amount of X-11880 in a sample. Santhi Ramachandran true PMID:35347128 X-11880 measurement efo:EFO_0800699 Quantification of the amount of X-12015 in a sample. Santhi Ramachandran true PMID:35347128 X-12015 measurement efo:EFO_0800700 Quantification of the amount of X-12026 in a sample. Santhi Ramachandran true PMID:35347128 X-12026 measurement efo:EFO_0800701 Quantification of the amount of X-12100 in a sample. Santhi Ramachandran true PMID:35347128 X-12100 measurement efo:EFO_0800702 Quantification of the amount of X-12101 in a sample. Santhi Ramachandran true PMID:35347128 X-12101 measurement efo:EFO_0800703 Quantification of the amount of X-12104 in a sample. Santhi Ramachandran true PMID:35347128 X-12104 measurement efo:EFO_0800704 Quantification of the amount of X-12111 in a sample. Santhi Ramachandran true PMID:35347128 X-12111 measurement efo:EFO_0800705 Quantification of the amount of X-12112 in a sample. Santhi Ramachandran true PMID:35347128 X-12112 measurement efo:EFO_0800706 Quantification of the amount of X-12117 in a sample. Santhi Ramachandran true PMID:35347128 X-12117 measurement efo:EFO_0800707 Quantification of the amount of X-12125 in a sample. Santhi Ramachandran true PMID:35347128 X-12125 measurement efo:EFO_0800708 Quantification of the amount of X-12126 in a sample. Santhi Ramachandran true PMID:35347128 X-12126 measurement efo:EFO_0800709 Quantification of the amount of X-12127 in a sample. Santhi Ramachandran true PMID:35347128 X-12127 measurement efo:EFO_0800710 Quantification of the amount of X-12193 in a sample. Santhi Ramachandran true PMID:35347128 X-12193 measurement efo:EFO_0800711 Quantification of the amount of X-12221 in a sample. Santhi Ramachandran true PMID:35347128 X-12221 measurement efo:EFO_0800712 Quantification of the amount of X-12262 in a sample. Santhi Ramachandran true PMID:35347128 X-12262 measurement efo:EFO_0800713 Quantification of the amount of X-12283 in a sample. Santhi Ramachandran true PMID:35347128 X-12283 measurement efo:EFO_0800714 Quantification of the amount of X-12306 in a sample. Santhi Ramachandran true PMID:35347128 X-12306 measurement efo:EFO_0800715 Quantification of the amount of X-12410 in a sample. Santhi Ramachandran true PMID:35347128 X-12410 measurement efo:EFO_0800716 Quantification of the amount of X-12411 in a sample. Santhi Ramachandran true PMID:35347128 X-12411 measurement efo:EFO_0800717 Quantification of the amount of X-12462 in a sample. Santhi Ramachandran true PMID:35347128 X-12462 measurement efo:EFO_0800718 Quantification of the amount of X-12543 in a sample. Santhi Ramachandran true PMID:35347128 X-12543 measurement efo:EFO_0800719 Quantification of the amount of X-12689 in a sample. Santhi Ramachandran true PMID:35347128 X-12689 measurement efo:EFO_0800720 Quantification of the amount of X-12707 in a sample. Santhi Ramachandran true PMID:35347128 X-12707 measurement efo:EFO_0800721 Quantification of the amount of X-12713 in a sample. Santhi Ramachandran true PMID:35347128 X-12713 measurement efo:EFO_0800722 Quantification of the amount of X-12714 in a sample. Santhi Ramachandran true PMID:35347128 X-12714 measurement efo:EFO_0800723 Quantification of the amount of X-12718 in a sample. Santhi Ramachandran true PMID:35347128 X-12718 measurement efo:EFO_0800724 Quantification of the amount of X-12730 in a sample. Santhi Ramachandran true PMID:35347128 X-12730 measurement efo:EFO_0800725 Quantification of the amount of X-12731 in a sample. Santhi Ramachandran true PMID:35347128 X-12731 measurement efo:EFO_0800726 Quantification of the amount of X-12738 in a sample. Santhi Ramachandran true PMID:35347128 X-12738 measurement efo:EFO_0800727 Quantification of the amount of X-12753 in a sample. Santhi Ramachandran true PMID:35347128 X-12753 measurement efo:EFO_0800728 Quantification of the amount of X-12812 in a sample. Santhi Ramachandran true PMID:35347128 X-12812 measurement efo:EFO_0800729 Quantification of the amount of X-12818 in a sample. Santhi Ramachandran true PMID:35347128 X-12818 measurement efo:EFO_0800730 Quantification of the amount of X-12822 in a sample. Santhi Ramachandran true PMID:35347128 X-12822 measurement efo:EFO_0800731 Quantification of the amount of X-12839 in a sample. Santhi Ramachandran true PMID:35347128 X-12839 measurement efo:EFO_0800732 Quantification of the amount of X-12849 in a sample. Santhi Ramachandran true PMID:35347128 X-12849 measurement efo:EFO_0800733 Quantification of the amount of X-12906 in a sample. Santhi Ramachandran true PMID:35347128 X-12906 measurement efo:EFO_0800734 Quantification of the amount of X-13007 in a sample. Santhi Ramachandran true PMID:35347128 X-13007 measurement efo:EFO_0800735 Quantification of the amount of X-13431 in a sample. Santhi Ramachandran true PMID:35347128 X-13431 measurement efo:EFO_0800736 Quantification of the amount of X-13507 in a sample. Santhi Ramachandran true PMID:35347128 X-13507 measurement efo:EFO_0800737 Quantification of the amount of X-13684 in a sample. Santhi Ramachandran true PMID:35347128 X-13684 measurement efo:EFO_0800738 Quantification of the amount of X-13695 in a sample. Santhi Ramachandran true PMID:35347128 X-13695 measurement efo:EFO_0800739 Quantification of the amount of X-13723 in a sample. Santhi Ramachandran true PMID:35347128 X-13723 measurement efo:EFO_0800740 Quantification of the amount of X-13726 in a sample. Santhi Ramachandran true PMID:35347128 X-13726 measurement efo:EFO_0800741 Quantification of the amount of X-13728 in a sample. Santhi Ramachandran true PMID:35347128 X-13728 measurement efo:EFO_0800742 Quantification of the amount of X-13729 in a sample. Santhi Ramachandran true PMID:35347128 X-13729 measurement efo:EFO_0800743 Quantification of the amount of X-13835 in a sample. Santhi Ramachandran true PMID:35347128 X-13835 measurement efo:EFO_0800744 Quantification of the amount of X-13844 in a sample. Santhi Ramachandran true PMID:35347128 X-13844 measurement efo:EFO_0800745 Quantification of the amount of X-13866 in a sample. Santhi Ramachandran true PMID:35347128 X-13866 measurement efo:EFO_0800746 Quantification of the amount of X-14082 in a sample. Santhi Ramachandran true PMID:35347128 X-14082 measurement efo:EFO_0800747 Quantification of the amount of X-14939 in a sample. Santhi Ramachandran true PMID:35347128 X-14939 measurement efo:EFO_0800748 Quantification of the amount of X-15245 in a sample. Santhi Ramachandran true PMID:35347128 X-15245 measurement efo:EFO_0800749 Quantification of the amount of X-15461 in a sample. Santhi Ramachandran true PMID:35347128 X-15461 measurement efo:EFO_0800750 Quantification of the amount of X-15469 in a sample. Santhi Ramachandran true PMID:35347128 X-15469 measurement efo:EFO_0800751 Quantification of the amount of X-15486 in a sample. Santhi Ramachandran true PMID:35347128 X-15486 measurement efo:EFO_0800752 Quantification of the amount of X-15492 in a sample. Santhi Ramachandran true PMID:35347128 X-15492 measurement efo:EFO_0800753 Quantification of the amount of X-15503 in a sample. Santhi Ramachandran true PMID:35347128 X-15503 measurement efo:EFO_0800754 Quantification of the amount of X-15666 in a sample. Santhi Ramachandran true PMID:35347128 X-15666 measurement efo:EFO_0800755 Quantification of the amount of X-15674 in a sample. Santhi Ramachandran true PMID:35347128 X-15674 measurement efo:EFO_0800756 Quantification of the amount of X-16087 in a sample. Santhi Ramachandran true PMID:35347128 X-16087 measurement efo:EFO_0800757 Quantification of the amount of X-16124 in a sample. Santhi Ramachandran true PMID:35347128 X-16124 measurement efo:EFO_0800758 Quantification of the amount of X-16397 in a sample. Santhi Ramachandran true PMID:35347128 X-16397 measurement efo:EFO_0800759 Quantification of the amount of X-16570 in a sample. Santhi Ramachandran true PMID:35347128 X-16570 measurement efo:EFO_0800760 Quantification of the amount of X-16576 in a sample. Santhi Ramachandran true PMID:35347128 X-16576 measurement efo:EFO_0800761 Quantification of the amount of X-16580 in a sample. Santhi Ramachandran true PMID:35347128 X-16580 measurement efo:EFO_0800762 Quantification of the amount of X-16649 in a sample. Santhi Ramachandran true PMID:35347128 X-16649 measurement efo:EFO_0800763 Quantification of the amount of X-16935 in a sample. Santhi Ramachandran true PMID:35347128 X-16935 measurement efo:EFO_0800764 Quantification of the amount of X-16938 in a sample. Santhi Ramachandran true PMID:35347128 X-16938 measurement efo:EFO_0800765 Quantification of the amount of X-16944 in a sample. Santhi Ramachandran true PMID:35347128 X-16944 measurement efo:EFO_0800766 Quantification of the amount of X-16946 in a sample. Santhi Ramachandran true PMID:35347128 X-16946 measurement efo:EFO_0800767 Quantification of the amount of X-17010 in a sample. Santhi Ramachandran true PMID:35347128 X-17010 measurement efo:EFO_0800768 Quantification of the amount of X-17137 in a sample. Santhi Ramachandran true PMID:35347128 X-17137 measurement efo:EFO_0800769 Quantification of the amount of X-17162 in a sample. Santhi Ramachandran true PMID:35347128 X-17162 measurement efo:EFO_0800770 Quantification of the amount of X-17185 in a sample. Santhi Ramachandran true PMID:35347128 X-17185 measurement efo:EFO_0800771 Quantification of the amount of X-17325 in a sample. Santhi Ramachandran true PMID:35347128 X-17325 measurement efo:EFO_0800772 Quantification of the amount of X-17335 in a sample. Santhi Ramachandran true PMID:35347128 X-17335 measurement efo:EFO_0800773 Quantification of the amount of X-17340 in a sample. Santhi Ramachandran true PMID:35347128 X-17340 measurement efo:EFO_0800774 Quantification of the amount of X-17351 in a sample. Santhi Ramachandran true PMID:35347128 X-17351 measurement efo:EFO_0800775 Quantification of the amount of X-17353 in a sample. Santhi Ramachandran true PMID:35347128 X-17353 measurement efo:EFO_0800776 Quantification of the amount of X-17354 in a sample. Santhi Ramachandran true PMID:35347128 X-17354 measurement efo:EFO_0800777 Quantification of the amount of X-17357 in a sample. Santhi Ramachandran true PMID:35347128 X-17357 measurement efo:EFO_0800778 Quantification of the amount of X-17361 in a sample. Santhi Ramachandran true PMID:35347128 X-17361 measurement efo:EFO_0800779 Quantification of the amount of X-17367 in a sample. Santhi Ramachandran true PMID:35347128 X-17367 measurement efo:EFO_0800780 Quantification of the amount of X-17371 in a sample. Santhi Ramachandran true PMID:35347128 X-17371 measurement efo:EFO_0800781 Quantification of the amount of X-17438 in a sample. Santhi Ramachandran true PMID:35347128 X-17438 measurement efo:EFO_0800782 Quantification of the amount of X-17612 in a sample. Santhi Ramachandran true PMID:35347128 X-17612 measurement efo:EFO_0800783 Quantification of the amount of X-17653 in a sample. Santhi Ramachandran true PMID:35347128 X-17653 measurement efo:EFO_0800784 Quantification of the amount of X-17654 in a sample. Santhi Ramachandran true PMID:35347128 X-17654 measurement efo:EFO_0800785 Quantification of the amount of X-17676 in a sample. Santhi Ramachandran true PMID:35347128 X-17676 measurement efo:EFO_0800786 Quantification of the amount of X-17685 in a sample. Santhi Ramachandran true PMID:35347128 X-17685 measurement efo:EFO_0800787 Quantification of the amount of X-17686 in a sample. Santhi Ramachandran true PMID:35347128 X-17686 measurement efo:EFO_0800788 Quantification of the amount of X-17690 in a sample. Santhi Ramachandran true PMID:35347128 X-17690 measurement efo:EFO_0800789 Quantification of the amount of X-18345 in a sample. Santhi Ramachandran true PMID:35347128 X-18345 measurement efo:EFO_0800790 Quantification of the amount of X-18886 in a sample. Santhi Ramachandran true PMID:35347128 X-18886 measurement efo:EFO_0800791 Quantification of the amount of X-18887 in a sample. Santhi Ramachandran true PMID:35347128 X-18887 measurement efo:EFO_0800792 Quantification of the amount of X-18888 in a sample. Santhi Ramachandran true PMID:35347128 X-18888 measurement efo:EFO_0800793 Quantification of the amount of X-18899 in a sample. Santhi Ramachandran true PMID:35347128 X-18899 measurement efo:EFO_0800794 Quantification of the amount of X-18901 in a sample. Santhi Ramachandran true PMID:35347128 X-18901 measurement efo:EFO_0800795 Quantification of the amount of X-18913 in a sample. Santhi Ramachandran true PMID:35347128 X-18913 measurement efo:EFO_0800796 Quantification of the amount of X-18921 in a sample. Santhi Ramachandran true PMID:35347128 X-18921 measurement efo:EFO_0800797 Quantification of the amount of X-18922 in a sample. Santhi Ramachandran true PMID:35347128 X-18922 measurement efo:EFO_0800798 Quantification of the amount of X-18935 in a sample. Santhi Ramachandran true PMID:35347128 X-18935 measurement efo:EFO_0800799 Quantification of the amount of X-19141 in a sample. Santhi Ramachandran true PMID:35347128 X-19141 measurement efo:EFO_0800800 Quantification of the amount of X-19183 in a sample. Santhi Ramachandran true PMID:35347128 X-19183 measurement efo:EFO_0800801 Quantification of the amount of X-19438 in a sample. Santhi Ramachandran true PMID:35347128 X-19438 measurement efo:EFO_0800802 Quantification of the amount of X-21258 in a sample. Santhi Ramachandran true PMID:35347128 X-21258 measurement efo:EFO_0800803 Quantification of the amount of X-21285 in a sample. Santhi Ramachandran true PMID:35347128 X-21285 measurement efo:EFO_0800804 Quantification of the amount of X-21286 in a sample. Santhi Ramachandran true PMID:35347128 X-21286 measurement efo:EFO_0800805 Quantification of the amount of X-21310 in a sample. Santhi Ramachandran true PMID:35347128 X-21310 measurement efo:EFO_0800806 Quantification of the amount of X-21312 in a sample. Santhi Ramachandran true PMID:35347128 X-21312 measurement efo:EFO_0800807 Quantification of the amount of X-21319 in a sample. Santhi Ramachandran true PMID:35347128 X-21319 measurement efo:EFO_0800808 Quantification of the amount of X-21339 in a sample. Santhi Ramachandran true PMID:35347128 X-21339 measurement efo:EFO_0800809 Quantification of the amount of X-21353 in a sample. Santhi Ramachandran true PMID:35347128 X-21353 measurement efo:EFO_0800810 Quantification of the amount of X-21355 in a sample. Santhi Ramachandran true PMID:35347128 X-21355 measurement efo:EFO_0800811 Quantification of the amount of X-21364 in a sample. Santhi Ramachandran true PMID:35347128 X-21364 measurement efo:EFO_0800812 Quantification of the amount of X-21383 in a sample. Santhi Ramachandran true PMID:35347128 X-21383 measurement efo:EFO_0800813 Quantification of the amount of X-21410 in a sample. Santhi Ramachandran true PMID:35347128 X-21410 measurement efo:EFO_0800814 Quantification of the amount of X-21441 in a sample. Santhi Ramachandran true PMID:35347128 X-21441 measurement efo:EFO_0800815 Quantification of the amount of X-21442 in a sample. Santhi Ramachandran true PMID:35347128 X-21442 measurement efo:EFO_0800816 Quantification of the amount of X-21448 in a sample. Santhi Ramachandran true PMID:35347128 X-21448 measurement efo:EFO_0800817 Quantification of the amount of X-21470 in a sample. Santhi Ramachandran true PMID:35347128 X-21470 measurement efo:EFO_0800818 Quantification of the amount of X-21471 in a sample. Santhi Ramachandran true PMID:35347128 X-21471 measurement efo:EFO_0800819 Quantification of the amount of X-21607 in a sample. Santhi Ramachandran true PMID:35347128 X-21607 measurement efo:EFO_0800820 Quantification of the amount of X-21733 in a sample. Santhi Ramachandran true PMID:35347128 X-21733 measurement efo:EFO_0800821 Quantification of the amount of X-21736 in a sample. Santhi Ramachandran true PMID:35347128 X-21736 measurement efo:EFO_0800822 Quantification of the amount of X-21740 in a sample. Santhi Ramachandran true PMID:35347128 X-21740 measurement efo:EFO_0800823 Quantification of the amount of X-21742 in a sample. Santhi Ramachandran true PMID:35347128 X-21742 measurement efo:EFO_0800824 Quantification of the amount of X-21752 in a sample. Santhi Ramachandran true PMID:35347128 X-21752 measurement efo:EFO_0800825 Quantification of the amount of X-21796 in a sample. Santhi Ramachandran true PMID:35347128 X-21796 measurement efo:EFO_0800826 Quantification of the amount of X-21803 in a sample. Santhi Ramachandran true PMID:35347128 X-21803 measurement efo:EFO_0800827 Quantification of the amount of X-21807 in a sample. Santhi Ramachandran true PMID:35347128 X-21807 measurement efo:EFO_0800828 Quantification of the amount of X-21815 in a sample. Santhi Ramachandran true PMID:35347128 X-21815 measurement efo:EFO_0800829 Quantification of the amount of X-21821 in a sample. Santhi Ramachandran true PMID:35347128 X-21821 measurement efo:EFO_0800830 Quantification of the amount of X-21829 in a sample. Santhi Ramachandran true PMID:35347128 X-21829 measurement efo:EFO_0800831 Quantification of the amount of X-21830 in a sample. Santhi Ramachandran true PMID:35347128 X-21830 measurement efo:EFO_0800832 Quantification of the amount of X-21831 in a sample. Santhi Ramachandran true PMID:35347128 X-21831 measurement efo:EFO_0800833 Quantification of the amount of X-21834 in a sample. Santhi Ramachandran true PMID:35347128 X-21834 measurement efo:EFO_0800834 Quantification of the amount of X-21839 in a sample. Santhi Ramachandran true PMID:35347128 X-21839 measurement efo:EFO_0800835 Quantification of the amount of X-21842 in a sample. Santhi Ramachandran true PMID:35347128 X-21842 measurement efo:EFO_0800836 Quantification of the amount of X-21845 in a sample. Santhi Ramachandran true PMID:35347128 X-21845 measurement efo:EFO_0800837 Quantification of the amount of X-21959 in a sample. Santhi Ramachandran true PMID:35347128 X-21959 measurement efo:EFO_0800838 Quantification of the amount of X-22143 in a sample. Santhi Ramachandran true PMID:35347128 X-22143 measurement efo:EFO_0800839 Quantification of the amount of X-22162 in a sample. Santhi Ramachandran true PMID:35347128 X-22162 measurement efo:EFO_0800840 Quantification of the amount of X-22508 in a sample. Santhi Ramachandran true PMID:35347128 X-22508 measurement efo:EFO_0800841 Quantification of the amount of X-22509 in a sample. Santhi Ramachandran true PMID:35347128 X-22509 measurement efo:EFO_0800842 Quantification of the amount of X-22519 in a sample. Santhi Ramachandran true PMID:35347128 X-22519 measurement efo:EFO_0800843 Quantification of the amount of X-22520 in a sample. Santhi Ramachandran true PMID:35347128 X-22520 measurement efo:EFO_0800844 Quantification of the amount of X-22771 in a sample. Santhi Ramachandran true PMID:35347128 X-22771 measurement efo:EFO_0800845 Quantification of the amount of X-22776 in a sample. Santhi Ramachandran true PMID:35347128 X-22776 measurement efo:EFO_0800846 Quantification of the amount of X-23157 in a sample. Santhi Ramachandran true PMID:35347128 X-23157 measurement efo:EFO_0800847 Quantification of the amount of X-23276 in a sample. Santhi Ramachandran true PMID:35347128 X-23276 measurement efo:EFO_0800848 Quantification of the amount of X-23583 in a sample. Santhi Ramachandran true PMID:35347128 X-23583 measurement efo:EFO_0800849 Quantification of the amount of X-23587 in a sample. Santhi Ramachandran true PMID:35347128 X-23587 measurement efo:EFO_0800850 Quantification of the amount of X-23590 in a sample. Santhi Ramachandran true PMID:35347128 X-23590 measurement efo:EFO_0800851 Quantification of the amount of X-23593 in a sample. Santhi Ramachandran true PMID:35347128 X-23593 measurement efo:EFO_0800852 Quantification of the amount of X-23636 in a sample. Santhi Ramachandran true PMID:35347128 X-23636 measurement efo:EFO_0800853 Quantification of the amount of X-23639 in a sample. Santhi Ramachandran true PMID:35347128 X-23639 measurement efo:EFO_0800854 Quantification of the amount of X-23641 in a sample. Santhi Ramachandran true PMID:35347128 X-23641 measurement efo:EFO_0800855 Quantification of the amount of X-23644 in a sample. Santhi Ramachandran true PMID:35347128 X-23644 measurement efo:EFO_0800856 Quantification of the amount of X-23655 in a sample. Santhi Ramachandran true PMID:35347128 X-23655 measurement efo:EFO_0800857 Quantification of the amount of X-23657 in a sample. Santhi Ramachandran true PMID:35347128 X-23657 measurement efo:EFO_0800858 Quantification of the amount of X-23662 in a sample. Santhi Ramachandran true PMID:35347128 X-23662 measurement efo:EFO_0800859 Quantification of the amount of X-23665 in a sample. Santhi Ramachandran true PMID:35347128 X-23665 measurement efo:EFO_0800860 Quantification of the amount of X-23666 in a sample. Santhi Ramachandran true PMID:35347128 X-23666 measurement efo:EFO_0800861 Quantification of the amount of X-23678 in a sample. Santhi Ramachandran true PMID:35347128 X-23678 measurement efo:EFO_0800862 Quantification of the amount of X-23680 in a sample. Santhi Ramachandran true PMID:35347128 X-23680 measurement efo:EFO_0800863 Quantification of the amount of X-23739 in a sample. Santhi Ramachandran true PMID:35347128 X-23739 measurement efo:EFO_0800864 Quantification of the amount of X-23780 in a sample. Santhi Ramachandran true PMID:35347128 X-23780 measurement efo:EFO_0800865 Quantification of the amount of X-23782 in a sample. Santhi Ramachandran true PMID:35347128 X-23782 measurement efo:EFO_0800866 Quantification of the amount of X-23787 in a sample. Santhi Ramachandran true PMID:35347128 X-23787 measurement efo:EFO_0800867 Quantification of the amount of X-23974 in a sample. Santhi Ramachandran true PMID:35347128 X-23974 measurement efo:EFO_0800868 Quantification of the amount of X-23997 in a sample. Santhi Ramachandran true PMID:35347128 X-23997 measurement efo:EFO_0800869 Quantification of the amount of X-24295 in a sample. Santhi Ramachandran true PMID:35347128 X-24295 measurement efo:EFO_0800870 Quantification of the amount of X-24306 in a sample. Santhi Ramachandran true PMID:35347128 X-24306 measurement efo:EFO_0800871 Quantification of the amount of X-24307 in a sample. Santhi Ramachandran true PMID:35347128 X-24307 measurement efo:EFO_0800872 Quantification of the amount of X-24309 in a sample. Santhi Ramachandran true PMID:35347128 X-24309 measurement efo:EFO_0800873 Quantification of the amount of X-24328 in a sample. Santhi Ramachandran true PMID:35347128 X-24328 measurement efo:EFO_0800874 Quantification of the amount of X-24334 in a sample. Santhi Ramachandran true PMID:35347128 X-24334 measurement efo:EFO_0800875 Quantification of the amount of X-24337 in a sample. Santhi Ramachandran true PMID:35347128 X-24337 measurement efo:EFO_0800876 Quantification of the amount of X-24344 in a sample. Santhi Ramachandran true PMID:35347128 X-24344 measurement efo:EFO_0800877 Quantification of the amount of X-24352 in a sample. Santhi Ramachandran true PMID:35347128 X-24352 measurement efo:EFO_0800878 Quantification of the amount of X-24411 in a sample. Santhi Ramachandran true PMID:35347128 X-24411 measurement efo:EFO_0800879 Quantification of the amount of X-24418 in a sample. Santhi Ramachandran true PMID:35347128 X-24418 measurement efo:EFO_0800880 Quantification of the amount of X-24422 in a sample. Santhi Ramachandran true PMID:35347128 X-24422 measurement efo:EFO_0800881 Quantification of the amount of X-24425 in a sample. Santhi Ramachandran true PMID:35347128 X-24425 measurement efo:EFO_0800882 Quantification of the amount of X-24431 in a sample. Santhi Ramachandran true PMID:35347128 X-24431 measurement efo:EFO_0800883 Quantification of the amount of X-24432 in a sample. Santhi Ramachandran true PMID:35347128 X-24432 measurement efo:EFO_0800884 Quantification of the amount of X-24455 in a sample. Santhi Ramachandran true PMID:35347128 X-24455 measurement efo:EFO_0800885 Quantification of the amount of X-24456 in a sample. Santhi Ramachandran true PMID:35347128 X-24456 measurement efo:EFO_0800886 Quantification of the amount of X-24462 in a sample. Santhi Ramachandran true PMID:35347128 X-24462 measurement efo:EFO_0800887 Quantification of the amount of X-24473 in a sample. Santhi Ramachandran true PMID:35347128 X-24473 measurement efo:EFO_0800888 Quantification of the amount of X-24475 in a sample. Santhi Ramachandran true PMID:35347128 X-24475 measurement efo:EFO_0800889 Quantification of the amount of X-24494 in a sample. Santhi Ramachandran true PMID:35347128 X-24494 measurement efo:EFO_0800890 Quantification of the amount of X-24518 in a sample. Santhi Ramachandran true PMID:35347128 X-24518 measurement efo:EFO_0800891 Quantification of the amount of X-24541 in a sample. Santhi Ramachandran true PMID:35347128 X-24541 measurement efo:EFO_0800892 Quantification of the amount of X-24544 in a sample. Santhi Ramachandran true PMID:35347128 X-24544 measurement efo:EFO_0800893 Quantification of the amount of X-24546 in a sample. Santhi Ramachandran true PMID:35347128 X-24546 measurement efo:EFO_0800894 Quantification of the amount of X-24549 in a sample. Santhi Ramachandran true PMID:35347128 X-24549 measurement efo:EFO_0800895 Quantification of the amount of X-24556 in a sample. Santhi Ramachandran true PMID:35347128 X-24556 measurement efo:EFO_0800896 Quantification of the amount of X-24571 in a sample. Santhi Ramachandran true PMID:35347128 X-24571 measurement efo:EFO_0800897 Quantification of the amount of X-24574 in a sample. Santhi Ramachandran true PMID:35347128 X-24574 measurement efo:EFO_0800898 Quantification of the amount of X-24588 in a sample. Santhi Ramachandran true PMID:35347128 X-24588 measurement efo:EFO_0800899 Quantification of the amount of X-24637 in a sample. Santhi Ramachandran true PMID:35347128 X-24637 measurement efo:EFO_0800900 Quantification of the amount of X-24657 in a sample. Santhi Ramachandran true PMID:35347128 X-24657 measurement efo:EFO_0800901 Quantification of the amount of X-24669 in a sample. Santhi Ramachandran true PMID:35347128 X-24669 measurement efo:EFO_0800902 Quantification of the amount of X-24699 in a sample. Santhi Ramachandran true PMID:35347128 X-24699 measurement efo:EFO_0800903 Quantification of the amount of X-24728 in a sample. Santhi Ramachandran true PMID:35347128 X-24728 measurement efo:EFO_0800904 Quantification of the amount of X-24736 in a sample. Santhi Ramachandran true PMID:35347128 X-24736 measurement efo:EFO_0800905 Quantification of the amount of X-24757 in a sample. Santhi Ramachandran true PMID:35347128 X-24757 measurement efo:EFO_0800906 Quantification of the amount of X-24762 in a sample. Santhi Ramachandran true PMID:35347128 X-24762 measurement efo:EFO_0800907 Quantification of the amount of X-24811 in a sample. Santhi Ramachandran true PMID:35347128 X-24811 measurement efo:EFO_0800908 Quantification of the amount of X-24812 in a sample. Santhi Ramachandran true PMID:35347128 X-24812 measurement efo:EFO_0800909 Quantification of the amount of X-24849 in a sample. Santhi Ramachandran true PMID:35347128 X-24849 measurement efo:EFO_0800910 Quantification of the amount of X-24947 in a sample. Santhi Ramachandran true PMID:35347128 X-24947 measurement efo:EFO_0800911 Quantification of the amount of X-24949 in a sample. Santhi Ramachandran true PMID:35347128 X-24949 measurement efo:EFO_0800912 Quantification of the amount of X-24951 in a sample. Santhi Ramachandran true PMID:35347128 X-24951 measurement efo:EFO_0800913 Quantification of the amount of X-24970 in a sample. Santhi Ramachandran true PMID:35347128 X-24970 measurement efo:EFO_0800914 Quantification of the amount of X-24972 in a sample. Santhi Ramachandran true PMID:35347128 X-24972 measurement efo:EFO_0800915 Quantification of the amount of X-24980 in a sample. Santhi Ramachandran true PMID:35347128 X-24980 measurement efo:EFO_0800916 Quantification of the amount of X-25172 in a sample. Santhi Ramachandran true PMID:35347128 X-25172 measurement efo:EFO_0800917 Quantification of the amount of X-25265 in a sample. Santhi Ramachandran true PMID:35347128 X-25265 measurement efo:EFO_0800918 Quantification of the amount of X-25266 in a sample. Santhi Ramachandran true PMID:35347128 X-25266 measurement efo:EFO_0800919 Quantification of the amount of X-25267 in a sample. Santhi Ramachandran true PMID:35347128 X-25267 measurement efo:EFO_0800920 Quantification of the amount of X-25271 in a sample. Santhi Ramachandran true PMID:35347128 X-25271 measurement efo:EFO_0800921 Quantification of the amount of X-25279 in a sample. Santhi Ramachandran true PMID:35347128 X-25279 measurement efo:EFO_0800922 Quantification of the amount of X-25343 in a sample. Santhi Ramachandran true PMID:35347128 X-25343 measurement efo:EFO_0800923 Quantification of the amount of X-25371 in a sample. Santhi Ramachandran true PMID:35347128 X-25371 measurement efo:EFO_0800924 Quantification of the amount of X-25417 in a sample. Santhi Ramachandran true PMID:35347128 X-25417 measurement efo:EFO_0800925 Quantification of the amount of X-25419 in a sample. Santhi Ramachandran true PMID:35347128 X-25419 measurement efo:EFO_0800926 Quantification of the amount of X-25420 in a sample. Santhi Ramachandran true PMID:35347128 X-25420 measurement efo:EFO_0800927 Quantification of the amount of X-25422 in a sample. Santhi Ramachandran true PMID:35347128 X-25422 measurement efo:EFO_0800928 Quantification of the amount of X-25433 in a sample. Santhi Ramachandran true PMID:35347128 X-25433 measurement efo:EFO_0800929 Quantification of the amount of X-25503 in a sample. Santhi Ramachandran true PMID:35347128 X-25503 measurement efo:EFO_0800930 Quantification of the amount of X-25519 in a sample. Santhi Ramachandran true PMID:35347128 X-25519 measurement efo:EFO_0800931 Quantification of the amount of X-25520 in a sample. Santhi Ramachandran true PMID:35347128 X-25520 measurement efo:EFO_0800932 Quantification of the amount of X-25617 in a sample. Santhi Ramachandran true PMID:35347128 X-25617 measurement efo:EFO_0800933 Quantification of the amount of X-25790 in a sample. Santhi Ramachandran true PMID:35347128 X-25790 measurement efo:EFO_0800934 Quantification of the amount of X-25793 in a sample. Santhi Ramachandran true PMID:35347128 X-25793 measurement efo:EFO_0800935 Quantification of the amount of X-25802 in a sample. Santhi Ramachandran true PMID:35347128 X-25802 measurement efo:EFO_0800936 Quantification of the amount of X-25828 in a sample. Santhi Ramachandran true PMID:35347128 X-25828 measurement efo:EFO_0800937 Quantification of the amount of X-25937 in a sample. Santhi Ramachandran true PMID:35347128 X-25937 measurement efo:EFO_0800938 Quantification of the amount of X-25957 in a sample. Santhi Ramachandran true PMID:35347128 X-25957 measurement efo:EFO_0800939 Quantification of the amount of X-26054 in a sample. Santhi Ramachandran true PMID:35347128 X-26054 measurement efo:EFO_0800940 Quantification of the amount of 4-acetamidophenylglucuronide in a sample. Santhi Ramachandran true PMID:35347128 4-acetamidophenylglucuronide measurement efo:EFO_0800941 Quantification of the amount of tartarate in a sample. Santhi Ramachandran true PMID:35347128 tartarate measurement efo:EFO_0800942 Quantification of the amount of 4-acetylphenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-acetylphenol sulfate measurement efo:EFO_0800943 Quantification of the amount of theanine in a sample. Santhi Ramachandran true PMID:35347128 theanine measurement efo:EFO_0800944 Quantification of the amount of tartronate (hydroxymalonate) in a sample. Santhi Ramachandran true PMID:35347128 tartronate (hydroxymalonate) measurement efo:EFO_0800945 Quantification of the amount of iminodiacetate (IDA) in a sample. Santhi Ramachandran true PMID:35347128 iminodiacetate (IDA) measurement efo:EFO_0800946 Quantification of the amount of EDTA in a sample. Santhi Ramachandran true PMID:35347128 EDTA measurement efo:EFO_0800947 Quantification of the amount of N-(2-furoyl)glycine in a sample. Santhi Ramachandran true PMID:35347128 N-(2-furoyl)glycine measurement efo:EFO_0800948 Quantification of the amount of 1,3-dimethylurate in a sample. Santhi Ramachandran true PMID:35347128 1,3-dimethylurate measurement efo:EFO_0800949 Quantification of the amount of 3,7-dimethylurate in a sample. Santhi Ramachandran true PMID:35347128 3,7-dimethylurate measurement efo:EFO_0800950 Quantification of the amount of 5-acetylamino-6-formylamino-3-methyluracil in a sample. Santhi Ramachandran true PMID:35347128 5-acetylamino-6-formylamino-3-methyluracil measurement efo:EFO_0800951 Quantification of the amount of 5-acetylamino-6-amino-3-methyluracil in a sample. Santhi Ramachandran true PMID:35347128 5-acetylamino-6-amino-3-methyluracil measurement efo:EFO_0800952 Quantification of the amount of 3-(3-hydroxyphenyl)propionate in a sample. Santhi Ramachandran true PMID:35347128 3-(3-hydroxyphenyl)propionate measurement efo:EFO_0800953 Quantification of the amount of ectoine in a sample. Santhi Ramachandran true PMID:35347128 ectoine measurement efo:EFO_0800954 Quantification of the amount of pyrraline in a sample. Santhi Ramachandran true PMID:35347128 pyrraline measurement efo:EFO_0800955 Quantification of the amount of O-cresol sulfate in a sample. Santhi Ramachandran true PMID:35347128 O-cresol sulfate measurement efo:EFO_0800956 Quantification of the amount of 3-ethylphenylsulfate in a sample. Santhi Ramachandran true PMID:35347128 3-ethylphenylsulfate measurement efo:EFO_0800957 Quantification of the amount of 2-ethylphenylsulfate in a sample. Santhi Ramachandran true PMID:35347128 2-ethylphenylsulfate measurement efo:EFO_0800958 Quantification of the amount of 4-allylphenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-allylphenol sulfate measurement efo:EFO_0800959 Quantification of the amount of 4-hydroxycoumarin in a sample. Santhi Ramachandran true PMID:35347128 4-hydroxycoumarin measurement efo:EFO_0800960 Quantification of the amount of 3-hydroxyhippurate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyhippurate measurement efo:EFO_0800961 Quantification of the amount of 7-methylurate in a sample. Santhi Ramachandran true PMID:35347128 7-methylurate measurement efo:EFO_0800962 Quantification of the amount of cinnamoylglycine in a sample. Santhi Ramachandran true PMID:35347128 cinnamoylglycine measurement efo:EFO_0800963 Quantification of the amount of 2,3-dihydroxyisovalerate in a sample. Santhi Ramachandran true PMID:35347128 2,3-dihydroxyisovalerate measurement efo:EFO_0800964 Quantification of the amount of hydroxycotinine in a sample. Santhi Ramachandran true PMID:35347128 hydroxycotinine measurement efo:EFO_0800965 Quantification of the amount of cotinine N-oxide in a sample. Santhi Ramachandran true PMID:35347128 cotinine N-oxide measurement efo:EFO_0800966 Quantification of the amount of solanidine in a sample. Santhi Ramachandran true PMID:35347128 solanidine measurement efo:EFO_0800967 Quantification of the amount of ethyl glucuronide in a sample. Santhi Ramachandran true PMID:35347128 ethyl glucuronide measurement efo:EFO_0800968 Quantification of the amount of 2-oxindole-3-acetate in a sample. Santhi Ramachandran true PMID:35347128 2-oxindole-3-acetate measurement efo:EFO_0800969 Quantification of the amount of dihydroferulate in a sample. Santhi Ramachandran true PMID:35347128 dihydroferulate measurement efo:EFO_0800970 Quantification of the amount of alliin in a sample. Santhi Ramachandran true PMID:35347128 alliin measurement efo:EFO_0800971 Quantification of the amount of mannonate in a sample. Santhi Ramachandran true PMID:35347128 mannonate measurement efo:EFO_0800972 Quantification of the amount of histidine betaine (hercynine) in a sample. Santhi Ramachandran true PMID:35347128 histidine betaine (hercynine) measurement efo:EFO_0800973 Quantification of the amount of 3-methyl catechol sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 3-methyl catechol sulfate (2) measurement efo:EFO_0800974 Quantification of the amount of 4-methylcatechol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-methylcatechol sulfate measurement efo:EFO_0800975 Quantification of the amount of 3-methyl catechol sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 3-methyl catechol sulfate (1) measurement efo:EFO_0800976 Quantification of the amount of 2-hydroxyibuprofen in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxyibuprofen measurement efo:EFO_0800977 Quantification of the amount of carboxyibuprofen in a sample. Santhi Ramachandran true PMID:35347128 carboxyibuprofen measurement efo:EFO_0800978 Quantification of the amount of guaiacol sulfate in a sample. Santhi Ramachandran true PMID:35347128 guaiacol sulfate measurement efo:EFO_0800979 Quantification of the amount of dimethyl sulfone in a sample. Santhi Ramachandran true PMID:35347128 dimethyl sulfone measurement efo:EFO_0800980 Quantification of the amount of 2-piperidinone in a sample. Santhi Ramachandran true PMID:35347128 2-piperidinone measurement efo:EFO_0800981 Quantification of the amount of indolin-2-one in a sample. Santhi Ramachandran true PMID:35347128 indolin-2-one measurement efo:EFO_0800982 Quantification of the amount of 2-aminophenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 2-aminophenol sulfate measurement efo:EFO_0800983 Quantification of the amount of 3-acetylphenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-acetylphenol sulfate measurement efo:EFO_0800984 Quantification of the amount of 3-hydroxycotinine glucuronide in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxycotinine glucuronide measurement efo:EFO_0800985 Quantification of the amount of S-allylcysteine in a sample. Santhi Ramachandran true PMID:35347128 S-allylcysteine measurement efo:EFO_0800986 Quantification of the amount of benzoylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 benzoylcarnitine measurement efo:EFO_0800987 Quantification of the amount of N-acetylalliin in a sample. Santhi Ramachandran true PMID:35347128 N-acetylalliin measurement efo:EFO_0800988 Quantification of the amount of N-methylpipecolate in a sample. Santhi Ramachandran true PMID:35347128 N-methylpipecolate measurement efo:EFO_0800989 Quantification of the amount of ferulic acid 4-sulfate in a sample. Santhi Ramachandran true PMID:35347128 ferulic acid 4-sulfate measurement efo:EFO_0800990 Quantification of the amount of 3-(3-hydroxyphenyl)propionate sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-(3-hydroxyphenyl)propionate sulfate measurement efo:EFO_0800991 Quantification of the amount of methyl glucopyranoside (alpha + beta) in a sample. Santhi Ramachandran true PMID:35347128 methyl glucopyranoside (alpha + beta) measurement efo:EFO_0800992 Quantification of the amount of 4-hydroxychlorothalonil in a sample. Santhi Ramachandran true PMID:35347128 4-hydroxychlorothalonil measurement efo:EFO_0800993 Quantification of the amount of isoeugenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 isoeugenol sulfate measurement efo:EFO_0800994 Quantification of the amount of 3-hydroxycinnamate sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxycinnamate sulfate measurement efo:EFO_0800995 Quantification of the amount of 3-hydroxypyridine sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxypyridine sulfate measurement efo:EFO_0800996 Quantification of the amount of 4-methylguaiacol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-methylguaiacol sulfate measurement efo:EFO_0800997 Quantification of the amount of methyl-4-hydroxybenzoate sulfate in a sample. Santhi Ramachandran true PMID:35347128 methyl-4-hydroxybenzoate sulfate measurement efo:EFO_0800998 Quantification of the amount of 4-vinylguaiacol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-vinylguaiacol sulfate measurement efo:EFO_0800999 Quantification of the amount of eugenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 eugenol sulfate measurement efo:EFO_0801000 Quantification of the amount of 2-methoxyresorcinol sulfate in a sample. Santhi Ramachandran true PMID:35347128 2-methoxyresorcinol sulfate measurement efo:EFO_0801001 Quantification of the amount of 2-acetamidophenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 2-acetamidophenol sulfate measurement efo:EFO_0801002 Quantification of the amount of acesulfame in a sample. Santhi Ramachandran true PMID:35347128 acesulfame measurement efo:EFO_0801003 Quantification of the amount of syringol sulfate in a sample. Santhi Ramachandran true PMID:35347128 syringol sulfate measurement efo:EFO_0801004 Quantification of the amount of 6-hydroxyindole sulfate in a sample. Santhi Ramachandran true PMID:35347128 6-hydroxyindole sulfate measurement efo:EFO_0801005 Quantification of the amount of propyl 4-hydroxybenzoate sulfate in a sample. Santhi Ramachandran true PMID:35347128 propyl 4-hydroxybenzoate sulfate measurement efo:EFO_0801006 Quantification of the amount of umbelliferone sulfate in a sample. Santhi Ramachandran true PMID:35347128 umbelliferone sulfate measurement efo:EFO_0801007 Quantification of the amount of daidzein sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 daidzein sulfate (2) measurement efo:EFO_0801008 Quantification of the amount of 1,2,3-benzenetriol sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 1,2,3-benzenetriol sulfate (2) measurement efo:EFO_0801009 Quantification of the amount of 3-methoxycatechol sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 3-methoxycatechol sulfate (1) measurement efo:EFO_0801010 Quantification of the amount of 3-methoxycatechol sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 3-methoxycatechol sulfate (2) measurement efo:EFO_0801011 Quantification of the amount of 3,4-methyleneheptanoate in a sample. Santhi Ramachandran true PMID:35347128 3,4-methyleneheptanoate measurement efo:EFO_0801012 Quantification of the amount of thioproline in a sample. Santhi Ramachandran true PMID:35347128 thioproline measurement efo:EFO_0801013 Quantification of the amount of caffeic acid sulfate in a sample. Santhi Ramachandran true PMID:35347128 caffeic acid sulfate measurement efo:EFO_0801014 Quantification of the amount of 4-acetamidobenzoate in a sample. Santhi Ramachandran true PMID:35347128 4-acetamidobenzoate measurement efo:EFO_0801015 Quantification of the amount of naringenin 7-glucuronide in a sample. Santhi Ramachandran true PMID:35347128 naringenin 7-glucuronide measurement efo:EFO_0801016 Quantification of the amount of ferulylglycine (1) in a sample. Santhi Ramachandran true PMID:35347128 ferulylglycine (1) measurement efo:EFO_0801017 Quantification of the amount of ferulylglycine (2) in a sample. Santhi Ramachandran true PMID:35347128 ferulylglycine (2) measurement efo:EFO_0801018 Quantification of the amount of perfluorooctanesulfonate (PFOS) in a sample. Santhi Ramachandran true PMID:35347128 perfluorooctanesulfonate (PFOS) measurement efo:EFO_0801019 Quantification of the amount of ethyl alpha-glucopyranoside in a sample. Santhi Ramachandran true PMID:35347128 ethyl alpha-glucopyranoside measurement efo:EFO_0801020 Quantification of the amount of methylnaphthyl sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 methylnaphthyl sulfate (1) measurement efo:EFO_0801021 Quantification of the amount of methylnaphthyl sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 methylnaphthyl sulfate (2) measurement efo:EFO_0801022 Quantification of the amount of 3-hydroxystachydrine in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxystachydrine measurement efo:EFO_0801023 Quantification of the amount of genistein sulfate in a sample. Santhi Ramachandran true PMID:35347128 genistein sulfate measurement efo:EFO_0801024 Quantification of the amount of perfluorooctanoate (PFOA) in a sample. Santhi Ramachandran true PMID:35347128 perfluorooctanoate (PFOA) measurement efo:EFO_0801025 Quantification of the amount of 3-formylindole in a sample. Santhi Ramachandran true PMID:35347128 3-formylindole measurement efo:EFO_0801026 Quantification of the amount of dihydroferulic acid sulfate in a sample. Santhi Ramachandran true PMID:35347128 dihydroferulic acid sulfate measurement efo:EFO_0801027 Quantification of the amount of 3-indoleglyoxylic acid in a sample. Santhi Ramachandran true PMID:35347128 3-indoleglyoxylic acid measurement efo:EFO_0801028 Quantification of the amount of ethyl beta-glucopyranoside in a sample. Santhi Ramachandran true PMID:35347128 ethyl beta-glucopyranoside measurement efo:EFO_0801029 Quantification of the amount of enterolactone sulfate in a sample. Santhi Ramachandran true PMID:35347128 enterolactone sulfate measurement efo:EFO_0801030 Quantification of the amount of 3-hydroxyhippurate sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxyhippurate sulfate measurement efo:EFO_0801031 Quantification of the amount of glucuronide of piperine metabolite C17H21NO3 (3) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of piperine metabolite C17H21NO3 (3) measurement efo:EFO_0801032 Quantification of the amount of glucuronide of piperine metabolite C17H21NO3 (4) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of piperine metabolite C17H21NO3 (4) measurement efo:EFO_0801033 Quantification of the amount of glucuronide of piperine metabolite C17H21NO3 (5) in a sample. Santhi Ramachandran true PMID:35347128 glucuronide of piperine metabolite C17H21NO3 (5) measurement efo:EFO_0801034 Quantification of the amount of sulfate of piperine metabolite C16H19NO3 (2) in a sample. Santhi Ramachandran true PMID:35347128 sulfate of piperine metabolite C16H19NO3 (2) measurement efo:EFO_0801035 Quantification of the amount of sulfate of piperine metabolite C16H19NO3 (3) in a sample. Santhi Ramachandran true PMID:35347128 sulfate of piperine metabolite C16H19NO3 (3) measurement efo:EFO_0801036 Quantification of the amount of sulfate of piperine metabolite C18H21NO3 (1) in a sample. Santhi Ramachandran true PMID:35347128 sulfate of piperine metabolite C18H21NO3 (1) measurement efo:EFO_0801037 Quantification of the amount of sulfate of piperine metabolite C18H21NO3 (3) in a sample. Santhi Ramachandran true PMID:35347128 sulfate of piperine metabolite C18H21NO3 (3) measurement efo:EFO_0801038 Quantification of the amount of 2-naphthol sulfate in a sample. Santhi Ramachandran true PMID:35347128 2-naphthol sulfate measurement efo:EFO_0801039 Quantification of the amount of (2,4 or 2,5)-dimethylphenol sulfate in a sample. Santhi Ramachandran true PMID:35347128 (2,4 or 2,5)-dimethylphenol sulfate measurement efo:EFO_0801040 Quantification of the amount of 4-ethylcatechol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-ethylcatechol sulfate measurement efo:EFO_0801041 Quantification of the amount of 4-allylcatechol sulfate in a sample. Santhi Ramachandran true PMID:35347128 4-allylcatechol sulfate measurement efo:EFO_0801042 Quantification of the amount of 2-hydroxyfluorene sulfate in a sample. Santhi Ramachandran true PMID:35347128 2-hydroxyfluorene sulfate measurement efo:EFO_0801043 Quantification of the amount of 3-hydroxypyridine glucuronide in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxypyridine glucuronide measurement efo:EFO_0801044 Quantification of the amount of dihydrocaffeate sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 dihydrocaffeate sulfate (2) measurement efo:EFO_0801045 Quantification of the amount of 3-(methylthio)acetaminophen sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-(methylthio)acetaminophen sulfate measurement efo:EFO_0801046 Quantification of the amount of 2,6-dihydroxybenzoic acid in a sample. Santhi Ramachandran true PMID:35347128 2,6-dihydroxybenzoic acid measurement efo:EFO_0801047 Quantification of the amount of 3-ethylcatechol sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 3-ethylcatechol sulfate (1) measurement efo:EFO_0801048 Quantification of the amount of 3-ethylcatechol sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 3-ethylcatechol sulfate (2) measurement efo:EFO_0801049 Quantification of the amount of 4-acetylcatechol sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 4-acetylcatechol sulfate (1) measurement efo:EFO_0801050 Quantification of the amount of 4-acetylcatechol sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 4-acetylcatechol sulfate (2) measurement efo:EFO_0801051 Quantification of the amount of 5-hydroxy-2-methylpyridine sulfate in a sample. Santhi Ramachandran true PMID:35347128 5-hydroxy-2-methylpyridine sulfate measurement efo:EFO_0801052 Quantification of the amount of 3-hydroxy-2-methylpyridine sulfate in a sample. Santhi Ramachandran true PMID:35347128 3-hydroxy-2-methylpyridine sulfate measurement efo:EFO_0801053 Quantification of the amount of 5-hydroxymethyl-2-furoylcarnitine in a sample. Santhi Ramachandran true PMID:35347128 5-hydroxymethyl-2-furoylcarnitine measurement efo:EFO_0801054 Quantification of the amount of 3,5-dichloro-2,6-dihydroxybenzoic acid in a sample. Santhi Ramachandran true PMID:35347128 3,5-dichloro-2,6-dihydroxybenzoic acid measurement efo:EFO_0801055 Quantification of the amount of (S)-a-amino-omega-caprolactam in a sample. Santhi Ramachandran true PMID:35347128 (S)-a-amino-omega-caprolactam measurement efo:EFO_0801056 Quantification of the amount of vanillic acid glycine in a sample. Santhi Ramachandran true PMID:35347128 vanillic acid glycine measurement efo:EFO_0801057 Quantification of the amount of 2-methoxyhydroquinone glucuronide (2) in a sample. Santhi Ramachandran true PMID:35347128 2-methoxyhydroquinone glucuronide (2) measurement efo:EFO_0801058 Quantification of the amount of 3-bromo-5-chloro-2,6-dihydroxybenzoic acid in a sample. Santhi Ramachandran true PMID:35347128 3-bromo-5-chloro-2,6-dihydroxybenzoic acid measurement efo:EFO_0801059 Quantification of the amount of 4-chlorobenzoic acid in a sample. Santhi Ramachandran true PMID:35347128 4-chlorobenzoic acid measurement efo:EFO_0801060 Quantification of the amount of N-acetyl-4-chlorophenylalanine in a sample. Santhi Ramachandran true PMID:35347128 N-acetyl-4-chlorophenylalanine measurement efo:EFO_0801061 Quantification of the amount of 2-methoxyhydroquinone sulfate (1) in a sample. Santhi Ramachandran true PMID:35347128 2-methoxyhydroquinone sulfate (1) measurement efo:EFO_0801062 Quantification of the amount of 2-methoxyhydroquinone sulfate (2) in a sample. Santhi Ramachandran true PMID:35347128 2-methoxyhydroquinone sulfate (2) measurement efo:EFO_0801063 Quantification of the amount of methyl indole-3-acetate in a sample. Santhi Ramachandran true PMID:35347128 methyl indole-3-acetate measurement efo:EFO_0801064 Quantification of the amount of gluconate in a sample. Santhi Ramachandran true PMID:35347128 gluconate measurement efo:EFO_0801065 Quantification of the amount of phytanate in a sample. Santhi Ramachandran true PMID:35347128 phytanate measurement efo:EFO_0801066 Quantification of the amount of arabonate in a sample. Santhi Ramachandran true PMID:35347128 arabonate measurement efo:EFO_0801067 Quantification of the amount of xylitol in a sample. Santhi Ramachandran true PMID:35347128 xylitol measurement efo:EFO_0801068 Quantification of the amount of N-acetylglucosamine in a sample. Santhi Ramachandran true PMID:35347128 N-acetylglucosamine measurement efo:EFO_0801069 Quantification of the amount of ribulonate in a sample. Santhi Ramachandran true PMID:35347128 ribulonate measurement efo:EFO_0801070 Quantification of the amount of xylulonate in a sample. Santhi Ramachandran true PMID:35347128 xylulonate measurement efo:EFO_0801071 Quantification of the amount of 2-methylcitrate in a sample. Santhi Ramachandran true PMID:35347128 2-methylcitrate measurement efo:EFO_0801072 Quantification of the amount of oleate (18:1) in a sample. Santhi Ramachandran true PMID:35347128 oleate (18:1) measurement efo:EFO_0801073 Quantification of the amount of butyrate (4:0) in a sample. Santhi Ramachandran true PMID:35347128 butyrate (4:0) measurement efo:EFO_0801074 Quantification of the amount of allopregnanolone sulfate in a sample. Santhi Ramachandran true PMID:35347128 allopregnanolone sulfate measurement efo:EFO_0801075 Quantification of the amount of platelet-activating factor in a sample. Elizabeth Lewis true PMID:34565479 AGEPC (acetyl glyceryl ether phosphorylcholine) levels PAF acether levels PAF levels [(2R)-2-acetyloxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate levels platelet activating factor levels platelet-activating factor measurement AGEPC (acetyl glyceryl ether phosphorylcholine) levels https://pubchem.ncbi.nlm.nih.gov/compound/108156 PAF acether levels https://pubchem.ncbi.nlm.nih.gov/compound/108156 PAF levels https://pubchem.ncbi.nlm.nih.gov/compound/108156 [(2R)-2-acetyloxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate levels https://pubchem.ncbi.nlm.nih.gov/compound/108156 platelet activating factor levels https://pubchem.ncbi.nlm.nih.gov/compound/108156 efo:EFO_0801076 Quantification of the amount of dihydrobiopterin in a sample. Elizabeth Lewis true PMID:34565479 dihydrobiopterin measurement efo:EFO_0801078 Quantification of some aspect of triclosan exposure, an antimicrobial agent used in some consumer products. true PMID:34619205 triclosan measurement efo:EFO_0801079 Quantification of some aspect of bisphenol A exposure, an endocrine-disrupting chemical used in the production of some polycarbonate products. true PMID:34619205 BPA measurement bisphenol A measurement efo:EFO_0801080 Quantification of the amount of some oxidative stress biomarker in a sample. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products. They can be measured in the blood, urine or skin. Arwa Ibrahim PMID:26415143 oxidative stress biomarker measurement efo:EFO_0801081 Quantification of the amount of 8-hydroxydeoxyguanosine in a sample. true PMID:34619205 8-OHdG levels 8-hydroxy-deoxyguanosine levels 8-hydroxydeoxyguanosine measurement efo:EFO_0801082 Quantification of the amount of 8-isoprostaglandin-F2alpha in a sample. true PMID:34619205 8-iso-PGF2α levels 8-iso-prostaglandin F2α levels 8-isoPGF2alpha levels 8-isoprostaglandin-F2alpha measurement efo:EFO_0801083 Quantification of the amount of lithostathine-1-alpha measurement in a sample. true PMID:36168886 islet cells regeneration factor (ICRF) levels islet of Langerhans regenerating protein (REG) levels pancreatic stone protein (PSP) levels pancreatic thread protein (PTP) levels regenerating islet-derived protein 1-alpha (REG-1-alpha) levels regenerating protein I alpha levels lithostathine-1-alpha measurement efo:EFO_0801085 Quantification of the amount of paraoxonase-1 in a sample. true PMID:35264221 PON1 measurement paraoxonase-1 measurement efo:EFO_0801086 Quantification of the IgG antibody isotype produced in response to bovine alpha casein antigen. true PMID:34804013 anti-alpha-casein IgG measurement efo:EFO_0801087 Quantification of the IgG antibody isotype produced in response to bovine beta casein antigen. true PMID:34804013 anti-beta-casein IgG measurement efo:EFO_0801088 Quantification of the IgG antibody isotype produced in response to feline herpes virus infection. true PMID:34804013 anti-feline herpes IgG measurement efo:EFO_0801089 Quantification of the IgG antibody isotype produced in response to influenza A subtype H1N1 virus infection. true PMID:34804013 anti-influenza A subtype H1N1 IgG measurement efo:EFO_0801090 Quantification of the IgG antibody isotype produced in response to influenza A subtype H3N2 virus infection. true PMID:34804013 anti-influenza A subtype H3N2 IgG measurement efo:EFO_0801091 Quantification of the IgA antibody isotype produced in response to saccharomyces cerevisiae infection. true PMID:34804013 anti-saccharomyces cerevisiae IgA measurement efo:EFO_0801092 Quantification of the IgG antibody isotype produced in response to Theiler's virus infection. true PMID:34804013 anti-Theiler's virus IgG measurement efo:EFO_0801093 Quantification of the amount of 1-methylguanine in a sample. Elizabeth Lewis true PMID:35995766 1-methylguanine measurement efo:EFO_0801094 Quantification of the amount of 1-methylguanosine in a sample. Elizabeth Lewis true PMID:35995766 1-methylguanosine measurement efo:EFO_0801095 Quantification of the amount of 1-methylhistamine in a sample. Elizabeth Lewis true PMID:35995766 1-methylhistamine measurement efo:EFO_0801096 Quantification of the amount of 11(12)-EET in a sample. Elizabeth Lewis true PMID:35995766 11(12)-epoxyeicosatrienoic acid 11(12)-EET measurement efo:EFO_0801097 Quantification of the amount of 12-oxo-ETE in a sample. Elizabeth Lewis true PMID:35995766 12-oxo-eicosatetraenoic acid 12-oxo-ETE measurement efo:EFO_0801098 Quantification of the amount of 14(15)-EET in a sample. Elizabeth Lewis true PMID:35995766 14(15)-epoxyeicosatrienoic acid 14(15)-EET measurement efo:EFO_0801099 Quantification of the amount of 15-oxo-ETE in a sample. Elizabeth Lewis true PMID:35995766 15-oxo-eicosatetraenoic acid 15-oxo-ETE measurement efo:EFO_0801100 Quantification of the amount of 2-aminoisobutyric acid in a sample. Elizabeth Lewis true PMID:35995766 2-aminoisobutyric acid measurement efo:EFO_0801101 Quantification of the amount of 2-ketoisovaleric acid in a sample. Elizabeth Lewis true PMID:35995766 2-ketoisovaleric acid measurement efo:EFO_0801102 Quantification of the amount of 4-aminohippuric acid in a sample. Elizabeth Lewis true PMID:35995766 4-aminohippuric acid measurement efo:EFO_0801103 Quantification of the amount of 4-hydroxy-3-methylacetophenone in a sample. Elizabeth Lewis true PMID:35995766 4-hydroxy-3-methylacetophenone measurement efo:EFO_0801104 Quantification of the amount of 5-hydroxytryptophol in a sample. Elizabeth Lewis true PMID:35995766 5-hydroxytryptophol measurement efo:EFO_0801105 Quantification of the amount of 5-MTHF in a sample. Elizabeth Lewis true PMID:35995766 5-methyltetrahydrofolate 5-MTHF measurement efo:EFO_0801106 Quantification of the amount of 5-oxo-ETE in a sample. Elizabeth Lewis true PMID:35995766 5-oxo-eicosatetraenoic acid 5-oxo-ETE measurement efo:EFO_0801107 Quantification of the amount of acetaminophen glucuronide in a sample. Elizabeth Lewis true PMID:35995766 acetaminophen glucuronide measurement efo:EFO_0801108 Quantification of the amount of acetaminophen in a sample. Elizabeth Lewis true PMID:35995766 acetaminophen measurement efo:EFO_0801109 Quantification of the amount of aconitic acid in a sample. Elizabeth Lewis true PMID:35995766 aconitic acid measurement efo:EFO_0801110 Quantification of the amount of alpha-glycerophosphocholine in a sample. Elizabeth Lewis true PMID:35995766 alpha-glycerophosphocholine measurement efo:EFO_0801111 Quantification of the amount of arachindonoyl phenylalanine in a sample. Elizabeth Lewis true PMID:35995766 arachindonoyl phenylalanine measurement efo:EFO_0801112 Quantification of the amount of arecaidine in a sample. Elizabeth Lewis true PMID:35995766 arecaidine measurement efo:EFO_0801113 Quantification of the amount of aspartic acid in a sample. Elizabeth Lewis true PMID:35995766 aspartic acid measurement efo:EFO_0801114 Quantification of the amount of atenolol in a sample. Elizabeth Lewis true PMID:35995766 atenolol measurement efo:EFO_0801115 Quantification of the amount of atorvastatin in a sample. Elizabeth Lewis true PMID:35995766 atorvastatin measurement efo:EFO_0801116 Quantification of the amount of ATP in a sample. Elizabeth Lewis true PMID:35995766 adenosine triphosphate measurement ATP measurement efo:EFO_0801117 Quantification of the amount of butyric acid in a sample. Elizabeth Lewis true PMID:35995766 butyric acid measurement efo:EFO_0801118 Quantification of the amount of butyrobetaine in a sample. Elizabeth Lewis true PMID:35995766 butyrobetaine measurement efo:EFO_0801119 Quantification of the amount of C10:2 carnitine in a sample. Elizabeth Lewis true PMID:35995766 decadienoylcarnitine C10:2 carnitine measurement efo:EFO_0801120 Quantification of the amount of C14:0 sphingomyelin in a sample. Elizabeth Lewis true PMID:35995766 C14:0 sphingomyelin measurement efo:EFO_0801121 Quantification of the amount of C14:2 carnitine in a sample. Elizabeth Lewis true PMID:35995766 tetradecadienoylcarnitine C14:2 carnitine measurement efo:EFO_0801122 Quantification of the amount of C18 carnitine in a sample. Elizabeth Lewis true PMID:35995766 C18 carnitine measurement efo:EFO_0801123 Quantification of the amount of C18:1 carnitine in a sample. Elizabeth Lewis true PMID:35995766 octadecenoylcarnitine C18:1 carnitine measurement efo:EFO_0801124 Quantification of the amount of C18:3 lysophosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C18:3 lysophosphatidylethanolamine measurement efo:EFO_0801125 Quantification of the amount of C20:0 lysophosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C20:0 lysophosphatidylethanolamine measurement efo:EFO_0801126 Quantification of the amount of C20:0 sphingomyelin in a sample. Elizabeth Lewis true PMID:35995766 C20:0 sphingomyelin measurement efo:EFO_0801127 Quantification of the amount of C20:1 lysophosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C20:1 lysophosphatidylethanolamine measurement efo:EFO_0801128 Quantification of the amount of C3-DC-CH3 carnitine in a sample. Elizabeth Lewis true PMID:35995766 C3-DC-CH3 carnitine measurement efo:EFO_0801129 Quantification of the amount of C30:0 phosphatidylcholine in a sample. Elizabeth Lewis true PMID:35995766 C30:0 phosphatidylcholine measurement efo:EFO_0801130 Quantification of the amount of C34:0 phosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C34:0 phosphatidylethanolamine measurement efo:EFO_0801131 Quantification of the amount of C34:1 DAG NH4 in a sample. Elizabeth Lewis true PMID:35995766 C34:1 DAG NH4 measurement efo:EFO_0801132 Quantification of the amount of C34:2 phosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C34:2 phosphatidylethanolamine measurement efo:EFO_0801133 Quantification of the amount of C34:2 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C34:2 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801134 Quantification of the amount of C34:3 phosphatidylcholine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C34:3 phosphatidylcholine plasmalogen measurement efo:EFO_0801135 Quantification of the amount of C34:3 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C34:3 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801136 Quantification of the amount of C36:2 phosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C36:2 phosphatidylethanolamine measurement efo:EFO_0801137 Quantification of the amount of C36:2 phosphatidylserine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C36:2 phosphatidylserine plasmalogen measurement efo:EFO_0801138 Quantification of the amount of C36:3 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C36:3 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801139 Quantification of the amount of C36:3 phosphatidylserine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C36:3 phosphatidylserine plasmalogen measurement efo:EFO_0801140 Quantification of the amount of C36:4 phosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C36:4 phosphatidylethanolamine measurement efo:EFO_0801141 Quantification of the amount of C36:5 phosphatidylcholine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C36:5 phosphatidylcholine plasmalogen measurement efo:EFO_0801142 Quantification of the amount of C36:5 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C36:5 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801143 Quantification of the amount of C38:4 phosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C38:4 phosphatidylethanolamine measurement efo:EFO_0801144 Quantification of the amount of C38:5 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C38:5 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801145 Quantification of the amount of C38:6 phosphatidylcholine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C38:6 phosphatidylcholine plasmalogen measurement efo:EFO_0801146 Quantification of the amount of C38:6 phosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C38:6 phosphatidylethanolamine measurement efo:EFO_0801147 Quantification of the amount of C38:6 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C38:6 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801148 Quantification of the amount of C38:7 phosphatidylcholine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C38:7 phosphatidylcholine plasmalogen measurement efo:EFO_0801149 Quantification of the amount of C38:7 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C38:7 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801150 Quantification of the amount of C4-OH carnitine in a sample. Elizabeth Lewis true PMID:35995766 C4-OH carnitine measurement efo:EFO_0801151 Quantification of the amount of C40:6 phosphatidylethanolamine in a sample. Elizabeth Lewis true PMID:35995766 C40:6 phosphatidylethanolamine measurement efo:EFO_0801152 Quantification of the amount of C40:7 phosphatidylethanolamine plasmalogen in a sample. Elizabeth Lewis true PMID:35995766 C40:7 phosphatidylethanolamine plasmalogen measurement efo:EFO_0801153 Quantification of the amount of C5 carnitine in a sample. Elizabeth Lewis true PMID:35995766 C5 carnitine measurement efo:EFO_0801154 Quantification of the amount of C7 carnitine in a sample. Elizabeth Lewis true PMID:35995766 heptanoylcarnitine C7 carnitine measurement efo:EFO_0801155 Quantification of the amount of C9 carnitine in a sample. Elizabeth Lewis true PMID:35995766 C9 carnitine measurement efo:EFO_0801156 Quantification of the amount of citric acid/Isocitric acid in a sample. Elizabeth Lewis true PMID:35995766 citric acid/isocitric acid measurement efo:EFO_0801157 Quantification of the amount of diacetylspermine in a sample. Elizabeth Lewis true PMID:35995766 diacetylspermine measurement efo:EFO_0801158 Quantification of the amount of DMGV in a sample. Elizabeth Lewis true PMID:35995766 dimethylguanidino valeric acid DMGV measurement efo:EFO_0801159 Quantification of the amount of fumaric acid in a sample. Elizabeth Lewis true PMID:35995766 fumaric acid measurement efo:EFO_0801160 Quantification of the amount of GABA in a sample. Elizabeth Lewis true PMID:35995766 gamma-aminobutyric acid GABA measurement efo:EFO_0801161 Quantification of the amount of gabapentin in a sample. Elizabeth Lewis true PMID:35995766 gabapentin measurement efo:EFO_0801162 Quantification of the amount of glutathione in the reduced state. Elizabeth Lewis true PMID:35995766 GSH reduced glutathione measurement efo:EFO_0801163 Quantification of the amount of glyceric acid in a sample. Elizabeth Lewis true PMID:35995766 glyceric acid measurement efo:EFO_0801164 Quantification of the amount of glyoxylic Acid in a sample. Elizabeth Lewis true PMID:35995766 glyoxylic acid measurement efo:EFO_0801165 Quantification of the amount of guanine in a sample. Elizabeth Lewis true PMID:35995766 guanine measurement efo:EFO_0801166 Quantification of the amount of HETE in a sample. Elizabeth Lewis true PMID:35995766 hydroxyeicosatetraenoic acid HETE measurement efo:EFO_0801167 Quantification of the amount of homogentisic acid in a sample. Elizabeth Lewis true PMID:35995766 homogentisic acid measurement efo:EFO_0801168 Quantification of the amount of hydroxyectoine in a sample. Elizabeth Lewis true PMID:35995766 hydroxyectoine measurement efo:EFO_0801169 Quantification of the amount of hydroxyphenylpyruvic acid in a sample. Elizabeth Lewis true PMID:35995766 hydroxyphenylpyruvic acid measurement efo:EFO_0801170 Quantification of the amount of indole-3-carboxylic acid in a sample. Elizabeth Lewis true PMID:35995766 indole-3-carboxylic acid measurement efo:EFO_0801171 Quantification of the amount of indole-3-lactic acid in a sample. Elizabeth Lewis true PMID:35995766 indole-3-lactic acid measurement efo:EFO_0801172 Quantification of the amount of indole-3-propanoic acid in a sample. Elizabeth Lewis true PMID:35995766 indole-3-propanoic acid measurement efo:EFO_0801173 Quantification of the amount of keto-isocaproic acid KIC / keto-methylvalerate KMV in a sample. Elizabeth Lewis true PMID:35995766 keto-isocaproic acid KIC / keto-methylvalerate KMV measurement efo:EFO_0801174 Quantification of the amount of lactic acid in a sample. Elizabeth Lewis true PMID:35995766 lactic acid measurement efo:EFO_0801175 Quantification of the amount of lisinopril in a sample. Elizabeth Lewis true PMID:35995766 lisinopril measurement efo:EFO_0801176 Quantification of the amount of malonic acid in a sample. Elizabeth Lewis true PMID:35995766 malonic acid measurement efo:EFO_0801177 Quantification of the amount of metformin in a sample. Elizabeth Lewis true PMID:35995766 metformin measurement efo:EFO_0801178 Quantification of the amount of methylhistidine in a sample. Elizabeth Lewis true PMID:35995766 methylhistidine measurement efo:EFO_0801179 Quantification of the amount of metoprolol in a sample. Elizabeth Lewis true PMID:35995766 metoprolol measurement efo:EFO_0801180 Quantification of the amount of metronidazole in a sample. Elizabeth Lewis true PMID:35995766 metronidazole measurement efo:EFO_0801181 Quantification of the amount of N-acetyl-L-aspartic acid in a sample. Elizabeth Lewis true PMID:35995766 N-acetyl-L-aspartic acid measurement efo:EFO_0801182 Quantification of the amount of N-acetyl-L-glutamic acid in a sample. Elizabeth Lewis true PMID:35995766 N-acetyl-L-glutamic acid measurement efo:EFO_0801183 Quantification of the amount of N-acetylaspartic acid in a sample. Elizabeth Lewis true PMID:35995766 N-acetylaspartic acid measurement efo:EFO_0801184 Quantification of the amount of N-arachidonoyl dopamine in a sample. Elizabeth Lewis true PMID:35995766 N-arachidonoyl dopamine measurement efo:EFO_0801185 Quantification of the amount of N-arachidonoyl taurine in a sample. Elizabeth Lewis true PMID:35995766 N-arachidonoyl taurine measurement efo:EFO_0801186 Quantification of the amount of N-carbamoyl-beta-alanine in a sample. Elizabeth Lewis true PMID:35995766 N-carbamoyl-beta-alanine measurement efo:EFO_0801187 Quantification of the amount of N-docosanoyl taurine in a sample. Elizabeth Lewis true PMID:35995766 N-docosanoyl taurine measurement efo:EFO_0801188 Quantification of the amount of N-lauroylglycine in a sample. Elizabeth Lewis true PMID:35995766 N-lauroylglycine measurement efo:EFO_0801189 Quantification of the amount of N-lignoceroyl taurine in a sample. Elizabeth Lewis true PMID:35995766 N-lignoceroyl taurine measurement efo:EFO_0801190 Quantification of the amount of N-nervonoyl taurine in a sample. Elizabeth Lewis true PMID:35995766 N-nervonoyl taurine measurement efo:EFO_0801191 Quantification of the amount of N-oleoyl taurine in a sample. Elizabeth Lewis true PMID:35995766 N-oleoyl taurine measurement efo:EFO_0801192 Quantification of the amount of N-palmitoyl taurine in a sample. Elizabeth Lewis true PMID:35995766 N-palmitoyl taurine measurement efo:EFO_0801193 Quantification of the amount of N1-acetylspermidine in a sample. Elizabeth Lewis true PMID:35995766 N1-acetylspermidine measurement efo:EFO_0801194 Quantification of the amount of Na_C34:1 DAG_or_TAG_fragment in a sample. Elizabeth Lewis true PMID:35995766 Na_C34:1 DAG_or_TAG_fragment measurement efo:EFO_0801195 Quantification of the amount of Na_C34:2 DAG_or_TAG_fragment in a sample. Elizabeth Lewis true PMID:35995766 Na_C34:2 DAG_or_TAG_fragment measurement efo:EFO_0801196 Quantification of the amount of NH4_C34:2 DAG_or_TAG_fragment in a sample. Elizabeth Lewis true PMID:35995766 NH4_C34:2 DAG_or_TAG_fragment measurement efo:EFO_0801197 Quantification of the amount of NH4_C34:3 DAG_or_TAG_fragment in a sample. Elizabeth Lewis true PMID:35995766 NH4_C34:3 DAG_or_TAG_fragment measurement efo:EFO_0801198 Quantification of the amount of NH4_C36:2 DAG_or_TAG_fragment in a sample. Elizabeth Lewis true PMID:35995766 NH4_C36:2 DAG_or_TAG_fragment measurement efo:EFO_0801199 Quantification of the amount of NH4_C36:3 DAG_or_TAG_fragment in a sample. Elizabeth Lewis true PMID:35995766 NH4_C36:3 DAG_or_TAG_fragment measurement efo:EFO_0801200 Quantification of the amount of NH4_C36:4 DAG_or_TAG_fragment in a sample. Elizabeth Lewis PMID:35995766 NH4_C36:4 DAG_or_TAG_fragment measurement efo:EFO_0801201 Quantification of the amount of NH4_C38:5 DAG_or_TAG_fragment in a sample. Elizabeth Lewis PMID:35995766 NH4_C38:5 DAG_or_TAG_fragment measurement efo:EFO_0801202 Quantification of the amount of NH4_C44:1 TAG in a sample. Elizabeth Lewis true PMID:35995766 NH4_C44:1 TAG measurement efo:EFO_0801203 Quantification of the amount of NH4_C44:2 TAG in a sample. Elizabeth Lewis true PMID:35995766 NH4_C44:2 TAG measurement efo:EFO_0801204 Quantification of the amount of NH4_C46:2 TAG in a sample. Elizabeth Lewis true PMID:35995766 NH4_C46:2 TAG measurement efo:EFO_0801205 Quantification of the amount of NH4_C46:3 TAG in a sample. Elizabeth Lewis true PMID:35995766 NH4_C46:3 TAG measurement efo:EFO_0801206 Quantification of the amount of NMMA in a sample. Elizabeth Lewis true PMID:35995766 N-methylmalonamic acid NMMA measurement efo:EFO_0801207 Quantification of the amount of oleoyl glycine in a sample. Elizabeth Lewis true PMID:35995766 oleoyl glycine measurement efo:EFO_0801208 Quantification of the amount of oleoyl leucine in a sample. Elizabeth Lewis true PMID:35995766 oleoyl leucine measurement efo:EFO_0801209 Quantification of the amount of oleoyl phenylalanine in a sample. Elizabeth Lewis true PMID:35995766 oleoyl phenylalanine measurement efo:EFO_0801210 Quantification of the amount of oleoyl serine in a sample. Elizabeth Lewis true PMID:35995766 oleoyl serine measurement efo:EFO_0801211 Quantification of the amount of oxalic acid in a sample. Elizabeth Lewis true PMID:35995766 oxalic acid measurement efo:EFO_0801212 Quantification of the amount of oxaloacetic acid in a sample. Elizabeth Lewis true PMID:35995766 oxaloacetic acid measurement efo:EFO_0801213 Quantification of the amount of oxypurinol in a sample. Elizabeth Lewis true PMID:35995766 oxypurinol measurement efo:EFO_0801214 Quantification of the amount of phenylalanine-d8 in a sample. Elizabeth Lewis true PMID:35995766 phenylalanine-d8 measurement efo:EFO_0801215 Quantification of the amount of pravastatin in a sample. Elizabeth Lewis true PMID:35995766 pravastatin measurement efo:EFO_0801216 Quantification of the amount of pro-gly in a sample. Elizabeth Lewis true PMID:35995766 pro-gly measurement efo:EFO_0801217 Quantification of the amount of pyruvic acid in a sample. Elizabeth Lewis true PMID:35995766 pyruvic acid measurement efo:EFO_0801218 Quantification of the amount of quinine in a sample. Elizabeth Lewis true PMID:35995766 quinine measurement efo:EFO_0801219 Quantification of the amount of simvastatin in a sample. Elizabeth Lewis true PMID:35995766 simvastatin measurement efo:EFO_0801220 Quantification of the amount of stearic acid in a sample. Elizabeth Lewis true PMID:35995766 stearic acid measurement efo:EFO_0801221 Quantification of the amount of trimethylbenzene in a sample. Elizabeth Lewis true PMID:35995766 trimethylbenzene measurement efo:EFO_0801222 Quantification of the amount of UDP-GlcNAc in a sample. Elizabeth Lewis true PMID:35995766 uridine-diphosphate-N-acetylglucosamine UDP-GlcNAc measurement efo:EFO_0801223 Quantification of the amount of valine-d8 in a sample. Elizabeth Lewis true PMID:35995766 valine-d8 measurement efo:EFO_0801224 Quantification of the amount of valsartan in a sample. Elizabeth Lewis true PMID:35995766 valsartan measurement efo:EFO_0801225 Quantification of the amount of verapamil in a sample. Elizabeth Lewis true PMID:35995766 verapamil measurement efo:EFO_0801226 Quantification of the amount of warfarin in a sample. Elizabeth Lewis true PMID:35995766 warfarin measurement efo:EFO_0801227 Quantification of body shape, which may be derived from principal component analysis (PCA) of anthropometric traits such as BMI, weight, hip circumference and waist circumference. true PMID:35461751 body shape measurement efo:EFO_0801228 Quantification of some aspect of an individual's microbiome of the skin. true PMID:36261456 skin microbiota measurement skin microbiome measurement efo:EFO_0801229 Quantification of some aspect of an individual's oral microbiome. true PMID:34875929 oral microbiota measurement salivary microbiome measurement oral microbiome measurement efo:EFO_0801230 Quantification of the amount of visfatin in a sample. true NCIT:C30138 PMID:34620218 nicotinamide phosphoribosyltransferase pre-B-cell colony-enhancing factor 1 visfatin measurement efo:EFO_0801231 Quantification of decadienylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 O-linoleyl-L-carnitine decadienylcarnitine measurement efo:EFO_0801232 Quantification of hydroxytetradecenoylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 hydroxytetradecenoylcarnitine measurement efo:EFO_0801233 Quantification of tetradecadienylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 tetradecadienylcarnitine measurement efo:EFO_0801234 Quantification of octadecenoylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 octadecenoylcarnitine measurement efo:EFO_0801235 Quantification of octadecadienylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 octadecadienylcarnitine measurement efo:EFO_0801236 Quantification of hydroxypropionylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 hydroxypropionylcarnitine measurement efo:EFO_0801237 Quantification of glutaconylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 glutaconylcarnitine measurement efo:EFO_0801238 Quantification of pimelylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 pimelylcarnitine measurement efo:EFO_0801239 Quantification of octenoylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 octenoylcarnitine measurement efo:EFO_0801240 Quantification of nonaylcarnitine measurement in a sample. Elizabeth Lewis true PMID:26068415 nonaylcarnitine measurement efo:EFO_0801241 Quantification of lysophosphatidylcholine acyl C16:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 lysophosphatidylcholine 16:0 lysophosphatidylcholine acyl C16:0 measurement efo:EFO_0801242 Quantification of lysophosphatidylcholine acyl C17:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 lysophosphatidylcholine 17:0 lysophosphatidylcholine acyl C17:0 measurement efo:EFO_0801243 Quantification of lysophosphatidylcholine acyl C28:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 lysophosphatidylcholine 28:0 lysophosphatidylcholine acyl C28:0 measurement efo:EFO_0801244 Quantification of lysophosphatidylcholine acyl C28:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 lysophosphatidylcholine 28:1 lysophosphatidylcholine acyl C28:1 measurement efo:EFO_0801245 Quantification of phosphatidylcholine diacyl C24:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 24:0 phosphatidylcholine diacyl C24:0 measurement efo:EFO_0801246 Quantification of phosphatidylcholine diacyl C28:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 28:1 phosphatidylcholine diacyl C28:1 measurement efo:EFO_0801247 Quantification of phosphatidylcholine diacyl C30:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 30:0 phosphatidylcholine diacyl C30:0 measurement efo:EFO_0801248 Quantification of phosphatidylcholine diacyl C32:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 32:0 phosphatidylcholine diacyl C32:0 measurement efo:EFO_0801249 Quantification of phosphatidylcholine diacyl C32:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 32:1 phosphatidylcholine diacyl C32:1 measurement efo:EFO_0801250 Quantification of phosphatidylcholine diacyl C32:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 32:2 phosphatidylcholine diacyl C32:2 measurement efo:EFO_0801251 Quantification of phosphatidylcholine diacyl C32:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 32:3 phosphatidylcholine diacyl C32:3 measurement efo:EFO_0801252 Quantification of phosphatidylcholine diacyl C34:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 34:1 phosphatidylcholine diacyl C34:1 measurement efo:EFO_0801253 Quantification of phosphatidylcholine diacyl C34:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 34:2 phosphatidylcholine diacyl C34:2 measurement efo:EFO_0801254 Quantification of phosphatidylcholine diacyl C34:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 34:3 phosphatidylcholine diacyl C34:3 measurement efo:EFO_0801255 Quantification of phosphatidylcholine diacyl C34:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 34:4 phosphatidylcholine diacyl C34:4 measurement efo:EFO_0801256 Quantification of phosphatidylcholine diacyl C36:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 36:0 phosphatidylcholine diacyl C36:0 measurement efo:EFO_0801257 Quantification of phosphatidylcholine diacyl C36:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 36:1 phosphatidylcholine diacyl C36:1 measurement efo:EFO_0801258 Quantification of phosphatidylcholine diacyl C36:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 36:2 phosphatidylcholine diacyl C36:2 measurement efo:EFO_0801259 Quantification of phosphatidylcholine diacyl C36:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 36:3 phosphatidylcholine diacyl C36:3 measurement efo:EFO_0801260 Quantification of phosphatidylcholine diacyl C36:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 36:4 phosphatidylcholine diacyl C36:4 measurement efo:EFO_0801261 Quantification of phosphatidylcholine diacyl C36:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 36:5 phosphatidylcholine diacyl C36:5 measurement efo:EFO_0801262 Quantification of phosphatidylcholine diacyl C36:6 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 36:6 phosphatidylcholine diacyl C36:6 measurement efo:EFO_0801263 Quantification of phosphatidylcholine diacyl C38:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 38:0 phosphatidylcholine diacyl C38:0 measurement efo:EFO_0801264 Quantification of phosphatidylcholine diacyl C38:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 38:1 phosphatidylcholine diacyl C38:1 measurement efo:EFO_0801265 Quantification of phosphatidylcholine diacyl C38:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 38:3 phosphatidylcholine diacyl C38:3 measurement efo:EFO_0801266 Quantification of phosphatidylcholine diacyl C38:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 38:4 phosphatidylcholine diacyl C38:4 measurement efo:EFO_0801267 Quantification of phosphatidylcholine diacyl C38:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 38:5 phosphatidylcholine diacyl C38:5 measurement efo:EFO_0801268 Quantification of phosphatidylcholine diacyl C38:6 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 38:6 phosphatidylcholine diacyl C38:6 measurement efo:EFO_0801269 Quantification of phosphatidylcholine diacyl C40:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 40:1 phosphatidylcholine diacyl C40:1 measurement efo:EFO_0801270 Quantification of phosphatidylcholine diacyl C40:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 40:2 phosphatidylcholine diacyl C40:2 measurement efo:EFO_0801271 Quantification of phosphatidylcholine diacyl C40:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 40:3 phosphatidylcholine diacyl C40:3 measurement efo:EFO_0801272 Quantification of phosphatidylcholine diacyl C40:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 40:4 phosphatidylcholine diacyl C40:4 measurement efo:EFO_0801273 Quantification of phosphatidylcholine diacyl C40:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 40:5 phosphatidylcholine diacyl C40:5 measurement efo:EFO_0801274 Quantification of phosphatidylcholine diacyl C40:6 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 40:6 phosphatidylcholine diacyl C40:6 measurement efo:EFO_0801275 Quantification of phosphatidylcholine diacyl C42:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 42:0 phosphatidylcholine diacyl C42:0 measurement efo:EFO_0801276 Quantification of phosphatidylcholine diacyl C42:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 42:1 phosphatidylcholine diacyl C42:1 measurement efo:EFO_0801277 Quantification of phosphatidylcholine diacyl C42:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 42:2 phosphatidylcholine diacyl C42:2 measurement efo:EFO_0801278 Quantification of phosphatidylcholine diacyl C42:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 42:4 phosphatidylcholine diacyl C42:4 measurement efo:EFO_0801279 Quantification of phosphatidylcholine diacyl C42:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 42:5 phosphatidylcholine diacyl C42:5 measurement efo:EFO_0801280 Quantification of phosphatidylcholine diacyl C42:6 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine 42:6 phosphatidylcholine diacyl C42:6 measurement efo:EFO_0801281 Quantification of phosphatidylcholine acyl-alkyl C30:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-30:0 phosphatidylcholine acyl-alkyl C30:0 measurement efo:EFO_0801282 Quantification of phosphatidylcholine acyl-alkyl C32:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-32:1 phosphatidylcholine acyl-alkyl C32:1 measurement efo:EFO_0801283 Quantification of phosphatidylcholine acyl-alkyl C32:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-32:2 phosphatidylcholine acyl-alkyl C32:2 measurement efo:EFO_0801284 Quantification of phosphatidylcholine acyl-alkyl C34:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-34:0 phosphatidylcholine acyl-alkyl C34:0 measurement efo:EFO_0801285 Quantification of phosphatidylcholine acyl-alkyl C34:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-34:1 phosphatidylcholine acyl-alkyl C34:1 measurement efo:EFO_0801286 Quantification of phosphatidylcholine acyl-alkyl C34:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-34:2 phosphatidylcholine acyl-alkyl C34:2 measurement efo:EFO_0801287 Quantification of phosphatidylcholine acyl-alkyl C34:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-34:3 phosphatidylcholine acyl-alkyl C34:3 measurement efo:EFO_0801288 Quantification of phosphatidylcholine acyl-alkyl C36:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-36:0 phosphatidylcholine acyl-alkyl C36:0 measurement efo:EFO_0801289 Quantification of phosphatidylcholine acyl-alkyl C36:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-36:1 phosphatidylcholine acyl-alkyl C36:1 measurement efo:EFO_0801290 Quantification of phosphatidylcholine acyl-alkyl C36:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-36:2 phosphatidylcholine acyl-alkyl C36:2 measurement efo:EFO_0801291 Quantification of phosphatidylcholine acyl-alkyl C36:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-36:3 phosphatidylcholine acyl-alkyl C36:3 measurement efo:EFO_0801292 Quantification of phosphatidylcholine acyl-alkyl C36:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-36:4 phosphatidylcholine acyl-alkyl C36:4 measurement efo:EFO_0801293 Quantification of phosphatidylcholine acyl-alkyl C36:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-36:5 phosphatidylcholine acyl-alkyl C36:5 measurement efo:EFO_0801294 Quantification of phosphatidylcholine acyl-alkyl C38:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-38:0 phosphatidylcholine acyl-alkyl C38:0 measurement efo:EFO_0801295 Quantification of phosphatidylcholine acyl-alkyl C38:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-38:1 phosphatidylcholine acyl-alkyl C38:1 measurement efo:EFO_0801296 Quantification of phosphatidylcholine acyl-alkyl C38:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-38:2 phosphatidylcholine acyl-alkyl C38:2 measurement efo:EFO_0801297 Quantification of phosphatidylcholine acyl-alkyl C38:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-38:3 phosphatidylcholine acyl-alkyl C38:3 measurement efo:EFO_0801298 Quantification of phosphatidylcholine acyl-alkyl C38:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-38:4 phosphatidylcholine acyl-alkyl C38:4 measurement efo:EFO_0801299 Quantification of phosphatidylcholine acyl-alkyl C38:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-38:5 phosphatidylcholine acyl-alkyl C38:5 measurement efo:EFO_0801300 Quantification of phosphatidylcholine acyl-alkyl C38:6 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-38:6 phosphatidylcholine acyl-alkyl C38:6 measurement efo:EFO_0801301 Quantification of phosphatidylcholine acyl-alkyl C40:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-40:1 phosphatidylcholine acyl-alkyl C40:1 measurement efo:EFO_0801302 Quantification of phosphatidylcholine acyl-alkyl C40:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-40:2 phosphatidylcholine acyl-alkyl C40:2 measurement efo:EFO_0801303 Quantification of phosphatidylcholine acyl-alkyl C40:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-40:3 phosphatidylcholine acyl-alkyl C40:3 measurement efo:EFO_0801304 Quantification of phosphatidylcholine acyl-alkyl C40:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-40:4 phosphatidylcholine acyl-alkyl C40:4 measurement efo:EFO_0801305 Quantification of phosphatidylcholine acyl-alkyl C40:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-40:5 phosphatidylcholine acyl-alkyl C40:5 measurement efo:EFO_0801306 Quantification of phosphatidylcholine acyl-alkyl C40:6 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-40:6 phosphatidylcholine acyl-alkyl C40:6 measurement efo:EFO_0801307 Quantification of phosphatidylcholine acyl-alkyl C42:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-42:0 phosphatidylcholine acyl-alkyl C42:0 measurement efo:EFO_0801308 Quantification of phosphatidylcholine acyl-alkyl C42:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-42:1 phosphatidylcholine acyl-alkyl C42:1 measurement efo:EFO_0801309 Quantification of phosphatidylcholine acyl-alkyl C42:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-42:2 phosphatidylcholine acyl-alkyl C42:2 measurement efo:EFO_0801310 Quantification of phosphatidylcholine acyl-alkyl C42:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-42:3 phosphatidylcholine acyl-alkyl C42:3 measurement efo:EFO_0801311 Quantification of phosphatidylcholine acyl-alkyl C42:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-42:4 phosphatidylcholine acyl-alkyl C42:4 measurement efo:EFO_0801312 Quantification of phosphatidylcholine acyl-alkyl C42:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-42:5 phosphatidylcholine acyl-alkyl C42:5 measurement efo:EFO_0801313 Quantification of phosphatidylcholine acyl-alkyl C44:3 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-44:3 phosphatidylcholine acyl-alkyl C44:3 measurement efo:EFO_0801314 Quantification of phosphatidylcholine acyl-alkyl C44:4 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-44:4 phosphatidylcholine acyl-alkyl C44:4 measurement efo:EFO_0801315 Quantification of phosphatidylcholine acyl-alkyl C44:5 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-44:5 phosphatidylcholine acyl-alkyl C44:5 measurement efo:EFO_0801316 Quantification of phosphatidylcholine acyl-alkyl C44:6 measurement in a sample. Elizabeth Lewis true PMID:26068415 phosphatidylcholine O-44:6 phosphatidylcholine acyl-alkyl C44:6 measurement efo:EFO_0801317 Quantification of sphingomyeline C16:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C16:0 measurement efo:EFO_0801318 Quantification of sphingomyeline C16:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C16:1 measurement efo:EFO_0801319 Quantification of sphingomyeline C18:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C18:0 measurement efo:EFO_0801320 Quantification of sphingomyeline C18:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C18:1 measurement efo:EFO_0801321 Quantification of sphingomyeline C20:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C20:2 measurement efo:EFO_0801322 Quantification of sphingomyeline C24:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C24:0 measurement efo:EFO_0801323 Quantification of sphingomyeline C24:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C24:1 measurement efo:EFO_0801324 Quantification of sphingomyeline C26:0 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C26:0 measurement efo:EFO_0801325 Quantification of sphingomyeline C26:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 sphingomyeline C26:1 measurement efo:EFO_0801326 Quantification of hydroxysphingomyeline C14:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 hydroxysphingomyeline C14:1 measurement efo:EFO_0801327 Quantification of hydroxysphingomyeline C16:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 hydroxysphingomyeline C16:1 measurement efo:EFO_0801328 Quantification of hydroxysphingomyeline C22:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 hydroxysphingomyeline C22:1 measurement efo:EFO_0801329 Quantification of hydroxysphingomyeline C22:2 measurement in a sample. Elizabeth Lewis true PMID:26068415 hydroxysphingomyeline C22:2 measurement efo:EFO_0801330 Quantification of hydroxysphingomyeline C24:1 measurement in a sample. Elizabeth Lewis true PMID:26068415 hydroxysphingomyeline C24:1 measurement efo:EFO_0801331 Quantification of 26S proteasome non-ATPase regulatory subunit 5 in a sample. Elizabeth Lewis true PMID:29875488 26S proteasome non-ATPase regulatory subunit 5 measurement efo:EFO_0801332 Quantification of 39S ribosomal protein L33, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 39S ribosomal protein L33, mitochondrial measurement efo:EFO_0801333 Quantification of 40S ribosomal protein S3a in a sample. Elizabeth Lewis true PMID:29875488 40S ribosomal protein S3a measurement efo:EFO_0801334 Quantification of 40S ribosomal protein S4, X isoform in a sample. Elizabeth Lewis true PMID:29875488 40S ribosomal protein S4, X isoform measurement efo:EFO_0801335 Quantification of 5-formyltetrahydrofolate cyclo-ligase in a sample. Elizabeth Lewis true PMID:29875488 5-formyltetrahydrofolate cyclo-ligase measurement efo:EFO_0801336 Quantification of 5'(3')-deoxyribonucleotidase, cytosolic type in a sample. Elizabeth Lewis true PMID:29875488 5'(3')-deoxyribonucleotidase, cytosolic type measurement efo:EFO_0801337 Quantification of 60S ribosomal protein L30 in a sample. Elizabeth Lewis true PMID:29875488 60S ribosomal protein L30 measurement efo:EFO_0801338 Quantification of a disintegrin and metalloproteinase with thrombospondin motifs 6 in a sample. Elizabeth Lewis true PMID:29875488 a disintegrin and metalloproteinase with thrombospondin motifs 6 measurement efo:EFO_0801339 Quantification of acid ceramidase in a sample. Elizabeth Lewis true PMID:29875488 acid ceramidase measurement efo:EFO_0801340 Quantification of activating signal cointegrator 1 complex subunit 1 in a sample. Elizabeth Lewis true PMID:29875488 activating signal cointegrator 1 complex subunit 1 measurement efo:EFO_0801341 Quantification of activator of 90 kDa heat shock protein ATPase homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 activator of 90 kDa heat shock protein ATPase homolog 1 measurement efo:EFO_0801342 Quantification of acyl-CoA-binding domain-containing protein 6 in a sample. Elizabeth Lewis true PMID:29875488 acyl-CoA-binding domain-containing protein 6 measurement efo:EFO_0801343 Quantification of acyl-CoA-binding domain-containing protein 7 in a sample. Elizabeth Lewis true PMID:29875488 acyl-CoA-binding domain-containing protein 7 measurement efo:EFO_0801344 Quantification of acylphosphatase-2 in a sample. Elizabeth Lewis true PMID:29875488 acylphosphatase-2 measurement efo:EFO_0801345 Quantification of adenylosuccinate synthetase isozyme 2 in a sample. Elizabeth Lewis true PMID:29875488 adenylosuccinate synthetase isozyme 2 measurement efo:EFO_0801346 Quantification of adhesion G protein-coupled receptor F5 in a sample. Elizabeth Lewis true PMID:29875488 adhesion G protein-coupled receptor F5 measurement efo:EFO_0801347 Quantification of adhesion G-protein coupled receptor F1 in a sample. Elizabeth Lewis true PMID:29875488 adhesion G-protein coupled receptor F1 measurement efo:EFO_0801348 Quantification of adipocyte plasma membrane-associated protein in a sample. Elizabeth Lewis true PMID:29875488 adipocyte plasma membrane-associated protein measurement efo:EFO_0801349 Quantification of ADP-ribose pyrophosphatase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribose pyrophosphatase, mitochondrial measurement efo:EFO_0801350 Quantification of ADP-ribosylation factor 6 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor 6 measurement efo:EFO_0801351 Quantification of ADP-ribosylation factor GTPase-activating protein 2 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor GTPase-activating protein 2 measurement efo:EFO_0801352 Quantification of ADP-ribosylation factor-binding protein GGA1 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor-binding protein GGA1 measurement efo:EFO_0801353 Quantification of ADP-ribosylation factor-binding protein GGA3 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor-binding protein GGA3 measurement efo:EFO_0801354 Quantification of ADP-ribosylation factor-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor-like protein 1 measurement efo:EFO_0801355 Quantification of ADP-ribosylation factor-like protein 11 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor-like protein 11 measurement efo:EFO_0801356 Quantification of ADP-ribosylation factor-like protein 3 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor-like protein 3 measurement efo:EFO_0801357 Quantification of agouti-signaling protein in a sample. Elizabeth Lewis true PMID:29875488 Agouti-signaling protein measurement efo:EFO_0801358 Quantification of adseverin in a sample. Elizabeth Lewis true PMID:29875488 adseverin measurement efo:EFO_0801359 Quantification of alanine--tRNA ligase, cytoplasmic in a sample. Elizabeth Lewis true PMID:29875488 alanine--tRNA ligase, cytoplasmic measurement efo:EFO_0801360 Quantification of alcohol dehydrogenase 1B in a sample. Elizabeth Lewis true PMID:29875488 alcohol dehydrogenase 1B measurement efo:EFO_0801361 Quantification of aldehyde dehydrogenase family 3 member B1 in a sample. Elizabeth Lewis true PMID:29875488 aldehyde dehydrogenase family 3 member B1 measurement efo:EFO_0801362 Quantification of aldehyde dehydrogenase, dimeric NADP-preferring in a sample. Elizabeth Lewis true PMID:29875488 aldehyde dehydrogenase, dimeric NADP-preferring measurement efo:EFO_0801363 Quantification of aldo-keto reductase family 1 member C1 in a sample. Elizabeth Lewis true PMID:29875488 aldo-keto reductase family 1 member C1 measurement efo:EFO_0801364 Quantification of aldose reductase in a sample. Elizabeth Lewis true PMID:29875488 aldose reductase measurement efo:EFO_0801365 Quantification of allergin-1 in a sample. Elizabeth Lewis true PMID:29875488 allergin-1 measurement efo:EFO_0801366 Quantification of alpha-(1,3)-fucosyltransferase 10 in a sample. Elizabeth Lewis true PMID:29875488 alpha-(1,3)-fucosyltransferase 10 measurement efo:EFO_0801367 Quantification of alpha-(1,3)-fucosyltransferase 9 in a sample. Elizabeth Lewis true PMID:29875488 alpha-(1,3)-fucosyltransferase 9 measurement efo:EFO_0801368 Quantification of alpha-(1,6)-fucosyltransferase in a sample. Elizabeth Lewis true PMID:29875488 alpha-(1,6)-fucosyltransferase measurement efo:EFO_0801369 Quantification of alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B in a sample. Elizabeth Lewis true PMID:29875488 alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B measurement efo:EFO_0801370 Quantification of alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase in a sample. Elizabeth Lewis true PMID:29875488 alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase measurement efo:EFO_0801371 Quantification of alpha-amylase 1 in a sample. Elizabeth Lewis true PMID:29875488 alpha-amylase 1 measurement efo:EFO_0801372 Quantification of alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 measurement efo:EFO_0801373 Quantification of alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 measurement efo:EFO_0801374 Quantification of alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 in a sample. Elizabeth Lewis true PMID:29875488 alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 measurement efo:EFO_0801375 Quantification of alpha-taxilin in a sample. Elizabeth Lewis true PMID:29875488 alpha-taxilin measurement efo:EFO_0801376 Quantification of alpha/beta hydrolase domain-containing protein 14A in a sample. Elizabeth Lewis true PMID:29875488 alpha/beta hydrolase domain-containing protein 14A measurement efo:EFO_0801377 Quantification of ameloblastin in a sample. Elizabeth Lewis true PMID:29875488 ameloblastin measurement efo:EFO_0801378 Quantification of amelogenin, X isoform in a sample. Elizabeth Lewis true PMID:29875488 amelogenin, X isoform measurement efo:EFO_0801379 Quantification of amyloid beta A4 precursor protein-binding family B member 2 in a sample. Elizabeth Lewis true PMID:29875488 amyloid beta A4 precursor protein-binding family B member 2 measurement efo:EFO_0801380 Quantification of amyloid-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 amyloid-like protein 2 measurement efo:EFO_0801381 Quantification of anaphase-promoting complex subunit 7 in a sample. Elizabeth Lewis true PMID:29875488 anaphase-promoting complex subunit 7 measurement efo:EFO_0801382 Quantification of angiopoietin-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 angiopoietin-related protein 1 measurement efo:EFO_0801383 Quantification of annexin A10 in a sample. Elizabeth Lewis true PMID:29875488 annexin A10 measurement efo:EFO_0801384 Quantification of AP-4 complex accessory subunit tepsin in a sample. Elizabeth Lewis true PMID:29875488 AP-4 complex accessory subunit tepsin measurement efo:EFO_0801385 Quantification of AP-4 complex subunit mu-1 in a sample. Elizabeth Lewis true PMID:29875488 AP-4 complex subunit mu-1 measurement efo:EFO_0801386 Quantification of APOBEC1 complementation factor in a sample. Elizabeth Lewis true PMID:29875488 APOBEC1 complementation factor measurement efo:EFO_0801387 Quantification of apolipoprotein A-V in a sample. Elizabeth Lewis true PMID:29875488 apolipoprotein A-V measurement efo:EFO_0801388 Quantification of apolipoprotein F in a sample. Elizabeth Lewis true PMID:29875488 apolipoprotein F measurement efo:EFO_0801389 Quantification of apoptosis-inducing factor 1, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 apoptosis-inducing factor 1, mitochondrial measurement efo:EFO_0801390 Quantification of apoptotic protease-activating factor 1 in a sample. Elizabeth Lewis true PMID:29875488 apoptotic protease-activating factor 1 measurement efo:EFO_0801391 Quantification of arachidonate 15-lipoxygenase B in a sample. Elizabeth Lewis true PMID:29875488 arachidonate 15-lipoxygenase B measurement efo:EFO_0801392 Quantification of arfaptin-1 in a sample. Elizabeth Lewis true PMID:29875488 arfaptin-1 measurement efo:EFO_0801393 Quantification of arfaptin-2 in a sample. Elizabeth Lewis true PMID:29875488 arfaptin-2 measurement efo:EFO_0801394 Quantification of arylamine N-acetyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 arylamine N-acetyltransferase 1 measurement efo:EFO_0801395 Quantification of arylsulfatase K in a sample. Elizabeth Lewis true PMID:29875488 arylsulfatase K measurement efo:EFO_0801396 Quantification of aspartyl/asparaginyl beta-hydroxylase in a sample. Elizabeth Lewis true PMID:29875488 aspartyl/asparaginyl beta-hydroxylase measurement efo:EFO_0801397 Quantification of asporin in a sample. Elizabeth Lewis true PMID:29875488 asporin measurement efo:EFO_0801398 Quantification of ATP-dependent RNA helicase DHX8 in a sample. Elizabeth Lewis true PMID:29875488 ATP-dependent RNA helicase DHX8 measurement efo:EFO_0801399 Quantification of augurin in a sample. Elizabeth Lewis true PMID:29875488 augurin measurement efo:EFO_0801400 Quantification of axin-2 in a sample. Elizabeth Lewis true PMID:29875488 axin-2 measurement efo:EFO_0801401 Quantification of b melanoma antigen 2 in a sample. Elizabeth Lewis true PMID:29875488 B melanoma antigen 2 measurement efo:EFO_0801402 Quantification of B-cell antigen receptor complex-associated protein alpha chain in a sample. Elizabeth Lewis true PMID:29875488 B-cell antigen receptor complex-associated protein alpha chain measurement efo:EFO_0801403 Quantification of B-cell lymphoma/leukemia 10 in a sample. Elizabeth Lewis true PMID:29875488 B-cell lymphoma/leukemia 10 measurement efo:EFO_0801404 Quantification of basic leucine zipper transcriptional factor ATF-like 3 in a sample. Elizabeth Lewis true PMID:29875488 basic leucine zipper transcriptional factor ATF-like 3 measurement efo:EFO_0801405 Quantification of basic salivary proline-rich protein 4 in a sample. Elizabeth Lewis true PMID:29875488 basic salivary proline-rich protein 4 measurement efo:EFO_0801406 Quantification of bcl10-interacting CARD protein in a sample. Elizabeth Lewis true PMID:29875488 bcl10-interacting CARD protein measurement efo:EFO_0801407 Quantification of beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 measurement efo:EFO_0801408 Quantification of beta-1,3-N-acetylglucosaminyltransferase radical fringe in a sample. Elizabeth Lewis true PMID:29875488 beta-1,3-N-acetylglucosaminyltransferase radical fringe measurement efo:EFO_0801409 Quantification of beta-1,4-galactosyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,4-galactosyltransferase 1 measurement efo:EFO_0801410 Quantification of beta-1,4-galactosyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,4-galactosyltransferase 2 measurement efo:EFO_0801411 Quantification of beta-1,4-galactosyltransferase 6 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,4-galactosyltransferase 6 measurement efo:EFO_0801412 Quantification of beta-1,4-glucuronyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,4-glucuronyltransferase 1 measurement efo:EFO_0801413 Quantification of beta-arrestin-1 in a sample. Elizabeth Lewis true PMID:29875488 beta-arrestin-1 measurement efo:EFO_0801414 Quantification of beta-crystallin B2 in a sample. Elizabeth Lewis true PMID:29875488 beta-crystallin B2 measurement efo:EFO_0801415 Quantification of beta-defensin 1 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 1 measurement efo:EFO_0801416 Quantification of beta-defensin 104 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 104 measurement efo:EFO_0801417 Quantification of beta-defensin 105 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 105 measurement efo:EFO_0801418 Quantification of beta-defensin 112 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 112 measurement efo:EFO_0801419 Quantification of beta-defensin 119 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 119 measurement efo:EFO_0801420 Quantification of beta-defensin 128 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 128 measurement efo:EFO_0801421 Quantification of beta-mannosidase in a sample. Elizabeth Lewis true PMID:29875488 beta-mannosidase measurement efo:EFO_0801422 Quantification of beta-sarcoglycan in a sample. Elizabeth Lewis true PMID:29875488 beta-sarcoglycan measurement efo:EFO_0801423 Quantification of beta-soluble NSF attachment protein in a sample. Elizabeth Lewis true PMID:29875488 beta-soluble NSF attachment protein measurement efo:EFO_0801424 Quantification of bifunctional polynucleotide phosphatase/kinase in a sample. Elizabeth Lewis true PMID:29875488 bifunctional polynucleotide phosphatase/kinase measurement efo:EFO_0801425 Quantification of bile salt-activated lipase in a sample. Elizabeth Lewis true PMID:29875488 bile salt-activated lipase measurement efo:EFO_0801426 Quantification of biliverdin reductase A in a sample. Elizabeth Lewis true PMID:29875488 biliverdin reductase A measurement efo:EFO_0801427 Quantification of bis(5'-adenosyl)-triphosphatase in a sample. Elizabeth Lewis true PMID:29875488 bis(5'-adenosyl)-triphosphatase measurement efo:EFO_0801428 Quantification of bombesin receptor-activated protein C6orf89 in a sample. Elizabeth Lewis true PMID:29875488 bombesin receptor-activated protein C6orf89 measurement efo:EFO_0801429 Quantification of BPI fold-containing family B member 1 in a sample. Elizabeth Lewis true PMID:29875488 BPI fold-containing family B member 1 measurement efo:EFO_0801430 Quantification of BRICHOS domain-containing protein 5 in a sample. Elizabeth Lewis true PMID:29875488 BRICHOS domain-containing protein 5 measurement efo:EFO_0801431 Quantification of bromodomain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 bromodomain-containing protein 1 measurement efo:EFO_0801432 Quantification of brorin in a sample. Elizabeth Lewis true PMID:29875488 brorin measurement efo:EFO_0801433 Quantification of C-type lectin domain family 12 member A in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 12 member A measurement efo:EFO_0801434 Quantification of C-type lectin domain family 2 member D in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 2 member D measurement efo:EFO_0801435 Quantification of C-type lectin domain family 4 member E in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 4 member E measurement efo:EFO_0801436 Quantification of C-type lectin domain family 5 member A in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 5 member A measurement efo:EFO_0801437 Quantification of C1GALT1-specific chaperone 1 in a sample. Elizabeth Lewis true PMID:29875488 C1GALT1-specific chaperone 1 measurement efo:EFO_0801438 Quantification of cadherin-7 in a sample. Elizabeth Lewis true PMID:29875488 cadherin-7 measurement efo:EFO_0801439 Quantification of cadherin-related family member 1 in a sample. Elizabeth Lewis true PMID:29875488 cadherin-related family member 1 measurement efo:EFO_0801440 Quantification of cadherin-related family member 5 in a sample. Elizabeth Lewis true PMID:29875488 cadherin-related family member 5 measurement efo:EFO_0801441 Quantification of calbindin in a sample. Elizabeth Lewis true PMID:29875488 calbindin measurement efo:EFO_0801442 Quantification of calcipressin-1 in a sample. Elizabeth Lewis true PMID:29875488 calcipressin-1 measurement efo:EFO_0801443 Quantification of calcyclin-binding protein in a sample. Elizabeth Lewis true PMID:29875488 calcyclin-binding protein measurement efo:EFO_0801444 Quantification of calnexin in a sample. Elizabeth Lewis true PMID:29875488 calnexin measurement efo:EFO_0801445 Quantification of calpain-2 catalytic subunit in a sample. Elizabeth Lewis true PMID:29875488 calpain-2 catalytic subunit measurement efo:EFO_0801446 Quantification of cAMP-dependent protein kinase type I-beta regulatory subunit in a sample. Elizabeth Lewis true PMID:29875488 cAMP-dependent protein kinase type I-beta regulatory subunit measurement efo:EFO_0801447 Quantification of carbohydrate sulfotransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 carbohydrate sulfotransferase 1 measurement efo:EFO_0801448 Quantification of carbohydrate sulfotransferase 11 in a sample. Elizabeth Lewis true PMID:29875488 carbohydrate sulfotransferase 11 measurement efo:EFO_0801449 Quantification of carbohydrate sulfotransferase 9 in a sample. Elizabeth Lewis true PMID:29875488 carbohydrate sulfotransferase 9 measurement efo:EFO_0801450 Quantification of carbonic anhydrase 5A, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 carbonic anhydrase 5A, mitochondrial measurement efo:EFO_0801451 Quantification of carboxypeptidase A2 in a sample. Elizabeth Lewis true PMID:29875488 carboxypeptidase A2 measurement efo:EFO_0801452 Quantification of carboxypeptidase A4 in a sample. Elizabeth Lewis true PMID:29875488 carboxypeptidase A4 measurement efo:EFO_0801453 Quantification of carboxypeptidase B in a sample. Elizabeth Lewis true PMID:29875488 carboxypeptidase B measurement efo:EFO_0801454 Quantification of carboxypeptidase M in a sample. Elizabeth Lewis true PMID:29875488 carboxypeptidase M measurement efo:EFO_0801455 Quantification of carboxypeptidase Z in a sample. Elizabeth Lewis true PMID:29875488 carboxypeptidase Z measurement efo:EFO_0801456 Quantification of carcinoembryonic antigen-related cell adhesion molecule 1 in a sample. Elizabeth Lewis true PMID:29875488 carcinoembryonic antigen-related cell adhesion molecule 1 measurement efo:EFO_0801457 Quantification of cartilage intermediate layer protein 1 in a sample. Elizabeth Lewis true PMID:29875488 cartilage intermediate layer protein 1 measurement efo:EFO_0801458 Quantification of casein kinase I isoform gamma-2 in a sample. Elizabeth Lewis true PMID:29875488 casein kinase I isoform gamma-2 measurement efo:EFO_0801459 Quantification of cation-dependent mannose-6-phosphate receptor in a sample. Elizabeth Lewis true PMID:29875488 cation-dependent mannose-6-phosphate receptor measurement efo:EFO_0801460 Quantification of CDGSH iron-sulfur domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 CDGSH iron-sulfur domain-containing protein 1 measurement efo:EFO_0801461 Quantification of cell growth regulator with EF hand domain protein 1 in a sample. Elizabeth Lewis true PMID:29875488 cell growth regulator with EF hand domain protein 1 measurement efo:EFO_0801462 Quantification of cell surface glycoprotein CD200 receptor 2 in a sample. Elizabeth Lewis true PMID:29875488 cell surface glycoprotein CD200 receptor 2 measurement efo:EFO_0801463 Quantification of cellular retinoic acid-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 cellular retinoic acid-binding protein 1 measurement efo:EFO_0801464 Quantification of centrin-2 in a sample. Elizabeth Lewis true PMID:29875488 centrin-2 measurement efo:EFO_0801465 Quantification of centrosomal protein of 57 kDa in a sample. Elizabeth Lewis true PMID:29875488 centrosomal protein of 57 kDa measurement efo:EFO_0801466 Quantification of cerebellin-1 in a sample. Elizabeth Lewis true PMID:29875488 cerebellin-1 measurement efo:EFO_0801467 Quantification of cerebellin-4 in a sample. Elizabeth Lewis true PMID:29875488 cerebellin-4 measurement efo:EFO_0801468 Quantification of cGMP-dependent protein kinase 1, beta isozyme in a sample. Elizabeth Lewis true PMID:29875488 cGMP-dependent protein kinase 1, beta isozyme measurement efo:EFO_0801469 Quantification of charged multivesicular body protein 3 in a sample. Elizabeth Lewis true PMID:29875488 charged multivesicular body protein 3 measurement efo:EFO_0801470 Quantification of chitinase-3-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 chitinase-3-like protein 1 measurement efo:EFO_0801471 Quantification of chitinase-3-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 chitinase-3-like protein 2 measurement efo:EFO_0801472 Quantification of chloride intracellular channel protein 5 in a sample. Elizabeth Lewis true PMID:29875488 chloride intracellular channel protein 5 measurement efo:EFO_0801473 Quantification of chondroitin sulfate N-acetylgalactosaminyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 chondroitin sulfate N-acetylgalactosaminyltransferase 2 measurement efo:EFO_0801474 Quantification of chordin-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 chordin-like protein 2 measurement efo:EFO_0801475 Quantification of chromobox protein homolog 7 in a sample. Elizabeth Lewis true PMID:29875488 chromobox protein homolog 7 measurement efo:EFO_0801476 Quantification of chymotrypsin-like protease CTRL-1 in a sample. Elizabeth Lewis true PMID:29875488 chymotrypsin-like protease CTRL-1 measurement efo:EFO_0801477 Quantification of chymotrypsinogen B in a sample. Elizabeth Lewis true PMID:29875488 chymotrypsinogen B measurement efo:EFO_0801478 Quantification of clathrin interactor 1 in a sample. Elizabeth Lewis true PMID:29875488 clathrin interactor 1 measurement efo:EFO_0801479 Quantification of CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 measurement efo:EFO_0801480 Quantification of CMRF35-like molecule 8 in a sample. Elizabeth Lewis true PMID:29875488 CMRF35-like molecule 8 measurement efo:EFO_0801481 Quantification of cochlin in a sample. Elizabeth Lewis true PMID:29875488 cochlin measurement efo:EFO_0801482 Quantification of coiled-coil domain-containing protein 126 in a sample. Elizabeth Lewis true PMID:29875488 coiled-coil domain-containing protein 126 measurement efo:EFO_0801483 Quantification of coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial measurement efo:EFO_0801484 Quantification of cold-inducible RNA-binding protein in a sample. Elizabeth Lewis true PMID:29875488 cold-inducible RNA-binding protein measurement efo:EFO_0801485 Quantification of colipase in a sample. Elizabeth Lewis true PMID:29875488 colipase measurement efo:EFO_0801486 Quantification of collagen alpha-1(I) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-1(I) chain measurement efo:EFO_0801487 Quantification of collagen alpha-1(VI) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-1(VI) chain measurement efo:EFO_0801488 Quantification of collagen alpha-1(XV) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-1(XV) chain measurement efo:EFO_0801489 Quantification of collagen alpha-2(IX) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-2(IX) chain measurement efo:EFO_0801490 Quantification of collagen alpha-2(XI) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-2(XI) chain measurement efo:EFO_0801491 Quantification of collectin-10 in a sample. Elizabeth Lewis true PMID:29875488 collectin-10 measurement efo:EFO_0801492 Quantification of complement C1q subcomponent subunit C in a sample. Elizabeth Lewis true PMID:29875488 complement C1q subcomponent subunit C measurement efo:EFO_0801493 Quantification of complement C1q tumor necrosis factor-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 complement C1q tumor necrosis factor-related protein 1 measurement efo:EFO_0801494 Quantification of complement C1q tumor necrosis factor-related protein 5 in a sample. Elizabeth Lewis true PMID:29875488 complement C1q tumor necrosis factor-related protein 5 measurement efo:EFO_0801495 Quantification of complement C1r subcomponent-like protein in a sample. Elizabeth Lewis true PMID:29875488 complement C1r subcomponent-like protein measurement efo:EFO_0801496 Quantification of contactin-associated protein-like 2 in a sample. Elizabeth Lewis true PMID:29875488 contactin-associated protein-like 2 measurement efo:EFO_0801497 Quantification of COP9 signalosome complex subunit 2 in a sample. Elizabeth Lewis true PMID:29875488 COP9 signalosome complex subunit 2 measurement efo:EFO_0801498 Quantification of core-binding factor subunit beta in a sample. Elizabeth Lewis true PMID:29875488 core-binding factor subunit beta measurement efo:EFO_0801499 Quantification of corneodesmosin in a sample. Elizabeth Lewis true PMID:29875488 corneodesmosin measurement efo:EFO_0801500 Quantification of cortexin-3 in a sample. Elizabeth Lewis true PMID:29875488 cortexin-3 measurement efo:EFO_0801501 Quantification of corticotropin-releasing factor-binding protein in a sample. Elizabeth Lewis true PMID:29875488 corticotropin-releasing factor-binding protein measurement efo:EFO_0801502 Quantification of CREB-binding protein in a sample. Elizabeth Lewis true PMID:29875488 CREB-binding protein measurement efo:EFO_0801503 Quantification of CRK-like protein in a sample. Elizabeth Lewis true PMID:29875488 CRK-like protein measurement efo:EFO_0801504 Quantification of CXADR-like membrane protein in a sample. Elizabeth Lewis true PMID:29875488 CXADR-like membrane protein measurement efo:EFO_0801505 Quantification of cyclic AMP-dependent transcription factor ATF-6 alpha in a sample. Elizabeth Lewis true PMID:29875488 cyclic AMP-dependent transcription factor ATF-6 alpha measurement efo:EFO_0801506 Quantification of cyclic AMP-responsive element-binding protein 3-like protein 4 in a sample. Elizabeth Lewis true PMID:29875488 cyclic AMP-responsive element-binding protein 3-like protein 4 measurement efo:EFO_0801507 Quantification of cyclin-C in a sample. Elizabeth Lewis true PMID:29875488 cyclin-C measurement efo:EFO_0801508 Quantification of cyclin-H in a sample. Elizabeth Lewis true PMID:29875488 cyclin-H measurement efo:EFO_0801509 Quantification of cystatin-8 in a sample. Elizabeth Lewis true PMID:29875488 cystatin-8 measurement efo:EFO_0801510 Quantification of cysteine-rich hydrophobic domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 cysteine-rich hydrophobic domain-containing protein 2 measurement efo:EFO_0801511 Quantification of cysteine-rich secretory protein 2 in a sample. Elizabeth Lewis true PMID:29875488 cysteine-rich secretory protein 2 measurement efo:EFO_0801512 Quantification of cysteine-rich secretory protein LCCL domain-containing 2 in a sample. Elizabeth Lewis true PMID:29875488 cysteine-rich secretory protein LCCL domain-containing 2 measurement efo:EFO_0801513 Quantification of cytochrome c oxidase assembly factor 3 homolog, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 cytochrome c oxidase assembly factor 3 homolog, mitochondrial measurement efo:EFO_0801514 Quantification of cytochrome c oxidase subunit 4 isoform 2, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 cytochrome c oxidase subunit 4 isoform 2, mitochondrial measurement efo:EFO_0801515 Quantification of cytochrome c oxidase subunit 6C in a sample. Elizabeth Lewis true PMID:29875488 cytochrome c oxidase subunit 6C measurement efo:EFO_0801516 Quantification of cytochrome c oxidase subunit 8A, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 cytochrome c oxidase subunit 8A, mitochondrial measurement efo:EFO_0801517 Quantification of cytohesin-2 in a sample. Elizabeth Lewis true PMID:29875488 cytohesin-2 measurement efo:EFO_0801518 Quantification of cytokine receptor common subunit beta in a sample. Elizabeth Lewis true PMID:29875488 cytokine receptor common subunit beta measurement efo:EFO_0801519 Quantification of D-glucuronyl C5-epimerase in a sample. Elizabeth Lewis true PMID:29875488 D-glucuronyl C5-epimerase measurement efo:EFO_0801520 Quantification of DCN1-like protein 5 in a sample. Elizabeth Lewis true PMID:29875488 DCN1-like protein 5 measurement efo:EFO_0801521 Quantification of dedicator of cytokinesis protein 9 in a sample. Elizabeth Lewis true PMID:29875488 dedicator of cytokinesis protein 9 measurement efo:EFO_0801522 Quantification of deformed epidermal autoregulatory factor 1 homolog in a sample. Elizabeth Lewis true PMID:29875488 deformed epidermal autoregulatory factor 1 homolog measurement efo:EFO_0801523 Quantification of deoxycytidine kinase in a sample. Elizabeth Lewis true PMID:29875488 deoxycytidine kinase measurement efo:EFO_0801524 Quantification of di-N-acetylchitobiase in a sample. Elizabeth Lewis true PMID:29875488 di-N-acetylchitobiase measurement efo:EFO_0801525 Quantification of diacylglycerol kinase beta in a sample. Elizabeth Lewis true PMID:29875488 diacylglycerol kinase beta measurement efo:EFO_0801526 Quantification of dihydrofolate reductase in a sample. Elizabeth Lewis true PMID:29875488 dihydrofolate reductase measurement efo:EFO_0801527 Quantification of dihydropteridine reductase in a sample. Elizabeth Lewis true PMID:29875488 dihydropteridine reductase measurement efo:EFO_0801528 Quantification of dipeptidase 2 in a sample. Elizabeth Lewis true PMID:29875488 dipeptidase 2 measurement efo:EFO_0801529 Quantification of disintegrin and metalloproteinase domain-containing protein 11 in a sample. Elizabeth Lewis true PMID:29875488 disintegrin and metalloproteinase domain-containing protein 11 measurement efo:EFO_0801530 Quantification of disintegrin and metalloproteinase domain-containing protein 23 in a sample. Elizabeth Lewis true PMID:29875488 disintegrin and metalloproteinase domain-containing protein 23 measurement efo:EFO_0801531 Quantification of DNA repair protein RAD51 homolog 4 in a sample. Elizabeth Lewis true PMID:29875488 DNA repair protein RAD51 homolog 4 measurement efo:EFO_0801532 Quantification of DNA repair protein XRCC4 in a sample. Elizabeth Lewis true PMID:29875488 DNA repair protein XRCC4 measurement efo:EFO_0801533 Quantification of DNA-(apurinic or apyrimidinic site) lyase in a sample. Elizabeth Lewis true PMID:29875488 DNA-(apurinic or apyrimidinic site) lyase measurement efo:EFO_0801534 Quantification of DNA-3-methyladenine glycosylase in a sample. Elizabeth Lewis true PMID:29875488 DNA-3-methyladenine glycosylase measurement efo:EFO_0801535 Quantification of DNA-directed RNA polymerases I and III subunit RPAC1 in a sample. Elizabeth Lewis true PMID:29875488 DNA-directed RNA polymerases I and III subunit RPAC1 measurement efo:EFO_0801536 Quantification of DNA/RNA-binding protein KIN17 in a sample. Elizabeth Lewis true PMID:29875488 DNA/RNA-binding protein KIN17 measurement efo:EFO_0801537 Quantification of DnaJ homolog subfamily B member 11 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily B member 11 measurement efo:EFO_0801538 Quantification of DnaJ homolog subfamily B member 14 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily B member 14 measurement efo:EFO_0801539 Quantification of DnaJ homolog subfamily B member 2 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily B member 2 measurement efo:EFO_0801540 Quantification of DnaJ homolog subfamily B member 9 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily B member 9 measurement efo:EFO_0801541 Quantification of DnaJ homolog subfamily C member 17 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily C member 17 measurement efo:EFO_0801542 Quantification of DnaJ homolog subfamily C member 30 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily C member 30 measurement efo:EFO_0801543 Quantification of docking protein 2 in a sample. Elizabeth Lewis true PMID:29875488 docking protein 2 measurement efo:EFO_0801544 Quantification of dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 in a sample. Elizabeth Lewis true PMID:29875488 dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 measurement efo:EFO_0801545 Quantification of dorsal root ganglia homeobox protein in a sample. Elizabeth Lewis true PMID:29875488 dorsal root ganglia homeobox protein measurement efo:EFO_0801546 Quantification of double-stranded RNA-binding protein Staufen homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 double-stranded RNA-binding protein Staufen homolog 1 measurement efo:EFO_0801547 Quantification of double-stranded RNA-binding protein Staufen homolog 2 in a sample. Elizabeth Lewis true PMID:29875488 double-stranded RNA-binding protein Staufen homolog 2 measurement efo:EFO_0801548 Quantification of dual specificity protein kinase CLK2 in a sample. Elizabeth Lewis true PMID:29875488 dual specificity protein kinase CLK2 measurement efo:EFO_0801549 Quantification of dual specificity protein phosphatase 13 isoform A in a sample. Elizabeth Lewis true PMID:29875488 dual specificity protein phosphatase 13 isoform A measurement efo:EFO_0801550 Quantification of dual specificity protein phosphatase 4 in a sample. Elizabeth Lewis true PMID:29875488 dual specificity protein phosphatase 4 measurement efo:EFO_0801551 Quantification of dynactin-associated protein in a sample. Elizabeth Lewis true PMID:29875488 dynactin-associated protein measurement efo:EFO_0801552 Quantification of E3 ubiquitin-protein ligase CBL in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase CBL measurement efo:EFO_0801553 Quantification of E3 ubiquitin-protein ligase DTX3L in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase DTX3L measurement efo:EFO_0801554 Quantification of E3 ubiquitin-protein ligase NEURL1 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase NEURL1 measurement efo:EFO_0801555 Quantification of E3 ubiquitin-protein ligase RNF128 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase RNF128 measurement efo:EFO_0801556 Quantification of E3 ubiquitin-protein ligase RNF13 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase RNF13 measurement efo:EFO_0801557 Quantification of E3 ubiquitin-protein ligase RNF8 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase RNF8 measurement efo:EFO_0801558 Quantification of ecto-ADP-ribosyltransferase 3 in a sample. Elizabeth Lewis true PMID:29875488 ecto-ADP-ribosyltransferase 3 measurement efo:EFO_0801559 Quantification of ecto-ADP-ribosyltransferase 4 in a sample. Elizabeth Lewis true PMID:29875488 ecto-ADP-ribosyltransferase 4 measurement efo:EFO_0801560 Quantification of ectonucleotide pyrophosphatase/phosphodiesterase family member 5 in a sample. Elizabeth Lewis true PMID:29875488 ectonucleotide pyrophosphatase/phosphodiesterase family member 5 measurement efo:EFO_0801561 Quantification of EH domain-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 EH domain-binding protein 1 measurement efo:EFO_0801562 Quantification of ELAV-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 ELAV-like protein 1 measurement efo:EFO_0801563 Quantification of EMILIN-3 in a sample. Elizabeth Lewis true PMID:29875488 EMILIN-3 measurement efo:EFO_0801564 Quantification of Ena/VASP-like protein in a sample. Elizabeth Lewis true PMID:29875488 Ena/VASP-like protein measurement efo:EFO_0801565 Quantification of endogenous retrovirus group V member 1 Env polyprotein in a sample. Elizabeth Lewis true PMID:29875488 endogenous retrovirus group V member 1 Env polyprotein measurement efo:EFO_0801566 Quantification of endoplasmic reticulum aminopeptidase 2 in a sample. Elizabeth Lewis true PMID:29875488 endoplasmic reticulum aminopeptidase 2 measurement efo:EFO_0801567 Quantification of endoplasmic reticulum lectin 1 in a sample. Elizabeth Lewis true PMID:29875488 endoplasmic reticulum lectin 1 measurement efo:EFO_0801568 Quantification of endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase in a sample. Elizabeth Lewis true PMID:29875488 endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase measurement efo:EFO_0801569 Quantification of endoplasmic reticulum resident protein 44 in a sample. Elizabeth Lewis true PMID:29875488 endoplasmic reticulum resident protein 44 measurement efo:EFO_0801570 Quantification of endoplasmin in a sample. Elizabeth Lewis true PMID:29875488 endoplasmin measurement efo:EFO_0801571 Quantification of endothelial differentiation-related factor 1 in a sample. Elizabeth Lewis true PMID:29875488 endothelial differentiation-related factor 1 measurement efo:EFO_0801572 Quantification of endothelin-2 in a sample. Elizabeth Lewis true PMID:29875488 endothelin-2 measurement efo:EFO_0801573 Quantification of enhancer of rudimentary homolog in a sample. Elizabeth Lewis true PMID:29875488 enhancer of rudimentary homolog measurement efo:EFO_0801574 Quantification of ephrin type-B receptor 3 in a sample. Elizabeth Lewis true PMID:29875488 ephrin type-B receptor 3 measurement efo:EFO_0801575 Quantification of epididymal secretory protein E1 in a sample. Elizabeth Lewis true PMID:29875488 epididymal secretory protein E1 measurement efo:EFO_0801576 Quantification of epididymal-specific lipocalin-10 in a sample. Elizabeth Lewis true PMID:29875488 epididymal-specific lipocalin-10 measurement efo:EFO_0801577 Quantification of epididymis-specific alpha-mannosidase in a sample. Elizabeth Lewis true PMID:29875488 epididymis-specific alpha-mannosidase measurement efo:EFO_0801578 Quantification of epiphycan in a sample. Elizabeth Lewis true PMID:29875488 epiphycan measurement efo:EFO_0801579 Quantification of ER membrane protein complex subunit 1 in a sample. Elizabeth Lewis true PMID:29875488 ER membrane protein complex subunit 1 measurement efo:EFO_0801580 Quantification of ER membrane protein complex subunit 4 in a sample. Elizabeth Lewis true PMID:29875488 ER membrane protein complex subunit 4 measurement efo:EFO_0801581 Quantification of erlin-1 in a sample. Elizabeth Lewis true PMID:29875488 erlin-1 measurement efo:EFO_0801582 Quantification of ERO1-like protein alpha in a sample. Elizabeth Lewis true PMID:29875488 ERO1-like protein alpha measurement efo:EFO_0801583 Quantification of ERO1-like protein beta in a sample. Elizabeth Lewis true PMID:29875488 ERO1-like protein beta measurement efo:EFO_0801584 Quantification of erythrocyte band 7 integral membrane protein in a sample. Elizabeth Lewis true PMID:29875488 erythrocyte band 7 integral membrane protein measurement efo:EFO_0801585 Quantification of erythroid membrane-associated protein in a sample. Elizabeth Lewis true PMID:29875488 erythroid membrane-associated protein measurement efo:EFO_0801586 Quantification of estrogen sulfotransferase in a sample. Elizabeth Lewis true PMID:29875488 estrogen sulfotransferase measurement efo:EFO_0801587 Quantification of ETS domain-containing protein Elk-1 in a sample. Elizabeth Lewis true PMID:29875488 ETS domain-containing protein Elk-1 measurement efo:EFO_0801588 Quantification of ETS domain-containing protein Elk-3 in a sample. Elizabeth Lewis true PMID:29875488 ETS domain-containing protein Elk-3 measurement efo:EFO_0801589 Quantification of eukaryotic translation initiation factor 1A, X-chromosomal in a sample. Elizabeth Lewis true PMID:29875488 eukaryotic translation initiation factor 1A, X-chromosomal measurement efo:EFO_0801590 Quantification of eukaryotic translation initiation factor 3 subunit G in a sample. Elizabeth Lewis true PMID:29875488 eukaryotic translation initiation factor 3 subunit G measurement efo:EFO_0801591 Quantification of eukaryotic translation initiation factor 3 subunit J in a sample. Elizabeth Lewis true PMID:29875488 eukaryotic translation initiation factor 3 subunit J measurement efo:EFO_0801592 Quantification of eukaryotic translation initiation factor 4B in a sample. Elizabeth Lewis true PMID:29875488 eukaryotic translation initiation factor 4B measurement efo:EFO_0801593 Quantification of eukaryotic translation initiation factor 4E type 2 in a sample. Elizabeth Lewis true PMID:29875488 eukaryotic translation initiation factor 4E type 2 measurement efo:EFO_0801594 Quantification of exosome complex component RRP40 in a sample. Elizabeth Lewis true PMID:29875488 exosome complex component RRP40 measurement efo:EFO_0801595 Quantification of exostosin-like 2 in a sample. Elizabeth Lewis true PMID:29875488 exostosin-like 2 measurement efo:EFO_0801596 Quantification of extracellular sulfatase Sulf-2 in a sample. Elizabeth Lewis true PMID:29875488 extracellular sulfatase Sulf-2 measurement efo:EFO_0801597 Quantification of ezrin in a sample. Elizabeth Lewis true PMID:29875488 ezrin measurement efo:EFO_0801598 Quantification of Fc receptor-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 Fc receptor-like protein 1 measurement efo:EFO_0801599 Quantification of Fc receptor-like protein 4 in a sample. Elizabeth Lewis true PMID:29875488 Fc receptor-like protein 4 measurement efo:EFO_0801600 Quantification of Fc receptor-like protein 6 in a sample. Elizabeth Lewis true PMID:29875488 Fc receptor-like protein 6 measurement efo:EFO_0801601 Quantification of fibronectin type III domain-containing protein 5 in a sample. Elizabeth Lewis true PMID:29875488 fibronectin type III domain-containing protein 5 measurement efo:EFO_0801602 Quantification of filamin-A in a sample. Elizabeth Lewis true PMID:29875488 filamin-A measurement efo:EFO_0801603 Quantification of follistatin-related protein 4 in a sample. Elizabeth Lewis true PMID:29875488 follistatin-related protein 4 measurement efo:EFO_0801604 Quantification of forkhead box protein J2 in a sample. Elizabeth Lewis true PMID:29875488 forkhead box protein J2 measurement efo:EFO_0801605 Quantification of four-jointed box protein 1 in a sample. Elizabeth Lewis true PMID:29875488 four-jointed box protein 1 measurement efo:EFO_0801606 Quantification of fructose-1,6-bisphosphatase 1 in a sample. Elizabeth Lewis true PMID:29875488 fructose-1,6-bisphosphatase 1 measurement efo:EFO_0801607 Quantification of fructose-2,6-bisphosphatase TIGAR in a sample. Elizabeth Lewis true PMID:29875488 fructose-2,6-bisphosphatase TIGAR measurement efo:EFO_0801608 Quantification of fructose-bisphosphate aldolase A in a sample. Elizabeth Lewis true PMID:29875488 fructose-bisphosphate aldolase A measurement efo:EFO_0801609 Quantification of fumarylacetoacetase in a sample. Elizabeth Lewis true PMID:29875488 fumarylacetoacetase measurement efo:EFO_0801610 Quantification of furin in a sample. Elizabeth Lewis true PMID:29875488 furin measurement efo:EFO_0801611 Quantification of galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 in a sample. Elizabeth Lewis true PMID:29875488 galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 measurement efo:EFO_0801612 Quantification of galanin-like peptide in a sample. Elizabeth Lewis true PMID:29875488 galanin-like peptide measurement efo:EFO_0801613 Quantification of gamma-aminobutyric acid receptor-associated protein-like 1 in a sample. Elizabeth Lewis true PMID:29875488 gamma-aminobutyric acid receptor-associated protein-like 1 measurement efo:EFO_0801614 Quantification of gamma-aminobutyric acid receptor-associated protein-like 2 in a sample. Elizabeth Lewis true PMID:29875488 gamma-aminobutyric acid receptor-associated protein-like 2 measurement efo:EFO_0801615 Quantification of gamma-aminobutyric acid type B receptor subunit 2 in a sample. Elizabeth Lewis true PMID:29875488 gamma-aminobutyric acid type B receptor subunit 2 measurement efo:EFO_0801616 Quantification of gamma-glutamyl hydrolase in a sample. Elizabeth Lewis true PMID:29875488 gamma-glutamyl hydrolase measurement efo:EFO_0801617 Quantification of gamma-interferon-inducible protein 16 in a sample. Elizabeth Lewis true PMID:29875488 gamma-interferon-inducible protein 16 measurement efo:EFO_0801618 Quantification of gap junction alpha-1 protein in a sample. Elizabeth Lewis true PMID:29875488 gap junction alpha-1 protein measurement efo:EFO_0801619 Quantification of GDH/6PGL endoplasmic bifunctional protein in a sample. Elizabeth Lewis true PMID:29875488 GDH/6PGL endoplasmic bifunctional protein measurement efo:EFO_0801620 Quantification of GDNF family receptor alpha-like in a sample. Elizabeth Lewis true PMID:29875488 GDNF family receptor alpha-like measurement efo:EFO_0801621 Quantification of GDP-fucose protein O-fucosyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 GDP-fucose protein O-fucosyltransferase 1 measurement efo:EFO_0801622 Quantification of GDP-fucose protein O-fucosyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 GDP-fucose protein O-fucosyltransferase 2 measurement efo:EFO_0801623 Quantification of general transcription factor II-I in a sample. Elizabeth Lewis true PMID:29875488 general transcription factor II-I measurement efo:EFO_0801624 Quantification of glia maturation factor gamma in a sample. Elizabeth Lewis true PMID:29875488 glia maturation factor gamma measurement efo:EFO_0801625 Quantification of glucokinase in a sample. Elizabeth Lewis true PMID:29875488 glucokinase measurement efo:EFO_0801626 Quantification of glucosamine 6-phosphate N-acetyltransferase in a sample. Elizabeth Lewis true PMID:29875488 glucosamine 6-phosphate N-acetyltransferase measurement efo:EFO_0801627 Quantification of glucosamine-6-phosphate isomerase 1 in a sample. Elizabeth Lewis true PMID:29875488 glucosamine-6-phosphate isomerase 1 measurement efo:EFO_0801628 Quantification of glucosidase 2 subunit beta in a sample. Elizabeth Lewis true PMID:29875488 glucosidase 2 subunit beta measurement efo:EFO_0801629 Quantification of glucoside xylosyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 glucoside xylosyltransferase 1 measurement efo:EFO_0801630 Quantification of glutamate receptor 4 in a sample. Elizabeth Lewis true PMID:29875488 glutamate receptor 4 measurement efo:EFO_0801631 Quantification of glutamate receptor ionotropic, delta-2 in a sample. Elizabeth Lewis true PMID:29875488 glutamate receptor ionotropic, delta-2 measurement efo:EFO_0801632 Quantification of glutaminyl-peptide cyclotransferase-like protein in a sample. Elizabeth Lewis true PMID:29875488 glutaminyl-peptide cyclotransferase-like protein measurement efo:EFO_0801633 Quantification of glutaredoxin-2, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 glutaredoxin-2, mitochondrial measurement efo:EFO_0801634 Quantification of glutaredoxin-like protein C5orf63 in a sample. Elizabeth Lewis true PMID:29875488 glutaredoxin-like protein C5orf63 measurement efo:EFO_0801635 Quantification of glutathione peroxidase 7 in a sample. Elizabeth Lewis true PMID:29875488 glutathione peroxidase 7 measurement efo:EFO_0801636 Quantification of glutathione S-transferase A1 in a sample. Elizabeth Lewis true PMID:29875488 glutathione S-transferase A1 measurement efo:EFO_0801637 Quantification of glutathione S-transferase A4 in a sample. Elizabeth Lewis true PMID:29875488 glutathione S-transferase A4 measurement efo:EFO_0801638 Quantification of glutathione S-transferase Mu 1 in a sample. Elizabeth Lewis true PMID:29875488 glutathione S-transferase Mu 1 measurement efo:EFO_0801639 Quantification of glutathione S-transferase omega-1 in a sample. Elizabeth Lewis true PMID:29875488 glutathione S-transferase omega-1 measurement efo:EFO_0801640 Quantification of glycerol-3-phosphate dehydrogenase 1-like protein in a sample. Elizabeth Lewis true PMID:29875488 glycerol-3-phosphate dehydrogenase 1-like protein measurement efo:EFO_0801641 Quantification of glycine N-methyltransferase in a sample. Elizabeth Lewis true PMID:29875488 glycine N-methyltransferase measurement efo:EFO_0801642 Quantification of glycogen phosphorylase, liver form in a sample. Elizabeth Lewis true PMID:29875488 glycogen phosphorylase, liver form measurement efo:EFO_0801643 Quantification of glycolipid transfer protein domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 glycolipid transfer protein domain-containing protein 2 measurement efo:EFO_0801644 Quantification of glycoprotein endo-alpha-1,2-mannosidase in a sample. Elizabeth Lewis true PMID:29875488 glycoprotein endo-alpha-1,2-mannosidase measurement efo:EFO_0801645 Quantification of glycoprotein hormone alpha-2 in a sample. Elizabeth Lewis true PMID:29875488 glycoprotein hormone alpha-2 measurement efo:EFO_0801646 Quantification of glycoprotein Xg in a sample. Elizabeth Lewis true PMID:29875488 glycoprotein Xg measurement efo:EFO_0801647 Quantification of glycosaminoglycan xylosylkinase in a sample. Elizabeth Lewis true PMID:29875488 glycosaminoglycan xylosylkinase measurement efo:EFO_0801648 Quantification of glycosyltransferase 8 domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 glycosyltransferase 8 domain-containing protein 1 measurement efo:EFO_0801649 Quantification of glypican-1 in a sample. Elizabeth Lewis true PMID:29875488 glypican-1 measurement efo:EFO_0801650 Quantification of Golgi membrane protein 1 in a sample. Elizabeth Lewis true PMID:29875488 Golgi membrane protein 1 measurement efo:EFO_0801651 Quantification of Golgi SNAP receptor complex member 1 in a sample. Elizabeth Lewis true PMID:29875488 Golgi SNAP receptor complex member 1 measurement efo:EFO_0801652 Quantification of GRAM domain-containing protein 1C in a sample. Elizabeth Lewis true PMID:29875488 GRAM domain-containing protein 1C measurement efo:EFO_0801653 Quantification of grancalcin in a sample. Elizabeth Lewis true PMID:29875488 grancalcin measurement efo:EFO_0801654 Quantification of granzyme K in a sample. Elizabeth Lewis true PMID:29875488 granzyme K measurement efo:EFO_0801655 Quantification of granzyme M in a sample. Elizabeth Lewis true PMID:29875488 granzyme M measurement efo:EFO_0801656 Quantification of gremlin-2 in a sample. Elizabeth Lewis true PMID:29875488 gremlin-2 measurement efo:EFO_0801657 Quantification of group XIIB secretory phospholipase A2-like protein in a sample. Elizabeth Lewis true PMID:29875488 group XIIB secretory phospholipase A2-like protein measurement efo:EFO_0801658 Quantification of growth factor receptor-bound protein 14 in a sample. Elizabeth Lewis true PMID:29875488 growth factor receptor-bound protein 14 measurement efo:EFO_0801659 Quantification of growth factor receptor-bound protein 7 in a sample. Elizabeth Lewis true PMID:29875488 growth factor receptor-bound protein 7 measurement efo:EFO_0801660 Quantification of GTP-binding protein GEM in a sample. Elizabeth Lewis true PMID:29875488 GTP-binding protein GEM measurement efo:EFO_0801661 Quantification of guanine nucleotide-binding protein G(k) subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 guanine nucleotide-binding protein G(k) subunit alpha measurement efo:EFO_0801662 Quantification of guanylate-binding protein 6 in a sample. Elizabeth Lewis true PMID:29875488 guanylate-binding protein 6 measurement efo:EFO_0801663 Quantification of guanylyl cyclase-activating protein 1 in a sample. Elizabeth Lewis true PMID:29875488 guanylyl cyclase-activating protein 1 measurement efo:EFO_0801664 Quantification of haloacid dehalogenase-like hydrolase domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 haloacid dehalogenase-like hydrolase domain-containing protein 2 measurement efo:EFO_0801665 Quantification of heat shock 70 kDa protein 1-like in a sample. Elizabeth Lewis true PMID:29875488 heat shock 70 kDa protein 1-like measurement efo:EFO_0801666 Quantification of heat shock 70 kDa protein 6 in a sample. Elizabeth Lewis true PMID:29875488 heat shock 70 kDa protein 6 measurement efo:EFO_0801667 Quantification of hematopoietic progenitor cell antigen CD34 in a sample. Elizabeth Lewis true PMID:29875488 hematopoietic progenitor cell antigen CD34 measurement efo:EFO_0801668 Quantification of hematopoietic prostaglandin D synthase in a sample. Elizabeth Lewis true PMID:29875488 hematopoietic prostaglandin D synthase measurement efo:EFO_0801669 Quantification of hemoglobin subunit theta-1 in a sample. Elizabeth Lewis true PMID:29875488 hemoglobin subunit theta-1 measurement efo:EFO_0801670 Quantification of hemoglobin subunit zeta in a sample. Elizabeth Lewis true PMID:29875488 hemoglobin subunit zeta measurement efo:EFO_0801671 Quantification of heparan sulfate glucosamine 3-O-sulfotransferase 3A1 in a sample. Elizabeth Lewis true PMID:29875488 heparan sulfate glucosamine 3-O-sulfotransferase 3A1 measurement efo:EFO_0801672 Quantification of hepatocyte nuclear factor 4-alpha in a sample. Elizabeth Lewis true PMID:29875488 hepatocyte nuclear factor 4-alpha measurement efo:EFO_0801673 Quantification of heterogeneous nuclear ribonucleoprotein D-like in a sample. Elizabeth Lewis true PMID:29875488 heterogeneous nuclear ribonucleoprotein D-like measurement efo:EFO_0801674 Quantification of heterogeneous nuclear ribonucleoprotein M in a sample. Elizabeth Lewis true PMID:29875488 heterogeneous nuclear ribonucleoprotein M measurement efo:EFO_0801675 Quantification of heterogeneous nuclear ribonucleoproteins C1/C2 in a sample. Elizabeth Lewis true PMID:29875488 heterogeneous nuclear ribonucleoproteins C1/C2 measurement efo:EFO_0801676 Quantification of high mobility group protein B2 in a sample. Elizabeth Lewis true PMID:29875488 high mobility group protein B2 measurement efo:EFO_0801677 Quantification of high mobility group protein B3 in a sample. Elizabeth Lewis true PMID:29875488 high mobility group protein B3 measurement efo:EFO_0801678 Quantification of histatin-1 in a sample. Elizabeth Lewis true PMID:29875488 histatin-1 measurement efo:EFO_0801679 Quantification of histo-blood group ABO system transferase in a sample. Elizabeth Lewis true PMID:29875488 histo-blood group ABO system transferase measurement efo:EFO_0801680 Quantification of histone deacetylase complex subunit SAP18 in a sample. Elizabeth Lewis true PMID:29875488 histone deacetylase complex subunit SAP18 measurement efo:EFO_0801681 Quantification of histone H1x in a sample. Elizabeth Lewis true PMID:29875488 histone H1x measurement efo:EFO_0801682 Quantification of histone-lysine N-methyltransferase 2C in a sample. Elizabeth Lewis true PMID:29875488 histone-lysine N-methyltransferase 2C measurement efo:EFO_0801683 Quantification of histone-lysine N-methyltransferase 2D in a sample. Elizabeth Lewis true PMID:29875488 histone-lysine N-methyltransferase 2D measurement efo:EFO_0801684 Quantification of HLA class II histocompatibility antigen, DM alpha chain in a sample. Elizabeth Lewis true PMID:29875488 HLA class II histocompatibility antigen, DM alpha chain measurement efo:EFO_0801685 Quantification of HLA class II histocompatibility antigen, DP beta 1 chain in a sample. Elizabeth Lewis true PMID:29875488 HLA class II histocompatibility antigen, DP beta 1 chain measurement efo:EFO_0801686 Quantification of HLA class II histocompatibility antigen, DQ alpha 2 chain in a sample. Elizabeth Lewis true PMID:29875488 HLA class II histocompatibility antigen, DQ alpha 2 chain measurement efo:EFO_0801687 Quantification of IGF-like family receptor 1 in a sample. Elizabeth Lewis true PMID:29875488 IGF-like family receptor 1 measurement efo:EFO_0801688 Quantification of immunoglobulin lambda-like polypeptide 1 in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin lambda-like polypeptide 1 measurement efo:EFO_0801689 Quantification of immunoglobulin superfamily DCC subclass member 3 in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin superfamily DCC subclass member 3 measurement efo:EFO_0801690 Quantification of immunoglobulin superfamily DCC subclass member 4 in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin superfamily DCC subclass member 4 measurement efo:EFO_0801691 Quantification of immunoglobulin-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin-binding protein 1 measurement efo:EFO_0801692 Quantification of inactive gamma-glutamyltranspeptidase 2 in a sample. Elizabeth Lewis true PMID:29875488 inactive gamma-glutamyltranspeptidase 2 measurement efo:EFO_0801693 Quantification of inactive pancreatic lipase-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 inactive pancreatic lipase-related protein 1 measurement efo:EFO_0801694 Quantification of inactive peptidyl-prolyl cis-trans isomerase FKBP6 in a sample. Elizabeth Lewis true PMID:29875488 inactive peptidyl-prolyl cis-trans isomerase FKBP6 measurement efo:EFO_0801695 Quantification of indoleamine 2,3-dioxygenase 1 in a sample. Elizabeth Lewis true PMID:29875488 indoleamine 2,3-dioxygenase 1 measurement efo:EFO_0801696 Quantification of inhibin beta C chain in a sample. Elizabeth Lewis true PMID:29875488 inhibin beta C chain measurement efo:EFO_0801697 Quantification of inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 in a sample. Elizabeth Lewis true PMID:29875488 inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 measurement efo:EFO_0801698 Quantification of inositol monophosphatase 3 in a sample. Elizabeth Lewis true PMID:29875488 inositol monophosphatase 3 measurement efo:EFO_0801699 Quantification of inositol polyphosphate 5-phosphatase OCRL-1 in a sample. Elizabeth Lewis true PMID:29875488 inositol polyphosphate 5-phosphatase OCRL-1 measurement efo:EFO_0801700 Quantification of insulin growth factor-like family member 3 in a sample. Elizabeth Lewis true PMID:29875488 insulin growth factor-like family member 3 measurement efo:EFO_0801701 Quantification of insulin growth factor-like family member 4 in a sample. Elizabeth Lewis true PMID:29875488 insulin growth factor-like family member 4 measurement efo:EFO_0801702 Quantification of insulin-like growth factor I in a sample. Elizabeth Lewis true PMID:29875488 insulin-like growth factor I measurement efo:EFO_0801703 Quantification of insulin-like growth factor-binding protein 3 in a sample. Elizabeth Lewis true PMID:29875488 insulin-like growth factor-binding protein 3 measurement efo:EFO_0801704 Quantification of integral membrane protein 2A in a sample. Elizabeth Lewis true PMID:29875488 integral membrane protein 2A measurement efo:EFO_0801705 Quantification of inter-alpha-trypsin inhibitor heavy chain H1 in a sample. Elizabeth Lewis true PMID:29875488 inter-alpha-trypsin inhibitor heavy chain H1 measurement efo:EFO_0801706 Quantification of inter-alpha-trypsin inhibitor heavy chain H5 in a sample. Elizabeth Lewis true PMID:29875488 inter-alpha-trypsin inhibitor heavy chain H5 measurement efo:EFO_0801707 Quantification of intercellular adhesion molecule 1 in a sample. Elizabeth Lewis true PMID:29875488 intercellular adhesion molecule 1 measurement efo:EFO_0801708 Quantification of intercellular adhesion molecule 4 in a sample. Elizabeth Lewis true PMID:29875488 intercellular adhesion molecule 4 measurement efo:EFO_0801709 Quantification of interferon regulatory factor 2 in a sample. Elizabeth Lewis true PMID:29875488 interferon regulatory factor 2 measurement efo:EFO_0801710 Quantification of interferon-induced protein with tetratricopeptide repeats 3 in a sample. Elizabeth Lewis true PMID:29875488 interferon-induced protein with tetratricopeptide repeats 3 measurement efo:EFO_0801711 Quantification of interleukin-1 receptor accessory protein in a sample. Elizabeth Lewis true PMID:29875488 interleukin-1 receptor accessory protein measurement efo:EFO_0801712 Quantification of interleukin-1 receptor antagonist protein in a sample. Elizabeth Lewis true PMID:29875488 interleukin-1 receptor antagonist protein measurement efo:EFO_0801713 Quantification of interleukin-1 receptor-like 1 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-1 receptor-like 1 measurement efo:EFO_0801714 Quantification of interleukin-1 receptor-like 2 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-1 receptor-like 2 measurement efo:EFO_0801715 Quantification of interleukin-12 receptor subunit beta-1 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-12 receptor subunit beta-1 measurement efo:EFO_0801716 Quantification of interleukin-15 receptor subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 interleukin-15 receptor subunit alpha measurement efo:EFO_0801717 Quantification of interleukin-16 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-16 measurement efo:EFO_0801718 Quantification of interleukin-17 receptor A in a sample. Elizabeth Lewis true PMID:29875488 interleukin-17 receptor A measurement efo:EFO_0801719 Quantification of interleukin-17 receptor B in a sample. Elizabeth Lewis true PMID:29875488 interleukin-17 receptor B measurement efo:EFO_0801720 Quantification of interleukin-17 receptor D in a sample. Elizabeth Lewis true PMID:29875488 interleukin-17 receptor D measurement efo:EFO_0801721 Quantification of interleukin-18 receptor 1 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-18 receptor 1 measurement efo:EFO_0801722 Quantification of interleukin-19 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-19 measurement efo:EFO_0801723 Quantification of interleukin-2 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-2 measurement efo:EFO_0801724 Quantification of interleukin-21 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-21 measurement efo:EFO_0801725 Quantification of interleukin-23 receptor in a sample. Elizabeth Lewis true PMID:29875488 interleukin-23 receptor measurement efo:EFO_0801726 Quantification of interleukin-25 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-25 measurement efo:EFO_0801727 Quantification of interleukin-27 receptor subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 interleukin-27 receptor subunit alpha measurement efo:EFO_0801728 Quantification of interleukin-31 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-31 measurement efo:EFO_0801729 Quantification of interleukin-5 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-5 measurement efo:EFO_0801730 Quantification of interleukin-5 receptor subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 interleukin-5 receptor subunit alpha measurement efo:EFO_0801731 Quantification of interleukin-6 receptor subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 interleukin-6 receptor subunit alpha measurement efo:EFO_0801732 Quantification of interleukin-6 receptor subunit beta in a sample. Elizabeth Lewis true PMID:29875488 interleukin-6 receptor subunit beta measurement efo:EFO_0801733 Quantification of intersectin-1 in a sample. Elizabeth Lewis true PMID:29875488 intersectin-1 measurement efo:EFO_0801734 Quantification of intestinal-type alkaline phosphatase in a sample. Elizabeth Lewis true PMID:29875488 intestinal-type alkaline phosphatase measurement efo:EFO_0801735 Quantification of isochorismatase domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 isochorismatase domain-containing protein 1 measurement efo:EFO_0801736 Quantification of IST1 homolog in a sample. Elizabeth Lewis true PMID:29875488 IST1 homolog measurement efo:EFO_0801737 Quantification of isthmin-1 in a sample. Elizabeth Lewis true PMID:29875488 isthmin-1 measurement efo:EFO_0801738 Quantification of janus kinase and microtubule-interacting protein 3 in a sample. Elizabeth Lewis true PMID:29875488 janus kinase and microtubule-interacting protein 3 measurement efo:EFO_0801739 Quantification of kallikrein-6 in a sample. Elizabeth Lewis true PMID:29875488 kallikrein-6 measurement efo:EFO_0801740 Quantification of KDEL motif-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 KDEL motif-containing protein 2 measurement efo:EFO_0801741 Quantification of kelch-like protein 13 in a sample. Elizabeth Lewis true PMID:29875488 kelch-like protein 13 measurement efo:EFO_0801742 Quantification of keratin-associated protein 2-4 in a sample. Elizabeth Lewis true PMID:29875488 keratin-associated protein 2-4 measurement efo:EFO_0801743 Quantification of keratinocyte differentiation-associated protein in a sample. Elizabeth Lewis true PMID:29875488 keratinocyte differentiation-associated protein measurement efo:EFO_0801744 Quantification of killer cell immunoglobulin-like receptor 2DL2 in a sample. Elizabeth Lewis true PMID:29875488 killer cell immunoglobulin-like receptor 2DL2 measurement efo:EFO_0801745 Quantification of killer cell immunoglobulin-like receptor 2DL5A in a sample. Elizabeth Lewis true PMID:29875488 killer cell immunoglobulin-like receptor 2DL5A measurement efo:EFO_0801746 Quantification of killer cell immunoglobulin-like receptor 2DS2 in a sample. Elizabeth Lewis true PMID:29875488 killer cell immunoglobulin-like receptor 2DS2 measurement efo:EFO_0801747 Quantification of kinesin-like protein KIF16B in a sample. Elizabeth Lewis true PMID:29875488 kinesin-like protein KIF16B measurement efo:EFO_0801748 Quantification of kinetochore protein NDC80 homolog in a sample. Elizabeth Lewis true PMID:29875488 kinetochore protein NDC80 homolog measurement efo:EFO_0801749 Quantification of kremen protein 1 in a sample. Elizabeth Lewis true PMID:29875488 kremen protein 1 measurement efo:EFO_0801750 Quantification of kunitz-type protease inhibitor 3 in a sample. Elizabeth Lewis true PMID:29875488 kunitz-type protease inhibitor 3 measurement efo:EFO_0801751 Quantification of kv channel-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 kv channel-interacting protein 1 measurement efo:EFO_0801752 Quantification of kynurenine--oxoglutarate transaminase 3 in a sample. Elizabeth Lewis true PMID:29875488 kynurenine--oxoglutarate transaminase 3 measurement efo:EFO_0801753 Quantification of lactase-phlorizin hydrolase in a sample. Elizabeth Lewis true PMID:29875488 lactase-phlorizin hydrolase measurement efo:EFO_0801754 Quantification of lamina-associated polypeptide 2, isoforms beta/gamma in a sample. Elizabeth Lewis true PMID:29875488 lamina-associated polypeptide 2, isoforms beta/gamma measurement efo:EFO_0801755 Quantification of laminin subunit alpha-4 in a sample. Elizabeth Lewis true PMID:29875488 laminin subunit alpha-4 measurement efo:EFO_0801756 Quantification of laminin subunit gamma-2 in a sample. Elizabeth Lewis true PMID:29875488 laminin subunit gamma-2 measurement efo:EFO_0801757 Quantification of LEM domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 LEM domain-containing protein 1 measurement efo:EFO_0801758 Quantification of leucine-rich PPR motif-containing protein, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich PPR motif-containing protein, mitochondrial measurement efo:EFO_0801759 Quantification of leucine-rich repeat and transmembrane domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat and transmembrane domain-containing protein 2 measurement efo:EFO_0801760 Quantification of leucine-rich repeat neuronal protein 1 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat neuronal protein 1 measurement efo:EFO_0801761 Quantification of leucine-rich repeat-containing protein 15 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat-containing protein 15 measurement efo:EFO_0801762 Quantification of leucine-rich repeat-containing protein 19 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat-containing protein 19 measurement efo:EFO_0801763 Quantification of leucine-rich repeat-containing protein 74A in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat-containing protein 74A measurement efo:EFO_0801764 Quantification of leukemia inhibitory factor in a sample. Elizabeth Lewis true PMID:29875488 leukemia inhibitory factor measurement efo:EFO_0801765 Quantification of leukocyte immunoglobulin-like receptor subfamily A member 4 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte immunoglobulin-like receptor subfamily A member 4 measurement efo:EFO_0801766 Quantification of leukocyte immunoglobulin-like receptor subfamily A member 5 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte immunoglobulin-like receptor subfamily A member 5 measurement efo:EFO_0801767 Quantification of leukocyte immunoglobulin-like receptor subfamily A member 6 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte immunoglobulin-like receptor subfamily A member 6 measurement efo:EFO_0801768 Quantification of leukocyte immunoglobulin-like receptor subfamily B member 4 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte immunoglobulin-like receptor subfamily B member 4 measurement efo:EFO_0801769 Quantification of leukocyte immunoglobulin-like receptor subfamily B member 5 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte immunoglobulin-like receptor subfamily B member 5 measurement efo:EFO_0801770 Quantification of lipase member N in a sample. Elizabeth Lewis true PMID:29875488 lipase member N measurement efo:EFO_0801771 Quantification of lon protease homolog, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 lon protease homolog, mitochondrial measurement efo:EFO_0801772 Quantification of low-density lipoprotein receptor-related protein 1, soluble in a sample. Elizabeth Lewis true PMID:29875488 low-density lipoprotein receptor-related protein 1, soluble measurement efo:EFO_0801773 Quantification of lutropin subunit beta in a sample. Elizabeth Lewis true PMID:29875488 lutropin subunit beta measurement efo:EFO_0801774 Quantification of lymphocyte antigen 6 complex locus protein G6c in a sample. Elizabeth Lewis true PMID:29875488 lymphocyte antigen 6 complex locus protein G6c measurement efo:EFO_0801775 Quantification of lysophosphatidylcholine acyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 lysophosphatidylcholine acyltransferase 2 measurement efo:EFO_0801776 Quantification of lysosomal acid phosphatase in a sample. Elizabeth Lewis true PMID:29875488 lysosomal acid phosphatase measurement efo:EFO_0801777 Quantification of lysosomal Pro-X carboxypeptidase in a sample. Elizabeth Lewis true PMID:29875488 lysosomal Pro-X carboxypeptidase measurement efo:EFO_0801778 Quantification of lysozyme g-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 lysozyme g-like protein 1 measurement efo:EFO_0801779 Quantification of lysozyme-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 lysozyme-like protein 2 measurement efo:EFO_0801780 Quantification of m-phase inducer phosphatase 2 in a sample. Elizabeth Lewis true PMID:29875488 m-phase inducer phosphatase 2 measurement efo:EFO_0801781 Quantification of MAGUK p55 subfamily member 6 in a sample. Elizabeth Lewis true PMID:29875488 MAGUK p55 subfamily member 6 measurement efo:EFO_0801782 Quantification of malignant T-cell-amplified sequence 1 in a sample. Elizabeth Lewis true PMID:29875488 malignant T-cell-amplified sequence 1 measurement efo:EFO_0801783 Quantification of mannosyl-oligosaccharide 1,2-alpha-mannosidase IB in a sample. Elizabeth Lewis true PMID:29875488 mannosyl-oligosaccharide 1,2-alpha-mannosidase IB measurement efo:EFO_0801784 Quantification of MANSC domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 MANSC domain-containing protein 1 measurement efo:EFO_0801785 Quantification of MANSC domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 MANSC domain-containing protein 4 measurement efo:EFO_0801786 Quantification of maspardin in a sample. Elizabeth Lewis true PMID:29875488 maspardin measurement efo:EFO_0801787 Quantification of mast cell-expressed membrane protein 1 in a sample. Elizabeth Lewis true PMID:29875488 mast cell-expressed membrane protein 1 measurement efo:EFO_0801788 Quantification of matrilin-4 in a sample. Elizabeth Lewis true PMID:29875488 matrilin-4 measurement efo:EFO_0801789 Quantification of matrix-remodeling-associated protein 7 in a sample. Elizabeth Lewis true PMID:29875488 matrix-remodeling-associated protein 7 measurement efo:EFO_0801790 Quantification of MAX gene-associated protein in a sample. Elizabeth Lewis true PMID:29875488 MAX gene-associated protein measurement efo:EFO_0801791 Quantification of mediator of RNA polymerase II transcription subunit 4 in a sample. Elizabeth Lewis true PMID:29875488 mediator of RNA polymerase II transcription subunit 4 measurement efo:EFO_0801792 Quantification of melanocyte protein PMEL in a sample. Elizabeth Lewis true PMID:29875488 melanocyte protein PMEL measurement efo:EFO_0801793 Quantification of melanoma-associated antigen 10 in a sample. Elizabeth Lewis true PMID:29875488 melanoma-associated antigen 10 measurement efo:EFO_0801794 Quantification of melanoma-associated antigen 3 in a sample. Elizabeth Lewis true PMID:29875488 melanoma-associated antigen 3 measurement efo:EFO_0801795 Quantification of membrane protein FAM174A in a sample. Elizabeth Lewis true PMID:29875488 membrane protein FAM174A measurement efo:EFO_0801796 Quantification of membrane-associated progesterone receptor component 2 in a sample. Elizabeth Lewis true PMID:29875488 membrane-associated progesterone receptor component 2 measurement efo:EFO_0801797 Quantification of metalloproteinase inhibitor 4 in a sample. Elizabeth Lewis true PMID:29875488 metalloproteinase inhibitor 4 measurement efo:EFO_0801798 Quantification of metallothionein-1F in a sample. Elizabeth Lewis true PMID:29875488 metallothionein-1F measurement efo:EFO_0801799 Quantification of MICAL-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 MICAL-like protein 2 measurement efo:EFO_0801800 Quantification of MICOS complex subunit MIC10 in a sample. Elizabeth Lewis true PMID:29875488 MICOS complex subunit MIC10 measurement efo:EFO_0801801 Quantification of microfibrillar-associated protein 2 in a sample. Elizabeth Lewis true PMID:29875488 microfibrillar-associated protein 2 measurement efo:EFO_0801802 Quantification of mineralocorticoid receptor in a sample. Elizabeth Lewis true PMID:29875488 mineralocorticoid receptor measurement efo:EFO_0801803 Quantification of mitochondrial sodium/hydrogen exchanger 9B2 in a sample. Elizabeth Lewis true PMID:29875488 mitochondrial sodium/hydrogen exchanger 9B2 measurement efo:EFO_0801804 Quantification of mitochondrial ubiquitin ligase activator of NFKB 1 in a sample. Elizabeth Lewis true PMID:29875488 mitochondrial ubiquitin ligase activator of NFKB 1 measurement efo:EFO_0801805 Quantification of mitogen-activated protein kinase kinase kinase 3 in a sample. Elizabeth Lewis true PMID:29875488 mitogen-activated protein kinase kinase kinase 3 measurement efo:EFO_0801806 Quantification of mitotic checkpoint serine/threonine-protein kinase BUB1 in a sample. Elizabeth Lewis true PMID:29875488 mitotic checkpoint serine/threonine-protein kinase BUB1 measurement efo:EFO_0801807 Quantification of mitotic spindle assembly checkpoint protein MAD1 in a sample. Elizabeth Lewis true PMID:29875488 mitotic spindle assembly checkpoint protein MAD1 measurement efo:EFO_0801808 Quantification of mothers against decapentaplegic homolog 4 in a sample. Elizabeth Lewis true PMID:29875488 mothers against decapentaplegic homolog 4 measurement efo:EFO_0801809 Quantification of multimerin-2 in a sample. Elizabeth Lewis true PMID:29875488 multimerin-2 measurement efo:EFO_0801810 Quantification of multiple coagulation factor deficiency protein 2 in a sample. Elizabeth Lewis true PMID:29875488 multiple coagulation factor deficiency protein 2 measurement efo:EFO_0801811 Quantification of multiple inositol polyphosphate phosphatase 1 in a sample. Elizabeth Lewis true PMID:29875488 multiple inositol polyphosphate phosphatase 1 measurement efo:EFO_0801812 Quantification of myc target protein 1 in a sample. Elizabeth Lewis true PMID:29875488 myc target protein 1 measurement efo:EFO_0801813 Quantification of myelin protein P0 in a sample. Elizabeth Lewis true PMID:29875488 myelin protein P0 measurement efo:EFO_0801814 Quantification of myotonin-protein kinase in a sample. Elizabeth Lewis true PMID:29875488 myotonin-protein kinase measurement efo:EFO_0801815 Quantification of n-acetylated-alpha-linked acidic dipeptidase 2 in a sample. Elizabeth Lewis true PMID:29875488 n-acetylated-alpha-linked acidic dipeptidase 2 measurement efo:EFO_0801816 Quantification of n-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase in a sample. Elizabeth Lewis true PMID:29875488 n-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase measurement efo:EFO_0801817 Quantification of n-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 n-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 measurement efo:EFO_0801818 Quantification of n-acetylserotonin O-methyltransferase-like protein in a sample. Elizabeth Lewis true PMID:29875488 n-acetylserotonin O-methyltransferase-like protein measurement efo:EFO_0801819 Quantification of n-acetyltransferase 14 in a sample. Elizabeth Lewis true PMID:29875488 n-acetyltransferase 14 measurement efo:EFO_0801820 Quantification of n-terminal Xaa-Pro-Lys N-methyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 n-terminal Xaa-Pro-Lys N-methyltransferase 1 measurement efo:EFO_0801821 Quantification of NAD kinase in a sample. Elizabeth Lewis true PMID:29875488 NAD kinase measurement efo:EFO_0801822 Quantification of NAD-dependent protein deacylase sirtuin-5, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 NAD-dependent protein deacylase sirtuin-5, mitochondrial measurement efo:EFO_0801823 Quantification of neogenin in a sample. Elizabeth Lewis true PMID:29875488 neogenin measurement efo:EFO_0801824 Quantification of nesprin-2 in a sample. Elizabeth Lewis true PMID:29875488 nesprin-2 measurement efo:EFO_0801825 Quantification of netrin-G1 in a sample. Elizabeth Lewis true PMID:29875488 netrin-G1 measurement efo:EFO_0801826 Quantification of neural cell adhesion molecule 1 in a sample. Elizabeth Lewis true PMID:29875488 neural cell adhesion molecule 1 measurement efo:EFO_0801827 Quantification of neural cell adhesion molecule 2 in a sample. Elizabeth Lewis true PMID:29875488 neural cell adhesion molecule 2 measurement efo:EFO_0801828 Quantification of neurensin-1 in a sample. Elizabeth Lewis true PMID:29875488 neurensin-1 measurement efo:EFO_0801829 Quantification of neurexin-1 in a sample. Elizabeth Lewis true PMID:29875488 neurexin-1 measurement efo:EFO_0801830 Quantification of neuroendocrine convertase 1 in a sample. Elizabeth Lewis true PMID:29875488 neuroendocrine convertase 1 measurement efo:EFO_0801831 Quantification of neurofascin in a sample. Elizabeth Lewis true PMID:29875488 neurofascin measurement efo:EFO_0801832 Quantification of neuron-specific protein family member 2 in a sample. Elizabeth Lewis true PMID:29875488 neuron-specific protein family member 2 measurement efo:EFO_0801833 Quantification of neuronal pentraxin-1 in a sample. Elizabeth Lewis true PMID:29875488 neuronal pentraxin-1 measurement efo:EFO_0801834 Quantification of neuronal pentraxin-2 in a sample. Elizabeth Lewis true PMID:29875488 neuronal pentraxin-2 measurement efo:EFO_0801835 Quantification of neuropeptide W in a sample. Elizabeth Lewis true PMID:29875488 neuropeptide W measurement efo:EFO_0801836 Quantification of neuropilin-2 in a sample. Elizabeth Lewis true PMID:29875488 neuropilin-2 measurement efo:EFO_0801837 Quantification of neutrophil cytosol factor 2 in a sample. Elizabeth Lewis true PMID:29875488 neutrophil cytosol factor 2 measurement efo:EFO_0801838 Quantification of next to BRCA1 gene 1 protein in a sample. Elizabeth Lewis true PMID:29875488 next to BRCA1 gene 1 protein measurement efo:EFO_0801839 Quantification of NHL repeat-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 NHL repeat-containing protein 3 measurement efo:EFO_0801840 Quantification of NHP2-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 NHP2-like protein 1 measurement efo:EFO_0801841 Quantification of nischarin in a sample. Elizabeth Lewis true PMID:29875488 nischarin measurement efo:EFO_0801842 Quantification of NKG2-E type II integral membrane protein in a sample. Elizabeth Lewis true PMID:29875488 NKG2-E type II integral membrane protein measurement efo:EFO_0801843 Quantification of NKG2D ligand 4 in a sample. Elizabeth Lewis true PMID:29875488 NKG2D ligand 4 measurement efo:EFO_0801844 Quantification of nmrA-like family domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 nmrA-like family domain-containing protein 1 measurement efo:EFO_0801845 Quantification of non-secretory ribonuclease in a sample. Elizabeth Lewis true PMID:29875488 non-secretory ribonuclease measurement efo:EFO_0801846 Quantification of normal mucosa of esophagus-specific gene 1 protein in a sample. Elizabeth Lewis true PMID:29875488 normal mucosa of esophagus-specific gene 1 protein measurement efo:EFO_0801847 Quantification of NTF2-related export protein 1 in a sample. Elizabeth Lewis true PMID:29875488 NTF2-related export protein 1 measurement efo:EFO_0801848 Quantification of nuclear factor erythroid 2-related factor 1 in a sample. Elizabeth Lewis true PMID:29875488 nuclear factor erythroid 2-related factor 1 measurement efo:EFO_0801849 Quantification of nuclear migration protein nudC in a sample. Elizabeth Lewis true PMID:29875488 nuclear migration protein nudC measurement efo:EFO_0801850 Quantification of nuclear pore complex-interacting protein family member B3 in a sample. Elizabeth Lewis true PMID:29875488 nuclear pore complex-interacting protein family member B3 measurement efo:EFO_0801851 Quantification of nuclear protein localization protein 4 homolog in a sample. Elizabeth Lewis true PMID:29875488 nuclear protein localization protein 4 homolog measurement efo:EFO_0801852 Quantification of nuclear receptor coactivator 2 in a sample. Elizabeth Lewis true PMID:29875488 nuclear receptor coactivator 2 measurement efo:EFO_0801853 Quantification of nuclear receptor subfamily 1 group D member 2 in a sample. Elizabeth Lewis true PMID:29875488 nuclear receptor subfamily 1 group D member 2 measurement efo:EFO_0801854 Quantification of nuclear receptor-binding protein in a sample. Elizabeth Lewis true PMID:29875488 nuclear receptor-binding protein measurement efo:EFO_0801855 Quantification of nuclear RNA export factor 1 in a sample. Elizabeth Lewis true PMID:29875488 nuclear RNA export factor 1 measurement efo:EFO_0801856 Quantification of nucleolin in a sample. Elizabeth Lewis true PMID:29875488 nucleolin measurement efo:EFO_0801857 Quantification of nucleosome assembly protein 1-like 2 in a sample. Elizabeth Lewis true PMID:29875488 nucleosome assembly protein 1-like 2 measurement efo:EFO_0801858 Quantification of obg-like ATPase 1 in a sample. Elizabeth Lewis true PMID:29875488 obg-like ATPase 1 measurement efo:EFO_0801859 Quantification of odorant-binding protein 2b in a sample. Elizabeth Lewis true PMID:29875488 odorant-binding protein 2b measurement efo:EFO_0801860 Quantification of oncostatin-M-specific receptor subunit beta in a sample. Elizabeth Lewis true PMID:29875488 oncostatin-M-specific receptor subunit beta measurement efo:EFO_0801861 Quantification of opalin in a sample. Elizabeth Lewis true PMID:29875488 opalin measurement efo:EFO_0801862 Quantification of out at first protein homolog in a sample. Elizabeth Lewis true PMID:29875488 out at first protein homolog measurement efo:EFO_0801863 Quantification of oxidoreductase HTATIP2 in a sample. Elizabeth Lewis true PMID:29875488 oxidoreductase HTATIP2 measurement efo:EFO_0801864 Quantification of oxysterol-binding protein-related protein 11 in a sample. Elizabeth Lewis true PMID:29875488 oxysterol-binding protein-related protein 11 measurement efo:EFO_0801865 Quantification of oxysterols receptor LXR-beta in a sample. Elizabeth Lewis true PMID:29875488 oxysterols receptor LXR-beta measurement efo:EFO_0801866 Quantification of paired immunoglobulin-like type 2 receptor alpha in a sample. Elizabeth Lewis true PMID:29875488 paired immunoglobulin-like type 2 receptor alpha measurement efo:EFO_0801867 Quantification of palmitoyl-protein thioesterase 1 in a sample. Elizabeth Lewis true PMID:29875488 palmitoyl-protein thioesterase 1 measurement efo:EFO_0801868 Quantification of PAX-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 PAX-interacting protein 1 measurement efo:EFO_0801869 Quantification of PDZK1-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 PDZK1-interacting protein 1 measurement efo:EFO_0801870 Quantification of peptide chain release factor 1-like, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 peptide chain release factor 1-like, mitochondrial measurement efo:EFO_0801871 Quantification of peptidyl-glycine alpha-amidating monooxygenase in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-glycine alpha-amidating monooxygenase measurement efo:EFO_0801872 Quantification of peptidyl-prolyl cis-trans isomerase FKBP14 in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-prolyl cis-trans isomerase FKBP14 measurement efo:EFO_0801873 Quantification of peptidyl-prolyl cis-trans isomerase FKBP7 in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-prolyl cis-trans isomerase FKBP7 measurement efo:EFO_0801874 Quantification of peptidyl-prolyl cis-trans isomerase H in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-prolyl cis-trans isomerase H measurement efo:EFO_0801875 Quantification of peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 measurement efo:EFO_0801876 Quantification of peptidyl-prolyl cis-trans isomerase-like 1 in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-prolyl cis-trans isomerase-like 1 measurement efo:EFO_0801877 Quantification of peptidyl-prolyl cis-trans isomerase-like 2 in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-prolyl cis-trans isomerase-like 2 measurement efo:EFO_0801878 Quantification of peroxisomal NADH pyrophosphatase NUDT12 in a sample. Elizabeth Lewis true PMID:29875488 peroxisomal NADH pyrophosphatase NUDT12 measurement efo:EFO_0801879 Quantification of phenylalanine--tRNA ligase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 phenylalanine--tRNA ligase, mitochondrial measurement efo:EFO_0801880 Quantification of phosducin-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 phosducin-like protein 2 measurement efo:EFO_0801881 Quantification of phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha measurement efo:EFO_0801882 Quantification of phosphatidylinositol-glycan-specific phospholipase D in a sample. Elizabeth Lewis true PMID:29875488 phosphatidylinositol-glycan-specific phospholipase D measurement efo:EFO_0801883 Quantification of phosphomevalonate kinase in a sample. Elizabeth Lewis true PMID:29875488 phosphomevalonate kinase measurement efo:EFO_0801884 Quantification of pirin in a sample. Elizabeth Lewis true PMID:29875488 pirin measurement efo:EFO_0801885 Quantification of plastin-2 in a sample. Elizabeth Lewis true PMID:29875488 plastin-2 measurement efo:EFO_0801886 Quantification of platelet endothelial aggregation receptor 1 in a sample. Elizabeth Lewis true PMID:29875488 platelet endothelial aggregation receptor 1 measurement efo:EFO_0801887 Quantification of platelet factor 4 variant in a sample. Elizabeth Lewis true PMID:29875488 platelet factor 4 variant measurement efo:EFO_0801888 Quantification of platelet-derived growth factor D in a sample. Elizabeth Lewis true PMID:29875488 platelet-derived growth factor D measurement efo:EFO_0801889 Quantification of platelet-derived growth factor receptor-like protein in a sample. Elizabeth Lewis true PMID:29875488 platelet-derived growth factor receptor-like protein measurement efo:EFO_0801890 Quantification of platelet-derived growth factor subunit A in a sample. Elizabeth Lewis true PMID:29875488 platelet-derived growth factor subunit A measurement efo:EFO_0801891 Quantification of pleckstrin homology domain-containing family A member 7 in a sample. Elizabeth Lewis true PMID:29875488 pleckstrin homology domain-containing family A member 7 measurement efo:EFO_0801892 Quantification of plexin-A1 in a sample. Elizabeth Lewis true PMID:29875488 plexin-A1 measurement efo:EFO_0801893 Quantification of poly(A) RNA polymerase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 poly(A) RNA polymerase, mitochondrial measurement efo:EFO_0801894 Quantification of poly(rC)-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 poly(rC)-binding protein 1 measurement efo:EFO_0801895 Quantification of poly(U)-binding-splicing factor PUF60 in a sample. Elizabeth Lewis true PMID:29875488 poly(U)-binding-splicing factor PUF60 measurement efo:EFO_0801896 Quantification of polyadenylate-binding protein 3 in a sample. Elizabeth Lewis true PMID:29875488 polyadenylate-binding protein 3 measurement efo:EFO_0801897 Quantification of polyadenylate-binding protein 4 in a sample. Elizabeth Lewis true PMID:29875488 polyadenylate-binding protein 4 measurement efo:EFO_0801898 Quantification of polycomb protein SCMH1 in a sample. Elizabeth Lewis true PMID:29875488 polycomb protein SCMH1 measurement efo:EFO_0801899 Quantification of polypeptide N-acetylgalactosaminyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 polypeptide N-acetylgalactosaminyltransferase 1 measurement efo:EFO_0801900 Quantification of polypeptide N-acetylgalactosaminyltransferase 16 in a sample. Elizabeth Lewis true PMID:29875488 polypeptide N-acetylgalactosaminyltransferase 16 measurement efo:EFO_0801901 Quantification of potassium voltage-gated channel subfamily E member 2 in a sample. Elizabeth Lewis true PMID:29875488 potassium voltage-gated channel subfamily E member 2 measurement efo:EFO_0801902 Quantification of potassium voltage-gated channel subfamily E regulatory beta subunit 5 in a sample. Elizabeth Lewis true PMID:29875488 potassium voltage-gated channel subfamily E regulatory beta subunit 5 measurement efo:EFO_0801903 Quantification of potassium-transporting ATPase subunit beta in a sample. Elizabeth Lewis true PMID:29875488 potassium-transporting ATPase subunit beta measurement efo:EFO_0801904 Quantification of PR domain zinc finger protein 1 in a sample. Elizabeth Lewis true PMID:29875488 PR domain zinc finger protein 1 measurement efo:EFO_0801905 Quantification of pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 in a sample. Elizabeth Lewis true PMID:29875488 pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 measurement efo:EFO_0801906 Quantification of pregnancy-specific beta-1-glycoprotein 3 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 3 measurement efo:EFO_0801907 Quantification of pregnancy-specific beta-1-glycoprotein 4 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 4 measurement efo:EFO_0801908 Quantification of pregnancy-specific beta-1-glycoprotein 5 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 5 measurement efo:EFO_0801909 Quantification of pregnancy-specific beta-1-glycoprotein 9 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 9 measurement efo:EFO_0801910 Quantification of prenylcysteine oxidase-like in a sample. Elizabeth Lewis true PMID:29875488 prenylcysteine oxidase-like measurement efo:EFO_0801911 Quantification of pro-FMRFamide-related neuropeptide FF in a sample. Elizabeth Lewis true PMID:29875488 pro-FMRFamide-related neuropeptide FF measurement efo:EFO_0801912 Quantification of proactivator polypeptide-like 1 in a sample. Elizabeth Lewis true PMID:29875488 proactivator polypeptide-like 1 measurement efo:EFO_0801913 Quantification of probable ATP-dependent RNA helicase DDX58 in a sample. Elizabeth Lewis true PMID:29875488 probable ATP-dependent RNA helicase DDX58 measurement efo:EFO_0801914 Quantification of probable carboxypeptidase X1 in a sample. Elizabeth Lewis true PMID:29875488 probable carboxypeptidase X1 measurement efo:EFO_0801915 Quantification of probable dimethyladenosine transferase in a sample. Elizabeth Lewis true PMID:29875488 probable dimethyladenosine transferase measurement efo:EFO_0801916 Quantification of probable G-protein coupled receptor 135 in a sample. Elizabeth Lewis true PMID:29875488 probable G-protein coupled receptor 135 measurement efo:EFO_0801917 Quantification of probable RNA-binding protein 23 in a sample. Elizabeth Lewis true PMID:29875488 probable RNA-binding protein 23 measurement efo:EFO_0801918 Quantification of probable RNA-binding protein EIF1AD in a sample. Elizabeth Lewis true PMID:29875488 probable RNA-binding protein EIF1AD measurement efo:EFO_0801919 Quantification of probable serine carboxypeptidase CPVL in a sample. Elizabeth Lewis true PMID:29875488 probable serine carboxypeptidase CPVL measurement efo:EFO_0801920 Quantification of procollagen C-endopeptidase enhancer 1 in a sample. Elizabeth Lewis true PMID:29875488 procollagen C-endopeptidase enhancer 1 measurement efo:EFO_0801921 Quantification of procollagen C-endopeptidase enhancer 2 in a sample. Elizabeth Lewis true PMID:29875488 procollagen C-endopeptidase enhancer 2 measurement efo:EFO_0801922 Quantification of procollagen galactosyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 procollagen galactosyltransferase 1 measurement efo:EFO_0801923 Quantification of proenkephalin-A in a sample. Elizabeth Lewis true PMID:29875488 proenkephalin-A measurement efo:EFO_0801924 Quantification of progonadoliberin-1 in a sample. Elizabeth Lewis true PMID:29875488 progonadoliberin-1 measurement efo:EFO_0801925 Quantification of progonadoliberin-2 in a sample. Elizabeth Lewis true PMID:29875488 progonadoliberin-2 measurement efo:EFO_0801926 Quantification of programmed cell death protein 1 in a sample. Elizabeth Lewis true PMID:29875488 programmed cell death protein 1 measurement efo:EFO_0801927 Quantification of programmed cell death protein 5 in a sample. Elizabeth Lewis true PMID:29875488 programmed cell death protein 5 measurement efo:EFO_0801928 Quantification of prolargin in a sample. Elizabeth Lewis true PMID:29875488 prolargin measurement efo:EFO_0801929 Quantification of prolow-density lipoprotein receptor-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 prolow-density lipoprotein receptor-related protein 1 measurement efo:EFO_0801930 Quantification of promotilin in a sample. Elizabeth Lewis true PMID:29875488 promotilin measurement efo:EFO_0801931 Quantification of prostaglandin F2 receptor negative regulator in a sample. Elizabeth Lewis true PMID:29875488 prostaglandin F2 receptor negative regulator measurement efo:EFO_0801932 Quantification of prostaglandin reductase 1 in a sample. Elizabeth Lewis true PMID:29875488 prostaglandin reductase 1 measurement efo:EFO_0801933 Quantification of prostaglandin-H2 D-isomerase in a sample. Elizabeth Lewis true PMID:29875488 prostaglandin-H2 D-isomerase measurement efo:EFO_0801934 Quantification of protachykinin-1 in a sample. Elizabeth Lewis true PMID:29875488 protachykinin-1 measurement efo:EFO_0801935 Quantification of protein C-ets-2 in a sample. Elizabeth Lewis true PMID:29875488 protein C-ets-2 measurement efo:EFO_0801936 Quantification of protein CEI in a sample. Elizabeth Lewis true PMID:29875488 protein CEI measurement efo:EFO_0801937 Quantification of protein CREG1 in a sample. Elizabeth Lewis true PMID:29875488 protein CREG1 measurement efo:EFO_0801938 Quantification of protein delta homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 protein delta homolog 1 measurement efo:EFO_0801939 Quantification of protein DEPP in a sample. Elizabeth Lewis true PMID:29875488 protein DEPP measurement efo:EFO_0801940 Quantification of protein DGCR14 in a sample. Elizabeth Lewis true PMID:29875488 protein DGCR14 measurement efo:EFO_0801941 Quantification of protein disulfide-isomerase A5 in a sample. Elizabeth Lewis true PMID:29875488 protein disulfide-isomerase A5 measurement efo:EFO_0801942 Quantification of protein eva-1 homolog C in a sample. Elizabeth Lewis true PMID:29875488 protein eva-1 homolog C measurement efo:EFO_0801943 Quantification of protein EVI2B in a sample. Elizabeth Lewis true PMID:29875488 protein EVI2B measurement efo:EFO_0801944 Quantification of protein FAM150B in a sample. Elizabeth Lewis true PMID:29875488 protein FAM150B measurement efo:EFO_0801945 Quantification of protein FAM151A in a sample. Elizabeth Lewis true PMID:29875488 protein FAM151A measurement efo:EFO_0801946 Quantification of protein FAM163A in a sample. Elizabeth Lewis true PMID:29875488 protein FAM163A measurement efo:EFO_0801947 Quantification of protein FAM171B in a sample. Elizabeth Lewis true PMID:29875488 protein FAM171B measurement efo:EFO_0801948 Quantification of protein FAM177A1 in a sample. Elizabeth Lewis true PMID:29875488 protein FAM177A1 measurement efo:EFO_0801949 Quantification of protein FAM189A2 in a sample. Elizabeth Lewis true PMID:29875488 protein FAM189A2 measurement efo:EFO_0801950 Quantification of protein kinase C-binding protein NELL1 in a sample. Elizabeth Lewis true PMID:29875488 protein kinase C-binding protein NELL1 measurement efo:EFO_0801951 Quantification of protein LDOC1 in a sample. Elizabeth Lewis true PMID:29875488 protein LDOC1 measurement efo:EFO_0801952 Quantification of protein MENT in a sample. Elizabeth Lewis true PMID:29875488 protein MENT measurement efo:EFO_0801953 Quantification of protein MRVI1 in a sample. Elizabeth Lewis true PMID:29875488 protein MRVI1 measurement efo:EFO_0801954 Quantification of protein NDRG4 in a sample. Elizabeth Lewis true PMID:29875488 protein NDRG4 measurement efo:EFO_0801955 Quantification of protein O-glucosyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 protein O-glucosyltransferase 1 measurement efo:EFO_0801956 Quantification of protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 measurement efo:EFO_0801957 Quantification of protein RIC-3 in a sample. Elizabeth Lewis true PMID:29875488 protein RIC-3 measurement efo:EFO_0801958 Quantification of protein S100-A11 in a sample. Elizabeth Lewis true PMID:29875488 protein S100-A11 measurement efo:EFO_0801959 Quantification of protein S100-A13 in a sample. Elizabeth Lewis true PMID:29875488 protein S100-A13 measurement efo:EFO_0801960 Quantification of protein S100-A5 in a sample. Elizabeth Lewis true PMID:29875488 protein S100-A5 measurement efo:EFO_0801961 Quantification of protein SEC13 homolog in a sample. Elizabeth Lewis true PMID:29875488 protein SEC13 homolog measurement efo:EFO_0801962 Quantification of protein sel-1 homolog 2 in a sample. Elizabeth Lewis true PMID:29875488 protein sel-1 homolog 2 measurement efo:EFO_0801963 Quantification of protein SERAC1 in a sample. Elizabeth Lewis true PMID:29875488 protein SERAC1 measurement efo:EFO_0801964 Quantification of protein shisa-3 homolog in a sample. Elizabeth Lewis true PMID:29875488 protein shisa-3 homolog measurement efo:EFO_0801965 Quantification of protein SPACA7 in a sample. Elizabeth Lewis true PMID:29875488 protein SPACA7 measurement efo:EFO_0801966 Quantification of protein syndesmos in a sample. Elizabeth Lewis true PMID:29875488 protein syndesmos measurement efo:EFO_0801967 Quantification of protein TMEPAI in a sample. Elizabeth Lewis true PMID:29875488 protein TMEPAI measurement efo:EFO_0801968 Quantification of protein unc-93 homolog B1 in a sample. Elizabeth Lewis true PMID:29875488 protein unc-93 homolog B1 measurement efo:EFO_0801969 Quantification of protein-tyrosine kinase 2-beta in a sample. Elizabeth Lewis true PMID:29875488 protein-tyrosine kinase 2-beta measurement efo:EFO_0801970 Quantification of protein-tyrosine sulfotransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 protein-tyrosine sulfotransferase 1 measurement efo:EFO_0801971 Quantification of protein-tyrosine sulfotransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 protein-tyrosine sulfotransferase 2 measurement efo:EFO_0801972 Quantification of protocadherin alpha-4 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin alpha-4 measurement efo:EFO_0801973 Quantification of protocadherin alpha-7 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin alpha-7 measurement efo:EFO_0801974 Quantification of protocadherin beta-10 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin beta-10 measurement efo:EFO_0801975 Quantification of protocadherin beta-2 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin beta-2 measurement efo:EFO_0801976 Quantification of protocadherin beta-4 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin beta-4 measurement efo:EFO_0801977 Quantification of protocadherin gamma-C5 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin gamma-C5 measurement efo:EFO_0801978 Quantification of protocadherin-10 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin-10 measurement efo:EFO_0801979 Quantification of pseudokinase FAM20A in a sample. Elizabeth Lewis true PMID:29875488 pseudokinase FAM20A measurement efo:EFO_0801980 Quantification of pulmonary surfactant-associated protein C in a sample. Elizabeth Lewis true PMID:29875488 pulmonary surfactant-associated protein C measurement efo:EFO_0801981 Quantification of purine nucleoside phosphorylase in a sample. Elizabeth Lewis true PMID:29875488 purine nucleoside phosphorylase measurement efo:EFO_0801982 Quantification of pyruvate kinase PKLR in a sample. Elizabeth Lewis true PMID:29875488 pyruvate kinase PKLR measurement efo:EFO_0801983 Quantification of RAB6-interacting Golgin in a sample. Elizabeth Lewis true PMID:29875488 RAB6-interacting Golgin measurement efo:EFO_0801984 Quantification of rab9 effector protein with kelch motifs in a sample. Elizabeth Lewis true PMID:29875488 rab9 effector protein with kelch motifs measurement efo:EFO_0801985 Quantification of rac GTPase-activating protein 1 in a sample. Elizabeth Lewis true PMID:29875488 rac GTPase-activating protein 1 measurement efo:EFO_0801986 Quantification of ragulator complex protein LAMTOR3 in a sample. Elizabeth Lewis true PMID:29875488 ragulator complex protein LAMTOR3 measurement efo:EFO_0801987 Quantification of rap1 GTPase-activating protein 1 in a sample. Elizabeth Lewis true PMID:29875488 rap1 GTPase-activating protein 1 measurement efo:EFO_0801988 Quantification of ras-related protein Rab-14 in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-14 measurement efo:EFO_0801989 Quantification of ras-related protein Rab-26 in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-26 measurement efo:EFO_0801990 Quantification of ras-related protein Rab-35 in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-35 measurement efo:EFO_0801991 Quantification of receptor-type tyrosine-protein phosphatase H in a sample. Elizabeth Lewis true PMID:29875488 receptor-type tyrosine-protein phosphatase H measurement efo:EFO_0801992 Quantification of recQ-mediated genome instability protein 1 in a sample. Elizabeth Lewis true PMID:29875488 recQ-mediated genome instability protein 1 measurement efo:EFO_0801993 Quantification of redox-regulatory protein FAM213A in a sample. Elizabeth Lewis true PMID:29875488 redox-regulatory protein FAM213A measurement efo:EFO_0801994 Quantification of regulation of nuclear pre-mRNA domain-containing protein 1A in a sample. Elizabeth Lewis true PMID:29875488 regulation of nuclear pre-mRNA domain-containing protein 1A measurement efo:EFO_0801995 Quantification of regulator of G-protein signaling 18 in a sample. Elizabeth Lewis true PMID:29875488 regulator of G-protein signaling 18 measurement efo:EFO_0801996 Quantification of regulator of G-protein signaling 19 in a sample. Elizabeth Lewis true PMID:29875488 regulator of G-protein signaling 19 measurement efo:EFO_0801997 Quantification of regulator of G-protein signaling 8 in a sample. Elizabeth Lewis true PMID:29875488 regulator of G-protein signaling 8 measurement efo:EFO_0801998 Quantification of regulator of microtubule dynamics protein 1 in a sample. Elizabeth Lewis true PMID:29875488 regulator of microtubule dynamics protein 1 measurement efo:EFO_0801999 Quantification of regulatory factor X-associated protein in a sample. Elizabeth Lewis true PMID:29875488 regulatory factor X-associated protein measurement efo:EFO_0802000 Quantification of RELT-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 RELT-like protein 1 measurement efo:EFO_0802001 Quantification of replication initiator 1 in a sample. Elizabeth Lewis true PMID:29875488 replication initiator 1 measurement efo:EFO_0802002 Quantification of retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta in a sample. Elizabeth Lewis true PMID:29875488 retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta measurement efo:EFO_0802003 Quantification of retinaldehyde-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 retinaldehyde-binding protein 1 measurement efo:EFO_0802004 Quantification of retinoic acid receptor responder protein 1 in a sample. Elizabeth Lewis true PMID:29875488 retinoic acid receptor responder protein 1 measurement efo:EFO_0802005 Quantification of retinoic acid receptor responder protein 3 in a sample. Elizabeth Lewis true PMID:29875488 retinoic acid receptor responder protein 3 measurement efo:EFO_0802006 Quantification of retinoid-binding protein 7 in a sample. Elizabeth Lewis true PMID:29875488 retinoid-binding protein 7 measurement efo:EFO_0802007 Quantification of retinol dehydrogenase 16 in a sample. Elizabeth Lewis true PMID:29875488 retinol dehydrogenase 16 measurement efo:EFO_0802008 Quantification of retroviral-like aspartic protease 1 in a sample. Elizabeth Lewis true PMID:29875488 retroviral-like aspartic protease 1 measurement efo:EFO_0802009 Quantification of rho GDP-dissociation inhibitor 1 in a sample. Elizabeth Lewis true PMID:29875488 rho GDP-dissociation inhibitor 1 measurement efo:EFO_0802010 Quantification of rho GDP-dissociation inhibitor 2 in a sample. Elizabeth Lewis true PMID:29875488 rho GDP-dissociation inhibitor 2 measurement efo:EFO_0802011 Quantification of rho GTPase-activating protein 25 in a sample. Elizabeth Lewis true PMID:29875488 rho GTPase-activating protein 25 measurement efo:EFO_0802012 Quantification of rho GTPase-activating protein 30 in a sample. Elizabeth Lewis true PMID:29875488 rho GTPase-activating protein 30 measurement efo:EFO_0802013 Quantification of rho guanine nucleotide exchange factor 1 in a sample. Elizabeth Lewis true PMID:29875488 rho guanine nucleotide exchange factor 1 measurement efo:EFO_0802014 Quantification of rho guanine nucleotide exchange factor 10 in a sample. Elizabeth Lewis true PMID:29875488 rho guanine nucleotide exchange factor 10 measurement efo:EFO_0802015 Quantification of rhophilin-2 in a sample. Elizabeth Lewis true PMID:29875488 rhophilin-2 measurement efo:EFO_0802016 Quantification of riboflavin kinase in a sample. Elizabeth Lewis true PMID:29875488 riboflavin kinase measurement efo:EFO_0802017 Quantification of ribonuclease 4 in a sample. Elizabeth Lewis true PMID:29875488 ribonuclease 4 measurement efo:EFO_0802018 Quantification of ribonuclease K6 in a sample. Elizabeth Lewis true PMID:29875488 ribonuclease K6 measurement efo:EFO_0802019 Quantification of ribonuclease pancreatic in a sample. Elizabeth Lewis true PMID:29875488 ribonuclease pancreatic measurement efo:EFO_0802020 Quantification of ribonuclease UK114 in a sample. Elizabeth Lewis true PMID:29875488 ribonuclease UK114 measurement efo:EFO_0802021 Quantification of ribonucleoside-diphosphate reductase large subunit in a sample. Elizabeth Lewis true PMID:29875488 ribonucleoside-diphosphate reductase large subunit measurement efo:EFO_0802022 Quantification of ribonucleoside-diphosphate reductase subunit M2 B in a sample. Elizabeth Lewis true PMID:29875488 ribonucleoside-diphosphate reductase subunit M2 B measurement efo:EFO_0802023 Quantification of ribose-5-phosphate isomerase in a sample. Elizabeth Lewis true PMID:29875488 ribose-5-phosphate isomerase measurement efo:EFO_0802024 Quantification of ribosomal protein S6 kinase alpha-6 in a sample. Elizabeth Lewis true PMID:29875488 ribosomal protein S6 kinase alpha-6 measurement efo:EFO_0802025 Quantification of ribulose-phosphate 3-epimerase in a sample. Elizabeth Lewis true PMID:29875488 ribulose-phosphate 3-epimerase measurement efo:EFO_0802026 Quantification of rieske domain-containing protein in a sample. Elizabeth Lewis true PMID:29875488 rieske domain-containing protein measurement efo:EFO_0802027 Quantification of RING finger protein 165 in a sample. Elizabeth Lewis true PMID:29875488 RING finger protein 165 measurement efo:EFO_0802028 Quantification of RNA polymerase II elongation factor ELL in a sample. Elizabeth Lewis true PMID:29875488 RNA polymerase II elongation factor ELL measurement efo:EFO_0802029 Quantification of RNA polymerase II subunit A C-terminal domain phosphatase SSU72 in a sample. Elizabeth Lewis true PMID:29875488 RNA polymerase II subunit A C-terminal domain phosphatase SSU72 measurement efo:EFO_0802030 Quantification of RNA-binding protein 24 in a sample. Elizabeth Lewis true PMID:29875488 RNA-binding protein 24 measurement efo:EFO_0802031 Quantification of RNA-binding protein 3 in a sample. Elizabeth Lewis true PMID:29875488 RNA-binding protein 3 measurement efo:EFO_0802032 Quantification of RNA-binding protein EWS in a sample. Elizabeth Lewis true PMID:29875488 RNA-binding protein EWS measurement efo:EFO_0802033 Quantification of rRNA methyltransferase 3, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 rRNA methyltransferase 3, mitochondrial measurement efo:EFO_0802034 Quantification of runt-related transcription factor 3 in a sample. Elizabeth Lewis true PMID:29875488 runt-related transcription factor 3 measurement efo:EFO_0802035 Quantification of salivary acidic proline-rich phosphoprotein 1/2 in a sample. Elizabeth Lewis true PMID:29875488 salivary acidic proline-rich phosphoprotein 1/2 measurement efo:EFO_0802036 Quantification of sarcoplasmic/endoplasmic reticulum calcium ATPase 3 in a sample. Elizabeth Lewis true PMID:29875488 sarcoplasmic/endoplasmic reticulum calcium ATPase 3 measurement efo:EFO_0802037 Quantification of scavenger receptor class A member 5 in a sample. Elizabeth Lewis true PMID:29875488 scavenger receptor class A member 5 measurement efo:EFO_0802038 Quantification of SCP2 sterol-binding domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 SCP2 sterol-binding domain-containing protein 1 measurement efo:EFO_0802039 Quantification of secreted frizzled-related protein 2 in a sample. Elizabeth Lewis true PMID:29875488 secreted frizzled-related protein 2 measurement efo:EFO_0802040 Quantification of secreted Ly-6/uPAR-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 secreted Ly-6/uPAR-related protein 1 measurement efo:EFO_0802041 Quantification of secretoglobin family 1C member 1 in a sample. Elizabeth Lewis true PMID:29875488 secretoglobin family 1C member 1 measurement efo:EFO_0802042 Quantification of secretogranin-3 in a sample. Elizabeth Lewis true PMID:29875488 secretogranin-3 measurement efo:EFO_0802043 Quantification of secretory phospholipase A2 receptor in a sample. Elizabeth Lewis true PMID:29875488 secretory phospholipase A2 receptor measurement efo:EFO_0802044 Quantification of segment polarity protein dishevelled homolog DVL-2 in a sample. Elizabeth Lewis true PMID:29875488 segment polarity protein dishevelled homolog DVL-2 measurement efo:EFO_0802045 Quantification of selenide, water dikinase 1 in a sample. Elizabeth Lewis true PMID:29875488 selenide, water dikinase 1 measurement efo:EFO_0802046 Quantification of selenoprotein S in a sample. Elizabeth Lewis true PMID:29875488 selenoprotein S measurement efo:EFO_0802047 Quantification of semaphorin-3B in a sample. Elizabeth Lewis true PMID:29875488 semaphorin-3B measurement efo:EFO_0802048 Quantification of semaphorin-3C in a sample. Elizabeth Lewis true PMID:29875488 semaphorin-3C measurement efo:EFO_0802049 Quantification of semaphorin-3G in a sample. Elizabeth Lewis true PMID:29875488 semaphorin-3G measurement efo:EFO_0802050 Quantification of semaphorin-4D in a sample. Elizabeth Lewis true PMID:29875488 semaphorin-4D measurement efo:EFO_0802051 Quantification of semenogelin-1 in a sample. Elizabeth Lewis true PMID:29875488 semenogelin-1 measurement efo:EFO_0802052 Quantification of semenogelin-2 in a sample. Elizabeth Lewis true PMID:29875488 semenogelin-2 measurement efo:EFO_0802053 Quantification of septin-10 in a sample. Elizabeth Lewis true PMID:29875488 septin-10 measurement efo:EFO_0802054 Quantification of serine protease inhibitor Kazal-type 2 in a sample. Elizabeth Lewis true PMID:29875488 serine protease inhibitor Kazal-type 2 measurement efo:EFO_0802055 Quantification of serine protease inhibitor Kazal-type 6 in a sample. Elizabeth Lewis true PMID:29875488 serine protease inhibitor Kazal-type 6 measurement efo:EFO_0802056 Quantification of serine-rich single-pass membrane protein 1 in a sample. Elizabeth Lewis true PMID:29875488 serine-rich single-pass membrane protein 1 measurement efo:EFO_0802057 Quantification of serine/arginine-rich splicing factor 7 in a sample. Elizabeth Lewis true PMID:29875488 serine/arginine-rich splicing factor 7 measurement efo:EFO_0802058 Quantification of serine/threonine-protein kinase MRCK alpha in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein kinase MRCK alpha measurement efo:EFO_0802059 Quantification of serine/threonine-protein kinase PAK 4 in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein kinase PAK 4 measurement efo:EFO_0802060 Quantification of serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha measurement efo:EFO_0802061 Quantification of serpin A12 in a sample. Elizabeth Lewis true PMID:29875488 serpin A12 measurement efo:EFO_0802062 Quantification of serpin A9 in a sample. Elizabeth Lewis true PMID:29875488 serpin A9 measurement efo:EFO_0802063 Quantification of SH3 domain-binding protein 2 in a sample. Elizabeth Lewis true PMID:29875488 SH3 domain-binding protein 2 measurement efo:EFO_0802064 Quantification of sialic acid-binding Ig-like lectin 10 in a sample. Elizabeth Lewis true PMID:29875488 sialic acid-binding Ig-like lectin 10 measurement efo:EFO_0802065 Quantification of sialic acid-binding Ig-like lectin 11 in a sample. Elizabeth Lewis true PMID:29875488 sialic acid-binding Ig-like lectin 11 measurement efo:EFO_0802066 Quantification of sialic acid-binding Ig-like lectin 12 in a sample. Elizabeth Lewis true PMID:29875488 sialic acid-binding Ig-like lectin 12 measurement efo:EFO_0802067 Quantification of sialic acid-binding Ig-like lectin 8 in a sample. Elizabeth Lewis true PMID:29875488 sialic acid-binding Ig-like lectin 8 measurement efo:EFO_0802068 Quantification of signal peptidase complex catalytic subunit SEC11C in a sample. Elizabeth Lewis true PMID:29875488 signal peptidase complex catalytic subunit SEC11C measurement efo:EFO_0802069 Quantification of signal-regulatory protein beta-1 in a sample. Elizabeth Lewis true PMID:29875488 signal-regulatory protein beta-1 measurement efo:EFO_0802070 Quantification of signal-regulatory protein beta-2 in a sample. Elizabeth Lewis true PMID:29875488 signal-regulatory protein beta-2 measurement efo:EFO_0802071 Quantification of signal-regulatory protein gamma in a sample. Elizabeth Lewis true PMID:29875488 signal-regulatory protein gamma measurement efo:EFO_0802072 Quantification of single Ig IL-1-related receptor in a sample. Elizabeth Lewis true PMID:29875488 single Ig IL-1-related receptor measurement efo:EFO_0802073 Quantification of ski-like protein in a sample. Elizabeth Lewis true PMID:29875488 ski-like protein measurement efo:EFO_0802074 Quantification of SLIT and NTRK-like protein 3 in a sample. Elizabeth Lewis true PMID:29875488 SLIT and NTRK-like protein 3 measurement efo:EFO_0802075 Quantification of small integral membrane protein 9 in a sample. Elizabeth Lewis true PMID:29875488 small integral membrane protein 9 measurement efo:EFO_0802076 Quantification of sodium-coupled monocarboxylate transporter 1 in a sample. Elizabeth Lewis true PMID:29875488 sodium-coupled monocarboxylate transporter 1 measurement efo:EFO_0802077 Quantification of sodium/potassium-transporting ATPase subunit alpha-1 in a sample. Elizabeth Lewis true PMID:29875488 sodium/potassium-transporting ATPase subunit alpha-1 measurement efo:EFO_0802078 Quantification of sodium/potassium-transporting ATPase subunit beta-2 in a sample. Elizabeth Lewis true PMID:29875488 sodium/potassium-transporting ATPase subunit beta-2 measurement efo:EFO_0802079 Quantification of solute carrier family 22 member 16 in a sample. Elizabeth Lewis true PMID:29875488 solute carrier family 22 member 16 measurement efo:EFO_0802080 Quantification of solute carrier family 35 member G2 in a sample. Elizabeth Lewis true PMID:29875488 solute carrier family 35 member G2 measurement efo:EFO_0802081 Quantification of sperm acrosome membrane-associated protein 3 in a sample. Elizabeth Lewis true PMID:29875488 sperm acrosome membrane-associated protein 3 measurement efo:EFO_0802082 Quantification of sperm-associated antigen 11A in a sample. Elizabeth Lewis true PMID:29875488 sperm-associated antigen 11A measurement efo:EFO_0802083 Quantification of spermatogenesis-associated protein 20 in a sample. Elizabeth Lewis true PMID:29875488 spermatogenesis-associated protein 20 measurement efo:EFO_0802084 Quantification of spliceosome RNA helicase DDX39B in a sample. Elizabeth Lewis true PMID:29875488 spliceosome RNA helicase DDX39B measurement efo:EFO_0802085 Quantification of splicing factor 1 in a sample. Elizabeth Lewis true PMID:29875488 splicing factor 1 measurement efo:EFO_0802086 Quantification of stabilin-1 in a sample. Elizabeth Lewis true PMID:29875488 stabilin-1 measurement efo:EFO_0802087 Quantification of stathmin-2 in a sample. Elizabeth Lewis true PMID:29875488 stathmin-2 measurement efo:EFO_0802088 Quantification of stathmin-3 in a sample. Elizabeth Lewis true PMID:29875488 stathmin-3 measurement efo:EFO_0802089 Quantification of stathmin-4 in a sample. Elizabeth Lewis true PMID:29875488 stathmin-4 measurement efo:EFO_0802090 Quantification of stem Cell Growth Factor-beta in a sample. Elizabeth Lewis true PMID:29875488 stem Cell Growth Factor-beta measurement efo:EFO_0802091 Quantification of steroidogenic acute regulatory protein, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 steroidogenic acute regulatory protein, mitochondrial measurement efo:EFO_0802092 Quantification of sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating in a sample. Elizabeth Lewis true PMID:29875488 sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating measurement efo:EFO_0802093 Quantification of stromal interaction molecule 1 in a sample. Elizabeth Lewis true PMID:29875488 stromal interaction molecule 1 measurement efo:EFO_0802094 Quantification of stromal membrane-associated protein 1 in a sample. Elizabeth Lewis true PMID:29875488 stromal membrane-associated protein 1 measurement efo:EFO_0802095 Quantification of stromelysin-2 in a sample. Elizabeth Lewis true PMID:29875488 stromelysin-2 measurement efo:EFO_0802096 Quantification of structural maintenance of chromosomes protein 3 in a sample. Elizabeth Lewis true PMID:29875488 structural maintenance of chromosomes protein 3 measurement efo:EFO_0802097 Quantification of submaxillary gland androgen-regulated protein 3A in a sample. Elizabeth Lewis true PMID:29875488 submaxillary gland androgen-regulated protein 3A measurement efo:EFO_0802098 Quantification of sulfatase-modifying factor 1 in a sample. Elizabeth Lewis true PMID:29875488 sulfatase-modifying factor 1 measurement efo:EFO_0802099 Quantification of sulfhydryl oxidase 1 in a sample. Elizabeth Lewis true PMID:29875488 sulfhydryl oxidase 1 measurement efo:EFO_0802100 Quantification of sulfhydryl oxidase 2 in a sample. Elizabeth Lewis true PMID:29875488 sulfhydryl oxidase 2 measurement efo:EFO_0802101 Quantification of sulfiredoxin-1 in a sample. Elizabeth Lewis true PMID:29875488 sulfiredoxin-1 measurement efo:EFO_0802102 Quantification of SUN domain-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 SUN domain-containing protein 3 measurement efo:EFO_0802103 Quantification of SUN domain-containing protein 5 in a sample. Elizabeth Lewis true PMID:29875488 SUN domain-containing protein 5 measurement efo:EFO_0802104 Quantification of suppressor of cytokine signaling 3 in a sample. Elizabeth Lewis true PMID:29875488 suppressor of cytokine signaling 3 measurement efo:EFO_0802105 Quantification of surfeit locus protein 1 in a sample. Elizabeth Lewis true PMID:29875488 surfeit locus protein 1 measurement efo:EFO_0802106 Quantification of Sushi domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 Sushi domain-containing protein 2 measurement efo:EFO_0802107 Quantification of switch-associated protein 70 in a sample. Elizabeth Lewis true PMID:29875488 switch-associated protein 70 measurement efo:EFO_0802108 Quantification of synaptotagmin-11 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-11 measurement efo:EFO_0802109 Quantification of synaptotagmin-like protein 4 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-like protein 4 measurement efo:EFO_0802110 Quantification of syntaxin-10 in a sample. Elizabeth Lewis true PMID:29875488 syntaxin-10 measurement efo:EFO_0802111 Quantification of syntaxin-2 in a sample. Elizabeth Lewis true PMID:29875488 syntaxin-2 measurement efo:EFO_0802112 Quantification of syntaxin-7 in a sample. Elizabeth Lewis true PMID:29875488 syntaxin-7 measurement efo:EFO_0802113 Quantification of syntaxin-8 in a sample. Elizabeth Lewis true PMID:29875488 syntaxin-8 measurement efo:EFO_0802114 Quantification of T-cell surface glycoprotein CD3 epsilon chain in a sample. Elizabeth Lewis true PMID:29875488 T-cell surface glycoprotein CD3 epsilon chain measurement efo:EFO_0802115 Quantification of T-cell surface protein tactile in a sample. Elizabeth Lewis true PMID:29875488 T-cell surface protein tactile measurement efo:EFO_0802116 Quantification of t-SNARE domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 t-SNARE domain-containing protein 1 measurement efo:EFO_0802117 Quantification of talin-2 in a sample. Elizabeth Lewis true PMID:29875488 talin-2 measurement efo:EFO_0802118 Quantification of tapasin in a sample. Elizabeth Lewis true PMID:29875488 tapasin measurement efo:EFO_0802119 Quantification of tapasin-related protein in a sample. Elizabeth Lewis true PMID:29875488 tapasin-related protein measurement efo:EFO_0802120 Quantification of tax1-binding protein 3 in a sample. Elizabeth Lewis true PMID:29875488 tax1-binding protein 3 measurement efo:EFO_0802121 Quantification of tenascin-X in a sample. Elizabeth Lewis true PMID:29875488 tenascin-X measurement efo:EFO_0802122 Quantification of tensin-2 in a sample. Elizabeth Lewis true PMID:29875488 tensin-2 measurement efo:EFO_0802123 Quantification of tensin-4 in a sample. Elizabeth Lewis true PMID:29875488 tensin-4 measurement efo:EFO_0802124 Quantification of testican-3 in a sample. Elizabeth Lewis true PMID:29875488 testican-3 measurement efo:EFO_0802125 Quantification of testis-expressed sequence 29 protein in a sample. Elizabeth Lewis true PMID:29875488 testis-expressed sequence 29 protein measurement efo:EFO_0802126 Quantification of testis-specific basic protein Y 1 in a sample. Elizabeth Lewis true PMID:29875488 testis-specific basic protein Y 1 measurement efo:EFO_0802127 Quantification of testis-specific chromodomain protein Y 1 in a sample. Elizabeth Lewis true PMID:29875488 testis-specific chromodomain protein Y 1 measurement efo:EFO_0802128 Quantification of thioredoxin domain-containing protein 5 in a sample. Elizabeth Lewis true PMID:29875488 thioredoxin domain-containing protein 5 measurement efo:EFO_0802129 Quantification of thioredoxin reductase 1, cytoplasmic in a sample. Elizabeth Lewis true PMID:29875488 thioredoxin reductase 1, cytoplasmic measurement efo:EFO_0802130 Quantification of thiosulfate sulfurtransferase in a sample. Elizabeth Lewis true PMID:29875488 thiosulfate sulfurtransferase measurement efo:EFO_0802131 Quantification of thrombospondin type-1 domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 thrombospondin type-1 domain-containing protein 1 measurement efo:EFO_0802132 Quantification of thymocyte nuclear protein 1 in a sample. Elizabeth Lewis true PMID:29875488 thymocyte nuclear protein 1 measurement efo:EFO_0802133 Quantification of toll-interacting protein in a sample. Elizabeth Lewis true PMID:29875488 toll-interacting protein measurement efo:EFO_0802134 Quantification of toll/interleukin-1 receptor domain-containing adapter protein in a sample. Elizabeth Lewis true PMID:29875488 toll/interleukin-1 receptor domain-containing adapter protein measurement efo:EFO_0802135 Quantification of tolloid-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 tolloid-like protein 1 measurement efo:EFO_0802136 Quantification of TOM1-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 TOM1-like protein 1 measurement efo:EFO_0802137 Quantification of torsin-1A-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 torsin-1A-interacting protein 1 measurement efo:EFO_0802138 Quantification of transcobalamin-1 in a sample. Elizabeth Lewis true PMID:29875488 transcobalamin-1 measurement efo:EFO_0802139 Quantification of transcobalamin-2 in a sample. Elizabeth Lewis true PMID:29875488 transcobalamin-2 measurement efo:EFO_0802140 Quantification of transcription factor RelB in a sample. Elizabeth Lewis true PMID:29875488 transcription factor RelB measurement efo:EFO_0802141 Quantification of transcription regulator protein BACH1 in a sample. Elizabeth Lewis true PMID:29875488 transcription regulator protein BACH1 measurement efo:EFO_0802142 Quantification of transferrin receptor protein 1 in a sample. Elizabeth Lewis true PMID:29875488 transferrin receptor protein 1 measurement efo:EFO_0802143 Quantification of transformer-2 protein homolog beta in a sample. Elizabeth Lewis true PMID:29875488 transformer-2 protein homolog beta measurement efo:EFO_0802144 Quantification of transforming protein RhoA in a sample. Elizabeth Lewis true PMID:29875488 transforming protein RhoA measurement efo:EFO_0802145 Quantification of translation initiation factor eIF-2B subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 translation initiation factor eIF-2B subunit alpha measurement efo:EFO_0802146 Quantification of transmembrane emp24 domain-containing protein 10 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane emp24 domain-containing protein 10 measurement efo:EFO_0802147 Quantification of transmembrane gamma-carboxyglutamic acid protein 1 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane gamma-carboxyglutamic acid protein 1 measurement efo:EFO_0802148 Quantification of transmembrane inner ear expressed protein in a sample. Elizabeth Lewis true PMID:29875488 transmembrane inner ear expressed protein measurement efo:EFO_0802149 Quantification of transmembrane protease serine 11D in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protease serine 11D measurement efo:EFO_0802150 Quantification of transmembrane protein 132A in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 132A measurement efo:EFO_0802151 Quantification of transmembrane protein 132B in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 132B measurement efo:EFO_0802152 Quantification of transmembrane protein 132C in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 132C measurement efo:EFO_0802153 Quantification of transmembrane protein 132D in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 132D measurement efo:EFO_0802154 Quantification of transmembrane protein 190 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 190 measurement efo:EFO_0802155 Quantification of transmembrane protein 2 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 2 measurement efo:EFO_0802156 Quantification of transmembrane protein 230 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 230 measurement efo:EFO_0802157 Quantification of transmembrane protein 59-like in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 59-like measurement efo:EFO_0802158 Quantification of transmembrane protein 87B in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 87B measurement efo:EFO_0802159 Quantification of trem-like transcript 2 protein in a sample. Elizabeth Lewis true PMID:29875488 trem-like transcript 2 protein measurement efo:EFO_0802160 Quantification of trem-like transcript 4 protein in a sample. Elizabeth Lewis true PMID:29875488 trem-like transcript 4 protein measurement efo:EFO_0802161 Quantification of triggering receptor expressed on myeloid cells 1 in a sample. Elizabeth Lewis true PMID:29875488 triggering receptor expressed on myeloid cells 1 measurement efo:EFO_0802162 Quantification of tRNA (guanine-N(7)-)-methyltransferase in a sample. Elizabeth Lewis true PMID:29875488 tRNA (guanine-N(7)-)-methyltransferase measurement efo:EFO_0802163 Quantification of tuberoinfundibular peptide of 39 residues in a sample. Elizabeth Lewis true PMID:29875488 tuberoinfundibular peptide of 39 residues measurement efo:EFO_0802164 Quantification of tubulin polymerization-promoting protein family member 2 in a sample. Elizabeth Lewis true PMID:29875488 tubulin polymerization-promoting protein family member 2 measurement efo:EFO_0802165 Quantification of tubulin--tyrosine ligase in a sample. Elizabeth Lewis true PMID:29875488 tubulin--tyrosine ligase measurement efo:EFO_0802166 Quantification of tubulin-specific chaperone A in a sample. Elizabeth Lewis true PMID:29875488 tubulin-specific chaperone A measurement efo:EFO_0802167 Quantification of tubulin-specific chaperone E in a sample. Elizabeth Lewis true PMID:29875488 tubulin-specific chaperone E measurement efo:EFO_0802168 Quantification of tumor necrosis factor receptor superfamily member 16 in a sample. Elizabeth Lewis true PMID:29875488 tumor necrosis factor receptor superfamily member 16 measurement efo:EFO_0802169 Quantification of tumor protein p53-inducible protein 11 in a sample. Elizabeth Lewis true PMID:29875488 tumor protein p53-inducible protein 11 measurement efo:EFO_0802170 Quantification of type 2 lactosamine alpha-2,3-sialyltransferase in a sample. Elizabeth Lewis true PMID:29875488 type 2 lactosamine alpha-2,3-sialyltransferase measurement efo:EFO_0802171 Quantification of tyrosine-protein kinase FRK in a sample. Elizabeth Lewis true PMID:29875488 tyrosine-protein kinase FRK measurement efo:EFO_0802172 Quantification of tyrosine-protein phosphatase non-receptor type 4 in a sample. Elizabeth Lewis true PMID:29875488 tyrosine-protein phosphatase non-receptor type 4 measurement efo:EFO_0802173 Quantification of tyrosine-protein phosphatase non-receptor type 7 in a sample. Elizabeth Lewis true PMID:29875488 tyrosine-protein phosphatase non-receptor type 7 measurement efo:EFO_0802174 Quantification of tyrosine-protein phosphatase non-receptor type 9 in a sample. Elizabeth Lewis true PMID:29875488 tyrosine-protein phosphatase non-receptor type 9 measurement efo:EFO_0802175 Quantification of tyrosine-protein phosphatase non-receptor type substrate 1 in a sample. Elizabeth Lewis true PMID:29875488 tyrosine-protein phosphatase non-receptor type substrate 1 measurement efo:EFO_0802176 Quantification of U1 small nuclear ribonucleoprotein A in a sample. Elizabeth Lewis true PMID:29875488 U1 small nuclear ribonucleoprotein A measurement efo:EFO_0802177 Quantification of ubiquilin-4 in a sample. Elizabeth Lewis true PMID:29875488 ubiquilin-4 measurement efo:EFO_0802178 Quantification of ubiquitin carboxyl-terminal hydrolase 21 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin carboxyl-terminal hydrolase 21 measurement efo:EFO_0802179 Quantification of ubiquitin carboxyl-terminal hydrolase 8 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin carboxyl-terminal hydrolase 8 measurement efo:EFO_0802180 Quantification of ubiquitin domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin domain-containing protein 2 measurement efo:EFO_0802181 Quantification of ubiquitin-conjugating enzyme E2 D4 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-conjugating enzyme E2 D4 measurement efo:EFO_0802182 Quantification of ubiquitin-conjugating enzyme E2 variant 1 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-conjugating enzyme E2 variant 1 measurement efo:EFO_0802183 Quantification of ubiquitin-like protein 4A in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-like protein 4A measurement efo:EFO_0802184 Quantification of UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 in a sample. Elizabeth Lewis true PMID:29875488 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 measurement efo:EFO_0802185 Quantification of UDP-glucuronosyltransferase 1-6 in a sample. Elizabeth Lewis true PMID:29875488 UDP-glucuronosyltransferase 1-6 measurement efo:EFO_0802186 Quantification of UDP-glucuronosyltransferase 2A1 in a sample. Elizabeth Lewis true PMID:29875488 UDP-glucuronosyltransferase 2A1 measurement efo:EFO_0802187 Quantification of UDP-N-acetylhexosamine pyrophosphorylase in a sample. Elizabeth Lewis true PMID:29875488 UDP-N-acetylhexosamine pyrophosphorylase measurement efo:EFO_0802188 Quantification of uncharacterized family 31 glucosidase KIAA1161 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized family 31 glucosidase KIAA1161 measurement efo:EFO_0802189 Quantification of uncharacterized protein C10orf35 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C10orf35 measurement efo:EFO_0802190 Quantification of uncharacterized protein C14orf93 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C14orf93 measurement efo:EFO_0802191 Quantification of uncharacterized protein C17orf78 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C17orf78 measurement efo:EFO_0802192 Quantification of uncharacterized protein C2orf66 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C2orf66 measurement efo:EFO_0802193 Quantification of uncharacterized protein C3orf18 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C3orf18 measurement efo:EFO_0802194 Quantification of uncharacterized protein C6orf226 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C6orf226 measurement efo:EFO_0802195 Quantification of uncharacterized protein C7orf69 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C7orf69 measurement efo:EFO_0802196 Quantification of uncharacterized protein KIAA0040 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein KIAA0040 measurement efo:EFO_0802197 Quantification of uncharacterized protein KIAA2013 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein KIAA2013 measurement efo:EFO_0802198 Quantification of unique cartilage matrix-associated protein in a sample. Elizabeth Lewis true PMID:29875488 unique cartilage matrix-associated protein measurement efo:EFO_0802199 Quantification of UPF0454 protein C12orf49 in a sample. Elizabeth Lewis true PMID:29875488 UPF0454 protein C12orf49 measurement efo:EFO_0802200 Quantification of UPF0488 protein C8orf33 in a sample. Elizabeth Lewis true PMID:29875488 UPF0488 protein C8orf33 measurement efo:EFO_0802201 Quantification of UPF0577 protein KIAA1324-like in a sample. Elizabeth Lewis true PMID:29875488 UPF0577 protein KIAA1324-like measurement efo:EFO_0802202 Quantification of UPF0696 protein C11orf68 in a sample. Elizabeth Lewis true PMID:29875488 UPF0696 protein C11orf68 measurement efo:EFO_0802203 Quantification of urea transporter 2 in a sample. Elizabeth Lewis true PMID:29875488 urea transporter 2 measurement efo:EFO_0802204 Quantification of uroplakin-3b-like protein in a sample. Elizabeth Lewis true PMID:29875488 uroplakin-3b-like protein measurement efo:EFO_0802205 Quantification of uroporphyrinogen-III synthase in a sample. Elizabeth Lewis true PMID:29875488 uroporphyrinogen-III synthase measurement efo:EFO_0802206 Quantification of UV excision repair protein RAD23 homolog B in a sample. Elizabeth Lewis true PMID:29875488 UV excision repair protein RAD23 homolog B measurement efo:EFO_0802207 Quantification of vacuolar protein sorting-associated protein 29 in a sample. Elizabeth Lewis true PMID:29875488 vacuolar protein sorting-associated protein 29 measurement efo:EFO_0802208 Quantification of vacuolar protein sorting-associated protein 4A in a sample. Elizabeth Lewis true PMID:29875488 vacuolar protein sorting-associated protein 4A measurement efo:EFO_0802209 Quantification of vacuolar protein sorting-associated protein 4B in a sample. Elizabeth Lewis true PMID:29875488 vacuolar protein sorting-associated protein 4B measurement efo:EFO_0802210 Quantification of valine--tRNA ligase in a sample. Elizabeth Lewis true PMID:29875488 valine--tRNA ligase measurement efo:EFO_0802211 Quantification of very long-chain acyl-CoA synthetase in a sample. Elizabeth Lewis true PMID:29875488 very long-chain acyl-CoA synthetase measurement efo:EFO_0802212 Quantification of vesicle transport through interaction with t-SNAREs homolog 1B in a sample. Elizabeth Lewis true PMID:29875488 vesicle transport through interaction with t-SNAREs homolog 1B measurement efo:EFO_0802213 Quantification of vesicle-associated membrane protein-associated protein A in a sample. Elizabeth Lewis true PMID:29875488 vesicle-associated membrane protein-associated protein A measurement efo:EFO_0802214 Quantification of vesicle-fusing ATPase in a sample. Elizabeth Lewis true PMID:29875488 vesicle-fusing ATPase measurement efo:EFO_0802215 Quantification of vigilin in a sample. Elizabeth Lewis true PMID:29875488 vigilin measurement efo:EFO_0802216 Quantification of VIP36-like protein in a sample. Elizabeth Lewis true PMID:29875488 VIP36-like protein measurement efo:EFO_0802217 Quantification of vitrin in a sample. Elizabeth Lewis true PMID:29875488 vitrin measurement efo:EFO_0802218 Quantification of voltage-dependent calcium channel subunit alpha-2/delta-3 in a sample. Elizabeth Lewis true PMID:29875488 voltage-dependent calcium channel subunit alpha-2/delta-3 measurement efo:EFO_0802219 Quantification of voltage-gated potassium channel subunit beta-2 in a sample. Elizabeth Lewis true PMID:29875488 voltage-gated potassium channel subunit beta-2 measurement efo:EFO_0802220 Quantification of WAP four-disulfide core domain protein 3 in a sample. Elizabeth Lewis true PMID:29875488 WAP four-disulfide core domain protein 3 measurement efo:EFO_0802221 Quantification of WD repeat-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 WD repeat-containing protein 1 measurement efo:EFO_0802222 Quantification of WSC domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 WSC domain-containing protein 2 measurement efo:EFO_0802223 Quantification of xyloside xylosyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 xyloside xylosyltransferase 1 measurement efo:EFO_0802224 Quantification of y-box-binding protein 2 in a sample. Elizabeth Lewis true PMID:29875488 y-box-binding protein 2 measurement efo:EFO_0802225 Quantification of zinc finger protein 175 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 175 measurement efo:EFO_0802226 Quantification of zinc finger protein 18 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 18 measurement efo:EFO_0802227 Quantification of zinc finger protein 276 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 276 measurement efo:EFO_0802228 Quantification of zinc-alpha-2-glycoprotein in a sample. Elizabeth Lewis true PMID:29875488 zinc-alpha-2-glycoprotein measurement efo:EFO_0802229 Quantification of zona pellucida sperm-binding protein 4 in a sample. Elizabeth Lewis true PMID:29875488 zona pellucida sperm-binding protein 4 measurement efo:EFO_0802230 Quantification of [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial measurement efo:EFO_0802231 Quantification of 17-beta-hydroxysteroid dehydrogenase 14 in a sample. Elizabeth Lewis true PMID:29875488 17-beta-hydroxysteroid dehydrogenase 14 measurement efo:EFO_0802232 Quantification of 2',3'-cyclic-nucleotide 3'-phosphodiesterase in a sample. Elizabeth Lewis true PMID:29875488 2',3'-cyclic-nucleotide 3'-phosphodiesterase measurement efo:EFO_0802233 Quantification of 26S proteasome non-ATPase regulatory subunit 1 in a sample. Elizabeth Lewis true PMID:29875488 26S proteasome non-ATPase regulatory subunit 1 measurement efo:EFO_0802234 Quantification of 26S proteasome non-ATPase regulatory subunit 11 in a sample. Elizabeth Lewis true PMID:29875488 26S proteasome non-ATPase regulatory subunit 11 measurement efo:EFO_0802235 Quantification of 26S proteasome non-ATPase regulatory subunit 4 in a sample. Elizabeth Lewis true PMID:29875488 26S proteasome non-ATPase regulatory subunit 4 measurement efo:EFO_0802236 Quantification of 3-mercaptopyruvate sulfurtransferase in a sample. Elizabeth Lewis true PMID:29875488 3-mercaptopyruvate sulfurtransferase measurement efo:EFO_0802237 Quantification of 39S ribosomal protein L14, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 39S ribosomal protein L14, mitochondrial measurement efo:EFO_0802238 Quantification of 39S ribosomal protein L34, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 39S ribosomal protein L34, mitochondrial measurement efo:EFO_0802239 Quantification of 39S ribosomal protein L52, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 39S ribosomal protein L52, mitochondrial measurement efo:EFO_0802240 Quantification of 4-hydroxy-2-oxoglutarate aldolase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 4-hydroxy-2-oxoglutarate aldolase, mitochondrial measurement efo:EFO_0802241 Quantification of 5'-nucleotidase in a sample. Elizabeth Lewis true PMID:29875488 5'-nucleotidase measurement efo:EFO_0802242 Quantification of 6-pyruvoyl tetrahydrobiopterin synthase in a sample. Elizabeth Lewis true PMID:29875488 6-pyruvoyl tetrahydrobiopterin synthase measurement efo:EFO_0802243 Quantification of 60S acidic ribosomal protein P2 in a sample. Elizabeth Lewis true PMID:29875488 60S acidic ribosomal protein P2 measurement efo:EFO_0802244 Quantification of 72 kDa inositol polyphosphate 5-phosphatase in a sample. Elizabeth Lewis true PMID:29875488 72 kDa inositol polyphosphate 5-phosphatase measurement efo:EFO_0802245 Quantification of a disintegrin and metalloproteinase with thrombospondin motifs 3 in a sample. Elizabeth Lewis true PMID:29875488 a disintegrin and metalloproteinase with thrombospondin motifs 3 measurement efo:EFO_0802246 Quantification of A/G-specific adenine DNA glycosylase in a sample. Elizabeth Lewis true PMID:29875488 A/G-specific adenine DNA glycosylase measurement efo:EFO_0802247 Quantification of aarF domain-containing protein kinase 4 in a sample. Elizabeth Lewis true PMID:29875488 aarF domain-containing protein kinase 4 measurement efo:EFO_0802248 Quantification of acetyl-CoA carboxylase 2 in a sample. Elizabeth Lewis true PMID:29875488 acetyl-CoA carboxylase 2 measurement efo:EFO_0802249 Quantification of acid-sensing ion channel 4 in a sample. Elizabeth Lewis true PMID:29875488 acid-sensing ion channel 4 measurement efo:EFO_0802250 Quantification of acidic leucine-rich nuclear phosphoprotein 32 family member A in a sample. Elizabeth Lewis true PMID:29875488 acidic leucine-rich nuclear phosphoprotein 32 family member A measurement efo:EFO_0802251 Quantification of actin-binding LIM protein 3 in a sample. Elizabeth Lewis true PMID:29875488 actin-binding LIM protein 3 measurement efo:EFO_0802252 Quantification of actin-related protein 2/3 complex subunit 3 in a sample. Elizabeth Lewis true PMID:29875488 actin-related protein 2/3 complex subunit 3 measurement efo:EFO_0802253 Quantification of activator of apoptosis harakiri in a sample. Elizabeth Lewis true PMID:29875488 activator of apoptosis harakiri measurement efo:EFO_0802254 Quantification of ADAMTS-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 ADAMTS-like protein 1 measurement efo:EFO_0802255 Quantification of adenosine 3'-phospho 5'-phosphosulfate transporter 2 in a sample. Elizabeth Lewis true PMID:29875488 adenosine 3'-phospho 5'-phosphosulfate transporter 2 measurement efo:EFO_0802256 Quantification of adenylosuccinate synthetase isozyme 1 in a sample. Elizabeth Lewis true PMID:29875488 adenylosuccinate synthetase isozyme 1 measurement efo:EFO_0802257 Quantification of adenylyltransferase and sulfurtransferase MOCS3 in a sample. Elizabeth Lewis true PMID:29875488 adenylyltransferase and sulfurtransferase MOCS3 measurement efo:EFO_0802258 Quantification of ADP-dependent glucokinase in a sample. Elizabeth Lewis true PMID:29875488 ADP-dependent glucokinase measurement efo:EFO_0802259 Quantification of ADP-ribosylation factor 3 in a sample. Elizabeth Lewis true PMID:29875488 ADP-ribosylation factor 3 measurement efo:EFO_0802260 Quantification of alanine aminotransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 alanine aminotransferase 1 measurement efo:EFO_0802261 Quantification of alcohol dehydrogenase 4 in a sample. Elizabeth Lewis true PMID:29875488 alcohol dehydrogenase 4 measurement efo:EFO_0802262 Quantification of all-trans-retinol 13,14-reductase in a sample. Elizabeth Lewis true PMID:29875488 all-trans-retinol 13,14-reductase measurement efo:EFO_0802263 Quantification of alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase in a sample. Elizabeth Lewis true PMID:29875488 alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase measurement efo:EFO_0802264 Quantification of alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C in a sample. Elizabeth Lewis true PMID:29875488 alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C measurement efo:EFO_0802265 Quantification of alpha-2,8-sialyltransferase 8B in a sample. Elizabeth Lewis true PMID:29875488 alpha-2,8-sialyltransferase 8B measurement efo:EFO_0802266 Quantification of alpha-2,8-sialyltransferase 8F in a sample. Elizabeth Lewis true PMID:29875488 alpha-2,8-sialyltransferase 8F measurement efo:EFO_0802267 Quantification of alpha-crystallin A chain in a sample. Elizabeth Lewis true PMID:29875488 alpha-crystallin A chain measurement efo:EFO_0802268 Quantification of alpha-internexin in a sample. Elizabeth Lewis true PMID:29875488 alpha-internexin measurement efo:EFO_0802269 Quantification of alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 in a sample. Elizabeth Lewis true PMID:29875488 alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 measurement efo:EFO_0802270 Quantification of alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 in a sample. Elizabeth Lewis true PMID:29875488 alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 measurement efo:EFO_0802271 Quantification of alpha-parvin in a sample. Elizabeth Lewis true PMID:29875488 alpha-parvin measurement efo:EFO_0802272 Quantification of alpha-S1-casein in a sample. Elizabeth Lewis true PMID:29875488 alpha-S1-casein measurement efo:EFO_0802273 Quantification of amphoterin-induced protein 1 in a sample. Elizabeth Lewis true PMID:29875488 amphoterin-induced protein 1 measurement efo:EFO_0802274 Quantification of AMSH-like protease in a sample. Elizabeth Lewis true PMID:29875488 AMSH-like protease measurement efo:EFO_0802275 Quantification of amyloid beta A4 precursor protein-binding family B member 1 in a sample. Elizabeth Lewis true PMID:29875488 amyloid beta A4 precursor protein-binding family B member 1 measurement efo:EFO_0802276 Quantification of amyloid beta A4 precursor protein-binding family B member 3 in a sample. Elizabeth Lewis true PMID:29875488 amyloid beta A4 precursor protein-binding family B member 3 measurement efo:EFO_0802277 Quantification of anaphase-promoting complex subunit 10 in a sample. Elizabeth Lewis true PMID:29875488 anaphase-promoting complex subunit 10 measurement efo:EFO_0802278 Quantification of angiogenic factor with G patch and FHA domains 1 in a sample. Elizabeth Lewis true PMID:29875488 angiogenic factor with G patch and FHA domains 1 measurement efo:EFO_0802279 Quantification of angiopoietin-like protein 8 in a sample. Elizabeth Lewis true PMID:29875488 angiopoietin-like protein 8 measurement efo:EFO_0802280 Quantification of angiopoietin-related protein 7 in a sample. Elizabeth Lewis true PMID:29875488 angiopoietin-related protein 7 measurement efo:EFO_0802281 Quantification of ankyrin repeat domain-containing protein 27 in a sample. Elizabeth Lewis true PMID:29875488 ankyrin repeat domain-containing protein 27 measurement efo:EFO_0802282 Quantification of ankyrin repeat domain-containing protein 46 in a sample. Elizabeth Lewis true PMID:29875488 ankyrin repeat domain-containing protein 46 measurement efo:EFO_0802283 Quantification of annexin A9 in a sample. Elizabeth Lewis true PMID:29875488 annexin A9 measurement efo:EFO_0802284 Quantification of anosmin-1 in a sample. Elizabeth Lewis true PMID:29875488 anosmin-1 measurement efo:EFO_0802285 Quantification of antigen-presenting glycoprotein CD1d in a sample. Elizabeth Lewis true PMID:29875488 antigen-presenting glycoprotein CD1d measurement efo:EFO_0802286 Quantification of arginine/serine-rich protein 1 in a sample. Elizabeth Lewis true PMID:29875488 arginine/serine-rich protein 1 measurement efo:EFO_0802287 Quantification of argininosuccinate lyase in a sample. Elizabeth Lewis true PMID:29875488 argininosuccinate lyase measurement efo:EFO_0802288 Quantification of armadillo repeat-containing protein 5 in a sample. Elizabeth Lewis true PMID:29875488 armadillo repeat-containing protein 5 measurement efo:EFO_0802289 Quantification of arrestin domain-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 arrestin domain-containing protein 3 measurement efo:EFO_0802290 Quantification of asialoglycoprotein receptor 2 in a sample. Elizabeth Lewis true PMID:29875488 asialoglycoprotein receptor 2 measurement efo:EFO_0802291 Quantification of astacin-like metalloendopeptidase in a sample. Elizabeth Lewis true PMID:29875488 astacin-like metalloendopeptidase measurement efo:EFO_0802292 Quantification of ATP-citrate synthase in a sample. Elizabeth Lewis true PMID:29875488 ATP-citrate synthase measurement efo:EFO_0802293 Quantification of ATP-dependent DNA helicase Q1 in a sample. Elizabeth Lewis true PMID:29875488 ATP-dependent DNA helicase Q1 measurement efo:EFO_0802294 Quantification of ATP-dependent RNA helicase A in a sample. Elizabeth Lewis true PMID:29875488 ATP-dependent RNA helicase A measurement efo:EFO_0802295 Quantification of ATP-dependent RNA helicase DDX25 in a sample. Elizabeth Lewis true PMID:29875488 ATP-dependent RNA helicase DDX25 measurement efo:EFO_0802296 Quantification of ATPase ASNA1 in a sample. Elizabeth Lewis true PMID:29875488 ATPase ASNA1 measurement efo:EFO_0802297 Quantification of ATPase family AAA domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 ATPase family AAA domain-containing protein 1 measurement efo:EFO_0802298 Quantification of ATPase family AAA domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 ATPase family AAA domain-containing protein 2 measurement efo:EFO_0802299 Quantification of b melanoma antigen 3 in a sample. Elizabeth Lewis true PMID:29875488 b melanoma antigen 3 measurement efo:EFO_0802300 Quantification of B-cell antigen receptor complex-associated protein beta chain in a sample. Elizabeth Lewis true PMID:29875488 B-cell antigen receptor complex-associated protein beta chain measurement efo:EFO_0802301 Quantification of B-cell receptor-associated protein 29 in a sample. Elizabeth Lewis true PMID:29875488 B-cell receptor-associated protein 29 measurement efo:EFO_0802302 Quantification of BAG family molecular chaperone regulator 3 in a sample. Elizabeth Lewis true PMID:29875488 BAG family molecular chaperone regulator 3 measurement efo:EFO_0802303 Quantification of BAG family molecular chaperone regulator 4 in a sample. Elizabeth Lewis true PMID:29875488 BAG family molecular chaperone regulator 4 measurement efo:EFO_0802304 Quantification of BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 in a sample. Elizabeth Lewis true PMID:29875488 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 measurement efo:EFO_0802305 Quantification of BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like in a sample. Elizabeth Lewis true PMID:29875488 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like measurement efo:EFO_0802306 Quantification of beclin-1 in a sample. Elizabeth Lewis true PMID:29875488 beclin-1 measurement efo:EFO_0802307 Quantification of BET1-like protein in a sample. Elizabeth Lewis true PMID:29875488 BET1-like protein measurement efo:EFO_0802308 Quantification of beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase in a sample. Elizabeth Lewis true PMID:29875488 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase measurement efo:EFO_0802309 Quantification of beta-1,3-galactosyltransferase 6 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,3-galactosyltransferase 6 measurement efo:EFO_0802310 Quantification of beta-1,3-glucosyltransferase in a sample. Elizabeth Lewis true PMID:29875488 beta-1,3-glucosyltransferase measurement efo:EFO_0802311 Quantification of beta-1,3-N-acetylglucosaminyltransferase manic fringe in a sample. Elizabeth Lewis true PMID:29875488 beta-1,3-N-acetylglucosaminyltransferase manic fringe measurement efo:EFO_0802312 Quantification of beta-1,4-galactosyltransferase 3 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,4-galactosyltransferase 3 measurement efo:EFO_0802313 Quantification of beta-1,4-galactosyltransferase 5 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,4-galactosyltransferase 5 measurement efo:EFO_0802314 Quantification of beta-1,4-galactosyltransferase 7 in a sample. Elizabeth Lewis true PMID:29875488 beta-1,4-galactosyltransferase 7 measurement efo:EFO_0802315 Quantification of beta-defensin 103 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 103 measurement efo:EFO_0802316 Quantification of beta-defensin 106 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 106 measurement efo:EFO_0802317 Quantification of beta-defensin 107 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 107 measurement efo:EFO_0802318 Quantification of beta-defensin 108B in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 108B measurement efo:EFO_0802319 Quantification of beta-defensin 110 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 110 measurement efo:EFO_0802320 Quantification of beta-defensin 113 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 113 measurement efo:EFO_0802321 Quantification of beta-defensin 115 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 115 measurement efo:EFO_0802322 Quantification of beta-defensin 116 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 116 measurement efo:EFO_0802323 Quantification of beta-defensin 118 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 118 measurement efo:EFO_0802324 Quantification of beta-defensin 121 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 121 measurement efo:EFO_0802325 Quantification of beta-defensin 123 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 123 measurement efo:EFO_0802326 Quantification of beta-defensin 125 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 125 measurement efo:EFO_0802327 Quantification of beta-defensin 134 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 134 measurement efo:EFO_0802328 Quantification of beta-defensin 135 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 135 measurement efo:EFO_0802329 Quantification of beta-defensin 136 in a sample. Elizabeth Lewis true PMID:29875488 beta-defensin 136 measurement efo:EFO_0802330 Quantification of beta-galactoside alpha-2,6-sialyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 beta-galactoside alpha-2,6-sialyltransferase 1 measurement efo:EFO_0802331 Quantification of bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 in a sample. Elizabeth Lewis true PMID:29875488 bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 measurement efo:EFO_0802332 Quantification of bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 measurement efo:EFO_0802333 Quantification of bile salt sulfotransferase in a sample. Elizabeth Lewis true PMID:29875488 bile salt sulfotransferase measurement efo:EFO_0802334 Quantification of bisphosphoglycerate mutase in a sample. Elizabeth Lewis true PMID:29875488 bisphosphoglycerate mutase measurement efo:EFO_0802335 Quantification of bolA-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 bolA-like protein 2 measurement efo:EFO_0802336 Quantification of BPI fold-containing family A member 1 in a sample. Elizabeth Lewis true PMID:29875488 BPI fold-containing family A member 1 measurement efo:EFO_0802337 Quantification of BRCA1-associated RING domain protein 1 in a sample. Elizabeth Lewis true PMID:29875488 BRCA1-associated RING domain protein 1 measurement efo:EFO_0802338 Quantification of BRISC complex subunit Abro1 in a sample. Elizabeth Lewis true PMID:29875488 BRISC complex subunit Abro1 measurement efo:EFO_0802339 Quantification of bromodomain testis-specific protein in a sample. Elizabeth Lewis true PMID:29875488 bromodomain testis-specific protein measurement efo:EFO_0802340 Quantification of BTB/POZ domain-containing protein KCTD5 in a sample. Elizabeth Lewis true PMID:29875488 BTB/POZ domain-containing protein KCTD5 measurement efo:EFO_0802341 Quantification of butyrophilin-like protein 9 in a sample. Elizabeth Lewis true PMID:29875488 butyrophilin-like protein 9 measurement efo:EFO_0802342 Quantification of C-type lectin domain family 10 member A in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 10 member A measurement efo:EFO_0802343 Quantification of C-type lectin domain family 14 member A in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 14 member A measurement efo:EFO_0802344 Quantification of C-type lectin domain family 2 member A in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 2 member A measurement efo:EFO_0802345 Quantification of C-type lectin domain family 2 member B in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 2 member B measurement efo:EFO_0802346 Quantification of C-type lectin domain family 2 member L in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 2 member L measurement efo:EFO_0802347 Quantification of C-type lectin domain family 4 member D in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 4 member D measurement efo:EFO_0802348 Quantification of C-type lectin domain family 6 member A in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 6 member A measurement efo:EFO_0802349 Quantification of C-type lectin domain family 7 member A in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin domain family 7 member A measurement efo:EFO_0802350 Quantification of C-type lectin-like domain family 1 in a sample. Elizabeth Lewis true PMID:29875488 C-type lectin-like domain family 1 measurement efo:EFO_0802351 Quantification of C-X-C motif chemokine 14 in a sample. Elizabeth Lewis true PMID:29875488 C-X-C motif chemokine 14 measurement efo:EFO_0802352 Quantification of cadherin-related family member 3 in a sample. Elizabeth Lewis true PMID:29875488 cadherin-related family member 3 measurement efo:EFO_0802353 Quantification of calcineurin B homologous protein 1 in a sample. Elizabeth Lewis true PMID:29875488 calcineurin B homologous protein 1 measurement efo:EFO_0802354 Quantification of calcineurin B homologous protein 3 in a sample. Elizabeth Lewis true PMID:29875488 calcineurin B homologous protein 3 measurement efo:EFO_0802355 Quantification of calcium uptake protein 3, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 calcium uptake protein 3, mitochondrial measurement efo:EFO_0802356 Quantification of calcium-binding and coiled-coil domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 calcium-binding and coiled-coil domain-containing protein 2 measurement efo:EFO_0802357 Quantification of calcium-binding protein 8 in a sample. Elizabeth Lewis true PMID:29875488 calcium-binding protein 8 measurement efo:EFO_0802358 Quantification of calcium-regulated heat stable protein 1 in a sample. Elizabeth Lewis true PMID:29875488 calcium-regulated heat stable protein 1 measurement efo:EFO_0802359 Quantification of calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A in a sample. Elizabeth Lewis true PMID:29875488 calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A measurement efo:EFO_0802360 Quantification of calcyphosin-like protein in a sample. Elizabeth Lewis true PMID:29875488 calcyphosin-like protein measurement efo:EFO_0802361 Quantification of calpain-3 in a sample. Elizabeth Lewis true PMID:29875488 calpain-3 measurement efo:EFO_0802362 Quantification of calsenilin in a sample. Elizabeth Lewis true PMID:29875488 calsenilin measurement efo:EFO_0802363 Quantification of calsyntenin-3 in a sample. Elizabeth Lewis true PMID:29875488 calsyntenin-3 measurement efo:EFO_0802364 Quantification of cAMP-regulated phosphoprotein 21 in a sample. Elizabeth Lewis true PMID:29875488 cAMP-regulated phosphoprotein 21 measurement efo:EFO_0802365 Quantification of cancer/testis antigen 55 in a sample. Elizabeth Lewis true PMID:29875488 cancer/testis antigen 55 measurement efo:EFO_0802366 Quantification of carbohydrate sulfotransferase 14 in a sample. Elizabeth Lewis true PMID:29875488 carbohydrate sulfotransferase 14 measurement efo:EFO_0802367 Quantification of carbohydrate sulfotransferase 3 in a sample. Elizabeth Lewis true PMID:29875488 carbohydrate sulfotransferase 3 measurement efo:EFO_0802368 Quantification of carbohydrate sulfotransferase 5 in a sample. Elizabeth Lewis true PMID:29875488 carbohydrate sulfotransferase 5 measurement efo:EFO_0802369 Quantification of carcinoembryonic antigen-related cell adhesion molecule 21 in a sample. Elizabeth Lewis true PMID:29875488 carcinoembryonic antigen-related cell adhesion molecule 21 measurement efo:EFO_0802370 Quantification of carcinoembryonic antigen-related cell adhesion molecule 4 in a sample. Elizabeth Lewis true PMID:29875488 carcinoembryonic antigen-related cell adhesion molecule 4 measurement efo:EFO_0802371 Quantification of cas scaffolding protein family member 4 in a sample. Elizabeth Lewis true PMID:29875488 cas scaffolding protein family member 4 measurement efo:EFO_0802372 Quantification of casein kinase I isoform delta in a sample. Elizabeth Lewis true PMID:29875488 casein kinase I isoform delta measurement efo:EFO_0802373 Quantification of caseinolytic peptidase B protein homolog in a sample. Elizabeth Lewis true PMID:29875488 caseinolytic peptidase B protein homolog measurement efo:EFO_0802374 Quantification of catenin alpha-2 in a sample. Elizabeth Lewis true PMID:29875488 catenin alpha-2 measurement efo:EFO_0802375 Quantification of cathepsin O in a sample. Elizabeth Lewis true PMID:29875488 cathepsin O measurement efo:EFO_0802376 Quantification of caveolin-2 in a sample. Elizabeth Lewis true PMID:29875488 caveolin-2 measurement efo:EFO_0802377 Quantification of CCR4-NOT transcription complex subunit 1 in a sample. Elizabeth Lewis true PMID:29875488 CCR4-NOT transcription complex subunit 1 measurement efo:EFO_0802378 Quantification of CD44 antigen in a sample. Elizabeth Lewis true PMID:29875488 CD44 antigen measurement efo:EFO_0802379 Quantification of CDGSH iron-sulfur domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 CDGSH iron-sulfur domain-containing protein 2 measurement efo:EFO_0802380 Quantification of cell adhesion molecule 4 in a sample. Elizabeth Lewis true PMID:29875488 cell adhesion molecule 4 measurement efo:EFO_0802381 Quantification of cell cycle checkpoint protein RAD1 in a sample. Elizabeth Lewis true PMID:29875488 cell cycle checkpoint protein RAD1 measurement efo:EFO_0802382 Quantification of cell cycle progression protein 1 in a sample. Elizabeth Lewis true PMID:29875488 cell cycle progression protein 1 measurement efo:EFO_0802383 Quantification of cell differentiation protein RCD1 homolog in a sample. Elizabeth Lewis true PMID:29875488 cell differentiation protein RCD1 homolog measurement efo:EFO_0802384 Quantification of cell division control protein 42 homolog in a sample. Elizabeth Lewis true PMID:29875488 cell division control protein 42 homolog measurement efo:EFO_0802385 Quantification of cell surface A33 antigen in a sample. Elizabeth Lewis true PMID:29875488 cell surface A33 antigen measurement efo:EFO_0802386 Quantification of cellular retinoic acid-binding protein 2 in a sample. Elizabeth Lewis true PMID:29875488 cellular retinoic acid-binding protein 2 measurement efo:EFO_0802387 Quantification of centromere protein W in a sample. Elizabeth Lewis true PMID:29875488 centromere protein W measurement efo:EFO_0802388 Quantification of ceramide synthase 5 in a sample. Elizabeth Lewis true PMID:29875488 ceramide synthase 5 measurement efo:EFO_0802389 Quantification of cerebral cavernous malformations 2 protein in a sample. Elizabeth Lewis true PMID:29875488 cerebral cavernous malformations 2 protein measurement efo:EFO_0802390 Quantification of ceroid-lipofuscinosis neuronal protein 5 in a sample. Elizabeth Lewis true PMID:29875488 ceroid-lipofuscinosis neuronal protein 5 measurement efo:EFO_0802391 Quantification of cGMP-dependent 3',5'-cyclic phosphodiesterase in a sample. Elizabeth Lewis true PMID:29875488 cGMP-dependent 3',5'-cyclic phosphodiesterase measurement efo:EFO_0802392 Quantification of chloride intracellular channel protein 4 in a sample. Elizabeth Lewis true PMID:29875488 chloride intracellular channel protein 4 measurement efo:EFO_0802393 Quantification of chondroadherin in a sample. Elizabeth Lewis true PMID:29875488 chondroadherin measurement efo:EFO_0802394 Quantification of chondroitin sulfate proteoglycan 4 in a sample. Elizabeth Lewis true PMID:29875488 chondroitin sulfate proteoglycan 4 measurement efo:EFO_0802395 Quantification of chordin in a sample. Elizabeth Lewis true PMID:29875488 chordin measurement efo:EFO_0802396 Quantification of choriogonadotropin subunit beta variant 2 in a sample. Elizabeth Lewis true PMID:29875488 choriogonadotropin subunit beta variant 2 measurement efo:EFO_0802397 Quantification of chromodomain-helicase-DNA-binding protein 7 in a sample. Elizabeth Lewis true PMID:29875488 chromodomain-helicase-DNA-binding protein 7 measurement efo:EFO_0802398 Quantification of chymotrypsin-C in a sample. Elizabeth Lewis true PMID:29875488 chymotrypsin-C measurement efo:EFO_0802399 Quantification of chymotrypsin-like elastase family member 2A in a sample. Elizabeth Lewis true PMID:29875488 chymotrypsin-like elastase family member 2A measurement efo:EFO_0802400 Quantification of chymotrypsin-like elastase family member 3B in a sample. Elizabeth Lewis true PMID:29875488 chymotrypsin-like elastase family member 3B measurement efo:EFO_0802401 Quantification of cilia- and flagella-associated protein 45 in a sample. Elizabeth Lewis true PMID:29875488 cilia- and flagella-associated protein 45 measurement efo:EFO_0802402 Quantification of clathrin heavy chain 1 in a sample. Elizabeth Lewis true PMID:29875488 clathrin heavy chain 1 measurement efo:EFO_0802403 Quantification of CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 measurement efo:EFO_0802404 Quantification of CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase in a sample. Elizabeth Lewis true PMID:29875488 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase measurement efo:EFO_0802405 Quantification of CMRF35-like molecule 1 in a sample. Elizabeth Lewis true PMID:29875488 CMRF35-like molecule 1 measurement efo:EFO_0802406 Quantification of CMRF35-like molecule 2 in a sample. Elizabeth Lewis true PMID:29875488 CMRF35-like molecule 2 measurement efo:EFO_0802407 Quantification of CMRF35-like molecule 7 in a sample. Elizabeth Lewis true PMID:29875488 CMRF35-like molecule 7 measurement efo:EFO_0802408 Quantification of CMRF35-like molecule 9 in a sample. Elizabeth Lewis true PMID:29875488 CMRF35-like molecule 9 measurement efo:EFO_0802409 Quantification of cocaine- and amphetamine-regulated transcript protein in a sample. Elizabeth Lewis true PMID:29875488 cocaine- and amphetamine-regulated transcript protein measurement efo:EFO_0802410 Quantification of coiled-coil domain-containing protein 134 in a sample. Elizabeth Lewis true PMID:29875488 coiled-coil domain-containing protein 134 measurement efo:EFO_0802411 Quantification of coiled-coil domain-containing protein 167 in a sample. Elizabeth Lewis true PMID:29875488 coiled-coil domain-containing protein 167 measurement efo:EFO_0802412 Quantification of coiled-coil domain-containing protein 51 in a sample. Elizabeth Lewis true PMID:29875488 coiled-coil domain-containing protein 51 measurement efo:EFO_0802413 Quantification of coiled-coil domain-containing protein 90B, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 coiled-coil domain-containing protein 90B, mitochondrial measurement efo:EFO_0802414 Quantification of coiled-coil-helix-coiled-coil-helix domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 coiled-coil-helix-coiled-coil-helix domain-containing protein 2 measurement efo:EFO_0802415 Quantification of cold shock domain-containing protein C2 in a sample. Elizabeth Lewis true PMID:29875488 cold shock domain-containing protein C2 measurement efo:EFO_0802416 Quantification of cold shock domain-containing protein E1 in a sample. Elizabeth Lewis true PMID:29875488 cold shock domain-containing protein E1 measurement efo:EFO_0802417 Quantification of colipase-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 colipase-like protein 2 measurement efo:EFO_0802418 Quantification of collagen alpha-1(XX) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-1(XX) chain measurement efo:EFO_0802419 Quantification of collagen alpha-1(XXVI) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-1(XXVI) chain measurement efo:EFO_0802420 Quantification of collagen alpha-1(XXVIII) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-1(XXVIII) chain measurement efo:EFO_0802421 Quantification of collagen alpha-3(VI) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-3(VI) chain measurement efo:EFO_0802422 Quantification of collagen alpha-5(VI) chain in a sample. Elizabeth Lewis true PMID:29875488 collagen alpha-5(VI) chain measurement efo:EFO_0802423 Quantification of collectrin in a sample. Elizabeth Lewis true PMID:29875488 collectrin measurement efo:EFO_0802424 Quantification of COMM domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 COMM domain-containing protein 1 measurement efo:EFO_0802425 Quantification of complement C1q tumor necrosis factor-related protein 3 in a sample. Elizabeth Lewis true PMID:29875488 complement C1q tumor necrosis factor-related protein 3 measurement efo:EFO_0802426 Quantification of complement C1q-like protein 4 in a sample. Elizabeth Lewis true PMID:29875488 complement C1q-like protein 4 measurement efo:EFO_0802427 Quantification of complement component C1q receptor in a sample. Elizabeth Lewis true PMID:29875488 complement component C1q receptor measurement efo:EFO_0802428 Quantification of conserved oligomeric Golgi complex subunit 8 in a sample. Elizabeth Lewis true PMID:29875488 conserved oligomeric Golgi complex subunit 8 measurement efo:EFO_0802429 Quantification of contactin-associated protein 1 in a sample. Elizabeth Lewis true PMID:29875488 contactin-associated protein 1 measurement efo:EFO_0802430 Quantification of corticoliberin in a sample. Elizabeth Lewis true PMID:29875488 corticoliberin measurement efo:EFO_0802431 Quantification of coxsackievirus and adenovirus receptor in a sample. Elizabeth Lewis true PMID:29875488 coxsackievirus and adenovirus receptor measurement efo:EFO_0802432 Quantification of CUB domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 CUB domain-containing protein 1 measurement efo:EFO_0802433 Quantification of cubilin in a sample. Elizabeth Lewis true PMID:29875488 cubilin measurement efo:EFO_0802434 Quantification of CUGBP Elav-like family member 2 in a sample. Elizabeth Lewis true PMID:29875488 CUGBP Elav-like family member 2 measurement efo:EFO_0802435 Quantification of cullin-3 in a sample. Elizabeth Lewis true PMID:29875488 cullin-3 measurement efo:EFO_0802436 Quantification of cullin-4B in a sample. Elizabeth Lewis true PMID:29875488 cullin-4B measurement efo:EFO_0802437 Quantification of cullin-9 in a sample. Elizabeth Lewis true PMID:29875488 cullin-9 measurement efo:EFO_0802438 Quantification of cullin-associated NEDD8-dissociated protein 1 in a sample. Elizabeth Lewis true PMID:29875488 cullin-associated NEDD8-dissociated protein 1 measurement efo:EFO_0802439 Quantification of cyclic AMP-responsive element-binding protein 3-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 cyclic AMP-responsive element-binding protein 3-like protein 1 measurement efo:EFO_0802440 Quantification of cyclin-dependent kinase 2-associated protein 1 in a sample. Elizabeth Lewis true PMID:29875488 cyclin-dependent kinase 2-associated protein 1 measurement efo:EFO_0802441 Quantification of cyclin-dependent kinase 4 inhibitor B in a sample. Elizabeth Lewis true PMID:29875488 cyclin-dependent kinase 4 inhibitor B measurement efo:EFO_0802442 Quantification of cyclin-dependent kinase inhibitor 3 in a sample. Elizabeth Lewis true PMID:29875488 cyclin-dependent kinase inhibitor 3 measurement efo:EFO_0802443 Quantification of cystathionine beta-synthase in a sample. Elizabeth Lewis true PMID:29875488 cystathionine beta-synthase measurement efo:EFO_0802444 Quantification of cysteine and glycine-rich protein 2 in a sample. Elizabeth Lewis true PMID:29875488 cysteine and glycine-rich protein 2 measurement efo:EFO_0802445 Quantification of cysteine--tRNA ligase, cytoplasmic in a sample. Elizabeth Lewis true PMID:29875488 cysteine--tRNA ligase, cytoplasmic measurement efo:EFO_0802446 Quantification of cysteine-rich motor neuron 1 protein in a sample. Elizabeth Lewis true PMID:29875488 cysteine-rich motor neuron 1 protein measurement efo:EFO_0802447 Quantification of cytochrome b-c1 complex subunit 7 in a sample. Elizabeth Lewis true PMID:29875488 cytochrome b-c1 complex subunit 7 measurement efo:EFO_0802448 Quantification of cytochrome b5 in a sample. Elizabeth Lewis true PMID:29875488 cytochrome b5 measurement efo:EFO_0802449 Quantification of cytochrome c oxidase subunit 5B, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 cytochrome c oxidase subunit 5B, mitochondrial measurement efo:EFO_0802450 Quantification of cytochrome c oxidase subunit 7A1, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 cytochrome c oxidase subunit 7A1, mitochondrial measurement efo:EFO_0802451 Quantification of cytoglobin in a sample. Elizabeth Lewis true PMID:29875488 cytoglobin measurement efo:EFO_0802452 Quantification of cytohesin-4 in a sample. Elizabeth Lewis true PMID:29875488 cytohesin-4 measurement efo:EFO_0802453 Quantification of cytohesin-interacting protein in a sample. Elizabeth Lewis true PMID:29875488 cytohesin-interacting protein measurement efo:EFO_0802454 Quantification of cytokine receptor-like factor 1 in a sample. Elizabeth Lewis true PMID:29875488 cytokine receptor-like factor 1 measurement efo:EFO_0802455 Quantification of DCC-interacting protein 13-alpha in a sample. Elizabeth Lewis true PMID:29875488 DCC-interacting protein 13-alpha measurement efo:EFO_0802456 Quantification of DCN1-like protein 3 in a sample. Elizabeth Lewis true PMID:29875488 DCN1-like protein 3 measurement efo:EFO_0802457 Quantification of DDB1- and CUL4-associated factor 5 in a sample. Elizabeth Lewis true PMID:29875488 DDB1- and CUL4-associated factor 5 measurement efo:EFO_0802458 Quantification of delta and Notch-like epidermal growth factor-related receptor in a sample. Elizabeth Lewis true PMID:29875488 delta and Notch-like epidermal growth factor-related receptor measurement efo:EFO_0802459 Quantification of deoxynucleoside triphosphate triphosphohydrolase SAMHD1 in a sample. Elizabeth Lewis true PMID:29875488 deoxynucleoside triphosphate triphosphohydrolase SAMHD1 measurement efo:EFO_0802460 Quantification of deoxyribonuclease-2-beta in a sample. Elizabeth Lewis true PMID:29875488 deoxyribonuclease-2-beta measurement efo:EFO_0802461 Quantification of derlin-1 in a sample. Elizabeth Lewis true PMID:29875488 derlin-1 measurement efo:EFO_0802462 Quantification of dermokine in a sample. Elizabeth Lewis true PMID:29875488 dermokine measurement efo:EFO_0802463 Quantification of desmin in a sample. Elizabeth Lewis true PMID:29875488 desmin measurement efo:EFO_0802464 Quantification of diamine acetyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 diamine acetyltransferase 1 measurement efo:EFO_0802465 Quantification of diamine acetyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 diamine acetyltransferase 2 measurement efo:EFO_0802466 Quantification of dihydrolipoyl dehydrogenase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 dihydrolipoyl dehydrogenase, mitochondrial measurement efo:EFO_0802467 Quantification of dihydropyrimidinase-related protein 3 in a sample. Elizabeth Lewis true PMID:29875488 dihydropyrimidinase-related protein 3 measurement efo:EFO_0802468 Quantification of dihydropyrimidinase-related protein 5 in a sample. Elizabeth Lewis true PMID:29875488 dihydropyrimidinase-related protein 5 measurement efo:EFO_0802469 Quantification of dipeptidase 1 in a sample. Elizabeth Lewis true PMID:29875488 dipeptidase 1 measurement efo:EFO_0802470 Quantification of disintegrin and metalloproteinase domain-containing protein 19 in a sample. Elizabeth Lewis true PMID:29875488 disintegrin and metalloproteinase domain-containing protein 19 measurement efo:EFO_0802471 Quantification of disintegrin and metalloproteinase domain-containing protein 29 in a sample. Elizabeth Lewis true PMID:29875488 disintegrin and metalloproteinase domain-containing protein 29 measurement efo:EFO_0802472 Quantification of disks large homolog 3 in a sample. Elizabeth Lewis true PMID:29875488 disks large homolog 3 measurement efo:EFO_0802473 Quantification of DNA dC->dU-editing enzyme APOBEC-3G in a sample. Elizabeth Lewis true PMID:29875488 DNA dC->dU-editing enzyme APOBEC-3G measurement efo:EFO_0802474 Quantification of DNA excision repair protein ERCC-1 in a sample. Elizabeth Lewis true PMID:29875488 DNA excision repair protein ERCC-1 measurement efo:EFO_0802475 Quantification of DNA polymerase eta in a sample. Elizabeth Lewis true PMID:29875488 DNA polymerase eta measurement efo:EFO_0802476 Quantification of DNA polymerase iota in a sample. Elizabeth Lewis true PMID:29875488 DNA polymerase iota measurement efo:EFO_0802477 Quantification of DNA primase small subunit in a sample. Elizabeth Lewis true PMID:29875488 DNA primase small subunit measurement efo:EFO_0802478 Quantification of DNA repair endonuclease XPF in a sample. Elizabeth Lewis true PMID:29875488 DNA repair endonuclease XPF measurement efo:EFO_0802479 Quantification of DNA repair protein XRCC1 in a sample. Elizabeth Lewis true PMID:29875488 DNA repair protein XRCC1 measurement efo:EFO_0802480 Quantification of DNA topoisomerase 2-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 DNA topoisomerase 2-binding protein 1 measurement efo:EFO_0802481 Quantification of DNA-binding protein inhibitor ID-1 in a sample. Elizabeth Lewis true PMID:29875488 DNA-binding protein inhibitor ID-1 measurement efo:EFO_0802482 Quantification of DNA-binding protein inhibitor ID-2 in a sample. Elizabeth Lewis true PMID:29875488 DNA-binding protein inhibitor ID-2 measurement efo:EFO_0802483 Quantification of DNA-binding protein SATB1 in a sample. Elizabeth Lewis true PMID:29875488 DNA-binding protein SATB1 measurement efo:EFO_0802484 Quantification of DNA-binding protein SATB2 in a sample. Elizabeth Lewis true PMID:29875488 DNA-binding protein SATB2 measurement efo:EFO_0802485 Quantification of DNA-directed DNA/RNA polymerase mu in a sample. Elizabeth Lewis true PMID:29875488 DNA-directed DNA/RNA polymerase mu measurement efo:EFO_0802486 Quantification of DnaJ homolog subfamily A member 4 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily A member 4 measurement efo:EFO_0802487 Quantification of DnaJ homolog subfamily B member 12 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily B member 12 measurement efo:EFO_0802488 Quantification of DnaJ homolog subfamily C member 10 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily C member 10 measurement efo:EFO_0802489 Quantification of DnaJ homolog subfamily C member 15 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily C member 15 measurement efo:EFO_0802490 Quantification of DnaJ homolog subfamily C member 18 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily C member 18 measurement efo:EFO_0802491 Quantification of DnaJ homolog subfamily C member 27 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily C member 27 measurement efo:EFO_0802492 Quantification of DnaJ homolog subfamily C member 4 in a sample. Elizabeth Lewis true PMID:29875488 DnaJ homolog subfamily C member 4 measurement efo:EFO_0802493 Quantification of double-strand break repair protein MRE11A in a sample. Elizabeth Lewis true PMID:29875488 double-strand break repair protein MRE11A measurement efo:EFO_0802494 Quantification of dual specificity protein phosphatase 15 in a sample. Elizabeth Lewis true PMID:29875488 dual specificity protein phosphatase 15 measurement efo:EFO_0802495 Quantification of dual specificity protein phosphatase 16 in a sample. Elizabeth Lewis true PMID:29875488 dual specificity protein phosphatase 16 measurement efo:EFO_0802496 Quantification of dual specificity protein phosphatase 6 in a sample. Elizabeth Lewis true PMID:29875488 dual specificity protein phosphatase 6 measurement efo:EFO_0802497 Quantification of dynein light chain Tctex-type 3 in a sample. Elizabeth Lewis true PMID:29875488 dynein light chain Tctex-type 3 measurement efo:EFO_0802498 Quantification of dyslexia-associated protein KIAA0319 in a sample. Elizabeth Lewis true PMID:29875488 dyslexia-associated protein KIAA0319 measurement efo:EFO_0802499 Quantification of dyslexia-associated protein KIAA0319-like protein in a sample. Elizabeth Lewis true PMID:29875488 dyslexia-associated protein KIAA0319-like protein measurement efo:EFO_0802500 Quantification of dystroglycan in a sample. Elizabeth Lewis true PMID:29875488 dystroglycan measurement efo:EFO_0802501 Quantification of E3 ISG15--protein ligase HERC5 in a sample. Elizabeth Lewis true PMID:29875488 E3 ISG15--protein ligase HERC5 measurement efo:EFO_0802502 Quantification of E3 ubiquitin-protein ligase CCNB1IP1 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase CCNB1IP1 measurement efo:EFO_0802503 Quantification of E3 ubiquitin-protein ligase DTX1 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase DTX1 measurement efo:EFO_0802504 Quantification of E3 ubiquitin-protein ligase FANCL in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase FANCL measurement efo:EFO_0802505 Quantification of E3 ubiquitin-protein ligase HECW1 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase HECW1 measurement efo:EFO_0802506 Quantification of e3 ubiquitin-protein ligase parkin in a sample. Elizabeth Lewis true PMID:29875488 e3 ubiquitin-protein ligase parkin measurement efo:EFO_0802507 Quantification of e3 ubiquitin-protein ligase pellino homolog 2 in a sample. Elizabeth Lewis true PMID:29875488 e3 ubiquitin-protein ligase pellino homolog 2 measurement efo:EFO_0802508 Quantification of E3 ubiquitin-protein ligase RBBP6 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase RBBP6 measurement efo:EFO_0802509 Quantification of e3 ubiquitin-protein ligase rififylin in a sample. Elizabeth Lewis true PMID:29875488 e3 ubiquitin-protein ligase rififylin measurement efo:EFO_0802510 Quantification of E3 ubiquitin-protein ligase RNF114 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase RNF114 measurement efo:EFO_0802511 Quantification of E3 ubiquitin-protein ligase RNF149 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase RNF149 measurement efo:EFO_0802512 Quantification of E3 ubiquitin-protein ligase RNF34 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase RNF34 measurement efo:EFO_0802513 Quantification of E3 ubiquitin-protein ligase ZFP91 in a sample. Elizabeth Lewis true PMID:29875488 E3 ubiquitin-protein ligase ZFP91 measurement efo:EFO_0802514 Quantification of early endosome antigen 1 in a sample. Elizabeth Lewis true PMID:29875488 early endosome antigen 1 measurement efo:EFO_0802515 Quantification of early placenta insulin-like peptide in a sample. Elizabeth Lewis true PMID:29875488 early placenta insulin-like peptide measurement efo:EFO_0802516 Quantification of ecto-NOX disulfide-thiol exchanger 2 in a sample. Elizabeth Lewis true PMID:29875488 ecto-NOX disulfide-thiol exchanger 2 measurement efo:EFO_0802517 Quantification of ectonucleoside triphosphate diphosphohydrolase 6 in a sample. Elizabeth Lewis true PMID:29875488 ectonucleoside triphosphate diphosphohydrolase 6 measurement efo:EFO_0802518 Quantification of EF-hand calcium-binding domain-containing protein 14 in a sample. Elizabeth Lewis true PMID:29875488 EF-hand calcium-binding domain-containing protein 14 measurement efo:EFO_0802519 Quantification of EH domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 EH domain-containing protein 4 measurement efo:EFO_0802520 Quantification of electroneutral sodium bicarbonate exchanger 1 in a sample. Elizabeth Lewis true PMID:29875488 electroneutral sodium bicarbonate exchanger 1 measurement efo:EFO_0802521 Quantification of EMI domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 EMI domain-containing protein 1 measurement efo:EFO_0802522 Quantification of engulfment and cell motility protein 1 in a sample. Elizabeth Lewis true PMID:29875488 engulfment and cell motility protein 1 measurement efo:EFO_0802523 Quantification of enhancer of mRNA-decapping protein 4 in a sample. Elizabeth Lewis true PMID:29875488 enhancer of mRNA-decapping protein 4 measurement efo:EFO_0802524 Quantification of envoplakin in a sample. Elizabeth Lewis true PMID:29875488 envoplakin measurement efo:EFO_0802525 Quantification of EP300-interacting inhibitor of differentiation 3 in a sample. Elizabeth Lewis true PMID:29875488 EP300-interacting inhibitor of differentiation 3 measurement efo:EFO_0802526 Quantification of ephrin-B2 in a sample. Elizabeth Lewis true PMID:29875488 ephrin-B2 measurement efo:EFO_0802527 Quantification of epididymal secretory protein E3-beta in a sample. Elizabeth Lewis true PMID:29875488 epididymal secretory protein E3-beta measurement efo:EFO_0802528 Quantification of epididymal-specific lipocalin-8 in a sample. Elizabeth Lewis true PMID:29875488 epididymal-specific lipocalin-8 measurement efo:EFO_0802529 Quantification of ES1 protein homolog, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 ES1 protein homolog, mitochondrial measurement efo:EFO_0802530 Quantification of essential MCU regulator, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 essential MCU regulator, mitochondrial measurement efo:EFO_0802531 Quantification of estradiol 17-beta-dehydrogenase 2 in a sample. Elizabeth Lewis true PMID:29875488 estradiol 17-beta-dehydrogenase 2 measurement efo:EFO_0802532 Quantification of ethanolamine kinase 1 in a sample. Elizabeth Lewis true PMID:29875488 ethanolamine kinase 1 measurement efo:EFO_0802533 Quantification of ETS homologous factor in a sample. Elizabeth Lewis true PMID:29875488 ETS homologous factor measurement efo:EFO_0802534 Quantification of ETS-related transcription factor Elf-5 in a sample. Elizabeth Lewis true PMID:29875488 ETS-related transcription factor Elf-5 measurement efo:EFO_0802535 Quantification of eukaryotic translation initiation factor 4 gamma 3 in a sample. Elizabeth Lewis true PMID:29875488 eukaryotic translation initiation factor 4 gamma 3 measurement efo:EFO_0802536 Quantification of exosome complex component CSL4 in a sample. Elizabeth Lewis true PMID:29875488 exosome complex component CSL4 measurement efo:EFO_0802537 Quantification of f-box only protein 3 in a sample. Elizabeth Lewis true PMID:29875488 f-box only protein 3 measurement efo:EFO_0802538 Quantification of f-box/LRR-repeat protein 4 in a sample. Elizabeth Lewis true PMID:29875488 f-box/LRR-repeat protein 4 measurement efo:EFO_0802539 Quantification of f-box/LRR-repeat protein 5 in a sample. Elizabeth Lewis true PMID:29875488 f-box/LRR-repeat protein 5 measurement efo:EFO_0802540 Quantification of fas apoptotic inhibitory molecule 3 in a sample. Elizabeth Lewis true PMID:29875488 fas apoptotic inhibitory molecule 3 measurement efo:EFO_0802541 Quantification of fAS-associated factor 2 in a sample. Elizabeth Lewis true PMID:29875488 fAS-associated factor 2 measurement efo:EFO_0802542 Quantification of fatty acid hydroxylase domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 fatty acid hydroxylase domain-containing protein 2 measurement efo:EFO_0802543 Quantification of fatty-acid amide hydrolase 2 in a sample. Elizabeth Lewis true PMID:29875488 fatty-acid amide hydrolase 2 measurement efo:EFO_0802544 Quantification of Fc receptor-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 Fc receptor-like protein 2 measurement efo:EFO_0802545 Quantification of Fc receptor-like protein 5 in a sample. Elizabeth Lewis true PMID:29875488 Fc receptor-like protein 5 measurement efo:EFO_0802546 Quantification of feline leukemia virus subgroup C receptor-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 feline leukemia virus subgroup C receptor-related protein 1 measurement efo:EFO_0802547 Quantification of fetal and adult testis-expressed transcript protein in a sample. Elizabeth Lewis true PMID:29875488 fetal and adult testis-expressed transcript protein measurement efo:EFO_0802548 Quantification of fibrinogen C domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 fibrinogen C domain-containing protein 1 measurement efo:EFO_0802549 Quantification of fibronectin type III domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 fibronectin type III domain-containing protein 4 measurement efo:EFO_0802550 Quantification of fibulin-1 in a sample. Elizabeth Lewis true PMID:29875488 fibulin-1 measurement efo:EFO_0802551 Quantification of flap endonuclease 1 in a sample. Elizabeth Lewis true PMID:29875488 flap endonuclease 1 measurement efo:EFO_0802552 Quantification of follistatin-related protein 5 in a sample. Elizabeth Lewis true PMID:29875488 follistatin-related protein 5 measurement efo:EFO_0802553 Quantification of forkhead box protein C2 in a sample. Elizabeth Lewis true PMID:29875488 forkhead box protein C2 measurement efo:EFO_0802554 Quantification of forkhead box protein L2 in a sample. Elizabeth Lewis true PMID:29875488 forkhead box protein L2 measurement efo:EFO_0802555 Quantification of fragile X mental retardation syndrome-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 fragile X mental retardation syndrome-related protein 1 measurement efo:EFO_0802556 Quantification of fructose-1,6-bisphosphatase isozyme 2 in a sample. Elizabeth Lewis true PMID:29875488 fructose-1,6-bisphosphatase isozyme 2 measurement efo:EFO_0802557 Quantification of fructose-bisphosphate aldolase C in a sample. Elizabeth Lewis true PMID:29875488 fructose-bisphosphate aldolase C measurement efo:EFO_0802558 Quantification of g-protein coupled receptor 26 in a sample. Elizabeth Lewis true PMID:29875488 g-protein coupled receptor 26 measurement efo:EFO_0802559 Quantification of G0/G1 switch protein 2 in a sample. Elizabeth Lewis true PMID:29875488 G0/G1 switch protein 2 measurement efo:EFO_0802560 Quantification of gamma-crystallin D in a sample. Elizabeth Lewis true PMID:29875488 gamma-crystallin D measurement efo:EFO_0802561 Quantification of gap junction alpha-8 protein in a sample. Elizabeth Lewis true PMID:29875488 gap junction alpha-8 protein measurement efo:EFO_0802562 Quantification of gap junction delta-2 protein in a sample. Elizabeth Lewis true PMID:29875488 gap junction delta-2 protein measurement efo:EFO_0802563 Quantification of gastric triacylglycerol lipase in a sample. Elizabeth Lewis true PMID:29875488 gastric triacylglycerol lipase measurement efo:EFO_0802564 Quantification of GDP-L-fucose synthase in a sample. Elizabeth Lewis true PMID:29875488 GDP-L-fucose synthase measurement efo:EFO_0802565 Quantification of GH3 domain-containing protein in a sample. Elizabeth Lewis true PMID:29875488 GH3 domain-containing protein measurement efo:EFO_0802566 Quantification of gigaxonin in a sample. Elizabeth Lewis true PMID:29875488 gigaxonin measurement efo:EFO_0802567 Quantification of glioma pathogenesis-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 glioma pathogenesis-related protein 1 measurement efo:EFO_0802568 Quantification of glucagon-like peptide 1 receptor in a sample. Elizabeth Lewis true PMID:29875488 glucagon-like peptide 1 receptor measurement efo:EFO_0802569 Quantification of glucocorticoid modulatory element-binding protein 2 in a sample. Elizabeth Lewis true PMID:29875488 glucocorticoid modulatory element-binding protein 2 measurement efo:EFO_0802570 Quantification of glutaminyl-peptide cyclotransferase in a sample. Elizabeth Lewis true PMID:29875488 glutaminyl-peptide cyclotransferase measurement efo:EFO_0802571 Quantification of glutathione S-transferase kappa 1 in a sample. Elizabeth Lewis true PMID:29875488 glutathione S-transferase kappa 1 measurement efo:EFO_0802572 Quantification of glutathione S-transferase theta-2B in a sample. Elizabeth Lewis true PMID:29875488 glutathione S-transferase theta-2B measurement efo:EFO_0802573 Quantification of glyceraldehyde-3-phosphate dehydrogenase, testis-specific in a sample. Elizabeth Lewis true PMID:29875488 glyceraldehyde-3-phosphate dehydrogenase, testis-specific measurement efo:EFO_0802574 Quantification of glycerophosphocholine phosphodiesterase GPCPD1 in a sample. Elizabeth Lewis true PMID:29875488 glycerophosphocholine phosphodiesterase GPCPD1 measurement efo:EFO_0802575 Quantification of glycolipid transfer protein in a sample. Elizabeth Lewis true PMID:29875488 glycolipid transfer protein measurement efo:EFO_0802576 Quantification of glycophorin-A in a sample. Elizabeth Lewis true PMID:29875488 glycophorin-A measurement efo:EFO_0802577 Quantification of glycoprotein hormones alpha chain in a sample. Elizabeth Lewis true PMID:29875488 glycoprotein hormones alpha chain measurement efo:EFO_0802578 Quantification of glycosyltransferase-like protein LARGE1 in a sample. Elizabeth Lewis true PMID:29875488 glycosyltransferase-like protein LARGE1 measurement efo:EFO_0802579 Quantification of granulocyte-macrophage colony-stimulating factor receptor subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 granulocyte-macrophage colony-stimulating factor receptor subunit alpha measurement efo:EFO_0802580 Quantification of GRB2-related adapter protein in a sample. Elizabeth Lewis true PMID:29875488 GRB2-related adapter protein measurement efo:EFO_0802581 Quantification of grpE protein homolog 1, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 grpE protein homolog 1, mitochondrial measurement efo:EFO_0802582 Quantification of GSK3-beta interaction protein in a sample. Elizabeth Lewis true PMID:29875488 GSK3-beta interaction protein measurement efo:EFO_0802583 Quantification of GTP cyclohydrolase 1 in a sample. Elizabeth Lewis true PMID:29875488 GTP cyclohydrolase 1 measurement efo:EFO_0802584 Quantification of GTP-binding protein Di-Ras3 in a sample. Elizabeth Lewis true PMID:29875488 GTP-binding protein Di-Ras3 measurement efo:EFO_0802585 Quantification of guanine deaminase in a sample. Elizabeth Lewis true PMID:29875488 guanine deaminase measurement efo:EFO_0802586 Quantification of guanine nucleotide exchange factor DBS in a sample. Elizabeth Lewis true PMID:29875488 guanine nucleotide exchange factor DBS measurement efo:EFO_0802587 Quantification of guanine nucleotide exchange factor VAV3 in a sample. Elizabeth Lewis true PMID:29875488 guanine nucleotide exchange factor VAV3 measurement efo:EFO_0802588 Quantification of guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 in a sample. Elizabeth Lewis true PMID:29875488 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 measurement efo:EFO_0802589 Quantification of guanylate cyclase activator 2B in a sample. Elizabeth Lewis true PMID:29875488 guanylate cyclase activator 2B measurement efo:EFO_0802590 Quantification of hemoglobin subunit gamma-1 in a sample. Elizabeth Lewis true PMID:29875488 hemoglobin subunit gamma-1 measurement efo:EFO_0802591 Quantification of HEPACAM family member 2 in a sample. Elizabeth Lewis true PMID:29875488 HEPACAM family member 2 measurement efo:EFO_0802592 Quantification of heparan sulfate glucosamine 3-O-sulfotransferase 3B1 in a sample. Elizabeth Lewis true PMID:29875488 heparan sulfate glucosamine 3-O-sulfotransferase 3B1 measurement efo:EFO_0802593 Quantification of heparan sulfate glucosamine 3-O-sulfotransferase 4 in a sample. Elizabeth Lewis true PMID:29875488 heparan sulfate glucosamine 3-O-sulfotransferase 4 measurement efo:EFO_0802594 Quantification of heparan-sulfate 6-O-sulfotransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 heparan-sulfate 6-O-sulfotransferase 2 measurement efo:EFO_0802595 Quantification of hepatocyte growth factor-regulated tyrosine kinase substrate in a sample. Elizabeth Lewis true PMID:29875488 hepatocyte growth factor-regulated tyrosine kinase substrate measurement efo:EFO_0802596 Quantification of hepatocyte nuclear factor 1-alpha in a sample. Elizabeth Lewis true PMID:29875488 hepatocyte nuclear factor 1-alpha measurement efo:EFO_0802597 Quantification of hephaestin-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 hephaestin-like protein 1 measurement efo:EFO_0802598 Quantification of high affinity immunoglobulin alpha and immunoglobulin mu Fc receptor in a sample. Elizabeth Lewis true PMID:29875488 high affinity immunoglobulin alpha and immunoglobulin mu Fc receptor measurement efo:EFO_0802599 Quantification of high mobility group protein 20A in a sample. Elizabeth Lewis true PMID:29875488 high mobility group protein 20A measurement efo:EFO_0802600 Quantification of histidine triad nucleotide-binding protein 2, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 histidine triad nucleotide-binding protein 2, mitochondrial measurement efo:EFO_0802601 Quantification of histone deacetylase complex subunit SAP30 in a sample. Elizabeth Lewis true PMID:29875488 histone deacetylase complex subunit SAP30 measurement efo:EFO_0802602 Quantification of histone H2A deubiquitinase MYSM1 in a sample. Elizabeth Lewis true PMID:29875488 histone H2A deubiquitinase MYSM1 measurement efo:EFO_0802603 Quantification of histone-lysine N-methyltransferase ASH1L in a sample. Elizabeth Lewis true PMID:29875488 histone-lysine N-methyltransferase ASH1L measurement efo:EFO_0802604 Quantification of histone-lysine N-methyltransferase SETD2 in a sample. Elizabeth Lewis true PMID:29875488 histone-lysine N-methyltransferase SETD2 measurement efo:EFO_0802605 Quantification of histone-lysine N-methyltransferase SETMAR in a sample. Elizabeth Lewis true PMID:29875488 histone-lysine N-methyltransferase SETMAR measurement efo:EFO_0802606 Quantification of histone-lysine N-methyltransferase SUV420H2 in a sample. Elizabeth Lewis true PMID:29875488 histone-lysine N-methyltransferase SUV420H2 measurement efo:EFO_0802607 Quantification of HLA class II histocompatibility antigen gamma chain in a sample. Elizabeth Lewis true PMID:29875488 HLA class II histocompatibility antigen gamma chain measurement efo:EFO_0802608 Quantification of homeobox protein TGIF2 in a sample. Elizabeth Lewis true PMID:29875488 homeobox protein TGIF2 measurement efo:EFO_0802609 Quantification of homogentisate 1,2-dioxygenase in a sample. Elizabeth Lewis true PMID:29875488 homogentisate 1,2-dioxygenase measurement efo:EFO_0802610 Quantification of HRAS-like suppressor 2 in a sample. Elizabeth Lewis true PMID:29875488 HRAS-like suppressor 2 measurement efo:EFO_0802611 Quantification of HRAS-like suppressor 3 in a sample. Elizabeth Lewis true PMID:29875488 HRAS-like suppressor 3 measurement efo:EFO_0802612 Quantification of hyaluronidase-1 in a sample. Elizabeth Lewis true PMID:29875488 hyaluronidase-1 measurement efo:EFO_0802613 Quantification of hydroxycarboxylic acid receptor 2 in a sample. Elizabeth Lewis true PMID:29875488 hydroxycarboxylic acid receptor 2 measurement efo:EFO_0802614 Quantification of hydroxymethylglutaryl-CoA synthase, cytoplasmic in a sample. Elizabeth Lewis true PMID:29875488 hydroxymethylglutaryl-CoA synthase, cytoplasmic measurement efo:EFO_0802615 Quantification of hydroxymethylglutaryl-CoA synthase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 hydroxymethylglutaryl-CoA synthase, mitochondrial measurement efo:EFO_0802616 Quantification of ig gamma-2, Kappa in a sample. Elizabeth Lewis true PMID:29875488 ig gamma-2, Kappa measurement efo:EFO_0802617 Quantification of ig Kappa chain V-I region HK102- like in a sample. Elizabeth Lewis true PMID:29875488 ig Kappa chain V-I region HK102- like measurement efo:EFO_0802618 Quantification of igLON family member 5 in a sample. Elizabeth Lewis true PMID:29875488 igLON family member 5 measurement efo:EFO_0802619 Quantification of immediate early response 3-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 immediate early response 3-interacting protein 1 measurement efo:EFO_0802620 Quantification of immunoglobulin J chain in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin J chain measurement efo:EFO_0802621 Quantification of immunoglobulin superfamily member 11 in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin superfamily member 11 measurement efo:EFO_0802622 Quantification of immunoglobulin superfamily member 8 in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin superfamily member 8 measurement efo:EFO_0802623 Quantification of importin subunit alpha-3 in a sample. Elizabeth Lewis true PMID:29875488 importin subunit alpha-3 measurement efo:EFO_0802624 Quantification of inactive dipeptidyl peptidase 10 in a sample. Elizabeth Lewis true PMID:29875488 inactive dipeptidyl peptidase 10 measurement efo:EFO_0802625 Quantification of inactive phospholipase D5 in a sample. Elizabeth Lewis true PMID:29875488 inactive phospholipase D5 measurement efo:EFO_0802626 Quantification of inactive ribonuclease-like protein 10 in a sample. Elizabeth Lewis true PMID:29875488 inactive ribonuclease-like protein 10 measurement efo:EFO_0802627 Quantification of inositol-trisphosphate 3-kinase A in a sample. Elizabeth Lewis true PMID:29875488 inositol-trisphosphate 3-kinase A measurement efo:EFO_0802628 Quantification of insulin gene enhancer protein ISL-1 in a sample. Elizabeth Lewis true PMID:29875488 insulin gene enhancer protein ISL-1 measurement efo:EFO_0802629 Quantification of insulin-induced gene 1 protein in a sample. Elizabeth Lewis true PMID:29875488 insulin-induced gene 1 protein measurement efo:EFO_0802630 Quantification of insulin-like 3 in a sample. Elizabeth Lewis true PMID:29875488 insulin-like 3 measurement efo:EFO_0802631 Quantification of insulin-like growth factor-binding protein-like 1 in a sample. Elizabeth Lewis true PMID:29875488 insulin-like growth factor-binding protein-like 1 measurement efo:EFO_0802632 Quantification of insulin-like peptide INSL5 in a sample. Elizabeth Lewis true PMID:29875488 insulin-like peptide INSL5 measurement efo:EFO_0802633 Quantification of insulin-like peptide INSL6 in a sample. Elizabeth Lewis true PMID:29875488 insulin-like peptide INSL6 measurement efo:EFO_0802634 Quantification of integral membrane protein 2B in a sample. Elizabeth Lewis true PMID:29875488 integral membrane protein 2B measurement efo:EFO_0802635 Quantification of integral membrane protein 2C in a sample. Elizabeth Lewis true PMID:29875488 integral membrane protein 2C measurement efo:EFO_0802636 Quantification of integral membrane protein DGCR2/IDD in a sample. Elizabeth Lewis true PMID:29875488 integral membrane protein DGCR2/IDD measurement efo:EFO_0802637 Quantification of integrin alpha-5 in a sample. Elizabeth Lewis true PMID:29875488 integrin alpha-5 measurement efo:EFO_0802638 Quantification of integrin alpha-L in a sample. Elizabeth Lewis true PMID:29875488 integrin alpha-L measurement efo:EFO_0802639 Quantification of integrin beta-7 in a sample. Elizabeth Lewis true PMID:29875488 integrin beta-7 measurement efo:EFO_0802640 Quantification of interferon alpha-14 in a sample. Elizabeth Lewis true PMID:29875488 interferon alpha-14 measurement efo:EFO_0802641 Quantification of interferon alpha-4 in a sample. Elizabeth Lewis true PMID:29875488 interferon alpha-4 measurement efo:EFO_0802642 Quantification of interferon alpha-5 in a sample. Elizabeth Lewis true PMID:29875488 interferon alpha-5 measurement efo:EFO_0802643 Quantification of interferon alpha-6 in a sample. Elizabeth Lewis true PMID:29875488 interferon alpha-6 measurement efo:EFO_0802644 Quantification of interferon alpha-8 in a sample. Elizabeth Lewis true PMID:29875488 interferon alpha-8 measurement efo:EFO_0802645 Quantification of interferon beta in a sample. Elizabeth Lewis true PMID:29875488 interferon beta measurement efo:EFO_0802646 Quantification of interferon lambda receptor 1 in a sample. Elizabeth Lewis true PMID:29875488 interferon lambda receptor 1 measurement efo:EFO_0802647 Quantification of interferon omega-1 in a sample. Elizabeth Lewis true PMID:29875488 interferon omega-1 measurement efo:EFO_0802648 Quantification of interferon regulatory factor 4 in a sample. Elizabeth Lewis true PMID:29875488 interferon regulatory factor 4 measurement efo:EFO_0802649 Quantification of interferon regulatory factor 6 in a sample. Elizabeth Lewis true PMID:29875488 interferon regulatory factor 6 measurement efo:EFO_0802650 Quantification of interferon regulatory factor 9 in a sample. Elizabeth Lewis true PMID:29875488 interferon regulatory factor 9 measurement efo:EFO_0802651 Quantification of interferon-induced protein with tetratricopeptide repeats 2 in a sample. Elizabeth Lewis true PMID:29875488 interferon-induced protein with tetratricopeptide repeats 2 measurement efo:EFO_0802652 Quantification of interleukin enhancer-binding factor 3 in a sample. Elizabeth Lewis true PMID:29875488 interleukin enhancer-binding factor 3 measurement efo:EFO_0802653 Quantification of interleukin-1 alpha in a sample. Elizabeth Lewis true PMID:29875488 interleukin-1 alpha measurement efo:EFO_0802654 Quantification of interleukin-12 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-12 measurement efo:EFO_0802655 Quantification of interleukin-13 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-13 measurement efo:EFO_0802656 Quantification of interleukin-17C in a sample. Elizabeth Lewis true PMID:29875488 interleukin-17C measurement efo:EFO_0802657 Quantification of interleukin-2 receptor subunit beta in a sample. Elizabeth Lewis true PMID:29875488 interleukin-2 receptor subunit beta measurement efo:EFO_0802658 Quantification of interleukin-31 receptor subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 interleukin-31 receptor subunit alpha measurement efo:EFO_0802659 Quantification of interleukin-32 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-32 measurement efo:EFO_0802660 Quantification of interleukin-36 gamma in a sample. Elizabeth Lewis true PMID:29875488 interleukin-36 gamma measurement efo:EFO_0802661 Quantification of interleukin-4 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-4 measurement efo:EFO_0802662 Quantification of interleukin-7 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-7 measurement efo:EFO_0802663 Quantification of interleukin-9 in a sample. Elizabeth Lewis true PMID:29875488 interleukin-9 measurement efo:EFO_0802664 Quantification of IQ domain-containing protein F1 in a sample. Elizabeth Lewis true PMID:29875488 IQ domain-containing protein F1 measurement efo:EFO_0802665 Quantification of iron-sulfur cluster assembly enzyme ISCU, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 iron-sulfur cluster assembly enzyme ISCU, mitochondrial measurement efo:EFO_0802666 Quantification of isoleucine--tRNA ligase, cytoplasmic in a sample. Elizabeth Lewis true PMID:29875488 isoleucine--tRNA ligase, cytoplasmic measurement efo:EFO_0802667 Quantification of junctophilin-1 in a sample. Elizabeth Lewis true PMID:29875488 junctophilin-1 measurement efo:EFO_0802668 Quantification of junctophilin-3 in a sample. Elizabeth Lewis true PMID:29875488 junctophilin-3 measurement efo:EFO_0802669 Quantification of kallikrein-15 in a sample. Elizabeth Lewis true PMID:29875488 kallikrein-15 measurement efo:EFO_0802670 Quantification of kelch-like protein 12 in a sample. Elizabeth Lewis true PMID:29875488 kelch-like protein 12 measurement efo:EFO_0802671 Quantification of kell blood group glycoprotein in a sample. Elizabeth Lewis true PMID:29875488 kell blood group glycoprotein measurement efo:EFO_0802672 Quantification of keratin, type I cytoskeletal 17 in a sample. Elizabeth Lewis true PMID:29875488 keratin, type I cytoskeletal 17 measurement efo:EFO_0802673 Quantification of keratin, type I cytoskeletal 20 in a sample. Elizabeth Lewis true PMID:29875488 keratin, type I cytoskeletal 20 measurement efo:EFO_0802674 Quantification of keratin, type II cytoskeletal 5 in a sample. Elizabeth Lewis true PMID:29875488 keratin, type II cytoskeletal 5 measurement efo:EFO_0802675 Quantification of keratin, type II cytoskeletal 7 in a sample. Elizabeth Lewis true PMID:29875488 keratin, type II cytoskeletal 7 measurement efo:EFO_0802676 Quantification of keratinocyte-associated transmembrane protein 2 in a sample. Elizabeth Lewis true PMID:29875488 keratinocyte-associated transmembrane protein 2 measurement efo:EFO_0802677 Quantification of killer cell immunoglobulin-like receptor 3DL3 in a sample. Elizabeth Lewis true PMID:29875488 killer cell immunoglobulin-like receptor 3DL3 measurement efo:EFO_0802678 Quantification of kin of IRRE-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 kin of IRRE-like protein 2 measurement efo:EFO_0802679 Quantification of kinesin-like protein KIF1C in a sample. Elizabeth Lewis true PMID:29875488 kinesin-like protein KIF1C measurement efo:EFO_0802680 Quantification of l-lactate dehydrogenase C chain in a sample. Elizabeth Lewis true PMID:29875488 l-lactate dehydrogenase C chain measurement efo:EFO_0802681 Quantification of lactase-like protein in a sample. Elizabeth Lewis true PMID:29875488 lactase-like protein measurement efo:EFO_0802682 Quantification of lactoferrin in a sample. Elizabeth Lewis true PMID:29875488 lactoferrin measurement efo:EFO_0802683 Quantification of lactosylceramide 4-alpha-galactosyltransferase in a sample. Elizabeth Lewis true PMID:29875488 lactosylceramide 4-alpha-galactosyltransferase measurement efo:EFO_0802684 Quantification of lactoylglutathione lyase in a sample. Elizabeth Lewis true PMID:29875488 lactoylglutathione lyase measurement efo:EFO_0802685 Quantification of ladinin-1 in a sample. Elizabeth Lewis true PMID:29875488 ladinin-1 measurement efo:EFO_0802686 Quantification of LDLR chaperone MESD in a sample. Elizabeth Lewis true PMID:29875488 LDLR chaperone MESD measurement efo:EFO_0802687 Quantification of leiomodin-1 in a sample. Elizabeth Lewis true PMID:29875488 leiomodin-1 measurement efo:EFO_0802688 Quantification of leucine-rich repeat and calponin homology domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat and calponin homology domain-containing protein 4 measurement efo:EFO_0802689 Quantification of leucine-rich repeat and fibronectin type III domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat and fibronectin type III domain-containing protein 1 measurement efo:EFO_0802690 Quantification of leucine-rich repeat and fibronectin type-III domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat and fibronectin type-III domain-containing protein 2 measurement efo:EFO_0802691 Quantification of leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 measurement efo:EFO_0802692 Quantification of leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 3 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 3 measurement efo:EFO_0802693 Quantification of leucine-rich repeat and transmembrane domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat and transmembrane domain-containing protein 1 measurement efo:EFO_0802694 Quantification of leucine-rich repeat LGI family member 3 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat LGI family member 3 measurement efo:EFO_0802695 Quantification of leucine-rich repeat neuronal protein 3 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat neuronal protein 3 measurement efo:EFO_0802696 Quantification of leucine-rich repeat transmembrane neuronal protein 2 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat transmembrane neuronal protein 2 measurement efo:EFO_0802697 Quantification of leucine-rich repeat transmembrane neuronal protein 4 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat transmembrane neuronal protein 4 measurement efo:EFO_0802698 Quantification of leucine-rich repeat-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat-containing protein 3 measurement efo:EFO_0802699 Quantification of leucine-rich repeat-containing protein 37A2 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat-containing protein 37A2 measurement efo:EFO_0802700 Quantification of leucine-rich repeat-containing protein 4B in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat-containing protein 4B measurement efo:EFO_0802701 Quantification of leucine-rich repeat-containing protein 4C in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat-containing protein 4C measurement efo:EFO_0802702 Quantification of leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 2 measurement efo:EFO_0802703 Quantification of leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 3 measurement efo:EFO_0802704 Quantification of leukocyte cell-derived chemotaxin 1 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte cell-derived chemotaxin 1 measurement efo:EFO_0802705 Quantification of leukocyte immunoglobulin-like receptor subfamily B member 3 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte immunoglobulin-like receptor subfamily B member 3 measurement efo:EFO_0802706 Quantification of leukocyte-associated immunoglobulin-like receptor 1 in a sample. Elizabeth Lewis true PMID:29875488 leukocyte-associated immunoglobulin-like receptor 1 measurement efo:EFO_0802707 Quantification of leukocyte-specific transcript 1 protein in a sample. Elizabeth Lewis true PMID:29875488 leukocyte-specific transcript 1 protein measurement efo:EFO_0802708 Quantification of LIM and cysteine-rich domains protein 1 in a sample. Elizabeth Lewis true PMID:29875488 LIM and cysteine-rich domains protein 1 measurement efo:EFO_0802709 Quantification of linker for activation of T-cells family member 1 in a sample. Elizabeth Lewis true PMID:29875488 linker for activation of T-cells family member 1 measurement efo:EFO_0802710 Quantification of linker for activation of T-cells family member 2 in a sample. Elizabeth Lewis true PMID:29875488 linker for activation of T-cells family member 2 measurement efo:EFO_0802711 Quantification of lipase member K in a sample. Elizabeth Lewis true PMID:29875488 lipase member K measurement efo:EFO_0802712 Quantification of lipocalin-1 in a sample. Elizabeth Lewis true PMID:29875488 lipocalin-1 measurement efo:EFO_0802713 Quantification of lupus La protein in a sample. Elizabeth Lewis true PMID:29875488 lupus La protein measurement efo:EFO_0802714 Quantification of lymphocyte antigen 6 complex locus protein G6d in a sample. Elizabeth Lewis true PMID:29875488 lymphocyte antigen 6 complex locus protein G6d measurement efo:EFO_0802715 Quantification of lymphocyte function-associated antigen 3 in a sample. Elizabeth Lewis true PMID:29875488 lymphocyte function-associated antigen 3 measurement efo:EFO_0802716 Quantification of lymphoid-restricted membrane protein in a sample. Elizabeth Lewis true PMID:29875488 lymphoid-restricted membrane protein measurement efo:EFO_0802717 Quantification of lysM and putative peptidoglycan-binding domain-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 lysM and putative peptidoglycan-binding domain-containing protein 3 measurement efo:EFO_0802718 Quantification of lysM and putative peptidoglycan-binding domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 lysM and putative peptidoglycan-binding domain-containing protein 4 measurement efo:EFO_0802719 Quantification of lysophospholipase-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 lysophospholipase-like protein 1 measurement efo:EFO_0802720 Quantification of lysosome-associated membrane glycoprotein 3 in a sample. Elizabeth Lewis true PMID:29875488 lysosome-associated membrane glycoprotein 3 measurement efo:EFO_0802721 Quantification of lysyl oxidase homolog 2 in a sample. Elizabeth Lewis true PMID:29875488 lysyl oxidase homolog 2 measurement efo:EFO_0802722 Quantification of macoilin in a sample. Elizabeth Lewis true PMID:29875488 macoilin measurement efo:EFO_0802723 Quantification of magnesium transporter NIPA4 in a sample. Elizabeth Lewis true PMID:29875488 magnesium transporter NIPA4 measurement efo:EFO_0802724 Quantification of MAGUK p55 subfamily member 7 in a sample. Elizabeth Lewis true PMID:29875488 MAGUK p55 subfamily member 7 measurement efo:EFO_0802725 Quantification of major prion protein in a sample. Elizabeth Lewis true PMID:29875488 major prion protein measurement efo:EFO_0802726 Quantification of malectin in a sample. Elizabeth Lewis true PMID:29875488 malectin measurement efo:EFO_0802727 Quantification of malonyl-CoA decarboxylase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 malonyl-CoA decarboxylase, mitochondrial measurement efo:EFO_0802728 Quantification of MAM domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 MAM domain-containing protein 2 measurement efo:EFO_0802729 Quantification of mannosyl-oligosaccharide 1,2-alpha-mannosidase IA in a sample. Elizabeth Lewis true PMID:29875488 mannosyl-oligosaccharide 1,2-alpha-mannosidase IA measurement efo:EFO_0802730 Quantification of marginal zone B- and B1-cell-specific protein in a sample. Elizabeth Lewis true PMID:29875488 marginal zone B- and B1-cell-specific protein measurement efo:EFO_0802731 Quantification of matrix-remodeling-associated protein 8 in a sample. Elizabeth Lewis true PMID:29875488 matrix-remodeling-associated protein 8 measurement efo:EFO_0802732 Quantification of MAX-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 MAX-interacting protein 1 measurement efo:EFO_0802733 Quantification of melanocortin-2 receptor accessory protein 2 in a sample. Elizabeth Lewis true PMID:29875488 melanocortin-2 receptor accessory protein 2 measurement efo:EFO_0802734 Quantification of melanocortin-2 receptor accessory protein in a sample. Elizabeth Lewis true PMID:29875488 melanocortin-2 receptor accessory protein measurement efo:EFO_0802735 Quantification of melanoma-associated antigen B10 in a sample. Elizabeth Lewis true PMID:29875488 melanoma-associated antigen B10 measurement efo:EFO_0802736 Quantification of membrane magnesium transporter 1 in a sample. Elizabeth Lewis true PMID:29875488 membrane magnesium transporter 1 measurement efo:EFO_0802737 Quantification of membrane protein FAM159B in a sample. Elizabeth Lewis true PMID:29875488 membrane protein FAM159B measurement efo:EFO_0802738 Quantification of membrane protein FAM174B in a sample. Elizabeth Lewis true PMID:29875488 membrane protein FAM174B measurement efo:EFO_0802739 Quantification of membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 measurement efo:EFO_0802740 Quantification of membrane-associated progesterone receptor component 1 in a sample. Elizabeth Lewis true PMID:29875488 membrane-associated progesterone receptor component 1 measurement efo:EFO_0802741 Quantification of methionine-R-sulfoxide reductase B3 in a sample. Elizabeth Lewis true PMID:29875488 methionine-R-sulfoxide reductase B3 measurement efo:EFO_0802742 Quantification of methylmalonyl-CoA epimerase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 methylmalonyl-CoA epimerase, mitochondrial measurement efo:EFO_0802743 Quantification of MICOS complex subunit MIC26 in a sample. Elizabeth Lewis true PMID:29875488 MICOS complex subunit MIC26 measurement efo:EFO_0802744 Quantification of microfibril-associated glycoprotein 4 in a sample. Elizabeth Lewis true PMID:29875488 microfibril-associated glycoprotein 4 measurement efo:EFO_0802745 Quantification of microfibrillar-associated protein 1 in a sample. Elizabeth Lewis true PMID:29875488 microfibrillar-associated protein 1 measurement efo:EFO_0802746 Quantification of microfibrillar-associated protein 5 in a sample. Elizabeth Lewis true PMID:29875488 microfibrillar-associated protein 5 measurement efo:EFO_0802747 Quantification of MIP18 family protein FAM96A in a sample. Elizabeth Lewis true PMID:29875488 MIP18 family protein FAM96A measurement efo:EFO_0802748 Quantification of mismatch repair endonuclease PMS2 in a sample. Elizabeth Lewis true PMID:29875488 mismatch repair endonuclease PMS2 measurement efo:EFO_0802749 Quantification of mitochondrial fission regulator 1 in a sample. Elizabeth Lewis true PMID:29875488 mitochondrial fission regulator 1 measurement efo:EFO_0802750 Quantification of mitochondrial peptide methionine sulfoxide reductase in a sample. Elizabeth Lewis true PMID:29875488 mitochondrial peptide methionine sulfoxide reductase measurement efo:EFO_0802751 Quantification of mitofusin-1 in a sample. Elizabeth Lewis true PMID:29875488 mitofusin-1 measurement efo:EFO_0802752 Quantification of mitotic-spindle organizing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 mitotic-spindle organizing protein 1 measurement efo:EFO_0802753 Quantification of MOB kinase activator 1A in a sample. Elizabeth Lewis true PMID:29875488 MOB kinase activator 1A measurement efo:EFO_0802754 Quantification of monoacylglycerol lipase ABHD12 in a sample. Elizabeth Lewis true PMID:29875488 monoacylglycerol lipase ABHD12 measurement efo:EFO_0802755 Quantification of motor neuron and pancreas homeobox protein 1 in a sample. Elizabeth Lewis true PMID:29875488 motor neuron and pancreas homeobox protein 1 measurement efo:EFO_0802756 Quantification of MRNA-capping enzyme in a sample. Elizabeth Lewis true PMID:29875488 MRNA-capping enzyme measurement efo:EFO_0802757 Quantification of MRNA-decapping enzyme 1A in a sample. Elizabeth Lewis true PMID:29875488 MRNA-decapping enzyme 1A measurement efo:EFO_0802758 Quantification of mucin-4 in a sample. Elizabeth Lewis true PMID:29875488 mucin-4 measurement efo:EFO_0802759 Quantification of mucosal addressin cell adhesion molecule 1 in a sample. Elizabeth Lewis true PMID:29875488 mucosal addressin cell adhesion molecule 1 measurement efo:EFO_0802760 Quantification of multidrug resistance-associated protein 6 in a sample. Elizabeth Lewis true PMID:29875488 multidrug resistance-associated protein 6 measurement efo:EFO_0802761 Quantification of multifunctional protein ADE2 in a sample. Elizabeth Lewis true PMID:29875488 multifunctional protein ADE2 measurement efo:EFO_0802762 Quantification of multiple epidermal growth factor-like domains protein 10 in a sample. Elizabeth Lewis true PMID:29875488 multiple epidermal growth factor-like domains protein 10 measurement efo:EFO_0802763 Quantification of multiple PDZ domain protein in a sample. Elizabeth Lewis true PMID:29875488 multiple PDZ domain protein measurement efo:EFO_0802764 Quantification of muscle, skeletal receptor tyrosine-protein kinase in a sample. Elizabeth Lewis true PMID:29875488 muscle, skeletal receptor tyrosine-protein kinase measurement efo:EFO_0802765 Quantification of myc box-dependent-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 myc box-dependent-interacting protein 1 measurement efo:EFO_0802766 Quantification of myc-associated zinc finger protein in a sample. Elizabeth Lewis true PMID:29875488 myc-associated zinc finger protein measurement efo:EFO_0802767 Quantification of myelin regulatory factor in a sample. Elizabeth Lewis true PMID:29875488 myelin regulatory factor measurement efo:EFO_0802768 Quantification of myeloid zinc finger 1 in a sample. Elizabeth Lewis true PMID:29875488 myeloid zinc finger 1 measurement efo:EFO_0802769 Quantification of myocardial zonula adherens protein in a sample. Elizabeth Lewis true PMID:29875488 myocardial zonula adherens protein measurement efo:EFO_0802770 Quantification of myocyte-specific enhancer factor 2C in a sample. Elizabeth Lewis true PMID:29875488 myocyte-specific enhancer factor 2C measurement efo:EFO_0802771 Quantification of myomesin-2 in a sample. Elizabeth Lewis true PMID:29875488 myomesin-2 measurement efo:EFO_0802772 Quantification of myosin-binding protein C, slow-type in a sample. Elizabeth Lewis true PMID:29875488 myosin-binding protein C, slow-type measurement efo:EFO_0802773 Quantification of myotubularin-related protein 1 in a sample. Elizabeth Lewis true PMID:29875488 myotubularin-related protein 1 measurement efo:EFO_0802774 Quantification of n-acetylgalactosaminyltransferase 7 in a sample. Elizabeth Lewis true PMID:29875488 n-acetylgalactosaminyltransferase 7 measurement efo:EFO_0802775 Quantification of n-acetylglucosamine-1-phosphotransferase subunit gamma in a sample. Elizabeth Lewis true PMID:29875488 n-acetylglucosamine-1-phosphotransferase subunit gamma measurement efo:EFO_0802776 Quantification of n-acetylglutamate synthase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 n-acetylglutamate synthase, mitochondrial measurement efo:EFO_0802777 Quantification of n-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase, isoform C in a sample. Elizabeth Lewis true PMID:29875488 n-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase, isoform C measurement efo:EFO_0802778 Quantification of n-lysine methyltransferase SMYD2 in a sample. Elizabeth Lewis true PMID:29875488 n-lysine methyltransferase SMYD2 measurement efo:EFO_0802779 Quantification of immunoglobulin heavy constant gamma 4 in a sample. Elizabeth Lewis true PMID:29875488 immunoglobulin heavy constant gamma 4 measurement efo:EFO_0802780 Quantification of NACHT, LRR and PYD domains-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 NACHT, LRR and PYD domains-containing protein 1 measurement efo:EFO_0802781 Quantification of NACHT, LRR and PYD domains-containing protein 10 in a sample. Elizabeth Lewis true PMID:29875488 NACHT, LRR and PYD domains-containing protein 10 measurement efo:EFO_0802782 Quantification of NACHT, LRR and PYD domains-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 NACHT, LRR and PYD domains-containing protein 4 measurement efo:EFO_0802783 Quantification of NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial measurement efo:EFO_0802784 Quantification of NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial measurement efo:EFO_0802785 Quantification of NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial measurement efo:EFO_0802786 Quantification of NADH-cytochrome b5 reductase 3 in a sample. Elizabeth Lewis true PMID:29875488 NADH-cytochrome b5 reductase 3 measurement efo:EFO_0802787 Quantification of natural cytotoxicity triggering receptor 3 ligand 1 in a sample. Elizabeth Lewis true PMID:29875488 natural cytotoxicity triggering receptor 3 ligand 1 measurement efo:EFO_0802788 Quantification of nectin-2 in a sample. Elizabeth Lewis true PMID:29875488 nectin-2 measurement efo:EFO_0802789 Quantification of nectin-3 in a sample. Elizabeth Lewis true PMID:29875488 nectin-3 measurement efo:EFO_0802790 Quantification of nectin-4 in a sample. Elizabeth Lewis true PMID:29875488 nectin-4 measurement efo:EFO_0802791 Quantification of netrin receptor UNC5A in a sample. Elizabeth Lewis true PMID:29875488 netrin receptor UNC5A measurement efo:EFO_0802792 Quantification of netrin receptor UNC5B in a sample. Elizabeth Lewis true PMID:29875488 netrin receptor UNC5B measurement efo:EFO_0802793 Quantification of neudesin in a sample. Elizabeth Lewis true PMID:29875488 neudesin measurement efo:EFO_0802794 Quantification of neugrin in a sample. Elizabeth Lewis true PMID:29875488 neugrin measurement efo:EFO_0802795 Quantification of neural proliferation differentiation and control protein 1 in a sample. Elizabeth Lewis true PMID:29875488 neural proliferation differentiation and control protein 1 measurement efo:EFO_0802796 Quantification of neuralized-like protein 4 in a sample. Elizabeth Lewis true PMID:29875488 neuralized-like protein 4 measurement efo:EFO_0802797 Quantification of neurexin-2-beta in a sample. Elizabeth Lewis true PMID:29875488 neurexin-2-beta measurement efo:EFO_0802798 Quantification of neurexophilin-3 in a sample. Elizabeth Lewis true PMID:29875488 neurexophilin-3 measurement efo:EFO_0802799 Quantification of neuritin in a sample. Elizabeth Lewis true PMID:29875488 neuritin measurement efo:EFO_0802800 Quantification of neuroepithelial cell-transforming gene 1 protein in a sample. Elizabeth Lewis true PMID:29875488 neuroepithelial cell-transforming gene 1 protein measurement efo:EFO_0802801 Quantification of neurofilament heavy polypeptide in a sample. Elizabeth Lewis true PMID:29875488 neurofilament heavy polypeptide measurement efo:EFO_0802802 Quantification of neuroligin-1 in a sample. Elizabeth Lewis true PMID:29875488 neuroligin-1 measurement efo:EFO_0802803 Quantification of neuromedin-B in a sample. Elizabeth Lewis true PMID:29875488 neuromedin-B measurement efo:EFO_0802804 Quantification of neuron-specific protein family member 1 in a sample. Elizabeth Lewis true PMID:29875488 neuron-specific protein family member 1 measurement efo:EFO_0802805 Quantification of neuron-specific vesicular protein calcyon in a sample. Elizabeth Lewis true PMID:29875488 neuron-specific vesicular protein calcyon measurement efo:EFO_0802806 Quantification of neuropeptide S in a sample. Elizabeth Lewis true PMID:29875488 neuropeptide S measurement efo:EFO_0802807 Quantification of neuropilin and tolloid-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 neuropilin and tolloid-like protein 1 measurement efo:EFO_0802808 Quantification of neuropilin and tolloid-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 neuropilin and tolloid-like protein 2 measurement efo:EFO_0802809 Quantification of neurotensin/neuromedin N in a sample. Elizabeth Lewis true PMID:29875488 neurotensin/neuromedin N measurement efo:EFO_0802810 Quantification of NFU1 iron-sulfur cluster scaffold homolog, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 NFU1 iron-sulfur cluster scaffold homolog, mitochondrial measurement efo:EFO_0802811 Quantification of NGFI-A-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 NGFI-A-binding protein 1 measurement efo:EFO_0802812 Quantification of NGFI-A-binding protein 2 in a sample. Elizabeth Lewis true PMID:29875488 NGFI-A-binding protein 2 measurement efo:EFO_0802813 Quantification of NKG2-A/NKG2-B type II integral membrane protein in a sample. Elizabeth Lewis true PMID:29875488 NKG2-A/NKG2-B type II integral membrane protein measurement efo:EFO_0802814 Quantification of NKG2D ligand 1 in a sample. Elizabeth Lewis true PMID:29875488 NKG2D ligand 1 measurement efo:EFO_0802815 Quantification of NKG2D ligand 2 in a sample. Elizabeth Lewis true PMID:29875488 NKG2D ligand 2 measurement efo:EFO_0802816 Quantification of NKG2D ligand 3 in a sample. Elizabeth Lewis true PMID:29875488 NKG2D ligand 3 measurement efo:EFO_0802817 Quantification of non-homologous end-joining factor 1 in a sample. Elizabeth Lewis true PMID:29875488 non-homologous end-joining factor 1 measurement efo:EFO_0802818 Quantification of noncompact myelin-associated protein in a sample. Elizabeth Lewis true PMID:29875488 noncompact myelin-associated protein measurement efo:EFO_0802819 Quantification of nuclear envelope phosphatase-regulatory subunit 1 in a sample. Elizabeth Lewis true PMID:29875488 nuclear envelope phosphatase-regulatory subunit 1 measurement efo:EFO_0802820 Quantification of nuclear nucleic acid-binding protein C1D in a sample. Elizabeth Lewis true PMID:29875488 nuclear nucleic acid-binding protein C1D measurement efo:EFO_0802821 Quantification of nuclear pore membrane glycoprotein 210-like in a sample. Elizabeth Lewis true PMID:29875488 nuclear pore membrane glycoprotein 210-like measurement efo:EFO_0802822 Quantification of nuclear protein MDM1 in a sample. Elizabeth Lewis true PMID:29875488 nuclear protein MDM1 measurement efo:EFO_0802823 Quantification of nuclear receptor ROR-beta in a sample. Elizabeth Lewis true PMID:29875488 nuclear receptor ROR-beta measurement efo:EFO_0802824 Quantification of nuclear receptor subfamily 4 group A member 1 in a sample. Elizabeth Lewis true PMID:29875488 nuclear receptor subfamily 4 group A member 1 measurement efo:EFO_0802825 Quantification of nuclear receptor subfamily 5 group A member 2 in a sample. Elizabeth Lewis true PMID:29875488 nuclear receptor subfamily 5 group A member 2 measurement efo:EFO_0802826 Quantification of nucleoside diphosphate-linked moiety X motif 8, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 nucleoside diphosphate-linked moiety X motif 8, mitochondrial measurement efo:EFO_0802827 Quantification of o-acetyl-ADP-ribose deacetylase MACROD1 in a sample. Elizabeth Lewis true PMID:29875488 o-acetyl-ADP-ribose deacetylase MACROD1 measurement efo:EFO_0802828 Quantification of odorant-binding protein 2a in a sample. Elizabeth Lewis true PMID:29875488 odorant-binding protein 2a measurement efo:EFO_0802829 Quantification of olfactomedin-like protein 3 in a sample. Elizabeth Lewis true PMID:29875488 olfactomedin-like protein 3 measurement efo:EFO_0802830 Quantification of oligophrenin-1 in a sample. Elizabeth Lewis true PMID:29875488 oligophrenin-1 measurement efo:EFO_0802831 Quantification of oligoribonuclease, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 oligoribonuclease, mitochondrial measurement efo:EFO_0802832 Quantification of orexigenic neuropeptide QRFP in a sample. Elizabeth Lewis true PMID:29875488 orexigenic neuropeptide QRFP measurement efo:EFO_0802833 Quantification of origin recognition complex subunit 6 in a sample. Elizabeth Lewis true PMID:29875488 origin recognition complex subunit 6 measurement efo:EFO_0802834 Quantification of ornithine decarboxylase antizyme 1 in a sample. Elizabeth Lewis true PMID:29875488 ornithine decarboxylase antizyme 1 measurement efo:EFO_0802835 Quantification of ornithine decarboxylase in a sample. Elizabeth Lewis true PMID:29875488 ornithine decarboxylase measurement efo:EFO_0802836 Quantification of orphan sodium- and chloride-dependent neurotransmitter transporter NTT5 in a sample. Elizabeth Lewis true PMID:29875488 orphan sodium- and chloride-dependent neurotransmitter transporter NTT5 measurement efo:EFO_0802837 Quantification of osteoclast-associated immunoglobulin-like receptor in a sample. Elizabeth Lewis true PMID:29875488 osteoclast-associated immunoglobulin-like receptor measurement efo:EFO_0802838 Quantification of osteocrin in a sample. Elizabeth Lewis true PMID:29875488 osteocrin measurement efo:EFO_0802839 Quantification of oxytocin-neurophysin 1 in a sample. Elizabeth Lewis true PMID:29875488 oxytocin-neurophysin 1 measurement efo:EFO_0802840 Quantification of P2X purinoceptor 6 in a sample. Elizabeth Lewis true PMID:29875488 P2X purinoceptor 6 measurement efo:EFO_0802841 Quantification of paired box protein Pax-4 in a sample. Elizabeth Lewis true PMID:29875488 paired box protein Pax-4 measurement efo:EFO_0802842 Quantification of palmitoleoyl-protein carboxylesterase NOTUM in a sample. Elizabeth Lewis true PMID:29875488 palmitoleoyl-protein carboxylesterase NOTUM measurement efo:EFO_0802843 Quantification of pantothenate kinase 3 in a sample. Elizabeth Lewis true PMID:29875488 pantothenate kinase 3 measurement efo:EFO_0802844 Quantification of papilin in a sample. Elizabeth Lewis true PMID:29875488 papilin measurement efo:EFO_0802845 Quantification of pappalysin-1 in a sample. Elizabeth Lewis true PMID:29875488 pappalysin-1 measurement efo:EFO_0802846 Quantification of pappalysin-2 in a sample. Elizabeth Lewis true PMID:29875488 pappalysin-2 measurement efo:EFO_0802847 Quantification of parathyroid hormone/parathyroid hormone-related peptide receptor in a sample. Elizabeth Lewis true PMID:29875488 parathyroid hormone/parathyroid hormone-related peptide receptor measurement efo:EFO_0802848 Quantification of patched domain-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 patched domain-containing protein 3 measurement efo:EFO_0802849 Quantification of PDZ and LIM domain protein 4 in a sample. Elizabeth Lewis true PMID:29875488 PDZ and LIM domain protein 4 measurement efo:EFO_0802850 Quantification of PDZ domain-containing protein 11 in a sample. Elizabeth Lewis true PMID:29875488 PDZ domain-containing protein 11 measurement efo:EFO_0802851 Quantification of peptidase inhibitor 15 in a sample. Elizabeth Lewis true PMID:29875488 peptidase inhibitor 15 measurement efo:EFO_0802852 Quantification of peptidyl-prolyl cis-trans isomerase FKBP2 in a sample. Elizabeth Lewis true PMID:29875488 peptidyl-prolyl cis-trans isomerase FKBP2 measurement efo:EFO_0802853 Quantification of peregrin in a sample. Elizabeth Lewis true PMID:29875488 peregrin measurement efo:EFO_0802854 Quantification of peroxidasin-like protein in a sample. Elizabeth Lewis true PMID:29875488 peroxidasin-like protein measurement efo:EFO_0802855 Quantification of peroxiredoxin-4 in a sample. Elizabeth Lewis true PMID:29875488 peroxiredoxin-4 measurement efo:EFO_0802856 Quantification of peroxisomal carnitine O-octanoyltransferase in a sample. Elizabeth Lewis true PMID:29875488 peroxisomal carnitine O-octanoyltransferase measurement efo:EFO_0802857 Quantification of peroxisomal membrane protein PEX14 in a sample. Elizabeth Lewis true PMID:29875488 peroxisomal membrane protein PEX14 measurement efo:EFO_0802858 Quantification of peroxisome proliferator-activated receptor alpha in a sample. Elizabeth Lewis true PMID:29875488 peroxisome proliferator-activated receptor alpha measurement efo:EFO_0802859 Quantification of PHD finger protein 3 in a sample. Elizabeth Lewis true PMID:29875488 PHD finger protein 3 measurement efo:EFO_0802860 Quantification of phosphatidate phosphatase PPAPDC1A in a sample. Elizabeth Lewis true PMID:29875488 phosphatidate phosphatase PPAPDC1A measurement efo:EFO_0802861 Quantification of phosphatidylinositol 5-phosphate 4-kinase type-2 alpha in a sample. Elizabeth Lewis true PMID:29875488 phosphatidylinositol 5-phosphate 4-kinase type-2 alpha measurement efo:EFO_0802862 Quantification of phosphatidylinositol transfer protein alpha isoform in a sample. Elizabeth Lewis true PMID:29875488 phosphatidylinositol transfer protein alpha isoform measurement efo:EFO_0802863 Quantification of phosphatidylinositol transfer protein beta isoform in a sample. Elizabeth Lewis true PMID:29875488 phosphatidylinositol transfer protein beta isoform measurement efo:EFO_0802864 Quantification of phosphoglycerate kinase 2 in a sample. Elizabeth Lewis true PMID:29875488 phosphoglycerate kinase 2 measurement efo:EFO_0802865 Quantification of phospholipase B-like 1 in a sample. Elizabeth Lewis true PMID:29875488 phospholipase B-like 1 measurement efo:EFO_0802866 Quantification of phospholipase D3 in a sample. Elizabeth Lewis true PMID:29875488 phospholipase D3 measurement efo:EFO_0802867 Quantification of phosphopantothenoylcysteine decarboxylase in a sample. Elizabeth Lewis true PMID:29875488 phosphopantothenoylcysteine decarboxylase measurement efo:EFO_0802868 Quantification of phosphoribosyl pyrophosphate synthase-associated protein 1 in a sample. Elizabeth Lewis true PMID:29875488 phosphoribosyl pyrophosphate synthase-associated protein 1 measurement efo:EFO_0802869 Quantification of pituitary adenylate cyclase-activating polypeptide in a sample. Elizabeth Lewis true PMID:29875488 pituitary adenylate cyclase-activating polypeptide measurement efo:EFO_0802870 Quantification of piwi-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 piwi-like protein 1 measurement efo:EFO_0802871 Quantification of plastin-1 in a sample. Elizabeth Lewis true PMID:29875488 plastin-1 measurement efo:EFO_0802872 Quantification of platelet glycoprotein V in a sample. Elizabeth Lewis true PMID:29875488 platelet glycoprotein V measurement efo:EFO_0802873 Quantification of pleckstrin homology domain-containing family A member 1 in a sample. Elizabeth Lewis true PMID:29875488 pleckstrin homology domain-containing family A member 1 measurement efo:EFO_0802874 Quantification of podocalyxin in a sample. Elizabeth Lewis true PMID:29875488 podocalyxin measurement efo:EFO_0802875 Quantification of poliovirus receptor in a sample. Elizabeth Lewis true PMID:29875488 poliovirus receptor measurement efo:EFO_0802876 Quantification of poly [ADP-ribose] polymerase 1 in a sample. Elizabeth Lewis true PMID:29875488 poly [ADP-ribose] polymerase 1 measurement efo:EFO_0802877 Quantification of poly [ADP-ribose] polymerase 11 in a sample. Elizabeth Lewis true PMID:29875488 poly [ADP-ribose] polymerase 11 measurement efo:EFO_0802878 Quantification of poly(A) polymerase gamma in a sample. Elizabeth Lewis true PMID:29875488 poly(A) polymerase gamma measurement efo:EFO_0802879 Quantification of poly(U)-specific endoribonuclease in a sample. Elizabeth Lewis true PMID:29875488 poly(U)-specific endoribonuclease measurement efo:EFO_0802880 Quantification of polyadenylate-binding protein-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 polyadenylate-binding protein-interacting protein 1 measurement efo:EFO_0802881 Quantification of polycystin-2 in a sample. Elizabeth Lewis true PMID:29875488 polycystin-2 measurement efo:EFO_0802882 Quantification of polypeptide N-acetylgalactosaminyltransferase 10 in a sample. Elizabeth Lewis true PMID:29875488 polypeptide N-acetylgalactosaminyltransferase 10 measurement efo:EFO_0802883 Quantification of polypeptide N-acetylgalactosaminyltransferase 11 in a sample. Elizabeth Lewis true PMID:29875488 polypeptide N-acetylgalactosaminyltransferase 11 measurement efo:EFO_0802884 Quantification of polypeptide N-acetylgalactosaminyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 polypeptide N-acetylgalactosaminyltransferase 2 measurement efo:EFO_0802885 Quantification of polypeptide N-acetylgalactosaminyltransferase 3 in a sample. Elizabeth Lewis true PMID:29875488 polypeptide N-acetylgalactosaminyltransferase 3 measurement efo:EFO_0802886 Quantification of polyphosphoinositide phosphatase in a sample. Elizabeth Lewis true PMID:29875488 polyphosphoinositide phosphatase measurement efo:EFO_0802887 Quantification of porphobilinogen deaminase in a sample. Elizabeth Lewis true PMID:29875488 porphobilinogen deaminase measurement efo:EFO_0802888 Quantification of potassium voltage-gated channel subfamily A member 10 in a sample. Elizabeth Lewis true PMID:29875488 potassium voltage-gated channel subfamily A member 10 measurement efo:EFO_0802889 Quantification of potassium voltage-gated channel subfamily E member 3 in a sample. Elizabeth Lewis true PMID:29875488 potassium voltage-gated channel subfamily E member 3 measurement efo:EFO_0802890 Quantification of potassium voltage-gated channel subfamily F member 1 in a sample. Elizabeth Lewis true PMID:29875488 potassium voltage-gated channel subfamily F member 1 measurement efo:EFO_0802891 Quantification of potassium voltage-gated channel subfamily G member 4 in a sample. Elizabeth Lewis true PMID:29875488 potassium voltage-gated channel subfamily G member 4 measurement efo:EFO_0802892 Quantification of POU domain, class 2, transcription factor 1 in a sample. Elizabeth Lewis true PMID:29875488 POU domain, class 2, transcription factor 1 measurement efo:EFO_0802893 Quantification of PR domain zinc finger protein 4 in a sample. Elizabeth Lewis true PMID:29875488 PR domain zinc finger protein 4 measurement efo:EFO_0802894 Quantification of pre-mRNA-processing factor 6 in a sample. Elizabeth Lewis true PMID:29875488 pre-mRNA-processing factor 6 measurement efo:EFO_0802895 Quantification of pregnancy-specific beta-1-glycoprotein 11 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 11 measurement efo:EFO_0802896 Quantification of pregnancy-specific beta-1-glycoprotein 2 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 2 measurement efo:EFO_0802897 Quantification of pregnancy-specific beta-1-glycoprotein 6 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 6 measurement efo:EFO_0802898 Quantification of pregnancy-specific beta-1-glycoprotein 8 in a sample. Elizabeth Lewis true PMID:29875488 pregnancy-specific beta-1-glycoprotein 8 measurement efo:EFO_0802899 Quantification of prestin in a sample. Elizabeth Lewis true PMID:29875488 prestin measurement efo:EFO_0802900 Quantification of pro-neuregulin-2, membrane-bound isoform in a sample. Elizabeth Lewis true PMID:29875488 pro-neuregulin-2, membrane-bound isoform measurement efo:EFO_0802901 Quantification of probable ATP-dependent RNA helicase DHX58 in a sample. Elizabeth Lewis true PMID:29875488 probable ATP-dependent RNA helicase DHX58 measurement efo:EFO_0802902 Quantification of probable E3 ubiquitin-protein ligase HERC1 in a sample. Elizabeth Lewis true PMID:29875488 probable E3 ubiquitin-protein ligase HERC1 measurement efo:EFO_0802903 Quantification of probable E3 ubiquitin-protein ligase HERC4 in a sample. Elizabeth Lewis true PMID:29875488 probable E3 ubiquitin-protein ligase HERC4 measurement efo:EFO_0802904 Quantification of probable E3 ubiquitin-protein ligase MID2 in a sample. Elizabeth Lewis true PMID:29875488 probable E3 ubiquitin-protein ligase MID2 measurement efo:EFO_0802905 Quantification of probable G-protein coupled receptor 101 in a sample. Elizabeth Lewis true PMID:29875488 probable G-protein coupled receptor 101 measurement efo:EFO_0802906 Quantification of probable inactive ribonuclease-like protein 13 in a sample. Elizabeth Lewis true PMID:29875488 probable inactive ribonuclease-like protein 13 measurement efo:EFO_0802907 Quantification of probable inactive serine protease 37 in a sample. Elizabeth Lewis true PMID:29875488 probable inactive serine protease 37 measurement efo:EFO_0802908 Quantification of probable palmitoyltransferase ZDHHC14 in a sample. Elizabeth Lewis true PMID:29875488 probable palmitoyltransferase ZDHHC14 measurement efo:EFO_0802909 Quantification of probable RNA-binding protein 19 in a sample. Elizabeth Lewis true PMID:29875488 probable RNA-binding protein 19 measurement efo:EFO_0802910 Quantification of procalcitonin in a sample. Elizabeth Lewis true PMID:29875488 procalcitonin measurement efo:EFO_0802911 Quantification of procollagen galactosyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 procollagen galactosyltransferase 2 measurement efo:EFO_0802912 Quantification of procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 in a sample. Elizabeth Lewis true PMID:29875488 procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 measurement efo:EFO_0802913 Quantification of procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 in a sample. Elizabeth Lewis true PMID:29875488 procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 measurement efo:EFO_0802914 Quantification of profilin-2 in a sample. Elizabeth Lewis true PMID:29875488 profilin-2 measurement efo:EFO_0802915 Quantification of prolactin-releasing peptide in a sample. Elizabeth Lewis true PMID:29875488 prolactin-releasing peptide measurement efo:EFO_0802916 Quantification of proline-rich protein 1 in a sample. Elizabeth Lewis true PMID:29875488 proline-rich protein 1 measurement efo:EFO_0802917 Quantification of prolyl 4-hydroxylase subunit alpha-1 in a sample. Elizabeth Lewis true PMID:29875488 prolyl 4-hydroxylase subunit alpha-1 measurement efo:EFO_0802918 Quantification of prolyl 4-hydroxylase subunit alpha-2 in a sample. Elizabeth Lewis true PMID:29875488 prolyl 4-hydroxylase subunit alpha-2 measurement efo:EFO_0802919 Quantification of prostate and testis expressed protein 1 in a sample. Elizabeth Lewis true PMID:29875488 prostate and testis expressed protein 1 measurement efo:EFO_0802920 Quantification of prostate-associated microseminoprotein in a sample. Elizabeth Lewis true PMID:29875488 prostate-associated microseminoprotein measurement efo:EFO_0802921 Quantification of proteasome assembly chaperone 3 in a sample. Elizabeth Lewis true PMID:29875488 proteasome assembly chaperone 3 measurement efo:EFO_0802922 Quantification of proteasome subunit alpha type-4 in a sample. Elizabeth Lewis true PMID:29875488 proteasome subunit alpha type-4 measurement efo:EFO_0802923 Quantification of proteasome subunit beta type-5 in a sample. Elizabeth Lewis true PMID:29875488 proteasome subunit beta type-5 measurement efo:EFO_0802924 Quantification of protein APCDD1 in a sample. Elizabeth Lewis true PMID:29875488 protein APCDD1 measurement efo:EFO_0802925 Quantification of protein arginine N-methyltransferase 3 in a sample. Elizabeth Lewis true PMID:29875488 protein arginine N-methyltransferase 3 measurement efo:EFO_0802926 Quantification of protein argonaute-1 in a sample. Elizabeth Lewis true PMID:29875488 protein argonaute-1 measurement efo:EFO_0802927 Quantification of protein CASC4 in a sample. Elizabeth Lewis true PMID:29875488 protein CASC4 measurement efo:EFO_0802928 Quantification of protein crumbs homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 protein crumbs homolog 1 measurement efo:EFO_0802929 Quantification of protein CYR61 in a sample. Elizabeth Lewis true PMID:29875488 protein CYR61 measurement efo:EFO_0802930 Quantification of protein delta homolog 2 in a sample. Elizabeth Lewis true PMID:29875488 protein delta homolog 2 measurement efo:EFO_0802931 Quantification of protein DGCR6 in a sample. Elizabeth Lewis true PMID:29875488 protein DGCR6 measurement efo:EFO_0802932 Quantification of protein disulfide-isomerase-like protein of the testis in a sample. Elizabeth Lewis true PMID:29875488 protein disulfide-isomerase-like protein of the testis measurement efo:EFO_0802933 Quantification of protein dpy-30 homolog in a sample. Elizabeth Lewis true PMID:29875488 protein dpy-30 homolog measurement efo:EFO_0802934 Quantification of protein enabled homolog in a sample. Elizabeth Lewis true PMID:29875488 protein enabled homolog measurement efo:EFO_0802935 Quantification of protein FAM134B in a sample. Elizabeth Lewis true PMID:29875488 protein FAM134B measurement efo:EFO_0802936 Quantification of protein FAM163B in a sample. Elizabeth Lewis true PMID:29875488 protein FAM163B measurement efo:EFO_0802937 Quantification of protein FAM172A in a sample. Elizabeth Lewis true PMID:29875488 protein FAM172A measurement efo:EFO_0802938 Quantification of protein FAM173A in a sample. Elizabeth Lewis true PMID:29875488 protein FAM173A measurement efo:EFO_0802939 Quantification of protein FAM19A2 in a sample. Elizabeth Lewis true PMID:29875488 protein FAM19A2 measurement efo:EFO_0802940 Quantification of protein FAM19A3 in a sample. Elizabeth Lewis true PMID:29875488 protein FAM19A3 measurement efo:EFO_0802941 Quantification of protein FAM19A4 in a sample. Elizabeth Lewis true PMID:29875488 protein FAM19A4 measurement efo:EFO_0802942 Quantification of protein FAM19A5 in a sample. Elizabeth Lewis true PMID:29875488 protein FAM19A5 measurement efo:EFO_0802943 Quantification of protein FAM209B in a sample. Elizabeth Lewis true PMID:29875488 protein FAM209B measurement efo:EFO_0802944 Quantification of protein FAM24B in a sample. Elizabeth Lewis true PMID:29875488 protein FAM24B measurement efo:EFO_0802945 Quantification of protein G6b in a sample. Elizabeth Lewis true PMID:29875488 protein G6b measurement efo:EFO_0802946 Quantification of protein GPR107 in a sample. Elizabeth Lewis true PMID:29875488 protein GPR107 measurement efo:EFO_0802947 Quantification of protein HEG homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 protein HEG homolog 1 measurement efo:EFO_0802948 Quantification of protein JTB in a sample. Elizabeth Lewis true PMID:29875488 protein JTB measurement efo:EFO_0802949 Quantification of protein kinase C-binding protein NELL2 in a sample. Elizabeth Lewis true PMID:29875488 protein kinase C-binding protein NELL2 measurement efo:EFO_0802950 Quantification of protein kish-A in a sample. Elizabeth Lewis true PMID:29875488 protein kish-A measurement efo:EFO_0802951 Quantification of protein kish-B in a sample. Elizabeth Lewis true PMID:29875488 protein kish-B measurement efo:EFO_0802952 Quantification of protein Largen in a sample. Elizabeth Lewis true PMID:29875488 protein Largen measurement efo:EFO_0802953 Quantification of protein NDNF in a sample. Elizabeth Lewis true PMID:29875488 protein NDNF measurement efo:EFO_0802954 Quantification of protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 measurement efo:EFO_0802955 Quantification of protein p13 MTCP-1 in a sample. Elizabeth Lewis true PMID:29875488 protein p13 MTCP-1 measurement efo:EFO_0802956 Quantification of protein phosphatase 1 regulatory subunit 3B in a sample. Elizabeth Lewis true PMID:29875488 protein phosphatase 1 regulatory subunit 3B measurement efo:EFO_0802957 Quantification of protein phosphatase 1A in a sample. Elizabeth Lewis true PMID:29875488 protein phosphatase 1A measurement efo:EFO_0802958 Quantification of protein phosphatase 1L in a sample. Elizabeth Lewis true PMID:29875488 protein phosphatase 1L measurement efo:EFO_0802959 Quantification of protein regulator of cytokinesis 1 in a sample. Elizabeth Lewis true PMID:29875488 protein regulator of cytokinesis 1 measurement efo:EFO_0802960 Quantification of protein ripply1 in a sample. Elizabeth Lewis true PMID:29875488 protein ripply1 measurement efo:EFO_0802961 Quantification of protein S100-A2 in a sample. Elizabeth Lewis true PMID:29875488 protein S100-A2 measurement efo:EFO_0802962 Quantification of protein SCO1 homolog, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 protein SCO1 homolog, mitochondrial measurement efo:EFO_0802963 Quantification of protein sprouty homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 protein sprouty homolog 1 measurement efo:EFO_0802964 Quantification of protein transport protein Sec61 subunit beta in a sample. Elizabeth Lewis true PMID:29875488 protein transport protein Sec61 subunit beta measurement efo:EFO_0802965 Quantification of protein transport protein Sec61 subunit gamma in a sample. Elizabeth Lewis true PMID:29875488 protein transport protein Sec61 subunit gamma measurement efo:EFO_0802966 Quantification of protein turtle homolog A in a sample. Elizabeth Lewis true PMID:29875488 protein turtle homolog A measurement efo:EFO_0802967 Quantification of protein tyrosine phosphatase type IVA 2 in a sample. Elizabeth Lewis true PMID:29875488 protein tyrosine phosphatase type IVA 2 measurement efo:EFO_0802968 Quantification of protein unc-13 homolog A in a sample. Elizabeth Lewis true PMID:29875488 protein unc-13 homolog A measurement efo:EFO_0802969 Quantification of protein YIPF6 in a sample. Elizabeth Lewis true PMID:29875488 protein YIPF6 measurement efo:EFO_0802970 Quantification of proteoglycan 3 in a sample. Elizabeth Lewis true PMID:29875488 proteoglycan 3 measurement efo:EFO_0802971 Quantification of protocadherin alpha-C2 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin alpha-C2 measurement efo:EFO_0802972 Quantification of protocadherin beta-1 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin beta-1 measurement efo:EFO_0802973 Quantification of protocadherin gamma-A8 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin gamma-A8 measurement efo:EFO_0802974 Quantification of protocadherin-15 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin-15 measurement efo:EFO_0802975 Quantification of protocadherin-9 in a sample. Elizabeth Lewis true PMID:29875488 protocadherin-9 measurement efo:EFO_0802976 Quantification of protrudin in a sample. Elizabeth Lewis true PMID:29875488 protrudin measurement efo:EFO_0802977 Quantification of pterin-4-alpha-carbinolamine dehydratase 2 in a sample. Elizabeth Lewis true PMID:29875488 pterin-4-alpha-carbinolamine dehydratase 2 measurement efo:EFO_0802978 Quantification of pterin-4-alpha-carbinolamine dehydratase in a sample. Elizabeth Lewis true PMID:29875488 pterin-4-alpha-carbinolamine dehydratase measurement efo:EFO_0802979 Quantification of putative apolipoprotein(a)-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 putative apolipoprotein(a)-like protein 2 measurement efo:EFO_0802980 Quantification of putative chondrosarcoma-associated gene 1 protein in a sample. Elizabeth Lewis true PMID:29875488 putative chondrosarcoma-associated gene 1 protein measurement efo:EFO_0802981 Quantification of putative inactive group IIC secretory phospholipase A2 in a sample. Elizabeth Lewis true PMID:29875488 putative inactive group IIC secretory phospholipase A2 measurement efo:EFO_0802982 Quantification of putative phospholipase B-like 2 in a sample. Elizabeth Lewis true PMID:29875488 putative phospholipase B-like 2 measurement efo:EFO_0802983 Quantification of putative pregnancy-specific beta-1-glycoprotein 7 in a sample. Elizabeth Lewis true PMID:29875488 putative pregnancy-specific beta-1-glycoprotein 7 measurement efo:EFO_0802984 Quantification of putative uncharacterized protein PQLC2L in a sample. Elizabeth Lewis true PMID:29875488 putative uncharacterized protein PQLC2L measurement efo:EFO_0802985 Quantification of pyrin domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 pyrin domain-containing protein 1 measurement efo:EFO_0802986 Quantification of pyruvate carboxylase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 pyruvate carboxylase, mitochondrial measurement efo:EFO_0802987 Quantification of radiation-inducible immediate-early gene IEX-1 in a sample. Elizabeth Lewis true PMID:29875488 radiation-inducible immediate-early gene IEX-1 measurement efo:EFO_0802988 Quantification of ran-binding protein 3 in a sample. Elizabeth Lewis true PMID:29875488 ran-binding protein 3 measurement efo:EFO_0802989 Quantification of rap guanine nucleotide exchange factor 5 in a sample. Elizabeth Lewis true PMID:29875488 rap guanine nucleotide exchange factor 5 measurement efo:EFO_0802990 Quantification of rap1 GTPase-GDP dissociation stimulator 1 in a sample. Elizabeth Lewis true PMID:29875488 rap1 GTPase-GDP dissociation stimulator 1 measurement efo:EFO_0802991 Quantification of ras-related protein Rab-22A in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-22A measurement efo:EFO_0802992 Quantification of ras-related protein Rab-27A in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-27A measurement efo:EFO_0802993 Quantification of ras-related protein Rab-27B in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-27B measurement efo:EFO_0802994 Quantification of ras-related protein Rab-39B in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-39B measurement efo:EFO_0802995 Quantification of ras-related protein Rab-7b in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rab-7b measurement efo:EFO_0802996 Quantification of ras-related protein Rap-2a in a sample. Elizabeth Lewis true PMID:29875488 ras-related protein Rap-2a measurement efo:EFO_0802997 Quantification of receptor-interacting serine/threonine-protein kinase 2 in a sample. Elizabeth Lewis true PMID:29875488 receptor-interacting serine/threonine-protein kinase 2 measurement efo:EFO_0802998 Quantification of receptor-type tyrosine-protein phosphatase delta in a sample. Elizabeth Lewis true PMID:29875488 receptor-type tyrosine-protein phosphatase delta measurement efo:EFO_0802999 Quantification of receptor-type tyrosine-protein phosphatase eta in a sample. Elizabeth Lewis true PMID:29875488 receptor-type tyrosine-protein phosphatase eta measurement efo:EFO_0803000 Quantification of receptor-type tyrosine-protein phosphatase R in a sample. Elizabeth Lewis true PMID:29875488 receptor-type tyrosine-protein phosphatase R measurement efo:EFO_0803001 Quantification of receptor-type tyrosine-protein phosphatase S in a sample. Elizabeth Lewis true PMID:29875488 receptor-type tyrosine-protein phosphatase S measurement efo:EFO_0803002 Quantification of receptor-type tyrosine-protein phosphatase U in a sample. Elizabeth Lewis true PMID:29875488 receptor-type tyrosine-protein phosphatase U measurement efo:EFO_0803003 Quantification of recoverin in a sample. Elizabeth Lewis true PMID:29875488 recoverin measurement efo:EFO_0803004 Quantification of regenerating islet-derived protein 3-alpha in a sample. Elizabeth Lewis true PMID:29875488 regenerating islet-derived protein 3-alpha measurement efo:EFO_0803005 Quantification of regulator of G-protein signaling 10 in a sample. Elizabeth Lewis true PMID:29875488 regulator of G-protein signaling 10 measurement efo:EFO_0803006 Quantification of regulator of G-protein signaling 3 in a sample. Elizabeth Lewis true PMID:29875488 regulator of G-protein signaling 3 measurement efo:EFO_0803007 Quantification of regulator of microtubule dynamics protein 3 in a sample. Elizabeth Lewis true PMID:29875488 regulator of microtubule dynamics protein 3 measurement efo:EFO_0803008 Quantification of RELT-like protein 2 in a sample. Elizabeth Lewis true PMID:29875488 RELT-like protein 2 measurement efo:EFO_0803009 Quantification of retbindin in a sample. Elizabeth Lewis true PMID:29875488 retbindin measurement efo:EFO_0803010 Quantification of reticulocalbin-2 in a sample. Elizabeth Lewis true PMID:29875488 reticulocalbin-2 measurement efo:EFO_0803011 Quantification of retina-specific copper amine oxidase in a sample. Elizabeth Lewis true PMID:29875488 retina-specific copper amine oxidase measurement efo:EFO_0803012 Quantification of retinoblastoma-binding protein 5 in a sample. Elizabeth Lewis true PMID:29875488 retinoblastoma-binding protein 5 measurement efo:EFO_0803013 Quantification of retinoblastoma-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 retinoblastoma-like protein 1 measurement efo:EFO_0803014 Quantification of retinoschisin in a sample. Elizabeth Lewis true PMID:29875488 retinoschisin measurement efo:EFO_0803015 Quantification of rho GTPase-activating protein 1 in a sample. Elizabeth Lewis true PMID:29875488 rho GTPase-activating protein 1 measurement efo:EFO_0803016 Quantification of rho GTPase-activating protein 36 in a sample. Elizabeth Lewis true PMID:29875488 rho GTPase-activating protein 36 measurement efo:EFO_0803017 Quantification of rho GTPase-activating protein 5 in a sample. Elizabeth Lewis true PMID:29875488 rho GTPase-activating protein 5 measurement efo:EFO_0803018 Quantification of rho guanine nucleotide exchange factor 2 in a sample. Elizabeth Lewis true PMID:29875488 rho guanine nucleotide exchange factor 2 measurement efo:EFO_0803019 Quantification of rho guanine nucleotide exchange factor 25 in a sample. Elizabeth Lewis true PMID:29875488 rho guanine nucleotide exchange factor 25 measurement efo:EFO_0803020 Quantification of rho guanine nucleotide exchange factor 7 in a sample. Elizabeth Lewis true PMID:29875488 rho guanine nucleotide exchange factor 7 measurement efo:EFO_0803021 Quantification of rho-associated protein kinase 2 in a sample. Elizabeth Lewis true PMID:29875488 rho-associated protein kinase 2 measurement efo:EFO_0803022 Quantification of rho-related GTP-binding protein Rho6 in a sample. Elizabeth Lewis true PMID:29875488 rho-related GTP-binding protein Rho6 measurement efo:EFO_0803023 Quantification of rho-related GTP-binding protein RhoD in a sample. Elizabeth Lewis true PMID:29875488 rho-related GTP-binding protein RhoD measurement efo:EFO_0803024 Quantification of rho-related GTP-binding protein RhoG in a sample. Elizabeth Lewis true PMID:29875488 rho-related GTP-binding protein RhoG measurement efo:EFO_0803025 Quantification of ribosome biogenesis protein TSR3 homolog in a sample. Elizabeth Lewis true PMID:29875488 ribosome biogenesis protein TSR3 homolog measurement efo:EFO_0803026 Quantification of ribosome-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 ribosome-binding protein 1 measurement efo:EFO_0803027 Quantification of ribosome-recycling factor, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 ribosome-recycling factor, mitochondrial measurement efo:EFO_0803028 Quantification of RING finger protein 122 in a sample. Elizabeth Lewis true PMID:29875488 RING finger protein 122 measurement efo:EFO_0803029 Quantification of RING finger protein 148 in a sample. Elizabeth Lewis true PMID:29875488 RING finger protein 148 measurement efo:EFO_0803030 Quantification of RING finger protein 150 in a sample. Elizabeth Lewis true PMID:29875488 RING finger protein 150 measurement efo:EFO_0803031 Quantification of RING finger protein 215 in a sample. Elizabeth Lewis true PMID:29875488 RING finger protein 215 measurement efo:EFO_0803032 Quantification of RING finger protein 219 in a sample. Elizabeth Lewis true PMID:29875488 RING finger protein 219 measurement efo:EFO_0803033 Quantification of RNA binding protein fox-1 homolog 2 in a sample. Elizabeth Lewis true PMID:29875488 RNA binding protein fox-1 homolog 2 measurement efo:EFO_0803034 Quantification of RNA demethylase ALKBH5 in a sample. Elizabeth Lewis true PMID:29875488 RNA demethylase ALKBH5 measurement efo:EFO_0803035 Quantification of RNA polymerase II elongation factor ELL2 in a sample. Elizabeth Lewis true PMID:29875488 RNA polymerase II elongation factor ELL2 measurement efo:EFO_0803036 Quantification of RNA-binding protein 28 in a sample. Elizabeth Lewis true PMID:29875488 RNA-binding protein 28 measurement efo:EFO_0803037 Quantification of RNA-binding protein 40 in a sample. Elizabeth Lewis true PMID:29875488 RNA-binding protein 40 measurement efo:EFO_0803038 Quantification of RNA-binding protein Nova-1 in a sample. Elizabeth Lewis true PMID:29875488 RNA-binding protein Nova-1 measurement efo:EFO_0803039 Quantification of roundabout homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 roundabout homolog 1 measurement efo:EFO_0803040 Quantification of RUN and FYVE domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 RUN and FYVE domain-containing protein 1 measurement efo:EFO_0803041 Quantification of s-methyl-5'-thioadenosine phosphorylase in a sample. Elizabeth Lewis true PMID:29875488 s-methyl-5'-thioadenosine phosphorylase measurement efo:EFO_0803042 Quantification of SAGA-associated factor 29 homolog in a sample. Elizabeth Lewis true PMID:29875488 SAGA-associated factor 29 homolog measurement efo:EFO_0803043 Quantification of SAYSvFN domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 SAYSvFN domain-containing protein 1 measurement efo:EFO_0803044 Quantification of scavenger receptor class A member 3 in a sample. Elizabeth Lewis true PMID:29875488 scavenger receptor class A member 3 measurement efo:EFO_0803045 Quantification of secretagogin in a sample. Elizabeth Lewis true PMID:29875488 secretagogin measurement efo:EFO_0803046 Quantification of secretoglobin family 1D member 2 in a sample. Elizabeth Lewis true PMID:29875488 secretoglobin family 1D member 2 measurement efo:EFO_0803047 Quantification of secretogranin-1 in a sample. Elizabeth Lewis true PMID:29875488 secretogranin-1 measurement efo:EFO_0803048 Quantification of secretogranin-2 in a sample. Elizabeth Lewis true PMID:29875488 secretogranin-2 measurement efo:EFO_0803049 Quantification of secretory carrier-associated membrane protein 5 in a sample. Elizabeth Lewis true PMID:29875488 secretory carrier-associated membrane protein 5 measurement efo:EFO_0803050 Quantification of semaphorin-4C in a sample. Elizabeth Lewis true PMID:29875488 semaphorin-4C measurement efo:EFO_0803051 Quantification of semaphorin-6C in a sample. Elizabeth Lewis true PMID:29875488 semaphorin-6C measurement efo:EFO_0803052 Quantification of semaphorin-7A in a sample. Elizabeth Lewis true PMID:29875488 semaphorin-7A measurement efo:EFO_0803053 Quantification of sentrin-specific protease 7 in a sample. Elizabeth Lewis true PMID:29875488 sentrin-specific protease 7 measurement efo:EFO_0803054 Quantification of sepiapterin reductase in a sample. Elizabeth Lewis true PMID:29875488 sepiapterin reductase measurement efo:EFO_0803055 Quantification of serine palmitoyltransferase 1 in a sample. Elizabeth Lewis true PMID:29875488 serine palmitoyltransferase 1 measurement efo:EFO_0803056 Quantification of serine palmitoyltransferase 2 in a sample. Elizabeth Lewis true PMID:29875488 serine palmitoyltransferase 2 measurement efo:EFO_0803057 Quantification of serine protease inhibitor Kazal-type 13 in a sample. Elizabeth Lewis true PMID:29875488 serine protease inhibitor Kazal-type 13 measurement efo:EFO_0803058 Quantification of serine protease inhibitor Kazal-type 5 in a sample. Elizabeth Lewis true PMID:29875488 serine protease inhibitor Kazal-type 5 measurement efo:EFO_0803059 Quantification of serine protease inhibitor Kazal-type 8 in a sample. Elizabeth Lewis true PMID:29875488 serine protease inhibitor Kazal-type 8 measurement efo:EFO_0803060 Quantification of serine protease inhibitor Kazal-type 9 in a sample. Elizabeth Lewis true PMID:29875488 serine protease inhibitor Kazal-type 9 measurement efo:EFO_0803061 Quantification of serine--tRNA ligase, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 serine--tRNA ligase, mitochondrial measurement efo:EFO_0803062 Quantification of serine/arginine-rich splicing factor 6 in a sample. Elizabeth Lewis true PMID:29875488 serine/arginine-rich splicing factor 6 measurement efo:EFO_0803063 Quantification of serine/threonine-protein kinase BRSK2 in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein kinase BRSK2 measurement efo:EFO_0803064 Quantification of serine/threonine-protein kinase DCLK3 in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein kinase DCLK3 measurement efo:EFO_0803065 Quantification of serine/threonine-protein kinase ULK3 in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein kinase ULK3 measurement efo:EFO_0803066 Quantification of serine/threonine-protein kinase VRK1 in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein kinase VRK1 measurement efo:EFO_0803067 Quantification of serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform in a sample. Elizabeth Lewis true PMID:29875488 serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform measurement efo:EFO_0803068 Quantification of serpin I2 in a sample. Elizabeth Lewis true PMID:29875488 serpin I2 measurement efo:EFO_0803069 Quantification of set1/Ash2 histone methyltransferase complex subunit ASH2 in a sample. Elizabeth Lewis true PMID:29875488 set1/Ash2 histone methyltransferase complex subunit ASH2 measurement efo:EFO_0803070 Quantification of SHC-transforming protein 2 in a sample. Elizabeth Lewis true PMID:29875488 SHC-transforming protein 2 measurement efo:EFO_0803071 Quantification of SHC-transforming protein 4 in a sample. Elizabeth Lewis true PMID:29875488 SHC-transforming protein 4 measurement efo:EFO_0803072 Quantification of sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase in a sample. Elizabeth Lewis true PMID:29875488 sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase measurement efo:EFO_0803073 Quantification of sialate O-acetylesterase in a sample. Elizabeth Lewis true PMID:29875488 sialate O-acetylesterase measurement efo:EFO_0803074 Quantification of signal peptide, CUB and EGF-like domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 signal peptide, CUB and EGF-like domain-containing protein 1 measurement efo:EFO_0803075 Quantification of signal-transducing adaptor protein 1 in a sample. Elizabeth Lewis true PMID:29875488 signal-transducing adaptor protein 1 measurement efo:EFO_0803076 Quantification of signaling lymphocytic activation molecule in a sample. Elizabeth Lewis true PMID:29875488 signaling lymphocytic activation molecule measurement efo:EFO_0803077 Quantification of signaling threshold-regulating transmembrane adapter 1 in a sample. Elizabeth Lewis true PMID:29875488 signaling threshold-regulating transmembrane adapter 1 measurement efo:EFO_0803078 Quantification of single-pass membrane and coiled-coil domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 single-pass membrane and coiled-coil domain-containing protein 2 measurement efo:EFO_0803079 Quantification of SLAM family member 8 in a sample. Elizabeth Lewis true PMID:29875488 SLAM family member 8 measurement efo:EFO_0803080 Quantification of SLIT and NTRK-like protein 4 in a sample. Elizabeth Lewis true PMID:29875488 SLIT and NTRK-like protein 4 measurement efo:EFO_0803081 Quantification of small conductance calcium-activated potassium channel protein 1 in a sample. Elizabeth Lewis true PMID:29875488 small conductance calcium-activated potassium channel protein 1 measurement efo:EFO_0803082 Quantification of small EDRK-rich factor 1 in a sample. Elizabeth Lewis true PMID:29875488 small EDRK-rich factor 1 measurement efo:EFO_0803083 Quantification of small integral membrane protein 10 in a sample. Elizabeth Lewis true PMID:29875488 small integral membrane protein 10 measurement efo:EFO_0803084 Quantification of SNARE-associated protein Snapin in a sample. Elizabeth Lewis true PMID:29875488 SNARE-associated protein Snapin measurement efo:EFO_0803085 Quantification of sodium channel subunit beta-2 in a sample. Elizabeth Lewis true PMID:29875488 sodium channel subunit beta-2 measurement efo:EFO_0803086 Quantification of sodium- and chloride-dependent glycine transporter 1 in a sample. Elizabeth Lewis true PMID:29875488 sodium- and chloride-dependent glycine transporter 1 measurement efo:EFO_0803087 Quantification of sodium-independent sulfate anion transporter in a sample. Elizabeth Lewis true PMID:29875488 sodium-independent sulfate anion transporter measurement efo:EFO_0803088 Quantification of sodium/iodide cotransporter in a sample. Elizabeth Lewis true PMID:29875488 sodium/iodide cotransporter measurement efo:EFO_0803089 Quantification of soluble calcium-activated nucleotidase 1 in a sample. Elizabeth Lewis true PMID:29875488 soluble calcium-activated nucleotidase 1 measurement efo:EFO_0803090 Quantification of solute carrier family 41 member 2 in a sample. Elizabeth Lewis true PMID:29875488 solute carrier family 41 member 2 measurement efo:EFO_0803091 Quantification of solute carrier organic anion transporter family member 5A1 in a sample. Elizabeth Lewis true PMID:29875488 solute carrier organic anion transporter family member 5A1 measurement efo:EFO_0803092 Quantification of sorting nexin-1 in a sample. Elizabeth Lewis true PMID:29875488 sorting nexin-1 measurement efo:EFO_0803093 Quantification of sorting nexin-17 in a sample. Elizabeth Lewis true PMID:29875488 sorting nexin-17 measurement efo:EFO_0803094 Quantification of sorting nexin-7 in a sample. Elizabeth Lewis true PMID:29875488 sorting nexin-7 measurement efo:EFO_0803095 Quantification of sorting nexin-8 in a sample. Elizabeth Lewis true PMID:29875488 sorting nexin-8 measurement efo:EFO_0803096 Quantification of spastin in a sample. Elizabeth Lewis true PMID:29875488 spastin measurement efo:EFO_0803097 Quantification of speckle-type POZ protein in a sample. Elizabeth Lewis true PMID:29875488 speckle-type POZ protein measurement efo:EFO_0803098 Quantification of sperm-associated antigen 11B in a sample. Elizabeth Lewis true PMID:29875488 sperm-associated antigen 11B measurement efo:EFO_0803099 Quantification of spermatogenesis-associated protein 9 in a sample. Elizabeth Lewis true PMID:29875488 spermatogenesis-associated protein 9 measurement efo:EFO_0803100 Quantification of splicing factor 3B subunit 4 in a sample. Elizabeth Lewis true PMID:29875488 splicing factor 3B subunit 4 measurement efo:EFO_0803101 Quantification of splicing factor U2AF 65 kDa subunit in a sample. Elizabeth Lewis true PMID:29875488 splicing factor U2AF 65 kDa subunit measurement efo:EFO_0803102 Quantification of sprouty-related, EVH1 domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 sprouty-related, EVH1 domain-containing protein 1 measurement efo:EFO_0803103 Quantification of SPRY domain-containing SOCS box protein 1 in a sample. Elizabeth Lewis true PMID:29875488 SPRY domain-containing SOCS box protein 1 measurement efo:EFO_0803104 Quantification of stanniocalcin-2 in a sample. Elizabeth Lewis true PMID:29875488 stanniocalcin-2 measurement efo:EFO_0803105 Quantification of stromal cell-derived factor 2-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 stromal cell-derived factor 2-like protein 1 measurement efo:EFO_0803106 Quantification of submaxillary gland androgen-regulated protein 3B in a sample. Elizabeth Lewis true PMID:29875488 submaxillary gland androgen-regulated protein 3B measurement efo:EFO_0803107 Quantification of succinate dehydrogenase assembly factor 2, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 succinate dehydrogenase assembly factor 2, mitochondrial measurement efo:EFO_0803108 Quantification of sulfotransferase 4A1 in a sample. Elizabeth Lewis true PMID:29875488 sulfotransferase 4A1 measurement efo:EFO_0803109 Quantification of suppressor of cytokine signaling 7 in a sample. Elizabeth Lewis true PMID:29875488 suppressor of cytokine signaling 7 measurement efo:EFO_0803110 Quantification of suprabasin in a sample. Elizabeth Lewis true PMID:29875488 suprabasin measurement efo:EFO_0803111 Quantification of Sushi domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 Sushi domain-containing protein 1 measurement efo:EFO_0803112 Quantification of Sushi domain-containing protein 3 in a sample. Elizabeth Lewis true PMID:29875488 Sushi domain-containing protein 3 measurement efo:EFO_0803113 Quantification of Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 measurement efo:EFO_0803114 Quantification of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related in a sample. Elizabeth Lewis true PMID:29875488 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related measurement efo:EFO_0803115 Quantification of synaptic vesicle glycoprotein 2A in a sample. Elizabeth Lewis true PMID:29875488 synaptic vesicle glycoprotein 2A measurement efo:EFO_0803116 Quantification of synaptosomal-associated protein 29 in a sample. Elizabeth Lewis true PMID:29875488 synaptosomal-associated protein 29 measurement efo:EFO_0803117 Quantification of synaptotagmin-17 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-17 measurement efo:EFO_0803118 Quantification of synaptotagmin-2 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-2 measurement efo:EFO_0803119 Quantification of synaptotagmin-3 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-3 measurement efo:EFO_0803120 Quantification of synaptotagmin-5 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-5 measurement efo:EFO_0803121 Quantification of synaptotagmin-7 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-7 measurement efo:EFO_0803122 Quantification of synaptotagmin-8 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-8 measurement efo:EFO_0803123 Quantification of synaptotagmin-like protein 1 in a sample. Elizabeth Lewis true PMID:29875488 synaptotagmin-like protein 1 measurement efo:EFO_0803124 Quantification of syntaxin-18 in a sample. Elizabeth Lewis true PMID:29875488 syntaxin-18 measurement efo:EFO_0803125 Quantification of syntaxin-1B in a sample. Elizabeth Lewis true PMID:29875488 syntaxin-1B measurement efo:EFO_0803126 Quantification of syntaxin-6 in a sample. Elizabeth Lewis true PMID:29875488 syntaxin-6 measurement efo:EFO_0803127 Quantification of t-box transcription factor TBX22 in a sample. Elizabeth Lewis true PMID:29875488 t-box transcription factor TBX22 measurement efo:EFO_0803128 Quantification of t-box transcription factor TBX3 in a sample. Elizabeth Lewis true PMID:29875488 t-box transcription factor TBX3 measurement efo:EFO_0803129 Quantification of t-box transcription factor TBX5 in a sample. Elizabeth Lewis true PMID:29875488 t-box transcription factor TBX5 measurement efo:EFO_0803130 Quantification of t-cell immunomodulatory protein in a sample. Elizabeth Lewis true PMID:29875488 t-cell immunomodulatory protein measurement efo:EFO_0803131 Quantification of t-cell receptor-associated transmembrane adapter 1 in a sample. Elizabeth Lewis true PMID:29875488 t-cell receptor-associated transmembrane adapter 1 measurement efo:EFO_0803132 Quantification of t-cell surface antigen CD2 in a sample. Elizabeth Lewis true PMID:29875488 t-cell surface antigen CD2 measurement efo:EFO_0803133 Quantification of t-cell surface glycoprotein CD3 gamma chain in a sample. Elizabeth Lewis true PMID:29875488 t-cell surface glycoprotein CD3 gamma chain measurement efo:EFO_0803134 Quantification of t-cell surface glycoprotein CD5 in a sample. Elizabeth Lewis true PMID:29875488 t-cell surface glycoprotein CD5 measurement efo:EFO_0803135 Quantification of t-cell surface glycoprotein CD8 beta chain in a sample. Elizabeth Lewis true PMID:29875488 t-cell surface glycoprotein CD8 beta chain measurement efo:EFO_0803136 Quantification of tachykinin-3 in a sample. Elizabeth Lewis true PMID:29875488 tachykinin-3 measurement efo:EFO_0803137 Quantification of tachykinin-4 in a sample. Elizabeth Lewis true PMID:29875488 tachykinin-4 measurement efo:EFO_0803138 Quantification of tax1-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 tax1-binding protein 1 measurement efo:EFO_0803139 Quantification of tenascin-R in a sample. Elizabeth Lewis true PMID:29875488 tenascin-R measurement efo:EFO_0803140 Quantification of teneurin-3 in a sample. Elizabeth Lewis true PMID:29875488 teneurin-3 measurement efo:EFO_0803141 Quantification of teneurin-4 in a sample. Elizabeth Lewis true PMID:29875488 teneurin-4 measurement efo:EFO_0803142 Quantification of tenomodulin in a sample. Elizabeth Lewis true PMID:29875488 tenomodulin measurement efo:EFO_0803143 Quantification of testis-specific serine/threonine-protein kinase 2 in a sample. Elizabeth Lewis true PMID:29875488 testis-specific serine/threonine-protein kinase 2 measurement efo:EFO_0803144 Quantification of tetratricopeptide repeat protein 17 in a sample. Elizabeth Lewis true PMID:29875488 tetratricopeptide repeat protein 17 measurement efo:EFO_0803145 Quantification of tetratricopeptide repeat protein 9B in a sample. Elizabeth Lewis true PMID:29875488 tetratricopeptide repeat protein 9B measurement efo:EFO_0803146 Quantification of thiamin pyrophosphokinase 1 in a sample. Elizabeth Lewis true PMID:29875488 thiamin pyrophosphokinase 1 measurement efo:EFO_0803147 Quantification of thioredoxin domain-containing protein 11 in a sample. Elizabeth Lewis true PMID:29875488 thioredoxin domain-containing protein 11 measurement efo:EFO_0803148 Quantification of thioredoxin in a sample. Elizabeth Lewis true PMID:29875488 thioredoxin measurement efo:EFO_0803149 Quantification of thioredoxin-interacting protein in a sample. Elizabeth Lewis true PMID:29875488 thioredoxin-interacting protein measurement efo:EFO_0803150 Quantification of thrombospondin type-1 domain-containing protein 7A in a sample. Elizabeth Lewis true PMID:29875488 thrombospondin type-1 domain-containing protein 7A measurement efo:EFO_0803151 Quantification of thrombospondin-3 in a sample. Elizabeth Lewis true PMID:29875488 thrombospondin-3 measurement efo:EFO_0803152 Quantification of thromboxane-A synthase in a sample. Elizabeth Lewis true PMID:29875488 thromboxane-A synthase measurement efo:EFO_0803153 Quantification of thyroid hormone receptor alpha in a sample. Elizabeth Lewis true PMID:29875488 thyroid hormone receptor alpha measurement efo:EFO_0803154 Quantification of thyrotropin-releasing hormone in a sample. Elizabeth Lewis true PMID:29875488 thyrotropin-releasing hormone measurement efo:EFO_0803155 Quantification of tight junction protein ZO-1 in a sample. Elizabeth Lewis true PMID:29875488 tight junction protein ZO-1 measurement efo:EFO_0803156 Quantification of tissue factor pathway inhibitor 2 in a sample. Elizabeth Lewis true PMID:29875488 tissue factor pathway inhibitor 2 measurement efo:EFO_0803157 Quantification of titin in a sample. Elizabeth Lewis true PMID:29875488 titin measurement efo:EFO_0803158 Quantification of TNF receptor-associated factor 4 in a sample. Elizabeth Lewis true PMID:29875488 TNF receptor-associated factor 4 measurement efo:EFO_0803159 Quantification of toll-like receptor 1 in a sample. Elizabeth Lewis true PMID:29875488 toll-like receptor 1 measurement efo:EFO_0803160 Quantification of torsin-1A-interacting protein 2 in a sample. Elizabeth Lewis true PMID:29875488 torsin-1A-interacting protein 2 measurement efo:EFO_0803161 Quantification of TOX high mobility group box family member 3 in a sample. Elizabeth Lewis true PMID:29875488 TOX high mobility group box family member 3 measurement efo:EFO_0803162 Quantification of TPA-induced transmembrane protein in a sample. Elizabeth Lewis true PMID:29875488 TPA-induced transmembrane protein measurement efo:EFO_0803163 Quantification of transcription factor TFIIIB component B'' homolog in a sample. Elizabeth Lewis true PMID:29875488 transcription factor TFIIIB component B'' homolog measurement efo:EFO_0803164 Quantification of transcription regulator protein BACH2 in a sample. Elizabeth Lewis true PMID:29875488 transcription regulator protein BACH2 measurement efo:EFO_0803165 Quantification of transcriptional activator protein Pur-alpha in a sample. Elizabeth Lewis true PMID:29875488 transcriptional activator protein Pur-alpha measurement efo:EFO_0803166 Quantification of transcriptional enhancer factor TEF-3 in a sample. Elizabeth Lewis true PMID:29875488 transcriptional enhancer factor TEF-3 measurement efo:EFO_0803167 Quantification of transcriptional enhancer factor TEF-5 in a sample. Elizabeth Lewis true PMID:29875488 transcriptional enhancer factor TEF-5 measurement efo:EFO_0803168 Quantification of transcriptional regulator Kaiso in a sample. Elizabeth Lewis true PMID:29875488 transcriptional regulator Kaiso measurement efo:EFO_0803169 Quantification of transcriptional repressor CTCF in a sample. Elizabeth Lewis true PMID:29875488 transcriptional repressor CTCF measurement efo:EFO_0803170 Quantification of transforming growth factor beta-1-induced transcript 1 protein in a sample. Elizabeth Lewis true PMID:29875488 transforming growth factor beta-1-induced transcript 1 protein measurement efo:EFO_0803171 Quantification of transgelin in a sample. Elizabeth Lewis true PMID:29875488 transgelin measurement efo:EFO_0803172 Quantification of translin in a sample. Elizabeth Lewis true PMID:29875488 translin measurement efo:EFO_0803173 Quantification of translocon-associated protein subunit alpha in a sample. Elizabeth Lewis true PMID:29875488 translocon-associated protein subunit alpha measurement efo:EFO_0803174 Quantification of transmembrane and coiled-coil domain-containing protein 5A in a sample. Elizabeth Lewis true PMID:29875488 transmembrane and coiled-coil domain-containing protein 5A measurement efo:EFO_0803175 Quantification of transmembrane and ubiquitin-like domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane and ubiquitin-like domain-containing protein 2 measurement efo:EFO_0803176 Quantification of transmembrane emp24 domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane emp24 domain-containing protein 2 measurement efo:EFO_0803177 Quantification of transmembrane emp24 domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane emp24 domain-containing protein 4 measurement efo:EFO_0803178 Quantification of transmembrane gamma-carboxyglutamic acid protein 4 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane gamma-carboxyglutamic acid protein 4 measurement efo:EFO_0803179 Quantification of transmembrane protease serine 11A in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protease serine 11A measurement efo:EFO_0803180 Quantification of transmembrane protease serine 11B in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protease serine 11B measurement efo:EFO_0803181 Quantification of transmembrane protease serine 5 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protease serine 5 measurement efo:EFO_0803182 Quantification of transmembrane protein 119 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 119 measurement efo:EFO_0803183 Quantification of transmembrane protein 234 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 234 measurement efo:EFO_0803184 Quantification of transmembrane protein 237 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 237 measurement efo:EFO_0803185 Quantification of transmembrane protein 40 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 40 measurement efo:EFO_0803186 Quantification of transmembrane protein 41B in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 41B measurement efo:EFO_0803187 Quantification of transmembrane protein 52 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 52 measurement efo:EFO_0803188 Quantification of transmembrane protein 70, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 70, mitochondrial measurement efo:EFO_0803189 Quantification of transmembrane protein 8B in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 8B measurement efo:EFO_0803190 Quantification of transmembrane protein 9 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein 9 measurement efo:EFO_0803191 Quantification of transmembrane protein C16orf54 in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein C16orf54 measurement efo:EFO_0803192 Quantification of transmembrane protein PVRIG in a sample. Elizabeth Lewis true PMID:29875488 transmembrane protein PVRIG measurement efo:EFO_0803193 Quantification of trem-like transcript 1 protein in a sample. Elizabeth Lewis true PMID:29875488 trem-like transcript 1 protein measurement efo:EFO_0803194 Quantification of tRNA pseudouridine synthase A, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 tRNA pseudouridine synthase A, mitochondrial measurement efo:EFO_0803195 Quantification of tropomodulin-1 in a sample. Elizabeth Lewis true PMID:29875488 tropomodulin-1 measurement efo:EFO_0803196 Quantification of tropomyosin alpha-3 chain in a sample. Elizabeth Lewis true PMID:29875488 tropomyosin alpha-3 chain measurement efo:EFO_0803197 Quantification of tubulointerstitial nephritis antigen-like in a sample. Elizabeth Lewis true PMID:29875488 tubulointerstitial nephritis antigen-like measurement efo:EFO_0803198 Quantification of tuftelin in a sample. Elizabeth Lewis true PMID:29875488 tuftelin measurement efo:EFO_0803199 Quantification of tuftelin-interacting protein 11 in a sample. Elizabeth Lewis true PMID:29875488 tuftelin-interacting protein 11 measurement efo:EFO_0803200 Quantification of tumor necrosis factor alpha-induced protein 3 in a sample. Elizabeth Lewis true PMID:29875488 tumor necrosis factor alpha-induced protein 3 measurement efo:EFO_0803201 Quantification of tumor necrosis factor receptor superfamily member 1A in a sample. Elizabeth Lewis true PMID:29875488 tumor necrosis factor receptor superfamily member 1A measurement efo:EFO_0803202 Quantification of tumor protein 63 in a sample. Elizabeth Lewis true PMID:29875488 tumor protein 63 measurement efo:EFO_0803203 Quantification of tumor susceptibility gene 101 protein in a sample. Elizabeth Lewis true PMID:29875488 tumor susceptibility gene 101 protein measurement efo:EFO_0803204 Quantification of twinfilin-1 in a sample. Elizabeth Lewis true PMID:29875488 twinfilin-1 measurement efo:EFO_0803205 Quantification of twisted gastrulation protein homolog 1 in a sample. Elizabeth Lewis true PMID:29875488 twisted gastrulation protein homolog 1 measurement efo:EFO_0803206 Quantification of TYMS opposite strand protein in a sample. Elizabeth Lewis true PMID:29875488 TYMS opposite strand protein measurement efo:EFO_0803207 Quantification of type III endosome membrane protein TEMP in a sample. Elizabeth Lewis true PMID:29875488 type III endosome membrane protein TEMP measurement efo:EFO_0803208 Quantification of tyrosine-protein kinase RYK in a sample. Elizabeth Lewis true PMID:29875488 tyrosine-protein kinase RYK measurement efo:EFO_0803209 Quantification of tyrosine-protein kinase transmembrane receptor ROR2 in a sample. Elizabeth Lewis true PMID:29875488 tyrosine-protein kinase transmembrane receptor ROR2 measurement efo:EFO_0803210 Quantification of tyrosyl-DNA phosphodiesterase 1 in a sample. Elizabeth Lewis true PMID:29875488 tyrosyl-DNA phosphodiesterase 1 measurement efo:EFO_0803211 Quantification of U6 snRNA phosphodiesterase in a sample. Elizabeth Lewis true PMID:29875488 U6 snRNA phosphodiesterase measurement efo:EFO_0803212 Quantification of ubiquinol-cytochrome-c reductase complex assembly factor 3 in a sample. Elizabeth Lewis true PMID:29875488 ubiquinol-cytochrome-c reductase complex assembly factor 3 measurement efo:EFO_0803213 Quantification of ubiquitin thioesterase OTUB2 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin thioesterase OTUB2 measurement efo:EFO_0803214 Quantification of ubiquitin-conjugating enzyme E2 B in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-conjugating enzyme E2 B measurement efo:EFO_0803215 Quantification of ubiquitin-conjugating enzyme E2 J1 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-conjugating enzyme E2 J1 measurement efo:EFO_0803216 Quantification of ubiquitin-conjugating enzyme E2 J2 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-conjugating enzyme E2 J2 measurement efo:EFO_0803217 Quantification of ubiquitin-conjugating enzyme E2 T in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-conjugating enzyme E2 T measurement efo:EFO_0803218 Quantification of ubiquitin-like modifier-activating enzyme ATG7 in a sample. Elizabeth Lewis true PMID:29875488 ubiquitin-like modifier-activating enzyme ATG7 measurement efo:EFO_0803219 Quantification of UBX domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 UBX domain-containing protein 4 measurement efo:EFO_0803220 Quantification of UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 in a sample. Elizabeth Lewis true PMID:29875488 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 measurement efo:EFO_0803221 Quantification of UDP-glucuronic acid decarboxylase 1 in a sample. Elizabeth Lewis true PMID:29875488 UDP-glucuronic acid decarboxylase 1 measurement efo:EFO_0803222 Quantification of UDP-glucuronosyltransferase 1-8 in a sample. Elizabeth Lewis true PMID:29875488 UDP-glucuronosyltransferase 1-8 measurement efo:EFO_0803223 Quantification of uncharacterized protein C17orf67 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C17orf67 measurement efo:EFO_0803224 Quantification of uncharacterized protein C17orf89 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C17orf89 measurement efo:EFO_0803225 Quantification of uncharacterized protein C19orf18 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C19orf18 measurement efo:EFO_0803226 Quantification of uncharacterized protein C1orf115 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C1orf115 measurement efo:EFO_0803227 Quantification of uncharacterized protein C1orf185 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C1orf185 measurement efo:EFO_0803228 Quantification of uncharacterized protein C1orf198 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C1orf198 measurement efo:EFO_0803229 Quantification of uncharacterized protein C1orf226 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C1orf226 measurement efo:EFO_0803230 Quantification of uncharacterized protein C22orf15 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C22orf15 measurement efo:EFO_0803231 Quantification of uncharacterized protein C2orf82 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein C2orf82 measurement efo:EFO_0803232 Quantification of uncharacterized protein KIAA1467 in a sample. Elizabeth Lewis true PMID:29875488 uncharacterized protein KIAA1467 measurement efo:EFO_0803233 Quantification of unconventional myosin-VI in a sample. Elizabeth Lewis true PMID:29875488 unconventional myosin-VI measurement efo:EFO_0803234 Quantification of UPF0258 protein KIAA1024 in a sample. Elizabeth Lewis true PMID:29875488 UPF0258 protein KIAA1024 measurement efo:EFO_0803235 Quantification of UPF0577 protein KIAA1324 in a sample. Elizabeth Lewis true PMID:29875488 UPF0577 protein KIAA1324 measurement efo:EFO_0803236 Quantification of UPF0729 protein C18orf32 in a sample. Elizabeth Lewis true PMID:29875488 UPF0729 protein C18orf32 measurement efo:EFO_0803237 Quantification of urea transporter 1 in a sample. Elizabeth Lewis true PMID:29875488 urea transporter 1 measurement efo:EFO_0803238 Quantification of uridine-cytidine kinase 2 in a sample. Elizabeth Lewis true PMID:29875488 uridine-cytidine kinase 2 measurement efo:EFO_0803239 Quantification of uromodulin-like 1 in a sample. Elizabeth Lewis true PMID:29875488 uromodulin-like 1 measurement efo:EFO_0803240 Quantification of uronyl 2-sulfotransferase in a sample. Elizabeth Lewis true PMID:29875488 uronyl 2-sulfotransferase measurement efo:EFO_0803241 Quantification of uroplakin-3b in a sample. Elizabeth Lewis true PMID:29875488 uroplakin-3b measurement efo:EFO_0803242 Quantification of urotensin-2 receptor in a sample. Elizabeth Lewis true PMID:29875488 urotensin-2 receptor measurement efo:EFO_0803243 Quantification of UTP--glucose-1-phosphate uridylyltransferase in a sample. Elizabeth Lewis true PMID:29875488 UTP--glucose-1-phosphate uridylyltransferase measurement efo:EFO_0803244 Quantification of UV excision repair protein RAD23 homolog A in a sample. Elizabeth Lewis true PMID:29875488 UV excision repair protein RAD23 homolog A measurement efo:EFO_0803245 Quantification of v-set and immunoglobulin domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 v-set and immunoglobulin domain-containing protein 1 measurement efo:EFO_0803246 Quantification of v-set and transmembrane domain-containing protein 2-like protein in a sample. Elizabeth Lewis true PMID:29875488 v-set and transmembrane domain-containing protein 2-like protein measurement efo:EFO_0803247 Quantification of v-set and transmembrane domain-containing protein 4 in a sample. Elizabeth Lewis true PMID:29875488 v-set and transmembrane domain-containing protein 4 measurement efo:EFO_0803248 Quantification of versican core protein in a sample. Elizabeth Lewis true PMID:29875488 versican core protein measurement efo:EFO_0803249 Quantification of vesicle transport protein USE1 in a sample. Elizabeth Lewis true PMID:29875488 vesicle transport protein USE1 measurement efo:EFO_0803250 Quantification of vesicle transport through interaction with t-SNAREs homolog 1A in a sample. Elizabeth Lewis true PMID:29875488 vesicle transport through interaction with t-SNAREs homolog 1A measurement efo:EFO_0803251 Quantification of vesicle-associated membrane protein 3 in a sample. Elizabeth Lewis true PMID:29875488 vesicle-associated membrane protein 3 measurement efo:EFO_0803252 Quantification of vesicle-associated membrane protein 4 in a sample. Elizabeth Lewis true PMID:29875488 vesicle-associated membrane protein 4 measurement efo:EFO_0803253 Quantification of vesicle-associated membrane protein 5 in a sample. Elizabeth Lewis true PMID:29875488 vesicle-associated membrane protein 5 measurement efo:EFO_0803254 Quantification of vesicle-associated membrane protein 8 in a sample. Elizabeth Lewis true PMID:29875488 vesicle-associated membrane protein 8 measurement efo:EFO_0803255 Quantification of vesicle-associated membrane protein-associated protein B/C in a sample. Elizabeth Lewis true PMID:29875488 vesicle-associated membrane protein-associated protein B/C measurement efo:EFO_0803256 Quantification of vesicle-trafficking protein SEC22a in a sample. Elizabeth Lewis true PMID:29875488 vesicle-trafficking protein SEC22a measurement efo:EFO_0803257 Quantification of vinculin in a sample. Elizabeth Lewis true PMID:29875488 vinculin measurement efo:EFO_0803258 Quantification of vinexin b in a sample. Elizabeth Lewis true PMID:29875488 vinexin b measurement efo:EFO_0803259 Quantification of von Willebrand factor C domain-containing protein 2-like in a sample. Elizabeth Lewis true PMID:29875488 von Willebrand factor C domain-containing protein 2-like measurement efo:EFO_0803260 Quantification of WAP four-disulfide core domain protein 10A in a sample. Elizabeth Lewis true PMID:29875488 WAP four-disulfide core domain protein 10A measurement efo:EFO_0803261 Quantification of WAP four-disulfide core domain protein 12 in a sample. Elizabeth Lewis true PMID:29875488 WAP four-disulfide core domain protein 12 measurement efo:EFO_0803262 Quantification of WAP four-disulfide core domain protein 13 in a sample. Elizabeth Lewis true PMID:29875488 WAP four-disulfide core domain protein 13 measurement efo:EFO_0803263 Quantification of WAP four-disulfide core domain protein 2 in a sample. Elizabeth Lewis true PMID:29875488 WAP four-disulfide core domain protein 2 measurement efo:EFO_0803264 Quantification of WAP four-disulfide core domain protein 5 in a sample. Elizabeth Lewis true PMID:29875488 WAP four-disulfide core domain protein 5 measurement efo:EFO_0803265 Quantification of WW domain binding protein 1-like in a sample. Elizabeth Lewis true PMID:29875488 WW domain binding protein 1-like measurement efo:EFO_0803266 Quantification of WW domain-binding protein 1 in a sample. Elizabeth Lewis true PMID:29875488 WW domain-binding protein 1 measurement efo:EFO_0803267 Quantification of xanthine dehydrogenase/oxidase in a sample. Elizabeth Lewis true PMID:29875488 xanthine dehydrogenase/oxidase measurement efo:EFO_0803268 Quantification of YTH domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 YTH domain-containing protein 1 measurement efo:EFO_0803269 Quantification of zinc finger protein in a sample. zinc finger protein measurement efo:EFO_0803270 Quantification of zinc finger protein 10 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 10 measurement efo:EFO_0803271 Quantification of zinc finger protein 134 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 134 measurement efo:EFO_0803272 Quantification of zinc finger protein 174 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 174 measurement efo:EFO_0803273 Quantification of zinc finger protein 180 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 180 measurement efo:EFO_0803274 Quantification of zinc finger protein 23 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 23 measurement efo:EFO_0803275 Quantification of zinc finger protein 264 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 264 measurement efo:EFO_0803276 Quantification of zinc finger protein 329 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 329 measurement efo:EFO_0803277 Quantification of zinc finger protein 334 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 334 measurement efo:EFO_0803278 Quantification of zinc finger protein 358 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 358 measurement efo:EFO_0803279 Quantification of zinc finger protein 382 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 382 measurement efo:EFO_0803280 Quantification of zinc finger protein 410 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 410 measurement efo:EFO_0803281 Quantification of zinc finger protein 415 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 415 measurement efo:EFO_0803282 Quantification of zinc finger protein 566 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 566 measurement efo:EFO_0803283 Quantification of zinc finger protein 75D in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 75D measurement efo:EFO_0803284 Quantification of zinc finger protein 774 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 774 measurement efo:EFO_0803285 Quantification of zinc finger protein 843 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein 843 measurement efo:EFO_0803286 Quantification of zinc finger protein SNAI2 in a sample. Elizabeth Lewis true PMID:29875488 zinc finger protein SNAI2 measurement efo:EFO_0803287 Quantification of zinc transporter 3 in a sample. Elizabeth Lewis true PMID:29875488 zinc transporter 3 measurement efo:EFO_0803288 Quantification of zinc transporter 5 in a sample. Elizabeth Lewis true PMID:29875488 zinc transporter 5 measurement efo:EFO_0803289 Quantification of zinc/RING finger protein 4 in a sample. Elizabeth Lewis true PMID:29875488 zinc/RING finger protein 4 measurement efo:EFO_0803290 Quantification of zona pellucida-like domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 zona pellucida-like domain-containing protein 1 measurement efo:EFO_0803291 Quantification of growth arrest and DNA damage-inducible proteins-interacting protein 1 in a sample. Elizabeth Lewis true PMID:29875488 growth arrest and DNA damage-inducible proteins-interacting protein 1 measurement efo:EFO_0803292 Quantification of NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial in a sample. Elizabeth Lewis true PMID:29875488 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial measurement efo:EFO_0803293 Quantification of complement C1q and tumor necrosis factor-related protein 9A in a sample. Elizabeth Lewis true PMID:29875488 complement C1q and tumor necrosis factor-related protein 9A measurement efo:EFO_0803294 Quantification of discoidin, CUB and LCCL domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 discoidin, CUB and LCCL domain-containing protein 2 measurement efo:EFO_0803295 Quantification of PH and SEC7 domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 PH and SEC7 domain-containing protein 2 measurement efo:EFO_0803296 Quantification of mono [ADP-ribose] polymerase PARP16 in a sample. Elizabeth Lewis true PMID:29875488 mono [ADP-ribose] polymerase PARP16 measurement efo:EFO_0803297 Quantification of CUB and Sushi domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 CUB and Sushi domain-containing protein 1 measurement efo:EFO_0803298 Quantification of ribosyldihydronicotinamide dehydrogenase [quinone] in a sample. Elizabeth Lewis true PMID:29875488 ribosyldihydronicotinamide dehydrogenase [quinone] measurement efo:EFO_0803299 Quantification of zinc fingers and homeoboxes protein 3 in a sample. Elizabeth Lewis true PMID:29875488 zinc fingers and homeoboxes protein 3 measurement efo:EFO_0803300 Quantification of nutritionally-regulated adipose and cardiac enriched protein homolog in a sample. Elizabeth Lewis true PMID:29875488 nutritionally-regulated adipose and cardiac enriched protein homolog measurement efo:EFO_0803301 Quantification of prostate and testis expressed protein 4 in a sample. Elizabeth Lewis true PMID:29875488 prostate and testis expressed protein 4 measurement efo:EFO_0803302 Quantification of PH and SEC7 domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 PH and SEC7 domain-containing protein 1 measurement efo:EFO_0803303 Quantification of NAD(P)H dehydrogenase [quinone] 1 in a sample. Elizabeth Lewis true PMID:29875488 NAD(P)H dehydrogenase [quinone] 1 measurement efo:EFO_0803304 Quantification of sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) in a sample. Elizabeth Lewis true PMID:29875488 sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) measurement efo:EFO_0803305 Quantification of 2-phosphoxylose phosphatase 1 in a sample. Elizabeth Lewis true PMID:29875488 2-phosphoxylose phosphatase 1 measurement efo:EFO_0803306 Quantification of arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 measurement efo:EFO_0803307 Quantification of NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 in a sample. Elizabeth Lewis true PMID:29875488 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 measurement efo:EFO_0803308 Quantification of v-set and immunoglobulin domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 v-set and immunoglobulin domain-containing protein 2 measurement efo:EFO_0803309 Quantification of CUB and zona pellucida-like domain-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 CUB and zona pellucida-like domain-containing protein 1 measurement efo:EFO_0803310 Quantification of carbonyl reductase [NADPH] 1 in a sample. Elizabeth Lewis true PMID:29875488 carbonyl reductase [NADPH] 1 measurement efo:EFO_0803311 Quantification of arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 measurement efo:EFO_0803312 Quantification of arf-GAP domain and FG repeat-containing protein 1 in a sample. Elizabeth Lewis true PMID:29875488 arf-GAP domain and FG repeat-containing protein 1 measurement efo:EFO_0803313 Quantification of p53 and DNA damage-regulated protein 1 in a sample. Elizabeth Lewis true PMID:29875488 p53 and DNA damage-regulated protein 1 measurement efo:EFO_0803314 Quantification of CUB and Sushi domain-containing protein 2 in a sample. Elizabeth Lewis true PMID:29875488 CUB and Sushi domain-containing protein 2 measurement efo:EFO_0803315 Quantification of carbonyl reductase [NADPH] 3 in a sample. Elizabeth Lewis true PMID:29875488 carbonyl reductase [NADPH] 3 measurement efo:EFO_0803316 Quantification of adipose tissue located around the abdomen. Santhi Ramachandran true PMID:35773277 abdominal adipose tissue measurement efo:EFO_0803317 Quantification of adipose tissue located around the gluteofemoral region, measuring hip and thigh fat. Santhi Ramachandran true PMID:35773277 gluteofemoral adipose tissue measurement efo:EFO_0803318 Quantification of the ratio of visceral to abdominal adipose tissue. Santhi Ramachandran true PMID:35773277 visceral:abdominal adipose tissue ratio measurement efo:EFO_0803319 Quantification of the ratio of visceral to gluteofemoral adipose tissue. Santhi Ramachandran true PMID:35773277 visceral:gluteofemoral adipose tissue ratio measurement efo:EFO_0803320 Quantification of the ratio of abdominal to gluteofemoral adipose tissue. Santhi Ramachandran true PMID:35773277 abdominal:gluteofemoral adipose tissue ratio measurement efo:EFO_0803322 Quantification of the presence or absence of some haplotype or allele in the HLA region. 2023-01-04T10:10:39Z Arwa Ibrahim true PMID:34976003 HLA allele carrier status efo:EFO_0803323 Quantification of S-warfarin in a sample. Elizabeth Lewis true PMID:36210801 S-warfarin measurement efo:EFO_0803324 Quantification of R-warfarin in a sample. Elizabeth Lewis true PMID:36210801 R-warfarin measurement efo:EFO_0803325 Quantification of RS-warfarin in a sample. Elizabeth Lewis true PMID:36210801 RS-warfarin measurement efo:EFO_0803326 Quantification of S-6-hydroxywarfarin in a sample. Elizabeth Lewis true PMID:36210801 S-6-hydroxywarfarin measurement efo:EFO_0803327 Quantification of R-6-hydroxywarfarin in a sample. Elizabeth Lewis true PMID:36210801 R-6-hydroxywarfarin measurement efo:EFO_0803328 Quantification of RS-6-hydroxywarfarin in a sample. Elizabeth Lewis true PMID:36210801 RS-6-hydroxywarfarin measurement efo:EFO_0803329 Quantification of S-7-hydroxywarfarin in a sample. Elizabeth Lewis true PMID:36210801 S-7-hydroxywarfarin measurement efo:EFO_0803330 Quantification of RS-10-hydroxywarfarin in a sample. Elizabeth Lewis true PMID:36210801 RS-10-hydroxywarfarin measurement efo:EFO_0803331 Quantification of the ratio of S-warfarin to R-warfarin in a sample. Elizabeth Lewis true PMID:36210801 S-warfarin to R-warfarin ratio measurement efo:EFO_0803332 Quantification of the ratio of S-6-hydroxywarfarin to S-warfarin in a sample. Elizabeth Lewis true PMID:36210801 S-6-hydroxywarfarin to S-warfarin ratio measurement efo:EFO_0803333 Quantification of the ratio of R-6-hydroxywarfarin to R-warfarin in a sample. Elizabeth Lewis true PMID:36210801 R-6-hydroxywarfarin to R-warfarin ratio measurement efo:EFO_0803334 Quantification of the ratio of S-7-hydroxywarfarin to S-warfarin in a sample. Elizabeth Lewis true PMID:36210801 S-7-hydroxywarfarin to S-warfarin ratio measurement efo:EFO_0803335 Quantification of the ratio of RS-10-hydroxywarfarin to RS-warfarin in a sample. Elizabeth Lewis true PMID:36210801 RS-10-hydroxywarfarin to RS-warfarin ratio measurement efo:EFO_0803336 Quantification of the amount of sphingomyelin 32:0 in a sample. Santhi Ramachandran true PMID:36209301 sphingomyelin 32:0 measurement efo:EFO_0803337 Quantification of the amount of sphingomyelin 34:1 in a sample. Santhi Ramachandran true PMID:36209301 sphingomyelin 34:1 measurement efo:EFO_0803338 Quantification of the amount of sphingomyelin 38:3 in a sample. Santhi Ramachandran true PMID:36209301 sphingomyelin 38:3 measurement efo:EFO_0803339 Quantification of the ratio of sphingomyelin 43:1/ 34:1 in a sample. Santhi Ramachandran true PMID:36209301 sphingomyelin 43:1/ 34:1 ratio measurement efo:EFO_0803340 Quantification of the amount of cardiolipin IgA antibody in a sample. Santhi Ramachandran true PMID:33441150 cardiolipin IgA antibody measurement efo:EFO_0803341 Quantification of the amount of cardiolipin IgM antibody in a sample. Santhi Ramachandran true PMID:33441150 cardiolipin IgM antibody measurement efo:EFO_0803342 Quantification of the amount of ammonia in a sample. Santhi Ramachandran true PMID:33441150 ammonia measurement efo:EFO_0803343 Quantification of the amount of amylase in a sample. Santhi Ramachandran true PMID:33441150 amylase measurement efo:EFO_0803344 Quantification of the anion gap which is the quantity difference between cations (positively charged ions) and anions (negatively charged ions) in serum, plasma, or urine. Santhi Ramachandran true PMID:33441150 Wikipedia:Anion_gap anion gap measurement efo:EFO_0803345 Quantification of the amount of carbon dioxide gas present in a sample. Santhi Ramachandran true PMID:33441150 carbon dioxide measurement efo:EFO_0803346 Quantification of the amount of carboxyhemoglobin (a stable complex of carbon monoxide and hemoglobin) in a sample. Santhi Ramachandran true PMID:33441150 Wikipedia:Carboxyhemoglobin carboxyhemoglobin measurement efo:EFO_0803347 Quantification of the amount of nucleated cells present in a sample. Santhi Ramachandran true PMID:33441150 nucleated cell count efo:EFO_0803348 Quantification of the amount of yellow color of a biological specimen, due to the presence of bile pigments. Santhi Ramachandran true PMID:33441150 PMID:33927553 I-index icterus index icteric index efo:EFO_0803349 Quantification of lipemia in a sample. Lipemia is a turbidity of the sample caused by accumulation of lipoprotein particles. Santhi Ramachandran true PMID:24627715 PMID:33441150 lipemic index efo:EFO_0803350 Quantification of the amount of intact parathyroid hormone in a sample. Intact parathyroid hormone consists of 84 amino acids and is the biologically active form of parathyroid hormone that is secreted into the circulation in response to low calcium levels. Santhi Ramachandran true PMID:31081903 PMID:33441150 intact parathyroid hormone measurement efo:EFO_0803351 Quantification of the partial pressure of oxygen in a sample. Santhi Ramachandran true PMID:33441150 PaO2 oxygen tension partial pressure of oxygen measurement efo:EFO_0803352 Quantification of the amount of prealbumin present in a sample. Santhi Ramachandran true PMID:33441150 transthyretin prealbumin measurement efo:EFO_0803353 The presence of autoantibodies in the serum that react against topoisomerase I. Santhi Ramachandran true PMID:33441150 anti-topoisomerase I antibody positivity efo:EFO_0803354 Quantification of the amount of tissue transglutaminase IgA antibody present in a sample. Santhi Ramachandran true PMID:33441150 tissue transglutaminase IgA antibody measurement efo:EFO_0803355 Quantification of the amount of calcitriol hormone present in a sample. It is the active form of vitamin D. Santhi Ramachandran true PMID:33441150 Wikipedia:Calcitriol 1,25(OH)2-D3 1,25-dihydroxycholecalciferol calcitriol measurement efo:EFO_0803356 Quantification of the amount of 25-hydroxyvitamin D2 present in a sample. Santhi Ramachandran true PMID:33441150 25-hydroxycalciferol 25-hydroxyergocalciferol 25-hydroxyvitamin D2 measurement efo:EFO_0803357 Quantification of the amount of 25-hydroxyvitamin D3 present in a sample. Santhi Ramachandran true PMID:33441150 25-hydroxycholecalciferol calcidiol calcifediol 25-hydroxyvitamin D3 measurement efo:EFO_0803358 Quantification of the amount of SARS-CoV-2 IgG antibody in a sample. 2023-01-27T15:34:45Z true PMID:36451823 anti-SARS-CoV-2 IgG measurement efo:EFO_0803359 Quantification of the amount of SARS-CoV-2 neutralizing antibodies in a sample. 2023-01-27T16:40:15Z true PMID:36451823 SARS-CoV-2 neutralizing antibody measurement efo:EFO_0803360 2023-01-30T14:55:20Z true PMID:36451823 Quantification of the amount of SARS-CoV-2 antibodies in a sample. SARS-CoV-2 antibody measurement efo:EFO_0803363 A measurement of the sum of durations of wakefulness episodes throughout the night, not including the wakefulness before sleep onset. Santhi Ramachandran true NCIt:C156554 WASO wake after sleep onset A measurement of the sum of durations of wakefulness episodes throughout the night, not including the wakefulness before sleep onset. PMID:36463630 efo:EFO_0803364 A relative measurement of the time spent asleep to the total time spent in bed. Santhi Ramachandran true NCIt:C156553 sleep efficiency A relative measurement of the time spent asleep to the total time spent in bed. PMID:36463630 efo:EFO_0803367 Quantification of some aspect of the use of antihyperlipidemic drugs. true PMID:36653479 lipid-lowering drug use measurement antihyperlipidemic drug use measurement efo:EFO_0803369 Quantification of vascular endothelial function. Endothelial function tests assess vascular tone, permeability, anticoagulation, and angiogenesis. They include non-invasive measures like the reactive hyperemia index (RHI) detected by pulse amplitude tonometry (PAT) or invasive procedures like cardiac catherization. Endothelial dysfunction results in aging-induced pathogenesis of both microvascular and macrovascular diseases. Arwa Ibrahim true vascular endothelial function measurement Quantification of vascular endothelial function. Endothelial function tests assess vascular tone, permeability, anticoagulation, and angiogenesis. They include non-invasive measures like the reactive hyperemia index (RHI) detected by pulse amplitude tonometry (PAT) or invasive procedures like cardiac catherization. Endothelial dysfunction results in aging-induced pathogenesis of both microvascular and macrovascular diseases. PMID:33117828 PMID:36620623 efo:EFO_0803370 A measure of the thickness of photoreceptor cell receptor (PCR) segments of the retina. It can be non-invasively measured using optical coherence tomography (OCT). Santhi Ramachandran true PMID:36848389 photoreceptor cell layer thickness measurement efo:EFO_0803371 A measure of the thickness of the outer nuclear layer of photoreceptor cell receptor segments of the retina. Santhi Ramachandran true PMID:36848389 outer nuclear layer thickness measurement efo:EFO_0803372 A measure of the thickness of inner segment of photoreceptor cell receptor segments of the retina. Santhi Ramachandran true PMID:36848389 inner segment thickness measurement efo:EFO_0803373 A measure of the thickness of outer segment of photoreceptor cell receptor segments of the retina. Santhi Ramachandran true PMID:36848389 outer segment thickness measurement efo:EFO_0803374 A measurement of the flow characteristics of blood and its elements. Hemorheology indicators include whole blood viscosity, plasma viscosity, erythrocyte aggregation, erythrocyte rigidity, erythrocyte deformation, fibrinogen, and hematocrit. Santhi Ramachandran true blood rheology measurement hemorheological measurement A measurement of the flow characteristics of blood and its elements. Hemorheology indicators include whole blood viscosity, plasma viscosity, erythrocyte aggregation, erythrocyte rigidity, erythrocyte deformation, fibrinogen, and hematocrit. PMID:36654975 efo:EFO_0803375 A measurement of the reversible formation of clumps of red blood cells under low-shear conditions or stasis. Santhi Ramachandran true erythrocyte aggregation A measurement of the reversible formation of clumps of red blood cells under low-shear conditions or stasis. PMID:36654975 Wikipedia:Erythrocyte_aggregation efo:EFO_0803376 A measurement of the ability of erythrocytes to change shape without rupturing, as they pass through narrow spaces, such as the microvasculature. Santhi Ramachandran true erythrocyte deformability A measurement of the ability of erythrocytes to change shape without rupturing, as they pass through narrow spaces, such as the microvasculature. PMID:36654975 Wikipedia:Erythrocyte_deformability efo:EFO_0803378 Quantification of visual masking, a phenomenon of visual perception which occurs when the visibility of one image, called a target, is reduced by the presence of another, called a mask. Timing arrangements include forward masking, backward masking, and simultaneous masking. Spatial arrangements include pattern masking and metacontrast. Visual masking deficits are potential schizophrenia endophenotypes. true visual masking mesurement Quantification of visual masking, a phenomenon of visual perception which occurs when the visibility of one image, called a target, is reduced by the presence of another, called a mask. Timing arrangements include forward masking, backward masking, and simultaneous masking. Spatial arrangements include pattern masking and metacontrast. Visual masking deficits are potential schizophrenia endophenotypes. PMID:36585402 Wikipedia:Visual_masking efo:EFO_0803380 Quantification or estimate of cardiovascular age, e.g. as derived from electrocardiograms (ECGs) or biomarkers. true heart age measurement cardiovascular age measurement Quantification or estimate of cardiovascular age, e.g. as derived from electrocardiograms (ECGs) or biomarkers. PMID:36587059 efo:EFO_0803381 Quantification of the volume of the fornix. true brain fornix volume cerebral fornix volume fornix volume measurement Quantification of the volume of the fornix. PMID:36707530 efo:EFO_0803382 Quantification of the space between a blood vessel and the brain's pia mater. It may be measured by magnetic resonance imaging as an imaging marker of cerebral small vessel disease. PVS Virchow-Robin space perivascular space measurement Quantification of the space between a blood vessel and the brain's pia mater. It may be measured by magnetic resonance imaging as an imaging marker of cerebral small vessel disease. PMID:37069360 efo:EFO_0803383 Quantification of ()-2-methylthiazolidine in blood plasma. Elizabeth Lewis HMDB:0031682 ()-2-methylthiazolidine measurement Quantification of ()-2-methylthiazolidine in blood plasma. PMID:36482414 efo:EFO_0803384 Quantification of (cis/trans)-aconitate in blood plasma. Elizabeth Lewis HMDB:0000958 KEGG COMPOUND:C02341 (cis/trans)-aconitate measurement Quantification of (cis/trans)-aconitate in blood plasma. PMID:36482414 efo:EFO_0803385 Quantification of 15-acetoxyscirpene-34-diol 4-O-a-D-glucopyranoside in blood plasma. Elizabeth Lewis HMDB:0035590 15-acetoxyscirpene-34-diol 4-O-a-D-glucopyranoside measurement Quantification of 15-acetoxyscirpene-34-diol 4-O-a-D-glucopyranoside in blood plasma. PMID:36482414 efo:EFO_0803386 Quantification of 2-deoxyglucose in blood plasma. Elizabeth Lewis HMDB:0062477 KEGG COMPOUND:C00586 2-deoxyglucose measurement Quantification of 2-deoxyglucose in blood plasma. PMID:36482414 efo:EFO_0803387 Quantification of 2-methylmaleate in blood plasma. Elizabeth Lewis HMDB:0000634 KEGG COMPOUND:C02226 2-methylmaleate measurement Quantification of 2-methylmaleate in blood plasma. PMID:36482414 efo:EFO_0803388 Quantification of 24-dimethyl-5-vinylthiazole in blood plasma. Elizabeth Lewis HMDB:0037285 24-dimethyl-5-vinylthiazole measurement Quantification of 24-dimethyl-5-vinylthiazole in blood plasma. PMID:36482414 efo:EFO_0803389 Quantification of 3-keto fusidic acid in blood plasma. Elizabeth Lewis HMDB:0060745 3-keto fusidic acid measurement Quantification of 3-keto fusidic acid in blood plasma. PMID:36482414 efo:EFO_0803390 Quantification of 4-hydroxyanigorootin in blood plasma. Elizabeth Lewis HMDB:0039972 4-hydroxyanigorootin measurement Quantification of 4-hydroxyanigorootin in blood plasma. PMID:36482414 efo:EFO_0803391 Quantification of 4-hydroxybenzyl isothiocyanate 4-acetylrhamnoside in blood plasma. Elizabeth Lewis HMDB:0032802 4-hydroxybenzyl isothiocyanate 4-acetylrhamnoside measurement Quantification of 4-hydroxybenzyl isothiocyanate 4-acetylrhamnoside in blood plasma. PMID:36482414 efo:EFO_0803392 Quantification of 4,8,12,15,19-docosapentaenoic acid in blood plasma. Elizabeth Lewis HMDB:0039133 4,8,12,15,19-docosapentaenoic acid measurement Quantification of 4,8,12,15,19-docosapentaenoic acid in blood plasma. PMID:36482414 efo:EFO_0803393 Quantification of 5-(hydroxyphenyl)-gamma-valerolactone-O-sulphate in blood plasma. Elizabeth Lewis HMDB:0059993 5-(hydroxyphenyl)-gamma-valerolactone-O-sulphate measurement Quantification of 5-(hydroxyphenyl)-gamma-valerolactone-O-sulphate in blood plasma. PMID:36482414 efo:EFO_0803394 Quantification of 5-hydroxy-2-furoic acid in blood plasma. Elizabeth Lewis HMDB:0059784 5-hydroxy-2-furoic acid measurement Quantification of 5-hydroxy-2-furoic acid in blood plasma. PMID:36482414 efo:EFO_0803395 Quantification of 5-hydroxytryptophan in blood plasma. Elizabeth Lewis HMDB:0000472 KEGG COMPOUND:C01017 5-hydroxytryptophan measurement Quantification of 5-hydroxytryptophan in blood plasma. PMID:36482414 efo:EFO_0803396 Quantification of 5-sulfo-13-benzenedicarboxylic acid in blood plasma. Elizabeth Lewis HMDB:0032822 5-sulfo-13-benzenedicarboxylic acid measurement Quantification of 5-sulfo-13-benzenedicarboxylic acid in blood plasma. PMID:36482414 efo:EFO_0803397 Quantification of 5(6)-pentyl-14-dioxan-2-one in blood plasma. Elizabeth Lewis HMDB:0037146 5(6)-pentyl-14-dioxan-2-one measurement Quantification of 5(6)-pentyl-14-dioxan-2-one in blood plasma. PMID:36482414 efo:EFO_0803398 Quantification of 6-hydroxy-5-(4-sulfophenyl)azo-2-naphthalenesulfonic acid in blood plasma. Elizabeth Lewis HMDB:0034022 6-hydroxy-5-(4-sulfophenyl)azo-2-naphthalenesulfonic acid measurement Quantification of 6-hydroxy-5-(4-sulfophenyl)azo-2-naphthalenesulfonic acid in blood plasma. PMID:36482414 efo:EFO_0803399 Quantification of 6-hydroxypentadecanedioic acid in blood plasma. Elizabeth Lewis HMDB:0031885 6-hydroxypentadecanedioic acid measurement Quantification of 6-hydroxypentadecanedioic acid in blood plasma. PMID:36482414 efo:EFO_0803400 Quantification of acetyllysine in blood plasma. Elizabeth Lewis HMDB:0000446 KEGG COMPOUND:C12989 N-alpha-Acetyl-L-lysine acetyllysine measurement Quantification of acetyllysine in blood plasma. PMID:36482414 efo:EFO_0803401 Quantification of alverine in blood plasma. Elizabeth Lewis HMDB:0015554 alverine measurement Quantification of alverine in blood plasma. PMID:36482414 efo:EFO_0803402 Quantification of anserine in blood plasma. Elizabeth Lewis HMDB:0000194 KEGG COMPOUND:C01262 anserine measurement Quantification of anserine in blood plasma. PMID:36482414 efo:EFO_0803403 Quantification of arachidic acid in blood plasma. Elizabeth Lewis HMDB:0002212 KEGG COMPOUND:C06425 arachidic acid measurement Quantification of arachidic acid in blood plasma. PMID:36482414 efo:EFO_0803404 Quantification of bakers yeast extract in blood plasma. Elizabeth Lewis HMDB:0032173 11H-Benzo[a]fluoren-11-ylacetic acid bakers yeast extract measurement Quantification of bakers yeast extract in blood plasma. PMID:36482414 efo:EFO_0803405 Quantification of bis(methylsulfonylmethyl) disulfide in blood plasma. Elizabeth Lewis HMDB:0041188 bis(methylsulfonylmethyl) disulfide measurement Quantification of bis(methylsulfonylmethyl) disulfide in blood plasma. PMID:36482414 efo:EFO_0803406 Quantification of cadaverine in blood plasma. Elizabeth Lewis HMDB:0002322 KEGG COMPOUND:C01672 cadaverine measurement Quantification of cadaverine in blood plasma. PMID:36482414 efo:EFO_0803407 Quantification of cinnamic acid in blood plasma. Elizabeth Lewis HMDB:0000567 KEGG COMPOUND:C10438 cinnamic acid measurement Quantification of cinnamic acid in blood plasma. PMID:36482414 efo:EFO_0803408 Quantification of coumarate in blood plasma. Elizabeth Lewis HMDB:0002035 KEGG COMPOUND:C00811 4-hydroxycinnamic acid coumarate measurement Quantification of coumarate in blood plasma. PMID:36482414 efo:EFO_0803409 Quantification of cucurbitacin I 2-glucoside in blood plasma. Elizabeth Lewis HMDB:0035701 cucurbitacin I 2-glucoside measurement Quantification of cucurbitacin I 2-glucoside in blood plasma. PMID:36482414 efo:EFO_0803410 Quantification of cytidine diphosphocholine in blood plasma. Elizabeth Lewis HMDB:0001413 KEGG COMPOUND:C00307 cytidine diphosphocholine measurement Quantification of cytidine diphosphocholine in blood plasma. PMID:36482414 efo:EFO_0803411 Quantification of deoxyadenosine monophosphate in blood plasma. Elizabeth Lewis HMDB:0000905 KEGG COMPOUND:C00360 deoxyadenosine monophosphate measurement Quantification of deoxyadenosine monophosphate in blood plasma. PMID:36482414 efo:EFO_0803412 Quantification of di-2-thienyl disulfide in blood plasma. Elizabeth Lewis HMDB:0037173 di-2-thienyl disulfide measurement Quantification of di-2-thienyl disulfide in blood plasma. PMID:36482414 efo:EFO_0803413 Quantification of diaminopimelate in blood plasma. Elizabeth Lewis HMDB:0001370 KEGG COMPOUND:C00666 diaminopimelate measurement Quantification of diaminopimelate in blood plasma. PMID:36482414 efo:EFO_0803414 Quantification of diethylenetriamine crosslinked with epichlorohydrin in blood plasma. Elizabeth Lewis HMDB:0032216 1-(4-chlorophenyl)-2,3-dimethyl-4-dimethylamino-2-butanol diethylenetriamine crosslinked with epichlorohydrin measurement Quantification of diethylenetriamine crosslinked with epichlorohydrin in blood plasma. PMID:36482414 efo:EFO_0803415 Quantification of docosatetraenoic acid in blood plasma. Elizabeth Lewis HMDB:0002226 KEGG COMPOUND:C16527 docosatetraenoic acid measurement Quantification of docosatetraenoic acid in blood plasma. PMID:36482414 efo:EFO_0803416 Quantification of ferulic acid in blood plasma. Elizabeth Lewis HMDB:0000954 KEGG COMPOUND:C01494 ferulic acid measurement Quantification of ferulic acid in blood plasma. PMID:36482414 efo:EFO_0803417 Quantification of glucosamine 6-phosphate in blood plasma. Elizabeth Lewis HMDB:0001254 KEGG COMPOUND:C00352 glucosamine 6-phosphate measurement Quantification of glucosamine 6-phosphate in blood plasma. PMID:36482414 efo:EFO_0803418 Quantification of glucosamine in blood plasma. Elizabeth Lewis HMDB:0001514 KEGG COMPOUND:C00329 glucosamine measurement Quantification of glucosamine in blood plasma. PMID:36482414 efo:EFO_0803419 Quantification of glycerol triundecanoate in blood plasma. Elizabeth Lewis HMDB:0031089 glycerol triundecanoate measurement Quantification of glycerol triundecanoate in blood plasma. PMID:36482414 efo:EFO_0803420 Quantification of heptadecanoic acid in blood plasma. Elizabeth Lewis HMDB:0002259 heptadecanoic acid measurement Quantification of heptadecanoic acid in blood plasma. PMID:36482414 efo:EFO_0803421 Quantification of homogentisate in blood plasma. Elizabeth Lewis HMDB:0000130 KEGG COMPOUND:C00544 homogentisate measurement Quantification of homogentisate in blood plasma. PMID:36482414 efo:EFO_0803422 Quantification of homolinoleic acid in blood plasma. Elizabeth Lewis HMDB:0060039 homolinoleic acid measurement Quantification of homolinoleic acid in blood plasma. PMID:36482414 efo:EFO_0803423 Quantification of indole ethanol (tryptophanol) in blood plasma. Elizabeth Lewis HMDB:0003447 KEGG COMPOUND:C00955 indole ethanol (tryptophanol) measurement Quantification of indole ethanol (tryptophanol) in blood plasma. PMID:36482414 efo:EFO_0803424 Quantification of indole-3-acetic-acid-O-glucuronide in blood plasma. Elizabeth Lewis HMDB:0060001 indole-3-acetic-acid-O-glucuronide measurement Quantification of indole-3-acetic-acid-O-glucuronide in blood plasma. PMID:36482414 efo:EFO_0803425 Quantification of inosine diphosphate in blood plasma. Elizabeth Lewis HMDB:0003335 KEGG COMPOUND:C00104 inosine diphosphate measurement Quantification of inosine diphosphate in blood plasma. PMID:36482414 efo:EFO_0803426 Quantification of lauroylcarnitine in blood plasma. Elizabeth Lewis HMDB:0002250 lauroylcarnitine measurement Quantification of lauroylcarnitine in blood plasma. PMID:36482414 efo:EFO_0803427 Quantification of licoagrodin in blood plasma. Elizabeth Lewis HMDB:0035372 licoagrodin measurement Quantification of licoagrodin in blood plasma. PMID:36482414 efo:EFO_0803428 Quantification of lysope(20:1) in blood plasma. Elizabeth Lewis HMDB:0011482 lysope(20:1) measurement Quantification of lysope(20:1) in blood plasma. PMID:36482414 efo:EFO_0803429 Quantification of melleolide M in blood plasma. Elizabeth Lewis HMDB:0035068 melleolide M measurement Quantification of melleolide M in blood plasma. PMID:36482414 efo:EFO_0803430 Quantification of metenamine in blood plasma. Elizabeth Lewis HMDB:0029598 metenamine measurement Quantification of metenamine in blood plasma. PMID:36482414 efo:EFO_0803431 Quantification of methyl jasmonate in blood plasma. Elizabeth Lewis HMDB:0036583 methyl jasmonate measurement Quantification of methyl jasmonate in blood plasma. PMID:36482414 efo:EFO_0803432 Quantification of mg(14:0/0:0/0:0) in blood plasma. Elizabeth Lewis HMDB:0011561 mg(14:0/0:0/0:0) measurement Quantification of mg(14:0/0:0/0:0) in blood plasma. PMID:36482414 efo:EFO_0803433 Quantification of mg(18:1/0:0/0:0) in blood plasma. Elizabeth Lewis HMDB:0011567 mg(18:1/0:0/0:0) measurement Quantification of mg(18:1/0:0/0:0) in blood plasma. PMID:36482414 efo:EFO_0803434 Quantification of myristoylglycine in blood plasma. Elizabeth Lewis HMDB:0013250 myristoylglycine measurement Quantification of myristoylglycine in blood plasma. PMID:36482414 efo:EFO_0803435 Quantification of mytilin B in blood plasma. Elizabeth Lewis HMDB:0033442 mytilin B measurement Quantification of mytilin B in blood plasma. PMID:36482414 efo:EFO_0803436 Quantification of N-acetyldehydroanonaine in blood plasma. Elizabeth Lewis HMDB:0041537 N-acetyldehydroanonaine measurement Quantification of N-acetyldehydroanonaine in blood plasma. PMID:36482414 efo:EFO_0803437 Quantification of N-desmethyltoremifene in blood plasma. Elizabeth Lewis HMDB:0061051 N-desmethyltoremifene measurement Quantification of N-desmethyltoremifene in blood plasma. PMID:36482414 efo:EFO_0803438 Quantification of N-hexadecanoylpyrrolidine in blood plasma. Elizabeth Lewis HMDB:0032740 N-hexadecanoylpyrrolidine measurement Quantification of N-hexadecanoylpyrrolidine in blood plasma. PMID:36482414 efo:EFO_0803439 Quantification of NaNa-dimethylhistamine in blood plasma. Elizabeth Lewis HMDB:0033438 NaNa-dimethylhistamine measurement Quantification of NaNa-dimethylhistamine in blood plasma. PMID:36482414 efo:EFO_0803440 Quantification of NeNe dimethyllysine in blood plasma. Elizabeth Lewis HMDB:0013287 NeNe dimethyllysine measurement Quantification of NeNe dimethyllysine in blood plasma. PMID:36482414 efo:EFO_0803441 Quantification of nicotinic acid mononucleotide in blood plasma. Elizabeth Lewis HMDB:0001132 nicotinic acid mononucleotide measurement Quantification of nicotinic acid mononucleotide in blood plasma. PMID:36482414 efo:EFO_0803442 Quantification of 12-hydroxydodecanoic acid in blood plasma. Elizabeth Lewis HMDB:0002059 12-hydroxydodecanoic acid measurement Quantification of 12-hydroxydodecanoic acid in blood plasma. PMID:36482414 efo:EFO_0803443 Quantification of oxoadipic acid in blood plasma. Elizabeth Lewis HMDB:0000225 KEGG COMPOUND:C00322 oxoadipic acid measurement Quantification of oxoadipic acid in blood plasma. PMID:36482414 efo:EFO_0803444 Quantification of p-coumaroyl vitisin A in blood plasma. Elizabeth Lewis HMDB:0029239 p-coumaroyl vitisin A measurement Quantification of p-coumaroyl vitisin A in blood plasma. PMID:36482414 efo:EFO_0803445 Quantification of pentasine in blood plasma. Elizabeth Lewis HMDB:0029803 pentasine measurement Quantification of pentasine in blood plasma. PMID:36482414 efo:EFO_0803446 Quantification of permetin A in blood plasma. Elizabeth Lewis HMDB:0030527 permetin A measurement Quantification of permetin A in blood plasma. PMID:36482414 efo:EFO_0803447 Quantification of phaeophorbide b in blood plasma. Elizabeth Lewis HMDB:0031149 phaeophorbide b measurement Quantification of phaeophorbide b in blood plasma. PMID:36482414 efo:EFO_0803448 Quantification of phosphocholine in blood plasma. Elizabeth Lewis HMDB:0001565 KEGG COMPOUND:C00588 phosphocholine measurement Quantification of phosphocholine in blood plasma. PMID:36482414 efo:EFO_0803449 Quantification of phosphoserine in blood plasma. Elizabeth Lewis HMDB:0000272 KEGG COMPOUND:C01005 phosphoserine measurement Quantification of phosphoserine in blood plasma. PMID:36482414 efo:EFO_0803450 Quantification of polyethylene oxidized in blood plasma. Elizabeth Lewis HMDB:0032472 polyethylene oxidized measurement Quantification of polyethylene oxidized in blood plasma. PMID:36482414 efo:EFO_0803451 Quantification of quinic acid in blood plasma. Elizabeth Lewis HMDB:0003072 KEGG COMPOUND:C06746 quinic acid measurement Quantification of quinic acid in blood plasma. PMID:36482414 efo:EFO_0803452 Quantification of quinidine barbiturate in blood plasma. Elizabeth Lewis HMDB:0015436 quinidine barbiturate measurement Quantification of quinidine barbiturate in blood plasma. PMID:36482414 efo:EFO_0803453 Quantification of S-japonin in blood plasma. Elizabeth Lewis HMDB:0035802 S-japonin measurement Quantification of S-japonin in blood plasma. PMID:36482414 efo:EFO_0803454 Quantification of santene in blood plasma. Elizabeth Lewis HMDB:0038140 santene measurement Quantification of santene in blood plasma. PMID:36482414 efo:EFO_0803455 Quantification of somniferine in blood plasma. Elizabeth Lewis HMDB:0038585 somniferine measurement Quantification of somniferine in blood plasma. PMID:36482414 efo:EFO_0803456 Quantification of sorbitan tristearate in blood plasma. Elizabeth Lewis HMDB:0029890 sorbitan tristearate measurement Quantification of sorbitan tristearate in blood plasma. PMID:36482414 efo:EFO_0803457 Quantification of sulfinoalanine in blood plasma. Elizabeth Lewis HMDB:0000996 KEGG COMPOUND:C00606 3-sulfinoalanine sulfinoalanine measurement Quantification of sulfinoalanine in blood plasma. PMID:36482414 efo:EFO_0803458 Quantification of sulforaphane in blood plasma. Elizabeth Lewis HMDB:0005792 sulforaphane measurement Quantification of sulforaphane in blood plasma. PMID:36482414 efo:EFO_0803459 Quantification of tetrasaccharide (glycogen, stachyose) in blood plasma. Elizabeth Lewis HMDB:0000757 KEGG COMPOUND:C00182 glycogen tetrasaccharide (glycogen, stachyose) measurement Quantification of tetrasaccharide (glycogen, stachyose) in blood plasma. PMID:36482414 efo:EFO_0803460 Quantification of thiopurine S-methyl ether in blood plasma. Elizabeth Lewis HMDB:0060412 KEGG COMPOUND:C03542 6-methylmercaptopurine thiopurine S-methyl ether measurement Quantification of thiopurine S-methyl ether in blood plasma. PMID:36482414 efo:EFO_0803461 Quantification of tsangane l 3-glucoside in blood plasma. Elizabeth Lewis HMDB:0040824 tsangane l 3-glucoside measurement Quantification of tsangane l 3-glucoside in blood plasma. PMID:36482414 efo:EFO_0803462 Quantification of tyrosol 4-sulfate in blood plasma. Elizabeth Lewis HMDB:0041785 tyrosol 4-sulfate measurement Quantification of tyrosol 4-sulfate in blood plasma. PMID:36482414 efo:EFO_0803463 Quantification of xanthurenic acid in blood plasma. Elizabeth Lewis HMDB:0000881 KEGG COMPOUND:C02470 xanthurenic acid measurement Quantification of xanthurenic acid in blood plasma. PMID:36482414 efo:EFO_0803464 Quantification of oxoglutarate in blood plasma. Elizabeth Lewis HMDB:0000208 KEGG COMPOUND:C00026 oxoglutarate measurement Quantification of oxoglutarate in blood plasma. PMID:36482414 efo:EFO_0803465 Quantification of lormetazepam in blood plasma. Elizabeth Lewis HMDB:0041919 lormetazepam measurement Quantification of lormetazepam in blood plasma. PMID:36482414 efo:EFO_0803466 Quantification of retinoic acid in blood plasma. Elizabeth Lewis HMDB:0001852 KEGG COMPOUND:C00777 all-trans-retinoic acid retinoic acid measurement Quantification of retinoic acid in blood plasma. PMID:36482414 efo:EFO_0803467 Quantification of nicotine in blood plasma. Elizabeth Lewis HMDB:0001934 KEGG COMPOUND:C00745 nicotine measurement Quantification of nicotine in blood plasma. PMID:36482414 efo:EFO_0803468 Quantification of (1R2R)-3-(12-dihydro-2-hydroxy-1-naphthalenyl)thio-2-oxopropanoic acid in blood plasma. Elizabeth Lewis KEGG COMPOUND:C14799 (1R2R)-3-(12-dihydro-2-hydroxy-1-naphthalenyl)thio-2-oxopropanoic acid measurement Quantification of (1R2R)-3-(12-dihydro-2-hydroxy-1-naphthalenyl)thio-2-oxopropanoic acid in blood plasma. PMID:36482414 efo:EFO_0803469 Quantification of (3S)-3-hydroxy-L-enduracididine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C20603 (3S)-3-hydroxy-L-enduracididine measurement Quantification of (3S)-3-hydroxy-L-enduracididine in blood plasma. PMID:36482414 efo:EFO_0803470 Quantification of (R)-23-dihydroxypropane-1-sulfonate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C19675 (R)-23-dihydroxypropane-1-sulfonate measurement Quantification of (R)-23-dihydroxypropane-1-sulfonate in blood plasma. PMID:36482414 efo:EFO_0803471 Quantification of 1-amino-24-dibromoanthraquinone in blood plasma. Elizabeth Lewis KEGG COMPOUND:C19211 1-amino-24-dibromoanthraquinone measurement Quantification of 1-amino-24-dibromoanthraquinone in blood plasma. PMID:36482414 efo:EFO_0803472 Quantification of 2-anthramine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C14417 2-aminoanthracene 2-anthramine measurement Quantification of 2-anthramine in blood plasma. PMID:36482414 efo:EFO_0803473 Quantification of 2-chloro-3-oxoadipate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C12836 2-chloro-3-oxoadipate measurement Quantification of 2-chloro-3-oxoadipate in blood plasma. PMID:36482414 efo:EFO_0803474 Quantification of 246-triaminotoluene in blood plasma. Elizabeth Lewis KEGG COMPOUND:C16400 246-triaminotoluene measurement Quantification of 246-triaminotoluene in blood plasma. PMID:36482414 efo:EFO_0803475 Quantification of 3-(phosphoacetylamido)-L-alanine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C04111 3-(phosphoacetylamido)-L-alanine measurement Quantification of 3-(phosphoacetylamido)-L-alanine in blood plasma. PMID:36482414 efo:EFO_0803476 Quantification of 3-methylthiopropanamine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C03354 3-methylthiopropylamine 3-methylthiopropanamine measurement Quantification of 3-methylthiopropanamine in blood plasma. PMID:36482414 efo:EFO_0803477 Quantification of 3-vinylbacteriochlorophyllide a in blood plasma. Elizabeth Lewis KEGG COMPOUND:C18152 3-deacetyl-3-vinylbacteriochlorophyllide A 3-vinylbacteriochlorophyllide a measurement Quantification of 3-vinylbacteriochlorophyllide a in blood plasma. PMID:36482414 efo:EFO_0803478 Quantification of 68-dimethyl-67-didehydroergoline in blood plasma. Elizabeth Lewis KEGG COMPOUND:C20409 68-dimethyl-67-didehydroergoline measurement Quantification of 68-dimethyl-67-didehydroergoline in blood plasma. PMID:36482414 efo:EFO_0803479 Quantification of 7-methylpyrido34-cpsoralen in blood plasma. Elizabeth Lewis KEGG COMPOUND:C19458 7-methylpyrido34-cpsoralen measurement Quantification of 7-methylpyrido34-cpsoralen in blood plasma. PMID:36482414 efo:EFO_0803480 Quantification of A 77003 in blood plasma. Elizabeth Lewis KEGG COMPOUND:C15660 A 77003 measurement Quantification of A 77003 in blood plasma. PMID:36482414 efo:EFO_0803481 Quantification of alpha-D-ribose 1-methylphosphonate 5-triphosphate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C20422 alpha-D-ribose 1-methylphosphonate 5-triphosphate measurement Quantification of alpha-D-ribose 1-methylphosphonate 5-triphosphate in blood plasma. PMID:36482414 efo:EFO_0803482 Quantification of alpha-ethyl-alphabeta-diphenyl-2-pyridineethanol in blood plasma. Elizabeth Lewis KEGG COMPOUND:C15028 alpha-ethyl-alphabeta-diphenyl-2-pyridineethanol measurement Quantification of alpha-ethyl-alphabeta-diphenyl-2-pyridineethanol in blood plasma. PMID:36482414 efo:EFO_0803483 Quantification of arg-vasopressin in blood plasma. Elizabeth Lewis KEGG COMPOUND:C13662 8-l-arginine vasopressin argipressin arg-vasopressin measurement Quantification of arg-vasopressin in blood plasma. PMID:36482414 efo:EFO_0803484 Quantification of atractyloside I in blood plasma. Elizabeth Lewis KEGG COMPOUND:C17866 atractyloside I measurement Quantification of atractyloside I in blood plasma. PMID:36482414 efo:EFO_0803485 Quantification of azothoate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C19020 azothoate measurement Quantification of azothoate in blood plasma. PMID:36482414 efo:EFO_0803486 Quantification of buthionine sulfoximine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C04543 s-butyl-dl-homocysteine-sr-sulfoximine buthionine sulfoximine measurement Quantification of buthionine sulfoximine in blood plasma. PMID:36482414 efo:EFO_0803487 Quantification of carpropamid in blood plasma. Elizabeth Lewis KEGG COMPOUND:C10932 carpropamid measurement Quantification of carpropamid in blood plasma. PMID:36482414 efo:EFO_0803488 Quantification of chloromethiuron in blood plasma. Elizabeth Lewis KEGG COMPOUND:C19026 chloromethiuron measurement Quantification of chloromethiuron in blood plasma. PMID:36482414 efo:EFO_0803489 Quantification of chlorophacinone in blood plasma. Elizabeth Lewis KEGG COMPOUND:C18514 chlorophacinone measurement Quantification of chlorophacinone in blood plasma. PMID:36482414 efo:EFO_0803490 Quantification of correolide in blood plasma. Elizabeth Lewis KEGG COMPOUND:C13849 correolide measurement Quantification of correolide in blood plasma. PMID:36482414 efo:EFO_0803491 Quantification of deacetylcolchicine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C16712 trimethylcolchicinic acid methyl ether deacetylcolchicine measurement Quantification of deacetylcolchicine in blood plasma. PMID:36482414 efo:EFO_0803492 Quantification of dehydroshikimate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C02652 dehydroshikimate measurement Quantification of dehydroshikimate in blood plasma. PMID:36482414 efo:EFO_0803493 Quantification of delphinine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C08677 delphinine measurement Quantification of delphinine in blood plasma. PMID:36482414 efo:EFO_0803494 Quantification of demethylphosphinothricin in blood plasma. Elizabeth Lewis KEGG COMPOUND:C17962 (2S)-2-amino-4-(hydroxyphosphinyl)butanoic acid demethylphosphinothricin measurement Quantification of demethylphosphinothricin in blood plasma. PMID:36482414 efo:EFO_0803495 Quantification of dibromobisphenol A in blood plasma. Elizabeth Lewis KEGG COMPOUND:C13622 33-dibromobisphenol A dibromobisphenol a measurement Quantification of dibromobisphenol A in blood plasma. PMID:36482414 efo:EFO_0803496 Quantification of dimethylphenylenediamine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C04203 dimethylphenylenediamine measurement Quantification of dimethylphenylenediamine in blood plasma. PMID:36482414 efo:EFO_0803497 Quantification of fenson in blood plasma. Elizabeth Lewis KEGG COMPOUND:C19030 fenson measurement Quantification of fenson in blood plasma. PMID:36482414 efo:EFO_0803498 Quantification of fluocinolone in blood plasma. Elizabeth Lewis KEGG COMPOUND:C07006 fluocinolone measurement Quantification of fluocinolone in blood plasma. PMID:36482414 efo:EFO_0803499 Quantification of GW 6471 in blood plasma. Elizabeth Lewis KEGG COMPOUND:C15620 GW 6471 measurement Quantification of GW 6471 in blood plasma. PMID:36482414 efo:EFO_0803500 Quantification of hodgkinsine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C09211 hodgkinsine measurement Quantification of hodgkinsine in blood plasma. PMID:36482414 efo:EFO_0803501 Quantification of indol-3-ylacetyl-myo-inositol L-arabinoside in blood plasma. Elizabeth Lewis KEGG COMPOUND:C04611 indol-3-ylacetyl-myo-inositol L-arabinoside measurement Quantification of indol-3-ylacetyl-myo-inositol L-arabinoside in blood plasma. PMID:36482414 efo:EFO_0803502 Quantification of istamycin C1 in blood plasma. Elizabeth Lewis KEGG COMPOUND:C17996 istamycin C1 measurement Quantification of istamycin C1 in blood plasma. PMID:36482414 efo:EFO_0803503 Quantification of mercaptoacetyl-phe-leu in blood plasma. Elizabeth Lewis KEGG COMPOUND:C03292 mercaptoacetyl-phe-leu measurement Quantification of mercaptoacetyl-phe-leu in blood plasma. PMID:36482414 efo:EFO_0803504 Quantification of minosaminomycin in blood plasma. Elizabeth Lewis KEGG COMPOUND:C17969 minosaminomycin measurement Quantification of minosaminomycin in blood plasma. PMID:36482414 efo:EFO_0803505 Quantification of N-phosphotaurocyamine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C03149 taurocyamine phosphate, N(omega)-phosphotaurocyamine N-phosphotaurocyamine measurement Quantification of N-phosphotaurocyamine in blood plasma. PMID:36482414 efo:EFO_0803506 Quantification of perphenazine maleate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C13540 perphenazine maleate measurement Quantification of perphenazine maleate in blood plasma. PMID:36482414 efo:EFO_0803507 Quantification of phenylmethanesulfonyl fluoride in blood plasma. Elizabeth Lewis KEGG COMPOUND:C06747 benzenemethanesulfonyl fluoride phenylmethanesulfonyl fluoride measurement Quantification of phenylmethanesulfonyl fluoride in blood plasma. PMID:36482414 efo:EFO_0803508 Quantification of phorbol 12-tiglate 13-decanoate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C09157 phorbol 12-tiglate 13-decanoate measurement Quantification of phorbol 12-tiglate 13-decanoate in blood plasma. PMID:36482414 efo:EFO_0803509 Quantification of potassium bicarbonate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C18606 potassium bicarbonate measurement Quantification of potassium bicarbonate in blood plasma. PMID:36482414 efo:EFO_0803510 Quantification of quinoclamin in blood plasma. Elizabeth Lewis KEGG COMPOUND:C18584 quinoclamin measurement Quantification of quinoclamin in blood plasma. PMID:36482414 efo:EFO_0803511 Quantification of quinoxyfen in blood plasma. Elizabeth Lewis KEGG COMPOUND:C18892 quinoxyfen measurement Quantification of quinoxyfen in blood plasma. PMID:36482414 efo:EFO_0803512 Quantification of rhodojaponin I in blood plasma. Elizabeth Lewis KEGG COMPOUND:C19992 grayanotoxane-56101416-pentol 23-epoxy- 614-diacetate (2beta3beta6beta14r)- rhodojaponin I measurement Quantification of rhodojaponin I in blood plasma. PMID:36482414 efo:EFO_0803513 Quantification of S-(4-bromophenyl)-mercaptopyruvate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C04264 S-(4-bromophenyl)-mercaptopyruvate measurement Quantification of S-(4-bromophenyl)-mercaptopyruvate in blood plasma. PMID:36482414 efo:EFO_0803514 Quantification of scutianine F in blood plasma. Elizabeth Lewis KEGG COMPOUND:C10014 scutianine F measurement Quantification of scutianine F in blood plasma. PMID:36482414 efo:EFO_0803515 Quantification of sodium nitroprusside dihydrate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C07695 sodium nitroprusside dihydrate measurement Quantification of sodium nitroprusside dihydrate in blood plasma. PMID:36482414 efo:EFO_0803516 Quantification of stigmatellin Y in blood plasma. Elizabeth Lewis KEGG COMPOUND:C12150 stigmatellin Y measurement Quantification of stigmatellin Y in blood plasma. PMID:36482414 efo:EFO_0803517 Quantification of sulfadimethoxine sodium in blood plasma. Elizabeth Lewis KEGG COMPOUND:C18386 sulfadimethoxine sodium measurement Quantification of sulfadimethoxine sodium in blood plasma. PMID:36482414 efo:EFO_0803518 Quantification of sulfoacetate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C14179 sulfoacetic acid sulfoacetate measurement Quantification of sulfoacetate in blood plasma. PMID:36482414 efo:EFO_0803519 Quantification of tiadinil in blood plasma. Elizabeth Lewis KEGG COMPOUND:C18550 tiadinil measurement Quantification of tiadinil in blood plasma. PMID:36482414 efo:EFO_0803520 Quantification of tridihexethyl bromide in blood plasma. Elizabeth Lewis KEGG COMPOUND:C11761 tridihexethyl bromide measurement Quantification of tridihexethyl bromide in blood plasma. PMID:36482414 efo:EFO_0803521 Quantification of tromethamine in blood plasma. Elizabeth Lewis KEGG COMPOUND:C07182 2-amino-2-(hydroxymethyl)-13-propanediol trometamol tromethamine measurement Quantification of tromethamine in blood plasma. PMID:36482414 efo:EFO_0803522 Quantification of zinc lactate in blood plasma. Elizabeth Lewis KEGG COMPOUND:C17389 zinc lactate measurement Quantification of zinc lactate in blood plasma. PMID:36482414 efo:EFO_0803523 Quantification of 2-chloro-45-xylyl N-hydroxy-N-methylcarbamate in blood plasma. Elizabeth Lewis T3DB:T3D0896 2-chloro-45-xylyl N-hydroxy-N-methylcarbamate measurement Quantification of 2-chloro-45-xylyl N-hydroxy-N-methylcarbamate in blood plasma. PMID:36482414 efo:EFO_0803524 Quantification of antimony(III) isopropoxide in blood plasma. Elizabeth Lewis T3DB:T3D1861 antimony(III) isopropoxide measurement Quantification of antimony(III) isopropoxide in blood plasma. PMID:36482414 efo:EFO_0803525 Quantification of ethyl thiocyanate in blood plasma. Elizabeth Lewis T3DB:T3D1675 ethyl thiocyanate measurement Quantification of ethyl thiocyanate in blood plasma. PMID:36482414 efo:EFO_0803526 Quantification of fenasulam in blood plasma. Elizabeth Lewis T3DB:T3D0966 fenasulam measurement Quantification of fenasulam in blood plasma. PMID:36482414 efo:EFO_0803527 Quantification of methylarsonic acid monosodium salt in blood plasma. Elizabeth Lewis T3DB:T3D0309 methylarsonic acid monosodium salt measurement Quantification of methylarsonic acid monosodium salt in blood plasma. PMID:36482414 efo:EFO_0803528 Quantification of methylmercuric dicyanamide in blood plasma. Elizabeth Lewis T3DB:T3D1350 methylmercuric dicyanamide measurement Quantification of methylmercuric dicyanamide in blood plasma. PMID:36482414 efo:EFO_0803529 Quantification of phenylmercuric borate in blood plasma. Elizabeth Lewis T3DB:T3D1363 phenylmercuric borate measurement Quantification of phenylmercuric borate in blood plasma. PMID:36482414 efo:EFO_0803530 Quantification of tribromodibenzofuran in blood plasma. Elizabeth Lewis T3DB:T3D2384 tribromodibenzofuran measurement Quantification of tribromodibenzofuran in blood plasma. PMID:36482414 efo:EFO_0803531 Quantification of uranyl acetate in blood plasma. Elizabeth Lewis T3DB:T3D1177 uranyl acetate measurement Quantification of uranyl acetate in blood plasma. PMID:36482414 Test No. 490: In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene OECD Organisation for Economic Cooperation and Development Test No. 406: Skin Sensitisation Test No. 405: Acute Eye Irritation/Corrosion Test No. 102: Melting Point/ Melting Range Test No. 109: Density of Liquids and Solids Test No. 113: Screening Test for Thermal Stability and Stability in Air Test No. 116: Fat Solubility of Solid and Liquid Substances Test No. 105: Water Solubility Test No. 318: Dispersion Stability of Nanomaterials in Simulated Environmental Media Test No. 312: Leaching in Soil Columns Test No. 305: Bioaccumulation in Fish: Aqueous and Dietary Exposure Test No. 442D: In Vitro Skin Sensitisation Test No. 417: Toxicokinetics Test No. 412: Subacute Inhalation Toxicity: 28-Day Study Test No. 413: Subchronic Inhalation Toxicity: 90-day Study Test No. 403: Acute Inhalation Toxicity Test No. 436: Acute Inhalation Toxicity – Acute Toxic Class Method Test No. 310: Ready Biodegradability - CO2 in sealed vessels (Headspace Test) Test No. 301: Ready Biodegradability Test No. 306: Biodegradability in Seawater Test No. 307: Aerobic and Anaerobic Transformation in Soil Test No. 308: Aerobic and Anaerobic Transformation in Aquatic Sediment Systems Test No. 309: Aerobic Mineralisation in Surface Water – Simulation Biodegradation Test Test No. 474: Mammalian Erythrocyte Micronucleus Test Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test Test No. 202: Daphnia sp. Acute Immobilisation Test Test No. 203: Fish, Acute Toxicity Test Test No. 442C: In Chemico Skin Sensitisation Test No. 442E: In Vitro Skin Sensitisation Test No. 501: Metabolism in Crops Test No. 492: Reconstructed human Cornea-like Epithelium (RhCE) test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage Test No. 491: Short Time Exposure In Vitro Test Method for Identifying i) Chemicals Inducing Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage Test No. 106: Adsorption -- Desorption Using a Batch Equilibrium Method AOP Decreased Fecundity via Aromatase Inhibition AOP Decreased Fecundity via Estrogen Receptor-alpha Antagonism AOP Decreased Fecundity via PPAR-gamma Activation AOP Steatosis Via DHB4 AOP Steatosis Via FXR and HSD17B4 AOP Steatosis Via IRS1, AKT, GSK3 and Lipogenesis AOP Steatosis Via IRS1, AKT2, TSC1 or TSC2 and Lipogenesis This is the Bayesian natural spline metaregression algorithm. A probability function is derived at each tested concentration within a bioassay using a natural spline metaregression algorithm. AOP Neural Tube Defect via Hoxb1 15.0 893 Neural Tube Defect Steatosis 2019-03-05T17:25:21Z Western Australia Ecoregion WWF:AA1310 https://www.worldwildlife.org/ecoregions/aa1310 Western Australian Mulga Shrublands Ecoregion 2019-03-05T17:51:32Z https://www.worldwildlife.org/biomes/deserts-and-xeric-shrublands Australasia Ecoregion 2019-03-05T17:52:41Z Southern central Australia Ecoregion WWF:AA1309 https://www.worldwildlife.org/ecoregions/aa1309 Tirari-Sturt Stony Desert Ecoregion 2019-03-05T17:54:35Z Eastern central Australia Ecoregion WWF:AA1308 https://www.worldwildlife.org/ecoregions/aa1308 Simpson Desert Region 2019-03-05T17:56:13Z Western Australia Ecoregion WWF:AA1307 https://www.worldwildlife.org/ecoregions/aa1307 Pilbara Shrublands Ecoregion 2019-03-05T18:10:52Z Western coast of Australia Ecoregion WWF:AA1301 https://www.worldwildlife.org/ecoregions/aa1301 Carnarvon Xeric Shrublands Ecoregion 2019-03-05T18:12:28Z Central Australia Ecoregion WWF:AA1302 https://www.worldwildlife.org/ecoregions/aa1302 Central Ranges Xeric Shrub Ecoregion 2019-03-05T18:15:11Z Western central Australia WWF:AA1303 https://www.worldwildlife.org/ecoregions/aa1303 Gibson Desert Ecoregion 2019-03-05T18:17:15Z Northwestern Australia WWF:AA1304 https://www.worldwildlife.org/ecoregions/aa1304 The Great Sandy-Tanami Desert Ecoregion 2019-03-05T18:24:06Z Southern Australia Ecoregion WWF:AA1305 https://www.worldwildlife.org/ecoregions/aa1305 Great Victoria Desert Ecoregion 2019-03-05T18:26:16Z Southern Australia Ecoregion WWF:AA1306 https://www.worldwildlife.org/ecoregions/aa1306 Nullarbor Plains Xeric Shrubland Ecoregion 2019-03-06T22:01:41Z https://www.worldwildlife.org/biomes/deserts-and-xeric-shrublands Afrotropical Ecoregion 2019-03-06T22:02:37Z Southern Africa: Southern Namibia into South Africa WWF:AT1322 https://www.worldwildlife.org/ecoregions/at1322 Succulent Karoo Ecoregion 2019-03-06T22:07:38Z WWF:AT1321 https://www.worldwildlife.org/ecoregions/at1321 Arabian Peninsula: Yemen and Saudi Arabia Yemen and Saudi Arabia Ecoregion 2019-03-06T22:11:38Z WWF:AT1320 https://www.worldwildlife.org/ecoregions/at1320 Arabian Peninsula: Yemen, Saudi Arabia, and Oman Yemen, Saudi Arabia, and Oman Ecoregion 2019-03-06T22:13:00Z WWF:AT1319 https://www.worldwildlife.org/ecoregions/at1319 Somali montane xeric woodlands ecoregion Somali Montane Xeric Woodland Ecoregion 2019-03-06T22:15:07Z Islands east of the Horn of Africa and south of Yemen Ecoregion WWF:AT1318 https://www.worldwildlife.org/ecoregions/at1318 Socotran Archipelago Ecoregion 2019-03-06T22:18:55Z WWF:AT1317 https://www.worldwildlife.org/ecoregions/at1317 Red Sea Coastal Desert Ecoregion 2019-03-06T22:20:56Z WWF:AT1316 https://www.worldwildlife.org/ecoregions/at1316 Namibian Savanna Woodland Ecoregion 2019-03-06T22:24:28Z Africa: Namibia Ecoregion WWF:AT1315 https://www.worldwildlife.org/ecoregions/at1315 Namib Desert Ecoregion 2019-03-06T22:26:15Z WWF:AT1314 https://www.worldwildlife.org/ecoregions/at1314 Nama Karoo Ecoregion 2019-03-06T22:28:43Z WWF:AT1313 https://www.worldwildlife.org/ecoregions/at1313 Masai Xeric Grasslands and Shrublands Ecoregion 2019-03-06T22:30:23Z WWF:AT1312 https://www.worldwildlife.org/ecoregions/at1312 Madagascar Succulent Woodlands Ecoregion 2019-03-06T22:31:29Z WWF:AT1311 https://www.worldwildlife.org/ecoregions/at1311 Madagascar spiny desert ecoregion Madagascar Spiny Thickets Ecoregion 2019-03-06T22:39:32Z WWF:AT1310 https://www.worldwildlife.org/ecoregions/at1310 Africa: Coastal Namibia and Angola Ecoregion Kaokoveld Desert Ecoregion 2019-03-06T22:42:47Z WWF:AT1309 https://www.worldwildlife.org/ecoregions/at1309 Kalahari Xeric Savanna Ecoregion 2019-03-06T22:44:54Z WWF:AT1308 https://www.worldwildlife.org/ecoregions/at1308 Southern Africa: Islands about half-way between southern Madagascar and southern Mozambique Ecoregion Ile Europa and Bassas da India Ecoregion 2019-03-06T22:46:58Z Eastern Africa: Somalia WWF:AT1307 https://www.worldwildlife.org/ecoregions/at1307 Hobyo Grassland and Shrubland Ecoregion 2019-03-06T22:54:57Z WWF:AT1306 https://www.worldwildlife.org/ecoregions/at1306 Arabian Peninsula: Oman and United Arab Emirates Ecoregion Oman and United Arab Emirates Ecoregion 2019-03-07T00:08:06Z WWF:AT1305 https://www.worldwildlife.org/ecoregions/at1305 Ethiopian Xeric Grasslands and Shrublands Ecoregion 2019-03-07T00:11:29Z WWF:AT1304 https://www.worldwildlife.org/ecoregions/at1304 Eritrean Coastal Desert Ecoregion 2019-03-07T00:13:33Z WWF:AT1303 https://www.worldwildlife.org/ecoregions/at1303 North central Africa: Eastern Chad and small area of western Sudan East Saharan Montane Xeric Woodland Ecoregion 2019-03-07T00:16:12Z WWF:AT1302 https://www.worldwildlife.org/ecoregions/at1302 Western Asia: Oman, Yemen, and Saudi Arabia Ecoregion Oman, Yemen, and Saudi Arabia Ecoregion 2019-03-07T00:18:09Z WWF:AT1301 https://www.worldwildlife.org/ecoregions/at1301 Aldabra Island Xeric Scrub Ecoregion 2019-04-26T23:38:50Z Indo-Malay Ecoregion 2019-04-26T23:40:13Z WWF:IM1304 Southern Asia: Western India into Pakistan Thar Desert 2019-04-27T00:12:51Z WWF:IM1303 Southern Asia: Eastern India and western Pakistan Northwestern Thorn Scrub Forests A polar front between the deep, cold Arctic air and the shallower, warmer polar air of northern latitudes on Earth. 2019-08-20T13:47:18Z envoAtmo envoPolar Arctic front A polar front between the deep, cold Arctic air and the shallower, warmer polar air of northern latitudes on Earth. A polar front between the deep, cold Antarctic air and the shallower, warmer polar air of southern latitudes on Earth. 2019-08-20T13:48:44Z envoAtmo envoPolar Antarctic front A polar front between the deep, cold Antarctic air and the shallower, warmer polar air of southern latitudes on Earth. Stellar radiation emitted from Sol. 2020-05-19T22:27:44Z Solar radiation example to be eventually removed example to be eventually removed failed exploratory term The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job Person:Alan Ruttenberg Person:Alan Ruttenberg failed exploratory term metadata complete Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. metadata complete organizational term Term created to ease viewing/sort terms for development purpose, and will not be included in a release term created to ease viewing/sort terms for development purpose, and will not be included in a release PERSON:Alan Ruttenberg organizational term ready for release Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." ready for release metadata incomplete Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. metadata incomplete uncurated Nothing done yet beyond assigning a unique class ID and proposing a preferred term. uncurated pending final vetting All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. pending final vetting core Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes. PERSON: Alan Ruttenberg PERSON: Melanie Courtot core obsolete_core true placeholder removed placeholder removed terms merged An editor note should explain what were the merged terms and the reason for the merge. terms merged term imported This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. term imported term split This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. term split This is to be used if none of the existing instances cover the reason for obsolescence. An editor note should indicate this new reason. We expect to be able to mine these new reasons and add instances as required. obsolete_other other true universal universal Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. Alan Ruttenberg Alan Ruttenberg A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf universal universal defined class defined class A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. Alan Ruttenberg Alan Ruttenberg defined class defined class named class expression named class expression A named class expression is a logical expression that is given a name. The name can be used in place of the expression. A named class expression is a logical expression that is given a name. The name can be used in place of the expression. named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions Alan Ruttenberg Alan Ruttenberg named class expression named class expression to be replaced with external ontology term Terms with this status should eventually replaced with a term from another ontology. Alan Ruttenberg group:OBI to be replaced with external ontology term requires discussion A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. Alan Ruttenberg group:OBI requires discussion Biocrates Life Sciences AG, a biotechnology company, develops and markets targeted metabolic phenotyping solutions that support the discovery and validation of biomarkers for complex multifactorial diseases in pre-clinical and clinical research. The company offers mass-spectrometry based reproducible and quantitative kits and services that analyze various endogenous metabolites; and tools for insight into pathways and metabolic signatures of diseases, such as cancer or neurodegenerative diseases. It also offers metabolic phenotyping, and biomarker discovery and development services. Alejandra Gonzalez-Beltran Philippe Rocca-Serra Biocrates Life Sciences AG https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=20741978 Biocrates AG Agilent Technologies is an American public research, development and manufacturing company established in 1999 as a spin-off from Hewlett-Packard. The resulting IPO of Agilent stock was the largest in the history of Silicon Valley at the time. The company provides analytical instruments, software, services and consumables for the entire laboratory workflow. Alejandra Gonzalez-Beltran Philippe Rocca-Serra Agilent https://en.wikipedia.org/wiki/Agilent_Technologies Agilent Technologies Bruker Corporation is a manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts and is the publicly traded parent company of Bruker Scientific Instruments (Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics) and Bruker Energy & Supercon Technologies (BEST) divisions. Bruker Bruker Corporation https://en.wikipedia.org/wiki/Bruker Bruker AG Thermo Fisher Scientific is an American multinational biotechnology product development company, created in 2006 by the merger of Thermo Electron and Fisher Scientific. Alejandra Gonzalez-Beltran Philippe Rocca-Serra https://en.wikipedia.org/wiki/Thermo_Fisher_Scientific Thermo Fisher Scientific An confidence interval with 95 percent probability that the true population value can be found. Jie Zheng 95% confidence interval Transformation-ML Transformation-ML file describing parameter transformations used in a GvHD experiment. Transformation-ML is a format standard of a digital entity that is conformant with the Transformation-ML standard.(http://wiki.ficcs.org/ficcs/Transformation-ML?action=AttachFile&do=get&target=Transformation-ML_v1.0.26.pdf) person:Jennifer Fostel web-page:http://wiki.ficcs.org/ficcs/Transformation-ML?action=AttachFile&do=get&target=Transformation-ML_v1.0.26.pdf Transformation-ML ACS d06.acs, ACS1.0 data file of well D06 of plate 2 of part 1 of a GvHD experiment. ACS is a format standard of a digital entity that is conformant with the Analytical Cytometry Standard. (http://www.isac-net.org/content/view/607/150/) person:Jennifer Fostel web-page:http://www.isac-net.org/content/view/607/150/ ACS XML RDF/XML file, OWL file, Compensation-ML file, WSDL document, SVG document XML is a format standard of a digital entity that is conformant with the W3C Extensible Markup Language Recommendation.(http://www.w3.org/XML/) person:Jennifer Fostel web-page:http://www.w3.org/XML/ XML RDF A FOAF file, a SKOS file, an OWL file. RDF is a format standard of a digital entity that is conformant with the W3C Resource Description Framework RDF/XML Syntax specification.(http://www.w3.org/RDF/) person:Jennifer Fostel web-page:http://www.w3.org/RDF/ RDF zip MagicDraw MDZIP archive, Java JAR file. zip is a format standard of a digital entity that is conformant with the PKWARE .ZIP file format specification (http://www.pkware.com/index.php?option=com_content&task=view&id=59&Itemid=103/) person:Jennifer Fostel web-page:http://www.pkware.com/index.php?option=com_content&task=view&id=59&Itemid=103/ zip tar Example.tar file. tar is a format standard of a digital entity that is conformant with the tape archive file format as standardized by POSIX.1-1998, POSIX.1-2001, or any other tar format compliant with the GNU tar specification. (http://www.gnu.org/software/tar/manual/) person:Jennifer Fostel web-page:http://www.gnu.org/software/tar/manual/ tar FCS d01.fcs, FCS3 data file of well D06 of plate 2 of part 1 of a GvHD experiment. FCS is a format standard of a digital entity that is conformant with the Flow Cytometry Data File Standard.(http://www.fcspress.com/) person:Jennifer Fostel web-page:http://www.fcspress.com/ FCS Compensation-ML compfoo.xml, Compensation-ML file describing compensation used in a GvHD experiment Compensation-ML is a format standard of a digital entity that is conformant with the Compensation-ML standard. (http://wiki.ficcs.org/ficcs/Compensation-ML?action=AttachFile&do=get&target=Compensation-ML_v1.0.24.pdf) person:Jennifer Fostel web-page:http://wiki.ficcs.org/ficcs/Compensation-ML?action=AttachFile&do=get&target=Compensation-ML_v1.0.24.pdf Compensation-ML Gating-ML foogate.xml, Gating-ML file describing gates used in a GvHD experiment. Gating-ML is a format standard of a digital entity that is conformant with the Gating-ML standard. (http://www.flowcyt.org/gating/) person:Jennifer Fostel web-page:http://www.flowcyt.org/gating/ Gating-ML OWL OBI ontology file, Basic Formal Ontology file, BIRNLex file, BioPAX file. OWL is a format standard of a digital entity that is conformant with the W3C Web Ontology Language specification.(http://www.w3.org/2004/OWL/) person:Jennifer Fostel web-page:http://www.w3.org/2004/OWL/ OWL obsolete_the supplier role of Affymetrix obsolete_the supplier role of Affymetrix true Affymetrix Affymetrix supplied microarray An organization which supplies technology, tools and protocols for use in high throughput applications Affymetrix Thermo Philippe Rocca-Serra Thermo Waters Philippe Rocca-Serra Waters BIO-RAD Philippe Rocca-Serra BIO-RAD GenePattern hierarchical clustering James Malone GenePattern hierarchical clustering Ambion Philippe Rocca-Serra Ambion Helicos Philippe Rocca-Serra Helicos Roche Philippe Rocca-Serra Roche Illumina Philippe Rocca-Serra Illumina GenePattern PCA GenePattern PCA GenePattern module SVM GenePattern module SVM is a GenePattern software module which is used to run a support vector machine data transformation. James Malone Ryan Brinkman GenePattern module SVM GenePattern k-nearest neighbors James Malone GenePattern k-nearest neighbors GenePattern LOOCV GenePattern LOOCV GenePattern k-means clustering James Malone GenePattern k-means clustering Agilent Philippe Rocca-Serra Agilent GenePattern module KMeansClustering GenePattern module KMeansClustering is a GenePattern software module which is used to perform a k Means clustering data transformation. James Malone PERSON: James Malone GenePattern module KMeansClustering GenePattern CART James Malone GenePattern CART GenePattern module CARTXValidation GenePattern module CARTXValidation is a GenePattern software module which uses a CART decision tree induction with a leave one out cross validation data transformations. GenePattern module CARTXValidation Li-Cor Philippe Rocca-Serra Li-Cor Bruker Corporation Philippe Rocca-Serra Bruker Corporation GenePattern module KNNXValidation GenePattern module KNNXValidation is a GenePattern software module which uses a k-nearest neighbours clustering with a leave one out cross validation data transformations. James Malone PERSON: James Malone GenePattern module KNNXValidation GenePattern module PeakMatch GenePattern module PeakMatch GenePattern module KNN GenePattern module KNN is a GenePattern software module which perform a k-nearest neighbors data transformation. James Malone GenePattern module KNN GenePattern module HierarchicalClustering GenePattern module HierarchicalClustering is a GenePattern software module which is used to perform a hierarchical clustering data transformation. James Malone PERSON: James Malone GenePattern module HierarchicalClustering GenePattern SVM James Malone GenePattern SVM Applied Biosystems Philippe Rocca-Serra Applied Biosystems GenePattern module PCA GenePattern module PCA is a GenePattern software module which is used to perform a principal components analysis dimensionality reduction data transformation. James Malone PERSON: James Malone GenePattern module PCA GenePattern peak matching James Malone Ryan Brinkman GenePattern peak matching Bruker Daltonics Philippe Rocca-Serra Bruker Daltonics GenePattern HeatMapViewer data visualization The GenePattern process of generating Heat Maps from clustered data. James Malone GenePattern HeatMapViewer data visualization GenePattern HierarchicalClusteringViewer data visualization The GenePattern process of generating hierarchical clustering visualization from clustered data. James Malone GenePattern HierarchicalClusteringViewer data visualization GenePattern module HeatMapViewer A GenePattern software module which is used to generate a heatmap view of data. James Malone GenePattern module HeatMapViewer GenePattern module HierarchicalClusteringViewer A GenePattern software module which is used to generate a view of data that has been hierarchically clustered. James Malone GenePattern module HierarchicalClusteringViewer Sysmex Corporation, Kobe, Japan WEB:http://www.sysmex.com/@2009/08/06 Sysmex Corporation, Kobe, Japan obsolete_the manufacturer role of Agilent obsolete_the manufacturer role of Agilent true obsolete_manufacturer role of Bruker Daltonics obsolete_manufacturer role of Bruker Daltonics true obsolete_the manufacturer role of Thermo obsolete_the manufacturer role of Thermo true obsolete_the manufacturer role of Li-Cor obsolete_the manufacturer role of Li-Cor true obsolete_the manufacturer role of Roche obsolete_the manufacturer role of Roche true obsolete_the manufacturer role of Ambion obsolete_the manufacturer role of Ambion true obsolete_the manufacturer role of BIO-RAD obsolete_the manufacturer role of BIO-RAD true obsolete_the regulator role of the FDA obsolete_the regulator role of the FDA true obsolete_the manufacturer role of Illumina obsolete_the manufacturer role of Illumina true obsolete_the manufacturer role of Helicos obsolete_the manufacturer role of Helicos true obsolete_manufacturer role of Bruker Corporation obsolete_manufacturer role of Bruker Corporation true obsolete_the manufacturer role of Waters obsolete_the manufacturer role of Waters true obsolete_manufacturer role of applied biosystems obsolete_manufacturer role of applied biosystems true U.S. Food and Drug Administration FDA U.S. Food and Drug Administration right handed right handed ambidexterous ambidexterous left handed left handed Edingburgh handedness inventory The Edinburgh Handedness Inventory is a set of questions used to assess the dominance of a person's right or left hand in everyday activities. The Edinburgh Handedness Inventory is a set of questions used to assess the dominance of a person's right or left hand in everyday activities. PERSON:Alan Ruttenberg PERSON:Jessica Turner PMID:5146491#Oldfield, R.C. (1971). The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia, 9, 97-113 WEB:http://www.cse.yorku.ca/course_archive/2006-07/W/4441/EdinburghInventory.html Edingburgh handedness inventory eBioscience Karin Breuer WEB:http://www.ebioscience.com/@2011/04/11 eBioscience Cytopeia Karin Breuer WEB:http://www.cytopeia.com/@2011/04/11 Cytopeia Exalpha Biological Karin Breuer WEB:http://www.exalpha.com/@2011/04/11 Exalpha Biological Apogee Flow Systems Karin Breuer WEB:http://www.apogeeflow.com/@2011/04/11 Apogee Flow Systems Exbio Antibodies Karin Breuer WEB:http://www.exbio.cz/@2011/04/11 Exbio Antibodies Becton Dickinson (BD Biosciences) Karin Breuer WEB:http://www.bdbiosciences.com/@2011/04/11 Becton Dickinson (BD Biosciences) Dako Cytomation Karin Breuer WEB:http://www.dakousa.com/@2011/04/11 Dako Cytomation Millipore Karin Breuer WEB:http://www.guavatechnologies.com/@2011/04/11 Millipore Antigenix Karin Breuer WEB:http://www.antigenix.com/@2011/04/11 Antigenix Partec Karin Breuer WEB:http://www.partec.de/@2011/04/11 Partec Beckman Coulter Karin Breuer WEB:http://www.beckmancoulter.com/@2011/04/11 Beckman Coulter Advanced Instruments Inc. (AI Companies) Karin Breuer WEB:http://www.aicompanies.com/@2011/04/11 Advanced Instruments Inc. (AI Companies) Miltenyi Biotec Karin Breuer WEB:http://www.miltenyibiotec.com/@2011/04/11 Miltenyi Biotec AES Chemunex Karin Breuer WEB:http://www.aeschemunex.com/@2011/04/11 AES Chemunex Bentley Instruments Karin Breuer WEB:http://bentleyinstruments.com/@2011/04/11 Bentley Instruments Invitrogen Karin Breuer WEB:http://www.invitrogen.com/@2011/04/11 Invitrogen Luminex Karin Breuer WEB:http://www.luminexcorp.com/@2011/04/11 Luminex CytoBuoy Karin Breuer WEB:http://www.cytobuoy.com/@2011/04/11 CytoBuoy Nimblegen An organization that focuses on manufacturing target enrichment probe pools for DNA sequencing. Person: Jie Zheng Nimblegen Pacific Biosciences An organization that supplies tools for studying the synthesis and regulation of DNA, RNA and protein. It developed a powerful technology platform called single molecule real-time (SMRT) technology which enables real-time analysis of biomolecules with single molecule resolution. Person: Jie Zheng Pacific Biosciences NanoString Technologies An organization that supplies life science tools for translational research and molecular diagnostics based on a novel digital molecular barcoding technology. The NanoString platform can provide simple, multiplexed digital profiling of single molecules. NanoString Technologies Thermo Fisher Scientific An organization that is an American multinational, biotechnology product development company, created in 2006 by the merger of Thermo Electron and Fisher Scientific. Chris Stoeckert, Helena Ellis https://en.wikipedia.org/wiki/Thermo_Fisher_Scientific Thermo Fisher Scientific G1: Well differentiated A histologic grade according to AJCC 7th edition indicating that the tumor cells and the organization of the tumor tissue appear close to normal. Chris Stoeckert, Helena Ellis G1 https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet NCI BBRB G1: Well differentiated G2: Moderately differentiated A histologic grade according to AJCC 7th edition indicating that the tumor cells are moderately differentiated and reflect an intermediate grade. Chris Stoeckert, Helena Ellis G2 https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet NCI BBRB G2: Moderately differentiated G3: Poorly differentiated A histologic grade according to AJCC 7th edition indicating that the tumor cells are poorly differentiated and do not look like normal cells and tissue. Chris Stoeckert, Helena Ellis G3 https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet NCI BBRB G3: Poorly differentiated G4: Undifferentiated A histologic grade according to AJCC 7th edition indicating that the tumor cells are undifferentiated and do not look like normal cells and tissue. Chris Stoeckert, Helena Ellis G4 https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet NCI BBRB G4: Undifferentiated G1 (Fuhrman) A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei are round, uniform, approximately 10um and that nucleoli are inconspicuous or absent. Chris Stoeckert, Helena Ellis Grade 1 NCI BBRB, OBI NCI BBRB G1 (Fuhrman) G2 (Fuhrman) A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei are slightly irregular, approximately 15um and nucleoli are evident. Chris Stoeckert, Helena Ellis Grade 2 NCI BBRB, OBI NCI BBRB G2 (Fuhrman) G3 (Fuhrman) A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei are very irregular, approximately 20um and nucleoli large and prominent. Chris Stoeckert, Helena Ellis Grade 3 NCI BBRB, OBI NCI BBRB G3 (Fuhrman) G4 (Fuhrman) A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei arei bizarre and multilobulated, 20um or greater and nucleoli are prominent and chromatin clumped. Chris Stoeckert, Helena Ellis Grade 4 NCI BBRB, OBI NCI BBRB G4 (Fuhrman) Low grade ovarian tumor A histologic grade for ovarian tumor according to a two-tier grading system indicating that the tumor is low grade. Chris Stoeckert, Helena Ellis Low grade NCI BBRB, OBI NCI BBRB Low grade ovarian tumor High grade ovarian tumor A histologic grade for ovarian tumor according to a two-tier grading system indicating that the tumor is high grade. Chris Stoeckert, Helena Ellis High grade NCI BBRB, OBI NCI BBRB High grade ovarian tumor G1 (WHO) A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is well differentiated. Chris Stoeckert, Helena Ellis G1 NCI BBRB, OBI NCI BBRB G1 (WHO) G2 (WHO) A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is moderately differentiated. Chris Stoeckert, Helena Ellis G2 NCI BBRB, OBI NCI BBRB G2 (WHO) G3 (WHO) A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is poorly differentiated. Chris Stoeckert, Helena Ellis G3 NCI BBRB, OBI NCI BBRB G3 (WHO) G4 (WHO) A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is undifferentiated. Chris Stoeckert, Helena Ellis G4 NCI BBRB, OBI NCI BBRB G4 (WHO) pT0 (colon) A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that there is no evidence of primary tumor. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ NCI BBRB pT0 (colon) pTis (colon) A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating carcinoma in situ (intraepithelial or invasion of lamina propria). Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ NCI BBRB pTis (colon) pT1 (colon) A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor invades submucosa. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ NCI BBRB pT1 (colon) pT2 (colon) A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor invades muscularis propria. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ NCI BBRB pT2 (colon) pT3 (colon) A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor invades subserosa or into non-peritionealized pericolic or perirectal tissues. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ NCI BBRB pT3 (colon) pT4a (colon) A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor perforates visceral peritoneum. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ NCI BBRB pT4a (colon) pT4b (colon) A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor directly invades other organs or structures. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ NCI BBRB pT4b (colon) pT0 (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that there is no evidence of primary tumor. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT0 (lung) pTis (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating carcinoma in situ. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pTis (lung) pT1 (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT1 (lung) pT1a (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is 2 cm or less in greatest dimension. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT1a (lung) pT1b (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 2 cm but not more than 3 cm in greatest dimension. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT1b (lung) pT2 (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 3 cm but not more than 7 cm or the tumor has any of the following features: involves main bronchus, 2 cm or more distal to the carina, invades visceral pleura, associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT2 (lung) pT2a (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 3 cm but not more than 5 cm in greatest dimension. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT2a (lung) pT2b (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 5 cm but not more than 7 cm in greatest dimension. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT2b (lung) pT3 (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 7 cm or one that directly invades any of: parietal pleura, chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardiu or the tumor is in the main bronchus less than 2 cm distal to the carina but without involvement of the carina or there is associated atelectasis or obstructive pneumonitis of the entire lung or there is separate tumor nodule(s) in the same lobe as the primary. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT3 (lung) pT4 (lung) A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina or there is separate tumor nodule(s) in a different ipsilateral lobe to that of the primary. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ NCI BBRB pT4 (lung) pT0 (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that there is no evidence of primary tumor. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT0 (kidney) pT1 (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is 7 cm or less in greatest dimension and limited to the kidney. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT1 (kidney) pT1a (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is 4 cm or less. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT1a (kidney) pT1b (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 4 cm but not more than 7 cm. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT1b (kidney) pT2 (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 7 cm in greatest dimension and limited to the kidney. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT2 (kidney) pT2a (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 7 cm but not more than 10 cm. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT2a (kidney) pT2b (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 10 cm and limited to the kidney. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT2b (kidney) pT3 (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond the Gerota fascia. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT3 (kidney) pT3a (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or the tumor invades perirenal and/or renal sinus fat (peripelvic) fat but not beyond Gerota fascia. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT3a (kidney) pT3b (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor grossly extends into vena cava below diaphragm. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT3b (kidney) pT3c (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor grossly extends into vena cava above the diaphragm or Invades the wall of the vena cava. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT3c (kidney) pT4 (kidney) A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor invades beyond Gerota fascia (including contiguous extension into the ipsilateral adrenal gland). Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ NCI BBRB pT4 (kidney) pT0 (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that there is no evidence of primary tumor. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT0 (ovary) pT1 (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to the ovaries (one or both). Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT1 (ovary) pT1a (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to one ovary; capsule intact, no tumor on ovarian surface and no malignant cells in ascites or peritoneal washings. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT1a (ovary) pT1b (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to both ovaries; capsule intact, no tumor on ovarian surface and no malignant cells in ascites or peritoneal washings. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT1b (ovary) pT1c (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to one or both ovaries with capsule ruptured, tumor on ovarian surface, or malignant cells in ascites or peritoneal washings. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT1c (ovary) pT2 (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor involves one or both ovaries with pelvic extension. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT2 (ovary) pT2a (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has extension and/or implants on uterus and/or tube(s) and no malignant cells in ascites or peritoneal washings. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT2a (ovary) pT2b (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has extension to other pelvic tissues and no malignant cells in ascites or peritoneal washings. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT2b (ovary) pT2c (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has pelvic extension with malignant cells in ascites or peritoneal washings. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT2c (ovary) pT3 (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT3 (ovary) pT3a (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has microscopic peritoneal metastasis beyond pelvis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT3a (ovary) pT3b (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has macroscopic peritoneal, metastatasis beyond pelvis, 2 cm or less in greatest dimension. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT3b (ovary) pT3c (ovary) A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has peritoneal metastasis beyond pelvis, more than 2 cm in greatest dimension and/or regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ NCI BBRB pT3c (ovary) pN0 (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating no regional lymph node metastsis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN0 (colon) pN1 (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 1-3 regional lymph nodes. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN1 (colon) pN1a (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 1 regional lymph node. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN1a (colon) pN1b (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 2-3 regional lymph nodes. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN1b (colon) pN1c (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating tumor deposit(s), i.e., satellites in the subserosa, or in non-peritonealized pericolic or perirectal soft tissue without regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN1c (colon) pN2 (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 4 or more regional lymph nodes. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN2 (colon) pN2a (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 4 to 6 regional lymph nodes. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN2a (colon) pN2b (colon) A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 7 or more regional lymph nodes. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ NCI BBRB pN2b (colon) pN0 (lung) A pathologic lymph node stage for lung according to AJCC 7th edition indicating no regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ NCI BBRB pN0 (lung) pN1 (lung) A pathologic lymph node stage for lung according to AJCC 7th edition indicating metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ NCI BBRB pN1 (lung) pN2 (lung) A pathologic lymph node stage for lung according to AJCC 7th edition indicating metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ NCI BBRB pN2 (lung) pN3 (lung) A pathologic lymph node stage for lung according to AJCC 7th edition indicating metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ NCI BBRB pN3 (lung) pN0 (kidney) A pathologic lymph node stage for kidney according to AJCC 7th edition indicating that there is no regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_n/ NCI BBRB pN0 (kidney) pN1 (kidney) A pathologic lymph node stage for kidney according to AJCC 7th edition indicating that there is regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_n/ NCI BBRB pN1 (kidney) pN0 (ovary) A pathologic lymph node stage for ovary according to AJCC 7th edition indicating that there is no regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_n/ NCI BBRB pN0 (ovary) pN1 (ovary) A pathologic lymph node stage for ovary according to AJCC 7th edition indicating that there is regional lymph node metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_n/ NCI BBRB pN1 (ovary) cM0 (colon) A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that there are no symptoms or signs of distant metastasis. Chris Stoeckert, Helena Ellis https://en.wikipedia.org/wiki/Cancer_staging#Pathological_M_Categorization_.28cM_and_pM.29 NCI BBRB cM0 (colon) cM1 (colon) A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that there is clinical evidence of distant metastases by history, physical examination, imaging studies, or invasive procedures, but without microscopic evidence of the presumed distant metastases. Chris Stoeckert, Helena Ellis https://en.wikipedia.org/wiki/Cancer_staging#Pathological_M_Categorization_.28cM_and_pM.29 NCI BBRB cM1 (colon) cM1a (colon) A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is confined to one organ based on clinical assessment. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ NCI BBRB cM1a (colon) cM1b (colon) A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is in more than one organ or the peritoneum based on clinical assessment. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ NCI BBRB cM1b (colon) pM1 (colon) A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that there is microscopic evidence confirming distant metastatic disease. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ NCI BBRB pM1 (colon) pM1a (colon) A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is confined to one organ and histologically confirmed. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ NCI BBRB pM1a (colon) pM1b (colon) A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is in more than one organ or the peritoneum and histologically confirmed. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ NCI BBRB pM1b (colon) cM0 (lung) A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is no distant metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ NCI BBRB cM0 (lung) cM1 (lung) A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there are distant metastases based on clinical assessment. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ NCI BBRB cM1 (lung) cM1a (lung) A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that metastasis is based on clinical assessment and a separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules OR malignant pleural or pericardial effusion. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ NCI BBRB cM1a (lung) cM1b (lung) A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is a distant metastases based on clinical assessment. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ NCI BBRB cM1b (lung) pM1 (lung) A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is a distant metastases that is histologically confirmed. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ NCI BBRB pM1 (lung) pM1a (lung) A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that metastasis is histologically confirmed and a separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules OR malignant pleural or pericardial effusion. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ NCI BBRB pM1a (lung) pM1b (lung) A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is a distant metastases that is histologically confirmed and associated with distant lymph nodes or carcinomatosis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ NCI BBRB pM1b (lung) cM0 (kidney) A pathologic distant metastases stage for kidney according to AJCC 7th edition indicating that there is no distant metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_m/ NCI BBRB cM0 (kidney) cM1 (kidney) A pathologic distant metastases stage for kidney according to AJCC 7th edition indicating that there are distant metastases based on clinical assessment. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_m/ NCI BBRB cM1 (kidney) pM1 (kidney) A pathologic distant metastases stage for kidney according to AJCC 7th edition indicating that there is a distant metastases that is histologically confirmed. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_m/ NCI BBRB pM1 (kidney) cM0 (ovary) A pathologic distant metastases stage for ovary according to AJCC 7th edition indicating that there is no distant metastasis. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_m/ NCI BBRB cM0 (ovary) cM1 (ovary) A pathologic distant metastases stage for ovary according to AJCC 7th edition indicating that there is distant metastasis except peritoneal metastasis based on clinical assessment. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_m/ NCI BBRB cM1 (ovary) pM1 (ovary) A pathologic distant metastases stage for ovary according to AJCC 7th edition indicating that there is distant metastasis except peritoneal metastasis that is histologically confirmed. Chris Stoeckert, Helena Ellis https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_m/ NCI BBRB pM1 (ovary) Occult Carcinoma (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating a small carcinoma, either asymptomatic or giving rise to metastases without symptoms due to the primary carcinoma. Chris Stoeckert, Helena Ellis Occult Carcinoma http://www.medilexicon.com/dictionary/14371 NCI BBRB Occult Carcinoma (AJCC 7th) Stage 0 (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating a carcinoma in situ (or melanoma in situ for melanoma of the skin or germ cell neoplasia in situ for testicular germ cell tumors) and generally is considered to have no metastatic potential. Chris Stoeckert, Helena Ellis Stage 0 https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage 0 (AJCC 7th) Stage I (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers that are smaller or less deeply invasive without regional disease or nodes. Chris Stoeckert, Helena Ellis Stage I https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage I (AJCC 7th) Stage IIA (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent but less than in Stage III and with differing characteristics from IIB and IIC. Chris Stoeckert, Helena Ellis Stage IIA https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IIA (AJCC 7th) Stage IIB (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent but less than in Stage III and with differing characteristics from IIA and IIC. Chris Stoeckert, Helena Ellis Stage IIB https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IIB (AJCC 7th) Stage IIC (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent but less than in Stage III and with differing characteristics from IIA and IIB. Chris Stoeckert, Helena Ellis Stage IIC https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IIC (AJCC 7th) Stage IIIA (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent greater than in Stage II and with differing characteristics from IIIB and IIIC. Chris Stoeckert, Helena Ellis Stage IIIA https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IIIA (AJCC 7th) Stage IIIB (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent greater than in Stage II and with differing characteristics from IIIA and IIIC. Chris Stoeckert, Helena Ellis Stage IIIB https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IIIB (AJCC 7th) Stage IIIC (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent greater than in Stage II and with differing characteristics from IIIA and IIIB. Chris Stoeckert, Helena Ellis Stage IIIC https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IIIC (AJCC 7th) Stage IVA (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers in patients who present with distant metastases at diagnosis and with differing characteristics from IVB. Chris Stoeckert, Helena Ellis Stage IVA https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IVA (AJCC 7th) Stage IVB (AJCC 7th) A clinical tumor stage group according to AJCC 7th edition indicating cancers in patients who present with distant metastases at diagnosis and with differing characteristics from IVA. Chris Stoeckert, Helena Ellis Stage IVB https://en.wikipedia.org/wiki/Cancer_staging NCI BBRB Stage IVB (AJCC 7th) Stage IA (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion <5 mm and the largest extension <7 mm. Chris Stoeckert, Helena Ellis Stage IA https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IA (FIGO) Stage IA1 (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating measured stromal invasion of <3.0 mm in depth and extension of <7.0 mm. Chris Stoeckert, Helena Ellis Stage IA1 https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IA1 (FIGO) Stage IA2 (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating measured stromal invasion of >3.0 mm and not >5.0 mm with an extension of not >7.0 mm. Chris Stoeckert, Helena Ellis Stage IA2 https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IA2 (FIGO) Stage IB (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA Chris Stoeckert, Helena Ellis Stage IB https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IB (FIGO) Stage IB1 (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating clinically visible lesion limited to the cervix uteri or pre-clinical cancers greater than stage IA <4.0 cm in greatest dimension. Chris Stoeckert, Helena Ellis Stage IB1 https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IB1 (FIGO) Stage IB2 (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating clinically visible lesion limited to the cervix uteri or pre-clinical cancers greater than stage IA >4.0 cm in greatest dimension. Chris Stoeckert, Helena Ellis Stage IB2 https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IB2 (FIGO) Stage IIA (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina without parametrial invasion. Chris Stoeckert, Helena Ellis Stage IIA https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IIA (FIGO) Stage IIA1 (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina without parametrial invasion and clinically visible lesion <4.0 cm in greatest dimension. Chris Stoeckert, Helena Ellis Stage IIA1 https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IIA1 (FIGO) Stage IIA2 (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina without parametrial invasion and clinically visible lesion >4.0 cm in greatest dimension. Chris Stoeckert, Helena Ellis Stage IIA2 https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IIA2 (FIGO) Stage IIB (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina with obvious parametrial invasion. Chris Stoeckert, Helena Ellis Stage IIB https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IIB (FIGO) Stage IIIA (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating tumour involves lower third of the vagina, with no extension to the pelvic wall. Chris Stoeckert, Helena Ellis Stage IIIA https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IIIA (FIGO) Stage IIIB (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating extension to the pelvic wall and/or hydronephrosis or non-functioning kidney. Chris Stoeckert, Helena Ellis Stage IIIB https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IIIB (FIGO) Stage IVA (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating spread of the growth to adjacent organs. Chris Stoeckert, Helena Ellis Stage IVA https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IVA (FIGO) Stage IVB (FIGO) An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating spread to distant organs. Chris Stoeckert, Helena Ellis Stage IVB https://en.wikipedia.org/wiki/Cervical_cancer_staging NCI BBRB Stage IVB (FIGO) Stage 1 (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1, N0, and M0. Chris Stoeckert, Helena Ellis Stage 1 https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 1 (FIGO) Stage 1A (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1a, N0, and M0. Chris Stoeckert, Helena Ellis Stage 1A https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 1A (FIGO) Stage 1B (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1b, N0, and M0. Chris Stoeckert, Helena Ellis Stage 1B https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 1B (FIGO) Stage 1C (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1c, N0, and M0. Chris Stoeckert, Helena Ellis Stage 1C https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 1C (FIGO) Stage 2 (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2, N0, and M0. Chris Stoeckert, Helena Ellis Stage 2 https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 2 (FIGO) Stage 2A (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2a, N0, and M0. Chris Stoeckert, Helena Ellis Stage 2A https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 2A (FIGO) Stage 2B (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2b, N0, and M0. Chris Stoeckert, Helena Ellis Stage 2B https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 2B (FIGO) Stage 2C (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2c, N0, and M0. Chris Stoeckert, Helena Ellis Stage 2C https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 2C (FIGO) Stage 3 (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of (T3, N0, and M0) or (T3,3a,3b, NX, and M0). Chris Stoeckert, Helena Ellis Stage 3 https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 3 (FIGO) Stage 3A (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T3a, N0, and M0 . Chris Stoeckert, Helena Ellis Stage 3A https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 3A (FIGO) Stage 3B (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T3b, N0, and M0 . Chris Stoeckert, Helena Ellis Stage 3B https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 3B (FIGO) Stage 3C (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of (T3c, N0,X and M0) or (any T, N1 and M0). Chris Stoeckert, Helena Ellis Stage 3C https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 3C (FIGO) Stage 4 (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of any T, any N, and M1. Chris Stoeckert, Helena Ellis Stage 4 https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage 4 (FIGO) Stage Unknown (FIGO) A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of (T0, N0, and M0) or (T1,1a-1c,2,2a-2c, NX, and M0) or (TX, N0,X, M0). Chris Stoeckert, Helena Ellis Stage Unknown https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ NCI BBRB Stage Unknown (FIGO) 3: symptomatic in bed more than 50% of the day but not bed ridden An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic and in bed for more than 50% of the day but is not bed ridden. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 3: symptomatic in bed more than 50% of the day but not bed ridden 2: symptomatic but in bed less than 50% of the day An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic but is in bed for less than 50% of the day. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 2: symptomatic but in bed less than 50% of the day 4: bed ridden An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic and is bed ridden. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 4: bed ridden 0: asymptomatic An Eastern Cooperative Oncology Group score value specification indicating a patient is asymptomatic. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 0: asymptomatic 1: symptomatic but fully ambulatory An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic but is fully ambulatory. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 1: symptomatic but fully ambulatory 100: asymptomatic A Karnofsky score vaue specification indicating that a patient is asymptomatic. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 100: asymptomatic 80-90: symptomatic but fully ambulatory A Karnofsky score vaue specification indicating that a patient is symptomatic but fully ambulatory. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 80-90: symptomatic but fully ambulatory 60-70: symptomatic but in bed less than 50% of the day A Karnofsky score vaue specification indicating that a patient is symptomatic but in bed less than 50% of the day. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 60-70: symptomatic but in bed less than 50% of the day 40-50: symptomatic, in bed more than 50% of the day, but not bed ridden A Karnofsky score vaue specification indicating that a patient is symptomatic, in bed more than 50% of the day, but not bed ridden. Chris Stoeckert, Helena Ellis NCI BBRB, OBI NCI BBRB 40-50: symptomatic, in bed more than 50% of the day, but not bed ridden Oxford Nanopore Technologies An organization that is developing and selling nanopore sequencing products and is based in the UK. James A. Overton https://en.wikipedia.org/wiki/Oxford_Nanopore_Technologies Oxford Nanopore Technologies BioGents An organization that manufactures mosquito traps and other mosquito control products. John Judkins WEB:https://eu.biogents.com/about-biogents/ BioGents Abbott A manufacturer of rapid point-of-care assay devices. John Judkins ORCID:0000-0001-6595-0902 WEB:https://www.globalpointofcare.abbott/en/about.html https://github.com/obi-ontology/obi/issues/1456 Abbott J. Mitra A manufacturer of in vitro diagnostic assay kits in India. John Judkins ORCID:0000-0001-6595-0902 WEB:https://jmitra.co.in/about-us/ https://github.com/obi-ontology/obi/issues/1456 J. Mitra InBios A manufacturer that specializes in in vitro diagnostic devices designed to test for infectious diseases. John Judkins ORCID:0000-0001-6595-0902 WEB:https://inbios.com/about/ https://github.com/obi-ontology/obi/issues/1456 InBios The term was added to the ontology on the assumption it was in scope, but it turned out later that it was not. This obsolesence reason should be used conservatively. Typical valid examples are: un-necessary grouping classes in disease ontologies, a phenotype term added on the assumption it was a disease. https://github.com/information-artifact-ontology/ontology-metadata/issues/77 https://orcid.org/0000-0001-5208-3432 out of scope axiom holds for all times ## Elucidation This is used when the statement/axiom is assumed to hold true 'eternally' ## How to interpret (informal) First the "atemporal" FOL is derived from the OWL using the standard interpretation. This axiom is temporalized by embedding the axiom within a for-all-times quantified sentence. The t argument is added to all instantiation predicates and predicates that use this relation. ## Example Class: nucleus SubClassOf: part_of some cell forall t : forall n : instance_of(n,Nucleus,t) implies exists c : instance_of(c,Cell,t) part_of(n,c,t) ## Notes This interpretation is *not* the same as an at-all-times relation axiom holds for all times ## Elucidation This is used when the first-order logic form of the relation is binary, and takes no temporal argument. ## Example: Class: limb SubClassOf: develops_from some lateral-plate-mesoderm forall t, t2: forall x : instance_of(x,Limb,t) implies exists y : instance_of(y,LPM,t2) develops_from(x,y) relation has no temporal argument pH A dimensionless concentration notation which denotes the acidity of a solution in terms of activity of hydrogen ions (H+). pH SVN $Revision: 717 $ IAO Release 2015-02-23 An analog medium for magnetic recording of audio and video information, made of a thin magnetizable coating on a long, narrow plastic tape, typically wound on a spool. analog magnetic tape A non-rewritable optical disc used to store digital data. CD compact disk A distributed and commoditized Internet-based computing resource, whereby shared services, software programs, and information storage facilities are provided to computers and other devices on demand, at locations of which the user may be unaware, like the electricity grid. cloud A rewritable digital medium for magnetic recording of audio, video and other data, made of a thin magnetizable coating on a long, narrow strip of plastic, usually wound on a spool. digital magnetic tape A non-rewritable optical disc storage medium resembling a compact disc (CD), usually used for video and data storage. A DVD has the same physical dimensions as a CD, but is capable of storing more than six times as much data. DVD digital versatile disc digital video disc A thin flexible strip of plastic or other material coated with light-sensitive emulsion upon which images can be recorded, typically using a camera, usually used to record photographic images or motion pictures. film A rewritable data storage medium that is composed of a disk of thin, flexible (floppy) magnetic storage medium encased in a square or rectangular plastic shell. Data are encoded magnetically by a read/write head that float on a cushion of air in close proximity to the surface of the rotated disk. floppy disk A non-volatile storage device for digital data, composed of one or more rigid discs (platters) mounted side by side on a motor-driven spindle within a metal case. Data are encoded magnetically by read/write heads that float on cushions of air in close proximity to the surfaces of the rotated platters. HD hard drive A global system of interconnected computer networks that uses the standard Internet Protocol Suite (TCP/IP) to serve billions of users worldwide. The internet connects millions of private, public, academic, business and governmental computers, that are individually attached to local networks linked together by a broad array of electronic, radio and optical networking technologies to form the internet. internet A private computer network, unconnected to the internet or separated from it by a firewall, that uses a network operating system and Internet Protocol technologies to permit an organization's information to be shared securely within that organization. intranet A thin flat material, typically made from wood pulp, mainly used for writing upon, for printing upon or for packaging. paper Abbreviation of Random Access Memory. A form of rewritable computer data storage that takes the form of integrated circuits that allow data to be stored and accessed in any order (i.e. at random), thereby achieving greater speed than for access of data stored in linear form on digital magnetic tape. RAM random access memory A digital storage device built entirely from solid electronic materials with no moving parts, e.g. a USB flash drive. solid state memory An analog sound storage medium consisting of a flat disc made of moulded vinyl plastic with an inscribed, modulated spiral groove. vinyl disk A system of interlinked hypertext documents written in HTML and accessed using the HTTP protocol via the Internet. WWW Web World Wide Web third planet from the Sun in the Solar System Earth third planet from the Sun in the Solar System https://www.wikidata.org/wiki/Q2 "Suni, or Jalca, is one of the eight Natural Regions of Peru. It is located in the Andes at an altitude between 3,500 and 4,000 metres above sea level. Suni has a dry and cold weather and there are many glacial valleys. The flora includes gramineous plants and shrubs such as the taya-taya (Caesalpinia spinosa), the quishuar (Buddleja coriacea), and the cantuta (Cantua buxifolia) which was considered sacred by the Incas. Even though it is hard for plants to grow because of the weather, people are able to cultivate such crops as quinoa, qañiwa, broad beans and ulluku (Ullucus tuberosus). The main fauna is the guinea pig and, among numerous other highland birds, the Chiguanco thrush." Jalca Suni "Suni, or Jalca, is one of the eight Natural Regions of Peru. It is located in the Andes at an altitude between 3,500 and 4,000 metres above sea level. Suni has a dry and cold weather and there are many glacial valleys. The flora includes gramineous plants and shrubs such as the taya-taya (Caesalpinia spinosa), the quishuar (Buddleja coriacea), and the cantuta (Cantua buxifolia) which was considered sacred by the Incas. Even though it is hard for plants to grow because of the weather, people are able to cultivate such crops as quinoa, qañiwa, broad beans and ulluku (Ullucus tuberosus). The main fauna is the guinea pig and, among numerous other highland birds, the Chiguanco thrush." https://en.wikipedia.org/wiki/Suni_(geography) Sun Sol Earth's interconnected water system World Ocean Earth's interconnected water system https://www.wikidata.org/wiki/Q715269 Wikipedia:Eparterial_bronchus https://github.com/obophenotype/uberon/issues/119 Wikipedia:Capitate_bone FBC:VH GO:0021729 MP:0009999 HP:0005289 GO:0003226 https://sourceforge.net/tracker/?func=detail&aid=3580301&group_id=76834&atid=1205376 Wikipedia:Persistent_left_superior_vena_cava https://github.com/obophenotype/uberon/issues/6 https://github.com/obophenotype/uberon/issues/7 Wikipedia:External_sphincter_muscle_of_female_urethra Wikipedia:External_sphincter_muscle_of_male_urethra GO:dph Wikipedia:Hypoblast ZFIN:cvs https://sourceforge.net/p/geneontology/ontology-requests/9676/ Wikipedia:Atlas_(anatomy)#Vertebral_foramen Wikipedia:Coat_(animal) EFO:0000240 Wikipedia:Rattlesnake#Rattle Wikipedia:Anal_gland UBERON:CL_meeting_20110725 http://retina.anatomy.upenn.edu/~lance/eye/retina_gross.html GO:0060682 Wikipedia:Hamate_bone Wikipedia:Proper_plantar_digital_arteries Wikipedia:Trapezium_(bone) https://sourceforge.net/tracker/?func=detail&aid=3123598&group_id=76834&atid=1205376 FBC:DOS FBC:VH GO:0072166 MP:0009996 Wikipedia:Superior_olivary_complex#Dorsal_periolivary_nucleus_.28DPO.29 http://www.ana.ed.ac.uk/database/humat/notes/extraemb/mesoder.htm FlyBase:FBrf0007733 FlyBase:FBrf0064792 GO:0003291 GO:0021729 GO_REF:0000021 Wikipedia:Neurofilament FBC:DOS Wikipedia:Corpus_cavernosum Wikipedia:Brodmann_area_39 Wikipedia:Adductor_muscles_of_the_hip Wikipedia:Pouch_(marsupial) http://people.eku.edu/ritchisong/feather_evolution.htm PMID:21558186 FlyBase:FBrf0089570 PHENOSCAPE:alex neuronames:3223 Wikipedia:Trapezoid_bone Wikipedia:Pisiform_joint ISBN:0073040584 PMID:23027930 BIRNLEX:1732 Wikipedia:Iris_muscle Wikipedia:Gastric_juice BIRNLEX:1734 GO:0003227 MP:0009988 Wikipedia:Node_of_ranvier ISBN:0073040584 FBC:VH MP:0010003 MP:0009946 MP:0009364 Wikipedia:Enteric_ganglia HP:0000606 Wikipedia:Pronucleus MP:0009990 PMID:21558186 Wikipedia:Brodmann_area_28 Wikipedia:Lumbar_spinal_cord Wikipedia:Brodmann_area_18 ISBN:0073040584 Wikipedia:Facial_skeleton https://sourceforge.net/tracker/?func=detail&atid=440764&aid=3413098&group_id=36855 Wikipedia:Aquatic_predation#Lunge_feeding GO:0061214 GO:0072003 neuronames:3214 PMCID:PMC2093943 http://people.eku.edu/ritchisong/feather_evolution.htm MP:0010002 GO:0061249 GO:0021728 Wikipedia:Intermediate_filament FBC:DOS FBC:VH FlyBase:FBrf0002482 FlyBase:FBrf0007196 FlyBase:FBrf0007735 FlyBase:FBrf0034076 PMID:20557782 PMID:20566102 PMID:14595018 https://sourceforge.net/tracker/?func=detail&aid=3123600&group_id=76834&atid=1205376 MP:0009989 GO:0003285 Wikipedia:Septum_secondum FBC:DOS FBC:VH Wikipedia:Articular https://github.com/obophenotype/uberon/issues/98 ISBN:0073040584 https://github.com/obophenotype/uberon/issues/1264 BIRNLEX:1755 https://github.com/obophenotype/uberon/issues/1161 neuronames:3218 HP:0000864 Wikipedia:Dorsal_digital_arteries# FBC:DOS Wikipedia:Digestive_system_of_gastropods#Hepatopancreas PMID:23027930 Wikipedia:Pancreaticoduodenal_artery Wikipedia:Flight_feather Wikipedia:Common_plantar_digital_arteries PMID:21558186 neuronames:3220 http://orcid.org/0000-0002-6601-2165 PMID:23153189 http://dev.biologists.org/content/128/22/4573.full GO:0003225 Wikipedia:Internal_spermatic_fascia MP:0009997 Wikipedia:Sclera#Histology Wikipedia:Brodmann_area_9 PMID:22622577 FBC:VH Wikipedia:Brodmann_area_26 http://purl.obolibrary.org/obo/uberon/docs/Connectivity-Design-Pattern GO:0003224 Wikipedia:Pterion HP:0003832 PMID:21558186 MP:0009993 FBC:DOS FBC:VH PHENOSCAPE:alex GO:0072165 HP:0003350 Wikipedia:Snout http://www.embryology.ch/anglais/turinary/urinhaute03.html https://github.com/obophenotype/mouse-anatomy-ontology/issues/56 PHENOSCAPE:Wasila neuronames:3221 http://purl.obolibrary.org/obo/uberon/docs/Connectivity-Design-Pattern Wikipedia:Temporomandibular_joint#Ligaments http://purl.obolibrary.org/obo/uberon/docs/Connectivity-Design-Pattern FBC:DOS GO:0021751 FlyBase:FBrf0006943 MP:0009994 Wikipedia:Epicondyle Wikipedia:Primordial_phallus https://sourceforge.net/tracker/?func=detail&aid=3515562&group_id=76834&atid=994726 10.0 Egon Willighagen Gareth Owen Janna Hastings Javier Millan Acosta Jiakang Chang Nina Jeliazkova The eNanoMapper Consortium The eNanoMapper project (https://www.enanomapper.net/), NanoCommons project (https://www.nanocommons.eu/) and ACEnano project (http://acenano-project.eu/) are creating a pan-European computational infrastructure for toxicological data management for ENMs, based on semantic web standards and ontologies. This ontology is an application ontology targeting the full domain of nanomaterial safety assessment. It re-uses several other ontologies including the NPO, CHEMINF, ChEBI, and ENVO. eNanoMapper ontology The eNanoMapper project (www.enanomapper.net) is creating a pan-European computational infrastructure for toxicological data management for ENMs, based on semantic web standards and ontologies. This ontology is an application ontology targeting the full domain of nanomaterial safety assessment. It re-uses several other ontologies including the NPO, CHEMINF, ChEBI, and ENVO. Ali Ayadi Denise Slenter Egon Willighagen Friederike Ehrhart Gareth Owen Haralambos Sarimveis Janna Hastings Javier Millan Acosta Jiakang Chang Laurent Winckers Linda Rieswijk NanoinformaTIX - Development and Implementation of a Sustainable Modelling Platform for NanoInformatics (Grant Agreement 814426) Consortium Nina Jeliazkova Oana Florean Philip Doganis The ACEnano - Analytical and Characterisation Excellence in nanomaterial risk assessment: A tiered approach (Grant Agreement 720952) Consortium The NanoCommons Consortium The RiskGONE Consortium The eNanoMapper Consortium The eNanoMapper project (https://www.enanomapper.net/), NanoCommons project (https://www.nanocommons.eu/) and ACEnano project (http://acenano-project.eu/) are creating a pan-European computational infrastructure for toxicological data management for ENMs, based on semantic web standards and ontologies. This ontology is an application ontology targeting the full domain of nanomaterial safety assessment. It re-uses several other ontologies including the NPO, CHEMINF, ChEBI, and ENVO. CC-BY 3.0 https://creativecommons.org/licenses/by/3.0/ eNanoMapper ontology The eNanoMapper project (https://www.enanomapper.net/), NanoCommons project (https://www.nanocommons.eu/) and ACEnano project (http://acenano-project.eu/) are creating a pan-European computational infrastructure for toxicological data management for ENMs, based on semantic web standards and ontologies. This ontology is an application ontology targeting the full domain of nanomaterial safety assessment. It re-uses several other ontologies including the NPO, CHEMINF, ChEBI, and ENVO. 10.0 Egon Willighagen Javier Millan Acosta Laurent Winckers CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ This ontology contains proposed extensions to the Basic Formal ON, which in due course will be submitted to the BFO. Laurent Winckers CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ This ontology contains proposed extensions to the Chemical Entities of Biological Interest, which in due course will be submitted to the ChEBI. Laurent Winckers CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ This ontology contains proposed extensions to the Chemical Methods Ontology, which in due course will be submitted to the CHMO. Egon Willighagen Janna Hastings Laurent Winckers Nina Jeliazkova These toxicological endpoints correspond to those listed in the OECD Harmonized Templates and associated guidelines for determining the toxicological effects of substances. This file is part of the eNanoMapper ontology project (http://www.enanomapper.net/) Egon Willighagen Jiakang Chang This file is part of the eNanoMapper ontology project (http://www.enanomapper.net/) Javier Millan Acosta This ontology contains proposed extensions to the NanoParticle Ontology, which in due course will be submitted to the NPO. Javier Millan Acosta Laurent Winckers CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ This ontology contains proposed extensions to the Ontology for Biomedical Investigations, which in due course will be submitted to the OBI. Laurent Winckers CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ This ontology contains proposed extensions to the Phenotype And Trait Ontology, which in due course will be submitted to the PATO. Egon Willighagen Person:Alan Ruttenberg A property representing a two or three character abbreviation that indicates the nature of each FULL_SYN term associated with a concept. (e.g., PT=Preferred Term; SY=Synonym) A property representing a two or three character abbreviation that indicates the nature of each FULL_SYN term associated with a concept. (e.g., PT=Preferred Term; SY=Synonym) NCI Hahn-Dantona, Elizabeth 2018-11-07 A property representing the organization that is the supplier or owner of each FULL_SYN term. A property representing the organization that is the supplier or owner of each FULL_SYN term. NCI Hahn-Dantona, Elizabeth 2018-11-07 Human Phenotype Ontology Consortium Monarch Initiative Peter Robinson Sebastian Köhler 05/09/2013 8 Jul 2021 The Human Phenotype Ontology (HPO) provides a standardized vocabulary of phenotypic abnormalities and clinical features encountered in human disease. Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* Peter Robinson, Sebastian Koehler, The Human Phenotype Ontology Consortium, and The Monarch Initiative Phenotypic abnormalities encountered in human disease Human Phenotype Ontology https://raw.githubusercontent.com/enanomapper/aop-ontology/patch/hpoUpdate/aopo.owl Slimmer 09:06:2022 14:24 2022-08-11 21:08:09 chebi_ontology human_phenotype 1.2 has_part Peter Robinson, Sebastian Koehler, Sandra Doelken, Chris Mungall, Melissa Haendel, Nicole Vasilevsky, Monarch Initiative, et al. chebi Author: ChEBI curation team ChEBI Release version 211 ChEBI subsumes and replaces the Chemical Ontology first Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* For any queries contact chebi-help@ebi.ac.uk Please see license of HPO at http://www.human-phenotype-ontology.org There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. contact: Stephan Schurer: stephan dot schurer at gmail dot com created by: Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* developed by Michael Ashburner & Pankaj Jaiswal. BAO BioAssay Ontology bioassay ontology 2.1 2.7.2 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. 8 Jul 2021 http://bioassayontology.org/bao/bao_complete_merged.owl Slimmer 2023-07-12 12:46:47 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology bioassay ontology 2.7.2 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. BFO 2 Reference: BFO does not claim to be a complete coverage of all entities. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning – coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation [17 BFO 2 Reference: BFO’s treatment of continuants and occurrents – as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality – earlier called the ‘SNAP’ and ‘SPAN’ perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science [30 BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. ‘Entity’ is an example of one such primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. Alan Ruttenberg Albert Goldfain Barry Smith Bill Duncan Bjoern Peters Chris Mungall David Osumi-Sutherland Fabian Neuhaus James A. Overton Janna Hastings Jie Zheng Jonathan Bona Larry Hunter Leonard Jacuzzo Ludger Jansen Mark Ressler Mathias Brochhausen Mauricio Almeida Melanie Courtot Pierre Grenon Randall Dipert Robert Rovetto Ron Rudnicki Stefan Schulz Thomas Bittner Werner Ceusters http://purl.obolibrary.org/obo/bfo/classes-only.owl Slimmer 2023-07-12 12:46:50 The http://purl.obolibary.org/obo/bfo/classes-only.owl variant of BFO ("bfo_classes_only.owl") includes only the class hierarchy and annotations from the full OWL version of BFO 2: http://purl.obolibary.org/obo/bfo.owl ("bfo.owl"). There are no object properties or logical axioms that use the object properties in bfo_classes_only.owl. As the logical axioms in the bfo_classes_only.owl variant are limited to subclass and disjoint assertions they are much weaker than the logical axioms in bfo.owl. If you plan to use the relations that define BFO 2, you should import bfo.owl instead of bfo_classes_only.owl. To the extent that the relations are used without importing bfo.owl, be mindful that they should be used in a manner consistent with their use in bfo.owl. Otherwise if your ontology is imported by a another ontology that imports bfo.owl there may be inconsistencies. See the BFO 2 release notes for further information about BFO 2. Please note that the current release of bfo.owl uses temporal relations when the subject or object is a continuant, a major change from BFO 1. This is an early version of BFO version 2 and has not yet been extensively reviewed by the project team members. Please see the project site http://code.google.com/p/bfo/ , the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel , the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx . This ontology is generated from a specification at http://bfo.googlecode.com/svn/trunk/src/ontology/owl-group/specification/ and with the code that generates the OWL version in http://bfo.googlecode.com/svn/trunk/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. A structured controlled vocabulary for the source of an enzyme comprising tissues, cell lines, cell types and cell cultures. The BRENDA Tissue Ontology (BTO) https://creativecommons.org/licenses/by/4.0/ http://purl.obolibrary.org/obo/bto.owl OBO-Edit 2.3.1 Slimmer 2023-07-12 12:46:56 23:10:2021 16:56 BrendaTissueOBO 1.2 Marion This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. https://raw.githubusercontent.com/enanomapper/ontologies/master/internal/ccont-ext.owl Matthias Ganzinger, matthias.ganzinger@med.uni-heidelberg.de Slimmer 2023-07-12 12:46:58 cell culture ontology (CCONT) 1.1 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. http://ftp.ebi.ac.uk/pub/databases/chebi/ontology/chebi.owl Slimmer 2023-06-08 11:39:04 27:05:2023 19:23 chebi_ontology 1.2 chebi Author: ChEBI curation team ChEBI Release version 222 ChEBI subsumes and replaces the Chemical Ontology first For any queries contact chebi-help@ebi.ac.uk developed by Michael Ashburner & Pankaj Jaiswal. This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. en Adam Goldstein Alan Ruttenberg Albert Goldfain Barry Smith Bjoern Peters Carlo Torniai Chris Mungall Chris Stoeckert Christian A. Boelling Clint Dowland Colin Batchelor Cristian Munteanu Darren Natale David Osumi-Sutherland Egon Willighagen Evan Bolton Gang Fu Gwen Frishkoff Holger Stenzhorn James A. Overton James Malone Janna Hastings Jennifer Fostel Jie Zheng Jonathan Rees Larisa Soldatova Lawrence Hunter Leonid Chepelev Mark Davies Mathias Brochhausen Matt Brush Melanie Courtot Michel Dumontier Michel Dumontier Ola Spjuth Paolo Ciccarese Pat Hayes Philippe Rocca-Serra Randy Dipert Ron Rudnicki Satya Sahoo Sivaram Arabandi Werner Ceusters William Duncan William Hogan Yongqun (Oliver) He Michel Dumontier The Information Artifact Ontology (IAO) is an ontology of information entities, originally driven by work by the OBI digital entity and realizable information entity branch. application/rdf+xml en CDK descriptor algorithm implementations Information Artifact Ontology (IAO) Supporting terminology for chemical information ontology (cheminf) chemical information ontology (cheminf) - information entities about chemical entities http://creativecommons.org/publicdomain/zero/1.0/ http://semanticchemistry.github.io/semanticchemistry/ontology/cheminf.owl Slimmer 2023-07-12 12:47:02 An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO Document containing upporting external terms IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 The chemical information ontology (cheminf) describes information entities about chemical entities. It provides qualitative and quantitative attributes to richly describe chemicals. The chemical information ontology (cheminf) intends to describe information entities about chemical entities. It means to provide qualitative and quantitative attributes to richly describe chemicals. To develop the ontology, you must change the default auto-create settings in Protege 4. Go to file>preferences>New Entities. Change the following: specified URI = http://semanticscience.org/resource/ Followed by '/', End with : AutoID AutoID - digit count = 6, prefix = CHEMINF_ 1.9.2 2.1.0 2022-11-07 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. alpha CHMO, the chemical methods ontology, describes methods used to collect data in chemical experiments, such as mass spectrometry and electron microscopy prepare and separate material for further analysis, such as sample ionisation, chromatography, and electrophoresis synthesise materials, such as epitaxy and continuous vapour deposition It also describes the instruments used in these experiments, such as mass spectrometers and chromatography columns. It is intended to be complementary to the Ontology for Biomedical Investigations (OBI). Chemical Methods Ontology http://purl.obolibrary.org/obo/chmo.owl Slimmer 2023-07-12 13:30:32 1.2 batchelorc This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. An ontology of cell types. Cell Ontology http://purl.obolibrary.org/obo/cl.owl Slimmer 2023-07-12 13:30:48 See PMID:15693950, PMID:12799354, PMID:20123131, PMID:21208450; Contact Alexander Diehl, addiehl@buffalo.edu, University at Buffalo. 2023-06-22 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. 1.4 Gautier Koscielny Laura Huerta Martinez Olamidipupo Ajigboye Paola Roncaglia Trish Whetzel Zoe May Pendlington Copyright [2014] EMBL - European Bioinformatics Institute Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License. You may obtain a copy of the License at http://www.apache.org/licenses/LICENSE-2.0 Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License. www.apache.org/licenses/LICENSE-2.0 http://www.ebi.ac.uk/efo/efo.owl Catherine Leroy Dani Welter Drashtti Vasant Ele Holloway Eleanor Williams Emma Kate Hastings Helen Parkinson James Malone Jon Ison Natalja Kurbatova Simon Jupp Sirarat Sarntivijai Tomasz Adamusiak Slimmer 2023-07-12 13:37:44 2023-07-05 3.55.1 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. http://orcid.org/0000-0002-6601-2165 http://orcid.org/0000-0002-8343-612X http://orcid.org/0000-0003-1604-1512 ENVO is an ontology which represents knowledge about environments,environmental processes, ecosystems, habitats, and related entities The Environment Ontology http://purl.obolibrary.org/obo/envo.owl https://github.com/EnvironmentOntology/envo/ https://github.com/EnvironmentOntology/envo/issues/ Slimmer 2023-07-12 13:37:51 ENVO Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/chemical_concentration.owl>) VersionIRI(<null>))) [Axioms: 679 Logical Axioms: 119] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute.owl>) VersionIRI(<null>))) [Axioms: 206 Logical Axioms: 34] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute_location.owl>) VersionIRI(<null>))) [Axioms: 168 Logical Axioms: 29] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_quality_location.owl>) VersionIRI(<null>))) [Axioms: 40 Logical Axioms: 6] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/process_attribute.owl>) VersionIRI(<null>))) [Axioms: 21 Logical Axioms: 2] 2023-02-13 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. http://environmentontology.org/ David Shotton Paolo Ciccarese Tim Clark David Shotton Paolo Ciccarese Silvio Peroni 2016-07-11 2018-03-29 FaBiO, the FRBR-aligned Bibliographic Ontology, is an ontology for recording and publishing on the Semantic Web descriptions of entities that are published or potentially publishable, and that contain or are referred to by bibliographic references, or entities used to define such bibliographic references. FaBiO entities are primarily textual publications such as books, magazines, newspapers and journals, and items of their content such as poems, conference papers and editorials. However, they also include blogs, web pages, datasets, computer algorithms, experimental protocols, formal specifications and vocabularies, legal records, governmental papers, technical and commercial reports and similar publications, and also anthologies, catalogues and similar collections. FaBiO classes are structured according to the FRBR schema of Works, Expressions, Manifestations and Items. Additional properties have been added to extends the FRBR data model by linking Works and Manifestations (fabio:hasManifestation and fabio:isManifestationOf), Works and Items (fabio:hasPortrayal and fabio:isPortrayedBy), and Expressions and Items (fabio:hasRepresentation and fabio:isRepresentedBy). This vocabulary is an expression in OWL 2 DL of the basic concepts and relations described in the IFLA report on the Functional Requirements for Bibliographic Records (FRBR), also described in Ian Davis's RDF vocabulary (http://vocab.org/frbr/core). This work is distributed under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/). Essential FRBR in OWL2 DL FaBiO, the FRBR-aligned Bibliographic Ontology https://svn.code.sf.net/p/sempublishing/code/FaBiO/2016-07-11-fabio-1_9_3.owl fabio http://purl.org/spar/fabio/ Slimmer 2023-07-12 13:37:56 FaBiO, the FRBR-aligned Bibliographic Ontology, is an ontology for recording and publishing on the Semantic Web bibliographic records of scholarly endeavours. It forms part of SPAR, a suite of Semantic Publishing and Referencing Ontologies. Other SPAR ontologies are described at http://purl.org/spar/. This ontology is available at http://purl.org/spar/fabio, and uses the namespace prefix fabio. The Essential FRBR in OWL2 DL Ontology (FRBR) is an expression in OWL 2 DL of the basic concepts and relations described in the IFLA report on the Functional Requirements for Bibliographic Records (FRBR), also described in Ian Davis's RDF vocabulary. **URL:** http://purl.org/spar/frbr **Creators**: [Paolo Ciccarese](http://orcid.org/0000-0002-5156-2703), [Silvio Peroni](http://orcid.org/0000-0003-0530-4305) **Contributors:**: [David Shotton](http://orcid.org/0000-0001-5506-523X) **License:** [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/legalcode) **Website:** http://www.sparontologies.net/ontologies/frbr 1.0.1 1.9.3 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. The Gene Ontology (GO) provides a framework and set of concepts for describing the functions of gene products from all organisms. Gene Ontology http://purl.obolibrary.org/obo/go.owl Slimmer 2023-07-12 13:38:26 gene_ontology 1.2 2023-06-11 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. en Adam Goldstein Alan Ruttenberg Albert Goldfain Barry Smith Bjoern Peters Carlo Torniai Chris Mungall Chris Stoeckert Christian A. Boelling Clint Dowland Darren Natale David Osumi-Sutherland Gwen Frishkoff Holger Stenzhorn James A. Overton James Malone Jennifer Fostel Jie Zheng Jonathan Rees Larisa Soldatova Lawrence Hunter Mathias Brochhausen Matt Brush Melanie Courtot Michel Dumontier Paolo Ciccarese Pat Hayes Philippe Rocca-Serra Randy Dipert Ron Rudnicki Satya Sahoo Sivaram Arabandi Werner Ceusters William Duncan William Hogan Yongqun (Oliver) He The Information Artifact Ontology (IAO) is an ontology of information entities, originally driven by work by the OBI digital entity and realizable information entity branch. Information Artifact Ontology (IAO) http://purl.obolibrary.org/obo/iao.owl Slimmer 2023-07-12 13:38:32 An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 2022-11-07 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. en http://nmrml.org/examples/ This artefact is an MSI-approved controlled vocabulary primarily developed under COSMOS EU and PhenoMeNal EU governance. The nmrCV is supporting the nmrML XML format with standardized terms. nmrML is a vendor agnostic open access NMR raw data standard. Its primaly role is analogous to the mzCV for the PSI-approved mzML XML format. It uses BFO2.0 as its Top level. This CV was derived from two predecessors (The NMR CV from the David Wishart Group, developed by Joseph Cruz) and the MSI nmr CV developed by Daniel Schober at the EBI. This simple taxonomy of terms (no DL semantics used) serves the nuclear magnetic resonance markup language (nmrML) with meaningful descriptors to amend the nmrML xml file with CV terms. Metabolomics scientists are encouraged to use this CV to annotrate their raw and experimental context data, i.e. within nmrML. The approach to have an exchange syntax mixed of an xsd and CV stems from the PSI mzML effort. The reason to branch out from an xsd into a CV is, that in areas where the terminology is likely to change faster than the nmrML xsd could be updated and aligned, an externally and decentrallised maintained CV can accompensate for such dynamics in a more flexible way. A second reason for this set-up is that semantic validity of CV terms used in an nmrML XML instance (allowed CV terms, position/relation to each other, cardinality) can be validated by rule-based proprietary validators: By means of cardinality specifications and XPath expressions defined in an XML mapping file (an instances of the CvMappingRules.xsd ), one can define what ontology terms are allowed in a specific location of the data model. BFO 2 Reference: BFO does not claim to provide complete coverage of entities of all types. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning - coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation. BFO 2 Reference: BFO's treatment of continuants and occurrents - as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality - earlier called the 'SNAP' and 'SPAN' perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science. BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. 'Entity' is an example of a primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. In case we like to be able to convert this owl CV back into the obo format, we should only use DL/owl constructs that are supported by obo. Hence, editors of this CV should take care not to use any higher descriptrion logics semantics, i.e. cardinality restrictions or defined terms using constructors. We should start to build the taxonomic backbone first and later connect the main axis via relations. If we want to use restrictions, we should only use existential quantifiers as the OBO format does not support universal quantification. List of terms required by current XSD (August 2013): these were bookmarked in CV (annotation property) and are visible in the new nmrTab: CVTerm occurrences: buffer-->buffer solvent-->solvent concentration standard type-->calibration compound , what is chemical shift reference ? What calibration_reference_shift under calibration compound ? concentration standard name we here see a use-mention problem arising for the CV. The xsd should probably change here to avoid this. encoding method (Quadrature detection method) is this the same as encoding method ? sample container-->NMR_sample_holder (spectrum) y axis type-->coordinate system descriptor post acquisition solvent suppression method Two usages in xsd, but with differrent type ? -->solvent suppression method calibration compound Two usages in xsd, but with differrent type ?-->calibration compound data transformation method-->data transformation method (spectral) projection method-->projection method spectral denoising method-->spectral denoising method window function method-->window function method baseline correction method-->baseline correction sample type-->NMR sample CVParam occurrences: file content-->data file content software type-->software source file type-->data file attribute (needs refactoring) instrument configuration type-->instrument configuration processing method type-->data processing method CVParamType occurrences: chemical shift standard-->chemical shift standard solvent suppression method-->solvent suppression method encoding scheme (Quadrature detection method)-->encoding method window function parameter-->window function parameter CVParamWithUnitType occurrences: CVParamWithUnitType is currently not used in the xsd and dangling ! I assume ValueWithUnitType substitutes it ? UserParamType occurrences: No CV terms needed ValueWithUnitType occurrences: These will have to be used from the Unit ontology. Alan Ruttenberg Albert Goldfain Alejandra Gonzalez-Beltran Andrea Porzel Andrew Lane Annick Moing Barry Smith Bill Duncan Bjoern Peters Catherine Deborde Chris Mungall Chris Taylor Daniel Jacob Daniel Schober David Osumi-Sutherland David Wishart Dennis Rubtsov Fabian Neuhaus Helen Jenkins Holger Stenzhorn Hunter Moseley Irena Spasic James A. Overton Janna Hastings Jie Zheng Jonathan Bona Joseph Cruz Larissa Soldatova Larry Hunter Leonard Jacuzzo Ludger Jansen Mark Ressler Marta Cascante Mathias Brochhausen Mauricio Almeida Melanie Courtot Michael Wilson Pedro Ramon de Atauri Carulla Philippe Rocca-Serra Pierre Grenon Randall Dipert Reza Salek Ron Rudnicki Selja Seppälä Silvia Marin Since this is a prolonged effort spanning a larger time period, there naturally were many people involved in the creation over the years and during different times. People involved in the term creation from ID >1400000 : This part of the NMR ontology was originally developed by the ontology working group (http://msi-ontology.sourceforge.net/) of the msi-metabolomicssociety (msi-workgroups.sf.net): Dennis Rubtsov (Un of Cambridge, UK) Helen Jenkins (Un of Wales, Aberystwyth, UK) Irena Spasic (Center for Integrative Systems Biology, Manchester, UK) Larissa Soldatova (University of Wales, Aberystwyth, UK) Philippe Rocca-Serra (EBI and MGED Society) Susanna-Assunta Sansone (EBI) People involved in the term creation from ID<1400000: Joseph Cruz Daniel Schober Michael Wilson Reza Salek Daniel Jacob David Wishart Terms with IDs ID<1400000 that were NOT asserted in the original Wishart obo file were created by Daniel Schober (COSMOS WP2). Its IDs were autogenerated with the Protege ID generator. Other people that substantially helped in revising the latest and Cosmos governed CV additions were: Michael Wilson, Wishart Group, Edmonton, Alberta, Canada Daniel Jacob, INRA, Bordeaux, France Annick Moing, INRA, Bordeaux, France Catherine Deborde, INRA, Bordeaux, France Reza Salek, EBI, Hinxton, UK Philippe Rocca-Serra, University of Oxford, Oxford, UK Andrea Porzel, IPB-Halle, Germany and the COSMOS WP2 team A paper describing the overall nmrML data standard and CV has been accepted by Analytical Chemistry (Manuscript ID: ac-2017-02795f.R1), title `nmrML: a community supported open data standard for the description, storage, and exchange of NMR data`, author(s): Schober, Daniel; Jacob, Daniel; Wilson, Michael; Cruz, Joseph; Marcu, Ana; Grant, Jason; Moing, Annick; Deborde, Catherine; de Figueiredo, Luis; Haug, Kenneth; Rocca-Serra, Philippe; Easton, John; Ebbels, Timothy; Hao, Jie; Ludwig, Christian; Günther, Ulrich; Rosato, Antonio; Klein, Matthias; Lewis, Ian; Luchinat, Claudio; Jones, Andrew; Grauslys, Arturas; Larralde, Martin; Yokochi, Masashi; Kobayashi, Naohiro; Porzel, Andrea; Griffin, Julian; Viant, Mark; Wishart, David; Steinbeck, Christoph; Salek, Reza; Neumann, Steffen Stefan Schulz Steffen Neumann Susanna-Assunta Sansone Teresa Fan Thomas Bittner Vitaly Selivanov Werner Ceusters Yongqun "Oliver" He Nuclear magnetic resonance (NMR) data annotation as required by the msi sanctioned open access nmrML XML format developed by the COSMOS EU project. Philippe Rocca-Serra an application ontology for supporting description and annotation of mass-spectrometry and nmr-spectroscopy based metabolomics experiments and fluxomics studies. OWL OWL https://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/3.0/ Metabolomics Standards Initiative Ontology (MSIO) nuclear magnetic resonance CV https://raw.githubusercontent.com/jmillanacosta/MSIO/master/MSIO-edit.owl This CV is to be used by metabolomics researchers, or basically any chenomics or proteomics researchers who apply the nmrML xml to store their NMRraw data in a vendor agnostic manner. But nmrML can also be used to capture experimental results and (limited) basic metadata like molecule to spectral feature assignments. https://github.com/nmrML/nmrML/issues Daniel Schober https://github.com/nmrML/nmrML https://github.com/nmrML/nmrML/tree/master/ontologies https://groups.google.com/forum/?hl=en#!forum/nmrml/join http://www.metabolomics-msi.org/ http://phenomenal-h2020.eu/home/ http://www.cosmos-fp7.eu/WP2 OBO-Edit 2.2 Slimmer Daniel Schober 2017-10-19T10:11:26Z 2023-07-12 13:43:48 Please see the project site https://github.com/BFO-ontology/BFO, the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel, the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx. This ontology is generated from a specification at https://github.com/BFO-ontology/BFO/tree/master/src/ontology/owl-group/specification/ and with the code that generates the OWL version in https://github.com/BFO-ontology/BFO/tree/master/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif. The BSD license on the BFO project site refers to code used to build BFO. This BFO 2.0 version represents a major update to BFO and is not strictly backwards compatible with BFO 1.1. The previous OWL version of BFO, version 1.1.1 will remain available at http://ifomis.org/bfo/1.1 and will no longer be updated. The BFO 2.0 OWL is a classes-only specification. The incorporation of core relations has been held over for a later version. This version (1.1.0) uses the Basic Formal Ontology (BFO) as its top level ontology. We might at some point close the resulting semantic gap by using OBI and IAO as intermediate bridges. http://www.metabolomicscentre.ca/nmrML/msi-nmr.obo 1.0 1.1.0 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. http://nmrml.org/cv/ en March 28, 2022 http://data.bioontology.org/ontologies/NCIT/submissions/82/download?apikey=8b5b7825-538d-40e0-9e9e-5ab9274a9aeb Slimmer 2022-08-11 21:37:39 NCI Thesaurus, a controlled vocabulary in support of NCI administrative and scientific activities. Produced by the Enterprise Vocabulary System (EVS), a project by the NCI Center for Biomedical Informatics and Information Technology. National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, U.S.A. 22.03d This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. Dennis G. Thomas NanoParticle Ontology (NPO): An ontology for representing the knowledge underlying the description and characterization of nanoparticles. http://purl.bioontology.org/ontology/npo https://raw.githubusercontent.com/enanomapper/npo/master/npo-inferred.owl Slimmer 2023-07-12 13:42:41 Inferred version created with Pellet reasoner in Protege editor (v. 4.1) The NPO was primarily developed by Dennis G. Thomas in collaboration with Nathan A. Baker and Rohit V. Pappu. This development was supported by the NIH through grants U54 CA119342 and U54 HG004028. 2013-05-31 (yyyy-mm-dd) This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. Product version Darrell R. Abernethy Elizabeth Blair Izabela Birsanescu Keith Burkhart Luca Toldo Mathias Brochhausen Sydni Joubran "Asiyah" Yu Lin Abra Guo Barry Smith Bingjian Yang David Ameriguian Desikan Jagannathan Edison Ong Jessica DeGuise Jiangan "Hardy" Xie Jiangan Xie Kelly Yang Kevin Mo Ling Wan Liwei Wang Meiu Wong Noemi Garg Qingping Liu Qiuyue Yang Rebecca Racz Shelley Zhang Sirarat Sarntivijai Sydni Joubran Yongqun "Oliver" He (YH) Zuoshuang "Allen" Xiang 2022-8-15 The Ontology of Adverse Eventsy (OAE) is a biomedical ontology in the domain of adverse events. OAE aims to standardize adverse event annotation, integrate various adverse event data, and support computer-assisted reasoning. OAE is a community-based ontology. Its development follows the OBO Foundry principles. Vaccine adverse events have been used as an initial testing use case. OAE also studies adverse events associated with the administration of drug and nutritional products, the operation of surgeries, and the usage of medical devices, etc. OWL-DL An ontology for the annotation of the adverse event domain. OAE: Ontology of Adverse Events http://purl.obolibrary.org/obo/oae.owl Slimmer 2023-07-12 13:42:52 1.2.47 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. Adrien Barton Barry Smith Huan Li Jean-François Ethier Jie Zheng Marcy Harris Qingzhi Liu Yongqun "Oliver" He Yu Lin OBCS stands for the Ontology of Biological and Clinical Statistics. OBCS is an ontology in the domain of biological and clinical statistics. It is aligned with the Basic Formal Ontology (BFO) and the Ontology for Biomedical Investigations (OBI). OBCS imports all possible biostatistics terms in OBI and includes many additional biostatistics terms, some of which were proposed and discussed in the OBI face-to-face workshop in Ann Arbor in 2012. http://purl.obolibrary.org/obo/obcs.owl Slimmer 2023-07-12 13:42:56 101 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. en Ontology for Biomedical Investigations Advisors for this project come from the IFOMIS group, Saarbruecken and from the Co-ODE group in Manchester Alan Ruttenberg Allyson Lister Barry Smith Bill Bug Bjoern Peters Carlo Torniai Chris Mungall Chris Stoeckert Chris Taylor Christian Bolling Cristian Cocos Daniel Rubin Daniel Schober Dawn Field Dirk Derom Elisabetta Manduchi Eric Deutsch Frank Gibson Gilberto Fragoso Helen C. Causton Helen Parkinson Holger Stenzhorn James A. Overton James Malone Jay Greenbaum Jeffrey Grethe Jennifer Fostel Jessica Turner Jie Zheng Joe White John Westbrook Kevin Clancy Larisa Soldatova Lawrence Hunter Liju Fan Luisa Montecchi Matthew Brush Matthew Pocock Melanie Courtot Melissa Haendel Mervi Heiskanen Monnie McGee Norman Morrison Philippe Rocca-Serra Phillip Lord Pierre Grenon Richard Bruskiewich Richard Scheuermann Robert Stevens Ryan R. Brinkman Stefan Wiemann Susanna-Assunta Sansone Tanya Gray Tina Hernandez-Boussard Trish Whetzel Yongqun He 2009-07-31 An ontology for representing biomedical investigations, including study designs, the collection and preparation of the targets of investigation, assays, instrumentation and reagents used, as well as the data generated and the types of analysis performed on the data to reach conclusions, and their documentation. OWL-DL An ontology for the annotation of biomedical and functional genomics experiments. http://creativecommons.org/licenses/by/4.0/ Ontology for Biomedical Investigations http://purl.obolibrary.org/obo/obi.owl Slimmer 2023-07-12 13:43:02 Please cite the OBI consortium http://purl.obolibrary.org/obo/obi where traditional citation is called for. However it is adequate that individual terms be attributed simply by use of the identifying PURL for the term, in projects that refer to them. 2023-03-10 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. An ontology of phenotypic qualities (properties, attributes or characteristics). PATO - the Phenotype And Trait Ontology http://purl.obolibrary.org/obo/pato.owl Slimmer 2023-07-12 13:43:13 quality 1.2 2023-05-18 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. en Contributors are those that engage in discussions in the context of SIO (in alphabetical order): sivaram arabandi christopher baker joachim baran jerven bolleman matthew brush alison callahan leonid chepelev kevin cohen melanie courtot geraint duck laura furlong elisa kendall tatsuya kushida luke mccarthy jim mccusker jose miguel cruz-toledo chris mungall robert hoehndorf simon jupp jin-dong kim dana klassen thomas luetteke james malone chris mungall david osumi-sutherland tazro ohta nuria queralt stephen reed alexandre riazanov matthias samwald robert stevens mark wilkinson karin verspoor natalia villanueva-rosales Michel Dumontier http://orcid.org/0000-0003-4727-9435 The semanticscience integrated ontology (SIO) provides a simple, integrated ontology (types, relations) for objects, processes and their attributes. This project provides foundational support for the Bio2RDF (http://bio2rdf.org) and SADI (http://sadiframework.org) projects. website: http://semanticscience.org email: sio-ontology@googlegroups.com mailing list: http://groups.google.com/group/sio-ontology 2010-03-29 free to use,share,modify. modify with attribution [http://creativecommons.org/licenses/by/4.0/]. Semanticscience Integrated Ontology (SIO) https://raw.githubusercontent.com/micheldumontier/semanticscience/master/ontology/sio.owl http://www.jbiomedsem.com/content/5/1/14 sio http://semanticscience.org/resource/ general class inclusion axioms: 'is part of' some 'physical entity' subClassOf 'is located in' some 'physical entity' role chains: 'has capability' o 'is realized in' -> 'is participant in' Slimmer 2023-07-12 13:43:17 http://sio.semanticscience.org 1.59 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. Uberon is an integrated cross-species anatomy ontology representing a variety of entities classified according to traditional anatomical criteria such as structure, function and developmental lineage. The ontology includes comprehensive relationships to taxon-specific anatomical ontologies, allowing integration of functional, phenotype and expression data. http://uberon.org ISBN:0030229073 Invertebrate Zoology, Barnes ISBN:0073040584 Vertebrates, Kardong ISBN:0123813611 Comparative Anatomy and Histology: A Mouse and Human Atlas, Treuting and Dintzis ISBN:0226313379 Fins into Limbs: Evolution, Development, and Transformation, Hall ISBN:0443065837 Human embryology, Larsen ISBN:0471888893 Comparative Vertebrate Neuroanatomy: Evolution and Adaptation by Butler and Hodos ISBN:0683400088 Stedman's Medical Dictionary ISBN:1588900649 Color Atlas and Textbook of Human Anatomy: Nervous system and sensory organs By Werner Kahle, Michael Frotscher ISBN:1588903958 Principles and practice of pediatric neurosurgery By A. Leland Albright, P. David Adelson, Ian F. Pollack ISBN:1607950324 Craniofacial Embryogenetics & Development, 2nd edition, Sperber ISBN:978-0-12-369548-2 Principles of Developmental Genetics, Sally A Moody ISBN:9780120749034 The laboratory rat ISBN:9780397517251 Surgical anatomy of the hand and upper extremity. By James R. Doyle and Michael J. Botte ISBN:9780674021839 The Tree of Life - Guillaume Lecointre, Herve Le Guyader ISBN:9780878932504 Developmental Biology MESH PMID:11433360 Placental development: lessons from mouse mutants PMID:16417468 Forgotten and novel aspects in pancreas development, Pieler and Chen aggregates AAO from 13:04:2012 aggregates TAO from 09:08:2012 aggregates VSAO from 16:07:2012 http://wiki.phenotypercn.org/wg/phenotypercn/index.php?title=Neural_Crest_Workshop http://wiki.phenotypercn.org/wiki/August_2012_Notes https://docs.google.com/document/d/16JZOuH9sh_a8uIXA4cqg0Q1H6MV5yCj3-rhuKsZoV_U/edit https://docs.google.com/document/d/1MnUgispgGfNQoezYzWzzGTnkAnI0gzRnJIwdip6MMtw/edit https://docs.google.com/document/d/1cPWBqrl_Qy7XHEWFqtR_PgQX61yRkgGuLaiDpnEXxkE/edit https://docs.google.com/document/d/1r9kNPpFYGdu0SpJDLyFAVQczBlG0wAZCBMd18gG3Ot8/edit# https://docs.google.com/spreadsheet/ccc?key=0Aj8NJdyb-leqdDM0R3hTVTRHRExDVjRCSkZEbDc5N1E#gid=0 Uber-anatomy ontology http://genomebiology.com/2012/13/1/R5 http://www.ncbi.nlm.nih.gov/pubmed/22293552 http://purl.obolibrary.org/obo/uberon.owl https://github.com/cmungall/uberon/ https://obo.svn.sourceforge.net/svnroot/obo/uberon/ https://github.com/obophenotype/uberon/issues/ https://lists.sourceforge.net/lists/listinfo/obo-anatomy Slimmer 2023-07-12 16:05:49 uberon 1.2 AEO BILA BSPO CARO EFO GO OG VSAO EHDAA EV NCIT OGES SCTID VHOG AAO part_of NCBITaxon:8292 DHBA part_of NCBITaxon:9606 EHDAA2 part_of NCBITaxon:9606 EMAPA part_of NCBITaxon:10090 FBbt part_of NCBITaxon:7227 FBdv part_of NCBITaxon:7227 FMA part_of NCBITaxon:9606 HAO part_of NCBITaxon:7399 HBA part_of NCBITaxon:9606 HsapDv part_of NCBITaxon:9606 MA part_of NCBITaxon:10090 MFO part_of NCBITaxon:8089 MmusDv part_of NCBITaxon:10090 OlatDv part_of NCBITaxon:8089 PBA part_of NCBITaxon:9443 SPD part_of NCBITaxon:6893 TADS part_of NCBITaxon:6939 TAO part_of NCBITaxon:32443 TGMA part_of NCBITaxon:44484 WBbt part_of NCBITaxon:6237 WBls part_of NCBITaxon:6237 XAO part_of NCBITaxon:8353 ZFA part_of NCBITaxon:7954 ZFS part_of NCBITaxon:7954 Aurelie Comte, Bill Bug, Catherine Leroy, Duncan Davidson and Trish Whetzel are also contributors. However their ORCIDs were not found. Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/TEMP>) VersionIRI(<null>))) [Axioms: 437 Logical Axioms: 0] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/uberon-bridge-to-bfo.owl>) VersionIRI(<null>))) [Axioms: 20 Logical Axioms: 9] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/uberon/disjoint_union_over.owl>) VersionIRI(<null>))) [Axioms: 38 Logical Axioms: 38] 2023-06-27 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. http://uberon.org http://purl.obolibrary.org/obo/uo.owl Slimmer 2023-07-12 13:43:44 2023-05-25 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. en Generated 04-11-2012 BFO:0000053 BFO bearer_of bearer_of bearer of BFO:0000056 uberon participates_in participates_in participates in X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) BFO:0000062 is preceded by takes place after external uberon preceded_by preceded_by disjoint_from part_of, but this cannot be expressed in OWL2 preceded by preceded_by is preceded by SIO:000249 takes place after Allen:precedes BFO:0000063 external precedes precedes precedes Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. BFO:0000068 begins_to_exist_during uberon existence_starts_during existence_starts_during existence_starts_during Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. https://orcid.org/0000-0002-6601-2165 Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. BFO:0000069 ceases_to_exist_during uberon existence_ends_during existence_ends_during todo - add full axioms to bfo existence_ends_during Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. https://orcid.org/0000-0002-6601-2165 To say that each spatiotemporal region s temporally_projects_onto some temporal region t is to say that t is the temporal extension of s. (axiom label in BFO2 Reference: [080-003]) To say that spatiotemporal region s spatially_projects_onto spatial region r at t is to say that r is the spatial extent of s at t. (axiom label in BFO2 Reference: [081-003]) To say that each spatiotemporal region s temporally_projects_onto some temporal region t is to say that t is the temporal extension of s. (axiom label in BFO2 Reference: [080-003]) To say that spatiotemporal region s spatially_projects_onto spatial region r at t is to say that r is the spatial extent of s at t. (axiom label in BFO2 Reference: [081-003]) x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer cjm 2009-07-31T02:15:46Z BSPO:0000096 uberon anterior_to anterior_to anterior_to x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer BSPO:cjm x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). BSPO:0000097 uberon distal_to distal_to distal_to x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). BSPO:cjm x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). BSPO:0000098 uberon dorsal_to dorsal_to dorsal_to x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). BSPO:cjm x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. BSPO:0000099 caudal_to uberon posterior_to posterior_to posterior_to x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. BSPO:cjm x proximal_to y iff x is closer to the point of attachment with the body than y. BSPO:0000100 uberon proximal_to proximal_to proximal_to x proximal_to y iff x is closer to the point of attachment with the body than y. BSPO:cjm x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). BSPO:0000102 uberon ventral_to ventral_to ventral_to x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). BSPO:cjm Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. BSPO:0000107 uberon deep_to deep_to deep_to Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. BSPO:cjm Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. BSPO:0000108 uberon superficial_to superficial_to superficial_to Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. BSPO:cjm X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. BSPO:0000120 uberon in_left_side_of in_left_side_of in_left_side_of http://purl.obolibrary.org/obo/uberon/references/reference_0000014 X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. BSPO:PATO_mtg_2009 X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. BSPO:0000121 uberon in_right_side_of in_right_side_of in_right_side_of http://purl.obolibrary.org/obo/uberon/references/reference_0000014 X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. BSPO:PATO_mtg_2009 X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. BSPO:0000122 uberon in_posterior_side_of in_posterior_side_of in_posterior_side_of X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. BSPO:PATO_mtg_2009 X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. BSPO:0000123 uberon in_anterior_side_of in_anterior_side_of in_anterior_side_of X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. BSPO:PATO_mtg_2009 X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. BSPO:0000124 uberon in_proximal_side_of in_proximal_side_of in_proximal_side_of X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. BSPO:PATO_mtg_2009 X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. BSPO:0000125 uberon in_distal_side_of in_distal_side_of in_distal_side_of X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. BSPO:PATO_mtg_2009 X in_lateral_side_of Y <=> if X is in_left_side_of Y or X is in_right_side_of Y. X is often, but not always a paired structure BSPO:0000126 uberon in_lateral_side_of in_lateral_side_of in_lateral_side_of http://purl.obolibrary.org/obo/uberon/references/reference_0000014 X in_lateral_side_of Y <=> if X is in_left_side_of Y or X is in_right_side_of Y. X is often, but not always a paired structure https://orcid.org/0000-0002-6601-2165 X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the superficial portion. BSPO:0001100 uberon in_superficial_part_of in_superficial_part_of in_superficial_part_of X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the superficial portion. BSPO:cjm X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the deep portion. BSPO:0001101 uberon in_deep_part_of in_deep_part_of in_deep_part_of X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the deep portion. BSPO:cjm X proximalmost_part_of Y <=> X is part_of Y and X is adjacent_to the proximal boundary of Y BSPO:0001106 uberon proximalmost_part_of proximalmost_part_of proximalmost_part_of X proximalmost_part_of Y <=> X is part_of Y and X is adjacent_to the proximal boundary of Y https://orcid.org/0000-0002-6601-2165 This relation holds when both the deep_to and ajdacent_to relationship similarly hold. BSPO:0001107 uberon immediately_deep_to immediately_deep_to immediately_deep_to This relation holds when both the deep_to and ajdacent_to relationship similarly hold. BSPO:cjm X distalmost_part_of Y <=> X is part_of Y and X is adjacent_to the distal boundary of Y BSPO:0001108 uberon distalmost_part_of distalmost_part_of distalmost_part_of X distalmost_part_of Y <=> X is part_of Y and X is adjacent_to the distal boundary of Y https://orcid.org/0000-0002-6601-2165 BSPO:0001113 uberon preaxialmost_part_of preaxialmost_part_of preaxialmost_part_of x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the postaxial side. BSPO:0001114 posterior_to (developmentally) uberon postaxial_to postaxial_to postaxial_to x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the postaxial side. http://medical-dictionary.thefreedictionary.com/postaxial posterior_to (developmentally) MA:th BSPO:0001115 uberon postaxialmost_part_of postaxialmost_part_of postaxialmost_part_of X intersects_median_plane of iff X crosses the midine plane of Y. BSPO:0005001 uberon intersects_midsagittal_plane_of intersects_midsagittal_plane_of intersects_midsagittal_plane_of x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the front. BSPO:1000000 anterior_to (developmentally) lateral (radial) to medial (tibial) to uberon preaxial_to preaxial_to preaxial_to x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the front. http://medical-dictionary.thefreedictionary.com/preaxial anterior_to (developmentally) MA:th FMA:85972 uberon continuous_with continuous_with sourced from FMA continuous_with relation between an artery and the structure is supplies with blood. FMA:86003 arterial supply of uberon supplies supplies source: FMA supplies arterial supply of FMA:86003 cjm 2012-03-14T10:35:44Z GOREL:0000040 external results_in results_in This relation is currently used to connect two regulation processes p1 and p2, such that if r1 regulates p1 and r2 regulates p2, and r1 results_in r2 then the regulation of p1 is required for the regulation of p2. For an example of use, see GO:0035958 'regulation of glyoxylate cycle by regulation of transcription from RNA polymerase II promoter'. Note that a precise definition of this relation is under discussion. After it has been formalized it will be added to RO, where it will have a RO ID. Note that the existing identifier and label are subject to change. results in GOREL:0001019 external results_in_division_of results_in_division_of use occurs_in results in division of GOREL:0002003 external results_in_distribution_of results_in_distribution_of results in distribution of GOREL:0002004 external results_in_fission_of results_in_fission_of results in fission of GOREL:0012006 external results_in_maintenance_of results_in_maintenance_of results in maintenance of RO:0000053 external bearer_of bearer_of bearer of RO:0000057 external has_participant has_participant has participant RO:0002007 external bounding_layer_of bounding_layer_of bounding layer of RO:0002008 external coincident_with coincident_with coincident with RO:0002013 external has_regulatory_component_activity has_regulatory_component_activity has regulatory component activity RO:0002014 external has_negative_regulatory_component_activity has_negative_regulatory_component_activity has negative regulatory component activity RO:0002016 external has_necessary_component_activity has_necessary_component_activity has necessary component activity Relation between occurrents, shares start and end boundaries. RO:0002082 coincides_with is_equal_to uberon simultaneous_with simultaneous_with simultaneous_with Relation between occurrents, shares start and end boundaries. Allen:is_equal_to https://orcid.org/0000-0002-6601-2165 X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. RO:0002087 http://semanticscience.org/resource/SIO_000251 directly preceded by is directly preceded by is immediately preceded by starts_at_end_of external uberon immediately_preceded_by immediately_preceded_by immediately preceded by immediately_preceded_by A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. SIO:000251 is immediately preceded by SIO:000251 RO:0002090 external immediately_precedes immediately_precedes immediately precedes A overlaps B if they share some part in common. RO:0002131 external uberon overlaps overlaps overlaps RO:0002158 uberon homologous_to homologous_to homologous_to RO:0002159 uberon serially_homologous_to serially_homologous_to serially_homologous_to RO:0002162 uberon in_taxon in_taxon in taxon RO:0002180 external has_component has_component has component RO:0002203 uberon develops_into develops_into develops_into RO:0002207 uberon directly_develops_from directly_develops_from directly_develops_from RO:0002215 external capable_of capable_of capable of RO:0002216 external uberon capable_of_part_of has_function_in capable_of_part_of has_function_in capable of part of has_function_in x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y RO:0002219 uberon surrounded_by surrounded_by surrounded_by x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y https://orcid.org/0000-0002-6601-2165 x adjacent_to y iff: x and y share a boundary RO:0002220 external uberon adjacent_to adjacent_to adjacent to adjacent_to inverse of surrounded_by RO:0002221 uberon surrounds surrounds surrounds inverse of surrounded_by https://orcid.org/0000-0002-6601-2165 Relation between occurrents, shares a start boundary with. RO:0002224 external uberon starts starts_with starts starts_with starts starts with Relation between occurrents, shares a start boundary with. Allen:starts https://orcid.org/0000-0002-6601-2165 RO:0002225 uberon develops_from_part_of develops_from_part_of develops_from_part_of RO:0002226 uberon develops_in develops_in This relation take from EHDAA2 - precise semantics yet to be defined develops_in Relation between occurrents, shares an end boundary with. RO:0002229 ends uberon finishes finishes finishes Relation between occurrents, shares an end boundary with. Allen:starts ZFS:finishes https://orcid.org/0000-0002-6601-2165 ends RO:0002229 RO:0002230 external ends_with ends_with ends with RO:0002231 external has_start_location has_start_location has start location RO:0002232 external has_end_location has_end_location has end location RO:0002233 external has_input has_input has input RO:0002234 external has_output has_output has output RO:0002254 uberon has_developmental_contribution_from has_developmental_contribution_from has developmental contribution from RO:0002255 uberon developmentally_contributes_to developmentally_contributes_to developmentally_contributes_to t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. RO:0002256 uberon developmentally_induced_by developmentally_induced_by sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F) developmentally_induced_by t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. GO:0001759 RO:0002285 uberon developmentally_replaces developmentally_replaces developmentally_replaces RO:0002295 external results_in_developmental_progression_of results_in_developmental_progression_of results in developmental progression of RO:0002296 external results_in_development_of results_in_development_of results in development of RO:0002297 external results_in_formation_of results_in_formation_of results in formation of RO:0002298 external results_in_morphogenesis_of results_in_morphogenesis_of results in morphogenesis of RO:0002299 external results_in_maturation_of results_in_maturation_of results in maturation of RO:0002304 external causally_upstream_of,_positive_effect causally_upstream_of,_positive_effect causally upstream of, positive effect RO:0002305 external causally_upstream_of,_negative_effect causally_upstream_of,_negative_effect causally upstream of, negative effect RO:0002315 external results_in_acquisition_of_features_of results_in_acquisition_of_features_of results in acquisition of features of RO:0002322 adapted_for uberon confers_advantage_in confers_advantage_in confers_advantage_in RO:0002332 external regulates_levels_of regulates_levels_of regulates levels of RO:0002334 external regulated_by regulated_by regulated by RO:0002335 external negatively_regulated_by negatively_regulated_by negatively regulated by RO:0002336 external positively_regulated_by positively_regulated_by positively regulated by RO:0002338 external has_target_start_location has_target_start_location has target start location RO:0002339 external has_target_end_location has_target_end_location has target end location RO:0002341 external results_in_transport_along results_in_transport_along results in transport along RO:0002342 external results_in_transport_across results_in_transport_across results in transport across RO:0002343 external results_in_growth_of results_in_growth_of results in growth of RO:0002344 external results_in_transport_to_from_or_in results_in_transport_to_from_or_in results in transport to from or in RO:0002348 external results_in_commitment_to results_in_commitment_to results in commitment to RO:0002349 external results_in_determination_of results_in_determination_of results in determination of RO:0002353 external output_of output_of output of RO:0002355 external results_in_structural_organization_of results_in_structural_organization_of results in structural organization of RO:0002356 external results_in_specification_of results_in_specification_of results in specification of FMA:85990 RO:0002371 uberon attaches_to attaches_to attaches_to m has_muscle_origin s iff m is attaches_to s, and it is the case that when m contracts, s does not move. The site of the origin tends to be more proximal and have greater mass than what the other end attaches to. dbpprop:origin RO:0002372 uberon has_muscle_origin has_muscle_origin has_muscle_origin m has_muscle_origin s iff m is attaches_to s, and it is the case that when m contracts, s does not move. The site of the origin tends to be more proximal and have greater mass than what the other end attaches to. Wikipedia:Insertion_(anatomy)#Muscles m has_muscle_insertion s iff m is attaches_to s, and it is the case that when m contracts, s moves. Insertions are usually connections of muscle via tendon to bone. dbpprop:insertion RO:0002373 uberon has_muscle_insertion has_muscle_insertion has_muscle_insertion m has_muscle_insertion s iff m is attaches_to s, and it is the case that when m contracts, s moves. Insertions are usually connections of muscle via tendon to bone. Wikipedia:Insertion_(anatomy) x has_fused_element y iff: there exists some z : x has_part z, z homologous_to y, and y is a distinct element, the boundary between x and z is largely fiat RO:0002374 uberon has_fused_element has_fused_element A single bone in one species may correspond to the fusion of two or more bones found as distinct elements in another. For example, tibiofibula has_fused_element tibia. A has_fused_element B does not imply that A has_part some B, rather than A has_part some B', where B' is not a subtype of B (because B is a distinct element but B' is a regional part) but has some evolutionary relationship to B. has_fused_element RO:0002404 external causally_downstream_of causally_downstream_of causally downstream of RO:0002405 external immediately_causally_downstream_of immediately_causally_downstream_of immediately causally downstream of RO:0002411 external causally_upstream_of causally_upstream_of causally upstream of RO:0002412 external immediately_causally_upstream_of immediately_causally_upstream_of immediately causally upstream of RO:0002418 external causally_upstream_of_or_within causally_upstream_of_or_within causally upstream of or within RO:0002427 external causally_downstream_of_or_within causally_downstream_of_or_within causally downstream of or within RO:0002505 external has_intermediate has_intermediate has intermediate RO:0002565 external results_in_movement_of results_in_movement_of results in movement of RO:0002578 external directly_regulates directly_regulates directly regulates RO:0002588 external results_in_assembly_of results_in_assembly_of results in assembly of RO:0002590 external results_in_disassembly_of results_in_disassembly_of results in disassembly of RO:0002591 external results_in_remodeling_of results_in_remodeling_of results in remodeling of RO:0002592 external results_in_organization_of results_in_organization_of results in organization of RO:0002608 external process_has_causal_agent process_has_causal_agent process has causal agent RO:0002629 external directly_positively_regulates directly_positively_regulates directly positively regulates RO:0002630 external directly_negatively_regulates directly_negatively_regulates directly negatively regulates RO:0003000 external produces produces produces RO:0003001 external uberon produced_by produced_by produced by produced_by RO:0004007 external has_primary_input_or_output has_primary_input_or_output has primary input or output RO:0004008 external has_primary_output has_primary_output has primary output RO:0004009 external has_primary_input has_primary_input has primary input RO:0012003 external acts_on_population_of acts_on_population_of acts on population of RO:0012008 external results_in_fusion_of results_in_fusion_of results in fusion of RO:0019000 gene_ontology regulates_characteristic regulates_characteristic regulates characteristic RO:0019001 gene_ontology positively_regulates_characteristic positively_regulates_characteristic positively regulates characteristic RO:0019002 gene_ontology negatively_regulates_characteristic negatively_regulates_characteristic negatively regulates characteristic RO:0040036 external results_in_changes_to_anatomical_or_cellular_structure results_in_changes_to_anatomical_or_cellular_structure results in changes to anatomical or cellular structure Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. UBREL:0000001 uberon connected_to connected_to Connection does not imply overlaps. connected to http://purl.obolibrary.org/obo/uberon/references/reference_0000004 Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. UBERONREF:0000004 x composed_primarily_of y iff: more than half of the mass of x is made from parts of y UBREL:0000002 uberon composed_primarily_of composed_primarily_of composed_primarily_of meter A length unit which is equal to the length of the path traveled by light in vacuum during a time interval of 1/299 792 458 of a second. m m metre "A length unit which is equal to the length of the path traveled by light in vacuum during a time interval of 1/299 792 458 of a second." [BIPM:BIPM, NIST:NIST] meter kilogram A mass unit which is equal to the mass of the International Prototype Kilogram kept by the BIPM at Svres, France. kg kg "A mass unit which is equal to the mass of the International Prototype Kilogram kept by the BIPM at Svres, France." [BIPM:BIPM, NIST:NIST] kilogram second A time unit which is equal to the duration of 9 192 631 770 periods of the radiation corresponding to the transition between the two hyperfine levels of the ground state of the caesium 133 atom. s sec s "A time unit which is equal to the duration of 9 192 631 770 periods of the radiation corresponding to the transition between the two hyperfine levels of the ground state of the caesium 133 atom." [BIPM:BIPM, NIST:NIST] second A "An electric current unit which is equal to the constant current which, if maintained in two straight parallel conductors of infinite length, of negligible circular cross-section, and placed 1 m apart in vacuum, would produce between these conductors a force equal to 2 x 10^[-7] newton per meter of length." [BIPM:BIPM, NIST:NIST] ampere K "A thermodynamic temperature unit which is equal to the fraction 1/273.16 of the thermodynamic temperature of the triple point of water." [BIPM:BIPM, NIST:NIST] kelvin mol "A substance unit which is equal to the amount of substance of a molecular system which contains as many elementary entities as there are atoms in 0.012 kilogram of carbon 12." [BIPM:BIPM, NIST:NIST] mole cd "A luminous intensity unit which equal to the luminous intensity, in a given direction, of a source that emits monochromatic radiation of frequency 540 x 1012 hertz and that has a radiant intensity in that direction of 1/683 watt per steradian." [BIPM:BIPM, NIST:NIST] candela centimeter A length unit which is equal to one hundredth of a meter or 10^[-2] m. cm centimetre cm "A length unit which is equal to one hundredth of a meter or 10^[-2] m." [NIST:NIST] centimeter millimeter A length unit which is equal to one thousandth of a meter or 10^[-3] m. mm millimetre mm "A length unit which is equal to one thousandth of a meter or 10^[-3] m." [NIST:NIST] millimeter micrometer A length unit which is equal to one millionth of a meter or 10^[-6] m. um micrometre micron um "A length unit which is equal to one millionth of a meter or 10^[-6] m." [NIST:NIST] micrometer nanometer A length unit which is equal to one thousandth of one millionth of a meter or 10^[-9] m. nm nanometre nm "A length unit which is equal to one thousandth of one millionth of a meter or 10^[-9] m." [NIST:NIST] nanometer angstrom A length unit which is equal to 10 [-10] m. Å "A length unit which is equal to 10 [-10] m." [NIST:NIST] angstrom picometre pm "A length unit which is equal to 10^[-12] m." [NIST:NIST] picometer gram A mass unit which is equal to one thousandth of a kilogram or 10^[-3] kg. g g "A mass unit which is equal to one thousandth of a kilogram or 10^[-3] kg." [NIST:NIST] gram milligram A mass unit which is equal to one thousandth of a gram or 10^[-3] g. mg mg "A mass unit which is equal to one thousandth of a gram or 10^[-3] g." [UOC:GVG] milligram microgram A mass unit which is equal to one millionth of a gram or 10^[-6] g. ug ug "A mass unit which is equal to one millionth of a gram or 10^[-6] g." [UOC:GVG] microgram nanogram A mass unit which is equal to one thousandth of one millionth of a gram or 10^[-9] g. ng ng "A mass unit which is equal to one thousandth of one millionth of a gram or 10^[-9] g." [UOC:GVG] nanogram picogram A mass unit which is equal to 10^[-12] g. pg pg "A mass unit which is equal to 10^[-12] g." [UOC:GVG] picogram fg "A mass unit which is equal to 10^[-15] g." [NIST:NIST] femtogram degree Celsius A temperature unit which is equal to one kelvin degree. However, they have their zeros at different points. The centigrade scale has its zero at 273.15 K. C degree C C "A temperature unit which is equal to one kelvin degree. However, they have their zeros at different points. The centigrade scale has its zero at 273.15 K." [NIST:NIST] degree Celsius ms "A time unit which is equal to one thousandth of a second or 10^[-3] s." [NIST:NIST] millisecond us "A time unit which is equal to one millionth of a second or 10^[-6] s." [NIST:NIST] microsecond ps "A time unit which is equal to 10^[-12] s." [NIST:NIST] picosecond minute A time unit which is equal to 60 seconds. min min "A time unit which is equal to 60 seconds." [Wikipedia:Wikipedia] minute hour A time unit which is equal to 3600 seconds or 60 minutes. h hr h "A time unit which is equal to 3600 seconds or 60 minutes." [Wikipedia:Wikipedia] hour day A time unit which is equal to 24 hours. "A time unit which is equal to 24 hours." [Wikipedia:Wikipedia] day week A time unit which is equal to 7 days. "A time unit which is equal to 7 days." [Wikipedia:Wikipedia] week month A time unit which is approximately equal to the length of time of one of cycle of the moon's phases which in science is taken to be equal to 30 days. "A time unit which is approximately equal to the length of time of one of cycle of the moon's phases which in science is taken to be equal to 30 days." [Wikipedia:Wikipedia] month year A time unit which is equal to 12 months which is science is taken to be equal to 365.25 days. "A time unit which is equal to 12 months which in science is taken to be equal to 365.25 days." [Wikipedia:Wikipedia] year mA "An electric current unit current which is equal to one thousandth of an ampere or 10^[-3] A." [UOC:GVG] milliampere uA "An electric current unit current which is equal to one millionth of an ampere or 10^[-6] A." [UOC:GVG] microampere micromole A substance unit equal to a millionth of a mol or 10^[-6] mol. umol umol "A substance unit equal to a millionth of a mol or 10^[-6] mol." [NIST:NIST] micromole mmol "A substance unit equal to a thousandth of a mol or 10^[-3] mol." [NIST:NIST] millimole nanomole A substance unit equal to one thousandth of one millionth of a mole or 10^[-9] mol. nmol nmol "A substance unit equal to one thousandth of one millionth of a mole or 10^[-9] mol." [NIST:NIST] nanomole picomole A substance unit equal to 10^[-12] mol. pmol pmol "A substance unit equal to 10^[-12] mol." [NIST:NIST] picomole fmol "A substance unit equal to 10^[-15] mol." [NIST:NIST] femtomole amol "A substance unit equal to 10^[-18] mol." [NIST:NIST] attomole molar A unit of concentration which expresses a concentration of 1 mole of solute per liter of solution (mol/L). M M "A unit of concentration which expresses a concentration of 1 mole of solute per liter of solution (mol/L)." [UOC:GVG] molar millimolar A unit of molarity which is equal to one thousandth of a molar or 10^[-3] M. mM mM "A unit of molarity which is equal to one thousandth of a molar or 10^[-3] M." [UOC:GVG] millimolar micromolar A unit of molarity which is equal to one millionth of a molar or 10^[-6] M. uM uM "A unit of molarity which is equal to one millionth of a molar or 10^[-6] M." [UOC:GVG] micromolar nanomolar A unit of molarity which is equal to one thousandth of one millionth of a molar or 10^[-9] M. nM nM "A unit of molarity which is equal to one thousandth of one millionth of a molar or 10^[-9] M." [UOC:GVG] nanomolar picomolar A unit of molarity which is equal to 10^[-12] M. pM pM "A unit of molarity which is equal to 10^[-12] M." [UOC:GVG] picomolar m "A unit of concentration which expresses a concentration of a solution of 1 mole per kilogram of solvent (mol/kg)." [UOC:GVG] molal mm "A molality unit which is equal to one thousandth of a molal or 10^[-3] m." [UOC:GVG] millimolal um "A molality unit which is equal to one millionth of a molal or 10^[-6] m." [UOC:GVG] micromolal nm "A molality unit which is equal to one thousandth of one millionth of a molal or 10^[-9] m." [UOC:GVG] nanomolal pm "A molality unit which is equal to 10^[-12] m." [UOC:GVG] picomolal fM "A unit of molarity which is equal to 10^[-15] M." [UOC:GVG] femtomolar N "A unit of concentration which is one gram equivalent of a solute per liter of solution. A gram equivalent weight or equivalent is a measure of the reactive capacity of a given molecule." [Wikipedia:Wikipedia] normal (x) chi "A concentration unit which denotes the number of moles of solute as a proportion of the total number of moles in a solution." [Wikipedia:Wikipedia] mole fraction m/s^[2] metre per second per second "An acceleration unit which is equal to the acceleration an object changing its velocity by 1meter/s over a time period that equals one second." [NIST:NIST] meter per second per second alpha rad/s^[2] "An angular unit acceleration which is equal to the angular acceleration of an object changing its angular velocity by 1rad/s over a time period that equals one second." [NIST:NIST] radian per second per second rad/s "An angular unit velocity which is equal to about 9.54930 rpm (revolutions per minute)." [NIST:NIST] radian per second m^[2] square metre "An area unit which is equal to an area enclosed by a square with sides each 1 meter long." [NIST:NIST] square meter cm^[2] square centimetre "An area unit which is equal to one ten thousandth of a square meter or 10^[-4] m^[2]." [NIST:NIST] square centimeter mm^[2] square millimetre "An area unit which is equal to one millionth of a square meter or 10^[-6] m^[2]." [NIST:NIST] square millimeter kg/m^[3] kilogram per cubic metre "A mass unit density which is equal to mass of an object in kilograms divided by the volume in cubic meters." [UOC:GVG] kilogram per cubic meter g/cm^[3] gram per cubic centimetre "A mass unit density which is equal to mass of an object in grams divided by the volume in cubic centimeters." [UOC:GVG] gram per cubic centimeter candela per square metre cd/m^[2] "A luminance unit which is equal to a luminous intensity of one candela radiating from a surface whose area is one square meter." [NIST:NIST] candela per square meter kg/m^[2] kilogram per square metre "An area density unit which is equal to the mass of an object in kilograms divided by the surface area in meters squared." [NIST:NIST] kilogram per square meter kg/mol "A molar mass unit which is equal to one kilogram of mass of one mole of chemical element or chemical compound." [NIST:NIST] kilogram per mole g/mol "A molar mass unit which is equal to one gram of mass of one mole of chemical element or chemical compound." [NIST:NIST] gram per mole cubic metre per mole m^[3]/mol "A molar volume unit which is equal to 1 cubic meter occupied by one mole of a substance in the form of a solid, liquid, or gas." [NIST:NIST] cubic meter per mole cm^[3]/mol cubic centimetre per mole "A molar volume unit which is equal to 1 cubic centimeter occupied by one mole of a substance in the form of a solid, liquid, or gas." [NIST:NIST] cubic centimeter per mole kg.m/s kilogram metre per second "A momentum unit which is equal to the momentum of a one kilogram mass object with a speed of one meter per second." [NIST:NIST] kilogram meter per second 1/s one turn per second "A rotational frequency unit which is equal to the number complete turn in a period of time that equals to 1 second." [NIST:NIST] turns per second cubic metre per kilogram m^[3]/kg "A specific volume unit which is equal to one cubic meter volume occupied by one kilogram of a particular substance." [NIST:NIST] cubic meter per kilogram m/s metre per second "A speed/velocity unit which is equal to the speed of an object traveling 1 meter distance in one second." [NIST:NIST] meter per second cubic metre m^[3] "A volume unit which is equal to the volume of a cube with edges one meter in length. One cubic meter equals to 1000 liters." [NIST:NIST] cubic meter cubic centimeter A volume unit which is equal to one millionth of a cubic meter or 10^[-9] m^[3], or to 1 ml. cc cc cm^3 cubic centimetre "A volume unit which is equal to one millionth of a cubic meter or 10^[-9] m^[3], or to 1 ml." [NIST:NIST] cubic centimeter milliliter A volume unit which is equal to one thousandth of a liter or 10^[-3] L, or to 1 cubic centimeter. ml millilitre ml "A volume unit which is equal to one thousandth of a liter or 10^[-3] L, or to 1 cubic centimeter." [NIST:NIST] milliliter liter A volume unit which is equal to one thousandth of a cubic meter or 10^[-3] m^[3], or to 1 decimeter. L L l litre "A volume unit which is equal to one thousandth of a cubic meter or 10^[-3] m^[3], or to 1 decimeter." [NIST:NIST] liter cubic decimeter A volume unit which is equal to one thousand of a cubic meter or 10^[-3] m^[3], or to 1 L. cubic decimetre dm^[3] "A volume unit which is equal to one thousand of a cubic meter or 10^[-3] m^[3], or to 1 L." [NIST:NIST] cubic decimeter microliter A volume unit which is equal to one millionth of a liter or 10^[-6] L. ul microlitre ul "A volume unit which is equal to one millionth of a liter or 10^[-6] L." [NIST:NIST] microliter nanoliter A volume unit which is equal to one thousandth of one millionth of a liter or 10^[-9] L. nl nanolitre nl "A volume unit which is equal to one thousandth of one millionth of a liter or 10^[-9] L." [NIST:NIST] nanoliter picoliter A volume unit which is equal to 10^[-12] L. pl picolitre pl "A volume unit which is equal to 10^[-12] L." [NIST:NIST] picoliter femtolitre fl "A volume unit which is equal to 10^[-15] L." [NIST:NIST] femtoliter hertz A frequency unit which is equal to 1 complete cycle of a recurring phenomenon in 1 second. Hz s^1 "A frequency unit which is equal to 1 complete cycle of a recurring phenomenon in 1 second." [NIST:NIST] hertz N "A force unit which is equal to the force required to cause an acceleration of 1m/s2 of a mass of 1 Kg in the direction of the force." [NIST:NIST] newton Pa "A pressure unit which is equal to the pressure or stress on a surface caused by a force of 1 newton spread over a surface of 1 m^[2]." [NIST:NIST] pascal J "An energy unit which is equal to the energy required when a force of 1 newton moves an object 1 meter in the direction of the force." [NIST:NIST] joule W "A power unit which is equal to the power used when work is done at the rate of 1 joule per second." [NIST:NIST] watt lx "An illuminance unit which is equal to the illuminance produced by 1 lumen evenly spread over an area 1 m^[2]." [NIST:NIST] lux lm "A luminous flux unit which is equal to the luminous flux emitted into 1 steradian by a point source of 1 candela." [NIST:NIST] lumen kat "A catalytic unit activity which is equal to the activity of a catalyst in moles per second, such as the amount of an enzyme needed to transform one mole of substrate per second." [NIST:NIST] katal rad "A plane angle unit which is equal to the angle subtended at the center of a circle by an arc equal in length to the radius of the circle, approximately 57 degrees 17 minutes and 44.6 seconds." [NIST:NIST] radian sr "A solid angle unit which is equal to the solid angle subtended at the center of a sphere by an area on the surface of the sphere that is equal to the radius squared." [NIST:NIST] steradian Bq "An activity (of a radionuclide) unit which is equal to the activity of a quantity of radioactive material in which one nucleus decays per second or there is one atom disintegration per second (dps)." [NIST:NIST] becquerel Ci "An activity (of a radionuclide) unit which is equal to the activity of a quantity of radioactive material in which there are 3.7 x 10^[10] atom disintegration per second (dps)." [ORCBS:ORCBS] curie Gy "An absorbed dose unit which is equal to the absorption of one joule of radiation energy by one kilogram of matter." [NIST:NIST] gray "An absorbed dose unit which is equal to 0.01 gray (Gy)." [Wikipedia:Wikipedia] rad R "An exposure unit which is equal to the amount of radiation required to liberate positive and negative charges of one electrostatic unit of charge in 1 cm^[3] of air at standard temperature and pressure (STP). This corresponds to the generation of approximately 2.0810^[9] ion pairs." [Wikipedia:Wikipedia] roentgen Sv "A dose equivalent unit which is equal to the absorption of one joule of radiation energy by one kilogram of matter." [NIST:NIST] sievert mSv "A dose equivalent unit which is equal to one thousandth of a sievert or 10^[-3] Sv." [NIST:NIST] millisievert uSv "A dose equivalent unit which is equal to one millionth of a sievert or 10^[-6] Sv." [NIST:NIST] microsievert rem "A dose equivalent unit which when multiplied by hundred is equal to one sievert or 1 Sv. 1 Sv is equal to 100 rem." [Wikipedia:Wikipedia] Roentgen equivalent man uGy "An absorbed dose unit which is equal to one millionth of a gray or 10^[-6] Gy." [NIST:NIST] microgray mGy "An absorbed dose unit which is equal to one thousandth of a gray or 10^[-3] Gy." [NIST:NIST] milligray nGy "An absorbed dose unit which is equal to one thousandth of a millionth of a gray or 10^[-9] Gy." [NIST:NIST] nanogray nSv "A dose equivalent unit which is equal to one thousandth of a millionth of a sievert or 10^[-9] Sv." [NIST:NIST] nanosievert mCi "An activity (of a radionuclide) unit which is equal to one thousandth of a curie or 10^[-3] Ci." [ORCBS:ORCBS] millicurie uCi "An activity (of a radionuclide) unit which is equal to one millionth of a curie or 10^[-6] Ci." [ORCBS:ORCBS] microcurie dpm "An activity (of a radionuclide) unit which is equal to the activity of a quantity of radioactive material in which one nucleus decays per minute or there is one atom disintegration per minute." [ORCBS:ORCBS] disintegrations per minute cpm "An activity (of a radionuclide) unit which is equal to the number of light emissions produced by ionizing radiation in one minute." [ORCBS:ORCBS] counts per minute ns "A time unit which is equal to one thousandth of one millionth of a second or 10^[-9] s." [NIST:NIST] nanosecond "A time unit which is equal to 100 years." [Wikipedia:Wikipedia] century "A time unit which represents the period over which the activity or concentration of a specified chemical or element falls to half its original activity or concentration." [MGED:MGED] half life ft-c "An illuminance unit which is equal to the illuminance produced by 1 lumen evenly spread over an area 1 foot^[2]. One footcandle is equal to 10.76 lux." [Wikipedia:Wikipedia] foot candle W/m^[2] watt per square metre "An irradiance unit which is equal to 1 watt of radiant power incident per one square meter surface area." [NIST:NIST] watt per square meter einstein per square metre per second einstein/sm^[2] mole per second and square meter mol/sm^2 "An irradiance unit which is equal to one einstein per square meter per second. One einstein is one mole of photons, regardless of their frequency. Therefore, the number of photons in an einstein is Avogadro's number." [Wikipedia:Wikipedia] einstein per square meter per second W/sr m^[2] watt per steradian per square metre "A radiance unit which is equal to one watt of radiant power incident per steradian solid angle per one square meter projected area of the source, as viewed from the given direction." [NIST:NIST] watt per steradian per square meter microeinstein per square metre per second micromole per second and square meter mmol/sm^2 umicroeinstein/sm^[2] "An irradiance unit which is equal to one microeinstein per square meter per second or 10^[-6] microeinstein/sm^[2]." [Wikipedia:Wikipedia] microeinstein per square meter per second W/sr "A radiant intensity unit which is equal to one kilogram meter squared per second cubed per steradian." [NIST:NIST] watt per steradian mass percentage A dimensionless concentration unit which denotes the mass of a substance in a mixture as a percentage of the mass of the entire mixture. % w/w percent weight pr weight w/w weight-weight percentage "A dimensionless concentration unit which denotes the mass of a substance in a mixture as a percentage of the mass of the entire mixture." [Wikipedia:Wikipedia] mass percentage mass volume percentage A dimensionless concentration unit which denotes the mass of the substance in a mixture as a percentage of the volume of the entire mixture. % w/v percent vol per vol (w/v) weight-volume percentage "A dimensionless concentration unit which denotes the mass of the substance in a mixture as a percentage of the volume of the entire mixture." [UOC:GVG] mass volume percentage volume percentage A dimensionless concentration unit which denotes the volume of the solute in mL per 100 mL of the resulting solution. % v/v percent vol per vol % (v/v) "A dimensionless concentration unit which denotes the volume of the solute in mL per 100 mL of the resulting solution." [UOC:GVG] volume percentage 10^[-2] pph "A dimensionless concentration notation which denotes the amount of a given substance in a total amount of 100 regardless of the units of measure as long as they are the same." [UOC:GVG] parts per hundred 10^[-3] ppth "A dimensionless concentration notation which denotes the amount of a given substance in a total amount of 1000 regardless of the units of measure as long as they are the same." [UOC:GVG] parts per thousand 10^[-6] ppm "A dimensionless concentration notation which denotes the amount of a given substance in a total amount of 1,000,000 regardless of the units of measure used as long as they are the same or 1 part in 10^[6]." [UOC:GVG] parts per million 10^[-9] ppb "A dimensionless concentration notation which denotes the amount of a given substance in a total amount of 1,000,000,000 regardless of the units of measure as long as they are the same or 1 part in 10^[9]." [UOC:GVG] parts per billion 10^[-12] ppt "A dimensionless concentration notation which denotes the amount of a given substance in a total amount of 1,000,000,000 regardless of the units of measure used as long as they are the same or 1 part in 10^[12]." [UOC:GVG] parts per trillion 10^[-15] ppq "A dimensionless concentration notation which denotes the amount of a given substance in a total amount of 1,000,000,000,000 regardless of the units of measure used as long as they are the same or 1 part in 10^[15]." [UOC:GVG] parts per quadrillion g/ml gram per millilitre "A mass unit density which is equal to mass of an object in grams divided by the volume in milliliter." [UOC:GVG] gram per milliliter kg/L kilogram per litre "A mass unit density which is equal to mass of an object in kilograms divided by the volume in liters." [UOC:GVG] kilogram per liter gram per liter A mass unit density which is equal to mass of an object in grams divided by the volume in liters. g per L g/L g/L gram per litre "A mass unit density which is equal to mass of an object in grams divided by the volume in liters." [UOC:GVG] gram per liter milligram per milliliter A mass unit density which is equal to mass of an object in milligrams divided by the volume in milliliters. mg per ml mg/ml mg/ml milligram per millilitre "A mass unit density which is equal to mass of an object in milligrams divided by the volume in milliliters." [UOC:GVG] milligram per milliliter U/ml unit per millilitre "A unit per milliliter unit which is equal to one unit of an agreed arbitrary amount per one milliliter." [Webmd:Webmd] unit per milliliter U/l unit per litre "A unit per milliliter unit which is equal to one unit of an agreed arbitrary amount per one liter." [UOC:GVG] unit per liter "A concentration unit which is a standard measure of the mass of a substance in a given volume (density)." [Wikipedia:Wikipedia] mass per unit volume U "A catalytic unit activity which is equal to the amount of the enzyme that catalyzes the conversion of 1 micro mole of substrate per minute." [Wikipedia:Wikipedia] enzyme unit kg/m kilogram per metre "An area density unit which is equal to the mass of an object in kilograms divided by one meter." [NIST:NIST] kilogram per meter "A plane angle unit which is equal to 1/360 of a full rotation or 1.7453310^[-2] rad." [Wikipedia:Wikipedia] degree "A dimensionless unit which denoted an irrational real number, approximately equal to 3.14159 which is the ratio of a circle's circumference to its diameter in Euclidean geometry." [Wikipedia:Wikipedia] pi "A dimensionless count unit which denotes the number of molecules." [MGED:MGED] molecule count "A dimensionless percent unit which denotes the homogeneity of a biomaterial." [MGED:MGED] purity percentage "A dimensionless percent unit which denotes the density of an attached or monolayer culture (e.g., cell culture)." [MGED:MGED] confluence percentage degree Fahrenheit A temperature unit which is equal to 5/9ths of a kelvin. Negative 40 degrees Fahrenheit is equal to negative 40 degrees Celsius. F "A temperature unit which is equal to 5/9ths of a kelvin. Negative 40 degrees Fahrenheit is equal to negative 40 degrees Celsius." [Wikipedia:Wikipedia] degree Fahrenheit l/kg litre per kilogram "A specific volume unit which is equal to one liter volume occupied by one kilogram of a particular substance." [NIST:NIST] liter per kilogram millilitre per kilogram ml/kg "A specific volume unit which is equal to a thousandth of a liter per kilogram or 10^[-3] l/kg." [NIST:NIST] milliliter per kilogram microlitre per kilogram ul/kg "A specific volume unit which is equal to one millionth of a liter per kilogram or 10^[-6] l/kg." [NIST:NIST] microliter per kilogram cells per millilitre cells per ml "A unit of cell concentration which is equal to one cell in a volume of 1 milliliter." [Bioedonline:Bioedonline] cells per milliliter kat/m^[3] katal per cubic metre "A catalytic (activity) concentration unit which is equal to 1 katal activity of a catalyst in a given volume of one cubic meter." [NIST:NIST] katal per cubic meter kat/l katal per litre "A catalytic (activity) concentration unit which is equal to 1 katal activity of a catalyst in a given volume of one thousandth of a cubic meter." [NIST:NIST] katal per liter millilitre per cubic metre ml/m^[3] "A volume per unit volume unit which is equal to one millionth of a liter of solute in one cubic meter of solution." [NIST:NIST] milliliter per cubic meter milliliter per liter A volume per unit volume unit which is equal to one millionth of a liter of solute in one liter of solution. ml per L ml/l millilitre per litre ml/l "A volume per unit volume unit which is equal to one millionth of a liter of solute in one liter of solution." [NIST:NIST] milliliter per liter gram per deciliter A mass density unit which is equal to mass of an object in grams divided by the volume in deciliters. g/dl g/dl gram per decilitre "A mass density unit which is equal to mass of an object in grams divided by the volume in deciliters." [UOC:GVG] gram per deciliter decilitre dl "A volume unit which is equal to one tenth of a liter or 10^[-1] L." [NIST:NIST] deciliter cfu "A dimensionless count unit which a measure of viable bacterial numbers." [Wikipedia:Wikipedia] colony forming unit pfu "A dimensionless count unit which a measure of plaque forming units in a given volume." [Wikipedia:Wikipedia] plaque forming unit colony forming unit per volume A concentration unit which a measure of viable bacterial numbers in a given volume. "A concentration unit which a measure of viable bacterial numbers in a given volume." [Wikipedia:Wikipedia] colony forming unit per volume cfu/ml colony forming unit per millilitre "A colony forming unit which a measure of viable bacterial numbers in one milliliter." [Wikipedia:Wikipedia] colony forming unit per milliliter pfu/ml plaque forming unit per millilitre "A concentration unit which a measure of plaque forming units in one milliliter." [UOC:GVG] plaque forming unit per milliliter dps "An activity (of a radionuclide) unit which is equal to the activity of a quantity of radioactive material in which one nucleus decays per second or there is one atom disintegration per second." [ORCBS:ORCBS] disintegrations per second V "An electric potential difference unit which is equal to the work per unit charge. One volt is the potential difference required to move one coulomb of charge between two points in a circuit while using one joule of energy." [Wikipedia:Wikipedia] volt C "An electrical charge unit which is equal to the amount of charge transferred by a current of 1 ampere in 1 second." [WordNet:WordNet] coulomb Da amu u unified atomic mass unit "An independently to the base SI units defined mass unit which is equal to one twelfth of the mass of an unbound atom of the carbon-12 nuclide, at rest and in its ground state." [Wikipedia:Wikipedia] dalton kDa "A mass unit which is equal to one thousand daltons." [Wikipedia:Wikipedia] kilodalton Wh "An energy unit which is equal to the amount of electrical energy equivalent to a one-watt load drawing power for one hour." [Wikipedia:Wikipedia] watt-hour "An energy unit which is equal to 1,000 watt-hours." [Wikipedia:Wikipedia] kilowatt-hour V s Wb volt-second "A magnetic flux unit which is equal to the amount of flux that when linked with a single turn of wire for an interval of one second will induce an electromotive force of one volt." [ScienceLobby:ScienceLobby] weber T Wb/m2 "A magnetic flux density unit which is equal to one weber per square meter." [WordNet:WordNet] tesla Vh "A magnetic flux unit which is equal to 3600 Wb." [UOC:GVG] volt-hour kVh "A magnetic flux unit which is equal to one thousand volt-hours." [UOC:GVG] kilovolt-hour "An information unit which refers to a digit in the binary numeral system, which consists of base 2 digits (ie there are only 2 possible values: 0 or 1)." [Wikipedia:Wikipedia] bit B "An information unit which is equal to 8 bits." [Wikipedia:Wikipedia] byte kB "An information unit which is equal to 1000 bytes." [Wikipedia:Wikipedia] kilobyte MB "An information unit which is equal to 1000 kB." [Wikipedia:Wikipedia] megabyte "An image resolution unit which is a standard measure of the amount of spatial detail in an image." [Wikipedia:Wikipedia] chroma sampling unit "An image resolution unit which is a standard measure of the amount of contrast available in a pixel." [Wikipedia:Wikipedia] dynamic range unit dpi "A spatial resolution unit which is a standard measure of the printing resolution, in particular the number of individual dots of ink a printer or toner can produce within a linear one-inch space." [Wikipedia:Wikipedia] dots per inch micrometer pixel "A spatial resolution unit which is equal to a pixel size of one micrometer." [Wikipedia:Wikipedia] micron pixel pixel density ppi "A spatial resolution unit which is a standard measure of the resolution of a computer display, related to the size of the display in inches and the total number of pixels in the horizontal and vertical directions." [Wikipedia:Wikipedia] pixels per inch pixels per millimetre "A spatial resolution unit which is a standard measure of the number of pixels in one millimeter length or width of a digital image divided by the physical length or width of a printed image." [Wikipedia:Wikipedia] pixels per millimeter basepair bp "A count unit which contains one nucleotide." [UO:GVG] base pair KiB "An information unit which is equal to 1024 B." [NIST:NIST] kibibyte MiB "An information unit which is equal to 1024 KiB." [NIST:NIST] mebibyte mV "An electric potential difference unit which is equal to one thousandth of a volt or 10^[-3] V." [UOC:GVG] millivolt kV "An electric potential difference unit which is equal to one thousand volts or 10^[3] V." [UOC:GVG] kilovolt uV "An electric potential difference unit which is equal to one millionth of a volt or 10^[-6] V." [UOC:GVG] microvolt nV "An electric potential difference unit which is equal to one billionth of a volt or 10^[-12] V." [UOC:GVG] nanovolt pV "An electric potential difference unit which is equal to one trillionth of a volt or 10^[-12] V." [UOC:GVG] picovolt MV "An electric potential difference unit which is equal to one million volts or 10^[6] V." [UOC:GVG] megavolt N/m newton per metre "A surface tension unit which is equal to one newton per meter." [NIST:NIST] newton per meter dyn/cm "A surface tension unit which is equal to one dyne per centimeter." [Wikipedia:Wikipedia] dyne per cm Pa s "A viscosity unit which is equal to one pascale per second." [NIST:NIST] pascal second P dyne s/cm^2 "A viscosity unit which is equal to one dyne second per square centimeter." [Wikipedia:Wikipedia] poise dB "A ratio unit which is an indicator of sound power per unit area." [techtarget:techtarget] decibel "A unit which is a standard measure of the estimate of the stochastic effect that a non-uniform radiation dose has on a human." [Wikipedia:Wikipedia] effective dose unit A V^-1 mho S "An electrical conduction unit which is equal to A/V." [NIST:NIST] siemens W/m K watt per metre kelvin "An heat conduction unit which is equal to one watt divided by meter kelvin." [NIST:NIST] watt per meter kelvin eV electron volt "A non-SI unit of energy (eV) defined as the energy acquired by a single unbound electron when it passes through an electrostatic potential difference of one volt. An electronvolt is equal to 1.602 176 53(14) x 10^-19 J." [Wikipedia:Wikipedia] electronvolt V/m volt per metre "The volt per meter is a unit of electric field strength equal to the a potential difference of 1 volt existing between two points that are 1 meter apart." [Wikipedia:http\://en.wikipedia.org/wiki/Electric_field] volt per meter AU "A dimensionless logarithmic unit assigned to a measure of absorbance of light through a partially absorbing substance, defined as -log10(I/I_0) where I = transmitted light and I_0 = incident light." [Wikipedia:http\://en.wikipedia.org/wiki/Absorbance] absorbance unit microliters per minute A volumetric flow rate unit which is equal to one microliter volume through a given surface in one minute. microlitres per minute uL/min "A volumetric flow rate unit which is equal to one microliter volume through a given surface in one minute." [UOC:GVG] microliters per minute millimeters of mercury mmHg "A unit of pressure equal to the amount of fluid pressure one millimeter deep in mercury at zero degrees centigrade on Earth." [url:en.wiktionary.org/wiki/mmHg] millimetres of mercury mg/L milligram per litre "A mass unit density which is equal to mass of an object in milligrams divided by the volume in liters." [UOC:GVG] milligram per liter microgram per millilitre ug/ml "A mass unit density which is equal to mass of an object in micrograms divided by the volume in millliters." [UOC:GVG] microgram per milliliter nanogram per millilitre ng/ml "A mass unit density which is equal to mass of an object in nanograms divided by the volume in milliliters." [UOC:GVG] nanogram per milliliter mU/ml milliunits per millilitre "A unit per milliliter unit which is equal to one thousandth of a unit of an agreed arbitrary amount per one milliliter." [UOC:GVG] milliunits per milliliter count per nanomolar second A rate unit which is equal to one over one nanomolar second. nM^-1 s^-1 "A rate unit which is equal to one over one nanomolar second." [UOC:GVG] count per nanomolar second count per molar second A rate unit which is equal to one over one molar second. M^-1 s^-1 "A rate unit which is equal to one over one molar second." [UOC:GVG] count per molar second "An area density unit which is equal to the mass of an object in kilograms divided by the surface area in hectares." [UO:GVG] kilogram per hectare count per nanomolar A rate unit which is equal to one over one nanomolar. 1/nM nM^-1 "A rate unit which is equal to one over one nanomolar." [UO:GVG] count per nanomolar count per molar A rate unit which is equal to one over one molar. 1/M M^-1 "A rate unit which is equal to one over one molar." [UO:GVG] count per molar microgram per liter A mass unit density which is equal to mass of an object in micrograms divided by the volume in liters. ng/ml ug/L microgram per litre ug/L "A mass unit density which is equal to mass of an object in micrograms divided by the volume in liters." [UOC:GVG] microgram per liter "A dose unit which is equal to 1 milligram of a toxic or pharmaceutical substance per kilogram body weight of the recipient subject." [UO:PC] milligram per kilogram "A dose unit which is equal to 1 milligram of a toxic or pharmaceutical substance per square meter of surface area of the recipient subject." [UO:PC] milligram per square meter "A concentration unit which is a standard measure of the amount of a toxic or pharmaceutical substance administered over time to a recipient subject, expressed in terms of the size of the subject." [UO:PC] dosage unit "A dosage unit which is equal to 1 milligram per day of a toxic or pharmaceutical substance per kilogram body weight of the recipient subject." [UO:PC] milligram per kilogram per day "A derived unit which is a measure of relative light intensity, as typically measured by a luminometer, spectrophotometer, or fluorimeter in biological research applications." [UO:PC] relative light unit "A relative light unit which is a measure of relative luminescence intensity." [UO:PC] relative luminescence unit "A relative light unit which is a measure of relative fluorescence intensity." [UO:PC] relative fluorescence unit mH megahertz "A frequency unit which is equal to one million hertz or 10^[6] V." [UOC:GVG] megaHertz cM "A unit used to express distances on a genetic map. In genetic mapping, distances between markers are determined by measuring the rate of meoitic recombination between them, which increases proportionately with the distance separating them. A cM is defined as the length of an interval in which there is a 1% probability of recombination. On the average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA, although this can vary widely due to hot and cold spots of recombination." [NCBI:http\://www.ncbi.nlm.nih.gov/SCIENCE96/Glossary.html] centiMorgan cR "A unit of genetic map distance defined corresponding to an interval in which there is a 1% probability of X-irradiation induced breakage. To be completely specified, the unit must be qualified by the radiation in dosage in rads (e.g. cR8000), because this determines the actual breakage probability." [NCBI:http\://www.ncbi.nlm.nih.gov/SCIENCE96/Glossary.html] centiRay Mb megabasepair "A unit equal to one million base pairs" [UOC:GVG] mega base pair Gb gigabasepair "A unit equal to one billion base pairs." [UOC:GVG] giga base pair square micrometre "An area unit which is equal to an area enclosed by a square with sides each 1 micrometer long." [NIST:NIST] square micrometer mS "An electrical conduction unit which is equal to one thousandth of a siemen or 10^[-3] siemens." [NIST:NIST] millisiemens "A specific concentration unit which is equal to 1 micromole in a given volume of one thousandth of a cubic meter." [NIST:NIST] micromole per litre "A specific concentration unit which is equal to 1 micromole of a given substance per kilogram of solvent." [UOB:LKSR] micromole per kilogram mm/day "A speed/velocity unit which is equal to the speed of an object traveling 1 millimeter distance in one day." [UOB:LKSR] millimeters per day kilometre per hour km/h "A speed/velocity unit which is equal to the speed of an object traveling 1 kilometer distance in one hour." [NIST:NIST] kilometer per hour mDa milli unified atomic mass unit millidalton mmu "A mass unit which is equal to 1/12 the mass of 12C" [Wikipedia:Wikipedia] milli HA "An area unit which is equal to an area of 10,000 square meters. Equivalent to 2.471 acres." [Wikipedia:Wikipedia] hectare in "A length unit which is equal to 0.0254 metres." [Wikipedia:Wikpiedia] inch mil th "A length unit which is equal to 0.0254 millimetres." [Wikipedia:Wikpiedia] thou ft "A length unit which is equal to 0.3048 metres, or 12 inches." [Wikipedia:Wikpiedia] foot yd "A length unit which is equal to 0.9144 metres, or 3 feet." [Wikipedia:Wikpiedia] yard ch "A length unit which is equal to 20.1168 metres, 66 feet, or 22 yards." [Wikipedia:Wikpiedia] chain fur "A length unit which is equal to 20,116.8 metres, 660 feet, or 10 chains." [Wikipedia:Wikpiedia] furlong mi "A length unit which is equal to 1,609.344 metres, or 8 furlongs." [Wikipedia:Wikpiedia] mile lea "A length unit which is equal to 3 miles, or 4,828.032 metres" [Wikipedia:Wikpiedia] league "A maritime length unit is one used primarily at sea." [Wikipedia:Wikpiedia] maritime length unit ftm "A maritime length unit which is equal to 6.08 feet, or 1.853184 metres" [Wikipedia:Wikpiedia] fathom "A maritime length unit which is equal to 608 feet, 100 fathoms, or 185.3184 metres" [Wikipedia:Wikpiedia] cable "A maritime length unit which is equal to 6,080 feet, 10 cables, or 1,853.184 metres" [Wikipedia:Wikpiedia] nautical mile "An area unit which is equal to an area of 25.292,852,64 square meters, or 1 square rod." [Wikipedia:Wikipedia] perch "An area unit which is equivalent to 1 furlong x 1 rod. This is equal to an area of 1,011.714,1056 square meters, or 40 square rods." [Wikipedia:Wikipedia] rood "An area unit which is equivalent to 1 furlong x 1 chain. This is equal to an area of 4,046.856,4224 square meters, or 43,500 square feet." [Wikipedia:Wikipedia] acre fl oz "An imperial volume unit which is equivalent to 28.413,0625 millilitres." [Wikipedia:Wikipedia] fluid ounce gi "An imperial volume unit which is equivalent to 142.065,3125 millilitres." [Wikipedia:Wikipedia] gill pt "An imperial volume unit which is equivalent to 568.261,25 millilitres." [Wikipedia:Wikipedia] pint qt "An imperial volume unit which is equivalent to 1,136.5225 millilitres, or two pints." [Wikipedia:Wikipedia] quart gal "An imperial volume unit which is equivalent to 4,546.09 millilitres, or 8 pints." [Wikipedia:Wikipedia] gallon gr "An imperial mass unit which is equivalent to 64.798,91 milligrams." [Wikipedia:Wikipedia] grain dr "An imperial mass unit which is equivalent to 1.771,845,195,3125 grams, or 1/256 of 1 pound." [Wikipedia:Wikipedia] drachm oz "An imperial mass unit which is equivalent to 28.349,523,125 grams, or 1/16 of 1 pound." [Wikipedia:Wikipedia] ounce lb "An imperial mass unit which is equivalent to 453.592,37 grams." [Wikipedia:Wikipedia] pound st "An imperial mass unit which is equivalent to 6,350.293,18 grams, or 14 pounds." [Wikipedia:Wikipedia] stone qr qtr "An imperial mass unit which is equivalent to 12.700,586,36 kilograms, or 28 pounds." [Wikipedia:Wikipedia] quarter cwt "An imperial mass unit which is equivalent to 50.802,345,44 kilograms, 112 pounds, or 8 stone." [Wikipedia:Wikipedia] hundredweight t "An imperial mass unit which is equivalent to 1,016.046,9088 kilograms, or 2,240 pounds." [Wikipedia:Wikipedia] ton "An imperial gravitational unit which is equivalent to a mass that accelerates by 1ft/s² when a force of one pound (lbf) is exerted on it." [Wikipedia:Wikipedia] slug metric teaspoon tsp "A metric teaspoon is a unit of measurement of volume widely used in cooking recipes and pharmaceutic prescriptions. It equals a 5mL volume." [Wikipedia:https://en.wikipedia.org/wiki/Teaspoon] teaspoon "DEPRECATED: Duplicate of http://purl.obolibrary.org/obo/UO_0000039. A substance unit which is equal to one millionth of a mole." [UOB:LTS] micromole g/m^[2] gram per square metre "An area density unit which is equal to the mass of an object in grams divided by the surface area in meters squared." [NIST:NIST] gram per square meter nanogram per microlitre ng/ul "A mass unit density which is equal to mass of an object in nanograms divided by the volume in microliters." [UOB:LTS] nanogram per microliter big calorie cal calorie food calorie kcal kilocalorie "A unit of energy widely used in nutrition, equivalent to the amount of heat needed to cause one kilogram of water to rise in temperature by one degree Celsius." [Wikipedia:Wikipedia] large calorie micrograms per bottle "A unit of mass concentration defined as the number of micrograms of a substance per 250 ml Wheaton bottle." [UOB:LTS] micrograms per wheaton bottle pA "An electric current unit current which is equal to one trillionth of an ampere or 10^[-12] A." [UOB:LTS] picoampere cGy "An absorbed dose unit which is equal to 0.01 gray (Gy)" [NIST:NIST] centigray GeV "A unit of energy that is equal to one thousand million electronvolts." [] gigaelectronvolt GeV/nucleon "Derived unit which is equal to the total kinetic energy of an atomic nucleus in GeV divided by the number of nucleons in the nucleus" [] gigaelectronvolt per nucleon MeV/nucleon "Derived unit which is equal to the total kinetic energy of an atomic nucleus in MeV divided by the number of nucleons in the nucleus" [] megaelectronvolt per nucleon keV/micron "A derived unit equal to the energy deposited by ionizing radiation per micron of path length in matter" [] kiloelectronvolt per micron Gy/min "A derived absorbed dose unit which is equal to one gray absorbed per minute." [NIST:NIST] gray per minute cGy/min "A derived absorbed dose unit which is equal to one centigray absorbed per minute." [NIST:NIST] centigray per minute mGy/day "A derived absorbed dose unit which is equal to one milligray absorbed per minute." [NIST:NIST] milligray per minute mGy/min "A derived absorbed dose unit which is equal to one milligray absorbed per day." [NIST:NIST] milligray per day mGy/h "A derived absorbed dose unit which is equal to one milligray absorbed per hour." [NIST:NIST] milligray per hour mGy/s "A derived absorbed dose unit which is equal to one milligray absorbed per second." [NIST:NIST] milligray per second kilometre km "A length unit which is equal to one thousand meters." [UOB:LKSR] kilometer mg/dl milligram per decilitre "A mass unit density which is equal to mass of an object in milligrams divided by the volume in deciliters." [UOB:LKSR] milligram per deciliter microgram per decilitre ug/dl "A mass unit density which is equal to mass of an object in micrograms divided by the volume in deciliters." [UOB:LKSR] microgram per deciliter x anteriorly_connected_to y iff the anterior part of x is connected to y. i.e. x connected_to y and x posterior_to y. uberon anteriorly_connected_to anteriorly connected to x anteriorly_connected_to y iff the anterior part of x is connected to y. i.e. x connected_to y and x posterior_to y. UBERONREF:0000004 FMA:85994 uberon branch_of Source: FMA. Editor note: we need to check if FMA branch_of implies part_of. the relation we intend to use here should - for example, see vestibulocochlear nerve branch_of carries uberon channel_for channel for uberon channels_from channels_from uberon channels_into channels_into Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. uberon connects Editors note: this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) connects Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. UBERONREF:0000004 x distally_connected_to y iff the distal part of x is connected to y. i.e. x connected_to y and x proximal_to y. uberon distally_connected_to distally connected to x distally_connected_to y iff the distal part of x is connected to y. i.e. x connected_to y and x proximal_to y. UBERONREF:0000004 drains blood from drains from uberon drains source: Wikipedia drains uberon enclosed_by enclosed_by x encloses y iff the convex hull formed by x contains all or the majority of y. uberon encloses encloses x encloses y iff the convex hull formed by x contains all or the majority of y. https://orcid.org/0000-0002-6601-2165 uberon evolved_from Status: experimental evolved_from uberon evolved_multiple_times_in Status: experimental evolved_multiple_times_in c existence_ends_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e before e2). uberon existence_ends_at existence_ends_at c existence_ends_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e before e2). https://orcid.org/0000-0002-6601-2165 Relation between continuant c and occurrent s, such that every instance of c ceases to exist before s. uberon existence_ends_before existence_ends_before Relation between continuant c and occurrent s, such that every instance of c ceases to exist before s. https://orcid.org/0000-0002-6601-2165 Relation between continuant and occurrent, such that c ceases to exist at the end of p. uberon existence_ends_with existence_ends_with Relation between continuant and occurrent, such that c ceases to exist at the end of p. https://orcid.org/0000-0002-6601-2165 Relation between continuant c and occurrent s, such that every instance of c comes into existing after some s has completed. uberon existence_starts_after disjoint_from existence_starts_during (but this cannot be expressed in OWL2) existence_starts_after Relation between continuant c and occurrent s, such that every instance of c comes into existing after some s has completed. https://orcid.org/0000-0002-6601-2165 uberon existence_starts_and_ends_during existence_starts_and_ends_during c existence_starts_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e2 before e) uberon existence_starts_at existence_starts_at c existence_starts_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e2 before e) https://orcid.org/0000-0002-6601-2165 uberon existence_starts_or_ends_during existence_starts_or_ends_during Relation between continuant and occurrent, such that c comes into existence at the start of p. uberon existence_starts_with existence_starts_with Relation between continuant and occurrent, such that c comes into existence at the start of p. https://orcid.org/0000-0002-6601-2165 uberon exists_during exists_during uberon has_end has_end m1 has_muscle_antagonist m2 iff m1 acts in opposition to m2, and m2 is responsible for returning the structure to its initial position. dbpprop:antagonist uberon has_muscle_antagonist has_muscle_antagonist m1 has_muscle_antagonist m2 iff m1 acts in opposition to m2, and m2 is responsible for returning the structure to its initial position. Wikipedia:Antagonist_(muscle) uberon has_start has_start FMA:85999 dbprop:nerve nerve supply uberon innervated_by http://code.google.com/p/obo-relations/issues/detail?id=6 innervated_by nerve supply FMA:85999 uberon output_of output_of x posteriorly_connected_to y iff the posterior part of x is connected to y. i.e. x connected_to y and x anterior_to y. uberon posteriorly_connected_to posteriorly connected to x posteriorly_connected_to y iff the posterior part of x is connected to y. i.e. x connected_to y and x anterior_to y. UBERONREF:0000004 x proximally_connected_to y iff the proximal part of x is connected to y. i.e. x connected_to y and x distal_to y. uberon proximally_connected_to proximally connected to x proximally_connected_to y iff the proximal part of x is connected to y. i.e. x connected_to y and x distal_to y. UBERONREF:0000004 C site_of P iff exists species S such that P occurs_in C for all members of S. Example: bursa of Fabricius site_of B-cell differentiation. uberon site_of site_of C site_of P iff exists species S such that P occurs_in C for all members of S. Example: bursa of Fabricius site_of B-cell differentiation. GOC:cjm uberon start_of start_of uberon subdivision_of placeholder relation. X = 'subdivision of A' and subdivision_of some B means that X is the mereological sum of A and B subdivision of . uberon transitively_anteriorly_connected_to transitively anteriorly connected to . UBERONREF:0000004 uberon transitively_connected_to transitively_connected to . uberon transitively_distally_connected_to transitively distally connected to . UBERONREF:0000004 . uberon transitively_proximally_connected_to transitively proximally connected to . UBERONREF:0000004 uberon tributary_of taken from the FMA tributary_of Example: Newton asserted that we are like dwarfs standing on the shoulders of giants [X]. The citing entity cites the cited entity as one that provides an authoritative description or definition of the subject under discussion. cites as authority A file accompanying a published journal article, containing additional information of relevance to the article, typically available from the publisher's web site via a hyperlink from the journal article itself. http://semanticscience.org/resource/SIO_000008 uberon has_quality has_quality has_quality http://semanticscience.org/resource/SIO_000657 transforms from uberon transformation_of transformation_of transformation_of transforms from SIO:000657 http://semanticscience.org/resource/SIO_000658 direct_transformation_of immediately transforms from uberon immediate_transformation_of immediate_transformation_of immediate_transformation_of direct_transformation_of https://orcid.org/0000-0002-6601-2165 immediately transforms from SIO:000658 suggestedNCIt